Induction	O
of	O
NF-KB	O
during	O
monocyte	O
differentiation	O
by	O
HIV	O
type	O
1	O
infection	O
.	O

The	O
production	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
progeny	O
was	O
followed	O
in	O
the	O
U937	O
promonocytic	O
cell	O
line	O
after	O
stimulation	O
either	O
with	O
retinoic	O
acid	O
or	O
PMA	O
,	O
and	O
in	O
purified	O
human	O
monocytes	O
and	O
macrophages	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
and	O
Southwestern	O
blotting	O
experiments	O
were	O
used	O
to	O
detect	O
the	O
binding	O
of	O
cellular	O
transactivation	O
factor	O
NF-KB	O
to	O
the	O
double	O
repeat-KB	O
enhancer	O
sequence	O
located	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

PMA	O
treatment	O
,	O
and	O
not	B-Negation
retinoic	I-Negation
acid	I-Negation
treatment	I-Negation
of	I-Negation
the	I-Negation
U937	I-Negation
cells	I-Negation
acts	O
in	O
inducing	O
NF-KB	O
expression	O
in	O
the	O
nuclei	O
.	O

In	O
nuclear	O
extracts	O
from	O
monocytes	O
or	O
macrophages	O
,	O
induction	O
of	O
NF-KB	O
occurred	O
only	O
if	O
the	O
cells	O
were	O
previously	O
infected	O
with	O
HIV-1	O
.	O

When	O
U937	O
cells	O
were	O
infected	O
with	O
HIV-1	O
,	O
no	B-Negation
induction	I-Negation
of	I-Negation
NF-KB	I-Negation
factor	I-Negation
was	I-Negation
detected	I-Negation
,	O
whereas	O
high	O
level	O
of	O
progeny	O
virions	O
was	O
produced	O
,	O
suggesting	B-Speculation
that	I-Speculation
this	I-Speculation
factor	I-Speculation
was	I-Speculation
not	I-Speculation
required	I-Speculation
for	I-Speculation
viral	I-Speculation
replication	I-Speculation
.	O

These	O
results	O
indicate	O
that	O
in	O
monocytic	O
cell	O
lineage	O
,	O
HIV-1	O
could	O
mimic	O
some	O
differentiation/activation	O
stimuli	O
allowing	O
nuclear	O
NF-KB	O
expression	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
by	O
a	O
novel	O
B-cell-specific	O
enhancer	O
element	O
.	O

A	O
new	O
B-cell-specific	O
enhancer	O
element	O
has	O
been	O
identified	O
3	O
'	O
of	O
E4	O
and	O
the	O
octamerlike	O
motifs	O
in	O
the	O
human	O
immunoglobulin	O
heavy-chain	O
gene	O
enhancer	O
.	O

Tandem	O
copies	O
of	O
this	O
67-bp	O
MnlI-AluI	O
fragment	O
,	O
when	O
fused	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
gene	O
driven	O
by	O
the	O
conalbumin	O
promoter	O
,	O
stimulated	O
transcription	O
in	O
B	O
cells	O
but	O
not	B-Negation
in	I-Negation
Jurkat	I-Negation
T	I-Negation
cells	I-Negation
or	I-Negation
HeLa	I-Negation
cells	I-Negation
.	O

Footprinting	O
analysis	O
revealed	O
that	O
the	O
identical	O
sequence	O
CCGAAACTGAAAAGG	O
,	O
designated	O
E6	O
,	O
was	O
protected	O
by	O
nuclear	O
extracts	O
from	O
B	O
cells	O
,	O
T	O
cells	O
,	O
or	O
HeLa	O
cells	O
.	O

Gel	O
mobility	O
shift	O
assays	O
using	O
a	O
synthetic	O
E6	O
motif	O
detected	O
a	O
B-cell-specific	O
complex	O
in	O
addition	O
to	O
a	O
ubiquitous	O
band	O
found	O
also	O
in	O
T	O
cells	O
and	O
HeLa	O
cells	O
.	O

In	O
agreement	O
with	O
the	O
results	O
of	O
gel	O
retardation	O
assays	O
,	O
tandem	O
copies	O
of	O
the	O
E6	O
motif	O
stimulated	O
transcription	O
in	O
ARH77	O
and	O
Raji	O
cells	O
but	O
not	B-Negation
in	I-Negation
Jurkat	I-Negation
or	I-Negation
HeLa	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
a	O
mutant	O
E6	O
motif	O
lost	O
both	O
in	O
vitro	O
binding	O
activity	O
and	O
in	O
vivo	O
enhancer	O
activity	O
.	O

In	O
striking	O
contrast	O
to	O
the	O
mouse	O
Ig	O
heavy-chain	O
enhancer	O
,	O
in	O
which	O
the	O
octamer	O
motif	O
acts	O
as	O
a	O
B-cell-specific	O
enhancer	O
element	O
,	O
the	O
human	O
enhancer	O
contains	O
an	O
octamerlike	O
sequence	O
with	O
one	O
base	O
substitution	O
which	O
bound	O
octamer-binding	O
proteins	O
with	O
only	O
very	O
low	O
affinity	O
and	O
showed	O
no	B-Negation
enhancer	I-Negation
activity	I-Negation
of	I-Negation
its	I-Negation
own	I-Negation
.	O

Interestingly	O
,	O
the	O
MnlI-AluI	O
fragment	O
could	O
suppress	O
the	O
basal-level	O
activity	O
of	O
the	O
conalbumin	O
promoter	O
in	O
both	O
Jurkat	O
and	O
HeLa	O
cells	O
.	O

Moreover	O
,	O
simian	O
virus	O
40	O
enhancer	O
activity	O
was	O
blocked	O
by	O
the	O
MnlI-AluI	O
fragment	O
in	O
HeLa	O
cells	O
but	O
not	B-Negation
in	I-Negation
B	I-Negation
cells	I-Negation
.	O

Thus	O
,	O
the	O
novel	O
enhancer	O
element	O
identified	O
in	O
this	O
study	O
is	O
probably	O
a	O
target	O
site	O
for	O
both	O
positive	O
and	O
negative	O
factors	O
.	O

The	O
NF	O
kappa	O
B	O
independent	O
cis-acting	O
sequences	O
in	O
HIV-1	O
LTR	O
responsive	O
to	O
T-cell	O
activation	O
.	O

The	O
rate	O
of	O
transcription	O
initiation	O
directed	O
by	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
increases	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
of	O
T	O
cells	O
.	O

Here	O
we	O
show	O
that	O
the	O
response	O
of	O
the	O
HIV-1	O
LTR	O
may	O
be	O
governed	O
by	O
two	O
independent	O
sequences	O
located	O
5	O
'	O
to	O
the	O
site	O
of	O
transcription	O
initiation	O
sequences	O
that	O
bind	O
either	O
NFAT-1	O
or	O
NF	O
kappa	O
B	O
.	O

The	O
rate	O
of	O
LTR-directed	O
gene	O
expression	O
increased	O
in	O
response	O
to	O
treatment	O
with	O
either	O
a	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
if	O
either	O
the	O
NFAT-1	O
or	O
NF	O
kappa	O
B	O
binding	O
sites	O
were	O
deleted	O
,	O
but	O
failed	B-Negation
to	I-Negation
respond	I-Negation
to	I-Negation
these	I-Negation
mitogenic	I-Negation
stimuli	I-Negation
if	I-Negation
both	I-Negation
sequences	I-Negation
were	I-Negation
absent	I-Negation
.	O

The	O
HIV-1	O
mutant	O
virus	O
containing	O
both	O
NF	O
kappa	O
B	O
and	O
NFAT-1	O
deletion	O
was	O
able	O
to	O
replicate	O
although	O
at	O
a	O
much	O
decreased	O
growth	O
rate	O
,	O
while	O
the	O
deletion	O
of	O
NFAT-1	O
alone	O
increased	O
the	O
viral	O
growth	O
rate	O
in	O
Jurkat	O
cells	O
.	O

Neither	B-Negation
deletion	I-Negation
of	I-Negation
NF	I-Negation
kappa	I-Negation
B	I-Negation
nor	I-Negation
deletion	I-Negation
of	I-Negation
NFAT-1	I-Negation
decreased	I-Negation
activation	I-Negation
of	I-Negation
viral	I-Negation
replication	I-Negation
by	I-Negation
phorbol	I-Negation
ester	I-Negation
.	O

Specific	O
depletion	O
of	O
the	O
B-cell	O
population	O
induced	O
by	O
aberrant	O
expression	O
of	O
human	O
interferon	O
regulatory	O
factor	O
1	O
gene	O
in	O
transgenic	O
mice	O
.	O

Interferons	O
(	O
IFNs	O
)	O
are	O
well	O
known	O
both	O
as	O
antiviral	O
proteins	O
and	O
as	O
potent	O
regulators	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
fact	O
,	O
IFNs	O
inhibit	O
growth	O
of	O
various	O
normal	O
and	O
transformed	O
cell	O
types	O
.	O

Previously	O
,	O
a	O
nuclear	O
factor	O
,	O
IRF-1	O
(	O
interferon	O
regulatory	O
factor	O
1	O
)	O
,	O
which	O
binds	O
to	O
type	O
I	O
IFN	O
and	O
some	O
IFN-inducible	O
gene	O
promoters	O
,	O
was	O
identified	O
and	O
cloned	O
.	O

Since	O
the	O
IRF-1	O
gene	O
is	O
both	O
virus	O
and	O
IFN	O
inducible	O
,	O
an	O
intriguing	O
issue	O
is	O
raised	O
as	O
to	O
whether	O
the	O
IRF-1	O
gene	O
is	O
functioning	O
in	O
IFN-mediated	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
transgenic	O
mice	O
carrying	O
the	O
human	O
IRF-1	O
gene	O
linked	O
to	O
the	O
human	O
immunoglobulin	O
heavy-chain	O
enhancer	O
.	O

In	O
the	O
transgenic	O
mice	O
,	O
all	O
the	O
lymphoid	O
tissues	O
examined	O
showed	O
a	O
dramatic	O
reduction	O
in	O
the	O
number	O
of	O
B	O
lymphocytes	O
(	O
B	O
cells	O
)	O
.	O

Preparation	O
and	O
analysis	O
of	O
bone	O
marrow	O
cells	O
from	O
the	O
chimeric	O
mice	O
indicated	O
that	O
the	O
bone	O
marrow	O
is	O
the	O
effective	O
site	O
for	O
specific	O
depletion	O
of	O
the	O
B-cell	O
population	O
.	O

In	O
fact	O
,	O
transgenic	O
bone	O
marrow	O
cells	O
cocultured	O
with	O
a	O
bone	O
marrow-derived	O
stromal	O
cell	O
line	O
revealed	O
an	O
altered	O
B-cell	O
maturation	O
pattern	O
.	O

Identification	O
and	O
cloning	O
of	O
TCF-1	O
,	O
a	O
T	O
lymphocyte-specific	O
transcription	O
factor	O
containing	O
a	O
sequence-specific	O
HMG	O
box	O
.	O

CD3-epsilon	O
expression	O
is	O
controlled	O
by	O
a	O
downstream	O
T	O
lymphocyte-specific	O
enhancer	O
element	O
.	O

We	O
report	O
the	O
identification	O
of	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
TCF-1	O
,	O
binding	O
to	O
this	O
element	O
.	O

The	O
multimerized	O
recognition	O
motif	O
of	O
TCF-1	O
constituted	O
a	O
T	O
cell-specific	O
enhancer	O
.	O

Subsequent	O
cloning	O
of	O
TCF-1	O
identified	O
three	O
splice	O
alternatives	O
.	O

TCF-1	O
contained	O
a	O
single	O
DNA-binding	O
HMG	O
box	O
most	O
closely	O
related	O
to	O
similar	O
boxes	O
in	O
the	O
putative	O
mammalian	O
sex-determining	O
gene	O
SRY	O
and	O
in	O
the	O
Schizosaccharomyces	O
pombe	O
Mc	O
mating	O
type	O
gene	O
.	O

TCF-1	O
mRNA	O
was	O
expressed	O
uniquely	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
cotransfection	O
into	O
non-T	O
cells	O
,	O
TCF-1	O
could	O
transactivate	O
through	O
its	O
cognate	O
motif	O
.	O

These	O
results	O
identify	O
TCF-1	O
as	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
,	O
which	O
might	O
play	O
a	O
role	O
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
activates	O
proenkephalin	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Upon	O
activation	O
,	O
T	O
lymphocytes	O
accumulate	O
high	O
levels	O
of	O
the	O
neuropeptide	O
enkephalin	O
which	O
correlate	O
with	O
high	O
levels	O
of	O
proenkephalin	O
mRNA	O
in	O
the	O
cells	O
.	O

Here	O
we	O
investigated	O
the	O
transcriptional	O
basis	O
for	O
these	O
changes	O
.	O

The	O
proenkephalin	O
promoter	O
contains	O
a	O
sequence	O
GGGGACGTCCCC	O
,	O
named	O
B2	O
,	O
which	O
is	O
similar	O
to	O
the	O
kappa	O
B	O
sequence	O
GGGGACTTTCC	O
,	O
the	O
binding	O
site	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
an	O
NF-kappa	O
B-like	O
binding	O
activity	O
to	O
the	O
B2	O
site	O
,	O
concomitant	O
with	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
.	O

Mutations	O
at	O
the	O
B2	O
site	O
abolish	O
this	O
transcriptional	O
activation	O
.	O

The	O
purified	O
homodimer	O
(	O
two	O
p50s	O
)	O
of	O
the	O
DNA-binding	O
subunit	O
of	O
NF-kappa	O
B	O
binds	O
the	O
B2	O
site	O
of	O
proenkephalin	O
relatively	O
better	O
than	O
does	O
the	O
heterotetramer	O
(	O
two	O
p65s	O
plus	O
two	O
p50s	O
)	O
form	O
of	O
the	O
factor	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
the	O
T-cell-specific	O
activation	O
of	O
the	O
proenkephalin	O
promoter	O
is	O
mediated	O
by	O
NF-kappa	O
B	O
.	O

However	O
,	O
as	O
NF-kappa	O
B	O
is	O
ubiquitous	O
and	O
the	O
transcriptional	O
activation	O
through	O
the	O
B2	O
site	O
is	O
T	O
cell	O
specific	O
,	O
yet	O
another	O
T-cell-specific	O
factor	O
which	O
synergizes	O
with	O
NF-kappa	O
B	O
should	O
be	O
considered	O
.	O

Expression	O
of	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
proto-oncogenes	O
in	O
human	O
peripheral-blood	O
granulocytes	O
.	O

We	O
have	O
found	O
that	O
purified	O
human	O
peripheral-blood	O
granulocytes	O
express	O
constitutively	O
significant	O
levels	O
of	O
proto-oncogenes	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
mRNA	O
.	O

Upon	O
functional	O
activation	O
of	O
granulocytes	O
by	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
the	O
levels	O
of	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
transcripts	O
were	O
increased	O
.	O

The	O
three	O
jun	O
genes	O
showed	O
a	O
similar	O
time	O
course	O
in	O
their	O
induction	O
by	O
PMA	O
,	O
maximal	O
mRNA	O
levels	O
being	O
reached	O
after	O
60	O
min	O
of	O
induction	O
.	O

These	O
results	O
suggest	O
that	O
expression	O
of	O
c-jun	O
,	O
jun	O
B	O
and	O
jun	O
D	O
genes	O
might	O
be	O
involved	O
in	O
terminal	O
granulocyte	O
differentiation	O
or	O
in	O
regulating	O
granulocyte	O
functionality	O
.	O

Platelet-activating	O
factor	O
induces	O
phospholipid	O
turnover	O
,	O
calcium	O
flux	O
,	O
arachidonic	O
acid	O
liberation	O
,	O
eicosanoid	O
generation	O
,	O
and	O
oncogene	O
expression	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Platelet-activating	O
factor	O
is	O
a	O
potent	O
mediator	O
of	O
the	O
inflammatory	O
response	O
.	O

Studies	O
of	O
the	O
actions	O
of	O
platelet-activating	O
factor	O
have	O
centered	O
mainly	O
around	O
neutrophils	O
,	O
monocytes	O
,	O
and	O
platelets	O
.	O

In	O
this	O
report	O
we	O
begin	O
to	O
uncover	O
the	O
influence	O
of	O
platelet-activating	O
factor	O
on	O
B	O
lymphocytes	O
.	O

Employing	O
the	O
EBV-transformed	O
human	O
B	O
cell	O
line	O
SKW6.4	O
,	O
we	O
demonstrate	O
that	O
platelet-activating	O
factor	O
significantly	O
alters	O
membrane	O
phospholipid	O
metabolism	O
indicated	O
by	O
the	O
incorporation	O
of	O
32P	O
into	O
phosphatidylcholine	O
,	O
phosphatidylinositol	O
,	O
and	O
phosphatidic	O
acid	O
but	O
not	O
significantly	O
into	O
phosphatidylethanolamine	O
at	O
concentrations	O
ranging	O
from	O
10	O
(	O
-9	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
.	O

The	O
inactive	O
precursor	O
,	O
lyso-platelet-activating	O
factor	O
,	O
at	O
a	O
concentration	O
as	O
high	O
as	O
10	O
(	O
-7	O
)	O
M	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
membrane	I-Negation
phospholipids	I-Negation
.	O

We	O
also	O
show	O
that	O
platelet-activating	O
factor	O
from	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
M	O
induced	O
rapid	O
and	O
significant	O
elevation	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
lyso-platelet-activating	O
factor	O
was	O
again	O
ineffective	O
.	O

We	O
further	O
demonstrate	O
the	O
impact	O
of	O
platelet-activating	O
factor	O
binding	O
to	O
B	O
cells	O
by	O
measuring	O
platelet-activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
and	O
5-hydroxyeicosatetraenoic	O
acid	O
production	O
.	O

Moreover	O
,	O
platelet-activating	O
factor	O
was	O
capable	O
of	O
inducing	O
transcription	O
of	O
the	O
nuclear	O
proto-oncogenes	O
c-fos	O
and	O
c-jun	O
.	O

Finally	O
we	O
explored	O
the	O
possible	O
role	O
of	O
5-hydroxyeicosatetraenoic	O
acid	O
as	O
a	O
regulator	O
of	O
arachidonic	O
acid	O
liberation	O
demonstrating	O
that	O
endogenous	O
5-lipoxygenase	O
activity	O
modulates	O
platelet-activating	O
factor	O
induced	O
arachidonic	O
acid	O
release	O
perhaps	O
acting	O
at	O
the	O
level	O
of	O
phospholipase	O
A2	O
.	O

In	O
summary	O
,	O
platelet-activating	O
factor	O
is	O
shown	O
here	O
to	O
have	O
a	O
direct	O
and	O
profound	O
effect	O
on	O
a	O
pure	O
B	O
cell	O
line	O
.	O

A	O
novel	O
HIV-1	O
isolate	O
containing	O
alterations	O
affecting	O
the	O
NF-kappa	O
B	O
element	O
.	O

Three	O
molecular	O
clones	O
of	O
HIV-1	O
,	O
derived	O
from	O
a	O
single	O
isolate	O
(	O
AL1	O
)	O
,	O
exhibited	O
distinct	O
replicative	O
and	O
cytopathic	O
properties	O
during	O
propagation	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
phenotypic	O
differences	O
observed	O
were	O
attributable	O
,	O
in	O
large	O
part	O
,	O
to	O
changes	O
affecting	O
the	O
viral	O
LTR	O
.	O

Nucleotide	O
sequence	O
and	O
PCR	O
analyses	O
demonstrated	O
the	O
presence	O
of	O
novel	O
duplications	O
or	O
deletions	O
involving	O
the	O
NF-kappa	O
B	O
motif	O
.	O

These	O
changes	O
in	O
the	O
enhancer	O
element	O
were	O
identified	O
in	O
the	O
original	O
AL1	O
virus	O
stock	O
.	O

Subcloning	O
of	O
the	O
variant	O
NF-kappa	O
B	O
segments	O
into	O
LTR-driven	O
CAT	O
expression	O
vectors	O
confirmed	O
a	O
correlation	O
between	O
promoter	O
activity	O
and	O
replicative/cytopathic	O
capacity	O
.	O

1,25-Dihydroxyvitamin	O
D3	O
receptor	O
RNA	O
:	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

1,25-Dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2D3	O
]	O
induces	O
differentiation	O
and	O
inhibits	O
proliferation	O
of	O
myeloid	O
leukemic	O
cells	O
from	O
various	O
lines	O
and	O
patients	O
;	O

these	O
effects	O
are	O
probably	O
mediated	O
through	O
the	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
.	O

Little	O
is	O
known	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
hematopoietic	O
cells	O
.	O

We	O
examined	O
the	O
expression	O
and	O
modulation	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
various	O
proliferating	O
and	O
nonproliferating	O
hematopoietic	O
cells	O
.	O

Constitutive	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
was	O
detected	O
in	O
various	O
kinds	O
of	O
hematopoietic	O
cells	O
,	O
including	O
macrophages	O
and	O
activated	O
T	O
lymphocytes	O
,	O
as	O
well	O
as	O
in	O
cell	O
lines	O
KG-1	O
(	O
myeloblasts	O
)	O
,	O
HL-60	O
(	O
promyelocytes	O
)	O
,	O
ML-3	O
(	O
myelomonoblasts	O
)	O
,	O
U937	O
,	O
THP-1	O
(	O
monoblasts	O
)	O
,	O
K562	O
(	O
erythroblasts	O
)	O
,	O
and	O
S-LB1	O
(	O
HTLV-1-transfected	O
T	O
lymphocytes	O
)	O
.	O

Receptor	O
transcripts	O
were	O
4.6	O
kilobases	O
(	O
kb	O
)	O
,	O
and	O
no	B-Negation
variant	I-Negation
sizes	I-Negation
were	I-Negation
observed	I-Negation
.	O

All	O
cell	O
lines	O
examined	O
in	O
this	O
group	O
also	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
.	O

Most	O
B	O
lymphocyte	O
lines	O
expressed	O
negligible	O
levels	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
and	O
protein	O
;	O
however	O
;	O
analysis	O
of	O
a	O
lymphoid/myeloid	O
somatic	O
hybrid	O
suggested	O
that	O
suppression	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
B	O
lymphocytes	O
may	O
be	O
a	O
dominant	O
characteristic	O
.	O

HL-60	O
cells	O
were	O
cultured	O
with	O
10	O
(	O
-7	O
)	O
mol/L	O
1,25	O
(	O
OH	O
)	O
2D3	O
for	O
24	O
to	O
72	O
hours	O
,	O
and	O
levels	O
of	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
and	O
its	O
RNA	O
were	O
examined	O
.	O

Levels	B-Negation
of	I-Negation
RNA	I-Negation
coding	I-Negation
for	I-Negation
the	I-Negation
receptor	I-Negation
were	I-Negation
not	I-Negation
modulated	I-Negation
by	I-Negation
exposure	I-Negation
to	I-Negation
high	I-Negation
levels	I-Negation
of	I-Negation
ligand	I-Negation
.	O

Levels	O
of	O
occupied	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
protein	O
increased	O
in	O
these	O
HL-60	O
cells	O
;	O
but	O
the	O
total	O
number	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
decreased	O
about	O
50	O
%	O
at	O
24	O
hours	O
and	O
returned	O
toward	O
normal	O
at	O
72	O
hours	O
.	O

Steady-state	B-Negation
levels	I-Negation
of	I-Negation
1,25	I-Negation
(	I-Negation
OH	I-Negation
)	I-Negation
2D3	I-Negation
receptor	I-Negation
RNA	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
terminal	I-Negation
differentiation	I-Negation
of	I-Negation
HL-60	I-Negation
toward	I-Negation
either	I-Negation
granulocytes	I-Negation
or	I-Negation
macrophages	I-Negation
.	O

Nondividing	O
macrophages	O
from	O
normal	O
individuals	O
also	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
.	O

In	O
contrast	O
,	O
nondividing	O
peripheral	O
blood	O
lymphocytes	O
from	O
normal	O
individuals	O
did	O
not	B-Negation
express	I-Negation
1,25	I-Negation
(	I-Negation
OH	I-Negation
)	I-Negation
2D3	I-Negation
receptor	I-Negation
RNA	I-Negation
;	O

with	O
stimulation	O
of	O
proliferation	O
of	O
these	O
cells	O
,	O
accumulation	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
markedly	O
.	O

Half-life	O
(	O
t1/2	O
)	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
in	O
T	O
lymphocytes	O
was	O
short	O
(	O
1	O
hour	O
)	O
as	O
determined	O
by	O
measuring	O
decay	O
of	O
the	O
message	O
after	O
addition	O
of	O
actinomycin	O
D	O
.	O

Consistent	O
with	O
this	O
short	O
t1/2	O
,	O
accumulation	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
RNA	O
increased	O
in	O
cells	O
as	O
their	O
protein	O
synthesis	O
was	O
inhibited	O
.	O

Further	O
studies	O
are	O
required	O
to	O
understand	O
the	O
physiologic	O
role	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
in	O
myeloid	O
cells	O
and	O
proliferating	O
T	O
lymphocytes	O
.	O

Kappa	O
B	O
binding	O
proteins	O
are	O
constitutively	O
expressed	O
in	O
an	O
IL-2	O
autocrine	O
human	O
T	O
cell	O
line	O
.	O

The	O
IL-2	O
and	O
the	O
IL-2-R	O
alpha	O
genes	O
are	O
both	O
expressed	O
transiently	O
in	O
normal	O
T	O
lymphocytes	O
after	O
Ag	O
or	O
mitogen	O
activation	O
.	O

In	O
contrast	O
,	O
the	O
human	O
T	O
cell	O
line	O
,	O
IARC	O
301	O
,	O
expresses	O
these	O
two	O
genes	O
constitutively	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
its	O
growth	O
depends	O
on	O
the	O
autocrine	O
production	O
of	O
this	O
T	O
cell	O
growth	O
factor	O
and	O
high	O
affinity	O
IL-2R	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusual	O
persistent	O
expression	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
in	O
these	O
IARC	O
301	O
T	O
cells	O
,	O
we	O
have	O
analyzed	O
the	O
interactions	O
of	O
constitutively	O
expressed	O
nuclear	O
proteins	O
with	O
the	O
5	O
'	O
flanking	O
regions	O
of	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
genes	O
using	O
both	O
DNase	O
I	O
footprinting	O
and	O
gel	O
retardation	O
techniques	O
.	O

We	O
have	O
found	O
that	O
a	O
region	O
in	O
both	O
genes	O
(	O
-276	O
to	O
-250	O
for	O
IL-2-R	O
alpha	O
and	O
-203	O
to	O
-183	O
for	O
IL-2	O
)	O
,	O
which	O
corresponds	O
to	O
a	O
kappa	O
B	O
enhancer	O
element	O
,	O
is	O
specifically	O
protected	O
by	O
nuclear	O
proteins	O
from	O
IARC	O
301	O
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
both	O
the	O
IL-2	O
and	O
IL-2-R	O
alpha	O
promoters	O
are	O
active	O
in	O
transient	O
transfection	O
assays	O
in	O
IARC	O
301	O
cells	O
.	O

In	O
contrast	O
,	O
mutation	O
of	O
the	O
kappa	O
B	O
enhancer	O
results	O
in	O
markedly	O
attenuated	O
activities	O
of	O
both	O
promoters	O
.	O

Two	O
proteins	O
binding	O
the	O
kappa	O
B	O
sequence	O
,	O
NF-kappa	O
B	O
and	O
KBF1	O
,	O
are	O
constitutively	O
expressed	O
in	O
IARC	O
301	O
nuclei	O
and	O
induced	O
by	O
PMA	O
and	O
PHA	O
in	O
Jurkat	O
.	O

They	O
bind	O
to	O
the	O
kappa	O
B	O
motifs	O
with	O
different	O
relative	O
affinities	O
that	O
may	O
reflect	O
their	O
different	O
contribution	O
in	O
the	O
expression	O
of	O
various	O
promoters	O
.	O

The	O
functional	O
domains	O
of	O
the	O
murine	O
Thy-1	O
gene	O
promoter	O
.	O

The	O
Thy-1	O
gene	O
promoter	O
resembles	O
a	O
``	O
housekeeping	O
``	O
promoter	O
in	O
that	O
it	O
is	O
located	O
within	O
a	O
methylation-free	O
island	O
,	O
lacks	B-Negation
a	I-Negation
canonical	I-Negation
TATA	I-Negation
box	I-Negation
,	O
and	O
displays	O
heterogeneity	O
in	O
the	O
5'-end	O
termini	O
of	O
the	O
mRNA	O
.	O

Using	O
transgenic	O
mice	O
,	O
we	O
show	O
that	O
this	O
promoter	O
does	O
not	B-Negation
confer	I-Negation
any	I-Negation
tissue	I-Negation
specificity	I-Negation
and	O
is	O
active	O
only	O
in	O
a	O
position-dependent	O
manner	O
.	O

It	O
can	O
only	O
be	O
activated	O
in	O
a	O
tissue-specific	O
manner	O
by	O
elements	O
that	O
lie	O
downstream	O
of	O
the	O
initiation	O
site	O
.	O

We	O
have	O
analyzed	O
the	O
functional	O
domains	O
of	O
the	O
minimal	O
Thy-1	O
promoter	O
and	O
show	O
that	O
the	O
dominant	O
promoter	O
elements	O
consist	O
of	O
multiple	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
Sp1	O
,	O
an	O
inverted	O
CCAAT	O
box	O
,	O
and	O
sequences	O
proximal	O
to	O
the	O
transcription	O
start	O
site	O
.	O

DNase	O
I	O
and	O
gel	O
mobility	O
shift	O
assays	O
show	O
the	O
binding	O
of	O
a	O
number	O
of	O
nuclear	O
factors	O
to	O
these	O
elements	O
,	O
including	O
Sp1	O
and	O
CP1	O
.	O

Our	O
results	O
show	O
that	O
the	O
structure	O
of	O
this	O
promoter	O
only	O
permits	O
productive	O
interactions	O
of	O
the	O
two	O
transcription	O
factors	O
Sp1	O
and	O
CP1	O
with	O
the	O
basal	O
transcription	O
machinery	O
in	O
the	O
presence	O
of	O
enhancer	O
sequences	O
.	O

Comparison	O
of	O
constitutive	O
and	O
inducible	O
transcriptional	O
enhancement	O
mediated	O
by	O
kappa	O
B-related	O
sequences	O
:	O
modulation	O
of	O
activity	O
in	O
B	O
cells	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
tax	O
gene	O
.	O

The	O
kappa	O
B	O
sequence	O
(	O
GGGACTTTCC	O
)	O
binds	O
a	O
factor	O
,	O
NF-kappa	O
B	O
,	O
that	O
is	O
constitutively	O
found	O
in	O
its	O
functional	O
,	O
DNA	O
binding	O
form	O
only	O
in	O
B	O
lymphocytes	O
.	O

A	O
factor	O
with	O
apparently	O
indistinguishable	O
sequence	O
specificity	O
can	O
be	O
induced	O
in	O
many	O
other	O
cell	O
types	O
,	O
where	O
it	O
is	O
used	O
to	O
regulate	O
inducible	O
gene	O
expression	O
.	O

For	O
example	O
,	O
kappa	O
B-related	O
sequences	O
have	O
been	O
shown	O
to	O
be	O
important	O
for	O
the	O
transcription	O
of	O
a	O
few	O
inducible	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
gene	O
and	O
the	O
beta-interferon	O
gene	O
.	O

However	O
,	O
these	O
genes	O
are	O
not	B-Negation
constitutively	I-Negation
active	I-Negation
in	I-Negation
B	I-Negation
lymphocytes	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
other	I-Speculation
regulatory	I-Speculation
mechanisms	I-Speculation
must	I-Speculation
play	I-Speculation
a	I-Speculation
role	I-Speculation
in	I-Speculation
determining	I-Speculation
the	I-Speculation
patterns	I-Speculation
of	I-Speculation
expression	I-Speculation
.	O

We	O
have	O
investigated	O
the	O
constitutive	O
and	O
inducible	O
transcriptional	O
activity	O
mediated	O
by	O
five	O
kappa	O
B-related	O
sequence	O
elements	O
in	O
two	O
different	O
cell	O
types	O
.	O

We	O
show	O
that	O
in	O
S194	O
plasma	O
cells	O
the	O
activity	O
of	O
each	O
element	O
correlates	O
well	O
with	O
the	O
relative	O
affinity	O
of	O
B-cell-derived	O
NF-kappa	O
B	O
for	O
that	O
element	O
.	O

This	O
leads	O
to	O
significantly	O
lower	O
transcription	O
enhancement	O
by	O
sites	O
derived	O
from	O
the	O
interleukin	O
2	O
receptor	O
or	O
T-cell	O
receptor	O
genes	O
in	O
S194	O
cells	O
.	O

However	O
,	O
in	O
either	O
EL-4	O
(	O
T	O
)	O
cells	O
or	O
S194	O
cells	O
,	O
both	O
lower-affinity	O
sites	O
can	O
be	O
significantly	O
induced	O
by	O
the	O
tax	O
gene	O
product	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
,	O
showing	O
that	O
NF-kappa	O
B	O
activity	O
can	O
be	O
modulated	O
even	O
in	O
a	O
B-cell	O
line	O
that	O
constitutively	O
expresses	O
this	O
factor	O
.	O

Isolation	O
of	O
a	O
rel-related	O
human	O
cDNA	O
that	O
potentially	O
encodes	O
the	O
65-kD	O
subunit	O
of	O
NF-kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1991	O
Oct	O
4	O
;	O
254	O
(	O
5028	O
)	O
:	O
11	O
]	O

A	O
DNA	O
probe	O
that	O
spanned	O
a	O
domain	O
conserved	O
among	O
the	O
proto-oncogene	O
c-rel	O
,	O
the	O
Drosophila	O
morphogen	O
dorsal	O
,	O
and	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
NF-kappa	O
B	O
was	O
generated	O
from	O
Jurkat	O
T	O
cell	O
complementary	O
DNA	O
with	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
degenerate	O
oligonucleotides	O
.	O

This	O
probe	O
was	O
used	O
to	O
identify	O
a	O
rel-related	O
complementary	O
DNA	O
that	O
hybridized	O
to	O
a	O
2.6-kilobase	O
messenger	O
RNA	O
present	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
complementary	O
DNA	O
resulted	O
in	O
the	O
synthesis	O
of	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
size	O
of	O
65	O
kilodaltons	O
(	O
kD	O
)	O
.	O

The	O
translated	O
protein	O
showed	O
weak	O
DNA	O
binding	O
with	O
a	O
specificity	O
for	O
the	O
kappa	O
B	O
binding	O
motif	O
.	O

This	O
protein-DNA	O
complex	O
comigrated	O
with	O
the	O
complex	O
obtained	O
with	O
the	O
purified	O
human	O
p65	O
NF-kappa	O
B	O
subunit	O
and	O
binding	O
was	O
inhibited	O
by	O
I	O
kappa	O
B-alpha	O
and	O
-beta	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
65-kD	O
protein	O
associated	O
with	O
the	O
p50	O
subunit	O
of	O
NF-kappa	O
B	O
and	O
the	O
kappa	O
B	O
probe	O
to	O
form	O
a	O
complex	O
with	O
the	O
same	O
electrophoretic	O
mobility	O
as	O
the	O
NF-kappa	O
B-DNA	O
complex	O
.	O

Therefore	O
the	O
rel-related	O
65-kD	O
protein	O
may	O
represent	O
the	O
p65	O
subunit	O
of	O
the	O
active	O
NF-kappa	O
B	O
transcription	O
factor	O
complex	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
number	O
in	O
posttraumatic	O
stress	O
disorder	O
.	O

OBJECTIVE	O
:	O
The	O
authors	O
'	O
objective	O
was	O
to	O
investigate	O
the	O
possibility	O
that	O
glucocorticoid	O
receptor	O
changes	O
may	O
be	O
involved	O
in	O
the	O
dysregulation	O
of	O
the	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
axis	O
in	O
posttraumatic	O
stress	O
disorder	O
(	O
PTSD	O
)	O
.	O

METHOD	O
:	O
They	O
measured	O
the	O
number	O
of	O
lymphocyte	O
cytosolic	O
glucocorticoid	O
receptors	O
and	O
plasma	O
cortisol	O
concentrations	O
in	O
15	O
consecutively	O
admitted	O
male	O
combat	O
Vietnam	O
veterans	O
with	O
PTSD	O
and	O
in	O
a	O
normal	O
comparison	O
group	O
of	O
11	O
subjects	O
.	O

RESULTS	O
:	O
Both	O
the	O
patients	O
and	O
the	O
normal	O
comparison	O
subjects	O
showed	O
a	O
morning-to-afternoon	O
decline	O
in	O
glucocorticoid	O
receptor	O
concentrations	O
,	O
paralleling	O
the	O
normal	O
diurnal	O
decline	O
in	O
cortisol	O
levels	O
.	O

The	O
number	O
of	O
glucocorticoid	O
receptors	O
was	O
63	O
%	O
greater	O
in	O
the	O
morning	O
and	O
26	O
%	O
greater	O
in	O
the	O
afternoon	O
in	O
the	O
patients	O
with	O
PTSD	O
than	O
in	O
the	O
normal	O
subjects	O
.	O

No	B-Negation
group	I-Negation
differences	I-Negation
in	I-Negation
cortisol	I-Negation
levels	I-Negation
were	I-Negation
observed	I-Negation
,	O
nor	B-Negation
were	I-Negation
glucocorticoid	I-Negation
receptor	I-Negation
number	I-Negation
and	I-Negation
cortisol	I-Negation
levels	I-Negation
correlated	I-Negation
.	O

The	O
number	O
of	O
morning	O
glucocorticoid	O
receptors	O
was	O
positively	O
correlated	O
with	O
symptoms	O
of	O
PTSD	O
and	O
anxiety	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
further	O
evidence	O
for	O
a	O
dysregulation	O
of	O
the	O
HPA	O
axis	O
in	O
PTSD	O
.	O

The	O
finding	O
that	O
patients	O
with	O
PTSD	O
had	O
a	O
substantially	O
greater	O
number	O
of	O
lymphocyte	O
glucocorticoid	O
receptors	O
than	O
normal	O
comparison	O
subjects	O
is	O
consistent	O
with	O
the	O
authors	O
'	O
previous	O
observations	O
of	O
low	O
24-hour	O
urinary	O
cortisol	O
excretion	O
in	O
subjects	O
with	O
PTSD	O
.	O

Furthermore	O
,	O
the	O
receptor	O
changes	O
observed	O
are	O
opposite	O
of	O
those	O
reported	O
in	O
major	O
depressive	O
disorder	O
.	O

The	O
present	O
data	O
,	O
along	O
with	O
other	O
findings	O
of	O
HPA	O
abnormalities	O
in	O
PTSD	O
,	O
support	O
the	O
possibility	O
of	O
a	O
greater	O
negative	O
feedback	O
sensitivity	O
at	O
one	O
or	O
more	O
levels	O
of	O
the	O
HPA	O
axis	O
.	O

A	O
thymus-specific	O
member	O
of	O
the	O
HMG	O
protein	O
family	O
regulates	O
the	O
human	O
T	O
cell	O
receptor	O
C	O
alpha	O
enhancer	O
.	O

The	O
human	O
T	O
cell-specific	O
transcription	O
factor	O
TCF-1	O
alpha	O
plays	O
a	O
key	O
role	O
in	O
the	O
tissue-specific	O
activation	O
of	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
C	O
alpha	O
enhancer	O
and	O
binds	O
to	O
pyrimidine-rich	O
elements	O
(	O
5'-PyCTTTG-3	O
'	O
)	O
present	O
in	O
a	O
variety	O
of	O
other	O
T	O
cell-specific	O
control	O
regions	O
.	O

Using	O
amino	O
acid	O
sequence	O
information	O
derived	O
from	O
the	O
DNA	O
affinity-purified	O
protein	O
,	O
we	O
have	O
now	O
isolated	O
cDNA	O
clones	O
encoding	O
TCF-1	O
alpha	O
.	O

The	O
TCF-1	O
alpha	O
cDNA	O
contains	O
a	O
single	O
68-amino-acid	O
domain	O
that	O
is	O
homologous	O
to	O
a	O
region	O
conserved	O
among	O
high-mobility	O
group	O
(	O
HMG	O
)	O
and	O
nonhistone	O
chromosomal	O
proteins	O
.	O

Expression	O
of	O
full-length	O
and	O
mutant	O
cDNA	O
clones	O
in	O
bacteria	O
reveal	O
that	O
the	O
single	O
HMG	O
motif	O
,	O
which	O
is	O
predicted	O
to	O
contain	O
two	O
extended	O
alpha-helical	O
segments	O
,	O
is	O
sufficient	O
to	O
direct	O
the	O
sequence-specific	O
binding	O
of	O
TCF-1	O
alpha	O
to	O
DNA	O
.	O

Northern	O
blot	O
experiments	O
demonstrate	O
further	O
that	O
TCF-1	O
alpha	O
mRNA	O
is	O
highly	O
tissue	O
specific	O
,	O
found	O
primarily	O
in	O
the	O
thymus	O
or	O
T	O
cell	O
lines	O
.	O

The	O
immature	O
CEM	O
T	O
cell	O
line	O
expresses	O
relatively	O
low	O
levels	O
of	O
TCF-1	O
alpha	O
mRNA	O
,	O
which	O
are	O
increased	O
upon	O
activation	O
of	O
these	O
cells	O
by	O
phorbol	O
esters	O
.	O

Interestingly	O
,	O
the	O
cloned	O
TCF-1	O
alpha	O
protein	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
human	O
TCR	O
alpha	O
enhancer	O
in	O
nonlymphoid	O
cell	O
lines	O
,	O
whereas	O
the	O
activity	O
of	O
the	O
endogenous	O
protein	O
in	O
T	O
cell	O
lines	O
is	O
strongly	O
dependent	O
on	O
an	O
additional	O
T	O
cell-specific	O
protein	O
that	O
interacts	O
with	O
the	O
core	O
enhancer	O
.	O

TCF-1	O
alpha	O
is	O
currently	O
unique	O
among	O
the	O
newly	O
emerging	O
family	O
of	O
DNA-binding	O
regulatory	O
proteins	O
that	O
share	O
the	O
HMG	O
motif	O
in	O
that	O
it	O
is	O
a	O
highly	O
tissue-specific	O
RNA	O
polymerase	O
II	O
transcription	O
factor	O
.	O

Immune	O
response	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
to	O
HBx-antigen	O
of	O
hepatitis	O
B	O
virus	O
.	O

The	O
hepatitis	O
B	O
virus	O
genome	O
encodes	O
a	O
transcriptional	O
transactivator	O
protein	O
designated	O
HBxAg	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
antigen	O
is	O
a	O
target	O
structure	O
for	O
human	O
T-lymphocytes	O
.	O

Using	O
recombinant	O
HBxAg	O
protein	O
,	O
we	O
found	O
HBxAg-specific	O
stimulation	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
in	O
patients	O
with	O
acute	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
6	O
)	O
and	O
chronic	O
hepatitis	O
B	O
virus	O
infection	O
(	O
6	O
of	O
17	O
)	O
but	O
not	B-Negation
in	I-Negation
healthy	I-Negation
individuals	I-Negation
.	O

With	O
HBxAg-specific	O
synthetic	O
polypeptides	O
,	O
several	O
T-cell	O
epitopes	O
were	O
identified	O
.	O

Most	O
were	O
located	O
in	O
the	O
carboxyterminal	O
half	O
of	O
the	O
HBxAg	O
protein	O
.	O

Five	O
T-cell	O
clones	O
specific	O
for	O
a	O
T-cell	O
epitope	O
located	O
at	O
the	O
carboxyterminal	O
region	O
of	O
HBxAg	O
were	O
established	O
and	O
found	O
to	O
belong	O
to	O
the	O
CD2/CD4-positive	O
,	O
CD8-negative	O
subtype	O
.	O

These	O
data	O
establish	O
for	O
the	O
first	O
time	O
HBxAg	O
as	O
an	O
antigen	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

A	O
study	O
on	O
the	O
circadian	O
rhythm	O
of	O
glucocorticoid	O
receptor	O
.	O

Circadian	O
rhythm	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
was	O
studied	O
in	O
the	O
rat	O
liver	O
and	O
human	O
peripheral	O
leukocytes	O
.	O

For	O
rats	O
exposed	O
to	O
a	O
natural	O
environmental	O
photic	O
cycle	O
or	O
a	O
12L	O
:	O
12D	O
artificial	O
light	O
regime	O
,	O
peak	O
values	O
of	O
hepatic	O
GR	O
were	O
detected	O
between	O
23:00	O
and	O
02:00	O
h	O
.	O

Except	O
for	O
a	O
4-hour	O
advancement	O
of	O
the	O
peak	O
,	O
a	O
similar	O
circadian	O
rhythm	O
of	O
hepatic	O
GR	O
was	O
detected	O
in	O
rats	O
reared	O
under	O
a	O
reversed	O
lighting	O
regimen	O
(	O
12D	O
:	O
12L	O
;	O
lights	O
on	O
between	O
18:30	O
and	O
06:30	O
h	O
)	O
.	O

In	O
human	O
leukocytes	O
,	O
the	O
peak	O
value	O
of	O
GR	O
was	O
found	O
to	O
parallel	O
that	O
of	O
plasma	O
cortisol	O
with	O
high	O
and	O
low	O
values	O
detected	O
at	O
04:00-08:00	O
h	O
and	O
23:00-24:00	O
h	O
,	O
respectively	O
.	O

In	O
patients	O
suffering	O
from	O
Cushing	O
's	O
syndrome	O
,	O
the	O
circadian	O
rhythm	O
of	O
plasma	O
cortisol	O
either	O
disappeared	O
or	O
was	O
inverted	O
while	O
that	O
of	O
GR	O
did	O
not	O
significantly	O
deviate	O
from	O
the	O
normal	O
subjects	O
.	O

For	O
apoplexic	O
patients	O
with	O
lesions	O
localized	O
to	O
the	O
base	O
of	O
the	O
brain	O
as	O
indicated	O
by	O
computerized	O
tomography	O
,	O
the	O
diurnal	O
variation	O
of	O
GR	O
was	O
abolished	O
.	O

Conversely	O
,	O
diurnal	O
rhythmicity	O
persisted	O
in	O
apoplexy	O
patients	O
whose	O
lesions	O
were	O
in	O
the	O
cerebral	O
cortex	O
.	O

Thus	O
,	O
we	O
postulated	O
that	O
the	O
circadian	O
modification	O
of	O
GR	O
was	O
independent	O
of	O
the	O
diurnal	O
fluctuations	O
in	O
plasma	O
cortisol	O
level	O
or	O
the	O
circadian	O
variations	O
in	O
environmental	O
lighting	O
and	O
that	O
the	O
rhythmicity	O
might	O
be	O
regulated	O
by	O
the	O
'	O
circadian	O
pacemaker	O
'	O
located	O
in	O
the	O
human	O
basal	O
brain	O
.	O

These	O
diurnal	O
variations	O
in	O
GR	O
might	O
serve	O
to	O
coordinate	O
the	O
reactivity	O
of	O
the	O
target	O
cells	O
to	O
cortisol	O
because	O
the	O
diurnal	O
rhythms	O
of	O
a	O
GR-mediated	O
response	O
,	O
the	O
fractional	O
inhibition	O
of	O
chemotactic	O
migration	O
rate	O
of	O
polymorphonuclear	O
leukocytes	O
by	O
cortisol	O
,	O
were	O
found	O
to	O
be	O
synchronous	O
with	O
those	O
of	O
GR	O
.	O

Multiple	O
Oct2	O
isoforms	O
are	O
generated	O
by	O
alternative	O
splicing	O
.	O

The	O
interaction	O
of	O
the	O
Oct2	O
transcription	O
factor	O
with	O
the	O
cognate	O
octamer	O
motif	O
ATGCAAAT	O
is	O
a	O
critical	O
determinant	O
of	O
the	O
lymphoid-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Ectopic	O
expression	O
of	O
cloned	O
Oct2	O
cDNA	O
was	O
shown	O
to	O
be	O
sufficient	O
to	O
reconstitute	O
at	O
least	O
some	O
aspects	O
of	O
this	O
regulation	O
in	O
non-lymphoid	O
cells	O
.	O

We	O
describe	O
the	O
isolation	O
and	O
characterization	O
of	O
multiple	O
cDNAs	O
encoding	O
mouse	O
Oct2	O
from	O
a	O
mature	O
B-cell	O
line	O
and	O
we	O
show	O
that	O
a	O
variety	O
of	O
isoforms	O
of	O
this	O
transcription	O
factor	O
is	O
generated	O
from	O
a	O
single	O
gene	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

All	O
the	O
isoforms	O
retain	O
the	O
previously	O
characterized	O
POU-domain	O
and	O
are	O
therefore	O
able	O
to	O
bind	O
to	O
the	O
octamer	O
motif	O
.	O

Different	O
amounts	O
of	O
the	O
various	O
isoforms	O
are	O
present	O
within	O
the	O
same	O
B-cell	O
regardless	O
of	O
the	O
developmental	O
stage	O
of	O
B-cell	O
differentiation	O
and	O
at	O
least	O
some	O
of	O
the	O
isoforms	O
are	O
conserved	O
between	O
mouse	O
and	O
humans	O
.	O

In	O
cotransfection	O
experiments	O
we	O
show	O
that	O
all	O
the	O
isoforms	O
are	O
able	O
to	O
activate	O
an	O
octamer	O
containing	O
promoter	O
element	O
in	O
fibroblasts	O
revealing	O
an	O
unexpected	O
functional	O
redundancy	O
.	O

Finally	O
,	O
we	O
show	O
that	O
one	O
of	O
the	O
isoforms	O
encodes	O
the	O
previously	O
described	O
lymphoid-specific	O
Oct2B	O
protein	O
which	O
has	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
the	O
function	O
of	O
the	O
octamer	O
motif	O
in	O
the	O
context	O
of	O
the	O
immunoglobulin	O
heavy-chain	O
(	O
IgH	O
)	O
enhancer	O
.	O

Murine	O
and	O
human	O
T-lymphocyte	O
GATA-3	O
factors	O
mediate	O
transcription	O
through	O
a	O
cis-regulatory	O
element	O
within	O
the	O
human	O
T-cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

A	O
family	O
of	O
transcriptional	O
activators	O
has	O
recently	O
been	O
identified	O
in	O
chickens	O
;	O

these	O
transcriptional	O
activators	O
recognize	O
a	O
common	O
consensus	O
motif	O
(	O
WGATAR	O
)	O
through	O
a	O
conserved	O
C4	O
zinc	O
finger	O
DNA-binding	O
domain	O
.	O

One	O
of	O
the	O
members	O
of	O
this	O
multigene	O
family	O
,	O
cGATA-3	O
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	O
cell	O
lineage	O
.	O

Analysis	O
of	O
human	O
and	O
murine	O
GATA-3	O
factors	O
shows	O
a	O
striking	O
degree	O
of	O
amino	O
acid	O
sequence	O
identity	O
and	O
similar	O
patterns	O
of	O
tissue	O
specificity	O
of	O
expression	O
in	O
these	O
three	O
organisms	O
.	O

The	O
murine	O
and	O
human	O
factors	O
are	O
abundantly	O
expressed	O
in	O
a	O
variety	O
of	O
human	O
and	O
murine	O
T-cell	O
lines	O
and	O
can	O
activate	O
transcription	O
through	O
a	O
tissue-specific	O
GATA-binding	O
site	O
identified	O
within	O
the	O
human	O
T-cell	O
receptor	O
delta	O
gene	O
enhancer	O
.	O

We	O
infer	O
that	O
the	O
murine	O
and	O
human	O
GATA-3	O
proteins	O
play	O
a	O
central	O
and	O
highly	O
conserved	O
role	O
in	O
vertebrate	O
T-cell-specific	O
transcriptional	O
regulation	O
.	O

Processing	O
of	O
the	O
precursor	O
of	O
NF-kappa	O
B	O
by	O
the	O
HIV-1	O
protease	O
during	O
acute	O
infection	O
.	O

Transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
genome	O
is	O
regulated	O
in	O
part	O
by	O
cellular	O
factors	O
and	O
is	O
stimulated	O
by	O
activation	O
of	O
latently	O
infected	O
T	O
cells	O
.	O

T-cell	O
activation	O
also	O
correlates	O
with	O
the	O
induction	O
of	O
the	O
factor	O
NF-kappa	O
B	O
which	O
binds	O
to	O
two	O
adjacent	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O

This	O
factor	O
consists	O
of	O
two	O
DNA-binding	O
subunits	O
of	O
relative	O
molecular	O
mass	O
50,000	O
(	O
50K	O
)	O
associated	O
with	O
two	O
65K	O
subunits	O
.	O

It	O
is	O
located	O
in	O
the	O
nucleus	O
in	O
mature	O
B	O
cells	O
,	O
but	O
is	O
present	O
in	O
other	O
cell	O
types	O
as	O
an	O
inactive	O
cytoplasmic	O
complex	O
.	O

External	O
stimuli	O
,	O
including	O
those	O
that	O
activate	O
T	O
cells	O
,	O
result	O
in	O
nuclear	O
translocation	O
of	O
active	O
NF-kappa	O
B	O
.	O

The	O
cloning	O
of	O
the	O
complementary	O
DNA	O
for	O
the	O
50K	O
subunit	O
helped	O
to	O
identify	O
an	O
exclusively	O
cytoplasmic	O
105K	O
precursor	O
(	O
p105	O
)	O
(	O
V.B.	O
,	O
P.K.	O
and	O
A.I.	O
,	O
manuscript	O
submitted	O
)	O
.	O

The	O
expression	O
of	O
active	O
NF-kappa	O
B	O
might	O
therefore	O
also	O
be	O
regulated	O
by	O
the	O
extent	O
of	O
processing	O
of	O
p105	O
.	O

Because	O
HIV-1	O
requires	O
active	O
NF-kappa	O
B	O
for	O
efficient	O
transcription	O
,	O
we	O
tested	O
the	O
effect	O
of	O
HIV-1	O
infection	O
on	O
the	O
processing	O
of	O
the	O
human	O
105K	O
precursor	O
.	O

We	O
show	O
here	O
that	O
the	O
HIV-1	O
protease	O
can	O
process	O
p105	O
and	O
increases	O
levels	O
of	O
active	O
nuclear	O
NF-kappa	O
B	O
complex	O
.	O

Vitamin	O
D	O
receptor	O
expression	O
in	O
human	O
lymphocytes	O
.	O

Signal	O
requirements	O
and	O
characterization	O
by	O
western	O
blots	O
and	O
DNA	O
sequencing	O
.	O

The	O
signals	O
controlling	O
the	O
expression	O
of	O
the	O
receptor	O
protein	O
for	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
in	O
normal	O
human	O
lymphocytes	O
and	O
the	O
relationship	O
of	O
this	O
protein	O
to	O
the	O
classical	O
vitamin	O
D	O
receptor	O
were	O
examined	O
.	O

Lymphocytes	O
activated	O
with	O
the	O
OKT3	O
antibody	O
to	O
the	O
T-cell	O
antigen	O
receptor	O
expressed	O
fewer	O
binding	O
sites	O
as	O
compared	O
to	O
lymphocytes	O
that	O
were	O
activated	O
by	O
the	O
polyclonal	O
activator	O
phytohemagglutinin	O
(	O
PHA	O
)	O
.	O

However	O
,	O
combination	O
of	O
OKT3	O
and	O
phorbol	O
myristate	O
acetate	O
produced	O
a	O
concentration	O
of	O
binding	O
sites	O
similar	O
to	O
the	O
PHA-activated	O
cells	O
.	O

The	O
receptor	O
from	O
OKT3	O
and	O
OKT3	O
+	O
phorbol	O
myristate	O
acetate-activated	O
lymphocytes	O
exhibited	O
decreased	O
binding	O
to	O
DNA-cellulose	O
compared	O
to	O
PHA-activated	O
lymphocytes	O
.	O

In	O
lymphocytes	O
activated	O
either	O
by	O
PHA	O
or	O
OKT3	O
(	O
but	O
not	B-Negation
in	I-Negation
resting	I-Negation
cells	I-Negation
)	O
,	O
a	O
50-kDa	O
species	O
cross-reacting	O
with	O
a	O
monoclonal	O
antibody	O
against	O
the	O
intestinal	O
vitamin	O
D	O
receptor	O
was	O
detected	O
.	O

Finally	O
,	O
RNA	O
from	O
activated	O
lymphocytes	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
using	O
oligonucleotide	O
primers	O
flanking	O
the	O
196	O
base	O
pair	O
long	O
region	O
encoding	O
the	O
DNA-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

The	O
amplified	O
product	O
showed	O
an	O
identical	O
nucleotide	O
sequence	O
to	O
the	O
DNA-binding	O
domain	O
of	O
the	O
human	O
intestinal	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
expression	O
of	O
the	O
1,25-	O
(	O
OH	O
)	O
2D3	O
receptor	O
in	O
lymphocytes	O
is	O
triggered	O
by	O
distinct	O
and	O
contingent	O
signals	O
,	O
and	O
that	O
the	O
protein	O
and	O
the	O
mRNA	O
encoding	O
it	O
are	O
identical	O
to	O
the	O
classical	O
vitamin	O
D	O
receptor	O
.	O

Cloning	O
of	O
murine	O
TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
interacting	O
with	O
functional	O
motifs	O
in	O
the	O
CD3-epsilon	O
and	O
T	O
cell	O
receptor	O
alpha	O
enhancers	O
.	O

CD3-epsilon	O
gene	O
expression	O
is	O
confined	O
to	O
the	O
T	O
cell	O
lineage	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
a	O
human	O
transcription	O
factor	O
,	O
TCF-1	O
,	O
that	O
binds	O
to	O
a	O
functional	O
element	O
in	O
the	O
T	O
lymphocyte-specific	O
enhancer	O
of	O
CD3-epsilon	O
.	O

In	O
a	O
panel	O
of	O
human	O
cell	O
lines	O
,	O
TCF-1	O
expression	O
was	O
restricted	O
to	O
T	O
lineage	O
cells	O
.	O

TCF-1	O
belonged	O
to	O
a	O
novel	O
family	O
of	O
genes	O
that	O
contain	O
the	O
so-called	O
high	O
mobility	O
group	O
1	O
(	O
HMG	O
)	O
box	O
.	O

Here	O
we	O
report	O
the	O
cloning	O
of	O
murine	O
TCF-1	O
.	O

Two	O
splice	O
alternatives	O
were	O
identified	O
that	B-Negation
were	I-Negation
not	I-Negation
previously	I-Negation
observed	I-Negation
in	I-Negation
human	I-Negation
TCF-1	I-Negation
.	O

Murine	O
and	O
human	O
TCF-1	O
displayed	O
a	O
95.5	O
%	O
overall	O
amino	O
acid	O
homology	O
.	O

Recombinant	O
murine	O
and	O
human	O
TCF-1	O
recognized	O
the	O
same	O
sequence	O
motif	O
in	O
the	O
CD3-epsilon	O
enhancer	O
as	O
judged	O
by	O
gel	O
retardation	O
and	O
methylation	O
interference	O
assays	O
.	O

With	O
the	O
murine	O
cDNA	O
clones	O
several	O
aspects	O
of	O
TCF-1	O
were	O
analyzed	O
.	O

First	O
,	O
deletion	O
analysis	O
revealed	O
that	O
a	O
region	O
of	O
TCF-1	O
containing	O
the	O
HMG	O
box	O
was	O
sufficient	O
for	O
sequence-specific	O
binding	O
.	O

Second	O
,	O
by	O
high	O
stringency	O
Northern	O
blotting	O
and	O
in	O
situ	O
hybridization	O
,	O
TCF-1	O
expression	O
was	O
shown	O
to	O
be	O
confined	O
to	O
the	O
thymus	O
and	O
to	O
the	O
T	O
cell	O
areas	O
of	O
the	O
spleen	O
.	O

Third	O
,	O
TCF-1	O
bound	O
specifically	O
to	O
a	O
functional	O
T	O
cell-specific	O
element	O
in	O
the	O
T	O
cell	O
receptor	O
alpha	O
(	O
TCR-alpha	O
)	O
enhancer	O
.	O

The	O
T	O
lineage-specific	O
expression	O
and	O
the	O
affinity	O
for	O
functional	O
motifs	O
in	O
the	O
TCR-alpha	O
and	O
CD3-epsilon	O
enhancers	O
imply	O
an	O
important	O
role	O
for	O
TCF-1	O
in	O
the	O
establishment	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

HIV	O
enhancer	O
activity	O
perpetuated	O
by	O
NF-kappa	O
B	O
induction	O
on	O
infection	O
of	O
monocytes	O
[	O
see	O
comments	O
]	O

Permissiveness	O
to	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
differs	O
in	O
T	O
lymphocytes	O
and	O
macrophages	O
.	O

In	O
T	O
cells	O
,	O
HIV	O
transcription	O
is	O
poorly	O
detected	O
in	O
vivo	O
.	O

Cloned	O
,	O
normal	O
T	O
lymphocytes	O
show	O
very	O
little	O
,	O
if	O
any	O
,	O
basal	O
activity	O
of	O
the	O
HIV	O
enhancer	O
and	O
low	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
the	O
HIV	O
enhancer	O
.	O

In	O
contrast	O
,	O
fixed	O
tissue	O
macrophages	O
express	O
detectable	O
HIV	O
proteins	O
,	O
indicating	O
permanent	O
virus	O
transcription	O
.	O

One	O
explanation	O
for	O
the	O
perpetuation	O
of	O
virus	O
infection	O
in	O
macrophages	O
could	O
be	O
sustained	O
nuclear	O
NF-kappa	O
B	O
expression	O
.	O

However	O
,	O
the	O
U937	O
monocytic	O
cell	O
line	O
,	O
which	O
is	O
fully	O
permissive	O
to	O
HIV	O
replication	O
,	O
is	O
known	O
to	O
express	O
only	O
low	O
levels	O
of	O
nuclear	O
NF-kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
chronic	O
HIV	O
infection	O
results	O
in	O
both	O
induction	O
of	O
a	O
nuclear	O
factor	O
with	O
antigenic	O
properties	O
indistinguishable	O
from	O
those	O
of	O
NF-kappa	O
B	O
and	O
permanently	O
increased	O
HIV	O
enhancer	O
activity	O
.	O

This	O
phenomenon	O
,	O
which	O
is	O
independent	O
of	O
tumour	O
necrosis	O
factor	O
,	O
is	O
associated	O
with	O
HIV	O
replication	O
,	O
and	O
is	O
thus	O
likely	O
to	O
explain	O
at	O
least	O
in	O
part	O
the	O
perpetuation	O
of	O
HIV	O
infection	O
in	O
monocytes	O
.	O

Role	O
for	O
the	O
Epstein-Barr	O
virus	O
nuclear	O
antigen	O
2	O
in	O
viral	O
promoter	O
switching	O
during	O
initial	O
stages	O
of	O
infection	O
.	O

During	O
latent	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
human	O
B	O
lymphocytes	O
,	O
six	O
viral	O
nuclear	O
antigen	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
long	O
primary	O
transcripts	O
by	O
means	O
of	O
alternative	O
splicing	O
and	O
alternative	O
polyadenylylation	O
sites	O
.	O

These	O
transcripts	O
initiate	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
that	O
function	O
in	O
a	O
mutually	O
exclusive	O
fashion	O
.	O

Wp	O
is	O
exclusively	O
utilized	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
of	O
primary	O
B	O
lymphocytes	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
usage	O
.	O

These	O
studies	O
have	O
been	O
extended	O
to	O
show	O
that	O
(	O
i	O
)	O
a	O
mutant	O
EBV	O
strain	O
lacking	B-Negation
the	I-Negation
gene	I-Negation
encoding	I-Negation
EBNA	I-Negation
2	I-Negation
fails	O
to	O
switch	O
from	O
Wp	O
to	O
Cp	O
usage	O
in	O
primary	O
B	O
lymphocytes	O
,	O
although	O
the	O
virus	O
contains	O
a	O
functional	O
Cp	O
;	O
(	O
ii	O
)	O
a	O
region	O
from	O
-429	O
to	O
-245	O
base	O
pairs	O
upstream	O
of	O
Cp	O
is	O
essential	O
for	O
Cp	O
activity	O
in	O
B	O
lymphocytes	O
,	O
but	O
only	O
in	O
the	O
context	O
of	O
upstream	O
and	O
downstream	O
sequences	O
;	O
(	O
iii	O
)	O
this	O
region	O
contains	O
an	O
EBNA	O
2-dependent	O
enhancer	O
;	O
and	O
(	O
iv	O
)	O
DNase	O
I	O
protection	O
employing	O
nuclear	O
extracts	O
from	O
B	O
and	O
T	O
lymphocytes	O
revealed	O
a	O
B-cell-specific	O
footprint	O
in	O
the	O
region	O
of	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O

These	O
results	O
support	O
a	O
model	O
for	O
viral	O
promoter	O
switching	O
during	O
the	O
initial	O
stages	O
of	O
infection	O
in	O
which	O
Wp	O
activity	O
leads	O
to	O
the	O
expression	O
of	O
EBNA	O
2	O
,	O
followed	O
by	O
activation	O
of	O
Cp	O
through	O
the	O
EBNA	O
2-dependent	O
enhancer	O
.	O

Glucocorticoid	O
receptor	O
characteristics	O
in	O
monocytes	O
of	O
patients	O
with	O
corticosteroid-resistant	O
bronchial	O
asthma	O
.	O

The	O
mechanism	O
of	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
has	O
been	O
studied	O
by	O
determining	O
the	O
rank	O
order	O
of	O
potency	O
for	O
different	O
corticosteroids	O
in	O
inhibiting	O
the	O
generation	O
of	O
a	O
3	O
kD	O
molecule	O
from	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
corticosteroid-sensitive	O
(	O
CS	O
)	O
and	O
corticosteroid-resistant	O
(	O
CR	O
)	O
asthmatic	O
subjects	O
,	O
which	O
augments	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
generation	O
by	O
human	O
neutrophils	O
(	O
PMN	O
)	O
stimulated	O
by	O
calcium	O
ionophore	O
.	O

In	O
addition	O
,	O
binding	O
studies	O
with	O
(	O
3H	O
)	O
dexamethasone	O
have	O
been	O
performed	O
to	O
determine	O
the	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
receptor	O
numbers	O
(	O
Ro	O
)	O
in	O
the	O
monocytes	O
of	O
these	O
two	O
groups	O
of	O
subjects	O
.	O

The	O
concentration	O
of	O
corticosteroid	O
producing	O
50	O
%	O
inhibition	O
(	O
IC50	O
)	O
was	O
600	O
nM	O
,	O
70	O
nM	O
,	O
and	O
0.5	O
nM	O
for	O
hydrocortisone	O
,	O
methylprednisolone	O
,	O
and	O
dexamethasone	O
,	O
respectively	O
,	O
in	O
monocytes	O
from	O
CS	O
individuals	O
.	O

There	O
was	O
only	O
weak	O
inhibition	O
of	O
the	O
generation	O
of	O
enhancing	O
activity	O
by	O
the	O
corticosteroids	O
in	O
the	O
CR	O
asthmatic	O
individuals	O
.	O

The	O
dexamethasone	O
Kd	O
was	O
2.45	O
	O
0.58	O
nM	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CS	O
group	O
and	O
1.6	O
	O
0.35	O
nM	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
of	O
patients	O
(	O
p	O
=	O
0.14	O
)	O
.	O

The	O
Ro	O
in	O
the	O
CS	O
group	O
was	O
3,605	O
	O
984	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
and	O
4,757	O
	O
692	O
binding	O
sites	O
per	O
nucleus	O
(	O
mean	O
	O
SEM	O
,	O
n	O
=	O
6	O
)	O
in	O
the	O
CR	O
group	O
(	O
p	O
=	O
0.23	O
)	O
.	O

These	O
findings	O
indicate	O
that	O
corticosteroid	O
resistance	O
in	O
bronchial	O
asthma	O
can	O
not	O
be	O
explained	O
by	O
abnormalities	O
in	O
corticosteroid	O
receptor	O
characteristics	O
.	O

Tissue-specific	O
expression	O
of	O
the	O
platelet	O
GPIIb	O
gene	O
.	O

One	O
of	O
the	O
major	O
objectives	O
in	O
the	O
study	O
of	O
thrombogenesis	O
is	O
to	O
determine	O
the	O
mechanisms	O
by	O
which	O
a	O
hematopoietic	O
progenitor	O
is	O
activated	O
and	O
committed	O
to	O
the	O
megakaryocytic	O
lineage	O
.	O

Recent	O
development	O
of	O
primary	O
cultures	O
of	O
human	O
megakaryocytes	O
and	O
the	O
molecular	O
cloning	O
of	O
genes	O
that	O
are	O
specific	O
to	O
this	O
lineage	O
offer	O
the	O
possibility	O
of	O
getting	O
some	O
insights	O
into	O
the	O
genetic	O
mechanisms	O
that	O
control	O
megakaryocytopoiesis	O
.	O

One	O
gene	O
of	O
interest	O
is	O
the	O
glycoprotein	O
IIb	O
(	O
GPIIb	O
)	O
gene	O
;	O

GPIIb	O
,	O
the	O
alpha	O
subunit	O
of	O
the	O
platelet	O
cytoadhesin	O
GPIIb-IIIa	O
,	O
is	O
produced	O
in	O
megakaryocytes	O
at	O
an	O
early	O
stage	O
of	O
the	O
differentiation	O
,	O
whereas	O
the	O
other	O
subunit	O
of	O
this	O
complex	O
,	O
GPIIIa	O
,	O
is	O
expressed	O
in	O
other	O
cells	O
.	O

For	O
these	O
reasons	O
,	O
the	O
5'-flanking	O
region	O
of	O
the	O
GPIIb	O
gene	O
was	O
used	O
to	O
identify	O
the	O
regions	O
that	O
interact	O
with	O
DNA-binding	O
nuclear	O
factors	O
.	O

A	O
fragment	O
extending	O
from	O
-643	O
to	O
+33	O
is	O
capable	O
of	O
controlling	O
the	O
tissue-specific	O
expression	O
of	O
the	O
CAT	O
gene	O
in	O
transfection	O
experiments	O
.	O

Within	O
this	O
region	O
,	O
we	O
have	O
identified	O
several	O
sequences	O
that	O
are	O
implicated	O
in	O
DNA	O
protein	O
interactions	O
as	O
shown	O
in	O
DNAse	O
I	O
footprints	O
and	O
gel	O
mobility	O
shift	O
assays	O
.	O

One	O
region	O
,	O
centered	O
at	O
-54	O
,	O
is	O
similar	O
to	O
a	O
nuclear	O
factor	O
E1-binding	O
site	O
,	O
and	O
a	O
region	O
located	O
at	O
position	O
-233	O
contains	O
a	O
CCAAT	O
motif	O
.	O

Two	O
domains	O
centered	O
at	O
positions	O
-345	O
and	O
-540	O
,	O
respectively	O
,	O
bind	O
proteins	O
that	O
are	O
present	O
in	O
megakaryocytic	O
cells	O
and	O
nonrelated	O
cells	O
as	O
well	O
.	O

Finally	O
,	O
two	O
other	O
domains	O
,	O
located	O
at	O
positions	O
-460	O
and	O
-510	O
,	O
interact	O
with	O
proteins	O
that	O
are	O
only	O
present	O
in	O
megakaryocytic	O
cells	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
region	O
containing	O
these	O
two	O
domains	O
results	O
in	O
a	O
significant	O
decrease	O
of	O
the	O
promoter	O
activity	O
.	O

It	O
is	O
very	O
likely	O
that	O
these	O
domains	O
bind	O
megakaryocyte-specific	O
nuclear	O
proteins	O
acting	O
as	O
positive	O
transcription	O
factors	O
.	O

Inhibition	O
of	O
protein	O
phosphatases	O
by	O
okadaic	O
acid	O
induces	O
AP1	O
in	O
human	O
T	O
cells	O
.	O

To	O
examine	O
the	O
role	O
of	O
protein	O
phosphatases	O
in	O
T	O
cell	O
activation	O
,	O
Jurkat	O
cells	O
were	O
treated	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
phosphatases	O
,	O
and	O
nuclear	O
extracts	O
were	O
examined	O
for	O
the	O
presence	O
of	O
AP1	O
as	O
a	O
measure	O
of	O
early	O
T	O
cell	O
activation	O
.	O

Okadaic	O
acid	O
was	O
found	O
to	O
be	O
a	O
potent	O
inducer	O
of	O
AP1	O
.	O

In	O
contrast	O
to	O
phorbol	O
esters	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
occurs	O
predominantly	O
by	O
transcriptional	O
activation	O
of	O
the	O
jun	O
and	O
fos	O
family	O
of	O
proto-oncogenes	O
.	O

Surprisingly	O
,	O
while	O
the	O
addition	O
of	O
phytohemagglutinin	O
further	O
enhanced	O
the	O
induction	O
of	O
AP1	O
,	O
the	O
addition	O
of	O
PMA	O
inhibited	O
it	O
.	O

Okadaic	O
acid	O
treatment	O
was	O
found	O
to	O
dramatically	O
increase	O
mRNA	O
transcripts	O
of	O
the	O
jun	O
family	O
of	O
proto-oncogenes	O
including	O
c-jun	O
,	O
junD	O
,	O
and	O
junB	O
and	O
to	O
a	O
lesser	O
extent	O
the	O
fos	O
family	O
including	O
c-fos	O
and	O
fra-1	O
.	O

By	O
comparison	O
,	O
PMA	O
is	O
a	O
very	O
inefficient	O
inducer	O
of	O
the	O
jun	O
gene	O
family	O
in	O
Jurkat	O
cells	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
the	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
,	O
PMA	O
inhibits	O
the	O
induction	O
of	O
c-jun	O
mRNA	O
by	O
okadaic	O
acid	O
.	O

Transfection	O
of	O
c-jun	O
promoter	O
constructs	O
confirmed	O
the	O
marked	O
difference	O
between	O
PMA	O
and	O
okadaic	O
acid	O
in	O
inducing	O
c-jun	O
transcription	O
.	O

The	O
induction	O
of	O
AP1	O
by	O
okadaic	O
acid	O
suggests	O
that	O
protein	O
phosphatases	O
1	O
and	O
2A	O
(	O
PP1	O
and	O
PP2A	O
)	O
may	O
be	O
involved	O
in	O
T	O
cell	O
activation	O
as	O
important	O
negative	O
regulators	O
of	O
the	O
transcription	O
factor	O
AP1	O
.	O

Demonstration	O
of	O
estrogen	O
and	O
progesterone	O
receptors	O
as	O
well	O
as	O
Ki-67	O
and	O
p-145	O
antigens	O
in	O
single	O
tumor	O
cells	O
from	O
blood	O
and	O
pleural	O
effusions	O
using	O
a	O
slide	O
assay	O
.	O

We	O
describe	O
a	O
slide	O
assay	O
that	O
allows	O
the	O
demonstration	O
of	O
antigens	O
localized	O
in	O
the	O
nucleus	O
from	O
isolated	O
white	O
blood	O
cells	O
as	O
well	O
as	O
from	O
single	O
tumor	O
cells	O
derived	O
from	O
malignant	O
effusions	O
.	O

With	O
the	O
antibodies	O
Ki-67	O
and	O
anti-p-145	O
an	O
increased	O
rate	O
of	O
nuclear	O
and	O
nucleolar	O
staining	O
resulted	O
in	O
cells	O
from	O
highly	O
malignant	O
lymphomas	O
.	O

An	O
almost	O
identical	O
reaction	O
was	O
obtained	O
when	O
tumor	O
cells	O
from	O
malignant	O
effusions	O
were	O
tested	O
.	O

Cells	O
isolated	O
from	O
the	O
blood	O
of	O
patients	O
with	O
leukemic	O
spread	O
of	O
lymphomas	O
of	O
low	O
malignancy	O
yielded	O
a	O
weak	O
staining	O
comparable	O
to	O
that	O
of	O
normal	O
mesothelial	O
cells	O
from	O
non-tumorous	O
cavity	O
fluids	O
.	O

The	O
detection	O
of	O
estrogen	O
and	O
progesterone	O
receptors	O
(	O
ER	O
and	O
PR	O
)	O
localized	O
in	O
the	O
cell	O
nucleus	O
can	O
be	O
achieved	O
by	O
the	O
same	O
assay	O
.	O

The	O
reaction	O
is	O
enhanced	O
by	O
incubation	O
of	O
the	O
tumor	O
cells	O
for	O
30	O
min	O
at	O
37	O
degrees	O
C	O
prior	O
to	O
fixation	O
.	O

Pleural	O
effusions	O
from	O
20	O
patients	O
with	O
breast	O
cancer	O
were	O
tested	O
.	O

ER	O
was	O
positive	O
in	O
13	O
and	O
PR	O
was	O
positive	O
in	O
12	O
of	O
the	O
20	O
samples	O
.	O

In	O
5	O
cases	O
there	O
was	O
a	O
divergent	O
reaction	O
with	O
ER	O
and	O
PR	O
antibody	O
.	O

The	O
hormone	O
receptors	O
of	O
the	O
primary	O
tumor	O
were	O
known	O
in	O
15	O
(	O
ER	O
)	O
and	O
14	O
(	O
PR	O
)	O
patients	O
,	O
respectively	O
.	O

In	O
each	O
cohort	O
there	O
was	O
only	O
one	O
case	O
with	O
a	O
negative	O
reaction	O
of	O
the	O
primary	O
tumor	O
and	O
a	O
positive	O
reaction	O
with	O
the	O
isolated	O
tumor	O
cells	O
from	O
the	O
pleural	O
effusions	O
.	O

These	O
results	O
indicate	O
that	O
the	O
demonstration	O
of	O
hormone	O
receptor	O
proteins	O
in	O
cells	O
from	O
malignant	O
effusions	O
is	O
possible	O
and	O
that	O
there	O
is	O
a	O
correlation	O
with	O
the	O
status	O
of	O
the	O
primary	O
site	O
of	O
cancer	O
.	O

Transforming	O
growth	O
factor-beta	O
suppresses	O
human	O
B	O
lymphocyte	O
Ig	O
production	O
by	O
inhibiting	O
synthesis	O
and	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
form	O
of	O
Ig	O
mRNA	O
.	O

Transforming	O
growth	O
factor-beta	O
(	O
TGF-beta	O
)	O
inhibits	O
B	O
cell	O
Ig	O
secretion	O
and	O
reduces	O
B	O
cell	O
membrane	O
Ig	O
expression	O
.	O

The	O
addition	O
of	O
TGF-beta	O
to	O
human	O
B	O
lymphocyte	O
cultures	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
Cowan	O
strain	O
I	O
and	O
IL-2	O
completely	O
inhibited	O
B	O
cell	O
Ig	O
secretion	O
(	O
greater	O
than	O
90	O
%	O
)	O
and	O
decreased	O
B	O
cell	O
surface	O
IgM	O
,	O
IgD	O
,	O
kappa	O
L	O
chain	O
,	O
and	O
lambda	O
L	O
chain	O
expression	O
.	O

In	O
contrast	O
,	O
TGF-beta	O
had	O
only	O
minimal	O
effects	O
on	O
two	O
other	O
B	O
cell	O
membrane	O
proteins	O
,	O
HLA-DR	O
and	O
CD20	O
.	O

Internal	O
labeling	O
with	O
[	O
35S	O
]	O
methionine	O
and	O
immunoprecipitation	O
with	O
anti-IgM	O
,	O
anti-kappa	O
,	O
and	O
anti-lambda	O
antibodies	O
revealed	O
a	O
striking	O
reduction	O
in	O
kappa	O
L	O
chain	O
in	O
the	O
presence	O
of	O
TGF-beta	O
.	O

A	O
less	O
pronounced	O
reduction	O
in	O
lambda	O
L	O
chain	O
and	O
microH	O
chain	O
was	O
also	O
noted	O
.	O

Northern	O
blot	O
analysis	O
of	O
RNA	O
purified	O
from	O
B	O
cells	O
treated	O
with	O
TGF-beta	O
for	O
varying	O
time	O
intervals	O
revealed	O
a	O
significant	O
decrease	O
in	O
steady	O
state	O
kappa	O
and	O
lambda	O
L	O
chain	O
mRNA	O
levels	O
.	O

Furthermore	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
switch	O
from	O
the	O
membrane	O
forms	O
of	O
mu	O
and	O
gamma	O
to	O
their	O
respective	O
secreted	O
forms	O
was	O
noted	O
in	O
the	O
presence	O
of	O
TGF-beta	O
.	O

Nuclear	O
run-on	O
experiments	O
demonstrated	O
decreased	O
transcription	O
of	O
kappa	O
L	O
chain	O
.	O

The	O
effects	O
of	O
TGF-beta	O
on	O
two	O
transcriptional	O
regulatory	O
factors	O
,	O
Oct-2	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
kappa	O
B	O
,	O
known	O
to	O
be	O
important	O
in	O
Ig	O
gene	O
transcription	O
were	O
examined	O
.	O

Oct-2	B-Negation
mRNA	I-Negation
levels	I-Negation
and	I-Negation
both	I-Negation
Oct-2	I-Negation
and	I-Negation
NF-kappa	I-Negation
B	I-Negation
proteins	I-Negation
in	I-Negation
nuclear	I-Negation
extracts	I-Negation
were	I-Negation
not	I-Negation
altered	I-Negation
by	I-Negation
treatment	I-Negation
with	I-Negation
TGF-beta	I-Negation
.	O

In	O
contrast	O
,	O
levels	O
of	O
the	O
transcriptional	O
factor	O
AP-1	O
,	O
which	B-Negation
is	I-Negation
not	I-Negation
known	I-Negation
to	I-Negation
be	I-Negation
important	I-Negation
in	I-Negation
B	I-Negation
cell	I-Negation
Ig	I-Negation
production	I-Negation
,	O
were	O
reduced	O
by	O
TGF-beta	O
.	O

These	O
findings	O
demonstrate	O
that	O
TGF-beta	O
decreases	O
B	O
lymphocyte	O
Ig	O
secretion	O
by	O
inhibiting	O
the	O
synthesis	O
of	O
Ig	O
mRNA	O
and	O
inhibiting	O
the	O
switch	O
from	O
the	O
membrane	O
form	O
to	O
the	O
secreted	O
forms	O
of	O
mu	O
and	O
gamma	O
mRNA	O
.	O

The	B-Speculation
mechanism	I-Speculation
by	I-Speculation
which	I-Speculation
TGF-beta	I-Speculation
inhibits	I-Speculation
Ig	I-Speculation
chain	I-Speculation
synthesis	I-Speculation
is	I-Speculation
unclear	I-Speculation
although	O
it	O
does	O
not	B-Negation
involve	I-Negation
inhibition	I-Negation
of	I-Negation
the	I-Negation
binding	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
or	I-Negation
Oct-2	I-Negation
to	I-Negation
their	I-Negation
respective	I-Negation
target	I-Negation
sequences	I-Negation
.	O

Differentiation-associated	O
expression	O
of	O
the	O
Epstein-Barr	O
virus	O
BZLF1	O
transactivator	O
protein	O
in	O
oral	O
hairy	O
leukoplakia	O
.	O

The	O
BZLF1	O
protein	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
a	O
key	O
immediate-early	O
protein	O
which	O
has	O
been	O
shown	O
to	O
disrupt	O
virus	O
latency	O
in	O
EBV-infected	O
B	O
cells	O
.	O

We	O
have	O
generated	O
a	O
monoclonal	O
antibody	O
,	O
BZ1	O
,	O
to	O
BZLF1	O
which	O
reacts	O
in	O
immunohistology	O
,	O
immunoblotting	O
,	O
and	O
immunoprecipitation	O
and	O
which	O
recognizes	O
both	O
the	O
active	O
,	O
dimeric	O
form	O
and	O
the	O
inactive	O
,	O
monomeric	O
form	O
of	O
the	O
protein	O
.	O

Biopsies	O
of	O
oral	O
hairy	O
leukoplakia	O
,	O
an	O
AIDS-associated	O
lesion	O
characterized	O
by	O
high-level	O
EBV	O
replication	O
,	O
were	O
examined	O
by	O
immunohistochemistry	O
using	O
the	O
BZ1	O
monoclonal	O
antibody	O
.	O

A	O
differentiation-associated	O
pattern	O
of	O
BZLF1	O
expression	O
was	O
observed	O
,	O
BZ1	O
reacting	O
with	O
nuclei	O
of	O
the	O
upper	O
spinous	O
layer	O
of	O
the	O
lesion	O
.	O

This	O
finding	O
suggests	O
that	O
the	O
BZLF1	O
promoter	O
may	O
be	O
regulated	O
by	O
the	O
degree	O
of	O
squamous	O
differentiation	O
.	O

A	O
comparison	O
of	O
in	O
situ	O
hybridization	O
to	O
EBV	O
DNA	O
and	O
viral	O
capsid	O
antigen	O
staining	O
with	O
BZ1	O
reactivity	O
suggested	O
that	O
BZLF1	O
expression	O
precedes	O
rampant	O
virus	O
replication	O
.	O

The	O
inability	O
to	O
detect	O
EBV	O
in	O
the	O
lower	O
epithelial	O
layers	O
of	O
oral	O
hairy	O
leukoplakia	O
raises	O
questions	O
concerning	O
the	O
nature	O
of	O
EBV	O
latency	O
and	O
persistence	O
in	O
stratified	O
squamous	O
epithelium	O
.	O

Transactivation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
promoter	O
by	O
human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
strains	O
GS	O
and	O
Z-29	O
in	O
primary	O
human	O
T	O
lymphocytes	O
and	O
identification	O
of	O
transactivating	O
HHV-6	O
(	O
GS	O
)	O
gene	O
fragments	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
and	O
accelerate	O
cytopathic	O
effects	O
in	O
HIV-infected	O
human	O
T	O
cells	O
.	O

This	O
study	O
examines	O
the	O
regions	O
of	O
the	O
HIV	O
promoter	O
required	O
for	O
HHV-6	O
transactivation	O
in	O
a	O
heterogeneous	O
population	O
of	O
primary	O
human	O
T	O
lymphocytes	O
with	O
or	O
without	B-Negation
antigenic	I-Negation
stimulation	I-Negation
.	O

Two	O
different	O
strains	O
of	O
HHV-6	O
,	O
GS	O
and	O
Z29	O
,	O
transactivated	O
the	O
HIV	O
promoter	O
.	O

The	O
GS	O
strain	O
transactivated	O
the	O
promoter	O
in	O
both	O
stimulated	O
and	O
resting	O
T	O
cells	O
,	O
while	O
the	O
Z29	O
strain	O
increased	O
HIV	O
promoter	O
activity	O
only	O
in	O
stimulated	O
T	O
cells	O
.	O

Three	O
DNA	O
clones	O
containing	O
HHV-6	O
(	O
GS	O
)	O
genomic	O
fragments	O
transactivated	O
the	O
HIV	O
promoter	O
in	O
cotransfected	O
T	O
cells	O
.	O

A	O
21.4-kb	O
DNA	O
clone	O
,	O
pZVB70	O
,	O
showed	O
the	O
highest	O
transactivating	O
ability	O
,	O
while	O
two	O
other	O
DNA	O
fragments	O
,	O
pZVB10	O
(	O
6.2	O
kb	O
)	O
and	O
pZVH14	O
(	O
8.7	O
kb	O
)	O
,	O
showed	O
lower	O
activity	O
.	O

One	O
of	O
these	O
clones	O
,	O
pZVH14	O
,	O
activated	O
the	O
HIV	O
promoter	O
construct	O
containing	O
a	O
mutation	O
in	O
the	O
NF	O
kappa	O
B	O
site	O
.	O

However	O
,	O
this	B-Negation
mutated	I-Negation
NF	I-Negation
kappa	I-Negation
B	I-Negation
promoter	I-Negation
was	I-Negation
not	I-Negation
transactivated	I-Negation
during	I-Negation
HHV-6	I-Negation
(	I-Negation
GS	I-Negation
)	I-Negation
infection	I-Negation
or	I-Negation
after	I-Negation
cotransfection	I-Negation
with	I-Negation
pZVB70	I-Negation
or	I-Negation
pZVB10	I-Negation
.	O

These	O
data	O
indicate	O
that	O
the	O
NF	O
kappa	O
B	O
sites	O
of	O
the	O
HIV	O
promoter	O
are	O
essential	O
for	O
its	O
transactivation	O
during	O
HHV-6	O
(	O
GS	O
)	O
infection	O
.	O

By	O
increasing	O
HIV	O
promoter	O
activity	O
in	O
primary	O
T	O
lymphocytes	O
,	O
HHV-6	O
may	O
consequently	O
increase	O
HIV	O
replication	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
cytopathic	O
effect	O
on	O
coinfected	O
human	O
T	O
cells	O
.	O

The	O
rhombotin	O
family	O
of	O
cysteine-rich	O
LIM-domain	O
oncogenes	O
:	O
distinct	O
members	O
are	O
involved	O
in	O
T-cell	O
translocations	O
to	O
human	O
chromosomes	O
11p15	O
and	O
11p13	O
.	O

A	O
chromosomal	O
translocation	O
in	O
a	O
T-cell	O
leukemia	O
involving	O
the	O
short	O
arm	O
of	O
human	O
chromosome	O
11	O
at	O
band	O
11p15	O
disrupts	O
the	O
rhombotin	O
gene	O
.	O

This	O
gene	O
encodes	O
a	O
protein	O
with	O
duplicated	O
cysteine-rich	O
regions	O
called	O
LIM	O
domains	O
,	O
which	O
show	O
homology	O
to	O
zinc-binding	O
proteins	O
and	O
to	O
iron-sulfur	O
centers	O
of	O
ferredoxins	O
.	O

Two	O
homologues	O
of	O
the	O
rhombotin	O
gene	O
have	O
now	O
been	O
isolated	O
.	O

One	O
of	O
these	O
,	O
designated	O
Rhom-2	O
,	O
is	O
located	O
on	O
human	O
chromosome	O
11	O
at	O
band	O
11p13	O
,	O
where	O
a	O
cluster	O
of	O
T-cell	O
leukemia-specific	O
translocations	O
occur	O
;	O

all	O
translocation	O
breakpoints	O
at	O
11p13	O
are	O
upstream	O
of	O
the	O
Rhom-2	O
gene	O
.	O

Human	O
and	O
mouse	O
Rhom-2	O
are	O
highly	O
conserved	O
and	O
,	O
like	O
rhombotin	O
,	O
encode	O
two	O
tandem	O
cysteine-rich	O
LIM	O
domains	O
.	O

Rhom-2	O
mRNA	O
is	O
expressed	O
in	O
early	O
mouse	O
development	O
in	O
central	O
nervous	O
system	O
,	O
lung	O
,	O
kidney	O
,	O
liver	O
,	O
and	O
spleen	O
but	O
only	O
very	O
low	O
levels	O
occur	O
in	O
thymus	O
.	O

The	O
other	O
gene	O
,	O
designated	O
Rhom-3	O
,	O
is	O
not	B-Negation
on	I-Negation
chromosome	I-Negation
11	I-Negation
but	O
also	O
retains	O
homology	O
to	O
the	O
LIM	O
domain	O
of	O
rhombotin	O
.	O

Since	O
the	O
Rhom-2	O
gene	O
is	O
such	O
a	O
common	O
site	O
of	O
chromosomal	O
damage	O
in	O
T-cell	O
tumors	O
,	O
the	O
consistency	O
of	O
translocations	O
near	O
the	O
rhombotin	O
gene	O
was	O
further	O
examined	O
.	O

A	O
second	O
translocation	O
adjacent	O
to	O
rhombotin	O
was	O
found	O
and	O
at	O
the	O
same	O
position	O
as	O
in	O
the	O
previous	O
example	O
.	O

Therefore	O
,	O
chromosome	O
bands	O
11p15	O
(	O
rhombotin	O
)	O
and	O
11p13	O
(	O
Rhom-2	O
)	O
are	O
consistent	O
sites	O
of	O
chromosome	O
translocation	O
in	O
T-cell	O
leukemia	O
,	O
with	O
the	O
11p15	O
target	O
more	O
rarely	O
involved	O
.	O

The	O
results	O
define	O
the	O
rhombotin	O
gene	O
family	O
as	O
a	O
class	O
of	O
T-cell	O
oncogenes	O
with	O
duplicated	O
cysteine-rich	O
LIM	O
domains	O
.	O

The	O
human	O
myelomonocytic	O
cell	O
line	O
U-937	O
as	O
a	O
model	O
for	O
studying	O
alterations	O
in	O
steroid-induced	O
monokine	O
gene	O
expression	O
:	O
marked	O
enhancement	O
of	O
lipopolysaccharide-stimulated	O
interleukin-1	O
beta	O
messenger	O
RNA	O
levels	O
by	O
1,25-dihydroxyvitamin	O
D3	O
.	O

The	O
active	O
metabolite	O
of	O
vitamin	O
D	O
,	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25-	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
is	O
a	O
potent	O
regulator	O
of	O
human	O
monocyte/macrophage	O
function	O
in	O
vitro	O
.	O

To	O
establish	O
a	O
model	O
for	O
1,25-	O
(	O
OH	O
)	O
2D3	O
regulation	O
of	O
human	O
monocyte	O
monokine	O
synthesis	O
,	O
three	O
human	O
cell	O
lines	O
(	O
U-937	O
,	O
THP-1	O
,	O
and	O
HL-60	O
)	O
were	O
examined	O
for	O
:	O
1	O
)	O
the	O
presence	O
of	O
functional	O
1,25-	O
(	O
OH	O
)	O
2D3	O
receptors	O
;	O
2	O
)	O
the	O
accumulation	O
of	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
mRNA	O
and	O
IL-1	O
beta	O
protein	O
in	O
response	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
;	O
and	O
3	O
)	O
the	O
regulation	O
of	O
this	O
response	O
by	O
1,25-	O
(	O
OH	O
)	O
2D3	O
.	O

All	O
three	O
cell	O
lines	O
expressed	O
vitamin	O
D	O
receptor	O
and	O
had	O
increased	O
levels	O
of	O
IL-1	O
beta	O
mRNA	O
in	O
response	O
to	O
LPS	O
.	O

Preincubation	O
of	O
cells	O
with	O
1,25-	O
(	O
OH	O
)	O
2D3	O
augmented	O
IL-1	O
beta	O
mRNA	O
levels	O
only	O
in	O
U-937	O
and	O
HL-60	O
cells	O
.	O

From	O
these	O
data	O
,	O
and	O
taking	O
into	O
consideration	O
their	O
state	O
of	O
differentiation	O
and	O
relative	O
ease	O
of	O
culture	O
,	O
U-937	O
was	O
chosen	O
over	O
HL-60	O
and	O
THP-1	O
as	O
the	O
cell	O
line	O
we	O
further	O
characterized	O
.	O

In	O
U-937	O
cells	O
,	O
optimum	O
time	O
and	O
dose	O
of	O
pretreatment	O
with	O
1,25-	O
(	O
OH	O
)	O
2D3	O
were	O
determined	O
to	O
be	O
12-24	O
h	O
at	O
a	O
receptor	O
saturating	O
concentration	O
of	O
1,25-	O
(	O
OH	O
)	O
2D3	O
(	O
10	O
nM	O
)	O
.	O

Preincubation	O
of	O
cells	O
with	O
1,25-	O
(	O
OH	O
)	O
2D3	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
time	I-Negation
course	I-Negation
of	I-Negation
IL-1	I-Negation
beta	I-Negation
mRNA	I-Negation
appearance	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
LPS	I-Negation
.	O

However	O
,	O
exposure	O
of	O
U-937	O
cells	O
to	O
1,25-	O
(	O
OH	O
)	O
2D3	O
increased	O
by	O
200	O
%	O
the	O
level	O
of	O
IL-1	O
beta	O
mRNA	O
detected	O
and	O
decreased	O
by	O
three	O
orders	O
of	O
magnitude	O
the	O
concentration	O
of	O
LPS	O
required	O
to	O
achieve	O
steady	O
state	O
mRNA	O
levels	O
equivalent	O
to	O
those	O
observed	O
in	O
U-937	O
cells	O
not	B-Negation
preincubated	I-Negation
with	I-Negation
the	I-Negation
hormone.2+o	I-Negation

Cortivazol	O
mediated	O
induction	O
of	O
glucocorticoid	O
receptor	O
messenger	O
ribonucleic	O
acid	O
in	O
wild-type	O
and	O
dexamethasone-resistant	O
human	O
leukemic	O
(	O
CEM	O
)	O
cells	O
.	O

Cortivazol	O
is	O
a	O
phenylpyrazolo	O
glucocorticoid	O
of	O
high	O
potency	O
and	O
unusual	O
structure	O
.	O

In	O
both	O
wild-type	O
and	O
highly	O
dexamethasone	O
(	O
dex	O
)	O
-resistant	O
clones	O
of	O
the	O
human	O
leukemic	O
cell	O
line	O
CEM	O
,	O
exposure	O
to	O
cortivazol	O
leads	O
to	O
cell	O
death	O
.	O

It	O
has	O
been	O
shown	O
recently	O
that	O
in	O
wild-type	O
CEM	O
cells	O
but	O
not	B-Negation
in	I-Negation
a	I-Negation
dex-resistant	I-Negation
,	I-Negation
glucocorticoid	I-Negation
receptor	I-Negation
(	I-Negation
GR	I-Negation
)	I-Negation
-defective	O
clone	O
ICR-27	O
TK-3	O
,	O
dex	O
induces	O
GR	O
mRNA	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
cortivazol	O
acts	O
in	O
dex-resistant	O
cells	O
by	O
making	O
use	O
of	O
the	O
residual	O
GR	O
found	O
there	O
,	O
wild-type	O
and	O
dex-resistant	O
clones	O
were	O
treated	O
with	O
various	O
concentrations	O
of	O
cortivazol	O
and	O
induction	O
of	O
GR	O
mRNA	O
was	O
studied	O
.	O

Cortivazol	O
significantly	O
induced	O
GR	O
mRNA	O
in	O
the	O
normal	O
CEM-C7	O
as	O
well	O
as	O
in	O
two	O
classes	O
of	O
dex-resistant	O
clones	O
,	O
although	O
the	O
dex-resistant	O
clones	O
needed	O
at	O
least	O
10	O
times	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
significant	O
GR	O
mRNA	O
induction	O
.	O

Increased	O
levels	O
of	O
GR	O
mRNA	O
were	O
noticed	O
as	O
early	O
as	O
3	O
h	O
after	O
treatment	O
.	O

A	O
general	O
correlation	O
between	O
induction	O
of	O
GR	O
mRNA	O
and	O
lysis	O
of	O
the	O
normal	O
and	O
dex-resistant	O
cells	O
was	O
found	O
.	O

Positive	O
induction	O
of	O
GR	O
mRNA	O
might	O
be	O
one	O
of	O
the	O
earliest	O
crucial	O
steps	O
in	O
the	O
lysis	O
of	O
normal	O
and	O
dex-resistant	O
CEM	O
cells	O
,	O
or	O
might	O
serve	O
as	O
a	O
marker	O
for	O
the	O
process	O
.	O

However	O
,	O
the	O
lysis	O
pathway	O
in	O
the	O
dex-resistant	O
cells	O
is	O
defective	O
in	O
that	O
dex-resistant	O
clones	O
needed	O
significantly	O
more	O
cortivazol	O
than	O
the	O
normal	O
cells	O
for	O
lysis	O
of	O
the	O
cells	O
.	O

Expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
on	O
alveolar	O
lymphocytes	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
is	O
known	O
to	O
be	O
produced	O
at	O
sites	O
of	O
granulomatous	O
reactions	O
.	O

In	O
order	O
to	O
characterize	O
the	O
cell	O
types	O
that	O
are	O
targets	O
for	O
this	O
immunoregulatory	O
hormone	O
,	O
we	O
have	O
evaluated	O
the	O
expression	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
on	O
peripheral	O
blood	O
T-lymphocytes	O
and	O
those	O
recovered	O
from	O
the	O
lung	O
by	O
bronchoalveolar	O
lavage	O
from	O
patients	O
with	O
pulmonary	O
granulomatous	O
diseases	O
(	O
tuberculosis	O
and	O
sarcoidosis	O
)	O
and	O
from	O
normal	O
control	O
subjects	O
using	O
combined	O
autoradiographic	O
and	O
immunohistochemical	O
techniques	O
.	O

Lavage	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
or	O
with	O
sarcoidosis	O
,	O
but	O
not	B-Negation
those	I-Negation
from	I-Negation
normal	I-Negation
control	I-Negation
subjects	I-Negation
,	O
expressed	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
as	O
demonstrated	O
by	O
binding	O
of	O
[	O
3H	O
]	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
which	O
was	O
inhibited	O
by	O
the	O
presence	O
of	O
excess	O
unlabeled	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
but	O
not	B-Negation
by	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
unlabeled	I-Negation
25	I-Negation
(	I-Negation
OH	I-Negation
)	I-Negation
D3	I-Negation
(	I-Negation
receptor-positive	I-Negation
lymphocytes	I-Negation
:	O
sarcoidosis	O
,	O
20	O
	O
12	O
%	O
;	O
tuberculosis	O
,	O
31	O
	O
17	O
%	O
)	O
.	O

In	O
contrast	O
,	O
blood	O
lymphocytes	O
from	O
patients	O
with	O
granulomatous	O
diseases	O
did	O
not	B-Negation
express	I-Negation
detectable	I-Negation
1,25	I-Negation
(	I-Negation
OH	I-Negation
)	I-Negation
2D3	I-Negation
receptors	I-Negation
.	O

The	O
percentage	O
of	O
lavage	O
T-lymphocytes	O
expressing	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
was	O
significantly	O
greater	O
for	O
patients	O
with	O
tuberculosis	O
presenting	O
with	O
isolated	O
hilar	O
adenopathy	O
than	O
for	O
patients	O
with	O
pulmonary	O
infiltrates	O
and/or	O
cavities	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
receptors	O
were	O
expressed	O
to	O
a	O
greater	O
extent	O
on	O
CD8+	O
T-lymphocytes	O
than	O
on	O
CD4+	O
T-lymphocytes	O
in	O
sarcoidosis	O
,	O
whereas	O
a	O
greater	O
proportion	O
of	O
CD4+	O
than	O
of	O
CD8+	O
T-lymphocytes	O
from	O
patients	O
with	O
tuberculosis	O
were	O
receptor-positive	O
.	O

These	O
findings	O
support	O
the	O
conclusion	O
that	O
the	O
interaction	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
with	O
its	O
receptor	O
on	O
T-lymphocytes	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
granulomatous	O
reactions	O
,	O
but	O
because	O
these	O
receptors	O
are	O
expressed	O
on	O
different	O
lymphocyte	O
populations	O
,	O
the	O
net	O
effect	O
of	O
this	O
potent	O
immunoregulatory	O
molecule	O
is	O
likely	O
different	O
in	O
sarcoidosis	O
and	O
tuberculosis	O
.	O

Inhibition	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
rel/NF-kappa	O
B	O
family	O
by	O
a	O
transdominant	O
negative	O
mutant	O
.	O

The	O
KBF1	O
factor	O
,	O
which	O
binds	O
to	O
the	O
enhancer	O
A	O
located	O
in	O
the	O
promoter	O
of	O
the	O
mouse	O
MHC	O
class	O
I	O
gene	O
H-2Kb	O
,	O
is	O
indistinguishable	O
from	O
the	O
p50	O
DNA	O
binding	O
subunit	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
,	O
which	O
regulates	O
a	O
series	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

The	O
KBF1/p50	O
factor	O
binds	O
as	O
a	O
homodimer	O
but	O
can	O
also	O
form	O
heterodimers	O
with	O
the	O
products	O
of	O
other	O
members	O
of	O
the	O
same	O
family	O
,	O
like	O
the	O
c-rel	O
and	O
v-rel	O
(	O
proto	O
)	O
oncogenes	O
.	O

The	O
dimerization	O
domain	O
of	O
KBF1/p50	O
is	O
contained	O
between	O
amino	O
acids	O
201	O
and	O
367	O
.	O

A	O
mutant	O
of	O
KBF1/p50	O
(	O
delta	O
SP	O
)	O
,	O
unable	B-Negation
to	I-Negation
bind	I-Negation
to	I-Negation
DNA	I-Negation
but	O
able	O
to	O
form	O
homo-	O
or	O
heterodimers	O
,	O
has	O
been	O
constructed	O
.	O

This	O
protein	O
reduces	O
or	O
abolishes	O
in	O
vitro	O
the	O
DNA	O
binding	O
activity	O
of	O
wild-type	O
proteins	O
of	O
the	O
same	O
family	O
(	O
KBF1/p50	O
,	O
c-	O
and	O
v-rel	O
)	O
.	O

This	O
mutant	O
also	O
functions	O
in	O
vivo	O
as	O
a	O
trans-acting	O
dominant	O
negative	O
regulator	O
:	O

the	O
transcriptional	O
inducibility	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
which	O
contains	O
two	O
potential	O
NF-kappa	O
B	O
binding	O
sites	O
)	O
by	O
phorbol	O
ester	O
(	O
PMA	O
)	O
is	O
inhibited	O
when	O
it	O
is	O
co-transfected	O
into	O
CD4+	O
T	O
cells	O
with	O
the	O
delta	O
SP	O
mutant	O
.	O

Similarly	O
the	O
basal	O
as	O
well	O
as	O
TNF	O
or	O
IL1-induced	O
activity	O
of	O
the	O
MHC	O
class	O
I	O
H-2Kb	O
promoter	O
can	O
be	O
inhibited	O
by	O
this	O
mutant	O
in	O
two	O
different	O
cell	O
lines	O
.	O

These	O
results	O
constitute	O
the	O
first	O
formal	O
demonstration	O
that	O
these	O
genes	O
are	O
regulated	O
by	O
members	O
of	O
the	O
rel/NF-kappa	O
B	O
family	O
.	O

Human	O
erythroid	O
5-aminolevulinate	O
synthase	O
:	O
promoter	O
analysis	O
and	O
identification	O
of	O
an	O
iron-responsive	O
element	O
in	O
the	O
mRNA	O
.	O

5-Aminolevulinate	O
synthase	O
(	O
ALAS	O
)	O
catalyzes	O
the	O
first	O
step	O
of	O
the	O
heme	O
biosynthetic	O
pathway	O
.	O

cDNA	O
clones	O
for	O
the	O
human	O
erythroid	O
ALAS	O
isozyme	O
were	O
isolated	O
from	O
a	O
fetal	O
liver	O
library	O
.	O

It	O
can	O
be	O
deduced	O
that	O
the	O
erythroid	O
ALAS	O
precursor	O
protein	O
has	O
a	O
molecular	O
weight	O
of	O
64.6	O
kd	O
,	O
and	O
is	O
similar	O
in	O
size	O
to	O
the	O
previously	O
isolated	O
human	O
housekeeping	O
ALAS	O
precursor	O
of	O
molecular	O
weight	O
70.6	O
kd	O
.	O

The	O
mature	O
mitochondrial	O
forms	O
of	O
the	O
erythroid	O
and	O
housekeeping	O
ALAS	O
isozymes	O
are	O
predicted	O
to	O
have	O
molecular	O
weights	O
of	O
59.5	O
kd	O
and	O
64.6	O
kd	O
,	O
respectively	O
.	O

The	O
two	O
isozymes	O
show	O
little	O
amino	O
acid	O
identity	O
in	O
their	O
N-terminal	O
signal	O
sequences	O
but	O
have	O
considerable	O
sequence	O
identity	O
in	O
the	O
C-terminal	O
two-thirds	O
of	O
their	O
proteins	O
.	O

An	O
analysis	O
of	O
the	O
immediate	O
promoter	O
of	O
the	O
human	O
erythroid	O
ALAS	O
gene	O
revealed	O
several	O
putative	O
erythroid-specific	O
cis-acting	O
elements	O
including	O
both	O
a	O
GATA-1	O
and	O
an	O
NF-E2	O
binding	O
site	O
.	O

An	O
iron-responsive	O
element	O
(	O
IRE	O
)	O
motif	O
has	O
been	O
identified	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
erythroid	O
ALAS	O
mRNA	O
,	O
but	O
is	O
not	B-Negation
present	I-Negation
in	I-Negation
the	I-Negation
housekeeping	I-Negation
ALAS	I-Negation
mRNA	I-Negation
.	O

Gel	O
retardation	O
experiments	O
established	O
that	O
this	O
IRE	O
motif	O
formed	O
a	O
protein-RNA	O
complex	O
with	O
cytosolic	O
extracts	O
from	O
human	O
K562	O
cells	O
and	O
this	O
binding	O
was	O
strongly	O
competed	O
with	O
IRE	O
transcripts	O
from	O
ferritin	O
or	O
transferrin	O
receptor	O
mRNAs	O
.	O

A	O
transcript	O
of	O
the	O
ALAS	O
IRE	O
,	O
mutated	O
in	O
the	O
conserved	O
loop	O
of	O
the	O
IRE	O
,	O
did	O
not	B-Negation
readily	I-Negation
form	I-Negation
this	I-Negation
protein-RNA	I-Negation
complex	I-Negation
.	O

These	O
results	O
suggest	O
that	O
the	O
IRE	O
motif	O
in	O
the	O
ALAS	O
mRNA	O
is	O
functional	O
and	O
imply	O
that	O
translation	O
of	O
the	O
mRNA	O
is	O
controlled	O
by	O
cellular	O
iron	O
availability	O
during	O
erythropoiesis	O
.	O

Human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
regulation	O
in	O
phorbol	O
ester	O
stimulated	O
T	O
and	O
B	O
cell	O
lines	O
.	O

The	O
minimal	O
region	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
gene	O
promoter	O
necessary	O
for	O
its	O
transcriptional	O
induction	O
by	O
phorbol	O
esters	O
(	O
PMA	O
)	O
in	O
human	O
T	O
and	O
B	O
lymphocyte	O
cell	O
lines	O
has	O
been	O
localized	O
between	O
-52	O
and	O
+89	O
nucleotides	O
(	O
nt	O
)	O
relative	O
to	O
the	O
gene	O
's	O
transcriptional	O
start	O
site	O
.	O

Comparison	O
of	O
these	O
sequences	O
to	O
those	O
required	O
to	O
mediate	O
virus	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
gene	O
reveal	O
significant	O
differences	O
,	O
and	O
thus	O
,	O
the	O
sequence	O
requirements	O
for	O
PMA	O
induction	O
are	O
distinct	O
from	O
those	O
that	O
mediate	O
induction	O
by	O
virus	O
or	O
LPS	O
.	O

Although	O
three	O
sites	O
in	O
the	O
TNF-alpha	O
promoter	O
(	O
kappa	O
1	O
,	O
kappa	O
2	O
,	O
and	O
kappa	O
3	O
)	O
specifically	O
bind	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
in	O
lymphoid	O
nuclear	O
extracts	O
,	O
TNF-alpha	O
mRNA	O
induction	O
by	O
PMA	O
does	O
not	B-Negation
correlate	I-Negation
with	I-Negation
NF-kappa	I-Negation
B	I-Negation
binding	I-Negation
activities	I-Negation
displayed	I-Negation
by	I-Negation
different	I-Negation
T	I-Negation
and	I-Negation
B	I-Negation
cell	I-Negation
lines	I-Negation
.	O

Moreover	O
,	O
kappa	O
1-kappa	O
3	O
can	O
each	O
be	O
deleted	O
from	O
the	O
TNF-alpha	O
promoter	O
with	O
little	O
effect	O
on	O
the	O
gene	O
's	O
inducibility	O
by	O
PMA	O
.	O

Therefore	O
,	O
TNF-alpha	O
mRNA	O
induction	O
by	O
PMA	O
,	O
like	O
its	O
induction	O
by	O
virus	O
and	O
LPS	O
,	O
is	B-Negation
not	I-Negation
primarily	I-Negation
mediated	I-Negation
by	I-Negation
NF-kappa	I-Negation
B	I-Negation
,	O
but	O
rather	O
is	O
mediated	O
through	O
other	O
sequences	O
and	O
protein	O
factors	O
.	O

Surprisingly	O
,	O
multimers	O
of	O
kappa	O
1-kappa	O
3	O
can	O
confer	O
PMA	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
in	O
a	O
B	O
(	O
Raji	O
)	O
,	O
but	O
not	B-Negation
a	I-Negation
T	I-Negation
(	I-Negation
HUT78	I-Negation
)	I-Negation
cell	I-Negation
line	I-Negation
.	O

However	O
they	O
are	O
not	B-Negation
functional	I-Negation
on	I-Negation
a	I-Negation
truncated	I-Negation
TNF-alpha	I-Negation
promoter	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
promoter	I-Speculation
context	I-Speculation
and	I-Speculation
cell	I-Speculation
type	I-Speculation
specificity	I-Speculation
influence	I-Speculation
the	I-Speculation
PMA	I-Speculation
inducible	I-Speculation
function	I-Speculation
of	I-Speculation
these	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
binding	I-Speculation
sites	I-Speculation
.	O

Towards	O
a	O
molecular	O
understanding	O
of	O
T-cell	O
differentiation	O
.	O

Lymphoid	O
differentiation	O
is	O
one	O
of	O
the	O
best	O
studied	O
examples	O
of	O
mammalian	O
development	O
.	O

Here	O
Hans	O
Clevers	O
and	O
Michael	O
Owen	O
describe	O
how	O
the	O
cloning	O
of	O
the	O
genes	O
that	O
encode	O
T-cell-specific	O
membrane	O
proteins	O
allows	O
the	O
identification	O
of	O
transcription	O
factors	O
that	O
control	O
the	O
expression	O
of	O
these	O
T-cell	O
genes	O
.	O

Such	O
transcription	O
factors	O
play	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
the	O
mature	O
T-cell	O
phenotype	O
by	O
functioning	O
as	O
'master	O
regulators	O
of	O
T-cell	O
differentiation	O
'	O
.	O

Regulation	O
of	O
jun	O
and	O
fos	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
the	O
macrophage	O
colony-stimulating	O
factor	O
.	O

The	O
macrophage	O
colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
is	O
required	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
mononuclear	O
phagocytes	O
.	O

However	O
,	O
the	O
signaling	O
events	O
responsible	O
for	O
these	O
effects	O
remain	O
unclear	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
M-CSF	O
on	O
potential	O
signaling	O
pathways	O
involving	O
expression	O
of	O
the	O
jun	O
and	O
fos	O
early	O
response	O
genes	O
.	O

Low	O
levels	O
of	O
c-jun	O
transcripts	O
were	O
detectable	O
in	O
resting	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Treatment	O
of	O
these	O
cells	O
with	O
10	O
(	O
3	O
)	O
units/ml	O
human	O
recombinant	O
M-CSF	O
was	O
associated	O
with	O
rapid	O
and	O
transient	O
increases	O
in	O
c-jun	O
mRNA	O
levels	O
.	O

Nuclear	O
run-on	O
assays	O
and	O
mRNA	O
stability	O
studies	O
demonstrated	O
that	O
M-CSF	O
regulates	O
c-jun	O
expression	O
by	O
both	O
an	O
increase	O
in	O
transcription	O
rate	O
and	O
a	O
prolongation	O
in	O
the	O
half-life	O
of	O
c-jun	O
transcripts	O
.	O

M-CSF	O
treatment	O
was	O
also	O
associated	O
with	O
a	O
rapid	O
induction	O
of	O
the	O
jun-B	O
gene	O
,	O
although	O
expression	O
of	O
this	O
gene	O
was	O
prolonged	O
compared	O
to	O
that	O
of	O
c-jun	O
.	O

We	O
further	O
demonstrate	O
that	O
M-CSF	O
increases	O
c-fos	O
mRNA	O
levels	O
in	O
human	O
monocytes	O
through	O
control	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Maximal	O
induction	O
of	O
the	O
c-fos	O
gene	O
was	O
followed	O
by	O
that	O
for	O
the	O
fos-B	O
gene	O
.	O

Moreover	O
,	O
M-CSF-induced	O
expression	O
of	O
the	O
fos-related	O
gene	O
,	O
fra-1	O
,	O
was	O
delayed	O
compared	O
to	O
that	O
for	O
both	O
c-fos	O
and	O
fos-B	O
.	O

Taken	O
together	O
,	O
the	O
results	O
indicate	O
that	O
M-CSF	O
treatment	O
is	O
associated	O
with	O
differential	O
activation	O
of	O
multiple	O
members	O
of	O
the	O
jun/fos	O
family	O
and	O
that	O
expression	O
of	O
these	O
genes	O
could	O
contribute	O
to	O
nuclear	O
signaling	O
mechanisms	O
that	O
regulate	O
a	O
specific	O
program	O
of	O
monocyte	O
differentiation	O
.	O

Cloning	O
of	O
a	O
human	O
homeobox	O
gene	O
that	O
resembles	O
a	O
diverged	O
Drosophila	O
homeobox	O
gene	O
and	O
is	O
expressed	O
in	O
activated	O
lymphocytes	O
.	O

A	O
new	O
homeobox	O
gene	O
,	O
HB24	O
,	O
has	O
been	O
isolated	O
from	O
a	O
human	O
B-lymphocyte	O
cDNA	O
library	O
.	O

Northern	O
blot	O
analysis	O
of	O
polyadenylated	O
RNA	O
purified	O
from	O
activated	O
human	O
B	O
cells	O
revealed	O
a	O
single	O
mRNA	O
transcript	O
of	O
approximately	O
2.3	O
kb	O
.	O

Two	O
cDNA	O
clones	O
were	O
sequenced	O
and	O
provided	O
2,250	O
nucleotides	O
(	O
nt	O
)	O
of	O
DNA	O
sequence	O
information	O
.	O

There	O
is	O
a	O
single	O
methionine	O
codon-initiated	O
open	O
reading	O
frame	O
of	O
1,458	O
nt	O
in	O
frame	O
with	O
a	O
homeobox	O
and	O
a	O
CAX	O
repeat	O
,	O
and	O
the	O
open	O
reading	O
frame	O
is	O
predicted	O
to	O
encode	O
a	O
protein	O
of	O
51,659	O
daltons	O
.	O

When	O
the	O
homeodomain	O
from	O
HB24	O
was	O
compared	O
to	O
known	O
mammalian	O
and	O
Drosophila	O
homeodomains	O
it	O
was	O
found	O
to	O
be	O
only	O
moderately	O
conserved	O
,	O
but	O
when	O
it	O
was	O
compared	O
to	O
a	O
highly	O
diverged	O
Drosophila	O
homeodomain	O
,	O
H2.0	O
,	O
it	O
was	O
found	O
to	O
be	O
80	O
%	O
identical	O
.	O

The	O
HB24	O
mRNA	O
was	O
absent	O
or	O
present	O
at	O
low	O
levels	O
in	O
normal	O
B	O
and	O
T	O
lymphocytes	O
;	O

however	O
,	O
with	O
the	O
appropriate	O
activation	O
signal	O
HB24	O
mRNA	O
was	O
induced	O
within	O
several	O
hours	O
even	O
in	O
the	O
presence	O
of	O
cycloheximide	O
.	O

Characterization	O
of	O
HB24	O
expression	O
in	O
lymphoid	O
and	O
select	O
developing	O
tissues	O
was	O
performed	O
by	O
in	O
situ	O
hybridization	O
.	O

Positive	O
hybridization	O
was	O
found	O
in	O
thymus	O
,	O
tonsil	O
,	O
bone	O
marrow	O
,	O
developing	O
vessels	O
,	O
and	O
in	O
fetal	O
brain	O
.	O

HB24	O
is	O
likely	O
to	O
have	O
an	O
important	O
role	O
in	O
lymphocytes	O
as	O
well	O
as	O
in	O
certain	O
developing	O
tissues	O
.	O

Severe	O
5-fluorouracil	O
toxicity	O
secondary	O
to	O
dihydropyrimidine	O
dehydrogenase	O
deficiency	O
.	O

A	O
potentially	O
more	O
common	O
pharmacogenetic	O
syndrome	O
.	O

This	O
study	O
describes	O
the	O
inheritance	O
of	O
a	O
defect	O
in	O
pyrimidine	O
catabolism	O
and	O
its	O
association	O
with	O
drug-induced	O
toxicity	O
in	O
a	O
patient	O
receiving	O
5-fluorouracil	O
(	O
FUra	O
)	O
as	O
adjuvant	O
chemotherapy	O
for	O
breast	O
carcinoma	O
.	O

The	O
study	O
population	O
included	O
the	O
affected	O
patient	O
(	O
proband	O
)	O
,	O
nine	O
of	O
her	O
blood	O
relatives	O
,	O
and	O
seven	O
healthy	O
volunteers	O
.	O

The	O
activity	O
of	O
dihydropyrimidine	O
dehydrogenase	O
(	O
DPD	O
)	O
,	O
the	O
initial	O
enzyme	O
of	O
pyrimidine	O
(	O
and	O
FUra	O
)	O
catabolism	O
,	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
was	O
measured	O
in	O
each	O
subject	O
by	O
a	O
specific	O
radiometric	O
assay	O
using	O
FUra	O
as	O
the	O
substrate	O
.	O

The	O
proband	O
had	O
no	B-Negation
detectable	I-Negation
DPD	I-Negation
activity	I-Negation
.	O

When	O
enzyme	O
levels	O
in	O
the	O
proband	O
and	O
relatives	O
were	O
compared	O
with	O
that	O
in	O
controls	O
,	O
an	O
autosomal	O
recessive	O
pattern	O
of	O
inheritance	O
was	O
demonstrated	O
.	O

This	O
is	O
the	O
third	O
patient	O
with	O
severe	O
FUra	O
toxicity	O
secondary	O
to	O
an	O
alteration	O
in	O
pyrimidine	O
catabolism	O
and	O
the	O
second	O
from	O
our	O
clinic	O
population	O
suggesting	O
that	O
the	O
frequency	O
of	O
this	O
genetic	O
defect	O
may	O
be	O
greater	O
than	O
previously	O
thought	O
.	O

Monitoring	O
DPD	O
activity	O
may	O
be	O
important	O
in	O
the	O
management	O
of	O
patients	O
experiencing	O
severe	O
toxicity	O
secondary	O
to	O
FUra	O
chemotherapy	O
.	O

Characterization	O
of	O
an	O
immediate-early	O
gene	O
induced	O
in	O
adherent	O
monocytes	O
that	O
encodes	O
I	O
kappa	O
B-like	O
activity	O
.	O

We	O
have	O
cloned	O
a	O
group	O
of	O
cDNAs	O
representing	O
mRNAs	O
that	O
are	O
rapidly	O
induced	O
following	O
adherence	O
of	O
human	O
monocytes	O
.	O

One	O
of	O
the	O
induced	O
transcripts	O
(	O
MAD-3	O
)	O
encodes	O
a	O
protein	O
of	O
317	O
amino	O
acids	O
with	O
one	O
domain	O
containing	O
five	O
tandem	O
repeats	O
of	O
the	O
cdc10/ankyrin	O
motif	O
,	O
which	O
is	O
60	O
%	O
similar	O
(	O
46	O
%	O
identical	O
)	O
to	O
the	O
ankyrin	O
repeat	O
region	O
of	O
the	O
precursor	O
of	O
NF-kappa	O
B/KBF1	O
p50	O
.	O

The	O
C-terminus	O
has	O
a	O
putative	O
protein	O
kinase	O
C	O
phosphorylation	O
site	O
.	O

In	O
vitro	O
translated	O
MAD-3	O
protein	O
was	O
found	O
to	O
specifically	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
the	O
p50/p65	O
NF-kappa	O
B	O
complex	O
but	O
not	B-Negation
that	I-Negation
of	I-Negation
the	I-Negation
p50/p50	I-Negation
KBF1	I-Negation
factor	I-Negation
or	I-Negation
of	I-Negation
other	I-Negation
DNA-binding	I-Negation
proteins	I-Negation
.	O

The	O
MAD-3	O
cDNA	O
encodes	O
an	O
I	O
kappa	O
B-like	O
protein	O
that	O
is	O
likely	O
to	O
be	O
involved	O
in	O
regulation	O
of	O
transcriptional	O
responses	O
to	O
NF-kappa	O
B	O
,	O
including	O
adhesion-dependent	O
pathways	O
of	O
monocyte	O
activation	O
.	O

Reactive	O
oxygen	O
intermediates	O
as	O
apparently	O
widely	O
used	O
messengers	O
in	O
the	O
activation	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
and	O
HIV-1	O
.	O

Hydrogen	O
peroxide	O
and	O
oxygen	O
radicals	O
are	O
agents	O
commonly	O
produced	O
during	O
inflammatory	O
processes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
micromolar	O
concentrations	O
of	O
H2O2	O
can	O
induce	O
the	O
expression	O
and	O
replication	O
of	O
HIV-1	O
in	O
a	O
human	O
T	O
cell	O
line	O
.	O

The	O
effect	O
is	O
mediated	O
by	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
which	O
is	O
potently	O
and	O
rapidly	O
activated	O
by	O
an	O
H2O2	O
treatment	O
of	O
cells	O
from	O
its	O
inactive	O
cytoplasmic	O
form	O
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well	O
characterized	O
antioxidant	O
which	O
counteracts	O
the	O
effects	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
in	O
living	O
cells	O
,	O
prevented	O
the	O
activation	O
of	O
NF-kappa	O
B	O
by	O
H2O2	O
.	O

NAC	O
and	O
other	O
thiol	O
compounds	O
also	O
blocked	O
the	O
activation	O
of	O
NF-kappa	O
B	O
by	O
cycloheximide	O
,	O
double-stranded	O
RNA	O
,	O
calcium	O
ionophore	O
,	O
TNF-alpha	O
,	O
active	O
phorbol	O
ester	O
,	O
interleukin-1	O
,	O
lipopolysaccharide	O
and	O
lectin	O
.	O

This	O
suggests	O
that	O
diverse	O
agents	O
thought	O
to	O
activate	O
NF-kappa	O
B	O
by	O
distinct	O
intracellular	O
pathways	O
might	O
all	O
act	O
through	O
a	O
common	O
mechanism	O
involving	O
the	O
synthesis	O
of	O
ROI	O
.	O

ROI	O
appear	O
to	O
serve	O
as	O
messengers	O
mediating	O
directly	O
or	O
indirectly	O
the	O
release	O
of	O
the	O
inhibitory	O
subunit	O
I	O
kappa	O
B	O
from	O
NF-kappa	O
B	O
.	O

HTLV-1	O
Tax	O
induces	O
expression	O
of	O
various	O
immediate	O
early	O
serum	O
responsive	O
genes	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
an	O
etiological	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

We	O
showed	O
here	O
by	O
mobility-shift	O
assay	O
that	O
T-cell	O
lines	O
transformed	O
with	O
the	O
virus	O
contained	O
high	O
levels	O
of	O
AP-1	O
activities	O
.	O

Consistent	O
with	O
this	O
result	O
,	O
these	O
cell	O
lines	O
expressed	O
increased	O
levels	O
of	O
mRNAs	O
encoding	O
the	O
AP-1	O
proteins	O
,	O
c-Fos	O
,	O
Fra-1	O
,	O
c-Jun	O
,	O
JunB	O
,	O
and	O
JunD	O
.	O

Previously	O
,	O
transcription	O
of	O
the	O
c-fos	O
gene	O
has	O
been	O
reported	O
to	O
be	O
transactivated	O
by	O
the	O
viral	O
transcription	O
factor	O
,	O
Tax1	O
.	O

By	O
using	O
the	O
human	O
T-cell	O
line	O
(	O
JPX-9	O
)	O
,	O
in	O
which	O
expression	O
of	O
the	O
Tax1	O
is	O
inducible	O
,	O
we	O
showed	O
that	O
expression	O
of	O
mRNAs	O
for	O
Fra-1	O
,	O
c-Jun	O
,	O
and	O
JunD	O
was	O
also	O
transactivated	O
by	O
Tax1	O
.	O

Moreover	O
,	O
Tax1	O
activated	O
expression	O
of	O
two	O
other	O
transcription	O
factors	O
having	O
zinc	O
finger	O
motifs	O
,	O
Egr-1	O
and	O
Egr-2	O
,	O
in	O
the	O
same	O
cells	O
.	O

The	O
Tax1-inducible	O
transcription	O
factors	O
identified	O
here	O
are	O
encoded	O
by	O
the	O
members	O
of	O
immediate	O
early	O
genes	O
under	O
the	O
control	O
of	O
growth	O
signals	O
.	O

Thus	O
,	O
Tax1	O
was	O
suggested	O
to	O
replace	O
growth	O
signals	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
this	O
mechanism	O
.	O

Contribution	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
binding	O
motifs	O
to	O
the	O
replicative	O
capacity	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
:	O
distinct	O
patterns	O
of	O
viral	O
growth	O
are	O
determined	O
by	O
T-cell	O
types	O
.	O

Starting	O
with	O
a	O
replication-incompetent	O
molecular	O
clone	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
lacking	B-Negation
all	I-Negation
the	I-Negation
NF-kappa	I-Negation
B	I-Negation
and	I-Negation
Sp1	I-Negation
binding	I-Negation
sites	I-Negation
present	I-Negation
in	I-Negation
the	I-Negation
native	I-Negation
long	I-Negation
terminal	I-Negation
repeat	I-Negation
(	I-Negation
LTR	I-Negation
)	I-Negation
,	O
proviruses	O
containing	O
reconstructed	O
LTRs	O
with	O
individual	O
or	O
combinations	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
elements	O
were	O
generated	O
and	O
evaluated	B-Speculation
for	I-Speculation
their	I-Speculation
capacity	I-Speculation
to	I-Speculation
produce	I-Speculation
virus	I-Speculation
progeny	I-Speculation
following	I-Speculation
transfection-cocultivation	I-Speculation
.	O

Virus	O
stocks	O
obtained	O
from	O
these	O
experiments	O
exhibited	O
a	O
continuum	O
of	O
replicative	O
capacities	O
in	O
different	O
human	O
T-cell	O
types	O
depending	O
on	O
which	O
element	O
(	O
s	O
)	O
was	O
present	O
in	O
the	O
LTR	O
.	O

For	O
example	O
,	O
in	O
experiments	O
involving	O
proviral	O
clones	O
with	O
LTRs	O
containing	O
one	O
or	O
two	O
NF-kappa	O
B	O
elements	O
(	O
and	O
no	B-Negation
Sp1	I-Negation
binding	I-Negation
sites	I-Negation
)	O
,	O
a	O
hierarchy	O
of	O
cellular	O
permissivity	O
to	O
virus	O
replication	O
(	O
peripheral	O
blood	O
lymphocytes	O
=	O
MT4	O
greater	O
than	O
H9	O
greater	O
than	O
CEM	O
greater	O
than	O
Jurkat	O
)	O
was	O
observed	O
.	O

Of	O
note	O
was	O
the	O
associated	O
emergence	O
of	O
second-site	O
LTR	O
revertants	O
which	O
involved	O
an	O
alteration	O
of	O
the	O
TATA	O
box	O
.	O

These	O
results	O
suggest	O
that	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
LTR	O
possesses	O
functional	O
redundancy	O
which	O
ensures	O
virus	O
replication	O
in	O
different	O
T-cell	O
types	O
and	O
is	O
capable	O
of	O
changing	O
depending	O
on	O
the	O
particular	O
combination	O
of	O
transcriptional	O
factors	O
present	O
.	O

Enhancement	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
replication	O
in	O
monocytes	O
by	O
1,25-dihydroxycholecalciferol	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
expression	O
and	O
replication	O
are	O
under	O
tight	O
regulatory	O
control	O
.	O

We	O
demonstrate	O
that	O
1,25-dihydroxycholecalciferol	O
[	O
1,25-	O
(	O
OH	O
)	O
2D3	O
]	O
enhances	O
the	O
replication	O
of	O
monocyte-	O
and	O
lymphocyte-tropic	O
strains	O
of	O
HIV-1	O
up	O
to	O
10,000-fold	O
in	O
monocyte	O
cell	O
lines	O
,	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
unfractionated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

1,25	O
(	O
OH	O
)	O
2D3	O
is	O
therefore	O
one	O
of	O
the	O
most	O
potent	O
regulators	O
of	O
HIV-1	O
replication	O
described	O
to	O
date	O
.	O

Precursors	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
enhance	O
HIV-1	O
replication	O
in	O
proportion	O
to	O
their	O
affinity	O
for	O
the	O
1,25	O
(	O
OH	O
)	O
2D3	O
intracellular	O
receptor	O
,	O
suggesting	O
that	O
1,25	O
(	O
OH	O
)	O
2D3	O
influences	O
HIV-1	O
replication	O
by	O
mechanisms	O
involving	O
this	O
receptor	O
.	O

These	O
studies	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
effective	O
therapy	O
of	O
HIV-1	O
infection	O
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
and	O
NF-kappa	O
B	O
activity	O
by	O
cysteine	O
and	O
cysteine	O
derivatives	O
.	O

HIV-1	O
proviral	O
DNA	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

HIV-1-infected	O
individuals	O
have	O
,	O
on	O
average	O
,	O
abnormally	O
high	O
levels	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
and	O
abnormally	O
low	O
plasma	O
cysteine	O
levels	O
.	O

We	O
therefore	O
investigated	O
the	O
effects	O
of	O
cysteine	O
and	O
related	O
thiols	O
on	O
HIV-1	O
replication	O
and	O
NF-kappa	O
B	O
expression	O
.	O

The	O
experiments	O
in	O
this	O
report	O
show	O
that	O
cysteine	O
or	O
N-acetylcysteine	O
(	O
NAC	O
)	O
raise	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
level	O
and	O
inhibit	O
HIV-1	O
replication	O
in	O
persistently	O
infected	O
Molt-4	O
and	O
U937	O
cells	O
.	O

However	O
,	O
inhibition	O
of	O
HIV-1	O
replication	O
appears	O
not	O
to	O
be	O
directly	O
correlated	O
with	O
GSH	O
levels	O
.	O

Cysteine	O
and	O
NAC	O
also	O
inhibit	O
NF-kappa	O
B	O
activity	O
as	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
chloramphenicol	O
acetyl-transferase	O
(	O
CAT	O
)	O
gene	O
expression	O
under	O
control	O
of	O
NF-kappa	O
B	O
binding	O
sites	O
in	O
uninfected	O
cells	O
.	O

This	O
suggests	O
that	O
the	O
cysteine	O
deficiency	O
in	O
HIV-1-infected	O
individuals	O
may	O
cause	O
an	O
over-expression	O
of	O
NF-kappa	O
B-dependent	O
genes	O
and	O
enhance	O
HIV-1	O
replication	O
.	O

NAC	O
may	O
be	O
considered	O
for	O
the	O
treatment	O
of	O
HIV-1-infected	O
individuals	O
.	O

Glucocorticoid	O
receptors	O
in	O
systemic	O
lupus	O
erythematosus	O
.	O

Glucocorticosteroids	O
remain	O
the	O
major	O
treatment	O
modality	O
for	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
but	O
their	O
mechanism	O
of	O
action	O
is	O
unclear	O
.	O

Over	O
the	O
past	O
decade	O
it	O
has	O
become	O
clear	O
that	O
glucocorticosteroid	O
receptors	O
play	O
a	O
significant	O
role	O
in	O
the	O
mechanism	O
of	O
glucocorticosteroid	O
action	O
.	O

We	O
studied	O
glucocorticosteroid	O
receptor	O
density	O
and	O
affinity	O
on	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
the	O
glucocorticosteroid	O
binding	O
assay	O
in	O
33	O
patients	O
with	O
SLE	O
who	O
had	O
taken	O
no	B-Negation
glucocorticosteroid	I-Negation
for	I-Negation
the	I-Negation
previous	I-Negation
6	I-Negation
months	I-Negation
and	I-Negation
in	I-Negation
32	I-Negation
healthy	I-Negation
controls	I-Negation
.	O

Patients	O
'	O
disease	O
activity	O
was	O
measured	O
by	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
(	O
SLEDAI	O
)	O
.	O

Glucocorticosteroid	O
receptors	O
on	O
leukocytes	O
of	O
patients	O
with	O
SLE	O
were	O
significantly	O
higher	O
than	O
in	O
healthy	O
controls	O
(	O
4419	O
	O
306	O
vs	O
3369	O
	O
196	O
,	O
p	O
less	O
than	O
0.005	O
)	O
.	O

The	O
binding	O
affinity	O
was	O
not	B-Negation
different	I-Negation
between	I-Negation
patients	I-Negation
and	I-Negation
controls	I-Negation
.	O

There	O
was	O
no	B-Negation
correlation	I-Negation
between	I-Negation
glucocorticosteroid	I-Negation
receptor	I-Negation
number	I-Negation
and	I-Negation
SLE	I-Negation
disease	I-Negation
activity	I-Negation
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	O
receptor	O
levels	O
in	O
patients	O
with	O
gynecomastia	O
]	O

The	O
number	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
13	O
men	O
with	O
gynecomastia	O
were	O
measured	O
by	O
radioligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
13	O
sex-	O
and	O
age-matched	O
healthy	O
subjects	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	O
in	O
leucocytes	O
was	O
significantly	O
increased	O
in	O
gynecomastia	O
(	O
Rs	O
of	O
leucocytes	O
were	O
1054	O
	O
254	O
sites/cell	O
)	O
.	O

It	O
suggested	O
that	O
increase	O
of	O
ER	O
levels	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
gynecomastia	O
.	O

[	O
Changes	O
in	O
levels	O
of	O
leucocytic	O
estrogen	O
receptor	O
in	O
patients	O
with	O
menopausal	O
type	O
II	O
diabetes	O
and	O
its	O
significance	O
]	O

The	O
number	O
of	O
estrogen	O
receptors	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
12	O
women	O
with	O
menopausal	O
type	O
II	O
diabetes	O
was	O
measured	O
with	O
radio-ligand	O
binding	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
menopausal	O
women	O
without	B-Negation
diabetes	I-Negation
and	O
12	O
normal	O
women	O
of	O
childbearing	O
age	O
.	O

It	O
was	O
found	O
that	O
the	O
number	O
of	O
ER	O
in	O
the	O
patients	O
was	O
significantly	O
decreased	O
.	O

Our	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	O
level	O
in	O
leukocytes	O
may	O
be	O
related	O
to	O
the	O
pathogenesis	O
of	O
type	O
II	O
diabetes	O
in	O
menopausal	O
period	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
.	O

Lymphocyte	O
glucocorticoid	O
receptor	O
binding	O
parameters	O
were	O
studied	O
in	O
15	O
severely	O
depressed	O
patients	O
during	O
depression	O
and	O
after	O
clinical	O
recovery	O
,	O
and	O
in	O
15	O
healthy	O
controls	O
.	O

There	O
was	O
no	B-Negation
difference	I-Negation
in	I-Negation
glucocorticoid	I-Negation
receptor	I-Negation
number	I-Negation
or	I-Negation
affinity	I-Negation
between	I-Negation
depressed	I-Negation
patients	I-Negation
and	I-Negation
recovered	I-Negation
or	I-Negation
control	I-Negation
subjects	I-Negation
.	O

Afternoon	O
ACTH	O
and	O
cortisol	O
concentrations	O
did	O
not	B-Negation
differ	I-Negation
significantly	I-Negation
between	I-Negation
the	I-Negation
three	I-Negation
groups	I-Negation
.	O

No	B-Negation
relationship	I-Negation
could	I-Negation
be	I-Negation
established	I-Negation
between	I-Negation
glucocorticoid	I-Negation
receptor	I-Negation
binding	I-Negation
and	I-Negation
antidepressant	I-Negation
medication	I-Negation
.	O

These	O
data	O
support	O
the	O
view	O
of	O
an	O
impaired	O
ligand-induced	O
plasticity	O
of	O
glucocorticoid	O
receptor	O
regulation	O
rather	O
than	O
the	O
hypothesis	O
of	O
decreased	O
glucocorticoid	O
receptor	O
numbers	O
during	O
depression	O
.	O

Nuclear	O
association	O
of	O
a	O
T-cell	O
transcription	O
factor	O
blocked	O
by	O
FK-506	O
and	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibit	O
T-	O
and	O
B-cell	O
activation	O
and	O
other	O
processes	O
essential	O
to	O
an	O
effective	O
immune	O
response	O
.	O

In	O
T	O
lymphocytes	O
these	O
drugs	O
disrupt	O
an	O
unknown	O
step	O
in	O
the	O
transmission	O
of	O
signals	O
from	O
the	O
T-cell	O
antigen	O
receptor	O
to	O
cytokine	O
genes	O
that	O
coordinate	O
the	O
immune	O
response	O
.	O

The	O
putative	O
intracellular	O
receptors	O
for	O
FK506	O
and	O
cyclosporin	O
are	O
cis-trans	O
prolyl	O
isomerases	O
.	O

Binding	O
of	O
the	O
drug	O
inhibits	O
isomerase	O
activity	O
,	O
but	O
studies	O
with	O
other	O
prolyl	O
isomerase	O
inhibitors	O
and	O
analysis	O
of	O
cyclosporin-resistant	O
mutants	O
in	O
yeast	O
suggest	O
that	O
the	O
effects	O
of	O
the	O
drug	O
result	O
from	O
the	O
formation	O
of	O
an	O
inhibitory	O
complex	O
between	O
the	O
drug	O
and	O
isomerase	O
,	O
and	O
not	O
from	O
inhibition	O
of	O
isomerase	O
activity	O
.	O

A	O
transcription	O
factor	O
,	O
NF-AT	O
,	O
which	O
is	O
essential	O
for	O
early	O
T-cell	O
gene	O
activation	O
,	O
seems	O
to	O
be	O
a	O
specific	O
target	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
action	O
because	O
transcription	O
directed	O
by	O
this	O
protein	O
is	O
blocked	O
in	O
T	O
cells	O
treated	O
with	O
these	O
drugs	O
,	O
with	O
little	O
or	O
no	O
effect	O
on	O
other	O
transcription	O
factors	O
such	O
as	O
AP-1	O
and	O
NF-kappa	O
B	O
.	O

Here	O
we	O
demonstrate	O
that	O
NF-AT	O
is	O
formed	O
when	O
a	O
signal	O
from	O
the	O
antigen	O
receptor	O
induces	O
a	O
pre-existing	O
cytoplasmic	O
subunit	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
combine	O
with	O
a	O
newly	O
synthesized	O
nuclear	O
subunit	O
of	O
NF-AT	O
.	O

FK506	O
and	O
cyclosporin	O
A	O
block	O
translocation	O
of	O
the	O
cytoplasmic	O
component	O
without	B-Negation
affecting	I-Negation
synthesis	I-Negation
of	I-Negation
the	I-Negation
nuclear	I-Negation
subunit	I-Negation
.	O

Regulation	O
of	O
M-CSF	O
expression	O
by	O
M-CSF	O
:	O
role	O
of	O
protein	O
kinase	O
C	O
and	O
transcription	O
factor	O
NF	O
kappa	O
B	O
.	O

Macrophage-colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
,	O
also	O
referred	O
to	O
as	O
CSF-1	O
,	O
regulates	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
and	O
functional	O
activity	O
of	O
monocytes	O
by	O
binding	O
to	O
a	O
single	O
class	O
of	O
high-affinity	O
cell	O
surface	O
receptors	O
,	O
known	O
to	O
be	O
the	O
product	O
of	O
the	O
c-fms	O
protooncogene	O
.	O

The	O
detection	O
of	O
both	O
M-CSF	O
and	O
c-fms	O
expression	O
by	O
cells	O
of	O
the	O
monocyte	O
lineage	O
has	O
suggested	O
that	O
M-CSF	O
may	O
act	O
by	O
an	O
autocrine	O
mechanism	O
.	O

Interestingly	O
,	O
it	O
has	O
been	O
shown	O
that	O
M-CSF	O
can	O
induce	O
the	O
expression	O
of	O
its	O
own	O
gene	O
.	O

Although	O
sensitivity	O
to	O
M-CSF	O
can	O
be	O
modulated	O
by	O
regulation	O
of	O
receptor	O
expression	O
and	O
function	O
,	O
M-CSF	O
responsiveness	O
is	O
largely	O
determined	O
at	O
a	O
postreceptor	O
level	O
.	O

To	O
date	O
,	O
little	O
is	O
known	O
about	O
the	O
intracellular	O
pathway	O
of	O
M-CSF	O
signal	O
transduction	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
changes	O
in	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
upon	O
exposure	O
of	O
monocytes	O
to	O
M-CSF	O
.	O

We	O
show	O
that	O
M-CSF	O
activates	O
and	O
translocates	O
PKC	O
.	O

Inhibition	O
of	O
PKC	O
by	O
the	O
isoquinoline	O
derivative	O
H7	O
abolishes	O
induction	O
of	O
M-CSF	O
by	O
M-CSF	O
.	O

Furthermore	O
,	O
activation	O
of	O
PKC	O
was	O
pertussis-toxin-sensitive	O
and	O
was	O
associated	O
with	O
the	O
detection	O
of	O
an	O
NF	O
kappa	O
B	O
protein	O
in	O
nuclear	O
extracts	O
of	O
M-CSF-induced	O
blood	O
monocytes	O
but	O
not	B-Negation
in	I-Negation
monocytes	I-Negation
exposed	I-Negation
to	I-Negation
medium	I-Negation
treatment	I-Negation
only	I-Negation
.	O

The	O
results	O
suggest	O
that	O
M-CSF	O
induction	O
of	O
M-CSF	O
involves	O
G	O
proteins	O
,	O
PKC	O
and	O
NF	O
kappa	O
B	O
.	O

NF-kappa	O
B	O
activation	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
is	O
independent	O
of	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
Ca	O
(	O
2+	O
)	O
-regulated	O
kinases	O
.	O

NF-kappa	O
B	O
is	O
a	O
DNA-binding	O
regulatory	O
factor	O
able	O
to	O
control	O
transcription	O
of	O
a	O
number	O
of	O
genes	O
,	O
including	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
genes	O
.	O

In	O
T	O
cells	O
,	O
NF-kappa	O
B	O
is	O
activated	O
upon	O
cellular	O
treatment	O
by	O
phorbol	O
esters	O
and	O
the	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
investigated	O
the	O
molecular	O
events	O
leading	O
to	O
NF-kappa	O
B	O
activation	O
by	O
TNF	O
alpha	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Jurkat	O
)	O
and	O
its	O
subclone	O
JCT6	O
,	O
which	O
presents	O
a	O
deficiency	O
in	O
the	O
PKA	O
transduction	O
pathway	O
.	O

We	O
found	O
that	O
in	O
both	O
cell	O
lines	O
,	O
both	O
phorbol	O
ester	O
and	O
TNF	O
alpha	O
were	O
able	O
to	O
activate	O
NF-kappa	O
B	O
.	O

Phorbol	O
activation	O
was	O
positively	O
modulated	O
by	O
Ca2+	O
influx	O
while	O
TNF	B-Negation
alpha	I-Negation
activation	I-Negation
was	I-Negation
not	I-Negation
.	O

Furthermore	O
,	O
while	O
PMA	O
activation	O
was	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
staurosporin	O
,	O
the	O
TNF	O
alpha	O
effect	O
was	O
unchanged	O
.	O

TNF	O
alpha	O
did	O
not	B-Negation
activate	I-Negation
cAMP	I-Negation
production	I-Negation
and	O
its	B-Negation
signal	I-Negation
was	I-Negation
not	I-Negation
modulated	I-Negation
by	I-Negation
cAMP	I-Negation
activators	I-Negation
.	O

Moreover	O
,	O
cAMP	O
activators	O
did	O
not	B-Negation
activate	I-Negation
NF-kappa	I-Negation
B	I-Negation
in	I-Negation
Jurkat	I-Negation
cells	I-Negation
.	O

Thus	O
,	O
TNF	B-Negation
alpha-induced	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
was	I-Negation
found	I-Negation
to	I-Negation
be	I-Negation
mediated	I-Negation
by	I-Negation
none	I-Negation
of	I-Negation
the	I-Negation
major	I-Negation
signal-mediating	I-Negation
kinases	I-Negation
such	I-Negation
as	I-Negation
protein	I-Negation
kinase	I-Negation
C	I-Negation
(	I-Negation
PKC	I-Negation
)	I-Negation
,	I-Negation
protein	I-Negation
kinase	I-Negation
A	I-Negation
,	I-Negation
or	I-Negation
Ca	I-Negation
(	I-Negation
2+	I-Negation
)	I-Negation
-regulated	I-Negation
kinases	I-Negation
.	O

Furthermore	O
,	O
we	O
found	O
that	O
cytoplasmic	O
acidification	O
facilitated	O
NF-kappa	O
B	O
activation	O
by	O
both	O
TNF	O
alpha	O
and	O
PKC	O
,	O
by	O
a	O
mechanism	O
that	O
increases	O
NF-kappa	O
B/I	O
kappa	O
B	O
dissociation	O
without	B-Negation
affecting	I-Negation
the	I-Negation
NF-kappa	I-Negation
B	I-Negation
translocation	I-Negation
step	I-Negation
.	O

NF-kappa	O
B	O
activity	O
in	O
T	O
cells	O
stably	O
expressing	O
the	O
Tax	O
protein	O
of	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
.	O

The	O
effect	O
of	O
constitutive	O
Tax	O
expression	O
on	O
the	O
interaction	O
of	O
NF-kappa	O
B	O
with	O
its	O
recognition	O
sequence	O
and	O
on	O
NF-kappa	O
B-dependent	O
gene	O
expression	O
was	O
examined	O
in	O
T	O
lymphoid	O
Jurkat	O
cell	O
lines	O
(	O
19D	O
and	O
9J	O
)	O
stably	O
transformed	O
with	O
a	O
Tax	O
expression	O
vector	O
.	O

Tax	O
expressing	O
T	O
cell	O
lines	O
contained	O
a	O
constitutive	O
level	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
,	O
detectable	O
by	O
mobility	O
shift	O
assay	O
and	O
uv	O
cross-linking	O
using	O
a	O
palindromic	O
NF-kappa	O
B	O
probe	O
homologous	O
to	O
the	O
interferon	O
beta	O
PRDII	O
site	O
.	O

In	O
Jurkat	O
and	O
NC2.10	O
induction	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
appearance	O
of	O
new	O
DNA	O
binding	O
proteins	O
of	O
85	O
,	O
75	O
,	O
and	O
54	O
kDa	O
,	O
whereas	O
in	O
Tax	O
expressing	O
cells	O
the	O
85-kDa	O
protein	O
and	O
a	O
92-kDa	O
DNA	O
binding	O
protein	O
were	O
constitutively	O
induced	O
.	O

Expression	O
of	O
Tax	O
protein	O
in	O
19D	O
and	O
9J	O
resulted	O
in	O
transcription	O
of	O
the	O
endogenous	O
NF-kappa	O
B-dependent	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
gene	O
and	O
increased	O
basal	O
level	O
expression	O
of	O
transfected	O
NF-kappa	O
B-regulated	O
promoters	O
.	O

Nonetheless	O
transcription	O
of	O
both	O
the	O
endogenous	O
and	O
the	O
transfected	O
gene	O
was	O
inducible	O
by	O
PMA	O
treatment	O
.	O

Tax	O
expression	O
in	O
Jurkat	O
T	O
cells	O
may	O
alter	O
the	O
stoichiometry	O
of	O
NF-kappa	O
B	O
DNA	O
binding	O
proteins	O
and	O
thus	O
change	O
the	O
expression	O
of	O
NF-kappa	O
B-regulated	O
promoters	O
.	O

Regulation	O
of	O
glucocorticoid	O
receptors	O
in	O
human	O
mononuclear	O
cells	O
:	O
effects	O
of	O
glucocorticoid	O
treatment	O
,	O
Cushing	O
's	O
disease	O
and	O
ketoconazole	O
.	O

Glucocorticoid	O
receptors	O
(	O
GcR	O
)	O
were	O
determined	O
by	O
a	O
whole	O
cell	O
assay	O
in	O
human	O
mononulear	O
leukocytes	O
(	O
hMNL	O
)	O
from	O
control	O
subjects	O
,	O
patients	O
receiving	O
glucocorticoid	O
therapy	O
for	O
systemic	O
diseases	O
and	O
Cushing	O
's	O
disease	O
patients	O
with	O
or	O
without	B-Negation
ketoconazole	I-Negation
therapy	I-Negation
.	O

Prolonged	O
corticosteroid	O
treatment	O
resulted	O
in	O
down-regulation	O
of	O
GcR	O
,	O
while	O
the	O
mean	O
level	O
of	O
GcR	O
in	O
Cushing	O
's	O
disease	O
was	O
normal	O
.	O

In	O
this	O
group	O
,	O
however	O
,	O
receptor	O
levels	O
and	O
morning	O
plasma	O
cortisol	O
values	O
showed	O
a	O
negative	O
correlation	O
,	O
indicating	O
a	O
subtle	O
down-regulatory	O
effect	O
.	O

Furthermore	O
,	O
GcR	O
were	O
unaltered	O
after	O
these	O
patients	O
received	O
ketoconazole	O
,	O
in	O
spite	O
of	O
a	O
marked	O
reduction	O
in	O
morning	O
plasma	O
cortisol	O
and	O
urinary	O
free	O
cortisol	O
.	O

We	O
also	O
observed	O
that	O
ketoconazole	O
was	O
a	O
weak	O
competitor	O
of	O
GcR	O
in	O
intact	O
cells	O
,	O
although	O
it	O
significantly	O
inhibited	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
in	O
cytosolic	O
preparations	O
from	O
rat	O
tissues	O
.	O

The	O
results	O
suggested	O
that	O
GcR	O
in	O
hMNL	O
are	O
down-regulated	O
by	O
synthetic	O
steroids	O
given	O
in	O
vivo	O
,	O
but	O
they	O
showed	O
very	O
mild	O
down-regulation	O
in	O
hypercortisolemic	O
patients	O
suffering	O
from	O
Cushing	O
's	O
disease	O
.	O

Finally	O
,	O
we	O
did	O
not	B-Negation
observed	I-Negation
either	I-Negation
up-regulation	I-Negation
or	I-Negation
antagonism	I-Negation
of	I-Negation
GcR	I-Negation
by	I-Negation
ketoconazole	I-Negation
treatment	I-Negation
,	I-Negation
at	I-Negation
the	I-Negation
time	I-Negation
that	I-Negation
cortisol	I-Negation
levels	I-Negation
of	I-Negation
patients	I-Negation
with	I-Negation
Cushing	I-Negation
's	I-Negation
disease	I-Negation
were	I-Negation
reduced	I-Negation
.	O

This	O
indicates	O
that	O
the	O
beneficial	O
effects	O
of	O
ketoconazole	O
in	O
Cushing	O
's	O
disease	O
are	O
due	O
to	O
adrenal	O
cortisol	O
suppression	O
and	O
not	O
to	O
interaction	O
with	O
GcR	O
of	O
target	O
cells	O
,	O
and	O
that	O
the	O
process	O
of	O
GcR	O
regulation	O
in	O
hMNL	O
is	O
a	O
complex	O
phenomenon	O
awaiting	O
further	O
elucidation	O
.	O

Glucocorticoid	O
receptors	O
in	O
lymphocytes	O
in	O
anorexia	O
nervosa	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
was	O
to	O
explore	O
the	O
down-regulation	O
of	O
the	O
glucocorticoid	O
receptors	O
during	O
hypercortisolaemia	O
in	O
anorexia	O
nervosa	O
.	O

DESIGN	O
:	O
Urine	O
and	O
plasma	O
samples	O
were	O
obtained	O
for	O
cortisol	O
determination	O
and	O
blood	O
lymphocytes	O
were	O
isolated	O
for	O
receptor	O
binding	O
studies	O
.	O

PATIENTS	O
:	O
Sixteen	O
anorexic	O
patients	O
,	O
aged	O
16-27	O
years	O
,	O
with	O
a	O
mean	O
	O
SEM	O
body	O
mass	O
index	O
of	O
14.2	O
	O
2.0	O
(	O
ranging	O
from	O
11.1	O
to	O
17.4	O
)	O
,	O
and	O
15	O
normal	O
women	O
were	O
studied	O
.	O

Six	O
patients	O
were	O
reinvestigated	O
after	O
a	O
significant	O
weight	O
gain	O
.	O

MEASUREMENTS	O
:	O
The	O
binding	O
capacity	O
and	O
affinity	O
of	O
the	O
glucocorticoid	O
receptors	O
were	O
measured	O
with	O
dexamethasone	O
as	O
ligand	O
on	O
lymphocytes	O
.	O

RESULTS	O
:	O
In	O
patients	O
,	O
both	O
total	O
and	O
free	O
plasma	O
cortisol	O
concentrations	O
were	O
higher	O
than	O
in	O
the	O
normal	O
women	O
,	O
as	O
was	O
their	O
urinary	O
free	O
cortisol	O
;	O

the	O
number	O
of	O
glucocorticoid	O
receptors	O
per	O
cell	O
(	O
Ro	O
)	O
and	O
the	O
binding	O
affinity	O
(	O
Kd	O
)	O
for	O
dexamethasone	O
were	O
,	O
however	O
,	O
not	O
significantly	O
different	O
(	O
Ro	O
:	O
7687	O
	O
1750	O
vs	O
7347	O
	O
1285	O
sites/cell	O
;	O
Kd	O
:	O
7.7	O
	O
2.4	O
vs	O
7.4	O
	O
1.7	O
nM	O
at	O
24	O
degrees	O
C	O
)	O
.	O

After	O
weight	O
gain	O
(	O
14	O
	O
2	O
to	O
16	O
	O
2	O
kg/m2	O
)	O
,	O
receptor	O
numbers	O
were	O
8421	O
	O
2126	O
(	O
pre	O
)	O
and	O
9011	O
	O
500	O
(	O
post	O
)	O
sites/cell	O
,	O
which	O
are	O
not	O
significantly	O
different	O
(	O
P	O
greater	O
than	O
0.2	O
)	O
;	O

the	O
Kd	O
was	O
unchanged	O
(	O
9.3	O
	O
2.6	O
vs	O
9.2	O
	O
2.4	O
nM	O
)	O
.	O

CONCLUSIONS	O
Hypercortisolaemia	O
does	O
not	B-Negation
down-regulate	I-Negation
the	I-Negation
lymphocyte	I-Negation
glucocorticoid	I-Negation
receptors	I-Negation
in	I-Negation
anorexia	I-Negation
nervosa	I-Negation
and	O
a	B-Speculation
post-receptor	I-Speculation
defect	I-Speculation
might	I-Speculation
be	I-Speculation
involved	I-Speculation
in	I-Speculation
peripheral	I-Speculation
tissue	I-Speculation
resistance	I-Speculation
to	I-Speculation
the	I-Speculation
effects	I-Speculation
of	I-Speculation
glucocorticoid	I-Speculation
hormones	I-Speculation
in	I-Speculation
undernutrition	I-Speculation
.	O

Tumor	O
necrosis	O
factor-alpha	O
mRNA	O
accumulation	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
.	O

Role	O
of	O
transcriptional	O
regulation	O
by	O
DNA	O
sequence	O
motifs	O
and	O
mRNA	O
stabilization	O
.	O

The	O
cytokine	O
TNF	O
mediates	O
many	O
of	O
the	O
pathologic	O
signs	O
of	O
cachexia	O
,	O
inflammation	O
,	O
and	O
sepsis	O
.	O

The	O
current	O
work	O
describes	O
the	O
regulation	O
of	O
TNF	O
in	O
human	O
myelomonocytic	O
cell	O
lines	O
after	O
PMA	O
stimulation	O
.	O

The	O
cell	O
lines	O
exhibit	O
a	O
low	O
level	O
of	O
constitutive	O
TNF	O
mRNA	O
expression	O
.	O

Within	O
2	O
to	O
4	O
h	O
of	O
PMA	O
exposure	O
,	O
steady	O
state	O
levels	O
of	O
TNF	O
mRNA	O
are	O
markedly	O
elevated	O
in	O
all	O
myelomonocytic	O
cell	O
lines	O
studied	O
.	O

This	O
rise	O
is	O
due	O
to	O
increased	O
mRNA	O
stability	O
,	O
which	O
increased	O
by	O
almost	O
twofold	O
,	O
and	O
to	O
an	O
overall	O
increase	O
in	O
transcription	O
,	O
which	O
rises	O
by	O
more	O
than	O
sixfold	O
.	O

At	O
the	O
level	O
of	O
the	O
genomic	O
TNF	O
gene	O
,	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
is	O
detected	O
within	O
the	O
TNF	O
promoter	O
between	O
-200	O
to	O
-100	O
bp	O
relative	O
to	O
the	O
transcription	O
initiation	O
site	O
.	O

Although	O
absent	O
in	O
nonexpressing	O
erythroleukemia	O
cell	O
lines	O
,	O
the	O
DNase	O
I	O
site	O
is	O
present	O
in	O
uninduced	O
myelomonocytic	O
cell	O
lines	O
and	O
is	B-Negation
not	I-Negation
changed	I-Negation
after	I-Negation
PMA	I-Negation
induction	I-Negation
.	O

The	O
PMA	O
induction	O
of	O
c-fos	O
mRNA	O
correlated	O
well	O
with	O
TNF	O
gene	O
induction	O
;	O

expression	O
of	O
genes	O
encoding	O
other	O
proteins	O
in	O
the	O
AP-1	O
complex	O
(	O
junB	O
and	O
junD	O
)	O
were	O
also	O
induced	O
by	O
PMA	O
.	O

The	O
nuclear	O
extracts	O
from	O
resting	O
and	O
induced	O
ML-1	O
cells	O
contain	O
proteins	O
binding	O
specifically	O
to	O
the	O
AP-1	O
,	O
AP-2	O
,	O
and	O
NF	O
kappa	O
B	O
sequence	O
located	O
within	O
the	O
TNF	O
promoter	O
.	O

PMA	O
induction	O
increases	O
the	O
level	O
of	O
a	O
number	O
of	O
specific	O
binding	O
complexes	O
relative	O
to	O
the	O
resting	O
cells	O
.	O

The	O
regulatory	O
mechanisms	O
of	O
the	O
human	O
and	O
murine	O
TNF	O
genes	O
are	O
discussed	O
.	O

USF-related	O
transcription	O
factor	O
,	O
HIV-TF1	O
,	O
stimulates	O
transcription	O
of	O
human	O
immunodeficiency	O
virus-1	O
.	O

The	O
transcription	O
factor	O
HIV-TF1	O
,	O
which	O
binds	O
to	O
a	O
region	O
about	O
60	O
bp	O
upstream	O
from	O
the	O
enhancer	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
,	O
was	O
purified	O
from	O
human	O
B	O
cells	O
.	O

HIV-TF1	O
had	O
a	O
molecular	O
weight	O
of	O
39,000	O
.	O

Binding	O
of	O
HIV-TF1	O
to	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
activated	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vitro	O
.	O

The	O
HIV-TF1-binding	O
site	O
in	O
HIV	O
LTR	O
was	O
similar	O
to	O
the	O
site	O
recognized	O
by	O
upstream	O
stimulatory	O
factor	O
(	O
USF	O
)	O
in	O
the	O
adenovirus	O
major	O
late	O
promoter	O
.	O

DNA-binding	O
properties	O
of	O
HIV-TF1	O
suggested	O
that	O
HIV-TF1	O
might	O
be	O
identical	O
or	O
related	O
to	O
USF	O
.	O

Interestingly	O
,	O
treatment	O
of	O
purified	O
HIV-TF1	O
by	O
phosphatase	O
greatly	O
reduced	O
its	O
DNA-binding	O
activity	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
HIV-TF1	O
was	O
essential	O
for	O
DNA	O
binding	O
.	O

The	O
disruption	O
of	O
HIV-TF1-binding	O
site	O
induced	O
a	O
60	O
%	O
decrease	O
in	O
the	O
level	O
of	O
transcription	O
from	O
the	O
HIV	O
promoter	O
in	O
vivo	O
.	O

These	O
results	O
suggest	O
that	O
HIV-TF1	O
is	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
HIV-1	O
.	O

The	O
effect	O
of	O
toremifene	O
therapy	O
on	O
serum	O
immunoglobulin	O
levels	O
in	O
breast	O
cancer	O
.	O

Estrogens	O
and	O
anti-estrogens	O
enhance	O
the	O
number	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
-secreting	O
cells	O
in	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
-stimulated	O
lymphocyte	O
cultures	O
.	O

Lymphocytes	O
from	O
patients	O
who	O
have	O
received	O
anti-estrogen	O
therapy	O
show	O
similar	O
enhancement	O
of	O
Ig-secreting	O
cells	O
after	O
PWM	O
stimulation	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
anti-estrogen	O
(	O
toremifene	O
)	O
therapy	O
on	O
serum	O
immunoglobulin	O
(	O
IgA	O
,	O
IgM	O
,	O
IgG	O
)	O
levels	O
in	O
breast	O
cancer	O
patients	O
was	O
investigated	O
.	O

Serum	O
Ig	O
levels	O
were	O
followed	O
up	O
to	O
two	O
years	O
after	O
or	O
during	O
the	O
therapy	O
.	O

An	O
unexpected	O
finding	O
was	O
that	O
the	O
Ig	O
levels	O
decreased	O
during	O
the	O
follow-up	O
period	O
.	O

This	O
decrease	O
was	O
seen	O
in	O
patients	O
who	O
responded	O
to	O
the	O
therapy	O
as	O
well	O
as	O
in	O
those	O
who	O
did	O
not	B-Negation
.	O

HIV1	O
infection	O
of	O
human	O
monocytes	O
and	O
macrophages	O
promotes	O
induction	O
or	O
translocation	O
of	O
NF-KB-related	O
factors	O
.	O

In	O
1991	O
,	O
we	O
demonstrated	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
3	O
different	O
factors	O
(	O
termed	O
B1	O
,	O
B2	O
and	O
B3	O
)	O
with	O
affinity	O
for	O
the	O
KB-enhancer	O
target	O
sequence	O
were	O
specifically	O
detected	O
in	O
nuclear	O
extracts	O
from	O
HIV1-infected	O
monocytes	O
and	O
macrophages	O
.	O

The	O
B2	O
factor	O
was	O
induced	O
in	O
the	O
nuclei	O
of	O
these	O
cells	O
only	O
upon	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
was	O
only	O
slightly	O
evident	O
in	O
nuclei	O
of	O
uninfected	O
cells	O
but	O
was	O
readily	O
detectable	O
in	O
nuclei	O
of	O
infected	O
monocytes	O
.	O

Its	O
expression	O
remained	O
very	O
low	O
in	O
nuclei	O
of	O
HIV1-infected	O
macrophages	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
B2	O
factor	O
is	O
expressed	O
in	O
the	O
cytosol	O
of	O
monocytes	O
and	O
macrophages	O
as	O
a	O
DNA-binding	O
protein	O
,	O
indicating	O
that	O
it	O
is	O
not	O
associated	O
with	O
an	O
inhibitor	O
(	O
IKB	O
)	O
.	O

This	O
factor	O
remained	O
clustered	O
in	O
the	O
cytosol	O
and	O
was	O
translocated	O
to	O
the	O
nuclei	O
only	O
after	O
HIV1	O
infection	O
.	O

The	O
B3	O
factor	O
is	O
detected	O
in	O
the	O
cytosol	O
only	O
when	O
cells	O
are	O
HIV1-infected	O
.	O

The	O
role	O
of	O
HIV1	O
infection	O
in	O
the	O
expression	O
and	O
the	O
translocation	O
of	O
these	O
factors	O
is	O
discussed	O
.	O

Induction	O
of	O
NF-kappa	O
B	O
during	O
monocyte	O
differentiation	O
is	O
associated	O
with	O
activation	O
of	O
HIV-gene	O
expression	O
.	O

Cells	O
of	O
the	O
monocyte-macrophage	O
lineage	O
are	O
important	O
targets	O
of	O
HIV	O
infection	O
.	O

We	O
report	O
here	O
that	O
the	O
phenotypic	O
differentiation	O
of	O
monocyte	O
cell	O
lines	O
induced	O
by	O
phorbol	O
esters	O
or	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
is	O
associated	O
with	O
expression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

In	O
parallel	O
with	O
such	O
differentiation	O
,	O
HIV	O
transcription	O
,	O
monitored	O
using	O
an	O
HIV	O
long	O
terminal	O
repeat	O
reporter	O
gene	O
construct	O
,	O
is	O
activated	O
in	O
such	O
cells	O
under	O
the	O
influence	O
of	O
enhanced	O
NF-kappa	O
B	O
expression	O
.	O

Also	O
,	O
in	O
a	O
promonocyte	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
,	O
NF-kappa	O
B	O
expression	O
and	O
HIV	O
transcription	O
were	O
enhanced	O
on	O
stimulation	O
with	O
phorbol	O
ester	O
or	O
TNF	O
alpha	O
.	O

Thus	O
,	O
stimulation	O
of	O
monocyte	O
cell	O
lines	O
by	O
phorbol	O
esters	O
or	O
TNF	O
alpha	O
induces	O
cell	O
differentiation	O
and	O
activates	O
HIV	O
transcription	O
.	O

Such	O
a	O
process	O
may	O
have	O
fundamental	O
implications	O
in	O
AIDS	O
pathogenesis	O
in	O
vivo	O
and	O
may	O
be	O
important	O
in	O
disease	O
progression	O
induced	O
by	O
opportunistic	O
infections	O
directly	O
or	O
indirectly	O
involving	O
macrophages	O
.	O

A	O
nuclear	O
factor	O
NF-GM2	O
that	O
interacts	O
with	O
a	O
regulatory	O
region	O
of	O
the	O
GM-CSF	O
gene	O
essential	O
for	O
its	O
induction	O
in	O
responses	O
to	O
T-cell	O
activation	O
:	O
purification	O
from	O
human	O
T-cell	O
leukemia	O
line	O
Jurkat	O
cells	O
and	O
similarity	O
to	O
NF-kappa	O
B	O
.	O

Activation	O
of	O
T	O
cells	O
by	O
antigen	O
,	O
lectin	O
,	O
or	O
a	O
combination	O
of	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
leads	O
to	O
the	O
induction	O
of	O
genes	O
for	O
a	O
set	O
of	O
lymphokines	O
,	O
including	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
.	O

We	O
demonstrated	O
in	O
earlier	O
studies	O
that	O
the	O
upstream	O
region	O
of	O
the	O
mouse	O
GM-CSF	O
promoter	O
at	O
positions	O
between	O
-95	O
and	O
-73	O
is	O
essential	O
for	O
transcriptional	O
activation	O
in	O
response	O
to	O
PMA/A23187	O
.	O

This	O
region	O
contains	O
two	O
DNA-binding	O
motifs	O
,	O
GM2	O
and	O
GC-box	O
.	O

The	O
GM2	O
sequence	O
(	O
GGTAGTTCCC	O
)	O
is	O
recognized	O
by	O
an	O
inducible	O
factor	O
NF-GM2	O
;	O
the	O
other	O
(	O
CCGCCC	O
)	O
by	O
constitutive	O
factors	O
A1	O
,	O
A2	O
,	O
and	O
B	O
.	O

To	O
elucidate	O
the	O
mechanism	O
of	O
GM-CSF	O
gene	O
activation	O
,	O
we	O
have	O
purified	O
the	O
inducible	O
factor	O
NF-GM2	O
from	O
the	O
nuclear	O
extract	O
of	O
stimulated	O
Jurkat	O
cells	O
on	O
the	O
basis	O
of	O
specific	O
DNA-binding	O
activity	O
.	O

The	O
purified	O
NF-GM2	O
consists	O
of	O
50	O
(	O
p50	O
)	O
and	O
65	O
kDa	O
(	O
p65	O
)	O
polypeptides	O
and	O
has	O
a	O
binding	O
activity	O
specific	O
for	O
both	O
the	O
GM-CSF	O
and	O
immunoglobulin	O
kappa	O
(	O
GGAAAGTCCC	O
)	O
enhancers	O
.	O

Electrophoretically	O
purified	O
p50	O
alone	O
can	O
form	O
a	O
protein-DNA	O
complex	O
,	O
but	O
in	O
the	O
mixture	O
,	O
p50	O
associates	O
preferentially	O
with	O
p65	O
to	O
form	O
the	O
NF-GM2	O
complex	O
.	O

In	O
addition	O
,	O
p65	O
gave	O
per	O
se	O
,	O
with	O
low	O
affinity	O
,	O
a	O
protein-DNA	O
complex	O
that	O
migrated	O
more	O
slowly	O
than	O
native	O
NF-GM2	O
complex	O
.	O

Furthermore	O
,	O
an	O
antiserum	O
against	O
KBF1	O
(	O
identical	O
to	O
50	O
kDa	O
NF-kappa	O
B	O
protein	O
)	O
reacted	O
with	O
the	O
p50	O
of	O
NF-GM2	O
,	O
indicating	O
that	O
the	O
NF-GM2	O
polypeptide	O
can	O
not	O
be	O
immunologically	O
differentiated	O
from	O
the	O
50	O
kDa	O
subunit	O
of	O
NF-kappa	O
B	O
.	O

The	O
purified	O
NF-GM2	O
activated	O
in	O
vitro	O
transcription	O
from	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
it	O
failed	B-Negation
to	I-Negation
stimulate	I-Negation
transcription	I-Negation
from	I-Negation
the	I-Negation
GM-CSF	I-Negation
promoter	I-Negation
harboring	I-Negation
the	I-Negation
GM2	I-Negation
sequence	I-Negation
.	O

This	O
suggests	O
that	O
the	O
activation	O
mechanism	O
of	O
the	O
GM-CSF	O
gene	O
through	O
the	O
GM2/GC-box	O
sequence	O
is	O
different	O
from	O
that	O
of	O
genes	O
carrying	O
the	O
kappa	O
B	O
enhancer	O
alone	O
.	O

Glucocorticoid	O
receptors	O
in	O
normal	O
leukocytes	O
:	O
effects	O
of	O
age	O
,	O
gender	O
,	O
season	O
,	O
and	O
plasma	O
cortisol	O
concentrations	O
.	O

We	O
measured	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
isolated	O
from	O
peripheral	O
blood	O
of	O
145	O
apparently	O
healthy	O
volunteers	O
(	O
86	O
men	O
and	O
59	O
women	O
)	O
.	O

An	O
age-related	O
decrease	O
in	O
the	O
number	O
of	O
GR	O
was	O
suggested	O
between	O
subjects	O
younger	O
than	O
20	O
years	O
and	O
elderly	O
subjects	O
;	O

there	O
was	O
no	B-Negation
apparent	I-Negation
seasonal	I-Negation
variation	I-Negation
in	I-Negation
GR	I-Negation
.	O

Gender	O
difference	O
in	O
the	O
number	O
of	O
GR	O
was	O
not	O
significant	O
,	O
although	O
women	O
showed	O
slightly	O
fewer	O
GR	O
.	O

Eight	O
patients	O
with	O
dermatomyositis/polymyositis	O
were	O
examined	O
to	O
determine	O
whether	O
the	O
number	O
of	O
GR	O
in	O
MNL	O
could	O
be	O
down-regulated	O
by	O
their	O
cognate	O
ligands	O
.	O

The	O
number	O
of	O
GR	O
in	O
MNL	O
from	O
these	O
patients	O
was	O
significantly	O
decreased	O
one	O
month	O
after	O
the	O
initiation	O
of	O
prednisolone	O
therapy	O
.	O

However	O
,	O
in	O
normal	O
subjects	O
,	O
the	O
GR	O
in	O
MNL	O
did	O
not	B-Negation
demonstrate	I-Negation
circadian	I-Negation
variation	I-Negation
,	O
in	O
contrast	O
to	O
concentrations	O
of	O
plasma	O
cortisol	O
.	O

Anti-CD2	O
receptor	O
antibodies	O
activate	O
the	O
HIV	O
long	O
terminal	O
repeat	O
in	O
T	O
lymphocytes	O
.	O

The	O
CD2	O
T	O
lymphocyte	O
glycoprotein	O
surface	O
molecule	O
mediates	O
both	O
cell	O
to	O
cell	O
adhesion	O
and	O
T	O
cell	O
activation	O
,	O
two	O
processes	O
that	O
are	O
involved	O
in	O
the	O
spread	O
of	O
HIV	O
infection	O
.	O

Treatment	O
of	O
chronically	O
HIV-infected	O
PBMC	O
with	O
anti-CD2	O
mAb	O
has	O
been	O
shown	O
to	O
induce	O
the	O
expression	O
of	O
infectious	O
virus	O
from	O
these	O
cultures	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
mechanisms	O
whereby	O
anti-CD2	O
antibodies	O
stimulate	O
viral	O
production	O
.	O

We	O
demonstrate	O
that	O
treatment	O
of	O
transiently	O
transfected	O
T	O
lymphocytes	O
with	O
anti-CD2	O
antibodies	O
results	O
in	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

Furthermore	O
,	O
CAT	O
assays	O
using	O
mutated	O
HIV	O
long	O
terminal	O
repeat-CAT	O
constructs	O
and	O
gel	O
shift	O
assays	O
demonstrate	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
NF-kappa	O
B	O
enhancer	O
.	O

These	O
studies	O
suggest	O
that	O
interaction	O
of	O
CD2	O
with	O
its	O
natural	O
ligand	O
,	O
LFA-3	O
,	O
may	O
play	O
a	O
role	O
in	O
regulation	O
of	O
HIV	O
expression	O
.	O

Nuclear	O
transcription	O
factors	O
that	O
bind	O
to	O
elements	O
of	O
the	O
IL-2	O
promoter	O
.	O

Induction	O
requirements	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
elements	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
the	O
stimulated	O
T	O
cell	O
line	O
,	O
Jurkat	O
.	O

The	O
sites	O
and	O
their	O
corresponding	O
nuclear	O
binding	O
factors	O
include	O
:	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
AP-3	O
,	O
OCT-1	O
,	O
and	O
NF-AT	O
.	O

The	O
latter	O
``	O
nuclear	O
factor	O
for	O
activated	O
T	O
cells	O
``	O
likely	O
contributes	O
to	O
the	O
tissue	O
specificity	O
of	O
IL-2	O
gene	O
expression	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
have	O
studied	O
these	O
transcription	O
factors	O
in	O
primary	O
T	O
cells	O
from	O
human	O
blood	O
to	O
verify	O
their	O
presence	O
in	O
a	O
physiologic	O
setting	O
and	O
to	O
identify	O
the	O
signals	O
that	O
stimulate	O
factor	O
activity	O
.	O

All	O
factors	O
are	O
induced	O
in	O
the	O
nuclei	O
of	O
T	O
cells	O
upon	O
activation	O
with	O
mitogens	O
but	O
not	B-Negation
with	I-Negation
exogenous	I-Negation
IL-2	I-Negation
growth	I-Negation
factor	I-Negation
.	O

However	O
,	O
the	O
signaling	O
requirements	O
and	O
sensitivity	O
to	O
protein	O
synthesis	O
inhibitors	O
differ	O
considerably	O
.	O

Only	O
the	O
activities	O
for	O
NF-AT	O
and	O
AP-1	O
sites	O
require	O
two	O
signals	O
for	O
optimal	O
induction	O
,	O
i.e.	O
,	O
PMA	O
plus	O
either	O
lectin	O
or	O
antibody	O
to	O
the	O
CD3	O
or	O
CD28	O
surface	O
molecules	O
.	O

Other	O
factors	O
are	O
induced	O
by	O
lectin	O
,	O
antibody	O
,	O
and/or	O
PMA	O
alone	O
.	O

After	O
appropriate	O
stimulation	O
,	O
both	O
NF-AT	O
and	O
AP-1	O
are	O
peculiarly	O
sensitive	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
anisomycin	O
.	O

Our	O
data	O
correlate	O
the	O
activity	O
of	O
NF-AT	O
and	O
AP-1	O
in	O
gel	O
shift	O
assays	O
with	O
the	O
two	O
signals	O
requirements	O
for	O
IL-2	O
gene	O
expression	O
.	O

An	O
erythroid	O
specific	O
enhancer	O
upstream	O
to	O
the	O
gene	O
encoding	O
the	O
cell-type	O
specific	O
transcription	O
factor	O
GATA-1	O
.	O

The	O
transcription	O
factor	O
GATA-1	O
is	O
expressed	O
in	O
a	O
subset	O
of	O
hemopoietic	O
cells	O
,	O
where	O
it	O
mediates	O
the	O
cell-type	O
specific	O
expression	O
of	O
several	O
genes	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
and	O
human	O
GATA-1	O
genes	O
.	O

A	O
region	O
upstream	O
to	O
the	O
first	O
exon	O
,	O
and	O
highly	O
conserved	O
between	O
mouse	O
and	O
man	O
,	O
acts	O
as	O
an	O
erythroid	O
specific	O
enhancer	O
in	O
transient	O
assays	O
,	O
if	O
linked	O
to	O
the	O
GATA-1	O
or	O
to	O
the	O
SV40	O
promoter	O
.	O

The	O
activity	O
of	O
the	O
enhancer	O
is	O
almost	O
completely	O
dependent	O
on	O
the	O
integrity	O
of	O
a	O
dimeric	O
GATA-1	O
binding	O
site	O
.	O

Demonstration	O
of	O
a	O
1,25-dihydroxyvitamin	O
D3-responsive	O
protein	O
in	O
human	O
lymphocytes	O
:	O
immunologic	O
crossreactivity	O
and	O
inverse	O
regulation	O
with	O
the	O
vitamin	O
D	O
receptor	O
.	O

Using	O
Western	O
blot	O
analysis	O
with	O
a	O
monoclonal	O
antibody	O
recognizing	O
a	O
17-amino	O
acid	O
epitope	O
of	O
the	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2D3	O
]	O
receptor	O
,	O
we	O
have	O
detected	O
two	O
crossreacting	O
proteins	O
in	O
activated	O
normal	O
human	O
lymphocytes	O
.	O

The	O
smaller	O
of	O
the	O
two	O
proteins	O
(	O
50	O
kDa	O
)	O
was	O
indistinguishable	O
from	O
the	O
classical	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
and	O
,	O
similar	O
to	O
the	O
classical	O
1,25	O
(	O
OH	O
)	O
2D3	O
receptor	O
,	O
was	O
upregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1,25	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
larger	O
crossreacting	O
protein	O
exhibited	O
an	O
electrophoretic	O
mobility	O
of	O
80	O
kDa	O
,	O
was	O
localized	O
in	O
the	O
cell	O
cytosol	O
,	O
and	O
appeared	B-Speculation
to	I-Speculation
be	I-Speculation
specific	I-Speculation
for	I-Speculation
activated	I-Speculation
lymphocytes	I-Speculation
since	O
it	B-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
several	I-Negation
other	I-Negation
human	I-Negation
cells	I-Negation
including	I-Negation
monocytes	I-Negation
.	O

More	O
strikingly	O
,	O
the	O
80-kDa	O
protein	O
was	O
downregulated	O
in	O
a	O
dose-dependent	O
fashion	O
by	O
1,25	O
(	O
OH	O
)	O
2D3	O
;	O

this	O
effect	O
was	O
independent	O
of	O
the	O
mode	O
of	O
lymphocyte	O
activation	O
and	O
specific	O
for	O
the	O
1,25	O
(	O
OH	O
)	O
2D3	O
metabolite	O
of	O
vitamin	O
D3	O
.	O

However	O
,	O
two	O
potent	O
immunosuppressive	O
agents	O
,	O
glucocorticoids	O
and	O
cyclosporin	O
A	O
,	O
also	O
inhibited	O
the	O
80-kDa	O
protein	O
.	O

T-helper-cell	O
determinants	O
in	O
protein	O
antigens	O
are	O
preferentially	O
located	O
in	O
cysteine-rich	O
antigen	O
segments	O
resistant	O
to	O
proteolytic	O
cleavage	O
by	O
cathepsin	O
B	O
,	O
L	O
,	O
and	O
D	O
.	O

We	O
report	O
on	O
a	O
computer	O
algorithm	O
capable	O
of	O
predicting	O
the	O
location	O
of	O
T-helper-cell	O
epitopes	O
in	O
protein	O
antigen	O
(	O
Ag	O
)	O
by	O
analysing	O
the	O
Ag	O
amino	O
acid	O
sequence	O
.	O

The	O
algorithm	O
was	O
constructed	O
with	O
the	O
aim	O
of	O
identifying	O
segments	O
in	O
Ag	O
which	O
are	O
resistant	O
to	O
proteolytic	O
degradation	O
by	O
the	O
enzymes	O
cathepsin	O
B	O
,	O
L	O
,	O
and	O
D	O
.	O

These	O
are	O
prominent	O
enzymes	O
in	O
the	O
endocytic	O
pathway	O
through	O
which	O
soluble	O
protein	O
Ag	O
enter	O
APC	O
,	O
and	O
resistant	O
segments	O
in	O
Ag	O
may	O
,	O
therefore	O
,	O
be	O
expected	O
to	O
contain	O
more	O
T-cell	O
determinants	O
than	O
susceptible	O
segments	O
.	O

From	O
information	O
available	O
in	O
the	O
literature	O
on	O
the	O
substrate	O
specificity	O
of	O
the	O
three	O
enzymes	O
,	O
it	O
is	O
clear	O
that	O
a	B-Negation
cysteine	I-Negation
is	I-Negation
not	I-Negation
accepted	I-Negation
in	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
S2	I-Negation
,	I-Negation
S1	I-Negation
,	I-Negation
S1	I-Negation
'	I-Negation
,	O
and	O
S2	O
'	O
subsites	O
of	O
cathepsin	O
B	O
and	O
L	O
,	O
and	O
not	B-Negation
in	I-Negation
the	I-Negation
S1	I-Negation
and	I-Negation
S1	I-Negation
'	I-Negation
subsites	I-Negation
of	I-Negation
cathepsin	I-Negation
D	I-Negation
.	O

Moreover	O
,	O
we	O
have	O
noticed	O
that	O
cysteine-containing	O
T-cell	O
determinants	O
in	O
a	O
number	O
of	O
protein	O
Ag	O
are	O
particularly	O
rich	O
in	O
the	O
amino	O
acids	O
alanine	O
,	O
glycine	O
,	O
lysine	O
,	O
leucine	O
,	O
serine	O
,	O
threonine	O
,	O
and	O
valine	O
.	O

By	O
searching	O
protein	O
Ag	O
for	O
clusters	O
of	O
amino	O
acids	O
containing	O
cysteine	O
and	O
two	O
of	O
the	O
other	O
amino	O
acids	O
we	O
were	O
able	O
to	O
predict	O
17	O
out	O
of	O
23	O
empirically	O
known	O
T-cell	O
determinants	O
in	O
the	O
Ag	O
with	O
a	O
relatively	O
low	O
number	O
of	O
false	O
(	O
positive	O
)	O
predictions	O
.	O

Furthermore	O
,	O
we	O
present	O
a	O
new	O
principle	O
for	O
searching	O
Ag	O
for	O
potential	O
amphipatic	O
alpha-helical	O
protein	O
segments	O
.	O

Such	O
segments	O
accord	O
well	O
with	O
empirically	O
known	O
T-cell	O
determinants	O
and	O
our	O
algorithm	O
produces	O
a	O
lower	O
number	O
of	O
false	O
positive	O
predictions	O
than	O
the	O
principle	O
based	O
on	O
discrete	O
Fourier	O
transformations	O
previously	O
described	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0/G1	O
switch	O
gene	O
containing	O
a	O
CpG-rich	O
island	O
encodes	O
a	O
small	O
basic	O
protein	O
with	O
the	O
potential	O
to	O
be	O
phosphorylated	O
.	O

Genes	O
actively	O
involved	O
in	O
the	O
G0/G1	O
switch	O
(	O
G0S	O
genes	O
)	O
may	O
be	O
differentially	O
expressed	O
during	O
the	O
lectin-induced	O
switch	O
of	O
lymphocytes	O
from	O
the	O
G0	O
to	O
the	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
.	O

This	O
paper	O
presents	O
studies	O
of	O
G0S2	O
,	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0S	O
genes	O
,	O
for	O
which	O
cDNAs	O
were	O
cloned	O
and	O
selected	O
on	O
the	O
basis	O
of	O
differential	O
cDNA	O
hybridization	O
.	O

G0S2	O
mRNA	O
increases	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	O
or	O
cycloheximide	O
to	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
nearly	O
full-length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
one	O
small	O
intron	O
and	O
an	O
open	O
reading	O
frame	O
in	O
the	O
second	O
exon	O
.	O

The	O
derived	O
103-amino-acid	O
basic	O
protein	O
has	O
two	O
potential	O
alpha-helical	O
domains	O
separated	O
by	O
a	O
hydrophobic	O
region	O
with	O
the	O
potential	O
to	O
generate	O
turns	O
and	O
assume	O
a	O
beta-sheet	O
conformation	O
.	O

Consistent	O
with	O
involvement	O
in	O
the	O
G0/G1	O
switch	O
,	O
the	O
protein	O
contains	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
protein	O
kinase	O
C	O
and	O
casein	O
kinase	O
II	O
.	O

The	O
gene	O
contains	O
a	O
CpG-rich	O
island	O
suggesting	O
expression	O
in	O
the	O
germ	O
line	O
.	O

An	O
upstream	O
segment	O
contains	O
tandem	O
dinucleotide	O
repeats	O
(	O
CT	O
)	O
19/	O
(	O
CA	O
)	O
16	O
.	O

There	O
is	O
a	O
suitably	O
located	O
TATA	O
box	O
,	O
but	O
potential	O
sites	O
for	O
CCAAT-box	O
binding	O
factors	O
are	O
far	O
upstream	O
,	O
embedded	O
in	O
a	O
42-nucleotide	O
repeat	O
element	O
.	O

Potential	O
sites	O
for	O
transcription	O
factors	O
AP1	O
,	O
AP2	O
,	O
and	O
AP3	O
are	O
consistent	O
with	O
rapid	O
transcriptional	O
activation	O
in	O
response	O
to	O
inducing	O
agents	O
.	O

Synergism	O
between	O
two	O
distinct	O
elements	O
of	O
the	O
HTLV-I	O
enhancer	O
during	O
activation	O
by	O
the	O
trans-activator	O
of	O
HTLV-I	O
.	O

We	O
have	O
conducted	O
functional	O
studies	O
of	O
the	O
enhancer	O
elements	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
using	O
the	O
human	O
T-cell	O
lines	O
Jurkat	O
and	O
MOLT	O
4	O
,	O
which	O
are	O
negative	O
for	O
HTLV-I	O
,	O
and	O
MT-2	O
and	O
TL-Mor	O
,	O
which	O
carry	O
the	O
proviral	O
genome	O
of	O
HTLV-I	O
.	O

Two	O
distinct	O
elements	O
have	O
been	O
implicated	O
in	O
function	O
of	O
the	O
HTLV-I	O
enhancer	O
.	O

One	O
is	O
the	O
21-base-pair	O
(	O
bp	O
)	O
core	O
element	O
that	O
is	O
responsible	O
for	O
trans-activation	O
by	O
the	O
HTLV-I	O
trans-activator	O
p40tax	O
and	O
that	O
has	O
the	O
ability	O
to	O
bind	O
to	O
cyclic-AMP	O
responsive	O
element	O
binding	O
factor	O
(	O
CREB	O
)	O
-like	O
factor	O
(	O
s	O
)	O
.	O

The	O
other	O
is	O
a	O
region	O
interposed	O
between	O
the	O
21-bp	O
elements	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
a	O
subfragment	O
(	O
C26	O
)	O
in	O
the	O
region	O
between	O
the	O
21-bp	O
elements	O
is	O
involved	O
in	O
trans-activation	O
by	O
p40tax	O
,	O
possibly	O
through	O
binding	O
to	O
an	O
NF-kappa	O
B-like	O
nuclear	O
factor	O
or	O
factors	O
.	O

Formation	O
of	O
the	O
protein-DNA	O
complex	O
with	O
the	O
C26	O
subfragment	O
was	O
positively	O
affected	O
by	O
p40tax	O
.	O

The	O
C26	O
element	O
conferred	O
partial	O
responsiveness	O
to	O
p40tax	O
when	O
linked	O
to	O
one	O
copy	O
of	O
the	O
21-bp	O
element	O
that	O
,	O
by	O
itself	O
,	O
showed	O
little	O
activation	O
in	O
response	O
to	O
p40tax	O
.	O

However	B-Negation
,	I-Negation
the	I-Negation
C26	I-Negation
element	I-Negation
alone	I-Negation
,	I-Negation
even	I-Negation
when	I-Negation
repeated	I-Negation
,	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
activated	I-Negation
by	I-Negation
p40tax	I-Negation
,	O
unlike	O
other	O
NF-kappa	O
B-binding	O
elements	O
.	O

In	O
contrast	O
,	O
the	O
C26	O
element	O
itself	O
was	O
profoundly	O
activated	O
upon	O
stimulation	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
.	O

These	O
findings	O
therefore	O
suggest	O
that	O
the	O
HTLV-I	O
enhancer	O
contains	O
multiple	O
functional	O
elements	O
,	O
including	O
binding	O
sites	O
for	O
at	O
least	O
CREB-	O
and	O
NF-kappa	O
B-like	O
factors	O
,	O
which	O
synergistically	O
cooperate	O
in	O
activation	O
of	O
the	O
HTLV-I	O
enhancer	O
in	O
response	O
to	O
p40tax	O
.	O

Our	O
results	O
also	O
demonstrate	O
that	O
TPA-dependent	O
activation	O
of	O
the	O
HTLV-I	O
enhancer	O
may	O
be	O
mediated	O
through	O
the	O
C26	O
element	O
.	O

v-erbA	O
overexpression	O
is	O
required	O
to	O
extinguish	O
c-erbA	O
function	O
in	O
erythroid	O
cell	O
differentiation	O
and	O
regulation	O
of	O
the	O
erbA	O
target	O
gene	O
CAII	O
.	O

The	O
v-erbA	O
oncoprotein	O
represents	O
a	O
retrovirus-transduced	O
oncogenic	O
version	O
of	O
the	O
thyroid	O
hormone	O
(	O
T3/T4	O
)	O
receptor	O
c-erbA	O
(	O
type	O
alpha	O
)	O
.	O

It	O
contributes	O
to	O
virus-induced	O
erythroleukemia	O
by	O
efficiently	O
arresting	O
differentiation	O
of	O
red	O
cell	O
progenitors	O
and	O
by	O
suppressing	O
transcription	O
of	O
erythrocyte-specific	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
v-erbA	O
and	O
c-erbA	O
bind	O
directly	O
to	O
sequences	O
within	O
the	O
promoter	O
of	O
the	O
erythrocyte-specific	O
carbonic	O
anhydrase	O
II	O
(	O
CAII	O
)	O
,	O
a	O
gene	O
whose	O
transcription	O
is	O
efficiently	O
suppressed	O
by	O
v-erbA	O
.	O

This	O
erbA-binding	O
site	O
confers	O
thyroid	O
hormone	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
in	O
transient	O
expression	O
experiments	O
and	O
is	O
a	O
target	O
for	O
efficient	O
down-regulation	O
of	O
CAII	O
transcription	O
by	O
the	O
v-erbA	O
oncoprotein	O
.	O

In	O
stably	O
transformed	O
erythroblasts	O
coexpressing	O
the	O
v-erbA	O
oncoprotein	O
and	O
the	O
c-erbA/T3	O
receptor	O
at	O
an	O
approximately	O
equimolar	O
ratio	O
,	O
c-erbA	O
activity	O
is	O
dominant	O
over	O
v-erbA	O
.	O

T3	O
efficiently	O
induced	O
erythroid	O
differentiation	O
in	O
these	O
cells	O
,	O
thus	O
overcoming	O
the	O
v-erbA-mediated	O
differentiation	O
arrest	O
.	O

Likewise	O
,	O
T3	O
activated	O
CAII	O
transcription	O
as	O
well	O
as	O
transient	O
expression	O
of	O
a	O
T3-responsive	O
reporter	O
gene	O
containing	O
the	O
CAII-specific	O
erbA-binding	O
site	O
.	O

The	O
c-erbA-dependent	O
activation	O
of	O
this	O
CAII	O
reporter	O
construct	O
could	O
only	O
be	O
suppressed	O
by	O
very	O
high	O
amounts	O
of	O
v-erbA	O
.	O

Our	O
results	O
suggest	O
that	O
overexpression	O
of	O
v-erbA	O
is	O
required	O
for	O
its	O
function	O
as	O
an	O
oncoprotein	O
.	O

Inhibition	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
by	O
dexamethasone	O
is	O
associated	O
with	O
down-regulation	O
of	O
c-fos	O
and	O
c-jun	O
(	O
AP-1	O
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
treatment	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
is	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	O
and	O
c-fos	O
early	O
response	O
genes	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
the	O
glucocorticoid	O
dexamethasone	O
inhibits	O
TPA-induced	O
increases	O
in	O
c-jun	O
and	O
c-fos	O
mRNA	O
levels	O
in	O
U-937	O
leukemia	O
cells	O
.	O

These	O
findings	O
were	O
associated	O
with	O
a	O
block	O
in	O
appearance	O
of	O
the	O
monocytic	O
phenotype	O
,	O
including	O
inhibition	O
of	O
TPA-induced	O
increases	O
in	O
lamin	O
A	O
,	O
lamin	O
C	O
,	O
and	O
vimentin	O
transcripts	O
.	O

Other	O
studies	O
have	O
demonstrated	O
that	O
TPA-induced	O
monocytic	O
differentiation	O
and	O
expression	O
of	O
the	O
c-jun	O
and	O
c-fos	O
genes	O
in	O
myeloid	O
leukemia	O
cells	O
are	O
regulated	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

The	O
finding	O
that	O
dexamethasone	O
has	O
no	B-Negation
effect	I-Negation
on	I-Negation
TPA-induced	I-Negation
activation	I-Negation
of	I-Negation
PKC	I-Negation
suggests	B-Speculation
that	I-Speculation
this	I-Speculation
glucocorticoid	I-Speculation
inhibits	I-Speculation
signals	I-Speculation
downstream	I-Speculation
or	I-Speculation
parallel	I-Speculation
to	I-Speculation
this	I-Speculation
enzyme	I-Speculation
.	O

Nuclear	O
run-on	O
assays	O
demonstrate	O
that	O
:	O
(	O
1	O
)	O
induction	O
of	O
c-jun	O
and	O
c-fos	O
expression	O
by	O
TPA	O
is	O
regulated	O
by	O
transcriptional	O
mechanisms	O
,	O
(	O
2	O
)	O
TPA-induced	O
expression	O
of	O
c-jun	O
and	O
c-fos	O
does	O
not	B-Negation
require	I-Negation
protein	I-Negation
synthesis	I-Negation
,	O
and	O
(	O
3	O
)	O
TPA-induced	O
expression	O
of	O
both	O
genes	O
is	O
inhibited	O
at	O
the	O
transcriptional	O
level	O
by	O
dexamethasone	O
.	O

To	O
further	O
define	O
the	O
effects	O
of	O
dexamethasone	O
at	O
the	O
molecular	O
level	O
,	O
we	O
prepared	O
a	O
series	O
of	O
deleted	O
c-jun	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Increases	O
in	O
CAT	O
activity	O
during	O
transient	O
expression	O
of	O
these	O
constructs	O
in	O
TPA-treated	O
U-937	O
cells	O
could	O
be	O
assigned	O
to	O
the	O
region	O
(	O
-97	O
to	O
-20	O
)	O
of	O
the	O
promoter	O
that	O
contains	O
the	O
AP-1	O
binding	O
site	O
.	O

This	O
induction	O
of	O
CAT	O
activity	O
was	O
sensitive	O
to	O
dexamethasone	O
.	O

These	O
findings	O
suggest	O
that	O
dexamethasone	O
down-regulates	O
TPA-induced	O
transcription	O
of	O
the	O
c-jun	O
gene	O
during	O
monocytic	O
differentiation	O
by	O
inhibiting	O
activation	O
of	O
the	O
AP-1	O
site	O
.	O

Charybdotoxin-sensitive	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
membrane	O
potential	O
changes	O
are	O
not	B-Negation
involved	I-Negation
in	I-Negation
human	I-Negation
T	I-Negation
or	I-Negation
B	I-Negation
cell	I-Negation
activation	I-Negation
and	I-Negation
proliferation	I-Negation
.	O

The	O
involvement	O
of	O
ion	O
channels	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
is	O
supported	O
by	O
many	O
reports	O
of	O
changes	O
in	O
ion	O
fluxes	O
and	O
membrane	O
potential	O
after	O
mitogen	O
binding	O
.	O

Human	O
T	O
and	O
B	O
lymphocytes	O
demonstrate	O
an	O
early	O
and	O
transient	O
hyperpolarization	O
after	O
ligand	O
binding	O
.	O

Inasmuch	O
as	O
the	O
change	O
in	O
membrane	O
potential	O
is	O
dependent	O
on	O
elevation	O
of	O
free	O
cytosolic	O
calcium	O
,	O
the	O
hyperpolarization	O
is	O
presumably	O
through	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-stimulated	O
K+	O
channels	O
.	O

We	O
have	O
used	O
charybdotoxin	O
,	O
a	O
known	O
inhibitor	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
K+	O
channels	O
,	O
to	O
study	O
the	O
role	O
of	O
these	O
channels	O
in	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

We	O
demonstrate	O
that	O
charybdotoxin	O
inhibits	O
the	O
ligand-induced	O
transient	O
membrane	O
hyperpolarization	O
in	O
B	O
and	O
T	O
cells	O
in	O
a	O
dose-dependent	O
fashion	O
,	O
without	B-Negation
affecting	I-Negation
changes	I-Negation
in	I-Negation
cytosolic	I-Negation
Ca2+	I-Negation
.	O

However	O
,	O
blockade	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-activated	O
K+	O
channel	O
is	O
not	B-Negation
associated	I-Negation
with	I-Negation
changes	I-Negation
in	I-Negation
cell-cycle	I-Negation
gene	I-Negation
activation	I-Negation
,	I-Negation
IL-2	I-Negation
production	I-Negation
,	I-Negation
IL-2R	I-Negation
expression	I-Negation
or	I-Negation
B	I-Negation
and	I-Negation
T	I-Negation
cell	I-Negation
mitogenesis	I-Negation
.	O

These	O
results	O
imply	O
that	O
membrane	O
potential	O
changes	O
secondary	O
to	O
the	O
ligand-dependent	O
opening	O
of	O
Ca	O
(	O
2+	O
)	O
-activated	O
K+	O
channels	O
are	O
not	O
involved	O
in	O
B	O
and	O
T	O
lymphocyte	O
activation	O
and	O
mitogenesis	O
.	O

Evaluation	O
of	O
the	O
role	O
of	O
ligand	O
and	O
thermal	O
activation	O
of	O
specific	O
DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
human	O
glucocorticoid	O
receptor	O
.	O

We	O
have	O
used	O
a	O
DNA-binding/immunoprecipitation	O
assay	O
to	O
analyze	O
the	O
capacity	O
of	O
human	O
glucocorticoid	O
receptor	O
(	O
hGR	O
)	O
,	O
generated	O
in	O
rabbit	O
reticulocyte	O
lysates	O
,	O
to	O
bind	O
DNA	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
indistinguishable	O
from	O
native	O
hGR	O
,	O
as	O
determined	O
by	O
migration	O
on	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gels	O
,	O
sedimentation	O
on	O
sucrose	O
density	O
gradients	O
,	O
and	O
reactivity	O
with	O
antipeptide	O
antibodies	O
generated	O
against	O
hGR	O
.	O

In	O
addition	O
,	O
cell-free	O
synthesized	O
hGR	O
was	O
capable	O
of	O
specific	O
binding	O
to	O
glucocorticoid	O
response	O
element	O
(	O
GRE	O
)	O
-containing	O
DNA	O
fragments	O
.	O

Using	O
this	O
assay	O
system	O
,	O
we	O
have	O
evaluated	O
the	O
contributions	O
of	O
ligand	O
binding	O
and	O
heat	O
activation	O
to	O
DNA	O
binding	O
by	O
these	O
glucocorticoid	O
receptors	O
.	O

In	O
vitro	O
translated	O
hGR	O
was	O
capable	O
of	O
selective	O
DNA	O
binding	O
even	O
in	O
the	O
absence	B-Negation
of	I-Negation
glucocorticoid	I-Negation
.	O

Treatment	O
with	O
dexamethasone	O
or	O
the	O
antiglucocorticoid	O
RU486	O
had	O
no	B-Negation
additional	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
DNA-binding	I-Negation
capacity	I-Negation
when	O
receptor	O
preparations	O
were	O
maintained	O
at	O
0	O
C	O
(	O
no	B-Negation
activation	I-Negation
)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
either	O
ligand	O
or	O
antagonist	O
in	O
combination	O
with	O
a	O
heat	O
activation	O
step	O
promoted	O
DNA	O
binding	O
by	O
approximately	O
3-fold	O
over	O
that	O
of	O
heat-activated	O
unliganded	O
receptors	O
.	O

Agonist	O
(	O
dexamethasone	O
)	O
was	O
slightly	O
more	O
effective	O
in	O
supporting	O
specific	O
DNA	O
binding	O
than	O
antagonist	O
(	O
RU486	O
)	O
.	O

DNA	O
binding	O
by	O
in	O
vitro	O
synthesized	O
GR	O
was	O
blocked	O
by	O
the	O
addition	O
of	O
sodium	O
molybdate	O
to	O
the	O
receptor	O
preparations	O
before	O
steroid	O
addition	O
and	O
thermal	O
activation	O
.	O

Addition	O
of	O
KCl	O
resulted	O
in	O
less	O
DNA	O
binding	O
either	O
due	O
to	O
blockage	O
of	O
DNA-receptor	O
complex	O
formation	O
or	O
disruption	O
of	O
the	O
complexes	O
.	O

The	O
specificity	O
of	O
DNA	O
binding	O
by	O
cell-free	O
synthesized	O
hGR	O
was	O
analyzed	O
further	O
by	O
examining	O
the	O
abilities	O
of	O
various	O
DNAs	O
to	O
compete	O
for	O
binding	O
to	O
a	O
naturally	O
occurring	O
GRE	O
found	O
in	O
the	O
mouse	O
mammary	O
tumor	O
virus-long	O
terminal	O
repeat	O
.	O

Oligonucleotides	O
containing	O
the	O
consensus	O
GRE	O
were	O
the	O
most	O
efficient	O
competitors	O
,	O
and	O
fragments	O
containing	O
regulatory	O
sequences	O
from	O
glucocorticoid-repressible	O
genes	O
were	O
somewhat	O
competitive	O
,	O
whereas	O
single	O
stranded	O
oligonucleotides	O
were	O
unable	B-Negation
to	I-Negation
compete	I-Negation
for	I-Negation
mouse	I-Negation
mammary	I-Negation
tumor	I-Negation
virus-long	I-Negation
terminal	I-Negation
repeat	I-Negation
DNA	I-Negation
binding	I-Negation
,	O
except	O
when	O
competitor	O
was	O
present	O
at	O
extremely	O
high	O
concentrations	O
.	O

Together	O
these	O
studies	O
indicate	O
that	O
hGR	O
synthesized	O
in	O
rabbit	O
reticulocyte	O
lysates	O
displays	O
many	O
of	O
the	O
same	O
properties	O
,	O
including	O
GRE-specific	O
DNA	O
binding	O
,	O
observed	O
for	O
glucocorticoid	O
receptor	O
present	O
in	O
cytosolic	O
extracts	O
of	O
mammalian	O
cells	O
and	O
tissues	O
.	O

Similarities	O
between	O
the	O
effects	O
of	O
dexamethasone	O
and	O
RU486	O
suggest	O
that	O
the	O
antiglucocorticoid	O
properties	O
of	O
RU486	O
do	O
not	O
occur	O
at	O
the	O
level	O
of	O
specific	O
DNA	O
binding	O
.	O

One	O
base	O
pair	O
change	O
abolishes	O
the	O
T	O
cell-restricted	O
activity	O
of	O
a	O
kB-like	O
proto-enhancer	O
element	O
from	O
the	O
interleukin	O
2	O
promoter	O
.	O

The	O
inducible	O
,	O
T	O
cell-specific	O
enhancers	O
of	O
murine	O
and	O
human	O
Interleukin	O
2	O
(	O
Il-2	O
)	O
genes	O
contain	O
the	O
kB-like	O
sequence	O
GGGATTTCACC	O
as	O
an	O
essential	O
cis-acting	O
enhancer	O
motif	O
.	O

When	O
cloned	O
in	O
multiple	O
copies	O
this	O
so-called	O
TCEd	O
(	O
distal	O
T	O
cell	O
element	O
)	O
acts	O
as	O
an	O
inducible	O
proto-enhancer	O
element	O
in	O
E14	O
T	O
lymphoma	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
HeLa	I-Negation
cells	I-Negation
.	O

In	O
extracts	O
of	O
induced	O
,	O
Il-2	O
secreting	O
El4	O
cells	O
three	O
individual	O
protein	O
factors	O
bind	O
to	O
TCEd	O
DNA	O
.	O

The	O
binding	O
of	O
the	O
most	O
prominent	O
factor	O
,	O
named	O
TCF-1	O
(	O
T	O
cell	O
factor	O
1	O
)	O
,	O
is	O
correlated	O
with	O
the	O
proto-enhancer	O
activity	O
of	O
TCEd	O
.	O

TCF-1	O
consists	O
of	O
two	O
polypeptides	O
of	O
about	O
50	O
kD	O
and	O
105	O
kD	O
;	O

the	O
former	O
seems	O
to	O
be	O
related	O
to	O
the	O
50	O
kD	O
polypeptide	O
of	O
NF-kB	O
.	O

Purified	O
NF-kB	O
is	O
also	O
able	O
to	O
bind	O
to	O
the	O
TCEd	O
,	O
but	O
TCF-1	O
binds	O
stronger	O
than	O
NF-kB	O
to	O
TCEd	O
DNA	O
.	O

The	O
conversion	O
of	O
the	O
TCEd	O
to	O
a	O
'	O
perfect	O
'	O
NF-kB	O
binding	O
site	O
leads	O
to	O
a	O
tighter	O
binding	O
of	O
NF-kB	O
to	O
TCEd	O
DNA	O
and	O
,	O
as	O
a	O
functional	O
consequence	O
,	O
to	O
the	O
activity	O
of	O
the	O
'	O
converted	O
'	O
TCEd	O
motifs	O
in	O
HeLa	O
cells	O
.	O

Thus	O
,	O
the	O
substitution	O
of	O
the	O
underlined	O
A	O
residue	O
to	O
a	O
C	O
within	O
the	O
GGGATTTCACC	O
motif	O
abolishes	O
its	O
T	O
cell-restricted	O
activity	O
and	O
leads	O
to	O
its	O
functioning	O
in	O
both	O
El4	O
cells	O
and	O
HeLa	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
lymphocyte-specific	O
factors	O
binding	O
to	O
the	O
TCEd	O
are	O
involved	O
in	O
the	O
control	O
of	O
T	O
cell	O
specific-transcription	O
of	O
the	O
Il-2	O
gene	O
.	O

Negative	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytes	O
:	O
role	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	O
NF-kappa	O
B	O
dimer	O
.	O

Although	O
monocytic	O
cells	O
can	O
provide	O
a	O
reservoir	O
for	O
viral	O
production	O
in	O
vivo	O
,	O
their	O
regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
transcription	O
can	O
be	O
either	O
latent	O
,	O
restricted	O
,	O
or	O
productive	O
.	O

These	B-Negation
differences	I-Negation
in	I-Negation
gene	I-Negation
expression	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
molecularly	I-Negation
defined	I-Negation
.	O

In	O
THP-1	O
cells	O
with	O
restricted	O
HIV	O
expression	O
,	O
there	O
is	O
an	O
absence	O
of	O
DNA-protein	O
binding	O
complex	O
formation	O
with	O
the	O
HIV-1	O
promoter-enhancer	O
associated	O
with	O
markedly	O
less	O
viral	O
RNA	O
production	O
.	O

This	O
absence	B-Negation
of	I-Negation
binding	I-Negation
was	O
localized	O
to	O
the	O
NF-kappa	O
B	O
region	O
of	O
the	O
HIV-1	O
enhancer	O
;	O

the	O
65-kDa	O
plus	O
50-kDa	O
NF-kappa	O
B	O
heterodimer	O
was	O
preferentially	O
lost	O
.	O

Adding	O
purified	O
NF-kappa	O
B	O
protein	O
to	O
nuclear	O
extracts	O
from	O
cells	O
with	O
restricted	O
expression	O
overcomes	O
this	O
lack	B-Negation
of	I-Negation
binding	I-Negation
.	O

In	O
addition	O
,	O
treatment	O
of	O
these	O
nuclear	O
extracts	O
with	O
sodium	O
deoxycholate	O
restored	O
their	O
ability	O
to	O
form	O
the	O
heterodimer	O
,	O
suggesting	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
NF-kappa	O
B	O
activity	O
.	O

Furthermore	O
,	O
treatment	O
of	O
nuclear	O
extracts	O
from	O
these	O
cells	O
that	O
had	O
restricted	O
expression	O
with	O
lipopolysaccharide	O
increased	O
viral	O
production	O
and	O
NF-kappa	O
B	O
activity	O
.	O

Antiserum	O
specific	O
for	O
NF-kappa	O
B	O
binding	O
proteins	O
,	O
but	O
not	B-Negation
c-rel-specific	I-Negation
antiserum	I-Negation
,	O
disrupted	O
heterodimer	O
complex	O
formation	O
.	O

Thus	O
,	O
both	O
NF-kappa	O
B-binding	O
complexes	O
are	O
needed	O
for	O
optimal	O
viral	O
transcription	O
.	O

Binding	O
of	O
the	O
65-kDa	O
plus	O
50-kDa	O
heterodimer	O
to	O
the	O
HIV-1	O
enhancer	O
can	O
be	O
negatively	O
regulated	O
in	O
monocytes	O
,	O
providing	O
one	O
mechanism	O
restricting	O
HIV-1	O
gene	O
expression	O
.	O

Isolation	O
of	O
a	O
candidate	O
repressor/activator	O
,	O
NF-E1	O
(	O
YY-1	O
,	O
delta	O
)	O
,	O
that	O
binds	O
to	O
the	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
immunoglobulin	O
heavy-chain	O
mu	O
E1	O
site	O
.	O

We	O
have	O
determined	O
that	O
the	O
developmental	O
control	O
of	O
immunoglobulin	O
kappa	O
3	O
'	O
enhancer	O
(	O
kappa	O
E3	O
'	O
)	O
activity	O
is	O
the	O
result	O
of	O
the	O
combined	O
influence	O
of	O
positive-	O
and	O
negative-acting	O
elements	O
.	O

We	O
show	O
that	O
a	O
central	O
core	O
in	O
the	O
kappa	O
E3	O
'	O
enhancer	O
is	O
active	O
at	O
the	O
pre-B-cell	O
stage	O
but	O
is	O
repressed	O
by	O
flanking	O
negative-acting	O
elements	O
.	O

The	O
negative-acting	O
sequences	O
repress	O
enhancer	O
activity	O
in	O
a	O
position-	O
and	O
orientation-independent	O
manner	O
at	O
the	O
pre-B-cell	O
stage	O
.	O

We	O
have	O
isolated	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
zinc	O
finger	O
protein	O
(	O
NF-E1	O
)	O
that	O
binds	O
to	O
the	O
negative-acting	O
segment	O
of	O
the	O
kappa	O
E3	O
'	O
enhancer	O
.	O

This	O
protein	O
also	O
binds	O
to	O
the	O
immunoglobulin	O
heavy-chain	O
enhancer	O
mu	O
E1	O
site	O
.	O

NF-E1	O
is	O
encoded	O
by	O
the	O
same	O
gene	O
as	O
the	O
YY-1	O
protein	O
,	O
which	O
binds	O
to	O
the	O
adeno-associated	O
virus	O
P5	O
promoter	O
.	O

NF-E1	O
is	O
also	O
the	O
human	O
homologue	O
of	O
the	O
mouse	O
delta	O
protein	O
,	O
which	O
binds	O
to	O
ribosomal	O
protein	O
gene	O
promoters	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
this	O
protein	O
contains	O
features	O
characteristic	O
of	O
transcriptional	O
activators	O
as	O
well	O
as	O
transcriptional	O
repressors	O
.	O

Cotransfection	O
studies	O
with	O
this	O
cDNA	O
indicate	O
that	O
it	O
can	O
repress	O
basal	O
promoter	O
activity	O
.	O

The	O
apparent	O
dual	O
function	O
of	O
this	O
protein	O
is	O
discussed	O
.	O

Clone	O
pAT	O
133	O
identifies	O
a	O
gene	O
that	O
encodes	O
another	O
human	O
member	O
of	O
a	O
class	O
of	O
growth	O
factor-induced	O
genes	O
with	O
almost	O
identical	O
zinc-finger	O
domains	O
.	O

We	O
report	O
the	O
structure	O
and	O
regulation	O
of	O
a	O
gene	O
represented	O
by	O
clone	O
pAT	O
133	O
,	O
which	O
is	O
induced	O
upon	O
transition	O
from	O
a	O
resting	O
state	O
(	O
G0	O
)	O
through	O
the	O
early	O
phase	O
of	O
the	O
cell	O
cycle	O
(	O
G1	O
)	O
.	O

The	O
pAT	O
133	O
gene	O
is	O
immediately	O
induced	O
,	O
with	O
FOS-like	O
kinetics	O
,	O
in	O
human	O
T	O
cells	O
and	O
in	O
fibroblasts	O
.	O

Primary	O
structure	O
analysis	O
showed	O
that	O
the	O
encoded	O
protein	O
contains	O
three	O
tandem	O
zinc-finger	O
sequences	O
of	O
the	O
type	O
Cys2-Xaa12-His2	O
.	O

This	O
zinc-finger	O
region	O
,	O
which	O
is	O
thought	O
to	O
bind	O
DNA	O
in	O
a	O
sequence-specific	O
manner	O
,	O
is	O
similar	O
(	O
greater	O
than	O
80	O
%	O
on	O
the	O
amino	O
acid	O
level	O
)	O
to	O
two	O
previously	O
described	O
transcription	O
factors	O
pAT	O
225/EGR1	O
and	O
pAT	O
591/EGR2	O
.	O

Except	O
for	O
the	O
conserved	O
zinc-finger	O
domains	O
,	O
the	O
amino	O
acid	O
sequences	O
of	O
the	O
three	O
proteins	O
are	O
distinct	O
.	O

This	O
structural	O
similarity	O
suggests	O
that	O
the	O
pAT	O
133	O
gene	O
encodes	O
a	O
transcription	O
factor	O
with	O
a	O
specific	O
biological	O
function	O
.	O

Comparing	O
the	O
regulation	O
of	O
these	O
related	O
zinc-finger-encoding	O
genes	O
showed	O
coordinate	O
induction	O
upon	O
mitogenic	O
stimulation	O
of	O
resting	O
T	O
lymphocytes	O
and	O
of	O
resting	O
fibroblasts	O
.	O

However	O
,	O
upon	O
transition	O
from	O
a	O
proliferating	O
(	O
G1	O
)	O
to	O
a	O
resting	O
state	O
of	O
the	O
cell	O
cycle	O
the	O
three	O
genes	O
were	O
differently	O
regulated	O
.	O

In	O
human	O
histiocytic	O
U937	O
cells	O
mRNA	O
of	O
clone	O
pAT	O
133	O
was	O
constitutively	O
expressed	O
,	O
whereas	O
mRNA	O
of	O
pAT	O
225/EGR1	O
was	O
induced	O
upon	O
induction	O
of	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
mRNA	B-Negation
representing	I-Negation
pAT	I-Negation
591/EGR2	I-Negation
was	I-Negation
not	I-Negation
expressed	I-Negation
in	I-Negation
these	I-Negation
cells	I-Negation
.	O

This	O
difference	O
in	O
gene	O
regulation	O
suggests	O
distinct	O
biological	O
roles	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
for	O
the	O
respective	O
proteins	O
.	O

cAMP-dependent	O
regulation	O
of	O
proenkephalin	O
by	O
JunD	O
and	O
JunB	O
:	O
positive	O
and	O
negative	O
effects	O
of	O
AP-1	O
proteins	O
.	O

We	O
demonstrate	O
that	O
JunD	O
,	O
a	O
component	O
of	O
the	O
AP-1	O
transcription	O
factor	O
complex	O
,	O
activates	O
transcription	O
of	O
the	O
human	O
proenkephalin	O
gene	O
in	O
a	O
fashion	O
that	O
is	O
completely	O
dependent	O
upon	O
the	O
cAMP-dependent	O
protein	O
kinase	O
,	O
protein	O
kinase	O
A	O
.	O

Activation	O
of	O
proenkephalin	O
transcription	O
by	O
JunD	O
is	O
dependent	O
upon	O
a	O
previously	O
characterized	O
cAMP-	O
,	O
phorbol	O
ester-	O
,	O
and	O
Ca	O
(	O
2+	O
)	O
-inducible	O
enhancer	O
,	O
and	O
JunD	O
is	O
shown	O
to	O
bind	O
the	O
enhancer	O
as	O
a	O
homodimer	O
.	O

Another	O
component	O
of	O
the	O
AP-1	O
transcription	O
complex	O
,	O
JunB	O
,	O
is	O
shown	O
to	O
inhibit	O
activation	O
mediated	O
by	O
JunD	O
.	O

As	O
a	O
homodimer	O
JunB	O
is	O
unable	B-Negation
to	I-Negation
bind	I-Negation
the	I-Negation
enhancer	I-Negation
;	O
however	O
in	O
the	O
presence	O
of	O
c-Fos	O
,	O
high-affinity	O
binding	O
is	O
observed	O
.	O

Furthermore	O
,	O
JunD	O
is	O
shown	O
to	O
activate	O
transcription	O
of	O
genes	O
linked	O
to	O
both	O
cAMP	O
and	O
phorbol	O
ester	O
response	O
elements	O
in	O
a	O
protein	O
kinase	O
A-dependent	O
fashion	O
,	O
further	O
blurring	O
the	O
distinction	O
between	O
these	O
response	O
elements	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcriptional	O
activity	O
of	O
an	O
AP-1-related	O
protein	O
is	O
regulated	O
by	O
the	O
cAMP-dependent	O
second-messenger	O
pathway	O
and	O
suggest	O
that	O
JunD	O
and	O
other	O
AP-1-related	O
proteins	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
by	O
cAMP-dependent	O
intracellular	O
signaling	O
pathways	O
.	O

Glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
.	O

Glucocorticoid	O
pharmacokinetics	O
,	O
glucocorticoid	O
receptor	O
characteristics	O
,	O
and	O
inhibition	O
of	O
peripheral	O
blood	O
T	O
cell	O
proliferation	O
by	O
glucocorticoids	O
in	O
vitro	O
.	O

A	O
total	O
of	O
37	O
chronic	O
,	O
severe	O
,	O
nonsmoking	O
asthmatic	O
patients	O
with	O
documented	O
reversible	O
airways	O
obstruction	O
were	O
classified	O
as	O
glucocorticoid-sensitive	O
or	O
-resistant	O
on	O
the	O
basis	O
of	O
changes	O
in	O
FEV1	O
,	O
FVC	O
,	O
and	O
peak	O
expiratory	O
flow	O
(	O
PEF	O
)	O
after	O
oral	O
prednisolone	O
.	O

The	O
resistant	O
patients	O
showed	O
no	B-Negation
significant	I-Negation
improvements	I-Negation
in	I-Negation
airflow	I-Negation
limitation	I-Negation
.	O

Phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
proliferation	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
from	O
the	O
sensitive	O
but	O
not	B-Negation
the	I-Negation
resistant	I-Negation
asthmatic	O
patients	O
was	O
significantly	O
(	O
p	O
less	O
than	O
0.01	O
)	O
inhibited	O
by	O
dexamethasone	O
(	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
,	O
reflecting	O
a	O
shift	O
of	O
the	O
dose-response	O
curve	O
.	O

When	O
all	O
the	O
asthmatic	O
patients	O
were	O
analyzed	O
together	O
,	O
there	O
was	O
a	O
significant	O
correlation	O
between	O
the	O
degree	O
of	O
sensitivity	O
of	O
T	O
cells	O
to	O
dexamethasone	O
and	O
the	O
clinical	O
responsiveness	O
to	O
prednisolone	O
(	O
p	O
less	O
than	O
0.01	O
)	O
.	O

No	B-Negation
differences	I-Negation
were	I-Negation
observed	I-Negation
between	I-Negation
six	I-Negation
of	I-Negation
the	I-Negation
sensitive	I-Negation
and	I-Negation
resistant	I-Negation
patients	I-Negation
in	I-Negation
the	I-Negation
clearance	I-Negation
of	I-Negation
plasma	I-Negation
prednisolone	I-Negation
derived	I-Negation
from	I-Negation
orally	I-Negation
administered	I-Negation
prednisone	I-Negation
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
glucocorticoid	O
receptors	O
were	O
also	O
characterized	O
in	O
five	O
sensitive	O
and	O
seven	O
resistant	O
patients	O
.	O

The	O
numbers	O
and	O
binding	O
affinities	O
of	O
these	O
receptors	O
could	O
not	B-Negation
account	I-Negation
for	I-Negation
the	I-Negation
observed	I-Negation
difference	I-Negation
in	I-Negation
the	I-Negation
susceptibility	I-Negation
of	I-Negation
these	I-Negation
cells	I-Negation
to	I-Negation
functional	I-Negation
inhibition	I-Negation
by	I-Negation
dexamethasone	I-Negation
in	I-Negation
vitro	I-Negation
.	O

These	O
results	O
suggest	O
that	O
clinical	O
glucocorticoid	O
resistance	O
in	O
chronic	O
asthma	O
does	O
not	O
reflect	O
abnormal	O
glucocorticoid	O
clearance	O
but	O
may	O
be	O
due	O
at	O
least	O
partly	O
to	O
a	O
relative	O
insensitivity	O
of	O
T	O
lymphocytes	O
to	O
glucocorticoids	O
.	O

This	O
lack	B-Negation
of	I-Negation
sensitivity	I-Negation
is	O
unexplained	O
but	O
is	O
not	B-Negation
attributable	I-Negation
to	I-Negation
abnormalities	I-Negation
of	I-Negation
cellular	I-Negation
glucocorticoid	I-Negation
receptors	I-Negation
.	O

Regulation	O
of	O
interleukin-1	O
beta	O
production	O
by	O
glucocorticoids	O
in	O
human	O
monocytes	O
:	O
the	O
mechanism	O
of	O
action	O
depends	O
on	O
the	O
activation	O
signal	O
.	O

Glucocorticoids	O
are	O
known	O
to	O
downregulate	O
interleukin-1	O
beta	O
production	O
in	O
monocytic	O
cells	O
by	O
two	O
different	O
mechanims	O
:	O
direct	O
inhibition	O
of	O
the	O
gene	O
transcription	O
and	O
destabilization	O
of	O
the	O
preformed	O
interleukin-1	O
beta	O
mRNA	O
.	O

Now	O
we	O
have	O
examined	O
the	O
effect	O
of	O
the	O
nature	O
of	O
the	O
monocyte	O
activating	O
signal	O
on	O
these	O
two	O
inhibitory	O
mechanims	O
.	O

When	O
human	O
monocytes	O
were	O
preincubated	O
with	O
dexamethasone	O
for	O
1	O
hour	O
and	O
then	O
stimulated	O
either	O
with	O
bacterial	O
lipopolysaccharide	O
or	O
phorbol	O
myristate	O
,	O
it	O
was	O
found	O
that	O
dexamethasone	O
inhibited	O
the	O
lipopolysaccharide-induced	O
interleukin-1	O
beta	O
protein	O
production	O
,	O
but	O
the	O
phorbol	O
myristate-induced	O
production	O
was	O
increased	O
3-10	O
fold	O
.	O

This	O
difference	O
was	O
also	O
seen	O
at	O
the	O
mRNA	O
level	O
.	O

When	O
dexamethasone	O
was	O
added	O
to	O
the	O
cultures	O
3	O
hours	O
after	O
the	O
stimulators	O
,	O
it	O
clearly	O
decreased	O
the	O
interleukin-1	O
beta	O
mRNA	O
levels	O
regardless	O
of	O
the	O
stimulator	O
used	O
(	O
although	O
the	O
effect	O
was	O
clearly	O
weaker	O
on	O
the	O
PMA-induced	O
mRNA	O
)	O
.	O

Thus	O
these	O
data	O
suggest	O
that	O
the	O
phorbol	O
myristate-induced	O
signal	O
(	O
prolonged	O
protein	O
kinase	O
C	O
activation	O
?	O
)	O
can	O
not	O
be	O
inhibited	O
by	O
prior	O
incubation	O
with	O
dexamethasone	O
and	O
it	O
also	O
protects	O
the	O
induced	O
mRNA	O
for	O
the	O
degradative	O
action	O
of	O
dexamethasone	O
.	O

Identification	O
of	O
transcriptional	O
suppressor	O
proteins	O
that	O
bind	O
to	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Two	O
different	O
proteins	O
which	O
independently	O
bound	O
to	O
neighboring	O
sequences	O
within	O
the	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
were	O
detected	O
in	O
the	O
nuclear	O
extract	O
of	O
a	O
virus-infected	O
human	O
T	O
cell	O
line	O
.	O

One	O
of	O
the	O
factors	O
bound	O
to	O
a	O
novel	O
dyad	O
symmetrical	O
sequence	O
.	O

This	O
sequence	O
is	O
well	O
conserved	O
in	O
various	O
HIV-1	O
isolates	O
and	O
partial	O
homology	O
was	O
found	O
with	O
the	O
promoter	O
region	O
of	O
the	O
human	O
retinoblastoma	O
gene	O
.	O

Similar	O
DNA	O
binding	O
activity	O
was	O
detected	O
in	O
a	O
variety	O
of	O
virus-uninfected	O
human	O
T	O
cell	O
lines	O
and	O
HeLa	O
cells	O
by	O
means	O
of	O
a	O
gel	O
mobility	O
shift	O
assay	O
.	O

The	O
other	O
factor	O
bound	O
to	O
a	O
putative	O
AP-1	O
recognition	O
sequence	O
predicted	O
for	O
the	O
HIV-1	O
NRE	O
.	O

However	O
,	O
this	O
factor	O
did	O
not	B-Negation
bind	I-Negation
to	I-Negation
a	I-Negation
typical	I-Negation
AP-1	I-Negation
site	I-Negation
.	O

The	O
insertion	O
of	O
multiple	O
copies	O
of	O
the	O
binding	O
site	O
for	O
the	O
former	O
or	O
latter	O
factor	O
into	O
a	O
heterologous	O
promoter	O
reduced	O
the	O
promoter	O
activity	O
to	O
one-tenth	O
or	O
one-third	O
,	O
respectively	O
.	O

Thus	O
,	O
each	O
factor	O
may	O
function	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
transcription	O
.	O

Constitutive	O
activation	O
of	O
NF-kB	O
in	O
human	O
thymocytes	O
.	O

NF-kB	O
is	O
a	O
eukaryotic	O
transcription	O
regulatory	O
factor	O
.	O

In	O
T	O
cells	O
and	O
T	O
cell	O
lines	O
,	O
NF-kB	O
is	O
bound	O
to	O
a	O
cytoplasmic	O
proteic	O
inhibitor	O
,	O
the	O
IkB	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
mitogens	O
(	O
phorbol	O
esters	O
)	O
or	O
cytokines	O
(	O
TNF	O
alpha	O
)	O
induces	O
NF-kB	O
nuclear	O
translocation	O
and	O
the	O
subsequent	O
expression	O
of	O
NF-kB	O
dependent	O
T	O
cell	O
genes	O
.	O

Here	O
we	O
examined	O
the	O
activation	O
of	O
NF-kB	O
in	O
human	O
T	O
cell	O
thymic	O
progenitors	O
.	O

We	O
report	O
differences	O
in	O
(	O
Ca2+	O
)	O
i	O
requirement	O
for	O
NF-kB	O
activation	O
in	O
thymocytes	O
as	O
compared	O
to	O
mature	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
indicated	O
that	O
thymocytes	O
have	O
a	O
constitutively	O
active	O
form	O
of	O
NF-kB	O
,	O
suggesting	O
that	O
they	O
are	O
activated	O
in	O
vivo	O
.	O

The	O
role	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
in	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
hemopoietic	O
differentiation	O
.	O

Terminal	O
differentiation	O
of	O
the	O
leukemic	O
cell	O
lines	O
U-937	O
and	O
HL-60	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
is	O
accompanied	O
by	O
marked	O
changes	O
in	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
expression	O
of	O
jun	O
and	O
fos	O
gene	O
family	O
members	O
is	O
induced	O
with	O
variable	O
kinetics	O
during	O
12-O-tetradecanoylphorbol-13-acetate	O
induced	O
differentiation	O
,	O
with	O
c-jun	O
expression	O
best	O
paralleling	O
differentiation	O
.	O

The	O
generation	O
of	O
AP-1	O
complexes	O
,	O
as	O
measured	O
by	O
DNA	O
binding	O
activity	O
,	O
closely	O
parallels	O
morphological	O
differentiation	O
.	O

Furthermore	O
,	O
the	O
ability	O
of	O
these	O
complexes	O
to	O
regulate	O
gene	O
expression	O
is	O
demonstrated	O
by	O
increased	O
transcription	O
from	O
an	O
AP-1	O
driven	O
reporter	O
construct	O
and	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
endogenous	O
AP-1	O
regulated	O
genes	O
.	O

Differentiation	O
assays	O
using	O
water	O
soluble	O
phorbol	O
esters	O
reveal	O
that	O
differentiation	O
becomes	O
irreversible	O
soon	O
after	O
AP-1	O
appears	O
.	O

This	O
tight	O
correlation	O
between	O
c-jun	O
expression	O
,	O
the	O
generation	O
of	O
AP-1	O
activity	O
,	O
and	O
differentiation	O
suggests	O
a	O
critical	O
role	O
for	O
this	O
gene	O
and	O
transcriptional	O
complex	O
during	O
this	O
process	O
.	O

TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
of	O
the	O
HMG	O
box	O
family	O
,	O
interacts	O
with	O
sequence	O
motifs	O
in	O
the	O
TCR	O
beta	O
and	O
TCR	O
delta	O
enhancers	O
.	O

We	O
have	O
recently	O
identified	O
and	O
cloned	O
TCF-1	O
,	O
a	O
T	O
cell-specific	O
transcription	O
factor	O
with	O
specificity	O
for	O
the	O
AACAAAG	O
motif	O
in	O
the	O
CD3	O
epsilon	O
enhancer	O
and	O
for	O
the	O
TTCAAAG	O
motif	O
in	O
the	O
TCR	O
alpha	O
enhancer	O
.	O

TCF-1	O
belongs	O
to	O
the	O
family	O
of	O
transcription-regulating	O
proteins	O
which	O
share	O
a	O
region	O
of	O
homology	O
termed	O
the	O
HMG-box	O
.	O

Here	O
,	O
we	O
show	O
by	O
gel	O
retardation	O
analysis	O
that	O
TCF-1	O
specifically	O
recognizes	O
the	O
T	O
beta	O
5	O
element	O
of	O
the	O
TCR	O
beta	O
enhancer	O
and	O
the	O
T	O
delta	O
7	O
element	O
of	O
the	O
TCR	O
delta	O
enhancer	O
.	O

Comparison	O
of	O
the	O
sequences	O
of	O
all	O
elements	O
recognized	O
by	O
TCF-1	O
defines	O
a	O
consensus	O
motif	O
A/T	O
A/T	O
C	O
A	O
A/G	O
A	O
G	O
.	O

These	O
observations	O
imply	O
that	O
TCF-1	O
is	O
involved	O
in	O
the	O
control	O
of	O
several	O
T	O
cell-specific	O
genes	O
and	O
might	O
thus	O
play	O
an	O
important	O
role	O
in	O
the	O
establishment	O
and	O
maintenance	O
of	O
the	O
mature	O
T	O
cell	O
phenotype	O
.	O

The	O
cellular	O
oncogene	O
c-myb	O
can	O
interact	O
synergistically	O
with	O
the	O
Epstein-Barr	O
virus	O
BZLF1	O
transactivator	O
in	O
lymphoid	O
cells	O
.	O

Regulation	O
of	O
replicative	O
functions	O
in	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
genome	O
is	O
mediated	O
through	O
activation	O
of	O
a	O
virally	O
encoded	O
transcription	O
factor	O
,	O
Z	O
(	O
BZLF1	O
)	O
.	O

We	O
have	O
shown	O
that	O
the	O
Z	O
gene	O
product	O
,	O
which	O
binds	O
to	O
AP-1	O
sites	O
as	O
a	O
homodimer	O
and	O
has	O
sequence	O
similarity	O
to	O
c-Fos	O
,	O
can	O
efficiently	O
activate	O
the	O
EBV	O
early	O
promoter	O
,	O
BMRF1	O
,	O
in	O
certain	O
cell	O
types	O
(	O
i.e.	O
,	O
HeLa	O
cells	O
)	O
but	O
not	B-Negation
others	I-Negation
(	I-Negation
i.e.	I-Negation
,	I-Negation
Jurkat	I-Negation
cells	I-Negation
)	I-Negation
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
c-myb	O
proto-oncogene	O
product	O
,	O
which	O
is	O
itself	O
a	O
DNA-binding	O
protein	O
and	O
transcriptional	O
transactivator	O
,	O
can	O
interact	O
synergistically	O
with	O
Z	O
in	O
activating	O
the	O
BMRF1	O
promoter	O
in	O
Jurkat	O
cells	O
(	O
a	O
T-cell	O
line	O
)	O
or	O
Raji	O
cells	O
(	O
an	O
EBV-positive	O
B-cell	O
)	O
,	O
whereas	O
the	O
c-myb	O
gene	O
product	O
by	O
itself	O
has	O
little	O
effect	O
.	O

The	O
simian	O
virus	O
40	O
early	O
promoter	O
is	O
also	O
synergistically	O
activated	O
by	O
the	O
Z/c-myb	O
combination	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
BMRF1	O
promoter	O
by	O
the	O
Z/c-myb	O
combination	O
appears	O
to	O
involve	O
direct	O
binding	O
by	O
the	O
Z	O
protein	O
but	O
not	O
the	O
c-myb	O
protein	O
.	O

A	O
30-bp	O
sequence	O
in	O
the	O
BMRF1	O
promoter	O
which	O
contains	O
a	O
Z	O
binding	O
site	O
(	O
a	O
consensus	O
AP-1	O
site	O
)	O
is	O
sufficient	O
to	O
transfer	O
high-level	O
lymphoid-specific	O
responsiveness	O
to	O
the	O
Z/c-myb	O
combination	O
to	O
a	O
heterologous	O
promoter	O
.	O

That	O
the	O
c-myb	O
oncogene	O
product	O
can	O
interact	O
synergistically	O
with	O
an	O
EBV-encoded	O
member	O
of	O
the	O
leucine	O
zipper	O
protein	O
family	O
suggests	O
c-myb	O
is	O
likely	O
to	O
engage	O
in	O
similar	O
interactions	O
with	O
cellularly	O
encoded	O
transcription	O
factors	O
.	O

The	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin-activated	O
human	O
platelets	O
are	O
forms	O
of	O
the	O
estrogen	O
receptor-related	O
27-kDa	O
heat	O
shock	O
protein	O
.	O

Thrombin	O
plays	O
a	O
critical	O
role	O
in	O
platelet	O
activation	O
,	O
hemostasis	O
,	O
and	O
thrombosis	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
leads	O
to	O
the	O
phosphorylation	O
of	O
multiple	O
proteins	O
,	O
most	O
of	O
which	O
are	O
unidentified	O
.	O

We	O
have	O
characterized	O
several	O
29-kDa	O
proteins	O
that	O
are	O
rapidly	O
phosphorylated	O
following	O
exposure	O
of	O
intact	O
human	O
platelets	O
to	O
thrombin	O
.	O

A	O
murine	O
monoclonal	O
antibody	O
raised	O
to	O
an	O
unidentified	O
estrogen	O
receptor-related	O
29-kDa	O
protein	O
selectively	O
recognized	O
these	O
proteins	O
as	O
well	O
as	O
a	O
more	O
basic	O
,	O
unphosphorylated	O
27-kDa	O
protein	O
.	O

Cellular	O
activation	O
by	O
thrombin	O
led	O
to	O
a	O
marked	O
shift	O
in	O
the	O
proportion	O
of	O
protein	O
from	O
the	O
27-kDa	O
unphosphorylated	O
form	O
to	O
the	O
29-kDa	O
phosphoprotein	O
species	O
.	O

Using	O
this	O
antibody	O
,	O
we	O
isolated	O
and	O
sequenced	O
a	O
human	O
cDNA	O
clone	O
encoding	O
a	O
protein	O
that	O
was	O
identical	O
to	O
the	O
mammalian	O
27-kDa	O
heat	O
shock	O
protein	O
(	O
HSP27	O
)	O
,	O
a	O
protein	O
of	O
uncertain	O
function	O
that	O
is	O
known	O
to	O
be	O
phosphorylated	O
to	O
several	O
forms	O
and	O
to	O
be	O
transcriptionally	O
induced	O
by	O
estrogen	O
.	O

The	O
29-kDa	O
proteins	O
were	O
confirmed	O
to	O
be	O
phosphorylated	O
forms	O
of	O
HSP27	O
by	O
immunoprecipitation	O
studies	O
.	O

Thus	O
,	O
the	O
``	O
estrogen	O
receptor-related	O
protein	O
``	O
is	O
HSP27	O
,	O
and	O
the	O
three	O
major	O
29-kDa	O
proteins	O
phosphorylated	O
in	O
thrombin-activated	O
platelets	O
are	O
forms	O
of	O
HSP27	O
.	O

These	O
data	O
suggest	O
a	O
role	O
for	O
HSP27	O
in	O
the	O
signal	O
transduction	O
events	O
of	O
platelet	O
activation	O
.	O

Characterization	O
of	O
a	O
cofactor	O
that	O
regulates	O
dimerization	O
of	O
a	O
mammalian	O
homeodomain	O
protein	O
.	O

Dimerization	O
among	O
transcription	O
factors	O
has	O
become	O
a	O
recurrent	O
theme	O
in	O
the	O
regulation	O
of	O
eukaryotic	O
gene	O
expression	O
.	O

Hepatocyte	O
nuclear	O
factor-1	O
alpha	O
(	O
HNF-1	O
alpha	O
)	O
is	O
a	O
homeodomain-containing	O
protein	O
that	O
functions	O
as	O
a	O
dimer	O
.	O

A	O
dimerization	O
cofactor	O
of	O
HNF-1	O
alpha	O
(	O
DCoH	O
)	O
was	O
identified	O
that	O
displayed	O
a	O
restricted	O
tissue	O
distribution	O
and	O
did	O
not	B-Negation
bind	I-Negation
to	I-Negation
DNA	I-Negation
,	O
but	O
,	O
rather	O
,	O
selectively	O
stabilized	O
HNF-1	O
alpha	O
dimers	O
.	O

The	O
formation	O
of	O
a	O
stable	O
tetrameric	O
DCoH-HNF-1	O
alpha	O
complex	O
,	O
which	O
required	O
the	O
dimerization	O
domain	O
of	O
HNF-1	O
alpha	O
,	O
did	O
not	B-Negation
change	I-Negation
the	I-Negation
DNA	I-Negation
binding	I-Negation
characteristics	I-Negation
of	I-Negation
HNF-1	I-Negation
alpha	I-Negation
,	O
but	O
enhanced	O
its	O
transcriptional	O
activity	O
.	O

However	O
,	O
DCoH	O
did	O
not	B-Negation
confer	I-Negation
transcriptional	I-Negation
activation	I-Negation
to	I-Negation
the	I-Negation
GAL4	I-Negation
DNA	I-Negation
binding	I-Negation
domain	I-Negation
.	O

These	O
results	O
indicate	O
that	O
DCoH	O
regulates	O
formation	O
of	O
transcriptionally	O
active	O
tetrameric	O
complexes	O
and	O
may	O
contribute	O
to	O
the	O
developmental	O
specificity	O
of	O
the	O
complex	O
.	O

High	O
affinity	O
aldosterone	O
binding	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
from	O
mononuclear	O
leukocytes	O
:	O
is	O
there	O
a	O
membrane	O
receptor	O
for	O
mineralocorticoids	O
?	O

In	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
the	O
intracellular	O
concentrations	O
of	O
sodium	O
,	O
potassium	O
and	O
calcium	O
,	O
cell	O
volume	O
and	O
the	O
sodium-proton-antiport	O
have	O
been	O
described	O
in	O
intact	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

In	O
the	O
present	O
paper	O
,	O
the	O
binding	O
of	O
a	O
[	O
125I	O
]	O
-labeled	O
aldosterone	O
derivative	O
to	O
plasma	O
membrane	O
rich	O
fractions	O
of	O
HML	O
was	O
studied	O
.	O

High	O
affinity	O
binding	O
of	O
the	O
radioligand	O
with	O
an	O
apparent	O
Kd	O
of	O
approximately	O
0.1	O
nM	O
was	O
found	O
.	O

Aldosterone	O
displaced	O
the	O
tracer	O
at	O
a	O
similar	O
Kd	O
.	O

Both	O
canrenone	O
and	O
cortisol	O
were	O
inactive	O
as	O
ligands	O
up	O
to	O
concentrations	O
of	O
0.1	O
microM	O
.	O

The	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
sites	O
with	O
a	O
high	O
affinity	O
for	O
aldosterone	O
,	O
but	O
not	B-Negation
for	I-Negation
cortisol	I-Negation
.	O

These	O
data	O
are	O
perfectly	O
compatible	O
with	O
major	O
properties	O
of	O
steroidal	O
effects	O
on	O
the	O
sodium-proton-antiport	O
in	O
HML	O
and	O
thus	O
very	O
likely	O
represent	O
membrane	O
receptors	O
for	O
aldosterone	O
.	O

Transcription	O
factor	O
requirements	O
for	O
U2	O
snRNA-encoding	O
gene	O
activation	O
in	O
B	O
lymphoid	O
cells	O
.	O

Transcription	O
of	O
a	O
human	O
U2	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
-encoding	O
gene	O
in	O
HeLa	O
cells	O
requires	O
a	O
distal	O
enhancer	O
element	O
,	O
which	O
is	O
composed	O
of	O
one	O
octamer	O
motif	O
(	O
Oct	O
)	O
and	O
three	O
Sp	O
1-binding	O
sites	O
.	O

To	O
study	O
the	O
transcription	O
factor	O
requirement	O
in	O
B-cells	O
,	O
different	O
U2	O
enhancer	O
constructions	O
were	O
transfected	O
into	O
the	O
lymphoid	O
cell	O
line	O
,	O
BJA-B	O
.	O

The	O
results	O
showed	O
that	O
the	O
activation	O
of	O
U2	O
snRNA	O
transcription	O
in	O
B-cells	O
also	O
requires	O
an	O
enhancer	O
comprising	O
both	O
the	O
Oct	O
and	O
at	O
least	O
one	O
Sp	O
1-binding	O
site	O
.	O

Deletion	O
of	O
all	O
the	O
Sp	O
1-binding	O
sites	O
from	O
the	O
enhancer	O
reduces	O
transcription	O
by	O
80-90	O
%	O
in	O
HeLa	O
,	O
as	O
well	O
as	O
in	O
BJA-B	O
cells	O
,	O
whereas	O
the	O
removal	O
of	O
the	O
octamer-binding	O
site	O
reduces	O
transcription	O
to	O
levels	O
below	O
detection	O
in	O
both	O
cell	O
types	O
.	O

Enhancers	O
containing	O
a	O
single	O
Oct	O
have	O
,	O
nevertheless	O
,	O
the	O
capacity	O
to	O
partially	O
activate	O
U2	O
snRNA	O
transcription	O
in	O
both	O
HeLa	O
cells	O
,	O
in	O
which	O
only	O
OTF-1	O
is	O
expressed	O
,	O
and	O
in	O
BJA-B	O
cells	O
in	O
which	O
OTF-2	O
is	O
the	O
predominantly	O
expressed	O
octamer-binding	O
factor	O
.	O

The	O
most	O
likely	O
interpretation	O
of	O
our	O
results	O
is	O
that	O
both	O
the	O
ubiquitous	O
transcription	O
factor	O
,	O
OTF-1	O
,	O
and	O
the	O
B-cell-specific	O
transcription	O
factor	O
,	O
OTF-2	O
,	O
can	O
activate	O
U2	O
snRNA	O
transcription	O
.	O

The	O
results	O
also	O
revealed	O
a	O
similar	O
functional	O
cooperation	O
between	O
the	O
transcription	O
factors	O
which	O
bind	O
to	O
the	O
Oct	O
and	O
the	O
adjacent	O
Sp	O
1-binding	O
site	O
in	O
BJA-B	O
cells	O
,	O
as	O
has	O
been	O
observed	O
in	O
HeLa	O
cells	O
,	O
since	O
a	O
template	O
which	O
contains	O
a	O
weak	O
binding	O
site	O
for	O
OTFs	O
expresses	O
wild-type	O
levels	O
of	O
U2	O
snRNA	O
in	O
both	O
cell	O
types	O
when	O
the	O
weak	O
octamer-binding	O
site	O
is	O
combined	O
with	O
a	O
Sp	O
1-binding	O
site	O
.	O

Cortisol	O
receptor	O
resistance	O
:	O
the	O
variability	O
of	O
its	O
clinical	O
presentation	O
and	O
response	O
to	O
treatment	O
.	O

Primary	O
(	O
partial	O
)	O
cortisol	O
receptor	O
resistance	O
was	O
previously	O
reported	O
in	O
a	O
total	O
of	O
7	O
patients	O
and	O
14	O
asymptomatic	O
family	O
members	O
.	O

Its	O
occurrence	O
is	O
considered	O
to	O
be	O
extremely	O
rare	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
on	O
6	O
patients	O
(	O
2	O
males	O
and	O
4	O
females	O
)	O
with	O
the	O
syndrome	O
.	O

The	O
first	O
male	O
patient	O
presented	O
with	O
mild	O
hypertension	O
.	O

Hydrochlorothiazide	O
therapy	O
resulted	O
in	O
life-threatening	O
hypokalemia	O
.	O

The	O
second	O
male	O
patient	O
had	O
slight	O
hypertension	O
without	B-Negation
hypokalemia	I-Negation
.	O

All	O
four	O
female	O
patients	O
presented	O
between	O
the	O
age	O
of	O
20-30	O
yr	O
with	O
acne	O
,	O
hirsutism	O
,	O
and	O
irregular	O
menstruations	O
.	O

Low	O
dose	O
dexamethasone	O
therapy	O
(	O
1-1.5	O
mg/day	O
)	O
was	O
of	O
clinical	O
benefit	O
in	O
these	O
patients	O
.	O

All	O
patients	O
showed	O
insufficient	O
suppression	O
of	O
serum	O
cortisol	O
concentrations	O
in	O
the	O
overnight	O
1-mg	O
dexamethasone	O
test	O
.	O

The	O
diurnal	O
rhythm	O
of	O
ACTH	O
and	O
cortisol	O
was	O
intact	O
,	O
albeit	O
at	O
an	O
elevated	O
level	O
.	O

There	O
was	O
a	O
normal	O
increase	O
in	O
ACTH	O
,	O
cortisol	O
,	O
and	O
GH	O
(	O
except	O
in	O
one	O
obese	O
patient	O
)	O
in	O
response	O
to	O
insulin-induced	O
hypoglycemia	O
,	O
while	O
cortisol	O
production	O
was	O
elevated	O
in	O
three	O
patients	O
.	O

Circulating	O
adrenal	O
androgen	O
levels	O
were	O
increased	O
in	O
all	O
patients	O
.	O

Glucocorticoid	O
receptors	O
were	O
investigated	O
in	O
a	O
whole	O
cell	O
dexamethasone	O
binding	O
assay	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
first	O
male	O
patient	O
,	O
the	O
number	O
of	O
receptors	O
was	O
very	O
low	O
,	O
while	O
the	O
affinity	O
was	O
lower	O
than	O
that	O
in	O
controls	O
.	O

A	O
lowered	O
affinity	O
to	O
dexamethasone	O
was	O
found	O
in	O
one	O
female	O
patient	O
,	O
while	O
a	O
lowered	O
number	O
of	O
receptors	O
was	O
found	O
in	O
three	O
patients	O
.	O

In	O
the	O
second	O
male	O
patient	O
,	O
no	B-Negation
abnormalities	I-Negation
were	I-Negation
found	I-Negation
.	O

As	O
a	O
bioassay	O
for	O
glucocorticoid	O
action	O
we	O
also	O
measured	O
dexamethasone	O
suppressibility	O
of	O
mitogen-stimulated	O
incorporation	O
of	O
[	O
3H	O
]	O
thymidine	O
in	O
mononuclear	O
leukocytes	O
.	O

In	O
the	O
male	O
patient	O
with	O
normal	O
receptor	O
status	O
,	O
dexamethasone	O
suppressibility	O
of	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
with	O
respect	O
to	O
both	O
maximal	O
suppression	O
and	O
IC50	O
.	O

Partial	O
cortisol	O
receptor	O
resistance	O
might	O
be	O
less	O
rare	O
than	O
previously	O
thought	O
.	O

In	O
the	O
six	O
patients	O
presented	O
,	O
at	O
least	O
three	O
different	O
forms	O
can	O
be	O
recognized	O
.	O

Therapy	O
with	O
dexamethasone	O
was	O
successful	O
in	O
female	O
patients	O
with	O
acne	O
and	O
hirsutism	O
,	O
as	O
the	O
secondary	O
increase	O
in	O
the	O
production	O
of	O
adrenal	O
androgens	O
was	O
effectively	O
controlled	O
.	O

Kappa	O
B-specific	O
DNA	O
binding	O
proteins	O
are	O
differentially	O
inhibited	O
by	O
enhancer	O
mutations	O
and	O
biological	O
oxidation	O
.	O

Kappa	O
B	O
(	O
kappa	O
B	O
)	O
enhancer	O
binding	O
proteins	O
isolated	O
from	O
the	O
nuclei	O
of	O
activated	O
human	O
T	O
cells	O
produce	O
two	O
distinct	O
nucleoprotein	O
complexes	O
when	O
incubated	O
with	O
the	O
kappa	O
B	O
element	O
from	O
the	O
interleukin-2	O
receptor-alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
.	O

These	O
two	O
DNA-protein	O
complexes	O
are	O
composed	O
of	O
at	O
least	O
four	O
host	O
proteins	O
(	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
p85	O
)	O
,	O
each	O
of	O
which	O
shares	O
structural	O
similarity	O
with	O
the	O
v-rel	O
oncogene	O
product	O
.	O

Nuclear	O
expression	O
of	O
these	O
proteins	O
is	O
induced	O
with	O
distinctly	O
biphasic	O
kinetics	O
following	O
phorbol	O
ester	O
activation	O
of	O
T	O
cells	O
(	O
p55/p75	O
early	O
and	O
p50/p85	O
late	O
)	O
.	O

DNA-protein	O
crosslinking	O
studies	O
have	O
revealed	O
that	O
the	O
more	O
rapidly	O
migrating	O
B2	O
complex	O
contains	O
both	O
p50	O
and	O
p55	O
while	O
the	O
more	O
slowly	O
migrating	O
B1	O
complex	O
is	O
composed	O
of	O
p50	O
,	O
p55	O
,	O
p75	O
,	O
and	O
p85	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
wild-type	O
IL-2R	O
alpha	O
kappa	O
B	O
enhancer	O
(	O
GGGGAATCTCCC	O
)	O
has	O
revealed	O
that	O
the	O
binding	O
of	O
p50	O
and	O
p55	O
(	O
B2	O
complex	O
)	O
is	O
particularly	O
sensitive	O
to	O
alteration	O
of	O
the	O
5	O
'	O
triplet	O
of	O
deoxyguanosine	O
residues	O
.	O

In	O
contrast	O
,	O
formation	O
of	O
the	O
B1	O
complex	O
,	O
reflecting	O
the	O
binding	O
of	O
p75	O
and	O
p85	O
,	O
critically	O
depends	O
upon	O
the	O
more	O
3	O
'	O
sequences	O
of	O
this	O
enhancer	O
element	O
.	O

DNA	O
binding	O
by	O
all	O
four	O
of	O
these	O
Rel-related	O
factors	O
is	O
blocked	O
by	O
selective	O
chemical	O
modification	O
of	O
lysine	O
and	O
arginine	O
residues	O
,	O
suggesting	O
that	O
both	O
of	O
these	O
basic	O
amino	O
acids	O
are	O
required	O
for	O
binding	O
to	O
the	O
kappa	O
B	O
element	O
.	O

Similarly	O
,	O
covalent	O
modification	O
of	O
free	O
sulfhydryl	O
groups	O
with	O
diamide	O
(	O
reversible	O
)	O
or	O
N-ethylmaleimide	O
(	O
irreversible	O
)	O
results	O
in	O
a	O
complete	O
loss	O
of	O
DNA	O
binding	O
activity	O
.	O

In	O
contrast	O
,	O
mild	O
oxidation	O
with	O
glucose	O
oxidase	O
selectively	O
inhibits	O
p75	O
and	O
p85	O
binding	O
while	O
not	B-Negation
blocking	I-Negation
p50	I-Negation
and	I-Negation
p55	I-Negation
interactions	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
reduced	O
cysteine	O
thiols	O
play	O
an	O
important	O
role	O
in	O
the	O
DNA	O
binding	O
activity	O
of	O
this	O
family	O
of	O
Rel-related	O
transcription	O
factors	O
.	O

A	O
novel	O
mitogen-inducible	O
gene	O
product	O
related	O
to	O
p50/p105-NF-kappa	O
B	O
participates	O
in	O
transactivation	O
through	O
a	O
kappa	O
B	O
site	O
.	O

A	O
Rel-related	O
,	O
mitogen-inducible	O
,	O
kappa	O
B-binding	O
protein	O
has	O
been	O
cloned	O
as	O
an	O
immediate-early	O
activation	O
gene	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
cDNA	O
has	O
an	O
open	O
reading	O
frame	O
of	O
900	O
amino	O
acids	O
capable	O
of	O
encoding	O
a	O
97-kDa	O
protein	O
.	O

This	O
protein	O
is	O
most	O
similar	O
to	O
the	O
105-kDa	O
precursor	O
polypeptide	O
of	O
p50-NF-kappa	O
B	O
.	O

Like	O
the	O
105-kDa	O
precursor	O
,	O
it	O
contains	O
an	O
amino-terminal	O
Rel-related	O
domain	O
of	O
about	O
300	O
amino	O
acids	O
and	O
a	O
carboxy-terminal	O
domain	O
containing	O
six	O
full	O
cell	O
cycle	O
or	O
ankyrin	O
repeats	O
.	O

In	O
vitro-translated	O
proteins	O
,	O
truncated	O
downstream	O
of	O
the	O
Rel	O
domain	O
and	O
excluding	O
the	O
repeats	O
,	O
bind	O
kappa	O
B	O
sites	O
.	O

We	O
refer	O
to	O
the	O
kappa	O
B-binding	O
,	O
truncated	O
protein	O
as	O
p50B	O
by	O
analogy	O
with	O
p50-NF-kappa	O
B	O
and	O
to	O
the	O
full-length	O
protein	O
as	O
p97	O
.	O

p50B	O
is	O
able	O
to	O
form	O
heteromeric	O
kappa	O
B-binding	O
complexes	O
with	O
RelB	O
,	O
as	O
well	O
as	O
with	O
p65	O
and	O
p50	O
,	O
the	O
two	O
subunits	O
of	O
NF-kappa	O
B	O
.	O

Transient-transfection	O
experiments	O
in	O
embryonal	O
carcinoma	O
cells	O
demonstrate	O
a	O
functional	O
cooperation	O
between	O
p50B	O
and	O
RelB	O
or	O
p65	O
in	O
transactivation	O
of	O
a	O
reporter	O
plasmid	O
dependent	O
on	O
a	O
kappa	O
B	O
site	O
.	O

The	O
data	O
imply	O
the	O
existence	O
of	O
a	O
complex	O
family	O
of	O
NF-kappa	O
B-like	O
transcription	O
factors	O
.	O

[	O
Changes	O
in	O
leucocytic	O
estrogen	O
receptor	O
levels	O
in	O
patients	O
with	O
climacteric	O
syndrome	O
and	O
therapeutic	O
effect	O
of	O
liuwei	O
dihuang	O
pills	O
]	O

The	O
numbers	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
in	O
human	O
peripheral	O
leucocytes	O
in	O
22	O
women	O
with	O
climacteric	O
syndrome	O
were	O
measured	O
by	O
radioligand	O
method	O
.	O

The	O
results	O
were	O
compared	O
with	O
those	O
of	O
12	O
normal	O
child-bearing-age	O
women	O
.	O

It	O
wat	O
found	O
that	O
the	O
contents	O
of	O
leucocytic	O
ER	O
in	O
climacteric	O
syndrome	O
patients	O
were	O
significantly	O
lower	O
than	O
normal	O
child-bearing-age	O
women	O
.	O

The	O
authors	O
used	O
a	O
Chinese	O
prescription	O
--	O
Liuwei	O
Dihuang	O
Pills	O
(	O
LDP	O
)	O
to	O
treat	O
the	O
patients	O
for	O
2	O
months	O
.	O

The	O
numbers	O
of	O
leucocytic	O
ER	O
were	O
significantly	O
increased	O
after	O
treatment	O
.	O

The	O
data	O
indicate	O
that	O
decrease	O
of	O
ER	O
levels	O
in	O
cell	O
may	O
involve	O
in	O
the	O
pathogenesis	O
of	O
climacteric	O
syndrome	O
.	O

LDP	O
not	O
only	O
increases	O
plasma	O
estradiol	O
levels	O
,	O
but	O
also	O
increases	O
the	O
leucocytic	O
ER	O
levels	O
.	O

This	O
may	O
be	O
the	O
basis	O
of	O
the	O
therapeutic	O
effect	O
on	O
the	O
disease	O
.	O

A	O
novel	O
primer	O
extension	O
method	O
to	O
detect	O
the	O
number	O
of	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
in	O
families	O
with	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
.	O

X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
(	O
SBMA	O
)	O
,	O
an	O
adult-onset	O
form	O
of	O
motor	O
neuron	O
disease	O
,	O
was	O
recently	O
reported	O
to	O
be	O
caused	O
by	O
amplification	O
of	O
the	O
CAG	O
repeats	O
in	O
the	O
androgen	O
receptor	O
gene	O
.	O

We	O
report	O
here	O
a	O
simple	O
and	O
rapid	O
strategy	O
to	O
detect	O
the	O
precise	O
number	O
of	O
the	O
CAGs	O
.	O

After	O
the	O
DNA	O
fragment	O
containing	O
the	O
CAG	O
repeats	O
is	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
,	O
a	O
primer	O
extension	O
is	O
carried	O
out	O
;	O

the	O
extension	O
of	O
the	O
end-labelled	O
reverse	O
primer	O
adjacent	O
to	O
3	O
'	O
end	O
of	O
CAG	O
repeats	O
stops	O
at	O
the	O
first	O
T	O
after	O
CAG	O
repeats	O
with	O
the	O
incorporation	O
of	O
dideoxy	O
ATP	O
in	O
the	O
reaction	O
mixture	O
.	O

The	O
resultant	O
primer	O
products	O
are	O
analysed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
autoradiography	O
.	O

This	O
method	O
could	O
be	O
quite	O
useful	O
to	O
detect	O
not	O
only	O
CAG	O
repeats	O
in	O
SBMA	O
but	O
also	O
other	O
polymorphic	O
dinucleotide	O
and	O
trinucleotide	O
repeats	O
.	O

Activity	O
of	O
the	O
kappa	O
B	O
enhancer	O
of	O
the	O
interleukin-2	O
receptor	O
alpha	O
chain	O
in	O
somatic	O
cell	O
hybrids	O
is	O
accompanied	O
by	O
the	O
nuclear	O
localization	O
of	O
NF-kappa	O
B	O
.	O

The	O
two	O
nuclear	O
proteins	O
NF-kappa	O
B	O
(	O
consisting	O
of	O
subunits	O
p50	O
andp65	O
)	O
and	O
the	O
DNA-binding	O
subunit	O
of	O
NF-kappa	O
B	O
(	O
p50	O
)	O
by	O
itself	O
,	O
also	O
called	O
KBF1	O
,	O
are	O
constitutively	O
expressed	O
and	O
localized	O
in	O
the	O
nucleus	O
of	O
the	O
human	O
T-cell	O
line	O
IARC	O
301.5	O
.	O

In	O
order	O
to	O
define	O
the	O
roles	O
of	O
these	O
two	O
factors	O
,	O
which	O
bind	O
to	O
the	O
same	O
kappa	O
B	O
enhancers	O
,	O
in	O
transcription	O
activation	O
we	O
have	O
prepared	O
somatic	O
cell	O
hybrids	O
between	O
IARC	O
301.5	O
and	O
a	O
murine	O
myeloma	O
.	O

Most	O
hybrids	O
express	O
both	O
KBF1	O
and	O
NF-kappa	O
B	O
in	O
their	O
nuclei	O
,	O
but	O
one	O
hybrid	O
expresses	O
only	O
KBF1	O
.	O

The	O
kappa	O
B	O
enhancer	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
is	O
functional	O
only	O
in	O
the	O
hybrids	O
expressing	O
nuclear	O
NF-kappa	O
B	O
.	O

These	O
findings	O
show	O
that	O
nuclear	O
NF-kappa	O
B	O
is	O
necessary	O
to	O
activate	O
the	O
kappa	O
B	O
enhancer	O
,	O
while	O
KBF1	O
by	O
itself	O
is	O
not	B-Negation
sufficient	I-Negation
.	O

We	O
propose	O
that	O
KBF1	O
is	O
a	O
competitive	O
inhibitor	O
of	O
NF-kappa	O
B	O
and	O
discuss	O
how	O
these	O
factors	O
may	O
be	O
involved	O
in	O
the	O
transient	O
expression	O
of	O
IL-2	O
and	O
IL-2R	O
alpha	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Influence	O
of	O
estradiol	O
and	O
tamoxifen	O
on	O
susceptibility	O
of	O
human	O
breast	O
cancer	O
cell	O
lines	O
to	O
lysis	O
by	O
lymphokine-activated	O
killer	O
cells	O
.	O

The	O
design	O
of	O
combination	O
hormonal	O
and	O
immunotherapeutic	O
protocols	O
for	O
breast	O
cancer	O
patients	O
may	O
be	O
facilitated	O
by	O
analysis	O
of	O
preclinical	O
in	O
vitro	O
model	O
systems	O
.	O

Estrogen	O
receptor	O
positive	O
(	O
ER+	O
:	O
MCF-7	O
)	O
and	O
negative	O
(	O
ER-	O
:	O
MDA-MB-231	O
)	O
human	O
breast	O
cancer	O
cell	O
lines	O
were	O
utilized	O
to	O
evaluate	O
the	O
effects	O
of	O
tamoxifen	O
(	O
TAM	O
)	O
and	O
estradiol	O
(	O
E2	O
)	O
on	O
modulation	O
of	O
breast	O
cancer	O
target	O
susceptibility	O
to	O
lysis	O
by	O
lymphokine-activated	O
killer	O
(	O
LAK	O
)	O
cells	O
.	O

E2-stimulated	O
ER+	O
cells	O
were	O
more	O
susceptible	O
to	O
lysis	O
by	O
LAK	O
cells	O
than	O
corresponding	O
TAM-treated	O
or	O
control	O
cells	O
,	O
while	O
treatment	O
of	O
ER-	O
cells	O
with	O
either	O
E2	O
or	O
TAM	O
alone	O
did	O
not	B-Negation
alter	I-Negation
from	I-Negation
control	I-Negation
their	I-Negation
susceptibility	I-Negation
to	I-Negation
this	I-Negation
immune-mediated	I-Negation
lysis	I-Negation
.	O

All	O
ER+	O
and	O
ER-	O
cells	O
tested	O
remained	O
sensitive	O
after	O
treatment	O
with	O
TAM	O
to	O
lysis	O
by	O
LAK	O
cells	O
.	O

In	O
addition	O
,	O
an	O
adenocarcinoma	O
reactive	O
human-mouse	O
chimeric	O
monoclonal	O
antibody	O
(	O
ING-1	O
)	O
was	O
able	O
to	O
significantly	O
boost	O
in	O
vivo	O
generated	O
LAK	O
cell-mediated	O
lysis	O
of	O
control	O
,	O
E2-treated	O
,	O
and	O
TAM-treated	O
ER+	O
and	O
ER-	O
cells	O
.	O

These	O
in	O
vitro	O
results	O
provide	O
a	O
preclinical	O
rationale	O
for	O
in	O
vivo	O
testing	O
of	O
TAM	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
and	O
breast	O
cancer	O
reactive	O
antibody-dependent	O
cellular	O
cytotoxicity	O
facilitating	O
antibody	O
in	O
patients	O
with	O
refractory	O
or	O
high	O
risk	O
breast	O
cancer	O
.	O

Glucocorticoid	O
receptor	O
and	O
inhibition	O
of	O
3-O-methyl-D-glucose	O
uptake	O
by	O
glucocorticoids	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
humans	O
:	O
correlation	O
between	O
receptor	O
level	O
and	O
hormone	O
effect	O
in	O
vitro	O
.	O

We	O
have	O
measured	O
the	O
glucocorticoid	O
receptor	O
concentration	O
in	O
mononuclear	O
and	O
polymorphonuclear	O
leukocytes	O
,	O
both	O
of	O
which	O
were	O
isolated	O
from	O
peripheral	O
blood	O
from	O
ten	O
healthy	O
male	O
volunteers	O
.	O

In	O
parallel	O
,	O
the	O
inhibitory	O
effect	O
of	O
dexamethasone	O
on	O
3-O-methyl-D-glucose	O
uptake	O
was	O
assayed	O
in	O
the	O
corresponding	O
mononuclear	O
leukocytes	O
.	O

The	O
glucocorticoid	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
correlated	O
with	O
those	O
in	O
polymorphonuclear	O
leukocytes	O
,	O
and	O
there	O
was	O
a	O
linear	O
relationship	O
between	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
and	O
glucocorticoid-mediated	O
inhibition	O
of	O
the	O
uptake	O
of	O
3-O-methyl-D-glucose	O
in	O
mononuclear	O
leukocytes	O
.	O

When	O
mononuclear	O
leukocytes	O
were	O
incubated	O
in	O
the	O
presence	O
of	O
8-bromo-cAMP	O
,	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
increased	O
and	O
a	O
more	O
pronounced	O
inhibitory	O
effect	O
of	O
dexamethasone	O
was	O
observed	O
on	O
the	O
transport	O
of	O
3-O-methyl-D-glucose	O
.	O

We	O
conclude	O
that	O
the	O
cellular	O
glucocorticoid	O
receptor	O
levels	O
in	O
peripheral	O
blood	O
leukocytes	O
reflect	O
in	O
vitro	O
responsiveness	O
to	O
glucocorticoids	O
in	O
mononuclear	O
leukocytes	O
from	O
healthy	O
males	O
,	O
and	O
that	O
the	O
individual	O
responsiveness	O
may	O
alter	O
upon	O
changes	O
in	O
the	O
cellular	O
levels	O
of	O
glucocorticoid	O
receptor	O
.	O

Stimulation	O
of	O
interferon	O
beta	O
gene	O
transcription	O
in	O
vitro	O
by	O
purified	O
NF-kappa	O
B	O
and	O
a	O
novel	O
TH	O
protein	O
.	O

The	O
human	O
interferon	O
beta	O
(	O
IFN-beta	O
)	O
regulatory	O
element	O
consists	O
of	O
multiple	O
enhanson	O
domains	O
which	O
are	O
targets	O
for	O
transcription	O
factors	O
involved	O
in	O
inducible	O
expression	O
of	O
the	O
promoter	O
.	O

To	O
further	O
characterize	O
the	O
protein-DNA	O
interactions	O
mediating	O
IFN-beta	O
induction	O
,	O
positive	O
regulatory	O
domain	O
(	O
PRD	O
)	O
II	O
binding	O
proteins	O
were	O
purified	O
from	O
phorbol	O
ester	O
induced	O
Jurkat	O
T-cells	O
and	O
from	O
IFN	O
primed	O
,	O
cycloheximide/polyinosinic-polycytidylic	O
acid	O
treated	O
HeLa	O
S3	O
cells	O
.	O

From	O
HeLa	O
cells	O
,	O
two	O
major	O
proteins	O
of	O
52	O
and	O
45	O
kilodaltons	O
(	O
kD	O
)	O
copurified	O
with	O
DNA	O
binding	O
activity	O
,	O
whereas	O
from	O
T-cells	O
,	O
four	O
proteins	O
--	O
a	O
major	O
protein	O
of	O
52	O
kD	O
and	O
three	O
minor	O
proteins	O
of	O
82	O
,	O
67	O
,	O
and	O
43-47	O
kD	O
--	O
were	O
purified	O
.	O

Also	O
,	O
an	O
induction	O
specific	O
DNA	O
binding	O
protein	O
was	O
purified	O
from	O
HeLa	O
cells	O
that	O
interacted	O
with	O
the	O
(	O
AAGTGA	O
)	O
4	O
tetrahexamer	O
sequence	O
and	O
the	O
PRDI	O
domain	O
.	O

This	O
protein	O
is	O
immunologically	O
distinct	O
from	O
IRF-1/ISGF2	O
.	O

Uninduced	O
or	O
Sendai	O
virus	O
induced	O
HeLa	O
extracts	O
were	O
used	O
to	O
examine	O
transcription	O
in	O
vitro	O
using	O
a	O
series	O
of	O
IFN	O
beta	O
promoter	O
deletions	O
.	O

Deletions	O
upstream	O
of	O
the	O
PRDII	O
element	O
increased	O
transcription	O
in	O
the	O
uninduced	O
extract	O
,	O
indicating	O
predominantly	O
negative	O
regulation	O
of	O
the	O
promoter	O
.	O

A	O
2-4-fold	O
increase	O
in	O
IFN-beta	O
promoter	O
transcription	O
was	O
observed	O
in	O
Sendai	O
virus	O
induced	O
extracts	O
,	O
and	O
deletion	O
of	O
PRDI	O
and	O
PRDII	O
elements	O
decreased	O
this	O
induced	O
level	O
of	O
transcription	O
.	O

When	O
purified	O
PRDII	O
and	O
tetrahexamer	O
binding	O
proteins	O
were	O
added	O
to	O
the	O
induced	O
extract	O
,	O
a	O
4-fold	O
increase	O
in	O
transcription	O
was	O
observed	O
.	O

These	O
experiments	O
demonstrate	O
that	O
it	O
is	O
possible	O
to	O
modulate	O
IFN-beta	O
transcription	O
in	O
vitro	O
but	O
indicate	O
that	O
additional	O
proteins	O
may	O
be	O
required	O
to	O
fully	O
activate	O
IFN-beta	O
transcription	O
.	O

Structure	O
function	O
analysis	O
of	O
vitamin	O
D	O
analogs	O
with	O
C-ring	O
modifications	O
.	O

Analogs	O
of	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
)	O
with	O
substitutions	O
on	O
C-11	O
were	O
synthesized	O
.	O

Small	O
apolar	O
substitutions	O
(	O
11	O
alpha-methyl	O
,	O
11	O
alpha-fluoromethyl	O
)	O
did	O
not	O
markedly	O
decrease	O
the	O
affinity	O
for	O
the	O
vitamin	O
D	O
receptor	O
,	O
but	O
larger	O
(	O
11	O
alpha-chloromethyl	O
or	O
11	O
alpha-	O
or	O
11	O
beta-phenyl	O
)	O
or	O
more	O
polar	O
substitutions	O
(	O
11	O
alpha-hydroxymethyl	O
,	O
11	O
alpha-	O
(	O
2-hydroxyethyl	O
]	O
decreased	O
the	O
affinity	O
to	O
less	O
than	O
5	O
%	O
of	O
that	O
of	O
1	O
alpha,25-OH	O
)	O
2D3	O
.	O

Their	O
affinity	O
for	O
the	O
vitamin	O
D-binding	O
protein	O
,	O
however	O
,	O
increased	O
up	O
to	O
4-fold	O
.	O

The	O
biological	O
activity	O
of	O
11	O
alpha-methyl-1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
closely	O
resembled	O
that	O
of	O
the	O
natural	O
hormone	O
on	O
normal	O
and	O
leukemic	O
cell	O
proliferation	O
and	O
bone	O
resorption	O
,	O
whereas	O
its	O
in	O
vivo	O
effect	O
on	O
calcium	O
metabolism	O
of	O
the	O
rachitic	O
chick	O
was	O
about	O
50	O
%	O
of	O
that	O
of	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
.	O

The	O
11	O
beta-methyl	O
analog	O
had	O
a	O
greater	O
than	O
10-fold	O
lower	O
activity	O
.	O

The	O
differentiating	O
effects	O
of	O
the	O
other	O
C-11	O
analogs	O
on	O
human	O
promyeloid	O
leukemia	O
cells	O
(	O
HL-60	O
)	O
agreed	O
well	O
with	O
their	O
bone-resorbing	O
activity	O
and	O
receptor	O
affinity	O
,	O
but	O
they	O
demonstrated	O
lower	O
calcemic	O
effects	O
in	O
vivo	O
.	O

Large	O
or	O
polar	O
substitutions	O
on	O
C-11	O
of	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
thus	O
impair	O
the	O
binding	O
of	O
the	O
vitamin	O
D	O
receptor	O
but	O
increase	O
the	O
affinity	O
to	O
vitamin	O
D-binding	O
protein	O
.	O

The	O
effects	O
of	O
many	O
C-11-substituted	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
analogs	O
on	O
HL-60	O
cell	O
differentiation	O
exceeded	O
their	O
activity	O
on	O
calcium	O
metabolism	O
.	O

Transcriptional	O
regulation	O
during	O
T-cell	O
development	O
:	O
the	O
alpha	O
TCR	O
gene	O
as	O
a	O
molecular	O
model	O
.	O

The	O
regulation	O
of	O
gene	O
expression	O
during	O
lymphocyte	O
differentiation	O
is	O
a	O
complex	O
process	O
involving	O
interactions	O
between	O
multiple	O
positive	O
and	O
negative	O
transcriptional	O
regulatory	O
elements	O
.	O

In	O
this	O
article	O
,	O
transcriptional	O
regulation	O
of	O
the	O
archetypal	O
T-cell-specific	O
gene	O
,	O
alpha	O
TCR	O
,	O
is	O
discussed	O
.	O

Major	O
recent	O
developments	O
,	O
including	O
the	O
identification	O
of	O
novel	O
families	O
of	O
transcription	O
factors	O
that	O
regulate	O
multiple	O
T-cell	O
genes	O
during	O
thymocyte	O
ontogeny	O
and	O
T-cell	O
activation	O
,	O
are	O
described	O
.	O

Cortisol	O
resistance	O
in	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

This	O
study	O
concerns	O
9	O
iv	O
drug	O
abusers	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
who	O
developed	O
hypercortisolism	O
without	B-Negation
the	I-Negation
clinical	I-Negation
signs	I-Negation
or	I-Negation
metabolic	I-Negation
consequences	I-Negation
of	I-Negation
hypercortisolism	I-Negation
.	O

All	O
patients	O
were	O
characterized	O
by	O
an	O
Addisonian	O
picture	O
(	O
weakness	O
,	O
weight	O
loss	O
,	O
hypotension	O
,	O
hyponatremia	O
,	O
and	O
intense	O
mucocutaneous	O
melanosis	O
)	O
.	O

An	O
acquired	O
form	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
was	O
suspected	O
.	O

We	O
,	O
therefore	O
,	O
examined	O
glucocorticoid	O
receptor	O
characteristics	O
on	O
mononuclear	O
leukocytes	O
by	O
measuring	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
the	O
effect	O
of	O
dexamethasone	O
on	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
,	O
which	O
is	O
one	O
of	O
the	O
effects	O
of	O
glucocorticoid	O
receptor	O
activation	O
.	O

Glucocorticoid	O
receptor	O
density	O
was	O
increased	O
in	O
AIDS	O
patients	O
with	O
an	O
Addisonian	O
picture	O
(	O
group	O
1	O
;	O
16.2	O
	O
9.4	O
fmol/million	O
cells	O
)	O
compared	O
to	O
values	O
in	O
12	O
AIDS	O
patients	O
without	B-Negation
an	I-Negation
Addisonian	I-Negation
picture	I-Negation
(	O
group	O
2	O
;	O
6.05	O
	O
2.6	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
and	O
sex-	O
and	O
age-matched	O
controls	O
(	O
3.15	O
	O
2.3	O
fmol/million	O
cells	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

The	O
affinity	O
of	O
glucocorticoid	O
receptors	O
(	O
Kd	O
)	O
was	O
strikingly	O
decreased	O
(	O
9.36	O
	O
3.44	O
nM	O
in	O
group	O
1	O
;	O
3.2	O
	O
1.5	O
nM	O
in	O
group	O
2	O
;	O
2.0	O
	O
0.8	O
nM	O
in	O
controls	O
;	O
P	O
less	O
than	O
0.01	O
)	O
.	O

[	O
3H	O
]	O
Thymidine	O
incorporation	O
was	O
decreased	O
dose-dependently	O
by	O
dexamethasone	O
in	O
controls	O
and	O
patients	O
;	O

the	O
effect	O
was	O
significantly	O
blunted	O
(	O
P	O
less	O
than	O
0.05	O
)	O
in	O
group	O
1	O
patients	O
,	O
which	O
suggests	O
that	O
activation	O
of	O
glucocorticoid	O
receptor	O
is	O
impaired	O
as	O
a	O
result	O
of	O
the	O
glucocorticoid	O
receptor	O
abnormality	O
.	O

In	O
conclusion	O
,	O
AIDS	O
patients	O
with	O
hypercortisolism	O
and	O
clinical	O
features	O
of	O
peripheral	O
resistance	O
to	O
glucocorticoids	O
are	O
characterized	O
by	O
abnormal	O
glucocorticoid	O
receptors	O
on	O
lymphocytes	O
.	O

Resistance	O
to	O
glucocorticoids	O
implies	O
a	O
complex	O
change	O
in	O
immune-endocrine	O
function	O
,	O
which	O
may	O
be	O
important	O
in	O
the	O
course	O
of	O
immunodeficiency	O
syndrome	O
.	O

Induction	O
of	O
monocytic	O
differentiation	O
and	O
NF-kappa	O
B-like	O
activities	O
by	O
human	O
immunodeficiency	O
virus	O
1	O
infection	O
of	O
myelomonoblastic	O
cells	O
.	O

The	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
infection	O
on	O
cellular	O
differentiation	O
and	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
have	O
been	O
investigated	O
in	O
a	O
new	O
model	O
of	O
myeloid	O
differentiation	O
.	O

PLB-985	O
cells	O
represent	O
a	O
bipotential	O
myelomonoblastic	O
cell	O
population	O
capable	O
of	O
either	O
granulocytic	O
or	O
monocytic	O
differentiation	O
after	O
induction	O
with	O
appropriate	O
inducers	O
.	O

By	O
virtue	O
of	O
the	O
presence	O
of	O
CD4	O
on	O
the	O
cell	O
surface	O
,	O
PLB-985	O
cells	O
were	O
chronically	O
infected	O
with	O
HIV-1	O
strain	O
IIIB	O
.	O

PLB-IIIB	O
cells	O
clearly	O
possessed	O
a	O
more	O
monocytic	O
phenotype	O
than	O
the	O
parental	O
myeloblasts	O
,	O
as	O
determined	O
by	O
differential	O
staining	O
,	O
increased	O
expression	O
of	O
the	O
myeloid-specific	O
surface	O
markers	O
,	O
and	O
transcription	O
of	O
the	O
c-fms	O
proto-oncogene	O
.	O

NF-kappa	O
B	O
binding	O
activity	O
was	O
inducible	O
by	O
tumor	O
necrosis	O
factor	O
and	O
phorbol	O
myristate	O
acetate	O
in	O
PLB-985	O
.	O

However	O
,	O
in	O
PLB-IIIB	O
cells	O
,	O
constitutive	O
expression	O
of	O
a	O
novel	O
NF-kappa	O
B	O
complex	O
was	O
detected	O
,	O
composed	O
of	O
proteins	O
ranging	O
between	O
70	O
and	O
110	O
kD	O
.	O

These	O
proteins	O
interacted	O
specifically	O
with	O
the	O
symmetric	O
NF-kappa	O
B	O
site	O
from	O
the	O
interferon	O
beta	O
(	O
IFN-beta	O
)	O
promoter	O
.	O

Mutations	O
affecting	O
the	O
5	O
'	O
guanine	O
residues	O
of	O
the	O
kappa	O
B	O
site	O
were	O
unable	B-Negation
to	I-Negation
compete	I-Negation
for	I-Negation
these	I-Negation
NF-kappa	I-Negation
B-related	I-Negation
proteins	I-Negation
.	O

Inducibility	O
of	O
endogenous	O
IFN-beta	O
and	O
IFN-alpha	O
RNA	O
was	O
also	O
increased	O
in	O
PLB-IIIB	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
HIV-1	O
infection	O
of	O
myelomonoblastic	O
cells	O
may	O
select	O
for	O
a	O
more	O
mature	O
monocytic	O
phenotype	O
and	O
that	O
unique	O
subunit	O
associations	O
of	O
NF-kappa	O
B	O
DNA	O
binding	O
proteins	O
may	O
contribute	O
to	O
differential	O
NF-kappa	O
B-mediated	O
gene	O
expression	O
.	O

The	O
AP-1	O
site	O
at	O
-150	O
bp	O
,	O
but	O
not	O
the	O
NF-kappa	O
B	O
site	O
,	O
is	O
likely	O
to	O
represent	O
the	O
major	O
target	O
of	O
protein	O
kinase	O
C	O
in	O
the	O
interleukin	O
2	O
promoter	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
antigen	O
results	O
in	O
activation	O
of	O
several	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
that	O
may	O
mediate	O
the	O
later	O
induction	O
of	O
activation-related	O
genes	O
.	O

We	O
have	O
examined	O
the	O
potential	O
role	O
of	O
PKC	O
in	O
induction	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T	O
cell	O
receptor/CD3	O
complex	O
.	O

We	O
have	O
previously	O
shown	O
that	O
prolonged	O
treatment	O
of	O
the	O
untransformed	O
T	O
cell	O
clone	O
Ar-5	O
with	O
phorbol	O
esters	O
results	O
in	O
downmodulation	O
of	O
the	O
alpha	O
and	O
beta	O
isozymes	O
of	O
PKC	O
,	O
and	O
abrogates	O
induction	O
of	O
IL-2	O
mRNA	O
and	O
protein	O
.	O

Here	O
we	O
show	O
that	O
phorbol	O
ester	O
treatment	O
also	O
abolishes	O
induction	O
of	O
chloramphenicol	O
acetyltransferase	O
activity	O
in	O
Ar-5	O
cells	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	O
promoter	O
linked	O
to	O
this	O
reporter	O
gene	O
.	O

The	O
IL-2	O
promoter	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factors	O
including	O
NFAT-1	O
,	O
Oct	O
,	O
NF-kappa	O
B	O
,	O
and	O
AP-1	O
,	O
which	O
are	O
all	O
potentially	O
sensitive	O
to	O
activation	O
of	O
PKC	O
.	O

We	O
show	O
that	O
induction	O
of	O
a	O
trimer	O
of	O
the	O
NFAT	O
and	O
Oct	O
sites	O
is	O
not	B-Negation
sensitive	I-Negation
to	I-Negation
phorbol	I-Negation
ester	I-Negation
treatment	I-Negation
,	O
and	O
that	O
mutations	O
in	O
the	O
NF-kappa	O
B	O
site	O
have	O
no	B-Negation
effect	I-Negation
on	I-Negation
inducibility	I-Negation
of	I-Negation
the	I-Negation
IL-2	I-Negation
promoter	I-Negation
.	O

In	O
contrast	O
,	O
mutations	O
in	O
the	O
AP-1	O
site	O
located	O
at	O
-150	O
bp	O
almost	O
completely	O
abrogate	O
induction	O
of	O
the	O
IL-2	O
promoter	O
,	O
and	O
appearance	O
of	O
an	O
inducible	O
nuclear	O
factor	O
binding	O
to	O
this	O
site	O
is	O
sensitive	O
to	O
PKC	O
depletion	O
.	O

Moreover	O
,	O
cotransfections	O
with	O
c-fos	O
and	O
c-jun	O
expression	O
plasmids	O
markedly	O
enhance	O
induction	O
of	O
the	O
IL-2	O
promoter	O
in	O
minimally	O
stimulated	O
T	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
AP-1	O
site	O
at	O
-150	O
bp	O
represents	O
a	O
major	O
,	O
if	O
not	O
the	O
only	O
,	O
site	O
of	O
PKC	O
responsiveness	O
in	O
the	O
IL-2	O
promoter	O
.	O

Interleukin	O
6-induced	O
differentiation	O
of	O
a	O
human	O
B	O
cell	O
line	O
into	O
IgM-secreting	O
plasma	O
cells	O
is	O
mediated	O
by	O
c-fos	O
.	O

The	O
role	O
of	O
the	O
protooncogene	O
c-fos	O
in	O
interleukin	O
(	O
IL	O
)	O
6-induced	O
B	O
cell	O
differentiation	O
was	O
assessed	O
.	O

Treatment	O
of	O
SKW	O
6.4	O
cells	O
with	O
IL	O
6	O
induced	O
a	O
transient	O
and	O
early	O
stimulation	O
of	O
c-fos	O
sense	O
mRNA	O
expression	O
.	O

The	O
effect	O
appeared	O
within	O
30	O
min	O
and	O
returned	O
to	O
basal	O
levels	O
after	O
2	O
h	O
.	O

The	O
addition	O
of	O
antisense	O
oligonucleotides	O
to	O
c-fos	O
significantly	O
inhibited	O
IL	O
6-induced	O
IgM	O
production	O
by	O
SKW	O
6.4	O
cells	O
(	O
p	O
less	O
than	O
0.001	O
)	O
,	O
whereas	O
control	O
oligonucleotides	O
had	O
no	B-Negation
inhibitory	I-Negation
effect	I-Negation
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
c-fos	O
is	O
involved	O
in	O
IL	O
6-induced	O
differentiation	O
of	O
SKW	O
6.4	O
cells	O
into	O
IgM-secreting	O
cells	O
.	O

Binding	O
of	O
erythroid	O
and	O
non-erythroid	O
nuclear	O
proteins	O
to	O
the	O
silencer	O
of	O
the	O
human	O
epsilon-globin-encoding	O
gene	O
.	O

To	O
clarify	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
developmental	O
control	O
of	O
hemoglobin-encoding	O
genes	O
we	O
have	O
been	O
studying	O
the	O
expression	O
of	O
these	O
genes	O
in	O
human	O
cells	O
in	O
continuous	O
culture	O
.	O

We	O
have	O
previously	O
reported	O
the	O
presence	O
of	O
a	O
transcriptional	O
control	O
element	O
with	O
the	O
properties	O
of	O
a	O
silencer	O
extending	O
from	O
-392	O
to	O
-177	O
bp	O
relative	O
to	O
the	O
cap	O
site	O
of	O
the	O
human	O
epsilon-globin-encoding	O
gene	O
[	O
Cao	O
et	O
al.	O
,	O
Proc.Natl.Acad.Sci.USA	O
86	O
(	O
1989	O
)	O
5306-5309	O
]	O
.	O

We	O
also	O
showed	O
that	O
this	O
silencer	O
has	O
stronger	O
inhibitory	O
activity	O
in	O
HeLa	O
cells	O
,	O
as	O
compared	O
to	O
K562	O
human	O
erythroleukemia	O
cells	O
.	O

Using	O
deletion	O
mutants	O
and	O
cis-cloned	O
synthetic	O
oligodeoxyribonucleotides	O
in	O
transient	O
expression	O
assays	O
,	O
nucleotide	O
sequences	O
responsible	O
for	O
this	O
effect	O
have	O
now	O
been	O
further	O
delimited	O
to	O
44	O
bp	O
located	O
from	O
-294	O
to	O
-251	O
bp	O
.	O

Gel	O
electrophoresis	O
mobility	O
shift	O
assays	O
and	O
DNaseI	O
footprinting	O
assays	O
demonstrate	O
that	O
these	O
negative	O
regulatory	O
sequences	O
are	O
recognized	O
differently	O
by	O
proteins	O
present	O
in	O
nuclear	O
extracts	O
obtained	O
from	O
HeLa	O
and	O
K562	O
cells	O
.	O

Two	O
binding	O
proteins	O
are	O
detected	O
in	O
K562	O
nuclear	O
extracts	O
,	O
while	O
only	O
one	O
is	O
found	O
in	O
extracts	O
from	O
HeLa	O
cells	O
.	O

Possible	O
mechanisms	O
by	O
which	O
these	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
epsilon-globin-encoding	O
gene	O
in	O
erythroid	O
and	O
non-erythroid	O
cells	O
are	O
discussed	O
.	O

Gangliosides	O
suppress	O
tumor	O
necrosis	O
factor	O
production	O
in	O
human	O
monocytes	O
.	O

Both	O
normal	O
and	O
malignant	O
cells	O
contain	O
gangliosides	O
as	O
important	O
cell	O
membrane	O
constituents	O
that	O
,	O
after	O
being	O
shed	O
,	O
may	O
influence	O
cells	O
of	O
the	O
immune	O
system	O
.	O

We	O
have	O
studied	O
the	O
impact	O
of	O
gangliosides	O
on	O
the	O
expression	O
of	O
TNF	O
in	O
blood	O
monocytes	O
and	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
.	O

Although	O
under	O
standard	O
culture	O
conditions	O
,	O
bovine	O
brain	O
gangliosides	O
(	O
100	O
micrograms/ml	O
)	O
suppressed	O
LPS-stimulated	O
TNF	O
production	O
5-fold	O
in	O
PBMC	O
and	O
10-fold	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
suppression	O
was	O
more	O
efficient	O
under	O
serum-free	O
conditions	O
.	O

Looking	O
at	O
highly	O
purified	O
gangliosides	O
,	O
GD3	O
,	O
GD1a	O
,	O
GM3	O
,	O
GM2	O
,	O
and	O
GM1	O
were	O
all	O
effective	O
in	O
reducing	O
TNF	O
production	O
in	O
PBMC	O
,	O
and	O
in	O
Mono	O
Mac	O
6	O
by	O
factor	O
10	O
to	O
50	O
.	O

The	O
suppressive	O
activity	O
was	O
lost	O
in	O
molecules	O
,	O
lacking	B-Negation
the	I-Negation
sugar	I-Negation
moiety	I-Negation
or	I-Negation
the	I-Negation
lipid	I-Negation
moiety	I-Negation
.	O

Gangliosides	O
appear	O
to	O
act	O
at	O
an	O
early	O
step	O
of	O
activation	O
in	O
that	O
TNF	O
transcripts	O
were	O
reduced	O
and	O
the	O
mobilization	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
was	O
blocked	O
.	O

Furthermore	O
,	O
in	O
time	O
kinetics	O
,	O
gangliosides	O
were	O
effective	O
for	O
up	O
to	O
30	O
min	O
after	O
addition	O
of	O
LPS	O
,	O
but	O
not	B-Negation
thereafter	I-Negation
.	O

However	O
,	O
the	O
expression	O
of	O
the	O
CD14	O
Ag	O
,	O
a	O
receptor	O
molecule	O
for	O
LPS-LPS	O
binding	O
protein	O
complexes	O
,	O
was	O
unaffected	O
by	O
gangliosides	O
.	O

Finally	O
,	O
when	O
using	O
Staphylococcus	O
aureus	O
or	O
platelet	O
activating	O
factor	O
as	O
a	O
stimulus	O
,	O
gangliosides	O
were	O
able	O
to	O
suppress	O
TNF	O
production	O
in	O
Mono	O
Mac	O
6	O
cells	O
by	O
factor	O
5	O
to	O
10	O
,	O
as	O
well	O
.	O

On	O
the	O
other	O
hand	O
,	O
phorbol	O
ester-induced	O
production	O
of	O
O2-	O
was	O
similar	O
in	O
cells	O
treated	O
with	O
and	O
without	B-Negation
gangliosides	I-Negation
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
TNF	O
gene	O
expression	O
in	O
monocytes	O
induced	O
by	O
different	O
types	O
of	O
stimuli	O
can	O
be	O
blocked	O
by	O
gangliosides	O
at	O
an	O
early	O
step	O
of	O
signal	O
transduction	O
.	O

T	O
cell-specific	O
negative	O
regulation	O
of	O
transcription	O
of	O
the	O
human	O
cytokine	O
IL-4	O
.	O

IL-4	O
secreted	O
by	O
activated	O
T	O
cells	O
is	O
a	O
pleiotropic	O
cytokine	O
affecting	O
growth	O
and	O
differentiation	O
of	O
diverse	O
cell	O
types	O
such	O
as	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
mast	O
cells	O
.	O

We	O
investigated	O
the	O
upstream	O
regulatory	O
elements	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

A	O
novel	O
T	O
cell-specific	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
composed	O
of	O
two	O
protein-binding	O
sites	O
were	O
mapped	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-4	O
gene	O
:	O
-311CTCCCTTCT-303	O
(	O
NRE-I	O
)	O
and	O
-288CTTTTTGCTT-TGC-300	O
(	O
NRE-II	O
)	O
.	O

A	O
T	O
cell-specific	O
protein	O
Neg-1	O
and	O
a	O
ubiquitous	O
protein	O
Neg-2	O
binding	O
to	O
NRE-I	O
and	O
NRE-II	O
,	O
respectively	O
,	O
were	O
identified	O
.	O

Furthermore	O
,	O
a	O
positive	O
regulatory	O
element	O
was	O
found	O
45	O
bp	O
downstream	O
of	O
the	O
NRE	O
.	O

The	O
enhancer	O
activity	O
of	O
the	O
PRE	O
was	O
completely	O
suppressed	O
when	O
the	O
NRE	O
was	O
present	O
.	O

These	O
data	O
suggest	O
that	O
IL-4	O
promoter	O
activity	O
is	O
normally	O
down-regulated	O
by	O
an	O
NRE	O
via	O
repression	O
of	O
the	O
enhancer	O
positive	O
regulatory	O
element	O
.	O

These	O
data	O
may	O
have	O
implications	O
for	O
the	O
stringent	O
control	O
of	O
IL-4	O
expression	O
in	O
T	O
cells	O
.	O

[	O
Regulatory	O
effect	O
of	O
insulin	O
on	O
glucocorticoid	O
receptor	O
in	O
human	O
peripheral	O
leukocytes	O
]	O

The	O
regulatory	O
effect	O
of	O
insulin	O
on	O
the	O
specific	O
binding	O
power	O
of	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
of	O
human	O
leukocytes	O
was	O
assessed	O
by	O
the	O
unoccupied	O
receptor	O
sites	O
capable	O
of	O
combining	O
with	O
[	O
3H	O
]	O
labelled	O
dexamethasone	O
measured	O
at	O
3	O
and	O
24	O
h	O
after	O
incubation	O
with	O
various	O
concentrations	O
of	O
insulin	O
added	O
to	O
the	O
medium	O
.	O

After	O
3	O
h	O
incubation	O
the	O
specific	O
binding	O
power	O
with	O
[	O
3H	O
]	O
Dex	O
was	O
decreased	O
by	O
23.3	O
	O
10.0	O
,	O
32.2	O
	O
13.2	O
and	O
54.3	O
	O
9.2	O
%	O
(	O
P	O
greater	O
than	O
0.05	O
,	O
P	O
greater	O
than	O
0.05	O
and	O
P	O
less	O
than	O
0.01	O
as	O
compared	O
with	O
the	O
control	O
value	O
of	O
100	O
in	O
the	O
absence	O
of	O
insulin	O
)	O
respectively	O
in	O
the	O
presence	O
of	O
20	O
mU/L	O
(	O
physiological	O
testing	O
concentration	O
)	O
,	O
200	O
mU/L	O
(	O
physiological	O
upper	O
limit	O
)	O
and	O
2,000	O
mU/L	O
(	O
pharmacological	O
concentration	O
)	O
insulin	O
in	O
the	O
incubation	O
medium	O
.	O

After	O
24	O
h	O
incubation	O
the	O
decrease	O
of	O
these	O
values	O
increased	O
respectively	O
to	O
43.5	O
	O
19.0	O
,	O
56.1	O
	O
20.7	O
and	O
80.2	O
	O
15.5	O
(	O
P	O
less	O
than	O
0.05	O
,	O
P	O
less	O
than	O
0.01	O
and	O
P	O
less	O
than	O
0.01	O
compared	O
with	O
control	O
)	O
.	O

Thus	O
the	O
inhibitory	O
effect	O
of	O
insulin	O
on	O
the	O
GR	O
binding	O
power	O
is	O
both	O
dose-	O
and	O
time-dependent	O
,	O
which	O
strongly	O
suggests	O
that	O
GR	O
is	O
tonically	O
controlled	O
by	O
insulin	O
concentration	O
change	O
under	O
physiological	O
conditions	O
.	O

Human	O
T	O
cell	O
activation	O
through	O
the	O
activation-inducer	O
molecule/CD69	O
enhances	O
the	O
activity	O
of	O
transcription	O
factor	O
AP-1	O
.	O

The	O
induction	O
of	O
the	O
AP-1	O
transcription	O
factor	O
has	O
been	O
ascribed	O
to	O
the	O
early	O
events	O
leading	O
to	O
T	O
cell	O
differentiation	O
and	O
activation	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
AP-1	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
stimulated	O
through	O
the	O
activation	O
inducer	O
molecule	O
(	O
AIM	O
)	O
/CD69	O
activation	O
pathway	O
.	O

Phorbol	O
esters	O
are	O
required	O
to	O
induce	O
AIM/CD69	O
cell-surface	O
expression	O
as	O
well	O
as	O
for	O
triggering	O
the	O
proliferation	O
of	O
T	O
cells	O
in	O
conjunction	O
with	O
anti-AIM	O
mAb	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
addition	O
of	O
anti-AIM	O
mAb	O
to	O
PMA-treated	O
T	O
lymphocytes	O
markedly	O
enhanced	O
the	O
binding	O
activity	O
of	O
AP-1	O
to	O
its	O
cognate	O
sequence	O
,	O
the	O
phorbol	O
ester	O
response	O
element	O
.	O

In	O
contrast	O
,	O
anti-AIM	O
mAb	O
did	O
not	B-Negation
induce	I-Negation
any	I-Negation
change	I-Negation
in	I-Negation
the	I-Negation
binding	I-Negation
activity	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
,	I-Negation
a	I-Negation
transcription	I-Negation
factor	I-Negation
whose	I-Negation
activity	I-Negation
is	I-Negation
also	I-Negation
regulated	I-Negation
by	I-Negation
protein	I-Negation
kinase	I-Negation
C	I-Negation
.	O

The	O
increase	O
in	O
AP-1-binding	O
activity	O
was	O
accompanied	O
by	O
the	O
marked	O
stimulation	O
of	O
the	O
transcription	O
of	O
c-fos	O
but	O
not	B-Negation
that	I-Negation
of	I-Negation
c-jun	I-Negation
.	O

Blockade	O
of	O
the	O
DNA-binding	O
complexes	O
with	O
an	O
anti-Fos	O
mAb	O
demonstrated	O
a	O
direct	O
participation	O
of	O
c-Fos	O
in	O
the	O
AP-1	O
complexes	O
induced	O
by	O
anti-AIM	O
mAb	O
.	O

Most	O
of	O
the	O
AP-1	O
activity	O
could	O
be	O
eliminated	O
when	O
the	O
anti-AIM	O
mAb	O
was	O
added	O
to	O
the	O
culture	O
medium	O
in	O
the	O
presence	O
of	O
cycloheximide	O
,	O
suggesting	O
that	O
de	O
novo	O
protein	O
synthesis	O
is	O
crucial	O
for	O
the	O
induction	O
of	O
AP-1-binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
evidence	O
that	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
cells	O
through	O
the	O
AIM	O
activation	O
pathway	O
regulate	O
the	O
activity	O
of	O
AP-1	O
.	O

Therefore	O
,	O
this	O
pathway	O
appears	O
as	O
a	O
crucial	O
step	O
in	O
the	O
initiation	O
of	O
early	O
T	O
cell	O
activation	O
events	O
.	O

cis-acting	O
sequences	O
required	O
for	O
inducible	O
interleukin-2	O
enhancer	O
function	O
bind	O
a	O
novel	O
Ets-related	O
protein	O
,	O
Elf-1	O
.	O

The	O
recent	O
definition	O
of	O
a	O
consensus	O
DNA	O
binding	O
sequence	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
has	O
allowed	O
the	O
identification	O
of	O
potential	O
Ets	O
binding	O
sites	O
in	O
the	O
promoters	O
and	O
enhancers	O
of	O
many	O
inducible	O
T-cell	O
genes	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
have	O
identified	O
two	O
potential	O
Ets	O
binding	O
sites	O
,	O
EBS1	O
and	O
EBS2	O
,	O
which	O
are	O
conserved	O
in	O
both	O
the	O
human	O
and	O
murine	O
interleukin-2	O
enhancers	O
.	O

Within	O
the	O
human	O
enhancer	O
,	O
these	O
two	O
sites	O
are	O
located	O
within	O
the	O
previously	O
defined	O
DNase	O
I	O
footprints	O
,	O
NFAT-1	O
and	O
NFIL-2B	O
,	O
respectively	O
.	O

Electrophoretic	O
mobility	O
shift	O
and	O
methylation	O
interference	O
analyses	O
demonstrated	O
that	O
EBS1	O
and	O
EBS2	O
are	O
essential	O
for	O
the	O
formation	O
of	O
the	O
NFAT-1	O
and	O
NFIL-2B	O
nuclear	O
protein	O
complexes	O
.	O

Furthermore	O
,	O
in	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
inducible	O
interleukin-2	O
enhancer	O
function	O
requires	O
the	O
presence	O
of	O
either	O
EBS1	O
or	O
EBS2	O
.	O

Two	O
well-characterized	O
Ets	O
family	O
members	O
,	O
Ets-1	O
and	O
Ets-2	O
,	O
are	O
reciprocally	O
expressed	O
during	O
T-cell	O
activation	O
.	O

Surprisingly	O
,	O
however	O
,	O
neither	B-Negation
of	I-Negation
these	I-Negation
proteins	I-Negation
bound	I-Negation
in	I-Negation
vitro	I-Negation
to	I-Negation
EBS1	I-Negation
or	I-Negation
EBS2	I-Negation
.	O

We	O
therefore	O
screened	O
a	O
T-cell	O
cDNA	O
library	O
under	O
low-stringency	O
conditions	O
with	O
a	O
probe	O
from	O
the	O
DNA	O
binding	O
domain	O
of	O
Ets-1	O
and	O
isolated	O
a	O
novel	O
Ets	O
family	O
member	O
,	O
Elf-1	O
.	O

Elf-1	O
contains	O
a	O
DNA	O
binding	O
domain	O
that	O
is	O
nearly	O
identical	O
to	O
that	O
of	O
E74	O
,	O
the	O
ecdysone-inducible	O
Drosophila	O
transcription	O
factor	O
required	O
for	O
metamorphosis	O
(	O
hence	O
the	O
name	O
Elf-1	O
,	O
for	O
E74-like	O
factor	O
1	O
)	O
.	O

Elf-1	O
bound	O
specifically	O
to	O
both	O
EBS1	O
and	O
EBS2	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
also	O
bound	O
to	O
the	O
purine-rich	O
CD3R	O
element	O
from	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
long	O
terminal	O
repeat	O
,	O
which	O
is	O
required	O
for	O
inducible	O
virus	O
expression	O
in	O
response	O
to	O
signalling	O
through	O
the	O
T-cell	O
receptor	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
multiple	O
Ets	O
family	O
members	O
with	O
apparently	O
distinct	O
DNA	O
binding	O
specificities	O
regulate	O
differential	O
gene	O
expression	O
in	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

Mineralocorticoids	O
and	O
mineralocorticoid	O
receptors	O
in	O
mononuclear	O
leukocytes	O
in	O
patients	O
with	O
pregnancy-induced	O
hypertension	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxycorticosterone	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
25	O
normal	O
pregnant	O
women	O
,	O
as	O
controls	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
status	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

MR	O
count	O
was	O
significantly	O
(	O
P	O
less	O
than	O
0.0005	O
)	O
decreased	O
in	O
the	O
PIH	O
group	O
(	O
148	O
	O
9	O
binding	O
sites/cell	O
)	O
compared	O
with	O
the	O
control	O
group	O
(	O
300	O
	O
17	O
binding	O
sites/cell	O
;	O
mean	O
	O
SEM	O
)	O
.	O

Plasma	O
aldosterone	O
in	O
women	O
with	O
PIH	O
was	O
281	O
	O
61	O
pmol/L	O
;	O

in	O
normal	O
pregnant	O
women	O
it	O
was	O
697	O
	O
172	O
pmol/L	O
(	O
P	O
less	O
than	O
0.025	O
)	O
.	O

Plasma	O
18-hydroxycorticosterone	O
was	O
also	O
significantly	O
(	O
P	O
less	O
than	O
0.025	O
)	O
lower	O
(	O
PIH	O
,	O
1071	O
	O
149	O
pmol/L	O
;	O
controls	O
,	O
1907	O
	O
318	O
pmol/L	O
)	O
.	O

These	O
values	O
were	O
determined	O
at	O
the	O
onset	O
of	O
clinical	O
symptoms	O
of	O
PIH	O
.	O

These	B-Negation
results	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
explained	I-Negation
by	I-Negation
receptor	I-Negation
down-regulation	I-Negation
due	O
to	O
higher	O
levels	O
of	O
mineralocorticoids	O
in	O
PIH	O
;	O

a	O
hitherto	O
unknown	O
mineralocorticoid	O
may	O
,	O
thus	O
,	O
be	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR	O
status	O
.	O

Mineralocorticoid	O
effector	O
mechanism	O
in	O
preeclampsia	O
.	O

Mineralocorticoid	O
effector	O
mechanisms	O
were	O
evaluated	O
in	O
29	O
patients	O
with	O
preeclampsia	O
and	O
in	O
25	O
uncomplicated	O
pregnancies	O
by	O
measurement	O
of	O
plasma	O
aldosterone	O
,	O
levels	O
of	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
in	O
mononuclear	O
leucocytes	O
,	O
and	O
subtraction	O
potential	O
difference	O
(	O
SPD	O
;	O
rectal	O
minus	O
oral	O
values	O
)	O
.	O

Mean	O
values	O
for	O
plasma	O
aldosterone	O
were	O
not	B-Negation
different	I-Negation
between	I-Negation
the	I-Negation
two	I-Negation
groups	I-Negation
,	O
but	O
significant	O
differences	O
were	O
observed	O
for	O
MR	O
(	O
preeclampsia	O
,	O
81	O
	O
44	O
receptors/cell	O
;	O
controls	O
,	O
306	O
	O
168	O
)	O
and	O
SPD	O
(	O
preeclampsia	O
,	O
65	O
	O
7	O
mV	O
;	O
controls	O
,	O
12	O
	O
5	O
mV	O
)	O
.	O

In	O
six	O
cases	O
we	O
determined	O
MR	O
,	O
plasma	O
aldosterone	O
,	O
and	O
SPD	O
in	O
patients	O
with	O
preeclampsia	O
before	O
and	O
3	O
months	O
after	O
delivery	O
.	O

MR	O
were	O
reduced	O
before	O
delivery	O
(	O
96	O
	O
27	O
receptors/cell	O
)	O
,	O
and	O
SPD	O
increased	O
(	O
64	O
	O
8	O
mV	O
)	O
,	O
with	O
both	O
parameters	O
normalizing	O
after	O
delivery	O
(	O
MR	O
,	O
242	O
	O
79	O
;	O
SPD	O
,	O
14.0	O
	O
4	O
mV	O
)	O
.	O

Aldosterone	O
levels	O
returned	O
to	O
normal	O
nonpregnant	O
values	O
after	O
delivery	O
.	O

These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
abnormalities	O
in	O
mineralocorticoid	O
effector	O
mechanisms	O
in	O
the	O
etiology	O
of	O
preeclampsia	O
and	O
could	O
be	O
an	O
useful	O
marker	O
for	O
diagnosis	O
.	O

A	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
containing	O
c-Rel-like	O
proteins	O
preferentially	O
interacts	O
with	O
interleukin-6	O
kappa	O
B-related	O
motifs	O
whose	O
activities	O
are	O
repressed	O
in	O
lymphoid	O
cells	O
.	O

The	O
proto-oncoprotein	O
c-Rel	O
is	O
a	O
member	O
of	O
the	O
nuclear	O
factor	O
kappa	O
B	O
transcription	O
factor	O
family	O
,	O
which	O
includes	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

We	O
show	O
here	O
that	O
c-Rel	O
binds	O
to	O
kappa	O
B	O
sites	O
as	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
p50	O
.	O

These	O
homodimers	O
and	O
heterodimers	O
show	O
distinct	O
DNA-binding	O
specificities	O
and	O
affinities	O
for	O
various	O
kappa	O
B	O
motifs	O
.	O

In	O
particular	O
,	O
the	O
c-Rel	O
homodimer	O
has	O
a	O
high	O
affinity	O
for	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
beta	O
interferon	O
kappa	O
B	O
sites	O
.	O

In	O
spite	O
of	O
its	O
association	O
with	O
p50	O
in	O
vitro	O
,	O
however	O
,	O
we	O
found	O
a	O
lymphoid	O
cell-specific	O
nuclear	O
factor	O
in	O
vivo	O
that	O
contains	O
c-Rel	O
but	O
not	B-Negation
p50	I-Negation
epitopes	I-Negation
;	O

this	O
factor	O
,	O
termed	O
IL-6	O
kappa	O
B	O
binding	O
factor	O
II	O
,	O
appears	O
to	O
contain	O
the	O
c-Rel	O
homodimer	O
and	O
preferentially	O
recognizes	O
several	O
IL-6	O
kappa	O
B-related	O
kappa	O
B	O
motifs	O
.	O

Although	O
it	O
has	O
been	O
previously	O
shown	O
that	O
the	O
IL-6	O
kappa	O
B	O
motif	O
functions	O
as	O
a	O
potent	O
IL-1/tumor	O
necrosis	O
factor-responsive	O
element	O
in	O
nonlymphoid	O
cells	O
,	O
its	O
activity	O
was	O
found	O
to	O
be	O
repressed	O
in	O
lymphoid	O
cells	O
such	O
as	O
a	O
Jurkat	O
T-cell	O
line	O
.	O

We	O
also	O
present	O
evidence	O
that	O
IL-6	O
kappa	O
B	O
binding	O
factor	O
II	O
functions	O
as	O
a	O
repressor	O
specific	O
for	O
IL-6	O
kappa	O
B-related	O
kappa	O
B	O
motifs	O
in	O
lymphoid	O
cells	O
.	O

Modulation	O
of	O
normal	O
erythroid	O
differentiation	O
by	O
the	O
endogenous	O
thyroid	O
hormone	O
and	O
retinoic	O
acid	O
receptors	O
:	O
a	O
possible	O
target	O
for	O
v-erbA	O
oncogene	O
action	O
.	O

The	O
v-erbA	O
oncogene	O
,	O
a	O
mutated	O
version	O
of	O
the	O
thyroid	O
hormone	O
receptor	O
alpha	O
(	O
c-erbA/TR-alpha	O
)	O
,	O
inhibits	O
erythroid	O
differentiation	O
and	O
constitutively	O
represses	O
transcription	O
of	O
certain	O
erythrocyte	O
genes	O
,	O
suggesting	O
a	O
normal	O
function	O
of	O
the	O
proto-oncogene	O
c-erbA	O
in	O
erythropoiesis	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
endogenous	O
thyroid	O
hormone	O
receptor	O
alpha	O
(	O
c-erbA/TR-alpha	O
)	O
and	O
the	O
closely	O
related	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR-alpha	O
)	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
erythroid	O
differentiation	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
distinctly	O
modulated	O
the	O
erythroid	O
differentiation	O
program	O
of	O
normal	O
erythroid	O
progenitors	O
and	O
erythroblasts	O
reversibly	O
transformed	O
by	O
a	O
conditional	O
tyrosine	O
kinase	O
oncogene	O
.	O

When	O
added	O
pulsewise	O
to	O
immature	O
cells	O
,	O
differentiation	O
was	O
accelerated	O
while	O
more	O
mature	O
cells	O
underwent	O
premature	O
cell	O
death	O
.	O

Thyroid	O
hormone	O
(	O
T3	O
)	O
alone	O
caused	O
similar	O
but	O
weaker	O
effects	O
.	O

Interestingly	O
,	O
T3	O
strongly	O
enhanced	O
the	O
action	O
of	O
RA	O
,	O
suggesting	O
cooperative	O
action	O
of	O
the	O
two	O
receptors	O
in	O
modulating	O
erythroid	O
differentiation	O
.	O

Expression	O
of	O
the	O
human	O
RAR-alpha	O
in	O
receptor-negative	O
erythroblasts	O
conferred	O
RA-induced	O
regulation	O
of	O
differentiation	O
to	O
the	O
otherwise	O
unresponsive	O
cells	O
,	O
thus	O
showing	O
that	O
the	O
RAR-alpha	O
is	O
essential	O
for	O
the	O
RA	O
effect	O
.	O

Likewise	O
,	O
enhanced	O
expression	O
of	O
exogenous	O
c-erbA/TR-alpha	O
in	O
erythroblasts	O
rendered	O
them	O
susceptible	O
to	O
modulation	O
of	O
differentiation	O
by	O
T3	O
,	O
suggesting	O
a	O
similar	O
function	O
of	O
both	O
receptors	O
.	O

Leukotriene	O
B4	O
stimulates	O
c-fos	O
and	O
c-jun	O
gene	O
transcription	O
and	O
AP-1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
,	O
a	O
potent	O
lipid	O
proinflammatory	O
mediator	O
,	O
on	O
the	O
expression	O
of	O
the	O
proto-oncogenes	O
c-jun	O
and	O
c-fos	O
.	O

In	O
addition	O
,	O
we	O
looked	O
at	O
the	O
modulation	O
of	O
nuclear	O
factors	O
binding	O
specifically	O
to	O
the	O
AP-1	O
element	O
after	O
LTB4	O
stimulation	O
.	O

LTB4	O
increased	O
the	O
expression	O
of	O
the	O
c-fos	O
gene	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O

The	O
c-jun	O
mRNA	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
human	O
peripheral-blood	O
monocytes	O
at	O
relatively	O
high	O
levels	O
,	O
was	O
also	O
slightly	O
augmented	O
by	O
LTB4	O
,	O
although	O
to	O
a	O
much	O
lower	O
extent	O
than	O
c-fos	O
.	O

The	O
kinetics	O
of	O
expression	O
of	O
the	O
two	O
genes	O
were	O
also	O
slightly	O
different	O
,	O
with	O
c-fos	O
mRNA	O
reaching	O
a	O
peak	O
at	O
15	O
min	O
after	O
stimulation	O
and	O
c-jun	O
at	O
30	O
min	O
.	O

Both	O
messages	O
rapidly	O
declined	O
thereafter	O
.	O

Stability	B-Negation
of	I-Negation
the	I-Negation
c-fos	I-Negation
and	I-Negation
c-jun	I-Negation
mRNA	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
LTB4	I-Negation
,	O
as	O
assessed	O
after	O
actinomycin	O
D	O
treatment	O
.	O

Nuclear	O
transcription	O
studies	O
in	O
vitro	O
showed	O
that	O
LTB4	O
increased	O
the	O
transcription	O
of	O
the	O
c-fos	O
gene	O
7-fold	O
and	O
the	O
c-jun	O
gene	O
1.4-fold	O
.	O

Resting	O
monocytes	O
contained	O
nuclear	O
factors	O
binding	O
to	O
the	O
AP-1	O
element	O
,	O
but	O
stimulation	O
of	O
monocytes	O
with	O
LTB4	O
induced	O
greater	O
AP-1-binding	O
activity	O
of	O
nuclear	O
proteins	O
.	O

These	O
results	O
indicate	O
that	O
LTB4	O
may	O
regulate	O
the	O
production	O
of	O
different	O
cytokines	O
by	O
modulating	O
the	O
yield	O
and/or	O
the	O
function	O
of	O
transcription	O
factors	O
such	O
as	O
AP-1-binding	O
proto-oncogene	O
products	O
.	O

An	O
11-base-pair	O
DNA	O
sequence	O
motif	O
apparently	O
unique	O
to	O
the	O
human	O
interleukin	O
4	O
gene	O
confers	O
responsiveness	O
to	O
T-cell	O
activation	O
signals	O
.	O

We	O
have	O
identified	O
a	O
DNA	O
segment	O
that	O
confers	O
responsiveness	O
to	O
antigen	O
stimulation	O
signals	O
on	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
4	O
gene	O
in	O
Jurkat	O
cells	O
.	O

The	O
human	O
IL-4	O
gene	O
,	O
of	O
10	O
kilobases	O
,	O
is	O
composed	O
of	O
four	O
exons	O
and	O
three	O
introns	O
.	O

A	O
cis-acting	O
element	O
(	O
P	O
sequence	O
)	O
resides	O
in	O
the	O
5	O
'	O
upstream	O
region	O
;	O

no	B-Negation
additional	I-Negation
DNA	I-Negation
segments	I-Negation
with	I-Negation
enhancer	I-Negation
activity	I-Negation
were	I-Negation
identified	I-Negation
in	I-Negation
the	I-Negation
human	I-Negation
IL-4	I-Negation
gene	I-Negation
.	O

For	O
further	O
mapping	O
purposes	O
,	O
a	O
fusion	O
promoter	O
was	O
constructed	O
with	O
the	O
granulocyte/macrophage	O
colony-stimulating	O
factor	O
basic	O
promoter	O
containing	O
60	O
base	O
pairs	O
of	O
sequence	O
upstream	O
from	O
the	O
cap	O
site	O
of	O
the	O
mouse	O
granulocyte/macrophage	O
colony-stimulating	O
factor	O
gene	O
and	O
various	O
lengths	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
of	O
the	O
IL-4	O
gene	O
.	O

The	O
P	O
sequence	O
was	O
located	O
between	O
positions	O
-79	O
and	O
-69	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
of	O
the	O
human	O
IL-4	O
gene	O
,	O
and	O
this	O
location	O
was	O
confirmed	O
by	O
base-substitution	O
mutations	O
.	O

The	O
plasmids	O
carrying	O
multiple	O
copies	O
of	O
the	O
P	O
sequence	O
showed	O
higher	O
responsiveness	O
to	O
the	O
stimulation	O
.	O

The	O
binding	O
protein	O
(	O
s	O
)	O
that	O
recognize	O
the	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
were	O
identified	O
by	O
DNA-mobility-shift	O
assays	O
.	O

The	O
binding	O
of	O
NF	O
(	O
P	O
)	O
(	O
a	O
DNA	O
binding	O
protein	O
that	O
specifically	O
recognizes	O
the	O
P	O
sequence	O
)	O
to	O
the	O
P	O
sequence	O
was	O
abolished	O
when	O
oligonucleotides	O
carrying	O
base	O
substitutions	O
were	O
used	O
,	O
indicating	O
that	O
the	O
NF	O
(	O
P	O
)	O
interaction	O
is	O
sequence-specific	O
and	O
that	O
binding	O
specificity	O
of	O
the	O
protein	O
paralleled	O
the	O
sequence	O
requirements	O
for	O
IL-4	O
expression	O
in	O
vivo	O
.	O

The	O
P	O
sequence	O
does	O
not	B-Negation
share	I-Negation
homology	I-Negation
with	I-Negation
the	I-Negation
5	I-Negation
'	I-Negation
upstream	I-Negation
sequence	I-Negation
of	I-Negation
the	I-Negation
IL-2	I-Negation
gene	I-Negation
,	O
even	O
though	O
surrounding	O
sequences	O
of	O
the	O
IL-4	O
gene	O
share	O
high	O
homology	O
with	O
the	O
IL-2	O
gene	O
.	O

We	O
conclude	O
that	O
a	O
different	O
set	O
of	O
proteins	O
recognize	O
IL-2	O
and	O
IL-4	O
genes	O
.	O

Glucocorticoid	O
receptor	O
binding	O
in	O
three	O
different	O
cell	O
types	O
in	O
major	O
depressive	O
disorder	O
:	O
lack	B-Negation
of	I-Negation
evidence	I-Negation
of	I-Negation
receptor	I-Negation
binding	I-Negation
defect	I-Negation
.	O

1	O
.	O
In	O
order	O
to	O
further	O
understand	O
the	O
apparent	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
,	O
circadian	O
variation	O
in	O
cortisol	O
concentration	O
,	O
dexamethasone	O
suppression	O
and	O
glucocorticoid	O
receptor	O
binding	O
in	O
mononuclear	O
leukocytes	O
,	O
polymorphonuclear	O
leukocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
were	O
measured	O
in	O
rigidly	O
defined	O
major	O
depressive	O
disorder	O
patients	O
and	O
non-depressed	O
psychiatric	O
controls	O
.	O

2	O
.	O
Mononuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
correlated	O
significantly	O
with	O
polymorphonuclear	O
leukocytes	O
binding	O
to	O
glucocorticoid	O
,	O
but	O
both	O
determinations	O
failed	O
to	O
differentiate	O
major	O
depressive	O
disorder	O
and	O
control	O
subjects	O
.	O

3	O
.	O
Initial	O
and	O
post-dexamethasone	O
in	O
vitro	O
fibroblast	O
binding	O
to	O
glucocorticoid	O
was	O
not	B-Negation
different	I-Negation
between	I-Negation
major	I-Negation
depressive	I-Negation
disorder	I-Negation
and	I-Negation
non-depressed	I-Negation
control	I-Negation
subjects	I-Negation
.	O

4	O
.	O
The	O
phenomenon	O
of	O
glucocorticoid	O
resistance	O
in	O
major	O
depressive	O
disorder	O
remains	O
unexplained	O
.	O

Kinetics	O
of	O
nuclear	O
translocation	O
and	O
turnover	O
of	O
the	O
vitamin	O
D	O
receptor	O
in	O
human	O
HL60	O
leukemia	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
--	O
coincident	O
rise	O
of	O
DNA-relaxing	O
activity	O
in	O
nuclear	O
extracts	O
.	O

High	O
affinity	O
receptors	O
(	O
VDR	O
)	O
for	O
1,25-dihydroxycholecalciferol	O
(	O
calcitriol	O
)	O
are	O
expressed	O
in	O
HL60	O
human	O
leukemia	O
cells	O
and	O
in	O
low	O
numbers	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

HL60	O
cells	O
,	O
expressing	O
some	O
characteristics	O
of	O
promyelocytes	O
,	O
can	O
be	O
induced	O
to	O
monocytoid	O
differentiation	O
by	O
calcitriol	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol/VDR	O
was	O
examined	O
after	O
exposure	O
of	O
whole	O
cells	O
to	O
10	O
(	O
-9	O
)	O
M/l	O
calcitriol	O
in	O
the	O
presence	O
and	O
absence	O
of	O
a	O
500-fold	O
excess	O
of	O
unlabeled	O
ligand	O
and	O
subsequent	O
isolation	O
of	O
nuclei	O
.	O

Specific	O
nuclear	O
translocation	O
of	O
[	O
3H	O
]	O
calcitriol/VDR	O
was	O
found	O
to	O
be	O
time	O
dependent	O
reaching	O
a	O
maximum	O
of	O
approximately	O
2100	O
binding	O
sites/nucleus	O
after	O
3	O
h	O
of	O
incubation	O
in	O
HL60	O
cells	O
,	O
whereas	O
a	O
maximum	O
of	O
approximately	O
310	O
binding	O
sites/nucleus	O
was	O
found	O
after	O
3	O
h	O
in	O
PBL	O
.	O

Pulse	O
exposure	O
of	O
HL60	O
to	O
radiolabeled	O
hormone	O
for	O
3	O
h	O
followed	O
by	O
culture	O
in	O
medium	O
without	B-Negation
serum	I-Negation
and	I-Negation
calcitriol	I-Negation
lead	O
to	O
nuclear	O
retention	O
of	O
approximately	O
1600	O
radiolabeled	O
VDR	O
by	O
8	O
h	O
and	O
approximately	O
1000	O
VDR	O
by	O
24	O
h	O
.	O

Radiolabeled	O
VDR	O
disappeared	O
from	O
the	O
nuclear	O
compartment	O
with	O
a	O
halflife	O
of	O
approximately	O
30	O
min	O
if	O
cells	O
were	O
cultured	O
with	O
identical	O
concentrations	O
of	O
unlabeled	O
hormone	O
after	O
the	O
pulse	O
(	O
pulse/chase-experiments	O
)	O
.	O

No	B-Negation
difference	I-Negation
of	I-Negation
VDR	I-Negation
retention	I-Negation
in	I-Negation
pulse	I-Negation
and	I-Negation
pulse/chase-experiments	I-Negation
was	I-Negation
seen	I-Negation
in	I-Negation
PBL	I-Negation
,	O
where	O
VDR	O
halflife	O
was	O
approximately	O
30	O
min	O
.	O

No	B-Negation
specific	I-Negation
translocation	I-Negation
into	I-Negation
the	I-Negation
nuclear	I-Negation
compartment	I-Negation
was	I-Negation
seen	I-Negation
when	I-Negation
isolated	I-Negation
nuclei	I-Negation
were	I-Negation
incubated	I-Negation
in	I-Negation
[	I-Negation
3H	I-Negation
]	I-Negation
calcitriol	I-Negation
.	O

Radiolabeled	O
hormone/receptor	O
complexes	O
of	O
nuclei	O
isolated	O
from	O
cells	O
exposed	O
for	O
3	O
h	O
to	O
radiolabeled	O
hormone	O
--	O
in	O
contrast	O
to	O
identical	O
experiments	O
with	O
intact	O
cells	O
--	O
did	O
not	B-Negation
disappear	I-Negation
from	I-Negation
the	I-Negation
nuclear	I-Negation
compartment	I-Negation
upon	I-Negation
incubation	I-Negation
of	I-Negation
nuclei	I-Negation
with	I-Negation
identical	I-Negation
concentrations	I-Negation
of	I-Negation
the	I-Negation
unlabeled	I-Negation
compound	I-Negation
.	O

The	O
activity	O
of	O
DNA	O
relaxing	O
enzymes	O
(	O
e.g	O
.	O

topoisomerases	O
I	O
and	O
II	O
)	O
in	O
nuclear	O
extracts	O
was	O
measured	O
using	O
a	O
PBR	O
322-relaxation-assay	O
.	O

Enhanced	O
overall	O
enzyme	O
activity	O
was	O
found	O
in	O
nuclear	O
extracts	O
by	O
1	O
h	O
after	O
incubation	O
with	O
calcitriol	O
(	O
final	O
ethanol	O
concentration	O
0.0001	O
%	O
v/v	O
)	O
in	O
HL60	O
and	O
PBL	O
.	O

The	O
enhanced	O
activity	O
disappeared	O
after	O
2	O
h	O
in	O
PBL	O
,	O
whereas	O
it	O
was	O
still	O
enhanced	O
by	O
4	O
h	O
in	O
HL60	O
.	O

No	B-Negation
effect	I-Negation
was	I-Negation
seen	I-Negation
in	I-Negation
ethanol	I-Negation
treated	I-Negation
controls	I-Negation
.	O

We	O
conclude	O
that	O
a	O
specific	O
nuclear	O
translocation	O
mechanism	O
exists	O
for	O
calcitriol	O
in	O
both	O
cell	O
types	O
examined	O
,	O
most	O
likely	O
due	O
to	O
translocation	O
of	O
receptor	O
proteins	O
after	O
hormone	O
binding	O
.	O

Translocated	O
hormone/receptor	O
complexes	O
compete	O
for	O
a	O
limited	O
number	O
of	O
specific	O
nuclear	O
binding	O
sites	O
.	O

Enhanced	O
activity	O
of	O
topoisomerases	O
in	O
nuclear	O
extracts	O
upon	O
translocation	O
of	O
VDR	O
might	O
reflect	O
interaction	O
of	O
both	O
within	O
the	O
nuclear	O
compartment	O
,	O
thus	O
initiating	O
DNA-unwinding	O
,	O
a	O
prerequisite	O
of	O
transcription	O
initiation	O
.	O

The	O
B	O
cell-specific	O
nuclear	O
factor	O
OTF-2	O
positively	O
regulates	O
transcription	O
of	O
the	O
human	O
class	O
II	O
transplantation	O
gene	O
,	O
DRA	O
.	O

The	O
promoter	O
of	O
the	O
major	O
histocompatibility	O
class	O
II	O
gene	O
DRA	O
contains	O
an	O
octamer	O
element	O
(	O
ATTTGCAT	O
)	O
that	O
is	O
required	O
for	O
efficient	O
DRA	O
expression	O
in	O
B	O
cells	O
.	O

Several	O
DNA-binding	O
proteins	O
are	O
known	O
to	O
bind	O
this	O
sequence	O
.	O

The	O
best	O
characterized	O
are	O
the	O
B	O
cell-specific	O
OTF-2	O
and	O
the	O
ubiquitous	O
OTF-1	O
.	O

This	O
report	O
directly	O
demonstrates	O
that	O
OTF-2	O
but	O
not	B-Negation
OTF-1	I-Negation
regulates	O
the	O
DRA	O
gene	O
.	O

In	O
vitro	O
transcription	O
analysis	O
using	O
protein	O
fractions	O
enriched	O
for	O
the	O
octamer-binding	O
protein	O
OTF-2	O
demonstrate	O
a	O
positive	O
functional	O
role	O
for	O
OTF-2	O
in	O
DRA	O
gene	O
transcription	O
.	O

In	O
contrast	O
,	O
OTF-1-enriched	O
protein	O
fractions	O
did	O
not	B-Negation
affect	I-Negation
DRA	I-Negation
gene	I-Negation
transcription	I-Negation
although	O
it	O
functionally	O
enhanced	O
the	O
transcription	O
of	O
another	O
gene	O
.	O

Recombinant	O
OTF-2	O
protein	O
produced	O
by	O
in	O
vitro	O
transcription/translation	O
could	O
also	O
enhance	O
DRA	O
gene	O
transcription	O
in	O
vitro	O
.	O

In	O
vivo	O
transient	O
transfection	O
studies	O
utilizing	O
an	O
OTF-2	O
expression	O
vector	O
resulted	O
in	O
similar	O
findings	O
:	O
that	O
OTF-2	O
protein	O
enhanced	O
DRA	O
gene	O
transcription	O
,	O
and	O
that	O
this	O
effect	O
requires	O
an	O
intact	O
octamer	O
element	O
.	O

Together	O
these	O
results	O
constitute	O
the	O
first	O
direct	O
evidence	O
of	O
a	O
positive	O
role	O
for	O
the	O
lymphoid-specific	O
octamer-binding	O
factor	O
in	O
DRA	O
gene	O
transcription	O
.	O

[	O
Regulation	O
of	O
intracellular	O
cholesterol	O
synthesis	O
in	O
hypercholesterolemia	O
by	O
glucocorticoids	O
]	O

The	O
rate	O
of	O
endogenous	O
cholesterol	O
synthesis	O
in	O
blood	O
lymphocytes	O
and	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
was	O
found	O
to	O
be	O
increased	O
in	O
comparison	O
with	O
healthy	O
donors	O
.	O

The	O
cells	O
of	O
hyperlipidemic	O
patients	O
had	O
lowered	O
levels	O
of	O
glucocorticoid	O
receptors	O
concomitantly	O
with	O
a	O
partial	O
loss	O
of	O
their	O
sensitivity	O
to	O
glucocorticoids	O
.	O

In	O
fibroblasts	O
from	O
patients	O
with	O
hereditary	O
hypercholesteremia	O
of	O
homozygous	O
type	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
did	O
not	B-Negation
exceed	I-Negation
10	I-Negation
%	I-Negation
of	I-Negation
their	I-Negation
content	I-Negation
in	I-Negation
normal	I-Negation
cells	I-Negation
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
patients	O
with	O
type	O
IIa	O
hyperlipidemia	O
seems	O
to	O
be	O
a	O
compensatory	O
response	O
of	O
cells	O
culminating	O
in	O
activation	O
of	O
endogenous	O
cholesterol	O
synthesis	O
.	O

Transcription	O
factor	O
activation	O
and	O
functional	O
stimulation	O
of	O
human	O
monocytes	O
.	O

Activation	O
of	O
expression	O
of	O
genes	O
encoding	O
transcription	O
factors	O
:	O
c-fos	O
and	O
c-jun	O
and	O
formation	O
of	O
AP1	O
transcriptional	O
complex	O
in	O
human	O
monocytes	O
was	O
investigated	O
.	O

It	O
was	O
found	O
that	O
lipopolysaccharide	O
induced	O
strongly	O
both	O
c-fos	O
and	O
c-jun	O
expression	O
as	O
well	O
as	O
AP1	O
formation	O
.	O

Interferon	O
gamma	O
activated	O
strongly	O
c-fos	O
and	O
weakly	O
c-jun	O
and	O
AP1	O
.	O

Tumor	O
necrosis	O
factor	O
induced	O
slightly	O
c-fos	O
and	O
had	O
almost	O
no	O
effect	O
on	O
c-jun	O
and	O
AP1	O
.	O

The	O
data	O
suggest	O
that	O
differences	O
in	O
functional	O
responses	O
elicited	O
in	O
monocytes	O
by	O
all	O
three	O
factors	O
may	O
be	O
dependent	O
on	O
different	O
routes	O
on	O
nuclear	O
signalling	O
employed	O
by	O
the	O
factors	O
.	O

Corticosteroid	O
receptors	O
and	O
lymphocyte	O
subsets	O
in	O
mononuclear	O
leukocytes	O
in	O
aging	O
.	O

Plasma	O
cortisol	O
and	O
aldosterone	O
levels	O
and	O
number	O
of	O
related	O
receptors	O
in	O
mononuclear	O
leukocytes	O
were	O
measured	O
in	O
49	O
healthy	O
aged	O
subjects	O
(	O
62-97	O
yr	O
)	O
and	O
in	O
21	O
adult	O
controls	O
(	O
21-50	O
yr	O
)	O
.	O

In	O
all	O
subjects	O
,	O
in	O
addition	O
,	O
lymphocyte	O
subsets	O
were	O
determined	O
as	O
an	O
index	O
of	O
corticosteroid	O
action	O
.	O

The	O
mean	O
number	O
of	O
type	O
I	O
and	O
type	O
II	O
receptors	O
was	O
significantly	O
lower	O
in	O
aged	O
subjects	O
than	O
in	O
controls	O
(	O
respectively	O
,	O
198	O
	O
96	O
and	O
272	O
	O
97	O
receptors/cell	O
for	O
type	O
I	O
,	O
and	O
1,794	O
	O
803	O
and	O
3,339	O
	O
918	O
for	O
type	O
II	O
receptors	O
)	O
.	O

Plasma	O
aldosterone	O
and	O
cortisol	O
and	O
lymphocyte	O
subsets	O
were	O
not	B-Negation
different	I-Negation
in	I-Negation
the	I-Negation
two	I-Negation
groups	I-Negation
.	O

All	O
of	O
the	O
parameters	O
were	O
also	O
tested	O
for	O
correlation	O
,	O
and	O
a	O
significant	O
inverse	O
correlation	O
was	O
found	O
between	O
age	O
and	O
type	O
I	O
and	O
type	O
II	O
receptors	O
when	O
all	O
subjects	O
were	O
plotted	O
and	O
between	O
aged	O
and	O
CD4	O
and	O
age	O
and	O
CD4/CD8	O
in	O
the	O
aged	O
group	O
.	O

These	O
data	O
show	O
that	O
aged	O
subjects	O
have	O
reductions	O
of	O
corticosteroid	O
receptors	O
that	O
are	O
not	B-Negation
associated	I-Negation
with	I-Negation
increase	I-Negation
of	I-Negation
related	I-Negation
steroids	I-Negation
and	O
that	O
this	O
situation	O
probably	B-Speculation
represents	I-Speculation
a	I-Speculation
concomitant	I-Speculation
of	I-Speculation
the	I-Speculation
normal	I-Speculation
aging	I-Speculation
process	I-Speculation
.	O

Stable	O
expression	O
of	O
HB24	O
,	O
a	O
diverged	O
human	O
homeobox	O
gene	O
,	O
in	O
T	O
lymphocytes	O
induces	O
genes	O
involved	O
in	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

A	O
diverged	O
homeobox	O
gene	O
,	O
HB24	O
,	O
which	O
is	O
known	O
to	O
be	O
induced	O
following	O
lymphocyte	O
activation	O
,	O
was	O
introduced	O
into	O
Jurkat	O
T	O
cells	O
under	O
the	O
control	O
of	O
a	O
constitutive	O
promoter	O
.	O

Stable	O
transfectants	O
of	O
HB24	O
were	O
established	O
that	O
expressed	O
high	O
levels	O
of	O
HB24	O
mRNA	O
and	O
possessed	O
an	O
altered	O
phenotype	O
suggestive	O
of	O
activated	O
T	O
cells	O
.	O

A	O
number	O
of	O
genes	O
known	O
to	O
be	O
induced	O
following	O
T	O
cell	O
activation	O
and	O
associated	O
with	O
cell	O
growth	O
were	O
increased	O
in	O
the	O
transfectants	O
,	O
including	O
c-fos	O
,	O
c-myc	O
,	O
c-myb	O
,	O
HLA-DR	O
,	O
lck	O
,	O
NF-kappa	O
B	O
,	O
interleukin-2	O
and	O
interleukin-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
.	O

Analysis	O
of	O
IL-2R	O
alpha	O
expression	O
by	O
transient	O
transfection	O
of	O
IL-2R	O
alpha	O
promoter	O
constructs	O
into	O
the	O
HB24	O
transfectants	O
revealed	O
constitutive	O
expression	O
(	O
about	O
60	O
%	O
of	O
phytohemagglutinin-	O
and	O
phorbol	O
ester-activated	O
Jurkat	O
cells	O
)	O
that	O
was	O
dependent	O
on	O
the	O
kappa	O
B	O
site	O
in	O
the	O
IL-2R	O
alpha	O
promoter	O
.	O

Furthermore	O
,	O
as	O
a	O
consequence	O
of	O
the	O
increased	O
HB24	O
mRNA	O
levels	O
,	O
the	O
Jurkat	O
HB24	O
transfectants	O
proliferated	O
more	O
rapidly	O
than	O
control	O
cell	O
lines	O
.	O

Thus	O
,	O
stable	O
expression	O
of	O
HB24	O
confers	O
an	O
activation	O
phenotype	O
on	O
a	O
human	O
T	O
cell	O
line	O
,	O
implicating	O
this	O
gene	O
as	O
an	O
important	O
transcriptional	O
factor	O
during	O
T	O
cell	O
activation	O
and	O
growth	O
.	O

Studies	O
on	O
the	O
biological	O
activity	O
of	O
triiodothyronine	O
sulfate	O
.	O

Hepatic	O
microsomes	O
and	O
isolated	O
hepatocytes	O
in	O
short	O
term	O
culture	O
desulfate	O
T3	O
sulfate	O
(	O
T3SO4	O
)	O
.	O

We	O
,	O
therefore	O
,	O
wished	O
to	O
determine	O
whether	O
T3SO4	O
could	O
mimic	O
the	O
action	O
of	O
thyroid	O
hormone	O
in	O
vitro	O
.	O

T3SO4	O
had	O
no	B-Negation
thyromimetic	I-Negation
effect	I-Negation
on	O
the	O
activity	O
of	O
Ca	O
(	O
2+	O
)	O
-ATPase	O
in	O
human	O
erythrocyte	O
membranes	O
at	O
doses	O
up	O
to	O
10,000	O
times	O
the	O
maximally	O
effective	O
dose	O
of	O
T3	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
.	O

In	O
GH4C1	O
pituitary	O
cells	O
,	O
T3SO4	O
failed	O
to	O
displace	O
[	O
125I	O
]	O
T3	O
from	O
nuclear	O
receptors	O
in	O
intact	O
cells	O
or	O
soluble	O
preparations	O
.	O

Thus	O
,	O
T3SO4	O
was	O
not	B-Negation
directly	I-Negation
thyromimetic	I-Negation
in	I-Negation
either	I-Negation
an	I-Negation
isolated	I-Negation
human	I-Negation
membrane	I-Negation
system	I-Negation
or	I-Negation
a	I-Negation
pituitary	I-Negation
cell	I-Negation
system	I-Negation
in	O
which	O
nuclear	O
receptor	O
occupancy	O
correlates	O
with	O
GH	O
synthesis	O
.	O

Thyroid	O
hormones	O
inhibit	O
[	O
3H	O
]	O
glycosaminoglycan	O
synthesis	O
by	O
cultured	O
human	O
dermal	O
fibroblasts	O
,	O
and	O
T3SO4	O
displayed	O
about	O
0.5	O
%	O
the	O
activity	O
of	O
T3	O
at	O
72	O
h	O
.	O

Human	O
fibroblasts	O
contained	O
roughly	O
the	O
same	O
level	O
of	O
microsomal	O
p-nitrophenyl	O
sulfatase	O
activity	O
as	O
that	O
previously	O
observed	O
in	O
hepatic	O
microsomes	O
.	O

Propylthiouracil	O
(	O
50	O
mumol/L	O
)	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
action	I-Negation
of	I-Negation
T3SO4	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
deiodination	I-Speculation
was	I-Speculation
not	I-Speculation
important	I-Speculation
for	I-Speculation
this	I-Speculation
activity	I-Speculation
of	I-Speculation
T3SO4	I-Speculation
.	O

Thus	O
,	O
it	O
appears	O
T3SO4	O
has	O
no	O
intrinsic	O
biological	O
activity	O
,	O
but	O
,	O
under	O
certain	O
circumstances	O
,	O
may	O
be	O
reactivated	O
by	O
desulfation	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
contains	O
Fos	O
and	O
Jun	O
.	O

The	O
nuclear	O
factor	O
NF-AT	O
(	O
ref.	O
1	O
)	O
is	O
induced	O
in	O
T	O
cells	O
stimulated	O
through	O
the	O
T-cell	O
receptor/CD3	O
complex	O
,	O
and	O
is	O
required	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
induction	O
.	O

Although	O
NF-AT	B-Negation
has	I-Negation
not	I-Negation
been	I-Negation
cloned	I-Negation
or	I-Negation
purified	I-Negation
,	O
there	O
is	O
evidence	O
that	O
it	O
is	O
a	O
major	O
target	O
for	O
immunosuppression	O
by	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
(	O
refs	O
2-7	O
)	O
.	O

NF-AT	O
induction	O
may	O
require	O
two	O
activation-dependent	O
events	O
:	O
the	O
CsA-sensitive	O
translocation	O
of	O
a	O
pre-existing	O
component	O
and	O
the	O
CsA-resistant	O
synthesis	O
of	O
a	O
nuclear	O
component	O
.	O

Here	O
we	O
report	O
that	O
the	O
newly	O
synthesized	O
nuclear	O
component	O
of	O
NF-AT	O
is	O
the	O
transcription	O
factor	O
AP-1	O
.	O

We	O
show	O
that	O
the	O
inducible	O
nuclear	O
form	O
of	O
NF-AT	O
contains	O
Fos	O
and	O
Jun	O
proteins	O
.	O

Furthermore	O
,	O
we	O
identify	O
a	O
pre-existing	O
NF-AT-binding	O
factor	O
that	O
is	O
present	O
in	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
.	O

On	O
the	O
basis	O
of	O
binding	O
,	O
reconstitution	O
and	O
cotransfection	O
experiments	O
,	O
we	O
propose	O
that	O
activation	O
of	O
NF-AT	O
occurs	O
in	O
at	O
least	O
two	O
stages	O
:	O
a	O
CsA-sensitive	O
stage	O
involving	O
modification	O
and/or	O
translocation	O
of	O
the	O
pre-existing	O
NF-AT	O
complex	O
,	O
and	O
a	O
CsA-insensitive	O
stage	O
involving	O
the	O
addition	O
of	O
newly	O
synthesized	O
Fos	O
or	O
Fos/Jun	O
proteins	O
to	O
the	O
pre-existing	O
complex	O
.	O

Interferon-gamma	O
potentiates	O
the	O
antiviral	O
activity	O
and	O
the	O
expression	O
of	O
interferon-stimulated	O
genes	O
induced	O
by	O
interferon-alpha	O
in	O
U937	O
cells	O
.	O

Binding	O
of	O
type	O
I	O
interferon	O
(	O
IFN-alpha/beta	O
)	O
to	O
specific	O
receptors	O
results	O
in	O
the	O
rapid	O
transcriptional	O
activation	O
,	O
independent	O
of	O
protein	O
synthesis	O
,	O
of	O
IFN-alpha-stimulated	O
genes	O
(	O
ISGs	O
)	O
in	O
human	O
fibroblasts	O
and	O
HeLa	O
and	O
Daudi	O
cell	O
lines	O
.	O

The	O
binding	O
of	O
ISGF3	O
(	O
IFN-stimulated	O
gene	O
factor	O
3	O
)	O
to	O
the	O
conserved	O
IFN-stimulated	O
response	O
element	O
(	O
ISRE	O
)	O
results	O
in	O
transcriptional	O
activation	O
.	O

This	O
factor	O
is	O
composed	O
of	O
a	O
DNA-binding	O
protein	O
(	O
ISGF3	O
gamma	O
)	O
,	O
which	O
normally	O
is	O
present	O
in	O
the	O
cytoplasm	O
,	O
and	O
other	O
IFN-alpha-activated	O
proteins	O
which	O
preexist	O
as	O
latent	O
cytoplasmic	O
precursors	O
(	O
ISGF3	O
alpha	O
)	O
.	O

We	O
have	O
found	O
that	O
ISG	O
expression	O
in	O
the	O
monocytic	O
U937	O
cell	O
line	O
differs	O
from	O
most	O
cell	O
lines	O
previously	O
examined	O
.	O

U937	O
cells	O
express	O
both	O
type	O
I	O
and	O
type	O
II	O
IFN	O
receptors	O
,	O
but	O
only	O
IFN-alpha	O
is	O
capable	O
of	O
inducing	O
antiviral	O
protection	O
in	O
these	O
cells	O
.	O

Pretreatment	O
with	O
IFN-gamma	O
potentiates	O
the	O
IFN-alpha-induced	O
protection	O
,	O
but	O
IFN-gamma	O
alone	O
does	O
not	B-Negation
have	I-Negation
any	I-Negation
antiviral	I-Negation
activity	I-Negation
.	O

ISG15	O
mRNA	O
accumulation	O
in	O
U937	O
cells	O
is	O
not	B-Negation
detectable	I-Negation
before	I-Negation
6	I-Negation
h	I-Negation
of	I-Negation
IFN-alpha	I-Negation
treatment	I-Negation
,	O
peaks	O
at	O
24	O
h	O
,	O
and	O
requires	O
protein	O
synthesis	O
.	O

Although	O
IFN-gamma	O
alone	O
does	O
not	B-Negation
induce	I-Negation
ISG	I-Negation
expression	I-Negation
,	O
IFN-gamma	O
pretreatment	O
markedly	O
increases	O
and	O
hastens	O
ISG	O
expression	O
and	O
transcriptional	O
induction	O
.	O

Nuclear	O
extracts	O
assayed	O
for	O
the	O
presence	O
of	O
ISRE	O
binding	O
factors	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
ISGF3	O
is	O
induced	O
by	O
IFN-alpha	O
within	O
6	O
h	O
from	O
undetectable	O
basal	O
levels	O
in	O
untreated	O
U937	O
cells	O
.	O

Activation	O
of	O
ISGF3	O
alpha	O
,	O
the	O
latent	O
component	O
of	O
ISGF3	O
,	O
occurs	O
rapidly	O
.	O

However	O
,	O
the	O
increase	O
in	O
ISGF3	O
activity	O
ultimately	O
correlates	O
with	O
the	O
accumulation	O
of	O
ISGF3	O
gamma	O
induced	O
by	O
IFN-alpha	O
or	O
IFN-gamma.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
mechanism	O
of	O
action	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

CsA	O
and	O
FK506	O
are	O
powerful	O
suppressors	O
of	O
the	O
immune	O
system	O
,	O
most	O
notably	O
of	O
T	O
cells	O
.	O

They	O
act	O
at	O
a	O
point	O
in	O
activation	O
that	O
lies	O
between	O
receptor	O
ligation	O
and	O
the	O
transcription	O
of	O
early	O
genes	O
.	O

Here	O
,	O
Stuart	O
Schreiber	O
and	O
Gerald	O
Crabtree	O
review	O
recent	O
findings	O
that	O
indicate	O
CsA	O
and	O
FK506	O
operate	O
as	O
prodrugs	O
:	O

they	O
bind	O
endogenous	O
intracellular	O
receptors	O
,	O
the	O
immunophilins	O
,	O
and	O
the	O
resulting	O
complex	O
targets	O
the	O
protein	O
phosphatase	O
,	O
calcineurin	O
,	O
to	O
exert	O
the	O
immunosuppressive	O
effect	O
.	O

[	O
Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	O
receptors	O
in	O
patients	O
with	O
deficiency-cold	O
vs	O
deficiency-heat	O
syndromes	O
]	O

Plasma	O
cortisol	O
concentration	O
and	O
blood	O
leukocyte	O
content	O
of	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
were	O
assayed	O
in	O
20	O
patients	O
with	O
deficiency	O
syndromes	O
,	O
10	O
cold	O
in	O
property	O
(	O
deficiency-cold	O
)	O
,	O
the	O
other	O
10	O
hot	O
in	O
property	O
(	O
deficiency-heat	O
)	O
,	O
and	O
also	O
in	O
10	O
healthy	O
individuals	O
as	O
normal	O
control	O
for	O
the	O
purpose	O
of	O
investigating	O
the	O
nature	O
of	O
cold	O
and	O
heat	O
syndromes	O
.	O

As	O
a	O
result	O
,	O
the	O
cases	O
of	O
deficiency-cold	O
syndrome	O
(	O
DCS	O
)	O
had	O
a	O
normal	O
concentration	O
of	O
plasma	O
cortisol	O
but	O
a	O
lowered	O
content	O
of	O
GCR	O
in	O
leukocytes	O
when	O
compared	O
with	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
;	O

the	O
cases	O
of	O
deficiency-heat	O
syndrome	O
(	O
DHS	O
)	O
had	O
a	O
higher	O
concentration	O
of	O
plasma	O
cortisol	O
than	O
the	O
normal	O
control	O
(	O
P	O
less	O
than	O
0.05	O
)	O
and	O
a	O
slightly	O
higher	O
content	O
of	O
GCR	O
in	O
leukocytes	O
.	O

It	O
was	O
concluded	O
that	O
the	O
DCS	O
is	O
characterized	O
by	O
diminished	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
,	O
while	O
the	O
DHS	O
,	O
by	O
augmented	O
biological	O
effects	O
of	O
adrenocortical	O
activity	O
.	O

Specific	O
NF-kappa	O
B	O
subunits	O
act	O
in	O
concert	O
with	O
Tat	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
.	O

NF-kappa	O
B	O
is	O
a	O
protein	O
complex	O
which	O
functions	O
in	O
concert	O
with	O
the	O
tat-I	O
gene	O
product	O
to	O
stimulate	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
transcription	O
.	O

To	O
determine	O
whether	O
specific	O
members	O
of	O
the	O
NF-kappa	O
B	O
family	O
contribute	O
to	O
this	O
effect	O
,	O
we	O
have	O
examined	O
the	O
abilities	O
of	O
different	O
NF-kappa	O
B	O
subunits	O
to	O
act	O
with	O
Tat-I	O
to	O
stimulate	O
transcription	O
of	O
HIV	O
in	O
Jurkat	O
T-leukemia	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
p49	O
(	O
100	O
)	O
DNA	O
binding	O
subunit	O
,	O
together	O
with	O
p65	O
,	O
can	O
act	O
in	O
concert	O
with	O
Tat-I	O
to	O
stimulate	O
the	O
expression	O
of	O
HIV-CAT	O
plasmid	O
.	O

Little	O
effect	O
was	O
observed	O
with	O
50-kDa	O
forms	O
of	O
p105	O
NF-kappa	O
B	O
or	O
rel	O
,	O
in	O
combination	O
with	O
p65	O
or	O
full-length	O
c-rel	O
,	O
which	O
do	O
not	B-Negation
stimulate	I-Negation
the	I-Negation
HIV	I-Negation
enhancer	I-Negation
in	I-Negation
these	I-Negation
cells	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
the	O
combination	O
of	O
p49	O
(	O
100	O
)	O
and	O
p65	O
NF-kappa	O
B	O
can	O
act	O
in	O
concert	O
with	O
the	O
tat-I	O
gene	O
product	O
to	O
stimulate	O
the	O
synthesis	O
of	O
HIV	O
RNA	O
.	O

Activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
is	O
not	B-Negation
dependent	I-Negation
on	I-Negation
NFAT-1	I-Negation
.	O

The	O
function	O
of	O
a	O
putative	O
NFAT-1	O
site	O
in	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
has	O
been	O
analyzed	O
.	O

Activation	O
by	O
the	O
T-cell	O
antigen	O
receptor	O
is	O
minimal	O
in	O
Jurkat	O
cells	O
and	O
is	O
mediated	O
by	O
the	O
kappa	O
B	O
sites	O
.	O

The	B-Negation
putative	I-Negation
NFAT-1	I-Negation
region	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
the	I-Negation
response	I-Negation
to	I-Negation
anti-CD3	I-Negation
or	I-Negation
to	I-Negation
mitogens	I-Negation
in	I-Negation
T-cell	I-Negation
,	I-Negation
B-cell	I-Negation
,	I-Negation
or	I-Negation
monocyte/macrophage	I-Negation
leukemia	I-Negation
lines	I-Negation
,	O
nor	B-Negation
is	I-Negation
it	I-Negation
a	I-Negation
cis-acting	I-Negation
negative	I-Negation
regulatory	I-Negation
element	I-Negation
.	O

Protein	O
kinase	O
C	O
activation	O
and	O
protooncogene	O
expression	O
in	O
differentiation/retrodifferentiation	O
of	O
human	O
U-937	O
leukemia	O
cells	O
.	O

Human	O
U-937	O
leukemia	O
cells	O
differentiate	O
along	O
the	O
monocytic	O
lineage	O
following	O
3-day	O
exposures	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

This	O
induction	O
of	O
differentiation	O
is	O
accompanied	O
by	O
adherence	O
and	O
loss	O
of	O
proliferation	O
,	O
as	O
well	O
as	O
expression/repression	O
of	O
differentiation-associated	O
genes	O
.	O

Long	O
term	O
culture	O
of	O
TPA-differentiated	O
U-937	O
cells	O
in	O
the	O
absence	O
of	O
phorbol	O
ester	O
for	O
32-36	O
days	O
resulted	O
in	O
a	O
process	O
of	O
retrodifferentiation	O
.	O

The	O
retrodifferentiated	O
cells	O
detached	O
from	O
the	O
substrate	O
and	O
reinitiated	O
proliferation	O
.	O

Other	O
cellular	O
parameters	O
,	O
such	O
as	O
glycosidase	O
activities	O
,	O
cytokine	O
release	O
,	O
and	O
filament	O
expression	O
,	O
returned	O
to	O
levels	O
similar	O
to	O
that	O
observed	O
in	O
uninduced	O
cells	O
.	O

Treatment	O
of	O
U-937	O
cells	O
with	O
TPA	O
resulted	O
in	O
a	O
rapid	O
translocation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
from	O
the	O
cytosol	O
to	O
cell	O
membrane	O
fractions	O
within	O
2-8	O
min	O
.	O

Increased	O
levels	O
of	O
membrane-associated	O
PKC	O
activity	O
persisted	O
until	O
17-29	O
days	O
.	O

However	O
,	O
longer	O
periods	O
of	O
incubation	O
were	O
associated	O
with	O
a	O
return	O
to	O
the	O
distribution	O
of	O
PKC	O
in	O
control	O
cells	O
.	O

Activation	O
of	O
PKC	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
certain	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
in	O
the	O
present	O
studies	O
,	O
TPA	O
rapidly	O
induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression	O
.	O

Levels	O
of	O
c-fos	O
and	O
c-jun	O
transcripts	O
remained	O
elevated	O
during	O
periods	O
of	O
PKC	O
activation	O
and	O
also	O
returned	O
to	O
levels	O
observed	O
in	O
control	O
cells	O
by	O
30-36	O
days	O
,	O
when	O
the	O
cells	O
entered	O
retrodifferentiation	O
.	O

Staurosporine	O
,	O
a	O
nonspecific	O
inhibitor	O
of	O
PKC	O
,	O
partially	O
blocked	O
TPA-induced	O
adherence	O
and	O
growth	O
inhibition	O
and	O
concomitantly	O
prevented	O
TPA-induced	O
c-fos	O
and	O
c-jun	O
gene	O
expression.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
promoter	O
of	O
the	O
CD19	O
gene	O
is	O
a	O
target	O
for	O
the	O
B-cell-specific	O
transcription	O
factor	O
BSAP	O
.	O

The	O
CD19	O
protein	O
is	O
expressed	O
on	O
the	O
surface	O
of	O
all	O
B-lymphoid	O
cells	O
with	B-Negation
the	I-Negation
exception	I-Negation
of	I-Negation
terminally	I-Negation
differentiated	I-Negation
plasma	I-Negation
cells	I-Negation
and	O
has	O
been	O
implicated	O
as	O
a	O
signal-transducing	O
receptor	O
in	O
the	O
control	O
of	O
proliferation	O
and	O
differentiation	O
.	O

Here	O
we	O
demonstrate	O
complete	O
correlation	O
between	O
the	O
expression	O
pattern	O
of	O
the	O
CD19	O
gene	O
and	O
the	O
B-cell-specific	O
transcription	O
factor	O
BSAP	O
in	O
a	O
large	O
panel	O
of	O
B-lymphoid	O
cell	O
lines	O
.	O

The	O
human	O
CD19	O
gene	O
has	O
been	O
cloned	O
,	O
and	O
several	O
BSAP-binding	O
sites	O
have	O
been	O
mapped	O
by	O
in	O
vitro	O
protein-DNA	O
binding	O
studies	O
.	O

In	O
particular	O
,	O
a	O
high-affinity	O
BSAP-binding	O
site	O
instead	B-Negation
of	I-Negation
a	I-Negation
TATA	I-Negation
sequence	I-Negation
is	O
located	O
in	O
the	O
-30	O
promoter	O
region	O
upstream	O
of	O
a	O
cluster	O
of	O
heterogeneous	O
transcription	O
start	O
sites	O
.	O

Moreover	O
,	O
this	O
site	O
is	O
occupied	O
by	O
BSAP	O
in	O
vivo	O
in	O
a	O
CD19-expressing	O
B-cell	O
line	O
but	O
not	B-Negation
in	I-Negation
plasma	I-Negation
or	I-Negation
HeLa	I-Negation
cells	I-Negation
.	O

This	O
high-affinity	O
site	O
has	O
been	O
conserved	O
in	O
the	O
promoters	O
of	O
both	O
human	O
and	O
mouse	O
CD19	O
genes	O
and	O
was	O
furthermore	O
shown	O
to	O
confer	O
B-cell	O
specificity	O
to	O
a	O
beta-globin	O
reporter	O
gene	O
in	O
transient	O
transfection	O
experiments	O
.	O

In	O
addition	O
,	O
BSAP	O
was	O
found	O
to	O
be	O
the	O
only	O
abundant	O
DNA-binding	O
activity	O
of	O
B-cell	O
nuclear	O
extracts	O
that	O
interacts	O
with	O
the	O
CD19	O
promoter	O
.	O

Together	O
,	O
this	O
evidence	O
strongly	O
implicates	O
BSAP	O
in	O
the	O
regulation	O
of	O
the	O
CD19	O
gene	O
.	O

Reduced	O
susceptibility	O
to	O
HIV-1	O
infection	O
of	O
ethyl-methanesulfonate-treated	O
CEM	O
subclones	O
correlates	O
with	O
a	O
blockade	O
in	O
their	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
.	O

We	O
have	O
described	O
the	O
isolation	O
of	O
chemically	O
induced	O
CEM	O
subclones	O
that	O
express	O
CD4	O
receptors	O
and	O
bind	O
soluble	O
gp120	O
,	O
yet	O
show	O
a	O
markedly	O
reduced	O
susceptibility	O
to	O
infection	O
with	O
HIV-1	O
.	O

Two	O
subclones	O
were	O
found	O
to	O
have	O
an	O
abnormal	O
response	O
to	O
the	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activator	O
PMA	O
.	O

PMA	O
treatment	O
induced	O
CD3	O
and	O
CD25	O
(	O
IL-2R	O
)	O
receptors	O
on	O
the	O
parental	O
line	O
and	O
on	O
other	O
ethyl-methanesulfonate-derived	O
subclones	O
,	O
but	O
not	B-Negation
on	I-Negation
these	I-Negation
two	I-Negation
mutants	I-Negation
.	O

Direct	O
assays	O
of	O
PKC	O
activity	O
were	O
conducted	O
.	O

Total	O
cellular	O
PKC	O
enzymatic	O
activity	O
was	O
found	O
to	O
be	O
normal	O
in	O
these	O
subclones	O
.	O

PMA-induced	O
CD4	O
down-modulation	O
occurred	O
normally	O
.	O

In	O
addition	O
,	O
activation	O
of	O
c-raf	O
kinase	O
was	O
normal	O
.	O

Since	O
HIV-1	O
long	O
terminal	O
repeat	O
contains	O
two	O
functional	O
nuclear	O
factor	O
kB	O
(	O
NF-kB	O
)	O
regulatory	O
elements	O
,	O
we	O
studied	O
the	O
ability	O
of	O
PMA	O
to	O
induce	O
NF-kB	O
binding	O
activity	O
by	O
different	O
assays	O
.	O

Chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
assays	O
using	O
the	O
HIV-1	O
(	O
-139	O
)	O
long	O
terminal	O
repeat-CAT	O
construct	O
showed	O
no	B-Negation
PMA	I-Negation
induction	I-Negation
of	I-Negation
CAT	I-Negation
activity	I-Negation
in	I-Negation
these	I-Negation
subclones	I-Negation
(	O
unlike	O
the	O
parental	O
line	O
and	O
other	O
subclones	O
)	O
.	O

Okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
did	O
not	B-Negation
overcome	I-Negation
the	I-Negation
defect	I-Negation
in	I-Negation
these	I-Negation
subclones	I-Negation
.	O

Gel	O
retardation	O
assays	O
,	O
using	O
a	O
32P-probe	O
containing	O
the	O
HIV-1	O
NF-kB	O
probe	O
and	O
nuclear	O
extracts	O
from	O
PMA-treated	O
cells	O
,	O
showed	O
significantly	O
reduced	O
induction	O
of	O
nuclear	O
NF-kB	O
binding	O
proteins	O
in	O
these	O
two	O
subclones	O
compared	O
with	O
wild	O
type	O
CEM	O
and	O
a	O
control	O
subclone	O
.	O

Deoxycholate	O
treatment	O
of	O
cytoplasmic	O
extracts	O
from	O
these	O
subclones	O
released	O
much	O
reduced	O
NF-kB	O
binding	O
proteins	O
from	O
their	O
cytoplasmic	O
pools	O
.	O

Thus	O
,	O
reduced	O
levels	O
of	O
PKC-induced	O
nuclear	O
NF-kB	O
activity	O
in	O
two	O
T	O
cell	O
subclones	O
did	O
not	B-Negation
affect	I-Negation
their	I-Negation
normal	I-Negation
cell	I-Negation
growth	I-Negation
,	O
but	O
correlated	O
with	O
a	O
pronounced	O
reduction	O
in	O
their	O
susceptibility	O
to	O
HIV-1	O
infection	O
.	O

Eicosanoids	O
in	O
breast	O
cancer	O
patients	O
before	O
and	O
after	O
mastectomy	O
.	O

In	O
19	O
patients	O
with	O
a	O
malignant	O
breast	O
tumor	O
,	O
tumor	O
tissue	O
and	O
blood	O
were	O
taken	O
to	O
determine	O
the	O
eicosanoid	O
profile	O
and	O
platelet	O
aggregation	O
.	O

Values	O
were	O
compared	O
with	O
those	O
of	O
patients	O
with	O
benign	O
tumors	O
(	O
n	O
=	O
4	O
)	O
,	O
or	O
undergoing	O
a	O
mammary	O
reduction	O
(	O
n	O
=	O
7	O
)	O
.	O

Postoperatively	O
,	O
blood	O
was	O
taken	O
as	O
well	O
in	O
order	O
to	O
compare	O
pre-	O
and	O
postoperative	O
values	O
.	O

Eicosanoids	O
were	O
measured	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
mammary	O
tissue	O
by	O
means	O
of	O
HPLC	O
;	O

furthermore	O
,	O
TXA2	O
,	O
6-keto-PGF1	O
alpha	O
,	O
and	O
PGE2	O
were	O
determined	O
by	O
RIA	O
.	O

Differences	O
in	O
pre-	O
and	O
postoperative	O
values	O
of	O
cancer	O
patients	O
were	O
seen	O
in	O
plasma	O
RIA	O
values	O
:	O

PGE2	O
and	O
6-k-PGF1	O
alpha	O
were	O
significantly	O
higher	O
preoperatively	O
when	O
compared	O
with	O
postoperatively	O
,	O
however	O
,	O
such	O
differences	O
were	O
seen	O
in	O
the	O
control	O
groups	O
as	O
well	O
.	O

Compared	O
to	O
benign	O
tumor	O
or	O
mammary	O
reduction	O
test	O
material	O
the	O
eicosanoid	O
profile	O
of	O
tissue	O
obtained	O
from	O
malignant	O
mammary	O
tumors	O
showed	O
important	O
differences	O
.	O

Except	O
for	O
PGF2	O
alpha	O
,	O
HHT	O
and	O
15-HETE	O
no	B-Negation
detectable	I-Negation
quantities	I-Negation
of	I-Negation
eicosanoids	I-Negation
were	I-Negation
found	I-Negation
in	I-Negation
the	I-Negation
non-tumor	I-Negation
material	I-Negation
,	O
whereas	O
in	O
the	O
malignant	O
tumor	O
material	O
substantial	O
quantities	O
of	O
a	O
number	O
of	O
eicosanoid	O
metabolites	O
were	O
present	O
.	O

Statistically	O
significant	O
correlations	O
could	O
be	O
established	O
between	O
patient/histopathology	O
data	O
and	O
the	O
results	O
of	O
the	O
platelet	O
aggregation	O
assays	O
,	O
e.g	O
.	O

between	O
menopausal	O
status	O
and	O
ADP	O
aggregation	O
;	O
oestrogen	O
receptor	O
(	O
+/-	O
)	O
and	O
collagen	O
and	O
arachidonic	O
acid	O
aggregation	O
,	O
inflammatory	O
cell	O
infiltration	O
score	O
and	O
arachidonic	O
acid	O
aggregation	O
and	O
fibrosis	O
score	O
and	O
ADP	O
aggregation	O
.	O

The	O
results	O
show	O
that	O
eicosanoid	O
synthesis	O
in	O
material	O
from	O
mammary	O
cancer	O
patients	O
is	O
different	O
from	O
that	O
in	O
benign	O
mammary	O
tissue	O
.	O

The	O
implications	O
,	O
in	O
particular	O
,	O
in	O
relation	O
to	O
future	O
prognosis	O
of	O
the	O
patient	O
,	O
remain	O
obscure	O
.	O

c-myc	O
mRNA	O
expression	O
in	O
minor	O
salivary	O
glands	O
of	O
patients	O
with	O
Sjogren	O
's	O
syndrome	O
.	O

c-myc	O
protooncogene	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B	O
cell	O
lymphoid	O
malignancies	O
and	O
high	O
levels	O
of	O
c-myc	O
mRNA	O
expression	O
are	O
observed	O
in	O
activated	O
blood	O
mononuclear	O
cells	O
.	O

Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
characterized	O
by	O
lymphocytic	O
infiltrates	O
of	O
exocrine	O
glands	O
,	O
remarkable	O
B	O
cell	O
hyperreactivity	O
and	O
a	O
strong	O
predisposition	O
to	O
B	O
cell	O
neoplasia	O
.	O

In	O
this	O
study	O
,	O
c-myc	O
protooncogene	O
mRNA	O
expression	O
in	O
29	O
labial	O
minor	O
salivary	O
gland	O
biopsies	O
from	O
patients	O
with	O
primary	O
SS	O
and	O
15	O
controls	O
was	O
examined	O
using	O
in	O
situ	O
hybridization	O
histochemistry	O
.	O

Two	O
40mer	O
oligonucleotides	O
from	O
the	O
1st	O
and	O
the	O
2nd	O
exon	O
of	O
the	O
c-myc	O
gene	O
,	O
labeled	O
with	O
35S	O
,	O
were	O
used	O
as	O
probes	O
.	O

To	O
detect	O
the	O
origin	O
of	O
the	O
cell	O
hybridized	O
with	O
a	O
c-myc	O
probe	O
,	O
a	O
combined	O
immunochemistry	O
in	O
situ	O
hybridization	O
histochemistry	O
technique	O
was	O
used	O
.	O

High	O
c-myc	O
mRNA	O
expression	O
was	O
detected	O
on	O
acinar	O
epithelial	O
cells	O
.	O

c-myc	O
did	O
not	B-Negation
correlate	I-Negation
with	I-Negation
c-fos	I-Negation
and	I-Negation
c-jun	I-Negation
protein	I-Negation
expression	I-Negation
.	O

Stronger	O
c-myc	O
mRNA	O
expression	O
was	O
detected	O
in	O
labial	O
salivary	O
glands	O
of	O
patients	O
with	O
longer	O
disease	O
duration	O
(	O
p	O
less	O
than	O
or	O
equal	O
to	O
0.002	O
)	O
and	O
more	O
intense	O
T	O
lymphocyte	O
infiltrates	O
(	O
p	O
less	O
than	O
0.05	O
)	O
although	O
these	O
patients	O
revealed	O
no	B-Negation
hypergammaglobulinemia	I-Negation
.	O

No	B-Negation
correlation	I-Negation
was	I-Negation
observed	I-Negation
between	I-Negation
c-myc	I-Negation
mRNA	I-Negation
and	I-Negation
B	I-Negation
lymphocyte	I-Negation
monoclonicity	I-Negation
or	I-Negation
lymphoma	I-Negation
.	O

In	O
conclusion	O
,	O
strong	O
c-myc	O
mRNA	O
expression	O
was	O
observed	O
on	O
epithelial	O
cells	O
of	O
labial	O
salivary	O
glands	O
from	O
patients	O
with	O
primary	O
SS	O
.	O

Our	O
findings	O
may	O
indicate	O
the	O
presence	O
of	O
a	O
reactivated	O
virus	O
hosted	O
in	O
these	O
cells	O
.	O

Cytoplasmic	O
domain	O
heterogeneity	O
and	O
functions	O
of	O
IgG	O
Fc	O
receptors	O
in	O
B	O
lymphocytes	O
.	O

B	O
lymphocytes	O
and	O
macrophages	O
express	O
closely	O
related	O
immunoglobulin	O
G	O
(	O
IgG	O
)	O
Fc	O
receptors	O
(	O
Fc	O
gamma	O
RII	O
)	O
that	O
differ	O
only	O
in	O
the	O
structures	O
of	O
their	O
cytoplasmic	O
domains	O
.	O

Because	O
of	O
cell	O
type-specific	O
alternative	O
messenger	O
RNA	O
splicing	O
,	O
B-cell	O
Fc	O
gamma	O
RII	O
contains	O
an	O
insertion	O
of	O
47	O
amino	O
acids	O
that	O
participates	O
in	O
determining	O
receptor	O
function	O
in	O
these	O
cells	O
.	O

Transfection	O
of	O
an	O
Fc	O
gamma	O
RII-negative	O
B-cell	O
line	O
with	O
complementary	O
DNA	O
's	O
encoding	O
the	O
two	O
splice	O
products	O
and	O
various	O
receptor	O
mutants	O
indicated	O
that	O
the	O
insertion	O
was	O
responsible	O
for	O
preventing	O
both	O
Fc	O
gamma	O
RII-mediated	O
endocytosis	O
and	O
Fc	O
gamma	O
RII-mediated	O
antigen	O
presentation	O
.	O

The	O
insertion	O
was	O
not	B-Negation
required	I-Negation
for	I-Negation
Fc	I-Negation
gamma	I-Negation
RII	I-Negation
to	I-Negation
modulate	I-Negation
surface	I-Negation
immunoglobulin-triggered	I-Negation
B-cell	I-Negation
activation	I-Negation
.	O

Instead	O
,	O
regulation	O
of	O
activation	O
involved	O
a	O
region	O
of	O
the	O
cytoplasmic	O
domain	O
common	O
to	O
both	O
the	O
lymphocyte	O
and	O
macrophage	O
receptor	O
isoforms	O
.	O

In	O
contrast	O
,	O
the	O
insertion	O
did	O
contribute	O
to	O
the	O
formation	O
of	O
caps	O
in	O
response	O
to	O
receptor	O
cross-linking	O
,	O
consistent	O
with	O
suggestions	O
that	O
the	O
lymphocyte	O
but	O
not	O
macrophage	O
form	O
of	O
the	O
receptor	O
can	O
associate	O
with	O
the	O
detergent-insoluble	O
cytoskeleton	O
.	O

Every	O
enhancer	O
works	O
with	O
every	O
promoter	O
for	O
all	O
the	O
combinations	O
tested	O
:	O

could	O
new	O
regulatory	O
pathways	O
evolve	O
by	O
enhancer	O
shuffling	O
?	O

The	O
promoters	O
and	O
enhancers	O
of	O
cell	O
type-specific	O
genes	O
are	O
often	O
conserved	O
in	O
evolution	O
,	O
and	O
hence	O
one	O
might	O
expect	O
that	O
a	O
given	O
enhancer	O
has	O
evolved	O
to	O
work	O
best	O
with	O
its	O
own	O
promoter	O
.	O

While	O
this	B-Speculation
expectation	I-Speculation
may	I-Speculation
be	I-Speculation
realized	I-Speculation
in	I-Speculation
some	I-Speculation
cases	I-Speculation
,	O
we	O
have	O
not	B-Negation
found	I-Negation
evidence	I-Negation
for	I-Negation
it	I-Negation
.	O

A	O
total	O
of	O
27	O
combinations	O
of	O
different	O
promoters	O
and	O
enhancers	O
were	O
tested	O
by	O
transfection	O
into	O
cultured	O
cells	O
.	O

We	O
found	O
that	O
the	O
relative	O
efficiency	O
of	O
the	O
enhancers	O
is	O
approximately	O
the	O
same	O
,	O
irrespective	O
of	O
the	O
type	O
of	O
promoter	O
used	O
,	O
i.e.	O
,	O
there	O
was	O
no	B-Negation
strong	I-Negation
preference	I-Negation
for	I-Negation
any	I-Negation
given	I-Negation
enhancer/promoter	I-Negation
combination	I-Negation
.	O

Notably	O
,	O
we	O
do	O
not	B-Negation
see	I-Negation
particularly	I-Negation
strong	I-Negation
transcription	I-Negation
when	I-Negation
the	I-Negation
immunoglobulin	I-Negation
kappa	I-Negation
enhancer	I-Negation
(	I-Negation
or	I-Negation
the	I-Negation
immunoglobulin	I-Negation
heavy	I-Negation
chain	I-Negation
enhancer	I-Negation
)	I-Negation
is	I-Negation
used	I-Negation
to	I-Negation
activate	I-Negation
a	I-Negation
kappa	I-Negation
gene	I-Negation
promoter	I-Negation
.	O

We	O
propose	O
that	O
a	O
generally	O
permissive	O
enhancer/promoter	O
interaction	O
is	O
of	O
evolutionary	O
benefit	O
for	O
higher	O
eukaryotes	O
:	O
by	O
enhancer	O
shuffling	O
,	O
genes	O
could	O
be	O
easily	O
brought	O
under	O
a	O
new	O
type	O
of	O
inducibility/cell	O
type	O
specificity	O
.	O

Heterodimerization	O
and	O
transcriptional	O
activation	O
in	O
vitro	O
by	O
NF-kappa	O
B	O
proteins	O
.	O

The	O
NF-kappa	O
B	O
family	O
of	O
transcription	O
proteins	O
represents	O
multiple	O
DNA	O
binding	O
,	O
rel	O
related	O
polypeptides	O
that	O
contribute	O
to	O
regulation	O
of	O
genes	O
involved	O
in	O
immune	O
responsiveness	O
and	O
inflammation	O
,	O
as	O
well	O
as	O
activation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

In	O
this	O
study	O
multiple	O
NF-kappa	O
B	O
related	O
polypeptides	O
ranging	O
from	O
85	O
to	O
45	O
kDa	O
were	O
examined	O
for	O
their	O
capacity	O
to	O
interact	O
with	O
the	O
PRDII	O
regulatory	O
element	O
of	O
interferon	O
beta	O
and	O
were	O
shown	O
to	O
possess	O
distinct	O
intrinsic	O
DNA	O
binding	O
affinities	O
for	O
this	O
NF-kappa	O
B	O
site	O
and	O
form	O
multiple	O
DNA	O
binding	O
homo-	O
and	O
heterodimer	O
complexes	O
in	O
co-renaturation	O
experiments	O
.	O

Furthermore	O
,	O
using	O
DNA	O
templates	O
containing	O
two	O
copies	O
of	O
the	O
PRDII	O
domain	O
linked	O
to	O
the	O
rabbit	O
beta	O
globin	O
gene	O
,	O
the	O
purified	O
polypeptides	O
specifically	O
stimulated	O
NF-kappa	O
B	O
dependent	O
transcription	O
in	O
an	O
in	O
vitro	O
reconstitution	O
assay	O
as	O
heterodimers	O
but	O
not	B-Negation
as	I-Negation
p50	I-Negation
homodimers	I-Negation
.	O

These	O
experiments	O
emphasize	O
the	O
role	O
of	O
NF-kappa	O
B	O
dimerization	O
as	O
a	O
distinct	O
level	O
of	O
transcriptional	O
control	O
that	O
may	O
permit	O
functional	O
diversification	O
of	O
a	O
limited	O
number	O
of	O
regulatory	O
proteins	O
.	O

Oct2	O
transactivation	O
from	O
a	O
remote	O
enhancer	O
position	O
requires	O
a	O
B-cell-restricted	O
activity	O
.	O

Previous	O
cotransfection	O
experiments	O
had	O
demonstrated	O
that	O
ectopic	O
expression	O
of	O
the	O
lymphocyte-specific	O
transcription	O
factor	O
Oct2	O
could	O
efficiently	O
activate	O
a	O
promoter	O
containing	O
an	O
octamer	O
motif	O
.	O

Oct2	O
expression	O
was	O
unable	B-Negation
to	I-Negation
stimulate	I-Negation
a	I-Negation
multimerized	I-Negation
octamer	I-Negation
enhancer	I-Negation
element	I-Negation
in	I-Negation
HeLa	I-Negation
cells	I-Negation
,	O
however	O
.	O

We	O
have	O
tested	O
a	O
variety	O
of	O
Oct2	O
isoforms	O
generated	O
by	O
alternative	O
splicing	O
for	O
the	O
capability	O
to	O
activate	O
an	O
octamer	O
enhancer	O
in	O
nonlymphoid	O
cells	O
and	O
a	O
B-cell	O
line	O
.	O

Our	O
analyses	O
show	O
that	O
several	O
Oct2	O
isoforms	O
can	O
stimulate	O
from	O
a	O
remote	O
position	O
but	O
that	O
this	O
stimulation	O
is	O
restricted	O
to	O
B	O
cells	O
.	O

This	O
result	O
indicates	O
the	O
involvement	O
of	O
either	O
a	O
B-cell-specific	O
cofactor	O
or	O
a	O
specific	O
modification	O
of	O
a	O
cofactor	O
or	O
the	O
Oct2	O
protein	O
in	O
Oct2-mediated	O
enhancer	O
activation	O
.	O

Mutational	O
analyses	O
indicate	O
that	O
the	O
carboxy-terminal	O
domain	O
of	O
Oct2	O
is	O
critical	O
for	O
enhancer	O
activation	O
.	O

Moreover	O
,	O
this	O
domain	O
conferred	O
enhancing	O
activity	O
when	O
fused	O
to	O
the	O
Oct1	O
protein	O
,	O
which	O
by	O
itself	O
was	O
unable	B-Negation
to	I-Negation
stimulate	I-Negation
from	I-Negation
a	I-Negation
remote	I-Negation
position	I-Negation
.	O

The	O
glutamine-rich	O
activation	O
domain	O
present	O
in	O
the	O
amino-terminal	O
portion	O
of	O
Oct2	O
and	O
the	O
POU	O
domain	O
contribute	O
only	O
marginally	O
to	O
the	O
transactivation	O
function	O
from	O
a	O
distal	O
position	O
.	O

Induction	O
of	O
the	O
POU	O
domain	O
transcription	O
factor	O
Oct-2	O
during	O
T-cell	O
activation	O
by	O
cognate	O
antigen	O
.	O

Oct-2	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
specifically	O
to	O
octamer	O
DNA	O
motifs	O
in	O
the	O
promoters	O
of	O
immunoglobulin	O
and	O
interleukin-2	O
genes	O
.	O

All	O
tumor	O
cell	O
lines	O
from	O
the	O
B-cell	O
lineage	O
and	O
a	O
few	O
from	O
the	O
T-cell	O
lineage	O
express	O
Oct-2	O
.	O

To	O
address	O
the	O
role	O
of	O
Oct-2	O
in	O
the	O
T-cell	O
lineage	O
,	O
we	O
studied	O
the	O
expression	O
of	O
Oct-2	O
mRNA	O
and	O
protein	O
in	O
nontransformed	O
human	O
and	O
mouse	O
T	O
cells	O
.	O

Oct-2	O
was	O
found	O
in	O
CD4+	O
and	O
CD8+	O
T	O
cells	O
prepared	O
from	O
human	O
peripheral	O
blood	O
and	O
in	O
mouse	O
lymph	O
node	O
T	O
cells	O
.	O

In	O
a	O
T-cell	O
clone	O
specific	O
for	O
pigeon	O
cytochrome	O
c	O
in	O
the	O
context	O
of	O
I-Ek	O
,	O
Oct-2	O
was	O
induced	O
by	O
antigen	O
stimulation	O
,	O
with	O
the	O
increase	O
in	O
Oct-2	O
protein	O
seen	O
first	O
at	O
3	O
h	O
after	O
activation	O
and	O
continuing	O
for	O
at	O
least	O
24	O
h	O
.	O

Oct-2	O
mRNA	O
induction	O
during	O
antigen-driven	O
T-cell	O
activation	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
,	O
as	O
well	O
as	O
by	O
protein	O
synthesis	O
inhibitors	O
.	O

These	O
results	O
suggest	O
that	O
Oct-2	O
participates	O
in	O
transcriptional	O
regulation	O
during	O
T-cell	O
activation	O
.	O

The	O
relatively	O
delayed	O
kinetics	O
of	O
Oct-2	O
induction	O
suggests	O
that	O
Oct-2	O
mediates	O
the	O
changes	O
in	O
gene	O
expression	O
which	O
occur	O
many	O
hours	O
or	O
days	O
following	O
antigen	O
stimulation	O
of	O
T	O
lymphocytes	O
.	O

[	O
Changes	O
in	O
plasma	O
interleukin-1	O
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	O
receptor	O
in	O
aged	O
long-distance	O
runner	O
]	O

For	O
the	O
study	O
of	O
the	O
changes	O
in	O
plasma	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
their	O
possible	O
relationship	O
with	O
the	O
changes	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
,	O
plasma	O
IL-1	O
and	O
GR	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
aged	O
long-distance	O
runner	O
were	O
measured	O
simultaneously	O
.	O

The	O
activity	O
of	O
IL-1	O
was	O
expressed	O
as	O
its	O
ability	O
to	O
stimulate	O
3H-TdR	O
incorporation	O
in	O
the	O
thymocytes	O
of	O
C57	O
mice	O
.	O

GR	O
was	O
determined	O
by	O
whole	O
cell	O
assay	O
with	O
3H-Dex	O
.	O

The	O
results	O
showed	O
that	O
the	O
activity	O
of	O
plasma	O
IL-1	O
in	O
aged	O
long-distance	O
runner	O
was	O
209	O
%	O
,	O
223	O
%	O
and	O
145	O
%	O
of	O
the	O
control	O
at	O
14.7-18.7	O
,	O
3.8-7.0	O
and	O
1.5-2.6	O
KD	O
fractions	O
.	O

The	O
GR	O
in	O
peripheral	O
blood	O
leukocytes	O
in	O
aged	O
runner	O
was	O
65	O
%	O
of	O
the	O
control	O
.	O

Possible	O
relationship	O
between	O
the	O
changes	O
in	O
IL-1	O
and	O
GR	O
in	O
aged	O
long-distance	O
runner	O
and	O
its	O
physiological	O
significance	O
are	O
discussed	O
.	O

Transcription	O
factor	O
AP-2	O
activates	O
gene	O
expression	O
of	O
HTLV-I	O
.	O

The	O
HTLV-I	O
LTR	O
contains	O
three	O
conserved	O
regulatory	O
elements	O
known	O
as	O
21	O
base	O
pair	O
repeats	O
which	O
are	O
required	O
for	O
stimulation	O
of	O
gene	O
expression	O
by	O
the	O
transactivator	O
protein	O
tax	O
.	O

Mutagenesis	O
indicates	O
that	O
the	O
21	O
bp	O
repeats	O
can	O
be	O
subdivided	O
into	O
three	O
motifs	O
,	O
A	O
,	O
B	O
and	O
C	O
,	O
each	O
of	O
which	O
influences	O
the	O
level	O
of	O
tax	O
activation	O
.	O

The	O
A	O
site	O
in	O
the	O
21	O
bp	O
repeat	O
has	O
strong	O
homology	O
with	O
previously	O
described	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
AP-2	O
.	O

We	O
demonstrated	O
that	O
AP-2	O
mRNA	O
was	O
present	O
in	O
T-lymphocytes	O
and	O
that	O
cellular	O
factors	O
from	O
both	O
non-transformed	O
and	O
transformed	O
T-lymphocytes	O
specifically	O
bound	O
to	O
the	O
consensus	O
motif	O
for	O
AP-2	O
in	O
each	O
21	O
bp	O
.	O

To	O
determine	O
the	O
role	O
of	O
AP-2	O
in	O
the	O
regulation	O
of	O
the	O
HTLV-I	O
LTR	O
gene	O
expression	O
,	O
we	O
used	O
an	O
AP-2	O
cDNA	O
in	O
DNA	O
binding	O
and	O
transient	O
expression	O
assays	O
.	O

Gel	O
retardation	O
and	O
methylation	O
interference	O
studies	O
revealed	O
that	O
bacterially	O
produced	O
AP-2	O
bound	O
specifically	O
and	O
with	O
high	O
affinity	O
to	O
all	O
three	O
21	O
bp	O
repeats	O
,	O
and	O
that	O
it	O
required	O
the	O
core	O
sequence	O
AGGC	O
for	O
specific	O
binding	O
.	O

Binding	O
of	O
AP-2	O
prevented	O
the	O
subsequent	O
binding	O
of	O
members	O
of	O
the	O
CREB/ATF	O
family	O
to	O
an	O
adjacent	O
regulatory	O
motif	O
in	O
the	O
21	O
bp	O
repeat	O
.	O

Transfection	O
of	O
an	O
AP-2	O
expression	O
construct	O
into	O
T-lymphocytes	O
activated	O
gene	O
expression	O
from	O
the	O
HTLV-I	O
LTR	O
.	O

At	O
least	O
two	O
21	O
bp	O
repeats	O
were	O
required	O
for	O
high	O
levels	O
of	O
AP-2	O
activation	O
and	O
mutagenesis	O
of	O
the	O
AP-2	O
consensus	O
binding	O
sequences	O
in	O
the	O
21	O
bp	O
repeats	O
eliminate	O
this	O
activation.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cell	O
cycle-dependent	O
initiation	O
and	O
lineage-dependent	O
abrogation	O
of	O
GATA-1	O
expression	O
in	O
pure	O
differentiating	O
hematopoietic	O
progenitors	O
.	O

The	B-Negation
programmed	I-Negation
activation/repression	I-Negation
of	I-Negation
transcription	I-Negation
factors	I-Negation
in	I-Negation
early	I-Negation
hematopoietic	I-Negation
differentiation	I-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
explored	I-Negation
.	O

The	O
DNA-binding	O
protein	O
GATA-1	O
is	O
required	O
for	O
normal	O
erythroid	O
development	O
and	O
regulates	O
erythroid-expressed	O
genes	O
in	O
maturing	O
erythroblasts	O
.	O

We	O
analyzed	O
GATA-1	O
expression	O
in	O
early	O
human	O
adult	O
hematopoiesis	O
by	O
using	O
an	O
in	O
vitro	O
system	O
in	O
which	O
``	O
pure	O
``	O
early	O
hematopoietic	O
progenitors	O
are	O
induced	O
to	O
gradual	O
and	O
synchronized	O
differentiation	O
selectively	O
along	O
the	O
erythroid	O
or	O
granulocyte-macrophage	O
pathway	O
by	O
differential	O
treatment	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

The	O
GATA-1	O
gene	O
,	O
though	O
virtually	O
silent	O
in	O
quiescent	O
progenitors	O
,	O
is	O
activated	O
after	O
entrance	O
into	O
the	O
cell	O
cycle	O
upon	O
stimulation	O
with	O
hematopoietic	O
growth	O
factors	O
.	O

Subsequently	O
,	O
increasing	O
expression	O
along	O
the	O
erythroid	O
pathway	O
contrasts	O
with	O
an	O
abrupt	O
downregulation	O
in	O
the	O
granulocyte-macrophage	O
lineage	O
.	O

These	O
results	O
suggest	O
a	O
microenvironment-directed	O
,	O
two-step	O
model	O
for	O
GATA-1	O
expression	O
in	O
differentiating	O
hematopoietic	O
progenitors	O
that	O
involves	O
(	O
i	O
)	O
cycle-dependent	O
initiation	O
and	O
(	O
ii	O
)	O
lineage-dependent	O
maintenance	O
or	O
suppression	O
.	O

Hypothetically	O
,	O
on/off	O
switches	O
of	O
lineage-restricted	O
transactivators	O
may	O
underlie	O
the	O
binary	O
fate	O
decisions	O
of	O
hematopoietic	O
progenitors	O
.	O

[	O
Age-related	O
changes	O
in	O
glucocorticoid	O
and	O
mineralocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
healthy	O
persons	O
and	O
patients	O
with	O
hypertension	O
]	O

It	O
has	O
been	O
found	O
that	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
the	O
peripheral	O
blood	O
of	O
healthy	O
elderly	O
subjects	O
increases	O
,	O
while	O
the	O
number	O
of	O
mineralocorticoid	O
receptors	O
decreases	O
.	O

The	O
mechanisms	O
of	O
hormone-receptor	O
interactions	O
in	O
hypertension	O
are	O
activated	O
:	O

the	O
number	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
binding	O
sites	O
grows	O
in	O
hypertensive	O
patients	O
.	O

Still	O
a	O
more	O
essential	O
rise	O
in	O
the	O
number	O
of	O
receptors	O
is	O
observed	O
in	O
mid-age	O
hypertensive	O
patients	O
than	O
in	O
elderly	O
ones	O
.	O

In	O
vivo	O
footprint	O
analysis	O
of	O
the	O
HLA-DRA	O
gene	O
promoter	O
:	O
cell-specific	O
interaction	O
at	O
the	O
octamer	O
site	O
and	O
up-regulation	O
of	O
X	O
box	O
binding	O
by	O
interferon	O
gamma	O
.	O

Analysis	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
gene	O
promoter	O
DRA	O
has	O
previously	O
identified	O
at	O
least	O
five	O
cis-acting	O
regions	O
required	O
for	O
maximal	O
expression	O
.	O

We	O
have	O
examined	O
the	O
DRA	O
promoter	O
for	O
protein-DNA	O
interactions	O
in	O
the	O
intact	O
cell	O
,	O
which	O
may	O
mediate	O
transcriptional	O
activation	O
.	O

Using	O
in	O
vivo	O
genomic	O
footprinting	O
we	O
identified	O
interactions	O
in	O
B-cell	O
lines	O
at	O
the	O
octamer	O
site	O
and	O
the	O
Y	O
,	O
X1	O
,	O
and	O
X2	O
boxes	O
.	O

Class	O
II	O
antigen	O
expressing	O
T-cell	O
lines	O
maintained	O
contacts	O
identical	O
to	O
B-cell	O
lines	O
,	O
while	O
class	O
II-negative	O
T-cell	O
lines	O
exhibited	O
no	B-Negation
interactions	I-Negation
.	O

In	O
lymphoid	O
cell	O
lines	O
,	O
the	O
octamer	O
site	O
is	O
occupied	O
and	O
required	O
for	O
maximal	O
expression	O
.	O

This	O
is	O
most	O
likely	O
due	O
to	O
the	O
presence	O
of	O
the	O
lymphoid-specific	O
OTF-2	O
factor	O
.	O

In	O
contrast	O
,	O
the	O
class	O
II-positive	O
nonlymphoid	O
glioblastoma	O
cell	O
line	O
does	O
not	B-Negation
exhibit	I-Negation
interactions	I-Negation
at	I-Negation
the	I-Negation
octamer	I-Negation
site	I-Negation
despite	O
the	O
presence	O
of	O
the	O
ubiquitous	O
OTF-1	O
factor	O
and	O
an	O
open	O
binding	O
site	O
.	O

Thus	O
,	O
the	O
DRA	O
promoter	O
discriminates	O
against	O
OTF-1	O
activation	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
in	O
the	O
glioblastoma	O
line	O
.	O

Interferon	O
gamma	O
induces	O
class	O
II	O
expression	O
in	O
this	O
glioblastoma	O
cell	O
line	O
and	O
,	O
in	O
parallel	O
,	O
up-regulates	O
X1	O
and	O
X2	O
box	O
protein-DNA	O
interactions	O
,	O
while	O
all	O
other	O
interactions	O
remain	O
unchanged	O
.	O

These	O
results	O
suggest	O
that	O
interferon	O
gamma	O
functions	O
on	O
a	O
poised	O
promoter	O
by	O
altering	O
weak	O
,	O
nonproductive	O
interactions	O
at	O
the	O
X	O
boxes	O
to	O
strong	O
interactions	O
.	O

These	O
findings	O
provide	O
direct	O
in	O
vivo	O
evidence	O
to	O
strongly	O
suggest	O
that	O
the	O
modulation	O
of	O
X1	O
and	O
X2	O
interactions	O
is	O
an	O
important	O
constituent	O
of	O
the	O
interferon	O
gamma	O
induction	O
pathway	O
.	O

Simple	O
derivation	O
of	O
TFIID-dependent	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Schizosaccharomyces	O
pombe	O
and	O
other	O
organisms	O
,	O
and	O
factors	O
required	O
for	O
transcriptional	O
activation	O
.	O

Resolution	O
of	O
whole	O
cell	O
extract	O
through	O
two	O
chromatographic	O
steps	O
yields	O
a	O
single	O
protein	O
fraction	O
requiring	O
only	O
the	O
addition	O
of	O
TFIID	O
for	O
the	O
initiation	O
of	O
transcription	O
at	O
RNA	O
polymerase	O
II	O
promoters	O
.	O

This	O
approach	O
allows	O
the	O
convenient	O
generation	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
systems	O
from	O
Saccharomyces	O
cerevisiae	O
,	O
human	O
lymphocytes	O
,	O
and	O
Schizosaccharomyces	O
pombe	O
.	O

TFIIDs	O
from	O
all	O
three	O
organisms	O
are	O
interchangeable	O
among	O
all	O
three	O
systems	O
.	O

The	O
S.	O
cerevisiae	O
and	O
Sch.	O
pombe	O
systems	O
support	O
effects	O
of	O
acidic	O
activator	O
proteins	O
,	O
provided	O
a	O
further	O
protein	O
fraction	O
from	O
S.	O
cerevisiae	O
is	O
supplied	O
.	O

This	O
further	O
fraction	O
is	O
distinct	O
from	O
the	O
mediator	O
of	O
transcriptional	O
activation	O
described	O
previously	O
and	O
represents	O
a	O
second	O
component	O
in	O
addition	O
to	O
general	O
initiation	O
factors	O
that	O
may	O
facilitate	O
a	O
response	O
to	O
acidic	O
activators	O
.	O

NF-kappa	O
B-dependent	O
induction	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
gene	O
promoter	O
underlies	O
self-perpetuation	O
of	O
human	O
immunodeficiency	O
virus	O
transcription	O
in	O
monocytic	O
cells	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
sustained	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
observed	O
in	O
U937	O
monocytic	O
cells	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
were	O
studied	O
.	O

The	O
activity	O
of	O
the	O
promoter	O
regulating	O
the	O
synthesis	O
of	O
the	O
p105	O
precursor	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
was	O
enhanced	O
in	O
these	O
cells	O
.	O

Deletions	O
in	O
this	O
promoter	O
indicated	O
that	O
this	O
upregulation	O
was	O
mediated	O
through	O
the	O
NF-kappa	O
B-	O
but	O
not	O
the	O
AP-1-binding	O
motif	O
,	O
by	O
bona	O
fide	O
p50/p65	O
heterodimers	O
.	O

Analysis	O
of	O
cytosolic	O
extracts	O
indicated	O
that	O
NF-kappa	O
B	O
levels	O
were	O
increased	O
in	O
HIV-infected	O
cells	O
.	O

In	O
contrast	O
to	O
the	O
transient	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
phorbol	O
ester	O
,	O
the	O
permanent	O
NF-kappa	O
B	O
translocation	O
induced	O
by	O
HIV	O
infection	O
was	O
not	B-Negation
dependent	I-Negation
on	I-Negation
PKC	I-Negation
isoenzymes	I-Negation
alpha	I-Negation
and	I-Negation
beta	I-Negation
as	O
shown	O
by	O
the	O
use	O
of	O
a	O
specific	O
inhibitor	O
(	O
GF	O
109203X	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
during	O
chronic	O
HIV	O
infection	O
of	O
U937	O
cells	O
,	O
continuous	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
translocation	O
results	O
in	O
p105	O
promoter	O
upregulation	O
with	O
subsequent	O
cytosolic	O
NF-kappa	O
B	O
accumulation	O
,	O
ready	O
for	O
further	O
translocation	O
.	O

This	O
HIV-mediated	O
mechanism	O
results	O
in	O
a	O
self-perpetuating	O
loop	O
of	O
NF-kappa	O
B	O
production	O
.	O

The	O
development	O
of	O
functionally	O
responsive	O
T	O
cells	O
.	O

The	O
work	O
reviewed	O
in	O
this	O
article	O
separates	O
T	O
cell	O
development	O
into	O
four	O
phases	O
.	O

First	O
is	O
an	O
expansion	O
phase	O
prior	O
to	O
TCR	O
rearrangement	O
,	O
which	O
appears	O
to	O
be	O
correlated	O
with	O
programming	O
of	O
at	O
least	O
some	O
response	O
genes	O
for	O
inducibility	O
.	O

This	O
phase	O
can	O
occur	O
to	O
some	O
extent	O
outside	O
of	O
the	O
thymus	O
.	O

However	O
,	O
the	O
profound	O
T	O
cell	O
deficit	O
of	O
nude	O
mice	O
indicates	O
that	O
the	O
thymus	O
is	O
by	O
far	O
the	O
most	O
potent	O
site	O
for	O
inducing	O
the	O
expansion	O
per	O
se	O
,	O
even	O
if	O
other	O
sites	O
can	O
induce	O
some	O
response	O
acquisition	O
.	O

Second	O
is	O
a	O
controlled	O
phase	O
of	O
TCR	O
gene	O
rearrangement	O
.	O

The	O
details	O
of	O
the	O
regulatory	O
mechanism	O
that	O
selects	O
particular	O
loci	O
for	O
rearrangement	O
are	O
still	O
not	B-Negation
known	I-Negation
.	O

It	O
seems	O
that	O
the	O
rearrangement	O
of	O
the	O
TCR	O
gamma	O
loci	O
in	O
the	O
gamma	O
delta	O
lineage	O
may	O
not	O
always	O
take	O
place	O
at	O
a	O
developmental	O
stage	O
strictly	O
equivalent	O
to	O
the	O
rearrangement	O
of	O
TCR	O
beta	O
in	O
the	O
alpha	O
beta	O
lineage	O
,	O
and	O
it	O
is	O
not	O
clear	O
just	O
how	O
early	O
the	O
two	O
lineages	O
diverge	O
.	O

In	O
the	O
TCR	O
alpha	O
beta	O
lineage	O
,	O
however	O
,	O
the	O
final	O
gene	O
rearrangement	O
events	O
are	O
accompanied	O
by	O
rapid	O
proliferation	O
and	O
an	O
interruption	O
in	O
cellular	O
response	O
gene	O
inducibility	O
.	O

The	O
loss	O
of	O
conventional	O
responsiveness	O
is	O
probably	O
caused	O
by	O
alterations	O
at	O
the	O
level	O
of	O
signaling	O
,	O
and	O
may	O
be	O
a	O
manifestation	O
of	O
the	O
physiological	O
state	O
that	O
is	O
a	O
precondition	O
for	O
selection	O
.	O

Third	O
is	O
the	O
complex	O
process	O
of	O
selection	O
.	O

Whereas	O
peripheral	O
T	O
cells	O
can	O
undergo	O
forms	O
of	O
positive	O
selection	O
(	O
by	O
antigen-driven	O
clonal	O
expansion	O
)	O
and	O
negative	O
selection	O
(	O
by	O
abortive	O
stimulation	O
leading	O
to	O
anergy	O
or	O
death	O
)	O
,	O
neither	B-Negation
is	I-Negation
exactly	I-Negation
the	I-Negation
same	I-Negation
phenomenon	I-Negation
that	I-Negation
occurs	I-Negation
in	I-Negation
the	I-Negation
thymic	I-Negation
cortex	I-Negation
.	O

Negative	B-Speculation
selection	I-Speculation
in	I-Speculation
the	I-Speculation
cortex	I-Speculation
appears	I-Speculation
to	I-Speculation
be	I-Speculation
a	I-Speculation
suicidal	I-Speculation
inversion	I-Speculation
of	I-Speculation
antigen	I-Speculation
responsiveness	I-Speculation
:	O
instead	B-Negation
of	I-Negation
turning	I-Negation
on	I-Negation
IL-2	I-Negation
expression	I-Negation
,	O
the	O
activated	O
cell	O
destroys	O
its	O
own	O
chromatin	O
.	O

The	B-Negation
genes	I-Negation
that	I-Negation
need	I-Negation
to	I-Negation
be	I-Negation
induced	I-Negation
for	I-Negation
this	I-Negation
response	I-Negation
are	I-Negation
not	I-Negation
yet	I-Negation
identified	I-Negation
,	O
but	O
it	O
is	O
unquestionably	O
a	O
form	O
of	O
activation	O
.	O

It	O
is	O
interesting	O
that	O
in	O
humans	O
and	O
rats	O
,	O
cortical	O
thymocytes	O
undergoing	O
negative	O
selection	O
can	O
still	O
induce	O
IL-2R	O
alpha	O
expression	O
and	O
even	O
be	O
rescued	O
in	O
vitro	O
,	O
if	O
exogenous	O
IL-2	O
is	O
provided	O
.	O

Perhaps	O
murine	O
thymocytes	O
are	O
denied	O
this	O
form	O
of	O
rescue	O
because	O
they	O
shut	O
off	O
IL-2R	O
beta	O
chain	O
expression	O
at	O
an	O
earlier	O
stage	O
or	O
because	O
they	O
may	O
be	O
uncommonly	O
Bcl-2	O
deficient	O
(	O
cf	O
.	O

Sentman	O
et	O
al.	O
,	O
1991	O
;	O
Strasser	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Even	O
so	O
,	O
medullary	O
thymocytes	O
remain	O
at	O
least	O
partially	O
susceptible	O
to	O
negative	O
selection	O
even	O
as	O
they	O
continue	O
to	O
mature	O
.	O

SRC-related	O
proto-oncogenes	O
and	O
transcription	O
factors	O
in	O
primary	O
human	O
T	O
cells	O
:	O
modulation	O
by	O
cyclosporin	O
A	O
and	O
FK506	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
induces	O
transcription	O
of	O
genes	O
encoding	O
for	O
lymphokines	O
.	O

Interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
is	O
controlled	O
transcriptionally	O
by	O
the	O
cooperative	O
activity	O
of	O
specific	O
trans-activating	O
factors	O
that	O
bind	O
to	O
the	O
IL-2	O
enhancer	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
inhibit	O
the	O
production	O
of	O
IL-2	O
in	O
T	O
lymphocytes	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

A	O
member	O
of	O
the	O
src	O
gene	O
family	O
,	O
the	O
lymphocyte-specific	O
protein	O
tyrosine	O
kinase	O
,	O
p56lck	O
,	O
has	O
been	O
implicated	O
in	O
IL-2	O
production	O
.	O

CsA	O
was	O
found	O
not	B-Negation
to	I-Negation
inhibit	I-Negation
lck	I-Negation
gene	I-Negation
expression	I-Negation
,	O
nor	B-Negation
the	I-Negation
activity	I-Negation
of	I-Negation
the	I-Negation
lck	I-Negation
gene	I-Negation
product	I-Negation
.	O

However	O
,	O
CsA	O
and	O
FK506	O
inhibit	O
the	O
appearance	O
of	O
DNA	O
binding	O
activity	O
of	O
factors	O
that	O
bind	O
to	O
the	O
NF-AT	O
and	O
AP-1	O
sites	O
in	O
the	O
IL-2	O
enhancer	O
.	O

Since	O
the	O
induction	O
of	O
NF-AT	O
and	O
AP-1	O
is	O
induced	O
by	O
the	O
same	O
stimuli	O
that	O
stimulate	O
IL-2	O
production	O
,	O
these	O
results	O
indicate	O
that	O
the	O
immunosuppressant	O
action	O
of	O
CsA	O
and	O
FK506	O
is	O
exerted	O
at	O
the	O
level	O
of	O
these	O
trans-activating	O
factors	O
.	O

TAR-independent	O
transactivation	O
by	O
Tat	O
in	O
cells	O
derived	O
from	O
the	O
CNS	O
:	O
a	O
novel	O
mechanism	O
of	O
HIV-1	O
gene	O
regulation	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
essential	O
for	O
productive	O
infection	O
and	O
is	O
a	O
potential	O
target	O
for	O
antiviral	O
therapy	O
.	O

Tat	O
,	O
a	O
potent	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
,	O
serves	O
to	O
greatly	O
increase	O
the	O
rate	O
of	O
transcription	O
directed	O
by	O
the	O
viral	O
promoter	O
.	O

This	O
induction	O
,	O
which	O
seems	O
to	O
be	O
an	O
important	O
component	O
in	O
the	O
progression	O
of	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
,	O
may	O
be	O
due	O
to	O
increased	O
transcriptional	O
initiation	O
,	O
increased	O
transcriptional	O
elongation	O
,	O
or	O
a	O
combination	O
of	O
these	O
processes	O
.	O

Much	O
attention	O
has	O
been	O
focused	O
on	O
the	O
interaction	O
of	O
Tat	O
with	O
a	O
specific	O
RNA	O
target	O
termed	O
TAR	O
(	O
transactivation	O
responsive	O
)	O
which	O
is	O
present	O
in	O
the	O
leader	O
sequence	O
of	O
all	O
HIV-1	O
mRNAs	O
.	O

This	O
interaction	O
is	O
believed	O
to	O
be	O
an	O
important	O
component	O
of	O
the	O
mechanism	O
of	O
transactivation	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
in	O
certain	O
CNS-derived	O
cells	O
Tat	O
is	O
capable	O
of	O
activating	O
HIV-1	O
through	O
a	O
TAR-independent	O
pathway	O
.	O

A	O
Tat-responsive	O
element	O
is	O
found	O
upstream	O
within	O
the	O
viral	O
promoter	O
that	O
in	O
glial-derived	O
cell	O
lines	O
allows	O
transactivation	O
in	O
the	O
absence	O
of	O
TAR	O
.	O

Deletion	O
mapping	O
and	O
hybrid	O
promoter	O
constructs	O
demonstrate	O
that	O
the	O
newly	O
identified	O
Tat-responsive	O
element	O
corresponds	O
to	O
a	O
sequence	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
previously	O
identified	O
as	O
the	O
HIV-1	O
enhancer	O
,	O
or	O
NF-kappa	O
B	O
domain	O
.	O

DNA	O
band-shift	O
analysis	O
reveals	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
glial	O
cells	O
that	O
differs	O
from	O
that	O
present	O
in	O
T	O
lymphoid	O
cells	O
.	O

Further	O
,	O
we	O
observe	O
that	O
TAR-deleted	O
mutants	O
of	O
HIV-1	O
demonstrate	O
normal	O
late	O
gene	O
expression	O
in	O
glial	O
cells	O
as	O
evidenced	O
by	O
syncytia	O
formation	O
and	O
production	O
of	O
viral	O
p24	O
antigen.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Bcl-2	O
:	O
a	O
repressor	O
of	O
lymphocyte	O
death	O
.	O

The	O
genes	O
and	O
mechanisms	O
that	O
control	O
programmed	O
cell	O
death	O
are	O
currently	O
the	O
subject	O
of	O
intense	O
study	O
.	O

The	O
bcl-2	O
gene	O
,	O
a	O
repressor	O
of	O
lymphocyte	O
death	O
,	O
is	O
perhaps	O
the	O
best	O
understood	O
of	O
the	O
programmed	O
cell	O
death	O
associated	O
genes	O
.	O

Here	O
,	O
Stanley	O
Korsmeyer	O
provides	O
a	O
brief	O
overview	O
of	O
bcl-2	O
,	O
concentrating	O
on	O
its	O
roles	O
in	O
B-	O
and	O
T-cell	O
development	O
and	O
in	O
oncogenesis	O
.	O

Mitogen	O
stimulation	O
of	O
T-cells	O
increases	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

We	O
have	O
analysed	O
the	O
effect	O
of	O
mitogenic	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
as	O
well	O
as	O
on	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
and	O
enhancer	O
activity	O
in	O
Jurkat	O
T-cells	O
.	O

Both	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
were	O
increased	O
after	O
Con	O
A	O
and	O
PHA	O
stimulation	O
.	O

Since	O
T-cell	O
stimulation	O
increases	O
both	O
intracellular	O
Ca2+	O
and	O
cAMP	O
levels	O
and	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
the	O
possible	O
involvement	O
of	O
these	O
intracellular	O
messengers	O
in	O
c-Fos	O
and	O
c-Jun	O
induction	O
was	O
tested	O
.	O

PMA	O
,	O
which	O
directly	O
activates	O
PKC	O
,	O
mimicked	O
the	O
effect	O
of	O
the	O
lectins	O
on	O
c-Fos	O
and	O
c-Jun	O
,	O
but	O
elevation	O
of	O
either	O
intracellular	O
Ca2+	O
or	O
cAMP	O
levels	O
had	O
little	O
or	O
no	B-Negation
effect	I-Negation
.	O

The	O
mitogen-induced	O
increase	O
of	O
c-Fos	O
and	O
c-Jun	O
immunoreactivity	O
was	O
inhibited	O
by	O
H-7	O
,	O
a	O
kinase	O
inhibitor	O
with	O
relatively	O
high	O
specificity	O
for	O
PKC	O
,	O
and	O
less	O
efficiently	O
by	O
H-8	O
,	O
a	O
structurally	O
related	O
kinase	O
inhibitor	O
less	O
active	O
on	O
PKC	O
,	O
but	O
more	O
active	O
on	O
cyclic	O
nucleotide-dependent	O
kinases	O
.	O

Con	O
A	O
stimulation	O
was	O
found	O
to	O
increase	O
both	O
binding	O
of	O
AP-1	O
to	O
the	O
AP-1	O
consensus	O
sequence	O
,	O
TRE	O
,	O
and	O
AP-1	O
enhancer	O
activity	O
,	O
in	O
Jurkat	O
cells	O
.	O

PMA	O
was	O
also	O
found	O
to	O
increase	O
the	O
AP-1	O
enhancer	O
activity	O
,	O
whereas	O
elevation	O
of	O
Ca2+	O
or	O
cAMP	O
had	O
only	O
minor	O
effects	O
.	O

We	O
conclude	O
that	O
stimulation	O
with	O
mitogenic	O
lectins	O
is	O
sufficient	O
to	O
increase	O
both	O
c-Fos	O
and	O
c-Jun	O
protein	O
levels	O
,	O
AP-1	O
binding	O
and	O
AP-1	O
enhancer	O
activity	O
in	O
Jurkat	O
cells	O
and	O
that	O
they	O
act	O
via	O
mechanisms	O
that	O
could	O
involve	O
the	O
activation	O
of	O
PKC	O
.	O

Functional	O
interaction	O
between	O
the	O
two	O
zinc	O
finger	O
domains	O
of	O
the	O
v-erb	O
A	O
oncoprotein	O
.	O

The	O
v-erb	O
A	O
oncogene	O
of	O
avian	O
erythroblastosis	O
virus	O
is	O
a	O
mutated	O
and	O
virally	O
transduced	O
copy	O
of	O
a	O
host	O
cell	O
gene	O
encoding	O
a	O
thyroid	O
hormone	O
receptor	O
.	O

The	O
protein	O
expressed	O
by	O
the	O
v-erb	O
A	O
oncogene	O
binds	O
to	O
DNA	O
and	O
acts	O
as	O
a	O
dominant	O
negative	O
inhibitor	O
of	O
both	O
the	O
thyroid	O
hormone	O
receptor	O
and	O
the	O
closely	O
related	O
retinoic	O
acid	O
receptor	O
.	O

The	O
v-erb	O
A	O
protein	O
has	O
sustained	O
two	O
amino	O
acid	O
alterations	O
within	O
its	O
DNA-binding	O
domain	O
relative	O
to	O
that	O
of	O
c-erb	O
A	O
,	O
one	O
of	O
which	O
,	O
at	O
serine	O
61	O
,	O
is	O
known	O
to	O
be	O
important	O
for	O
v-erb	O
A	O
function	O
in	O
the	O
neoplastic	O
cell	O
.	O

We	O
report	O
here	O
that	O
the	O
second	O
alteration	O
,	O
at	O
threonine	O
78	O
,	O
also	O
plays	O
an	O
important	O
,	O
although	O
more	O
indirect	O
,	O
role	O
:	O

alteration	O
of	O
the	O
sequence	O
at	O
threonine	O
78	O
such	O
that	O
it	O
resembles	O
that	O
of	O
c-erb	O
A	O
can	O
act	O
as	O
an	O
intragenic	O
suppressor	O
and	O
can	O
partially	O
restore	O
function	O
to	O
a	O
v-erb	O
A	O
protein	O
rendered	O
defective	O
due	O
to	O
a	O
mutation	O
at	O
position	O
61	O
.	O

Threonine	O
78	O
lies	O
within	O
the	O
D-box	O
of	O
the	O
v-erb	O
A	O
protein	O
,	O
a	B-Speculation
region	I-Speculation
thought	I-Speculation
to	I-Speculation
mediate	I-Speculation
receptor-receptor	I-Speculation
dimerizations	I-Speculation
,	O
and	O
is	O
not	B-Negation
in	I-Negation
physical	I-Negation
proximity	I-Negation
to	I-Negation
the	I-Negation
serine	I-Negation
at	I-Negation
position	I-Negation
61	I-Negation
.	O

It	O
therefore	O
appears	O
that	O
an	O
indirect	O
interaction	O
occurs	O
between	O
these	O
two	O
sites	O
and	O
that	O
this	O
interaction	O
is	O
crucial	O
for	O
v-erb	O
A	O
function	O
.	O

Pax-5	O
encodes	O
the	O
transcription	O
factor	O
BSAP	O
and	O
is	O
expressed	O
in	O
B	O
lymphocytes	O
,	O
the	O
developing	O
CNS	O
,	O
and	O
adult	O
testis	O
.	O

BSAP	O
has	O
been	O
identified	O
previously	O
as	O
a	O
transcription	O
factor	O
that	O
is	O
expressed	O
at	O
early	O
,	O
but	O
not	B-Negation
late	I-Negation
,	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Biochemical	O
purification	O
and	O
cDNA	O
cloning	O
has	O
now	O
revealed	O
that	O
BSAP	O
belongs	O
to	O
the	O
family	O
of	O
paired	O
domain	O
proteins	O
.	O

BSAP	O
is	O
encoded	O
by	O
the	O
Pax-5	O
gene	O
and	O
has	O
been	O
highly	O
conserved	O
between	O
human	O
and	O
mouse	O
.	O

An	O
intact	O
paired	O
domain	O
was	O
shown	O
to	O
be	O
both	O
necessary	O
and	O
sufficient	O
for	O
DNA	O
binding	O
of	O
BSAP	O
.	O

Binding	O
studies	O
with	O
several	O
BSAP	O
recognition	O
sequences	O
demonstrated	O
that	O
the	O
sequence	O
specificity	O
of	O
BSAP	O
differs	O
from	O
that	O
of	O
the	O
distantly	O
related	O
paired	O
domain	O
protein	O
Pax-1	O
.	O

During	O
embryogenesis	O
,	O
the	O
BSAP	O
gene	O
is	O
transiently	O
expressed	O
in	O
the	O
mesencephalon	O
and	O
spinal	O
cord	O
with	O
a	O
spatial	O
and	O
temporal	O
expression	O
pattern	O
that	O
is	O
distinct	O
from	O
that	O
of	O
other	O
Pax	O
genes	O
in	O
the	O
developing	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Later	O
,	O
the	O
expression	O
of	O
the	O
BSAP	O
gene	O
shifts	O
to	O
the	O
fetal	O
liver	O
where	O
it	O
correlates	O
with	O
the	O
onset	O
of	O
B	O
lymphopoiesis	O
.	O

BSAP	O
expression	O
persists	O
in	O
B	O
lymphocytes	O
and	O
is	O
also	O
seen	O
in	O
the	O
testis	O
of	O
the	O
adult	O
mouse	O
.	O

All	O
of	O
this	O
evidence	O
indicates	O
that	O
the	O
transcription	O
factor	O
BSAP	O
may	O
not	O
only	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
differentiation	O
but	O
also	O
in	O
neural	O
development	O
and	O
spermatogenesis	O
.	O

Okadaic	O
acid	O
is	O
a	O
potent	O
inducer	O
of	O
AP-1	O
,	O
NF-kappa	O
B	O
,	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
human	O
B	O
lymphocytes	O
.	O

Treatment	O
of	O
human	O
B	O
lymphocytes	O
with	O
an	O
optimal	O
concentration	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
phosphatases	O
1	O
and	O
2A	O
,	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
,	O
AP-1	O
and	O
a	O
marked	O
increase	O
in	O
NF-kappa	O
B	O
levels	O
.	O

In	O
contrast	O
,	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
levels	I-Negation
of	I-Negation
the	I-Negation
octamer	I-Negation
binding	I-Negation
proteins	I-Negation
,	I-Negation
Oct-1	I-Negation
or	I-Negation
Oct-2	I-Negation
,	O
were	O
found	O
.	O

Since	O
both	O
AP-1	O
and	O
NF-kappa	O
B	O
have	O
been	O
reported	O
to	O
be	O
important	O
in	O
the	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
gene	O
we	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
on	O
TNF-alpha	O
mRNA	O
levels	O
.	O

Treatment	O
with	O
okadaic	O
acid	O
resulted	O
in	O
a	O
striking	O
increase	O
in	O
TNF-alpha	O
mRNA	O
transcripts	O
within	O
1	O
h	O
of	O
stimulation	O
and	O
large	O
amounts	O
of	O
TNF-alpha	O
were	O
released	O
into	O
the	O
culture	O
media	O
.	O

Although	O
okadaic	O
acid	O
provides	O
a	O
potent	O
inductive	O
signal	O
for	O
AP-1	O
and	O
NF-kappa	O
B	O
it	O
did	O
not	B-Negation
induce	I-Negation
either	I-Negation
B	I-Negation
cell	I-Negation
proliferation	I-Negation
or	I-Negation
immunoglobulin	I-Negation
secretion	I-Negation
.	O

A	O
novel	O
Ets-related	O
transcription	O
factor	O
,	O
Elf-1	O
,	O
binds	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
regulatory	O
elements	O
that	O
are	O
required	O
for	O
inducible	O
trans	O
activation	O
in	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
are	O
structurally	O
related	O
retroviruses	O
which	O
both	O
cause	O
AIDS	O
in	O
humans	O
.	O

Although	O
both	O
viruses	O
establish	O
latency	O
in	O
quiescent	O
human-peripheral-blood	O
T	O
cells	O
,	O
the	O
asymptomatic	O
phase	O
of	O
HIV-2	O
infection	O
may	O
be	O
more	O
prolonged	O
than	O
that	O
of	O
HIV-1	O
.	O

The	O
latent	O
phases	O
of	O
both	O
HIV-1	O
and	O
HIV-2	O
infection	O
have	O
been	O
shown	O
to	O
be	O
disrupted	O
by	O
T-cell	O
activation	O
,	O
a	O
process	O
that	O
requires	O
host	O
cell	O
transcription	O
factors	O
.	O

In	O
the	O
case	O
of	O
HIV-1	O
,	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
is	O
sufficient	O
for	O
inducible	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
,	O
factors	O
in	O
addition	O
to	O
NF-kappa	O
B	O
are	O
required	O
to	O
activate	O
HIV-2	O
transcription	O
in	O
infected	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
Ets-related	O
transcription	O
factor	O
,	O
Elf-1	O
,	O
binds	O
specifically	O
to	O
two	O
purine-rich	O
motifs	O
in	O
the	O
HIV-2	O
enhancer	O
.	O

Mutagenesis	O
experiments	O
demonstrated	O
that	O
these	O
Elf-1	O
binding	O
sites	O
are	O
required	O
for	O
induction	O
of	O
HIV-2	O
transcription	O
following	O
T-cell-receptor-mediated	O
T-cell	O
activation	O
.	O

Moreover	O
,	O
Elf-1	O
is	O
the	O
only	O
factor	O
present	O
in	O
activated	O
T-cell	O
nuclear	O
extracts	O
that	O
binds	O
to	O
these	O
sites	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Thus	O
,	O
Elf-1	O
is	O
a	O
novel	O
transcription	O
factor	O
that	O
appears	O
to	O
be	O
required	O
for	O
the	O
T-cell-receptor-mediated	O
trans	O
activation	O
of	O
HIV-2	O
gene	O
expression	O
.	O

These	O
results	O
may	O
explain	O
differences	O
in	O
the	O
clinical	O
spectra	O
of	O
diseases	O
caused	O
by	O
HIV-1	O
and	O
HIV-2	O
and	O
may	O
also	O
have	O
implications	O
for	O
the	O
design	O
of	O
therapeutic	O
approaches	O
to	O
HIV-2	O
infection	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
inhibits	O
NF-kappa	O
B	O
induction	O
in	O
human	O
T	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
can	O
establish	O
a	O
persistent	O
and	O
latent	O
infection	O
in	O
CD4+	O
T	O
lymphocytes	O
(	O
W.C.Greene	O
,	O
N.Engl.J.	O
Med.324	O
:	O
308-317	O
,	O
1991	O
;	O
S.M.Schnittman	O
,	O
M.C.Psallidopoulos	O
,	O
H.C.	O
Lane	O
,	O
L.Thompson	O
,	O
M.Baseler	O
,	O
F.Massari	O
,	O
C.H.Fox	O
,	O
N.P.Salzman	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
245	O
:	O
305-308	O
,	O
1989	O
)	O
.	O

Production	O
of	O
HIV-1	O
from	O
latently	O
infected	O
cells	O
requires	O
host	O
cell	O
activation	O
by	O
T-cell	O
mitogens	O
(	O
T.Folks	O
,	O
D.M.Powell	O
,	O
M.M.Lightfoote	O
,	O
S.Benn	O
,	O
M.A.	O
Martin	O
,	O
and	O
A.S.Fauci	O
,	O
Science	O
231	O
:	O
600-602	O
,	O
1986	O
;	O
D.Zagury	O
,	O
J.	O
Bernard	O
,	O
R.Leonard	O
,	O
R.Cheynier	O
,	O
M.Feldman	O
,	O
P.S.Sarin	O
,	O
and	O
R.C.	O
Gallo	O
,	O
Science	O
231	O
:	O
850-853	O
,	O
1986	O
)	O
.	O

This	O
activation	O
is	O
mediated	O
by	O
the	O
host	O
transcription	O
factor	O
NF-kappa	O
B	O
[	O
G.Nabel	O
and	O
D.Baltimore	O
,	O
Nature	O
(	O
London	O
)	O
326	O
:	O
711-717	O
,	O
1987	O
]	O
.	O

We	O
report	O
here	O
that	O
the	O
HIV-1-encoded	O
Nef	O
protein	O
inhibits	O
the	O
induction	O
of	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
by	O
T-cell	O
mitogens	O
.	O

However	O
,	O
Nef	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
DNA-binding	I-Negation
activity	I-Negation
of	I-Negation
other	I-Negation
transcription	I-Negation
factors	I-Negation
implicated	I-Negation
in	I-Negation
HIV-1	I-Negation
regulation	I-Negation
,	I-Negation
including	I-Negation
SP-1	I-Negation
,	I-Negation
USF	I-Negation
,	I-Negation
URS	I-Negation
,	I-Negation
and	I-Negation
NF-AT	I-Negation
.	O

Additionally	O
,	O
Nef	O
inhibits	O
the	O
induction	O
of	O
HIV-1-	O
and	O
interleukin	O
2-directed	O
gene	O
expression	O
,	O
and	O
the	O
effect	O
on	O
HIV-1	O
transcription	O
depends	O
on	O
an	O
intact	O
NF-kappa	O
B-binding	O
site	O
.	O

These	O
results	O
indicate	O
that	O
defective	O
recruitment	O
of	O
NF-kappa	O
B	O
may	O
underlie	O
Nef	O
's	O
negative	O
transcriptional	O
effects	O
on	O
the	O
HIV-1	O
and	O
interleukin	O
2	O
promoters	O
.	O

Further	O
evidence	O
suggests	O
that	O
Nef	O
inhibits	O
NF-kappa	O
B	O
induction	O
by	O
interfering	O
with	O
a	O
signal	O
derived	O
from	O
the	O
T-cell	O
receptor	O
complex	O
.	O

[	O
Effect	O
of	O
antihypertensive	O
therapy	O
with	O
captopril	O
on	O
gluco-	O
and	O
mineralocorticoid	O
receptors	O
of	O
peripheral	O
blood	O
lymphocytes	O
in	O
hypertensive	O
patients	O
of	O
various	O
age	O
]	O

Binding	O
of	O
3H-dexamethasone	O
and	O
3H-aldosterone	O
by	O
peripheral	O
lymphocyte	O
receptors	O
was	O
investigated	O
in	O
healthy	O
persons	O
and	O
hypertensive	O
patients	O
before	O
and	O
after	O
2-week	O
captopril	O
treatment	O
.	O

The	O
number	O
of	O
glucocorticoid	O
and	O
mineralocorticoid	O
binding	O
sites	O
was	O
increased	O
in	O
hypertensives	O
vs	O
normotensives	O
.	O

The	O
treatment	O
with	O
the	O
ACE	O
inhibitor	O
captopril	O
led	O
to	O
activation	O
of	O
hormone-receptor	O
interactions	O
.	O

There	O
was	O
a	O
more	O
marked	O
rise	O
of	O
the	O
number	O
of	O
receptors	O
in	O
middle-aged	O
(	O
44-55	O
years	O
)	O
hypertensives	O
vs	O
elderly	O
(	O
61-80	O
years	O
)	O
subjects	O
after	O
captopril	O
treatment	O
.	O

Leukotriene	O
B4	O
transcriptionally	O
activates	O
interleukin-6	O
expression	O
involving	O
NK-chi	O
B	O
and	O
NF-IL6	O
.	O

Leukotriene	O
B4	O
(	O
LTB4	O
)	O
is	O
a	O
notable	O
participant	O
in	O
inflammation	O
and	O
chemotaxis	O
.	O

It	O
is	O
,	O
however	O
,	O
still	O
unclear	O
whether	O
LTB4	O
acts	O
in	O
this	O
regard	O
directly	O
or	O
indirectly	O
by	O
stimulating	O
the	O
release	O
of	O
chemotactic	O
and	O
inflammatory	O
cytokines	O
.	O

Here	O
we	O
report	O
that	O
LTB4	O
induces	O
synthesis	O
of	O
interleukin	O
(	O
IL	O
)	O
-6	O
by	O
human	O
blood	O
monocytes	O
through	O
transcriptional	O
activation	O
of	O
the	O
IL-6	O
gene	O
.	O

We	O
furthermore	O
demonstrate	O
that	O
this	O
process	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-chi	O
B	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
of	O
NF-IL6	O
,	O
while	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	O
,	O
shown	O
to	O
otherwise	O
confer	O
IL-6	O
inducibility	O
,	O
appeared	O
to	O
be	O
unaffected	O
by	O
LTB4	O
.	O

Involvement	O
of	O
NF-chi	O
B	O
and	O
NF-IL6	O
in	O
induction	O
of	O
IL-6	O
transcription	O
by	O
monocytes	O
was	O
demonstrated	O
using	O
deleted	O
forms	O
of	O
the	O
IL-6	O
promoter	O
.	O

Activation	O
of	O
the	O
IL-6	O
promoter	O
by	O
LTB4	O
was	O
not	O
only	O
associated	O
with	O
accumulation	O
of	O
the	O
respective	O
transcripts	O
but	O
resulted	O
in	O
synthesis	O
of	O
functional	O
IL-6	O
protein	O
as	O
well	O
.	O

In	O
addition	O
,	O
LTB4	O
mediated	O
transactivation	O
of	O
a	O
heterologous	O
promoter	O
construct	O
containing	O
the	O
NF-chi	O
B	O
or	O
the	O
NF-IL6	O
enhancer	O
,	O
but	O
not	B-Negation
the	I-Negation
AP-1	I-Negation
enhancer	I-Negation
.	O

The	B-Speculation
signaling	I-Speculation
events	I-Speculation
mediating	I-Speculation
this	I-Speculation
effect	I-Speculation
appeared	I-Speculation
to	I-Speculation
involve	I-Speculation
the	I-Speculation
release	I-Speculation
of	I-Speculation
H2O2	I-Speculation
,	O
since	O
LTB4	O
failed	B-Negation
to	I-Negation
induce	I-Negation
NF-chi	I-Negation
B	I-Negation
or	I-Negation
NF-IL6	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
the	I-Negation
scavenger	I-Negation
of	I-Negation
H2O2	I-Negation
,	I-Negation
N-acetyl-L-cysteine	I-Negation
.	O

Estrogen	O
binding	O
sites	O
in	O
peripheral	O
blood	O
monocytes	O
and	O
effects	O
of	O
danazol	O
on	O
their	O
sites	O
in	O
vitro	O
.	O

1	O
.	O
This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
presence	O
of	O
estrogen	O
type	O
I	O
(	O
high	O
affinity	O
,	O
low	O
capacity	O
)	O
and	O
type	O
II	O
(	O
low	O
affinity	O
,	O
high	O
capacity	O
)	O
binding	O
sites	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
the	O
effects	O
of	O
danazol	O
on	O
these	O
sites	O
.	O

2	O
.	O
These	O
two	O
types	O
of	O
estrogen	O
binding	O
sites	O
existed	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

3	O
.	O
Danazol	O
bound	O
to	O
these	O
sites	O
in	O
high	O
concentration	O
(	O
10	O
(	O
-6	O
)	O
M	O
,	O
clinical	O
serum	O
concentration	O
during	O
danazol	O
therapy	O
)	O
and	O
decreased	O
the	O
number	O
of	O
both	O
sites	O
.	O

4	O
.	O
It	O
is	O
suggested	O
that	O
danazol	O
has	O
an	O
anti-estrogenic	O
action	O
to	O
the	O
monocytes	O
through	O
the	O
competition	O
and	O
suppression	O
of	O
estrogen	O
binding	O
sites	O
as	O
seen	O
in	O
the	O
estrogen	O
target	O
organ	O
.	O

[	O
Mechanism	O
of	O
action	O
of	O
steroid	O
hormones	O
.	O
I	O
.	O
Estrogens	O
]	O

The	O
steroid	O
hormone	O
are	O
very	O
versatile	O
molecules	O
:	O

although	O
they	O
are	O
related	O
among	O
them	O
by	O
their	O
chemical	O
structure	O
,	O
they	O
have	O
very	O
diverse	O
functions	O
and	O
including	O
antagonic	O
.	O

Their	O
action	O
mechanism	O
is	O
not	B-Negation
completely	I-Negation
cleared	I-Negation
.	O

The	O
estrogens	O
participate	O
in	O
the	O
regulation	O
of	O
practically	O
all	O
the	O
reproductive	O
and	O
sexual	O
events	O
of	O
the	O
female	O
,	O
although	O
the	O
intracellular	O
actions	O
by	O
which	O
they	O
take	O
place	O
are	O
not	B-Negation
well	I-Negation
known	I-Negation
and	O
the	O
proposed	O
models	O
do	O
not	B-Negation
adequately	I-Negation
satisfy	I-Negation
the	I-Negation
questions	I-Negation
.	O

Currently	O
it	O
is	O
accepted	O
the	O
existence	O
of	O
a	O
cytoplasmic	O
and/or	O
nuclear	O
receptor	O
,	O
without	B-Negation
explaining	I-Negation
satisfactorily	I-Negation
how	I-Negation
the	I-Negation
hormones	I-Negation
come	I-Negation
to	I-Negation
the	I-Negation
nucleus	I-Negation
.	O

The	O
endocrine	O
events	O
that	O
are	O
rapidly	O
expressed	O
(	O
seconds	O
)	O
are	O
due	O
to	O
a	O
possible	O
interaction	O
with	O
cellular	O
membrane	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
analyze	O
and	O
concilliate	O
the	O
reported	O
data	O
on	O
the	O
mechanism	O
of	O
action	O
of	O
estrogens	O
.	O

Stable	O
expression	O
of	O
transdominant	O
Rev	O
protein	O
in	O
human	O
T	O
cells	O
inhibits	O
human	O
immunodeficiency	O
virus	O
replication	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
Rev	O
protein	O
is	O
essential	O
for	O
viral	O
structural	O
protein	O
expression	O
(	O
Gag	O
,	O
Pol	O
,	O
and	O
Env	O
)	O
and	O
,	O
hence	O
,	O
for	O
viral	O
replication	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
mutant	O
forms	O
of	O
Rev	O
have	O
been	O
identified	O
that	O
inhibit	O
wild-type	O
Rev	O
activity	O
and	O
therefore	O
suppress	O
viral	O
replication	O
.	O

To	O
determine	O
whether	O
such	O
transdominant	O
Rev	O
proteins	O
could	O
provide	O
long-term	O
protection	O
against	O
HIV	O
infection	O
without	O
affecting	O
T	O
cell	O
function	O
,	O
T	O
leukemia	O
cell	O
lines	O
were	O
stably	O
transduced	O
with	O
a	O
retroviral	O
vector	O
encoding	O
a	O
transdominant	O
mutant	O
of	O
the	O
Rev	O
protein	O
,	O
M10	O
.	O

While	O
all	O
the	O
M10-expressing	O
cell	O
lines	O
remained	O
infectable	O
by	O
HIV-1	O
,	O
these	O
same	O
cells	O
failed	B-Negation
to	I-Negation
support	I-Negation
a	I-Negation
productive	I-Negation
replication	I-Negation
cycle	I-Negation
when	I-Negation
infected	I-Negation
with	I-Negation
a	I-Negation
cloned	I-Negation
isolate	I-Negation
of	I-Negation
HIV-1	I-Negation
.	O

In	O
addition	O
,	O
two	O
out	O
of	O
three	O
M10-expressing	O
CEM	O
clones	O
were	O
also	O
resistant	O
to	O
highly	O
productive	O
infection	O
by	O
a	O
heterogeneous	O
HIV-1	O
pool	O
.	O

Expression	O
of	O
M10	O
did	O
not	B-Negation
affect	I-Negation
induction	I-Negation
of	I-Negation
HIV	I-Negation
transcription	I-Negation
mediated	I-Negation
by	I-Negation
the	I-Negation
kappa	I-Negation
B	I-Negation
regulatory	I-Negation
element	I-Negation
or	I-Negation
Tat	I-Negation
.	O

Importantly	O
,	O
constitutive	O
expression	O
of	O
Rev	O
M10	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
secretion	I-Negation
of	I-Negation
interleukin	I-Negation
2	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
mitogen	I-Negation
stimulation	I-Negation
of	I-Negation
EL-4	I-Negation
and	I-Negation
Jurkat	I-Negation
cells	I-Negation
.	O

The	O
inhibition	O
of	O
HIV	O
infection	O
in	O
cells	O
stably	O
expressing	O
a	O
transdominant	O
Rev	O
protein	O
,	O
in	O
the	O
absence	O
of	O
any	O
deleterious	O
effect	O
on	O
T	O
cell	O
function	O
,	O
suggests	O
that	O
such	O
a	O
strategy	O
could	O
provide	O
a	O
therapeutic	O
effect	O
in	O
the	O
T	O
lymphocytes	O
of	O
acquired	O
immunodeficiency	O
syndrome	O
patients	O
.	O

Glucocorticoid	O
receptor	O
in	O
patients	O
with	O
lupus	O
nephritis	O
:	O
relationship	O
between	O
receptor	O
levels	O
in	O
mononuclear	O
leukocytes	O
and	O
effect	O
of	O
glucocorticoid	O
therapy	O
.	O

We	O
investigated	O
the	O
clinical	O
significance	O
of	O
glucocorticoid	O
receptor	O
determination	O
in	O
20	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
who	O
afterwards	O
developed	O
nephrotic	O
syndrome	O
.	O

Glucocorticoid	O
receptor	O
concentrations	O
in	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
in	O
these	O
patients	O
were	O
comparable	O
with	O
those	O
in	O
both	O
other	O
patients	O
with	O
SLE	O
and	O
healthy	O
persons	O
.	O

Improvement	O
in	O
urinary	O
protein	O
excretion	O
and	O
in	O
disease	O
activity	O
,	O
which	O
was	O
scored	O
according	O
to	O
the	O
SLE	O
Disease	O
Activity	O
Index	O
system	O
of	O
the	O
University	O
of	O
Toronto	O
,	O
closely	O
related	O
to	O
the	O
glucocorticoid	O
receptor	O
concentrations	O
in	O
MNL	O
isolated	O
from	O
the	O
corresponding	O
patients	O
.	O

In	O
summary	O
,	O
glucocorticoid	O
receptor	O
determination	O
in	O
patients	O
with	O
lupus	O
nephritis	O
may	O
be	O
a	O
predictive	O
clue	O
for	O
assessing	O
responsiveness	O
to	O
glucocorticoid	O
therapy	O
.	O

Selection	O
of	O
optimal	O
kappa	O
B/Rel	O
DNA-binding	O
motifs	O
:	O
interaction	O
of	O
both	O
subunits	O
of	O
NF-kappa	O
B	O
with	O
DNA	O
is	O
required	O
for	O
transcriptional	O
activation	O
.	O

Analysis	O
of	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
complex	O
has	O
revealed	O
that	O
both	O
proteins	O
can	O
interact	O
with	O
related	O
DNA	O
sequences	O
through	O
either	O
homo-	O
or	O
heterodimer	O
formation	O
.	O

In	O
addition	O
,	O
the	O
product	O
of	O
the	O
proto-oncogene	O
c-rel	O
can	O
bind	O
to	O
similar	O
DNA	O
motifs	O
by	O
itself	O
or	O
as	O
a	O
heterodimer	O
with	O
p50	O
or	O
p65	O
.	O

However	O
,	O
these	O
studies	O
have	O
used	O
a	O
limited	O
number	O
of	O
known	O
kappa	O
B	O
DNA	O
motifs	O
,	O
and	O
the	B-Negation
question	I-Negation
of	I-Negation
the	I-Negation
optimal	I-Negation
DNA	I-Negation
sequences	I-Negation
preferred	I-Negation
by	I-Negation
each	I-Negation
homodimer	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
addressed	I-Negation
.	O

Using	O
purified	O
recombinant	O
p50	O
,	O
p65	O
,	O
and	O
c-Rel	O
proteins	O
,	O
optimal	O
DNA-binding	O
motifs	O
were	O
selected	O
from	O
a	O
pool	O
of	O
random	O
oligonucleotides	O
.	O

Alignment	O
of	O
the	O
selected	O
sequences	O
allowed	O
us	O
to	O
predict	O
a	O
consensus	O
sequence	O
for	O
binding	O
of	O
the	O
individual	O
homodimeric	O
Rel-related	O
proteins	O
,	O
and	O
DNA-protein	O
binding	O
analysis	O
of	O
the	O
selected	O
DNA	O
sequences	O
revealed	O
sequence	O
specificity	O
of	O
the	O
proteins	O
.	O

Contrary	O
to	O
previous	O
assumptions	O
,	O
we	O
observed	O
that	O
p65	O
homodimers	O
can	O
interact	O
with	O
a	O
subset	O
of	O
DNA	O
sequences	O
not	B-Negation
recognized	I-Negation
by	I-Negation
p50	I-Negation
homodimers	I-Negation
.	O

Differential	O
binding	O
affinities	O
were	O
also	O
obtained	O
with	O
p50-	O
and	O
c-Rel-selected	O
sequences	O
.	O

Using	O
either	O
a	O
p50-	O
or	O
p65-selected	O
kappa	O
B	O
motif	O
,	O
which	O
displayed	O
differential	O
binding	O
with	O
respect	O
to	O
the	O
other	O
protein	O
,	O
little	O
to	O
no	B-Negation
binding	I-Negation
was	O
observed	O
with	O
the	O
heterodimeric	O
NF-kappa	O
B	O
complex	O
.	O

Similarly	O
,	O
in	O
transfection	O
experiments	O
in	O
which	O
the	O
selective	O
kappa	O
B	O
binding	O
sites	O
were	O
used	O
to	O
drive	O
the	O
expression	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
,	O
the	O
p65-	O
and	O
p50-selected	O
motifs	O
were	O
activated	O
only	O
in	O
the	O
presence	O
of	O
p65	O
and	O
p50/65	O
(	O
a	O
chimeric	O
protein	O
with	O
the	O
p50	O
DNA	O
binding	O
domain	O
and	O
p65	O
activation	O
domain	O
)	O
expression	O
vectors	O
,	O
respectively	O
,	O
and	O
neither	B-Negation
demonstrated	I-Negation
a	I-Negation
significant	I-Negation
response	I-Negation
to	I-Negation
stimuli	I-Negation
that	I-Negation
induce	I-Negation
NF-kappa	I-Negation
B	I-Negation
activity	I-Negation
.	O

These	O
findings	O
demonstrate	O
that	O
interaction	O
of	O
both	O
subunits	O
of	O
the	O
heterodimeric	O
NF-kappa	O
B	O
complex	O
with	O
DNA	O
is	O
required	O
for	O
DNA	O
binding	O
and	O
transcriptional	O
activation	O
and	O
suggest	O
that	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
individual	O
rel-related	O
proteins	O
will	O
differ	O
dramatically	O
,	O
depending	O
on	O
the	O
specific	O
kappa	O
B	O
motifs	O
present	O
.	O

Characterization	O
of	O
a	O
new	O
tissue-specific	O
transcription	O
factor	O
binding	O
to	O
the	O
simian	O
virus	O
40	O
enhancer	O
TC-II	O
(	O
NF-kappa	O
B	O
)	O
element	O
.	O

We	O
have	O
biochemically	O
and	O
functionally	O
characterized	O
a	O
new	O
transcription	O
factor	O
,	O
NP-TCII	O
,	O
which	O
is	O
present	O
in	O
nuclei	O
from	O
unstimulated	O
T	O
and	O
B	O
lymphocytes	O
but	O
is	B-Negation
not	I-Negation
found	I-Negation
in	I-Negation
nonhematopoietic	I-Negation
cells	I-Negation
.	O

This	O
factor	O
has	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
NF-kappa	O
B	O
but	O
is	O
unrelated	O
to	O
this	O
or	O
other	O
Rel	O
proteins	O
by	O
functional	O
and	O
biochemical	O
criteria	O
.	O

It	O
can	O
also	O
be	O
distinguished	O
from	O
other	O
previously	O
described	O
lymphocyte-specific	O
DNA-binding	O
proteins	O
.	O

The	O
candidate	O
oncoprotein	O
Bcl-3	O
is	O
an	O
antagonist	O
of	O
p50/NF-kappa	O
B-mediated	O
inhibition	O
.	O

The	O
candidate	O
oncogene	O
bcl-3	O
was	O
discovered	O
as	O
a	O
translocation	O
into	O
the	O
immunoglobulin	O
alpha-locus	O
in	O
some	O
cases	O
of	O
B-cell	O
chronic	O
lymphocytic	O
leukaemias	O
.	O

The	O
protein	O
Bcl-3	O
contains	O
seven	O
so-called	O
ankyrin	O
repeats	O
.	O

Similar	O
repeat	O
motifs	O
are	O
found	O
in	O
a	O
number	O
of	O
diverse	O
regulatory	O
proteins	O
but	O
the	O
motifs	O
of	O
Bcl-3	O
are	O
most	O
closely	O
related	O
to	O
those	O
found	O
in	O
I	O
kappa	O
B	O
proteins	O
in	O
which	O
the	O
ankyrin	O
repeat	O
domain	O
is	O
thought	O
to	O
be	O
directly	O
involved	O
in	O
inhibition	O
of	O
NF-kappa	O
B	O
activity	O
.	O

No	B-Negation
biological	I-Negation
function	I-Negation
has	I-Negation
yet	I-Negation
been	I-Negation
described	I-Negation
for	I-Negation
Bcl-3	I-Negation
,	O
but	O
it	O
was	O
noted	O
recently	O
that	O
Bcl-3	O
interferes	O
with	O
DNA-binding	O
of	O
the	O
p50	O
subunit	O
of	O
NF-kappa	O
B	O
in	O
vitro	O
.	O

Here	O
we	O
demonstrate	O
that	O
Bcl-3	O
can	O
aid	O
kappa	O
B	O
site-dependent	O
transcription	O
in	O
vivo	O
by	O
counteracting	O
the	O
inhibitory	O
effects	O
of	O
p50/NF-kappa	O
B	O
homodimers	O
.	O

Bcl-3	O
may	O
therefore	O
aid	O
activation	O
of	O
select	O
NF-kappa	O
B-regulated	O
genes	O
,	O
including	O
those	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
.	O

A	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	O
receptors	O
:	O
decreased	O
receptor	O
concentration	O
in	O
myocardial	O
infarction	O
.	O

A	O
major	O
difficulty	O
in	O
determination	O
of	O
glucocorticoid	O
receptor	O
sites	O
is	O
the	O
very	O
complicated	O
assay	O
procedure	O
.	O

Therefore	O
,	O
we	O
describe	O
a	O
microtitre	O
assay	O
system	O
for	O
glucocorticoid	O
receptors	O
which	O
is	O
a	O
whole-cell	O
competitive	O
binding	O
radioassay	O
using	O
[	O
3H	O
]	O
-dexamethasone	O
as	O
radioligand	O
.	O

This	O
modification	O
of	O
a	O
previously	O
described	O
protocol	O
simplifies	O
and	O
reduces	O
laboratory	O
work	O
and	O
allows	O
assay	O
reproducibility	O
to	O
be	O
controlled	O
more	O
reliably	O
.	O

Thus	O
enabled	O
to	O
perform	O
the	O
test	O
on	O
multiple	O
blood	O
samples	O
in	O
parallel	O
,	O
we	O
investigated	O
cardiac	O
infarction	O
patients	O
over	O
a	O
12-day	O
period	O
to	O
test	O
if	O
glucocorticoid	O
receptor	O
binding	O
is	O
altered	O
in	O
this	O
'	O
stressful	O
'	O
disease	O
.	O

On	O
the	O
first	O
day	O
of	O
the	O
disease	O
,	O
glucocorticoid	O
receptor	O
capacity	O
was	O
significantly	O
decreased	O
without	B-Negation
alteration	I-Negation
of	I-Negation
the	I-Negation
receptor-ligand	I-Negation
affinity	I-Negation
,	O
whereas	O
on	O
days	O
4	O
and	O
12	O
the	O
number	O
of	O
receptor	O
sites	O
was	O
normal	O
again	O
.	O

This	O
result	O
fits	O
well	O
into	O
the	O
general	O
observation	O
of	O
stress-induced	O
down-regulation	O
of	O
immune	O
responses	O
.	O

Regulation	O
of	O
c-jun	O
expression	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
by	O
okadaic	O
acid	O
.	O

The	O
present	O
work	O
has	O
examined	O
the	O
effects	O
of	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
type	O
1	O
and	O
2A	O
protein	O
phosphatases	O
,	O
on	O
the	O
regulation	O
of	O
c-jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
leukemia	O
cells	O
.	O

The	O
results	O
demonstrate	O
that	O
okadaic	O
acid	O
treatment	O
is	O
associated	O
with	O
induction	O
of	O
a	O
differentiated	O
monocyte	O
phenotype	O
characterized	O
by	O
:	O
(	O
a	O
)	O
growth	O
arrest	O
;	O
(	O
b	O
)	O
increases	O
in	O
Mac-1	O
cell	O
surface	O
antigen	O
expression	O
;	O
(	O
c	O
)	O
down-regulation	O
of	O
c-myc	O
transcripts	O
;	O
and	O
(	O
d	O
)	O
induction	O
of	O
tumor	O
necrosis	O
factor	O
gene	O
expression	O
.	O

This	O
induction	O
of	O
monocytic	O
differentiation	O
was	O
associated	O
with	O
transient	O
increases	O
in	O
c-jun	O
mRNA	O
levels	O
,	O
which	O
were	O
maximal	O
at	O
6	O
h	O
.	O

Similar	O
effects	O
were	O
obtained	O
for	O
the	O
c-fos	O
gene	O
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	O
transcription	O
in	O
U-937	O
cells	O
and	O
that	O
this	O
rate	O
is	O
increased	O
approximately	O
40-fold	O
following	O
okadaic	O
acid	O
exposure	O
.	O

c-jun	O
mRNA	O
levels	O
were	O
superinduced	O
in	O
cells	O
treated	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
,	O
whereas	O
inhibition	O
of	O
protein	O
synthesis	O
had	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
okadaic	O
acid-induced	O
c-jun	O
transcription	O
.	O

The	O
half-life	O
of	O
c-jun	O
mRNA	O
was	O
similar	O
(	O
45-50	O
min	O
)	O
in	O
both	O
untreated	O
and	O
okadaic	O
acid-induced	O
cells	O
.	O

In	O
contrast	O
,	O
treatment	O
with	O
both	O
okadaic	O
acid	O
and	O
cycloheximide	O
was	O
associated	O
with	O
stabilization	O
(	O
t	O
1/2	O
=	O
90	O
min	O
)	O
of	O
c-jun	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
indicate	O
that	O
the	O
induction	O
of	O
c-jun	O
transcription	O
by	O
okadaic	O
acid	O
is	O
controlled	O
primarily	O
by	O
a	O
transcriptional	O
mechanism	O
.	O

Since	O
previous	O
studies	O
have	O
demonstrated	O
that	O
the	O
c-jun	O
gene	O
is	O
autoinduced	O
by	O
Jun/AP-1	O
,	O
we	O
also	O
studied	O
transcription	O
of	O
c-jun	O
promoter	O
(	O
positions	O
-132/+170	O
)	O
-reporter	O
gene	O
constructs	O
with	O
and	O
without	B-Negation
a	I-Negation
mutated	I-Negation
AP-1	I-Negation
element.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Activation	O
of	O
NF-kappa	O
B	O
by	O
interleukin	O
2	O
in	O
human	O
blood	O
monocytes	O
.	O

We	O
report	O
here	O
that	O
interleukin	O
2	O
(	O
IL-2	O
)	O
acts	O
on	O
human	O
blood	O
monocytes	O
by	O
enhancing	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
p55	O
)	O
.	O

Similarly	O
,	O
IL-2	O
activates	O
NF-kappa	O
B	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
U	O
937	O
,	O
but	O
not	B-Negation
in	I-Negation
resting	I-Negation
human	I-Negation
T-cells	I-Negation
.	O

This	O
effect	O
is	O
detectable	O
within	O
15	O
min	O
and	O
peaks	O
1	O
h	O
after	O
exposure	O
to	O
IL-2	O
.	O

Enhanced	O
NF-kappa	O
B	O
binding	O
activity	O
is	O
followed	O
by	O
functional	O
activation	O
in	O
that	O
inducibility	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
is	O
mediated	O
by	O
enhanced	O
NF-kappa	O
B	O
binding	O
and	O
that	O
a	O
heterologous	O
promoter	O
containing	O
the	O
NF-kappa	O
B	O
consensus	O
sequence	O
(	O
-291	O
to	O
-245	O
)	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
chain	O
gene	O
is	O
activated	O
.	O

In	O
addition	O
,	O
IL-2	O
is	O
capable	O
of	O
increasing	O
transcript	O
levels	O
of	O
the	O
p50	O
gene	O
coding	O
for	O
the	O
p50	O
subunit	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
,	O
whereas	O
mRNA	O
levels	O
of	O
the	O
p65	O
NF-kappa	O
B	O
gene	O
remained	O
unchanged	O
.	O

Single	O
point	O
estimation	O
of	O
glucocorticoid	O
receptors	O
in	O
lymphocytes	O
of	O
normal	O
subjects	O
and	O
of	O
children	O
under	O
long	O
term	O
glucocorticoid	O
treatment	O
.	O

A	O
single	O
point	O
assay	O
of	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
in	O
human	O
lymphocytes	O
based	O
on	O
the	O
measurement	O
of	O
specific	O
dexamethasone	O
binding	O
has	O
been	O
developed	O
and	O
compared	O
with	O
a	O
common	O
multi-point	O
Scatchard	O
analysis	O
.	O

The	O
assay	O
conditions-concentration	O
of	O
the	O
ligand	O
20	O
nmol/l	O
,	O
incubation	O
time	O
2	O
h	O
and	O
the	O
cell	O
count	O
2-6	O
mil.	O
cells/tube	O
in	O
the	O
assay	O
volume	O
0.25	O
ml	O
were	O
found	O
to	O
be	O
optimal	O
.	O

An	O
attempt	O
was	O
also	O
undertaken	O
to	O
use	O
a	O
cell	O
harvester	O
for	O
the	O
separation	O
of	O
cells	O
from	O
unbound	O
ligand	O
.	O

Though	O
specifically	O
bound	O
dexamethasone	O
measured	O
by	O
whole-cell	O
assay	O
and	O
that	O
using	O
cell	O
harvester	O
correlated	O
well	O
,	O
almost	O
by	O
one	O
order	O
lower	O
values	O
obtained	O
with	O
the	O
latter	O
method	O
render	O
it	O
non-applicable	O
for	O
receptor	O
quantitation	O
.	O

The	O
results	O
from	O
9	O
healthy	O
volunteers	O
(	O
average	O
GR	O
concentration	O
7131	O
	O
1256	O
sites/cell	O
)	O
correlated	O
excellently	O
with	O
those	O
obtained	O
by	O
the	O
Scatchard	O
analysis	O
.	O

The	O
single	O
point	O
assay	O
has	O
been	O
also	O
applied	O
for	O
determination	O
of	O
GH	O
in	O
10	O
children	O
treated	O
with	O
large	O
doses	O
of	O
prednisone	O
.	O

The	O
average	O
values	O
from	O
healthy	O
volunteers	O
did	O
not	B-Negation
differ	I-Negation
significantly	I-Negation
from	I-Negation
those	I-Negation
found	I-Negation
in	I-Negation
these	I-Negation
children	I-Negation
,	O
though	O
much	O
broader	O
range	O
was	O
found	O
in	O
patients	O
.	O

A	O
novel	O
B	O
cell-derived	O
coactivator	O
potentiates	O
the	O
activation	O
of	O
immunoglobulin	O
promoters	O
by	O
octamer-binding	O
transcription	O
factors	O
.	O

A	O
novel	O
B	O
cell-restricted	O
activity	O
,	O
required	O
for	O
high	O
levels	O
of	O
octamer/Oct-dependent	O
transcription	O
from	O
an	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
promoter	O
,	O
was	O
detected	O
in	O
an	O
in	O
vitro	O
system	O
consisting	O
of	O
HeLa	O
cell-derived	O
extracts	O
complemented	O
with	O
fractionated	O
B	O
cell	O
nuclear	O
proteins	O
.	O

The	O
factor	O
responsible	O
for	O
this	O
activity	O
was	O
designated	O
Oct	O
coactivator	O
from	O
B	O
cells	O
(	O
OCA-B	O
)	O
.	O

OCA-B	O
stimulates	O
the	O
transcription	O
from	O
an	O
IgH	O
promoter	O
in	O
conjunction	O
with	O
either	O
Oct-1	O
or	O
Oct-2	O
but	O
shows	O
no	B-Negation
significant	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
octamer/Oct-dependent	I-Negation
transcription	I-Negation
of	I-Negation
the	I-Negation
ubiquitously	I-Negation
expressed	I-Negation
histone	I-Negation
H2B	I-Negation
promoter	I-Negation
and	I-Negation
the	I-Negation
transcription	I-Negation
of	I-Negation
USF-	I-Negation
and	I-Negation
Sp1-regulated	I-Negation
promoters	I-Negation
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
OCA-B	O
is	O
a	O
tissue-	O
,	O
promoter-	O
,	O
and	O
factor-specific	O
coactivator	O
and	O
that	O
OCA-B	O
may	O
be	O
a	O
major	O
determinant	O
for	O
B	O
cell-specific	O
activation	O
of	O
immunoglobulin	O
promoters	O
.	O

In	O
light	O
of	O
the	O
evidence	O
showing	O
physical	O
and	O
functional	O
interactions	O
between	O
Oct	O
factors	O
and	O
OCA-B	O
,	O
we	O
propose	O
a	O
mechanism	O
of	O
action	O
for	O
OCA-B	O
and	O
discuss	O
the	O
implications	O
of	O
OCA-B	O
for	O
the	O
transcriptional	O
regulation	O
of	O
other	O
tissue-specific	O
promoters	O
.	O

The	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
promoter	O
region	O
in	O
macrophage	O
,	O
T	O
cell	O
,	O
and	O
B	O
cell	O
lines	O
.	O

The	O
1311-base	O
pair	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
promoter	O
region	O
was	O
fused	O
to	O
the	O
luciferase	O
(	O
Luc	O
)	O
reporter	O
gene	O
and	O
studied	O
in	O
a	O
transient	O
transfection	O
system	O
in	O
three	O
TNF	O
producing	O
cell	O
lines	O
,	O
the	O
U937	O
macrophage	O
cell	O
line	O
,	O
the	O
MLA	O
144	O
T	O
cell	O
line	O
,	O
and	O
the	O
729-6	O
B	O
cell	O
line	O
.	O

This	O
full	O
length	O
promoter	O
construct	O
can	O
be	O
induced	O
by	O
phorbol	O
13-myristate	O
acetate	O
(	O
PMA	O
)	O
in	O
each	O
of	O
these	O
cell	O
types	O
.	O

Analysis	O
of	O
a	O
series	O
of	O
5'-truncations	O
showed	O
several	O
peaks	O
of	O
basal	O
and	O
PMA	O
induced	O
activity	O
suggesting	O
the	O
presence	O
of	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

A	O
PMA	O
responsive	O
element	O
was	O
localized	O
to	O
a	O
region	O
between	O
-95	O
and	O
-36	O
bp	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
.	O

Within	O
this	O
region	O
,	O
single	O
AP-2-	O
and	O
AP-1-like	O
consensus	O
sequences	O
were	O
noted	O
.	O

These	O
AP-2	O
and	O
AP-1	O
sites	O
were	O
each	O
modified	O
with	O
a	O
double	O
point	O
mutation	O
.	O

A	O
modest	O
(	O
20-50	O
%	O
)	O
reduction	O
in	O
TNF	O
promoter	O
activity	O
was	O
observed	O
with	O
the	O
AP-2	O
site	O
mutation	O
.	O

However	O
,	O
mutation	O
of	O
the	O
AP-1	O
site	O
markedly	O
diminished	O
both	O
the	O
basal	O
and	O
PMA-activated	O
promoter	O
activity	O
.	O

Also	O
co-transfections	O
of	O
the	O
wild-type	O
promoter	O
construct	O
with	O
an	O
AP-1/c-jun	O
expression	O
vector	O
resulted	O
in	O
augmented	O
basal	O
and	O
PMA-induced	O
promoter	O
activity	O
.	O

Redox	O
status	O
of	O
cells	O
influences	O
constitutive	O
or	O
induced	O
NF-kappa	O
B	O
translocation	O
and	O
HIV	O
long	O
terminal	O
repeat	O
activity	O
in	O
human	O
T	O
and	O
monocytic	O
cell	O
lines	O
.	O

We	O
have	O
tested	O
the	O
hypothesis	O
that	O
cellular	O
activation	O
events	O
occurring	O
in	O
T	O
lymphocytes	O
and	O
monocytes	O
and	O
mediated	O
through	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
are	O
dependent	O
upon	O
the	O
constitutive	O
redox	O
status	O
of	O
these	O
cells	O
.	O

We	O
used	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidants	O
(	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
nordihydroquairetic	O
acid	O
,	O
or	O
alpha-tocopherol	O
(	O
vitamin	O
E	O
)	O
to	O
show	O
that	O
peroxyl	O
radical	O
scavenging	O
in	O
unstimulated	O
and	O
PMA-	O
or	O
TNF-stimulated	O
cells	O
blocks	O
the	O
functions	O
depending	O
on	O
NF-kappa	O
B	O
activation	O
.	O

BHA	O
was	O
found	O
to	O
suppress	O
not	O
only	O
PMA-	O
or	O
TNF-induced	O
,	O
but	O
also	O
constitutive	O
,	O
HIV-enhancer	O
activity	O
concomitant	O
to	O
an	O
inhibition	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
both	O
lymphoblastoid	O
T	O
(	O
J.Jhan	O
)	O
and	O
monocytic	O
(	O
U937	O
)	O
cell	O
lines	O
.	O

This	O
was	O
also	O
true	O
for	O
KBF	O
(	O
p50	O
homodimer	O
)	O
binding	O
activity	O
in	O
U937	O
cells	O
.	O

Secretion	O
of	O
TNF	O
,	O
the	O
product	O
of	O
another	O
NF-kappa	O
B-dependent	O
gene	O
,	O
was	O
abolished	O
by	O
BHA	O
in	O
PMA-stimulated	O
U937	O
cells	O
.	O

The	O
anti-oxidative	O
effect	O
of	O
BHA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
thiol	O
,	O
but	O
not	B-Negation
glutathione	I-Negation
,	O
content	O
in	O
stimulated	O
and	O
unstimulated	O
T	O
cell	O
,	O
whereas	O
TNF	O
stimulation	O
itself	O
barely	O
modified	O
the	O
cellular	O
thiol	O
level	O
.	O

Oxidative	O
stress	O
obtained	O
by	O
the	O
addition	O
of	O
H2O2	O
to	O
the	O
culture	O
medium	O
of	O
J.Jhan	O
or	O
U937	O
cells	O
could	O
not	O
by	O
itself	O
induce	O
NF-kappa	O
B	O
activation	O
.	O

These	O
observations	O
suggest	O
that	O
TNF	O
and	O
PMA	O
do	O
not	O
lead	O
to	O
NF-kappa	O
B	O
activation	O
through	O
induction	O
of	O
changes	O
in	O
the	O
cell	O
redox	O
status	O
.	O

Rather	O
,	O
TNF	O
and	O
PMA	O
can	O
exert	O
their	O
effect	O
only	O
if	O
cells	O
are	O
in	O
an	O
appropriate	O
redox	O
status	O
,	O
because	O
prior	O
modification	O
toward	O
reduction	O
with	O
BHA	O
treatment	O
prevents	O
this	O
activation	O
.	O

It	O
appears	O
that	O
a	O
basal	O
redox	O
equilibrium	O
tending	O
toward	O
oxidation	O
is	O
a	O
prerequisite	O
for	O
full	O
activation	O
of	O
transduction	O
pathways	O
regulating	O
the	O
activity	O
of	O
NF-kappa	O
B-dependent	O
genes	O
.	O

Expression	O
of	O
c-fos	O
,	O
c-jun	O
and	O
jun	O
B	O
in	O
peripheral	O
blood	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
adults	O
.	O

The	O
expression	O
of	O
c-fos	O
,	O
c-jun	O
and	O
jun	O
B	O
proto-oncogenes	O
was	O
studied	O
in	O
phytohemagglutinin	O
(	O
PHA	O
)	O
activated	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
from	O
young	O
and	O
aged	O
humans	O
.	O

Specific	O
mRNAs	O
for	O
c-fos	O
and	O
c-jun	O
were	O
detectable	O
within	O
30	O
min	O
after	O
cell	O
activation	O
and	O
reached	O
maximal	O
levels	O
within	O
2	O
h	O
.	O

Both	O
c-fos	O
and	O
jun	O
B	O
mRNAs	O
decreased	O
to	O
pre-activation	O
levels	O
within	O
6	O
h	O
,	O
while	O
c-jun	O
mRNA	O
remained	O
elevated	O
.	O

In	B-Negation
PHA-activated	I-Negation
PBL	I-Negation
,	I-Negation
no	I-Negation
age-related	I-Negation
differences	I-Negation
were	I-Negation
observed	I-Negation
in	I-Negation
c-fos	I-Negation
or	I-Negation
jun	I-Negation
B	I-Negation
mRNA	I-Negation
expression	I-Negation
.	O

However	O
,	O
c-jun	O
mRNA	O
levels	O
decreased	O
significantly	O
(	O
1.73	O
	O
0.08	O
vs.	O
1.16	O
	O
0.09	O
arbitrary	O
units	O
,	O
P	O
<	O
0.01	O
,	O
young	O
vs.	O
old	O
)	O
in	O
PBL	O
from	O
elderly	O
individuals	O
activated	O
with	O
PHA	O
.	O

Because	O
previous	O
work	O
has	O
demonstrated	O
that	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
display	O
normal	O
proliferative	O
responses	O
when	O
activated	O
via	O
the	O
anti-CD2	O
pathway	O
,	O
c-jun	O
and	O
jun	O
B	O
mRNA	O
expression	O
was	O
also	O
studied	O
in	O
anti-CD2-activated	O
purified	O
T	O
cells	O
.	O

No	B-Negation
age-related	I-Negation
differences	I-Negation
were	I-Negation
found	I-Negation
in	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
either	I-Negation
of	I-Negation
these	I-Negation
two	I-Negation
proto-oncogenes	I-Negation
by	I-Negation
anti-CD2	I-Negation
activated	I-Negation
T	I-Negation
cells	I-Negation
.	O

These	O
results	O
suggest	O
that	O
the	O
decreased	O
IL-2	O
production	O
and	O
proliferative	O
response	O
displayed	O
by	O
PHA-activated	O
PBL	O
from	O
elderly	O
adults	O
may	O
be	O
related	O
to	O
age-related	O
changes	O
in	O
c-jun	O
mRNA	O
expression	O
and	O
in	O
the	O
ratio	O
of	O
c-fos	O
to	O
c-jun	O
mRNA	O
.	O

Characterization	O
of	O
a	O
novel	O
T	O
lymphocyte	O
protein	O
which	O
binds	O
to	O
a	O
site	O
related	O
to	O
steroid/thyroid	O
hormone	O
receptor	O
response	O
elements	O
in	O
the	O
negative	O
regulatory	O
sequence	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

We	O
have	O
previously	O
identified	O
a	O
T	O
lymphocyte	O
protein	O
which	O
binds	O
to	O
a	O
site	O
within	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
virus	O
gene	O
expression	O
.	O

The	O
palindromic	O
site	O
(	O
site	O
B	O
)	O
recognized	O
by	O
this	O
protein	O
is	O
related	O
to	O
the	O
palindromic	O
binding	O
sites	O
of	O
members	O
of	O
the	O
steroid/thyroid	O
hormone	O
receptor	O
family	O
.	O

Here	O
we	O
characterize	O
the	O
T	O
cell	O
protein	O
binding	O
to	O
this	O
site	O
as	O
a	O
100	O
kD	O
protein	O
which	O
is	O
most	O
abundant	O
in	O
T	O
cells	O
and	O
which	O
binds	O
to	O
site	O
B	O
as	O
a	O
200	O
kD	O
complex	O
.	O

This	O
protein	O
is	O
distinct	O
from	O
other	O
members	O
of	O
the	O
steroid/thyroid	O
hormone	O
receptor	O
family	O
including	O
the	O
COUP	O
protein	O
which	O
has	O
a	O
closely	O
related	O
DNA	O
binding	O
specificity	O
.	O

A	O
mechanism	O
for	O
the	O
antiinflammatory	O
effects	O
of	O
corticosteroids	O
:	O
the	O
glucocorticoid	O
receptor	O
regulates	O
leukocyte	O
adhesion	O
to	O
endothelial	O
cells	O
and	O
expression	O
of	O
endothelial-leukocyte	O
adhesion	O
molecule	O
1	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
.	O

Corticosteroids	O
are	O
the	O
preeminent	O
antiinflammatory	O
agents	O
although	O
the	B-Negation
molecular	I-Negation
mechanisms	I-Negation
that	I-Negation
impart	I-Negation
their	I-Negation
efficacy	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
defined	I-Negation
.	O

The	O
endothelium	O
plays	O
a	O
critical	O
role	O
in	O
inflammation	O
by	O
directing	O
circulating	O
leukocytes	O
into	O
extravascular	O
tissues	O
by	O
expressing	O
adhesive	O
molecules	O
for	O
leukocytes	O
[	O
e.g.	O
,	O
endothelial-leukocyte	O
adhesion	O
molecule	O
1	O
(	O
ELAM-1	O
)	O
and	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM-1	O
)	O
]	O
.	O

We	O
therefore	O
determined	O
whether	O
corticosteroids	O
suppress	O
inflammation	O
by	O
inhibiting	O
endothelial	O
expression	O
of	O
adhesion	O
molecules	O
for	O
neutrophils	O
(	O
polymorphonuclear	O
leukocytes	O
)	O
.	O

Preincubation	O
of	O
endothelial	O
cells	O
with	O
endotoxin	O
[	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
1	O
microgram/ml	O
]	O
led	O
to	O
a	O
4-fold	O
increase	O
in	O
subsequent	O
adherence	O
of	O
polymorphonuclear	O
leukocytes	O
(	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
10	O
)	O
to	O
endothelial	O
cells	O
,	O
an	O
increase	O
that	O
was	O
markedly	O
attenuated	O
when	O
endothelial	O
cells	O
were	O
treated	O
with	O
dexamethasone	O
(	O
IC50	O
<	O
1	O
nM	O
,	O
P	O
<	O
0.0001	O
,	O
n	O
=	O
6	O
or	O
7	O
)	O
during	O
preincubation	O
with	O
LPS	O
.	O

Moreover	O
,	O
the	O
steroid	O
receptor	O
agonist	O
cortisol	O
(	O
10	O
microM	O
)	O
,	O
but	O
not	B-Negation
its	I-Negation
inactive	I-Negation
metabolite	I-Negation
tetrahydrocortisol	I-Negation
(	I-Negation
10	I-Negation
microM	I-Negation
)	I-Negation
,	O
diminished	O
LPS-induced	O
endothelial	O
cell	O
adhesiveness	O
.	O

Further	O
evidence	O
that	O
the	O
action	O
of	O
dexamethasone	O
was	O
mediated	O
through	O
ligation	O
of	O
corticosteroid	O
receptors	O
[	O
human	O
glucocorticoid	O
receptors	O
(	O
hGRs	O
)	O
]	O
was	O
provided	O
by	O
experiments	O
utilizing	O
the	O
steroid	O
antagonist	O
RU-486	O
.	O

RU-486	O
(	O
10	O
microM	O
)	O
,	O
which	O
prevents	O
translocation	O
of	O
ligated	O
hGR	O
to	O
the	O
nucleus	O
by	O
inhibiting	O
dissociation	O
of	O
hGR	O
from	O
heat	O
shock	O
protein	O
90	O
,	O
completely	O
aborted	O
the	O
effect	O
of	O
dexamethasone	O
on	O
adhesiveness	O
of	O
endothelial	O
cells	O
(	O
P	O
<	O
0.0005	O
,	O
n	O
=	O
3	O
)	O
.	O

Treatment	O
of	O
endothelial	O
cells	O
with	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
stimulated	O
transcription	O
of	O
ELAM-1	O
,	O
as	O
shown	O
by	O
Northern	O
blot	O
analysis	O
,	O
and	O
expression	O
of	O
membrane-associated	O
ELAM-1	O
and	O
ICAM-1	O
,	O
as	O
shown	O
by	O
quantitative	O
immunofluorescence	O
(	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
9	O
)	O
.	O

Dexamethasone	O
markedly	O
inhibited	O
LPS-stimulated	O
accumulation	O
of	O
mRNA	O
for	O
ELAM-1	O
and	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
IC50	O
<	O
10	O
nM	O
,	O
both	O
P	O
<	O
0.001	O
,	O
n	O
=	O
4-9	O
)	O
;	O

inhibition	O
of	O
expression	O
by	O
dexamethasone	O
was	O
reversed	O
by	O
RU-486	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
4-6	O
)	O
.	O

As	O
in	O
the	O
adhesion	O
studies	O
,	O
cortisol	O
but	O
not	B-Negation
tetrahydrocortisol	I-Negation
inhibited	O
expression	O
of	O
ELAM-1	O
and	O
ICAM-1	O
(	O
both	O
P	O
<	O
0.005	O
,	O
n	O
=	O
3	O
or	O
4	O
)	O
9	O
.	O

In	O
contrast	O
,	O
sodium	O
salicylate	O
(	O
1	O
mM	O
)	O
inhibited	O
neither	B-Negation
adhesion	I-Negation
nor	I-Negation
expression	I-Negation
of	I-Negation
these	I-Negation
adhesion	I-Negation
molecules	I-Negation
.	O

These	O
studies	O
suggest	O
that	O
antagonism	O
by	O
dexamethasone	O
of	O
endotoxin-induced	O
inflammation	O
is	O
a	O
specific	O
instance	O
of	O
the	O
general	O
biological	O
principle	O
that	O
the	O
glucocorticoid	O
receptor	O
is	O
a	O
hormone-dependent	O
regulator	O
of	O
transcription	O
.	O

Membrane	O
receptors	O
for	O
aldosterone	O
:	O
a	O
novel	O
pathway	O
for	O
mineralocorticoid	O
action	O
.	O

Rapid	O
nongenomic	O
in	O
vitro	O
effects	O
of	O
aldosterone	O
on	O
intracellular	O
electrolytes	O
,	O
cell	O
volume	O
,	O
and	O
Na	O
(	O
+	O
)	O
-H+	O
antiport	O
have	O
been	O
found	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
HML	O
)	O
.	O

Binding	O
of	O
125I-labeled	O
aldosterone	O
to	O
plasma	O
membranes	O
of	O
HML	O
shares	O
important	O
features	O
with	O
these	O
functional	O
data	O
.	O

This	O
includes	O
a	O
very	O
low	O
apparent	O
dissociation	O
constant	O
(	O
Kd	O
)	O
of	O
0.1	O
nM	O
for	O
both	O
aldosterone	O
and	O
the	O
effect	O
on	O
the	O
Na	O
(	O
+	O
)	O
-H	O
(	O
+	O
)	O
-antiport	O
,	O
a	O
high	O
turnover	O
rate	O
,	O
and	O
the	O
almost	O
exclusive	O
binding	O
selectivity	O
for	O
aldosterone	O
.	O

Dexamethasone	O
,	O
RU	O
26988	O
,	O
corticosterone	O
,	O
ouabain	O
,	O
amiloride	O
,	O
and	O
18-hydroxyprogesterone	O
were	O
inactive	O
as	O
ligands	O
.	O

Deoxycorticosterone	O
acetate	O
had	O
an	O
intermediate	O
activity	O
with	O
an	O
apparent	O
Kd	O
of	O
100	O
nM	O
.	O

These	O
findings	O
are	O
the	O
first	O
to	O
demonstrate	O
membrane	O
binding	O
of	O
aldosterone	O
being	O
compatible	O
with	O
major	O
aspects	O
of	O
its	O
nongenomic	O
effects	O
.	O

Reticuloendotheliosis	O
virus	O
long	O
terminal	O
repeat	O
elements	O
are	O
efficient	O
promoters	O
in	O
cells	O
of	O
various	O
species	O
and	O
tissue	O
origin	O
,	O
including	O
human	O
lymphoid	O
cells	O
.	O

Promiscuous	O
transcriptional	O
activity	O
of	O
the	O
reticuloendotheliosis	O
virus	O
(	O
REV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
was	O
detected	O
in	O
transient	O
expression	O
assays	O
using	O
LTR-chloramphenicol	O
acetyltransferase-encoding	O
gene	O
chimeras	O
,	O
and	O
cells	O
of	O
diverse	O
species	O
and	O
tissue	O
type	O
;	O

levels	O
of	O
expression	O
from	O
two	O
different	O
REV	O
LTRs	O
correlate	O
with	O
reports	O
of	O
pathogenicity	O
of	O
the	O
respective	O
viruses	O
in	O
vivo	O
.	O

REVs	O
do	O
not	B-Negation
encode	I-Negation
a	I-Negation
transactivator	I-Negation
targeted	I-Negation
to	I-Negation
the	I-Negation
viral	I-Negation
LTR	I-Negation
,	O
and	O
cells	O
infected	O
with	O
Marek	O
's	O
disease	O
virus	O
,	O
a	O
herpesvirus	O
with	O
an	O
overlapping	O
host	O
range	O
,	O
do	O
not	B-Negation
express	I-Negation
factors	I-Negation
that	I-Negation
preferentially	I-Negation
enhance	I-Negation
expression	I-Negation
from	I-Negation
REV	I-Negation
or	I-Negation
avian	I-Negation
sarcoma/leukemia	I-Negation
virus	I-Negation
LTRs	I-Negation
.	O

REV	O
LTRs	O
work	O
efficiently	O
in	O
human	O
lymphoid	O
cells	O
,	O
and	O
are	O
viable	O
alternatives	O
to	O
promoters	O
commonly	O
used	O
for	O
expression	O
of	O
cloned	O
genes	O
.	O

They	O
may	O
also	O
prove	O
useful	O
in	O
the	O
identification	O
of	O
new	O
,	O
ubiquitous	O
cellular	O
transcription	O
factors	O
.	O

Natural	O
variants	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
:	O
analysis	O
of	O
promoters	O
with	O
duplicated	O
DNA	O
regulatory	O
motifs	O
.	O

Sequence	O
variation	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV-1	O
was	O
analyzed	O
in	O
viral	O
isolates	O
of	O
17	O
infected	O
individuals	O
.	O

Two	O
classes	O
of	O
LTR	O
size	O
variants	O
were	O
found	O
.	O

One	O
HIV-1	O
variant	O
was	O
detected	O
containing	O
an	O
additional	O
binding	O
site	O
for	O
the	O
transcription	O
factor	O
Sp1	O
.	O

Another	O
LTR	O
size	O
variation	O
was	O
observed	O
in	O
four	O
patients	O
in	O
a	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappa	O
B	O
enhancer	O
.	O

This	O
variation	O
was	O
the	O
result	O
of	O
a	O
duplication	O
of	O
a	O
short	O
DNA	O
sequence	O
(	O
CTG-motif	O
)	O
.	O

Cell	O
culture	O
experiments	O
demonstrated	O
that	O
the	O
natural	O
variant	O
with	O
four	O
Sp1	O
sites	O
had	O
a	O
slightly	O
higher	O
promoter	O
activity	O
and	O
viral	O
replication	O
rate	O
than	O
the	O
isogenic	O
control	O
LTR	O
with	O
three	O
Sp1	O
sites	O
.	O

No	B-Negation
positive	I-Negation
effect	I-Negation
of	I-Negation
the	I-Negation
duplicated	I-Negation
CTG-motif	I-Negation
could	I-Negation
be	I-Negation
detected	I-Negation
.	O

In	O
order	O
to	O
measure	O
small	O
differences	O
in	O
virus	O
production	O
more	O
accurately	O
,	O
equal	O
amounts	O
of	O
a	O
size	O
variant	O
and	O
the	O
wild-type	O
plasmid	O
were	O
cotransfected	O
into	O
T-cells	O
.	O

The	O
virus	O
with	O
four	O
Sp1	O
sites	O
did	O
outgrow	O
the	O
three	O
Sp1	O
virus	O
in	O
35	O
days	O
of	O
culture	O
and	O
CTG-monomer	O
virus	O
outcompeted	O
the	O
CTG-dimer	O
virus	O
in	O
42	O
days	O
.	O

Based	O
on	O
these	O
results	O
we	O
estimate	O
a	O
5-10	O
%	O
difference	O
in	O
virus	O
production	O
of	O
the	O
LTR	O
variants	O
when	O
compared	O
to	O
that	O
of	O
wild-type	O
.	O

SCL	O
and	O
related	O
hemopoietic	O
helix-loop-helix	O
transcription	O
factors	O
.	O

The	O
helix-loop-helix	O
(	O
HLH	O
)	O
proteins	O
are	O
a	O
family	O
of	O
transcription	O
factors	O
that	O
include	O
proteins	O
critical	O
to	O
differentiation	O
and	O
development	O
in	O
species	O
ranging	O
from	O
plants	O
to	O
mammals	O
.	O

Five	O
members	O
of	O
this	O
family	O
(	O
MYC	O
,	O
SCL	O
,	O
TAL-2	O
,	O
LYL-1	O
and	O
E2A	O
)	O
are	O
implicated	O
in	O
oncogenic	O
events	O
in	O
human	O
lymphoid	O
tumors	O
because	O
of	O
their	O
consistent	O
involvement	O
in	O
chromosomal	O
translocations	O
.	O

Although	O
activated	O
in	O
T	O
cell	O
leukemias	O
,	O
expression	O
of	O
SCL	O
and	O
LYL-1	O
is	O
low	O
or	O
undetectable	O
in	O
normal	O
T	O
cell	O
populations	O
.	O

SCL	O
is	O
expressed	O
in	O
erythroid	O
,	O
megakaryocyte	O
and	O
mast	O
cell	O
populations	O
(	O
the	O
same	O
cell	O
lineages	O
as	O
GATA-1	O
,	O
a	O
zinc-finger	O
transcription	O
factor	O
)	O
.	O

In	O
addition	O
,	O
both	O
SCL	O
and	O
GATA-1	O
undergo	O
coordinate	O
modulation	O
during	O
chemically	O
induced	O
erythroid	O
differentiation	O
of	O
mouse	O
erythroleukemia	O
cells	O
and	O
are	O
down-modulated	O
during	O
myeloid	O
differentiation	O
of	O
human	O
K562	O
cells	O
,	O
thus	O
implying	O
a	O
role	O
for	O
SCL	O
in	O
erythroid	O
differentiation	O
events	O
.	O

However	O
,	O
in	O
contrast	O
to	O
GATA-1	O
,	O
SCL	O
is	O
expressed	O
in	O
the	O
developing	O
brain	O
.	O

Studies	O
of	O
the	O
function	O
of	O
SCL	O
suggest	O
it	O
is	O
also	O
important	O
in	O
proliferation	O
and	O
self-renewal	O
events	O
in	O
erythroid	O
cells	O
.	O

Transcription	O
of	O
the	O
hypersensitive	O
site	O
HS2	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

In	O
the	O
human	O
genome	O
,	O
the	O
erythroid-specific	O
hypersensitive	O
site	O
HS2	O
enhancer	O
regulates	O
the	O
transcription	O
of	O
the	O
downstream	O
beta-like	O
globin	O
genes	O
10-50	O
kilobases	O
away	O
.	O

The	O
mechanism	O
of	O
HS2	O
enhancer	O
function	O
is	O
not	B-Negation
known	I-Negation
.	O

The	O
present	O
study	O
employs	O
RNA	O
protection	O
assays	O
to	O
analyze	O
the	O
transcriptional	O
status	O
of	O
the	O
HS2	O
enhancer	O
in	O
transfected	O
recombinant	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
plasmids	O
.	O

In	O
erythroid	O
K562	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
active	O
,	O
the	O
HS2	O
sequence	O
directs	O
the	O
synthesis	O
of	O
long	O
enhancer	O
transcripts	O
that	O
are	O
initiated	O
apparently	O
from	O
within	O
the	O
enhancer	O
and	O
elongated	O
through	O
the	O
intervening	O
DNA	O
into	O
the	O
cis-linked	O
CAT	O
gene	O
.	O

In	O
nonerythroid	O
HL-60	O
cells	O
in	O
which	O
the	O
HS2	O
enhancer	O
is	O
inactive	O
,	O
long	O
enhancer	O
transcripts	O
are	O
not	B-Negation
detectable	I-Negation
.	O

Splitting	O
the	O
HS2	O
enhancer	O
between	O
two	O
tandem	O
Ap1	O
sites	O
abolishes	O
the	O
synthesis	O
of	O
a	O
group	O
of	O
long	O
enhancer	O
transcripts	O
and	O
results	O
in	O
loss	O
of	O
enhancer	O
function	O
and	O
transcriptional	O
silencing	O
of	O
the	O
cis-linked	O
CAT	O
gene	O
.	O

In	O
directing	O
the	O
synthesis	O
of	O
RNA	O
through	O
the	O
intervening	O
DNA	O
and	O
the	O
gene	O
by	O
a	O
tracking	O
and	O
transcription	O
mechanism	O
,	O
the	O
HS2	O
enhancer	O
may	O
(	O
i	O
)	O
open	O
up	O
the	O
chromatin	O
structure	O
of	O
a	O
gene	O
domain	O
and	O
(	O
ii	O
)	O
deliver	O
enhancer	O
binding	O
proteins	O
to	O
the	O
promoter	O
sequence	O
where	O
they	O
may	O
stimulate	O
the	O
transcription	O
of	O
the	O
gene	O
at	O
the	O
cap	O
site	O
.	O

Phorbol	O
ester	O
reduces	O
constitutive	O
nuclear	O
NF	O
kappa	O
B	O
and	O
inhibits	O
HIV-1	O
production	O
in	O
mature	O
human	O
monocytic	O
cells	O
.	O

NF	O
kappa	O
B	O
is	O
a	O
potent	O
mediator	O
of	O
specific	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
transcription	O
of	O
the	O
HIV-1	O
genome	O
in	O
promonocytic	O
leukemias	O
.	O

There	O
is	O
little	O
information	O
available	O
on	O
the	O
response	O
of	O
NF	O
kappa	O
B	O
to	O
cytokines	O
in	O
normal	O
human	O
monocytes	O
.	O

We	O
have	O
used	O
a	O
32P-labeled	O
oligonucleotide	O
derived	O
from	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
long	O
terminal	O
repeat	O
,	O
which	O
contains	O
a	O
tandem	O
repeat	O
of	O
the	O
NF	O
kappa	O
B	O
binding	O
sequence	O
,	O
as	O
a	O
probe	O
in	O
a	O
gel	O
retardation	O
assay	O
to	O
study	O
this	O
transcription	O
factor	O
.	O

Using	O
this	O
assay	O
,	O
we	O
have	O
detected	O
NF	O
kappa	O
B	O
in	O
extracts	O
of	O
nuclei	O
from	O
normal	O
human	O
monocytes	O
.	O

Treatment	O
of	O
normal	O
monocytes	O
with	O
12-0-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
for	O
4-24	O
h	O
caused	O
the	O
complete	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
nuclear	O
extracts	O
of	O
monocytes	O
.	O

A	O
similar	O
result	O
was	O
obtained	O
with	O
the	O
mature	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
.	O

The	O
constitutive	O
transcription	O
factor	O
SP1	O
was	O
unaffected	O
by	O
addition	O
of	O
TPA	O
.	O

The	O
disappearance	O
of	O
NF	O
kappa	O
B	O
from	O
the	O
nucleus	O
was	O
concentration	O
dependent	O
between	O
10	O
and	O
50	O
ng/ml	O
of	O
phorbol	O
ester	O
.	O

In	O
THP-1	O
cells	O
,	O
TPA	O
also	O
induced	O
a	O
new	O
,	O
faster-migrating	O
NF	O
kappa	O
B	O
species	O
not	B-Negation
induced	I-Negation
in	I-Negation
monocytes	I-Negation
.	O

Protein	O
kinase	O
C	O
inhibitor	O
staurosporine	O
,	O
but	O
not	B-Negation
cyclic	I-Negation
nucleotide-dependent	I-Negation
protein	I-Negation
kinase	I-Negation
inhibitor	I-Negation
HA-1004	I-Negation
,	O
also	O
dramatically	O
reduced	O
constitutive	O
levels	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Finally	O
,	O
TPA	O
addition	O
to	O
monocytes	O
infected	O
with	O
HIV-1	O
inhibited	O
HIV-1	O
replication	O
,	O
as	O
determined	O
by	O
reverse	O
transcriptase	O
assays	O
,	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

These	O
results	O
are	O
in	O
striking	O
contrast	O
to	O
the	O
increase	O
in	O
nuclear	O
NF	O
kappa	O
B	O
and	O
HIV-1	O
replication	O
induced	O
by	O
phorbol	O
esters	O
in	O
promonocytic	O
leukemia	O
cells	O
U937	O
and	O
HL-60	O
,	O
and	O
emphasize	O
the	O
importance	O
of	O
studying	O
cytokine	O
regulation	O
of	O
HIV-1	O
in	O
normal	O
monocytes	O
.	O

Ablation	O
of	O
transplanted	O
HTLV-I	O
Tax-transformed	O
tumors	O
in	O
mice	O
by	O
antisense	O
inhibition	O
of	O
NF-kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Science	O
1993	O
Mar	O
12	O
;	O
259	O
(	O
5101	O
)	O
:	O
1523	O
]	O

Mice	O
transgenic	O
for	O
the	O
human	O
T	O
cell	O
leukemia	O
virus	O
(	O
HTLV-I	O
)	O
Tax	O
gene	O
develop	O
fibroblastic	O
tumors	O
that	O
express	O
NF-kappa	O
B-inducible	O
early	O
genes	O
.	O

In	O
vitro	O
inhibition	O
of	O
NF-kappa	O
B	O
expression	O
by	O
antisense	O
oligodeoxynucleotides	O
(	O
ODNs	O
)	O
inhibited	O
growth	O
of	O
these	O
culture-adapted	O
Tax-transformed	O
fibroblasts	O
as	O
well	O
as	O
an	O
HTLV-I-transformed	O
human	O
lymphocyte	O
line	O
.	O

In	O
contrast	O
,	O
antisense	O
inhibition	O
of	O
Tax	O
itself	O
had	O
no	B-Negation
apparent	I-Negation
effect	I-Negation
on	I-Negation
cell	I-Negation
growth	I-Negation
.	O

Mice	O
treated	O
with	O
antisense	O
to	O
NF-kappa	O
B	O
ODNs	O
showed	O
rapid	O
regression	O
of	O
transplanted	O
fibrosarcomas	O
.	O

This	O
suggests	O
that	O
NF-kappa	O
B	O
expression	O
may	O
be	O
necessary	O
for	O
the	O
maintenance	O
of	O
the	O
malignant	O
phenotype	O
and	O
provides	O
a	O
therapeutic	O
approach	O
for	O
HTLV-I-associated	O
disease	O
.	O

Inhibition	O
of	O
anti-CD3	O
monoclonal	O
antibody-induced	O
T-cell	O
proliferation	O
by	O
dexamethasone	O
,	O
isoproterenol	O
,	O
or	O
prostaglandin	O
E2	O
either	O
alone	O
or	O
in	O
combination	O
.	O

1	O
.	O
The	O
purpose	O
of	O
these	O
studies	O
was	O
to	O
investigate	O
the	O
modulation	O
of	O
the	O
proliferation	O
of	O
human	O
T	O
cells	O
obtained	O
from	O
peripheral	O
blood	O
by	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
isoproterenol	O
(	O
ISO	O
)	O
,	O
and	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
.	O

The	O
former	O
two	O
substances	O
interact	O
with	O
T	O
cells	O
via	O
the	O
glucocorticoid	O
and	O
beta-adrenergic	O
receptors	O
respectively	O
.	O

When	O
occupied	O
by	O
their	O
natural	O
ligands	O
,	O
glucocorticosteroids	O
and	O
catecholamines	O
,	O
these	O
receptors	O
have	O
a	O
role	O
in	O
modulating	O
T-cell	O
function	O
during	O
stress	O
.	O

During	O
the	O
inflammatory	O
response	O
increased	O
levels	O
of	O
PGE2	O
bind	O
to	O
their	O
receptors	O
on	O
T	O
cells	O
and	O
thus	O
alter	O
responsiveness	O
.	O

Proliferation	O
of	O
T	O
cells	O
was	O
induced	O
by	O
immobilized	O
anti-CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
an	O
additional	O
costimulatory	O
signal	O
delivered	O
by	O
anti-CD28	O
mAb	O
.	O

2	O
.	O
Various	O
physiologic	O
concentrations	O
of	O
DEX	O
,	O
ISO	O
,	O
or	O
PGE2	O
were	O
added	O
at	O
the	O
time	O
of	O
initiation	O
of	O
the	O
cultures	O
and	O
subsequent	O
proliferation	O
of	O
the	O
unstimulated	O
T	O
cells	O
was	O
determined	O
.	O

The	O
results	O
demonstrate	O
that	O
physiologic	O
concentrations	O
of	O
all	O
three	O
of	O
these	O
agents	O
inhibit	O
the	O
anti-CD3	O
mAb-induced	O
proliferation	O
of	O
T	O
cells	O
.	O

3	O
.	O
Although	O
DEX	O
and	O
PGE2	O
were	O
equipotent	O
in	O
suppressing	O
T-cell	O
proliferation	O
,	O
ISO	O
was	O
much	O
less	O
effective	O
.	O

4	O
.	O
Because	O
concomitant	O
elevations	O
in	O
the	O
peripheral	O
levels	O
of	O
these	O
substances	O
may	O
occur	O
,	O
experiments	O
were	O
performed	O
to	O
determine	O
the	O
T-cell	O
inhibitory	O
effects	O
of	O
DEX	O
together	O
with	O
either	O
PGE2	O
or	O
ISO	O
.	O

Synergistic	O
suppression	O
of	O
T-cell	O
proliferation	O
was	O
observed	O
when	O
various	O
concentrations	O
of	O
DEX	O
and	O
PGE2	O
,	O
but	O
not	B-Negation
DEX	I-Negation
and	I-Negation
ISO	I-Negation
,	O
were	O
added	O
to	O
cultures	O
.	O

This	B-Negation
synergistic	I-Negation
suppression	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
explained	I-Negation
by	I-Negation
an	I-Negation
increase	I-Negation
in	I-Negation
cAMP	I-Negation
accumulation	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
stimulated	I-Negation
with	I-Negation
DEX	I-Negation
and	I-Negation
PGE2	I-Negation
.	O

5	O
.	O
Finally	O
,	O
the	O
addition	O
of	O
anti-CD28	O
mAb	O
to	O
anti-CD3	O
mAb-stimulated	O
T	O
cells	O
overcame	O
much	O
of	O
the	O
suppression	O
of	O
proliferation	O
induced	O
by	O
PGE2	O
or	O
ISO	O
but	O
less	O
so	O
than	O
that	O
induced	O
by	O
DEX	O
.	O

Targeted	O
degradation	O
of	O
c-Fos	O
,	O
but	O
not	B-Negation
v-Fos	I-Negation
,	O
by	O
a	O
phosphorylation-dependent	O
signal	O
on	O
c-Jun	O
.	O

The	O
proto-oncogene	O
products	O
c-Fos	O
and	O
c-Jun	O
heterodimerize	O
through	O
their	O
leucine	O
zippers	O
to	O
form	O
the	O
AP-1	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
heterodimer	O
is	O
regulated	O
by	O
signal-dependent	O
phosphorylation	O
and	O
dephosphorylation	O
events	O
.	O

The	O
stability	O
of	O
c-Fos	O
was	O
found	O
to	O
also	O
be	O
controlled	O
by	O
intracellular	O
signal	O
transduction	O
.	O

In	O
transient	O
expression	O
and	O
in	O
vitro	O
degradation	O
experiments	O
,	O
the	O
stability	O
of	O
c-Fos	O
was	O
decreased	O
when	O
the	O
protein	O
was	O
dimerized	O
with	O
phosphorylated	O
c-Jun	O
.	O

c-Jun	O
protein	O
isolated	O
from	O
phorbol	O
ester-induced	O
cells	O
did	O
not	B-Negation
target	I-Negation
c-Fos	I-Negation
for	I-Negation
degradation	I-Negation
,	O
which	O
suggests	B-Speculation
that	I-Speculation
c-Fos	I-Speculation
is	I-Speculation
transiently	I-Speculation
stabilized	I-Speculation
after	I-Speculation
stimulation	I-Speculation
of	I-Speculation
cell	I-Speculation
growth	I-Speculation
.	O

v-Fos	O
protein	O
,	O
the	O
retroviral	O
counterpart	O
of	O
c-Fos	O
,	O
was	O
not	B-Negation
susceptible	I-Negation
to	I-Negation
degradation	I-Negation
targeted	I-Negation
by	I-Negation
c-Jun	I-Negation
.	O

Mutations	O
in	O
the	O
Pit-1	O
gene	O
in	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
.	O

Pit-1	O
is	O
a	O
pituitary-specific	O
transcription	O
factor	O
that	O
binds	O
to	O
and	O
transactivates	O
promoters	O
of	O
growth	O
hormone	O
and	O
prolactin	O
genes	O
.	O

In	O
three	O
unrelated	O
Japanese	O
children	O
with	O
combined	O
pituitary	O
hormone	O
deficiency	O
,	O
we	O
identified	O
three	O
point	O
mutations	O
in	O
the	O
Pit-1	O
gene	O
,	O
Pro24Leu	O
,	O
Arg143Gln	O
,	O
and	O
Arg271Trp	O
,	O
located	O
on	O
the	O
major	O
transactivation	O
region	O
,	O
POU-specific	O
domain	O
,	O
and	O
POU-homeodomain	O
,	O
respectively	O
.	O

Calcitriol	O
:	O
a	O
hematolymphopoietrope	O
?	O
[	O
editorial	O
]	O

A	O
MEDLINE	O
search	O
of	O
the	O
English-language	O
literature	O
was	O
conducted	O
using	O
the	O
indexing	O
terms	O
'immunology	O
,	O
calcitriol	O
and	O
vitamin	O
D	O
'	O
to	O
identify	O
studies	O
indicating	O
a	O
role	O
for	O
calcitriol	O
as	O
a	O
primary	O
immunomodulator	O
.	O

Sixty-six	O
papers	O
published	O
between	O
January	O
1956	O
and	O
June	O
1991	O
were	O
identified	O
.	O

Forty-five	O
of	O
these	O
reports	O
are	O
cited	O
in	O
this	O
review	O
.	O

The	O
data	O
strongly	O
suggest	O
an	O
endocrine	O
,	O
autocrine	O
and/or	O
paracrine	O
role	O
for	O
calcitriol	O
in	O
immune	O
regulation	O
.	O

No	B-Negation
unifying	I-Negation
hypothesis	I-Negation
has	I-Negation
yet	I-Negation
emerged	I-Negation
explaining	I-Negation
this	I-Negation
collection	I-Negation
of	I-Negation
data	I-Negation
.	O

This	O
paper	O
provides	O
a	O
brief	O
review	O
of	O
immune	O
properties	O
currently	O
attributed	O
to	O
calcitriol	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
and	O
elevation	O
of	O
cAMP	O
interact	O
synergistically	O
to	O
raise	O
c-Fos	O
and	O
AP-1	O
activity	O
in	O
Jurkat	O
cells	O
.	O

We	O
have	O
earlier	O
found	O
that	O
in	O
Jurkat	O
cells	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enhances	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
accumulation	O
induced	O
by	O
adenosine	O
receptor	O
stimulation	O
or	O
activation	O
of	O
Gs	O
.	O

Here	O
we	O
have	O
therefore	O
examined	O
the	O
effect	O
of	O
the	O
phorbol	O
ester	O
PMA	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
which	O
stimulates	O
PKC	O
and	O
a	O
combination	O
of	O
the	O
adenosine	O
receptor	O
agonist	O
NECA	O
(	O
5'-	O
(	O
N-ethyl	O
)	O
-carboxamido	O
adenosine	O
)	O
and	O
forskolin	O
to	O
raise	O
cAMP	O
,	O
on	O
the	O
levels	O
of	O
c-Fos	O
and	O
Jun	O
and	O
on	O
the	O
binding	O
and	O
transcriptional	O
activity	O
of	O
the	O
transcription	O
factor	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
.	O

PMA	O
treatment	O
caused	O
a	O
concentration-	O
and	O
time-dependent	O
increase	O
in	O
both	O
c-Fos	O
and	O
Jun	O
immunoreactivity	O
in	O
contrast	O
to	O
cAMP	O
elevation	O
that	O
had	O
only	O
a	O
slight	O
effect	O
.	O

Both	O
PMA	O
and	O
the	O
combination	O
of	O
NECA	O
and	O
forskolin	O
acted	O
together	O
either	O
to	O
increase	O
(	O
c-Fos	O
)	O
or	O
decrease	O
(	O
Jun	O
)	O
protein	O
levels	O
as	O
well	O
as	O
increasing	O
AP-1	O
binding	O
,	O
as	O
judged	O
by	O
gel-shift	O
assay	O
,	O
and	O
AP-1	O
transcriptional	O
activity	O
.	O

Furthermore	O
there	O
was	O
a	O
clear-cut	O
synergy	O
between	O
the	O
PKC	O
stimulator	O
and	O
the	O
cAMP	O
elevating	O
agents	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
PKC	O
and	O
elevation	O
of	O
cAMP	O
leads	O
to	O
an	O
enhanced	O
AP-1	O
transcriptional	O
activity	O
in	O
a	O
T-leukemia	O
cell	O
line	O
,	O
suggesting	O
that	O
the	O
previously	O
observed	O
interaction	O
between	O
the	O
parallel	O
signal	O
transduction	O
pathways	O
may	O
have	O
functional	O
consequences	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

The	O
use	O
of	O
interferon-gamma-treated	O
U937	O
cells	O
in	O
chemiluminescence	O
assays	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
of	O
potential	O
clinical	O
significance	O
.	O

The	O
chemiluminescent	O
(	O
CL	O
)	O
response	O
of	O
interferon-gamma-treated	O
U937	O
(	O
IFN-U937	O
)	O
cells	O
to	O
sensitized	O
target	O
cells	O
has	O
been	O
used	O
to	O
detect	O
red	O
cell	O
,	O
platelet	O
and	O
granulocyte	O
antibodies	O
.	O

A	O
clone	O
of	O
U937	O
cells	O
was	O
selected	O
which	O
expressed	O
Fc	O
receptor	O
I	O
(	O
Fc	O
gamma	O
RI	O
)	O
and	O
which	O
,	O
after	O
incubation	O
with	O
IFN-gamma	O
for	O
72	O
h	O
,	O
was	O
capable	O
of	O
generating	O
high	O
levels	O
of	O
lucigenin-enhanced	O
CL	O
.	O

The	O
CL	O
responses	O
of	O
IFN-U937	O
cells	O
and	O
peripheral	O
blood	O
human	O
monocytes	O
to	O
sensitized	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
were	O
then	O
compared	O
.	O

Assays	O
using	O
monocytes	O
or	O
IFN-U937	O
cells	O
were	O
of	O
comparable	O
sensitivity	O
for	O
detection	O
of	O
antibodies	O
against	O
all	O
three	O
types	O
of	O
target	O
cell	O
.	O

In	O
addition	O
,	O
the	O
use	O
of	O
IFN-U937	O
cells	O
reduced	O
interassay	O
variation	O
and	O
simplified	O
assay	O
performance	O
.	O

The	O
potential	O
clinical	O
usefulness	O
of	O
these	O
CL	O
assays	O
was	O
suggested	O
by	O
the	O
ability	O
of	O
both	O
monocytes	O
and	O
IFN-U937	O
cells	O
to	O
respond	O
to	O
red	O
cells	O
,	O
platelets	O
or	O
granulocytes	O
sensitized	O
with	O
sera	O
from	O
pregnant	O
women	O
whose	O
babies	O
had	O
either	O
haemolytic	O
disease	O
of	O
the	O
newborn	O
(	O
HDN	O
)	O
,	O
alloimmune	O
thrombocytopenia	O
or	O
alloimmune	O
neutropenia	O
respectively	O
.	O

In	O
addition	O
,	O
monocytes	O
and	O
IFN-U937	O
cells	O
both	O
responded	O
to	O
red	O
cells	O
sensitized	O
with	O
antibodies	O
against	O
a	O
variety	O
of	O
specificities	O
of	O
assumed	O
(	O
although	O
not	O
documented	O
)	O
clinical	O
significance	O
for	O
blood	O
transfusion	O
recipients	O
.	O

In	O
contrast	O
,	O
monocytes	O
and	O
IFN-U937	O
cells	O
responded	O
only	O
weakly	O
to	O
red	O
cells	O
sensitized	O
with	O
either	O
anti-D	O
in	O
sera	O
from	O
mothers	O
of	O
babies	O
unaffected	O
by	O
HDN	O
,	O
or	O
with	O
antisera	O
containing	O
high	O
titre	O
antibodies	O
with	O
specificities	O
not	B-Negation
normally	I-Negation
associated	I-Negation
with	I-Negation
significantly	I-Negation
reduced	I-Negation
red	I-Negation
cell	I-Negation
survival	I-Negation
.	O

Involvement	O
of	O
Alu	O
sequences	O
in	O
the	O
cell-specific	O
regulation	O
of	O
transcription	O
of	O
the	O
gamma	O
chain	O
of	O
Fc	O
and	O
T	O
cell	O
receptors	O
.	O

The	O
Fc	O
epsilon	O
RI-gamma	O
chains	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
hematopoietic	O
cells	O
where	O
they	O
play	O
a	O
critical	O
role	O
in	O
signal	O
transduction	O
.	O

They	O
are	O
part	O
of	O
the	O
high	O
affinity	O
IgE	O
receptor	O
in	O
mast	O
cells	O
,	O
basophils	O
,	O
Langerhans	O
cells	O
,	O
and	O
possibly	O
other	O
cells	O
;	O
a	O
component	O
of	O
the	O
low	O
affinity	O
receptor	O
for	O
IgG	O
(	O
Fc	O
gamma	O
RIIIA	O
or	O
CD16	O
)	O
in	O
natural	O
killer	O
cells	O
and	O
macrophages	O
;	O
and	O
part	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
in	O
subsets	O
of	O
T	O
cells	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
transcriptional	O
regulation	O
of	O
the	O
gamma	O
chain	O
gene	O
by	O
analyzing	O
the	O
2.5-kilobase	O
sequence	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

This	O
sequence	O
contains	O
a	O
promoter	O
specific	O
to	O
cells	O
of	O
hematopoietic	O
lineage	O
.	O

However	O
,	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
only	O
partial	O
because	O
it	O
is	O
active	O
in	O
all	O
of	O
the	O
hematopoietic	O
cells	O
tested	O
here	O
,	O
regardless	O
of	O
whether	O
they	O
constitutively	O
express	O
Fc	O
epsilon	O
RI-gamma	O
chain	O
transcripts	O
.	O

We	O
have	O
identified	O
two	O
adjacent	O
cis-acting	O
regulatory	O
elements	O
,	O
both	O
of	O
which	O
are	O
part	O
of	O
an	O
Alu	O
repeat	O
.	O

The	O
first	O
(	O
-445/-366	O
)	O
is	O
a	O
positive	O
element	O
active	O
in	O
both	O
basophils	O
and	O
T	O
cells	O
.	O

The	O
second	O
(	O
-365/-264	O
)	O
binds	O
to	O
nuclear	O
factors	O
,	O
which	O
appear	O
to	O
be	O
different	O
in	O
basophils	O
and	O
T	O
cells	O
,	O
and	O
acts	O
as	O
a	O
negative	O
element	O
in	O
basophils	O
and	O
as	O
a	O
positive	O
one	O
in	O
T	O
cells	O
.	O

Thus	O
,	O
this	O
Alu	O
repeat	O
(	O
90	O
%	O
identical	O
to	O
Alu	O
consensus	O
sequences	O
)	O
has	O
evolved	O
to	O
become	O
both	O
a	O
positive	O
and	O
negative	O
regulator	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer/promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
and	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	O
,	O
both	O
of	O
which	O
are	O
highly	O
conserved	O
in	O
HIV	O
and	O
simian	O
immunodeficiency	O
virus	O
isolates	O
.	O

To	O
delineate	O
the	O
effects	O
of	O
these	O
motifs	O
on	O
the	O
replicative	O
capacity	O
of	O
HIV	O
and	O
to	O
explore	O
the	O
possibility	O
of	O
extending	O
the	O
virus	O
host	O
range	O
,	O
known	O
heterologous	O
enhancer/promoters	O
were	O
inserted	O
into	O
the	O
HIV-1	O
LTR	O
in	O
place	O
of	O
the	O
NF-kappa	O
B	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
effects	O
of	O
these	O
substitutions	O
on	O
viral	O
replication	O
in	O
transfected	O
HeLa	O
cells	O
and	O
on	O
HIV	O
infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
or	O
continuous	O
T-leukemia	O
cell	O
lines	O
were	O
evaluated	O
.	O

HIVs	O
in	O
which	O
the	O
NF-	O
kappa	O
B/Sp1	O
enhancer	O
plus	O
the	O
downstream	O
TATA	O
element	O
were	O
replaced	O
with	O
heterologous	O
enhancer/promoters	O
were	O
also	O
constructed	O
.	O

Viruses	O
containing	O
the	O
human	O
cytomegalovirus	O
immediate-early	O
enhancer	O
exhibited	O
infectious	O
kinetics	O
similar	O
to	O
that	O
of	O
wild-type	O
HIV	O
in	O
activated	O
human	O
peripheral	O
blood	O
lymphocytes	O
and	O
AA2	O
cells	O
but	O
replicated	O
less	O
efficiently	O
in	O
H9	O
and	O
CEM	O
cells	O
.	O

These	O
studies	O
indicate	O
that	O
heterologous	O
enhancer	O
elements	O
are	O
capable	O
of	O
restoring	O
Tat	O
responsiveness	O
to	O
the	O
HIV	O
LTR	O
in	O
the	O
context	O
of	O
directing	O
reporter	O
gene	O
expression	O
as	O
well	O
as	O
in	O
the	O
production	O
of	O
infectious	O
progeny	O
virions	O
.	O

Tyrosine	O
phosphorylation	O
is	O
a	O
mandatory	O
proximal	O
step	O
in	O
radiation-induced	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
pathway	O
in	O
human	O
B-	O
lymphocyte	O
precursors	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1993	O
Apr	O
15	O
;	O
90	O
(	O
8	O
)	O
:	O
3775	O
]	O

Ionizing	O
radiation	O
triggers	O
a	O
signal	O
in	O
human	O
B-lymphocyte	O
precursors	O
that	O
is	O
intimately	O
linked	O
to	O
an	O
active	O
protein-tyrosine	O
kinase	O
regulatory	O
pathway	O
.	O

We	O
show	O
that	O
in	O
B-lymphocyte	O
precursors	O
,	O
irradiation	O
with	O
gamma-rays	O
leads	O
to	O
(	O
i	O
)	O
stimulation	O
of	O
phosphatidylinositol	O
turnover	O
;	O
(	O
ii	O
)	O
downstream	O
activation	O
by	O
covalent	O
modification	O
of	O
multiple	O
serine-specific	O
protein	O
kinases	O
,	O
including	O
protein	O
kinase	O
C	O
;	O
and	O
(	O
iii	O
)	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

All	O
of	O
the	O
radiation-induced	O
signals	O
were	O
effectively	O
prevented	O
by	O
the	O
protein-tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
.	O

Thus	O
,	O
tyrosine	O
phosphorylation	O
is	O
an	O
important	O
and	O
perhaps	O
mandatory	O
proximal	O
step	O
in	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
C	O
signaling	O
cascade	O
in	O
human	O
B-lymphocyte	O
precursors	O
.	O

Our	O
report	O
expands	O
current	O
knowledge	O
of	O
the	O
radiation-induced	O
signaling	O
cascade	O
by	O
clarifying	O
the	O
chronological	O
sequence	O
of	O
biochemical	O
events	O
that	O
follow	O
irradiation	O
.	O

Photoaffinity	O
labeling	O
of	O
plasma	O
membrane	O
receptors	O
for	O
aldosterone	O
from	O
human	O
mononuclear	O
leukocytes	O
.	O

Non-genomic	O
effects	O
of	O
aldosterone	O
on	O
the	O
sodium-proton-antiport	O
have	O
been	O
shown	O
in	O
human	O
mononuclear	O
leukocytes	O
which	O
could	O
be	O
related	O
to	O
a	O
new	O
aldosterone	O
membrane	O
receptor	O
.	O

In	O
the	O
present	O
paper	O
plasma	O
membranes	O
from	O
human	O
mononuclear	O
leukocytes	O
were	O
covalently	O
photolabeled	O
with	O
a	O
[	O
125I	O
]	O
-aldosterone	O
derivative	O
.	O

Sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
electrophoresis	O
showed	O
significant	O
aldosterone	O
binding	O
at	O
a	O
molecular	O
weight	O
of	O
approximately	O
50000	O
Dalton	O
which	O
was	O
absent	O
with	O
1	O
microM	O
cold	O
aldosterone	O
,	O
but	O
not	B-Negation
cortisol	I-Negation
in	O
the	O
binding	O
media	O
.	O

The	O
presence	O
of	O
the	O
sulfhydryl	O
agent	O
dithiothreitol	O
did	O
not	B-Negation
affect	I-Negation
results	I-Negation
suggesting	B-Speculation
the	I-Speculation
absence	I-Speculation
of	I-Speculation
disulfide	I-Speculation
bridges	I-Speculation
in	I-Speculation
the	I-Speculation
steroid	I-Speculation
binding	I-Speculation
domain	I-Speculation
of	I-Speculation
the	I-Speculation
receptor	I-Speculation
.	O

These	O
data	O
are	O
the	O
first	O
to	O
define	O
the	O
molecular	O
weight	O
of	O
the	O
membrane	O
receptor	O
for	O
aldosterone	O
.	O

Alpha-lipoic	O
acid	O
is	O
a	O
potent	O
inhibitor	O
of	O
NF-kappa	O
B	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
results	O
from	O
infection	O
with	O
a	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
region	O
of	O
HIV	O
proviral	O
DNA	O
contains	O
binding	O
sites	O
for	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
and	O
this	O
transcriptional	O
activator	O
appears	O
to	O
regulate	O
HIV	O
activation	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
NF-kappa	O
B	O
activation	O
.	O

The	O
present	O
study	O
was	O
based	O
on	O
reports	O
that	O
antioxidants	O
which	O
eliminate	O
ROS	O
should	O
block	O
the	O
activation	O
of	O
NF-kappa	O
B	O
and	O
subsequently	O
HIV	O
transcription	O
,	O
and	O
thus	O
antioxidants	O
can	O
be	O
used	O
as	O
therapeutic	O
agents	O
for	O
AIDS	O
.	O

Incubation	O
of	O
Jurkat	O
T	O
cells	O
(	O
1	O
x	O
10	O
(	O
6	O
)	O
cells/ml	O
)	O
with	O
a	O
natural	O
thiol	O
antioxidant	O
,	O
alpha-lipoic	O
acid	O
,	O
prior	O
to	O
the	O
stimulation	O
of	O
cells	O
was	O
found	O
to	O
inhibit	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
tumor	O
necrosis	O
factor-alpha	O
(	O
25	O
ng/ml	O
)	O
or	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
50	O
ng/ml	O
)	O
.	O

The	O
inhibitory	O
action	O
of	O
alpha-lipoic	O
acid	O
was	O
found	O
to	O
be	O
very	O
potent	O
as	O
only	O
4	O
mM	O
was	O
needed	O
for	O
a	O
complete	O
inhibition	O
,	O
whereas	O
20	O
mM	O
was	O
required	O
for	O
N-acetylcysteine	O
.	O

These	O
results	O
indicate	O
that	O
alpha-lipoic	O
acid	O
may	O
be	O
effective	O
in	O
AIDS	O
therapeutics	O
.	O

A	O
human	O
putative	O
lymphocyte	O
G0/G1	O
switch	O
gene	O
homologous	O
to	O
a	O
rodent	O
gene	O
encoding	O
a	O
zinc-binding	O
potential	O
transcription	O
factor	O
.	O

G0S24	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
genes	O
(	O
putative	O
G0/G1	O
switch	O
regulatory	O
genes	O
)	O
that	O
are	O
expressed	O
transiently	O
within	O
1-2	O
hr	O
of	O
the	O
addition	O
of	O
lectin	O
or	O
cycloheximide	O
to	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Comparison	O
of	O
a	O
full-length	O
cDNA	O
sequence	O
with	O
the	O
corresponding	O
genomic	O
sequence	O
reveals	O
an	O
open	O
reading	O
frame	O
of	O
326	O
amino	O
acids	O
,	O
distributed	O
across	O
two	O
exons	O
.	O

Potential	O
phosphorylation	O
sites	O
include	O
the	O
sequence	O
PSPTSPT	O
,	O
which	O
resembles	O
an	O
RNA	O
polymerase	O
II	O
repeat	O
reported	O
to	O
be	O
a	O
target	O
of	O
the	O
cell	O
cycle	O
control	O
kinase	O
cdc2	O
.	O

Comparison	O
of	O
the	O
derived	O
protein	O
sequence	O
with	O
those	O
of	O
rodent	O
homologs	O
allows	O
classification	O
into	O
three	O
groups	O
.	O

Group	O
1	O
contains	O
G0S24	O
and	O
the	O
rat	O
and	O
mouse	O
TIS11	O
genes	O
(	O
also	O
known	O
as	O
TTP	O
,	O
Nup475	O
,	O
and	O
Zfp36	O
)	O
.	O

Members	O
of	O
this	O
group	O
have	O
three	O
tetraproline	O
repeats	O
.	O

Groups	O
1	O
and	O
2	O
have	O
a	O
serine-rich	O
region	O
and	O
an	O
``	O
arginine	O
element	O
``	O
(	O
RRLPIF	O
)	O
at	O
the	O
carboxyl	O
terminus	O
.	O

All	O
groups	O
contain	O
cysteine-	O
and	O
histidine-rich	O
putative	O
zinc	O
finger	O
domains	O
and	O
a	O
serine-phenylalanine	O
``	O
SFS	O
``	O
domain	O
similar	O
to	O
part	O
of	O
the	O
large	O
subunit	O
of	O
eukaryotic	O
RNA	O
polymerase	O
II	O
.	O

Comparison	O
of	O
group	O
1	O
human	O
and	O
mouse	O
genomic	O
sequences	O
shows	O
high	O
conservation	O
in	O
the	O
5	O
'	O
flank	O
and	O
exons	O
.	O

A	O
CpG	O
island	O
suggests	O
expression	O
in	O
the	O
germ	O
line	O
.	O

G0S24	O
has	O
potential	O
sites	O
for	O
transcription	O
factors	O
in	O
the	O
5	O
'	O
flank	O
and	O
intron	O
;	O

these	O
include	O
a	O
serum	O
response	O
element	O
.	O

Protein	O
and	O
genomic	O
sequences	O
show	O
similarities	O
with	O
those	O
of	O
a	O
variety	O
of	O
proteins	O
involved	O
in	O
transcription	O
,	O
suggesting	O
that	O
the	O
G0S24	O
product	O
has	O
a	O
similar	O
role	O
.	O

Interleukin-4	O
inhibits	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
c-jun	O
and	O
c-fos	O
messenger	O
RNA	O
and	O
activator	O
protein-1	O
binding	O
activity	O
in	O
human	O
monocytes	O
.	O

We	O
studied	O
the	O
effect	O
of	O
interleukin-4	O
(	O
IL-4	O
)	O
on	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
two	O
immediate	O
early	O
genes	O
c-fos	O
and	O
c-jun	O
.	O

These	O
genes	O
encode	O
proteins	O
that	O
form	O
the	O
dimeric	O
complex	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
which	O
is	O
active	O
as	O
a	O
transcriptional	O
factor	O
.	O

Maximal	O
accumulation	O
of	O
either	O
c-fos	O
and	O
c-jun	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
occurred	O
30	O
minutes	O
after	O
LPS	O
addition	O
.	O

When	O
cells	O
were	O
treated	O
with	O
IL-4	O
for	O
5	O
hours	O
before	O
LPS	O
activation	O
,	O
both	O
the	O
c-fos	O
and	O
the	O
c-jun	O
mRNA	O
expression	O
was	O
decreased	O
.	O

The	O
inhibition	O
of	O
c-fos	O
and	O
c-jun	O
expression	O
by	O
IL-4	O
in	O
LPS-treated	O
cells	O
was	O
shown	O
to	O
be	O
due	O
to	O
a	O
lower	O
transcription	O
rate	O
of	O
the	O
c-fos	O
and	O
c-jun	O
genes	O
.	O

IL-4	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
stability	I-Negation
of	I-Negation
the	I-Negation
c-fos	I-Negation
and	I-Negation
c-jun	I-Negation
transcripts	I-Negation
.	O

Finally	O
,	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
evidence	O
was	O
obtained	O
that	O
IL-4	O
inhibits	O
LPS-induced	O
expression	O
of	O
AP-1	O
protein	O
.	O

These	O
data	O
indicate	O
that	O
IL-4	O
suppresses	O
the	O
induction	O
of	O
transcription	O
factors	O
in	O
human	O
activated	O
monocytes	O
.	O

Ras	O
oncogene	O
transformation	O
of	O
human	O
B	O
lymphoblasts	O
is	O
associated	O
with	O
lymphocyte	O
activation	O
and	O
with	O
a	O
block	O
of	O
differentiation	O
.	O

The	O
p21ras	O
small	O
GTP	O
binding	O
proteins	O
participate	O
in	O
signal	O
transduction	O
from	O
cell	O
surface	O
receptors	O
and	O
affect	O
neoplastic	O
transformation	O
and	O
development	O
in	O
many	O
different	O
cell	O
types	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
relationship	O
between	O
ras	O
transformation	O
and	O
differentiation	O
of	O
human	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
expression	O
of	O
the	O
T24	O
Ha-ras	O
oncogene	O
in	O
EBV-immortalized	O
B	O
lymphoblasts	O
was	O
associated	O
with	O
the	O
induction	O
of	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
subunit	O
,	O
with	O
an	O
impaired	O
immunoglobulin	O
gene	O
expression	O
,	O
altered	O
adhesion	O
properties	O
and	O
increased	O
survival	O
in	O
serum-free	O
medium	O
.	O

Since	O
induction	O
of	O
the	O
IL-2	O
receptor	O
alpha	O
subunit	O
is	O
a	O
hallmark	O
of	O
lymphocyte	O
activation	O
,	O
we	O
suggest	O
that	O
p21ras	O
naturally	O
triggers	O
B	O
cell	O
activation	O
.	O

The	O
ras-transformed	O
lymphocytes	O
displayed	O
a	O
fully	O
functional	O
IL-2r	O
,	O
as	O
assessed	O
by	O
c-fos	O
induction	O
following	O
treatment	O
with	O
IL-2	O
;	O
nevertheless	O
,	O
they	B-Negation
were	I-Negation
not	I-Negation
growth	I-Negation
stimulated	I-Negation
by	I-Negation
this	I-Negation
lymphokine	I-Negation
.	O

The	O
decreased	O
expression	O
of	O
immunoglobulin	O
genes	O
indicates	O
that	O
the	O
ras	O
oncogene	O
blocks	O
terminal	O
differentiation	O
to	O
plasma	O
cells	O
,	O
possibly	O
by	O
inhibiting	O
the	O
activity	O
of	O
lymphocyte-specific	O
transcription	O
factors	O
.	O

Somewhat	O
unexpectedly	O
,	O
the	O
constitutive	O
p21ras	O
activity	O
did	O
not	B-Negation
cause	I-Negation
an	I-Negation
increased	I-Negation
DNA	I-Negation
binding	I-Negation
of	I-Negation
transcription	I-Negation
factors	I-Negation
PEA1	I-Negation
(	I-Negation
AP1	I-Negation
)	I-Negation
,	I-Negation
PEA3	I-Negation
,	I-Negation
Oct-2	I-Negation
or	I-Negation
NF-kB	I-Negation
.	O

Transcription	O
factor	O
GATA-1	O
and	O
erythroid	O
development	O
.	O

In	O
summary	O
,	O
we	O
derived	O
an	O
experimental	O
system	O
that	O
allows	O
us	O
to	O
dissect	O
the	O
function	O
of	O
GATA-1	O
in	O
red	O
cell	O
development	O
at	O
a	O
genetic	O
level	O
.	O

We	O
have	O
established	O
the	O
essential	O
nature	O
of	O
GATA-1	O
during	O
both	O
primitive	O
and	O
definitive	O
erythropoiesis	O
.	O

By	O
ablating	O
the	O
expression	O
of	O
the	O
endogenous	O
GATA-1	O
gene	O
,	O
we	O
are	O
in	O
a	O
position	O
to	O
introduce	O
a	O
variety	O
of	O
constructs	O
that	O
harbor	O
subtle	O
modifications	O
in	O
flanking	O
or	O
protein-coding	O
sequences	O
.	O

We	O
can	O
now	O
study	O
regulatory	O
regions	O
and	O
functional	O
domains	O
of	O
the	O
protein	O
in	O
the	O
context	O
of	O
a	O
true	O
erythroid	O
environment	O
,	O
experiments	O
that	O
have	O
not	B-Negation
been	I-Negation
possible	I-Negation
heretofore	I-Negation
.	O

Although	O
the	O
assay	O
involves	O
the	O
dramatic	O
loss	O
of	O
red	O
cell	O
production	O
,	O
it	O
should	O
be	O
possible	O
to	O
define	O
important	O
regulatory	O
domains	O
that	O
can	O
then	O
be	O
assayed	O
using	O
less	O
stringent	O
systems	O
,	O
such	O
as	O
cell-free	O
extracts	O
for	O
in	O
vitro	O
transcription	O
.	O

The	O
ideal	O
situation	O
would	O
be	O
analyses	O
conducted	O
in	O
GATA-1-	O
erythroid	O
cells	O
.	O

However	O
,	O
these	B-Negation
cells	I-Negation
have	I-Negation
been	I-Negation
impossible	I-Negation
to	I-Negation
generate	I-Negation
given	O
the	O
requirement	O
of	O
GATA-1	O
for	O
Epo	O
receptor	O
expression	O
and	O
red	O
cell	O
viability	O
(	O
C.	O
Simon	O
and	O
S.	O
Orkin	O
,	O
unpublished	O
observations	O
)	O
.	O

It	O
may	O
be	O
possible	O
to	O
produce	O
such	O
cells	O
by	O
first	O
expressing	O
the	O
Epo	O
receptor	O
under	O
the	O
influence	O
of	O
a	O
constitutive	O
promoter	O
and	O
then	O
targeting	O
the	O
GATA-1	O
gene	O
.	O

If	O
GATA-1-	O
red	O
cells	O
were	O
available	O
,	O
the	O
analyses	O
would	O
involve	O
the	O
actual	O
transcription	O
of	O
or	O
chromatin	O
structure	O
surrounding	O
the	O
globin	O
genes	O
.	O

Structure-function	O
studies	O
of	O
the	O
GATA-1	O
protein	O
could	O
be	O
greatly	O
simplified	O
and	O
a	O
larger	O
number	O
of	O
mutants	O
studied	O
.	O

However	O
,	O
the	O
ES	O
cell	O
system	O
can	O
be	O
used	O
as	O
an	O
alternative	O
until	O
targeted	O
erythroleukemia	O
cells	O
become	O
available	O
.	O

Other	O
applications	O
involve	O
the	O
introduction	O
of	O
other	O
GATA-binding	O
protein	O
family	O
members	O
to	O
determine	O
whether	O
they	O
rescue	O
the	O
mutation	O
.	O

If	O
they	O
can	B-Negation
not	I-Negation
,	O
chimeric	O
proteins	O
can	O
be	O
tested	O
to	O
identify	O
which	O
amino	O
acids	O
distinguish	O
the	O
different	O
family	O
members	O
.	O

We	O
feel	O
that	O
these	O
experiments	O
are	O
vital	O
to	O
understanding	O
the	O
function	O
of	O
GATA-1	O
during	O
erythroid	O
ontogeny	O
.	O

How	O
does	O
GATA-1	O
regulate	O
red	O
cell	O
genes	O
like	O
globin	O
or	O
the	O
Epo	O
receptor	O
?	O

Once	O
we	O
identify	O
the	O
functional	O
domains	O
of	O
the	O
GATA-binding	O
proteins	O
,	O
we	O
hope	O
to	O
learn	O
what	O
proteins	O
GATA-1	O
binds	O
to	O
in	O
the	O
basic	O
transcription	O
machinery	O
or	O
in	O
chromatin	O
.	O

Is	O
GATA-1	O
necessary	O
for	O
globin	O
gene	O
switching	O
?	O

GATA-1	O
may	O
be	O
modified	O
differently	O
during	O
development	O
so	O
that	O
the	O
locus	O
control	O
region	O
can	O
interact	O
with	O
different	O
globin	O
promoters	O
.	O

We	O
may	O
find	O
that	O
one	O
region	O
of	O
the	O
protein	O
is	O
required	O
for	O
embryonic	O
expression	O
and	O
another	O
for	O
adult	O
globin	O
gene	O
expression	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
Egr-1	O
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
along	O
the	O
macrophage	O
lineage	O
.	O

We	O
have	O
isolated	O
cDNA	O
clones	O
of	O
myeloid	O
differentiation	O
primary	O
response	O
(	O
MyD	O
)	O
genes	O
,	O
activated	O
in	O
the	O
absence	O
of	O
de	O
novo	O
protein	O
synthesis	O
following	O
induction	O
for	O
differentiation	O
along	O
either	O
the	O
macrophage	O
or	O
granulocyte	O
lineage	O
in	O
human	O
myeloblastic	O
leukemia	O
HL-60	O
cells	O
.	O

One	O
cDNA	O
clone	O
of	O
a	O
primary	O
response	O
gene	O
,	O
expressed	O
upon	O
macrophage	O
differentiation	O
,	O
encoded	O
for	O
Egr-1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
.	O

The	O
Egr-1	O
gene	O
was	O
observed	O
to	O
be	O
transcriptionally	O
silent	O
in	O
HL-60	O
cells	O
,	O
but	O
active	O
in	O
U-937	O
and	O
M1	O
cells	O
,	O
the	O
latter	O
two	O
being	O
predetermined	O
for	O
macrophage	O
differentiation	O
.	O

Egr-1	O
antisense	O
oligomers	O
in	O
the	O
culture	O
media	O
blocked	O
macrophage	O
differentiation	O
in	O
both	O
myeloid	O
leukemia	O
cell	O
lines	O
and	O
normal	O
myeloblasts	O
.	O

HL-60	O
cells	O
constitutively	O
expressing	O
an	O
Egr-1	O
transgene	O
(	O
HL-60Egr-1	O
)	O
could	O
be	O
induced	O
for	O
macrophage	O
,	O
but	O
not	O
granulocyte	O
,	O
differentiation	O
.	O

These	O
observations	O
indicate	O
that	O
expression	O
of	O
Egr-1	O
is	O
essential	O
for	O
and	O
restricts	O
differentiation	O
of	O
myeloblasts	O
along	O
the	O
macrophage	O
lineage	O
.	O

Activation	O
of	O
lymphokine	O
genes	O
in	O
T	O
cells	O
:	O
role	O
of	O
cis-acting	O
DNA	O
elements	O
that	O
respond	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

Activation	O
of	O
T	O
cells	O
is	O
initiated	O
by	O
the	O
recognition	O
of	O
antigen	O
on	O
antigen	O
presenting	O
cells	O
to	O
exert	O
the	O
effector	O
functions	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Two	O
types	O
of	O
helper	O
T	O
cell	O
(	O
Th	O
)	O
clones	O
(	O
Th1	O
and	O
Th2	O
)	O
are	O
defined	O
on	O
the	O
basis	O
of	O
different	O
patterns	O
of	O
cytokine	O
(	O
lymphokine	O
)	O
secretion	O
.	O

They	O
determine	O
the	O
outcome	O
of	O
an	O
antigenic	O
response	O
toward	O
humoral	O
or	O
cell-mediated	O
immunity	O
.	O

Although	O
lymphokine	O
genes	O
are	O
coordinately	O
regulated	O
upon	O
antigen	O
stimulation	O
,	O
they	O
are	O
regulated	O
by	O
the	O
mechanisms	O
common	O
to	O
all	O
as	O
well	O
as	O
those	O
which	O
are	O
unique	O
to	O
each	O
gene	O
.	O

For	O
most	O
lymphokine	O
genes	O
,	O
a	O
combination	O
of	O
phorbol	O
esters	O
(	O
phorbol	O
12-myristate	O
13	O
acetate	O
,	O
PMA	O
)	O
and	O
calcium	O
ionophores	O
(	O
A23187	O
)	O
is	O
required	O
for	O
their	O
maximal	O
induction	O
.	O

Yet	O
phorbol	O
ester	O
alone	O
or	O
calcium	O
ionophore	O
alone	O
produce	O
several	O
lymphokines	O
.	O

The	O
production	O
of	O
the	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
completely	O
dependent	O
on	O
the	O
two	O
signals	O
.	O

We	O
have	O
previously	O
found	O
a	O
cis-acting	O
region	O
spanning	O
the	O
GM-CSF	O
promoter	O
region	O
(	O
positions	O
-95	O
to	O
+27	O
)	O
that	O
confers	O
inducibility	O
to	O
reporter	O
genes	O
in	O
transient	O
transfection	O
assays	O
.	O

Further	O
analysis	O
identified	O
three	O
elements	O
required	O
for	O
efficient	O
induction	O
,	O
referred	O
to	O
as	O
GM2	O
,	O
GC-box	O
and	O
conserved	O
lymphokine	O
element	O
(	O
CLE0	O
)	O
.	O

GM2	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
binding	O
is	O
inducible	O
by	O
PMA	O
.	O

One	O
protein	O
,	O
NF-GM2	O
is	O
similar	O
to	O
the	O
transcription	O
factor	O
NF-kB	O
.	O

GC-box	O
is	O
a	O
binding	O
site	O
for	O
constitutively	O
bound	O
proteins	O
.	O

CLEO	O
defines	O
a	O
binding	O
site	O
for	O
protein	O
(	O
s	O
)	O
whose	O
optimum	O
binding	O
is	O
stimulated	O
by	O
PMA	O
and	O
A23187	O
.	O

Viral	O
trans-activators	O
such	O
as	O
Tax	O
(	O
human	O
T	O
cell	O
leukemia	O
virus-1	O
,	O
HTLV-1	O
)	O
and	O
E2	O
(	O
bovine	O
papilloma	O
virus	O
,	O
BPV	O
)	O
proteins	O
are	O
other	O
agents	O
which	O
activate	O
lymphokine	O
gene	O
expression	O
by	O
bypassing	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
mediated	O
signaling	O
.	O

The	O
trans-activation	O
domain	O
of	O
E2	O
and	O
Tax	O
is	O
interchangeable	O
although	O
they	O
have	O
no	B-Negation
obvious	I-Negation
sequence	I-Negation
homology	I-Negation
between	I-Negation
them	I-Negation
.	O

The	O
viral	O
trans-activators	O
appear	O
to	O
target	O
specific	O
DNA	O
binding	O
protein	O
such	O
as	O
NF-kB	O
and	O
Sp1	O
to	O
cis-acting	O
DNA	O
site	O
and	O
promote	O
lymphokine	O
gene	O
expression	O
without	O
TCR-mediated	O
stimulation	O
.	O

Expression	O
of	O
tal-1	O
and	O
GATA-binding	O
proteins	O
during	O
human	O
hematopoiesis	O
.	O

Tal-1	O
rearrangements	O
are	O
associated	O
with	O
nearly	O
30	O
%	O
of	O
human	O
T	O
acute	O
lymphoblastic	O
leukemia	O
.	O

Tal-1	O
gene	O
encodes	O
a	O
putative	O
transcription	O
factor	O
with	O
a	O
basic	O
helix-loop-helix	O
domain	O
and	O
is	O
known	O
to	O
be	O
predominantly	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

We	O
investigated	O
the	O
pattern	O
of	O
tal-1	O
expression	O
in	O
purified	O
human	O
hematopoietic	O
cells	O
by	O
in	O
situ	O
hybridization	O
and	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Both	O
methods	O
demonstrated	O
that	O
the	O
tal-1	O
gene	O
is	O
expressed	O
in	O
megakaryocytes	O
and	O
erythroblasts	O
as	O
well	O
as	O
in	O
basophilic	O
granulocytes	O
.	O

In	O
addition	O
,	O
our	O
results	O
indicate	O
that	O
the	O
tal-1	O
1A	O
promoter	O
,	O
which	O
contains	O
two	O
consensus	O
GATA-binding	O
sites	O
,	O
is	O
active	O
mainly	O
in	O
these	O
lineages	O
.	O

Because	O
the	O
GATA-1	O
gene	O
is	O
known	O
to	O
transactivate	O
several	O
genes	O
specific	O
for	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mastocytic/basophilic	O
lineages	O
,	O
we	O
studied	O
GATA-1	O
expression	O
in	O
these	O
purified	O
hematopoietic	O
cells	O
.	O

We	O
found	O
that	O
GATA-1	O
and	O
tal-1	O
genes	O
are	O
coexpressed	O
in	O
these	O
three	O
lineages	O
.	O

Remarkably	O
,	O
the	O
expression	O
of	O
both	O
genes	O
is	O
downmodulated	O
during	O
erythroid	O
and	O
megakaryocytic	O
terminal	O
maturation	O
.	O

In	O
immature	O
hematopoietic	O
cells	O
,	O
tal-1	O
and	O
GATA-1	O
genes	O
are	O
coexpressed	O
in	O
committed	O
progenitors	O
cells	O
(	O
CD34+/CD38	O
(	O
2+	O
)	O
)	O
,	O
whereas	O
they	O
are	O
not	B-Negation
detectable	I-Negation
in	I-Negation
the	I-Negation
most	I-Negation
primitive	I-Negation
cells	I-Negation
(	I-Negation
CD34	I-Negation
(	I-Negation
2+	I-Negation
)	I-Negation
/CD38-	I-Negation
)	I-Negation
.	O

In	O
contrast	O
,	O
GATA-2	O
is	O
strongly	O
expressed	O
in	O
both	O
most	O
primitive	O
and	O
committed	O
progenitors	O
cells	O
,	O
whereas	O
GATA-3	O
is	O
mostly	O
detected	O
in	O
most	O
primitive	O
ones	O
.	O

Altogether	O
our	O
results	O
strongly	O
suggest	O
that	O
GATA-1	O
modulates	O
the	O
transcription	O
of	O
tal-1	O
during	O
the	O
differentiation	O
of	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
basosophilic	O
lineages	O
.	O

Cell-type-specific	O
transactivation	O
of	O
the	O
parathyroid	O
hormone-related	O
protein	O
gene	O
promoter	O
by	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
tax	O
and	O
HTLV-II	O
tax	O
proteins	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
and	O
HTLV-II	O
Tax	O
proteins	O
are	O
potent	O
transactivators	O
of	O
viral	O
and	O
cellular	O
gene	O
expression	O
.	O

Using	O
deletion	O
mutants	O
,	O
the	O
downstream	O
parathyroid	O
hormone-related	O
protein	O
(	O
PTHrP	O
)	O
promoter	O
is	O
shown	O
to	O
be	O
responsive	O
to	O
both	O
HTLV-I	O
and	O
HTLV-II	O
Tax	O
as	O
well	O
as	O
the	O
AP1/c-jun	O
proto-oncogene	O
.	O

Transactivation	O
of	O
PTHrP	O
by	O
Tax	O
was	O
seen	O
in	O
T	O
cells	O
but	O
not	B-Negation
in	I-Negation
B-cell	I-Negation
lines	I-Negation
or	I-Negation
fibroblasts	I-Negation
.	O

A	O
carboxy	O
terminal	O
Tax	O
deletion	O
mutant	O
was	O
deficient	O
in	O
transactivation	O
of	O
both	O
the	O
PTHrP	O
and	O
IL2R	O
alpha	O
promoters	O
but	O
not	B-Negation
the	I-Negation
HTLV-I	I-Negation
long	I-Negation
terminal	I-Negation
repeat	I-Negation
(	I-Negation
LTR	I-Negation
)	I-Negation
.	O

Exogenous	O
provision	O
of	O
NFkB	O
rescued	O
IL2R	O
alpha	O
expression	O
but	O
not	B-Negation
the	I-Negation
PTHrP	I-Negation
promoter	I-Negation
.	O

Thus	O
,	O
HTLV-I	O
Tax	O
,	O
HTLV-II	O
Tax	O
,	O
and	O
c-jun	O
transactivate	O
PTHrP	O
and	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
hypercalcemia	O
in	O
adult	O
T-cell	O
leukemia	O
.	O

Interleukin-3	O
expression	O
by	O
activated	O
T	O
cells	O
involves	O
an	O
inducible	O
,	O
T-cell-specific	O
factor	O
and	O
an	O
octamer	O
binding	O
protein	O
.	O

Interleukin-3	O
(	O
IL-3	O
)	O
is	O
exclusively	O
expressed	O
by	O
activated	O
T	O
and	O
natural	O
killer	O
cells	O
,	O
a	O
function	O
that	O
is	O
tightly	O
controlled	O
both	O
in	O
a	O
lineage-specific	O
and	O
in	O
a	O
stimulation-dependent	O
manner	O
.	O

We	O
have	O
investigated	O
the	O
protein	O
binding	O
characteristics	O
and	O
functional	O
importance	O
of	O
the	O
ACT-1-activating	O
region	O
of	O
the	O
IL-3	O
promoter	O
.	O

This	O
region	O
binds	O
an	O
inducible	O
,	O
T-cell-specific	O
factor	O
over	O
its	O
5	O
'	O
end	O
,	O
a	O
site	O
that	O
is	O
necessary	O
for	O
the	O
expression	O
of	O
IL-3	O
in	O
the	O
absence	O
of	O
other	O
upstream	O
elements	O
.	O

Over	O
its	O
3	O
'	O
end	O
,	O
it	O
binds	O
a	O
factor	O
that	O
is	O
ubiquitously	O
and	O
constitutively	O
expressed	O
.	O

This	O
factor	O
is	O
Oct-1	O
or	O
an	O
immunologically	O
related	O
octamer-binding	O
protein	O
,	O
and	O
it	O
plays	O
a	O
role	O
in	O
coordinating	O
the	O
activity	O
of	O
several	O
regulatory	O
elements	O
.	O

These	O
characteristics	O
make	O
the	O
ACT-1	O
site	O
analogous	O
to	O
the	O
activating	O
ARRE-1	O
site	O
in	O
the	O
IL-2	O
promoter	O
.	O

Furthermore	O
,	O
and	O
despite	O
a	O
lack	B-Negation
of	I-Negation
sequence	I-Negation
homology	I-Negation
,	O
the	O
promoters	O
of	O
IL-3	O
and	O
IL-2	O
share	O
an	O
organizational	O
pattern	O
of	O
regulatory	O
elements	O
that	B-Speculation
is	I-Speculation
likely	I-Speculation
to	I-Speculation
be	I-Speculation
important	I-Speculation
for	I-Speculation
the	I-Speculation
T-cell-specific	I-Speculation
expression	I-Speculation
of	I-Speculation
these	I-Speculation
genes	I-Speculation
.	O

I	O
kappa	O
B/MAD-3	O
masks	O
the	O
nuclear	O
localization	O
signal	O
of	O
NF-kappa	O
B	O
p65	O
and	O
requires	O
the	O
transactivation	O
domain	O
to	O
inhibit	O
NF-kappa	O
B	O
p65	O
DNA	O
binding	O
.	O

The	O
active	O
nuclear	O
form	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
complex	O
is	O
composed	O
of	O
two	O
DNA	O
binding	O
subunits	O
,	O
NF-kappa	O
B	O
p65	O
and	O
NF-kappa	O
B	O
p50	O
,	O
both	O
of	O
which	O
share	O
extensive	O
N-terminal	O
sequence	O
homology	O
with	O
the	O
v-rel	O
oncogene	O
product	O
.	O

The	O
NF-kappa	O
B	O
p65	O
subunit	O
provides	O
the	O
transactivation	O
activity	O
in	O
this	O
complex	O
and	O
serves	O
as	O
an	O
intracellular	O
receptor	O
for	O
a	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappa	O
B	O
,	O
termed	O
I	O
kappa	O
B	O
.	O

In	O
contrast	O
,	O
NF-kappa	O
B	O
p50	O
alone	O
fails	B-Negation
to	I-Negation
stimulate	I-Negation
kappa	I-Negation
B-directed	I-Negation
transcription	I-Negation
,	O
and	O
based	O
on	O
prior	O
in	O
vitro	O
studies	O
,	O
is	B-Negation
not	I-Negation
directly	I-Negation
regulated	I-Negation
by	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
critical	O
regulatory	O
interaction	O
between	O
NF-kappa	O
B	O
and	O
I	O
kappa	O
B/MAD-3	O
,	O
a	O
series	O
of	O
human	O
NF-kappa	O
B	O
p65	O
mutants	O
was	O
identified	O
that	O
functionally	O
segregated	O
DNA	O
binding	O
,	O
I	O
kappa	O
B-mediated	O
inhibition	O
,	O
and	O
I	O
kappa	O
B-induced	O
nuclear	O
exclusion	O
of	O
this	O
transcription	O
factor	O
.	O

Results	O
from	O
in	O
vivo	O
expression	O
studies	O
performed	O
with	O
these	O
NF-kappa	O
B	O
p65	O
mutants	O
revealed	O
the	O
following	O
:	O

1	O
)	O
I	O
kappa	O
B/MAD-3	O
completely	O
inhibits	O
NF-kappa	O
B	O
p65-dependent	O
transcriptional	O
activation	O
mediated	O
through	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
kappa	O
B	O
enhancer	O
in	O
human	O
T	O
lymphocytes	O
,	O
2	O
)	O
the	O
binding	O
of	O
I	O
kappa	O
B/MAD-3	O
to	O
NF-kappa	O
B	O
p65	O
is	O
sufficient	O
to	O
retarget	O
NF-kappa	O
B	O
p65	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
,	O
3	O
)	O
selective	O
deletion	O
of	O
the	O
functional	O
nuclear	O
localization	O
signal	O
present	O
in	O
the	O
Rel	O
homology	O
domain	O
of	O
NF-kappa	O
B	O
p65	O
disrupts	O
its	O
ability	O
to	O
engage	O
I	O
kappa	O
B/MAD-3	O
,	O
and	O
4	O
)	O
the	O
unique	O
C-terminus	O
of	O
NF-kappa	O
B	O
p65	O
attenuates	O
its	O
own	O
nuclear	O
localization	O
and	O
contains	O
sequences	O
that	O
are	O
required	O
for	O
I	O
kappa	O
B-mediated	O
inhibition	O
of	O
NF-kappa	O
B	O
p65	O
DNA	O
binding	O
activity	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
nuclear	O
localization	O
signal	O
and	O
transactivation	O
domain	O
of	O
NF-kappa	O
B	O
p65	O
constitute	O
a	O
bipartite	O
system	O
that	O
is	O
critically	O
involved	O
in	O
the	O
inhibitory	O
function	O
of	O
I	O
kappa	O
B/MAD-3	O
.	O

Unexpectedly	O
,	O
our	O
in	O
vivo	O
studies	O
also	O
demonstrate	O
that	O
I	O
kappa	O
B/MAD-3	O
binds	O
directly	O
to	O
NF-kappa	O
B	O
p50	O
.	O

This	O
interaction	O
is	O
functional	O
as	O
it	O
leads	O
to	O
retargeting	O
of	O
NF-kappa	O
B	O
p50	O
from	O
the	O
nucleus	O
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
no	B-Negation
loss	I-Negation
of	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
is	I-Negation
observed	I-Negation
,	O
presumably	B-Speculation
reflecting	I-Speculation
the	I-Speculation
unique	I-Speculation
C-terminal	I-Speculation
domain	I-Speculation
that	I-Speculation
is	I-Speculation
distinct	I-Speculation
from	I-Speculation
that	I-Speculation
present	I-Speculation
in	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
p65	I-Speculation
.	O

Surrogate	O
thyroglobulin	O
receptors	O
and	O
T	O
cell	O
proliferation	O
in	O
Hashimoto	O
's	O
thyroiditis	O
.	O

Immunoglobulin	O
molecules	O
on	O
the	O
surface	O
of	O
a	O
B	O
lymphocyte	O
are	O
the	O
endogenous	O
``	O
receptors	O
``	O
to	O
which	O
specific	O
antigens	O
bind	O
.	O

Studies	O
in	O
mice	O
have	O
shown	O
that	O
a	O
monoclonal	O
antibody	O
,	O
conjugated	O
with	O
palmitate	O
to	O
provide	O
a	O
lipid	O
tail	O
,	O
can	O
be	O
inserted	O
into	O
the	O
cell	O
membrane	O
to	O
provide	O
a	O
``	O
surrogate	O
``	O
antigen	O
receptor	O
.	O

We	O
have	O
investigated	O
whether	O
a	O
palmitate	O
conjugate	O
of	O
a	O
human	O
monoclonal	O
antibody	O
specific	O
for	O
thyroglobulin	O
(	O
TG	O
)	O
could	O
function	O
as	O
a	O
surrogate	O
TG	O
receptor	O
on	O
blood	O
mononuclear	O
cells	O
separated	O
into	O
fractions	O
enriched	O
for	O
T	O
cells	O
or	O
depleted	O
of	O
T	O
cells	O
(	O
non-T	O
cells	O
)	O
.	O

Using	O
flow	O
cytometry	O
,	O
we	O
detected	O
surrogate	O
TG	O
receptors	O
on	O
non-T	O
(	O
but	O
not	B-Negation
on	I-Negation
T	I-Negation
)	O
cells	O
from	O
11	O
of	O
11	O
individuals	O
studied	O
(	O
5	O
Hashimoto	O
patients	O
and	O
6	O
control	O
donors	O
)	O
.	O

In	O
contrast	O
,	O
endogenous	O
TG	O
receptors	O
could	O
only	O
be	O
detected	O
on	O
non-T	O
cells	O
from	O
1	O
of	O
3	O
Hashimoto	O
patients	O
and	O
from	O
0	O
of	O
4	O
control	O
donors	O
.	O

Because	O
of	O
the	O
efficient	O
binding	O
of	O
TG	O
by	O
surrogate	O
receptors	O
on	O
non-T	O
cells	O
,	O
we	O
assessed	O
the	O
ability	O
of	O
such	O
cells	O
to	O
present	O
TG	O
to	O
T	O
cells	O
.	O

Proliferation	O
in	O
response	O
to	O
TG	O
was	O
observed	O
in	O
T	O
cells	O
from	O
only	O
1	O
of	O
5	O
Hashimoto	O
patients	O
.	O

This	O
low	O
frequency	O
of	O
response	O
was	O
no	B-Negation
different	I-Negation
from	I-Negation
that	I-Negation
previously	I-Negation
detected	I-Negation
using	I-Negation
cultures	I-Negation
of	I-Negation
T	I-Negation
cells	I-Negation
and	I-Negation
autologous	I-Negation
dendritic	I-Negation
cells	I-Negation
.	O

Therefore	O
,	O
the	B-Negation
successful	I-Negation
generation	I-Negation
of	I-Negation
surrogate	I-Negation
receptors	I-Negation
on	I-Negation
non-T	I-Negation
cells	I-Negation
is	I-Negation
not	I-Negation
associated	I-Negation
with	I-Negation
more	I-Negation
efficient	I-Negation
TG	I-Negation
presentation	I-Negation
of	I-Negation
T	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
the	O
significance	O
of	O
the	O
present	O
study	O
is	O
that	O
the	O
T	O
cells	O
,	O
not	B-Negation
the	I-Negation
antigen-presenting	I-Negation
cells	I-Negation
,	O
are	B-Speculation
likely	I-Speculation
to	I-Speculation
be	I-Speculation
the	I-Speculation
limiting	I-Speculation
element	I-Speculation
in	I-Speculation
the	I-Speculation
T	I-Speculation
cell	I-Speculation
proliferative	I-Speculation
response	I-Speculation
to	I-Speculation
TG	I-Speculation
and	I-Speculation
other	I-Speculation
thyroid	I-Speculation
autoantigens	I-Speculation
.	O

The	O
Epstein-Barr	O
virus	O
nuclear	O
antigen	O
2	O
interacts	O
with	O
an	O
EBNA2	O
responsive	O
cis-element	O
of	O
the	O
terminal	O
protein	O
1	O
gene	O
promoter	O
.	O

The	O
Epstein-Barr	O
virus	O
protein	O
EBNA2	O
acts	O
as	O
a	O
transcriptional	O
activator	O
of	O
cellular	O
and	O
viral	O
genes	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
immortalization	O
of	O
human	O
primary	O
B-cells	O
by	O
EBV	O
.	O

We	O
have	O
shown	O
previously	O
that	O
EBNA2	O
transactivates	O
the	O
promoters	O
of	O
the	O
latent	O
membrane	O
antigens	O
LMP	O
,	O
TP1	O
and	O
TP2	O
.	O

The	O
promoter	O
of	O
the	O
TP1	O
gene	O
was	O
chosen	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
molecular	O
mechanism	O
of	O
EBNA2	O
mediated	O
transactivation	O
.	O

To	O
identify	O
an	O
EBNA2	O
dependent	O
cis-acting	O
element	O
,	O
various	O
TP1	O
promoter-reporter	O
gene	O
constructs	O
were	O
transfected	O
in	O
the	O
absence	O
and	O
presence	O
of	O
an	O
EBNA2	O
expression	O
vector	O
into	O
the	O
established	O
B-cell	O
line	O
BL41-P3HR1	O
.	O

We	O
were	O
able	O
to	O
delineate	O
an	O
81	O
bp	O
EBNA2	O
responsive	O
region	O
between	O
-258	O
and	O
-177	O
relative	O
to	O
the	O
TP1	O
RNA	O
start	O
site	O
.	O

The	O
element	O
worked	O
in	O
either	O
orientation	O
and	O
could	O
mediate	O
EBNA2	O
dependent	O
transactivation	O
on	O
a	O
heterologous	O
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
revealed	O
three	O
specific	O
protein-DNA	O
complexes	O
formed	O
with	O
sequences	O
of	O
the	O
EBNA2	O
responsive	O
element	O
.	O

Two	O
of	O
these	O
were	O
not	B-Negation
cell	I-Negation
type	I-Negation
specific	I-Negation
,	O
but	O
the	O
third	O
was	O
detected	O
only	O
in	O
EBNA2	O
positive	O
cell	O
extracts	O
.	O

Gel-shift	O
analysis	O
in	O
the	O
presence	O
of	O
EBNA2	O
specific	O
monoclonal	O
antibodies	O
revealed	O
that	O
EBNA2	O
is	O
a	O
component	O
of	O
the	O
third	O
complex	O
.	O

Thus	O
,	O
these	O
experiments	O
demonstrate	O
that	O
EBNA2	O
interacts	O
with	O
an	O
EBNA2	O
responsive	O
cis-element	O
of	O
the	O
TP1	O
promoter	O
.	O

ras	O
protein	O
activity	O
is	O
essential	O
for	O
T-cell	O
antigen	O
receptor	O
signal	O
transduction	O
.	O

In	O
a	O
Jurkat	O
cell	O
model	O
of	O
T-cell	O
activation	O
an	O
interleukin-2	O
promoter/reporter	O
gene	O
construct	O
was	O
activated	O
by	O
antigen	O
receptor	O
agonism	O
in	O
combination	O
with	O
the	O
lymphokine	O
interleukin-1	O
.	O

Antigen	O
receptor	O
signals	O
could	O
be	O
mimicked	O
by	O
suboptimal	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
with	O
phorbol	O
esters	O
in	O
combination	O
with	O
calcium	O
mobilization	O
by	O
an	O
ionophore	O
.	O

In	O
cotransfection	O
experiments	O
,	O
oncogenic	O
rats	O
obviated	O
the	O
need	O
for	O
PKC	O
stimulation	O
but	O
did	O
not	B-Negation
replace	I-Negation
either	I-Negation
the	I-Negation
calcium	I-Negation
signal	I-Negation
or	I-Negation
interleukin-1	I-Negation
.	O

Activated	O
ras	O
expression	O
also	O
replaced	O
the	O
requirement	O
for	O
PKC	O
stimulation	O
in	O
activation	O
of	O
the	O
T-cell	O
transcription	O
factor	O
NF-AT	O
.	O

A	O
dominant	O
inhibitory	O
ras	O
mutant	O
specifically	O
blocked	O
antigen	O
receptor	O
agonism	O
,	O
indicating	O
that	O
ras	O
activity	O
is	O
required	O
for	O
antigen	O
receptor	O
signaling	O
.	O

In	O
addition	O
,	O
an	O
inhibitor	O
of	O
PKC	O
blocked	O
both	O
activated	O
ras	O
and	O
phorbol	O
ester	O
stimulation	O
,	O
suggesting	O
a	O
role	O
for	O
ras	O
upstream	O
of	O
PKC	O
.	O

Characterization	O
of	O
the	O
nuclear	O
and	O
cytoplasmic	O
components	O
of	O
the	O
lymphoid-specific	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
complex	O
.	O

The	O
lymphoid-specific	O
transcription	O
complex	O
,	O
NF-AT	O
,	O
is	O
involved	O
in	O
early	O
gene	O
activation	O
in	O
T	O
cells	O
and	O
is	O
assembled	O
from	O
a	O
pre-existing	O
,	O
T	O
cell	O
restricted	O
cytoplasmic	O
factor	O
and	O
an	O
inducible	O
ubiquitous	O
nuclear	O
component	O
within	O
30	O
min	O
after	O
activation	O
through	O
the	O
antigen	O
receptor	O
.	O

Recent	O
studies	O
have	O
implicated	O
the	O
family	O
of	O
AP1	O
factors	O
as	O
components	O
of	O
the	O
murine	O
NF-AT	O
complex	O
.	O

Evidence	O
is	O
provided	O
here	O
that	O
the	O
nuclear	O
component	O
of	O
human	O
NF-AT	O
contains	O
the	O
phorbol	O
ester-inducible	O
transcription	O
factor	O
AP1	O
(	O
Jun/Fos	O
)	O
.	O

We	O
further	O
characterize	O
which	O
AP1	O
family	O
members	O
can	O
assume	O
this	O
role	O
.	O

Antisera	O
to	O
Fos	O
inhibits	O
NF-AT	O
DNA	O
binding	O
as	O
does	O
an	O
oligonucleotide	O
containing	O
a	O
binding	O
site	O
for	O
AP1	O
.	O

Constitutive	O
expression	O
in	O
vivo	O
of	O
Fos	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
Fra-1	O
,	O
eliminates	O
the	O
requirement	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
stimulation	O
,	O
leaving	O
NF-AT-directed	O
transcription	O
responsive	O
to	O
calcium	O
ionophore	O
alone	O
.	O

Overexpression	O
of	O
cJun	O
or	O
JunD	O
,	O
but	O
not	B-Negation
JunB	I-Negation
,	O
also	O
eliminates	O
the	O
requirement	O
for	O
PMA	O
,	O
indicating	B-Speculation
that	I-Speculation
many	I-Speculation
but	I-Speculation
not	I-Speculation
all	I-Speculation
Jun-	I-Speculation
and	I-Speculation
Fos-related	I-Speculation
proteins	I-Speculation
functionally	I-Speculation
activate	I-Speculation
NF-AT-dependent	I-Speculation
transcription	I-Speculation
in	I-Speculation
the	I-Speculation
presence	I-Speculation
of	I-Speculation
the	I-Speculation
cytoplasmic	I-Speculation
component	I-Speculation
.	O

NF-AT	O
DNA	O
binding	O
can	O
be	O
reconstituted	O
in	O
vitro	O
using	O
semi-purified	O
AP1	O
proteins	O
mixed	O
with	O
cytosol	O
from	O
T	O
lymphocytes	O
.	O

Fos	O
proteins	O
are	O
not	B-Negation
needed	I-Negation
for	I-Negation
this	I-Negation
reconstitution	I-Negation
,	O
and	O
although	O
JunB	O
is	O
not	B-Negation
functional	I-Negation
,	O
it	O
can	B-Speculation
participate	I-Speculation
in	I-Speculation
the	I-Speculation
NF-AT	I-Speculation
DNA	I-Speculation
binding	I-Speculation
complex	I-Speculation
.	O

Finally	O
,	O
we	O
have	O
partially	O
purified	O
the	O
cytoplasmic	O
component	O
of	O
NF-AT	O
and	O
show	O
by	O
elution	O
and	O
renaturation	O
from	O
SDS-polyacrylamide	O
gel	O
electrophoresis	O
gels	O
that	O
it	O
has	O
a	O
molecular	O
mass	O
between	O
94	O
and	O
116	O
kDa	O
and	O
may	O
have	O
multiple	O
differentially	O
modified	O
forms	O
.	O

The	O
c-rel	O
protooncogene	O
product	O
represses	O
NF-kappa	O
B	O
p65-mediated	O
transcriptional	O
activation	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
type	O
1	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
and	O
the	O
5	O
'	O
regulatory	O
region	O
of	O
the	O
gene	O
encoding	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
subunit	O
(	O
IL-2R	O
alpha	O
)	O
share	O
functional	O
kappa	O
B	O
enhancer	O
elements	O
involved	O
in	O
the	O
regulation	O
of	O
these	O
inducible	O
transcription	O
units	O
during	O
T-cell	O
activation	O
.	O

These	O
kappa	O
B	O
enhancer	O
elements	O
are	O
recognized	O
by	O
a	O
structurally	O
related	O
family	O
of	O
interactive	O
proteins	O
that	O
includes	O
p50	O
,	O
p65	O
,	O
and	O
the	O
product	O
of	O
the	O
c-rel	O
protooncogene	O
(	O
c-Rel	O
)	O
.	O

Recent	O
biochemical	O
studies	O
have	O
shown	O
that	O
p65	O
and	O
p50	O
form	O
the	O
prototypical	O
NF-kappa	O
B	O
complex	O
,	O
which	O
is	O
rapidly	O
translocated	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
during	O
T-cell	O
activation	O
.	O

This	O
intracellular	O
signaling	O
complex	O
potently	O
stimulates	O
kappa	O
B-directed	O
transcription	O
from	O
either	O
the	O
HIV-1	O
LTR	O
or	O
the	O
IL-2R	O
alpha	O
promoter	O
via	O
the	O
strong	O
transactivation	O
domain	O
present	O
in	O
p65	O
.	O

We	O
now	O
demonstrate	O
that	O
nuclear	O
expression	O
of	O
human	O
c-Rel	O
,	O
which	O
is	O
induced	O
by	O
either	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
with	O
delayed	O
kinetics	O
relative	O
to	O
p65	O
,	O
markedly	O
represses	O
p65-mediated	O
activation	O
of	O
these	O
transcription	O
units	O
.	O

These	O
inhibitory	O
effects	O
of	O
c-Rel	O
correlate	O
with	O
its	O
DNA-binding	O
activity	O
but	O
not	B-Negation
with	I-Negation
its	I-Negation
ability	I-Negation
to	I-Negation
heterodimerize	I-Negation
with	I-Negation
p50	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
c-Rel	I-Speculation
inhibition	I-Speculation
involves	I-Speculation
competition	I-Speculation
with	I-Speculation
p50/p65	I-Speculation
for	I-Speculation
occupancy	I-Speculation
of	I-Speculation
the	I-Speculation
kappa	I-Speculation
B	I-Speculation
enhancer	I-Speculation
element	I-Speculation
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
one	O
function	O
of	O
c-Rel	O
is	O
as	O
a	O
physiologic	O
repressor	O
of	O
the	O
HIV-1	O
LTR	O
and	O
IL-2R	O
alpha	O
promoters	O
,	O
serving	O
to	O
efficiently	O
counter	O
the	O
strong	O
transcriptional	O
activating	O
effects	O
of	O
p65	O
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	O
II	O
MHC	O
X1	O
box	O
DNA-binding	O
proteins	O
in	O
wild-type	O
and	O
class	O
II-deficient	O
B	O
cells	O
.	O

The	O
X	O
box	O
region	O
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
in	O
B	O
lymphocytes	O
.	O

Although	O
several	O
class	O
II	O
promoter-specific	O
DNA	O
binding	O
factors	O
have	O
been	O
described	O
,	O
only	O
the	O
X	O
box	O
region	O
factor	O
,	O
RFX	O
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
class	O
II-deficient	O
congenital	O
immunodeficiency	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	O
box	O
DNA-binding	O
proteins	O
in	O
class	O
II	O
gene	O
expression	O
,	O
the	O
role	O
of	O
the	O
X	O
box	O
region	O
was	O
examined	O
in	O
both	O
class	O
II-positive	O
and	O
-negative	O
lymphoid	O
cells	O
.	O

In	O
addition	O
to	O
the	O
wild-type	O
B	O
cell	O
line	O
Raji	O
,	O
two	O
class	O
II	O
transcriptional	O
mutant	O
cell	O
lines	O
,	O
SJO	O
and	O
RJ2.2.5	O
,	O
and	O
Jurkat	O
,	O
a	O
class	O
II	O
negative	O
T	O
cell	O
line	O
,	O
were	O
examined	O
.	O

In	O
contrast	O
to	O
wild-type	O
B	O
cells	O
,	O
neither	B-Negation
of	I-Negation
the	I-Negation
class	I-Negation
II	I-Negation
mutant	I-Negation
cell	I-Negation
lines	I-Negation
could	I-Negation
use	I-Negation
the	I-Negation
X	I-Negation
box	I-Negation
region	I-Negation
to	I-Negation
direct	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
a	I-Negation
transiently	I-Negation
transfected	I-Negation
reporter	I-Negation
gene	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
the	I-Speculation
X	I-Speculation
box-dependent	I-Speculation
transcriptional	I-Speculation
pathway	I-Speculation
is	I-Speculation
defective	I-Speculation
in	I-Speculation
these	I-Speculation
cells	I-Speculation
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	O
box	O
DNA-binding	O
protein	O
RFX	O
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild-type	O
B	O
cells	O
and	O
the	O
mutant	O
RJ2.2.5	O
but	O
was	O
absent	O
in	O
SJO	O
and	O
Jurkat	O
.	O

However	O
,	O
other	O
X1	O
box-specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	O
lines	O
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	O
binding	O
proteins	O
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	O
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA-binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1-specific	O
factors	O
.	O

One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	O
activity	O
.	O

A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	O
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	B-Negation
detectable	I-Negation
levels	I-Negation
of	I-Negation
the	I-Negation
band	I-Negation
1pk	I-Negation
activity	I-Negation
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box-specific	O
DNA-binding	O
activities	O
exist	O
in	O
all	O
lymphoid	O
cells	O
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	O
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

Replication	O
of	O
type	O
1	O
human	O
immunodeficiency	O
viruses	O
containing	O
linker	O
substitution	O
mutations	O
in	O
the	O
-201	O
to	O
-130	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
.	O

In	O
previous	O
transfection	O
analyses	O
using	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
system	O
,	O
we	O
determined	O
that	O
linker	O
substitution	O
(	O
LS	O
)	O
mutations	O
between	O
-201	O
and	O
-130	O
(	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
caused	O
moderate	O
decreases	O
in	O
LTR	O
transcriptional	O
activity	O
in	O
a	O
T-cell	O
line	O
(	O
S.L.Zeichner	O
,	O
J.Y.H.	O
Kim	O
,	O
and	O
J.C.Alwine	O
,	O
J.Virol.65:2436-2444	O
,	O
1991	O
)	O
.	O

In	O
order	O
to	O
confirm	O
the	O
significance	O
of	O
this	O
region	O
in	O
the	O
context	O
of	O
viral	O
replication	O
,	O
we	O
constructed	O
several	O
of	O
these	O
LS	O
mutations	O
(	O
-201	O
to	O
-184	O
,	O
-183	O
to	O
-166	O
,	O
-165	O
to	O
-148	O
,	O
and	O
-148	O
to	O
-130	O
)	O
in	O
proviruses	O
and	O
prepared	O
viral	O
stocks	O
by	O
cocultivation	O
of	O
transfected	O
RD	O
cells	O
with	O
CEMx174	O
cells	O
.	O

In	O
addition	O
,	O
two	O
mutations	O
between	O
-93	O
and	O
-76	O
and	O
between	O
-75	O
and	O
-58	O
were	O
utilized	O
,	O
since	O
they	O
affect	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
-	O
and	O
Sp1-binding	O
sites	O
and	O
were	O
expected	O
to	O
diminish	O
viral	O
replication	O
.	O

Our	O
results	O
suggest	O
that	O
while	O
transfection	O
analyses	O
offer	O
an	O
adequate	O
approximation	O
of	O
the	O
effects	O
of	O
the	O
LS	O
mutations	O
,	O
the	O
analysis	O
of	O
viral	O
replication	O
using	O
a	O
mutant	O
viral	O
stock	O
presents	O
a	O
more	O
accurate	O
picture	O
,	O
which	O
is	O
sometimes	O
at	O
variance	O
with	O
the	O
transfection	O
results	O
.	O

Three	O
mutants	O
(	O
-201/-184	O
NXS	O
,	O
-165/-148	O
NXS	O
,	O
and	O
-147/-130	O
NXS	O
)	O
had	O
effects	O
on	O
viral	O
replication	O
that	O
were	O
much	O
more	O
severe	O
than	O
the	O
effects	O
predicted	O
from	O
their	O
performance	O
in	O
transfection	O
analyses	O
,	O
and	O
the	B-Negation
effects	I-Negation
of	I-Negation
two	I-Negation
LS	I-Negation
mutations	I-Negation
(	I-Negation
-201/-184	I-Negation
NXS	I-Negation
and	I-Negation
-183/-166	I-Negation
NXS	I-Negation
)	I-Negation
were	I-Negation
not	I-Negation
predicted	I-Negation
by	I-Negation
their	I-Negation
effects	I-Negation
in	I-Negation
transfection	I-Negation
.	O

In	O
addition	O
,	O
we	O
observed	O
cell	O
type-specific	O
permissiveness	O
to	O
replication	O
of	O
some	O
mutant	O
viruses	O
.	O

In	O
the	O
cell	O
types	O
tested	O
,	O
the	O
LS	O
mutations	O
indicated	O
an	O
apparent	O
requirement	O
not	O
only	O
for	O
the	O
intact	O
NF-kappa	O
B	O
and	O
SP1-binding	O
sites	O
but	O
also	O
for	O
several	O
regions	O
between	O
-201	O
and	O
-130	O
not	O
previously	O
associated	O
with	O
viral	O
infectivity	O
.	O

Dimerization	O
of	O
NF-KB2	O
with	O
RelA	O
(	O
p65	O
)	O
regulates	O
DNA	O
binding	O
,	O
transcriptional	O
activation	O
,	O
and	O
inhibition	O
by	O
an	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	O
)	O
.	O

Inducible	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
regulated	O
by	O
a	O
cellular	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

NF-kappa	O
B	O
is	O
composed	O
of	O
distinct	O
subunits	O
;	O
five	O
independent	O
genes	O
,	O
NFKB1	O
(	O
p105	O
)	O
,	O
NFKB2	O
(	O
p100	O
)	O
,	O
RelA	O
(	O
p65	O
)	O
,	O
c-rel	O
and	O
relB	O
,	O
that	O
encode	O
related	O
proteins	O
that	O
bind	O
to	O
kappa	O
B	O
DNA	O
elements	O
have	O
been	O
isolated	O
.	O

We	O
have	O
previously	O
found	O
that	O
NFKB2	O
(	O
p49/p52	O
)	O
acts	O
in	O
concert	O
with	O
RelA	O
(	O
p65	O
)	O
to	O
stimulate	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
T-leukemia	O
cells	O
.	O

Here	O
we	O
examine	O
the	O
biochemical	O
basis	O
for	O
the	O
transcriptional	O
regulation	O
of	O
HIV	O
by	O
NFKB2	O
.	O

Using	O
Scatchard	O
analysis	O
,	O
we	O
have	O
determined	O
the	O
dissociation	O
constants	O
of	O
homodimeric	O
p49	O
and	O
heterodimeric	O
p49/p65	O
for	O
binding	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

p49	O
has	O
a	O
approximately	O
18-fold-lower	O
affinity	O
for	O
the	O
HIV	O
kappa	O
B	O
site	O
(	O
KD	O
=	O
69.1	O
pM	O
)	O
than	O
does	O
the	O
approximately	O
50-kDa	O
protein	O
NFKB1	O
(	O
p50	O
)	O
derived	O
from	O
p105	O
(	O
KD	O
=	O
3.9	O
pM	O
)	O
.	O

In	O
contrast	O
,	O
the	O
affinity	O
of	O
heterodimeric	O
NFKB2	O
(	O
p49	O
)	O
/RelA	O
(	O
p65	O
)	O
for	O
this	O
site	O
is	O
approximately	O
6-fold	O
higher	O
(	O
KD	O
=	O
11.8	O
pM	O
)	O
than	O
that	O
of	O
p49	O
alone	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
in	O
vitro	O
transcription	O
was	O
stimulated	O
18-fold	O
by	O
the	O
addition	O
of	O
preformed	O
,	O
heterodimeric	O
NFKB2	O
(	O
p49	O
)	O
/RelA	O
(	O
p65	O
)	O
protein	O
.	O

Transcriptional	O
activation	O
of	O
the	O
HIV	O
enhancer	O
was	O
also	O
subject	O
to	O
regulation	O
by	O
recently	O
cloned	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	O
)	O
.	O

Recombinant	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	O
)	O
inhibited	O
the	O
DNA	O
binding	O
activity	O
of	O
p65	O
,	O
p49/p65	O
,	O
and	O
p50/p65	O
but	O
stimulated	O
the	O
binding	O
of	O
NFKB2	O
(	O
p49	O
)	O
or	O
NFKB1	O
(	O
p50	O
)	O
.	O

Functional	O
activation	O
of	O
an	O
HIV	O
reporter	O
plasmid	O
by	O
p49/p65	O
in	O
transiently	O
transfected	O
Jurkat	O
T-leukemia	O
cells	O
was	O
also	O
inhibited	O
by	O
coexpression	O
of	O
MAD-3	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

The	O
human	O
prointerleukin	O
1	O
beta	O
gene	O
requires	O
DNA	O
sequences	O
both	O
proximal	O
and	O
distal	O
to	O
the	O
transcription	O
start	O
site	O
for	O
tissue-specific	O
induction	O
.	O

In	O
these	O
studies	O
,	O
we	O
have	O
identified	O
DNA	O
sequences	O
and	O
specific	O
protein	O
interactions	O
necessary	O
for	O
transcriptional	O
regulation	O
of	O
the	O
human	O
prointerleukin	O
1	O
beta	O
(	O
proIL-1	O
beta	O
)	O
gene	O
.	O

A	O
cell-type-independent	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-responsive	O
enhancer	O
element	O
located	O
between	O
-3757	O
and	O
-2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
start	O
site	O
(	O
cap	O
site	O
)	O
consisted	O
of	O
at	O
least	O
six	O
discrete	O
subregions	O
which	O
were	O
essential	O
to	O
the	O
maximal	O
induction	O
by	O
LPS	O
in	O
transfected	O
monocytes	O
.	O

The	O
enhancer	O
also	O
appeared	O
to	O
mediate	O
phorbol	O
myristate	O
acetate	O
induction	O
in	O
monocytes	O
and	O
IL-1	O
responsiveness	O
in	O
fibroblasts	O
.	O

Deletion	O
and	O
base	O
substitution	O
mutations	O
along	O
with	O
DNA	O
binding	O
studies	O
demonstrated	O
that	O
the	O
enhancer	O
contained	O
a	O
minimum	O
of	O
three	O
functional	O
protein	O
binding	O
sequences	O
,	O
two	O
of	O
which	O
appeared	O
to	O
be	O
important	O
for	O
gene	O
induction	O
.	O

One	O
of	O
the	O
essential	O
proteins	O
which	O
bound	O
to	O
the	O
enhancer	O
was	O
similar	O
or	O
identical	O
to	O
members	O
of	O
the	O
C/EBP	O
family	O
of	O
transcription	O
factors	O
required	O
for	O
both	O
IL-1-	O
and	O
LPS-specific	O
induction	O
of	O
the	O
IL-6	O
gene	O
(	O
i.e.	O
,	O
the	O
NF-IL6	O
proteins	O
)	O
.	O

When	O
ligated	O
to	O
the	O
proIL-1	O
beta	O
cap	O
site-proximal	O
region	O
(	O
located	O
between	O
-131	O
to	O
+12	O
)	O
,	O
both	O
the	O
proIL-1	O
beta	O
and	O
the	O
simian	O
virus	O
40	O
enhancer	O
elements	O
functioned	O
more	O
efficiently	O
in	O
monocytes	O
than	O
in	O
HeLa	O
cells	O
,	O
which	O
are	O
not	B-Negation
normally	I-Negation
competent	I-Negation
for	I-Negation
IL-1	I-Negation
beta	I-Negation
expression	I-Negation
.	O

When	O
ligated	O
to	O
the	O
murine	O
c-fos	O
promoter	O
,	O
however	O
,	O
the	O
proIL-1	O
beta	O
enhancer	O
was	O
inducible	O
in	O
phorbol	O
myristate	O
acetate-stimulated	O
HeLa	O
cells	O
,	O
suggesting	O
the	O
existence	O
of	O
a	O
proIL-1	O
beta	O
promoter-proximal	O
requirement	O
for	O
tissue	O
specificity	O
.	O

Expression	O
of	O
PILOT	O
,	O
a	O
putative	O
transcription	O
factor	O
,	O
requires	O
two	O
signals	O
and	O
is	O
cyclosporin	O
A	O
sensitive	O
in	O
T	O
cells	O
.	O

Few	O
known	O
genes	O
(	O
IL-2	O
,	O
members	O
of	O
the	O
IL-8	O
family	O
,	O
interferon-gamma	O
)	O
are	O
induced	O
in	O
T	O
cells	O
only	O
through	O
the	O
combined	O
effect	O
of	O
phorbol	O
myristic	O
acetate	O
(	O
PMA	O
)	O
and	O
a	O
Ca	O
(	O
2+	O
)	O
-ionophore	O
,	O
and	O
expression	O
of	O
only	O
these	O
genes	O
can	O
be	O
fully	O
suppressed	O
by	O
Cyclosporin	O
A	O
(	O
CyA	O
)	O
.	O

We	O
have	O
identified	O
a	O
putative	O
transcription	O
factor	O
,	O
designated	O
PILOT	O
,	O
with	O
an	O
identical	O
dual	O
signal	O
requirement	O
for	O
expression	O
.	O

Induction	O
of	O
the	O
PILOT	O
gene	O
is	O
detectable	O
in	O
human	O
T	O
cells	O
20	O
min	O
following	O
activation	O
in	O
the	O
presence	O
of	O
cycloheximide	O
and	O
is	O
fully	O
suppressed	O
by	O
CyA	O
.	O

The	O
PILOT	O
protein	O
has	O
a	O
calculated	O
M	O
(	O
r	O
)	O
of	O
42.6	O
kDa	O
and	O
contains	O
three	O
zinc	O
fingers	O
of	O
the	O
C2H2-type	O
at	O
the	O
carboxyl-terminus	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
zinc	O
finger	O
regions	O
of	O
the	O
transcription	O
factors	O
EGR1	O
,	O
EGR2	O
,	O
and	O
pAT	O
133	O
.	O

In	O
contrast	O
to	O
T	O
cells	O
,	O
in	O
fibroblasts	O
PILOT	O
gene	O
expression	O
requires	O
only	O
one	O
signal	O
(	O
PMA	O
)	O
and	O
is	B-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
CyA	I-Negation
.	O

This	O
observation	O
directly	O
demonstrates	O
the	O
existence	O
of	O
a	O
Ca2+	O
signal-dependent	O
regulatory	O
element	O
obligatory	O
for	O
expression	O
of	O
some	O
genes	O
in	O
T	O
cells	O
but	O
not	B-Negation
in	I-Negation
fibroblasts	I-Negation
.	O

This	O
differential	O
expression	O
model	O
will	O
be	O
valuable	O
in	O
the	O
dissection	O
of	O
the	O
dual	O
signal	O
pathway	O
in	O
T	O
cells	O
and	O
the	O
effects	O
of	O
CyA	O
upon	O
it	O
.	O

Human	O
CD4	O
lymphocytes	O
specifically	O
recognize	O
a	O
peptide	O
representing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	O
protein	O
pml/RAR	O
alpha	O
present	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

Fusion	O
proteins	O
present	O
in	O
leukemic	O
cells	O
frequently	O
contain	O
a	O
new	O
amino	O
acid	O
at	O
the	O
fusion	O
point	O
.	O

We	O
tested	O
whether	O
a	O
peptide	O
(	O
BCR1/25	O
)	O
encompassing	O
the	O
fusion	O
region	O
of	O
the	O
hybrid	O
molecule	O
pml/RAR	O
alpha	O
,	O
which	O
is	O
selectively	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
recognized	O
by	O
human	O
T	O
lymphocytes	O
in	O
vitro	O
.	O

CD4+	O
lymphocytes	O
,	O
at	O
both	O
polyclonal	O
and	O
clonal	O
level	O
,	O
recognized	O
peptide	O
BCR1/25	O
in	O
an	O
HLA-DR	O
--	O
restricted	O
fashion	O
on	O
presentation	O
by	O
autologous	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
or	O
by	O
APC	O
expressing	O
the	O
HLA-DR11	O
restricting	O
molecule	O
.	O

Control	B-Negation
peptides	I-Negation
corresponding	I-Negation
to	I-Negation
the	I-Negation
normal	I-Negation
pml	I-Negation
and	I-Negation
RAR	I-Negation
alpha	I-Negation
proteins	I-Negation
were	I-Negation
not	I-Negation
recognized	I-Negation
.	O

One	O
clone	O
(	O
DEG5	O
)	O
also	O
exerted	O
a	O
high	O
and	O
specific	O
cytotoxicity	O
against	O
autologous	O
cells	O
pulsed	O
with	O
BCR1/25	O
.	O

The	O
autologous	O
DE	O
LCL	O
containing	O
a	O
transduced	O
pml/RAR	O
alpha	O
fusion	O
gene	O
and	O
expressing	O
a	O
bcr1	O
type	O
of	O
the	O
pml/RAR	O
alpha	O
hybrid	O
protein	O
induced	O
the	O
proliferation	O
of	O
DE	O
anti-BCR1/25	O
T	O
cell	O
clones	O
.	O

It	O
is	O
concluded	O
that	O
the	O
bcr1	O
type-pml/RAR	O
alpha	O
fusion	O
protein	O
of	O
APL	O
contains	O
an	O
antigenic	O
site	O
,	O
absent	O
from	O
the	O
normal	O
parent	O
molecules	O
and	O
recognized	O
by	O
human	O
CD4+	O
lymphocytes	O
.	O

A	O
serum	O
response	O
element	O
and	O
a	O
binding	O
site	O
for	O
NF-Y	O
mediate	O
the	O
serum	O
response	O
of	O
the	O
human	O
thrombospondin	O
1	O
gene	O
.	O

The	O
expression	O
of	O
thrombospondin	O
1	O
(	O
TSP	O
1	O
)	O
,	O
a	O
member	O
of	O
the	O
TSP	O
gene	O
family	O
,	O
is	O
rapidly	O
induced	O
by	O
growth	O
factors	O
.	O

We	O
tested	O
the	O
ability	O
of	O
human	O
TSP	O
1-chloramphenicol	O
acetyltransferase	O
constructs	O
to	O
respond	O
to	O
serum	O
in	O
stably	O
transfected	O
NIH-3T3	O
cells	O
.	O

Two	O
transcriptional	O
elements	O
in	O
the	O
TSP	O
1	O
promoter	O
,	O
a	O
distal	O
element	O
at	O
-1280	O
and	O
a	O
proximal	O
element	O
at	O
-65	O
,	O
were	O
required	O
for	O
the	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
to	O
serum	O
.	O

The	O
distal	O
element	O
contains	O
the	O
5'-CC	O
(	O
A+T	O
)	O
6GG-3	O
'	O
consensus	O
sequence	O
characteristic	O
of	O
a	O
serum-response	O
element	O
(	O
SRE	O
)	O
.	O

Deletions	O
or	O
mutations	O
in	O
this	O
element	O
reduced	O
the	O
serum	O
response	O
of	O
the	O
TSP	O
1	O
gene	O
by	O
80-90	O
%	O
.	O

In	O
gel-shift	O
assays	O
,	O
the	O
-1280	O
element	O
and	O
the	O
c-fos	O
SRE	O
cross-competed	O
,	O
whereas	O
their	O
functional	O
and	O
binding	O
mutants	O
did	O
not	B-Negation
.	O

The	O
proximal	O
element	O
contains	O
the	O
sequence	O
5'-GGCCAATGGG-3	O
'	O
,	O
which	O
closely	O
resembles	O
the	O
consensus	O
binding	O
motif	O
for	O
the	O
CCAAT-binding	O
factor	O
NF-Y	O
(	O
CBF	O
,	O
CP1	O
,	O
alpha	O
CP1	O
)	O
.	O

Deletions	O
or	O
mutations	O
in	O
this	O
element	O
also	O
reduced	O
the	O
serum	O
response	O
by	O
80-90	O
%	O
.	O

Methylation	O
interference	O
analysis	O
of	O
the	O
-65	O
region	O
identified	O
a	O
pattern	O
of	O
contacts	O
with	O
nuclear	O
factors	O
resembling	O
that	O
for	O
NF-Y	O
,	O
and	O
an	O
NF-Y-binding	O
site	O
and	O
the	O
proximal	O
TSP	O
1	O
element	O
cross-competed	O
in	O
gel-shift	O
assays	O
,	O
whereas	O
their	O
binding	O
mutants	O
did	O
not	B-Negation
.	O

Finally	O
,	O
an	O
abbreviated	O
TSP	O
1	O
promoter/5'-flank	O
,	O
containing	O
the	O
SRE-	O
and	O
NF-Y-binding	O
sites	O
,	O
mediated	O
a	O
serum	O
response	O
that	O
was	O
close	O
in	O
magnitude	O
to	O
that	O
of	O
the	O
parent	O
promoter	O
.	O

We	O
conclude	O
that	O
the	O
serum	O
response	O
of	O
the	O
human	O
TSP	O
1	O
gene	O
requires	O
the	O
coordinated	O
function	O
of	O
an	O
SRE-	O
and	O
NF-Y-binding	O
site	O
.	O

Suppression	O
of	O
a	O
cellular	O
differentiation	O
program	O
by	O
phorbol	O
esters	O
coincides	O
with	O
inhibition	O
of	O
binding	O
of	O
a	O
cell-specific	O
transcription	O
factor	O
(	O
NF-E2	O
)	O
to	O
an	O
enhancer	O
element	O
required	O
for	O
expression	O
of	O
an	O
erythroid-specific	O
gene	O
.	O

Induction	O
by	O
hemin	O
increases	O
,	O
while	O
induction	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
represses	O
,	O
erythroid-specific	O
gene	O
expression	O
in	O
the	O
human	O
cell	O
line	O
K562	O
.	O

We	O
analyzed	O
the	O
effects	O
of	O
hemin	O
or	O
TPA	O
induction	O
on	O
the	O
binding	O
and	O
activity	O
of	O
transcription	O
factors	O
at	O
a	O
regulatory	O
element	O
found	O
within	O
the	O
transcriptional	O
regulatory	O
sequences	O
of	O
many	O
erythroid-specific	O
genes	O
.	O

TPA	O
induction	O
increases	O
the	O
binding	O
of	O
ubiquitous	O
AP-1	O
factors	O
to	O
this	O
element	O
.	O

TPA	O
induction	O
inhibits	O
the	O
binding	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF-E2	O
to	O
this	O
transcriptional	O
control	O
element	O
.	O

Hemin	O
induction	O
of	O
K562	O
cells	O
does	O
not	B-Negation
facilitate	I-Negation
the	I-Negation
binding	I-Negation
of	I-Negation
NF-E2	I-Negation
to	I-Negation
its	I-Negation
recognition	I-Negation
site	I-Negation
.	O

Hemin	O
induction	O
appears	O
to	O
nonspecifically	O
increase	O
the	O
expression	O
of	O
transiently	O
transfected	O
genes	O
in	O
K562	O
cells	O
.	O

Beyond	O
this	O
nonspecific	O
increase	O
in	O
gene	O
expression	O
,	O
hemin	O
induction	O
acts	O
to	O
increase	O
the	O
activity	O
of	O
the	O
lineage	O
limited	O
transcription	O
factor	O
NF-E2	O
.	O

The	O
divergent	O
effects	O
of	O
hemin	O
and	O
TPA	O
on	O
gene	O
expression	O
in	O
K562	O
cells	O
are	O
mediated	O
,	O
in	O
part	O
,	O
by	O
their	O
contrasting	O
effects	O
on	O
the	O
transcription	O
factor	O
NF-E2	O
.	O

The	O
interleukin	O
2	O
CD28-responsive	O
complex	O
contains	O
at	O
least	O
three	O
members	O
of	O
the	O
NF	O
kappa	O
B	O
family	O
:	O
c-Rel	O
,	O
p50	O
,	O
and	O
p65	O
.	O

Optimal	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
.	O

One	O
signal	O
can	O
be	O
delivered	O
by	O
the	O
antigen-specific	O
T-cell	O
receptor	O
,	O
and	O
the	O
second	O
signal	O
is	O
provided	O
by	O
the	O
costimulatory	O
molecule	O
(	O
s	O
)	O
delivered	O
by	O
the	O
antigen-presenting	O
cell	O
.	O

CD28	O
is	O
a	O
T-cell	O
surface	O
molecule	O
and	O
stimulation	O
through	O
this	O
protein	O
plays	O
an	O
important	O
role	O
in	O
delivering	O
the	O
second	O
activation	O
signal	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
CD28-mediated	O
signal	O
transduction	O
involves	O
the	O
rel	O
family	O
proteins	O
--	O
c-Rel	O
,	O
p50	O
,	O
and	O
p65	O
.	O

Treatment	O
of	O
peripheral	O
blood	O
T	O
cells	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
anti-CD28	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
results	O
in	O
augmentation	O
of	O
nuclear	O
c-Rel	O
,	O
p50	O
,	O
and	O
p65	O
,	O
and	O
this	O
augmentation	O
can	O
occur	O
in	O
the	O
presence	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
.	O

It	O
is	O
also	O
shown	O
in	O
this	O
report	O
that	O
,	O
in	O
response	O
to	O
PMA/anti-CD28	O
mAb	O
or	O
anti-CD3/anti-CD28	O
mAb	O
,	O
c-Rel	O
,	O
p50	O
,	O
and	O
p65	O
are	O
associated	O
with	O
CD28-responsive	O
element	O
present	O
in	O
the	O
promoter	O
of	O
the	O
human	O
interleukin	O
2	O
gene	O
.	O

The	O
functional	O
significance	O
of	O
c-Rel	O
involvement	O
in	O
the	O
CD28-responsive	O
complex	O
is	O
demonstrated	O
by	O
transient	O
transfection	O
analysis	O
,	O
where	O
cotransfection	O
of	O
c-Rel	O
augments	O
the	O
level	O
of	O
expression	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
linked	O
to	O
the	O
CD28-responsive	O
element	O
.	O

Expression	O
of	O
the	O
Tat	O
protein	O
of	O
HIV1	O
in	O
human	O
promonocytic	O
U937	O
cells	O
.	O

Numerous	O
studies	O
have	O
shown	O
that	O
,	O
upon	O
HIV1	O
infection	O
,	O
human	O
promonocytic	O
U937	O
cells	O
were	O
induced	O
to	O
differentiate	O
,	O
as	O
indicated	O
,	O
for	O
example	O
,	O
by	O
increased	O
expression	O
of	O
adhesion	O
molecules	O
.	O

One	O
of	O
the	O
viral	O
proteins	O
involved	O
in	O
this	O
process	O
might	O
be	O
the	O
Tat	O
protein	O
.	O

Indeed	O
,	O
this	O
viral	O
protein	O
,	O
which	O
is	O
essential	O
for	O
productive	O
infection	O
,	O
has	O
also	O
been	O
shown	O
to	O
display	O
growth-stimulating	O
properties	O
and	O
immunomodulatory	O
activities	O
.	O

In	O
order	O
to	O
apprehend	O
the	O
role	O
of	O
the	O
HIV1	O
tat	O
gene	O
in	O
inducing	O
the	O
differentiation	O
of	O
HIV1-infected	O
U937	O
cells	O
,	O
we	O
have	O
successfully	O
introduced	O
this	O
gene	O
into	O
U937	O
cells	O
by	O
infecting	O
them	O
with	O
retroviral	O
particles	O
transducing	O
tat	O
.	O

The	O
effect	O
of	O
the	O
Tat	O
protein	O
constitutively	O
expressed	O
by	O
these	O
cells	O
upon	O
their	O
differentiation	O
was	O
then	O
evaluated	O
by	O
looking	O
for	O
the	O
expression	O
of	O
the	O
c-fos	O
and	O
of	O
the	O
c-fms	O
proto-oncogenes	O
which	O
are	O
linked	O
to	O
the	O
differentiation	O
of	O
myelomonoblastic	O
cells	O
.	O

Northern	O
blot	O
analysis	O
revealed	O
in	O
these	O
cells	O
,	O
an	O
increase	O
in	O
the	O
transcription	O
of	O
these	O
two	O
proto-oncogenes	O
,	O
and	O
this	O
increase	O
was	O
amplified	O
after	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
.	O

No	B-Negation
such	I-Negation
increase	I-Negation
was	I-Negation
observed	I-Negation
in	I-Negation
control	I-Negation
U937	I-Negation
cells	I-Negation
.	O

These	O
results	O
indicate	O
that	O
,	O
among	O
HIV1	O
gene	O
products	O
,	O
the	O
Tat	O
protein	O
appears	O
to	O
trigger	O
monocytic	O
differentiation	O
,	O
and	O
suggests	O
that	O
this	O
viral	O
protein	O
directs	O
progenitors	O
of	O
the	O
monocyte/macrophage	O
lineage	O
towards	O
a	O
differentiation	O
stage	O
in	O
which	O
production	O
of	O
viral	O
antigens	O
and	O
virions	O
might	O
be	O
more	O
efficient	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid-specific	O
promoter	O
.	O

Mammal	O
pyruvate	O
kinases	O
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	O
the	O
erythroid	O
(	O
R-PK	O
)	O
or	O
the	O
hepatic	O
(	O
L-PK	O
)	O
isozymes	O
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	O
and	O
trans-acting	O
elements	O
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R-PK	O
DNA	O
fragment	O
extending	O
from	O
-870	O
to	O
+54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid-specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	O
family	O
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	O
factor	O
GATA-1	O
.	O

Although	O
the	O
-20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	B-Negation
bind	I-Negation
TFIID	I-Negation
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	O
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue-specific	O
expression	O
of	O
this	O
R-PK	O
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co-transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R-PK	O
promoter	O
in	O
HeLa	O
cells	O
.	O

Stimulation	O
of	O
interleukin-1	O
alpha	O
and	O
interleukin-1	O
beta	O
production	O
in	O
human	O
monocytes	O
by	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
.	O

Protein	O
phosphatases	O
1	O
and	O
2A	O
are	O
important	O
in	O
regulating	O
cellular	O
functions	O
by	O
controlling	O
the	O
phosphorylation	O
state	O
of	O
their	O
substrates	O
.	O

In	O
human	O
monocytes	O
,	O
the	O
inhibitors	O
of	O
these	O
phosphatases	O
,	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
,	O
were	O
found	O
to	O
increase	O
the	O
mRNA	O
accumulation	O
and	O
cytokine	O
production	O
of	O
interleukin-1	O
beta	O
and	O
interleukin-1	O
alpha	O
.	O

The	O
increased	O
mRNA	O
accumulation	O
was	O
found	O
to	O
be	O
primarily	O
because	O
of	O
the	O
increase	O
in	O
the	O
transcription	O
rate	O
of	O
the	O
interleukin-1	O
genes	O
.	O

Stimulation	O
of	O
interleukin-1	O
gene	O
transcription	O
may	O
be	O
caused	O
by	O
the	O
stimulation	O
of	O
transcription	O
factor	O
activities	O
,	O
including	O
those	O
of	O
AP-1	O
,	O
by	O
these	O
protein	O
phosphatase	O
inhibitors	O
.	O

Okadaic	O
acid	O
increased	O
the	O
synthesis	O
of	O
the	O
interleukin-1	O
beta	O
precursor	O
and	O
mature	O
forms	O
and	O
their	O
secretion	O
.	O

This	O
increased	O
processing	O
and	O
secretion	O
correlated	O
with	O
the	O
stimulation	O
of	O
IL-1	O
beta	O
convertase	O
mRNA	O
accumulation	O
.	O

The	O
stimulation	O
of	O
interleukin-1	O
alpha	O
production	O
by	O
okadaic	O
acid	O
was	O
more	O
modest	O
than	O
that	O
of	O
interleukin-1	O
beta	O
.	O

However	O
,	O
the	O
phosphorylation	O
of	O
the	O
precursor	O
interleukin-1	O
alpha	O
cytokine	O
was	O
increased	O
.	O

These	O
results	O
show	O
that	O
protein	O
phosphatase	O
1	O
and	O
2A	O
inhibitors	O
exert	O
multiple	O
effects	O
on	O
cytokine	O
production	O
in	O
human	O
monocytes	O
and	O
suggest	O
that	O
these	O
two	O
phosphatases	O
play	O
important	O
roles	O
in	O
regulating	O
interleukin-1	O
production	O
.	O

Cell	O
type-	O
and	O
stage-specific	O
expression	O
of	O
the	O
CD20/B1	O
antigen	O
correlates	O
with	O
the	O
activity	O
of	O
a	O
diverged	O
octamer	O
DNA	O
motif	O
present	O
in	O
its	O
promoter	O
.	O

The	O
CD20	O
(	O
B1	O
)	O
gene	O
encodes	O
a	O
B	O
cell-specific	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
human	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Studies	O
with	O
5	O
'	O
deletion	O
CD20	O
promoter-CAT	O
constructs	O
have	O
previously	O
revealed	O
two	O
regions	O
of	O
the	O
promoter	O
between	O
bases	O
-186	O
and	O
-280	O
and	O
between	O
bases	O
-280	O
and	O
-454	O
which	O
contained	O
positive	O
regulatory	O
elements	O
.	O

In	O
this	O
study	O
we	O
identified	O
a	O
sequence	O
element	O
present	O
in	O
the	O
most	O
proximal	O
region	O
located	O
between	O
bases	O
-214	O
and	O
-201	O
,	O
TTCTTCTAATTAA	O
,	O
which	O
is	O
important	O
in	O
the	O
high	O
constitutive	O
expression	O
of	O
CD20	O
in	O
mature	O
B	O
cells	O
and	O
the	O
induction	O
of	O
CD20	O
in	O
pre-B	O
cells	O
.	O

This	O
sequence	O
element	O
was	O
referred	O
to	O
as	O
the	O
BAT	O
box	O
and	O
its	O
deletion	O
significantly	O
reduced	O
the	O
activity	O
of	O
a	O
CD20	O
promoter-CAT	O
construct	O
in	O
B	O
cells	O
.	O

Mobility	O
shift	O
assays	O
with	O
various	O
mutant	O
probes	O
and	O
B	O
cell	O
nuclear	O
extracts	O
demonstrated	O
that	O
the	O
core	O
sequence	O
TAAT	O
was	O
essential	O
for	O
binding	O
to	O
this	O
site	O
.	O

Cross	O
competition	O
experiments	O
with	O
an	O
octamer	O
sequence	O
from	O
the	O
Ig	O
heavy	O
chain	O
promoter	O
,	O
the	O
BAT	O
box	O
,	O
and	O
a	O
TA-rich	O
sequence	O
present	O
in	O
the	O
CD21	O
promoter	O
revealed	O
that	O
all	O
three	O
sequences	O
bound	O
the	O
same	O
nuclear	O
proteins	O
suggesting	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct-1	O
and	O
Oct-2	O
.	O

Southwestern	O
blotting	O
and	O
UV	O
cross-linking	O
studies	O
confirmed	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
were	O
Oct-1	O
and	O
Oct-2	O
.	O

The	O
affinity	O
of	O
the	O
BAT	O
box	O
binding	O
proteins	O
for	O
the	O
BAT	O
box	O
was	O
approximately	O
25-fold	O
less	O
than	O
for	O
the	O
octamer	O
sequence	O
and	O
the	O
BAT	O
box	O
binding	O
proteins	O
dissociated	O
from	O
the	O
BAT	O
box	O
10-fold	O
more	O
rapidly	O
than	O
from	O
the	O
octamer	O
sequence	O
.	O

Despite	O
this	O
lower	O
affinity	O
,	O
a	O
trimer	O
of	O
the	O
BAT	O
box	O
sequence	O
was	O
as	O
efficiently	O
transactivated	O
by	O
an	O
Oct-2	O
expression	O
vector	O
as	O
was	O
a	O
trimer	O
of	O
the	O
octamer	O
sequence	O
in	O
HeLa	O
cells	O
.	O

The	O
BAT	O
box	O
and	O
Oct-2	O
were	O
also	O
implicated	O
in	O
the	O
induction	O
of	O
CD20	O
in	O
the	O
pre-B	O
cell	O
line	O
,	O
PB-697	O
,	O
via	O
phorbol	O
esters	O
.	O

The	O
induction	O
of	O
CD20	O
mRNA	O
was	O
temporally	O
associated	O
with	O
induction	O
of	O
Oct-2	O
mRNA	O
and	O
a	O
BAT	O
box-deleted	O
CD20-CAT	O
construct	O
,	O
in	O
contrast	O
to	O
the	O
wild	O
type	O
,	O
was	O
poorly	O
induced	O
by	O
phorbol	O
esters	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
the	O
BAT	O
box	O
binding	O
proteins	O
are	O
important	O
in	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
CD20	O
and	O
perhaps	O
CD21	O
.	O

Transcription	O
factor	O
jun-B	O
is	O
target	O
of	O
autoreactive	O
T-cells	O
in	O
IDDM	O
.	O

Target	O
antigens	O
defined	O
by	O
autoantibodies	O
in	O
IDDM	O
include	O
insulin	O
,	O
a	O
putative	O
glycolipid	O
that	O
reacts	O
with	O
islet	O
cell	O
antibodies	O
,	O
and	O
a	O
64,000-M	O
(	O
r	O
)	O
protein	O
recently	O
identified	O
as	O
glutamic	O
acid	O
decarboxylase	O
.	O

In	O
addition	O
,	O
some	O
IDDM	O
sera	O
that	O
contain	O
antibodies	O
to	O
glutamic	O
acid	O
decarboxylase	O
also	O
coprecipitate	O
a	O
38,000-M	O
(	O
r	O
)	O
protein	O
from	O
islets	O
.	O

This	O
study	O
used	O
a	O
high	O
titer	O
anti-38,000-M	O
(	O
r	O
)	O
serum	O
to	O
screen	O
bacteriophage	O
lambda	O
cDNA	O
expression	O
libraries	O
and	O
identified	O
human	O
islet	O
and	O
placental	O
clones	O
encoding	O
jun-B	O
,	O
the	O
nuclear	O
transcription	O
protein	O
,	O
of	O
predicted	O
38,000	O
M	O
(	O
r	O
)	O
.	O

Peripheral	O
blood	O
T-cells	O
exhibited	O
significant	O
proliferation	O
in	O
response	O
to	O
a	O
recombinant	O
fragment	O
of	O
jun-B	O
(	O
amino	O
acids	O
1-180	O
)	O
in	O
12	O
of	O
17	O
(	O
71	O
%	O
)	O
recent-onset	O
IDDM	O
subjects	O
,	O
8	O
of	O
16	O
(	O
50	O
%	O
)	O
ICA-positive	O
first-degree	O
relatives	O
of	O
IDDM	O
subjects	O
who	O
were	O
at	O
risk	O
,	O
3	O
of	O
12	O
(	O
25	O
%	O
)	O
other	O
autoimmune	O
disease	O
subjects	O
,	O
and	O
0	O
of	O
10	O
healthy	O
control	O
subjects	O
.	O

Proliferation	O
to	O
tetanus	O
toxoid	O
did	O
not	B-Negation
differ	I-Negation
significantly	I-Negation
between	I-Negation
the	I-Negation
groups	I-Negation
.	O

Responses	O
to	O
jun-B	O
were	O
not	B-Negation
related	I-Negation
to	I-Negation
age	I-Negation
,	I-Negation
sex	I-Negation
,	I-Negation
or	I-Negation
human	I-Negation
leukocyte	I-Negation
antigen	I-Negation
status	I-Negation
.	O

Thus	O
,	O
autoreactive	O
T-cells	O
identify	O
a	O
novel	O
antigen	O
,	O
p38	O
jun-B	O
,	O
in	O
IDDM	O
and	O
appear	O
to	O
indicate	O
subjects	O
at	O
risk	O
for	O
the	O
development	O
of	O
clinical	O
disease	O
.	O

Transcriptional	O
regulation	O
of	O
interleukin	O
3	O
(	O
IL3	O
)	O
in	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Role	O
of	O
AP-1-	O
and	O
octamer-binding	O
proteins	O
in	O
control	O
of	O
IL3	O
gene	O
expression	O
.	O

We	O
have	O
investigated	O
the	O
molecular	O
and	O
biochemical	O
basis	O
for	O
activation	O
of	O
interleukin	O
3	O
(	O
IL3	O
)	O
gene	O
expression	O
in	O
primary	O
human	O
T	O
lymphocytes	O
following	O
CD3	O
and	O
CD2	O
receptor	O
stimulation	O
or	O
activation	O
by	O
phytohemagglutinin	O
plus	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

Using	O
transfection	O
and	O
reporter	O
gene	O
assays	O
specifically	O
designed	O
for	O
primary	O
T	O
lymphocytes	O
in	O
conjunction	O
with	O
gel	O
retardation	O
assays	O
,	O
Western	O
blot	O
analyses	O
and	O
UV	O
cross-linking	O
studies	O
,	O
we	O
found	O
that	O
c-Jun	O
,	O
c-Fos	O
,	O
and	O
octamer-binding	O
proteins	O
play	O
a	O
major	O
role	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL3	O
gene	O
via	O
their	O
interaction	O
with	O
two	O
specific	O
regions	O
contained	O
within	O
the	O
IL3	O
5'-flanking	O
sequence	O
.	O

Additionally	O
,	O
the	O
region	O
between	O
bases	O
-107	O
and	O
-59	O
of	O
the	O
IL3	O
promoter	O
containing	O
putative	O
AP-2	O
and	O
Sp1	O
binding	O
motifs	O
appears	O
necessary	O
for	O
basal	O
level	O
expression	O
of	O
the	O
IL3	O
gene	O
.	O

The	O
data	O
also	O
indicate	O
that	O
CD2	O
receptor	O
activation	O
and	O
phytohemagglutinin	O
plus	O
phorbol	O
12-myristate	O
13-acetate	O
stimulation	O
augment	O
T	O
cell	O
IL3	O
gene	O
expression	O
through	O
the	O
same	O
cis-	O
and	O
trans-activating	O
signals	O
.	O

These	O
results	O
should	O
contribute	O
to	O
a	O
better	O
understanding	O
of	O
the	O
regulation	O
of	O
IL3	O
gene	O
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O

Transcriptional	O
activation	O
of	O
human	O
zeta	O
2	O
globin	O
promoter	O
by	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS-40	O
)	O
:	O
functional	O
role	O
of	O
specific	O
nuclear	O
factor-DNA	O
complexes	O
.	O

We	O
studied	O
the	O
functional	O
interaction	O
between	O
human	O
embryonic	O
zeta	O
2	O
globin	O
promoter	O
and	O
the	O
alpha	O
globin	O
regulatory	O
element	O
(	O
HS-40	O
)	O
located	O
40	O
kb	O
upstream	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
.	O

It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	O
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high-level	O
zeta	O
2	O
globin	O
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O

Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	O
plasmids	O
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	O
enhancer-mediated	O
activity	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	O
enhancer-zeta	O
2	O
globin	O
promoter	O
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O

The	O
functional	O
domains	O
of	O
HS-40	O
were	O
also	O
mapped	O
.	O

Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF-E2/AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	O
in	O
the	O
erythroid-specific	O
activation	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site-directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	O
function	O
of	O
one	O
of	O
the	O
two	O
NF-E2/AP1	O
motifs	O
of	O
HS-40	O
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF-E2	O
but	O
not	B-Negation
AP1	I-Negation
transcription	I-Negation
factor	I-Negation
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	O
enhancer	O
region	O
in	O
K562	O
cells	O
,	O
adult	O
nucleated	O
erythroblasts	O
,	O
and	O
different	O
nonerythroid	O
cells	O
.	O

All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS-40	O
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
living	O
K562	O
cells	O
but	O
not	O
in	O
nonerythroid	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	O
sequence	O
motifs	O
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

In	O
comparison	O
to	O
K562	O
,	O
nucleated	O
erythroblasts	O
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	O
factor	O
binding	O
in	O
vivo	O
at	O
the	O
HS-40	O
region	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	O
embryonic	O
zeta	O
2	O
globin	O
gene	O
and	O
the	O
fetal/adult	O
alpha	O
globin	O
genes	O
is	O
mediated	O
by	O
erythroid	O
cell-specific	O
and	O
developmental	O
stage-specific	O
nuclear	O
factor-DNA	O
complexes	O
which	O
form	O
at	O
the	O
enhancer	O
(	O
HS-40	O
)	O
and	O
the	O
globin	O
promoters	O
.	O

Interaction	O
between	O
NF-kappa	O
B-	O
and	O
serum	O
response	O
factor-binding	O
elements	O
activates	O
an	O
interleukin-2	O
receptor	O
alpha-chain	O
enhancer	O
specifically	O
in	O
T	O
lymphocytes	O
.	O

We	O
find	O
that	O
a	O
short	O
enhancer	O
element	O
containing	O
the	O
NF-kappa	O
B	O
binding	O
site	O
from	O
the	O
interleukin-2	O
receptor	O
alpha-chain	O
gene	O
(	O
IL-2R	O
alpha	O
)	O
is	O
preferentially	O
activated	O
in	O
T	O
cells	O
.	O

The	O
IL-2R	O
alpha	O
enhancer	O
binds	O
NF-kappa	O
B	O
poorly	O
and	O
is	O
only	O
weakly	O
activated	O
by	O
the	O
NF-kappa	O
B	O
site	O
alone	O
.	O

Serum	O
response	O
factor	O
(	O
SRF	O
)	O
binds	O
to	O
a	O
site	O
adjacent	O
to	O
the	O
NF-kappa	O
B	O
site	O
in	O
the	O
IL-2R	O
enhancer	O
,	O
and	O
both	O
sites	O
together	O
have	O
strong	O
transcriptional	O
activity	O
specifically	O
in	O
T	O
cells	O
.	O

Surprisingly	O
,	O
the	O
levels	O
of	O
SRF	O
constitutively	O
expressed	O
in	O
T	O
cells	O
are	O
consistently	O
higher	O
than	O
in	O
other	O
cell	O
types	O
.	O

Overexpression	O
of	O
SRF	O
in	O
B	O
cells	O
causes	O
the	O
IL-2R	O
enhancer	O
to	O
function	O
as	O
well	O
as	O
it	O
does	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
the	O
high	O
level	O
of	O
SRF	O
binding	O
in	O
T	O
cells	O
is	O
functionally	O
important	O
.	O

The	O
transcriptionally	O
active	O
factors	O
mediating	O
the	O
effect	O
of	O
the	O
HTLV-I	O
Tax	O
transactivator	O
on	O
the	O
IL-2R	O
alpha	O
kappa	O
B	O
enhancer	O
include	O
the	O
product	O
of	O
the	O
c-rel	O
proto-oncogene	O
.	O

The	O
transactivator	O
HTLV-I	O
Tax	O
activates	O
the	O
promoter	O
of	O
the	O
gene	O
coding	O
for	O
the	O
interleukin	O
2	O
alpha-chain	O
receptor	O
(	O
IL-2R	O
alpha	O
)	O
via	O
a	O
kappa	O
B	O
site	O
that	O
can	O
bind	O
several	O
protein	O
species	O
of	O
the	O
rel	O
family	O
.	O

Tax1	O
strongly	O
activates	O
the	O
enhancer	O
activity	O
of	O
this	O
motif	O
,	O
in	O
both	O
epithelial	O
HeLa	O
and	O
lymphoid	O
Jurkat	O
cells	O
.	O

This	B-Negation
activation	I-Negation
was	I-Negation
not	I-Negation
observed	I-Negation
in	I-Negation
undifferentiated	I-Negation
embryocarcinoma	I-Negation
F9	I-Negation
cells	I-Negation
.	O

Overexpression	O
of	O
the	O
p50	O
,	O
p65	O
and	O
Rel	O
proteins	O
in	O
these	O
cells	O
showed	O
that	O
significant	O
activation	O
of	O
the	O
IL-2R	O
alpha	O
kappa	O
B	O
site	O
was	O
observed	O
only	O
with	O
Rel	O
and	O
Rel	O
plus	O
p65	O
.	O

Moreover	O
,	O
whereas	O
both	O
Tax	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
are	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
NF-kappa	O
B	O
to	O
the	O
IL-2R	O
alpha	O
kappa	O
B	O
site	O
,	O
PMA	O
is	O
functionally	O
inactive	O
.	O

Using	O
the	O
DNA	O
affinity	O
precipitation	O
assay	O
,	O
we	O
observed	O
that	O
Tax1	O
is	O
able	O
to	O
efficiently	O
induce	O
the	O
binding	O
of	O
Rel	O
,	O
whereas	O
PMA	O
is	O
not	B-Negation
.	O

This	O
established	O
a	O
clear	O
difference	O
between	O
both	O
stimuli	O
,	O
indicating	O
that	O
Rel	O
is	O
the	O
functionally	O
active	O
factor	O
.	O

We	O
conclude	O
from	O
these	O
results	O
that	O
the	O
functional	O
activity	O
of	O
members	O
of	O
the	O
rel	O
family	O
is	O
regulated	O
by	O
their	O
interaction	O
with	O
DNA	O
and	O
that	O
Rel	O
can	O
be	O
a	O
potent	O
transcriptional	O
activator	O
on	O
specific	O
kappa	O
B	O
sites	O
.	O

NF-kappa	O
B	O
controls	O
expression	O
of	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
:	O
evidence	O
for	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
participates	O
in	O
many	O
parts	O
of	O
the	O
genetic	O
program	O
mediating	O
T	O
lymphocyte	O
activation	O
and	O
growth	O
.	O

Nuclear	O
expression	O
of	O
NF-kappa	O
B	O
occurs	O
after	O
its	O
induced	O
dissociation	O
from	O
its	O
cytoplasmic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
.	O

Phorbol	O
ester	O
and	O
tumor	O
necrosis	O
factor-alpha	O
induction	O
of	O
nuclear	O
NF-kappa	O
B	O
is	O
associated	O
with	O
both	O
the	O
degradation	O
of	O
performed	O
I	O
kappa	O
B	O
alpha	O
and	O
the	O
activation	O
of	O
I	O
kappa	O
B	O
alpha	O
gene	O
expression	O
.	O

Transfection	O
studies	O
indicate	O
that	O
the	O
I	O
kappa	O
B	O
alpha	O
gene	O
is	O
specifically	O
induced	O
by	O
the	O
65-kilodalton	O
transactivating	O
subunit	O
of	O
NF-kappa	O
B	O
.	O

Association	O
of	O
the	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
with	O
p65	O
restores	O
intracellular	O
inhibition	O
of	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
and	O
prolongs	O
the	O
survival	O
of	O
this	O
labile	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
show	O
that	O
NF-kappa	O
B	O
controls	O
the	O
expression	O
of	O
I	O
kappa	O
B	O
alpha	O
by	O
means	O
of	O
an	O
inducible	O
autoregulatory	O
pathway	O
.	O

p105	O
and	O
p98	O
precursor	O
proteins	O
play	O
an	O
active	O
role	O
in	O
NF-kappa	O
B-mediated	O
signal	O
transduction	O
.	O

The	O
Rel/NF-kappa	O
B	O
family	O
of	O
transcription	O
factors	O
is	O
composed	O
of	O
two	O
distinct	O
subgroups	O
,	O
proteins	O
that	O
undergo	O
proteolytic	O
processing	O
and	O
contain	O
SWI6/ankyrin	O
repeats	O
in	O
their	O
carboxyl	O
termini	O
(	O
p105	O
,	O
p98	O
)	O
,	O
and	O
those	O
without	B-Negation
such	I-Negation
repeats	I-Negation
that	O
do	O
not	B-Negation
require	I-Negation
processing	I-Negation
(	I-Negation
p65	I-Negation
,	I-Negation
c-Rel	I-Negation
,	I-Negation
RelB	I-Negation
,	I-Negation
and	I-Negation
Dorsal	I-Negation
)	I-Negation
.	O

We	O
demonstrate	O
that	O
the	O
p105	O
and	O
p98	O
precursors	O
share	O
functional	O
properties	O
with	O
the	O
I	O
kappa	O
B	O
proteins	O
,	O
which	O
also	O
contain	O
SWI6/ankyrin	O
repeats	O
.	O

Both	O
p105	O
and	O
p98	O
were	O
found	O
to	O
form	O
stable	O
complexes	O
with	O
other	O
Rel/NF-kappa	O
B	O
family	O
members	O
,	O
including	O
p65	O
and	O
c-Rel	O
.	O

Association	O
with	O
the	O
precursors	O
is	O
sufficient	O
for	O
cytoplasmic	O
retention	O
of	O
either	O
p65	O
or	O
c-Rel	O
,	O
both	O
of	O
which	O
are	O
otherwise	O
nuclear	O
.	O

These	O
complexes	O
undergo	O
stimulus-responsive	O
processing	O
to	O
produce	O
active	O
p50/c-Rel	O
and	O
p55/c-Rel	O
complexes	O
.	O

These	O
observations	O
suggest	O
a	O
second	O
pathway	O
leading	O
to	O
NF-kappa	O
B	O
induction	O
,	O
in	O
which	O
processing	O
of	O
the	O
precursors	O
rather	O
than	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
plays	O
a	O
major	O
role	O
.	O

Mutual	O
regulation	O
of	O
the	O
transcriptional	O
activator	O
NF-kappa	O
B	O
and	O
its	O
inhibitor	O
,	O
I	O
kappa	O
B-alpha	O
.	O

The	O
NK-kappa	O
B	O
transcription	O
factor	O
complex	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
by	O
the	O
inhibitory	O
protein	O
I	O
kappa	O
B-alpha	O
(	O
MAD-3	O
)	O
.	O

Various	O
cellular	O
stimuli	O
relieve	O
this	O
inhibition	O
by	O
mechanisms	O
largely	O
unknown	O
,	O
leading	O
to	O
NF-kappa	O
B	O
nuclear	O
localization	O
and	O
transactivation	O
of	O
its	O
target	O
genes	O
.	O

It	O
is	O
demonstrated	O
here	O
with	O
human	O
T	O
lymphocytes	O
and	O
monocytes	O
that	O
different	O
stimuli	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
cause	O
rapid	O
degradation	O
of	O
I	O
kappa	O
B-alpha	O
,	O
with	O
concomitant	O
activation	O
of	O
NF-kappa	O
B	O
,	O
followed	O
by	O
a	O
dramatic	O
increase	O
in	O
I	O
kappa	O
B-alpha	O
mRNA	O
and	O
protein	O
synthesis	O
.	O

Transfection	O
studies	O
reveal	O
that	O
the	O
I	O
kappa	O
B-alpha	O
mRNA	O
and	O
the	O
encoded	O
protein	O
are	O
potently	O
induced	O
by	O
NF-kappa	O
B	O
and	O
by	O
homodimers	O
of	O
p65	O
and	O
of	O
c-Rel	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
NF-kappa	O
B	O
and	O
I	O
kappa	O
B-alpha	O
mutually	O
regulate	O
each	O
other	O
in	O
a	O
cycle	O
:	O

saturating	O
amounts	O
of	O
the	O
inhibitory	O
I	O
kappa	O
B-alpha	O
protein	O
are	O
destroyed	O
upon	O
stimulation	O
,	O
allowing	O
rapid	O
activation	O
of	O
NF-kappa	O
B	O
.	O

Subsequently	O
,	O
I	O
kappa	O
B-alpha	O
mRNA	O
and	O
protein	O
levels	O
are	O
quickly	O
induced	O
by	O
the	O
activated	O
NF-kappa	O
B	O
.	O

This	O
resurgence	O
of	O
I	O
kappa	O
B-alpha	O
protein	O
acts	O
to	O
restore	O
an	O
equilibrium	O
in	O
which	O
NF-kappa	O
B	O
is	O
again	O
inhibited	O
.	O

Induced	O
myeloid	O
differentiation	O
of	O
K562	O
cells	O
with	O
downregulation	O
of	O
erythroid	O
and	O
megakaryocytic	O
transcription	O
factors	O
:	O
a	O
novel	O
experimental	O
model	O
for	O
hemopoietic	O
lineage	O
restriction	O
.	O

The	O
human	O
erythroleukemia	O
cell	O
line	O
K562	O
can	O
be	O
induced	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

Here	O
we	O
demonstrate	O
that	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
induced	O
K562	O
cells	O
to	O
differentiate	O
along	O
a	O
third	O
pathway	O
.	O

This	O
was	O
accompanied	O
by	O
downregulation	O
of	O
two	O
transcription	O
factors	O
normally	O
expressed	O
in	O
erythroid	O
,	O
mast	O
and	O
megakaryocyte	O
lineages	O
.	O

Northern	O
analysis	O
demonstrated	O
coordinate	O
downregulation	O
of	O
alpha	O
globin	O
and	O
gamma	O
globin	O
in	O
addition	O
to	O
the	O
two	O
lineage-restricted	O
transcription	O
factors	O
,	O
SCL	O
and	O
GATA-1	O
.	O

Proliferation	O
of	O
the	O
K562	O
cells	O
was	O
also	O
suppressed	O
.	O

Clonal	O
assay	O
showed	O
that	O
the	O
suppression	O
was	O
irreversible	O
and	O
appeared	O
analogous	O
to	O
the	O
commitment	O
of	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
to	O
terminal	O
differentiation	O
.	O

In	O
contrast	O
to	O
MEL	O
cells	O
,	O
however	O
,	O
K562	O
cells	O
acquired	O
a	O
macrophage-like	O
morphology	O
and	O
exhibited	O
a	O
complete	O
failure	O
to	O
generate	O
benzidine-positive	O
cells	O
.	O

Electron	O
microscopy	O
revealed	O
a	O
marked	O
increase	O
in	O
granules	O
resembling	O
those	O
specific	O
for	O
eosinophils	O
.	O

Surface	O
marker	O
analysis	O
showed	O
that	O
HMBA-induced	O
cells	O
expressed	O
reduced	O
levels	O
of	O
glycophorin	O
A	O
,	O
CD5	O
,	O
CD7	O
and	O
CD11b	O
.	O

No	B-Negation
upregulation	I-Negation
of	I-Negation
megakaryocyte	I-Negation
or	I-Negation
lymphoid	I-Negation
markers	I-Negation
occurred	I-Negation
.	O

Thus	O
the	O
response	O
of	O
K562	O
cells	O
to	O
HMBA	O
may	O
provide	O
a	O
useful	O
experimental	O
system	O
for	O
studying	O
the	O
molecular	O
mechanisms	O
responsible	O
for	O
downmodulation	O
of	O
lineage-restricted	O
transcription	O
factors	O
during	O
hemopoietic	O
lineage	O
commitment	O
.	O

The	O
Sp1	O
transcription	O
factor	O
binds	O
the	O
CD11b	O
promoter	O
specifically	O
in	O
myeloid	O
cells	O
in	O
vivo	O
and	O
is	O
essential	O
for	O
myeloid-specific	O
promoter	O
activity	O
.	O

The	O
myeloid	O
integrin	O
CD11b	O
is	O
expressed	O
selectively	O
on	O
the	O
surface	O
of	O
mature	O
macrophages	O
,	O
monocytes	O
,	O
neutrophils	O
,	O
and	O
natural	O
killer	O
cells	O
.	O

Lineage-specific	O
expression	O
is	O
controlled	O
at	O
the	O
level	O
of	O
mRNA	O
transcription	O
.	O

Recent	O
isolation	O
of	O
the	O
CD11b	O
promoter	O
shows	O
that	O
92	O
base	O
pairs	O
(	O
bp	O
)	O
of	O
5'-flanking	O
DNA	O
are	O
sufficient	O
to	O
direct	O
myeloid-specific	O
expression	O
of	O
a	O
reporter	O
gene	O
.	O

To	O
characterize	O
regulatory	O
sequences	O
important	O
for	O
promoter	O
activity	O
,	O
we	O
performed	O
linker	O
scanning	O
analysis	O
of	O
the	O
92-bp	O
CD11b	O
promoter	O
and	O
demonstrate	O
that	O
a	O
sequence	O
at	O
bp	O
-60	O
is	O
essential	O
for	O
CD11b	O
promoter	O
activity	O
.	O

We	O
show	O
that	O
this	O
sequence	O
binds	O
the	O
transcription	O
factor	O
Sp1	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vivo	O
the	O
Sp1	O
site	O
is	O
bound	O
only	O
in	O
myeloid	O
(	O
U937	O
)	O
cells	O
,	O
not	B-Negation
in	I-Negation
cervical	I-Negation
carcinoma	I-Negation
(	I-Negation
HeLa	I-Negation
)	I-Negation
cells	I-Negation
.	O

In	O
addition	O
,	O
the	O
macrophage	O
transcription	O
factor	O
PU.1	O
binds	O
the	O
CD11b	O
promoter	O
in	O
vitro	O
and	O
in	O
vivo	O
close	O
to	O
the	O
Sp1	O
site	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
binding	O
of	O
a	O
myeloid-specific	O
factor	O
(	O
PU.1	O
)	O
allows	O
a	O
general	O
factor	O
(	O
Sp1	O
)	O
to	O
bind	O
in	O
a	O
tissue-specific	O
fashion	O
thereby	O
contributing	O
to	O
the	O
myeloid-specific	O
expression	O
of	O
CD11b	O
.	O

Costimulation	O
of	O
peripheral	O
blood	O
T	O
cell	O
activation	O
by	O
human	O
endothelial	O
cells	O
.	O

Enhanced	O
IL-2	O
transcription	O
correlates	O
with	O
increased	O
c-fos	O
synthesis	O
and	O
increased	O
Fos	O
content	O
of	O
AP-1	O
.	O

Endothelial	O
cells	O
(	O
EC	O
)	O
act	O
as	O
APC	O
for	O
resting	O
PBL	O
in	O
vitro	O
,	O
and	O
may	O
have	O
important	O
roles	O
in	O
vivo	O
in	O
the	O
pathogenesis	O
of	O
allograft	O
rejection	O
and	O
delayed	O
hypersensitivity	O
.	O

We	O
previously	O
reported	O
that	O
human	O
umbilical	O
vein	O
EC	O
provide	O
costimulatory	O
signals	O
to	O
PHA-stimulated	O
PBL	O
via	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
and	O
an	O
unidentified	O
ligand	O
pair	O
,	O
resulting	O
in	O
a	O
three-	O
to	O
eight-fold	O
enhancement	O
of	O
IL-2	O
production	O
.	O

The	O
physiologic	O
relevance	O
of	O
this	O
increase	O
was	O
demonstrated	O
by	O
the	O
proliferative	O
advantage	O
provided	O
by	O
EC	O
to	O
PBL	O
suboptimally	O
stimulated	O
with	O
mAb	O
OKT3	O
.	O

We	O
now	O
report	O
that	O
EC	O
costimulation	O
causes	O
increased	O
levels	O
of	O
IL-2	O
mRNA	O
as	O
a	O
result	O
of	O
increased	O
IL-2	O
transcription	O
in	O
PBL	O
.	O

We	O
therefore	O
examined	O
the	O
effects	O
of	O
EC	O
on	O
T	O
cell	O
nuclear	O
factors	O
known	O
to	O
regulate	O
IL-2	O
transcription	O
,	O
including	O
c-jun	O
and	O
c-fos-two	O
components	O
of	O
the	O
transcription	O
factor	O
AP-1	O
,	O
NFAT	O
,	O
and	O
others	O
.	O

PBL	O
constitutively	O
express	O
c-jun	O
transcripts	O
,	O
and	O
the	B-Negation
level	I-Negation
of	I-Negation
c-jun	I-Negation
mRNA	I-Negation
is	I-Negation
not	I-Negation
altered	I-Negation
by	I-Negation
PHA	I-Negation
activation	I-Negation
in	I-Negation
the	I-Negation
absence	I-Negation
or	I-Negation
presence	I-Negation
of	I-Negation
EC	I-Negation
.	O

In	O
contrast	O
,	O
c-fos	O
mRNA	O
is	O
absent	O
from	O
resting	O
T	O
cells	O
and	O
is	O
induced	O
on	O
PHA	O
activation	O
.	O

EC	O
alone	O
do	O
not	B-Negation
induce	I-Negation
c-fos	I-Negation
mRNA	I-Negation
but	O
augment	O
the	O
level	O
of	O
c-fos	O
mRNA	O
in	O
PHA-activated	O
T	O
cells	O
by	O
3-	O
to	O
10-fold	O
.	O

This	O
effect	O
is	O
largely	O
independent	O
of	O
the	O
CD2	O
:	O
lymphocyte	O
function-associated	O
Ag-3	O
pathway	O
.	O

Gel-shift	O
analysis	O
reveals	O
the	O
constitutive	O
presence	O
of	O
nuclear	O
factors	O
in	O
resting	O
PBL	O
that	O
bind	O
to	O
the	O
proximal	O
AP-1	O
site	O
of	O
the	O
IL-2	O
promoter	O
and	O
that	O
contain	O
immunoreactive	O
c-Jun	O
but	O
not	B-Negation
c-Fos	I-Negation
protein	I-Negation
.	O

In	O
contrast	O
,	O
AP-1	O
from	O
PHA-activated	O
cells	O
contains	O
c-Jun	O
and	O
low	O
levels	O
of	O
c-Fos	O
.	O

Strikingly	O
,	O
costimulation	O
with	O
EC	O
results	O
in	O
a	O
dramatic	O
increase	O
(	O
up	O
to	O
15-fold	O
)	O
in	O
the	O
c-Fos	O
content	O
of	O
AP-1	O
.	O

Levels	B-Negation
of	I-Negation
other	I-Negation
nuclear	I-Negation
factors	I-Negation
involved	I-Negation
in	I-Negation
IL-2	I-Negation
regulation	I-Negation
were	I-Negation
not	I-Negation
altered	I-Negation
by	I-Negation
EC	I-Negation
,	O
although	O
NFAT-DNA	O
complexes	O
migrated	O
at	O
a	O
slightly	O
different	O
mobility	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
that	O
changes	O
in	O
the	O
composition	O
of	O
transcription	O
factor	O
AP-1	O
is	O
a	O
key	O
molecular	O
mechanism	O
for	O
increasing	O
IL-2	O
transcription	O
and	O
may	O
underlie	O
the	O
phenomenon	O
of	O
costimulation	O
by	O
EC	O
.	O

A	O
protein	O
of	O
the	O
AP-1	O
family	O
is	O
a	O
component	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
is	O
a	O
transcriptional	O
activator	O
involved	O
in	O
the	O
induction	O
of	O
IL-2	O
gene	O
expression	O
.	O

The	O
response	O
element	O
for	O
NF-AT	O
is	O
a	O
sequence	O
localized	O
between	O
-285/-254	O
in	O
the	O
IL-2	O
regulatory	O
region	O
.	O

The	B-Negation
composition	I-Negation
of	I-Negation
NF-AT	I-Negation
protein	I-Negation
is	I-Negation
still	I-Negation
not	I-Negation
fully	I-Negation
elucidated	I-Negation
.	O

We	O
demonstrate	O
that	O
,	O
in	O
normal	O
human	O
T	O
cells	O
,	O
an	O
AP-1	O
protein	O
is	O
a	O
component	O
of	O
the	O
NF-AT	O
protein	O
complex	O
.	O

This	O
was	O
evidenced	O
by	O
the	O
ability	O
of	O
the	O
AP-1	O
site	O
to	O
compete	O
with	O
the	O
NF-AT	O
site	O
for	O
binding	O
to	O
NF-AT	O
and	O
by	O
the	O
capacity	O
of	O
immobilized	O
anti-Jun	O
and	O
anti-Fos	O
antibodies	O
to	O
deplete	O
NF-AT-binding	O
activity	O
from	O
nuclear	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O

There	O
was	O
no	B-Negation
detectable	I-Negation
binding	I-Negation
of	I-Negation
in	I-Negation
vitro	I-Negation
translated	I-Negation
Jun/Fos	I-Negation
heterodimer	I-Negation
(	I-Negation
AP-1	I-Negation
)	I-Negation
to	I-Negation
the	I-Negation
NF-AT	I-Negation
sequence	I-Negation
,	O
and	O
the	O
NF-AT	O
sequence	O
was	O
unable	B-Negation
to	I-Negation
inhibit	I-Negation
the	I-Negation
binding	I-Negation
of	I-Negation
Jun/Fos	I-Negation
to	I-Negation
the	I-Negation
AP-1	I-Negation
sequence	I-Negation
.	O

The	O
presence	O
of	O
an	O
AP-1	O
protein	O
in	O
the	O
NF-AT	O
protein	O
complex	O
may	O
regulate	O
NF-AT-binding	O
activity	O
through	O
protein-protein	O
interaction	O
.	O

Functional	O
antagonism	O
between	O
vitamin	O
D3	O
and	O
retinoic	O
acid	O
in	O
the	O
regulation	O
of	O
CD14	O
and	O
CD23	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
cells	O
.	O

1,25	O
alpha-Dihydroxicholecalciferol	O
(	O
VitD3	O
)	O
and	O
retinoic	O
acid	O
(	O
RA	O
)	O
are	O
important	O
regulators	O
of	O
the	O
proliferation	O
and	O
differentiation	O
of	O
several	O
cell	O
types	O
.	O

This	O
paper	O
describes	O
how	O
the	O
expression	O
of	O
the	O
monocyte-macrophage	O
Ag	O
,	O
CD14	O
,	O
and	O
the	O
low	O
affinity	O
Fc	O
receptor	O
for	O
IgE	O
,	O
CD23	O
,	O
were	O
inversely	O
regulated	O
during	O
VitD3-	O
and	O
RA-induced	O
monocytic	O
differentiation	O
of	O
human	O
U-937	O
monoblasts	O
.	O

PMA	O
induced	O
the	O
expression	O
of	O
both	O
CD14	O
and	O
CD23	O
mRNA	O
and	O
protein	O
.	O

Exposure	O
to	O
VitD3	O
rapidly	O
induced	O
the	O
de	O
novo	O
expression	O
of	O
CD14	O
mRNA	O
and	O
protein	O
.	O

The	O
addition	O
of	O
cycloheximide	O
completely	O
blocked	O
the	O
VitD3	O
induction	O
of	O
CD14	O
mRNA	O
expression	O
,	O
indicating	O
that	O
the	O
induction	O
was	O
dependent	O
on	O
ongoing	O
protein	O
synthesis	O
.	O

While	O
inducing	O
CD14	O
expression	O
,	O
VitD3	O
concomitantly	O
suppressed	O
the	O
basal	O
,	O
PMA-	O
,	O
and	O
RA-inducible	O
CD23	O
expression	O
in	O
a	O
dose-dependent	O
manner	O
.	O

In	O
contrast	O
,	O
U-937	O
cells	O
induced	O
by	O
RA	O
strongly	O
increased	O
their	O
expression	O
of	O
CD23	O
mRNA	O
and	O
protein	O
,	O
whereas	O
they	O
completely	O
lacked	B-Negation
detectable	I-Negation
CD14	I-Negation
cell	I-Negation
surface	I-Negation
or	I-Negation
mRNA	I-Negation
expression	I-Negation
.	O

Furthermore	O
,	O
the	O
VitD3-	O
and	O
the	O
PMA-induced	O
CD14	O
expression	O
was	O
inhibited	O
as	O
a	O
temporal	O
consequence	O
of	O
the	O
RA-induced	O
differentiation	O
.	O

The	O
results	O
suggest	O
that	O
there	O
exists	O
a	O
functional	O
antagonism	O
between	O
VitD3	O
and	O
RA	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
regulation	O
of	O
certain	O
immune	O
and	O
inflammatory	O
responses	O
through	O
their	O
inverse	O
effects	O
on	O
CD14	O
and	O
CD23	O
gene	O
expression	O
.	O

The	O
lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
is	O
imitated	O
by	O
recombinant	O
B-cells	O
.	O

Lytic	O
transition	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
initiated	O
by	O
distinct	O
immediate	O
early	O
regulators	O
of	O
the	O
viral	O
cycle	O
,	O
in	O
synchronization	O
to	O
temporary	O
,	O
permissive	O
conditions	O
during	O
host	O
cell	O
differentiation	O
.	O

We	O
developed	O
eukaryotic	O
vectors	O
suitable	O
to	O
imitate	O
the	O
processes	O
involved	O
in	O
lytic	O
transition	O
in	O
cell	O
culture	O
systems	O
.	O

Two	O
stable	O
B	O
cell	O
lines	O
were	O
established	O
:	O

R59Z	O
activator	O
cells	O
were	O
used	O
to	O
induce	O
lytic	O
EBV	O
expression	O
in	O
a	O
constitutive	O
manner	O
by	O
the	O
production	O
of	O
the	O
BZLF	O
1	O
trans-activator	O
(	O
Zta	O
)	O
.	O

R7-57	O
reporter	O
cells	O
,	O
on	O
the	O
other	O
hand	O
,	O
signaled	O
induced	O
activity	O
of	O
the	O
lytic	O
origin	O
of	O
EBV	O
replication	O
(	O
ori	O
Lyt	O
)	O
.	O

Different	O
modes	O
,	O
like	O
chemical	O
induction	O
,	O
lytic	O
superinfection	O
with	O
EBV	O
and	O
single	O
gene	O
trans-activation	O
converted	O
the	O
recombinant	O
ori	O
Lyt	O
element	O
in	O
R7-57	O
reporter	O
cells	O
.	O

BZLF	O
1	O
,	O
transiently	O
expressed	O
in	O
R7-57	O
reporter	O
cells	O
,	O
was	O
the	O
only	O
EBV	O
trans-activator	O
found	O
,	O
sufficient	O
in	O
inducing	O
the	O
viral	O
lytic	O
cycle	O
.	O

Basing	O
on	O
these	O
experiments	O
,	O
trans-cellular	O
activation	O
of	O
EBV	O
was	O
tested	O
by	O
cocultivation	O
of	O
BZLF	O
1-expressing	O
R59Z	O
activator	O
cells	O
with	O
the	O
R7-57	O
reporter	O
line	O
.	O

No	B-Negation
lytic	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
reporter	I-Negation
cells	I-Negation
could	I-Negation
be	I-Negation
measured	I-Negation
,	I-Negation
neither	I-Negation
by	I-Negation
cocultivation	I-Negation
of	I-Negation
activator	I-Negation
cells	I-Negation
nor	I-Negation
by	I-Negation
coincubation	I-Negation
of	I-Negation
BZLF	I-Negation
1-containing	I-Negation
cell	I-Negation
lysates	I-Negation
.	O

Latency	O
breaking	O
activity	O
,	O
however	O
,	O
was	O
transferred	O
from	O
activator	O
to	O
reporter	O
cells	O
when	O
active	O
,	O
exogenous	O
virus	O
was	O
added	O
.	O

The	O
cell	O
system	O
described	O
in	O
these	O
experiments	O
provides	O
a	O
tool	O
for	O
the	O
detection	O
of	O
EBV	O
reactivation	O
and	O
demonstrates	O
the	O
potential	O
of	O
the	O
lytic	O
regulatory	O
gene	O
BZLF	O
1	O
.	O

Immobilization	O
and	O
recovery	O
of	O
fusion	O
proteins	O
and	O
B-lymphocyte	O
cells	O
using	O
magnetic	O
separation	O
.	O

A	O
new	O
approach	O
to	O
facilitate	O
immobilization	O
and	O
affinity	O
purification	O
of	O
recombinant	O
proteins	O
and	O
selected	O
human	O
B	O
lymphocytes	O
has	O
been	O
developed	O
.	O

Using	O
magnetic	O
beads	O
with	O
attached	O
DNA	O
containing	O
the	O
Escherichia	O
coli	O
lac	O
operator	O
,	O
fusion	O
proteins	O
comprising	O
the	O
DNA-binding	O
lac	O
repressor	O
could	O
be	O
affinity-purified	O
and	O
recovered	O
by	O
gentle	O
elution	O
conditions	O
,	O
such	O
as	O
with	O
a	O
lactose	O
analogue	O
or	O
by	O
enzymatic	O
means	O
using	O
either	O
deoxyribonuclease	O
(	O
DNase	O
)	O
or	O
restriction	O
endonucleases	O
.	O

The	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
a	O
DNA-binding	O
protein	O
can	O
be	O
used	O
for	O
affinity	O
purification	O
of	O
fusion	O
proteins	O
as	O
exemplified	O
by	O
the	O
specific	O
and	O
gentle	O
recovery	O
of	O
beta-galactosidase	O
and	O
alkaline	O
phosphatase	O
from	O
bacterial	O
lysates	O
using	O
immunomagnetic	O
separation	O
.	O

The	O
approach	O
was	O
further	O
extended	O
to	O
cell	O
separation	O
by	O
the	O
efficient	O
recovery	O
and	O
elution	O
of	O
human	O
CD37	O
B	O
lymphocytes	O
from	O
peripheral	O
blood	O
.	O

Negative	O
transcriptional	O
regulation	O
of	O
human	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	O
transcription	O
factors	O
AP-1	O
and	O
NF-AT	O
.	O

IL-2	O
gene	O
transcription	O
is	O
affected	O
by	O
several	O
nuclear	O
proteins	O
.	O

We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL-2	O
gene	O
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	O
proteins	O
that	O
bind	O
to	O
the	O
IL-2	O
promoter	O
.	O

Nuclear	O
extracts	O
from	O
primary	O
human	O
T	O
lymphocytes	O
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	O
and	O
NF-AT	O
,	O
but	O
not	B-Negation
of	I-Negation
NF-kB	I-Negation
and	I-Negation
OCT-1/OAF	I-Negation
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	O
gene	O
promoter	O
.	O

To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL-2	O
promoter	O
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O

Jurkat	O
cells	O
were	O
transfected	O
with	O
plasmids	O
containing	O
either	O
the	O
intact	O
IL-2	O
promoter	O
or	O
its	O
AP-1	O
,	O
NF-AT	O
,	O
and	O
NF-kB	O
motifs	O
.	O

Dex	O
inhibited	O
the	O
IL-2	O
promoter	O
and	O
the	O
AP-1	O
,	O
but	O
not	B-Negation
the	I-Negation
NF-AT	I-Negation
and	I-Negation
NF-kB	I-Negation
plasmids	I-Negation
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	O
promoter	O
and	O
the	O
NF-AT	O
,	O
but	O
not	B-Negation
the	I-Negation
AP-1	I-Negation
and	I-Negation
NF-kB	I-Negation
plasmids	I-Negation
.	O

These	O
results	O
suggest	O
that	O
in	O
human	O
T	O
lymphocytes	O
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL-2	O
gene	O
transcription	O
through	O
interference	O
with	O
transcription	O
factors	O
AP-1	O
and	O
NF-AT	O
.	O

We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	O
factors	O
,	O
AP-1	O
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O

Lymphocytes	O
from	O
the	O
site	O
of	O
disease	O
suggest	O
adenovirus	O
is	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O

The	O
assessment	O
of	O
synovial	O
lymphocyte	O
reactivity	O
to	O
adenovirus	O
antigen	O
stimulation	O
was	O
undertaken	O
in	O
patients	O
with	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O

The	O
3H-thymidine	O
uptake	O
procedure	O
was	O
employed	O
,	O
incorporating	O
multiple	O
microbiological	O
antigens	O
.	O

Five	O
patients	O
were	O
found	O
with	O
repeated	O
maximal	O
responses	O
to	O
adenovirus	O
antigen	O
;	O
in	O
one	O
of	O
these	O
adenovirus	O
nucleotide	O
sequences	O
were	O
present	O
in	O
a	O
synovial	O
biopsy	O
specimen	O
.	O

It	O
is	O
concluded	O
that	O
adenovirus	O
may	O
be	O
one	O
cause	O
of	O
persistent	O
or	O
recurrent	O
inflammatory	O
arthritis	O
.	O

Human	O
CD3-CD16+	O
natural	O
killer	O
cells	O
express	O
the	O
hGATA-3	O
T	O
cell	O
transcription	O
factor	O
and	O
an	O
unrearranged	O
2.3-kb	O
TcR	O
delta	O
transcript	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
delta	O
transcripts	O
expressed	O
by	O
CD3-CD16+	O
cells	O
and	O
we	O
investigated	O
whether	O
these	O
cells	O
expressed	O
the	O
hGATA-3	O
T	O
cell	O
transcription	O
factor	O
and	O
the	O
recombination-activating	O
gene	O
(	O
RAG	O
)	O
-1	O
.	O

Multiple	O
TcR	O
delta	O
transcripts	O
deriving	O
from	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
were	O
detected	O
in	O
both	O
polyclonal	O
and	O
clonal	O
CD3-CD16+	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lines	O
.	O

Two	O
unrearranged	O
TcR	O
delta	O
transcripts	O
had	O
a	O
size	O
similar	O
to	O
that	O
of	O
the	O
functional	O
TcR	O
delta	O
mRNA	O
(	O
2.3	O
and	O
1.3	O
kb	O
)	O
found	O
in	O
TcR	O
gamma/delta+	O
T	O
lymphocytes	O
.	O

Sequence	O
analysis	O
of	O
nine	O
different	O
2.3-kb	O
cDNA	O
clones	O
obtained	O
from	O
NK-derived	O
polyA+	O
RNA	O
confirmed	O
that	O
they	O
corresponded	O
to	O
an	O
unrearranged	O
TcR	O
delta	O
gene	O
.	O

These	O
cDNA	O
were	O
2343	O
bp	O
long	O
and	O
their	O
transcription	O
initiation	O
site	O
was	O
located	O
814	O
bp	O
upstream	O
from	O
the	O
J	O
delta	O
1	O
segment	O
.	O

The	O
sequence	O
located	O
upstream	O
of	O
the	O
J	O
delta	O
1	O
segment	O
corresponded	O
to	O
the	O
previously	O
reported	O
germ-line	O
sequence	O
.	O

The	O
J	O
delta	O
1	O
segment	O
was	O
correctly	O
spliced	O
to	O
C	O
delta	O
;	O
in	O
addition	O
the	O
four	O
C	O
delta	O
exons	O
were	O
found	O
to	O
be	O
already	O
assembled	O
.	O

Two	O
polyadenylation	O
sites	O
were	O
present	O
in	O
the	O
fourth	O
C	O
delta	O
exon	O
.	O

However	O
,	O
only	O
that	O
located	O
at	O
the	O
3	O
'	O
end	O
appeared	O
to	O
be	O
utilized	O
in	O
the	O
2.3-kb	O
cDNA	O
.	O

The	O
expression	O
of	O
hGATA-3	O
,	O
a	O
T	O
cell-specific	O
factor	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
transcription	O
of	O
TcR	O
delta	O
locus	O
,	O
was	O
analyzed	O
by	O
Northern	O
blot	O
,	O
in	O
cultured	O
NK	O
cell	O
population	O
and	O
clones	O
(	O
but	O
not	B-Negation
in	I-Negation
freshly	I-Negation
derived	I-Negation
cell	I-Negation
populations	I-Negation
)	O
.	O

All	O
NK	O
clones	O
and	O
cell	O
lines	O
studied	O
were	O
found	O
to	O
express	O
hGATA-3-specific	O
mRNA	O
,	O
suggesting	O
that	O
hGATA-3	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
unrearranged	O
TcR	O
delta	O
gene	O
expression	O
in	O
NK	O
cells	O
.	O

Finally	O
,	O
no	B-Negation
transcription	I-Negation
of	I-Negation
the	I-Negation
RAG-1	I-Negation
gene	I-Negation
could	I-Negation
be	I-Negation
detected	I-Negation
in	I-Negation
all	I-Negation
NK	I-Negation
cell	I-Negation
lines	I-Negation
or	I-Negation
clones	I-Negation
analyzed	I-Negation
.	O

Cell-specific	O
expression	O
of	O
helix-loop-helix	O
transcription	O
factors	O
encoded	O
by	O
the	O
E2A	O
gene	O
.	O

The	O
E2A	O
gene	O
encodes	O
transcription	O
factors	O
of	O
the	O
helix-loop-helix	O
family	O
that	O
are	O
implicated	O
in	O
cell-specific	O
gene	O
expression	O
as	O
part	O
of	O
dimeric	O
complexes	O
that	O
interact	O
with	O
E	O
box	O
enhancer	O
elements	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
transcripts	O
of	O
the	O
E2A	O
gene	O
can	O
be	O
detected	O
in	O
a	O
wide	O
range	O
of	O
cell	O
types	O
.	O

We	O
have	O
now	O
examined	O
expression	O
of	O
the	O
mouse	O
E2A	O
gene	O
at	O
the	O
protein	O
level	O
using	O
polyclonal	O
antisera	O
directed	O
against	O
distinct	O
portions	O
of	O
the	O
E2A	O
protein	O
to	O
probe	O
blots	O
of	O
cellular	O
extracts	O
.	O

A	O
73	O
kDa	O
protein	O
was	O
identified	O
by	O
this	O
analysis	O
:	O

this	O
protein	O
is	O
highly	O
enriched	O
in	O
cell	O
lines	O
of	O
B	O
lymphoid	O
origin	O
as	O
compared	O
to	O
pancreatic	O
beta-cells	O
and	O
fibroblast	O
cells	O
.	O

The	O
detection	O
of	O
this	O
protein	O
selectively	O
in	O
extracts	O
of	O
lymphoid	O
cells	O
correlates	O
with	O
the	O
presence	O
of	O
the	O
E	O
box-binding	O
activity	O
LEF1/BCF1	O
in	O
these	O
cells	O
;	O

this	O
binding	O
activity	O
was	O
previously	O
shown	O
to	O
be	O
efficiently	O
recognized	O
by	O
antiserum	O
directed	O
against	O
E2A	O
gene	O
products	O
.	O

Transfection	O
of	O
cells	O
with	O
full	O
length	O
E2A	O
cDNA	O
leads	O
to	O
appearance	O
of	O
protein	O
co-migrating	O
with	O
the	O
73	O
kDa	O
protein	O
on	O
SDS	O
gel	O
electrophoresis	O
and	O
co-migrating	O
with	O
LEF1/BCF1	O
on	O
mobility	O
shift	O
analysis	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
view	O
that	O
the	O
DNA-binding	O
activity	O
LEF1/BCF1	O
is	O
a	O
homodimer	O
of	O
E2A	O
proteins	O
;	O

the	O
selective	O
appearance	O
of	O
this	O
putative	O
cell-specific	O
transcription	O
factor	O
in	O
B	O
lymphoid	O
cells	O
seems	O
to	O
be	O
attributable	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
elevated	O
E2A	O
protein	O
concentrations	O
in	O
these	O
cells	O
.	O

HIV-1	O
Nef	O
protein	O
inhibits	O
the	O
recruitment	O
of	O
AP-1	O
DNA-binding	O
activity	O
in	O
human	O
T-cells	O
.	O

The	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
HIV-1-LTR	O
,	O
contains	O
binding	O
sites	O
for	O
several	O
cellular	O
transcription	O
factors	O
which	O
contribute	O
to	O
HIV-1	O
gene	O
expression	O
.	O

Our	O
previous	O
studies	O
on	O
the	O
function	O
of	O
the	O
HIV-1-encoded	O
Nef	O
protein	O
suggested	O
that	O
Nef	O
may	O
be	O
an	O
inhibitor	O
HIV-1	O
transcription	O
.	O

To	O
determine	O
whether	O
Nef	O
affects	O
the	O
binding	O
of	O
cellular	O
factors	O
implicated	O
in	O
HIV-1	O
regulation	O
,	O
32P-labeled	O
oligonucleotides	O
corresponding	O
to	O
the	O
binding	O
sites	O
were	O
incubated	O
with	O
nuclear	O
extracts	O
prepared	O
from	O
Nef-expressing	O
T-cell	O
lines	O
that	O
were	O
not	O
stimulated	O
or	O
were	O
stimulated	O
with	O
T-cell	O
mitogens	O
.	O

We	O
found	O
that	O
Nef	O
inhibited	O
the	O
recruitment	O
of	O
AP-1	O
DNA-binding	O
activity	O
in	O
mitogen-stimulated	O
human	O
T-cells	O
.	O

Additionally	O
,	O
Nef	O
expressing	O
cells	O
were	O
transiently	O
transfected	O
with	O
a	O
plasmid	O
in	O
which	O
HIV-1	O
AP-1	O
DNA	O
recognition	O
sequences	O
were	O
cloned	O
downstream	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
.	O

Mitogen-mediated	O
transcriptional	O
activation	O
of	O
the	O
CAT	O
gene	O
in	O
this	O
construct	O
was	O
inhibited	O
in	O
Nef-expressing	O
cells	O
but	O
not	B-Negation
in	I-Negation
control	I-Negation
cells	I-Negation
.	O

These	O
studies	O
suggest	O
that	O
,	O
by	O
inhibiting	O
AP-1	O
activation	O
,	O
Nef	O
may	O
play	O
a	O
role	O
in	O
regulating	O
HIV-1	O
gene	O
expression	O
in	O
infected	O
T-cells	O
.	O

Hypertension	O
in	O
pregnancy	O
.	O

Pregnancy-induced	O
hypertension	O
(	O
PIH	O
)	O
is	O
a	O
frequent	O
cause	O
of	O
maternal	O
and	O
neonatal	O
morbidity	O
and	O
mortality	O
.	O

In	O
the	O
present	O
study	O
we	O
focused	O
on	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
mainly	O
on	O
the	O
role	O
of	O
mineralocorticoids	O
,	O
reversed	O
blood	O
pressure	O
patterns	O
,	O
and	O
the	O
resulting	O
necessity	O
of	O
continuous	O
monitoring	O
of	O
the	O
preeclamptic	O
mother	O
.	O

Problems	O
of	O
antihypertensive	O
therapy	O
are	O
discussed	O
and	O
the	O
first	O
results	O
of	O
a	O
pilot	O
study	O
with	O
Urapidil	O
are	O
presented	O
.	O

To	O
examine	O
the	O
role	O
of	O
mineralocorticoids	O
in	O
the	O
pathophysiology	O
of	O
PIH	O
,	O
we	O
studied	O
plasma	O
aldosterone	O
and	O
18-hydroxy-corticosterone	O
(	O
18-OH-B	O
)	O
levels	O
in	O
25	O
women	O
with	O
PIH	O
and	O
in	O
25	O
healthy	O
pregnant	O
women	O
.	O

Furthermore	O
,	O
we	O
evaluated	O
the	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
count	O
in	O
mononuclear	O
leukocytes	O
in	O
the	O
2	O
groups	O
.	O

The	O
MR-count	O
was	O
significantly	O
decreased	O
in	O
the	O
PIH-group	O
.	O

The	O
values	O
of	O
plasma	O
aldosterone	O
and	O
18-OH-B	O
were	O
also	O
low	O
.	O

These	B-Negation
results	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
explained	I-Negation
by	I-Negation
receptor	I-Negation
down-regulation	I-Negation
due	I-Negation
to	I-Negation
higher	I-Negation
level	I-Negation
of	I-Negation
mineralocorticoids	I-Negation
of	I-Negation
the	I-Negation
zona	I-Negation
glomerulosa	I-Negation
.	O

Perhaps	O
deoxycorticosterone	O
or	O
a	O
hitherto	O
unknown	O
mineralocorticoid	O
is	O
responsible	O
for	O
the	O
hypertension	O
and	O
altered	O
MR-status	O
.	O

The	O
first	O
results	O
of	O
continuous	O
blood	O
pressure	O
measurements	O
with	O
a	O
noninvasive	O
,	O
real-time	O
blood	O
pressure	O
monitor	O
(	O
Finapres	O
)	O
are	O
presented	O
.	O

The	O
comparison	O
of	O
the	O
obtained	O
values	O
with	O
intraarterial	O
measurements	O
demonstrates	O
a	O
good	O
correlation	O
between	O
the	O
two	O
methods	O
.	O

We	O
also	O
report	O
on	O
the	O
first	O
experiences	O
with	O
Urapidil	O
in	O
the	O
treatment	O
of	O
hypertension	O
in	O
severe	O
preeclampsia	O
.	O

The	O
data	O
show	O
that	O
hypertension	O
in	O
preeclamptic	O
women	O
can	O
be	O
treated	O
by	O
Urapidil	O
without	O
side	O
effects	O
or	O
reflex-tachycardia	O
.	O

Further	O
studies	O
will	O
have	O
to	O
prove	O
if	O
Urapidil	O
is	O
suited	O
for	O
prepartal	O
treatment	O
of	O
PIH	O
as	O
well	O
.	O

Aldosterone-specific	O
membrane	O
receptors	O
and	O
rapid	O
non-genomic	O
actions	O
of	O
mineralocorticoids	O
.	O

Functional	O
studies	O
in	O
extrarenal	O
,	O
non-epithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
,	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton	O
exchanger	O
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
min	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol	O
1,4,5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	B-Negation
changes	I-Negation
clearly	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
explained	I-Negation
by	I-Negation
genomic	I-Negation
mechanisms	I-Negation
,	I-Negation
which	I-Negation
are	I-Negation
responsible	I-Negation
for	I-Negation
later	I-Negation
effects	I-Negation
than	I-Negation
the	I-Negation
membrane	I-Negation
related	I-Negation
rapid	I-Negation
responses	I-Negation
.	O

The	O
mechanisms	O
underlying	O
these	O
rapid	O
effects	O
of	O
aldosterone	O
on	O
electrolytes	O
have	O
been	O
extensively	O
studied	O
in	O
human	O
lymphocytes	O
,	O
which	O
thus	O
may	O
represent	O
valuable	O
tools	O
in	O
the	O
delineation	O
of	O
the	O
receptor-effector	O
mechanisms	O
involved	O
.	O

The	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
its	O
rapid	O
time	O
course	O
,	O
10,000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Adenovirus	O
E1A	O
inhibits	O
IFN-induced	O
resistance	O
to	O
cytolysis	O
by	O
natural	O
killer	O
cells	O
.	O

Infection	O
of	O
target	O
cells	O
with	O
cytopathic	O
viruses	O
inhibits	O
IFN	O
induction	O
of	O
cytolytic	O
resistance	O
to	O
NK	O
cell-mediated	O
cytolysis	O
[	O
IFN-mediated	O
cytoprotection	O
(	O
IFN-MCP	O
)	O
]	O
.	O

It	O
has	O
been	O
thought	O
that	O
the	O
virally	O
induced	O
inhibition	O
of	O
IFN-MCP	O
is	O
secondary	O
to	O
the	O
shutdown	O
of	O
cellular	O
macromolecular	O
synthesis	O
that	O
accompanies	O
cytopathic	O
virus	O
infections	O
.	O

Group	O
C	O
,	O
adenovirus	O
serotype	O
5	O
(	O
Ad5	O
)	O
infection	O
inhibits	O
both	O
IFN-MCP	O
and	O
cellular	O
protein	O
synthesis	O
.	O

This	O
study	O
determined	O
if	O
the	O
Ad5-induced	O
inhibition	O
of	O
IFN-MCP	O
was	O
independent	O
of	O
adenovirus	O
(	O
Ad	O
)	O
infection	O
and	O
secondary	O
only	O
to	O
the	O
expression	O
of	O
the	O
Ad	O
early	O
region	O
1A	O
gene	O
(	O
E1A	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
4-h	O
NK	O
cytolysis	O
assays	O
were	O
performed	O
on	O
IFN-gamma-treated	O
human	O
cells	O
infected	O
with	O
an	O
Ad5	O
E1A	O
deletion	O
mutant	O
,	O
dl343	O
,	O
or	O
transfected	O
with	O
the	O
Ad5	O
E1A	O
gene	O
.	O

IFN-MCP	B-Negation
was	I-Negation
not	I-Negation
inhibited	I-Negation
by	I-Negation
infection	I-Negation
with	I-Negation
dl343	I-Negation
,	O
despite	O
the	O
production	O
of	O
large	O
amounts	O
of	O
both	O
early	O
(	O
E1B	O
,	O
p55	O
)	O
and	O
late	O
(	O
hexon	O
)	O
Ad	O
proteins	O
.	O

In	O
contrast	O
to	O
E1A-negative	O
,	O
parental	O
cell	O
lines	O
,	O
IFN-MCP	O
was	O
blocked	O
in	O
Ad5	O
E1A-transfected	O
epithelial	O
and	O
fibroblastic	O
cell	O
lines	O
.	O

Genetic	O
mapping	O
studies	O
within	O
the	O
E1A	O
gene	O
demonstrated	O
that	O
expression	O
of	O
only	O
the	O
first	O
exon	O
of	O
E1A	O
was	O
sufficient	O
to	O
inhibit	O
IFN-MCP	O
.	O

DNA	O
sequence	O
homology	O
of	O
E1A	O
genes	O
between	O
different	O
Ad	O
groups	O
(	O
group	O
A	O
,	O
Ad12	O
;	O
group	O
C	O
,	O
Ad5	O
)	O
is	O
limited	O
almost	O
entirely	O
to	O
three	O
conserved	O
regions	O
located	O
within	O
the	O
first	O
exon	O
of	O
E1A	O
.	O

Because	O
IFN-MCP	O
was	O
also	O
blocked	O
in	O
Ad12	O
E1A-transfected	O
cell	O
lines	O
,	O
expression	O
of	O
one	O
or	O
more	O
of	O
the	O
E1A-conserved	O
regions	O
may	O
be	O
necessary	O
to	O
inhibit	O
IFN-MCP	O
.	O

In	O
summary	O
,	O
the	O
expression	O
of	O
E1A	O
gene	O
products	O
inhibited	O
IFN-MCP	O
independently	O
of	O
virus	O
infection	O
.	O

E1A	O
's	O
inhibition	O
of	O
IFN-MCP	O
has	O
the	O
net	O
effect	O
of	O
promoting	O
the	O
selective	O
NK	O
cell-mediated	O
clearance	O
of	O
Ad-infected	O
or	O
Ad-transformed	O
human	O
cells	O
.	O

A	O
chimeric	O
type	O
II	O
/	O
type	O
I	O
interleukin-1	O
receptor	O
can	O
mediate	O
interleukin-1	O
induction	O
of	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

The	O
type	O
I	O
interleukin-1	O
receptor	O
(	O
IL-1R	O
)	O
is	O
capable	O
of	O
transducing	O
a	O
signal	O
resulting	O
in	O
promoter	O
activation	O
in	O
T	O
cells	O
.	O

This	O
signal	O
transduction	O
is	O
dependent	O
on	O
the	O
cytoplasmic	O
domain	O
,	O
which	O
consists	O
of	O
213	O
amino	O
acids	O
.	O

In	O
contrast	O
to	O
the	O
type	O
I	O
receptor	O
,	O
the	O
type	O
II	O
IL-1R	O
has	O
a	O
small	O
cytoplasmic	O
tail	O
,	O
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
receptor	O
is	O
a	O
signal-transducing	O
or	O
a	O
regulatory	O
molecule	O
.	O

Here	O
we	O
report	O
that	O
the	O
type	O
II	O
IL-1R	O
does	O
not	B-Negation
mediate	I-Negation
gene	I-Negation
activation	I-Negation
in	I-Negation
Jurkat	I-Negation
cells	I-Negation
.	O

However	O
,	O
a	O
hybrid	O
receptor	O
composed	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
regions	O
of	O
the	O
human	O
type	O
II	O
interleukin-1	O
fused	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
type	O
I	O
IL-1R	O
was	O
capable	O
of	O
transducing	O
a	O
signal	O
across	O
the	O
membrane	O
resulting	O
in	O
a	O
pattern	O
of	O
gene	O
activation	O
identical	O
to	O
that	O
mediated	O
by	O
the	O
type	O
I	O
IL-1R	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
extracellular	O
domain	O
of	O
the	O
type	O
II	O
IL-1R	O
was	O
capable	O
of	O
functionally	O
interacting	O
with	O
interleukin-1	O
and	O
transmitting	O
the	O
resulting	O
signal	O
to	O
a	O
heterologous	O
cytoplasmic	O
domain	O
.	O

A	O
mutation	O
of	O
the	O
glucocorticoid	O
receptor	O
in	O
primary	O
cortisol	O
resistance	O
.	O

The	B-Negation
precise	I-Negation
molecular	I-Negation
abnormalities	I-Negation
that	I-Negation
cause	I-Negation
primary	I-Negation
cortisol	I-Negation
resistance	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
completely	I-Negation
described	I-Negation
.	O

In	O
a	O
subject	O
with	O
primary	O
cortisol	O
resistance	O
we	O
have	O
observed	O
glucocorticoid	O
receptors	O
(	O
hGR	O
)	O
with	O
a	O
decreased	O
affinity	O
for	O
dexamethasone	O
.	O

We	O
hypothesize	O
that	O
a	O
mutation	O
of	O
the	O
hGR	O
glucocorticoid-binding	O
domain	O
is	O
the	O
cause	O
of	O
cortisol	O
resistance	O
.	O

Total	O
RNA	O
isolated	O
from	O
the	O
index	O
subject	O
's	O
mononuclear	O
leukocytes	O
was	O
used	O
to	O
produce	O
first	O
strand	O
hGR	O
cDNAs	O
,	O
and	O
the	O
entire	O
hGR	O
cDNA	O
was	O
amplified	O
in	O
segments	O
and	O
sequenced	O
.	O

At	O
nucleotide	O
2,317	O
we	O
identified	O
a	O
homozygous	O
A	O
for	O
G	O
point	O
mutation	O
that	O
predicts	O
an	O
isoleucine	O
(	O
ATT	O
)	O
for	O
valine	O
(	O
GTT	O
)	O
substitution	O
at	O
amino	O
acid	O
729	O
.	O

When	O
the	O
wild-type	O
hGR	O
and	O
hGR-Ile	O
729	O
were	O
expressed	O
in	O
COS-1	O
cells	O
and	O
assayed	O
for	O
[	O
3H	O
]	O
-Dexamethasone	O
binding	O
,	O
the	O
dissociation	O
constants	O
were	O
0.799	O
	O
0.068	O
and	O
1.54	O
	O
0.06	O
nM	O
(	O
mean	O
	O
SEM	O
)	O
(	O
P	O
<	O
0.01	O
)	O
,	O
respectively	O
.	O

When	O
the	O
wild-type	O
hGR	O
and	O
hGR-Ile	O
729	O
were	O
expressed	O
in	O
CV-1	O
cells	O
that	O
were	O
cotransfected	O
with	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
long	O
terminal	O
repeat	O
fused	O
to	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
gene	O
,	O
the	O
hGR-Ile	O
729	O
conferred	O
a	O
fourfold	O
decrease	O
in	O
apparent	O
potency	O
on	O
dexamethasone	O
stimulation	O
of	O
CAT	O
activity	O
.	O

The	O
isoleucine	O
for	O
valine	O
substitution	O
at	O
amino	O
acid	O
729	O
impairs	O
the	O
function	O
of	O
the	O
hGR	O
and	O
is	O
the	O
likely	O
cause	O
of	O
primary	O
cortisol	O
resistance	O
in	O
this	O
subject	O
.	O

Mice	O
deficient	O
for	O
the	O
55	O
kd	O
tumor	O
necrosis	O
factor	O
receptor	O
are	O
resistant	O
to	O
endotoxic	O
shock	O
,	O
yet	O
succumb	O
to	O
L.	O
monocytogenes	O
infection	O
.	O

The	O
multiple	O
biological	O
activities	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
mediated	O
by	O
two	O
distinct	O
cell	O
surface	O
receptors	O
of	O
55	O
kd	O
(	O
TNFRp55	O
)	O
and	O
75	O
kd	O
(	O
TNFRp75	O
)	O
.	O

Using	O
gene	O
targeting	O
,	O
we	O
generated	O
a	O
TNFRp55-deficient	O
mouse	O
strain	O
.	O

Cells	O
from	O
TNFRp55-/-mutant	O
mice	O
lack	B-Negation
expression	I-Negation
of	I-Negation
TNFRp55	I-Negation
but	O
display	O
normal	O
numbers	O
of	O
high	O
affinity	O
TNFRp75	O
molecules	O
.	O

Thymocyte	O
development	O
and	O
lymphocyte	O
populations	O
are	O
unaltered	O
,	O
and	O
clonal	B-Negation
deletion	I-Negation
of	I-Negation
potentially	I-Negation
self-reactive	I-Negation
T	I-Negation
cells	I-Negation
is	I-Negation
not	I-Negation
impaired	I-Negation
.	O

However	O
,	O
TNF	O
signaling	O
is	O
largely	O
abolished	O
,	O
as	O
judged	O
by	O
the	O
failure	O
of	O
TNF	O
to	O
induce	O
NF-kappa	O
B	O
in	O
T	O
lymphocytes	O
from	O
TNFRp55-deficient	O
mice	O
.	O

The	O
loss	O
of	O
TNFRp55	O
function	O
renders	O
mice	O
resistant	O
to	O
lethal	O
dosages	O
of	O
either	O
lipopolysaccharides	O
or	O
S.	O
aureus	O
enterotoxin	O
B	O
.	O

In	O
contrast	O
,	O
TNFRp55-deficient	O
mice	O
are	O
severely	O
impaired	O
to	O
clear	O
L.	O
monocytogenes	O
and	O
readily	O
succumb	O
to	O
infection	O
.	O

Thus	O
,	O
the	O
55	O
kd	O
TNFR	O
plays	O
a	O
decisive	O
role	O
in	O
the	O
host	O
's	O
defense	O
against	O
microorganisms	O
and	O
their	O
pathogenic	O
factors	O
.	O

Cloning	O
and	O
functional	O
characterization	O
of	O
early	O
B-cell	O
factor	O
,	O
a	O
regulator	O
of	O
lymphocyte-specific	O
gene	O
expression	O
.	O

Early	O
B-cell	O
factor	O
(	O
EBF	O
)	O
was	O
identified	O
previously	O
as	O
a	O
tissue-specific	O
and	O
differentiation	O
stage-specific	O
DNA-binding	O
protein	O
that	O
participates	O
in	O
the	O
regulation	O
of	O
the	O
pre-B	O
and	O
B	O
lymphocyte-specific	O
mb-1	O
gene	O
.	O

Partial	O
amino	O
acid	O
sequences	O
obtained	O
from	O
purified	O
EBF	O
were	O
used	O
to	O
isolate	O
cDNA	O
clones	O
,	O
which	O
by	O
multiple	O
criteria	O
encode	O
EBF	O
.	O

The	O
recombinant	O
polypeptide	O
formed	O
sequence-specific	O
complexes	O
with	O
the	O
EBF-binding	O
site	O
in	O
the	O
mb-1	O
promoter	O
.	O

The	O
cDNA	O
hybridized	O
to	O
multiple	O
transcripts	O
in	O
pre-B	O
and	O
B-cell	O
lines	O
,	O
but	O
transcripts	B-Negation
were	I-Negation
not	I-Negation
detected	I-Negation
at	I-Negation
significant	I-Negation
levels	I-Negation
in	I-Negation
plasmacytoma	I-Negation
,	I-Negation
T-cell	I-Negation
,	I-Negation
and	I-Negation
nonlymphoid	I-Negation
cell	I-Negation
lines	I-Negation
.	O

Expression	O
of	O
recombinant	O
EBF	O
in	O
transfected	O
nonlymphoid	O
cells	O
strongly	O
activated	O
transcription	O
from	O
reporter	O
plasmids	O
containing	O
functional	O
EBF-binding	O
sites	O
.	O

Analysis	O
of	O
DNA	O
binding	O
by	O
deletion	O
mutants	O
of	O
EBF	O
identified	O
an	O
amino-terminal	O
cysteine-rich	O
DNA-binding	O
domain	O
lacking	B-Negation
obvious	I-Negation
sequence	I-Negation
similarity	I-Negation
to	I-Negation
known	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

DNA-binding	O
assays	O
with	O
cotranslated	O
wild-type	O
and	O
truncated	O
forms	O
of	O
EBF	O
indicated	O
that	O
the	O
protein	O
interacts	O
with	O
its	O
site	O
as	O
a	O
homodimer	O
.	O

Deletions	O
delineated	O
a	O
carboxy-terminal	O
dimerization	O
region	O
containing	O
two	O
repeats	O
of	O
15	O
amino	O
acids	O
that	O
show	O
similarity	O
with	O
the	O
dimerization	O
domains	O
of	O
basic-helix-loop-helix	O
proteins	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	O
represents	O
a	O
novel	O
regulator	O
of	O
B	O
lymphocyte-specific	O
gene	O
expression	O
.	O

[	O
The	O
trend	O
of	O
molecular	O
biology	O
study	O
on	O
eosinophils	O
]	O

Recently	O
,	O
many	O
investigators	O
have	O
been	O
interested	O
in	O
the	O
study	O
on	O
eosinophil	O
biology	O
since	O
genes	O
association	O
with	O
eosinophils	O
such	O
as	O
interleukin-5	O
or	O
eosinophil	O
granule	O
proteins	O
(	O
EPO	O
,	O
ECP	O
,	O
EDN	O
,	O
MBP	O
,	O
and	O
CLC	O
)	O
,	O
were	O
isolated	O
.	O

However	O
,	O
the	B-Negation
molecular	I-Negation
basis	I-Negation
for	I-Negation
the	I-Negation
commitment	I-Negation
of	I-Negation
progenitors	I-Negation
to	I-Negation
the	I-Negation
eosinophil	I-Negation
lineage	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
determined	I-Negation
.	O

The	O
mechanism	O
by	O
which	O
eosinophil-specific	O
genes	O
encoding	O
primary	O
and	O
secondary	O
granule	O
proteins	O
(	O
e.g.	O
ECP	O
,	O
EDN	O
,	O
EPO	O
,	O
MBP	O
,	O
and	O
CLC	O
)	O
are	O
expressed	O
and	O
regulated	O
during	O
eosinophilopoiesis	O
is	O
also	O
unknown	O
.	O

In	O
this	O
paper	O
,	O
I	O
described	O
the	O
characterization	O
of	O
genes	O
encoding	O
eosinophil	O
granule	O
proteins	O
and	O
the	O
mRNA	O
expression	O
of	O
GATA-1	O
binding	O
transcription	O
factor	O
during	O
eosinophil	O
differentiation	O
.	O

Regulation	O
of	O
the	O
Ets-related	O
transcription	O
factor	O
Elf-1	O
by	O
binding	O
to	O
the	O
retinoblastoma	O
protein	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
(	O
Rb	O
)	O
is	O
a	O
nuclear	O
phosphoprotein	O
that	O
regulates	O
cell	O
cycle	O
progression	O
.	O

Elf-1	O
is	O
a	O
lymphoid-specific	O
Ets	O
transcription	O
factor	O
that	O
regulates	O
inducible	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

In	O
this	O
report	O
,	O
it	O
is	O
demonstrated	O
that	O
Elf-1	O
contains	O
a	O
sequence	O
motif	O
that	O
is	O
highly	O
related	O
to	O
the	O
Rb	O
binding	O
sites	O
of	O
several	O
viral	O
oncoproteins	O
and	O
binds	O
to	O
the	O
pocket	O
region	O
of	O
Rb	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Elf-1	O
binds	O
exclusively	O
to	O
the	O
underphosphorylated	O
form	O
of	O
Rb	O
and	O
fails	O
to	O
bind	O
to	O
Rb	O
mutants	O
derived	O
from	O
patients	O
with	O
retinoblastoma	O
.	O

Co-immunoprecipitation	O
experiments	O
demonstrated	O
an	O
association	O
between	O
Elf-1	O
and	O
Rb	O
in	O
resting	O
normal	O
human	O
T	O
cells	O
.	O

After	O
T	O
cell	O
activation	O
,	O
the	O
phosphorylation	O
of	O
Rb	O
results	O
in	O
the	O
release	O
of	O
Elf-1	O
,	O
which	O
is	O
correlated	O
temporally	O
with	O
the	O
activation	O
of	O
Elf-1-mediated	O
transcription	O
.	O

Overexpression	O
of	O
a	O
phosphorylation-defective	O
form	O
of	O
Rb	O
inhibited	O
Elf-1-dependent	O
transcription	O
during	O
T	O
cell	O
activation	O
.	O

These	O
results	O
demonstrate	O
that	O
Rb	O
interacts	O
specifically	O
with	O
a	O
lineage-restricted	O
Ets	O
transcription	O
factor	O
.	O

This	O
regulated	O
interaction	O
may	O
be	O
important	O
for	O
the	O
coordination	O
of	O
lineage-specific	O
effector	O
functions	O
such	O
as	O
lymphokine	O
production	O
with	O
cell	O
cycle	O
progression	O
in	O
activated	O
T	O
cells	O
.	O

Activation	O
of	O
primary	O
human	O
T-lymphocytes	O
through	O
CD2	O
plus	O
CD28	O
adhesion	O
molecules	O
induces	O
long-term	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
.	O

Stimulation	O
of	O
highly	O
purified	O
human	O
T-cells	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
induces	O
and	O
maintains	O
proliferation	O
for	O
more	O
than	O
3	O
weeks	O
.	O

This	O
potent	O
interleukin	O
2	O
(	O
IL-2	O
)	O
-dependent	O
activation	O
does	O
not	B-Negation
require	I-Negation
monocytes	I-Negation
or	I-Negation
accessory	I-Negation
cells	I-Negation
.	O

Long-lasting	O
IL-2	O
receptivity	O
is	O
associated	O
with	O
high-level	O
expression	O
of	O
the	O
inducible	O
IL-2	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
that	O
is	O
regulated	O
at	O
both	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

Increase	O
of	O
IL-2R	O
alpha	O
gene	O
transcription	O
involves	O
the	O
enhanced	O
binding	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
to	O
its	O
consensus	O
sequence	O
in	O
the	O
5'-regulatory	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
.	O

To	O
dissect	O
the	O
molecular	O
basis	O
for	O
the	O
unusually	O
persistent	O
transcription	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
NF-kappa	O
B	O
binding	O
to	O
a	O
radiolabeled	O
IL-2R	O
alpha	O
kappa	O
B-specific	O
oligonucleotide	O
probe	O
during	O
the	O
time	O
course	O
of	O
CD2	O
+	O
CD28	O
activation	O
.	O

Resting	O
T-cell	O
nuclear	O
extracts	O
contained	O
KBF1/p50	O
homodimer	O
.	O

After	O
stimulation	O
,	O
two	O
new	O
kappa	O
B-specific	O
complexes	O
were	O
identified	O
as	O
NF-kappa	O
B	O
p50-p65	O
heterodimer	O
and	O
putative	O
c-Rel	O
homodimer	O
or	O
c-Rel-p65	O
heterodimer	O
.	O

Both	O
inducible	O
complexes	O
persisted	O
for	O
at	O
least	O
3	O
weeks	O
.	O

Their	O
relative	O
levels	O
were	O
very	O
similar	O
for	O
the	O
duration	O
of	O
proliferation	O
.	O

In	O
parallel	O
,	O
CD2	O
+	O
CD28	O
activation	O
triggered	O
a	O
significant	O
intracellular	O
thiol	O
decrease	O
,	O
suggesting	O
that	O
oxygen	O
radicals	O
are	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
adhesion	O
molecules	O
.	O

Finally	O
,	O
micromolar	O
amounts	O
of	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxygen	O
radical	O
scavenger	O
that	O
efficiently	O
blocked	O
the	O
nuclear	O
appearance	O
of	O
NF-kappa	O
B	O
in	O
T-lymphocytes	O
,	O
also	O
inhibited	O
IL-2	O
secretion	O
,	O
IL-2R	O
alpha	O
cell	O
surface	O
expression	O
,	O
and	O
T-cell	O
proliferation	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
long-term	O
activation	O
of	O
human	O
primary	O
T-lymphocytes	O
via	O
CD2	O
+	O
CD28	O
.	O

Oxidoreductive	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
.	O

Involvement	O
of	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	O
.	O

We	O
have	O
investigated	O
an	O
oxidoreductive	O
regulatory	O
pathway	O
for	O
the	O
DNA	O
binding	O
activity	O
of	O
a	O
pleiotropic	O
cellular	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
has	O
been	O
investigated	O
by	O
using	O
NF	O
kappa	O
B	O
prepared	O
from	O
the	O
nucleus	O
and	O
the	O
cytosol	O
of	O
the	O
primary	O
human	O
T	O
lymphocytes	O
.	O

We	O
show	O
that	O
a	O
cellular	O
reducing	O
catalyst	O
thioredoxin	O
(	O
Trx	O
)	O
plays	O
a	O
major	O
role	O
in	O
activation	O
of	O
the	O
DNA	O
binding	O
of	O
NF	O
kappa	O
B	O
in	O
vitro	O
and	O
stimulation	O
of	O
transcription	O
from	O
the	O
NF	O
kappa	O
B-dependent	O
gene	O
expression	O
.	O

We	O
demonstrate	O
evidence	O
suggesting	O
that	O
redox	O
regulation	O
of	O
NF	O
kappa	O
B	O
by	O
Trx	O
might	O
be	O
exerted	O
at	O
a	O
step	O
after	O
dissociation	O
of	O
the	O
inhibitory	O
molecule	O
I	O
kappa	O
B	O
,	O
a	O
cytosolic-anchoring	O
protein	O
for	O
NF	O
kappa	O
B	O
.	O

To	O
examine	O
the	O
effect	O
of	O
Trx	O
in	O
intact	O
cells	O
,	O
we	O
performed	O
transient	O
assay	O
with	O
a	O
chloramphenicol	O
acetyltransferase-expressing	O
plasmid	O
under	O
the	O
control	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
and	O
an	O
effector	O
plasmid	O
expressing	O
human	O
Trx	O
.	O

The	O
promoter	O
activity	O
from	O
HIV	O
long	O
terminal	O
repeat	O
was	O
greatly	O
augmented	O
by	O
co-transfecting	O
the	O
Trx-expressing	O
plasmid	O
,	O
whose	O
effect	O
was	O
dependent	O
on	O
the	O
NF	O
kappa	O
B-binding	O
sites	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
cysteine	O
residue	O
(	O
s	O
)	O
of	O
NF	O
kappa	O
B	O
might	O
be	O
involved	O
in	O
the	O
DNA-recognition	O
by	O
NF	O
kappa	O
B	O
and	O
that	O
the	O
redox	O
control	O
mechanism	O
mediated	O
by	O
Trx	O
might	O
have	O
a	O
regulatory	O
role	O
in	O
the	O
NF	O
kappa	O
B-mediated	O
gene	O
expression	O
.	O

These	O
results	O
may	O
also	O
provide	O
a	O
clue	O
to	O
understanding	O
of	O
the	O
molecular	O
process	O
of	O
AIDS	O
pathogenesis	O
and	O
its	O
possible	O
biochemical	O
intervention	O
.	O

Expression	O
levels	O
of	O
the	O
thyrotropin	O
receptor	O
gene	O
in	O
autoimmune	O
thyroid	O
disease	O
:	O
coregulation	O
with	O
parameters	O
of	O
thyroid	O
function	O
and	O
inverse	O
relation	O
to	O
major	O
histocompatibility	O
complex	O
classes	O
I	O
and	O
II	O
.	O

Using	O
a	O
human	O
TSH	O
receptor	O
(	O
TSH-R	O
)	O
cDNA	O
probe	O
,	O
we	O
investigated	O
TSH-R	O
transcript	O
levels	O
in	O
13	O
human	O
thyroid	O
fragments	O
by	O
Northern	O
blot	O
analysis	O
;	O

7	O
Graves	O
'	O
disease	O
,	O
2	O
Hashimoto	O
's	O
disease	O
,	O
3	O
endemic	O
goiter	O
,	O
and	O
1	O
healthy	O
thyroid	O
gland	O
were	O
studied	O
.	O

TSH-R	O
expression	O
levels	O
were	O
variable	O
,	O
but	O
displayed	O
a	O
close	O
correlation	O
to	O
the	O
expression	O
of	O
thyroid	O
peroxidase	O
(	O
r	O
=	O
0.703	O
;	O
P	O
<	O
0.05	O
)	O
,	O
thyroglobulin	O
(	O
r	O
=	O
0.817	O
;	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
nuclear	O
oncogene	O
c-fos	O
(	O
r	O
=	O
0.935	O
;	O
P	O
<	O
0.001	O
)	O
,	O
but	O
not	B-Negation
c-myc	I-Negation
.	O

Overall	O
,	O
TSH-R	O
transcript	O
levels	O
were	O
low	O
or	O
absent	O
in	O
those	O
thyroids	O
in	O
which	O
expression	O
of	O
the	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
(	O
MHC	O
I	O
or	O
II	O
)	O
was	O
high	O
,	O
thus	O
establishing	O
an	O
inverse	O
relation	O
(	O
MHC	O
I	O
,	O
r	O
=	O
-0.791	O
;	O
P	O
<	O
0.01	O
;	O
MHC	O
II	O
,	O
r	O
=	O
-0.784	O
;	O
P	O
<	O
0.01	O
)	O
.	O

In	O
situ	O
hybridization	O
showed	O
that	O
apart	O
from	O
lymphocytes	O
,	O
thyroid	O
cells	O
themselves	O
were	O
the	O
source	O
of	O
MHC	O
II	O
transcripts	O
.	O

gamma-Interferon	O
expression	O
was	O
only	O
detectable	O
in	O
1	O
Hashimoto	O
's	O
goiter	O
.	O

Our	O
findings	O
suggest	O
that	O
next	O
to	O
lymphocyte	O
infiltration	O
,	O
active	O
regulatory	O
events	O
in	O
the	O
thyrocyte	O
are	O
responsible	O
for	O
the	O
inverse	O
relation	O
between	O
functional	O
parameters	O
(	O
TSH-R	O
,	O
thyroid	O
peroxidase	O
,	O
thyroglobulin	O
,	O
and	O
c-fos	O
)	O
and	O
immunological	O
markers	O
(	O
MHC	O
I	O
and	O
II	O
)	O
.	O

Regulation	O
of	O
the	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
gene	O
by	O
mycobacterial	O
components	O
and	O
lipopolysaccharide	O
is	O
mediated	O
by	O
two	O
nuclear	O
factor-IL6	O
motifs	O
.	O

The	O
cytokines	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
in	O
vitro	O
after	O
stimulation	O
with	O
mycobacteria	O
and	O
are	O
considered	O
to	O
mediate	O
pathophysiologic	O
events	O
,	O
including	O
granuloma	O
formation	O
and	O
systemic	O
symptoms	O
.	O

We	O
demonstrated	O
that	O
the	O
Mycobacterium	O
tuberculosis	O
cell	O
wall	O
component	O
lipoarabinomannan	O
(	O
LAM	O
)	O
is	O
a	O
very	O
potent	O
inducer	O
of	O
IL-1	O
beta	O
gene	O
expression	O
in	O
human	O
monocytes	O
and	O
investigated	O
the	O
mechanism	O
of	O
this	O
effect	O
.	O

We	O
localized	O
the	O
LAM-	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
,	O
and	O
TNF-alpha-inducible	O
promoter	O
activity	O
to	O
a	O
-131/+15	O
(	O
positions	O
-131	O
to	O
+15	O
)	O
DNA	O
fragment	O
of	O
the	O
IL-1	O
beta	O
gene	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	O
acetyltransferase	O
assay	O
.	O

Within	O
this	O
DNA	O
fragment	O
,	O
there	O
were	O
two	O
novel	O
9-bp	O
motifs	O
(	O
-90/-82	O
and	O
-40/-32	O
)	O
with	O
high	O
homology	O
to	O
the	O
nuclear	O
factor-IL6	O
(	O
NF-IL6	O
)	O
binding	O
site	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
the	O
two	O
NF-IL-6	O
motifs	O
could	O
be	O
independently	O
activated	O
by	O
LAM	O
,	O
LPS	O
,	O
or	O
TNF-alpha	O
and	O
that	O
they	O
acted	O
in	O
an	O
orientation-independent	O
manner	O
.	O

DNA	O
mobility	O
shift	O
assay	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
(	O
s	O
)	O
from	O
LAM-	O
,	O
LPS-	O
,	O
or	O
TNF-alpha-	O
stimulated	O
THP-1	O
cells	O
to	O
the	O
NF-IL6	O
motifs	O
.	O

We	O
conclude	O
that	O
the	O
two	O
NF-IL6	O
sites	O
mediate	O
induction	O
of	O
IL-1	O
beta	O
in	O
response	O
to	O
the	O
stimuli	O
LAM	O
,	O
LPS	O
,	O
and	O
TNF-alpha	O
.	O

Synergism	O
between	O
the	O
CD3	O
antigen-	O
and	O
CD2	O
antigen-derived	O
signals	O
.	O

Exploration	O
at	O
the	O
level	O
of	O
induction	O
of	O
DNA-binding	O
proteins	O
and	O
characterization	O
of	O
the	O
inhibitory	O
activity	O
of	O
cyclosporine	O
.	O

We	O
have	O
demonstrated	O
earlier	O
that	O
the	O
crosslinkage	O
of	O
the	O
CD3/TCR	O
complex	O
with	O
the	O
CD2	O
antigen	O
results	O
in	O
the	O
proliferation	O
of	O
normal	O
human	O
T	O
cells	O
.	O

The	O
effect	O
of	O
this	O
synergism	O
was	O
perceptible	O
at	O
the	O
level	O
of	O
induction	O
of	O
the	O
IL-2	O
gene	O
,	O
a	O
process	O
critical	O
for	O
T	O
cell	O
growth	O
.	O

To	O
further	O
understand	O
the	O
molecular	O
and	O
nuclear	O
basis	O
for	O
this	O
synergism	O
,	O
we	O
have	O
explored	O
the	O
induction	O
of	O
DNA-binding	O
proteins	O
in	O
highly	O
purified	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
the	O
CD3	O
and/or	O
CD2	O
proteins	O
.	O

The	O
effect	O
of	O
transmembrane	O
signaling	O
of	O
T	O
cells	O
with	O
ionomycin	O
,	O
and/or	O
sn-1,2	O
dioctanoyl	O
glycerol	O
,	O
was	O
also	O
determined	O
.	O

The	O
emergence	O
of	O
nuclear	O
binding	O
proteins	O
was	O
investigated	O
using	O
interleukin-2	O
sequence	O
specific	O
oligonucleotide	O
probes	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Our	O
studies	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
CD3	O
antigen-derived	O
signals	O
and	O
CD2	O
antigen-derived	O
signals	O
are	O
synergistic	O
in	O
inducing	O
the	O
emergence	O
of	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
NF-AT1	O
,	O
AP-1	O
,	O
and	O
NF-kB	O
sites	O
located	O
in	O
the	O
promoter/enhancer	O
region	O
of	O
the	O
IL-2	O
gene	O
.	O

Moreover	O
,	O
cyclosporine	O
,	O
at	O
concentrations	O
readily	O
accomplished	O
in	O
clinical	O
practice	O
,	O
was	O
found	O
to	O
inhibit	O
the	O
emergence	O
of	O
these	O
DNA-binding	O
proteins	O
in	O
normal	O
human	O
T	O
cells	O
signaled	O
via	O
cell	O
surface	O
proteins	O
implicated	O
in	O
antigen-dependent	O
T	O
cell	O
activation	O
and	O
in	O
T	O
cells	O
stimulated	O
by	O
mobilization	O
of	O
cellular	O
calcium	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

Calcium	O
dependent	O
activation	O
of	O
the	O
NF-AT	O
transcription	O
factor	O
by	O
p59fyn	O
.	O

A	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
a	O
T-cell	O
antigen	O
receptor	O
element	O
was	O
activated	O
in	O
Jurkat	O
cells	O
by	O
antigen	O
receptor	O
triggering	O
or	O
by	O
a	O
combination	O
of	O
phorbol	O
myristate	O
acetate	O
,	O
which	O
activates	O
protein	O
kinase	O
C	O
,	O
and	O
a	O
calcium	O
ionophore	O
.	O

Both	O
these	O
signals	O
were	O
necessary	O
for	O
expression	O
of	O
the	O
reporter	O
gene	O
.	O

When	O
co-transfected	O
with	O
a	O
construct	O
capable	O
of	O
overexpressing	O
the	O
tyrosine	O
kinase	O
p59fyn	O
,	O
the	O
reporter	O
gene	O
was	O
activated	O
by	O
PMA	O
alone	O
.	O

Thus	O
p59fyn	O
could	O
replace	O
the	O
calcium	O
ionophore	O
but	O
not	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
activation	O
by	O
p59fyn	O
plus	O
PMA	O
was	O
blocked	O
by	O
EGTA	O
and	O
by	O
the	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
.	O

Cell-specific	O
bifunctional	O
role	O
of	O
Jun	O
oncogene	O
family	O
members	O
on	O
glucocorticoid	O
receptor-dependent	O
transcription	O
.	O

Interaction	O
between	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-	O
and	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
-mediated	O
signaling	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
the	O
PKC	O
activating	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
to	O
inhibit	O
GR-dependent	O
transcription	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Here	O
we	O
report	O
that	O
this	O
interference	O
is	O
cell	O
specific	O
,	O
as	O
TPA	O
augmented	O
dexamethasone-induced	O
transcriptional	O
activation	O
of	O
the	O
MMTV	O
LTR	O
in	O
several	O
T	O
cell	O
lines	O
but	O
was	O
inhibitory	O
in	O
NIH-3T3	O
fibroblasts	O
.	O

TPA-GR	O
synergism	O
was	O
determined	O
to	O
have	O
occurred	O
at	O
the	O
GR-responsive	O
element	O
(	O
GRE	O
)	O
level	O
by	O
functional	O
analysis	O
of	O
deletion	O
mutants	O
or	O
synthetic	O
GRE	O
oligonucleotides	O
driving	O
chloramphenicol	O
acetyl-transferase	O
expression	O
.	O

Synergism	O
required	O
an	O
intact	O
GR	O
DNA-binding	O
domain	O
,	O
whereas	O
amino-	O
or	O
carboxyl-terminal	O
domains	O
were	O
dispensable	O
.	O

The	O
effect	O
was	O
abrogated	O
by	O
the	O
PKC	O
inhibitor	O
staurosporine	O
,	O
suggesting	O
a	O
role	O
for	O
PKC	O
.	O

Increased	O
c-jun	O
,	O
jun-B	O
,	O
and	O
jun-D	O
expression	O
above	O
basal	O
levels	O
and	O
increased	O
transcriptional	O
activity	O
of	O
AP-1/TPA	O
responsive	O
elements	O
fused	O
to	O
chloramphenicol	O
acetyl-transferase	O
vectors	O
were	O
observed	O
in	O
T	O
cells	O
treated	O
with	O
TPA	O
alone	O
or	O
in	O
combination	O
with	O
dexamethasone	O
.	O

The	O
ability	O
of	O
Jun	O
proteins	O
to	O
cooperate	O
with	O
GR	O
in	O
T	O
cells	O
has	O
been	O
investigated	O
after	O
transfection	O
of	O
c-jun	O
,	O
jun-B	O
,	O
or	O
jun-D	O
expression	O
vectors	O
,	O
which	O
augmented	O
GR-dependent	O
transcription	O
from	O
either	O
MMTV	O
LTR	O
or	O
GRE	O
.	O

Conversely	O
,	O
c-jun	O
and	O
jun-B	O
transfection	O
blunted	O
GR-dependent	O
transcription	O
in	O
HeLa	O
cells	O
.	O

The	O
presence	O
of	O
c-fos	O
had	O
a	O
negative	O
influence	O
on	O
GR	O
function	O
and	O
correlated	O
with	O
the	O
cell-specific	O
synergistic	O
or	O
antagonistic	O
activity	O
of	O
Jun	O
with	O
respect	O
to	O
GR	O
;	O

high	O
basal	O
expression	O
of	O
c-fos	O
as	O
well	O
as	O
AP-1	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
were	O
observed	O
in	O
HeLa	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

Furthermore	O
overexpression	O
of	O
exogenous	O
c-fos	O
has	O
an	O
inhibitory	O
effect	O
on	O
GR-dependent	O
transcription	O
from	O
GRE	O
in	O
T	O
cells	O
.	O

We	O
propose	O
that	O
Jun	O
plays	O
a	O
bifunctional	O
role	O
on	O
GR-dependent	O
transcriptional	O
activation	O
of	O
GRE	O
,	O
selecting	O
either	O
synergistic	O
or	O
antagonistic	O
activity	O
depending	O
on	O
the	O
cell-specific	O
microenvironment	O
.	O

In	O
this	O
regard	O
,	O
intracellular	O
levels	O
of	O
c-fos	O
appear	O
to	O
be	O
influential	O
.	O

A	O
concatenated	O
form	O
of	O
Epstein-Barr	O
viral	O
DNA	O
in	O
lymphoblastoid	O
cell	O
lines	O
induced	O
by	O
transfection	O
with	O
BZLF1	O
.	O

The	O
replicative	O
form	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
DNA	O
was	O
studied	O
using	O
two	O
lymphoblastoid	O
cell	O
lines	O
,	O
X50-7	O
and	O
6F11	O
,	O
which	O
are	O
latently	O
infected	O
by	O
Epstein-Barr	O
virus	O
.	O

The	O
lytic	O
cycle	O
of	O
EBV	O
infection	O
was	O
induced	O
by	O
transfection	O
of	O
the	O
cells	O
with	O
the	O
BRLF1/BZLF1	O
coding	O
region	O
of	O
the	O
P3HR-1	O
defective	O
genome	O
.	O

We	O
combined	O
two	O
techniques	O
to	O
identify	O
the	O
productive	O
replicative	O
form	O
of	O
Epstein-Barr	O
viral	O
DNA	O
in	O
the	O
lytic	O
cycle-induced	O
cells	O
.	O

Restriction	O
enzyme	O
analysis	O
followed	O
by	O
Southern	O
blot	O
hybridization	O
identified	O
a	O
significant	O
increase	O
in	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
.	O

This	O
indicates	O
an	O
increase	O
in	O
either	O
episomal	O
DNA	O
or	O
concatameric	O
linear	O
DNA	O
.	O

Southern	O
blot	O
analysis	O
of	O
in	O
situ	O
lysing	O
gels	O
revealed	O
that	O
the	O
cellular	O
content	O
of	O
linear	O
EBV	O
DNA	O
was	O
also	O
increased	O
significantly	O
after	O
the	O
initiation	O
of	O
the	O
viral	O
lytic	O
cycle	O
,	O
while	O
the	O
amount	O
of	O
circular	O
DNA	O
remained	O
approximately	O
constant	O
.	O

We	O
propose	O
from	O
these	O
results	O
that	O
the	O
source	O
of	O
the	O
fused	O
fragment	O
encompassing	O
both	O
ends	O
of	O
EBV	O
DNA	O
is	O
a	O
concatenated	O
linear	O
EBV	O
DNA	O
molecule	O
,	O
and	O
that	O
such	O
a	O
concatenated	O
molecule	O
most	O
likely	O
represents	O
a	O
replicative	O
form	O
of	O
EBV	O
DNA	O
in	O
productively	O
infected	O
cells	O
.	O

Regulation	O
of	O
the	O
beta-globin	O
locus	O
.	O

Transcription	O
of	O
the	O
human	O
beta-globin	O
gene	O
cluster	O
depends	O
upon	O
upstream	O
regulatory	O
sequences	O
,	O
which	O
are	O
collectively	O
termed	O
the	O
locus	O
control	O
region	O
.	O

Recent	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
the	O
individual	O
genes	O
of	O
the	O
cluster	O
are	O
regulated	O
through	O
development	O
.	O

The	O
crux	O
of	O
transcriptional	O
activation	O
is	O
how	O
the	O
locus	O
control	O
region	O
communicates	O
with	O
the	O
gene-proximal	O
regulatory	O
elements	O
.	O

Ectopic	O
expression	O
of	O
a	O
conditional	O
GATA-2/estrogen	O
receptor	O
chimera	O
arrests	O
erythroid	O
differentiation	O
in	O
a	O
hormone-dependent	O
manner	O
.	O

The	O
GATA	O
factors	O
are	O
a	O
family	O
of	O
transcriptional	O
regulatory	O
proteins	O
in	O
eukaryotes	O
that	O
share	O
extensive	O
homology	O
in	O
their	O
DNA-binding	O
domains	O
.	O

One	O
enigmatic	O
aspect	O
of	O
GATA	O
factor	O
expression	O
is	O
that	O
several	O
GATA	O
proteins	O
,	O
which	O
ostensibly	O
share	O
the	O
same	O
DNA-binding	O
site	O
specificity	O
,	O
are	O
coexpressed	O
in	O
erythroid	O
cells	O
.	O

To	O
elucidate	O
the	O
roles	O
of	O
individual	O
GATA	O
factors	O
in	O
erythropoiesis	O
,	O
conditional	O
alleles	O
of	O
GATA-1	O
,	O
GATA-2	O
,	O
and	O
GATA-3	O
were	O
prepared	O
by	O
fusing	O
each	O
of	O
the	O
factors	O
to	O
the	O
hormone-binding	O
domain	O
of	O
the	O
human	O
estrogen	O
receptor	O
(	O
ER	O
)	O
.	O

These	O
GATA/ER	O
chimeric	O
factors	O
were	O
shown	O
to	O
be	O
hormone-inducible	O
trans-activating	O
proteins	O
in	O
transient	O
transfection	O
assays	O
.	O

When	O
stably	O
introduced	O
into	O
primary	O
erythroblasts	O
or	O
conditionally	O
transformed	O
erythroid	O
progenitors	O
cells	O
,	O
exogenous	O
GATA-2/ER	O
promoted	O
proliferation	O
and	O
inhibited	O
terminal	O
differentiation	O
in	O
an	O
estrogen-dependent	O
manner	O
.	O

These	O
phenotypic	O
effects	O
are	O
specifically	O
attributable	O
to	O
the	O
action	O
of	O
ectopically	O
expressed	O
GATA-2/ER	O
because	O
erythroblasts	O
expressing	O
exogenous	O
GATA-2	O
are	O
constitutively	O
arrested	O
in	O
differentiation	O
and	O
because	O
erythroid	O
progenitors	O
expressing	O
either	O
Gal/ER	O
or	O
GATA-3/ER	O
do	O
not	B-Negation
display	I-Negation
a	I-Negation
hormone-responsive	I-Negation
block	I-Negation
in	I-Negation
differentiation	I-Negation
.	O

Thus	O
,	O
the	O
GATA-2	O
transcription	O
factor	O
appears	O
to	O
play	O
a	O
role	O
in	O
regulating	O
the	O
self-renewal	O
capacity	O
of	O
early	O
erythroid	O
progenitor	O
cells	O
.	O

Lipopolysaccharide	O
induces	O
phosphorylation	O
of	O
MAD3	O
and	O
activation	O
of	O
c-Rel	O
and	O
related	O
NF-kappa	O
B	O
proteins	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Many	O
effects	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
on	O
gene	O
expression	O
,	O
including	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
,	O
in	O
monocytic	O
cells	O
are	O
mediated	O
by	O
activation	O
of	O
kappa	O
B	O
DNA-binding	O
proteins	O
.	O

However	O
,	O
the	O
specific	O
members	O
of	O
the	O
NF-kappa	O
B/Rel	O
transcription	O
factor	O
family	O
involved	O
in	O
the	O
LPS	O
response	O
,	O
and	O
the	O
mechanisms	O
through	O
which	O
LPS-generated	O
signals	O
are	O
transduced	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
LPS	O
induces	O
nuclear	O
expression	O
of	O
c-Rel/p50	O
heterodimers	O
as	O
well	O
as	O
p50/p65	O
(	O
NF-kappa	O
B	O
)	O
kappa	O
B	O
DNA-binding	O
complexes	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Nuclear	O
localization	O
of	O
these	O
proteins	O
occurred	O
concomitantly	O
with	O
a	O
rapid	O
decrease	O
in	O
their	O
cytosolic	O
levels	O
and	O
was	O
independent	O
of	O
phorbol	O
ester-sensitive	O
protein	O
kinase	O
C	O
.	O

Within	O
24	O
h	O
following	O
LPS	O
stimulation	O
there	O
was	O
a	O
striking	O
increase	O
in	O
the	O
levels	O
of	O
c-Rel	O
,	O
p105	O
,	O
and	O
p50	O
in	O
the	O
cytosol	O
.	O

The	O
increased	O
levels	O
of	O
these	O
proteins	O
correlated	O
with	O
increases	O
in	O
the	O
amounts	O
of	O
their	O
mRNAs	O
during	O
LPS	O
activation	O
of	O
THP-1	O
cells	O
.	O

LPS	O
activation	O
of	O
THP-1	O
cells	O
resulted	O
in	O
phosphorylation	O
of	O
MAD3	O
(	O
an	O
I	O
kappa	O
B-like	O
protein	O
)	O
,	O
a	O
rapid	O
increase	O
in	O
MAD3	O
mRNA	O
,	O
and	O
an	O
increase	O
in	O
MAD3	O
protein	O
by	O
2	O
h	O
.	O

Thus	O
,	O
LPS	O
activation	O
of	O
human	O
monocytic	O
cells	O
results	O
in	O
nuclear	O
expression	O
of	O
c-Rel/p50	O
and	O
p50/p65	O
(	O
NF-kappa	O
B	O
)	O
and	O
induces	O
phosphorylation	O
of	O
MAD3	O
.	O

Induction	O
of	O
CD8	O
antigen	O
and	O
suppressor	O
activity	O
by	O
glucocorticoids	O
in	O
a	O
CEM	O
human	O
leukemic	O
cell	O
clone	O
.	O

The	O
relationship	O
between	O
glucocorticoid	O
effect	O
and	O
regulation	O
of	O
cell	O
surface	O
antigens	O
was	O
investigated	O
in	O
two	O
models	O
of	O
leukemic	O
cell	O
lines	O
,	O
CEM	O
C7	O
denoted	O
(	O
r+	O
,	O
ly+	O
)	O
and	O
CEM	O
C1	O
(	O
r+	O
,	O
ly-	O
)	O
.	O

The	O
reactivity	O
of	O
murine	O
monoclonal	O
antibodies	O
,	O
anti-CD4-FITC	O
,	O
anti-CD8-FITC	O
,	O
anti-CD2-FITC	O
and	O
anti-calla-FITC	O
,	O
were	O
analyzed	O
using	O
flow	O
cytometry	O
.	O

The	O
suppressor	O
function	O
was	O
determined	O
using	O
[	O
3H	O
]	O
thymidine	O
incorporation	O
into	O
phytohemagglutinin-activated	O
peripheral	O
blood	O
lymphocytes	O
.	O

Dexamethasone	O
treatment	O
of	O
a	O
human	O
leukemic	O
cell	O
clone	O
CEM	O
C7	O
caused	O
an	O
increase	O
in	O
a	O
subset	O
of	O
cells	O
expressing	O
the	O
surface	O
antigen	O
CD8	O
,	O
which	O
is	O
present	O
on	O
suppressor	O
and	O
cytotoxic	O
T-lymphocytes	O
.	O

By	O
comparison	O
,	O
there	O
was	O
no	B-Negation
modification	I-Negation
of	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
CD4	I-Negation
antigen	I-Negation
,	O
which	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
these	O
cells	O
.	O

After	O
two	O
days	O
of	O
treatment	O
with	O
5	O
x	O
10	O
(	O
-8	O
)	O
M	O
dexamethasone	O
,	O
CEM	O
C7	O
cells	O
showed	O
a	O
two-fold	O
increase	O
in	O
suppressor	O
activity	O
compared	O
to	O
untreated	O
cells	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	B-Negation
regulation	I-Negation
by	I-Negation
glucocorticoids	I-Negation
of	I-Negation
either	I-Negation
the	I-Negation
CD8	I-Negation
or	I-Negation
CD4	I-Negation
antigens	I-Negation
in	I-Negation
the	I-Negation
leukemic	I-Negation
clone	I-Negation
CEM	I-Negation
C1	I-Negation
.	O

Furthermore	O
,	O
no	B-Negation
modification	I-Negation
of	I-Negation
the	I-Negation
suppressor	I-Negation
function	I-Negation
in	I-Negation
CEM	I-Negation
C1	I-Negation
cells	I-Negation
by	I-Negation
dexamethasone	I-Negation
was	I-Negation
observed	I-Negation
.	O

In	O
the	O
human	O
leukemic	O
cells	O
studied	O
here	O
,	O
the	O
ability	O
to	O
induce	O
CD8	O
antigen	O
expression	O
in	O
a	O
CD4+	O
cells	O
correlates	O
with	O
the	O
ability	O
to	O
induce	O
cell	O
lysis	O
in	O
a	O
glucocorticoid	O
receptor	O
positive	O
cell	O
population	O
.	O

Molecular	O
basis	O
of	O
a	O
multiple	O
lymphokine	O
deficiency	O
in	O
a	O
patient	O
with	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
previously	O
reported	O
that	O
the	O
T	O
lymphocytes	O
of	O
a	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
are	O
defective	O
in	O
the	O
transcription	O
of	O
several	O
lymphokine	O
genes	O
that	O
include	O
IL2	O
,	O
IL3	O
,	O
IL4	O
,	O
and	O
IL5	O
,	O
which	O
encode	O
interleukins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
(	O
IL-2	O
,	O
-3	O
,	O
-4	O
,	O
and	O
-5	O
)	O
.	O

To	O
determine	O
whether	O
the	O
defect	O
in	O
the	O
patient	O
's	O
T	O
lymphocytes	O
involved	O
a	O
trans-acting	O
factor	O
common	O
to	O
the	O
affected	O
lymphokine	O
genes	O
,	O
we	O
examined	O
the	O
ability	O
of	O
nuclear	O
factors	O
from	O
the	O
patient	O
's	O
T	O
lymphocytes	O
to	O
bind	O
response	O
elements	O
present	O
in	O
the	O
regulatory	O
region	O
of	O
IL2	O
.	O

Nuclear	O
factor	O
NF-kB	O
,	O
activation	O
protein	O
1	O
(	O
AP-1	O
)	O
,	O
OCT-1	O
,	O
and	O
NF-IL-2B	O
binding	O
activity	O
were	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
to	O
its	O
response	O
element	O
in	O
the	O
IL2	O
enhancer	O
and	O
to	O
an	O
NF-AT-like	O
response	O
element	O
present	O
in	O
the	O
IL4	O
enhancer	O
was	O
abnormal	O
.	O

To	O
ascertain	O
whether	O
the	O
abnormal	O
NF-AT	O
binding	O
activity	O
was	O
related	O
to	O
an	O
impaired	O
function	O
,	O
we	O
transfected	O
patient	O
and	O
control	O
T	O
lymphocytes	O
with	O
constructs	O
containing	O
the	O
reporter	O
gene	O
encoding	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
under	O
the	O
control	O
of	O
the	O
entire	O
IL2	O
regulatory	O
region	O
or	O
of	O
multimers	O
of	O
individual	O
enhancer	O
sequences	O
.	O

CAT	O
expression	O
directed	O
by	O
the	O
IL2	O
regulatory	O
region	O
or	O
by	O
a	O
multimer	O
of	O
the	O
NF-AT-binding	O
site	O
was	O
markedly	O
lower	O
in	O
the	O
patient	O
relative	O
to	O
controls	O
.	O

In	O
contrast	O
,	O
CAT	O
gene	O
expression	O
directed	O
by	O
a	O
multimer	O
of	O
the	O
OCT-1	O
proximal	O
(	O
OCT-1p	O
)	O
-binding	O
site	O
was	O
equivalent	O
in	O
patient	O
and	O
controls	O
.	O

These	O
results	O
indicate	O
that	O
an	O
abnormality	O
of/or	O
influencing	O
NF-AT	O
may	O
underlie	O
the	O
multiple	O
lymphokine	O
deficiency	O
in	O
this	O
patient	O
.	O

Expression	O
of	O
mRNA	O
for	O
the	O
GATA-binding	O
proteins	O
in	O
human	O
eosinophils	O
and	O
basophils	O
:	O
potential	O
role	O
in	O
gene	O
transcription	O
.	O

The	O
expression	O
of	O
the	O
hematopoietic	O
transcription	O
factors	O
GATA-1	O
,	O
GATA-2	O
,	O
and	O
GATA-3	O
was	O
studied	O
in	O
eosinophils	O
and	O
basophils	O
.	O

Eosinophils	O
express	O
mRNA	O
for	O
GATA-1	O
,	O
GATA-2	O
,	O
and	O
GATA-3	O
.	O

Basophils	O
express	O
GATA-2	O
and	O
GATA-3	O
.	O

Treatment	O
of	O
HL-60	O
eosinophilic	O
sublines	O
with	O
either	O
interleukin-5	O
or	O
butyric	O
acid	O
increased	O
the	O
expression	O
of	O
GATA-1	O
mRNA	O
concomitant	O
with	O
the	O
expression	O
of	O
eosinophil-specific	O
genes	O
,	O
whereas	O
levels	O
of	O
GATA-2	O
mRNA	O
remained	O
relatively	O
constant	O
.	O

The	O
presence	O
of	O
mRNA	O
for	O
these	O
proteins	O
in	O
eosinophils	O
and	O
basophils	O
suggests	O
that	O
gene	O
transcription	O
in	O
these	O
lineages	O
may	O
be	O
regulated	O
by	O
GATA-binding	O
proteins	O
.	O

Proliferation	O
index	O
as	O
a	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O

BACKGROUND	O
.	O

The	O
proliferative	O
activity	O
of	O
tumors	O
has	O
been	O
extensively	O
investigated	O
with	O
different	O
approaches	O
,	O
among	O
which	O
the	O
use	O
of	O
the	O
monoclonal	O
antibody	O
Ki-67	O
represents	O
an	O
easy	O
and	O
reliable	O
means	O
of	O
assessing	O
cell	O
proliferation	O
.	O

In	O
this	O
study	O
,	O
the	O
proliferative	O
activity	O
of	O
129	O
primary	O
breast	O
cancers	O
was	O
investigated	O
,	O
and	O
the	O
results	O
were	O
related	O
to	O
prognosis	O
.	O

METHODS	O
.	O

Tumor	O
samples	O
,	O
obtained	O
from	O
129	O
patients	O
who	O
underwent	O
surgery	O
between	O
January	O
1987	O
and	O
December	O
1988	O
,	O
were	O
processed	O
for	O
staining	O
by	O
an	O
immunohistochemical	O
procedure	O
(	O
avidin-biotin	O
complex	O
)	O
.	O

The	O
median	O
time	O
of	O
observation	O
was	O
42	O
months	O
(	O
range	O
,	O
31-55	O
months	O
)	O
.	O

Life-table	O
analysis	O
(	O
Mantel-Cox	O
)	O
was	O
used	O
to	O
assess	O
the	O
probability	O
of	O
disease-free	O
survival	O
(	O
DFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

RESULTS	O
.	O

Tumors	O
with	O
high	O
Ki-67	O
proliferation	O
indices	O
(	O
>	O
20	O
%	O
)	O
were	O
associated	O
with	O
a	O
higher	O
4-year	O
probability	O
of	O
relapse	O
of	O
disease	O
(	O
55.3	O
%	O
versus	O
79.1	O
%	O
;	O
P	O
=	O
0.003	O
)	O
and	O
death	O
(	O
71	O
%	O
versus	O
95.6	O
%	O
;	O
P	O
=	O
0.00005	O
)	O
when	O
compared	O
with	O
tumors	O
with	O
low	O
Ki-67	O
values	O
.	O

In	O
addition	O
,	O
this	O
proliferative	O
parameter	O
maintained	O
its	O
prognostic	O
significance	O
when	O
the	O
patients	O
were	O
stratified	O
according	O
to	O
lymph	O
node	O
involvement	O
,	O
menopausal	O
status	O
,	O
and	O
nuclear	O
estrogen	O
receptor	O
content	O
.	O

CONCLUSIONS	O
.	O

Tumor	O
proliferative	O
activity	O
as	O
evaluated	O
by	O
the	O
monoclonal	O
antibody	O
Ki-67	O
seems	O
to	O
be	O
an	O
effective	O
indicator	O
of	O
prognosis	O
in	O
breast	O
cancer	O
for	O
DFS	O
and	O
OS	O
.	O

Defective	O
translocation	O
of	O
protein	O
kinase	O
C	O
in	O
multidrug-resistant	O
HL-60	O
cells	O
confers	O
a	O
reversible	O
loss	O
of	O
phorbol	O
ester-induced	O
monocytic	O
differentiation	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
human	O
HL-60	O
myeloid	O
leukemia	O
cells	O
differentiate	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

This	O
event	O
is	O
associated	O
with	O
induction	O
of	O
the	O
c-jun	O
early	O
response	O
gene	O
and	O
appearance	O
of	O
a	O
monocytic	O
phenotype	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
vincristine-selected	O
,	O
multidrug	O
resistance	O
on	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
-induced	O
HL-60	O
cell	O
differentiation	O
.	O

The	O
results	O
demonstrate	O
that	O
multidrug-resistant	O
HL-60	O
cells	O
,	O
designated	O
HL-60/vinc	O
,	O
fail	O
to	O
respond	O
to	O
TPA	O
with	O
an	O
increase	O
in	O
c-jun	O
transcripts	O
or	O
other	O
phenotypic	O
characteristics	O
of	O
monocytic	O
differentiation	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
HL-60/vinc	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	O
protein	O
phosphatases	O
,	O
induces	O
c-jun	O
transcription	O
,	O
growth	O
arrest	O
,	O
and	O
expression	O
of	O
the	O
c-fms	O
gene	O
.	O

Studies	O
were	O
also	O
performed	O
with	O
an	O
HL-60/vinc	O
revertant	O
(	O
HL-60/vinc/R	O
)	O
line	O
that	O
has	O
regained	O
partial	O
sensitivity	O
to	O
vincristine	O
.	O

The	O
finding	O
that	O
HL-60/vinc/R	O
cells	O
respond	O
to	O
TPA	O
with	O
induction	O
of	O
a	O
monocytic	O
phenotype	O
,	O
but	O
not	B-Negation
c-jun	I-Negation
expression	I-Negation
,	O
suggests	B-Speculation
that	I-Speculation
c-jun	I-Speculation
induction	I-Speculation
is	I-Speculation
not	I-Speculation
obligatory	I-Speculation
for	I-Speculation
monocytic	I-Speculation
differentiation	I-Speculation
.	O

Other	O
studies	O
further	O
demonstrate	O
that	O
the	O
jun-B	O
and	O
fra-1	O
genes	O
are	O
induced	O
by	O
TPA	O
in	O
both	O
HL-60/vinc	O
and	O
HL-60/vinc/R	O
cells	O
,	O
whereas	O
c-fos	O
expression	O
is	O
attenuated	O
in	O
the	O
HL-60/vinc	O
line	O
.	O

Since	O
TPA	O
activates	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
we	O
examined	O
translocation	O
of	O
PKC	O
from	O
the	O
cytosol	O
to	O
the	O
membrane	O
fraction	O
.	O

Although	O
HL-60	O
and	O
HL-60/vinc/R	O
cells	O
demonstrated	O
translocation	O
of	O
PKC	O
activity	O
,	O
this	O
subcellular	O
redistribution	O
was	O
undetectable	O
in	O
HL-60/vinc	O
cells	O
.	O

Activity	O
of	O
the	O
mitogen-activated	O
protein	O
kinase	O
family	O
with	O
associated	O
phosphorylation	O
of	O
c-Jun	O
Y-peptide	O
was	O
markedly	O
diminished	O
in	O
TPA-treated	O
HL-60/vinc	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
response	I-Negation
to	I-Negation
okadaic	I-Negation
acid	I-Negation
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
vincristine	O
resistance	O
confers	O
insensitivity	O
to	O
TPA-induced	O
differentiation	O
and	O
can	O
include	O
defects	O
in	O
PKC-mediated	O
signaling	O
events	O
and	O
induction	O
of	O
jun/fos	O
early	O
response	O
gene	O
expression	O
.	O

Differential	O
contribution	O
of	O
herpes	O
simplex	O
virus	O
type	O
1	O
gene	O
products	O
and	O
cellular	O
factors	O
to	O
the	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
provirus	O
.	O

We	O
have	O
previously	O
reported	O
that	O
infection	O
with	O
herpes	O
simplex	O
virus	O
type	O
1	O
(	O
HSV-1	O
)	O
activates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
provirus	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
HIV-1	O
provirus	O
correlated	O
with	O
the	O
activation	O
of	O
binding	O
of	O
55-	O
and	O
85-kDa	O
proteins	O
to	O
the	O
kappa	O
B	O
enhancer	O
and	O
binding	O
of	O
the	O
50-kDa	O
HLP-1	O
protein	O
to	O
the	O
LBP-1	O
sequences	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
.	O

Further	O
examination	O
of	O
this	O
system	O
has	O
shown	O
that	O
the	O
inhibition	O
of	O
HSV-1	O
replication	O
by	O
the	O
antiviral	O
drug	O
acyclovir	O
does	O
not	B-Negation
inhibit	I-Negation
HSV-1-mediated	I-Negation
induction	I-Negation
of	I-Negation
HIV-1	I-Negation
provirus	I-Negation
.	O

Surprisingly	O
,	O
the	O
NF-kappa	O
B	O
and	O
HLP-1	O
binding	O
activities	O
were	O
substantially	O
inhibited	O
in	O
acyclovir-treated	O
cells	O
.	O

In	O
the	O
transient-transfection	O
assay	O
,	O
ICP0	O
,	O
but	O
not	B-Negation
ICP4	I-Negation
,	O
activated	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
promoter	O
region	O
and	O
the	O
effect	O
of	O
ICP0	O
was	O
greatly	O
enhanced	O
in	O
the	O
presence	O
of	O
the	O
NF-kappa	O
B	O
binding	O
proteins	O
,	O
suggesting	B-Speculation
that	I-Speculation
induction	I-Speculation
of	I-Speculation
the	I-Speculation
HIV-1	I-Speculation
provirus	I-Speculation
involves	I-Speculation
cooperation	I-Speculation
between	I-Speculation
the	I-Speculation
HSV-1-activated	I-Speculation
cellular	I-Speculation
factor	I-Speculation
,	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
,	I-Speculation
and	I-Speculation
the	I-Speculation
virus-encoded	I-Speculation
transactivator	I-Speculation
,	I-Speculation
ICP0	I-Speculation
.	O

Glucocorticoid	O
receptors	O
in	O
mononuclear	O
cells	O
of	O
patients	O
with	O
sepsis	O
.	O

Glucocorticoid	O
receptor	O
(	O
GR	O
)	O
hormone-binding	O
activity	O
was	O
studied	O
by	O
a	O
whole-cell	O
method	O
in	O
mononuclear	O
cells	O
(	O
MNC	O
)	O
from	O
peripheral	O
blood	O
of	O
7	O
patients	O
during	O
the	O
hemodynamic	O
compensatory	O
phase	O
of	O
sepsis	O
.	O

4	O
patients	O
were	O
receiving	O
dopamine	O
,	O
which	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
GR	I-Negation
count	I-Negation
.	O

The	O
patients	O
'	O
plasma	O
cortisol	O
concentrations	O
were	O
normal	O
or	O
slightly	O
elevated	O
.	O

Despite	O
a	O
wide	O
range	O
,	O
the	O
mean	O
GR	O
count	O
and	O
affinity	O
in	O
MNC	O
from	O
septic	O
patients	O
did	O
not	B-Negation
differ	I-Negation
from	I-Negation
those	I-Negation
in	I-Negation
normal	I-Negation
controls	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
glucocorticoids	I-Speculation
could	I-Speculation
still	I-Speculation
be	I-Speculation
effective	I-Speculation
in	I-Speculation
the	I-Speculation
hemodynamic	I-Speculation
compensatory	I-Speculation
phase	I-Speculation
of	I-Speculation
sepsis	I-Speculation
.	O

Dependence	O
for	O
the	O
proliferative	O
response	O
to	O
erythropoietin	O
on	O
an	O
established	O
erythroid	O
differentiation	O
program	O
in	O
a	O
human	O
hematopoietic	O
cell	O
line	O
,	O
UT-7	O
.	O

Erythroid	O
differentiation	O
involves	O
the	O
activation	O
of	O
a	O
number	O
of	O
erythroid-specific	O
genes	O
,	O
most	O
of	O
which	O
,	O
including	O
the	O
globin	O
genes	O
and	O
the	O
erythropoietin	O
receptor	O
(	O
Epo-R	O
)	O
gene	O
,	O
are	O
,	O
at	O
least	O
in	O
part	O
,	O
regulated	O
by	O
the	O
transcription	O
factor	O
GATA-1	O
.	O

In	O
order	O
to	O
understand	O
the	O
relationship	O
,	O
if	O
any	O
,	O
between	O
expression	O
of	O
GATA-1	O
,	O
response	O
to	O
Epo	O
and	O
erythroid	O
differentiation	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
GATA-1	O
,	O
Epo-R	O
and	O
globin	O
genes	O
in	O
an	O
Epo-dependent	O
human	O
cell	O
line	O
,	O
UT-7	O
Epo	O
.	O

The	O
results	O
were	O
compared	O
to	O
those	O
obtained	O
with	O
the	O
parental	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
-dependent	O
cell	O
line	O
,	O
UT-7	O
,	O
which	O
has	O
a	O
predominantly	O
megakaryoblastic	O
phenotype	O
and	O
is	O
unable	B-Negation
to	I-Negation
proliferate	I-Negation
continuously	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
Epo	I-Negation
.	O

UT-7	O
Epo	O
and	O
UT-7	O
expressed	O
similar	O
levels	O
of	O
GATA-1	O
mRNA	O
and	O
binding	O
activity	O
.	O

The	O
two	O
lines	O
also	O
expressed	O
comparable	O
levels	O
of	O
Epo-R	O
mRNA	O
while	O
the	O
number	O
of	O
Epo-binding	O
sites	O
on	O
UT-7	O
Epo	O
cells	O
was	O
one-sixth	O
the	O
number	O
of	O
UT-7	O
cells	O
(	O
2400	O
	O
3	O
vs	O
.	O

13,800	O
	O
300	O
)	O
.	O

This	O
difference	O
in	O
the	O
number	O
of	O
binding	O
sites	O
could	O
be	O
due	O
to	O
differences	O
in	O
cell	O
surface	O
(	O
UT-7	O
cells	O
are	O
20	O
%	O
smaller	O
than	O
the	O
parental	O
UT-7	O
cells	O
)	O
or	O
in	O
receptor	O
turnover	O
.	O

By	O
Northern	O
analysis	O
,	O
UT-7	O
cells	O
expressed	O
detectable	O
levels	O
of	O
beta-	O
and	O
gamma-globin	O
but	O
not	B-Negation
alpha-globin	I-Negation
.	O

In	O
comparison	O
,	O
UT-7	O
Epo	O
cells	O
expressed	O
alpha-globin	O
and	O
higher	O
levels	O
of	O
gamma-globin	O
(	O
5-fold	O
)	O
and	O
beta-globin	O
(	O
from	O
barely	O
to	O
clearly	O
detectable	O
)	O
.	O

Globin	O
chains	O
(	O
alpha	O
,	O
beta	O
and	O
gamma	O
)	O
were	O
clearly	O
detectable	O
by	O
affinity	O
chromatography	O
in	O
UT-7	O
Epo	O
but	O
not	B-Negation
in	I-Negation
UT-7	I-Negation
cells	I-Negation
.	O

The	O
frequency	O
of	O
the	O
cells	O
which	O
expressed	O
beta-	O
and	O
gamma-globin	O
genes	O
in	O
the	O
two	O
cell	O
populations	O
was	O
measured	O
by	O
immunofluorescence	O
with	O
beta-	O
and	O
gamma-specific	O
antibodies	O
.	O

The	O
number	O
of	O
gamma-positive	O
cells	O
and	O
their	O
fluorescence	O
intensity	O
were	O
higher	O
in	O
UT-7	O
Epo	O
than	O
in	O
UT-7	O
cells	O
(	O
0	O
to	O
17	O
%	O
barely	O
positive	O
cells	O
and	O
23	O
to	O
40	O
%	O
clearly	O
positive	O
cells	O
,	O
respectively	O
)	O
,	O
indicating	O
that	O
the	O
increase	O
in	O
globin	O
mRNA	O
observed	O
in	O
UT-7	O
Epo	O
is	O
due	O
to	O
both	O
an	O
increase	O
of	O
gene	O
expression	O
per	O
cell	O
and	O
an	O
increase	O
in	O
numbers	O
of	O
cells	O
containing	O
gamma-globin	O
.	O

The	B-Negation
levels	I-Negation
of	I-Negation
GATA-1	I-Negation
,	I-Negation
Epo-R	I-Negation
and	I-Negation
globin	I-Negation
mRNA	I-Negation
expressed	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
a	I-Negation
24-hour	I-Negation
incubation	I-Negation
of	I-Negation
either	I-Negation
cell	I-Negation
line	I-Negation
with	I-Negation
Epo	I-Negation
,	I-Negation
GM-CSF	I-Negation
or	I-Negation
interleukin-3	I-Negation
(	I-Negation
IL-3	I-Negation
)	I-Negation
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Transcriptional	O
activation	O
of	O
the	O
macrophage	O
colony-stimulating	O
factor	O
gene	O
by	O
IL-2	O
is	O
associated	O
with	O
secretion	O
of	O
bioactive	O
macrophage	O
colony-stimulating	O
factor	O
protein	O
by	O
monocytes	O
and	O
involves	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
(	O
Mo	O
)	O
constitutively	O
display	O
the	O
beta-chain	O
of	O
the	O
receptor	O
for	O
IL-2	O
,	O
whereas	O
expression	O
of	O
the	O
IL-2R	O
alpha-chain	O
is	O
not	B-Negation
constitutive	I-Negation
but	O
inducible	O
with	O
IL-2	O
.	O

Here	O
we	O
report	O
that	O
binding	O
of	O
human	O
IL-2	O
to	O
its	O
binding	O
site	O
leads	O
to	O
transcriptional	O
activation	O
of	O
the	O
macrophage	O
CSF	O
(	O
M-CSF	O
)	O
gene	O
in	O
Mo	O
resulting	O
in	O
accumulation	O
of	O
M-CSF	O
mRNA	O
and	O
subsequent	O
release	O
of	O
bioactive	O
M-CSF	O
protein	O
as	O
demonstrated	O
by	O
ELISA	O
and	O
inhibition	O
of	O
IL-2	O
induced	O
release	O
of	O
an	O
activity-stimulating	O
growth	O
of	O
monocyte-type	O
colonies	O
by	O
a	O
neutralizing	O
anti-M-CSF	O
antibody	O
.	O

Transcriptional	O
activation	O
of	O
the	O
M-CSF	O
gene	O
by	O
IL-2	O
is	O
preceded	O
by	O
enhanced	O
binding	O
activity	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
to	O
its	O
recognition	O
sequence	O
in	O
the	O
5	O
'	O
regulatory	O
enhancer	O
region	O
of	O
the	O
M-CSF	O
gene	O
.	O

Moreover	O
,	O
using	O
a	O
heterologous	O
promoter	O
(	O
herpes	O
thymidine	O
kinase	O
)	O
construct	O
containing	O
the	O
NF-kappa	O
B	O
consensus	O
sequence	O
,	O
it	O
is	O
shown	O
that	O
NF-kappa	O
B	O
binding	O
by	O
an	O
IL-2-induced	O
monocyte-derived	O
nuclear	O
protein	O
confers	O
reporter	O
gene	O
(	O
human	O
growth	O
hormone	O
)	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
IL-2	O
induces	O
gene	O
expression	O
of	O
M-CSF	O
in	O
human	O
blood-derived	O
Mo	O
and	O
provide	O
evidence	O
for	O
involvement	O
of	O
NF-kappa	O
B	O
in	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
.	O

Comparative	O
analysis	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
complex	O
in	O
human	O
T	O
and	O
B	O
lymphocytes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
is	O
a	O
transcriptional	O
activator	O
that	O
binds	O
to	O
sequences	O
in	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
and	O
is	O
thought	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
T	O
cell-specific	O
inducibility	O
of	O
IL-2	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
showed	O
that	O
specific	O
NFAT	O
binding	O
activity	O
could	O
also	O
be	O
induced	O
in	O
human	O
B	O
cells	O
.	O

The	O
B	O
cell	O
NFAT	O
complex	O
,	O
however	O
,	O
was	O
not	B-Negation
functional	I-Negation
,	O
since	O
it	O
failed	B-Negation
to	I-Negation
activate	I-Negation
transcription	I-Negation
from	I-Negation
an	I-Negation
NFAT-driven	I-Negation
chloramphenicol	I-Negation
acetyltransferase	I-Negation
(	I-Negation
CAT	I-Negation
)	I-Negation
construct	I-Negation
.	O

Competition	O
with	O
an	O
AP-1	O
motif	O
or	O
with	O
anti-Jun	O
and	O
anti-Fos	O
antibodies	O
abolished	O
binding	O
to	O
the	O
NFAT	O
motif	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
indicating	O
that	O
Jun	O
and	O
Fos	O
are	O
critical	O
for	O
NFAT	O
complex	O
formation	O
in	O
both	O
cell	O
types	O
.	O

Purified	O
recombinant	O
Jun	O
and	O
Fos	O
proteins	O
failed	O
to	O
bind	O
directly	O
to	O
the	O
NFAT	O
motif	O
.	O

However	O
,	O
when	O
combined	O
with	O
unstimulated	O
B	O
or	O
T	O
cell	O
extracts	O
,	O
full-length	O
,	O
but	O
not	B-Negation
truncated	I-Negation
,	O
Jun/Fos	O
heterodimers	O
were	O
able	O
to	O
form	O
an	O
NFAT	O
complex	O
,	O
indicating	B-Speculation
the	I-Speculation
presence	I-Speculation
of	I-Speculation
a	I-Speculation
constitutively	I-Speculation
expressed	I-Speculation
nuclear	I-Speculation
factor	I-Speculation
(	I-Speculation
s	I-Speculation
)	I-Speculation
in	I-Speculation
B	I-Speculation
and	I-Speculation
T	I-Speculation
cells	I-Speculation
necessary	I-Speculation
for	I-Speculation
the	I-Speculation
formation	I-Speculation
of	I-Speculation
the	I-Speculation
NFAT	I-Speculation
complex	I-Speculation
in	I-Speculation
both	I-Speculation
cell	I-Speculation
types	I-Speculation
.	O

An	O
NFAT	O
oligonucleotide	O
carrying	O
mutations	O
in	O
the	O
5	O
'	O
purine-rich	O
part	O
of	O
the	O
NFAT	O
sequence	O
failed	B-Negation
to	I-Negation
form	I-Negation
a	I-Negation
complex	I-Negation
and	I-Negation
to	I-Negation
compete	I-Negation
with	I-Negation
the	I-Negation
wild	I-Negation
type	I-Negation
motif	I-Negation
for	I-Negation
NFAT	I-Negation
complex	I-Negation
formation	I-Negation
in	I-Negation
both	I-Negation
T	I-Negation
and	I-Negation
B	I-Negation
cells	I-Negation
.	O

We	O
therefore	O
propose	O
a	O
model	O
whereby	O
a	O
core	O
NFAT	O
complex	O
consisting	O
of	O
Jun	O
,	O
Fos	O
,	O
and	O
a	O
constitutive	O
nuclear	O
factor	O
is	O
formed	O
in	O
both	O
T	O
and	O
B	O
cells	O
,	O
but	O
an	O
additional	O
factor	O
and/or	O
post-translational	O
modification	O
of	O
a	O
factor	O
,	O
missing	O
in	O
B	O
cells	O
,	O
might	O
be	O
required	O
for	O
transactivation	O
by	O
NFAT	O
.	O

1,25-Dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
synergistically	O
induce	O
monocytic	O
cell	O
differentiation	O
:	O
FOS	O
and	O
RB	O
expression	O
.	O

1,25-dihydroxy	O
vitamin	O
D3	O
and	O
12-O-tetradecanoyl	O
phorbol-13-acetate	O
(	O
TPA	O
)	O
interact	O
synergistically	O
to	O
induce	O
monocytic	O
differentiation	O
of	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O

Addition	O
of	O
TPA	O
causes	O
an	O
otherwise	O
ineffective	O
dose	O
of	O
1,25-dihydroxy	O
vitamin	O
D3	O
to	O
induce	O
differentiation	O
.	O

The	O
induced	O
differentiation	O
depends	O
on	O
the	O
simultaneous	O
(	O
vs.	O
sequential	O
)	O
presence	O
of	O
both	O
agents	O
.	O

The	O
kinetics	O
of	O
induced	O
differentiation	O
are	O
consistent	O
with	O
a	O
G1	O
specific	O
cellular	O
response	O
to	O
initiate	O
the	O
metabolic	O
cascade	O
culminating	O
in	O
cell	O
differentiation	O
.	O

The	O
induced	O
differentiation	O
occurs	O
with	O
down-regulation	O
of	O
c-fos	O
protein	O
and	O
an	O
accompanying	O
up-regulation	O
of	O
RB	O
protein	O
expression	O
,	O
consistent	O
with	O
a	O
possible	O
need	O
for	O
up-regulated	O
RB	O
expression	O
to	O
maintain	O
a	O
given	O
differentiated	O
phenotype	O
and	O
suppress	O
transcriptional	O
activators	O
that	O
might	O
typically	O
be	O
associated	O
with	O
proliferation	O
.	O

Regulation	O
of	O
lymphoid-specific	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
enhancer	O
by	O
ETS-domain	O
proteins	O
.	O

The	O
enhancer	O
for	O
the	O
immunoglobulin	O
mu	O
heavy	O
chain	O
gene	O
(	O
IgH	O
)	O
activates	O
a	O
heterologous	O
gene	O
at	O
the	O
pre-B	O
cell	O
stage	O
of	O
B	O
lymphocyte	O
differentiation	O
.	O

A	O
lymphoid-specific	O
element	O
,	O
microB	O
,	O
is	O
necessary	O
for	O
enhancer	O
function	O
in	O
pre-B	O
cells	O
.	O

A	O
microB	O
binding	O
protein	O
is	O
encoded	O
by	O
the	O
PU.1/Spi-1	O
proto-oncogene	O
.	O

Another	O
sequence	O
element	O
,	O
microA	O
,	O
was	O
identified	O
in	O
the	O
mu	O
enhancer	O
that	O
binds	O
the	O
product	O
of	O
the	O
ets-1	O
proto-oncogene	O
.	O

The	O
microA	O
motif	O
was	O
required	O
for	O
microB-dependent	O
enhancer	O
activity	O
,	O
which	O
suggests	O
that	O
a	O
minimal	O
B	O
cell-specific	O
enhancer	O
is	O
composed	O
of	O
both	O
the	O
PU.1	O
and	O
Ets-1	O
binding	O
sites	O
.	O

Co-expression	O
of	O
both	O
PU.1	O
and	O
Ets-1	O
in	O
nonlymphoid	O
cells	O
trans-activated	O
reporter	O
plasmids	O
that	O
contained	O
the	O
minimal	O
mu	O
enhancer	O
.	O

These	O
results	O
implicate	O
two	O
members	O
of	O
the	O
Ets	O
family	O
in	O
the	O
activation	O
of	O
IgH	O
gene	O
expression	O
.	O

Differential	O
autoregulation	O
of	O
glucocorticoid	O
receptor	O
expression	O
in	O
human	O
T-	O
and	O
B-cell	O
lines	O
.	O

Regulation	O
of	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
expression	O
by	O
its	O
cognate	O
ligand	O
was	O
examined	O
in	O
the	O
glucocorticoid-sensitive	O
human	O
leukemic	O
T-cell	O
line	O
6TG1.1	O
and	O
in	O
the	O
human	O
B-cell	O
line	O
IM-9	O
.	O

In	O
contrast	O
to	O
the	O
decrease	O
in	O
GR	O
mRNA	O
seen	O
in	O
IM-9	O
cells	O
after	O
treatment	O
with	O
1	O
microM	O
dexamethasone	O
for	O
16-18	O
h	O
,	O
treatment	O
of	O
6TG1.1	O
cells	O
resulted	O
in	O
an	O
8-fold	O
increase	O
in	O
GR	O
mRNA	O
,	O
as	O
determined	O
by	O
Northern	O
blot	O
and	O
RNase	O
protection	O
analysis	O
,	O
with	O
a	O
corresponding	O
3-	O
to	O
4-fold	O
increase	O
in	O
GR	O
protein	O
.	O

Half-maximal	O
induction	O
of	O
GR	O
mRNA	O
and	O
protein	O
in	O
6TG1.1	O
cells	O
was	O
observed	O
between	O
10-100	O
nM	O
dexamethasone	O
,	O
and	O
inclusion	O
of	O
1	O
microM	O
RU	O
38486	O
completely	O
blocked	O
the	O
effects	O
of	O
100	O
nM	O
dexamethasone	O
,	O
demonstrating	O
that	O
positive	O
autoregulation	O
of	O
GR	O
expression	O
in	O
6TG1.1	O
cells	O
is	O
a	O
receptor-mediated	O
response	O
.	O

Positive	O
autoregulation	O
of	O
GR	O
expression	O
was	O
also	O
observed	O
in	O
glucocorticoid-resistant	O
CEM-C1	O
cells	O
,	O
which	O
contain	O
functional	O
GR	O
,	O
but	O
whose	O
growth	O
is	O
unaffected	O
by	O
glucocorticoids	O
.	O

Thus	O
,	O
positive	O
autoregulation	O
is	O
neither	B-Negation
a	I-Negation
consequence	I-Negation
nor	I-Negation
the	I-Negation
sole	I-Negation
cause	I-Negation
of	I-Negation
growth	I-Negation
arrest	I-Negation
.	O

The	O
degree	O
of	O
negative	O
autoregulation	O
in	O
IM-9	O
cells	O
and	O
positive	O
autoregulation	O
in	O
6TG1.1	O
cells	O
was	O
unaffected	O
by	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
.	O

Measurement	O
of	O
GR	O
mRNA	O
turnover	O
in	O
6TG1.1	O
cells	O
treated	O
with	O
actinomycin-D	O
revealed	O
a	O
half-life	O
of	O
2.5	O
h	O
,	O
which	O
was	O
unaffected	O
by	O
dexamethasone	O
treatment	O
.	O

A	O
similar	O
half-life	O
was	O
determined	O
in	O
IM-9	O
cells	O
and	O
was	O
also	O
unaffected	O
by	O
steroid	O
treatment	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
interpretation	O
that	O
glucocorticoid-mediated	O
autoregulation	O
of	O
GR	O
expression	O
is	O
a	O
tissue-specific	O
primary	O
transcriptional	O
response	O
.	O

The	O
p65	O
subunit	O
of	O
NF-kappa	O
B	O
regulates	O
I	O
kappa	O
B	O
by	O
two	O
distinct	O
mechanisms	O
.	O

Transcription	O
factor	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
is	O
generally	O
localized	O
to	O
the	O
cytoplasm	O
by	O
its	O
inhibitor	O
I	O
kappa	O
B	O
.	O

Overproduced	O
I	O
kappa	O
B	O
,	O
free	O
from	O
NF-kappa	O
B	O
,	O
is	O
rapidly	O
degraded	O
.	O

Overexpression	O
of	O
p65	O
increases	O
endogenous	O
I	O
kappa	O
B	O
protein	O
in	O
both	O
carcinoma	O
and	O
lymphoid	O
cells	O
by	O
two	O
mechanisms	O
:	O
protein	O
stabilization	O
and	O
increased	O
transcription	O
of	O
I	O
kappa	O
B	O
mRNA	O
.	O

In	O
contrast	O
,	O
p65	O
delta	O
,	O
a	O
naturally	O
occurring	O
splice	O
variant	O
,	O
fails	O
to	O
markedly	O
augment	O
I	O
kappa	O
B	O
protein	O
levels	O
.	O

Both	O
overexpressed	O
p65	O
and	O
coexpressed	O
p50	O
are	O
cytoplasmic	O
,	O
whereas	O
p65	O
delta	O
is	O
partly	O
nuclear	O
,	O
indicating	O
that	O
the	O
I	O
kappa	O
B	O
induced	O
by	O
p65	O
can	O
maintain	O
NF-kappa	O
B	O
in	O
the	O
cytoplasm	O
.	O

Thus	O
,	O
p65	O
and	O
I	O
kappa	O
B	O
are	O
linked	O
in	O
an	O
autoregulatory	O
loop	O
,	O
ensuring	O
that	O
NF-kappa	O
B	O
is	O
held	O
in	O
the	O
cytoplasm	O
until	O
cells	O
are	O
specifically	O
induced	O
to	O
translocate	O
it	O
to	O
the	O
nucleus	O
.	O

Cell	O
cycle	O
analysis	O
of	O
E2F	O
in	O
primary	O
human	O
T	O
cells	O
reveals	O
novel	O
E2F	O
complexes	O
and	O
biochemically	O
distinct	O
forms	O
of	O
free	O
E2F	O
.	O

The	O
transcription	O
factor	O
E2F	O
activates	O
the	O
expression	O
of	O
multiple	O
genes	O
involved	O
in	O
cell	O
proliferation	O
,	O
such	O
as	O
c-myc	O
and	O
the	O
dihydrofolate	O
reductase	O
gene	O
.	O

Regulation	O
of	O
E2F	O
involves	O
its	O
interactions	O
with	O
other	O
cellular	O
proteins	O
,	O
including	O
the	O
retinoblastoma	O
protein	O
(	O
Rb	O
)	O
,	O
the	O
Rb-related	O
protein	O
p107	O
,	O
cyclin	O
A	O
,	O
and	O
cdk2	O
.	O

We	O
undertook	O
a	O
detailed	O
analysis	O
of	O
E2F	O
DNA-binding	O
activities	O
and	O
their	O
cell	O
cycle	O
behavior	O
in	O
primary	O
human	O
T	O
cells	O
.	O

Three	O
E2F	O
DNA-binding	O
activities	O
were	O
identified	O
in	O
resting	O
(	O
G0	O
)	O
T	O
cells	O
with	O
mobilities	O
in	O
gel	O
shift	O
assays	O
distinct	O
from	O
those	O
of	O
previously	O
defined	O
E2F	O
complexes	O
.	O

One	O
of	O
these	O
activities	O
was	O
found	O
to	O
be	O
a	O
novel	O
,	O
less	O
abundant	O
,	O
Rb-E2F	O
complex	O
.	O

The	O
most	O
prominent	O
E2F	O
activity	O
in	O
resting	O
T	O
cells	O
(	O
termed	O
complex	O
X	O
)	O
was	O
abundant	O
in	O
both	O
G0	O
and	O
G1	O
but	O
disappeared	O
as	O
cells	O
entered	O
S	O
phase	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
negatively	O
regulating	O
E2F	O
function	O
.	O

Complex	O
X	O
could	O
be	O
dissociated	O
by	O
adenovirus	O
E1A	O
with	O
a	O
requirement	O
for	O
an	O
intact	O
E1A	O
conserved	O
region	O
2	O
.	O

However	O
,	O
X	O
failed	B-Negation
to	I-Negation
react	I-Negation
with	I-Negation
a	I-Negation
variety	I-Negation
of	I-Negation
antibodies	I-Negation
against	I-Negation
Rb	I-Negation
or	I-Negation
p107	I-Negation
,	O
implicating	B-Speculation
the	I-Speculation
involvement	I-Speculation
of	I-Speculation
an	I-Speculation
E1A-binding	I-Speculation
protein	I-Speculation
other	I-Speculation
than	I-Speculation
Rb	I-Speculation
or	I-Speculation
p107	I-Speculation
.	O

In	O
addition	O
to	O
these	O
novel	O
E2F	O
complexes	O
,	O
three	O
distinct	O
forms	O
of	O
unbound	O
(	O
free	O
)	O
E2F	O
were	O
resolved	O
in	O
gel	O
shift	O
experiments	O
.	O

These	O
species	O
showed	O
different	O
cell	O
cycle	O
kinetics	O
.	O

UV	O
cross-linking	O
experiments	O
suggested	O
that	O
a	O
distinct	O
E2F	O
DNA-binding	O
protein	O
is	O
uniquely	O
associated	O
with	O
the	O
S-phase	O
p107	O
complex	O
and	O
is	O
not	O
associated	O
with	O
Rb	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
E2F	O
consists	O
of	O
multiple	O
,	O
biochemically	O
distinct	O
DNA-binding	O
proteins	O
which	O
function	O
at	O
different	O
points	O
in	O
the	O
cell	O
cycle	O
.	O

Occurrence	O
of	O
a	O
silencer	O
of	O
the	O
interleukin-2	O
gene	O
in	O
naive	O
but	O
not	B-Negation
in	I-Negation
memory	I-Negation
resting	I-Negation
T	I-Negation
helper	I-Negation
lymphocytes	I-Negation
.	O

In	O
the	O
immune	O
system	O
the	O
first	O
activation	O
of	O
a	O
naive	O
T	O
cell	O
by	O
antigen	O
is	O
a	O
key	O
step	O
in	O
the	O
shaping	O
of	O
the	O
peripheral	O
T	O
cell	O
specificity	O
repertoire	O
and	O
maintenance	O
of	O
self-tolerance	O
.	O

In	O
the	O
present	O
study	O
,	O
analysis	O
of	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
activation	O
shows	O
that	O
naive	O
human	O
helper	O
T	O
cells	O
(	O
cord	O
blood	O
CD4+	O
T	O
cells	O
,	O
adult	O
CD4+CD45RO-	O
T	O
cells	O
)	O
regulate	O
IL-2	O
transcription	O
by	O
a	O
mechanism	O
involving	O
both	O
a	O
silencer	O
and	O
an	O
activator	O
acting	O
on	O
the	O
purine-rich	O
IL-2	O
promoter	O
elements	O
(	O
NF-AT	O
binding	O
sites	O
)	O
.	O

By	O
contrast	O
,	O
memory	O
cells	O
,	O
either	O
in	O
vitro	O
activated	O
helper	O
T	O
cells	O
reverting	O
to	O
a	O
resting	O
state	O
,	O
or	O
CD4+	O
T	O
(	O
memory	O
)	O
clones	O
,	O
or	O
CD4+CD45RO+	O
T	O
cells	O
isolated	O
ex	O
vivo	O
,	O
no	B-Negation
longer	I-Negation
have	I-Negation
a	I-Negation
silencer	I-Negation
.	O

Their	O
IL-2	O
transcription	O
seems	O
to	O
be	O
controlled	O
solely	O
by	O
the	O
transition	O
from	O
inactive	O
to	O
active	O
functional	O
state	O
of	O
a	O
positive	O
transcription	O
factor	O
binding	O
to	O
these	O
promoter	O
elements	O
as	O
well	O
as	O
its	O
cytoplasmic	O
or	O
nuclear	O
location	O
:	O

in	O
resting	O
memory	O
T	O
cells	O
the	O
activator	O
is	O
located	O
in	O
the	O
cytoplasm	O
and	O
is	O
inactive	O
,	O
whereas	O
in	O
stimulated	O
cells	O
it	O
is	O
functional	O
in	O
promoting	O
transcription	O
and	O
now	O
resides	O
in	O
the	O
nucleus	O
.	O

Thus	O
,	O
the	O
regulation	O
of	O
the	O
gene	O
coding	O
for	O
the	O
main	O
T	O
cell	O
growth	O
factor	O
changes	O
irreversibly	O
after	O
the	O
first	O
encounter	O
of	O
T	O
cells	O
with	O
antigen	O
.	O

It	O
is	O
most	O
likely	O
that	O
the	O
presence	O
of	O
a	O
silencer	O
contributes	O
to	O
the	O
more	O
stringent	O
activation	O
requirements	O
of	O
naive	O
CD4+	O
T	O
cells	O
.	O

Single	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
androgen	O
receptor	O
gene	O
mutations	O
in	O
patients	O
with	O
androgen	O
insensitivity	O
syndromes	O
:	O
application	O
for	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
therapy	O
.	O

Recent	O
studies	O
indicate	O
that	O
mutations	O
in	O
the	O
androgen	O
receptor	O
gene	O
are	O
associated	O
with	O
androgen	O
insensitivity	O
syndromes	O
,	O
a	O
heterogeneous	O
group	O
of	O
related	O
disorders	O
involving	O
defective	O
sexual	O
differentiation	O
in	O
karyotypic	O
males	O
.	O

In	O
this	O
report	O
,	O
we	O
address	O
the	O
possibility	O
of	O
rapid	O
mutational	O
analysis	O
of	O
the	O
androgen	O
receptor	O
gene	O
for	O
initial	O
diagnosis	O
,	O
genetic	O
counseling	O
,	O
and	O
molecular	O
subclassification	O
of	O
affected	O
patients	O
and	O
their	O
families	O
.	O

DNA	O
from	O
peripheral	O
blood	O
leukocytes	O
of	O
six	O
patients	O
from	O
five	O
families	O
with	O
various	O
degrees	O
of	O
androgen	O
insensitivity	O
was	O
studied	O
.	O

Exons	O
2	O
to	O
8	O
of	O
the	O
androgen	O
receptor	O
gene	O
were	O
analyzed	O
using	O
a	O
combination	O
of	O
single	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
DNA	O
sequencing	O
.	O

Female	O
family	O
members	O
were	O
also	O
studied	O
to	O
identify	O
heterozygote	O
carriers	O
.	O

Point	O
mutations	O
in	O
the	O
AR	O
gene	O
were	O
identified	O
in	O
all	O
six	O
patients	O
,	O
and	O
all	O
mutations	O
caused	O
amino	O
acid	O
substitutions	O
.	O

One	O
patient	O
with	O
incomplete	O
androgen	O
insensitivity	O
was	O
a	O
mosaic	O
for	O
the	O
mutation	O
.	O

Four	O
of	O
the	O
five	O
mothers	O
,	O
as	O
well	O
as	O
a	O
young	O
sister	O
of	O
one	O
patient	O
,	O
were	O
carriers	O
of	O
the	O
mutation	O
present	O
in	O
the	O
affected	O
child	O
.	O

Our	O
data	O
show	O
that	O
new	O
mutations	O
may	O
occur	O
in	O
the	O
androgen	O
receptor	O
gene	O
leading	O
to	O
sporadic	O
androgen	O
insensitivity	O
syndrome	O
.	O

Molecular	O
genetic	O
characterization	O
of	O
the	O
variant	O
allele	O
can	O
serve	O
as	O
a	O
primary	O
tool	O
for	O
diagnosis	O
and	O
subsequent	O
therapy	O
,	O
and	O
can	O
provide	O
a	O
basis	O
for	O
distinguishing	O
heterozygous	O
carriers	O
in	O
familial	O
androgen	O
resistance	O
.	O

The	O
identification	O
of	O
carriers	O
is	O
of	O
substantial	O
clinical	O
importance	O
for	O
genetic	O
counseling	O
.	O

Minimally	O
modified	O
low	O
density	O
lipoprotein-induced	O
inflammatory	O
responses	O
in	O
endothelial	O
cells	O
are	O
mediated	O
by	O
cyclic	O
adenosine	O
monophosphate	O
.	O

We	O
have	O
previously	O
shown	O
that	O
minimally	O
oxidized	O
LDL	O
(	O
MM-LDL	O
)	O
activated	O
endothelial	O
cells	O
to	O
increase	O
their	O
interaction	O
with	O
monocytes	O
but	O
not	B-Negation
neutrophils	I-Negation
,	O
inducing	O
monocyte	O
but	O
not	B-Negation
neutrophil	I-Negation
binding	O
and	O
synthesis	O
of	O
monocyte	O
chemotactic	O
protein-1	O
and	O
monocyte	O
colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
.	O

In	O
the	O
present	O
studies	O
we	O
have	O
examined	O
the	O
signaling	O
pathways	O
by	O
which	O
this	O
monocyte-specific	O
response	O
is	O
induced	O
.	O

Both	B-Negation
induction	I-Negation
of	I-Negation
monocyte	I-Negation
binding	I-Negation
and	I-Negation
mRNA	I-Negation
levels	I-Negation
for	I-Negation
M-CSF	I-Negation
by	I-Negation
MM-LDL	I-Negation
were	I-Negation
not	I-Negation
inhibited	I-Negation
in	I-Negation
protein	I-Negation
kinase	I-Negation
C-depleted	I-Negation
endothelial	I-Negation
cells	I-Negation
.	O

A	O
number	O
of	O
our	O
studies	O
indicate	O
that	O
cAMP	O
is	O
the	O
second	O
messenger	O
for	O
the	O
effects	O
of	O
MM-LDL	O
cited	O
above	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
MM-	O
LDL	O
caused	O
a	O
173	O
%	O
increase	O
in	O
intracellular	O
cAMP	O
levels	O
.	O

Agents	O
which	O
increased	O
cAMP	O
levels	O
,	O
including	O
cholera	O
toxin	O
,	O
pertussis	O
toxin	O
,	O
dibutyryl	O
cAMP	O
,	O
and	O
isoproterenol	O
mimicked	O
the	O
actions	O
of	O
MM-LDL	O
.	O

Agents	O
which	O
elevated	O
cAMP	O
were	O
also	O
shown	O
to	O
activate	O
NF	O
kappa	O
B	O
,	O
suggesting	O
a	O
role	O
for	O
this	O
transcription	O
factor	O
in	O
activation	O
of	O
monocyte-endothelial	O
interactions	O
.	O

Although	O
endothelial	B-Speculation
leukocyte	I-Speculation
adhesion	I-Speculation
molecule	I-Speculation
(	I-Speculation
ELAM	I-Speculation
)	I-Speculation
mRNA	I-Speculation
synthesis	I-Speculation
can	I-Speculation
be	I-Speculation
regulated	I-Speculation
by	I-Speculation
NF	I-Speculation
kappa	I-Speculation
B	I-Speculation
,	O
ELAM	B-Negation
was	I-Negation
not	I-Negation
expressed	I-Negation
and	O
ELAM	O
mRNA	O
was	O
only	O
slightly	O
elevated	O
in	O
response	O
to	O
MM-LDL	O
.	O

We	O
present	O
evidence	O
that	O
induction	O
of	O
neutrophil	O
binding	O
by	O
LPS	O
is	O
actually	O
suppressed	O
by	O
agents	O
that	O
elevated	O
cAMP	O
levels	O
.	O

Antisense	O
oligonucleotides	O
to	O
the	O
p65	O
subunit	O
of	O
NF-kappa	O
B	O
block	O
CD11b	O
expression	O
and	O
alter	O
adhesion	O
properties	O
of	O
differentiated	O
HL-60	O
granulocytes	O
.	O

NF-kappa	O
B	O
is	O
a	O
pleiotropic	O
regulator	O
of	O
a	O
variety	O
of	O
genes	O
implicated	O
in	O
the	O
cellular	O
response	O
to	O
injury	O
.	O

This	O
function	O
has	O
been	O
attributed	O
to	O
the	O
coordinated	O
binding	O
of	O
subunits	O
of	O
NF-kappa	O
B	O
to	O
distinct	O
regions	O
of	O
the	O
promoter	O
elements	O
of	O
numerous	O
genes	O
,	O
including	O
cytokines	O
,	O
growth	O
factor	O
receptors	O
,	O
and	O
adhesion	O
molecules	O
.	O

Antisense	O
phosphorothioate	O
oligonucleotides	O
to	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF-kappa	O
B	O
complex	O
were	O
used	O
to	O
define	O
the	O
physiologic	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
resting	O
and	O
stimulated	O
granulocytes	O
.	O

A	O
reduction	O
in	O
the	O
expression	O
of	O
p65	O
was	O
produced	O
by	O
treatment	O
with	O
the	O
phosphorothioate	O
antisense	O
oligodeoxynucleotide	O
.	O

This	O
reduction	O
was	O
accompanied	O
by	O
rapid	O
changes	O
in	O
the	O
cellular	O
adhesion	O
of	O
dimethyl	O
sulfoxide-differentiated	O
HL-60	O
leukemia	O
cells	O
stimulated	O
by	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
.	O

These	O
effects	O
were	O
characterized	O
by	O
a	O
marked	O
reduction	O
in	O
CD11b	O
integrin	O
expression	O
on	O
the	O
surface	O
of	O
treated	O
cells	O
.	O

Furthermore	O
,	O
the	O
p65	O
antisense	O
oligomer	O
effectively	O
abolished	O
an	O
upregulation	O
of	O
CD11b	O
that	O
was	O
produced	O
by	O
formyl-met-leu-phe	O
and	O
TPA	O
.	O

However	O
,	O
the	O
p65	O
antisense	O
phosphorothioate	O
oligodeoxynucleotide	O
had	O
no	B-Negation
significant	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
production	I-Negation
of	I-Negation
reactive	I-Negation
oxygen	I-Negation
intermediates	I-Negation
or	I-Negation
on	I-Negation
phagocytosis	I-Negation
by	I-Negation
these	I-Negation
cells	I-Negation
.	O

These	O
findings	O
indicate	O
that	O
antisense	O
oligomers	O
to	O
p65	O
can	O
be	O
used	O
to	O
define	O
the	O
role	O
of	O
NF-kappa	O
B	O
in	O
the	O
activation	O
pathways	O
of	O
neutrophils	O
.	O

Costimulation	O
of	O
cAMP	O
and	O
protein	O
kinase	O
C	O
pathways	O
inhibits	O
the	O
CD3-dependent	O
T	O
cell	O
activation	O
and	O
leads	O
to	O
a	O
persistent	O
expression	O
of	O
the	O
AP-1	O
transcription	O
factor	O
.	O

The	O
effects	O
mediated	O
by	O
a	O
combined	O
stimulation	O
of	O
cAMP-	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-dependent	O
pathways	O
have	O
been	O
investigated	O
in	O
different	O
cellular	O
systems	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
they	O
may	O
complement	O
each	O
other	O
in	O
activating	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
upon	O
the	O
stimulation	O
of	O
both	O
pathways	O
T	O
lymphocytes	O
became	O
refractory	O
to	O
activation	O
via	O
the	O
CD3/T	O
cell	O
receptor	O
(	O
TcR	O
)	O
complex	O
.	O

T	O
cells	O
preincubated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
dibutyryl	O
cAMP	O
(	O
Bt2cAMP	O
)	O
displayed	O
a	O
deficient	O
proliferative	O
ability	O
in	O
response	O
to	O
anti-CD3	O
mAb	O
stimulation	O
,	O
whereas	O
lymphocytes	O
treated	O
individually	O
with	O
either	O
Bt2cAMP	O
or	O
PMA	O
responded	O
comparably	O
to	O
untreated	O
samples	O
.	O

We	O
detected	O
an	O
association	O
between	O
the	O
reduced	O
mitogenic	O
response	O
and	O
low	O
expression	O
of	O
both	O
interleukin-2	O
(	O
IL-2	O
)	O
and	O
the	O
alpha	O
chain	O
(	O
CD25	O
)	O
of	O
the	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
.	O

Analysis	O
of	O
intracellular	O
Ca2+	O
mobilization	O
suggested	O
that	O
the	O
CD3/TcR-dependent	O
signal	O
transduction	O
was	O
impaired	O
in	O
PMA/Bt2cAMP-treated	O
cells	O
.	O

Remarkably	O
,	O
we	O
observed	O
that	O
these	O
samples	O
displayed	O
a	O
persistent	O
expression	O
of	O
the	O
c-fos	O
protooncogene	O
,	O
associated	O
to	O
an	O
increased	O
AP-1	O
DNA-binding	O
activity	O
,	O
whereas	O
no	B-Negation
variations	I-Negation
of	I-Negation
CREB	I-Negation
or	I-Negation
NF-kB	I-Negation
were	I-Negation
detected	I-Negation
.	O

Neither	B-Negation
Bt2cAMP	I-Negation
nor	I-Negation
PMA	I-Negation
individually	I-Negation
mediated	I-Negation
these	I-Negation
sustained	I-Negation
effects	I-Negation
,	O
which	O
therefore	O
appear	B-Speculation
as	I-Speculation
a	I-Speculation
consequence	I-Speculation
of	I-Speculation
the	I-Speculation
interplay	I-Speculation
between	I-Speculation
both	I-Speculation
metabolic	I-Speculation
stimuli	I-Speculation
.	O

Altogether	O
,	O
the	O
data	O
provide	O
the	O
evidence	O
that	O
both	O
pathways	O
complement	O
each	O
other	O
in	O
regulating	O
gene	O
expression	O
and	O
,	O
conversely	O
,	O
downregulate	O
the	O
TcR	O
transduction	O
mechanisms	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
,	O
a	O
mediator	O
of	O
lipopolysaccharide	O
effects	O
.	O

Exposure	O
of	O
certain	O
cell	O
types	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
an	O
inducible	O
transcription	O
factor	O
.	O

One	O
of	O
NF-kappa	O
B	O
's	O
unique	O
properties	O
is	O
its	O
posttranslational	O
activation	O
via	O
release	O
of	O
an	O
inhibitory	O
subunit	O
,	O
called	O
inhibitor	O
of	O
NF-kappa	O
B	O
(	O
I	O
kappa	O
B	O
)	O
,	O
from	O
a	O
sequestered	O
cytoplasmic	O
form	O
.	O

This	O
event	O
is	O
also	O
triggered	O
under	O
various	O
other	O
conditions	O
of	O
biomedical	O
importance	O
.	O

Other	O
bacterial	O
toxins	O
,	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF	O
)	O
,	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
T	O
cell	O
mitogens	O
,	O
UV	O
light	O
,	O
gamma	O
rays	O
and	O
oxidative	O
stress	O
were	O
reported	O
to	O
induce	O
NF-kappa	O
B	O
.	O

The	O
activated	O
form	O
of	O
NF-kappa	O
B	O
,	O
which	O
is	O
rapidly	O
taken	O
up	O
into	O
nuclei	O
,	O
initiates	O
transcription	O
from	O
immediate	O
early	O
genes	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

Most	O
of	O
the	O
target	O
genes	O
for	O
NF-kappa	O
B	O
are	O
of	O
relevance	O
for	O
the	O
immune	O
response	O
and	O
can	O
be	O
grouped	O
into	O
those	O
encoding	O
cytokines	O
,	O
cell	O
surface	O
receptors	O
,	O
acute	O
phase	O
proteins	O
and	O
viral	O
genomes	O
,	O
such	O
as	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

We	O
will	O
discuss	O
recent	O
experimental	O
evidences	O
suggesting	O
that	O
LPS	O
might	O
share	O
a	O
pathway	O
of	O
NF-kappa	O
B	O
activation	O
with	O
other	O
inducers	O
of	O
the	O
factor	O
.	O

This	O
common	O
pathway	O
may	O
involve	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
as	O
messenger	O
molecules	O
.	O

Human	O
T	O
cell	O
transcription	O
factor	O
GATA-3	O
stimulates	O
HIV-1	O
expression	O
.	O

A	O
family	O
of	O
transcriptional	O
activating	O
proteins	O
,	O
the	O
GATA	O
factors	O
,	O
has	O
been	O
shown	O
to	O
bind	O
to	O
a	O
consensus	O
motif	O
through	O
a	O
highly	O
conserved	O
C4	O
zinc	O
finger	O
DNA	O
binding	O
domain	O
.	O

One	O
member	O
of	O
this	O
multigene	O
family	O
,	O
GATA-3	O
,	O
is	O
most	O
abundantly	O
expressed	O
in	O
T	O
lymphocytes	O
,	O
a	O
cellular	O
target	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
and	O
replication	O
.	O

In	O
vitro	O
DNase	O
I	O
footprinting	O
analysis	O
revealed	O
six	O
hGATA-3	O
binding	O
sites	O
in	O
the	O
U3	O
region	O
(	O
the	O
transcriptional	O
regulatory	O
domain	O
)	O
of	O
the	O
HIV-1	O
LTR	O
.	O

Cotransfection	O
of	O
an	O
hGATA-3	O
expression	O
plasmid	O
with	O
a	O
reporter	O
plasmid	O
whose	O
transcription	O
is	O
directed	O
by	O
the	O
HIV-1	O
LTR	O
resulted	O
in	O
6-	O
to	O
10-fold	O
stimulation	O
of	O
LTR-mediated	O
transcription	O
,	O
whereas	O
site	O
specific	O
mutation	O
of	O
these	O
GATA	O
sites	O
resulted	O
in	O
virtual	O
abrogation	O
of	O
the	O
activation	O
by	O
hGATA-3	O
.	O

Further	O
,	O
deletion	O
of	O
the	O
hGATA-3	O
transcriptional	O
activation	O
domain	O
abolished	O
GATA-dependent	O
HIV-1	O
trans-activation	O
,	O
showing	O
that	O
the	O
stimulation	O
of	O
viral	O
transcription	O
observed	O
is	O
a	O
direct	O
effect	O
of	O
cotransfected	O
hGATA-3	O
.	O

Introduction	O
of	O
the	O
HIV-1	O
plasmids	O
in	O
which	O
the	O
GATA	O
sites	O
have	O
been	O
mutated	O
into	O
human	O
T	O
lymphocytes	O
also	O
caused	O
a	O
significant	O
reduction	O
in	O
LTR-mediated	O
transcription	O
at	O
both	O
the	O
basal	O
level	O
and	O
in	O
(	O
PHA-	O
plus	O
PMA-	O
)	O
stimulated	O
T	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
in	O
addition	O
to	O
its	O
normal	O
role	O
in	O
T	O
lymphocyte	O
gene	O
regulation	O
,	O
hGATA-3	O
may	O
also	O
play	O
a	O
significant	O
role	O
in	O
HIV-1	O
transcriptional	O
activation	O
.	O

Analysis	O
of	O
the	O
preexisting	O
and	O
nuclear	O
forms	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
3	O
is	O
an	O
inducible	O
DNA-binding	O
protein	O
that	O
is	O
essential	O
for	O
transcriptional	O
induction	O
of	O
the	O
IL-2	O
gene	O
during	O
T	O
cell	O
activation	O
.	O

NF-AT	O
is	O
thought	O
to	O
consist	O
of	O
two	O
components	O
:	O
a	O
ubiquitous	O
,	O
inducible	O
nuclear	O
component	O
that	O
we	O
have	O
identified	O
as	O
Fos	O
and	O
Jun	O
proteins	O
,	O
and	O
a	O
preexisting	O
,	O
T	O
cell-specific	O
component	O
(	O
NF-ATp	O
)	O
which	O
is	O
the	O
target	O
for	O
the	O
immunosuppressive	O
agents	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

We	O
have	O
previously	O
shown	O
that	O
nuclear	O
extracts	O
from	O
activated	O
T	O
cells	O
form	O
two	O
inducible	O
NF-AT	O
complexes	O
with	O
an	O
oligonucleotide	O
corresponding	O
to	O
the	O
distal	O
NF-AT	O
site	O
of	O
the	O
murine	O
IL-2	O
promoter	O
,	O
although	O
hypotonic	O
extracts	O
of	O
unstimulated	O
T	O
cells	O
form	O
a	O
single	O
complex	O
containing	O
NF-ATp	O
.	O

We	O
show	O
that	O
the	O
ability	O
to	O
detect	O
NF-ATp	O
in	O
a	O
gel	O
shift	O
assay	O
,	O
which	O
is	O
essential	O
for	O
purification	O
and	O
biochemical	O
studies	O
of	O
this	O
protein	O
,	O
is	O
strikingly	O
dependent	O
on	O
the	O
precise	O
sequence	O
of	O
the	O
NF-AT	O
oligonucleotide	O
used	O
as	O
the	O
labeled	O
probe	O
.	O

Moreover	O
we	O
present	O
evidence	O
that	O
the	O
component	O
that	O
forms	O
the	O
faster-migrating	O
(	O
``	O
lower	O
``	O
)	O
nuclear	O
NF-AT	O
complex	O
is	O
derived	O
by	O
a	O
calcium-dependent	O
,	O
cyclosporin-sensitive	O
,	O
posttranslational	O
modification	O
of	O
NF-ATp	O
,	O
and	O
that	O
Fos	O
and	O
Jun	O
proteins	O
stabilize	O
its	O
interaction	O
with	O
DNA	O
.	O

The	O
results	O
are	O
discussed	O
in	O
the	O
context	O
of	O
a	O
model	O
relating	O
the	O
two	O
nuclear	O
NF-AT	O
complexes	O
to	O
NF-ATp	O
.	O

Enhancing	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
human	O
NK	O
cell	O
activity	O
.	O

The	O
in	O
vitro	O
effect	O
of	O
17	O
beta-estradiol	O
on	O
NK	O
activity	O
was	O
studied	O
.	O

The	O
proliferation	O
and	O
NK	O
activity	O
of	O
YT-N17	O
(	O
a	O
human	O
NK-like	O
cell	O
line	O
)	O
were	O
enhanced	O
by	O
17	O
beta-estradiol	O
(	O
E2	O
)	O
,	O
and	O
the	O
enhancement	O
was	O
blocked	O
by	O
tamoxifen	O
(	O
Tx	O
)	O
,	O
an	O
antagonist	O
of	O
E2	O
.	O

On	O
the	O
contrary	O
,	O
other	O
steroid	O
hormones	O
such	O
as	O
Tx	O
,	O
progesterone	O
,	O
and	O
testosterone	O
had	O
no	B-Negation
effect	I-Negation
.	O

YT-N17	O
contained	O
11.8	O
fmol/mg	O
protein	O
of	O
estrogen	O
receptor	O
(	O
mean	O
of	O
two	O
independent	O
assays	O
)	O
,	O
a	O
value	O
which	O
was	O
5-10-fold	O
higher	O
than	O
that	O
of	O
other	O
hematopoietic	O
cell	O
lines	O
.	O

An	O
enhancement	O
of	O
NK	O
activity	O
by	O
E2	O
was	O
also	O
seen	O
in	O
large	O
granular	O
lymphocytes	O
obtained	O
from	O
normal	O
subjects	O
,	O
and	O
it	O
was	O
again	O
suppressed	O
by	O
Tx	O
.	O

These	O
data	O
suggest	O
that	O
E2	O
is	O
one	O
of	O
the	O
activating	O
factors	O
for	O
NK/LGL	O
cells	O
.	O

Cytokine	O
modulation	O
of	O
HIV	O
expression	O
.	O

Cytokines	O
,	O
the	O
peptide	O
hormones	O
which	O
control	O
the	O
homeostasis	O
of	O
the	O
immune	O
system	O
and	O
also	O
play	O
a	O
fundamental	O
role	O
in	O
inflammatory	O
and	O
immune	O
mediated	O
reactions	O
,	O
have	O
been	O
involved	O
at	O
multiple	O
levels	O
in	O
the	O
pathogenesis	O
of	O
the	O
acquired	O
immune	O
deficiency	O
syndrome	O
(	O
AIDS	O
)	O
.	O

Infection	O
with	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
has	O
been	O
shown	O
to	O
induce	O
production	O
of	O
several	O
cytokines	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Conversely	O
,	O
several	O
cytokines	O
modulate	O
the	O
levels	O
of	O
HIV	O
expression	O
in	O
infected	O
cells	O
of	O
both	O
T	O
lymphocytic	O
and	O
mononuclear	O
phagocytic	O
lineage	O
.	O

Activated	O
mononuclear	O
cells	O
,	O
particularly	O
B	O
cells	O
which	O
are	O
in	O
a	O
state	O
of	O
chronic	O
activation	O
in	O
HIV	O
infected	O
individuals	O
,	O
release	O
HIV-inductive	O
cytokines	O
and	O
thus	O
play	O
a	O
potentially	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

Tumor	O
necrosis	O
factor	O
receptor	O
expression	O
and	O
signal	O
transduction	O
in	O
HIV-1-infected	O
cells	O
.	O

OBJECTIVE	O
:	O
To	O
examine	O
the	O
inter-relationship	O
between	O
HIV-1	O
infection	O
and	O
the	O
cell	O
surface	O
receptors	O
for	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
,	O
an	O
immunoregulatory	O
cytokine	O
that	O
can	O
enhance	O
HIV-1	O
replication	O
.	O

DESIGN	O
:	O
Infected	O
promyelocytic	O
and	O
promonocytic	O
cells	O
were	O
examined	O
because	O
they	O
normally	O
express	O
both	O
types	O
of	O
TNF	O
receptors	O
.	O

METHODS	O
:	O
TNF	O
receptor	O
surface	O
expression	O
was	O
determined	O
by	O
specific	O
monoclonal	O
antibody	O
recognition	O
and	O
flow	O
cytometry	O
,	O
and	O
signal	O
transduction	O
was	O
detected	O
by	O
gel	O
shift	O
analysis	O
.	O

HIV-1	O
activation	O
and	O
expression	O
was	O
quantitated	O
by	O
reverse	O
transcriptase	O
assay	O
.	O

RESULTS	O
:	O
In	O
the	O
OM-10.1	O
promyelocytic	O
model	O
of	O
chronic	O
infection	O
,	O
TNF-alpha-induced	O
HIV-1	O
expression	O
also	O
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
75	O
kd	O
TNF	O
receptor	O
(	O
TR75	O
)	O
expression	O
although	O
55	B-Negation
kD	I-Negation
TNF	I-Negation
receptor	I-Negation
(	I-Negation
TR55	I-Negation
)	I-Negation
levels	I-Negation
were	I-Negation
not	I-Negation
dramatically	I-Negation
altered	I-Negation
.	O

A	O
series	O
of	O
uninfected	O
parental	O
HL-60	O
subclones	O
all	O
reduced	O
TR75	O
surface	O
expression	O
in	O
response	O
to	O
TNF-alpha	O
treatment	O
.	O

Enhanced	O
TR75	O
expression	O
on	O
OM-10.1	O
cells	O
followed	O
the	O
same	O
TNF-alpha-dose	O
dependency	O
as	O
that	O
observed	O
for	O
HIV-1	O
production	O
.	O

An	O
increase	O
in	O
TR75	O
expression	O
was	O
also	O
evident	O
during	O
the	O
peak	O
of	O
an	O
acute	O
HIV-1	O
infection	O
of	O
HL-60	O
promyelocytes	O
.	O

Although	O
TR55	O
expression	O
was	O
unaltered	O
during	O
TNF-alpha-induced	O
HIV	O
activation	O
,	O
this	O
receptor	O
was	O
still	O
involved	O
in	O
the	O
viral	O
activation	O
process	O
.	O

Antibody	O
cross-linking	O
of	O
TR55	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
TNF-alpha	O
,	O
induced	O
maximal	O
HIV-1	O
expression	O
,	O
an	O
up-modulation	O
of	O
surface	O
TR75	O
,	O
and	O
nuclear	O
NF-kappa	O
B	O
activity	O
in	O
OM-10.1	O
cultures	O
.	O

Surprisingly	O
,	O
this	O
was	O
the	O
case	O
even	O
when	O
an	O
antagonistic	O
anti-TR55	O
antibody	O
was	O
used	O
.	O

Anti-TR55	O
antibody	O
cross-linking	O
in	O
chronically	O
infected	O
U1	O
promonocytic	O
cultures	O
could	O
only	O
partially	O
substitute	O
for	O
TNF-alpha-induced	O
HIV-1	O
expression	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
demonstrated	O
that	O
HIV-1	O
infection	O
can	O
selectively	O
influence	O
the	O
surface	O
expression	O
of	O
TNF	O
receptors	O
,	O
potentially	O
influencing	O
its	O
own	O
expression	O
and	O
altering	O
normal	O
immunoregulatory	O
signal	O
transduction	O
.	O

FK506	O
and	O
ciclosporin	O
:	O
molecular	O
probes	O
for	O
studying	O
intracellular	O
signal	O
transduction	O
.	O

The	O
immunosuppressants	O
ciclosporin	O
and	O
FK506	O
block	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal-transduction	O
pathway	O
emanating	O
from	O
the	O
T-cell	O
receptor	O
,	O
thereby	O
inhibiting	O
the	O
activation	O
of	O
helper	O
T	O
cells	O
.	O

Using	O
these	O
drugs	O
as	O
probes	O
,	O
chemists	O
and	O
biologists	O
have	O
uncovered	O
several	O
intracellular	O
signalling	O
molecules	O
bridging	O
the	O
generation	O
of	O
second-messenger	O
Ca2+	O
ions	O
and	O
the	O
transcriptional	O
activation	O
of	O
IL-2	O
,	O
among	O
which	O
are	O
calmodulin	O
,	O
calcineurin	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
.	O

Hence	O
,	O
Ca2+	O
binds	O
to	O
calmodulin	O
,	O
leading	O
to	O
the	O
binding	O
of	O
calmodulin	O
to	O
calcineurin	O
;	O
the	O
activated	O
calcineurin	O
,	O
in	O
turn	O
,	O
may	O
dephosphorylate	O
the	O
cytoplasmic	O
subunit	O
of	O
NF-AT	O
,	O
resulting	O
in	O
its	O
translocation	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
to	O
form	O
a	O
competent	O
transcriptional	O
activator	O
.	O

As	O
described	O
by	O
Jun	O
Liu	O
,	O
these	O
drugs	O
manifest	O
their	O
effects	O
in	O
an	O
unprecedented	O
fashion	O
.	O

They	O
do	O
not	B-Negation
directly	I-Negation
intercept	I-Negation
intracellular	I-Negation
signalling	I-Negation
molecules	I-Negation
.	O

Instead	O
,	O
they	O
form	O
tight	O
complexes	O
with	O
two	O
different	O
classes	O
of	O
abundant	O
cytosolic	O
receptors	O
called	O
immunophilins	O
upon	O
entering	O
the	O
cell	O
,	O
and	O
consequently	O
inhibit	O
their	O
peptidyl	O
prolyl	O
cis-trans	O
isomerase	O
activities	O
.	O

The	O
two	O
structurally	O
distinct	O
immunophilin-drug	O
complexes	O
bind	O
to	O
,	O
and	O
inhibit	O
,	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
.	O

The	O
impaired	O
transcription	O
factor	O
AP-1	O
DNA	O
binding	O
activity	O
in	O
lymphocytes	O
derived	O
from	O
subjects	O
with	O
some	O
symptoms	O
of	O
premature	O
aging	O
.	O

The	O
study	O
of	O
human	O
disorders	O
known	O
as	O
premature	O
aging	O
syndromes	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
cellular	O
senescence	O
.	O

The	O
main	O
feature	O
of	O
cellular	O
senescence	O
in	O
vitro	O
is	O
cessation	O
of	O
cell	O
proliferation	O
.	O

Down	O
syndrome	O
(	O
DS	O
)	O
and	O
neuronal	O
ceroid-lypofuscinosis	O
(	O
NCL	O
)	O
are	O
clinically	O
characterized	O
by	O
the	O
premature	O
onset	O
of	O
numerous	O
features	O
normally	O
associated	O
with	O
human	O
aging	O
.	O

Phytohemagglutinin	O
stimulated	O
lymphocytes	O
derived	O
from	O
DS	O
subjects	O
showed	O
a	O
statistically	O
significant	O
diminished	O
proliferation	O
capacity	O
in	O
comparison	O
with	O
lymphocytes	O
derived	O
from	O
NCL	O
and	O
healthy	O
individuals	O
.	O

We	O
demonstrated	O
,	O
by	O
applying	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
slightly	O
impaired	O
AP-1	O
DNA	O
binding	O
activity	O
in	O
NCL	O
lymphocytes	O
and	O
strong	O
in	O
DS	O
ones	O
.	O

Our	O
results	O
showed	O
that	O
the	O
same	O
molecular	O
mechanisms	O
of	O
proliferation	O
cessation	O
could	O
exist	O
in	O
fibroblasts	O
characterized	O
by	O
replicative	O
senescence	O
and	O
in	O
lymphocytes	O
derived	O
from	O
individuals	O
with	O
premature	O
aging	O
syndromes	O
(	O
Down	O
)	O
.	O

Inhibition	O
of	O
HIV-1	O
latency	O
reactivation	O
by	O
dehydroepiandrosterone	O
(	O
DHEA	O
)	O
and	O
an	O
analog	O
of	O
DHEA	O
.	O

The	O
initial	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
most	O
individuals	O
usually	O
results	O
in	O
the	O
establishment	O
of	O
a	O
latent	O
or	O
chronic	O
infection	O
before	O
eventual	O
progression	O
toward	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

HIV-1	O
can	O
also	O
establish	O
a	O
latent	O
or	O
persistent	O
infection	O
in	O
some	O
T	O
cell	O
lines	O
that	O
show	O
minimal	O
constitutive	O
virus	O
expression	O
.	O

However	O
,	O
activation	O
of	O
the	O
T	O
cell	O
lines	O
leading	O
to	O
enhanced	O
HIV-1	O
replication	O
can	O
be	O
induced	O
by	O
antigens	O
,	O
mitogens	O
,	O
and	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
[	O
TNF-alpha	O
]	O
,	O
interleukin	O
1	O
,	O
and	O
interleukin-2	O
)	O
.	O

Various	O
gene	O
products	O
from	O
other	O
viruses	O
(	O
HTLV-1	O
,	O
HSV	O
,	O
EBV	O
,	O
CMV	O
,	O
HBV	O
,	O
and	O
HHV-6	O
)	O
can	O
also	O
enhance	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
reporter	O
gene	O
activity	O
.	O

On	O
the	O
basis	O
of	O
these	O
observations	O
,	O
it	O
has	O
been	O
proposed	O
that	O
reactivation	O
of	O
latent	O
HIV-1	O
harbored	O
in	O
chronically	O
infected	O
T	O
lymphocytes	O
,	O
monocytes	O
,	O
or	O
macrophages	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

So	O
far	O
,	O
there	O
are	O
no	B-Negation
drugs	I-Negation
or	I-Negation
therapy	I-Negation
available	I-Negation
that	I-Negation
can	I-Negation
provide	I-Negation
protection	I-Negation
against	I-Negation
HIV-1	I-Negation
latency	I-Negation
reactivation	I-Negation
.	O

ACH-2	O
,	O
derived	O
from	O
a	O
human	O
T	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
is	O
chronically	O
infected	O
with	O
HIV-1	O
,	O
with	O
low	O
levels	O
of	O
constitutive	O
virus	O
expression	O
.	O

ACH-2	O
can	O
be	O
converted	O
to	O
productive	O
infection	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
mitogen	O
or	O
cytokines	O
(	O
TNF-alpha	O
)	O
,	O
or	O
infection	O
with	O
HSV	O
.	O

Therefore	O
the	O
ACH-2	O
cell	O
line	O
is	O
a	O
good	O
candidate	O
for	O
studying	O
the	O
effects	O
of	O
drugs	O
on	O
HIV-1	O
activation	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
that	O
DHEA	O
and	O
synthetic	O
analogs	O
of	O
DHEA	O
can	O
be	O
modest	O
inhibitors	O
of	O
HIV-1	O
IIIB	O
replication	O
in	O
phytohemagglutinin-stimulated	O
peripheral	O
blood	O
lymphocyte	O
cultures	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cellular	O
immune	O
and	O
cytokine	O
pathways	O
resulting	O
in	O
tissue	O
factor	O
expression	O
and	O
relevance	O
to	O
septic	O
shock	O
.	O

Cells	O
of	O
monocyte	O
lineage	O
serve	O
as	O
effector	O
cells	O
in	O
the	O
cellular	O
immune	O
response	O
.	O

In	O
addition	O
,	O
they	O
respond	O
to	O
LPS	O
and	O
cytokines	O
with	O
activation	O
and	O
expression	O
of	O
inflammatory	O
effector	O
gene	O
products	O
similar	O
to	O
those	O
elicited	O
by	O
the	O
antigen	O
driven	O
response	O
.	O

The	O
response	O
to	O
antigen	O
proceeds	O
at	O
the	O
T	O
helper	O
cell	O
level	O
through	O
two	O
independent	O
forms	O
of	O
cellular	O
collaboration	O
,	O
contact	O
and	O
lymphokine	O
.	O

We	O
review	O
the	O
control	O
of	O
expression	O
of	O
the	O
Tissue	O
Factor	O
(	O
TF	O
)	O
gene	O
and	O
the	O
function	O
of	O
the	O
TF	O
protein	O
.	O

The	O
enhanced	O
initiation	O
of	O
transcription	O
of	O
the	O
TF	O
gene	O
appears	O
to	O
require	O
engagement	O
of	O
a	O
56	O
bp	O
LPS	O
Response	O
Element	O
,	O
an	O
enhancer	O
that	O
is	O
engaged	O
by	O
both	O
AP-1	O
type	O
heterodimeric	O
complexes	O
as	O
well	O
as	O
NF	O
kappa	O
B	O
like	O
heterodimeric	O
complexes	O
.	O

Dissociation	O
of	O
NF	O
kappa	O
B	O
from	O
Ig	O
kappa	O
B	O
by	O
cytokine	O
and	O
LPS	O
stimulation	O
,	O
and	O
possibly	O
activated	O
T	O
cells	O
,	O
may	O
represent	O
a	O
common	O
pathway	O
to	O
induction	O
of	O
the	O
TF	O
and	O
other	O
inflammatory	O
genes	O
.	O

Enhancement	O
of	O
expression	O
of	O
TF	O
is	O
observed	O
upon	O
adhesion	O
of	O
Mo	O
to	O
endothelial	O
cells	O
and	O
extracellular	O
matrix	O
proteins	O
,	O
as	O
well	O
as	O
upon	O
engagement	O
of	O
leukocyte	O
integrins	O
.	O

The	O
biological	O
effects	O
that	O
follow	O
from	O
expression	O
of	O
TF	O
by	O
vascular	O
cells	O
have	O
been	O
resolved	O
by	O
analysis	O
of	O
function	O
aided	O
by	O
the	O
use	O
of	O
recombinant	O
full	O
length	O
TF	O
and	O
truncated	O
surface	O
domain	O
of	O
TF	O
.	O

The	O
rules	O
of	O
assembly	O
of	O
the	O
cognate	O
ligands	O
of	O
TF	O
,	O
namely	O
the	O
zymogen	O
plasma	O
factors	O
VII	O
and	O
the	O
serine	O
protease	O
factor	O
VIIa	O
,	O
with	O
the	O
soluble	O
surface	O
domain	O
of	O
TF	O
in	O
free	O
solution	O
,	O
in	O
the	O
presence	O
of	O
phospholipid	O
surfaces	O
and	O
cell	O
surface	O
and	O
of	O
the	O
anchored	O
TF	O
molecule	O
have	O
been	O
described	O
.	O

It	O
is	O
evident	O
that	O
assembly	O
of	O
the	O
surface	O
domain	O
of	O
TF	O
with	O
VIIa	O
to	O
form	O
the	O
binary	O
TF.VIIa	O
complex	O
induces	O
a	O
significant	O
increase	O
in	O
the	O
Kcat	O
of	O
the	O
catalytic	O
domain	O
of	O
VIIa	O
for	O
small	O
peptidyl	O
substrates	O
and	O
more	O
profoundly	O
for	O
protein	O
substrate	O
.	O

This	O
provides	O
substantial	O
evidence	O
for	O
an	O
allosteric	O
effect	O
on	O
the	O
catalytic	O
cleft	O
of	O
VIIa	O
that	O
is	O
imparted	O
by	O
binding	O
to	O
TF	O
,	O
its	O
cognate	O
catalytic	O
cofactor	O
.	O

It	O
is	O
also	O
evident	O
that	O
the	O
TF.VIIa	O
complex	O
is	O
proteolytically	O
active	O
and	O
can	O
activate	O
the	O
zymogen	O
plasma	O
factor	O
X	O
to	O
the	O
serine	O
protease	O
Xa	O
in	O
free	O
solution	O
,	O
inferring	O
that	O
extended	O
substrate	O
recognition	O
by	O
induced	O
structural	O
loci	O
of	O
the	O
TF.VIIa	O
complex	O
are	O
created	O
from	O
either	O
or	O
both	O
proteins	O
to	O
constitute	O
a	O
new	O
recognition	O
structure	O
.	O

It	O
is	O
also	O
evident	O
that	O
association	O
of	O
X	O
with	O
charged	O
phospholipid	O
surfaces	O
enhances	O
the	O
proteolytic	O
activation	O
of	O
this	O
zymogen	O
by	O
increasing	O
recognition	O
and	O
susceptibility	O
of	O
the	O
sessile	O
peptide	O
bond	O
deduced	O
from	O
the	O
markedly	O
decreased	O
Km	O
and	O
increased	O
Kcat	O
.	O

Visualization	O
of	O
the	O
endogenous	O
NF-kappa	O
B	O
p50	O
subunit	O
in	O
the	O
nucleus	O
of	O
follicular	O
dendritic	O
cells	O
in	O
germinal	O
centers	O
.	O

NF-kappa	O
B	O
,	O
a	O
50	O
kDa/65	O
kDa	O
(	O
p50/p65	O
)	O
heterodimer	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
various	O
immune	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
NF-kappa	O
B	O
is	O
related	O
to	O
a	O
particular	O
cell	O
type	O
and/or	O
differentiation	O
step	O
during	O
immunopoiesis	O
.	O

Using	O
in	O
situ	O
hybridization	O
on	O
sections	O
from	O
non	O
HIV	O
hyperplastic	O
lymph	O
nodes	O
,	O
we	O
found	O
that	O
the	O
gene	O
of	O
the	O
105	O
kDa	O
precursor	O
of	O
p50	O
was	O
overexpressed	O
in	O
the	O
light	O
zone	O
of	O
germinal	O
centers	O
,	O
with	O
a	O
network	O
aspect	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

By	O
immunohistochemistry	O
,	O
p50	O
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
,	O
confirming	O
the	O
involvement	O
of	O
FDC	O
.	O

Furthermore	O
,	O
p50	O
protein	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
all	O
lymphocytes	O
.	O

Thus	O
,	O
we	O
focused	O
our	O
study	O
on	O
isolated	O
FDC	O
clusters	O
from	O
normal	O
tonsils	O
.	O

As	O
showed	O
on	O
tissue	O
sections	O
,	O
we	O
detected	O
the	O
p50	O
in	O
both	O
cytoplasm	O
and	O
nucleus	O
of	O
FDC	O
.	O

Nuclei	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
were	O
negative	O
.	O

We	O
next	O
studied	O
p65	O
and	O
c-Rel	O
protein	O
expression	O
in	O
FDC	O
clusters	O
.	O

p65	O
was	O
detected	O
in	O
the	O
cytoplasm	O
of	O
FDC	O
,	O
whereas	O
nuclei	O
were	O
negative	O
.	O

Furthermore	O
,	O
p65	O
was	O
detected	O
in	O
the	O
nuclei	O
of	O
some	O
lymphocytes	O
.	O

c-Rel	O
protein	O
was	O
detected	O
only	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
and	O
not	B-Negation
in	I-Negation
the	I-Negation
nucleus	I-Negation
and	I-Negation
cytoplasm	I-Negation
of	I-Negation
FDC	I-Negation
.	O

Our	O
results	O
indicated	O
that	O
,	O
in	O
the	O
context	O
of	O
T	O
cell-dependent	O
B	O
cell	O
immunopoiesis	O
occurring	O
in	O
FDC	O
clusters	O
,	O
p50	O
is	O
mainly	O
related	O
to	O
FDC	O
with	O
a	O
massive	O
overexpression	O
in	O
the	O
nuclei	O
,	O
whereas	O
p65	O
is	O
expressed	O
in	O
a	O
scattered	O
manner	O
in	O
the	O
nuclei	O
of	O
lymphocytes	O
and	O
c-Rel	O
protein	O
exclusively	O
in	O
the	O
cytoplasm	O
of	O
lymphocytes	O
from	O
FDC	O
clusters	O
.	O

These	O
results	O
suggested	O
that	O
the	O
two	O
subunits	O
of	O
NF-kappa	O
B	O
and	O
the	O
c-Rel	O
protein	O
have	O
different	O
roles	O
in	O
different	O
cell	O
types	O
during	O
B	O
cell	O
immunopoiesis	O
.	O

Involvement	O
of	O
transcription	O
factor	O
YB-1	O
in	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
basal	O
gene	O
expression	O
.	O

Sequences	O
which	O
control	O
basal	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
transcription	O
likely	O
play	O
an	O
important	O
role	O
in	O
initiation	O
and	O
maintenance	O
of	O
virus	O
replication	O
.	O

We	O
previously	O
identified	O
and	O
analyzed	O
a	O
45-nucleotide	O
sequence	O
(	O
downstream	O
regulatory	O
element	O
1	O
[	O
DRE	O
1	O
]	O
)	O
,	O
+195	O
to	O
+240	O
,	O
at	O
the	O
boundary	O
of	O
the	O
R/U5	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
which	O
is	O
required	O
for	O
HTLV-I	O
basal	O
transcription	O
.	O

We	O
identified	O
a	O
protein	O
,	O
p37	O
,	O
which	O
specifically	O
bound	O
to	O
DRE	O
1	O
.	O

An	O
affinity	O
column	O
fraction	O
,	O
containing	O
p37	O
,	O
stimulated	O
HTLV-I	O
transcription	O
approximately	O
12-fold	O
in	O
vitro	O
.	O

We	O
now	O
report	O
the	O
identification	O
of	O
a	O
cDNA	O
clone	O
(	O
15B-7	O
)	O
,	O
from	O
a	O
Jurkat	O
expression	O
library	O
,	O
that	O
binds	O
specifically	O
to	O
the	O
DRE	O
1	O
regulatory	O
sequence	O
.	O

Binding	O
of	O
the	O
cDNA	O
fusion	O
protein	O
,	O
similarly	O
to	O
the	O
results	O
obtained	O
with	O
purified	O
Jurkat	O
protein	O
,	O
was	O
decreased	O
by	O
introduction	O
of	O
site-specific	O
mutations	O
in	O
the	O
DRE	O
1	O
regulatory	O
sequence	O
.	O

In	O
vitro	O
transcription	O
and	O
translation	O
of	O
15B-7	O
cDNA	O
produced	O
a	O
fusion	O
protein	O
which	O
bound	O
specifically	O
to	O
the	O
HTLV-I	O
+195	O
to	O
+240	O
oligonucleotide	O
.	O

The	O
partial	O
cDNA	O
encodes	O
a	O
protein	O
which	O
is	O
homologous	O
to	O
the	O
C-terminal	O
196	O
amino	O
acids	O
of	O
the	O
36-kDa	O
transcription	O
factor	O
,	O
YB-1	O
.	O

Cotransfection	O
of	O
a	O
YB-1	O
expression	O
plasmid	O
increases	O
HTLV-I	O
basal	O
transcription	O
approximately	O
14-fold	O
in	O
Jurkat	O
T	O
lymphocytes	O
.	O

On	O
the	O
basis	O
of	O
the	O
molecular	O
weight	O
,	O
DNA-binding	O
characteristics	O
,	O
and	O
in	O
vivo	O
transactivation	O
activity	O
,	O
we	O
suggest	O
that	O
the	O
previously	O
identified	O
DRE	O
1-binding	O
protein	O
,	O
p37	O
,	O
is	O
YB-1	O
.	O

Chlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
and	O
the	O
human	O
immune	O
system	O
.	O

1	O
.	O
Blood	O
cell	O
receptors	O
in	O
volunteers	O
with	O
moderately	O
increased	O
body	O
burdens	O
.	O

Using	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
and	O
flow	O
cytometry	O
,	O
we	O
studied	O
a	O
variety	O
of	O
surface	O
receptors	O
on	O
lymphocyte	O
subpopulations	O
of	O
workers	O
with	O
moderately	O
increased	O
body	O
burdens	O
of	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
and	O
of	O
other	O
polychlorinated	O
dibenzo-p-dioxins	O
and	O
dibenzofurans	O
(	O
PCDD/PCDF	O
)	O
,	O
expressed	O
here	O
as	O
International-Toxicity	O
Equivalencies	O
(	O
I-TE	O
)	O
.	O

The	O
hypothesis	O
to	O
be	O
tested	O
was	O
whether	O
or	O
not	O
humans	O
exhibit	O
a	O
similar	O
susceptibility	O
to	O
PCDDs/PCDFs	O
with	O
respect	O
to	O
the	O
surface	O
receptors	O
found	O
previously	O
to	O
respond	O
to	O
small	O
doses	O
of	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
in	O
Callithrix	O
jacchus	O
.	O

These	O
are	O
:	O
helper-inducer	O
(	O
memory	O
)	O
T	O
cells	O
(	O
CD4+CD45R0+CD45RA-CD29highCD11a+	O
)	O
,	O
CD20+	O
B	O
cells	O
,	O
and	O
cytotoxic	O
T	O
cells	O
(	O
CD8+CD56+/CD57+	O
)	O
.	O

Furthermore	O
,	O
68	O
triple-labellings	O
with	O
mAbs	O
were	O
performed	O
on	O
the	O
cells	O
of	O
each	O
volunteer	O
to	O
possibly	O
generate	O
further	O
hypotheses	O
.	O

It	O
was	O
evaluated	O
whether	O
any	O
of	O
the	O
variables	O
might	O
be	O
used	O
as	O
a	O
biomarker	O
of	O
effects	O
for	O
this	O
class	O
of	O
compounds	O
.	O

There	O
were	O
two	O
main	O
goals	O
:	O
(	O
1	O
)	O
to	O
evaluate	O
whether	O
workers	O
with	O
a	O
moderately	O
increased	O
PCDD/PCDF-body	O
burden	O
[	O
25-140	O
ppt	O
TCDD	O
or	O
104-522	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
exhibit	O
changes	O
in	O
the	O
surface	O
receptors	O
of	O
white	O
blood	O
cells	O
,	O
as	O
observed	O
in	O
previous	O
studies	O
in	O
non-human	O
primates	O
,	O
and	O
(	O
2	O
)	O
to	O
clarify	O
whether	O
persons	O
at	O
the	O
upper	O
range	O
[	O
10-23	O
ppt	O
TCDD	O
or	O
30-90	O
ppt	O
I-TE	O
in	O
blood	O
fat	O
]	O
of	O
the	O
body	O
burden	O
reference	O
values	O
of	O
a	O
not	O
particularly	O
exposed	O
population	O
show	O
detectable	O
deviations	O
in	O
these	O
immunological	O
variables	O
,	O
when	O
compared	O
with	O
persons	O
at	O
the	O
lower	O
and	O
medium	O
range	O
[	O
1-3	O
ppt	O
TCDD	O
or	O
9-29	O
ppt	O
I-TE	O
]	O
of	O
these	O
body	O
burden	O
reference	O
values	O
.	O

Regression	O
analysis	O
of	O
our	O
data	O
revealed	O
slight	O
trends	O
for	O
some	O
of	O
the	O
biomarkers	O
(	O
e.g	O
.	O

CD45R0+	O
)	O
.	O

With	O
one	O
exception	O
,	O
these	O
were	O
all	O
increases	O
.	O

None	O
of	O
the	O
alterations	O
observed	O
are	O
of	O
medical	O
relevance	O
.	O

The	O
slight	O
increase	O
in	O
the	O
percentage	O
of	O
CD4+CD45R0+	O
cells	O
remained	O
significant	O
even	O
after	O
covariant	O
analysis	O
taking	O
age-related	O
changes	O
into	O
account	O
.	O

Altogether	O
,	O
the	O
data	O
do	O
not	B-Negation
provide	I-Negation
any	I-Negation
evidence	I-Negation
to	I-Negation
support	I-Negation
an	I-Negation
assumption	I-Negation
that	I-Negation
moderately	I-Negation
increased	I-Negation
body	I-Negation
burdens	I-Negation
of	I-Negation
PCDDs/PCDFs	I-Negation
in	I-Negation
adults	I-Negation
induce	I-Negation
decreases	I-Negation
in	I-Negation
the	I-Negation
cellular	I-Negation
components	I-Negation
of	I-Negation
the	I-Negation
human	I-Negation
immune	I-Negation
system	I-Negation
.	O

Adult	O
humans	O
certainly	O
are	O
less	O
susceptible	O
to	O
this	O
action	O
of	O
PCDDs/PCDFs	O
than	O
adolescent	O
Callithrix	O
jacchus	O
.	O

The	O
lymphotoxin	O
promoter	O
is	O
stimulated	O
by	O
HTLV-I	O
tax	O
activation	O
of	O
NF-kappa	O
B	O
in	O
human	O
T-cell	O
lines	O
.	O

The	O
HTLV-I	O
transcriptional	O
activator	O
tax	O
was	O
used	O
to	O
gain	O
insight	O
into	O
the	O
mechanism	O
of	O
lymphotoxin	O
(	O
LT	O
;	O
TNF-beta	O
)	O
gene	O
induction	O
.	O

Tax-expressing	O
cell	O
lines	O
produce	O
LT	O
biologic	O
activity	O
.	O

An	O
LT	O
promoter	O
(	O
LT-293	O
)	O
CAT	O
construct	O
that	O
contained	O
an	O
NF-kappa	O
B	O
site	O
was	O
active	O
in	O
the	O
LT-producing	O
C81-66-45	O
cell	O
line	O
,	O
which	O
contains	O
defective	O
HTLV-I	O
but	O
expresses	O
tax	O
.	O

The	O
observation	O
that	O
a	O
mutated	O
LT-kappa	O
B	O
construct	O
(	O
M1-CAT	O
)	O
was	O
inactive	O
in	O
C81-66-45	O
,	O
confirmed	O
the	O
importance	O
of	O
NF-kappa	O
B	O
in	O
LT	O
gene	O
expression	O
.	O

Tax	O
was	O
transfected	O
into	O
HTLV-I-negative	O
human	O
T-cell	O
lines	O
.	O

Jurkat	O
T	O
cells	O
stably	O
expressing	O
tax	O
contained	O
elevated	O
levels	O
of	O
NF-kappa	O
B	O
that	O
directly	O
bound	O
to	O
the	O
LT-kappa	O
B	O
site	O
.	O

Tax	O
co-transfected	O
with	O
reporter	O
constructs	O
into	O
Jurkat	O
cells	O
maximally	O
activated	O
HTLV-I-LTR-CAT	O
and	O
kappa	O
B-fos-CAT	O
and	O
also	O
activated	O
LT-293	O
to	O
a	O
lesser	O
extent	O
.	O

In	O
JM	O
T	O
cells	O
,	O
tax	O
induced	O
LT-293	O
activity	O
by	O
two-	O
to	O
four-fold	O
,	O
though	O
there	O
was	O
no	B-Negation
induction	I-Negation
of	I-Negation
M1-CAT	I-Negation
.	O

The	O
increase	O
in	O
LT-293	O
CAT	O
activity	O
mirrored	O
the	O
increase	O
in	O
LT	O
biologic	O
activity	O
seen	O
under	O
these	O
conditions	O
.	O

These	O
studies	O
,	O
the	O
first	O
to	O
demonstrate	O
induction	O
of	O
LT	O
promoter	O
activity	O
over	O
basal	O
levels	O
,	O
indicate	O
that	O
HTLV-I	O
tax	O
causes	O
low-level	O
activation	O
of	O
both	O
endogenous	O
LT	O
and	O
the	O
LT	O
promoter	O
,	O
at	O
least	O
in	O
part	O
through	O
activation	O
of	O
NF-kappa	O
B	O
.	O

Transient	O
pseudohypoaldosteronism	O
in	O
obstructive	O
renal	O
disease	O
with	O
transient	O
reduction	O
of	O
lymphocytic	O
aldosterone	O
receptors	O
.	O

Results	O
in	O
two	O
affected	O
infants	O
.	O

We	O
report	O
two	O
patients	O
with	O
transient	O
pseudohypoaldosteronism	O
due	O
to	O
obstructive	O
renal	O
disease	O
.	O

Both	O
patients	O
presented	O
with	O
a	O
salt-losing	O
episode	O
simulating	O
adrenal	O
insufficiency	O
.	O

In	O
one	O
patient	O
,	O
transient	O
reduction	O
of	O
aldosterone	O
receptors	O
could	O
be	O
documented	O
,	O
while	O
in	O
the	O
second	O
patient	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
were	O
consistent	O
with	O
transient	O
pseudohypoaldosteronism	O
.	O

Aldosterone	O
receptors	O
were	O
normal	O
in	O
both	O
patients	O
when	O
studied	O
after	O
the	O
surgical	O
correction	O
of	O
the	O
obstruction	O
.	O

The	O
macrophage	O
transcription	O
factor	O
PU.1	O
directs	O
tissue-specific	O
expression	O
of	O
the	O
macrophage	O
colony-stimulating	O
factor	O
receptor	O
.	O

The	O
macrophage	O
colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
receptor	O
is	O
expressed	O
in	O
a	O
tissue-specific	O
fashion	O
from	O
two	O
distinct	O
promoters	O
in	O
monocytes/macrophages	O
and	O
the	O
placenta	O
.	O

In	O
order	O
to	O
further	O
understand	O
the	O
transcription	O
factors	O
which	O
play	O
a	O
role	O
in	O
the	O
commitment	O
of	O
multipotential	O
progenitors	O
to	O
the	O
monocyte/macrophage	O
lineage	O
,	O
we	O
have	O
initiated	O
an	O
investigation	O
of	O
the	O
factors	O
which	O
activate	O
the	O
M-CSF	O
receptor	O
very	O
early	O
during	O
the	O
monocyte	O
differentiation	O
process	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
monocytic	O
M-CSF	O
receptor	O
promoter	O
directs	O
reporter	O
gene	O
activity	O
in	O
a	O
tissue-specific	O
fashion	O
.	O

Since	O
one	O
of	O
the	O
few	O
transcription	O
factors	O
which	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
monocyte	O
genes	O
is	O
the	O
macrophage-	O
and	O
B-cell-specific	O
PU.1	O
transcription	O
factor	O
,	O
we	O
investigated	O
whether	O
PU.1	O
binds	O
and	O
activates	O
the	O
M-CSF	O
receptor	O
promoter	O
.	O

Here	O
we	O
demonstrate	O
that	O
both	O
in	O
vitro-translated	O
PU.1	O
and	O
PU.1	O
from	O
nuclear	O
extracts	O
bind	O
to	O
a	O
specific	O
site	O
in	O
the	O
M-CSF	O
receptor	O
promoter	O
just	O
upstream	O
from	O
the	O
major	O
transcription	O
initiation	O
site	O
.	O

Mutations	O
in	O
this	O
site	O
which	O
eliminate	O
PU.1	O
binding	O
decrease	O
M-CSF	O
receptor	O
promoter	O
activity	O
significantly	O
in	O
macrophage	O
cell	O
lines	O
only	O
.	O

Furthermore	O
,	O
PU.1	O
transactivates	O
the	O
M-CSF	O
receptor	O
promoter	O
in	O
nonmacrophage	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
PU.1	O
plays	O
a	O
major	O
role	O
in	O
macrophage	O
gene	O
regulation	O
and	O
development	O
by	O
directing	O
the	O
expression	O
of	O
a	O
receptor	O
for	O
a	O
key	O
macrophage	O
growth	O
factor	O
.	O

Increased	O
natural	O
killer	O
cell	O
activity	O
correlates	O
with	O
low	O
or	O
negative	O
expression	O
of	O
the	O
HER-2/neu	O
oncogene	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

BACKGROUND	O
.	O

Increased	O
expression	O
of	O
the	O
HER-2/neu	O
oncogene	O
in	O
breast	O
cancer	O
correlates	O
with	O
decreased	O
estrogen	O
receptor	O
concentration	O
and	O
seems	O
to	O
be	O
an	O
important	O
prognostic	O
factor	O
.	O

The	O
authors	O
investigated	O
whether	O
there	O
is	O
a	O
correlation	O
between	O
HER-2/neu	O
expression	O
and	O
immunologic	O
parameters	O
representing	O
tumor	O
defense	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

METHOD	O
.	O

A	O
Western	O
blot	O
analysis	O
was	O
used	O
to	O
investigate	O
HER-2/neu	O
expression	O
,	O
whereas	O
a	O
chromium-release	O
assay	O
using	O
the	O
K562	O
cell	O
line	O
as	O
target	O
was	O
used	O
to	O
measure	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
.	O

RESULTS	O
.	O

In	O
patients	O
with	O
breast	O
cancer	O
,	O
NK	O
cell	O
activity	O
was	O
significantly	O
higher	O
compared	O
with	O
patients	O
with	O
benign	O
tumors	O
(	O
P	O
=	O
0.006	O
)	O
or	O
healthy	O
control	O
subjects	O
(	O
P	O
=	O
0.002	O
)	O
.	O

Moreover	O
,	O
23.3	O
%	O
of	O
patients	O
with	O
breast	O
cancer	O
showed	O
an	O
overexpression	O
of	O
HER-2/neu	O
protein	O
.	O

Within	O
this	O
group	O
of	O
patients	O
,	O
NK	O
cell	O
activity	O
was	O
significantly	O
lower	O
(	O
45.6	O
	O
16.1	O
%	O
)	O
compared	O
with	O
the	O
group	O
with	O
no	B-Negation
HER-2/neu	I-Negation
overexpression	I-Negation
(	I-Negation
57.3	I-Negation
	I-Negation
11.0	I-Negation
%	I-Negation
)	I-Negation
.	O

NK	O
cell	O
activity	O
did	O
not	B-Negation
increase	I-Negation
in	I-Negation
patients	I-Negation
with	I-Negation
HER-2/neu	I-Negation
overexpression	I-Negation
.	O

Thus	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
correlation	O
of	O
cytolytic	O
effector	O
cell	O
function	O
with	O
HER-2/neu	O
expression	O
of	O
the	O
tumor	O
(	O
P	O
=	O
0.003	O
)	O
,	O
and	O
HER-2/neu	O
overexpression	O
correlated	O
with	O
a	O
negative	O
estrogen	O
receptor	O
status	O
(	O
P	O
=	O
0.005	O
)	O
.	O

CONCLUSION	O
.	O

These	O
data	O
add	O
further	O
evidence	O
to	O
previous	O
observations	O
from	O
the	O
authors	O
'	O
laboratory	O
that	O
certain	O
tumor	O
characteristics	O
may	O
be	O
associated	O
with	O
reactions	O
of	O
the	O
host	O
with	O
breast	O
cancer	O
.	O

Induction	O
of	O
tyrosine	O
phosphorylation	O
and	O
T-cell	O
activation	O
by	O
vanadate	O
peroxide	O
,	O
an	O
inhibitor	O
of	O
protein	O
tyrosine	O
phosphatases	O
.	O

Rapid	O
tyrosine	O
phosphorylation	O
of	O
key	O
cellular	O
proteins	O
is	O
a	O
crucial	O
event	O
in	O
the	O
transduction	O
of	O
activation	O
signals	O
to	O
T-lymphocytes	O
.	O

The	O
regulatory	O
role	O
of	O
protein	O
tyrosine	O
phosphatases	O
(	O
PTPases	O
)	O
in	O
this	O
process	O
was	O
explored	O
by	O
studying	O
the	O
effects	O
of	O
a	O
powerful	O
PTPase	O
inhibitor	O
,	O
vanadate	O
peroxide	O
(	O
pervanadate	O
)	O
,	O
on	O
the	O
activation	O
cascade	O
of	O
Jurkat	O
human	O
leukaemic	O
T-cells	O
.	O

Pervanadate	O
induced	O
activation	O
of	O
the	O
tyrosine	O
kinases	O
lck	O
and	O
fyn	O
(	O
4-	O
and	O
3-fold	O
respectively	O
)	O
and	O
a	O
dramatic	O
increase	O
in	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
proteins	O
,	O
notably	O
phospholipase	O
C	O
gamma	O
1	O
.	O

After	O
this	O
event	O
,	O
we	O
observed	O
a	O
rise	O
in	O
intracellular	O
Ca2+	O
concentration	O
,	O
corresponding	O
to	O
an	O
influx	O
.	O

This	O
effect	O
required	O
surface	O
expression	O
of	O
the	O
CD45	O
PTPase	O
and	O
was	B-Negation
not	I-Negation
observed	I-Negation
in	I-Negation
CD45-deficient	I-Negation
variants	I-Negation
of	I-Negation
Jurkat	I-Negation
cells	I-Negation
.	O

In	O
the	O
CD45-negative	O
variant	O
,	O
the	O
effect	O
of	O
pervanadate	O
on	O
tyrosine	O
phosphorylation	O
was	O
globally	O
decreased	O
and	O
some	O
phosphorylated	O
substrates	O
were	O
specifically	O
missing	O
.	O

Pervanadate	O
also	O
stimulated	O
transcription	O
of	O
the	O
c-fos	O
gene	O
and	O
accumulation	O
of	O
its	O
mRNA	O
as	O
well	O
as	O
several	O
other	O
hallmarks	O
of	O
T-lymphocyte	O
activation	O
such	O
as	O
surface	O
expression	O
of	O
the	O
CD69	O
antigen	O
and	O
the	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
CD25	O
)	O
.	O

Pervanadate	O
synergized	O
with	O
signals	O
delivered	O
by	O
T-cell	O
antigen	O
receptor	O
engagement	O
or	O
by	O
a	O
phorbol	O
ester	O
to	O
induce	O
interleukin	O
2	O
production	O
.	O

Pervanadate	O
activated	O
NF-kappa	O
B	O
,	O
as	O
shown	O
by	O
an	O
increase	O
in	O
DNA-binding	O
activity	O
of	O
this	O
transcription	O
factor	O
.	O

We	O
thus	O
conclude	O
that	O
PTPases	O
play	O
a	O
crucial	O
role	O
in	O
the	O
negative	O
regulation	O
of	O
signal	O
transduction	O
culminating	O
in	O
T-lymphocyte	O
activation	O
.	O

Moreover	O
,	O
induction	O
of	O
tyrosine	O
phosphorylation	O
appears	O
sufficient	O
per	O
se	O
to	O
initiate	O
a	O
complete	O
activation	O
programme	O
.	O

Steroid-resistant	O
asthma	O
.	O

Cellular	O
mechanisms	O
contributing	O
to	O
inadequate	O
response	O
to	O
glucocorticoid	O
therapy	O
.	O

The	O
current	O
study	O
examined	O
whether	O
alterations	O
in	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
binding	O
contribute	O
to	O
poor	O
response	O
to	O
glucocorticoid	O
therapy	O
in	O
asthma	O
.	O

29	O
asthma	O
patients	O
with	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(	O
FEV1	O
)	O
<	O
70	O
%	O
predicted	O
were	O
studied	O
.	O

Patients	O
were	O
classified	O
as	O
steroid	O
sensitive	O
(	O
SS	O
)	O
if	O
their	O
morning	O
FEV1	O
increased	O
>	O
30	O
%	O
after	O
a	O
1-wk	O
course	O
of	O
oral	O
prednisone	O
20	O
mg	O
twice	O
daily	O
and	O
steroid	O
resistant	O
(	O
SR	O
)	O
if	O
they	O
failed	O
to	O
increase	O
>	O
15	O
%	O
.	O

PBMC	O
obtained	O
from	O
these	O
two	O
groups	O
,	O
17	O
SR	O
and	O
12	O
SS	O
,	O
as	O
well	O
as	O
12	O
normal	O
controls	O
were	O
analyzed	O
.	O

SR	O
patients	O
had	O
two	O
distinguishable	O
GR	O
binding	O
abnormalities	O
:	O

15	O
of	O
the	O
17	O
SR	O
patients	O
demonstrated	O
a	O
significantly	O
reduced	O
GR	O
binding	O
affinity	O
,	O
as	O
compared	O
with	O
SS	O
patients	O
(	O
P	O
=	O
0.0001	O
)	O
and	O
normal	O
controls	O
(	O
P	O
=	O
0.0001	O
)	O
.	O

This	O
defect	O
was	O
localized	O
to	O
T	O
cells	O
and	O
reverted	O
to	O
normal	O
after	O
48	O
h	O
in	O
culture	O
media	O
.	O

However	O
,	O
incubation	O
with	O
a	O
combination	O
of	O
IL-2	O
and	O
IL-4	O
sustained	O
this	O
abnormality	O
.	O

The	O
other	O
two	O
SR	O
patients	O
had	O
an	O
abnormally	O
low	O
GR	O
number	O
with	O
normal	O
binding	O
affinity	O
that	O
was	O
not	B-Negation
limited	I-Negation
to	I-Negation
T	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
GR	O
number	O
failed	O
to	O
normalize	O
after	O
incubation	O
in	O
media	O
alone	O
or	O
IL-2	O
and	O
IL-4	O
.	O

Therefore	O
,	O
SR	O
asthma	O
may	O
be	O
due	O
to	O
more	O
than	O
one	O
abnormality	O
,	O
the	O
majority	O
related	O
to	O
a	O
reversible	O
cytokine-induced	O
reduction	O
in	O
GR	O
binding	O
affinity	O
and	O
the	O
second	O
related	O
to	O
an	O
irreversible	O
reduction	O
in	O
GR	O
number	O
.	O

These	O
findings	O
may	O
have	O
important	O
implications	O
for	O
the	O
design	O
of	O
alternative	O
treatment	O
approaches	O
for	O
recalcitrant	O
asthma	O
.	O

Rhabdomyosarcomas	O
do	O
not	B-Negation
contain	I-Negation
mutations	I-Negation
in	I-Negation
the	I-Negation
DNA	I-Negation
binding	I-Negation
domains	I-Negation
of	I-Negation
myogenic	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

Skeletal	O
myogenesis	O
is	O
regulated	O
by	O
a	O
group	O
of	O
transcription	O
factors	O
(	O
MyoD	O
,	O
myogenin	O
,	O
myf5	O
,	O
and	O
myf6	O
)	O
that	O
are	O
``	O
basic	O
helix-loop-helix	O
``	O
proteins	O
that	O
bind	O
to	O
the	O
promoters	O
of	O
muscle-specific	O
genes	O
and	O
promote	O
their	O
expression	O
.	O

We	O
have	O
previously	O
shown	O
that	O
after	O
a	O
mutation	O
of	O
Leu122	O
to	O
Arg	O
the	O
DNA	O
binding	O
basic	O
domain	O
of	O
MyoD	O
confers	O
c-myc-like	O
functional	O
characteristics	O
to	O
the	O
protein	O
.	O

In	O
this	O
study	O
we	O
used	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
to	O
determine	O
whether	O
such	O
mutations	O
occur	O
naturally	O
in	O
rhabdomyosarcomas	O
.	O

We	O
have	O
found	O
that	O
the	O
basic	O
domains	O
of	O
all	O
the	O
myogenic	O
factors	O
remain	O
unaltered	O
in	O
rhabdomyosarcomas	O
.	O

Selection	O
against	O
such	O
mutations	O
may	O
be	O
the	O
result	O
of	O
functional	O
redundancy	O
of	O
these	O
myogenic	O
transcription	O
factors	O
.	O

Increased	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
gene	O
expression	O
after	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
through	O
a	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1994	O
Jul	O
15	O
;	O
153	O
(	O
2	O
)	O
:910	O
]	O

Previous	O
studies	O
have	O
suggested	O
that	O
gangliosides	O
have	O
an	O
important	O
role	O
in	O
cell	O
signaling	O
and	O
recognition	O
.	O

However	O
,	O
their	B-Negation
specific	I-Negation
function	I-Negation
in	I-Negation
these	I-Negation
processes	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
clearly	I-Negation
defined	I-Negation
.	O

A	O
mAb	O
,	O
R24	O
,	O
that	O
reacts	O
specifically	O
with	O
a	O
cell	O
surface	O
ganglioside	O
(	O
GD3	O
)	O
has	O
been	O
demonstrated	O
to	O
stimulate	O
proliferation	O
of	O
T	O
cells	O
derived	O
from	O
human	O
peripheral	O
blood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
mechanisms	O
by	O
which	O
the	O
R24	O
mAb	O
affects	O
T	O
cell	O
functions	O
.	O

We	O
have	O
observed	O
that	O
the	O
R24	O
mAb	O
stimulates	O
GD3+	O
T	O
cell	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
surface	O
marker	O
expression	O
of	O
IL-2R	O
alpha-chain	O
,	O
IL-2R	O
beta-chain	O
,	O
HLA-DR	O
,	O
CD11a	O
,	O
and	O
CD11c	O
.	O

Additionally	O
,	O
IFN-gamma	O
activity	O
but	O
not	B-Negation
IL-1	I-Negation
,	I-Negation
IL-2	I-Negation
,	I-Negation
or	I-Negation
IL-4	I-Negation
activity	I-Negation
was	O
present	O
in	O
culture	O
supernatants	O
72	O
h	O
after	O
R24	O
stimulation	O
.	O

In	O
some	O
donors	O
,	O
increased	O
IL-6	O
and	O
TNF-alpha	O
activity	O
also	O
was	O
detected	O
after	O
R24	O
treatment	O
.	O

Furthermore	O
,	O
R24	O
treatment	O
resulted	O
in	O
translocation	O
of	O
c-rel	O
,	O
but	O
little	O
or	O
no	O
NF	O
kappa	O
B	O
p50	O
or	O
p65	O
,	O
from	O
the	O
cytoplasm	O
to	O
the	O
nucleus	O
and	O
an	O
increase	O
of	O
NF	O
kappa	O
B	O
binding	O
complexes	O
containing	O
c-rel	O
and	O
p50	O
.	O

This	O
treatment	O
also	O
caused	O
increased	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
.	O

R24-stimulated	O
increases	O
in	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cell	O
surface	O
protein	O
expression	O
could	O
be	O
blocked	O
by	O
cyclosporin	O
and	O
staurosporin	O
,	O
indicating	O
that	O
cyclophilin/calcineurin	O
and	O
protein	O
kinase	O
C	O
may	O
be	O
involved	O
in	O
the	O
R24	O
signaling	O
pathway	O
.	O

Additionally	O
,	O
herbimycin	O
A	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
blocked	O
the	O
R24-stimulated	O
increase	O
in	O
proliferation	O
but	O
not	B-Negation
cytotoxicity	I-Negation
at	O
concentrations	O
consistent	O
with	O
specificity	O
for	O
tyrosine	O
kinases	O
.	O

These	O
results	O
suggest	O
that	O
multiple	O
biochemical	O
pathways	O
are	O
involved	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
by	O
R24	O
.	O

The	O
SCL	O
protein	O
displays	O
cell-specific	O
heterogeneity	O
in	O
size	O
.	O

SCL	O
protein	O
production	O
was	O
examined	O
in	O
a	O
variety	O
of	O
hemopoietic	O
cell	O
lines	O
by	O
immunoblotting	O
using	O
specific	O
polyclonal	O
antisera	O
.	O

SCL	O
protein	O
was	O
detected	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
mast	O
and	O
early	O
myeloid	O
cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
several	O
lymphoid	O
leukemia	O
cell	O
lines	O
which	O
are	O
known	O
to	O
harbor	O
SCL	O
gene	O
rearrangements	O
.	O

In	O
most	O
cell	O
lines	O
,	O
proteins	O
of	O
molecular	O
weight	O
49	O
and	O
44	O
kDa	O
were	O
found	O
,	O
however	O
two	O
myeloid	O
cell	O
lines	O
expressed	O
only	O
lower	O
molecular	O
weight	O
species	O
of	O
24	O
and	O
22	O
kDa	O
.	O

This	O
size	O
discrepancy	O
appeared	O
to	O
be	O
due	O
to	O
cell-specific	O
translational	O
regulation	O
,	O
since	O
overexpression	O
of	O
a	O
retrovirally	O
transfected	O
SCL	O
gene	O
yielded	O
the	O
higher	O
molecular	O
weight	O
forms	O
in	O
most	O
cell	O
lines	O
(	O
GP+E-86	O
,	O
AT2.5	O
,	O
M1	O
)	O
but	O
only	O
the	O
22	O
kDa	O
form	O
in	O
the	O
myeloid	O
cell	O
line	O
,	O
WEHI-3B/D+	O
.	O

Overexpression	O
of	O
full-length	O
SCL	O
protein	O
in	O
the	O
lymphoid	O
cell	O
lines	O
,	O
SupT1	O
and	O
Raji	O
,	O
did	O
not	B-Negation
alter	I-Negation
cell	I-Negation
phenotype	I-Negation
and	O
there	O
was	O
no	B-Negation
evidence	I-Negation
for	I-Negation
autoregulation	I-Negation
of	I-Negation
SCL	I-Negation
transcription	I-Negation
.	O

The	O
restricted	O
pattern	O
of	O
SCL	O
protein	O
synthesis	O
is	O
consistent	O
with	O
the	O
restricted	O
expression	O
of	O
SCL	O
mRNA	O
documented	O
previously	O
.	O

In	O
addition	O
,	O
the	O
present	O
results	O
indicate	O
that	O
SCL	O
protein	O
size	O
was	O
determined	O
by	O
regulation	O
of	O
translation	O
in	O
a	O
cell-specific	O
manner	O
.	O

Activation	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
promoter	O
in	O
T	O
cells	O
requires	O
cooperative	O
binding	O
of	O
Elf-1	O
and	O
AP-1	O
transcription	O
factors	O
.	O

The	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
gene	O
has	O
been	O
studied	O
extensively	O
as	O
a	O
model	O
system	O
of	O
transcriptional	O
induction	O
during	O
T-lymphocyte	O
activation	O
.	O

The	O
GM-CSF	O
gene	O
is	O
not	B-Negation
expressed	I-Negation
in	I-Negation
resting	I-Negation
peripheral	I-Negation
blood	I-Negation
T	I-Negation
cells	I-Negation
but	O
is	O
rapidly	O
induced	O
at	O
the	O
transcriptional	O
level	O
following	O
activation	O
through	O
the	O
cell	O
surface	O
T-cell	O
receptor	O
.	O

A	O
highly	O
conserved	O
19-bp	O
element	O
located	O
immediately	O
5	O
'	O
of	O
the	O
human	O
GM-CSF	O
TATA	O
box	O
(	O
bp	O
-34	O
to	O
-52	O
)	O
,	O
herein	O
called	O
purine	O
box	O
1	O
(	O
PB1	O
)	O
,	O
has	O
been	O
shown	O
to	O
bind	O
a	O
T-cell	O
nuclear	O
protein	O
complex	O
and	O
to	O
be	O
required	O
for	O
transcriptional	O
induction	O
of	O
the	O
GM-CSF	O
gene	O
following	O
T-cell	O
activation	O
.	O

The	O
PB1	O
sequence	O
motif	O
is	O
highly	O
conserved	O
in	O
both	O
human	O
and	O
murine	O
GM-CSF	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
PB1	O
element	O
alone	O
confers	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
following	O
transfection	O
into	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
addition	O
,	O
we	O
identify	O
a	O
major	O
PB1	O
nuclear	O
protein-binding	O
complex	O
that	O
is	O
not	B-Negation
present	I-Negation
in	I-Negation
resting	I-Negation
peripheral	I-Negation
blood	I-Negation
T	I-Negation
cells	I-Negation
but	O
is	O
rapidly	O
induced	O
following	O
T-cell	O
activation	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
PB1	O
is	O
composed	O
of	O
adjacent	O
binding	O
sites	O
for	O
Ets	O
and	O
AP-1	O
transcription	O
factors	O
.	O

In	O
vitro	O
mutagenesis	O
experiments	O
demonstrated	O
that	O
both	O
the	O
Ets	O
and	O
AP-1	O
sites	O
are	O
required	O
for	O
binding	O
of	O
the	O
inducible	O
PB1	O
nuclear	O
protein	O
complex	O
and	O
for	O
the	O
transcriptional	O
activity	O
of	O
this	O
element	O
and	O
the	O
GM-CSF	O
promoter	O
in	O
activated	O
T	O
cells	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
associates	O
with	O
and	O
is	O
negatively	O
regulated	O
by	O
the	O
NF-kappa	O
B2	O
p100	O
gene	O
product	O
:	O

implications	O
for	O
viral	O
latency	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
,	O
an	O
aggressive	O
and	O
often	O
fatal	O
malignancy	O
of	O
activated	O
human	O
CD4	O
T	O
cells	O
.	O

HTLV-I	O
encodes	O
an	O
essential	O
40-kDa	O
protein	O
termed	O
Tax	O
that	O
not	O
only	O
transactivates	O
the	O
long	O
terminal	O
repeat	O
of	O
this	O
retrovirus	O
but	O
also	O
induces	O
an	O
array	O
of	O
cellular	O
genes	O
.	O

Tax-mediated	O
transformation	O
of	O
T	O
cells	O
likely	O
involves	O
the	O
deregulated	O
expression	O
of	O
various	O
cellular	O
genes	O
that	O
normally	O
regulate	O
lymphocyte	O
growth	O
produced	O
by	O
altered	O
activity	O
of	O
various	O
endogenous	O
host	O
transcription	O
factors	O
.	O

In	O
particular	O
,	O
Tax	O
is	O
capable	O
of	O
modulating	O
the	O
expression	O
or	O
activity	O
of	O
various	O
host	O
transcription	O
factors	O
,	O
including	O
members	O
of	O
the	O
NF-kappa	O
B/Rel	O
and	O
CREB/ATF	O
families	O
,	O
as	O
well	O
as	O
the	O
cellular	O
factors	O
HEB-1	O
and	O
p67SRF	O
.	O

An	O
additional	O
distinguishing	O
characteristic	O
of	O
HTLV-I	O
infection	O
is	O
the	O
profound	O
state	O
of	O
viral	O
latency	O
that	O
is	O
present	O
in	O
circulating	O
primary	O
leukemic	O
T	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
HTLV-I	O
Tax	O
can	O
physically	O
associate	O
with	O
p100	O
,	O
the	O
product	O
of	O
the	O
Rel-related	O
NF-kappa	O
B2	O
gene	O
,	O
both	O
in	O
transfected	O
cells	O
and	O
in	O
HTLV-I-infected	O
leukemic	O
T-cell	O
lines	O
.	O

Furthermore	O
,	O
the	O
physical	O
interaction	O
of	O
Tax	O
with	O
p100	O
leads	O
to	O
the	O
inhibition	O
of	O
Tax-induced	O
activation	O
of	O
the	O
HTLV-I	O
and	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeats	O
,	O
reflecting	O
p100-mediated	O
cytoplasmic	O
sequestration	O
of	O
the	O
normally	O
nuclearly	O
expressed	O
Tax	O
protein	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	O
that	O
selectively	O
fails	O
to	O
activate	O
nuclear	O
NF-kappa	O
B	O
expression	O
does	O
not	B-Negation
associate	I-Negation
with	I-Negation
p100	I-Negation
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Regulation	O
of	O
the	O
BZLF1	O
promoter	O
of	O
Epstein-Barr	O
virus	O
by	O
second	O
messengers	O
in	O
anti-immunoglobulin-treated	O
B	O
cells	O
.	O

Initiation	O
of	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
lytic	O
cycle	O
is	O
dependent	O
on	O
the	O
transcription	O
of	O
the	O
BZLF1	O
gene	O
.	O

The	O
BZLF1	O
gene	O
promoter	O
(	O
Zp	O
)	O
was	O
activated	O
by	O
crosslinking	O
of	O
cell	O
surface	O
immunoglobulin	O
(	O
Ig	O
)	O
with	O
anti-Ig	O
antibody	O
in	O
B	O
cells	O
,	O
even	O
in	O
the	O
absence	O
of	O
other	O
viral	O
genes	O
.	O

We	O
identified	O
several	O
anti-Ig	O
response	O
elements	O
within	O
Zp	O
,	O
which	O
were	O
originally	O
defined	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
response	O
elements	O
(	O
ZI	O
repeats	O
and	O
ZII	O
,	O
an	O
AP-1-like	O
domain	O
)	O
.	O

Since	O
anti-Ig	O
crosslinking	O
leads	O
to	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
an	O
increase	O
in	O
intracellular	O
calcium	O
level	O
,	O
Zp	O
was	O
tested	O
for	O
the	O
response	O
to	O
these	O
cellular	O
factors	O
.	O

Treatment	O
with	O
calcium	O
ionophore	O
A23187	O
increased	O
Zp	O
activity	O
.	O

When	O
the	O
calcium	O
ionophore	O
was	O
used	O
in	O
conjunction	O
with	O
TPA	O
,	O
a	O
PKC	O
activator	O
,	O
the	O
Zp	O
induction	O
was	O
synergistically	O
enhanced	O
.	O

1-	O
(	O
5-Isoquinolinyl	O
sulfonyl	O
)	O
-2-methylpiperazine	O
,	O
an	O
inhibitor	O
of	O
PKC	O
,	O
inhibited	O
the	O
anti-Ig	O
inducibility	O
of	O
Zp	O
.	O

Calmodulin	O
antagonists	O
,	O
compound	O
R24571	O
and	O
trifluoperazine	O
,	O
blocked	O
the	O
Zp	O
activation	O
with	O
anti-Ig	O
.	O

These	O
findings	O
suggest	O
that	O
Zp	O
responds	O
directly	O
to	O
changes	O
in	O
the	O
activity	O
of	O
both	O
PKC	O
and	O
calcium/calmodulin-dependent	O
protein	O
kinase	O
.	O

Requirement	O
of	O
tyrosine	O
kinase	O
activation	O
for	O
the	O
anti-Ig-mediated	O
Zp	O
activation	O
was	O
also	O
demonstrated	O
through	O
the	O
use	O
of	O
the	O
tyrosine	O
kinase	O
inhibitor	O
herbimycin	O
.	O

These	O
cellular	O
gene	O
regulatory	O
molecules	O
induced	O
with	O
anti-Ig	O
may	O
cooperatively	O
play	O
an	O
important	O
part	O
in	O
achieving	O
efficient	O
EBV	O
activation	O
as	O
seen	O
with	O
anti-Ig	O
treatment	O
in	O
B	O
cells	O
.	O

Retinoic	O
acid	O
downmodulates	O
erythroid	O
differentiation	O
and	O
GATA1	O
expression	O
in	O
purified	O
adult-progenitor	O
culture	O
.	O

All-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
is	O
an	O
important	O
morphogen	O
in	O
vertebrate	O
development	O
,	O
a	O
normal	O
constituent	O
in	O
human	O
adult	O
blood	O
and	O
is	O
also	O
involved	O
in	O
the	O
control	O
of	O
cell	O
growth	O
and	O
differentiation	O
in	O
acute	O
promyelocytic	O
leukemia	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
RA	O
on	O
normal	O
hematopoiesis	O
by	O
using	O
early	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
stringently	O
purified	O
from	O
adult	O
peripheral	O
blood	O
.	O

In	O
clonogenetic	O
fetal	O
calf	O
serum-supplemented	O
(	O
FCS+	O
)	O
or	O
-nonsupplemented	O
(	O
FCS-	O
)	O
culture	O
treated	O
with	O
saturating	O
levels	O
of	O
interleukin-3	O
(	O
IL-3	O
)	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
and	O
erythropoietin	O
(	O
Ep	O
)	O
(	O
combined	O
with	O
c-kit	O
ligand	O
in	O
FCS	O
(	O
-	O
)	O
-culture	O
conditions	O
)	O
,	O
RA	O
induces	O
a	O
dramatic	O
dose-dependent	O
shift	O
from	O
erythroid	O
to	O
granulomonocytic	O
colony	O
formation	O
,	O
the	O
latter	O
colonies	O
being	O
essentially	O
represented	O
by	O
granulocytic	O
clones	O
.	O

This	O
shift	O
is	O
apparently	O
not	O
caused	O
by	O
a	O
recruitment	O
phenomenon	O
,	O
because	O
in	O
FCS+	O
culture	O
,	O
the	O
total	O
number	O
of	O
colonies	O
is	O
not	O
significantly	O
modified	O
by	O
RA	O
addition	O
.	O

In	O
FCS-	O
liquid-suspension	O
culture	O
supplemented	O
with	O
saturating	O
Ep	O
level	O
and	O
low-dose	O
IL-3/GM-CSF	O
,	O
adult	O
HPC	O
undergo	O
unilineage	O
erythropoietic	O
differentiation	O
:	O

Here	O
again	O
,	O
treatment	O
with	O
high-dose	O
RA	O
induces	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

Studies	O
on	O
RA	O
time-response	O
or	O
pulse	O
treatment	O
in	O
semisolid	O
or	O
liquid	O
culture	O
show	O
that	O
early	O
RA	O
addition	O
is	O
most	O
effective	O
,	O
thus	O
indicating	O
that	O
early	O
but	O
not	O
late	O
HPC	O
are	O
sensitive	O
to	O
its	O
action	O
.	O

We	O
then	O
analyzed	O
the	O
expression	O
of	O
the	O
master	O
GATA1	O
gene	O
,	O
which	O
encodes	O
a	O
finger	O
transcription	O
factor	O
required	O
for	O
normal	O
erythroid	O
development	O
;	O

addition	O
of	O
RA	O
to	O
HPC	O
stimulated	O
into	O
unilineage	O
erythropoietic	O
differentiation	O
in	O
liquid	O
culture	O
caused	O
a	O
virtually	O
complete	O
inhibition	O
of	O
GATA1	O
mRNA	O
induction	O
.	O

These	O
results	O
indicate	O
that	O
RA	O
directly	O
inhibits	O
the	O
erythroid	O
differentiation	O
program	O
at	O
the	O
level	O
of	O
early	O
adult	O
HPC	O
,	O
and	O
may	O
lead	O
to	O
a	O
shift	O
from	O
the	O
erythroid	O
to	O
granulocytic	O
differentiation	O
pathway	O
.	O

This	O
phenomenon	O
is	O
correlated	O
with	O
inhibition	O
of	O
GATA1	O
induction	O
in	O
the	O
early	O
stages	O
of	O
erythropoietic	O
differentiation	O
.	O

Effects	O
of	O
CD45	O
on	O
NF-kappa	O
B	O
.	O

Implications	O
for	O
replication	O
of	O
HIV-1	O
.	O

Increased	O
levels	O
of	O
replication	O
of	O
the	O
HIV	O
type	O
1	O
are	O
observed	O
after	O
the	O
activation	O
of	O
infected	O
T	O
cells	O
through	O
the	O
TCR	O
.	O

However	O
,	O
anti-CD45	O
antibodies	O
inhibit	O
these	O
effects	O
in	O
cells	O
from	O
infected	O
individuals	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
interrelationships	O
between	O
CD45	O
and	O
HIV-1	O
further	O
.	O

We	O
measured	O
effects	O
on	O
the	O
HIV-1	O
LTR	O
in	O
T	O
cell	O
lines	O
that	O
were	O
stimulated	O
with	O
antibodies	O
against	O
CD45	O
and	O
in	O
those	O
that	O
lacked	B-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
CD45	I-Negation
on	I-Negation
their	I-Negation
surfaces	I-Negation
.	O

First	O
,	O
anti-CD45	O
antibodies	O
did	O
not	B-Negation
affect	I-Negation
basal	I-Negation
but	O
decreased	O
activated	O
levels	O
of	O
expression	O
from	O
the	O
HIV-1	O
LTR	O
.	O

Second	O
,	O
T	O
cells	O
,	O
which	O
lack	B-Negation
CD45	I-Negation
and	O
can	O
not	B-Negation
signal	I-Negation
via	I-Negation
the	I-Negation
TCR	I-Negation
,	O
supported	O
higher	O
levels	O
of	O
viral	O
replication	O
and	O
gene	O
expression	O
.	O

This	O
was	O
due	O
to	O
the	O
presence	O
of	O
active	O
NF-kappa	O
B	O
complexes	O
in	O
the	O
nucleus	O
of	O
CD45-	O
T	O
cells	O
.	O

Additionally	O
,	O
infected	O
T	O
cells	O
displayed	O
lower	O
levels	O
of	O
CD45	O
on	O
their	O
surfaces	O
.	O

Thus	O
,	O
CD45	O
plays	O
an	O
active	O
role	O
in	O
the	O
physiology	O
of	O
T	O
cells	O
and	O
in	O
the	O
replication	O
of	O
HIV-1	O
.	O

Induction	O
of	O
phosphatidylinositol	O
turnover	O
and	O
EGR-1	O
mRNA	O
expression	O
by	O
crosslinking	O
of	O
surface	O
IgM	O
and	O
IgD	O
in	O
the	O
human	O
B	O
cell	O
line	O
B104	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
B104	O
,	O
expressed	O
surface	O
IgM	O
(	O
sIgM	O
)	O
and	O
surface	O
IgD	O
(	O
sIgD	O
)	O
,	O
and	O
that	O
crosslinking	O
of	O
sIgM	O
and	O
sIgD	O
by	O
anti-IgM	O
antibody	O
(	O
Ab	O
)	O
and	O
anti-IgD	O
Ab	O
,	O
respectively	O
,	O
induced	O
Ca2+	O
influx	O
to	O
almost	O
the	O
same	O
degree	O
,	O
whereas	O
only	O
sIgM-crosslinking	O
caused	O
B104	O
cell	O
death	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
accumulation	O
of	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
,	O
the	O
hydrolysis	O
of	O
inositol	O
phosphates	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activity	O
and	O
the	O
induction	O
of	O
Egr-1	O
and	O
c-fos	O
mRNA	O
expression	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
to	O
examine	O
differences	O
in	O
the	O
signals	O
mediated	O
through	O
sIgM	O
and	O
sIgD	O
in	O
B104	O
cells	O
.	O

Both	O
sIgM-	O
and	O
sIgD-crosslinking	O
with	O
antibodies	O
induced	O
elevation	O
of	O
cAMP	O
levels	O
,	O
phosphatidylinositol	O
turnover	O
,	O
PKC	O
activation	O
and	O
expression	O
of	O
Egr-1	O
and	O
c-fos	O
mRNA	O
,	O
although	O
sIgM-crosslinking	O
was	O
more	O
effective	O
than	O
sIgD-crosslinking	O
,	O
presumably	O
due	O
to	O
the	O
higher	O
expression	O
of	O
sIgM	O
than	O
of	O
sIgD	O
.	O

Egr-1	O
mRNA	O
expression	O
induced	O
by	O
sIgM-	O
and	O
sIgD-crosslinking	O
was	O
inhibited	O
by	O
H7	O
,	O
erbstatin	O
and	O
genistein	O
,	O
but	O
not	B-Negation
by	I-Negation
HA1004	I-Negation
.	O

Erbstatin	O
and	O
genistein	O
inhibited	O
the	O
sIg-crosslinking-induced	O
Egr-1	O
mRNA	O
expression	O
in	O
a	O
dose-dependent	O
manner	O
parallel	O
to	O
that	O
observed	O
in	O
the	O
inhibition	O
of	O
sIg-crosslinking-induced	O
protein	O
tyrosine	O
phosphorylation	O
.	O

Phorbol	O
myristate	O
acetate	O
induced	O
Egr-1	O
mRNA	O
expression	O
but	O
forskolin	O
and	O
dibutyryl	O
cyclic	O
AMP	O
did	O
not	B-Negation
.	O

These	O
findings	O
suggest	O
that	O
the	O
Egr-1	O
mRNA	O
activating	O
signals	O
through	O
sIgM	O
and	O
sIgD	O
are	O
protein	O
tyrosine	O
kinase-	O
and	O
PKC-dependent	O
,	O
but	O
protein	O
kinase	O
A-independent	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
rescued	O
B104	O
cells	O
from	O
death	O
induced	O
by	O
anti-IgM	O
Ab	O
,	O
but	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
Egr-1	I-Negation
and	I-Negation
c-fos	I-Negation
mRNA	I-Negation
,	O
showing	O
that	O
CsA	O
and	O
FK506	O
affect	O
signal	O
transducers	O
differently	B-Speculation
from	I-Speculation
or	I-Speculation
downstream	I-Speculation
to	I-Speculation
these	I-Speculation
molecules	I-Speculation
.	O

The	O
difference	O
in	O
signals	O
transduced	O
through	O
sIgM	O
and	O
sIgD	O
in	O
B104	O
cells	O
is	O
discussed	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
,	O
a	O
natural	O
bacterial	O
cell	O
wall	O
breakdown	O
product	O
,	O
induces	O
interleukin-1	O
beta	O
and	O
interleukin-6	O
expression	O
in	O
human	O
monocytes	O
.	O

A	O
study	O
of	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
inflammatory	O
cytokine	O
expression	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1994	O
Jun	O
17	O
;	O
269	O
(	O
24	O
)	O
:16983	O
]	O

It	O
is	O
believed	O
that	O
induction	O
of	O
cytokine	O
expression	O
by	O
bacterial	O
cell	O
wall	O
components	O
plays	O
a	O
role	O
in	O
the	O
development	O
and	O
course	O
of	O
sepsis	O
.	O

However	O
,	O
most	O
attention	O
has	O
been	O
focused	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

We	O
studied	O
the	O
ability	O
of	O
N-acetylglucosaminyl-1,6-anhydro-N-acetylmuramyl-L-alanyl-D-isoglutamyl-m-diaminopimelyl-D-alanine	O
(	O
G	O
(	O
Anh	O
)	O
MTetra	O
)	O
,	O
a	O
naturally	O
occurring	O
breakdown	O
product	O
of	O
peptidoglycan	O
that	O
is	O
produced	O
by	O
soluble	O
lytic	O
transglycosylase	O
of	O
Escherichia	O
coli	O
,	O
to	O
induce	O
cytokine	O
expression	O
in	O
human	O
monocytes	O
.	O

G	O
(	O
Anh	O
)	O
MTetra	O
was	O
found	O
to	O
strongly	O
induce	O
interleukin	O
(	O
IL	O
)	O
-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
after	O
2	O
h	O
and	O
IL-1	O
beta	O
and	O
IL-6	O
protein	O
secretion	O
after	O
48	O
h	O
of	O
activation	O
.	O

The	O
increase	O
in	O
mRNA	O
accumulation	O
was	O
at	O
least	O
partly	O
due	O
to	O
an	O
increase	O
in	O
the	O
transcription	O
rates	O
of	O
the	O
respective	O
genes	O
and	O
was	O
accompanied	O
by	O
a	O
strong	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
activator	O
protein-1	O
transcription	O
factor	O
expression	O
.	O

Experiments	O
using	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
tyrosine	O
kinase-dependent	O
pathways	O
revealed	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
involves	O
activation	O
of	O
an	O
H7-inhibitable	O
pathway	O
.	O

By	O
using	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
,	O
it	O
was	O
shown	O
that	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-6	O
mRNA	O
expression	O
depends	O
on	O
the	O
synthesis	O
of	O
new	O
protein	O
,	O
whereas	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	O
beta	O
mRNA	O
accumulation	O
does	O
not	B-Negation
.	O

When	O
responses	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
were	O
compared	O
with	O
those	O
to	O
LPS	O
and	O
muramyldipeptide	O
(	O
MDP	O
)	O
,	O
it	O
was	O
found	O
that	O
the	O
optimal	O
response	O
to	O
G	O
(	O
Anh	O
)	O
MTetra	O
induction	O
was	O
similar	O
to	O
that	O
of	O
LPS	O
but	O
significantly	O
higher	O
than	O
the	O
response	O
to	O
MDP	O
.	O

Furthermore	O
,	O
maximal	O
G	O
(	O
Anh	O
)	O
MTetra-induced	O
IL-1	O
beta	O
and	O
IL-6	O
mRNA	O
expression	O
could	O
be	O
enhanced	O
by	O
co-stimulation	O
with	O
LPS	O
or	O
MDP	O
,	O
suggesting	O
that	O
different	O
receptors	O
and/or	O
transduction	O
pathways	O
were	O
involved	O
.	O

These	O
results	O
indicate	O
that	O
G	O
(	O
Anh	O
)	O
MTetra	O
induces	O
IL-1	O
beta	O
and	O
IL-6	O
expression	O
in	O
human	O
monocytes	O
suggesting	O
a	O
possible	O
role	O
for	O
G	O
(	O
Anh	O
)	O
MTetra	O
in	O
the	O
release	O
of	O
cytokines	O
during	O
sepsis	O
.	O

Human	O
interferon	O
regulatory	O
factor	O
2	O
gene	O
.	O

Intron-exon	O
organization	O
and	O
functional	O
analysis	O
of	O
5'-flanking	O
region	O
.	O

Interferon	O
regulatory	O
factor	O
2	O
(	O
IRF-2	O
)	O
is	O
a	O
transcriptional	O
regulatory	O
protein	O
that	O
terminates	O
interferon	O
beta	O
expression	O
initiated	O
by	O
interferon	O
regulatory	O
factor	O
1	O
.	O

In	O
this	O
study	O
,	O
we	O
isolated	O
the	O
genomic	O
DNA	O
for	O
human	O
IRF-2	O
gene	O
,	O
determined	O
the	O
intron-exon	O
structure	O
of	O
the	O
human	O
IRF-2	O
gene	O
,	O
mapped	O
the	O
major	O
transcription	O
initiation	O
site	O
,	O
identified	O
a	O
number	O
of	O
potential	O
regulatory	O
elements	O
in	O
the	O
5'-flanking	O
region	O
,	O
and	O
localized	O
the	O
IRF-2	O
gene	O
on	O
human	O
chromosome	O
4	O
.	O

The	O
IRF-2	O
promoter	O
region	O
contains	O
a	O
CpG	O
island	O
,	O
with	O
several	O
GC	O
boxes	O
,	O
a	O
putative	B-Speculation
NF-kappa	I-Speculation
B-binding	I-Speculation
site	I-Speculation
,	O
and	O
a	O
CAAT	O
box	O
,	O
but	O
no	B-Negation
TATA	I-Negation
box	I-Negation
.	O

When	O
the	O
promoter	O
region	O
was	O
linked	O
with	O
a	O
heterologous	O
reporter	O
gene	O
,	O
we	O
found	O
that	O
the	O
promoter	O
region	O
is	O
inducible	O
by	O
both	O
interferons	O
(	O
interferon-alpha	O
and	O
-gamma	O
)	O
and	O
interferon	O
regulatory	O
factor	O
1	O
.	O

The	O
region	O
which	O
induced	O
these	O
inductions	O
was	O
identified	O
as	O
being	O
confined	O
to	O
40	O
nucleotides	O
5	O
'	O
to	O
the	O
major	O
transcriptional	O
initiation	O
site	O
by	O
testing	O
a	O
series	O
of	O
clones	O
with	O
truncated	O
promoter	O
of	O
IRF-2	O
.	O

This	O
region	O
contains	O
elements	O
which	O
are	O
shared	O
with	O
the	O
transcriptional	O
enhancers	O
of	O
other	O
genes	O
including	O
interferon	O
regulatory	O
factor	O
1	O
,	O
interferon	O
beta	O
,	O
and	O
interferon-inducible	O
genes	O
.	O

These	O
data	O
suggest	O
that	O
interferon	O
regulatory	O
factor	O
1	O
not	O
only	O
triggers	O
the	O
activation	O
of	O
the	O
interferon	O
signal	O
transduction	O
pathway	O
,	O
but	O
also	O
may	O
play	O
a	O
role	O
in	O
limiting	O
the	O
duration	O
of	O
this	O
response	O
by	O
activating	O
the	O
transcription	O
of	O
IRF-2	O
.	O

rel	O
Is	O
rapidly	O
tyrosine-phosphorylated	O
following	O
granulocyte-colony	O
stimulating	O
factor	O
treatment	O
of	O
human	O
neutrophils	O
.	O

Stimulation	O
of	O
neutrophils	O
with	O
granulocyte-colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
results	O
in	O
an	O
enhanced	O
respiratory	O
burst	O
,	O
prolonged	O
survival	O
,	O
and	O
increased	O
tumor	O
cell	O
killing	O
.	O

The	O
effects	O
of	O
G-CSF	O
are	O
mediated	O
by	O
binding	O
to	O
specific	O
,	O
high	O
affinity	O
receptors	O
.	O

G-CSF	O
receptors	O
lack	B-Negation
intrinsic	I-Negation
tyrosine	I-Negation
kinase	I-Negation
activity	I-Negation
,	O
but	O
activation	O
of	O
the	O
receptor	O
results	O
in	O
the	O
rapid	O
induction	O
of	O
tyrosine	O
kinase	O
activity	O
.	O

Antiphosphotyrosine	O
immunoblots	O
of	O
whole	O
cell	O
lysates	O
prepared	O
from	O
neutrophils	O
show	O
that	O
the	O
G-CSF	O
rapidly	O
induces	O
prominent	O
tyrosine	O
phosphorylation	O
of	O
a	O
protein	O
of	O
a	O
relative	O
molecular	O
mass	O
of	O
80	O
kDa	O
.	O

Using	O
monospecific	O
antibodies	O
,	O
the	O
80-kDa	O
tyrosine-phosphorylated	O
protein	O
has	O
been	O
shown	O
to	O
be	O
p80c-rel	O
,	O
a	O
proto-oncogene	O
belonging	O
to	O
a	O
family	O
of	O
transcriptional	O
regulators	O
which	O
include	O
NF-kB	O
.	O

The	O
induction	O
of	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	O
was	O
unique	O
to	O
G-CSF	O
in	O
that	O
granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
which	O
also	O
stimulates	O
neutrophils	O
and	O
induces	O
tyrosine	O
phosphorylation	O
does	O
not	B-Negation
result	I-Negation
in	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
of	I-Negation
p80c-rel	I-Negation
.	O

The	B-Negation
consequences	I-Negation
of	I-Negation
p80c-rel	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
are	I-Negation
not	I-Negation
yet	I-Negation
known	I-Negation
;	O

however	O
,	O
tyrosine-phosphorylated	O
p80c-rel	O
is	O
capable	O
of	O
binding	O
to	O
DNA	O
,	O
and	O
G-CSF	O
stimulation	O
results	O
in	O
an	O
increase	O
in	O
the	O
amount	O
of	O
p80c-rel	O
which	O
binds	O
to	O
DNA	O
.	O

These	O
results	O
demonstrate	O
that	O
one	O
of	O
the	O
first	O
biochemical	O
events	O
which	O
occurs	O
in	O
neutrophils	O
following	O
G-CSF	O
stimulation	O
,	O
activation	O
of	O
a	O
tyrosine	O
kinase	O
,	O
leads	O
directly	O
to	O
the	O
tyrosine	O
phosphorylation	O
of	O
p80c-rel	O
.	O

Thus	O
,	O
the	O
tyrosine	O
kinase	O
activated	O
by	O
G-CSF	O
appears	O
to	O
directly	O
transduce	O
a	O
signal	O
to	O
a	O
protein	O
which	O
functions	O
as	O
a	O
transcriptional	O
regulator	O
.	O

Autoregulation	O
of	O
the	O
NF-kappa	O
B	O
transactivator	O
RelA	O
(	O
p65	O
)	O
by	O
multiple	O
cytoplasmic	O
inhibitors	O
containing	O
ankyrin	O
motifs	O
.	O

RelA	O
(	O
p65	O
)	O
functions	O
as	O
the	O
critical	O
transactivating	O
component	O
of	O
the	O
heterodimeric	O
p50-p65	O
NF-kappa	O
B	O
complex	O
and	O
contains	O
a	O
high-affinity	O
binding	O
site	O
for	O
its	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

After	O
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
rapidly	O
degraded	O
in	O
concert	O
with	O
the	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
tumor	O
necrosis	O
factor	O
alpha-induced	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
in	O
human	O
T	O
cells	O
is	O
preceded	O
by	O
its	O
rapid	O
phosphorylation	O
in	O
vivo	O
.	O

However	O
,	O
these	O
effects	O
on	O
I	O
kappa	O
B	O
alpha	O
result	O
in	O
nuclear	O
mobilization	O
of	O
only	O
a	O
fraction	O
of	O
the	O
entire	O
cytoplasmic	O
pool	O
of	O
RelA	O
.	O

Subsequent	O
studies	O
have	O
revealed	O
that	O
(	O
i	O
)	O
cytoplasmic	O
RelA	O
is	O
stably	O
associated	O
not	O
only	O
with	O
I	O
kappa	O
B	O
alpha	O
but	O
also	O
with	O
other	O
ankyrin	O
motif-rich	O
proteins	O
including	O
the	O
products	O
of	O
the	O
NF-kappa	O
B2	O
(	O
p100	O
)	O
and	O
NF-kappa	O
B1	O
(	O
p105	O
)	O
genes	O
;	O
(	O
ii	O
)	O
in	O
contrast	O
to	O
RelA-I	O
kappa	O
B	O
alpha	O
,	O
RelA-p100	B-Negation
cytoplasmic	I-Negation
complexes	I-Negation
are	I-Negation
not	I-Negation
dissociated	I-Negation
following	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha	I-Negation
activation	I-Negation
;	O
(	O
iii	O
)	O
p100	O
functions	O
as	O
a	O
potent	O
inhibitor	O
of	O
RelA-mediated	O
transcription	O
in	O
vivo	O
;	O
(	O
iv	O
)	O
the	O
interaction	O
of	O
RelA	O
and	O
p100	O
involves	O
the	O
conserved	O
Rel	O
homology	O
domain	O
of	O
both	O
proteins	O
but	O
not	B-Negation
the	I-Negation
nuclear	I-Negation
localization	I-Negation
signal	I-Negation
of	I-Negation
RelA	I-Negation
,	O
which	O
is	O
required	O
for	O
I	O
kappa	O
B	O
alpha	O
binding	O
;	O
(	O
v	O
)	O
p100	O
inhibition	O
of	O
RelA	O
function	O
requires	O
the	O
C-terminal	O
ankyrin	O
motif	O
domain	O
,	O
which	O
mediates	O
cytoplasmic	O
retention	O
of	O
RelA	O
;	O
and	O
(	O
vi	O
)	O
as	O
observed	O
with	O
I	O
kappa	O
B	O
alpha	O
,	O
nuclear	O
RelA	O
stimulates	O
p100	O
mRNA	O
and	O
protein	O
expression	O
.	O

These	O
findings	O
thus	O
reveal	O
the	O
presence	O
of	O
a	O
second	O
inducible	O
autoregulated	O
inhibitory	O
pathway	O
that	O
helps	O
ensure	O
the	O
rapid	O
but	O
transient	O
action	O
of	O
nuclear	O
NF-kappa	O
B	O
.	O

Calcineurin	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
inactivate	O
I	O
kappa	O
B/MAD3	O
,	O
an	O
inhibitor	O
of	O
NF-kappa	O
B	O
.	O

The	O
interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
consists	O
of	O
several	O
independent	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
responsive	O
elements	O
.	O

The	O
induction	O
of	O
promoters	O
dependent	O
on	O
these	O
elements	O
is	O
inhibitable	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
tacrolimus	O
(	O
FK-506	O
)	O
.	O

Calcineurin	O
,	O
a	O
Ca2+/calmodulin-dependent	O
protein	O
phosphatase	O
,	O
is	O
the	O
FK-506-	O
and	O
CsA-sensitive	O
enzyme	O
required	O
for	O
TcR	O
mediated	O
activation	O
of	O
the	O
IL-2	O
promoter	O
.	O

We	O
report	O
that	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
partially	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
activate	O
the	O
IL-2	O
promoter	O
elements	O
IL-2A	O
(	O
which	O
binds	O
the	O
factors	O
OAP	O
and	O
Oct-1	O
)	O
and	O
IL-2E	O
(	O
which	O
binds	O
NF-AT	O
)	O
,	O
and	O
completely	O
substitutes	O
for	O
the	O
Ca2+	O
co-stimulus	O
required	O
to	O
stimulate	O
an	O
NF-kappa	O
B-dependent	O
element	O
.	O

Calcineurin	O
stimulates	O
the	O
NF-kappa	O
B	O
element	O
by	O
enhancing	O
inactivation	O
of	O
I	O
kappa	O
B/MAD3	O
,	O
an	O
inhibitor	O
of	O
NF-kappa	O
B	O
,	O
thereby	O
increasing	O
the	O
amount	O
of	O
nuclear	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
in	O
vivo	O
that	O
activation	O
of	O
a	O
protein	O
phosphatase	O
can	O
inactivate	O
I	O
kappa	O
B	O
,	O
and	O
suggest	O
one	O
possible	O
explanation	O
for	O
mechanism-based	O
toxicities	O
associated	O
with	O
FK-506	O
and	O
CsA	O
by	O
demonstrating	O
that	O
these	O
drugs	O
can	O
inhibit	O
the	O
calcineurin-dependent	O
activation	O
of	O
a	O
virtually	O
ubiquitous	O
transcription	O
factor	O
.	O

Direct	O
exposure	O
to	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
increases	O
infectivity	O
of	O
human	O
erythrocytes	O
to	O
a	O
malarial	O
parasite	O
.	O

Direct	O
exposure	O
to	O
10	O
nM	O
2,3,7,8-TCDD	O
caused	O
a	O
75	O
%	O
increase	O
and	O
a	O
2-fold	O
increase	O
in	O
the	O
infectivity	O
of	O
isolated	O
human	O
erythrocytes	O
to	O
P.	O
falciparum	O
after	O
48	O
hours	O
when	O
the	O
parasites	O
were	O
in	O
an	O
unsynchronized	O
or	O
synchronized	O
state	O
of	O
growth	O
,	O
respectively	O
.	O

Treatment	O
of	O
human	O
erythrocytes	O
with	O
10	O
microM	O
sodium	O
orthovanadate	O
(	O
NaOV	O
)	O
,	O
an	O
inhibitor	O
of	O
plasma	O
membrane	O
Ca-ATPase	O
and	O
phosphotyrosine	O
phosphatase	O
,	O
decreased	O
parasitemia	O
by	O
30	O
%	O
.	O

Co-treatment	O
of	O
RBCs	O
with	O
TCDD	O
and	O
NaOV	O
completely	O
blocked	O
the	O
TCDD-induced	O
increase	O
in	O
parasitemia	O
.	O

Because	O
erythrocytes	O
are	O
anucleated	O
,	O
these	O
results	O
are	O
discussed	O
as	O
evidence	O
for	O
biochemical	O
changes	O
by	O
TCDD	O
without	B-Negation
requiring	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
gene	I-Negation
products	I-Negation
.	O

Comparative	O
mapping	O
of	O
SRY	O
in	O
the	O
great	O
apes	O
.	O

Cytogenetic	O
studies	O
of	O
the	O
primate	O
Y	O
chromosomes	O
have	O
suggested	O
that	O
extensive	O
rearrangements	O
have	O
occurred	O
during	O
evolution	O
of	O
the	O
great	O
apes	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridization	O
to	O
define	O
these	O
rearrangements	O
at	O
the	O
molecular	O
level	O
.	O

pHU-14	O
,	O
a	O
probe	O
including	O
sequences	O
from	O
the	O
sex	O
determining	O
gene	O
SRY	O
,	O
hybridizes	O
close	O
to	O
the	O
early	O
replicating	O
pseudoautosomal	O
segment	O
in	O
a	O
telomeric	O
or	O
subtelomeric	O
position	O
of	O
the	O
Y	O
chromosomes	O
of	O
all	O
great	O
apes	O
.	O

The	O
low	O
copy	O
repeat	O
detected	O
by	O
the	O
probe	O
Fr35-II	O
is	O
obviously	O
included	O
in	O
Y	O
chromosomal	O
rearrangements	O
during	O
hominid	O
evolution	O
.	O

These	O
results	O
,	O
combined	O
with	O
previous	O
studies	O
,	O
suggest	O
that	O
the	O
Y	O
chromosome	O
in	O
great	O
apes	O
has	O
a	O
conserved	O
region	O
including	O
the	O
pseudoautosomal	O
region	O
and	O
the	O
testis-determining	O
region	O
.	O

The	O
rest	O
of	O
the	O
Y	O
chromosome	O
has	O
undergone	O
several	O
rearrangements	O
in	O
the	O
different	O
great	O
apes	O
.	O

Detection	O
of	O
minimal	O
residual	O
disease	O
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
by	O
RT-PCR	O
:	O
necessity	O
of	O
chemotherapy	O
following	O
ATRA	O
therapy	O
.	O

The	O
PML/RAR	O
alpha	O
fusion	O
gene	O
resulting	O
from	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
is	O
a	O
specific	O
marker	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

We	O
examined	O
bone	O
marrow	O
cells	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
to	O
detect	O
residual	O
PML/RAR	O
alpha	O
mRNA-containing	O
cells	O
following	O
treatment	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
cytotoxic	O
chemotherapy	O
in	O
a	O
patient	O
with	O
APL	O
.	O

This	O
RT-PCR	O
assay	O
can	O
detect	O
one	O
leukemic	O
cell	O
in	O
10	O
(	O
2	O
)	O
normal	O
cells	O
in	O
vitro	O
.	O

We	O
show	O
that	O
PML/RAR	O
alpha	O
mRNA	O
was	O
still	O
detectable	O
despite	O
clinical	O
remission	O
following	O
ATRA	O
treatment	O
,	O
but	O
undetectable	O
following	O
consolidation	O
with	O
chemotherapy	O
.	O

These	O
data	O
show	O
that	O
this	O
technique	O
is	O
useful	O
for	O
the	O
identification	O
of	O
minimal	O
residual	O
disease	O
in	O
patients	O
with	O
APL	O
and	O
that	O
cytotoxic	O
chemotherapy	O
following	O
ATRA	O
therapy	O
is	O
required	O
for	O
the	O
elimination	O
of	O
APL	O
cells	O
.	O

Genes	O
encoding	O
general	O
initiation	O
factors	O
for	O
RNA	O
polymerase	O
II	O
transcription	O
are	O
dispersed	O
in	O
the	O
human	O
genome	O
.	O

General	O
transcription	O
factors	O
are	O
required	O
for	O
accurate	O
initiation	O
of	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

Human	O
cDNAs	O
encoding	O
subunits	O
of	O
these	O
factors	O
have	O
been	O
cloned	O
and	O
sequenced	O
.	O

Using	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
,	O
we	O
show	O
here	O
that	O
the	O
genes	O
encoding	O
the	O
TATA-box	O
binding	O
protein	O
(	O
TBP	O
)	O
,	O
TFIIB	O
,	O
TFIIE	O
alpha	O
,	O
TFIIE	O
beta	O
,	O
RAP30	O
,	O
RAP74	O
and	O
the	O
62	O
kDa	O
subunit	O
,	O
of	O
TFIIH	O
are	O
located	O
at	O
the	O
human	O
chromosomal	O
bands	O
6q26-27	O
,	O
1p21-22	O
,	O
3q21-24	O
,	O
8p12	O
,	O
13q14	O
,	O
19p13.3	O
and	O
11p14-15.1	O
,	O
respectively	O
.	O

This	O
dispersed	O
localization	O
of	O
a	O
group	O
of	O
functionally	O
related	O
gene	O
provides	O
insights	O
into	O
the	O
molecular	O
mechanism	O
of	O
human	O
genome	O
evolution	O
and	O
their	O
possible	O
involvement	O
in	O
human	O
diseases	O
.	O

Patterns	O
of	O
Pan	O
expression	O
and	O
role	O
of	O
Pan	O
proteins	O
in	O
endocrine	O
cell	O
type-specific	O
complex	O
formation	O
.	O

The	O
Pan	O
gene	O
encodes	O
at	O
least	O
two	O
distinct	O
transcripts	O
,	O
Pan-1	O
and	O
Pan-2	O
(	O
also	O
known	O
as	O
E47	O
and	O
E12	O
,	O
respectively	O
)	O
,	O
by	O
the	O
mechanism	O
of	O
alternative	O
RNA	O
splicing	O
.	O

Northern	O
blot	O
analyses	O
performed	O
on	O
rat	O
and	O
mouse	O
tissues	O
have	O
detected	O
ubiquitously	O
expressed	O
Pan	O
transcripts	O
,	O
but	O
the	B-Negation
abundance	I-Negation
,	I-Negation
distribution	I-Negation
,	I-Negation
and	I-Negation
form	I-Negation
of	I-Negation
Pan	I-Negation
proteins	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
clearly	I-Negation
defined	I-Negation
.	O

Studies	O
of	O
cell	O
lines	O
representing	O
endocrine	O
,	O
fibroblast	O
,	O
and	O
lymphoid	O
lineages	O
using	O
polyclonal	O
antisera	O
to	O
detect	O
E2A	O
proteins	O
have	O
suggested	O
that	O
significant	O
E2A	O
protein	O
expression	O
is	O
restricted	O
to	O
B-lymphocytes	O
.	O

We	O
have	O
developed	O
a	O
monoclonal	O
antibody	O
,	O
Yae	O
,	O
which	O
is	O
specific	O
for	O
Pan/E2A	O
proteins	O
,	O
and	O
have	O
used	O
the	O
Yae	O
antibody	O
to	O
examine	O
a	O
variety	O
of	O
endocrine	O
and	O
nonendocrine	O
cell	O
lineages	O
for	O
differences	O
in	O
Pan/E2A	O
protein	O
expression	O
,	O
subcellular	O
localization	O
,	O
and	O
heteromeric	O
complex	O
formation	O
.	O

In	O
contrast	O
to	O
previous	O
results	O
obtained	O
using	O
polyclonal	O
antiseras	O
to	O
detect	O
Pan/E2A	O
proteins	O
,	O
we	O
report	O
comparable	O
levels	O
of	O
Pan	O
proteins	O
in	O
GH/PRL-	O
and	O
insulin-producing	O
,	O
B-	O
and	O
T-lymphocyte	O
cells	O
.	O

IEF-1	O
,	O
a	O
pancreatic	O
beta-cell	O
type-specific	O
complex	O
believed	O
to	O
regulate	O
insulin	O
expression	O
,	O
is	O
demonstrated	O
to	O
consist	O
of	O
at	O
least	O
two	O
distinct	O
species	O
,	O
one	O
of	O
which	O
does	O
not	B-Negation
contain	I-Negation
Pan	I-Negation
molecules	I-Negation
.	O

Although	O
it	O
has	O
been	O
postulated	O
that	O
pituitary	O
endocrine	O
cells	O
and	O
pancreatic	O
endocrine	O
beta-cells	O
share	O
identical	O
Pan/E2A	O
complexes	O
,	O
native-Western	O
analyses	O
of	O
pituitary	O
and	O
endocrine	O
beta-cells	O
detect	O
Pan	O
proteins	O
in	O
distinct	O
cell	O
type-specific	O
complexes	O
.	O

Interferon	O
alpha	O
selectively	O
affects	O
expression	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
in	O
late	O
stage	O
cells	O
in	O
the	O
monocytic	O
but	O
not	B-Negation
the	I-Negation
granulocytic	I-Negation
lineage	I-Negation
.	O

The	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	O
)	O
is	O
expressed	O
constitutively	O
in	O
cells	O
of	O
the	O
myeloid	O
lineage	O
,	O
appearing	O
in	O
myeloblast	O
cells	O
in	O
some	O
cases	O
of	O
acute	O
myeloid	O
leukemia	O
and	O
consistently	O
being	O
detected	O
in	O
promyelocyte	O
stage	O
cells	O
as	O
well	O
as	O
in	O
all	O
later	O
stage	O
cells	O
including	O
peripheral	O
blood	O
monocytes	O
and	O
granulocytes	O
.	O

The	O
human	O
myeloid	O
leukemia	O
cell	O
lines	O
,	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
,	O
express	O
similar	O
levels	O
of	O
immunochemically	O
detectable	O
MNDA	O
.	O

Although	O
,	O
the	O
level	O
of	O
MNDA	O
mRNA	O
in	O
primary	O
monocytes	O
is	O
very	O
low	O
it	O
was	O
up-regulated	O
at	O
6	O
h	O
following	O
the	O
addition	O
of	O
interferon	O
alpha	O
.	O

The	O
effect	O
of	O
interferon	O
alpha	O
on	O
the	O
MNDA	O
mRNA	O
is	O
also	O
observed	O
in	O
the	O
cell	O
lines	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
.	O

The	O
MNDA	O
mRNA	O
level	O
in	O
primary	O
granulocytes	O
was	O
unaffected	O
by	O
addition	O
of	O
interferon	O
alpha	O
and	O
other	O
agents	O
including	O
interferon	O
gamma	O
,	O
endotoxin	O
,	O
poly	O
(	O
I	O
)	O
.poly	O
(	O
C	O
)	O
,	O
and	O
FMLP	O
.	O

The	O
MNDA	O
mRNA	O
level	O
in	O
the	O
myeloid	O
cell	O
lines	O
was	O
also	O
unaffected	O
by	O
the	O
latter	O
four	O
agents	O
.	O

Induction	O
of	O
differentiation	O
in	O
the	O
myeloid	O
cell	O
lines	O
with	O
phorbol	O
ester	O
induces	O
monocyte	O
differentiation	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
MNDA	O
mRNA	O
level	O
.	O

This	O
reduced	O
level	O
of	O
mRNA	O
could	O
then	O
be	O
elevated	O
with	O
subsequent	O
interferon	O
alpha	O
treatment	O
.	O

The	B-Speculation
effects	I-Speculation
of	I-Speculation
phorbol	I-Speculation
ester	I-Speculation
on	I-Speculation
MNDA	I-Speculation
mRNA	I-Speculation
appeared	I-Speculation
to	I-Speculation
be	I-Speculation
associated	I-Speculation
with	I-Speculation
induced	I-Speculation
differentiation	I-Speculation
since	O
inhibiting	O
cell	O
proliferation	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
level	I-Negation
of	I-Negation
MNDA	I-Negation
mRNA	I-Negation
and	O
cell	B-Negation
cycle	I-Negation
variation	I-Negation
in	I-Negation
MNDA	I-Negation
mRNA	I-Negation
levels	I-Negation
were	I-Negation
not	I-Negation
observed	I-Negation
.	O

The	O
ability	O
of	O
interferon	O
alpha	O
to	O
up-regulate	O
MNDA	O
mRNA	O
in	O
phorbol	O
ester	O
treated	O
myeloid	O
cell	O
lines	O
is	O
consistent	O
with	O
the	O
observations	O
made	O
in	O
primary	O
monocytes	O
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Calcineurin	O
potentiates	O
activation	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
gene	O
in	O
T	O
cells	O
:	O

involvement	O
of	O
the	O
conserved	O
lymphokine	O
element	O
0	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
and	O
interleukin-2	O
(	O
IL-2	O
)	O
are	O
produced	O
by	O
stimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
human	O
T	O
cell	O
leukemia	O
Jurkat	O
cells	O
.	O

The	O
expression	O
of	O
GM-CSF	O
and	O
IL-2	O
is	O
inhibited	O
by	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
.	O

Earlier	O
studies	O
on	O
the	O
IL-2	O
gene	O
expression	O
showed	O
that	O
overexpression	O
of	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2+/calmodulin-dependent	O
protein	O
phosphatase	O
,	O
can	O
stimulate	O
transcription	O
from	O
the	O
IL-2	O
promoter	O
through	O
the	O
NF-AT-binding	O
site	O
.	O

In	O
this	O
study	O
,	O
we	O
obtained	O
evidence	O
that	O
transfection	O
of	O
the	O
cDNAs	O
for	O
CN	O
A	O
(	O
catalytic	O
)	O
and	O
CN	O
B	O
(	O
regulatory	O
)	O
subunits	O
also	O
augments	O
transcription	O
from	O
the	O
GM-CSF	O
promoter	O
and	O
recovers	O
the	O
transcription	O
inhibited	O
by	O
CsA	O
.	O

The	O
constitutively	O
active	O
type	O
of	O
the	O
CN	O
A	O
subunit	O
,	O
which	O
lacks	B-Negation
the	I-Negation
auto-inhibitory	I-Negation
and	I-Negation
calmodulin-binding	I-Negation
domains	I-Negation
,	O
acts	O
in	O
synergy	O
with	O
PMA	O
to	O
activate	O
transcription	O
from	O
the	O
GM-CSF	O
promoter	O
.	O

We	O
also	O
found	O
that	O
the	O
active	O
CN	O
partially	O
replaces	O
calcium	O
ionophore	O
in	O
synergy	O
with	O
PMA	O
to	O
induce	O
expression	O
of	O
endogenous	O
GM-CSF	O
and	O
IL-2	O
.	O

By	O
multimerizing	O
the	O
regulatory	O
elements	O
of	O
the	O
GM-CSF	O
promoter	O
,	O
we	O
found	O
that	O
one	O
of	O
the	O
target	O
sites	O
for	O
the	O
CN	O
action	O
is	O
the	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
located	O
at	O
positions	O
between	O
-54	O
and	O
-40	O
.	O

Mobility	O
shift	O
assays	O
showed	O
that	O
the	O
CLE0	O
sequence	O
has	O
an	O
AP1-binding	O
site	O
and	O
is	O
associated	O
with	O
an	O
NF-AT-like	O
factor	O
,	O
termed	O
NF-CLE0	O
gamma	O
.	O

NF-CLE0	O
gamma	O
binding	O
is	O
induced	O
by	O
PMA/A23187	O
and	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

These	O
results	O
suggest	O
that	O
CN	O
is	O
involved	O
in	O
the	O
coordinated	O
induction	O
of	O
the	O
GM-CSF	O
and	O
IL-2	O
genes	O
and	O
that	O
the	O
CLE0	O
sequence	O
of	O
the	O
GM-CSF	O
gene	O
is	O
a	O
functional	O
analogue	O
of	O
the	O
NF-AT-binding	O
site	O
in	O
the	O
IL-2	O
promoter	O
,	O
which	O
mediates	O
signals	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Novel	O
aldosterone	O
receptors	O
:	O
specificity-conferring	O
mechanism	O
at	O
the	O
level	O
of	O
the	O
cell	O
membrane	O
.	O

Functional	O
studies	O
in	O
extra-renal	O
,	O
nonepithelial	O
cells	O
such	O
as	O
smooth	O
muscle	O
cells	O
and	O
more	O
recently	O
circulating	O
human	O
lymphocytes	O
have	O
provided	O
increasing	O
evidence	O
that	O
aldosterone	O
produces	O
not	O
only	O
classical	O
genomic	O
effects	O
,	O
but	O
also	O
rapid	O
non-genomic	O
effects	O
on	O
transmembrane	O
electrolyte	O
movements	O
.	O

These	O
involve	O
activation	O
of	O
the	O
sodium/proton-exchanger	O
of	O
the	O
cell	O
membrane	O
at	O
very	O
low	O
,	O
physiological	O
concentrations	O
of	O
aldosterone	O
with	O
an	O
acute	O
onset	O
within	O
1-2	O
minutes	O
.	O

A	O
second	O
messenger	O
cascade	O
involved	O
is	O
the	O
inositol-1,4,5-trisphosphate/calcium	O
pathway	O
which	O
responds	O
over	O
the	O
same	O
rapid	O
time	O
course	O
.	O

Such	B-Negation
changes	I-Negation
clearly	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
explained	I-Negation
by	I-Negation
genomic	I-Negation
mechanisms	I-Negation
,	I-Negation
which	I-Negation
are	I-Negation
responsible	I-Negation
for	I-Negation
later	I-Negation
effects	I-Negation
than	I-Negation
the	I-Negation
membrane-related	I-Negation
rapid	I-Negation
responses	I-Negation
.	O

In	O
addition	O
to	O
its	O
rapid	O
time	O
course	O
the	O
unique	O
characteristics	O
of	O
this	O
new	O
pathway	O
for	O
steroid	O
action	O
include	O
a	O
10000-fold	O
selectivity	O
for	O
aldosterone	O
over	O
cortisol	O
and	O
the	O
ineffectiveness	O
of	O
spironolactones	O
,	O
classical	O
mineralocorticoid	O
antagonists	O
,	O
as	O
antagonists	O
of	O
the	O
response	O
.	O

Subsequently	O
binding	O
sites	O
have	O
been	O
demonstrated	O
in	O
the	O
plasma	O
membrane	O
of	O
human	O
lymphocytes	O
which	O
show	O
pharmacological	O
(	O
aldosterone	O
specificity	O
)	O
and	O
kinetic	O
(	O
high	O
turnover	O
)	O
properties	O
identical	O
with	O
those	O
of	O
the	O
rapid	O
aldosterone	O
effects	O
in	O
the	O
same	O
cells	O
.	O

SDS-PAGE	O
analysis	O
of	O
the	O
receptor	O
protein	O
has	O
shown	O
a	O
molecular	O
weight	O
of	O
approximately	O
50	O
kD	O
.	O

The	O
present	O
paper	O
reviews	O
the	O
data	O
supporting	O
a	O
new	O
,	O
two-step	O
model	O
for	O
non-genomic	O
and	O
genomic	O
aldosterone	O
effects	O
.	O

It	O
also	O
suggests	O
a	O
novel	O
specificity-conferring	O
mechanism	O
for	O
mineralocorticoid	O
action	O
at	O
the	O
membrane	O
level	O
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
interleukin-2	O
receptor	O
alpha	O
and	O
-beta	O
subunit	O
expression	O
by	O
human	O
T	O
cells	O
.	O

To	O
determine	O
the	O
mechanism	O
of	O
glucocorticoid	O
(	O
GC	O
)	O
-mediated	O
inhibition	O
of	O
T	O
cell	O
functions	O
,	O
the	O
effect	O
of	O
dexamethasone	O
(	O
DM	O
)	O
on	O
T	O
cell	O
proliferation	O
and	O
interleukin-2	O
receptor	O
(	O
IL-2R	O
)	O
generation	O
were	O
studied	O
.	O

Dexamethasone	O
inhibited	O
IL-2-induced	O
T	O
cell	O
proliferation	O
by	O
30	O
%	O
-	O
88	O
%	O
,	O
relative	O
to	O
its	O
concentration	O
within	O
the	O
cultures	O
.	O

The	O
effect	O
of	O
DM	O
on	O
expression	O
of	O
IL-2R	O
alpha	O
(	O
Tac	O
,	O
p55	O
,	O
CD25	O
)	O
and	O
beta	O
(	O
p75	O
)	O
genes	O
in	O
activated	O
T	O
cells	O
was	O
examined	O
next	O
.	O

In	O
T	O
cells	O
stimulated	O
with	O
purified	O
phytohemagglutinin	O
(	O
PHA-p	O
)	O
and	O
4	O
beta-phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
addition	O
of	O
DM	O
to	O
the	O
cultures	O
resulted	O
in	O
a	O
60	O
%	O
reduction	O
in	O
IL-2R	O
alpha	O
and	O
a	O
30	O
%	O
reduction	O
in	O
IL-2R	O
beta	O
membrane	O
expression	O
compared	O
to	O
T	O
cells	O
cultured	O
in	O
the	O
absence	O
of	O
DM	O
(	O
p	O
<	O
0.01	O
)	O
.	O

Inhibition	O
of	O
membrane	O
IL-2R	O
alpha	O
and	O
IL-2R	O
beta	O
expression	O
by	O
10	O
(	O
-6	O
)	O
M	O
DM	O
was	O
partially	O
reversible	O
by	O
recombinant	O
human	O
IL-2	O
(	O
rhIL-2	O
)	O
.	O

By	O
Northern	O
blot	O
analysis	O
,	O
DM	O
caused	O
a	O
comparable	O
decrease	O
in	O
IL-2R	O
alpha	O
and	O
in	O
IL-2R	O
beta	O
mRNA	O
levels	O
to	O
membrane	O
receptor	O
expression	O
in	O
mitogen-stimulated	O
T	O
cells	O
.	O

By	O
in	O
vitro	O
transcription	O
assays	O
,	O
DM	O
regulated	O
IL-2R	O
alpha	O
gene	O
expression	O
at	O
a	O
transcriptional	O
level	O
while	O
transcription	O
of	O
IL-2R	O
beta	O
gene	O
was	O
unaffected	O
by	O
DM	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
DM	O
on	O
IL-2R	O
alpha	O
transcription	O
was	O
examined	O
by	O
determining	O
the	O
mRNA	O
levels	O
of	O
the	O
p50	O
subunit	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
that	O
stimulates	O
IL-2R	O
alpha	O
gene	O
expression	O
.	O

The	O
data	O
indicate	O
that	O
10	O
(	O
-6	O
)	O
M	O
DM	O
increased	O
T	O
cell	O
p50	O
NF-kappa	O
B	O
mRNA	O
levels	O
by	O
four-fold	O
compared	O
to	O
the	O
levels	O
obtained	O
in	O
the	O
absence	O
of	O
DM	O
.	O

Further	O
,	O
the	O
level	O
of	O
nuclear	O
proteins	O
capable	O
of	O
binding	O
to	O
the	O
NF-kappa	O
B	O
sites	O
in	O
activated	O
T	O
cells	O
increased	O
in	O
response	O
to	O
DM	O
.	O

In	O
sum	O
,	O
DM	O
regulates	O
T	O
cell	O
membrane	O
expression	O
of	O
IL-2R	O
by	O
more	O
than	O
one	O
molecular	O
mechanism	O
.	O

Function	O
and	O
activation	O
of	O
NF-kappa	O
B	O
in	O
the	O
immune	O
system	O
.	O

NF-kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

Nevertheless	O
,	O
its	O
properties	O
seem	O
to	O
be	O
most	O
extensively	O
exploited	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Among	O
these	O
properties	O
are	O
NF-kappa	O
B	O
's	O
rapid	O
posttranslational	O
activation	O
in	O
response	O
to	O
many	O
pathogenic	O
signals	O
,	O
its	O
direct	O
participation	O
in	O
cytoplasmic/nuclear	O
signaling	O
,	O
and	O
its	O
potency	O
to	O
activate	O
transcription	O
of	O
a	O
great	O
variety	O
of	O
genes	O
encoding	O
immunologically	O
relevant	O
proteins	O
.	O

In	O
vertebrates	O
,	O
five	O
distinct	O
DNA	O
binding	O
subunits	O
are	O
currently	O
known	O
which	O
might	O
extensively	O
heterodimerize	O
,	O
thereby	O
forming	O
complexes	O
with	O
distinct	O
transcriptional	O
activity	O
,	O
DNA	O
sequence	O
specificity	O
,	O
and	O
cell	O
type-	O
and	O
cell	O
stage-	O
specific	O
distribution	O
.	O

The	O
activity	O
of	O
DNA	O
binding	O
NF-kappa	O
B	O
dimers	O
is	O
tightly	O
controlled	O
by	O
accessory	O
proteins	O
called	O
I	O
kappa	O
B	O
subunits	O
of	O
which	O
there	O
are	O
also	O
five	O
different	O
species	O
currently	O
known	O
in	O
vertebrates	O
.	O

I	O
kappa	O
B	O
proteins	O
inhibit	O
DNA	O
binding	O
and	O
prevent	O
nuclear	O
uptake	O
of	O
NF-kappa	O
B	O
complexes	O
.	O

An	O
exception	O
is	O
the	O
Bcl-3	O
protein	O
which	O
in	O
addition	O
can	O
function	O
as	O
a	O
transcription	O
activating	O
subunit	O
in	O
th	O
nucleus	O
.	O

Other	O
I	O
kappa	O
B	O
proteins	O
are	O
rather	O
involved	O
in	O
terminating	O
NF-kappa	O
B	O
's	O
activity	O
in	O
the	O
nucleus	O
.	O

The	O
intracellular	O
events	O
that	O
lead	O
to	O
the	O
inactivation	O
of	O
I	O
kappa	O
B	O
,	O
i.e.	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
are	O
complex	O
.	O

They	O
involve	O
phosphorylation	O
and	O
proteolytic	O
reactions	O
and	O
seem	O
to	O
be	O
controlled	O
by	O
the	O
cells	O
'	O
redox	O
status	O
.	O

Interference	O
with	O
the	O
activation	O
or	O
activity	O
of	O
NF-kappa	O
B	O
may	O
be	O
beneficial	O
in	O
suppressing	O
toxic/septic	O
shock	O
,	O
graft-vs-host	O
reactions	O
,	O
acute	O
inflammatory	O
reactions	O
,	O
acute	O
phase	O
response	O
,	O
and	O
radiation	O
damage	O
.	O

The	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
by	O
antioxidants	O
and	O
specific	O
protease	O
inhibitors	O
may	O
provide	O
a	O
pharmacological	O
basis	O
for	O
interfering	O
with	O
these	O
acute	O
processes	O
.	O

Pentoxifylline	O
for	O
the	O
treatment	O
of	O
infection	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

Cytokine	O
dysregulation	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
has	O
been	O
documented	O
in	O
numerous	O
studies	O
and	O
has	O
been	O
cited	O
as	O
an	O
important	O
component	O
in	O
the	O
pathogenesis	O
of	O
this	O
retroviral	O
infection	O
.	O

Pharmacological	O
modification	O
of	O
cytokine	O
dysregulation	O
,	O
therefore	O
,	O
has	O
been	O
suggested	O
as	O
a	O
therapeutic	O
modality	O
for	O
HIV-1	O
infection	O
.	O

Dr.	O
Dezube	O
of	O
Beth	O
Israel	O
Hospital	O
(	O
Boston	O
)	O
concisely	O
reviews	O
the	O
state	O
of	O
our	O
knowledge	O
regarding	O
the	O
effects	O
of	O
pentoxifylline	O
on	O
expression	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
a	O
cytokine	O
known	O
to	O
influence	O
HIV-1	O
replication	O
and	O
to	O
play	O
a	O
possible	O
role	O
in	O
the	O
clinical	O
manifestations	O
of	O
advanced	O
infection	O
with	O
this	O
virus	O
.	O

Pentoxifylline	O
,	O
a	O
trisubstituted	O
xanthine	O
derivative	O
,	O
has	O
been	O
used	O
to	O
decrease	O
blood	O
viscosity	O
and	O
is	O
reasonably	O
well	O
tolerated	O
by	O
most	O
recipients	O
of	O
the	O
drug	O
.	O

Results	O
of	O
preliminary	O
studies	O
,	O
many	O
of	O
which	O
were	O
conducted	O
by	O
Dr	O
.	O

Dezube	O
,	O
suggest	O
that	O
use	O
of	O
this	O
agent	O
in	O
combination	O
with	O
antiretroviral	O
compounds	O
may	O
prove	O
useful	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
HIV-1	O
infection	O
.	O

Increased	O
interleukin	O
2	O
transcription	O
in	O
murine	O
lymphocytes	O
by	O
ciprofloxacin	O
.	O

The	O
fluoroquinolone	O
antibiotic	O
,	O
ciprofloxacin	O
(	O
cipro	O
)	O
,	O
induces	O
hyperproduction	O
of	O
interleukin	O
2	O
(	O
IL-2	O
)	O
and	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
in	O
stimulated	O
human	O
peripheral	O
blood	O
lymphocytes	O
.	O

In	O
this	O
investigation	O
an	O
enhanced	O
and	O
prolonged	O
IL-2	O
and	O
IL-2	O
mRNA	O
response	O
was	O
also	O
detected	O
in	O
both	O
stimulated	O
(	O
T	O
cell	O
mitogens	O
or	O
alloantigens	O
)	O
murine	O
splenocytes	O
and	O
in	O
the	O
stimulated	O
murine	O
T	O
cell	O
line	O
EL-4	O
in	O
the	O
presence	O
of	O
ciprofloxacin	O
(	O
5-80	O
micrograms/ml	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	B-Negation
antibiotics	I-Negation
.	O

However	O
,	O
in	O
contrast	O
to	O
human	O
lymphocytes	O
,	O
IFN-gamma	O
production	O
was	O
inhibited	O
and	O
IFN-gamma	O
mRNA	O
levels	O
were	O
unaffected	O
at	O
24	O
h	O
and	O
only	O
slightly	O
upregulated	O
at	O
48	O
and	O
72	O
h	O
of	O
culture	O
in	O
murine	O
splenocytes	O
incubated	O
with	O
cipro	O
(	O
20	O
micrograms/ml	O
)	O
.	O

EL-4	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
IL-2	O
promoter	O
and	O
enhancer	O
region	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
.	O

Analysis	O
of	O
CAT	O
activity	O
revealed	O
that	O
cipro	O
enhanced	O
IL-2	O
gene	O
induction	O
.	O

In	O
addition	O
,	O
EL-4	O
cells	O
incubated	O
with	O
ciprofloxacin	O
showed	O
an	O
early	O
peak	O
and	O
more	O
activated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT-1	O
)	O
as	O
compared	O
to	O
control	O
cells	O
without	B-Negation
antibiotics	I-Negation
.	O

Cipro	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
nuclear	I-Negation
transcription	I-Negation
factors	I-Negation
AP-1	I-Negation
or	I-Negation
NFIL-2A	I-Negation
.	O

Taken	O
together	O
,	O
cipro	O
inhibited	O
IFN-gamma	O
synthesis	O
,	O
but	O
enhanced	O
IL-2	O
production	O
in	O
murine	O
lymphocytes	O
by	O
means	O
of	O
influencing	O
NFAT-1	O
and	O
causing	O
an	O
increased	O
IL-2	O
transcription	O
.	O

Multiple	O
prolactin-responsive	O
elements	O
mediate	O
G1	O
and	O
S	O
phase	O
expression	O
of	O
the	O
interferon	O
regulatory	O
factor-1	O
gene	O
.	O

The	O
interferon	O
regulatory	O
factor-1	O
(	O
IRF-1	O
)	O
gene	O
is	O
both	O
an	O
immediate-early	O
G1	O
phase	O
gene	O
and	O
an	O
S	O
phase	O
gene	O
inducible	O
by	O
PRL	O
in	O
rat	O
Nb2	O
T	O
lymphocytes	O
.	O

To	O
understand	O
the	O
mechanism	O
by	O
which	O
PRL	O
regulates	O
the	O
biphasic	O
expression	O
of	O
IRF-1	O
,	O
we	O
cloned	O
the	O
rat	O
IRF-1	O
gene	O
and	O
functionally	O
characterized	O
the	O
IRF-1	O
promoter	O
.	O

Upon	O
transfection	O
into	O
Nb2	O
T	O
cells	O
,	O
1.7	O
kilobases	O
(	O
kb	O
)	O
of	O
IRF-1	O
5'-flanking	O
DNA	O
linked	O
to	O
a	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
mediated	O
a	O
30-fold	O
induction	O
of	O
CAT	O
enzyme	O
activity	O
in	O
response	O
to	O
24	O
h	O
of	O
PRL	O
stimulation	O
.	O

Deletion	O
mutants	O
containing	O
1.3	O
,	O
0.6	O
,	O
and	O
0.2	O
kb	O
5'-flanking	O
DNA	O
were	O
incrementally	O
less	O
transcriptionally	O
active	O
,	O
although	O
0.2	O
kb	O
still	O
mediated	O
a	O
12-fold	O
induction	O
by	O
PRL	O
.	O

The	O
sequence	O
between	O
-1.7	O
and	O
-0.2	O
kb	O
linked	O
to	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
failed	B-Negation
to	I-Negation
respond	I-Negation
to	I-Negation
PRL	I-Negation
stimulation	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
activity	I-Speculation
of	I-Speculation
upstream	I-Speculation
PRL	I-Speculation
response	I-Speculation
elements	I-Speculation
may	I-Speculation
require	I-Speculation
an	I-Speculation
interaction	I-Speculation
with	I-Speculation
promoter-proximal	I-Speculation
elements	I-Speculation
.	O

By	O
assaying	O
CAT	O
enzyme	O
activity	O
across	O
a	O
24-h	O
PRL	O
induction	O
time	O
course	O
,	O
we	O
were	O
able	O
to	O
assign	O
G1	O
vs.	O
S	O
phase	O
PRL	O
responses	O
of	O
the	O
IRF-1	O
gene	O
to	O
different	O
regions	O
of	O
the	O
IRF-1	O
5'-flanking	O
and	O
promoter	O
DNA	O
.	O

The	O
0.2-kb	O
IRF-CAT	O
construct	O
was	O
induced	O
by	O
PRL	O
stimulation	O
during	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
contrast	O
,	O
the	O
1.7-kb	O
IRF-CAT	O
construct	O
was	O
inducible	O
by	O
PRL	O
during	O
both	O
G1	O
and	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Hence	O
,	O
the	O
PRL-induced	O
biphasic	O
expression	O
of	O
the	O
IRF-1	O
gene	O
appears	O
to	O
be	O
controlled	O
by	O
separate	O
PRL-responsive	O
elements	O
:	O

elements	O
in	O
the	O
first	O
0.2	O
kb	O
of	O
the	O
IRF-1	O
promoter	O
region	O
act	O
during	O
early	O
activation	O
,	O
and	O
elements	O
between	O
0.2	O
and	O
1.7	O
kb	O
act	O
in	O
concert	O
with	O
the	O
proximal	O
0.2-kb	O
region	O
during	O
S	O
phase	O
progression	O
.	O

Description	O
and	O
functional	O
implications	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
sex-determining	O
gene	O
SRY	O
.	O

The	O
sex-determining	O
gene	O
SRY	O
was	O
screened	O
for	O
molecular	O
alteration	O
in	O
an	O
XY	O
sex-reversed	O
female	O
by	O
single-strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
technique	O
.	O

An	O
A-to-G	O
transition	O
was	O
detected	O
which	O
leads	O
to	O
an	O
exchange	O
of	O
a	O
tyrosine	O
by	O
a	O
cysteine	O
in	O
the	O
SRY	O
protein	O
.	O

The	O
affected	O
tyrosine	O
residue	O
located	O
at	O
the	O
C	O
terminus	O
of	O
the	O
DNA	O
binding	O
protein	O
is	O
evolutionarily	O
strongly	O
conserved	O
among	O
the	O
members	O
of	O
the	O
HMG	O
box	O
containing	O
proteins	O
.	O

Using	O
gel	O
shift	O
assay	O
and	O
peptide	O
synthesis	O
such	O
a	O
mutation	O
is	O
shown	O
to	O
abolish	O
the	O
SRY	O
protein	O
DNA	O
binding	O
ability	O
.	O

The	O
involvement	O
of	O
this	O
particular	O
amino	O
acid	O
in	O
the	O
binding	O
specificity	O
is	O
also	O
discussed	O
.	O

Evidence	O
for	O
a	O
trans-acting	O
activator	O
function	O
regulating	O
the	O
expression	O
of	O
the	O
human	O
CD5	O
antigen	O
.	O

Interspecies	O
somatic	O
cell	O
hybrids	O
were	O
generated	O
by	O
fusing	O
the	O
mouse	O
T-lymphoma	O
cell	O
line	O
,	O
BW5147	O
,	O
with	O
normal	O
human	O
T	O
lymphocytes	O
at	O
different	O
stages	O
of	O
differentiation	O
.	O

Thymocytes	O
,	O
activated	O
peripheral	O
T	O
lymphocytes	O
,	O
or	O
an	O
activated	O
T-cell	O
clone	O
were	O
used	O
as	O
human	O
partners	O
,	O
respectively	O
,	O
in	O
three	O
independent	O
fusions	O
.	O

Irrespective	O
of	O
the	O
human	O
cell	O
partner	O
used	O
for	O
fusion	O
,	O
a	O
certain	O
number	O
of	O
hybrids	O
lost	O
CD5	O
surface	O
expression	O
over	O
a	O
period	O
of	O
time	O
in	O
culture	O
.	O

Analysis	O
at	O
the	O
phenotype	O
and	O
genetic	O
level	O
showed	O
that	O
lack	B-Negation
of	I-Negation
CD5	I-Negation
expression	I-Negation
was	O
due	O
neither	B-Negation
to	I-Negation
segregation	I-Negation
of	I-Negation
human	I-Negation
autosome	I-Negation
11	I-Negation
,	I-Negation
on	I-Negation
which	I-Negation
the	I-Negation
CD5	I-Negation
gene	I-Negation
has	I-Negation
been	I-Negation
mapped	I-Negation
,	I-Negation
nor	I-Negation
to	I-Negation
deletion	I-Negation
of	I-Negation
the	I-Negation
CD5	I-Negation
structural	I-Negation
gene	I-Negation
.	O

Furthermore	O
,	O
loss	O
of	O
CD5	O
surface	O
expression	O
correlated	O
with	O
the	O
absence	O
of	O
specific	O
mRNA	O
.	O

Since	O
these	O
hybrids	O
preferentially	O
segregate	O
human	O
chromosomes	O
,	O
these	O
results	O
indicate	O
the	O
existence	O
of	O
a	O
non-syntenic	O
trans-active	O
locus	O
,	O
or	O
loci	O
,	O
positively	O
controlling	O
the	O
expression	O
of	O
the	O
human	O
CD5	O
gene	O
.	O

Prevalence	O
of	O
aneuploidy	O
,	O
overexpressed	O
ER	O
,	O
and	O
overexpressed	O
EGFR	O
in	O
random	O
breast	O
aspirates	O
of	O
women	O
at	O
high	O
and	O
low	O
risk	O
for	O
breast	O
cancer	O
.	O

Breast	O
tissue	O
biomarkers	O
which	O
accurately	O
predict	O
breast	O
cancer	O
development	O
within	O
a	O
10	O
year	O
period	O
in	O
high	O
risk	O
women	O
are	O
needed	O
but	O
currently	O
not	B-Negation
available	I-Negation
.	O

We	O
initiated	O
this	O
study	O
to	O
determine	O
1	O
)	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
breast	O
tissue	O
abnormalities	O
in	O
a	O
group	O
of	O
women	O
at	O
high	O
risk	O
for	O
breast	O
cancer	O
,	O
and	O
2	O
)	O
if	O
the	O
prevalence	O
of	O
biomarker	O
abnormalities	O
is	O
greater	O
in	O
high	O
risk	O
than	O
in	O
low	O
risk	O
women	O
.	O

Eligible	O
high	O
risk	O
women	O
were	O
those	O
with	O
a	O
first	O
degree	O
relative	O
with	O
breast	O
cancer	O
,	O
prior	O
breast	O
cancer	O
,	O
or	O
precancerous	O
mastopathy	O
.	O

Low	O
risk	O
women	O
were	O
those	O
without	B-Negation
these	I-Negation
or	I-Negation
other	I-Negation
major	I-Negation
identifiable	I-Negation
risk	I-Negation
factors	I-Negation
.	O

Ductal	O
cells	O
were	O
obtained	O
via	O
random	O
fine	O
needle	O
aspirations	O
and	O
cytologically	O
classified	O
.	O

Biomarkers	O
included	O
DNA	O
ploidy	O
,	O
estrogen	O
receptor	O
(	O
ER	O
)	O
,	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
.	O

The	O
prevalence	O
of	O
DNA	O
aneuploidy	O
was	O
30	O
%	O
,	O
overexpression	O
of	O
ER	O
10	O
%	O
,	O
and	O
overexpression	O
of	O
EGFR	O
35	O
%	O
,	O
in	O
the	O
206	O
high	O
risk	O
women	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
(	O
projected	O
probability	O
)	O
of	O
developing	O
breast	O
cancer	O
was	O
4.5	O
%	O
.	O

The	O
prevalence	O
of	O
aneuploidy	O
and	O
overexpressed	O
EGFR	O
was	O
significantly	O
higher	O
in	O
the	O
high	O
risk	O
women	O
than	O
in	O
the	O
25	O
low	O
risk	O
controls	O
(	O
p	O
<	O
0.002	O
)	O
,	O
whose	O
median	O
10	O
year	O
Gail	O
risk	O
was	O
0.7	O
%	O
.	O

The	O
difference	O
in	O
the	O
prevalence	O
of	O
ER	O
overexpression	O
between	O
high	O
and	O
low	O
risk	O
groups	O
was	O
not	B-Negation
statistically	I-Negation
significant	I-Negation
(	I-Negation
p	I-Negation
=	I-Negation
0.095	I-Negation
)	I-Negation
.	O

This	O
may	O
be	O
due	O
to	O
the	O
low	O
prevalence	O
of	O
overexpressed	O
ER	O
and	O
the	O
small	O
number	O
of	O
controls	O
.	O

A	O
significant	O
difference	O
was	O
noted	O
in	O
the	O
prevalence	O
of	O
one	O
or	O
more	O
abnormal	O
biomarkers	O
between	O
the	O
high	O
risk	O
and	O
low	O
risk	O
women	O
(	O
p	O
<	O
0.001	O
)	O
.	O

A	O
large	O
prospective	O
trial	O
is	O
needed	O
to	O
determine	O
if	O
one	O
or	O
more	O
of	O
these	O
biomarkers	O
,	O
is	O
predictive	O
of	O
breast	O
cancer	O
development	O
.	O

[	O
The	O
changes	O
in	O
glucocorticoid	O
receptors	O
in	O
peripheral	O
leukocytes	O
in	O
asthmatic	O
subjects	O
]	O

The	O
number	O
of	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
in	O
peripheral	O
leukocytes	O
was	O
determined	O
by	O
radioligand-binding	O
assay	O
in	O
extrinsic	O
and	O
intrinsic	O
asthmatics	O
.	O

Their	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
.	O

The	O
results	O
showed	O
that	O
the	O
average	O
number	O
of	O
GCR	O
in	O
asthmatics	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
there	O
was	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	O
and	O
the	O
course	O
of	O
asthma	O
.	O

Besides	O
,	O
there	O
was	O
also	O
a	O
linear	O
correlation	O
between	O
the	O
number	O
of	O
GCR	O
and	O
the	O
age	O
of	O
the	O
initial	O
attack	O
of	O
asthma	O
.	O

No	B-Negation
difference	I-Negation
in	I-Negation
plasma	I-Negation
cortisol	I-Negation
level	I-Negation
was	I-Negation
found	I-Negation
between	I-Negation
asthmatics	I-Negation
and	I-Negation
healthy	I-Negation
subjects	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
there	O
is	O
no	O
primary	O
and	O
general	O
impairment	O
of	O
glucocorticoid	O
metabolism	O
in	O
the	O
asthmatics	O
,	O
but	O
the	O
number	O
of	O
GCR	O
in	O
the	O
asthmatics	O
is	O
lower	O
than	O
that	O
in	O
healthy	O
controls	O
.	O

The	O
decrease	O
of	O
the	O
number	O
of	O
GCR	O
in	O
asthmatics	O
,	O
we	O
think	O
,	O
is	O
related	O
to	O
heredity	O
and	O
repeated	O
attacks	O
of	O
asthma	O
.	O

Alternate	O
immune	O
system	O
targets	O
for	O
TCDD	O
:	O
lymphocyte	O
stem	O
cells	O
and	O
extrathymic	O
T-cell	O
development	O
.	O

We	O
here	O
summarize	O
evidence	O
that	O
thymic	O
atrophy	O
induced	O
by	O
2,3,7,8-tetrachlorodibenzo-p-dioxin	O
(	O
TCDD	O
)	O
can	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
damage	O
to	O
extrathymic	O
T-cell	O
precursors	O
in	O
bone	O
marrow	O
and	O
fetal	O
liver	O
.	O

This	O
atrophy	O
induction	O
does	O
not	B-Negation
involve	I-Negation
apoptotic	I-Negation
mechanisms	I-Negation
in	I-Negation
thymocytes	I-Negation
affected	I-Negation
by	I-Negation
the	I-Negation
bcl-2	I-Negation
proto-oncogene	I-Negation
.	O

TCDD	O
mediates	O
atrophy	O
induction	O
through	O
its	O
specific	O
receptor	O
(	O
the	O
AhR	O
)	O
and	O
not	B-Negation
through	I-Negation
effects	I-Negation
on	I-Negation
the	I-Negation
estrogen	I-Negation
receptor	I-Negation
.	O

Both	O
TCDD	O
and	O
estradiol	O
induce	O
extrathymic	O
T-cell	O
differentiation	O
in	O
the	O
liver	O
.	O

These	O
extrathymic	O
T-cell	O
populations	O
include	O
cells	O
expressing	O
elevated	O
levels	O
of	O
V	O
beta	O
T-cell	O
receptors	O
that	O
are	O
normally	O
deleted	O
in	O
thymic	O
development	O
.	O

Alteration	O
of	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membrane	O
by	O
glucocorticoids	O
and	O
the	O
influence	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
.	O

High-dose	O
pulse	O
glucocorticoid	O
therapy	O
has	O
been	O
used	O
successfully	O
in	O
the	O
clinic	O
in	O
severe	O
pathological	O
conditions	O
for	O
about	O
20	O
years	O
.	O

The	O
mode	O
of	O
glucocorticoid	O
action	O
after	O
administration	O
of	O
such	O
megadoses	O
is	O
inexplicable	O
up	O
to	O
now	O
.	O

It	O
is	O
supposed	O
that	O
some	O
effects	O
may	O
be	O
due	O
to	O
membrane	O
alterations	O
.	O

In	O
the	O
present	O
in-vitro	O
experiments	O
the	O
effect	O
of	O
dexamethasone	O
,	O
of	O
further	O
glucocorticoids	O
,	O
and	O
of	O
the	O
glucocorticoid	O
receptor	O
antagonist	O
RU	O
486	O
,	O
on	O
structural	O
order	O
of	O
human	O
erythrocyte	O
ghost	O
membranes	O
was	O
investigated	O
by	O
determining	O
the	O
steady-state	O
fluorescence	O
anisotropy	O
of	O
diphenylhexatriene	O
(	O
DPH	O
)	O
.	O

Dexamethasone	O
was	O
found	O
to	O
induce	O
a	O
significant	O
decrease	O
in	O
membrane	O
structural	O
order	O
at	O
concentrations	O
of	O
about	O
10	O
(	O
-6	O
)	O
M	O
in	O
a	O
concentration-dependent	O
manner	O
.	O

We	O
found	O
a	O
correlation	O
between	O
the	O
uptake	O
of	O
dexamethasone	O
by	O
the	O
ghost	O
membranes	O
and	O
the	O
decrease	O
in	O
the	O
structural	O
order	O
.	O

The	O
other	O
glucocorticoids	O
tested	O
,	O
methylprednisolone	O
and	O
corticosterone	O
,	O
were	O
also	O
effective	O
at	O
concentrations	O
of	O
10	O
(	O
-5	O
)	O
M	O
or	O
greater	O
.	O

We	O
observed	O
no	B-Negation
change	I-Negation
in	I-Negation
membrane	I-Negation
structural	I-Negation
order	I-Negation
with	I-Negation
RU	I-Negation
486	I-Negation
up	I-Negation
to	I-Negation
a	I-Negation
concentration	I-Negation
of	I-Negation
10	I-Negation
(	I-Negation
-4	I-Negation
)	I-Negation
M	I-Negation
.	O

However	O
,	O
simultaneous	O
incubation	O
of	O
RU	O
486	O
with	O
dexamethasone	O
caused	O
a	O
distinct	O
interference	O
of	O
RU	O
486	O
with	O
dexamethasone	O
.	O

Thus	O
,	O
the	O
glucocorticoid-induced	O
membrane	O
perturbation	O
,	O
the	O
possibility	O
to	O
inhibit	O
it	O
by	O
RU	O
486	O
,	O
and	O
the	O
inactivity	O
of	O
the	O
structurally	O
related	O
progesterone	O
,	O
refer	O
to	O
relatively	O
specific	O
binding	O
sites	O
for	O
the	O
glucocorticoids	O
in	O
the	O
membrane	O
of	O
erythrocyte	O
ghosts	O
.	O

Cloning	O
and	O
characterization	O
of	O
NF-ATc	O
and	O
NF-ATp	O
:	O
the	O
cytoplasmic	O
components	O
of	O
NF-AT	O
.	O

Present	O
evidence	O
indicates	O
a	O
pathway	O
of	O
signal	O
transmission	O
in	O
T	O
cells	O
that	O
is	O
outlined	O
in	O
figure	O
1	O
.	O

The	O
elevation	O
in	O
intracellular	O
calcium	O
that	O
is	O
induced	O
by	O
interactions	O
at	O
the	O
antigen	O
receptor	O
leads	O
to	O
the	O
activation	O
of	O
the	O
calcium-dependent	O
phosphatase	O
calcineurin	O
.	O

This	O
in	O
turn	O
leads	O
to	O
the	O
nuclear	O
association	O
of	O
the	O
cytosolic	O
component	O
of	O
NF-ATc	O
.	O

The	O
activation	O
of	O
calcineurin	O
and	O
the	O
nuclear	O
import	O
of	O
NF-ATc	O
can	O
both	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
or	O
FK506	O
in	O
complex	O
with	O
their	O
respective	O
immunophilins	O
.	O

Once	O
in	O
the	O
nucleus	O
,	O
NF-ATc	O
interacts	O
with	O
NF-ATn	O
to	O
form	O
an	O
active	O
transcriptional	O
complex	O
.	O

NF-ATn	O
is	O
a	O
ubiquitous	O
protein	O
,	O
can	O
be	O
synthesized	O
in	O
response	O
to	O
PMA	O
,	O
and	O
has	O
many	O
similarities	O
to	O
AP-1	O
.	O

The	O
mechanism	O
by	O
which	O
NF-ATc	O
enters	O
the	O
nucleus	O
is	O
unknown	O
,	O
and	O
although	O
it	B-Speculation
appears	I-Speculation
to	I-Speculation
require	I-Speculation
calcineurin	I-Speculation
,	O
NF-ATc	B-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
shown	I-Negation
to	I-Negation
be	I-Negation
an	I-Negation
in	I-Negation
vivo	I-Negation
substrate	I-Negation
of	I-Negation
calcineurin	I-Negation
.	O

Alternative	O
mechanisms	O
include	O
the	O
possibility	O
that	O
NF-ATc	O
operates	O
on	O
some	O
cytoplasmic	O
anchor	O
or	O
that	O
other	O
proteins	O
that	O
are	O
controlled	O
by	O
calcineurin	O
carry	O
out	O
the	O
nuclear	O
import	O
of	O
NF-ATc	O
.	O

Although	O
NF-ATp	O
copurifies	O
with	O
NF-ATc	O
,	O
there	O
is	O
as	O
yet	O
no	B-Negation
understanding	I-Negation
of	I-Negation
how	I-Negation
NF-ATp	I-Negation
is	I-Negation
functioning	I-Negation
in	I-Negation
vivo	I-Negation
.	O

Now	O
that	O
these	O
proteins	O
are	O
purified	O
and	O
cloned	O
,	O
the	O
major	O
goals	O
will	O
be	O
to	O
understand	O
their	O
role	O
and	O
the	O
roles	O
of	O
other	O
family	O
members	O
in	O
thymic	O
development	O
.	O

Changes	O
in	O
triiodothyronine	O
(	O
T3	O
)	O
mononuclear	O
leukocyte	O
receptor	O
kinetics	O
after	O
T3	O
administration	O
and	O
multiple	O
cold-air	O
exposures	O
.	O

Repeated	O
cold-air	O
exposures	O
increase	O
human	O
triiodothyronine	O
(	O
T3	O
)	O
plasma	O
clearance	O
rates	O
.	O

To	O
study	O
the	O
response	O
of	O
the	O
nuclear	O
T3	O
receptor	O
(	O
NT3R	O
)	O
in	O
this	O
condition	O
,	O
binding	O
characteristics	O
were	O
analyzed	O
in	O
human	O
mononuclear	O
leukocytes	O
(	O
MNL	O
)	O
.	O

In	O
addition	O
,	O
we	O
supplemented	O
one	O
group	O
of	O
individuals	O
with	O
a	O
daily	O
oral	O
replacement	O
dose	O
of	O
T3	O
to	O
isolate	O
the	O
influence	O
of	O
serum	O
thyroxine	O
(	O
T4	O
)	O
and	O
thyrotropin	O
(	O
TSH	O
)	O
levels	O
on	O
receptor	O
kinetics	O
.	O

The	O
subjects	O
were	O
exposed	O
to	O
cold	O
air	O
(	O
4	O
degrees	O
C	O
)	O
twice/d	O
,	O
30	O
min/exposure	O
,	O
for	O
a	O
total	O
of	O
80	O
exposures	O
.	O

The	O
T3-	O
subjects	O
received	O
placebo	O
[	O
n	O
=	O
8	O
]	O
and	O
the	O
T3+	O
subjects	O
received	O
T3	O
(	O
30	O
micrograms/d	O
)	O
[	O
n	O
=	O
8	O
]	O
in	O
a	O
double-blind	O
fashion	O
.	O

Mononuclear	O
leukocytes	O
were	O
isolated	O
from	O
peripheral	O
blood	O
before	O
the	O
cold	O
exposure	O
and	O
drug	O
regimen	O
began	O
,	O
and	O
then	O
after	O
every	O
20	O
exposures	O
.	O

The	O
dissociation	O
constant	O
(	O
Kd	O
)	O
and	O
maximum	O
binding	O
capacity	O
(	O
MBC	O
)	O
of	O
the	O
NT3R	O
values	O
were	O
log	O
transformed	O
to	O
minimize	O
between-subject	O
variability	O
.	O

In	O
the	O
T3+	O
group	O
,	O
serum	O
total	O
thyroxine	O
(	O
TT4	O
)	O
,	O
free	O
T4	O
(	O
FT4	O
)	O
,	O
and	O
TSH	O
were	O
approx	O
50	O
%	O
lower	O
than	O
both	O
basal	O
and	O
T3-values	O
.	O

The	O
log10Kd	O
increased	O
0.304	O
	O
0.139	O
(	O
p	O
<	O
0.04	O
)	O
and	O
the	O
log10MBC	O
increased	O
0.49	O
	O
0.10	O
(	O
p	O
<	O
0.001	O
)	O
in	O
the	O
T3+	O
subjects	O
compared	O
to	O
baseline	O
.	O

This	O
change	O
in	O
MBC	O
represents	O
a	O
311	O
%	O
increase	O
in	O
the	O
MBC	O
over	O
baseline	O
and	O
a	O
fivefold	O
increase	O
over	O
placebo-treated	O
subjects	O
.	O

The	O
T3-	O
group	O
showed	O
no	B-Negation
change	I-Negation
in	I-Negation
MBC	I-Negation
over	I-Negation
the	I-Negation
study	I-Negation
.	O

These	O
results	O
describe	O
for	O
the	O
first	O
time	O
the	O
rapid	O
modulation	O
of	O
the	O
NT3R	O
in	O
response	O
to	O
the	O
combined	O
influence	O
of	O
cold	O
exposure	O
and	O
reduced	O
circulating	O
T4	O
and	O
TSH	O
.	O

BCL-6	O
and	O
the	O
molecular	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O

The	O
results	O
presented	O
identify	O
the	O
first	O
genetic	O
lesion	O
associated	O
with	O
DLCL	O
,	O
the	O
most	O
clinically	O
relevant	O
form	O
of	O
NHL	O
.	O

Although	O
no	B-Negation
proof	I-Negation
yet	I-Negation
exists	I-Negation
of	I-Negation
a	I-Negation
role	I-Negation
for	I-Negation
these	I-Negation
lesions	I-Negation
in	I-Negation
DLCL	I-Negation
pathogenesis	I-Negation
,	O
the	O
feature	O
of	O
the	O
BCL-6	O
gene	O
product	O
,	O
its	O
specific	O
pattern	O
of	O
expression	O
in	O
B	O
cells	O
,	O
and	O
the	O
clustering	O
of	O
lesions	O
disrupting	O
its	O
regulatory	O
domain	O
strongly	O
suggest	B-Speculation
that	I-Speculation
deregulation	I-Speculation
of	I-Speculation
BCL-6	I-Speculation
expression	I-Speculation
may	I-Speculation
contribute	I-Speculation
to	I-Speculation
DLCL	I-Speculation
development	I-Speculation
.	O

A	O
more	O
precise	O
definition	O
of	O
the	O
role	O
of	O
BCL-6	O
in	O
normal	O
and	O
neoplastic	O
B-cell	O
development	O
is	O
the	O
goal	O
of	O
ongoing	O
study	O
of	O
transgenic	O
mice	O
engineered	O
either	O
to	O
express	O
BCL-6	O
under	O
heterologous	O
promoters	O
or	O
lacking	B-Negation
BCL-6	I-Negation
function	I-Negation
due	O
to	O
targeted	O
deletions	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
the	O
understanding	O
of	O
DLCL	O
pathogenesis	O
,	O
the	O
identification	O
of	O
BCL-6	O
lesions	O
may	O
have	O
relevant	O
clinical	O
implications	O
.	O

DLCL	O
represent	O
a	O
heterogeneous	O
group	O
of	O
neoplasms	O
which	O
are	O
treated	O
homogeneously	O
despite	O
the	O
fact	O
that	O
only	O
50	O
%	O
of	O
patients	O
experience	O
long-term	O
disease-free	O
survival	O
(	O
Schneider	O
et	O
al.	O
1990	O
)	O
.	O

The	O
fact	O
that	O
BCL-6	O
rearrangements	O
identify	O
biologically	O
and	O
clinically	O
distinct	O
subsets	O
of	O
DLCL	O
suggests	O
that	O
these	O
lesions	O
may	O
be	O
useful	O
as	O
markers	O
in	O
selection	O
of	O
differential	O
therapeutic	O
strategies	O
based	O
on	O
different	O
risk	O
groups	O
.	O

Furthermore	O
,	O
the	O
BCL-6	O
rearrangements	O
can	O
be	O
used	O
to	O
identify	O
and	O
monitor	O
the	O
malignant	O
clone	O
with	O
sensitive	O
PCR-based	O
techniques	O
.	O

Since	O
clinical	O
remission	O
has	O
been	O
observed	O
in	O
a	O
significant	O
fraction	O
of	O
DLCL	O
cases	O
,	O
these	O
markers	O
may	O
serve	O
as	O
critical	O
tools	O
for	O
sensitive	O
monitoring	O
of	O
minimal	O
residual	O
disease	O
and	O
early	O
diagnosis	O
of	O
relapse	O
(	O
Gribben	O
et	O
al.	O
1993	O
)	O
.	O

Selective	O
effects	O
of	O
DNA	O
damaging	O
agents	O
on	O
HIV	O
long	O
terminal	O
repeat	O
activation	O
and	O
virus	O
replication	O
in	O
vitro	O
.	O

Much	O
attention	O
has	O
recently	O
focused	O
on	O
the	O
observation	O
that	O
UV	O
light	O
can	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Although	O
the	O
mechanism	O
of	O
LTR	O
activation	O
remains	O
obscure	O
,	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	O
that	O
it	O
is	O
a	O
result	O
of	O
activation	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
(	O
s	O
)	O
following	O
signaling	O
events	O
related	O
to	O
generalized	O
DNA	O
damage	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
data	O
demonstrating	O
that	O
HIV	O
LTR	O
activation	O
is	O
not	B-Negation
a	I-Negation
general	I-Negation
consequence	I-Negation
of	I-Negation
cellular	I-Negation
DNA	I-Negation
damage	I-Negation
,	O
but	O
rather	O
a	O
process	O
unique	O
to	O
specific	O
genotoxic	O
stimuli	O
,	O
and	O
that	O
it	O
does	O
not	O
necessarily	O
depend	O
on	O
activation	O
of	O
NF-kappa	O
B	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
several	O
of	O
these	O
agents	O
can	O
significantly	O
increase	O
HIV	O
replication	O
and	O
accelerate	O
CD4-positive	O
lymphocyte	O
cytotoxicity	O
in	O
vitro	O
.	O

These	O
findings	O
,	O
therefore	O
,	O
could	O
have	O
clinical	O
significance	O
to	O
AIDS	O
patients	O
with	O
malignancies	O
who	O
are	O
undergoing	O
radiotherapy	O
and	O
chemotherapy	O
.	O

Characterization	O
and	O
purification	O
of	O
a	O
protein	O
kinase	O
C	O
substrate	O
in	O
human	O
B	O
cells	O
.	O

Identification	O
as	O
lymphocyte-specific	O
protein	O
1	O
(	O
LSP1	O
)	O
.	O

Incubation	O
of	O
B-chronic	O
lymphocytic	O
leukemia	O
(	O
B-CLL	O
)	O
cells	O
with	O
phorbol	O
esters	O
resulted	O
in	O
the	O
phosphorylation	O
of	O
two	O
major	O
PKC	O
substrates	O
,	O
MARCKS	O
(	O
myristoylated	O
,	O
alanine-rich	O
C	O
kinase	O
substrate	O
)	O
and	O
MRP	O
(	O
MARCKS-related	O
protein	O
)	O
,	O
and	O
of	O
a	O
third	O
protein	O
,	O
with	O
an	O
apparent	O
m.w.	O
of	O
60,000	O
that	O
was	O
the	O
most	O
prominent	O
protein	O
kinase	O
C	O
substrate	O
in	O
these	O
cells	O
.	O

p60	O
phosphorylation	O
was	O
time	O
and	O
PMA	O
dose	O
dependent	O
,	O
and	O
was	O
induced	O
by	O
cell-permeable	O
diacylglycerol	O
,	O
but	O
not	B-Negation
by	I-Negation
inactive	I-Negation
phorbol	I-Negation
esters	I-Negation
.	O

Two-dimensional	O
electrophoretic	O
analysis	O
of	O
the	O
protein	O
phosphorylation	O
pattern	O
from	O
the	O
B	O
cell	O
line	O
CESS	O
demonstrated	O
the	O
identity	O
between	O
the	O
p60	O
protein	O
expressed	O
in	O
this	O
cell	O
line	O
and	O
that	O
expressed	O
in	O
B-CLL	O
cells	O
.	O

p60	O
was	O
purified	O
from	O
CESS	O
cells	O
and	O
peptide	O
microsequencing	O
of	O
this	O
protein	O
revealed	O
that	O
it	O
was	O
lymphocyte-specific	O
protein	O
1	O
(	O
LSP1	O
)	O
,	O
that	O
is	O
here	O
characterized	O
as	O
the	O
most	O
prominent	O
protein	O
kinase	O
C	O
substrate	O
in	O
B	O
cells	O
.	O

Differential	O
regulation	O
of	O
IL-6	O
gene	O
transcription	O
and	O
expression	O
by	O
IL-4	O
and	O
IL-10	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL-4	O
and	O
IL-10	O
inhibit	O
the	O
cytokine	O
production	O
and	O
mRNA	O
expression	O
by	O
monocytes/macrophages	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
of	O
the	O
inhibitory	O
effect	O
on	O
transcriptional	O
or	O
post-transcriptional	O
regulation	O
of	O
IL-6	O
gene	O
expression	O
by	O
IL-4	O
and	O
IL-10	O
,	O
we	O
studied	O
IL-6	O
production	O
,	O
expression	O
level	O
of	O
IL-6	O
mRNA	O
,	O
IL-6	O
promoter	O
activity	O
,	O
transcriptional	O
activity	O
of	O
NF-kappaB	O
and	O
NF-IL-6	O
,	O
and	O
IL-6	O
mRNA	O
stability	O
in	O
human	O
monocytic	O
cell	O
lines	O
,	O
THP-1	O
and	O
U937	O
,	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
in	O
the	O
absence	O
or	O
the	O
presence	O
of	O
IL-4	O
or	O
IL-10	O
.	O

Both	O
IL-4	O
and	O
IL-10	O
were	O
seen	O
to	O
inhibit	O
IL-6	O
production	O
and	O
the	O
expression	O
of	O
IL-6	O
mRNA	O
in	O
both	O
monocytic	O
cell	O
lines	O
studied	O
.	O

In	O
chloramphenicol	O
acetyltransferase	O
assays	O
,	O
utilizing	O
the	O
transient	O
transfection	O
of	O
a	O
chloramphenicol	O
acetyltransferase	O
reporter	O
plasmid	O
containing	O
the	O
IL-6	O
gene	O
promoter	O
,	O
IL-4	O
,	O
but	O
not	B-Negation
IL-10	I-Negation
,	O
suppressed	O
the	O
transcriptional	O
activity	O
of	O
the	O
IL-6	O
gene	O
promoter	O
stimulated	O
by	O
PMA	O
and	O
LPS	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
IL-4	O
,	O
but	O
not	B-Negation
IL-10	I-Negation
,	O
inhibited	O
nuclear	O
NF-kappaB	O
activity	O
,	O
and	O
that	O
IL-4	O
and	O
IL-10	O
did	O
not	B-Negation
affect	I-Negation
NF-IL-6	I-Negation
activity	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
IL-10	O
enhanced	O
the	O
degradation	O
of	O
IL-6	O
mRNA	O
in	O
a	O
mRNA	O
stability	O
assay	O
.	O

These	O
results	O
suggest	O
that	O
IL-4	O
may	O
inhibit	O
the	O
transcription	O
of	O
the	O
IL-6	O
gene	O
by	O
affecting	O
NF-kappaB	O
binding	O
activity	O
,	O
while	O
IL-10	O
may	O
inhibit	O
the	O
IL-6	O
mRNA	O
levels	O
post-transcriptionally	O
,	O
without	O
suppressing	O
promoter	O
activity	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
IL-4	O
and	O
IL-10	O
inhibit	O
IL-6	O
production	O
by	O
different	O
mechanisms	O
in	O
human	O
monocytic	O
cell	O
lines	O
.	O

IL-13	O
induces	O
phosphorylation	O
and	O
activation	O
of	O
JAK2	O
Janus	O
kinase	O
in	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
:	O

similarities	O
between	O
IL-4	O
and	O
IL-13	O
signaling	O
.	O

We	O
have	O
recently	O
reported	O
that	O
IL-13R	O
may	O
share	O
a	O
component	O
with	O
IL-4R	O
.	O

Here	O
we	O
report	O
that	O
both	O
IL-4	O
and	O
IL-13	O
share	O
signaling	O
events	O
in	O
human	O
colon	O
carcinoma	O
cell	O
lines	O
(	O
HT-29	O
and	O
WiDr	O
)	O
.	O

IL-13	O
caused	O
rapid	O
phosphorylation	O
of	O
the	O
three	O
out	O
of	O
four	O
members	O
of	O
the	O
known	O
Janus	O
family	O
of	O
kinases	O
(	O
JAKs	O
)	O
.	O

We	O
show	O
that	O
JAK2	O
kinase	O
is	O
rapidly	O
phosphorylated	O
and	O
activated	O
in	O
response	O
to	O
IL-13	O
.	O

Within	O
1	O
min	O
of	O
activation	O
,	O
JAK2	O
was	O
phosphorylated	O
,	O
and	O
peaked	O
in	O
10	O
min	O
.	O

In	O
addition	O
,	O
IL-13	O
phosphorylated	O
insulin	O
response	O
substrate-1	O
,	O
IL-4R	O
p140	O
,	O
JAK1	O
,	O
and	O
Tyk2	O
,	O
but	O
not	B-Negation
JAK3	I-Negation
kinase	I-Negation
.	O

IL-4	O
also	O
stimulated	O
all	O
three	O
kinases	O
and	O
substrates	O
,	O
but	O
unlike	O
in	O
immune	O
cells	O
,	O
IL-4	O
did	O
not	B-Negation
involve	I-Negation
JAK3	I-Negation
activation	I-Negation
for	I-Negation
its	I-Negation
signaling	I-Negation
in	I-Negation
colon	I-Negation
cancer	I-Negation
cell	I-Negation
lines	I-Negation
.	O

Furthermore	O
,	O
JAK2	O
associated	O
with	O
the	O
IL-4R	O
p140	O
before	O
and	O
after	O
stimulation	O
with	O
IL-13	O
.	O

Both	O
IL-13	O
and	O
IL-4	O
induced	O
phosphorylation	O
of	O
IL-4	O
STAT	O
(	O
STAT6	O
)	O
but	O
not	B-Negation
STAT1	I-Negation
,	I-Negation
STAT3	I-Negation
,	I-Negation
or	I-Negation
STAT5	I-Negation
.	O

125I-IL-13	O
did	O
not	B-Negation
bind	I-Negation
to	I-Negation
colon	I-Negation
cancer	I-Negation
cell	I-Negation
lines	I-Negation
,	O
but	O
unlabeled	O
IL-13	O
competed	O
for	O
the	O
binding	O
of	O
125I-IL-4	O
.	O

Our	O
data	O
suggest	O
that	O
IL-13	O
utilizes	O
IL-4R	O
and	O
its	O
signaling	O
pathway	O
,	O
and	O
JAK2	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
IL-4R	O
and	O
IL-13R	O
in	O
colon	O
cancer	O
cells	O
.	O

Effects	O
of	O
interleukin-10	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
responses	O
to	O
Cryptococcus	O
neoformans	O
,	O
Candida	O
albicans	O
,	O
and	O
lipopolysaccharide	O
.	O

Deactivation	O
of	O
mononuclear	O
phagocytes	O
is	O
critical	O
to	O
limit	O
the	O
inflammatory	O
response	O
but	O
can	O
be	O
detrimental	O
in	O
the	O
face	O
of	O
progressive	O
infection	O
.	O

We	O
compared	O
the	O
effects	O
of	O
the	O
deactivating	O
cytokine	O
interleukin	O
10	O
(	O
IL-10	O
)	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cell	O
(	O
PBMC	O
)	O
responses	O
to	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
Cryptococcus	O
neoformans	O
,	O
and	O
Candida	O
albicans	O
.	O

IL-10	O
effected	O
dose-dependent	O
inhibition	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
release	O
in	O
PBMC	O
stimulated	O
by	O
LPS	O
and	O
C.	O
neoformans	O
,	O
with	O
significant	O
inhibition	O
seen	O
with	O
0.1	O
U/ml	O
and	O
greater	O
than	O
90	O
%	O
inhibition	O
noted	O
with	O
10	O
U/ml	O
.	O

In	O
contrast	O
,	O
even	O
at	O
doses	O
as	O
high	O
as	O
100	O
U/ml	O
,	O
IL-10	O
inhibited	O
TNF-alpha	O
release	O
in	O
response	O
to	O
C.	O
albicans	O
by	O
only	O
50	O
%	O
.	O

IL-10	O
profoundly	O
inhibited	O
release	O
of	O
IL-1beta	O
from	O
PBMC	O
stimulated	O
by	O
all	O
three	O
stimuli	O
.	O

TNF-alpha	O
mRNA	O
and	O
release	O
was	O
inhibited	O
even	O
if	O
IL-10	O
was	O
added	O
up	O
to	O
8	O
h	O
after	O
cryptococcal	O
stimulation	O
.	O

In	O
contrast	O
,	O
inhibition	O
of	O
IL-1	O
beta	O
mRNA	O
was	O
of	O
lesser	O
magnitude	O
and	O
occurred	O
only	O
when	O
IL-10	O
was	O
added	O
within	O
2	O
h	O
of	O
cryptococcal	O
stimulation	O
.	O

IL-10	O
inhibited	O
translocation	O
of	O
NF-kappaB	O
in	O
response	O
to	O
LPS	O
but	O
not	B-Negation
the	I-Negation
fungal	I-Negation
stimuli	I-Negation
.	O

All	O
three	O
stimuli	O
induced	O
IL-10	O
production	O
in	O
PBMC	O
,	O
although	O
over	O
10-fold	O
less	O
IL-10	O
was	O
released	O
in	O
response	O
to	O
C.	O
neoformans	O
compared	O
with	O
LPS	O
and	O
C.	O
albicans	O
.	O

Thus	O
,	O
while	O
IL-10	O
has	O
deactivating	O
effects	O
on	O
PBMC	O
responses	O
to	O
all	O
three	O
stimuli	O
,	O
disparate	O
stimulus-	O
and	O
response-specific	O
patterns	O
of	O
deactivation	O
are	O
seen	O
.	O

Inhibition	O
by	O
IL-10	O
of	O
proinflammatory	O
cytokine	O
release	O
appears	O
to	O
occur	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
for	O
TNF-alpha	O
and	O
both	O
transcriptionally	O
and	O
posttranscriptionally	O
for	O
IL-1beta	O
.	O

Activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
in	O
a	O
cyclosporin	O
A-resistant	O
pathway	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
the	O
immunosuppressive	O
drug	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
the	O
inactivation	O
of	O
the	O
Ca2+/calmodulin-dependent	O
serine-threonine	O
phosphatase	O
calcineurin	O
by	O
the	O
drug-immunophilin	O
complex	O
.	O

Inactive	O
calcineurin	O
is	O
unable	B-Negation
to	I-Negation
activate	I-Negation
the	I-Negation
nuclear	I-Negation
factor	I-Negation
of	I-Negation
activated	I-Negation
T	I-Negation
cells	I-Negation
(	I-Negation
NFAT	I-Negation
)	I-Negation
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
.	O

IL-2	O
production	O
by	O
CsA-treated	O
cells	O
is	O
therefore	O
dramatically	O
reduced	O
.	O

We	O
demonstrate	O
here	O
,	O
however	O
,	O
that	O
NFAT	O
can	O
be	O
activated	O
,	O
and	O
significant	O
levels	O
of	O
IL-2	O
can	O
be	O
produced	O
by	O
the	O
CsA-resistant	O
CD28-signaling	O
pathway	O
.	O

In	O
transient	O
transfection	O
assays	O
,	O
both	O
multicopy	O
NFAT-	O
and	O
IL-2	O
promoter-beta-galactosidase	O
reporter	O
gene	O
constructs	O
could	O
be	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
/alpha-CD28	O
stimulation	O
,	O
and	O
this	O
activation	O
was	O
resistant	O
to	O
CsA	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
the	O
induction	O
of	O
a	O
CsA-resistant	O
NFAT	O
complex	O
in	O
the	O
nuclear	O
extracts	O
of	O
peripheral	O
blood	O
T	O
cells	O
stimulated	O
with	O
PMA	O
plus	O
alphaCD28	O
.	O

Peripheral	O
blood	O
T	O
cells	O
stimulated	O
with	O
PMA/alphaCD28	O
produced	O
IL-2	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
NFAT	O
can	O
be	O
activated	O
and	O
IL-2	O
can	O
be	O
produced	O
in	O
a	O
calcineurin	O
independent	O
manner	O
.	O

Age-related	O
decreases	O
in	O
IL-2	O
production	O
by	O
human	O
T	O
cells	O
are	O
associated	O
with	O
impaired	O
activation	O
of	O
nuclear	O
transcriptional	O
factors	O
AP-1	O
and	O
NF-AT	O
.	O

Although	O
transcriptional	O
factors	O
AP-1	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
are	O
important	O
for	O
the	O
normal	O
induction	O
of	O
IL-2	O
,	O
it	O
is	O
unknown	O
if	O
the	O
age-related	O
decline	O
in	O
IL-2	O
production	O
by	O
activated	O
human	O
T	O
cells	O
may	O
be	O
associated	O
with	O
aberrancies	O
in	O
transcriptional	O
regulatory	O
proteins	O
.	O

In	O
the	O
current	O
studies	O
,	O
IL-2	O
production	O
by	O
T	O
cells	O
from	O
elderly	O
(	O
mean	O
78	O
years	O
)	O
and	O
young	O
(	O
mean	O
37	O
years	O
)	O
humans	O
was	O
measured	O
in	O
cultures	O
stimulated	O
with	O
PHA	O
,	O
PHA	O
plus	O
PMA	O
,	O
crosslinked	O
anti-CD3	O
mAB	O
OKT3	O
plus	O
PMA	O
,	O
or	O
PMA	O
plus	O
ionomycin	O
.	O

Substantial	O
decreases	O
of	O
IL-2	O
production	O
were	O
observed	O
for	O
cell	O
cultures	O
from	O
7	O
of	O
12	O
elderly	O
individuals	O
in	O
response	O
to	O
the	O
different	O
stimuli	O
,	O
whereas	O
the	O
levels	O
of	O
IL-2	O
produced	O
by	O
stimulated	O
T	O
cells	O
from	O
other	O
elderly	O
individuals	O
were	O
equivalent	O
to	O
those	O
observed	O
for	O
stimulated	O
T	O
cells	O
of	O
young	O
subjects	O
.	O

Analyses	O
of	O
nuclear	O
extracts	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
showed	O
that	O
decreased	O
IL-2	O
production	O
by	O
stimulated	O
T	O
cells	O
of	O
elderly	O
individuals	O
was	O
closely	O
associated	O
with	O
impairments	O
in	O
the	O
activation	O
of	O
both	O
AP-1	O
and	O
NF-AT	O
.	O

By	O
contrast	O
,	O
T	O
cells	O
from	O
elderly	O
subjects	O
with	O
normal	O
levels	O
of	O
IL-2	O
production	O
exhibited	O
normal	O
activation	O
of	O
AP-1	O
and	O
NF-AT	O
.	O

In	O
addition	O
,	O
the	O
results	O
of	O
competition	O
experiments	O
analyzing	O
the	O
normal	O
components	O
of	O
NF-AT	O
showed	O
that	O
the	O
age-related	O
reductions	O
in	O
stimulus-dependent	O
NF-AT	O
complexes	O
corresponded	O
to	O
the	O
slow	O
migrating	O
complexes	O
that	O
were	O
composed	O
of	O
c-Fos/c-Jun	O
AP-1	O
.	O

The	O
resting	O
and	O
stimulated	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
reduced	O
in	O
T	O
cells	O
from	O
certain	O
elderly	O
individuals	O
;	O

however	O
,	O
alterations	O
of	O
NF	O
kappa	O
B	O
did	O
not	B-Negation
correlate	I-Negation
with	I-Negation
changes	I-Negation
in	I-Negation
IL-2	I-Negation
expression	I-Negation
.	O

Thus	O
,	O
these	O
results	O
show	O
that	O
age-related	O
impairments	O
in	O
the	O
activation	O
of	O
AP-1	O
and	O
NF-AT	O
are	O
closely	O
associated	O
with	O
decreased	O
expression	O
of	O
IL-2	O
and	O
further	O
suggest	O
that	O
aberrancies	O
in	O
the	O
signaling	O
pathways	O
important	O
for	O
the	O
induction	O
of	O
transcriptionally	O
active	O
c-Fos/c-Jun	O
AP-1	O
may	O
contribute	O
to	O
the	O
impaired	O
activation	O
of	O
NF-AT	O
.	O

Transcription	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
--	O
basic	O
research	O
and	O
clinical	O
perspectives	O
for	O
gastroenterology	O
.	O

Tissue	O
specific	O
regulation	O
of	O
gene	O
expression	O
by	O
transcription	O
factors	O
is	O
a	O
fascinating	O
new	O
field	O
in	O
molecular	O
immunology	O
.	O

This	O
review	O
summarizes	O
data	O
on	O
specific	O
regulation	O
of	O
promoters	O
and	O
enhancers	O
by	O
nuclear	O
trans-acting	O
factors	O
in	O
lymphocytes	O
.	O

The	O
structural	O
classes	O
of	O
transcription	O
factors	O
are	O
described	O
and	O
basic	O
methods	O
for	O
detection	O
and	O
analysis	O
of	O
transcription	O
factors	O
are	O
detailed	O
.	O

Furthermore	O
,	O
the	O
most	O
important	O
trans-acting	O
factors	O
of	O
T	O
and	O
B	O
lymphocytes	O
(	O
e.g.	O
NF-kB	O
,	O
NF-AT	O
and	O
STAT	O
families	O
)	O
and	O
their	O
functional	O
importance	O
are	O
described	O
.	O

Several	O
methods	O
for	O
specific	O
down-regulation	O
of	O
transcription	O
factors	O
are	O
shown	O
that	O
may	O
be	O
relevant	O
to	O
treatment	O
of	O
human	O
disease	O
.	O

The	O
data	O
are	O
discussed	O
with	O
regard	O
to	O
their	O
potential	O
clinical	O
relevance	O
for	O
gastroenterology	O
.	O

Modulation	O
of	O
the	O
expression	O
of	O
the	O
IFN-gamma	O
receptor	O
beta-chain	O
controls	O
responsiveness	O
to	O
IFN-gamma	O
in	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

IFN-gamma	O
has	O
potent	O
antiproliferative	O
and	O
apoptotic	O
effects	O
in	O
T	O
cells	O
that	O
are	O
important	O
in	O
determining	O
T	O
cell	O
development	O
and	O
polarized	O
differentiation	O
.	O

Therefore	O
,	O
any	O
event	O
that	O
enables	O
T	O
cells	O
to	O
become	O
less	O
responsive	O
to	O
IFN-gamma	O
may	O
potentially	O
alter	O
immune	O
responsiveness	O
to	O
Ag	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
human	O
peripheral	O
blood	O
T	O
cells	O
that	O
are	O
stimulated	O
through	O
the	O
TCR	O
and	O
expanded	O
with	O
IL-2	O
are	O
unresponsive	O
to	O
IFN-gamma	O
,	O
as	O
determined	O
by	O
a	O
lack	B-Negation
of	I-Negation
activation	I-Negation
of	I-Negation
jak	I-Negation
kinases	I-Negation
and	O
the	O
transcription	O
factor	O
,	O
STAT1	O
(	O
alpha	O
)	O
,	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
.	O

This	O
nonresponsiveness	O
occurs	O
because	O
of	O
a	O
lack	B-Negation
of	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
beta-chain	I-Negation
(	I-Negation
accessory	I-Negation
factor	I-Negation
)	I-Negation
of	I-Negation
the	I-Negation
IFN-gamma	I-Negation
receptor	I-Negation
,	O
while	O
at	O
the	O
same	O
time	O
maintaining	O
IFN-gamma	O
receptor	O
alpha-chain	O
expression	O
.	O

Expression	O
of	O
the	O
beta-chain	O
can	O
be	O
restored	O
by	O
secondary	O
TCR	O
ligation	O
or	O
PMA	O
treatment	O
.	O

T	O
cell	O
blasts	O
treated	O
with	O
PMA	O
are	O
now	O
responsive	O
to	O
IFN-gamma	O
.	O

When	O
freshly	O
isolated	O
,	O
highly	O
enriched	O
(	O
>	O
98	O
%	O
)	O
T	O
cells	O
are	O
examined	O
for	O
IFN-gamma	O
responsiveness	O
;	O

these	O
cells	O
can	O
respond	O
to	O
IFN-gamma	O
and	O
express	O
beta-chain	O
.	O

Therefore	O
,	O
as	O
T	O
cells	O
progress	O
from	O
primary	O
TCR	O
activation	O
through	O
IL-2-dependent	O
proliferation	O
,	O
followed	O
by	O
secondary	O
TCR	O
stimulation	O
,	O
their	O
responsiveness	O
to	O
IFN-gamma	O
varies	O
,	O
and	O
this	O
may	O
affect	O
their	O
ability	O
to	O
participate	O
in	O
an	O
ongoing	O
immune	O
response	O
.	O

Recombinant	O
NFAT1	O
(	O
NFATp	O
)	O
is	O
regulated	O
by	O
calcineurin	O
in	O
T	O
cells	O
and	O
mediates	O
transcription	O
of	O
several	O
cytokine	O
genes	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
identified	O
two	O
new	O
isoforms	O
of	O
the	O
transcription	O
factor	O
NFAT1	O
(	O
previously	O
termed	O
NFATp	O
)	O
that	O
are	O
the	O
predominant	O
isoforms	O
expressed	O
in	O
murine	O
and	O
human	O
T	O
cells	O
.	O

When	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
recombinant	O
NFAT1	O
is	O
regulated	O
,	O
as	O
expected	O
,	O
by	O
the	O
calmodulin-dependent	O
phosphatase	O
calcineurin	O
,	O
and	O
its	O
function	O
is	O
inhibited	O
by	O
the	O
immunosuppressive	O
agent	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Transactivation	O
by	O
recombinant	O
NFAT1	O
in	O
Jurkat	O
T	O
cells	O
requires	O
dual	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
;	O

this	O
activity	O
is	O
potentiated	O
by	O
coexpression	O
of	O
constitutively	O
active	O
calcineurin	O
and	O
is	O
inhibited	O
by	O
CsA	O
.	O

Immunocytochemical	O
analysis	O
indicates	O
that	O
recombinant	O
NFAT1	O
localizes	O
in	O
the	O
cytoplasm	O
of	O
transiently	O
transfected	O
T	O
cells	O
and	O
translocates	O
into	O
the	O
nucleus	O
in	O
a	O
CsA-sensitive	O
manner	O
following	O
ionomycin	O
stimulation	O
.	O

When	O
expressed	O
in	O
COS	O
cells	O
,	O
however	O
,	O
NFAT1	O
is	O
capable	O
of	O
transactivation	O
,	O
but	O
it	B-Negation
is	I-Negation
not	I-Negation
regulated	I-Negation
correctly	I-Negation
:	O

its	B-Negation
subcellular	I-Negation
localization	I-Negation
and	I-Negation
transcriptional	I-Negation
function	I-Negation
are	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
stimulation	I-Negation
of	I-Negation
the	I-Negation
COS	I-Negation
cells	I-Negation
with	I-Negation
ionomycin	I-Negation
and	I-Negation
phorbol	I-Negation
12-myristate	I-Negation
13-acetate	I-Negation
.	O

Recombinant	O
NFAT1	O
can	O
mediate	O
transcription	O
of	O
the	O
interleukin-2	O
,	O
interleukin-4	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
promoters	O
in	O
T	O
cells	O
,	O
suggesting	O
that	O
NFAT1	O
contributes	O
to	O
the	O
CsA-sensitive	O
transcription	O
of	O
these	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Epstein-Barr	O
virus	O
nuclear	O
antigen	O
2	O
and	O
latent	O
membrane	O
protein	O
independently	O
transactivate	O
p53	O
through	O
induction	O
of	O
NF-kappaB	O
activity	O
.	O

B-cell	O
immortalization	O
by	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
dependent	O
on	O
permanent	O
control	O
of	O
the	O
cellular	O
processes	O
which	O
normally	O
regulate	O
cell	O
division	O
and	O
apoptosis	O
,	O
functions	O
possessed	O
by	O
p53	O
in	O
a	O
number	O
of	O
normal	O
cell	O
types	O
.	O

In	O
studies	O
initiated	O
to	O
evaluate	O
relationships	O
between	O
EBV	O
latent	O
genes	O
and	O
p53	O
,	O
p53	O
levels	O
were	O
found	O
to	O
increase	O
approximately	O
10-fold	O
4	O
to	O
5	O
days	O
after	O
EBV	O
infection	O
of	O
purified	O
resting	O
human	O
B	O
cells	O
;	O

the	O
induced	O
p53	O
was	O
transcriptionally	O
active	O
.	O

Latent	O
membrane	O
protein	O
1	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
EBV	O
nuclear	O
antigen	O
2	O
mediated	O
the	O
increase	O
in	O
p53	O
levels	O
via	O
activation	O
of	O
the	O
NF-kappaB	O
transcription	O
factor	O
.	O

Differential	O
utilization	O
of	O
Janus	O
kinase-signal	O
transducer	O
activator	O
of	O
transcription	O
signaling	O
pathways	O
in	O
the	O
stimulation	O
of	O
human	O
natural	O
killer	O
cells	O
by	O
IL-2	O
,	O
IL-12	O
,	O
and	O
IFN-alpha	O
.	O

IL-2-	O
,	O
IL-12-	O
,	O
and	O
IFN-alpha-mediated	O
signaling	O
pathways	O
were	O
analyzed	O
in	O
primary	O
NK	O
cells	O
and	O
in	O
the	O
NK3.3	O
cell	O
line	O
.	O

Gel	O
mobility	O
shift	O
and	O
immunoprecipitation	O
analyses	O
revealed	O
that	O
in	O
addition	O
to	O
activating	O
STAT3	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-3	O
)	O
and	O
STAT5	O
,	O
IL-2	O
induced	O
tyrosine	O
and	O
serine	O
phosphorylation	O
of	O
STAT1	O
alpha	O
,	O
which	O
formed	O
IFN-gamma-activated	O
sequence-binding	O
complexes	O
by	O
itself	O
and	O
with	O
STAT3	O
.	O

Although	O
IL-2	O
and	O
IFN-alpha	O
activated	O
STAT1	O
alpha	O
and	O
STAT5	O
,	O
IL-2	O
predominantly	O
activated	O
STAT5	O
,	O
while	O
IFN-alpha	O
predominantly	O
activated	O
STAT1	O
alpha	O
.	O

IL-2	O
induced	O
less	O
STAT1	O
alpha	O
activation	O
and	O
IFN-alpha	O
induced	O
greater	O
STAT5	O
activation	O
in	O
NK3.3	O
cells	O
compared	O
with	O
preactivated	O
primary	O
NK	O
cells	O
.	O

In	O
NK3.3	O
cells	O
,	O
IL-2	O
induced	O
comparable	O
formation	O
of	O
c-fos	O
promoter	O
sis-inducible	O
element	O
IFN-gamma-activated	O
sequence-binding	O
complexes	O
containing	O
STAT3	O
alone	O
with	O
complexes	O
containing	O
STAT3	O
and	O
STAT1	O
alpha	O
,	O
while	O
in	O
preactivated	O
primary	O
NK	O
cells	O
,	O
it	O
preferentially	O
induced	O
complexes	O
containing	O
STAT3	O
and	O
STAT1	O
alpha	O
.	O

Thus	O
,	O
signaling	O
in	O
NK3.3	O
cells	O
is	O
not	O
always	O
identical	O
with	O
that	O
in	O
primary	O
NK	O
cells	O
.	O

In	O
contrast	O
to	O
IL-2	O
and	O
IFN-alpha	O
,	O
IL-12	O
induced	O
strong	O
tyrosine	O
phosphorylation	O
of	O
STAT4	O
and	O
variable	O
weak	O
phosphorylation	O
of	O
STAT3	O
.	O

However	O
,	O
supershift	O
analyses	O
using	O
the	O
c-fos	O
promoter	O
sis-inducible	O
element	O
probe	O
showed	O
that	O
IL-12	O
activated	O
STAT4	O
,	O
STAT1	O
alpha	O
,	O
and	O
STAT3	O
,	O
and	O
induced	O
complexes	O
containing	O
STAT4	O
only	O
,	O
STAT4	O
with	O
STAT1	O
alpha	O
,	O
STAT3	O
with	O
STAT1	O
alpha	O
,	O
or	O
STAT1	O
alpha	O
only	O
in	O
preactivated	O
primary	O
NK	O
cells	O
.	O

STAT1	O
alpha	O
activation	O
by	O
IL-12	O
correlated	O
with	O
increased	O
phosphorylation	O
of	O
serine	O
,	O
but	O
not	B-Negation
tyrosine	I-Negation
.	O

Finally	O
,	O
IL-2	O
induced	O
tyrosine	O
phosphorylation	O
of	O
JAK1	O
and	O
JAK3	O
,	O
while	O
IL-12	O
induced	O
phosphorylation	O
of	O
JAK2	O
and	O
TYK2	O
in	O
both	O
preactivated	O
primary	O
NK	O
and	O
NK3.3	O
cells	O
.	O

Differential	O
phosphorylation	O
and	O
consequent	O
differential	O
activation	O
of	O
both	O
separate	O
and	O
overlapping	O
STAT	O
proteins	O
by	O
IL-2	O
,	O
IL-12	O
,	O
and	O
IFN-alpha	O
may	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
similarities	O
and	O
differences	O
in	O
the	O
actions	O
of	O
these	O
cytokines	O
on	O
NK	O
cells	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
stimulate	O
transcriptional	O
activation	O
of	O
c-jun	O
and	O
suppress	O
IL-2	O
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Sublethal	O
levels	O
of	O
oxidative	O
stress	O
are	O
well	O
known	O
to	O
alter	O
T	O
cell	O
functional	O
responses	O
,	O
but	O
the	O
underlying	O
mechanisms	O
are	O
unknown	O
.	O

The	O
current	O
study	O
examined	O
the	O
effects	O
of	O
oxidative	O
stress	O
on	O
transcriptional	O
activities	O
mediated	O
by	O
c-Fos/c-Jun	O
AP-1	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
.	O

The	O
present	O
results	O
show	O
that	O
Jurkat	O
T	O
cells	O
acutely	O
exposed	O
to	O
micromolar	O
concentrations	O
of	O
H2O2	O
exhibit	O
substantial	O
increases	O
in	O
AP-1	O
binding	O
activity	O
and	O
the	O
expression	O
of	O
c-jun	O
but	O
not	B-Negation
c-fos	I-Negation
mRNA	I-Negation
.	O

The	O
preferential	O
induction	O
of	O
c-jun	O
by	O
H2O2	O
did	O
not	B-Negation
represent	I-Negation
redox	I-Negation
stabilization	I-Negation
of	I-Negation
mRNA	I-Negation
transcripts	I-Negation
,	O
and	O
oxidative	O
signals	O
closely	O
resembled	O
PHA/PMA	O
stimulation	O
by	O
effectively	O
transactivating	O
the	O
full	O
length	O
c-jun	O
promoter	O
via	O
the	O
proximal	O
jun1	O
tumor	O
promoter-responsive	O
element	O
(	O
TRE	O
)	O
-like	O
promoter	O
element	O
.	O

Similarly	O
,	O
the	O
complexes	O
binding	O
the	O
consensus	O
AP-1	O
TRE	O
and	O
jun	O
TRE-like	O
motifs	O
in	O
cells	O
exposed	O
to	O
oxidative	O
signals	O
or	O
PHA/PMA	O
were	O
indistinguishable	O
,	O
being	O
composed	O
of	O
c-Fos	O
,	O
c-Jun	O
,	O
and	O
JunD	O
.	O

However	O
,	O
PHA/PMA	O
but	O
not	B-Negation
oxidative	I-Negation
signals	I-Negation
induced	O
the	O
coordinate	O
activation	O
of	O
reporter	O
constructs	O
containing	O
the	O
AP-1-TRE	O
,	O
NF-AT	O
,	O
and	O
IL-2	O
promoter	O
regions	O
along	O
with	O
IL-2	O
mRNA	O
expression	O
.	O

Furthermore	O
,	O
sublethal	O
levels	O
of	O
H2O2	O
actively	O
suppressed	O
the	O
transcriptional	O
activation	O
of	O
NF-AT	O
and	O
IL-2	O
reporters	O
as	O
well	O
as	O
the	O
expression	O
of	O
IL-2	O
mRNA	O
in	O
cells	O
stimulated	O
with	O
PHA/PMA	O
.	O

Gel	O
shift	O
analysis	O
revealed	O
that	O
oxidative	O
suppression	O
of	O
NF-AT	O
represented	O
inhibition	O
in	O
the	O
early	O
generation	O
of	O
NFAT	O
complexes	O
rather	B-Negation
than	I-Negation
the	I-Negation
binding	I-Negation
of	I-Negation
preformed	I-Negation
NF-AT	I-Negation
complexes	I-Negation
.	O

These	O
results	O
suggest	O
that	O
oxidative	O
signals	O
can	O
positively	O
and	O
negatively	O
regulate	O
T	O
cell	O
transcriptional	O
events	O
and	O
that	O
changes	O
in	O
cellular	O
redox	O
can	O
uncouple	O
AP-1	O
regulation	O
of	O
c-jun	O
from	O
transcriptional	O
up-regulation	O
of	O
IL-2	O
via	O
NF-AT	O
.	O

Glucocorticoids	O
and	O
interferon-alpha	O
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
.	O

Some	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
(	O
AIDS	O
)	O
develop	O
glucocorticoid	O
resistance	O
characterized	O
by	O
low	O
receptor	O
affinity	O
(	O
Kd	O
)	O
for	O
glucocorticoids	O
in	O
mononuclear	O
,	O
cells	O
and	O
high	O
values	O
of	O
ACTH	O
and	O
cortisol	O
.	O

As	O
glucocorticoids	O
regulate	O
interferon-alpha	O
(	O
IFN	O
alpha	O
)	O
production	O
,	O
we	O
hypothesized	O
that	O
IFN	O
alpha	O
,	O
a	O
cytokine	O
produced	O
predominantly	O
by	O
monocytes	O
in	O
AIDS	O
,	O
should	O
be	O
increased	O
in	O
cortisol-resistant	O
AIDS	O
,	O
attributing	O
the	O
lack	O
of	O
cortisol	O
inhibition	O
to	O
IFN	O
alpha	O
production	O
.	O

Therefore	O
,	O
we	O
examined	O
glucocorticoid	O
receptor	O
characteristics	O
on	O
monocytes	O
by	O
[	O
3H	O
]	O
dexamethasone	O
binding	O
and	O
measured	O
IFN	O
alpha	O
,	O
cortisol	O
,	O
and	O
ACTH	O
in	O
AIDS	O
patients	O
with	O
(	O
AIDS-GR	O
)	O
or	O
without	B-Negation
glucocorticoid	I-Negation
resistance	I-Negation
(	I-Negation
AIDS-C	I-Negation
)	I-Negation
and	I-Negation
controls	I-Negation
(	I-Negation
C	I-Negation
)	I-Negation
.	O

Monocytes	O
of	O
AIDS-GR	O
patients	O
had	O
a	O
receptor	O
Kd	O
of	O
10.5	O
	O
4.2	O
nmol/L	O
that	O
was	O
higher	O
than	O
that	O
in	O
the	O
AIDS-C	O
group	O
(	O
2.9	O
	O
0.8	O
nmol/L	O
)	O
and	O
normal	O
subjects	O
(	O
2.0	O
	O
0.8	O
nmol/L	O
;	O
P	O
<	O
0.01	O
)	O
.	O

IFN	O
alpha	O
levels	O
were	O
increased	O
in	O
the	O
AIDS-GR	O
group	O
(	O
17	O
	O
6	O
vs	O
.	O

4	O
	O
1	O
U/mL	O
in	O
the	O
AIDS-C	O
group	O
and	O
2	O
	O
0.5	O
U/mL	O
in	O
the	O
C	O
group	O
;	O
P	O
<	O
0.01	O
)	O
.	O

Correlations	O
were	O
found	O
between	O
plasma	O
IFN	O
alpha	O
and	O
receptor	O
Kd	O
on	O
monocytes	O
of	O
AIDS-GR	O
(	O
r	O
=	O
0.77	O
)	O
and	O
between	O
IFN	O
alpha	O
and	O
plasma	O
cortisol	O
in	O
the	O
same	O
group	O
(	O
r	O
=	O
0.74	O
)	O
.	O

The	O
poly	O
(	O
I	O
)	O
-poly	O
(	O
C	O
)	O
-induced	O
IFN	O
alpha	O
production	O
by	O
monocytes	O
was	O
inhibited	O
by	O
glucocorticoids	O
in	O
the	O
C	O
and	O
AIDS-C	O
groups	O
(	O
approximately	O
80	O
%	O
inhibition	O
in	O
both	O
groups	O
)	O
;	O

the	O
effect	O
was	O
reversed	O
by	O
the	O
receptor	O
antagonist	O
RU-38486	O
.	O

By	O
contrast	O
,	O
glucocorticoids	O
failed	O
to	O
inhibit	O
IFNalpha	O
production	O
from	O
AIDS-GR	O
monocytes	O
(	O
approximately	O
20	O
%	O
inhibition	O
)	O
.	O

In	O
conclusion	O
,	O
elevated	O
IFN	O
alpha	O
levels	O
in	O
AIDS-GR	O
may	O
be	O
due	O
to	O
the	O
lack	O
of	O
inhibitory	O
effect	O
of	O
cortisol	O
on	O
IFN	O
alpha	O
production	O
due	O
to	O
cortisol	O
resistance	O
in	O
monocytes	O
.	O

Cooperation	O
between	O
core	O
binding	O
factor	O
and	O
adjacent	O
promoter	O
elements	O
contributes	O
to	O
the	O
tissue-specific	O
expression	O
of	O
interleukin-3	O
.	O

Tissue-specific	O
expression	O
of	O
interleukin-3	O
(	O
IL-3	O
)	O
is	O
mediated	O
via	O
cis-acting	O
elements	O
located	O
within	O
315	O
base	O
pairs	O
of	O
the	O
transcription	O
start	O
.	O

This	O
is	O
achieved	O
in	O
part	O
through	O
the	O
positive	O
activities	O
of	O
the	O
AP-1	O
and	O
Elf-1	O
sites	O
in	O
the	O
IL-3	O
promoter	O
.	O

The	O
contribution	O
to	O
T	O
cell-specific	O
expression	O
by	O
other	O
promoter	O
sites	O
was	O
assessed	O
in	O
a	O
transient	O
expression	O
assay	O
with	O
IL-3	O
promoter	O
constructs	O
linked	O
to	O
a	O
luciferase	O
gene	O
,	O
focusing	O
initially	O
on	O
the	O
core	O
binding	O
factor	O
(	O
CBF	O
)	O
site	O
,	O
which	O
is	O
footprinted	O
in	O
vivo	O
upon	O
T	O
cell	O
activation	O
.	O

Activity	O
of	O
the	O
CBF	O
site	O
is	O
shown	O
to	O
be	O
critically	O
dependent	O
on	O
the	O
adjacent	O
activator	O
site	O
Act-1	O
.	O

Together	O
the	O
Act-1	O
and	O
CBF	O
sites	O
form	O
a	O
functional	O
unit	O
(	O
AC	O
unit	O
)	O
with	O
dual	O
activity	O
.	O

The	O
AC	O
unit	O
is	O
demonstrated	O
to	O
enhance	O
basal	O
activity	O
of	O
promoters	O
both	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

This	O
activity	O
is	O
further	O
inducible	O
in	O
activated	O
T	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
fibroblasts	I-Negation
.	O

In	O
addition	O
to	O
the	O
already	O
identified	O
NIP	O
repressor	O
site	O
,	O
evidence	O
is	O
presented	O
for	O
a	O
second	O
repressor	O
region	O
that	O
restricts	O
promoter	O
activity	O
in	O
fibroblasts	O
.	O

Finally	O
,	O
a	O
novel	O
positive	O
regulatory	O
element	O
has	O
been	O
mapped	O
in	O
the	O
IL-3	O
promoter	O
between	O
nucleotide	O
-180	O
and	O
-210	O
that	O
leads	O
to	O
increased	O
expression	O
in	O
T	O
cells	O
.	O

Together	O
these	O
results	O
demonstrate	O
that	O
T	O
cell	O
expression	O
of	O
IL-3	O
is	O
not	B-Negation
specified	I-Negation
by	I-Negation
the	I-Negation
activity	I-Negation
of	I-Negation
a	I-Negation
single	I-Negation
tissue-specific	I-Negation
element	I-Negation
,	O
but	O
instead	O
involves	O
multiple	O
interacting	O
elements	O
that	O
provide	O
both	O
specific	O
positive	O
regulation	O
in	O
T	O
cells	O
and	O
specific	O
negative	O
regulation	O
in	O
fibroblasts	O
.	O

A	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	O
helicase	O
defect	O
in	O
repair/transcription	O
factor	O
TFIIH	O
of	O
xeroderma	O
pigmentosum	O
group	O
B	O
affects	O
both	O
DNA	O
repair	O
and	O
transcription	O
.	O

XPB	O
is	O
a	O
subunit	O
of	O
the	O
basal	O
transcription	O
factor	O
TFIIH	O
,	O
which	O
is	O
also	O
involved	O
in	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
potentially	O
in	O
cell	O
cycle	O
regulation	O
.	O

A	O
frameshift	O
mutation	O
in	O
the	O
3'-end	O
of	O
the	O
XPB	O
gene	O
is	O
responsible	O
for	O
a	O
concurrence	O
of	O
two	O
disorders	O
:	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
and	O
Cockayne	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O

We	O
have	O
isolated	O
TFIIH	O
from	O
cells	O
derived	O
from	O
a	O
patient	O
(	O
XP11BE	O
)	O
who	O
carries	O
this	O
frameshift	O
mutation	O
(	O
TFIIHmut	O
)	O
and	O
from	O
the	O
mother	O
of	O
this	O
patient	O
(	O
TFIIHwt	O
)	O
to	O
determine	O
the	O
biochemical	O
consequences	O
of	O
the	O
mutation	O
.	O

Although	O
identical	O
in	O
composition	O
and	O
stoichiometry	O
to	O
TFIIHwt	O
,	O
TFIIHmut	O
shows	O
a	O
reduced	O
3	O
'	O
--	O
>	O
5	O
'	O
XPB	O
helicase	O
activity	O
.	O

A	O
decrease	O
in	O
helicase	O
and	O
DNA-dependent	O
ATPase	O
activities	O
was	O
also	O
observed	O
with	O
the	O
mutated	O
recombinant	O
XPB	O
protein	O
.	O

The	O
XPB	O
mutation	O
causes	O
a	O
severe	O
NER	O
defect	O
.	O

In	O
addition	O
,	O
we	O
provide	O
evidence	O
for	O
a	O
decrease	O
in	O
basal	O
transcription	O
activity	O
in	O
vitro	O
.	O

The	O
latter	O
defect	O
may	O
provide	O
an	O
explanation	O
for	O
many	O
of	O
the	O
XP	O
and	O
CS	O
symptoms	O
that	O
are	O
difficult	O
to	O
rationalize	O
based	O
solely	O
on	O
an	O
NER	O
defect	O
.	O

Thus	O
,	O
this	O
work	O
presents	O
the	O
first	O
detailed	O
analysis	O
of	O
a	O
naturally	O
occurring	O
mutation	O
in	O
a	O
basal	O
transcription	O
factor	O
and	O
supports	O
the	O
concept	O
that	O
the	O
combined	O
XP/CS	O
clinical	O
entity	O
is	O
actually	O
the	O
result	O
of	O
a	O
combined	O
transcription/repair	O
deficiency	O
.	O

Signals	O
leading	O
to	O
the	O
activation	O
of	O
NF-kappa	O
B	O
transcription	O
factor	O
are	O
stronger	O
in	O
neonatal	O
than	O
adult	O
T	O
lymphocytes	O
.	O

The	B-Negation
molecular	I-Negation
background	I-Negation
of	I-Negation
the	I-Negation
defects	I-Negation
in	I-Negation
the	I-Negation
immune	I-Negation
reactivity	I-Negation
of	I-Negation
human	I-Negation
neonates	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
fully	I-Negation
elucidated	I-Negation
.	O

As	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
has	O
a	O
central	O
role	O
in	O
the	O
control	O
of	O
transcription	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
the	O
authors	O
have	O
analysed	O
the	O
activation	O
of	O
NF-kappa	O
B	O
in	O
human	O
umbilical	O
cord	O
T	O
lymphocytes	O
.	O

The	O
activity	O
was	O
tested	O
by	O
quantitating	O
the	O
nuclear	O
proteins	O
binding	O
to	O
an	O
oligonucleotide	O
containing	O
the	O
consensus	O
kappa	O
B	O
binding	O
sequence	O
(	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
.	O

The	O
data	O
obtained	O
demonstrate	O
that	O
phorbol	O
dibutyrate/calcium	O
ionophore	O
A23187	O
(	O
PDBu/iono	O
)	O
combination	O
induced	O
a	O
clearly	O
higher	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
in	O
neonatal	O
than	O
adult	O
T	O
cells	O
.	O

This	O
higher	O
NF-kappa	O
B	O
activity	O
was	O
restricted	O
to	O
the	O
CD4+	O
T-cell	O
subset	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
antibodies	O
directed	O
against	O
the	O
major	O
components	O
of	O
NF-kappa	O
B	O
the	O
p50	O
and	O
RelA	O
(	O
p65	O
)	O
proteins	O
,	O
indicated	O
that	O
the	O
composition	O
of	O
NF-kappa	O
B	O
was	O
similar	O
in	O
neonatal	O
and	O
adult	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
neonatal	O
T	O
cells	O
are	O
exposed	O
to	O
oxidative	O
stress-inducing	O
signals	O
during	O
delivery	O
and/or	O
are	O
inherently	O
more	O
sensitive	O
to	O
NF-kappa	O
B	O
activating	O
signals	O
than	O
adult	O
T	O
cells	O
.	O

Characterization	O
of	O
Grb2-binding	O
proteins	O
in	O
human	O
platelets	O
activated	O
by	O
Fc	O
gamma	O
RIIA	O
cross-linking	O
.	O

Glutathione-S-transferase	O
(	O
GST	O
)	O
-Grb2	O
fusion	O
proteins	O
have	O
been	O
used	O
to	O
identify	O
the	O
potential	O
role	O
of	O
Grb2-binding	O
proteins	O
in	O
platelet	O
activation	O
by	O
the	O
platelet	O
low-affinity	O
IgG	O
receptor	O
,	O
Fc	O
gamma	O
RIIA	O
.	O

Two	O
tyrosine	O
phosphoproteins	O
of	O
38	O
and	O
63	O
kD	O
bind	O
to	O
the	O
SH2	O
domain	O
of	O
Grb2	O
following	O
Fc	O
gamma	O
RIIA	O
stimulation	O
of	O
platelets	O
.	O

Both	O
are	O
located	O
in	O
the	O
particulate	O
fraction	O
following	O
platelet	O
activation	O
and	O
are	O
also	O
able	O
to	O
bind	O
to	O
a	O
GST-construct	O
containing	O
the	O
SH2	O
and	O
SH3	O
domains	O
of	O
phospholipase	O
C	O
gamma	O
1	O
.	O

p38	O
also	O
forms	O
a	O
complex	O
with	O
the	O
tyrosine	O
kinase	O
csk	O
in	O
stimulated	O
cells	O
and	O
is	O
a	O
substrate	O
for	O
the	O
kinase	O
.	O

The	O
SH3	O
domains	O
of	O
Grb2	O
form	O
a	O
stable	O
complex	O
with	O
SOS1	O
and	O
two	O
proteins	O
of	O
75	O
kD	O
and	O
120	O
kD	O
,	O
which	O
undergo	O
tyrosine	O
phosphorylation	O
in	O
Fc	O
gamma	O
RIIA	O
stimulated	O
cells	O
.	O

The	O
75-kD	O
protein	O
is	O
recognized	O
by	O
antibodies	O
to	O
SLP-76	O
,	O
which	O
has	O
recently	O
been	O
isolated	O
from	O
T	O
cells	O
and	O
sequenced	O
.	O

Tyrosine	O
phosphorylation	O
of	O
p38	O
and	O
p63	O
is	O
also	O
observed	O
in	O
platelets	O
stimulated	O
by	O
the	O
tyrosine	O
kinase-linked	O
receptor	O
agonist	O
collagen	O
and	O
by	O
the	O
G	O
protein-coupled	O
receptor	O
agonist	O
thrombin	O
,	O
although	O
phosphorylation	O
of	O
SLP-76	O
is	O
only	O
observed	O
in	O
collagen-stimulated	O
platelets	O
.	O

p38	O
and	O
p63	O
may	O
provide	O
a	O
docking	O
site	O
for	O
Grb2	O
,	O
thereby	O
linking	O
Grb2	O
SH3-binding	O
proteins	O
SOS1	O
,	O
SLP-76	O
,	O
and	O
p120	O
to	O
downstream	O
signalling	O
events	O
.	O

Retinoic	O
acid	O
activates	O
interferon	O
regulatory	O
factor-1	O
gene	O
expression	O
in	O
myeloid	O
cells	O
.	O

All-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
the	O
drug	O
of	O
choice	O
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

ATRA	O
induces	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
of	O
APL	O
cells	O
into	O
mature	O
granulocytes	O
.	O

However	O
,	O
the	B-Negation
molecular	I-Negation
mechanisms	I-Negation
involved	I-Negation
in	I-Negation
ATRA-dependent	I-Negation
growth	I-Negation
inhibition	I-Negation
and	I-Negation
cellular	I-Negation
differentiation	I-Negation
are	I-Negation
not	I-Negation
presently	I-Negation
understood	I-Negation
.	O

The	O
NB4	O
cell	O
line	O
,	O
which	O
is	O
derived	O
from	O
the	O
bone	O
marrow	O
of	O
a	O
patient	O
with	O
APL	O
during	O
relapse	O
,	O
can	O
be	O
used	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
growth	O
and	O
differentiation	O
of	O
APL	O
cells	O
.	O

Because	O
interferon	O
(	O
IFN	O
)	O
regulatory	O
factors	O
(	O
IRF-1	O
and	O
IRF-2	O
)	O
and	O
other	O
IFN-inducible	O
gene	O
products	O
regulate	O
cell	O
growth	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
ATRA	O
on	O
the	O
expression	O
of	O
these	O
genes	O
.	O

We	O
show	O
that	O
ATRA	O
directly	O
activates	O
IRF-1	O
gene	O
expression	O
,	O
followed	O
by	O
activation	O
of	O
IRF-2	O
and	O
2'-5	O
'	O
oligoadenylate	O
synthetase	O
(	O
OAS	O
)	O
gene	O
expression	O
with	O
slower	O
kinetics	O
.	O

In	O
addition	O
to	O
NB4	O
cells	O
,	O
ATRA	O
also	O
activated	O
IRF-1	O
gene	O
expression	O
in	O
HL-60	O
,	O
U937	O
,	O
and	O
THP-1	O
cells	O
,	O
which	O
all	O
respond	O
to	O
ATRA	O
by	O
growth	O
inhibition	O
.	O

A	O
more	O
than	O
additive	O
increase	O
in	O
IRF-1	O
gene	O
expression	O
was	O
seen	O
with	O
ATRA	O
and	O
IFN-gamma	O
in	O
NB4	O
cells	O
.	O

ATRA	O
did	O
not	B-Negation
activate	I-Negation
nuclear	I-Negation
factor	I-Negation
kappa	I-Negation
B	I-Negation
or	I-Negation
signal	I-Negation
transducer	I-Negation
and	I-Negation
activator	I-Negation
of	I-Negation
transcription	I-Negation
(	I-Negation
STAT	I-Negation
)	I-Negation
activation	I-Negation
pathways	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
an	I-Speculation
alternate	I-Speculation
mechanism	I-Speculation
is	I-Speculation
involved	I-Speculation
in	I-Speculation
IRF-1	I-Speculation
gene	I-Speculation
activation	I-Speculation
.	O

The	O
ATRA-induced	O
expression	O
of	O
IRF-1	O
,	O
an	O
activator	O
of	O
transcription	O
and	O
repressor	O
of	O
transformation	O
,	O
may	O
be	O
one	O
of	O
the	O
molecular	O
mechanisms	O
of	O
ATRA-induced	O
growth	O
inhibition	O
,	O
and	O
the	O
basis	O
for	O
the	O
synergistic	O
actions	O
of	O
ATRA	O
and	O
IFNs	O
in	O
myeloid	O
leukemia	O
cells	O
.	O

The	O
c-Jun	O
delta-domain	O
inhibits	O
neuroendocrine	O
promoter	O
activity	O
in	O
a	O
DNA	O
sequence-	O
and	O
pituitary-specific	O
manner	O
.	O

The	O
transcription	O
and	O
transformation	O
activity	O
of	O
c-Jun	O
is	O
governed	O
by	O
a	O
27-amino	O
acid	O
regulatory	O
motif	O
,	O
labeled	O
the	O
delta-domain	O
,	O
which	O
is	O
deleted	O
in	O
v-Jun	O
.	O

We	O
have	O
previously	O
shown	O
that	O
c-Jun	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rat	O
prolactin	O
(	O
rPRL	O
)	O
promoter	O
activity	O
induced	O
by	O
either	O
oncogenic	O
Ras	O
or	O
phorbol	O
esters	O
.	O

Here	O
,	O
we	O
have	O
characterized	O
the	O
structural	O
and	O
cell-specific	O
requirements	O
for	O
this	O
c-Jun	O
inhibitory	O
response	O
,	O
and	O
we	O
show	O
that	O
this	O
c-Jun	O
inhibitory	O
response	O
mapped	O
to	O
the	O
rPRL	O
footprint	O
II	O
repressor	O
site	O
,	O
was	O
pituitary-specific	O
and	O
required	O
the	O
c-Jun	O
delta-domain	O
.	O

Moreover	O
,	O
alteration	O
of	O
any	O
one	O
of	O
these	O
features	O
(	O
e.g.	O
,	O
cis-element	O
,	O
trans-factor	O
,	O
or	O
cell-specific	O
background	O
)	O
switched	O
c-Jun	O
to	O
a	O
transcriptional	O
activator	O
of	O
the	O
rPRL	O
promoter	O
.	O

In	O
HeLa	O
nonpituitary	O
cells	O
,	O
c-Jun	O
alone	O
activated	O
the	O
rPRL	O
promoter	O
via	O
the	O
most	O
proximal	O
GHF-1/Pit-1	O
binding	O
site	O
,	O
footprint	O
I	O
,	O
and	O
synergized	O
with	O
GHF-1	O
.	O

Finally	O
,	O
recombinant	O
GHF-1	O
interacted	O
directly	O
with	O
c-Jun	O
but	O
not	B-Negation
c-Fos	I-Negation
proteins	I-Negation
.	O

These	O
data	O
provide	O
important	O
fundamental	O
insights	O
into	O
the	O
molecular	O
mechanisms	O
by	O
which	O
the	O
c-Jun	O
delta-domain	O
functions	O
as	O
a	O
modulatory	O
switch	O
and	O
further	O
imply	O
that	O
the	O
functional	O
role	O
of	O
c-Jun	O
is	O
dictated	O
by	O
cell-specific	O
influences	O
and	O
the	O
delta-domain	O
motif	O
.	O

BCL-6	O
,	O
a	O
POZ/zinc-finger	O
protein	O
,	O
is	O
a	O
sequence-specific	O
transcriptional	O
repressor	O
.	O

Approximately	O
40	O
%	O
of	O
diffuse	O
large	O
cell	O
lymphoma	O
are	O
associated	O
with	O
chromosomal	O
translocations	O
that	O
deregulate	O
the	O
expression	O
of	O
the	O
BCL6	O
gene	O
by	O
juxtaposing	O
heterologous	O
promoters	O
to	O
the	O
BCL-6	O
coding	O
domain	O
.	O

The	O
BCL6	O
gene	O
encodes	O
a	O
95-kDa	O
protein	O
containing	O
six	O
C-terminal	O
zinc-finger	O
motifs	O
and	O
an	O
N-terminal	O
POZ	O
domain	O
,	O
suggesting	O
that	O
it	O
may	O
function	O
as	O
a	O
transcription	O
factor	O
.	O

By	O
using	O
a	O
DNA	O
sequence	O
selected	O
for	O
its	O
ability	O
to	O
bind	O
recombinant	O
BCL-6	O
in	O
vitro	O
,	O
we	O
show	O
here	O
that	O
BCL-6	O
is	O
present	O
in	O
DNA-binding	O
complexes	O
in	O
nuclear	O
extracts	O
from	O
various	O
B-cell	O
lines	O
.	O

In	O
transient	O
transfectin	O
experiments	O
,	O
BCL6	O
can	O
repress	O
transcription	O
from	O
promoters	O
linked	O
to	O
its	O
DNA	O
target	O
sequence	O
and	O
this	O
activity	O
is	O
dependent	O
upon	O
specific	O
DNA-binding	O
and	O
the	O
presence	O
of	O
an	O
intact	O
N-terminal	O
half	O
of	O
the	O
protein	O
.	O

We	O
demonstrate	O
that	O
this	O
part	O
of	O
the	O
BCL6	O
molecule	O
contains	O
an	O
autonomous	O
transrepressor	O
domain	O
and	O
that	O
two	O
noncontiguous	O
regions	O
,	O
including	O
the	O
POZ	O
motif	O
,	O
mediate	O
maximum	O
transrepressive	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
the	O
BCL-6	O
protein	O
can	O
function	O
as	O
a	O
sequence-specific	O
transcriptional	O
repressor	O
and	O
have	O
implications	O
for	O
the	O
role	O
of	O
BCL6	O
in	O
normal	O
lymphoid	O
development	O
and	O
lymphomagenesis	O
.	O

Constitutive	O
expression	O
of	O
specific	O
interferon	O
isotypes	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
normal	O
individuals	O
and	O
in	O
promonocytic	O
U937	O
cells	O
.	O

Constitutive	O
expression	O
of	O
IFN-alpha5	O
and	O
IFN-beta	O
was	O
detected	O
in	O
different	O
lymphoid	O
cells	O
including	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
normal	O
individuals	O
following	O
amplification	O
of	O
IFN	O
mRNA	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
of	O
the	O
amplified	O
product	O
.	O

The	O
activated	O
form	O
of	O
the	O
interferon-induced	O
transcription	O
factor	O
complex	O
ISGF3	O
was	O
also	O
detected	O
in	O
nuclear	O
extracts	O
from	O
uninduced	O
cells	O
.	O

Culture	O
supernatants	O
from	O
uninduced	O
U937	O
cells	O
were	O
also	O
found	O
to	O
activate	O
an	O
ISRE	O
cloned	O
upstream	O
of	O
the	O
luciferase	O
reporter	O
gene	O
,	O
indicating	O
the	O
presence	O
of	O
endogenous	O
IFN	O
activity	O
equivalent	O
to	O
approximately	O
0.3	O
to	O
0.5	O
IU/mL	O
.	O

This	O
endogenous	O
IFN	O
was	O
also	O
shown	O
to	O
play	O
a	O
role	O
in	O
maintaining	O
the	O
basal	O
level	O
of	O
expression	O
of	O
the	O
major	O
histocompatibility	O
class	O
I	O
genes	O
in	O
lymphoid	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
IFN-alpha5	O
and	O
IFN-beta	O
are	O
produced	O
at	O
low	O
levels	O
in	O
normal	O
tissues	O
and	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cell	O
function	O
and	O
in	O
the	O
maintenance	O
of	O
homeostasis	O
.	O

Mechanisms	O
of	O
transactivation	O
by	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells-1	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells-family	O
proteins	O
(	O
NFAT1/NFATp	O
,	O
NFATc	O
,	O
NFAT3	O
,	O
and	O
NFAT4/NFATx/NFATc3	O
)	O
play	O
a	O
key	O
role	O
in	O
the	O
transcription	O
of	O
cytokine	O
genes	O
and	O
other	O
genes	O
during	O
the	O
immune	O
response	O
.	O

We	O
have	O
defined	O
the	O
mechanisms	O
of	O
transactivation	O
by	O
NFAT1	O
.	O

NFAT1	O
possesses	O
two	O
transactivation	O
domains	O
whose	B-Negation
sequences	I-Negation
are	I-Negation
not	I-Negation
conserved	I-Negation
in	I-Negation
the	I-Negation
other	I-Negation
NFAT-family	I-Negation
proteins	I-Negation
,	O
and	O
a	O
conserved	O
DNA-binding	O
domain	O
that	O
mediates	O
the	O
recruitment	O
of	O
cooperating	O
nuclear	O
transcription	O
factors	O
even	O
when	O
it	O
is	O
expressed	O
in	O
the	O
absence	B-Negation
of	I-Negation
other	I-Negation
regions	I-Negation
of	I-Negation
the	I-Negation
protein	I-Negation
.	O

The	O
activity	O
of	O
the	O
NH2-terminal	O
transactivation	O
domain	O
is	O
modulated	O
by	O
an	O
adjacent	O
regulatory	O
region	O
that	O
contains	O
several	O
conserved	O
sequence	O
motifs	O
represented	O
only	O
in	O
the	O
NFAT	O
family	O
.	O

Our	O
results	O
emphasize	O
the	O
multiple	O
levels	O
at	O
which	O
NFAT-dependent	O
transactivation	O
is	O
regulated	O
,	O
and	O
predict	O
significant	O
differences	O
in	O
the	O
architecture	O
of	O
cooperative	O
transcription	O
complexes	O
containing	O
different	O
NFAT-family	O
proteins	O
.	O

The	O
Ets	O
protein	O
Spi-B	O
is	O
expressed	O
exclusively	O
in	O
B	O
cells	O
and	O
T	O
cells	O
during	O
development	O
.	O

Spi-B	O
and	O
PU.1	O
are	O
hematopoietic-specific	O
transcription	O
factors	O
that	O
constitute	O
a	O
subfamily	O
of	O
the	O
Ets	O
family	O
of	O
DNA-binding	O
proteins	O
.	O

Here	O
we	O
show	O
that	O
contrary	O
to	O
previous	O
reports	O
,	O
PU.1	O
and	O
Spi-B	O
have	O
very	O
different	O
expression	O
patterns	O
.	O

PU.1	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
B	O
cells	O
,	O
mast	O
cells	O
,	O
megakaryocytes	O
,	O
macrophages	O
,	O
neutrophils	O
,	O
and	O
immature	O
erythroid	O
cells	O
and	O
at	O
lower	O
levels	O
in	O
mature	O
erythrocytes	O
.	O

PU.1	O
is	O
completely	O
absent	O
from	O
peripheral	O
T	O
cells	O
and	O
most	O
T	O
cell	O
lines	O
based	O
on	O
sensitive	O
RT-PCR	O
assays	O
.	O

In	O
contrast	O
,	O
Spi-B	O
is	O
expressed	O
exclusively	O
in	O
lymphoid	O
cells	O
and	O
can	O
be	O
detected	O
in	O
early	O
fetal	O
thymus	O
and	O
spleen	O
.	O

In	O
situ	O
hybridizations	O
of	O
adult	O
murine	O
tissues	O
demonstrate	O
Spi-B	O
mRNA	O
in	O
the	O
medulla	O
of	O
the	O
thymus	O
,	O
the	O
white	O
pulp	O
of	O
the	O
spleen	O
,	O
and	O
the	O
germinal	O
centers	O
of	O
lymph	O
nodes	O
.	O

Spi-B	O
expression	O
is	O
very	O
abundant	O
in	O
B	O
cells	O
and	O
both	O
Spi-B	O
mRNA	O
and	O
protein	O
are	O
detected	O
in	O
some	O
T	O
cells	O
.	O

In	O
situ	O
hybridization	O
and	O
Northern	O
blot	O
analysis	O
suggest	O
that	O
Spi-B	O
gene	O
expression	O
increases	O
during	O
B	O
cell	O
maturation	O
and	O
decreases	O
during	O
T	O
cell	O
maturation	O
.	O

Gel-retardation	O
experiments	O
show	O
that	O
Spi-B	O
can	O
bind	O
to	O
all	O
putative	B-Speculation
PU.1	I-Speculation
binding	I-Speculation
sites	I-Speculation
,	O
but	O
do	O
not	B-Negation
reveal	I-Negation
any	I-Negation
preferred	I-Negation
Spi-B	I-Negation
binding	I-Negation
site	I-Negation
.	O

Finally	O
,	O
both	O
PU.1	O
and	O
Spi-B	O
function	O
as	O
transcriptional	O
activators	O
of	O
the	O
immunoglobulin	O
light-chain	O
enhancer	O
E	O
lambda	O
2.4	O
when	O
coexpressed	O
with	O
Pip	O
(	O
PU.1-interaction	O
partner	O
)	O
in	O
NIH-3T3	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
differences	O
in	O
patterns	O
of	O
expression	O
between	O
Spi-B	O
and	O
PU.1	O
distinguish	O
the	O
function	O
of	O
each	O
protein	O
during	O
development	O
of	O
the	O
immune	O
system	O
.	O

Precise	O
alignment	O
of	O
sites	O
required	O
for	O
mu	O
enhancer	O
activation	O
in	O
B	O
cells	O
.	O

The	O
lymphocyte-specific	O
immunoglobulin	O
mu	O
heavy-chain	O
gene	O
intronic	O
enhancer	O
is	O
regulated	O
by	O
multiple	O
nuclear	O
factors	O
.	O

The	O
previously	O
defined	O
minimal	O
enhancer	O
containing	O
the	O
muA	O
,	O
muE3	O
,	O
and	O
muB	O
sites	O
is	O
transactivated	O
by	O
a	O
combination	O
of	O
the	O
ETS-domain	O
proteins	O
PU.1	O
and	O
Ets-1	O
in	O
nonlymphoid	O
cells	O
.	O

The	O
core	O
GGAAs	O
of	O
the	O
muA	O
and	O
muB	O
sites	O
are	O
separated	O
by	O
30	O
nucleotides	O
,	O
suggesting	O
that	O
ETS	O
proteins	O
bind	O
to	O
these	O
sites	O
from	O
these	O
same	O
side	O
of	O
the	O
DNA	O
helix	O
.	O

We	O
tested	O
the	O
necessity	O
for	O
appropriate	O
spatial	O
alignment	O
of	O
these	O
elements	O
by	O
using	O
mutated	O
enhancers	O
with	O
altered	O
spacings	O
.	O

A	O
4-	O
or	O
10-bp	O
insertion	O
between	O
muE3	O
and	O
muB	O
inactivated	O
the	O
mu	O
enhancer	O
in	O
S194	O
plasma	O
cells	O
but	O
did	O
not	B-Negation
affect	I-Negation
in	I-Negation
vitro	I-Negation
binding	I-Negation
of	I-Negation
Ets-1	I-Negation
,	I-Negation
PU.1	I-Negation
,	I-Negation
or	I-Negation
the	I-Negation
muE3-binding	I-Negation
protein	I-Negation
TFE3	I-Negation
,	I-Negation
alone	I-Negation
or	I-Negation
in	I-Negation
pairwise	I-Negation
combinations	I-Negation
.	O

Circular	O
permutation	O
and	O
phasing	O
analyses	O
demonstrated	O
that	O
PU.1	O
binding	O
but	O
not	B-Negation
TFE3	I-Negation
or	I-Negation
Ets-1	I-Negation
bends	O
mu	O
enhancer	O
DNA	O
toward	O
the	O
major	O
groove	O
.	O

We	O
propose	O
that	O
the	O
requirement	O
for	O
precise	O
spacing	O
of	O
the	O
muA	O
and	O
muB	O
elements	O
is	O
due	O
in	O
part	O
to	O
a	O
directed	O
DNA	O
bend	O
induced	O
by	O
PU.1	O
.	O

C/EBP	O
activators	O
are	O
required	O
for	O
HIV-1	O
replication	O
and	O
proviral	O
induction	O
in	O
monocytic	O
cell	O
lines	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
C/EBP	O
sites	O
and	O
C/EBP	O
transcriptional	O
activators	O
are	O
necessary	O
for	O
HIV-1	O
LTR	O
activity	O
in	O
monocytes/macrophages	O
.	O

We	O
have	O
investigated	O
the	O
role	O
that	O
C/EBP	O
proteins	O
play	O
in	O
induction	O
and	O
replication	O
of	O
HIV-1	O
.	O

Ectopic	O
expression	O
of	O
the	O
dominant	O
negative	O
C/EBP	O
protein	O
LIP	O
inhibited	O
HIV-1	O
mRNA	O
and	O
virus	O
production	O
in	O
activated	O
U1	O
cells	O
,	O
demonstrating	O
that	O
C/EBP	O
proteins	O
are	O
required	O
for	O
provirus	O
induction	O
.	O

U1	O
lines	O
overexpressing	O
C/EBP	O
activator	O
NF-IL-6	O
produced	O
more	O
viral	O
mRNA	O
and	O
virus	O
particles	O
following	O
cellular	O
activation	O
than	O
control	O
lines	O
,	O
demonstrating	O
that	O
C/EBP	O
proteins	O
are	O
limiting	O
for	O
virus	O
transcription	O
.	O

HIV-1	O
harboring	O
mutations	O
within	O
two	O
C/EBP	O
sites	O
were	O
crippled	O
in	O
their	O
ability	O
to	O
replicate	O
in	O
U937	O
promonocytic	O
cells	O
,	O
indicating	O
that	O
these	O
sites	O
are	O
required	O
for	O
replication	O
.	O

These	O
data	O
identify	O
C/EBP	O
proteins	O
as	O
regulators	O
of	O
HIV-1	O
expression	O
in	O
monocytes/macrophages	O
.	O

Reversal	O
of	O
apoptosis	O
by	O
the	O
leukaemia-associated	O
E2A-HLF	O
chimaeric	O
transcription	O
factor	O
.	O

The	O
E2A-HLF	O
(	O
for	O
hepatic	O
leukaemia	O
factor	O
)	O
fusion	O
gene	O
,	O
formed	O
by	O
action	O
of	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
(	O
q22	O
;	O
p13	O
)	O
chromosomal	O
translocation	O
,	O
drives	O
the	O
leukaemic	O
transformation	O
of	O
early	O
B-cell	O
precursors	O
,	O
but	O
the	O
mechanism	O
of	O
this	O
activity	O
remains	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
human	O
leukaemia	O
cells	O
carrying	O
the	O
translocation	O
t	O
(	O
17	O
;	O
19	O
)	O
rapidly	O
died	O
by	O
apoptosis	O
when	O
programmed	O
to	O
express	O
a	O
dominant-negative	O
suppressor	O
of	O
the	O
fusion	O
protein	O
E2A-HLF	O
,	O
indicating	O
that	O
the	O
chimaeric	O
oncoprotein	O
probably	O
affects	O
cell	O
survival	O
rather	O
than	O
cell	O
growth	O
.	O

Moreover	O
,	O
when	O
introduced	O
into	O
murine	O
pro-B	O
lymphocytes	O
,	O
the	O
oncogenic	O
E2A-HLF	O
fusion	O
protein	O
reversed	O
both	O
interleukin-3-dependent	O
and	O
p53-mediated	O
apoptosis	O
.	O

The	O
close	O
homology	O
of	O
the	O
basic	O
region/leucine	O
zipper	O
(	O
bZIP	O
)	O
DNA-binding	O
and	O
dimerization	O
domain	O
of	O
HLF	O
to	O
that	O
of	O
the	O
CES-2	O
cell-death	O
specification	O
protein	O
of	O
Caenorhabditis	O
elegans	O
suggests	O
a	O
model	O
of	O
leukaemogenesis	O
in	O
which	O
E2A-HLF	O
blocks	O
an	O
early	O
step	O
within	O
an	O
evolutionarily	O
conserved	O
cell-death	O
pathway	O
.	O

Effects	O
of	O
IL-10	O
and	O
IL-4	O
on	O
LPS-induced	O
transcription	O
factors	O
(	O
AP-1	O
,	O
NF-IL6	O
and	O
NF-kappa	O
B	O
)	O
which	O
are	O
involved	O
in	O
IL-6	O
regulation	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
,	O
like	O
IL-4	O
,	O
is	O
known	O
to	O
inhibit	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

We	O
showed	O
that	O
both	O
IL-10	O
and	O
IL-4	O
inhibit	O
LPS-induced	O
IL-6	O
mRNA	O
and	O
protein	O
expression	O
by	O
inhibiting	O
the	O
transcription	O
rate	O
of	O
the	O
IL-6	O
gene	O
.	O

The	O
strong	O
inhibition	O
of	O
the	O
IL-6	O
transcription	O
rate	O
prompted	O
us	O
to	O
study	O
the	O
effect	O
of	O
IL-10	O
and	O
IL-4	O
on	O
the	O
expression	O
of	O
transcription	O
factors	O
.	O

We	O
questioned	O
whether	O
or	O
not	O
IL-10	O
and	O
IL-4	O
affected	O
the	O
expression	O
of	O
transcription	O
factors	O
that	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
the	O
IL-6	O
transcription	O
rate	O
,	O
namely	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
nuclear	O
factor	O
IL-6	O
(	O
NF-IL6	O
)	O
,	O
and	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappaB	O
)	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
we	O
showed	O
that	O
IL-10	O
and	O
IL-4	O
inhibited	O
LPS-induced	O
AP-1	O
binding	O
activity	O
.	O

The	O
inhibiting	O
effect	O
of	O
IL-4	O
was	O
slightly	O
more	O
pronounced	O
than	O
that	O
of	O
IL-10	O
.	O

Downregulation	O
of	O
LPS-induced	O
AP-1	O
was	O
accompanied	O
,	O
and	O
thus	O
possibly	O
explained	O
,	O
by	O
a	O
reduced	O
expression	O
at	O
mRNA	O
level	O
of	O
the	O
two	O
major	O
components	O
of	O
the	O
AP-1	O
complex	O
,	O
namely	O
c-fos	O
and	O
c-jun	O
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Binding	O
activity	O
of	O
NF-IL6	O
was	O
also	O
strongly	O
inhibited	O
by	O
IL-4	O
whereas	O
IL-10	O
showed	O
no	B-Negation
effect	I-Negation
.	O

NF-IL6	O
mRNA	O
levels	O
were	O
not	B-Negation
affected	I-Negation
by	I-Negation
IL-10	I-Negation
or	I-Negation
IL-4	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
IL-4	I-Speculation
affects	I-Speculation
binding	I-Speculation
activity	I-Speculation
of	I-Speculation
preexisting	I-Speculation
NF-IL6	I-Speculation
.	O

Neither	B-Negation
IL-10	I-Negation
nor	I-Negation
IL-4	I-Negation
inhibited	I-Negation
LPS-induced	I-Negation
NF-kappa	I-Negation
B	I-Negation
binding	I-Negation
activity	I-Negation
.	O

In	O
agreement	O
with	O
this	O
finding	O
,	O
Northern	O
experiments	O
where	O
p65	O
and	O
p105	O
mRNA	O
levels	O
were	O
determined	O
,	O
demonstrated	O
that	O
expression	B-Negation
of	I-Negation
these	I-Negation
components	I-Negation
of	I-Negation
the	I-Negation
NF-kappa	I-Negation
B	I-Negation
transcription	I-Negation
factor	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
IL-10	I-Negation
or	I-Negation
IL-4	I-Negation
.	O

Furthermore	O
,	O
neither	B-Negation
IL-10	I-Negation
nor	I-Negation
IL-4	I-Negation
showed	I-Negation
any	I-Negation
effect	I-Negation
on	I-Negation
I-kappa	I-Negation
B	I-Negation
mRNA	I-Negation
expression	I-Negation
as	O
determined	O
by	O
Northern	O
experiments	O
.	O

Thus	O
,	O
IL-10	O
and	O
IL-4	O
similarly	O
affect	O
IL-6	O
expression	O
.	O

However	O
,	O
for	O
IL-4	O
this	O
was	O
accompanied	O
with	O
a	O
reduction	O
of	O
AP-1	O
and	O
NF-IL6	O
binding	O
activity	O
whereas	O
IL-10	O
only	O
inhibited	O
AP-1	O
binding	O
activity	O
.	O

Inhibition	O
of	O
transcription	O
factor	O
Stat1	O
activity	O
in	O
mononuclear	O
cell	O
cultures	O
and	O
T	O
cells	O
by	O
the	O
cyclic	O
AMP	O
signaling	O
pathway	O
.	O

Activation	O
of	O
T	O
cells	O
results	O
in	O
a	O
cascade	O
of	O
gene	O
activation	O
and	O
subsequent	O
proliferation	O
and	O
differentiation	O
into	O
effector	O
phenotypes	O
.	O

The	O
regulation	O
of	O
transcription	O
factors	O
belonging	O
to	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
was	O
analyzed	O
in	O
PHA-activated	O
mononuclear	O
cells	O
and	O
in	O
purified	O
T	O
cells	O
activated	O
by	O
cross-linking	O
cell	O
surface	O
CD3	O
.	O

Cell	O
activation	O
resulted	O
in	O
a	O
delayed	O
induction	O
of	O
STAT	O
DNA-binding	O
activity	O
,	O
which	O
was	O
sustained	O
for	O
several	O
days	O
,	O
was	O
composed	O
predominantly	O
of	O
Stat1	O
and	O
Stat3	O
,	O
and	O
was	O
blocked	O
by	O
cycloheximide	O
and	O
actinomycin	O
D	O
.	O

Increased	O
Stat1	O
and	O
Stat3	O
mRNA	O
and	O
protein	O
levels	O
were	O
detected	O
,	O
respectively	O
4	O
and	O
24	O
h	O
after	O
activation	O
.	O

Stimulation	O
of	O
the	O
cAMP	O
signal	O
transduction	O
pathway	O
,	O
which	O
skews	O
cytokine	O
production	O
toward	O
a	O
Th2	O
pattern	O
,	O
resulted	O
in	O
the	O
preferential	O
suppression	O
of	O
Stat1	O
activity	O
.	O

cAMP	O
inhibited	O
the	O
induction	O
of	O
expression	O
of	O
IL-2	O
receptor	O
components	O
,	O
but	O
did	O
not	B-Negation
inhibit	I-Negation
IL-4	I-Negation
receptor	I-Negation
alpha-chain	I-Negation
and	I-Negation
CD69	I-Negation
expression	I-Negation
or	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
activator	I-Negation
protein	I-Negation
1	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

cAMP	O
signaling	O
inhibited	O
Stat1	O
at	O
several	O
different	O
levels	O
,	O
including	O
suppression	O
of	O
DNA	O
binding	O
and	O
down-regulation	O
of	O
Stat1	O
protein	O
and	O
mRNA	O
levels	O
.	O

Our	O
results	O
demonstrate	O
the	O
regulation	O
of	O
STAT	O
activity	O
by	O
a	O
signaling	O
pathway	O
that	O
regulates	O
the	O
T	O
cell	O
functional	O
phenotype	O
and	O
is	O
distinct	O
from	O
the	O
cytokine-activated	O
Janus	O
kinase-STAT	O
signaling	O
pathway	O
.	O

oriP	O
is	O
essential	O
for	O
EBNA	O
gene	O
promoter	O
activity	O
in	O
Epstein-Barr	O
virus-immortalized	O
lymphoblastoid	O
cell	O
lines	O
.	O

During	O
Epstein-Barr	O
virus	O
latent	O
infection	O
of	O
B	O
lymphocytes	O
in	O
vitro	O
,	O
six	O
viral	O
nuclear	O
antigens	O
(	O
EBNAs	O
)	O
are	O
expressed	O
from	O
one	O
of	O
two	O
promoters	O
,	O
Cp	O
or	O
Wp	O
,	O
whose	O
activities	O
are	O
mutually	O
exclusive	O
.	O

Upon	O
infection	O
,	O
Wp	O
is	O
initially	O
active	O
,	O
followed	O
by	O
a	O
switch	O
to	O
Cp	O
for	O
the	O
duration	O
of	O
latency	O
.	O

In	O
this	O
study	O
,	O
the	O
region	O
upstream	O
of	O
Cp	O
was	O
analyzed	O
for	O
the	O
presence	O
of	O
cis	O
elements	O
involved	O
in	O
regulating	O
the	O
activities	O
of	O
the	O
EBNA	O
gene	O
promoters	O
in	O
established	O
in	O
vitro	O
immortalized	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

It	O
was	O
determined	O
that	O
oriP	O
,	O
the	O
origin	O
for	O
episomal	O
maintenance	O
during	O
latency	O
,	O
is	O
essential	O
for	O
efficient	O
transcription	O
initiation	O
from	O
either	O
Cp	O
or	O
Wp	O
in	O
LCLs	O
,	O
as	O
well	O
as	O
in	O
some	O
Burkitt	O
's	O
lymphoma	O
cell	O
lines	O
.	O

Deletion	O
of	O
the	O
EBNA2-dependent	O
enhancer	O
located	O
upstream	O
of	O
Cp	O
resulted	O
in	O
a	O
ca.	O
two-	O
to	O
fivefold	O
reduction	O
in	O
Cp	O
activity	O
in	O
the	O
LCLs	O
assayed	O
.	O

More	O
extensive	O
deletion	O
of	O
sequences	O
upstream	O
of	O
Cp	O
,	O
including	O
the	O
EBNA2-dependent	O
enhancer	O
,	O
resulted	O
in	O
nearly	O
complete	O
loss	O
of	O
Cp	O
activity	O
.	O

This	O
loss	O
of	O
activity	O
was	O
shown	O
to	O
correlate	O
with	O
deletion	O
of	O
two	O
CCAAT	O
boxes	O
,	O
a	O
proximal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-61	O
to	O
-65	O
and	O
a	O
distal	O
CCAAT	O
box	O
located	O
at	O
bp	O
-253	O
to	O
-257	O
,	O
upstream	O
of	O
Cp	O
.	O

Site-directed	O
mutagenesis	O
of	O
these	O
cis	O
elements	O
demonstrated	O
that	O
Cp	O
activity	O
is	O
highly	O
dependent	O
on	O
the	O
presence	O
of	O
a	O
properly	O
positioned	O
CCAAT	O
box	O
,	O
with	O
the	O
dependence	O
on	O
the	O
distal	O
CCAAT	O
box	O
apparent	O
only	O
when	O
the	O
proximal	O
CCAAT	O
box	O
was	O
deleted	O
or	O
mutated	O
.	O

Deletion	O
of	O
the	O
glucocorticoid	O
response	O
elements	O
located	O
at	O
ca.	O
bp	O
-850	O
upstream	O
of	O
Cp	O
did	O
not	B-Negation
result	I-Negation
in	I-Negation
a	I-Negation
significant	I-Negation
loss	I-Negation
in	I-Negation
activity	I-Negation
.	O

In	O
general	O
,	O
deletions	O
which	O
diminished	O
Cp	O
activity	O
resulted	O
in	O
induction	O
of	O
Wp	O
activity	O
,	O
consistent	O
with	O
suppression	O
of	O
Wp	O
activity	O
by	O
transcriptional	O
interference	O
from	O
Cp	O
.	O

The	O
identification	O
of	O
oriP	O
and	O
the	O
EBNA2-dependent	O
enhancer	O
as	O
the	O
major	O
positive	O
cis	O
elements	O
involved	O
in	O
regulating	O
Cp	O
activity	O
in	O
LCL	O
suggests	O
that	O
EBNA	O
gene	O
transcription	O
is	O
largely	O
autoregulated	O
by	O
EBNA	O
1	O
and	O
EBNA	O
2	O
.	O

Various	O
modes	O
of	O
basic	O
helix-loop-helix	O
protein-mediated	O
regulation	O
of	O
murine	O
leukemia	O
virus	O
transcription	O
in	O
lymphoid	O
cell	O
lines	O
.	O

The	O
transcriptionally	O
regulatory	O
regions	O
of	O
the	O
lymphomagenic	O
Akv	O
and	O
SL3-3	O
murine	O
leukemia	O
retroviruses	O
(	O
MLVs	O
)	O
contain	O
two	O
types	O
of	O
E-box	O
consensus	O
motifs	O
,	O
CAGATG	O
.	O

One	O
type	O
,	O
EA/S	O
,	O
is	O
located	O
in	O
the	O
upstream	O
promoter	O
region	O
,	O
and	O
the	O
other	O
,	O
E	O
(	O
gre	O
)	O
,	O
is	O
located	O
in	O
a	O
tandem	O
repeat	O
with	O
enhancer	O
properties	O
.	O

We	O
have	O
examined	O
the	O
requirements	O
of	O
the	O
individual	O
E-boxes	O
in	O
MLV	O
transcriptional	O
regulation	O
.	O

In	O
lymphoid	O
cell	O
lines	O
only	O
,	O
the	O
E	O
(	O
gre	O
)	O
-binding	O
protein	O
complexes	O
included	O
ALF1	O
or	O
HEB	O
and	O
E2A	O
basic	O
helix-loop-helix	O
proteins	O
.	O

Ectopic	O
ALF1	O
and	O
E2A	O
proteins	O
required	O
intact	O
E	O
(	O
gre	O
)	O
motifs	O
for	O
mediating	O
transcriptional	O
activation	O
.	O

ALF1	O
transactivated	O
transcription	O
of	O
Akv	O
MLV	O
through	O
the	O
two	O
E	O
(	O
gre	O
)	O
motifs	O
equally	O
,	O
whereas	O
E2A	O
protein	O
required	O
the	O
promoter-proximal	O
E	O
(	O
gre	O
)	O
motif	O
.	O

In	O
T-	O
and	O
B-cell	O
lines	O
,	O
the	O
E	O
(	O
gre	O
)	O
motifs	O
were	O
of	O
major	O
importance	O
for	O
Akv	O
MLV	O
transcriptional	O
activity	O
,	O
while	O
the	O
EA/S	O
motif	O
had	O
some	O
effect	O
.	O

In	O
contrast	O
,	O
neither	B-Negation
E	I-Negation
(	I-Negation
gre	I-Negation
)	I-Negation
nor	I-Negation
EA/S	I-Negation
motifs	I-Negation
contributed	I-Negation
pronouncedly	I-Negation
to	I-Negation
Akv	I-Negation
MLV	I-Negation
transcription	I-Negation
in	I-Negation
NIH	I-Negation
3T3	I-Negation
cells	I-Negation
lacking	I-Negation
DNA-binding	I-Negation
ALF1	I-Negation
or	I-Negation
HEB	I-Negation
and	I-Negation
E2A	I-Negation
proteins	I-Negation
.	O

The	O
Id1	O
protein	O
was	O
found	O
to	O
repress	O
ALF1	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
ectopic	O
Id1	O
repressed	O
E	O
(	O
gre	O
)	O
-directed	O
but	O
not	B-Negation
EA/S-directed	I-Negation
MLV	I-Negation
transcription	I-Negation
in	O
lymphoid	O
cell	O
lines	O
.	O

In	O
conclusion	O
,	O
E	O
(	O
gre	O
)	O
motifs	O
and	O
interacting	O
basic	O
helix-loop-helix	O
proteins	O
are	O
important	O
determinants	O
for	O
MLV	O
transcriptional	O
activity	O
in	O
lymphocytic	O
cell	O
lines	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
posttranscriptional	O
trans-activator	O
Rex	O
contains	O
a	O
nuclear	O
export	O
signal	O
.	O

The	O
Rex	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
is	O
required	O
for	O
the	O
nuclear	O
export	O
of	O
unspliced	O
viral	O
mRNA	O
and	O
,	O
therefore	O
,	O
for	O
virus	O
replication	O
.	O

In	O
this	O
manuscript	O
,	O
we	O
demonstrate	O
that	O
Rex	O
shuttles	O
between	O
the	O
nucleus	O
and	O
the	O
cytoplasm	O
and	O
that	O
its	O
activation	O
domain	O
constitutes	O
a	O
nuclear	O
export	O
signal	O
that	O
specifies	O
efficient	O
transport	O
to	O
the	O
cytoplasm	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
a	O
model	O
for	O
Rex-mediated	O
trans-activation	O
in	O
which	O
Rex-viral	O
mRNA	O
complexes	O
are	O
targeted	O
for	O
nuclear	O
export	O
by	O
the	O
direct	O
action	O
of	O
the	O
activation	O
domain	O
.	O

Multiple	O
p21ras	O
effector	O
pathways	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
transcription	O
factor	O
,	O
Nuclear	O
Factor	O
of	O
Activated	O
T	O
cells	O
(	O
NFAT	O
)	O
is	O
a	O
major	O
target	O
for	O
p21ras	O
and	O
calcium	O
signalling	O
pathways	O
in	O
the	O
IL-2	O
gene	O
and	O
is	O
induced	O
by	O
p21ras	O
signals	O
acting	O
in	O
synergy	O
with	O
calcium/calcineurin	O
signals	O
.	O

One	O
p21ras	O
effector	O
pathway	O
involves	O
the	O
MAP	O
kinase	O
ERK-2	O
,	O
and	O
we	O
have	O
examined	O
its	O
role	O
in	O
NFAT	O
regulation	O
.	O

Expression	O
of	O
dominant	O
negative	O
MAPKK-1	O
prevents	O
NFAT	O
induction	O
.	O

Constitutively	O
active	O
MAPKK-1	O
fully	O
activates	O
ERK-2	O
and	O
the	O
transcription	O
factor	O
Elk-1	O
,	O
but	O
does	O
not	B-Negation
substitute	I-Negation
for	I-Negation
activated	I-Negation
p21ras	I-Negation
and	I-Negation
synergize	I-Negation
with	I-Negation
calcium/calcineurin	I-Negation
signals	I-Negation
to	I-Negation
induce	I-Negation
NFAT	I-Negation
.	O

Expression	O
of	O
dominant	O
negative	O
N17Rac	O
alsoprevents	O
TCR	O
and	O
p21ras	O
activation	O
of	O
NFAT	O
,	O
but	O
without	B-Negation
interfering	I-Negation
with	I-Negation
the	I-Negation
ERK-2	I-Negation
pathway	I-Negation
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
NFAT	O
binding	O
site	O
is	O
mediated	O
by	O
a	O
complex	O
comprising	O
a	O
member	O
of	O
the	O
NFAT	O
group	O
and	O
AP-1	O
family	O
proteins	O
.	O

The	O
induction	O
of	O
AP-1	O
by	O
p21ras	O
alsorequires	O
Rac-1	O
function	O
.	O

Activated	O
Rac-1	O
could	O
mimic	O
activated	O
p21ras	O
to	O
induce	O
AP-1	O
but	O
not	O
to	O
induce	O
NFAT	O
.	O

Moreover	O
,	O
the	O
combination	O
of	O
activated	O
MAPKK-1	O
and	O
Rac-1	O
could	B-Negation
not	I-Negation
substitute	I-Negation
for	I-Negation
activated	I-Negation
p21ras	I-Negation
and	I-Negation
synergize	I-Negation
with	I-Negation
calcium	I-Negation
signals	I-Negation
to	I-Negation
induce	I-Negation
NFAT	I-Negation
.	O

Thus	O
,	O
p21ras	O
regulation	O
of	O
NFAT	O
in	O
T	O
cells	O
requires	O
the	O
activity	O
of	O
multiple	O
effector	O
pathways	O
including	O
those	O
regulated	O
by	O
MAPKK-1/ERK-2	O
and	O
Rac-1	O
.	O

Protein-tyrosine	O
kinase	O
activation	O
is	O
required	O
for	O
lipopolysaccharide	O
induction	O
of	O
interleukin	O
1beta	O
and	O
NFkappaB	O
activation	O
,	O
but	O
not	B-Negation
NFkappaB	I-Negation
nuclear	I-Negation
translocation	I-Negation
.	O

In	O
human	O
monocytes	O
,	O
interleukin	O
1beta	O
protein	O
production	O
and	O
steady	O
state	O
mRNA	O
levels	O
are	O
increased	O
in	O
response	O
to	O
lipopolysaccharide	O
,	O
predominantly	O
as	O
a	O
result	O
of	O
increased	O
transcription	O
of	O
the	O
interleukin	O
1beta	O
gene	O
.	O

Expression	O
of	O
interleukin	O
1beta	O
and	O
other	O
cytokines	O
,	O
such	O
as	O
interleukin	O
6	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
has	O
been	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NFkappaB	O
.	O

Since	O
recent	O
studies	O
have	O
shown	O
that	O
lipopolysaccharide-induced	B-Negation
tyrosine	I-Negation
kinase	I-Negation
activation	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
NFkappaB	I-Negation
nuclear	I-Negation
translocation	I-Negation
,	O
we	O
sought	O
to	O
determine	O
whether	B-Speculation
NFkappaB	I-Speculation
translocated	I-Speculation
in	I-Speculation
the	I-Speculation
absence	I-Speculation
of	I-Speculation
tyrosine	I-Speculation
kinase	I-Speculation
activity	I-Speculation
was	I-Speculation
active	I-Speculation
in	I-Speculation
stimulating	I-Speculation
transcription	I-Speculation
.	O

We	O
have	O
found	O
that	O
,	O
in	O
the	O
human	O
pro-monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
interleukin	O
1beta	O
is	O
dependent	O
on	O
tyrosine	O
kinase	O
activation	O
.	O

Tyrosine	O
kinases	O
are	O
not	B-Negation
required	I-Negation
for	I-Negation
lipopolysaccharide-mediated	I-Negation
nuclear	I-Negation
translocation	I-Negation
of	I-Negation
NFkappaB	I-Negation
.	O

However	O
,	O
in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
the	O
ability	O
of	O
NFkappaB	O
to	O
stimulate	O
transcription	O
is	O
impaired	O
.	O

This	O
inhibition	O
of	O
transcription	O
is	O
specific	O
for	O
NFkappaB	O
;	O

in	O
the	O
absence	O
of	O
tyrosine	O
kinase	O
activity	O
,	O
AP-1-dependent	O
transcription	O
is	O
enhanced	O
.	O

These	O
results	O
suggest	O
that	O
,	O
while	O
lipopolysaccharide-induced	O
expression	O
of	O
inflammatory	O
mediators	O
requires	O
tyrosine	O
kinase	O
activity	O
,	O
tyrosine	O
kinase	O
activity	O
is	O
not	O
obligatory	O
for	O
lipopolysaccharide	O
signal	O
transduction	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
preferentially	O
activates	O
the	O
94-kD	O
STAT5A	O
and	O
an	O
80-kD	O
STAT5A	O
isoform	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
induces	O
immediate	O
effects	O
in	O
monocytes	O
by	O
activation	O
of	O
the	O
Janus	O
kinase	O
(	O
JAK2	O
)	O
and	O
STAT	O
transcription	O
factor	O
(	O
STAT5	O
)	O
pathway	O
.	O

Recent	O
studies	O
have	O
identified	O
homologues	O
of	O
STAT5	O
,	O
STAT5A	O
,	O
and	O
STAT5B	O
,	O
as	O
well	O
as	O
lower	O
molecular	O
weight	O
variants	O
of	O
STAT5	O
.	O

To	O
define	O
the	O
activation	O
of	O
the	O
STAT5	O
homologues	O
and	O
lower	O
molecular	O
weight	O
variant	O
in	O
human	O
monocytes	O
and	O
monocytes	O
differentiated	O
into	O
macrophages	O
by	O
culture	O
in	O
macrophage-CSF	O
(	O
M-CSF	O
)	O
,	O
we	O
measured	O
the	O
GM-CSF	O
induced	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	O
,	O
STAT5B	O
,	O
and	O
any	O
lower	O
molecular	O
weight	O
STAT5	O
isoforms	O
.	O

Freshly	O
isolated	O
monocytes	O
expressed	O
94-kD	O
STAT5A	O
,	O
92-kD	O
STAT5B	O
,	O
and	O
an	O
80-kD	O
STAT5A	O
molecule	O
.	O

Whereas	O
94-kD	O
STAT5A	O
was	O
clearly	O
tyrosine	O
phosphorylated	O
and	O
bound	O
to	O
the	O
enhancer	O
element	O
,	O
the	O
gamma	O
response	O
region	O
(	O
GRR	O
)	O
,	O
of	O
the	O
Fc	O
gamma	O
RI	O
gene	O
,	O
substantially	O
less	O
tyrosine	O
phosphorylated	O
STAT5B	O
bound	O
to	O
the	O
immobilized	O
GRR	O
element	O
.	O

Macrophages	O
lost	O
their	O
ability	O
to	O
express	O
the	O
80-kD	O
STAT5A	O
protein	O
,	O
but	O
retained	O
their	O
ability	O
to	O
activate	O
STAT5A	O
.	O

STAT5A-STAT5A	O
homodimers	O
and	O
STAT5A-STAT5B	O
heterodimers	O
formed	O
in	O
response	O
to	O
GM-CSF	O
.	O

Therefore	O
,	O
activation	O
of	O
STAT5A	O
predominates	O
compared	O
to	O
STAT5B	O
when	O
assayed	O
by	O
direct	O
immunoprecipitation	O
and	O
by	O
evaluation	O
of	O
bound	O
STATs	O
to	O
immobilized	O
GRR	O
.	O

Selective	O
activation	O
of	O
STAT5	O
homologues	O
in	O
addition	O
to	O
generation	O
of	O
lower	O
molecular	O
isoforms	O
may	O
provide	O
specificity	O
and	O
control	O
to	O
genes	O
expressed	O
in	O
response	O
to	O
cytokines	O
such	O
as	O
GM-CSF	O
.	O

LYSP100-associated	O
nuclear	O
domains	O
(	O
LANDs	O
)	O
:	O
description	O
of	O
a	O
new	O
class	O
of	O
subnuclear	O
structures	O
and	O
their	O
relationship	O
to	O
PML	O
nuclear	O
bodies	O
.	O

The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
gene	O
in	O
t	O
(	O
15	O
;	O
17	O
)	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
,	O
creating	O
a	O
PML-RAR	O
alpha	O
fusion	O
oncoprotein	O
.	O

The	O
PML	O
gene	O
product	O
has	O
been	O
localized	O
to	O
subnuclear	O
dot-like	O
structures	O
variously	O
termed	O
PODs	O
,	O
ND10s	O
,	O
Kr	O
bodies	O
,	O
or	O
PML	O
nuclear	O
bodies	O
(	O
PML	O
NBs	O
)	O
.	O

The	O
present	O
study	O
describes	O
the	O
cloning	O
of	O
a	O
lymphoid-restricted	O
gene	O
,	O
LYSP100	O
,	O
that	O
is	O
homologous	O
to	O
another	O
protein	O
that	O
localizes	O
to	O
PML	O
NBs	O
,	O
SP100	O
.	O

In	O
addition	O
to	O
SP100	O
homology	O
regions	O
,	O
one	O
LYSP100	O
cDNA	O
isoform	O
contains	O
a	O
bromodomain	O
and	O
a	O
PHD/TTC	O
domain	O
,	O
which	O
are	O
present	O
in	O
a	O
variety	O
of	O
transcriptional	O
regulatory	O
proteins	O
.	O

By	O
immunofluorescence	O
,	O
LYSP100	O
was	O
localized	O
to	O
nuclear	O
dots	O
that	O
were	O
surprisingly	O
largely	O
nonoverlapping	O
with	O
PML	O
NBs	O
.	O

However	O
,	O
a	O
minority	O
of	O
LYSP100	O
nuclear	O
dots	O
exactly	O
colocalized	O
with	O
PML	O
and	O
SP100	O
.	O

We	O
term	O
the	O
LYSP100	O
structures	O
``	O
LANDs	O
,	O
``	O
for	O
LYSP100-associated	O
nuclear	O
domains	O
.	O

Although	O
LYSP100	O
is	O
expressed	O
only	O
in	O
lymphoid	O
cells	O
,	O
LANDs	O
could	O
be	O
visualized	O
in	O
HeLa	O
cells	O
by	O
transfection	O
of	O
a	O
LYSP100	O
cDNA	O
.	O

Immunoelectron	O
microscopy	O
revealed	O
LANDs	O
to	O
be	O
globular	O
,	O
electron-dense	O
structures	O
morphologically	O
distinct	O
from	O
the	O
annular	O
structures	O
characteristic	O
of	O
PML	O
NBs	O
.	O

LANDs	O
were	O
most	O
often	O
found	O
in	O
the	O
nucleoplasm	O
,	O
but	O
were	O
also	O
found	O
at	O
the	O
nuclear	O
membrane	O
and	O
in	O
the	O
cytoplasm	O
,	O
suggesting	O
that	O
these	O
structures	O
may	O
traffic	O
between	O
the	O
cytoplasm	O
and	O
the	O
nucleus	O
.	O

By	O
double-immunogold	O
labeling	O
of	O
PML	O
and	O
LYSP100	O
,	O
some	O
LANDs	O
were	O
shown	O
to	O
contain	O
both	O
PML	O
and	O
LYSP100	O
.	O

Thus	O
,	O
PML	O
is	O
localized	O
to	O
a	O
second	O
subnuclear	O
domain	O
that	O
is	O
morphologically	O
and	O
biochemically	O
distinct	O
from	O
PML	O
NBs	O
.	O

Abnormalities	O
of	O
p16	O
,	O
p15	O
and	O
CDK4	O
genes	O
in	O
recurrent	O
malignant	O
astrocytomas	O
.	O

Abnormalities	O
in	O
the	O
p16	O
,	O
p15	O
and	O
CDK4	O
genes	O
that	O
regulate	O
transition	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
have	O
been	O
implicated	O
in	O
the	O
malignant	O
progression	O
of	O
astrocytomas	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
demonstrate	O
that	O
dysfunction	O
of	O
these	O
genes	O
also	O
occurs	O
during	O
recurrence	O
of	O
glial	O
tumors	O
that	O
were	O
highly	O
malignant	O
at	O
first	O
presentation	O
.	O

Analysis	O
of	O
10	O
matched	O
pairs	O
of	O
high	O
grade	O
malignant	O
astrocytomas	O
and	O
their	O
subsequent	O
recurrences	O
identified	O
three	O
distinct	O
groups	O
.	O

The	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
A	O
did	O
not	B-Negation
show	I-Negation
structural	I-Negation
alterations	I-Negation
in	I-Negation
the	I-Negation
p16	I-Negation
,	I-Negation
p15	I-Negation
or	I-Negation
CDK4	I-Negation
genes	I-Negation
,	O
whereas	O
homozygous	O
codeletion	O
of	O
p16	O
and	O
p15	O
was	O
observed	O
in	O
both	O
primary	O
and	O
recurrent	O
tumors	O
in	O
Group	O
B	O
.	O

The	O
primary	O
tumors	O
in	O
Group	O
C	O
had	O
a	O
normal	O
profile	O
of	O
p16	O
,	O
p15	O
and	O
CDK4	O
at	O
presentation	O
.	O

Upon	O
recurrence	O
,	O
however	O
,	O
the	O
tumors	O
sustained	O
either	O
deletion	O
of	O
p16	O
alone	O
or	O
codeletion	O
of	O
both	O
p16	O
and	O
p15	O
or	O
amplification	O
of	O
CDK4	O
.	O

Analysis	O
of	O
the	O
molecular	O
differences	O
between	O
primary	O
anaplastic	O
astrocytomas/glioblastomas	O
and	O
their	O
subsequent	O
recurrences	O
,	O
which	O
are	O
clinically	O
indistinguishable	O
,	O
may	O
provide	O
better	O
therapeutic	O
options	O
for	O
treatment	O
.	O

CTL	O
recognition	O
of	O
an	O
altered	O
peptide	O
associated	O
with	O
asparagine	O
bond	O
rearrangement	O
.	O

Implications	O
for	O
immunity	O
and	O
vaccine	O
design	O
.	O

The	B-Negation
extent	I-Negation
to	I-Negation
which	I-Negation
peptides	I-Negation
containing	I-Negation
chemically	I-Negation
and	I-Negation
post-translationally	I-Negation
modified	I-Negation
amino	I-Negation
acid	I-Negation
side	I-Negation
chains	I-Negation
are	I-Negation
recognized	I-Negation
by	I-Negation
primed	I-Negation
CTL	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
clearly	I-Negation
defined	I-Negation
.	O

We	O
report	O
on	O
the	O
CTL	O
recognition	O
of	O
a	O
MHC	O
class	O
I-restricted	O
peptide	O
containing	O
a	O
cyclized	O
asparagine	O
(	O
succinimide	O
)	O
residue	O
.	O

This	O
modification	O
of	O
the	O
asparagine	O
side	O
chain	O
is	O
a	O
common	O
intermediate	O
structure	O
during	O
deamidation	O
,	O
isomerization	O
,	O
and	O
bond	O
rearrangements	O
of	O
amide-containing	O
amino	O
acids	O
and	O
also	O
occurs	O
as	O
a	O
side	O
reaction	O
in	O
peptide	O
synthesis	O
.	O

The	O
CTL	O
specifically	O
recognized	O
the	O
succinimide-containing	O
peptide	O
showing	O
only	O
weak	O
cross-reactivity	O
at	O
high	O
concentrations	O
of	O
the	O
parent	O
peptide	O
containing	O
unmodified	O
asparagine	O
.	O

Similarly	O
,	O
CTL	O
raised	O
against	O
the	O
parent	O
peptide	O
did	O
not	B-Negation
recognize	I-Negation
the	I-Negation
succinimide	I-Negation
derivative	I-Negation
of	I-Negation
this	I-Negation
peptide	I-Negation
.	O

Naturally	O
processed	O
forms	O
of	O
these	O
structures	O
are	O
likely	O
to	O
occur	O
given	O
the	O
importance	O
and	O
frequency	O
of	O
deamidation	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Moreover	O
,	O
since	O
succinimide	O
intermediates	O
of	O
deamidated	O
peptides	O
can	O
occasionally	O
be	O
very	O
stable	O
,	O
these	O
peptides	O
have	O
the	O
potential	O
to	O
act	O
as	O
altered	O
self-Ags	O
with	O
significant	O
implications	O
for	O
autoimmunity	O
.	O

In	O
addition	O
,	O
unwanted	O
and	O
potentially	O
hazardous	O
specificities	O
may	O
be	O
elicited	O
when	O
using	O
synthetic	O
peptides	O
in	O
subunit	O
vaccines	O
in	O
which	O
succinimide	O
residues	O
may	O
form	O
spontaneously	O
during	O
storage	O
or	O
chemical	O
synthesis	O
.	O

[	O
NGFI-B/nur77	O
family	O
involved	O
in	O
T-cell	O
apoptosis	O
]	O

NGFI-B/nur77	O
is	O
a	O
member	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
.	O

NGFI-B/nur77	O
and	O
its	O
related	O
genes	O
constitute	O
a	O
family	O
and	O
the	O
NGFI-B/nur77	O
family	O
consists	O
of	O
three	O
subtypes	O
,	O
named	O
nur77	O
alpha	O
,	O
nur77	O
beta	O
,	O
nur77	O
gamma	O
.	O

We	O
cloned	O
human	O
nur77	O
beta	O
cDNA	O
,	O
called	O
TINUR	O
.	O

Although	O
NGFI-B/nur77	O
is	O
essential	O
for	O
TCR-mediated	O
apoptosis	O
in	O
T-cell	O
hybridomas	O
,	O
the	O
reports	O
on	O
nur77	O
knock-out	O
mice	O
and	O
nur77	O
dominant	O
negative	O
transgenic	O
mice	O
suggest	O
that	O
there	O
is	O
a	O
functional	O
redundancy	O
among	O
NGFI-B/nur77	O
family	O
.	O

NGFI-B/nur77	O
binds	O
to	O
the	O
response	O
element	O
by	O
monomer	O
or	O
heterodimer	O
with	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
.	O

Assuming	O
that	O
9-cis-retinoic	O
acid	O
(	O
9-cis-RA	O
)	O
inhibits	O
TCR-mediated	O
apoptosis	O
,	O
nur77	O
may	O
cause	O
apoptosis	O
by	O
monomer	O
in	O
the	O
absence	O
of	O
9-cis-RA	O
and	O
may	O
inhibit	O
apoptosis	O
by	O
heterodimer	O
with	O
RXR	O
in	O
the	O
presence	O
of	O
9-cis-RA	O
.	O

Interaction	O
of	O
the	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
tax	O
transactivator	O
with	O
transcription	O
factor	O
IIA	O
.	O

The	O
Tax	O
protein	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
a	O
40-kDa	O
transcriptional	O
activator	O
which	O
is	O
critical	O
for	O
HTLV-1	O
gene	O
regulation	O
and	O
virus-induced	O
cellular	O
transformation	O
.	O

Tax	O
is	O
localized	O
to	O
the	O
DNA	O
through	O
its	O
interaction	O
with	O
the	O
site-specific	O
activators	O
cyclic	O
AMP-responsive	O
element-binding	O
protein	O
,	O
NF-kappaB	O
,	O
and	O
serum	O
response	O
factor	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
recruitment	O
of	O
Tax	O
to	O
the	O
DNA	O
positions	O
Tax	O
for	O
interaction	O
with	O
the	O
basal	O
transcriptional	O
machinery	O
.	O

On	O
the	O
basis	O
of	O
several	O
independent	O
assays	O
,	O
we	O
now	O
report	O
a	O
physical	O
and	O
functional	O
interaction	O
between	O
Tax	O
and	O
the	O
transcription	O
factor	O
,	O
TFIIA	O
.	O

First	O
,	O
Tax	O
was	O
found	O
to	O
interact	O
with	O
the	O
35-kDa	O
(	O
alpha	O
)	O
subunit	O
of	O
TFIIA	O
in	O
the	O
yeast	O
two-hybrid	O
interaction	O
system	O
.	O

Importantly	O
,	O
two	O
previously	O
characterized	O
mutants	O
with	O
point	O
mutations	O
in	O
Tax	O
,	O
M32	O
(	O
Y196A	O
,	O
K197S	O
)	O
and	O
M41	O
(	O
H287A	O
,	O
P288S	O
)	O
,	O
which	O
were	O
shown	O
to	O
be	O
defective	O
in	O
Tax-activated	O
transcription	O
were	O
unable	B-Negation
to	I-Negation
interact	I-Negation
with	I-Negation
TFIIA	I-Negation
in	I-Negation
this	I-Negation
assay	I-Negation
.	O

Second	O
,	O
a	O
glutathione-S-transferase	O
(	O
GST	O
)	O
affinity-binding	O
assay	O
showed	O
that	O
the	O
interaction	O
of	O
holo-TFIIA	O
with	O
GST-Tax	O
was	O
20-fold	O
higher	O
than	O
that	O
observed	O
with	O
either	O
the	O
GST-Tax	O
M32	O
activation	O
mutant	O
or	O
the	O
GST	O
control	O
.	O

Third	O
,	O
a	O
coimmunoprecipitation	O
assay	O
showed	O
that	O
in	O
HTLV-1-infected	O
human	O
T	O
lymphocytes	O
,	O
Tax	O
and	O
TFIIA	O
were	O
associated	O
.	O

Finally	O
,	O
TFIIA	O
facilitates	O
Tax	O
transactivation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
vitro	O
transcription	O
studies	O
showed	O
reduced	O
levels	O
of	O
Tax-activated	O
transcription	O
in	O
cell	O
extracts	O
depleted	O
of	O
TFIIA	O
.	O

In	O
addition	O
,	O
transfection	O
of	O
human	O
T	O
lymphocytes	O
with	O
TFIIA	O
expression	O
vectors	O
enhanced	O
Tax-activated	O
transcription	O
of	O
an	O
HTLV-1	O
long	O
terminal	O
repeat-chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
.	O

Our	O
study	O
suggests	O
that	O
the	O
interaction	O
of	O
Tax	O
with	O
the	O
transcription	O
factor	O
TFIIA	O
may	O
play	O
a	O
role	O
in	O
Tax-mediated	O
transcriptional	O
activation	O
.	O

Peptide	O
vaccination	O
can	O
lead	O
to	O
enhanced	O
tumor	O
growth	O
through	O
specific	O
T-cell	O
tolerance	O
induction	O
.	O

Vaccination	O
with	O
synthetic	O
peptides	O
representing	O
cytotoxic	O
T	O
lymphocyte	O
(	O
CTL	O
)	O
epitopes	O
can	O
lead	O
to	O
a	O
protective	O
CTL-mediated	O
immunity	O
against	O
tumors	O
or	O
viruses	O
.	O

We	O
now	O
report	O
that	O
vaccination	O
with	O
a	O
CTL	O
epitope	O
derived	O
from	O
the	O
human	O
adenovirus	O
type	O
5	O
E1A-region	O
(	O
Ad5E1A234-243	O
)	O
,	O
which	O
can	O
serve	O
as	O
a	O
target	O
for	O
tumor-eradicating	O
CTL	O
,	O
enhances	O
rather	B-Negation
than	I-Negation
inhibits	I-Negation
the	O
growth	O
of	O
Ad5E1A-expressing	O
tumors	O
.	O

This	O
adverse	O
effect	O
of	O
peptide	O
vaccination	O
was	O
rapidly	O
evoked	O
,	O
required	O
low	O
doses	O
of	O
peptide	O
(	O
10	O
micrograms	O
)	O
,	O
and	O
was	O
achieved	O
by	O
a	O
mode	O
of	O
peptide	O
delivery	O
that	O
induces	O
protective	O
T-cell-mediated	O
immunity	O
in	O
other	O
models	O
.	O

Ad5E1A-specific	B-Negation
CTL	I-Negation
activity	I-Negation
could	I-Negation
no	I-Negation
longer	I-Negation
be	I-Negation
isolated	I-Negation
from	I-Negation
mice	I-Negation
after	I-Negation
injection	I-Negation
of	I-Negation
Ad5E1A-peptide	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
tolerization	I-Speculation
of	I-Speculation
Ad5E1A-specific	I-Speculation
CTL	I-Speculation
activity	I-Speculation
causes	I-Speculation
the	I-Speculation
enhanced	I-Speculation
tumor	I-Speculation
outgrowth	I-Speculation
.	O

In	O
contrast	O
to	O
peptide	O
vaccination	O
,	O
immunization	O
with	O
adenovirus	O
,	O
expressing	O
Ad5E1A	O
,	O
induced	O
Ad5E1A-specific	O
immunity	O
and	O
prevented	O
the	O
outgrowth	O
of	O
Ad5E1A-expressing	O
tumors	O
.	O

These	O
results	O
show	O
that	O
immunization	O
with	O
synthetic	O
peptides	O
can	O
lead	O
to	O
the	O
elimination	O
of	O
anti-tumor	O
CTL	O
responses	O
.	O

These	O
findings	O
are	O
important	O
for	O
the	O
design	O
of	O
safe	O
peptide-based	O
vaccines	O
against	O
tumors	O
,	O
allogeneic	O
organ	O
transplants	O
,	O
and	O
T-cell-mediated	O
autoimmune	O
diseases	O
.	O

Transgenic	O
expression	O
of	O
PML/RARalpha	O
impairs	O
myelopoiesis	O
.	O

The	O
translocation	O
found	O
in	O
acute	O
promyelocytic	O
leukemia	O
rearranges	O
the	O
promyelocytic	O
leukemia	O
gene	O
(	O
PML	O
)	O
on	O
chromosome	O
15	O
with	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RARalpha	O
)	O
on	O
chromosome	O
17	O
.	O

This	O
yields	O
a	O
fusion	O
transcript	O
,	O
PML/RARalpha	O
,	O
a	O
transcription	O
factor	O
with	O
reported	O
dominant	O
negative	O
functions	O
in	O
the	O
absence	O
of	O
hormone	O
.	O

Clinical	O
remissions	O
induced	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
treatment	O
in	O
acute	O
promyelocytic	O
leukemia	O
are	O
linked	O
to	O
PML/RARalpha	O
expression	O
in	O
leukemic	O
cells	O
.	O

To	O
evaluate	O
the	O
PML/RARalpha	O
role	O
in	O
myelopoiesis	O
,	O
transgenic	O
mice	O
expressing	O
PML/RARalpha	O
were	O
engineered	O
.	O

A	O
full-length	O
PML/RARalpha	O
cDNA	O
driven	O
by	O
the	O
CD11b	O
promoter	O
was	O
expressed	O
in	O
transgenic	O
mice	O
.	O

Expression	O
was	O
confirmed	O
in	O
the	O
bone	O
marrow	O
with	O
a	O
reverse	O
transcription	O
PCR	O
assay	O
.	O

Basal	O
total	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
did	O
not	B-Negation
appreciably	I-Negation
differ	I-Negation
between	I-Negation
PML/RARalpha	I-Negation
transgenic	I-Negation
and	I-Negation
control	I-Negation
mice	I-Negation
.	O

Cell	O
sorter	O
analysis	O
of	O
CD11b+	O
bone	O
marrow	O
cells	O
revealed	O
similar	O
CD11b+	O
populations	O
in	O
transgenic	O
and	O
control	O
mice	O
.	O

However	O
,	O
in	O
vitro	O
clonal	O
growth	O
assays	O
performed	O
on	O
peripheral	O
blood	O
from	O
transgenic	O
versus	O
control	O
mice	O
revealed	O
a	O
marked	O
reduction	O
of	O
myeloid	O
progenitors	O
,	O
especially	O
in	O
those	O
responding	O
to	O
granulocyte/macrophage	O
colony-stimulating	O
factor	O
.	O

Granulocyte/macrophage	O
colony-stimulating	O
factor	O
and	O
kit	O
ligand	O
cotreatment	O
did	O
not	B-Negation
overcome	I-Negation
this	I-Negation
inhibition	I-Negation
.	O

Impaired	O
myelopoiesis	O
in	O
vivo	O
was	O
shown	O
by	O
stressing	O
these	O
mice	O
with	O
sublethal	O
irradiation	O
.	O

Following	O
irradiation	O
,	O
PML/RARalpha	O
transgenic	O
mice	O
,	O
as	O
compared	O
with	O
controls	O
,	O
more	O
rapidly	O
depressed	O
peripheral	O
white	O
blood	O
cell	O
and	O
granulocyte	O
counts	O
.	O

As	O
expected	O
,	O
nearly	O
all	O
control	O
mice	O
(	O
94.4	O
%	O
)	O
survived	O
irradiation	O
,	O
yet	O
this	O
irradiation	O
was	O
lethal	O
to	O
45.8	O
%	O
of	O
PML/RARalpha	O
transgenic	O
mice	O
.	O

Lethality	O
was	O
associated	O
with	O
more	O
severe	O
leukopenia	O
in	O
transgenic	O
versus	O
control	O
mice	O
.	O

Retinoic	O
acid	O
treatment	O
of	O
irradiated	O
PML/RARalpha	O
mice	O
enhanced	O
granulocyte	O
recovery	O
.	O

These	O
data	O
suggest	O
that	O
abnormal	O
myelopoiesis	O
due	O
to	O
PML/RARalpha	O
expression	O
is	O
an	O
early	O
event	O
in	O
oncogenic	O
transformation	O
.	O

Defective	O
transcription	O
of	O
the	O
IL-2	O
gene	O
is	O
associated	O
with	O
impaired	O
expression	O
of	O
c-Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
in	O
anergic	O
T	O
helper	O
1	O
cells	O
.	O

Anergic	O
CD4+	O
Th	O
cells	O
do	O
not	B-Negation
produce	I-Negation
IL-2	I-Negation
when	I-Negation
challenged	I-Negation
with	I-Negation
Ag-pulsed	I-Negation
accessory	I-Negation
cells	I-Negation
because	O
of	O
a	O
transcriptional	O
defect	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
that	O
these	O
anergic	O
T	O
cells	O
are	O
defective	O
in	O
their	O
ability	O
to	O
up-regulate	O
protein	O
binding	O
and	O
transactivation	O
at	O
two	O
critical	O
IL-2	O
DNA	O
enhancer	O
elements	O
:	O
NF-AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
;	O
a	O
sequence	O
that	O
binds	O
a	O
heterotrimeric	O
NFATp	O
,	O
Fos	O
,	O
and	O
Jun	O
protein	O
complex	O
)	O
and	O
Activator	O
Protein-1	O
(	O
AP-1	O
)	O
(	O
that	O
binds	O
Fos	O
and	O
Jun	O
heterodimers	O
)	O
.	O

Western	O
blot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
that	O
the	O
impaired	O
DNA-protein	O
interactions	O
in	O
anergic	O
T	O
cells	O
were	O
associated	O
with	O
poor	O
expression	O
of	O
the	O
inducible	O
AP-1	O
family	O
members	O
c-Fos	O
,	O
FosB	O
,	O
and	O
JunB	O
.	O

However	O
,	O
the	O
reduced	O
expression	O
of	O
these	O
proteins	O
was	O
not	B-Negation
the	I-Negation
result	I-Negation
of	I-Negation
a	I-Negation
global	I-Negation
TCR/CD3-signaling	I-Negation
defect	I-Negation
because	O
CD3	O
cross-linking	O
induced	O
an	O
equivalent	O
increase	O
in	O
intracellular-free	O
calcium	O
ions	O
,	O
as	O
well	O
as	O
NFATp	O
dephosphorylation	O
,	O
translocation	O
to	O
the	O
nucleus	O
,	O
and	O
DNA	O
binding	O
in	O
both	O
normal	O
and	O
anergic	O
T	O
cells	O
.	O

Thus	O
,	O
defective	O
IL-2	O
gene	O
transcription	O
appears	O
to	O
be	O
due	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
a	O
selective	O
block	O
in	O
the	O
expression	O
of	O
the	O
AP-1	O
Fos	O
and	O
Jun	O
family	O
members	O
in	O
anergic	O
T	O
cells	O
.	O

Elevated	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB-mediated	O
transcription	O
in	O
human	O
monocytic	O
cells	O
and	O
endothelial	O
cells	O
.	O

The	O
NF-kappaB/Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
many	O
genes	O
in	O
activated	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
molecular	O
mechanism	O
by	O
which	O
agents	O
that	O
elevate	O
intracellular	O
cAMP	O
inhibit	O
the	O
expression	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
,	O
tissue	O
factor	O
,	O
endothelial	O
leukocyte	O
adhesion	O
molecule-1	O
,	O
and	O
vascular	O
cell	O
adhesion	O
molecule-1	O
genes	O
.	O

Both	O
forskolin	O
and	O
dibutyryl	O
cAMP	O
,	O
which	O
elevate	O
intracellular	O
cAMP	O
by	O
independent	O
mechanisms	O
,	O
inhibited	O
TNFalpha	O
and	O
tissue	O
factor	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Induction	O
of	O
NF-kappaB-dependent	O
gene	O
expression	O
in	O
transiently	O
transfected	O
human	O
monocytic	O
THP-1	O
cells	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
was	O
inhibited	O
by	O
elevated	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Elevated	O
cAMP	O
did	O
not	B-Negation
prevent	I-Negation
nuclear	I-Negation
translocation	I-Negation
of	I-Negation
p50/p65	I-Negation
and	I-Negation
c-Rel/p65	I-Negation
heterodimers	I-Negation
,	I-Negation
decrease	I-Negation
nuclear	I-Negation
translocation	I-Negation
of	I-Negation
p65	I-Negation
,	I-Negation
or	I-Negation
significantly	I-Negation
modify	I-Negation
TNFalpha-induced	I-Negation
phosphorylation	I-Negation
of	I-Negation
p65	I-Negation
.	O

Functional	O
studies	O
demonstrated	O
that	O
transcriptional	O
activation	O
of	O
a	O
plasmid	O
containing	O
multimerized	O
kappaB	O
sites	O
by	O
p65	O
was	O
inhibited	O
by	O
agents	O
that	O
elevate	O
cAMP	O
and	O
by	O
overexpression	O
of	O
the	O
catalytic	O
subunit	O
of	O
PKA	O
.	O

This	O
study	O
indicates	O
that	O
activation	O
of	O
PKA	O
reduces	O
the	O
induction	O
of	O
a	O
distinct	O
set	O
of	O
genes	O
in	O
monocytes	O
and	O
endothelial	O
cells	O
by	O
inhibiting	O
NF-kappaB-mediated	O
transcription	O
.	O

Characterization	O
of	O
a	O
new	O
isoform	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
gene	O
family	O
member	O
NFATc	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1996	O
Dec	O
27	O
;	O
271	O
(	O
52	O
)	O
:33705	O
]	O

The	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
/FK506-sensitive	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
expression	O
of	O
cytokine	O
genes	O
in	O
T	O
cells	O
.	O

Although	O
NFAT	O
has	O
been	O
recently	O
shown	O
to	O
be	O
inducible	O
in	O
several	O
non-T	O
immune	O
cells	O
,	O
the	O
NFAT	O
gene	O
family	O
members	O
characterized	O
to	O
date	O
have	O
been	O
isolated	O
only	O
from	O
T	O
cells	O
.	O

To	O
further	O
characterize	O
NFAT	O
function	O
in	O
human	O
B	O
cells	O
and	O
to	O
demonstrate	O
cytokine	O
gene	O
specificity	O
of	O
NFAT	O
proteins	O
,	O
we	O
report	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
cDNA	O
clone	O
from	O
the	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
cDNA	O
clone	O
encodes	O
a	O
new	O
isoform	O
,	O
NFATc.beta	O
,	O
of	O
the	O
NFAT	O
gene	O
family	O
member	O
NFATc	O
(	O
designated	O
here	O
NFATc.alpha	O
)	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
NFATc.beta	O
differs	O
from	O
that	O
of	O
NFATc	O
.	O

alpha	O
in	O
the	O
first	O
NH2-terminal	O
29	O
residues	O
and	O
contains	O
an	O
additional	O
region	O
of	O
142	O
residues	O
at	O
the	O
COOH	O
terminus	O
.	O

Northern	O
analysis	O
using	O
a	O
probe	O
encompassing	O
a	O
common	O
region	O
of	O
both	O
isoforms	O
showed	O
two	O
mRNA	O
species	O
of	O
2.7	O
and	O
4.5	O
kilobase	O
pairs	O
,	O
while	O
an	O
NFATc.beta-specific	O
probe	O
detected	O
only	O
the	O
4.5-kilobase	O
pair	O
mRNA	O
which	O
was	O
preferentially	O
expressed	O
in	O
the	O
spleen	O
.	O

Transient	O
expression	O
of	O
NFATc.beta	O
was	O
capable	O
of	O
activating	O
an	O
interleukin-2	O
NFAT-driven	O
reporter	O
gene	O
in	O
stimulated	O
Jurkat	O
cells	O
in	O
a	O
CsA-sensitive	O
manner	O
.	O

However	O
,	O
NFATc.beta	O
neither	B-Negation
bound	I-Negation
to	I-Negation
the	I-Negation
kappa3	I-Negation
element	I-Negation
(	I-Negation
an	I-Negation
NFAT-binding	I-Negation
site	I-Negation
)	I-Negation
in	I-Negation
the	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
promoter	I-Negation
nor	I-Negation
activated	I-Negation
the	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
promoter	I-Negation
in	I-Negation
cotransfection	I-Negation
assays	I-Negation
.	O

These	O
data	O
suggest	O
that	O
different	O
members	O
or	O
isoforms	O
of	O
NFAT	O
gene	O
family	O
may	O
regulate	O
inducible	O
expression	O
of	O
different	O
cytokine	O
genes	O
.	O

Activation	O
of	O
human	O
monocytic	O
cells	O
by	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
lipoproteins	O
and	O
synthetic	O
lipopeptides	O
proceeds	O
via	O
a	O
pathway	O
distinct	O
from	O
that	O
of	O
lipopolysaccharide	O
but	O
involves	O
the	O
transcriptional	O
activator	O
NF-kappa	O
B	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
lipoproteins	O
of	O
Treponema	O
pallidum	O
and	O
Borrelia	O
burgdorferi	O
are	O
key	O
inflammatory	O
mediators	O
during	O
syphilis	O
and	O
Lyme	O
disease	O
.	O

A	O
principal	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
more	O
precisely	O
similarities	O
and	O
divergences	O
among	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-	O
and	O
lipoprotein-lipopeptide-induced	O
immune	O
cell	O
signaling	O
events	O
.	O

Like	O
LPS	O
,	O
purified	O
native	O
B.	O
burgdorferi	O
OspA	O
and	O
synthetic	O
analogs	O
of	O
OspA	O
,	O
OspB	O
,	O
and	O
two	O
T.	O
pallidum	O
lipoproteins	O
(	O
Tpp47	O
and	O
Tpp17	O
)	O
all	O
induced	O
NF-kappa	O
B	O
translocation	O
in	O
THP-1	O
human	O
monocytoid	O
cells	O
.	O

Acylation	O
of	O
OspA	O
and	O
the	O
synthetic	O
peptides	O
was	O
requisite	O
for	O
cell	O
activation	O
.	O

Polymyxin	O
B	O
abrogated	O
only	O
the	O
response	O
to	O
LPS	O
.	O

By	O
using	O
70Z/3-derived	O
pre-B-cell	O
lines	O
either	B-Speculation
lacking	I-Speculation
or	I-Speculation
expressing	I-Speculation
human	I-Speculation
CD14	I-Speculation
(	I-Speculation
the	I-Speculation
LPS	I-Speculation
receptor	I-Speculation
)	I-Speculation
,	O
it	O
was	O
observed	O
that	O
expression	O
of	O
human	O
CD14	O
imparted	O
responsiveness	O
to	O
LPS	O
but	O
not	B-Negation
to	I-Negation
OspA	I-Negation
or	I-Negation
spirochetal	I-Negation
lipopeptides	I-Negation
(	O
assessed	O
by	O
induction	O
of	O
NF-kappa	O
B	O
and	O
expression	O
of	O
surface	O
immunoglobulin	O
M	O
)	O
.	O

Finally	O
,	O
the	O
biological	O
relevance	O
of	O
the	O
observation	O
that	O
T.	O
pallidum	O
lipoproteins-lipopeptides	O
induce	O
both	O
NF-kappa	O
B	O
and	O
cytokine	O
production	O
in	O
monocytes	O
was	O
supported	O
by	O
the	O
ability	O
of	O
the	O
synthetic	O
analogs	O
to	O
promote	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
chronically	O
infected	O
U1	O
monocytoid	O
cells	O
;	O

these	O
observations	O
also	O
suggest	O
a	O
potential	O
mechanism	O
whereby	O
a	O
syphilitic	O
chancre	O
can	O
serve	O
as	O
a	O
cofactor	O
for	O
human	O
immunodeficiency	O
virus	O
transmission	O
.	O

The	O
combined	O
data	O
lend	O
additional	O
support	O
to	O
the	O
proposal	O
that	O
spirochetal	O
lipoproteins	O
and	O
LPS	O
initiate	O
monocyte	O
activation	O
via	O
different	O
cell	O
surface	O
events	O
but	O
that	O
the	O
signaling	O
pathways	O
ultimately	O
converge	O
to	O
produce	O
qualitatively	O
similar	O
cellular	O
responses	O
.	O

Chronic	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
infection	O
of	O
myeloid	O
cells	O
disrupts	O
the	O
autoregulatory	O
control	O
of	O
the	O
NF-kappaB/Rel	O
pathway	O
via	O
enhanced	O
IkappaBalpha	O
degradation	O
.	O

Productive	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
causes	O
sustained	O
NF-kappaB	O
DNA-binding	O
activity	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
direct	O
temporal	O
correlation	O
exists	O
between	O
HIV	O
infection	O
and	O
the	O
appearance	O
of	O
NF-kappaB	O
DNA-binding	O
activity	O
in	O
myelomonoblastic	O
PLB-985	O
cells	O
.	O

To	O
examine	O
the	O
molecular	O
basis	O
of	O
constitutive	O
NF-kappaB	O
DNA-binding	O
activity	O
in	O
HIV1-infected	O
cells	O
,	O
we	O
analyzed	O
the	O
phosphorylation	O
and	O
turnover	O
of	O
IkappaBalpha	O
protein	O
,	O
the	O
activity	O
of	O
the	O
double-stranded	O
RNA-dependent	O
protein	O
kinase	O
(	O
PKR	O
)	O
and	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	O
subunits	O
in	O
the	O
PLB-985	O
and	O
U937	O
myeloid	O
cell	O
models	O
.	O

HIV-1	O
infection	O
resulted	O
in	O
constitutive	O
,	O
low-level	O
expression	O
of	O
type	O
1	O
interferon	O
(	O
IFN	O
)	O
at	O
the	O
mRNA	O
level	O
.	O

Constitutive	O
PKR	O
activity	O
was	O
also	O
detected	O
in	O
HIV-1-infected	O
cells	O
as	O
a	O
result	O
of	O
low-level	O
IFN	O
production	O
,	O
since	O
the	O
addition	O
of	O
anti-IFN-alpha/beta	O
antibody	O
to	O
the	O
cells	O
decreased	O
PKR	O
expression	O
.	O

Furthermore	O
,	O
the	O
analysis	O
of	O
IkappaBalpha	O
turnover	O
demonstrated	O
an	O
increased	O
degradation	O
of	O
IkappaBalpha	O
in	O
HIV-1-infected	O
cells	O
that	O
may	O
account	O
for	O
the	O
constitutive	O
DNA	O
binding	O
activity	O
.	O

A	O
dramatic	O
increase	O
in	O
the	O
intracellular	O
levels	O
of	O
NF-kappaB	O
subunits	O
c-Rel	O
and	O
NF-kappaB2	O
p100	O
and	O
a	O
moderate	O
increase	O
in	O
NF-kappaB2	O
p52	O
and	O
RelA	O
(	O
p65	O
)	O
were	O
detected	O
in	O
HIV-1-infected	O
cells	O
,	O
whereas	O
NF-kappaB1	B-Negation
p105/p50	I-Negation
levels	I-Negation
were	I-Negation
not	I-Negation
altered	I-Negation
relative	I-Negation
to	I-Negation
the	I-Negation
levels	I-Negation
in	I-Negation
uninfected	I-Negation
cells	I-Negation
.	O

We	O
suggest	O
that	O
HIV-1	O
infection	O
of	O
myeloid	O
cells	O
induces	O
IFN	O
production	O
and	O
PKR	O
activity	O
,	O
which	O
in	O
turn	O
contribute	O
to	O
enhanced	O
IkappaBalpha	O
phosphorylation	O
and	O
subsequent	O
degradation	O
.	O

Nuclear	O
translocation	O
of	O
NF-kappaB	O
subunits	O
may	O
ultimately	O
increase	O
the	O
intracellular	O
pool	O
of	O
NF-kappaB/IkappaBalpha	O
by	O
an	O
autoregulatory	O
mechanism	O
.	O

Enhanced	O
turnover	O
of	O
IkappaBalpha	O
and	O
the	O
accumulation	O
of	O
NF-kappaB/Rel	O
proteins	O
may	O
contribute	O
to	O
the	O
chronically	O
activated	O
state	O
of	O
HIV-1-infected	O
cells	O
.	O

Transcriptional	O
analysis	O
of	O
Epstein-Barr	O
virus	O
gene	O
expression	O
in	O
EBV-positive	O
gastric	O
carcinoma	O
:	O
unique	O
viral	O
latency	O
in	O
the	O
tumour	O
cells	O
.	O

Although	O
case-oriented	O
evidence	O
for	O
an	O
association	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
with	O
gastric	O
carcinoma	O
has	O
been	O
accumulating	O
recently	O
,	O
the	O
interaction	O
(	O
s	O
)	O
between	O
EBV	O
and	O
gastric	O
epithelial	O
cells	O
is/are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
seven	O
EBV-positive	O
gastric	O
carcinoma	O
tissues	O
for	O
viral	O
gene	O
expression	O
at	O
the	O
mRNA	O
level	O
,	O
from	O
which	O
studies	O
on	O
the	O
EBV	O
oncogenicity	O
in	O
human	O
epithelial	O
cells	O
will	O
benefit	O
.	O

Reverse	O
transcription-PCR	O
analysis	O
showed	O
that	O
all	O
seven	O
EBV-positive	O
tumour	O
tissues	O
constitutively	O
expressed	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
1	O
mRNA	O
,	O
but	O
not	B-Negation
EBNA2	I-Negation
mRNA	I-Negation
.	O

The	O
EBNA	O
transcription	O
was	O
initiated	O
from	O
one	O
of	O
three	O
EBNA	O
promoters	O
,	O
Qp	O
:	O

by	O
contrast	O
,	O
both	O
Cp	O
and	O
Wp	O
were	O
silent	O
,	O
thus	O
resulting	O
in	O
the	O
lack	B-Negation
of	I-Negation
EBNA2	I-Negation
mRNA	I-Negation
.	O

Latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
2A	O
mRNA	O
was	O
detected	O
in	O
three	O
of	O
seven	O
cases	O
;	O

however	O
,	O
neither	B-Negation
LMP1	I-Negation
nor	I-Negation
LMP2B	I-Negation
mRNA	I-Negation
was	I-Negation
detected	I-Negation
in	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
tumours	I-Negation
tested	I-Negation
.	O

Transcripts	O
from	O
the	O
BamHI-A	O
region	O
of	O
the	O
viral	O
genome	O
were	O
detectable	O
in	O
all	O
cases	O
.	O

BZLF1	B-Negation
mRNA	I-Negation
and	I-Negation
the	I-Negation
product	I-Negation
,	I-Negation
an	I-Negation
immediate-early	I-Negation
gene	I-Negation
for	I-Negation
EBV	I-Negation
replication	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
expressed	I-Negation
in	I-Negation
any	I-Negation
of	I-Negation
them	I-Negation
,	O
thereby	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
tumour	I-Speculation
cells	I-Speculation
carried	I-Speculation
EBV	I-Speculation
genomes	I-Speculation
in	I-Speculation
a	I-Speculation
tightly	I-Speculation
latent	I-Speculation
form	I-Speculation
.	O

These	O
findings	O
further	O
extended	O
our	O
previous	O
data	O
regarding	O
EBV	O
latency	O
in	O
gastric	O
carcinoma	O
cells	O
at	O
the	O
protein	O
level	O
,	O
and	O
have	O
affirmed	O
that	O
the	O
programme	O
of	O
viral	O
gene	O
expression	O
in	O
the	O
tumour	O
more	O
closely	O
resembles	O
'latency	O
I	O
'	O
represented	O
by	O
Burkitt	O
's	O
lymphoma	O
than	O
'latency	O
II	O
'	O
represented	O
by	O
the	O
majority	O
of	O
nasopharyngeal	O
carcinomas	O
.	O

Sequence-specific	O
DNA	O
binding	O
of	O
the	O
B-cell-specific	O
coactivator	O
OCA-B	O
.	O

B-cell-specific	O
transcription	O
of	O
immunoglobulin	O
genes	O
is	O
mediated	O
by	O
the	O
interaction	O
of	O
a	O
POU	O
domain	O
containing	O
transcription	O
factor	O
Oct-1	O
or	O
Oct-2	O
,	O
with	O
the	O
B-cell-specific	O
coactivator	O
OCA-B	O
(	O
Bob-1	O
,	O
OBF-1	O
)	O
and	O
a	O
prototype	O
octamer	O
element	O
.	O

We	O
find	O
that	O
OCA-B	O
binds	O
DNA	O
directly	O
in	O
the	O
major	O
groove	O
between	O
the	O
two	O
subdomains	O
of	O
the	O
POU	O
domain	O
,	O
requiring	O
both	O
an	O
A	O
at	O
the	O
fifth	O
position	O
of	O
the	O
octamer	O
element	O
and	O
contact	O
with	O
the	O
POU	O
domain	O
.	O

An	O
amino-terminal	O
fragment	O
of	O
OCA-B	O
binds	O
the	O
octamer	O
site	O
in	O
the	O
absence	O
of	O
a	O
POU	O
domain	O
with	O
the	O
same	O
sequence	O
specificity	O
.	O

Coactivator	O
OCA-B	O
may	O
undergo	O
a	O
POU-dependent	O
conformational	O
change	O
that	O
exposes	O
its	O
amino	O
terminus	O
,	O
allowing	O
it	O
to	O
recognize	O
specific	O
DNA	O
sequences	O
in	O
the	O
major	O
groove	O
within	O
the	O
binding	O
site	O
for	O
Oct-1	O
or	O
Oct-2	O
.	O

The	O
recognition	O
of	O
both	O
the	O
POU	O
domain	O
and	O
the	O
octamer	O
sequence	O
by	O
OCA-B	O
provides	O
a	O
mechanism	O
for	O
differential	O
regulation	O
of	O
octamer	O
sites	O
containing	O
genes	O
by	O
the	O
ubiquitous	O
factor	O
Oct-1	O
.	O

The	O
role	O
of	O
early	O
growth	O
response	O
gene	O
1	O
(	O
egr-1	O
)	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

The	O
induction	O
of	O
immediate	O
early	O
genes	O
in	O
cells	O
of	O
the	O
immune	O
system	O
is	O
critical	O
to	O
determining	O
the	O
ultimate	O
outcome	O
of	O
exposure	O
to	O
antigen	O
.	O

The	O
importance	O
of	O
many	O
of	O
these	O
genes	O
relates	O
to	O
the	O
role	O
their	O
transcription	O
factor	O
products	O
play	O
in	O
dictating	O
patterns	O
of	O
expression	O
of	O
downstream	O
,	O
function-related	O
genes	O
.	O

Evidence	O
from	O
several	O
systems	O
indicates	O
that	O
the	O
immediate	O
early	O
gene	O
,	O
egr-1	O
may	O
be	O
of	O
particular	O
importance	O
in	O
the	O
immune	O
system	O
.	O

Recently	O
,	O
the	O
egr-1	O
promoter	O
has	O
been	O
shown	O
to	O
be	O
highly	O
responsive	O
to	O
the	O
diverse	O
biochemical	O
signals	O
generated	O
by	O
antigen	O
and	O
cytokines	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Furthermore	O
,	O
an	O
important	O
role	O
for	O
egr-1	O
in	O
determining	O
the	O
differentiation	O
pathway	O
of	O
myeloid	O
cell	O
precursors	O
has	O
been	O
recently	O
elaborated	O
.	O

Finally	O
,	O
potential	O
targets	O
of	O
regulation	O
by	O
the	O
zinc-finger	O
transcription	O
factor	O
encoded	O
by	O
egr-1	O
include	O
the	O
interleukin-2	O
,	O
CD44	O
,	O
ICAM-1	O
,	O
and	O
tumor	O
necrosis	O
factor	O
genes	O
.	O

The	O
role	O
of	O
egr-1	O
in	O
regulation	O
of	O
the	O
immune	O
response	O
will	O
be	O
discussed	O
in	O
the	O
context	O
of	O
these	O
recent	O
studies	O
.	O

Translocation	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
:	O
a	O
new	O
variant	O
translocation	O
in	O
a	O
patient	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
of	O
B-cell	O
type	O
with	O
BCL6	O
rearrangement	O
.	O

We	O
report	O
a	O
65-year-old	O
woman	O
with	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
carrying	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
and	O
BCL6	O
rearrangement	O
in	O
the	O
affected	O
cells	O
.	O

She	O
had	O
generalized	O
lymphadenopathy	O
and	O
the	O
bone	O
marrow	O
was	O
infiltrated	O
by	O
lymphoma	O
cells	O
at	O
presentation	O
.	O

Histological	O
diagnosis	O
was	O
``	O
malignant	O
lymphoma	O
,	O
diffuse	O
,	O
large	O
cell	O
``	O
type	O
according	O
to	O
an	O
International	O
Working	O
Formulation	O
.	O

Chromosome	O
analysis	O
revealed	O
a	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q11	O
)	O
,	O
which	O
is	O
a	O
new	O
variant	O
translocation	O
of	O
t	O
(	O
3	O
;	O
14	O
)	O
(	O
q27	O
;	O
q32	O
)	O
.	O

Southern	O
blot	O
analysis	O
showed	O
rearrangement	O
of	O
BCL6	O
,	O
JH	O
,	O
and	O
TCR	O
beta	O
but	O
not	B-Negation
of	I-Negation
TCR	I-Negation
delta	I-Negation
.	O

Cosmid	O
probe	O
of	O
BCL6	O
hybridized	O
to	O
14q11	O
and	O
3q27	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
.	O

Although	O
the	O
band	O
14q11	O
is	O
a	O
locus	O
of	O
T-cell	O
receptor	O
alpha-	O
and	O
delta-chains	O
(	O
TCR	O
alpha/delta	O
)	O
,	O
lymphoma	O
cells	O
expressed	O
B-cell	O
,	O
IgGk	O
phenotype	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
novel	O
proto-oncogene	O
in	O
the	O
vicinity	O
of	O
TCR	O
alpha/delta	O
is	O
involved	O
in	O
this	O
translocation	O
.	O

Cross	O
talk	O
between	O
cell	O
death	O
and	O
cell	O
cycle	O
progression	O
:	O
BCL-2	O
regulates	O
NFAT-mediated	O
activation	O
.	O

BCL-2-deficient	O
T	O
cells	O
demonstrate	O
accelerated	O
cell	O
cycle	O
progression	O
and	O
increased	O
apoptosis	O
following	O
activation	O
.	O

Increasing	O
the	O
levels	O
of	O
BCL-2	O
retarded	O
the	O
G0	O
--	O
>	O
S	O
transition	O
,	O
sustained	O
the	O
levels	O
of	O
cyclin-dependent	O
kinase	O
inhibitor	O
p27Kip1	O
,	O
and	O
repressed	O
postactivation	O
death	O
.	O

Proximal	O
signal	O
transduction	O
events	O
and	O
immediate	O
early	O
gene	O
transcription	O
were	O
unaffected	O
.	O

However	O
,	O
the	O
transcription	O
and	O
synthesis	O
of	O
interleukin	O
2	O
and	O
other	O
delayed	O
early	O
cytokines	O
were	O
markedly	O
attenuated	O
by	O
BCL-2	O
.	O

In	O
contrast	O
,	O
a	O
cysteine	O
protease	O
inhibitor	O
that	O
also	O
blocks	O
apoptosis	O
had	O
no	B-Negation
substantial	I-Negation
affect	I-Negation
upon	I-Negation
cytokine	I-Negation
production	I-Negation
.	O

InterleUkin	O
2	O
expression	O
requires	O
several	O
transcription	O
factors	O
of	O
which	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
and	O
NFAT-mediated	O
transactivation	O
were	O
impaired	O
by	O
BCL-2	O
.	O

Thus	O
,	O
select	O
genetic	O
aberrations	O
in	O
the	O
apoptotic	O
pathway	O
reveal	O
a	O
cell	O
autonomous	O
coregulation	O
of	O
activation	O
.	O

Activation	O
of	O
Stat	O
5b	O
in	O
erythroid	O
progenitors	O
correlates	O
with	O
the	O
ability	O
of	O
ErbB	O
to	O
induce	O
sustained	O
cell	O
proliferation	O
.	O

Self	O
renewal	O
of	O
normal	O
erythroid	O
progenitors	O
is	O
induced	O
by	O
the	O
receptor	O
tyrosine	O
kinase	O
c-ErbB	O
,	O
whereas	O
other	O
receptors	O
(	O
c-Kit/Epo-R	O
)	O
regulate	O
erythroid	O
differentiation	O
.	O

To	O
address	O
possible	O
mechanisms	O
that	O
could	O
explain	O
this	O
selective	O
activity	O
of	O
c-ErbB	O
,	O
we	O
analyzed	O
the	O
ability	O
of	O
these	O
receptors	O
to	O
activate	O
the	O
different	O
members	O
of	O
the	O
Stat	O
transcription	O
factor	O
family	O
.	O

Ligand	O
activation	O
of	O
c-ErbB	O
induced	O
the	O
tyrosine	O
phosphorylation	O
,	O
DNA-binding	O
,	O
and	O
reporter	O
gene	O
transcription	O
of	O
Stat	O
5b	O
in	O
erythroblasts	O
.	O

In	O
contrast	O
,	O
ligand	O
activation	O
of	O
c-Kit	O
was	O
unable	B-Negation
to	I-Negation
induce	I-Negation
any	I-Negation
of	I-Negation
these	I-Negation
effects	I-Negation
in	I-Negation
the	I-Negation
same	I-Negation
cells	I-Negation
.	O

Activation	O
of	O
the	O
erythropoietin	O
receptor	O
caused	O
specific	O
DNA-binding	O
of	O
Stat	O
5b	O
,	O
but	O
failed	B-Negation
to	I-Negation
induce	I-Negation
reporter	I-Negation
gene	I-Negation
transcription	I-Negation
.	O

These	O
biochemical	O
findings	O
correlate	O
perfectly	O
with	O
the	O
selective	O
ability	O
of	O
c-ErbB	O
to	O
cause	O
sustained	O
self	O
renewal	O
in	O
erythroid	O
progenitors	O
.	O

Calcineurin	O
mutants	O
render	O
T	O
lymphocytes	O
resistant	O
to	O
cyclosporin	O
A	O
.	O

The	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
have	O
been	O
widely	O
used	O
to	O
prevent	O
and	O
treat	O
graft	O
rejection	O
after	O
human	O
organ	O
and	O
tissue	O
transplantations	O
.	O

CsA	O
and	O
FK506	O
associate	O
with	O
intracellular	O
binding	O
proteins	O
(	O
i.e.	O
,	O
CsA	O
with	O
cyclophilin	O
A	O
and	O
FK506	O
with	O
FKBP12	O
)	O
to	O
form	O
protein/drug	O
complexes	O
that	O
suppress	O
the	O
immune	O
system	O
by	O
preventing	O
activation	O
of	O
T	O
cells	O
in	O
response	O
to	O
antigen	O
presentation	O
.	O

The	O
common	O
target	O
of	O
CsA	O
and	O
FK506	O
is	O
calcineurin	O
,	O
a	O
Ca2+/calmodulin-regulated	O
,	O
serine/threonine-specific	O
protein	O
phosphatase	O
that	O
regulates	O
the	O
nuclear	O
import	O
of	O
a	O
transcription	O
factor	O
,	O
NF-AT	O
,	O
required	O
for	O
expression	O
of	O
T	O
cell	O
activation	O
genes	O
.	O

In	O
previous	O
studies	O
,	O
we	O
identified	O
calcineurin	O
mutations	O
that	O
block	O
binding	O
by	O
the	O
cyclophilin	O
A/CsA	O
or	O
FKBP12/FK506	O
complexes	O
and	O
thereby	O
render	O
yeast	O
cells	O
resistant	O
to	O
the	O
antifungal	O
effects	O
of	O
CsA	O
or	O
FK506	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
corresponding	O
mutations	O
in	O
murine	O
calcineurin	O
render	O
the	O
T	O
cell	O
receptor	O
signal	O
transduction	O
cascade	O
CsA	O
resistant	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

Our	O
findings	O
support	O
the	O
recently	O
determined	O
calcineurin	O
X-ray	O
crystal	O
structure	O
,	O
provide	O
evidence	O
that	O
calcineurin	O
is	O
the	O
only	O
CsA-sensitive	O
component	O
limiting	O
signaling	O
from	O
the	O
T	O
cell	O
receptor	O
to	O
the	O
nucleus	O
,	O
and	O
suggest	O
a	O
means	O
to	O
render	O
cells	O
and	O
tissues	O
resistant	O
to	O
the	O
toxic	O
side	O
effects	O
of	O
CsA	O
and	O
FK506	O
.	O

Retinoid	O
differentiation	O
therapy	O
in	O
promyelocytic	O
leukemia	O
.	O

Acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
a	O
specific	O
type	O
of	O
acute	O
myeloid	O
leukemia	O
characterized	O
by	O
the	O
morphology	O
of	O
the	O
blast	O
cells	O
,	O
a	O
specific	O
t	O
(	O
15	O
;	O
17	O
)	O
translocation	O
,	O
and	O
risks	O
of	O
definite	O
coagulopathy	O
.	O

Recently	O
this	O
leukemia	O
was	O
further	O
characterized	O
by	O
an	O
exquisite	O
sensitivity	O
to	O
all-trans	O
retinoic	O
acid	O
's	O
differentiation	O
effect	O
and	O
the	O
production	O
of	O
a	O
fusion	O
gene	O
altering	O
the	O
gene	O
of	O
RARalpha	O
and	O
a	O
novel	O
gene	O
PML	O
.	O

In	O
vivo	O
differentiation	O
therapy	O
with	O
retinoids	O
in	O
APL	O
patients	O
follows	O
strict	O
guidelines	O
related	O
both	O
to	O
the	O
APL	O
cell	O
and	O
the	O
biodisposal	O
of	O
all-trans	O
retinoic	O
acid	O
.	O

Epstein-Barr	O
viral	O
latency	O
is	O
disrupted	O
by	O
the	O
immediate-early	O
BRLF1	O
protein	O
through	O
a	O
cell-specific	O
mechanism	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
the	O
causative	O
agent	O
of	O
infectious	O
mononucleosis	O
,	O
is	O
a	O
human	O
herpesvirus	O
associated	O
with	O
epithelial	O
cell	O
malignancies	O
(	O
nasopharyngeal	O
carcinoma	O
)	O
as	O
well	O
as	O
B-cell	O
malignancies	O
.	O

Understanding	O
how	O
viral	O
latency	O
is	O
disrupted	O
is	O
a	O
central	O
issue	O
in	O
herpesvirus	O
biology	O
.	O

Epithelial	O
cells	O
are	O
the	O
major	O
site	O
of	O
lytic	O
EBV	O
replication	O
within	O
the	O
human	O
host	O
,	O
and	O
viral	O
reactivation	O
occurs	O
in	O
EBV-associated	O
nasopharyngeal	O
carcinomas	O
.	O

It	O
is	O
known	O
that	O
expression	O
of	O
a	O
single	O
viral	O
immediate-early	O
protein	O
,	O
BZLF1	O
,	O
is	O
sufficient	O
to	O
initiate	O
the	O
switch	O
from	O
latent	O
to	O
lytic	O
infection	O
in	O
B	O
cells	O
.	O

Cellular	O
regulation	O
of	O
BZLF1	O
transcription	O
is	O
therefore	O
thought	O
to	O
play	O
a	O
key	O
role	O
in	O
regulating	O
the	O
stringency	O
of	O
viral	O
latency	O
.	O

Here	O
we	O
show	O
that	O
,	O
unexpectedly	O
,	O
expression	O
of	O
another	O
viral	O
immediate-early	O
protein	O
,	O
BRLF1	O
,	O
can	O
disrupt	O
viral	O
latency	O
in	O
an	O
epithelial	O
cell-specific	O
fashion	O
.	O

Therefore	O
,	O
the	O
mechanisms	O
leading	O
to	O
disruption	O
of	O
EBV	O
latency	O
appear	O
to	O
be	O
cell-type	O
specific	O
.	O

IL4	O
and	O
IL13	O
receptors	O
share	O
the	O
gamma	O
c	O
chain	O
and	O
activate	O
STAT6	O
,	O
STAT3	O
and	O
STAT5	O
proteins	O
in	O
normal	O
human	O
B	O
cells	O
.	O

IL13	O
induces	O
the	O
same	O
biological	O
effects	O
as	O
IL4	O
in	O
normal	O
human	O
B	O
cells	O
.	O

We	O
show	O
that	O
as	O
in	O
the	O
IL4R	O
complex	O
,	O
both	O
IL4R	O
alpha	O
and	O
IL2R	O
gamma	O
c	O
are	O
components	O
of	O
the	O
IL13R	O
and	O
that	O
both	O
cytokines	O
induced	O
STAT6	O
,	O
STAT3	O
and	O
STAT5	O
activation	O
in	O
B	O
cells	O
.	O

In	O
spite	O
of	O
this	O
similar	O
downstream	O
signalling	O
,	O
IL4	O
and	O
IL13	O
used	O
a	O
different	O
set	O
of	O
Janus	O
kinases	O
:	O

IL13	O
is	O
unable	B-Negation
to	I-Negation
activate	I-Negation
JAK1	I-Negation
and	I-Negation
JAK3	I-Negation
.	O

Attenuated	O
function	O
of	O
a	O
variant	O
form	O
of	O
the	O
helix-loop-helix	O
protein	O
,	O
Id-3	O
,	O
generated	O
by	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

The	O
Id	O
family	O
of	O
helix-loop-helix	O
proteins	O
function	O
as	O
negative	O
regulators	O
of	O
DNA	O
binding	O
,	O
basic	O
helix-loop-helix	O
proteins	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

We	O
report	O
here	O
on	O
the	O
identification	O
of	O
a	O
17	O
kDa	O
variant	O
of	O
the	O
14	O
kDa	O
Id-3	O
protein	O
termed	O
Id-3L	O
(	O
long	O
version	O
)	O
which	O
possesses	O
a	O
unique	O
60	O
amino	O
acid	O
carboxy-terminus	O
generated	O
by	O
read	O
through	O
of	O
a	O
'	O
coding	O
intron	O
'	O
and	O
alternative	O
splicing	O
.	O

Northern	O
analysis	O
revealed	O
expression	O
of	O
a	O
minor	O
1.1	O
kb	O
Id-3L	O
transcript	O
together	O
with	O
the	O
predominant	O
0.95	O
kb	O
Id-3	O
transcript	O
in	O
the	O
majority	O
of	O
adult	O
human	O
tissues	O
analysed	O
.	O

The	O
variant	O
Id-3L	O
protein	O
is	O
functionally	O
distinguishable	O
from	O
conventional	O
Id-3	O
since	O
in	O
in	O
vitro	O
DNA	O
mobility	O
shift	O
assays	O
,	O
it	O
was	O
greatly	O
impaired	O
in	O
its	O
ability	O
to	O
abrogate	O
binding	O
of	O
the	O
basic	O
helix-loop-helix	O
protein	O
,	O
E47	O
,	O
to	O
an	O
E	O
box	O
recognition	O
sequence	O
.	O

Multifactor	O
cis-dominant	O
negative	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
in	O
anergized	O
T	O
cells	O
.	O

The	B-Negation
molecular	I-Negation
mechanism	I-Negation
underlying	I-Negation
IL-2	I-Negation
transcriptional	I-Negation
blockade	I-Negation
in	I-Negation
anergic	I-Negation
T	I-Negation
cell	I-Negation
clones	I-Negation
is	I-Negation
not	I-Negation
fully	I-Negation
understood	I-Negation
.	O

To	O
examine	O
whether	O
an	O
active	O
negative	O
regulatory	O
process	O
occurs	O
,	O
we	O
created	O
a	O
reporter	O
construct	O
containing	O
as	O
an	O
enhancer	O
four	O
copies	O
of	O
the	O
NF-AT	O
site	O
and	O
one	O
copy	O
of	O
the	O
octamer	O
site	O
(	O
4X	O
NF-AT-Oct	O
)	O
.	O

This	O
construct	O
was	O
only	O
slightly	O
reduced	O
(	O
1.3-fold	O
)	O
in	O
its	O
expression	O
when	O
stimulated	O
under	O
anergic	O
conditions	O
,	O
while	O
a	O
whole	O
mouse	O
IL-2	O
enhancer	O
construct	O
showed	O
a	O
reduction	O
of	O
4.3-fold	O
.	O

Addition	O
of	O
the	O
-176	O
to	O
-96	O
sequence	O
to	O
the	O
4X	O
NF-AT-Oct	O
construct	O
did	O
not	B-Negation
impart	I-Negation
the	I-Negation
ability	I-Negation
to	I-Negation
be	I-Negation
affected	I-Negation
by	I-Negation
anergy	I-Negation
,	O
but	O
addition	O
of	O
the	O
-236	O
to	O
-96	O
sequence	O
did	O
,	O
demonstrating	O
that	O
anergy	O
is	O
an	O
active	O
inhibitory	O
process	O
and	O
that	O
more	O
than	O
the	O
presence	O
of	O
the	O
-150	O
AP-1	O
binding	O
site	O
(	O
-152	O
to	O
-147	O
)	O
is	O
required	O
to	O
mediate	O
the	O
effect	O
.	O

Mutational	O
studies	O
of	O
the	O
-236	O
to	O
-96	O
sequence	O
indicated	O
that	O
the	O
presence	O
of	O
both	O
the	O
-130	O
AP-1-like	O
site	O
(	O
-187	O
to	O
-181	O
)	O
and	O
the	O
-150	O
proximal	O
AP-1	O
site	O
were	O
necessary	O
to	O
observe	O
anergy	O
.	O

Because	O
the	B-Negation
-180	I-Negation
site	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
trans-activation	I-Negation
,	O
it	O
was	O
possible	B-Speculation
to	I-Speculation
confirm	I-Speculation
by	I-Speculation
mutation	I-Speculation
in	I-Speculation
the	I-Speculation
normal	I-Speculation
mouse	I-Speculation
IL-2	I-Speculation
enhancer	I-Speculation
that	I-Speculation
this	I-Speculation
site	I-Speculation
is	I-Speculation
absolutely	I-Speculation
essential	I-Speculation
for	I-Speculation
anergy	I-Speculation
induction	I-Speculation
.	O

The	O
simplest	O
model	O
to	O
explain	O
these	O
results	O
is	O
that	O
anergy	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
multiple	O
transcription	O
factors	O
that	O
exert	O
a	O
cis-acting	O
dominant	O
negative	O
regulatory	O
effect	O
on	O
the	O
trans-activation	O
of	O
the	O
IL-2	O
gene	O
.	O

Characterization	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
gene	O
promoter	O
.	O

MNDA	O
(	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
)	O
is	O
an	O
interferon	O
alpha	O
regulated	O
nuclear	O
protein	O
expressed	O
only	O
in	O
cells	O
of	O
the	O
human	O
myelomonocytic	O
lineage	O
.	O

To	O
identify	O
mechanisms	O
responsible	O
for	O
this	O
lineage-specific	O
and	O
interferon-regulated	O
expression	O
,	O
the	O
5	O
'	O
flanking	O
sequence	O
of	O
the	O
gene	O
has	O
been	O
characterized	O
.	O

Two	O
interferon-stimulated	O
response	O
elements	O
(	O
ISRE	O
)	O
flank	O
a	O
multiple	O
transcription	O
start	O
site	O
region	O
identifying	O
MNDA	O
as	O
a	O
TATA-less	O
interferon-regulated	O
gene	O
.	O

Other	O
DNA	O
elements	O
present	O
include	O
a	O
cluster	O
of	O
Myb	O
sites	O
,	O
several	O
Ets	O
,	O
an	O
Ets	O
related	O
PU.1	O
site	O
and	O
an	O
Sp1	O
site	O
located	O
within	O
600	O
bp	O
of	O
the	O
transcription	O
start	O
sites	O
.	O

In	O
addition	O
,	O
DNA	O
methylation	O
was	O
revealed	O
as	O
one	O
of	O
the	O
possible	O
factors	O
in	O
establishing	O
MNDA	O
expression	O
.	O

The	O
5	O
'	O
flanking	O
sequence	O
has	O
promoter	O
activity	O
which	O
is	O
elevated	O
by	O
interferon	O
alpha	O
.	O

The	O
findings	O
indicate	O
that	O
MNDA	O
expression	O
is	O
regulated	O
by	O
mechanisms	O
similar	O
to	O
other	O
myelomonocytic	O
cell	O
specific	O
genes	O
and	O
genes	O
up-regulated	O
by	O
interferon	O
alpha	O
.	O

Regulation	O
of	O
GM-CSF	O
gene	O
transcription	O
by	O
core-binding	O
factor	O
.	O

GM-CSF	O
gene	O
activation	O
in	O
T	O
cells	O
is	O
known	O
to	O
involve	O
the	O
transcription	O
factors	O
nuclear	O
factor-kappa	O
B	O
,	O
AP-1	O
,	O
NFAT	O
,	O
and	O
Sp1	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
human	O
GM-CSF	O
promoter	O
and	O
enhancer	O
also	O
encompass	O
binding	O
sites	O
for	O
core-binding	O
factor	O
(	O
CBF	O
)	O
.	O

Significantly	O
,	O
the	O
CBF	O
sites	O
are	O
in	O
each	O
case	O
contained	O
within	O
the	O
minimum	O
essential	O
core	O
regions	O
required	O
for	O
inducible	O
activation	O
of	O
transcription	O
.	O

Furthermore	O
,	O
these	O
core	O
regions	O
of	O
the	O
enhancer	O
and	O
promoter	O
each	O
encompass	O
closely	O
linked	O
binding	O
sites	O
for	O
CBF	O
,	O
AP-1	O
,	O
and	O
NFATp	O
.	O

The	O
GM-CSF	O
promoter	O
CBF	O
site	O
TGTGGTCA	O
is	O
located	O
51	O
bp	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
and	O
also	O
overlaps	O
a	O
YY-1	O
binding	O
site	O
.	O

A	O
2-bp	O
mutation	O
within	O
the	O
CBF	O
site	O
resulted	O
in	O
a	O
2-3-fold	O
decrease	O
in	O
the	O
activities	O
of	O
both	O
a	O
69-bp	O
proximal	O
promoter	O
fragment	O
and	O
a	O
627-bp	O
full-length	O
promoter	O
fragment	O
.	O

Stepwise	O
deletions	O
into	O
the	O
proximal	O
promoter	O
also	O
revealed	O
that	O
the	O
CBF	O
site	O
,	O
but	O
not	B-Negation
the	I-Negation
YY-1	I-Negation
site	I-Negation
,	O
was	O
required	O
for	O
efficient	O
induction	O
of	O
transcriptional	O
activation	O
.	O

The	O
AML1	O
and	O
CBF	O
beta	O
genes	O
that	O
encode	O
CBF	O
each	O
have	O
the	O
ability	O
to	O
influence	O
cell	O
growth	O
and	O
differentiation	O
and	O
have	O
been	O
implicated	O
as	O
proto-oncogenes	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

This	O
study	O
adds	O
GM-CSF	O
to	O
a	O
growing	O
list	O
of	O
cytokines	O
and	O
receptors	O
that	O
are	O
regulated	O
by	O
CBF	O
and	O
which	O
control	O
the	O
growth	O
,	O
differentiation	O
,	O
and	O
activation	O
of	O
hemopoietic	O
cells	O
.	O

The	O
GM-CSF	O
locus	O
may	O
represent	O
one	O
of	O
several	O
target	O
genes	O
that	O
are	O
dysregulated	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Tyloxapol	O
inhibits	O
NF-kappa	O
B	O
and	O
cytokine	O
release	O
,	O
scavenges	O
HOCI	O
,	O
and	O
reduces	O
viscosity	O
of	O
cystic	O
fibrosis	O
sputum	O
.	O

Cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
develop	O
progressive	O
cytokine-mediated	O
inflammatory	O
lung	O
disease	O
,	O
with	O
abundant	O
production	O
of	O
thick	O
,	O
tenacious	O
,	O
protease-	O
and	O
oxidant-rich	O
purulent	O
airway	O
secretions	O
that	O
are	O
difficult	O
to	O
clear	O
even	O
with	O
physiotherapy	O
.	O

In	O
the	O
search	O
for	O
a	O
potential	O
treatment	O
,	O
we	O
have	O
tested	O
tyloxapol	O
,	O
an	O
alkylaryl	O
polyether	O
alcohol	O
polymer	O
detergent	O
previously	O
used	O
as	O
a	O
mucolytic	O
agent	O
in	O
adult	O
chronic	O
bronchitis	O
.	O

Tyloxapol	O
inhibits	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappa	O
B	O
(	O
NK-kappa	O
B	O
)	O
,	O
reduces	O
resting	O
secretion	O
of	O
the	O
cytokine	O
interleukin-8	O
(	O
IL-8	O
)	O
in	O
cultured	O
human	O
monocytes	O
,	O
and	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
release	O
of	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
,	O
and	O
the	O
eiconsanoids	O
thromboxane	O
A2	O
and	O
leukotriene	O
B4	O
(	O
LTB4	O
)	O
.	O

We	O
have	O
previously	O
shown	O
that	O
tyloxapol	O
is	O
a	O
potent	O
antioxidant	O
for	O
hydroxyl	O
radicals	O
(	O
OH	O
)	O
.	O

Tyloxapol	O
(	O
0.05	O
to	O
0.1	O
%	O
wt/vol	O
)	O
effectively	O
scavenges	O
the	O
oxidant	O
hypochlorous	O
acid	O
(	O
HOCl	O
;	O
1	O
to	O
7.5	O
mM	O
)	O
in	O
vitro	O
,	O
and	O
protects	O
from	O
HOCl-mediated	O
lung	O
injury	O
in	O
rats	O
.	O

Tyloxapol	O
also	O
reduces	O
the	O
viscosity	O
of	O
CF	O
sputum	O
(	O
from	O
463	O
	O
133	O
to	O
128	O
	O
52	O
centipoise	O
)	O
.	O

We	O
conclude	O
that	O
tyloxapol	O
is	O
potentially	O
useful	O
as	O
a	O
new	O
antiinflammatory	O
therapy	O
for	O
CF	O
lung	O
disease	O
,	O
and	O
could	O
possibly	O
promote	O
clearance	O
of	O
secretions	O
in	O
the	O
CF	O
airway	O
.	O

Abnormality	O
of	O
Oct-1	O
DNA	O
binding	O
in	O
T	O
cells	O
from	O
Sjogren	O
's	O
syndrome	O
patients	O
.	O

Primary	O
Sjogren	O
's	O
syndrome	O
(	O
SS	O
)	O
is	O
an	O
autoimmune	O
rheumatic	O
disease	O
characterized	O
by	O
T	O
cell	O
hypoactivity	O
.	O

To	O
understand	O
the	O
diminished	O
T	O
cell	O
response	O
to	O
activation	O
signals	O
,	O
we	O
measured	O
nucleoprotein	O
DNA-binding	O
activities	O
regulating	O
gene	O
expression	O
during	O
T	O
cell	O
activation	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Peripheral	O
blood	O
lymphocytes	O
from	O
9/19	O
SS	O
patients	O
were	O
found	O
to	O
be	O
defective	O
in	O
their	O
ability	O
to	O
bind	O
an	O
october	O
sequence	O
(	O
Oct-1	O
)	O
.	O

This	O
Oct-1-binding	O
phenotype	O
remained	O
stable	O
in	O
culture	O
for	O
up	O
to	O
3	O
days	O
prior	O
to	O
activation	O
.	O

This	B-Negation
abnormality	I-Negation
was	I-Negation
not	I-Negation
seen	I-Negation
in	I-Negation
resting	I-Negation
T	I-Negation
cells	I-Negation
nor	I-Negation
T	I-Negation
cells	I-Negation
from	I-Negation
patients	I-Negation
with	I-Negation
systemic	I-Negation
lupus	I-Negation
erythematosus	I-Negation
,	I-Negation
rheumatoid	I-Negation
arthritis	I-Negation
(	I-Negation
RA	I-Negation
)	I-Negation
,	I-Negation
or	I-Negation
SS	I-Negation
accompanied	I-Negation
by	I-Negation
RA	I-Negation
.	O

The	O
SS	O
Oct-1	O
DNA-binding	O
abnormality	O
correlated	O
significantly	O
with	O
an	O
inability	O
of	O
cells	O
to	O
exit	O
the	O
Gzero/G1	O
cell	O
cycle	O
phase	O
when	O
stimulated	O
in	O
vitro	O
.	O

Importantly	O
,	O
nucleoprotein	O
extracts	O
showing	O
decreased	O
DNA-binding	O
activity	O
had	O
normal	O
amounts	O
of	O
Oct-1	O
proteins	O
as	O
determined	O
by	O
immunoprecipitation	O
,	O
implying	O
a	O
functional	O
defect	O
in	O
the	O
Oct-1	O
protein	O
.	O

Moreover	O
,	O
defective	O
DNA	O
binding	O
was	O
corrected	O
by	O
treatment	O
with	O
acid	O
phosphatase	O
.	O

Severe	O
combined	O
immunodeficiency	O
due	O
to	O
defective	O
binding	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
in	O
T	O
lymphocytes	O
of	O
two	O
male	O
siblings	O
.	O

Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
and	O
alloreactive	O
T	O
cell	O
lines	O
of	O
two	O
male	O
infants	O
born	O
to	O
consanguinous	O
parents	O
and	O
presenting	O
with	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
showed	O
a	O
pronounced	O
deficiency	O
in	O
T	O
cell	O
activation	O
.	O

Although	O
phenotypically	O
normal	O
,	O
the	O
proliferative	O
response	O
of	O
the	O
childrens	O
'	O
T	O
cells	O
was	O
strongly	O
reduced	O
but	O
could	O
be	O
improved	O
by	O
the	O
addition	O
of	O
interleukin-2	O
(	O
IL-2	O
)	O
.	O

Furthermore	O
both	O
childrens	O
'	O
T	O
cells	O
were	O
unable	B-Negation
to	I-Negation
produce	I-Negation
the	I-Negation
cytokines	I-Negation
IL-2	I-Negation
,	I-Negation
interferon-gamma	I-Negation
(	I-Negation
IFN-gamma	I-Negation
)	I-Negation
,	I-Negation
IL-4	I-Negation
and	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
(	I-Negation
TNF-alpha	I-Negation
)	I-Negation
.	O

This	B-Negation
multiple	I-Negation
cytokine	I-Negation
production	I-Negation
deficiency	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
restored	I-Negation
by	I-Negation
IL-2	I-Negation
or	I-Negation
co-stimulatory	I-Negation
signals	I-Negation
provided	I-Negation
by	I-Negation
antigen-presenting	I-Negation
cells	I-Negation
(	I-Negation
APC	I-Negation
)	I-Negation
.	O

Moreover	O
,	O
mRNA	B-Negation
for	I-Negation
IL-2	I-Negation
and	I-Negation
IFN-gamma	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
detected	I-Negation
.	O

In	O
contrast	O
,	O
expression	O
of	O
the	O
activation-dependent	O
cell	O
surface	O
markers	O
CD25	O
and	O
CD69	O
was	O
within	O
normal	O
limits	O
.	O

To	O
determine	O
whether	O
the	O
functional	O
defect	O
of	O
the	O
patients	O
'	O
T	O
cells	O
was	O
due	O
to	O
the	O
absence	O
or	O
abnormal	O
binding	O
of	O
transcription	O
factors	O
involved	O
in	O
cytokine	O
gene	O
expression	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
used	O
to	O
examine	O
the	O
DNA	O
binding	O
of	O
AP-1	O
,	O
Oct	O
,	O
CREB	O
,	O
SP1	O
,	O
NF-kappa	O
B	O
and	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
to	O
their	O
respective	O
response	O
elements	O
in	O
the	O
promoter	O
of	O
the	O
IL-2	O
gene	O
.	O

Whereas	O
AP-1	O
,	O
NF-kappa	O
B	O
,	O
Oct	O
,	O
CREB	O
and	O
SP1	O
displayed	O
normal	O
binding	O
activities	O
in	O
nuclear	O
extracts	O
,	O
the	O
binding	O
of	O
NF-AT	O
to	O
its	O
IL-2	O
promoter	O
response	O
element	O
was	O
barely	O
detectable	O
both	O
before	O
and	O
after	O
T	O
cell	O
stimulation	O
.	O

Our	O
results	O
strongly	O
suggest	O
that	O
this	O
NF-AT/DNA	O
binding	O
defect	O
is	O
responsible	O
for	O
the	O
multiple	O
cytokine	O
deficiency	O
and	O
the	O
SCID	O
phenotype	O
observed	O
in	O
the	O
two	O
infant	O
brothers	O
.	O

Requirements	O
for	O
induction	O
of	O
vitamin	O
D-mediated	O
gene	O
regulation	O
in	O
normal	O
human	O
B	O
lymphocytes	O
.	O

Mature	O
human	O
lymphocytes	O
are	O
unique	O
targets	O
of	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha,25	O
(	O
OH	O
)	O
2D3	O
)	O
in	O
that	O
vitamin	O
D	O
receptors	O
(	O
VDR	O
)	O
are	O
not	B-Negation
constitutively	I-Negation
expressed	I-Negation
,	O
and	O
specific	O
cellular	O
activation	O
signals	O
are	O
required	O
for	O
both	O
the	O
up-regulation	O
of	O
VDR	O
and	O
establishment	O
of	O
reactivity	O
to	O
the	O
lipophilic	O
ligand	O
.	O

Treatment	O
of	O
B	O
lymphocytes	O
with	O
the	O
cytokine	O
IL-4	O
(	O
IL-4	O
)	O
,	O
in	O
the	O
absence	O
of	O
prior	O
activation	O
,	O
induces	O
a	O
weak	O
up-regulation	O
of	O
VDR	O
expression	O
but	O
fails	B-Negation
to	I-Negation
generate	I-Negation
vitamin	I-Negation
D-responsive	I-Negation
element	I-Negation
(	I-Negation
VDRE	I-Negation
)	I-Negation
-reactive	I-Negation
nuclear	I-Negation
protein	I-Negation
complexes	I-Negation
or	I-Negation
to	I-Negation
initiate	I-Negation
the	I-Negation
genomic	I-Negation
transcription	I-Negation
of	I-Negation
25-hydroxyvitamin	I-Negation
D3	I-Negation
24-hydroxylase	I-Negation
.	O

Stimulation	O
of	O
B	O
lymphocytes	O
by	O
either	O
ligation	O
of	O
CD40	O
Ag	O
or	O
cross-linking	O
the	O
Ig	O
receptor	O
is	O
also	O
insufficient	O
to	O
render	O
B	O
lymphocytes	O
responsive	O
to	O
1	O
alpha,25	O
(	O
OH	O
)	O
2D3	O
.	O

However	O
,	O
this	O
apparent	O
lack	O
of	O
response	O
to	O
the	O
secosterol	O
can	O
be	O
overcome	O
by	O
stimulation	O
of	O
B	O
lymphocytes	O
with	O
a	O
combination	O
of	O
these	O
cellular	O
activation	O
signals	O
,	O
which	O
are	O
sufficient	O
to	O
lead	O
to	O
G1	O
cell	O
cycle	O
progression	O
.	O

In	O
the	O
presence	O
of	O
1	O
alpha,25	O
(	O
OH	O
)	O
2D3	O
,	O
cellular	O
activation	O
associated	O
with	O
stimulation	O
of	O
such	O
a	O
progression	O
appears	O
to	O
be	O
sufficient	O
for	O
the	O
up-regulation	O
of	O
VDR	O
message	O
and	O
protein	O
and	O
necessary	O
for	O
the	O
establishment	O
of	O
VDRE	O
binding	O
complexes	O
and	O
the	O
induction	O
of	O
24-hydroxylase	O
message	O
.	O

Furthermore	O
,	O
biologic	O
functions	O
are	O
modulated	O
,	O
in	O
that	O
the	O
hormone	O
inhibits	O
proliferation	O
in	O
a	O
subset	O
of	O
the	O
activated	O
B	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
reactivity	O
to	O
1	O
alpha,25	O
(	O
OH	O
)	O
2D3	O
is	O
tightly	O
regulated	O
in	O
B	O
lymphocytes	O
,	O
requiring	O
specific	O
signals	O
for	O
its	O
initiation	O
.	O

Cell-type-specific	O
regulation	O
of	O
the	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
in	O
B	O
cells	O
and	O
T	O
cells	O
by	O
NFATp	O
and	O
ATF-2/JUN	O
.	O

The	O
human	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
gene	O
is	O
one	O
of	O
the	O
earliest	O
genes	O
transcribed	O
after	O
the	O
stimulation	O
of	O
a	O
B	O
cell	O
through	O
its	O
antigen	O
receptor	O
or	O
via	O
the	O
CD-40	O
pathway	O
.	O

In	O
both	O
cases	O
,	O
induction	O
of	O
TNF-alpha	O
gene	O
transcription	O
can	O
be	O
blocked	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
suggested	O
a	O
role	O
for	O
the	O
NFAT	O
family	O
of	O
proteins	O
in	O
the	O
regulation	O
of	O
the	O
gene	O
in	O
B	O
cells	O
.	O

Furthermore	O
,	O
in	O
T	O
cells	O
,	O
two	O
molecules	O
of	O
NFATp	O
bind	O
to	O
the	O
TNF-alpha	O
promoter	O
element	O
kappa	O
3	O
in	O
association	O
with	O
ATF-2	O
and	O
Jun	O
proteins	O
bound	O
to	O
an	O
immediately	O
adjacent	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
site	O
.	O

Here	O
,	O
using	O
the	O
murine	O
B-cell	O
lymphoma	O
cell	O
line	O
A20	O
,	O
we	O
show	O
that	O
the	O
TNF-alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
.	O

In	O
A20	O
B	O
cells	O
,	O
the	B-Negation
TNF-alpha	I-Negation
gene	I-Negation
is	I-Negation
not	I-Negation
regulated	I-Negation
by	I-Negation
NFATp	I-Negation
bound	I-Negation
to	I-Negation
the	I-Negation
kappa	I-Negation
3	I-Negation
element	I-Negation
.	O

Instead	O
,	O
ATF-2	O
and	O
Jun	O
proteins	O
bind	O
to	O
the	O
composite	O
kappa	O
3/CRE	O
site	O
and	O
NFATp	O
binds	O
to	O
a	O
newly	O
identified	O
second	O
NFAT	O
site	O
centered	O
at	O
-76	O
nucleotides	O
relative	O
to	O
the	O
TNF-alpha	O
transcription	O
start	O
site	O
.	O

This	O
new	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
calcium-mediated	O
,	O
cyclosporin	O
A-sensitive	O
induction	O
of	O
TNF-alpha	O
in	O
both	O
A20	O
B	O
cells	O
and	O
Ar-5	O
cells	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
quantitative	O
DNase	O
footprinting	O
of	O
the	O
TNF-alpha	O
promoter	O
using	O
increasing	O
amounts	O
of	O
recombinant	O
NFATp	O
demonstrated	O
that	O
the	O
-76	O
site	O
binds	O
to	O
NFATp	O
with	O
a	O
higher	O
affinity	O
than	O
the	O
kappa	O
3	O
site	O
.	O

Two	O
other	O
previously	O
unrecognized	O
NFATp-binding	O
sites	O
in	O
the	O
proximal	O
TNF-alpha	O
promoter	O
were	O
also	O
identified	O
by	O
this	O
analysis	O
.	O

Thus	O
,	O
through	O
the	O
differential	O
use	O
of	O
the	O
same	O
promoter	O
element	O
,	O
the	O
composite	O
kappa	O
3/CRE	O
site	O
,	O
the	O
TNF-alpha	O
gene	O
is	O
regulated	O
in	O
a	O
cell-type-specific	O
manner	O
in	O
response	O
to	O
the	O
same	O
extracellular	O
signal	O
.	O

Analysis	O
of	O
the	O
ligand-binding	O
domain	O
of	O
human	O
retinoic	O
acid	O
receptor	O
alpha	O
by	O
site-directed	O
mutagenesis	O
.	O

Three	O
subtypes	O
of	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
,	O
termed	O
RAR	O
alpha	O
,	O
RAR	O
beta	O
,	O
and	O
RAR	O
gamma	O
,	O
have	O
been	O
described	O
.	O

They	O
are	O
composed	O
of	O
different	O
structural	O
domains	O
,	O
including	O
distinct	O
domains	O
for	O
DNA	O
and	O
ligand	O
binding	O
.	O

RARs	O
specifically	O
bind	O
all-trans-retinoic	O
acid	O
(	O
RA	O
)	O
,	O
9-cis-RA	O
,	O
and	O
retinoid	O
analogs	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
functional	O
role	O
of	O
cysteine	O
and	O
arginine	O
residues	O
in	O
the	O
ligand-binding	O
domain	O
of	O
hRAR	O
alpha	O
(	O
hRAR	O
alpha-LBD	O
,	O
amino	O
acids	O
154	O
to	O
462	O
)	O
.	O

All	O
conserved	O
cysteine	O
and	O
arginine	O
residues	O
in	O
this	O
domain	O
were	O
mutated	O
by	O
site-directed	O
mutagenesis	O
,	O
and	O
the	O
mutant	O
proteins	O
were	O
characterized	O
by	O
blocking	O
reactions	O
,	O
ligand-binding	O
experiments	O
,	O
transactivation	O
assays	O
,	O
and	O
protease	O
mapping	O
.	O

Changes	O
of	O
any	O
cysteine	O
residue	O
of	O
the	O
hRAR	O
alpha-LBD	O
had	O
no	O
significant	O
influence	O
on	O
the	O
binding	O
of	O
all-trans	O
RA	O
or	O
9-cis	O
RA	O
.	O

Interestingly	O
,	O
residue	O
C-235	O
is	O
specifically	O
important	O
in	O
antagonist	O
binding	O
.	O

With	O
respect	O
to	O
arginine	O
residues	O
,	O
only	O
the	O
two	O
single	O
mutations	O
of	O
R-276	O
and	O
R-394	O
to	O
alanine	O
showed	O
a	O
dramatic	O
decrease	O
of	O
agonist	O
and	O
antagonist	O
binding	O
whereas	O
the	O
R272A	O
mutation	O
showed	O
only	O
a	O
slight	O
effect	O
.	O

For	O
all	O
other	O
arginine	O
mutations	O
,	O
no	B-Negation
differences	I-Negation
in	I-Negation
affinity	I-Negation
were	I-Negation
detectable	I-Negation
.	O

The	O
two	O
mutations	O
R217A	O
and	O
R294A	O
caused	O
an	O
increased	O
binding	O
efficiency	O
for	O
antagonists	O
but	O
no	B-Negation
change	I-Negation
in	I-Negation
agonist	I-Negation
binding	I-Negation
.	O

From	O
these	O
results	O
,	O
we	O
can	O
conclude	O
that	O
electrostatic	O
interactions	O
of	O
retinoids	O
with	O
the	O
RAR	O
alpha-LBD	O
play	O
a	O
significant	O
role	O
in	O
ligand	O
binding	O
.	O

In	O
addition	O
,	O
antagonists	O
show	O
distinctly	O
different	O
requirements	O
for	O
efficient	O
binding	O
,	O
which	O
may	O
contribute	O
to	O
their	O
interference	O
in	O
the	O
ligand-inducible	O
transactivation	O
function	O
of	O
RAR	O
alpha	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
beta	O
subunit	O
of	O
human	O
proximal	O
sequence	O
element-binding	O
transcription	O
factor	O
and	O
its	O
involvement	O
in	O
transcription	O
of	O
small	O
nuclear	O
RNA	O
genes	O
by	O
RNA	O
polymerases	O
II	O
and	O
III	O
.	O

The	O
proximal	O
sequence	O
element	O
(	O
PSE	O
)	O
-binding	O
transcription	O
factor	O
(	O
PTF	O
)	O
,	O
which	O
binds	O
the	O
PSE	O
of	O
both	O
RNA	O
polymerase	O
II-	O
and	O
RNA	O
polymerase	O
III-transcribed	O
mammalian	O
small	O
nuclear	O
RNA	O
(	O
snRNA	O
)	O
genes	O
,	O
is	O
essential	O
for	O
their	O
transcription	O
.	O

We	O
previously	O
reported	O
the	O
purification	O
of	O
human	O
PTF	O
,	O
a	O
complex	O
of	O
four	O
subunits	O
,	O
and	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
PTF	O
gamma	O
and	O
delta	O
subunits	O
.	O

Here	O
we	O
describe	O
the	O
isolation	O
and	O
expression	O
of	O
a	O
cDNA	O
encoding	O
PTF	O
beta	O
,	O
as	O
well	O
as	O
functional	O
studies	O
using	O
anti-PTF	O
beta	O
antibodies	O
.	O

Native	O
PTF	O
beta	O
,	O
in	O
either	O
protein	O
fractions	O
or	O
a	O
PTF-Oct-1-DNA	O
complex	O
,	O
can	O
be	O
recognized	O
by	O
polyclonal	O
antibodies	O
raised	O
against	O
recombinant	O
PTF	O
beta	O
.	O

Immunodepletion	O
studies	O
show	O
that	O
PTF	O
beta	O
is	O
required	O
for	O
transcription	O
of	O
both	O
classes	O
of	O
snRNA	O
genes	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
immunoprecipitation	O
analyses	O
demonstrate	O
that	O
substantial	O
and	O
similar	O
molar	O
amounts	O
of	O
TATA-binding	O
protein	O
(	O
TBP	O
)	O
and	O
TFIIIB90	O
can	O
weakly	O
associate	O
with	O
PTF	O
at	O
low	O
salt	O
conditions	O
,	O
but	O
this	O
association	O
is	O
dramatically	O
reduced	O
at	O
high	O
salt	O
concentrations	O
.	O

Along	O
with	O
our	O
previous	O
demonstration	O
of	O
both	O
physical	O
interactions	O
between	O
PTF	O
gamma/PTF	O
delta	O
and	O
TBP	O
and	O
the	O
involvement	O
of	O
TFIIIB90	O
in	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
these	O
results	O
are	O
consistent	O
with	O
the	O
notion	O
that	O
a	O
TBP-containing	O
complex	O
related	O
to	O
TFIIIB	O
is	O
required	O
for	O
the	O
transcription	O
of	O
class	O
III	O
snRNA	O
genes	O
,	O
and	O
acts	O
through	O
weak	O
interaction	O
with	O
the	O
four-subunit	O
PTF	O
.	O

Induction	O
of	O
bcl-2	O
expression	O
by	O
phosphorylated	O
CREB	O
proteins	O
during	O
B-cell	O
activation	O
and	O
rescue	O
from	O
apoptosis	O
.	O

Engagement	O
of	O
surface	O
immunoglobulin	O
on	O
mature	O
B	O
cells	O
leads	O
to	O
rescue	O
from	O
apoptosis	O
and	O
to	O
proliferation	O
.	O

Levels	O
of	O
bcl-2	O
mRNA	O
and	O
protein	O
increase	O
with	O
cross-linking	O
of	O
surface	O
immunoglobulin	O
.	O

We	O
have	O
located	O
the	O
major	O
positive	O
regulatory	O
region	O
for	O
control	O
of	O
bcl-2	O
expression	O
in	O
B	O
cells	O
in	O
the	O
5'-flanking	O
region	O
.	O

The	O
positive	O
region	O
can	O
be	O
divided	O
into	O
an	O
upstream	O
and	O
a	O
downstream	O
regulatory	O
region	O
.	O

The	O
downstream	O
regulatory	O
region	O
contains	O
a	O
cyclic	O
AMP-responsive	O
element	O
(	O
CRE	O
)	O
.	O

We	O
show	O
by	O
antibody	O
supershift	O
experiments	O
and	O
UV	O
cross-linking	O
followed	O
by	O
denaturing	O
polyacrylamide	O
gel	O
electrophoresis	O
that	O
both	O
CREB	O
and	O
ATF	O
family	O
members	O
bind	O
to	O
this	O
region	O
in	O
vitro	O
.	O

Mutations	O
of	O
the	O
CRE	O
site	O
that	O
result	O
in	O
loss	O
of	O
CREB	O
binding	O
also	O
lead	O
to	O
loss	O
of	O
functional	O
activity	O
of	O
the	O
bcl-2	O
promoter	O
in	O
transient-transfection	O
assays	O
.	O

The	O
presence	O
of	O
an	O
active	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
implies	O
that	O
the	O
regulation	O
of	O
bcl-2	O
expression	O
is	O
linked	O
to	O
a	O
signal	O
transduction	O
pathway	O
in	O
B	O
cells	O
.	O

Treatment	O
of	O
the	O
mature	O
B-cell	O
line	O
BAL-17	O
with	O
either	O
anti-immunoglobulin	O
M	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
leads	O
to	O
an	O
increase	O
in	O
bcl-2	O
expression	O
that	O
is	O
mediated	O
by	O
the	O
CRE	O
site	O
.	O

Treatment	O
of	O
the	O
more	O
immature	O
B-cell	O
line	O
,	O
Ramos	O
,	O
with	O
phorbol	O
esters	O
rescues	O
the	O
cells	O
from	O
calcium-dependent	O
apoptosis	O
.	O

bcl-2	O
expression	O
is	O
increased	O
following	O
phorbol	O
ester	O
treatment	O
,	O
and	O
the	O
increased	O
expression	O
is	O
dependent	O
on	O
the	O
CRE	O
site	O
.	O

These	O
stimuli	O
result	O
in	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

The	O
phosphorylation	O
of	O
CREB	O
that	O
results	O
in	O
activation	O
is	O
mediated	O
by	O
protein	O
kinase	O
C	O
rather	B-Negation
than	I-Negation
by	I-Negation
protein	I-Negation
kinase	I-Negation
A	I-Negation
.	O

Although	O
the	O
CRE	O
site	O
is	O
necessary	O
,	O
optimal	O
induction	O
of	O
bcl-2	O
expression	O
requires	O
participation	O
of	O
the	O
upstream	O
regulatory	O
element	O
,	O
suggesting	O
that	O
phosphorylation	O
of	O
CREB	O
alters	O
its	O
interaction	O
with	O
the	O
upstream	O
regulatory	O
element	O
.	O

The	O
CRE	O
site	O
in	O
the	O
bcl-2	O
promoter	O
appears	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
induction	O
of	O
bcl-2	O
expression	O
during	O
the	O
activation	O
of	O
mature	O
B	O
cells	O
and	O
during	O
the	O
rescue	O
of	O
immature	O
B	O
cells	O
from	O
apoptosis	O
.	O

It	O
is	O
possible	O
that	O
the	O
CRE	O
site	O
is	O
responsible	O
for	O
induction	O
of	O
bcl-2	O
expression	O
in	O
other	O
cell	O
types	O
,	O
particularly	O
those	O
in	O
which	O
protein	O
kinase	O
C	O
is	O
involved	O
.	O

Interleukin-6	O
promotes	O
multiple	O
myeloma	O
cell	O
growth	O
via	O
phosphorylation	O
of	O
retinoblastoma	O
protein	O
.	O

Interleukin-6	O
(	O
IL-6	O
)	O
mediates	O
autocrine	O
and	O
paracrine	O
growth	O
of	O
multiple	O
myeloma	O
(	O
MM	O
)	O
cells	O
and	O
inhibits	O
tumor	O
cell	O
apoptosis	O
.	O

Abnormalities	O
of	O
retinoblastoma	O
protein	O
(	O
pRB	O
)	O
and	O
mutations	O
of	O
RB	O
gene	O
have	O
been	O
reported	O
in	O
up	O
to	O
70	O
%	O
of	O
MM	O
patients	O
and	O
80	O
%	O
of	O
MM-derived	O
cell	O
lines	O
.	O

Because	O
dephosphorylated	O
(	O
activated	O
)	O
pRB	O
blocks	O
transition	O
from	O
G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
whereas	O
phosphorylated	O
(	O
inactivated	O
)	O
pRB	O
releases	O
this	O
growth	O
arrest	O
,	O
we	O
characterized	O
the	O
role	O
of	O
pRB	O
in	O
IL-6-mediated	O
MM	O
cell	O
growth	O
.	O

Both	O
phosphorylated	O
and	O
dephosphorylated	O
pRB	O
were	O
expressed	O
in	O
all	O
serum-starved	O
MM	O
patient	O
cells	O
and	O
MM-derived	O
cell	O
lines	O
,	O
but	O
pRB	O
was	O
predominantly	O
in	O
its	O
phosphorylated	O
form	O
.	O

In	O
MM	O
cells	O
that	O
proliferated	O
in	O
response	O
to	O
IL-6	O
,	O
exogenous	O
IL-6	O
downregulated	O
dephosphorylated	O
pRB	O
and	O
decreased	O
dephosphorylated	O
pRB-E2F	O
complexes	O
.	O

Importantly	O
,	O
culture	O
of	O
MM	O
cells	O
with	O
RB	O
antisense	O
,	O
but	O
not	B-Negation
RB	I-Negation
sense	I-Negation
,	O
oligonucleotide	O
(	O
ODN	O
)	O
triggered	O
IL-6	O
secretion	O
and	O
proliferation	O
in	O
MM	O
cells	O
;	O

however	O
,	O
proliferation	O
was	O
only	O
partially	O
inhibited	O
by	O
neutralizing	O
anti-IL-6	O
monoclonal	O
antibody	O
(	O
MoAb	O
)	O
.	O

In	O
contrast	O
to	O
MM	O
cells	O
,	O
normal	O
splenic	O
B	O
cells	O
express	O
dephosphorylated	O
pRB	O
.	O

Although	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
triggers	O
a	O
shift	O
from	O
dephosphorylated	O
to	O
phosphorylated	O
pRB	O
and	O
proliferation	O
of	O
B	O
cells	O
,	O
the	O
addition	O
of	O
exogenous	O
IL-6	O
to	O
CD40L-treated	O
B	O
cells	O
does	O
not	B-Negation
alter	I-Negation
either	I-Negation
pRB	I-Negation
or	I-Negation
proliferation	I-Negation
,	O
as	O
observed	O
in	O
MM	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
phosphorylated	O
pRB	O
is	O
constitutively	O
expressed	O
in	O
MM	O
cells	O
and	O
that	O
IL-6	O
further	O
shifts	O
pRB	O
from	O
its	O
dephosphorylated	O
to	O
its	O
phosphorylated	O
form	O
,	O
thereby	O
promoting	O
MM	O
cell	O
growth	O
via	O
two	O
mechanisms	O
;	O
by	O
decreasing	O
the	O
amount	O
of	O
E2F	O
bound	O
by	O
dephosphorylated	O
pRB	O
due	O
to	O
reduced	O
dephosphorylated	O
pRB	O
,	O
thereby	O
releasing	O
growth	O
arrest	O
;	O
and	O
by	O
upregulating	O
IL-6	O
secretion	O
by	O
MM	O
cells	O
and	O
related	O
IL-6-mediated	O
autocrine	O
tumor	O
cell	O
growth	O
.	O

JNK	O
(	O
c-Jun	O
NH2-terminal	O
kinase	O
)	O
is	O
a	O
target	O
for	O
antioxidants	O
in	O
T	O
lymphocytes	O
.	O

AP-1	O
has	O
been	O
shown	O
to	O
behave	O
as	O
a	O
redox-sensitive	O
transcription	O
factor	O
that	O
can	O
be	O
activated	O
by	O
both	O
oxidant	O
and	O
antioxidant	O
stimuli	O
.	O

However	O
,	O
the	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
AP-1	O
by	O
antioxidants	O
are	O
largely	O
unknown	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
the	O
structurally	O
unrelated	O
antioxidant	O
agents	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
butylated	O
hydroxyanisole	O
,	O
and	O
Nacetylcysteine	O
activated	O
JNK	O
(	O
c-Jun	O
NH2-terminal	O
kinase	O
)	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
activation	O
differed	O
substantially	O
from	O
that	O
mediated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
or	O
produced	O
by	O
costimulation	O
with	O
antibodies	O
against	O
the	O
T	O
cell	O
receptor-CD3	O
complex	O
and	O
to	O
CD28	O
.	O

The	O
activation	O
of	O
JNK	O
by	O
classical	O
T	O
cell	O
stimuli	O
was	O
transient	O
,	O
whereas	O
that	O
mediated	O
by	O
PDTC	O
and	O
butylated	O
hydroxyanisole	O
(	O
but	O
not	B-Negation
N-acetylcysteine	I-Negation
)	O
was	O
sustained	O
.	O

The	O
kinetics	O
of	O
JNK	O
activation	O
correlated	O
with	O
the	O
expression	O
of	O
c-jun	O
which	O
was	O
transient	O
after	O
stimulation	O
with	O
PMA	O
plus	O
ionophore	O
and	O
prolonged	O
in	O
response	O
to	O
PDTC	O
,	O
which	O
also	O
transiently	O
induced	O
c-fos	O
.	O

In	O
addition	O
,	O
JNK	O
activation	O
by	O
PMA	O
plus	O
ionophore	O
was	O
sensitive	O
to	O
inhibitors	O
of	O
signaling	O
pathways	O
involving	O
Ca2+	O
,	O
protein	O
kinase	O
C	O
,	O
and	O
tyrosine	O
phosphorylation	O
,	O
which	O
failed	B-Negation
to	I-Negation
inhibit	I-Negation
the	I-Negation
activation	I-Negation
mediated	I-Negation
by	I-Negation
PDTC	I-Negation
.	O

Transfection	O
of	O
trans-dominant	O
negative	O
expression	O
vectors	O
of	O
ras	O
and	O
raf	O
,	O
together	O
with	O
AP-1-dependent	O
reporter	O
constructs	O
,	O
as	O
well	O
as	O
Western	O
blot	O
analysis	O
using	O
anti-ERK	O
(	O
extracellular	O
signal-regulated	O
kinase	O
)	O
antibodies	O
,	O
indicated	B-Speculation
that	I-Speculation
the	B-Negation
Ras/Raf/ERK	I-Negation
pathway	I-Negation
did	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
mediate	I-Speculation
the	I-Speculation
effect	I-Speculation
of	I-Speculation
the	I-Speculation
antioxidant	I-Speculation
.	O

However	O
,	O
the	O
combined	O
treatment	O
with	O
PDTC	O
and	O
PMA	O
,	O
two	O
agents	O
that	O
synergize	O
on	O
AP-1	O
activation	O
,	O
resulted	O
in	O
the	O
persistent	O
phosphorylation	O
of	O
ERK-2	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
identify	O
JNK	O
as	O
a	O
target	O
of	O
antioxidant	O
agents	O
which	O
can	O
be	O
regulated	O
differentially	O
under	O
oxidant	O
and	O
antioxidant	O
conditions	O
.	O

Cytomegalovirus	O
modulates	O
interleukin-6	O
gene	O
expression	O
.	O

Complications	O
after	O
lung	O
transplantation	O
include	O
the	O
development	O
of	O
rejection	O
and	O
an	O
increased	O
incidence	O
of	O
infection	O
,	O
particularly	O
with	O
cytomegalovirus	O
(	O
CMV	O
)	O
.	O

Several	O
recent	O
studies	O
have	O
suggested	O
that	O
interleukin	O
(	O
IL	O
)	O
-6	O
may	O
be	O
used	O
to	O
detect	O
both	O
infection	O
and	O
rejection	O
after	O
lung	O
transplantation	O
.	O

In	O
addition	O
,	O
IL-6	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
.	O

Because	O
CMV	O
is	O
also	O
associated	O
with	O
the	O
development	O
of	O
bronchiolitis	O
obliterans	O
after	O
transplantation	O
,	O
we	O
determined	O
whether	O
CMV	O
induces	O
IL-6	O
gene	O
expression	O
.	O

We	O
demonstrated	O
that	O
CMV	O
infection	O
increased	O
both	O
IL-6	O
protein	O
and	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
also	O
demonstrated	O
that	O
the	O
CMV	O
immediate	O
early	O
1	O
gene	O
product	O
increased	O
expression	O
of	O
the	O
IL-6	O
promoter	O
.	O

This	O
effect	O
of	O
the	O
CMV	O
immediate	O
early	O
1	O
gene	O
product	O
was	O
dependent	O
upon	O
the	O
presence	O
of	O
specific	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
IL-6	O
promoter	O
.	O

These	O
studies	O
demonstrate	O
that	O
CMV	O
may	O
be	O
an	O
important	O
cofactor	O
in	O
the	O
development	O
of	O
rejection	O
and	O
infection	O
after	O
transplantation	O
through	O
its	O
effects	O
on	O
IL-6	O
.	O

E3	O
,	O
a	O
hematopoietic-specific	O
transcript	O
directly	O
regulated	O
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
maturation	O
mediated	O
by	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
has	O
been	O
implicated	O
in	O
myeloid	O
development	O
.	O

We	O
have	O
used	O
differential	O
hybridization	O
analysis	O
of	O
a	O
cDNA	O
library	O
constructed	O
from	O
the	O
murine	O
RA-inducible	O
MPRO	O
promyelocyte	O
cell	O
line	O
to	O
identify	O
immediate-early	O
genes	O
induced	O
by	O
RA	O
during	O
granulocytic	O
differentiation	O
.	O

E3	O
,	O
one	O
of	O
nine	O
sequences	O
identified	O
,	O
was	O
upregulated	O
in	O
an	O
immediate-early	O
manner	O
,	O
with	O
transcript	O
levels	O
peaking	O
after	O
60	O
minutes	O
exposure	O
to	O
RA	O
.	O

E3	O
transcripts	O
were	O
RA-inducible	O
in	O
HL60	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
an	I-Negation
RA-resistant	I-Negation
subclone	I-Negation
,	I-Negation
HL60R	I-Negation
,	I-Negation
that	I-Negation
harbors	I-Negation
a	I-Negation
mutated	I-Negation
RAR	I-Negation
alpha	I-Negation
gene	I-Negation
.	O

However	O
,	O
when	O
HL60R	O
cells	O
were	O
transduced	O
with	O
a	O
functional	O
copy	O
of	O
the	O
RAR	O
alpha	O
gene	O
,	O
RA	O
induced	O
a	O
10-fold	O
increase	O
in	O
E3	O
mRNA	O
levels	O
.	O

E3	O
transcripts	O
are	O
present	O
in	O
the	O
myeloid	O
,	O
B-lymphoid	O
,	O
and	O
erythroid	O
lineages	O
,	O
absent	O
in	O
nonhematopoietic	O
cells	O
,	O
and	O
encode	O
a	O
highly	O
hydrophobic	O
,	O
potentially	O
phosphorylated	O
polypeptide	O
of	O
unknown	O
function	O
with	O
significant	O
homology	O
to	O
a	O
putative	O
protein	O
expressed	O
in	O
myeloid	O
cells	O
.	O

The	O
murine	O
E3	O
promoter	O
harbors	O
a	O
single	O
bipartite	O
retinoic	O
acid	O
response	O
element	O
which	O
in	O
transient	O
transfection	O
assays	O
conferred	O
RA	O
sensitivity	O
.	O

These	O
results	O
indicate	O
that	O
E3	O
is	O
a	O
hematopoietic-specific	O
gene	O
that	O
is	O
an	O
immediate	O
target	O
for	O
the	O
activated	O
RAR	O
alpha	O
during	O
myelopoiesis	O
.	O

Interstitial	O
deletion	O
constitutes	O
the	O
major	O
mechanism	O
for	O
loss	O
of	O
heterozygosity	O
on	O
chromosome	O
20q	O
in	O
polycythemia	O
vera	O
.	O

An	O
acquired	O
deletion	O
of	O
the	O
long	O
arm	O
of	O
chromosome	O
20	O
is	O
a	O
recurrent	O
abnormality	O
in	O
myeloproliferative	O
disorders	O
,	O
particularly	O
polycythemia	O
vera	O
and	O
myelodysplastic	O
syndromes	O
.	O

The	O
association	O
of	O
20q	O
deletions	O
with	O
myeloid	O
``	O
stem	O
cell	O
``	O
disorders	O
suggests	O
that	O
the	O
deletions	O
mark	O
the	O
site	O
of	O
one	O
or	O
more	O
genes	O
,	O
loss	O
or	O
inactivation	O
of	O
which	O
plays	O
a	O
role	O
in	O
the	O
regulation	O
of	O
normal	O
hematopoietic	O
progenitors	O
.	O

We	O
have	O
recently	O
performed	O
a	O
detailed	O
molecular	O
analysis	O
of	O
20q	O
deletions	O
in	O
peripheral	O
blood	O
(	O
PB	O
)	O
granulocytes	O
and	O
defined	O
a	O
commonly	O
deleted	O
region	O
of	O
16	O
to	O
21	O
centimorgan	O
(	O
cM	O
)	O
.	O

To	O
further	O
reduce	O
the	O
size	O
of	O
the	O
common	O
deleted	O
region	O
we	O
have	O
searched	O
for	O
small	O
deletions	O
or	O
mitotic	O
recombination	O
events	O
,	O
neither	B-Negation
of	I-Negation
which	I-Negation
would	I-Negation
be	I-Negation
detected	I-Negation
by	I-Negation
conventional	I-Negation
cytogenetics	I-Negation
.	O

We	O
have	O
studied	O
48	O
patients	O
with	O
polycythemia	O
vera	O
and	O
four	O
patients	O
with	O
idiopathic	O
myelofibrosis	O
.	O

In	O
each	O
case	O
,	O
cytogenetic	O
analysis	O
had	O
either	O
failed	O
or	O
had	O
shown	O
no	B-Negation
abnormalities	I-Negation
of	I-Negation
chromosome	I-Negation
20	I-Negation
.	O

Seventeen	O
microsatellite	O
markers	O
that	O
span	O
the	O
common	O
deleted	O
region	O
were	O
used	O
to	O
search	O
for	O
loss	O
of	O
heterozygosity	O
in	O
granulocyte	O
DNA	O
.	O

No	B-Negation
instance	I-Negation
of	I-Negation
microsatellite	I-Negation
instability	I-Negation
was	I-Negation
observed	I-Negation
in	I-Negation
a	I-Negation
total	I-Negation
of	I-Negation
880	I-Negation
comparisons	I-Negation
of	I-Negation
granulocyte	I-Negation
and	I-Negation
T-cell	I-Negation
DNA	I-Negation
.	O

Granulocyte	O
DNA	O
from	O
four	O
patients	O
exhibited	O
allele	O
loss	O
on	O
20q	O
.	O

In	O
each	O
case	O
the	O
allele	O
loss	O
was	O
caused	O
by	O
an	O
interstitial	O
deletion	O
because	O
heterozygosity	O
at	O
distal	O
markers	O
was	O
retained	O
and	O
because	O
quantitative	O
Southern	O
blotting	O
demonstrated	O
hemizygosity	O
.	O

Loss	O
of	O
heterozygosity	O
in	O
PB	O
granulocytes	O
would	O
be	O
masked	O
by	O
the	O
presence	O
of	O
significant	O
numbers	O
of	O
normal	O
granulocytes	O
not	O
derived	O
from	O
the	O
malignant	O
clone	O
.	O

Therefore	O
,	O
the	O
human	O
androgen	O
receptor	O
assay	O
(	O
HUMARA	O
)	O
was	O
used	O
to	O
determine	O
granulocyte	O
clonality	O
.	O

In	O
21	O
of	O
27	O
informative	O
female	O
patients	O
the	O
majority	O
of	O
the	O
granulocytes	O
were	O
clonally	O
derived	O
.	O

In	O
5	O
patients	O
the	O
granulocytes	O
appeared	O
polyclonal	O
and	O
in	O
1	O
patient	O
unilateral	O
X	O
inactivation	O
was	O
observed	O
in	O
both	O
granulocytes	O
and	O
T	O
cells	O
.	O

These	O
results	O
show	O
that	O
,	O
in	O
the	O
vast	O
majority	O
of	O
patients	O
presented	O
here	O
,	O
the	O
failure	B-Negation
to	I-Negation
detect	I-Negation
loss	I-Negation
of	I-Negation
heterozygosity	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
attributed	I-Negation
to	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
normal	I-Negation
polyclonal	I-Negation
granulocytes	I-Negation
.	O

Our	O
results	O
therefore	O
show	O
that	O
allele	O
loss	O
on	O
chromosome	O
20q	O
in	O
polycythemia	O
vera	O
does	O
not	B-Negation
commonly	I-Negation
involve	I-Negation
mitotic	I-Negation
recombination	I-Negation
or	I-Negation
chromosome	I-Negation
loss	I-Negation
and	O
that	O
microsatellite	O
instability	O
is	O
a	O
rare	O
event	O
in	O
this	O
disorder	O
.	O

Transcriptional	O
control	O
of	O
steroid-regulated	O
apoptosis	O
in	O
murine	O
thymoma	O
cells	O
.	O

Early	O
studies	O
in	O
murine	O
T	O
cell	O
lines	O
indicated	O
that	O
transcriptional	O
transactivation	O
functions	O
encoded	O
in	O
the	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
N-terminal	O
domain	O
are	O
required	O
for	O
glucocorticoid-mediated	O
apoptosis	O
.	O

However	O
,	O
more	O
recent	O
studies	O
in	O
human	O
T	O
cell	O
lines	O
have	O
suggested	O
that	O
the	O
N-terminal	O
domain	O
is	O
not	O
necessary	O
for	O
steroid-regulated	O
apoptosis	O
and	O
that	O
GR-mediated	O
transrepression	O
may	O
be	O
the	O
more	O
critical	O
mechanism	O
.	O

To	O
better	O
understand	O
the	O
contribution	O
of	O
the	O
GR	O
N-terminal	O
transactivation	O
domain	O
in	O
mediating	O
murine	O
thymocyte	O
apoptosis	O
,	O
we	O
stably	O
transfected	O
GR	O
,	O
GR	O
variants	O
,	O
and	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
into	O
receptor-negative	O
S49	O
murine	O
thymoma	O
cells	O
.	O

GR	O
expression	O
levels	O
were	O
shown	O
to	O
be	O
rate-limiting	O
for	O
initiating	O
the	O
apoptotic	O
pathway	O
,	O
and	O
a	O
positive	O
correlation	O
between	O
steroid	O
sensitivity	O
and	O
GR-mediated	O
induction	O
of	O
an	O
integrated	O
mouse	O
mammary	O
tumor	O
virus	O
(	O
MMTV	O
)	O
LTR	O
reporter	O
gene	O
was	O
observed	O
.	O

Analysis	O
of	O
GR	O
chimeric	O
receptors	O
containing	O
the	O
potent	O
VP16	O
and	O
E1A	O
viral	O
transactivation	O
domains	O
in	O
place	O
of	O
the	O
GR	O
N	O
terminus	O
revealed	O
that	O
even	O
low	O
level	O
expression	O
of	O
these	O
receptors	O
resulted	O
in	O
both	O
enhanced	O
steroid	O
sensitivity	O
and	O
MMTV	O
induction	O
,	O
thus	O
supporting	O
a	O
role	O
for	O
transactivation	O
in	O
apoptosis	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
AR	O
can	O
initiate	O
apoptosis	O
in	O
S49	O
cells	O
after	O
treatment	O
with	O
5	O
alpha-dihydrotestosterone	O
,	O
despite	O
its	O
relative	O
inability	O
to	O
induce	O
high	O
level	O
expression	O
of	O
MMTV	O
.	O

To	O
investigate	O
this	O
further	O
,	O
we	O
examined	O
the	O
steroid-regulated	O
expression	O
of	O
an	O
endogenous	O
thymocyte-specific	O
gene	O
called	O
GIG18	O
.	O

We	O
found	O
that	O
GIG18	O
was	O
rapidly	O
induced	O
to	O
comparable	O
levels	O
by	O
both	O
AR	O
and	O
GR	O
,	O
demonstrating	O
that	O
AR	O
can	O
indeed	O
function	O
as	O
a	O
transcriptional	O
activator	O
in	O
S49	O
cells	O
and	O
,	O
moreover	O
,	O
that	O
GIG18	O
induction	O
may	O
be	O
a	O
marker	O
of	O
early	O
apoptotic	O
events	O
in	O
steroid-treated	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
our	O
conclusion	O
that	O
transcriptional	O
transactivation	O
is	O
a	O
necessary	O
signaling	O
component	O
of	O
S49	O
cell	O
apoptosis	O
,	O
although	O
an	O
additional	O
role	O
for	O
GR-mediated	O
transrepression	O
can	O
not	O
be	O
excluded	O
.	O

Suppression	O
of	O
c-jun	O
by	O
antisense	O
oligonucleotides	O
inhibits	O
cell	O
adhesion	O
but	O
not	B-Negation
respiratory	I-Negation
burst	I-Negation
during	O
phorbol	O
ester-induced	O
differentiation	O
of	O
U937	O
human	O
monoblastic	O
cells	O
.	O

We	O
studied	O
the	O
role	O
of	O
the	O
immediate	O
early	O
gene	O
c-jun	O
in	O
cell	O
proliferation	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
differentiation	O
in	O
U937	O
human	O
monoblastic	O
cells	O
,	O
using	O
c-jun-specific	O
antisense	O
(	O
AS	O
)	O
phosphorothioate	O
oligonucleotides	O
.	O

In	O
selecting	O
the	O
most	O
specific	O
and	O
potent	O
oligonucleotide	O
sequence	O
,	O
we	O
performed	O
extensive	O
analyses	O
for	O
the	O
binding	O
specificity	O
between	O
all	O
candidates	O
of	O
c-jun	O
AS	O
oligonucleotides	O
and	O
the	O
whole	O
sequences	O
in	O
GenBank	O
database	O
,	O
using	O
a	O
computer	O
program	O
.	O

Among	O
the	O
20	O
selected	O
oligonucleotides	O
,	O
two	O
potent	O
15-mer	O
AS	O
oligonucleotides	O
(	O
C-JUN	O
AS	O
oligonucleotides	O
)	O
exhibited	O
significant	O
inhibition	O
of	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
between	O
2	O
and	O
10	O
microM	O
.	O

Reverse	O
transcription-PCR	O
and	O
Western	O
blot	O
analysis	O
demonstrated	O
that	O
10	O
microM	O
of	O
C-JUN	O
AS	O
oligonucleotides	O
reduced	O
c-jun	O
expression	O
at	O
both	O
the	O
mRNA	O
and	O
protein	O
levels	O
.	O

More	O
importantly	O
,	O
C-JUN	O
AS	O
oligonucleotides	O
showed	O
distinct	O
effects	O
on	O
two	O
markers	O
of	O
PMA-induced	O
differentiation	O
;	O

the	O
C-JUN	O
AS	O
oligonucleotides	O
inhibited	O
cell	O
adhesion	O
,	O
whereas	O
they	O
did	O
not	B-Negation
affect	I-Negation
another	I-Negation
marker	I-Negation
of	I-Negation
differentiation	I-Negation
,	I-Negation
respiratory	I-Negation
burst	I-Negation
(	I-Negation
measured	I-Negation
by	I-Negation
nitro	I-Negation
blue	I-Negation
tetrazolium	I-Negation
reduction	I-Negation
assay	I-Negation
)	I-Negation
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
c-jun	O
in	O
both	O
cell	O
proliferation	O
and	O
PMA-induced	O
cell	O
adhesion	O
but	O
not	O
in	O
PMA-induced	O
respiratory	O
burst	O
in	O
U937	O
cells	O
.	O

Human	O
TAFII	O
105	O
is	O
a	O
cell	O
type-specific	O
TFIID	O
subunit	O
related	O
to	O
hTAFII130	O
.	O

We	O
previously	O
characterized	O
Drosophila	O
and	O
human	O
TAF	O
subunits	O
that	O
make	O
up	O
the	O
core	O
TFIID	O
complex	O
found	O
in	O
all	O
cells	O
.	O

Here	O
,	O
we	O
report	O
that	O
differentiated	O
B	O
cells	O
contain	O
a	O
novel	O
substoichiometric	O
TAF	O
of	O
105	O
kDa	O
not	B-Negation
found	I-Negation
associated	I-Negation
with	I-Negation
TFIID	I-Negation
isolated	I-Negation
from	I-Negation
other	I-Negation
cell	I-Negation
types	I-Negation
.	O

The	O
cDNA	O
encoding	O
hTAFII105	O
reveals	O
a	O
highly	O
conserved	O
C-terminal	O
domain	O
shared	O
by	O
hTAFII130	O
and	O
oTAFII110	O
,	O
while	O
the	O
N-terminal	O
coactivator	O
domain	O
has	O
diverged	O
significantly	O
.	O

All	O
cells	O
tested	O
express	O
TAFII105	O
mRNA	O
,	O
but	O
only	O
B	O
cells	O
contain	O
significant	O
levels	O
of	O
protein	O
associated	O
with	O
TFIID	O
.	O

Transient	O
overexpression	O
of	O
hTAFII105	O
selectively	O
squelches	O
the	O
transcription	O
of	O
some	O
genes	O
in	O
B	O
cells	O
.	O

These	O
properties	O
suggest	O
that	O
TAFII105	O
is	O
a	O
cell	O
type-specific	O
subunit	O
of	O
TFIID	O
that	O
may	O
be	O
responsible	O
for	O
mediating	O
transcription	O
by	O
a	O
subset	O
of	O
activators	O
in	O
B	O
cells	O
.	O

Uneven	O
X	O
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha-galactosidase	O
A	O
gene	O
.	O

We	O
describe	O
two	O
female	O
monozygotic	O
(	O
MZ	O
)	O
twins	O
heterozygous	O
for	O
Fabry	O
disease	O
,	O
an	O
X	O
linked	O
disorder	O
resulting	O
from	O
the	O
deficient	O
activity	O
of	O
alpha-galactosidase	O
A	O
.	O

While	O
one	O
of	O
the	O
twins	O
was	O
clinically	O
affected	O
,	O
the	O
other	O
was	O
asymptomatic	O
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	O
in	O
blood	O
leucocytes	O
,	O
skin	O
fibroblasts	O
,	O
Epstein-Barr	O
virus	O
transformed	O
lymphoid	O
cell	O
lines	O
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O

Molecular	O
analysis	O
of	O
the	O
alpha-galactosidase	O
A	O
gene	O
permitted	O
the	O
identification	O
of	O
an	O
as	O
yet	O
undescribed	O
point	O
mutation	O
at	O
position	O
10182	O
of	O
exon	O
5	O
which	O
causes	O
an	O
Asp	O
to	O
Asn	O
substitution	O
at	O
codon	O
231	O
.	O

Single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
again	O
showed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
a	O
normal	O
pattern	O
in	O
their	O
parents	O
.	O

The	O
basis	O
for	O
the	O
discordant	O
expression	O
of	O
this	O
d	O
novo	O
mutation	O
in	O
the	O
twins	O
was	O
investigated	O
by	O
studying	O
their	O
X	O
inactivation	O
status	O
.	O

Analysis	O
of	O
the	O
inactive	O
X	O
specific	O
methylation	O
at	O
the	O
androgen	O
receptor	O
gene	O
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins	O
'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O

While	O
the	O
maternally	O
derived	O
X	O
chromosome	O
was	O
preferentially	O
active	O
in	O
the	O
asymptomatic	O
twin	O
,	O
the	O
paternal	O
X	O
chromosome	O
was	O
active	O
in	O
the	O
other	O
,	O
affected	O
twin	O
and	O
was	O
found	O
in	O
her	O
hemizygotic	O
nephew	O
.	O

These	O
data	O
suggest	O
that	O
the	O
paternal	O
X	O
chromosome	O
carries	O
the	O
de	O
novo	O
alpha-galactosidase	O
A	O
mutation	O
and	O
that	O
uneven	O
X	O
inactivation	O
is	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
this	O
novel	O
female	O
MZ	O
twin	O
pair	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

Signaling	O
by	O
IL-2	O
and	O
related	O
cytokines	O
:	O
JAKs	O
,	O
STATs	O
,	O
and	O
relationship	O
to	O
immunodeficiency	O
.	O

Cytokines	O
that	O
bind	O
to	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
common	O
gamma	O
chain	O
(	O
gamma	O
c	O
)	O
,	O
including	O
IL-2	O
,	O
IL-4	O
,	O
IL-7	O
,	O
IL-9	O
,	O
and	O
IL-15	O
,	O
are	O
important	O
for	O
the	O
growth	O
and	O
differentiation	O
of	O
T	O
and	O
B	O
lymphocytes	O
,	O
natural	O
killer	O
cells	O
,	O
macrophages	O
,	O
and	O
monoctyes	O
.	O

These	O
cytokines	O
have	O
overlapping	O
biological	O
effects	O
that	O
in	O
part	O
result	O
from	O
the	O
use	O
of	O
the	O
shared	O
receptor	O
subunit	O
gamma	O
c	O
.	O

Recently	O
it	O
has	O
become	O
clear	O
that	O
these	O
cytokines	O
activate	O
a	O
number	O
of	O
important	O
intracellular	O
signaling	O
molecules	O
,	O
including	O
the	O
Janus	O
kinases	O
JAK1	O
and	O
JAK3	O
and	O
members	O
of	O
the	O
transcription	O
factor	O
family	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
.	O

The	O
discovery	O
of	O
these	O
signaling	O
pathways	O
has	O
led	O
to	O
important	O
new	O
insights	O
into	O
their	O
role	O
in	O
lymphocyte	O
maturation	O
,	O
as	O
it	O
has	O
emerged	O
that	O
mutations	O
in	O
the	O
genes	O
encoding	O
both	O
gamma	O
c	O
and	O
JAK3	O
result	O
in	O
similar	O
forms	O
of	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
.	O

In	O
this	O
review	O
we	O
examine	O
the	O
structure	O
and	O
function	O
of	O
cytokine	O
receptors	O
and	O
the	O
signaling	O
pathways	O
involved	O
in	O
their	O
regulation	O
of	O
gene	O
expression	O
.	O

Furthermore	O
,	O
we	O
discuss	O
recent	O
advances	O
that	O
have	O
led	O
to	O
a	O
better	O
understanding	O
of	O
how	O
cytokines	O
elicit	O
intracellular	O
responses	O
,	O
as	O
well	O
as	O
their	O
role	O
in	O
normal	O
lymphoid	O
development	O
.	O

Eosinophil	O
priming	O
by	O
cytokines	O
:	O
from	O
cellular	O
signal	O
to	O
in	O
vivo	O
modulation	O
.	O

Eosinophils	O
play	O
an	O
important	O
role	O
in	O
the	O
effector	O
phase	O
of	O
allergic	O
inflammation	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
conversion	O
of	O
the	O
unprimed	O
eosinophil	O
phenotype	O
in	O
the	O
peripheral	O
blood	O
of	O
normal	O
individuals	O
to	O
the	O
primed	O
phenotype	O
found	O
in	O
the	O
peripheral	O
blood	O
and	O
tissues	O
of	O
allergic	O
patients	O
,	O
a	O
phenomenon	O
called	O
priming	O
.	O

Recent	O
data	O
on	O
the	O
signals	O
initiated	O
after	O
cytokine	O
receptor	O
activation	O
on	O
eosinophils	O
will	O
be	O
reviewed	O
.	O

Molecular	O
mechanisms	O
of	O
steroid	O
action	O
:	O
a	O
novel	O
type	O
of	O
cross-talk	O
between	O
glucocorticoids	O
and	O
NF-kappa	O
B	O
transcription	O
factors	O
.	O

Despite	O
the	O
widespread	O
use	O
of	O
glucocorticoids	O
in	O
the	O
treatment	O
of	O
diseases	O
characterized	O
by	O
inflammation	O
,	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
hormones	O
exert	O
this	O
beneficial	O
effect	O
in	O
patients	O
with	O
asthma	O
remains	O
to	O
be	O
elucidated	O
.	O

Therefore	O
,	O
we	O
have	O
studied	O
the	O
transcriptional	O
regulation	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
as	O
adhesion	O
molecules	O
are	O
likely	O
to	O
play	O
a	O
causal	O
role	O
in	O
inflammation	O
in	O
promoting	O
cell-cell	O
and	O
cell-matrix	O
interactions	O
.	O

We	O
observed	O
that	O
in	O
a	O
monocytic	O
(	O
U937	O
)	O
and	O
a	O
bronchial	O
epithelial	O
(	O
H292	O
)	O
cell-line	O
dexamethasone	O
strongly	O
suppressed	O
basal	O
and	O
induced	O
ICAM-1	O
expression	O
.	O

Subsequent	O
analysis	O
of	O
the	O
human	O
ICAM-1	O
promoter	O
has	O
revealed	O
that	O
both	O
12-O-tetradecanoylphorbol	O
13-acetate	O
(	O
TPA	O
)	O
and	O
tumour	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
upregulate	O
ICAM-1	O
expression	O
through	O
the	O
presence	O
of	O
a	O
nuclear	O
factor	O
(	O
NF-kappa	O
B	O
)	O
target	O
sequence	O
(	O
TGGAAATTCC	O
)	O
.	O

No	B-Negation
glucocorticoid	I-Negation
recognition	I-Negation
sequences	I-Negation
are	I-Negation
present	I-Negation
in	I-Negation
this	I-Negation
promoter	I-Negation
region	I-Negation
and	O
dexamethasone	O
is	O
still	O
able	O
to	O
repress	O
transcription	O
when	O
the	O
multimerized	O
NF-kappa	O
B	O
sequence	O
is	O
transactivated	O
by	O
TNF-alpha	O
upon	O
transfection	O
in	O
293	O
cells	O
.	O

We	O
propose	O
that	O
direct	O
interaction	O
between	O
the	O
glucocorticoid	O
receptor	O
and	O
nuclear	O
factor-kappa	O
B	O
factors	O
is	O
at	O
least	O
a	O
partial	O
explanation	O
for	O
the	O
effects	O
of	O
this	O
hormone	O
in	O
inflammatory	O
diseases	O
.	O

The	O
suppression	O
of	O
T	O
cell	O
function	O
and	O
NF	O
(	O
kappa	O
)	O
B	O
expression	O
by	O
serine	O
protease	O
inhibitors	O
is	O
blocked	O
by	O
N-acetylcysteine	O
.	O

Direct	O
evidence	O
that	O
N-acetylcysteine	O
(	O
NAC	O
)	O
enhances	O
the	O
immune	O
response	O
of	O
peripheral	O
blood	O
T	O
cells	O
at	O
the	O
level	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
is	O
presented	O
.	O

In	O
addition	O
,	O
NAC	O
blocks	O
the	O
suppression	O
of	O
T	O
cell	O
mitogenesis	O
and	O
cytokine	O
production	O
by	O
protease	O
inhibitors	O
such	O
as	O
N-tosylphenylalanine	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
.	O

The	O
proliferative	O
responses	O
of	O
purified	O
CD4+	O
or	O
CD8+	O
T	O
cells	O
are	O
suppressed	O
more	O
strongly	O
by	O
TPCK	O
when	O
anti-CD28	O
rather	B-Negation
than	I-Negation
the	I-Negation
phorbol	I-Negation
ester	I-Negation
PMA	I-Negation
is	O
used	O
as	O
the	O
mitogenic	O
coactivator	O
.	O

Cytokine	O
(	O
IL-2	O
,	O
IL-6	O
,	O
INF-gamma	O
)	O
production	O
is	O
inhibited	O
95-100	O
%	O
by	O
concentrations	O
of	O
TPCK	O
that	O
totally	O
suppress	O
the	O
mitogenesis	O
of	O
CD4+	O
or	O
CD8+	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
find	O
that	O
TPCK	O
virtually	O
abolishes	O
(	O
to	O
less	O
than	O
1	O
%	O
)	O
the	O
levels	O
of	O
NF	O
(	O
kappa	O
)	O
B	O
(	O
but	O
not	B-Negation
Oct-1	I-Negation
)	O
found	O
in	O
nuclear	O
and	O
whole	O
cell	O
extracts	O
of	O
activated	O
T	O
cells	O
.	O

Strikingly	O
,	O
the	O
immunosuppressive	O
effects	O
of	O
TPCK	O
are	O
blocked	O
when	O
T	O
cells	O
are	O
pretreated	O
for	O
15	O
min	O
with	O
5	O
mM	O
NAC	O
.	O

NAC	O
not	O
only	O
blocks	O
the	O
effect	O
of	O
TPCK	O
but	O
enhances	O
mitogenesis	O
and	O
cytokine	O
production	O
(	O
>	O
2.5-fold	O
in	O
some	O
cases	O
)	O
upon	O
activation	O
of	O
unsuppressed	O
T	O
cells	O
.	O

Our	O
data	O
support	O
the	O
notion	O
that	O
NF	O
(	O
kappa	O
)	O
B	O
and	O
I	O
(	O
kappa	O
)	O
B	O
proteases	O
play	O
obligate	O
roles	O
in	O
T	O
cell	O
activation	O
and	O
mitogenesis	O
,	O
roles	O
that	O
are	O
enhanced	O
significantly	O
by	O
NAC	O
.	O

IL-12-induced	O
activation	O
of	O
NK	O
and	O
T	O
cells	O
occurs	O
in	O
the	O
absence	O
of	O
immediate-early	O
activation	O
gene	O
expression	O
.	O

The	O
responses	O
of	O
lymphocytes	O
to	O
IL-2	O
and	O
IL-12	O
,	O
involving	O
proliferation	O
,	O
differentiation	O
,	O
and	O
cytokine	O
production	O
,	O
are	O
only	O
partially	O
overlapping	O
,	O
and	O
may	O
depend	O
on	O
induced	O
differential	O
expression	O
of	O
specific	O
sets	O
of	O
genes	O
.	O

Using	O
reverse-transcription	O
PCR	O
differential	O
display	O
,	O
we	O
isolated	O
an	O
mRNA	O
species	O
expressed	O
in	O
IL-2-	O
but	O
not	B-Negation
IL-12-stimulated	I-Negation
NK	I-Negation
cells	I-Negation
.	O

This	O
was	O
identified	O
as	O
the	O
mRNA	O
encoding	O
the	O
transcription	O
factor	O
egr-1	O
,	O
which	O
is	O
expressed	O
with	O
fast	O
kinetics	O
in	O
T	O
and	O
NK	O
cells	O
upon	O
IL-2	O
,	O
but	O
not	B-Negation
IL-12	I-Negation
,	O
stimulation	O
.	O

Analysis	O
of	O
the	O
accumulation	O
of	O
mRNA-encoding	O
members	O
of	O
the	O
AP-1	O
transcription	O
factor	O
family	O
demonstrated	O
that	O
c-fos	O
and	O
junB	O
are	O
also	O
expressed	O
upon	O
stimulation	O
of	O
NK	O
and	O
T	O
cells	O
with	O
IL-2	O
,	O
but	O
not	B-Negation
IL-12	I-Negation
,	O
whereas	O
expression	B-Negation
of	I-Negation
c-jun	I-Negation
and	I-Negation
junD	I-Negation
is	I-Negation
not	I-Negation
modified	I-Negation
by	I-Negation
either	I-Negation
cytokine	I-Negation
.	O

Accordingly	O
,	O
increased	O
AP-1	O
DNA-binding	O
activity	O
and	O
AP-1-dependent	O
transcriptional	O
activity	O
were	O
detected	O
exclusively	O
in	O
IL-2-stimulated	O
cells	O
.	O

Analysis	O
of	O
the	O
expression	O
of	O
genes	O
reported	O
to	O
regulate	O
cytokine-induced	O
proliferation	O
demonstrated	O
that	O
both	O
IL-2	O
and	O
IL-12	O
induce	O
c-myc	O
mRNA	O
accumulation	O
in	O
NK	O
and	O
T	O
cells	O
,	O
whereas	O
only	O
IL-2	O
induces	O
bcl-2	O
expression	O
.	O

Our	O
data	O
provide	O
the	O
first	O
demonstration	O
that	O
IL-12-mediated	O
activation	O
of	O
T	O
and	O
NK	O
cells	O
does	O
not	B-Negation
involve	I-Negation
expression	I-Negation
of	I-Negation
members	I-Negation
of	I-Negation
the	I-Negation
immediate-early	I-Negation
activation	I-Negation
genes	I-Negation
family	I-Negation
(	I-Negation
egr-1	I-Negation
,	I-Negation
c-fos	I-Negation
,	I-Negation
and	I-Negation
junB	I-Negation
)	I-Negation
,	I-Negation
AP-1	I-Negation
transcriptional	I-Negation
activity	I-Negation
,	I-Negation
or	I-Negation
bcl-2	I-Negation
expression	I-Negation
.	O

This	O
indicates	O
that	O
functional	O
differences	O
observed	O
in	O
IL-2-	O
and	O
IL-12-stimulated	O
cells	O
may	O
depend	O
,	O
at	O
least	O
in	O
part	O
,	O
on	O
differential	O
gene	O
regulation	O
.	O

A	O
critical	O
role	O
of	O
Sp1-	O
and	O
Ets-related	O
transcription	O
factors	O
in	O
maintaining	O
CTL-specific	O
expression	O
of	O
the	O
mouse	O
perforin	O
gene	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
potential	O
cis-elements	O
involved	O
in	O
transcriptional	O
regulation	O
of	O
the	O
mouse	O
perforin	O
gene	O
.	O

DNase	O
I	O
hypersensitive	O
site	O
(	O
DHS	O
)	O
mapping	O
revealed	O
that	O
the	O
perforin	O
locus	O
contained	O
six	O
DHS	O
within	O
7.0	O
kb	O
of	O
the	O
5	O
'	O
upstream	O
sequence	O
(	O
-7.0	O
kb	O
)	O
and	O
two	O
DHS	O
in	O
intron	O
2	O
.	O

The	O
six	O
5	O
'	O
upstream	O
and	O
one	O
intronic	O
DHS	O
were	O
detected	O
in	O
only	O
perforin-expressing	O
lymphocytes	O
.	O

Chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
activities	O
directed	O
by	O
5	O
'	O
upstream	O
promoter	O
were	O
detected	O
preferentially	O
in	O
perforin-expressing	O
cell	O
lines	O
.	O

A	O
construct	O
termed	O
PFP5a	O
containing	O
-795	O
bp	O
exhibited	O
the	O
highest	O
CAT	O
activity	O
,	O
and	O
PFP9a20	O
containing	O
only	O
-73	O
bp	O
also	O
produced	O
significantly	O
high	O
CAT	O
activity	O
in	O
CTLL-R8	O
cells	O
.	O

The	O
proximal	O
region	O
in	O
PFP9a20	O
contained	O
two	O
potential	O
Sp1	O
binding	O
sites	O
(	O
GC	O
box	O
and	O
GT	O
box	O
)	O
and	O
one	O
Ets	O
binding	O
site	O
(	O
EBS	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
showed	O
that	O
each	O
of	O
the	O
cis-elements	O
bound	O
specific	O
protein	O
factors	O
.	O

When	O
single-point	O
mutation	O
was	O
introduced	O
to	O
each	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
in	O
PFP9a20	O
,	O
at	O
least	O
3-fold	O
less	O
CAT	O
activity	O
was	O
observed	O
in	O
CTLL-R8	O
cells	O
.	O

To	O
confirm	O
the	O
importance	O
of	O
the	O
three	O
cis-acting	O
elements	O
in	O
the	O
perforin	O
gene	O
expression	O
,	O
point	O
mutation	O
was	O
introduced	O
again	O
to	O
each	O
proximal	O
GC	O
box	O
,	O
EBS	O
,	O
and	O
GT	O
box	O
of	O
PFP5a	O
.	O

The	O
point	O
mutations	O
resulted	O
in	O
a	O
2.5-	O
to	O
3-fold	O
reduction	O
of	O
CAT	O
activity	O
.	O

The	O
results	O
suggest	O
that	O
a	O
combination	O
of	O
the	O
three	O
proximal	O
cis-acting	O
elements	O
may	O
constitute	O
a	O
minimal	O
region	O
responsible	O
for	O
CTL-specific	O
expression	O
of	O
perforin	O
.	O

Soluble	O
factors	O
secreted	O
by	O
activated	O
T-lymphocytes	O
modulate	O
the	O
transcription	O
of	O
the	O
immunosuppressive	O
cytokine	O
TGF-beta	O
2	O
in	O
glial	O
cells	O
.	O

Coordination	O
of	O
the	O
immune	O
response	O
to	O
injury	O
or	O
disease	O
in	O
the	O
brain	O
is	O
postulated	O
to	O
involve	O
bi-directional	O
discourse	O
between	O
the	O
immune	O
system	O
and	O
the	O
central	O
nervous	O
system	O
.	O

This	O
cross	O
communication	O
involves	O
soluble	O
mediators	O
,	O
including	O
various	O
growth	O
factors	O
,	O
cytokines	O
,	O
and	O
neuropeptides	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
supernatant	O
from	O
activated	O
T-lymphocytes	O
is	O
able	O
to	O
induce	O
the	O
transcription	O
of	O
a	O
potent	O
cytokine	O
,	O
TGF-beta	O
2	O
in	O
glial	O
cells	O
.	O

The	O
activating	O
stimulus	O
invokes	O
signaling	O
mechanisms	O
distinct	O
from	O
known	O
kinase	O
or	O
protease	O
pathways	O
.	O

Activation	O
of	O
TGF-beta	O
2	O
transcription	O
correlates	O
with	O
the	O
loss	O
of	O
binding	O
activity	O
for	O
an	O
80	O
kDA	O
glial	O
labile	O
repressor	O
protein	O
,	O
GLRP	O
,	O
to	O
a	O
responsive	O
region	O
within	O
the	O
TFG-beta	O
2	O
promoter	O
.	O

Although	O
GLRP	O
shares	O
some	O
characteristics	O
with	O
the	O
inducible	O
transcription	O
factor	O
AP-1	O
,	O
it	O
appears	O
to	O
be	O
distinct	O
from	O
known	O
AP-1	O
family	O
members	O
.	O

These	O
data	O
along	O
with	O
previous	O
observations	O
demonstrating	O
the	O
potent	O
immunosuppressive	O
activity	O
of	O
TGF-beta	O
2	O
,	O
support	O
a	O
model	O
for	O
a	O
feedback	O
mechanism	O
between	O
the	O
activated	O
T-lymphocytes	O
and	O
astrocytes	O
via	O
TGF-beta	O
2	O
to	O
regulate	O
the	O
immune	O
response	O
.	O

Dual	O
action	O
of	O
retinoic	O
acid	O
on	O
human	O
embryonic/fetal	O
hematopoiesis	O
:	O
blockade	O
of	O
primitive	O
progenitor	O
proliferation	O
and	O
shift	O
from	O
multipotent/erythroid/monocytic	O
to	O
granulocytic	O
differentiation	O
program	O
.	O

In	O
preliminary	O
studies	O
,	O
we	O
have	O
analyzed	O
the	O
hematopoietic	O
growth	O
factor	O
(	O
HGF	O
)	O
requirement	O
of	O
hematopoietic	O
progenitor	O
cells	O
(	O
HPCs	O
)	O
purified	O
from	O
embryonic-fetal	O
liver	O
(	O
FL	O
)	O
and	O
grown	O
in	O
fetal	O
calf	O
serum-supplemented	O
(	O
FCS+	O
)	O
clonogenic	O
culture	O
.	O

The	O
key	O
role	O
of	O
erythropoietin	O
(	O
Epo	O
)	O
for	O
colony	O
formation	O
by	O
early	O
erythroid	O
progenitors	O
(	O
burst-forming	O
units-erythroid	O
[	O
BFU-E	O
]	O
)	O
has	O
been	O
confirmed	O
.	O

Furthermore	O
,	O
in	O
the	O
absence	O
of	O
exogenous	O
HGFs	O
,	O
FL	O
monocytic	O
progenitors	O
(	O
colony-forming	O
unit	O
monocyte	O
[	O
CFU-M	O
]	O
)	O
generate	O
large	O
colonies	O
exclusively	O
composed	O
of	O
monocytes-macrophages	O
;	O

these	O
colonies	O
are	O
absent	O
in	O
FCS-	O
clonogenic	O
culture	O
.	O

On	O
this	O
basis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
its	O
isomer	O
9-cis	O
RA	O
in	O
FL	O
hematopoiesis	O
.	O

Both	O
compounds	O
modulate	O
the	O
growth	O
of	O
purified	O
FL	O
HPCs	O
,	O
which	O
show	O
a	O
dose-dependent	O
shift	O
from	O
mixed/erythroid/	O
monocytic	O
to	O
granulocytic	O
colony	O
formation	O
.	O

Studies	O
on	O
unicellular	O
and	O
paired	O
daughter	O
cell	O
culture	O
unequivocally	O
indicate	O
that	O
the	O
shift	O
is	O
mediated	O
by	O
modulation	O
of	O
the	O
HPC	O
differentiation	O
program	O
to	O
the	O
granulopoietic	O
pathway	O
(	O
rather	O
than	O
RA-induced	O
down-modulation	O
of	O
multipotent/erythroid/monocytic	O
HPC	O
growth	O
coupled	O
with	O
recruitment	O
of	O
granulocytic	O
HPCs	O
)	O
.	O

ATRA	O
and	O
9-cis	O
RA	O
also	O
exert	O
their	O
effect	O
on	O
the	O
proliferation	O
of	O
primitive	O
HPCs	O
(	O
high-proliferative	O
potential	O
colony-forming	O
cells	O
[	O
HPP-CFCs	O
]	O
)	O
and	O
putative	O
hematopoietic	O
stem	O
cells	O
(	O
HSCs	O
;	O
assayed	O
in	O
Dexter-type	O
long-term	O
culture	O
)	O
.	O

High	O
concentrations	O
of	O
either	O
compound	O
(	O
1	O
)	O
drastically	O
reduced	O
the	O
number	O
of	O
primary	O
HPP-CFC	O
colonies	O
and	O
totally	O
abolished	O
their	O
recloning	O
capacity	O
and	O
(	O
2	O
)	O
inhibited	O
HSC	O
proliferation	O
.	O

It	O
is	O
crucial	O
that	O
these	O
results	O
mirror	O
recent	O
observations	O
indicating	O
that	O
murine	O
adult	O
HPCs	O
transduced	O
with	O
dominant	O
negative	O
ATRA	O
receptor	O
(	O
RAR	O
)	O
gene	O
are	O
immortalized	O
and	O
show	O
a	O
selective	O
blockade	O
of	O
granulocytic	O
differentiation	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
ATRA/9-cis	O
RA	O
may	O
play	O
a	O
key	O
role	O
in	O
FL	O
hematopoiesis	O
via	O
a	O
dual	O
effect	O
hypothetically	O
mediated	O
by	O
interaction	O
with	O
the	O
RAR/RXR	O
heterodimer	O
,	O
ie	O
,	O
inhibition	O
of	O
HSC/	O
primitive	O
HPC	O
proliferation	O
and	O
induction	O
of	O
CFU-GEMM/	O
BFU-E/CFU-M	O
shift	O
from	O
the	O
multipotent/erythroid/monocytic	O
to	O
the	O
granulocytic-neutrophilic	O
differentiation	O
program	O
.	O

Vitamin	O
D3-	O
and	O
retinoic	O
acid-induced	O
monocytic	O
differentiation	O
:	O
interactions	O
between	O
the	O
endogenous	O
vitamin	O
D3	O
receptor	O
,	O
retinoic	O
acid	O
receptors	O
,	O
and	O
retinoid	O
X	O
receptors	O
in	O
U-937	O
cells	O
.	O

Retinoic	O
acid	O
(	O
RA	O
)	O
and	O
1,25	O
alpha-dihydroxycholecalciferol	O
(	O
VitD3	O
)	O
are	O
potent	O
regulators	O
of	O
hematopoletic	O
differentiation	O
.	O

Yet	O
,	O
little	O
is	O
known	O
as	O
to	O
how	O
the	O
RA	O
and	O
VitD3	O
receptor	O
network	O
operates	O
in	O
hematopoietic	O
cells	O
,	O
and	O
whether	O
receptor	O
interactions	O
can	O
explain	O
the	O
interplay	O
between	O
the	O
RA-	O
and	O
VitD3-signaling	O
pathways	O
during	O
differentiation	O
.	O

Therefore	O
,	O
we	O
analyzed	O
the	O
expression	O
,	O
DNA	O
binding	O
,	O
and	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
RA	O
and	O
VitD3	O
receptors	O
[	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
,	O
retinoid	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
and	O
VitD3	O
receptor	O
(	O
VDR	O
)	O
]	O
in	O
the	O
U-937	O
cell	O
line	O
,	O
in	O
which	O
RA	O
and	O
VitD3	O
induce	O
distinct	O
monocytic	O
differentiation	O
pathways	O
.	O

VitD3	O
induction	O
resulted	O
in	O
the	O
formation	O
of	O
VDR/RXR	O
DNA-binding	O
complexes	O
on	O
both	O
VitD3	O
response	O
elements	O
and	O
RA	O
response	O
elements	O
(	O
RAREs	O
)	O
.	O

However	O
,	O
transcriptional	O
activation	O
was	O
only	O
observed	O
from	O
a	O
VitD3	O
response	O
element-driven	O
reporter	O
construct	O
.	O

Several	O
DNA-binding	O
complexes	O
were	O
detected	O
on	O
RAREs	O
in	O
undifferentiated	O
cells	O
.	O

Stimulation	O
by	O
RA	O
resulted	O
in	O
increased	O
RAR	O
beta/RXR	O
DNA	O
binding	O
,	O
activated	O
RARE-dependent	O
transcription	O
,	O
and	O
increased	O
expression	O
of	O
RAR-beta	O
.	O

Concomitant	O
stimulation	O
by	O
VitD3	O
inhibited	O
the	O
RA-stimulated	O
formation	O
of	O
RAR	O
beta/RXR	O
heterodimers	O
,	O
favoring	O
VDR/RXR	O
binding	O
to	O
the	O
RARE	O
.	O

Also	O
,	O
VitD3	O
inhibited	O
the	O
expression	O
of	O
CD23	O
and	O
CD49f	O
,	O
characteristic	O
markers	O
of	O
retinoid-induced	O
U-937	O
cell	O
differentiation	O
.	O

In	O
contrast	O
,	O
neither	B-Negation
the	I-Negation
RA-stimulated	I-Negation
,	I-Negation
RARE-mediated	I-Negation
transcription	I-Negation
nor	I-Negation
the	I-Negation
induced	I-Negation
RAR-beta	I-Negation
expression	I-Negation
was	I-Negation
suppressed	I-Negation
by	I-Negation
VitD3	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
VitD3	I-Speculation
selectively	I-Speculation
inhibited	I-Speculation
the	I-Speculation
retinoid-induced	I-Speculation
differentiation	I-Speculation
program	I-Speculation
but	I-Speculation
not	I-Speculation
the	I-Speculation
RARE-mediated	I-Speculation
signal	I-Speculation
.	O

These	O
results	O
demonstrate	O
a	O
complex	O
role	O
for	O
VitD3	O
in	O
modifying	O
the	O
retinoid	O
differentiation	O
pathway	O
and	O
may	O
have	O
implications	O
for	O
differentiation-inducing	O
therapy	O
of	O
hematopoietic	O
tumors	O
.	O

Regulation	O
of	O
interferon-gamma	O
gene	O
expression	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	O
)	O
,	O
also	O
known	O
as	O
type	O
II	O
interferon	O
,	O
is	O
an	O
important	O
immunoregulatory	O
gene	O
that	O
has	O
multiple	O
effects	O
on	O
the	O
development	O
,	O
maturation	O
,	O
and	O
function	O
of	O
the	O
immune	O
system	O
.	O

IFN-gamma	O
mRNA	O
and	O
protein	O
are	O
expressed	O
predominantly	O
by	O
T	O
cells	O
and	O
large	O
granular	O
lymphocytes	O
.	O

The	O
IFN-gamma	O
mRNA	O
is	O
induced/inhibited	O
in	O
these	O
cell	O
types	O
by	O
a	O
wide	O
variety	O
of	O
extracellular	O
signals	O
,	O
thus	O
implicating	O
a	O
number	O
of	O
diverse	O
,	O
yet	O
convergent	O
signal	O
transduction	O
pathways	O
in	O
its	O
transcriptional	O
control	O
.	O

In	O
this	O
review	O
,	O
I	O
describe	O
how	O
DNA	O
methylation	O
and	O
specific	O
DNA	O
binding	O
proteins	O
may	O
regulate	O
transcription	O
of	O
the	O
IFN-gamma	O
gene	O
in	O
response	O
to	O
extracellular	O
signals	O
.	O

Inorganic	O
lead	O
activates	O
NF-kappa	O
B	O
in	O
primary	O
human	O
CD4+	O
T	O
lymphocytes	O
.	O

Inorganic	O
lead	O
(	O
Pb	O
)	O
is	O
a	O
ubiquitous	O
environmental	O
contaminant	O
that	O
produces	O
a	O
variety	O
of	O
effects	O
on	O
humoral	O
and	O
cell	O
mediated	O
immune	O
responses	O
.	O

The	O
underlying	O
molecular	O
mechanism	O
for	O
Pb	O
's	O
complex	O
effects	O
on	O
the	O
immune	O
system	O
remain	O
obscure	O
.	O

Many	O
of	O
Pb	O
's	O
effects	O
on	O
the	O
immune	O
system	O
could	O
be	O
explained	O
through	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF-kappa	O
B	O
.	O

NF-kappa	O
B	O
is	O
critical	O
for	O
T	O
lymphocyte	O
function	O
and	O
is	O
a	O
strong	O
inducer	O
of	O
HIV-LTR	O
activation	O
.	O

We	O
demonstrate	O
that	O
Pb	O
at	O
physiologically	O
relevant	O
concentrations	O
activates	O
NF-kappa	O
B	O
in	O
primary	O
human	O
CD4+	O
T	O
lymphocytes	O
.	O

Pb-induced	O
activation	O
of	O
NF-kappa	O
B	O
is	O
blocked	O
by	O
antibodies	O
for	O
p65	O
and	O
p50	O
subunits	O
but	O
not	B-Negation
cRel	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
the	I-Speculation
p65	I-Speculation
:	I-Speculation
p50	I-Speculation
heterodimer	I-Speculation
(	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
)	I-Speculation
is	I-Speculation
involved	I-Speculation
.	O

Functional	O
activation	O
of	O
gene	O
expression	O
by	O
Pb	O
was	O
confirmed	O
using	O
primary	O
CD4+	O
T	O
cells	O
transfected	O
with	O
an	O
NF-kappa	O
B	O
dependent	O
reporter	O
gene	O
construct	O
.	O

Pb	O
did	O
not	B-Negation
activate	I-Negation
NF-kappa	I-Negation
B	I-Negation
in	I-Negation
4	I-Negation
different	I-Negation
T	I-Negation
cell	I-Negation
lines	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
lymphoid	I-Speculation
cell	I-Speculation
lines	I-Speculation
may	I-Speculation
not	I-Speculation
be	I-Speculation
reliable	I-Speculation
surrogates	I-Speculation
for	I-Speculation
the	I-Speculation
study	I-Speculation
of	I-Speculation
transcriptional	I-Speculation
activation	I-Speculation
in	I-Speculation
human	I-Speculation
T	I-Speculation
cells	I-Speculation
.	O

These	O
data	O
suggest	O
that	O
NF-kappa	O
B	O
may	O
be	O
an	O
important	O
molecular	O
mediator	O
of	O
Pb-induced	O
immunotoxicity	O
.	O

Calcium-dependent	O
immediate-early	O
gene	O
induction	O
in	O
lymphocytes	O
is	O
negatively	O
regulated	O
by	O
p21Ha-ras	O
.	O

The	O
induction	O
of	O
immediate-early	O
(	O
IE	O
)	O
response	O
genes	O
,	O
such	O
as	O
egr-1	O
,	O
c-fos	O
,	O
and	O
c-jun	O
,	O
occurs	O
rapidly	O
after	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

The	O
process	O
of	O
activation	O
involves	O
calcium	O
mobilization	O
,	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
and	O
phosphorylation	O
of	O
tyrosine	O
kinases	O
.	O

p21	O
(	O
ras	O
)	O
,	O
a	O
guanine	O
nucleotide	O
binding	O
factor	O
,	O
mediates	O
T-cell	O
signal	O
transduction	O
through	O
PKC-dependent	O
and	O
PKC-independent	O
pathways	O
.	O

The	O
involvement	O
of	O
p21	O
(	O
ras	O
)	O
in	O
the	O
regulation	O
of	O
calcium-dependent	O
signals	O
has	O
been	O
suggested	O
through	O
analysis	O
of	O
its	O
role	O
in	O
the	O
activation	O
of	O
NF-AT	O
.	O

We	O
have	O
investigated	O
the	O
inductions	O
of	O
the	O
IE	O
genes	O
in	O
response	O
to	O
calcium	O
signals	O
in	O
Jurkat	O
cells	O
(	O
in	O
the	O
presence	O
of	O
activated	O
p21	O
(	O
ras	O
)	O
)	O
and	O
their	O
correlated	O
consequences	O
.	O

The	O
expression	O
of	O
activated	O
p21	O
(	O
ras	O
)	O
negatively	O
regulated	O
the	O
induction	O
of	O
IE	O
genes	O
by	O
calcium	O
ionophore	O
.	O

This	O
inhibition	O
of	O
calcium-activated	O
IE	O
gene	O
induction	O
was	O
reversed	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
,	O
suggesting	O
the	O
involvement	O
of	O
calcineurin	O
in	O
this	O
regulation	O
.	O

A	O
later	O
result	O
of	O
inhibition	O
of	O
this	O
activation	O
pathway	O
by	O
p21	O
(	O
ras	O
)	O
was	O
down-regulation	O
of	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
AP-1	O
and	O
subsequent	O
coordinate	O
reductions	O
in	O
IL-2	O
gene	O
expression	O
and	O
protein	O
production	O
.	O

These	O
results	O
suggest	O
that	O
p2l	O
(	O
ras	O
)	O
is	O
an	O
essential	O
mediator	O
in	O
generating	O
not	O
only	O
positive	O
but	O
also	O
negative	O
modulatory	O
mechanisms	O
controlling	O
the	O
competence	O
of	O
T	O
cells	O
in	O
response	O
to	O
inductive	O
stimulations	O
.	O

CD14-mediated	O
signal	O
pathway	O
of	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
expression	O
of	O
inflammatory	O
cytokines	O
in	O
monocytes/macrophages	O
via	O
CD14	O
,	O
one	O
of	O
the	O
LPS	O
receptors	O
,	O
which	O
is	O
expressed	O
predominantly	O
in	O
these	O
cells	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
Porphyromonas	O
gingivalis	O
LPS	O
(	O
P-LPS	O
)	O
also	O
is	O
able	O
to	O
induce	O
inflammatory	O
cytokines	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
determine	O
whether	O
CD14	O
is	O
expressed	O
in	O
gingival	O
fibroblasts	O
and	O
to	O
define	O
the	O
P-LPS-mediated	O
signal-transducing	O
mechanism	O
in	O
the	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
unexpectedly	O
by	O
immunohistochemical	O
,	O
Western	O
blotting	O
(	O
immunoblotting	O
)	O
,	O
and	O
Northern	O
(	O
RNA	O
)	O
blotting	O
assays	O
that	O
CD14	O
is	O
expressed	O
at	O
high	O
density	O
in	O
human	O
gingival	O
fibroblasts	O
.	O

P-LPS-induced	O
expression	O
of	O
the	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
gene	O
in	O
the	O
cells	O
was	O
inhibited	O
markedly	O
by	O
treatment	O
with	O
anti-human	O
CD14	O
antibody	O
and	O
was	O
completely	O
inhibited	O
by	O
herbimycin	O
A	O
,	O
a	O
potent	O
inhibitor	O
of	O
tyrosine	O
kinase	O
.	O

The	O
inhibitor	O
also	O
dramatically	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
of	O
and	O
MCP-1	O
production	O
by	O
the	O
cells	O
.	O

Furthermore	O
,	O
P-LPS-induced	O
expression	O
of	O
the	O
MCP-1	O
gene	O
in	O
the	O
cells	O
also	O
was	O
blocked	O
by	O
inhibitors	O
of	O
two	O
transcription	O
factors	O
,	O
i.e.	O
,	O
curcumin	O
,	O
an	O
inhibitor	O
of	O
AP-1	O
,	O
and	O
pyrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
of	O
NF-kappaB	O
.	O

Both	O
inhibitors	O
inhibited	O
monocyte	O
chemotactic	O
activity	O
in	O
the	O
culture	O
supernatant	O
of	O
P-LPS-treated	O
cells	O
.	O

Gel	O
shift	O
mobility	O
assay	O
showed	O
stimulation	O
of	O
the	O
AP-1	O
and	O
NF-kappaB	O
contents	O
in	O
P-LPS-treated	O
cells	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
demonstrate	O
the	O
expression	O
of	O
CD14	O
in	O
human	O
gingival	O
fibroblasts	O
and	O
to	O
show	O
that	O
the	O
signal-transducing	O
pathway	O
of	O
P-LPS	O
in	O
the	O
cells	O
is	O
mediated	O
by	O
CD14	O
.	O

Tyrosines	O
113	O
,	O
128	O
,	O
and	O
145	O
of	O
SLP-76	O
are	O
required	O
for	O
optimal	O
augmentation	O
of	O
NFAT	O
promoter	O
activity	O
.	O

SLP-76	O
(	O
SH2	O
domain	O
leukocyte	O
protein	O
of	O
76	O
kDa	O
)	O
is	O
a	O
recently	O
identified	O
substrate	O
of	O
the	O
TCR-stimulated	O
protein	O
tyrosine	O
kinases	O
that	O
functions	O
in	O
the	O
signal	O
transduction	O
cascade	O
linking	O
the	O
TCR	O
with	O
IL-2	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
engagement	O
of	O
the	O
TCR	O
results	O
in	O
tyrosine	O
phosphorylation	O
of	O
SLP-76	O
in	O
its	O
amino-terminal	O
acidic	O
region	O
.	O

Two	O
tyrosines	O
(	O
Y113	O
and	O
Y128	O
)	O
fall	O
within	O
an	O
identical	O
five	O
amino-acid	O
motif	O
and	O
are	O
shown	O
to	O
be	O
phosphorylated	O
upon	O
TCR	O
ligation	O
.	O

Although	O
mutation	O
of	O
either	O
Y113	O
and	O
Y128	O
has	O
a	O
minimal	O
effect	O
on	O
SLP-76	O
function	O
,	O
mutation	O
of	O
both	O
residues	O
decreases	O
significantly	O
the	O
ability	O
of	O
SLP-76	O
to	O
promote	O
T	O
cell	O
activation	O
.	O

A	O
third	O
tyrosine	O
within	O
the	O
amino-terminal	O
region	O
(	O
Y145	O
)	O
appears	O
to	O
be	O
the	O
most	O
important	O
for	O
optimal	O
SLP-76	O
function	O
,	O
as	O
altering	O
it	O
alone	O
to	O
phenylalanine	O
has	O
a	O
potent	O
impact	O
on	O
SLP-76	O
augmentation	O
of	O
NFAT	O
promoter	O
activity	O
.	O

The	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
,	O
but	O
not	B-Negation
its	I-Negation
regulatory	I-Negation
domain	I-Negation
,	O
is	O
sufficient	O
for	O
inducing	O
IL-2	O
production	O
.	O

The	O
lymphoid	O
src	O
kinase	O
pp56	O
(	O
lck	O
)	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
the	O
induction	O
of	O
different	O
T	O
lymphocyte	O
responses	O
,	O
including	O
CD4-mediated	O
enhancement	O
of	O
Ag-induced	O
T	O
cell	O
activation	O
,	O
early	O
T	O
cell	O
differentiation	O
,	O
induction	O
of	O
IL-2	O
production	O
,	O
and	O
cytotoxicity	O
.	O

It	O
is	O
assumed	O
that	O
pp56	O
(	O
lck	O
)	O
acts	O
on	O
these	O
processes	O
by	O
phosphorylating	O
substrates	O
.	O

However	O
,	O
it	O
has	O
been	O
recently	O
reported	O
that	O
the	O
NH2	O
regulatory	O
domain	O
is	O
sufficient	O
to	O
mediate	O
CD4	O
accessory	O
function	O
.	O

In	O
this	O
report	O
we	O
address	O
the	O
contribution	O
of	O
the	O
regulatory	O
and	O
catalytic	O
domains	O
of	O
pp56	O
(	O
lck	O
)	O
to	O
another	O
function	O
of	O
this	O
enzyme	O
independent	O
of	O
CD4	O
:	O
TCR-induced	O
IL-2	O
production	O
.	O

Two	O
pp56	O
(	O
lck	O
)	O
mutants	O
lacking	B-Negation
either	I-Negation
the	I-Negation
entire	I-Negation
catalytic	I-Negation
domain	I-Negation
or	I-Negation
the	I-Negation
entire	I-Negation
NH2	I-Negation
regulatory	I-Negation
domain	I-Negation
were	O
generated	O
,	O
and	O
their	O
abilities	O
to	O
trigger	O
transactivation	O
of	O
the	O
TCR-regulated	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
region	O
of	O
the	O
IL-2	O
promoter	O
were	O
compared	O
.	O

Only	O
the	O
catalytic	O
,	O
but	O
not	B-Negation
the	I-Negation
NH2	I-Negation
regulatory	I-Negation
,	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
was	O
able	O
to	O
induce	O
NF-AT	O
region	O
transactivation	O
on	O
its	O
own	O
and	O
to	O
cooperate	O
with	O
other	O
intracellular	O
signals	O
to	O
trigger	O
this	O
response	O
.	O

Moreover	O
,	O
the	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
was	O
able	O
to	O
induce	O
IL-2	O
cytokine	O
production	O
to	O
an	O
extent	O
similar	O
to	O
that	O
of	O
wild-type	O
pp56	O
(	O
lck	O
)	O
.	O

We	O
conclude	O
that	O
different	O
domains	O
of	O
the	O
pp56	O
(	O
lck	O
)	O
molecule	O
contribute	O
to	O
regulate	O
distinct	O
biologic	O
functions	O
.	O

In	O
fact	O
,	O
while	O
the	O
NH2	O
regulatory	O
domain	O
is	O
sufficient	O
to	O
mediate	O
CD4	O
accessory	O
function	O
,	O
we	O
show	O
here	O
that	O
the	O
catalytic	O
domain	O
of	O
pp56	O
(	O
lck	O
)	O
is	O
sufficient	O
for	O
induction	O
of	O
IL-2	O
production	O
,	O
mimicking	O
TCR	O
ligation	O
.	O

Isolation	O
and	O
characterization	O
of	O
murine	O
fra-1	O
:	O
induction	O
mediated	O
by	O
CD40	O
and	O
surface	O
Ig	O
is	O
protein	O
kinase	O
C	O
dependent	O
.	O

The	O
murine	O
fra-1	O
gene	O
,	O
encoding	O
Fos-related	O
Ag	O
1	O
,	O
was	O
isolated	O
from	O
a	O
splenic	O
cDNA	O
library	O
and	O
sequenced	O
.	O

Murine	O
fra-1	O
was	O
highly	O
homologous	O
to	O
rat	O
and	O
human	O
fra-1	O
.	O

Oligonucleotide	O
primers	O
based	O
on	O
the	O
murine	O
sequence	O
were	O
used	O
to	O
construct	O
a	O
quantitative	O
reverse	O
transcription-PCR	O
assay	O
for	O
gene	O
expression	O
.	O

B	O
lymphocyte	O
stimulation	O
via	O
both	O
CD40	O
and	O
surface	O
Ig	O
(	O
sIg	O
)	O
receptors	O
substantially	O
induced	O
fra-1	O
expression	O
,	O
and	O
for	O
both	O
receptors	O
,	O
induction	O
was	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
dependent	O
.	O

This	O
contrasts	O
with	O
induction	O
of	O
c-fos	O
by	O
both	O
CD40	O
and	O
sIg	O
,	O
which	O
is	O
PKC	O
independent	O
and	O
indicates	O
that	O
CD40	O
is	O
capable	O
of	O
signaling	O
through	O
PKC	O
or	O
a	O
closely	O
related	O
kinase	O
.	O

Induction	O
of	O
fra-1	O
following	O
engagement	O
of	O
CD40	O
did	O
not	B-Negation
require	I-Negation
protein	I-Negation
synthesis	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
PKC-dependent	I-Speculation
linkage	I-Speculation
between	I-Speculation
CD40	I-Speculation
and	I-Speculation
fra-1	I-Speculation
is	I-Speculation
direct	I-Speculation
.	O

CD40-mediated	O
fra-1	O
induction	O
did	O
require	O
tyrosine	O
kinase	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
CD40	O
,	O
like	O
sIg	O
,	O
may	O
employ	O
PKC	O
in	O
producing	O
select	O
outcomes	O
,	O
that	O
individual	O
B	O
cell	O
receptors	O
may	O
signal	O
downstream	O
events	O
via	O
both	O
PKC-dependent	O
and	O
PKC-independent	O
pathways	O
,	O
and	O
that	O
multiple	O
signal	O
transduction	O
pathways	O
may	O
be	O
used	O
to	O
activate	O
the	O
expression	O
of	O
closely	O
related	O
genes	O
.	O

Apoptosis	O
signaling	O
pathways	O
in	O
normal	O
T	O
cells	O
:	O
differential	O
activity	O
of	O
Bcl-2	O
and	O
IL-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
on	O
glucocorticoid-	O
and	O
Fas-mediated	O
cytotoxicity	O
.	O

Fas-mediated	O
apoptosis	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
the	O
immune	O
response	O
in	O
peripheral	O
T	O
cells	O
.	O

Restimulation	O
of	O
T	O
cell	O
blasts	O
up-regulates	O
Fas	O
and	O
Fas	O
ligand	O
expression	O
,	O
with	O
subsequent	O
interaction	O
leading	O
to	O
cell	O
death	O
.	O

Overexpression	O
of	O
Bcl-2	O
in	O
tumor	O
cells	O
blocks	O
apoptosis	O
induced	O
by	O
many	O
stimuli	O
,	O
but	O
inhibition	B-Negation
of	I-Negation
Fas-mediated	I-Negation
killing	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
consistently	I-Negation
observed	I-Negation
.	O

To	O
examine	O
the	O
behavior	O
of	O
Bcl-2	O
in	O
normal	O
cells	O
,	O
T	O
cell	O
blasts	O
were	O
transiently	O
transfected	O
with	O
Bcl-2	O
and	O
related	O
gene	O
products	O
to	O
determine	O
the	O
effect	O
on	O
apoptotic	O
signaling	O
.	O

Transient	O
overexpression	O
of	O
Bcl-2	O
in	O
mouse	O
and	O
human	O
T	O
cell	O
blasts	O
did	O
not	B-Negation
block	I-Negation
Fas-mediated	I-Negation
apoptosis	I-Negation
,	O
whereas	O
etoposide-	O
and	O
glucocorticoid-induced	O
cytotoxicity	O
was	O
potently	O
inhibited	O
.	O

Expression	O
of	O
Bcl-xL	O
and	O
adenovirus	O
E1B	O
19K	O
did	O
not	B-Negation
interfere	I-Negation
with	I-Negation
anti-Fas	I-Negation
killing	I-Negation
.	O

In	O
contrast	O
,	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
Ac-DEVD-CHO	O
and	O
CrmA	O
blocked	O
Fas-mediated	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
peripheral	O
T	O
cells	O
use	O
distinct	O
apoptosis	O
signaling	O
pathways	O
with	O
differential	O
sensitivity	O
to	O
Bcl-2	O
and	O
interleukin-1beta-converting	O
enzyme	O
family	O
protease	O
inhibitors	O
.	O

Since	O
T	O
cells	O
normally	O
express	O
Bcl-2	O
and	O
Bcl-xL	O
following	O
activation	O
,	O
their	O
inability	O
to	O
block	O
Fas-mediated	O
apoptosis	O
may	O
allow	O
for	O
the	O
elimination	O
of	O
self-reactive	O
cells	O
and	O
the	O
appropriate	O
regulation	O
of	O
immune	O
responses	O
.	O

Comparative	O
analysis	O
identifies	O
conserved	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factor	O
3	O
binding	O
sites	O
in	O
the	O
human	O
and	O
simian	O
Epstein-Barr	O
virus	O
oncogene	O
LMP1	O
.	O

Nonhuman	O
primates	O
are	O
naturally	O
infected	O
with	O
a	O
B-lymphotropic	O
herpesvirus	O
closely	O
related	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

These	O
simian	O
EBV	O
share	O
considerable	O
genetic	O
,	O
biologic	O
,	O
and	O
epidemiologic	O
features	O
with	O
human	O
EBV	O
,	O
including	O
virus-induced	O
tumorigenesis	O
.	O

However	O
,	O
latent	O
,	O
transformation-associated	O
viral	O
genes	O
demonstrate	O
marked	O
sequence	O
divergence	O
among	O
species	O
despite	O
the	O
conserved	O
functions	O
.	O

We	O
have	O
cloned	O
the	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
homologs	O
from	O
the	O
simian	O
EBV	O
naturally	O
infecting	O
baboons	O
(	O
cercopithicine	O
herpesvirus	O
12	O
,	O
herpesvirus	O
papio	O
)	O
and	O
rhesus	O
monkeys	O
(	O
cercopithicine	O
herpesvirus	O
15	O
)	O
for	O
a	O
comparative	O
study	O
with	O
the	O
human	O
EBV	O
oncogene	O
.	O

The	O
transmembrane	O
domains	O
are	O
well	O
conserved	O
,	O
but	O
there	O
is	O
striking	O
sequence	O
divergence	O
of	O
the	O
carboxy-terminal	O
cytoplasmic	O
domain	O
essential	O
for	O
B-cell	O
immortalization	O
and	O
interaction	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
signaling	O
pathway	O
.	O

Nevertheless	O
,	O
the	O
simian	O
EBV	O
LMP1s	O
retain	O
most	O
functions	O
in	O
common	O
with	O
EBV	O
LMP1	O
,	O
including	O
the	O
ability	O
to	O
induce	O
NF-	O
(	O
kappa	O
)	O
B	O
activity	O
in	O
human	O
cells	O
,	O
to	O
bind	O
the	O
tumor	O
necrosis	O
factor-associated	O
factor	O
3	O
(	O
TRAF3	O
)	O
in	O
vitro	O
,	O
and	O
to	O
induce	O
expression	O
of	O
tumor	O
necrosis	O
factor-responsive	O
genes	O
,	O
such	O
as	O
ICAM1	O
,	O
in	O
human	O
B	O
lymphocytes	O
.	O

Multiple	O
TRAF3	O
binding	O
sites	O
containing	O
a	O
PXQXT/S	O
core	O
sequence	O
can	O
be	O
identified	O
in	O
the	O
simian	O
EBV	O
LMP1s	O
by	O
an	O
in	O
vitro	O
binding	O
assay	O
.	O

A	O
PXQXT/S-containing	O
sequence	O
is	O
also	O
present	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
Hodgkin	O
's	O
disease	O
marker	O
,	O
CD30	O
,	O
and	O
binds	O
TRAF3	O
in	O
vitro	O
.	O

The	O
last	O
13	O
amino	O
acids	O
containing	O
a	O
PXQXT/S	O
sequence	O
are	O
highly	O
conserved	O
in	O
human	O
and	O
simian	O
EBV	O
LMP1	O
but	O
do	O
not	B-Negation
bind	I-Negation
TRAF3	I-Negation
,	O
suggesting	B-Speculation
a	I-Speculation
distinct	I-Speculation
role	I-Speculation
for	I-Speculation
this	I-Speculation
conserved	I-Speculation
region	I-Speculation
of	I-Speculation
LMP1	I-Speculation
.	O

The	O
conserved	O
TRAF3	O
binding	O
sites	O
in	O
LMP1	O
and	O
the	O
CD30	O
Hodgkin	O
's	O
disease	O
marker	O
provides	O
further	O
evidence	O
that	O
a	O
TRAF3-mediated	O
signal	O
transduction	O
pathway	O
may	O
be	O
important	O
in	O
malignant	O
transformation	O
.	O

Rapid	O
shuttling	O
of	O
NF-AT	O
in	O
discrimination	O
of	O
Ca2+	O
signals	O
and	O
immunosuppression	O
.	O

Cells	O
need	O
to	O
distinguish	O
between	O
transient	O
Ca2+	O
signals	O
that	O
induce	O
events	O
such	O
as	O
muscle	O
contraction	O
,	O
secretion	O
,	O
adhesion	O
and	O
synaptic	O
transmission	O
,	O
and	O
sustained	O
Ca2+	O
signals	O
that	O
are	O
involved	O
in	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
latter	O
class	O
of	O
events	O
is	O
blocked	O
in	O
lymphocytes	O
by	O
the	O
immunosuppressive	O
drugs	O
cyclosporin	O
A	O
and	O
FK506	O
,	O
which	O
inhibit	O
calcineurin	O
,	O
a	O
Ca2+-activated	O
serine/threonine	O
phosphatase	O
necessary	O
for	O
the	O
nuclear	O
import	O
of	O
NF-AT	O
transcription	O
factors	O
.	O

Here	O
we	O
report	O
that	O
sustained	O
high	O
concentrations	O
of	O
Ca2+	O
,	O
but	O
not	B-Negation
transient	I-Negation
pulses	I-Negation
,	O
are	O
required	O
to	O
maintain	O
NF-AT	O
transcription	O
factors	O
in	O
the	O
nucleus	O
,	O
where	O
they	O
participate	O
in	O
Ca2+-dependent	O
induction	O
of	O
genes	O
required	O
for	O
lymphocyte	O
activation	O
and	O
proliferation	O
.	O

Furthermore	O
,	O
overexpression	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
NF-AT	O
,	O
but	O
not	B-Negation
Jun	I-Negation
,	I-Negation
Fos	I-Negation
,	I-Negation
NF-kappaB	I-Negation
,	I-Negation
Oct	I-Negation
or	I-Negation
Ets	I-Negation
family	O
members	O
,	O
renders	O
the	O
interleukin-2	O
enhancer	O
in	O
Jurkat	O
T	O
lymphocytes	O
resistant	O
to	O
FK506	O
and	O
cyclosporin	O
A	O
.	O

Thus	O
a	O
primary	O
effect	O
of	O
these	O
immunosuppressive	O
reagents	O
is	O
to	O
control	O
the	O
subcellular	O
localization	O
of	O
the	O
NF-AT	O
family	O
of	O
transcription	O
factors	O
.	O

Interferons	O
induce	O
normal	O
and	O
aberrant	O
retinoic-acid	O
receptors	O
type	O
alpha	O
in	O
acute	O
promyelocytic	O
leukemia	O
cells	O
:	O

potentiation	O
of	O
the	O
induction	O
of	O
retinoid-dependent	O
differentiation	O
markers	O
.	O

Treatment	O
of	O
the	O
acute	O
promyelocytic	O
(	O
APL	O
)	O
cell	O
line	O
NB4	O
with	O
interferon	O
alpha	O
(	O
IFN	O
(	O
alpha	O
)	O
)	O
,	O
as	O
well	O
as	O
IFN	O
(	O
beta	O
)	O
and	O
gamma	O
,	O
results	O
in	O
an	O
increased	O
expression	O
of	O
the	O
transcripts	O
coding	O
for	O
retinoic-acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
(	O
alpha	O
)	O
)	O
and	O
the	O
leukemia-specific	O
retinoic	O
acid	O
receptor	O
PML-RAR	O
.	O

Transcriptional	O
induction	O
of	O
the	O
RAR	O
(	O
alpha	O
)	O
and	O
PML-RAR	O
mRNAs	O
is	O
rapid	O
and	O
it	O
is	O
parallelled	O
by	O
an	O
increase	O
in	O
the	O
corresponding	O
proteins	O
.	O

Up-regulation	O
of	O
RAR	O
(	O
alpha	O
)	O
and	O
PML-RAR	O
gene	O
expression	O
by	O
IFN	O
(	O
alpha	O
)	O
is	O
accompanied	O
by	O
a	O
strong	O
potentiation	O
in	O
the	O
induction	O
of	O
2	O
retinoid-dependent	O
granulocytic	O
markers	O
,	O
i.e.	O
,	O
granulocyte-colony-stimulating	O
factor	O
receptor	O
mRNA	O
and	O
leukocyte	O
alkaline	O
phosphatase	O
.	O

However	O
,	O
IFN	O
(	O
alpha	O
)	O
does	O
not	B-Negation
have	I-Negation
any	I-Negation
effects	I-Negation
on	I-Negation
the	I-Negation
retinoid-dependent	I-Negation
regulation	I-Negation
of	I-Negation
the	I-Negation
myeloid	I-Negation
surface	I-Negation
markers	I-Negation
CD11b	I-Negation
and	I-Negation
CD33	I-Negation
.	O

The	O
IFN-dependent	O
increase	O
in	O
RAR	O
(	O
alpha	O
)	O
levels	O
and	O
the	O
enhancing	O
effect	O
of	O
the	O
cytokine	O
on	O
retinoid-dependent	O
granulocytic	O
markers	O
expression	O
may	B-Speculation
be	I-Speculation
a	I-Speculation
characteristic	I-Speculation
of	I-Speculation
PML-RAR	I-Speculation
positive	I-Speculation
cells	I-Speculation
,	O
since	O
the	B-Negation
phenomena	I-Negation
are	I-Negation
not	I-Negation
observed	I-Negation
in	I-Negation
HL-60	I-Negation
promyelocytes	I-Negation
.	O

Interferons	O
as	O
well	O
as	O
retinoids	O
inhibit	O
the	O
growth	O
of	O
NB4	O
cells	O
,	O
although	O
the	O
2	O
classes	O
of	O
compounds	O
do	O
not	O
significantly	O
interact	O
in	O
terms	O
of	O
anti-proliferative	O
activity	O
.	O

These	O
results	O
suggest	O
the	O
possible	O
use	O
of	O
combinations	O
between	O
IFNs	O
and	O
retinoic	O
acid	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
APL	O
patients	O
.	O

Susceptibility	O
to	O
natural	O
killer	O
cells	O
and	O
down	O
regulation	O
of	O
MHC	O
class	O
I	O
expression	O
in	O
adenovirus	O
12	O
transformed	O
cells	O
are	O
regulated	O
by	O
different	O
E1A	O
domains	O
.	O

All	O
human	O
adenoviruses	O
transform	O
rodent	O
cells	O
in	O
vitro	O
,	O
but	O
only	O
cells	O
transformed	O
by	O
serotypes	O
belonging	O
to	O
subgroups	O
A	O
(	O
Ad12	O
)	O
and	O
B	O
(	O
Ad3	O
)	O
are	O
tumorigenic	O
for	O
immunocompetent	O
animals	O
.	O

In	O
these	O
cells	O
,	O
the	O
expression	O
of	O
MHC-class	O
I	O
antigens	O
is	O
repressed	O
and	O
might	O
allow	O
them	O
to	O
escape	O
from	O
recognition	O
by	O
cytotoxic	O
T	O
lymphocytes	O
(	O
CTL	O
)	O
and	O
to	O
develop	O
in	O
tumor	O
.	O

Furthermore	O
,	O
these	O
cell	O
lines	O
appear	O
resistant	O
to	O
lysis	O
by	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
.	O

To	O
determine	O
the	O
E1A	O
domain	O
(	O
s	O
)	O
responsible	O
for	O
these	O
properties	O
several	O
cell	O
lines	O
were	O
created	O
by	O
transforming	O
baby	O
rat	O
kidney	O
(	O
BRK	O
)	O
cells	O
with	O
a	O
set	O
of	O
plasmids	O
expressing	O
different	O
Ad2/Ad12	O
hybrid	O
E1A	O
gene	O
products	O
.	O

The	O
MHC	O
class	O
1	O
gene	O
expression	O
was	O
inhibited	O
in	O
cells	O
expressing	O
the	O
Ad12	O
13S	O
mRNA	O
product	O
and	O
in	O
cells	O
transformed	O
with	O
Ad2/Ad12	O
hybrid	O
E1A	O
gene	O
product	O
harboring	O
the	O
C-terminal	O
part	O
of	O
the	O
conserved	O
region	O
(	O
CR	O
)	O
3	O
of	O
Ad12	O
.	O

Susceptibility	O
of	O
these	O
transformed	O
cell	O
lines	O
to	O
NK	O
cells	O
was	O
determined	O
by	O
cytolytic	O
assays	O
.	O

The	O
results	O
obtained	O
suggest	O
that	O
two	O
Ad12	O
E1A	O
domains	O
are	O
required	O
to	O
induce	O
resistance	O
of	O
the	O
cell	O
lines	O
to	O
NK	O
cells	O
.	O

An	O
IL-2	O
response	O
element	O
in	O
the	O
human	O
IL-2	O
receptor	O
alpha	O
chain	O
promoter	O
is	O
a	O
composite	O
element	O
that	O
binds	O
Stat5	O
,	O
Elf-1	O
,	O
HMG-I	O
(	O
Y	O
)	O
and	O
a	O
GATA	O
family	O
protein	O
.	O

Expression	O
of	O
the	O
human	O
interleukin-2	O
(	O
IL-2	O
)	O
receptor	O
alpha	O
chain	O
gene	O
is	O
potently	O
upregulated	O
by	O
its	O
own	O
ligand	O
,	O
IL-2	O
.	O

In	O
this	O
study	O
,	O
we	O
characterize	O
an	O
essential	O
upstream	O
IL-2	O
response	O
element	O
that	O
contains	O
both	O
consensus	O
and	O
non-consensus	O
GAS	O
motifs	O
,	O
two	O
putative	O
Ets	O
binding	O
sites	O
(	O
EBS	O
)	O
,	O
one	O
of	O
which	O
overlaps	O
the	O
consensus	O
GAS	O
motif	O
,	O
and	O
a	O
GATA	O
motif	O
,	O
which	O
overlaps	O
the	O
non-consensus	O
GAS	O
motif	O
.	O

We	O
demonstrate	O
that	O
although	O
the	O
individual	O
components	O
of	O
this	O
element	O
do	O
not	B-Negation
respond	I-Negation
to	I-Negation
IL-2	I-Negation
,	O
together	O
they	O
form	O
a	O
composite	O
element	O
capable	O
of	O
conferring	O
IL-2	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
.	O

Multiple	O
factors	O
including	O
Stat5	O
,	O
Elf-1	O
,	O
HMG-I	O
(	O
Y	O
)	O
and	O
GATA	O
family	O
proteins	O
bind	O
to	O
the	O
IL-2	O
response	O
element	O
and	O
mutation	O
of	O
any	O
one	O
of	O
these	O
binding	O
sites	O
diminishes	O
the	O
activity	O
of	O
this	O
element	O
.	O

An	O
unidentified	O
Ets	O
family	O
protein	O
binds	O
to	O
the	O
EBS	O
overlapping	O
the	O
consensus	O
GAS	O
motif	O
and	O
appears	O
to	O
negatively	O
regulate	O
the	O
human	O
IL-2R	O
alpha	O
promoter	O
.	O

Thus	O
,	O
IL-2-induced	O
IL-2R	O
alpha	O
promoter	O
activity	O
requires	O
a	O
complex	O
upstream	O
element	O
,	O
which	O
appears	O
to	O
contain	O
binding	O
sites	O
for	O
both	O
positive	O
and	O
negative	O
regulatory	O
factors	O
.	O

Tyrosine	O
kinase	O
and	O
cAMP-dependent	O
protein	O
kinase	O
activities	O
in	O
CD40-activated	O
human	O
B	O
lymphocytes	O
.	O

In	O
vitro	O
,	O
human	O
B	O
lymphocytes	O
undergo	O
long-term	O
proliferation	O
when	O
activated	O
through	O
CD40	O
,	O
a	O
protein	O
expressed	O
on	O
their	O
cell	O
surface	O
.	O

The	O
nature	O
of	O
CD40-dependent	O
signals	O
in	O
proliferating	O
fresh	O
human	O
Epstein-Barr	O
virus-negative	O
B	O
lymphocytes	O
is	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
a	O
CD40-dependent	O
B	O
cell	O
culture	O
system	O
was	O
used	O
to	O
examine	O
the	O
role	O
of	O
different	O
signal	O
transduction	O
elements	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
depletion	O
generated	O
by	O
a	O
long-term	O
phorbol	O
12	O
myristate	O
13-acetate	O
treatment	O
had	O
weak	O
effects	O
on	O
proliferation	O
.	O

Rather	O
,	O
tyrosine	O
phosphorylation	O
was	O
shown	O
to	O
be	O
directly	O
involved	O
in	O
mediating	O
CD40-dependent	O
signals	O
.	O

The	O
use	O
of	O
the	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
-specific	O
inhibitor	O
herbimycin	O
A	O
dramatically	O
decreased	O
cellular	O
proliferation	O
without	B-Negation
altering	I-Negation
the	I-Negation
activity	I-Negation
of	I-Negation
the	I-Negation
human	I-Negation
immunodeficiency	I-Negation
virus-1	I-Negation
long	I-Negation
terminal	I-Negation
repeat	I-Negation
(	I-Negation
HIV-1	I-Negation
LTR	I-Negation
)	I-Negation
,	O
a	O
promoter	O
largely	O
dependent	O
on	O
the	O
binding	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

In	O
contrast	O
,	O
the	O
cAMP-dependent	O
protein	O
kinase	O
specific	O
inhibitor	O
H-89	O
totally	O
inhibited	O
HIV-1	O
LTR	O
activity	O
at	O
a	O
concentration	O
as	O
low	O
as	O
100	O
nM	O
without	B-Negation
affecting	I-Negation
cellular	I-Negation
proliferation	I-Negation
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
assay	O
using	O
an	O
NF-kappa	O
B	O
binding	O
sequence	O
from	O
the	O
kappa	O
light	O
chain	O
as	O
a	O
probe	O
,	O
revealed	O
that	O
both	O
p65	O
(	O
RelA	O
)	O
and	O
c-Rel	O
were	O
present	O
in	O
CD40-stimulated	O
B	O
cells	O
.	O

While	O
PKC	O
depletion	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
NF-kappa	I-Negation
B	I-Negation
level	I-Negation
,	O
treatment	O
of	O
B	O
lymphocytes	O
with	O
H-89	O
or	O
herbimycin	O
A	O
provoked	O
a	O
decrease	O
in	O
the	O
NF-kappa	O
B	O
level	O
.	O

These	O
observations	O
establish	O
the	O
importance	O
of	O
different	O
signal	O
transducing	O
pathways	O
leading	O
to	O
CD40	O
activation	O
of	O
B	O
lymphocytes	O
.	O

Active	O
suppression	O
of	O
the	O
class	O
II	O
transactivator-encoding	O
AIR-1	O
locus	O
is	O
responsible	O
for	O
the	O
lack	B-Negation
of	I-Negation
major	I-Negation
histocompatibility	I-Negation
complex	I-Negation
class	I-Negation
II	I-Negation
gene	I-Negation
expression	I-Negation
observed	O
during	O
differentiation	O
from	O
B	O
cells	O
to	O
plasma	O
cells	O
.	O

In	O
this	O
study	O
the	O
genetic	O
control	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
gene	O
expression	O
during	O
the	O
transition	O
from	O
B	O
cell	O
to	O
plasma	O
cell	O
has	O
been	O
analyzed	O
.	O

Class	O
II	O
molecules	O
are	O
not	B-Negation
expressed	I-Negation
in	I-Negation
plasma	I-Negation
cells	I-Negation
because	O
of	O
an	O
active	O
suppression	O
resulting	O
in	O
the	O
abrogation	O
of	O
class	O
II	O
gene	O
transcription	O
.	O

We	O
show	O
here	O
that	O
the	O
plasma	O
cell-specific	O
repressor	O
function	O
,	O
designated	O
SIR	O
(	O
suppressor	O
of	O
immune	O
response	O
genes	O
)	O
,	O
does	O
not	B-Negation
act	I-Negation
directly	I-Negation
on	I-Negation
the	I-Negation
transcription	I-Negation
of	I-Negation
class	I-Negation
II	I-Negation
genes	I-Negation
,	O
but	O
instead	O
on	O
the	O
transcription	O
of	O
the	O
AIR-1	O
gene	O
,	O
whose	O
product	O
,	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
,	O
is	O
fundamental	O
for	O
the	O
regulation	O
of	O
the	O
constitutive	O
and	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

This	O
was	O
unambiguously	O
demonstrated	O
by	O
the	O
fact	O
that	O
plasmacytoma	O
x	O
B	O
cell	O
hybrids	O
carrying	O
an	O
AIR-1	O
locus	O
derived	O
from	O
CIITA-expressing	O
cells	O
do	O
not	B-Negation
express	I-Negation
CIITA-specific	I-Negation
transcripts	I-Negation
.	O

Transfection	O
of	O
a	O
cDNA	O
containing	O
the	O
human	O
CIITA	O
coding	O
sequence	O
under	O
the	O
control	O
of	O
an	O
heterologous	O
promoter	O
restores	O
expression	O
of	O
human	O
MHC	O
class	O
II	O
genes	O
in	O
the	O
hybrids	O
and	O
is	O
responsible	O
for	O
de	O
novo	O
expression	O
of	O
mouse	O
MHC	O
class	O
II	O
genes	O
in	O
both	O
the	O
mouse	O
plasmacytoma	O
cell	O
line	O
and	O
the	O
hybrids	O
.	O

These	O
results	O
confirm	O
and	O
extend	O
the	O
notion	O
of	O
the	O
functional	O
conservation	O
of	O
the	O
AIR-1	O
gene	O
product	O
across	O
species	O
barriers	O
.	O

Interestingly	O
,	O
in	O
CIITA-transfected	O
cell	O
hybrids	O
,	O
cell	B-Negation
surface	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
human	I-Negation
HLA-DQ	I-Negation
heterodimer	I-Negation
was	I-Negation
not	I-Negation
observed	I-Negation
.	O

This	O
result	O
was	O
not	B-Negation
attributable	I-Negation
to	I-Negation
lack	I-Negation
of	I-Negation
HLA-DQ	I-Negation
alpha	I-Negation
or	I-Negation
-DQ	I-Negation
beta	I-Negation
transcription	I-Negation
,	O
because	O
both	O
transcripts	O
were	O
present	O
in	O
the	O
CIITA-transfected	O
hybrids	O
,	O
although	O
at	O
reduced	O
levels	O
.	O

These	O
findings	O
further	O
support	O
our	O
previous	O
observations	O
on	O
the	O
distinct	O
regulation	O
of	O
expression	O
of	O
the	O
human	O
HLA-DQ	O
class	O
II	O
subset	O
,	O
which	O
may	O
be	O
thus	O
controlled	O
at	O
the	O
posttranscriptional	O
level	O
by	O
a	O
CIITA-independent	O
mechanism	O
.	O

Chromosome	O
1	O
aneusomy	O
with	O
1p36	O
under-representation	O
is	O
related	O
to	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
high	O
c-erb	O
B-2	O
and	O
loss	O
of	O
bcl-2	O
expression	O
in	O
ductal	O
breast	O
carcinoma	O
.	O

Chromosome	O
1	O
abnormalities	O
with	O
loss	O
of	O
1p36	O
have	O
been	O
investigated	O
in	O
95	O
breast-cancer	O
samples	O
by	O
means	O
of	O
a	O
dual-target	O
fluorescence	O
in-situ	O
hybridization	O
(	O
FISH	O
)	O
technique	O
using	O
the	O
pUC	O
1.77	O
and	O
p1-79	O
probes	O
,	O
specific	O
for	O
the	O
1q12	O
and	O
1p36	O
regions	O
,	O
respectively	O
.	O

Abnormalities	O
for	O
one	O
or	O
both	O
probes	O
were	O
detected	O
in	O
83/95	O
samples	O
.	O

Relative	O
1p36	O
under-representation	O
was	O
found	O
in	O
79/95	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
alterations	O
was	O
studied	O
by	O
comparing	O
the	O
FISH	O
results	O
with	O
several	O
parameters	O
currently	O
used	O
in	O
breast-cancer	O
pathology	O
.	O

Distinct	O
patterns	O
of	O
chromosome	O
1	O
abnormalities	O
were	O
found	O
among	O
the	O
histologic	O
types	O
of	O
breast	O
carcinoma	O
.	O

Lobular	O
or	O
mucinous	O
samples	O
showed	O
few	O
or	O
no	O
alterations	O
,	O
whereas	O
most	O
ductal	O
samples	O
had	O
high	O
chromosome	O
1	O
polysomy	O
with	O
under-representation	O
of	O
1p36	O
.	O

In	O
ductal	O
carcinomas	O
,	O
chromosome	O
1	O
alterations	O
increased	O
with	O
histologic	O
grade	O
,	O
DNA	O
aneuploidy	O
,	O
loss	O
of	O
bcl-2	O
and	O
high	O
c-erb	O
B-2	O
expression	O
.	O

These	O
associations	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
.	O

No	B-Negation
correlation	I-Negation
between	I-Negation
chromosome	I-Negation
1	I-Negation
alterations	I-Negation
and	I-Negation
nuclear	I-Negation
grade	I-Negation
,	I-Negation
age	I-Negation
,	I-Negation
size	I-Negation
,	I-Negation
lymph-node	I-Negation
involvement	I-Negation
,	I-Negation
hormonal	I-Negation
receptor	I-Negation
presence	I-Negation
,	I-Negation
proliferation	I-Negation
activity	I-Negation
or	I-Negation
p53	I-Negation
protein	I-Negation
expression	I-Negation
was	I-Negation
detected	I-Negation
.	O

These	O
results	O
indicate	O
the	O
utility	O
of	O
this	O
FISH	O
technique	O
for	O
a	O
better	O
definition	O
of	O
the	O
biological	O
characteristics	O
of	O
ductal	O
carcinomas	O
.	O

Silencing	O
of	O
human	O
fetal	O
globin	O
expression	O
is	O
impaired	O
in	O
the	O
absence	O
of	O
the	O
adult	O
beta-globin	O
gene	O
activator	O
protein	O
EKLF	O
.	O

Globin	O
genes	O
are	O
subject	O
to	O
tissue-specific	O
and	O
developmental	O
stage-specific	O
regulation	O
.	O

A	O
switch	O
from	O
human	O
fetal	O
(	O
gamma	O
)	O
-to	O
adult	O
(	O
beta	O
)	O
-	O
globin	O
expression	O
occurs	O
within	O
erythroid	O
precursor	O
cells	O
of	O
the	O
adult	O
lineage	O
.	O

Previously	O
we	O
and	O
others	O
showed	O
by	O
targeted	O
gene	O
disruption	O
that	O
the	O
zinc	O
finger	O
gene	O
,	O
erythroid	O
Kruppel-like	O
factor	O
(	O
EKLF	O
)	O
,	O
is	O
required	O
for	O
expression	O
of	O
the	O
beta-globin	O
gene	O
in	O
mice	O
,	O
presumably	O
through	O
interaction	O
with	O
a	O
high-affinity	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
.	O

To	O
examine	O
the	O
role	O
of	O
EKLF	O
in	O
the	O
developmental	O
regulation	O
of	O
the	O
human	O
gamma-globin	O
gene	O
we	O
interbred	O
EKLF	O
heterozygotes	O
(	O
	O
)	O
with	O
mice	O
harboring	O
a	O
human	O
beta-globin	O
yeast	O
artificial	O
chromosome	O
transgene	O
.	O

We	O
find	O
that	O
in	O
the	O
absence	O
of	O
EKLF	O
,	O
while	O
human	O
beta-globin	O
expression	O
is	O
dramatically	O
reduced	O
,	O
gamma-globin	O
transcripts	O
are	O
elevated	O
approximately	O
5-fold	O
.	O

Impaired	O
silencing	O
of	O
gamma-globin	O
expression	O
identifies	O
EKLF	O
as	O
the	O
first	O
transcription	O
factor	O
participating	O
quantitatively	O
in	O
the	O
gamma-globin	O
to	O
beta-globin	O
switch	O
.	O

Our	O
findings	O
are	O
compatible	O
with	O
a	O
competitive	O
model	O
of	O
switching	O
in	O
which	O
EKLF	O
mediates	O
an	O
adult	O
stage-specific	O
interaction	O
between	O
the	O
beta-globin	O
gene	O
promoter	O
and	O
the	O
locus	O
control	O
region	O
that	O
excludes	O
the	O
gamma-globin	O
gene	O
.	O

Modulatory	O
effects	O
of	O
glucocorticoids	O
and	O
catecholamines	O
on	O
human	O
interleukin-12	O
and	O
interleukin-10	O
production	O
:	O
clinical	O
implications	O
.	O

Interleukin-12	O
(	O
IL-12	O
)	O
is	O
a	O
key	O
inducer	O
of	O
differentiation	O
of	O
uncommitted	O
T	O
helper	O
(	O
TH	O
)	O
cells	O
toward	O
the	O
TH1	O
phenotype	O
,	O
which	O
regulates	O
cellular	O
immunity	O
,	O
whereas	O
IL-10	O
inhibits	O
TH1	O
functions	O
and	O
potentiates	O
TH2-regulated	O
responses	O
(	O
i.e.	O
,	O
humoral	O
immunity	O
)	O
.	O

To	O
examine	O
the	O
potential	O
effects	O
of	O
stress	O
on	O
TH1/TH2	O
balance	O
,	O
we	O
studied	O
the	O
ability	O
of	O
three	O
prototype	O
stress	O
hormones-dexamethasone	O
(	O
a	O
synthetic	O
glucocorticoid	O
)	O
and	O
the	O
catecholamines	O
norepinephrine	O
and	O
epinephrine-to	O
alter	O
the	O
production	O
of	O
IL-12	O
(	O
p70	O
)	O
and	O
IL-10	O
induced	O
by	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
in	O
human	O
whole	O
blood	O
.	O

Dexamethasone	O
inhibited	O
LPS-induced	O
bioactive	O
IL-12	O
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiologically	O
relevant	O
concentrations	O
;	O

it	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
IL-10	I-Negation
secretion	I-Negation
.	O

The	O
glucocorticoid-induced	O
reduction	O
of	O
IL-12	O
production	O
was	O
antagonized	O
by	O
RU	O
486	O
,	O
a	O
glucocorticoid-receptor	O
antagonist	O
,	O
suggesting	O
that	O
it	O
was	O
mediated	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

Norepinephrine	O
and	O
epinephrine	O
alsosuppressed	O
IL-12	O
production	O
in	O
a	O
dose-dependent	O
fashion	O
and	O
at	O
physiological	O
concentrations	O
;	O

both	O
catecholamines	O
,	O
however	O
,	O
dose-dependently	O
increased	O
the	O
production	O
of	O
IL-10	O
.	O

The	O
effects	O
of	O
either	O
catecholamine	O
on	O
IL-12	O
or	O
IL-10	O
secretion	O
were	O
blocked	O
completely	O
by	O
propranolol	O
,	O
a	O
beta-adrenoreceptor	O
antagonist	O
,	O
indicating	O
that	O
they	O
were	O
mediated	O
by	O
the	O
beta-adrenergic	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
central	O
nervous	O
system	O
may	O
regulate	O
IL-12	O
and	O
IL-10	O
secretion	O
and	O
,	O
hence	O
,	O
TH1/TH2	O
balance	O
via	O
the	O
peripheral	O
end-effectors	O
of	O
the	O
stress	O
system	O
.	O

Thus	O
,	O
stress	O
may	O
cause	O
a	O
selective	O
suppression	O
of	O
TH1	O
functions	O
and	O
a	O
shift	O
toward	O
a	O
TH2	O
cytokine	O
pattern	O
rather	O
than	O
generalized	O
TH	O
suppression	O
.	O

The	O
TH1-to-TH2	O
shift	O
may	O
be	O
responsible	O
for	O
the	O
stress-induced	O
susceptibility	O
of	O
the	O
organism	O
to	O
certain	O
infections	O
.	O

Through	O
the	O
same	O
or	O
a	O
reciprocal	O
mechanism	O
,	O
states	O
associated	O
with	O
chronic	O
hyperactivity	O
or	O
hypoactivity	O
of	O
the	O
stress	O
system	O
might	O
influence	O
the	O
susceptibility	O
of	O
an	O
individual	O
to	O
certain	O
autoimmune	O
,	O
allergic	O
,	O
infectious	O
,	O
or	O
neoplastic	O
diseases	O
.	O

Nasal	O
NK-	O
and	O
T-cell	O
lymphomas	O
share	O
the	O
same	O
type	O
of	O
Epstein-Barr	O
virus	O
latency	O
as	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
.	O

Nasal	O
T/NK-cell	O
lymphomas	O
can	O
be	O
further	O
separated	O
into	O
those	O
of	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
lineage	O
or	O
of	O
T-cell	O
lineage	O
,	O
with	O
differences	O
in	O
cellular	O
phenotype	O
,	O
T-cell	O
receptor	O
(	O
TcR	O
)	O
gene	O
rearrangement	O
and	O
TcR	O
transcript	O
expression	O
.	O

Both	O
NK-	O
and	O
T-cell	O
subtypes	O
are	O
closely	O
associated	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

In	O
this	O
study	O
,	O
EBV	O
gene	O
expression	O
was	O
determined	O
in	O
23	O
cases	O
of	O
nasal	O
lymphoma	O
(	O
NL	O
)	O
by	O
in	O
situ	O
hybridisation	O
(	O
ISH	O
)	O
,	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
and	O
immunohistochemistry	O
(	O
IH	O
)	O
.	O

Of	O
the	O
23	O
cases	O
,	O
19	O
were	O
classified	O
as	O
NK-cell	O
and	O
4	O
as	O
T-cell	O
tumours	O
.	O

ISH	O
for	O
EBV-encoded	O
small	O
non-polyadenylated	O
RNAs	O
showed	O
that	O
all	O
cases	O
,	O
whether	O
NK	O
or	O
T	O
,	O
harboured	O
EBV	O
in	O
virtually	O
all	O
tumour	O
cells	O
.	O

RT-PCR	O
demonstrated	O
that	O
NL	O
of	O
both	O
subtypes	O
expressed	O
EBNAI	O
of	O
the	O
QUK	O
splice	O
pattern	O
,	O
the	O
latent	O
membrane	O
proteins	O
,	O
LMP1	O
and	O
2	O
and	O
the	O
BamHI	O
A	O
rightward	O
transcripts	O
in	O
the	O
absence	O
of	O
EBNA2	O
mRNAs	O
,	O
compatible	O
with	O
the	O
latency	O
type	O
II	O
pattern	O
.	O

In	O
addition	O
,	O
analysis	O
of	O
EBV	O
protein	O
expression	O
by	O
IH	O
revealed	O
a	O
heterogeneous	O
pattern	O
of	O
EBV	O
gene	O
expression	O
at	O
the	O
single-cell	O
level	O
consisting	O
of	O
both	O
LMP1+	O
and	O
LMP1-	O
tumour	O
cells	O
,	O
suggesting	O
a	O
mixture	O
of	O
latency	O
I	O
and	O
II	O
.	O

Although	O
2	O
early	O
lytic	O
transcripts	O
,	O
BZLF1	O
and	O
BHRF1	O
,	O
were	O
also	O
detected	O
in	O
13	O
and	O
10	O
cases	O
,	O
respectively	O
,	O
the	O
lack	B-Negation
of	I-Negation
ZEBRA	I-Negation
staining	I-Negation
in	O
any	O
case	O
indicates	B-Speculation
that	I-Speculation
these	I-Speculation
lytic	I-Speculation
transcripts	I-Speculation
are	I-Speculation
most	I-Speculation
likely	I-Speculation
expressed	I-Speculation
by	I-Speculation
rare	I-Speculation
cells	I-Speculation
in	I-Speculation
the	I-Speculation
biopsies	I-Speculation
entering	I-Speculation
lytic	I-Speculation
cycle	I-Speculation
.	O

The	O
viral	O
transcriptional	O
pattern	O
similar	O
to	O
that	O
of	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
's	O
disease	O
suggests	O
that	O
EBV	O
can	O
exploit	O
common	O
regulatory	O
mechanisms	O
for	O
gene	O
transcription	O
in	O
diverse	O
host	O
cell	O
types	O
.	O

Down-regulation	O
of	O
immunogenic	O
proteins	O
(	O
EBNA2-EBNA6	O
)	O
in	O
nasal	O
lymphoma	O
may	O
enable	O
tumour	O
cells	O
to	O
evade	O
host	O
cytotoxic	O
T-cell	O
surveillance	O
.	O

Lack	B-Negation
of	I-Negation
IL-12	I-Negation
signaling	I-Negation
in	I-Negation
human	I-Negation
allergen-specific	I-Negation
Th2	I-Negation
cells	I-Negation
.	O

IL-12	O
is	O
a	O
powerful	O
skewer	O
of	O
CD4+	O
T	O
cell	O
responses	O
toward	O
the	O
Th1	O
phenotype	O
by	O
inducing	O
IFN-gamma	O
production	O
in	O
naive	O
Th	O
cells	O
.	O

In	O
the	O
present	O
study	O
we	O
addressed	O
the	O
question	O
of	O
whether	O
IL-12	O
can	O
reverse	O
established	O
Th2	O
responses	O
into	O
Th1/Th0	O
responses	O
by	O
inducing	O
IFN-gamma	O
production	O
in	O
memory	O
Th2	O
cells	O
.	O

To	O
this	O
aim	O
,	O
allergen-specific	O
CD4+	O
T	O
cell	O
clones	O
(	O
TCC	O
)	O
were	O
generated	O
from	O
the	O
peripheral	O
blood	O
of	O
three	O
atopic	O
patients	O
,	O
and	O
their	O
cytokine	O
profiles	O
were	O
analyzed	O
.	O

The	O
majority	O
of	O
these	O
TCC	O
exhibited	O
a	O
strongly	O
polarized	O
Th2	O
cytokine	O
profile	O
,	O
and	O
the	B-Negation
production	I-Negation
of	I-Negation
IFN-gamma	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
induced	I-Negation
by	I-Negation
exogenous	I-Negation
IL-12	I-Negation
.	O

Only	O
those	O
TCC	O
with	O
low	O
IFN-gamma	O
levels	O
in	O
the	O
absence	O
of	O
IL-12	O
responded	O
to	O
IL-12	O
by	O
additional	O
enhancement	O
of	O
IFN-gamma	O
production	O
.	O

The	O
IL-12	O
nonresponsiveness	O
of	O
the	O
Th2	O
clones	O
was	O
further	O
evident	O
by	O
the	O
total	O
lack	B-Negation
of	I-Negation
IL-12-induced	I-Negation
phosphorylation	I-Negation
of	I-Negation
STAT4	I-Negation
(	I-Negation
signal	I-Negation
transducer	I-Negation
and	I-Negation
activator	I-Negation
of	I-Negation
transcription-4	I-Negation
)	I-Negation
,	O
a	O
transcription	O
factor	O
that	O
is	O
typically	O
involved	O
in	O
IL-12	O
signaling	O
.	O

Consequently	O
,	O
IL-12	O
also	O
failed	O
to	O
induce	O
the	O
DNA-binding	O
activity	O
of	O
STAT4-containing	O
complexes	O
in	O
the	O
nuclei	O
of	O
these	O
Th2	O
clones	O
.	O

All	O
TCC	O
expressed	O
equal	O
levels	O
of	O
the	O
low-affinity	O
IL-12R	O
beta1	O
subunit	O
.	O

Our	O
results	O
indicate	O
that	O
human	O
allergen-specific	O
Th	O
cells	O
with	O
strongly	O
polarized	O
Th2	O
cytokine	O
profiles	O
do	O
not	O
respond	O
to	O
IL-12	O
and	O
,	O
therefore	O
,	O
can	O
not	O
be	O
induced	O
to	O
produce	O
IFN-gamma	O
.	O

The	O
apparent	O
high	O
frequency	O
of	O
IL-12-nonresponsive	O
Th	O
cells	O
within	O
the	O
allergen-specific	O
populations	O
in	O
atopic	O
patients	O
predicts	O
a	O
limited	O
skewing	O
potential	O
of	O
IL-12	O
in	O
the	O
case	O
of	O
established	O
Th2	O
responses	O
,	O
but	O
only	O
affecting	O
newly	O
recruited	O
naive	O
Th	O
cells	O
.	O

Characterization	O
of	O
a	O
CD43/leukosialin-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T-lymphoblastoid	O
cells	O
.	O

The	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
J393	O
induces	O
apoptosis	O
in	O
Jurkat	O
T-cells	O
.	O

NH2-terminal	O
amino	O
acid	O
sequence	O
analysis	O
identified	O
the	O
140-kDa	O
surface	O
antigen	O
for	O
mAb	O
J393	O
as	O
CD43/leukosialin	O
,	O
the	O
major	O
sialoglycoprotein	O
of	O
leukocytes	O
.	O

While	O
Jurkat	O
cells	O
co-expressed	O
two	O
discrete	O
cell-surface	O
isoforms	O
of	O
CD43	O
,	O
recognized	O
by	O
mAb	O
J393	O
and	O
mAb	O
G10-2	O
,	O
respectively	O
,	O
only	O
J393/CD43	O
signaled	O
apoptosis	O
.	O

J393/CD43	O
was	O
found	O
to	O
be	O
hyposialylated	O
,	O
bearing	O
predominantly	O
O-linked	O
monosaccharide	O
glycans	O
,	O
whereas	O
G10-2/CD43	O
bore	O
complex	O
sialylated	O
tetra-	O
and	O
hexasaccharide	O
chains	O
.	O

Treatment	O
with	O
soluble	O
,	O
bivalent	O
mAb	O
J393	O
killed	O
25-50	O
%	O
of	O
the	O
cell	O
population	O
,	O
while	O
concomitant	O
engagement	O
of	O
either	O
the	O
CD3.TcR	O
complex	O
or	O
the	O
integrins	O
CD18	O
and	O
CD29	O
significantly	O
potentiated	O
this	O
effect	O
.	O

Treatment	O
of	O
Jurkat	O
cells	O
with	O
mAb	O
J393	O
induced	O
tyrosine	O
phosphorylation	O
of	O
specific	O
protein	O
substrates	O
that	O
underwent	O
hyperphosphorylation	O
upon	O
antigen	O
receptor	O
costimulation	O
.	O

Tyrosine	O
kinase	O
inhibition	O
by	O
herbimycin	O
A	O
diminished	O
J393/CD43-mediated	O
apoptosis	O
,	O
whereas	O
inhibition	O
of	O
phosphotyrosine	O
phosphatase	O
activity	O
by	O
bis	O
(	O
maltolato	O
)	O
oxovanadium-IV	O
enhanced	O
cell	O
death	O
.	O

Signal	O
transduction	O
through	O
tyrosine	O
kinase	O
activation	O
may	O
lead	O
to	O
altered	O
gene	O
expression	O
,	O
as	O
J393/CD43	O
ligation	O
prompted	O
decreases	O
in	O
the	O
nuclear	O
localization	O
of	O
the	O
transcriptional	O
regulatory	O
protein	O
NF-kappaB	O
and	O
proteins	O
binding	O
the	O
interferon-inducible	O
regulatory	O
element	O
.	O

Since	O
peripheral	O
blood	O
T-lymphocytes	O
express	O
cryptic	O
epitopes	O
for	O
mAb	O
J393	O
,	O
these	O
findings	O
demonstrate	O
the	O
existence	O
of	O
a	O
tightly	O
regulated	O
CD43-mediated	O
pathway	O
for	O
inducing	O
apoptosis	O
in	O
human	O
T-cell	O
lineages	O
.	O

Stat3	O
recruitment	O
by	O
two	O
distinct	O
ligand-induced	O
,	O
tyrosine-phosphorylated	O
docking	O
sites	O
in	O
the	O
interleukin-10	O
receptor	O
intracellular	O
domain	O
.	O

Recent	O
work	O
has	O
shown	O
that	O
IL-10	O
induces	O
activation	O
of	O
the	O
JAK-STAT	O
signaling	O
pathway	O
.	O

To	O
define	O
the	O
mechanism	O
underlying	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
protein	O
recruitment	O
to	O
the	O
interleukin	O
10	O
(	O
IL-10	O
)	O
receptor	O
,	O
the	O
STAT	O
proteins	O
activated	O
by	O
IL-10	O
in	O
different	O
cell	O
populations	O
were	O
first	O
defined	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

In	O
all	O
cells	O
tested	O
,	O
IL-10	O
activated	O
Stat1	O
and	O
Stat3	O
and	O
induced	O
the	O
formation	O
of	O
three	O
distinct	O
DNA	O
binding	O
complexes	O
that	O
contained	O
different	O
combinations	O
of	O
these	O
two	O
transcription	O
factors	O
.	O

IL-10	O
also	O
activated	O
Stat5	O
in	O
Ba/F3	O
cells	O
that	O
stably	O
expressed	O
the	O
murine	O
IL-10	O
receptor	O
.	O

Using	O
a	O
structure-function	O
mutagenesis	O
approach	O
,	O
two	O
tyrosine	O
residues	O
(	O
Tyr427	O
and	O
Tyr477	O
)	O
in	O
the	O
intracellular	O
domain	O
of	O
the	O
murine	O
IL-10	O
receptor	O
were	O
found	O
to	O
be	O
redundantly	O
required	O
for	O
receptor	O
function	O
and	O
for	O
activation	O
of	O
Stat3	O
but	O
not	B-Negation
for	I-Negation
Stat1	I-Negation
or	I-Negation
Stat5	I-Negation
.	O

Twelve	O
amino	O
acid	O
peptides	O
encompassing	O
either	O
of	O
these	O
two	O
tyrosine	O
residues	O
in	O
phosphorylated	O
form	O
coprecipitated	O
Stat3	O
but	O
not	B-Negation
Stat1	I-Negation
and	O
blocked	O
IL-10-induced	O
Stat3	O
phosphorylation	O
in	O
a	O
cell-free	O
system	O
.	O

In	O
contrast	O
,	O
tyrosine-phosphorylated	O
peptides	O
containing	O
Tyr374	O
or	O
Tyr396	O
did	O
not	B-Negation
interact	I-Negation
with	I-Negation
Stat3	I-Negation
or	I-Negation
block	I-Negation
Stat3	I-Negation
activation	I-Negation
.	O

These	O
data	O
demonstrate	O
that	O
Stat3	O
but	O
not	B-Negation
Stat1	I-Negation
or	I-Negation
Stat5	I-Negation
is	O
directly	O
recruited	O
to	O
the	O
ligand-activated	O
IL-10	O
receptor	O
by	O
binding	O
to	O
specific	O
but	O
redundant	O
receptor	O
intracellular	O
domain	O
sequences	O
containing	O
phosphotyrosine	O
.	O

This	O
study	O
thus	O
supports	O
the	O
concept	O
that	O
utilization	O
of	O
distinct	O
STAT	O
proteins	O
by	O
different	O
cytokine	O
receptors	O
is	O
dependent	O
on	O
the	O
expression	O
of	O
particular	O
ligand-activatable	O
,	O
tyrosine-containing	O
STAT	O
docking	O
sites	O
in	O
receptor	O
intracellular	O
domains	O
.	O

Identification	O
and	O
characterization	O
of	O
a	O
leukocyte-specific	O
component	O
of	O
the	O
nuclear	O
body	O
.	O

The	O
nuclear	O
body	O
(	O
NB	O
)	O
is	O
a	O
cellular	O
organelle	O
that	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

The	O
NB	O
is	O
also	O
a	O
target	O
of	O
antibodies	O
in	O
the	O
serum	O
of	O
patients	O
with	O
the	O
autoimmune	O
disease	O
primary	O
biliary	O
cirrhosis	O
.	O

In	O
this	O
study	O
,	O
serum	O
from	O
a	O
patient	O
with	O
primary	O
biliary	O
cirrhosis	O
was	O
used	O
to	O
identify	O
a	O
cDNA	O
encoding	O
a	O
novel	O
component	O
of	O
the	O
NB	O
,	O
a	O
140-kDa	O
protein	O
designated	O
Sp140	O
.	O

The	O
predicted	O
amino	O
acid	O
sequence	O
of	O
the	O
amino-terminal	O
portion	O
of	O
Sp140	O
was	O
similar	O
to	O
Sp100	O
,	O
a	O
previously	O
identified	O
NB	O
protein	O
.	O

The	O
carboxyl	O
portion	O
of	O
Sp140	O
contained	O
a	O
zinc-finger	O
domain	O
and	O
a	O
bromodomain	O
,	O
motifs	O
that	O
are	O
present	O
in	O
proteins	O
regulating	O
gene	O
transcription	O
.	O

High	O
levels	O
of	O
Sp140	O
mRNA	O
were	O
detected	O
in	O
human	O
spleen	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
but	O
not	B-Negation
other	I-Negation
human	I-Negation
tissues	I-Negation
.	O

The	O
level	O
of	O
SP140	O
mRNA	O
in	O
myeloid	O
precursor	O
cell	O
lines	O
HL60	O
and	O
NB4	O
markedly	O
increased	O
in	O
response	O
to	O
chemically	O
induced	O
cellular	O
differentiation	O
.	O

Immunohistochemical	O
techniques	O
were	O
used	O
to	O
demonstrate	O
that	O
SP140	O
localized	O
to	O
the	O
NB	O
in	O
differentiated	O
HL60	O
and	O
NB4	O
cells	O
.	O

The	O
location	O
of	O
Sp140	O
in	O
the	O
NB	O
,	O
and	O
expression	O
of	O
this	O
gene	O
in	O
cells	O
involved	O
in	O
host	O
defense	O
,	O
suggest	O
that	O
Sp140	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
acute	O
promyelocytic	O
leukemia	O
and	O
viral	O
infection	O
.	O

T-cell-directed	O
TAL-1	O
expression	O
induces	O
T-cell	O
malignancies	O
in	O
transgenic	O
mice	O
.	O

The	O
TAL-1	O
gene	O
specifies	O
for	O
a	O
basic	O
domain-helix-loop-helix	O
protein	O
,	O
which	O
is	O
involved	O
in	O
the	O
control	O
of	O
normal	O
hematopoiesis	O
.	O

In	O
human	O
pathology	O
,	O
the	O
TAL-1	O
gene	O
product	O
is	O
expressed	O
in	O
a	O
high	O
percentage	O
of	O
T-cell	O
acute	O
lymphoblastic	O
leukemias	O
in	O
the	O
pediatric	O
age	O
range	O
;	O

however	O
,	O
it	B-Negation
has	I-Negation
not	I-Negation
been	I-Negation
established	I-Negation
whether	I-Negation
the	I-Negation
expression	I-Negation
has	I-Negation
a	I-Negation
causal	I-Negation
role	I-Negation
in	I-Negation
oncogenesis	I-Negation
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
phenotype	O
of	O
mouse	O
transgenic	O
lines	O
obtained	O
by	O
inducing	O
tal-1	O
protein	O
expression	O
in	O
lymphoid	O
tissues	O
using	O
the	O
LCK	O
promoter	O
.	O

The	O
survival	O
rate	O
of	O
tal-1	O
transgenic	O
animals	O
was	O
much	O
lower	O
as	O
compared	O
with	O
control	O
mice	O
.	O

Histopathological	O
analysis	O
revealed	O
lymphomas	O
of	O
T-cell	O
type	O
,	O
often	O
comprising	O
a	O
minor	O
B-cell	O
component	O
.	O

Some	O
mice	O
showed	O
marked	O
splenic	O
lymphocyte	O
depletion	O
.	O

Primary	O
lymphocyte	O
cultures	O
showed	O
partial	O
independence	O
from	O
exogenous	O
growth	O
stimuli	O
and	O
increased	O
resistance	O
to	O
low-serum	O
apoptosis	O
.	O

To	O
further	O
unravel	O
the	O
tal-1	O
oncogenic	O
potential	O
,	O
a	O
strain	O
of	O
tal-1	O
transgenic	O
mice	O
was	O
crossbred	O
with	O
p53-/-	O
mice	O
;	O

the	O
survival	O
rate	O
in	O
these	O
animals	O
was	O
reduced	O
by	O
more	O
than	O
one-half	O
when	O
compared	O
with	O
that	O
of	O
tal-1	O
mice	O
,	O
and	O
histopathological	O
analysis	O
revealed	O
exclusively	O
T-cell	O
lymphomas	O
.	O

These	O
data	O
indicate	O
that	O
TAL-1	O
,	O
expressed	O
in	O
T	O
cells	O
,	O
is	O
per	O
se	O
a	O
potent	O
oncogene	O
,	O
which	O
may	O
exert	O
a	O
key	O
leukemogenetic	O
role	O
in	O
the	O
majority	O
of	O
T-cell	O
acute	O
lymphoblastic	O
leukemias	O
.	O

Naive	O
(	O
CD45RA+	O
)	O
T	O
lymphocytes	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress-induced	O
signals	O
than	O
memory	O
(	O
CD45RO+	O
)	O
cells	O
.	O

Formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
after	O
oxidative	O
stress	O
has	O
been	O
shown	O
to	O
be	O
an	O
activation	O
signal	O
for	O
T	O
lymphocytes	O
,	O
e.g.	O
,	O
expression	O
of	O
IL-2	O
and	O
its	O
receptor	O
are	O
induced	O
.	O

These	O
ROI-induced	O
effects	O
can	O
,	O
to	O
a	O
large	O
extent	O
,	O
be	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O

Now	O
we	O
have	O
examined	O
whether	O
naive	O
and	O
memory	O
T	O
lymphocytes	O
differ	O
in	O
their	O
sensitivity	O
to	O
ROI-mediated	O
signals	O
.	O

When	O
CD45RA+	O
(	O
naive	O
)	O
and	O
CD45RO+	O
(	O
memory	O
)	O
T	O
lymphocytes	O
were	O
directly	O
stimulated	O
with	O
H2O2	O
,	O
NF-kappaB	O
nuclear	O
translocation	O
was	O
stronger	O
in	O
naive	O
cells	O
than	O
in	O
memory	O
cells	O
and	O
it	O
could	O
be	O
induced	O
with	O
lower	O
doses	O
.	O

The	O
composition	O
of	O
the	O
induced	O
nuclear	O
NF-kappaB	O
(	O
levels	O
of	O
p50	O
and	O
RelA	O
proteins	O
)	O
was	O
similar	O
in	O
these	O
cell	O
types	O
.	O

The	O
magnitude	O
and	O
kinetics	O
of	O
intracellular	O
ROI	O
were	O
similar	O
,	O
suggesting	O
that	O
there	O
were	O
no	O
differences	O
in	O
ROI-forming	O
mechanisms	O
or	O
antioxidative	O
capacities	O
.	O

The	O
probable	O
regulatory	O
point	O
was	O
the	O
cytoplasmic	O
IkappaB	O
inhibitor	O
:	O

in	O
CD45RA+	O
cells	O
,	O
H2O2	O
caused	O
a	O
more	O
profound	O
depression	O
in	O
the	O
levels	O
of	O
IkappaB	O
alpha	O
.	O

These	O
findings	O
indicate	O
that	O
T	O
cells	O
representing	O
different	O
activation	O
and/or	O
differentiation	O
stages	O
can	O
be	O
differentially	O
responsive	O
to	O
ROI-mediated	O
signals	O
.	O

Potent	O
gene	O
regulatory	O
and	O
antiproliferative	O
activities	O
of	O
20-methyl	O
analogues	O
of	O
1,25	O
dihydroxyvitamin	O
D3	O
.	O

The	O
biological	O
active	O
form	O
of	O
vitamin	O
D3	O
,	O
1,25-dihydroxyvitamin	O
D3	O
(	O
VD	O
)	O
,	O
regulates	O
cellular	O
growth	O
and	O
differentiation	O
.	O

This	O
provides	O
the	O
hormone	O
with	O
an	O
interesting	O
therapeutic	O
potential	O
.	O

However	O
,	O
hypercalcemia	O
is	O
a	O
side	O
effect	O
,	O
which	O
is	O
caused	O
by	O
VD	O
's	O
classical	O
action	O
,	O
the	O
regulation	O
of	O
calcium	O
homeostasis	O
.	O

This	O
made	O
the	O
need	O
for	O
VD	O
analogues	O
with	O
selectively	O
increased	O
cell	O
regulatory	O
properties	O
.	O

Studies	O
with	O
20-epi	O
analogues	O
pointed	O
out	O
the	O
importance	O
of	O
the	O
carbon-20	O
position	O
and	O
led	O
to	O
the	O
development	O
of	O
20-methyl	O
derivatives	O
of	O
VD	O
.	O

In	O
this	O
report	O
the	O
biological	O
properties	O
of	O
the	O
compounds	O
ZK161422	O
and	O
ZK157202	O
,	O
which	O
are	O
20-methyl-	O
and	O
20-methyl-23-eneanalogues	O
,	O
respectively	O
,	O
have	O
been	O
analyzed	O
in	O
comparison	O
with	O
VD	O
.	O

Both	O
compounds	O
show	O
about	O
2-fold	O
lower	O
affinity	O
to	O
the	O
VD	O
receptor	O
(	O
VDR	O
)	O
than	O
VD	O
.	O

However	O
,	O
compared	O
to	O
VD	O
,	O
their	O
antiproliferative	O
effect	O
is	O
up	O
to	O
30-fold	O
higher	O
on	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
even	O
up	O
to	O
300-fold	O
higher	O
on	O
human	O
breast	O
cancer	O
MCF-7	O
cells	O
.	O

Whereas	O
the	O
hypercalcemic	O
effect	O
for	O
ZK157202	O
is	O
also	O
increased	O
10-fold	O
,	O
ZK161422	O
has	O
the	O
same	O
calcium-mobilizing	O
potency	O
as	O
VD	O
.	O

Moreover	O
,	O
ZK161422	O
,	O
but	O
not	B-Negation
ZK157202	I-Negation
,	O
showed	O
preference	O
for	O
gene	O
activation	O
from	O
a	O
promoter	O
carrying	O
a	O
VD	O
response	O
element	O
with	O
a	O
palindromic	O
arrangement	O
of	O
two	O
hexameric	O
receptor	O
binding	O
sites	O
spaced	O
by	O
9	O
nucleotides	O
(	O
IP9	O
)	O
rather	B-Negation
than	I-Negation
for	I-Negation
activation	I-Negation
from	I-Negation
a	I-Negation
response	I-Negation
element	I-Negation
formed	I-Negation
by	I-Negation
a	I-Negation
direct	I-Negation
repeat	I-Negation
spaced	I-Negation
by	I-Negation
3	I-Negation
nucleotides	I-Negation
(	I-Negation
DR3	I-Negation
)	I-Negation
.	O

This	O
observation	O
supports	O
a	O
model	O
,	O
in	O
which	O
promoter	O
selectivity	O
reflects	O
the	O
selectively	O
increased	O
antiproliferative	O
effect	O
of	O
VD	O
analogues	O
.	O

Interferon	O
augments	O
PML	O
and	O
PML/RAR	O
alpha	O
expression	O
in	O
normal	O
myeloid	O
and	O
acute	O
promyelocytic	O
cells	O
and	O
cooperates	O
with	O
all-trans	O
retinoic	O
acid	O
to	O
induce	O
maturation	O
of	O
a	O
retinoid-resistant	O
promyelocytic	O
cell	O
line	O
.	O

The	O
PML	O
gene	O
is	O
fused	O
to	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
gene	O
(	O
RAR	O
alpha	O
)	O
in	O
the	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
15	O
;	O
17	O
translocation	O
.	O

PML	O
is	O
expressed	O
in	O
diverse	O
tissues	O
and	O
cell	O
lines	O
and	O
localized	O
in	O
the	O
nucleus	O
with	O
a	O
typical	O
speckled	O
pattern	O
.	O

In	O
the	O
bone	O
marrow	O
,	O
it	O
is	O
preferentially	O
expressed	O
in	O
myeloid	O
cells	O
.	O

PML	O
appears	O
to	O
be	O
transcriptionally	O
regulated	O
by	O
class	O
I	O
and	O
II	O
interferons	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
interferons	O
modulate	O
the	O
function	O
and	O
growth	O
and	O
differentiation	O
potential	O
of	O
normal	O
myeloid	O
cells	O
and	O
precursors	O
by	O
activating	O
PML-dependent	O
pathways	O
.	O

Similarly	O
,	O
interferons	O
could	O
act	O
on	O
APL	O
cells	O
,	O
alone	O
or	O
in	O
combination	O
with	O
all-trans	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
especially	O
if	O
the	O
PML/RAR	O
alpha	O
fusion	O
transcript	O
that	O
results	O
from	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
is	O
induced	O
by	O
interferon	O
.	O

We	O
report	O
here	O
that	O
PML	O
is	O
expressed	O
at	O
low	O
levels	O
or	O
not	B-Negation
expressed	I-Negation
in	O
normal	O
circulating	O
human	O
monocytes	O
,	O
lymphocytes	O
,	O
and	O
polymorphonucleate	O
cells	O
,	O
but	O
is	O
markedly	O
induced	O
by	O
interferon	O
;	O
that	O
PML	O
and	O
PML/RAR	O
alpha	O
expression	O
is	O
augmented	O
by	O
interferon	O
in	O
the	O
NB4	O
APL	O
cell	O
line	O
,	O
which	O
carries	O
the	O
t	O
(	O
15	O
;	O
17	O
)	O
,	O
and	O
in	O
APL	O
blasts	O
from	O
patients	O
;	O
that	O
interferon	O
inhibits	O
growth	O
and	O
survival	O
of	O
NB4	O
APL	O
cells	O
in	O
cooperation	O
with	O
RA	O
;	O
that	O
interferons	O
alone	O
have	O
minimal	O
maturation	O
effect	O
on	O
NB4	O
cells	O
;	O
and	O
,	O
finally	O
,	O
that	O
interferon	O
gamma	O
,	O
but	O
not	B-Negation
alpha	I-Negation
or	I-Negation
beta	I-Negation
,	O
induces	O
maturation	O
and	O
growth	O
suppression	O
of	O
NB4	O
cells	O
with	O
de	O
novo	O
retinoid	O
resistance	O
,	O
and	O
partially	O
restores	O
RA	O
response	O
.	O

Generation	O
of	O
CD1+RelB+	O
dendritic	O
cells	O
and	O
tartrate-resistant	O
acid	O
phosphatase-positive	O
osteoclast-like	O
multinucleated	O
giant	O
cells	O
from	O
human	O
monocytes	O
.	O

We	O
previously	O
showed	O
that	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
and	O
macrophage	O
colony-stimulating	O
factor	O
(	O
M-CSF	O
)	O
stimulate	O
the	O
differentiation	O
of	O
human	O
monocytes	O
into	O
two	O
phenotypically	O
distinct	O
types	O
of	O
macrophages	O
.	O

However	O
,	O
in	O
vivo	O
,	O
not	O
only	O
CSF	O
but	O
also	O
many	O
other	O
cytokines	O
are	O
produced	O
under	O
various	O
conditions	O
.	O

Those	O
cytokines	O
may	O
modulate	O
the	O
differentiation	O
of	O
monocytes	O
by	O
CSFs	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
showed	O
that	O
CD14+	O
adherent	O
human	O
monocytes	O
can	O
differentiate	O
into	O
CD1+relB+	O
dendritic	O
cells	O
(	O
DC	O
)	O
by	O
the	O
combination	O
of	O
GM-CSF	O
plus	O
interleukin-4	O
(	O
IL-4	O
)	O
and	O
that	O
they	O
differentiate	O
into	O
tartrate-resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
-positive	O
osteoclast-like	O
multinucleated	O
giant	O
cells	O
(	O
MGC	O
)	O
by	O
the	O
combination	O
of	O
M-CSF	O
plus	O
IL-4	O
.	O

However	O
,	O
the	O
monocyte-derived	O
DC	O
were	O
not	B-Negation
terminally	I-Negation
differentiated	I-Negation
cells	I-Negation
;	O

they	O
could	O
still	O
convert	O
to	O
macrophages	O
in	O
response	O
to	O
M-CSF	O
.	O

Tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
stimulated	O
the	O
terminal	O
differentiation	O
of	O
the	O
DC	O
by	O
downregulating	O
the	O
expression	O
of	O
the	O
M-CSF	O
receptor	O
,	O
cfms	O
mRNA	O
,	O
and	O
aborting	O
the	O
potential	O
to	O
convert	O
to	O
macrophages	O
.	O

In	O
contrast	O
to	O
IL-4	O
,	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
had	O
no	B-Negation
demonstrable	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
differentiation	I-Negation
of	I-Negation
monocytes	I-Negation
.	O

Rather	O
,	O
IFN-gamma	O
antagonized	O
the	O
effect	O
of	O
IL-4	O
and	O
suppressed	O
the	O
DC	O
and	O
MGC	O
formation	O
induced	O
by	O
GM-CSF	O
+	O
IL-4	O
and	O
M-CSF	O
+	O
IL-4	O
,	O
respectively	O
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
a	O
new	O
aspect	O
to	O
our	O
knowledge	O
of	O
monocyte	O
differentiation	O
and	O
provide	O
evidence	O
that	O
human	O
monocytes	O
are	O
flexible	O
in	O
their	O
differentiation	O
potential	O
and	O
are	O
precursors	O
not	O
only	O
of	O
macrophages	O
but	O
also	O
of	O
CD1+relB+DC	O
and	O
TRAP-positive	O
MGC	O
.	O

Such	O
a	O
diverse	O
pathway	O
of	O
monocyte	O
differentiation	O
may	O
constitute	O
one	O
of	O
the	O
basic	O
mechanisms	O
of	O
immune	O
regulation	O
.	O

T	O
cell	O
response	O
to	O
Epstein-Barr	O
virus	O
transactivators	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

Rheumatoid	O
arthritis	O
is	O
a	O
multistep	O
disorder	O
associated	O
with	O
autoimmune	O
features	O
of	O
yet	O
unknown	O
etiology	O
.	O

Implication	B-Speculation
of	I-Speculation
viruses	I-Speculation
such	I-Speculation
as	I-Speculation
Epstein-Barr	I-Speculation
virus	I-Speculation
(	I-Speculation
EBV	I-Speculation
)	I-Speculation
in	I-Speculation
rheumatoid	I-Speculation
arthritis	I-Speculation
pathogenesis	I-Speculation
has	I-Speculation
been	I-Speculation
suspected	I-Speculation
on	I-Speculation
the	I-Speculation
basis	I-Speculation
of	I-Speculation
several	I-Speculation
indirect	I-Speculation
observations	I-Speculation
,	O
but	O
thus	O
far	O
,	O
a	B-Negation
direct	I-Negation
link	I-Negation
between	I-Negation
EBV	I-Negation
and	I-Negation
rheumatoid	I-Negation
arthritis	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
provided	I-Negation
.	O

Here	O
we	O
show	O
that	O
a	O
large	O
fraction	O
of	O
T	O
cells	O
infiltrating	O
affected	O
joints	O
from	O
a	O
patient	O
with	O
chronic	O
rheumatoid	O
arthritis	O
recognizes	O
two	O
EBV	O
transactivators	O
(	O
BZLF1	O
and	O
BMLF1	O
)	O
in	O
a	O
major	O
histocompatibility	O
complex-restricted	O
fashion	O
.	O

Responses	O
to	O
these	O
EBV	O
antigens	O
by	O
synovial	O
lymphocytes	O
from	O
several	O
other	O
chronic	O
rheumatoid	O
arthritis	O
patients	O
were	O
readily	O
detectable	O
.	O

Thus	O
these	O
results	O
suggest	O
a	O
direct	O
contribution	O
of	O
EBV	O
to	O
chronic	O
rheumatoid	O
arthritis	O
pathogenesis	O
.	O

They	O
also	O
demonstrate	O
for	O
the	O
first	O
time	O
the	O
occurrence	O
of	O
T	O
cell	O
responses	O
against	O
EBV	O
transactivating	O
factors	O
,	O
which	O
might	O
be	O
central	O
in	O
the	O
control	O
of	O
virus	O
reactivation	O
.	O

Differential	O
nuclear	O
localization	O
of	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
proteins	O
in	O
human	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
in	O
situ	O
.	O

The	O
Rel/NF-kappa	O
B	O
proteins	O
,	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
c-Rel	O
,	O
and	O
RelB	O
,	O
constitute	O
a	O
family	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
positive	O
regulation	O
of	O
a	O
variety	O
of	O
genes	O
during	O
the	O
immune	O
response	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
RelB	O
knockout	O
mice	O
have	O
no	B-Negation
dendritic	I-Negation
cells	I-Negation
(	I-Negation
DC	I-Negation
)	I-Negation
.	O

An	O
overexpression	O
of	O
p50	O
has	O
been	O
described	O
in	O
follicular	O
dendritic	O
cells	O
(	O
FDC	O
)	O
.	O

A	O
constitutive	O
NF-kappa	O
B	O
activity	O
has	O
been	O
reported	O
in	O
mature	O
macrophages	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
some	O
of	O
the	O
Rel/NF-kappa	O
B	O
proteins	O
were	O
key	O
nuclear	O
factors	O
in	O
functions	O
of	O
accessory	O
cells	O
of	O
the	O
immune	O
response	O
.	O

Therefore	O
,	O
we	O
investigated	O
in	O
situ	O
the	O
nuclear	O
localization	O
of	O
Rel/NF-kappa	O
B	O
proteins	O
in	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
by	O
immunohistochemistry	O
and	O
double	O
labeling	O
by	O
immunofluorescence	O
from	O
five	O
normal	O
human	O
tonsils	O
and	O
five	O
lymph	O
nodes	O
with	O
follicular	O
hyperplasia	O
.	O

Nuclear	O
p65	O
and	O
c-Rel	O
proteins	O
were	O
found	O
in	O
all	O
cell	O
types	O
including	O
lymphocytes	O
.	O

In	O
germinal	O
centers	O
GC	O
,	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
were	O
found	O
in	O
the	O
nuclei	O
of	O
FDC	O
only	O
and	O
were	B-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
the	I-Negation
nuclei	I-Negation
of	I-Negation
CD68+	I-Negation
cells	I-Negation
.	O

In	O
T	O
cell	O
areas	O
,	O
p50	O
,	O
p52	O
,	O
and	O
RelB	O
were	O
found	O
in	O
the	O
nuclei	O
of	O
HLA-DR+	O
cells	O
with	O
an	O
antigen-presenting	O
cell	O
(	O
APC	O
)	O
morphology	O
.	O

p52	O
and	O
RelB	O
were	O
detected	O
in	O
the	O
nuclei	O
in	O
both	O
CD1a+	O
and	O
CD68+	O
cells	O
from	O
the	O
T	O
cell	O
area	O
,	O
whereas	O
p50	O
was	O
found	O
only	O
in	O
CD68-	O
and	O
CD1a-	O
cells	O
.	O

Cells	O
with	O
nuclear	O
p50	O
were	O
negative	B-Negation
for	I-Negation
the	I-Negation
CD38	I-Negation
,	I-Negation
CD20	I-Negation
and	I-Negation
CD2	I-Negation
markers	I-Negation
.	O

These	O
results	O
show	O
that	O
,	O
physiologically	O
,	O
high	O
levels	O
of	O
nuclear	O
of	O
p50	O
,	O
p52	O
and	O
RelB	O
are	O
restricted	O
to	O
accessory	O
cells	O
of	O
the	O
immune	O
system	O
,	O
which	O
include	O
FDC	O
in	O
GC	O
,	O
and	O
DC	O
and	O
macrophages	O
in	O
the	O
T	O
cell	O
zone	O
,	O
that	O
specialized	O
scavenger	O
macrophages	O
from	O
GC	O
do	O
not	B-Negation
have	I-Negation
detectable	I-Negation
levels	I-Negation
of	I-Negation
p52	I-Negation
and	I-Negation
RelB	I-Negation
,	O
whereas	O
macrophages	O
from	O
the	O
T	O
cell	O
area	O
,	O
known	O
to	O
present	O
the	O
antigen	O
to	O
T	O
cells	O
,	O
do	O
have	O
both	O
nuclear	O
p52	O
and	O
RelB	O
,	O
and	O
that	O
in	O
the	O
T	O
cell	O
zone	O
,	O
p52	O
and	O
RelB	O
are	O
located	O
in	O
nuclei	O
of	O
both	O
CD1a+	O
,	O
CD68+	O
or	O
both	O
,	O
cells	O
APC	O
,	O
whereas	O
p50	O
is	O
restricted	O
to	O
CD1a-	O
and	O
CD68-	O
APC	O
.	O

The	O
different	O
patterns	O
of	O
p50	O
,	O
p52	O
and	O
RelB	O
protein	O
nuclear	O
localization	O
may	O
provide	O
insight	O
into	O
their	O
different	O
roles	O
during	O
the	O
immune	O
response	O
in	O
vivo	O
.	O

Signal	O
transduction	O
by	O
DR3	O
,	O
a	O
death	O
domain-containing	O
receptor	O
related	O
to	O
TNFR-1	O
and	O
CD95	O
.	O

Tumor	O
necrosis	O
factor	O
receptor-1	O
(	O
TNFR-1	O
)	O
and	O
CD95	O
(	O
also	O
called	O
Fas	O
or	O
APO-1	O
)	O
are	O
cytokine	O
receptors	O
that	O
engage	O
the	O
apoptosis	O
pathway	O
through	O
a	O
region	O
of	O
intracellular	O
homology	O
,	O
designated	O
the	O
``	O
death	O
domain.	O
``	O

Another	O
death	O
domain-containing	O
member	O
of	O
the	O
TNFR	O
family	O
,	O
death	O
receptor	O
3	O
(	O
DR3	O
)	O
,	O
was	O
identified	O
and	O
was	O
shown	O
to	O
induce	O
both	O
apoptosis	O
and	O
activation	O
of	O
nuclear	O
factor	O
kappaB	O
.	O

Expression	O
of	O
DR3	O
appears	O
to	O
be	O
restricted	O
to	O
tissues	O
enriched	O
in	O
lymphocytes	O
.	O

DR3	O
signal	O
transduction	O
is	O
mediated	O
by	O
a	O
complex	O
of	O
intracellular	O
signaling	O
molecules	O
including	O
TRADD	O
,	O
TRAF2	O
,	O
FADD	O
,	O
and	O
FLICE	O
.	O

Thus	O
,	O
DR3	O
likely	O
plays	O
a	O
role	O
in	O
regulating	O
lymphocyte	O
homeostasis	O
.	O

Cloning	O
and	O
expression	O
of	O
the	O
Epstein-Barr	O
virus-encoded	O
dUTPase	O
:	O
patients	O
with	O
acute	O
,	O
reactivated	O
or	O
chronic	O
virus	O
infection	O
develop	O
antibodies	O
against	O
the	O
enzyme	O
.	O

The	O
gene	O
encoding	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-specific	O
dUTPase	O
was	O
amplified	O
from	O
virus	O
DNA	O
by	O
PCR	O
.	O

The	O
active	O
enzyme	O
was	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
in	O
insect	O
cells	O
as	O
a	O
non-fusion	O
protein	O
.	O

The	O
protein	O
from	O
E.	O
coli	O
specifically	O
converted	O
dUTP	O
to	O
dUMP	O
and	O
did	O
not	B-Negation
react	I-Negation
with	I-Negation
other	I-Negation
dNTPs	I-Negation
or	I-Negation
NTPs	I-Negation
.	O

Preliminary	O
experiments	O
yielded	O
a	O
Km	O
value	O
of	O
about	O
0.8	O
microM	O
for	O
dUTP	O
.	O

MAbs	O
against	O
the	O
dUTPase	O
reacted	O
with	O
a	O
protein	O
of	O
approximately	O
31	O
kDa	O
in	O
12-O-tetradecanoyl-phorbol-13-acetate	O
(	O
TPA	O
)	O
-stimulated	O
B	O
cells	O
harbouring	O
either	O
type	O
1	O
or	O
type	O
2	O
EBV	O
.	O

The	O
protein	O
was	O
found	O
in	O
untreated	O
cells	O
at	O
low	O
levels	O
,	O
whereas	O
induction	O
of	O
the	O
lytic	O
replication	O
cycle	O
by	O
TPA	O
treatment	O
or	O
by	O
providing	O
the	O
immediate	O
early	O
transactivator	O
BZLF1	O
in	O
trans	O
resulted	O
in	O
increased	O
expression	O
.	O

We	O
demonstrated	O
that	O
the	O
virus	O
dUTPase	O
isolated	O
from	O
EBV-infected	O
cells	O
is	O
a	O
phosphoprotein	O
.	O

The	O
protein	O
expressed	O
in	O
insect	O
cells	O
was	O
used	O
to	O
test	O
for	O
the	O
presence	O
of	O
specific	O
antibodies	O
in	O
sera	O
from	O
normal	O
,	O
healthy	O
carriers	O
and	O
from	O
patients	O
with	O
various	O
diseases	O
.	O

While	O
the	O
sera	O
of	O
EBV-negative	O
individuals	O
(	O
0/3	O
)	O
or	O
healthy	O
carriers	O
(	O
0/33	O
)	O
did	O
not	B-Negation
contain	I-Negation
detectable	I-Negation
levels	I-Negation
of	I-Negation
antibodies	I-Negation
,	O
patients	O
with	O
mononucleosis	O
(	O
5/18	O
)	O
,	O
chronic	O
EBV	O
infection	O
(	O
2/7	O
)	O
,	O
EBV	O
reactivation	O
(	O
7/20	O
)	O
and	O
human	O
immunodeficiency	O
virus	O
infection	O
(	O
5/24	O
)	O
showed	O
elevated	O
antibody	O
titres	O
against	O
the	O
enzyme	O
.	O

This	O
indicated	O
that	O
the	O
dUTPase	O
is	O
expressed	O
during	O
EBV	O
replication	O
and	O
reactivation	O
.	O

The	O
enzyme	O
might	O
therefore	O
be	O
a	O
potential	O
target	O
for	O
drug	O
therapy	O
under	O
conditions	O
of	O
active	O
DNA	O
replication	O
.	O

Prostaglandin	O
E2	O
induction	O
of	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
elements	O
in	O
human	O
T	O
lymphocytes	O
.	O

Prostaglandins	O
of	O
the	O
E	O
series	O
are	O
immunomodulatory	O
agents	O
which	O
exert	O
inhibitory	O
as	O
well	O
as	O
stimulatory	O
effects	O
on	O
a	O
variety	O
of	O
immune	O
responses	O
.	O

Since	O
it	O
is	O
known	O
that	O
PGE2	O
is	O
able	O
to	O
increase	O
cAMP	O
levels	O
,	O
we	O
investigated	O
whether	O
it	O
can	O
affect	O
gene	O
expression	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factors	O
which	O
bind	O
enhancer	O
elements	O
in	O
the	O
promoter	O
regions	O
of	O
cAMP-regulated	O
genes	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
demonstrated	O
that	O
a	O
short	O
treatment	O
of	O
human	O
T	O
lymphocytes	O
with	O
PGE2	O
induces	O
specific	O
binding	O
activity	O
to	O
CRE	O
and	O
AP-2	O
,	O
but	O
not	B-Negation
AP-1	I-Negation
,	O
DNA	O
elements	O
.	O

Since	O
the	O
okadaic	O
acid	O
,	O
a	O
potent	O
protein	O
phosphatase	O
inhibitor	O
,	O
prolongs	O
the	O
induction	O
of	O
the	O
binding	O
activity	O
,	O
phosphorylation	O
events	O
are	O
likely	O
to	O
occur	O
.	O

This	O
activity	O
seems	O
to	O
be	O
due	O
to	O
increased	O
cAMP	O
levels	O
because	O
forskolin	O
and	O
IBMX	O
mimic	O
the	O
effects	O
of	O
PGE2	O
.	O

More	O
interestingly	O
,	O
transfection	O
experiments	O
with	O
CRE-CAT	O
plasmide	O
show	O
that	O
PGE2	O
activates	O
the	O
transcription	O
of	O
a	O
CRE-containing	O
promoter	O
.	O

These	O
data	O
support	O
the	O
positive	O
role	O
for	O
PGE2	O
on	O
some	O
immune	O
functions	O
.	O

Regulation	O
of	O
cytokine	O
and	O
cytokine	O
receptor	O
expression	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GCS	O
)	O
profoundly	O
inhibit	O
several	O
aspects	O
of	O
T	O
cell	O
immunity	O
largely	O
through	O
inhibition	O
of	O
cytokine	O
expression	O
at	O
the	O
transcriptional	O
and	O
posttranscriptional	O
levels	O
.	O

GCS	O
were	O
also	O
reported	O
to	O
act	O
indirectly	O
by	O
inducing	O
transforming	O
growth	O
factor-beta	O
expression	O
,	O
which	O
in	O
turn	O
blocks	O
T	O
cell	O
immunity	O
.	O

In	O
exerting	O
their	O
antiproliferative	O
effects	O
,	O
GCS	O
diffuse	O
into	O
target	O
cells	O
where	O
they	O
bind	O
their	O
cytoplasmic	O
receptor	O
,	O
which	O
in	O
turn	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
inhibits	O
transcription	O
of	O
cytokine	O
genes	O
through	O
direct	O
binding	O
to	O
the	O
glucocorticoid	O
response	O
elements	O
(	O
GRE	O
)	O
,	O
which	O
are	O
located	O
in	O
the	O
promoter	O
region	O
of	O
cytokine	O
genes	O
or	O
,	O
alternatively	O
,	O
through	O
antagonism	O
of	O
the	O
action	O
of	O
transcription	O
factors	O
required	O
for	O
optimal	O
transcriptional	O
activation	O
.	O

In	O
contrast	O
to	O
their	O
inhibitory	O
effects	O
on	O
cytokine	O
expression	O
,	O
GCS	O
up-regulate	O
cytokine	O
receptor	O
expression	O
that	O
correlates	O
with	O
enhanced	O
cytokine	O
effects	O
on	O
target	O
cells	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
the	O
current	O
state	O
of	O
knowledge	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
GCS	O
,	O
including	O
the	O
phenomenon	O
of	O
steroid-induced	O
rebound	O
,	O
which	O
ensues	O
upon	O
GCS	O
withdrawal	O
.	O

The	O
Oct-2	O
transcription	O
factor	O
.	O

The	O
Oct-2	O
transcription	O
factor	O
is	O
a	O
member	O
of	O
the	O
POU	O
(	O
Pit-Oct-Unc	O
)	O
family	O
of	O
transcription	O
factors	O
and	O
is	O
expressed	O
only	O
in	O
B	O
lymphocytes	O
and	O
in	O
neuronal	O
cells	O
but	O
not	B-Negation
in	I-Negation
other	I-Negation
cell	I-Negation
types	I-Negation
.	O

The	O
primary	O
RNA	O
transcript	O
of	O
the	O
gene	O
is	O
subject	O
to	O
alternative	O
splicing	O
to	O
yield	O
different	O
variants	O
which	O
can	O
either	O
activate	O
or	O
repress	O
gene	O
expression	O
.	O

The	O
forms	O
produced	O
in	O
B	O
lymphocytes	O
have	O
a	O
predominantly	O
activating	O
effect	O
on	O
gene	O
expression	O
whereas	O
those	O
produced	O
in	O
neuronal	O
cells	O
have	O
a	O
predominantly	O
inhibitory	O
effect	O
and	O
can	O
repress	O
the	O
expression	O
of	O
both	O
the	O
herpes	O
simplex	O
virus	O
immediate-early	O
genes	O
and	O
the	O
cellular	O
tyrosine	O
hydroxylase	O
gene	O
.	O

Thus	O
Oct-2	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
cellular	O
gene	O
expression	O
in	O
both	O
B	O
cells	O
and	O
neuronal	O
cells	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
viral	O
latency	O
.	O

Tissue	O
and	O
cell-type	O
specific	O
expression	O
of	O
the	O
tuberous	O
sclerosis	O
gene	O
,	O
TSC2	O
,	O
in	O
human	O
tissues	O
.	O

TSC2	O
is	O
a	O
gene	O
on	O
chromosome	O
16p13.3	O
associated	O
with	O
the	O
autosomal	O
dominant	O
neurocutaneous	O
disorder	O
,	O
tuberous	O
sclerosis	O
complex	O
(	O
TSC	O
)	O
.	O

By	O
using	O
a	O
partial	O
nucleotide	O
sequence	O
from	O
the	O
cloned	O
TSC2	O
and	O
polymerase	O
chain	O
reaction	O
methodology	O
,	O
we	O
constructed	O
a	O
digoxigenin-labeled	O
complementary	O
DNA	O
probe	O
to	O
examine	O
TSC2	O
gene	O
expression	O
in	O
autopsy-	O
or	O
biopsy-derived	O
human	O
tissues	O
by	O
in	O
situ	O
hybridization	O
.	O

TSC2	O
messenger	O
RNA	O
was	O
widely	O
expressed	O
in	O
various	O
cell	O
types	O
throughout	O
the	O
body	O
,	O
including	O
epithelia	O
,	O
lymphocytes	O
,	O
and	O
cells	O
with	O
endocrine	O
functions	O
,	O
e.g.	O
,	O
adrenal	O
cortex	O
and	O
anterior	O
pituitary	O
.	O

It	O
was	O
prominently	O
and	O
selectively	O
(	O
within	O
the	O
central	O
nervous	O
system	O
)	O
expressed	O
in	O
pyramidal	O
cells	O
of	O
the	O
cerebral	O
cortex	O
and	O
other	O
motor	O
neurons	O
,	O
e.g.	O
,	O
in	O
spinal	O
cord	O
and	O
brainstem	O
nuclei	O
.	O

Visceral	O
TSC2	O
expression	O
was	O
comparable	O
in	O
autopsy	O
tissues	O
from	O
patients	O
with	O
and	O
without	B-Negation
TSC	I-Negation
;	O

TSC2	O
messenger	O
RNA	O
expression	O
was	O
most	O
prominent	O
in	O
cells	O
with	O
a	O
rapid	O
mitotic	O
rate	O
and	O
turnover	O
,	O
e.g.	O
,	O
epithelia	O
and	O
lymphocytes	O
,	O
with	O
central	O
nervous	O
system	O
pyramidal	O
cells	O
and	O
other	O
neurons	O
being	O
an	O
obvious	O
exception	O
,	O
and/or	O
in	O
cells	O
with	O
important	O
secretory/transport	O
functions	O
.	O

This	O
widespread	O
expression	O
of	O
the	O
TSC2	O
gene	O
supports	O
the	O
view	O
that	O
it	O
encodes	O
a	O
protein	O
vital	O
to	O
cell	O
growth	O
and	O
metabolism	O
or	O
one	O
that	O
functions	O
as	O
a	O
tumor/growth	O
suppressor	O
.	O

Cell	O
specific	O
expression	O
of	O
human	O
Bruton	O
's	O
agammaglobulinemia	O
tyrosine	O
kinase	O
gene	O
(	O
Btk	O
)	O
is	O
regulated	O
by	O
Sp1-	O
and	O
Spi-1/PU.1-family	O
members	O
.	O

Bruton	O
's	O
agammaglobulinemia	O
tyrosine	O
kinase	O
(	O
Btk	O
)	O
is	O
a	O
cytoplasmic	O
tyrosine	O
kinase	O
involved	O
in	O
the	O
human	O
disease	O
X-linked	O
agammaglobulinemia	O
(	O
XLA	O
)	O
.	O

The	O
gene	O
is	O
expressed	O
in	O
all	O
hematopoietic	O
cells	O
with	O
the	O
exception	O
of	O
T-cells	O
and	O
plasma	O
cells	O
.	O

For	O
this	O
expression	O
pattern	O
the	O
first	O
280	O
bp	O
upstream	O
of	O
the	O
major	O
transcriptional	O
start	O
site	O
seems	O
to	O
be	O
sufficient	O
.	O

In	O
vitro	O
footprinting	O
analysis	O
within	O
this	O
part	O
of	O
the	O
promoter	O
revealed	O
two	O
Sp1	O
binding	O
sites	O
as	O
well	O
as	O
a	O
PU-box	O
.	O

The	O
transcription	O
factor	O
Spi-1/PU.1	O
as	O
well	O
as	O
the	O
closely	O
related	O
factor	O
Spi-B	O
bound	O
to	O
the	O
PU-box	O
in	O
B-cells	O
.	O

In	O
the	O
erythroleukemia	O
cell	O
line	O
K562	O
,	O
due	O
to	O
the	O
absence	O
of	O
Spi-B	O
,	O
only	O
PU.1	O
bound	O
to	O
the	O
Btk	O
promoter	O
.	O

Mutation	O
of	O
either	O
site	O
reduced	O
the	O
expression	O
in	O
transient	O
transfection	O
experiments	O
.	O

However	O
,	O
mutation	O
of	O
the	O
PU	O
box	O
had	O
no	B-Negation
effect	I-Negation
in	I-Negation
the	I-Negation
T-cell	I-Negation
line	I-Negation
Jurkat	I-Negation
,	O
where	O
none	B-Negation
of	I-Negation
the	I-Negation
Spi-1	I-Negation
family	I-Negation
members	I-Negation
is	I-Negation
expressed	I-Negation
.	O

In	O
addition	O
Spi-B	O
as	O
well	O
as	O
PU.1	O
were	O
able	O
to	O
transactivate	O
Btk	O
expression	O
.	O

In	O
fetal	O
liver	O
of	O
PU.1-/-	O
mice	O
,	O
which	O
lack	B-Negation
lymphoid	I-Negation
and	I-Negation
myeloid	I-Negation
cells	I-Negation
,	O
expression	O
of	O
Btk	O
was	O
reduced	O
two-	O
to	O
threefold	O
but	O
not	B-Negation
abolished	I-Negation
.	O

Collectively	O
this	O
study	O
shows	O
that	O
expression	O
of	O
the	O
Btk	O
gene	O
is	O
regulated	O
by	O
the	O
combined	O
action	O
of	O
Sp1-	O
and	O
PU.1-family	O
members	O
.	O

Elf-1	O
and	O
Stat5	O
bind	O
to	O
a	O
critical	O
element	O
in	O
a	O
new	O
enhancer	O
of	O
the	O
human	O
interleukin-2	O
receptor	O
alpha	O
gene	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1997	O
Apr	O
;	O
17	O
(	O
4	O
)	O
:2351	O
]	O

The	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
is	O
a	O
key	O
regulator	O
of	O
lymphocyte	O
proliferation	O
.	O

IL-2R	O
alpha	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Interleukin	O
2	O
(	O
IL-2	O
)	O
stimulates	O
IL-2R	O
alpha.	O
transcription	O
,	O
thereby	O
amplifying	O
expression	O
of	O
its	O
own	O
high-affinity	O
receptor	O
.	O

IL-2R	O
alpha	O
transcription	O
is	O
at	O
least	O
in	O
part	O
controlled	O
by	O
two	O
positive	O
regulatory	O
regions	O
,	O
PRRI	O
and	O
PRRII	O
.	O

PRRI	O
is	O
an	O
inducible	O
proximal	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-276	O
and	O
-244	O
,	O
which	O
contains	O
NF-kappaB	O
and	O
SRE/CArG	O
motifs	O
.	O

PRRII	O
is	O
a	O
T-cell-specific	O
enhancer	O
,	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
,	O
which	O
binds	O
the	O
T-cell-specific	O
Ets	O
protein	O
Elf-1	O
and	O
HMG-I	O
(	O
Y	O
)	O
proteins	O
.	O

However	O
,	O
none	O
of	O
these	O
proximal	O
regions	O
account	O
for	O
the	O
induction	O
of	O
IL-2R	O
alpha	O
transcription	O
by	O
IL-2	O
.	O

To	O
find	O
new	O
regulatory	O
regions	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
,	O
8.5	O
kb	O
of	O
the	O
5	O
'	O
end	O
noncoding	O
sequence	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
have	O
been	O
sequenced	O
.	O

We	O
identified	O
an	O
86-nucleotide	O
fragment	O
that	O
is	O
90	O
%	O
identical	O
to	O
the	O
recently	O
characterized	O
murine	O
IL-2-responsive	O
element	O
(	O
mIL-2rE	O
)	O
.	O

This	O
putative	O
human	O
IL-2rE	O
,	O
designated	O
PRRIII	O
,	O
confers	O
IL-2	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

PRRIII	O
contains	O
a	O
Stat	O
protein	O
binding	O
site	O
that	O
overlaps	O
with	O
an	O
EBS	O
motif	O
(	O
GASd/EBSd	O
)	O
.	O

These	O
are	O
essential	O
for	O
IL-2	O
inducibility	O
of	O
PRRIII/CAT	O
reporter	O
constructs	O
.	O

IL-2	O
induced	O
the	O
binding	O
of	O
Stat5a	O
and	O
b	O
proteins	O
to	O
the	O
human	O
GASd	O
element	O
.	O

To	O
confirm	O
the	O
physiological	O
relevance	O
of	O
these	O
findings	O
,	O
we	O
carried	O
out	O
in	O
vivo	O
footprinting	O
experiments	O
which	O
showed	O
that	O
stimulation	O
of	O
IL-2R	O
alpha	O
expression	O
correlated	O
with	O
occupancy	O
of	O
the	O
GASd	O
element	O
.	O

Our	O
data	O
demonstrate	O
a	O
major	O
role	O
of	O
the	O
GASd/EBSd	O
element	O
in	O
IL-2R	O
alpha	O
regulation	O
and	O
suggest	O
that	O
the	O
T-cell-specific	O
Elf-1	O
factor	O
can	O
serve	O
as	O
a	O
transcriptional	O
repressor	O
.	O

Association	O
of	O
TRAF1	O
,	O
TRAF2	O
,	O
and	O
TRAF3	O
with	O
an	O
Epstein-Barr	O
virus	O
LMP1	O
domain	O
important	O
for	O
B-lymphocyte	O
transformation	O
:	O
role	O
in	O
NF-kappaB	O
activation	O
.	O

The	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
appears	O
to	O
be	O
a	O
constitutively	O
activated	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
on	O
the	O
basis	O
of	O
an	O
intrinsic	O
ability	O
to	O
aggregate	O
in	O
the	O
plasma	O
membrane	O
and	O
an	O
association	O
of	O
its	O
cytoplasmic	O
carboxyl	O
terminus	O
(	O
CT	O
)	O
with	O
TNFR-associated	O
factors	O
(	O
TRAFs	O
)	O
.	O

We	O
now	O
show	O
that	O
in	O
EBV-transformed	O
B	O
lymphocytes	O
most	O
of	O
TRAF1	O
or	O
TRAF3	O
and	O
5	O
%	O
of	O
TRAF2	O
are	O
associated	O
with	O
LMP1	O
and	O
that	O
most	O
of	O
LMP1	O
is	O
associated	O
with	O
TRAF1	O
or	O
TRAF3	O
.	O

TRAF1	O
,	O
TRAF2	O
,	O
and	O
TRAF3	O
bind	O
to	O
a	O
single	O
site	O
in	O
the	O
LMP1	O
CT	O
corresponding	O
to	O
amino	O
acids	O
(	O
aa	O
)	O
199	O
to	O
214	O
,	O
within	O
a	O
domain	O
which	O
is	O
important	O
for	O
B-lymphocyte	O
growth	O
transformation	O
(	O
aa	O
187	O
to	O
231	O
)	O
.	O

Further	O
deletional	O
and	O
alanine	O
mutagenesis	O
analyses	O
and	O
comparison	O
with	O
TRAF	O
binding	O
sequences	O
in	O
CD40	O
,	O
in	O
CD30	O
,	O
and	O
in	O
the	O
LMP1	O
of	O
other	O
lymphycryptoviruses	O
provide	O
the	O
first	O
evidence	O
that	O
PXQXT/S	O
is	O
a	O
core	O
TRAF	O
binding	O
motif	O
.	O

The	O
negative	O
effects	O
of	O
point	O
mutations	O
in	O
the	O
LMP1	O
(	O
1-231	O
)	O
core	O
TRAF	O
binding	O
motif	O
on	O
TRAF	O
binding	O
and	O
NF-kappaB	O
activation	O
genetically	O
link	O
the	O
TRAFs	O
to	O
LMP1	O
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	O
activation	O
.	O

NF-kappaB	O
activation	O
by	O
LMP1	O
(	O
1-231	O
)	O
is	O
likely	O
to	O
be	O
mediated	O
by	O
TRAF1/TRAF2	O
heteroaggregates	O
since	O
TRAF1	O
is	O
unique	O
among	O
the	O
TRAFs	O
in	O
coactivating	O
NF-kappaB	O
with	O
LMP1	O
(	O
1-231	O
)	O
,	O
a	O
TRAF2	O
dominant-negative	O
mutant	O
can	O
block	O
LMP1	O
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	O
activation	O
as	O
well	O
as	O
TRAF1	O
coactivation	O
,	O
and	O
30	O
%	O
of	O
TRAF2	O
is	O
associated	O
with	O
TRAF1	O
in	O
EBV-transformed	O
B	O
cells	O
.	O

TRAF3	O
is	O
a	O
negative	O
modulator	O
of	O
LMP1	O
(	O
1-231	O
)	O
-mediated	O
NF-kappaB	O
activation	O
.	O

Surprisingly	O
,	O
TRAF1	O
,	O
-2	O
,	O
or	O
-3	O
does	O
not	B-Negation
interact	I-Negation
with	I-Negation
the	I-Negation
terminal	I-Negation
LMP1	I-Negation
CT	I-Negation
aa	I-Negation
333	I-Negation
to	I-Negation
386	I-Negation
which	I-Negation
can	I-Negation
independently	I-Negation
mediate	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
.	O

The	O
constitutive	O
association	O
of	O
TRAFs	O
with	O
LMP1	O
through	O
the	O
aa	O
187	O
to	O
231	O
domain	O
which	O
is	O
important	O
in	O
NF-kappaB	O
activation	O
and	O
primary	O
B-lymphocyte	O
growth	O
transformation	O
implicates	O
TRAF	O
aggregation	O
in	O
LMP1	O
signaling	O
.	O

CD40	O
,	O
but	O
not	B-Negation
lipopolysaccharide	I-Negation
and	I-Negation
anti-IgM	I-Negation
stimulation	I-Negation
of	I-Negation
primary	I-Negation
B	I-Negation
lymphocytes	I-Negation
,	O
leads	O
to	O
a	O
persistent	O
nuclear	O
accumulation	O
of	O
RelB	O
.	O

In	O
this	O
study	O
we	O
analyzed	O
the	O
effect	O
of	O
CD40	O
stimulation	O
on	O
the	O
activity	O
and	O
nuclear	O
appearance	O
of	O
Rel/nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
factors	O
in	O
primary	O
murine	O
B	O
lymphocytes	O
.	O

We	O
show	O
that	O
triggering	O
of	O
CD40	O
signaling	O
pathway	O
(	O
s	O
)	O
by	O
CD40	O
ligands	O
expressed	O
on	O
L	O
cells	O
led	O
to	O
strong	O
activation	O
of	O
an	O
NF-kappaB-controlled	O
beta-globin	O
reporter	O
gene	O
in	O
primary	O
B	O
lymphocytes	O
from	O
transgenic	O
mice	O
.	O

Analyses	O
of	O
nuclear	O
translocation	O
of	O
individual	O
members	O
of	O
Rel	O
proteins	O
after	O
CD40	O
induction	O
of	O
primary	O
B	O
cells	O
showed	O
a	O
strong	O
and	O
long-lasting	O
accumulation	O
of	O
RelB	O
and	O
,	O
less	O
pronounced	O
,	O
of	O
c-Rel	O
.	O

LPS	O
stimulation	O
did	O
not	B-Negation
give	I-Negation
rise	I-Negation
to	I-Negation
a	I-Negation
persistent	I-Negation
nuclear	I-Negation
accumulation	I-Negation
of	I-Negation
RelB	I-Negation
and	I-Negation
c-Rel	I-Negation
,	O
whereas	O
nuclear	O
c-Rel	O
,	O
but	O
not	B-Negation
RelB	I-Negation
,	O
accumulated	O
after	O
B	O
cell	O
receptor	O
stimulation	O
.	O

CD40	O
induced	O
not	O
only	O
nuclear	O
translocation	O
but	O
also	O
de	O
novo	O
synthesis	O
of	O
RelB	O
RNA	O
and	O
protein	O
.	O

S107	O
plasmacytoma	O
cells	O
,	O
which	O
express	O
CD40	O
but	O
are	O
defective	O
for	O
the	O
nuclear	O
appearance	O
of	O
p50/p65-NF-kappaB	O
,	O
do	O
not	B-Negation
express	I-Negation
RelB	I-Negation
after	I-Negation
CD40	I-Negation
stimulation	I-Negation
.	O

In	O
S107	O
cells	O
stably	O
transfected	O
with	O
relB	O
genes	O
,	O
stimulation	O
of	O
nuclear	O
RelB	O
translocation	O
by	O
CD40	O
was	O
observed	O
.	O

These	O
results	O
indicate	O
that	O
stimulation	O
of	O
CD40	O
signaling	O
pathways	O
exerts	O
a	O
long-lasting	O
stimulatory	O
effect	O
on	O
both	O
the	O
transcription	O
and	O
nuclear	O
translocation	O
of	O
RelB	O
.	O

Since	O
LPS	O
and	O
anti-IgM	O
were	O
unable	B-Negation
to	I-Negation
activate	I-Negation
RelB	I-Negation
,	O
CD40	B-Speculation
appears	I-Speculation
to	I-Speculation
trigger	I-Speculation
a	I-Speculation
special	I-Speculation
program	I-Speculation
of	I-Speculation
gene	I-Speculation
expression	I-Speculation
involved	I-Speculation
in	I-Speculation
the	I-Speculation
proliferation	I-Speculation
and/or	I-Speculation
differentiation	I-Speculation
of	I-Speculation
B	I-Speculation
lymphocytes	I-Speculation
.	O

Sterol	O
dependent	O
LDL-receptor	O
gene	O
transcription	O
in	O
lymphocytes	O
from	O
normal	O
and	O
CML	O
patients	O
.	O

Sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
recognized	O
to	O
regulate	O
various	O
key	O
genes	O
coding	O
for	O
especially	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
-receptor	O
,	O
3-hydroxy-3-methylglutaryl	O
coenzyme	O
A	O
(	O
HMG-CoA	O
)	O
reductase	O
and	O
HMG-CoA	O
synthase	O
known	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
cholesterol	O
feedback	O
mechanism	O
.	O

The	O
deranged	O
cholesterol	O
feedback	O
mechanism	O
has	O
been	O
widely	O
recognised	O
in	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Consequently	O
,	O
the	O
present	O
study	O
was	O
addressed	O
to	O
understand	O
this	O
phenomenon	O
and	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
the	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	O
therapy	O
.	O

Further	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
sterol	O
modulated	O
LDL-receptor	O
gene	O
transcription	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
alpha-interferon	O
through	O
its	O
receptor	O
initiates	O
phosphatidic	O
acid	O
dependent	O
signalling	O
which	O
in	O
turn	O
regulates	O
the	O
affinity	O
of	O
47	O
kDa	O
sterol	O
regulatory	O
element	O
binding	O
factor	O
as	O
well	O
as	O
LDL-receptor	O
gene	O
transcription	O
in	O
lymphocytes	O
from	O
CML	O
patients	O
.	O

Effects	O
of	O
Ara-C	O
on	O
neutral	O
sphingomyelinase	O
and	O
mitogen-	O
and	O
stress-activated	O
protein	O
kinases	O
in	O
T-lymphocyte	O
cell	O
lines	O
.	O

Neutral	O
sphingomyelinase	O
(	O
SMase	O
)	O
can	O
be	O
activated	O
by	O
extracellular	O
signals	O
to	O
produce	O
ceramide	O
,	O
which	O
may	O
affect	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activities	O
.	O

Neutral	O
SMase	O
activity	O
was	O
assessed	O
in	O
membranes	O
from	O
Jurkat	O
,	O
a	O
human	O
T-cell	O
line	O
,	O
and	O
EL4	O
,	O
a	O
murine	O
T-cell	O
line	O
.	O

Ara-C	O
activated	O
SMase	O
with	O
10	O
minutes	O
in	O
both	O
Jurkat	O
and	O
EL4	O
cells	O
,	O
while	O
phorbol	O
ester	O
(	O
PMA	O
)	O
had	O
no	B-Negation
effect	I-Negation
.	O

PMA	O
,	O
but	O
not	B-Negation
Ara-C	I-Negation
or	I-Negation
ceramides	I-Negation
,	O
activated	O
ERK	O
MAPKS	O
,	O
in	O
Jurkat	O
and	O
EL4	O
.	O

PMA	O
acted	O
synergistically	O
with	O
ionomycin	O
to	O
activate	O
JNK	O
MAPKs	O
in	O
Jurkat	O
and	O
EL4	O
within	O
10	O
minutes	O
.	O

Ara-C	O
activated	O
JNKs	O
only	O
after	O
prolonged	O
incubation	O
(	O
90-120	O
minutes	O
)	O
.	O

Thus	O
,	O
ceramide	O
is	O
not	B-Negation
a	I-Negation
positive	I-Negation
signal	I-Negation
for	I-Negation
ERK	I-Negation
activation	I-Negation
in	I-Negation
T-cell	I-Negation
lines	I-Negation
.	O

The	O
effects	O
of	O
Ara-C	O
on	O
JNK	O
activity	O
may	O
be	O
mediated	O
through	O
secondary	O
response	O
pathways	O
.	O

[	O
Cortisone-resistant	O
bronchial	O
asthma	O
]	O

There	O
is	O
general	O
agreement	O
on	O
the	O
inflammatory	O
pathogenesis	O
of	O
bronchial	O
asthma	O
:	O

an	O
accumulation	O
of	O
activated	O
eosinophils	O
,	O
degranulated	O
mast	O
cells	O
,	O
T	O
lymphocytes	O
and	O
in	O
very	O
severe	O
forms	O
,	O
granulocytes	O
has	O
constantly	O
been	O
found	O
in	O
the	O
bronchial	O
mucosa	O
.	O

In	O
allergic	O
bronchial	O
asthma	O
,	O
inflammation	O
seems	O
to	O
be	O
orchestrated	O
predominantly	O
by	O
a	O
subset	O
of	O
T	O
lymphocytes	O
,	O
with	O
a	O
phenotype	O
similar	O
to	O
the	O
Th2	O
subset	O
able	O
to	O
produce	O
IL-4	O
and	O
IL-5	O
.	O

Although	O
corticosteroids	O
are	O
the	O
most	O
potent	O
therapeutic	O
agents	O
used	O
for	O
this	O
disease	O
,	O
their	O
anti-inflammatory	O
effect	O
differs	O
from	O
patient	O
to	O
patient	O
.	O

Some	O
criteria	O
which	O
can	O
be	O
used	O
to	O
define	O
steroid-resistant	O
bronchial	O
asthma	O
are	O
listed	O
here	O
.	O

This	O
review	O
analyzes	O
various	O
molecular	O
alterations	O
responsible	O
for	O
the	O
deficient	O
response	O
to	O
corticosteroid	O
treatment	O
observed	O
in	O
steroid-resistant	O
bronchial	O
asthmatic	O
subjects	O
.	O

New	O
knowledge	O
on	O
the	O
mechanism	O
of	O
steroid	O
resistance	O
may	O
have	O
important	O
implications	O
for	O
the	O
treatment	O
of	O
chronic	O
asthma	O
and	O
other	O
diseases	O
.	O

Expression	O
of	O
Egr-1	O
correlates	O
with	O
the	O
transformed	O
phenotype	O
and	O
the	O
type	O
of	O
viral	O
latency	O
in	O
EBV	O
genome	O
positive	O
lymphoid	O
cell	O
lines	O
.	O

In	O
this	O
paper	O
we	O
have	O
investigated	O
the	O
role	O
of	O
Egr-1	O
in	O
B	O
cell	O
growth	O
regulation	O
by	O
examining	O
the	O
gene	O
expression	O
in	O
a	O
panel	O
of	O
B	O
cell	O
lines	O
,	O
including	O
both	O
EBV	O
genome	O
negative	O
and	O
EBV	O
carrying	O
cell	O
lines	O
.	O

Egr-1	O
expression	O
correlates	O
with	O
the	O
cellular	O
phenotype	O
and	O
the	O
specific	O
pattern	O
of	O
viral	O
latency	O
established	O
within	O
the	O
individual	O
cell	O
lines	O
.	O

Thus	O
,	O
constitutive	O
activation	O
of	O
Egr-1	O
gene	O
is	O
invariably	O
associated	O
with	O
unrestricted	O
expression	O
of	O
viral	O
latent	O
genes	O
in	O
all	O
group	O
III	O
EBV	O
genome	O
carrying	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
Egr-1	O
expression	O
is	O
abrogated	O
in	O
group	O
I	O
Burkitt	O
tumor	O
cells	O
,	O
irrespective	O
of	O
the	O
EBV	O
genome	O
carrying	O
status	O
.	O

Activated	O
viral	O
gene	O
expression	O
associated	O
with	O
phenotypic	O
conversion	O
of	O
group	O
I	O
cell	O
lines	O
in	O
to	O
group	O
II	O
or	O
III	O
restores	O
the	O
Egr-1	O
gene	O
expression	O
.	O

Several	O
forms	O
of	O
EGR-1	O
protein	O
are	O
found	O
within	O
the	O
different	O
groups	O
of	O
cell	O
lines	O
,	O
and	O
the	O
binding	O
activity	O
to	O
DNA	O
consensus	O
sequences	O
was	O
investigated	O
.	O

Finally	O
,	O
time	O
course	O
analysis	O
of	O
Egr-1	O
expression	O
during	O
the	O
early	O
steps	O
of	O
EBV	O
infection	O
in	O
vitro	O
demonstrated	O
that	O
Egr-1	O
is	O
upregulated	O
within	O
minutes	O
from	O
the	O
initial	O
interaction	O
with	O
the	O
B	O
lymphocyte	O
.	O

The	O
proximal	O
regulatory	O
element	O
of	O
the	O
interferon-gamma	O
promoter	O
mediates	O
selective	O
expression	O
in	O
T	O
cells	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	O
)	O
is	O
produced	O
by	O
natural	O
killer	O
cells	O
and	O
certain	O
subsets	O
of	O
T	O
cells	O
,	O
but	O
the	O
basis	O
for	O
its	O
selective	O
expression	O
is	O
unknown	O
.	O

Within	O
the	O
region	O
between	O
-108	O
and	O
-40	O
base	O
pairs	O
of	O
the	O
IFN-gamma	O
promoter	O
are	O
two	O
conserved	O
and	O
essential	O
regulatory	O
elements	O
,	O
which	O
confer	O
activation-specific	O
expression	O
in	O
T	O
cells	O
.	O

This	O
report	O
describes	O
studies	O
indicating	O
that	O
the	O
most	O
proximal	O
of	O
these	O
two	O
regulatory	O
elements	O
is	O
an	O
important	O
determinant	O
of	O
its	O
restricted	O
expression	O
.	O

The	O
proximal	O
element	O
is	O
a	O
composite	O
site	O
that	O
binds	O
members	O
of	O
the	O
CREB/ATF	O
,	O
AP-1	O
,	O
and	O
octamer	O
families	O
of	O
transcription	O
factors	O
.	O

Jun	O
is	O
essential	O
for	O
activation-induced	O
transcription	O
and	O
binds	O
preferably	O
as	O
a	O
heterodimer	O
with	O
ATF-2	O
.	O

In	O
contrast	O
,	O
CREB	O
appears	O
to	O
dampen	O
transcription	O
from	O
this	O
element	O
.	O

The	O
CpG	O
dinucleotide	O
in	O
this	O
element	O
is	O
selectively	O
methylated	O
in	O
Th2	O
T	O
cells	O
and	O
other	O
cells	O
that	O
do	O
not	B-Negation
express	I-Negation
IFN-gamma	I-Negation
,	O
and	O
methylation	O
markedly	O
reduces	O
transcription	O
factor	O
binding	O
.	O

As	O
a	O
target	O
for	O
DNA	O
methylation	O
and	O
for	O
binding	O
of	O
transcription	O
factors	O
that	O
mediate	O
or	O
impede	O
transcription	O
,	O
this	O
element	O
appears	O
to	O
play	O
a	O
central	O
role	O
in	O
controlling	O
IFN-gamma	O
expression	O
.	O

Activation	O
of	O
nuclear	O
factor-kappaB	O
via	O
T	O
cell	O
receptor	O
requires	O
a	O
Raf	O
kinase	O
and	O
Ca2+	O
influx	O
.	O

Functional	O
synergy	O
between	O
Raf	O
and	O
calcineurin	O
.	O

Signals	O
transduced	O
via	O
the	O
TCR	O
activate	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
,	O
which	O
,	O
in	O
turn	O
,	O
is	O
critical	O
to	O
the	O
transcriptional	O
induction	O
of	O
many	O
genes	O
important	O
for	O
the	O
proliferation	O
and	O
expression	O
of	O
a	O
differentiated	O
phenotype	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
protein	O
kinase	O
C	O
activator	O
PMA	O
in	O
combination	O
with	O
Ca2+	O
ionophores	O
mimics	O
this	O
process	O
,	O
and	O
the	O
two	O
agents	O
are	O
often	O
substituted	O
for	O
TCR	O
stimulation	O
,	O
bypassing	O
the	O
TCR	O
.	O

Here	O
we	O
identify	O
intracellular	O
signaling	O
components	O
involved	O
in	O
activation	O
of	O
NF-kappaB	O
following	O
TCR	O
stimulation	O
.	O

TCR	O
signaling	O
was	O
triggered	O
by	O
treating	O
Jurkat	O
T	O
cells	O
with	O
PHA	O
or	O
anti-CD3	O
Abs	O
,	O
and	O
NF-kappaB	O
activation	O
was	O
monitored	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
and/or	O
by	O
kappaB-dependent	O
reporter	O
assays	O
.	O

Contrary	O
to	O
the	O
idea	O
that	O
protein	O
kinase	O
C	O
is	O
involved	O
in	O
TCR-mediated	O
activation	O
of	O
NF-kappaB	O
,	O
high	O
doses	O
of	O
staurosporine	O
did	O
not	B-Negation
interfere	I-Negation
with	I-Negation
activation	I-Negation
of	I-Negation
NF-kappaB	I-Negation
by	I-Negation
PHA	I-Negation
,	O
while	O
the	O
same	O
dose	O
of	O
staurosporine	O
completely	O
blocked	O
activation	O
by	O
PMA	O
.	O

PHA-induced	O
kappaB-dependent	O
reporter	O
activity	O
was	O
,	O
however	O
,	O
effectively	O
blocked	O
by	O
a	O
dominant	O
negative	O
form	O
of	O
Raf-1	O
,	O
suggesting	O
a	O
critical	O
role	O
for	O
a	O
Raf	O
kinase	O
.	O

The	O
TCR-mediated	O
activation	O
of	O
NF-kappaB	O
was	O
also	O
dependent	O
on	O
a	O
Ca2+	O
influx	O
,	O
because	O
the	O
Ca2+	O
channel	O
blocker	O
,	O
SK	O
&	O
F	O
96365	O
,	O
as	O
well	O
as	O
other	O
agents	O
that	O
prevented	O
the	O
Ca2+	O
influx	O
,	O
inhibited	O
NF-kappaB	O
activation	O
.	O

Cotransfection	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
largely	O
substituted	O
for	O
the	O
Ca2+	O
requirement	O
and	O
reversed	O
the	O
blockade	O
by	O
SK	O
&	O
F	O
96365	O
.	O

Consistent	O
with	O
these	O
observations	O
,	O
coexpression	O
of	O
constitutively	O
active	O
forms	O
of	O
Raf-1	O
and	O
calcineurin	O
synergistically	O
induced	O
kappaB-dependent	O
reporter	O
activity	O
,	O
suggesting	O
a	O
physiologically	O
relevant	O
functional	O
interaction	O
between	O
the	O
kinase	O
and	O
the	O
phosphatase	O
.	O

Induction	O
of	O
the	O
CD11b	O
gene	O
during	O
activation	O
of	O
the	O
monocytic	O
cell	O
line	O
U937	O
requires	O
a	O
novel	O
nuclear	O
factor	O
MS-2	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Immunol	O
1999	O
Jul	O
15	O
;	O
163	O
(	O
2	O
)	O
:1091	O
]	O

The	O
differentiation	O
of	O
myeloid	O
precursors	O
into	O
mature	O
myelomonocytic	O
cells	O
is	O
characterized	O
by	O
the	O
induction	O
of	O
the	O
gene	O
encoding	O
the	O
beta2	O
integrin	O
CD11b	O
.	O

The	O
transcription	O
factors	O
Sp1	O
and	O
PU.1	O
prime	O
the	O
CD11b	O
promoter	O
,	O
but	O
the	O
nature	O
of	O
the	O
factors	O
responsible	O
for	O
its	O
inducible	O
expression	O
are	O
unknown	O
.	O

In	O
addition	O
to	O
the	O
CD11b	O
gene	O
,	O
the	O
homologous	O
genes	O
encoding	O
CD11a	O
and	O
CD11c	O
also	O
exhibit	O
inducible	O
expression	O
during	O
myeloid	O
differentiation	O
.	O

Therefore	O
,	O
we	O
compared	O
the	O
nucleotide	O
sequences	O
of	O
the	O
CD11a	O
,	O
CD11b	O
,	O
and	O
CD11c	O
gene	O
promoters	O
to	O
identify	O
common	O
elements	O
that	O
might	O
contribute	O
to	O
inducible	O
expression	O
.	O

This	O
analysis	O
identified	O
one	O
such	O
element	O
repeated	O
four	O
times	O
within	O
the	O
CD11b	O
promoter	O
.	O

Mutation	O
of	O
these	O
elements	O
indicated	O
that	O
two	O
,	O
MS-2beta	O
and	O
MS-2gamma	O
,	O
are	O
critical	O
to	O
the	O
induction	O
of	O
the	O
CD11b	O
gene	O
during	O
differentiation	O
of	O
the	O
pro-monocytic	O
cell	O
line	O
U937	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
indicate	O
that	O
MS-2beta	O
and	O
MS-2gamma	O
interact	O
with	O
nuclear	O
factors	O
that	O
are	O
induced	O
during	O
U937	O
differentiation	O
.	O

These	O
factors	O
are	O
detected	O
at	O
the	O
time	O
the	O
CD11b	O
promoter	O
is	O
activated	O
.	O

The	O
molecular	O
mass	O
of	O
these	O
factors	O
is	O
approximately	O
28	O
kDa	O
,	O
and	O
their	O
DNA	O
binding	O
characteristics	O
are	O
indistinguishable	O
from	O
those	O
of	O
the	O
novel	O
nuclear	O
factor	O
MS-2	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
MS-2	O
mediates	O
induction	O
of	O
the	O
CD11b	O
gene	O
as	O
cells	O
of	O
the	O
monocytic	O
lineage	O
mature	O
.	O

The	O
presence	O
of	O
multiple	O
potential	O
binding	O
sites	O
for	O
MS-2	O
in	O
the	O
promoter	O
regions	O
of	O
a	O
wide	O
range	O
of	O
genes	O
expressed	O
in	O
mature	O
myeloid	O
cells	O
suggests	O
this	O
factor	O
plays	O
a	O
general	O
role	O
in	O
myeloid	O
differentiation	O
.	O

HIV-1	O
LTR	O
activity	O
in	O
human	O
CD40-activated	O
B	O
lymphocytes	O
is	O
dependent	O
on	O
NF-kappaB	O
.	O

CD40-stimulated	O
human	O
B	O
lymphocytes	O
are	O
highly	O
permissive	O
to	O
a	O
productive	O
infection	O
by	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

In	O
these	O
cells	O
,	O
nuclear	O
factors	O
involved	O
in	O
activation	O
of	O
the	O
HIV-1	O
LTR	O
,	O
which	O
contains	O
the	O
transcriptional	O
control	O
elements	O
of	O
the	O
virus	O
,	O
are	O
unknown	O
.	O

Transient	O
expression	O
assays	O
with	O
plasmids	O
containing	O
deleted	O
parts	O
of	O
the	O
LTR	O
region	O
linked	O
to	O
a	O
reporter	O
gene	O
showed	O
that	O
the	O
NF-kappaB	O
binding	O
site	O
was	O
essential	O
for	O
HIV-1	O
LTR	O
activity	O
in	O
CD40-stimulated	O
B	O
lymphocytes	O
.	O

In	O
addition	O
,	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
revealed	O
that	O
important	O
NF-kappaB	O
binding	O
activity	O
composed	O
of	O
at	O
least	O
p50	O
,	O
p65	O
,	O
and	O
c-Rel	O
NF-kappaB	O
subunits	O
was	O
present	O
in	O
nuclei	O
of	O
CD40-stimulated	O
B	O
cells	O
.	O

These	O
results	O
confirm	O
at	O
a	O
molecular	O
level	O
the	O
ability	O
of	O
HIV-1	O
to	O
replicate	O
in	O
B	O
cells	O
and	O
that	O
this	O
activity	O
is	O
strongly	O
associated	O
with	O
NF-kappaB	O
.	O

Mutation	O
of	O
tyrosines	O
492/493	O
in	O
the	O
kinase	O
domain	O
of	O
ZAP-70	O
affects	O
multiple	O
T-cell	O
receptor	O
signaling	O
pathways	O
.	O

The	O
protein-tyrosine	O
kinase	O
ZAP-70	O
is	O
implicated	O
,	O
together	O
with	O
the	O
Src	O
kinase	O
p56	O
(	O
lck	O
)	O
,	O
in	O
controlling	O
the	O
early	O
steps	O
of	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
signaling	O
cascade	O
.	O

To	O
help	O
elucidate	O
further	O
the	O
mechanism	O
by	O
which	O
ZAP-70	O
regulates	O
these	O
initial	O
events	O
,	O
we	O
used	O
a	O
dominant-negative	O
mutant	O
approach	O
.	O

We	O
overexpressed	O
in	O
the	O
Jurkat	O
T-cell	O
line	O
ZAP-70	O
mutated	O
on	O
Tyr-492	O
and	O
Tyr-493	O
in	O
the	O
putative	O
regulatory	O
loop	O
of	O
its	O
kinase	O
domain	O
.	O

This	O
mutant	O
inhibited	O
TCR-induced	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
by	O
interfering	O
with	O
both	O
intracellular	O
calcium	O
increase	O
and	O
Ras-regulated	O
activation	O
of	O
extracellular	O
signal-regulated	O
kinases	O
.	O

Moreover	O
,	O
TCR-induced	O
phosphorylation	O
of	O
pp36-38	O
,	O
thought	O
to	O
play	O
a	O
role	O
upstream	O
of	O
these	O
pathways	O
,	O
was	O
found	O
to	O
be	O
reduced	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
wild-type	O
ZAP-70	O
induced	O
constitutive	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
ZAP-70	O
mutant	O
studied	O
here	O
could	O
be	O
phosphorylated	O
on	O
tyrosine	O
when	O
associated	O
to	O
the	O
TCR	O
zeta	O
chain	O
and	O
was	O
able	O
to	O
bind	O
p56	O
(	O
lck	O
)	O
.	O

This	O
result	O
demonstrates	O
that	O
Tyr-492	O
and	O
Tyr-493	O
are	O
not	B-Negation
responsible	I-Negation
for	I-Negation
the	I-Negation
Src	I-Negation
homology	I-Negation
domain	I-Negation
2-mediated	I-Negation
association	I-Negation
of	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
with	I-Negation
ZAP-70	I-Negation
.	O

Our	O
data	O
are	O
most	O
consistent	O
with	O
a	O
model	O
in	O
which	O
recruitment	O
to	O
the	O
TCR	O
allows	O
ZAP-70	O
autophosphorylation	O
and	O
binding	O
to	O
p56	O
(	O
lck	O
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
Tyr-492	O
and/or	O
Tyr-493	O
with	O
consequent	O
up-regulation	O
of	O
the	O
ZAP-70	O
kinase	O
activity	O
.	O

ZAP-70	O
will	O
then	O
be	O
able	O
to	O
effectively	O
control	O
phosphorylation	O
of	O
its	O
substrates	O
and	O
lead	O
to	O
gene	O
activation	O
.	O

Dexamethasone	O
suppression	O
test	O
:	O
corticosteroid	O
receptors	O
regulation	O
in	O
mononuclear	O
leukocytes	O
of	O
young	O
and	O
aged	O
subjects	O
.	O

The	O
dexamethasone	O
suppression	O
test	O
(	O
DST	O
)	O
is	O
considered	O
an	O
indicator	O
of	O
the	O
function	O
of	O
the	O
adrenal	O
pituitary	O
axis	O
.	O

The	O
effect	O
of	O
the	O
steroid	O
is	O
mediated	O
by	O
its	O
binding	O
to	O
corticosteroid	O
receptors	O
.	O

We	O
previously	O
suggested	O
that	O
the	O
measurement	O
of	O
corticosteroid	O
receptors	O
in	O
lymphocytes	O
is	O
an	O
index	O
of	O
an	O
analogous	O
pattern	O
in	O
brain	O
.	O

In	O
the	O
present	O
study	O
,	O
corticosteroid	O
Type	O
I	O
and	O
Type	O
II	O
receptors	O
in	O
mononuclear	O
leukocytes	O
were	O
measured	O
in	O
10	O
elderly	O
subjects	O
and	O
in	O
9	O
young	O
adults	O
,	O
before	O
and	O
after	O
overnight	O
DST	O
(	O
1	O
mg	O
)	O
.	O

Receptors	O
were	O
measured	O
by	O
radioreceptor	O
assay	O
.	O

In	O
all	O
the	O
subjects	O
,	O
dexamethasone	O
was	O
able	O
to	O
suppress	O
plasma	O
cortisol	O
.	O

The	O
number	O
of	O
Type	O
I	O
and	O
Type	O
II	O
receptors	O
before	O
the	O
test	O
was	O
lower	O
in	O
elderly	O
subjects	O
than	O
in	O
adults	O
.	O

In	O
the	O
control	O
group	O
,	O
dexamethasone	O
produced	O
a	O
significant	O
depression	O
of	O
Type	O
I	O
receptors	O
(	O
from	O
267	O
	O
72	O
to	O
169	O
	O
71	O
receptors	O
per	O
cell	O
)	O
,	O
which	O
can	O
be	O
interpreted	O
as	O
a	O
primary	O
involvement	O
of	O
Type	O
I	O
receptors	O
in	O
the	O
response	O
to	O
dexamethasone	O
;	O

Type	O
II	O
receptors	O
decreased	O
in	O
half	O
the	O
subjects	O
(	O
from	O
2849	O
	O
703	O
to	O
2345	O
	O
569	O
receptors	O
per	O
cell	O
)	O
.	O

In	O
elderly	O
healthy	O
subjects	O
,	O
Type	O
II	O
receptors	O
were	O
also	O
significantly	O
decreased	O
(	O
from	O
1796	O
	O
671	O
to	O
720	O
	O
345	O
)	O
.	O

We	O
suggest	O
that	O
in	O
young	O
subjects	O
Type	O
II	O
receptors	O
are	O
initially	O
up-regulated	O
by	O
dexamethasone	O
,	O
and	O
then	O
down-regulated	O
,	O
while	O
in	O
aged	O
subjects	O
an	O
up-regulation	O
can	O
not	O
be	O
achieved	O
,	O
as	O
suggested	O
by	O
the	O
higher	O
values	O
of	O
plasma	O
cortisol	O
usually	O
found	O
in	O
aging	O
subjects	O
.	O

Lymphocytes	O
from	O
CML	O
patients	O
lack	B-Negation
a	I-Negation
47	I-Negation
kDa	I-Negation
factor	I-Negation
having	I-Negation
affinity	I-Negation
for	I-Negation
a	I-Negation
genomic	I-Negation
sterol	I-Negation
regulatory	I-Negation
sequence	I-Negation
.	O

Deranged	O
cellular	O
cholesterol	O
homeostasis	O
has	O
been	O
widely	O
recognized	O
in	O
the	O
initiation	O
as	O
well	O
as	O
progression	O
of	O
various	O
types	O
of	O
cancers	O
including	O
chronic	O
myeloid	O
leukaemia	O
(	O
CML	O
)	O
.	O

Since	O
the	O
human	O
genomic	O
sterol	O
regulatory	O
element	O
(	O
SRE	O
)	O
has	O
been	O
shown	O
to	O
regulate	O
various	O
key	O
genes	O
involved	O
in	O
this	O
phenomenon	O
,	O
the	O
present	O
study	O
revealed	O
the	O
existence	O
of	O
a	O
unique	O
47	O
kDa	O
protein	O
factor	O
having	O
affinity	O
for	O
this	O
SRE	O
sequence	O
in	O
lymphocytes	O
from	O
normal	O
subjects	O
,	O
as	O
well	O
as	O
its	O
absence	O
in	O
lymphocytes	O
from	O
untreated	O
CML	O
patients	O
.	O

However	O
,	O
this	O
factor	O
appeared	O
when	O
these	O
CML	O
patients	O
achieved	O
complete	O
haematological	O
remission	O
(	O
CHR	O
)	O
through	O
alpha-interferon	O
therapy	O
.	O

Furthermore	O
,	O
an	O
inverse	O
relationship	O
was	O
also	O
observed	O
between	O
the	O
LDL	O
receptor	O
gene	O
expression	O
at	O
the	O
transcriptional	O
level	O
and	O
the	O
binding	O
affinity	O
of	O
this	O
47	O
kDa	O
protein	O
factor	O
to	O
the	O
SRE	O
sequence	O
.	O

Based	O
upon	O
these	O
results	O
we	O
propose	O
that	O
this	O
factor	O
may	O
have	O
a	O
role	O
in	O
pathophysiology	O
of	O
chronic	O
myeloid	O
leukaemia	O
.	O

Synergistic	O
interactions	O
between	O
overlapping	O
binding	O
sites	O
for	O
the	O
serum	O
response	O
factor	O
and	O
ELK-1	O
proteins	O
mediate	O
both	O
basal	O
enhancement	O
and	O
phorbol	O
ester	O
responsiveness	O
of	O
primate	O
cytomegalovirus	O
major	O
immediate-early	O
promoters	O
in	O
monocyte	O
and	O
T-lymphocyte	O
cell	O
types	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
is	O
nonpermissive	O
or	O
persistent	O
in	O
many	O
lymphoid	O
and	O
myeloid	O
cell	O
types	O
but	O
can	O
be	O
activated	O
in	O
differentiated	O
macrophages	O
.	O

We	O
have	O
shown	O
elsewhere	O
that	O
both	O
the	O
major	O
immediate-early	O
gene	O
(	O
MIE	O
)	O
and	O
lytic	O
cycle	O
infectious	O
progeny	O
virus	O
expression	O
can	O
be	O
induced	O
in	O
otherwise	O
nonpermissive	O
monocyte-like	O
U-937	O
cell	O
cultures	O
infected	O
with	O
either	O
human	O
CMV	O
(	O
HCMV	O
)	O
or	O
simian	O
CMV	O
(	O
SCMV	O
)	O
by	O
treatment	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Two	O
multicopy	O
basal	O
enhancer	O
motifs	O
within	O
the	O
SCMV	O
MIE	O
enhancer	O
,	O
namely	O
,	O
11	O
copies	O
of	O
the	O
16-bp	O
cyclic	O
AMP	O
response	O
element	O
(	O
CRE	O
)	O
and	O
3	O
copies	O
of	O
novel	O
17-bp	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
binding	O
sites	O
referred	O
to	O
as	O
the	O
SNE	O
(	O
SRF/NFkappaB-like	O
element	O
)	O
,	O
as	O
well	O
as	O
four	O
classical	O
NFkappaB	O
sites	O
within	O
the	O
HCMV	O
version	O
,	O
contribute	O
to	O
TPA	O
responsiveness	O
in	O
transient	O
assays	O
in	O
monocyte	O
and	O
T-cell	O
types	O
.	O

The	O
SCMV	O
SNE	O
sites	O
contain	O
potential	O
overlapping	O
core	O
recognition	O
binding	O
motifs	O
for	O
SRF	O
,	O
Rel/NFkappaB	O
,	O
ETS	O
,	O
and	O
YY1	O
class	O
transcription	O
factors	O
but	O
fail	B-Negation
to	I-Negation
respond	I-Negation
to	I-Negation
either	I-Negation
serum	I-Negation
or	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha	I-Negation
.	O

Therefore	O
,	O
to	O
evaluate	O
the	O
mechanism	O
of	O
TPA	O
responsiveness	O
of	O
the	O
SNE	O
motifs	O
and	O
of	O
a	O
related	O
16-bp	O
SEE	O
(	O
SRF/ETS	O
element	O
)	O
motif	O
found	O
in	O
the	O
HCMV	O
and	O
chimpanzee	O
CMV	O
MIE	O
enhancers	O
,	O
we	O
have	O
examined	O
the	O
functional	O
responses	O
and	O
protein	O
binding	O
properties	O
of	O
multimerized	O
wild-type	O
and	O
mutant	O
elements	O
added	O
upstream	O
to	O
the	O
SCMV	O
MIE	O
or	O
simian	O
virus	O
40	O
minimal	O
promoter	O
regions	O
in	O
the	O
U-937	O
,	O
K-562	O
,	O
HL-60	O
,	O
THP-1	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

Unlike	O
classical	O
NFkappaB	O
sites	O
,	O
neither	B-Negation
the	I-Negation
SNE	I-Negation
nor	I-Negation
the	I-Negation
SEE	I-Negation
motif	I-Negation
responded	I-Negation
to	I-Negation
phosphatase	I-Negation
inhibition	I-Negation
by	I-Negation
okadaic	I-Negation
acid	I-Negation
.	O

However	O
,	O
the	O
TPA	O
responsiveness	O
of	O
both	O
CMV	O
elements	O
proved	O
to	O
involve	O
synergistic	O
interactions	O
between	O
the	O
core	O
SRF	O
binding	O
site	O
(	O
CCATATATGG	O
)	O
and	O
the	O
adjacent	O
inverted	O
ETS	O
binding	O
motifs	O
(	O
TTCC	O
)	O
,	O
which	O
correlated	O
directly	O
with	O
formation	O
of	O
a	O
bound	O
tripartite	O
complex	O
containing	O
both	O
the	O
cellular	O
SRF	O
and	O
ELK-1	O
proteins	O
.	O

This	O
protein	O
complex	O
was	O
more	O
abundant	O
in	O
U-937	O
,	O
K-562	O
,	O
and	O
HeLa	O
cell	O
extracts	O
than	O
in	O
Raji	O
,	O
HF	O
,	O
BALB/c	O
3T3	O
,	O
or	O
HL-60	O
cells	O
,	O
but	O
the	O
binding	O
activity	O
was	O
altered	O
only	O
twofold	O
after	O
TPA	O
treatment	O
.	O

A	O
40-fold	O
stimulation	O
of	O
chloramphenicol	O
acetyltransferase	O
activity	O
mediated	O
by	O
four	O
tandem	O
repeats	O
of	O
the	O
SNE	O
could	O
be	O
induced	O
within	O
2	O
h	O
(	O
and	O
up	O
to	O
250-fold	O
within	O
6	O
h	O
)	O
after	O
addition	O
of	O
TPA	O
in	O
DNA-transfected	O
U-937	O
cells	O
,	O
indicating	O
that	O
the	O
stimulation	O
appeared	O
likely	O
to	O
be	O
a	O
true	O
protein	O
kinase	O
C-mediated	O
signal	O
transduction	O
event	O
rather	O
than	O
a	O
differentiation	O
response	O
.	O

Slight	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
core	O
SRF	O
binding	O
site	O
compared	O
with	O
that	O
of	O
the	O
classical	O
c-Fos	O
promoter	O
serum	O
response	O
element	O
,	O
together	O
with	O
differences	O
in	O
the	O
spacing	O
between	O
the	O
SRF	O
and	O
ETS	O
motifs	O
,	O
appear	O
to	O
account	O
for	O
the	O
inability	O
of	O
the	O
SCMV	O
SNEs	O
to	O
respond	O
to	O
serum	O
induction	O
.	O

Acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
inhibit	O
LPS-induced	O
NF-kappa	O
B/c-Rel	O
nuclear	O
translocation	O
,	O
and	O
synthesis	O
of	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
tumor	O
necrosis	O
factor	O
alfa	O
(	O
TNF-alpha	O
)	O
in	O
human	O
monocytes	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
acetylsalicylic	O
acid	O
and	O
sodium	O
salicylate	O
on	O
the	O
LPS-induced	O
synthesis	O
of	O
the	O
pro-coagulant	O
protein	O
tissue	O
factor	O
(	O
TF	O
)	O
and	O
the	O
pro-inflammatory	O
protein	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
,	O
as	O
well	O
as	O
the	O
prostaglandin	O
PGE2	O
in	O
human	O
monocytes	O
.	O

Both	O
drugs	O
dose-dependently	O
inhibited	O
LPS-induced	O
TF	O
and	O
TNF-alpha	O
synthesis	O
at	O
the	O
mRNA	O
and	O
the	O
protein	O
level	O
,	O
and	O
reduced	O
PGE2	O
production	O
.	O

As	O
evidenced	O
by	O
electro	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
the	O
use	O
of	O
a	O
NF-kappa	O
B	O
prototypic	O
probe	O
,	O
these	O
drugs	O
probably	O
exert	O
their	O
inhibitory	O
effects	O
by	O
interference	O
with	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B/c-Rel	O
proteins	O
.	O

These	O
data	O
may	O
expand	O
the	O
understanding	O
of	O
the	O
anti-thrombotic	O
and	O
anti-inflammatory	O
effects	O
of	O
these	O
drugs	O
when	O
activation	O
of	O
monocytes	O
occurs	O
.	O

Octamer	O
independent	O
activation	O
of	O
transcription	O
from	O
the	O
kappa	O
immunoglobulin	O
germline	O
promoter	O
.	O

Previous	O
analyses	O
of	O
immunoglobulin	O
V	O
region	O
promoters	O
has	O
led	O
to	O
the	O
discovery	O
of	O
a	O
common	O
octamer	O
motif	O
which	O
is	O
functionally	O
important	O
in	O
the	O
tissue-specific	O
and	O
developmentally	O
regulated	O
transcriptional	O
activation	O
of	O
immunoglobulin	O
genes	O
.	O

The	O
germline	O
promoters	O
(	O
Ko	O
)	O
located	O
upstream	O
of	O
the	O
J	O
region	O
gene	O
segments	O
of	O
the	O
kappa	O
locus	O
also	O
contain	O
an	O
octamer	O
motif	O
(	O
containing	O
a	O
single	O
base	O
pair	O
mutation	O
and	O
referred	O
to	O
as	O
the	O
variant	O
octamer	O
)	O
which	O
has	O
been	O
shown	O
previously	O
to	O
bind	O
Oct-1	O
and	O
Oct-2	O
transcription	O
factors	O
in	O
vitro	O
.	O

To	O
further	O
elucidate	O
the	O
role	O
of	O
this	O
variant	O
octamer	O
motif	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
from	O
the	O
unrearranged	O
kappa	O
locus	O
,	O
we	O
have	O
quantitated	O
the	O
relative	O
binding	O
affinity	O
of	O
Oct-1	O
and	O
Oct-2	O
for	O
the	O
variant	O
octamer	O
motif	O
and	O
determined	O
the	O
functional	O
role	O
of	O
this	O
octamer	O
motif	O
in	O
transcriptional	O
activation	O
.	O

We	O
find	O
that	O
,	O
although	O
the	O
variant	O
octamer	O
motif	O
binds	O
Oct-1	O
and	O
Oct-2	O
in	O
vitro	O
with	O
5-fold	O
lower	O
affinity	O
than	O
the	O
consensus	O
octamer	O
motif	O
,	O
mutation	O
of	O
the	O
variant	O
octamer	O
motif	O
to	O
either	O
a	O
consensus	O
octamer	O
or	O
non-octamer	O
motif	O
has	O
no	B-Negation
effect	I-Negation
on	I-Negation
transcriptional	I-Negation
activation	I-Negation
from	I-Negation
the	I-Negation
germline	I-Negation
promoter	I-Negation
.	O

We	O
also	O
find	O
significant	O
differences	O
in	O
activation	O
of	O
germline	O
and	O
V	O
region	O
promoters	O
by	O
kappa	O
enhancers	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
germline	O
promoters	O
and	O
V	O
region	O
promoters	O
differ	O
in	O
their	O
dependence	O
on	O
octamer	O
for	O
activation	O
and	O
respond	O
differently	O
to	O
enhancer	O
activation	O
.	O

These	O
findings	O
have	O
important	O
implications	O
in	O
regulation	O
of	O
germline	O
transcription	O
as	O
well	O
as	O
concomitant	O
activation	O
of	O
the	O
V-J	O
recombination	O
of	O
the	O
kappa	O
light	O
chain	O
locus	O
.	O

Characterization	O
of	O
the	O
murine	O
cyclin-dependent	O
kinase	O
inhibitor	O
gene	O
p27Kip1	O
.	O

The	O
cyclin-dependent	O
kinase	O
inhibitor	O
p27Kip1	O
plays	O
an	O
important	O
role	O
in	O
regulating	O
cell-cycle	O
progression	O
.	O

p27Kip1	O
directly	O
inhibits	O
the	O
catalytic	O
activity	O
of	O
cyclin/cdks	O
(	O
cyclin-dependent	O
kinase	O
)	O
complexes	O
and/or	O
interferes	O
physically	O
with	O
cyclin/cdks	O
activation	O
by	O
CAK	O
.	O

Interestingly	O
,	O
the	O
expression	O
level	O
of	O
p27Kip1	O
mRNA	O
was	O
maximal	O
in	O
resting	O
Go	O
T-cells	O
and	O
rapidly	O
declined	O
following	O
anti-CD3	O
activation	O
.	O

We	O
report	O
here	O
the	O
cloning	O
of	O
p27Kip1	O
gene	O
from	O
murine	O
genomic	O
DNA	O
and	O
the	O
functional	O
analysis	O
of	O
the	O
promoter	O
of	O
the	O
p27Kip1	O
gene	O
.	O

The	O
gene	O
consists	O
of	O
at	O
least	O
three	O
exons	O
and	O
spans	O
more	O
than	O
5.6	O
kb	O
of	O
DNA	O
.	O

Primer	O
extension	O
and	O
nuclease	O
S1	O
protection	O
analysis	O
revealed	O
two	O
major	O
transcription	O
initiation	O
sites	O
.	O

The	O
promoter	O
region	O
lacked	B-Negation
a	I-Negation
TATA	I-Negation
box	I-Negation
but	O
contained	O
potential	O
binding	O
sites	O
for	O
the	O
transcriptional	O
factors	O
including	O
two	O
Sp1	O
,	O
CRE	O
,	O
Myb	O
and	O
NFkB	O
located	O
at	O
positions	O
-153	O
,	O
-178	O
,	O
-286	O
,	O
-875	O
,	O
and	O
-1011	O
,	O
respectively	O
.	O

To	O
analyze	O
the	O
regulatory	O
mechanisms	O
controlling	O
p27Kip1	O
gene	O
expression	O
,	O
we	O
characterized	O
the	O
5'-flanking	O
region	O
from	O
nt	O
-1609	O
to	O
+178	O
.	O

The	O
-326	O
to	O
-615	O
region	O
contained	O
positive	O
regulatory	O
elements	O
.	O

Glucocorticoid-mediated	O
inhibition	O
of	O
RANTES	O
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O

The	O
chemokine	O
RANTES	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
inflammatory	O
diseases	O
including	O
asthma	O
and	O
rhinitis	O
which	O
are	O
frequently	O
treated	O
with	O
glucocorticoids	O
.	O

We	O
observed	O
that	O
dexamethasone	O
dramatically	O
inhibited	O
RANTES	O
mRNA	O
expression	O
dose	O
dependently	O
in	O
anti-CD3	O
activated	O
Hut-78	O
T	O
cells	O
and	O
human	O
PBMCs	O
.	O

Inhibition	B-Negation
of	I-Negation
RANTES	I-Negation
expression	I-Negation
did	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
be	I-Speculation
secondary	I-Speculation
to	I-Speculation
IL-2	I-Speculation
inhibition	I-Speculation
and	I-Speculation
required	I-Speculation
binding	I-Speculation
to	I-Speculation
the	I-Speculation
intracellular	I-Speculation
glucocorticoid	I-Speculation
receptor	I-Speculation
.	O

The	O
down-regulation	O
of	O
RANTES	O
expression	O
by	O
glucocorticoids	O
in	O
T	O
cells	O
may	O
directly	O
contribute	O
to	O
the	O
efficacy	O
of	O
these	O
agents	O
in	O
suppressing	O
cellular	O
infiltration	O
and	O
to	O
their	O
anti-inflammatory	O
properties	O
.	O

A	O
novel	O
SP-1	O
site	O
in	O
the	O
human	O
interleukin-1	O
beta	O
promoter	O
confers	O
preferential	O
transcriptional	O
activity	O
in	O
keratinocytes	O
.	O

To	O
investigate	O
the	O
mechanisms	O
of	O
transcriptional	O
activation	O
of	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
in	O
non-monocytic	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
reporter	O
plasmids	O
with	O
the	O
bacterial	O
chloramphenicol	O
acetyltransferase	O
gene	O
linked	O
to	O
various	O
parts	O
of	O
the	O
human	O
IL-1beta	O
promoter	O
and	O
performed	O
transient	O
transfection	O
experiments	O
.	O

We	O
identified	O
a	O
promoter	O
segment	O
that	O
activates	O
transcription	O
most	O
efficiently	O
in	O
keratinocytes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
with	O
a	O
43-mer	O
oligonucleotide	O
derived	O
from	O
the	O
functionally	O
identified	O
cis-acting	O
element	O
revealed	O
specific	O
complexes	O
.	O

By	O
competition	O
analysis	O
with	O
transcription	O
factor	O
consensus	O
sequence	O
oligonucleotides	O
and	O
by	O
immunosupershift	O
,	O
transcription	O
factor	O
SP-1	O
or	O
a	O
closely	O
related	O
protein	O
was	O
shown	O
to	O
bind	O
to	O
this	O
regulatory	O
element	O
.	O

The	O
closest	O
match	O
to	O
the	O
known	O
SP-1	O
consensus	O
sequence	O
within	O
the	O
respective	O
region	O
is	O
a	O
TCCCCTCCCCT	O
motif	O
.	O

Mutation	O
of	O
this	O
motif	O
almost	O
completely	O
,	O
and	O
specifically	O
,	O
abolished	O
the	O
binding	O
of	O
two	O
low-mobility	O
complexes	O
and	O
led	O
to	O
a	O
95	O
%	O
decrease	O
of	O
constitutive	O
transcriptional	O
activation	O
of	O
a	O
reporter	O
construct	O
IL-1beta	O
(	O
-170/+108	O
)	O
.	O

Likewise	O
,	O
activation	O
of	O
this	O
reporter	O
construct	O
by	O
tumor	O
necrosis	O
factor-alpha	O
depended	O
on	O
the	O
SP-1	O
site	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
so-far-unrecognized	O
SP-1	O
site	O
in	O
the	O
human	O
IL-1beta	O
promoter	O
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
this	O
gene	O
in	O
keratinocytes	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
lymphocyte	O
activation	O
in	O
patients	O
with	O
steroid-sensitive	O
and	O
steroid-resistant	O
asthma	O
.	O

BACKGROUND	O
:	O
Glucocorticoids	O
are	O
important	O
medications	O
used	O
to	O
control	O
the	O
airway	O
inflammation	O
associated	O
with	O
asthma	O
.	O

Synthetic	O
glucocorticoids	O
vary	O
in	O
their	O
binding	O
affinity	O
for	O
the	O
glucocorticoid	O
receptor	O
(	O
GCR	O
)	O
.	O

METHODS	O
:	O
We	O
compared	O
hydrocortisone	O
,	O
beclomethasone	O
dipropionate	O
,	O
triamcinolone	O
acetonide	O
,	O
flunisolide	O
,	O
and	O
budesonide	O
with	O
regard	O
to	O
their	O
capacity	O
to	O
inhibit	O
phytohemagglutinin-induced	O
peripheral	O
blood	O
mononuclear	O
cell	O
proliferation	O
from	O
six	O
patients	O
with	O
steroid-sensitive	O
asthma	O
and	O
seven	O
patients	O
with	O
steroid-resistant	O
asthma	O
.	O

Peripheral	O
blood	O
mononuclear	O
cell	O
GCR	O
binding	O
affinities	O
for	O
dexamethasone	O
and	O
budesonide	O
were	O
also	O
determined	O
for	O
both	O
patient	O
groups	O
by	O
using	O
a	O
radioligand	O
binding	O
assay	O
and	O
Scatchard	O
analysis	O
.	O

RESULTS	O
:	O
Dose-dependent	O
inhibition	O
was	O
demonstrated	O
for	O
all	O
glucocorticoids	O
in	O
both	O
patient	O
groups	O
,	O
with	O
the	O
steroid-resistant	O
group	O
requiring	O
approximately	O
2	O
log-fold	O
more	O
glucocorticoids	O
for	O
an	O
equivalent	O
degree	O
of	O
inhibition	O
.	O

The	O
mean	O
concentrations	O
necessary	O
to	O
cause	O
50	O
%	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50s	O
)	O
for	O
the	O
steroid-sensitive	O
group	O
ranged	O
from	O
2	O
x	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
budesonide	O
to	O
7	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
hydrocortisone	O
,	O
whereas	O
the	O
mean	O
IC50s	O
for	O
the	O
steroid-resistant	O
group	O
ranged	O
from	O
approximately	O
2	O
x	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
budesonide	O
to	O
greater	O
than	O
10	O
(	O
-6	O
)	O
mol/L	O
for	O
hydrocortisone	O
.	O

In	O
addition	O
,	O
a	O
significant	O
correlation	O
was	O
noted	O
between	O
the	O
degree	O
of	O
inhibition	O
of	O
lymphocyte	O
proliferation	O
(	O
IC50	O
)	O
and	O
the	O
binding	O
affinity	O
of	O
dexamethasone	O
to	O
the	O
GCR	O
.	O

Patients	O
with	O
steroid-resistant	O
asthma	O
have	O
been	O
shown	O
to	O
have	O
a	O
reduced	O
GCR	O
binding	O
affinity	O
.	O

The	O
GCR	O
binding	O
affinity	O
for	O
budesonide	O
was	O
significantly	O
higher	O
in	O
both	O
groups	O
(	O
i.e.	O
,	O
lower	O
dissociation	O
constant	O
)	O
than	O
that	O
obtained	O
for	O
dexamethasone	O
.	O

CONCLUSION	O
:	O
These	O
data	O
suggest	O
that	O
glucocorticoids	O
such	O
as	O
budesonide	O
,	O
by	O
virtue	O
of	O
their	O
high	O
GCR	O
binding	O
affinities	O
and	O
greater	O
ability	O
to	O
suppress	O
lymphocyte	O
proliferation	O
,	O
may	O
therefore	O
be	O
beneficial	O
in	O
the	O
management	O
of	O
difficult-to-control	O
asthma	O
.	O

Involvement	O
of	O
nuclear	O
factor-kappa	O
B	O
activation	O
in	O
IgE	O
synthesis	O
in	O
human	O
B	O
cells	O
.	O

Nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
a	O
transcription	O
factor	O
that	O
binds	O
to	O
the	O
consensus	O
DNA	O
sequence	O
in	O
the	O
cis-acting	O
elements	O
of	O
various	O
genes	O
.	O

Although	O
NF-kappa	O
B	O
activates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
,	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
NF-kappa	O
B	O
activation	O
in	O
the	O
induction	O
of	O
IgE	O
synthesis	O
in	O
human	O
B	O
cells	O
.	O

Therefore	O
we	O
first	O
examined	O
the	O
participation	O
of	O
NF-kappa	O
B	O
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O

Stimulation	O
of	O
DND39	O
cells	O
with	O
IL-4	O
or	O
anti-CD40	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
activated	O
phosphatidylinositol	O
3-kinase	O
and	O
subsequently	O
induced	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
,	O
which	O
was	O
identified	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

n-Acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
blocked	O
NF-kappa	O
B	O
activation	O
caused	O
by	O
IL-4	O
and	O
by	O
anti-CD40	O
mAb	O
.	O

Although	O
inhibition	O
of	O
IL-4-driven	O
germline	O
C	O
epsilon	O
transcription	O
by	O
NAC	O
was	O
not	B-Negation
sufficient	I-Negation
,	O
the	O
agent	O
remarkably	O
diminished	O
anti-CD40	O
mAb-mediated	O
up-regulation	O
of	O
germline	O
C	O
epsilon	O
transcription	O
.	O

Second	O
,	O
we	O
studied	O
the	O
effect	O
of	O
NAC	O
on	O
IgE	O
synthesis	O
in	O
human	O
normal	O
B	O
cells	O
costimulated	O
with	O
IL-4	O
and	O
anti-CD40	O
mAb	O
.	O

NAC	O
was	O
effective	O
in	O
inhibiting	O
mature	O
C	O
epsilon	O
transcription	O
and	O
IgE	O
synthesis	O
in	O
the	O
T	O
cell-independent	O
culture	O
system	O
.	O

However	O
,	O
NAC	O
did	O
not	O
significantly	O
affect	O
the	O
spontaneous	O
production	O
of	O
IgE	O
by	O
atopic	O
B	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
NF-kappa	O
B	O
activity	O
is	O
commonly	O
inducible	O
in	O
DND39	O
cells	O
by	O
IL-4	O
and	O
anti-CD40	O
mAb	O
and	O
suggest	O
that	O
NF-kappa	O
B	O
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
IgE	O
synthesis	O
in	O
B	O
cells	O
.	O

[	O
Molecular	O
mechanisms	O
of	O
age-related	O
lymphocyte	O
dysfunction	O
]	O

Aging	O
is	O
classically	O
accompanied	O
by	O
a	O
dysregulation	O
of	O
the	O
immunologic	O
machinery	O
.	O

As	O
a	O
consequence	O
,	O
the	O
immune	O
response	O
developed	O
in	O
senescent	O
organisms	O
is	O
usually	O
inappropriate	O
,	O
often	O
inefficient	O
,	O
sometimes	O
aberrant	O
,	O
and	O
potentially	O
detrimental	O
.	O

The	O
age-associated	O
immune	O
dysfunction	O
may	O
be	O
implicated	O
to	O
some	O
degree	O
in	O
the	O
extreme	O
susceptibility	O
of	O
the	O
elderly	O
to	O
infection	O
and	O
neoplasia	O
and	O
may	O
even	O
participate	O
in	O
various	O
aspects	O
of	O
senescence	O
.	O

The	O
current	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
underlying	O
immunosenescence	O
is	O
still	O
fragmentary	O
.	O

The	O
most	O
extensively	O
studied	O
phenomenon	O
is	O
the	O
progressive	O
decline	O
in	O
the	O
proliferative	O
capacities	O
of	O
T	O
lymphocytes	O
with	O
aging	O
.	O

The	O
loss	O
of	O
proliferative	O
potential	O
in	O
response	O
to	O
antigenic	O
challenge	O
is	O
a	O
characteristic	O
feature	O
of	O
immune	O
senescence	O
.	O

It	O
is	O
directly	O
implicated	O
in	O
the	O
emergence	O
of	O
the	O
age-related	O
immune	O
deficiency	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
show	O
how	O
the	O
accumulation	O
of	O
various	O
biochemical	O
lesions	O
with	O
advancing	O
age	O
leads	O
to	O
the	O
failure	O
of	O
a	O
critical	O
cell	O
function	O
,	O
namely	O
the	O
activation-induced	O
lymphocyte	O
proliferation	O
.	O

The	O
biochemical	O
modifications	O
responsible	O
for	O
the	O
defect	O
in	O
transduction	O
and	O
execution	O
of	O
the	O
proliferative	O
signal	O
are	O
analyzed	O
as	O
a	O
function	O
of	O
age	O
.	O

The	O
multiple	O
alterations	O
observed	O
on	O
the	O
various	O
biochemical	O
pathways	O
may	O
appear	O
as	O
a	O
consequence	O
of	O
a	O
unique	O
deleterious	O
mechanism	O
more	O
fundamentally	O
related	O
to	O
the	O
process	O
of	O
senescence	O
such	O
as	O
the	O
inability	O
to	O
cope	O
with	O
oxidative	O
stress	O
.	O

Stimulation	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
zinc	O
and	O
related	O
cations	O
.	O

Zinc	O
is	O
an	O
important	O
trace	O
element	O
for	O
immune	O
function	O
.	O

Here	O
,	O
we	O
show	O
that	O
zinc	O
addition	O
in	O
a	O
serum-	O
and	O
lipopolysaccharide-free	O
cell	O
culture	O
system	O
leads	O
to	O
significantly	O
enhanced	O
levels	O
of	O
interleukin	O
1	O
beta	O
(	O
IL-1	O
beta	O
)	O
and	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
and	O
to	O
expression	O
of	O
the	O
corresponding	O
mRNA	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Structurally	O
related	O
divalent	O
cations	O
like	O
cobalt	O
,	O
nickel	O
,	O
and	O
mercury	O
also	O
partially	O
increase	O
monokine	O
secretion	O
but	O
to	O
a	O
much	O
lower	O
and	O
thus	O
insignificant	O
extent	O
.	O

They	O
fail	B-Negation
to	I-Negation
induce	I-Negation
mRNA	I-Negation
of	I-Negation
TNF-alpha	I-Negation
after	I-Negation
3	I-Negation
h	I-Negation
of	I-Negation
culture	I-Negation
.	O

Therefore	O
,	O
monokine	O
induction	O
is	O
a	O
zinc-specific	O
effect	O
influenced	O
by	O
the	O
physicochemical	O
properties	O
of	O
the	O
ion	O
.	O

Confirmation	O
of	O
the	O
unique	O
significance	O
of	O
zinc	O
for	O
immune	O
function	O
provides	O
a	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
specific	O
zinc-mediated	O
immune	O
modulation	O
.	O

Sequence	O
analysis	O
and	O
expression	O
in	O
cultured	O
lymphocytes	O
of	O
the	O
human	O
FOSB	O
gene	O
(	O
G0S3	O
)	O
.	O

G0S3	O
is	O
a	O
member	O
of	O
a	O
set	O
of	O
putative	O
G0/G1	O
switch	O
regulatory	O
genes	O
(	O
G0S	O
genes	O
)	O
selected	O
by	O
screening	O
cDNA	O
libraries	O
prepared	O
from	O
human	O
blood	O
mononuclear	O
cells	O
cultured	O
for	O
2	O
hr	O
with	O
lectin	O
and	O
cycloheximide	O
.	O

The	O
sequence	O
shows	O
high	O
homology	O
with	O
the	O
murine	O
FOSB	O
gene	O
,	O
which	O
encodes	O
a	O
component	O
of	O
the	O
AP1	O
transcriptional	O
regulator	O
.	O

Comparison	O
of	O
cDNA	O
and	O
genomic	O
sequences	O
reveals	O
a	O
4-exon	O
structure	O
characteristic	O
of	O
the	O
FOS	O
family	O
of	O
genes	O
.	O

Freshly	O
isolated	O
cells	O
show	O
high	O
levels	O
of	O
FOSB/G0S3	O
and	O
FOS/G0S7	O
mRNAs	O
,	O
which	O
decline	O
rapidly	O
during	O
incubation	O
in	O
culture	O
medium	O
.	O

The	O
kinetics	O
of	O
expression	O
suggest	O
that	O
the	O
high	O
initial	O
levels	O
are	O
caused	O
by	O
the	O
isolation	O
procedure	O
,	O
and	O
do	O
not	O
reflect	O
constitutive	O
expression	O
.	O

In	O
cells	O
preincubated	O
for	O
a	O
day	O
,	O
levels	O
of	O
FOS	O
mRNA	O
reach	O
a	O
maximum	O
20	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
3	O
hr	O
.	O

Levels	O
of	O
FOSB	O
mRNA	O
reach	O
a	O
maximum	O
40	O
min	O
after	O
the	O
addition	O
of	O
lectin	O
and	O
decline	O
to	O
control	O
levels	O
over	O
the	O
next	O
6	O
hr	O
.	O

In	O
freshly	O
isolated	O
cells	O
,	O
both	O
FOS	O
and	O
FOSB	O
mRNAs	O
increase	O
dramatically	O
in	O
response	O
to	O
the	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
.	O

In	O
preincubated	O
cells	O
,	O
the	O
cycloheximide	O
response	O
is	O
decreased	O
,	O
especially	O
in	O
the	O
case	O
of	O
FOSB	O
.	O

These	O
differences	O
in	O
expression	O
of	O
FOS	O
and	O
FOSB	O
suggest	O
different	O
roles	O
and	O
regulation	O
.	O

Regions	O
of	O
low	O
base	O
order-dependent	O
stem-loop	O
potential	O
in	O
the	O
region	O
of	O
the	O
gene	O
are	O
defined	O
.	O

These	O
indicate	O
where	O
base	O
order	O
has	O
been	O
adapted	O
for	O
purposes	O
other	O
than	O
stem-loop	O
stability	O
(	O
e.g.	O
,	O
encoding	O
proteins	O
or	O
gene	O
regulation	O
)	O
.	O

Regions	O
of	O
low	O
potential	O
in	O
a	O
68.5-kb	O
genomic	O
segment	O
containing	O
the	O
FOSB	O
gene	O
suggest	O
that	O
the	O
potential	O
may	O
help	O
locate	O
genes	O
in	O
uncharted	O
DNA	O
sequences	O
.	O

Signaling	O
via	O
IL-2	O
and	O
IL-4	O
in	O
JAK3-deficient	O
severe	O
combined	O
immunodeficiency	O
lymphocytes	O
:	O
JAK3-dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
IL-2	O
and	O
IL-4	O
bind	O
to	O
receptors	O
containing	O
the	O
common	O
gamma	O
chain	O
and	O
JAK3	O
.	O

Although	O
JAK3	O
is	O
required	O
for	O
proper	O
lymphoid	O
development	O
,	O
the	B-Negation
precise	I-Negation
roles	I-Negation
of	I-Negation
this	I-Negation
kinase	I-Negation
in	I-Negation
IL-2	I-Negation
and	I-Negation
IL-4	I-Negation
signaling	I-Negation
in	I-Negation
lymphocytes	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
defined	I-Negation
.	O

Here	O
,	O
we	O
have	O
studied	O
IL-2	O
and	O
IL-4	O
signaling	O
in	O
B	O
cell	O
lines	O
lacking	B-Negation
JAK3	I-Negation
.	O

Although	O
IL-2-induced	O
phosphorylation	O
of	O
IL-2R	O
beta	O
,	O
JAK1	O
,	O
and	O
STAT5	O
all	O
required	O
the	O
presence	O
of	O
JAK3	O
,	O
IL-4-mediated	O
phosphorylation	O
of	O
JAK1	O
,	O
STAT6	O
,	O
and	O
insulin	O
receptor	O
substrates	O
1	O
and	O
2	O
did	O
not	B-Negation
.	O

However	O
,	O
IL-4-induced	O
effects	O
were	O
clearly	O
improved	O
following	O
JAK3	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
IL-4	O
signaling	O
occurs	O
in	O
the	O
absence	O
of	O
of	O
JAK3	O
,	O
but	O
is	O
comparatively	O
inefficient	O
.	O

These	O
findings	O
may	O
help	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
the	O
immunodeficiency	O
that	O
occurs	O
with	O
mutations	O
of	O
JAK3	O
and	O
may	O
suggest	O
a	O
mechanism	O
for	O
the	O
pleiotropic	O
effects	O
of	O
IL-4	O
.	O

Identification	O
of	O
Bcd	O
,	O
a	O
novel	O
proto-oncogene	O
expressed	O
in	O
B-cells	O
.	O

A	O
novel	O
B-cell	O
derived	O
(	O
Bcd	O
)	O
oncogene	O
has	O
been	O
isolated	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
one	O
B-cell	O
chronic	O
lymphocytic	O
leukemia	O
(	O
B-CLL	O
)	O
patient	O
using	O
DNA	O
transfer	O
and	O
a	O
mouse	O
tumorigenicity	O
assay	O
.	O

The	O
Bcd	O
proto-oncogene	O
was	O
activated	O
by	O
a	O
truncation	O
in	O
the	O
5	O
'	O
UTR	O
.	O

It	O
predicts	O
for	O
two	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
.	O

ORF1	O
consists	O
of	O
240	O
bp	O
that	O
would	O
encode	O
80	O
amino	O
acids	O
,	O
while	O
the	O
major	O
ORF2	O
consists	O
of	O
648	O
bp	O
capable	O
of	O
coding	O
for	O
216	O
amino	O
acids	O
.	O

Predicted	O
peptide	O
sequence	O
of	O
ORF2	O
contained	O
a	O
zinc	O
finger	O
domain	O
which	O
showed	O
significant	O
homology	O
to	O
GC	O
box	O
binding	O
proteins	O
BTEB2	O
and	O
SP1	O
.	O

Transfection	O
of	O
an	O
expression	O
vector	O
containing	O
ORF2	O
but	O
not	B-Negation
full	I-Negation
length	I-Negation
cDNA	I-Negation
was	O
able	O
to	O
transform	O
NIH3T3	O
cells	O
and	O
induce	O
tumors	O
in	O
nude	O
mice	O
.	O

Bcd	O
mRNA	O
transcripts	O
of	O
<	O
or	O
=	O
2.6	O
kb	O
were	O
selectively	O
expressed	O
in	O
PBL	O
and	O
testis	O
of	O
healthy	O
individuals	O
.	O

Within	O
the	O
PBL	O
,	O
Bcd	O
gene	O
expression	O
was	O
restricted	O
to	O
CD19+	O
B-cells	O
and	O
absent	O
from	O
CD14+	O
monocytes	O
and	O
T-cells	O
.	O

Bcd	O
transcripts	O
were	O
detected	O
in	O
all	O
normal	O
PBL	O
samples	O
tested	O
but	O
not	B-Negation
in	I-Negation
several	I-Negation
malignant	I-Negation
human	I-Negation
B-cell	I-Negation
lines	I-Negation
and	O
not	B-Negation
in	I-Negation
50	I-Negation
%	I-Negation
of	I-Negation
B-cells	I-Negation
from	I-Negation
B-CLL	I-Negation
patients	I-Negation
.	O

However	O
,	O
stimulation	O
of	O
B-cells	O
from	O
B-CLL	O
patients	O
under	O
conditions	O
which	O
induced	O
differentiation	O
into	O
plasma	O
cells	O
was	O
associated	O
with	O
induction	O
of	O
Bcd	O
gene	O
expression	O
.	O

The	O
Bcd	O
gene	O
may	O
therefore	O
play	O
an	O
important	O
role	O
in	O
B-cell	O
growth	O
and	O
development	O
.	O

Pancreatic	O
development	O
and	O
maturation	O
of	O
the	O
islet	O
B	O
cell	O
.	O

Studies	O
of	O
pluripotent	O
islet	O
cultures	O
.	O

Pancreas	O
organogenesis	O
is	O
a	O
highly	O
regulated	O
process	O
,	O
in	O
which	O
two	O
anlage	O
evaginate	O
from	O
the	O
primitive	O
gut	O
.	O

They	O
later	O
fuse	O
,	O
and	O
,	O
under	O
the	O
influence	O
of	O
the	O
surrounding	O
mesenchyme	O
,	O
the	O
mature	O
organ	O
develops	O
,	O
being	O
mainly	O
composed	O
of	O
ductal	O
,	O
exocrine	O
and	O
endocrine	O
compartments	O
.	O

Early	O
buds	O
are	O
characterized	O
by	O
a	O
branching	O
morphogenesis	O
of	O
the	O
ductal	O
epithelium	O
from	O
which	O
endocrine	O
and	O
exocrine	O
precursor	O
cells	O
bud	O
to	O
eventually	O
form	O
the	O
two	O
other	O
compartments	O
.	O

The	O
three	O
compartments	O
are	O
thought	O
to	O
be	O
of	O
common	O
endodermal	O
origin	O
;	O
in	O
contrast	O
to	O
earlier	O
hypotheses	O
,	O
which	O
suggested	O
that	O
the	O
endocrine	O
compartment	O
was	O
of	O
neuroectodermal	O
origin	O
.	O

It	O
is	O
thus	O
generally	O
believed	O
that	O
the	O
pancreatic	O
endocrine-lineage	O
possesses	O
the	O
ability	O
to	O
mature	O
along	O
a	O
differentiation	O
pathway	O
that	O
shares	O
many	O
characteristics	O
with	O
those	O
of	O
neuronal	O
differentiation	O
.	O

During	O
recent	O
years	O
,	O
studies	O
of	O
insulin-gene	O
regulation	O
and	O
,	O
in	O
particular	O
,	O
the	O
tissue-specific	O
transcriptional	O
control	O
of	O
insulin-gene	O
activity	O
have	O
provided	O
information	O
on	O
pancreas	O
development	O
in	O
general	O
.	O

The	O
present	O
review	O
summarizes	O
these	O
findings	O
,	O
with	O
a	O
special	O
focus	O
on	O
our	O
own	O
studies	O
on	O
pluripotent	O
endocrine	O
cultures	O
of	O
rat	O
pancreas	O
.	O

Induction	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
by	O
low-density	O
lipoprotein	O
.	O

Low-density	O
lipoprotein	O
(	O
LDL	O
)	O
is	O
a	O
well-established	O
risk	O
factor	O
for	O
atherosclerosis	O
.	O

When	O
endothelial	O
cells	O
are	O
incubated	O
with	O
this	O
lipoprotein	O
in	O
pathophysiologic	O
amounts	O
,	O
the	O
cells	O
are	O
activated	O
.	O

Among	O
the	O
documented	O
cellular	O
responses	O
to	O
LDL	O
is	O
increased	O
recruitment	O
of	O
monocytes	O
,	O
which	O
are	O
believed	O
to	O
play	O
a	O
major	O
role	O
in	O
promoting	O
intimal	O
plaque	O
formation	O
.	O

The	O
findings	O
presented	O
here	O
link	O
an	O
atheogenic	O
lipoprotein	O
,	O
LDL	O
,	O
with	O
the	O
induction	O
of	O
an	O
adhesion	O
molecule	O
important	O
in	O
atherogenesis	O

Human	O
LDL	O
induces	O
the	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
transcriptionally	O
with	O
an	O
increase	O
in	O
mRNA	O
levels	O
through	O
activation	O
of	O
the	O
VCAM	O
promoter	O
.	O

This	O
effect	O
is	O
blocked	O
by	O
anti-VCAM	O
antibodies	O
.	O

After	O
a	O
2-day	O
incubation	O
in	O
LDL	O
,	O
the	O
binding	O
of	O
NF-kappa	O
B	O
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
key	O
oxidative-stress	O
sensor	O
for	O
VCAM	O
regulation	O
,	O
remains	O
at	O
basal	O
level	O
.	O

In	O
contrast	O
,	O
the	O
binding	O
activities	O
of	O
AP-1	O
and	O
GATA	O
,	O
on	O
the	O
other	O
hand	O
,	O
are	O
increased	O
by	O
LDL	O
.	O

Thus	O
,	O
a	O
component	O
of	O
LDL-enhanced	O
endothelial	O
recruitment	O
of	O
monocytes	O
is	O
attributed	O
to	O
VCAM-1	O
expression	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
through	O
AP-1	O
and	O
GATA	O
.	O

These	O
data	O
identify	O
LDL	O
as	O
a	O
VCAM-inducer	O
possibly	O
distinct	O
from	O
cytokines	O
and	O
endotoxin	O
.	O

The	O
NF-kappa	O
B	O
inhibitor	O
,	O
tepoxalin	O
,	O
suppresses	O
surface	O
expression	O
of	O
the	O
cell	O
adhesion	O
molecules	O
CD62E	O
,	O
CD11b/CD18	O
and	O
CD106	O
.	O

Tepoxalin	O
,	O
a	O
dual	O
enzyme	O
inhibitor	O
of	O
cyclooxygenase	O
and	O
5-lipoxygenase	O
has	O
been	O
shown	O
to	O
inhibit	O
T-cell	O
activation	O
.	O

Its	O
immunosuppressive	O
property	O
is	O
distinct	O
from	O
cyclosporin	O
because	O
only	O
tepoxalin	O
,	O
but	O
not	B-Negation
cyclosporin	I-Negation
,	O
suppresses	O
NF-kappa	O
B	O
activation	O
.	O

Here	O
we	O
report	O
that	O
tepoxalin	O
selectively	O
inhibits	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
,	O
CD54	O
)	O
/MAC-1	O
(	O
CD11b/CD18	O
)	O
dependent	O
adhesion	O
of	O
polymorphonuclear	O
cells	O
to	O
IL-1	O
activated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

The	O
mechanism	O
of	O
inhibition	O
is	O
related	O
to	O
the	O
surface	O
expression	O
of	O
several	O
cell	O
adhesion	O
molecules	O
.	O

Flow	O
cytometry	O
analyses	O
on	O
cultured	O
cells	O
that	O
were	O
treated	O
with	O
tepoxalin	O
or	O
antisense	O
oligonucleotides	O
to	O
the	O
P65/p50	O
subunit	O
of	O
NF-kappa	O
B	O
,	O
and	O
then	O
stimulated	O
with	O
PMA	O
,	O
revealed	O
a	O
reduced	O
expression	O
of	O
CD11b/CD18	O
on	O
monocytic	O
HL60	O
cells	O
,	O
and	O
endothelial	O
adhesion	O
molecule-1	O
(	O
CD62E	O
)	O
and	O
vascular	O
adhesion	O
molecule-1	O
(	O
CD106	O
)	O
on	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
.	O

Expression	O
of	O
other	O
adhesion	O
molecules	O
such	O
as	O
lymphocyte	O
function	O
associated-antigen-1	O
(	O
CD11a/CD18	O
)	O
and	O
CD54	O
were	O
unaffected	O
.	O

Tepoxalin	O
also	O
inhibited	O
the	O
secretion	O
of	O
a	O
NF-kappa	O
B	O
regulated	O
chemokine	O
,	O
IL-8	O
,	O
a	O
known	O
inducer	O
of	O
CD11b/CD18	O
expression	O
.	O

Thus	O
the	O
suppression	O
of	O
CD11b/CD18	O
expression	O
by	O
tepoxalin	O
may	O
involve	O
IL-8	O
.	O

Our	O
results	O
suggest	O
that	O
by	O
inhibiting	O
NF-kappa	O
B	O
activation	O
,	O
surface	O
expression	O
of	O
several	O
adhesion	O
molecules	O
can	O
be	O
modulated	O
and	O
that	O
tepoxalin	O
may	O
be	O
useful	O
in	O
treating	O
selected	O
adhesion	O
mediated	O
events	O
such	O
as	O
leukocyte	O
migration	O
or	O
atherosclerotic	O
plaque	O
formation	O
.	O

Expression	O
of	O
erythroid-specific	O
genes	O
in	O
megakaryoblastic	O
disorders	O
.	O

Currently	O
available	O
data	O
indicate	O
that	O
erythroid	O
and	O
megakaryocytic	O
differentiation	O
pathways	O
are	O
closely	O
related	O
to	O
each	O
other	O
,	O
and	O
there	O
may	O
exist	O
progenitor	O
cells	O
common	O
to	O
those	O
two	O
lineages	O
may	O
exist	O
.	O

Acute	O
megakaryoblastic	O
leukemia	O
(	O
AML-M7	O
)	O
and	O
transient	O
myeloproliferative	O
disorder	O
in	O
Down	O
's	O
syndrome	O
(	O
TMD	O
)	O
are	O
characterized	O
by	O
rapid	O
growth	O
of	O
abnormal	O
blast	O
cells	O
which	O
express	O
megakaryocytic	O
markers	O
.	O

These	O
blast	O
cells	O
express	O
lineage-specific	O
transcription	O
factors	O
such	O
as	O
GATA-1	O
common	O
to	O
these	O
lineages	O
and	O
frequently	O
express	O
erythroid-specific	O
mRNAs	O
such	O
as	O
gamma-globin	O
and	O
erythroid	O
delta-aminolevulinate	O
synthase	O
(	O
ALAS-E	O
)	O
,	O
indicating	O
that	O
most	O
of	O
the	O
blasts	O
in	O
M7	O
and	O
TMD	O
cases	O
have	O
erythroid	O
and	O
megakaryocytic	O
phenotypes	O
.	O

These	O
results	O
suggest	O
that	O
blasts	O
in	O
M7	O
and	O
TMD	O
may	O
correspond	O
to	O
progenitors	O
of	O
both	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

Nuclear	O
NF-ATp	O
is	O
a	O
hallmark	O
of	O
unstimulated	O
B	O
cells	O
from	O
B-CLL	O
patients	O
.	O

B	O
lymphocytes	O
from	O
the	O
peripheral	O
blood	O
of	O
patients	O
with	O
chronic	O
lymphocytic	O
leukaemia	O
(	O
CLL	O
)	O
were	O
analysed	O
for	O
the	O
nuclear	O
presence	O
and	O
DNA	O
binding	O
of	O
a	O
panel	O
of	O
transcription	O
factors	O
which	O
are	O
involved	O
in	O
the	O
gene	O
control	O
of	O
lymphoid	O
cells	O
.	O

The	O
following	O
transcription	O
factors	O
were	O
studied	O
:	O
the	O
Octamer	O
factors	O
Oct-1	O
and	O
Oct-2	O
,	O
members	O
of	O
the	O
AP-1	O
factor	O
family	O
,	O
NF-AT	O
factors	O
,	O
in	O
particular	O
NF-ATp	O
,	O
and	O
members	O
of	O
the	O
Rel/NF-kB	O
family	O
.	O

We	O
show	O
that	O
the	O
constitutive	O
nuclear	O
translocation	O
of	O
NF-ATp	O
,	O
a	O
member	O
of	O
the	O
growing	O
family	O
of	O
NF-AT	O
factors	O
,	O
is	O
a	O
hallmark	O
of	O
nonstimulated	O
B	O
cells	O
from	O
CLL	O
patients	O
that	O
distinguishes	O
B-CLL	O
cells	O
from	O
'	O
normal	O
'	O
B	O
lymphocytes	O
.	O

Constitutive	O
nuclear	O
appearance	O
was	O
also	O
observed	O
for	O
NF-kB2/p52	O
.	O

Constitutive	O
binding	O
of	O
further	O
factor	O
proteins	O
to	O
DNA	O
,	O
such	O
as	O
JunD	O
,	O
c-Fos	O
and	O
FosB	O
,	O
was	O
detected	O
in	O
several	O
patients	O
whereas	O
the	O
localisation	O
and	O
DNA	O
binding	O
of	O
other	O
factors	O
such	O
as	O
c-Jun	O
,	O
RelA/p65	O
and	O
c-Rel	O
was	O
unaltered	O
.	O

It	O
is	O
remarkable	O
that	O
in	O
B-CLL	O
cells	O
the	O
nuclear	O
appearance	O
and	O
DNA	O
binding	O
of	O
specific	O
transcription	O
factors	O
is	O
dramatically	O
affected	O
whereas	O
other	O
members	O
of	O
the	O
same	O
factor	O
family	O
remained	O
unaltered	O
in	O
these	O
leukemic	O
cells	O
.	O

It	O
remains	O
to	O
be	O
shown	O
which	O
molecular	O
events	O
lead	O
to	O
the	O
specific	O
'	O
pre-activation	O
'	O
,	O
i.e.	O
constitutive	O
nuclear	O
translocation	O
and	O
DNA	O
binding	O
,	O
of	O
these	O
members	O
of	O
NF-AT	O
,	O
NF-kB	O
and	O
AP-1	O
factor	O
families	O
.	O

[	O
The	O
value	O
of	O
the	O
clinical	O
test	O
of	O
glucocorticoid	O
receptors	O
of	O
peripheral	O
blood	O
leukocytes	O
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
]	O

In	O
order	O
to	O
inquire	O
into	O
the	O
functional	O
state	O
of	O
adrenal	O
cortex	O
in	O
patients	O
with	O
pulmonary	O
heart	O
disease	O
,	O
the	O
number	O
of	O
glucocorticoid	O
receptors	O
(	O
GCR	O
)	O
of	O
peripheral	O
blood	O
leukocytes	O
in	O
patients	O
with	O
chronic	O
pulmonary	O
heart	O
disease	O
was	O
determined	O
with	O
radioligand-binding	O
assay	O
and	O
the	O
corresponding	O
plasma	O
cortisol	O
levels	O
were	O
assessed	O
with	O
radioimmune	O
assays	O
.	O

The	O
results	O
showed	O
that	O
the	O
number	O
of	O
GCR	O
in	O
the	O
patients	O
was	O
significantly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
and	O
it	O
was	O
increased	O
when	O
their	O
health	O
state	O
was	O
improved	O
.	O

However	O
,	O
it	O
was	O
still	O
lower	O
than	O
that	O
in	O
healthy	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

The	O
number	O
of	O
GCR	O
in	O
the	O
patients	O
was	O
greatly	O
increased	O
when	O
these	O
patients	O
were	O
treated	O
with	O
oxygen	O
(	O
P	O
<	O
0.01	O
)	O
.	O

No	O
difference	O
in	O
plasma	O
cortisol	O
was	O
found	O
between	O
the	O
patients	O
and	O
the	O
healthy	O
subjects	O
(	O
P	O
>	O
0.05	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
function	O
of	O
adrenal	O
cortex	O
may	O
be	O
improved	O
by	O
the	O
compensation	O
mechanism	O
of	O
the	O
patients	O
,	O
but	O
the	O
lower	O
GCR	O
number	O
was	O
the	O
result	O
of	O
lacking	O
of	O
oxygen	O
in	O
the	O
patients	O
.	O

The	O
number	O
of	O
GCR	O
may	O
be	O
improved	O
by	O
inhalation	O
of	O
oxygen	O
.	O

Therefore	O
oxygen	O
therapy	O
is	O
helpful	O
in	O
raising	O
the	O
activity	O
of	O
glucocorticoid	O
receptors	O
and	O
controlling	O
the	O
development	O
of	O
the	O
disease	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
subunit	O
p65	O
mRNA	O
accumulation	O
in	O
lipopolysaccharide-stimulated	O
human	O
monocytic	O
cells	O
treated	O
with	O
sodium	O
salicylate	O
.	O

Lipopolysaccharide	O
is	O
one	O
of	O
the	O
most	O
potent	O
trigger	O
substances	O
for	O
monocytes	O
and	O
macrophages	O
causing	O
secretion	O
of	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor	O
and	O
interleukin-1	O
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factors	O
involved	O
in	O
regulation	O
of	O
these	O
cytokine	O
genes	O
is	O
still	O
unknown	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
;	O
heterodimer	O
of	O
p50	O
and	O
p65	O
)	O
proteins	O
have	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
gene	O
transcription	O
of	O
inflammatory	O
mediators	O
when	O
monocytes	O
are	O
stimulated	O
with	O
lipopolysaccharide	O
.	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
such	O
as	O
salicylates	O
have	O
been	O
used	O
to	O
treat	O
symptoms	O
of	O
inflammation	O
,	O
and	O
a	O
new	O
mechanism	O
of	O
drug	O
action	O
was	O
suggested	O
recently	O
.	O

Salicylates	O
have	O
been	O
shown	O
to	O
inhibit	O
lipopolysaccharide-induced	O
gene	O
transcription	O
via	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
NF-kappa	O
B	O
inhibitor	O
``	O
I	O
kappa	O
B	O
``	O
,	O
blocking	O
the	O
translocation	O
of	O
NF-kappa	O
B	O
into	O
the	O
nuclear	O
compartment	O
.	O

However	O
,	O
the	B-Negation
nature	I-Negation
of	I-Negation
the	I-Negation
subunit	I-Negation
involved	I-Negation
in	I-Negation
this	I-Negation
mechanism	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
defined	I-Negation
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
salicylates	O
affect	O
cytokine	O
gene	O
transcription	O
,	O
the	O
amount	O
of	O
active	O
and	O
inactive	O
NF-kappa	O
B	O
and	O
NF-kappa	O
B	O
mRNA	O
,	O
in	O
Porphyromonas	O
gingivalis	O
lipopolysaccharide-stimulated	O
human	O
monocytic	O
cells	O
was	O
assessed	O
.	O

High	O
doses	O
of	O
sodium	O
salicylate	O
suppressed	O
NF-kappa	O
B	O
p65	O
mRNA	O
accumulation	O
,	O
resulting	O
in	O
suppression	O
of	O
total	O
NF-kappa	O
B	O
,	O
p50	O
on	O
tissue	O
oligonucleotide	O
had	O
no	B-Negation
effects	I-Negation
on	I-Negation
lipopolysaccharide-induced	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
.	O

The	O
data	O
demonstrate	O
that	O
the	O
p65	O
subunit	O
of	O
NF-kappa	O
B	O
is	O
inhibited	O
by	O
salicylate	O
treatment	O
and	O
highlight	O
the	O
role	O
of	O
salicylate	O
in	O
the	O
control	O
of	O
gene	O
expression	O
of	O
inflammatory	O
mediators	O
.	O

Lack	B-Negation
of	I-Negation
T-cell-mediated	I-Negation
recognition	I-Negation
of	I-Negation
the	I-Negation
fusion	I-Negation
region	I-Negation
of	I-Negation
the	I-Negation
pml/RAR-alpha	I-Negation
hybrid	I-Negation
protein	I-Negation
by	I-Negation
lymphocytes	I-Negation
of	I-Negation
acute	I-Negation
promyelocytic	I-Negation
leukemia	I-Negation
patients	I-Negation
.	O

In	O
previous	O
studies	O
,	O
it	O
was	O
shown	O
that	O
the	O
fusion	O
region	O
of	O
the	O
pml/RAR-alpha	O
protein	O
,	O
expressed	O
by	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
cells	O
,	O
can	O
be	O
specifically	O
recognized	O
in	O
vitro	O
by	O
donor	O
(	O
D.	O
E.	O
)	O
CD4	O
T	O
cells	O
in	O
a	O
HLA	O
class	O
II	O
DR11-restricted	O
fashion	O
.	O

We	O
present	O
here	O
the	O
results	O
on	O
the	O
recognition	O
of	O
several	O
pml/RAR-alpha	O
peptides	O
by	O
APL	O
patients	O
expressing	O
HLA	O
DR11	O
.	O

The	O
in	O
vitro	O
immunization	O
of	O
peripheral	O
blood	O
lymphocytes	O
from	O
four	O
patients	O
in	O
remission	O
(	O
S.R.	O
,	O
F.R.	O
,	O
M.M.	O
,	O
P.	O
G.	O
)	O
with	O
BCR1/25	O
,	O
a	O
25-mer	O
pml/RAR-alpha	O
,	O
did	O
not	B-Negation
elicit	I-Negation
either	I-Negation
a	I-Negation
polyclonal	I-Negation
or	I-Negation
a	I-Negation
clonal	I-Negation
immune	I-Negation
response	I-Negation
specific	I-Negation
to	I-Negation
the	I-Negation
peptide	I-Negation
.	O

We	O
then	O
generated	O
new	O
donor	O
anti-pml/RAR-alpha	O
CD4	O
(	O
+	O
)	O
T-cell	O
clones	O
.	O

These	O
clones	O
were	O
tested	O
for	O
their	O
recognition	O
of	O
BCR1/25	O
.	O

One	O
clone	O
(	O
C3/5	O
,	O
CD3	O
(	O
+	O
)	O
,	O
CD4	O
(	O
+	O
)	O
,	O
CD8	O
(	O
-	O
)	O
)	O
was	O
selected	O
for	O
further	O
analysis	O
.	O

Clone	O
C3/5	O
showed	O
specific	O
proliferation	O
,	O
cytotoxicity	O
,	O
and	O
cytokine	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
)	O
production	O
when	O
challenged	O
with	O
autologous	O
lymphoblastic	O
cell	O
lines	O
pulsed	O
with	O
peptide	O
BCR1/25	O
.	O

C3/5	O
cells	O
developed	O
specific	O
proliferation	O
and	O
cytotoxicity	O
when	O
challenged	O
with	O
peptide-pulsed	O
lymphoblastic	O
cell	O
lines	O
and	O
peripheral	O
blood	O
lymphocytes	O
from	O
the	O
four	O
DR11	O
(	O
+	O
)	O
APL	O
patients	O
.	O

APL	B-Negation
blasts	I-Negation
,	I-Negation
available	I-Negation
only	I-Negation
from	I-Negation
patients	I-Negation
F.R.	I-Negation
and	I-Negation
P.G.	I-Negation
,	I-Negation
were	I-Negation
not	I-Negation
lysed	I-Negation
by	I-Negation
C3/5	I-Negation
and	O
were	O
unable	B-Negation
to	I-Negation
present	I-Negation
peptide	I-Negation
BCR1/25	I-Negation
.	O

Incubation	O
of	O
APL	O
cells	O
with	O
IFN-gamma	O
failed	B-Negation
to	I-Negation
induce	I-Negation
HLA	I-Negation
class	I-Negation
II	I-Negation
molecules	I-Negation
and	O
recognition	O
by	O
the	O
C3/5	O
clone	O
.	O

Since	O
APL	O
cells	O
do	O
not	B-Negation
express	I-Negation
HLA	I-Negation
class	I-Negation
II	I-Negation
molecules	I-Negation
,	O
we	O
tested	O
in	O
two	O
donors	O
(	O
D.E.	O
and	O
C.H.R.	O
)	O
and	O
in	O
patients	O
S.R.and	O
P.G.whether	O
the	I-Speculation
use	I-Speculation
of	I-Speculation
9-mer	I-Speculation
peptides	I-Speculation
(	I-Speculation
BCR1/9	I-Speculation
)	I-Speculation
would	I-Speculation
generate	I-Speculation
a	I-Speculation
CD8/HLA	I-Speculation
class	I-Speculation
I-restricted	I-Speculation
response	I-Speculation
.	O

No	B-Negation
peptide-specific	I-Negation
T-cell	I-Negation
line	I-Negation
or	I-Negation
clone	I-Negation
could	I-Negation
be	I-Negation
generated	I-Negation
from	I-Negation
both	I-Negation
donors	I-Negation
and	I-Negation
patients	I-Negation
.	O

These	O
findings	O
are	O
discussed	O
in	O
relation	O
to	O
possible	O
therapeutic	O
approaches	O
to	O
the	O
immunotherapy	O
of	O
APL	O
.	O

Reactive	O
oxygen	O
intermediate-dependent	O
NF-kappaB	O
activation	O
by	O
interleukin-1beta	O
requires	O
5-lipoxygenase	O
or	O
NADPH	O
oxidase	O
activity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
role	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
in	O
NF-kappaB	O
activation	O
by	O
proinflammatory	O
cytokines	O
was	O
cell	O
specific	O
.	O

However	O
,	O
the	O
sources	O
for	O
ROIs	O
in	O
various	O
cell	O
types	O
are	O
yet	O
to	O
be	O
determined	O
and	O
might	O
include	O
5-lipoxygenase	O
(	O
5-LOX	O
)	O
and	O
NADPH	O
oxidase	O
.	O

5-LOX	O
and	O
5-LOX	O
activating	O
protein	O
(	O
FLAP	O
)	O
are	O
coexpressed	O
in	O
lymphoid	O
cells	O
but	O
not	B-Negation
in	I-Negation
monocytic	I-Negation
or	I-Negation
epithelial	I-Negation
cells	I-Negation
.	O

Stimulation	O
of	O
lymphoid	O
cells	O
with	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
led	O
to	O
ROI	O
production	O
and	O
NF-kappaB	O
activation	O
,	O
which	O
could	O
both	O
be	O
blocked	O
by	O
antioxidants	O
or	O
FLAP	O
inhibitors	O
,	O
confirming	O
that	O
5-LOX	O
was	O
the	O
source	O
of	O
ROIs	O
and	O
was	O
required	O
for	O
NF-kappaB	O
activation	O
in	O
these	O
cells	O
.	O

IL-1beta	O
stimulation	O
of	O
epithelial	O
cells	O
did	O
not	B-Negation
generate	I-Negation
any	I-Negation
ROIs	I-Negation
and	O
NF-kappaB	B-Negation
induction	I-Negation
was	I-Negation
not	I-Negation
influenced	I-Negation
by	I-Negation
5-LOX	I-Negation
inhibitors	I-Negation
.	O

However	O
,	O
reintroduction	O
of	O
a	O
functional	O
5-LOX	O
system	O
in	O
these	O
cells	O
allowed	O
ROI	O
production	O
and	O
5-LOX-dependent	O
NF-kappaB	O
activation	O
.	O

In	O
monocytic	O
cells	O
,	O
IL-1beta	O
treatment	O
led	O
to	O
a	O
production	O
of	O
ROIs	O
which	O
is	O
independent	O
of	O
the	O
5-LOX	O
enzyme	O
but	O
requires	O
the	O
NADPH	O
oxidase	O
activity	O
.	O

This	O
pathway	O
involves	O
the	O
Rac1	O
and	O
Cdc42	O
GTPases	O
,	O
two	O
enzymes	O
which	B-Negation
are	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
by	I-Negation
IL-1beta	I-Negation
in	I-Negation
epithelial	I-Negation
cells	I-Negation
.	O

In	O
conclusion	O
,	O
three	O
different	O
cell-specific	O
pathways	O
lead	O
to	O
NF-kappaB	O
activation	O
by	O
IL-1beta	O
:	O
a	O
pathway	O
dependent	O
on	O
ROI	O
production	O
by	O
5-LOX	O
in	O
lymphoid	O
cells	O
,	O
an	O
ROI-	O
and	O
5-LOX-independent	O
pathway	O
in	O
epithelial	O
cells	O
,	O
and	O
a	O
pathway	O
requiring	O
ROI	O
production	O
by	O
NADPH	O
oxidase	O
in	O
monocytic	O
cells	O
.	O

Activation-dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	O
Fas	O
promoter	O
requires	O
NF-kappaB	O
p50-p65	O
recruitment	O
.	O

Fas	O
(	O
CD95	O
)	O
and	O
Fas	O
ligand	O
(	O
CD95L	O
)	O
are	O
an	O
interacting	O
receptor-ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	O
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL-mediated	O
apoptosis	O
.	O

Although	O
Fas	O
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation-induced	O
Fas	O
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	O
T-cell	O
line	O
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P/I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T-cell	O
receptor	O
activation	O
.	O

Although	O
resting	O
Jurkat	O
cells	O
express	O
Fas	O
,	O
Fas	O
mRNA	O
was	O
induced	O
approximately	O
10-fold	O
in	O
2	O
h	O
upon	O
P/I	O
stimulation	O
.	O

Using	O
sequential	O
deletion	O
mutants	O
of	O
the	O
human	O
fas	O
promoter	O
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	O
sequence	O
(	O
positions	O
-306	O
to	O
-260	O
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	O
composite	O
binding	O
site	O
for	O
both	O
the	O
Sp1	O
and	O
NF-kappaB	O
transcription	O
factors	O
at	O
positions	O
-295	O
to	O
-286	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	O
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50-p65	O
NF-kappaB	O
heterodimers	O
after	O
P/I	O
activation	O
.	O

Sp1	O
and	O
NF-kappaB	O
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	O
and	O
recombinant	O
p50	O
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	O
composite	O
site	O
in	O
P/I-inducible	O
fas	O
promoter	O
activation	O
was	O
verified	O
by	O
using	O
kappaB-Sp1	O
concatamers	O
(	O
-295	O
to	O
-286	O
)	O
in	O
a	O
thymidine	O
kinase	O
promoter-driven	O
reporter	O
construct	O
and	O
native	O
promoter	O
constructs	O
in	O
Jurkat	O
cells	O
overexpressing	O
IkappaB-alpha	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB-Sp1	O
element	O
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation-dependent	O
fas	O
promoter	O
induction	O
.	O

RFLAT-1	O
:	O
a	O
new	O
zinc	O
finger	O
transcription	O
factor	O
that	O
activates	O
RANTES	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

RANTES	O
(	O
Regulated	O
upon	O
Activation	O
,	O
Normal	O
T	O
cell	O
Expressed	O
and	O
Secreted	O
)	O
is	O
a	O
chemoattractant	O
cytokine	O
(	O
chemokine	O
)	O
important	O
in	O
the	O
generation	O
of	O
inflammatory	O
infiltrate	O
and	O
human	O
immunodeficiency	O
virus	O
entry	O
into	O
immune	O
cells	O
.	O

RANTES	O
is	O
expressed	O
late	O
(	O
3-5	O
days	O
)	O
after	O
activation	O
in	O
T	O
lymphocytes	O
.	O

Using	O
expression	O
cloning	O
,	O
we	O
identified	O
the	O
first	O
``	O
late	O
``	O
T	O
lymphocyte	O
associated	O
transcription	O
factor	O
and	O
named	O
it	O
``	O
RANTES	O
Factor	O
of	O
Late	O
Activated	O
T	O
Lymphocytes-1	O
``	O
(	O
RFLAT-1	O
)	O
.	O

RFLAT-1	O
is	O
a	O
novel	O
,	O
phosphorylated	O
,	O
zinc	O
finger	O
transcription	O
factor	O
that	O
is	O
expressed	O
in	O
T	O
cells	O
3	O
days	O
after	O
activation	O
,	O
coincident	O
with	O
RANTES	O
expression	O
.	O

While	O
Rel	O
proteins	O
play	O
the	O
dominant	O
role	O
in	O
RANTES	O
gene	O
expression	O
in	O
fibroblasts	O
,	O
RFLAT-1	O
is	O
a	O
strong	O
transactivator	O
for	O
RANTES	O
in	O
T	O
cells	O
.	O

Interleukin-10	O
inhibits	O
expression	O
of	O
both	O
interferon	O
alpha-	O
and	O
interferon	O
gamma-	O
induced	O
genes	O
by	O
suppressing	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
helps	O
maintain	O
polarized	O
T-helper	O
cells	O
in	O
a	O
T-helper	O
lymphocyte	O
2	O
(	O
Th2	O
)	O
phenotype	O
.	O

Part	O
of	O
this	O
process	O
involves	O
the	O
prevention	O
of	O
the	O
development	O
of	O
Th1	O
cells	O
,	O
which	O
are	O
a	O
primary	O
source	O
of	O
interferon	O
gamma	O
(	O
IFNgamma	O
)	O
,	O
a	O
potent	O
activator	O
of	O
monocytes	O
and	O
an	O
inhibitor	O
of	O
Th2	O
proliferation	O
.	O

Because	O
monocytes	O
and	O
macrophages	O
are	O
important	O
mediators	O
of	O
Th1-type	O
responses	O
,	O
such	O
as	O
delayed-type	O
hypersensitivity	O
,	O
we	O
sought	O
to	O
determine	O
if	O
IL-10	O
could	O
directly	O
mediate	O
inhibition	O
of	O
IFNgamma-	O
and	O
IFNalpha-induced	O
gene	O
expression	O
in	O
these	O
cells	O
.	O

Highly	O
purified	O
monocytes	O
were	O
incubated	O
with	O
IL-10	O
for	O
60	O
to	O
90	O
minutes	O
before	O
the	O
addition	O
of	O
IFNgamma	O
or	O
IFNalpha	O
.	O

IL-10	O
preincubation	O
resulted	O
in	O
the	O
inhibition	O
of	O
gene	O
expression	O
for	O
several	O
IFN-induced	O
genes	O
,	O
such	O
as	O
IP-10	O
,	O
ISG54	O
,	O
and	O
intercellular	O
adhesion	O
molecule-1	O
.	O

The	O
reduction	O
in	O
gene	O
expression	O
resulted	O
from	O
the	O
ability	O
of	O
IL-10	O
to	O
suppress	O
IFN-induced	O
assembly	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
to	O
specific	O
promoter	O
motifs	O
on	O
IFNalpha-	O
and	O
IFNgamma-inducible	O
genes	O
.	O

This	O
was	O
accomplished	O
by	O
preventing	O
the	O
IFN-induced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
a	O
component	O
of	O
both	O
IFNalpha-	O
and	O
IFNgamma-induced	O
DNA	O
binding	O
complexes	O
.	O

Therefore	O
,	O
IL-10	O
can	O
directly	O
inhibit	O
STAT-dependent	O
early	O
response	O
gene	O
expression	O
induced	O
by	O
both	O
IFNalpha	O
and	O
IFNgamma	O
in	O
monocytes	O
by	O
suppressing	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
.	O

This	O
may	O
occur	O
through	O
the	O
ability	O
of	O
IL-10	O
to	O
induce	O
expression	O
of	O
the	O
gene	O
,	O
suppressor	O
of	O
cytokine	O
signaling	O
3	O
(	O
SOCS3	O
)	O
.	O

The	O
Megakaryocyte/Platelet-specific	O
enhancer	O
of	O
the	O
alpha2beta1	O
integrin	O
gene	O
:	O
two	O
tandem	O
AP1	O
sites	O
and	O
the	O
mitogen-activated	O
protein	O
kinase	O
signaling	O
cascade	O
.	O

The	O
alpha2beta1	O
integrin	O
,	O
a	O
collagen	O
receptor	O
on	O
platelets	O
and	O
megakaryocytes	O
,	O
is	O
required	O
for	O
normal	O
platelet	O
function	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
alpha2	O
integrin	O
gene	O
in	O
cells	O
undergoing	O
megakaryocytic	O
differentiation	O
requires	O
a	O
core	O
promoter	O
between	O
bp	O
-30	O
and	O
-92	O
,	O
a	O
silencer	O
between	O
bp	O
-92	O
and	O
-351	O
,	O
and	O
megakaryocytic	O
enhancers	O
in	O
the	O
distal	O
5	O
'	O
flank	O
.	O

We	O
have	O
now	O
identified	O
a	O
229-bp	O
region	O
of	O
the	O
distal	O
5	O
'	O
flank	O
of	O
the	O
alpha2	O
integrin	O
gene	O
required	O
for	O
high-level	O
enhancer	O
activity	O
in	O
cells	O
with	O
megakaryocytic	O
features	O
.	O

Two	O
tandem	O
AP1	O
binding	O
sites	O
with	O
dyad	O
symmetry	O
are	O
required	O
for	O
enhancer	O
activity	O
and	O
for	O
DNA-protein	O
complex	O
formation	O
with	O
members	O
of	O
the	O
c-fos/c-jun	O
family	O
.	O

The	O
requirement	O
for	O
AP1	O
activation	O
suggested	O
a	O
role	O
for	O
the	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
in	O
regulating	O
alpha2	O
integrin	O
gene	O
expression	O
.	O

Inhibition	O
of	O
the	O
MAP	O
kinase	O
cascade	O
with	O
PD98059	O
,	O
a	O
specific	O
inhibitor	O
of	O
MAPK	O
kinase	O
1	O
,	O
prevented	O
the	O
expression	O
of	O
the	O
alpha2	O
integrin	O
subunit	O
in	O
cells	O
induced	O
to	O
become	O
megakaryocytic	O
.	O

We	O
provide	O
a	O
model	O
of	O
megakaryocytic	O
differentiation	O
in	O
which	O
expression	O
of	O
the	O
alpha2	O
integrin	O
gene	O
requires	O
signaling	O
via	O
the	O
MAP	O
kinase	O
pathway	O
to	O
activate	O
two	O
tandem	O
AP1	O
binding	O
sites	O
in	O
the	O
alpha2	O
integrin	O
enhancer	O
.	O

Differential	O
expression	O
and	O
phosphorylation	O
of	O
CTCF	O
,	O
a	O
c-myc	O
transcriptional	O
regulator	O
,	O
during	O
differentiation	O
of	O
human	O
myeloid	O
cells	O
.	O

CTCF	O
is	O
a	O
transcriptional	O
repressor	O
of	O
the	O
c-myc	O
gene	O
.	O

Although	O
CTCF	O
has	O
been	O
characterized	O
in	O
some	O
detail	O
,	O
there	O
is	O
very	O
little	O
information	O
about	O
the	O
regulation	O
of	O
CTCF	O
activity	O
.	O

Therefore	O
we	O
investigated	O
CTCF	O
expression	O
and	O
phosphorylation	O
during	O
induced	O
differentiation	O
of	O
human	O
myeloid	O
leukemia	O
cells	O
.	O

We	O
found	O
that	O
:	O
(	O
i	O
)	O
both	O
CTCF	O
mRNA	O
and	O
protein	O
are	O
down-regulated	O
during	O
terminal	O
differentiation	O
in	O
most	O
cell	O
lines	O
tested	O
;	O
(	O
ii	O
)	O
CTCF	O
down-regulation	O
is	O
retarded	O
and	O
less	O
pronounced	O
than	O
that	O
of	O
c-myc	O
;	O
(	O
iii	O
)	O
CTCF	O
protein	O
is	O
differentially	O
phosphorylated	O
and	O
the	O
phosphorylation	O
profiles	O
depend	O
on	O
the	O
differentiation	O
pathway	O
.	O

We	O
concluded	O
that	O
CTCF	O
expression	O
and	O
activity	O
is	O
controlled	O
at	O
transcriptional	O
and	O
post-transcriptional	O
levels	O
.	O

T-cell	O
expression	O
of	O
the	O
human	O
GATA-3	O
gene	O
is	O
regulated	O
by	O
a	O
non-lineage-specific	O
silencer	O
.	O

The	O
GATA-3	O
transcription	O
factor	O
is	O
required	O
for	O
development	O
of	O
the	O
T-cell	O
lineage	O
and	O
Th2	O
cytokine	O
gene	O
expression	O
in	O
CD4	O
T-cells	O
.	O

We	O
have	O
mapped	O
the	O
DNase-I-hypersensitive	O
(	O
HS	O
)	O
regions	O
of	O
the	O
human	O
GATA-3	O
gene	O
in	O
T-cells	O
and	O
non-T-cells	O
and	O
studied	O
their	O
transcriptional	O
activities	O
.	O

HS	O
I-III	O
,	O
located	O
5	O
'	O
from	O
the	O
transcriptional	O
initiation	O
site	O
,	O
were	O
found	O
in	O
hematopoietic	O
and	O
non-hematopoietic	O
cells	O
,	O
whereas	O
HS	O
IV-VII	O
,	O
located	O
3	O
'	O
from	O
the	O
transcriptional	O
start	O
site	O
,	O
were	O
exclusively	O
observed	O
in	O
T-cells	O
.	O

Among	O
these	O
hypersensitive	O
sites	O
,	O
two	O
transcriptional	O
control	O
elements	O
were	O
found	O
,	O
one	O
in	O
the	O
first	O
intron	O
of	O
the	O
GATA-3	O
gene	O
and	O
the	O
other	O
between	O
8.3	O
and	O
5.9	O
kilobases	O
5	O
'	O
from	O
the	O
GATA-3	O
transcriptional	O
initiation	O
site	O
.	O

The	O
first	O
intron	O
acted	O
as	O
a	O
strong	O
transcriptional	O
activator	O
in	O
a	O
position-dependent	O
manner	O
and	O
with	O
no	B-Negation
cell-type	I-Negation
specificity	I-Negation
.	O

The	O
upstream	O
regulatory	O
element	O
could	O
confer	O
T-cell	O
specificity	O
to	O
the	O
GATA-3	O
promoter	O
activity	O
,	O
and	O
analysis	O
of	O
this	O
region	O
revealed	O
a	O
707-base	O
pair	O
silencer	O
that	O
drastically	O
inhibited	O
GATA-3	O
promoter	O
activity	O
in	O
non-T-cells	O
.	O

Two	O
CAGGTG	O
E-boxes	O
,	O
located	O
at	O
the	O
5'-	O
and	O
3'-ends	O
of	O
the	O
silencer	O
,	O
were	O
necessary	O
for	O
this	O
silencer	O
activity	O
.	O

The	O
3'-CAGGTG	O
E-box	O
could	O
bind	O
USF	O
proteins	O
,	O
the	O
ubiquitous	O
repressor	O
ZEB	O
,	O
or	O
the	O
basic	O
helix-loop-helix	O
proteins	O
E2A	O
and	O
HEB	O
,	O
and	O
we	O
showed	O
that	O
a	O
competition	O
between	O
ZEB	O
and	O
E2A/HEB	O
proteins	O
is	O
involved	O
in	O
the	O
silencer	O
activity	O
.	O

AML	O
and	O
Ets	O
proteins	O
regulate	O
the	O
I	O
alpha1	O
germ-line	O
promoter	O
.	O

The	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
class	O
switch	O
recombination	O
of	O
B	O
lymphocytes	O
preferentially	O
targets	O
unrearranged	O
IgH	O
genes	O
that	O
have	O
already	O
been	O
rendered	O
transcriptionally	O
active	O
.	O

Transcription	O
of	O
the	O
germ-line	O
IgH	O
genes	O
is	O
controlled	O
by	O
intervening	O
(	O
I	O
)	O
regions	O
upstream	O
of	O
their	O
switch	O
regions	O
.	O

The	O
I	O
alpha1	O
promoter	O
activates	O
transcription	O
of	O
the	O
human	O
germ-line	O
C	O
alpha1	O
gene	O
for	O
IgA1	O
and	O
mediates	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-beta1	O
responsiveness	O
of	O
this	O
locus	O
.	O

Here	O
we	O
show	O
that	O
the	O
I	O
alpha1	O
promoter	O
contains	O
several	O
binding	O
sites	O
for	O
the	O
AML/PEBP2/CBF	O
family	O
of	O
transcription	O
factors	O
and	O
that	O
AML	O
and	O
Ets	O
proteins	O
are	O
major	O
regulators	O
of	O
the	O
basal	O
and	O
TGF-beta-inducible	O
promoter	O
activity	O
.	O

Our	O
data	O
constitute	O
a	O
starting	O
point	O
for	O
studies	O
to	O
elucidate	O
the	O
molecular	O
mechanism	O
by	O
which	O
TGF-beta	O
regulates	O
IgA	O
production	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
isolated	O
from	O
patients	O
with	O
diabetic	O
nephropathy	O
show	O
increased	O
activation	O
of	O
the	O
oxidative-stress	O
sensitive	O
transcription	O
factor	O
NF-kappaB	O
.	O

Increased	O
oxidative	O
stress	O
and	O
subsequent	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
has	O
been	O
linked	O
to	O
the	O
development	O
of	O
late	O
diabetic	O
complications	O
.	O

To	O
determine	O
whether	O
oxidative	O
stress	O
dependent	O
NF-kappaB	O
activation	O
is	O
evident	O
in	O
patients	O
with	O
diabetic	O
nephropathy	O
we	O
used	O
an	O
Electrophoretic	O
Mobility	O
Shift	O
Assay	O
based	O
semiquantitative	O
detection	O
system	O
which	O
enabled	O
us	O
to	O
determine	O
NF-kappaB	O
activation	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
examined	O
33	O
patients	O
with	O
diabetes	O
mellitus	O
(	O
Type	O
I	O
and	O
Type	O
II	O
)	O
.	O

Patients	O
with	O
diabetic	O
nephropathy	O
showed	O
higher	O
NF-kappaB	O
binding	O
activity	O
in	O
Electrophoretic	O
Mobility	O
Shift	O
Assays	O
and	O
stronger	O
immunohistological	O
staining	O
for	O
activated	O
NF-kappaBp65	O
than	O
patients	O
without	B-Negation
renal	I-Negation
complications	I-Negation
.	O

NF-kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
degree	O
of	O
albuminuria	O
(	O
r	O
=	O
0.316	O
)	O
and	O
with	O
thrombomodulin	O
plasma	O
concentrations	O
(	O
r	O
=	O
0.33	O
)	O
,	O
indicative	O
for	O
albuminuria	O
associated	O
endothelial	O
dysfunction	O
.	O

In	O
a	O
3	O
day	O
intervention	O
study	O
in	O
which	O
600	O
mg	O
of	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
per	O
day	O
were	O
given	O
to	O
nine	O
patients	O
with	O
diabetic	O
nephropathy	O
oxidative	O
stress	O
in	O
plasma	O
samples	O
was	O
decreased	O
by	O
48	O
%	O
and	O
NF-kappaB	O
binding	O
activity	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
38	O
%	O
.	O

In	O
conclusion	O
,	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
in	O
ex	O
vivo	O
isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
patients	O
with	O
diabetes	O
mellitus	O
correlates	O
with	O
the	O
degree	O
of	O
diabetic	O
nephropathy	O
.	O

NF-kappaB	O
activation	O
is	O
at	O
least	O
in	O
part	O
dependent	O
on	O
oxidative	O
stress	O
since	O
thioctic	O
acid	O
(	O
alpha-lipoic	O
acid	O
)	O
reduced	O
NF-kappaB	O
binding	O
activity	O
.	O

Activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
by	O
Gardnerella	O
vaginalis	O
.	O

Bacterial	O
vaginosis	O
(	O
BV	O
)	O
is	O
associated	O
with	O
an	O
increased	O
rate	O
of	O
sexual	O
transmission	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
type	O
1	O
,	O
and	O
Gardnerella	O
vaginalis	O
is	O
frequently	O
isolated	O
from	O
the	O
genital	O
tracts	O
of	O
women	O
with	O
BV	O
.	O

G.	O
vaginalis	O
lysates	O
were	O
found	O
to	O
significantly	O
stimulate	O
HIV	O
expression	O
in	O
monocytoid	O
cells	O
.	O

Stimulation	O
was	O
significantly	O
higher	O
when	O
lysates	O
were	O
heated	O
at	O
100	O
degrees	O
C	O
for	O
5	O
min	O
but	O
was	O
reduced	O
by	O
treatment	O
with	O
lysozyme	O
or	O
protease	O
.	O

G.	O
vaginalis	O
lysates	O
also	O
activated	O
HIV	O
expression	O
in	O
certain	O
T	O
cell	O
lines	O
.	O

G.	O
vaginalis	O
lysates	O
activated	O
HIV	O
long-terminal	O
repeat	O
transcription	O
in	O
HIV-infected	O
cells	O
and	O
increased	O
NF-kappaB	O
binding	O
activity	O
,	O
indicating	O
an	O
effect	O
by	O
G.	O
vaginalis	O
on	O
HIV	O
transcription	O
.	O

The	O
activation	O
of	O
HIV	O
production	O
by	O
G.	O
vaginalis	O
suggests	O
that	O
genital	O
tract	O
infection	O
with	O
G.	O
vaginalis	O
increases	O
the	O
risk	O
of	O
HIV	O
transmission	O
by	O
increasing	O
HIV	O
expression	O
in	O
the	O
genital	O
tract	O
.	O

This	O
may	O
explain	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
increased	O
rate	O
of	O
HIV	O
transmission	O
in	O
women	O
with	O
BV	O
.	O

Interferon-alpha	O
activates	O
multiple	O
STAT	O
proteins	O
and	O
upregulates	O
proliferation-associated	O
IL-2Ralpha	O
,	O
c-myc	O
,	O
and	O
pim-1	O
genes	O
in	O
human	O
T	O
cells	O
.	O

Interferon-alpha	O
(	O
IFN-alpha	O
)	O
is	O
a	O
pleiotropic	O
cytokine	O
that	O
has	O
antiviral	O
,	O
antiproliferative	O
,	O
and	O
immunoregulatory	O
functions	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
IFN-alpha	O
has	O
an	O
important	O
role	O
in	O
T-cell	O
biology	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
IL-2Ralpha	O
,	O
c-myc	O
,	O
and	O
pim-1	O
genes	O
in	O
anti-CD3-activated	O
human	O
T	O
lymphocytes	O
.	O

The	O
induction	O
of	O
these	O
genes	O
is	O
associated	O
with	O
interleukin-2	O
(	O
IL-2	O
)	O
-induced	O
T-cell	O
proliferation	O
.	O

Treatment	O
of	O
T	O
lymphocytes	O
with	O
IFN-alpha	O
,	O
IL-2	O
,	O
IL-12	O
,	O
and	O
IL-15	O
upregulated	O
IL-2Ralpha	O
,	O
c-myc	O
,	O
and	O
pim-1	O
gene	O
expression	O
.	O

IFN-alpha	O
also	O
sensitized	O
T	O
cells	O
to	O
IL-2-induced	O
proliferation	O
,	O
further	O
suggesting	O
that	O
IFN-alpha	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
T-cell	O
mitogenesis	O
.	O

When	O
we	O
analyzed	O
the	O
nature	O
of	O
STAT	O
proteins	O
capable	O
of	O
binding	O
to	O
IL-2Ralpha	O
,	O
pim-1	O
,	O
and	O
IRF-1	O
GAS	O
elements	O
after	O
cytokine	O
stimulation	O
,	O
we	O
observed	O
IFN-alpha-induced	O
binding	O
of	O
STAT1	O
,	O
STAT3	O
,	O
and	O
STAT4	O
,	O
but	O
not	B-Negation
STAT5	I-Negation
to	O
all	O
of	O
these	O
elements	O
.	O

Yet	O
,	O
IFN-alpha	O
was	O
able	O
to	O
activate	O
binding	O
of	O
STAT5	O
to	O
the	O
high-affinity	O
IFP53	O
GAS	O
site	O
.	O

IFN-alpha	O
enhanced	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
,	O
STAT3	O
,	O
STAT4	O
,	O
STAT5a	O
,	O
and	O
STAT5b	O
.	O

IL-12	O
induced	O
STAT4	O
and	O
IL-2	O
and	O
IL-15	O
induced	O
STAT5	O
binding	O
to	O
the	O
GAS	O
elements	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
IFN-alpha	O
,	O
IL-2	O
,	O
IL-12	O
,	O
and	O
IL-15	O
have	O
overlapping	O
activities	O
on	O
human	O
T	O
cells	O
.	O

These	O
findings	O
thus	O
emphasize	O
the	O
importance	O
of	O
IFN-alpha	O
as	O
a	O
T-cell	O
regulatory	O
cytokine	O
.	O

Anti-rheumatic	O
compound	O
aurothioglucose	O
inhibits	O
tumor	O
necrosis	O
factor-alpha-induced	O
HIV-1	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O

NF-kappaB	O
is	O
a	O
potent	O
cellular	O
activator	O
of	O
HIV-1	O
gene	O
expression	O
.	O

Down-regulation	O
of	O
NF-kappaB	O
activation	O
is	O
known	O
to	O
inhibit	O
HIV	O
replication	O
from	O
the	O
latently	O
infected	O
cells	O
.	O

Gold	O
compounds	O
have	O
been	O
effectively	O
used	O
for	O
many	O
decades	O
in	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

We	O
previously	O
reported	O
that	O
gold	O
compounds	O
,	O
especially	O
aurothioglucose	O
(	O
AuTG	O
)	O
containing	O
monovalent	O
gold	O
ion	O
,	O
inhibited	O
the	O
DNA-binding	O
of	O
NF-kappaB	O
in	O
vitro	O
.	O

In	O
this	O
report	O
we	O
have	O
examined	O
the	O
efficacy	O
of	O
the	O
gold	O
compound	O
AuTG	O
as	O
an	O
inhibitor	O
of	O
HIV	O
replication	O
in	O
latently	O
infected	O
OM10.1	O
and	O
Ach2	O
cells	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha-induced	O
HIV-1	O
replication	O
in	O
OM10.1	O
or	O
Ach2	O
cells	O
was	O
significantly	O
inhibited	O
by	O
non-cytotoxic	O
doses	O
of	O
AuTG	O
(	O
>	O
10	O
microM	O
in	O
OM10.1	O
cells	O
and	O
>	O
25	O
F.M	O
in	O
Ach2	O
cells	O
)	O
,	O
while	O
25	O
microM	O
of	O
the	O
counter-anion	O
thioglucose	O
(	O
TG	O
)	O
or	O
gold	O
compound	O
containing	O
divalent	O
gold	O
ion	O
,	O
HAuCl3	O
,	O
had	O
no	B-Negation
effect	I-Negation
.	O

The	O
effect	O
of	O
AuTG	O
on	O
NF-kappaB-dependent	O
gene	O
expression	O
was	O
confirmed	O
by	O
a	O
transient	O
CAT	O
assay	O
.	O

Specific	O
staining	O
as	O
well	O
as	O
electron	O
microscopic	O
examinations	O
revealed	O
the	O
accumulation	O
of	O
metal	O
gold	O
in	O
the	O
cells	O
,	O
supporting	O
our	O
previous	O
hypothesis	O
that	O
gold	O
ions	O
could	O
block	O
NF-kappaB-DNA	O
binding	O
by	O
a	O
redox	O
mechanism	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
monovalent	O
gold	O
compound	O
AuTG	O
is	O
a	O
potentially	O
useful	O
drug	O
for	O
the	O
treatment	O
of	O
patients	O
infected	O
with	O
HIV	O
.	O

Evidence	O
for	O
suppressed	O
activity	O
of	O
the	O
transcription	O
factor	O
NFAT1	O
at	O
its	O
proximal	O
binding	O
element	O
P0	O
in	O
the	O
IL-4	O
promoter	O
associated	O
with	O
enhanced	O
IL-4	O
gene	O
transcription	O
in	O
T	O
cells	O
of	O
atopic	O
patients	O
.	O

Allergen-specific	O
T	O
cells	O
in	O
atopic	O
patients	O
are	O
polarized	O
IL-4-producing	O
Th2	O
cells	O
,	O
promoting	O
IgE	O
synthesis	O
by	O
B	O
cells	O
.	O

The	O
molecular	O
basis	O
for	O
increased	O
IL-4	O
gene	O
expression	O
in	O
atopy	O
is	O
not	O
fully	O
understood	O
.	O

IL-4	O
gene	O
regulation	O
in	O
general	O
involves	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
of	O
which	O
NFAT1	O
and	O
NFAT2	O
are	O
most	O
prominent	O
in	O
peripheral	O
T	O
cells	O
.	O

Recently	O
,	O
a	O
unique	O
inhibitory	O
role	O
of	O
NFAT1	O
in	O
IL-4	O
gene	O
control	O
was	O
shown	O
in	O
the	O
mouse	O
.	O

In	O
a	O
series	O
of	O
electrophoretic	O
mobility	O
shift	O
assays	O
with	O
protein	O
extracts	O
of	O
highly	O
polarized	O
Th2	O
clones	O
from	O
atopics	O
and	O
Th1	O
clones	O
from	O
controls	O
we	O
compared	O
DNA-binding	O
activities	O
at	O
the	O
two	O
NFAT-binding	O
elements	O
P0	O
and	O
P1	O
of	O
the	O
crucial	O
proximal	O
human	O
IL-4	O
promoter	O
.	O

At	O
the	O
most	O
proximal	O
P0	O
site	O
,	O
NFAT-containing	O
complexes	O
devoid	O
of	O
NFAT2	O
were	O
readily	O
inducible	O
in	O
the	O
Th1	O
clones	O
,	O
but	O
hardly	O
or	O
not	B-Negation
in	I-Negation
the	I-Negation
Th2	I-Negation
clones	I-Negation
.	O

In	O
contrast	O
,	O
both	O
in	O
Th1	O
and	O
Th2	O
clones	O
NFAT-containing	O
complexes	O
were	O
strongly	O
inducible	O
at	O
the	O
P1	O
site	O
,	O
consisting	O
of	O
NFAT2	O
and	O
a	O
P0-compatible	O
NFAT	O
activity	O
,	O
without	B-Negation
apparent	I-Negation
differences	I-Negation
between	I-Negation
Th1	I-Negation
and	I-Negation
Th2	I-Negation
clones	I-Negation
.	O

Like	O
in	O
Th2	O
clones	O
,	O
suppressed	O
NFAT-P0	O
complex	O
formation	O
was	O
observed	O
also	O
at	O
the	O
polyclonal	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
of	O
three	O
of	O
five	O
severe	O
atopic	O
dermatitis	O
patients	O
with	O
strongly	O
elevated	O
serum	O
IgE	O
levels	O
,	O
but	O
not	B-Negation
in	I-Negation
control	I-Negation
PBMC	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
high-level	O
IL-4	O
production	O
in	O
atopic	O
Th2	O
cells	O
is	O
associated	O
with	O
selective	O
reduction	O
of	O
suppressive	O
NFAT1	O
activity	O
at	O
the	O
IL-4	O
P0	O
element	O
and	O
that	O
some	O
patients	O
with	O
this	O
multifactorial	O
disease	O
may	O
have	O
a	O
putative	O
systemic	O
disorder	O
at	O
this	O
level	O
.	O

Nuclear	O
factor-kappa	O
B	O
activity	O
in	O
T	O
cells	O
from	O
patients	O
with	O
rheumatic	O
diseases	O
:	O
a	O
preliminary	O
report	O
.	O

OBJECTIVE	O
:	O
The	O
NF-kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
or	O
inflammatory	O
response	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
distinctive	O
patterns	O
of	O
NF-kappa	O
B	O
activation	O
are	O
seen	O
in	O
different	O
forms	O
of	O
joint	O
disease	O
.	O

METHODS	O
:	O
The	O
DNA	O
binding	O
activity	O
of	O
these	O
nucleoproteins	O
was	O
examined	O
in	O
purified	O
synovial	O
and	O
peripheral	O
T	O
cells	O
from	O
patients	O
with	O
various	O
chronic	O
rheumatic	O
diseases	O
(	O
12	O
:	O
four	O
with	O
rheumatoid	O
arthritis	O
;	O
five	O
with	O
spondyloarthropathies	O
;	O
and	O
three	O
with	O
osteoarthritis	O
)	O
.	O

RESULTS	O
:	O
Electrophoretic	O
mobility	O
shift	O
assays	O
disclosed	O
two	O
specific	O
complexes	O
bound	O
to	O
a	O
NF-kappa	O
B	O
specific	O
32P-labelled	O
oligonucleotide	O
in	O
nucleoproteins	O
extracted	O
from	O
purified	O
T	O
cells	O
isolated	O
from	O
synovial	O
fluid	O
and	O
peripheral	O
blood	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

The	O
complexes	O
consisted	O
of	O
p50/p50	O
homodimers	O
and	O
p50/p65	O
heterodimers	O
.	O

Increased	O
NF-kappa	O
B	O
binding	O
to	O
DNA	O
in	O
synovial	O
T	O
cells	O
was	O
observed	O
relative	O
to	O
peripheral	O
T	O
cells	O
.	O

In	O
non-rheumatoid	O
arthritis	O
,	O
binding	O
of	O
NF-kappa	O
B	O
in	O
synovial	O
T	O
cells	O
was	O
exclusively	O
mediated	O
by	O
p50/p50	O
homodimers	O
.	O

CONCLUSION	O
:	O
Overall	O
,	O
the	O
results	O
suggest	O
that	O
NF-kappa	O
B	O
may	O
play	O
a	O
central	O
part	O
in	O
the	O
activation	O
of	O
infiltrating	O
T	O
cells	O
in	O
chronic	O
rheumatoid	O
arthritis	O
.	O

The	O
activation	O
of	O
this	O
nuclear	O
factor	O
is	O
qualitatively	O
different	O
in	O
rheumatoid	O
synovial	O
T	O
cells	O
to	O
that	O
in	O
other	O
forms	O
of	O
non-rheumatoid	O
arthritis	O
(	O
for	O
example	O
,	O
osteoarthritis	O
,	O
spondyloarthropathies	O
)	O
.	O

N-acetyl-L-cysteine	O
inhibits	O
primary	O
human	O
T	O
cell	O
responses	O
at	O
the	O
dendritic	O
cell	O
level	O
:	O
association	O
with	O
NF-kappaB	O
inhibition	O
.	O

N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
is	O
an	O
antioxidant	O
molecule	O
endowed	O
with	O
immunomodulatory	O
properties	O
.	O

To	O
investigate	O
the	O
effect	O
of	O
NAC	O
on	O
the	O
induction	O
phase	O
of	O
T	O
cell	O
responses	O
,	O
we	O
analyzed	O
its	O
action	O
on	O
human	O
dendritic	O
cells	O
(	O
DC	O
)	O
derived	O
from	O
adherent	O
PBMC	O
cultured	O
with	O
IL-4	O
and	O
granulocyte-macrophage	O
CSF	O
.	O

We	O
first	O
found	O
that	O
NAC	O
inhibited	O
the	O
constitutive	O
as	O
well	O
as	O
the	O
LPS-induced	O
activity	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O

In	O
parallel	O
,	O
NAC	O
was	O
shown	O
to	O
down-regulate	O
the	O
production	O
of	O
cytokines	O
by	O
DC	O
as	O
well	O
as	O
their	O
surface	O
expression	O
of	O
HLA-DR	O
,	O
CD86	O
(	O
B7-2	O
)	O
,	O
and	O
CD40	O
molecules	O
both	O
at	O
the	O
basal	O
state	O
and	O
upon	O
LPS	O
activation	O
.	O

NAC	O
also	O
inhibited	O
DC	O
responses	O
induced	O
by	O
CD40	O
engagement	O
.	O

The	O
inhibitory	O
effects	O
of	O
NAC	O
were	O
not	B-Negation
due	I-Negation
to	I-Negation
nonspecific	I-Negation
toxicity	I-Negation
as	O
neither	B-Negation
the	I-Negation
viability	I-Negation
of	I-Negation
DC	I-Negation
nor	I-Negation
their	I-Negation
mannose	I-Negation
receptor-mediated	I-Negation
endocytosis	I-Negation
were	I-Negation
modified	I-Negation
by	I-Negation
NAC	I-Negation
.	O

Finally	O
,	O
we	O
found	O
that	O
the	O
addition	O
of	O
NAC	O
to	O
MLR	O
between	O
naive	O
T	O
cells	O
and	O
allogeneic	O
DC	O
resulted	O
in	O
a	O
profound	O
inhibition	O
of	O
alloreactive	O
responses	O
,	O
which	B-Speculation
could	I-Speculation
be	I-Speculation
attributed	I-Speculation
to	I-Speculation
a	I-Speculation
defect	I-Speculation
of	I-Speculation
DC	I-Speculation
as	O
APC-independent	B-Negation
T	I-Negation
cell	I-Negation
responses	I-Negation
were	I-Negation
not	I-Negation
inhibited	I-Negation
by	I-Negation
NAC	I-Negation
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NAC	O
might	O
impair	O
the	O
generation	O
of	O
primary	O
immune	O
responses	O
in	O
humans	O
through	O
its	O
inhibitory	O
action	O
on	O
DC	O
.	O

Bacterial	O
lipopolysaccharide	O
activates	O
nuclear	O
factor-kappaB	O
through	O
interleukin-1	O
signaling	O
mediators	O
in	O
cultured	O
human	O
dermal	O
endothelial	O
cells	O
and	O
mononuclear	O
phagocytes	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-mediated	O
immune	O
responses	O
,	O
including	O
activation	O
of	O
monocytes	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
,	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
Gram-negative	O
bacteria-induced	O
sepsis	O
syndrome	O
.	O

Activation	O
of	O
NF-kappaB	O
is	O
thought	O
to	O
be	O
required	O
for	O
cytokine	O
release	O
from	O
LPS-responsive	O
cells	O
,	O
a	O
critical	O
step	O
for	O
endotoxic	O
effects	O
.	O

Here	O
we	O
investigated	O
the	O
role	O
and	O
involvement	O
of	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF-alpha	O
)	O
signal	O
transducer	O
molecules	O
in	O
LPS	O
signaling	O
in	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
HDMEC	O
)	O
and	O
THP-1	O
monocytic	O
cells	O
.	O

LPS	O
stimulation	O
of	O
HDMEC	O
and	O
THP-1	O
cells	O
initiated	O
an	O
IL-1	O
receptor-like	O
NF-kappaB	O
signaling	O
cascade	O
.	O

In	O
transient	O
cotransfection	O
experiments	O
,	O
dominant	O
negative	O
mutants	O
of	O
the	O
IL-1	O
signaling	O
pathway	O
,	O
including	O
MyD88	O
,	O
IRAK	O
,	O
IRAK2	O
,	O
and	O
TRAF6	O
inhibited	O
both	O
IL-1-	O
and	O
LPS-induced	O
NF-kappaB-luciferase	O
activity	O
.	O

LPS-induced	B-Negation
NF-kappaB	I-Negation
activation	I-Negation
was	I-Negation
not	I-Negation
inhibited	I-Negation
by	I-Negation
a	I-Negation
dominant	I-Negation
negative	I-Negation
mutant	I-Negation
of	I-Negation
TRAF2	I-Negation
that	I-Negation
is	I-Negation
involved	I-Negation
in	I-Negation
TNF	I-Negation
signaling	I-Negation
.	O

LPS-induced	B-Negation
activation	I-Negation
of	I-Negation
NF-kappaB-responsive	I-Negation
reporter	I-Negation
gene	I-Negation
was	I-Negation
not	I-Negation
inhibited	I-Negation
by	I-Negation
IL-1	I-Negation
receptor	I-Negation
antagonist	I-Negation
.	O

TLR2	O
and	O
TLR4	O
were	O
expressed	O
on	O
the	O
cell	O
surface	O
of	O
HDMEC	O
and	O
THP-1	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
a	O
signal	O
transduction	O
molecule	O
in	O
the	O
LPS	O
receptor	O
complex	O
may	O
belong	O
to	O
the	O
IL-1	O
receptor/toll-like	O
receptor	O
(	O
TLR	O
)	O
super	O
family	O
,	O
and	O
the	O
LPS	O
signaling	O
cascade	O
uses	O
an	O
analogous	O
molecular	O
framework	O
for	O
signaling	O
as	O
IL-1	O
in	O
mononuclear	O
phagocytes	O
and	O
endothelial	O
cells	O
.	O

Selective	O
activation	O
and	O
functional	O
significance	O
of	O
p38alpha	O
mitogen-activated	O
protein	O
kinase	O
in	O
lipopolysaccharide-stimulated	O
neutrophils	O
.	O

Activation	O
of	O
leukocytes	O
by	O
proinflammatory	O
stimuli	O
selectively	O
initiates	O
intracellular	O
signal	O
transduction	O
via	O
sequential	O
phosphorylation	O
of	O
kinases	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
of	O
human	O
neutrophils	O
is	O
known	O
to	O
result	O
in	O
activation	O
of	O
p38	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPk	O
)	O
;	O
however	O
,	O
the	O
upstream	O
activator	O
(	O
s	O
)	O
of	O
p38	O
MAPk	O
is	O
unknown	O
,	O
and	O
consequences	O
of	O
p38	O
MAPk	O
activation	O
remain	O
largely	O
undefined	O
.	O

We	O
investigated	O
the	O
MAPk	O
kinase	O
(	O
MKK	O
)	O
that	O
activates	O
p38	O
MAPk	O
in	O
response	O
to	O
LPS	O
,	O
the	O
p38	O
MAPk	O
isoforms	O
that	O
are	O
activated	O
as	O
part	O
of	O
this	O
pathway	O
,	O
and	O
the	O
functional	O
responses	O
affected	O
by	O
p38	O
MAPk	O
activation	O
.	O

Although	O
MKK3	O
,	O
MKK4	O
,	O
and	O
MKK6	O
all	O
activated	O
p38	O
MAPk	O
in	O
experimental	O
models	O
,	O
only	O
MKK3	O
was	O
found	O
to	O
activate	O
recombinant	O
p38	O
MAPk	O
in	O
LPS-treated	O
neutrophils	O
.	O

Of	O
p38	O
MAPk	O
isoforms	O
studied	O
,	O
only	O
p38alpha	O
and	O
p38delta	O
were	O
detected	O
in	O
neutrophils	O
.	O

LPS	O
stimulation	O
selectively	O
activated	O
p38alpha	O
.	O

Specific	O
inhibitors	O
of	O
p38alpha	O
MAPk	O
blocked	O
LPS-induced	O
adhesion	O
,	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	O
)	O
activation	O
,	O
and	O
synthesis	O
of	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

Inhibition	O
of	O
p38alpha	O
MAPk	O
resulted	O
in	O
a	O
transient	O
decrease	O
in	O
TNF-alpha	O
mRNA	O
accumulation	O
but	O
persistent	O
loss	O
of	O
TNF-alpha	O
synthesis	O
.	O

These	O
findings	O
support	O
a	O
pathway	O
by	O
which	O
LPS	O
stimulation	O
of	O
neutrophils	O
results	O
in	O
activation	O
of	O
MKK3	O
,	O
which	O
in	O
turn	O
activates	O
p38alpha	O
MAPk	O
,	O
ultimately	O
regulating	O
adhesion	O
,	O
NF-kappaB	O
activation	O
,	O
enhanced	O
gene	O
expression	O
of	O
TNF-alpha	O
,	O
and	O
regulation	O
of	O
TNF-alpha	O
synthesis	O
.	O

Inhibition	O
of	O
IL-4-inducible	O
gene	O
expression	O
in	O
human	O
monocytes	O
by	O
type	O
I	O
and	O
type	O
II	O
interferons	O
.	O

The	O
Th2-type	O
cytokines	O
,	O
interleukin-4	O
(	O
IL-4	O
)	O
and	O
interleukin-13	O
(	O
IL-13	O
)	O
,	O
induce	O
expression	O
of	O
a	O
distinct	O
subset	O
of	O
genes	O
in	O
human	O
monocytes	O
,	O
including	O
FcepsilonRIIb	O
(	O
CD23	O
)	O
,	O
15-lipoxygenase	O
,	O
IL-1	O
receptor	O
antagonist	O
(	O
IL-1ra	O
)	O
,	O
and	O
type	O
I	O
and	O
type	O
II	O
IL-1	O
receptors	O
(	O
IL-1R	O
)	O
.	O

Type	O
I	O
interferons	O
(	O
IFN-alpha	O
and	O
IFN-beta	O
)	O
and	O
type	O
II	O
interferon	O
(	O
IFN-gamma	O
)	O
inhibit	O
induction	O
of	O
these	O
genes	O
by	O
IL-4	O
and	O
IL-13	O
.	O

However	O
,	O
the	B-Negation
mechanism	I-Negation
by	I-Negation
which	I-Negation
IFNs	I-Negation
mediate	I-Negation
this	I-Negation
inhibition	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
defined	I-Negation
.	O

In	O
this	O
overview	O
,	O
we	O
discuss	O
the	O
role	O
of	O
the	O
transcription	O
factor	O
,	O
STAT6	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-6	O
)	O
in	O
mediating	O
IL-4-	O
and	O
IL-13-induced	O
gene	O
expression	O
in	O
monocytes	O
.	O

We	O
also	O
discuss	O
our	O
recent	O
findings	O
that	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
suppress	O
IL-4/IL-13-inducible	O
gene	O
expression	O
by	O
inhibiting	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	O
.	O

The	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
inhibit	O
IL-4/IL-13-induced	O
STAT6	O
activity	O
is	O
dose-	O
and	O
time-dependent	O
,	O
and	O
is	O
not	B-Negation
unique	I-Negation
to	I-Negation
monocytes	I-Negation
because	O
IFNs	O
induce	O
the	O
same	O
effects	O
in	O
fibroblasts	O
.	O

Inhibition	O
of	O
STAT6	O
activity	O
is	O
not	B-Negation
evident	I-Negation
unless	O
cells	O
are	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
h	O
before	O
IL-4	O
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
can	O
be	O
blocked	O
by	O
actinomycin	O
D	O
,	O
indicating	O
a	O
requirement	O
for	O
de	O
novo	O
transcription	O
.	O

We	O
propose	O
a	O
model	O
in	O
which	O
stimulation	O
of	O
monocytes	O
by	O
IFN	O
activates	O
de	O
novo	O
synthesis	O
of	O
an	O
inhibitory	O
factor	O
,	O
possibly	O
one	O
or	O
more	O
members	O
of	O
the	O
SOCS/	O
SSI/CIS	O
gene	O
family	O
,	O
capable	O
of	O
suppressing	O
activation	O
of	O
STAT6	O
by	O
IL-4	O
and	O
IL-13	O
.	O

Because	O
STAT6	O
activation	O
plays	O
an	O
essential	O
role	O
in	O
IL-4/IL-13-induced	O
gene	O
expression	O
,	O
the	O
ability	O
of	O
IFN-beta	O
and	O
IFN-gamma	O
to	O
inhibit	O
STAT6	O
activity	O
provides	O
an	O
explanation	O
for	O
how	O
IFNs	O
can	O
suppress	O
IL-4/IL-13-inducible	O
gene	O
expression	O
.	O

Involvement	O
of	O
NF-kappaB	O
p50/p65	O
heterodimer	O
in	O
activation	O
of	O
the	O
human	O
pro-interleukin-1beta	O
gene	O
at	O
two	O
subregions	O
of	O
the	O
upstream	O
enhancer	O
element	O
.	O

A	O
region	O
between-3134	O
and	O
-2729	O
bp	O
upstream	O
from	O
the	O
transcription	O
site	O
of	O
the	O
human	O
pro-interleukin	O
1beta	O
(	O
proIL-1beta	O
)	O
gene	O
was	O
identified	O
as	O
an	O
LPS-responsive	O
enhancer	O
element	O
.	O

In	O
this	O
study	O
,	O
the	O
influence	O
of	O
the	O
sequences	O
located	O
between	O
-3134	O
and	O
-2987	O
on	O
the	O
transcriptional	O
activity	O
of	O
the	O
proIL-1beta	O
gene	O
in	O
LPS-stimulated	O
Raw	O
264.7	O
cells	O
was	O
examined	O
in	O
detail	O
.	O

The	O
results	O
obtained	O
by	O
transient	O
transfection	O
of	O
fos	O
-CAT	O
constructs	O
that	O
contained	O
serial	O
5'-deletion	O
mutations	O
showed	O
that	O
the	O
region	O
between	O
-3134	O
and	O
-3059	O
appears	O
to	O
be	O
required	O
for	O
the	O
induction	O
of	O
transcription	O
by	O
LPS	O
.	O

Gel	O
shift	O
assay	O
studies	O
with	O
synthetic	O
oligonucleotides	O
corresponding	O
to	O
partial	O
sequences	O
of	O
the	O
latter	O
region	O
and	O
nuclear	O
extracts	O
from	O
stimulated	O
cells	O
revealed	O
specific	O
protein	O
binding	O
sites	O
between	O
-3110	O
and	O
-3090	O
and	O
between	O
-3079	O
and	O
-3059	O
.	O

These	O
specific	O
bindings	O
were	O
time	O
and	O
LPS	O
dose	O
dependent	O
.	O

The	O
results	O
of	O
supershift	O
analysis	O
using	O
specific	O
antibodies	O
against	O
transcription	O
factors	O
suggested	O
that	O
both	O
binding	O
complexes	O
contained	O
the	O
NF-kappaB	O
components	O
p50	O
and	O
p65	O
,	O
and	O
did	O
not	O
contain	O
other	O
NF-kappaB	O
proteins	O
(	O
p52	O
,	O
c-Rel	O
,	O
Rel	O
B	O
)	O
,	O
AP-1	O
proteins	O
(	O
c-Fos	O
,	O
C-Jun	O
)	O
,	O
CREB	O
or	O
C/EBPbeta	O
(	O
NF-IL6	O
)	O
.	O

Mutation	O
of	O
either	O
of	O
the	O
putative	O
NF-kappaB-binding	O
sites	O
in	O
the	O
enhancer	O
element	O
decreased	O
the	O
LPS-stimulated	O
transcriptional	O
activity	O
.	O

These	O
data	O
indicated	O
that	O
two	O
NF-kappaB-binding	O
sites	O
,	O
which	O
are	O
located	O
between	O
-3134	O
and	O
-3059	O
,	O
are	O
critical	O
for	O
the	O
activation	O
of	O
proIL-1beta	O
gene	O
transcription	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Phosphorylation	O
of	O
TRAF2	O
inhibits	O
binding	O
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

TRAF2	O
is	O
a	O
signal	O
transducing	O
adaptor	O
molecule	O
which	O
binds	O
to	O
the	O
CD40	O
cytoplasmic	O
domain	O
.	O

We	O
have	O
found	O
that	O
it	O
is	O
phosphorylated	O
,	O
predominantly	O
on	O
serine	O
residues	O
,	O
when	O
transiently	O
overexpressed	O
in	O
293	O
cells	O
.	O

The	O
phosphorylation	O
appears	O
to	O
be	O
related	O
to	O
the	O
signaling	O
events	O
that	O
are	O
activated	O
by	O
TRAF2	O
under	O
these	O
circumstances	O
,	O
since	O
two	O
nonfunctional	O
mutants	O
were	O
found	O
to	O
be	O
phosphorylated	O
significantly	O
less	O
than	O
the	O
wild-type	O
protein	O
.	O

Furthermore	O
,	O
the	O
phosphorylation	O
status	O
of	O
TRAF2	O
had	O
significant	O
effects	O
on	O
the	O
ability	O
of	O
the	O
protein	O
to	O
bind	O
to	O
CD40	O
,	O
as	O
evidenced	O
by	O
our	O
observations	O
that	O
the	O
CD40	O
cytoplasmic	O
domain	O
interacted	O
preferentially	O
with	O
underphosphorylated	O
TRAF2	O
and	O
that	O
phosphatase	O
treatment	O
significantly	O
enhanced	O
the	O
binding	O
of	O
TRAF2	O
to	O
CD40	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
the	O
phosphorylation	O
of	O
TRAF2	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
regulating	O
signaling	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
influence	O
the	O
CD40-TRAF2	O
interaction	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cobalt	O
chloride-induced	O
signaling	O
in	O
endothelium	O
leading	O
to	O
the	O
augmented	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
and	O
transendothelial	O
migration	O
of	O
monocyte-like	O
HL-60	O
cells	O
is	O
blocked	O
by	O
PAF-receptor	O
antagonist	O
.	O

In	O
response	O
to	O
hypoxia	O
,	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
and	O
leukocytes	O
exhibit	O
increased	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
while	O
diapedesis	O
of	O
leukocytes	O
through	O
the	O
blood	O
vessel	O
increases	O
.	O

However	O
,	O
the	O
cellular	O
signaling	O
pathway	O
(	O
s	O
)	O
caused	O
by	O
hypoxia	O
is	O
poorly	O
understood	O
.	O

We	O
utilized	O
CoCl2	O
as	O
a	O
mimetic	O
molecule	O
for	O
hypoxia	O
to	O
study	O
cellular	O
signaling	O
pathways	O
.	O

We	O
found	O
that	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
CoCl2	O
at	O
2	O
mM	O
concentration	O
induced	O
the	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	O
(	O
VCAM-1	O
)	O
and	O
activation	O
of	O
transcription	O
factor	O
NF-kappaB	O
in	O
the	O
nuclear	O
extracts	O
of	O
HUVEC	O
.	O

Furthermore	O
,	O
CoCl2	O
also	O
caused	O
time-dependent	O
tyrosine	O
phosphorylation	O
of	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
isoform	O
ERK2	O
without	B-Negation
significantly	I-Negation
affecting	I-Negation
ERK1	I-Negation
,	O
indicating	B-Speculation
ERK2	I-Speculation
is	I-Speculation
the	I-Speculation
preferred	I-Speculation
substrate	I-Speculation
for	I-Speculation
upstream	I-Speculation
kinase	I-Speculation
of	I-Speculation
the	I-Speculation
MAPK	I-Speculation
pathway	I-Speculation
.	O

Inhibitors	O
of	O
MAP	O
kinase	O
(	O
PD98059	O
)	O
or	O
platelet-activating	O
factor	O
(	O
PAF	O
)	O
-	O
receptor	O
antagonist	O
(	O
CV3988	O
)	O
inhibited	O
the	O
CoCl2-induced	O
NF-kappaB	O
activation	O
and	O
VCAM-1	O
expression	O
.	O

Augmented	O
expression	O
of	O
VCAM-1	O
led	O
to	O
increased	O
SS	O
RBC	O
adhesion	O
,	O
inhibitable	O
by	O
a	O
VCAM-1	O
antibody	O
.	O

Additionally	O
,	O
CoCl2	O
caused	O
a	O
two-	O
to	O
threefold	O
increase	O
in	O
the	O
rate	O
of	O
transendothelial	O
migration	O
of	O
monocyte-like	O
HL-60	O
cells	O
and	O
a	O
twentyfold	O
increase	O
in	O
phosphorylation	O
of	O
platelet	O
endothelial	O
cell	O
adhesion	O
molecules	O
(	O
PECAM-1	O
)	O
.	O

The	O
transendothelial	O
migration	O
of	O
monocytes	O
was	O
inhibited	O
by	O
an	O
antibody	O
to	O
PECAM-1	O
.	O

Both	O
phosphorylation	O
of	O
PECAM-1	O
and	O
transendothelial	O
migration	O
of	O
monocytes	O
in	O
response	O
to	O
CoCl2	O
were	O
inhibited	O
by	O
protein	O
kinase	O
inhibitor	O
(	O
GF109203X	O
)	O
and	O
augmented	O
by	O
protein	O
phosphatase	O
inhibitor	O
(	O
Calyculin	O
A	O
)	O
.	O

Our	O
data	O
suggests	O
that	O
CoCl2-induced	O
cellular	O
signals	O
directing	O
increased	O
expression	O
of	O
VCAM-1	O
in	O
HUVEC	O
involve	O
downstream	O
activation	O
of	O
MAP	O
kinase	O
and	O
NF-kappaB	O
,	O
while	O
the	O
phosphorylation	O
of	O
PECAM-1	O
occurs	O
as	O
a	O
result	O
of	O
activation	O
of	O
PKC	O
.	O

We	O
conclude	O
that	O
PAF-receptor	O
antagonist	O
inhibits	O
the	O
CoCl2-	O
or	O
hypoxia-induced	O
increase	O
in	O
the	O
adhesion	O
of	O
SS	O
RBC	O
,	O
PECAM-1	O
phosphorylation	O
,	O
and	O
the	O
concomitant	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

Molecular	O
mechanisms	O
of	O
neutrophil-endothelial	O
cell	O
adhesion	O
induced	O
by	O
redox	O
imbalance	O
.	O

Previous	O
studies	O
have	O
implicated	O
a	O
role	O
for	O
intracellular	O
thiols	O
in	O
the	O
activation	O
of	O
nuclear	O
factor-kappaB	O
and	O
transcriptional	O
regulation	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
changes	O
in	O
endothelial	O
cell	O
glutathione	O
(	O
GSH	O
)	O
or	O
oxidized	O
glutathione	O
(	O
GSSG	O
)	O
can	O
alter	O
neutrophil	O
adhesivity	O
and	O
to	O
define	O
the	O
molecular	O
mechanism	O
that	O
underlies	O
this	O
GSSG/GSH-induced	O
adhesion	O
response	O
.	O

Treatment	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
(	O
HUVEC	O
)	O
monolayers	O
for	O
6	O
hours	O
with	O
0.2	O
mmol/L	O
diamide	O
and	O
1	O
mmol/L	O
buthionine	O
sulfoximine	O
(	O
BSO	O
)	O
decreased	O
GSH	O
levels	O
and	O
increased	O
the	O
ratio	O
of	O
GSSG	O
to	O
GSH	O
without	B-Negation
cell	I-Negation
toxicity	I-Negation
.	O

These	O
redox	O
changes	O
are	O
similar	O
to	O
those	O
observed	O
with	O
anoxia/reoxygenation	O
.	O

Diamide	O
plus	O
BSO-induced	O
thiol/disulfide	O
imbalance	O
was	O
associated	O
with	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
with	O
peak	O
responses	O
observed	O
at	O
15	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
.	O

N-Acetylcysteine	O
treatment	O
attenuated	O
neutrophil	O
adhesion	O
in	O
both	O
phases	O
,	O
which	O
indicated	O
a	O
role	O
for	O
GSH	O
in	O
the	O
adhesion	O
responses	O
.	O

Interestingly	O
,	O
phase	O
1	O
adhesion	O
was	O
inversely	O
correlated	O
with	O
GSH	O
levels	O
but	O
not	B-Negation
with	I-Negation
the	I-Negation
GSSG/GSH	I-Negation
ratio	I-Negation
,	O
whereas	O
phase	O
2	O
neutrophil	O
adhesion	O
was	O
positively	O
correlated	O
with	O
GSSG/GSH	O
ratio	O
but	O
not	B-Negation
with	I-Negation
GSH	I-Negation
levels	I-Negation
.	O

Intercellular	O
adhesion	O
molecule-1	O
and	O
P-selectin-specific	O
monoclonal	O
antibodies	O
attenuated	O
the	O
increased	O
neutrophil	O
adhesion	O
during	O
both	O
phases	O
,	O
whereas	O
an	O
anti-E-selectin	O
monoclonal	O
antibody	O
also	O
attenuated	O
the	O
phase	O
2	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
that	O
contained	O
nuclear	O
factor-kappaB	O
or	O
activator	O
protein-1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
the	O
phase	O
2	O
response	O
,	O
which	O
implicated	O
a	O
role	O
for	O
de	O
novo	O
protein	O
synthesis	O
.	O

Surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
,	O
P-selectin	O
,	O
and	O
E-selectin	O
on	O
HUVECs	O
correlated	O
with	O
the	O
phase	O
1	O
and	O
2	O
neutrophil	O
adhesion	O
responses	O
.	O

This	O
study	O
demonstrates	O
that	O
changes	O
in	O
endothelial	O
cell	O
GSSG/GSH	O
cause	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
,	O
which	O
leads	O
to	O
a	O
2-phase	O
neutrophil-endothelial	O
adhesion	O
response	O
.	O

Decreased	O
proteasome-mediated	O
degradation	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
:	O
A	O
role	O
in	O
immune	O
senescence	O
.	O

Induction	O
of	O
NFkappaB	O
is	O
a	O
highly	O
regulated	O
process	O
requiring	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteasome-mediated	O
degradation	O
of	O
the	O
cytosolic	O
inhibitor	O
IkappaBalpha	O
.	O

Analyses	O
of	O
the	O
regulation	O
of	O
IkappaBalpha	O
in	O
TNF-alpha-treated	O
T	O
lymphocytes	O
from	O
young	O
and	O
elderly	O
donors	O
revealed	O
severely	O
compromised	O
degradation	O
of	O
IkappaBalpha	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

Examination	B-Negation
of	I-Negation
activation-induced	I-Negation
phosphorylation	I-Negation
and	I-Negation
ubiquitination	I-Negation
of	I-Negation
IkappaBalpha	I-Negation
did	I-Negation
not	I-Negation
demonstrate	I-Negation
any	I-Negation
significant	I-Negation
age-related	I-Negation
alterations	I-Negation
.	O

However	O
,	O
examination	O
of	O
proteasome	O
activity	O
in	O
these	O
T	O
cells	O
using	O
fluorogenic	O
peptide	O
assays	O
revealed	O
a	O
significant	O
age-related	O
decline	O
in	O
chymotryptic	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
a	O
decline	O
in	O
proteasome	O
activity	O
results	O
in	O
a	O
failure	O
to	O
fully	O
degrade	O
IkappaBalpha	O
in	O
the	O
elderly	O
.	O

This	O
failure	O
to	O
degrade	O
IkappaBalpha	O
may	O
underlie	O
both	O
the	O
observed	O
decrease	O
in	O
NFkappaB	O
induction	O
and	O
the	O
IL-2	O
receptor	O
expression	O
in	O
TNF-treated	O
T	O
cells	O
during	O
aging	O
.	O

Thus	O
,	O
decreased	O
proteasome-mediated	O
degradation	O
may	O
be	O
central	O
to	O
immune	O
dysfunction	O
that	O
accompanies	O
aging	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Identification	O
of	O
upstream	O
regulatory	O
elements	O
that	O
repress	O
expression	O
of	O
adult	O
beta-like	O
globin	O
genes	O
in	O
a	O
primitive	O
erythroid	O
environment	O
.	O

Our	O
investigations	O
have	O
focused	O
on	O
localizing	O
cis-elements	O
responsible	O
for	O
the	O
down	O
regulation	O
of	O
the	O
adult	O
beta-like	O
globin	O
genes	O
(	O
delta	O
and	O
beta	O
)	O
in	O
immature	O
,	O
or	O
primitive	O
erythroid	O
tissues	O
.	O

We	O
studied	O
their	O
activity	O
after	O
transfection	O
into	O
K562	O
cells	O
,	O
an	O
erythroleukemia	O
cell	O
line	O
with	O
an	O
embryonic-fetal	O
phenotype	O
.	O

Analyzed	O
DNA	O
sequences	O
included	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-500	O
to	O
+50bp	O
(	O
promoter	O
regions	O
)	O
,	O
truncated	O
delta	O
and	O
beta	O
5	O
'	O
flanking	O
regions	O
extending	O
from	O
approximately	O
-250	O
to	O
+50	O
bp	O
,	O
and	O
chimeric	O
promoter	O
constructions	O
,	O
which	O
consisted	O
of	O
a	O
distal	O
delta	O
or	O
beta	O
fragment	O
fused	O
to	O
a	O
proximal	O
beta	O
or	O
delta	O
sequence	O
.	O

In	O
CAT	O
reporter	O
constructions	O
no	B-Negation
appreciable	I-Negation
level	I-Negation
of	I-Negation
CAT	I-Negation
activity	I-Negation
was	I-Negation
supported	I-Negation
by	I-Negation
the	I-Negation
beta	I-Negation
globin	I-Negation
promoter	I-Negation
,	O
and	O
only	O
low	O
level	O
activity	O
by	O
the	O
delta	O
promoter	O
.	O

Truncation	O
of	O
the	O
beta	O
globin	O
promoter	O
led	O
to	O
a	O
2-3	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
deletion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
led	O
to	O
a	O
10	O
fold	O
decrease	O
in	O
expression	O
.	O

Coupling	O
of	O
the	O
upstream	O
beta	O
globin	O
sequence	O
from	O
approximately	O
-500	O
to	O
-250	O
bp	O
to	O
the	O
truncated	O
delta	O
promoter	O
fragment	O
led	O
to	O
complete	O
extinction	O
of	O
transcription	O
activity	O
,	O
consistent	O
with	O
a	O
negative	O
regulatory	O
effect	O
of	O
the	O
beta	O
globin	O
gene	O
upstream	O
element	O
(	O
s	O
)	O
.	O

Fusion	O
of	O
the	O
upstream	O
portion	O
of	O
the	O
delta	O
promoter	O
to	O
the	O
truncated	O
beta	O
globin	O
promoter	O
yielded	O
a	O
modest	O
increase	O
in	O
promoter	O
strength	O
relative	O
to	O
the	O
truncated	O
beta	O
gene	O
promoter	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
positive	O
transcriptional	O
element	O
(	O
s	O
)	O
in	O
the	O
upstream	O
delta	O
globin	O
regulatory	O
region	O
.	O

Site-directed	O
mutagenesis	O
of	O
binding	O
sites	O
for	O
the	O
repressor	O
proteins	O
BP1	O
and	O
BP2	O
in	O
the	O
upstream	O
portion	O
of	O
the	O
beta	O
globin	O
gene	O
flanking	O
region	O
led	O
to	O
a	O
4-6	O
fold	O
increase	O
in	O
promoter	O
activity	O
.	O

DNase	O
I	O
footprinting	O
of	O
the	O
upstream	O
delta-globin	O
region	O
revealed	O
protected	O
sequences	O
corresponding	O
to	O
consensus	O
binding	O
sites	O
for	O
GATA-1	O
and	O
BP2	O
.	O

These	O
results	O
confirm	O
that	O
sequences	O
in	O
the	O
upstream	O
promoter	O
region	O
of	O
the	O
adult	O
beta	O
globin	O
gene	O
contribute	O
to	O
its	O
factor-mediated	O
suppression	O
early	O
in	O
development	O
and	O
then	O
may	O
modulate	O
its	O
expression	O
at	O
a	O
later	O
stage	O
.	O

Reduction	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
expression	O
and	O
signalling	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
from	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
upon	O
treatment	O
with	O
desferrioxamine	O
.	O

Recent	O
evidence	O
indicates	O
that	O
the	O
rate	O
of	O
progression	O
of	O
the	O
HIV-1	O
disease	O
is	O
significantly	O
reduced	O
in	O
thalassaemia	O
major	O
patients	O
upon	O
treatment	O
with	O
high	O
doses	O
of	O
desferrioxamine	O
(	O
DFX	O
)	O
.	O

The	O
authors	O
have	O
previously	O
demonstrated	O
that	O
in	O
vitro	O
exposure	O
of	O
mononuclear	O
cells	O
to	O
DFX	O
decreases	O
the	O
bioavailability	O
of	O
tumour	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
which	O
has	O
a	O
stimulatory	O
effect	O
on	O
HIV-1	O
replication	O
.	O

In	O
this	O
study	O
,	O
therefore	O
,	O
TNF-alpha	O
bioavailability	O
from	O
mononuclear	O
cells	O
isolated	O
from	O
10	O
patients	O
with	O
thalassaemia	O
or	O
sickle	O
cell	O
anaemia	O
given	O
DFX	O
as	O
compared	O
to	O
10	O
untreated	O
subjects	O
has	O
been	O
evaluated	O
.	O

Evidence	O
is	O
presented	O
showing	O
that	O
DFX	O
treatment	O
reduces	O
TNF-alpha	O
bioavailability	O
(	O
P	O
<	O
0.05	O
)	O
by	O
inhibiting	O
its	O
steady	O
state	O
(	O
P	O
<	O
0.05	O
)	O
and	O
by	O
enhancing	O
its	O
inactivation	O
through	O
binding	O
to	O
soluble	O
TNF-alpha	O
receptor	O
type	O
II	O
(	O
P	O
<	O
0.05	O
)	O
.	O

We	O
also	O
show	O
that	O
DFX	O
treatment	O
limits	O
the	O
in	O
vivo	O
activation	O
of	O
NF-kappaB	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
both	O
TNF-alpha	O
gene	O
transcription	O
and	O
TNF-alpha	O
signalling	O
(	O
P	O
<	O
0.005	O
)	O
.	O

We	O
conclude	O
that	O
TNF-alpha	O
bioavailability	O
and	O
signalling	O
are	O
impaired	O
in	O
patients	O
upon	O
DFX	O
treatment	O
.	O

This	O
mechanism	O
may	O
contribute	O
to	O
delayed	O
progression	O
of	O
the	O
HIV-1	O
infection	O
in	O
vivo	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Involvement	O
of	O
adenylate	O
cyclase	O
and	O
p70	O
(	O
S6	O
)	O
-kinase	O
activation	O
in	O
IL-10	O
up-regulation	O
in	O
human	O
monocytes	O
by	O
gp41	O
envelope	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Our	O
previous	O
results	O
show	O
that	O
recombinant	O
gp41	O
(	O
aa565-647	O
)	O
,	O
the	O
extracellular	O
domain	O
of	O
HIV-1	O
transmembrane	O
glycoprotein	O
,	O
stimulates	O
interleukin-10	O
(	O
IL-10	O
)	O
production	O
in	O
human	O
monocytes	O
.	O

The	O
signal	O
cascade	O
transducing	O
this	O
effect	O
is	O
not	O
yet	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
whether	O
gp41-induced	O
IL-10	O
up-regulation	O
is	O
mediated	O
by	O
the	O
previously	O
described	O
synergistic	O
activation	O
of	O
cAMP	O
and	O
NF-kappaB	O
pathways	O
.	O

gp41	O
induced	O
cAMP	O
accumulation	O
in	O
monocytes	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
and	O
the	O
adenylate	O
cyclase	O
inhibitor	O
SQ	O
22536	O
suppressed	O
gp41-induced	O
IL-10	O
production	O
in	O
monocytes	O
.	O

In	O
contrast	O
,	O
gp41	O
failed	B-Negation
to	I-Negation
stimulate	I-Negation
NF-kappaB	I-Negation
binding	I-Negation
activity	I-Negation
in	I-Negation
as	I-Negation
much	I-Negation
as	I-Negation
no	I-Negation
NF-kappaB	I-Negation
bound	I-Negation
to	I-Negation
the	I-Negation
main	I-Negation
NF-kappaB-binding	I-Negation
site	I-Negation
2	I-Negation
of	I-Negation
the	I-Negation
IL-10	I-Negation
promoter	I-Negation
after	I-Negation
addition	I-Negation
of	I-Negation
gp41	I-Negation
.	O

We	O
also	O
examined	O
the	O
involvement	O
of	O
other	O
signal	O
transduction	O
pathways	O
.	O

Specific	O
inhibitors	O
of	O
p70	O
(	O
S6	O
)	O
-kinase	O
(	O
rapamycin	O
)	O
,	O
and	O
Gi	O
protein	O
(	O
pertussis	O
toxin	O
)	O
,	O
prevented	O
induction	O
of	O
IL-10	O
production	O
by	O
gp41	O
in	O
monocytes	O
,	O
while	O
inhibitors	O
of	O
the	O
phosphatidylinositol	O
3-kinase	O
(	O
PI	O
3-kinase	O
)	O
(	O
wortmannin	O
)	O
and	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
pathway	O
(	O
PD	O
98059	O
)	O
did	O
not	B-Negation
.	O

Thus	O
HIV-1	O
gp41-induced	O
IL-10	O
up-regulation	O
in	O
monocytes	O
may	O
not	O
involve	O
NF-kappaB	O
,	O
MAPK	O
,	O
or	O
PI	O
3-kinase	O
activation	O
,	O
but	O
rather	O
may	O
operate	O
through	O
activation	O
of	O
adenylate	O
cyclase	O
and	O
pertussis-toxin-sensitive	O
Gi/Go	O
protein	O
to	O
effect	O
p70	O
(	O
S6	O
)	O
-kinase	O
activation	O
.	O

Estrone	O
potentiates	O
myeloid	O
cell	O
differentiation	O
:	O
a	O
role	O
for	O
17	O
beta-hydroxysteroid	O
dehydrogenase	O
in	O
modulating	O
hemopoiesis	O
.	O

Hormones	O
such	O
as	O
1	O
alpha	O
,	O
25-dihydroxy	O
vitamin	O
D3	O
(	O
D3	O
)	O
,	O
all-trans	O
retinoic	O
acid	O
,	O
and	O
9-cis	O
retinoic	O
acid	O
stimulate	O
differentiation	O
of	O
myeloid	O
progenitor	O
cells	O
via	O
their	O
interaction	O
with	O
specific	O
hormone	O
receptors	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
cells	O
to	O
these	O
agents	O
is	O
not	O
merely	O
governed	O
by	O
the	O
expression	O
of	O
their	O
receptors	O
and	O
the	O
availability	O
of	O
ligand	O
to	O
bind	O
them	O
.	O

Recent	O
studies	O
from	O
our	O
group	O
suggested	O
that	O
the	O
actions	O
of	O
D3	O
and	O
retinoids	O
on	O
myelopoiesis	O
also	O
are	O
influenced	O
by	O
endogenous	O
mechanisms	O
involving	O
other	O
steroid	O
hormones	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
influence	O
of	O
local	O
estrogen	O
metabolism	O
on	O
the	O
differentiation	O
of	O
HL60	O
cells	O
and	O
normal	O
primitive	O
myeloid	O
progenitor	O
cells	O
.	O

Quantitative	O
thin-layer	O
chromatography	O
(	O
TLC	O
)	O
analyses	O
showed	O
that	O
HL60	O
and	O
normal	O
cells	O
are	O
able	O
to	O
generate	O
estrone	O
(	O
E1	O
)	O
from	O
estradiol	O
(	O
E2	O
)	O
.	O

Neither	B-Negation
cell	I-Negation
population	I-Negation
generated	I-Negation
significant	I-Negation
amounts	I-Negation
of	I-Negation
E2	I-Negation
from	I-Negation
E1	I-Negation
.	O

Reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
and	O
Northern	O
analyses	O
confirmed	O
that	O
normal	O
and	O
leukemic	O
myeloid	O
progenitor	O
cells	O
expressed	O
mRNA	O
for	O
the	O
type	O
I	O
and	O
IV	O
isoforms	O
of	O
17	O
beta-hydroxysteroid	O
dehydrogenase	O
.	O

Conversion	O
of	O
E2	O
to	O
E1	O
was	O
upregulated	O
within	O
24	O
hours	O
when	O
HL60	O
cells	O
were	O
treated	O
with	O
either	O
all-trans	O
retinoic	O
acid	O
or	O
D3	O
at	O
doses	O
that	O
induce	O
their	O
differentiation	O
toward	O
neutrophils	O
or	O
monocytes	O
,	O
respectively	O
.	O

Similarly	O
,	O
D3-induced	O
monocyte	O
differentiation	O
of	O
normal	O
myeloid	O
progenitor	O
cells	O
was	O
associated	O
with	O
increased	O
capacity	O
to	O
generate	O
E1	O
from	O
E2	O
.	O

When	O
HL60	O
cells	O
or	O
normal	O
myeloid	O
progenitor	O
cells	O
were	O
exposed	O
to	O
exogenous	O
E1	O
they	O
became	O
more	O
sensitive	O
to	O
the	O
differentiation-inducing	O
effects	O
of	O
D3	O
.	O

Data	O
presented	O
provide	O
further	O
evidence	O
for	O
the	O
local	O
modulation	O
of	O
myelopoiesis	O
by	O
intracrine	O
mechanisms	O
.	O

In	O
particular	O
,	O
our	O
findings	O
suggest	O
that	O
local	O
metabolism	O
of	O
steroids	O
by	O
normal	O
as	O
well	O
as	O
leukemic	O
myeloid	O
cells	O
influences	O
their	O
responsiveness	O
to	O
D3	O
and	O
retinoids	O
.	O

Constitutive	O
activation	O
of	O
NF-kappaB	O
in	O
primary	O
adult	O
T-cell	O
leukemia	O
cells	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
an	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
viral	O
protein	O
Tax	O
induces	O
the	O
activation	O
and	O
nuclear	O
translocalization	O
of	O
transcription	O
factor	O
NF-kappaB	O
,	O
which	O
is	O
proposed	O
to	O
play	O
a	O
crucial	O
role	O
in	O
the	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV-I	O
.	O

However	O
,	O
the	B-Negation
HTLV-I	I-Negation
genes	I-Negation
including	I-Negation
Tax	I-Negation
are	I-Negation
not	I-Negation
expressed	I-Negation
significantly	I-Negation
in	I-Negation
primary	I-Negation
leukemic	I-Negation
cells	I-Negation
from	I-Negation
ATL	I-Negation
patients	I-Negation
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
basis	O
for	O
NF-kappaB	O
activation	O
in	O
freshly	O
isolated	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
.	O

We	O
found	O
that	O
leukemic	O
cells	O
from	O
ATL	O
patients	O
,	O
like	O
HTLV-I-infected	O
T-cell	O
lines	O
,	O
display	O
constitutive	O
NF-kappaB	O
DNA	O
binding	O
activity	O
and	O
increased	O
degradation	O
of	O
IkappaBalpha	O
(	O
an	O
inhibitor	O
of	O
NF-kappaB	O
)	O
.	O

Whereas	O
the	O
NF-kappaB	O
binding	O
activity	O
in	O
Tax-expressing	O
T-cell	O
lines	O
consisted	O
mostly	O
of	O
p50/c-Rel	O
,	O
fresh	O
ATL	O
samples	O
contained	O
p50/p50	O
and	O
p50/p65	O
heterodimers	O
.	O

One	O
T-cell	O
line	O
derived	O
from	O
ATL	O
leukemic	O
cells	O
,	O
TL-Om1	O
,	O
displayed	O
constitutive	O
NF-kappaB	O
activity	O
,	O
as	O
well	O
as	O
enhanced	O
degradation	O
of	O
IkappaBalpha	O
,	O
despite	O
the	O
lack	B-Negation
of	I-Negation
detectable	I-Negation
Tax	I-Negation
expression	I-Negation
.	O

Interestingly	O
,	O
the	O
NF-kappaB	O
in	O
TL-Om1	O
consists	O
of	O
p50/p50	O
and	O
p50/p65	O
like	O
that	O
in	O
fresh	O
primary	O
leukemic	O
cells	O
.	O

Our	O
results	O
suggest	O
that	O
activation	O
of	O
NF-kappaB	O
occurs	O
through	O
a	O
Tax-independent	O
mechanism	O
in	O
leukemic	O
cells	O
of	O
ATL	O
patients	O
,	O
possibly	O
due	O
to	O
differential	O
NF-kappaB	O
subunit	O
activation	O
.	O

Apoptosis-resistant	O
T	O
cells	O
have	O
a	O
deficiency	O
in	O
NF-kappaB-mediated	O
induction	O
of	O
Fas	O
ligand	O
transcription	O
.	O

Apoptosis	O
induced	O
through	O
the	O
TCR	O
in	O
CD4+	O
T	O
cells	O
is	O
mostly	O
mediated	O
by	O
the	O
inducible	O
expression	O
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
as	O
a	O
primary	O
event	O
leading	O
to	O
the	O
commitment	O
to	O
death	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
transcriptional	O
events	O
that	O
regulate	O
this	O
expression	O
,	O
we	O
took	O
advantage	O
of	O
our	O
previously	O
described	O
mutant	O
Jurkat	O
cells	O
.	O

These	O
cells	O
are	O
deficient	O
in	O
FasL	O
expression	O
and	O
apoptosis	O
induced	O
upon	O
TCR	O
triggering	O
,	O
although	O
their	O
cytokine	O
(	O
IL-2	O
and	O
IFN-gamma	O
)	O
production	O
is	O
normal	O
.	O

Here	O
we	O
show	O
that	O
both	O
a	O
FasL-	O
and	O
a	O
consensus	O
NF-kappaB-	O
reporter	O
construct	O
are	O
inefficiently	O
induced	O
in	O
these	O
cells	O
compared	O
to	O
wild-type	O
cells	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
the	O
inducible	O
transcriptional	O
activity	O
of	O
the	O
FasL	O
reporter	O
is	O
abolished	O
by	O
specific	O
inhibitors	O
of	O
NF-kappaB	O
activation	O
.	O

Thus	O
,	O
we	O
could	O
trace	O
the	O
deficit	O
of	O
the	O
mutant	O
cells	O
to	O
an	O
inefficient	O
NF-kappaB	O
activation	O
,	O
evidencing	O
a	O
relevant	O
role	O
for	O
NF-kappaB	O
in	O
the	O
regulation	O
of	O
FasL	O
expression	O
in	O
activated	O
T	O
cells	O
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
FasL	O
versus	O
cytokine	O
gene	O
expression	O
is	O
differentially	O
sensitive	O
to	O
NF-kappaB	O
deprivation	O
.	O

NF-kappaB	O
regulates	O
Fas/APO-1/CD95-	O
and	O
TCR-	O
mediated	O
apoptosis	O
of	O
T	O
lymphocytes	O
.	O

The	O
maintenance	O
of	O
lymphocyte	O
homeostasis	O
by	O
apoptosis	O
is	O
a	O
critical	O
regulatory	O
mechanism	O
in	O
the	O
normal	O
immune	O
system	O
.	O

The	O
transcription	O
factor	O
NF-kappaB	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
protecting	O
cells	O
against	O
death	O
mediated	O
by	O
TNF	O
We	O
show	O
here	O
that	O
NF-kappaB	O
also	O
has	O
a	O
role	O
in	O
regulating	O
Fas/APO-1/CD95-mediated	O
death	O
,	O
a	O
major	O
pathway	O
of	O
peripheral	O
T	O
cell	O
death	O
.	O

Transfection	O
of	O
Jurkat	O
cells	O
with	O
the	O
NF-kappaB	O
subunits	O
p50	O
and	O
p65	O
confers	O
resistance	O
against	O
Fas-mediated	O
apoptosis	O
.	O

Reciprocally	O
,	O
inhibition	O
of	O
NF-kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
or	O
a	O
dominant	O
form	O
of	O
the	O
NF-kappaB	O
inhibitor	O
,	O
IkappaB	O
,	O
makes	O
the	O
cells	O
more	O
susceptible	O
to	O
Fas-mediated	O
apoptosis	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
NF-kappaB	O
activation	O
by	O
a	O
soluble	O
peptide	O
inhibitor	O
rendered	O
a	O
T	O
cell	O
hybridoma	O
more	O
susceptible	O
to	O
TCR-mediated	O
apoptosis	O
.	O

Correspondingly	O
,	O
transfection	O
of	O
p50	O
and	O
p65	O
provided	O
considerable	O
protection	O
from	O
TCR-mediated	O
apoptosis	O
.	O

These	O
observations	O
were	O
corroborated	O
by	O
studies	O
on	O
Fas-mediated	O
death	O
in	O
primary	O
T	O
cells	O
.	O

Concanavalin	O
A-activated	O
cycling	O
T	O
cell	O
blasts	O
from	O
mice	O
that	O
are	O
transgenic	O
for	O
the	O
dominant	O
IkappaB	O
molecule	O
have	O
increased	O
sensitivity	O
to	O
Fas-mediated	O
apoptosis	O
,	O
associated	O
with	O
a	O
down-regulation	O
of	O
NF-kappaB	O
complexes	O
in	O
the	O
nucleus	O
.	O

In	O
addition	O
,	O
blocking	O
TNF	O
,	O
itself	O
a	O
positive	O
regulator	O
of	O
NF-kappaB	O
,	O
with	O
neutralizing	O
antibodies	O
renders	O
the	O
cells	O
more	O
susceptible	O
to	O
anti-Fas-mediated	O
apoptosis	O
.	O

In	O
summary	O
,	O
our	O
results	O
provide	O
compelling	O
evidence	O
that	O
NF-kappaB	O
protects	O
against	O
Fas-mediated	O
death	O
and	O
is	O
likely	O
to	O
be	O
an	O
important	O
regulator	O
of	O
T	O
cell	O
homeostasis	O
and	O
tolerance	O
.	O

Evidence	O
for	O
distinct	O
intracellular	O
signaling	O
pathways	O
in	O
CD34+	O
progenitor	O
to	O
dendritic	O
cell	O
differentiation	O
from	O
a	O
human	O
cell	O
line	O
model	O
.	O

Intracellular	O
signals	O
that	O
mediate	O
differentiation	O
of	O
pluripotent	O
hemopoietic	O
progenitors	O
to	O
dendritic	O
cells	O
(	O
DC	O
)	O
are	O
largely	O
undefined	O
.	O

We	O
have	O
previously	O
shown	O
that	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
(	O
with	O
phorbol	O
ester	O
(	O
PMA	O
)	O
alone	O
)	O
specifically	O
induces	O
differentiation	O
of	O
primary	O
human	O
CD34+	O
hemopoietic	O
progenitor	O
cells	O
(	O
HPC	O
)	O
to	O
mature	O
DC	O
.	O

We	O
now	O
find	O
that	O
cytokine-driven	O
(	O
granulocyte-macrophage	O
CSF	O
and	O
TNF-alpha	O
)	O
CD34+	O
HPC	O
--	O
>	O
DC	O
differentiation	O
is	O
preferentially	O
blocked	O
by	O
inhibitors	O
of	O
PKC	O
activation	O
.	O

To	O
further	O
identify	O
intracellular	O
signals	O
and	O
downstream	O
events	O
important	O
in	O
CD34+	O
HPC	O
--	O
>	O
DC	O
differentiation	O
we	O
have	O
characterized	O
a	O
human	O
leukemic	O
cell	O
line	O
model	O
of	O
this	O
process	O
.	O

The	O
CD34+	O
myelomonocytic	O
cell	O
line	O
KG1	O
differentiates	O
into	O
dendritic-like	O
cells	O
in	O
response	O
to	O
granulocyte-macrophage	O
CSF	O
plus	O
TNF-alpha	B-Speculation
,	I-Speculation
or	I-Speculation
PMA	I-Speculation
(	O
with	O
or	O
without	B-Negation
the	I-Negation
calcium	I-Negation
ionophore	I-Negation
ionomycin	I-Negation
,	I-Negation
or	I-Negation
TNF-alpha	I-Negation
)	O
,	O
with	O
different	O
stimuli	O
mediating	O
different	O
aspects	O
of	O
the	O
process	O
.	O

Phenotypic	O
DC	O
characteristics	O
of	O
KG1	O
dendritic-like	O
cells	O
include	O
morphology	O
(	O
loosely	O
adherent	O
cells	O
with	O
long	O
neurite	O
processes	O
)	O
,	O
MHC	O
I+/MHC	O
IIbright/CD83+/CD86+/CD14-	O
surface	O
Ag	O
expression	O
,	O
and	O
RelB	O
and	O
DC-CK1	O
gene	O
expression	O
.	O

Functional	O
DC	O
characteristics	O
include	O
fluid	O
phase	O
macromolecule	O
uptake	O
(	O
FITC-dextran	O
)	O
and	O
activation	O
of	O
resting	O
T	O
cells	O
.	O

Comparison	O
of	O
KG1	O
to	O
the	O
PMA-unresponsive	O
subline	O
KG1a	O
reveals	O
differences	O
in	O
expression	O
of	O
TNF	O
receptors	O
1	O
and	O
2	O
;	O
PKC	O
isoforms	O
alpha	O
,	O
beta	O
I	O
,	O
beta	O
II	O
,	O
and	O
mu	O
;	O
and	O
RelB	O
,	O
suggesting	O
that	O
these	O
components/pathways	O
are	O
important	O
for	O
DC	O
differentiation	O
.	O

Together	O
,	O
these	O
findings	O
demonstrate	O
that	O
cytokine	O
or	O
phorbol	O
ester	O
stimulation	O
of	O
KG1	O
is	O
a	O
model	O
of	O
human	O
CD34+	O
HPC	O
to	O
DC	O
differentiation	O
and	O
suggest	O
that	O
specific	O
intracellular	O
signaling	O
pathways	O
mediate	O
specific	O
events	O
in	O
DC	O
lineage	O
commitment	O
.	O

IL-2-mediated	O
cell	O
cycle	O
progression	O
and	O
inhibition	O
of	O
apoptosis	O
does	O
not	B-Negation
require	I-Negation
NF-kappa	I-Negation
B	I-Negation
or	I-Negation
activating	I-Negation
protein-1	I-Negation
activation	I-Negation
in	I-Negation
primary	I-Negation
human	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
IL-2	O
growth	O
hormone	O
is	O
the	O
major	O
growth	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
during	O
a	O
developing	O
immune	O
response	O
.	O

IL-2	O
is	O
required	O
not	O
only	O
for	O
cell	O
cycle	O
progression	O
but	O
also	O
to	O
protect	O
Ag-activated	O
T	O
cells	O
from	O
programmed	O
cell	O
death	O
.	O

In	O
several	O
cell	O
types	O
,	O
activation	O
of	O
NF-kappa	O
B	O
and/or	O
activating	O
protein-1	O
(	O
AP-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
extremely	O
important	O
in	O
blocking	O
apoptosis	O
.	O

To	O
determine	O
whether	O
either	O
or	O
both	O
of	O
these	O
transcription	O
factors	O
are	O
involved	O
in	O
cell	O
survival	O
or	O
cell	O
cycle	O
progression	O
in	O
response	O
to	O
IL-2	O
,	O
primary	O
human	O
T	O
cells	O
responsive	O
to	O
the	O
growth	O
factor	O
were	O
analyzed	O
for	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

The	O
current	O
study	O
clearly	O
demonstrates	O
that	O
IL-2	O
does	O
not	B-Negation
induce	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
degradation	I-Negation
or	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
in	I-Negation
primary	I-Negation
human	I-Negation
T	I-Negation
cells	I-Negation
that	I-Negation
respond	I-Negation
to	I-Negation
IL-2	I-Negation
by	I-Negation
entering	I-Negation
the	I-Negation
cell	I-Negation
cycle	I-Negation
and	I-Negation
avoiding	I-Negation
apoptosis	I-Negation
.	O

Similarly	O
,	O
IL-2	O
neither	B-Negation
activates	I-Negation
JNK	I-Negation
nor	I-Negation
increases	I-Negation
AP-1	I-Negation
binding	I-Negation
activity	I-Negation
to	I-Negation
a	I-Negation
consensus	I-Negation
o-tetradecanoylphorbol	I-Negation
13-acetate	I-Negation
(	I-Negation
TPA	I-Negation
)	I-Negation
response	I-Negation
element	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
growth	O
factor	O
does	O
induce	O
the	O
activation	O
of	O
STAT3	O
and	O
STAT5	O
in	O
these	O
cells	O
,	O
as	O
has	O
been	O
previously	O
demonstrated	O
.	O

These	O
data	O
show	O
that	O
neither	B-Negation
NF-kappa	I-Negation
B	I-Negation
nor	I-Negation
AP-1	I-Negation
activation	I-Negation
is	I-Negation
required	I-Negation
for	I-Negation
IL-2-mediated	I-Negation
survival	I-Negation
or	I-Negation
cell	I-Negation
cycle	I-Negation
progression	I-Negation
in	I-Negation
activated	I-Negation
primary	I-Negation
human	I-Negation
T	I-Negation
cells	I-Negation
.	O

Impaired	O
fetal	O
thymocyte	O
development	O
after	O
efficient	O
adenovirus-mediated	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
.	O

We	O
introduce	O
a	O
new	O
experimental	O
system	O
combining	O
adenovirus-mediated	O
gene	O
transfer	O
and	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

This	O
system	O
allowed	O
us	O
to	O
efficiently	O
express	O
in	O
developing	O
thymocytes	O
a	O
mutant	O
form	O
of	O
the	O
NF-kappa	O
B	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
(	O
mut-I	O
kappa	O
B	O
)	O
and	O
to	O
study	O
the	O
maturation	O
defects	O
occurring	O
when	O
NF-kappa	O
B	O
activation	O
is	O
inhibited	O
during	O
fetal	O
development	O
.	O

Fetal	O
thymocytes	O
infected	O
with	O
adenovirus	O
containing	O
mut-I	O
kappa	O
B	O
were	O
found	O
to	O
develop	O
normally	O
until	O
the	O
CD44-CD25+	O
,	O
CD4-CD8-	O
double-negative	O
stage	O
,	O
while	O
production	O
of	O
more	O
mature	O
double-positive	O
and	O
single-positive	O
populations	O
was	O
strongly	O
decreased	O
.	O

Proliferation	O
,	O
as	O
measured	O
by	O
the	O
percentage	O
of	O
cells	O
in	O
cycle	O
appeared	O
normal	O
,	O
as	O
did	O
rearrangement	O
and	O
expression	O
of	O
the	O
TCR	O
beta-chain	O
.	O

However	O
,	O
apoptosis	O
was	O
much	O
higher	O
in	O
FTOC	O
infected	O
with	O
adenovirus	O
containing	O
mut-I	O
kappa	O
B	O
than	O
in	O
FTOC	O
infected	O
with	O
a	O
control	O
virus	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-kappa	O
B	O
plays	O
a	O
crucial	O
role	O
in	O
ensuring	O
the	O
differentiation	O
and	O
survival	O
of	O
thymocytes	O
in	O
the	O
early	O
stages	O
of	O
their	O
development	O
.	O

Differential	O
regulation	O
of	O
4E-BP1	O
and	O
4E-BP2	O
,	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
.	O

Human	O
myeloid	O
differentiation	O
is	O
accompanied	O
by	O
a	O
decrease	O
in	O
cell	O
proliferation	O
.	O

Because	O
the	O
translation	O
rate	O
is	O
an	O
important	O
determinant	O
of	O
cell	O
proliferation	O
,	O
we	O
have	O
investigated	O
translation	O
initiation	O
during	O
human	O
myeloid	O
cell	O
differentiation	O
using	O
the	O
HL-60	O
promyelocytic	O
leukemia	O
cell	O
line	O
and	O
the	O
U-937	O
monoblastic	O
cell	O
line	O
.	O

A	O
decrease	O
in	O
the	O
translation	O
rate	O
is	O
observed	O
when	O
the	O
cells	O
are	O
induced	O
to	O
differentiate	O
along	O
the	O
monocytic/macrophage	O
pathway	O
or	O
along	O
the	O
granulocytic	O
pathway	O
.	O

The	O
inhibition	O
in	O
protein	O
synthesis	O
correlates	O
with	O
specific	O
regulation	O
of	O
two	O
repressors	O
of	O
translation	O
initiation	O
,	O
4E-BP1	O
and	O
4E-BP2	O
.	O

Induction	O
of	O
HL-60	O
and	O
U-937	O
cell	O
differentiation	O
into	O
monocytes/macrophages	O
by	O
IFN-gamma	O
or	O
PMA	O
results	O
in	O
a	O
dephosphorylation	O
and	O
consequent	O
activation	O
of	O
4E-BP1	O
.	O

Dephosphorylation	O
of	O
4E-BP1	O
was	O
also	O
observed	O
when	O
U-937	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
monocytes/macrophages	O
following	O
treatment	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
.	O

In	O
contrast	O
,	O
treatment	O
of	O
HL-60	O
cells	O
with	O
retinoic	O
acid	O
or	O
DMSO	O
,	O
which	O
results	O
in	O
a	O
granulocytic	O
differentiation	O
of	O
these	O
cells	O
,	O
decreases	O
4E-BP1	O
amount	O
without	B-Negation
affecting	I-Negation
its	I-Negation
phosphorylation	I-Negation
and	O
strongly	O
increases	O
4E-BP2	O
amount	O
.	O

Taken	O
together	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
differential	O
regulation	O
of	O
the	O
translational	O
machinery	O
during	O
human	O
myeloid	O
differentiation	O
,	O
specific	O
to	O
the	O
monocytic/macrophage	O
pathway	O
or	O
to	O
the	O
granulocytic	O
pathway	O
.	O

Stimulation	O
of	O
CD40	O
on	O
immunogenic	O
human	O
malignant	O
melanomas	O
augments	O
their	O
cytotoxic	O
T	O
lymphocyte-mediated	O
lysis	O
and	O
induces	O
apoptosis	O
.	O

Here	O
,	O
we	O
report	O
the	O
functional	O
expression	O
of	O
CD40	O
on	O
human	O
malignant	O
melanomas	O
(	O
MMs	O
)	O
.	O

Comparison	O
of	O
tumor	O
specimen	O
from	O
MM	O
precursor	O
lesions	O
,	O
primary	O
tumors	O
,	O
and	O
metastases	O
revealed	O
that	O
CD40	O
surface	O
expression	O
is	O
down-regulated	O
during	O
tumor	O
progression	O
.	O

CD40	O
expression	O
was	O
confirmed	O
in	O
7	O
human	O
MM	O
cell	O
lines	O
established	O
from	O
immunogenic	O
primary	O
tumors	O
or	O
metastases	O
,	O
whereas	O
11	O
cell	O
lines	O
established	O
from	O
advanced	O
stages	O
were	O
CD40	O
negative	O
.	O

CD40	O
expression	O
could	O
be	O
enhanced	O
in	O
CD40-positive	O
MM	O
by	O
stimulation	O
with	O
IFN-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
but	O
not	B-Negation
by	I-Negation
interleukin	I-Negation
(	I-Negation
IL	I-Negation
)	I-Negation
-1beta	I-Negation
or	I-Negation
CD40	I-Negation
triggering	I-Negation
.	O

CD40	O
ligation	O
on	O
MM	O
by	O
CD40L-transfected	O
murine	O
L-cells	O
or	O
by	O
a	O
soluble	O
CD40L	O
fusion	O
protein	O
up-regulated	O
their	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
and	O
MHC	O
class	O
I	O
and	O
class	O
II	O
molecules	O
and	O
their	O
secretion	O
of	O
IL-6	O
,	O
IL-8	O
,	O
tumor	O
necrosis	O
factor-a	O
,	O
and	O
granulocyte	O
macrophage	O
colony-stimulating	O
factor	O
and	O
also	O
induced	O
a	O
rapid	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
.	O

Furthermore	O
,	O
CD40	O
ligation	O
of	O
a	O
HLA-A2+	O
,	O
MelanA/MART1+	O
MM	O
cell	O
line	O
enhanced	O
its	O
susceptibility	O
to	O
specific	O
lysis	O
by	O
a	O
HLA-A2-restricted	O
,	O
MelanA/MART-1-specific	O
CTL	O
clone	O
.	O

Finally	O
,	O
CD40	O
ligation	O
induced	O
growth	O
inhibition	O
and	O
apoptosis	O
in	O
MM	O
.	O

These	O
results	O
indicate	O
that	O
CD40-CD40L	O
interactions	O
may	O
play	O
an	O
important	O
role	O
in	O
augmenting	O
antitumor	O
immunity	O
and	O
inducing	O
apoptosis	O
in	O
some	O
CD40-positive	O
immunogenic	O
human	O
MMs	O
.	O

Essential	O
role	O
of	O
alveolar	O
macrophages	O
in	O
intrapulmonary	O
activation	O
of	O
NF-kappaB	O
.	O

Acute	O
inflammatory	O
injury	O
in	O
rat	O
lung	O
induced	O
by	O
deposition	O
of	O
immunoglobulin	O
G	O
immune	O
complexes	O
requires	O
expression	O
of	O
cytokines	O
and	O
chemokines	O
as	O
well	O
as	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
.	O

There	O
is	O
little	O
direct	O
evidence	O
regarding	O
the	O
role	O
of	O
alveolar	O
macrophages	O
in	O
these	O
activation	O
events	O
.	O

In	O
the	O
present	O
studies	O
,	O
rat	O
lungs	O
were	O
depleted	O
of	O
alveolar	O
macrophages	O
by	O
airway	O
instillation	O
of	O
liposome-encapsulated	O
dichloromethylene	O
diphosphonate	O
.	O

These	O
procedures	O
,	O
which	O
greatly	O
reduced	O
the	O
number	O
of	O
retrievable	O
alveolar	O
macrophages	O
,	O
suppressed	O
activation	O
of	O
lung	O
NF-kappaB	O
in	O
the	O
inflammatory	O
model	O
.	O

In	O
addition	O
,	O
bronchoalveolar	O
lavage	O
levels	O
of	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
and	O
the	O
CXC	O
chemokine	O
,	O
macrophage	O
inflammatory	O
protein-2	O
,	O
were	O
substantially	O
reduced	O
.	O

In	O
parallel	O
,	O
upregulation	O
of	O
the	O
lung	O
vascular	O
adhesion	O
molecule	O
,	O
intercellular	O
adhesion	O
molecule-1	O
,	O
was	O
greatly	O
reduced	O
by	O
intrapulmonary	O
instillation	O
of	O
phosphonate-containing	O
liposomes	O
.	O

Neutrophil	O
accumulation	O
and	O
development	O
of	O
lung	O
injury	O
were	O
also	O
substantially	O
diminished	O
.	O

Lung	O
instillation	O
of	O
TNF-alpha	O
in	O
alveolar	O
macrophage-depleted	O
rats	O
restored	O
the	O
NF-kappaB	O
activation	O
response	O
in	O
whole	O
lung	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
this	O
inflammatory	O
model	O
,	O
initial	O
activation	O
of	O
NF-kappaB	O
occurs	O
in	O
alveolar	O
macrophages	O
and	O
the	O
ensuing	O
production	O
of	O
TNF-alpha	O
may	O
propagate	O
NF-kappaB	O
activation	O
to	O
other	O
cell	O
types	O
in	O
the	O
lung	O
.	O

Inhibition	O
of	O
cyclooxygenase-2	O
expression	O
by	O
4-trifluoromethyl	O
derivatives	O
of	O
salicylate	O
,	O
triflusal	O
,	O
and	O
its	O
deacetylated	O
metabolite	O
,	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
.	O

The	O
therapeutic	O
potential	O
of	O
drugs	O
that	O
block	O
the	O
induction	O
of	O
cyclooxygenase-2	O
has	O
been	O
emphasized	O
.	O

When	O
two	O
4-trifluoromethyl	O
salicylate	O
derivatives	O
[	O
2-acetoxy-4-trifluoromethyl-benzoic	O
acid	O
(	O
triflusal	O
)	O
and	O
its	O
deacetylated	O
metabolite	O
2-hydroxy-4-trifluoromethylbenzoic	O
acid	O
(	O
HTB	O
)	O
]	O
were	O
compared	O
with	O
aspirin	O
and	O
sodium	O
salicylate	O
as	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
inhibitors	O
,	O
we	O
observed	O
that	O
in	O
bacterial	O
lipopolysaccharide-activated	O
human	O
blood	O
,	O
triflusal	O
,	O
aspirin	O
,	O
and	O
HTB	O
,	O
but	O
not	B-Negation
sodium	I-Negation
salicylate	I-Negation
,	O
inhibited	O
COX-2-mediated	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
production	O
(	O
IC50	O
=	O
0.16	O
,	O
0.18	O
,	O
0.39	O
,	O
and	O
>	O
10	O
mM	O
,	O
respectively	O
)	O
.	O

However	O
,	O
only	O
triflusal	O
and	O
aspirin	O
inhibited	O
purified	O
COX-2	O
enzyme	O
.	O

To	O
test	O
this	O
apparent	O
discrepancy	O
,	O
we	O
realized	O
that	O
HTB	O
and	O
triflusal	O
(	O
but	O
neither	B-Negation
aspirin	I-Negation
nor	I-Negation
salicylate	I-Negation
)	O
produced	O
a	O
concentration-dependent	O
inhibition	O
of	O
COX-2	O
protein	O
expression	O
in	O
peripheral	O
human	O
mononuclear	O
cells	O
.	O

This	O
observation	O
was	O
further	O
confirmed	O
in	O
a	O
rat	O
air	O
pouch	O
model	O
in	O
vivo	O
,	O
in	O
which	O
both	O
aspirin	O
and	O
triflusal	O
inhibited	O
PGE2	O
production	O
(	O
ID50	O
=	O
18.9	O
and	O
11.4	O
mg/kg	O
p.o.	O
,	O
respectively	O
)	O
but	O
only	O
triflusal-treated	O
animals	O
showed	O
a	O
decrease	O
in	O
COX-2	O
expression	O
.	O

This	O
different	O
behavior	O
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
ability	O
of	O
HTB	O
and	O
triflusal	O
to	O
block	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
to	O
a	O
higher	O
extent	O
than	O
aspirin	O
and	O
sodium	O
salicylate	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
inhibiting	O
the	O
COX-2	O
activity	O
at	O
therapeutic	O
concentrations	O
,	O
triflusal	O
is	O
able	O
to	O
block	O
through	O
its	O
metabolite	O
HTB	O
the	O
expression	O
of	O
new	O
enzyme	O
,	O
and	O
hence	O
the	O
resumption	O
of	O
PGE2	O
synthesis	O
.	O

Triflusal	O
and	O
HTB	O
may	O
exert	O
beneficial	O
effects	O
in	O
processes	O
in	O
which	O
de	O
novo	O
COX-2	O
expression	O
is	O
involved	O
and	O
,	O
in	O
a	O
broader	O
sense	O
,	O
in	O
pathological	O
situations	O
in	O
which	O
genes	O
under	O
nuclear	O
factor-kappaB	O
control	O
are	O
up-regulated	O
.	O

Expression	O
of	O
IkappaBalpha	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O

According	O
to	O
current	O
models	O
the	O
inhibitory	O
capacity	O
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
would	O
be	O
mediated	O
through	O
the	O
retention	O
of	O
Rel/NF-kappaB	O
proteins	O
in	O
the	O
cytosol	O
.	O

However	O
,	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
has	O
also	O
been	O
detected	O
in	O
the	O
nucleus	O
of	O
cell	O
lines	O
and	O
when	O
overexpressed	O
by	O
transient	O
transfection	O
.	O

To	O
gain	O
better	O
insight	O
into	O
the	O
potential	O
role	O
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
in	O
a	O
physiological	O
context	O
we	O
have	O
analysed	O
its	O
presence	O
in	O
the	O
nucleus	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

We	O
demonstrate	O
the	O
nuclear	O
localization	O
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
in	O
PBL	O
by	O
different	O
techniques	O
:	O
Western	O
blot	O
,	O
indirect	O
immunofluorescence	O
and	O
electron	O
microscopy	O
.	O

Low	O
levels	O
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
were	O
detected	O
in	O
resting	O
cells	O
whereas	O
a	O
superinduction	O
was	O
obtained	O
after	O
PMA	O
activation	O
.	O

The	O
nuclear	O
pool	O
of	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
showed	O
a	O
higher	O
stability	O
than	O
cytosolic	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
and	O
was	O
partially	O
independent	O
of	O
the	O
resynthesis	O
of	O
the	O
protein	O
.	O

Unexpectedly	O
,	O
the	O
presence	O
of	O
nuclear	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
did	O
not	B-Negation
inhibit	I-Negation
NF-kappaB	I-Negation
binding	I-Negation
to	I-Negation
DNA	I-Negation
and	O
this	O
phenomenon	O
was	O
not	B-Negation
due	I-Negation
to	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
IkappaBbeta	I-Negation
at	I-Negation
the	I-Negation
nuclear	I-Negation
level	I-Negation
.	O

Immunoprecipitation	O
experiments	O
failed	B-Negation
to	I-Negation
demonstrate	I-Negation
an	I-Negation
association	I-Negation
between	I-Negation
nuclear	I-Negation
I	I-Negation
(	I-Negation
kappa	I-Negation
)	I-Negation
B	I-Negation
(	I-Negation
alpha	I-Negation
)	I-Negation
and	I-Negation
NF-kappaB	I-Negation
proteins	I-Negation
.	O

Our	O
results	O
demonstrate	O
that	O
in	O
resting	O
and	O
PMA-activated	O
human	O
PBL	O
,	O
I	O
(	O
kappa	O
)	O
B	O
(	O
alpha	O
)	O
is	O
present	O
in	O
the	O
nucleus	O
in	O
an	B-Negation
apparently	I-Negation
inactive	I-Negation
form	I-Negation
unable	I-Negation
to	I-Negation
disrupt	I-Negation
NF-kappaB	I-Negation
binding	I-Negation
from	I-Negation
DNA	I-Negation
.	O

PGG-glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1,3	O
)	O
-glucan	O
,	O
enhances	O
the	O
oxidative	O
burst	O
response	O
,	O
microbicidal	O
activity	O
,	O
and	O
activates	O
an	O
NF-kappa	O
B-like	O
factor	O
in	O
human	O
PMN	O
:	O
evidence	O
for	O
a	O
glycosphingolipid	O
beta-	O
(	O
1,3	O
)	O
-glucan	O
receptor	O
.	O

PGG-Glucan	O
,	O
a	O
soluble	O
beta-	O
(	O
1,6	O
)	O
-branched	O
beta-	O
(	O
1,3	O
)	O
-linked	O
glucose	O
homopolymer	O
derived	O
from	O
the	O
cell	O
wall	O
of	O
the	O
yeast	O
Saccharomyces	O
cerevisiae	O
,	O
is	O
an	O
immunomodulator	O
which	O
enhances	O
leukocyte	O
anti-infective	O
activity	O
and	O
enhances	O
myeloid	O
and	O
megakaryocyte	O
progenitor	O
proliferation	O
.	O

Incubation	O
of	O
human	O
whole	O
blood	O
with	O
PGG-Glucan	O
significantly	O
enhanced	O
the	O
oxidative	O
burst	O
response	O
of	O
subsequently	O
isolated	O
blood	O
leukocytes	O
to	O
both	O
soluble	O
and	O
particulate	O
activators	O
in	O
a	O
dose-dependent	O
manner	O
,	O
and	O
increased	O
leukocyte	O
microbicidal	O
activity	O
.	O

No	B-Negation
evidence	I-Negation
for	I-Negation
inflammatory	I-Negation
cytokine	I-Negation
production	I-Negation
was	I-Negation
obtained	I-Negation
under	I-Negation
these	I-Negation
conditions	I-Negation
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
PGG-Glucan	O
induced	O
the	O
activation	O
of	O
an	O
NF-kappaB-like	O
nuclear	O
transcription	O
factor	O
in	O
purified	O
human	O
neutrophils	O
.	O

The	O
binding	O
of	O
3H-PGG-Glucan	O
to	O
human	O
leukocyte	O
membranes	O
was	O
specific	O
,	O
concentration-dependent	O
,	O
saturable	O
,	O
and	O
high	O
affinity	O
(	O
Kd	O
approximately	O
6	O
nM	O
)	O
.	O

A	O
monoclonal	O
antibody	O
specific	O
to	O
the	O
glycosphingolipid	O
lactosylceramide	O
was	O
able	O
to	O
inhibit	O
activation	O
of	O
the	O
NF-kappaB-like	O
factor	O
by	O
PGG-Glucan	O
,	O
and	O
ligand	O
binding	O
data	O
,	O
including	O
polysaccharide	O
specificity	O
,	O
suggested	O
that	O
the	O
PGG-Glucan	O
binding	O
moiety	O
was	O
lactosylceramide	O
.	O

These	O
results	O
indicate	O
that	O
PGG-Glucan	O
enhances	O
neutrophil	O
anti-microbial	O
functions	O
and	O
that	O
interaction	O
between	O
this	O
beta-glucan	O
and	O
human	O
neutrophils	O
is	O
mediated	O
by	O
the	O
glycosphingolipid	O
lactosylceramide	O
present	O
at	O
the	O
cell	O
surface	O
.	O

[	O
Corticoids	O
and	O
allergy	O
]	O

Inflammation	O
is	O
constantly	O
observed	O
in	O
allergic	O
reactions	O
.	O

Corticosteroids	O
are	O
most	O
effective	O
in	O
preventing	O
the	O
late	O
phase	O
of	O
allergic	O
reaction	O
.	O

The	O
action	O
of	O
glucocorticosteroids	O
is	O
mediated	O
through	O
glucocorticoid	O
receptors	O
present	O
in	O
the	O
cellular	O
cytoplasm	O
.	O

When	O
activated	O
,	O
glucocorticoid	O
receptors	O
form	O
a	O
dimer	O
and	O
bind	O
to	O
DNA	O
after	O
migration	O
into	O
the	O
nucleus	O
.	O

Interaction	O
to	O
DNA	O
induces	O
changes	O
in	O
the	O
transcription	O
rate	O
,	O
leading	O
to	O
either	O
gene	O
induction	O
or	O
gene	O
repression	O
.	O

Glucocorticoid	O
receptors	O
are	O
also	O
able	O
to	O
interact	O
with	O
transcriptional	O
factors	O
such	O
as	O
AP-1	O
(	O
activator	O
protein-1	O
)	O
of	O
NF-kappa	O
B	O
(	O
nuclear	O
factor-kappa	O
B	O
)	O
.	O

Through	O
these	O
actions	O
glucocorticosteroids	O
are	O
susceptible	O
to	O
modify	O
functions	O
of	O
cells	O
involved	O
in	O
the	O
allergic	O
inflammatory	O
response	O
.	O

They	O
are	O
in	O
particular	O
able	O
to	O
inhibit	O
most	O
of	O
the	O
pro-inflammatory	O
functions	O
of	O
the	O
eosinophils	O
.	O

Activation	O
of	O
NF-kappaB	O
in	O
Mycobacterium	O
tuberculosis-	O
induced	O
interleukin-2	O
receptor	O
expression	O
in	O
mononuclear	O
phagocytes	O
.	O

Soluble	O
interleukin-2	O
receptor-alpha	O
(	O
IL-2Ralpha	O
)	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
the	O
sera	O
of	O
patients	O
with	O
advanced	O
tuberculosis	O
,	O
and	O
levels	O
decline	O
after	O
therapy	O
in	O
accordance	O
with	O
improvement	O
of	O
radiologic	O
findings	O
.	O

We	O
investigated	O
expression	O
of	O
the	O
IL-2Ralpha	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
cells	O
in	O
active	O
pulmonary	O
tuberculosis	O
,	O
and	O
evaluated	O
the	O
mechanism	O
Mycobacterium	O
tuberculosis	O
induces	O
in	O
the	O
IL-2Ralpha	O
using	O
the	O
THP-1	O
mononuclear	O
phagocyte	O
cell	O
line	O
.	O

We	O
found	O
IL-2Ralpha	O
expression	O
to	O
be	O
increased	O
in	O
BAL	O
cells	O
from	O
involved	O
sites	O
of	O
active	O
pulmonary	O
tuberculosis	O
.	O

Expression	O
of	O
the	O
alpha-chain	O
of	O
IL-2Ralpha	O
on	O
peripheral	O
blood	O
monocytes	O
(	O
PBM	O
)	O
was	O
induced	O
by	O
M.	O
tuberculosis	O
by	O
flow	O
cytometry	O
evaluation	O
.	O

Northern	O
analysis	O
demonstrated	O
increased	O
IL-2Ralpha	O
gene	O
expression	O
after	O
stimulation	O
with	O
M.	O
tuberculosis	O
which	O
was	O
further	O
induced	O
by	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
.	O

The	O
IL-2Ralpha	O
promoter	O
containing	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappaB	O
)	O
site	O
was	O
transcriptionally	O
induced	O
by	O
M.	O
tuberculosis	O
and	O
this	O
NF-kappaB	O
site	O
could	O
confer	O
inducibility	O
to	O
a	O
heterologous	O
herpes	O
thymidine	O
kinase	O
(	O
TK	O
)	O
promoter	O
by	O
M.	O
tuberculosis	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
revealed	O
specific	O
binding	O
of	O
nuclear	O
protein	O
to	O
the	O
NF-kappaB	O
site	O
upon	O
induction	O
with	O
M.	O
tuberculosis	O
.	O

Using	O
antibodies	O
against	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
NF-kappaB	O
in	O
EMSAs	O
,	O
the	O
involvement	O
of	O
both	O
p50	O
and	O
p65	O
proteins	O
was	O
further	O
demonstrated	O
.	O

Functional	O
expression	O
of	O
the	O
IL-2Ralpha	O
on	O
mononuclear	O
phagocytes	O
in	O
M.	O
tuberculosis	O
infection	O
may	O
play	O
an	O
important	O
immunomodulatory	O
role	O
in	O
the	O
host	O
response	O
.	O

Regulation	O
of	O
the	O
megakaryocytic	O
glycoprotein	O
IX	O
promoter	O
by	O
the	O
oncogenic	O
Ets	O
transcription	O
factor	O
Fli-1	O
.	O

Glycoprotein	O
(	O
GP	O
)	O
IX	O
is	O
a	O
subunit	O
of	O
the	O
von	O
Willebrand	O
receptor	O
,	O
GPIb-V-IX	O
,	O
which	O
mediates	O
adhesion	O
of	O
platelets	O
to	O
the	O
subendothelium	O
of	O
damaged	O
blood	O
vessels	O
.	O

Previous	O
characterization	O
of	O
the	O
GPIX	O
promoter	O
identified	O
a	O
functional	O
Ets	O
site	O
that	O
,	O
when	O
disrupted	O
,	O
reduced	O
promoter	O
activity	O
.	O

However	O
,	O
the	O
Ets	O
protein	O
(	O
s	O
)	O
that	O
regulated	O
GPIX	O
promoter	O
expression	O
was	O
unknown	O
.	O

In	O
this	O
study	O
,	O
transient	O
cotransfection	O
of	O
several	O
GPIX	O
promoter/reporter	O
constructs	O
into	O
293T	O
kidney	O
fibroblasts	O
with	O
a	O
Fli-1	O
expression	O
vector	O
shows	O
that	O
the	O
oncogenic	O
protein	O
Fli-1	O
can	O
transactivate	O
the	O
GPIX	O
promoter	O
when	O
an	O
intact	O
GPIX	O
Ets	O
site	O
is	O
present	O
.	O

In	O
addition	O
,	O
Fli-1	O
binding	O
of	O
the	O
GPIX	O
Ets	O
site	O
was	O
identified	O
in	O
antibody	O
supershift	O
experiments	O
in	O
nuclear	O
extracts	O
derived	O
from	O
hematopoietic	O
human	O
erythroleukemia	O
cells	O
.	O

Comparative	O
studies	O
showed	O
that	O
Fli-1	O
was	O
also	O
able	O
to	O
transactivate	O
the	O
GPIbalpha	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
the	O
GPIIb	O
promoter	O
.	O

Immunoblot	O
analysis	O
identified	O
Fli-1	O
protein	O
in	O
lysates	O
derived	O
from	O
platelets	O
.	O

In	O
addition	O
,	O
expression	O
of	O
Fli-1	O
was	O
identified	O
immunohistochemically	O
in	O
megakaryocytes	O
derived	O
from	O
CD34	O
(	O
+	O
)	O
cells	O
treated	O
with	O
the	O
megakaryocyte	O
differentiation	O
and	O
proliferation	O
factor	O
,	O
thrombopoietin	O
.	O

These	O
results	O
suggest	O
that	O
Fli-1	O
is	O
likely	O
to	O
regulate	O
lineage-specific	O
genes	O
during	O
megakaryocytopoiesis	O
.	O

Role	O
of	O
cellular	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factors	O
in	O
NF-kappaB	O
activation	O
and	O
lymphocyte	O
transformation	O
by	O
herpesvirus	O
Saimiri	O
STP	O
.	O

The	O
STP	O
oncoproteins	O
of	O
the	O
herpesvirus	O
saimiri	O
(	O
HVS	O
)	O
subgroup	O
A	O
strain	O
11	O
and	O
subgroup	O
C	O
strain	O
488	O
are	O
now	O
found	O
to	O
be	O
stably	O
associated	O
with	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factor	O
(	O
TRAF	O
)	O
1	O
,	O
2	O
,	O
or	O
3	O
.	O

Mutational	O
analyses	O
identified	O
residues	O
of	O
PXQXT/S	O
in	O
STP-A11	O
as	O
critical	O
for	O
TRAF	O
association	O
.	O

In	O
addition	O
,	O
a	O
somewhat	O
divergent	O
region	O
of	O
STP-C488	O
is	O
critical	O
for	O
TRAF	O
association	O
.	O

Mutational	O
analysis	O
also	O
revealed	O
that	O
STP-C488	O
induced	O
NF-kappaB	O
activation	O
that	O
was	O
correlated	O
with	O
its	O
ability	O
to	O
associate	O
with	O
TRAFs	O
.	O

The	O
HVS	O
STP-C488	O
P10	O
--	O
>	O
R	O
mutant	O
was	O
deficient	O
in	O
human	O
T-lymphocyte	O
transformation	O
to	O
interleukin-2-independent	O
growth	O
but	O
showed	O
wild-type	O
phenotype	O
for	O
marmoset	O
T-lymphocyte	O
transformation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

The	O
STP-C488	O
P10	O
--	O
>	O
R	O
mutant	O
was	O
also	O
defective	O
in	O
Rat-1	O
fibroblast	O
transformation	O
,	O
and	O
fibroblast	O
cell	O
transformation	O
was	O
blocked	O
by	O
a	O
TRAF2	O
dominant-negative	O
mutant	O
.	O

These	O
data	O
implicate	O
TRAFs	O
in	O
STP-C488-mediated	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Other	O
factors	O
are	O
implicated	O
in	O
immortalization	O
of	O
common	O
marmoset	O
T	O
lymphocytes	O
and	O
may	O
also	O
be	O
critical	O
in	O
the	O
transformation	O
of	O
human	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

Studies	O
into	O
the	O
effect	O
of	O
tyrosine	O
phosphatase	O
inhibitor	O
phenylarsine	O
oxide	O
on	O
NFkappaB	O
activation	O
in	O
T	O
lymphocytes	O
during	O
aging	O
:	O
evidence	O
for	O
altered	O
IkappaB-alpha	O
phosphorylation	O
and	O
degradation	O
.	O

Nuclear	O
Factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
is	O
a	O
critical	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Treatment	O
of	O
T	O
cells	O
with	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
TNF-alpha	O
,	O
leads	O
to	O
the	O
translocation	O
of	O
the	O
active	O
p65-50	O
heterodimer	O
to	O
the	O
nucleus	O
,	O
albeit	O
at	O
a	O
lower	O
level	O
in	O
T	O
cells	O
from	O
the	O
elderly	O
.	O

We	O
demonstrate	O
here	O
that	O
pretreatment	O
with	O
PAO	O
results	O
in	O
the	O
inhibition	O
of	O
NFkappaB	O
induction	O
in	O
TNF-alpha	O
treated	O
T	O
cells	O
,	O
suggesting	O
a	O
role	O
for	O
PAO-sensitive	O
phosphatase	O
in	O
the	O
activation	O
of	O
the	O
NFkappaB	O
via	O
this	O
pathway	O
in	O
human	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
demonstrates	O
that	O
aging	O
does	O
not	B-Negation
influence	I-Negation
the	I-Negation
sensitivity	I-Negation
of	I-Negation
this	I-Negation
phosphatase	I-Negation
.	O

Treatment	O
with	O
DMP	O
prior	O
to	O
treatment	O
with	O
PAO	O
and	O
TNF	O
abolishes	O
the	O
inhibition	O
induced	O
by	O
PAO	O
,	O
in	O
T	O
cells	O
from	O
both	O
young	O
and	O
old	O
donors	O
,	O
alike	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
a	O
failure	B-Negation
to	I-Negation
degrade	I-Negation
IkappaB-alpha	I-Negation
in	I-Negation
cytosols	I-Negation
of	I-Negation
TNF-treated	I-Negation
T	I-Negation
cells	I-Negation
pretreated	I-Negation
with	I-Negation
PAO	I-Negation
is	O
due	O
to	O
its	O
interference	O
with	O
the	O
phosphorylation	O
of	O
IkappaB-alpha	O
and	O
not	B-Negation
due	I-Negation
to	I-Negation
its	I-Negation
inhibitory	I-Negation
effect	I-Negation
on	I-Negation
proteasomal	I-Negation
degradation	I-Negation
.	O

These	O
data	O
collectively	O
suggest	O
that	O
PAO	O
interferes	O
with	O
the	O
phosphorylation	O
and	O
the	O
regulated	O
degradation	O
of	O
IkappaB-alpha	O
,	O
induced	O
by	O
TNF	O
,	O
without	O
affecting	O
the	O
chymotryptic	O
activity	O
of	O
the	O
proteasome	O
,	O
independent	O
of	O
age	O
.	O

A	O
novel	O
lipopolysaccharide-induced	O
transcription	O
factor	O
regulating	O
tumor	O
necrosis	O
factor	O
alpha	O
gene	O
expression	O
:	O
molecular	O
cloning	O
,	O
sequencing	O
,	O
characterization	O
,	O
and	O
chromosomal	O
assignment	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
a	O
potent	O
stimulator	O
of	O
monocytes	O
and	O
macrophages	O
,	O
causing	O
secretion	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
and	O
other	O
inflammatory	O
mediators	O
.	O

Given	O
the	O
deleterious	O
effects	O
to	O
the	O
host	O
of	O
TNF-alpha	O
,	O
it	O
has	O
been	O
postulated	O
that	O
TNF-alpha	O
gene	O
expression	O
must	O
be	O
tightly	O
regulated	O
.	O

The	O
nature	O
of	O
the	O
nuclear	O
factor	O
(	O
s	O
)	O
that	O
control	O
TNF-alpha	O
gene	O
transcription	O
in	O
humans	O
remains	O
obscure	O
,	O
although	O
NF-kappaB	O
has	O
been	O
suggested	O
.	O

Our	O
previous	O
studies	O
pertaining	O
to	O
macrophage	O
response	O
to	O
LPS	O
identified	O
a	O
novel	O
DNA-binding	O
domain	O
located	O
from	O
-550	O
to	O
-487	O
in	O
the	O
human	O
TNF-alpha	O
promoter	O
that	O
contains	O
transcriptional	O
activity	O
,	O
but	O
lacks	B-Negation
any	I-Negation
known	I-Negation
NF-kappaB-binding	I-Negation
sites	I-Negation
.	O

We	O
have	O
used	O
this	O
DNA	O
fragment	O
to	O
isolate	O
and	O
purify	O
a	O
60-kDa	O
protein	O
binding	O
to	O
this	O
fragment	O
and	O
obtained	O
its	O
amino-terminal	O
sequence	O
,	O
which	O
was	O
used	O
to	O
design	O
degenerate	O
probes	O
to	O
screen	O
a	O
cDNA	O
library	O
from	O
THP-1	O
cells	O
.	O

A	O
novel	O
cDNA	O
clone	O
(	O
1.8	O
kb	O
)	O
was	O
isolated	O
and	O
fully	O
sequenced	O
.	O

Characterization	O
of	O
this	O
cDNA	O
clone	O
revealed	O
that	O
its	O
induction	O
was	O
dependent	O
on	O
LPS	O
activation	O
of	O
THP-1	O
cells	O
;	O
hence	O
,	O
the	O
name	O
LPS-induced	O
TNF-alpha	O
factor	O
(	O
LITAF	O
)	O
.	O

Inhibition	O
of	O
LITAF	O
mRNA	O
expression	O
in	O
THP-1	O
cells	O
resulted	O
in	O
a	O
reduction	O
of	O
TNF-alpha	O
transcripts	O
.	O

In	O
addition	O
,	O
high	O
level	O
of	O
expression	O
of	O
LITAF	O
mRNA	O
was	O
observed	O
predominantly	O
in	O
the	O
placenta	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
lymph	O
nodes	O
,	O
and	O
the	O
spleen	O
.	O

Finally	O
,	O
chromosomal	O
localization	O
using	O
fluorescence	O
in	O
situ	O
hybridization	O
revealed	O
that	O
LITAF	O
mapped	O
to	O
chromosome	O
16p12-16p13.3	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
LITAF	O
plays	O
an	O
important	O
role	O
in	O
the	O
activation	O
of	O
the	O
human	O
TNF-alpha	O
gene	O
and	O
proposes	O
a	O
new	O
mechanism	O
to	O
control	O
TNF-alpha	O
gene	O
expression	O
.	O

Engagement	O
of	O
natural	O
cytotoxicity	O
programs	O
regulates	O
AP-1	O
expression	O
in	O
the	O
NKL	O
human	O
NK	O
cell	O
line	O
.	O

NK	O
cell	O
cytotoxicity	O
is	O
a	O
fast	O
and	O
efficient	O
mechanism	O
of	O
target	O
cell	O
lysis	O
.	O

Using	O
transcription	O
analysis	O
,	O
such	O
as	O
multiplex	O
messenger	O
assays	O
,	O
we	O
show	O
here	O
that	O
natural	O
cytotoxicity	O
exerted	O
by	O
the	O
human	O
NKL	O
cell	O
line	O
correlates	O
with	O
mRNA	O
accumulation	O
of	O
very	O
early	O
activator	O
protein	O
(	O
AP	O
)	O
-1	O
transcription	O
factor	O
genes	O
such	O
as	O
JunB	O
,	O
FosB	O
and	O
c-Fos	O
.	O

In	O
addition	O
,	O
DNA-binding	O
activities	O
of	O
Jun-Fos	O
heterodimers	O
were	O
observed	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
during	O
the	O
course	O
of	O
natural	O
cytotoxicity	O
.	O

Interaction	O
between	O
immunoglobulin-like	O
transcript-2/leukocyte	O
Ig-like	O
receptor	O
1	O
on	O
NKL	O
cells	O
and	O
HLA-B27	O
on	O
target	O
cells	O
leads	O
to	O
an	O
impairment	O
of	O
NKL	O
natural	O
cytotoxicity	O
,	O
which	O
correlates	O
with	O
an	O
absence	B-Negation
of	I-Negation
JunB	I-Negation
,	I-Negation
FosB	I-Negation
,	I-Negation
and	I-Negation
c-Fos	I-Negation
transcription	I-Negation
,	O
as	O
well	O
as	O
an	O
absence	B-Negation
of	I-Negation
their	I-Negation
DNA-binding	I-Negation
activity	I-Negation
.	O

Our	O
studies	O
thus	O
indicate	O
that	O
,	O
despite	O
the	O
rapidity	O
of	O
NK	O
cell-mediated	O
lysis	O
,	O
AP-1	O
transcription	O
factor	O
is	O
activated	O
during	O
the	O
early	O
stage	O
of	O
NK	O
cell	O
cytolytic	O
programs	O
and	O
that	O
engagement	O
of	O
NK	O
cell	O
inhibitory	O
receptors	O
for	O
MHC	O
class	O
I	O
molecules	O
impairs	O
the	O
very	O
early	O
activation	O
of	O
AP-1	O
.	O

Human	O
cytomegalovirus	O
binding	O
to	O
human	O
monocytes	O
induces	O
immunoregulatory	O
gene	O
expression	O
.	O

To	O
continue	O
our	O
investigation	O
of	O
the	O
cellular	O
events	O
that	O
occur	O
following	O
human	O
CMV	O
(	O
HCMV	O
)	O
infection	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
cellular	O
activation	O
following	O
viral	O
binding	O
to	O
human	O
monocytes	O
.	O

First	O
,	O
we	O
showed	O
that	O
viral	O
binding	O
induced	O
a	O
number	O
of	O
immunoregulatory	O
genes	O
(	O
IL-1beta	O
,	O
A20	O
,	O
NF-kappaB-p105/p50	O
,	O
and	O
IkappaBalpha	O
)	O
in	O
unactivated	O
monocytes	O
and	O
that	O
neutralizing	O
Abs	O
to	O
the	O
major	O
HCMV	O
glycoproteins	O
,	O
gB	O
(	O
UL55	O
)	O
and	O
gH	O
(	O
UL75	O
)	O
,	O
inhibited	O
the	O
induction	O
of	O
these	O
genes	O
.	O

Next	O
,	O
we	O
demonstrated	O
that	O
these	O
viral	O
ligands	O
directly	O
up-regulated	O
monocyte	O
gene	O
expression	O
upon	O
their	O
binding	O
to	O
their	O
appropriate	O
cellular	O
receptors	O
.	O

We	O
then	O
investigated	O
if	O
HCMV	O
binding	O
also	O
resulted	O
in	O
the	O
translation	O
and	O
secretion	O
of	O
cytokines	O
.	O

Our	O
results	O
showed	O
that	O
HCMV	O
binding	O
to	O
monocytes	O
resulted	O
in	O
the	O
production	O
and	O
release	O
of	O
IL-1beta	O
protein	O
.	O

Because	O
these	O
induced	O
gene	O
products	O
have	O
NF-kappaB	O
sites	O
in	O
their	O
promoter	O
regions	O
,	O
we	O
next	O
examined	O
whether	O
there	O
was	O
an	O
up-regulation	O
of	O
nuclear	O
NF-kappaB	O
levels	O
.	O

These	O
experiments	O
showed	O
that	O
,	O
in	O
fact	O
,	O
NF-kappaB	O
was	O
translocated	O
to	O
the	O
nucleus	O
following	O
viral	O
binding	O
or	O
purified	O
viral	O
ligand	O
binding	O
.	O

Changes	O
in	O
IkappaBalpha	O
levels	O
correlated	O
with	O
the	O
changes	O
in	O
NF-kappaB	O
translocation	O
.	O

Lastly	O
,	O
we	O
demonstrated	O
that	O
p38	O
kinase	O
activity	O
played	O
a	O
central	O
role	O
in	O
IL-1beta	O
production	O
and	O
that	O
it	O
was	O
rapidly	O
up-regulated	O
following	O
infection	O
.	O

These	O
results	O
support	O
our	O
hypothesis	O
that	O
HCMV	O
initiates	O
a	O
signal	O
transduction	O
pathway	O
that	O
leads	O
to	O
monocyte	O
activation	O
and	O
pinpoints	O
a	O
potential	O
mechanism	O
whereby	O
HCMV	O
infection	O
of	O
monocytes	O
can	O
result	O
in	O
profound	O
pathogenesis	O
,	O
especially	O
in	O
chronic	O
inflammatory-type	O
conditions	O
.	O

Signal	O
transduction	O
pathways	O
activated	O
in	O
endothelial	O
cells	O
following	O
infection	O
with	O
Chlamydia	O
pneumoniae	O
.	O

Chlamydia	O
pneumoniae	O
is	O
an	O
important	O
respiratory	O
pathogen	O
.	O

Recently	O
,	O
its	O
presence	O
has	O
been	O
demonstrated	O
in	O
atherosclerotic	O
lesions	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
C.	O
pneumoniae-mediated	O
activation	O
of	O
endothelial	O
cells	O
and	O
demonstrated	O
an	O
enhanced	O
expression	O
of	O
endothelial	O
adhesion	O
molecules	O
followed	O
by	O
subsequent	O
rolling	O
,	O
adhesion	O
,	O
and	O
transmigration	O
of	O
leukocytes	O
(	O
monocytes	O
,	O
granulocytes	O
)	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
mAbs	O
against	O
endothelial	O
and/or	O
leukocyte	O
adhesion	O
molecules	O
(	O
beta1	O
and	O
beta2	O
integrins	O
)	O
.	O

Additionally	O
,	O
activation	O
of	O
different	O
signal	O
transduction	O
pathways	O
in	O
C.	O
pneumoniae-infected	O
endothelial	O
cells	O
was	O
shown	O
:	O
protein	O
tyrosine	O
phosphorylation	O
,	O
up-regulation	O
of	O
phosphorylated	O
p42/p44	O
mitogen-activated	O
protein	O
kinase	O
,	O
and	O
NF-kappaB	O
activation/translocation	O
occurred	O
within	O
10-15	O
min	O
.	O

Increased	O
mRNA	O
and	O
surface	O
expression	O
of	O
E-selectin	O
,	O
ICAM-1	O
,	O
and	O
VCAM-1	O
were	O
noted	O
within	O
hours	O
.	O

Thus	O
,	O
C.	O
pneumoniae	O
triggers	O
a	O
cascade	O
of	O
events	O
that	O
could	O
lead	O
to	O
endothelial	O
activation	O
,	O
inflammation	O
,	O
and	O
thrombosis	O
,	O
which	O
in	O
turn	O
may	O
result	O
in	O
or	O
may	O
promote	O
atherosclerosis	O
.	O

Extracellular-regulated	O
kinase	O
1/2	O
,	O
Jun	O
N-terminal	O
kinase	O
,	O
and	O
c-Jun	O
are	O
involved	O
in	O
NF-kappa	O
B-dependent	O
IL-6	O
expression	O
in	O
human	O
monocytes	O
.	O

In	O
the	O
present	O
study	O
we	O
investigated	O
the	O
possible	O
involvement	O
of	O
the	O
mitogen-activated	O
protein	O
kinase	O
family	O
members	O
extracellular-regulated	O
kinase	O
1/2	O
(	O
ERK1/2	O
)	O
and	O
c-Jun	O
N-terminal	O
kinase	O
(	O
JNK	O
)	O
in	O
mediating	O
IL-6	O
gene	O
expression	O
in	O
human	O
monocytes	O
,	O
in	O
particular	O
their	O
role	O
in	O
enhancing	O
NF-kappa	O
B	O
activity	O
.	O

Freshly	O
isolated	O
monocytes	O
treated	O
with	O
the	O
protein	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
secreted	O
high	O
levels	O
of	O
IL-6	O
protein	O
,	O
which	O
coincided	O
with	O
enhanced	O
binding	O
activity	O
of	O
NF-kappa	O
B	O
as	O
well	O
as	O
with	O
phosphorylation	O
and	O
activation	O
of	O
the	O
ERK1/2	O
and	O
JNK	O
proteins	O
.	O

The	O
ERK	O
pathway-specific	O
inhibitor	O
PD98059	O
inhibited	O
IL-6	O
secretion	O
from	O
monocytes	O
.	O

Transient	O
overexpression	O
of	O
inactive	O
mutants	O
of	O
either	O
Raf-1	O
or	O
JNK1	O
showed	O
that	O
both	O
pathways	O
were	O
involved	O
in	O
kappa	O
B-dependent	O
IL-6	O
promoter	O
activity	O
.	O

By	O
using	O
PD98059	O
,	O
we	O
demonstrated	O
that	O
the	O
Raf1/MEK1/ERK1/2	O
pathway	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
DNA	I-Negation
binding	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
but	O
,	O
rather	O
,	O
acted	O
at	O
the	O
level	O
of	O
transcriptional	O
activity	O
of	O
NF-kappa	O
B	O
.	O

Interestingly	O
,	O
it	O
was	O
shown	O
that	O
NF-kappa	O
B-mediated	O
gene	O
transcription	O
,	O
both	O
in	O
the	O
context	O
of	O
the	O
IL-6	O
promoter	O
as	O
well	O
as	O
on	O
its	O
own	O
,	O
was	O
dependent	O
on	O
both	O
serine	O
kinase	O
activity	O
and	O
interaction	O
with	O
c-Jun	O
protein	O
.	O

We	O
conclude	O
that	O
okadaic	O
acid-induced	O
IL-6	O
gene	O
expression	O
is	O
at	O
least	O
partly	O
mediated	O
through	O
the	O
ERK1/2	O
and	O
JNK	O
pathway-dependent	O
activation	O
of	O
NF-kappa	O
B	O
transcriptional	O
capacity	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
JNK	O
pathway	O
may	O
regulate	O
NF-kappa	O
B-mediated	O
gene	O
transcription	O
through	O
its	O
phosphorylation	O
and	O
activation	O
of	O
c-Jun	O
.	O

Differential	O
induction	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
protein	O
10	O
following	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
is	O
related	O
to	O
the	O
changes	O
of	O
nuclear	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
and	O
kappaB	O
sites	O
.	O

We	O
examined	O
chemokine	O
gene	O
expression	O
following	O
the	O
differentiation	O
of	O
a	O
monocyte	O
,	O
macrophage	O
cell	O
lineage	O
.	O

The	O
human	O
monoblastic	O
cell	O
line	O
,	O
U937	O
was	O
differentiated	O
to	O
macrophages	O
by	O
the	O
treatment	O
with	O
either	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
or	O
vitamin	O
D3	O
(	O
VitD3	O
)	O
.	O

The	O
gene	O
expression	O
of	O
interferon	O
(	O
IFN	O
)	O
-inducible	O
protein	O
10	O
(	O
IP-10	O
)	O
(	O
a	O
CXC	O
chemokine	O
)	O
was	O
markedly	O
augmented	O
by	O
the	O
IFNgamma	O
treatment	O
in	O
PMA-	O
or	O
RA-differentiated	O
U937	O
cells	O
,	O
but	O
only	O
marginally	O
in	O
undifferentiated	O
or	O
VitD3-treated	O
cells	O
.	O

In	O
contrast	O
,	O
another	O
inducible	O
gene	O
expression	O
of	O
monocyte	O
chemotactic	O
protein-1	O
(	O
a	O
CC	O
chemokine	O
)	O
and	O
the	O
activation	O
of	O
the	O
transcriptional	O
factor	O
(	O
FcRFgamma	O
)	O
bound	O
to	O
the	O
gamma	O
response	O
region	O
were	O
similarly	O
or	O
less	O
abundantly	O
induced	O
by	O
IFNgamma	O
treatment	O
in	O
PMA-	O
or	O
RA-differentiated	O
U937	O
cells	O
,	O
indicating	O
that	O
increased	O
IP-10	O
mRNA	O
induction	O
was	O
not	O
due	O
to	O
the	O
augmented	O
ability	O
of	O
the	O
cells	O
to	O
respond	O
to	O
the	O
presence	O
of	O
IFNgamma	O
.	O

Increased	O
expression	O
of	O
IFNgamma-induced	O
IP-10	O
mRNA	O
following	O
the	O
differentiation	O
of	O
U937	O
cells	O
was	O
mediated	O
largely	O
by	O
augmented	O
transcriptional	O
activity	O
of	O
the	O
gene	O
and	O
was	O
related	O
to	O
differentiation-dependent	O
changes	O
of	O
the	O
proteins	O
bound	O
to	O
IFN	O
stimulus	O
response	O
element	O
(	O
ISRE	O
)	O
and	O
kB	O
sites	O
,	O
suggesting	O
that	O
these	O
nuclear	O
proteins	O
may	O
determine	O
the	O
IP-10	O
mRNA	O
inducibility	O
by	O
IFNgamma	O
.	O

Fludarabine-induced	O
immunosuppression	O
is	O
associated	O
with	O
inhibition	O
of	O
STAT1	O
signaling	O
.	O

Fludarabine	O
is	O
a	O
nucleoside	O
analog	O
used	O
in	O
the	O
treatment	O
of	O
hematologic	O
malignancies	O
that	O
can	O
induce	O
severe	O
and	O
prolonged	O
immunosuppression	O
.	O

Although	O
it	O
can	O
be	O
incorporated	O
into	O
the	O
DNA	O
of	O
dividing	O
cells	O
,	O
fludarabine	O
is	O
also	O
a	O
potent	O
inhibitor	O
of	O
cells	O
with	O
a	O
low	O
growth	O
fraction	O
,	O
thus	O
it	O
must	O
have	O
other	O
mechanisms	O
of	O
action	O
.	O

STAT1	O
,	O
which	O
is	O
activated	O
in	O
response	O
to	O
many	O
lymphocyte-activating	O
cytokines	O
including	O
the	O
interferons	O
,	O
is	O
essential	O
for	O
cell-mediated	O
immunity	O
,	O
as	O
the	O
absence	B-Negation
of	I-Negation
this	I-Negation
protein	I-Negation
is	O
associated	O
with	O
prominent	O
defects	O
in	O
the	O
ability	O
to	O
control	O
viral	O
infections	O
.	O

Here	O
we	O
show	O
that	O
fludarabine	O
,	O
but	O
not	B-Negation
the	I-Negation
immunosuppressant	I-Negation
cyclosporine	I-Negation
A	I-Negation
,	O
inhibits	O
the	O
cytokine-induced	O
activation	O
of	O
STAT1	O
and	O
STAT1-dependent	O
gene	O
transcription	O
in	O
normal	O
resting	O
or	O
activated	O
lymphocytes	O
.	O

Fludarabine	O
caused	O
a	O
specific	O
depletion	O
of	O
STAT1	O
protein	O
(	O
and	O
mRNA	O
)	O
but	O
not	B-Negation
of	I-Negation
other	I-Negation
STATs	I-Negation
.	O

This	O
loss	O
of	O
STAT1	O
was	O
also	O
seen	O
in	O
cells	O
from	O
patients	O
treated	O
with	O
fludarabine	O
in	O
vivo	O
.	O

Brief	O
exposure	O
to	O
fludarabine	O
led	O
to	O
a	O
sustained	O
loss	O
of	O
STAT1	O
,	O
analogous	O
to	O
the	O
prolonged	O
period	O
of	O
immunosuppression	O
induced	O
by	O
exposure	O
to	O
the	O
drug	O
in	O
vivo	O
.	O

Thus	O
,	O
STAT1	O
may	O
be	O
a	O
useful	O
target	O
in	O
the	O
development	O
of	O
new	O
immunosuppressive	O
and	O
antineoplastic	O
agents	O
.	O

Suppressive	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
human	O
endothelial	O
cell	O
activation	O
and	O
induction	O
of	O
heat	O
shock	O
proteins	O
.	O

BACKGROUND	O
:	O
Studies	O
from	O
our	O
laboratory	O
have	O
shown	O
that	O
the	O
earliest	O
stages	O
of	O
atherosclerosis	O
may	O
be	O
mediated	O
by	O
an	O
autoimmune	O
reaction	O
against	O
heat	O
shock	O
protein	O
60	O
(	O
Hsp60	O
)	O
.	O

The	O
interactions	O
of	O
Hsp60-specific	O
T	O
cells	O
with	O
arterial	O
endothelial	O
cells	O
(	O
EC	O
)	O
require	O
expression	O
of	O
both	O
Hsp60	O
and	O
certain	O
adhesion	O
molecules	O
shown	O
to	O
be	O
induced	O
simultaneously	O
in	O
EC	O
by	O
mechanical	O
and	O
other	O
types	O
of	O
stress	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
suppression	O
of	O
T	O
cell-mediated	O
immune	O
responses	O
by	O
cyclosporin	O
A	O
(	O
CyA	O
)	O
enhanced	O
atherosclerotic	O
lesion	O
formation	O
in	O
mice	O
.	O

In	O
contrast	O
,	O
aspirin	O
was	O
found	O
to	O
lower	O
the	O
risk	O
of	O
myocardial	O
infarction	O
in	O
men	O
.	O

These	O
conflicting	O
observations	O
may	O
be	O
due	O
to	O
different	O
effects	O
of	O
anti-inflammatory	O
agents	O
on	O
adhesion	O
molecule	O
and	O
Hsp	O
expression	O
in	O
EC	O
,	O
respectively	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
CyA	O
,	O
aspirin	O
,	O
and	O
indomethacin	O
on	O
T	O
cell	O
proliferation	O
using	O
a	O
proliferation	O
assay	O
.	O

To	O
explore	O
the	O
expression	O
of	O
adhesion	O
molecules	O
,	O
monocyte	O
chemoattractant	O
protein-1	O
(	O
MCP-1	O
)	O
,	O
and	O
Hsp60	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
Northern	O
blot	O
analyses	O
were	O
used	O
.	O

To	O
examine	O
the	O
activation	O
status	O
of	O
the	O
transcription	O
factors	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
and	O
heat	O
shock	O
factor-1	O
(	O
HSF-1	O
)	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
were	O
performed	O
.	O

RESULTS	O
:	O
With	B-Negation
the	I-Negation
exception	I-Negation
of	I-Negation
indomethacin	I-Negation
,	O
the	O
used	O
immunosuppressive	O
and	O
anti-inflammatory	O
agents	O
significantly	O
inhibited	O
T	O
cell	O
proliferation	O
in	O
response	O
to	O
influenza	O
virus	O
antigen	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Interestingly	O
,	O
CyA	O
and	O
indomethacin	O
did	O
not	B-Negation
suppress	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
(	I-Negation
TNF-alpha	I-Negation
)	I-Negation
-induced	I-Negation
adhesion	I-Negation
molecule	I-Negation
expression	I-Negation
on	I-Negation
HUVECs	I-Negation
,	O
whereas	O
aspirin	O
had	O
an	O
inhibitory	O
effect	O
.	O

These	O
observations	O
correlated	O
with	O
the	O
modulation	O
of	O
NF-kappaB	O
activity	O
in	O
EC	O
.	O

All	O
agents	O
tested	O
induced	O
expression	O
of	O
Hsp60	O
6	O
hr	O
after	O
application	O
.	O

In	O
addition	O
,	O
aspirin	O
and	O
indomethacin	O
,	O
but	O
not	B-Negation
CyA	I-Negation
,	O
induced	O
Hsp70	O
expression	O
in	O
HUVECs	O
that	O
correlated	O
with	O
induction	O
of	O
HSF-1	O
activity	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
the	O
tested	O
agents	O
(	O
except	B-Negation
indomethacin	I-Negation
)	O
are	O
inhibitors	O
of	O
the	O
T	O
cell-mediated	O
immune	O
response	O
,	O
as	O
expected	O
,	O
that	O
aspirin	O
is	O
an	O
effective	O
suppressor	O
of	O
adhesion	O
molecule	O
expression	O
,	O
and	O
that	O
all	O
three	O
agents	O
can	O
induce	O
Hsp60	O
in	O
HUVECs	O
.	O

These	O
data	O
provide	O
the	O
molecular	O
basis	O
for	O
the	O
notion	O
that	O
(	O
1	O
)	O
part	O
of	O
the	O
anti-atherogenic	O
effect	O
of	O
aspirin	O
may	O
be	O
due	O
to	O
the	O
prevention	O
of	O
the	O
adhesion	O
of	O
sensitized	O
T	O
cells	O
to	O
stressed	O
EC	O
;	O
(	O
2	O
)	O
that	O
part	O
of	O
the	O
atherosclerosis-promoting	O
effect	O
of	O
CyA	O
may	O
be	O
due	O
to	O
its	O
potential	O
as	O
an	O
inducer	O
of	O
Hsp60	O
expression	O
and	O
its	O
inability	O
to	O
down-regulate	O
adhesion	O
molecule	O
expression	O
on	O
EC	O
;	O
and	O
(	O
3	O
)	O
that	O
down-regulation	O
of	O
MCP-1	O
expression	O
by	O
aspirin	O
may	O
result	O
in	O
decreased	O
recruitment	O
of	O
monocytes	O
into	O
the	O
arterial	O
intima	O
beneath	O
stressed	O
EC	O
.	O

Amelioration	O
of	O
rat	O
cerulein	O
pancreatitis	O
by	O
guamerin-derived	O
peptide	O
,	O
a	O
novel	O
elastase	O
inhibitor	O
.	O

Increased	O
activity	O
of	O
various	O
proteases	O
is	O
observed	O
in	O
both	O
human	O
and	O
experimental	O
pancreatitis	O
;	O
however	O
,	O
the	O
information	O
on	O
the	O
effects	O
of	O
specific	O
protease	O
inhibitors	O
on	O
the	O
disease	O
is	O
limited	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
a	O
novel	O
elastase	O
inhibitor	O
,	O
guamerin-derived	O
synthetic	O
peptide	O
(	O
GDSP	O
)	O
,	O
improves	O
the	O
parameters	O
of	O
cerulein-induced	O
acute	O
pancreatitis	O
in	O
the	O
rat	O
.	O

The	O
effects	O
of	O
GDSP	O
on	O
pancreatic	O
weight	O
,	O
serum	O
amylase	O
and	O
lipase	O
,	O
morphologic	O
changes	O
in	O
the	O
pancreas	O
,	O
neutrophil	O
infiltration	O
,	O
and	O
nuclear	O
factor	O
KB	O
(	O
NF-KB	O
)	O
activation	O
were	O
measured	O
in	O
rats	O
infused	O
with	O
supramaximal	O
dose	O
of	O
cerulein	O
(	O
5	O
(	O
g/kg/h	O
)	O
for	O
6	O
h	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
also	O
measured	O
on	O
superoxide	O
formation	O
by	O
activated	O
human	O
neutrophils	O
.	O

The	O
effects	O
of	O
GDSP	O
were	O
compared	O
with	O
those	O
of	O
another	O
elastase	O
inhibitor	O
,	O
elastatinal	O
.	O

GDSP	O
significantly	O
inhibited	O
edema	O
formation	O
,	O
neutrophil	O
infiltration	O
,	O
acinar	O
cell	O
damage	O
,	O
and	O
plasma	O
lipase	O
and	O
amylase	O
increases	O
caused	O
by	O
cerulein	O
.	O

GDSP	O
also	O
completely	O
inhibited	O
superoxide	O
formation	O
in	O
the	O
human	O
neutrophils	O
stimulated	O
by	O
N-formyl-methionine-leucine-phenyl-alanine	O
(	O
fMLP	O
)	O
or	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

Elastatinal	O
had	O
some	O
of	O
the	O
same	O
effects	O
as	O
GDSP	O
but	O
was	O
less	O
potent	O
and	O
effective	O
.	O

These	O
results	O
demonstrate	O
a	O
beneficial	O
effect	O
of	O
GDSP	O
,	O
a	O
novel	O
specific	O
elastase	O
inhibitor	O
,	O
on	O
the	O
development	O
of	O
rat	O
cerulein	O
pancreatitis	O
.	O

Inhibition	O
of	O
T	O
cell	O
signaling	O
by	O
mitogen-activated	O
protein	O
kinase-targeted	O
hematopoietic	O
tyrosine	O
phosphatase	O
(	O
HePTP	O
)	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
to	O
produce	O
cytokines	O
is	O
regulated	O
by	O
the	O
counterbalance	O
of	O
protein-tyrosine	O
kinases	O
and	O
protein-tyrosine	O
phosphatases	O
,	O
many	O
of	O
which	O
have	O
a	O
high	O
degree	O
of	O
substrate	O
specificity	O
because	O
of	O
physical	O
association	O
with	O
their	O
targets	O
.	O

Overexpression	O
of	O
hematopoietic	O
protein-tyrosine	O
phosphatase	O
(	O
HePTP	O
)	O
results	O
in	O
suppression	O
of	O
T	O
lymphocyte	O
activation	O
as	O
measured	O
by	O
T	O
cell	O
antigen	O
receptor-induced	O
activation	O
of	O
transcription	O
factors	O
binding	O
to	O
the	O
5	O
'	O
promoter	O
of	O
the	O
interleukin-2	O
gene	O
.	O

Efforts	O
to	O
pinpoint	O
the	O
exact	O
site	O
of	O
action	O
and	O
specificity	O
of	O
HePTP	O
in	O
the	O
signaling	O
cascade	O
revealed	O
that	O
HePTP	O
acts	O
directly	O
on	O
the	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
Erk1	O
and	O
2	O
and	O
consequently	O
reduces	O
the	O
magnitude	O
and	O
duration	O
of	O
their	O
catalytic	O
activation	O
in	O
intact	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
HePTP	O
had	O
no	B-Negation
effects	I-Negation
on	I-Negation
N-terminal	I-Negation
c-Jun	I-Negation
kinase	I-Negation
or	I-Negation
on	I-Negation
events	I-Negation
upstream	I-Negation
of	I-Negation
the	I-Negation
MAP	I-Negation
kinases	I-Negation
.	O

The	O
specificity	O
of	O
HePTP	O
correlated	O
with	O
its	O
physical	O
association	O
through	O
its	O
noncatalytic	O
N	O
terminus	O
with	O
Erk	O
and	O
another	O
MAP	O
kinase	O
,	O
p38	O
,	O
but	O
not	B-Negation
Jnk	I-Negation
or	I-Negation
other	I-Negation
proteins	I-Negation
.	O

We	O
propose	O
that	O
HePTP	O
plays	O
a	O
negative	O
role	O
in	O
antigen	O
receptor	O
signaling	O
by	O
specifically	O
regulating	O
MAP	O
kinases	O
in	O
the	O
cytosol	O
and	O
at	O
early	O
time	O
points	O
of	O
T	O
cell	O
activation	O
before	O
the	O
activation-induced	O
expression	O
of	O
nuclear	O
dual-specific	O
MAP	O
kinase	O
phosphatases	O
.	O

Angiotensin	O
II	O
activates	O
the	O
proinflammatory	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
in	O
human	O
monocytes	O
.	O

The	O
renin-angiotensin	O
system	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
.	O

A	O
common	O
feature	O
of	O
all	O
stages	O
of	O
atherosclerosis	O
is	O
inflammation	O
of	O
the	O
vessel	O
wall	O
.	O

The	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
participates	O
in	O
most	O
signaling	O
pathways	O
involved	O
in	O
inflammation	O
.	O

This	O
study	O
therefore	O
examined	O
the	O
effect	O
of	O
angiotensin	O
(	O
ANG	O
)	O
II	O
on	O
NF-kappaB	O
activation	O
in	O
monocytic	O
cells	O
,	O
a	O
major	O
cellular	O
component	O
of	O
human	O
atheroma	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

ANG	O
II	O
,	O
like	O
TNFalpha	O
,	O
caused	O
rapid	O
activation	O
of	O
NF-kappaB	O
in	O
human	O
mononuclear	O
cells	O
isolated	O
from	O
peripheral	O
blood	O
by	O
Ficoll	O
density	O
gradient	O
.	O

This	O
ANG	O
II	O
effect	O
was	O
blocked	O
by	O
the	O
angiotensin	O
AT1	O
receptor	O
antagonist	O
losartan	O
.	O

Specificity	O
of	O
ANG	O
II-induced	O
NF-kappaB	O
activation	O
was	O
ascertained	O
by	O
supershift	O
and	O
competition	O
experiments	O
.	O

Moreover	O
,	O
ANG	O
II	O
stimulated	O
NF-kappaB	O
activation	O
in	O
human	O
monocytes	O
,	O
but	O
not	B-Negation
in	I-Negation
lymphocytes	I-Negation
from	I-Negation
the	I-Negation
same	I-Negation
preparation	I-Negation
.	O

Together	O
,	O
the	O
data	O
demonstrate	O
the	O
ability	O
of	O
the	O
vasoactive	O
peptide	O
ANG	O
II	O
to	O
activate	O
inflammatory	O
pathways	O
in	O
human	O
monocytes	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

SHP2-interacting	O
transmembrane	O
adaptor	O
protein	O
(	O
SIT	O
)	O
,	O
a	O
novel	O
disulfide-linked	O
dimer	O
regulating	O
human	O
T	O
cell	O
activation	O
.	O

T	O
lymphocytes	O
express	O
several	O
low	O
molecular	O
weight	O
transmembrane	O
adaptor	O
proteins	O
that	O
recruit	O
src	O
homology	O
(	O
SH	O
)	O
2	O
domain-containing	O
intracellular	O
molecules	O
to	O
the	O
cell	O
membrane	O
via	O
tyrosine-based	O
signaling	O
motifs	O
.	O

We	O
describe	O
here	O
a	O
novel	O
molecule	O
of	O
this	O
group	O
termed	O
SIT	O
(	O
SHP2	O
interacting	O
transmembrane	O
adaptor	O
protein	O
)	O
.	O

SIT	O
is	O
a	O
disulfide-linked	O
homodimeric	O
glycoprotein	O
that	O
is	O
expressed	O
in	O
lymphocytes	O
.	O

After	O
tyrosine	O
phosphorylation	O
by	O
src	O
and	O
possibly	O
syk	O
protein	O
tyrosine	O
kinases	O
SIT	O
recruits	O
the	O
SH2	O
domain-containing	O
tyrosine	O
phosphatase	O
SHP2	O
via	O
an	O
immunoreceptor	O
tyrosine-based	O
inhibition	O
motif	O
.	O

Overexpression	O
of	O
SIT	O
in	O
Jurkat	O
cells	O
downmodulates	O
T	O
cell	O
receptor-	O
and	O
phytohemagglutinin-mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
by	O
interfering	O
with	O
signaling	O
processes	O
that	O
are	O
probably	O
located	O
upstream	O
of	O
activation	O
of	O
phospholipase	O
C	O
.	O

However	O
,	O
binding	B-Negation
of	I-Negation
SHP2	I-Negation
to	I-Negation
SIT	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
inhibition	I-Negation
of	I-Negation
NF-AT	I-Negation
induction	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
SIT	I-Speculation
not	I-Speculation
only	I-Speculation
regulates	I-Speculation
NF-AT	I-Speculation
activity	I-Speculation
but	I-Speculation
also	I-Speculation
controls	I-Speculation
NF-AT	I-Speculation
unrelated	I-Speculation
pathways	I-Speculation
of	I-Speculation
T	I-Speculation
cell	I-Speculation
activation	I-Speculation
involving	I-Speculation
SHP2	I-Speculation
.	O

GrpL	O
,	O
a	O
Grb2-related	O
adaptor	O
protein	O
,	O
interacts	O
with	O
SLP-76	O
to	O
regulate	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
activation	O
.	O

Propagation	O
of	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
involves	O
a	O
number	O
of	O
adaptor	O
molecules	O
.	O

SH2	O
domain-containing	O
protein	O
76	O
(	O
SLP-76	O
)	O
interacts	O
with	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
Vav	O
to	O
activate	O
the	O
nuclear	O
factor	O
of	O
activated	O
cells	O
(	O
NF-AT	O
)	O
,	O
and	O
its	O
expression	O
is	O
required	O
for	O
normal	O
T	O
cell	O
development	O
.	O

We	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
Grb2-like	O
adaptor	O
molecule	O
designated	O
as	O
Grb2-related	O
protein	O
of	O
the	O
lymphoid	O
system	O
(	O
GrpL	O
)	O
.	O

Expression	O
of	O
GrpL	O
is	O
restricted	O
to	O
hematopoietic	O
tissues	O
,	O
and	O
it	O
is	O
distinguished	O
from	O
Grb2	O
by	O
having	O
a	O
proline-rich	O
region	O
.	O

GrpL	O
can	O
be	O
coimmunoprecipitated	O
with	O
SLP-76	O
but	O
not	B-Negation
with	I-Negation
Sos1	I-Negation
or	I-Negation
Sos2	I-Negation
from	I-Negation
Jurkat	I-Negation
cell	I-Negation
lysates	I-Negation
.	O

In	O
contrast	O
,	O
Grb2	O
can	O
be	O
coimmunoprecipitated	O
with	O
Sos1	O
and	O
Sos2	O
but	O
not	B-Negation
with	I-Negation
SLP-76	I-Negation
.	O

Moreover	O
,	O
tyrosine-phosphorylated	O
LAT/pp36/38	O
in	O
detergent	O
lysates	O
prepared	O
from	O
anti-CD3	O
stimulated	O
T	O
cells	O
associated	O
with	O
Grb2	O
but	O
not	B-Negation
GrpL	I-Negation
.	O

These	O
data	O
reveal	O
the	O
presence	O
of	O
distinct	O
complexes	O
involving	O
GrpL	O
and	O
Grb2	O
in	O
T	O
cells	O
.	O

A	O
functional	O
role	O
of	O
the	O
GrpL-SLP-76	O
complex	O
is	O
suggested	O
by	O
the	O
ability	O
of	O
GrpL	O
to	O
act	O
alone	O
or	O
in	O
concert	O
with	O
SLP-76	O
to	O
augment	O
NF-AT	O
activation	O
in	O
Jurkat	O
T	O
cells	O
.	O

Unexpected	O
and	O
coordinated	O
expression	O
of	O
Spi-1	O
,	O
Fli-1	O
,	O
and	O
megakaryocytic	O
genes	O
in	O
four	O
Epo-dependent	O
cell	O
lines	O
established	O
from	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

Most	O
erythroleukemic	O
cell	O
lines	O
established	O
in	O
vitro	O
coexpress	O
erythrocytic	O
and	O
megakaryocytic	O
markers	O
that	O
often	O
are	O
associated	O
with	O
expression	O
of	O
Spi-1	O
and/or	O
Fli-1	O
transcription	O
factors	O
known	O
as	O
transactivators	O
of	O
megakaryocyte-specific	O
promoters	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
possibility	O
of	O
establishing	O
new	O
cell	O
lines	O
keeping	O
strictly	O
erythroid-specific	O
properties	O
in	O
vitro	O
through	O
the	O
targeted	O
and	O
conditional	O
immortalization	O
of	O
erythrocytic	O
progenitors	O
.	O

For	O
that	O
purpose	O
,	O
we	O
established	O
several	O
lines	O
of	O
transgenic	O
mice	O
displaying	O
erythroid-specific	O
expression	O
of	O
a	O
thermosensitive	O
SV40	O
T	O
antigen	O
.	O

As	O
expected	O
,	O
these	O
transgenic	O
mice	O
developed	O
splenomegaly	O
due	O
to	O
the	O
massive	O
amplification	O
of	O
Ter	O
119	O
positive	O
erythroid	O
nucleated	O
cells	O
expressing	O
T	O
antigen	O
.	O

Despite	O
this	O
drastic	O
effect	O
in	O
vivo	O
,	O
the	O
in	O
vitro	O
immortalization	O
of	O
erythropoietin-dependent	O
erythroid	O
progenitors	O
unexpectedly	O
occurred	O
at	O
low	O
frequency	O
,	O
and	O
all	O
four	O
cell	O
lines	O
established	O
expressed	O
both	O
erythrocytic	O
(	O
globins	O
)	O
and	O
megakaryocytic	O
markers	O
(	O
glycoprotein	O
IIb	O
,	O
platelet	O
factor	O
4	O
)	O
as	O
well	O
as	O
Spi-1	O
and	O
Fli-1	O
transcripts	O
at	O
permissive	O
temperature	O
.	O

Switching	O
the	O
cells	O
to	O
the	O
nonpermissive	O
temperature	O
led	O
to	O
a	O
marked	O
increase	O
in	O
globin	O
gene	O
expression	O
and	O
concomitant	O
decrease	O
in	O
expression	O
of	O
Spi-1	O
,	O
Fli-1	O
,	O
and	O
megakaryocytic	O
genes	O
in	O
an	O
erythropoietin-dependent	O
manner	O
.	O

Interestingly	O
,	O
enhanced	O
expression	O
of	O
Spi-1	O
and	O
Fli-1	O
genes	O
already	O
was	O
detected	O
in	O
the	O
Ter	O
119	O
positive	O
cell	O
population	O
of	O
transgenic	O
mice	O
spleen	O
in	O
vivo	O
.	O

However	O
,	O
like	O
normal	O
Ter	O
119	O
erythroid	O
cells	O
,	O
these	O
Ter	O
119	O
positive	O
cells	O
from	O
transgenic	O
mice	O
still	O
expressed	O
high	O
levels	O
of	O
beta-globin	O
and	O
very	O
low	O
or	O
undetectable	O
glycoprotein	O
IIb	O
and	O
platelet	O
factor	O
4	O
megakaryocytic	O
transcripts	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
unexpected	O
expression	O
of	O
megakaryocytic	O
genes	O
is	O
a	O
specific	O
property	O
of	O
immortalized	O
cells	O
that	O
can	O
not	O
be	O
explained	O
only	O
by	O
enhanced	O
expression	O
of	O
Spi-1	O
and/or	O
Fli-1	O
genes	O
.	O

LPS-Induced	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
release	O
in	O
human	O
monocytes	O
are	O
protein	O
tyrosine	O
kinase	O
dependent	O
and	O
protein	O
kinase	O
C	O
independent	O
.	O

BACKGROUND	O
:	O
Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
is	O
an	O
important	O
mediator	O
of	O
septic	O
shock	O
.	O

Endotoxin	O
(	O
LPS	O
)	O
signal	O
transduction	O
in	O
human	O
monocytes	O
leads	O
to	O
activation	O
of	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	O
)	O
and	O
TNF-alpha	O
release	O
.	O

Previous	O
studies	O
have	O
implicated	O
activation	O
of	O
both	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
in	O
LPS-induced	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
production	O
.	O

We	O
hypothesized	O
that	O
inhibition	O
of	O
either	O
PKC	O
or	O
PTK	O
would	O
decrease	O
LPS-induced	O
NF-kappaB	O
DNA	O
binding	O
and	O
TNF-alpha	O
release	O
in	O
human	O
monocytes	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
monocytes	O
were	O
stimulated	O
with	O
PMA	O
(	O
50	O
ng/ml	O
)	O
alone	O
or	O
LPS	O
(	O
100	O
ng/ml	O
)	O
with	O
and	O
without	O
a	O
nonspecific	O
serine/threonine	O
protein	O
kinase	O
inhibitor	O
staurosporine	O
(	O
Stauro	O
)	O
,	O
a	O
specific	O
pan-PKC	O
inhibitor	O
bisindolylmaleimide	O
(	O
Bis	O
)	O
,	O
or	O
an	O
inhibitor	O
of	O
PTK	O
genistein	O
(	O
Gen	O
)	O
.	O

TNF-alpha	O
release	O
in	O
culture	O
supernatants	O
was	O
measured	O
by	O
an	O
ELISA	O
.	O

NF-kappaB	O
DNA	O
binding	O
was	O
evaluated	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
LPS	O
increased	O
NF-kappaB	O
DNA	O
binding	O
and	O
TNF-alpha	O
release	O
in	O
human	O
monocytes	O
.	O

Nonspecific	O
protein	O
kinase	O
inhibition	O
inhibited	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
release	O
,	O
while	O
specific	O
PKC	O
inhibition	O
with	O
Bis	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
LPS-induced	I-Negation
NF-kappaB	I-Negation
DNA	I-Negation
binding	I-Negation
or	I-Negation
TNF-alpha	I-Negation
release	I-Negation
.	O

PTK	O
inhibition	O
with	O
Gen	O
attenuated	O
both	O
LPS-induced	O
NF-kappaB	O
DNA	O
binding	O
and	O
TNF-alpha	O
production	O
in	O
human	O
monocytes	O
.	O

Direct	O
activation	O
of	O
PKC	O
with	O
PMA	O
induced	O
both	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
production	O
by	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
LPS-induced	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
release	O
in	O
human	O
monocytes	O
are	O
independent	O
of	O
PKC	O
activity	O
.	O

Furthermore	O
,	O
our	O
results	O
provide	O
evidence	O
that	O
PTK	O
plays	O
a	O
role	O
in	O
LPS-induced	O
NF-kappaB	O
activation	O
and	O
TNF-alpha	O
release	O
in	O
human	O
monocytes	O
and	O
thus	O
could	O
be	O
a	O
potential	O
therapeutic	O
target	O
in	O
inflammatory	O
states	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Cellular	O
disposition	O
of	O
sulphamethoxazole	O
and	O
its	O
metabolites	O
:	O
implications	O
for	O
hypersensitivity	O
.	O

1.	O
Bioactivation	O
of	O
sulphamethoxazole	O
(	O
SMX	O
)	O
to	O
chemically-reactive	O
metabolites	O
and	O
subsequent	O
protein	O
conjugation	O
is	O
thought	O
to	O
be	O
involved	O
in	O
SMX	O
hypersensitivity	O
.	O

We	O
have	O
therefore	O
examined	O
the	O
cellular	O
metabolism	O
,	O
disposition	O
and	O
conjugation	O
of	O
SMX	O
and	O
its	O
metabolites	O
in	O
vitro	O
.	O

2.	O
Flow	O
cytometry	O
revealed	O
binding	O
of	O
N-hydroxy	O
(	O
SMX-NHOH	O
)	O
and	O
nitroso	O
(	O
SMX-NO	O
)	O
metabolites	O
of	O
SMX	O
,	O
but	O
not	B-Negation
of	I-Negation
SMX	I-Negation
itself	I-Negation
,	O
to	O
the	O
surface	O
of	O
viable	O
white	O
blood	O
cells	O
.	O

Cellular	O
haptenation	O
by	O
SMX-NO	O
was	O
reduced	O
by	O
exogenous	O
glutathione	O
(	O
GSH	O
)	O
.	O

3.	O
SMX-NHOH	O
and	O
SMX-NO	O
were	O
rapidly	O
reduced	O
back	O
to	O
the	O
parent	O
compound	O
by	O
cysteine	O
(	O
CYS	O
)	O
,	O
GSH	O
,	O
human	O
peripheral	O
blood	O
cells	O
and	O
plasma	O
,	O
suggesting	O
that	O
this	O
is	O
an	O
important	O
and	O
ubiquitous	O
bioinactivation	O
mechanism	O
.	O

4.	O
Fluorescence	O
HPLC	O
showed	O
that	O
SMX-NHOH	O
and	O
SMX-NO	O
depleted	O
CYS	O
and	O
GSH	O
in	O
buffer	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
in	O
cells	O
and	O
plasma	O
.	O

5.	O
Neutrophil	O
apoptosis	O
and	O
inhibition	O
of	O
neutrophil	O
function	O
were	O
induced	O
at	O
lower	O
concentrations	O
of	O
SMX-NHOH	O
and	O
SMX-NO	O
than	O
those	O
inducing	O
loss	O
of	O
membrane	O
viability	O
,	O
with	O
SMX	O
having	O
no	B-Negation
effect	I-Negation
.	O

Lymphocytes	O
were	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
more	O
sensitive	O
to	O
the	O
direct	O
cytotoxic	O
effects	O
of	O
SMX-NO	O
than	O
neutrophils	O
.	O

6.	O
Partitioning	O
of	O
SMX-NHOH	O
into	O
red	O
blood	O
cells	O
was	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
lower	O
than	O
with	O
the	O
hydroxylamine	O
of	O
dapsone	O
.	O

7.	O
Our	O
results	O
suggest	O
that	O
the	O
balance	O
between	O
oxidation	O
of	O
SMX	O
to	O
its	O
toxic	O
metabolites	O
and	O
their	O
reduction	O
is	O
an	O
important	O
protective	O
cellular	O
mechanism	O
.	O

If	O
an	O
imbalance	O
exists	O
,	O
haptenation	O
of	O
the	O
toxic	O
metabolites	O
to	O
bodily	O
proteins	O
including	O
the	O
surface	O
of	O
viable	O
cells	O
can	O
occur	O
,	O
and	O
may	O
result	O
in	O
drug	O
hypersensitivity	O
.	O

Tcf-1-mediated	O
transcription	O
in	O
T	O
lymphocytes	O
:	O
differential	O
role	O
for	O
glycogen	O
synthase	O
kinase-3	O
in	O
fibroblasts	O
and	O
T	O
cells	O
.	O

Beta-catenin	O
is	O
the	O
vertebrate	O
homolog	O
of	O
the	O
Drosophila	O
segment	O
polarity	O
gene	O
Armadillo	O
and	O
plays	O
roles	O
in	O
both	O
cell-cell	O
adhesion	O
and	O
transduction	O
of	O
the	O
Wnt	O
signaling	O
cascade	O
.	O

Recently	O
,	O
members	O
of	O
the	O
Lef/Tcf	O
transcription	O
factor	O
family	O
have	O
been	O
identified	O
as	O
protein	O
partners	O
of	O
beta-catenin	O
,	O
explaining	O
how	O
beta-catenin	O
alters	O
gene	O
expression	O
.	O

Here	O
we	O
report	O
that	O
in	O
T	O
cells	O
,	O
Tcf-1	O
also	O
becomes	O
transcriptionally	O
active	O
through	O
interaction	O
with	O
beta-catenin	O
,	O
suggesting	O
that	O
the	O
Wnt	O
signal	O
transduction	O
pathway	O
is	O
operational	O
in	O
T	O
lymphocytes	O
as	O
well	O
.	O

However	O
,	O
although	O
Wnt	O
signals	O
are	O
known	O
to	O
inhibit	O
the	O
activity	O
of	O
the	O
negative	O
regulatory	O
protein	O
kinase	O
glycogen	O
synthase	O
kinase-3beta	O
(	O
GSK-3beta	O
)	O
,	O
resulting	O
in	O
increased	O
levels	O
of	O
beta-catenin	O
,	O
we	O
find	O
no	B-Negation
evidence	I-Negation
for	I-Negation
involvement	I-Negation
of	I-Negation
GSK-3beta	I-Negation
in	I-Negation
Tcf-mediated	I-Negation
transcription	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

That	O
is	O
,	O
a	O
dominant	O
negative	O
GSK-3beta	O
does	O
not	O
specifically	O
activate	O
Tcf	O
transcription	O
and	O
stimuli	O
(	O
lithium	O
or	O
phytohemagglutinin	O
)	O
that	O
inhibit	O
GSK-3beta	O
activity	O
also	O
do	O
not	B-Negation
activate	I-Negation
Tcf	I-Negation
reporter	I-Negation
genes	I-Negation
.	O

Thus	O
,	O
inhibition	O
of	O
GSK-3beta	O
is	O
insufficient	O
to	O
activate	O
Tcf-dependent	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

In	O
contrast	O
,	O
in	O
C57MG	O
fibroblast	O
cells	O
,	O
lithium	O
inactivates	O
GSK-3beta	O
and	O
induces	O
Tcf-controlled	O
transcription	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
that	O
lithium	O
can	O
alter	O
gene	O
expression	O
of	O
Tcf-responsive	O
genes	O
,	O
and	O
points	O
to	O
a	O
difference	O
in	O
regulation	O
of	O
Wnt	O
signaling	O
between	O
fibroblasts	O
and	O
lymphocytes	O
.	O

CIITA-induced	O
occupation	O
of	O
MHC	O
class	O
II	O
promoters	O
is	O
independent	O
of	O
the	O
cooperative	O
stabilization	O
of	O
the	O
promoter-bound	O
multi-protein	O
complexes	O
.	O

Precise	O
regulation	O
of	O
MHC	O
class	O
II	O
expression	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
control	O
of	O
the	O
immune	O
response	O
.	O

The	O
transactivator	O
CIITA	O
behaves	O
as	O
a	O
master	O
controller	O
of	O
constitutive	O
and	O
inducible	O
MHC	O
class	O
II	O
gene	O
activation	O
,	O
but	O
its	O
exact	O
mechanism	O
of	O
action	O
is	O
not	O
known	O
.	O

Activation	O
of	O
MHC	O
class	O
II	O
promoters	O
requires	O
binding	O
of	O
at	O
least	O
three	O
distinct	O
multi-protein	O
complexes	O
(	O
RFX	O
,	O
X2BP	O
and	O
NF-Y	O
)	O
.	O

It	O
is	O
known	O
that	O
the	O
stability	O
of	O
this	O
binding	O
results	O
from	O
cooperative	O
interactions	O
between	O
these	O
proteins	O
.	O

We	O
show	O
here	O
that	O
expression	O
of	O
CIITA	O
in	O
MHC	O
class	O
II-	O
cells	O
triggers	O
occupation	O
of	O
the	O
promoters	O
by	O
these	O
complexes	O
.	O

This	O
observation	O
raised	O
the	O
possibility	O
that	O
the	O
effect	O
of	O
CIITA	O
on	O
promoter	O
occupation	O
is	O
mediated	O
by	O
an	O
effect	O
on	O
the	O
cooperative	O
stabilization	O
of	O
the	O
DNA-bound	O
multi-protein	O
complexes	O
.	O

We	O
show	O
,	O
however	O
,	O
that	O
the	O
presence	O
of	O
CIITA	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
stability	I-Negation
of	I-Negation
the	I-Negation
higher-order	I-Negation
protein	I-Negation
complex	I-Negation
formed	I-Negation
on	I-Negation
DNA	I-Negation
by	I-Negation
RFX	I-Negation
,	I-Negation
X2BP	I-Negation
and	I-Negation
NF-Y	I-Negation
.	O

This	O
suggests	O
other	O
mechanisms	O
for	O
CIITA-induced	O
promoter	O
occupancy	O
,	O
such	O
as	O
an	O
effect	O
on	O
chromatin	O
structure	O
leading	O
to	O
increased	O
accessibility	O
of	O
MHC	O
class	O
II	O
promoters	O
.	O

This	O
ability	O
of	O
CIITA	O
to	O
facilitate	O
promoter	O
occupation	O
is	O
undissociable	O
from	O
its	O
transactivation	O
potential	O
.	O

Finally	O
,	O
we	O
conclude	O
that	O
this	O
effect	O
of	O
CIITA	O
is	O
cell-type	O
specific	O
,	O
since	O
expression	O
of	O
CIITA	O
is	O
not	B-Negation
required	I-Negation
for	I-Negation
normal	I-Negation
occupation	I-Negation
of	I-Negation
MHC	I-Negation
class	I-Negation
II	I-Negation
promoters	I-Negation
in	I-Negation
B	I-Negation
lymphocytes	I-Negation
.	O

Immunosuppressant	O
PG490	O
(	O
triptolide	O
)	O
inhibits	O
T-cell	O
interleukin-2	O
expression	O
at	O
the	O
level	O
of	O
purine-box/nuclear	O
factor	O
of	O
activated	O
T-cells	O
and	O
NF-kappaB	O
transcriptional	O
activation	O
.	O

PG490	O
(	O
triptolide	O
)	O
is	O
a	O
diterpene	O
triepoxide	O
with	O
potent	O
immunosuppressive	O
and	O
antiinflammatory	O
properties	O
.	O

PG490	O
inhibits	O
interleukin	O
(	O
IL	O
)	O
-2	O
expression	O
by	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
antibody	O
to	O
CD3	O
(	O
IC50	O
of	O
10	O
ng/ml	O
)	O
,	O
and	O
with	O
PMA	O
and	O
ionomycin	O
(	O
Iono	O
,	O
IC50	O
of	O
40	O
ng/ml	O
)	O
.	O

In	O
Jurkat	O
T-cells	O
,	O
PG490	O
inhibits	O
PMA/Iono-stimulated	O
IL-2	O
transcription	O
.	O

PG490	O
inhibits	O
the	O
induction	O
of	O
DNA	O
binding	O
activity	O
at	O
the	O
purine-box/antigen	O
receptor	O
response	O
element	O
(	O
ARRE	O
)	O
/nuclear	O
factor	O
of	O
activated	O
T-cells	O
(	O
NF-AT	O
)	O
target	O
sequence	O
but	O
not	B-Negation
at	I-Negation
the	I-Negation
NF-kappaB	I-Negation
site	I-Negation
.	O

PG490	O
can	O
completely	O
inhibit	O
transcriptional	O
activation	O
at	O
the	O
purine-box/ARRE/NF-AT	O
and	O
NF-kappaB	O
target	O
DNA	O
sequences	O
triggered	O
by	O
all	O
stimuli	O
examined	O
(	O
PMA	O
,	O
PMA/Iono	O
,	O
tumor	O
necrosis	O
factor-alpha	O
)	O
.	O

PG490	O
also	O
inhibits	O
PMA-stimulated	O
activation	O
of	O
a	O
chimeric	O
transcription	O
factor	O
in	O
which	O
the	O
C-terminal	O
TA1	O
transactivation	O
domain	O
of	O
NF-kappaB	O
p65	O
is	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
GAL4	O
.	O

In	O
16HBE	O
human	O
bronchial	O
epithelial	O
cells	O
,	O
IL-8	O
expression	O
is	O
regulated	O
predominantly	O
by	O
NF-kappaB	O
,	O
and	O
PG490	O
but	O
not	B-Negation
cyclosporin	I-Negation
A	I-Negation
can	O
completely	O
inhibit	O
expression	O
of	O
IL-8	O
.	O

The	O
mechanism	O
of	O
PG490	O
inhibition	O
of	O
cytokine	O
gene	O
expression	O
differs	O
from	O
cyclosporin	O
A	O
and	O
involves	O
nuclear	O
inhibition	O
of	O
transcriptional	O
activation	O
of	O
NF-kappaB	O
and	O
the	O
purine-box	O
regulator	O
operating	O
at	O
the	O
ARRE/NF-AT	O
site	O
at	O
a	O
step	O
after	O
specific	O
DNA	O
binding	O
.	O

Activation	O
of	O
nuclear	O
factor-kappaB	O
by	O
lipopolysaccharide	O
in	O
mononuclear	O
leukocytes	O
is	O
prevented	O
by	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
.	O

In	O
monocytes	O
,	O
lipopolysaccharide	O
induces	O
synthesis	O
and	O
activity	O
of	O
the	O
85-kDa	O
cytosolic	O
phospholipase	O
A2	O
.	O

This	O
enzyme	O
releases	O
arachidonic	O
acid	O
and	O
lyso-phospholipids	O
from	O
membranes	O
which	O
are	O
metabolized	O
to	O
eicosanoids	O
and	O
platelet-activating-factor	O
.	O

These	O
lipid	O
mediators	O
increase	O
activity	O
of	O
transcription	O
factors	O
and	O
expression	O
of	O
cytokine	O
genes	O
indicating	O
a	O
function	O
for	O
cytosolic	O
phospholipase	O
A2	O
in	O
signal	O
transduction	O
and	O
inflammation	O
.	O

We	O
have	O
shown	O
previously	O
that	O
trifluoromethylketone	O
inhibitors	O
of	O
cytosolic	O
phospholipase	O
A2	O
suppressed	O
interleukin-1beta	O
protein	O
and	O
steady-state	O
mRNA	O
levels	O
in	O
human	O
lipopolysaccharide-stimulated	O
peripheral	O
blood	O
mononuclear	O
leukocytes	O
.	O

In	O
this	O
study	O
,	O
the	O
subcellular	O
mechanisms	O
were	O
analyzed	O
by	O
which	O
trifluoromethylketones	O
interfere	O
with	O
gene	O
expression	O
.	O

We	O
found	O
that	O
they	O
reduced	O
the	O
initial	O
interleukin-1beta	O
mRNA	O
transcription	O
rate	O
through	O
prevention	O
of	O
degradation	O
of	O
inhibitor-kappaB	O
alpha	O
.	O

Consequently	O
,	O
cytosolic	O
activation	O
,	O
nuclear	O
translocation	O
and	O
DNA-binding	O
of	O
nuclear	O
factor-kappaB	O
were	O
decreased	O
.	O

Trifluoromethylketones	O
ameliorate	O
chronic	O
inflammation	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
therapeutic	O
potency	O
may	O
reside	O
in	O
retention	O
of	O
inactive	O
nuclear	O
factor-kappaB	O
in	O
the	O
cytosol	O
thereby	O
abrogating	O
interleukin-1beta	O
gene	O
transcription	O
.	O

Molecular	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
during	O
the	O
immune	O
response	O
.	O

Cytokine	O
expression	O
by	O
immune	O
system	O
cells	O
plays	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
.	O

On	O
first	O
encounter	O
with	O
antigen	O
,	O
naive	O
CD4+	O
T	O
helper	O
(	O
Th	O
)	O
cells	O
differentiate	O
into	O
cytokine-producing	O
effector	O
cells	O
.	O

Two	O
types	O
of	O
effector	O
cells	O
characterized	O
by	O
their	O
distinct	O
expression	O
of	O
cytokine	O
profiles	O
have	O
been	O
described	O
.	O

Th1	O
cells	O
produce	O
IL-2	O
and	O
IFN-gamma	O
,	O
whereas	O
Th2	O
cells	O
produce	O
IL-4	O
,	O
IL-5	O
,	O
IL-6	O
,	O
IL-10	O
,	O
and	O
IL-13	O
.	O

In	O
many	O
pathological	O
situations	O
,	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
immune	O
responses	O
determines	O
the	O
outcome	O
of	O
diverse	O
immunologically	O
mediated	O
clinical	O
syndromes	O
including	O
infectious	O
,	O
autoimmune	O
,	O
and	O
allergic	O
diseases	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
tissue-specific	O
expression	O
of	O
Th1/Th2-like	O
cytokines	O
has	O
remained	O
elusive	O
.	O

In	O
this	O
review	O
we	O
evaluate	O
the	O
possible	O
in	O
vivo	O
role	O
of	O
different	O
transcription	O
factors	O
and	O
transcriptional	O
mechanisms	O
in	O
T	O
cell	O
differentiation	O
and	O
the	O
immune	O
response	O
.	O

The	O
evolutionarily	O
conserved	O
sequence	O
upstream	O
of	O
the	O
human	O
Ig	O
heavy	O
chain	O
S	O
gamma	O
3	O
region	O
is	O
an	O
inducible	O
promoter	O
:	O
synergistic	O
activation	O
by	O
CD40	O
ligand	O
and	O
IL-4	O
via	O
cooperative	O
NF-kappa	O
B	O
and	O
STAT-6	O
binding	O
sites	O
.	O

Germline	O
C	O
gamma	O
gene	O
transcription	O
is	O
a	O
crucial	O
event	O
in	O
the	O
process	O
that	O
leads	O
to	O
switch	O
DNA	O
recombination	O
to	O
IgG	O
,	O
but	O
its	O
regulation	O
in	O
the	O
human	O
is	O
poorly	O
understood	O
.	O

We	O
took	O
advantage	O
of	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
B	O
cell	O
differentiation	O
,	O
IgM+	O
IgD+	O
CL-01	O
cells	O
,	O
to	O
define	O
the	O
role	O
of	O
the	O
I	O
gamma	O
3	O
evolutionarily	O
conserved	O
sequence	O
(	O
ECS	O
)	O
in	O
the	O
germline	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

The	O
I	O
gamma	O
3	O
ECS	O
lies	O
upstream	O
of	O
the	O
major	O
I	O
gamma	O
3	O
transcription	O
initiation	O
site	O
and	O
displays	O
more	O
than	O
90	O
%	O
identity	O
with	O
the	O
corresponding	O
human	O
I	O
gamma	O
1	O
,	O
I	O
gamma	O
2	O
,	O
and	O
I	O
gamma	O
4	O
regions	O
.	O

Reporter	O
luciferase	O
gene	O
vectors	O
containing	O
the	O
human	O
gamma	O
3	O
ECS	O
were	O
used	O
to	O
transfect	O
CL-01	O
cells	O
,	O
which	O
have	O
been	O
shown	O
to	O
undergo	O
Smu	O
--	O
>	O
S	O
gamma	O
3	O
DNA	O
recombination	O
,	O
upon	O
engagement	O
of	O
CD40	O
by	O
CD40	O
ligand	O
(	O
CD40L	O
)	O
and	O
exposure	O
to	O
IL-4	O
.	O

In	O
these	O
transfected	O
CL-01	O
cells	O
,	O
CD40	O
:	O
CD40L	O
engagement	O
and	O
exposure	O
to	O
IL-4	O
synergistically	O
induced	O
gamma	O
3	O
ECS-dependent	O
luciferase	O
reporter	O
gene	O
activation	O
.	O

Targeted	O
mutational	O
analysis	O
demonstrated	O
that	O
a	O
tandem	O
NF-kappa	O
B/Rel	O
binding	O
motif	O
is	O
critical	O
for	O
the	O
gamma	O
3	O
ECS	O
responsiveness	O
to	O
both	O
CD40L	O
and	O
IL-4	O
,	O
while	O
a	O
STAT-6-binding	O
site	O
is	O
additionally	O
required	O
for	O
IL-4	O
inducibility	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
p50/p65/c-Rel	O
and	O
STAT-6	O
are	O
effectively	O
induced	O
by	O
CD40L	O
and	O
IL-4	O
,	O
respectively	O
,	O
and	O
bind	O
to	O
specific	O
DNA	O
motifs	O
within	O
the	O
ECS	O
.	O

These	O
partially	O
overlapping	O
CD40L	O
and	O
IL-4	O
responsive	O
elements	O
are	O
functionally	O
cooperative	O
as	O
the	O
disruption	O
of	O
one	O
of	O
them	O
prevents	O
synergistic	O
promoter	O
activation	O
.	O

Thus	O
,	O
the	O
gamma	O
3	O
ECS	O
is	O
an	O
inducible	O
promoter	O
containing	O
cis	O
elements	O
that	O
critically	O
mediate	O
CD40L	O
and	O
IL-4-triggered	O
transcriptional	O
activation	O
of	O
the	O
human	O
C	O
gamma	O
3	O
gene	O
.	O

Thrombin-induced	O
p65	O
homodimer	O
binding	O
to	O
downstream	O
NF-kappa	O
B	O
site	O
of	O
the	O
promoter	O
mediates	O
endothelial	O
ICAM-1	O
expression	O
and	O
neutrophil	O
adhesion	O
.	O

We	O
investigated	O
the	O
mechanisms	O
by	O
which	O
proinflammatory	O
mediator	O
,	O
thrombin	O
,	O
released	O
during	O
intravascular	O
coagulation	O
and	O
tissue	O
injury	O
,	O
induces	O
ICAM-1	O
(	O
CD54	O
)	O
expression	O
in	O
endothelial	O
cells	O
.	O

Stimulation	O
of	O
HUVEC	O
with	O
thrombin	O
resulted	O
in	O
dose-	O
and	O
time-dependent	O
increases	O
in	O
ICAM-1	O
mRNA	O
and	O
cell	O
surface	O
expression	O
and	O
in	O
ICAM-1-dependent	O
endothelial	O
adhesivity	O
toward	O
polymorphonuclear	O
leukocytes	O
.	O

Transient	O
transfection	O
of	O
endothelial	O
cells	O
with	O
ICAM-1	O
promoter	O
luciferase	O
reporter	O
gene	O
(	O
ICAM-1LUC	O
)	O
constructs	O
indicated	O
that	O
deletion	O
of	O
upstream	O
NF-kappa	O
B	O
site	O
(	O
-533	O
bases	O
from	O
translation	O
start	O
site	O
)	O
had	O
no	O
effect	O
on	O
thrombin	O
responsiveness	O
,	O
whereas	O
mutation/deletion	O
of	O
downstream	O
NF-kappa	O
B	O
site	O
(	O
-223	O
bases	O
from	O
the	O
translation	O
start	O
site	O
)	O
prevented	O
the	O
activation	O
of	O
ICAM-1	O
promoter	O
,	O
indicating	O
that	O
the	O
downstream	O
NF-kappa	O
B	O
site	O
is	O
critical	O
for	O
thrombin	O
inducibility	O
.	O

NF-kappa	O
B-directed	O
luciferase	O
activity	O
increased	O
approximately	O
3-fold	O
when	O
cells	O
transfected	O
with	O
the	O
plasmid	O
pNF-kappa	O
BLUC	O
containing	O
five	O
copies	O
of	O
consensus	O
NF-kappa	O
B	O
site	O
linked	O
to	O
a	O
minimal	O
adenovirus	O
E1B	O
promoter-luciferase	O
gene	O
were	O
exposed	O
to	O
thrombin	O
,	O
indicating	O
that	O
activation	O
of	O
NF-kappa	O
B	O
was	O
essential	O
for	O
thrombin	O
response	O
.	O

Gel	O
supershift	O
assays	O
demonstrated	O
that	O
thrombin	O
induced	O
binding	O
of	O
NF-kappa	O
Bp65	O
(	O
Rel	O
A	O
)	O
to	O
downstream	O
NF-kappa	O
B	O
site	O
of	O
the	O
ICAM-1	O
promoter	O
.	O

Thrombin	O
receptor	O
activation	O
peptide	O
,	O
a	O
14-amino-acid	O
peptide	O
representing	O
the	O
new	O
NH2	O
terminus	O
of	O
proteolytically	O
activated	O
receptor-1	O
,	O
mimicked	O
thrombin	O
's	O
action	O
in	O
inducing	O
ICAM-1	O
expression	O
.	O

These	O
data	O
indicate	O
that	O
thrombin	O
activates	O
endothelial	O
ICAM-1	O
expression	O
and	O
polymorphonuclear	O
leukocyte	O
adhesion	O
by	O
NF-kappa	O
Bp65	O
binding	O
to	O
the	O
downstream	O
NF-kappa	O
B	O
site	O
of	O
ICAM-1	O
promoter	O
after	O
proteolytically	O
activated	O
receptor-1	O
activation	O
.	O

Regulation	O
of	O
Fas	O
ligand	O
expression	O
and	O
cell	O
death	O
by	O
apoptosis-linked	O
gene	O
4	O
.	O

Programmed	O
cell	O
death	O
is	O
a	O
process	O
required	O
for	O
the	O
normal	O
development	O
of	O
an	O
organism	O
.	O

One	O
of	O
the	O
best	O
understood	O
apoptotic	O
pathways	O
occurs	O
in	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
Fas/Fas	O
ligand	O
(	O
FasL	O
)	O
interaction	O
.	O

During	O
studies	O
of	O
apoptosis	O
induced	O
by	O
T	O
cell-receptor	O
engagement	O
,	O
we	O
identified	O
ALG-4F	O
,	O
a	O
truncated	O
transcript	O
that	O
prevents	O
T	O
cell-receptor-induced	O
FasL	O
upregulation	O
and	O
cell	O
death	O
.	O

Overexpression	O
of	O
full-length	O
ALG-4	O
induced	O
transcription	O
of	O
FasL	O
and	O
,	O
consequently	O
,	O
apoptosis	O
.	O

These	O
results	O
indicate	O
that	O
ALG-4	O
is	O
necessary	O
and	O
sufficient	O
for	O
FasL	O
expression	O
.	O

Fas/FasL	O
interaction	O
initiates	O
cell	O
death	O
in	O
many	O
other	O
systems	O
,	O
and	O
its	O
dysregulation	O
is	O
a	O
mechanism	O
by	O
which	O
several	O
pathologic	O
conditions	O
arise	O
.	O

Understanding	O
the	O
molecular	O
mechanisms	O
of	O
FasL	O
regulation	O
could	O
be	O
very	O
useful	O
in	O
elucidating	O
how	O
these	O
diseases	O
develop	O
and	O
in	O
identifying	O
potential	O
therapeutic	O
targets	O
.	O

High	O
molecular	O
weight	O
dextran	O
sulfate	O
increases	O
the	O
activity	O
of	O
NF-kappaB-regulated	O
promoter	O
in	O
monocyte-derived	O
macrophages	O
.	O

It	O
is	O
known	O
that	O
sulfated	O
polysaccharides	O
can	O
mimic	O
the	O
action	O
of	O
common	O
T-cell	O
mitogens	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
of	O
the	O
mitogenic	O
effect	O
of	O
high	O
molecular	O
weight	O
dextran	O
sulfate	O
(	O
HMDS	O
)	O
,	O
monocyte-derived	O
macrophages	O
were	O
transfected	O
with	O
recombinant	O
plasmid	O
containing	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
promoter	O
,	O
which	O
is	O
regulated	O
by	O
transcription	O
factor	O
NF-kappaB	O
.	O

We	O
observed	O
that	O
HMDS	O
,	O
similar	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
increases	O
the	O
expression	O
of	O
CAT	O
reporter	O
gene	O
suggesting	O
increased	O
activity	O
of	O
NF-kappaB	O
.	O

The	O
activation	O
of	O
NF-kappaB	O
correlated	O
with	O
the	O
increased	O
expression	O
of	O
B7.1	O
molecules	O
.	O

It	O
was	O
postulated	O
that	O
this	O
NF-kappaB-regulated	O
promoter	O
might	O
play	O
a	O
role	O
in	O
the	O
activation	O
of	O
the	O
accessory	O
cells	O
as	O
well	O
as	O
the	O
rate	O
of	O
replication	O
of	O
HIV-1	O
in	O
monocyte-derived	O
macrophages	O
.	O

CTLA-4-Mediated	O
inhibition	O
of	O
early	O
events	O
of	O
T	O
cell	O
proliferation	O
.	O

CTLA-4	O
engagement	O
by	O
mAbs	O
inhibits	O
,	O
while	O
CD28	O
enhances	O
,	O
IL-2	O
production	O
and	O
proliferation	O
upon	O
T	O
cell	O
activation	O
.	O

Here	O
,	O
we	O
have	O
analyzed	O
the	O
mechanisms	O
involved	O
in	O
CTLA-4-mediated	O
inhibition	O
of	O
T	O
cell	O
activation	O
of	O
naive	O
CD4+	O
T	O
cells	O
using	O
Ab	O
cross-linking	O
.	O

CTLA-4	O
ligation	O
inhibited	O
CD3/CD28-induced	O
IL-2	O
mRNA	O
accumulation	O
by	O
inhibiting	O
IL-2	O
transcription	O
,	O
which	O
appears	O
to	O
be	O
mediated	O
in	O
part	O
through	O
decreasing	O
NF-AT	O
accumulation	O
in	O
the	O
nuclei	O
.	O

However	O
,	O
CTLA-4	B-Negation
ligation	I-Negation
did	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
affect	I-Speculation
the	I-Speculation
CD28-mediated	I-Speculation
stabilization	I-Speculation
of	I-Speculation
IL-2	I-Speculation
mRNA	I-Speculation
.	O

Further	O
,	O
CTLA-4	O
engagement	O
inhibited	O
progression	O
through	O
the	O
cell	O
cycle	O
by	O
inhibiting	O
the	O
production	O
of	O
cyclin	O
D3	O
,	O
cyclin-dependent	O
kinase	O
(	O
cdk	O
)	O
4	O
,	O
and	O
cdk6	O
when	O
the	O
T	O
cells	O
were	O
stimulated	O
with	O
anti-CD3/CD28	O
and	O
with	O
anti-CD3	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
CTLA-4	O
signaling	O
inhibits	O
events	O
early	O
in	O
T	O
cell	O
activation	O
both	O
at	O
IL-2	O
transcription	O
and	O
at	O
the	O
level	O
of	O
IL-2-independent	O
events	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
does	O
not	O
simply	O
oppose	O
CD28-mediated	O
costimulation	O
.	O

Fibroblast	O
growth	O
factor-1	O
(	O
FGF-1	O
)	O
enhances	O
IL-2	O
production	O
and	O
nuclear	O
translocation	O
of	O
NF-kappaB	O
in	O
FGF	O
receptor-bearing	O
Jurkat	O
T	O
cells	O
.	O

Fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
are	O
heparin-binding	O
proteins	O
crucial	O
to	O
embryogenesis	O
,	O
angiogenesis	O
,	O
and	O
wound	O
healing	O
.	O

FGF-1	O
is	O
abundantly	O
expressed	O
in	O
the	O
synovium	O
in	O
rheumatoid	O
arthritis	O
and	O
in	O
rejecting	O
allografts	O
,	O
sites	O
of	O
chronic	O
immune-mediated	O
inflammation	O
.	O

The	O
frequency	O
of	O
FGF-1-responsive	O
T	O
cells	O
is	O
increased	O
in	O
the	O
peripheral	O
blood	O
of	O
these	O
disorders	O
,	O
and	O
a	O
high	O
percentage	O
of	O
infiltrating	O
T	O
cells	O
in	O
rheumatoid	O
arthritis	O
synovium	O
express	O
receptors	O
for	O
FGF-1	O
.	O

To	O
understand	O
the	O
action	O
of	O
FGF-1	O
in	O
T	O
cells	O
,	O
studies	O
were	O
initiated	O
in	O
Jurkat	O
T	O
cells	O
that	O
express	O
the	O
signaling	O
isoform	O
of	O
FGF	O
receptor-1	O
.	O

These	O
experiments	O
show	O
that	O
FGF-1	O
stimulation	O
of	O
Jurkat	O
T	O
cells	O
provides	O
a	O
second	O
signal	O
that	O
augments	O
TCR-mediated	O
IL-2	O
production	O
.	O

Analogous	O
to	O
costimulation	O
via	O
CD28	O
,	O
this	O
activity	O
is	O
mediated	O
through	O
activation	O
of	O
Rel/kappaB	O
,	O
a	O
family	O
of	O
transcription	O
factors	O
known	O
to	O
regulate	O
IL-2	O
and	O
other	O
activation-inducible	O
proteins	O
.	O

FGF-1	O
alone	O
induces	O
modest	O
nuclear	O
translocation	O
of	O
kappaB-binding	O
proteins	O
,	O
and	O
this	O
translocation	O
is	O
enhanced	O
by	O
the	O
combination	O
of	O
anti-CD3	O
and	O
FGF-1	O
.	O

This	O
NF-kappaB	O
binding	O
complex	O
is	O
composed	O
of	O
transcriptionally	O
active	O
p65	O
(	O
RelA	O
)	O
/p50	O
heterodimers	O
and	O
results	O
primarily	O
from	O
the	O
targeted	O
degradation	O
of	O
IkappaB-alpha	O
,	O
an	O
inhibitor	O
that	O
sequesters	O
Rel/kappaB	O
in	O
the	O
cytoplasm	O
.	O

These	O
data	O
are	O
the	O
first	O
to	O
show	O
a	O
connection	O
between	O
FGF-1	O
signaling	O
and	O
NF-kappaB	O
activation	O
outside	O
of	O
embryonic	O
development	O
.	O

The	O
signaling	O
events	O
that	O
link	O
FGF	O
receptor-1	O
engagement	O
and	O
NF-kappaB	O
activation	O
in	O
Jurkat	O
are	O
probably	B-Speculation
distinct	I-Speculation
from	I-Speculation
the	I-Speculation
CD28	I-Speculation
costimulation	I-Speculation
pathway	I-Speculation
,	O
since	O
FGF-1-induced	O
Rel/kappaB	O
binding	O
proteins	O
do	O
not	B-Negation
contain	I-Negation
significant	I-Negation
levels	I-Negation
of	I-Negation
c-Rel	I-Negation
and	O
are	O
not	B-Negation
identical	I-Negation
with	I-Negation
the	I-Negation
CD28	I-Negation
response	I-Negation
complex	I-Negation
.	O

Signaling	O
through	O
the	O
lymphotoxin-beta	O
receptor	O
stimulates	O
HIV-1	O
replication	O
alone	O
and	O
in	O
cooperation	O
with	O
soluble	O
or	O
membrane-bound	O
TNF-alpha	O
.	O

The	O
level	O
of	O
ongoing	O
HIV-1	O
replication	O
within	O
an	O
individual	O
is	O
critical	O
to	O
HIV-1	O
pathogenesis	O
.	O

Among	O
host	O
immune	O
factors	O
,	O
the	O
cytokine	O
TNF-alpha	O
has	O
previously	O
been	O
shown	O
to	O
increase	O
HIV-1	O
replication	O
in	O
various	O
monocyte	O
and	O
T	O
cell	O
model	O
systems	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
signaling	O
through	O
the	O
TNF	O
receptor	O
family	O
member	O
,	O
the	O
lymphotoxin-beta	O
(	O
LT-beta	O
)	O
receptor	O
(	O
LT-betaR	O
)	O
,	O
also	O
regulates	O
HIV-1	O
replication	O
.	O

Furthermore	O
,	O
HIV-1	O
replication	O
is	O
cooperatively	O
stimulated	O
when	O
the	O
distinct	O
LT-betaR	O
and	O
TNF	O
receptor	O
systems	O
are	O
simultaneously	O
engaged	O
by	O
their	O
specific	O
ligands	O
.	O

Moreover	O
,	O
in	O
a	O
physiological	O
coculture	O
cellular	O
assay	O
system	O
,	O
we	O
show	O
that	O
membrane-bound	O
TNF-alpha	O
and	O
LT-alpha1beta2	O
act	O
virtually	O
identically	O
to	O
their	O
soluble	O
forms	O
in	O
the	O
regulation	O
of	O
HIV-1	O
replication	O
.	O

Thus	O
,	O
cosignaling	O
via	O
the	O
LT-beta	O
and	O
TNF-alpha	O
receptors	O
is	O
probably	O
involved	O
in	O
the	O
modulation	O
of	O
HIV-1	O
replication	O
and	O
the	O
subsequent	O
determination	O
of	O
HIV-1	O
viral	O
burden	O
in	O
monocytes	O
.	O

Intriguingly	O
,	O
surface	O
expression	O
of	O
LT-alpha1beta2	O
is	O
up-regulated	O
on	O
a	O
T	O
cell	O
line	O
acutely	O
infected	O
with	O
HIV-1	O
,	O
suggesting	O
a	O
positive	O
feedback	O
loop	O
between	O
HIV-1	O
infection	O
,	O
LT-alpha1beta2	O
expression	O
,	O
and	O
HIV-1	O
replication	O
.	O

Given	O
the	O
critical	O
role	O
that	O
LT-alpha1beta2	O
plays	O
in	O
lymphoid	O
architecture	O
,	O
we	O
speculate	O
that	O
LT-alpha1beta2	O
may	O
be	O
involved	O
in	O
HIV-associated	O
abnormalities	O
of	O
the	O
lymphoid	O
organs	O
.	O

Resistance	O
to	O
tumor	O
necrosis	O
factor	O
induced	O
apoptosis	O
in	O
vitro	O
correlates	O
with	O
high	O
metastatic	O
capacity	O
of	O
cells	O
in	O
vivo	O
.	O

TNF	O
is	O
one	O
of	O
the	O
cytokines	O
secreted	O
by	O
the	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Our	O
data	O
demonstrate	O
that	O
those	O
cell	O
lines	O
lacking	B-Negation
capability	I-Negation
to	I-Negation
form	I-Negation
metastatic	I-Negation
tumors	I-Negation
in	I-Negation
vivo	I-Negation
are	O
susceptible	O
to	O
TNF	O
induced	O
apoptosis	O
in	O
vitro	O
.	O

However	O
,	O
cell	O
lines	O
with	O
high	O
metastatic	O
potential	O
are	O
resistant	O
to	O
TNF	O
in	O
vitro	O
.	O

Furthermore	O
,	O
the	O
same	O
cell	O
lines	O
were	O
resistant	O
to	O
cytolytic	O
action	O
of	O
other	O
cytotoxic	O
proteins	O
secreted	O
by	O
LAK	O
cells	O
.	O

Our	O
data	O
showed	O
that	O
TNF	O
resistance	O
in	O
vitro	O
correlates	O
with	O
the	O
increased	O
level	O
of	O
transcription	O
factor	O
NF-kappaB	O
.	O

This	O
finding	O
may	O
provide	O
a	O
tool	O
to	O
improve	O
current	O
protocols	O
of	O
immunotherapy	O
and	O
insights	O
to	O
how	O
tumor	O
cells	O
are	O
or	O
are	O
not	O
killed	O
by	O
LAK	O
cells	O
.	O

NF-kappaB	O
activation	O
is	O
required	O
for	O
C5a-induced	O
interleukin-8	O
gene	O
expression	O
in	O
mononuclear	O
cells	O
.	O

C5a	O
,	O
a	O
potent	O
peptide	O
chemoattractant	O
,	O
stimulates	O
interleukin-8	O
(	O
IL-8	O
)	O
secretion	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

Experiments	O
were	O
conducted	O
to	O
understand	O
the	O
mechanisms	O
for	O
C5a-induced	O
IL-8	O
production	O
,	O
which	O
was	O
14-fold	O
greater	O
than	O
that	O
in	O
unstimulated	O
cells	O
by	O
2	O
hours	O
.	O

IL-8	O
secretion	O
was	O
accompanied	O
by	O
accumulation	O
of	O
IL-8	O
mRNA	O
in	O
the	O
cytosol	O
and	O
by	O
nuclear	O
expression	O
of	O
a	O
kappaB	O
DNA	O
binding	O
activity	O
within	O
30	O
minutes	O
.	O

AP-1	O
but	O
not	B-Negation
NF-IL-6	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
was	O
also	O
detected	O
in	O
C5a-stimulated	O
PBMC	O
;	O
however	O
,	O
its	O
delayed	O
expression	O
(	O
maximal	O
at	O
4	O
hours	O
)	O
suggested	B-Speculation
a	I-Speculation
less	I-Speculation
important	I-Speculation
role	I-Speculation
in	I-Speculation
the	I-Speculation
rapid	I-Speculation
production	I-Speculation
of	I-Speculation
IL-8	I-Speculation
.	O

The	O
correlation	O
between	O
C5a-induced	O
kappaB	O
binding	O
activity	O
and	O
IL-8	O
gene	O
expression	O
was	O
examined	O
in	O
the	O
RAW264.7	O
macrophage	O
cells	O
using	O
reporter	O
genes	O
directed	O
by	O
the	O
kappaB	O
sequence	O
from	O
IkappaBalpha	O
and	O
IL-8	O
promoter	O
regions	O
.	O

C5a-induced	O
reporter	O
gene	O
expression	O
was	O
abolished	O
by	O
introducing	O
mutations	O
into	O
the	O
kappaB	O
sites	O
and	O
by	O
coexpression	O
of	O
a	O
dominant	O
negative	O
IkappaBalpha	O
construct	O
resistant	O
to	O
agonist-induced	O
phosphorylation	O
.	O

Pertussis	O
toxin	O
,	O
which	O
ADP-ribosylates	O
the	O
Gi	O
proteins	O
known	O
to	O
couple	O
to	O
the	O
C5a	O
receptor	O
,	O
produced	O
minimal	O
inhibition	O
of	O
C5a-induced	O
IL-8	O
expression	O
and	O
had	O
little	O
effect	O
on	O
C5a-induced	O
calcium	O
mobilization	O
in	O
RAW264.7	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
NF-kappaB	O
activation	O
is	O
required	O
for	O
C5a-induced	O
IL-8	O
gene	O
expression	O
and	O
that	O
this	O
response	O
is	O
mediated	O
primarily	O
through	O
a	O
pertussis	O
toxin-insensitive	O
pathway	O
.	O

Transcriptional	O
targeting	O
of	O
retroviral	O
vectors	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

Targeted	O
expression	O
to	O
specific	O
tissues	O
or	O
cell	O
lineages	O
is	O
a	O
necessary	O
feature	O
of	O
a	O
gene	O
therapy	O
vector	O
for	O
many	O
clinical	O
applications	O
,	O
such	O
as	O
correction	O
of	O
hemoglobinopathies	O
or	O
thalassemias	O
by	O
transplantation	O
of	O
genetically	O
modified	O
hematopoietic	O
stem	O
cells	O
.	O

We	O
developed	O
retroviral	O
vectors	O
in	O
which	O
the	O
constitutive	O
viral	O
enhancer	O
in	O
the	O
U3	O
region	O
of	O
the	O
3	O
'	O
LTR	O
is	O
replaced	O
by	O
an	O
autoregulatory	O
enhancer	O
of	O
the	O
erythroid-specific	O
GATA-1	O
transcription	O
factor	O
gene	O
.	O

The	O
replaced	O
enhancer	O
is	O
propagated	O
to	O
the	O
5	O
'	O
LTR	O
upon	O
integration	O
into	O
the	O
target	O
cell	O
genome	O
.	O

The	O
modified	O
vectors	O
were	O
used	O
to	O
transduce	O
human	O
hematopoietic	O
cell	O
lines	O
,	O
cord	O
blood-derived	O
CD34	O
(	O
+	O
)	O
stem/progenitor	O
cells	O
,	O
and	O
murine	O
bone	O
marrow	O
repopulating	O
stem	O
cells	O
.	O

The	O
expression	O
of	O
appropriate	O
reporter	O
genes	O
(	O
triangle	O
upLNGFR	O
,	O
EGFP	O
)	O
was	O
analyzed	O
in	O
the	O
differentiated	O
progeny	O
of	O
transduced	O
stem	O
cells	O
in	O
vitro	O
,	O
in	O
liquid	O
culture	O
as	O
well	O
as	O
in	O
clonogenic	O
assay	O
,	O
and	O
in	O
vivo	O
,	O
after	O
bone	O
marrow	O
transplantation	O
in	O
lethally	O
irradiated	O
mice	O
.	O

The	O
GATA-1	O
autoregulatory	O
enhancer	O
effectively	O
restricts	O
the	O
expression	O
of	O
the	O
LTR-driven	O
proviral	O
transcription	O
unit	O
to	O
the	O
erythroblastic	O
progeny	O
of	O
both	O
human	O
progenitors	O
and	O
mouse-repopulating	O
stem	O
cells	O
.	O

Packaging	B-Negation
of	I-Negation
viral	I-Negation
particles	I-Negation
,	I-Negation
integration	I-Negation
into	I-Negation
the	I-Negation
target	I-Negation
genome	I-Negation
,	I-Negation
and	I-Negation
stability	I-Negation
of	I-Negation
the	I-Negation
integrated	I-Negation
provirus	I-Negation
are	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
the	I-Negation
LTR	I-Negation
modification	I-Negation
.	O

Enhancer	O
replacement	O
is	O
therefore	O
an	O
effective	O
strategy	O
to	O
target	O
expression	O
of	O
a	O
retroviral	O
transgene	O
to	O
a	O
specific	O
progeny	O
of	O
transduced	O
hematopoietic	O
stem	O
cells	O
.	O

An	O
essential	O
role	O
for	O
NF-kappaB	O
in	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
survival	O
.	O

The	O
transcription	O
factor	O
,	O
NF-kappaB	O
,	O
is	O
important	O
for	O
T-cell	O
activation	O
,	O
B-cell	O
maturation	O
,	O
and	O
human	O
immunodeficiency	O
virus	O
transcription	O
and	O
plays	O
a	O
role	O
in	O
alternatively	O
mediating	O
and	O
protecting	O
against	O
apoptosis	O
in	O
a	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
a	B-Negation
role	I-Negation
for	I-Negation
NF-kappaB	I-Negation
in	I-Negation
human	I-Negation
CD34	I-Negation
(	I-Negation
+	I-Negation
)	I-Negation
bone	I-Negation
marrow	I-Negation
cells	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
described	I-Negation
.	O

We	O
provide	O
evidence	O
here	O
that	O
virtually	O
all	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cells	O
express	O
NF-kappaB	O
that	O
can	O
be	O
activated	O
by	O
exposure	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
a	O
variety	O
of	O
cytokines	O
,	O
eg	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
,	O
interleukin-3	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	O
may	O
be	O
required	O
for	O
human	O
CD34	O
(	O
+	O
)	O
bone	O
marrow	O
cell	O
clonogenic	O
function	O
and	O
survival	O
.	O

These	O
results	O
offer	O
insight	O
into	O
a	O
new	O
role	O
for	O
NF-kappaB	O
in	O
maintaining	O
survival	O
and	O
function	O
in	O
hematopoietic	O
stem	O
and	O
progenitor	O
cells	O
and	O
suggest	O
that	O
proposed	O
strategies	O
involving	O
inhibition	O
of	O
NF-kappaB	O
activation	O
as	O
an	O
adjunct	O
to	O
cancer	O
chemotherapy	O
should	O
be	O
approached	O
with	O
caution	O
.	O

Unicellular-unilineage	O
erythropoietic	O
cultures	O
:	O
molecular	O
analysis	O
of	O
regulatory	O
gene	O
expression	O
at	O
sibling	O
cell	O
level	O
.	O

In	O
vitro	O
studies	O
on	O
hematopoietic	O
control	O
mechanisms	O
have	O
been	O
hampered	O
by	O
the	O
heterogeneity	O
of	O
the	O
analyzed	O
cell	O
populations	O
,	O
ie	O
,	O
lack	B-Negation
of	I-Negation
lineage	I-Negation
specificity	I-Negation
and	I-Negation
developmental	I-Negation
stage	I-Negation
homogeneity	I-Negation
of	I-Negation
progenitor/precursor	I-Negation
cells	I-Negation
growing	I-Negation
in	I-Negation
culture	I-Negation
.	O

We	O
developed	O
unicellular	O
culture	O
systems	O
for	O
unilineage	O
differentiation	O
of	O
purified	O
hematopoietic	O
progenitor	O
cells	O
followed	O
by	O
daughter	O
cell	O
analysis	O
at	O
cellular	O
and	O
molecular	O
level	O
.	O

In	O
the	O
culture	O
system	O
reported	O
here	O
,	O
(	O
1	O
)	O
the	O
growth	O
factor	O
(	O
GF	O
)	O
stimulus	O
induces	O
cord	O
blood	O
(	O
CB	O
)	O
progenitor	O
cells	O
to	O
proliferate	O
and	O
differentiate/mature	O
exclusively	O
along	O
the	O
erythroid	O
lineage	O
;	O
(	O
2	O
)	O
this	O
erythropoietic	O
wave	O
is	O
characterized	O
by	O
less	O
than	O
4	O
%	O
apoptotic	O
cells	O
;	O
(	O
3	O
)	O
asymmetric	B-Negation
divisions	I-Negation
are	I-Negation
virtually	I-Negation
absent	I-Negation
,	O
ie	O
,	O
nonresponsive	O
hematopoietic	O
progenitors	O
with	O
no	B-Negation
erythropoietic	I-Negation
potential	I-Negation
are	O
forced	O
into	O
apoptosis	O
;	O
(	O
4	O
)	O
the	O
system	O
is	O
cell	O
division	O
controlled	O
(	O
cdc	O
)	O
,	O
ie	O
,	O
the	O
number	O
of	O
divisions	O
performed	O
by	O
each	O
cell	O
is	O
monitored	O
.	O

Single-cell	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analysis	O
was	O
applied	O
to	O
this	O
culture	O
system	O
to	O
investigate	O
gene	O
expression	O
of	O
diverse	O
receptors	O
,	O
markers	O
of	O
differentiation	O
,	O
and	O
transcription	O
factors	O
(	O
EKLF	O
,	O
GATA-1	O
,	O
GATA-2	O
,	O
p45	O
NF-E2	O
,	O
PU.1	O
,	O
and	O
SCL/Tal1	O
)	O
at	O
discrete	O
stages	O
of	O
erythropoietic	O
development	O
.	O

Freshly	O
isolated	O
CD34	O
(	O
+	O
)	O
cells	O
expressed	O
CD34	O
,	O
c-kit	O
,	O
PU.1	O
,	O
and	O
GATA-2	O
but	O
did	O
not	B-Negation
express	I-Negation
CD36	I-Negation
,	I-Negation
erythropoietin	I-Negation
receptor	I-Negation
(	I-Negation
EpoR	I-Negation
)	I-Negation
,	I-Negation
SCL/Tal1	I-Negation
,	I-Negation
EKLF	I-Negation
,	I-Negation
NF-E2	I-Negation
,	I-Negation
GATA-1	I-Negation
,	I-Negation
or	I-Negation
glyocophorin	I-Negation
A	I-Negation
(	I-Negation
GPA	I-Negation
)	I-Negation
.	O

In	O
early	O
to	O
intermediate	O
stages	O
of	O
erythroid	O
differentiation	O
we	O
monitored	O
the	O
induction	O
of	O
CD36	O
,	O
Tal1	O
,	O
EKLF	O
,	O
NF-E2	O
,	O
and	O
GATA-1	O
that	O
preceeded	O
expression	O
of	O
EpoR	O
.	O

In	O
late	O
stages	O
of	O
erythroid	O
maturation	O
,	O
GPA	O
was	O
upregulated	O
,	O
whereas	O
CD34	O
,	O
c-kit	O
,	O
PU.1	O
,	O
and	O
GATA-2	O
were	O
barely	O
or	O
not	B-Negation
detected	I-Negation
.	O

In	O
addition	O
,	O
competitive	O
single-cell	O
RT-PCR	O
was	O
used	O
to	O
assay	O
CD34	O
mRNA	O
transcripts	O
in	O
sibling	O
CD34	O
(	O
+	O
)	O
CD38	O
(	O
-	O
)	O
cells	O
differentiating	O
in	O
unilineage	O
erythroid	O
cultures	O
:	O
this	O
analysis	O
allowed	O
us	O
to	O
semiquantitate	O
the	O
gradual	O
downmodulation	O
of	O
CD34	O
mRNA	O
from	O
progenitor	O
cells	O
through	O
their	O
differentiating	O
erythroid	O
progeny	O
.	O

It	O
is	O
concluded	O
that	O
this	O
novel	O
culture	O
system	O
,	O
coupled	O
with	O
single-cell	O
RT-PCR	O
analysis	O
,	O
may	O
eliminate	O
the	O
ambiguities	O
intrinsic	O
to	O
molecular	O
studies	O
on	O
heterogeneous	O
populations	O
of	O
hematopoietic	O
progenitors/precursors	O
growing	O
in	O
culture	O
,	O
particularly	O
in	O
the	O
initial	O
stages	O
of	O
development	O
.	O

Control	O
of	O
cell	O
cycle	O
entry	O
and	O
apoptosis	O
in	O
B	O
lymphocytes	O
infected	O
by	O
Epstein-Barr	O
virus	O
.	O

Infection	O
of	O
human	O
B	O
cells	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
activation	O
of	O
the	O
cell	O
cycle	O
and	O
cell	O
growth	O
.	O

To	O
interpret	O
the	O
mechanisms	O
by	O
which	O
EBV	O
activates	O
the	O
cell	O
,	O
we	O
have	O
assayed	O
many	O
proteins	O
involved	O
in	O
control	O
of	O
the	O
G0	O
and	O
G1	O
phases	O
of	O
the	O
cell	O
cycle	O
and	O
regulation	O
of	O
apoptosis	O
.	O

In	O
EBV	O
infection	O
most	O
of	O
the	O
changes	O
,	O
including	O
the	O
early	O
induction	O
of	O
cyclin	O
D2	O
,	O
are	O
dependent	O
on	O
expression	O
of	O
EBV	O
genes	O
,	O
but	O
an	O
alteration	O
in	O
the	O
E2F-4	O
profile	O
was	O
partly	O
independent	O
of	O
viral	O
gene	O
expression	O
,	O
presumably	O
occurring	O
in	O
response	O
to	O
signal	O
transduction	O
activated	O
when	O
the	O
virus	O
binds	O
to	O
its	O
receptor	O
,	O
CD21	O
.	O

By	O
comparing	O
the	O
expression	O
of	O
genes	O
controlling	O
apoptosis	O
,	O
including	O
those	O
encoding	O
several	O
members	O
of	O
the	O
BCL-2	O
family	O
of	O
proteins	O
,	O
the	O
known	O
relative	O
resistance	O
of	O
EBV-immortalized	O
B-cell	O
lines	O
to	O
apoptosis	O
induced	O
by	O
low	O
serum	O
was	O
found	O
to	O
correlate	O
with	O
expression	O
of	O
both	O
BCL-2	O
and	O
A20	O
.	O

A20	O
can	O
be	O
regulated	O
by	O
the	O
NF-kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
be	O
activated	O
by	O
the	O
EBV	O
LMP-1	O
protein	O
.	O

Quantitative	O
assays	O
demonstrated	O
a	O
direct	O
temporal	O
relationship	O
between	O
LMP-1	O
protein	O
levels	O
and	O
active	O
NF-kappaB	O
during	O
the	O
time	O
course	O
of	O
infection	O
.	O

Immortalization	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	O
lymphocytes	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
mutants	O
expressed	O
in	O
a	O
functional	O
molecular	O
clone	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
transcriptional	O
trans-activator	O
Tax	O
has	O
been	O
demonstrated	O
to	O
have	O
transforming	O
activity	O
in	O
multiple	O
cell	O
culture	O
and	O
transgenic-mouse	O
models	O
.	O

In	O
addition	O
to	O
activating	O
transcription	O
from	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
through	O
the	O
cyclic	O
AMP	O
response	O
element	O
binding	O
protein/activating	O
transcription	O
factor	O
(	O
CREB/ATF	O
)	O
family	O
of	O
transcription	O
factors	O
,	O
Tax	O
activates	O
the	O
expression	O
of	O
multiple	O
cellular	O
promoters	O
through	O
the	O
NF-kappaB	O
pathway	O
of	O
transcriptional	O
activation	O
.	O

The	O
Tax	O
mutants	O
M22	O
and	O
M47	O
have	O
previously	O
been	O
demonstrated	O
to	O
selectively	O
abrogate	O
the	O
ability	O
of	O
Tax	O
to	O
activate	O
transcription	O
through	O
the	O
NF-kappaB	O
or	O
CREB/ATF	O
pathway	O
,	O
respectively	O
.	O

These	O
mutations	O
were	O
introduced	O
in	O
the	O
tax	O
gene	O
of	O
the	O
ACH	O
functional	O
molecular	O
clone	O
of	O
HTLV-1	O
,	O
and	O
virus	O
produced	O
from	O
the	O
mutant	O
ACH	O
clones	O
was	O
examined	O
for	O
the	O
ability	O
to	O
replicate	O
and	O
immortalize	O
primary	O
human	O
lymphocytes	O
.	O

While	O
virus	O
derived	O
from	O
the	O
clone	O
containing	O
the	O
M47	O
mutation	O
retained	O
the	O
ability	O
to	O
immortalize	O
T	O
lymphocytes	O
,	O
the	O
M22	O
mutant	O
lost	O
the	O
ability	O
to	O
immortalize	O
infected	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
activation	O
of	O
the	O
CREB/ATF	O
pathway	O
by	O
Tax	O
is	O
dispensable	O
for	O
the	O
immortalization	O
of	O
T	O
cells	O
by	O
HTLV-1	O
,	O
whereas	O
activation	O
of	O
the	O
NF-kappaB	O
pathway	O
may	O
be	O
critical	O
.	O

HIV-1	O
reactivation	O
in	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
infected	O
adults	O
upon	O
in	O
vitro	O
CD4	O
cross-linking	O
by	O
ligands	O
of	O
the	O
CDR2-loop	O
in	O
extracellular	O
domain	O
1	O
.	O

HIV-1	O
infects	O
resting	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
but	O
remains	O
inactive	O
state	O
until	O
subsequent	O
cell	O
activation	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
cross-linking	O
of	O
cell	O
surface	O
CD4	O
by	O
gp120-anti-gp120	O
immune	O
complexes	O
or	O
heat-inactivated	O
HIV-1	O
(	O
iHIV-1	O
)	O
is	O
sufficient	O
to	O
trigger	O
activation	O
signals	O
leading	O
to	O
virus	O
reactivation	O
(	O
9	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
NF-kappaB	O
nuclear	O
translocation	O
and	O
stimulation	O
of	O
virus	O
production	O
by	O
iHIV-1	O
were	O
strictly	O
linked	O
to	O
the	O
concentrations	O
of	O
viral	O
proteins	O
used	O
as	O
exogenous	O
stimuli	O
.	O

Moreover	O
,	O
we	O
further	O
investigated	O
the	O
physiologic	O
relevance	O
of	O
these	O
observations	O
.	O

When	O
submitted	O
to	O
an	O
in	O
vitro	O
CD4	O
cross-linking	O
by	O
iHIV-1	O
,	O
PBMCs	O
from	O
HIV-1-infected	O
patients	O
were	O
found	O
to	O
produce	O
virus	O
.	O

This	O
viral	O
reactivation	O
was	O
associated	O
with	O
increased	O
NF-kappaB	O
nuclear	O
translocation	O
in	O
patients	O
'	O
PBMCs	O
.	O

Additionally	O
,	O
virus	O
reactivation	O
in	O
resting	O
PBMCs	O
infected	O
in	O
vitro	O
with	O
HIV-1	O
was	O
found	O
to	O
be	O
specifically	O
induced	O
by	O
ligands	O
of	O
the	O
CDR2-loop	O
in	O
domain	O
1	O
(	O
D1	O
)	O
of	O
CD4	O
(	O
virus	O
envelope	O
and	O
anti-CD4	O
monoclonal	O
antibodies	O
)	O
.	O

In	O
contrast	O
,	O
virus	B-Negation
reactivation	I-Negation
was	I-Negation
not	I-Negation
observed	I-Negation
following	I-Negation
CD4	I-Negation
oligomerization	I-Negation
by	I-Negation
antibodies	I-Negation
that	I-Negation
bind	I-Negation
other	I-Negation
epitopes	I-Negation
in	I-Negation
D1	I-Negation
,	I-Negation
including	I-Negation
the	I-Negation
D1/CDR3-loop	I-Negation
.	O

Finally	O
,	O
soluble	O
CD4	O
(	O
sCD4	O
)	O
prevented	O
virus	O
reactivation	O
by	O
D1/CDR2-loop	O
ligands	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
signaling	O
events	O
initiated	O
in	O
PBMCs	O
by	O
oligomerization	O
of	O
CD4	O
at	O
the	O
D1/CDR2-loop	O
can	O
trigger	O
HIV-1	O
upregulation	O
in	O
infected	O
individuals	O
.	O

Defining	O
therapeutic	O
targets	O
by	O
using	O
adenovirus	O
:	O
blocking	O
NF-kappaB	O
inhibits	O
both	O
inflammatory	O
and	O
destructive	O
mechanisms	O
in	O
rheumatoid	O
synovium	O
but	O
spares	O
anti-inflammatory	O
mediators	O
.	O

The	O
role	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
has	O
long	O
been	O
a	O
subject	O
of	O
controversy	O
.	O

We	O
used	O
an	O
adenoviral	O
technique	O
of	O
blocking	O
NF-kappaB	O
through	O
overexpression	O
of	O
the	O
inhibitory	O
subunit	O
IkappaBalpha	O
,	O
which	O
has	O
the	O
advantage	O
that	O
it	O
can	O
be	O
used	O
in	O
the	O
diseased	O
tissue	O
itself	O
,	O
with	O
>	O
90	O
%	O
of	O
the	O
synovial	O
macrophages	O
,	O
fibroblasts	O
,	O
and	O
T	O
cells	O
infected	O
.	O

We	O
found	O
that	O
the	O
spontaneous	O
production	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
other	O
pro-inflammatory	O
cytokines	O
is	O
NF-kappaB-dependent	O
in	O
rheumatoid	O
synovial	O
tissue	O
,	O
in	O
contrast	O
to	O
the	O
main	O
anti-inflammatory	O
mediators	O
,	O
like	O
IL-10	O
and	O
-11	O
,	O
and	O
the	O
IL-1	O
receptor	O
antagonist	O
.	O

Of	O
even	O
more	O
interest	O
,	O
IkappaBalpha	O
overexpression	O
inhibited	O
the	O
production	O
of	O
matrix	O
metalloproteinases	O
1	O
and	O
3	O
while	O
not	B-Negation
affecting	I-Negation
their	I-Negation
tissue	I-Negation
inhibitor	I-Negation
.	O

Blocking	O
NF-kappaB	O
in	O
the	O
rheumatoid	O
joint	O
thus	O
has	O
a	O
very	O
beneficial	O
profile	O
,	O
reducing	O
both	O
the	O
inflammatory	O
response	O
and	O
the	O
tissue	O
destruction	O
.	O

The	O
adenoviral	O
technique	O
described	O
here	O
has	O
widespread	O
applicability	O
,	O
allowing	O
rapid	O
testing	O
of	O
the	O
effects	O
of	O
blocking	O
a	O
potential	O
therapeutic	O
target	O
in	O
either	O
cultures	O
of	O
normal	O
cells	O
or	O
in	O
the	O
diseased	O
tissue	O
itself	O
.	O

Cell	O
growth-regulated	O
expression	O
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
mediated	O
by	O
the	O
transcription	O
factor	O
E2F	O
.	O

Initiation	O
of	O
DNA	O
replication	O
requires	O
the	O
function	O
of	O
MCM	O
gene	O
products	O
,	O
which	O
participate	O
in	O
ensuring	O
that	O
DNA	O
replication	O
occurs	O
only	O
once	O
in	O
the	O
cell	O
cycle	O
.	O

Expression	O
of	O
all	O
mammalian	O
genes	O
of	O
the	O
MCM	O
family	O
is	O
induced	O
by	O
growth	O
stimulation	O
,	O
unlike	O
yeast	O
,	O
and	O
the	O
mRNA	O
levels	O
peak	O
at	O
G1/S	O
boundary	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
transcriptional	O
activities	O
of	O
isolated	O
human	O
MCM	O
gene	O
promoters	O
.	O

Human	O
MCM5	O
and	O
MCM6	O
promoters	O
with	O
mutation	O
in	O
the	O
E2F	O
sites	O
failed	B-Negation
in	I-Negation
promoter	I-Negation
regulation	I-Negation
following	I-Negation
serum	I-Negation
stimulation	I-Negation
and	I-Negation
exogenous	I-Negation
E2F	I-Negation
expression	I-Negation
.	O

In	O
addition	O
,	O
we	O
identified	O
a	O
novel	O
E2F-like	O
sequence	O
in	O
human	O
MCM6	O
promoter	O
which	O
cooperates	O
with	O
the	O
authentic	O
E2F	O
sites	O
in	O
E2F-dependent	O
regulation	O
.	O

Forced	O
expression	O
of	O
E2F1	O
could	O
induce	O
expression	O
of	O
all	O
members	O
of	O
the	O
endogenous	O
MCM	O
genes	O
in	O
rat	O
embryonal	O
fibroblast	O
REF52	O
cells	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
growth-regulated	O
expression	O
of	O
mammalian	O
MCM5	O
and	O
MCM6	O
genes	O
,	O
and	O
presumably	O
other	O
MCM	O
members	O
,	O
is	O
primarily	O
regulated	O
by	O
E2F	O
through	O
binding	O
to	O
multiple	O
E2F	O
sites	O
in	O
the	O
promoters	O
.	O

Non-steroidal	O
anti-inflammatory	O
drugs	O
inhibit	O
the	O
expression	O
of	O
cytokines	O
and	O
induce	O
HSP70	O
in	O
human	O
monocytes	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
the	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
activate	O
heat	O
shock	O
transcription	O
factor	O
(	O
HSF1	O
)	O
from	O
a	O
latent	O
cytoplasmic	O
form	O
to	O
a	O
nuclear	O
,	O
DNA	O
binding	O
state	O
.	O

As	O
HSF1	O
can	O
function	O
as	O
both	O
an	O
activator	O
of	O
heat	O
shock	O
genes	O
and	O
a	O
repressor	O
of	O
non-heat	O
shock	O
genes	O
such	O
as	O
IL1B	O
and	O
c-	O
fos	O
,	O
we	O
have	O
examined	O
the	O
potential	O
role	O
of	O
HSF1	O
in	O
the	O
effects	O
of	O
NSAIDs	O
on	O
gene	O
expression	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O

We	O
found	O
that	O
two	O
members	O
of	O
the	O
NSAIDs	O
,	O
sodium	O
salicylate	O
and	O
sulindac	O
repress	O
the	O
IL1B	O
promoter	O
to	O
similar	O
degree	O
to	O
heat	O
shock	O
or	O
HSF1	O
overexpression	O
.	O

In	O
addition	O
,	O
sodium	O
salicylate	O
and	O
additional	O
NSAIDs	O
used	O
at	O
concentrations	O
that	O
activate	O
HSF1	O
also	O
inhibited	O
the	O
expression	O
of	O
other	O
monocytic	O
genes	O
(	O
TNF-alpha	O
,	O
IL-1beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
IL-10	O
,	O
ICAM-1	O
)	O
activated	O
by	O
exposure	O
to	O
a	O
pro-inflammatory	O
stimulus	O
(	O
lipopolysaccharide	O
,	O
LPS	O
)	O
.	O

At	O
least	O
in	O
the	O
case	O
of	O
the	O
IL1B	O
promoter	O
,	O
repression	B-Negation
did	I-Negation
not	I-Negation
seem	B-Speculation
to	I-Speculation
involve	I-Speculation
another	I-Speculation
factor	I-Speculation
whose	I-Speculation
activity	I-Speculation
is	I-Speculation
affected	I-Speculation
by	I-Speculation
the	I-Speculation
NSAIDs	I-Speculation
,	O
NFkappaB	O
as	O
the	O
IL1B	O
promoter	O
fragment	O
used	O
in	O
our	O
studies	O
is	O
not	B-Negation
NFkappaB	I-Negation
responsive	I-Negation
and	O
binds	O
specifically	O
to	O
HSF1	O
.	O

Exposure	O
to	O
NSAIDs	O
had	O
a	O
complex	O
effect	O
on	O
HSP	O
gene	O
expression	O
and	O
while	O
sulindac	O
activated	O
the	O
stress	O
responsive	O
HSP70B	O
promoter	O
,	O
sodium	O
salicylate	O
did	O
not	B-Negation
.	O

In	O
addition	O
,	O
only	O
a	O
subset	O
of	O
the	O
NSAIDs	O
induced	O
HSP70	O
mRNA	O
species	O
.	O

These	O
findings	O
reflect	O
the	O
properties	O
of	O
HSF1	O
which	O
can	O
be	O
activated	O
to	O
at	O
least	O
two	O
DNA	O
binding	O
forms	O
only	O
one	O
of	O
which	O
activates	O
heat	O
shock	O
promoters	O
and	O
suggest	O
that	O
individual	O
NSAID	O
family	O
members	O
may	O
differentially	O
induce	O
one	O
or	O
other	O
of	O
these	O
forms	O
.	O

Overall	O
therefore	O
,	O
exposure	O
to	O
NSAIDs	O
leads	O
to	O
a	O
profound	O
switch	O
in	O
gene	O
expression	O
in	O
monocytic	O
cells	O
,	O
with	O
suppression	O
of	O
genes	O
involved	O
in	O
macrophage	O
activation	O
and	O
induction	O
of	O
stress	O
genes	O
and	O
HSF1	O
appears	O
to	O
play	O
a	O
regulatory	O
role	O
in	O
these	O
effects	O
.	O

Copyright	O
1999	O
Academic	O
Press	O
.	O

Disruption	O
of	O
alpha	O
beta	O
but	O
not	B-Negation
of	I-Negation
gamma	I-Negation
delta	I-Negation
T	O
cell	O
development	O
by	O
overexpression	O
of	O
the	O
helix-loop-helix	O
protein	O
Id3	O
in	O
committed	O
T	O
cell	O
progenitors	O
.	O

Enforced	O
expression	O
of	O
Id3	O
,	O
which	O
has	O
the	O
capacity	O
to	O
inhibit	O
many	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
,	O
in	O
human	O
CD34	O
(	O
+	O
)	O
hematopoietic	O
progenitor	O
cells	O
that	O
have	O
not	B-Negation
undergone	I-Negation
T	I-Negation
cell	I-Negation
receptor	I-Negation
(	I-Negation
TCR	I-Negation
)	I-Negation
gene	I-Negation
rearrangements	I-Negation
inhibits	O
development	O
of	O
the	O
transduced	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
in	O
a	O
fetal	O
thymic	O
organ	O
culture	O
(	O
FTOC	O
)	O
.	O

Here	O
we	O
document	O
that	O
overexpression	O
of	O
Id3	O
,	O
in	O
progenitors	O
that	O
have	O
initiated	O
TCR	O
gene	O
rearrangements	O
(	O
pre-T	O
cells	O
)	O
,	O
inhibits	O
development	O
into	O
TCRalpha	O
beta	O
but	O
not	B-Negation
into	I-Negation
TCRgamma	I-Negation
delta	I-Negation
T	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
Id3	O
impedes	O
expression	O
of	O
recombination	O
activating	O
genes	O
and	O
downregulates	O
pre-Talpha	O
mRNA	O
.	O

These	O
observations	O
suggest	O
possible	O
mechanisms	O
by	O
which	O
Id3	O
overexpression	O
can	O
differentially	O
affect	O
development	O
of	O
pre-T	O
cells	O
into	O
TCRalpha	O
beta	O
and	O
gamma	O
delta	O
cells	O
.	O

We	O
also	O
observed	O
that	O
cell	O
surface	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
cells	O
with	O
rearranged	O
TCR	O
genes	O
developed	O
from	O
Id3-transduced	O
but	O
not	B-Negation
from	I-Negation
control-transduced	I-Negation
pre-T	O
cells	O
in	O
an	O
FTOC	O
.	O

These	O
cells	O
had	O
properties	O
of	O
both	O
natural	O
killer	O
(	O
NK	O
)	O
and	O
pre-T	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
bHLH	O
factors	O
are	O
required	O
to	O
control	O
T	O
cell	O
development	O
after	O
the	O
T/NK	O
developmental	O
checkpoint	O
.	O

Rel/NF-kappaB	O
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
by	O
inducing	O
the	O
expression	O
of	O
Jagged1	O
,	O
a	O
ligand	O
for	O
Notch	O
receptors	O
.	O

Jagged1	O
belongs	O
to	O
the	O
DSL	O
family	O
of	O
ligands	O
for	O
Notch	O
receptors	O
that	O
control	O
the	O
proliferation	O
and	O
differentiation	O
of	O
various	O
cell	O
lineages	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
transcription	O
factors	O
that	O
regulate	O
its	O
expression	O
.	O

Here	O
,	O
we	O
show	O
that	O
Jagged1	O
is	O
a	O
Rel/NF-kappaB-responsive	O
gene	O
.	O

Both	O
c-Rel	O
and	O
RelA	O
induced	O
jagged1	O
gene	O
expression	O
,	O
whereas	O
a	O
mutant	O
defective	O
for	O
transactivation	O
did	O
not	B-Negation
.	O

Importantly	O
,	O
jagged1	O
transcripts	O
were	O
also	O
upregulated	O
by	O
endogenous	O
NF-kappaB	O
activation	O
and	O
this	O
effect	O
was	O
inhibited	O
by	O
a	O
dominant	O
mutant	O
of	O
IkappaBalpha	O
,	O
a	O
physiological	O
inhibitor	O
of	O
NF-kappaB	O
.	O

Cell	O
surface	O
expression	O
of	O
Jagged1	O
in	O
c-Rel-expressing	O
cell	O
monolayers	O
led	O
to	O
a	O
functional	O
interaction	O
with	O
lymphocytes	O
expressing	O
the	O
Notch1/TAN-1	O
receptor	O
.	O

This	O
correlated	O
with	O
the	O
initiation	O
of	O
signaling	O
downstream	O
of	O
Notch	O
,	O
as	O
evidenced	O
by	O
increased	O
levels	O
of	O
HES-1	O
transcripts	O
in	O
co-cultivated	O
T	O
cells	O
and	O
of	O
CD23	O
transcripts	O
in	O
co-cultivated	O
B	O
cells	O
.	O

Consistent	O
with	O
its	O
Rel/NF-kappaB-dependent	O
induction	O
,	O
Jagged1	O
was	O
found	O
to	O
be	O
highly	O
expressed	O
in	O
splenic	O
B	O
cells	O
where	O
c-Rel	O
is	O
expressed	O
constitutively	O
.	O

These	O
results	O
demonstrate	O
that	O
c-Rel	O
can	O
trigger	O
the	O
Notch	O
signaling	O
pathway	O
in	O
neighboring	O
cells	O
by	O
inducing	O
jagged1	O
gene	O
expression	O
,	O
and	O
suggest	O
a	O
role	O
for	O
Jagged1	O
in	O
B-cell	O
activation	O
,	O
differentiation	O
or	O
function	O
.	O

These	O
findings	O
also	O
highlight	O
the	O
potential	O
for	O
an	O
interplay	O
between	O
the	O
Notch	O
and	O
NF-kappaB	O
signaling	O
pathways	O
in	O
the	O
immune	O
system	O
.	O

Transcriptional	O
control	O
of	O
the	O
IL-5	O
gene	O
by	O
human	O
helper	O
T	O
cells	O
:	O
IL-5	O
synthesis	O
is	O
regulated	O
independently	O
from	O
IL-2	O
or	O
IL-4	O
synthesis	O
.	O

BACKGROUND	O
:	O
IL-5	O
is	O
fundamentally	O
involved	O
in	O
eosinophilic	O
inflammation	O
.	O

Control	O
of	O
IL-5	O
production	O
may	O
be	O
effective	O
for	O
the	O
management	O
of	O
allergic	O
diseases	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
find	O
the	O
transcriptional	O
mechanisms	O
that	O
regulate	O
the	O
IL-5	O
gene	O
to	O
selectively	O
control	O
IL-5	O
synthesis	O
.	O

METHODS	O
:	O
Allergen-specific	O
T-cell	O
clones	O
and	O
T-cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	O
gene	O
was	O
investigated	O
with	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
analysis	O
.	O

RESULTS	O
:	O
A	O
human	O
IL-5	O
promoter/enhancer-luciferase	O
gene	O
construct	O
,	O
pIL-5	O
(	O
-511	O
)	O
Luc	O
,	O
was	O
transcribed	O
on	O
activation	O
of	O
IL-5-producing	O
T-cell	O
clones	O
,	O
but	O
not	B-Negation
IL-5-nonproducing	I-Negation
clones	I-Negation
.	O

pIL-5	O
(	O
-511	O
)	O
Luc	O
was	O
transcribed	O
by	O
T-cell	O
hybridomas	O
derived	O
from	O
fusion	O
between	O
IL-5-producing	O
T-cell	O
clones	O
and	O
an	O
IL-5	O
gene-nonexpressing	O
T-cell	O
line	O
,	O
but	O
not	B-Negation
by	I-Negation
hybridomas	I-Negation
derived	I-Negation
from	I-Negation
IL-5-nonproducing	I-Negation
T-cell	I-Negation
clones	I-Negation
.	O

IL-5	O
synthesis	O
was	O
not	O
only	O
induced	O
by	O
T-cell	O
receptor	O
stimulation	O
but	O
also	O
by	O
IL-2	O
receptor	O
stimulation	O
.	O

Binding	O
of	O
NF-AT	O
,	O
NF-kappaB	O
,	O
and	O
AP-1	O
was	O
induced	O
by	O
T-cell	O
receptor	O
(	O
TcR	O
)	O
stimulation	O
,	O
although	O
there	O
was	O
no	B-Negation
significant	I-Negation
upregulation	I-Negation
of	I-Negation
binding	I-Negation
by	I-Negation
IL-2	I-Negation
stimulation	I-Negation
.	O

CONCLUSION	O
:	O
IL-5	O
synthesis	O
by	O
human	O
helper	O
T	O
cells	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

A	O
unique	O
transcriptional	O
mechanism	O
distinct	O
from	O
those	O
regulating	O
the	O
IL-2	O
or	O
IL-4	O
genes	O
seems	O
to	O
control	O
the	O
IL-5	O
gene	O
.	O

Selective	O
regulation	O
of	O
IL-5	O
gene	O
transcription	O
may	O
be	O
useful	O
for	O
treating	O
eosinophlic	O
inflammation	O
.	O

Regulation	O
of	O
low	O
shear	O
flow-induced	O
HAEC	O
VCAM-1	O
expression	O
and	O
monocyte	O
adhesion	O
.	O

We	O
recently	O
reported	O
that	O
prolonged	O
exposure	O
of	O
human	O
aortic	O
endothelial	O
cells	O
(	O
HAEC	O
)	O
to	O
low	O
shear	O
stress	O
flow	O
patterns	O
is	O
associated	O
with	O
a	O
sustained	O
increase	O
in	O
the	O
activated	O
form	O
of	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
.	O

Here	O
we	O
investigate	O
the	O
hypothesis	O
that	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	O
is	O
responsible	O
for	O
enhanced	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM-1	O
)	O
resulting	O
in	O
augmented	O
endothelial	O
cell-monocyte	O
(	O
EC-Mn	O
)	O
adhesion	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
intracellular	O
oxidant	O
activity	O
.	O

Before	O
exposure	O
to	O
low	O
shear	O
(	O
2	O
dyn/cm2	O
)	O
for	O
6	O
h	O
,	O
HAEC	O
were	O
preincubated	O
with	O
or	O
without	B-Negation
the	I-Negation
antioxidants	I-Negation
pyrrolidine	I-Negation
dithiocarbamate	I-Negation
(	I-Negation
PDTC	I-Negation
)	I-Negation
or	I-Negation
N-acetyl-L-cysteine	I-Negation
(	I-Negation
NAC	I-Negation
)	I-Negation
.	O

PDTC	O
strongly	O
inhibited	O
low	O
shear-induced	O
activation	O
of	O
NF-kappaB	O
,	O
expression	O
of	O
VCAM-1	O
,	O
and	O
EC-Mn	O
adhesion	O
.	O

Paradoxically	O
,	O
NAC	O
exerted	O
a	O
positive	O
effect	O
on	O
low	O
shear-induced	O
VCAM-1	O
expression	O
and	O
EC-Mn	O
adhesion	O
and	O
only	O
slightly	O
downregulated	O
NF-kappaB	O
activation	O
.	O

However	O
,	O
cytokine-induced	O
NF-kappaB	O
activation	O
and	O
VCAM-1	O
expression	O
are	O
blocked	O
by	O
both	O
PDTC	O
and	O
NAC	O
.	O

These	O
data	O
suggest	O
that	O
NF-kappaB	O
plays	O
a	O
key	O
role	O
in	O
low	O
shear-induced	O
VCAM-1	O
expression	O
and	O
that	O
pathways	O
mediating	O
low	O
shear-	O
and	O
cytokine-induced	O
EC-Mn	O
adhesion	O
may	O
be	O
differentially	O
regulated	O
.	O

Nuclear	O
localization	O
and	O
formation	O
of	O
beta-catenin-lymphoid	O
enhancer	O
factor	O
1	O
complexes	O
are	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
activation	I-Negation
of	I-Negation
gene	I-Negation
expression	I-Negation
.	O

In	O
response	O
to	O
activation	O
of	O
the	O
Wnt	O
signaling	O
pathway	O
,	O
beta-catenin	O
accumulates	O
in	O
the	O
nucleus	O
,	O
where	O
it	O
cooperates	O
with	O
LEF/TCF	O
(	O
for	O
lymphoid	O
enhancer	O
factor	O
and	O
T-cell	O
factor	O
)	O
transcription	O
factors	O
to	O
activate	O
gene	O
expression	O
.	O

The	O
mechanisms	O
by	O
which	O
beta-catenin	O
undergoes	O
this	O
shift	O
in	O
location	O
and	O
participates	O
in	O
activation	O
of	O
gene	O
transcription	O
are	O
unknown	O
.	O

We	O
demonstrate	O
here	O
that	O
beta-catenin	O
can	O
be	O
imported	O
into	O
the	O
nucleus	O
independently	O
of	O
LEF/TCF	O
binding	O
,	O
and	O
it	O
may	O
also	O
be	O
exported	O
from	O
nuclei	O
.	O

We	O
have	O
introduced	O
a	O
small	O
deletion	O
within	O
beta-catenin	O
(	O
Delta19	O
)	O
that	O
disrupts	O
binding	O
to	O
LEF-1	O
,	O
E-cadherin	O
,	O
and	O
APC	O
but	O
not	B-Negation
axin	I-Negation
.	O

This	O
Delta19	O
beta-catenin	O
mutant	O
localizes	O
to	O
the	O
nucleus	O
because	O
it	O
may	O
not	O
be	O
efficiently	O
sequestered	O
in	O
the	O
cytoplasm	O
.	O

The	O
nuclear	O
localization	O
of	O
Delta19	O
definitively	O
demonstrates	O
that	O
the	O
mechanisms	O
by	O
which	O
beta-catenin	O
localizes	O
in	O
the	O
nucleus	O
are	O
completely	O
independent	O
of	O
LEF/TCF	O
factors	O
.	O

beta-Catenin	O
and	O
LEF-1	O
complexes	O
can	O
activate	O
reporter	O
gene	O
expression	O
in	O
a	O
transformed	O
T-lymphocyte	O
cell	O
line	O
(	O
Jurkat	O
)	O
but	O
not	B-Negation
in	I-Negation
normal	I-Negation
T	I-Negation
lymphocytes	I-Negation
,	O
even	O
though	O
both	O
factors	O
are	O
nuclear	O
.	O

Thus	O
,	O
localization	O
of	O
both	O
factors	O
to	O
the	O
nucleus	O
is	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
activation	I-Negation
of	I-Negation
gene	I-Negation
expression	I-Negation
.	O

Excess	O
beta-catenin	O
can	O
squelch	O
reporter	O
gene	O
activation	O
by	O
LEF-1-beta-catenin	O
complexes	O
but	O
not	B-Negation
activation	I-Negation
by	I-Negation
the	I-Negation
transcription	I-Negation
factor	I-Negation
VP16	I-Negation
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
a	O
third	O
component	O
is	O
necessary	O
for	O
gene	O
activation	O
and	O
that	O
this	O
third	O
component	O
may	O
vary	O
with	O
cell	O
type	O
.	O

Paradoxical	O
priming	O
effects	O
of	O
IL-10	O
on	O
cytokine	O
production	O
.	O

IL-10	O
is	O
a	O
well-known	O
immunosuppressive	O
and/or	O
anti-inflammatory	O
cytokine	O
.	O

However	O
,	O
we	O
report	O
in	O
vitro	O
experimental	O
studies	O
in	O
which	O
IL-10	O
primed	O
leukocytes	O
and	O
led	O
to	O
an	O
enhanced	O
production	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
upon	O
further	O
stimulation	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Monocytes	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
prepared	O
from	O
whole	O
blood	O
maintained	O
for	O
20	O
h	O
at	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
recombinant	O
human	O
IL-10	O
had	O
an	O
enhanced	O
capacity	O
to	O
produce	O
TNF	O
in	O
response	O
to	O
LPS	O
.	O

In	O
addition	O
to	O
TNF	O
,	O
LPS-induced	O
IL-6	O
and	O
spontaneous	O
IL-1ra	O
production	O
were	O
also	O
enhanced	O
.	O

When	O
isolated	O
PBMC	O
were	O
first	O
cultured	O
for	O
20	O
h	O
in	O
the	O
presence	O
of	O
IL-10	O
on	O
Teflon	O
to	O
prevent	O
adherence	O
,	O
washed	O
to	O
remove	O
IL-10	O
and	O
then	O
further	O
cultured	O
in	O
plastic	O
dishes	O
for	O
an	O
additional	O
20	O
h	O
in	O
the	O
presence	O
of	O
LPS	O
or	O
IL-1beta	O
,	O
an	O
enhanced	O
release	O
of	O
TNF	O
was	O
observed	O
.	O

This	O
was	O
not	B-Negation
the	I-Negation
case	I-Negation
when	I-Negation
PBMC	I-Negation
were	I-Negation
pre-cultured	I-Negation
in	I-Negation
plastic	I-Negation
multidishes	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
IL-10	I-Negation
.	O

TNF	O
mRNA	O
expression	O
induced	O
by	O
LPS	O
was	O
decreased	O
when	O
the	O
pre-treatment	O
of	O
PBMC	O
with	O
IL-10	O
was	O
performed	O
on	O
plastic	O
,	O
whereas	O
this	O
was	O
not	B-Negation
the	I-Negation
case	I-Negation
when	I-Negation
cells	I-Negation
were	I-Negation
pre-cultured	I-Negation
with	I-Negation
IL-10	I-Negation
on	I-Negation
Teflon	I-Negation
.	O

Furthermore	O
,	O
NFkappaB	O
translocation	O
following	O
LPS	O
activation	O
was	O
higher	O
after	O
IL-10	O
pre-treatment	O
on	O
Teflon	O
than	O
on	O
plastic	O
.	O

Interestingly	O
,	O
an	O
enhanced	O
frequency	O
of	O
CD16	O
and	O
CD68	O
(	O
+	O
)	O
cells	O
among	O
the	O
CD14	O
(	O
+	O
)	O
cells	O
was	O
observed	O
in	O
the	O
presence	O
of	O
IL-10	O
,	O
independently	O
of	O
the	O
pre-culture	O
conditions	O
of	O
the	O
PBMC	O
.	O

Altogether	O
,	O
these	O
results	O
indicate	O
that	O
the	O
IL-10-induced	O
up-regulation	O
of	O
cytokine	O
production	O
depends	O
on	O
the	O
prevention	O
of	O
monocyte	O
adherence	O
by	O
red	O
cells	O
in	O
the	O
whole	O
blood	O
assays	O
or	O
by	O
cultures	O
of	O
PBMC	O
on	O
Teflon	O
.	O

In	O
contrast	O
,	O
the	O
adherence	O
parameter	O
has	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
IL-10-induced	I-Negation
modulation	I-Negation
of	I-Negation
some	I-Negation
monocyte	I-Negation
surface	I-Negation
markers	I-Negation
.	O

Different	O
sequence	O
requirements	O
for	O
expression	O
in	O
erythroid	O
and	O
megakaryocytic	O
cells	O
within	O
a	O
regulatory	O
element	O
upstream	O
of	O
the	O
GATA-1	O
gene	O
.	O

The	O
lineage-restricted	O
transcription	O
factor	O
GATA-1	O
is	O
required	O
for	O
differentiation	O
of	O
erythroid	O
and	O
megakaryocytic	O
cells	O
.	O

We	O
have	O
localized	O
a	O
317	O
base	O
pair	O
cis-acting	O
regulatory	O
element	O
,	O
HS	O
I	O
,	O
associated	O
with	O
a	O
hematopoietic-specific	O
DNase	O
I	O
hypersensitive	O
site	O
,	O
which	O
lies	O
approx.	O
3.7	O
kilobases	O
upstream	O
of	O
the	O
murine	O
hematopoietic-specific	O
GATA-1	O
IE	O
promoter	O
.	O

HS	O
I	O
directs	O
high-level	O
expression	O
of	O
reporter	O
GATA-1/lacZ	O
genes	O
to	O
primitive	O
and	O
definitive	O
erythroid	O
cells	O
and	O
megakaryocytes	O
in	O
transgenic	O
mice	O
.	O

Comparative	O
sequence	O
analysis	O
of	O
HS	O
I	O
between	O
human	O
and	O
mouse	O
shows	O
approx.	O
63	O
%	O
nucleotide	O
identity	O
with	O
a	O
more	O
conserved	O
core	O
of	O
169	O
base	O
pairs	O
(	O
86	O
%	O
identity	O
)	O
.	O

This	O
core	O
contains	O
a	O
GATA	O
site	O
separated	O
by	O
10	O
base	O
pairs	O
from	O
an	O
E-box	O
motif	O
.	O

The	O
composite	O
motif	O
binds	O
a	O
multi-protein	O
hematopoietic-specific	O
transcription	O
factor	O
complex	O
which	O
includes	O
GATA-1	O
,	O
SCL/tal-1	O
,	O
E2A	O
,	O
Lmo2	O
and	O
Ldb-1	O
.	O

Point	O
mutations	O
of	O
the	O
GATA	O
site	O
abolishes	O
HS	O
I	O
function	O
,	O
whereas	O
mutation	O
of	O
the	O
E-box	O
motif	O
still	O
allows	O
reporter	O
gene	O
expression	O
in	O
both	O
lineages	O
.	O

Strict	O
dependence	O
of	O
HS	O
I	O
activity	O
on	O
a	O
GATA	O
site	O
implies	O
that	O
assembly	O
of	O
a	O
protein	O
complex	O
containing	O
a	O
GATA-factor	O
,	O
presumably	O
GATA-1	O
or	O
GATA-2	O
,	O
is	O
critical	O
to	O
activating	O
or	O
maintaining	O
its	O
function	O
.	O

Further	O
dissection	O
of	O
the	O
317	O
base	O
pair	O
region	O
demonstrates	O
that	O
,	O
whereas	O
all	O
317	O
base	O
pairs	O
are	O
required	O
for	O
expression	O
in	O
megakaryocytes	O
,	O
only	O
the	O
5	O
'	O
62	O
base	O
pairs	O
are	O
needed	O
for	O
erythroid-specific	O
reporter	O
expression	O
.	O

These	O
findings	O
demonstrate	O
differential	O
lineage	O
requirements	O
for	O
expression	O
within	O
the	O
HS	O
I	O
element	O
.	O

Monocyte	O
arrest	O
and	O
transmigration	O
on	O
inflamed	O
endothelium	O
in	O
shear	O
flow	O
is	O
inhibited	O
by	O
adenovirus-mediated	O
gene	O
transfer	O
of	O
IkappaB-alpha	O
.	O

Mobilization	O
of	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
activates	O
transcription	O
of	O
genes	O
encoding	O
endothelial	O
adhesion	O
molecules	O
and	O
chemokines	O
that	O
contribute	O
to	O
monocyte	O
infiltration	O
critical	O
in	O
atherogenesis	O
.	O

Inhibition	O
of	O
NF-kappaB	O
has	O
been	O
achieved	O
by	O
pharmacological	O
and	O
genetic	O
approaches	O
;	O
however	O
,	O
monocyte	B-Negation
interactions	I-Negation
with	I-Negation
activated	I-Negation
endothelium	I-Negation
in	I-Negation
shear	I-Negation
flow	I-Negation
following	I-Negation
gene	I-Negation
transfer	I-Negation
of	I-Negation
the	I-Negation
NF-kappaB	I-Negation
inhibitor	I-Negation
IkappaB-alpha	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
studied	I-Negation
.	O

We	O
found	O
that	O
overexpression	O
of	O
IkappaB-alpha	O
in	O
endothelial	O
cells	O
using	O
a	O
recombinant	O
adenovirus	O
prevented	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
-induced	O
degradation	O
of	O
IkappaB-alpha	O
and	O
suppressed	O
the	O
upregulation	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
,	O
and	O
E-selectin	O
mRNA	O
and	O
surface	O
protein	O
expression	O
and	O
the	O
upregulation	O
of	O
transcripts	O
for	O
the	O
chemokines	O
monocyte	O
chemoattractant	O
protein	O
1	O
(	O
MCP-1	O
)	O
and	O
growth-related	O
activity-alpha	O
(	O
GRO-alpha	O
)	O
by	O
TNF-alpha	O
.	O

This	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
endothelial	O
MCP-1	O
secretion	O
and	O
GRO-alpha	O
immobilization	O
.	O

Adhesion	O
assays	O
under	O
physiological	O
shear	O
flow	O
conditions	O
showed	O
that	O
firm	O
arrest	O
,	O
spreading	O
,	O
and	O
transmigration	O
of	O
monocytes	O
on	O
TNF-alpha-activated	O
endothelium	O
was	O
markedly	O
inhibited	O
by	O
IkappaB-alpha	O
overexpression	O
.	O

Inhibition	O
with	O
monoclonal	O
antibodies	O
and	O
peptide	O
antagonists	O
inferred	O
that	O
this	O
was	O
due	O
to	O
reduced	O
expression	O
of	O
Ig	O
integrin	O
ligand	O
as	O
well	O
as	O
of	O
chemokines	O
specifically	O
involved	O
in	O
these	O
events	O
.	O

In	O
contrast	O
,	O
rolling	O
of	O
monocytes	O
was	O
increased	O
by	O
IkappaB-alpha	O
transfer	O
and	O
was	O
partly	O
mediated	O
by	O
P-selectin	O
;	O
however	O
,	O
it	O
appeared	O
to	O
be	O
unaffected	O
by	O
the	O
inhibition	O
of	O
E-selectin	O
induction	O
.	O

Thus	O
,	O
our	O
data	O
provide	O
novel	O
evidence	O
that	O
selective	O
modulation	O
of	O
NF-kappaB	O
by	O
adenoviral	O
transfer	O
of	O
IkappaB-alpha	O
impairs	O
the	O
expression	O
of	O
multiple	O
endothelial	O
gene	O
products	O
required	O
for	O
subsequent	O
monocyte	O
arrest	O
and	O
emigration	O
in	O
shear	O
flow	O
and	O
thus	O
for	O
monocyte	O
infiltration	O
in	O
atherosclerotic	O
plaques	O
.	O

SLP-76	O
and	O
Vav	O
function	O
in	O
separate	O
,	O
but	O
overlapping	O
pathways	O
to	O
augment	O
interleukin-2	O
promoter	O
activity	O
.	O

SLP-76	O
and	O
Vav	O
,	O
two	O
hematopoietic	O
cell	O
specific	O
molecules	O
,	O
are	O
critical	O
for	O
T	O
cell	O
development	O
and	O
activation	O
.	O

Following	O
T	O
cell	O
antigen	O
receptor	O
stimulation	O
,	O
SLP-76	O
and	O
Vav	O
both	O
undergo	O
tyrosine	O
phosphorylation	O
and	O
associate	O
with	O
each	O
other	O
via	O
the	O
SH2	O
domain	O
of	O
Vav	O
and	O
phosphorylated	O
tyrosines	O
of	O
SLP-76	O
.	O

Furthermore	O
,	O
SLP-76	O
and	O
Vav	O
have	O
a	O
synergistic	O
effect	O
on	O
interleukin	O
(	O
IL	O
)	O
-2	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
two	O
tyrosines	O
,	O
Tyr-113	O
and	O
Tyr-128	O
,	O
of	O
SLP-76	O
are	O
required	O
for	O
its	O
binding	O
to	O
Vav	O
,	O
both	O
in	O
vitro	O
and	O
in	O
intact	O
cells	O
.	O

Surprisingly	O
,	O
we	O
find	O
also	O
that	O
the	B-Negation
interaction	I-Negation
between	I-Negation
SLP-76	I-Negation
and	I-Negation
Vav	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
their	I-Negation
cooperation	I-Negation
in	I-Negation
augmenting	I-Negation
IL-2	I-Negation
promoter	I-Negation
activity	I-Negation
,	O
as	O
the	B-Speculation
two	I-Speculation
molecules	I-Speculation
appear	I-Speculation
to	I-Speculation
function	I-Speculation
in	I-Speculation
different	I-Speculation
signaling	I-Speculation
pathways	I-Speculation
upstream	I-Speculation
of	I-Speculation
IL-2	I-Speculation
gene	I-Speculation
expression	I-Speculation
.	O

Overexpression	O
of	O
SLP-76	O
in	O
the	O
Jurkat	O
T	O
cell	O
line	O
potentiates	O
the	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP-1	O
transcription	O
factors	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
Vav	O
leads	O
to	O
enhanced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
activity	O
without	B-Negation
affecting	I-Negation
AP-1	I-Negation
.	O

Additionally	O
,	O
overexpression	O
of	O
Vav	O
,	O
but	O
not	B-Negation
SLP-76	I-Negation
,	O
augments	O
CD28-induced	O
IL-2	O
promoter	O
activity	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
synergy	O
between	O
SLP-76	O
and	O
Vav	O
in	O
regulating	O
IL-2	O
gene	O
expression	O
reflects	O
the	O
cooperation	O
between	O
different	O
signaling	O
pathways	O
.	O

Targeted	O
remodeling	O
of	O
human	O
beta-globin	O
promoter	O
chromatin	O
structure	O
produces	O
increased	O
expression	O
and	O
decreased	O
silencing	O
.	O

The	O
chromatin	O
structure	O
of	O
the	O
human	O
beta-globin	O
gene	O
locus	O
assumes	O
a	O
transcriptionally-active	O
conformation	O
in	O
erythroid	O
cells	O
.	O

One	O
feature	O
of	O
this	O
chromatin	O
reorganization	O
is	O
the	O
formation	O
of	O
DNase	O
1	O
hypersensitive	O
sites	O
in	O
the	O
regions	O
of	O
active	O
globin	O
gene	O
promoters	O
.	O

This	O
reorganization	O
requires	O
the	O
globin	O
locus	O
control	O
region	O
and	O
is	O
associated	O
with	O
normal	O
expression	O
of	O
the	O
beta-like	O
globin	O
genes	O
.	O

To	O
determine	O
whether	O
it	O
is	O
possible	O
to	O
artificially	O
enhance	O
the	O
opening	O
of	O
the	O
chromatin	O
structure	O
of	O
a	O
minimal	O
beta-globin	O
promoter	O
,	O
we	O
placed	O
a	O
101bp	O
,	O
erythroid-specific	O
DNase	O
1	O
hypersensitive	O
site-forming	O
element	O
(	O
HSFE	O
)	O
immediately	O
upstream	O
of	O
the	O
beta-globin	O
promoter	O
and	O
gene	O
.	O

This	O
element	O
includes	O
binding	O
sites	O
for	O
NF-E2	O
,	O
AP-1	O
,	O
GATA-1	O
and	O
Sp-1	O
.	O

Constructs	O
were	O
stably	O
transfected	O
into	O
murine	O
erythroleukemia	O
cells	O
and	O
promoter	O
chromatin	O
structure	O
and	O
gene	O
expression	O
were	O
analyzed	O
.	O

The	O
HSFE	O
induced	O
an	O
area	O
of	O
enhanced	O
DNase	O
1	O
hypersensitivity	O
extending	O
from	O
the	O
transcriptional	O
start	O
site	O
to	O
-300bp	O
of	O
the	O
artificial	O
promoter	O
and	O
significantly	O
increased	O
the	O
proportion	O
of	O
beta-globin	O
promoters	O
in	O
an	O
open	O
chromatin	O
configuration	O
.	O

This	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulted	O
in	O
3-fold	O
increases	O
in	O
beta-globin	O
gene	O
transcription	O
and	O
induction	O
,	O
and	O
inhibited	O
long-term	O
beta-globin	O
gene	O
silencing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
relatively	O
small	O
cis-acting	O
element	O
is	O
able	O
to	O
enhance	O
remodeling	O
of	O
promoter	O
chromatin	O
structure	O
resulting	O
in	O
increased	O
beta-globin	O
gene	O
expression	O
.	O

In	O
vivo	O
inhibition	O
of	O
NF-kappa	O
B	O
in	O
T-lineage	O
cells	O
leads	O
to	O
a	O
dramatic	O
decrease	O
in	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
and	O
to	O
increased	O
cell	O
apoptosis	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
,	O
but	O
not	B-Negation
to	I-Negation
abnormal	I-Negation
thymopoiesis	I-Negation
.	O

To	O
understand	O
the	O
role	O
of	O
NF-kappa	O
B	O
complexes	O
in	O
T	O
cell	O
development	O
and	O
activation	O
,	O
we	O
have	O
generated	O
transgenic	O
mice	O
in	O
which	O
RelA	O
and	O
c-Rel	O
complexes	O
were	O
selectively	O
inhibited	O
in	O
the	O
T-lineage	O
cells	O
by	O
specific	O
expression	O
of	O
a	O
trans-dominant	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Transgene	O
expression	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
thymic	I-Negation
development	I-Negation
,	O
but	O
led	O
to	O
lowered	O
numbers	O
of	O
splenic	O
T	O
cells	O
and	O
to	O
a	O
dramatic	O
decrease	O
in	O
the	O
ex	O
vivo	O
proliferative	O
response	O
of	O
splenic	O
T	O
lymphocytes	O
.	O

Analysis	O
of	O
IL-2	O
and	O
IL-2R	O
alpha	O
expression	O
demonstrated	O
that	O
the	O
perturbation	O
of	O
the	O
proliferation	O
response	O
was	O
not	B-Negation
attributable	I-Negation
to	I-Negation
an	I-Negation
abnormal	I-Negation
expression	I-Negation
of	I-Negation
these	I-Negation
genes	I-Negation
.	O

In	O
contrast	O
,	O
expression	O
of	O
IL-4	O
,	O
IL-10	O
,	O
and	O
IFN-gamma	O
was	O
strongly	O
inhibited	O
in	O
the	O
transgenic	O
T	O
cells	O
.	O

The	O
proliferative	O
deficiency	O
of	O
the	O
transgenic	O
T	O
cells	O
was	O
associated	O
with	O
an	O
increased	O
apoptosis	O
.	O

These	O
results	O
point	O
out	O
the	O
involvement	O
of	O
NF-kappa	O
B/Rel	O
family	O
proteins	O
in	O
growth	O
signaling	O
pathways	O
by	O
either	O
regulating	O
proteins	O
involved	O
in	O
the	O
IL-2	O
signaling	O
or	O
by	O
functionally	O
interfering	O
with	O
the	O
cell	O
cycle	O
progression	O
.	O

CD28	O
costimulation	O
augments	O
IL-2	O
secretion	O
of	O
activated	O
lamina	O
propria	O
T	O
cells	O
by	O
increasing	O
mRNA	O
stability	O
without	B-Negation
enhancing	I-Negation
IL-2	I-Negation
gene	I-Negation
transactivation	I-Negation
.	O

The	O
pathways	O
leading	O
to	O
activation	O
in	O
lamina	O
propria	O
(	O
LP	O
)	O
T	O
cells	O
are	O
different	O
from	O
peripheral	O
T	O
cells	O
.	O

LP	O
T	O
cells	O
exhibit	O
enhanced	O
IL-2	O
secretion	O
when	O
activated	O
through	O
the	O
CD2	O
pathway	O
.	O

Coligation	O
of	O
CD28	O
leads	O
to	O
synergistic	O
enhancement	O
of	O
IL-2	O
secretion	O
.	O

Previous	O
studies	O
have	O
characterized	O
the	O
CD28	O
augmentation	O
of	O
TCR-mediated	O
signaling	O
in	O
peripheral	O
blood	O
T	O
cells	O
through	O
transcriptional	O
activation	O
of	O
an	O
IL-2	O
promoter	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
,	O
along	O
with	O
enhanced	O
mRNA	O
stability	O
.	O

This	O
study	O
characterized	O
molecular	O
events	O
involved	O
in	O
CD28	O
costimulation	O
of	O
IL-2	O
production	O
in	O
LP	O
mononuclear	O
cells	O
(	O
LPMC	O
)	O
.	O

LPMC	O
exhibited	O
increased	O
IL-2	O
production	O
in	O
response	O
to	O
CD28	O
costimulation	O
,	O
compared	O
with	O
cells	O
activated	O
through	O
CD2	O
alone	O
.	O

IL-2	O
secretion	O
was	O
paralleled	O
by	O
increased	O
expression	O
of	O
IL-2	O
mRNA	O
,	O
resulting	O
from	O
enhanced	O
IL-2	O
mRNA	O
stability	O
.	O

In	O
contrast	O
to	O
transcriptional	O
activation	O
in	O
PBMC	O
,	O
EMSA	O
revealed	O
that	O
CD28	O
coligation	O
of	O
CD2-activated	O
LPMC	O
does	O
not	B-Negation
result	I-Negation
in	I-Negation
increased	I-Negation
binding	I-Negation
of	I-Negation
trans-factors	I-Negation
to	I-Negation
the	I-Negation
CD28RE	I-Negation
,	O
nor	B-Negation
did	I-Negation
Western	I-Negation
blots	I-Negation
detect	I-Negation
changes	I-Negation
in	I-Negation
I-kappaBalpha	I-Negation
or	I-Negation
I-kappaBbeta	I-Negation
levels	I-Negation
following	I-Negation
CD28	I-Negation
coligation	I-Negation
.	O

Furthermore	O
,	O
CD28	O
coligation	O
fails	B-Negation
to	I-Negation
enhance	I-Negation
IL-2	I-Negation
promoter-reporter	I-Negation
or	I-Negation
RE/AP	I-Negation
construct	I-Negation
expression	I-Negation
in	I-Negation
CD2-activated	I-Negation
LPMC	I-Negation
.	O

The	O
results	O
reported	O
herein	O
indicate	O
that	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
CD28	O
cosignaling	O
and	O
regulation	O
of	O
IL-2	O
secretion	O
in	O
LP	O
T	O
cells	O
are	O
unique	O
to	O
that	O
compartment	O
and	O
differ	O
from	O
those	O
seen	O
in	O
peripheral	O
blood	O
T	O
cells	O
.	O

These	O
observations	O
suggest	O
a	O
biological	O
significance	O
for	O
different	O
mechanisms	O
of	O
IL-2	O
activation	O
in	O
initiation	O
and	O
maintenance	O
of	O
the	O
cytokine	O
repertoire	O
found	O
in	O
the	O
mucosa	O
.	O

Repression	O
by	O
Ikaros	O
and	O
Aiolos	O
is	O
mediated	O
through	O
histone	O
deacetylase	O
complexes	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid	O
lineage-determining	O
factors	O
Ikaros	O
and	O
Aiolos	O
can	O
function	O
as	O
strong	O
transcriptional	O
repressors	O
.	O

This	O
function	O
is	O
mediated	O
through	O
two	O
repression	O
domains	O
and	O
is	O
dependent	O
upon	O
the	O
promoter	O
context	O
and	O
cell	O
type	O
.	O

Repression	O
by	O
Ikaros	O
proteins	O
correlates	O
with	O
hypo-acetylation	O
of	O
core	O
histones	O
at	O
promoter	O
sites	O
and	O
is	O
relieved	O
by	O
histone	O
deacetylase	O
inhibitors	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
Ikaros	O
and	O
its	O
repression	O
domains	O
can	O
interact	O
in	O
vivo	O
and	O
in	O
vitro	O
with	O
the	O
mSin3	O
family	O
of	O
co-repressors	O
which	O
bind	O
to	O
histone	O
deacetylases	O
.	O

Based	O
on	O
these	O
and	O
our	O
recent	O
findings	O
of	O
associations	O
between	O
Ikaros	O
and	O
Mi-2-HDAC	O
,	O
we	O
propose	O
that	O
Ikaros	O
family	O
members	O
modulate	O
gene	O
expression	O
during	O
lymphocyte	O
development	O
by	O
recruiting	O
distinct	O
histone	O
deacetylase	O
complexes	O
to	O
specific	O
promoters	O
.	O

New	O
immunosuppressive	O
drug	O
PNU156804	O
blocks	O
IL-2-dependent	O
proliferation	O
and	O
NF-kappa	O
B	O
and	O
AP-1	O
activation	O
.	O

We	O
had	O
previously	O
shown	O
that	O
the	O
drug	O
undecylprodigiosin	O
(	O
UP	O
)	O
blocks	O
human	O
lymphocyte	O
proliferation	O
in	O
vitro	O
.	O

We	O
have	O
now	O
investigated	O
the	O
mechanism	O
of	O
action	O
of	O
a	O
new	O
analogue	O
of	O
UP	O
,	O
PNU156804	O
,	O
which	O
shows	O
a	O
more	O
favorable	O
activity	O
profile	O
than	O
UP	O
in	O
mice	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
biological	O
effect	O
of	O
PNU156804	O
in	O
vitro	O
is	O
indistinguishable	O
from	O
UP	O
:	O
PNU156804	O
blocks	O
human	O
T	O
cell	O
proliferation	O
in	O
mid-late	O
G1	O
,	O
as	O
determined	O
by	O
cell	O
cycle	O
analysis	O
,	O
expression	O
of	O
cyclins	O
,	O
and	O
cyclin-dependent	O
kinases	O
and	O
retinoblastoma	O
phosphorylation	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
PNU156804	O
does	O
not	B-Negation
block	I-Negation
significantly	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
either	I-Negation
IL-2	I-Negation
or	I-Negation
IL-2R	I-Negation
alpha-	I-Negation
and	I-Negation
gamma-chains	I-Negation
but	O
inhibits	O
IL-2-dependent	O
T	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
several	O
molecular	O
pathways	O
that	O
are	O
known	O
to	O
be	O
activated	O
by	O
IL-2	O
in	O
T	O
cells	O
.	O

We	O
show	O
that	O
PNU156804	O
does	O
not	B-Negation
inhibit	I-Negation
c-myc	I-Negation
and	I-Negation
bcl-2	I-Negation
mRNA	I-Negation
induction	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
PNU156804	O
efficiently	O
inhibits	O
the	O
activation	O
of	O
the	O
NF-kappa	O
B	O
and	O
AP-1	O
transcription	O
factors	O
.	O

PNU156804	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
is	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
degradation	O
of	O
I	O
kappa	O
B-alpha	O
and	O
I	O
kappa	O
B-beta	O
.	O

PNU156804	O
action	O
is	O
restricted	O
to	O
some	O
signaling	O
pathways	O
;	O
it	O
does	O
not	B-Negation
affect	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
by	I-Negation
PMA	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
but	O
blocks	O
that	O
induced	O
by	O
CD40	O
cross-linking	O
in	O
B	O
lymphocytes	O
.	O

We	O
conclude	O
that	O
the	O
prodigiosin	O
family	O
of	O
immunosuppressants	O
is	O
a	O
new	O
family	O
of	O
molecules	O
that	O
show	O
a	O
novel	O
target	O
specificity	O
clearly	O
distinct	O
from	O
that	O
of	O
other	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporin	O
A	O
,	O
FK506	O
,	O
and	O
rapamycin	O
.	O

IL-12	O
induces	O
IFN	O
regulating	O
factor-1	O
(	O
IRF-1	O
)	O
gene	O
expression	O
in	O
human	O
NK	O
and	O
T	O
cells	O
.	O

IL-12	O
is	O
a	O
critical	O
immunoregulatory	O
cytokine	O
that	O
promotes	O
cell-mediated	O
immune	O
responses	O
and	O
the	O
differentiation	O
of	O
naive	O
CD4+	O
cells	O
to	O
Th1	O
cells	O
;	O
however	O
,	O
relatively	O
few	O
IL-12	O
target	O
genes	O
have	O
been	O
identified	O
.	O

To	O
better	O
clarify	O
the	O
molecular	O
basis	O
of	O
IL-12	O
action	O
,	O
we	O
set	O
out	O
to	O
characterize	O
genes	O
up-regulated	O
by	O
IL-12	O
,	O
first	O
by	O
contrasting	O
IL-12-	O
and	O
IFN-alpha-inducible	O
genes	O
.	O

We	O
identified	O
several	O
genes	O
up-regulated	O
by	O
IL-12	O
,	O
namely	O
,	O
MIP-1alpha	O
,	O
MIP-1beta	O
,	O
IL-1RA	O
,	O
and	O
IFN	O
regulatory	O
factor-1	O
(	O
IRF-1	O
)	O
.	O

IRF-1	O
is	O
a	O
transcription	O
factor	O
regulated	O
by	O
IFNs	O
that	O
is	O
also	O
essential	O
for	O
Th1	O
responses	O
.	O

We	O
demonstrated	O
that	O
IL-12	O
directly	O
up-regulates	O
IRF-1	O
to	O
the	O
same	O
extent	O
as	O
IFN-alpha	O
in	O
normal	O
human	O
T	O
cells	O
and	O
in	O
NK	O
cells	O
.	O

We	O
showed	O
that	O
IL-12	O
had	O
a	O
direct	O
effect	O
on	O
IRF-1	O
,	O
an	B-Negation
effect	I-Negation
not	I-Negation
mediated	I-Negation
indirectly	I-Negation
by	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
IFN-gamma	I-Negation
production	I-Negation
.	O

Furthermore	O
,	O
IL-2	O
and	O
IL-12	O
synergistically	O
induced	O
IRF-1	O
,	O
whereas	O
IFN-alpha	O
and	O
IL-12	O
did	O
not	B-Negation
.	O

The	O
participation	O
of	O
STAT4	O
in	O
the	O
regulation	O
of	O
IRF-1	O
was	O
demonstrated	O
in	O
two	O
ways	O
.	O

First	O
,	O
STAT4	O
was	O
required	O
for	O
the	O
IL-12-dependent	O
transactivation	O
of	O
an	O
IRF-1	O
reporter	O
construct	O
,	O
and	O
second	O
,	O
STAT4	O
binding	O
to	O
the	O
IRF-1	O
promoter	O
was	O
shown	O
using	O
EMSA	O
.	O

In	O
contrast	O
to	O
IL-12	O
,	O
no	B-Negation
up-regulation	I-Negation
of	I-Negation
IRF-1	I-Negation
was	I-Negation
found	I-Negation
in	I-Negation
IL-4-stimulated	I-Negation
cells	I-Negation
,	O
and	O
IL-4	O
did	O
not	B-Negation
block	I-Negation
IL-12-dependent	I-Negation
up-regulation	I-Negation
of	I-Negation
IRF-1	I-Negation
.	O

Therefore	O
,	O
IRF-1	O
may	O
be	O
an	O
important	O
contributor	O
to	O
IL-12	O
signaling	O
,	O
and	O
we	O
speculate	O
that	O
the	O
defective	O
IL-12	O
responses	O
seen	O
in	O
IRF-1-/-	O
mice	O
might	O
be	O
attributable	O
,	O
in	O
part	O
,	O
to	O
the	O
absence	O
of	O
this	O
transcription	O
factor	O
.	O

Transcriptional	O
regulation	O
of	O
T	O
lymphocyte	O
development	O
and	O
function	O
.	O

The	O
development	O
and	O
function	O
of	O
T	O
lymphocytes	O
are	O
regulated	O
tightly	O
by	O
signal	O
transduction	O
pathways	O
that	O
include	O
specific	O
cell-surface	O
receptors	O
,	O
intracellular	O
signaling	O
molecules	O
,	O
and	O
nuclear	O
transcription	O
factors	O
.	O

Since	O
1988	O
,	O
several	O
families	O
of	O
functionally	O
important	O
T	O
cell	O
transcription	O
factors	O
have	O
been	O
identified	O
.	O

These	O
include	O
the	O
Ikaros	O
,	O
LKLF	O
,	O
and	O
GATA3	O
zinc-finger	O
proteins	O
;	O
the	O
Ets	O
,	O
CREB/ATF	O
,	O
and	O
NF-kappa	O
B/Rel/NFAT	O
transcription	O
factors	O
;	O
the	O
Stat	O
proteins	O
;	O
and	O
HMG	O
box	O
transcription	O
factors	O
such	O
as	O
LEF1	O
,	O
TCF1	O
,	O
and	O
Sox4	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
our	O
current	O
understanding	O
of	O
the	O
transcriptional	O
regulation	O
of	O
T	O
cell	O
development	O
and	O
function	O
with	O
particular	O
emphasis	O
on	O
the	O
results	O
of	O
recent	O
gene	O
targeting	O
and	O
transgenic	O
experiments	O
.	O

In	O
addition	O
to	O
increasing	O
our	O
understanding	O
of	O
the	O
molecular	O
pathways	O
that	O
regulate	O
T	O
cell	O
development	O
and	O
function	O
,	O
these	O
results	O
have	O
suggested	O
novel	O
targets	O
for	O
genetic	O
and	O
pharmacological	O
manipulation	O
of	O
T	O
cell	O
immunity	O
.	O

Binding	O
of	O
YY1	O
and	O
Oct1	O
to	O
a	O
novel	O
element	O
that	O
downregulates	O
expression	O
of	O
IL-5	O
in	O
human	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
IL-5	O
controls	O
development	O
of	O
eosinophilia	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
allergic	O
diseases	O
.	O

In	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
,	O
elevated	O
IL-5	O
has	O
been	O
detected	O
in	O
peripheral	O
blood	O
and	O
the	O
airways	O
.	O

IL-5	O
is	O
produced	O
mainly	O
by	O
activated	O
T	O
cells	O
,	O
and	O
its	O
expression	O
is	O
regulated	O
at	O
the	O
transcriptional	O
level	O
.	O

OBJECTIVE	O
:	O
This	O
study	O
focuses	O
on	O
the	O
functional	O
analysis	O
of	O
the	O
human	O
IL-5	O
(	O
hIL-5	O
)	O
promoter	O
and	O
characterization	O
of	O
cis	O
-regulatory	O
elements	O
and	O
transcription	O
factors	O
involved	O
in	O
the	O
suppression	O
of	O
IL-5	O
transcription	O
in	O
T	O
cells	O
.	O

METHODS	O
:	O
Methods	O
used	O
in	O
this	O
study	O
include	O
DNase	O
I	O
footprint	O
assays	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
and	O
functional	O
analysis	O
by	O
mammalian	O
cell	O
transfection	O
involving	O
deletion	O
analysis	O
and	O
site-directed	O
mutagenesis	O
.	O

RESULTS	O
:	O
We	O
identified	O
5	O
protein	O
binding	O
regions	O
(	O
BRs	O
)	O
located	O
within	O
the	O
proximal	O
hIL-5	O
promoter	O
.	O

Functional	O
analysis	O
indicates	O
that	O
the	O
BRs	O
are	O
involved	O
in	O
control	O
of	O
hIL-5	O
promoter	O
activity	O
.	O

Two	B-Negation
of	I-Negation
these	I-Negation
regions	I-Negation
,	I-Negation
BR3	I-Negation
and	I-Negation
BR4	I-Negation
located	I-Negation
at	I-Negation
positions	I-Negation
-102	I-Negation
to	I-Negation
-73	I-Negation
,	I-Negation
have	I-Negation
not	I-Negation
previously	I-Negation
been	I-Negation
described	I-Negation
as	I-Negation
regulators	I-Negation
of	I-Negation
IL-5	I-Negation
expression	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

We	O
show	O
that	O
the	O
BR3	O
sequence	O
contains	O
a	O
novel	O
negative	O
regulatory	O
element	O
located	O
at	O
positions	O
-90	O
to	O
-79	O
of	O
the	O
hIL-5	O
promoter	O
,	O
which	O
binds	O
Oct1	O
,	O
octamer-like	O
,	O
and	O
YY1	O
nuclear	O
factors	O
.	O

Substitution	O
mutations	O
,	O
which	O
abolished	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
BR3	O
sequence	O
,	O
significantly	O
increased	O
hIL-5	O
promoter	O
activity	O
in	O
activated	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
Oct1	O
,	O
YY1	O
,	O
and	O
octamer-like	O
factors	O
binding	O
to	O
the	O
-90/-79	O
sequence	O
within	O
the	O
proximal	O
IL-5	O
promoter	O
are	O
involved	O
in	O
suppression	O
of	O
IL-5	O
transcription	O
in	O
T	O
cells	O
.	O

Direct	O
interaction	O
of	O
hematopoietic	O
transcription	O
factors	O
PU.1	O
and	O
GATA-1	O
:	O
functional	O
antagonism	O
in	O
erythroid	O
cells	O
.	O

Malignant	O
transformation	O
usually	O
inhibits	O
terminal	O
cell	O
differentiation	O
but	O
the	B-Negation
precise	I-Negation
mechanisms	I-Negation
involved	I-Negation
are	I-Negation
not	I-Negation
understood	I-Negation
.	O

PU.1	O
is	O
a	O
hematopoietic-specific	O
Ets	O
family	O
transcription	O
factor	O
that	O
is	O
required	O
for	O
development	O
of	O
some	O
lymphoid	O
and	O
myeloid	O
lineages	O
.	O

PU.1	O
can	O
also	O
act	O
as	O
an	O
oncoprotein	O
as	O
activation	O
of	O
its	O
expression	O
in	O
erythroid	O
precursors	O
by	O
proviral	O
insertion	O
or	O
transgenesis	O
causes	O
erythroleukemias	O
in	O
mice	O
.	O

Restoration	O
of	O
terminal	O
differentiation	O
in	O
the	O
mouse	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
requires	O
a	O
decline	O
in	O
the	O
level	O
of	O
PU.1	O
,	O
indicating	O
that	O
PU.1	O
can	O
block	O
erythroid	O
differentiation	O
.	O

Here	O
we	O
investigate	O
the	O
mechanism	O
by	O
which	O
PU.1	O
interferes	O
with	O
erythroid	O
differentiation	O
.	O

We	O
find	O
that	O
PU.1	O
interacts	O
directly	O
with	O
GATA-1	O
,	O
a	O
zinc	O
finger	O
transcription	O
factor	O
required	O
for	O
erythroid	O
differentiation	O
.	O

Interaction	O
between	O
PU.1	O
and	O
GATA-1	O
requires	O
intact	O
DNA-binding	O
domains	O
in	O
both	O
proteins	O
.	O

PU.1	O
represses	O
GATA-1-mediated	O
transcriptional	O
activation	O
.	O

Both	O
the	O
DNA	O
binding	O
and	O
transactivation	O
domains	O
of	O
PU.1	O
are	O
required	O
for	O
repression	O
and	O
both	O
domains	O
are	O
also	O
needed	O
to	O
block	O
terminal	O
differentiation	O
in	O
MEL	O
cells	O
.	O

We	O
also	O
show	O
that	O
ectopic	O
expression	O
of	O
PU.1	O
in	O
Xenopus	O
embryos	O
is	O
sufficient	O
to	O
block	O
erythropoiesis	O
during	O
normal	O
development	O
.	O

Furthermore	O
,	O
introduction	O
of	O
exogenous	O
GATA-1	O
in	O
both	O
MEL	O
cells	O
and	O
Xenopus	O
embryos	O
and	O
explants	O
relieves	O
the	O
block	O
to	O
erythroid	O
differentiation	O
imposed	O
by	O
PU.1	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
stoichiometry	O
of	O
directly	O
interacting	O
but	O
opposing	O
transcription	O
factors	O
may	O
be	O
a	O
crucial	O
determinant	O
governing	O
processes	O
of	O
normal	O
differentiation	O
and	O
malignant	O
transformation	O
.	O

Potent	O
and	O
stable	O
attenuation	O
of	O
live-HIV-1	O
by	O
gain	O
of	O
a	O
proteolysis-resistant	O
inhibitor	O
of	O
NF-kappaB	O
(	O
IkappaB-alphaS32/36A	O
)	O
and	O
the	O
implications	O
for	O
vaccine	O
development	O
.	O

Live-attenuated	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
are	O
candidates	O
for	O
Acquired	O
Immunodeficiency	O
Syndrome	O
(	O
AIDS	O
)	O
vaccine	O
.	O

Based	O
on	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
model	O
for	O
AIDS	O
,	O
loss-of-function	O
(	O
e.g.	O
deletion	O
of	O
accessory	O
genes	O
such	O
as	O
nef	O
)	O
has	O
been	O
forwarded	O
as	O
a	O
primary	O
approach	O
for	O
creating	O
enfeebled	O
,	O
but	O
replication-competent	O
,	O
HIV-1/SIV	O
.	O

Regrettably	O
,	O
recent	O
evidence	O
suggests	O
that	O
loss-of-function	O
alone	O
is	O
not	O
always	O
sufficient	O
to	O
prevent	O
the	O
emergence	O
of	O
virulent	O
mutants	O
.	O

New	O
strategies	O
that	O
attenuate	O
via	O
mechanisms	O
distinct	O
from	O
loss-of-function	O
are	O
needed	O
for	O
enhancing	O
the	O
safety	O
phenotype	O
of	O
viral	O
genome	O
.	O

Here	O
,	O
we	O
propose	O
gain-of-function	O
to	O
be	O
used	O
simultaneously	O
with	O
loss-of-function	O
as	O
a	O
novel	O
approach	O
for	O
attenuating	O
HIV-1	O
.	O

We	O
have	O
constructed	O
an	O
HIV-1	O
genome	O
carrying	O
the	O
cDNA	O
of	O
a	O
proteolysis-resistant	O
nuclear	O
factor-kappaB	O
inhibitor	O
(	O
IkappaB-alphaS32/36A	O
)	O
in	O
the	O
nef	O
region	O
.	O

HIV-1	O
expressing	O
IkappaB-alphaS32/36A	O
down-regulates	O
viral	O
expression	O
and	O
is	O
highly	O
attenuated	O
in	O
both	O
Jurkat	O
and	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

We	O
provide	O
formal	O
proof	O
that	O
the	O
phenotypic	O
and	O
attenuating	O
characteristics	O
of	O
IkappaB-alphaS32/36A	O
permit	O
its	O
stable	O
maintenance	O
in	O
a	O
live	O
,	O
replicating	O
HIV-1	O
despite	O
180	O
days	O
of	O
forced	O
ex	O
vivo	O
passaging	O
in	O
tissue	O
culture	O
.	O

As	O
compared	O
with	O
other	O
open-reading	O
frames	O
embedded	O
into	O
HIV/SIV	O
genome	O
,	O
this	O
degree	O
of	O
stability	O
is	O
unprecedented	O
.	O

Thus	O
,	O
IkappaB-alphaS32/36A	O
offers	O
proof-of-principle	O
that	O
artifactually	O
gained	O
functions	O
,	O
when	O
used	O
to	O
attenuate	O
the	O
replication	O
of	O
live	O
HIV-1	O
,	O
can	O
be	O
stable	O
.	O

These	O
findings	O
illustrate	O
gain-of-function	O
as	O
a	O
feasible	O
strategy	O
for	O
developing	O
safer	O
live-attenuated	O
HIVs	O
to	O
be	O
tested	O
as	O
candidates	O
for	O
AIDS	O
vaccine	O
.	O

Human	O
alveolar	O
macrophages	O
are	O
markedly	O
deficient	O
in	O
REF-1	O
and	O
AP-1	O
DNA	O
binding	O
activity	O
.	O

Although	O
many	O
functions	O
of	O
human	O
alveolar	O
macrophages	O
are	O
altered	O
compared	O
with	O
their	O
precursor	O
cell	O
,	O
the	O
blood	O
monocyte	O
(	O
monocyte	O
)	O
,	O
the	B-Negation
reason	I-Negation
(	I-Negation
s	I-Negation
)	I-Negation
for	I-Negation
these	I-Negation
functional	I-Negation
changes	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
determined	I-Negation
.	O

We	O
recently	O
reported	O
that	O
human	O
alveolar	O
macrophages	O
do	O
not	B-Negation
express	I-Negation
AP-1	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
(	O
Monick	O
,	O
M.	O
M.	O
,	O
Carter	O
,	O
A.	O
B.	O
,	O
Gudmundsson	O
,	O
G.	O
,	O
Geist	O
,	O
L.	O
J.	O
,	O
and	O
Hunninghake	O
,	O
G.	O
W.	O
(	O
1998	O
)	O
Am.	O
J.	O
Physiol.	O
275	O
,	O
L389-L397	O
)	O
.	O

To	O
determine	O
why	O
alveolar	O
macrophages	O
do	O
not	B-Negation
express	I-Negation
AP-1	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
,	O
we	O
first	O
showed	O
that	O
there	O
was	O
not	B-Negation
a	I-Negation
decrease	I-Negation
in	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
FOS	I-Negation
and	I-Negation
JUN	I-Negation
proteins	I-Negation
that	I-Negation
make	I-Negation
up	I-Negation
the	I-Negation
AP-1	I-Negation
complex	I-Negation
.	O

There	O
was	O
,	O
however	O
,	O
a	O
significant	O
difference	O
in	O
the	O
amounts	O
of	O
the	O
nuclear	O
protein	O
,	O
REF-1	O
(	O
which	O
regulates	O
AP-1	O
DNA	O
binding	O
by	O
altering	O
the	O
redox	O
status	O
of	O
FOS	O
and	O
JUN	O
proteins	O
)	O
,	O
in	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

In	O
addition	O
,	O
in	O
vitro	O
differentiation	O
of	O
monocytes	O
to	O
a	O
macrophage-like	O
cell	O
resulted	O
in	O
decreased	O
amounts	O
of	O
REF-1	O
.	O

Finally	O
,	O
addition	O
of	O
REF-1	O
from	O
activated	O
monocytes	O
to	O
alveolar	O
macrophage	O
nuclear	O
proteins	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
AP-1	O
DNA	O
binding	O
.	O

These	O
studies	O
strongly	O
suggest	O
that	O
the	O
process	O
of	O
differentiation	O
of	O
monocytes	O
into	O
alveolar	O
macrophages	O
is	O
associated	O
with	O
a	O
loss	O
of	O
REF-1	O
and	O
AP-1	O
activity	O
.	O

This	O
observation	O
may	O
explain	O
,	O
in	O
part	O
,	O
some	O
of	O
the	O
functional	O
differences	O
observed	O
for	O
alveolar	O
macrophages	O
compared	O
with	O
monocytes	O
.	O

A	O
polymorphism	O
that	O
affects	O
OCT-1	O
binding	O
to	O
the	O
TNF	O
promoter	O
region	O
is	O
associated	O
with	O
severe	O
malaria	O
[	O
see	O
comments	O
]	O

Genetic	O
variation	O
in	O
cytokine	O
promoter	O
regions	O
is	O
postulated	O
to	O
influence	O
susceptibility	O
to	O
infection	O
,	O
but	O
the	O
molecular	O
mechanisms	O
by	O
which	O
such	O
polymorphisms	O
might	O
affect	O
gene	O
regulation	O
are	O
unknown	O
.	O

Through	O
systematic	O
DNA	O
footprinting	O
of	O
the	O
TNF	O
(	O
encoding	O
tumour	O
necrosis	O
factor	O
,	O
TNF	O
)	O
promoter	O
region	O
,	O
we	O
have	O
identified	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
that	O
causes	O
the	O
helix-turn-helix	O
transcription	O
factor	O
OCT-1	O
to	O
bind	O
to	O
a	O
novel	O
region	O
of	O
complex	O
protein-DNA	O
interactions	O
and	O
alters	O
gene	O
expression	O
in	O
human	O
monocytes	O
.	O

The	O
OCT-1-binding	O
genotype	O
,	O
found	O
in	O
approximately	O
5	O
%	O
of	O
Africans	O
,	O
is	O
associated	O
with	O
fourfold	O
increased	O
susceptibility	O
to	O
cerebral	O
malaria	O
in	O
large	O
case-control	O
studies	O
of	O
West	O
African	O
and	O
East	O
African	O
populations	O
,	O
after	O
correction	O
for	O
other	O
known	O
TNF	O
polymorphisms	O
and	O
linked	O
HLA	O
alleles	O
.	O

Novel	O
therapies	O
for	O
inflammatory	O
bowel	O
disease	O
.	O

Looking	O
back	O
at	O
successes	O
and	O
failures	O
in	O
newer	O
approaches	O
to	O
treating	O
IBD	O
,	O
it	O
is	O
tempting	O
--	O
although	O
still	O
difficult	O
--	O
to	O
draw	O
conclusions	O
about	O
pathogenesis	O
.	O

When	O
a	O
therapy	O
proves	O
effective	O
,	O
do	O
clinicians	O
truly	O
know	O
how	O
it	O
works	O
?	O

Even	O
with	O
a	O
therapy	O
as	O
specific	O
as	O
anti-TNF	O
antibody	O
,	O
it	O
is	O
not	O
clear	O
if	O
the	O
benefit	O
is	O
attributable	O
to	O
simple	O
binding	O
and	O
clearance	O
of	O
TNF-alpha	O
or	O
to	O
binding	O
on	O
the	O
cell	O
surface	O
and	O
subsequent	O
deletion	O
of	O
the	O
activated	O
macrophage	O
.	O

When	O
a	O
drug	O
appears	O
to	O
be	O
less	O
effective	O
than	O
preclinical	O
models	O
suggest	O
,	O
can	O
failures	O
in	O
effectiveness	O
from	O
delivery	O
or	O
dosing	O
be	O
differentiated	O
?	O

The	O
disappointing	O
results	O
of	O
clinical	O
trials	O
with	O
IL-10	O
--	O
so	O
at	O
odds	O
with	O
the	O
prediction	O
of	O
benefit	O
from	O
animal	O
models	O
--	O
bring	O
into	O
question	O
the	O
validity	O
of	O
those	O
models	O
as	O
well	O
as	O
the	O
soundness	O
of	O
design	O
of	O
the	O
clinical	O
trials	O
on	O
which	O
efficacy	O
of	O
IL-10	O
is	O
judged	O
.	O

The	O
variability	O
of	O
response	O
even	O
to	O
the	O
most	O
narrowly	O
targeted	O
agents	O
suggests	O
that	O
these	O
diseases	O
are	O
far	O
more	O
heterogeneous	O
in	O
humans	O
than	O
in	O
their	O
murine	O
counterparts	O
.	O

Clinicians	O
are	O
only	O
just	O
beginning	O
to	O
recognize	O
subclinical	O
markers	O
of	O
response	O
,	O
and	O
it	O
may	O
soon	O
be	O
possible	O
to	O
predict	O
response	O
on	O
the	O
basis	O
of	O
genetic	O
composition	O
.	O

For	O
the	O
moment	O
,	O
however	O
,	O
the	O
field	O
of	O
pharmacogenetics	O
is	O
embryonic	O
.	O

Challenges	O
in	O
developing	O
new	O
therapeutic	O
strategies	O
include	O
not	O
only	O
identifying	O
novel	O
agents	O
,	O
but	O
also	O
improving	O
the	O
definitions	O
of	O
clinical	O
endpoints	O
and	O
defining	O
efficacy	O
at	O
the	O
biologic	O
level	O
.	O

Only	O
through	O
considered	O
evaluation	O
of	O
clinical	O
evidence	O
may	O
clinicians	O
determine	O
which	O
therapies	O
should	O
remain	O
novelties	O
and	O
which	O
should	O
become	O
an	O
accepted	O
part	O
of	O
the	O
armamentarium	O
.	O

PPARalpha	O
activators	O
inhibit	O
cytokine-induced	O
vascular	O
cell	O
adhesion	O
molecule-1	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
Adhesion	O
molecule	O
expression	O
on	O
the	O
endothelial	O
cell	O
(	O
EC	O
)	O
surface	O
is	O
critical	O
for	O
leukocyte	O
recruitment	O
to	O
atherosclerotic	O
lesions	O
.	O

Better	O
understanding	O
of	O
transcriptional	O
regulation	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
may	O
provide	O
important	O
insight	O
into	O
plaque	O
formation	O
.	O

Peroxisome	O
proliferator-activated	O
receptor-alpha	O
(	O
PPARalpha	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
family	O
,	O
regulates	O
gene	O
expression	O
in	O
response	O
to	O
certain	O
fatty	O
acids	O
and	O
fibric	O
acid	O
derivatives	O
.	O

The	O
present	O
study	O
investigated	O
PPARalpha	O
expression	O
in	O
human	O
ECs	O
and	O
their	O
regulation	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Immunohistochemistry	O
revealed	O
that	O
human	O
carotid	O
artery	O
ECs	O
express	O
PPARalpha	O
.	O

Pretreatment	O
of	O
cultured	O
human	O
ECs	O
with	O
the	O
PPARalpha	O
activators	O
fenofibrate	O
or	O
WY14643	O
inhibited	O
TNF-alpha-induced	O
VCAM-1	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
,	O
an	O
effect	O
not	B-Negation
seen	I-Negation
with	I-Negation
PPARgamma	I-Negation
activators	I-Negation
.	O

Both	O
PPARalpha	O
activators	O
decreased	O
cytokine-induced	O
VCAM-1	O
mRNA	O
expression	O
without	B-Negation
altering	I-Negation
its	I-Negation
mRNA	I-Negation
half-life	I-Negation
.	O

Transient	O
transfection	O
of	O
deletional	O
VCAM-1	O
promoter	O
constructs	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
fenofibrate	O
inhibits	O
VCAM-1	O
transcription	O
in	O
part	O
by	O
inhibiting	O
NF-kappaB	O
.	O

Finally	O
,	O
PPARalpha	O
activators	O
significantly	O
reduced	O
adhesion	O
of	O
U937	O
cells	O
to	O
cultured	O
human	O
ECs	O
.	O

CONCLUSIONS	O
:	O
Human	O
ECs	O
express	O
PPARalpha	O
,	O
a	O
potentially	O
important	O
regulator	O
of	O
atherogenesis	O
through	O
its	O
transcriptional	O
control	O
of	O
VCAM-1	O
gene	O
expression	O
.	O

Such	O
findings	O
also	O
have	O
implications	O
regarding	O
the	O
clinical	O
use	O
of	O
lipid-lowering	O
agents	O
,	O
like	O
fibric	O
acids	O
,	O
which	O
can	O
activate	O
PPARalpha	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
protects	O
infected	O
T	O
cells	O
from	O
apoptosis	O
.	O

Parasites	O
have	O
evolved	O
a	O
plethora	O
of	O
strategies	O
to	O
ensure	O
their	O
survival	O
.	O

The	O
intracellular	O
parasite	O
Theileria	O
parva	O
secures	O
its	O
propagation	O
and	O
spreads	O
through	O
the	O
infected	O
animal	O
by	O
infecting	O
and	O
transforming	O
T	O
cells	O
,	O
inducing	O
their	O
continuous	O
proliferation	O
and	O
rendering	O
them	O
metastatic	O
.	O

In	O
previous	O
work	O
,	O
we	O
have	O
shown	O
that	O
the	O
parasite	O
induces	O
constitutive	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
,	O
by	O
inducing	O
the	O
constitutive	O
degradation	O
of	O
its	O
cytoplasmic	O
inhibitors	O
.	O

The	B-Negation
biological	I-Negation
significance	I-Negation
of	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
in	I-Negation
T.	I-Negation
parva-infected	I-Negation
cells	I-Negation
,	I-Negation
however	I-Negation
,	I-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
defined	I-Negation
.	O

Cells	O
that	O
have	O
been	O
transformed	O
by	O
viruses	O
or	O
oncogenes	O
can	O
persist	O
only	O
if	O
they	O
manage	O
to	O
avoid	O
destruction	O
by	O
the	O
apoptotic	O
mechanisms	O
that	O
are	O
activated	O
on	O
transformation	O
and	O
that	O
contribute	O
to	O
maintain	O
cellular	O
homeostasis	O
.	O

We	O
now	O
demonstrate	O
that	O
parasite-induced	O
NF-kappaB	O
activation	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
survival	O
of	O
T.	O
parva-transformed	O
T	O
cells	O
by	O
conveying	O
protection	O
against	O
an	O
apoptotic	O
signal	O
that	O
accompanies	O
parasite-mediated	O
transformation	O
.	O

Consequently	O
,	O
inhibition	O
of	O
NF-kappaB	O
nuclear	O
translocation	O
and	O
the	O
expression	O
of	O
dominant	O
negative	O
mutant	O
forms	O
of	O
components	O
of	O
the	O
NF-kappaB	O
activation	O
pathway	O
,	O
such	O
as	O
IkappaBalpha	O
or	O
p65	O
,	O
prompt	O
rapid	O
apoptosis	O
of	O
T.	O
parva-transformed	O
T	O
cells	O
.	O

Our	O
findings	O
offer	O
important	O
insights	O
into	O
parasite	O
survival	O
strategies	O
and	O
demonstrate	O
that	O
parasite-induced	O
constitutive	O
NF-kappaB	O
activation	O
is	O
an	O
essential	O
step	O
in	O
maintaining	O
the	O
transformed	O
phenotype	O
of	O
the	O
infected	O
cells	O
.	O

Downregulation	O
of	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
is	O
not	B-Negation
a	I-Negation
prerequisite	I-Negation
for	I-Negation
erythroid	I-Negation
or	I-Negation
megakaryocytic	I-Negation
differentiation	I-Negation
of	I-Negation
the	I-Negation
leukemic	I-Negation
cell	I-Negation
line	I-Negation
K562	I-Negation
.	O

The	O
Wilms	O
'	O
tumor	O
gene	O
(	O
WT1	O
)	O
encodes	O
a	O
transcription	O
factor	O
of	O
the	O
zinc	O
finger	O
type	O
.	O

A	O
high	O
expression	O
of	O
WT1	O
has	O
been	O
detected	O
in	O
a	O
range	O
of	O
acute	O
leukemias	O
,	O
and	O
WT1	O
is	O
downregulated	O
during	O
induced	O
differentiation	O
of	O
some	O
leukemic	O
cell	O
lines	O
.	O

Overexpression	O
of	O
WT1	O
in	O
some	O
myeloid	O
cell	O
lines	O
confers	O
resistance	O
to	O
differentiation	O
induction	O
.	O

These	O
observations	O
suggest	O
that	O
a	O
high	O
WT1	O
expression	O
in	O
hematopoietic	O
cells	O
is	O
incompatible	O
with	O
differentiation	O
.	O

In	O
this	O
study	O
,	O
each	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
was	O
constitutively	O
overexpressed	O
in	O
the	O
leukemic	O
cell	O
line	O
K562	O
.	O

K562	O
cells	O
express	O
endogenous	O
WT1	O
,	O
which	O
is	O
downregulated	O
as	O
a	O
response	O
to	O
induced	O
differentiation	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
pathways	O
.	O

We	O
now	O
demonstrate	O
that	O
a	O
forced	O
exogenous	O
expression	O
of	O
the	O
four	O
different	O
isoforms	O
of	O
WT1	O
in	O
K562	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
differentiation	I-Negation
response	I-Negation
,	O
as	O
judged	O
by	O
accumulation	O
of	O
hemoglobin	O
in	O
response	O
to	O
hemin	O
or	O
the	O
expression	O
of	O
megakaryocytic	O
cell	O
surface	O
markers	O
in	O
response	O
to	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

We	O
conclude	O
that	O
downregulation	O
of	O
WT1	O
during	O
induced	O
differentiation	O
of	O
K562	O
cells	O
is	O
not	B-Negation
a	I-Negation
prerequisite	I-Negation
for	I-Negation
erythroid	I-Negation
or	I-Negation
megakaryocytic	I-Negation
differentiation	I-Negation
of	I-Negation
these	I-Negation
cells	I-Negation
.	O

GATA-1	O
and	O
erythropoietin	O
cooperate	O
to	O
promote	O
erythroid	O
cell	O
survival	O
by	O
regulating	O
bcl-xL	O
expression	O
.	O

The	O
transcription	O
factor	O
GATA-1	O
is	O
essential	O
for	O
normal	O
erythropoiesis	O
.	O

By	O
examining	O
in	O
vitro-differentiated	O
embryonic	O
stem	O
cells	O
,	O
we	O
showed	O
previously	O
that	O
in	O
the	O
absence	B-Negation
of	I-Negation
GATA-1	I-Negation
,	O
committed	O
erythroid	O
precursors	O
fail	B-Negation
to	I-Negation
complete	I-Negation
maturation	I-Negation
and	O
instead	O
undergo	O
apoptosis	O
.	O

The	O
mechanisms	O
by	O
which	O
GATA-1	O
controls	O
cell	O
survival	O
are	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
in	O
erythroid	O
cells	O
,	O
GATA-1	O
strongly	O
induces	O
the	O
expression	O
of	O
the	O
anti-apoptotic	O
protein	O
bcl-xL	O
,	O
but	O
not	B-Negation
the	I-Negation
related	I-Negation
proteins	I-Negation
bcl-2	I-Negation
and	I-Negation
mcl-1	I-Negation
.	O

Consistent	O
with	O
a	O
role	O
for	O
bcl-xL	O
in	O
mediating	O
GATA-1-induced	O
erythroid	O
cell	O
survival	O
,	O
in	O
vitro-differentiated	O
bcl-xL-/-	O
embryonic	O
stem	O
cells	O
fail	B-Negation
to	I-Negation
generate	I-Negation
viable	I-Negation
mature	I-Negation
definitive	I-Negation
erythroid	I-Negation
cells	I-Negation
,	O
a	O
phenotype	O
resembling	O
that	O
of	O
GATA-1	O
gene	O
disruption	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
erythropoietin	O
,	O
which	O
is	O
also	O
required	O
for	O
erythroid	O
cell	O
survival	O
,	O
cooperates	O
with	O
GATA-1	O
to	O
stimulate	O
bcl-xL	O
gene	O
expression	O
and	O
to	O
maintain	O
erythroid	O
cell	O
viability	O
during	O
terminal	O
maturation	O
.	O

Together	O
,	O
our	O
data	O
show	O
that	O
bcl-xL	O
is	O
essential	O
for	O
normal	O
erythroid	O
development	O
and	O
suggest	O
a	O
regulatory	O
hierarchy	O
in	O
which	O
bcl-xL	O
is	O
a	O
critical	O
downstream	O
effector	O
of	O
GATA-1	O
and	O
erythropoietin-mediated	O
signals	O
.	O

NF-kappaB	O
functions	O
as	O
both	O
a	O
proapoptotic	O
and	O
antiapoptotic	O
regulatory	O
factor	O
within	O
a	O
single	O
cell	O
type	O
.	O

Recently	O
NF-kappaB	O
has	O
been	O
shown	O
to	O
have	O
both	O
proapoptotic	O
and	O
antiapoptotic	O
functions	O
.	O

In	O
T	O
cell	O
hybridomas	O
,	O
both	O
T	O
cell	O
activators	O
and	O
glucocorticoids	O
induce	O
apoptosis	O
.	O

Here	O
we	O
show	O
that	O
blockade	O
of	O
NF-kappaB	O
activity	O
,	O
using	O
a	O
dominant	O
negative	O
IkappaBalpha	O
,	O
has	O
opposite	O
effects	O
on	O
these	O
two	O
apoptotic	O
signals	O
.	O

Treatment	O
with	O
PMA	O
plus	O
ionomycin	O
(	O
P/I	O
)	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	O
Ligand	O
(	O
FasL	O
)	O
and	O
induction	O
of	O
apoptosis	O
.	O

Inhibition	O
of	O
NF-kappaB	O
activity	O
inhibits	O
the	O
P/I	O
mediated	O
induction	O
of	O
FasL	O
mRNA	O
and	O
decreases	O
the	O
level	O
of	O
apoptosis	O
in	O
these	O
cultures	O
,	O
thus	O
establishing	O
NF-kappaB	O
as	O
a	O
proapoptotic	O
factor	O
in	O
this	O
context	O
.	O

Conversely	O
,	O
inhibition	O
of	O
NF-kappaB	O
confers	O
a	O
tenfold	O
increase	O
in	O
glucocorticoid	O
mediated	O
apoptosis	O
,	O
establishing	O
that	O
NF-kappaB	O
also	O
functions	O
as	O
an	O
antiapoptotic	O
factor	O
.	O

We	O
conclude	O
that	O
NF-kappaB	O
is	O
a	O
context-dependent	O
apoptosis	O
regulator	O
.	O

Our	O
data	O
suggests	O
that	O
NF-kappaB	O
may	O
function	O
as	O
an	O
antiapoptotic	O
factor	O
in	O
thymocytes	O
while	O
functioning	O
as	O
a	O
proapoptotic	O
factor	O
in	O
mature	O
peripheral	O
T	O
cells	O
.	O

3-deazaadenosine	O
,	O
a	O
S-adenosylhomocysteine	O
hydrolase	O
inhibitor	O
,	O
has	O
dual	O
effects	O
on	O
NF-kappaB	O
regulation	O
.	O

Inhibition	O
of	O
NF-kappaB	O
transcriptional	O
activity	O
and	O
promotion	O
of	O
IkappaBalpha	O
degradation	O
.	O

Previously	O
we	O
reported	O
that	O
3-deazaadenosine	O
(	O
DZA	O
)	O
,	O
a	O
potent	O
inhibitor	O
and	O
substrate	O
for	O
S-adenosylhomocysteine	O
hydrolase	O
inhibits	O
bacterial	O
lipopolysaccharide-induced	O
transcription	O
of	O
tumor	O
necrosis	O
factor-alpha	O
and	O
interleukin-1beta	O
in	O
mouse	O
macrophage	O
RAW	O
264.7	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
the	O
effects	O
of	O
DZA	O
on	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
regulation	O
.	O

DZA	O
inhibits	O
the	O
transcriptional	O
activity	O
of	O
NF-kappaB	O
through	O
the	O
hindrance	O
of	O
p65	O
(	O
Rel-A	O
)	O
phosphorylation	O
without	B-Negation
reduction	I-Negation
of	I-Negation
its	I-Negation
nuclear	I-Negation
translocation	I-Negation
and	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
.	O

The	O
inhibitory	O
effect	O
of	O
DZA	O
on	O
NF-kappaB	O
transcriptional	O
activity	O
is	O
potentiated	O
by	O
the	O
addition	O
of	O
homocysteine	O
.	O

Taken	O
together	O
,	O
DZA	O
promotes	O
the	O
proteolytic	O
degradation	O
of	O
IkappaBalpha	O
,	O
but	O
not	B-Negation
IkappaBbeta	I-Negation
,	O
resulting	O
in	O
an	O
increase	O
of	O
DNA	O
binding	O
activity	O
of	O
NF-kappaB	O
in	O
the	O
nucleus	O
in	O
the	O
absence	B-Negation
of	I-Negation
its	I-Negation
transcriptional	I-Negation
activity	I-Negation
in	I-Negation
RAW	I-Negation
264.7	I-Negation
cells	I-Negation
.	O

The	O
reduction	O
of	O
IkappaBalpha	O
by	O
DZA	O
is	O
neither	B-Negation
involved	I-Negation
in	I-Negation
IkappaB	I-Negation
kinase	I-Negation
complex	I-Negation
activation	I-Negation
nor	I-Negation
modulated	I-Negation
by	I-Negation
the	I-Negation
addition	I-Negation
of	I-Negation
homocysteine	I-Negation
.	O

This	O
study	O
strongly	O
suggests	O
that	O
DZA	O
may	O
be	O
a	O
potent	O
drug	O
for	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
NF-kappaB	O
plays	O
a	O
central	O
pathogenic	O
role	O
,	O
as	O
well	O
as	O
a	O
useful	O
tool	O
for	O
studying	O
the	O
regulation	O
and	O
physiological	O
functions	O
of	O
NF-kappaB	O
.	O

STAT1	O
activation	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
:	O
role	O
of	O
adhesion	O
molecules	O
.	O

Human	O
monocytes	O
isolated	O
from	O
peripheral	O
blood	O
of	O
healthy	O
donors	O
show	O
a	O
time-dependent	O
differentiation	O
into	O
macrophages	O
upon	O
in	O
vitro	O
cultivation	O
,	O
closely	O
mimicking	O
their	O
in	O
vivo	O
migration	O
and	O
maturation	O
into	O
extravascular	O
tissues	O
.	O

The	B-Negation
mediator	I-Negation
(	I-Negation
s	I-Negation
)	I-Negation
of	I-Negation
this	I-Negation
maturation	I-Negation
process	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
yet	I-Negation
defined	I-Negation
.	O

We	O
investigated	O
the	O
involvement	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
in	O
this	O
phenomenon	O
and	O
reported	O
the	O
specific	O
,	O
time-dependent	O
,	O
activation	O
of	O
STAT1	O
protein	O
starting	O
at	O
day	O
0/1	O
of	O
cultivation	O
and	O
maximally	O
expressed	O
at	O
day	O
5	O
.	O

STAT1	O
activity	O
was	O
evident	O
on	O
the	O
STAT	O
binding	O
sequences	O
(	O
SBE	O
)	O
present	O
in	O
the	O
promoters	O
of	O
genes	O
which	O
are	O
up-regulated	O
during	O
monocyte	O
to	O
macrophage	O
maturation	O
such	O
as	O
FcgammaRI	O
and	O
ICAM-1	O
,	O
and	O
in	O
the	O
promoter	O
of	O
the	O
transcription	O
factor	O
IFN	O
regulatory	O
factor-1	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
laminin	O
was	O
studied	O
to	O
investigate	O
mechanisms	O
involved	O
in	O
STAT1	O
activation	O
.	O

Compared	O
with	O
monocytes	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
freshly	O
isolated	O
cells	O
allowed	O
to	O
adhere	O
either	O
to	O
fibronectin-	O
or	O
laminin-coated	O
flasks	O
exhibited	O
an	O
increased	O
STAT1	O
binding	O
activity	O
both	O
in	O
control	O
and	O
in	O
IFN-gamma-treated	O
cells	O
.	O

The	O
molecular	O
events	O
leading	O
to	O
enhanced	O
STAT1	O
activation	O
and	O
cytokine	O
responsiveness	O
concerned	O
both	O
Y701	O
and	O
S727	O
STAT1	O
phosphorylation	O
.	O

Exogenous	O
addition	O
of	O
transforming	O
growth	O
factor-beta	O
,	O
which	O
exerts	O
an	O
inhibitory	O
effect	O
on	O
some	O
monocytic	O
differentiation	O
markers	O
,	O
inhibited	O
macrophage	O
maturation	O
,	O
integrin	O
expression	O
and	O
STAT1	O
binding	O
activity	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
STAT1	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
differentiation/maturation	O
process	O
of	O
monocytes	O
as	O
an	O
early	O
transcription	O
factor	O
initially	O
activated	O
by	O
adherence	O
and	O
then	O
able	O
to	O
modulate	O
the	O
expression	O
of	O
functional	O
genes	O
,	O
such	O
as	O
ICAM-1	O
and	O
FcgammaRI	O
.	O

Inhibition	O
of	O
NF-kappa	O
B	O
activity	O
in	O
human	O
T	O
lymphocytes	O
induces	O
caspase-dependent	O
apoptosis	O
without	B-Negation
detectable	I-Negation
activation	I-Negation
of	I-Negation
caspase-1	I-Negation
and	I-Negation
-3	I-Negation
.	O

NF-kappa	O
B	O
is	O
involved	O
in	O
the	O
transcriptional	O
control	O
of	O
various	O
genes	O
that	O
act	O
as	O
extrinsic	O
and	O
intrinsic	O
survival	O
factors	O
for	O
T	O
cells	O
.	O

Our	O
findings	O
show	O
that	O
suppression	O
of	O
NF-kappa	O
B	O
activity	O
with	O
cell-permeable	O
SN50	O
peptide	O
,	O
which	O
masks	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF-kappa	O
B1	O
dimers	O
and	O
prevents	O
their	O
nuclear	O
localization	O
,	O
induces	O
apoptosis	O
in	O
resting	O
normal	O
human	O
PBL	O
.	O

Inhibition	O
of	O
NF-kappa	O
B	O
resulted	O
in	O
the	O
externalization	O
of	O
phosphatidylserine	O
,	O
induction	O
of	O
DNA	O
breaks	O
,	O
and	O
morphological	O
changes	O
consistent	O
with	O
apoptosis	O
.	O

DNA	O
fragmentation	O
was	O
efficiently	O
blocked	O
by	O
the	O
caspase	O
inhibitor	O
Z-VAD-fmk	O
and	O
partially	O
blocked	O
by	O
Ac-DEVD-fmk	O
,	O
suggesting	O
that	O
SN50-mediated	O
apoptosis	O
is	O
caspase-dependent	O
.	O

Interestingly	O
,	O
apoptosis	O
induced	O
by	O
NF-kappa	O
B	O
suppression	O
,	O
in	O
contrast	O
to	O
that	O
induced	O
by	O
TPEN	O
(	O
N	O
,	O
N	O
,	O
N	O
'	O
,	O
N'-tetrakis	O
[	O
2-pyridylmethyl	O
]	O
ethylenediamine	O
)	O
or	O
soluble	O
Fas	O
ligand	O
(	O
CD95	O
)	O
,	O
was	O
observed	O
in	O
the	O
absence	B-Negation
of	I-Negation
active	I-Negation
death	I-Negation
effector	I-Negation
proteases	I-Negation
caspase-1-like	I-Negation
(	I-Negation
IL-1	I-Negation
converting	I-Negation
enzyme	I-Negation
)	I-Negation
,	I-Negation
caspase-3-like	I-Negation
(	I-Negation
CPP32/Yama/apopain	I-Negation
)	I-Negation
,	I-Negation
and	I-Negation
caspase-6-like	I-Negation
and	O
without	B-Negation
cleavage	I-Negation
of	I-Negation
caspase-3	I-Negation
substrates	I-Negation
poly	I-Negation
(	I-Negation
ADP-ribose	I-Negation
)	I-Negation
polymerase	I-Negation
and	I-Negation
DNA	I-Negation
fragmentation	I-Negation
factor-45	I-Negation
.	O

These	O
findings	O
suggest	O
either	O
low	O
level	O
of	O
activation	O
is	O
required	O
or	O
that	O
different	O
caspases	O
are	O
involved	O
.	O

Preactivation	O
of	O
T	O
cells	O
resulting	O
in	O
NF-kappa	O
B	O
nuclear	O
translocation	O
protected	O
cells	O
from	O
SN50-induced	O
apoptosis	O
.	O

Our	O
findings	O
demonstrate	O
an	O
essential	O
role	O
of	O
NF-kappa	O
B	O
in	O
survival	O
of	O
naive	O
PBL	O
.	O

Signaling	O
events	O
induced	O
by	O
lipopolysaccharide-activated	O
toll-like	O
receptor	O
2	O
.	O

Human	O
Toll-like	O
receptor	O
2	O
(	O
TLR2	O
)	O
is	O
a	O
signaling	O
receptor	O
that	O
responds	O
to	O
LPS	O
and	O
activates	O
NF-kappaB	O
.	O

Here	O
,	O
we	O
investigate	O
further	O
the	O
events	O
triggered	O
by	O
TLR2	O
in	O
response	O
to	O
LPS	O
.	O

We	O
show	O
that	O
TLR2	O
associates	O
with	O
the	O
high-affinity	O
LPS	O
binding	O
protein	O
membrane	O
CD14	O
to	O
serve	O
as	O
an	O
LPS	O
receptor	O
complex	O
,	O
and	O
that	O
LPS	O
treatment	O
enhances	O
the	O
oligomerization	O
of	O
TLR2	O
.	O

Concomitant	O
with	O
receptor	O
oligomerization	O
,	O
the	O
IL-1R-associated	O
kinase	O
(	O
IRAK	O
)	O
is	O
recruited	O
to	O
the	O
TLR2	O
complex	O
.	O

Intracellular	O
deletion	O
variants	O
of	O
TLR2	O
lacking	B-Negation
C-terminal	I-Negation
13	I-Negation
or	I-Negation
141	I-Negation
aa	I-Negation
fail	B-Negation
to	I-Negation
recruit	I-Negation
IRAK	I-Negation
,	O
which	O
is	O
consistent	O
with	O
the	O
inability	O
of	O
these	O
mutants	O
to	O
transmit	O
LPS	O
cellular	O
signaling	O
.	O

Moreover	O
,	O
both	O
deletion	O
mutants	O
could	O
still	O
form	O
complexes	O
with	O
wild-type	O
TLR2	O
and	O
act	O
in	O
a	O
dominant-negative	O
(	O
DN	O
)	O
fashion	O
to	O
block	O
TLR2-mediated	O
signal	O
transduction	O
.	O

DN	O
constructs	O
of	O
myeloid	O
differentiation	O
protein	O
,	O
IRAK	O
,	O
TNF	O
receptor-associated	O
factor	O
6	O
,	O
and	O
NF-kappaB-inducing	O
kinase	O
,	O
when	O
coexpressed	O
with	O
TLR2	O
,	O
abrogate	O
TLR2-mediated	O
NF-kappaB	O
activation	O
.	O

These	O
results	O
reveal	O
a	O
conserved	O
signaling	O
pathway	O
for	O
TLR2	O
and	O
IL-1Rs	O
and	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
inhibition	O
of	O
TLR2	O
by	O
DN	O
variants	O
.	O

Activation	O
of	O
the	O
Janus	O
kinase	O
3-STAT5a	O
pathway	O
after	O
CD40	O
triggering	O
of	O
human	O
monocytes	O
but	O
not	B-Negation
of	I-Negation
resting	I-Negation
B	I-Negation
cells	I-Negation
.	O

CD40/CD40	O
ligand	O
interactions	O
play	O
a	O
key	O
role	O
in	O
the	O
immune	O
responses	O
of	O
B	O
lymphocytes	O
,	O
monocytes	O
,	O
and	O
dendritic	O
cells	O
.	O

The	O
signal	O
transduction	O
events	O
triggered	O
by	O
cross-linking	O
of	O
the	O
CD40	O
receptor	O
have	O
been	O
widely	O
studied	O
in	O
B	O
cell	O
lines	O
,	O
but	O
little	O
is	O
known	O
about	O
signaling	O
following	O
CD40	O
stimulation	O
of	O
monocytes	O
and	O
resting	O
tonsillar	O
B	O
cells	O
.	O

Therefore	O
,	O
we	O
studied	O
the	O
CD40	O
pathway	O
in	O
highly	O
purified	O
human	O
monocytes	O
and	O
resting	O
B	O
cells	O
.	O

After	O
CD40	O
triggering	O
,	O
a	O
similar	O
activation	O
of	O
the	O
NF-kappaB	O
(	O
but	O
not	B-Negation
of	I-Negation
the	I-Negation
AP-1	I-Negation
)	O
transcription	O
factor	O
complex	O
occurred	O
in	O
both	O
cell	O
preparations	O
.	O

However	O
,	O
the	O
components	O
of	O
the	O
NF-kappaB	O
complexes	O
were	O
different	O
in	O
monocytes	O
and	O
B	O
cells	O
,	O
because	O
p50	O
is	O
part	O
of	O
the	O
NF-kappaB	O
complex	O
induced	O
by	O
CD40	O
triggering	O
in	O
both	O
monocytes	O
and	O
B	O
cells	O
,	O
whereas	O
p65	O
was	O
only	O
induced	O
in	O
B	O
cells	O
.	O

In	O
contrast	O
,	O
although	O
the	O
Janus	O
kinase	O
3	O
tyrosine	O
kinase	O
was	O
associated	O
with	O
CD40	O
molecules	O
in	O
both	O
monocytes	O
and	O
resting	O
B	O
cells	O
,	O
Janus	O
kinase	O
3	O
phosphorylation	O
induction	O
was	O
observed	O
only	O
in	O
CD40-activated	O
monocytes	O
,	O
with	O
subsequent	O
induction	O
of	O
STAT5a	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
signals	O
in	O
human	O
B	O
cells	O
and	O
monocytes	O
differ	O
following	O
CD40	O
stimulation	O
.	O

This	O
observation	O
is	O
consistent	O
with	O
the	O
detection	O
of	O
normal	O
CD40-induced	O
monocyte	O
activation	O
in	O
patients	O
with	O
CD40	O
ligand+	O
hyper	O
IgM	O
syndrome	O
in	O
whom	O
a	O
defect	O
in	O
CD40-induced	O
B	O
cell	O
activation	O
has	O
been	O
reported	O
.	O

Suppression	O
of	O
NF-kappaB	O
activation	O
in	O
normal	O
T	O
cells	O
by	O
supernatant	O
fluid	O
from	O
human	O
renal	O
cell	O
carcinomas	O
.	O

T	O
lymphocytes	O
from	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
show	O
reduced	O
immune	O
function	O
and	O
impaired	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF-kappaB	O
.	O

We	O
determined	O
the	O
mechanism	O
of	O
NF-kappaB	O
suppression	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
and	O
determined	O
whether	O
supernatant	O
fluid	O
from	O
RCC	O
explants	O
(	O
RCC-S	O
)	O
induced	O
the	O
same	O
phenotype	O
of	O
NF-kappaB	O
suppression	O
in	O
normal	O
T	O
cells	O
that	O
is	O
observed	O
in	O
patient	O
T	O
cells	O
.	O

The	O
pattern	O
of	O
kappaB-binding	O
activity	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
was	O
altered	O
as	O
compared	O
to	O
that	O
seen	O
in	O
T	O
cells	O
obtained	O
from	O
normal	O
volunteers	O
.	O

In	O
some	O
patients	O
,	O
no	B-Negation
activation	I-Negation
of	I-Negation
RelA/NFkappaB1-binding	I-Negation
activity	I-Negation
was	I-Negation
detectable	I-Negation
,	O
while	O
in	O
others	O
kappaB-binding	O
activity	O
was	O
modestly	O
induced	O
but	O
the	O
duration	O
was	O
reduced	O
.	O

IkappaBalpha	O
was	O
degraded	O
normally	O
following	O
stimulation	O
in	O
both	O
normal	O
controls	O
and	O
T	O
cells	O
from	O
RCC	O
patients	O
.	O

RCC-S	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
cytoplasmic	I-Negation
levels	I-Negation
of	I-Negation
RelA	I-Negation
and	I-Negation
NF-kappaB1	I-Negation
but	O
did	O
suppress	O
their	O
nuclear	O
localization	O
and	O
inhibited	O
the	O
activation	O
of	O
RelA/NF-kappaB1	O
binding	O
complexes	O
.	O

These	O
results	O
show	O
that	O
RCC-S	O
can	O
induce	O
in	O
normal	O
T	O
cells	O
the	O
same	O
phenotype	O
of	O
impaired	O
NF-kappaB	O
activation	O
that	O
is	O
detected	O
in	O
T	O
cells	O
of	O
RCC	O
patient	O
.	O

It	O
also	O
appears	O
that	O
NF-kappaB	O
suppression	O
by	O
RCC-S	O
may	O
contribute	O
to	O
the	O
immunosuppression	O
of	O
host	O
immunity	O
.	O

Monoclonal	O
anti-endothelial	O
cell	O
antibodies	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
activate	O
endothelial	O
cells	O
from	O
large	O
vessels	O
.	O

OBJECTIVE	O
:	O
To	O
create	O
monoclonal	O
anti-endothelial	O
cell	O
antibodies	O
(	O
mAECA	O
)	O
from	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
to	O
evaluate	O
their	O
ability	O
to	O
activate	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
and	O
to	O
characterize	O
the	O
mechanism	O
of	O
EC	O
activation	O
.	O

METHODS	O
:	O
A	O
panel	O
of	O
mAECA	O
was	O
generated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
a	O
patient	O
with	O
Takayasu	O
arteritis	O
,	O
using	O
Epstein-Barr	O
virus	O
transformation	O
.	O

Activity	O
against	O
macrovascular	O
EC	O
(	O
HUVEC	O
)	O
and	O
microvascular	O
EC	O
(	O
human	O
bone	O
marrow	O
EC	O
immortalized	O
by	O
SV40	O
)	O
antigens	O
was	O
detected	O
by	O
enzyme-linked	O
immunosorbent	O
assay	O
.	O

Inhibition	O
studies	O
were	O
used	O
to	O
select	O
the	O
monoclonal	O
antibodies	O
(	O
mAECA	O
)	O
which	O
share	O
the	O
same	O
EC	O
epitope	O
binding	O
specificity	O
as	O
the	O
total	O
IgG-AECA	O
from	O
the	O
Takayasu	O
arteritis	O
patient	O
.	O

The	O
binding	O
of	O
the	O
mAECA	O
to	O
human	O
aortic	O
EC	O
was	O
studied	O
by	O
immunohistochemistry	O
.	O

The	O
secretion	O
levels	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
and	O
von	O
Willebrand	O
factor	O
(	O
vWF	O
)	O
were	O
determined	O
,	O
to	O
serve	O
as	O
markers	O
for	O
EC	O
activation	O
.	O

The	O
activated	O
EC	O
were	O
examined	O
for	O
the	O
adherence	O
of	O
a	O
monocytic	O
cell	O
line	O
(	O
U937	O
)	O
,	O
as	O
well	O
as	O
for	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
,	O
and	O
E-selectin	O
.	O

In	O
addition	O
,	O
nuclear	O
extracts	O
of	O
the	O
mAECA-treated	O
EC	O
were	O
analyzed	O
for	O
the	O
induction	O
of	O
translocation	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
,	O
using	O
a	O
specific	O
NF-kappaB	O
oligoprobe	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

RESULTS	O
:	O
Six	O
mAECA	O
were	O
selected	O
,	O
the	O
mixture	O
of	O
which	O
produced	O
100	O
%	O
inhibition	O
of	O
binding	O
of	O
the	O
original	O
IgG	O
(	O
from	O
the	O
patient	O
with	O
Takayasu	O
arteritis	O
)	O
to	O
HUVEC	O
.	O

All	O
mAECA	O
possessed	O
high	O
activity	O
against	O
macrovascular	O
EC	O
,	O
but	O
none	B-Negation
had	I-Negation
significant	I-Negation
antimicrovascular	I-Negation
EC	I-Negation
activity	I-Negation
.	O

The	O
mAECA	O
,	O
but	O
not	B-Negation
normal	I-Negation
human	I-Negation
IgG	I-Negation
,	O
had	O
anti-human	O
aortic	O
EC	O
activity	O
.	O

Four	O
of	O
the	O
6	O
mAECA	O
activated	O
EC	O
,	O
manifested	O
by	O
increased	O
IL-6	O
and	O
vWF	O
secretion	O
.	O

The	O
4	O
mAECA	O
induced	O
EC	O
expression	O
of	O
adhesion	O
molecules	O
and	O
increased	O
adhesion	O
of	O
U937	O
monocytic	O
cells	O
to	O
EC	O
.	O

In	O
addition	O
,	O
these	O
mAECA	O
stimulated	O
the	O
nuclear	O
translocation	O
of	O
the	O
NF-kappaB	O
transcription	O
factor	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
AECA	O
may	O
directly	O
stimulate	O
EC	O
in	O
Takayasu	O
arteritis	O
through	O
elevation	O
of	O
adhesion	O
molecule	O
expression	O
associated	O
with	O
NF-kappaB	O
activation	O
and	O
adhesion	O
of	O
monocytes	O
,	O
and	O
may	O
therefore	O
play	O
a	O
pathogenic	O
role	O
in	O
the	O
development	O
of	O
the	O
vasculopathy	O
in	O
Takayasu	O
arteritis	O
.	O

The	O
Epstein-Barr	O
virus	O
oncoprotein	O
latent	O
membrane	O
protein	O
1	O
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
proteins	O
TRADD	O
and	O
receptor-interacting	O
protein	O
(	O
RIP	O
)	O
but	O
does	O
not	B-Negation
induce	I-Negation
apoptosis	I-Negation
or	I-Negation
require	I-Negation
RIP	I-Negation
for	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
.	O

A	O
site	O
in	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
transforming	O
protein	O
LMP1	O
that	O
constitutively	O
associates	O
with	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
(	O
TNFR1	O
)	O
-associated	O
death	O
domain	O
protein	O
TRADD	O
to	O
mediate	O
NF-kappaB	O
and	O
c-Jun	O
N-terminal	O
kinase	O
activation	O
is	O
critical	O
for	O
long-term	O
lymphoblastoid	O
cell	O
proliferation	O
.	O

We	O
now	O
find	O
that	O
LMP1	O
signaling	O
through	O
TRADD	O
differs	O
from	O
TNFR1	O
signaling	O
through	O
TRADD	O
.	O

LMP1	O
needs	O
only	O
11	O
amino	O
acids	O
to	O
activate	O
NF-kappaB	O
or	O
synergize	O
with	O
TRADD	O
in	O
NF-kappaB	O
activation	O
,	O
while	O
TNFR1	O
requires	O
approximately	O
70	O
residues	O
.	O

Further	O
,	O
LMP1	O
does	O
not	B-Negation
require	I-Negation
TRADD	I-Negation
residues	I-Negation
294	I-Negation
to	I-Negation
312	I-Negation
for	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
,	O
while	O
TNFR1	O
requires	O
TRADD	O
residues	O
296	O
to	O
302	O
.	O

LMP1	O
is	O
partially	O
blocked	O
for	O
NF-kappaB	O
activation	O
by	O
a	O
TRADD	O
mutant	O
consisting	O
of	O
residues	O
122	O
to	O
293	O
.	O

Unlike	O
TNFR1	O
,	O
LMP1	O
can	O
interact	O
directly	O
with	O
receptor-interacting	O
protein	O
(	O
RIP	O
)	O
and	O
stably	O
associates	O
with	O
RIP	O
in	O
EBV-transformed	O
lymphoblastoid	O
cell	O
lines	O
.	O

Surprisingly	O
,	O
LMP1	O
does	O
not	B-Negation
require	I-Negation
RIP	I-Negation
for	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
.	O

Despite	O
constitutive	O
association	O
with	O
TRADD	O
or	O
RIP	O
,	O
LMP1	O
does	O
not	B-Negation
induce	I-Negation
apoptosis	I-Negation
in	I-Negation
EBV-negative	I-Negation
Burkitt	I-Negation
lymphoma	I-Negation
or	I-Negation
human	I-Negation
embryonic	I-Negation
kidney	I-Negation
293	I-Negation
cells	I-Negation
.	O

These	O
results	O
add	O
a	O
different	O
perspective	O
to	O
the	O
molecular	O
interactions	O
through	O
which	O
LMP1	O
,	O
TRADD	O
,	O
and	O
RIP	O
participate	O
in	O
B-lymphocyte	O
activation	O
and	O
growth	O
.	O

Regulatory	O
effects	O
of	O
interleukin-11	O
during	O
acute	O
lung	O
inflammatory	O
injury	O
.	O

The	O
role	O
of	O
interleukin-11	O
(	O
IL-11	O
)	O
was	O
evaluated	O
in	O
the	O
IgG	O
immune	O
complex	O
model	O
of	O
acute	O
lung	O
injury	O
in	O
rats	O
.	O

IL-11	O
mRNA	O
and	O
protein	O
were	O
both	O
up-regulated	O
during	O
the	O
course	O
of	O
this	O
inflammatory	O
response	O
.	O

Exogenously	O
administered	O
IL-11	O
substantially	O
reduced	O
,	O
in	O
a	O
dose-dependent	O
manner	O
,	O
the	O
intrapulmonary	O
accumulation	O
of	O
neutrophils	O
and	O
the	O
lung	O
vascular	O
leak	O
of	O
albumin	O
.	O

These	O
in	O
vivo	O
anti-inflammatory	O
effects	O
of	O
IL-11	O
were	O
associated	O
with	O
reduced	O
NF-kappaB	O
activation	O
in	O
lung	O
,	O
reduced	O
levels	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
in	O
bronchoalveolar	O
lavage	O
(	O
BAL	O
)	O
fluids	O
,	O
and	O
diminished	O
up-regulation	O
of	O
lung	O
vascular	O
ICAM-1	O
.	O

It	O
is	O
interesting	O
that	O
IL-11	O
did	O
not	B-Negation
affect	I-Negation
BAL	I-Negation
fluid	I-Negation
content	I-Negation
of	I-Negation
the	I-Negation
CXC	I-Negation
chemokines	I-Negation
,	I-Negation
macrophage	I-Negation
inflammatory	I-Negation
protein-2	I-Negation
(	I-Negation
MIP-2	I-Negation
)	I-Negation
and	I-Negation
cytokine-inducible	I-Negation
neutrophil	I-Negation
chemoattractant	I-Negation
(	I-Negation
CINC	I-Negation
)	I-Negation
;	O
the	O
presence	O
of	O
IL-11	O
did	O
not	B-Negation
affect	I-Negation
these	I-Negation
chemokines	I-Negation
.	O

However	O
,	O
BAL	O
content	O
of	O
C5a	O
was	O
reduced	O
by	O
IL-11	O
.	O

These	O
data	O
indicate	O
that	O
IL-11	O
is	O
a	O
regulatory	O
cytokine	O
in	O
the	O
lung	O
and	O
that	O
,	O
like	O
other	O
members	O
of	O
this	O
family	O
,	O
its	O
anti-inflammatory	O
properties	O
appear	O
to	O
be	O
linked	O
to	O
its	O
suppression	O
of	O
NF-kappaB	O
activation	O
,	O
diminished	O
production	O
of	O
TNF-alpha	O
,	O
and	O
reduced	O
up-regulation	O
of	O
lung	O
vascular	O
ICAM-1	O
.	O

ETS	O
transcription	O
factors	O
regulate	O
an	O
enhancer	O
activity	O
in	O
the	O
third	O
intron	O
of	O
TNF-alpha	O
.	O

We	O
describe	O
an	O
enhancer	O
site	O
in	O
the	O
third	O
intron	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
.	O

A	O
reporter	O
construct	O
containing	O
the	O
5'-flanking	O
region	O
of	O
the	O
mouse	O
TNF-alpha	O
gene	O
displayed	O
weak	O
activity	O
when	O
transfected	O
into	O
RAW264.7	O
macrophage-like	O
cells	O
.	O

The	O
addition	O
of	O
the	O
third	O
intron	O
of	O
TNF-alpha	O
to	O
this	O
construct	O
resulted	O
in	O
an	O
enhancement	O
of	O
CAT	O
protein	O
.	O

This	O
enhancement	O
was	O
eliminated	O
if	O
a	O
conserved	O
20-bp	O
sequence	O
was	O
removed	O
from	O
the	O
intron	O
or	O
if	O
a	O
dominant-negative	O
ets-binding	O
factor	O
was	O
co-transfected	O
with	O
the	O
reporter	O
gene	O
.	O

Mutations	O
of	O
this	O
site	O
that	O
destroyed	O
potential	O
ets	O
transcription	O
factor	O
binding	O
sites	O
had	O
reduced	O
transcriptional	O
activity	O
.	O

The	O
major	O
transcription	O
factor	O
that	O
bound	O
to	O
the	O
oligonucleotide	O
was	O
confirmed	O
to	O
be	O
GABP	O
by	O
supershift	O
and	O
competition	O
analysis	O
.	O

In	O
RAW264.7	O
cells	O
,	O
the	O
binding	O
was	O
constitutive	O
,	O
however	O
,	O
in	O
bone	O
marrow-derived	O
macrophages	O
binding	O
activity	O
was	O
shown	O
to	O
be	O
interferon-gamma	O
inducible	O
.	O

This	O
may	O
imply	O
a	O
role	O
for	O
ets	O
transcription	O
factors	O
in	O
the	O
production	O
of	O
TNF-alpha	O
.	O

Abnormal	O
NF-kappa	O
B	O
activity	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
is	O
associated	O
with	O
decreased	O
p65-RelA	O
protein	O
expression	O
.	O

Numerous	O
cellular	O
and	O
biochemical	O
abnormalities	O
in	O
immune	O
regulation	O
have	O
been	O
described	O
in	O
patients	O
with	O
systemic	O
lupus	O
erythematosus	O
(	O
SLE	O
)	O
,	O
including	O
surface	O
Ag	O
receptor-initiated	O
signaling	O
events	O
and	O
lymphokine	O
production	O
.	O

Because	O
NF-kappa	O
B	O
contributes	O
to	O
the	O
transcription	O
of	O
numerous	O
inflammatory	O
genes	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
molecular	O
target	O
of	O
antiinflammatory	O
drugs	O
,	O
we	O
sought	O
to	O
characterize	O
the	O
functional	O
role	O
of	O
the	O
NF-kappa	O
B	O
protein	O
complex	O
in	O
lupus	O
T	O
cells	O
.	O

Freshly	O
isolated	O
T	O
cells	O
from	O
lupus	O
patients	O
,	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
and	O
normal	O
individuals	O
were	O
activated	O
physiologically	O
via	O
the	O
TCR	O
with	O
anti-CD3	O
and	O
anti-CD28	O
Abs	O
to	O
assess	O
proximal	O
membrane	O
signaling	O
,	O
and	O
with	O
PMA	O
and	O
a	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
to	O
bypass	O
membrane-mediated	O
signaling	O
events	O
.	O

We	O
measured	O
the	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
by	O
gel	O
shift	O
analysis	O
.	O

When	O
compared	O
with	O
normal	O
cells	O
,	O
the	O
activation	O
of	O
NF-kappa	O
B	O
activity	O
in	O
SLE	O
patients	O
was	O
significantly	O
decreased	O
in	O
SLE	O
,	O
but	O
not	B-Negation
in	I-Negation
RA	I-Negation
,	O
patients	O
.	O

NF-kappa	B-Negation
B	I-Negation
binding	I-Negation
activity	I-Negation
was	I-Negation
absent	I-Negation
in	I-Negation
several	I-Negation
SLE	I-Negation
patients	I-Negation
who	I-Negation
were	I-Negation
not	I-Negation
receiving	I-Negation
any	I-Negation
medication	I-Negation
,	I-Negation
including	I-Negation
corticosteroids	I-Negation
.	O

Also	O
,	O
NF-kappa	B-Negation
B	I-Negation
activity	I-Negation
remained	I-Negation
absent	I-Negation
in	I-Negation
follow-up	I-Negation
studies	I-Negation
.	O

In	O
supershift	O
experiments	O
using	O
specific	O
Abs	O
,	O
we	O
showed	O
that	O
,	O
in	O
the	O
group	O
of	O
SLE	O
patients	O
who	O
displayed	O
undetectable	O
NF-kappa	O
B	O
activity	O
,	O
p65	B-Negation
complexes	I-Negation
were	I-Negation
not	I-Negation
formed	I-Negation
.	O

Finally	O
,	O
immunoblot	O
analysis	O
of	O
nuclear	O
extracts	O
showed	O
decreased	O
or	O
absent	B-Negation
p65	I-Negation
protein	I-Negation
levels	I-Negation
.	O

As	O
p65	O
complexes	O
are	O
transcriptionally	O
active	O
in	O
comparison	O
to	O
the	O
p50	O
homodimer	O
,	O
this	O
novel	O
finding	O
may	O
provide	O
insight	O
on	O
the	O
origin	O
of	O
abnormal	O
cytokine	O
or	O
other	O
gene	O
transcription	O
in	O
SLE	O
patients	O
.	O

Possible	O
differences	O
in	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
different	O
glucocorticoid	O
hormone	O
compounds	O
.	O

Different	O
glucocorticoid	O
hormones	O
(	O
GCH	O
)	O
show	O
differences	O
in	O
the	O
intensity	O
and	O
in	O
the	O
kinetics	O
of	O
their	O
immunomodulating	O
activity	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
of	O
action	O
of	O
GCH	O
is	O
under	O
investigation	O
,	O
but	O
is	O
has	O
been	O
noted	O
that	O
they	O
exert	O
immune	O
activity	O
via	O
the	O
genomic	O
pathway	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
prednisone	O
(	O
PDN	O
)	O
,	O
deflazacort	O
(	O
DFC	O
)	O
,	O
and	O
dexamethasone	O
(	O
DXM	O
)	O
on	O
the	O
production	O
of	O
cytokines	O
(	O
IL-2	O
,	O
IL-6	O
,	O
TNF-alpha	O
,	O
IL-10	O
)	O
by	O
peripheral	O
T	O
lymphocytes	O
,	O
and	O
the	O
effects	O
on	O
the	O
inhibition	O
of	O
NF-kB	O
DNA	O
binding	O
activity	O
by	O
activated	O
Jurkat	O
cell	O
line	O
.	O

The	O
data	O
obtained	O
show	O
that	O
the	O
three	O
GCH	O
molecules	O
exert	O
an	O
immunosuppression	O
on	O
cytokine	O
production	O
by	O
T	O
lymphocytes	O
and	O
a	O
strong	O
decrease	O
in	O
the	O
nuclear	O
translocation	O
of	O
NF-kB	O
in	O
Jurkat	O
cells	O
;	O
moreover	O
,	O
(	O
a	O
)	O
not	O
all	O
the	O
cytokines	O
investigated	O
were	O
affected	O
,	O
and	O
not	B-Negation
with	I-Negation
the	I-Negation
same	I-Negation
intensity	I-Negation
,	O
by	O
the	O
three	O
GCH	O
and	O
(	O
b	O
)	O
DXM	O
inhibited	O
the	O
binding	O
activity	O
of	O
NF-kB	O
less	O
than	O
that	O
of	O
DFC	O
and	O
PDN	O
.	O

These	O
data	O
are	O
in	O
agreement	O
with	O
the	O
concept	O
that	O
different	O
GCH	O
compounds	O
might	O
differ	O
in	O
their	O
binding	O
and	O
affinity	O
properties	O
,	O
tissue-specific	O
metabolism	O
,	O
and	O
interaction	O
with	O
transcription	O
factor	O
.	O

The	O
p53	O
paradox	O
in	O
the	O
pathogenesis	O
of	O
tumor	O
progression	O
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
p53	O
molecule	O
appears	O
in	O
two	O
different	O
forms	O
:	O
the	O
mutant	O
p53	O
that	O
stimulates	O
tumor	O
progression	O
,	O
and	O
wild	O
type	O
p53	O
that	O
inhibits	O
tumor	O
progression	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
established	O
that	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
can	O
activate	O
the	O
expression	O
of	O
wild	O
type	O
p53	O
in	O
concert	O
with	O
the	O
nuclear	O
transcription	O
factor	O
,	O
NF-kappa	O
B	O
.	O

Both	O
TNF-alpha	O
and	O
NF-kappa	O
B	O
are	O
also	O
involved	O
in	O
the	O
stimulation	O
of	O
the	O
pathway	O
that	O
leads	O
to	O
the	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
and	O
,	O
hence	O
,	O
antigen	O
presentation	O
to	O
the	O
T	O
cells	O
.	O

In	O
this	O
paper	O
we	O
shall	O
advance	O
the	O
hypothesis	O
that	O
:	O
(	O
i	O
)	O
TNF-alpha	O
indirectly	O
controls	O
immune	O
surveillance	O
;	O
and	O
(	O
ii	O
)	O
TNF-alpha	O
controls	O
DNA	O
repair	O
and	O
tumor	O
suppression	O
through	O
the	O
regulation	O
of	O
wild	O
type	O
p53	O
.	O

Thus	O
,	O
it	O
is	O
hypothesized	O
that	O
elevated	O
TNF-alpha	O
is	O
primarily	O
responsible	O
for	O
promoting	O
tumor	O
progression	O
.	O

Stimulation	O
of	O
neutrophil	O
interleukin-8	O
production	O
by	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
.	O

We	O
evaluated	O
the	O
ability	O
of	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
(	O
MBP	O
)	O
to	O
stimulate	O
interleukin	O
(	O
IL	O
)	O
-8	O
production	O
by	O
neutrophils	O
.	O

MBP	O
over	O
the	O
concentration	O
range	O
of	O
0.1	O
to	O
10	O
microM	O
stimulated	O
the	O
release	O
of	O
up	O
to	O
approximately	O
8	O
ng/ml	O
IL-8	O
.	O

Incubation	O
with	O
2	O
microM	O
MBP	O
showed	O
that	O
,	O
after	O
a	O
1	O
h	O
lag	O
,	O
the	O
level	O
of	O
IL-8	O
release	O
increased	O
with	O
time	O
for	O
approximately	O
10	O
h	O
.	O

At	O
the	O
2	O
microM	O
concentration	O
,	O
eosinophil	O
cationic	O
protein	O
,	O
eosinophil-derived	O
neurotoxin	O
,	O
and	O
eosinophil	O
peroxidase	O
did	O
not	B-Negation
stimulate	I-Negation
significant	I-Negation
levels	I-Negation
of	I-Negation
IL-8	I-Negation
production	I-Negation
.	O

MBP	O
stimulated	O
2-fold	O
increases	O
in	O
IL-8	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
after	O
1	O
and	O
3	O
h	O
of	O
incubation	O
,	O
which	O
were	O
blocked	O
by	O
pretreatment	O
with	O
actinomycin	O
D	O
.	O

However	O
,	O
stimulation	O
with	O
MBP	O
did	O
not	B-Negation
produce	I-Negation
an	I-Negation
increase	I-Negation
in	I-Negation
the	I-Negation
binding	I-Negation
activity	I-Negation
of	I-Negation
nuclear	I-Negation
factor	I-Negation
(	I-Negation
NF	I-Negation
)	I-Negation
-kappaB	I-Negation
or	I-Negation
activator	I-Negation
protein-1	I-Negation
.	O

No	O
NF-IL-6	O
binding	O
activity	O
was	O
detected	O
in	O
the	O
same	O
nuclear	O
extracts	O
.	O

In	O
addition	O
,	O
stimulation	O
with	O
MBP	O
prolonged	O
the	O
stability	O
of	O
IL-8	O
mRNA	O
.	O

MBP	O
also	O
induced	O
transient	O
increases	O
in	O
mRNA	O
for	O
macrophage	O
inflammatory	O
protein	O
(	O
MIP	O
)	O
-1alpha	O
and	O
MIP-1beta	O
,	O
but	O
did	O
not	B-Negation
stimulate	I-Negation
the	I-Negation
release	I-Negation
of	I-Negation
either	I-Negation
chemokine	I-Negation
.	O

These	O
findings	O
indicate	O
that	O
MBP	O
is	O
selective	O
among	O
the	O
eosinophil	O
granule	O
proteins	O
as	O
a	O
stimulus	O
for	O
neutrophil	O
IL-8	O
release	O
and	O
,	O
further	O
,	O
that	O
stimulation	O
of	O
neutrophil	O
IL-8	O
release	O
by	O
MBP	O
involves	O
both	O
transcriptional	O
and	O
posttranscriptional	O
regulation	O
.	O

We	O
postulate	O
that	O
MBP-induced	O
release	O
of	O
IL-8	O
by	O
neutrophils	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
acute	O
asthma	O
and	O
other	O
inflammatory	O
lung	O
diseases	O
.	O

PPARgamma	O
activation	O
induces	O
the	O
expression	O
of	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
gene	O
in	O
human	O
monocytes	O
.	O

The	O
peroxisome-proliferator	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
of	O
ligand	O
activated	O
transcription	O
factors	O
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
anti-diabetic	O
actions	O
of	O
the	O
thiazolidinediones	O
(	O
TZDs	O
)	O
.	O

PPARgamma	O
induces	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
lipid	O
anabolism	O
,	O
including	O
the	O
adipocyte	O
fatty	O
acid	O
binding	O
protein	O
(	O
aP2	O
)	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
adipocyte	O
differentiation	O
.	O

PPARgamma	O
is	O
also	O
expressed	O
in	O
hematopoietic	O
cells	O
and	O
is	O
up-regulated	O
in	O
activated	O
monocytes/macrophages	O
.	O

Activation	O
of	O
PPARgamma	O
may	O
play	O
a	O
role	O
in	O
the	O
induction	O
of	O
differentiation	O
of	O
macrophages	O
to	O
foam	O
cells	O
that	O
are	O
associated	O
with	O
atherosclerotic	O
lesions	O
.	O

We	O
report	O
that	O
both	O
natural	O
and	O
synthetic	O
PPARgamma	O
agonists	O
induce	O
time-	O
and	O
dose-dependent	O
increases	O
in	O
aP2	O
mRNA	O
in	O
both	O
primary	O
human	O
monocytes	O
and	O
the	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
.	O

These	O
data	O
suggest	O
that	O
PPARgamma	O
activation	O
may	O
play	O
a	O
role	O
in	O
monocyte	O
differentiation	O
and	O
function	O
analogous	O
to	O
its	O
well-characterized	O
role	O
in	O
adipocytes	O
.	O

Reactive	O
oxygen	O
intermediate-release	O
of	O
fibre-exposed	O
monocytes	O
increases	O
inflammatory	O
cytokine-mRNA	O
level	O
,	O
protein	O
tyrosine	O
kinase	O
and	O
NF-kappaB	O
activity	O
in	O
co-cultured	O
bronchial	O
epithelial	O
cells	O
(	O
BEAS-2B	O
)	O
.	O

Some	O
pulmonary	O
diseases	O
like	O
bronchitis	O
or	O
asthma	O
bronchiale	O
are	O
mediated	O
by	O
inflammatory	O
mechanisms	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Alveolar	O
macrophages	O
are	O
located	O
directly	O
in	O
the	O
surrounding	O
of	O
these	O
cells	O
,	O
so	O
that	O
we	O
suppose	O
an	O
interaction	O
between	O
epithelial	O
cells	O
and	O
macrophages	O
regarding	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
.	O

For	O
measuring	O
the	O
contribution	O
of	O
macrophages	O
to	O
the	O
release	O
of	O
inflammatory	O
mediators	O
by	O
bronchial	O
epithelial	O
cells	O
,	O
we	O
established	O
an	O
in	O
vitro	O
model	O
of	O
co-cultured	O
blood	O
monocytes	O
(	O
BM	O
)	O
and	O
BEAS-2B	O
cells	O
in	O
a	O
transwell	O
system	O
(	O
Costar	O
)	O
.	O

BM	O
were	O
exposed	O
to	O
Chrysotile	O
B	O
and	O
soot	O
particle	O
FR	O
101	O
in	O
a	O
concentration	O
of	O
100	O
microg/10	O
(	O
6	O
)	O
cells	O
.	O

After	O
up	O
to	O
90	O
min	O
exposure	O
time	O
ELISA	O
,	O
EMSA	O
(	O
electromobility	O
shift	O
assay	O
)	O
and	O
RT-PCR	O
were	O
used	O
to	O
measure	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
protein	O
activity	O
of	O
NF-kappaB	O
and	O
cytokine	O
(	O
IL-1beta	O
,	O
IL-6	O
,	O
TNF-alpha	O
)	O
specific	O
mRNA	O
levels	O
in	O
BEAS-2B	O
cells	O
.	O

We	O
observed	O
an	O
increase	O
in	O
protein	O
tyrosine	O
kinase	O
activity	O
(	O
up	O
to	O
1.8	O
	O
0.5-fold	O
)	O
and	O
NF-kappaB	O
protein	O
activity	O
in	O
BEAS-2B	O
cells	O
after	O
particle	O
or	O
fibre	O
exposure	O
of	O
co-cultured	O
BM	O
.	O

Consecutive	O
IL-1beta-	O
,	O
IL-6-	O
and	O
TNF-alpha-mRNA	O
were	O
elevated	O
(	O
up	O
to	O
1.9	O
	O
0.58-fold	O
)	O
.	O

Protein	O
tyrosine	O
kinase	O
activity	O
,	O
NF-kappaB	O
activity	O
,	O
and	O
the	O
synthesis	O
of	O
cytokine-specific	O
mRNA	O
were	O
inhibited	O
by	O
antioxidants	O
.	O

These	O
data	O
suggest	O
a	O
ROI-dependent	O
NF-kappaB	O
mediated	O
transcription	O
of	O
inflammatory	O
cytokines	O
in	O
bronchial	O
epithelial	O
cells	O
.	O

Host	O
defense	O
mechanisms	O
triggered	O
by	O
microbial	O
lipoproteins	O
through	O
toll-like	O
receptors	O
.	O

The	O
generation	O
of	O
cell-mediated	O
immunity	O
against	O
many	O
infectious	O
pathogens	O
involves	O
the	O
production	O
of	O
interleukin-12	O
(	O
IL-12	O
)	O
,	O
a	O
key	O
signal	O
of	O
the	O
innate	O
immune	O
system	O
.	O

Yet	O
,	O
for	O
many	O
pathogens	O
,	O
the	O
molecules	O
that	O
induce	O
IL-12	O
production	O
by	O
macrophages	O
and	O
the	O
mechanisms	O
by	O
which	O
they	O
do	O
so	O
remain	O
undefined	O
.	O

Here	O
it	O
is	O
shown	O
that	O
microbial	O
lipoproteins	O
are	O
potent	O
stimulators	O
of	O
IL-12	O
production	O
by	O
human	O
macrophages	O
,	O
and	O
that	O
induction	O
is	O
mediated	O
by	O
Toll-like	O
receptors	O
(	O
TLRs	O
)	O
.	O

Several	O
lipoproteins	O
stimulated	O
TLR-dependent	O
transcription	O
of	O
inducible	O
nitric	O
oxide	O
synthase	O
and	O
the	O
production	O
of	O
nitric	O
oxide	O
,	O
a	O
powerful	O
microbicidal	O
pathway	O
.	O

Activation	O
of	O
TLRs	O
by	O
microbial	O
lipoproteins	O
may	O
initiate	O
innate	O
defense	O
mechanisms	O
against	O
infectious	O
pathogens	O
.	O

Cell	O
activation	O
and	O
apoptosis	O
by	O
bacterial	O
lipoproteins	O
through	O
toll-like	O
receptor-2	O
.	O

Apoptosis	O
is	O
implicated	O
in	O
the	O
generation	O
and	O
resolution	O
of	O
inflammation	O
in	O
response	O
to	O
bacterial	O
pathogens	O
.	O

All	O
bacterial	O
pathogens	O
produce	O
lipoproteins	O
(	O
BLPs	O
)	O
,	O
which	O
trigger	O
the	O
innate	O
immune	O
response	O
.	O

BLPs	O
were	O
found	O
to	O
induce	O
apoptosis	O
in	O
THP-1	O
monocytic	O
cells	O
through	O
human	O
Toll-like	O
receptor-2	O
(	O
hTLR2	O
)	O
.	O

BLPs	O
also	O
initiated	O
apoptosis	O
in	O
an	O
epithelial	O
cell	O
line	O
transfected	O
with	O
hTLR2	O
.	O

In	O
addition	O
,	O
BLPs	O
stimulated	O
nuclear	O
factor-kappaB	O
,	O
a	O
transcriptional	O
activator	O
of	O
multiple	O
host	O
defense	O
genes	O
,	O
and	O
activated	O
the	O
respiratory	O
burst	O
through	O
hTLR2	O
.	O

Thus	O
,	O
hTLR2	O
is	O
a	O
molecular	O
link	O
between	O
microbial	O
products	O
,	O
apoptosis	O
,	O
and	O
host	O
defense	O
mechanisms	O
.	O

Tissue-specific	O
regulation	O
of	O
the	O
ecto-5'-nucleotidase	O
promoter	O
.	O

Role	O
of	O
the	O
camp	O
response	O
element	O
site	O
in	O
mediating	O
repression	O
by	O
the	O
upstream	O
regulatory	O
region	O
.	O

We	O
have	O
isolated	O
the	O
5	O
'	O
region	O
of	O
the	O
ecto-5'-nucleotidase	O
(	O
low	O
K	O
(	O
m	O
)	O
5'-NT	O
)	O
gene	O
and	O
established	O
that	O
a	O
969-base	O
pair	O
(	O
bp	O
)	O
fragment	O
confers	O
cell-specific	O
expression	O
of	O
a	O
CAT	O
reporter	O
gene	O
that	O
correlates	O
with	O
the	O
expression	O
of	O
endogenous	O
ecto-5'-NT	O
mRNA	O
and	O
enzymatic	O
activity	O
.	O

A	O
768-bp	O
upstream	O
negative	O
regulatory	O
region	O
has	O
been	O
identified	O
that	O
conferred	O
lymphocyte-specific	O
negative	O
regulation	O
in	O
a	O
heterologous	O
system	O
with	O
a	O
244-bp	O
deoxycytidine	O
kinase	O
core	O
promoter	O
.	O

DNase	O
I	O
footprinting	O
identified	O
several	O
protected	O
areas	O
including	O
Sp1	O
,	O
Sp1/AP-2	O
,	O
and	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
binding	O
sites	O
within	O
the	O
201-bp	O
core	O
promoter	O
region	O
and	O
Sp1	O
,	O
NRE-2a	O
,	O
TCF-1/LEF-1	O
,	O
and	O
Sp1/NF-AT	O
binding	O
sites	O
in	O
the	O
upstream	O
regulatory	O
region	O
.	O

Whereas	O
the	O
CRE	O
site	O
was	O
essential	O
in	O
mediating	O
the	O
negative	O
activity	O
of	O
the	O
upstream	O
regulatory	O
region	O
in	O
Jurkat	O
but	O
not	B-Negation
in	I-Negation
HeLa	I-Negation
cells	I-Negation
,	O
mutation	O
of	O
the	O
Sp1/AP-2	O
site	O
decreased	O
promoter	O
activity	O
in	O
both	O
cell	O
lines	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
of	O
proteins	O
binding	O
to	O
the	O
CRE	O
site	O
identified	O
both	O
ATF-1	O
and	O
ATF-2	O
in	O
Jurkat	O
cells	O
.	O

Finally	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
increased	O
the	O
activity	O
of	O
both	O
the	O
core	O
and	O
the	O
969-bp	O
promoter	O
fragments	O
,	O
and	O
this	O
increase	O
was	O
abrogated	O
by	O
mutations	O
at	O
the	O
CRE	O
site	O
.	O

In	O
summary	O
,	O
we	O
have	O
identified	O
a	O
tissue-specific	O
regulatory	O
region	O
5	O
'	O
of	O
the	O
ecto-5'-NT	O
core	O
promoter	O
that	O
requires	O
the	O
presence	O
of	O
a	O
functional	O
CRE	O
site	O
within	O
the	O
basal	O
promoter	O
for	O
its	O
suppressive	O
activity	O
.	O

NF-kappaB-mediated	O
up-regulation	O
of	O
Bcl-x	O
and	O
Bfl-1/A1	O
is	O
required	O
for	O
CD40	O
survival	O
signaling	O
in	O
B	O
lymphocytes	O
.	O

Activation	O
of	O
CD40	O
is	O
essential	O
for	O
thymus-dependent	O
humoral	O
immune	O
responses	O
and	O
rescuing	O
B	O
cells	O
from	O
apoptosis	O
.	O

Many	O
of	O
the	O
effects	O
of	O
CD40	O
are	O
believed	O
to	O
be	O
achieved	O
through	O
altered	O
gene	O
expression	O
.	O

In	O
addition	O
to	O
Bcl-x	O
,	O
a	O
known	O
CD40-regulated	O
antiapoptotic	O
molecule	O
,	O
we	O
identified	O
a	O
related	O
antiapoptotic	O
molecule	O
,	O
A1/Bfl-1	O
,	O
as	O
a	O
CD40-inducible	O
gene	O
.	O

Inhibition	O
of	O
the	O
NF-kappaB	O
pathway	O
by	O
overexpression	O
of	O
a	O
dominant-active	O
inhibitor	O
of	O
NF-kappaB	O
abolished	O
CD40-induced	O
up-regulation	O
of	O
both	O
the	O
Bfl-1	O
and	O
Bcl-x	O
genes	O
and	O
also	O
eliminated	O
the	O
ability	O
of	O
CD40	O
to	O
rescue	O
Fas-induced	O
cell	O
death	O
.	O

Within	O
the	O
upstream	O
promoter	O
region	O
of	O
Bcl-x	O
,	O
a	O
potential	O
NF-kappaB-binding	O
sequence	O
was	O
found	O
to	O
support	O
NF-kappaB-dependent	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
expression	O
of	O
physiological	O
levels	O
of	O
Bcl-x	O
protected	O
B	O
cells	O
from	O
Fas-mediated	O
apoptosis	O
in	O
the	O
absence	B-Negation
of	I-Negation
NF-kappaB	I-Negation
signaling	I-Negation
.	O

Thus	O
,	O
our	O
results	O
suggest	O
that	O
CD40-mediated	O
cell	O
survival	O
proceeds	O
through	O
NF-kappaB-dependent	O
up-regulation	O
of	O
Bcl-2	O
family	O
members	O
.	O

Distinctive	O
gene	O
expression	O
patterns	O
in	O
human	O
mammary	O
epithelial	O
cells	O
and	O
breast	O
cancers	O
.	O

cDNA	O
microarrays	O
and	O
a	O
clustering	O
algorithm	O
were	O
used	O
to	O
identify	O
patterns	O
of	O
gene	O
expression	O
in	O
human	O
mammary	O
epithelial	O
cells	O
growing	O
in	O
culture	O
and	O
in	O
primary	O
human	O
breast	O
tumors	O
.	O

Clusters	O
of	O
coexpressed	O
genes	O
identified	O
through	O
manipulations	O
of	O
mammary	O
epithelial	O
cells	O
in	O
vitro	O
also	O
showed	O
consistent	O
patterns	O
of	O
variation	O
in	O
expression	O
among	O
breast	O
tumor	O
samples	O
.	O

By	O
using	O
immunohistochemistry	O
with	O
antibodies	O
against	O
proteins	O
encoded	O
by	O
a	O
particular	O
gene	O
in	O
a	O
cluster	O
,	O
the	O
identity	O
of	O
the	O
cell	O
type	O
within	O
the	O
tumor	O
specimen	O
that	O
contributed	O
the	O
observed	O
gene	O
expression	O
pattern	O
could	O
be	O
determined	O
.	O

Clusters	O
of	O
genes	O
with	O
coherent	O
expression	O
patterns	O
in	O
cultured	O
cells	O
and	O
in	O
the	O
breast	O
tumors	O
samples	O
could	O
be	O
related	O
to	O
specific	O
features	O
of	O
biological	O
variation	O
among	O
the	O
samples	O
.	O

Two	O
such	O
clusters	O
were	O
found	O
to	O
have	O
patterns	O
that	O
correlated	O
with	O
variation	O
in	O
cell	O
proliferation	O
rates	O
and	O
with	O
activation	O
of	O
the	O
IFN-regulated	O
signal	O
transduction	O
pathway	O
,	O
respectively	O
.	O

Clusters	O
of	O
genes	O
expressed	O
by	O
stromal	O
cells	O
and	O
lymphocytes	O
in	O
the	O
breast	O
tumors	O
also	O
were	O
identified	O
in	O
this	O
analysis	O
.	O

These	O
results	O
support	O
the	O
feasibility	O
and	O
usefulness	O
of	O
this	O
systematic	O
approach	O
to	O
studying	O
variation	O
in	O
gene	O
expression	O
patterns	O
in	O
human	O
cancers	O
as	O
a	O
means	O
to	O
dissect	O
and	O
classify	O
solid	O
tumors	O
.	O

Bcl-2-mediated	O
drug	O
resistance	O
:	O
inhibition	O
of	O
apoptosis	O
by	O
blocking	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
(	O
NFAT	O
)	O
-induced	O
Fas	O
ligand	O
transcription	O
.	O

Bcl-2	O
inhibits	O
apoptosis	O
induced	O
by	O
a	O
variety	O
of	O
stimuli	O
,	O
including	O
chemotherapy	O
drugs	O
and	O
glucocorticoids	O
.	O

It	O
is	O
generally	O
accepted	O
that	O
Bcl-2	O
exerts	O
its	O
antiapoptotic	O
effects	O
mainly	O
by	O
dimerizing	O
with	O
proapoptotic	O
members	O
of	O
the	O
Bcl-2	O
family	O
such	O
as	O
Bax	O
and	O
Bad	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
the	O
antiapoptotic	O
effects	O
is	O
unclear	O
.	O

Paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
dynamics	O
kill	O
cells	O
in	O
a	O
Fas/Fas	O
ligand	O
(	O
FasL	O
)	O
-dependent	O
manner	O
;	O
antibody	O
to	O
FasL	O
inhibits	O
paclitaxel-induced	O
apoptosis	O
.	O

We	O
have	O
found	O
that	O
Bcl-2	O
overexpression	O
leads	O
to	O
the	O
prevention	O
of	O
chemotherapy	O
(	O
paclitaxel	O
)	O
-induced	O
expression	O
of	O
FasL	O
and	O
blocks	O
paclitaxel-induced	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
this	O
effect	O
is	O
that	O
Bcl-2	O
prevents	O
the	O
nuclear	O
translocation	O
of	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
lymphocytes	O
,	O
a	O
transcription	O
factor	O
activated	O
by	O
microtubule	O
damage	O
)	O
by	O
binding	O
and	O
sequestering	O
calcineurin	O
,	O
a	O
calcium-dependent	O
phosphatase	O
that	O
must	O
dephosphorylate	O
NFAT	O
to	O
move	O
to	O
the	O
nucleus	O
.	O

Without	B-Negation
NFAT	I-Negation
nuclear	I-Negation
translocation	I-Negation
,	O
the	B-Negation
FasL	I-Negation
gene	I-Negation
is	I-Negation
not	I-Negation
transcribed	I-Negation
.	O

Thus	O
,	O
it	O
appears	O
that	O
paclitaxel	O
and	O
other	O
drugs	O
that	O
disturb	O
microtubule	O
function	O
kill	O
cells	O
at	O
least	O
in	O
part	O
through	O
the	O
induction	O
of	O
FasL	O
.	O

Furthermore	O
,	O
Bcl-2	O
antagonizes	O
drug-induced	O
apoptosis	O
by	O
inhibiting	O
calcineurin	O
activation	O
,	O
blocking	O
NFAT	O
nuclear	O
translocation	O
,	O
and	O
preventing	O
FasL	O
expression	O
.	O

The	O
effects	O
of	O
Bcl-2	O
can	O
be	O
overcome	O
,	O
at	O
least	O
partially	O
,	O
through	O
phosphorylation	O
of	O
Bcl-2	O
.	O

Phosphorylated	O
Bcl-2	O
can	B-Negation
not	I-Negation
bind	I-Negation
calcineurin	I-Negation
,	I-Negation
and	I-Negation
NFAT	I-Negation
activation	I-Negation
,	I-Negation
FasL	I-Negation
expression	I-Negation
,	O
and	O
apoptosis	O
can	B-Speculation
occur	I-Speculation
after	I-Speculation
Bcl-2	I-Speculation
phosphorylation	I-Speculation
.	O

Retinoblastoma	O
protein	O
expression	O
leads	O
to	O
reduced	O
Oct-1	O
DNA	O
binding	O
activity	O
and	O
enhances	O
interleukin-8	O
expression	O
.	O

Tumor	B-Negation
cell	I-Negation
lines	I-Negation
with	I-Negation
a	I-Negation
defective	I-Negation
retinoblastoma	I-Negation
gene	I-Negation
are	I-Negation
unable	I-Negation
to	I-Negation
transcribe	I-Negation
the	I-Negation
HLA	I-Negation
class	I-Negation
II	I-Negation
genes	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
IFN-gamma	I-Negation
treatment	I-Negation
,	O
and	O
reconstitution	O
of	O
functional	O
Rb	O
rescues	O
IFN-gamma-induced	O
class	O
II	O
gene	O
expression	O
.	O

However	O
,	O
the	O
molecular	O
mechanism	O
of	O
Rb	O
rescue	O
of	O
the	O
class	O
II	O
genes	O
is	O
unknown	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
Rb	O
expression	O
on	O
the	O
activation	O
of	O
the	O
promoter	O
for	O
HLA-DRA	O
,	O
the	O
prototype	O
class	O
II	O
gene	O
.	O

Oct-1	O
,	O
a	O
POU	O
domain	O
transcription	O
factor	O
,	O
was	O
identified	O
as	O
a	O
repressor	O
of	O
HLA-DRA	O
promoter	O
activity	O
in	O
the	O
Rb-defective	O
cells	O
.	O

Rb	O
expression	O
led	O
to	O
phosphorylation	O
of	O
Oct-1	O
,	O
thus	O
relieving	O
its	O
repressive	O
effect	O
.	O

Oct-1	O
has	O
also	O
been	O
shown	O
to	O
repress	O
interleukin	O
8	O
promoter	O
activity	O
.	O

Consistent	O
with	O
reduced	O
levels	O
of	O
Oct-1	O
DNA	O
binding	O
activity	O
in	O
the	O
Rb-transformed	O
cell	O
lines	O
,	O
interleukin	O
8	O
expression	O
is	O
higher	O
in	O
these	O
cell	O
lines	O
.	O

Protein	O
kinase	O
C	O
and	O
calcineurin	O
synergize	O
to	O
activate	O
IkappaB	O
kinase	O
and	O
NF-kappaB	O
in	O
T	O
lymphocytes	O
.	O

The	O
nuclear	O
factor	O
of	O
kappaB	O
(	O
NF-kappaB	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
is	O
key	O
in	O
the	O
regulation	O
of	O
the	O
immune	O
response	O
and	O
inflammation	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
cross-linking	O
is	O
in	O
part	O
required	O
for	O
activation	O
of	O
NF-kappaB	O
,	O
which	O
is	O
dependent	O
on	O
the	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaBalpha	O
.	O

By	O
using	O
Jurkat	O
and	O
primary	O
human	O
T	O
lymphocytes	O
,	O
we	O
demonstrate	O
that	O
the	O
simultaneous	O
activation	O
of	O
two	O
second	O
messengers	O
of	O
the	O
TCR-initiated	O
signal	O
transduction	O
,	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
calcineurin	O
,	O
results	O
in	O
the	O
synergistic	O
activation	O
of	O
the	O
IkappaBalpha	O
kinase	O
(	O
IKK	O
)	O
complex	O
but	O
not	B-Negation
of	I-Negation
another	I-Negation
putative	I-Negation
IkappaBalpha	I-Negation
kinase	I-Negation
,	I-Negation
p90	I-Negation
(	I-Negation
rsk	I-Negation
)	I-Negation
.	O

We	O
also	O
demonstrate	O
that	O
the	O
IKK	O
complex	O
,	O
but	O
not	B-Negation
p90	I-Negation
(	I-Negation
rsk	I-Negation
)	I-Negation
,	O
is	O
responsible	O
for	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
IkappaBalpha	O
mediated	O
by	O
the	O
co-activation	O
of	O
PKC	O
and	O
calcineurin	O
.	O

Each	O
second	O
messenger	O
is	O
necessary	O
,	O
as	O
inhibition	O
of	O
either	O
one	O
reverses	O
the	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
IkappaBalpha	O
phosphorylation	O
in	O
vivo	O
.	O

Overexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
IKKalpha	O
and	O
-beta	O
demonstrates	O
that	O
only	O
IKKbeta	O
is	O
the	O
target	O
for	O
PKC	O
and	O
calcineurin	O
.	O

These	O
results	O
indicate	O
that	O
within	O
the	O
TCR/CD3	O
signal	O
transduction	O
pathway	O
both	O
PKC	O
and	O
calcineurin	O
are	O
required	O
for	O
the	O
effective	O
activation	O
of	O
the	O
IKK	O
complex	O
and	O
NF-kappaB	O
in	O
T	O
lymphocytes	O
.	O

C/EBPbeta	O
and	O
GATA-1	O
synergistically	O
regulate	O
activity	O
of	O
the	O
eosinophil	O
granule	O
major	O
basic	O
protein	O
promoter	O
:	O
implication	O
for	O
C/EBPbeta	O
activity	O
in	O
eosinophil	O
gene	O
expression	O
.	O

Eosinophil	O
granule	O
major	O
basic	O
protein	O
(	O
MBP	O
)	O
is	O
expressed	O
exclusively	O
in	O
eosinophils	O
and	O
basophils	O
in	O
hematopoietic	O
cells	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
a	O
major	O
positive	O
regulatory	O
role	O
for	O
GATA-1	O
and	O
a	O
negative	O
regulatory	O
role	O
for	O
GATA-2	O
in	O
MBP	O
gene	O
transcription	O
.	O

Further	O
analysis	O
of	O
the	O
MBP	O
promoter	O
region	O
identified	O
a	O
C/EBP	O
(	O
CCAAT/enhancer-binding	O
protein	O
)	O
consensus	O
binding	O
site	O
6	O
bp	O
upstream	O
of	O
the	O
functional	O
GATA-binding	O
site	O
in	O
the	O
MBP	O
gene	O
.	O

In	O
the	O
cell	O
line	O
HT93A	O
,	O
which	O
is	O
capable	O
of	O
differentiating	O
towards	O
both	O
the	O
eosinophil	O
and	O
neutrophil	O
lineages	O
in	O
response	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
,	O
C/EBPalpha	O
mRNA	O
expression	O
decreased	O
significantly	O
concomitant	O
with	O
eosinophilic	O
and	O
neutrophilic	O
differentiation	O
,	O
whereas	O
C/EBPbeta	O
expression	O
was	O
markedly	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
showed	O
that	O
recombinant	O
C/EBPbeta	O
protein	O
could	O
bind	O
to	O
the	O
potential	O
C/EBP-binding	O
site	O
(	O
bp	O
-90	O
to	O
-82	O
)	O
in	O
the	O
MBP	O
promoter	O
.	O

Furthermore	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
C/EBPbeta	O
and	O
GATA-1	O
can	O
bind	O
simultaneously	O
to	O
the	O
C/EBP-	O
and	O
GATA-binding	O
sites	O
in	O
the	O
MBP	O
promoter	O
.	O

To	O
determine	O
the	O
functionality	O
of	O
both	O
the	O
C/EBP-	O
and	O
GATA-	O
binding	O
sites	O
,	O
we	O
analyzed	O
whether	O
C/EBPbeta	O
and	O
GATA-1	O
can	O
stimulate	O
the	O
MBP	O
promoter	O
in	O
the	O
C/EBPbeta	O
and	O
GATA-1	O
negative	O
Jurkat	O
T-cell	O
line	O
.	O

Cotransfection	O
with	O
C/EBPbeta	O
and	O
GATA-1	O
expression	O
vectors	O
produced	O
a	O
5-fold	O
increase	O
compared	O
with	O
cotransfection	O
with	O
the	O
C/EBPbeta	O
or	O
GATA-1	O
expression	O
vectors	O
individually	O
.	O

In	O
addition	O
,	O
GST	O
pull-down	O
experiments	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
human	O
GATA-1	O
and	O
C/EBPbeta	O
.	O

Expression	O
of	O
FOG	O
(	O
riend	O
ATA	O
)	O
,	O
which	O
binds	O
to	O
GATA-1	O
and	O
acts	O
as	O
a	O
cofactor	O
for	O
GATA-binding	O
proteins	O
,	O
decreased	O
transactivation	O
activity	O
of	O
GATA-1	O
for	O
the	O
MBP	O
promoter	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
that	O
both	O
GATA-1	O
and	O
C/EBPbeta	O
synergistically	O
transactivate	O
the	O
promoter	O
of	O
an	O
eosinophil-specific	O
granule	O
protein	O
gene	O
and	O
that	O
FOG	O
may	O
act	O
as	O
a	O
negative	O
cofactor	O
for	O
the	O
eosinophil	O
lineage	O
,	O
unlike	O
its	O
positively	O
regulatory	O
function	O
for	O
the	O
erythroid	O
and	O
megakaryocyte	O
lineages	O
.	O

Thymocyte-thymic	O
epithelial	O
cell	O
interaction	O
leads	O
to	O
high-level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
exclusively	O
in	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
:	O
a	O
critical	O
role	O
for	O
tumor	O
necrosis	O
factor	O
and	O
interleukin-7	O
.	O

This	O
work	O
aims	O
at	O
identifying	O
the	O
thymocyte	O
subpopulation	O
able	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
replication	O
under	O
the	O
biological	O
stimuli	O
of	O
the	O
thymic	O
microenvironment	O
.	O

In	O
this	O
report	O
we	O
demonstrate	O
that	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
induces	O
a	O
high-level	O
replication	O
of	O
the	O
T-tropic	O
primary	O
isolate	O
HIV-1	O
(	O
B-LAIp	O
)	O
exclusively	O
in	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
thymocytes	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
interleukin-7	O
(	O
IL-7	O
)	O
,	O
secreted	O
during	O
this	O
interaction	O
,	O
are	O
critical	O
cytokines	O
for	O
HIV	O
long	O
terminal	O
repeat	O
transactivation	O
through	O
NF-kappaB-dependent	O
activation	O
.	O

TNF	O
is	O
the	O
major	O
inducer	O
of	O
NF-kappaB	O
and	O
particularly	O
of	O
the	O
p50-p65	O
complex	O
,	O
whereas	O
IL-7	O
acts	O
as	O
a	O
cofactor	O
by	O
sustaining	O
the	O
expression	O
of	O
the	O
p75	O
TNF	O
receptor	O
.	O

The	O
requirement	O
for	O
TNF	O
is	O
further	O
confirmed	O
by	O
the	O
observation	O
that	O
the	O
inability	O
of	O
the	O
intermediate	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
thymocytes	O
to	O
replicate	O
the	O
virus	O
is	O
associated	O
with	O
a	O
defect	O
in	O
TNF	O
production	O
during	O
their	O
interaction	O
with	O
TEC	O
and	O
correlates	O
with	O
the	O
absence	B-Negation
of	I-Negation
nuclear	I-Negation
NF-kappaB	I-Negation
activity	I-Negation
in	I-Negation
these	I-Negation
freshly	I-Negation
isolated	I-Negation
thymocytes	I-Negation
.	O

Addition	O
of	O
exogenous	O
TNF	O
to	O
the	O
intermediate	O
thymocyte	O
cultures	O
induces	O
NF-kappaB	O
activity	O
and	O
is	O
sufficient	O
to	O
promote	O
HIV	O
replication	O
in	O
the	O
cocultures	O
with	O
TEC	O
.	O

The	O
other	O
major	O
subpopulation	O
expressing	O
the	O
CD4	O
receptor	O
,	O
namely	O
,	O
the	O
double-positive	O
(	O
DP	O
)	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
+	O
)	O
CD3	O
(	O
+/-	O
)	O
thymocytes	O
,	O
despite	O
the	O
entry	O
of	O
the	O
virus	O
,	O
do	O
not	B-Negation
produce	I-Negation
a	I-Negation
significant	I-Negation
level	I-Negation
of	I-Negation
virus	I-Negation
,	O
presumably	B-Speculation
because	I-Speculation
they	I-Speculation
are	I-Speculation
unresponsive	I-Speculation
to	I-Speculation
TNF	I-Speculation
and	I-Speculation
IL-7	I-Speculation
.	O

Together	O
,	O
these	O
data	O
suggest	O
that	O
in	O
vivo	O
,	O
despite	O
an	O
efficient	O
entry	O
of	O
the	O
virus	O
in	O
all	O
the	O
CD4	O
(	O
+	O
)	O
subpopulations	O
,	O
a	O
high	O
viral	O
load	O
may	O
be	O
generated	O
exclusively	O
within	O
the	O
mature	O
CD4	O
(	O
+	O
)	O
CD8	O
(	O
-	O
)	O
CD3	O
(	O
+	O
)	O
subset	O
of	O
thymocytes	O
.	O

However	O
,	O
under	O
conditions	O
of	O
inflammatory	O
response	O
after	O
infection	O
,	O
TNF	O
might	O
also	O
be	O
present	O
in	O
the	O
intermediate	O
thymocyte	O
compartment	O
,	O
leading	O
to	O
efficient	O
HIV	O
replication	O
in	O
these	O
cells	O
.	O

IL-2-independent	O
activation	O
and	O
proliferation	O
in	O
human	O
T	O
cells	O
induced	O
by	O
CD28	O
.	O

Although	O
the	O
role	O
of	O
CD28	O
in	O
T	O
cell	O
costimulation	O
is	O
firmly	O
established	O
,	O
the	O
mechanisms	O
by	O
which	O
it	O
exerts	O
its	O
costimulatory	O
actions	O
are	O
less	O
clear	O
.	O

In	O
many	O
circumstances	O
it	O
is	O
difficult	O
to	O
distinguish	O
the	O
effects	O
of	O
CD28	O
from	O
subsequent	O
actions	O
of	O
cytokines	O
,	O
such	O
as	O
IL-2	O
,	O
on	O
T	O
cell	O
proliferation	O
.	O

Here	O
,	O
we	O
report	O
a	O
model	O
of	O
CD28	O
costimulation	O
using	O
PMA	O
plus	O
the	O
natural	O
ligand	O
CD80	O
that	O
resulted	O
in	O
very	O
limited	O
stimulation	O
of	O
IL-2	O
,	O
as	O
evidenced	O
by	O
both	O
cytokine	O
production	O
and	O
IL-2	O
promoter	O
stimulation	O
.	O

Promoter	O
assays	O
revealed	O
CD28-dependent	O
effects	O
on	O
both	O
NF-kappaB	O
and	O
AP-1	O
,	O
but	O
not	B-Negation
on	I-Negation
NF-AT	I-Negation
or	I-Negation
the	I-Negation
intact	I-Negation
IL-2	I-Negation
promoter	I-Negation
.	O

In	O
addition	O
,	O
T	O
cell	O
proliferation	O
was	O
completely	O
resistant	O
to	O
the	O
actions	O
of	O
the	O
immunosuppressant	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

Moreover	O
T	O
cell	O
proliferation	O
was	O
unaffected	O
by	O
the	O
addition	O
of	O
blocking	O
Abs	O
to	O
both	O
IL-2	O
and	O
the	O
IL-2	O
receptor	O
,	O
demonstrating	O
that	O
this	O
form	O
of	O
costimulation	O
by	O
CD28	O
was	O
independent	O
of	O
IL-2	O
.	O

We	O
also	O
investigated	O
the	O
effects	O
of	O
stimulating	O
T	O
cell	O
blasts	O
with	O
CD80	O
alone	O
and	O
found	O
that	O
there	O
was	O
a	O
limited	O
requirement	O
for	O
IL-2	O
in	O
this	O
system	O
.	O

We	O
conclude	O
that	O
CD28	O
costimulation	O
can	O
cause	O
substantial	O
T	O
cell	O
proliferation	O
in	O
the	O
absence	B-Negation
of	I-Negation
IL-2	I-Negation
,	O
which	O
is	O
driven	O
by	O
a	O
soluble	O
factor	O
independent	O
of	O
NF-AT	O
transactivation	O
.	O

Suppression	O
of	O
TNFalpha-mediated	O
NFkappaB	O
activity	O
by	O
myricetin	O
and	O
other	O
flavonoids	O
through	O
downregulating	O
the	O
activity	O
of	O
IKK	O
in	O
ECV304	O
cells	O
.	O

Flavonoids	O
are	O
a	O
group	O
of	O
naturally-occurring	O
phenolic	O
compounds	O
in	O
the	O
plant	O
kingdom	O
,	O
and	O
many	O
flavonoids	O
are	O
found	O
with	O
vascular	O
protective	O
properties	O
.	O

Nevertheless	O
how	O
the	O
protective	O
response	O
is	O
exerted	O
by	O
flavonoids	O
is	O
not	O
well	O
characterized	O
.	O

In	O
view	O
of	O
the	O
nuclear	O
factor-kappaB	O
(	O
NFkappaB	O
)	O
may	O
play	O
a	O
central	O
role	O
in	O
the	O
initiation	O
of	O
atherosclerosis	O
,	O
prevention	O
of	O
the	O
activation	O
of	O
NFkappaB	O
represents	O
an	O
important	O
role	O
in	O
protecting	O
vascular	O
injury	O
.	O

In	O
this	O
study	O
,	O
the	O
effects	O
of	O
flavonoids	O
on	O
NFkappaB/inhibitor-kappaB	O
(	O
IkappaB	O
)	O
system	O
in	O
ECV304	O
cells	O
activated	O
with	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNFalpha	O
)	O
were	O
examined	O
.	O

We	O
investigated	O
the	O
inhibitory	O
action	O
of	O
six	O
flavonoids	O
on	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
activity	O
,	O
an	O
enzyme	O
recently	O
found	O
to	O
phosphorylate	O
critical	O
serine	O
residues	O
of	O
IkappaB	O
for	O
degradation	O
.	O

Of	O
six	O
flavonoids	O
tested	O
,	O
myricetin	O
was	O
found	O
to	O
strongly	O
inhibit	O
IKK	O
kinase	O
activity	O
,	O
and	O
prevent	O
the	O
degradation	O
of	O
IkappaBalpha	O
and	O
IkappaBbeta	O
in	O
activated	O
endothelial	O
cells	O
.	O

Furthermore	O
,	O
myricetin	O
was	O
also	O
found	O
to	O
inhibit	O
NFkappaB	O
activity	O
correlated	O
with	O
suppression	O
of	O
monocyte	O
adhesion	O
to	O
ECV304	O
cells	O
.	O

Therefore	O
we	O
conclude	O
that	O
flavonoids	O
may	O
be	O
of	O
therapeutic	O
value	O
for	O
vascular	O
disease	O
through	O
down	O
regulation	O
of	O
NFkappaB/IkappaB	O
system	O
.	O

Copyright	O
1999	O
Wiley-Liss	O
,	O
Inc	O
.	O

Induction	O
of	O
a	O
functional	O
vitamin	O
D	O
receptor	O
in	O
all-trans-retinoic	O
acid-induced	O
monocytic	O
differentiation	O
of	O
M2-type	O
leukemic	O
blast	O
cells	O
.	O

Different	O
types	O
of	O
acute	O
myeloid	O
leukemia	O
blast	O
cells	O
were	O
induced	O
to	O
differentiate	O
in	O
vitro	O
with	O
all-trans-retinoic	O
acid	O
(	O
ATRA	O
)	O
and	O
vitamin	O
D3	O
(	O
VD	O
)	O
.	O

M0/M1	O
leukemic	O
cells	O
are	O
not	B-Negation
sensitive	I-Negation
to	I-Negation
differentiating	I-Negation
agents	I-Negation
,	O
whereas	O
M3	O
leukemic	O
cells	O
are	O
induced	O
to	O
undergo	O
granulocytic	O
differentiation	O
after	O
ATRA	O
treatment	O
but	O
are	O
not	B-Negation
sensitive	I-Negation
to	I-Negation
VD	I-Negation
.	O

M2	O
leukemic	O
blast	O
cells	O
behave	O
differently	O
because	O
they	O
undergo	O
monocytic	O
differentiation	O
with	O
both	O
the	O
differentiation	O
inducers	O
.	O

To	O
gain	O
some	O
insight	O
into	O
the	O
maturation	O
of	O
M2-type	O
leukemic	O
cells	O
,	O
we	O
studied	O
the	O
molecular	O
mechanisms	O
underlying	O
monocytic	O
differentiation	O
induced	O
by	O
ATRA	O
and	O
VD	O
in	O
spontaneous	O
M2	O
blast	O
cells	O
as	O
well	O
as	O
in	O
Kasumi-1	O
cells	O
(	O
an	O
acute	O
myeloid	O
leukemia	O
M2-type	O
cell	O
line	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
ATRA	O
as	O
well	O
as	O
VD	O
efficiently	O
increases	O
the	O
nuclear	O
abundance	O
of	O
VD	O
receptor	O
(	O
VDR	O
)	O
and	O
promotes	O
monocytic	O
differentiation	O
.	O

VDR	O
is	O
functionally	O
active	O
in	O
ATRA-treated	O
Kasumi-1	O
cells	O
because	O
it	O
efficiently	O
heterodimerizes	O
with	O
retinoid	O
X	O
receptor	O
,	O
binds	O
to	O
a	O
DR3-type	O
vitamin	O
D-responsive	O
element	O
,	O
and	O
activates	O
the	O
transcription	O
of	O
a	O
vitamin	O
D-responsive	O
element-regulated	O
reporter	O
gene	O
.	O

Consistent	O
with	O
these	O
findings	O
,	O
VD-responsive	O
genes	O
are	O
induced	O
by	O
ATRA	O
treatment	O
of	O
Kasumi-1	O
cells	O
,	O
suggesting	O
that	O
the	O
genetic	O
program	O
underlying	O
monocytic	O
differentiation	O
is	O
activated	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ATRA	O
increases	O
the	O
nuclear	O
abundance	O
of	O
a	O
functional	O
VDR	O
is	O
still	O
unknown	O
,	O
but	O
our	O
data	O
clearly	O
indicate	O
that	O
the	O
M2	O
leukemic	O
cell	O
context	O
is	O
only	O
permissive	O
of	O
monocytic	O
differentiation	O
.	O

Signal	O
transduction	O
pathways	O
triggered	O
by	O
the	O
FcepsilonRIIb	O
receptor	O
(	O
CD23	O
)	O
in	O
human	O
monocytes	O
lead	O
to	O
nuclear	O
factor-kappaB	O
activation	O
.	O

BACKGROUND	O
:	O
Alveolar	O
macrophages	O
play	O
a	O
key	O
role	O
in	O
the	O
initiation	O
of	O
the	O
inflammatory	O
reaction	O
of	O
allergic	O
asthma	O
.	O

Alveolar	O
macrophages	O
and	O
peripheral	O
blood	O
monocytes	O
are	O
activated	O
when	O
IgE/allergen	O
immune	O
complexes	O
bind	O
to	O
the	O
CD23	O
receptor	O
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
investigate	O
the	O
molecular	O
mechanisms	O
regulating	O
this	O
early	O
inflammatory	O
response	O
.	O

We	O
have	O
focused	O
on	O
the	O
study	O
of	O
the	O
signal	O
transduction	O
pathways	O
triggered	O
by	O
CD23	O
in	O
human	O
monocytes	O
and	O
the	O
promonocytic	O
cell	O
line	O
U937	O
.	O

METHODS	O
:	O
CD23	O
was	O
cross-linked	O
in	O
human	O
monocytes	O
and	O
U937	O
cells	O
with	O
IgE	O
immune	O
complexes	O
.	O

Surface	O
expression	O
of	O
CD23	O
was	O
determined	O
by	O
FACS	O
analysis	O
.	O

Transcription	O
factor	O
activation	O
and	O
gene	O
transcription	O
were	O
studied	O
by	O
gel-shift	O
assays	O
and	O
Northern	O
blot	O
analysis	O
,	O
respectively	O
.	O

IkappaBalpha	O
phosphorylation	O
and	O
degradation	O
was	O
analyzed	O
by	O
Western	O
blot	O
.	O

RESULTS	O
:	O
Nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
gene	O
activation	O
that	O
follows	O
CD23	O
cross-linking	O
in	O
monocytes	O
.	O

CD23-induced	O
NF-kappaB	O
is	O
a	O
heterodimer	O
composed	O
of	O
p65/p50	O
subunits	O
.	O

NF-kappaB	O
nuclear	O
translocation	O
is	O
secondary	O
to	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
the	O
NF-kappaB	O
inhibitory	O
molecule	O
IkappaBalpha	O
.	O

Tyrosine	O
kinase-dependent	O
,	O
and	O
not	B-Negation
protein	I-Negation
kinase	I-Negation
C-dependent	I-Negation
,	O
pathways	O
mediate	O
CD23-triggered	O
NF-kappaB	O
activation	O
but	O
do	O
not	B-Negation
participate	I-Negation
in	I-Negation
the	I-Negation
direct	I-Negation
phosphorylation	I-Negation
of	I-Negation
IkappaBalpha	I-Negation
.	O

IkappaBalpha	O
degradation	O
and	O
NF-kappaB	O
nuclear	O
translocation	O
correlate	O
with	O
transcriptional	O
activation	O
of	O
the	O
inflammatory	O
cytokines	O
TNF-alpha	O
and	O
IL-1beta	O
.	O

CONCLUSIONS	O
:	O
NF-kappaB	O
is	O
the	O
main	O
transcription	O
factor	O
involved	O
in	O
the	O
signal	O
transduction	O
pathway	O
of	O
CD23	O
in	O
monocytes	O
.	O

Dopamine	O
stimulates	O
expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
via	O
NF-kappaB	O
in	O
cells	O
of	O
the	O
immune	O
system	O
.	O

Recent	O
studies	O
have	O
reported	O
that	O
lymphocytes	O
produce	O
,	O
transport	O
and	O
bind	O
dopamine	O
present	O
in	O
plasma	O
.	O

However	O
,	O
the	B-Negation
action	I-Negation
of	I-Negation
dopamine	I-Negation
on	I-Negation
HIV-1	I-Negation
gene	I-Negation
expression	I-Negation
in	I-Negation
cells	I-Negation
of	I-Negation
the	I-Negation
immune	I-Negation
system	I-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
examined	I-Negation
.	O

Here	O
,	O
we	O
have	O
investigated	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
by	O
dopamine	O
in	O
Jurkat	O
T	O
cells	O
and	O
in	O
primary	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

HIV-1	O
replication	O
was	O
increased	O
by	O
dopamine	O
,	O
which	O
correlated	O
with	O
the	O
increased	O
levels	O
of	O
HIV-1	O
transactivation	O
.	O

Our	O
transient	O
expression	O
data	O
revealed	O
that	O
dopamine	O
stimulated	O
transcription	O
through	O
the	O
NF-kappaB	O
element	O
present	O
in	O
the	O
long	O
terminal	O
repeat	O
.	O

The	O
importance	O
of	O
NF-kappaB	O
sites	O
was	O
confirmed	O
by	O
using	O
vectors	O
containing	O
wild-type	O
or	O
mutant	O
kappaB	O
sites	O
in	O
a	O
heterologous	O
promoter	O
.	O

Consistent	O
with	O
the	O
role	O
of	O
NF-kappaB	O
in	O
mediating	O
dopamine	O
responsiveness	O
,	O
the	O
proteasome	O
inhibitor	O
MG132	O
abolished	O
dopamine-induced	O
transcriptional	O
activation	O
.	O

We	O
further	O
explored	O
the	O
effect	O
of	O
dopamine	O
in	O
the	O
presence	O
of	O
phorbol	O
esters	O
or	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
known	O
to	O
activate	O
NF-kappaB	O
.	O

The	O
combination	O
of	O
dopamine	O
and	O
TNF-alpha	O
led	O
to	O
a	O
stimulation	O
of	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

However	O
,	O
in	O
contrast	O
with	O
TNF-alpha	O
,	O
dopamine	O
treatment	O
did	O
not	B-Negation
affect	I-Negation
NF-kappaB	I-Negation
DNA	I-Negation
binding	I-Negation
activity	I-Negation
nor	I-Negation
the	I-Negation
concentrations	I-Negation
of	I-Negation
p50	I-Negation
,	I-Negation
p65	I-Negation
and	I-Negation
IkappaB-alpha	I-Negation
proteins	I-Negation
,	O
which	O
suggests	B-Speculation
a	I-Speculation
distinct	I-Speculation
NF-kappaB	I-Speculation
activation	I-Speculation
mechanism	I-Speculation
.	O

These	O
results	O
reveal	O
a	O
new	O
link	O
between	O
the	O
dopamine	O
system	O
,	O
cytokine	O
signaling	O
pathway	O
and	O
regulation	O
of	O
gene	O
expression	O
via	O
the	O
involvement	O
of	O
NF-kappaB	O
in	O
T	O
cells	O
and	O
PBMC	O
.	O

Differential	O
effects	O
of	O
lipopolysaccharide	O
and	O
tumor	O
necrosis	O
factor	O
on	O
monocytic	O
IkappaB	O
kinase	O
signalsome	O
activation	O
and	O
IkappaB	O
proteolysis	O
.	O

The	O
inflammatory	O
mediators	O
lipopolysaccharide	O
(	O
LPS	O
)	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
are	O
potent	O
activators	O
of	O
NF-kappaB	O
.	O

This	O
study	O
compared	O
the	O
effect	O
of	O
these	O
stimuli	O
on	O
endogenous	O
IkappaB	O
kinase	O
(	O
IKK	O
)	O
signalsome	O
activation	O
and	O
IkappaB	O
phosphorylation/proteolysis	O
in	O
human	O
monocytic	O
cells	O
and	O
investigated	O
the	O
role	O
of	O
the	O
signalsome	O
proteins	O
IKK-alpha	O
,	O
IKK-beta	O
,	O
NF-kappaB-inducing	O
kinase	O
(	O
NIK	O
)	O
,	O
IKK-gamma	O
(	O
NF-kappaB	O
essential	O
modulator	O
)	O
,	O
and	O
IKK	O
complex-associated	O
protein	O
.	O

Kinase	O
assays	O
showed	O
that	O
TNF	O
elicited	O
a	O
rapid	O
but	O
short-lived	O
induction	O
of	O
IKK	O
activity	O
with	O
a	O
3-fold	O
greater	O
effect	O
on	O
IKK-alpha	O
than	O
on	O
IKK-beta	O
,	O
peaking	O
at	O
5	O
min	O
.	O

In	O
contrast	O
,	O
LPS	O
predominantly	O
stimulated	O
IKK-beta	O
activity	O
,	O
which	O
slowly	O
increased	O
,	O
peaking	O
at	O
30	O
min	O
.	O

A	O
second	O
peak	O
was	O
observed	O
at	O
a	O
later	O
time	O
point	O
following	O
LPS	O
stimulation	O
,	O
which	O
consisted	O
of	O
both	O
IKK-alpha	O
and	O
-beta	O
activity	O
.	O

The	O
endogenous	O
levels	O
of	O
the	O
signalsome	O
components	O
were	O
unaffected	O
by	O
stimulation	O
.	O

Furthermore	O
,	O
our	O
studies	O
showed	O
association	O
of	O
the	O
IKK-alpha/beta	O
heterodimer	O
with	O
NIK	O
,	O
IkappaB-alpha	O
and	O
-epsilon	O
in	O
unstimulated	O
cells	O
.	O

Exposure	O
to	O
LPS	O
or	O
TNF	O
led	O
to	O
differential	O
patterns	O
of	O
IkappaB-alpha	O
and	O
IkappaB-epsilon	O
disappearance	O
from	O
and	O
reassembly	O
with	O
the	O
signalsome	O
,	O
whereas	O
IKK-alpha	O
,	O
IKK-beta	O
,	O
and	O
NIK	O
remained	O
complex-associated	O
.	O

NIK	O
can	B-Negation
not	I-Negation
phosphorylate	I-Negation
IkappaB-alpha	I-Negation
directly	I-Negation
,	O
but	O
it	B-Speculation
appears	I-Speculation
to	I-Speculation
be	I-Speculation
a	I-Speculation
functionally	I-Speculation
important	I-Speculation
subunit	I-Speculation
,	O
because	O
mutated	O
NIK	O
inhibited	O
stimulus-induced	O
kappaB-dependent	O
transcription	O
more	O
effectively	O
than	O
mutated	O
IKK-alpha	O
or	O
-beta	O
.	O

Overexpression	O
of	O
IKK	O
complex-associated	O
protein	O
inhibited	O
stimulus-mediated	O
transcription	O
,	O
whereas	O
NF-kappaB	O
essential	O
modulator	O
enhanced	O
it	O
.	O

The	O
understanding	O
of	O
LPS-	O
and	O
TNF-induced	O
signaling	O
may	O
allow	O
the	O
development	O
of	O
specific	O
strategies	O
to	O
treat	O
sepsis-associated	O
disease	O
.	O

AML1	O
(	O
CBFalpha2	O
)	O
cooperates	O
with	O
B	O
cell-specific	O
activating	O
protein	O
(	O
BSAP/PAX5	O
)	O
in	O
activation	O
of	O
the	O
B	O
cell-specific	O
BLK	O
gene	O
promoter	O
.	O

AML1	O
plays	O
a	O
critical	O
role	O
during	O
hematopoiesis	O
and	O
chromosomal	O
translocations	O
involving	O
AML1	O
are	O
commonly	O
associated	O
with	O
different	O
forms	O
of	O
leukemia	O
,	O
including	O
pre-B	O
acute	O
lymphoblastic	O
leukemia	O
.	O

To	O
understand	O
the	O
function	O
of	O
AML1	O
during	O
B	O
cell	O
differentiation	O
,	O
we	O
analyzed	O
regulatory	O
regions	O
of	O
B	O
cell-specific	O
genes	O
for	O
potential	O
AML1-binding	O
sites	O
and	O
have	O
identified	O
a	O
putative	O
AML1-binding	O
site	O
in	O
the	O
promoter	O
of	O
the	O
B	O
cell-specific	O
tyrosine	O
kinase	O
gene	O
,	O
blk	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
transient	O
transfection	O
assays	O
demonstrate	O
that	O
AML1	O
binds	O
specifically	O
to	O
this	O
site	O
in	O
the	O
blk	O
promoter	O
and	O
this	O
binding	O
site	O
is	O
important	O
for	O
blk	O
promoter	O
activity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
binding	O
analysis	O
revealed	O
that	O
the	O
AML1	O
runt	O
DNA-binding	O
domain	O
physically	O
interacts	O
with	O
the	O
paired	O
DNA-binding	O
domain	O
of	O
BSAP	O
,	O
a	O
B	O
cell-specific	O
transcription	O
factor	O
.	O

BSAP	O
has	O
been	O
shown	O
previously	O
to	O
be	O
important	O
for	O
B	O
cell-specific	O
regulation	O
of	O
the	O
blk	O
gene	O
.	O

Physical	O
interaction	O
of	O
AML1	O
with	O
BSAP	O
correlates	O
with	O
functional	O
cooperativity	O
in	O
transfection	O
studies	O
where	O
AML1	O
and	O
BSAP	O
synergistically	O
activate	O
blk	O
promoter	O
transcription	O
by	O
more	O
than	O
50-fold	O
.	O

These	O
results	O
demonstrate	O
physical	O
and	O
functional	O
interactions	O
between	O
AML1	O
and	O
BSAP	O
and	O
suggest	O
that	O
AML1	O
is	O
an	O
important	O
factor	O
for	O
regulating	O
a	O
critical	O
B	O
cell-specific	O
gene	O
,	O
blk	O
.	O

c-Maf	O
induces	O
monocytic	O
differentiation	O
and	O
apoptosis	O
in	O
bipotent	O
myeloid	O
progenitors	O
.	O

The	O
transcriptional	O
mechanisms	O
that	O
drive	O
colony-forming	O
unit	O
granulocyte-macrophage	O
(	O
CFU-GM	O
)	O
myeloid	O
progenitors	O
to	O
differentiate	O
into	O
cells	O
of	O
either	O
the	O
granulocytic	O
or	O
monocytic	O
lineage	O
are	O
not	O
fully	O
understood	O
.	O

We	O
have	O
shown	O
that	O
the	O
c-Maf	O
and	O
c-Myb	O
transcription	O
factors	O
physically	O
interact	O
in	O
myeloid	O
cells	O
to	O
form	O
inhibitory	O
complexes	O
that	O
hinder	O
transactivation	O
of	O
c-Myb	O
target	O
genes	O
through	O
direct	O
binding	O
to	O
Myb	O
consensus	O
sites	O
.	O

These	O
complexes	O
arise	O
in	O
a	O
developmentally	O
regulated	O
pattern	O
,	O
peaking	O
at	O
the	O
promyelocyte	O
stage	O
,	O
or	O
in	O
cell	O
model	O
systems	O
,	O
appearing	O
soon	O
after	O
the	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

We	O
wished	O
to	O
determine	O
if	O
this	O
developmentally	O
related	O
interaction	O
is	O
a	O
consequence	O
of	O
myeloid	O
differentiation	O
or	O
an	O
intrinsic	O
differentiating	O
stimulus	O
.	O

Because	O
the	O
elevated	O
Myb	O
:	O
Maf	O
status	O
seen	O
in	O
differentiating	O
cells	O
can	O
be	O
recapitulated	O
by	O
overexpression	O
of	O
c-Maf	O
in	O
myeloid	O
cell	O
lines	O
,	O
we	O
inducibly	O
expressed	O
the	O
c-Maf	O
cDNA	O
in	O
2	O
bipotent	O
human	O
myeloid	O
progenitor	O
cells	O
.	O

Elevated	O
levels	O
of	O
c-Maf	O
protein	O
led	O
to	O
marked	O
increases	O
in	O
Myb	O
:	O
Maf	O
complexes	O
and	O
the	O
accumulation	O
of	O
monocyte/macrophage	O
cells	O
,	O
followed	O
by	O
eventual	O
programmed	O
cell	O
death	O
.	O

Analysis	O
of	O
targets	O
that	O
could	O
mediate	O
these	O
phenotypic	O
changes	O
indicated	O
that	O
c-Maf	O
likely	O
plays	O
a	O
key	O
role	O
in	O
myeloid	O
cell	O
development	O
through	O
dual	O
mechanisms	O
;	O
inhibition	O
of	O
a	O
select	O
set	O
of	O
c-Myb	O
regulated	O
targets	O
,	O
such	O
as	O
Bcl-2	O
and	O
CD13/APN	O
,	O
coupled	O
with	O
the	O
activation	O
of	O
as	O
yet	O
undefined	O
differentiation-promoting	O
genes	O
.	O

Nuclear	O
factor-kappaB-dependent	O
induction	O
of	O
interleukin-8	O
gene	O
expression	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
:	O
evidence	O
for	O
an	O
antioxidant	O
sensitive	O
activating	O
pathway	O
distinct	O
from	O
nuclear	O
translocation	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
is	O
a	O
pluripotent	O
activator	O
of	O
inflammation	O
by	O
inducing	O
a	O
proinflammatory	O
cytokine	O
cascade	O
.	O

This	O
phenomenon	O
is	O
mediated	O
,	O
in	O
part	O
,	O
through	O
inducible	O
expression	O
of	O
the	O
CXC	O
chemokine	O
,	O
interleukin-8	O
(	O
IL-8	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TNFalpha-inducible	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
IL-8	O
expression	O
by	O
``	O
monocyte-like	O
``	O
U937	O
histiocytic	O
lymphoma	O
cells	O
.	O

TNFalpha	O
is	O
a	O
rapid	O
activator	O
of	O
IL-8	O
gene	O
expression	O
by	O
U937	O
,	O
producing	O
a	O
50-fold	O
induction	O
of	O
mRNA	O
within	O
1	O
hour	O
of	O
treatment	O
.	O

In	O
gene	O
transfection	O
assays	O
,	O
the	O
effect	O
of	O
TNFalpha	O
requires	O
the	O
presence	O
of	O
an	O
inducible	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
(	O
Rel	O
A	O
)	O
binding	O
site	O
in	O
the	O
IL-8	O
promoter	O
.	O

TNFalpha	O
treatment	O
induces	O
a	O
rapid	O
translocation	O
of	O
the	O
65	O
kD	O
transcriptional	O
activator	O
NF-kappaB	O
subunit	O
,	O
Rel	O
A	O
,	O
whose	O
binding	O
in	O
the	O
nucleus	O
occurs	O
before	O
changes	O
in	O
intracellular	O
ROS	O
.	O

Pretreatment	O
(	O
or	O
up	O
to	O
15	O
minutes	O
posttreatment	O
)	O
relative	O
to	O
TNFalpha	O
with	O
the	O
antioxidant	O
dimethyl	O
sulfoxide	O
(	O
DMSO	O
)	O
(	O
2	O
%	O
[	O
vol/vol	O
]	O
)	O
blocks	O
80	O
%	O
of	O
NF-kappaB-dependent	O
transcription	O
.	O

Surprisingly	O
,	O
however	O
,	O
DMSO	O
has	O
no	B-Negation
effect	I-Negation
on	I-Negation
inducible	I-Negation
Rel	I-Negation
A	I-Negation
binding	I-Negation
.	O

Similar	O
selective	O
effects	O
on	O
NF-kappaB	O
transcription	O
are	O
seen	O
with	O
the	O
unrelated	O
antioxidants	O
,	O
N-acetylcysteine	O
(	O
NAC	O
)	O
and	O
vitamin	O
C	O
.	O

These	O
data	O
indicate	O
that	O
TNFalpha	O
induces	O
a	O
delayed	O
ROS-dependent	O
signalling	O
pathway	O
that	O
is	O
required	O
for	O
NF-kappaB	O
transcriptional	O
activation	O
and	O
is	O
separable	O
from	O
that	O
required	O
for	O
its	O
nuclear	O
translocation	O
.	O

Further	O
definition	O
of	O
this	O
pathway	O
will	O
yield	O
new	O
insights	O
into	O
inflammation	O
initiated	O
by	O
TNFalpha	O
signalling	O
.	O

Neutrophil	O
maturation	O
and	O
the	O
role	O
of	O
retinoic	O
acid	O
.	O

Neutrophil	O
maturation	O
occurs	O
in	O
well	O
defined	O
morphological	O
stages	O
that	O
correlate	O
with	O
the	O
acquisition	O
of	O
molecular	O
markers	O
associated	O
with	O
neutrophil	O
function	O
.	O

A	O
variety	O
of	O
factors	O
are	O
known	O
to	O
play	O
a	O
role	O
in	O
terminal	O
neutrophil	O
maturation	O
,	O
including	O
the	O
vitamin	O
A	O
derivative	O
,	O
retinoic	O
acid	O
.	O

Retinoic	O
acid	O
can	O
directly	O
modulate	O
gene	O
expression	O
via	O
binding	O
to	O
its	O
nuclear	O
receptors	O
,	O
which	O
can	O
,	O
in	O
turn	O
,	O
activate	O
transcription	O
of	O
target	O
genes	O
.	O

A	O
role	O
for	O
retinoic	O
acid	O
during	O
neutrophil	O
maturation	O
has	O
been	O
suggested	O
from	O
a	O
variety	O
of	O
sources	O
.	O

Here	O
we	O
present	O
a	O
review	O
of	O
the	O
mechanism	O
of	O
retinoic	O
acid	O
receptor	O
action	O
and	O
the	O
major	O
evidence	O
showing	O
that	O
normal	O
retinoid	O
signaling	O
is	O
required	O
for	O
neutrophil	O
maturation	O
.	O

Induction	O
of	O
Bcl-x	O
(	O
L	O
)	O
expression	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
through	O
NF-kappaB	O
in	O
apoptosis-resistant	O
T-cell	O
transfectants	O
with	O
Tax	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	O
is	O
thought	O
to	O
play	O
a	O
pivotal	O
role	O
in	O
immortalization	O
of	O
T	O
cells	O
.	O

We	O
have	O
recently	O
shown	O
that	O
the	O
expression	O
of	O
Tax	O
protected	O
the	O
mouse	O
T-cell	O
line	O
CTLL-2	O
against	O
apoptosis	O
induced	O
by	O
interleukin-2	O
(	O
IL-2	O
)	O
deprivation	O
and	O
converted	O
its	O
growth	O
from	O
being	O
IL-2	O
dependent	O
to	O
being	O
IL-2	O
independent	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
constitutive	O
expression	O
of	O
bcl-xl	O
but	O
not	B-Negation
bcl-2	I-Negation
,	I-Negation
bcl-xs	I-Negation
,	I-Negation
bak	I-Negation
,	I-Negation
bad	I-Negation
,	I-Negation
or	I-Negation
bax	I-Negation
was	O
associated	O
with	O
apoptosis	O
resistance	O
after	O
IL-2	O
deprivation	O
in	O
CTLL-2	O
cells	O
that	O
expressed	O
Tax	O
.	O

Transient-transfection	O
assays	O
showed	O
that	O
bcl-x	O
promoter	O
was	O
transactivated	O
by	O
wild-type	O
Tax	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
mutant	O
Tax	O
retaining	O
transactivating	O
ability	O
through	O
NF-kappaB	O
.	O

Deletion	O
or	O
substitution	O
of	O
a	O
putative	O
NF-kappaB	O
binding	O
site	O
identified	O
in	O
the	O
bcl-x	O
promoter	O
significantly	O
decreased	O
Tax-induced	O
transactivation	O
.	O

This	O
NF-kappaB-like	O
element	O
was	O
able	O
to	O
form	O
a	O
complex	O
with	O
NF-kappaB	O
family	O
proteins	O
in	O
vitro	O
.	O

Furthermore	O
,	O
Tax-induced	O
transactivation	O
of	O
the	O
bcl-x	O
promoter	O
was	O
also	O
diminished	O
by	O
the	O
mutant	O
IkappaBalpha	O
,	O
which	O
specifically	O
inhibits	O
NF-kappaB	O
activity	O
.	O

Our	O
findings	O
suggest	O
that	O
constitutive	O
expression	O
of	O
Bcl-x	O
(	O
L	O
)	O
induced	O
by	O
Tax	O
through	O
the	O
NF-kappaB	O
pathway	O
contributes	O
to	O
the	O
inhibition	O
of	O
apoptosis	O
in	O
CTLL-2	O
cells	O
after	O
IL-2	O
deprivation	O
.	O

Interferons	O
inhibit	O
activation	O
of	O
STAT6	O
by	O
interleukin	O
4	O
in	O
human	O
monocytes	O
by	O
inducing	O
SOCS-1	O
gene	O
expression	O
.	O

Interferons	O
(	O
IFNs	O
)	O
inhibit	O
induction	O
by	O
IL-4	O
of	O
multiple	O
genes	O
in	O
human	O
monocytes	O
.	O

However	O
,	O
the	B-Negation
mechanism	I-Negation
by	I-Negation
which	I-Negation
IFNs	I-Negation
mediate	I-Negation
this	I-Negation
inhibition	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
defined	I-Negation
.	O

IL-4	O
activates	O
gene	O
expression	O
by	O
inducing	O
tyrosine	O
phosphorylation	O
,	O
homodimerization	O
,	O
and	O
nuclear	O
translocation	O
of	O
the	O
latent	O
transcription	O
factor	O
,	O
STAT6	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-6	O
)	O
.	O

STAT6-responsive	O
elements	O
are	O
characteristically	O
present	O
in	O
the	O
promoters	O
of	O
IL-4-inducible	O
genes	O
.	O

Because	O
STAT6	O
activation	O
is	O
essential	O
for	O
IL-4-induced	O
gene	O
expression	O
,	O
we	O
examined	O
the	O
ability	O
of	O
type	O
I	O
and	O
type	O
II	O
IFNs	O
to	O
regulate	O
activation	O
of	O
STAT6	O
by	O
IL-4	O
in	O
primary	O
human	O
monocytes	O
.	O

Pretreatment	O
of	O
monocytes	O
with	O
IFN-beta	O
or	O
IFN-gamma	O
,	O
but	O
not	B-Negation
IL-1	I-Negation
,	I-Negation
IL-2	I-Negation
,	I-Negation
macrophage	I-Negation
colony-stimulating	I-Negation
factor	I-Negation
,	I-Negation
granulocyte/macrophage	I-Negation
colony-stimulating	I-Negation
factor	I-Negation
,	I-Negation
IL-6	I-Negation
,	I-Negation
or	I-Negation
transforming	I-Negation
growth	I-Negation
factor	I-Negation
beta	I-Negation
suppressed	O
activation	O
of	O
STAT6	O
by	O
IL-4	O
.	O

This	O
inhibition	O
was	O
associated	O
with	O
decreased	O
tyrosine	O
phosphorylation	O
and	O
nuclear	O
translocation	O
of	O
STAT6	O
and	O
was	O
not	B-Negation
evident	I-Negation
unless	O
the	O
cells	O
were	O
preincubated	O
with	O
IFN	O
for	O
at	O
least	O
1	O
hr	O
before	O
IL-4	O
stimulation	O
.	O

Furthermore	O
,	O
inhibition	O
by	O
IFN	O
could	O
be	O
blocked	O
by	O
cotreatment	O
with	O
actinomycin	O
D	O
and	O
correlated	O
temporally	O
with	O
induction	O
of	O
the	O
JAK/STAT	O
inhibitory	O
gene	O
,	O
SOCS-1	O
.	O

Forced	O
expression	O
of	O
SOCS-1	O
in	O
a	O
macrophage	O
cell	O
line	O
,	O
RAW264	O
,	O
markedly	O
suppressed	O
trans-activation	O
of	O
an	O
IL-4-inducible	O
reporter	O
as	O
well	O
as	O
IL-6-	O
and	O
IFN-gamma-induced	O
reporter	O
gene	O
activity	O
.	O

These	O
findings	O
demonstrate	O
that	O
IFNs	O
inhibit	O
IL-4-induced	O
activation	O
of	O
STAT6	O
and	O
STAT6-dependent	O
gene	O
expression	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
inducing	O
expression	O
of	O
SOCS-1	O
.	O

Increased	O
IkappaB	O
expression	O
and	O
diminished	O
nuclear	O
NF-kappaB	O
in	O
human	O
mononuclear	O
cells	O
following	O
hydrocortisone	O
injection	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
hydrocortisone	O
and	O
other	O
glucocorticoids	O
inhibit	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
by	O
mononuclear	O
(	O
MNC	O
)	O
and	O
polymorphonuclear	O
leucocytes	O
(	O
PMNL	O
)	O
.	O

Since	O
NF-kappaB/IkappaB	O
system	O
regulates	O
the	O
transcription	O
of	O
proinflammatory	O
genes	O
,	O
including	O
those	O
responsible	O
for	O
ROS	O
generation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
hydrocortisone	O
may	O
stimulate	O
IkappaB	O
production	O
thus	O
inhibiting	O
NF-kappaB	O
translocation	O
from	O
the	O
cytosol	O
into	O
the	O
nucleus	O
in	O
MNC	O
,	O
in	O
vivo	O
.	O

One	O
hundred	O
milligram	O
of	O
hydrocortisone	O
was	O
injected	O
intravenously	O
into	O
4	O
normal	O
subjects	O
.	O

Blood	O
samples	O
were	O
obtained	O
prior	O
to	O
the	O
injection	O
and	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
8	O
and	O
24	O
hr	O
after	O
the	O
injection	O
.	O

Nuclear	O
extracts	O
and	O
total	O
cell	O
lysates	O
were	O
prepared	O
from	O
MNC	O
by	O
standard	O
techniques	O
.	O

IkappaB	O
levels	O
in	O
MNC	O
homogenates	O
increased	O
at	O
1	O
hr	O
,	O
peaked	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
decrease	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

NF-kappaB	O
in	O
MNC	O
nuclear	O
extracts	O
decreased	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
gradually	O
increased	O
at	O
8	O
hr	O
and	O
returned	O
back	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

The	O
total	O
protein	O
content	O
of	O
NF-kappaB	O
subunit	O
(	O
P65	O
)	O
in	O
MNC	O
lysates	O
also	O
showed	O
a	O
decrease	O
following	O
hydrocortisone	O
injection	O
.	O

This	O
decrease	O
was	O
observed	O
at	O
2	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
4	O
hr	O
,	O
and	O
returned	O
to	O
baseline	O
levels	O
at	O
24	O
hr	O
.	O

ROS	O
generation	O
inhibition	O
paralleled	O
NF-kappaB	O
levels	O
in	O
the	O
nucleus	O
.	O

It	O
was	O
inhibited	O
at	O
1	O
hr	O
,	O
reached	O
a	O
nadir	O
at	O
2-4	O
hr	O
,	O
started	O
to	O
increase	O
at	O
8	O
hr	O
,	O
and	O
returned	O
to	O
basal	O
levels	O
at	O
24	O
hr	O
.	O

Our	O
data	O
demonstrate	O
that	O
hydrocortisone	O
induces	O
IkappaB	O
and	O
suppresses	O
NF-kappaB	O
expression	O
in	O
MNC	O
in	O
parallel	O
.	O

IkappaB	O
further	O
reduces	O
the	O
translocation	O
of	O
NF-kappaB	O
into	O
the	O
nucleus	O
thus	O
preventing	O
the	O
expression	O
of	O
proinflammatory	O
genes	O
.	O

Renal	O
cell	O
carcinoma-derived	O
gangliosides	O
suppress	O
nuclear	O
factor-kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
(	O
NFkappaB	O
)	O
is	O
impaired	O
in	O
T	O
cells	O
from	O
patients	O
with	O
renal	O
cell	O
carcinomas	O
(	O
RCCs	O
)	O
.	O

In	O
circulating	O
T	O
cells	O
from	O
a	O
subset	O
of	O
patients	O
with	O
RCCs	O
,	O
the	O
suppression	O
of	O
NFkappaB	O
binding	O
activity	O
is	O
downstream	O
from	O
the	O
stimulus-induced	O
degradation	O
of	O
the	O
cytoplasmic	O
factor	O
IkappaBalpha	O
.	O

Tumor-derived	O
soluble	O
products	O
from	O
cultured	O
RCC	O
explants	O
inhibit	O
NFkappaB	O
activity	O
in	O
T	O
cells	O
from	O
healthy	O
volunteers	O
,	O
despite	O
a	O
normal	O
level	O
of	O
stimulus-induced	O
IkappaBalpha	O
degradation	O
in	O
these	O
cells	O
.	O

The	O
inhibitory	O
agent	O
has	O
several	O
features	O
characteristic	O
of	O
a	O
ganglioside	O
,	O
including	O
sensitivity	O
to	O
neuraminidase	O
but	O
not	B-Negation
protease	I-Negation
treatment	O
;	O
hydrophobicity	O
;	O
and	O
molecular	O
weight	O
less	O
than	O
3	O
kDa	O
.	O

Indeed	O
,	O
we	O
detected	O
gangliosides	O
in	O
supernatants	O
from	O
RCC	O
explants	O
and	O
not	B-Negation
from	I-Negation
adjacent	I-Negation
normal	I-Negation
kidney	I-Negation
tissue	I-Negation
.	O

Gangliosides	O
prepared	O
from	O
RCC	O
supernatants	O
,	O
as	O
well	O
as	O
the	O
purified	O
bovine	O
gangliosides	O
G	O
(	O
m1	O
)	O
and	O
G	O
(	O
d1a	O
)	O
,	O
suppressed	O
NFkappaB	O
binding	O
activity	O
in	O
T	O
cells	O
and	O
reduced	O
expression	O
of	O
the	O
cytokines	O
IL-2	O
and	O
IFN-gamma	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
suggest	O
that	O
tumor-derived	O
gangliosides	O
may	O
blunt	O
antitumor	O
immune	O
responses	O
in	O
patients	O
with	O
RCCs	O
.	O

Affinity-driven	O
peptide	O
selection	O
of	O
an	O
NFAT	O
inhibitor	O
more	O
selective	O
than	O
cyclosporin	O
A	O
[	O
see	O
comments	O
]	O

The	O
flow	O
of	O
information	O
from	O
calcium-mobilizing	O
receptors	O
to	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
-dependent	O
genes	O
is	O
critically	O
dependent	O
on	O
interaction	O
between	O
the	O
phosphatase	O
calcineurin	O
and	O
the	O
transcription	O
factor	O
NFAT	O
.	O

A	O
high-affinity	O
calcineurin-binding	O
peptide	O
was	O
selected	O
from	O
combinatorial	O
peptide	O
libraries	O
based	O
on	O
the	O
calcineurin	O
docking	O
motif	O
of	O
NFAT	O
.	O

This	O
peptide	O
potently	O
inhibited	O
NFAT	O
activation	O
and	O
NFAT-dependent	O
expression	O
of	O
endogenous	O
cytokine	O
genes	O
in	O
T	O
cells	O
,	O
without	B-Negation
affecting	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
other	I-Negation
cytokines	I-Negation
that	I-Negation
require	I-Negation
calcineurin	I-Negation
but	I-Negation
not	I-Negation
NFAT	I-Negation
.	O

Substitution	O
of	O
the	O
optimized	O
peptide	O
sequence	O
into	O
the	O
natural	O
calcineurin	O
docking	O
site	O
increased	O
the	O
calcineurin	O
responsiveness	O
of	O
NFAT	O
.	O

Compounds	O
that	O
interfere	O
selectively	O
with	O
the	O
calcineurin-NFAT	O
interaction	O
without	B-Negation
affecting	I-Negation
calcineurin	I-Negation
phosphatase	I-Negation
activity	I-Negation
may	B-Speculation
be	I-Speculation
useful	I-Speculation
as	I-Speculation
therapeutic	I-Speculation
agents	I-Speculation
that	I-Speculation
are	I-Speculation
less	I-Speculation
toxic	I-Speculation
than	I-Speculation
current	I-Speculation
drugs	I-Speculation
.	O

NF-X2	O
that	O
binds	O
to	O
the	O
DRA	O
X2-box	O
is	O
activator	O
protein	O
1	O
.	O

Expression	O
cloning	O
of	O
c-Jun	O
.	O

Human	O
class	O
II	O
MHC	O
Ag	O
are	O
a	O
family	O
of	O
cell	O
surface	O
glycoproteins	O
.	O

Their	O
constitutive	O
expression	O
is	O
limited	O
to	O
B	O
lymphocytes	O
and	O
thymic	O
epithelial	O
cells	O
.	O

In	O
many	O
other	O
cells	O
their	O
expression	O
can	O
be	O
induced	O
by	O
IFN-gamma	O
.	O

Conserved	O
upstream	O
promoter	O
sequences	O
regulate	O
this	O
tissue-specific	O
expression	O
of	O
class	O
II	O
genes	O
.	O

In	O
the	O
DRA	O
promoter	O
,	O
one	O
of	O
these	O
cis-acting	O
regulatory	O
motifs	O
is	O
the	O
X2-box	O
to	O
which	O
nuclear	O
factor	O
X2	O
(	O
NF-X2	O
)	O
binds	O
.	O

Here	O
,	O
we	O
present	O
the	O
isolation	O
and	O
characterization	O
of	O
the	O
full-length	O
cDNA	O
clone	O
encoding	O
NF-X2	O
.	O

This	O
cDNA	O
clone	O
was	O
isolated	O
by	O
expression	O
cDNA	O
cloning	O
,	O
and	O
encodes	O
the	O
human	O
c-Jun	O
protein	O
,	O
which	O
together	O
with	O
c-Fos	O
forms	O
the	O
heterodimeric	O
activator	O
protein-1	O
transcription	O
complex	O
.	O

Whereas	O
c-Fos/c-Jun	O
heterodimers	O
do	O
not	B-Negation
exist	I-Negation
in	I-Negation
B	I-Negation
cells	I-Negation
,	O
they	O
form	O
and	O
bind	O
to	O
the	O
X2-box	O
in	O
class	O
II	O
nonexpressing	O
cells	O
.	O

Thus	O
,	O
c-Fos/c-Jun	O
heterodimers	O
might	O
contribute	O
to	O
the	O
repression	O
of	O
DRA	O
gene	O
expression	O
.	O

Suppression	O
of	O
signals	O
required	O
for	O
activation	O
of	O
transcription	O
factor	O
NF-kappa	O
B	O
in	O
cells	O
constitutively	O
expressing	O
the	O
HTLV-I	O
Tax	O
protein	O
.	O

Transient	O
short-term	O
expression	O
of	O
the	O
Tax	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type-I	O
(	O
HTLV-I	O
)	O
leads	O
to	O
activation	O
of	O
the	O
pleiotropic	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

Consistent	O
with	O
findings	O
obtained	O
with	O
transient	O
expression	O
assays	O
,	O
we	O
observed	O
marked	O
accumulation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
in	O
the	O
nucleus	O
of	O
Namalwa	O
B	O
lymphoid	O
cells	O
,	O
which	O
constitutively	O
express	O
Tax	O
.	O

In	O
contrast	O
,	O
NF-kappa	B-Negation
B	I-Negation
activity	I-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
the	I-Negation
nucleus	I-Negation
following	I-Negation
long-term	I-Negation
expression	I-Negation
of	I-Negation
Tax	I-Negation
in	I-Negation
Jurkat	I-Negation
T	I-Negation
lymphocytes	I-Negation
.	O

The	O
ability	O
of	O
both	O
mitogens	O
and	O
cytokines	O
to	O
activate	O
NF-kappa	O
B	O
was	O
also	O
blocked	O
in	O
Jurkat	O
cells	O
constitutively	O
expressing	O
Tax	O
.	O

However	O
,	O
the	O
activation	O
of	O
other	O
mitogen-inducible	O
transcription	O
factors	O
,	O
such	O
as	O
Fos	O
and	O
Jun	O
,	O
was	O
unaffected	O
.	O

Thus	O
,	O
depending	O
on	O
the	O
cellular	O
environment	O
,	O
the	O
short-	O
and	O
long-term	O
effects	O
of	O
Tax	O
expression	O
can	O
be	O
quite	O
different	O
.	O

Consequently	O
,	O
one	O
function	O
of	O
Tax	O
in	O
cells	O
infected	O
with	O
HTLV-I	O
might	O
involve	O
cell-type-specific	O
suppression	O
,	O
as	O
opposed	O
to	O
activation	O
,	O
of	O
distinct	O
signal	O
pathways	O
.	O

The	O
cells	O
lines	O
described	O
here	O
should	O
be	O
useful	O
for	O
the	O
delineation	O
of	O
signaling	O
pathways	O
utilized	O
in	O
the	O
selective	O
regulation	O
of	O
gene	O
expression	O
.	O

Stimulation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
gene	O
expression	O
by	O
the	O
cytomegalovirus	O
and	O
HIV-2	O
transactivator	O
gene	O
.	O

Human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
often	O
causes	O
latent	O
infection	O
.	O

Transactivation	O
by	O
some	O
DNA	O
viruses	O
has	O
been	O
implicated	O
in	O
inducing	O
HIV-1	O
replication	O
and	O
pathogenesis	O
.	O

The	O
transactivator	O
(	O
IE-2	O
)	O
gene	O
of	O
the	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
enhance	O
HIV-2	O
as	O
well	O
as	O
HIV-1	O
gene	O
expression	O
in	O
vitro	O
.	O

This	O
inducer	O
can	O
act	O
in	O
concert	O
with	O
the	O
HIV-2	O
tat	O
gene	O
and	O
T-cell	O
activation	O
in	O
enhancing	O
gene	O
expression	O
in	O
human	O
CD4+	O
lymphocytes	O
.	O

While	O
the	O
HIV-2	O
and	O
HIV-1	O
tat	O
genes	O
and	O
T-cell	O
activators	O
apparently	O
employ	O
independent	O
modes	O
of	O
action	O
,	O
the	O
CMV	O
transactivator	O
in	O
combination	O
with	O
the	O
HIV-2	O
tat	O
or	O
T-cell	O
activators	O
may	O
employ	O
a	O
gene	O
activation	O
pathway	O
with	O
some	O
common	O
and	O
some	O
distinct	O
components	O
.	O

Both	O
HIV-2	O
and	O
CMV	O
transactivators	O
enhance	O
HIV-2	O
gene	O
expression	O
by	O
transcriptional	O
activation	O
involving	O
transcript	O
initiation	O
as	O
well	O
as	O
elongation	O
,	O
with	O
CMV	O
transactivator	O
affecting	O
elongation	O
more	O
than	O
the	O
initiation	O
.	O

A	O
significant	O
proportion	O
of	O
transcripts	O
appear	O
to	O
terminate	O
prematurely	O
in	O
the	O
absence	O
of	O
transactivators	O
.	O

Deletion	O
mutation	O
analysis	O
of	O
the	O
HIV-2	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
suggests	O
that	O
the	O
element	O
that	O
responds	O
to	O
CMV	O
transactivation	O
in	O
human	O
CD4+	O
lymphocytes	O
is	O
either	O
a	O
diffuse	O
one	O
or	O
located	O
downstream	O
of	O
the	O
HIV-2	O
enhancer	O
element	O
.	O

Human	O
immunodeficiency	O
virus	O
type-2	O
gene	O
expression	O
:	O
two	O
enhancers	O
and	O
their	O
activation	O
by	O
T-cell	O
activators	O
.	O

The	O
human	O
immunodeficiency	O
viruses	O
(	O
HIVs	O
)	O
may	O
include	O
a	O
spectrum	O
of	O
retroviruses	O
with	O
varying	O
potential	O
to	O
infect	O
their	O
host	O
,	O
undergo	O
long	O
periods	O
of	O
latent	O
infection	O
,	O
and	O
induce	O
pathology	O
.	O

Since	O
expression	O
of	O
the	O
viruses	O
is	O
in	O
large	O
part	O
regulated	O
by	O
the	O
sequence	O
elements	O
in	O
their	O
long	O
terminal	O
repeats	O
(	O
LTRs	O
)	O
,	O
this	O
study	O
was	O
directed	O
to	O
an	O
analysis	O
of	O
the	O
regulatory	O
elements	O
in	O
the	O
HIV-2	O
LTR	O
.	O

The	O
HIV-2	O
LTR	O
was	O
found	O
to	O
contain	O
two	O
enhancers	O
.	O

One	O
of	O
these	O
enhancers	O
is	O
,	O
in	O
part	O
,	O
identical	O
to	O
the	O
HIV-1	O
enhancer	O
.	O

This	O
enhancer	O
in	O
HIV-1	O
is	O
the	O
T-cell	O
activation	O
response	O
element	O
;	O
in	O
HIV-2	O
,	O
however	O
,	O
it	O
is	O
the	O
second	O
enhancer	O
that	O
is	O
mainly	O
responsible	O
for	O
activation	O
in	O
response	O
to	O
T-cell	O
activators	O
.	O

The	O
second	O
enhancer	O
interacts	O
with	O
two	O
nuclear	O
binding	O
proteins	O
(	O
85	O
kD	O
and	O
27	O
kD	O
mobility	O
)	O
that	O
appear	O
to	O
be	O
required	O
for	O
optimal	O
enhancer	O
function	O
and	O
activation	O
.	O

Observations	O
such	O
as	O
these	O
encourage	O
the	O
speculation	O
that	O
there	O
may	O
be	O
subtle	O
differences	O
in	O
the	O
regulation	O
of	O
HIV-1	O
and	O
HIV-2	O
expression	O
that	O
may	O
be	O
relevant	O
to	O
the	O
possible	O
longer	O
latency	O
and	O
reduced	O
pathogenicity	O
of	O
HIV-2	O
.	O

Purification	O
of	O
TCF-1	O
alpha	O
,	O
a	O
T-cell-specific	O
transcription	O
factor	O
that	O
activates	O
the	O
T-cell	O
receptor	O
C	O
alpha	O
gene	O
enhancer	O
in	O
a	O
context-dependent	O
manner	O
.	O

The	O
differentiation	O
of	O
T	O
cells	O
into	O
functionally	O
diverse	O
subpopulations	O
is	O
controlled	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
and	O
silencing	O
;	O
however	O
,	O
little	O
is	O
known	O
in	O
detail	O
about	O
the	O
proteins	O
that	O
influence	O
this	O
developmental	O
process	O
.	O

We	O
have	O
purified	O
a	O
new	O
T-cell-specific	O
factor	O
,	O
TCF-1	O
alpha	O
,	O
that	O
is	O
implicated	O
in	O
the	O
activation	O
of	O
genes	O
encoding	O
a	O
major	O
component	O
of	O
the	O
human	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
.	O

TCF-1	O
alpha	O
,	O
originally	O
identified	O
and	O
purified	O
through	O
its	O
binding	O
sites	O
on	O
the	O
HIV-1	O
promoter	O
,	O
was	O
found	O
to	O
bind	O
to	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
to	O
promoters	O
for	O
several	O
genes	O
expressed	O
at	O
significantly	O
earlier	O
stages	O
of	O
T-cell	O
development	O
than	O
the	O
TCR	O
alpha	O
gene	O
(	O
e.g.	O
,	O
p56lck	O
and	O
CD3	O
delta	O
)	O
.	O

Sequences	O
related	O
to	O
the	O
TCF-1	O
alpha	O
binding	O
motif	O
(	O
5'-GGCACCCTTTGA-3	O
'	O
)	O
are	O
also	O
found	O
in	O
the	O
human	O
TCR	O
delta	O
(	O
and	O
possibly	O
TCR	O
beta	O
)	O
enhancers	O
.	O

Southwestern	O
and	O
gel	O
renaturation	O
experiments	O
with	O
the	O
use	O
of	O
purified	O
protein	O
fractions	O
revealed	O
that	O
TCF-1	O
alpha	O
activity	O
is	O
derived	O
from	O
a	O
family	O
of	O
57-	O
to	O
53-kD	O
proteins	O
that	O
are	O
abundantly	O
expressed	O
in	O
mature	O
and	O
immature	O
T-cell	O
lines	O
(	O
Jurkat	O
,	O
CCRF-CEM	O
)	O
and	O
not	B-Negation
in	I-Negation
mature	I-Negation
B	I-Negation
cells	I-Negation
(	I-Negation
JY	I-Negation
,	I-Negation
Namalwa	I-Negation
)	I-Negation
or	I-Negation
nonlymphoid	I-Negation
(	I-Negation
HeLa	I-Negation
)	I-Negation
cell	I-Negation
lines	I-Negation
.	O

A	O
small	O
95-bp	O
fragment	O
of	O
the	O
TCR	O
alpha	O
control	O
region	O
that	O
contains	O
the	O
TCF-1	O
alpha	O
binding	O
site	O
juxtaposed	O
between	O
a	O
cAMP-response	O
element	O
(	O
the	O
CRE	O
or	O
T	O
alpha	O
1	O
motif	O
)	O
and	O
the	O
binding	O
site	O
for	O
a	O
distinct	O
lymphoid-specific	O
protein	O
(	O
TCF-2	O
alpha	O
)	O
behaved	O
as	O
a	O
potent	O
T-cell-specific	O
enhancer	O
in	O
vivo	O
.	O

Tandem	O
copies	O
of	O
this	O
enhancer	O
functioned	O
synergistically	O
in	O
mature	O
(	O
Jurkat	O
)	O
T-cell	O
lines	O
as	O
well	O
as	O
resting	O
and	O
activated	O
immature	O
(	O
CCRF-CEM	O
)	O
T-cell	O
lines	O
.	O

Mutation	O
of	O
the	O
TCF-1	O
alpha	O
binding	O
site	O
diminished	O
enhancer	O
activity	O
and	O
disrupted	O
the	O
synergism	O
observed	O
in	O
vivo	O
between	O
tandem	O
enhancer	O
repeats	O
.	O

The	O
TCF-1	O
alpha	O
binding	O
site	O
was	O
also	O
required	O
for	O
TCR	O
alpha	O
enhancer	O
activity	O
in	O
transcriptionally	O
active	O
extracts	O
from	O
Jurkat	O
but	O
not	B-Negation
HeLa	I-Negation
cells	I-Negation
,	O
confirming	O
that	O
TCF-1	O
alpha	O
is	O
a	O
T-cell-specific	O
transcription	O
factor	O
.	O

Curiously	O
,	O
the	O
TCF-1	O
alpha	O
binding	O
element	O
was	O
inactive	O
in	O
vivo	O
when	O
removed	O
from	O
its	O
neighboring	O
elements	O
on	O
the	O
TCR	O
alpha	O
enhancer	O
and	O
positioned	O
in	O
one	O
or	O
more	O
copies	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
.	O

Thus	O
,	O
the	O
transcriptional	O
activity	O
of	O
TCF-1	O
alpha	O
appears	O
to	O
depend	O
on	O
the	O
TCF-2	O
alpha	O
and	O
T	O
alpha	O
1	O
(	O
CREB	O
)	O
transcription	O
factors	O
and	O
the	O
context	O
of	O
its	O
binding	O
site	O
within	O
the	O
TCR	O
alpha	O
enhancer	O
.	O

A	O
novel	O
T-cell	O
trans-activator	O
that	O
recognizes	O
a	O
phorbol	O
ester-inducible	O
element	O
of	O
the	O
interleukin-2	O
promoter	O
.	O

The	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
promoter	O
is	O
recognized	O
by	O
several	O
cell-type-specific	O
and	O
ubiquitous	O
transcriptional	O
regulators	O
that	O
integrate	O
information	O
transmitted	O
by	O
various	O
signaling	O
systems	O
leading	O
to	O
IL-2	O
production	O
and	O
T-cell	O
activation	O
.	O

Using	O
a	O
combination	O
of	O
transfection	O
,	O
protein-DNA	O
binding	O
,	O
and	O
in	O
vitro	O
transcription	O
methods	O
,	O
we	O
have	O
discovered	O
the	O
novel	O
T-cell-specific	O
transcriptional	O
activator	O
TCF-1	O
(	O
for	O
T-Cell	O
Factor-1	O
)	O
,	O
which	O
recognizes	O
a	O
T-cell-specific	O
response	O
element	O
(	O
TCE	O
)	O
located	O
within	O
the	O
IL-2	O
promoter	O
.	O

Although	O
the	O
TCE	O
is	O
similar	O
in	O
sequence	O
to	O
a	O
consensus	O
NF	O
kappa	O
B	O
site	O
,	O
several	O
criteria	O
indicate	O
that	O
TCF-1	O
is	O
distinct	O
from	O
NF	O
kappa	O
B	O
.	O

However	O
,	O
like	O
NF	O
kappa	O
B	O
,	O
TCF-1	O
activity	O
is	O
induced	O
by	O
phorbol	O
esters	O
and	O
other	O
T-cell	O
activators	O
.	O

Two	O
distinct	O
transcription	O
factors	O
that	O
bind	O
the	O
immunoglobulin	O
enhancer	O
microE5/kappa	O
2	O
motif	O
.	O

Activity	O
of	O
the	O
immunoglobulin	O
heavy	O
and	O
kappa	O
light	O
chain	O
gene	O
enhancers	O
depends	O
on	O
a	O
complex	O
interplay	O
of	O
ubiquitous	O
and	O
developmentally	O
regulated	O
proteins	O
.	O

Two	O
complementary	O
DNAs	O
were	O
isolated	O
that	O
encode	O
proteins	O
,	O
denoted	O
ITF-1	O
and	O
ITF-2	O
,	O
that	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
cell	O
types	O
and	O
bind	O
the	O
microE5/kappa	O
2	O
motif	O
found	O
in	O
both	O
heavy	O
and	O
kappa	O
light	O
chain	O
enhancers	O
.	O

The	O
complementary	O
DNAs	O
are	O
the	O
products	O
of	O
distinct	O
genes	O
,	O
yet	O
both	O
ITF-1	O
and	O
ITF-2	O
are	O
structurally	O
and	O
functionally	O
similar	O
.	O

The	O
two	O
proteins	O
interact	O
with	O
one	O
another	O
through	O
their	O
putative	O
helix-loop-helix	O
motifs	O
and	O
each	O
possesses	O
a	O
distinct	O
domain	O
that	O
dictates	O
transcription	O
activation	O
.	O

A	O
factor	O
known	O
to	O
bind	O
to	O
endogenous	O
Ig	O
heavy	O
chain	O
enhancer	O
only	O
in	O
lymphocytes	O
is	O
a	O
ubiquitously	O
active	O
transcription	O
factor	O
.	O

The	O
transcriptional	O
enhancer	O
located	O
in	O
the	O
first	O
intron	O
of	O
the	O
immunoglobulin	O
heavy	O
chain	O
constant	O
region	O
is	O
a	O
major	O
determinant	O
of	O
B-cell-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
.	O

Like	O
other	O
enhancers	O
,	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
contains	O
several	O
short	O
sequence	O
motifs	O
that	O
bind	O
specific	O
transcription	O
factors	O
.	O

Each	O
binding	O
site	O
contributes	O
to	O
the	O
overall	O
activity	O
of	O
the	O
enhancer	O
,	O
however	O
no	B-Negation
single	I-Negation
element	I-Negation
seems	B-Speculation
absolutely	I-Speculation
required	I-Speculation
for	I-Speculation
activity	I-Speculation
.	O

For	O
a	O
better	O
understanding	O
of	O
the	O
Ig	O
heavy	O
chain	O
enhancer	O
components	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
individual	O
sequence	O
elements	O
.	O

We	O
find	O
that	O
the	O
factor	O
that	O
binds	O
to	O
the	O
E3	O
enhancer	O
motif	O
,	O
CATGTGGC	O
,	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
.	O

It	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
both	O
B	O
cells	O
and	O
non-B	O
cells	O
,	O
where	O
it	O
can	O
mediate	O
transcriptional	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

However	O
,	O
despite	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
a	O
transfected	O
reporter	O
gene	O
,	O
the	B-Speculation
factor	I-Speculation
is	I-Speculation
apparently	I-Speculation
unable	B-Negation
to	I-Negation
bind	I-Negation
to	I-Negation
the	I-Negation
endogenous	I-Negation
Ig	I-Negation
heavy	I-Negation
chain	I-Negation
enhancer	I-Negation
in	I-Negation
non-lymphoid	I-Negation
cells	I-Negation
:	O
In	O
previous	O
experiments	O
by	O
others	O
,	O
the	O
characteristic	O
in	O
vivo	O
footprint	O
of	O
this	O
factor	O
,	O
designated	O
NF-muE3	O
,	O
was	O
detected	O
in	O
B	O
cells	O
but	O
not	B-Negation
in	I-Negation
non-B	I-Negation
cells	I-Negation
.	O

From	O
this	O
and	O
other	O
findings	O
the	O
picture	O
emerges	O
that	O
there	O
are	O
at	O
least	O
three	O
categories	O
of	O
factors	O
which	O
mediate	O
cell-type-specific	O
transcription	O
in	O
B	O
lymphocytes	O
:	O
(	O
a	O
)	O
cell-specific	O
factors	O
such	O
as	O
Oct-2A	O
and	O
Oct-2B	O
that	B-Negation
are	I-Negation
not	I-Negation
expressed	I-Negation
in	I-Negation
most	I-Negation
other	I-Negation
cell	I-Negation
types	I-Negation
:	O
(	O
b	O
)	O
ubiquitous	O
factors	O
such	O
as	O
NF-kappa	O
B	O
that	O
are	O
constitutively	O
active	O
in	O
B	O
cells	O
but	O
are	O
sequestered	O
in	O
an	O
inactive	O
form	O
in	O
other	O
cells	O
;	O
(	O
c	O
)	O
ubiquitously	O
active	O
factors	O
,	O
exemplified	O
by	O
the	O
one	O
binding	O
to	O
the	O
E3	O
sequence	O
motif	O
.	O

This	O
factor	O
is	O
present	O
in	O
an	O
active	O
form	O
in	O
a	O
variety	O
of	O
cell	O
types	O
but	O
is	B-Speculation
apparently	I-Speculation
unable	B-Negation
to	I-Negation
bind	I-Negation
to	I-Negation
the	I-Negation
endogenous	I-Negation
Ig	I-Negation
heavy	I-Negation
chain	I-Negation
enhancer	I-Negation
in	I-Negation
non-B	I-Negation
cells	I-Negation
,	O
perhaps	B-Speculation
due	I-Speculation
to	I-Speculation
a	I-Speculation
non-permissive	I-Speculation
chromatin	I-Speculation
structure	I-Speculation
of	I-Speculation
the	I-Speculation
Ig	I-Speculation
heavy	I-Speculation
chain	I-Speculation
locus	I-Speculation
.	O

Transcriptional	O
and	O
post-transcriptional	O
regulation	O
of	O
c-jun	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
human	O
myeloid	O
leukemic	O
cells	O
.	O

AP-1	O
,	O
the	O
polypeptide	O
product	O
of	O
c-jun	O
,	O
recognizes	O
and	O
binds	O
to	O
specific	O
DNA	O
sequences	O
and	O
stimulates	O
transcription	O
of	O
genes	O
responsive	O
to	O
certain	O
growth	O
factors	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
.	O

We	O
studied	O
the	O
effects	O
of	O
TPA	O
on	O
the	O
regulation	O
of	O
c-jun	O
gene	O
expression	O
in	O
HL-60	O
cells	O
during	O
monocytic	O
differentiation	O
.	O

Low	O
levels	O
of	O
c-jun	O
transcripts	O
were	O
detectable	O
in	O
untreated	O
HL-60	O
leukemic	O
cells	O
,	O
increased	O
significantly	O
by	O
6	O
h	O
,	O
and	O
reached	O
near	O
maximal	O
levels	O
by	O
24	O
h	O
of	O
exposure	O
to	O
32	O
nM	O
TPA	O
.	O

Similar	O
kinetics	O
of	O
c-jun	O
induction	O
by	O
TPA	O
were	O
observed	O
in	O
human	O
U-937	O
and	O
THP-1	O
monocytic	O
leukemia	O
cells	O
.	O

Similar	O
findings	O
were	O
obtained	O
with	O
bryostatin	O
1	O
(	O
10	O
nM	O
)	O
,	O
another	O
activator	O
of	O
protein	O
kinase	O
C	O
and	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

Furthermore	O
,	O
1,25-dihydroxyvitamin	O
D3	O
(	O
0.5	O
microM	O
)	O
,	O
a	O
structurally	O
distinct	O
agent	O
which	O
also	O
induces	O
HL-60	O
monocytic	O
differentiation	O
,	O
increased	O
c-jun	O
expression	O
.	O

TPA	O
treatment	O
of	O
HL-60	O
cells	O
in	O
the	O
presence	O
of	O
cycloheximide	O
was	O
associated	O
with	O
superinduction	O
of	O
c-jun	O
transcripts	O
.	O

Run-on	O
analysis	O
demonstrated	O
detectable	O
levels	O
of	O
c-jun	O
gene	O
transcription	O
in	O
untreated	O
HL-60	O
cells	O
,	O
and	O
that	O
exposure	O
to	O
TPA	O
increases	O
this	O
rate	O
3.3-fold	O
.	O

Treatment	O
of	O
HL-60	O
cells	O
with	O
both	O
TPA	O
and	O
cycloheximide	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
rates	I-Negation
of	I-Negation
c-jun	I-Negation
transcription	I-Negation
.	O

The	O
half-life	O
of	O
c-jun	O
RNA	O
as	O
determined	O
by	O
treating	O
HL-60	O
cells	O
with	O
TPA	O
and	O
actinomycin	O
D	O
was	O
30	O
min	O
.	O

In	O
contrast	O
,	O
the	O
half-life	O
of	O
c-jun	O
RNA	O
in	O
TPA-treated	O
HL-60	O
cells	O
exposed	O
to	O
cycloheximide	O
and	O
actinomycin	O
D	O
was	O
greater	O
than	O
2	O
h	O
.	O

These	O
findings	O
suggested	O
that	O
the	O
increase	O
in	O
c-jun	O
RNA	O
observed	O
during	O
TPA-induced	O
monocytic	O
differentiation	O
is	O
mediated	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

Identification	O
of	O
a	O
novel	O
factor	O
that	O
interacts	O
with	O
an	O
immunoglobulin	O
heavy-chain	O
promoter	O
and	O
stimulates	O
transcription	O
in	O
conjunction	O
with	O
the	O
lymphoid	O
cell-specific	O
factor	O
OTF2	O
.	O

The	O
tissue-specific	O
expression	O
of	O
the	O
MOPC	O
141	O
immunoglobulin	O
heavy-chain	O
gene	O
was	O
studied	O
by	O
using	O
in	O
vitro	O
transcription	O
.	O

B-cell-specific	O
transcription	O
of	O
this	O
gene	O
was	O
dependent	O
on	O
the	O
octamer	O
element	O
5'-ATGCAAAG-3	O
'	O
,	O
located	O
in	O
the	O
upstream	O
region	O
of	O
this	O
promoter	O
and	O
in	O
the	O
promoters	O
of	O
all	O
other	O
immunoglobulin	O
heavy-	O
and	O
light-chain	O
genes	O
.	O

The	O
interaction	O
of	O
purified	O
octamer	O
transcription	O
factors	O
1	O
and	O
2	O
(	O
OTF1	O
and	O
OTF2	O
)	O
with	O
the	O
MOPC	O
141	O
promoter	O
was	O
studied	O
by	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
.	O

Purified	O
OTF1	O
from	O
HeLa	O
cells	O
and	O
OTF1	O
and	O
OTF2	O
from	O
B	O
cells	O
bound	O
to	O
identical	O
sequences	O
within	O
the	O
heavy-chain	O
promoter	O
.	O

The	O
OTF	O
interactions	O
we	O
observed	O
extended	O
over	O
the	O
heptamer	O
element	O
5'-CTCAGGA-3	O
'	O
,	O
and	O
it	O
seems	O
likely	O
that	O
the	O
binding	O
of	O
the	O
purified	O
factors	O
involves	O
cooperation	O
between	O
octamer	O
and	O
heptamer	O
sites	O
in	O
this	O
promoter	O
.	O

In	O
addition	O
to	O
these	O
elements	O
,	O
we	O
identified	O
a	O
second	O
regulatory	O
element	O
,	O
the	O
N	O
element	O
with	O
the	O
sequence	O
5'-GGAACCTCCCCC-3	O
'	O
.	O

The	O
N	O
element	O
could	O
independently	O
mediate	O
low	O
levels	O
of	O
transcription	O
in	O
both	O
B-cell	O
and	O
HeLa-cell	O
extracts	O
,	O
and	O
,	O
in	O
conjunction	O
with	O
the	O
octamer	O
element	O
,	O
it	O
can	O
promote	O
high	O
levels	O
of	O
transcription	O
in	O
B-cell	O
extracts	O
.	O

The	O
N	O
element	O
bound	O
a	O
transcription	O
factor	O
,	O
NTF	O
,	O
that	O
is	O
ubiquitous	O
in	O
cell-type	O
distribution	O
,	O
and	O
NTF	O
was	O
distinct	O
from	O
any	O
of	O
the	O
previously	O
described	O
proteins	O
that	O
bind	O
to	O
similar	O
sequences	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
NTF	O
and	O
OTF2	O
interactions	O
(	O
both	O
with	O
their	O
cognate	O
DNA	O
elements	O
and	O
possibly	O
at	O
the	O
protein-protein	O
level	O
)	O
may	O
be	O
critical	O
to	O
B-cell-specific	O
expression	O
and	O
that	O
these	O
interactions	O
provide	O
additional	O
pathways	O
for	O
regulating	O
gene	O
expression	O
.	O

Involvement	O
of	O
a	O
second	O
lymphoid-specific	O
enhancer	O
element	O
in	O
the	O
regulation	O
of	O
immunoglobulin	O
heavy-chain	O
gene	O
expression	O
.	O

To	O
determine	O
whether	O
enhancer	O
elements	O
in	O
addition	O
to	O
the	O
highly	O
conserved	O
octamer	O
(	O
OCTA	O
)	O
-nucleotide	O
motif	O
are	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
immunoglobulin	O
heavy-chain	O
(	O
IgH	O
)	O
gene	O
,	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
mutating	O
the	O
binding	O
site	O
for	O
a	O
putative	O
additional	O
lymphoid-specific	O
transcription	O
factor	O
,	O
designated	O
NF-microB	O
,	O
in	O
the	O
murine	O
IgH	O
enhancer	O
.	O

We	O
demonstrate	O
that	O
the	O
NF-microB-binding	O
site	O
plays	O
a	O
critical	O
role	O
in	O
the	O
IgH	O
enhancer	O
,	O
because	O
mutation	O
of	O
the	O
microB	O
DNA	O
motif	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
IgH	O
enhancer	O
in	O
cells	O
of	O
the	O
B-cell	O
lineage	O
but	O
not	B-Negation
in	I-Negation
nonlymphoid	I-Negation
cells	I-Negation
.	O

This	O
effect	O
was	O
comparable	O
to	O
or	O
even	O
stronger	O
than	O
the	O
effect	O
of	O
a	O
mutation	O
in	O
the	O
OCTA	O
site	O
.	O

Moreover	O
,	O
combined	O
mutation	O
of	O
both	O
microB	O
and	O
OCTA	O
sites	O
further	O
reduced	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
.	O

Interestingly	O
,	O
alteration	O
of	O
either	O
the	O
microB	O
or	O
E3	O
site	O
in	O
a	O
70-base-pair	O
fragment	O
of	O
the	O
IgH	O
enhancer	O
that	O
lacks	B-Negation
the	I-Negation
binding	I-Negation
site	I-Negation
for	I-Negation
OCTA	I-Negation
abolished	O
enhancer	O
activity	O
in	O
lymphoid	O
cells	O
completely	O
.	O

Nevertheless	O
,	O
a	O
multimer	O
of	O
the	O
microB	O
motif	O
alone	O
showed	O
no	B-Negation
enhancer	I-Negation
activity	I-Negation
.	O

DNase	O
footprinting	O
analysis	O
corroborated	O
the	O
functional	O
data	O
showing	O
that	O
a	O
lymphoid-specific	O
protein	O
binds	O
to	O
the	O
microB	O
DNA	O
motif	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
microB	O
element	O
is	O
a	O
new	O
crucial	O
element	O
important	O
for	O
lymphoid-specific	O
expression	O
of	O
the	O
IgH	O
gene	O
but	O
that	O
interaction	O
with	O
another	O
enhancer	O
element	O
is	O
essential	O
for	O
its	O
activity	O
.	O

The	O
expression	O
of	O
c-fos	O
,	O
c-jun	O
,	O
and	O
c-myc	O
genes	O
is	O
regulated	O
by	O
heat	O
shock	O
in	O
human	O
lymphoid	O
cells	O
.	O

The	O
effect	O
of	O
heat	O
shock	O
on	O
the	O
expression	O
of	O
the	O
nuclear	O
protooncogenes	O
c-fos	O
,	O
c-jun	O
,	O
and	O
c-myc	O
was	O
studied	O
in	O
human	O
lymphoid	O
cells	O
.	O

Heat	O
shock	O
caused	O
an	O
increase	O
in	O
c-fos	O
and	O
c-jun	O
mRNA	O
levels	O
and	O
a	O
decrease	O
in	O
c-myc	O
mRNA	O
levels	O
in	O
pre-B	O
(	O
Hyon	O
)	O
and	O
T	O
(	O
DND-41	O
)	O
cell	O
lines	O
as	O
well	O
as	O
in	O
freshly	O
isolated	O
normal	O
human	O
thymocytes	O
.	O

The	O
changes	O
in	O
the	O
mRNA	O
levels	O
of	O
these	O
protooncogenes	O
in	O
Hyon	O
cells	O
were	O
most	O
pronounced	O
at	O
42	O
and	O
43	O
degrees	O
C	O
;	O
kinetic	O
analysis	O
demonstrated	O
that	O
the	O
changes	O
could	O
be	O
detected	O
within	O
30	O
min	O
of	O
heat	O
shock	O
.	O

Altered	O
transcription	O
of	O
c-fos	O
and	O
c-myc	O
genes	O
was	O
the	O
primary	O
effect	O
of	O
heat	O
shock	O
.	O

Secondarily	O
,	O
heat	O
shock	O
of	O
Hyon	O
cells	O
stabilized	O
the	O
c-myc	O
mRNA	O
level	O
by	O
increasing	O
its	O
half-life	O
from	O
24	O
to	O
45	O
min	O
.	O

The	O
overall	O
effect	O
of	O
heat	O
shock	O
on	O
c-myc	O
mRNA	O
level	O
,	O
however	O
,	O
was	O
a	O
marked	O
inhibition	O
of	O
its	O
transcription	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
transcription	O
of	O
nuclear	O
protooncogenes	O
is	O
regulated	O
by	O
heat	O
shock	O
indicating	O
a	O
role	O
for	O
nuclear	O
protooncogenes	O
in	O
the	O
stress	O
response	O
of	O
lymphoid	O
cells	O
.	O

Tandem	O
AP-1-binding	O
sites	O
within	O
the	O
human	O
beta-globin	O
dominant	O
control	O
region	O
function	O
as	O
an	O
inducible	O
enhancer	O
in	O
erythroid	O
cells	O
.	O

A	O
powerful	O
enhancer	O
has	O
been	O
mapped	O
to	O
an	O
18-bp	O
DNA	O
segment	O
located	O
11	O
kb	O
5	O
'	O
to	O
the	O
human	O
epsilon-globin	O
gene	O
within	O
the	O
dominant	O
control	O
or	O
locus-activating	O
region	O
.	O

This	O
enhancer	O
is	O
inducible	O
in	O
K562	O
human	O
erythroleukemia	O
cells	O
,	O
increasing	O
linked	O
gamma-globin	O
promoter/luciferase	O
gene	O
expression	O
to	O
170-fold	O
over	O
an	O
enhancerless	O
construct	O
.	O

The	O
enhancer	O
consists	O
of	O
tandem	O
AP-1-binding	O
sites	O
,	O
phased	O
10	O
bp	O
apart	O
,	O
which	O
are	O
both	O
required	O
for	O
full	O
activity	O
.	O

DNA-protein	O
binding	O
assays	O
with	O
nuclear	O
extracts	O
from	O
induced	O
cells	O
demonstrate	O
a	O
high	O
molecular	O
weight	O
complex	O
on	O
the	O
enhancer	O
.	O

The	O
formation	O
of	O
this	O
complex	O
also	O
requires	O
both	O
AP-1	O
sites	O
and	O
correlates	O
with	O
maximal	O
enhancer	O
activity	O
.	O

Induction	O
of	O
the	O
enhancer	O
may	O
have	O
a	O
role	O
in	O
the	O
increase	O
in	O
globin	O
gene	O
transcription	O
that	O
characterizes	O
erythroid	O
maturation	O
.	O

Enhancer	O
activity	O
appears	O
to	O
be	O
mediated	O
by	O
the	O
binding	O
of	O
a	O
complex	O
of	O
proteins	O
from	O
the	O
jun	O
and	O
fos	O
families	O
to	O
tandem	O
AP-1	O
consensus	O
sequences	O
.	O

Adherence-dependent	O
increase	O
in	O
human	O
monocyte	O
PDGF	O
(	O
B	O
)	O
mRNA	O
is	O
associated	O
with	O
increases	O
in	O
c-fos	O
,	O
c-jun	O
,	O
and	O
EGR2	O
mRNA	O
.	O

Adherence	O
is	O
an	O
important	O
initial	O
step	O
in	O
the	O
transition	O
of	O
a	O
circulating	O
monocyte	O
to	O
a	O
tissue	O
macrophage	O
.	O

This	O
differentiation	O
is	O
accompanied	O
by	O
an	O
augmented	O
capacity	O
to	O
generate	O
growth	O
factors	O
.	O

We	O
hypothesized	O
that	O
adherence	O
itself	O
might	O
be	O
an	O
important	O
trigger	O
for	O
a	O
sequence	O
of	O
gene	O
activation	O
culminating	O
in	O
cells	O
with	O
increased	O
mRNA	O
encoding	O
profibrotic	O
growth	O
factors	O
such	O
as	O
platelet-derived	O
growth	O
factor	O
B	O
subunit	O
(	O
PDGF	O
[	O
B	O
]	O
)	O
and	O
transforming	O
growth	O
factor-beta	O
(	O
TGF-beta	O
)	O
.	O

After	O
in	O
vitro	O
adherence	O
,	O
human	O
monocytes	O
had	O
a	O
biphasic	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
with	O
peaks	O
at	O
6	O
h	O
and	O
13	O
d	O
.	O

No	B-Negation
increase	I-Negation
in	I-Negation
TGF-beta	I-Negation
mRNA	I-Negation
was	I-Negation
observed	I-Negation
.	O

The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
adherence	O
dependent	O
,	O
and	O
in	O
addition	O
,	O
was	O
abrogated	O
when	O
the	O
cytoskeletal	O
integrity	O
was	O
compromised	O
by	O
cytochalasin	O
D	O
.	O

The	O
6-h	O
increase	O
in	O
PDGF	O
(	O
B	O
)	O
mRNA	O
was	O
unaltered	O
by	O
adherence	O
in	O
the	O
presence	O
of	O
the	O
monocyte	O
stimulus	O
lipopolysaccharide	O
.	O

Adherence	O
to	O
either	O
fibronectin	O
or	O
collagen-coated	O
plastic	O
had	O
little	O
consistent	O
effect	O
on	O
PDGF	O
(	O
B	O
)	O
mRNA	O
accumulation	O
.	O

The	O
increased	O
PDGF	O
(	O
B	O
)	O
mRNA	O
observed	O
in	O
adherent	O
monocytes	O
was	O
accompanied	O
by	O
increases	O
in	O
mRNAs	O
of	O
the	O
early	O
growth	O
response	O
genes	O
c-fos	O
(	O
maximal	O
at	O
20	O
min	O
)	O
,	O
c-jun	O
,	O
and	O
EGR2	O
(	O
maximal	O
at	O
6-24	O
h	O
)	O
.	O

The	O
increase	O
in	O
c-jun	O
and	O
EGR2	O
,	O
but	O
not	B-Negation
c-fos	I-Negation
,	O
mRNA	O
was	O
also	O
abrogated	O
by	O
cytochalasin	O
D	O
.	O

These	O
observations	O
suggest	O
that	O
adherence	O
results	O
in	O
increases	O
of	O
c-fos	O
,	O
c-jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
increases	O
in	O
c-jun	O
,	O
EGR2	O
,	O
and	O
PDGF	O
(	O
B	O
)	O
may	O
depend	O
on	O
cytoskeletal	O
rearrangement	O
.	O

Modulation	O
of	O
these	O
events	O
at	O
the	O
time	O
of	O
adherence	O
offers	O
a	O
mechanism	O
by	O
which	O
differential	O
priming	O
of	O
the	O
cells	O
may	O
be	O
accomplished	O
.	O

Interferon-gamma	O
and	O
the	O
sexual	O
dimorphism	O
of	O
autoimmunity	O
.	O

The	O
sexual	O
difference	O
in	O
the	O
incidence	O
of	O
autoimmune	O
diseases	O
has	O
remained	O
an	O
enigma	O
for	O
many	O
years	O
.	O

In	O
the	O
examination	O
of	O
the	O
induction	O
of	O
autoimmunity	O
in	O
transgenic	O
mice	O
,	O
evidence	O
has	O
been	O
obtained	O
further	O
implicating	O
the	O
lymphokine	O
interferon-gamma	O
in	O
the	O
etiology	O
of	O
autoimmunity	O
.	O

Sex	O
steroid	O
regulation	O
of	O
the	O
production	O
of	O
this	O
molecule	O
,	O
as	O
well	O
as	O
other	O
cytokines	O
,	O
may	O
help	O
explain	O
the	O
gender-specific	O
differences	O
in	O
the	O
immune	O
system	O
,	O
including	O
autoimmunity	O
.	O

Single	O
cell	O
assay	O
of	O
a	O
transcription	O
factor	O
reveals	O
a	O
threshold	O
in	O
transcription	O
activated	O
by	O
signals	O
emanating	O
from	O
the	O
T-cell	O
antigen	O
receptor	O
.	O

Stimulation	O
of	O
T	O
lymphocytes	O
through	O
their	O
antigen	O
receptor	O
leads	O
to	O
the	O
appearance	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
NF-AT	O
and	O
NF-kappa	O
B	O
,	O
which	O
are	O
involved	O
in	O
regulating	O
genes	O
required	O
for	O
immunologic	O
activation	O
.	O

To	O
investigate	O
the	O
activity	O
of	O
a	O
single	O
transcription	O
factor	O
in	O
individual	O
viable	O
cells	O
,	O
we	O
have	O
applied	O
an	O
assay	O
that	O
uses	O
the	O
fluorescence-activated	O
cell	O
sorter	O
to	O
quantitate	O
beta-galactosidase	O
(	O
beta-gal	O
)	O
.	O

We	O
have	O
analyzed	O
the	O
distribution	O
of	O
NF-AT	O
transcriptional	O
activity	O
among	O
T	O
cells	O
undergoing	O
activation	O
by	O
using	O
a	O
construct	O
in	O
which	O
three	O
tandem	O
copies	O
of	O
the	O
NF-AT-binding	O
site	O
directs	O
transcription	O
of	O
the	O
lacZ	O
gene	O
.	O

Unexpectedly	O
,	O
stimulation	O
of	O
cloned	O
stably	O
transfected	O
Jurkat	O
T	O
cells	O
leads	O
to	O
a	O
bimodal	O
pattern	O
of	O
beta-gal	O
expression	O
in	O
which	O
some	O
cells	O
express	O
no	B-Negation
beta-gal	I-Negation
and	O
others	O
express	O
high	O
levels	O
.	O

This	B-Negation
expression	I-Negation
pattern	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
accounted	I-Negation
for	I-Negation
by	I-Negation
cell-cycle	I-Negation
position	I-Negation
or	I-Negation
heritable	I-Negation
variation	I-Negation
.	O

Further	O
results	O
,	O
in	O
which	O
beta-gal	O
activity	O
is	O
correlated	O
with	O
NF-AT-binding	O
activity	O
,	O
indicate	O
that	O
the	O
concentration	O
of	O
NF-AT	O
must	O
exceed	O
a	O
critical	O
threshold	O
before	O
transcription	O
initiates	O
.	O

This	O
threshold	O
likely	O
reflects	O
the	O
NF-AT	O
concentration-dependent	O
assembly	O
of	O
transcription	O
complexes	O
at	O
the	O
promoter	O
.	O

Similar	O
constructs	O
controlled	O
by	O
NF-kappa	O
B	O
or	O
the	O
entire	O
interleukin-2	O
enhancer	O
show	O
bimodal	O
expression	O
patterns	O
during	O
induction	O
,	O
suggesting	O
that	O
thresholds	O
set	O
by	O
the	O
concentration	O
of	O
transcription	O
factors	O
may	O
be	O
a	O
common	O
property	O
of	O
inducible	O
genes	O
.	O

Two	O
distinct	O
signal	O
transmission	O
pathways	O
in	O
T	O
lymphocytes	O
are	O
inhibited	O
by	O
complexes	O
formed	O
between	O
an	O
immunophilin	O
and	O
either	O
FK506	O
or	O
rapamycin	O
.	O

Proliferation	O
and	O
immunologic	O
function	O
of	O
T	O
lymphocytes	O
are	O
initiated	O
by	O
signals	O
from	O
the	O
antigen	O
receptor	O
that	O
are	O
inhibited	O
by	O
the	O
immunosuppressant	O
FK506	O
but	O
not	B-Negation
by	I-Negation
its	I-Negation
structural	I-Negation
analog	I-Negation
,	I-Negation
rapamycin	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
interleukin	O
2	O
(	O
IL-2	O
)	O
-induced	O
signals	O
are	O
blocked	O
by	O
rapamycin	O
but	O
not	B-Negation
by	I-Negation
FK506	I-Negation
.	O

Remarkably	O
,	O
these	O
two	O
drugs	O
inhibit	O
each	O
other	O
's	O
actions	O
,	O
raising	O
the	O
possibility	O
that	O
both	O
act	O
by	O
means	O
of	O
a	O
common	O
immunophilin	O
(	O
immunosuppressant	O
binding	O
protein	O
)	O
.	O

We	O
find	O
that	O
the	O
dissociation	O
constant	O
of	O
rapamycin	O
to	O
the	O
FK506	O
binding	O
protein	O
FKBP	O
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
is	O
close	O
to	O
the	O
dissociation	O
constant	O
of	O
FK506	O
to	O
FKBP	O
(	O
Kd	O
=	O
0.4	O
nM	O
)	O
and	O
to	O
their	O
effective	O
biologic	O
inhibitory	O
concentrations	O
.	O

However	O
,	O
an	O
excess	O
of	O
rapamycin	O
is	O
needed	O
to	O
revert	O
FK506-mediated	O
inhibition	O
of	O
IL-2	O
production	O
,	O
apoptosis	O
,	O
and	O
transcriptional	O
activation	O
of	O
NF-AT	O
,	O
a	O
T-cell-specific	O
transcription	O
factor	O
necessary	O
for	O
IL-2	O
gene	O
activation	O
.	O

Similarly	O
,	O
an	O
excess	O
of	O
FK506	O
is	O
needed	O
to	O
revert	O
rapamycin-mediated	O
inhibition	O
of	O
IL-2-induced	O
proliferation	O
.	O

The	O
drug	O
concentrations	O
required	O
for	O
antagonism	O
may	O
be	O
explained	O
by	O
the	O
relative	O
affinity	O
of	O
the	O
drugs	O
to	O
,	O
and	O
by	O
the	O
abundance	O
of	O
,	O
the	O
immunophilin	O
FKBP	O
.	O

FKBP	O
has	O
been	O
shown	O
to	O
catalyze	O
the	O
interconversion	O
of	O
the	O
cis-	O
and	O
trans-rotamers	O
of	O
the	O
peptidyl-prolyl	O
amide	O
bond	O
of	O
peptide	O
substrates	O
;	O
here	O
we	O
show	O
that	O
rapamycin	O
,	O
like	O
FK506	O
,	O
is	O
a	O
potent	O
inhibitor	O
of	O
the	O
rotamase	O
activity	O
of	O
FKBP	O
(	O
Ki	O
=	O
0.2	O
nM	O
)	O
.	O

Neither	B-Negation
FKBP	I-Negation
binding	I-Negation
nor	I-Negation
inhibition	I-Negation
of	I-Negation
rotamase	I-Negation
activity	I-Negation
of	I-Negation
FKBP	I-Negation
alone	I-Negation
is	I-Negation
sufficient	I-Negation
to	I-Negation
explain	I-Negation
the	I-Negation
biologic	I-Negation
actions	I-Negation
of	I-Negation
these	I-Negation
drugs	I-Negation
.	O

Rather	O
,	O
these	O
findings	O
suggest	O
that	O
immunophilin	O
bound	O
to	O
FK506	O
interferes	O
with	O
antigen	O
receptor-induced	O
signals	O
,	O
while	O
rapamycin	O
bound	O
to	O
the	O
immunophilin	O
interferes	O
with	O
IL-2-induced	O
signals	O
.	O

Transcriptional	O
down-regulation	O
of	O
c-myc	O
expression	O
by	O
protein	O
synthesis-dependent	O
and	O
-independent	O
pathways	O
in	O
a	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
.	O

We	O
show	O
that	O
in	O
the	O
human	O
T	O
lymphoblastic	O
tumor	O
cell	O
line	O
Molt4	O
c-myc	O
mRNA	O
and	O
protein	O
expression	O
is	O
down-regulated	O
after	O
exposure	O
to	O
dimethyl	O
sulfoxide	O
,	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
or	O
to	O
the	O
calcium	O
ionophore	O
A23187	O
,	O
which	O
raises	O
the	O
intracellular	O
calcium	O
concentration	O
.	O

A	O
block	O
to	O
RNA	O
elongation	O
is	O
largely	O
responsible	O
for	O
decreased	O
c-myc	O
transcription	O
.	O

Although	O
negative	O
regulation	O
by	O
dimethyl	O
sulfoxide	O
takes	O
place	O
even	O
when	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
cycloheximide	O
,	O
the	O
phorbol	O
myristate	O
acetate	O
effect	O
is	O
blocked	O
to	O
some	O
extent	O
only	O
by	O
cycloheximide	O
.	O

The	O
calcium	O
ionophore-induced	O
c-myc	O
suppression	O
,	O
however	O
,	O
strictly	O
requires	O
de	O
novo	O
protein	O
synthesis	O
.	O

Therefore	O
,	O
two	O
different	O
negative	O
regulatory	O
pathways	O
are	O
involved	O
in	O
c-myc	O
regulation	O
:	O
one	O
which	O
is	O
independent	O
and	O
one	O
which	O
depends	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

The	O
latter	O
one	O
appears	O
to	O
be	O
mediated	O
by	O
a	O
rapidly	O
calcium-dependent	O
induced	O
gene	O
product	O
.	O

Induction	O
of	O
immediate	O
early	O
response	O
genes	O
by	O
macrophage	O
colony-stimulating	O
factor	O
in	O
normal	O
human	O
monocytes	O
.	O

A	O
group	O
of	O
coordinately	O
induced	O
protooncogenes	O
,	O
cytoskeletal	O
,	O
and	O
extracellular	O
matrix	O
genes	O
have	O
been	O
termed	O
immediate	O
early	O
response	O
genes	O
,	O
and	O
their	O
induction	O
has	O
been	O
associated	O
with	O
growth	O
factor-stimulated	O
cell	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
induction	O
of	O
these	O
genes	O
by	O
macrophage-CSF	O
(	O
M-CSF	O
)	O
in	O
human	O
monocytes	O
that	O
do	O
not	B-Negation
proliferate	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
M-CSF	I-Negation
but	O
require	O
the	O
factor	O
for	O
optimal	O
cell	O
differentiation	O
.	O

Normal	O
human	O
monocytes	O
were	O
isolated	O
,	O
carefully	O
washed	O
,	O
and	O
incubated	O
for	O
36	O
to	O
48	O
h	O
in	O
fetal	O
bovine	O
serum-containing	O
medium	O
.	O

At	O
the	O
end	O
of	O
this	O
incubation	O
the	O
resting	O
cells	O
were	O
stimulated	O
with	O
M-CSF	O
,	O
and	O
RNA	O
was	O
isolated	O
for	O
analysis	O
by	O
Northern	O
blotting	O
.	O

RNA	O
from	O
control	O
resting	O
cells	O
contained	O
low	O
to	O
undetectable	O
levels	O
of	O
c-jun	O
,	O
fibronectin	O
receptor	O
,	O
and	O
actin	O
mRNA	O
.	O

Within	O
15	O
to	O
30	O
min	O
of	O
addition	O
of	O
M-CSF	O
,	O
however	O
,	O
there	O
was	O
a	O
dramatic	O
coordinate	O
induction	O
of	O
these	O
genes	O
.	O

The	O
c-jun	O
gene	O
expression	O
was	O
very	O
transient	O
and	O
was	O
not	B-Negation
detectable	I-Negation
by	I-Negation
60	I-Negation
min	I-Negation
after	I-Negation
M-CSF	I-Negation
addition	I-Negation
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
actin	O
and	O
fibronectin	O
receptor	O
mRNA	O
was	O
more	O
sustained	O
,	O
and	O
the	O
expression	O
of	O
these	O
genes	O
remained	O
elevated	O
at	O
24	O
to	O
48	O
h	O
after	O
M-CSF	O
addition	O
.	O

We	O
also	O
observed	O
the	O
induction	O
of	O
the	O
myelomonocytic	O
specific	O
tyrosine	O
kinase	O
hck	O
gene	O
simultaneously	O
with	O
the	O
other	O
immediate	O
early	O
response	O
genes	O
.	O

The	O
protein	O
synthesis	O
inhibitor	O
cycloheximide	O
did	O
not	B-Negation
block	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
any	I-Negation
of	I-Negation
these	I-Negation
genes	I-Negation
,	O
and	O
in	O
fact	O
,	O
super-induced	O
the	O
expression	O
of	O
c-jun	O
and	O
hck	O
.	O

Nuclear	O
run	O
on	O
transcription	O
of	O
the	O
c-jun	O
,	O
hck	O
,	O
and	O
actin	O
genes	O
.	O

Therefore	O
,	O
in	O
normal	O
human	O
monocytes	O
M-CSF	O
induces	O
immediate	O
early	O
response	O
genes	O
without	B-Negation
inducing	I-Negation
cell	I-Negation
proliferation	I-Negation
.	O

These	O
genes	O
may	O
then	O
play	O
a	O
role	O
in	O
altering	O
the	O
physiologic	O
status	O
of	O
the	O
cells	O
in	O
response	O
to	O
CSF	O
.	O

Stimulation	O
of	O
a	O
human	O
T-cell	O
clone	O
with	O
anti-CD3	O
or	O
tumor	O
necrosis	O
factor	O
induces	O
NF-kappa	O
B	O
translocation	O
but	O
not	B-Negation
human	I-Negation
immunodeficiency	I-Negation
virus	I-Negation
1	I-Negation
enhancer-dependent	I-Negation
transcription	I-Negation
.	O

The	O
expression	O
of	O
transiently	O
transfected	O
expression	O
vectors	O
under	O
the	O
control	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
or	O
its	O
enhancer	O
sequence	O
and	O
the	O
translocation	O
of	O
the	O
HIV	O
enhancer-binding	O
protein	O
NF-kappa	O
B	O
were	O
analyzed	O
in	O
two	O
human	O
T-cell	O
clones	O
stimulated	O
through	O
their	O
T-cell	O
receptor	O
complex	O
or	O
by	O
tumor	O
necrosis	O
factor	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

We	O
found	O
a	O
dissociation	O
of	O
NF-kappa	O
B	O
translocation	O
from	O
transactivation	O
of	O
either	O
the	O
HIV	O
LTR	O
or	O
the	O
HIV	O
enhancer	O
.	O

Interleukin	O
2	O
induced	O
proliferation	O
but	O
not	B-Negation
NF-kappa	I-Negation
B	I-Negation
translocation	I-Negation
or	I-Negation
LTR	I-Negation
transactivation	I-Negation
.	O

Phorbol	O
ester	O
or	O
specific	O
antigen	O
recognition	O
induced	O
HIV	O
LTR	O
transactivation	O
,	O
whereas	O
stimulation	O
with	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
did	O
not	B-Negation
.	O

The	O
two	O
latter	O
signals	O
were	O
nevertheless	O
able	O
to	O
induce	O
NF-kappa	O
B	O
translocation	O
with	O
a	O
pattern	O
in	O
the	O
band-shift	O
assay	O
indistinguishable	O
from	O
that	O
observed	O
using	O
phorbol	O
ester	O
.	O

Our	O
finding	O
that	O
induction	O
of	O
NF-kappa	O
B	O
by	O
tumor	O
necrosis	O
factor	O
or	O
antibody	O
to	O
CD3	O
is	O
not	B-Negation
sufficient	I-Negation
to	I-Negation
induce	I-Negation
HIV	I-Negation
enhancer-dependent	I-Negation
transcription	I-Negation
in	I-Negation
cloned	I-Negation
T	I-Negation
cells	I-Negation
contrasts	O
with	O
results	O
obtained	O
in	O
most	O
lymphoblastoid	O
T-cell	O
lines	O
and	O
indicates	B-Speculation
that	I-Speculation
normal	I-Speculation
T	I-Speculation
lymphocytes	I-Speculation
differ	I-Speculation
from	I-Speculation
tumoral	I-Speculation
T	I-Speculation
cells	I-Speculation
in	I-Speculation
terms	I-Speculation
of	I-Speculation
requirements	I-Speculation
for	I-Speculation
HIV	I-Speculation
LTR	I-Speculation
activation	I-Speculation
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
events	O
linked	O
to	O
T-cell	O
activation	O
,	O
in	O
addition	O
to	O
NF-kappa	O
B	O
translocation	O
per	O
se	O
,	O
induce	O
functional	O
interactions	O
of	O
the	O
NF-kappa	O
B	O
complex	O
with	O
the	O
HIV	O
enhancer	O
.	O

Characterization	O
of	O
defensin	O
resistance	O
phenotypes	O
associated	O
with	O
mutations	O
in	O
the	O
phoP	O
virulence	O
regulon	O
of	O
Salmonella	O
typhimurium	O
.	O

The	O
defensin	O
sensitivities	O
of	O
Salmonella	O
typhimurium	O
strains	O
with	O
mutations	O
in	O
the	O
phoP/phoQ	O
two-component	O
virulence	O
regulon	O
were	O
tested	O
by	O
using	O
purified	O
defensins	O
NP-1	O
and	O
NP-2	O
.	O

Strains	O
with	O
mutations	O
in	O
either	O
gene	O
of	O
the	O
regulatory	O
pair	O
(	O
phoP	O
[	O
transcriptional	O
activator	O
]	O
or	O
phoQ	O
[	O
membrane	O
sensor	O
kinase	O
]	O
)	O
had	O
increased	O
sensitivities	O
to	O
defensin	O
.	O

The	O
predicted	O
periplasmic	O
domain	O
of	O
the	O
PhoQ	O
protein	O
contained	O
a	O
markedly	O
anionic	O
domain	O
that	O
could	O
interact	O
with	O
cationic	O
proteins	O
and	O
that	O
could	O
be	O
responsible	O
for	O
resistance	O
to	O
defensin	O
.	O

Because	O
insertion	O
mutations	O
in	O
phoP	O
are	O
polar	O
on	O
phoQ	O
,	O
we	O
constructed	O
strains	O
that	O
expressed	O
the	O
PhoQ	O
protein	O
in	O
the	O
absence	B-Negation
of	I-Negation
PhoP	I-Negation
to	O
test	O
whether	B-Speculation
resistance	I-Speculation
to	I-Speculation
defensin	I-Speculation
requires	I-Speculation
only	I-Speculation
the	I-Speculation
phoQ	I-Speculation
gene	I-Speculation
product	I-Speculation
.	O

We	O
found	O
that	O
resistance	O
to	O
defensin	O
requires	O
the	O
function	O
of	O
both	O
components	O
of	O
this	O
regulatory	O
system	O
,	O
because	O
strains	O
expressing	O
PhoQ	O
without	B-Negation
PhoP	I-Negation
were	O
still	O
markedly	O
sensitive	O
to	O
defensins	O
.	O

This	O
implied	O
that	O
a	O
pag	O
(	O
phoP-activated	O
gene	O
)	O
product	O
is	O
responsible	O
for	O
defensin	O
resistance	O
.	O

We	O
also	O
tested	O
for	O
the	O
ability	O
of	O
defensins	O
NP-1	O
,	O
NP-5	O
,	O
and	O
HNP-1	O
to	O
activate	O
pag	O
expression	O
and	O
found	O
that	O
these	O
peptides	O
have	O
no	B-Negation
effect	I-Negation
.	O

Defensin	O
resistance	O
is	O
not	O
the	O
only	O
virulence	O
characteristic	O
controlled	O
by	O
the	O
PhoP-PhoQ	O
regulon	O
because	O
mutations	O
in	O
pagC	O
,	O
as	O
well	O
as	O
ones	O
in	O
the	O
phoP	O
locus	O
that	O
resulted	O
in	O
constitutive	O
pag	O
activation	O
(	O
phenotype	O
PhoPc	O
)	O
,	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
defensin	I-Negation
resistance	I-Negation
,	O
even	O
though	O
they	O
rendered	O
the	O
organism	O
avirulent	O
and	O
deficient	O
in	O
survival	O
within	O
macrophages	O
.	O

The	O
virulence	O
defect	O
conferred	O
by	O
mutations	O
in	O
the	O
phoP-phoQ	O
two-component	O
regulatory	O
system	O
is	O
not	O
completely	O
explained	O
by	O
alterations	O
in	O
resistance	O
to	O
cationic	O
proteins	O
and	O
involves	O
the	O
control	O
of	O
other	O
proteins	O
necessary	O
for	O
S.	O
typhimurium	O
survival	O
within	O
macrophages	O
.	O

Involvement	O
of	O
cyclic	O
AMP-dependent	O
protein	O
kinases	O
in	O
the	O
signal	O
transduction	O
pathway	O
for	O
interleukin-1	O
.	O

Expression	O
of	O
a	O
highly	O
specific	O
protein	O
inhibitor	O
for	O
cyclic	O
AMP-dependent	O
protein	O
kinases	O
in	O
interleukin-1	O
(	O
IL-1	O
)	O
-responsive	O
cells	O
blocked	O
IL-1-induced	O
gene	O
transcription	O
that	O
was	O
driven	O
by	O
the	O
kappa	O
immunoglobulin	O
enhancer	O
or	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
.	O

This	O
inhibitor	O
did	O
not	B-Negation
affect	I-Negation
protein	I-Negation
kinase	I-Negation
C-mediated	I-Negation
gene	I-Negation
transcription	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
cyclic	I-Speculation
AMP-dependent	I-Speculation
protein	I-Speculation
kinases	I-Speculation
are	I-Speculation
involved	I-Speculation
in	I-Speculation
the	I-Speculation
signal	I-Speculation
transduction	I-Speculation
pathway	I-Speculation
for	I-Speculation
IL-1	I-Speculation
in	I-Speculation
a	I-Speculation
number	I-Speculation
of	I-Speculation
responsive	I-Speculation
cell	I-Speculation
types	I-Speculation
.	O

Lipopolysaccharide	O
is	O
a	O
potent	O
monocyte/macrophage-specific	O
stimulator	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
.	O

Lipopolysaccharide	O
(	O
LPS	O
)	O
potently	O
stimulates	O
human	O
immunodeficiency	O
virus	O
type	O
1-long	O
terminal	O
repeat	O
(	O
HIV-1-LTR	O
)	O
CAT	O
constructs	O
transfected	O
into	O
monocyte/macrophage-like	O
cell	O
lines	O
but	O
not	B-Negation
a	I-Negation
T	I-Negation
cell	I-Negation
line	I-Negation
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
through	O
the	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrate	O
that	O
LPS	O
induces	O
a	O
DNA	O
binding	O
activity	O
indistinguishable	O
from	O
NF-kappa	O
B	O
in	O
U937	O
and	O
THP-1	O
cells	O
.	O

LPS	O
is	O
also	O
shown	O
to	O
dramatically	O
increase	O
HIV-1	O
production	O
from	O
a	O
chronically	O
infected	O
monocyte/macrophage-like	O
cloned	O
cell	O
line	O
,	O
U1	O
,	O
which	O
produces	O
very	O
low	O
levels	O
of	O
HIV-1	O
at	O
baseline	O
.	O

The	O
stimulation	O
of	O
viral	O
production	O
from	O
this	O
cell	O
line	O
occurs	O
only	O
if	O
these	O
cells	O
are	O
treated	O
with	O
granulocyte/macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
before	O
treatment	O
with	O
LPS	O
.	O

This	O
stimulation	O
of	O
HIV-1	O
production	O
is	O
correlated	O
with	O
an	O
increase	O
in	O
the	O
level	O
of	O
HIV-1	O
RNA	O
and	O
and	O
activation	O
of	O
NF-kappa	O
B	O
.	O

LPS	O
is	O
not	B-Negation
able	I-Negation
to	I-Negation
induce	I-Negation
HIV-1	I-Negation
production	I-Negation
in	I-Negation
a	I-Negation
cloned	I-Negation
T	I-Negation
cell	I-Negation
line	I-Negation
.	O

The	O
effect	O
of	O
LPS	O
on	O
HIV-1	O
replication	O
occurs	O
at	O
picogram	O
per	O
milliliter	O
concentrations	O
and	O
may	O
be	O
clinically	O
significant	O
in	O
understanding	O
the	O
variability	O
of	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
.	O

Inducible	O
nuclear	O
factor	O
binding	O
to	O
the	O
kappa	O
B	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
can	O
be	O
blocked	O
by	O
cyclosporin	O
A	O
in	O
a	O
signal-dependent	O
manner	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
is	O
thought	O
to	O
exert	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
expression	O
of	O
a	O
distinct	O
set	O
of	O
lymphokine	O
genes	O
which	O
are	O
induced	O
upon	O
T-cell	O
activation	O
,	O
among	O
them	O
the	O
gene	O
coding	O
for	O
interleukin-2	O
.	O

In	O
addition	O
,	O
the	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
is	O
partially	O
suppressed	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
mechanisms	O
underlying	O
suppression	O
by	O
CsA	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
this	O
drug	O
on	O
transcription	O
factors	O
in	O
T	O
cells	O
.	O

Here	O
we	O
report	O
that	O
the	O
formation	O
of	O
two	O
distinct	O
mitogen-inducible	O
DNA-binding	O
complexes	O
,	O
the	O
kappa	O
B	O
complex	O
within	O
the	O
HIV	O
enhancer	O
and	O
the	O
NFAT-1	O
complex	O
within	O
the	O
interleukin-2	O
enhancer	O
,	O
is	O
inhibited	O
in	O
the	O
presence	O
of	O
CsA	O
.	O

The	O
kappa	O
B-binding	O
activity	O
with	O
the	O
HIV	O
enhancer	O
is	O
inhibited	O
only	O
if	O
it	O
is	O
activated	O
via	O
the	O
mitogen	O
phytohemagglutinin	O
whereas	O
phorbol	O
myristate	O
acetate-mediated	O
activation	O
is	O
completely	O
insensitive	O
to	O
the	O
drug	O
.	O

This	O
suggests	O
a	O
model	O
in	O
which	O
functionally	O
indistinguishable	O
kappa	O
B	O
complexes	O
can	O
be	O
activated	O
via	O
two	O
separate	O
pathways	O
of	O
signal	O
transduction	O
distinguishable	O
by	O
CsA	O
.	O

Cell-specific	O
differences	O
in	O
activation	O
of	O
NF-kappa	O
B	O
regulatory	O
elements	O
of	O
human	O
immunodeficiency	O
virus	O
and	O
beta	O
interferon	O
promoters	O
by	O
tumor	O
necrosis	O
factor	O
.	O

Three	O
aspects	O
of	O
the	O
involvement	O
of	O
tumor	O
necrosis	O
factor	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
pathogenesis	O
were	O
examined	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
mRNA	O
production	O
was	O
analyzed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
in	O
monocytic	O
U937	O
cells	O
and	O
in	O
a	O
chronically	O
HIV	O
infected	O
U937	O
cell	O
line	O
(	O
U9-IIIB	O
)	O
.	O

TNF-alpha	O
RNA	O
was	O
undetectable	O
in	O
U937	O
cells	O
,	O
whereas	O
a	O
low	O
constitutive	O
level	O
was	O
detected	O
in	O
U9-IIIB	O
cells	O
.	O

Paramyxovirus	O
infection	O
induced	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
steady-state	O
level	O
of	O
TNF-alpha	O
RNA	O
in	O
U9-IIIB	O
cells	O
compared	O
with	O
U937	O
cells	O
,	O
suggesting	O
that	O
HIV-infected	O
monocytic	O
cells	O
produced	O
higher	O
levels	O
of	O
TNF-alpha	O
than	O
did	O
normal	O
cells	O
after	O
a	O
secondary	O
virus	O
infection	O
.	O

The	O
effects	O
of	O
TNF-alpha	O
on	O
gene	O
expression	O
were	O
examined	O
by	O
transient	O
expression	O
assays	O
using	O
reporter	O
chloramphenicol	O
acetyltransferase	O
plasmids	O
linked	O
to	O
regulatory	O
elements	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
the	O
beta	O
interferon	O
promoter	O
.	O

In	O
U937	O
and	O
Jurkat	O
T	O
lymphoid	O
cells	O
,	O
the	O
inducibility	O
of	O
the	O
different	O
hybrid	O
promoters	O
by	O
TNF-alpha	O
or	O
phorbol	O
ester	O
varied	O
in	O
a	O
cell	O
type-	O
and	O
promoter	O
context-specific	O
manner	O
;	O
the	O
levels	O
of	O
gene	O
activity	O
of	O
NF-kappa	O
B-containing	O
plasmids	O
correlated	O
directly	O
with	O
induction	O
of	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
.	O

Although	O
the	O
intact	O
beta	O
interferon	O
promoter	O
was	O
only	O
weakly	O
stimulated	O
by	O
phorbol	O
ester	O
or	O
TNF-alpha	O
,	O
multimers	O
of	O
the	O
PRDII	O
NF-kappa	O
B-binding	O
domain	O
were	O
inducible	O
by	O
both	O
agents	O
.	O

TNF-alpha	O
was	O
able	O
to	O
increase	O
expression	O
of	O
the	O
HIV	O
LTR	O
in	O
T	O
cells	O
,	O
but	O
in	O
monocytic	O
cells	O
,	O
TNF-alpha	O
did	O
not	B-Negation
induce	I-Negation
the	I-Negation
HIV	I-Negation
LTR	I-Negation
above	I-Negation
a	I-Negation
constitutive	I-Negation
level	I-Negation
of	I-Negation
activity	I-Negation
.	O

This	B-Speculation
level	I-Speculation
of	I-Speculation
NF-kappa	I-Speculation
B-independent	I-Speculation
activity	I-Speculation
appears	I-Speculation
to	I-Speculation
be	I-Speculation
sufficient	I-Speculation
for	I-Speculation
virus	I-Speculation
multiplication	I-Speculation
,	O
since	O
TNF-alpha	O
treatment	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
kinetics	I-Negation
of	I-Negation
de	I-Negation
novo	I-Negation
HIV	I-Negation
type	I-Negation
1	I-Negation
(	I-Negation
HIV-1	I-Negation
)	I-Negation
infection	I-Negation
and	I-Negation
viral	I-Negation
RNA	I-Negation
production	I-Negation
in	I-Negation
U937	I-Negation
cells	I-Negation
.	O

However	O
,	O
in	O
Jurkat	O
cells	O
,	O
TNF-alpha	O
dramatically	O
enhanced	O
the	O
spread	O
of	O
HIV-1	O
through	O
the	O
cell	O
population	O
and	O
increased	O
viral	O
RNA	O
synthesis	O
,	O
indicating	O
that	O
in	O
T	O
cells	O
HIV-1	O
multiplication	O
was	O
stimulated	O
by	O
TNF-alpha	O
treatment	O
.	O

Astrocytes	O
and	O
glioblastoma	O
cells	O
express	O
novel	O
octamer-DNA	O
binding	O
proteins	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	O
and	O
B	O
cell	O
type	O
Oct-2	O
proteins	O
.	O

The	O
'octamer	O
'	O
sequence	O
,	O
ATGCAAAT	O
or	O
its	O
complement	O
ATTTGCAT	O
,	O
is	O
a	O
key	O
element	O
for	O
the	O
transcriptional	O
regulation	O
of	O
immunoglobulin	O
genes	O
in	O
B-lymphocytes	O
as	O
well	O
as	O
a	O
number	O
of	O
housekeeping	O
genes	O
in	O
all	O
cell	O
types	O
.	O

In	O
lymphocytes	O
,	O
the	O
octamer-binding	O
protein	O
Oct-2A	O
and	O
variants	O
thereof	O
are	O
thought	O
to	O
contribute	O
to	O
the	O
B-cell	O
specific	O
gene	O
expression	O
,	O
while	O
the	O
ubiquitous	O
protein	O
Oct-1	O
seems	O
to	O
control	O
general	O
octamer	O
site-dependent	O
transcription	O
.	O

Various	O
other	O
genes	O
,	O
for	O
example	O
interleukin-1	O
and	O
MHC	O
class	O
II	O
genes	O
,	O
contain	O
an	O
octamer	O
sequence	O
in	O
the	O
promoter	O
and	O
are	O
expressed	O
in	O
cells	O
of	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

This	O
prompted	O
us	O
to	O
analyze	O
the	O
octamer-binding	O
proteins	O
in	O
the	O
latter	O
cells	O
.	O

Using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
at	O
least	O
six	O
novel	O
octamer	O
binding	O
proteins	O
were	O
detected	O
in	O
nuclear	O
extracts	O
of	O
cultured	O
mouse	O
astrocytes	O
.	O

These	O
proteins	O
are	O
differentially	O
expressed	O
in	O
human	O
glioblastoma	O
and	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nervous	O
system-derived	O
(	O
N-Oct	O
)	O
proteins	O
bound	O
to	O
the	O
octamer	O
DNA	O
sequence	O
in	O
a	O
manner	O
which	O
is	O
indistinguishable	O
from	O
the	O
Oct-1	O
and	O
Oct-2A	O
proteins	O
.	O

The	O
relationship	O
of	O
the	O
N-Oct	O
proteins	O
to	O
Oct-1	O
and	O
Oct-2A	O
was	O
analyzed	O
by	O
proteolytic	O
clipping	O
bandshift	O
assays	O
and	O
by	O
their	O
reactivity	O
towards	O
antisera	O
raised	O
against	O
recombinant	O
Oct-1	O
and	O
Oct-2A	O
proteins	O
.	O

On	O
the	O
basis	O
of	O
these	O
assays	O
,	O
all	O
N-Oct-factors	O
were	O
found	O
to	O
be	O
distinct	O
from	O
the	O
ubiquitous	O
Oct-1	O
and	O
the	O
lymphoid-specific	O
Oct-2A	O
proteins	O
.	O

In	O
melanoma	O
cells	O
that	O
contain	O
the	O
N-Oct-3	O
factor	O
,	O
a	B-Negation
transfected	I-Negation
lymphocyte-specific	I-Negation
promoter	I-Negation
was	I-Negation
neither	I-Negation
activated	I-Negation
nor	I-Negation
was	I-Negation
it	I-Negation
repressed	I-Negation
upon	I-Negation
contransfection	I-Negation
with	I-Negation
an	I-Negation
Oct-2A	I-Negation
expression	I-Negation
vector	I-Negation
.	O

We	O
therefore	O
speculate	O
that	O
N-Oct-3	O
and	O
other	O
N-Oct	O
factors	O
have	O
a	O
specific	O
role	O
in	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
.	O

Cloning	O
of	O
a	O
mitogen-inducible	O
gene	O
encoding	O
a	O
kappa	O
B	O
DNA-binding	O
protein	O
with	O
homology	O
to	O
the	O
rel	O
oncogene	O
and	O
to	O
cell-cycle	O
motifs	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mitogen-inducible	O
gene	O
isolated	O
from	O
human	O
T	O
cells	O
that	O
predicts	O
a	O
protein	O
of	O
968	O
amino	O
acids	O
.	O

The	O
amino-terminal	O
domain	O
has	O
regions	O
homologous	O
to	O
the	O
oncogene	O
rel	O
and	O
to	O
the	O
developmentally	O
important	O
gene	O
dorsal	O
of	O
Drosophila	O
.	O

The	O
carboxy-terminal	O
domain	O
contains	O
repeat	O
structures	O
found	O
in	O
a	O
variety	O
of	O
proteins	O
that	O
are	O
involved	O
in	O
cell-cycle	O
control	O
of	O
yeast	O
and	O
in	O
tissue	O
differentiation	O
in	O
Drosophila	O
and	O
Ceanorhabditis	O
elegans	O
,	O
as	O
well	O
as	O
in	O
the	O
putative	O
human	O
oncogene	O
bcl-3	O
and	O
in	O
the	O
ankyrin	O
protein	O
.	O

A	O
truncated	O
form	O
of	O
the	O
product	O
of	O
this	O
gene	O
translated	O
in	O
vitro	O
is	O
a	O
DNA-binding	O
protein	O
which	O
interacts	O
specifically	O
with	O
the	O
kappa	O
B	O
binding	O
site	O
found	O
in	O
many	O
inducible	O
genes	O
,	O
including	O
the	O
enhancer	O
in	O
human	O
immunodeficiency	O
virus	O
.	O

This	O
gene	O
is	O
yet	O
another	O
in	O
a	O
growing	O
list	O
of	O
important	O
regulatory	O
molecules	O
whose	O
expression	O
is	O
transcriptionally	O
induced	O
upon	O
cellular	O
activation	O
.	O

Regulation	O
of	O
gene	O
expression	O
with	O
double-stranded	O
phosphorothioate	O
oligonucleotides	O
.	O

Alteration	O
of	O
gene	O
transcription	O
by	O
inhibition	O
of	O
specific	O
transcriptional	O
regulatory	O
proteins	O
is	O
necessary	O
for	O
determining	O
how	O
these	O
factors	O
participate	O
in	O
cellular	O
differentiation	O
.	O

The	O
functions	O
of	O
these	O
proteins	O
can	O
be	O
antagonized	O
by	O
several	O
methods	O
,	O
each	O
with	O
specific	O
limitations	O
.	O

Inhibition	O
of	O
sequence-specific	O
DNA-binding	O
proteins	O
was	O
achieved	O
with	O
double-stranded	O
(	O
ds	O
)	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
octamer	O
or	O
kappa	O
B	O
consensus	O
sequences	O
.	O

The	O
phosphorothioate	O
oligonucleotides	O
specifically	O
bound	O
either	O
octamer	O
transcription	O
factor	O
or	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
.	O

The	O
modified	O
oligonucleotides	O
accumulated	O
in	O
cells	O
more	O
effectively	O
than	O
standard	O
ds	O
oligonucleotides	O
and	O
modulated	O
gene	O
expression	O
in	O
a	O
specific	O
manner	O
.	O

Octamer-dependent	O
activation	O
of	O
a	O
reporter	O
plasmid	O
or	O
NF-kappa	O
B-dependent	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
enhancer	O
was	O
inhibited	O
when	O
the	O
appropriate	O
phosphorothioate	O
oligonucleotide	O
was	O
added	O
to	O
a	O
transiently	O
transfected	O
B	O
cell	O
line	O
.	O

Addition	O
of	O
phosphorothioate	O
oligonucleotides	O
that	O
contained	O
the	O
octamer	O
consensus	O
to	O
Jurkat	O
T	O
leukemia	O
cells	O
inhibited	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
to	O
a	O
degree	O
similar	O
to	O
that	O
observed	O
with	O
a	O
mutated	O
octamer	O
site	O
in	O
the	O
IL-2	O
enhancer	O
.	O

The	O
ds	O
phosphorothioate	O
oligonucleotides	O
probably	O
compete	O
for	O
binding	O
of	O
specific	O
transcription	O
factors	O
and	O
may	O
provide	O
anti-viral	O
,	O
immunosuppressive	O
,	O
or	O
other	O
therapeutic	O
effects	O
.	O

Differences	O
in	O
transcriptional	O
enhancers	O
of	O
HIV-1	O
and	O
HIV-2	O
.	O

Response	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

T	O
cell	O
activation	O
results	O
in	O
high	O
levels	O
of	O
HIV	O
replication	O
and	O
is	O
thought	O
to	O
be	O
one	O
mechanism	O
leading	O
to	O
the	O
conversion	O
from	O
latent	O
to	O
active	O
viral	O
infection	O
.	O

In	O
HIV-1	O
,	O
the	O
sequences	O
that	O
respond	O
to	O
these	O
signaling	O
events	O
are	O
found	O
in	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
comprise	O
the	O
transcriptional	O
enhancer	O
,	O
which	O
contains	O
two	O
conserved	O
binding	O
sites	O
for	O
the	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
.	O

The	O
corresponding	O
region	O
in	O
the	O
second	O
AIDS	O
retrovirus	O
,	O
HIV-2	O
,	O
contains	O
a	O
conserved	O
and	O
a	O
divergent	O
NF	O
kappa	O
B	O
binding	O
site	O
.	O

We	O
demonstrate	O
that	O
the	O
HIV-1	O
LTR	O
responds	O
better	O
than	O
the	O
HIV-2	O
LTR	O
to	O
T	O
cell	O
activation	O
signals	O
.	O

These	O
qualitative	O
differences	O
in	O
the	O
response	O
to	O
T	O
cell	O
activation	O
are	O
reproduced	O
not	O
only	O
when	O
HIV-1	O
or	O
HIV-2	O
enhancers	O
are	O
placed	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
also	O
when	O
these	O
enhancers	O
are	O
switched	O
between	O
their	O
respective	O
LTR	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
NF	O
kappa	O
B	O
binds	O
to	O
both	O
conserved	O
sites	O
in	O
the	O
HIV-1	O
transcriptional	O
enhancer	O
and	O
only	O
to	O
the	O
single	O
conserved	O
site	O
in	O
the	O
HIV-2	O
transcriptional	O
enhancer	O
.	O

Instead	B-Negation
of	I-Negation
NF	I-Negation
kappa	I-Negation
B	I-Negation
,	O
the	O
activator	O
protein	O
3	O
binds	O
to	O
the	O
divergent	O
site	O
in	O
HIV-2	O
.	O

In	O
conclusion	O
,	O
HIV-1	O
and	O
HIV-2	O
are	O
differentially	O
regulated	O
by	O
T	O
cell	O
activation	O
signals	O
,	O
and	O
this	O
difference	O
may	O
account	O
for	O
the	O
longer	O
period	O
of	O
viral	O
latency	O
observed	O
with	O
HIV-2	O
than	O
with	O
HIV-1	O
infection	O
.	O

An	O
in	O
vitro	O
globin	O
gene	O
switching	O
model	O
based	O
on	O
differentiated	O
embryonic	O
stem	O
cells	O
.	O

We	O
used	O
mouse	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
to	O
study	O
globin	O
gene	O
expression	O
and	O
switching	O
in	O
vitro	O
.	O

We	O
show	O
that	O
ES-derived	O
embryoid	O
bodies	O
express	O
the	O
full	O
complement	O
of	O
mouse	O
embryonic	O
globin	O
genes	O
in	O
the	O
correct	O
temporal	O
order	O
and	O
that	O
on	O
further	O
differentiation	O
,	O
a	O
switch	O
occurs	O
to	O
the	O
fetal/adult	O
genes	O
.	O

In	O
addition	O
,	O
the	O
erythroid-specific	O
transcription	O
factor	O
NF-E1	O
was	O
shown	O
to	O
be	O
expressed	O
coordinately	O
with	O
that	O
of	O
globin	O
in	O
embryoid	O
bodies	O
.	O

We	O
conclude	O
from	O
these	O
experiments	O
that	O
the	O
ES	O
cell	O
system	O
provides	O
a	O
good	O
model	O
to	O
study	O
hematopoietic	O
development	O
.	O

When	O
the	O
human	O
epsilon-	O
or	O
beta-globin	O
genes	O
driven	O
by	O
the	O
dominant	O
control	O
region	O
(	O
DCR	O
)	O
are	O
introduced	O
into	O
this	O
system	O
,	O
the	B-Negation
human	I-Negation
epsilon-globin	I-Negation
gene	I-Negation
,	I-Negation
in	I-Negation
contrast	I-Negation
to	I-Negation
the	I-Negation
beta-globin	I-Negation
gene	I-Negation
,	I-Negation
is	I-Negation
not	I-Negation
deregulated	I-Negation
by	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
the	I-Negation
DCR	I-Negation
and	O
is	O
expressed	O
strictly	O
as	O
an	O
embryonic	O
gene	O
.	O

We	O
conclude	O
from	O
this	O
that	O
the	B-Negation
epsilon-globin	I-Negation
gene	I-Negation
is	I-Negation
not	I-Negation
regulated	I-Negation
by	I-Negation
competition	I-Negation
with	I-Negation
other	I-Negation
genes	I-Negation
in	I-Negation
the	I-Negation
human	I-Negation
beta-globin	I-Negation
locus	I-Negation
.	O

Functional	O
analysis	O
of	O
cis-linked	O
regulatory	O
sequences	O
in	O
the	O
HLA	O
DRA	O
promoter	O
by	O
transcription	O
in	O
vitro	O
.	O

Two	O
consensus	O
sequences	O
,	O
called	O
X	O
and	O
Y	O
boxes	O
,	O
capable	O
of	O
binding	O
nuclear	O
proteins	O
and	O
regulating	O
expression	O
in	O
B	O
cells	O
have	O
been	O
defined	O
within	O
the	O
immediate	O
upstream	O
region	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
promoters	O
.	O

Unlike	O
other	O
class	O
II	O
promoters	O
,	O
the	O
HLA-DR	O
alpha	O
(	O
DRA	O
)	O
promoter	O
also	O
contains	O
one	O
element	O
identical	O
to	O
the	O
``	O
octamer	O
``	O
motif	O
of	O
immunoglobulin	O
variable	O
region	O
promoters	O
that	O
is	O
responsible	O
for	O
B	O
cell-specific	O
transcription	O
.	O

This	O
``	O
octamer	O
``	O
in	O
the	O
context	O
of	O
DRA	O
appears	O
capable	O
of	O
binding	O
both	O
the	O
ubiquitous	O
(	O
OTF-1	O
)	O
and	O
lymphoid-specific	O
(	O
OTF-2	O
)	O
``	O
octamer	O
``	O
binding	O
proteins	O
,	O
but	O
at	O
least	O
one	O
other	O
distinct	O
``	O
octamer	O
``	O
complex	O
was	O
found	O
.	O

In	O
order	O
to	O
characterize	O
the	O
function	O
of	O
cis-acting	O
elements	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
system	O
in	O
which	O
a	O
DRA	O
promoter	O
construct	O
is	O
transcribed	O
more	O
efficiently	O
in	O
extracts	O
from	O
B	O
cells	O
than	O
in	O
extracts	O
from	O
class	O
II-negative	O
HeLa	O
cells	O
.	O

5	O
'	O
deletion	O
constructs	O
which	O
lacked	B-Negation
the	I-Negation
Y	I-Negation
box	I-Negation
,	O
but	O
retained	O
the	O
``	O
octamer	O
``	O
motif	O
and	O
TATA	O
box	O
were	O
completely	O
inactive	O
,	O
and	O
internal	O
deletion	O
of	O
the	O
Y	O
box	O
reduced	O
transcription	O
by	O
95	O
%	O
.	O

Using	O
supercoiled	O
,	O
but	O
not	B-Negation
linear	I-Negation
templates	I-Negation
,	O
we	O
observed	O
differences	O
in	O
transcription	O
efficiencies	O
from	O
templates	O
lacking	B-Speculation
or	I-Speculation
disrupting	I-Speculation
the	I-Speculation
X	I-Speculation
consensus	I-Speculation
element	I-Speculation
that	O
reflect	O
effects	O
of	O
random	O
replacement	O
of	O
X	O
box	O
sequences	O
in	O
transient	O
expression	O
assays	O
.	O

Demonstration	O
of	O
the	O
complete	O
dependence	O
on	O
the	O
Y	O
box	O
in	O
this	O
system	O
suggests	O
that	O
,	O
despite	O
its	O
demonstrated	O
importance	O
in	O
the	O
DRA	O
promoter	O
,	O
the	O
DRA	O
``	O
octamer	O
``	O
does	O
not	O
utilize	O
OTF-2	O
in	O
a	O
manner	O
analogous	O
to	O
immunoglobulin	O
promoters	O
in	O
B	O
cells	O
.	O

Characterization	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer-binding	O
proteins	O
from	O
the	O
human	O
T-cell	O
line	O
Jurkat	O
.	O

The	O
transcription	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
under	O
the	O
control	O
of	O
cellular	O
proteins	O
that	O
bind	O
to	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Among	O
the	O
protein-binding	O
regions	O
of	O
the	O
HIV-1	O
LTR	O
is	O
the	O
transcription-enhancer	O
region	O
.	O

We	O
show	O
that	O
at	O
least	O
one	O
inducible	O
,	O
C1	O
,	O
and	O
one	O
constitutive	O
,	O
C2	O
,	O
protein	O
can	O
bind	O
to	O
the	O
HIV	O
enhancer	O
in	O
Jurkat	O
cells	O
.	O

The	O
two	O
proteins	O
differ	O
in	O
their	O
surface	O
charge	O
,	O
since	O
they	O
are	O
separable	O
by	O
anion-exchange	O
chromatography	O
.	O

Bivalent	O
cations	O
such	O
as	O
Mg2+	O
and	O
Zn2+	O
differentially	O
affect	O
their	O
binding	O
to	O
oligonucleotides	O
which	O
contain	O
the	O
HIV-enhancer	O
domain	O
.	O

Both	O
C1	O
and	O
C2	O
proteins	O
also	O
bind	O
to	O
a	O
similar	O
sequence	O
found	O
in	O
the	O
interleukin-2-receptor	O
alpha-subunit	O
enhancer	O
.	O

The	O
inducible	O
C1	O
protein	O
was	O
partially	O
purified	O
by	O
three	O
chromatographic	O
steps	O
and	O
characterized	O
by	O
u.v.	O
cross-linking	O
as	O
a	O
47	O
kDa	O
protein	O
.	O

The	O
ubiquitous	O
octamer-binding	O
protein	O
(	O
s	O
)	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
.	O

All	O
immunoglobulin	O
genes	O
contain	O
a	O
conserved	O
octanucleotide	O
promoter	O
element	O
,	O
ATGCAAAT	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
required	O
for	O
their	O
normal	O
B-cell-specific	O
transcription	O
.	O

Proteins	O
that	O
bind	O
this	O
octamer	O
have	O
been	O
purified	O
,	O
and	O
cDNAs	O
encoding	O
octamer-binding	O
proteins	O
have	O
been	O
cloned	O
.	O

Some	O
of	O
these	O
proteins	O
(	O
referred	O
to	O
as	O
OTF-2	O
)	O
are	O
lymphoid	O
specific	O
,	O
whereas	O
at	O
least	O
one	O
other	O
,	O
and	O
possibly	O
more	O
(	O
referred	O
to	O
as	O
OTF-1	O
)	O
,	O
is	O
found	O
ubiquitously	O
in	O
all	O
cell	O
types	O
.	O

The	O
exact	O
role	O
of	O
these	O
different	O
proteins	O
in	O
directing	O
the	O
tissue-specific	O
expression	O
of	O
immunoglobulin	O
genes	O
is	O
unclear	O
.	O

We	O
have	O
identified	O
two	O
human	O
pre-B-cell	O
lines	O
that	O
contain	O
extremely	O
low	O
levels	O
of	O
OTF-2	O
yet	O
still	O
express	O
high	O
levels	O
of	O
steady-state	O
immunoglobulin	O
heavy-chain	O
mRNA	O
in	O
vivo	O
and	O
efficiently	O
transcribe	O
an	O
immunoglobulin	O
gene	O
in	O
vitro	O
.	O

Addition	O
of	O
a	O
highly	O
enriched	O
preparation	O
of	O
OTF-1	O
made	O
from	O
one	O
of	O
these	O
pre-B	O
cells	O
or	O
from	O
HeLa	O
cells	O
specifically	O
stimulated	O
in	O
vitro	O
transcription	O
of	O
an	O
immunoglobulin	O
gene	O
.	O

Furthermore	O
,	O
OFT-1	O
appeared	O
to	O
have	O
approximately	O
the	O
same	O
transactivation	O
ability	O
as	O
OTF-2	O
when	O
normalized	O
for	O
binding	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
OTF-1	O
,	O
without	O
OTF-2	O
,	O
is	O
sufficient	O
for	O
transcription	O
of	O
immunoglobulin	O
genes	O
and	O
that	O
OTF-2	O
alone	O
is	O
not	O
responsible	O
for	O
the	O
B-cell-specific	O
regulation	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Tax-independent	O
binding	O
of	O
multiple	O
cellular	O
factors	O
to	O
Tax-response	O
element	O
DNA	O
of	O
HTLV-I	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
promoter	O
contains	O
three	O
copies	O
of	O
imperfect	O
repeats	O
of	O
a	O
21-base	O
pair	O
sequence	O
designated	O
here	O
as	O
TRE	O
(	O
Tax-response	O
element	O
)	O
that	O
is	O
responsive	O
to	O
the	O
virally	O
encoded	O
transactivator	O
protein	O
Tax	O
.	O

We	O
have	O
identified	O
and	O
separated	O
four	O
nuclear	O
proteins	O
from	O
C81-66-45	O
cells	O
,	O
an	O
HTLV-I	O
immortalized	O
Tax-expressing	O
human	O
T-lymphocyte	O
line	O
(	O
Salahuddin	O
et	O
al.	O
,	O
1983	O
)	O
,	O
that	O
interact	O
with	O
the	O
TRE-DNA	O
,	O
none	B-Negation
of	I-Negation
which	I-Negation
are	I-Negation
identical	I-Negation
with	I-Negation
the	I-Negation
Tax-protein	I-Negation
.	O

The	O
proteins	O
identified	O
have	O
molecular	O
weights	O
of	O
about	O
32	O
,	O
36	O
to	O
42	O
,	O
50	O
and	O
110	O
kD	O
.	O

Four	O
different	O
methods	O
were	O
used	O
to	O
identify	O
the	O
proteins	O
.	O

First	O
,	O
from	O
different	O
cell	O
lines	O
three	O
or	O
all	O
four	O
of	O
the	O
nuclear	O
proteins	O
were	O
specifically	O
cross-linked	O
by	O
UV	O
irradiation	O
to	O
the	O
radioactively	O
labeled	O
TRE-DNA	O
fragment	O
.	O

Second	O
,	O
TRE-DNA	O
binding	O
proteins	O
sedimented	O
through	O
a	O
glycerol	O
density	O
gradient	O
at	O
rates	O
corresponding	O
to	O
proteins	O
of	O
native	O
molecular	O
weights	O
of	O
35	O
to	O
50	O
kD	O
and	O
110	O
kD	O
.	O

Third	O
,	O
only	O
the	O
50	O
kD	O
protein	O
was	O
retained	O
on	O
a	O
biotinylated	O
DNA-streptavidin	O
matrix	O
when	O
the	O
DNA	O
fragment	O
contained	O
the	O
TRE-DNA	O
.	O

Fourth	O
,	O
extensive	O
purification	O
by	O
several	O
cycles	O
of	O
TRE-DNA	O
affinity	O
chromatography	O
resulted	O
in	O
the	O
32	O
,	O
36	O
to	O
42	O
and	O
110	O
kD	O
proteins	O
and	O
to	O
less	O
extent	O
the	O
50	O
kD	O
factor	O
.	O

Two	O
abundant	O
proteins	O
of	O
75	O
and	O
80	O
kD	O
were	O
competed	O
out	O
by	O
poly	O
[	O
d	O
(	O
I-C	O
)	O
]	O
in	O
all	O
reactions	O
.	O

The	O
cAMP-response	O
element	O
CRE	O
,	O
TGACGTCA	O
,	O
present	O
in	O
the	O
21	O
base-pair	O
sequence	O
,	O
appears	O
to	O
be	O
essential	O
for	O
specific	O
protein-TRE-DNA	O
interactions	O
because	O
mutation	O
of	O
the	O
two	O
G	O
's	O
destroys	O
this	O
complex	O
.	O

This	O
result	O
suggests	O
that	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
,	O
CREB	O
,	O
is	O
involved	O
in	O
the	O
protein-TRE-DNA	O
complex	O
and	O
in	O
mediating	O
the	O
Tax	O
response	O
.	O

Cell	O
type	O
specificity	O
and	O
activation	O
requirements	O
for	O
NFAT-1	O
(	O
nuclear	O
factor	O
of	O
activated	O
T-cells	O
)	O
transcriptional	O
activity	O
determined	O
by	O
a	O
new	O
method	O
using	O
transgenic	O
mice	O
to	O
assay	O
transcriptional	O
activity	O
of	O
an	O
individual	O
nuclear	O
factor	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T-cells	O
(	O
NFAT-1	O
)	O
is	O
a	O
transcription	O
factor	O
which	O
is	O
considered	O
to	O
be	O
an	O
important	O
regulator	O
in	O
early	O
T-cell	O
activation	O
.	O

We	O
have	O
developed	O
a	O
system	O
to	O
monitor	O
the	O
transcriptional	O
activity	O
of	O
NFAT-1	O
at	O
the	O
single	O
cell	O
level	O
in	O
whole	O
animals	O
.	O

The	O
system	O
is	O
based	O
on	O
the	O
use	O
of	O
an	O
oligomerized	O
NFAT-1	O
binding	O
motif	O
that	O
directs	O
transcription	O
of	O
SV40	O
T-antigen	O
in	O
transgenic	O
mice	O
.	O

This	O
report	O
represents	O
the	O
first	O
demonstration	O
that	O
a	O
multimerized	O
short	O
binding	O
motif	O
can	O
function	O
appropriately	O
in	O
transgenic	O
mice	O
.	O

NFAT-1	O
activity	O
had	O
previously	O
been	O
thought	O
to	O
be	O
confined	O
to	O
activated	O
T-lymphocytes	O
upon	O
release	O
of	O
intracellular	O
calcium	O
.	O

By	O
targeting	O
NFAT-1-dependent	O
gene	O
expression	O
in	O
transgenic	O
mice	O
we	O
discovered	O
new	O
sites	O
of	O
NFAT-1	O
activity	O
.	O

Besides	O
in	O
T-lymphocytes	O
NFAT-1	O
activity	O
could	O
also	O
be	O
induced	O
in	O
T-lymphocyte-depleted	O
spleen	O
cells	O
and	O
purified	O
B-lymphocytes	O
and	O
requires	O
agents	O
that	O
both	O
release	O
intracellular	O
calcium	O
and	O
activate	O
protein	O
kinase	O
C	O
.	O

A	O
difference	O
in	O
the	O
time	O
course	O
of	O
appearance	O
of	O
NFAT-1	O
activity	O
between	O
T-lymphocytes	O
and	O
non-T-lymphocytes	O
was	O
revealed	O
.	O

Constitutive	O
expression	O
was	O
observed	O
in	O
a	O
small	O
population	O
of	O
cells	O
in	O
the	O
dermis	O
and	O
some	O
mice	O
have	O
developed	O
skin	O
lesions	O
.	O

Interestingly	O
,	O
the	O
tissue	O
pattern	O
of	O
expression	O
of	O
the	O
NFAT-1	O
activity	O
resembles	O
the	O
expression	O
pattern	O
described	O
for	O
HIV-LTR/tat	O
transgenic	O
mice	O
(	O
Vogel	O
,	O
J.	O
,	O
Hinrichs	O
,	O
S.	O
H.	O
,	O
Reynolds	O
,	O
R.	O
K.	O
,	O
Luciw	O
,	O
P.	O
A.	O
,	O
and	O
Jay	O
,	O
G.	O
(	O
1988	O
)	O
Nature	O
335	O
,	O
606-611	O
)	O
.	O

This	O
similarity	O
in	O
expression	O
and	O
the	O
fact	O
that	O
NFAT-1	O
has	O
been	O
shown	O
to	O
bind	O
functional	O
sequences	O
in	O
HIV-LTR	O
suggest	O
a	O
role	O
for	O
NFAT-1	O
in	O
dermal	O
activation	O
of	O
the	O
HIV-LTR	O
.	O

NF-kappa	O
B	O
as	O
inducible	O
transcriptional	O
activator	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
gene	O
.	O

The	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
induced	O
upon	O
activation	O
of	O
T	O
cells	O
with	O
phytohemagglutinin	O
and	O
active	O
phorbolester	O
and	O
upon	O
expression	O
of	O
tax1	O
,	O
a	O
transactivating	O
protein	O
of	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
.	O

The	O
same	O
agents	O
induce	O
transcription	O
from	O
the	O
interleukin-2	O
receptor	O
alpha-chain	O
and	O
interleukin-2	O
genes	O
,	O
depending	O
on	O
promoter	O
elements	O
that	O
bind	O
the	O
inducible	O
transcription	O
factor	O
NF-kappa	O
B	O
(	O
or	O
an	O
NF-kappa	O
B-like	O
factor	O
)	O
.	O

We	O
therefore	O
tested	O
the	O
possibility	O
that	O
the	O
GM-CSF	O
gene	O
is	O
also	O
regulated	O
by	O
a	O
cognate	O
motif	O
for	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
.	O

A	O
recent	O
functional	O
analysis	O
by	O
Miyatake	O
et	O
al.	O
(	O
S.	O
Miyatake	O
,	O
M.	O
Seiki	O
,	O
M.	O
Yoshida	O
,	O
and	O
K.	O
Arai	O
,	O
Mol.	O
Cell.	O
Biol.	O
8:5581-5587	O
,	O
1988	O
)	O
described	O
a	O
short	O
promoter	O
region	O
in	O
the	O
GM-CSF	O
gene	O
that	O
conferred	O
strong	O
inducibility	O
by	O
T-cell-activating	O
signals	O
and	O
tax1	O
,	O
but	O
no	B-Negation
NF-kappa	I-Negation
B-binding	I-Negation
motifs	I-Negation
were	I-Negation
identified	I-Negation
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
showed	O
binding	O
of	O
purified	O
human	O
NF-kappa	O
B	O
and	O
of	O
the	O
NF-kappa	O
B	O
activated	O
in	O
Jurkat	O
T	O
cells	O
to	O
an	O
oligonucleotide	O
comprising	O
the	O
GM-CSF	O
promoter	O
element	O
responsible	O
for	O
mediating	O
responsiveness	O
to	O
T-cell-activating	O
signals	O
and	O
tax1	O
.	O

As	O
shown	O
by	O
a	O
methylation	O
interference	O
analysis	O
and	O
oligonucleotide	O
competition	O
experiments	O
,	O
purified	O
NF-kappa	O
B	O
binds	O
at	O
positions	O
-82	O
to	O
-91	O
(	O
GGGAACTACC	O
)	O
of	O
the	O
GM-CSF	O
promoter	O
sequence	O
with	O
an	O
affinity	O
similar	O
to	O
that	O
with	O
which	O
it	O
binds	O
to	O
the	O
biologically	O
functional	O
kappa	O
B	O
motif	O
in	O
the	O
beta	O
interferon	O
promoter	O
(	O
GGGAAATTCC	O
)	O
.	O

Two	O
kappa	O
B-like	O
motifs	O
at	O
positions	O
-98	O
to	O
-108	O
of	O
the	O
GM-CSF	O
promoter	O
were	O
also	O
recognized	O
but	O
with	O
much	O
lower	O
affinities	O
.	O

Our	O
data	O
provide	O
strong	O
evidence	O
that	O
the	O
expression	O
of	O
the	O
GM-CSF	O
gene	O
following	O
T-cell	O
activation	O
is	O
controlled	O
by	O
binding	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
to	O
a	O
high-affinity	O
binding	O
site	O
in	O
the	O
GM-CSF	O
promoter	O
.	O

Octamer	O
transcription	O
factors	O
and	O
the	O
cell	O
type-specificity	O
of	O
immunoglobulin	O
gene	O
expression	O
.	O

Antibodies	O
are	O
produced	O
exclusively	O
in	O
B	O
lymphocytes	O
.	O

The	O
expression	O
of	O
the	O
antibody-encoding	O
genes	O
,	O
the	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
,	O
is	O
also	O
restricted	O
to	O
B	O
cells	O
.	O

The	O
octamer	O
sequence	O
ATGCAAAT	O
is	O
present	O
in	O
the	O
promoter	O
and	O
the	O
enhancer	O
of	O
Ig	O
genes	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
its	O
tissue-specific	O
expression	O
.	O

This	O
sequence	O
motif	O
is	O
a	O
binding	O
site	O
for	O
nuclear	O
proteins	O
,	O
the	O
so-called	O
octamer	O
transcription	O
factors	O
(	O
Oct	O
or	O
OTF	O
factors	O
)	O
.	O

The	O
Oct-1	O
protein	O
is	O
present	O
in	O
all	O
cell	O
types	O
analyzed	O
so	O
far	O
,	O
whereas	O
Oct-2A	O
and	O
Oct-2B	O
are	O
found	O
mainly	O
in	O
B	O
lymphocytes	O
.	O

All	O
three	O
proteins	O
show	O
the	O
same	O
sequence	O
specificity	O
and	O
binding	O
affinity	O
.	O

It	O
appears	O
that	O
the	O
B	O
cell-specific	O
expression	O
of	O
Ig	O
genes	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
cell	O
type-specific	O
Oct	O
factors	O
,	O
and	O
that	O
there	O
are	O
both	O
quantitative	O
and	O
qualitative	O
differences	O
between	O
Oct-1	O
and	O
Oct-2	O
factors	O
.	O

Recently	O
,	O
a	O
number	O
of	O
other	O
octamer	O
factor	O
variants	O
were	O
identified	O
.	O

Many	O
of	O
these	O
may	O
be	O
created	O
by	O
alternative	O
splicing	O
of	O
a	O
primary	O
transcript	O
of	O
one	O
Oct	O
factor	O
gene	O
and	O
may	O
serve	O
a	O
specific	O
function	O
in	O
the	O
fine	O
tuning	O
of	O
gene	O
expression	O
.	O

ETS1	O
transactivates	O
the	O
human	O
GM-CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
PMA	O
and	O
ionomycin	O
.	O

Activation	O
of	O
T	O
helper	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
one	O
such	O
cytokine	O
whose	O
increased	O
expression	O
results	O
partly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	O
elements	O
with	O
NF	O
kappa	O
B	O
,	O
AP-1	O
and	O
ETS-like	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	O
gene	O
,	O
which	O
are	O
important	O
for	O
transcriptional	O
activity	O
following	O
PMA	O
and	O
ionomycin	O
stimulation	O
.	O

A	O
number	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
are	O
expressed	O
in	O
T	O
cells	O
,	O
including	O
ETS1	O
and	O
ELF1	O
.	O

Here	O
we	O
describe	O
the	O
ability	O
of	O
these	O
factors	O
to	O
interact	O
with	O
a	O
site	O
(	O
GM5	O
)	O
,	O
located	O
within	O
the	O
CLE0	O
element	O
,	O
-47	O
to	O
-40	O
upstream	O
of	O
the	O
GM-CSF	O
transcription	O
initiation	O
site	O
.	O

Exogenous	O
ETS1	O
,	O
but	O
not	B-Negation
ELF1	I-Negation
,	O
can	O
transactivate	O
GM-CSF	O
,	O
through	O
the	O
GM5	O
site	O
,	O
in	O
a	O
PMA/ionomycin	O
dependent	O
manner	O
.	O

Other	O
unidentified	O
ETS-like	O
factors	O
present	O
in	O
Jurkat	O
cells	O
are	O
also	O
capable	O
of	O
binding	O
GM5	O
.	O

Mutation	O
of	O
the	O
core	O
ETS	O
binding	O
site	O
from	O
-GGAA-	O
to	O
-GGAT-	O
prevents	O
the	O
binding	O
of	O
ETS-like	O
factors	O
with	B-Negation
the	I-Negation
exception	I-Negation
of	I-Negation
ETS1	I-Negation
.	O

The	O
GM-CSF	O
promoter	O
,	O
modified	O
in	O
this	O
way	O
to	O
be	O
ETS1	O
specific	O
,	O
is	O
fully	O
responsive	O
to	O
PMA/ionomycin	O
induction	O
,	O
in	O
addition	O
to	O
ETS1	O
transactivation	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
ionomycin	O
.	O

Together	O
these	O
data	O
suggest	O
that	O
ETS1	O
may	O
be	O
involved	O
in	O
mediating	O
the	O
increased	O
GM-CSF	O
production	O
associated	O
with	O
T	O
cell	O
activation	O
.	O

Tissue-specific	O
regulation	O
of	O
the	O
rabbit	O
15-lipoxygenase	O
gene	O
in	O
erythroid	O
cells	O
by	O
a	O
transcriptional	O
silencer	O
.	O

The	O
15-lipoxygenase	O
(	O
lox	O
)	O
gene	O
is	O
expressed	O
in	O
a	O
tissue-specific	O
manner	O
,	O
predominantly	O
in	O
erythroid	O
cells	O
but	O
also	O
in	O
airway	O
epithelial	O
cells	O
and	O
eosinophils	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
the	O
5	O
'	O
flanking	O
DNA	O
of	O
the	O
15-lox	O
gene	O
contains	O
sequences	O
which	O
down-regulate	O
its	O
activity	O
in	O
a	O
variety	O
of	O
non-erythroid	O
cell	O
lines	O
but	O
not	B-Negation
in	I-Negation
two	I-Negation
erythroid	I-Negation
cell	I-Negation
lines	I-Negation
.	O

The	O
element	O
has	O
characteristics	O
of	O
a	O
transcriptional	O
'silencer	O
'	O
since	O
it	O
functions	O
in	O
both	O
orientations	O
.	O

The	O
main	O
activity	O
of	O
the	O
silencer	O
has	O
been	O
mapped	O
to	O
the	O
first	O
900	O
bp	O
of	O
5	O
'	O
flanking	O
DNA	O
,	O
which	O
contains	O
nine	O
binding	O
sites	O
for	O
a	O
nuclear	O
factor	O
present	O
in	O
non-erythroid	O
cells	O
but	O
not	B-Negation
in	I-Negation
erythroid	I-Negation
cells	I-Negation
.	O

These	O
binding	O
sites	O
have	O
similar	O
sequences	O
and	O
multiple	O
copies	O
of	O
the	O
binding	O
sites	O
confer	O
tissue-specific	O
down-regulation	O
when	O
attached	O
to	O
a	O
minimal	O
lox	O
promoter	O
fragment	O
.	O

The	O
5	O
'	O
flanking	O
DNA	O
also	O
contains	O
a	O
cluster	O
of	O
three	O
binding	O
sites	O
for	O
the	O
GATA	O
family	O
of	O
transcription	O
factors	O
.	O

Coexpression	O
of	O
NF-kappa	O
B/Rel	O
and	O
Sp1	O
transcription	O
factors	O
in	O
human	O
immunodeficiency	O
virus	O
1-induced	O
,	O
dendritic	O
cell-T-cell	O
syncytia	O
.	O

Productive	O
infection	O
of	O
T	O
cells	O
with	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
typically	O
requires	O
that	O
the	O
T	O
cells	O
be	O
stimulated	O
with	O
antigens	O
or	O
mitogens	O
.	O

This	O
requirement	O
has	O
been	O
attributed	O
to	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
,	O
which	O
synergizes	O
with	O
the	O
constitutive	O
transcription	O
factor	O
Sp1	O
to	O
drive	O
the	O
HIV-1	O
promoter	O
.	O

Recently	O
,	O
we	O
have	O
found	O
that	O
vigorous	O
replication	O
of	O
HIV-1	O
takes	O
place	O
in	O
nonactivated	O
memory	O
T	O
cells	O
after	O
syncytium	O
formation	O
with	O
dendritic	O
cells	O
(	O
DCs	O
)	O
.	O

These	O
syncytia	O
lack	B-Negation
activated	I-Negation
cells	I-Negation
as	O
determined	O
by	O
an	O
absence	B-Negation
of	I-Negation
staining	I-Negation
for	I-Negation
Ki-67	I-Negation
cell	I-Negation
cycle	I-Negation
antigen	I-Negation
.	O

The	O
expression	O
and	O
activity	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
were	O
,	O
therefore	O
,	O
analyzed	O
in	O
isolated	O
T	O
cells	O
and	O
DCs	O
from	O
humans	O
and	O
mice	O
.	O

We	O
have	O
used	O
immunolabeling	O
,	O
Western	O
blot	O
analysis	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
and	O
supershift	O
assays	O
.	O

T	O
cells	O
lack	B-Negation
active	I-Negation
NF-kappa	I-Negation
B	I-Negation
but	O
express	O
Sp1	O
as	O
expected	O
.	O

DCs	O
express	O
high	O
levels	O
of	O
all	O
known	O
NF-kappa	O
B	O
and	O
Rel	O
proteins	O
,	O
with	O
activity	O
residing	O
primarily	O
within	O
RelB	O
,	O
p50	O
,	O
and	O
p65	O
.	O

However	O
,	O
DCs	O
lack	B-Negation
Sp1	I-Negation
,	O
which	O
may	B-Speculation
explain	I-Speculation
the	I-Speculation
failure	I-Speculation
of	I-Speculation
HIV-1	I-Speculation
to	I-Speculation
replicate	I-Speculation
in	I-Speculation
purified	I-Speculation
DCs	I-Speculation
.	O

Coexpression	O
of	O
NF-kappa	O
B	O
and	O
Sp1	O
occurs	O
in	O
the	O
heterologous	O
DC-T-cell	O
syncytia	O
that	O
are	O
induced	O
by	O
HIV-1	O
.	O

Therefore	O
,	O
HIV-1-induced	O
cell	O
fusion	O
brings	O
together	O
factors	O
that	O
upregulate	O
virus	O
transcription	O
.	O

Since	O
DCs	O
and	O
memory	O
T	O
cells	O
frequently	O
traffic	O
together	O
in	O
situ	O
,	O
these	O
unusual	O
heterologous	O
syncytia	O
could	O
develop	O
in	O
infected	O
individuals	O
and	O
lead	O
to	O
chronic	O
HIV-1	O
replication	O
without	B-Negation
ostensible	I-Negation
immune	I-Negation
stimulation	I-Negation
.	O

Down-regulation	O
of	O
NF-kappa	O
B	O
protein	O
levels	O
in	O
activated	O
human	O
lymphocytes	O
by	O
1,25-dihydroxyvitamin	O
D3	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1996	O
Jan	O
9	O
;	O
93	O
(	O
1	O
)	O
:524	O
]	O

The	O
effect	O
of	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2	O
)	O
D3	O
]	O
,	O
a	O
steroid	O
hormone	O
with	O
immunomodulating	O
properties	O
,	O
on	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
proteins	O
was	O
examined	O
in	O
in	O
vitro	O
activated	O
normal	O
human	O
lymphocytes	O
by	O
Western	O
blot	O
analysis	O
.	O

Over	O
a	O
72-hr	O
period	O
of	O
activation	O
,	O
the	O
expression	O
of	O
the	O
50-kDa	O
NF-kappa	O
B	O
,	O
p50	O
,	O
and	O
its	O
precursor	O
,	O
p105	O
,	O
was	O
increased	O
progressively	O
.	O

When	O
cells	O
were	O
activated	O
in	O
the	O
presence	O
of	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
the	O
levels	O
of	O
the	O
mature	O
protein	O
as	O
well	O
as	O
its	O
precursor	O
were	O
decreased	O
.	O

The	O
effect	O
of	O
the	O
hormone	O
on	O
the	O
levels	O
of	O
p50	O
was	O
demonstrable	O
in	O
the	O
cytosolic	O
and	O
nuclear	O
compartments	O
;	O
it	O
required	O
between	O
4	O
and	O
8	O
hr	O
and	O
was	O
specific	O
,	O
as	O
25-hydroxyvitamin	O
D3	O
and	O
24,25-dihydroxyvitamin	O
D3	O
were	O
ineffective	O
.	O

Besides	O
p50	O
,	O
1,25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
levels	O
of	O
another	O
NF-kappa	O
B	O
protein	O
,	O
namely	O
c-rel	O
.	O

In	O
addition	O
,	O
1,25	O
(	O
OH	O
)	O
2D3	O
decreased	O
the	O
abundance	O
of	O
a	O
specific	O
DNA-protein	O
complex	O
formed	O
upon	O
incubation	O
of	O
nuclear	O
extracts	O
from	O
activated	O
lymphocytes	O
with	O
a	O
labeled	O
NF-kappa	O
B	O
DNA	O
binding	O
motif	O
.	O

Further	O
,	O
1,25	O
(	O
OH	O
)	O
2D3	O
inhibited	O
the	O
transcriptional	O
activity	O
of	O
NF-kappa	O
B	O
in	O
Jurkat	O
cells	O
transiently	O
transfected	O
with	O
a	O
construct	O
containing	O
four	O
tandem	O
repeats	O
of	O
the	O
NF-kappa	O
B	O
binding	O
sequence	O
of	O
the	O
immunoglobulin	O
kappa	O
light	O
chain	O
gene	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O

These	O
observations	O
demonstrate	O
directly	O
that	O
there	O
is	O
de	O
novo	O
synthesis	O
of	O
NF-kappa	O
B	O
during	O
human	O
lymphocyte	O
activation	O
and	O
suggest	O
that	O
this	O
process	O
is	O
hormonally	O
regulated	O
.	O

Costimulation	O
requirement	O
for	O
AP-1	O
and	O
NF-kappa	O
B	O
transcription	O
factor	O
activation	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
IL-2	O
promoter	O
requires	O
T-cell	O
costimulation	O
delivered	O
by	O
the	O
TCR	O
and	O
the	O
auxiliary	O
receptor	O
CD28	O
.	O

Several	O
transcription	O
factors	O
participate	O
in	O
IL-2	O
promoter	O
activation	O
,	O
among	O
which	O
are	O
AP-1-like	O
factors	O
and	O
NF-kappa	O
B	O
.	O

Protein	O
phosphorylation	O
has	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
these	O
two	O
factors	O
:	O
(	O
1	O
)	O
it	O
induces	O
the	O
transactivating	O
capacity	O
of	O
the	O
AP-1	O
protein	O
c-Jun	O
;	O
and	O
(	O
2	O
)	O
it	O
is	O
involved	O
in	O
the	O
release	O
of	O
the	O
cytoplasmic	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
from	O
NF-kappa	O
B	O
,	O
allowing	O
translocation	O
of	O
the	O
latter	O
into	O
the	O
nucleus	O
.	O

We	O
have	O
recently	O
shown	O
that	O
both	O
phosphorylation	O
processes	O
require	O
T-cell	O
costimulation	O
.	O

Furthermore	O
,	O
in	O
activated	O
T	O
cells	O
,	O
the	O
kinetics	O
of	O
the	O
two	O
phosphorylation	O
events	O
are	O
essentially	O
similar	O
.	O

According	O
to	O
our	O
results	O
,	O
however	O
,	O
the	O
kinases	O
responsible	O
for	O
the	O
two	O
processes	O
are	O
distinct	O
entities	O
.	O

Whereas	O
TPCK	O
inhibits	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
and	O
,	O
consequently	O
,	O
activation	O
of	O
NF-kappa	O
B	O
,	O
it	O
markedly	O
enhances	O
the	O
activity	O
of	O
JNK	O
,	O
the	O
MAP	O
kinase-related	O
kinase	O
that	O
phosphorylates	O
the	O
transactivation	O
domain	O
of	O
c-Jun	O
.	O

We	O
,	O
therefore	O
,	O
propose	O
the	O
activation	O
scheme	O
presented	O
in	O
FIGURE	O
3	O
for	O
T-cell	O
costimulation	O
.	O

Costimulation	O
results	O
in	O
the	O
activation	O
of	O
a	O
signaling	O
pathway	O
that	O
leads	O
to	O
the	O
simultaneous	O
induction	O
of	O
the	O
two	O
transcription	O
factors	O
,	O
AP-1	O
and	O
NF-kappa	O
B	O
.	O

Integration	O
of	O
the	O
signals	O
generated	O
by	O
TCR	O
and	O
CD28	O
engagement	O
occurs	O
along	O
this	O
pathway	O
,	O
which	O
then	O
bifurcates	O
to	O
induce	O
I	O
kappa	O
B	O
phosphorylation	O
and	O
NF-kappa	O
B	O
activation	O
on	O
the	O
one	O
hand	O
,	O
and	O
JNK	O
activation	O
and	O
c-Jun	O
phosphorylation	O
on	O
the	O
other	O
.	O

We	O
are	O
currently	O
engaged	O
in	O
defining	O
where	O
the	O
two	O
signals	O
integrate	O
along	O
the	O
AP-1/NF-kappa	O
B	O
pathway	O
.	O

Cupric	O
ion	O
blocks	O
NF	O
kappa	O
B	O
activation	O
through	O
inhibiting	O
the	O
signal-induced	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

A	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
which	O
regulates	O
expression	O
of	O
various	O
cellular	O
genes	O
involved	O
in	O
immune	O
responses	O
and	O
viral	O
genes	O
including	O
HIV	O
,	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
as	O
a	O
complex	O
with	O
an	O
inhibitory	O
protein	O
I	O
kappa	O
B	O
.	O

Various	O
extracellular	O
signals	O
induce	O
phosphorylation	O
and	O
rapid	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
to	O
release	O
NF	O
kappa	O
B	O
.	O

Cu2+	O
was	O
found	O
to	O
inhibit	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
induced	O
by	O
TNF-alpha	O
,	O
TPA	O
,	O
or	O
H2O2	O
.	O

Deoxycholate	O
treatment	O
of	O
the	O
cytoplasmic	O
extract	O
prepared	O
from	O
cells	O
stimulated	O
by	O
TNF-alpha	O
in	O
the	O
presence	O
of	O
Cu2+	O
resulted	O
in	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
from	O
I	O
kappa	O
B	O
alpha	O
,	O
indicating	O
that	O
Cu2+	O
interferes	O
with	O
the	O
dissociation	O
of	O
the	O
NF	O
kappa	O
B-I	O
kappa	O
B	O
complex	O
.	O

Neither	B-Negation
phosphorylation	I-Negation
nor	I-Negation
degradation	I-Negation
of	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
was	I-Negation
observed	I-Negation
upon	I-Negation
TNF-alpha	I-Negation
stimulation	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
Cu2+	I-Negation
.	O

These	O
results	O
indicate	O
that	O
Cu2+	O
inhibits	O
the	O
release	O
of	O
NF	O
kappa	O
B	O
by	O
blockade	O
of	O
a	O
signal	O
leading	O
to	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Salicylates	O
inhibit	O
lipopolysaccharide-induced	O
transcriptional	O
activation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Binding	O
of	O
plasma	O
Factor	O
VII/VIIa	O
to	O
the	O
tissue	O
factor	O
(	O
TF	O
)	O
receptor	O
initiates	O
the	O
coagulation	O
protease	O
cascades	O
.	O

TF	O
expression	O
by	O
circulating	O
monocytes	O
is	O
associated	O
with	O
thrombotic	O
and	O
inflammatory	O
complications	O
in	O
a	O
variety	O
of	O
diseases	O
.	O

Transcriptional	O
activation	O
of	O
the	O
human	O
TF	O
gene	O
in	O
monocytic	O
cells	O
exposed	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
family	O
of	O
anti-inflammatory	O
agents	O
,	O
known	O
as	O
the	O
salicylates	O
,	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
activity	O
and	O
TF	O
gene	O
transcription	O
in	O
human	O
monocytes	O
and	O
monocytic	O
THP-1	O
cells	O
at	O
clinically	O
relevant	O
doses	O
.	O

Furthermore	O
,	O
sodium	O
salicylate	O
blocked	O
the	O
LPS-induced	O
proteolytic	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
prevented	O
the	O
nuclear	O
translocation	O
of	O
c-Rel/p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
two	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
,	O
ibuprofen	O
and	O
indomethacin	O
,	O
did	O
not	B-Negation
inhibit	I-Negation
LPS	I-Negation
induction	I-Negation
of	I-Negation
the	I-Negation
TF	I-Negation
gene	I-Negation
.	O

These	O
results	O
indicated	O
that	O
salicylates	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
by	O
preventing	O
nuclear	O
translocation	O
of	O
c-Rel/p65	O
heterodimers	O
.	O

The	O
clinical	O
benefits	O
of	O
salicylates	O
in	O
the	O
treatment	O
of	O
several	O
diseases	O
,	O
including	O
atherosclerosis	O
and	O
rheumatoid	O
arthritis	O
,	O
may	O
be	O
related	O
to	O
their	O
ability	O
to	O
reduce	O
monocyte	O
gene	O
expression	O
.	O

CIITA	O
activates	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
.	O

It	O
has	O
long	O
been	O
a	O
puzzle	O
that	O
MHC	O
class	O
II	O
molecules	O
are	O
expressed	O
in	O
human	O
T	O
cells	O
after	O
activation	O
but	O
not	B-Negation
in	I-Negation
mouse	I-Negation
T	I-Negation
cells	I-Negation
;	O
this	B-Speculation
expression	I-Speculation
is	I-Speculation
believed	I-Speculation
to	I-Speculation
play	I-Speculation
a	I-Speculation
role	I-Speculation
in	I-Speculation
the	I-Speculation
cell	I-Speculation
mediated	I-Speculation
immune	I-Speculation
response	I-Speculation
.	O

Recently	O
the	O
MHC	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
has	O
been	O
reported	O
to	O
be	O
a	O
major	O
regulatory	O
factor	O
for	O
both	O
the	O
constitutive	O
and	O
IFN	O
inducible	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

Here	O
we	O
show	O
that	O
human	O
T	O
cells	O
expressing	O
MHC	O
class	O
II	O
have	O
CIITA	O
transcripts	O
while	O
MHC	O
class	O
II-negative	O
human	O
T	O
cells	O
and	O
mouse	O
T	O
cells	O
do	O
not	B-Negation
.	O

The	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
in	O
mouse	O
T	O
cells	O
can	O
be	O
reconstituted	O
upon	O
transfection	O
with	O
the	O
human	O
CIITA	O
cDNA	O
.	O

These	O
data	O
indicate	O
that	O
the	O
expression	O
of	O
CIITA	O
explains	O
the	O
expression	O
or	O
lack	O
of	O
expression	O
of	O
MHC	O
class	O
II	O
in	O
human	O
and	O
mouse	O
T	O
cells	O
respectively	O
.	O

Identification	O
of	O
an	O
I	O
kappa	O
B	O
alpha-associated	O
protein	O
kinase	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
and	O
determination	O
of	O
its	O
phosphorylation	O
sites	O
on	O
I	O
kappa	O
B	O
alpha	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
stored	O
in	O
the	O
cytoplasm	O
as	O
an	O
inactive	O
form	O
through	O
interaction	O
with	O
I	O
kappa	O
B	O
.	O

Stimulation	O
of	O
cells	O
leads	O
to	O
a	O
rapid	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
which	O
is	O
presumed	O
to	O
be	O
important	O
for	O
the	O
subsequent	O
degradation	O
.	O

We	O
have	O
recently	O
reported	O
the	O
establishment	O
of	O
a	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-dependent	O
cell-free	O
activation	O
system	O
of	O
NF-kappa	O
B	O
in	O
association	O
with	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
a	O
kinase	O
in	O
cell	O
extracts	O
from	O
the	O
LPS-stimulated	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
that	O
specifically	O
binds	O
and	O
phosphorylates	O
I	O
kappa	O
B	O
alpha	O
.	O

LPS	O
stimulation	O
transiently	O
enhanced	O
the	O
I	O
kappa	O
B	O
alpha-bound	O
kinase	O
activity	O
in	O
THP-1	O
cells	O
.	O

Mutational	O
analyses	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
competition	O
experiments	O
with	O
the	O
synthetic	O
peptides	O
identified	O
major	O
phosphorylation	O
sites	O
by	O
the	O
bound	O
kinase	O
as	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
C-terminal	O
acidic	O
domain	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
peptide	O
,	O
corresponding	O
to	O
the	O
C-terminal	O
acidic	O
domain	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
blocked	O
the	O
LPS-induced	O
NF-kappa	O
B	O
activation	O
as	O
well	O
as	O
inducible	O
phosphorylation	O
of	O
endogenous	O
I	O
kappa	O
B	O
alpha	O
in	O
a	O
cell-free	O
system	O
using	O
THP-1	O
cells	O
.	O

These	O
results	O
suggested	O
that	O
the	O
bound	O
kinase	O
is	O
involved	O
in	O
the	O
signaling	O
pathway	O
of	O
LPS	O
by	O
inducing	O
the	O
phosphorylation	O
of	O
the	O
C-terminal	O
region	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
subsequent	O
dissociation	O
of	O
the	O
NF-kappa	O
B.I	O
kappa	O
B	O
alpha	O
complex	O
.	O

Triggering	O
of	O
the	O
human	O
interleukin-6	O
gene	O
by	O
interferon-gamma	O
and	O
tumor	O
necrosis	O
factor-alpha	O
in	O
monocytic	O
cells	O
involves	O
cooperation	O
between	O
interferon	O
regulatory	O
factor-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
Sp1	O
transcription	O
factors	O
.	O

We	O
investigated	O
the	O
molecular	O
basis	O
of	O
the	O
synergistic	O
induction	O
by	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
/tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
of	O
human	O
interleukin-6	O
(	O
IL-6	O
)	O
gene	O
in	O
THP-1	O
monocytic	O
cells	O
,	O
and	O
compared	O
it	O
with	O
the	O
basis	O
of	O
this	O
induction	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Functional	O
studies	O
with	O
IL-6	O
promoter	O
demonstrated	O
that	O
three	O
regions	O
are	O
the	O
targets	O
of	O
the	O
IFN-gamma	O
and/or	O
TNF-alpha	O
action	O
,	O
whereas	O
only	O
one	O
of	O
these	O
regions	O
seemed	O
to	O
be	O
implicated	O
in	O
LPS	O
activation	O
.	O

The	O
three	O
regions	O
concerned	O
are	O
:	O
1	O
)	O
a	O
region	O
between	O
-73	O
and	O
-36	O
,	O
which	O
is	O
the	O
minimal	O
element	O
inducible	O
by	O
LPS	O
or	O
TNF-alpha	O
;	O
2	O
)	O
an	O
element	O
located	O
between	O
-181	O
and	O
-73	O
,	O
which	O
appeared	O
to	O
regulate	O
the	O
response	O
to	O
IFN-gamma	O
and	O
TNF-alpha	O
negatively	O
;	O
and	O
3	O
)	O
a	O
distal	O
element	O
upstream	O
of	O
-224	O
,	O
which	O
was	O
inducible	O
by	O
IFN-gamma	O
alone	O
.	O

LPS	O
signaling	O
was	O
found	O
to	O
involve	O
NF	O
kappa	O
B	O
activation	O
by	O
the	O
p50/p65	O
heterodimers	O
.	O

Synergistic	O
induction	O
of	O
the	O
IL-6	O
gene	O
by	O
IFN-gamma	O
and	O
TNF-alpha	O
,	O
in	O
monocytic	O
cells	O
,	O
involved	O
cooperation	O
between	O
the	O
IRF-1	O
and	O
NF	O
kappa	O
B	O
p65	O
homodimers	O
with	O
concomitant	O
removal	O
of	O
the	O
negative	O
effect	O
of	O
the	O
retinoblastoma	O
control	O
element	O
present	O
in	O
the	O
IL-6	O
promoter	O
.	O

This	O
removal	O
occurred	O
by	O
activation	O
of	O
the	O
constitutive	O
Sp1	O
factor	O
,	O
whose	O
increased	O
binding	O
activity	O
and	O
phosphorylation	O
were	O
mediated	O
by	O
IFN-gamma	O
.	O

Thrombin	O
and	O
thrombin	O
receptor	O
agonist	O
peptide	O
induce	O
early	O
events	O
of	O
T	O
cell	O
activation	O
and	O
synergize	O
with	O
TCR	O
cross-linking	O
for	O
CD69	O
expression	O
and	O
interleukin	O
2	O
production	O
.	O

Thrombin	O
stimulation	O
of	O
the	O
T	O
leukemic	O
cell	O
line	O
Jurkat	O
induced	O
a	O
transient	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
.	O

Proteolytic	O
activity	O
of	O
the	O
enzyme	O
was	O
required	O
for	O
this	O
effect	O
since	O
diisopropyl	O
fluorophosphate-thrombin	O
failed	B-Negation
to	I-Negation
increase	I-Negation
[	I-Negation
Ca2+	I-Negation
]	I-Negation
i	I-Negation
.	O

Furthermore	O
,	O
hirudin	O
and	O
anti-thrombin	O
III	O
inhibited	O
the	O
thrombin-induced	O
[	O
Ca2+	O
]	O
i	O
rise	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
synthetic	O
thrombin	O
receptor	O
agonist	O
peptide	O
(	O
TRP	O
)	O
of	O
7	O
residues	O
(	O
SFLLRNP	O
)	O
was	O
found	O
to	O
be	O
as	O
effective	O
as	O
thrombin	O
for	O
[	O
Ca2+	O
]	O
i	O
mobilization	O
,	O
and	O
both	O
agonists	O
induced	O
Ca2+	O
release	O
exclusively	O
from	O
internal	O
stores	O
.	O

Thrombin	O
stimulated	O
tyrosine	O
phosphorylation	O
of	O
several	O
proteins	O
of	O
molecular	O
mass	O
40	O
,	O
42	O
,	O
70	O
,	O
120	O
,	O
and	O
130	O
kDa	O
.	O

There	O
was	O
a	O
good	O
correlation	O
between	O
thrombin-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
latter	O
three	O
proteins	O
and	O
Ca2+	O
mobilization	O
.	O

Thrombin	O
and	O
TRP	O
also	O
caused	O
translocation	O
of	O
protein	O
kinase	O
C	O
from	O
the	O
cytosol	O
to	O
the	O
plasma	O
membrane	O
.	O

As	O
a	O
likely	O
consequence	O
of	O
these	O
events	O
,	O
thrombin	O
activated	O
the	O
nuclear	O
factor	O
NF-kB	O
.	O

Several	O
cell	O
lines	O
of	O
hematopoietic	O
origin	O
including	O
the	O
leukemic	O
T	O
cell	O
line	O
HPB.ALL	O
and	O
the	O
erythroleukemic	O
cell	O
line	O
K562	O
were	O
responsive	O
to	O
thrombin	O
,	O
whereas	O
others	O
such	O
as	O
THP1	O
,	O
a	O
myelomonocytic	O
cell	O
line	O
,	O
and	O
BL2	O
,	O
a	O
Burkitt	O
lymphoma	O
were	O
refractory	O
to	O
thrombin	O
or	O
TRP	O
stimulation	O
.	O

The	O
magnitude	O
of	O
the	O
thrombin	O
response	O
in	O
the	O
different	O
cell	O
types	O
paralleled	O
the	O
expression	O
of	O
the	O
thrombin	O
receptor	O
mRNA	O
.	O

We	O
found	O
that	O
activation	O
of	O
Jurkat	O
T	O
cells	O
by	O
a	O
combination	O
of	O
phytohemagglutinin	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
led	O
to	O
a	O
dramatic	O
inhibition	O
of	O
thrombin	O
receptor	O
mRNA	O
expression	O
and	O
to	O
a	O
concomitant	O
loss	O
of	O
the	O
thrombin	O
response	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
thrombin	O
and	O
TRP	O
enhanced	O
CD69	O
expression	O
and	O
interleukin	O
2	O
production	O
induced	O
by	O
T	O
cell	O
receptor	O
cross-linking	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
peripheral	O
blood	O
lymphocytes	O
.	O

These	O
findings	O
highlight	O
the	O
role	O
of	O
thrombin	O
as	O
a	O
potential	O
regulator	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
interleukin-8	O
AP-1	O
and	O
kappa	O
B-like	O
sites	O
are	O
genetic	O
end	O
targets	O
of	O
FK506-sensitive	O
pathway	O
accompanied	O
by	O
calcium	O
mobilization	O
.	O

FK506	O
,	O
an	O
immunosuppressant	O
,	O
inhibits	O
the	O
production	O
of	O
several	O
cytokines	O
in	O
T	O
lymphocytes	O
.	O

We	O
observed	O
that	O
FK506	O
suppressed	O
the	O
transcription	O
of	O
a	O
chemotactic	O
cytokine	O
,	O
interleukin-8	O
(	O
IL-8	O
)	O
in	O
a	O
human	O
T	O
cell	O
line	O
,	O
Jurkat	O
cells	O
,	O
activated	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
calcium	O
(	O
Ca2+	O
)	O
ionophore	O
(	O
ionomycin	O
)	O
.	O

By	O
deleted	O
and	O
mutated	O
analysis	O
of	O
the	O
IL-8	O
promoters	O
,	O
the	O
AP-1	O
and	O
kappa	O
B-like	O
sites	O
were	O
identified	O
as	O
the	O
responsive	O
elements	O
for	O
PMA	O
and	O
ionomycin	O
.	O

FK506	O
suppressed	O
the	O
transcriptions	O
through	O
the	O
AP-1	O
or	O
kappa	O
B-like	O
sites	O
induced	O
by	O
PMA	O
plus	O
Ca	O
(	O
2+	O
)	O
-mobilizing	O
agents	O
,	O
but	O
not	B-Negation
those	I-Negation
induced	I-Negation
by	I-Negation
Ca	I-Negation
(	I-Negation
2+	I-Negation
)	I-Negation
-independent	I-Negation
stimuli	I-Negation
.	O

In	O
gel	O
retardation	O
analysis	O
,	O
FK506	O
had	O
little	O
effect	O
on	O
the	O
binding	O
to	O
the	O
AP-1	O
site	O
of	O
PMA/ionomycin-induced	O
nuclear	O
factors	O
,	O
which	O
were	O
recognized	O
with	O
anti-JunD	O
or	O
c-Fos	O
antibody	O
.	O

In	O
contrast	O
,	O
FK506	O
or	O
EGTA	O
(	O
Ca2+	O
chelator	O
)	O
similarly	O
affected	O
the	O
formation	O
of	O
kappa	O
B-like	O
site	O
binding	O
complexes	O
,	O
which	B-Negation
were	I-Negation
not	I-Negation
recognized	I-Negation
by	I-Negation
any	I-Negation
antibodies	I-Negation
against	I-Negation
the	I-Negation
human	I-Negation
Rel	I-Negation
family	I-Negation
proteins	I-Negation
(	I-Negation
c-Rel	I-Negation
,	I-Negation
p65	I-Negation
,	I-Negation
p50	I-Negation
,	I-Negation
and	I-Negation
p49	I-Negation
)	I-Negation
.	O

Furthermore	O
,	O
we	O
confirmed	O
the	O
previous	O
report	O
that	O
FK506	O
suppressed	O
the	O
PMA/ionomycin-induced	O
activation	O
through	O
authentic	O
kappa	O
B	O
site	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
gene	O
,	O
to	O
which	O
NF-kappa	O
B	O
binding	O
was	O
also	O
decreased	O
by	O
FK506	O
,	O
indicating	O
that	O
both	O
IL-8	O
kappa	O
B-like	O
site	O
and	O
Ig	O
kappa	O
B	O
site	O
are	O
FK506-sensitive	O
in	O
spite	O
of	O
the	O
difference	O
of	O
binding	O
factors	O
.	O

Our	O
results	O
indicate	O
that	O
not	O
only	O
the	O
reported	O
IL-2	O
NF-AT	O
and	O
NFIL-2A	O
sites	O
and	O
Ig	O
kappa	O
B	O
site	O
,	O
but	O
also	O
the	O
IL-8	O
AP-1	O
and	O
kappa	O
B-like	O
sites	O
are	O
terminals	O
of	O
FK506-sensitive	O
pathway	O
involving	O
Ca2+	O
mobilization	O
.	O

Sp1	O
is	O
a	O
critical	O
factor	O
for	O
the	O
monocytic	O
specific	O
expression	O
of	O
human	O
CD14	O
.	O

CD14	O
is	O
a	O
membrane	O
glycoprotein	O
expressed	O
specifically	O
on	O
monocytes	O
and	O
macrophages	O
,	O
and	O
its	O
expression	O
is	O
markedly	O
increased	O
during	O
the	O
process	O
of	O
monocyte	O
differentiation	O
.	O

In	O
order	O
to	O
study	O
CD14	O
gene	O
regulation	O
,	O
the	O
human	O
CD14	O
gene	O
was	O
cloned	O
from	O
a	O
partial	O
EcoRI	O
digested	O
chromosome	O
5	O
library	O
.	O

A	O
5.5-kilobase	O
genomic	O
clone	O
contained	O
the	O
full-length	O
CD14	O
coding	O
sequence	O
and	O
4.2	O
kilobases	O
of	O
5'-upstream	O
sequence	O
.	O

One	O
major	O
and	O
one	O
minor	O
transcription	O
start	O
site	O
were	O
identified	O
101	O
and	O
130	O
base	O
pairs	O
(	O
bp	O
)	O
upstream	O
,	O
respectively	O
,	O
from	O
the	O
protein	O
translation	O
start	O
ATG	O
.	O

A	O
DNA	O
fragment	O
containing	O
128	O
bp	O
of	O
upstream	O
sequence	O
had	O
strong	O
,	O
monocyte-specific	O
promoter	O
activity	O
in	O
the	O
CD14	O
positive	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
as	O
compared	O
to	O
the	O
nonmonocytic	O
cell	O
lines	O
HeLa	O
and	O
REX	O
.	O

Four	O
regions	O
in	O
this	O
DNA	O
fragment	O
interact	O
with	O
nuclear	O
proteins	O
isolated	O
from	O
monocytic	O
cells	O
.	O

The	O
Sp1	O
transcription	O
factor	O
bound	O
to	O
three	O
different	O
regions	O
in	O
the	O
CD14	O
promoter	O
.	O

Mutation	O
of	O
the	O
major	O
Sp1	O
binding	O
site	O
(	O
-110	O
bp	O
)	O
decreased	O
tissue-specific	O
promoter	O
activity	O
,	O
and	O
these	O
results	O
,	O
together	O
with	O
transactivation	O
experiments	O
,	O
demonstrate	O
that	O
Sp1	O
plays	O
a	O
critical	O
role	O
in	O
the	O
tissue-specific	O
expression	O
of	O
CD14	O
in	O
monocytic	O
cells	O
.	O

CD14	O
Sp1	O
site	O
oligonucleotides	O
bound	O
preferentially	O
to	O
a	O
105-kDa	O
Sp1	O
species	O
,	O
which	O
is	O
present	O
in	O
higher	O
relative	O
levels	O
in	O
monocytic	O
than	O
non-monocytic	O
cells	O
,	O
suggesting	O
that	O
modification	O
of	O
Sp1	O
,	O
such	O
as	O
phosphorylation	O
,	O
may	O
explain	O
how	O
the	O
Sp1	O
site	O
mediates	O
monocytic	O
specific	O
promoter	O
activity	O
.	O

Tolerance	O
to	O
lipopolysaccharide	O
involves	O
mobilization	O
of	O
nuclear	O
factor	O
kappa	O
B	O
with	O
predominance	O
of	O
p50	O
homodimers	O
.	O

Stimulation	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
leads	O
to	O
rapid	O
and	O
transient	O
expression	O
of	O
cytokines	O
like	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
.	O

When	O
such	O
cells	O
are	O
precultured	O
for	O
2	O
days	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
(	O
20	O
ng/ml	O
)	O
followed	O
by	O
stimulation	O
with	O
a	O
high	O
dose	O
of	O
LPS	O
(	O
1	O
microgram/ml	O
)	O
,	O
expression	O
of	O
the	O
TNF	O
gene	O
is	O
minimal	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
.	O

In	O
nuclear	O
run-on	O
analysis	O
,	O
such	O
tolerant	O
cells	O
show	O
only	O
a	O
low	O
degree	O
of	O
transcription	O
,	O
indicating	O
that	O
tolerance	O
operates	O
at	O
or	O
upstream	O
of	O
the	O
transcription	O
level	O
.	O

The	O
CD14	O
LPS	O
receptor	O
is	O
,	O
however	O
,	O
up-regulated	O
(	O
not	B-Negation
down-regulated	I-Negation
)	O
in	O
tolerant	O
cells	O
,	O
and	O
LPS	O
can	B-Speculation
,	I-Speculation
in	I-Speculation
fact	I-Speculation
,	I-Speculation
still	I-Speculation
lead	I-Speculation
to	I-Speculation
activation	I-Speculation
of	I-Speculation
tolerant	I-Speculation
cells	I-Speculation
as	I-Speculation
evidenced	I-Speculation
by	I-Speculation
mobilization	I-Speculation
of	I-Speculation
the	I-Speculation
transcription	I-Speculation
factor	I-Speculation
nuclear	I-Speculation
factor	I-Speculation
kappa	I-Speculation
B	I-Speculation
(	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
)	I-Speculation
.	O

Resolution	O
of	O
the	O
NF-kappa	O
B	O
complex	O
in	O
gel	O
shift	O
analysis	O
shows	O
that	O
the	O
binding	O
protein	O
,	O
mobilized	O
in	O
naive	O
Mono	O
Mac	O
6	O
cells	O
,	O
consists	O
mainly	O
of	O
p50-p65	O
heterodimers	O
,	O
while	O
in	O
tolerant	O
cells	O
,	O
the	O
p50	O
homodimer	O
is	O
predominant	O
.	O

This	O
increase	O
in	O
p50	O
homodimers	O
coincides	O
with	O
an	O
increase	O
in	O
p105	O
mRNA	O
,	O
suggestive	O
of	O
a	O
transcriptional	O
up-regulation	O
of	O
p50	O
.	O

Reporter	O
gene	O
analysis	O
reveals	O
that	O
the	O
NF-kappa	O
B	O
complex	O
mobilized	O
in	O
tolerant	O
cells	O
is	O
functionally	O
inactive	O
in	O
that	O
NF-kappa	O
B-dependent	O
luciferase	O
constructs	O
containing	O
the	O
human	O
immunodeficiency	O
virus	O
long	O
terminal	O
repeat	O
or	O
the	O
TNF	O
5'-region	O
show	O
only	O
minimal	O
transactivation	O
after	O
LPS	O
stimulation	O
.	O

Similar	O
to	O
Mono	O
Mac	O
6	O
cells	O
,	O
primary	O
blood	O
monocytes	O
,	O
when	O
precultured	O
with	O
a	O
low	O
dose	O
of	O
LPS	O
,	O
also	O
become	O
tolerant	O
and	O
produce	O
little	O
TNF	O
after	O
LPS	O
stimulation	O
.	O

The	O
tolerant	O
blood	O
monocytes	O
also	O
up-regulate	O
CD14	O
,	O
and	O
they	O
mobilize	O
NF-kappa	O
B	O
with	O
a	O
predominance	O
of	O
p50	O
homodimers	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
tolerance	O
to	O
LPS	O
is	O
determined	O
by	O
post-receptor	O
mechanisms	O
that	O
involve	O
an	O
altered	O
composition	O
of	O
the	O
NF-kappa	O
B	O
complex	O
.	O

Alpha-tocopherol	O
inhibits	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
to	O
cultured	O
human	O
endothelial	O
cells	O
.	O

Antioxidants	O
have	O
been	O
proposed	O
to	O
be	O
anti-atherosclerotic	O
agents	O
;	O
however	O
,	O
the	O
mechanisms	O
underlying	O
their	O
beneficial	O
effects	O
are	O
poorly	O
understood	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
alpha-tocopherol	O
(	O
alpha-tcp	O
)	O
on	O
one	O
cellular	O
event	O
in	O
atherosclerotic	O
plaque	O
development	O
,	O
monocyte	O
adhesion	O
to	O
stimulated	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Human	O
umbilical	O
vein	O
ECs	O
were	O
pretreated	O
with	O
alpha-tcp	O
before	O
stimulation	O
with	O
known	O
agonists	O
of	O
monocyte	O
adhesion	O
:	O
IL-1	O
(	O
10	O
ng/ml	O
)	O
,	O
LPS	O
(	O
10	O
ng/ml	O
)	O
,	O
thrombin	O
(	O
30	O
U/ml	O
)	O
,	O
or	O
PMA	O
(	O
10	O
nM	O
)	O
.	O

Agonist-induced	O
monocytic	O
cell	O
adhesion	O
,	O
but	O
not	B-Negation
basal	I-Negation
adhesion	I-Negation
,	O
was	O
inhibited	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
by	O
alpha-tcp	O
.	O

The	O
IC50	O
of	O
alpha-tcp	O
on	O
an	O
IL-1-induced	O
response	O
was	O
45	O
microM	O
.	O

The	O
inhibition	O
correlated	O
with	O
a	O
decrease	O
in	O
steady	O
state	O
levels	O
of	O
E-selectin	O
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
E-selectin	O
which	O
is	O
consistent	O
with	O
the	O
ability	O
of	O
a	O
monoclonal	O
antibody	O
to	O
E-selectin	O
to	O
inhibit	O
monocytic	O
cell	O
adhesion	O
in	O
this	O
system	O
.	O

Probucol	O
(	O
50	O
microM	O
)	O
and	O
N-acetylcysteine	O
(	O
20	O
mM	O
)	O
also	O
inhibited	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
;	O
whereas	O
,	O
several	O
other	O
antioxidants	O
had	O
no	B-Negation
significant	I-Negation
effect	I-Negation
.	O

Protein	B-Negation
kinase	I-Negation
C	I-Negation
(	I-Negation
PKC	I-Negation
)	I-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
play	I-Speculation
a	I-Speculation
role	I-Speculation
in	I-Speculation
the	I-Speculation
alpha-tcp	I-Speculation
effect	I-Speculation
since	O
no	B-Negation
suppression	I-Negation
of	I-Negation
phosphorylation	I-Negation
of	I-Negation
PKC	I-Negation
substrates	I-Negation
was	I-Negation
observed	I-Negation
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
is	O
reported	O
to	O
be	O
necessary	O
but	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
E-selectin	I-Negation
expression	I-Negation
in	I-Negation
EC	I-Negation
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
failed	B-Negation
to	I-Negation
show	I-Negation
an	I-Negation
alpha-tcp-induced	I-Negation
decrease	I-Negation
in	I-Negation
activation	I-Negation
of	I-Negation
this	I-Negation
transcription	I-Negation
factor	I-Negation
after	I-Negation
cytokine	I-Negation
stimulation	I-Negation
.	O

It	O
has	O
been	O
hypothesized	O
that	O
alpha-tcp	O
acts	O
as	O
an	O
anti-atherosclerotic	O
molecule	O
by	O
inhibiting	O
generation	O
of	O
oxidized	O
LDL	O
--	O
a	O
putative	O
triggering	O
molecule	O
in	O
the	O
atherosclerotic	O
process	O
.	O

Our	O
results	O
point	O
to	O
a	O
novel	O
alternative	O
mechanism	O
of	O
action	O
of	O
alpha-tcp	O
.	O

Upregulation	O
of	O
bcl-2	O
by	O
the	O
Epstein-Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
:	O
a	O
B-cell-specific	O
response	O
that	O
is	O
delayed	O
relative	O
to	O
NF-kappa	O
B	O
activation	O
and	O
to	O
induction	O
of	O
cell	O
surface	O
markers	O
.	O

An	O
ability	O
of	O
the	O
Epstein-Barr	O
virus	O
latent	O
membrane	O
protein	O
LMP1	O
to	O
enhance	O
the	O
survival	O
of	O
infected	O
B	O
cells	O
through	O
upregulation	O
of	O
the	O
bcl-2	O
oncogene	O
was	O
first	O
suggested	O
by	O
experiments	O
involving	O
gene	O
transfection	O
and	O
the	O
selection	O
of	O
stable	O
LMP1+	O
clones	O
(	O
S.Henderson	O
,	O
M.	O
Rowe	O
,	O
C.Gregory	O
,	O
F.Wang	O
,	O
E.Kieff	O
,	O
and	O
A.Rickinson	O
,	O
Cell	O
65:1107-1115	O
,	O
1991	O
)	O
.	O

However	O
,	O
it	O
was	O
not	O
possible	O
to	O
ascertain	O
whether	O
Bcl-2	O
upregulation	O
was	O
a	O
specific	O
consequence	O
of	O
LMP1	O
expression	O
or	O
an	O
artifact	O
of	O
the	O
selection	O
procedure	O
whereby	O
rare	O
Bcl-2+	O
cells	O
already	O
present	O
in	O
the	O
starting	O
population	O
might	O
best	O
be	O
able	O
to	O
tolerate	O
the	O
potentially	O
toxic	O
effects	O
of	O
LMP1	O
.	O

We	O
therefore	O
reexamined	O
this	O
issue	O
by	O
using	O
two	O
different	O
experimental	O
approaches	O
that	O
allowed	O
LMP1-	O
induced	O
effects	O
to	O
be	O
monitored	O
immediately	O
following	O
expression	O
of	O
the	O
viral	O
protein	O
and	O
in	O
the	O
absence	B-Negation
of	I-Negation
selective	I-Negation
pressures	I-Negation
;	O
activation	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
and	O
upregulation	O
of	O
the	O
cell	O
adhesion	O
molecule	O
ICAM-1	O
were	O
used	O
as	O
early	O
indices	O
of	O
LMP1	O
function	O
.	O

In	O
the	O
first	O
approach	O
,	O
stable	O
clones	O
of	O
two	O
B-cell	O
lines	O
carrying	O
an	O
LMP1	O
gene	O
under	O
the	O
control	O
of	O
an	O
inducible	O
metallothionein	O
promoter	O
were	O
induced	O
to	O
express	O
LMP1	O
in	O
all	O
cells	O
.	O

Activation	O
of	O
NK-kappa	O
B	O
and	O
upregulation	O
of	O
ICAM-1	O
occurred	O
within	O
24	O
h	O
and	O
were	O
followed	O
at	O
48	O
to	O
72	O
h	O
by	O
upregulation	O
of	O
Bcl-2	O
.	O

In	O
the	O
second	O
approach	O
,	O
we	O
tested	O
the	O
generality	O
of	O
this	O
phenomenon	O
by	O
transiently	O
expressing	O
LMP1	O
from	O
a	O
strong	O
constitutively	O
active	O
promoter	O
in	O
a	O
range	O
of	O
different	O
cell	O
types	O
.	O

All	O
six	O
B-cell	O
lines	O
tested	O
showed	O
NF-kappa	O
B	O
activation	O
in	O
response	O
to	O
LMP1	O
expression	O
,	O
and	O
this	O
was	O
followed	O
in	O
five	O
of	O
six	O
lines	O
by	O
expression	O
of	O
ICAM-1	O
and	O
Bcl-2	O
.	O

In	O
the	O
same	O
experiments	O
,	O
all	O
three	O
non-B-cell	O
lines	O
showed	O
NF-kappa	O
B	O
activation	O
and	O
ICAM-1	O
upregulation	O
but	O
never	B-Negation
any	I-Negation
effect	I-Negation
upon	I-Negation
Bcl-2	I-Negation
.	O

We	O
therefore	O
conclude	O
that	O
Bcl-2	O
upregulation	O
is	O
part	O
of	O
the	O
panoply	O
of	O
cellular	O
changes	O
induced	O
by	O
LMP1	O
but	O
that	O
the	O
effect	O
is	O
cell	O
type	O
specific	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
whilst	O
NF-kappa	O
B	O
may	O
be	O
an	O
essential	O
component	O
of	O
LMP1	O
signal	O
transduction	O
,	O
other	O
cell-specific	O
factors	O
may	O
be	O
required	O
to	O
effect	O
some	O
functions	O
of	O
the	O
viral	O
protein	O
.	O

CD14-mediated	O
translocation	O
of	O
nuclear	O
factor-kappa	O
B	O
induced	O
by	O
lipopolysaccharide	O
does	O
not	B-Negation
require	I-Negation
tyrosine	I-Negation
kinase	I-Negation
activity	I-Negation
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
is	O
believed	O
to	O
interact	O
with	O
macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
mediators	O
and	O
systemic	O
symptoms	O
including	O
hemodynamic	O
instability	O
and	O
shock	O
.	O

CD14	O
,	O
a	O
glycosylphosphatidylinositol-linked	O
antigen	O
,	O
functions	O
as	O
an	O
LPS	O
signaling	O
receptor	O
.	O

A	O
critical	O
issue	O
concerns	O
the	O
mechanism	O
by	O
which	O
CD14	O
,	O
which	O
has	O
no	B-Negation
transmembrane	I-Negation
domain	I-Negation
,	O
transduces	O
its	O
signal	O
following	O
LPS	O
binding	O
.	O

Recently	O
,	O
investigators	O
have	O
hypothesized	O
that	O
CD14-mediated	O
signaling	O
is	O
effected	O
through	O
a	O
receptor-associated	O
tyrosine	O
kinase	O
(	O
TK	O
)	O
,	O
suggesting	O
a	O
multicomponent	O
receptor	O
model	O
of	O
LPS	O
signaling	O
.	O

Wild-type	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-K1	O
cells	O
can	O
be	O
activated	O
by	O
endotoxin	O
to	O
release	O
arachidonate	O
following	O
transfection	O
with	O
human	O
CD14	O
(	O
CHO/CD14	O
)	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
NF-kappa	O
B	O
is	O
correlated	O
with	O
a	O
number	O
of	O
LPS-inducible	O
responses	O
.	O

We	O
sought	O
to	O
determine	O
if	O
this	O
pathway	O
were	O
present	O
in	O
CHO/CD14	O
cells	O
and	O
to	O
elucidate	O
the	O
relationship	O
of	O
NF-kappa	O
B	O
activation	O
to	O
the	O
CD14	O
receptor	O
system	O
.	O

LPS-stimulated	O
translocation	O
of	O
NF-kappa	O
B	O
in	O
CHO/CD14	O
cells	O
resembled	O
the	O
same	O
response	O
in	O
the	O
murine	O
macrophage-like	O
cell	O
line	O
RAW	O
264.7	O
.	O

Protein	O
synthesis	O
inhibitors	O
and	O
corticosteroids	O
,	O
which	O
suppress	O
arachidonate	O
release	O
and	O
the	O
synthesis	O
of	O
proinflammatory	O
cytokines	O
,	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
translocation	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
in	I-Negation
CHO/CD14	I-Negation
or	I-Negation
RAW	I-Negation
264.7	I-Negation
cells	I-Negation
,	O
demonstrating	O
that	O
NF-kappa	O
B	O
translocation	O
is	O
an	O
early	O
event	O
.	O

Although	O
TK	O
activity	O
was	O
consistently	O
observed	O
by	O
immunoblotting	O
extracts	O
from	O
activated	O
RAW	O
264.7	O
cells	O
,	O
LPS-induced	O
phosphotyrosine	O
residues	O
were	O
not	B-Negation
observed	I-Negation
from	I-Negation
similarly	I-Negation
treated	I-Negation
CHO/CD14	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
the	O
TK	O
inhibitors	O
herbimycin	O
A	O
and	O
genistein	O
failed	B-Negation
to	I-Negation
inhibit	I-Negation
translocation	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
in	I-Negation
CHO/CD14	I-Negation
or	I-Negation
RAW	I-Negation
264.7	I-Negation
cells	I-Negation
,	O
although	O
both	O
of	O
these	O
agents	O
inhibited	O
LPS-induced	O
TK	O
activity	O
in	O
RAW	O
264.7	O
cells	O
.	O

These	O
results	O
imply	O
that	O
TK	O
activity	O
is	O
not	O
obligatory	O
for	O
CD14-mediated	O
signal	O
transduction	O
to	O
occur	O
in	O
response	O
to	O
LPS	O
.	O

Regulation	O
of	O
CD14	O
expression	O
during	O
monocytic	O
differentiation	O
induced	O
with	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
.	O

CD14	O
,	O
a	O
monocyte/macrophage	O
receptor	O
for	O
the	O
complex	O
of	O
LPS	O
and	O
LPS	O
binding	O
protein	O
,	O
is	O
a	O
differentiation	O
marker	O
for	O
the	O
monocyte/macrophage	O
lineage	O
.	O

We	O
have	O
analyzed	O
the	O
regulation	O
of	O
CD14	O
expression	O
during	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
VitD3	O
)	O
-induced	O
monocytic	O
differentiation	O
.	O

Using	O
FACS	O
,	O
Northern	O
blotting	O
,	O
and	O
nuclear	O
run-on	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
up-regulation	O
of	O
CD14	O
expression	O
during	O
monocytic	O
cell	O
maturation	O
is	O
regulated	O
mainly	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
,	O
and	O
that	O
new	O
protein	O
synthesis	O
is	O
required	O
for	O
CD14	O
induction	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
and	O
demonstrated	O
its	O
tissue-specific	O
promoter	O
activity	O
.	O

Using	O
stable	O
transfection	O
of	O
the	O
monocytoid	O
U937	O
cell	O
line	O
with	O
a	O
series	O
of	O
deletion	O
mutants	O
of	O
the	O
CD14	O
5	O
'	O
upstream	O
sequence	O
coupled	O
to	O
a	O
reporter	O
gene	O
construct	O
,	O
we	O
show	O
that	O
bp	O
-128	O
to	O
-70	O
is	O
the	O
critical	O
region	O
for	O
the	O
induction	O
of	O
CD14	O
expression	O
.	O

This	O
region	O
contains	O
two	O
binding	O
sites	O
for	O
the	O
Sp1	O
transcription	O
factor	O
.	O

A	O
3-bp	O
mutation	O
at	O
the	O
distal	O
Sp1-binding	O
site	O
not	O
only	O
eliminates	O
Sp1	O
interaction	O
,	O
but	O
also	O
abolishes	O
most	O
of	O
the	O
VitD3	O
induction	O
of	O
CD14	O
expression	O
.	O

Electrophoretic	O
mobility	O
shift	O
analysis	O
does	O
not	B-Negation
detect	I-Negation
a	I-Negation
direct	I-Negation
interaction	I-Negation
of	I-Negation
the	I-Negation
CD14	I-Negation
distal	I-Negation
Sp1-binding	I-Negation
site	I-Negation
with	I-Negation
the	I-Negation
vitamin	I-Negation
D3	I-Negation
receptor	I-Negation
and	I-Negation
its	I-Negation
partner	I-Negation
,	I-Negation
the	I-Negation
retinoid	I-Negation
X	I-Negation
receptor	I-Negation
.	O

These	O
data	O
demonstrate	O
that	O
VitD3	O
induces	O
CD14	O
indirectly	O
through	O
some	O
intermediary	O
factor	O
,	O
and	O
suggest	O
a	O
critical	O
role	O
for	O
Sp1	O
in	O
this	O
process	O
.	O

Calcium	O
signalling	O
in	O
T	O
cells	O
stimulated	O
by	O
a	O
cyclophilin	O
B-binding	O
protein	O
.	O

The	O
immunosuppressant	O
drug	O
cyclosporin	O
A	O
blocks	O
a	O
calcium-dependent	O
signal	O
from	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
that	O
normally	O
leads	O
to	O
T-cell	O
activation	O
.	O

When	O
bound	O
to	O
cyclophilin	O
,	O
cyclosporin	O
A	O
binds	O
and	O
inactivates	O
the	O
key	O
signalling	O
intermediate	O
calcineurin	O
.	O

To	O
identify	O
potential	O
cellular	O
homologues	O
of	O
cyclosporin	O
A	O
that	O
might	O
regulate	O
calcium	O
signalling	O
,	O
we	O
have	O
cloned	O
human	O
genes	O
encoding	O
cyclophilin	O
B-binding-proteins	O
using	O
the	O
yeast	O
two-hybrid	O
system	O
.	O

One	O
gene	O
product	O
,	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
,	O
specifically	O
induced	O
transcription	O
from	O
the	O
interleukin-2	O
enhancer	O
,	O
by	O
activating	O
the	O
T-cell-specific	O
transcription	O
factors	O
NF-AT	O
and	O
NF-IL2A	O
.	O

This	O
protein	O
,	O
termed	O
calcium-signal	O
modulating	O
cyclophilin	O
ligand	O
(	O
CAML	O
)	O
,	O
acts	O
downstream	O
of	O
the	O
TCR	O
and	O
upstream	O
of	O
calcineurin	O
by	O
causing	O
an	O
influx	O
of	O
calcium	O
.	O

CAML	B-Speculation
appears	I-Speculation
to	I-Speculation
be	I-Speculation
a	I-Speculation
new	I-Speculation
participant	I-Speculation
in	I-Speculation
the	I-Speculation
calcium-signal	I-Speculation
transduction	I-Speculation
pathway	I-Speculation
,	O
implicating	O
cyclophilin	O
B	O
in	O
calcium	O
signalling	O
,	O
even	O
in	O
the	O
absence	B-Negation
of	I-Negation
cyclosporin	I-Negation
.	O

Inducible	O
binding	O
to	O
the	O
c-fos	O
serum	O
response	O
element	O
during	O
T	O
cell	O
activation	O
is	O
regulated	O
by	O
a	O
phosphotyrosine-containing	O
protein	O
.	O

The	O
proto-oncogene	O
c-fos	O
is	O
an	O
immediate-early	O
gene	O
,	O
and	O
one	O
of	O
the	O
first	O
genes	O
transcribed	O
after	O
stimulation	O
of	O
most	O
cells	O
with	O
a	O
variety	O
of	O
ligands	O
.	O

Fos	O
expression	O
may	O
be	O
a	O
pivotal	O
event	O
in	O
converting	O
ligand-receptor	O
interactions	O
at	O
the	O
membrane	O
into	O
functional	O
modulation	O
of	O
cell	O
phenotype	O
.	O

The	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
in	O
the	O
c-fos	O
regulatory	O
region	O
participates	O
in	O
induction	O
of	O
transcription	O
by	O
various	O
growth	O
factors	O
and	O
by	O
phorbol	O
esters	O
and	O
subsequent	O
squelching	O
of	O
transcription	O
.	O

We	O
show	O
that	O
an	O
inducible	O
protein	O
complex	O
(	O
Band	O
A	O
)	O
binds	O
to	O
SRE	O
DNA	O
within	O
10	O
min	O
after	O
mitogenic	O
stimulation	O
of	O
human	O
PBL-T	O
,	O
and	O
becomes	O
nondetectable	O
by	O
60	O
min	O
.	O

Band	O
A	O
contains	O
the	O
serum	O
response	O
factor	O
plus	O
additional	O
factor	O
(	O
s	O
)	O
.	O

A	O
protein	O
that	O
is	O
phosphorylated	O
on	O
a	O
tyrosine	O
residue	O
in	O
resting	O
PBL-T	O
suppresses	O
binding	O
of	O
a	O
component	O
of	O
Band	O
A	O
to	O
the	O
SRE	O
motif	O
.	O

Upon	O
stimulation	O
of	O
the	O
cells	O
,	O
this	O
protein	O
no	B-Negation
longer	I-Negation
prevents	I-Negation
binding	I-Negation
of	I-Negation
DNA	I-Negation
by	I-Negation
Band	I-Negation
A	I-Negation
,	O
and	O
suppression	O
of	O
binding	O
is	O
restored	O
within	O
30	O
min	O
.	O

The	O
phosphorylated	O
tyrosine	O
residue	O
itself	O
is	O
important	O
for	O
the	O
protein-protein	O
interaction	O
.	O

Steel	O
factor	O
affects	O
SCL	O
expression	O
during	O
normal	O
erythroid	O
differentiation	O
.	O

Steel	O
factor	O
is	O
one	O
of	O
the	O
growth	O
factors	O
that	O
controls	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
cells	O
and	O
SCL	O
,	O
also	O
known	O
as	O
Tcl-5	O
or	O
Tal-1	O
,	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
erythropoiesis	O
.	O

In	O
this	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
SCL	O
in	O
the	O
proliferation	O
of	O
human	O
peripheral	O
blood	O
burst-forming	O
unit-erythroid	O
(	O
BFU-E	O
)	O
and	O
the	O
effects	O
of	O
Steel	O
factor	O
on	O
SCL	O
expression	O
in	O
proliferating	O
erythroid	O
cells	O
.	O

BFU-E-derived	O
colonies	O
increase	O
progressively	O
in	O
size	O
,	O
as	O
determined	O
by	O
cell	O
number	O
,	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
colony	O
size	O
(	O
10-fold	O
expansion	O
)	O
occurring	O
between	O
day	O
7	O
and	O
day	O
10	O
.	O

SCL	O
protein	O
levels	O
in	O
BFU-E-derived	O
cells	O
were	O
highest	O
in	O
day	O
7	O
cells	O
and	O
decreased	O
progressively	O
from	O
day	O
7	O
to	O
day	O
14	O
of	O
culture	O
,	O
suggesting	O
an	O
association	O
of	O
SCL	O
with	O
erythroid	O
proliferation	O
.	O

In	O
contrast	O
,	O
SCL	O
mRNA	O
levels	O
did	O
not	B-Negation
decrease	I-Negation
significantly	I-Negation
between	I-Negation
day	I-Negation
7	I-Negation
and	I-Negation
day	I-Negation
14	I-Negation
cells	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
posttranscriptional	I-Speculation
mechanisms	I-Speculation
are	I-Speculation
largely	I-Speculation
responsible	I-Speculation
for	I-Speculation
the	I-Speculation
decrease	I-Speculation
in	I-Speculation
SCL	I-Speculation
protein	I-Speculation
observed	I-Speculation
.	O

The	O
role	O
of	O
SCL	O
in	O
Steel	O
factor-induced	O
erythroid	O
proliferation	O
was	O
then	O
examined	O
.	O

In	O
BFU-E-derived	O
colonies	O
cultured	O
with	O
Steel	O
factor	O
,	O
colony	O
size	O
was	O
significantly	O
increased	O
compared	O
to	O
control	O
.	O

In	O
day	O
7	O
and	O
day	O
10	O
erythroid	O
precursors	O
cultured	O
with	O
Steel	O
factor	O
,	O
SCL	O
protein	O
was	O
increased	O
significantly	O
compared	O
to	O
control	O
.	O

The	O
increase	O
in	O
SCL	O
protein	O
levels	O
in	O
early	O
erythroid	O
precursors	O
stimulated	O
with	O
Steel	O
factor	O
suggests	O
one	O
mechanism	O
through	O
which	O
Steel	O
factor	O
may	O
enhance	O
normal	O
erythroid	O
proliferation	O
.	O

SCL	O
mRNA	O
levels	O
assessed	O
by	O
Northern	O
blot	O
in	O
day	O
7	O
cells	O
did	O
not	O
increase	O
significantly	O
in	O
response	O
to	O
Steel	O
factor	O
stimulation	O
,	O
suggesting	O
that	O
posttranscriptional	O
mechanisms	O
may	O
also	O
be	O
important	O
in	O
the	O
increase	O
in	O
SCL	O
protein	O
observed	O
in	O
response	O
to	O
Steel	O
.	O

Cross-linking	O
CD40	O
on	O
B	O
cells	O
rapidly	O
activates	O
nuclear	O
factor-kappa	O
B	O
.	O

The	O
B	O
cell-associated	O
surface	O
molecule	O
CD40	O
functions	O
to	O
regulate	O
B	O
cell	O
responses	O
.	O

Cross-linking	O
CD40	O
on	O
B	O
cells	O
can	O
lead	O
to	O
homotypic	O
cell	O
adhesion	O
,	O
IL-6	O
production	O
,	O
and	O
,	O
in	O
combination	O
with	O
cytokines	O
,	O
to	O
Ig	O
isotype	O
switching	O
.	O

Tyrosine	O
kinase	O
activity	O
is	O
increased	O
shortly	O
after	O
engagement	O
of	O
this	O
receptor	O
.	O

Little	O
is	O
known	O
about	O
how	O
the	O
very	O
early	O
events	O
induced	O
by	O
CD40	O
cross-linking	O
link	O
to	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
and	O
NF-kappa	O
B-like	O
transcription	O
factors	O
are	O
activated	O
after	O
cross-linking	O
CD40	O
on	O
resting	O
human	O
tonsillar	O
B	O
cells	O
and	O
on	O
B	O
cell	O
lines	O
.	O

The	O
activation	O
is	O
rapid	O
and	O
is	O
mediated	O
through	O
a	O
tyrosine	O
kinase-dependent	O
pathway	O
.	O

The	O
complexes	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
contain	O
p50	O
,	O
p65	O
(	O
RelA	O
)	O
,	O
c-Rel	O
,	O
and	O
most	O
likely	O
other	O
components	O
.	O

By	O
using	O
transient	O
transfection	O
assays	O
,	O
we	O
found	O
that	O
cross-linking	O
CD40	O
supports	O
NF-kappa	O
B-dependent	O
gene	O
expression	O
.	O

Our	O
results	O
define	O
the	O
NF-kappa	O
B	O
system	O
as	O
an	O
intermediate	O
event	O
in	O
CD40	O
signaling	O
and	O
suggest	O
that	O
the	O
CD40	O
pathway	O
can	O
influence	O
the	O
expression	O
of	O
B	O
cell-associated	O
genes	O
with	O
NF-kappa	O
B	O
consensus	O
sites	O
.	O

Separation	O
of	O
oxidant-initiated	O
and	O
redox-regulated	O
steps	O
in	O
the	O
NF-kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Studies	O
presented	O
here	O
show	O
that	O
overall	O
NF-kappa	O
B	O
signal	O
transduction	O
begins	O
with	O
a	O
parallel	O
series	O
of	O
stimuli-specific	O
pathways	O
through	O
which	O
cytokines	O
(	O
tumor	O
necrosis	O
factor	O
alpha	O
)	O
,	O
oxidants	O
(	O
hydrogen	O
peroxide	O
and	O
mitomycin	O
C	O
)	O
,	O
and	O
phorbol	O
ester	O
(	O
phorbol	O
12-myristate	O
13-acetate	O
)	O
individually	O
initiate	O
signaling	O
.	O

These	O
initial	O
pathways	O
culminate	O
in	O
a	O
common	O
pathway	O
through	O
which	O
all	O
of	O
the	O
stimulating	O
agents	O
ultimately	O
signal	O
NF-kappa	O
B	O
activation	O
.	O

We	O
distinguish	O
the	O
stimuli-specific	O
pathways	O
by	O
showing	O
that	O
the	O
oxidative	O
stimuli	O
trigger	O
NF-kappa	O
B	O
activation	O
in	O
only	O
one	O
of	O
two	O
human	O
T-cell	O
lines	O
(	O
Wurzburg	O
but	O
not	B-Negation
Jurkat	I-Negation
)	O
,	O
whereas	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
readily	O
stimulate	O
in	O
both	O
lines	O
.	O

We	O
propose	O
the	O
common	O
pathway	O
as	O
the	O
simplest	O
way	O
of	O
accounting	O
for	O
the	O
common	O
requirements	O
and	O
properties	O
of	O
the	O
signaling	O
pathway	O
.	O

We	O
include	O
a	O
redox-regulatory	O
mechanism	O
(	O
s	O
)	O
in	O
this	O
common	O
pathway	O
to	O
account	O
for	O
the	O
previously	O
demonstrated	O
redox	O
regulation	O
of	O
NF-kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
(	O
in	O
which	O
oxidants	O
do	O
n't	O
activate	O
NF-kappa	O
B	O
)	O
;	O
we	O
put	O
tyrosine	O
phosphorylation	O
in	O
the	O
common	O
pathway	O
by	O
showing	O
that	O
kinase	O
activity	O
(	O
inhibitable	O
by	O
herbimycin	O
A	O
and	O
tyrphostin	O
47	O
)	O
is	O
required	O
for	O
NF-kappa	O
B	O
activation	O
by	O
all	O
stimuli	O
tested	O
in	O
both	O
cell	O
lines	O
.	O

Since	O
internal	O
sites	O
of	O
oxidant	O
production	O
have	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
cytokine-stimulated	O
activation	O
of	O
NF-kappa	O
B	O
,	O
and	O
since	O
tyrosine	O
kinase	O
and	O
phosphatase	O
activities	O
are	O
known	O
to	O
be	O
altered	O
by	O
oxidants	O
,	O
these	O
findings	O
suggest	O
that	O
intracellular	O
redox	O
status	O
controls	O
NF-kappa	O
B	O
activation	O
by	O
regulating	O
tyrosine	O
phosphorylation	O
event	O
(	O
s	O
)	O
within	O
the	O
common	O
step	O
of	O
the	O
NF-kappa	O
B	O
signal	O
transduction	O
pathway	O
.	O

Transcription-independent	O
turnover	O
of	O
I	O
kappa	O
B	O
alpha	O
during	O
monocyte	O
adherence	O
:	O
implications	O
for	O
a	O
translational	O
component	O
regulating	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
.	O

We	O
identified	O
I	O
kappa	O
B	O
alpha/MAD-3	O
as	O
an	O
immediate-early	O
gene	O
in	O
human	O
monocytes	O
that	O
is	O
expressed	O
in	O
response	O
to	O
a	O
variety	O
of	O
signals	O
,	O
including	O
adhesion	O
,	O
lipopolysaccharide	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

Within	O
5	O
min	O
of	O
monocyte	O
adhesion	O
,	O
the	O
level	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
protein	O
is	O
markedly	O
diminished	O
but	O
is	O
rapidly	O
replaced	O
in	O
a	O
cycloheximide-sensitive	O
manner	O
within	O
20	O
min	O
.	O

Accompanying	O
the	O
rapid	O
turnover	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
protein	O
is	O
simultaneous	O
translocation	O
of	O
NF-kappa	O
B-related	O
transcription	O
factors	O
to	O
nuclei	O
of	O
adhered	O
monocytes	O
.	O

The	O
demonstration	O
that	O
NF-kappa	O
B	O
can	O
regulate	O
I	O
kappa	O
B	O
alpha/MAD-3	O
gene	O
transcription	O
in	O
other	O
cell	O
types	O
suggested	O
that	O
the	O
rapid	O
increase	O
in	O
steady-state	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
we	O
observed	O
within	O
30	O
min	O
of	O
monocyte	O
adherence	O
would	O
result	O
from	O
NF-kappa	O
B-dependent	O
transcriptional	O
stimulation	O
of	O
the	O
I	O
kappa	O
B	O
alpha/MAD-3	O
gene	O
.	O

Nuclear	O
run-on	O
analyses	O
indicated	O
that	O
,	O
instead	O
,	O
while	O
several	O
immediate-early	O
cytokine	O
genes	O
,	O
such	O
as	O
the	O
interleukin	O
1	O
beta	O
(	O
IL-1	O
beta	O
)	O
gene	O
,	O
were	O
transcriptionally	O
activated	O
during	O
monocyte	O
adhesion	O
,	O
the	O
rate	O
of	O
I	O
kappa	O
B	O
alpha/MAD-3	O
gene	O
transcription	O
remained	O
constant	O
.	O

The	O
adherence-dependent	O
increase	O
in	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
was	O
also	O
not	B-Negation
a	I-Negation
consequence	I-Negation
of	I-Negation
mRNA	I-Negation
stabilization	I-Negation
events	I-Negation
.	O

Interestingly	O
,	O
while	O
increases	O
in	O
both	O
IL-1	O
beta	O
and	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
were	O
detected	O
in	O
nuclei	O
of	O
adherent	O
monocytes	O
,	O
cytoplasmic	O
levels	O
of	O
IL-1	O
beta	O
mRNA	O
increased	O
during	O
adherence	O
whereas	O
those	O
of	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
did	O
not	B-Negation
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
two	O
interactive	O
mechanisms	O
regulate	O
monocytic	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
levels	O
.	O

We	O
propose	O
that	O
adherent	O
monocytes	O
regulate	O
nuclear	O
processing	O
(	O
or	O
decay	O
)	O
of	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
,	O
thereby	O
increasing	O
mRNA	O
levels	O
without	O
stimulating	O
I	O
kappa	O
B	O
alpha/MAD-3	O
gene	O
transcription	O
.	O

Moreover	O
,	O
since	O
inhibition	O
of	O
protein	O
synthesis	O
leads	O
to	O
accumulation	O
of	O
I	O
kappa	O
B	O
alpha/MAD-3	O
mRNA	O
without	B-Negation
stimulating	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha/MAD-3	I-Negation
gene	I-Negation
transcription	I-Negation
,	O
we	O
suggest	B-Speculation
that	I-Speculation
low	I-Speculation
cytoplasmic	I-Speculation
levels	I-Speculation
of	I-Speculation
I	I-Speculation
kappa	I-Speculation
B	I-Speculation
alpha/MAD-3	I-Speculation
mRNA	I-Speculation
are	I-Speculation
maintained	I-Speculation
by	I-Speculation
a	I-Speculation
translation-dependent	I-Speculation
degradation	I-Speculation
mechanism	I-Speculation
.	O

E2F-1	O
and	O
a	O
cyclin-like	O
DNA	O
repair	O
enzyme	O
,	O
uracil-DNA	O
glycosylase	O
,	O
provide	O
evidence	O
for	O
an	O
autoregulatory	O
mechanism	O
for	O
transcription	O
.	O

The	O
cell	O
cycle-dependent	O
transcription	O
factor	O
,	O
E2F-1	O
,	O
regulates	O
the	O
cyclin-like	O
species	O
of	O
the	O
DNA	O
repair	O
enzyme	O
uracil-DNA	O
glycosylase	O
(	O
UDG	O
)	O
gene	O
in	O
human	O
osteosarcoma	O
(	O
Saos-2	O
)	O
cells	O
.	O

We	O
demonstrate	O
,	O
through	O
the	O
deletion	O
of	O
the	O
human	O
UDG	O
promoter	O
sequences	O
,	O
that	O
expression	O
of	O
E2F-1	O
activates	O
the	O
UDG	O
promoter	O
through	O
several	O
E2F	O
sites	O
.	O

The	O
major	O
putative	O
downstream	O
site	O
for	O
E2F	O
,	O
located	O
in	O
the	O
first	O
exon	O
,	O
serves	O
as	O
a	O
target	O
for	O
E2F-1/DP1	O
complex	O
binding	O
in	O
vitro	O
.	O

We	O
also	O
provide	O
evidence	O
for	O
the	O
functional	O
relationship	O
between	O
the	O
cyclin-like	O
UDG	O
gene	O
product	O
and	O
E2F	O
.	O

High	O
levels	O
of	O
UDG	O
expression	O
in	O
a	O
transient	O
transfection	O
assay	O
result	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
activity	O
through	O
elements	O
specific	O
for	O
E2F-mediated	O
transcription	O
.	O

Overexpression	O
of	O
UDG	O
in	O
Saos	O
2	O
cells	O
was	O
observed	O
to	O
delay	O
growth	O
late	O
in	O
G1	O
phase	O
and	O
transiently	O
arrest	O
these	O
cells	O
from	O
progressing	O
into	O
the	O
S	O
phase	O
.	O

This	O
hypothetical	O
model	O
integrates	O
one	O
mechanism	O
of	O
DNA	O
repair	O
with	O
the	O
cell	O
cycle	O
control	O
of	O
gene	O
transcription	O
,	O
likely	O
through	O
E2F	O
.	O

This	O
implicates	O
E2F	O
as	O
a	O
multifunctional	O
target	O
for	O
proteins	O
and	O
enzymes	O
,	O
possibly	O
,	O
responsive	O
to	O
DNA	O
damage	O
through	O
the	O
negative	O
effect	O
of	O
UDG	O
on	O
E2F-mediated	O
transcriptional	O
activity	O
.	O

Aspirin	O
inhibits	O
nuclear	O
factor-kappa	O
B	O
mobilization	O
and	O
monocyte	O
adhesion	O
in	O
stimulated	O
human	O
endothelial	O
cells	O
.	O

BACKGROUND	O
:	O
The	O
induction	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
and	O
E-selectin	O
by	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF	O
)	O
is	O
mediated	O
by	O
mobilization	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

Since	O
salicylates	O
have	O
been	O
reported	O
to	O
inhibit	O
NF-kappa	O
B	O
activation	O
by	O
preventing	O
the	O
degradation	O
of	O
its	O
inhibitor	O
I	O
kappa	O
B	O
,	O
we	O
studied	O
a	O
potential	O
inhibition	O
of	O
this	O
pathway	O
by	O
acetylsalicylate	O
(	O
aspirin	O
)	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Gel-shift	O
analyses	O
demonstrated	O
dose-dependent	O
inhibition	O
of	O
TNF-induced	O
NF-kappa	O
B	O
mobilization	O
by	O
aspirin	O
at	O
concentrations	O
ranging	O
from	O
1	O
to	O
10	O
mmol/L	O
.	O

Induction	O
of	O
VCAM-1	O
and	O
E-selectin	O
surface	O
expression	O
by	O
TNF	O
was	O
dose-dependently	O
reduced	O
by	O
aspirin	O
over	O
the	O
same	O
range	O
,	O
while	O
induction	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
was	O
hardly	O
affected	O
.	O

Aspirin	O
appeared	O
to	O
prevent	O
VCAM-1	O
transcription	O
,	O
since	O
it	O
dose-dependently	O
inhibited	O
induction	O
of	O
VCAM-1	O
mRNA	O
by	O
TNF	O
.	O

As	O
a	O
functional	O
consequence	O
,	O
adhesion	O
of	O
U937	O
monocytes	O
to	O
TNF-stimulated	O
HUVECs	O
was	O
markedly	O
reduced	O
by	O
aspirin	O
due	O
to	O
suppression	O
of	O
VCAM-1	O
and	O
E-selectin	O
upregulation	O
.	O

These	B-Negation
effects	I-Negation
of	I-Negation
aspirin	I-Negation
were	I-Negation
not	I-Negation
related	I-Negation
to	I-Negation
the	I-Negation
inhibition	I-Negation
of	I-Negation
cyclooxygenase	I-Negation
activity	I-Negation
,	O
since	O
indomethacin	O
was	O
ineffective	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
aspirin	O
inhibits	O
NF-kappa	O
B	O
mobilization	O
,	O
induction	O
of	O
VCAM-1	O
and	O
E-selectin	O
,	O
and	O
subsequent	O
monocyte	O
adhesion	O
in	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	O
,	O
thereby	O
providing	O
an	O
additional	O
mechanism	O
for	O
therapeutic	O
effects	O
of	O
aspirin	O
.	O

Monocyte	O
tethering	O
by	O
P-selectin	O
regulates	O
monocyte	O
chemotactic	O
protein-1	O
and	O
tumor	O
necrosis	O
factor-alpha	O
secretion	O
.	O

Signal	O
integration	O
and	O
NF-kappa	O
B	O
translocation	O
[	O
see	O
comments	O
]	O

Adhesion	O
molecules	O
that	O
tether	O
circulating	O
leukocytes	O
to	O
endothelial	O
cells	O
may	O
also	O
transduce	O
or	O
modulate	O
outside-in	O
signals	O
for	O
cellular	O
activation	O
,	O
providing	O
an	O
initial	O
regulatory	O
point	O
in	O
the	O
inflammatory	O
response	O
.	O

Adhesion	O
of	O
human	O
monocytes	O
to	O
P-selectin	O
,	O
the	O
most	O
rapidly	O
expressed	O
endothelial	O
tethering	O
factor	O
,	O
increased	O
the	O
secretion	O
of	O
monocyte	O
chemotactic	O
protein-1	O
(	O
MCP-1	O
)	O
and	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
by	O
the	O
leukocytes	O
when	O
they	O
were	O
stimulated	O
with	O
platelet-activating	O
factor	O
.	O

Increased	O
cytokine	O
secretion	O
was	O
specifically	O
inhibited	O
by	O
G1	O
,	O
an	O
anti-P-selectin	O
mAb	O
that	O
prevents	O
P-selectin	O
from	O
binding	O
to	O
its	O
ligand	O
(	O
P-selectin	O
glycoprotein	O
ligand-1	O
)	O
on	O
myeloid	O
cells	O
.	O

Moreover	O
,	O
tethering	O
by	O
P-selectin	O
specifically	O
enhanced	O
nuclear	O
translocation	O
of	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
required	O
for	O
expression	O
of	O
MCP-1	O
,	O
TNF-alpha	O
,	O
and	O
other	O
immediate-early	O
genes	O
.	O

These	O
results	O
demonstrate	O
that	O
P-selectin	O
,	O
through	O
its	O
ligands	O
on	O
monocytes	O
,	O
may	O
locally	O
regulate	O
cytokine	O
secretion	O
in	O
inflamed	O
tissues	O
.	O

Danazol	O
decreases	O
transcription	O
of	O
estrogen	O
receptor	O
gene	O
in	O
human	O
monocytes	O
.	O

1.	O
Administration	O
of	O
danazol	O
for	O
over	O
one	O
month	O
reduced	O
the	O
levels	O
of	O
estrogen	O
receptor	O
(	O
ER	O
)	O
and	O
its	O
mRNA	O
to	O
approximately	O
50	O
and	O
20	O
%	O
,	O
respectively	O
in	O
monocytes	O
.	O

2.	O
Danazol	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
degradation	I-Negation
rate	I-Negation
of	I-Negation
ER	I-Negation
mRNA	I-Negation
in	I-Negation
monocytes	I-Negation
.	O

3.	O
Danazol	O
decreased	O
the	O
transcription	O
rate	O
of	O
ER	O
gene	O
to	O
approximately	O
50	O
%	O
in	O
monocytes	O
in	O
a	O
run-on	O
assay	O
.	O

4.	O
Danazol	O
may	O
release	O
estrogen	O
predominance	O
via	O
the	O
reduction	O
of	O
transcription	O
for	O
ER	O
gene	O
,	O
which	O
leads	O
to	O
the	O
reduction	O
of	O
ER	O
mRNA	O
and	O
ER	O
expressions	O
in	O
monocytes	O
.	O

Cross-linking	O
of	O
CD30	O
induces	O
HIV	O
expression	O
in	O
chronically	O
infected	O
T	O
cells	O
.	O

CD30	O
,	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
is	O
expressed	O
constitutively	O
on	O
the	O
surface	O
of	O
the	O
human	O
T	O
cell	O
line	O
ACH-2	O
,	O
which	O
is	O
chronically	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV	O
)	O
-1	O
.	O

We	O
demonstrate	O
that	O
cross-linking	O
CD30	O
with	O
an	O
anti-CD30-specific	O
monoclonal	O
antibody	O
,	O
which	O
mimics	O
the	O
described	O
biological	O
activities	O
of	O
the	O
CD30	O
ligand	O
(	O
CD30L	O
)	O
,	O
results	O
in	O
HIV	O
expression	O
.	O

CD30	O
cross-linking	O
does	O
not	B-Negation
alter	I-Negation
proliferation	I-Negation
of	I-Negation
ACH-2	I-Negation
cells	I-Negation
and	O
the	B-Negation
induction	I-Negation
of	I-Negation
HIV	I-Negation
expression	I-Negation
is	I-Negation
not	I-Negation
mediated	I-Negation
by	I-Negation
endogenous	I-Negation
TNF	I-Negation
alpha/beta	I-Negation
.	O

Furthermore	O
,	O
cross-linking	O
of	O
CD30	O
leads	O
to	O
NF-kappa	O
B	O
activation	O
and	O
enhanced	O
HIV	O
transcription	O
.	O

Thus	O
,	O
CD30-CD30L	O
interactions	O
mediate	O
the	O
induction	O
of	O
HIV	O
expression	O
by	O
a	O
kappa	O
B-dependent	O
pathway	O
that	O
is	O
independent	O
of	O
TNF	O
.	O

This	O
mechanism	O
may	O
be	O
important	O
in	O
the	O
activation	O
of	O
HIV	O
expression	O
from	O
latently	O
infected	O
CD4+	O
T	O
cells	O
,	O
especially	O
in	O
lymphoid	O
organs	O
where	O
cell	O
to	O
cell	O
contact	O
is	O
conducive	O
to	O
receptor-ligand	O
interactions	O
.	O

Integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
cytokine	O
message	O
induction	O
in	O
monocytic	O
cells	O
.	O

A	O
possible	O
signaling	O
role	O
for	O
the	O
Syk	O
tyrosine	O
kinase	O
.	O

Activation	O
of	O
cytoplasmic	O
tyrosine	O
kinases	O
is	O
an	O
important	O
aspect	O
of	O
signal	O
transduction	O
mediated	O
by	O
integrins	O
.	O

In	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
,	O
either	O
integrin-dependent	O
cell	O
adhesion	O
to	O
fibronectin	O
or	O
ligation	O
of	O
beta	O
1	O
integrins	O
with	O
antibodies	O
causes	O
a	O
rapid	O
and	O
intense	O
tyrosine	O
phosphorylation	O
of	O
two	O
sets	O
of	O
proteins	O
of	O
about	O
65-75	O
and	O
120-125	O
kDa	O
.	O

In	O
addition	O
,	O
integrin	O
ligation	O
leads	O
to	O
nuclear	O
translocation	O
of	O
the	O
p50	O
and	O
p65	O
subunits	O
of	O
the	O
NF-kappa	O
B	O
transcription	O
factor	O
,	O
to	O
activation	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
containing	O
NF-kappa	O
B	O
sites	O
,	O
and	O
to	O
increased	O
levels	O
of	O
mRNAs	O
for	O
immediate-early	O
genes	O
,	O
including	O
the	O
cytokine	O
interleukin	O
(	O
IL	O
)	O
-1	O
beta	O
.	O

The	O
tyrosine	O
kinase	O
inhibitors	O
genistein	O
and	O
herbimycin	O
A	O
block	O
both	O
integrin-mediated	O
tyrosine	O
phosphorylation	O
and	O
increases	O
in	O
IL-1	O
beta	O
message	O
levels	O
,	O
indicating	O
a	O
causal	O
relationship	O
between	O
the	O
two	O
events	O
.	O

The	O
components	O
tyrosine	O
phosphorylated	O
subsequent	O
to	O
cell	O
adhesion	O
include	O
paxillin	O
,	O
pp125FAK	O
,	O
and	O
the	O
SH2	O
domain	O
containing	O
tyrosine	O
kinase	O
Syk	O
.	O

In	O
contrast	O
,	O
integrin	O
ligation	O
with	O
antibodies	O
induces	O
tyrosine	O
phosphorylation	O
of	O
Syk	O
but	O
not	B-Negation
of	I-Negation
FAK	I-Negation
or	I-Negation
paxillin	I-Negation
.	O

In	O
adhering	O
cells	O
,	O
pre-treatment	O
with	O
cytochalasin	O
D	O
suppresses	O
tyrosine	O
phosphorylation	O
of	O
FAK	O
and	O
paxillin	O
but	O
not	B-Negation
of	I-Negation
Syk	I-Negation
,	O
while	O
IL-1	O
beta	O
message	O
induction	O
is	O
unaffected	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
Syk	O
tyrosine	O
kinase	O
may	O
be	O
an	O
important	O
component	O
of	O
an	O
integrin	O
signaling	O
pathway	O
in	O
monocytic	O
cells	O
,	O
leading	O
to	O
activation	O
of	O
NF-kappa	O
B	O
and	O
to	O
increased	O
levels	O
of	O
cytokine	O
messages	O
.	O

Nitric	O
oxide	O
decreases	O
cytokine-induced	O
endothelial	O
activation	O
.	O

Nitric	O
oxide	O
selectively	O
reduces	O
endothelial	O
expression	O
of	O
adhesion	O
molecules	O
and	O
proinflammatory	O
cytokines	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
limits	O
endothelial	O
activation	O
,	O
we	O
treated	O
cytokine-stimulated	O
human	O
saphenous	O
vein	O
endothelial	O
cells	O
with	O
several	O
NO	O
donors	O
and	O
assessed	O
their	O
effects	O
on	O
the	O
inducible	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
.	O

In	O
a	O
concentration-dependent	O
manner	O
,	O
NO	O
inhibited	O
interleukin	O
(	O
IL	O
)	O
-1	O
alpha-stimulated	O
VCAM-1	O
expression	O
by	O
35-55	O
%	O
as	O
determined	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
and	O
flow	O
cytometry	O
.	O

This	O
inhibition	O
was	O
paralleled	O
by	O
reduced	O
monocyte	O
adhesion	O
to	O
endothelial	O
monolayers	O
in	O
nonstatic	O
assays	O
,	O
was	O
unaffected	O
by	O
cGMP	O
analogues	O
,	O
and	O
was	O
quantitatively	O
similar	O
after	O
stimulation	O
by	O
either	O
IL-1	O
alpha	O
,	O
IL-1	O
beta	O
,	O
IL-4	O
,	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
alpha	O
)	O
,	O
or	O
bacterial	O
lipopolysaccharide	O
.	O

NO	O
also	O
decreased	O
the	O
endothelial	O
expression	O
of	O
other	O
leukocyte	O
adhesion	O
molecules	O
(	O
E-selectin	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
intercellular	O
adhesion	O
molecule-1	O
)	O
and	O
secretable	O
cytokines	O
(	O
IL-6	O
and	O
IL-8	O
)	O
.	O

Inhibition	O
of	O
endogenous	O
NO	O
production	O
by	O
L-N-monomethyl-arginine	O
also	O
induced	O
the	O
expression	O
of	O
VCAM-1	O
,	O
but	O
did	O
not	B-Negation
augment	I-Negation
cytokine-induced	I-Negation
VCAM-1	I-Negation
expression	I-Negation
.	O

Nuclear	O
run-on	O
assays	O
,	O
transfection	O
studies	O
using	O
various	O
VCAM-1	O
promoter	O
reporter	O
gene	O
constructs	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
indicated	O
that	O
NO	O
represses	O
VCAM-1	O
gene	O
transcription	O
,	O
in	O
part	O
,	O
by	O
inhibiting	O
NF-kappa	O
B	O
.	O

We	O
propose	O
that	O
NO	O
's	O
ability	O
to	O
limit	O
endothelial	O
activation	O
and	O
inhibit	O
monocyte	O
adhesion	O
may	O
contribute	O
to	O
some	O
of	O
its	O
antiatherogenic	O
and	O
antiinflammatory	O
properties	O
within	O
the	O
vessel	O
wall	O
.	O

Distinct	O
signaling	O
properties	O
identify	O
functionally	O
different	O
CD4	O
epitopes	O
.	O

The	O
CD4	O
coreceptor	O
interacts	O
with	O
non-polymorphic	O
regions	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
molecules	O
on	O
antigen-presenting	O
cells	O
and	O
contributes	O
to	O
T	O
cell	O
activation	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
CD4	O
triggering	O
on	O
T	O
cell	O
activating	O
signals	O
in	O
a	O
lymphoma	O
model	O
using	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
which	O
recognize	O
different	O
CD4	O
epitopes	O
.	O

We	O
demonstrate	O
that	O
CD4	O
triggering	O
delivers	O
signals	O
capable	O
of	O
activating	O
the	O
NF-AT	O
transcription	O
factor	O
which	O
is	O
required	O
for	O
interleukin-2	O
gene	O
expression	O
.	O

Whereas	O
different	O
anti-CD4	O
mAb	O
or	O
HIV-1	O
gp120	O
could	O
all	O
trigger	O
activation	O
of	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
phosphorylation	O
of	O
the	O
Shc	O
adaptor	O
protein	O
,	O
which	O
mediates	O
signals	O
to	O
Ras	O
,	O
they	O
differed	O
significantly	O
in	O
their	O
ability	O
to	O
activate	O
NF-AT	O
.	O

Lack	O
of	O
full	O
activation	O
of	O
NF-AT	O
could	O
be	O
correlated	O
to	O
a	O
dramatically	O
reduced	O
capacity	O
to	O
induce	O
calcium	O
flux	O
and	O
could	O
be	O
complemented	O
with	O
a	O
calcium	O
ionophore	O
.	O

The	O
results	O
identify	O
functionally	O
distinct	O
epitopes	O
on	O
the	O
CD4	O
coreceptor	O
involved	O
in	O
activation	O
of	O
the	O
Ras/protein	O
kinase	O
C	O
and	O
calcium	O
pathways	O
.	O

Lipopolysaccharide-induced	O
E-selectin	O
expression	O
requires	O
continuous	O
presence	O
of	O
LPS	O
and	O
is	O
inhibited	O
by	O
bactericidal/permeability-increasing	O
protein	O
.	O

Endothelial	O
cells	O
stimulated	O
by	O
LPS	O
express	O
E-selectin	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
neutrophil	O
adhesion	O
during	O
inflammation	O
.	O

E-selectin	O
is	O
induced	O
within	O
1-2	O
h	O
,	O
peaks	O
at	O
4-6	O
h	O
,	O
and	O
gradually	O
returns	O
to	O
basal	O
level	O
by	O
24	O
h	O
.	O

rBPI21	O
,	O
a	O
recombinant	O
N-terminal	O
fragment	O
of	O
human	O
bactericidal/permeability-increasing	O
protein	O
(	O
BPI	O
)	O
,	O
inhibited	O
LPS-induced	O
E-selectin	O
expression	O
when	O
added	O
at	O
the	O
same	O
time	O
as	O
,	O
and	O
up	O
to	O
6	O
h	O
after	O
,	O
LPS	O
.	O

Delayed	O
administration	O
of	O
rBPI21	O
also	O
affected	O
LPS-mediated	O
activation	O
of	O
the	O
nuclear	O
factor	O
,	O
NF-kappa	O
B	O
.	O

Two	O
to	O
4	O
h	O
following	O
LPS	O
addition	O
to	O
endothelial	O
cells	O
,	O
when	O
NF-kappa	O
B	O
was	O
already	O
activated	O
,	O
addition	O
of	O
rBPI21	O
resulted	O
in	O
marked	O
reduction	O
of	O
NF-kappa	O
B	O
detectable	O
at	O
4	O
or	O
6	O
h	O
.	O

These	O
results	O
indicate	O
that	O
endothelial	O
activation	O
requires	O
continuous	O
presence	O
of	O
LPS	O
,	O
and	O
rBPI21	O
acts	O
to	O
reverse	O
LPS-mediated	O
endothelial	O
activation	O
by	O
interrupting	O
the	O
on-going	O
LPS	O
signal	O
.	O

Costimulation	O
of	O
human	O
CD4+	O
T	O
cells	O
with	O
LFA-3	O
and	O
B7	O
induce	O
distinct	O
effects	O
on	O
AP-1	O
and	O
NF-kappa	O
B	O
transcription	O
factors	O
.	O

We	O
have	O
earlier	O
shown	O
that	O
stimulation	O
of	O
human	O
CD4+	O
T	O
cells	O
with	O
SEA	O
presented	O
on	O
Chinese	O
hamster	O
ovary	O
(	O
CHO	O
)	O
-DR	O
transfectants	O
coexpressing	O
either	O
B7	O
or	O
LFA-3	O
resulted	O
in	O
distinct	O
cytokine	O
profiles	O
.	O

We	O
now	O
demonstrate	O
that	O
B7	O
,	O
but	O
not	B-Negation
LFA-3	I-Negation
,	O
strongly	O
costimulated	O
IL-2	O
transcription	O
and	O
mRNA	O
expression	O
in	O
CD4+	O
T	O
cells	O
.	O

Maximal	O
increase	O
in	O
IL-2	O
transcription	O
was	O
recorded	O
with	O
CHO-DR/B7/LFA-3	O
,	O
suggesting	O
a	O
cooperative	O
effect	O
of	O
B7	O
and	O
LFA-3	O
at	O
the	O
transcriptional	O
level	O
.	O

Gel-shift	O
analysis	O
demonstrated	O
that	O
stimulation	O
of	O
CD4+	O
T	O
cells	O
with	O
CHO-DR	O
and	O
staphylococcal	O
enterotoxin	O
A	O
was	O
sufficient	O
to	O
induce	O
significant	O
amounts	O
of	O
NF-kappa	O
B	O
binding	O
proteins	O
,	O
whereas	O
induction	O
of	O
AP-1	O
binding	O
proteins	O
required	O
costimulation	O
.	O

LFA-3	O
induced	O
moderate	O
levels	O
of	O
AP-1	O
,	O
but	O
did	O
not	B-Negation
influence	I-Negation
the	I-Negation
levels	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
,	O
while	O
B7	O
costimulation	O
strongly	O
induced	O
both	O
AP-1	O
and	O
substantially	O
enhanced	O
NF-kappa	O
B	O
binding	O
proteins	O
.	O

The	O
CHO-DR/B7/LFA-3	O
triple	O
transfectant	O
induced	O
a	O
further	O
increase	O
in	O
AP-1	O
and	O
NF-kappa	O
B	O
binding	O
proteins	O
compared	O
with	O
the	O
double	O
transfectants	O
.	O

The	O
level	O
of	O
Oct-1	O
binding	O
proteins	O
remained	O
similar	O
in	O
all	O
samples	O
.	O

Super-shift	O
analysis	O
revealed	O
that	O
the	O
NF-kappa	O
B	O
complex	O
of	O
costimulated	O
CD4+	O
T	O
cells	O
contained	O
large	O
amounts	O
of	O
p50	O
,	O
substantial	O
amounts	O
of	O
p65	O
,	O
and	O
marginal	O
levels	O
of	O
c-Rel	O
proteins	O
.	O

The	O
AP-1	O
binding	O
proteins	O
contained	O
c-Jun	O
,	O
Jun-D	O
,	O
and	O
Fra-1	O
,	O
but	O
marginal	O
amounts	O
of	O
Jun-B	O
and	O
c-Fos	O
.	O

Our	O
results	O
indicate	O
distinct	O
effects	O
of	O
B7	O
and	O
LFA-3	O
costimulation	O
on	O
the	O
activity	O
of	O
AP-1	O
and	O
NF-kappa	O
B	O
.	O

These	O
may	O
partly	O
account	O
for	O
the	O
differential	O
effects	O
of	O
B7	O
and	O
LFA-3	O
costimulation	O
on	O
IL-2	O
expression	O
.	O

Regulation	O
of	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
and	O
E-selectin	O
expression	O
in	O
endothelial	O
cells	O
by	O
cyclosporin	O
A	O
and	O
the	O
T-cell	O
transcription	O
factor	O
NFAT	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
was	O
originally	O
described	O
as	O
a	O
T-cell-specific	O
transcription	O
factor	O
athat	O
supported	O
the	O
activation	O
of	O
cytokine	O
gene	O
expression	O
and	O
mediated	O
the	O
immunoregulatory	O
effects	O
of	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

As	O
we	O
observed	O
that	O
activated	O
endothelial	O
cells	O
also	O
expressed	O
NFAT	O
,	O
we	O
tested	O
the	O
antiinflammatory	O
properties	O
of	O
CsA	O
in	O
endothelial	O
cells	O
.	O

Significantly	O
,	O
CsA	O
completely	O
suppressed	O
the	O
induction	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
inhibited	O
the	O
activity	O
of	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
gene	O
regulatory	O
elements	O
that	O
use	O
NFAT	O
by	O
60	O
%	O
.	O

CsA	O
similarly	O
mediated	O
a	O
reduction	O
of	O
up	O
to	O
65	O
%	O
in	O
GM-CSF	O
mRNA	O
and	O
protein	O
expression	O
in	O
activated	O
endothelial	O
cells	O
.	O

CsA	O
also	O
suppressed	O
E-selectin	O
,	O
but	O
not	B-Negation
vascular	I-Negation
cell	I-Negation
adhesion	I-Negation
molecule-1	I-Negation
(	I-Negation
VCAM-1	I-Negation
)	I-Negation
expression	I-Negation
in	I-Negation
endothelial	I-Negation
cells	I-Negation
,	O
even	O
though	O
the	O
E-selectin	O
promoter	O
is	O
activated	O
by	O
NF-kappa	O
B	O
rather	B-Negation
than	I-Negation
NFAT	I-Negation
.	O

Hence	O
,	O
induction	O
of	O
cell	O
surface	O
expression	O
of	O
this	O
leukocyte	O
adhesion	O
molecule	O
by	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
was	O
reduced	O
by	O
40	O
%	O
in	O
the	O
presence	O
of	O
CsA	O
,	O
and	O
this	O
was	O
reflected	O
by	O
a	O
29	O
%	O
decrease	O
in	O
neutrophil	O
adhesion	O
.	O

The	O
effects	O
of	O
CsA	O
on	O
endothelial	O
cells	O
were	O
also	O
detected	O
at	O
the	O
chromatin	O
structure	O
level	O
,	O
as	O
DNasel	O
hypersensitive	O
sites	O
within	O
both	O
the	O
GM-CSF	O
enhancer	O
and	O
the	O
E-selectin	O
promoter	O
were	O
suppressed	O
by	O
CsA	O
.	O

This	O
represents	O
the	O
first	O
report	O
of	O
NFAT	O
in	O
endothelial	O
cells	O
and	O
suggests	O
mechanisms	O
by	O
which	O
CsA	O
could	O
function	O
as	O
an	O
antiinflammatory	O
agent	O
.	O

Signalling	O
via	O
CD28	O
of	O
human	O
naive	O
neonatal	O
T	O
lymphocytes	O
.	O

Accessory	O
molecules	O
play	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
the	O
T	O
cell	O
response	O
to	O
antigenic	O
challenge	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
CD28	O
in	O
modulating	O
the	O
'naive	O
'	O
neonatal	O
T	O
cell	O
response	O
to	O
anti-CD2-mediated	O
activation	O
.	O

To	O
compare	O
the	O
role	O
of	O
CD28	O
,	O
neonatal	O
and	O
adult	O
T	O
cells	O
were	O
stimulated	O
with	O
a	O
pair	O
of	O
mitogenic	O
anti-CD2	O
antibodies	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
anti-CD28	I-Negation
MoAb	I-Negation
.	O

With	O
anti-CD2	O
alone	O
,	O
neonatal	O
T	O
cells	O
proliferated	O
slightly	O
but	O
produced	O
no	B-Negation
detectable	I-Negation
IL-2	I-Negation
,	O
whereas	O
adult	O
T	O
cells	O
proliferated	O
vigorously	O
,	O
with	O
significant	O
IL-2	O
production	O
.	O

Costimulation	O
with	O
anti-CD28	O
MoAb	O
greatly	O
enhanced	O
the	O
proliferative	O
response	O
of	O
neonatal	O
T	O
cells	O
to	O
levels	O
equivalent	O
to	O
those	O
of	O
adult	O
T	O
cells	O
,	O
whereas	O
adult	O
T	O
cells	O
showed	O
only	O
slight	O
increases	O
.	O

Although	O
IL-2	O
secretion	O
was	O
increased	O
in	O
the	O
presence	O
of	O
anti-CD28	O
MoAb	O
,	O
neonatal	O
T	O
cell	O
IL-2	O
production	O
remained	O
lower	O
than	O
in	O
adults	O
.	O

In	O
contrast	O
,	O
enhancement	O
of	O
IL-2	O
mRNA	O
expression	O
in	O
neonates	O
was	O
similar	O
to	O
adult	O
levels	O
.	O

Anti-CD28	O
MoAb	O
costimulation	O
increased	O
NF	O
kappa	O
B	O
levels	O
in	O
neonates	O
,	O
albeit	O
to	O
levels	O
lower	O
than	O
that	O
of	O
adults	O
.	O

The	O
cellular	O
mechanism	O
governing	O
the	O
diminished	O
proliferative	O
response	O
of	O
neonatal	O
T	O
lymphocytes	O
to	O
anti-CD2	O
may	O
therefore	O
be	O
due	O
to	O
decreased	O
NF	O
kappa	O
B	O
induction	O
,	O
reduced	O
IL-2	O
mRNA	O
expression	O
and	O
deficient	O
IL-2	O
production	O
.	O

Although	O
anti-CD28	O
MoAb	O
costimulation	O
enhances	O
all	O
of	O
the	O
above	O
signals	O
,	O
NF	O
kappa	O
B	O
and	O
IL-2	O
levels	O
remain	O
lower	O
than	O
in	O
adults	O
,	O
suggesting	O
the	O
need	O
for	O
further	O
activation	O
requirements	O
in	O
the	O
neonate	O
.	O

Regulation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
cytokine	O
gene	O
expression	O
in	O
myeloid	O
cells	O
by	O
NF-kappa	O
B/Rel	O
transcription	O
factors	O
.	O

CD4+	O
macrophages	O
in	O
tissues	O
such	O
as	O
lung	O
,	O
skin	O
,	O
and	O
lymph	O
nodes	O
,	O
promyelocytic	O
cells	O
in	O
bone	O
marrow	O
,	O
and	O
peripheral	O
blood	O
monocytes	O
serve	O
as	O
important	O
targets	O
and	O
reservoirs	O
for	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

HIV-1-infected	O
myeloid	O
cells	O
are	O
often	O
diminished	O
in	O
their	O
ability	O
to	O
participate	O
in	O
chemotaxis	O
,	O
phagocytosis	O
,	O
and	O
intracellular	O
killing	O
.	O

HIV-1	O
infection	O
of	O
myeloid	O
cells	O
can	O
lead	O
to	O
the	O
expression	O
of	O
surface	O
receptors	O
associated	O
with	O
cellular	O
activation	O
and/or	O
differentiation	O
that	O
increase	O
the	O
responsiveness	O
of	O
these	O
cells	O
to	O
cytokines	O
secreted	O
by	O
neighboring	O
cells	O
as	O
well	O
as	O
to	O
bacteria	O
or	O
other	O
pathogens	O
.	O

Enhancement	O
of	O
HIV-1	O
replication	O
is	O
related	O
in	O
part	O
to	O
increased	O
DNA-binding	O
activity	O
of	O
cellular	O
transcription	O
factors	O
such	O
as	O
NF-kappa	O
B	O
.	O

NF-kappa	O
B	O
binds	O
to	O
the	O
HIV-1	O
enhancer	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
and	O
contributes	O
to	O
the	O
inducibility	O
of	O
HIV-1	O
gene	O
expression	O
in	O
response	O
to	O
multiple	O
activating	O
agents	O
.	O

Phosphorylation	O
and	O
degradation	O
of	O
the	O
cytoplasmic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
are	O
crucial	O
regulatory	O
events	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
.	O

Both	O
N-	O
and	O
C-terminal	O
residues	O
of	O
I	O
kappa	O
B	O
alpha	O
are	O
required	O
for	O
inducer-mediated	O
degradation	O
.	O

Chronic	O
HIV-1	O
infection	O
of	O
myeloid	O
cells	O
leads	O
to	O
constitutive	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
and	O
provides	O
an	O
intranuclear	O
environment	O
capable	O
of	O
perpetuating	O
HIV-1	O
replication	O
.	O

Increased	O
intracellular	O
stores	O
of	O
latent	O
NF-kappa	O
B	O
may	O
also	O
result	O
in	O
rapid	O
inducibility	O
of	O
NF-kappa	O
B-dependent	O
cytokine	O
gene	O
expression	O
.	O

In	O
response	O
to	O
secondary	O
pathogenic	O
infections	O
or	O
antigenic	O
challenge	O
,	O
cytokine	O
gene	O
expression	O
is	O
rapidly	O
induced	O
,	O
enhanced	O
,	O
and	O
sustained	O
over	O
prolonged	O
periods	O
in	O
HIV-1-infected	O
myeloid	O
cells	O
compared	O
with	O
uninfected	O
cells	O
.	O

Elevated	O
levels	O
of	O
several	O
inflammatory	O
cytokines	O
have	O
been	O
detected	O
in	O
the	O
sera	O
of	O
HIV-1-infected	O
individuals	O
.	O

Secretion	O
of	O
myeloid	O
cell-derived	O
cytokines	O
may	O
both	O
increase	O
virus	O
production	O
and	O
contribute	O
to	O
AIDS-associated	O
disorders	O
.	O

Transcriptional	O
repression	O
of	O
the	O
interleukin-2	O
gene	O
by	O
vitamin	O
D3	O
:	O
direct	O
inhibition	O
of	O
NFATp/AP-1	O
complex	O
formation	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
.	O

T-lymphocyte	O
proliferation	O
is	O
suppressed	O
by	O
1,25-dihydroxyvitamin	O
D3	O
[	O
1,25	O
(	O
OH	O
)	O
2D3	O
]	O
,	O
the	O
active	O
metabolite	O
of	O
vitamin	O
D3	O
,	O
and	O
is	O
associated	O
with	O
a	O
decrease	O
in	O
interleukin	O
2	O
(	O
IL-2	O
)	O
,	O
gamma	O
interferon	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
mRNA	O
levels	O
.	O

We	O
report	O
here	O
that	O
1,25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
Jurkat	O
cells	O
is	O
cycloheximide	O
resistant	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
transcriptional	O
repressive	O
effect	O
on	O
IL-2	O
expression	O
by	O
the	O
vitamin	O
D3	O
receptor	O
(	O
VDR	O
)	O
.	O

We	O
therefore	O
examined	O
vitamin	O
D3-mediated	O
repression	O
of	O
activated	O
IL-2	O
expression	O
by	O
cotransfecting	O
Jurkat	O
cells	O
with	O
IL-2	O
promoter/reporter	O
constructs	O
and	O
a	O
VDR	O
overexpression	O
vector	O
and	O
by	O
DNA	O
binding	O
.	O

We	O
delineated	O
an	O
element	O
conferring	O
both	O
DNA	O
binding	O
by	O
the	O
receptor	O
in	O
vitro	O
and	O
1,25	O
(	O
OH	O
)	O
2D3-mediated	O
repression	O
in	O
vivo	O
to	O
a	O
short	O
40-bp	O
region	O
encompassing	O
an	O
important	O
positive	O
regulatory	O
element	O
,	O
NF-AT-1	O
,	O
which	O
is	O
bound	O
by	O
a	O
T-cell-specific	O
transcription	O
factor	O
,	O
NFATp	O
,	O
as	O
well	O
as	O
by	O
AP-1	O
.	O

VDR	B-Negation
DNA-binding	I-Negation
mutants	I-Negation
were	I-Negation
unable	I-Negation
to	I-Negation
either	I-Negation
bind	I-Negation
to	I-Negation
this	I-Negation
element	I-Negation
in	I-Negation
vitro	I-Negation
or	I-Negation
repress	I-Negation
in	I-Negation
vivo	I-Negation
;	O
the	O
VDR	O
DNA-binding	O
domain	O
alone	O
,	O
however	O
,	O
bound	O
the	O
element	O
but	O
also	O
could	O
not	B-Negation
repress	I-Negation
IL-2	I-Negation
expression	I-Negation
.	O

These	O
results	O
indicate	O
that	O
DNA	O
binding	O
by	O
VDR	O
is	O
necessary	O
but	O
not	O
sufficient	O
to	O
mediate	O
IL-2	O
repression	O
.	O

By	O
combining	O
partially	O
purified	O
proteins	O
in	O
vitro	O
,	O
we	O
observed	O
the	O
loss	O
of	O
the	O
bound	O
NFATp/AP-1-DNA	O
complex	O
upon	O
inclusion	O
of	O
VDR	O
or	O
VDR-retinoid	O
X	O
receptor	O
.	O

Order	O
of	O
addition	O
and	O
off-rate	O
experiments	O
indicate	O
that	O
the	O
VDR-retinoid	O
X	O
receptor	O
heterodimer	O
blocks	O
NFATp/AP-1	O
complex	O
formation	O
and	O
then	O
stably	O
associates	O
with	O
the	O
NF-AT-1	O
element	O
.	O

This	O
direct	O
inhibition	O
by	O
a	O
nuclear	O
hormone	O
receptor	O
of	O
transcriptional	O
activators	O
of	O
the	O
IL-2	O
gene	O
may	O
provide	O
a	O
mechanistic	O
explanation	O
of	O
how	O
vitamin	O
derivatives	O
can	O
act	O
as	O
potent	O
immunosuppressive	O
agents	O
.	O

An	O
interferon-gamma	O
activation	O
sequence	O
mediates	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IgG	O
Fc	O
receptor	O
type	O
IC	O
gene	O
by	O
interferon-gamma	O
.	O

Expression	O
of	O
the	O
IgG	O
Fc	O
receptor	O
type	O
I	O
(	O
Fc	O
gamma	O
RI	O
)	O
on	O
myeloid	O
cells	O
is	O
dramatically	O
increased	O
by	O
treatment	O
with	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
.	O

We	O
observed	O
that	O
Fc	O
gamma	O
RI	O
transcript	O
levels	O
in	O
monoblast-like	O
U937	O
cells	O
were	O
elevated	O
within	O
3	O
hr	O
and	O
peaked	O
12	O
hr	O
after	O
exposure	O
to	O
IFN-gamma	O
.	O

Treatment	O
of	O
U937	O
with	O
IFN-gamma	O
for	O
9	O
hr	O
in	O
the	O
presence	O
of	O
cycloheximide	O
led	O
to	O
super-induction	O
of	O
Fc	O
gamma	O
RI	O
expression	O
.	O

Nuclear	O
run-on	O
analysis	O
revealed	O
that	O
the	O
rate	O
of	O
Fc	O
gamma	O
RI	O
transcription	O
was	O
increased	O
by	O
IFN-gamma	O
.	O

Genomic	O
sequence	O
upstream	O
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
was	O
cloned	O
and	O
subjected	O
to	O
primer	O
extension	O
analysis	O
,	O
which	O
demonstrated	O
a	O
single	O
transcription	O
initiation	O
site	O
without	B-Negation
a	I-Negation
TATA	I-Negation
box	I-Negation
.	O

Transient	O
transfections	O
of	O
CAT	O
reporter	O
gene	O
constructs	O
containing	O
various	O
Fc	O
gamma	O
RIC	O
promoter	O
sequences	O
into	O
U937	O
cells	O
revealed	O
that	O
a	O
20-bp	O
region	O
surrounding	O
the	O
transcription	O
start	O
site	O
(	O
-7	O
to	O
+13	O
)	O
was	O
capable	O
of	O
mediating	O
transcription	O
initiation	O
and	O
that	O
an	O
IFN-gamma	O
responsive	O
element	O
(	O
GIRE	O
)	O
was	O
present	O
within	O
74	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
17-bp	O
sequence	O
between	O
positions	O
-51	O
and	O
-35	O
conferred	O
IFN-gamma	O
responsiveness	O
on	O
a	O
heterologous	O
promoter	O
.	O

Double-stranded	O
GIRE	O
sequence	O
,	O
but	O
not	B-Negation
a	I-Negation
scrambled	I-Negation
sequence	I-Negation
,	O
was	O
specifically	O
bound	O
by	O
nuclear	O
proteins	O
from	O
IFN-gamma	O
treated	O
U937	O
cells	O
.	O

Gel	O
shift	O
experiments	O
further	O
showed	O
that	O
the	O
STAT1	O
alpha	O
protein	O
bound	O
to	O
the	O
Fc	O
gamma	O
RIC	O
GIRE	O
in	O
response	O
to	O
IFN-gamma	O
treatment	O
of	O
U937	O
cells	O
.	O

The	O
Fc	O
gamma	O
RIC	O
GIRE	O
is	O
homologous	O
to	O
the	O
IFN-gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
of	O
the	O
guanylate	O
binding	O
protein	O
and	O
to	O
X	O
box	O
elements	O
of	O
class	O
II	O
MHC	O
genes	O
.	O

Our	O
results	O
demonstrate	O
that	O
transcriptional	O
regulation	O
of	O
the	O
Fc	O
gamma	O
RIC	O
gene	O
by	O
IFN-gamma	O
involves	O
the	O
binding	O
of	O
STAT1	O
alpha	O
to	O
a	O
17-bp	O
GAS	O
homology	O
in	O
the	O
proximal	O
promoter	O
.	O

Immunosuppression	O
by	O
glucocorticoids	O
:	O
inhibition	O
of	O
NF-kappa	O
B	O
activity	O
through	O
induction	O
of	O
I	O
kappa	O
B	O
synthesis	O
[	O
see	O
comments	O
]	O

Glucocorticoids	O
are	O
among	O
the	O
most	O
potent	O
anti-inflammatory	O
and	O
immunosuppressive	O
agents	O
.	O

They	O
inhibit	O
synthesis	O
of	O
almost	O
all	O
known	O
cytokines	O
and	O
of	O
several	O
cell	O
surface	O
molecules	O
required	O
for	O
immune	O
function	O
,	O
but	O
the	O
mechanism	O
underlying	O
this	O
activity	O
has	O
been	O
unclear	O
.	O

Here	O
it	O
is	O
shown	O
that	O
glucocorticoids	O
are	O
potent	O
inhibitors	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
in	O
mice	O
and	O
cultured	O
cells	O
.	O

This	O
inhibition	O
is	O
mediated	O
by	O
induction	O
of	O
the	O
I	O
kappa	O
B	O
alpha	O
inhibitory	O
protein	O
,	O
which	O
traps	O
activated	O
NF-kappa	O
B	O
in	O
inactive	O
cytoplasmic	O
complexes	O
.	O

Because	O
NF-kappa	O
B	O
activates	O
many	O
immunoregulatory	O
genes	O
in	O
response	O
to	O
pro-inflammatory	O
stimuli	O
,	O
the	O
inhibition	O
of	O
its	O
activity	O
can	O
be	O
a	O
major	O
component	O
of	O
the	O
anti-inflammatory	O
activity	O
of	O
glucocorticoids	O
.	O

Pathogenesis	O
of	O
atherosclerosis	O
.	O

The	O
earliest	O
lesion	O
in	O
the	O
development	O
of	O
an	O
atherosclerotic	O
plaque	O
is	O
the	O
fatty	O
streak	O
.	O

This	O
chronic	O
inflammatory	O
reaction	O
results	O
from	O
a	O
sequence	O
of	O
events	O
that	O
begins	O
with	O
the	O
trapping	O
of	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
in	O
the	O
subendothelial	O
space	O
of	O
the	O
artery	O
wall	O
.	O

The	O
trapped	O
LDL	O
is	O
seeded	O
with	O
oxidative	O
species	O
released	O
by	O
the	O
overlying	O
endothelium	O
,	O
and	O
lipid	O
oxidation	O
is	O
initiated	O
within	O
the	O
LDL	O
particle	O
.	O

Some	O
of	O
the	O
lipids	O
that	O
result	O
lead	O
to	O
the	O
activation	O
of	O
NFkB-like	O
transcription	O
factors	O
that	O
cause	O
the	O
expression	O
of	O
genes	O
whose	O
protein	O
products	O
mediate	O
monocyte	O
binding	O
,	O
monocyte	O
chemotaxis	O
into	O
the	O
subendothelial	O
space	O
,	O
and	O
conversion	O
into	O
macrophages	O
.	O

At	O
least	O
1	O
major	O
gene	O
modulates	O
the	O
oxidation	O
of	O
LDL	O
lipids	O
and/or	O
the	O
biologic	O
response	O
to	O
these	O
lipids	O
.	O

The	O
inverse	O
relation	O
between	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
and	O
atherosclerotic	O
events	O
may	O
in	O
part	O
be	O
due	O
to	O
enzymes	O
associated	O
with	O
HDL	O
that	O
destroy	O
the	O
biologically	O
active	O
lipids	O
generated	O
in	O
LDL	O
.	O

HMG-I	O
binds	O
to	O
GATA	O
motifs	O
:	O
implications	O
for	O
an	O
HPFH	O
syndrome	O
.	O

We	O
have	O
examined	O
binding	O
of	O
the	O
nuclear	O
protein	O
HMG-I	O
to	O
the	O
human	O
gamma-globin	O
promoter	O
.	O

We	O
find	O
that	O
HMG-I	O
binds	O
preferentially	O
to	O
the	O
more	O
3	O
'	O
of	O
a	O
pair	O
of	O
GATA	O
motifs	O
in	O
the	O
gamma-globin	O
promoter	O
;	O
this	O
paired	O
motif	O
is	O
bound	O
by	O
the	O
erythroid	O
factor	O
GATA-1	O
.	O

A	O
naturally	O
occurring	O
mutation	O
(	O
-175	O
T-C	O
)	O
in	O
the	O
area	O
bound	O
by	O
HMG-I	O
results	O
in	O
overexpression	O
of	O
gamma-globin	O
in	O
adult	O
red	O
blood	O
cells	O
(	O
HPFH	O
)	O
and	O
up-regulation	O
of	O
the	O
gamma-globin	O
promoter	O
in	O
in	O
vitro	O
expression	O
assays	O
;	O
HMG-I	O
does	O
not	B-Negation
bind	I-Negation
to	I-Negation
this	I-Negation
mutant	I-Negation
sequence	I-Negation
.	O

A	O
survey	O
of	O
GATA	O
motifs	O
from	O
other	O
globin	O
cis-elements	O
demonstrates	O
HMG-I	O
binding	O
to	O
most	O
of	O
them	O
.	O

These	O
findings	O
implicate	O
HMG-I	O
in	O
the	O
HPFH	O
phenotype	O
;	O
we	O
speculate	O
that	O
it	O
may	O
participate	O
in	O
the	O
formation	O
of	O
multiprotein	O
complexes	O
that	O
regulate	O
globin	O
gene	O
expression	O
.	O

The	O
myeloid	O
zinc	O
finger	O
gene	O
,	O
MZF-1	O
,	O
regulates	O
the	O
CD34	O
promoter	O
in	O
vitro	O
.	O

MZF-1	O
is	O
a	O
C2H2	O
zinc	O
finger	O
gene	O
encoding	O
a	O
putative	O
transcriptional	O
regulator	O
of	O
myeloid	O
differentiation	O
.	O

The	O
MZF-1	O
protein	O
contains	O
13	O
C2H2	O
zinc	O
fingers	O
arranged	O
in	O
bipartite	O
DNA	O
binding	O
domains	O
containing	O
zinc	O
fingers	O
through	O
4	O
and	O
,	O
in	O
the	O
carboxy-terminus	O
,	O
5	O
through	O
13	O
.	O

We	O
previously	O
identified	O
the	O
DNA	O
consensus	O
binding	O
site	O
recognized	O
by	O
the	O
two	O
DNA	O
binding	O
domains	O
.	O

To	O
assess	O
the	O
transcription	O
regulatory	O
function	O
of	O
MZF-1	O
,	O
the	O
full-length	O
MZF-1	O
coding	O
region	O
was	O
fused	O
to	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
yeast	O
transactivator	O
GAL4	O
.	O

The	O
expression	O
vector	O
was	O
cotransfected	O
with	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
regulated	O
by	O
the	O
thymidine	O
kinase	O
promoter	O
containing	O
GAL4	O
DNA	O
binding	O
sites	O
into	O
NIH	O
3T3	O
,	O
293	O
,	O
K562	O
,	O
and	O
Jurkat	O
cell	O
lines	O
.	O

MZF-1	O
represses	O
CAT	O
reporter	O
gene	O
expression	O
via	O
GAL4	O
binding	O
sites	O
in	O
the	O
nonhematopoietic	O
cell	O
lines	O
NIH	O
3T3	O
and	O
293	O
.	O

In	O
contrast	O
,	O
MZF-1	O
activates	O
CAT	O
reporter	O
gene	O
expression	O
in	O
the	O
hematopoietic	O
cell	O
lines	O
K562	O
and	O
Jurkat	O
.	O

The	O
MZF-1	O
binding	O
sites	O
are	O
present	O
in	O
the	O
promoters	O
of	O
several	O
genes	O
expressed	O
during	O
myeloid	O
differentiation	O
,	O
including	O
the	O
CD34	O
promoter	O
.	O

MZF-1	O
transcriptional	O
regulation	O
of	O
this	O
physiologically	O
relevant	O
promoter	O
was	O
assessed	O
in	O
both	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
lines	O
.	O

Recombinant	O
MZF-1	O
protein	O
specifically	O
binds	O
to	O
the	O
consensus	O
binding	O
sites	O
in	O
the	O
CD34	O
promoter	O
in	O
mobility	O
shift	O
assays	O
.	O

MZF-1	O
expression	O
vectors	O
were	O
cotransfected	O
with	O
the	O
luciferase	O
reporter	O
plasmids	O
regulated	O
by	O
the	O
CD34	O
promoter	O
into	O
both	O
nonhematopoietic	O
and	O
hematopoietic	O
cell	O
lines	O
.	O

As	O
with	O
the	O
heterologous	O
DNA	O
binding	O
domain	O
,	O
MZF-1	O
represses	O
reporter	O
gene	O
expression	O
in	O
nonhematopoietic	O
cell	O
lines	O
and	O
activates	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
.	O

Activation	O
of	O
CD34	O
expression	O
in	O
hematopoietic	O
cell	O
lines	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
intact	O
MZF-1	O
binding	O
sites	O
.	O

The	O
cell	O
type-specific	O
regulation	O
of	O
the	O
CD34	O
promoter	O
by	O
MZF-1	O
suggests	O
the	O
presence	O
of	O
tissue-specific	O
regulators/adapters	O
or	O
differential	O
MZF-1	O
modifications	O
that	O
determine	O
MZF-1	O
transcriptional	O
regulatory	O
function	O
.	O

The	O
normal	O
cell	O
cycle	O
activation	O
program	O
is	O
exploited	O
during	O
the	O
infection	O
of	O
quiescent	O
B	O
lymphocytes	O
by	O
Epstein-Barr	O
virus	O
.	O

B	O
lymphocytes	O
in	O
the	O
peripheral	O
circulation	O
are	O
maintained	O
in	O
a	O
non-proliferative	O
state	O
.	O

Antigen	O
recognition	O
stimulates	O
limited	O
proliferation	O
,	O
whereas	O
infection	O
with	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
results	O
in	O
continual	O
proliferation	O
and	O
the	O
outgrowth	O
of	O
immortal	O
cell	O
lines	O
.	O

Because	O
it	O
is	O
not	O
clear	O
at	O
which	O
point	O
in	O
cell	O
cycle	O
the	O
peripheral	O
B	O
lymphocytes	O
are	O
arrested	O
,	O
we	O
characterized	O
the	O
expression	O
of	O
several	O
cell	O
cycle-associated	O
genes	O
in	O
quiescent	O
and	O
stimulated	O
cells	O
.	O

We	O
show	O
that	O
the	O
expression	O
of	O
four	O
cell	O
genes	O
,	O
cdc-2	O
,	O
cyclin	O
E	O
,	O
CD23	O
,	O
and	O
cyclin	O
D2	O
,	O
are	O
up-regulated	O
approximately	O
100-fold	O
as	O
a	O
result	O
of	O
EBV-mediated	O
immortalization	O
.	O

Because	O
these	O
genes	O
play	O
a	O
positive	O
role	O
in	O
cell	O
proliferation	O
,	O
we	O
suggest	O
that	O
this	O
regulatory	O
switch	O
contributes	O
to	O
controlling	O
entry	O
into	O
the	O
cell	O
cycle	O
.	O

Transient	O
stimulation	O
of	O
quiescent	O
B	O
lymphocytes	O
with	O
either	O
a	O
cocktail	O
of	O
anti-CD40	O
,	O
anti-IgM	O
,	O
and	O
IL4	O
,	O
or	O
EBV	O
results	O
in	O
the	O
rapid	O
expression	O
of	O
the	O
same	O
four	O
genes	O
,	O
suggesting	O
that	O
,	O
after	O
infection	O
,	O
EBV	O
exploits	O
the	O
normal	O
program	O
of	O
B-lymphocyte	O
cell	O
cycle	O
activation	O
.	O

CD30	O
ligation	O
induces	O
nuclear	O
factor-kappa	O
B	O
activation	O
in	O
human	O
T	O
cell	O
lines	O
.	O

CD30	O
is	O
a	O
recently	O
described	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor/nerve	O
growth	O
factor	O
receptor	O
superfamily	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
following	O
incubation	O
of	O
L540	O
cells	O
(	O
Hodgkin	O
's	O
disease-derived	O
,	O
T	O
cell-like	O
,	O
CD30+	O
cells	O
)	O
with	O
the	O
agonistic	O
anti-CD30	O
monoclonal	O
antibodies	O
(	O
mAb	O
)	O
M44	O
and	O
M67	O
,	O
two	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
DNA	O
binding	O
activities	O
were	O
induced	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
retardation	O
assays	O
.	O

The	O
effect	O
of	O
the	O
mAb	O
towards	O
NF-kappa	O
B	O
activation	O
was	O
rapid	O
,	O
as	O
it	O
occurred	O
within	O
20	O
min	O
,	O
and	O
was	O
sustained	O
for	O
up	O
to	O
6	O
h	O
.	O

By	O
comparison	O
,	O
an	O
isotype-matched	O
antibody	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
.	O

Moreover	O
,	O
in	O
human	O
T	O
helper	O
(	O
Th	O
)	O
clones	O
functionally	O
characterized	O
as	O
being	O
of	O
the	O
type	O
0	O
,	O
type	O
1	O
and	O
type	O
2	O
(	O
28	O
%	O
,	O
<	O
1	O
%	O
und	O
93	O
%	O
CD30+	O
,	O
respectively	O
)	O
,	O
the	O
extent	O
of	O
CD30-mediated	O
NF-kappa	O
B	O
activation	O
correlated	O
with	O
the	O
proportion	O
of	O
CD30+	O
cells	O
.	O

In	O
all	O
cell	O
lines	O
investigated	O
,	O
the	O
NF-kappa	O
B	O
complexes	O
induced	O
following	O
CD30	O
engagement	O
were	O
shown	O
to	O
contain	O
p50	O
NF-kappa	O
B1	O
,	O
p65	O
RelA	O
,	O
and	O
possibly	O
other	O
transcription	O
factors	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
nuclear	O
translocation	O
and	O
activation	O
of	O
NF-kappa	O
B	O
rank	O
among	O
the	O
short-term	O
cellular	O
responses	O
elicited	O
following	O
CD30	O
ligation	O
.	O

Constitutive	O
NF-kappa	O
B	O
activation	O
,	O
enhanced	O
granulopoiesis	O
,	O
and	O
neonatal	O
lethality	O
in	O
I	O
kappa	O
B	O
alpha-deficient	O
mice	O
.	O

Transcription	O
factors	O
belonging	O
to	O
the	O
NF-kappa	O
B	O
family	O
are	O
controlled	O
by	O
inhibitory	O
I	O
kappa	O
B	O
proteins	O
,	O
mainly	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
.	O

Apparently	O
normal	O
at	O
birth	O
,	O
I	O
kappa	O
B	O
alpha-/-	O
mice	O
exhibit	O
severe	O
runting	O
,	O
skin	O
defects	O
,	O
and	O
extensive	O
granulopoiesis	O
postnatally	O
,	O
typically	O
dying	O
by	O
8	O
days	O
.	O

Hematopoietic	O
tissues	O
from	O
these	O
mice	O
display	O
elevated	O
levels	O
of	O
both	O
nuclear	O
NF-kappa	O
B	O
and	O
mRNAs	O
of	O
some	O
,	O
but	O
not	O
all	O
,	O
genes	O
thought	O
to	O
be	O
regulated	O
by	O
NF-kappa	O
B	O
.	O

NF-kappa	O
B	O
elevation	O
results	O
in	O
these	O
phenotypic	O
abnormalities	O
because	O
mice	O
lacking	B-Negation
both	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
and	I-Negation
the	I-Negation
p50	I-Negation
subunit	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
show	O
a	O
dramatically	O
delayed	O
onset	O
of	O
abnormalities	O
.	O

In	O
contrast	O
to	O
hematopoietic	O
cells	O
,	O
I	O
kappa	O
B	O
alpha-/-	O
embryonic	O
fibroblasts	O
show	O
minimal	O
constitutive	O
NF-kappa	O
B	O
,	O
as	O
well	O
as	O
normal	O
signal-dependent	O
NF-kappa	O
B	O
activation	O
that	O
is	O
concomitant	O
with	O
I	O
kappa	O
B	O
beta	O
degradation	O
.	O

Our	O
results	O
indicate	O
that	O
I	O
kappa	O
b	O
beta	O
,	O
but	O
not	O
I	O
kappa	O
B	O
alpha	O
,	O
is	O
required	O
for	O
the	O
signal-dependent	O
activation	O
of	O
NF-kappa	O
B	O
in	O
fibroblasts	O
.	O

However	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
required	O
for	O
the	O
postinduction	O
repression	O
of	O
NF-kappa	O
B	O
in	O
fibroblasts	O
.	O

These	O
results	O
define	O
distinct	O
roles	O
for	O
the	O
two	O
forms	O
of	O
I	O
kappa	O
B	O
and	O
demonstrate	O
the	O
necessity	O
for	O
stringent	O
control	O
of	O
NF-kappa	O
B	O
.	O

Vitamin	O
E	O
therapy	O
of	O
acute	O
CCl4-induced	O
hepatic	O
injury	O
in	O
mice	O
is	O
associated	O
with	O
inhibition	O
of	O
nuclear	O
factor	O
kappa	O
B	O
binding	O
.	O

Oxidative	O
stress	O
,	O
with	O
reactive	O
oxygen	O
intermediate	O
formation	O
,	O
may	O
represent	O
a	O
common	O
mechanism	O
by	O
which	O
liver	O
injury	O
is	O
induced	O
by	O
diverse	O
etiologies	O
.	O

Oxidative	O
stress	O
enhances	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activity	O
,	O
and	O
NF-kappa	O
B	O
activity	O
has	O
been	O
shown	O
to	O
enhance	O
the	O
expression	O
of	O
cytotoxic	O
cytokines	O
.	O

Acute	O
hepatic	O
injury	O
caused	O
by	O
reactive	O
oxygen	O
intermediate	O
production	O
was	O
induced	O
by	O
an	O
intraperitoneal	O
injection	O
of	O
CCl4	O
in	O
mice	O
.	O

This	O
injury	O
was	O
significantly	O
inhibited	O
by	O
intravenous	O
pretreatment	O
of	O
the	O
mice	O
with	O
a	O
water-soluble	O
emulsion	O
of	O
alpha-tocopherol	O
.	O

Alpha-tocopherol	O
treatment	O
of	O
the	O
mice	O
given	O
the	O
CCl4	O
also	O
reduced	O
the	O
NF-kappa	O
B	O
binding	O
to	O
levels	O
approaching	O
those	O
found	O
in	O
normal	O
mice	O
.	O

In	O
vitro	O
treatment	O
of	O
a	O
monocyte/macrophage	O
cell	O
line	O
with	O
CCl4	O
led	O
to	O
enhanced	O
NF-kappa	O
B	O
binding	O
and	O
an	O
increase	O
in	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
messenger	O
RNA	O
levels	O
.	O

Liver	O
specimens	O
taken	O
from	O
patients	O
with	O
acute	O
fulminant	O
hepatitis	O
had	O
markedly	O
increased	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
comparison	O
with	O
the	O
binding	O
of	O
normal	O
livers	O
.	O

These	O
data	O
demonstrate	O
that	O
abolishing	O
acute	O
hepatic	O
injury	O
with	O
alpha-tocopherol	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
also	O
eliminated	O
increased	O
NF-kappa	O
B	O
binding	O
.	O

It	O
is	O
tempting	O
to	O
speculate	O
that	O
enhanced	O
NF-kappa	O
B	O
expression	O
caused	O
by	O
free	O
radical	O
production/oxidative	O
stress	O
may	O
modulate	O
liver	O
injury	O
,	O
perhaps	O
through	O
an	O
effect	O
on	O
cytotoxic	O
cytokine	O
synthesis	O
.	O

Activation	O
of	O
the	O
signal	O
transducer	O
and	O
transcription	O
(	O
STAT	O
)	O
signaling	O
pathway	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Critical	O
role	O
for	O
IL-6	O
.	O

The	O
T	O
cell	O
activation	O
is	O
initiated	O
by	O
interaction	O
of	O
specific	O
Ags	O
with	O
TCR	O
,	O
followed	O
by	O
activation	O
of	O
intracellular	O
biochemical	O
events	O
leading	O
to	O
activation	O
of	O
several	O
genes	O
.	O

The	O
activation	O
of	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
in	O
a	O
primary	O
TCR-mediated	O
activation	O
of	O
T	O
cells	O
have	O
been	O
explored	O
.	O

In	O
purified	O
human	O
peripheral	O
blood	O
T	O
cells	O
,	O
nuclear	O
STAT	O
proteins	O
were	O
activated	O
approximately	O
3	O
h	O
after	O
activation	O
by	O
cross-linked	O
anti-CD3	O
Abs	O
.	O

These	O
STAT	O
proteins	O
were	O
detected	O
by	O
using	O
the	O
IFN-gamma-activated	O
sequence	O
(	O
GAS	O
)	O
and	O
related	O
oligonucleotides	O
as	O
probes	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

Analysis	O
of	O
the	O
nuclear	O
extracts	O
with	O
anti-STAT	O
Abs	O
indicated	O
that	O
they	O
contained	O
STAT-3	O
and	O
additional	O
proteins	O
crossreactive	O
with	O
the	O
STAT	O
family	O
.	O

The	O
induction	O
of	O
STAT	O
activity	O
was	O
inhibited	O
completely	O
by	O
pretreatment	O
with	O
either	O
cycloheximide	O
or	O
cyclosporin	O
A	O
,	O
thus	O
indicating	O
that	O
the	O
induction	O
was	O
due	O
to	O
a	O
secondary	O
factor	O
produced	O
by	O
the	O
activated	O
T	O
cells	O
.	O

As	O
neutralizing	O
anti-IL-6	O
Abs	O
effectively	O
down-regulated	O
the	O
early	O
induction	O
of	O
STAT	O
proteins	O
and	O
as	O
exogenously	O
added	O
IL-6	O
rapidly	O
activated	O
DNA	O
binding	O
similar	O
to	O
TCR-mediated	O
bindings	O
,	O
it	O
can	O
be	O
concluded	O
that	O
IL-6	O
is	O
the	O
factor	O
responsible	O
for	O
the	O
activation	O
of	O
STAT	O
proteins	O
in	O
a	O
primary	O
T	O
cell	O
response	O
.	O

Regulation	O
of	O
IkB	O
alpha	O
phosphorylation	O
by	O
PKC-	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
signal	O
transduction	O
pathways	O
.	O

The	O
Ca	O
(	O
2+	O
)	O
-dependent	O
phosphatase	O
calcineurin	O
,	O
a	O
target	O
of	O
FK506	O
and	O
CsA	O
,	O
synergizes	O
with	O
PKC-induced	O
activation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
in	O
T	O
cell	O
lines	O
.	O

We	O
have	O
investigated	O
whether	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
and	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
these	O
two	O
pathways	O
lead	O
to	O
NF-kappa	O
B	O
activation	O
.	O

While	O
this	O
synergy	O
is	O
present	O
in	O
other	O
cell	O
types	O
,	O
in	O
the	O
monocytic	O
cell	O
line	O
U937	O
calcineurin	O
is	O
also	O
sufficient	O
to	O
activate	O
NF-kappa	O
B	O
.	O

Having	O
previously	O
shown	O
that	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
PKC-dependent	O
pathways	O
synergize	O
by	O
accelerating	O
the	O
degradation	O
of	O
IkB	O
alpha	O
,	O
we	O
focused	O
on	O
the	O
regulation	O
of	O
IkB	O
alpha	O
phosphorylation	O
.	O

While	O
PKC-dependent	O
pathways	O
sequentially	O
result	O
in	O
the	O
phosphorylation	O
and	O
in	O
an	O
incomplete	O
degradation	O
of	O
IkB	O
alpha	O
in	O
T	O
cell	O
lines	O
,	O
co-activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
accelerates	O
the	O
rate	O
of	O
IkB	O
alpha	O
phosphorylation	O
and	O
results	O
in	O
its	O
complete	O
degradation	O
.	O

Activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
alone	O
do	O
not	B-Negation
result	I-Negation
in	I-Negation
the	I-Negation
phosphorylation	I-Negation
and/or	I-Negation
degradation	I-Negation
of	I-Negation
IkB	I-Negation
alpha	I-Negation
in	I-Negation
Jurkat	I-Negation
T	I-Negation
or	I-Negation
in	I-Negation
U937	I-Negation
cells	I-Negation
.	O

Treatment	O
of	O
T	O
cells	O
with	O
the	O
selective	O
PKC	O
inhibitor	O
GF109203X	O
abrogates	O
the	O
PMA-induced	O
IkB	O
alpha	O
phosphorylation/degradation	O
irrespective	O
of	O
activation	O
of	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
but	O
not	B-Negation
the	I-Negation
phosphorylation	I-Negation
and	I-Negation
degradation	I-Negation
of	I-Negation
IkB	I-Negation
alpha	I-Negation
induced	I-Negation
by	I-Negation
TNF-alpha	I-Negation
,	I-Negation
a	I-Negation
PKC-independent	I-Negation
stimulus	I-Negation
.	O

Contrary	O
to	O
the	O
interaction	O
with	O
PKC	O
,	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
synergize	O
with	O
TNF-alpha	O
not	B-Negation
at	I-Negation
the	I-Negation
level	I-Negation
of	I-Negation
IkB	I-Negation
alpha	I-Negation
phosphorylation	I-Negation
,	O
but	O
at	O
the	O
level	O
of	O
its	O
degradation	O
.	O

These	O
results	O
indicate	O
that	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathways	O
,	O
including	O
the	O
phosphatase	O
calcineurin	O
,	O
participate	O
in	O
the	O
regulation	O
of	O
NF-kappa	O
B	O
in	O
a	O
cell	O
specific	O
fashion	O
and	O
synergize	O
with	O
PKC-dependent	O
and	O
-independent	O
pathways	O
at	O
the	O
level	O
of	O
IkB	O
alpha	O
phosphorylation	O
and	O
degradation	O
.	O

Triggering	O
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b/CD18	O
)	O
induces	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
in	O
human	O
monocytes	O
and	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	O
monocytic	O
cells	O
.	O

Monocyte/macrophages	O
may	O
harbor	O
HIV	O
in	O
a	O
nonproductive	O
fashion	O
for	O
prolonged	O
periods	O
of	O
time	O
.	O

Viral	O
gene	O
expression	O
may	O
be	O
reactivated	O
by	O
stimulation	O
of	O
the	O
cells	O
with	O
LPS	O
or	O
cytokines	O
such	O
as	O
TNF-alpha	O
in	O
vitro	O
.	O

The	O
effect	O
of	O
LPS	O
and	O
TNF-alpha	O
is	O
mediated	O
by	O
their	O
ability	O
to	O
induce	O
nuclear	O
translocation	O
of	O
the	O
DNA-binding	O
heterodimer	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
,	O
which	O
binds	O
to	O
a	O
specific	O
sequence	O
in	O
the	O
HIV-long	O
terminal	O
repeat	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
triggering	O
of	O
complement	O
receptors	O
CR1	O
(	O
CD35	O
)	O
and	O
CR3	O
(	O
CD11b/CD18	O
)	O
enhances	O
viral	O
replication	O
in	O
HIV-infected	O
human	O
monocytic	O
cells	O
.	O

Monocytic	O
cell	O
lines	O
and	O
normal	O
peripheral	O
blood	O
monocytes	O
were	O
infected	O
with	O
HIV-1	O
in	O
vitro	O
and	O
cultured	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
F	I-Negation
(	I-Negation
ab	I-Negation
'	I-Negation
)	I-Negation
2	I-Negation
fragments	I-Negation
of	I-Negation
monoclonal	I-Negation
anti-CR1	I-Negation
or	I-Negation
anti-CR3	I-Negation
Abs	I-Negation
or	I-Negation
with	I-Negation
C3	I-Negation
fragments	I-Negation
.	O

Stimulation	O
of	O
CR1	O
or	O
CR3	O
induces	O
a	O
two-	O
to	O
fourfold	O
increase	O
in	O
the	O
amount	O
of	O
cell-associated	O
and	O
released	O
p24	O
Ag	O
in	O
cell	O
cultures	O
that	O
was	O
equivalent	O
to	O
that	O
observed	O
in	O
control	O
cultures	O
triggered	O
with	O
LPS	O
.	O

We	O
further	O
observed	O
that	O
stimulation	O
of	O
CR1	O
or	O
CR3	O
induces	O
the	O
nuclear	O
translocation	O
of	O
NF-kappa	O
B	O
p50/p65	O
in	O
infected	O
cells	O
.	O

Translocation	O
of	O
NF-kappa	O
B	O
p50/p65	O
was	O
also	O
observed	O
following	O
stimulation	O
of	O
CR1	O
or	O
CR3	O
of	O
uninfected	O
peripheral	O
blood	O
monocytes	O
from	O
HIV-seronegative	O
donors	O
.	O

The	O
amount	O
of	O
protein	O
translocated	O
was	O
similar	O
to	O
that	O
observed	O
when	O
cells	O
were	O
stimulated	O
with	O
rhTNF-alpha	O
.	O

TNF-alpha	O
did	O
not	B-Negation
mediate	I-Negation
the	I-Negation
translocation	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
p50/p65	I-Negation
induced	I-Negation
by	I-Negation
triggering	I-Negation
of	I-Negation
complement	I-Negation
receptors	I-Negation
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
HIV	O
gene	O
expression	O
may	O
be	O
activated	O
in	O
infected	O
monocytes	O
through	O
interaction	O
of	O
the	O
cells	O
with	O
complement-opsonized	O
particles	O
and	O
that	O
enhanced	O
viral	O
replication	O
is	O
associated	O
with	O
C3	O
receptor-mediated	O
nuclear	O
translocation	O
of	O
the	O
NF-kappa	O
B	O
complex	O
.	O

Nuclear	O
factor-IL6	O
activates	O
the	O
human	O
IL-4	O
promoter	O
in	O
T	O
cells	O
.	O

Positive	O
regulatory	O
element	O
I	O
(	O
PRE-I	O
)	O
is	O
a	O
strong	O
enhancer	O
element	O
essential	O
for	O
expression	O
of	O
the	O
human	O
IL-4	O
gene	O
.	O

To	O
identify	O
transcription	O
factors	O
binding	O
to	O
PRE-I	O
,	O
we	O
screened	O
a	O
cDNA	O
expression	O
library	O
from	O
Jurkat	O
T	O
cells	O
and	O
isolated	O
a	O
cDNA	O
encoding	O
nuclear	O
factor	O
(	O
NF	O
)	O
-IL6	O
(	O
also	O
known	O
as	O
C/EBP	O
beta	O
)	O
.	O

NF-IL6	O
mRNA	O
was	O
found	O
in	O
human	O
Jurkat	O
T	O
cells	O
and	O
in	O
the	O
mouse	O
Th2	O
clone	O
D10	O
,	O
but	O
not	B-Negation
in	I-Negation
Th1	I-Negation
clone	I-Negation
29	I-Negation
.	O

rNF-IL6	O
expressed	O
in	O
bacteria	O
was	O
shown	O
to	O
specifically	O
bind	O
to	O
PRE-I	O
.	O

PRE-I	O
forms	O
multiple	O
DNA-protein	O
complexes	O
with	O
nuclear	O
extracts	O
from	O
Jurkat	O
cells	O
.	O

Some	O
of	O
these	O
complexes	O
were	O
demonstrated	O
to	O
contain	O
NF-IL6	O
by	O
using	O
anti-C/EBP	O
beta	O
Abs	O
.	O

Overexpression	O
of	O
NF-IL6	O
enhanced	O
expression	O
of	O
the	O
chloramphenicol	O
acetyl	O
transferase	O
reporter	O
gene	O
linked	O
to	O
the	O
PRE-I-thymidine	O
kinase	O
or	O
the	O
human	O
IL-4	O
promoter	O
more	O
than	O
10-fold	O
in	O
Jurkat	O
cells	O
.	O

Promoter	O
deletion	O
studies	O
revealed	O
two	O
additional	O
NF-IL6	O
binding	O
sites	O
located	O
at	O
positions	O
-44	O
to	O
-36	O
(	O
C/EBP	O
proximal	O
)	O
and	O
-87	O
to	O
-79	O
(	O
C/EBP	O
medial	O
)	O
,	O
respectively	O
.	O

Our	O
results	O
demonstrate	O
that	O
NF-IL6	O
is	O
involved	O
in	O
transcriptional	O
activation	O
of	O
the	O
human	O
IL-4	O
promoter	O
in	O
T	O
cells	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
promoter	O
activity	O
by	O
AML1-related	O
transcription	O
factor	O
,	O
PEBP2	O
.	O

The	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
gene	O
promoter	O
contains	O
a	O
consensus	O
sequence	O
for	O
the	O
polyomavirus	O
enhancer	O
binding-protein	O
2	O
(	O
PEBP2	O
)	O
transcription	O
factor	O
,	O
which	O
consists	O
of	O
alpha	O
and	O
beta	O
subunits	O
.	O

There	O
are	O
at	O
least	O
two	O
genes	O
,	O
alpha	O
A	O
and	O
alpha	O
B	O
,	O
encoding	O
the	O
alpha	O
subunit	O
.	O

alpha	O
B	O
is	O
the	O
mouse	O
homologue	O
of	O
human	O
AML1	O
gene	O
detected	O
at	O
the	O
breakpoints	O
of	O
t	O
(	O
8	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
21	O
)	O
myeloid	O
leukemias	O
.	O

We	O
examined	O
alpha	O
A1	O
(	O
an	O
alpha	O
A-gene	O
product	O
)	O
and	O
alpha	O
B1	O
and	O
alpha	O
B2	O
(	O
two	O
alpha	O
B-encoded	O
isomers	O
)	O
for	O
their	O
effects	O
on	O
the	O
GM-CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
,	O
alpha	O
B1	O
,	O
and	O
alpha	O
B2	O
proteins	O
bound	O
the	O
PEBP2	O
site	O
within	O
the	O
mouse	O
GM-CSF	O
promoter	O
.	O

PEBP2	O
alpha	O
A1	O
and	O
alpha	O
B1	O
enhanced	O
the	O
expression	O
of	O
the	O
GM-CSF	O
promoter-driven	O
reporter	O
plasmid	O
in	O
unstimulated	O
and	O
12-O-tetradecanoylphorbol	O
13-acetate/phytohemagglutinin-stimulated	O
human	O
Jurkat	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
promoter	O
activity	O
was	O
suppressed	O
by	O
alpha	O
B2	O
.	O

Coexpression	O
of	O
alpha	O
B1	O
and	O
alpha	O
B2	O
showed	O
that	O
the	O
promoter	O
activity	O
could	O
be	O
determined	O
by	O
the	O
alpha	O
B1/alpha	O
B2	O
ratio	O
.	O

Jurkat	O
cell	O
extract	O
contained	O
PEBP2	O
site-binding	O
protein	O
(	O
s	O
)	O
that	O
cross-reacted	O
with	O
antimouse	O
alpha	O
A1	O
antibodies	O
.	O

Northern	O
blot	O
analysis	O
indicated	O
the	O
expression	O
of	O
human	O
PEBP2	O
alpha	O
A	O
,	O
alpha	O
B	O
(	O
AML1	O
)	O
,	O
and	O
beta	O
genes	O
in	O
Jurkat	O
cells	O
.	O

Although	O
further	O
studies	O
are	O
required	O
to	O
determine	O
the	O
precise	O
role	O
of	O
PEBP2	O
in	O
the	O
GM-CSF	O
promoter	O
activity	O
,	O
the	O
present	O
findings	O
suggested	O
the	O
importance	O
of	O
the	O
relative	O
ratio	O
of	O
different	O
PEBP2	O
isoforms	O
in	O
regulating	O
the	O
levels	O
of	O
the	O
promoter	O
activity	O
.	O

The	O
peri-kappa	O
B	O
site	O
mediates	O
human	O
immunodeficiency	O
virus	O
type	O
2	O
enhancer	O
activation	O
in	O
monocytes	O
but	O
not	B-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

Human	O
immunodeficiency	O
virus	O
type	O
2	O
(	O
HIV-2	O
)	O
,	O
like	O
HIV-1	O
,	O
causes	O
AIDS	O
and	O
is	O
associated	O
with	O
AIDS	O
cases	O
primarily	O
in	O
West	O
Africa	O
.	O

HIV-1	O
and	O
HIV-2	O
display	O
significant	O
differences	O
in	O
nucleic	O
acid	O
sequence	O
and	O
in	O
the	O
natural	O
history	O
of	O
clinical	O
disease	O
.	O

Consistent	O
with	O
these	O
differences	O
,	O
we	O
have	O
previously	O
demonstrated	O
that	O
the	O
enhancer/promoter	O
region	O
of	O
HIV-2	O
functions	O
quite	O
differently	O
from	O
that	O
of	O
HIV-1	O
.	O

Whereas	O
activation	O
of	O
the	O
HIV-1	O
enhancer	O
following	O
T-cell	O
stimulation	O
is	O
mediated	O
largely	O
through	O
binding	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
to	O
two	O
adjacent	O
kappa	O
B	O
sites	O
in	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
,	O
activation	O
of	O
the	O
HIV-2	O
enhancer	O
in	O
monocytes	O
and	O
T	O
cells	O
is	O
dependent	O
on	O
four	O
cis-acting	O
elements	O
:	O
a	O
single	O
kappa	O
B	O
site	O
,	O
two	O
purine-rich	O
binding	O
sites	O
,	O
PuB1	O
and	O
PuB2	O
,	O
and	O
a	O
pets	O
site	O
.	O

We	O
have	O
now	O
identified	O
a	O
novel	O
cis-acting	O
element	O
within	O
the	O
HIV-2	O
enhancer	O
,	O
immediately	O
upstream	O
of	O
the	O
kappa	O
B	O
site	O
,	O
designated	O
peri-kappa	O
B	O
.	O

This	O
site	O
is	O
conserved	O
among	O
isolates	O
of	O
HIV-2	O
and	O
the	O
closely	O
related	O
simian	O
immunodeficiency	O
virus	O
,	O
and	O
transfection	O
assays	O
show	O
this	O
site	O
to	O
mediate	O
HIV-2	O
enhancer	O
activation	O
following	O
stimulation	O
of	O
monocytic	O
but	O
not	B-Negation
T-cell	I-Negation
lines	I-Negation
.	O

This	O
is	O
the	O
first	O
description	O
of	O
an	O
HIV-2	O
enhancer	O
element	O
which	O
displays	O
such	O
monocyte	O
specificity	O
,	O
and	O
no	B-Negation
comparable	I-Negation
enhancer	I-Negation
element	I-Negation
has	I-Negation
been	I-Negation
clearly	I-Negation
defined	I-Negation
for	I-Negation
HIV-1	I-Negation
.	O

While	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
from	O
both	O
peripheral	O
blood	O
monocytes	O
and	O
T	O
cells	O
binds	O
the	O
peri-kappa	O
B	O
site	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggest	O
that	O
either	O
a	O
different	O
protein	O
binds	O
to	O
this	O
site	O
in	O
monocytes	O
versus	O
T	O
cells	O
or	O
that	O
the	O
protein	O
recognizing	O
this	O
enhancer	O
element	O
undergoes	O
differential	O
modification	O
in	O
monocytes	O
and	O
T	O
cells	O
,	O
thus	O
supporting	O
the	O
transfection	O
data	O
.	O

Further	O
,	O
while	O
specific	O
constitutive	O
binding	O
to	O
the	O
peri-kappa	O
B	O
site	O
is	O
seen	O
in	O
monocytes	O
,	O
stimulation	O
with	O
phorbol	O
esters	O
induces	O
additional	O
,	O
specific	O
binding	O
.	O

Understanding	O
the	O
monocyte-specific	O
function	O
of	O
the	O
peri-kappa	O
B	O
factor	O
may	O
ultimately	O
provide	O
insight	O
into	O
the	O
different	O
role	O
monocytes	O
and	O
T	O
cells	O
play	O
in	O
HIV	O
pathogenesis	O
.	O

Thapsigargin	O
induces	O
IL-2	O
receptor	O
alpha-chain	O
in	O
human	O
peripheral	O
and	O
Jurkat	O
T	O
cells	O
via	O
a	O
protein	O
kinase	O
C-independent	O
mechanism	O
.	O

Thapsigargin	O
(	O
TG	O
)	O
,	O
an	O
inhibitor	O
of	O
Ca	O
(	O
2+	O
)	O
-ATPase	O
,	O
depletes	O
intracellular	O
Ca2+	O
stores	O
and	O
induces	O
a	O
sustained	O
Ca2+	O
influx	O
without	B-Negation
altering	I-Negation
phosphatidyl	I-Negation
inositol	I-Negation
levels	I-Negation
.	O

TG	O
plus	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
but	O
not	B-Negation
TG	I-Negation
alone	I-Negation
induced	O
IL-2	O
in	O
Jurkat	O
T	O
cells	O
,	O
suggesting	B-Speculation
that	I-Speculation
TG	I-Speculation
had	I-Speculation
no	I-Speculation
effect	I-Speculation
on	I-Speculation
protein	I-Speculation
kinase	I-Speculation
C	I-Speculation
(	I-Speculation
PKC	I-Speculation
)	I-Speculation
.	O

However	O
,	O
TG	O
induced	O
increases	O
in	O
IL-2R	O
alpha	O
protein	O
as	O
well	O
as	O
IL-2R	O
alpha	O
mRNA	O
in	O
Jurkat	O
T	O
cells	O
in	O
a	O
dose-dependent	O
manner	O
.	O

A	O
similar	O
increase	O
in	O
IL-2R	O
alpha	O
by	O
TG	O
was	O
also	O
observed	O
in	O
human	O
peripheral	O
T	O
cells	O
.	O

Further	O
,	O
like	O
PMA	O
,	O
TG	O
markedly	O
induced	O
NF	O
kappa	O
B	O
in	O
Jurkat	O
T	O
cells	O
.	O

However	O
,	O
TG	O
and	O
PMA	O
exhibited	O
a	O
synergistic	O
action	O
on	O
IL-2R	O
alpha	O
expression	O
,	O
suggesting	O
that	O
TG	O
and	O
PMA	O
induce	O
IL-2R	O
alpha	O
through	O
distinct	O
pathways	O
.	O

PMA-	O
but	O
not	B-Negation
TG-induced	I-Negation
IL-2R	I-Negation
alpha	I-Negation
is	O
inhibited	O
by	O
the	O
PKC	O
inhibitor	O
H7	O
,	O
whereas	O
TG-	O
but	O
not	B-Negation
PMA-induced	I-Negation
IL-2R	I-Negation
alpha	I-Negation
was	O
inhibited	O
by	O
cholera	O
toxin	O
,	O
forskolin	O
and	O
1,9-dideoxy	O
forskolin	O
.	O

In	O
toto	O
,	O
these	O
results	O
suggest	O
that	O
TG	O
induces	O
IL-2R	O
alpha	O
in	O
human	O
T	O
cells	O
through	O
a	O
PKC-independent	O
pathway	O
.	O

A	O
functional	O
T-cell	O
receptor	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	O
activity	O
.	O

Stimulation	O
of	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
induces	O
activation	O
of	O
multiple	O
tyrosine	O
kinases	O
,	O
resulting	O
in	O
phosphorylation	O
of	O
numerous	O
intracellular	O
substrates	O
.	O

One	O
substrate	O
is	O
p95vav	O
,	O
which	O
is	O
expressed	O
exclusively	O
in	O
hematopoietic	O
and	O
trophoblast	O
cells	O
.	O

It	O
contains	O
a	O
number	O
of	O
structural	O
motifs	O
,	O
including	O
Src	O
homology	O
2	O
,	O
Src	O
homology	O
3	O
,	O
and	O
pleckstrin	O
homology	O
domains	O
and	O
a	O
putative	O
guanine	O
nucleotide	O
exchange	O
domain	O
.	O

The	O
role	O
of	O
p95vav	O
in	O
TCR-mediated	O
signaling	O
processes	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
that	O
overexpression	O
of	O
p95vav	O
alone	O
in	O
Jurkat	O
T	O
cells	O
leads	O
to	O
activation	O
of	O
the	O
nuclear	O
factors	O
,	O
including	O
NFAT	O
,	O
involved	O
in	O
interleukin-2	O
expression	O
.	O

Furthermore	O
,	O
p95vav	O
synergizes	O
with	O
TCR	O
stimulation	O
in	O
inducing	O
NFAT-	O
and	O
interleukin-2-dependent	O
transcription	O
.	O

In	O
contrast	O
,	O
NFAT	B-Negation
activation	I-Negation
by	I-Negation
a	I-Negation
G-protein-coupled	I-Negation
receptor	I-Negation
is	I-Negation
not	I-Negation
modulated	I-Negation
by	I-Negation
p95vav	I-Negation
overexpression	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
effect	I-Speculation
is	I-Speculation
specific	I-Speculation
to	I-Speculation
the	I-Speculation
TCR	I-Speculation
signaling	I-Speculation
pathways	I-Speculation
.	O

Although	O
removal	O
of	O
the	O
first	O
67	O
amino	O
acids	O
of	O
p95vav	O
activates	O
its	O
transforming	O
potential	O
in	O
NIH	O
3T3	O
cells	O
,	O
this	O
region	O
appears	O
to	O
be	O
required	O
for	O
its	O
function	O
in	O
T	O
cells	O
.	O

We	O
further	O
demonstrate	O
that	O
the	B-Negation
p95vav-induced	I-Negation
NFAT	I-Negation
activation	I-Negation
is	I-Negation
not	I-Negation
mimicked	I-Negation
by	I-Negation
Ras	I-Negation
activation	I-Negation
,	O
though	O
its	O
function	O
is	O
dependent	O
upon	O
Ras	O
and	O
Raf	O
.	O

Furthermore	O
,	O
the	O
activating	O
function	O
of	O
p95vav	O
is	O
blocked	O
by	O
FK506	O
,	O
suggesting	O
that	O
its	O
activity	O
also	O
depends	O
on	O
calcineurin	O
.	O

To	O
further	O
dissect	O
p95vav	O
involvement	O
in	O
TCR	O
signaling	O
,	O
we	O
analyzed	O
various	O
Jurkat	O
mutants	O
deficient	O
in	O
TCR	O
signaling	O
function	O
or	O
TCR	O
expression	O
and	O
showed	O
that	O
an	O
intact	O
TCR	O
signaling	O
pathway	O
is	O
required	O
for	O
p95vav	O
to	O
function	O
.	O

However	O
,	O
overexpression	B-Negation
of	I-Negation
p95vav	I-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
influence	I-Speculation
TCR-induced	I-Speculation
protein	I-Speculation
tyrosine	I-Speculation
phosphorylation	I-Speculation
or	I-Speculation
increases	I-Speculation
in	I-Speculation
cytoplasmic	I-Speculation
free	I-Speculation
calcium	I-Speculation
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
that	O
p95vav	O
plays	O
an	O
important	O
role	O
at	O
an	O
yet	O
unidentified	O
proximal	O
position	O
in	O
the	O
TCR	O
signaling	O
cascade	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
by	O
phosphatase	O
inhibitors	O
involves	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
at	O
phosphatase	O
2A-sensitive	O
sites	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
by	O
various	O
cellular	O
stimuli	O
involves	O
the	O
phosphorylation	O
and	O
subsequent	O
degradation	O
of	O
its	O
inhibitor	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
although	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
serine/threonine	O
phosphatases	O
in	O
the	O
regulation	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
was	O
investigated	O
.	O

Our	O
studies	O
demonstrate	O
that	O
incubation	O
of	O
human	O
T	O
cells	O
with	O
low	O
concentrations	O
(	O
approximately	O
1-5	O
nM	O
)	O
of	O
calyculin	O
A	O
or	O
okadaic	O
acid	O
,	O
potent	O
inhibitors	O
of	O
protein	O
phosphatase	O
type	O
1	O
(	O
PP-1	O
)	O
and	O
type	O
2A	O
(	O
PP-2A	O
)	O
,	O
induces	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
even	O
in	O
the	O
absence	B-Negation
of	I-Negation
any	I-Negation
cellular	I-Negation
stimulus	I-Negation
.	O

This	B-Negation
action	I-Negation
of	I-Negation
the	I-Negation
phosphatase	I-Negation
inhibitors	I-Negation
,	I-Negation
which	I-Negation
is	I-Negation
associated	I-Negation
with	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
the	I-Negation
RelA.p50	I-Negation
NF-kappa	I-Negation
B	I-Negation
heterodimer	I-Negation
,	I-Negation
is	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
agents	I-Negation
that	I-Negation
block	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
phosphorylation	I-Negation
by	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha	I-Negation
(	I-Negation
TNF-alpha	I-Negation
)	I-Negation
.	O

Furthermore	O
,	O
the	O
phosphorylated	O
I	O
kappa	O
B	O
alpha	O
from	O
calyculin	O
A-treated	O
cells	O
,	O
but	O
not	B-Negation
that	I-Negation
from	I-Negation
TNF-alpha-stimulated	I-Negation
cells	I-Negation
,	O
is	O
sensitive	O
to	O
PP-2A	O
in	O
vitro	O
,	O
suggesting	B-Speculation
the	I-Speculation
existence	I-Speculation
of	I-Speculation
fundamental	I-Speculation
differences	I-Speculation
in	I-Speculation
the	I-Speculation
phosphorylation	I-Speculation
of	I-Speculation
I	I-Speculation
kappa	I-Speculation
B	I-Speculation
alpha	I-Speculation
induced	I-Speculation
by	I-Speculation
the	I-Speculation
two	I-Speculation
different	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
inducers	I-Speculation
.	O

However	O
,	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
phosphorylation	O
by	O
both	O
TNF-alpha	O
and	O
the	O
phosphatase	O
inhibitors	O
is	O
associated	O
with	O
the	O
subsequent	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

We	O
further	O
demonstrate	O
that	O
TNF-alpha-	O
and	O
calyculin	O
A-induced	O
I	O
kappa	O
B	O
alpha	O
degradation	O
exhibits	O
similar	O
but	O
not	B-Negation
identical	I-Negation
sensitivities	O
to	O
a	O
proteasome	O
inhibitor	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
,	O
mediated	O
through	O
both	O
the	O
TNF-alpha-inducible	O
and	O
the	O
PP-2A-opposing	O
kinases	O
,	O
may	O
serve	O
to	O
target	O
I	O
kappa	O
B	O
alpha	O
for	O
proteasome-mediated	O
degradation	O
.	O

Functional	O
roles	O
of	O
the	O
transcription	O
factor	O
Oct-2A	O
and	O
the	O
high	O
mobility	O
group	O
protein	O
I/Y	O
in	O
HLA-DRA	O
gene	O
expression	O
.	O

The	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
HLA-DRA	O
is	O
expressed	O
in	O
B	O
cells	O
,	O
activated	O
T	O
lymphocytes	O
,	O
and	O
in	O
antigen-presenting	O
cells	O
.	O

In	O
addition	O
,	O
HLA-DRA	O
gene	O
expression	O
is	O
inducible	O
in	O
a	O
variety	O
of	O
cell	O
types	O
by	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
.	O

Here	O
we	O
show	O
that	O
the	O
lymphoid-specific	O
transcription	O
factor	O
Oct-2A	O
plays	O
a	O
critical	O
role	O
in	O
HLA-DRA	O
gene	O
expression	O
in	O
class	O
II-positive	O
B	O
cell	O
lines	O
,	O
and	O
that	O
the	O
high	O
mobility	O
group	O
protein	O
(	O
HMG	O
)	O
I/Y	O
binds	O
to	O
multiple	O
sites	O
within	O
the	O
DRA	O
promoter	O
,	O
including	O
the	O
Oct-2A	O
binding	O
site	O
.	O

Coexpression	O
of	O
HMG	O
I/Y	O
and	O
Oct-2	O
in	O
cell	O
lines	O
lacking	B-Negation
Oct-2	I-Negation
results	O
in	O
high	O
levels	O
of	O
HLA-DRA	O
gene	O
expression	O
,	O
and	O
in	O
vitro	O
DNA-binding	O
studies	O
reveal	O
that	O
HMG	O
I/Y	O
stimulates	O
Oct-2A	O
binding	O
to	O
the	O
HLA-DRA	O
promoter	O
.	O

Thus	O
,	O
Oct-2A	O
and	O
HMG	O
I/Y	O
may	O
synergize	O
to	O
activate	O
HLA-DRA	O
expression	O
in	O
B	O
cells	O
.	O

By	O
contrast	O
,	O
Oct-2A	O
is	O
not	B-Negation
involved	I-Negation
in	I-Negation
the	I-Negation
IFN-gamma	I-Negation
induction	I-Negation
of	I-Negation
the	I-Negation
HLA-DRA	I-Negation
gene	I-Negation
in	I-Negation
HeLa	I-Negation
cells	I-Negation
,	O
but	O
antisense	O
HMG	O
I/Y	O
dramatically	O
decreases	O
the	O
level	O
of	O
induction	O
.	O

We	O
conclude	O
that	O
distinct	O
sets	O
of	O
transcription	O
factors	O
are	O
involved	O
in	O
the	O
two	O
modes	O
of	O
HLA-DRA	O
expression	O
,	O
and	O
that	O
HMG	O
I/Y	O
may	O
be	O
important	O
for	O
B	O
cell-specific	O
expression	O
,	O
and	O
is	O
essential	O
for	O
IFN-gamma	O
induction	O
.	O

Interleukin	O
4	O
activates	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
which	O
interacts	O
with	O
an	O
interferon-gamma	O
activation	O
site-like	O
sequence	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
in	O
a	O
human	O
B	O
cell	O
line	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Janus	O
kinase	O
3	O
and	O
interleukin-4	O
Stat	O
.	O

Germ	O
line	O
C	O
transcripts	O
can	O
be	O
induced	O
by	O
IL-4	O
in	O
the	O
human	O
B	O
cell	O
line	O
,	O
BL-2	O
.	O

Utilizing	O
a	O
IFN-gamma	O
activation	O
site-like	O
DNA	O
sequence	O
element	O
located	O
upstream	O
of	O
the	O
I	O
epsilon	O
exon	O
,	O
we	O
demonstrated	O
by	O
gel	O
mobility	O
shift	O
assays	O
that	O
IL-4	O
induced	O
a	O
binding	O
activity	O
in	O
the	O
cytosol	O
and	O
nucleus	O
of	O
BL-2	O
cells	O
.	O

This	O
factor	O
was	O
designated	O
IL-4	O
NAF	O
(	O
IL-4-induced	O
nuclear-activating	O
factors	O
)	O
and	O
was	O
identified	O
as	O
a	O
tyrosine	O
phosphoprotein	O
,	O
which	O
translocates	O
from	O
the	O
cytosol	O
to	O
the	O
nucleus	O
upon	O
IL-4	O
treatment	O
.	O

Because	O
these	O
are	O
the	O
characteristics	O
of	O
a	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
(	O
Stat	O
)	O
protein	O
,	O
we	O
determined	O
whether	B-Speculation
antibodies	I-Speculation
to	I-Speculation
Stat	I-Speculation
proteins	I-Speculation
will	I-Speculation
interfere	I-Speculation
with	I-Speculation
gel	I-Speculation
mobility	I-Speculation
shift	I-Speculation
and	O
found	O
that	O
antibodies	O
to	O
IL-4	O
Stat	O
,	O
also	O
known	O
as	O
Stat6	O
,	O
but	O
not	B-Negation
antibodies	I-Negation
to	I-Negation
other	I-Negation
Stat	I-Negation
proteins	I-Negation
,	O
interfere	O
with	O
the	O
formation	O
of	O
the	O
IL-4	O
NAF	O
complex	O
.	O

Congruous	O
with	O
the	O
involvement	O
of	O
a	O
Stat	O
protein	O
,	O
IL-4	O
induced	O
robust	O
Janus	O
kinase	O
3	O
(	O
JAK3	O
)	O
activity	O
in	O
BL-2	O
cells	O
.	O

Cotransfection	O
of	O
JAK3	O
with	O
IL-4	O
Stat	O
into	O
COS-7	O
cells	O
produced	O
an	O
intracellular	O
activity	O
which	O
bound	O
the	O
same	O
IFN-gamma	O
activation	O
site-like	O
sequence	O
and	O
comigrated	O
with	O
IL-4	O
NAF	O
in	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

These	O
results	O
show	O
that	O
IL-4	O
NAF	O
is	O
IL-4	O
Stat	O
,	O
which	O
is	O
activated	O
by	O
JAK3	O
in	O
response	O
to	O
IL-4	O
receptor	O
engagement	O
.	O

Multiple	O
signals	O
are	O
required	O
for	O
function	O
of	O
the	O
human	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
gene	O
promoter	O
in	O
T	O
cells	O
.	O

The	O
human	O
granulocyte-macrophage	O
CSF	O
(	O
GM-CSF	O
)	O
gene	O
is	O
expressed	O
in	O
T	O
cells	O
in	O
response	O
to	O
TCR	O
activation	O
that	O
can	O
be	O
mimicked	O
by	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
and	O
Ca2+	O
ionophore	O
.	O

The	O
gene	O
contains	O
a	O
proximal	O
functional	O
promoter	O
region	O
(	O
-620	O
to	O
+34	O
)	O
,	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3	O
kb	O
upstream	O
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
the	O
response	O
of	O
the	O
gene	O
to	O
TCR	O
activation	O
.	O

The	O
proximal	O
promoter	O
contains	O
a	O
region	O
termed	O
CLEO	O
(	O
-54	O
to	O
-31	O
)	O
that	O
consists	O
of	O
a	O
purine-rich	O
element	O
abutting	O
an	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
-like	O
site	O
,	O
as	O
well	O
as	O
an	O
upstream	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
site	O
(	O
-85	O
to	O
-76	O
)	O
and	O
a	O
CK-1	O
element	O
(	O
-101	O
to	O
-92	O
)	O
.	O

We	O
show	O
in	O
this	O
work	O
that	O
mutations	O
in	O
either	O
the	O
purine-rich	O
region	O
of	O
the	O
CLEO	O
element	O
or	O
the	O
NF-kappa	O
B	O
site	O
result	O
in	O
reduced	O
PMA/Ca2+	O
activation	O
of	O
a	O
620-bp	O
human	O
GM-CSF	O
promoter-luciferase	O
reporter	O
construct	O
in	O
Jurkat	O
T	O
cells	O
by	O
65	O
%	O
and	O
50	O
%	O
,	O
respectively	O
.	O

The	O
major	O
inducible	O
protein	O
complex	O
that	O
binds	O
to	O
the	O
human	O
CLEO	O
(	O
hCLEO	O
)	O
element	O
is	O
an	O
AP-1-like	O
complex	O
that	O
is	O
inducible	O
by	O
PMA	O
alone	O
,	O
but	O
shows	O
increased	O
binding	O
in	O
response	O
to	O
PMA	O
together	O
with	O
Ca2+	O
ionophore	O
.	O

Although	O
the	O
binding	O
of	O
this	O
complex	O
is	O
not	B-Negation
cyclosporin-sensitive	I-Negation
,	O
promoter	O
induction	O
is	O
inhibited	O
by	O
cyclosporin	O
treatment	O
.	O

A	O
second	O
weak	O
inducible	O
complex	O
resembling	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
was	O
also	O
observed	O
binding	O
to	O
the	O
hCLEO	O
region	O
.	O

By	O
using	O
recombinant	O
proteins	O
,	O
we	O
confirmed	O
that	O
AP-1	O
,	O
NF-ATp	O
,	O
and	O
a	O
higher	O
order	O
NF-ATp/AP-1	O
complex	O
could	O
all	O
form	O
with	O
the	O
hCLEO	O
element	O
,	O
and	O
we	O
have	O
also	O
defined	O
the	O
sequence	O
requirements	O
for	O
binding	O
of	O
each	O
of	O
these	O
complexes	O
.	O

We	O
found	O
that	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
calcineurin	O
could	O
substitute	O
for	O
Ca2+	O
ionophore	O
and	O
synergize	O
with	O
PMA	O
to	O
activate	O
the	O
GM-CSF	O
promoter	O
,	O
and	O
conversely	O
that	O
mutant-activated	O
Ras	O
could	O
substitute	O
for	O
PMA	O
and	O
cooperate	O
with	O
Ca2+	O
ionophore	O
.	O

Co-expression	O
of	O
Ras	O
and	O
calcineurin	O
,	O
however	O
,	O
did	O
not	B-Negation
activate	I-Negation
the	I-Negation
GM-CSF	I-Negation
promoter	I-Negation
,	O
but	O
required	O
the	O
additional	O
expression	O
of	O
NF-kappa	O
B	O
p65	O
.	O

These	O
results	O
imply	O
that	O
at	O
least	O
three	O
signals	O
are	O
required	O
to	O
activate	O
the	O
GM-CSF	O
proximal	O
promoter	O
,	O
and	O
that	O
the	O
signals	O
impinge	O
on	O
distinct	O
transcription	O
factors	O
that	O
bind	O
to	O
the	O
hCLEO	O
and	O
NF-kappa	O
B	O
regions	O
of	O
the	O
promoter	O
.	O

An	O
IRF-1-dependent	O
pathway	O
of	O
DNA	O
damage-induced	O
apoptosis	O
in	O
mitogen-activated	O
T	O
lymphocytes	O
.	O

Lymphocytes	O
are	O
particularly	O
susceptible	O
to	O
DNA	O
damage-induced	O
apoptosis	O
,	O
a	O
response	O
which	O
may	O
serve	O
as	O
a	O
form	O
of	O
'altruistic	O
suicide	O
'	O
to	O
counter	O
their	O
intrinsic	O
high	O
potential	O
for	O
mutation	O
and	O
clonal	O
expansion	O
.	O

The	O
tumour	O
suppressor	O
p53	O
has	O
been	O
shown	O
to	O
regulate	O
this	O
type	O
of	O
apoptosis	O
in	O
thymocytes	O
,	O
but	O
an	O
as	O
yet	O
unknown	O
,	O
p53-independent	O
pathway	O
(	O
s	O
)	O
appears	O
to	O
mediate	O
the	O
same	O
event	O
in	O
mitogen-activated	O
mature	O
T	O
lymphocytes	O
.	O

Here	O
we	O
show	O
DNA	O
damage-induced	O
apoptosis	O
in	O
these	O
T	O
lymphocytes	O
is	O
dependent	O
on	O
the	O
antioncogenic	O
transcription	O
factor	O
interferon	O
regulatory	O
factor	O
(	O
IRF	O
)	O
-1	O
.	O

Thus	O
two	O
different	O
anti-onco-genic	O
transcription	O
factors	O
,	O
p53	O
and	O
IRF-1	O
,	O
are	O
required	O
for	O
distinct	O
apoptotic	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

We	O
also	O
show	O
that	O
mitogen	O
induction	O
of	O
the	O
interleukin-1	O
beta	O
converting	O
enzyme	O
(	O
ICE	O
)	O
gene	O
,	O
a	O
mammalian	O
homologue	O
of	O
the	O
Caenorhabditis	O
elegans	O
cell	O
death	O
gene	O
ced-3	O
,	O
is	O
IRF-1-dependent	O
.	O

Ectopic	O
overexpression	O
of	O
IRF-1	O
results	O
in	O
the	O
activation	O
of	O
the	O
endogenous	O
gene	O
for	O
ICE	O
and	O
enhances	O
the	O
sensitivity	O
of	O
cells	O
to	O
radiation-induced	O
apoptosis	O
.	O

Regulation	O
of	O
c-jun	O
mRNA	O
expression	O
by	O
hydroxyurea	O
in	O
human	O
K562	O
cells	O
during	O
erythroid	O
differentiation	O
[	O
published	O
erratum	O
appears	O
in	O
Biochim	O
Biophys	O
Acta	O
1995	O
Dec	O
27	O
;	O
1264	O
(	O
3	O
)	O
:409	O
]	O

Hydroxyurea	O
(	O
HU	O
)	O
is	O
an	O
antitumor	O
agent	O
which	O
also	O
induces	O
hemoglobinization	O
during	O
erythroid	O
differentiation	O
.	O

In	O
addition	O
,	O
HU	O
stimulates	O
the	O
synthesis	O
of	O
fetal	O
hemoglobin	O
in	O
sickle	O
cell	O
anemia	O
patients	O
.	O

To	O
further	O
understand	O
its	O
mechanism	O
of	O
action	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
HU	O
on	O
regulation	O
of	O
c-jun	O
expression	O
prior	O
to	O
the	O
onset	O
of	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

HU	O
induced	O
a	O
dose-dependent	O
stimulation	O
of	O
c-jun	O
synthesis	O
.	O

The	O
levels	O
of	O
c-jun	O
mRNA	O
was	O
elevated	O
4	O
to	O
7.5-fold	O
by	O
HU	O
within	O
2	O
h	O
.	O

This	O
was	O
followed	O
by	O
a	O
gradual	O
decline	O
to	O
the	O
basal	O
level	O
by	O
24	O
h	O
.	O

Both	O
nuclear	O
run-on	O
and	O
actinomycin	O
D	O
pulse	O
experiments	O
strongly	O
indicate	O
that	O
HU	O
regulates	O
c-jun	O
mRNA	O
expression	O
by	O
increasing	O
the	O
rate	O
of	O
synthesis	O
as	O
well	O
as	O
stabilizing	O
the	O
c-jun	O
mRNA	O
.	O

In	O
addition	O
,	O
the	O
level	O
of	O
jun	O
protein	O
was	O
elevated	O
by	O
2	O
to	O
5-fold	O
within	O
4	O
h	O
in	O
HU	O
treated	O
cells	O
.	O

Furthermore	O
,	O
concentrations	O
of	O
HU	O
below	O
250	O
microM	O
slightly	O
increased	O
the	O
5X	O
AP-1/CAT	O
activity	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
HU	O
induces	O
both	O
transcriptional	O
and	O
post-transcription	O
regulation	O
of	O
c-jun	O
during	O
erythroid	O
differentiation	O
.	O

Characterization	O
of	O
5	O
'	O
end	O
of	O
human	O
thromboxane	O
receptor	O
gene	O
.	O

Organizational	O
analysis	O
and	O
mapping	O
of	O
protein	O
kinase	O
C	O
--	O
responsive	O
elements	O
regulating	O
expression	O
in	O
platelets	O
.	O

Platelet	O
thromboxane	O
receptors	O
are	O
acutely	O
and	O
reversibly	O
upregulated	O
after	O
acute	O
myocardial	O
infarction	O
.	O

To	O
determine	O
if	O
platelet	O
thromboxane	O
receptors	O
are	O
under	O
transcriptional	O
control	O
,	O
we	O
isolated	O
and	O
characterized	O
human	O
genomic	O
DNA	O
clones	O
containing	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
.	O

The	O
exon-intron	O
structure	O
of	O
the	O
5	O
'	O
portion	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
determined	O
initially	O
by	O
comparing	O
the	O
nucleotide	O
sequence	O
of	O
the	O
5	O
'	O
flanking	O
genomic	O
clone	O
with	O
that	O
of	O
a	O
novel	O
human	O
uterine	O
thromboxane	O
receptor	O
cDNA	O
that	O
extended	O
the	O
mRNA	O
141	O
bp	O
further	O
upstream	O
than	O
the	O
previously	O
identified	O
human	O
placental	O
cDNA	O
.	O

A	O
major	O
transcription	O
initiation	O
site	O
was	O
located	O
in	O
three	O
human	O
tissues	O
approximately	O
560	O
bp	O
upstream	O
from	O
the	O
translation	O
initiation	O
codon	O
and	O
380	O
bp	O
upstream	O
from	O
any	O
previously	O
identified	O
transcription	O
initiation	O
site	O
.	O

The	O
thromboxane	O
receptor	O
gene	O
has	O
neither	B-Negation
a	I-Negation
TATA	I-Negation
nor	I-Negation
a	I-Negation
CAAT	I-Negation
consensus	I-Negation
site	I-Negation
.	O

Promoter	O
function	O
of	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
was	O
evaluated	O
by	O
transfection	O
of	O
thromboxane	O
receptor	O
gene	O
promoter/chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
chimera	O
plasmids	O
into	O
platelet-like	O
K562	O
cells	O
.	O

Thromboxane	O
receptor	O
promoter	O
activity	O
,	O
as	O
assessed	O
by	O
CAT	O
expression	O
,	O
was	O
relatively	O
weak	O
but	O
was	O
significantly	O
enhanced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Functional	O
analysis	O
of	O
5	O
'	O
deletion	O
constructs	O
in	O
transfected	O
K562	O
cells	O
and	O
gel	O
mobility	O
shift	O
localized	O
the	O
major	O
phorbol	O
ester-responsive	O
motifs	O
in	O
the	O
thromboxane	O
receptor	O
gene	O
promoter	O
to	O
a	O
cluster	O
of	O
activator	O
protein-2	O
(	O
AP-2	O
)	O
binding	O
consensus	O
sites	O
located	O
approximately	O
1.8	O
kb	O
5	O
'	O
from	O
the	O
transcription	O
initiation	O
site	O
.	O

These	O
studies	O
are	O
the	O
first	O
to	O
determine	O
the	O
structure	O
and	O
organization	O
of	O
the	O
5	O
'	O
end	O
of	O
the	O
thromboxane	O
receptor	O
gene	O
and	O
demonstrate	O
that	O
thromboxane	O
receptor	O
gene	O
expression	O
can	O
be	O
regulated	O
by	O
activation	O
of	O
protein	O
kinase	O
C	O
via	O
induction	O
of	O
an	O
AP-2-like	O
nuclear	O
factor	O
binding	O
to	O
upstream	O
promoter	O
elements	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
mechanism	O
for	O
previously	O
described	O
upregulation	O
of	O
platelet	O
thromboxane	O
receptors	O
after	O
acute	O
myocardial	O
infarction	O
is	O
increased	O
thromboxane	O
receptor	O
gene	O
transcription	O
in	O
platelet-progenitor	O
cells	O
.	O

IL-2	O
gene	O
expression	O
and	O
NF-kappa	O
B	O
activation	O
through	O
CD28	O
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	O
.	O

Activation	O
of	O
the	O
CD28	O
surface	O
receptor	O
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	O
(	O
IL-2	O
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	O
T	O
lymphocytes	O
we	O
show	O
that	O
CD28	O
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28-mediated	O
activation	O
of	O
the	O
NF-kappa	O
B/CD28-responsive	O
complex	O
and	O
IL-2	O
expression	O
.	O

Delineation	O
of	O
the	O
CD28	O
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	O
A2	O
and	O
5-lipoxygenase	O
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	O
metabolites	O
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	O
expression	O
via	O
NF-kappa	O
B	O
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	O
costimulatory	O
pathway	O
.	O

Infection	O
and	O
replication	O
of	O
Tat-	O
human	O
immunodeficiency	O
viruses	O
:	O
genetic	O
analyses	O
of	O
LTR	O
and	O
tat	O
mutations	O
in	O
primary	O
and	O
long-term	O
human	O
lymphoid	O
cells	O
.	O

Tat	O
is	O
an	O
essential	O
regulatory	O
protein	O
for	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Mutations	O
in	O
the	O
tat	O
gene	O
have	O
been	O
shown	O
to	O
block	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
.	O

Several	O
studies	O
have	O
established	O
that	O
Tat	O
releases	O
an	O
elongation	O
block	O
to	O
the	O
transcription	O
of	O
HIV	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
;	O
however	O
,	O
it	O
is	O
not	O
known	O
whether	O
this	O
mechanism	O
alone	O
is	O
sufficient	O
to	O
explain	O
the	O
block	O
to	O
HIV	O
replication	O
in	O
human	O
T	O
cells	O
when	O
Tat	O
is	O
absent	O
.	O

It	O
is	O
possible	O
that	O
Tat	O
is	O
also	O
needed	O
for	O
other	O
functions	O
during	O
HIV	O
replication	O
.	O

To	O
test	O
these	O
hypotheses	O
,	O
we	O
studied	O
several	O
tat	O
mutants	O
,	O
including	O
two	O
stop	O
codon	O
mutants	O
and	O
one	O
deletion	O
mutant	O
using	O
replication-competent	O
HIV-1	O
constructs	O
carrying	O
wild-type	O
or	O
mutant	O
LTRs	O
with	O
modifications	O
in	O
the	O
NF-kappa	O
B	O
and/or	O
Sp1	O
binding	O
sites	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tat-	O
HIV-1	O
with	O
wild-type	O
LTRs	O
can	O
replicate	O
in	O
HeLa	O
cells	O
,	O
and	O
the	O
virus	O
produced	O
from	O
HeLa	O
cells	O
can	O
infect	O
primary	O
peripheral	O
blood	O
lymphocytes	O
and	O
macrophages	O
.	O

It	O
was	O
found	O
that	O
the	O
propagation	O
of	O
the	O
Tat	O
mutants	O
containing	O
wild-type	O
LTRs	O
was	O
less	O
efficient	O
than	O
that	O
of	O
the	O
LTR-modified	O
Tat	O
mutants	O
.	O

Large	O
amounts	O
of	O
viral	O
RNA	O
and	O
particles	O
were	O
synthesized	O
in	O
infections	O
established	O
using	O
the	O
tat	O
mutants	O
that	O
contain	O
modified	O
LTRs	O
.	O

However	O
,	O
this	O
efficient	O
propagation	O
of	O
the	O
LTR-modified	O
tat	O
mutants	O
was	O
restricted	O
to	O
some	O
lymphoid	O
cell	O
lines	O
that	O
have	O
been	O
transformed	O
with	O
other	O
viruses	O
.	O

Thus	O
,	O
despite	O
its	O
essential	O
role	O
for	O
releasing	O
an	O
elongation	O
block	O
,	O
Tat	B-Negation
is	I-Negation
not	I-Negation
otherwise	I-Negation
absolutely	I-Negation
required	I-Negation
for	I-Negation
synthesis	I-Negation
of	I-Negation
full-length	I-Negation
HIV	I-Negation
transcripts	I-Negation
and	I-Negation
assembly	I-Negation
of	I-Negation
virus	I-Negation
particles	I-Negation
.	O

Direct	O
sequencing	O
of	O
the	O
viral	O
genomes	O
and	O
reinfection	O
kinetics	O
showed	O
no	O
evidence	O
of	O
wild-type	O
reversion	O
even	O
after	O
prolonged	O
infection	O
with	O
the	O
Tat-	O
virus	O
.	O

The	O
implications	O
for	O
in	O
vivo	O
HIV-1	O
replication	O
and	O
potential	O
application	O
of	O
this	O
system	O
to	O
the	O
study	O
of	O
alternative	O
Tat	O
function	O
are	O
discussed	O
.	O

Activation	O
and	O
expression	O
of	O
the	O
nuclear	O
factors	O
of	O
activated	O
T	O
cells	O
,	O
NFATp	O
and	O
NFATc	O
,	O
in	O
human	O
natural	O
killer	O
cells	O
:	O
regulation	O
upon	O
CD16	O
ligand	O
binding	O
.	O

The	O
putative	O
factors	O
that	O
couple	O
the	O
signal	O
transduction	O
from	O
surface	O
receptors	O
to	O
the	O
activation	O
of	O
cytokine	O
synthesis	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
have	O
not	O
been	O
elucidated	O
.	O

We	O
report	O
here	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFATp	O
)	O
,	O
a	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
-sensitive	O
factor	O
that	O
regulates	O
the	O
transcription	O
of	O
several	O
cytokines	O
,	O
mediates	O
CD16-induced	O
activation	O
of	O
cytokine	O
genes	O
in	O
human	O
NK	O
cells	O
.	O

CD16	O
(	O
Fc	O
gamma	O
RIIIA	O
)	O
-induced	O
expression	O
of	O
cytokine	O
mRNA	O
in	O
NK	O
cells	O
occurs	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
.	O

Stimulation	O
of	O
NK	O
cells	O
with	O
CD16	O
ligands	O
induces	O
NFAT-like	O
DNA	O
binding	O
activity	O
in	O
the	O
nuclear	O
extracts	O
from	O
these	O
cells	O
,	O
as	O
detected	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

This	O
occurs	O
with	O
fast	O
kinetics	O
after	O
stimulation	O
,	O
via	O
a	O
CsA-sensitive	O
and	O
Ca	O
(	O
2+	O
)	O
-dependent	O
mechanism	O
that	O
does	O
not	B-Negation
require	I-Negation
de	I-Negation
novo	I-Negation
protein	I-Negation
synthesis	I-Negation
.	O

NK	O
cell	O
NFAT	O
is	O
present	O
in	O
the	O
cytosol	O
of	O
nonstimulated	O
cells	O
,	O
migrates	O
to	O
the	O
nucleus	O
upon	O
stimulation	O
,	O
and	O
can	O
associate	O
with	O
AP-1	O
.	O

Two	O
distinct	O
molecules	O
,	O
NFATp	O
and	O
NFATc	O
,	O
have	O
been	O
reported	O
to	O
mediate	O
NFAT	O
activity	O
.	O

The	O
results	O
of	O
supershift	O
assays	O
using	O
NFATp-	O
and	O
NFATc-	O
specific	O
antibodies	O
indicate	O
that	O
NK	O
cell	O
activation	O
early	O
after	O
CD16	O
ligand	O
binding	O
involves	O
primarily	O
,	O
if	O
not	O
exclusively	O
,	O
NFATp	O
,	O
and	O
Western	O
blot	O
analysis	O
shows	O
that	O
this	O
has	O
the	O
same	O
electrophoretic	O
mobility	O
(	O
approximately	O
120	O
kD	O
)	O
as	O
that	O
of	O
T	O
lymphocytes	O
.	O

NK	O
cells	O
do	O
not	B-Negation
express	I-Negation
NFATc	I-Negation
constitutively	I-Negation
,	O
but	O
NFATc	O
mRNA	O
accumulation	O
is	O
induced	O
in	O
these	O
cells	O
within	O
2	O
h	O
of	O
stimulation	O
with	O
CD16	O
ligands	O
.	O

However	O
,	O
supershift	O
assays	O
using	O
the	O
available	O
mAb	O
recognizing	O
the	O
T	O
cell	O
NFATc	O
revealed	O
no	B-Negation
detectable	I-Negation
NFATc	I-Negation
protein	I-Negation
in	I-Negation
nuclear	I-Negation
and	I-Negation
cytoplasmic	I-Negation
extracts	I-Negation
from	I-Negation
CD16-	I-Negation
or	I-Negation
phorbol	I-Negation
ester-stimulated	I-Negation
cells	I-Negation
at	I-Negation
any	I-Negation
time	I-Negation
tested	I-Negation
,	I-Negation
up	I-Negation
to	I-Negation
4	I-Negation
h	I-Negation
.	O

These	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
that	O
both	O
CsA-sensitive	O
transcription	O
factors	O
,	O
NFATp	O
and	O
NFATc	O
,	O
are	O
expressed	O
in	O
human	O
NK	O
cells	O
,	O
and	O
that	O
their	O
activation	O
and/or	O
expression	O
can	O
be	O
regulated	O
in	O
primary	O
cells	O
by	O
a	O
single	O
stimulus	O
,	O
that	O
,	O
in	O
the	O
case	O
of	O
CD16	O
in	O
NK	O
cells	O
,	O
results	O
in	O
early	O
activation	O
of	O
NFATp	O
and	O
subsequently	O
induced	O
expression	O
of	O
NFATc	O
mRNA	O
.	O

Constitutive	O
activation	O
of	O
different	O
Jak	O
tyrosine	O
kinases	O
in	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
tax	O
protein	O
or	O
virus-transformed	O
cells	O
.	O

HTLV-1	O
infection	O
causes	O
an	O
adult	O
T	O
cell	O
leukemia	O
in	O
humans	O
.	O

The	O
viral	O
encoded	O
protein	O
tax	O
,	O
is	O
thought	O
to	O
play	O
an	O
important	O
role	O
in	O
oncogenesis	O
.	O

Our	O
previous	O
data	O
obtained	O
from	O
a	O
tax	O
transgenic	O
mouse	O
model	O
revealed	O
that	O
tax	O
transforms	O
mouse	O
fibroblasts	O
but	O
not	B-Negation
thymocytes	I-Negation
,	O
despite	O
comparable	O
levels	O
of	O
tax	O
expression	O
in	O
both	O
tissues	O
.	O

Constitutive	O
tyrosine	O
phosphorylation	O
of	O
a	O
130-kD	O
protein	O
(	O
s	O
)	O
was	O
observed	O
in	O
the	O
tax	O
transformed	O
fibroblast	O
B	O
line	O
and	O
in	O
HTLV-1	O
transformed	O
human	O
lymphoid	O
lines	O
,	O
but	O
not	B-Negation
in	I-Negation
thymocytes	I-Negation
from	I-Negation
Thy-tax	I-Negation
transgenic	I-Negation
mice	I-Negation
.	O

Phosphotyrosine	O
immunoprecipitation	O
followed	O
by	O
Western	O
blot	O
analysis	O
with	O
a	O
set	O
of	O
Jak	O
kinase	O
specific	O
antibodies	O
,	O
identified	O
p130	O
as	O
Jak2	O
in	O
the	O
tax	O
transformed	O
mouse	O
fibroblastic	O
cell	O
line	O
and	O
Jak3	O
in	O
HTLV-1	O
transformed	O
human	O
T	O
cell	O
lines	O
.	O

Phosphorylation	O
of	O
Jak2	O
in	O
tax	O
transformed	O
cells	O
resulted	O
from	O
high	O
expression	O
of	O
IL-6	O
.	O

Tyrosine	O
phosphorylation	O
of	O
this	O
protein	O
could	O
also	O
be	O
induced	O
in	O
Balb/c3T3	O
cells	O
using	O
a	O
supernatant	O
from	O
the	O
B	O
line	O
,	O
which	O
was	O
associated	O
with	O
induction	O
of	O
cell	O
proliferation	O
.	O

Both	O
phosphorylation	O
and	O
proliferation	O
were	O
inhibited	O
by	O
IL-6	O
neutralizing	O
antibodies	O
.	O

Constitutive	O
phosphorylation	O
of	O
Jak	O
kinases	O
may	O
facilitate	O
tumor	O
growth	O
in	O
both	O
HTLV-1	O
infected	O
human	O
T	O
cells	O
and	O
the	O
transgenic	O
mouse	O
model	O
.	O

Regulation	O
of	O
transcription	O
of	O
the	O
human	O
erythropoietin	O
receptor	O
gene	O
by	O
proteins	O
binding	O
to	O
GATA-1	O
and	O
Sp1	O
motifs	O
.	O

Erythropoietin	O
(	O
Epo	O
)	O
,	O
the	O
primary	O
regulator	O
of	O
the	O
production	O
of	O
erythroid	O
cells	O
,	O
acts	O
by	O
binding	O
to	O
a	O
cell	O
surface	O
receptor	O
(	O
EpoR	O
)	O
on	O
erythroid	O
progenitors	O
.	O

We	O
used	O
deletion	O
analysis	O
and	O
transfection	O
assays	O
with	O
reporter	O
gene	O
constructs	O
to	O
examine	O
the	O
transcription	O
control	O
elements	O
in	O
the	O
5	O
'	O
flanking	O
region	O
of	O
the	O
human	O
EpoR	O
gene	O
.	O

In	O
erythroid	O
cells	O
most	O
of	O
the	O
transcription	O
activity	O
was	O
contained	O
in	O
a	O
150	O
bp	O
promoter	O
fragment	O
with	O
binding	O
sites	O
for	O
transcription	O
factors	O
AP2	O
,	O
Sp1	O
and	O
the	O
erythroid-specific	O
GATA-1	O
.	O

The	O
150	O
bp	O
hEpoR	O
promoter	O
exhibited	O
high	O
and	O
low	O
activity	O
in	O
erythroid	O
OCIM1	O
and	O
K562	O
cells	O
,	O
respectively	O
,	O
reflecting	O
the	O
high	O
and	O
low	O
levels	O
of	O
constitutive	O
hEpoR	O
expression	O
.	O

The	O
GATA-1	O
and	O
Sp1	O
binding	O
sites	O
in	O
this	O
promoter	O
lacking	B-Negation
a	I-Negation
TATA	I-Negation
sequence	I-Negation
were	O
necessary	O
for	O
a	O
high	O
level	O
of	O
transcription	O
activation	O
.	O

Protein-DNA	O
binding	O
studies	O
suggested	O
that	O
Sp1	O
and	O
two	O
other	O
CCGCCC	O
binding	O
proteins	O
from	O
erythroid	O
and	O
non-erythroid	O
cells	O
could	O
bind	O
to	O
the	O
Sp1	O
binding	O
motif	O
.	O

By	O
increasing	O
GATA-1	O
levels	O
via	O
co-transfection	O
,	O
we	O
were	O
able	O
to	O
transactivate	O
the	O
hEpoR	O
promoter	O
in	O
K562	O
cells	O
and	O
non-erythroid	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
the	I-Negation
highly	I-Negation
active	I-Negation
OCIM1	I-Negation
cells	I-Negation
,	O
although	O
GATA-1	O
mRNA	O
levels	O
were	O
comparable	O
in	O
OCIM1	O
and	O
K562	O
.	O

Interestingly	O
,	O
when	O
we	O
mutated	O
the	O
Sp1	O
site	O
,	O
resulting	O
in	O
a	O
marked	O
decrease	O
in	O
hEpoR	O
promoter	O
activity	O
,	O
we	O
could	O
restore	O
transactivation	O
by	O
increasing	O
GATA-1	O
levels	O
in	O
OCIM1	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
while	O
GATA-1	O
can	O
transactivate	O
the	O
EpoR	O
promoter	O
,	O
the	O
level	O
of	O
hEpoR	O
gene	O
expression	O
does	O
not	O
depend	O
on	O
GATA-1	O
alone	O
.	O

Rather	O
,	O
hEpoR	O
transcription	O
activity	O
depends	O
on	O
coordination	O
between	O
Sp1	O
and	O
GATA-1	O
with	O
other	O
cell-specific	O
factors	O
,	O
including	O
possibly	O
other	O
Sp1-like	O
binding	O
proteins	O
,	O
to	O
provide	O
high	O
level	O
,	O
tissue-specific	O
expression	O
.	O

TCL1	O
oncogene	O
activation	O
in	O
preleukemic	O
T	O
cells	O
from	O
a	O
case	O
of	O
ataxia-telangiectasia	O
.	O

The	O
TCL1	O
oncogene	O
on	O
human	O
chromosome	O
14q32.1	O
is	O
involved	O
in	O
chromosome	O
translocations	O
[	O
t	O
(	O
14	O
;	O
14	O
)	O
(	O
q11	O
;	O
q32.1	O
)	O
and	O
t	O
(	O
7	O
;	O
14	O
)	O
(	O
q35	O
;	O
q32.1	O
)	O
]	O
and	O
inversions	O
[	O
inv14	O
(	O
q11	O
;	O
q32.1	O
)	O
]	O
with	O
TCR	O
alpha/beta	O
loci	O
in	O
T-cell	O
leukemias	O
,	O
such	O
as	O
T-prolymphocytic	O
(	O
T-PLL	O
)	O
.	O

It	O
is	O
also	O
involved	O
in	O
T-	O
acute	O
and-	O
chronic	O
leukemias	O
arising	O
in	O
cases	O
of	O
ataxia-telangiectasia	O
(	O
AT	O
)	O
,	O
an	O
immunodeficiency	O
syndrome	O
.	O

Similar	O
chromosomal	O
rearrangements	O
occur	O
also	O
in	O
the	O
clonally	O
expanded	O
T	O
cells	O
in	O
AT	O
patients	O
before	O
the	O
appearance	O
of	O
the	O
overt	O
leukemia	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
of	O
TCL1	O
mRNA	O
and	O
protein	O
in	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBLs	O
)	O
from	O
four	O
AT	O
cases	O
and	O
from	O
healthy	O
controls	O
.	O

We	O
found	O
that	O
the	O
TCL1	O
gene	O
was	O
overexpressed	O
in	O
the	O
PBLs	O
of	O
an	O
AT	O
patient	O
with	O
a	O
large	O
clonal	O
T-cell	O
population	O
exhibiting	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
but	O
not	B-Negation
in	I-Negation
the	I-Negation
lymphocytes	I-Negation
of	I-Negation
the	I-Negation
other	I-Negation
cases	I-Negation
.	O

Fluorescence	O
in	O
situ	O
hybridization	O
of	O
the	O
TCL1	O
genomic	O
locus	O
to	O
lymphocyte	O
metaphases	O
from	O
the	O
AT	O
patient	O
with	O
the	O
T-cell	O
clonal	O
expansion	O
showed	O
that	O
the	O
breakpoint	O
of	O
the	O
t	O
(	O
14	O
;	O
14	O
)	O
translocation	O
lies	O
within	O
the	O
TCL1	O
locus	O
and	O
is	O
accompanied	O
by	O
an	O
inverted	O
duplication	O
of	O
the	O
distal	O
part	O
of	O
chromosome	O
14	O
.	O

These	O
data	O
indicate	O
that	O
TCL1	O
is	O
activated	O
in	O
preleukemic	O
clonal	O
cells	O
as	O
a	O
consequence	O
of	O
chromosome	O
translocation	O
involving	O
sequences	O
from	O
the	O
TCR	O
locus	O
at	O
14q11	O
.	O

Deregulation	O
of	O
TCL1	O
is	O
the	O
first	O
event	O
in	O
the	O
initiation	O
of	O
malignancy	O
in	O
these	O
types	O
of	O
leukemias	O
and	O
represents	O
a	O
potential	O
tool	O
for	O
clinical	O
evaluation	O
.	O

Interleukin-2	O
promoter	O
activity	O
in	O
Epstein-Barr	O
virus-transformed	O
B	O
lymphocytes	O
is	O
controlled	O
by	O
nuclear	O
factor-chi	O
B	O
.	O

The	O
regulation	O
of	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
expression	O
has	O
been	O
investigated	O
mainly	O
in	O
T	O
lymphocytes	O
,	O
the	O
predominant	O
producers	O
of	O
IL-2	O
.	O

However	O
,	O
B	O
cells	O
can	O
also	O
synthesize	O
IL-2	O
.	O

In	O
the	O
present	O
study	O
we	O
analyzed	O
the	O
control	O
of	O
IL-2	O
promoter	O
activity	O
in	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-transformed	O
B	O
cell	O
clones	O
which	O
are	O
capable	O
of	O
secreting	O
IL-2	O
at	O
a	O
low	O
level	O
after	O
stimulation	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
the	O
Ca2+	O
ionophore	O
ionomycin	O
.	O

Transient	O
transfections	O
using	O
reporter	O
constructs	O
with	O
multiples	O
of	O
transcription	O
factor	O
binding	O
sites	O
from	O
the	O
IL-2	O
promoter	O
[	O
distal	O
nuclear	O
factor	O
(	O
NF	O
)	O
-AT	O
,	O
proximal	O
NF-AT	O
,	O
AP-1/Octamer	O
(	O
UPS	O
)	O
or	O
NF-chi	O
B	O
(	O
TCEd	O
)	O
sites	O
]	O
were	O
performed	O
.	O

In	O
EBV-transformed	O
B	O
clones	O
,	O
the	O
chi	O
B	O
site	O
exerted	O
the	O
strongest	O
inducible	O
activity	O
;	O
the	O
NF-AT	O
binding	O
sites	O
showed	O
either	O
no	O
or	O
only	O
weak	O
activity	O
compared	O
to	O
Jurkat	O
T	O
cells	O
.	O

An	O
IL-2	O
promoter	O
bearing	O
a	O
defective	O
NF-chi	O
B	O
site	O
was	O
completely	O
inactive	O
in	O
EBV-transformed	O
B	O
cells	O
,	O
while	O
it	O
still	O
had	O
activity	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
seven	O
EBV-B	O
cell	O
clones	O
or	O
lines	O
differing	O
in	O
their	O
capacity	O
to	O
secrete	O
IL-2	O
,	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
correlated	O
well	O
with	O
the	O
status	O
of	O
IL-2	O
secretion	O
.	O

Similarly	O
,	O
a	O
human	O
immunodeficiency	O
virus	O
promoter	O
,	O
whose	O
activity	O
is	O
controlled	O
through	O
chi	O
B	O
factors	O
,	O
was	O
found	O
to	O
be	O
active	O
in	O
the	O
IL-2	O
producing	O
EBV-B	O
cells	O
,	O
but	O
inactive	O
in	O
the	O
non-IL-2-producing	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
using	O
protein	O
extracts	O
from	O
EBV-B	O
cells	O
and	O
the	O
IL-2	O
NF-chi	O
B	O
probe	O
revealed	O
the	O
constitutive	O
generation	O
of	O
chi	O
B	O
complexes	O
in	O
IL-2-secreting	O
cells	O
consisting	O
mainly	O
of	O
heterodimeric	O
p50/p65	O
complexes	O
.	O

A	O
weaker	O
chi	O
B	O
complex	O
formation	O
and	O
faster-migrating	O
complexes	O
were	O
detected	O
in	O
non-IL-2-secreting	O
cells	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
IL-2	O
NF-chi	O
B	O
site	O
is	O
indispensable	O
for	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
EBV-transformed	O
B	O
cells	O
,	O
whereas	O
other	O
transcription	O
factors	O
appear	O
to	O
be	O
less	O
important	O
for	O
IL-2	O
expression	O
in	O
these	O
cells	O
.	O

Ubiquitin-mediated	O
processing	O
of	O
NF-kappa	O
B	O
transcriptional	O
activator	O
precursor	O
p105	O
.	O

Reconstitution	O
of	O
a	O
cell-free	O
system	O
and	O
identification	O
of	O
the	O
ubiquitin-carrier	O
protein	O
,	O
E2	O
,	O
and	O
a	O
novel	O
ubiquitin-protein	O
ligase	O
,	O
E3	O
,	O
involved	O
in	O
conjugation	O
.	O

In	O
most	O
cases	O
,	O
the	O
transcriptional	O
factor	O
NF-kappa	O
B	O
is	O
a	O
heterodimer	O
consisting	O
of	O
two	O
subunits	O
,	O
p50	O
and	O
p65	O
,	O
which	O
are	O
encoded	O
by	O
two	O
distinct	O
genes	O
of	O
the	O
Rel	O
family	O
.	O

p50	O
is	O
translated	O
as	O
a	O
precursor	O
of	O
105	O
kDa	O
.	O

The	O
C-terminal	O
domain	O
of	O
the	O
precursor	O
is	O
rapidly	O
degraded	O
,	O
forming	O
the	O
mature	O
p50	O
subunit	O
consisted	O
of	O
the	O
N-terminal	O
region	O
of	O
the	O
molecule	O
.	O

The	O
mechanism	O
of	O
generation	O
of	O
p50	O
is	O
not	O
known	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
ubiquitin-proteasome	O
system	O
is	O
involved	O
in	O
the	O
process	O
;	O
however	O
,	O
the	O
specific	O
enzymes	O
involved	O
and	O
the	O
mechanism	O
of	O
limited	O
proteolysis	O
,	O
in	O
which	O
half	O
of	O
the	O
molecule	O
is	O
spared	O
,	O
have	O
been	O
obscure	O
.	O

Palombella	O
and	O
colleagues	O
(	O
Palombella	O
,	O
V.J.	O
,	O
Rando	O
,	O
O.J.	O
,	O
Goldberg	O
,	O
A.L.	O
,	O
and	O
Maniatis	O
,	O
T.	O
(	O
1994	O
)	O
Cell	O
78	O
,	O
773-785	O
)	O
have	O
shown	O
that	O
ubiquitin	O
is	O
required	O
for	O
the	O
processing	O
in	O
a	O
cell-free	O
system	O
of	O
a	O
truncated	O
,	O
artificially	O
constructed	O
,	O
60-kDa	O
precursor	O
.	O

They	O
have	O
also	O
shown	O
that	O
proteasome	O
inhibitors	O
block	O
the	O
processing	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
reconstitution	O
of	O
a	O
cell-free	O
processing	O
system	O
and	O
demonstrate	O
directly	O
that	O
:	O
(	O
a	O
)	O
the	O
ubiquitin-proteasome	O
system	O
is	O
involved	O
in	O
processing	O
of	O
the	O
intact	O
p105	O
precursor	O
,	O
(	O
b	O
)	O
conjugation	O
of	O
ubiquitin	O
to	O
the	O
precursor	O
is	O
an	O
essential	O
intermediate	O
step	O
in	O
the	O
processing	O
,	O
(	O
c	O
)	O
the	O
recently	O
discovered	O
novel	O
species	O
of	O
the	O
ubiquitin-carrier	O
protein	O
,	O
E2-F1	O
,	O
that	O
is	O
involved	O
in	O
the	O
conjugation	O
and	O
degradation	O
of	O
p53	O
,	O
is	O
also	O
required	O
for	O
the	O
limited	O
processing	O
of	O
the	O
p105	O
precursor	O
,	O
and	O
(	O
d	O
)	O
a	O
novel	O
,	O
approximately	O
320-kDa	O
species	O
of	O
ubiquitin-protein	O
ligase	O
,	O
is	O
involved	O
in	O
the	O
process	O
.	O

This	O
novel	O
enzyme	O
is	O
distinct	O
from	O
E6-AP	O
,	O
the	O
p53-conjugating	O
ligase	O
,	O
and	O
from	O
E3	O
alpha	O
,	O
the	O
``	O
N-end	O
rule	O
``	O
ligase	O
.	O

The	O
hematopoietic	O
transcription	O
factor	O
PU.1	O
is	O
downregulated	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
.	O

PU.1	O
is	O
a	O
hematopoietic	O
transcription	O
factor	O
belonging	O
to	O
the	O
Ets-family	O
.	O

It	O
is	O
identical	O
to	O
the	O
Spi-1	O
oncogene	O
,	O
which	O
is	O
implicated	O
in	O
spleen	O
focus-forming	O
virus-induced	O
murine	O
erythroleukemias	O
.	O

PU.1	O
seems	O
to	O
be	O
required	O
for	O
early	O
development	O
of	O
multiple	O
hematopoietic	O
lineages	O
,	O
but	O
its	O
expression	O
in	O
mature	O
cells	O
is	O
preferentially	O
observed	O
in	O
cells	O
of	O
the	O
B-cell-and	O
monocyte/macrophage-differentiation	O
lineage	O
.	O

It	O
binds	O
the	O
so-called	O
Pu	O
box	O
,	O
an	O
important	O
tissue-specific	O
regulatory	O
DNA	O
element	O
present	O
in	O
a	O
number	O
of	O
genes	O
expressed	O
in	O
these	O
cell	O
lineages	O
.	O

We	O
have	O
analyzed	O
the	O
expression	O
and	O
activity	O
of	O
PU.1	O
during	O
human	O
B-cell	O
development	O
using	O
a	O
panel	O
of	O
B-cell	O
lines	O
representing	O
different	O
stages	O
of	O
maturation	O
,	O
from	O
early	O
precursors	O
to	O
differentiated	O
plasma	O
cells	O
.	O

PU.1	O
mRNA	O
expression	O
and	O
PU.1	O
DNA	O
binding	O
activity	O
,	O
as	O
measured	O
by	O
Northern	O
blot	O
analysis	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
were	O
evident	O
in	O
cell	O
lines	O
representing	O
pro-B	O
,	O
pre-B	O
,	O
and	O
mature	O
B	O
cells	O
.	O

We	O
could	O
also	O
show	O
Pu	O
box-dependent	O
transactivation	O
of	O
a	O
reporter	O
gene	O
in	O
transient	O
transfections	O
in	O
these	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
in	O
a	O
number	O
of	O
multiple	O
myeloma	O
cell	O
lines	O
,	O
representing	O
differentiated	O
,	O
plasma	O
cell-like	O
B	O
cells	O
,	O
PU.1	O
DNA	O
binding	O
activity	O
,	O
mRNA	O
expression	O
,	O
and	O
Pu	B-Negation
box-dependent	I-Negation
transactivation	I-Negation
were	I-Negation
absent	I-Negation
or	O
detectable	O
at	O
a	O
very	O
low	O
level	O
.	O

In	O
lymphoblastoid	O
cell	O
lines	O
,	O
which	O
exemplify	O
an	O
intermediate	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
a	O
reduced	O
expression	O
and	O
activity	O
were	O
observed	O
.	O

The	O
findings	O
in	O
the	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represent	O
the	O
first	O
examples	O
of	O
B	O
cells	O
with	O
downregulated	O
PU.1	O
expression	O
and	O
apparently	O
contradict	O
observations	O
in	O
the	O
murine	O
system	O
in	O
which	O
PU.1	O
is	O
expressed	O
and	O
active	O
in	O
plasmacytoma	O
cell	O
lines	O
.	O

At	O
present	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
lack	O
of	O
PU.1	O
expression	O
and	O
activity	O
in	O
human	O
multiple	O
myeloma	O
cell	O
lines	O
represents	O
a	O
malignancy-associated	O
defect	O
in	O
these	O
cells	O
or	O
exemplifies	O
a	O
normal	O
developmental	O
regulation	O
in	O
terminally	O
differentiated	O
B	O
cells	O
.	O

A	O
regulatory	O
element	O
in	O
the	O
human	O
interleukin	O
2	O
gene	O
promoter	O
is	O
a	O
binding	O
site	O
for	O
the	O
zinc	O
finger	O
proteins	O
Sp1	O
and	O
EGR-1	O
.	O

Activation	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
after	O
antigen	O
recognition	O
is	O
a	O
critical	O
event	O
for	O
T	O
cell	O
proliferation	O
and	O
effector	O
function	O
.	O

Prior	O
studies	O
have	O
identified	O
several	O
transcription	O
factors	O
that	O
contribute	O
to	O
the	O
activity	O
of	O
the	O
IL-2	O
promoter	O
in	O
stimulated	O
T	O
lymphocytes	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
regulatory	O
element	O
within	O
the	O
IL-2	O
promoter	O
located	O
immediately	O
upstream	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
domain	O
.	O

This	O
region	O
(	O
termed	O
the	O
zinc	O
finger	O
protein	O
binding	O
region	O
(	O
ZIP	O
)	O
)	O
serves	O
as	O
binding	O
site	O
for	O
two	O
differently	O
regulated	O
zinc	O
finger	O
proteins	O
:	O
the	O
constitutively	O
expressed	O
transcription	O
factor	O
Sp1	O
and	O
the	O
inducible	O
early	O
growth	O
response	O
protein	O
EGR-1	O
.	O

In	O
unstimulated	O
cells	O
which	O
do	O
not	B-Negation
secrete	I-Negation
IL-2	I-Negation
,	O
only	O
Sp1	O
binds	O
to	O
this	O
region	O
,	O
while	O
in	O
stimulated	O
IL-2	O
secreting	O
cells	O
the	O
inducible	O
EGR-1	O
protein	O
recognizes	O
this	O
element	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
the	O
ZIP	O
site	O
serves	O
as	O
an	O
activator	O
for	O
IL-2	O
gene	O
expression	O
,	O
and	O
a	O
combination	O
of	O
ZIP	O
and	O
NFAT	O
binding	O
sites	O
is	O
required	O
for	O
maximal	O
IL-2	O
promoter	O
activity	O
.	O

These	O
results	O
suggest	O
a	O
critical	O
role	O
of	O
the	O
ZIP	O
site	O
for	O
IL-2	O
promoter	O
activity	O
.	O

Nitric	O
oxide-stimulated	O
guanine	O
nucleotide	O
exchange	O
on	O
p21ras	O
.	O

The	O
protooncogene	O
p21ras	O
,	O
a	O
monomeric	O
G	O
protein	O
family	O
member	O
,	O
plays	O
a	O
critical	O
role	O
in	O
converting	O
extracellular	O
signals	O
into	O
intracellular	O
biochemical	O
events	O
.	O

Here	O
,	O
we	O
report	O
that	O
nitric	O
oxide	O
(	O
NO	O
)	O
activates	O
p21ras	O
in	O
human	O
T	O
cells	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
GTP-bound	O
p21ras	O
.	O

In	O
vitro	O
studies	O
using	O
pure	O
recombinant	O
p21ras	O
demonstrate	O
that	O
the	O
activation	O
is	O
direct	O
and	O
reversible	O
.	O

Circular	O
dichroism	O
analysis	O
reveals	O
that	O
NO	O
induces	O
a	O
profound	O
conformational	O
change	O
in	O
p21ras	O
in	O
association	O
with	O
GDP/GTP	O
exchange	O
.	O

The	O
mechanism	O
of	O
activation	O
is	O
due	O
to	O
S-nitrosylation	O
of	O
a	O
critical	O
cysteine	O
residue	O
which	O
stimulates	O
guanine	O
nucleotide	O
exchange	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
p21ras	O
is	O
essential	O
for	O
NO-induced	O
downstream	O
signaling	O
,	O
such	O
as	O
NF-kappa	O
B	O
activation	O
,	O
and	O
that	O
endogenous	O
NO	O
can	O
activate	O
p21ras	O
in	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
the	O
same	O
cell	O
.	O

These	O
studies	O
identify	O
p21ras	O
as	O
a	O
target	O
of	O
NO	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
NO	O
activates	O
p21ras	O
by	O
an	O
action	O
which	O
mimics	O
that	O
of	O
guanine	O
nucleotide	O
exchange	O
factors	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
vacuolar	O
H	O
(	O
+	O
)	O
-ATPase	O
B2	O
subunit	O
gene	O
in	O
differentiating	O
THP-1	O
cells	O
.	O

Monocyte-macrophage	O
differentiation	O
was	O
used	O
as	O
a	O
model	O
system	O
for	O
studying	O
gene	O
regulation	O
of	O
the	O
human	O
vacuolar	O
H	O
(	O
+	O
)	O
-ATPase	O
(	O
V-ATPase	O
)	O
.	O

We	O
examined	O
mRNA	O
levels	O
of	O
various	O
V-ATPase	O
subunits	O
during	O
differentiation	O
of	O
both	O
native	O
monocytes	O
and	O
the	O
cell	O
line	O
THP-1	O
,	O
and	O
found	O
that	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
could	O
account	O
for	O
increases	O
in	O
cell	O
V-ATPase	O
content	O
.	O

From	O
nuclear	O
runoff	O
experiments	O
,	O
we	O
found	O
that	O
one	O
subunit	O
in	O
particular	O
,	O
the	O
B2	O
isoform	O
(	O
Mr	O
=	O
56,000	O
)	O
,	O
was	O
amplified	O
primarily	O
by	O
transcriptional	O
means	O
.	O

We	O
have	O
begun	O
to	O
examine	O
the	O
structure	O
of	O
the	O
B2	O
subunit	O
promoter	O
region	O
.	O

Isolation	O
and	O
sequencing	O
of	O
the	O
first	O
exon	O
and	O
5'-flanking	O
region	O
of	O
this	O
gene	O
reveal	O
a	O
TATA-less	O
promoter	O
with	O
a	O
high	O
G	O
+	O
C	O
content	O
.	O

Primer	O
extension	O
and	O
ribonuclease	O
protection	O
analyses	O
indicate	O
a	O
single	O
major	O
transcriptional	O
start	O
site	O
.	O

We	O
transfected	O
promoter-luciferase	O
reporter	O
plasmids	O
into	O
THP-1	O
cells	O
to	O
define	O
sequences	O
that	O
mediate	O
transcriptional	O
control	O
during	O
monocyte	O
differentiation	O
.	O

We	O
found	O
that	O
sequences	O
downstream	O
from	O
the	O
transcriptional	O
start	O
site	O
were	O
sufficient	O
to	O
confer	O
increased	O
expression	O
during	O
THP-1	O
differentiation	O
.	O

DNase	O
I	O
footprinting	O
and	O
sequence	O
analysis	O
revealed	O
the	O
existence	O
of	O
multiple	O
AP2	O
and	O
Sp1	O
binding	O
sites	O
in	O
the	O
5'-untranslated	O
and	O
proximal	O
coding	O
regions	O
.	O

Functional	O
characterization	O
of	O
novel	O
IL-2	O
transcriptional	O
inhibitors	O
.	O

IL-2-mediated	O
T	O
cell	O
proliferation	O
is	O
a	O
critical	O
early	O
event	O
in	O
the	O
inflammatory	O
process	O
.	O

Formation	O
of	O
the	O
NFAT-1	O
transcriptional	O
complex	O
on	O
the	O
IL-2	O
promoter	O
is	O
essential	O
for	O
IL-2	O
transcription	O
.	O

Using	O
a	O
cell	O
line	O
that	O
is	O
stably	O
transfected	O
with	O
a	O
trimer	O
of	O
the	O
NFAT-1	O
regulatory	O
element	O
linked	O
to	O
a	O
lac-Z	O
reporter	O
gene	O
,	O
we	O
screened	O
for	O
inhibitors	O
of	O
NFAT-1-mediated	O
beta-galactosidase	O
activity	O
.	O

WIN	O
61058	O
and	O
WIN	O
53071	O
were	O
identified	O
as	O
microM	O
inhibitors	O
.	O

These	O
compounds	O
also	O
inhibited	O
beta-galactosidase	O
mRNA	O
levels	O
.	O

Similar	O
inhibition	O
of	O
NFAT-1-mediated	O
gene	O
expression	O
was	O
observed	O
in	O
a	O
second	O
cell	O
line	O
,	O
which	O
is	O
stably	O
transfected	O
with	O
NFAT-1	O
regulatory	O
elements	O
linked	O
to	O
the	O
reporter	O
gene	O
for	O
sCD8	O
.	O

At	O
10	O
microM	O
,	O
both	O
compounds	O
inhibited	O
IL-2	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
NFAT-1-linked	O
lac-Z	O
transfectants	O
,	O
and	O
in	O
human	O
lymphocytes	O
.	O

Both	O
compounds	O
inhibited	O
the	O
mixed	O
lymphocyte	O
reaction	O
,	O
and	O
this	O
inhibition	O
was	O
reversed	O
by	O
exogenous	O
IL-2	O
.	O

WIN	O
53071	O
inhibited	O
IL-2	O
production	O
induced	O
in	O
the	O
calcium-dependent	O
PMA	O
and	O
ionomycin	O
pathway	O
.	O

Conversely	O
,	O
calcium-independent	O
anti-CD28	O
Ab	O
and	O
PMA-induced	O
IL-2	O
production	O
was	O
resistant	O
.	O

Both	O
compounds	O
altered	O
the	O
NFAT-1	O
transcriptional	O
complex	O
,	O
causing	O
its	O
retarded	O
mobility	O
on	O
gels	O
.	O

By	O
these	O
functional	O
criteria	O
,	O
we	O
believe	O
we	O
have	O
identified	O
two	O
structurally	O
distinct	O
,	O
novel	O
inhibitors	O
of	O
NFAT-1-mediated	O
transcription	O
.	O

cDNA	O
cloning	O
of	O
a	O
NGFI-B/nur77-related	O
transcription	O
factor	O
from	O
an	O
apoptotic	O
human	O
T	O
cell	O
line	O
.	O

A	O
human	O
T	O
lymphoid	O
cell	O
line	O
,	O
PEER	O
,	O
dies	O
by	O
apoptosis	O
in	O
the	O
presence	O
of	O
PMA	O
and	O
calcium	O
ionophore	O
.	O

A	O
new	O
gene	O
,	O
TINUR	O
,	O
was	O
cloned	O
from	O
apoptotic	O
PEER	O
cells	O
.	O

The	O
expression	O
of	O
the	O
TINUR	O
gene	O
is	O
induced	O
within	O
1	O
h	O
after	O
the	O
cross-linking	O
of	O
the	O
T	O
cell	O
Ag	O
receptor	O
complex	O
.	O

TINUR	O
belongs	O
to	O
the	O
NGFI-B/nur77	O
family	O
of	O
the	O
steroid	O
receptor	O
superfamily	O
and	O
is	O
an	O
orphan	O
receptor	O
.	O

TINUR	O
binds	O
to	O
the	O
same	O
DNA	O
sequence	O
as	O
NGFI-B/nur77	O
.	O

We	O
also	O
propose	O
that	O
the	O
NGFI-B/nur77	O
family	O
can	O
be	O
classified	O
into	O
two	O
subtypes	O
.	O

Platelet-activating	O
factor	O
stimulates	O
transcription	O
of	O
the	O
heparin-binding	O
epidermal	O
growth	O
factor-like	O
growth	O
factor	O
in	O
monocytes	O
.	O

Correlation	O
with	O
an	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

Human	O
peripheral	O
blood	O
monocytes	O
responded	O
to	O
stimulation	O
of	O
platelet-activating	O
factor	O
(	O
PAF	O
)	O
with	O
up-regulation	O
of	O
the	O
transcript	O
for	O
heparin-binding	O
epidermal	O
growth	O
factor-like	O
growth	O
factor	O
(	O
HB-EGF	O
)	O
,	O
a	O
potent	O
mitogen	O
for	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
function	O
of	O
PAF	O
was	O
observed	O
at	O
nanomolar	O
concentrations	O
of	O
the	O
ligand	O
,	O
starting	O
at	O
30	O
min	O
after	O
stimulation	O
.	O

The	O
PAF-induced	O
up-regulation	O
of	O
HB-EGF	O
mRNA	O
was	O
accompanied	O
by	O
an	O
increase	O
in	O
kappa	O
B	O
binding	O
activity	O
.	O

These	O
functions	O
of	O
PAF	O
appeared	O
to	O
be	O
mediated	O
through	O
the	O
cell	O
surface	O
PAF	O
receptors	O
,	O
as	O
two	O
PAF	O
receptor	O
antagonists	O
,	O
WEB	O
2086	O
and	O
L-659,989	O
,	O
blocked	O
both	O
the	O
up-regulation	O
of	O
HB-EGF	O
mRNA	O
and	O
kappa	O
B	O
binding	O
activity	O
induced	O
by	O
PAF	O
.	O

The	O
antagonists	O
,	O
however	O
,	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
phorbol	I-Negation
ester-induced	I-Negation
up-regulation	I-Negation
of	I-Negation
HB-EGF	I-Negation
mRNA	I-Negation
and	I-Negation
kappa	I-Negation
B	I-Negation
binding	I-Negation
activity	I-Negation
.	O

Pretreatment	O
of	O
monocytes	O
with	O
pertussis	O
toxin	O
inhibited	O
these	O
functions	O
of	O
PAF	O
,	O
whereas	O
cholera	O
toxin	O
had	O
no	B-Negation
inhibitory	I-Negation
effect	I-Negation
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
an	O
inhibitor	O
for	O
NF-kappa	O
B	O
activation	O
,	O
markedly	O
reduced	O
PAF-stimulated	O
kappa	O
B	O
binding	O
activity	O
as	O
well	O
as	O
up-regulation	O
of	O
HB-EGF	O
mRNA	O
.	O

These	O
results	O
suggest	O
a	O
potential	O
role	O
of	O
PAF	O
in	O
HB-EGF	O
expression	O
and	O
provide	O
evidence	O
that	O
this	O
stimulation	O
may	O
occur	O
through	O
increased	O
kappa	O
B	O
binding	O
activity	O
.	O

IL-1	O
receptor	O
and	O
TCR	O
signals	O
synergize	O
to	O
activate	O
NF-kappa	O
B-mediated	O
gene	O
transcription	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
IL-1	O
receptor	O
(	O
IL-1R	O
)	O
-	O
and	O
TCR-initiated	O
signals	O
can	O
interact	O
synergistically	O
to	O
increase	O
the	O
rate	O
of	O
transcription	O
of	O
several	O
lymphokine	O
and	O
lymphokine	O
receptor	O
genes	O
during	O
the	O
competence	O
phase	O
of	O
the	O
activation	O
program	O
in	O
T	O
helper	O
lymphocytes	O
.	O

In	O
this	O
report	O
we	O
describe	O
how	O
signals	O
initiated	O
through	O
the	O
type	O
I	O
IL-1R	O
interact	O
with	O
signals	O
from	O
the	O
antigen	O
receptor	O
to	O
synergistically	O
augment	O
the	O
transactivating	O
properties	O
of	O
NF-kappa	O
B	O
.	O

The	O
synergistic	O
antigen	O
receptor	O
initiated	O
signals	O
are	O
mediated	O
through	O
protein	O
kinase	O
C	O
because	O
they	O
can	O
be	O
mimicked	O
by	O
the	O
phorbol	O
ester	O
,	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
but	O
not	B-Negation
with	I-Negation
calcium	I-Negation
ionophores	I-Negation
;	O
and	O
are	O
staurosporine	O
sensitive	O
but	O
cyclosporine	O
resistant	O
.	O

Gel	O
shift	O
analyses	O
demonstrate	O
that	O
NF-kappa	O
B	O
nuclear	O
translocation	O
is	O
stimulated	O
primarily	O
by	O
IL-1	O
rather	B-Negation
than	I-Negation
by	I-Negation
antigen	I-Negation
receptor	I-Negation
signals	I-Negation
.	O

Western	O
blot	O
and	O
phosphorylation	O
analyses	O
demonstrate	O
that	O
the	O
synergistic	O
effect	O
on	O
NF-kappa	O
B	O
functional	O
activity	O
is	O
independent	O
of	O
I	O
kappa	O
B	O
alpha	O
(	O
MAD3	O
)	O
-NF-kappa	O
B	O
dissociation	O
in	O
the	O
cytosol	O
and	O
is	B-Negation
not	I-Negation
associated	I-Negation
with	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
nuclear	I-Negation
translocation	I-Negation
.	O

The	O
IL-1-induced	O
NF-kappa	O
B	O
DNA	O
nuclear	O
localization	O
is	O
transient	O
and	O
can	O
be	O
prolonged	O
either	O
by	O
an	O
antigen	O
receptor-initiated	O
signal	O
or	O
by	O
inhibiting	O
protein	O
synthesis	O
.	O

These	O
results	O
suggest	O
that	O
IL-1	O
induces	O
both	O
NF-kappa	O
B	O
nuclear	O
translocation	O
and	O
the	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
terminating	O
NF-kappa	O
B-DNA	O
interaction	O
in	O
the	O
nucleus	O
.	O

Antigen	O
receptor	O
signals	O
prolong	O
NF-kappa	O
B-DNA	O
interaction	O
,	O
probably	O
by	O
functionally	O
antagonizing	O
the	O
IL-1-induced	O
synthesis	O
of	O
a	O
protein	O
(	O
s	O
)	O
responsible	O
for	O
the	O
transient	O
NF-kappa	O
B-DNA	O
interaction	O
and	O
consequently	O
synergistically	O
enhance	O
IL-1-induced	O
NF-kappa	O
B-dependent	O
gene	O
transcription	O
.	O

Induction	O
of	O
transcription	O
factors	O
in	O
human	O
T	O
lymphocytes	O
by	O
aspirin-like	O
drugs	O
.	O

Aspirin-like	O
drugs	O
(	O
ALD	O
)	O
induce	O
calcium	O
mobilization	O
,	O
an	O
essential	O
component	O
of	O
T	O
cell	O
activation	O
,	O
but	O
do	O
not	B-Negation
induce	I-Negation
the	I-Negation
biosynthesis	I-Negation
of	I-Negation
IL-2	I-Negation
.	O

To	O
understand	O
the	O
extent	O
to	O
which	O
ALD	O
may	O
mimic	O
mitogenic	O
stimulation	O
,	O
we	O
studied	O
cytoplasmic	O
and	O
nuclear	O
signaling	O
steps	O
in	O
ALD-treated	O
T	O
cells	O
.	O

We	O
found	O
that	O
ALD	O
induce	O
a	O
transient	O
activation	O
of	O
protein	O
kinase	O
(	O
PKC	O
)	O
but	O
have	O
no	B-Negation
effect	I-Negation
(	I-Negation
in	I-Negation
comparison	I-Negation
to	I-Negation
anti-CD3	I-Negation
antibodies	I-Negation
)	I-Negation
on	I-Negation
protein	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
nor	I-Negation
on	I-Negation
PCL	I-Negation
gamma	I-Negation
1	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
.	O

ALD-induced	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
are	O
independent	O
of	O
tyrosine	O
protein	O
kinase	O
activity	O
as	O
shown	O
by	O
the	O
lack	B-Negation
of	I-Negation
effect	I-Negation
of	I-Negation
herbimycin	I-Negation
,	I-Negation
a	I-Negation
tyrosine-protein	I-Negation
kinase-specific	I-Negation
inhibitor	I-Negation
.	O

Although	O
we	O
detected	O
no	B-Negation
IL-2	I-Negation
mRNA	I-Negation
in	I-Negation
ALD-treated	I-Negation
cells	I-Negation
,	O
the	O
nuclei	O
of	O
these	O
cells	O
contain	O
proteins	O
capable	O
of	O
binding	O
to	O
three	O
regulatory	O
sequences	O
in	O
the	O
IL-2	O
promoter	O
region	O
:	O
NFAT	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
AP-1	O
.	O

These	O
binding	O
activities	O
are	O
expressed	O
only	O
in	O
activated	O
T	O
cells	O
.	O

The	O
expression	O
of	O
AP-1	O
depended	O
on	O
calcium	O
mobilization	O
and	O
PKC	O
activation	O
.	O

These	O
data	O
suggest	B-Speculation
that	I-Speculation
ALD	I-Speculation
cause	I-Speculation
transient	I-Speculation
but	I-Speculation
significant	I-Speculation
changes	I-Speculation
in	I-Speculation
T	I-Speculation
cell	I-Speculation
transmembrane	I-Speculation
signaling	I-Speculation
,	O
although	O
some	B-Negation
events	I-Negation
induced	I-Negation
by	I-Negation
stimulation	I-Negation
with	I-Negation
anti-CD3	I-Negation
antibodies	I-Negation
are	I-Negation
not	I-Negation
induced	I-Negation
by	I-Negation
ALD	I-Negation
.	O

The	O
signal	O
is	O
transmitted	O
to	O
the	O
nucleus	O
and	O
induces	O
DNA-binding	O
activity	O
by	O
several	O
transcription	O
factors	O
.	O

However	O
,	O
the	O
ALD	O
stimulus	O
is	O
not	B-Negation
capable	I-Negation
of	I-Negation
causing	I-Negation
complete	I-Negation
T	I-Negation
cell	I-Negation
activation	I-Negation
.	O

Interleukin	O
(	O
IL	O
)	O
-10	O
inhibits	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
activation	O
in	O
human	O
monocytes	O
.	O

IL-10	O
and	O
IL-4	O
suppress	O
cytokine	O
synthesis	O
by	O
different	O
mechanisms	O
.	O

Our	O
previous	O
studies	O
in	O
human	O
monocytes	O
have	O
demonstrated	O
that	O
interleukin	O
(	O
IL	O
)	O
-10	O
inhibits	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-stimulated	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
IL-1	O
beta	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
by	O
blocking	O
gene	O
transcription	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
,	O
we	O
now	O
show	O
that	O
,	O
in	O
monocytes	O
stimulated	O
with	O
LPS	O
or	O
TNF	O
alpha	O
,	O
IL-10	O
inhibits	O
nuclear	O
stimulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
expression	O
of	O
inflammatory	O
cytokine	O
genes	O
.	O

Several	B-Negation
other	I-Negation
transcription	I-Negation
factors	I-Negation
including	I-Negation
NF-IL-6	I-Negation
,	I-Negation
AP-1	I-Negation
,	I-Negation
AP-2	I-Negation
,	I-Negation
GR	I-Negation
,	I-Negation
CREB	I-Negation
,	I-Negation
Oct-1	I-Negation
,	I-Negation
and	I-Negation
Sp-1	I-Negation
are	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
IL-10	I-Negation
.	O

This	O
selective	O
inhibition	O
by	O
IL-10	O
of	O
NF	O
kappa	O
B	O
activation	O
occurs	O
rapidly	O
and	O
in	O
a	O
dose-dependent	O
manner	O
and	O
correlates	O
well	O
with	O
IL-10	O
's	O
cytokine	O
synthesis	O
inhibitory	O
activity	O
in	O
terms	O
of	O
both	O
kinetics	O
and	O
dose	O
responsiveness	O
.	O

Furthermore	O
,	O
compounds	O
such	O
as	O
tosylphenylalanyl	O
chloromethyl	O
ketone	O
and	O
pyrrolidinedithiocarbamate	O
that	O
are	O
known	O
to	O
selectively	O
inhibit	O
NF	O
kappa	O
B	O
activation	O
block	O
cytokine	O
gene	O
transcription	O
in	O
LPS-stimulated	O
monocytes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
inhibition	O
of	O
NF	O
kappa	O
B	O
activation	O
may	O
be	O
an	O
important	O
mechanism	O
for	O
IL-10	O
suppression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

IL-4	O
,	O
another	O
cytokine	O
that	O
inhibits	O
cytokine	O
mRNA	O
accumulation	O
in	O
monocytes	O
,	O
shows	O
little	O
inhibitory	O
effect	O
on	O
LPS-induced	O
NF	O
kappa	O
B	O
activation	O
.	O

Further	O
examination	O
reveals	O
that	O
,	O
unlike	O
IL-10	O
,	O
IL-4	O
enhances	O
mRNA	O
degradation	O
and	O
does	O
not	B-Negation
suppress	I-Negation
cytokine	I-Negation
gene	I-Negation
transcription	I-Negation
.	O

These	O
data	O
indicate	O
that	O
IL-10	O
and	O
IL-4	O
inhibit	O
cytokine	O
production	O
by	O
different	O
mechanisms	O
.	O

Activation	O
of	O
transcription	O
by	O
binding	O
of	O
NF-E1	O
(	O
YY1	O
)	O
to	O
a	O
newly	O
identified	O
element	O
in	O
the	O
first	O
exon	O
of	O
the	O
human	O
DR	O
alpha	O
gene	O
.	O

A	O
previously	O
unrecognized	O
element	O
,	O
located	O
downstream	O
of	O
the	O
start	O
site	O
of	O
transcription	O
in	O
the	O
first	O
exon	O
of	O
the	O
DR	O
alpha	O
gene	O
,	O
has	O
been	O
defined	O
that	O
enhances	O
promoter	O
activity	O
up	O
to	O
eightfold	O
in	O
a	O
position-dependent	O
manner	O
.	O

Mutations	O
in	O
this	O
DNA-binding	O
site	O
abolished	O
binding	O
of	O
a	O
nuclear	O
factor	O
in	O
human	O
B	O
cell	O
nuclear	O
extract	O
and	O
decreased	O
the	O
activity	O
of	O
the	O
DR	O
alpha	O
promoter	O
to	O
a	O
basal	O
level	O
.	O

Significant	O
sequence	O
homology	O
of	O
this	O
element	O
was	O
found	O
in	O
the	O
DNA	O
of	O
the	O
DR	O
beta	O
,	O
DP	O
alpha	O
and	O
-beta	O
,	O
and	O
DQ	O
alpha	O
genes	O
,	O
always	O
located	O
downstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

The	O
nuclear	O
factor	O
binds	O
to	O
the	O
DR	O
alpha	O
and	O
DP	O
alpha	O
element	O
but	O
not	B-Negation
to	I-Negation
the	I-Negation
element	I-Negation
in	I-Negation
the	I-Negation
DQ	I-Negation
alpha	I-Negation
gene	I-Negation
.	O

It	O
was	O
identified	O
as	O
NF-E1	O
(	O
YY1	O
)	O
.	O

This	O
protein	O
,	O
previously	O
identified	O
by	O
its	O
binding	O
to	O
the	O
Ig	O
kappa	O
3	O
'	O
enhancer	O
and	O
the	O
Ig	O
heavy	O
chain	O
mu	O
E1	O
site	O
,	O
thus	O
also	O
appears	O
to	O
be	O
quite	O
important	O
in	O
the	O
regulation	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

Mouse	O
interleukin-2	O
receptor	O
alpha	O
gene	O
expression	O
.	O

Interleukin-1	O
and	O
interleukin-2	O
control	O
transcription	O
via	O
distinct	O
cis-acting	O
elements	O
.	O

We	O
have	O
shown	O
that	O
interleukin-1	O
(	O
IL-1	O
)	O
and	O
IL-2	O
control	O
IL-2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
transcription	O
in	O
CD4-CD8-	O
murine	O
T	O
lymphocyte	O
precursors	O
.	O

Here	O
we	O
map	O
the	O
cis-acting	O
elements	O
that	O
mediate	O
interleukin	O
responsiveness	O
of	O
the	O
mouse	O
IL-2R	O
alpha	O
gene	O
using	O
a	O
thymic	O
lymphoma-derived	O
hybridoma	O
(	O
PC60	O
)	O
.	O

The	O
transcriptional	O
response	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
to	O
stimulation	O
by	O
IL-1	O
+	O
IL-2	O
is	O
biphasic	O
.	O

IL-1	O
induces	O
a	O
rapid	O
,	O
protein	O
synthesis-independent	O
appearance	O
of	O
IL-2R	O
alpha	O
mRNA	O
that	O
is	O
blocked	O
by	O
inhibitors	O
of	O
NF-kappa	O
B	O
activation	O
.	O

It	O
also	O
primes	O
cells	O
to	O
become	O
IL-2	O
responsive	O
and	O
thereby	O
prepares	O
the	O
second	O
phase	O
,	O
in	O
which	O
IL-2	O
induces	O
a	O
100-fold	O
further	O
increase	O
in	O
IL-2R	O
alpha	O
transcripts	O
.	O

Transient	O
transfection	O
experiments	O
show	O
that	O
several	O
elements	O
in	O
the	O
promoter-proximal	O
region	O
of	O
the	O
IL-2R	O
alpha	O
gene	O
contribute	O
to	O
IL-1	O
responsiveness	O
,	O
most	O
importantly	O
an	O
NF-kappa	O
B	O
site	O
conserved	O
in	O
the	O
human	O
and	O
mouse	O
gene	O
.	O

IL-2	O
responsiveness	O
,	O
on	O
the	O
other	O
hand	O
,	O
depends	O
on	O
a	O
78-nucleotide	O
segment	O
1.3	O
kilobases	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

This	O
segment	O
functions	O
as	O
an	O
IL-2-inducible	O
enhancer	O
and	O
lies	O
within	O
a	O
region	O
that	O
becomes	O
DNase	O
I	O
hypersensitive	O
in	O
normal	O
T	O
cells	O
in	O
which	O
IL-2R	O
alpha	O
expression	O
has	O
been	O
induced	O
.	O

IL-2	O
responsiveness	O
requires	O
three	O
distinct	O
elements	O
within	O
the	O
enhancer	O
.	O

Two	O
of	O
these	O
are	O
potential	O
binding	O
sites	O
for	O
STAT	O
proteins	O
.	O

Coupling	O
of	O
a	O
signal	O
response	O
domain	O
in	O
I	O
kappa	O
B	O
alpha	O
to	O
multiple	O
pathways	O
for	O
NF-kappa	O
B	O
activation	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF-kappa	O
B	O
plays	O
a	O
central	O
role	O
in	O
the	O
induced	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
and	O
in	O
many	O
aspects	O
of	O
the	O
genetic	O
program	O
mediating	O
normal	O
T-cell	O
activation	O
and	O
growth	O
.	O

The	O
nuclear	O
activity	O
of	O
NF-kappa	O
B	O
is	O
tightly	O
regulated	O
from	O
the	O
cytoplasmic	O
compartment	O
by	O
an	O
inhibitory	O
subunit	O
called	O
I	O
kappa	O
B	O
alpha	O
.	O

This	O
cytoplasmic	O
inhibitor	O
is	O
rapidly	O
phosphorylated	O
and	O
degraded	O
in	O
response	O
to	O
a	O
diverse	O
set	O
of	O
NF-kappa	O
B-inducing	O
agents	O
,	O
including	O
T-cell	O
mitogens	O
,	O
proinflammatory	O
cytokines	O
,	O
and	O
viral	O
transactivators	O
such	O
as	O
the	O
Tax	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

To	O
explore	O
these	O
I	O
kappa	O
B	O
alpha-dependent	O
mechanisms	O
for	O
NF-kappa	O
B	O
induction	O
,	O
we	O
identified	O
novel	O
mutants	O
of	O
I	O
kappa	O
B	O
alpha	O
that	O
uncouple	O
its	O
inhibitory	O
and	O
signal-transducing	O
functions	O
in	O
human	O
T	O
lymphocytes	O
.	O

Specifically	O
,	O
removal	O
of	O
the	O
N-terminal	O
36	O
amino	O
acids	O
of	O
I	O
kappa	O
B	O
alpha	O
failed	B-Negation
to	I-Negation
disrupt	I-Negation
its	I-Negation
ability	I-Negation
to	I-Negation
form	I-Negation
latent	I-Negation
complexes	I-Negation
with	I-Negation
NF-kappa	I-Negation
B	I-Negation
in	I-Negation
the	I-Negation
cytoplasm	I-Negation
.	O

However	O
,	O
this	O
deletion	O
mutation	O
prevented	O
the	O
induced	O
phosphorylation	O
,	O
degradative	O
loss	O
,	O
and	O
functional	O
release	O
of	O
I	O
kappa	O
B	O
alpha	O
from	O
NF-kappa	O
B	O
in	O
Tax-expressing	O
cells	O
.	O

Alanine	O
substitutions	O
introduced	O
at	O
two	O
serine	O
residues	O
positioned	O
within	O
this	O
N-terminal	O
regulatory	O
region	O
of	O
I	O
kappa	O
B	O
alpha	O
also	O
yielded	O
constitutive	O
repressors	O
that	O
escaped	O
from	O
Tax-induced	O
turnover	O
and	O
that	O
potently	O
inhibited	O
immune	O
activation	O
pathways	O
for	O
NF-kappa	O
B	O
induction	O
,	O
including	O
those	O
initiated	O
from	O
antigen	O
and	O
cytokine	O
receptors	O
.	O

In	O
contrast	O
,	O
introduction	O
of	O
a	O
phosphoserine	O
mimetic	O
at	O
these	O
sites	O
rectified	O
this	O
functional	O
defect	O
,	O
a	O
finding	O
consistent	O
with	O
a	O
causal	O
linkage	O
between	O
the	O
phosphorylation	O
status	O
and	O
proteolytic	O
stability	O
of	O
this	O
cytoplasmic	O
inhibitor	O
.	O

Together	O
,	O
these	O
in	O
vivo	O
studies	O
define	O
a	O
critical	O
signal	O
response	O
domain	O
in	O
I	O
kappa	O
B	O
alpha	O
that	O
coordinately	O
controls	O
the	O
biologic	O
activities	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
NF-kappa	O
B	O
in	O
response	O
to	O
viral	O
and	O
immune	O
stimuli	O
.	O

HIV	O
type	O
1	O
protease	O
activation	O
of	O
NF-kappa	O
B	O
within	O
T	O
lymphoid	O
cells	O
.	O

NF-kappa	O
B	O
is	O
a	O
nuclear	O
protein	O
of	O
the	O
rel	O
oncogene	O
family	O
capable	O
of	O
enhancing	O
transcription	O
of	O
several	O
cellular	O
genes	O
,	O
including	O
IL-2	O
and	O
the	O
IL-2	O
receptor	O
,	O
and	O
viral	O
genes	O
transcribed	O
from	O
the	O
HIV-1	O
LTR	O
.	O

It	O
has	O
been	O
reported	O
that	O
HIV-1	O
protease	O
may	O
cleave	O
the	O
NF-kappa	O
B	O
precursor	O
to	O
its	O
active	O
form	O
in	O
vitro	O
.	O

In	O
this	O
study	O
the	O
effects	O
of	O
HIV	O
protease	O
on	O
NF-kappa	O
B	O
precursor	O
activation	O
were	O
examined	O
in	O
Jurkat	O
T	O
cells	O
by	O
introducing	O
a	O
protease	O
expression	O
vector	O
into	O
the	O
cells	O
.	O

Increased	O
NF-kappa	O
B	O
activity	O
was	O
observed	O
and	O
this	O
increased	O
activity	O
was	O
blocked	O
by	O
a	O
specific	O
inhibitor	O
of	O
the	O
viral	O
protease	O
.	O

Viral	O
transcription	O
,	O
as	O
measured	O
using	O
LTR-CAT	O
assays	O
,	O
was	O
only	O
slightly	O
enhanced	O
in	O
the	O
HIV-protease	O
expressing	O
cells	O
,	O
while	O
secretion	B-Negation
of	I-Negation
IL-2	I-Negation
and	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
IL-2	I-Negation
receptor	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
.	O

The	O
limited	O
activation	O
of	O
NF-kappa	O
B	O
by	O
HIV	O
protease	O
appears	O
unlikely	O
to	O
have	O
a	O
significant	O
effect	O
on	O
virus	O
expression	O
or	O
T	O
cell	O
function	O
.	O

The	O
retinoblastoma	O
gene	O
product	O
negatively	O
regulates	O
transcriptional	O
activation	O
mediated	O
by	O
the	O
human	O
cytomegalovirus	O
IE2	O
protein	O
.	O

The	O
IE2	O
gene	O
product	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
is	O
one	O
of	O
a	O
few	O
viral	O
regulatory	O
proteins	O
expressed	O
immediately	O
upon	O
infection	O
of	O
the	O
host	O
cell	O
.	O

It	O
is	O
a	O
potent	O
transcriptional	O
activator	O
of	O
many	O
viral	O
and	O
cellular	O
promoters	O
.	O

We	O
found	O
that	O
the	O
retinoblastoma	O
susceptibility	O
gene	O
product	O
(	O
Rb	O
)	O
dramatically	O
suppressed	O
this	O
IE2	O
transactivation	O
of	O
various	O
promoters	O
.	O

However	O
,	O
unlike	O
another	O
tumor	O
suppressor	O
protein	O
,	O
p53	O
,	O
Rb	O
did	O
not	O
have	O
any	O
significant	O
effect	O
on	O
basal	O
levels	O
of	O
transcription	O
,	O
suggesting	O
that	O
Rb	O
specifically	O
interacts	O
with	O
IE2	O
rather	O
than	O
other	O
cellular	O
factors	O
involved	O
in	O
the	O
general	O
transcription	O
machinery	O
.	O

We	O
found	O
by	O
protein-affinity	O
chromatography	O
that	O
Rb	O
in	O
nuclear	O
extracts	O
or	O
produced	O
by	O
in	O
vitro	O
translation	O
directly	O
bound	O
to	O
IE2	O
.	O

Our	O
results	O
suggest	O
that	O
Rb	O
may	O
regulate	O
the	O
life	O
cycle	O
of	O
HCMV	O
,	O
which	O
is	O
endemic	O
in	O
the	O
human	O
population	O
.	O

Furthermore	O
,	O
these	O
data	O
may	O
provide	O
new	O
insights	O
into	O
the	O
slow	O
rate	O
of	O
HCMV	O
DNA	O
replication	O
in	O
cells	O
and	O
the	O
possible	O
involvement	O
of	O
HCMV	O
in	O
tumorigenesis	O
.	O

Epstein-Barr	O
virus	O
replicative	O
gene	O
transcription	O
during	O
de	O
novo	O
infection	O
of	O
human	O
thymocytes	O
:	O
simultaneous	O
early	O
expression	O
of	O
BZLF-1	O
and	O
its	O
repressor	O
RAZ	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
known	O
to	O
infect	O
B	O
cells	O
and	O
epithelial	O
cells	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
EBV	O
can	O
also	O
infect	O
a	O
subset	O
of	O
thymocytes	O
.	O

Infection	O
of	O
thymocytes	O
was	O
accompanied	O
by	O
the	O
appearance	O
of	O
linear	O
EBV	O
genome	O
within	O
8	O
hr	O
of	O
infection	O
.	O

Circularization	B-Negation
of	I-Negation
the	I-Negation
EBV	I-Negation
genome	I-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
.	O

This	O
is	O
in	O
contrast	O
to	O
the	O
infection	O
in	O
B	O
cells	O
where	O
the	O
genome	O
can	O
circularize	O
within	O
24	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
the	O
BamHI	O
ZLF-1	O
gene	O
product	O
,	O
ZEBRA	O
,	O
by	O
RT-PCR	O
,	O
was	O
observed	O
within	O
8	O
hr	O
of	O
infection	O
.	O

The	O
appearance	O
of	O
a	O
novel	O
fusion	O
transcript	O
(	O
RAZ	O
)	O
,	O
which	O
comprised	O
regions	O
of	O
the	O
BZLF-1	O
locus	O
and	O
the	O
adjacent	O
BRLF-1	O
locus	O
,	O
was	O
detected	O
by	O
RT-PCR	O
.	O

ZEBRA	O
protein	O
was	O
also	O
identified	O
in	O
infected	O
thymocytes	O
by	O
immunoprecipitation	O
.	O

In	O
addition	O
,	O
we	O
demonstrated	O
that	O
the	O
EBNA-1	O
gene	O
in	O
infected	O
thymocytes	O
was	O
transcribed	O
from	O
the	O
Fp	O
promoter	O
,	O
rather	B-Negation
than	I-Negation
from	I-Negation
the	I-Negation
Cp/Wp	I-Negation
promoter	I-Negation
which	I-Negation
is	I-Negation
used	I-Negation
in	I-Negation
latently	I-Negation
infected	I-Negation
B	I-Negation
cells	I-Negation
.	O

Transcripts	O
encoding	O
gp350/220	O
,	O
the	O
major	O
coat	O
protein	O
of	O
EBV	O
,	O
were	O
identified	O
,	O
but	O
we	O
did	O
not	B-Negation
find	I-Negation
any	I-Negation
evidence	I-Negation
of	I-Negation
transcription	I-Negation
from	I-Negation
the	I-Negation
LMP-2A	I-Negation
or	I-Negation
EBER-1	I-Negation
loci	I-Negation
in	I-Negation
infected	I-Negation
thymocytes	I-Negation
.	O

These	O
observations	O
suggest	O
that	O
de	O
novo	O
EBV	O
infection	O
of	O
thymocytes	O
differs	O
from	O
infection	O
of	O
B	O
cells	O
.	O

The	O
main	O
difference	O
is	O
that	O
with	O
thymocytes	O
,	O
no	O
evidence	O
could	O
be	O
found	O
that	O
the	O
virus	O
ever	O
circularizes	O
.	O

Rather	O
,	O
EBV	O
remains	O
in	O
a	O
linear	O
configuration	O
from	O
which	O
replicative	O
genes	O
are	O
transcribed	O
.	O

Induction	O
of	O
Sp1	O
phosphorylation	O
and	O
NF-kappa	O
B-independent	O
HIV	O
promoter	O
domain	O
activity	O
in	O
T	O
lymphocytes	O
stimulated	O
by	O
okadaic	O
acid	O
.	O

In	O
contrast	O
to	O
the	O
purely	O
enhancer-dependent	O
effect	O
of	O
cytokines	O
such	O
as	O
TNF	O
on	O
the	O
activity	O
of	O
the	O
HIV	O
regulatory	O
region	O
(	O
LTR	O
)	O
,	O
we	O
observed	O
that	O
okadaic	O
acid	O
(	O
OKA	O
)	O
activates	O
HIV	O
transcription	O
through	O
both	O
the	O
enhancer	O
,	O
responding	O
to	O
the	O
factor	O
NF-kappa	O
B	O
,	O
and	O
the	O
promoter	O
domain	O
of	O
the	O
LTR	O
.	O

The	O
inducibility	O
of	O
HIV	O
LTR-driven	O
luciferase	O
expression	O
constructs	O
in	O
lymphoblastoid	O
cells	O
stimulated	O
by	O
OKA	O
depended	O
on	O
both	O
functional	O
Sp1	O
binding	O
elements	O
and	O
the	O
ability	O
of	O
the	O
TATA	O
box	O
to	O
bind	O
the	O
protein	O
TBP	O
.	O

In	O
both	O
transformed	O
and	O
normal	O
lymphocytes	O
,	O
OKA	O
stimulation	O
induced	O
intense	O
phosphorylation	O
of	O
the	O
constitutively	O
expressed	O
Sp1	O
protein	O
in	O
the	O
nucleus	O
,	O
a	O
property	O
of	O
OKA	O
not	B-Negation
shared	I-Negation
by	I-Negation
TNF	I-Negation
,	I-Negation
phorbol	I-Negation
ester	I-Negation
,	I-Negation
or	I-Negation
PHA	I-Negation
and	I-Negation
interleukin	I-Negation
2	I-Negation
.	O

Responsiveness	O
of	O
LTR	O
constructs	O
deleted	O
of	O
kappa	O
B	O
elements	O
to	O
HIV	O
Tat	O
expression	O
was	O
increased	O
upon	O
OKA	O
but	O
not	B-Negation
TNF	I-Negation
stimulation	I-Negation
.	O

Our	O
results	O
suggest	O
that	O
SP1	O
phosphorylation	O
induced	O
by	O
OKA	O
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
serine-threonine	O
phosphatase	O
PP2A	O
,	O
facilitates	O
the	O
formation	O
of	O
a	O
transcription	O
complex	O
involving	O
general	O
transcription	O
factors	O
,	O
HIV	O
Tat	O
,	O
and	O
Sp1	O
proteins	O
.	O

The	O
formation	O
of	O
this	O
complex	O
would	O
increase	O
,	O
independently	O
of	O
an	O
in	O
synergy	O
with	O
NF-kappa	O
B	O
,	O
the	O
low	O
basal	O
activity	O
of	O
the	O
HIV	O
LTR	O
observed	O
in	O
normal	O
T	O
lymphocytes	O
.	O

Human	O
MHC	O
class	O
II	O
gene	O
transcription	O
directed	O
by	O
the	O
carboxyl	O
terminus	O
of	O
CIITA	O
,	O
one	O
of	O
the	O
defective	O
genes	O
in	O
type	O
II	O
MHC	O
combined	O
immune	O
deficiency	O
.	O

Type	O
II	O
major	O
histocompatibility	O
complex	O
combined	O
immune	O
deficiency	O
(	O
type	O
II	O
MHC	O
CID	O
or	O
bare	O
lymphocyte	O
syndrome	O
)	O
is	O
a	O
congenital	O
immunodeficiency	O
disease	O
characterized	O
by	O
absent	B-Negation
MHC	I-Negation
class	I-Negation
II	I-Negation
expression	I-Negation
.	O

Four	O
distinct	O
complementation	O
groups	O
have	O
been	O
identified	O
.	O

Recently	O
,	O
the	O
defective	O
gene	O
in	O
group	O
II	O
type	O
II	O
MHC	O
CID	O
has	O
been	O
isolated	O
and	O
termed	O
CIITA	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
CIITA	O
is	O
an	O
MHC	O
class	O
II	O
gene-specific	O
transcription	O
activator	O
.	O

The	O
transcription	O
activation	O
function	O
is	O
provided	O
by	O
the	O
N-terminal	O
acidic	O
domain	O
(	O
amino	O
acids	O
26-137	O
)	O
,	O
which	O
is	O
experimentally	O
exchangeable	O
with	O
a	O
heterologous	O
viral	O
transcription-activating	O
domain	O
.	O

The	O
specificity	O
of	O
CIITA	O
for	O
three	O
major	O
MHC	O
class	O
II	O
genes	O
,	O
DR	O
,	O
DQ	O
and	O
DP	O
,	O
is	O
mediated	O
by	O
its	O
remaining	O
C-terminal	O
residues	O
(	O
amino	O
acids	O
317-1130	O
)	O
.	O

The	O
transactivation	O
of	O
multiple	O
cis	O
elements	O
,	O
especially	O
S	O
and	O
X2	O
,	O
of	O
the	O
DR	O
alpha	O
proximal	O
promoter	O
in	O
group	O
II	O
CID	O
cells	O
is	O
CIITA	O
dependent	O
.	O

Since	O
CIITA	O
overexpression	O
in	O
normal	O
cells	O
did	O
not	B-Negation
increase	I-Negation
class	I-Negation
II	I-Negation
expression	I-Negation
,	O
we	O
propose	B-Speculation
that	I-Speculation
initiation	I-Speculation
of	I-Speculation
CIITA	I-Speculation
expression	I-Speculation
serves	I-Speculation
as	I-Speculation
the	I-Speculation
on-off	I-Speculation
switch	I-Speculation
,	I-Speculation
while	I-Speculation
availability	I-Speculation
of	I-Speculation
downstream	I-Speculation
interactor	I-Speculation
(	I-Speculation
s	I-Speculation
)	I-Speculation
limits	I-Speculation
transcription	I-Speculation
.	O

Identification	O
of	O
two	O
novel	O
regulatory	O
elements	O
within	O
the	O
5'-untranslated	O
region	O
of	O
the	O
human	O
A	O
gamma-globin	O
gene	O
.	O

Interaction	O
between	O
the	O
stage	O
selector	O
element	O
(	O
SSE	O
)	O
in	O
the	O
proximal	O
gamma-globin	O
promoter	O
and	O
hypersensitivity	O
site	O
2	O
in	O
the	O
locus	O
control	O
region	O
partly	O
mediates	O
the	O
competitive	O
silencing	O
of	O
the	O
beta-globin	O
promoter	O
in	O
the	O
fetal	O
developmental	O
stage	O
.	O

We	O
have	O
now	O
demonstrated	O
that	O
a	O
second	O
SSE-like	O
element	O
in	O
the	O
5'-untranslated	O
region	O
of	O
the	O
gamma-gene	O
also	O
contributes	O
to	O
this	O
competitive	O
silencing	O
of	O
the	O
beta-gene	O
.	O

Utilizing	O
transient	O
transfection	O
assays	O
in	O
the	O
fetal	O
erythroid	O
cell	O
line	O
,	O
K562	O
,	O
we	O
have	O
shown	O
that	O
the	O
core	O
enhancer	O
of	O
hypersensitivity	O
site	O
2	O
can	O
preferentially	O
interact	O
with	O
the	O
proximal	O
gamma-promoter	O
in	O
the	O
absence	B-Negation
of	I-Negation
the	I-Negation
SSE	I-Negation
,	O
completely	O
silencing	O
a	O
linked	O
beta-promoter	O
.	O

Mutation	O
of	O
a	O
20-base	O
pair	O
sequence	O
of	O
the	O
gamma-gene	O
5'-untranslated	O
region	O
(	O
UTR	O
)	O
led	O
to	O
derepression	O
of	O
beta-promoter	O
activity	O
.	O

A	O
marked	O
activation	O
of	O
gamma-promoter	O
activity	O
was	O
also	O
observed	O
with	O
this	O
mutation	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
repressor	O
.	O

Fine	O
mutagenesis	O
dissected	O
these	O
activities	O
to	O
different	O
regions	O
of	O
the	O
5'-UTR	O
.	O

The	O
stage	O
selector	O
activity	O
was	O
localized	O
to	O
a	O
region	O
centered	O
on	O
nucleotides	O
+13	O
to	O
+15	O
.	O

Electromobility	O
shift	O
assays	O
utilizing	O
this	O
sequence	O
demonstrated	O
binding	O
of	O
a	O
fetal	O
and	O
erythroid-specific	O
protein	O
.	O

The	O
repressor	O
activity	O
of	O
the	O
5'-UTR	O
was	O
localized	O
to	O
tandem	O
GATA-like	O
sites	O
,	O
which	O
appear	O
to	O
bind	O
a	O
complex	O
of	O
two	O
proteins	O
,	O
one	O
of	O
which	O
is	O
the	O
erythroid	O
transcription	O
factor	O
GATA-1	O
.	O

These	O
results	O
indicate	O
that	O
the	O
5'-UTR	O
of	O
the	O
gamma-gene	O
contains	O
sequences	O
that	O
may	O
be	O
important	O
for	O
its	O
transcriptional	O
and	O
developmental	O
regulation	O
.	O

Abnormal	O
regulation	O
of	O
the	O
IL-2	O
promoter	O
in	O
lpr	O
CD4-CD8-	O
T	O
lymphocytes	O
results	O
in	O
constitutive	O
expression	O
of	O
a	O
novel	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells-binding	O
factor	O
.	O

The	O
inert	O
quality	O
of	O
MRL-Ipr/Ipr	O
(	O
Ipr	O
)	O
peripheral	O
CD4-CD8-	O
(	O
CD4-8-	O
)	O
T	O
cells	O
manifests	O
primarily	O
as	O
an	O
inability	O
to	O
proliferate	O
or	O
produce	O
IL-2	O
in	O
response	O
to	O
TCR	O
or	O
mitogenic	O
stimulation	O
.	O

Yet	O
these	O
same	O
cells	O
do	O
initiate	O
early	O
TCR-mediated	O
signaling	O
events	O
,	O
such	O
as	O
generation	O
of	O
inositol	O
phosphates	O
and	O
increased	O
intracellular	O
calcium	O
.	O

They	O
also	O
display	O
constitutively	O
high	O
levels	O
of	O
p59fyn	O
and	O
CD3	O
zeta	O
tyrosine	O
phosphorylation	O
.	O

The	O
generation	O
of	O
second	O
messengers	O
in	O
T	O
cells	O
normally	O
leads	O
to	O
downstream	O
signaling	O
that	O
results	O
in	O
transcriptional	O
activation	O
of	O
the	O
IL-2	O
gene	O
.	O

We	O
,	O
therefore	O
,	O
compared	O
the	O
activation	O
state	O
of	O
the	O
IL-2	O
gene	O
promoter	O
region	O
in	O
freshly	O
isolated	O
and	O
stimulated	O
Ipr	O
CD4-8-	O
T	O
cells	O
with	O
that	O
of	O
normal	O
T	O
lymphocytes	O
.	O

Levels	O
of	O
the	O
octamer	O
,	O
NF-kappa	O
B	O
(	O
p50-p65	O
heterodimer	O
)	O
,	O
and	O
AP-1	O
transcriptional	O
factors	O
are	O
constitutively	O
elevated	O
in	O
freshly	O
isolated	O
Ipr	O
CD4-8-	O
T	O
cells	O
,	O
consistent	O
with	O
the	O
activated	O
phenotype	O
of	O
these	O
cells	O
.	O

Upon	O
stimulation	O
with	O
mitogens	O
,	O
formation	O
of	O
the	O
transactivating	O
complex	O
,	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
,	O
occurs	O
with	O
normal	O
kinetics	O
in	O
Ipr	O
CD4-8-	O
T	O
cells	O
.	O

Yet	O
,	O
the	O
levels	O
of	O
the	O
activating	O
NF-AT	O
complex	O
never	O
reach	O
those	O
observed	O
in	O
similarly	O
stimulated	O
normal	O
T	O
cells	O
.	O

Furthermore	O
,	O
nuclear	O
extracts	O
from	O
Ipr	O
CD4-8-	O
T	O
cells	O
display	O
high	O
levels	O
of	O
a	O
novel	O
specific	O
binding	O
activity	O
at	O
the	O
NF-AT	O
site	O
,	O
which	O
is	O
present	O
at	O
much	O
lower	O
levels	O
in	O
freshly	O
isolated	O
normal	O
T	O
lymphocytes	O
.	O

Upon	O
mitogenic	O
stimulation	O
,	O
the	O
binding	O
activity	O
of	O
the	O
novel	O
NF-AT-binding	O
factor	O
is	O
rapidly	O
down-regulated	O
in	O
normal	O
T	O
cells	O
,	O
but	O
persists	O
at	O
high	O
levels	O
in	O
Ipr	O
CD4-8-	O
T	O
cells	O
.	O

These	O
two	O
abnormalities	O
at	O
the	O
NF-AT	O
site	O
provide	O
a	O
potential	O
mechanism	O
to	O
account	O
for	O
the	O
defect	O
in	O
IL-2	O
production	O
from	O
Ipr	O
CD4-8-	O
T	O
cells	O
.	O

GM-CSF	O
and	O
IL-2	O
share	O
common	O
control	O
mechanisms	O
in	O
response	O
to	O
costimulatory	O
signals	O
in	O
T	O
cells	O
.	O

Antigen	O
complexed	O
with	O
major	O
histocompatibility	O
complex	O
class	O
I	O
or	O
II	O
molecules	O
on	O
the	O
surface	O
of	O
antigen	O
presenting	O
cells	O
interacts	O
with	O
the	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
on	O
the	O
surface	O
of	O
T	O
cells	O
and	O
initiates	O
an	O
activation	O
cascade	O
.	O

So	O
called	O
costimulatory	O
signals	O
,	O
mediated	O
by	O
other	O
cell	O
surface	O
interactions	O
or	O
soluble	O
cytokines	O
produced	O
by	O
antigen	O
presenting	O
cells	O
,	O
are	O
also	O
required	O
for	O
complete	O
T	O
cell	O
activation	O
.	O

High	O
levels	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
also	O
required	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

The	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
requires	O
sequences	O
in	O
the	O
promoter	O
as	O
well	O
as	O
a	O
powerful	O
enhancer	O
located	O
3kb	O
upstream	O
to	O
respond	O
to	O
TCR-like	O
signals	O
.	O

These	O
promoter	O
and	O
enhancer	O
regions	O
are	O
mainly	O
activated	O
by	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

The	O
activation	O
of	O
NFAT	O
by	O
TCR	O
signals	O
has	O
been	O
well	O
described	O
for	O
interleukin-2	O
(	O
IL-2	O
)	O
and	O
IL-4	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

Costimulatory	O
signals	O
,	O
such	O
as	O
activation	O
of	O
the	O
CD28	O
cell	O
surface	O
molecule	O
on	O
T	O
cells	O
,	O
lead	O
to	O
activation	O
through	O
a	O
distinct	O
region	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
promoter	O
.	O

This	O
region	O
is	O
termed	O
the	O
CK-1	O
or	O
CD28RE	O
and	O
appears	O
to	O
bind	O
specific	O
members	O
of	O
the	O
NF-kappa	O
B	O
family	O
of	O
transcription	O
factors	O
.	O

Human	O
T	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
infects	O
T	O
cells	O
and	O
can	O
lead	O
to	O
increase	O
GM-CSF	O
expression	O
.	O

We	O
have	O
found	O
that	O
the	O
HTLV-1	O
transactivator	O
protein	O
,	O
tax	O
,	O
acts	O
as	O
a	O
costimulatory	O
signal	O
for	O
GM-CSF	O
and	O
IL-2	O
gene	O
transcription	O
,	O
in	O
that	O
it	O
can	O
cooperate	O
with	O
TCR	O
signals	O
to	O
mediate	O
high	O
level	O
gene	O
expression	O
.	O

Tax	O
activates	O
the	O
GM-CSF	O
promoter	O
through	O
the	O
CK-1/CD28RE	O
region	O
and	O
also	O
activates	O
nuclear	O
factor-kappa	O
B	O
binding	O
to	O
this	O
region	O
.	O

However	O
,	O
other	O
transcription	O
factors	O
or	O
coactivators	O
of	O
NF-kappa	O
B	O
are	O
required	O
for	O
tax	O
activation	O
but	O
these	O
remain	O
to	O
be	O
identified	O
.	O

The	O
CK-1/CD28RE	O
of	O
GM-CSF	O
shows	O
a	O
high	O
degree	O
of	O
similarity	O
to	O
the	O
IL-2	O
CD28RE	O
and	O
the	O
IL-3	O
gene	O
also	O
contains	O
a	O
related	O
region	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
fact	O
that	O
both	O
GM-CSF	O
and	O
IL-2	O
respond	O
to	O
TCR	O
signals	O
via	O
NFAT	O
,	O
implies	O
a	O
high	O
degree	O
of	O
conservation	O
in	O
the	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

MIP1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
,	O
a	O
novel	O
transcription	O
factor	O
expressed	O
in	O
hematopoietic	O
cells	O
that	O
is	O
crucial	O
for	O
transcription	O
of	O
the	O
human	O
MIP-1	O
alpha	O
gene	O
.	O

Murine	O
macrophage	O
inflammatory	O
protein	O
1	O
alpha	O
(	O
MIP-1	O
alpha	O
)	O
and	O
its	O
human	O
equivalent	O
(	O
GOS19	O
,	O
LD78	O
,	O
or	O
AT464	O
)	O
are	O
members	O
of	O
the	O
-C-C	O
family	O
of	O
low-molecular-weight	O
chemokines	O
.	O

Secreted	O
from	O
activated	O
T	O
cells	O
and	O
macrophages	O
,	O
bone	O
marrow-derived	O
MIP-1	O
alpha/GOS19	O
inhibits	O
primitive	O
hematopoietic	O
stem	O
cells	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
homeostatic	O
control	O
of	O
stem	O
cell	O
proliferation	O
.	O

It	O
also	O
induces	O
chemotaxis	O
and	O
inflammatory	O
responses	O
in	O
mature	O
cell	O
types	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
understand	O
the	O
mechanisms	O
which	O
control	O
the	O
expression	O
of	O
MIP-1	O
alpha/GOS19	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
in	O
Jurkat	O
T	O
cells	O
,	O
a	O
set	O
of	O
widely	O
expressed	O
transcription	O
factors	O
(	O
the	O
ICK-1	O
family	O
)	O
affect	O
the	O
GOS19	O
promoter	O
.	O

One	O
member	O
,	O
ICK-1A	O
,	O
behaves	O
as	O
a	O
strong	O
negative	O
regulator	O
.	O

In	O
this	O
communication	O
,	O
we	O
provide	O
evidence	O
that	O
the	O
pathway	O
of	O
induction	O
in	O
the	O
macrophage	O
cell	O
line	O
U937	O
is	O
different	O
from	O
that	O
in	O
Jurkat	O
cells	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
ICK-1	O
binding	O
site	O
does	O
not	B-Negation
confer	I-Negation
negative	I-Negation
regulation	I-Negation
in	I-Negation
U937	I-Negation
cells	I-Negation
.	O

We	O
provide	O
evidence	O
for	O
an	O
additional	O
binding	O
site	O
,	O
the	O
MIP-1	O
alpha	O
nuclear	O
protein	O
(	O
MNP	O
)	O
site	O
,	O
which	O
overlaps	O
the	O
ICK-1	O
site	O
.	O

Interaction	O
of	O
nuclear	O
extracts	O
from	O
various	O
cell	O
lines	O
and	O
tissue	O
with	O
the	O
MNP	O
site	O
leads	O
to	O
the	O
formation	O
of	O
fast-migrating	O
protein-DNA	O
complexes	O
with	O
similar	O
but	O
distinct	O
electrophoretic	O
mobilities	O
.	O

A	O
mutation	O
of	O
the	O
MNP	O
site	O
which	O
does	O
not	B-Negation
abrogate	I-Negation
ICK-1	I-Negation
binding	I-Negation
inactivates	O
the	O
GOS19.1	O
promoter	O
in	O
U937	O
cells	O
and	O
reduces	O
its	O
activity	O
by	O
fourfold	O
in	O
Jurkat	O
cells	O
.	O

We	O
propose	O
that	O
the	O
MNP	O
protein	O
(	O
s	O
)	O
binding	O
at	O
the	O
MNP	O
site	O
constitutes	O
a	O
novel	O
transcription	O
factor	O
(	O
s	O
)	O
expressed	O
in	O
hematopoietic	O
cells	O
.	O

Activation	O
of	O
pp90rsk	O
and	O
early	O
growth	O
response-1	O
gene	O
expression	O
by	O
pokeweed	O
mitogen	O
in	O
human	O
B	O
cells	O
.	O

The	O
present	O
studies	O
have	O
examined	O
the	O
effects	O
of	O
pokeweed	O
mitogen	O
(	O
PWM	O
)	O
on	O
the	O
induction	O
of	O
early	O
growth	O
response-1	O
gene	O
(	O
EGR-1	O
)	O
in	O
normal	O
human	O
B	O
cells	O
.	O

PWM	O
regulates	O
EGR-1	O
gene	O
expression	O
by	O
both	O
transcriptional	O
and	O
post-transcriptional	O
mechanisms	O
.	O

Transient	O
transfection	O
assays	O
with	O
EGR-1	O
promoter	O
fragments	O
linked	O
to	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
demonstrated	O
that	O
PWM	O
induced	O
EGR-1	O
transcription	O
is	O
conferred	O
by	O
the	O
CArG	O
motif	O
(	O
C	O
C	O
[	O
AT	O
]	O
6GG	O
)	O
in	O
the	O
EGR-1	O
promoter	O
.	O

The	O
results	O
further	O
demonstrated	O
the	O
activation	O
of	O
S6	O
kinase	O
(	O
pp90rsk	O
)	O
,	O
evidenced	O
by	O
phosphorylation	O
of	O
S6	O
and	O
serum	O
response	O
factor	O
(	O
SRF	O
)	O
peptides	O
,	O
in	O
PWM	O
treated	O
B	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
PWM	O
is	O
able	O
to	O
initiate	O
an	O
intracytoplasmic	O
signalling	O
cascade	O
and	O
EGR-1	O
induction	O
in	O
normal	O
human	O
B	O
cells	O
.	O

Modulation	O
of	O
transcription	O
factor	O
NF	O
kappa	O
B	O
activity	O
by	O
intracellular	O
glutathione	O
levels	O
and	O
by	O
variations	O
of	O
the	O
extracellular	O
cysteine	O
supply	O
.	O

HIV-infected	O
individuals	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
decreased	O
plasma	O
cysteine	O
and	O
cystine	O
concentrations	O
and	O
decreased	O
intracellular	O
glutathione	O
levels	O
.	O

We	O
now	O
show	O
that	O
a	O
depletion	O
of	O
intracellular	O
glutathione	O
in	O
a	O
human	O
T	O
cell	O
line	O
(	O
Molt-4	O
)	O
inhibits	O
the	O
activation	O
and	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF	O
kappa	O
B	O
,	O
whereas	O
incubation	O
with	O
increasing	O
extracellular	O
concentrations	O
of	O
cysteine	O
inhibits	O
the	O
DNA-binding	O
and	O
transactivating	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

Because	O
inhibition	O
of	O
DNA-binding	O
activity	O
is	O
associated	O
with	O
increasing	O
intracellular	O
glutathione	O
disulfide	O
levels	O
and	O
GSSG	O
can	O
be	O
shown	O
to	O
inhibit	O
the	O
DNA-binding	O
activity	O
directly	O
in	O
cell-free	O
systems	O
,	O
our	O
studies	O
suggest	O
that	O
GSSG	O
is	O
a	O
physiologically	O
relevant	O
inhibitor	O
in	O
intact	O
cells	O
also	O
.	O

NF	O
kappa	O
B	O
controls	O
many	O
immunologically	O
important	O
genes	O
,	O
so	O
our	O
studies	O
suggest	O
that	O
the	O
immune	O
system	O
may	O
be	O
sensitive	O
not	O
only	O
against	O
a	O
cysteine	O
and	O
glutathione	O
deficiency	O
but	O
also	O
against	O
an	O
excess	O
of	O
cysteine	O
.	O

Expression	O
of	O
Ah	O
receptor	O
(	O
TCDD	O
receptor	O
)	O
during	O
human	O
monocytic	O
differentiation	O
.	O

We	O
have	O
previously	O
found	O
a	O
high	O
expression	O
of	O
human	O
Ah	O
receptor	O
(	O
TCDD	O
receptor	O
)	O
mRNA	O
in	O
peripheral	O
blood	O
cells	O
of	O
individuals	O
.	O

In	O
this	O
paper	O
,	O
the	O
expression	O
of	O
this	O
gene	O
in	O
blood	O
cells	O
was	O
first	O
investigated	O
in	O
fractions	O
of	O
nucleated	O
cells	O
,	O
revealing	O
predominant	O
expression	O
of	O
the	O
Ah	O
receptor	O
gene	O
in	O
the	O
monocyte	O
fraction	O
.	O

Then	O
the	O
expression	O
levels	O
of	O
AhR	O
mRNA	O
in	O
various	O
hematopoietic	O
cell	O
lines	O
were	O
examined	O
together	O
with	O
those	O
of	O
Arnt	O
and	O
P450IA1	O
.	O

AhR	O
was	O
expressed	O
at	O
high	O
levels	O
in	O
monocytoid	O
U937	O
,	O
THP1	O
,	O
and	O
HEL/S	O
cells	O
,	O
and	O
at	O
moderate	O
levels	O
in	O
promyelocytic	O
HL60	O
cells	O
and	O
erythroblastic	O
HEL	O
cells	O
.	O

However	O
,	O
it	B-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
lymphoid	I-Negation
cells	I-Negation
MOLT4	I-Negation
(	I-Negation
T	I-Negation
cell	I-Negation
)	I-Negation
and	I-Negation
BALL1	I-Negation
(	I-Negation
B	I-Negation
cell	I-Negation
)	I-Negation
,	I-Negation
nor	I-Negation
in	I-Negation
K562	I-Negation
erythroblasts	I-Negation
.	O

Furthermore	O
,	O
a	O
specific	O
induction	O
of	O
AhR	O
during	O
monocytic	O
differentiation	O
was	O
investigated	O
in	O
HL60	O
and	O
HEL	O
cells	O
.	O

HL60	O
cells	O
were	O
induced	O
to	O
differentiate	O
toward	O
monocytes-macrophages	O
by	O
incubation	O
with	O
phorbol	O
ester	O
,	O
showing	O
a	O
5-	O
to	O
2-fold	O
increase	O
of	O
AhR	O
mRNA	O
.	O

The	O
incubation	O
with	O
transforming	O
growth	O
factor	O
beta	O
1	O
and	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
resulted	O
in	O
a	O
5-	O
to	O
7-fold	O
increase	O
of	O
AhR	O
mRNA	O
.	O

The	O
HEL	O
cells	O
also	O
exhibited	O
a	O
similar	O
elevation	O
of	O
AhR	O
mRNA	O
level	O
,	O
when	O
they	O
had	O
differentiated	O
toward	O
monocyte-macrophage	O
cells	O
by	O
these	O
combined	O
inducers	O
,	O
but	O
little	O
change	O
in	O
the	O
mRNA	O
level	O
was	O
observed	O
when	O
the	O
cells	O
were	O
induced	O
to	O
differentiate	O
into	O
other	O
cell	O
types	O
.	O

Treatment	O
of	O
the	O
differentiated	O
HL60	O
cells	O
with	O
3-methylcholanthrene	O
,	O
a	O
ligand	O
of	O
AhR	O
,	O
induced	O
the	O
expression	O
of	O
the	O
P450IA1	O
gene	O
.	O

These	O
results	O
indicated	O
that	O
expression	O
of	O
AhR	O
mRNA	O
was	O
significantly	O
induced	O
during	O
monocytic	O
differentiation	O
and	O
that	O
the	O
differentiated	O
cells	O
were	O
responsive	O
to	O
xenobiotics	O
.	O

Our	O
results	O
suggest	O
that	O
AhR	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
function	O
of	O
monocytes	O
and	O
also	O
in	O
the	O
eventual	O
activation	O
of	O
environmental	O
carcinogens	O
.	O

Platelet-activating	O
factor	O
(	O
PAF	O
)	O
positively	O
auto-regulates	O
the	O
expression	O
of	O
human	O
PAF	O
receptor	O
transcript	O
1	O
(	O
leukocyte-type	O
)	O
through	O
NF-kappa	O
B	O
.	O

The	O
human	O
platelet-activating	O
factor	O
receptor	O
(	O
PAFR	O
)	O
gene	O
is	O
transcribed	O
by	O
two	O
distinct	O
promoters	O
(	O
promoter	O
1	O
and	O
promoter	O
2	O
)	O
to	O
generate	O
two	O
transcripts	O
(	O
designated	O
as	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
)	O
,	O
though	O
their	O
open	O
reading	O
frames	O
are	O
identical	O
.	O

By	O
primer	O
extension	O
analysis	O
to	O
discriminate	O
two	O
transcripts	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
PAFR	O
transcript	O
1	O
(	O
leukocyte-type	O
)	O
,	O
but	O
not	B-Negation
PAFR	I-Negation
transcript	I-Negation
2	I-Negation
(	I-Negation
tissue-type	I-Negation
)	I-Negation
,	O
are	O
upregulated	O
by	O
PAF	O
as	O
well	O
as	O
by	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
in	O
the	O
human	O
stomach	O
cancer	O
cell	O
line	O
(	O
JR-St	O
cells	O
)	O
which	O
expresses	O
both	O
functional	O
PAFR	O
transcript	O
1	O
and	O
PAFR	O
transcript	O
2	O
endogenously	O
.	O

Functional	O
analysis	O
of	O
the	O
promoter	O
1	O
with	O
a	O
transient	O
expression	O
assay	O
using	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
gene	O
as	O
a	O
reporter	O
showed	O
that	O
both	O
PAF	O
and	O
TPA	O
activated	O
the	O
promoter	O
1	O
but	O
not	B-Negation
the	I-Negation
deleted	I-Negation
promoter	I-Negation
lacking	I-Negation
the	I-Negation
three	I-Negation
consensus	I-Negation
binding	I-Negation
sites	I-Negation
for	I-Negation
NF-kappa	I-Negation
B	I-Negation
located	I-Negation
from	I-Negation
-571	I-Negation
bp	I-Negation
to	I-Negation
-459	I-Negation
bp	I-Negation
.	O

These	O
findings	O
suggest	O
a	O
molecular	O
mechanism	O
of	O
positive	O
regulation	O
of	O
PAFR	O
gene	O
expression	O
by	O
PAF	O
through	O
NF-kappa	O
B	O
,	O
possibly	O
by	O
a	O
phosphorylation	O
reaction	O
involving	O
protein	O
kinase	O
C	O
by	O
PAF	O
.	O

Characterization	O
of	O
the	O
CD48	O
gene	O
demonstrates	O
a	O
positive	O
element	O
that	O
is	O
specific	O
to	O
Epstein-Barr	O
virus-immortalized	O
B-cell	O
lines	O
and	O
contains	O
an	O
essential	O
NF-kappa	O
B	O
site	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infection	O
of	O
mature	O
,	O
resting	O
B	O
cells	O
drives	O
them	O
to	O
become	O
lymphoblasts	O
expressing	O
high	O
levels	O
of	O
cell	O
surface	O
molecules	O
,	O
such	O
as	O
CD48	O
,	O
characteristically	O
expressed	O
on	O
normal	O
activated	O
B	O
cells	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
identification	O
of	O
an	O
enhancer	O
element	O
in	O
the	O
CD48	O
gene	O
which	O
reproducibly	O
confers	O
strong	O
transcriptional	O
activity	O
only	O
in	O
EBV-positive	O
B-lymphoblastoid	O
cell	O
lines	O
.	O

The	B-Negation
element	I-Negation
is	I-Negation
not	I-Negation
activated	I-Negation
upon	I-Negation
infection	I-Negation
of	I-Negation
established	I-Negation
EBV-negative	I-Negation
B-cell	I-Negation
lines	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
EBV	I-Speculation
fails	I-Speculation
to	I-Speculation
drive	I-Speculation
these	I-Speculation
cells	I-Speculation
to	I-Speculation
a	I-Speculation
fully	I-Speculation
lymphoblastoid	I-Speculation
phenotype	I-Speculation
.	O

An	O
NF-kappa	O
B	O
binding	O
site	O
is	O
an	O
essential	O
component	O
of	O
the	O
element	O
but	O
alone	O
is	O
not	B-Negation
sufficient	I-Negation
to	I-Negation
account	I-Negation
for	I-Negation
the	I-Negation
activity	I-Negation
or	I-Negation
the	I-Negation
specificity	I-Negation
of	I-Negation
the	I-Negation
element	I-Negation
.	O

We	O
have	O
detected	O
a	O
specific	O
nuclear	O
protein	O
complex	O
that	O
binds	O
to	O
the	O
element	O
and	O
show	O
that	O
NF-kappa	O
B1	O
(	O
p50	O
)	O
is	O
a	O
part	O
of	O
this	O
complex	O
.	O

The	O
EBV-encoded	O
latent	O
membrane	O
protein	O
1	O
is	O
capable	O
of	O
transactivating	O
the	O
isolated	O
CD48	O
NF-kappa	O
B	O
site	O
but	O
not	B-Negation
the	I-Negation
intact	I-Negation
element	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
latent	I-Speculation
membrane	I-Speculation
protein	I-Speculation
1-driven	I-Speculation
activation	I-Speculation
of	I-Speculation
NF-kappa	I-Speculation
B/Rel	I-Speculation
must	I-Speculation
interact	I-Speculation
with	I-Speculation
other	I-Speculation
regulatory	I-Speculation
pathways	I-Speculation
to	I-Speculation
control	I-Speculation
expression	I-Speculation
of	I-Speculation
cellular	I-Speculation
genes	I-Speculation
as	I-Speculation
EBV	I-Speculation
drives	I-Speculation
resting	I-Speculation
B	I-Speculation
cells	I-Speculation
into	I-Speculation
the	I-Speculation
cell	I-Speculation
cycle	I-Speculation
.	O

Distinct	O
roles	O
of	O
the	O
molecular	O
chaperone	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
via	O
the	O
basic	O
helix-loop-helix	O
and	O
PAS	O
domains	O
.	O

The	O
intracellular	O
dioxin	O
receptor	O
mediates	O
signal	O
transduction	O
by	O
dioxin	O
and	O
functions	O
as	O
a	O
ligand-activated	O
transcription	O
factor	O
.	O

It	O
contains	O
a	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
motif	O
contiguous	O
with	O
a	O
Per-Arnt-Sim	O
(	O
PAS	O
)	O
homology	O
region	O
.	O

In	O
extracts	O
from	O
nonstimulated	O
cells	O
the	O
receptor	O
is	O
recovered	O
in	O
an	O
inducible	O
cytoplasmic	O
form	O
associated	O
with	O
the	O
90-kDa	O
heat	O
shock	O
protein	O
(	O
hsp90	O
)	O
,	O
a	O
molecular	O
chaperone	O
.	O

We	O
have	O
reconstituted	O
ligand-dependent	O
activation	O
of	O
the	O
receptor	O
to	O
a	O
DNA-binding	O
form	O
by	O
using	O
the	O
dioxin	O
receptor	O
and	O
its	O
bHLH-PAS	O
partner	O
factor	O
Arnt	O
expressed	O
by	O
in	O
vitro	O
translation	O
in	O
reticulocyte	O
lysate	O
.	O

Deletion	O
of	O
the	O
PAS	O
domain	O
of	O
the	O
receptor	O
resulted	O
in	O
constitutive	O
dimerization	O
with	O
Arnt	O
.	O

In	O
contrast	O
,	O
this	O
receptor	O
mutant	O
showed	O
low	O
levels	O
of	O
xenobiotic	O
response	O
element-binding	O
activity	O
,	O
indicating	O
that	O
the	O
PAS	O
domain	O
may	O
be	O
important	O
for	O
DNA-binding	O
affinity	O
and/or	O
specificity	O
of	O
the	O
receptor	O
.	O

It	O
was	O
not	B-Negation
possible	I-Negation
to	I-Negation
reconstitute	I-Negation
dioxin	I-Negation
receptor	I-Negation
function	I-Negation
with	I-Negation
proteins	I-Negation
expressed	I-Negation
in	I-Negation
wheat	I-Negation
germ	I-Negation
lysate	I-Negation
.	O

In	O
line	O
with	O
these	O
observations	O
,	O
reticulocyte	O
lysate	O
but	O
not	B-Negation
wheat	I-Negation
germ	I-Negation
lysate	I-Negation
promoted	O
the	O
association	O
of	O
de	O
novo	O
synthesized	O
dioxin	O
receptor	O
with	O
hsp90	O
.	O

At	O
least	O
two	O
distinct	O
domains	O
of	O
the	O
receptor	O
mediated	O
interaction	O
with	O
hsp90	O
:	O
the	O
ligand-binding	O
domain	O
located	O
within	O
the	O
PAS	O
region	O
and	O
,	O
surprisingly	O
,	O
the	O
bHLH	O
domain	O
.	O

Whereas	O
ligand-binding	O
activity	O
correlated	O
with	O
association	O
with	O
hsp90	O
,	O
bHLH-hsp90	O
interaction	O
appeared	O
to	O
be	O
important	O
for	O
DNA-binding	O
activity	O
but	O
not	O
for	O
dimerization	O
of	O
the	O
receptor	O
.	O

Several	O
distinct	O
roles	O
for	O
hsp90	O
in	O
modulating	O
dioxin	O
receptor	O
function	O
are	O
therefore	O
likely	O
:	O
correct	O
folding	O
of	O
the	O
ligand-binding	O
domain	O
,	O
interference	O
with	O
Arnt	O
heterodimerization	O
,	O
and	O
folding	O
of	O
a	O
DNA-binding	O
conformation	O
of	O
the	O
bHLH	O
domain	O
.	O

Thus	O
,	O
the	O
dioxin	O
receptor	O
system	O
provides	O
a	O
complex	O
and	O
interesting	O
model	O
of	O
the	O
regulation	O
of	O
transcription	O
factors	O
by	O
hsp90	O
.	O

T-cell	O
functional	O
regions	O
of	O
the	O
human	O
IL-3	O
proximal	O
promoter	O
.	O

The	O
human	O
interleukin-3	O
(	O
IL-3	O
)	O
gene	O
is	O
expressed	O
almost	O
exclusively	O
in	O
activated	O
T	O
cells	O
.	O

Its	O
expression	O
is	O
regulated	O
at	O
both	O
the	O
transcriptional	O
and	O
post-transcriptional	O
level	O
.	O

We	O
have	O
previously	O
shown	O
that	O
treatment	O
of	O
Jurkat	O
T	O
cells	O
with	O
phytohemaglutinin	O
(	O
PHA	O
)	O
and	O
the	O
phorbol	O
ester	O
,	O
PMA	O
,	O
activated	O
transcription	O
initiation	O
from	O
the	O
IL-3	O
gene	O
.	O

To	O
define	O
the	O
regions	O
of	O
the	O
gene	O
required	O
for	O
transcription	O
activation	O
,	O
we	O
generated	O
a	O
series	O
of	O
reporter	O
constructs	O
containing	O
different	O
regions	O
of	O
the	O
IL-3	O
gene	O
5	O
'	O
and	O
3	O
'	O
flanking	O
sequences	O
.	O

Both	O
positive	O
and	O
negative	O
regulatory	O
elements	O
were	O
identified	O
in	O
the	O
proximal	O
5	O
'	O
flanking	O
region	O
of	O
the	O
IL-3	O
gene	O
.	O

The	O
promoter	O
region	O
between	O
-173	O
and	O
-60	O
contained	O
the	O
strongest	O
activating	O
elements	O
.	O

The	O
transcription	O
factor	O
AP-1	O
could	O
bind	O
to	O
this	O
positive	O
activator	O
region	O
of	O
the	O
promoter	O
.	O

We	O
also	O
examined	O
the	O
function	O
of	O
the	O
IL-3	O
CK-1/CK-2	O
elements	O
that	O
are	O
present	O
in	O
many	O
cytokine	O
genes	O
and	O
found	O
that	O
they	O
acted	O
as	O
a	O
repressor	O
of	O
basal	O
level	O
expression	O
when	O
cloned	O
upstream	O
of	O
a	O
heterologous	O
promoter	O
but	O
were	O
also	O
inducible	O
by	O
PMA/PHA	O
.	O

Two	O
distinct	O
signalling	O
pathways	O
are	O
involved	O
in	O
the	O
control	O
of	O
the	O
biphasic	O
junB	O
transcription	O
induced	O
by	O
interleukin-6	O
in	O
the	O
B	O
cell	O
hybridoma	O
7TD1	O
.	O

We	O
have	O
measured	O
the	O
level	O
of	O
junB	O
mRNA	O
in	O
the	O
B	O
hybridoma	O
cell	O
line	O
7TD1	O
,	O
under	O
interleukin-6	O
(	O
IL-6	O
)	O
stimulation	O
.	O

IL-6	O
increases	O
junB	O
mRNA	O
in	O
a	O
biphasic	O
fashion	O
.	O

The	O
first	O
early-induced	O
peak	O
was	O
transient	O
and	O
likely	O
corresponds	O
to	O
the	O
well	O
documented	O
typical	O
junB	O
mRNA	O
,	O
stimulated	O
in	O
response	O
to	O
numerous	O
growth	O
factors	O
,	O
including	O
IL-6	O
.	O

At	O
variance	O
,	O
the	O
second	O
peak	O
which	B-Negation
has	I-Negation
never	I-Negation
been	I-Negation
reported	I-Negation
previously	I-Negation
,	O
lasted	O
several	O
hours	O
.	O

As	O
a	O
consequence	O
of	O
its	O
effect	O
on	O
junB	O
mRNA	O
,	O
IL-6	O
stimulated	O
,	O
in	O
a	O
biphasic	O
fashion	O
,	O
the	O
nuclear	O
accumulation	O
of	O
the	O
JunB	O
protein	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrated	O
that	O
IL-6	O
regulation	O
occurred	O
exclusively	O
at	O
the	O
transcriptional	O
level	O
and	O
that	O
the	O
bimodal	O
increase	O
of	O
junB	O
mRNA	O
and	O
JunB	O
protein	O
can	O
be	O
accounted	O
for	O
by	O
a	O
biphasic	O
stimulation	O
of	O
junB	O
transcription	O
.	O

Furthermore	O
,	O
our	O
data	O
point	O
to	O
two	O
major	O
differences	O
between	O
the	O
mechanism	O
of	O
control	O
of	O
the	O
early	O
and	O
the	O
late	O
IL-6-induced	O
junB	O
transcription	O
waves	O
.	O

First	O
,	O
cycloheximide	O
strongly	O
potentiated	O
the	O
transcription	O
of	O
the	O
second	O
wave	O
,	O
whereas	O
it	O
failed	B-Negation
to	I-Negation
affect	I-Negation
the	I-Negation
early-induced	I-Negation
burst	I-Negation
.	O

Second	O
,	O
tyrphostin	O
,	O
a	O
tyrosine	O
kinase	O
inhibitor	O
,	O
impaired	O
the	O
expression	O
of	O
the	O
first	O
but	O
not	B-Negation
the	I-Negation
second	I-Negation
junB	I-Negation
mRNA	I-Negation
peak	I-Negation
.	O

Conversely	O
,	O
genistein	O
,	O
another	O
tyrosine	O
kinase	O
inhibitor	O
,	O
totally	O
abolished	O
the	O
expression	O
of	O
the	O
second	O
peak	O
of	O
junB	O
mRNA	O
whereas	O
it	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
first	I-Negation
peak	I-Negation
.	O

Altogether	O
these	O
data	O
indicate	O
that	O
,	O
in	O
7TD1	O
cells	O
,	O
IL-6	O
controls	O
junB	O
transcription	O
in	O
a	O
biphasic	O
fashion	O
by	O
means	O
of	O
two	O
separate	O
transduction	O
pathways	O
.	O

Biphasic	O
control	O
of	O
nuclear	O
factor-kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
complex	O
:	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
activation	O
by	O
the	O
T	O
cell	O
receptor	O
(	O
TcR	O
)	O
/CD3	O
complex	O
in	O
primary	O
human	O
T	O
cells	O
has	O
been	O
studied	O
at	O
various	O
times	O
after	O
activation	O
.	O

Only	O
p50	O
NF-kappa	O
B	O
protein	O
bound	O
the	O
kappa	O
B	O
element	O
of	O
interleukin-2	O
receptor	O
(	O
IL-2R	O
)	O
alpha	O
chain	O
promoter	O
on	O
resting	O
T	O
cells	O
.	O

However	O
,	O
immediately	O
after	O
TcR/CD3	O
cross-linking	O
(	O
after	O
approximately	O
1	O
h	O
;	O
immediate	O
)	O
binding	O
of	O
p50.p65	O
heterodimers	O
was	O
observed	O
.	O

p50.c-rel	O
heterodimers	O
were	O
also	O
detected	O
bound	O
to	O
this	O
sequence	O
at	O
early	O
time	O
points	O
(	O
7-16	O
h	O
;	O
early	O
)	O
,	O
and	O
both	O
remained	O
active	O
at	O
later	O
time	O
points	O
(	O
40	O
h	O
;	O
late	O
)	O
after	O
activation	O
.	O

This	O
regulation	O
takes	O
place	O
mainly	O
at	O
the	O
level	O
of	O
nuclear	O
translocation	O
of	O
p65	O
and	O
c-rel	O
,	O
at	O
immediate	O
and	O
early	O
time	O
points	O
.	O

Activation	O
also	O
induced	O
c-rel	O
and	O
p105/p50	O
mRNA	O
synthesis	O
,	O
but	O
not	B-Negation
p65	I-Negation
mRNA	I-Negation
whose	I-Negation
expression	I-Negation
was	I-Negation
constitutive	I-Negation
.	O

Interestingly	O
,	O
all	O
those	O
early	O
and	O
late	O
events	O
,	O
but	O
not	B-Negation
the	I-Negation
immediate	I-Negation
ones	I-Negation
,	O
were	O
inhibited	O
by	O
a	O
neutralizing	O
anti-tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
monoclonal	O
antibody	O
.	O

Similarly	O
,	O
cycloheximide	O
prevented	O
the	O
p65	O
and	O
c-rel	O
translocation	O
and	O
consequent	O
formation	O
of	O
active	O
binding	O
heterodimers	O
,	O
at	O
early	O
and	O
late	O
times	O
.	O

Cyclosporin	O
A	O
impaired	O
not	O
only	O
early	O
and	O
late	O
,	O
but	O
also	O
immediate	O
events	O
;	O
however	O
,	O
addition	O
of	O
TNF-alpha	O
prevented	O
all	O
inhibition	O
.	O

These	O
results	O
indicate	O
that	O
the	O
regulation	O
of	O
NF-kappa	O
B	O
activation	O
during	O
T	O
cell	O
activation	O
by	O
TcR/CD3	O
signals	O
is	O
biphasic	O
:	O
TcR/CD3	O
triggers	O
its	O
immediate	O
translocation	O
,	O
which	O
is	O
transient	O
if	O
no	O
TNF-alpha	O
is	O
present	O
.	O

TNF-alpha	O
,	O
therefore	O
,	O
emerges	O
as	O
the	O
main	O
factor	O
responsible	O
for	O
a	O
second	O
phase	O
of	O
NF-kappa	O
B	O
regulation	O
,	O
controlling	O
both	O
translocation	O
of	O
p65	O
and	O
c-rel	O
,	O
and	O
new	O
mRNA	O
synthesis	O
for	O
c-rel	O
and	O
p105/p50	O
.	O

Protein	O
kinase	O
C	O
is	O
not	B-Negation
a	I-Negation
downstream	I-Negation
effector	I-Negation
of	I-Negation
p21ras	I-Negation
in	I-Negation
activated	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
aim	O
of	O
this	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
,	O
downstream	O
of	O
p21ras	O
,	O
in	O
activating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
.	O

It	O
has	O
been	O
reported	O
that	O
PKC	O
is	O
an	O
effector	O
of	O
p21ras	O
in	O
T	O
cells	O
.	O

Data	O
is	O
presented	O
,	O
using	O
the	O
potent	O
and	O
selective	O
PKC	O
inhibitor	O
Ro	O
31-8425	O
and	O
transient	O
expression	O
of	O
a	O
constitutively	O
active	O
ras	O
mutant	O
,	O
which	O
clearly	O
shows	O
that	O
PKC	O
is	O
not	B-Negation
downstream	I-Negation
of	I-Negation
p21ras	I-Negation
in	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
NF-AT	I-Negation
and	I-Negation
AP-1	I-Negation
transcriptional	I-Negation
activity	I-Negation
and	I-Negation
in	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
IL-2	I-Negation
in	I-Negation
human	I-Negation
Jurkat	I-Negation
T	I-Negation
cells	I-Negation
.	O

Reporter	O
gene	O
experiments	O
demonstrated	O
that	O
NF-kappa	O
B	O
transcriptional	O
activity	O
is	O
not	B-Negation
affected	I-Negation
by	I-Negation
expression	I-Negation
of	I-Negation
activated	I-Negation
p21ras	I-Negation
.	O

The	O
signaling	O
pathways	O
involving	O
PKC	O
activation	O
,	O
calcium	O
mobilization	O
and	O
ras	O
activation	O
combine	O
to	O
provide	O
the	O
necessary	O
components	O
for	O
production	O
of	O
IL-2	O
during	O
T	O
cell	O
activation	O
.	O

Association	O
of	O
alterations	O
in	O
NF-kappa	O
B	O
moieties	O
with	O
HIV	O
type	O
1	O
proviral	O
latency	O
in	O
certain	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virally	O
encoded	O
and	O
cellular	O
proteins	O
.	O

A	O
wide	O
spectrum	O
of	O
levels	O
of	O
HIV-1	O
expression	O
have	O
been	O
demonstrated	O
in	O
various	O
cells	O
,	O
both	O
in	O
cell	O
culture	O
and	O
in	O
vivo	O
.	O

Molecular	O
mechanisms	O
leading	O
to	O
restricted	O
HIV-1	O
replication	O
may	O
differ	O
between	O
certain	O
cell	O
types	O
.	O

It	O
is	O
now	O
demonstrated	O
that	O
HIV-1	O
proviral	O
latency	O
in	O
the	O
monocytic	O
cell	O
line	O
U1	O
,	O
in	O
which	O
only	O
extremely	O
low	O
levels	O
of	O
HIV-1	O
expression	O
are	O
detected	O
in	O
the	O
baseline	O
unstimulated	O
state	O
,	O
is	O
associated	O
with	O
alterations	O
in	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
moieties	O
demonstrated	O
in	O
these	O
cells	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
and	O
in	O
situ	O
UV	O
cross-linking	O
studies	O
.	O

A	O
predominance	O
of	O
p50	O
NF-kappa	O
B	O
moieties	O
and	O
possibly	B-Speculation
p50	I-Speculation
homodimers	I-Speculation
or	I-Speculation
closely	I-Speculation
related	I-Speculation
species	I-Speculation
,	O
rather	B-Negation
than	I-Negation
the	I-Negation
p50-p56	I-Negation
heterodimer	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
that	I-Negation
is	I-Negation
the	I-Negation
predominant	I-Negation
NF-kappa	I-Negation
B	I-Negation
species	I-Negation
in	I-Negation
most	I-Negation
T	I-Negation
lymphocytic	I-Negation
and	I-Negation
monocytic	I-Negation
cells	I-Negation
,	O
is	O
demonstrated	O
in	O
the	O
nuclei	O
of	O
U1	O
cells	O
.	O

This	O
pattern	O
of	O
NF-kappa	O
B-related	O
moieties	O
differs	O
from	O
the	O
latently	O
infected	O
T	O
lymphocytic	O
cell	O
line	O
ACH-2	O
,	O
and	O
from	O
the	O
U937	O
monocytic	O
line	O
,	O
the	O
parental	O
cell	O
line	O
of	O
the	O
U1	O
cellular	O
clone	O
.	O

As	O
such	O
,	O
these	O
data	O
suggest	O
that	O
different	O
proximal	O
mechanisms	O
may	O
lead	O
to	O
restricted	O
HIV-1	O
replication	O
in	O
various	O
cell	O
types	O
.	O

Overexpression	O
of	O
protein	O
kinase	O
C-zeta	O
stimulates	O
leukemic	O
cell	O
differentiation	O
.	O

A	O
function	O
for	O
protein	O
kinase	O
C-zeta	O
(	O
PKC-zeta	O
)	O
,	O
a	O
member	O
of	O
the	O
phorbol	O
ester	O
nonresponsive	O
atypical	O
protein	O
kinase	O
C	O
subfamily	O
,	O
in	O
modulating	O
differentiation	O
was	O
examined	O
in	O
the	O
leukemic	O
U937	O
cell	O
.	O

Transfected	O
U937	O
cells	O
stably	O
overexpressing	O
PKC-zeta	O
displayed	O
a	O
longer	O
doubling	O
time	O
,	O
lower	O
saturation	O
density	O
at	O
confluency	O
,	O
and	O
an	O
increase	O
in	O
adherence	O
to	O
plastic	O
as	O
compared	O
to	O
control	O
cells	O
.	O

PKC-zeta	O
cells	O
expressed	O
a	O
more	O
differentiated	O
phenotype	O
as	O
assessed	O
by	O
changes	O
in	O
morphology	O
,	O
surface	O
antigen	O
expression	O
,	O
and	O
lysosomal	O
enzyme	O
activities	O
and	O
were	O
distinct	O
from	O
parental	O
U937	O
cells	O
stimulated	O
to	O
differentiate	O
by	O
exposure	O
to	O
phorbol	O
esters	O
.	O

In	O
contrast	O
to	O
parental	O
U937	O
cells	O
,	O
PKC-zeta	O
cells	O
constitutively	O
expressed	O
mRNA	O
transcripts	O
for	O
c-jun	O
and	O
a	O
low	O
mobility	O
AP-1	O
binding	O
activity	O
.	O

Thus	O
,	O
PKC-zeta	O
overexpression	O
stimulates	O
a	O
type	O
of	O
phenotypic	O
differentiation	O
that	O
differs	O
significantly	O
from	O
maturation	O
occurring	O
upon	O
activation	O
of	O
other	O
PKC	O
subfamilies	O
induced	O
by	O
phorbol	O
ester	O
treatment	O
.	O

Increased	O
expression	O
of	O
the	O
c-jun	O
protooncogene	O
and	O
an	O
increase	O
in	O
AP-1	O
binding	O
activity	O
in	O
PKC-zeta	O
cells	O
provides	O
a	O
potential	O
mechanism	O
for	O
explaining	O
the	O
altered	O
differentiation	O
status	O
of	O
this	O
cell	O
.	O

Posttranscriptional	O
regulation	O
of	O
macrophage	O
tissue	O
factor	O
expression	O
by	O
antioxidants	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
expression	O
by	O
cells	O
of	O
monocyte/macrophage	O
lineage	O
represents	O
an	O
important	O
mechanism	O
underlying	O
the	O
initiation	O
of	O
fibrin	O
deposition	O
at	O
sites	O
of	O
extravascular	O
inflammation	O
.	O

Recent	O
evidence	O
suggests	O
a	O
role	O
for	O
oxidant	O
stress	O
in	O
the	O
signalling	O
pathway	O
of	O
various	O
cell	O
types	O
by	O
virtue	O
of	O
its	O
ability	O
to	O
induce	O
DNA	O
binding	O
of	O
various	O
transcription	O
factors	O
,	O
including	O
nuclear	O
factor	O
kappa	O
B	O
and	O
AP-1	O
.	O

The	O
effect	O
of	O
antioxidant	O
treatment	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
TF	O
expression	O
was	O
examined	O
in	O
murine	O
peritoneal	O
macrophages	O
and	O
human	O
monocytes	O
.	O

Both	O
pyrrolidine	O
dithiocarbamate	O
,	O
an	O
oxidant	O
scavenger	O
,	O
and	O
N-acetyl-cysteine	O
,	O
a	O
precursor	O
of	O
the	O
endogenous	O
antioxidant	O
glutathione	O
,	O
inhibited	O
stimulation	O
of	O
macrophage	O
procoagulant	O
activity	O
by	O
LPS	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
neither	B-Negation
of	I-Negation
these	I-Negation
agents	I-Negation
reduced	I-Negation
LPS-stimulated	I-Negation
TF	I-Negation
mRNA	I-Negation
accumulation	I-Negation
,	O
thereby	O
suggesting	B-Speculation
a	I-Speculation
posttranscriptional	I-Speculation
mechanism	I-Speculation
for	I-Speculation
the	I-Speculation
effect	I-Speculation
.	O

Immunofluorescence	O
studies	O
of	O
human	O
monocytes	O
using	O
polyclonal	O
anti-TF	O
antibody	O
showed	O
that	O
N-acetyl-cysteine	O
treatment	O
prevented	O
the	O
characteristic	O
plasmalemmal	O
localization	O
of	O
TF	O
antigen	O
that	O
occurs	O
in	O
response	O
to	O
LPS	O
.	O

Western	O
blot	O
analysis	O
showed	O
that	O
N-acetyl-cysteine	O
reduced	O
the	O
accumulation	O
of	O
the	O
47-kD	O
mature	O
glycoprotein	O
in	O
LPS-treated	O
cells	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
results	O
of	O
the	O
immunofluorescence	O
studies	O
.	O

Furthermore	O
,	O
these	O
conditions	O
did	O
not	B-Negation
result	I-Negation
in	I-Negation
an	I-Negation
accumulation	I-Negation
of	I-Negation
the	I-Negation
less	I-Negation
mature	I-Negation
forms	I-Negation
of	I-Negation
TF	I-Negation
.	O

When	O
considered	O
together	O
,	O
these	O
data	O
suggest	O
that	O
antioxidants	O
exert	O
their	O
effects	O
by	O
impairing	O
translation	O
and/or	O
by	O
causing	O
degradation	O
of	O
newly	O
translated	O
protein	O
.	O

The	O
effect	O
of	O
antioxidants	O
on	O
tumor	O
necrosis	O
factor	O
appeared	O
to	O
be	O
species	O
specific	O
,	O
with	O
no	O
effect	O
on	O
LPS-induced	O
tumor	O
necrosis	O
factor	O
in	O
murine	O
cells	O
,	O
but	O
with	O
inhibition	O
in	O
human	O
monocytes	O
.	O

The	O
posttranscriptional	O
effect	O
of	O
antioxidants	O
on	O
TF	O
expression	O
data	O
suggests	O
a	O
novel	O
mechanism	O
whereby	O
these	O
agents	O
might	O
modulate	O
monocyte/macrophage	O
activation	O
.	O

Regulation	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
p105	O
in	O
monocytes	O
and	O
macrophages	O
persistently	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
.	O

The	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
human	O
monocytes/macrophages	O
are	O
partially	O
understood	O
.	O

Persistent	O
HIV	O
infection	O
of	O
U937	O
monocytic	O
cells	O
results	O
in	O
NF-kappa	O
B	O
activation	O
.	O

Whether	O
virus-induced	O
NF-kappa	O
B	O
activation	O
is	O
a	O
mechanism	O
that	O
favors	O
continuous	O
viral	O
replication	O
in	O
macrophages	O
remains	O
unknown	O
.	O

To	O
further	O
delineate	O
the	O
molecular	O
mechanisms	O
involved	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
in	O
HIV-infected	O
monocytes	O
and	O
macrophages	O
,	O
we	O
have	O
focused	O
on	O
the	O
regulation	O
of	O
the	O
I	O
kappa	O
B	O
molecules	O
.	O

First	O
,	O
we	O
show	O
that	O
persistent	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
not	O
only	O
in	O
monocytic	O
cells	O
but	O
also	O
in	O
macrophages	O
.	O

In	O
HIV-infected	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
protein	O
levels	O
are	O
decreased	O
secondary	O
to	O
enhanced	O
protein	O
degradation	O
.	O

This	O
parallels	O
the	O
increased	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
secondary	O
to	O
increased	O
I	O
kappa	O
B	O
alpha	O
gene	O
transcription	O
,	O
i.e.	O
,	O
increased	O
RNA	O
and	O
transcriptional	O
activity	O
of	O
its	O
promoter-enhancer	O
.	O

Another	O
protein	O
with	O
I	O
kappa	O
B	O
function	O
,	O
p105	O
,	O
is	O
also	O
modified	O
in	O
HIV-infected	O
cells	O
:	O
p105	O
and	O
p50	O
steady-state	O
protein	O
levels	O
are	O
increased	O
as	O
a	O
result	O
of	O
increased	O
synthesis	O
and	O
proteolytic	O
processing	O
of	O
p105	O
.	O

Transcriptional	O
activity	O
of	O
p105	O
is	O
also	O
increased	O
in	O
infected	O
cells	O
and	O
is	O
also	O
mediated	O
by	O
NF-kappa	O
B	O
through	O
a	O
specific	O
kappa	O
B	O
motif	O
.	O

These	O
results	O
demonstrate	O
the	O
existence	O
of	O
a	O
triple	O
autoregulatory	O
loop	O
in	O
monocytes	O
and	O
macrophages	O
involving	O
HIV	O
,	O
p105	O
and	O
p50	O
,	O
and	O
MAD3	O
,	O
with	O
the	O
end	O
result	O
of	O
persistent	O
NF-kappa	O
B	O
activation	O
and	O
viral	O
persistence	O
.	O

Furthermore	O
,	O
persistent	O
HIV	O
infection	O
of	O
monocytes	O
and	O
macrophages	O
provides	O
a	O
useful	O
model	O
with	O
which	O
to	O
study	O
concomitant	O
modifications	O
of	O
different	O
I	O
kappa	O
B	O
molecules	O
.	O

Expression	O
and	O
genomic	O
configuration	O
of	O
GM-CSF	O
,	O
IL-3	O
,	O
M-CSF	O
receptor	O
(	O
C-FMS	O
)	O
,	O
early	O
growth	O
response	O
gene-1	O
(	O
EGR-1	O
)	O
and	O
M-CSF	O
genes	O
in	O
primary	O
myelodysplastic	O
syndromes	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
seventeen	O
patients	O
with	O
primary	O
myelodysplastic	O
syndromes	O
(	O
MDS	O
)	O
in	O
advanced	O
stage	O
were	O
enriched	O
for	O
blasts	O
and	O
tested	O
for	O
(	O
1	O
)	O
karyotype	O
,	O
(	O
2	O
)	O
genomic	O
configuration	O
and	O
(	O
3	O
)	O
expression	O
of	O
IL-3	O
,	O
GM-CSF	O
,	O
FMS	O
and	O
EGR-1	O
genes	O
which	O
are	O
all	O
located	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
5	O
.	O

The	O
expression	O
of	O
the	O
M-CSF	O
gene	O
,	O
that	O
has	O
been	O
recently	O
reassigned	O
to	O
the	O
short	O
arm	O
of	O
chromosome	O
1	O
(	O
lp	O
)	O
,	O
was	O
also	O
investigated	O
.	O

Aims	O
of	O
the	O
study	O
were	O
to	O
(	O
1	O
)	O
assess	O
the	O
potential	O
role	O
of	O
the	O
expression	O
of	O
these	O
genes	O
in	O
the	O
maintenance	O
and	O
expansion	O
of	O
the	O
neoplastic	O
clones	O
and	O
(	O
2	O
)	O
search	O
for	O
constitutional	O
losses	O
or	O
rearrangements	O
of	O
one	O
allele	O
followed	O
by	O
a	O
deletion	O
of	O
the	O
second	O
allele	O
of	O
the	O
same	O
genes	O
in	O
the	O
leukemic	O
cells	O
.	O

The	O
latter	O
issue	O
was	O
investigated	O
by	O
comparing	O
,	O
in	O
8	O
cases	O
,	O
constitutive	O
DNA	O
from	O
skin	O
fibroblasts	O
with	O
leukemic	O
DNA	O
.	O

Eleven	O
of	O
the	O
17	O
patients	O
had	O
abnormal	O
karyotypes	O
.	O

The	O
M-CSF	O
gene	O
was	O
expressed	O
in	O
6	O
cases	O
and	O
the	O
FMS	O
and	O
the	O
EGR-1	O
genes	O
were	O
expressed	O
in	O
2	O
of	O
the	O
latter	O
cases	O
.	O

An	O
autocrine	O
mechanism	O
of	O
growth	O
could	O
be	O
hypothesized	O
only	O
for	O
the	O
2	O
patients	O
whose	O
cells	O
expressed	O
both	O
the	O
M-CSF	O
and	O
FMS	O
genes	O
.	O

No	B-Negation
germline	I-Negation
changes	I-Negation
or	I-Negation
rearrangements	I-Negation
were	I-Negation
observed	I-Negation
in	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
genes	I-Negation
studied	I-Negation
.	O

Thus	O
,	O
deregulation	B-Negation
of	I-Negation
genes	I-Negation
encoding	I-Negation
for	I-Negation
certain	I-Negation
hemopoietic	I-Negation
growth	I-Negation
factors	I-Negation
or	I-Negation
receptors	I-Negation
does	I-Negation
not	I-Negation
seem	B-Speculation
to	I-Speculation
represent	I-Speculation
a	I-Speculation
major	I-Speculation
mechanism	I-Speculation
of	I-Speculation
MDS	I-Speculation
progression	I-Speculation
.	O

OBF-1	O
,	O
a	O
novel	O
B	O
cell-specific	O
coactivator	O
that	O
stimulates	O
immunoglobulin	O
promoter	O
activity	O
through	O
association	O
with	O
octamer-binding	O
proteins	O
.	O

Recent	O
biochemical	O
and	O
genetic	O
studies	O
indicate	O
that	O
in	O
addition	O
to	O
the	O
octamer-binding	O
proteins	O
Oct-1	O
and	O
Oct-2	O
,	O
other	O
B	O
cell	O
components	O
are	O
required	O
for	O
lymphoid-restricted	O
,	O
octamer	O
site-mediated	O
immunoglobulin	O
gene	O
promoter	O
activity	O
.	O

Using	O
a	O
genetic	O
screen	O
in	O
yeast	O
,	O
we	O
have	O
isolated	O
B	O
cell-derived	O
cDNAs	O
encoding	O
Oct-binding	O
factor	O
1	O
(	O
OBF-1	O
)	O
,	O
a	O
novel	O
protein	O
that	O
specifically	O
associates	O
with	O
Oct-1	O
and	O
Oct-2	O
.	O

Biochemical	O
studies	O
demonstrate	O
that	O
OBF-1	O
has	O
no	B-Negation
intrinsic	I-Negation
DNA-binding	I-Negation
activity	I-Negation
and	O
recognizes	O
the	O
POU	O
domains	O
of	O
Oct-1	O
and	O
Oct-2	O
,	O
but	O
not	B-Negation
those	I-Negation
of	I-Negation
Oct-4	I-Negation
and	I-Negation
Oct-6	I-Negation
.	O

The	O
OBF-1	O
mRNA	O
is	O
expressed	O
in	O
a	O
highly	O
cell-specific	O
manner	O
,	O
being	O
most	O
abundant	O
in	O
B	O
cells	O
and	O
essentially	O
absent	B-Negation
in	I-Negation
most	I-Negation
of	I-Negation
the	I-Negation
other	I-Negation
cells	I-Negation
or	I-Negation
tissues	I-Negation
tested	I-Negation
.	O

Furthermore	O
,	O
expression	O
of	O
OBF-1	O
in	O
HeLa	O
cells	O
selectively	O
stimulates	O
the	O
activity	O
of	O
a	O
natural	O
immunoglobulin	O
promoter	O
in	O
an	O
octamer	O
site-dependent	O
manner	O
.	O

Thus	O
,	O
OBF-1	O
has	O
all	O
the	O
properties	O
expected	O
for	O
a	O
B	O
cell-specific	O
transcriptional	O
coactivator	O
protein	O
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
human	O
leukemic	O
cells	O
is	O
caused	O
by	O
the	O
repressive	O
function	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Induction	O
of	O
apoptosis	O
in	O
lymphocytes	O
,	O
which	O
may	O
account	O
for	O
the	O
therapeutic	O
effects	O
of	O
glucocorticoids	O
in	O
various	O
diseases	O
including	O
leukemia	O
,	O
depends	O
on	O
the	O
glucocorticoid	O
receptor	O
.	O

However	O
,	O
the	B-Negation
events	I-Negation
leading	I-Negation
from	I-Negation
the	I-Negation
activated	I-Negation
receptor	I-Negation
to	I-Negation
cell	I-Negation
lysis	I-Negation
are	I-Negation
not	I-Negation
understood	I-Negation
.	O

A	O
prevailing	O
hypothesis	O
postulates	O
induction	O
of	O
so-called	O
'lysis	O
genes	O
'	O
by	O
the	O
activated	O
receptor	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
an	O
activation-deficient	O
glucocorticoid	O
receptor	O
mutant	O
is	O
as	O
effective	O
as	O
the	O
wild-type	O
receptor	O
in	O
repression	O
of	O
AP-1	O
activity	O
,	O
inhibition	O
of	O
interleukin-2	O
production	O
,	O
inhibition	O
of	O
c-myc	O
expression	O
and	O
induction	O
of	O
apoptosis	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
retinoic	O
acid	O
can	O
also	O
induce	O
apoptosis	O
in	O
these	O
cells	O
through	O
the	O
retinoic	O
acid	O
receptor	O
,	O
whose	O
repressive	O
functions	O
but	O
not	B-Negation
target	I-Negation
site	I-Negation
specificity	I-Negation
,	O
are	O
similar	O
to	O
those	O
of	O
the	O
glucocorticoid	O
receptor	O
.	O

Therefore	O
,	O
the	O
primary	O
effect	O
of	O
the	O
receptor	O
in	O
glucocorticoid-mediated	O
apoptosis	O
correlates	O
with	O
transcriptional	O
repression	O
rather	B-Negation
than	I-Negation
activation	I-Negation
and	O
could	B-Speculation
be	I-Speculation
mediated	I-Speculation
by	I-Speculation
interference	I-Speculation
with	I-Speculation
other	I-Speculation
transcription	I-Speculation
factors	I-Speculation
required	I-Speculation
for	I-Speculation
cell	I-Speculation
survival	I-Speculation
.	O

Expression	O
of	O
the	O
Runt	O
domain-encoding	O
PEBP2	O
alpha	O
genes	O
in	O
T	O
cells	O
during	O
thymic	O
development	O
.	O

The	O
PEBP2	O
alpha	O
A	O
and	O
PEBP2	O
alpha	O
B	O
genes	O
encode	O
the	O
DNA-binding	O
subunit	O
of	O
a	O
murine	O
transcription	O
factor	O
,	O
PEBP2	O
,	O
which	O
is	O
implicated	O
as	O
a	O
T-cell-specific	O
transcriptional	O
regulator	O
.	O

These	O
two	O
related	O
genes	O
share	O
the	O
evolutionarily	O
conserved	O
region	O
encoding	O
the	O
Runt	O
domain	O
.	O

PEBP2	O
alpha	O
B	O
is	O
the	O
murine	O
counterpart	O
of	O
human	O
AML1	O
,	O
which	O
is	O
located	O
at	O
the	O
breakpoints	O
of	O
the	O
8	O
;	O
21	O
and	O
3	O
;	O
21	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

Northern	O
(	O
RNA	O
)	O
blots	O
of	O
various	O
adult	O
mouse	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
expression	O
of	O
both	O
genes	O
were	O
most	O
prominent	O
in	O
the	O
thymus	O
.	O

Furthermore	O
,	O
transcripts	O
of	O
PEBP2	O
alpha	O
A	O
and	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
were	O
detected	O
in	O
T	O
lymphocytes	O
in	O
the	O
thymuses	O
from	O
day	O
16	O
embryos	O
and	O
newborns	O
,	O
as	O
well	O
as	O
4-week-old	O
adult	O
mice	O
,	O
by	O
in	O
situ	O
hybridization	O
.	O

The	O
expression	O
of	O
the	O
genes	O
persisted	O
in	O
peripheral	O
lymph	O
nodes	O
of	O
adult	O
mice	O
.	O

The	O
transcripts	O
were	O
detected	O
in	O
all	O
the	O
CD4-	O
CD8-	O
,	O
CD4+	O
CD8+	O
,	O
CD4+	O
CD8-	O
,	O
and	O
CD4-	O
CD8+	O
cell	O
populations	O
.	O

The	O
results	O
indicated	O
that	O
both	O
genes	O
are	O
expressed	O
in	O
T	O
cells	O
throughout	O
their	O
development	O
,	O
supporting	O
the	O
notion	O
that	O
PEBP2	O
is	O
a	O
T-cell-specific	O
transcription	O
factor	O
.	O

Transcripts	O
of	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
were	O
also	O
detected	O
in	O
day	O
12	O
fetal	O
hematopoietic	O
liver	O
and	O
in	O
the	O
bone	O
marrow	O
cells	O
of	O
newborn	O
mice	O
.	O

The	O
implication	O
of	O
mouse	O
AML1/PEBP2	O
alpha	O
B	O
expression	O
in	O
hematopoietic	O
cells	O
other	O
than	O
those	O
of	O
T-cell	O
lineage	O
is	O
discussed	O
in	O
relation	O
to	O
myeloid	O
leukemogenesis	O
.	O

Regulation	O
of	O
cell-type-specific	O
interleukin-2	O
receptor	O
alpha-chain	O
gene	O
expression	O
:	O
potential	O
role	O
of	O
physical	O
interactions	O
between	O
Elf-1	O
,	O
HMG-I	O
(	O
Y	O
)	O
,	O
and	O
NF-kappa	O
B	O
family	O
proteins	O
.	O

The	O
interleukin	O
2	O
receptor	O
alpha-chain	O
(	O
IL-2R	O
alpha	O
)	O
gene	O
is	O
rapidly	O
and	O
potently	O
induced	O
in	O
T	O
cells	O
in	O
response	O
to	O
mitogenic	O
stimuli	O
.	O

Previously	O
,	O
an	O
inducible	O
enhancer	O
between	O
nucleotides	O
-299	O
and	O
-228	O
that	O
contains	O
NF-kappa	O
B	O
and	O
CArG	O
motifs	O
was	O
identified	O
.	O

We	O
now	O
report	O
the	O
characterization	O
of	O
a	O
second	O
essential	O
positive	O
regulatory	O
element	O
located	O
between	O
nucleotides	O
-137	O
and	O
-64	O
that	O
binds	O
Elf-1	O
and	O
HMG-I	O
(	O
Y	O
)	O
.	O

This	O
element	O
had	O
maximal	O
activity	O
in	O
lymphoid	O
cells	O
,	O
paralleling	O
the	O
cell	O
type	O
specificity	O
of	O
Elf-1	O
expression	O
.	O

Transcription	O
from	O
the	O
IL-2R	O
alpha	O
promoter	O
was	O
inhibited	O
when	O
either	O
the	O
Elf-1	O
or	O
the	O
HMG-I	O
(	O
Y	O
)	O
binding	O
site	O
was	O
mutated	O
.	O

Coexpression	O
of	O
both	O
proteins	O
activated	O
transcription	O
of	O
the	O
-137	O
to	O
-64	O
element	O
in	O
COS-7	O
cells	O
.	O

Elf-1	O
physically	O
associated	O
with	O
HMG-I	O
and	O
with	O
NF-kappa	O
B	O
p50	O
and	O
c-Rel	O
in	O
vitro	O
,	O
suggesting	O
that	O
protein-protein	O
interactions	O
might	O
functionally	O
coordinate	O
the	O
actions	O
of	O
the	O
upstream	O
and	O
downstream	O
positive	O
regulatory	O
elements	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
physical	O
interaction	O
between	O
an	O
Ets	O
family	O
member	O
and	O
NF-kappa	O
B	O
family	O
proteins	O
.	O

These	O
findings	O
provide	O
significant	O
new	O
insights	O
into	O
the	O
protein-protein	O
and	O
protein-DNA	O
interactions	O
that	O
regulate	O
cell-type-specific	O
and	O
inducible	O
IL-2R	O
alpha	O
gene	O
expression	O
and	O
also	O
have	O
implications	O
for	O
other	O
genes	O
regulated	O
by	O
Elf-1	O
and	O
NF-kappa	O
B	O
family	O
proteins	O
.	O

Effects	O
of	O
glucocorticoids	O
on	O
transcription	O
factor	O
activation	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Glucocorticoids	O
have	O
an	O
inhibitory	O
effect	O
on	O
inflammatory	O
and	O
immune	O
responses	O
,	O
and	O
this	O
may	O
be	O
through	O
the	O
modulation	O
of	O
transcription	O
factor	O
binding	O
to	O
DNA	O
.	O

The	O
interaction	O
of	O
the	O
transcription	O
factors	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
,	O
and	O
cAMP-responsive	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
with	O
DNA	O
and	O
glucocorticoid	O
receptors	O
(	O
GR	O
)	O
was	O
analyzed	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
gel	O
mobility	O
shift	O
assays	O
.	O

TNF-alpha	O
,	O
IL-1	O
beta	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
treatment	O
increased	O
AP-1	O
and	O
NF	O
kappa	O
B	O
DNA	O
binding	O
by	O
up	O
to	O
200	O
%	O
but	O
decreased	O
CREB	O
binding	O
(	O
38	O
%	O
)	O
over	O
a	O
60-min	O
time	O
course	O
.	O

Dexamethasone	O
produced	O
a	O
rapid	O
and	O
sustained	O
increase	O
in	O
glucocorticoid	O
response	O
element	O
binding	O
and	O
a	O
concomitant	O
40-50	O
%	O
decrease	O
in	O
AP-1	O
,	O
NF	O
kappa	O
B	O
,	O
and	O
CREB	O
DNA	O
binding	O
that	O
was	O
blocked	O
by	O
combined	O
dexamethasone	O
and	O
cytokine	O
or	O
PMA	O
treatment	O
.	O

These	O
latter	O
effects	O
were	O
due	O
to	O
increases	O
in	O
the	O
nuclear	O
localization	O
of	O
GR	O
,	O
not	B-Negation
to	I-Negation
reduced	I-Negation
amounts	I-Negation
of	I-Negation
the	I-Negation
other	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

This	O
suggests	O
that	O
in	O
these	O
cells	O
GR	O
within	O
the	O
nucleus	O
interacts	O
with	O
cytokine-stimulated	O
transcription	O
factors	O
by	O
the	O
process	O
of	O
cross	O
coupling	O
.	O

This	O
may	O
be	O
an	O
important	O
molecular	O
site	O
of	O
steroid	O
action	O
.	O

Isolation	O
of	O
cDNA	O
clones	O
for	O
42	O
different	O
Kruppel-related	O
zinc	O
finger	O
proteins	O
expressed	O
in	O
the	O
human	O
monoblast	O
cell	O
line	O
U-937	O
.	O

To	O
study	O
the	O
complexity	O
and	O
structural	O
characteristics	O
of	O
zinc	O
finger	O
proteins	O
expressed	O
during	O
human	O
hematopoiesis	O
and	O
to	O
isolate	O
novel	O
regulators	O
of	O
blood	O
cell	O
development	O
,	O
a	O
degenerate	O
oligonucleotide	O
probe	O
specific	O
for	O
a	O
consensus	O
zinc	O
finger	O
peptide	O
domain	O
was	O
used	O
to	O
isolate	O
63	O
cDNA	O
clones	O
for	O
Kruppel-related	O
zinc	O
finger	O
genes	O
from	O
the	O
human	O
monoblast	O
cell	O
line	O
U-937	O
.	O

By	O
extensive	O
nucleotide	O
sequence	O
and	O
Northern	O
blot	O
analysis	O
,	O
these	O
cDNA	O
clones	O
were	O
found	O
to	O
originate	O
from	O
approximately	O
42	O
different	O
genes	O
(	O
HZF	O
1-42	O
)	O
of	O
which	O
only	O
8	O
have	O
previously	O
been	O
described	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
a	O
majority	O
of	O
these	O
genes	O
were	O
expressed	O
at	O
comparable	O
levels	O
in	O
U-937	O
and	O
HeLa	O
cells	O
.	O

The	O
large	O
number	O
of	O
individual	O
genes	O
represented	O
among	O
the	O
63	O
clones	O
and	O
their	O
apparent	O
non-cell-type-specific	O
expression	O
suggest	O
that	O
the	O
majority	O
of	O
the	O
Kruppel-related	O
zinc	O
finger	O
genes	O
are	O
likely	O
to	O
be	O
expressed	O
in	O
most	O
human	O
tissues	O
.	O

In	O
contrast	O
,	O
some	O
of	O
the	O
genes	O
displayed	O
a	O
restricted	O
expression	O
pattern	O
,	O
indicating	O
that	O
they	O
represent	O
potential	O
regulators	O
of	O
monocyte	O
differentiation	O
or	O
proliferation	O
.	O

Detailed	O
structural	O
analysis	O
of	O
the	O
first	O
12	O
cDNAs	O
(	O
HZF	O
1-10	O
)	O
and	O
a	O
partial	O
characterization	O
of	O
HZF	O
11-42	O
revealed	O
that	O
a	O
common	O
feature	O
of	O
human	O
Kruppel-related	O
zinc	O
finger	O
proteins	O
is	O
the	O
presence	O
of	O
tandem	O
arrays	O
of	O
zinc	O
fingers	O
ranging	O
in	O
number	O
from	O
3	O
to	O
over	O
20	O
that	O
are	O
preferentially	O
located	O
in	O
the	O
carboxy-terminal	O
regions	O
of	O
the	O
proteins	O
.	O

In	O
addition	O
,	O
several	O
novel	O
KRAB-containing	O
zinc	O
finger	O
genes	O
and	O
a	O
novel	O
conserved	O
sequence	O
element	O
were	O
identified	O
.	O

Calcium/calmodulin-dependent	O
protein	O
kinase	O
II	O
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C-mediated	O
pathways	O
for	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
.	O

Engagement	O
of	O
the	O
T	O
cell	O
receptor	O
for	O
antigen	O
activates	O
phospholipase	O
C	O
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
.	O

Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin-dependent	O
kinases	O
including	O
the	O
multifunctional	O
Ca2+/calmodulin-dependent	O
protein	O
kinase	O
II	O
(	O
CaM-K	O
II	O
)	O
,	O
as	O
well	O
as	O
calcineurin	O
,	O
a	O
type	O
2B	O
protein	O
phosphatase	O
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	O
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM-K	O
II	O
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	O
and	O
phosphatases	O
(	O
gamma	O
B*CaM-K	O
and	O
delta	O
CaM-AI	O
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	O
gene	O
transcription	O
and	O
their	O
interactions	O
with	O
PKC-dependent	O
signaling	O
systems	O
.	O

gamma	O
B*CaM-K	O
and	O
delta	O
CaM-AI	O
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	O
T	O
cells	O
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	O
promoter	O
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
reporter	O
gene	O
.	O

Cotransfection	O
of	O
gamma	O
B*CaM-K	O
with	O
the	O
IL-2	O
promoter	O
construct	O
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	O
effect	O
of	O
CaM-K	O
II	O
on	O
IL-2	O
promoter	O
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF-AT	O
transactivating	O
pathways	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	O
CaM-AI	O
superinduced	O
IL-2	O
promoter	O
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	O
B*CaM-K	O
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	O
promoter	O
by	O
delta	O
CaM-AI	O
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	O
promoter	O
also	O
was	O
used	O
.	O

gamma	O
B*CaM-K	O
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	O
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	O
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM-K	O
II	O
may	O
exert	O
negative	O
influences	O
on	O
cytokine	O
gene	O
transcription	O
in	O
human	O
T	O
cells	O
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross-talk	O
with	O
the	O
calcineurin-	O
and	O
PKC-	O
dependent	O
signaling	O
systems	O
.	O

Control	O
of	O
I	O
kappa	O
B-alpha	O
proteolysis	O
by	O
site-specific	O
,	O
signal-induced	O
phosphorylation	O
.	O

I	O
kappa	O
B-alpha	O
inhibits	O
transcription	O
factor	O
NF-kappa	O
B	O
by	O
retaining	O
it	O
in	O
the	O
cytoplasm	O
.	O

Various	O
stimuli	O
,	O
typically	O
those	O
associated	O
with	O
stress	O
or	O
pathogens	O
,	O
rapidly	O
inactivate	O
I	O
kappa	O
B-alpha	O
.	O

This	O
liberates	O
NF-kappa	O
B	O
to	O
translocate	O
to	O
the	O
nucleus	O
and	O
initiate	O
transcription	O
of	O
genes	O
important	O
for	O
the	O
defense	O
of	O
the	O
organism	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
correlates	O
with	O
phosphorylation	O
of	O
I	O
kappa	O
B-alpha	O
and	O
requires	O
the	O
proteolysis	O
of	O
this	O
inhibitor	O
.	O

When	O
either	O
serine-32	O
or	O
serine-36	O
of	O
I	O
kappa	O
B-alpha	O
was	O
mutated	O
,	O
the	O
protein	O
did	O
not	B-Negation
undergo	I-Negation
signal-induced	I-Negation
phosphorylation	I-Negation
or	I-Negation
degradation	I-Negation
,	O
and	O
NF-kappa	B-Negation
B	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
activated	I-Negation
.	O

These	O
results	O
suggest	O
that	O
phosphorylation	O
at	O
one	O
or	O
both	O
of	O
these	O
residues	O
is	O
critical	O
for	O
activation	O
of	O
NF-kappa	O
B	O
.	O

HIV-1	O
Nef	O
leads	O
to	O
inhibition	O
or	O
activation	O
of	O
T	O
cells	O
depending	O
on	O
its	O
intracellular	O
localization	O
.	O

Nef	O
of	O
primate	O
lentiviruses	O
is	O
required	O
for	O
viremia	O
and	O
progression	O
to	O
AIDS	O
in	O
monkeys	O
.	O

Negative	O
,	O
positive	O
,	O
and	O
no	B-Negation
effects	I-Negation
of	I-Negation
Nef	I-Negation
have	O
also	O
been	O
reported	O
on	O
viral	O
replication	O
in	O
cells	O
.	O

To	O
reconcile	O
these	O
observations	O
,	O
we	O
expressed	O
a	O
hybrid	O
CD8-Nef	O
protein	O
in	O
Jurkat	O
cells	O
.	O

Two	O
opposite	O
phenotypes	O
were	O
found	O
,	O
which	O
depended	O
on	O
the	O
intracellular	O
localization	O
of	O
Nef	O
.	O

Expressed	O
in	O
the	O
cytoplasm	O
or	O
on	O
the	O
cell	O
surface	O
,	O
the	O
chimera	O
inhibited	O
or	O
activated	O
early	O
signaling	O
events	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
.	O

Activated	O
Jurkat	O
cells	O
died	O
by	O
apoptosis	O
,	O
and	O
only	O
cells	O
with	O
mutated	O
nef	O
genes	O
expressing	O
truncated	O
Nefs	O
survived	O
,	O
which	O
rendered	O
Nef	O
nonfunctional	O
.	O

These	O
mutations	O
paralleled	O
those	O
in	O
other	O
viral	O
strains	O
passaged	O
in	O
vitro	O
.	O

Not	O
only	O
do	O
these	O
positional	O
effects	O
of	O
Nef	O
reconcile	O
diverse	O
phenotypes	O
of	O
Nef	O
and	O
suggest	O
a	O
role	O
for	O
its	O
N-terminal	O
myristylation	O
,	O
but	O
they	O
also	O
explain	O
effects	O
of	O
Nef	O
in	O
HIV	O
infection	O
and	O
progression	O
to	O
AIDS	O
.	O

LMP-1	O
activates	O
NF-kappa	O
B	O
by	O
targeting	O
the	O
inhibitory	O
molecule	O
I	O
kappa	O
B	O
alpha	O
.	O

LMP-1	O
,	O
an	O
Epstein-Barr	O
virus	O
membrane	O
protein	O
expressed	O
during	O
latent	O
infection	O
,	O
has	O
oncogenic	O
properties	O
,	O
as	O
judged	O
from	O
its	O
ability	O
to	O
transform	O
B	O
lymphocytes	O
and	O
rodent	O
fibroblasts	O
.	O

LMP-1	O
induces	O
the	O
expression	O
of	O
bcl2	O
,	O
an	O
oncogene	O
which	O
protects	O
cells	O
from	O
apoptosis	O
,	O
as	O
well	O
as	O
of	O
genes	O
encoding	O
other	O
proteins	O
involved	O
in	O
cell	O
regulation	O
and	O
growth	O
control	O
.	O

The	O
mechanisms	O
by	O
which	O
LMP-1	O
upregulates	O
these	O
proteins	O
is	O
unknown	O
,	O
but	O
it	O
is	O
plausible	O
that	O
LMP-1	O
modifies	O
signal	O
transduction	O
pathways	O
that	O
result	O
in	O
the	O
activation	O
of	O
one	O
or	O
more	O
transcription	O
factors	O
that	O
ultimately	O
regulate	O
transcription	O
of	O
oncogenic	O
genes	O
.	O

NF-kappa	O
B	O
,	O
a	O
transcription	O
factor	O
controlling	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
activation	O
and	O
growth	O
control	O
,	O
has	O
been	O
shown	O
to	O
be	O
activated	O
by	O
LMP-1	O
.	O

The	O
mechanism	O
(	O
s	O
)	O
regulating	O
this	O
activation	O
remains	O
unknown	O
.	O

Our	O
data	O
indicate	O
that	O
increased	O
NF-kappa	O
B	O
DNA	O
binding	O
and	O
functional	O
activity	O
are	O
present	O
in	O
B-lymphoid	O
cells	O
stably	O
or	O
transiently	O
expressing	O
LMP-1	O
.	O

I	O
kappa	O
B	O
alpha	O
is	O
selectively	O
modified	O
in	O
LMP-1-expressing	O
B	O
cells	O
.	O

A	O
phosphorylated	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
increased	O
protein	O
turnover-degradation	O
correlate	O
with	O
increased	O
NF-kappa	O
B	O
nuclear	O
translocation	O
.	O

This	O
results	O
in	O
increased	O
transcription	O
of	O
NF-kappa	O
B-dependent-genes	O
,	O
including	O
those	O
encoding	O
p105	O
and	O
I	O
kappa	O
B	O
alpha	O
(	O
MAD3	O
)	O
.	O

These	O
results	O
indicate	O
that	O
LMP-1	O
activates	O
NF-kappa	O
B	O
in	O
B-cell	O
lines	O
by	O
targeting	O
I	O
kappa	O
B	O
alpha	O
.	O

Identification	O
of	O
the	O
pathways	O
activated	O
by	O
LMP-1	O
to	O
result	O
in	O
posttranslational	O
modifications	O
of	O
I	O
kappa	O
B	O
alpha	O
will	O
aid	O
in	O
determining	O
the	O
role	O
of	O
this	O
virus-host	O
cell	O
protein	O
interaction	O
in	O
Epstein-Barr	O
virus-mediated	O
oncogenesis	O
.	O

The	O
regulation	O
of	O
HIV	O
by	O
retinoic	O
acid	O
correlates	O
with	O
cellular	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
.	O

OBJECTIVES	O
:	O
To	O
analyze	O
the	O
effect	O
of	O
retinoic	O
acids	O
(	O
RA	O
)	O
on	O
HIV-1	O
expression	O
and	O
correlate	O
this	O
effect	O
with	O
expression	O
levels	O
of	O
RA	O
receptors	O
(	O
RARs	O
)	O
in	O
T-lymphoid	O
and	O
monocytoid	O
cell	O
lines	O
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
effect	O
of	O
all-trans	O
and	O
9-cis	O
RA	O
on	O
HIV-1	O
production	O
in	O
T-lymphoid	O
(	O
H9	O
,	O
CEM	O
)	O
and	O
monocytoid	O
(	O
U937	O
,	O
THP-1	O
)	O
cell	O
lines	O
was	O
measured	O
during	O
acute	O
and	O
chronic	O
infection	O
.	O

The	O
expression	O
levels	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
,	O
receptor	O
for	O
all-trans	O
RA	O
)	O
and	O
the	O
human	O
retinoid-X	O
receptor	O
alpha	O
(	O
hRXR	O
alpha	O
receptor	O
for	O
9-cis	O
RA	O
)	O
were	O
determined	O
by	O
Northern	O
blot	O
analysis	O
.	O

RESULTS	O
:	O
Both	O
all-trans	O
and	O
9-cis	O
RA	O
inhibited	O
virus	O
replication	O
in	O
HIV-1	O
IIIB-infected	O
monocytoid	O
cells	O
,	O
in	O
the	O
presence	O
and	O
absence	B-Negation
of	I-Negation
the	I-Negation
co-stimulatory	I-Negation
agent	I-Negation
phorbol	I-Negation
myristate	I-Negation
acetate	I-Negation
(	I-Negation
PMA	I-Negation
)	I-Negation
.	O

The	O
retinoids	O
had	O
weak	O
or	O
no	B-Negation
stimulatory	I-Negation
effects	I-Negation
on	I-Negation
HIV	I-Negation
production	I-Negation
by	I-Negation
T-cell	I-Negation
lines	I-Negation
.	O

HIV	O
production	O
by	O
PMA-stimulated	O
T-cell	O
lines	O
was	O
inhibited	O
by	O
these	O
retinoids	O
.	O

The	O
9-cis	O
RA	O
was	O
generally	O
more	O
effective	O
than	O
all-trans	O
RA	O
in	O
inhibiting	O
HIV	O
production	O
and	O
in	O
combination	O
generally	O
more	O
effective	O
than	O
the	O
single	O
agents	O
alone	O
.	O

Human	O
RAR	O
alpha	O
was	O
expressed	O
in	O
H9	O
,	O
U937	O
and	O
THP-1	O
cells	O
,	O
but	O
almost	O
undetectable	O
in	O
CEM	O
cells	O
.	O

Human	O
RXR	O
alpha	O
was	O
significantly	O
expressed	O
in	O
U937	O
and	O
THP-1	O
cells	O
,	O
weakly	O
expressed	O
in	O
H9	O
cells	O
and	O
not	B-Negation
detectable	I-Negation
in	I-Negation
CEM	I-Negation
cells	I-Negation
.	O

After	O
stimulation	O
by	O
PMA	O
,	O
RXR	O
alpha	O
expression	O
increased	O
in	O
H9	O
and	O
U937	O
cells	O
but	O
not	B-Negation
in	I-Negation
CEM	I-Negation
cells	I-Negation
.	O

Human	O
RAR	O
alpha	O
expression	O
was	O
unchanged	O
in	O
H9	O
and	O
CEM	O
cells	O
,	O
and	O
elevated	O
in	O
U937	O
cells	O
,	O
after	O
PMA	O
stimulation	O
.	O

CONCLUSION	O
:	O
The	O
effect	O
of	O
RA	O
on	O
HIV-1	O
expression	O
was	O
cell-type-dependent	O
and	O
partially	O
correlated	O
with	O
cellular	O
expression	O
of	O
RARs	O
.	O

Endogenous	O
or	O
exogenously	O
administered	O
RA	O
may	O
have	O
a	O
significant	O
role	O
in	O
HIV	O
regulation	O
.	O

Identification	O
of	O
human	O
TR2	O
orphan	O
receptor	O
response	O
element	O
in	O
the	O
transcriptional	O
initiation	O
site	O
of	O
the	O
simian	O
virus	O
40	O
major	O
late	O
promoter	O
[	O
published	O
erratum	O
appears	O
in	O
J	O
Biol	O
Chem	O
1995	O
Nov	O
3	O
;	O
270	O
(	O
44	O
)	O
:26721	O
]	O

A	O
DNA	O
response	O
element	O
(	O
TR2RE-SV40	O
)	O
for	O
the	O
TR2	O
orphan	O
receptor	O
,	O
a	O
member	O
of	O
the	O
steroid-thyroid	O
hormone	O
receptor	O
superfamily	O
,	O
has	O
been	O
identified	O
in	O
the	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
+55	O
region	O
(	O
nucleotide	O
numbers	O
368-389	O
,	O
5'-GTTAAGGTTCGTAGGTCATGGA-3	O
'	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
,	O
using	O
in	O
vitro	O
translated	O
TR2	O
orphan	O
receptor	O
with	O
a	O
molecular	O
mass	O
of	O
67	O
kilodaltons	O
,	O
showed	O
a	O
specific	O
binding	O
with	O
high	O
affinity	O
(	O
dissociation	O
constant	O
=	O
9	O
nM	O
)	O
for	O
this	O
DNA	O
sequence	O
.	O

DNA-swap	O
experiments	O
using	O
chloramphenicol	O
acetyl-transferase	O
assay	O
demonstrated	O
that	O
androgen	O
can	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
SV40	O
early	O
promoter	O
via	O
the	O
interaction	O
between	O
this	O
TR2RE-SV40	O
and	O
the	O
chimeric	O
receptor	O
AR/TR2/AR	O
with	O
the	O
DNA-binding	O
domain	O
of	O
the	O
TR2	O
orphan	O
receptor	O
flanked	O
by	O
the	O
N-terminal	O
and	O
androgen-binding	O
domains	O
of	O
the	O
androgen	O
receptor	O
.	O

In	O
addition	O
,	O
this	O
TR2RE-SV40	O
can	O
function	O
as	O
a	O
repressor	O
to	O
suppress	O
the	O
transcriptional	O
activities	O
of	O
both	O
SV40	O
early	O
and	O
late	O
promoters	O
.	O

Together	O
,	O
these	O
data	O
suggest	O
the	O
TR2RE-SV40	O
may	O
represent	O
the	O
first	O
identified	O
natural	O
DNA	O
response	O
element	O
for	O
the	O
TR2	O
orphan	O
receptor	O
that	O
may	O
function	O
as	O
a	O
repressor	O
for	O
the	O
SV40	O
gene	O
expression	O
.	O

Mapping	O
of	O
the	O
interaction	O
site	O
of	O
the	O
defective	O
transcription	O
factor	O
in	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
mutant	O
cell	O
line	O
clone-13	O
to	O
the	O
divergent	O
X2-box	O
.	O

We	O
have	O
previously	O
described	O
a	O
mutant	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Clone-13	O
,	O
that	O
expresses	O
HLA-DQ	O
in	O
the	O
absence	B-Negation
of	I-Negation
HLA-DR	I-Negation
and	I-Negation
-DP	I-Negation
.	O

Several	O
criteria	O
indicated	O
that	O
the	O
defect	O
in	O
this	O
cell	O
line	O
influences	O
the	O
activity	O
of	O
an	O
isotype-specific	O
transcription	O
factor	O
.	O

Indeed	O
,	O
transient	O
transfection	O
of	O
HLA-DRA	O
and	O
DQB	O
reporter	O
constructs	O
indicated	O
that	O
the	O
affected	O
factor	O
operates	O
via	O
cis-elements	O
located	O
between	O
-141	O
base	O
pairs	O
and	O
the	O
transcription	O
initiation	O
site	O
.	O

A	O
series	O
of	O
hybrid	O
DRA/DQB	O
reporter	O
constructs	O
was	O
generated	O
to	O
further	O
map	O
the	O
relevant	O
cis-elements	O
in	O
this	O
system	O
.	O

Insertion	O
of	O
oligonucleotides	O
spanning	O
the	O
DQB	O
X-box	O
(	O
but	O
not	B-Negation
the	I-Negation
DQB-W	I-Negation
region	I-Negation
or	I-Negation
the	I-Negation
DQB	I-Negation
Y-box	I-Negation
)	O
upstream	O
of	O
-141	O
in	O
a	O
DRA	O
reporter	O
plasmid	O
rescued	O
expression	O
to	O
nearly	O
wild-type	O
levels	O
.	O

Substitution	O
promoters	O
were	O
then	O
generated	O
where	O
the	O
entire	O
X-box	O
,	O
or	O
only	O
the	O
X1-	O
or	O
X2-boxes	O
of	O
HLA-DRA	O
were	O
replaced	O
with	O
the	O
analogous	O
regions	O
of	O
HLA-DQB	O
.	O

The	O
DQB	O
X2-box	O
was	O
able	O
to	O
restore	O
expression	O
to	O
the	O
silent	O
DRA	O
reporter	O
construct	O
.	O

Moreover	O
,	O
replacement	O
of	O
the	O
DQB	O
X2-box	O
with	O
the	O
DRA	O
X2-box	O
markedly	O
diminished	O
the	O
activity	O
of	O
the	O
DQB	O
promoter	O
in	O
the	O
mutant	O
cell	O
.	O

None	B-Negation
of	I-Negation
the	I-Negation
hybrid	I-Negation
reporter	I-Negation
constructs	I-Negation
were	I-Negation
defective	I-Negation
when	I-Negation
transfected	I-Negation
into	I-Negation
the	I-Negation
wild-type	I-Negation
,	I-Negation
HLA-DR/-DQ	I-Negation
positive	I-Negation
parental	I-Negation
cell	I-Negation
line	I-Negation
,	I-Negation
Jijoye	I-Negation
.	O

These	O
studies	O
suggest	O
that	O
the	O
divergent	O
X2-box	O
of	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
plays	O
an	O
important	O
role	O
in	O
influencing	O
differential	O
expression	O
of	O
the	O
human	O
class	O
II	O
isotypes	O
.	O

[	O
Regulation	O
of	O
transcription	O
of	O
the	O
interleukin-2	O
gene	O
in	O
B-lymphocytes	O
]	O

Since	O
most	O
B	O
cell	O
clones	O
immortalized	O
with	O
EBV	O
virus	O
can	O
be	O
induced	O
to	O
produce	O
interleukin-2	O
,	O
a	O
typical	O
T	O
cell	O
cytokine	O
,	O
we	O
studied	O
the	O
role	O
of	O
different	O
elements	O
of	O
the	O
IL-2	O
promoter	O
in	O
such	O
clones	O
by	O
transfection	O
.	O

It	O
was	O
found	O
,	O
in	O
particular	O
,	O
that	O
the	O
element	O
TCEd	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NF-kB	O
,	O
is	O
very	O
active	O
in	O
all	O
three	O
B	O
clones	O
tested	O
.	O

This	O
element	O
has	O
no	B-Negation
activity	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
of	I-Negation
the	I-Negation
Jurkat	I-Negation
line	I-Negation
.	O

The	O
NFATd	O
element	O
,	O
which	O
binds	O
the	O
transcription	O
factor	O
NFAT-1	O
and	O
is	O
very	O
active	O
in	O
T	O
cells	O
,	O
is	O
only	O
weakly	O
active	O
in	O
one	O
B	O
clone	O
and	O
not	B-Negation
at	I-Negation
all	I-Negation
in	I-Negation
another	I-Negation
.	O

Different	O
elements	O
thus	O
contribute	O
to	O
IL-2	O
promoter	O
activity	O
in	O
different	O
cells	O
.	O

ERP	O
,	O
a	O
new	O
member	O
of	O
the	O
ets	O
transcription	O
factor/oncoprotein	O
family	O
:	O
cloning	O
,	O
characterization	O
,	O
and	O
differential	O
expression	O
during	O
B-lymphocyte	O
development	O
.	O

The	O
ets	O
gene	O
family	O
encodes	O
a	O
group	O
of	O
proteins	O
which	O
function	O
as	O
transcription	O
factors	O
under	O
physiological	O
conditions	O
and	O
,	O
if	O
aberrantly	O
expressed	O
,	O
can	O
cause	O
cellular	O
transformation	O
.	O

We	O
have	O
recently	O
identified	O
two	O
regulatory	O
elements	O
in	O
the	O
murine	O
immunoglobulin	O
heavy-chain	O
(	O
IgH	O
)	O
enhancer	O
,	O
pi	O
and	O
microB	O
,	O
which	O
exhibit	O
striking	O
similarity	O
to	O
binding	O
sites	O
for	O
ets-related	O
proteins	O
.	O

To	O
identify	O
ets-related	O
transcriptional	O
regulators	O
expressed	O
in	O
pre-B	O
lymphocytes	O
that	O
may	O
interact	O
with	O
either	O
the	O
pi	O
or	O
the	O
microB	O
site	O
,	O
we	O
have	O
used	O
a	O
PCR	O
approach	O
with	O
degenerate	O
oligonucleotides	O
encoding	O
conserved	O
sequences	O
in	O
all	O
members	O
of	O
the	O
ets	O
family	O
.	O

We	O
have	O
cloned	O
the	O
gene	O
for	O
a	O
new	O
ets-related	O
transcription	O
factor	O
,	O
ERP	O
(	O
ets-related	O
protein	O
)	O
,	O
from	O
the	O
murine	O
pre-B	O
cell	O
line	O
BASC	O
6C2	O
and	O
from	O
mouse	O
lung	O
tissue	O
.	O

The	O
ERP	O
protein	O
contains	O
a	O
region	O
of	O
high	O
homology	O
with	O
the	O
ETS	O
DNA-binding	O
domain	O
common	O
to	O
all	O
members	O
of	O
the	O
ets	O
transcription	O
factor/oncoprotein	O
family	O
.	O

Three	O
additional	O
smaller	O
regions	O
show	O
homology	O
to	O
the	O
ELK-1	O
and	O
SAP-1	O
genes	O
,	O
a	O
subgroup	O
of	O
the	O
ets	O
gene	O
family	O
that	O
interacts	O
with	O
the	O
serum	O
response	O
factor	O
.	O

Full-length	O
ERP	O
expresses	O
only	O
negligible	O
DNA-binding	O
activity	O
by	O
itself	O
.	O

Removal	O
of	O
the	O
carboxy	O
terminus	O
enables	O
ERP	O
to	O
interact	O
with	O
a	O
variety	O
of	O
ets-binding	O
sites	O
including	O
the	O
E74	O
site	O
,	O
the	O
IgH	O
enhancer	O
pi	O
site	O
,	O
and	O
the	O
lck	O
promoter	O
ets	O
site	O
,	O
suggesting	O
a	O
carboxy-terminal	O
negative	O
regulatory	O
domain	O
.	O

At	O
least	O
three	O
ERP-related	O
transcripts	O
are	O
expressed	O
in	O
a	O
variety	O
of	O
tissues	O
.	O

However	O
,	O
within	O
the	O
B-cell	O
lineage	O
,	O
ERP	O
is	O
highly	O
expressed	O
primarily	O
at	O
early	O
stages	O
of	O
B-lymphocyte	O
development	O
,	O
and	O
expression	O
declines	O
drastically	O
upon	O
B-cell	O
maturation	O
,	O
correlating	O
with	O
the	O
enhancer	O
activity	O
of	O
the	O
IgH	O
pi	O
site	O
.	O

These	O
data	O
suggest	O
that	O
ERP	O
might	O
play	O
a	O
role	O
in	O
B-cell	O
development	O
and	O
in	O
IgH	O
gene	O
regulation	O
.	O

NF-kappa	O
B-dependent	O
and	O
-independent	O
pathways	O
of	O
HIV	O
activation	O
in	O
a	O
chronically	O
infected	O
T	O
cell	O
line	O
.	O

J	O
delta	O
K	O
cells	O
were	O
isolated	O
as	O
a	O
chronically	O
infected	O
survivor	O
cell	O
line	O
,	O
following	O
infection	O
of	O
Jurkat	O
CD4+	O
T	O
cells	O
with	O
dl-NF	O
,	O
a	O
mutated	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
containing	O
a	O
deletion	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
NF-kappa	O
B	O
sites	O
.	O

J	O
delta	O
K	O
cells	O
exhibited	O
very	O
low	O
levels	O
of	O
constitutive	O
HIV	O
production	O
.	O

HIV-1	O
expression	O
was	O
activated	O
from	O
J	O
delta	O
K	O
cells	O
by	O
treatment	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
sodium	O
butyrate	O
(	O
NaB	O
)	O
,	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
,	O
but	O
not	B-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha	I-Negation
(	I-Negation
TNF-alpha	I-Negation
)	I-Negation
,	O
confirming	O
the	O
role	O
of	O
NF-kappa	O
B	O
in	O
mediating	O
TNF-alpha	O
induction	O
of	O
HIV	O
transcription	O
.	O

The	O
strong	O
induction	O
of	O
HIV	O
expression	O
by	O
NaB	O
or	O
HMBA	O
in	O
J	O
delta	O
K	O
cells	O
clearly	O
demonstrates	O
the	O
existence	O
of	O
NF-kappa	O
B-independent	O
mechanisms	O
of	O
HIV	O
activation	O
in	O
chronically	O
infected	O
cells	O
.	O

J	O
delta	O
K	O
cells	O
may	O
provide	O
a	O
useful	O
model	O
for	O
characterizing	O
NF-kappa	O
B-independent	O
transcriptional	O
activation	O
of	O
the	O
HIV	O
LTR	O
.	O

Appraisal	O
of	O
potential	O
therapeutic	O
index	O
of	O
antioxidants	O
on	O
the	O
basis	O
of	O
their	O
in	O
vitro	O
effects	O
on	O
HIV	O
replication	O
in	O
monocytes	O
and	O
interleukin	O
2-induced	O
lymphocyte	O
proliferation	O
.	O

Antioxidant	O
molecules	O
have	O
been	O
suggested	O
to	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
HIV-infected	O
patients	O
.	O

To	O
evaluate	O
this	O
possibility	O
,	O
we	O
examined	O
in	O
vitro	O
the	O
effects	O
of	O
two	O
types	O
of	O
antioxidant	O
molecules	O
in	O
terms	O
of	O
inhibition	O
of	O
HIV	O
replication	O
in	O
monocytes	O
,	O
one	O
of	O
the	O
main	O
reservoirs	O
of	O
HIV	O
,	O
and	O
also	O
in	O
terms	O
of	O
modulation	O
of	O
the	O
immune	O
competence	O
as	O
measured	O
by	O
PBMC	O
proliferation	O
.	O

We	O
tested	O
the	O
effects	O
of	O
BHA	O
,	O
a	O
phenolic	O
,	O
lipid-soluble	O
,	O
chain-breaking	O
antioxidant	O
,	O
and	O
NAC	O
,	O
a	O
known	O
glutathione	O
precursor	O
with	O
some	O
direct	O
free-radical	O
scavenging	O
properties	O
as	O
well	O
,	O
on	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
in	O
latently	O
infected	O
U1	O
cells	O
and	O
in	O
productively	O
and	O
chronically	O
infected	O
U937	O
cells	O
.	O

Both	O
antioxidants	O
inhibited	O
TNF-	O
or	O
PMA-induced	O
NF-kappa	O
B	O
activity	O
in	O
U1	O
cells	O
,	O
as	O
well	O
as	O
the	O
sustained	O
NF-kappa	O
B	O
activity	O
permanently	O
induced	O
by	O
the	O
virus	O
itself	O
in	O
chronically	O
HIV-infected	O
U937	O
cells	O
.	O

This	O
resulted	O
in	O
only	O
a	O
partial	O
inhibition	O
of	O
TNF-	O
or	O
PMA-	O
induced	O
HIV	O
replication	O
in	O
U1	O
cells	O
,	O
and	O
no	B-Negation
detectable	I-Negation
effect	I-Negation
on	I-Negation
HIV	I-Negation
replication	I-Negation
in	I-Negation
chronically	I-Negation
infected	I-Negation
U937	I-Negation
cells	I-Negation
.	O

This	O
may	O
be	O
the	O
first	O
limitation	O
to	O
potential	O
antiviral	O
effects	O
of	O
antioxidant	O
therapies	O
.	O

Another	O
limitation	O
is	O
that	O
antioxidant	O
concentrations	O
high	O
enough	O
to	O
block	O
NK-kappa	O
B	O
activation	O
were	O
shown	O
to	O
have	O
a	O
suppressive	O
effect	O
on	O
immune	O
functions	O
in	O
vitro	O
,	O
because	O
NAC	O
and	O
BHA	O
blocked	O
IL-2-induced	O
PBMC	O
proliferation	O
.	O

These	O
data	O
warrant	O
prudence	O
in	O
the	O
design	O
of	O
antioxidant-based	O
therapies	O
aimed	O
at	O
suppressing	O
HIV	O
replication	O
.	O

Signals	O
transduced	O
through	O
the	O
CD4	O
molecule	O
on	O
T	O
lymphocytes	O
activate	O
NF-kappa	O
B	O
.	O

We	O
have	O
demonstrated	O
that	O
native	O
envelope	O
glycoproteins	O
of	O
HIV-1	O
,	O
gp160	O
can	O
induce	O
activation	O
of	O
the	O
transcription	O
factor	O
,	O
NF-kappa	O
B	O
.	O

The	O
stimulatory	O
effects	O
of	O
gp160	O
are	O
mediated	O
through	O
the	O
CD4	O
molecule	O
,	O
since	O
pretreatment	O
with	O
soluble	O
CD4	O
abrogates	O
its	O
activity	O
.	O

The	O
gp160-induced	O
NF-kappa	O
B	O
complex	O
consists	O
of	O
p65	O
,	O
p50	O
and	O
c-rel	O
proteins	O
.	O

The	O
stimulatory	O
effect	O
of	O
gp160	O
on	O
NF-kappa	O
B	O
activation	O
is	O
protein	O
synthesis	O
independent	O
,	O
is	O
dependent	O
upon	O
protein	O
tyrosine	O
phosphorylation	O
,	O
and	O
abrogated	O
by	O
inhibitors	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
gp160-mediated	O
activation	O
of	O
NF-kappa	O
B	O
in	O
CD4	O
positive	O
T	O
cells	O
may	O
be	O
involved	O
in	O
biological	O
effects	O
,	O
e.g.	O
,	O
enhanced	O
HIV	O
replication	O
,	O
hypergammaglobulinemia	O
,	O
increased	O
cytokine	O
secretion	O
,	O
hypercellularity	O
in	O
bone	O
marrow	O
and	O
apoptosis	O
.	O

Role	O
of	O
HIV-1	O
Nef	O
expression	O
in	O
activation	O
pathways	O
in	O
CD4+	O
T	O
cells	O
.	O

The	O
role	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV-1	O
)	O
Nef	O
protein	O
in	O
T	O
cell	O
activation	O
pathways	O
was	O
investigated	O
using	O
a	O
Jurkat	O
CD4+	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
Nef	O
expression	O
vector	O
.	O

Secretion	O
of	O
IL-2	O
and	O
TNF-alpha	O
,	O
surface	O
expression	O
of	O
IL-2R	O
,	O
and	O
DNA-binding	O
activity	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
(	O
Fos/Jun	O
)	O
complex	O
in	O
response	O
to	O
phorbol	O
myristate	O
acetate	O
,	O
TNF-alpha	O
,	O
or	O
immobilized	O
antibodies	O
to	O
CD3	O
were	O
monitored	O
.	O

These	B-Negation
parameters	I-Negation
were	I-Negation
not	I-Negation
modified	I-Negation
by	I-Negation
Nef	I-Negation
expression	I-Negation
in	I-Negation
Jurkat	I-Negation
cells	I-Negation
,	O
whereas	O
stimulation	O
with	O
the	O
same	O
stimuli	O
resulted	O
in	O
partial	O
inhibition	O
of	O
LTR	O
activation	O
in	O
Nef+	O
Jurkat	O
cells	O
.	O

This	B-Negation
inhibition	I-Negation
was	I-Negation
not	I-Negation
mediated	I-Negation
through	I-Negation
Nef	I-Negation
phosphorylation	I-Negation
on	I-Negation
Thr-15	I-Negation
or	I-Negation
GTP-binding	I-Negation
activity	I-Negation
because	O
mutations	O
in	O
critical	O
sites	O
did	O
not	B-Negation
alter	I-Negation
this	I-Negation
inhibition	I-Negation
.	O

Analysis	O
of	O
truncated	O
LTRs	O
confirmed	O
that	O
inhibition	O
of	O
LTR	O
activation	O
was	O
not	B-Negation
mediated	I-Negation
through	I-Negation
NF-kappa	I-Negation
B-binding	I-Negation
activity	I-Negation
but	O
through	O
the	O
region	O
containing	O
the	O
negative	O
responding	O
elements	O
(	O
NREs	O
)	O
.	O

These	O
results	O
suggest	O
that	O
Nef	O
downmodulates	O
LTR	O
activation	O
without	O
significantly	O
inhibiting	O
the	O
capacity	O
of	O
T	O
cells	O
to	O
respond	O
to	O
immunological	O
activations	O
.	O

A	O
low	O
NM23.H1	O
gene	O
expression	O
identifying	O
high	O
malignancy	O
human	O
melanomas	O
.	O

The	O
NM23	O
gene	O
has	O
been	O
proposed	O
as	O
a	O
metastasis-suppressor	O
gene	O
,	O
and	O
its	O
use	O
has	O
been	O
suggested	O
as	O
prognostic	O
factor	O
.	O

NM23	O
was	O
identified	O
in	O
a	O
system	O
of	O
murine	O
melanoma	O
cell	O
lines	O
,	O
in	O
which	O
an	O
inverse	O
relationship	O
was	O
found	O
between	O
NM23	O
expression	O
and	O
metastatic	O
ability	O
.	O

In	O
a	O
human	O
malignant	O
melanoma	O
study	O
NM23	O
expression	O
was	O
found	O
to	O
be	O
significantly	O
lower	O
in	O
metastases	O
that	O
developed	O
less	O
than	O
24	O
months	O
after	O
diagnosis	O
of	O
the	O
primary	O
tumours	O
.	O

The	O
present	O
paper	O
studies	O
the	O
expression	O
of	O
the	O
NM23.H1	O
gene	O
in	O
cell	O
lines	O
which	O
derive	O
from	O
primary	O
or	O
metastatic	O
human	O
malignant	O
melanomas	O
in	O
relation	O
to	O
staging	O
,	O
infiltration	O
degree	O
,	O
lymphocytic	O
infiltration	O
,	O
cell	O
morphology	O
,	O
cell	O
pigmentation	O
,	O
karyotype	O
,	O
and	O
disease-free	O
survival	O
.	O

The	O
level	O
of	O
mRNA	O
expression	O
of	O
the	O
NM23	O
gene	O
is	O
significantly	O
lower	O
in	O
cell	O
lines	O
that	O
derive	O
from	O
more	O
infiltrating	O
primary	O
melanomas	O
than	O
in	O
cell	O
lines	O
obtained	O
from	O
less	O
infiltrating	O
tumours	O
.	O

Moreover	O
,	O
cell	O
lines	O
derived	O
from	O
tumours	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
more	O
than	O
24	O
months	O
(	O
24-58	O
months	O
)	O
express	O
the	O
NM23	O
gene	O
at	O
higher	O
levels	O
than	O
cell	O
lines	O
obtained	O
from	O
melanomas	O
of	O
patients	O
with	O
a	O
disease-free	O
survival	O
of	O
less	O
than	O
24	O
months	O
(	O
6-15	O
months	O
)	O
.	O

T	O
cells	O
from	O
renal	O
cell	O
carcinoma	O
patients	O
exhibit	O
an	O
abnormal	O
pattern	O
of	O
kappa	O
B-specific	O
DNA-binding	O
activity	O
:	O
a	O
preliminary	O
report	O
.	O

Recent	O
data	O
suggest	O
that	O
the	O
poor	O
induction	O
of	O
a	O
T-cell	O
response	O
to	O
human	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
may	O
be	O
related	O
to	O
alterations	O
in	O
signal	O
transduction	O
pathways	O
.	O

We	O
report	O
that	O
T	O
cells	O
from	O
RCC	O
patients	O
have	O
two	O
alterations	O
in	O
kappa	O
B	O
motif-specific	O
DNA-binding	O
activity	O
.	O

The	O
first	O
alteration	O
involves	O
the	O
constitutive	O
expression	O
of	O
substantial	O
kappa	O
B-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
which	O
was	O
observed	O
in	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

The	O
magnitude	O
of	O
kappa	O
B	O
activity	O
in	O
unstimulated	O
patient	O
T	O
cells	O
was	O
similar	O
to	O
that	O
observed	O
in	O
T	O
cells	O
from	O
normal	O
individuals	O
that	O
had	O
been	O
activated	O
in	O
vitro	O
.	O

On	O
the	O
basis	O
of	O
Western	O
blotting	O
experiments	O
using	O
antibodies	O
to	O
kappa	O
B/Rel	O
family	O
proteins	O
,	O
the	O
kappa	O
B-binding	O
activity	O
constitutively	O
expressed	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
is	O
composed	O
mostly	O
of	O
the	O
NF-kappa	O
B1	O
(	O
p50	O
)	O
subunit	O
.	O

The	O
second	O
abnormality	O
in	O
kappa	O
B-binding	O
activity	O
in	O
T	O
cells	O
from	O
these	O
patients	O
is	O
that	O
RelA	B-Negation
,	I-Negation
a	I-Negation
member	I-Negation
of	I-Negation
the	I-Negation
Rel	I-Negation
homology	I-Negation
family	I-Negation
which	I-Negation
is	I-Negation
part	I-Negation
of	I-Negation
the	I-Negation
normal	I-Negation
NF-kappa	I-Negation
B	I-Negation
complex	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
induced	I-Negation
in	I-Negation
the	I-Negation
nucleus	I-Negation
following	I-Negation
activation	I-Negation
.	O

Western	O
blotting	O
analysis	O
did	O
not	B-Negation
detect	I-Negation
any	I-Negation
RelA	I-Negation
in	I-Negation
nuclear	I-Negation
extracts	I-Negation
either	I-Negation
before	I-Negation
or	I-Negation
after	I-Negation
stimulation	I-Negation
of	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
altered	O
kappa	O
B-binding	O
activity	O
in	O
T	O
cells	O
from	O
RCC	O
patients	O
may	O
impair	O
their	O
capacity	O
to	O
respond	O
normally	O
to	O
various	O
stimuli	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
in	O
vivo	O
is	O
regulated	O
by	O
multiple	O
phosphorylations	O
.	O

The	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
in	O
intact	O
cells	O
is	O
mechanistically	O
not	O
well	O
understood	O
.	O

Therefore	O
we	O
investigated	O
the	O
modifications	O
imposed	O
on	O
NF-kappa	O
B/I	O
kappa	O
B	O
components	O
following	O
stimulation	O
and	O
show	O
that	O
the	O
final	O
step	O
of	O
NF-kappa	O
B	O
induction	O
in	O
vivo	O
involves	O
phosphorylation	O
of	O
several	O
members	O
of	O
the	O
NF-kappa	O
B/I	O
kappa	O
B	O
protein	O
families	O
.	O

In	O
HeLa	O
cells	O
as	O
well	O
as	O
in	O
B	O
cells	O
,	O
TNF-alpha	O
rapidly	O
induced	O
nuclear	O
translocation	O
primarily	O
of	O
p50-p65	O
,	O
but	O
not	B-Negation
of	I-Negation
c-rel	I-Negation
.	O

Both	O
NF-kappa	O
B	O
precursors	O
and	O
I	O
kappa	O
B	O
alpha	O
became	O
strongly	O
phosphorylated	O
with	O
the	O
same	O
kinetics	O
.	O

In	O
addition	O
to	O
the	O
inducible	O
phosphorylation	O
after	O
stimulation	O
,	O
B	O
lymphocytes	O
containing	O
constitutive	O
nuclear	O
NF-kappa	O
B	O
revealed	O
constitutively	O
phosphorylated	O
p65	O
and	O
I	O
kappa	O
B	O
alpha	O
.	O

Phosphorylation	O
was	O
accompanied	O
by	O
induced	O
processing	O
of	O
the	O
precursors	O
p100	O
and	O
p105	O
and	O
by	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

As	O
an	O
in	O
vitro	O
model	O
we	O
show	O
that	O
phosphorylation	O
of	O
p105	O
impedes	O
its	O
ability	O
to	O
interact	O
with	O
NF-kappa	O
B	O
,	O
as	O
has	O
been	O
shown	O
before	O
for	O
I	O
kappa	O
B	O
alpha	O
.	O

Surprisingly	O
,	O
even	O
p65	O
,	O
but	O
not	B-Negation
c-rel	I-Negation
,	O
was	O
phosphorylated	O
after	O
induction	O
in	O
vivo	O
,	O
suggesting	B-Speculation
that	I-Speculation
TNF-alpha	I-Speculation
selectively	I-Speculation
activates	I-Speculation
only	I-Speculation
specific	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
heteromers	I-Speculation
and	I-Speculation
that	I-Speculation
modifications	I-Speculation
regulate	I-Speculation
not	I-Speculation
only	I-Speculation
I	I-Speculation
kappa	I-Speculation
B	I-Speculation
molecules	I-Speculation
but	I-Speculation
also	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
molecules	I-Speculation
.	O

In	O
fact	O
,	O
cellular	O
NF-kappa	O
B	O
activity	O
was	O
phosphorylation-dependent	O
and	O
the	O
DNA	O
binding	O
activity	O
of	O
p65-containing	O
NF-kappa	O
B	O
was	O
enhanced	O
by	O
phosphorylation	O
in	O
vitro	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
induction	O
by	O
hydrogen	O
peroxide	O
of	O
NF-kappa	O
B	O
translocation	O
to	O
the	O
nucleus	O
,	O
which	O
is	O
assumed	O
to	O
be	O
triggered	O
by	O
reactive	O
oxygen	O
intermediates	O
,	O
also	O
coincided	O
with	O
incorporation	O
of	O
phosphate	O
into	O
the	O
same	O
subunits	O
that	O
were	O
modified	O
after	O
stimulation	O
by	O
TNF-alpha	O
.	O

Thus	O
,	O
phosphorylation	O
appears	O
to	O
be	O
a	O
general	O
mechanism	O
for	O
activation	O
of	O
NF-kappa	O
B	O
in	O
vivo	O
.	O

An	O
active	O
v-abl	O
protein	O
tyrosine	O
kinase	O
blocks	O
immunoglobulin	O
light-chain	O
gene	O
rearrangement	O
.	O

Lymphoid	O
cells	O
transformed	O
by	O
Abelson	O
murine	O
leukemia	O
virus	O
have	O
provided	O
one	O
of	O
the	O
classic	O
models	O
for	O
study	O
of	O
early	O
B-cell	O
development	O
and	O
immunoglobulin	O
rearrangement	O
.	O

Most	O
of	O
these	O
cells	O
have	O
rearranged	O
their	O
heavy-chain	O
locus	O
but	O
not	B-Negation
their	I-Negation
light	I-Negation
chain	I-Negation
genes	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
an	I-Speculation
active	I-Speculation
v-abl	I-Speculation
protein	I-Speculation
interferes	I-Speculation
with	I-Speculation
this	I-Speculation
differentiation	I-Speculation
step	I-Speculation
.	O

To	O
test	O
this	O
hypothesis	O
,	O
light-chain	O
gene	O
structure	O
was	O
examined	O
in	O
pre-B	O
cells	O
transformed	O
by	O
temperature-sensitive	O
mutants	O
of	O
the	O
Abelson	O
virus	O
and	O
in	O
derivatives	O
that	O
survive	O
at	O
the	O
nonpermissive	O
temperature	O
because	O
they	O
express	O
a	O
human	O
BCL-2	O
gene	O
.	O

Our	O
studies	O
reveal	O
that	O
inactivation	O
of	O
the	O
v-abl	O
protein	O
tyrosine	O
kinase	O
triggers	O
high-frequency	O
rearrangement	O
of	O
kappa	O
and	O
lambda	O
light-chain	O
genes	O
.	O

These	O
events	O
are	O
accompanied	O
by	O
marked	O
increases	O
in	O
the	O
expression	O
of	O
RAG-1	O
and	O
RAG-2	O
RNAs	O
.	O

These	O
increases	O
occur	O
in	O
the	O
absence	B-Negation
of	I-Negation
protein	I-Negation
synthesis	I-Negation
but	O
are	O
dependent	O
on	O
inactivation	O
of	O
the	O
v-abl	O
protein	O
tyrosine	O
kinase	O
.	O

As	O
documented	O
in	O
the	O
accompanying	O
paper	O
(	O
Klug	O
et	O
al.	O
,	O
this	O
issue	O
)	O
,	O
an	O
active	O
v-abl	O
protein	O
also	O
suppresses	O
the	O
activity	O
of	O
NF-kappa	O
B/rel	O
and	O
expression	O
controlled	O
by	O
the	O
kappa	O
intron	O
enhancer	O
.	O

Together	O
these	O
data	O
demonstrate	O
that	O
the	O
v-abl	O
protein	O
specifically	O
interferes	O
with	O
light-chain	O
gene	O
rearrangement	O
by	O
suppressing	O
at	O
least	O
two	O
pathways	O
essential	O
for	O
this	O
stage	O
of	O
B-cell	O
differentiation	O
and	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
is	O
important	O
in	O
regulating	O
RAG	O
gene	O
expression	O
.	O

[	O
An	O
overexpression	O
of	O
retinoic	O
acid	O
receptor	O
alpha	O
blocks	O
myeloid	O
cell	O
differentiation	O
at	O
the	O
promyelocyte	O
stage	O
]	O

Retinoic	O
acid	O
(	O
RA	O
)	O
,	O
a	O
vitamin	O
A	O
derivative	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
effects	O
related	O
to	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

The	O
pleiotropic	O
effects	O
of	O
RA	O
are	O
thought	O
to	O
be	O
mediated	O
through	O
specific	O
nuclear	O
RA	O
receptors	O
(	O
RARs	O
)	O
.	O

RARs	O
are	O
members	O
of	O
the	O
steroid/thyroid	O
hormone	O
receptor	O
superfamily	O
and	O
exhibit	O
a	O
molecular	O
structure	O
that	O
possess	O
discrete	O
DNA-binding	O
and	O
RA	O
(	O
ligand	O
)	O
-binding	O
domains	O
.	O

In	O
hematopoietic	O
system	O
,	O
RA	O
and	O
RARs	O
,	O
predominantly	O
RAR	O
alpha	O
may	O
play	O
key	O
roles	O
for	O
the	O
proliferation	O
and	O
differentiation	O
of	O
hematopoietic	O
progenitors	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
how	O
RA	O
and	O
RARs	O
are	O
involved	O
in	O
regulating	O
normal	O
hematopoietic	O
differentiation	O
.	O

To	O
make	O
clear	O
the	O
roles	O
of	O
RA	O
and	O
RAR	O
alpha	O
in	O
the	O
normal	O
hematopoiesis	O
,	O
I	O
have	O
introduced	O
the	O
construct	O
of	O
human	O
RAR	O
alpha	O
(	O
hRAR	O
alpha	O
)	O
into	O
murine	O
bone	O
marrow	O
cells	O
with	O
retroviral	O
vector	O
,	O
and	O
selected	O
infected	O
cells	O
with	O
drug	O
resistant	O
marker	O
(	O
Neo	O
(	O
r	O
)	O
)	O
cultured	O
on	O
the	O
stroma	O
cell	O
line	O
(	O
PA6-neo	O
)	O
,	O
and	O
analyzed	O
the	O
behavior	O
of	O
infected	O
cells	O
.	O

All	O
of	O
procedure	O
were	O
done	O
in	O
vitro	O
.	O

Most	O
cells	O
infected	O
with	O
hRAR	O
alpha	O
exhibited	O
promyelocytic	O
morphology	O
and	O
were	O
thought	O
to	O
be	O
blocked	O
at	O
the	O
promyelocytic	O
stage	O
in	O
their	O
myeloid	O
differentiation	O
.	O

Furthermore	O
,	O
these	O
immature	O
cells	O
differentiated	O
terminally	O
into	O
mature	O
granulocytes	O
by	O
adding	O
with	O
RA	O
(	O
10	O
(	O
-6	O
)	O
M	O
)	O
.	O

RAR	O
alpha	O
infected	O
cells	O
were	O
also	O
able	O
to	O
differentiate	O
into	O
mature	O
macrophages	O
in	O
the	O
both	O
of	O
long	O
term	O
culture	O
and	O
IL3	O
colony	O
.	O

These	O
observations	O
suggest	O
that	O
an	O
overexpression	O
of	O
RAR	O
alpha	O
alone	O
is	O
effective	O
to	O
suppress	O
myeloid	O
cell	O
differentiation	O
and	O
RAR	O
alpha	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
terminal	O
differentiation	O
of	O
myeloid	O
precursors	O
.	O

The	O
system	O
described	O
here	O
may	O
serve	O
as	O
a	O
model	O
for	O
studying	O
the	O
the	O
essential	O
genes	O
for	O
differentiation	O
of	O
normal	O
bone	O
marrow	O
cells	O
.	O

Regulation	O
of	O
interleukin-2	O
receptor	O
alpha	O
chain	O
expression	O
and	O
nuclear	O
factor.kappa	O
B	O
activation	O
by	O
protein	O
kinase	O
C	O
in	O
T	O
lymphocytes	O
.	O

Autocrine	O
role	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

The	O
regulation	O
of	O
interleukin-2	O
receptor	O
alpha	O
chain	O
(	O
IL-2R	O
alpha	O
)	O
expression	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
activation	O
by	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
in	O
resting	O
T	O
cells	O
,	O
has	O
been	O
studied	O
.	O

Treatment	O
of	O
human	O
resting	O
T	O
cells	O
with	O
phorbol	O
esters	O
strongly	O
induced	O
the	O
expression	O
of	O
IL-2R	O
alpha	O
and	O
the	O
activation	O
of	O
NF.kappa	O
B	O
.	O

This	O
activation	O
was	O
due	O
to	O
the	O
translocation	O
of	O
p65	O
and	O
c-Rel	O
NF.kappa	O
B	O
proteins	O
from	O
cytoplasmic	O
stores	O
to	O
the	O
nucleus	O
,	O
where	O
they	O
bound	O
the	O
kappa	O
B	O
sequence	O
of	O
the	O
IL-2R	O
alpha	O
promoter	O
either	O
as	O
p50.p65	O
or	O
as	O
p50.c-Rel	O
heterodimers	O
.	O

Interestingly	O
,	O
all	O
of	O
those	O
events	O
were	O
largely	O
indirect	O
and	O
mediated	O
by	O
endogenously	O
secreted	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
as	O
they	O
were	O
strongly	O
inhibited	O
by	O
a	O
neutralizing	O
anti-TNF	O
alpha	O
monoclonal	O
antibody	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
which	O
blocked	O
TNF	O
alpha	O
production	O
induced	O
by	O
PKC	O
,	O
strongly	O
inhibited	O
IL-2R	O
alpha	O
and	O
NF.kappa	O
B	O
activation	O
.	O

The	O
addition	O
of	O
either	O
TNF	O
alpha	O
or	O
IL-2	O
partially	O
recovered	O
cyclosporin	O
A-induced	O
IL-2R	O
alpha	O
inhibition	O
,	O
but	O
only	O
TNF	O
alpha	O
completely	O
recovered	O
NF.kappa	O
B	O
activation	O
.	O

Those	O
results	O
indicate	O
that	O
,	O
in	O
resting	O
T	O
cells	O
,	O
PKC	O
activation	O
has	O
only	O
a	O
triggering	O
role	O
,	O
whereas	O
the	O
endogenously	O
secreted	O
TNF	O
alpha	O
plays	O
an	O
essential	O
role	O
in	O
the	O
quantitative	O
control	O
of	O
the	O
expression	O
of	O
IL-2R	O
alpha	O
chain	O
or	O
NF.kappa	O
B	O
activation	O
.	O

Protease	O
inhibitors	O
block	O
lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
by	O
preventing	O
activation	O
of	O
c-Rel/p65	O
heterodimers	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
is	O
expressed	O
rapidly	O
by	O
human	O
monocytes	O
exposed	O
to	O
bacterial	O
endotoxin	O
(	O
lipopolysaccharide	O
,	O
or	O
LPS	O
)	O
.	O

Transcriptional	O
regulation	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B-like	O
site	O
in	O
the	O
TF	O
promoter	O
.	O

Nuclear	O
translocation	O
of	O
cytosolic	O
c-Rel/p65	O
heterodimers	O
and	O
other	O
members	O
of	O
the	O
NF-kappa	O
B/Rel	O
family	O
requires	O
dissociation	O
and	O
proteolytic	O
degradation	O
of	O
the	O
inhibitor	O
protein	O
,	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
protease	O
inhibitors	O
N	O
alpha-tosylphenylalanyl	O
chloromethyl	O
ketone	O
(	O
TPCK	O
)	O
and	O
N	O
alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
(	O
TLCK	O
)	O
block	O
activation	O
of	O
NF-kappa	O
B/Rel	O
proteins	O
by	O
preventing	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
.	O

To	O
determine	O
if	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
expression	O
,	O
freshly	O
isolated	O
human	O
monocytes	O
and	O
monocytic	O
THP-1	O
cells	O
were	O
pretreated	O
with	O
these	O
inhibitors	O
for	O
30	O
min	O
before	O
LPS	O
stimulation	O
.	O

Both	O
TPCK	O
and	O
TLCK	O
inhibited	O
LPS	O
induction	O
of	O
TF	O
protein	O
,	O
TF	O
mRNA	O
and	O
TF	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

These	O
inhibitors	O
specifically	O
prevented	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
nuclear	O
translocation	O
of	O
c-Rel/p65	O
heterodimers	O
.	O

In	O
contrast	O
,	O
TPCK	O
and	O
TLCK	O
did	O
not	B-Negation
block	I-Negation
induction	I-Negation
of	I-Negation
an	I-Negation
immediate-early	I-Negation
gene	I-Negation
encoding	I-Negation
the	I-Negation
transcription	I-Negation
factor	I-Negation
,	I-Negation
Egr-1	I-Negation
.	O

Taken	O
together	O
,	O
these	O
data	O
indicated	O
that	O
inhibiting	O
nuclear	O
translocation	O
of	O
c-Rel/p65	O
heterodimers	O
prevented	O
LPS	O
induction	O
of	O
TF	O
gene	O
transcription	O
in	O
monocytic	O
cells	O
.	O

A	O
family	O
of	O
serine	O
proteases	O
expressed	O
exclusively	O
in	O
myelo-monocytic	O
cells	O
specifically	O
processes	O
the	O
nuclear	O
factor-kappa	O
B	O
subunit	O
p65	O
in	O
vitro	O
and	O
may	O
impair	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
these	O
cells	O
.	O

Two	O
groups	O
of	O
U937	O
promonocytic	O
cells	O
were	O
obtained	O
by	O
limiting	O
dilution	O
cloning	O
which	O
differed	O
strikingly	O
in	O
their	O
ability	O
to	O
support	O
human	O
immunodeficiency	O
virus	O
1	O
(	O
HIV-1	O
)	O
replication	O
.	O

``	O
Plus	O
``	O
clones	O
replicated	O
the	O
virus	O
efficiently	O
,	O
whereas	O
``	O
minus	O
``	O
clones	O
did	O
not	B-Negation
.	O

We	O
examined	O
these	O
clones	O
for	O
differences	O
in	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
activity	O
which	O
might	O
account	O
for	O
the	O
observed	O
phenomenon	O
.	O

Stimulation	O
of	O
plus	O
clones	O
liberated	O
the	O
classical	O
p50-p65	O
complex	O
from	O
cytoplasmic	O
pools	O
,	O
whereas	O
minus	O
clones	O
produced	O
an	O
apparently	O
novel	O
,	O
faster-migrating	O
complex	O
,	O
as	O
judged	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

It	O
is	O
surprising	O
that	O
the	O
faster-migrating	O
complex	O
was	O
composed	O
also	O
of	O
p50	O
and	O
p65	O
.	O

However	O
,	O
the	O
p65	O
subunit	O
was	O
COOH-terminally	O
truncated	O
,	O
as	O
shown	O
by	O
immunoprecipitation	O
.	O

The	O
truncation	O
resulted	O
from	O
limited	O
proteolysis	O
of	O
p65	O
during	O
cellular	O
extraction	O
which	O
released	O
particular	O
lysosomal	O
serine	O
proteases	O
,	O
such	O
as	O
elastase	O
,	O
cathepsin	O
G	O
,	O
and	O
proteinase	O
3	O
.	O

These	O
specific	O
proteases	O
are	O
coordinately	O
expressed	O
and	O
were	O
present	O
exclusively	O
in	O
the	O
minus	O
U937	O
clones	O
,	O
but	O
not	B-Negation
in	I-Negation
the	I-Negation
plus	I-Negation
clones	I-Negation
,	O
as	O
demonstrated	O
in	O
the	O
case	O
of	O
cathepsin	O
G	O
.	O

In	O
addition	O
,	O
these	O
proteases	O
were	O
detected	O
in	O
certain	O
subclones	O
of	O
THP-1	O
and	O
HL-60	O
cells	O
and	O
in	O
primary	O
monocytes	O
,	O
in	O
each	O
case	O
correlating	O
with	O
the	O
truncated	O
from	O
of	O
p65	O
.	O

We	O
demonstrate	O
in	O
vitro	O
cleavage	O
of	O
p65	O
by	O
purified	O
elastase	O
and	O
cathepsin	O
G	O
.	O

It	O
is	O
possible	O
that	O
particular	O
serine	O
proteases	O
may	O
have	O
inhibiting	O
effects	O
on	O
the	O
replication	O
of	O
HIV-1	O
in	O
myelo-monocytic	O
cells	O
.	O

The	O
data	O
also	O
demonstrate	O
that	O
special	O
precautions	O
must	O
be	O
taken	O
when	O
making	O
extracts	O
from	O
myelo-monocytic	O
cells	O
.	O

Arrested	O
development	O
:	O
understanding	O
v-abl	O
.	O

The	O
protein	O
tyrosine	O
kinase	O
activity	O
of	O
the	O
v-abl	O
oncogene	O
has	O
been	O
demonstrated	O
to	O
subvert	O
the	O
normal	O
second	O
messenger	O
systems	O
used	O
by	O
lymphoid	O
cells	O
for	O
growth	O
and	O
differentiation	O
.	O

Transformation	O
of	O
bone	O
marrow	O
with	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
results	O
in	O
the	O
appearance	O
of	O
B	O
cell	O
lineage	O
cells	O
arrested	O
at	O
the	O
pre-B	O
cell	O
stage	O
.	O

Recent	O
reports	O
have	O
characterized	O
these	O
cells	O
expressing	O
high	O
v-abl	O
kinase	O
activity	O
as	O
deficient	O
in	O
detectable	O
NF-kappaB	O
DNA	O
binding	O
activity	O
and	O
low	O
level	O
RAG	O
gene	O
expression	O
.	O

These	O
observations	O
suggest	O
that	O
v-abl	O
may	O
be	O
inhibiting	O
the	O
differentiation	O
of	O
B	O
cells	O
by	O
blocking	O
these	O
two	O
crucial	O
elements	O
in	O
the	O
maturation	O
pathway	O
.	O

Distinct	O
DNase-I	O
hypersensitive	O
sites	O
are	O
associated	O
with	O
TAL-1	O
transcription	O
in	O
erythroid	O
and	O
T-cell	O
lines	O
.	O

The	O
tal-1	O
gene	O
,	O
frequently	O
activated	O
in	O
human	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
,	O
is	O
expressed	O
in	O
the	O
erythroid	O
,	O
megakaryocytic	O
,	O
and	O
mast	O
cell	O
lineages	O
during	O
normal	O
hematopoiesis	O
.	O

To	O
gain	O
further	O
insight	O
into	O
the	O
molecular	O
mechanisms	O
that	O
control	O
tal-1	O
expression	O
,	O
we	O
investigated	O
tal-1	O
chromatin	O
structure	O
in	O
erythroid/megakaryocytic	O
cell	O
lines	O
and	O
in	O
T-cell	O
lines	O
either	O
with	O
or	O
without	B-Negation
tal-1	I-Negation
rearrangements	I-Negation
.	O

Tal-1	O
transcription	O
was	O
shown	O
to	O
be	O
monoallelic	O
in	O
Jurkat	O
,	O
a	O
T-cell	O
line	O
that	O
expresses	O
tal-1	O
in	O
the	O
absence	B-Negation
of	I-Negation
apparent	I-Negation
genomic	I-Negation
alteration	I-Negation
of	I-Negation
the	I-Negation
locus	I-Negation
.	O

Methylation	O
studies	O
indicated	O
that	O
the	O
tal-15	O
'	O
GC-rich	O
region	O
behaves	O
like	O
a	O
CpG	O
island	O
,	O
hypomethylated	O
in	O
normal	O
cells	O
,	O
and	O
methylated	O
de	O
novo	O
on	O
transcriptionally	O
inactive	O
alleles	O
in	O
established	O
cell	O
lines	O
.	O

Five	O
major	O
DNase-I	O
hypersensitive	O
sites	O
(	O
HS	O
)	O
were	O
mapped	O
in	O
the	O
tal-1	O
locus	O
.	O

HS	O
I	O
,	O
IV	O
,	O
and	O
V	O
were	O
exclusively	O
observed	O
in	O
the	O
erythroid/megakaryocytic	O
cell	O
lines	O
that	O
express	O
tal-1	O
from	O
the	O
promoters	O
1a	O
and	O
1b	O
.	O

HS	O
II	O
was	O
weak	O
in	O
hematopoietic	O
cell	O
lines	O
,	O
absent	B-Negation
in	I-Negation
Hela	I-Negation
,	O
and	O
greatly	O
enhanced	O
in	O
Jurkat	O
,	O
suggesting	B-Speculation
that	I-Speculation
this	I-Speculation
region	I-Speculation
might	I-Speculation
be	I-Speculation
implicated	I-Speculation
in	I-Speculation
the	I-Speculation
cis-activation	I-Speculation
of	I-Speculation
tal-1	I-Speculation
promoter	I-Speculation
1b	I-Speculation
in	I-Speculation
this	I-Speculation
cell	I-Speculation
line	I-Speculation
.	O

HS	O
III	O
was	O
weak	O
in	O
HEL	O
and	O
Jurkat	O
,	O
and	O
greatly	O
enhanced	O
in	O
DU528	O
,	O
a	O
T-cell	O
line	O
that	O
bears	O
a	O
t	O
(	O
1	O
;	O
14	O
)	O
and	O
initiates	O
tal-1	O
transcription	O
within	O
exon	O
4	O
.	O

These	O
results	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
are	O
associated	O
with	O
the	O
use	O
of	O
the	O
different	O
tal-1	O
promoters	O
.	O

Functions	O
of	O
glutathione	O
and	O
glutathione	O
disulfide	O
in	O
immunology	O
and	O
immunopathology	O
.	O

Even	O
a	O
moderate	O
increase	O
in	O
the	O
cellular	O
cysteine	O
supply	O
elevates	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
and	O
glutathione	O
disulfide	O
(	O
GSSG	O
)	O
levels	O
and	O
potentiates	O
immunological	O
functions	O
of	O
lymphocytes	O
in	O
vitro	O
.	O

At	O
low	O
GSSG	O
levels	O
,	O
T	O
cells	O
can	B-Negation
not	I-Negation
optimally	I-Negation
activate	I-Negation
the	I-Negation
immunologically	I-Negation
important	I-Negation
transcription	I-Negation
factor	I-Negation
NF	I-Negation
kappa	I-Negation
B	I-Negation
,	O
whereas	O
high	O
GSSG	O
levels	O
inhibit	O
the	O
DNA	O
binding	O
activity	O
of	O
NF	O
kappa	O
B	O
.	O

The	O
effects	O
of	O
GSSG	O
are	O
antagonized	O
by	O
reduced	O
thioredoxin	O
(	O
TRX	O
)	O
.	O

As	O
the	O
protein	O
tyrosine	O
kinase	O
activities	O
p56lck	O
and	O
p59fyn	O
are	O
activated	O
in	O
intact	O
cells	O
by	O
hydrogen	O
peroxide	O
,	O
they	O
are	O
likely	O
targets	O
for	O
GSSG	O
action	O
.	O

These	O
redox-regulated	O
enzymes	O
trigger	O
signal	O
cascades	O
for	O
NF	O
kappa	O
B	O
activation	O
and	O
transduce	O
signals	O
from	O
the	O
T	O
cell	O
antigen	O
receptor	O
,	O
from	O
CD4	O
and	O
CD8	O
molecules	O
,	O
and	O
from	O
the	O
IL-2	O
receptor	O
beta-chain	O
.	O

The	O
effector	O
phase	O
of	O
cytotoxic	O
T	O
cell	O
responses	O
and	O
IL-2-dependent	O
functions	O
are	O
inhibited	O
even	O
by	O
a	O
partial	O
depletion	O
of	O
the	O
intracellular	O
GSH	O
pool	O
.	O

As	O
signal	O
transduction	O
is	O
facilitated	O
by	O
prooxidant	O
conditions	O
,	O
we	O
propose	O
that	O
the	O
well-known	O
immunological	O
consequences	O
of	O
GSH	O
depletion	O
ultimately	O
may	O
be	O
results	O
of	O
the	O
accompanying	O
GSSG	O
deficiency	O
.	O

As	O
HIV-infected	O
patients	O
and	O
SIV-infected	O
rhesus	O
macaques	O
have	O
,	O
on	O
the	O
average	O
,	O
significantly	O
decreased	O
plasma	O
cyst	O
(	O
e	O
)	O
ine	O
and	O
intracellular	O
GSH	O
levels	O
,	O
we	O
also	O
hypothesize	O
that	O
AIDS	O
may	O
be	O
the	O
consequence	O
of	O
a	O
GSSG	O
deficiency	O
as	O
well	O
.	O

Erythropoietin-dependent	O
induction	O
of	O
hemoglobin	O
synthesis	O
in	O
a	O
cytokine-dependent	O
cell	O
line	O
M-TAT	O
.	O

M-TAT	O
is	O
a	O
cytokine-dependent	O
cell	O
line	O
with	O
the	O
potential	O
to	O
differentiate	O
along	O
the	O
erythroid	O
and	O
megakaryocytic	O
lineages	O
.	O

We	O
cultured	O
M-TAT	O
cells	O
long	O
term	O
(	O
>	O
1	O
year	O
)	O
in	O
the	O
continuous	O
presence	O
of	O
erythropoietin	O
(	O
EPO	O
)	O
,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
,	O
or	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
.	O

These	O
long	O
term	O
cultures	O
are	O
referred	O
to	O
as	O
M-TAT/EPO	O
,	O
M-TAT/GM-CSF	O
,	O
and	O
M-TAT/SCF	O
cells	O
,	O
respectively	O
.	O

Hemoglobin	O
concentration	O
and	O
gamma-globin	O
and	O
erythroid	O
delta-aminolevulinate	O
synthase	O
mRNA	O
levels	O
were	O
significantly	O
higher	O
in	O
M-TAT/EPO	O
cells	O
than	O
in	O
M-TAT/GM-CSF	O
cells	O
.	O

When	O
the	O
supplemented	O
cytokine	O
was	O
switched	O
from	O
GM-CSF	O
to	O
EPO	O
,	O
hemoglobin	O
synthesis	O
in	O
M-TAT/GM-CSF	O
cells	O
increased	O
rapidly	O
(	O
within	O
5	O
h	O
)	O
,	O
and	O
the	O
level	O
of	O
GATA-1	O
mRNA	O
increased	O
.	O

In	O
contrast	O
,	O
the	O
addition	O
of	O
GM-CSF	O
to	O
the	O
M-TAT/EPO	O
cell	O
culture	O
decreased	O
the	O
amount	O
of	O
hemoglobin	O
,	O
even	O
in	O
the	O
presence	O
of	O
EPO	O
,	O
indicating	O
that	O
the	O
EPO	O
signal	O
for	O
erythroid	O
differentiation	O
is	O
suppressed	O
by	O
GM-CSF	O
.	O

Thus	O
,	O
erythroid	O
development	O
of	O
M-TAT	O
cells	O
is	O
promoted	O
by	O
EPO	O
and	O
suppressed	O
by	O
GM-CSF	O
.	O

These	O
results	O
support	O
the	O
hypothesis	O
that	O
EPO	O
actively	O
influences	O
the	O
programming	O
of	O
gene	O
expression	O
required	O
for	O
erythroid	O
progenitor	O
cell	O
differentiation	O
.	O

One	O
gene	O
,	O
two	O
transcripts	O
:	O
isolation	O
of	O
an	O
alternative	O
transcript	O
encoding	O
for	O
the	O
autoantigen	O
La/SS-B	O
from	O
a	O
cDNA	O
library	O
of	O
a	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

A	O
cDNA	O
library	O
was	O
prepared	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
an	O
autoimmune	O
patient	O
with	O
primary	O
Sjogrens	O
'	O
syndrome	O
.	O

The	O
cDNA	O
library	O
was	O
screened	O
with	O
the	O
patients	O
own	O
autoimmune	O
serum	O
being	O
monospecific	O
for	O
the	O
nuclear	O
autoantigen	O
La/SS-B	O
.	O

Thereby	O
an	O
alternative	O
type	O
of	O
La	O
mRNA	O
was	O
identified	O
that	O
differed	O
from	O
the	O
known	O
La	O
mRNA	O
due	O
to	O
an	O
exchange	O
of	O
the	O
exon	O
1	O
.	O

Sequencing	O
of	O
the	O
genomic	O
region	O
between	O
the	O
exons	O
1	O
and	O
2	O
showed	O
that	O
the	O
alternative	O
5'-end	O
is	O
a	O
part	O
of	O
the	O
intron	O
.	O

In	O
addition	O
,	O
the	O
presence	O
of	O
an	O
alternative	O
promoter	O
site	O
,	O
which	O
exists	O
within	O
the	O
intron	O
downstream	O
of	O
the	O
exon	O
1	O
,	O
became	O
evident	O
.	O

In	O
consequence	O
,	O
the	O
alternative	O
La	O
mRNA	O
is	O
the	O
result	O
of	O
a	O
promoter	O
switching	O
combined	O
with	O
an	O
alternative	O
splicing	O
mechanism	O
.	O

In	O
the	O
intron	O
,	O
further	O
transcription	O
factor	O
binding	O
sites	O
,	O
including	O
a	O
NF-kappa	O
B	O
element	O
,	O
were	O
identified	O
leading	O
to	O
the	O
suggestion	O
that	O
the	O
expression	O
of	O
the	O
gene	O
encoding	O
for	O
the	O
nuclear	O
autoantigen	O
La/SS-B	O
alters	O
in	O
dependence	O
on	O
disease	O
conditions	O
.	O

Functional	O
Myc-Max	O
heterodimer	O
is	O
required	O
for	O
activation-induced	O
apoptosis	O
in	O
T	O
cell	O
hybridomas	O
.	O

T	O
cell	O
hybridomas	O
respond	O
to	O
activation	O
signals	O
by	O
undergoing	O
apoptotic	O
cell	O
death	O
,	O
and	O
this	O
is	O
likely	O
to	O
represent	O
comparable	O
events	O
related	O
to	O
tolerance	O
induction	O
in	O
immature	O
and	O
mature	O
T	O
cells	O
in	O
vivo	O
.	O

Previous	O
studies	O
using	O
antisense	O
oligonucleotides	O
implicated	O
the	O
c-Myc	O
protein	O
in	O
the	O
phenomenon	O
of	O
activation-induced	O
apoptosis	O
.	O

This	O
role	O
for	O
c-Myc	O
in	O
apoptosis	O
is	O
now	O
confirmed	O
in	O
studies	O
using	O
a	O
dominant	O
negative	O
form	O
of	O
its	O
heterodimeric	O
binding	O
partner	O
,	O
Max	O
,	O
which	O
we	O
show	O
here	O
inhibits	O
activation-induced	O
apoptosis	O
.	O

Further	O
,	O
coexpression	O
of	O
a	O
reciprocally	O
mutant	O
Myc	O
protein	O
capable	O
of	O
forming	O
functional	O
heterodimers	O
with	O
the	O
mutant	O
Max	O
can	O
compensate	O
for	O
the	O
dominant	O
negative	O
activity	O
and	O
restore	O
activation-induced	O
apoptosis	O
.	O

These	O
results	O
imply	O
that	O
Myc	O
promotes	O
activation-induced	O
apoptosis	O
by	O
obligatory	O
heterodimerization	O
with	O
Max	O
,	O
and	O
therefore	O
,	O
by	O
regulating	O
gene	O
transcription	O
.	O

DNA-binding	O
studies	O
of	O
the	O
Epstein-Barr	O
virus	O
nuclear	O
antigen	O
2	O
(	O
EBNA-2	O
)	O
:	O
evidence	O
for	O
complex	O
formation	O
by	O
latent	O
membrane	O
protein	O
gene	O
promoter-binding	O
proteins	O
in	O
EBNA-2-positive	O
cell	O
lines	O
.	O

The	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
nuclear	O
antigen	O
2	O
(	O
EBNA-2	O
)	O
protein	O
is	O
essential	O
for	O
the	O
immortalization	O
of	O
human	O
primary	O
B	O
cells	O
by	O
EBV	O
.	O

EBNA-2	O
trans-activates	O
cellular	O
and	O
viral	O
genes	O
like	O
CD23	O
,	O
c-fgr	O
,	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
and	O
terminal	O
protein	O
1	O
(	O
TP1	O
)	O
.	O

Trans-activation	O
of	O
the	O
TP1	O
promoter	O
and	O
of	O
the	O
BamHI	O
C	O
promoter	O
has	O
already	O
been	O
investigated	O
in	O
detail	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
protein-protein	O
interactions	O
and	O
not	O
by	O
direct	O
binding	O
of	O
EBNA-2	O
type	O
A	O
(	O
of	O
EBV	O
type	O
1	O
)	O
to	O
the	O
DNA	O
.	O

EBNA-2	O
is	O
able	O
to	O
trans-activate	O
the	O
expression	O
of	O
the	O
LMP	O
gene	O
in	O
several	O
cell	O
lines	O
.	O

Various	O
reports	O
have	O
delineated	O
the	O
cis-acting	O
elements	O
of	O
the	O
LMP	O
promoter	O
through	O
which	O
EBNA-2	O
mediates	O
trans-activation	O
.	O

To	O
determine	O
whether	O
EBNA-2	O
also	O
trans-activates	O
the	O
LMP	O
promoter	O
by	O
protein-protein	O
interactions	O
,	O
we	O
performed	O
a	O
series	O
of	O
gel	O
retardation	O
assays	O
and	O
competition	O
experiments	O
with	O
LMP	O
promoter	O
fragments	O
of	O
different	O
sizes	O
.	O

We	O
determined	O
that	O
the	O
protein-binding	O
region	O
on	O
the	O
LMP	O
promoter	O
was	O
within	O
a	O
42	O
bp	O
fragment	O
encompassing	O
nucleotides	O
-135	O
to	O
-176	O
relative	O
to	O
the	O
LMP	O
transcriptional	O
start	O
site	O
.	O

None	O
of	O
the	O
DNA	O
fragments	O
investigated	O
indicated	O
interaction	O
of	O
EBNA-2	O
with	O
the	O
DNA	O
via	O
protein-protein	O
interactions	O
.	O

No	O
significant	O
differences	O
between	O
EBNA-2-positive	O
and	O
EBNA-2-negative	O
nuclear	O
extracts	O
could	O
be	O
seen	O
in	O
the	O
gel	O
retardation	O
assay	O
under	O
conditions	O
that	O
clearly	O
showed	O
binding	O
of	O
EBNA-2A	O
to	O
the	O
TP1	O
promoter	O
.	O

However	O
,	O
analysis	O
of	O
sucrose	O
gradient	O
fractions	O
in	O
the	O
gel	O
retardation	O
assay	O
provided	O
evidence	O
that	O
the	O
LMP	O
promoter-binding	O
proteins	O
form	O
a	O
complex	O
of	O
higher	O
M	O
(	O
r	O
)	O
in	O
EBNA-2-positive	O
cell	O
extracts	O
.	O

These	O
complexes	O
were	O
destroyed	O
by	O
detergent	O
.	O

We	O
deduce	O
from	O
these	O
results	O
that	O
EBNA-2-positive	O
cells	O
might	O
indeed	O
contain	O
specific	O
complexes	O
bound	O
to	O
the	O
LMP	O
promoter	O
which	O
are	O
,	O
however	O
,	O
too	O
labile	O
to	O
be	O
detected	O
in	O
a	O
standard	O
gel	O
retardation	O
assay	O
.	O

Enhanced	O
responsiveness	O
to	O
nuclear	O
factor	O
kappa	O
B	O
contributes	O
to	O
the	O
unique	O
phenotype	O
of	O
simian	O
immunodeficiency	O
virus	O
variant	O
SIVsmmPBj14	O
.	O

Infection	O
with	O
a	O
variant	O
of	O
simian	O
immunodeficiency	O
virus	O
,	O
SIVsmmPBj14	O
,	O
leads	O
to	O
severe	O
acute	O
disease	O
in	O
macaques	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
functional	O
significance	O
of	O
previously	O
described	O
mutations	O
in	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
and	O
to	O
elucidate	O
their	O
contribution	O
to	O
the	O
unique	O
phenotype	O
of	O
SIVsmmPBj14	O
.	O

LTR-directed	O
transcription	O
was	O
measured	O
by	O
using	O
luciferase	O
reporter	O
constructs	O
that	O
were	O
transiently	O
transfected	O
into	O
cultured	O
cells	O
.	O

In	O
a	O
wide	O
range	O
of	O
cell	O
types	O
,	O
the	O
basal	O
transcriptional	O
activity	O
of	O
the	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
be	O
2-	O
to	O
4.5-fold	O
higher	O
than	O
that	O
of	O
an	O
LTR	O
from	O
a	O
non-acutely	O
pathogenic	O
strain	O
.	O

These	O
LTRs	O
differ	O
by	O
five	O
point	O
mutations	O
and	O
a	O
22-bp	O
duplication	O
in	O
SIVsmmPBj14	O
,	O
which	O
includes	O
a	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF	O
kappa	O
B	O
)	O
site	O
.	O

Transcriptional	O
differences	O
between	O
these	O
LTRs	O
were	O
further	O
enhanced	O
by	O
two-	O
to	O
threefold	O
upon	O
treatment	O
of	O
cells	O
with	O
phorbol	O
ester	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
or	O
by	O
cotransfection	O
with	O
plasmids	O
expressing	O
NF	O
kappa	O
B	O
subunits	O
.	O

Mutagenesis	O
studies	O
,	O
and	O
the	O
use	O
of	O
a	O
reporter	O
construct	O
containing	O
an	O
enhancerless	O
promoter	O
,	O
indicate	O
that	O
these	O
transcriptional	O
effects	O
are	O
due	O
principally	O
to	O
the	O
22-bp	O
sequence	O
duplication	O
and	O
the	O
NF	O
kappa	O
B	O
site	O
contained	O
within	O
it	O
.	O

Finally	O
,	O
infectious	O
virus	O
stocks	O
that	O
were	O
isogenic	O
except	O
for	O
the	O
LTR	O
were	O
generated	O
.	O

The	O
LTR	O
from	O
SIVsmmPBj14	O
was	O
found	O
to	O
confer	O
an	O
increase	O
in	O
the	O
kinetics	O
of	O
virus	O
replication	O
in	O
cultured	O
cells	O
.	O

Inclusion	O
of	O
this	O
LTR	O
in	O
recombinant	O
SIVs	O
also	O
resulted	O
in	O
a	O
two-	O
to	O
threefold	O
rise	O
in	O
the	O
extent	O
of	O
cellular	O
proliferation	O
that	O
was	O
induced	O
in	O
quiescent	O
simian	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

These	O
studies	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
LTR	O
mutations	O
assist	O
SIVsmmPBj14	O
in	O
responding	O
efficiently	O
to	O
cellular	O
stimulation	O
and	O
allow	O
it	O
to	O
replicate	O
to	O
high	O
titers	O
during	O
the	O
acute	O
phase	O
of	O
viral	O
infection	O
.	O

Identification	O
of	O
a	O
region	O
which	O
directs	O
the	O
monocytic	O
activity	O
of	O
the	O
colony-stimulating	O
factor	O
1	O
(	O
macrophage	O
colony-stimulating	O
factor	O
)	O
receptor	O
promoter	O
and	O
binds	O
PEBP2/CBF	O
(	O
AML1	O
)	O
.	O

The	O
receptor	O
for	O
the	O
macrophage	O
colony-stimulating	O
factor	O
(	O
or	O
colony-stimulating	O
factor	O
1	O
[	O
CSF-1	O
]	O
)	O
is	O
expressed	O
from	O
different	O
promoters	O
in	O
monocytic	O
cells	O
and	O
placental	O
trophoblasts	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
monocyte-specific	O
expression	O
of	O
the	O
CSF-1	O
receptor	O
is	O
regulated	O
at	O
the	O
level	O
of	O
transcription	O
by	O
a	O
tissue-specific	O
promoter	O
whose	O
activity	O
is	O
stimulated	O
by	O
the	O
monocyte/B-cell-specific	O
transcription	O
factor	O
PU.1	O
(	O
D.-E.Zhang	O
,	O
C.J.Hetherington	O
,	O
H.-M.Chen	O
,	O
and	O
D.G.Tenen	O
,	O
Mol.Cell.	O
Biol.14:373-381	O
,	O
1994	O
)	O
.	O

Here	O
we	O
report	O
that	O
the	O
tissue	O
specificity	O
of	O
this	O
promoter	O
is	O
also	O
mediated	O
by	O
sequences	O
in	O
a	O
region	O
II	O
(	O
bp	O
-88	O
to	O
-	O
59	O
)	O
,	O
which	O
lies	O
10	O
bp	O
upstream	O
from	O
the	O
PU.1-binding	O
site	O
.	O

When	O
analyzed	O
by	O
DNase	O
footprinting	O
,	O
region	O
II	O
was	O
protected	O
preferentially	O
in	O
monocytic	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
confirmed	O
that	O
region	O
II	O
interacts	O
specifically	O
with	O
nuclear	O
proteins	O
from	O
monocytic	O
cells	O
.	O

Two	O
gel	O
shift	O
complexes	O
(	O
Mono	O
A	O
and	O
Mono	O
B	O
)	O
were	O
formed	O
with	O
separate	O
sequence	O
elements	O
within	O
this	O
region	O
.	O

Competition	O
and	O
supershift	O
experiments	O
indicate	O
that	O
Mono	O
B	O
contains	O
a	O
member	O
of	O
the	O
polyomavirus	O
enhancer-binding	O
protein	O
2/core-binding	O
factor	O
(	O
PEBP2/CBF	O
)	O
family	O
,	O
which	O
includes	O
the	O
AML1	O
gene	O
product	O
,	O
while	O
Mono	O
A	O
is	O
a	O
distinct	O
complex	O
preferentially	O
expressed	O
in	O
monocytic	O
cells	O
.	O

Promoter	B-Negation
constructs	I-Negation
with	I-Negation
mutations	I-Negation
in	I-Negation
these	I-Negation
sequence	I-Negation
elements	I-Negation
were	I-Negation
no	I-Negation
longer	I-Negation
expressed	I-Negation
specifically	I-Negation
in	I-Negation
monocytes	I-Negation
.	O

Furthermore	O
,	O
multimerized	O
region	O
II	O
sequence	O
elements	O
enhanced	O
the	O
activity	O
of	O
a	O
heterologous	O
thymidine	O
kinase	O
promoter	O
in	O
monocytic	O
cells	O
but	O
not	B-Negation
other	I-Negation
cell	I-Negation
types	I-Negation
tested	I-Negation
.	O

These	O
results	O
indicate	O
that	O
the	O
monocyte/B-cell-specific	O
transcription	O
factor	O
PU.1	O
and	O
the	O
Mono	O
A	O
and	O
Mono	O
B	O
protein	O
complexes	O
act	O
in	O
concert	O
to	O
regulate	O
monocyte-specific	O
transcription	O
of	O
the	O
CSF-1	O
receptor	O
.	O

A	O
factor	O
that	O
regulates	O
the	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
DPA	O
is	O
a	O
member	O
of	O
a	O
subfamily	O
of	O
zinc	O
finger	O
proteins	O
that	O
includes	O
a	O
Drosophila	O
developmental	O
control	O
protein	O
.	O

A	O
novel	O
DNA	O
sequence	O
element	O
termed	O
the	O
J	O
element	O
involved	O
in	O
the	O
regulated	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
was	O
recently	O
described	O
.	O

To	O
study	O
this	O
element	O
and	O
its	O
role	O
in	O
class	O
II	O
gene	O
regulation	O
further	O
,	O
a	O
cDNA	O
library	O
was	O
screened	O
with	O
oligonucleotide	O
probes	O
containing	O
both	O
the	O
S	O
element	O
and	O
the	O
nearby	O
J	O
element	O
of	O
the	O
human	O
DPA	O
gene	O
.	O

Several	O
DNA	O
clones	O
were	O
obtained	O
by	O
this	O
procedure	O
,	O
one	O
of	O
which	O
,	O
clone	O
18	O
,	O
is	O
reported	O
and	O
characterized	O
here	O
.	O

It	O
encodes	O
a	O
protein	O
predicted	O
to	O
contain	O
688	O
amino	O
acid	O
residues	O
,	O
including	O
11	O
zinc	O
finger	O
motifs	O
of	O
the	O
C2H2	O
type	O
in	O
the	O
C-terminal	O
region	O
,	O
that	O
are	O
Kruppel-like	O
in	O
the	O
conservation	O
of	O
the	O
H/C	O
link	O
sequence	O
connecting	O
them	O
.	O

The	O
160	O
N-terminal	O
amino	O
acids	O
in	O
the	O
nonfinger	O
region	O
of	O
clone	O
18	O
are	O
highly	O
homologous	O
with	O
similar	O
regions	O
of	O
several	O
other	O
human	O
,	O
mouse	O
,	O
and	O
Drosophila	O
sequences	O
,	O
defining	O
a	O
subfamily	O
of	O
Kruppel-like	O
zinc	O
finger	O
proteins	O
termed	O
TAB	O
(	O
tramtrack	O
[	O
ttk	O
]	O
-associated	O
box	O
)	O
here	O
.	O

One	O
of	O
the	O
Drosophila	O
sequences	O
,	O
ttk	O
,	O
is	O
a	O
developmental	O
control	O
gene	O
,	O
while	O
a	O
second	O
does	O
not	B-Negation
contain	I-Negation
a	I-Negation
zinc	I-Negation
finger	I-Negation
region	I-Negation
but	O
encodes	O
a	O
structure	O
important	O
in	O
oocyte	O
development	O
.	O

An	O
acidic	O
activation	O
domain	O
is	O
located	O
between	O
the	O
N-terminal	O
conserved	O
region	O
of	O
clone	O
18	O
and	O
its	O
zinc	O
fingers	O
.	O

This	O
protein	O
appears	O
to	O
require	O
both	O
the	O
S	O
and	O
J	O
elements	O
,	O
which	O
are	O
separated	O
by	O
10	O
bp	O
for	O
optimal	O
binding	O
.	O

Antisense	O
cDNA	O
to	O
clone	O
18	O
inhibited	O
the	O
expression	O
of	O
a	O
reporter	O
construct	O
containing	O
the	O
DPA	O
promoter	O
,	O
indicating	O
its	O
functional	O
importance	O
in	O
the	O
expression	O
of	O
this	O
class	O
II	O
gene	O
.	O

Glucocorticoid-induced	O
apoptosis	O
of	O
lymphoid	O
cells	O
.	O

The	O
induction	O
of	O
cell	O
death	O
in	O
lymphoid	O
cells	O
by	O
glucocorticoids	O
is	O
one	O
of	O
the	O
earliest	O
and	O
most	O
thoroughly	O
studied	O
models	O
of	O
apoptosis	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
apoptosis	O
occurs	O
in	O
lymphocytes	O
is	O
unknown	O
many	O
biochemical	O
and	O
molecular	O
changes	O
have	O
been	O
shown	O
to	O
occur	O
in	O
these	O
cells	O
in	O
response	O
to	O
glucocorticoids	O
.	O

The	O
role	O
of	O
chromatin	O
degradation	O
and	O
endonucleases	O
in	O
the	O
apoptotic	O
process	O
has	O
been	O
closely	O
studied	O
,	O
as	O
well	O
as	O
the	O
involvement	O
of	O
several	O
oncogenes	O
in	O
glucocorticoid-induced	O
cell	O
lysis	O
.	O

In	O
addition	O
,	O
the	O
clinical	O
importance	O
of	O
glucocorticoid-induced	O
apoptosis	O
in	O
the	O
treatment	O
of	O
lymphoid	O
neoplasms	O
has	O
recently	O
received	O
increased	O
attention	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
by	O
a	O
Tat-activated	O
,	O
transduced	O
interferon	O
gene	O
:	O
targeted	O
expression	O
to	O
human	O
immunodeficiency	O
virus	O
type	O
1-infected	O
cells	O
.	O

We	O
have	O
examined	O
the	O
feasibility	O
of	O
using	O
interferon	O
(	O
IFN	O
)	O
gene	O
transfer	O
as	O
a	O
novel	O
approach	O
to	O
anti-human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
therapy	O
in	O
this	O
study	O
.	O

To	O
limit	O
expression	O
of	O
a	O
transduced	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-IFNA2	O
(	O
the	O
new	O
approved	O
nomenclature	O
for	O
IFN	O
genes	O
is	O
used	O
throughout	O
this	O
article	O
)	O
hybrid	O
gene	O
to	O
the	O
HIV-1-infected	O
cells	O
,	O
HIV-1	O
LTR	O
was	O
modified	O
.	O

Deletion	O
of	O
the	O
NF-kappa	O
B	O
elements	O
of	O
the	O
HIV-1	O
LTR	O
significantly	O
inhibited	O
Tat-mediated	O
transactivation	O
in	O
T-cell	O
lines	O
,	O
as	O
well	O
as	O
in	O
a	O
monocyte	O
line	O
,	O
U937	O
.	O

Replacement	O
of	O
the	O
NF-kappa	O
B	O
elements	O
in	O
the	O
HIV-1	O
LTR	O
by	O
a	O
DNA	O
fragment	O
derived	O
from	O
the	O
5'-flanking	O
region	O
of	O
IFN-stimulated	O
gene	O
15	O
(	O
ISG15	O
)	O
,	O
containing	O
the	O
IFN-stimulated	O
response	O
element	O
,	O
partially	O
restored	O
Tat-mediated	O
activation	O
of	O
LTR	O
in	O
T	O
cells	O
as	O
well	O
as	O
in	O
monocytes	O
.	O

Insertion	O
of	O
this	O
chimeric	O
promoter	O
(	O
ISG15	O
LTR	O
)	O
upstream	O
of	O
the	O
human	O
IFNA2	O
gene	O
directed	O
high	O
levels	O
of	O
IFN	O
synthesis	O
in	O
Tat-expressing	O
cells	O
,	O
while	O
this	O
promoter	O
was	O
not	B-Negation
responsive	I-Negation
to	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha-mediated	I-Negation
activation	I-Negation
.	O

ISG15-LTR-IFN	O
hybrid	O
gene	O
inserted	O
into	O
the	O
retrovirus	O
vector	O
was	O
transduced	O
into	O
Jurkat	O
and	O
U937	O
cells	O
.	O

Selected	O
transfected	O
clones	O
produced	O
low	O
levels	O
of	O
IFN	O
A	O
(	O
IFNA	O
)	O
constitutively	O
,	O
and	O
their	O
abilities	O
to	O
express	O
interleukin-2	O
and	O
interleukin-2	O
receptor	O
upon	O
stimulation	O
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
were	O
retained	O
.	O

Enhancement	O
of	O
IFNA	O
synthesis	O
observed	O
upon	O
HIV-1	O
infection	O
resulted	O
in	O
significant	O
inhibition	O
of	O
HIV-1	O
replication	O
for	O
a	O
period	O
of	O
at	O
least	O
30	O
days	O
.	O

Virus	O
isolated	O
from	O
IFNA-producing	O
cells	O
was	O
able	O
to	O
replicate	O
in	O
the	O
U937	O
cells	O
but	O
did	O
not	B-Negation
replicate	I-Negation
efficiently	I-Negation
in	I-Negation
U937	I-Negation
cells	I-Negation
transduced	I-Negation
with	I-Negation
the	I-Negation
IFNA	I-Negation
gene	I-Negation
.	O

These	O
results	O
suggest	O
that	O
targeting	O
IFN	O
synthesis	O
to	O
HIV-1-infected	O
cells	O
is	O
an	O
attainable	O
goal	O
and	O
that	O
autocrine	O
IFN	O
synthesis	O
results	O
in	O
a	O
long-lasting	O
and	O
permanent	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

Pyrrolidine	O
dithiocarbamate	O
,	O
a	O
potent	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
,	O
prevents	O
apoptosis	O
in	O
human	O
promyelocytic	O
leukemia	O
HL-60	O
cells	O
and	O
thymocytes	O
.	O

We	O
examined	O
the	O
effect	O
of	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
which	O
potently	O
blocks	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
on	O
the	O
induction	O
of	O
apoptosis	O
by	O
a	O
variety	O
of	O
agents	O
.	O

Treatment	O
of	O
a	O
human	O
promyelocytic	O
leukemia	O
cell	O
line	O
,	O
HL-60	O
,	O
with	O
10	O
micrograms/mL	O
etoposide	O
or	O
2	O
microM	O
1-beta-D-arabinofuranosylcytosine	O
induced	O
NF-kappa	O
B	O
activation	O
within	O
1	O
hr	O
and	O
subsequently	O
caused	O
apoptosis	O
within	O
3-4	O
hr	O
.	O

The	O
simultaneous	O
addition	O
of	O
50-500	O
microM	O
PDTC	O
with	O
these	O
agents	O
blocked	O
NF-kappa	O
B	O
activation	O
and	O
completely	O
abrogated	O
both	O
morphologically	O
apoptotic	O
changes	O
and	O
internucleosomal	O
DNA	O
fragmentation	O
for	O
up	O
to	O
6	O
hr	O
.	O

However	O
,	O
PDTC	O
failed	B-Negation
to	I-Negation
inhibit	I-Negation
the	I-Negation
endonuclease	I-Negation
activity	I-Negation
contained	I-Negation
in	I-Negation
the	I-Negation
whole	I-Negation
cell	I-Negation
lysates	I-Negation
.	O

The	O
inhibitory	O
effect	O
of	O
PDTC	O
was	O
also	O
observed	O
in	O
etoposide-	O
and	O
dexamethasone-induced	O
apoptosis	O
in	O
human	O
thymocytes	O
at	O
a	O
concentration	O
of	O
1-10	O
microM	O
.	O

Since	O
PDTC	O
has	O
both	O
antioxidant	O
and	O
metal-ion	O
chelating	O
activities	O
,	O
we	O
tested	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
(	O
antioxidant	O
)	O
or	O
o-phenanthroline	O
(	O
OP	O
)	O
(	O
metal-ion	O
chelator	O
)	O
on	O
the	O
induction	O
of	O
apoptosis	O
.	O

Pretreatment	O
of	O
HL-60	O
cells	O
or	O
thymocytes	O
with	O
100-500	O
microM	O
OP	O
for	O
2	O
hr	O
,	O
but	O
not	B-Negation
10-60	I-Negation
mM	I-Negation
NAC	I-Negation
,	O
suppressed	O
subsequent	O
occurrence	O
of	O
apoptosis	O
induced	O
by	O
etoposide	O
.	O

These	O
results	O
suggest	O
that	O
the	O
activation	O
of	O
NF-kappa	O
B	O
plays	O
an	O
important	O
role	O
in	O
the	O
apoptotic	O
process	O
of	O
human	O
hematopoietic	O
cells	O
.	O

Differential	O
regulation	O
of	O
proto-oncogenes	O
c-jun	O
and	O
c-fos	O
in	O
T	O
lymphocytes	O
activated	O
through	O
CD28	O
.	O

The	O
T	O
cell	O
surface	O
molecule	O
CD28	O
binds	O
to	O
ligands	O
on	O
accessory	O
cells	O
and	O
APCs	O
,	O
playing	O
an	O
important	O
costimulatory	O
role	O
in	O
the	O
response	O
of	O
T	O
cells	O
to	O
Ags	O
.	O

Our	O
knowledge	O
of	O
the	O
intracellular	O
signaling	O
pathways	O
coupled	O
to	O
this	O
receptor	O
is	O
incomplete	O
.	O

In	O
addition	O
to	O
activation	O
of	O
phospholipase	O
C	O
gamma	O
1	O
,	O
ligation	O
of	O
this	O
receptor	O
also	O
seems	O
to	O
activate	O
a	O
calcium-independent	O
,	O
CD28-specific	O
pathway	O
.	O

In	O
this	O
paper	O
,	O
we	O
report	O
that	O
cross-linking	O
of	O
CD28	O
(	O
but	O
not	B-Negation
CD2	I-Negation
,	I-Negation
CD5	I-Negation
,	I-Negation
LFA-1	I-Negation
,	I-Negation
or	I-Negation
CD7	I-Negation
)	O
leads	O
to	O
an	O
elevation	O
of	O
c-jun	O
mRNA	O
,	O
with	O
only	O
minimal	O
activation	O
of	O
c-fos	O
expression	O
.	O

CD28-dependent	O
induction	O
of	O
c-jun	O
expression	O
requires	O
protein	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
does	O
not	B-Negation
depend	I-Negation
on	I-Negation
activation	I-Negation
of	I-Negation
a	I-Negation
phorbol	I-Negation
ester-responsive	I-Negation
protein	I-Negation
kinase	I-Negation
C	I-Negation
or	I-Negation
elevation	I-Negation
of	I-Negation
cytosolic	I-Negation
calcium	I-Negation
.	O

Furthermore	O
,	O
CD28-dependent	B-Negation
elevation	I-Negation
of	I-Negation
c-jun	I-Negation
mRNA	I-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
be	I-Speculation
mediated	I-Speculation
at	I-Speculation
the	I-Speculation
level	I-Speculation
of	I-Speculation
mRNA	I-Speculation
stability	I-Speculation
.	O

A	O
mechanism	O
is	O
suggested	O
whereby	O
expression	O
of	O
c-jun	O
and	O
junB	O
,	O
in	O
the	O
absence	O
of	O
members	O
of	O
the	O
fos	O
family	O
,	O
can	O
prevent	O
inappropriate	O
activation	O
of	O
T	O
cells	O
caused	O
by	O
ligation	O
of	O
CD28	O
in	O
the	O
absence	O
of	O
a	O
specific	O
antigenic	O
stimulus	O
.	O

Constitutive	O
nuclear	O
NF-kappa	O
B	O
in	O
cells	O
of	O
the	O
monocyte	O
lineage	O
.	O

In	O
monocytes	O
,	O
the	O
nuclear	O
factor	O
NF-kappa	O
B	O
has	O
been	O
invoked	O
as	O
an	O
important	O
transcription	O
factor	O
in	O
the	O
expression	O
of	O
cytokine	O
genes	O
,	O
of	O
cell-surface	O
receptors	O
and	O
in	O
the	O
expression	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

In	O
such	O
cells	O
,	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	O
B	O
can	O
be	O
detected	O
without	B-Negation
intentional	I-Negation
stimulation	I-Negation
.	O

In	O
our	O
studies	O
,	O
cells	O
of	O
the	O
human	O
monocytic	O
line	O
Mono	O
Mac	O
6	O
,	O
cultured	O
in	O
medium	O
containing	O
fetal-calf	O
serum	O
and	O
low	O
levels	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
also	O
exhibit	O
such	O
'constitutive	O
'	O
NF-kappa	O
B	O
,	O
as	O
demonstrated	O
by	O
mobility-shift	O
analysis	O
of	O
nuclear	O
extracts	O
.	O

This	O
nuclear	O
NF-kappa	O
B	O
was	O
still	O
present	O
when	O
contaminant	O
LPS	O
was	O
removed	O
by	O
ultrafiltration	O
and	O
when	O
serum	O
was	O
omitted	O
.	O

Protein-DNA	O
complexes	O
of	O
constitutive	O
NF-kappa	O
B	O
are	O
similar	O
in	O
mobility	O
to	O
the	O
LPS-induced	O
NF-kappa	O
B	O
and	O
both	O
are	O
recognized	O
by	O
an	O
antibody	O
specific	O
to	O
the	O
p50	O
subunit	O
of	O
NF-kappa	O
B	O
.	O

By	O
contrast	O
,	O
treatment	O
of	O
cells	O
with	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
will	O
only	O
block	O
LPS-induced	O
NF-kappa	O
B	O
,	O
but	O
not	B-Negation
the	I-Negation
constitutive	I-Negation
binding	I-Negation
protein	I-Negation
.	O

Using	O
LPS-free	O
and	O
serum-free	O
conditions	O
,	O
constitutive	O
NF-kappa	O
B	O
can	O
be	O
detected	O
in	O
different	O
cell	O
lines	O
of	O
the	O
monocytic	O
lineage	O
(	O
HL60	O
,	O
U937	O
,	O
THP-1	O
,	O
Mono	O
Mac	O
1	O
and	O
Mono	O
Mac	O
6	O
)	O
,	O
but	O
not	B-Negation
in	I-Negation
Molt	I-Negation
4	I-Negation
T	I-Negation
cells	I-Negation
or	I-Negation
K562	I-Negation
stem	I-Negation
cells	I-Negation
.	O

When	O
ordered	O
according	O
to	O
stage	O
of	O
maturation	O
,	O
the	B-Negation
amount	I-Negation
of	I-Negation
constitutive	I-Negation
NF-kappa	I-Negation
B	I-Negation
was	I-Negation
not	I-Negation
increased	I-Negation
in	I-Negation
more	I-Negation
mature	I-Negation
cell	I-Negation
lines	I-Negation
.	O

Furthermore	O
,	O
when	O
inducing	O
differentiation	O
in	O
Mono	O
Mac	O
6	O
cells	O
,	O
with	O
vitamin	O
D3	O
,	O
no	B-Negation
change	I-Negation
in	I-Negation
constitutive	I-Negation
or	I-Negation
inducible	I-Negation
NF-kappa	I-Negation
B	I-Negation
can	I-Negation
be	I-Negation
detected	I-Negation
.	O

Analysis	O
of	O
primary	O
cells	O
revealed	O
substantial	O
constitutive	O
NF-kappa	O
B-binding	O
activity	O
in	O
blood	O
monocytes	O
,	O
pleural	O
macrophages	O
and	O
alveolar	O
macrophages	O
.	O

The	O
constitutive	O
NF-kappa	O
B	O
appears	O
to	O
be	O
functionally	O
active	O
,	O
since	O
a	O
low	O
level	O
of	O
tumour	O
necrosis	O
factor	O
(	O
TNF	O
)	O
transcript	O
is	O
detectable	O
in	O
monocytes	O
,	O
and	O
this	O
level	O
can	O
be	O
increased	O
by	O
blocking	O
transcript	O
degradation	O
using	O
cycloheximide	O
.	O

The	O
level	O
of	O
constitutive	O
NF-kappa	O
B	O
in	O
these	O
cells	O
is	O
variable	O
and	O
is	O
frequently	O
found	O
to	O
be	O
lower	O
in	O
the	O
more	O
mature	O
macrophages	O
.	O

Constitutive	B-Negation
NF-kappa	I-Negation
B	I-Negation
was	I-Negation
not	I-Negation
maintained	I-Negation
by	I-Negation
autocrine	I-Negation
action	I-Negation
of	I-Negation
cytokines	I-Negation
TNF	I-Negation
,	I-Negation
interleukin	I-Negation
6	I-Negation
,	I-Negation
interleukin	I-Negation
10	I-Negation
,	I-Negation
granulocyte-macrophage	I-Negation
colony-stimulating	I-Negation
factor	I-Negation
or	I-Negation
macrophage	I-Negation
colony-stimulating	I-Negation
factor	I-Negation
,	O
since	O
neutralizing	O
antibodies	O
did	O
not	B-Negation
reduce	I-Negation
constitutive	I-Negation
DNA-binding	I-Negation
activity	I-Negation
.	O

Furthermore	O
,	O
blockade	O
of	O
prostaglandin	O
or	O
leukotriene	O
biosynthesis	O
did	O
not	B-Negation
affect	I-Negation
constitutive	I-Negation
NF-kappa	I-Negation
B	I-Negation
.	O

(	O
ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O

Nonpituitary	O
human	O
prolactin	O
gene	O
transcription	O
is	O
independent	O
of	O
Pit-1	O
and	O
differentially	O
controlled	O
in	O
lymphocytes	O
and	O
in	O
endometrial	O
stroma	O
.	O

Expression	O
of	O
the	O
human	O
PRL	O
(	O
hPRL	O
)	O
gene	O
in	O
extrapituitary	O
sites	O
such	O
as	O
the	O
uterus	O
(	O
decidualized	O
endometrial	O
stroma	O
and	O
myometrium	O
)	O
and	O
cells	O
of	O
the	O
hematopoietic	O
lineage	O
is	O
directed	O
by	O
an	O
alternative	O
promoter	O
which	O
is	O
located	O
approximately	O
6	O
kilobases	O
(	O
kb	O
)	O
upstream	O
of	O
the	O
pituitary-specific	O
start	O
site	O
.	O

In	O
order	O
to	O
delineate	O
the	O
tissue-specific	O
mechanisms	O
governing	O
the	O
control	O
of	O
nonpituitary	O
PRL	O
gene	O
expression	O
,	O
we	O
have	O
cloned	O
and	O
sequenced	O
3	O
kb	O
5'-flanking	O
DNA	O
of	O
the	O
upstream	O
decidual/lymphoid	O
(	O
dPRL	O
)	O
promoter	O
.	O

Based	O
on	O
sequence	O
homology	O
we	O
identified	O
two	O
binding	O
motifs	O
for	O
Pit-1	O
and	O
seven	O
half-sites	O
for	O
glucocorticoid	O
receptor/progesterone	O
receptor	O
(	O
PR	O
)	O
binding	O
.	O

We	O
focused	O
our	O
studies	O
on	O
the	O
role	O
of	O
Pit-1	O
and	O
of	O
PR	O
as	O
potential	O
transcriptional	O
regulators	O
,	O
since	O
the	O
POU	O
domain	O
protein	O
Pit-1	O
is	O
essential	O
in	O
the	O
control	O
of	O
pituitary	O
PRL	O
expression	O
,	O
and	O
progesterone	O
induces	O
decidual	O
transformation	O
of	O
the	O
endometrial	O
stroma	O
,	O
a	O
differentiation	O
process	O
during	O
which	O
the	O
decidual	O
PRL	O
gene	O
is	O
activated	O
.	O

We	O
demonstrate	O
in	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
lymphocytes	O
and	O
endometrial	O
stroma	O
,	O
that	O
Pit-1	O
is	O
not	B-Negation
involved	I-Negation
in	I-Negation
the	I-Negation
regulation	I-Negation
of	I-Negation
dPRL	I-Negation
promoter/reporter	I-Negation
gene	I-Negation
constructs	I-Negation
carrying	I-Negation
3	I-Negation
kb	I-Negation
5'-flanking	I-Negation
DNA	I-Negation
.	O

Our	O
experiments	O
also	O
show	O
that	O
activated	O
PR	O
does	O
not	B-Negation
confer	I-Negation
direct	I-Negation
transcriptional	I-Negation
control	I-Negation
on	I-Negation
the	I-Negation
dPRL	I-Negation
promoter	I-Negation
.	O

When	O
we	O
compared	O
the	O
activity	O
of	O
the	O
transfected	O
dPRL	O
promoter	O
in	O
PRL-secreting	O
and	O
nonsecreting	O
lymphoid	O
cells	O
,	O
we	O
found	O
that	O
the	O
3	O
kb	O
5'-flanking	O
region	O
of	O
the	O
dPRL	O
promoter	O
did	O
not	B-Negation
contain	I-Negation
elements	I-Negation
restricting	I-Negation
expression	I-Negation
to	I-Negation
only	I-Negation
those	I-Negation
lymphocytes	I-Negation
that	I-Negation
produce	I-Negation
PRL	I-Negation
but	O
allowed	O
expression	O
of	O
fusion	O
reporter	O
genes	O
irrespective	O
of	O
the	O
status	O
of	O
the	O
endogenous	O
PRL	O
gene	O
.	O

This	O
was	O
in	O
sharp	O
contrast	O
to	O
endometrial	O
cells	O
where	O
3	O
kb	O
5'-flanking	O
DNA	O
conferred	O
strong	O
transcriptional	O
activation	O
on	O
the	O
dPRL	O
promoter	O
in	O
decidualized	O
endometrial	O
stromal	O
cells	O
actively	O
secreting	O
PRL	O
,	O
but	O
did	O
not	B-Negation
allow	I-Negation
transcription	I-Negation
in	I-Negation
undifferentiated	I-Negation
non-PRL-secreting	I-Negation
endometrial	I-Negation
stromal	I-Negation
cells	I-Negation
.	O

Activation	O
of	O
the	O
dPRL	O
promoter	O
construct	O
in	O
these	O
undifferentiated	O
cells	O
could	O
however	O
be	O
induced	O
by	O
the	O
addition	O
of	O
cAMP	O
,	O
in	O
the	O
absence	B-Negation
of	I-Negation
progesterone	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
a	I-Speculation
signal	I-Speculation
transduced	I-Speculation
through	I-Speculation
the	I-Speculation
cAMP	I-Speculation
signaling	I-Speculation
pathway	I-Speculation
is	I-Speculation
a	I-Speculation
primary	I-Speculation
inducer	I-Speculation
of	I-Speculation
decidual	I-Speculation
PRL	I-Speculation
gene	I-Speculation
expression	I-Speculation
.	O

Activation	O
of	O
early	O
growth	O
response	O
1	O
gene	O
transcription	O
and	O
pp90rsk	O
during	O
induction	O
of	O
monocytic	O
differentiation	O
.	O

The	O
present	O
work	O
has	O
studied	O
mechanisms	O
responsible	O
for	O
induction	O
of	O
early	O
growth	O
response	O
1	O
(	O
EGR-1	O
)	O
gene	O
expression	O
during	O
monocytic	O
differentiation	O
of	O
U-937	O
myeloid	O
leukemia	O
cells	O
.	O

Differentiation	O
of	O
U-937	O
cells	O
with	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
an	O
activator	O
of	O
the	O
serine/threonine	O
protein	O
kinase	O
C	O
,	O
was	O
associated	O
with	O
transcriptional	O
activation	O
of	O
EGR-1	O
promoter-reporter	O
constructs	O
.	O

The	O
EGR-1	O
promoter	O
contains	O
six	O
CC	O
(	O
A/T	O
)	O
6GG	O
(	O
CArG	O
)	O
motifs	O
.	O

The	O
two	O
5'-most	O
distal	O
CArG	O
sequences	O
conferred	O
TPA	O
inducibility	O
.	O

In	O
contrast	O
,	O
there	O
was	O
little	O
effect	O
of	O
TPA	O
on	O
EGR-1	O
transcription	O
in	O
a	O
TPA-resistant	O
U-937	O
cell	O
variant	O
,	O
designated	O
TUR	O
.	O

Treatment	O
of	O
both	O
U-937	O
and	O
TUR	O
cells	O
with	O
okadaic	O
acid	O
,	O
an	O
inhibitor	O
of	O
serine/threonine	O
protein	O
phosphatases	O
1	O
and	O
2A	O
,	O
was	O
associated	O
with	O
induction	O
of	O
monocytic	O
differentiation	O
and	O
EGR-1	O
transcription	O
through	O
the	O
5'-most	O
CArG	O
element	O
.	O

Since	O
these	O
findings	O
supported	O
the	O
involvement	O
of	O
serine/threonine	O
protein	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
EGR-1	O
expression	O
,	O
we	O
studied	O
activation	O
of	O
the	O
40S	O
ribosomal	O
protein	O
S6	O
serine/threonine	O
kinases	O
,	O
pp70S6K	O
and	O
pp90rsk	O
.	O

Although	O
both	O
kinases	O
participate	O
in	O
regulating	O
cell	O
growth	O
,	O
there	O
was	O
no	B-Negation
detectable	I-Negation
activation	I-Negation
of	I-Negation
pp70S6K	I-Negation
during	I-Negation
TPA-	I-Negation
or	I-Negation
okadaic	I-Negation
acid-induced	I-Negation
monocytic	I-Negation
differentiation	I-Negation
.	O

Moreover	O
,	O
rapamycin	O
,	O
an	O
inhibitor	O
of	O
pp70S6K	O
activation	O
,	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
induction	I-Negation
of	I-Negation
EGR-1	I-Negation
expression	I-Negation
.	O

In	O
contrast	O
,	O
analysis	O
of	O
pp90rsk	O
activity	O
by	O
phosphorylation	O
of	O
a	O
peptide	O
derived	O
from	O
S6	O
protein	O
demonstrated	O
stimulation	O
of	O
this	O
kinase	O
in	O
TPA-treated	O
U-937	O
,	O
and	O
not	B-Negation
TUR	I-Negation
,	O
cells	O
.	O

Okadaic	O
acid	O
treatment	O
of	O
both	O
cell	O
types	O
was	O
associated	O
with	O
activation	O
of	O
pp90rsk	O
.	O

Effects	O
of	O
prostaglandin	O
E2	O
on	O
Th0-type	O
human	O
T	O
cell	O
clones	O
:	O
modulation	O
of	O
functions	O
of	O
nuclear	O
proteins	O
involved	O
in	O
cytokine	O
production	O
.	O

The	O
effects	O
of	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
on	O
cytokine	O
production	O
and	O
proliferation	O
of	O
the	O
CD4+	O
human	O
helper	O
T	O
cell	O
clone	O
SP-B21	O
were	O
investigated	O
.	O

In	O
cells	O
stimulated	O
with	O
anti-CD3	O
mAb	O
,	O
PGE2	O
inhibited	O
cell	O
proliferation	O
and	O
the	O
production	O
of	O
all	O
the	O
cytokines	O
examined	O
.	O

Addition	O
of	O
rIL-2	O
fully	O
restored	O
the	O
proliferative	O
response	O
and	O
partially	O
restored	O
the	O
production	O
of	O
IL-4	O
and	O
IL-5	O
,	O
but	O
not	B-Negation
that	I-Negation
of	I-Negation
other	I-Negation
cytokines	I-Negation
.	O

In	O
contrast	O
,	O
in	O
cells	O
stimulated	O
with	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
/A23187	O
,	O
PGE2	O
enhanced	O
the	O
production	O
of	O
IL-4	O
and	O
IL-5	O
,	O
and	O
only	O
partially	O
inhibited	O
the	O
production	O
of	O
other	O
cytokines	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
PGE2	O
vary	O
depending	O
on	O
the	O
mode	O
of	O
T	O
cell	O
activation	O
,	O
and	O
the	O
IL-4	O
and	O
IL-5	O
are	O
regulated	O
differently	O
from	O
other	O
cytokines	O
.	O

In	O
a	O
mobility	O
shift	O
assay	O
,	O
only	O
the	O
NF-kappa	O
B	O
(	O
p50/p50	O
)	O
homodimer	O
was	O
observed	O
in	O
a	O
complex	O
formed	O
with	O
the	O
kappa	O
B	O
sequence	O
in	O
unstimulated	O
SP-B21	O
cells	O
.	O

When	O
cells	O
were	O
stimulated	O
with	O
anti-CD3	O
mAb	O
or	O
PMA/A23187	O
,	O
a	O
complex	O
formation	O
of	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
heterodimer	O
with	O
the	O
kappa	O
B	O
sequence	O
was	O
induced	O
.	O

Interestingly	O
,	O
PGE2	O
or	O
di-butyryl	O
(	O
Bt2	O
)	O
cAMP	O
abolished	O
the	O
binding	O
of	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
heterodimer	O
to	O
the	O
kappa	O
B	O
sequence	O
in	O
cells	O
stimulated	O
with	O
anti-CD3	O
mAb	O
but	O
not	B-Negation
with	I-Negation
PMA/A23187	I-Negation
.	O

Our	O
results	O
suggest	O
that	O
the	O
target	O
of	O
PGE2	O
action	O
is	O
a	O
component	O
in	O
the	O
signal	O
transduction	O
pathway	O
leading	O
to	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
.	O

However	O
,	O
the	O
inhibition	O
of	O
the	O
T	O
cell	O
activation	O
signals	O
by	O
PGE2	O
is	O
selective	O
.	O

PGE2	O
enhanced	O
the	O
complex	O
formation	O
with	O
NF-AT	O
,	O
AP-1	O
and	O
CLE0	O
sequences	O
when	O
the	O
cells	O
were	O
activated	O
by	O
either	O
anti-CD3	O
mAb	O
or	O
PMA/A23187	O
stimulation	O
.	O

It	O
seems	O
therefore	O
that	O
PGE2	O
,	O
by	O
elevating	O
cAMP	O
levels	O
,	O
interferes	O
with	O
the	O
activation	O
pathway	O
for	O
NF-kappa	O
B	O
but	O
not	O
for	O
NF-AT	O
,	O
AP-1	O
or	O
CLE0	O
binding	O
protein	O
.	O

Long-term	O
inositol	O
phosphate	O
release	O
,	O
but	O
not	B-Negation
tyrosine	I-Negation
kinase	I-Negation
activity	I-Negation
,	O
correlates	O
with	O
IL-2	O
secretion	O
and	O
NF-AT	O
induction	O
in	O
anti-CD3-activated	O
peripheral	O
human	O
T	O
lymphocytes	O
.	O

The	O
cascade	O
of	O
events	O
within	O
the	O
first	O
few	O
minutes	O
of	O
T	O
cell	O
stimulation	O
has	O
been	O
well	O
characterized	O
.	O

Although	O
many	O
second	O
messengers	O
have	O
been	O
shown	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
T	O
cell	O
activation	O
in	O
a	O
number	O
of	O
model	O
systems	O
,	O
the	B-Negation
rate-limiting	I-Negation
step	I-Negation
in	I-Negation
peripheral	I-Negation
T	I-Negation
cells	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
demonstrated	I-Negation
.	O

To	O
model	O
effective	O
versus	O
ineffective	O
CD3-mediated	O
stimulation	O
in	O
peripheral	O
T	O
cells	O
,	O
we	O
used	O
two	O
anti-CD3	O
mAbs	O
that	O
differ	O
in	O
their	O
ability	O
to	O
stimulate	O
purified	O
T	O
cells	O
:	O
OKT3	O
,	O
which	O
causes	O
early	O
second	O
messenger	O
generation	O
but	O
is	B-Negation
unable	I-Negation
to	I-Negation
activate	I-Negation
T	I-Negation
cells	I-Negation
without	I-Negation
a	I-Negation
second	I-Negation
signal	I-Negation
,	O
and	O
64.1	O
,	O
which	O
stimulates	O
T	O
cell	O
proliferation	O
on	O
its	O
own	O
.	O

We	O
found	O
that	O
tyrosine	O
kinase	O
activity	O
was	O
similar	O
for	O
both	O
mAbs	O
over	O
a	O
period	O
of	O
hours	O
.	O

However	O
,	O
the	O
inositol	O
phosphate	O
response	O
was	O
stronger	O
for	O
64.1	O
than	O
for	O
OKT3	O
.	O

To	O
tie	O
these	O
events	O
to	O
gene	O
activation	O
,	O
we	O
measured	O
NF-kappa	O
B	O
and	O
NF-AT	O
activity	O
in	O
the	O
nucleus	O
after	O
anti-CD3	O
stimulation	O
.	O

Both	O
stimuli	O
induced	O
the	O
appearance	O
of	O
the	O
NF-kappa	O
B	O
components	O
(	O
c-Rel	O
,	O
p65	O
(	O
RelA	O
)	O
,	O
and	O
p50	O
(	O
NF-kappa	O
B1	O
)	O
)	O
and	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
in	O
the	O
nucleus	O
.	O

However	O
,	O
only	O
64.1	O
induced	O
NF-AT	O
in	O
the	O
nucleus	O
,	O
correlating	O
with	O
its	O
ability	O
to	O
activate	O
T	O
cells	O
.	O

Thus	O
,	O
NF-AT	O
induction	O
and	O
IL-2	O
secretion	O
were	O
correlated	O
with	O
the	O
levels	O
of	O
inositol	O
phosphate	O
release	O
but	O
not	B-Negation
with	I-Negation
gross	I-Negation
levels	I-Negation
of	I-Negation
tyrosine	I-Negation
kinase	I-Negation
activity	I-Negation
induced	I-Negation
late	I-Negation
following	I-Negation
the	I-Negation
response	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
NF-kappa	O
B	O
induction	O
and	O
IL-2	O
receptor	O
expression	O
occurred	O
even	O
with	O
the	O
smaller	O
second	O
messenger	O
response	O
generated	O
by	O
OKT3	O
.	O

ZAP-70	O
tyrosine	O
kinase	O
,	O
CD45	O
,	O
and	O
T	O
cell	O
receptor	O
involvement	O
in	O
UV-	O
and	O
H2O2-induced	O
T	O
cell	O
signal	O
transduction	O
.	O

Several	O
mammalian	O
responses	O
to	O
UV	O
irradiation	O
,	O
including	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
are	O
believed	O
to	O
involve	O
tyrosine	O
phosphorylation	O
.	O

UV	O
irradiation	O
and	O
H2O2	O
treatment	O
of	O
T	O
lymphocytes	O
induce	O
protein	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
similar	O
to	O
those	O
observed	O
following	O
biological	O
stimulation	O
.	O

We	O
have	O
examined	O
the	O
role	O
of	O
cell	O
surface	O
molecules	O
in	O
these	O
responses	O
.	O

Normal	O
T	O
lymphocytes	O
whose	O
surface	O
expression	O
of	O
CD3	O
was	O
depleted	O
showed	O
impaired	O
UV-induced	O
tyrosine	O
phosphorylation	O
and	O
Ca2+	O
signals	O
.	O

Similarly	O
,	O
Jurkat	O
T	O
cell	O
lines	O
deficient	O
in	O
CD3	O
or	O
CD45	O
expression	O
also	O
gave	O
impaired	O
UV	O
responses	O
.	O

However	O
,	O
all	O
these	O
cell	O
types	O
still	O
gave	O
strong	O
Ca2+	O
and	O
tyrosine	O
phosphorylation	O
responses	O
to	O
H2O2	O
.	O

The	O
T	O
cell	O
tyrosine	O
kinase	O
ZAP-70	O
was	O
found	O
to	O
be	O
highly	O
responsive	O
to	O
UV	O
and	O
H2O2	O
treatment	O
.	O

ZAP-70	O
responsiveness	O
to	O
UV	O
required	O
expression	O
of	O
both	O
CD3	O
and	O
CD45	O
,	O
whereas	O
only	O
CD3	O
was	O
required	O
for	O
the	O
response	O
to	O
H2O2	O
.	O

UV-induced	O
activation	O
of	O
NF-kappa	O
B	O
was	O
blocked	O
by	O
CD3	O
depletion	O
,	O
indicating	O
the	O
importance	O
of	O
such	O
cell	O
surface	O
molecules	O
in	O
biological	O
responses	O
to	O
UV	O
.	O

In	O
nonlymphoid	O
cells	O
,	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
displayed	O
increased	O
tyrosine	O
phosphorylation	O
within	O
seconds	O
of	O
UV	O
irradiation	O
.	O

These	O
results	O
suggest	O
that	O
UV-induced	O
signal	O
transduction	O
is	O
mediated	O
via	O
cell	O
surface	O
receptors	O
that	O
normally	O
respond	O
to	O
biological	O
stimulation	O
,	O
whereas	O
H2O2	O
is	O
able	O
to	O
partially	O
bypass	O
this	O
requirement	O
.	O

Inhibition	O
of	O
NF-kappa	O
B	O
by	O
sodium	O
salicylate	O
and	O
aspirin	O
[	O
see	O
comments	O
]	O

The	O
transcription	O
factor	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
critical	O
for	O
the	O
inducible	O
expression	O
of	O
multiple	O
cellular	O
and	O
viral	O
genes	O
involved	O
in	O
inflammation	O
and	O
infection	O
including	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
IL-6	O
,	O
and	O
adhesion	O
molecules	O
.	O

The	O
anti-inflammatory	O
drugs	O
sodium	O
salicylate	O
and	O
aspirin	O
inhibited	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
which	O
further	O
explains	O
the	O
mechanism	O
of	O
action	O
of	O
these	O
drugs	O
.	O

This	O
inhibition	O
prevented	O
the	O
degradation	O
of	O
the	O
NF-kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
therefore	O
NF-kappa	O
B	O
was	O
retained	O
in	O
the	O
cytosol	O
.	O

Sodium	O
salicylate	O
and	O
aspirin	O
also	O
inhibited	O
NF-kappa	O
B-dependent	O
transcription	O
from	O
the	O
Ig	O
kappa	O
enhancer	O
and	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
transfected	O
T	O
cells	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
:	O
role	O
of	O
multiple	O
regulatory	O
sites	O
.	O

Interleukin	O
2	O
(	O
IL-2	O
)	O
is	O
an	O
important	O
lymphokine	O
required	O
in	O
the	O
process	O
of	O
T	O
cell	O
activation	O
,	O
proliferation	O
,	O
clonal	O
expansion	O
and	O
differentiation	O
.	O

The	O
IL-2	O
gene	O
displays	O
both	O
T	O
cell	O
specific	O
and	O
inducible	O
expression	O
:	O
it	O
is	O
only	O
expressed	O
in	O
CD4+	O
T	O
cells	O
after	O
antigenic	O
or	O
mitogenic	O
stimulation	O
.	O

Several	O
cis-acting	O
regulatory	O
sites	O
are	O
required	O
for	O
induction	O
of	O
the	O
IL-2	O
gene	O
after	O
stimulation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
analysed	O
the	O
function	O
of	O
these	O
cis-acting	O
regulatory	O
sites	O
in	O
the	O
context	O
of	O
the	O
native	O
IL-2	O
enhancer	O
and	O
promoter	O
sequence	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
the	O
NFAT	O
(	O
-276	O
to	O
-261	O
)	O
,	O
the	O
distal	O
octamer	O
(	O
-256	O
to	O
-248	O
)	O
and	O
the	O
proximal	O
octamer	O
(	O
-75	O
to	O
-66	O
)	O
sites	O
not	O
only	O
act	O
as	O
enhancers	O
of	O
IL-2	O
gene	O
transcription	O
in	O
the	O
presence	O
of	O
cellular	O
stimulation	O
,	O
but	O
also	O
have	O
a	O
silencing	O
effect	O
on	O
IL-2	O
gene	O
expression	O
in	O
resting	O
cells	O
.	O

Two	O
other	O
sites	O
display	O
disparate	O
effects	O
on	O
IL-2	O
gene	O
expression	O
in	O
different	O
T	O
leukemia	O
cell	O
lines	O
:	O
the	O
distal	O
purine	O
box	O
(	O
-291	O
to	O
-277	O
)	O
and	O
the	O
proximal	O
purine	O
box	O
sites	O
(	O
-145	O
to	O
-128	O
)	O
.	O

Finally	O
,	O
the	O
AP-1	O
(	O
-186	O
to	O
-176	O
)	O
and	O
the	O
kappa	O
B	O
sites	O
(	O
-206	O
to	O
-195	O
)	O
respond	O
to	O
different	O
cellular	O
activation	O
in	O
EL4	O
cells	O
.	O

The	O
AP-1	O
site	O
mediated	O
the	O
response	O
to	O
PMA	O
stimulation	O
while	O
the	O
kappa	O
B	O
site	O
responded	O
to	O
IL-1	O
stimulation	O
.	O

These	O
data	O
suggest	O
that	O
the	O
regulation	O
of	O
IL-2	O
gene	O
expression	O
is	O
a	O
complex	O
process	O
and	O
multiple	O
cis-acting	O
regulatory	O
sites	O
interact	O
to	O
exert	O
different	O
effects	O
in	O
T	O
cells	O
representative	O
of	O
alternative	O
stages	O
of	O
differentiation	O
.	O

Superantigens	O
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Binding	O
of	O
superantigens	O
to	O
MHC	O
class	O
II	O
molecules	O
results	O
in	O
transduction	O
of	O
biochemical	O
signals	O
leading	O
to	O
cellular	O
activation	O
and	O
gene	O
expression	O
.	O

We	O
demonstrate	O
that	O
the	O
staphylococcal	O
superantigens	O
toxic	O
shock	O
syndrome	O
toxin-1	O
(	O
TSST-1	O
)	O
and	O
staphylococcal	O
enterotoxin	O
A	O
(	O
SEA	O
)	O
activate	O
HIV-1-LTR-driven	O
transcription	O
of	O
chloramphenicol	O
acetyl	O
transferase	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
THP-1	O
.	O

Induction	O
of	O
HIV-1-LTR-driven	O
transcription	O
in	O
THP-1	O
cells	O
by	O
superantigens	O
was	O
associated	O
with	O
the	O
induction	O
of	O
nuclear	O
factor-kappa	O
B	O
DNA-binding	O
activity	O
.	O

Superantigens	O
also	O
increased	O
viral	O
protein	O
secretion	O
from	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor-pretreated	O
chronically	O
infected	O
human	O
monocytic	O
cell	O
line	O
U1	O
.	O

Induction	O
of	O
HIV-1	O
gene	O
expression	O
in	O
monocytic	O
cells	O
by	O
superantigens	O
occurred	O
via	O
tumor	O
necrosis	O
factor-alpha-dependent	O
and	O
-independent	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
superantigens	O
and	O
other	O
MHC	O
class	O
II	O
ligands	O
may	O
activate	O
HIV-1	O
gene	O
expression	O
in	O
monocytes/macrophages	O
.	O

DNA-binding	O
and	O
transcriptional	O
regulatory	O
properties	O
of	O
hepatic	O
leukemia	O
factor	O
(	O
HLF	O
)	O
and	O
the	O
t	O
(	O
17	O
;	O
19	O
)	O
acute	O
lymphoblastic	O
leukemia	O
chimera	O
E2A-HLF	O
.	O

The	O
t	O
(	O
17	O
;	O
19	O
)	O
translocation	O
in	O
acute	O
lymphoblastic	O
leukemias	O
results	O
in	O
creation	O
of	O
E2A-hepatic	O
leukemia	O
factor	O
(	O
HLF	O
)	O
chimeric	O
proteins	O
that	O
contain	O
the	O
DNA-binding	O
and	O
protein	O
dimerization	O
domains	O
of	O
the	O
basic	O
leucine	O
zipper	O
(	O
bZIP	O
)	O
protein	O
HLF	O
fused	O
to	O
a	O
portion	O
of	O
E2A	O
proteins	O
with	O
transcriptional	O
activation	O
properties	O
.	O

An	O
in	O
vitro	O
binding	O
site	O
selection	O
procedure	O
was	O
used	O
to	O
determine	O
DNA	O
sequences	O
preferentially	O
bound	O
by	O
wild-type	O
HLF	O
and	O
chimeric	O
E2A-HLF	O
proteins	O
isolated	O
from	O
various	O
t	O
(	O
17	O
;	O
19	O
)	O
-bearing	O
leukemias	O
.	O

All	O
were	O
found	O
to	O
selectively	O
bind	O
the	O
consensus	O
sequence	O
5'-GTTACGTAAT-3	O
'	O
with	O
high	O
affinity	O
.	O

Wild-type	O
and	O
chimeric	O
HLF	O
proteins	O
also	O
bound	O
closely	O
related	O
sites	O
identified	O
previously	O
for	O
bZIP	O
proteins	O
of	O
both	O
the	O
proline-	O
and	O
acidic	O
amino	O
acid-rich	O
(	O
PAR	O
)	O
and	O
C/EBP	O
subfamilies	O
;	O
however	O
,	O
E2A-HLF	O
proteins	O
were	O
significantly	O
less	O
tolerant	O
of	O
certain	O
deviations	O
from	O
the	O
HLF	O
consensus	O
binding	O
site	O
.	O

These	O
differences	O
were	O
directly	O
attributable	O
to	O
loss	O
of	O
an	O
HLF	O
ancillary	O
DNA-binding	O
domain	O
in	O
all	O
E2A-HLF	O
chimeras	O
and	O
were	O
further	O
exacerbated	O
by	O
a	O
zipper	O
mutation	O
in	O
one	O
isolate	O
.	O

Both	O
wild-type	O
and	O
chimeric	O
HLF	O
proteins	O
displayed	O
transcriptional	O
activator	O
properties	O
in	O
lymphoid	O
and	O
nonlymphoid	O
cells	O
on	O
reporter	O
genes	O
containing	O
HLF	O
or	O
C/EBP	O
consensus	O
binding	O
sites	O
.	O

But	O
on	O
reporter	O
genes	O
with	O
nonoptimal	O
binding	O
sites	O
,	O
their	O
transcriptional	O
properties	O
diverged	O
and	O
E2A-HLF	O
competitively	O
inhibited	O
activation	O
by	O
wild-type	O
PAR	O
proteins	O
.	O

These	O
findings	O
establish	O
a	O
spectrum	O
of	O
binding	O
site-specific	O
transcriptional	O
properties	O
for	O
E2A-HLF	O
which	O
may	O
preferentially	O
activate	O
expression	O
of	O
select	O
subordinate	O
genes	O
as	O
a	O
homodimer	O
and	O
potentially	O
antagonize	O
expression	O
of	O
others	O
through	O
heteromeric	O
interactions	O
.	O

Inhibition	O
of	O
activation	O
of	O
transcription	O
factor	O
AP-1	O
by	O
CD28	O
signalling	O
in	O
human	O
T-cells	O
.	O

Co-stimulation	O
of	O
T-lymphocytes	O
by	O
T-cell	O
receptor	O
(	O
TcR	O
)	O
occupancy	O
and	O
activation	O
of	O
the	O
CD28	O
surface	O
molecule	O
results	O
in	O
enhanced	O
proliferation	O
and	O
interleukin	O
2	O
(	O
IL-2	O
)	O
production	O
.	O

The	O
increase	O
in	O
IL-2	O
gene	O
expression	O
triggered	O
by	O
CD28	O
involves	O
a	O
kappa	O
B-like	O
sequence	O
in	O
the	O
5'-regulatory	O
region	O
of	O
the	O
IL-2	O
promoter	O
,	O
called	O
CD28-responsive	O
element	O
.	O

Stimulation	O
of	O
T-cells	O
by	O
agonistic	O
anti-CD28	O
antibodies	O
in	O
conjunction	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-	O
or	O
TcR-derived	O
signals	O
induces	O
the	O
enhanced	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

Here	O
we	O
report	O
that	O
CD28	O
engagement	O
,	O
however	O
,	O
exerts	O
opposite	O
effects	O
on	O
the	O
transcription	O
factor	O
AP-1	O
.	O

Whereas	O
anti-CD28	O
together	O
with	O
PMA	O
increased	O
the	O
DNA	O
binding	O
and	O
trans-activation	O
activity	O
of	O
NF-kappa	O
B	O
,	O
PMA-induced	O
activation	O
of	O
AP-1	O
was	O
significantly	O
suppressed	O
.	O

The	O
inhibitory	O
effect	O
exerted	O
by	O
anti-CD28	O
was	O
observed	O
at	O
the	O
level	O
of	O
DNA	O
binding	O
as	O
well	O
as	O
in	O
functional	O
reporter-gene	O
assays	O
.	O

These	O
results	O
suggest	O
that	O
the	O
two	O
transcription	O
factors	O
are	O
independently	O
regulated	O
and	O
may	O
perform	O
different	O
functions	O
during	O
T-cell	O
activation	O
.	O

Induction	O
of	O
IL-8	O
expression	O
in	O
T	O
cells	O
uses	O
the	O
CD28	O
costimulatory	O
pathway	O
.	O

IL-8	O
,	O
a	O
potent	O
chemotactic	O
factor	O
for	O
neutrophil	O
granulocytes	O
and	O
lymphocytes	O
,	O
is	O
a	O
proinflammatory	O
cytokine	O
secreted	O
by	O
a	O
variety	O
of	O
cell	O
types	O
,	O
including	O
T	O
cells	O
.	O

Stimulation	O
of	O
the	O
CD28	O
cell	O
surface	O
molecule	O
delivers	O
costimulatory	O
signals	O
essential	O
for	O
lymphokine	O
production	O
in	O
activated	O
T	O
cells	O
via	O
a	O
conserved	O
sequence	O
element	O
found	O
in	O
the	O
promoter	O
of	O
several	O
lymphokine	O
genes	O
.	O

Anti-CD28-stimulated	O
T	O
cells	O
produced	O
significant	O
amounts	O
of	O
IL-8	O
;	O
additionally	O
,	O
costimulation	O
with	O
anti-CD3	O
and	O
anti-CD28	O
Abs	O
resulted	O
in	O
a	O
synergistic	O
induction	O
of	O
IL-8	O
secretion	O
.	O

Sequence	O
homology	O
,	O
single	O
nucleotide	O
mutations	O
,	O
and	O
anti-CD28	O
Ab	O
stimulation	O
studies	O
established	O
that	O
the	O
NF-kappa	O
B-like	O
sequence	O
in	O
the	O
promoter	O
of	O
the	O
IL-8	O
gene	O
functioned	O
as	O
a	O
CD28	O
response	O
element	O
.	O

Furthermore	O
,	O
cyclosporin	O
A	O
,	O
but	O
not	B-Negation
rapamycin	I-Negation
,	O
blocked	O
the	O
synergistic	O
induction	O
of	O
IL-8	O
expression	O
achieved	O
with	O
anti-CD3	O
and	O
anti-CD28	O
costimulation	O
.	O

The	O
involvement	O
of	O
a	O
CD28	O
response	O
element	O
in	O
the	O
induction	O
of	O
IL-8	O
expression	O
in	O
activated	O
T	O
cells	O
may	O
provide	O
new	O
insights	O
into	O
the	O
pathogenesis	O
and	O
persistence	O
of	O
immune	O
disorders	O
characterized	O
by	O
increased	O
levels	O
of	O
IL-8	O
,	O
such	O
as	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

Signals	O
and	O
nuclear	O
factors	O
that	O
regulate	O
the	O
expression	O
of	O
interleukin-4	O
and	O
interleukin-5	O
genes	O
in	O
helper	O
T	O
cells	O
.	O

Mouse	O
thymoma	O
line	O
EL-4	O
cells	O
produce	O
cytokines	O
such	O
as	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
IL-3	O
,	O
IL-4	O
,	O
IL-10	O
,	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
in	O
response	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

EL-4	O
cells	O
also	O
produce	O
low	O
levels	O
of	O
IL-5	O
when	O
stimulated	O
by	O
PMA	O
alone	O
;	O
however	O
,	O
cAMP	O
greatly	O
augments	O
PMA-dependent	O
IL-5	O
production	O
.	O

A	O
transient	O
transfection	O
assay	O
revealed	O
that	O
two	O
signals	O
,	O
PMA	O
and	O
cAMP	O
,	O
are	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-5	O
promoter	O
.	O

In	O
contrast	O
,	O
cAMP	O
almost	O
completely	O
inhibited	O
the	O
PMA-dependent	O
activation	O
of	O
the	O
endogenous	O
IL-2	O
gene	O
,	O
as	O
well	O
as	O
the	O
transfected	O
IL-2	O
promoter	O
.	O

These	O
results	O
indicate	O
that	O
the	O
IL-5	O
gene	O
is	O
positively	O
regulated	O
by	O
cAMP	O
in	O
a	O
manner	O
opposite	O
to	O
that	O
for	O
the	O
IL-2	O
gene	O
.	O

One	O
of	O
the	O
nuclear	O
factors	O
(	O
NFs	O
)	O
that	O
regulates	O
the	O
response	O
of	O
the	O
IL-5	O
promoter	O
to	O
cAMP	O
and	O
PMA	O
has	O
properties	O
similar	O
to	O
NF	O
for	O
activated	O
t	O
cell	O
.	O

The	O
P	O
sequence	O
of	O
the	O
IL-4	O
gene	O
,	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
PMA	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF	O
kappa	O
B	O
and	O
the	O
NF-activated	O
T	O
cell	O
binding	O
sites	O
.	O

We	O
attempted	O
to	O
determine	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF-kappa	O
B	O
and	O
nuclear	O
factor	O
for	O
activated	O
T	O
cell	O
(	O
NF-AT	O
)	O
.	O

In	O
electromobility	O
shift	O
assays	O
both	O
NF-kappa	O
B	O
(	O
P65	O
or	O
P65/P50	O
heterodimer	O
)	O
and	O
NF-AT	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

However	O
,	O
sequence	O
specificity	O
of	O
NF-AT	O
was	O
more	O
similar	O
to	O
that	O
of	O
NF	O
(	O
P	O
)	O
,	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	O
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
.	O

These	O
results	O
indicate	O
that	O
a	O
component	O
or	O
components	O
of	O
NF-AT	O
have	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
,	O
whereas	O
NF-kappa	O
B	O
alone	O
does	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
Jurkat	O
crude	O
extract	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
NF-AT-like	O
factors	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
IL-4	O
and	O
IL-5	O
genes	O
.	O

Structure	O
and	O
expression	O
of	O
the	O
human	O
GATA3	O
gene	O
.	O

GATA3	O
,	O
a	O
member	O
of	O
the	O
GATA	O
family	O
that	O
is	O
abundantly	O
expressed	O
in	O
the	O
T-lymphocyte	O
lineage	O
,	O
is	O
thought	O
to	O
participate	O
in	O
T-cell	O
receptor	O
gene	O
activation	O
through	O
binding	O
to	O
enhancers	O
.	O

To	O
understand	O
GATA3	O
gene	O
regulation	O
,	O
we	O
cloned	O
the	O
human	O
gene	O
and	O
the	O
5	O
'	O
end	O
of	O
the	O
mouse	O
GATA3	O
gene	O
.	O

We	O
show	O
that	O
the	O
human	O
GATA3	O
gene	O
contains	O
six	O
exons	O
distributed	O
over	O
17	O
kb	O
of	O
DNA	O
.	O

The	O
two	O
human	O
GATA3	O
zinc	O
fingers	O
are	O
encoded	O
by	O
two	O
separate	O
exons	O
highly	O
conserved	O
with	O
those	O
of	O
GATA1	O
,	O
but	O
no	B-Negation
other	I-Negation
structural	I-Negation
homologies	I-Negation
between	I-Negation
these	I-Negation
two	I-Negation
genes	I-Negation
can	I-Negation
be	I-Negation
found	I-Negation
.	O

The	O
human	O
and	O
mouse	O
GATA3	O
transcription	O
units	O
start	O
at	O
a	O
major	O
initiation	O
site	O
.	O

The	O
promoter	O
sequence	O
analysis	O
of	O
these	O
two	O
genes	O
revealed	O
that	O
they	O
are	O
embedded	O
within	O
a	O
CpG	O
island	O
and	O
share	O
structural	O
features	O
often	O
found	O
in	O
the	O
promoters	O
of	O
housekeeping	O
genes	O
.	O

Finally	O
,	O
we	O
show	O
that	O
a	O
DNA	O
fragment	O
containing	O
the	O
human	O
GATA3	O
transcription	O
unit	O
,	O
3	O
kb	O
upstream	O
from	O
the	O
initiation	O
site	O
and	O
4	O
kb	O
downstream	O
from	O
the	O
polyadenylation	O
site	O
,	O
displays	O
T-cell	O
specificity	O
.	O

Overproduction	O
of	O
NFKB2	O
(	O
lyt-10	O
)	O
and	O
c-Rel	O
:	O
a	O
mechanism	O
for	O
HTLV-I	O
Tax-mediated	O
trans-activation	O
via	O
the	O
NF-kappa	O
B	O
signalling	O
pathway	O
.	O

Molecular	O
,	O
biochemical	O
and	O
epidemiological	O
evidence	O
implicate	O
HTLV-I	O
as	O
an	O
etiologic	O
agent	O
of	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
.	O

The	O
Tax	O
protein	O
of	O
HTLV-I	O
,	O
a	O
positive	O
transcriptional	O
activator	O
of	O
HTLV-I	O
gene	O
expression	O
,	O
is	O
a	O
viral	O
oncogene	O
that	O
also	O
increases	O
transcription	O
of	O
cellular	O
genes	O
including	O
GM-CSF	O
,	O
IL-2R	O
alpha	O
and	O
IL-2	O
.	O

One	O
of	O
the	O
cellular	O
targets	O
of	O
the	O
trans-activating	O
effects	O
of	O
Tax	O
is	O
the	O
NF-kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
,	O
pleiotropic	O
regulators	O
of	O
immunoregulatory	O
,	O
cytokine	O
and	O
viral	O
gene	O
expression	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
NFKB2	O
(	O
lyt-10	O
)	O
and	O
c-Rel	O
are	O
overexpressed	O
in	O
HTLV-I	O
infected	O
and	O
Tax-expressing	O
cells	O
and	O
,	O
together	O
,	O
account	O
for	O
the	O
majority	O
of	O
the	O
constitutive	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
these	O
cells	O
before	O
and	O
after	O
PMA	O
stimulation	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
a	O
Tax-dependent	O
correlation	O
between	O
expression	O
of	O
NFKB2	O
(	O
p100	O
)	O
and	O
processing	O
to	O
the	O
DNA	O
binding	O
NFKB2	O
(	O
p52	O
)	O
form	O
,	O
induction	O
of	O
c-Rel	O
,	O
and	O
trans-activation	O
of	O
NF-kappa	O
B-mediated	O
gene	O
expression	O
.	O

Furthermore	O
,	O
the	O
NFKB2	O
precursor	O
is	O
physically	O
associated	O
with	O
c-Rel	O
and	O
with	O
Tax	O
in	O
HTLV-I	O
infected	O
cells	O
.	O

We	O
propose	O
that	O
NFKB2	O
synthesis	O
and	O
processing	O
allows	O
continuous	O
nuclear	O
expression	O
of	O
an	O
otherwise	O
cytoplasmic	O
protein	O
and	O
,	O
in	O
conjunction	O
with	O
overexpression	O
of	O
c-Rel	O
,	O
NFKB2	O
alters	O
the	O
NF-kappa	O
B	O
signalling	O
pathway	O
and	O
contributes	O
to	O
leukemic	O
transformation	O
of	O
T	O
cells	O
by	O
HTLV-I	O
.	O

trans-activation	O
of	O
the	O
HIV	O
promoter	O
by	O
a	O
cDNA	O
and	O
its	O
genomic	O
clones	O
of	O
human	O
herpesvirus-6	O
.	O

Human	O
herpesvirus	O
6	O
(	O
HHV-6	O
)	O
is	O
a	O
lymphotropic	O
herpesvirus	O
,	O
and	O
in	O
vitro	O
,	O
it	O
can	O
productively	O
infect	O
human	O
CD4+	O
T	O
cells	O
as	O
HIV-1	O
.	O

Co-infection	O
of	O
T	O
cells	O
by	O
HIV-1	O
and	O
HHV-6	O
can	O
lead	O
to	O
both	O
activation	O
of	O
the	O
HIV-1	O
promoter	O
and	O
acceleration	O
of	O
the	O
cytopathic	O
effects	O
.	O

An	O
HHV-6	O
(	O
GS	O
)	O
cDNA	O
clone	O
,	O
pCD41	O
,	O
encoding	O
for	O
a	O
41-kDa	O
nuclear	O
protein	O
was	O
identified	O
and	O
characterized	O
previously	O
(	O
Chang	O
and	O
Balachandran	O
,	O
J.	O
Virol.	O
65	O
,	O
2884-2894	O
and	O
7085	O
,	O
1991	O
)	O
.	O

Sequence	O
analyses	O
show	O
that	O
this	O
protein	O
has	O
significant	O
homology	O
with	O
the	O
human	O
cytomegalovirus	O
UL44	O
gene	O
coding	O
for	O
the	O
ICP36	O
family	O
of	O
early-late-class	O
phosphoprotein	O
.	O

Using	O
this	O
cDNA	O
as	O
the	O
probe	O
,	O
a	O
3.8-kb	O
EcoRI	O
genomic	O
fragment	O
encoding	O
the	O
HHV-6	O
(	O
GS	O
)	O
P41	O
was	O
cloned	O
and	O
designated	O
as	O
pGD41	O
.	O

When	O
cotransfected	O
with	O
the	O
HIV	O
LTR	O
CAT	O
into	O
CV-1	O
cells	O
,	O
both	O
the	O
pCD41	O
and	O
pGD41	O
clones	O
trans-activated	O
the	O
HIV	O
LTR	O
.	O

Sequence	O
analyses	O
of	O
pCD41	O
indicate	O
that	O
there	O
are	O
two	O
potential	O
open	O
reading	O
frames	O
(	O
ORFs	O
)	O
,	O
A	O
and	O
B	O
,	O
which	O
are	O
homologous	O
to	O
the	O
ORFs	O
found	O
in	O
the	O
genomic	O
clone	O
pGD41	O
.	O

Deletion	O
constructs	O
of	O
the	O
pCD41	O
clone	O
demonstrated	O
that	O
ORF-A	O
was	O
critical	O
for	O
the	O
HIV	O
LTR	O
activation	O
.	O

Deletion	O
analyses	O
of	O
the	O
pCD41	O
ORF-A	O
and	O
the	O
use	O
of	O
promoter	O
constructs	O
further	O
mapped	O
an	O
internal	O
functional	O
promoter	O
within	O
the	O
pCD41	O
sequence	O
that	O
can	O
direct	O
the	O
synthesis	O
of	O
the	O
trans-activating	O
protein	O
.	O

By	O
using	O
HIV	O
LTR	O
deletion	O
mutants	O
,	O
the	O
NF-kappa	O
B	O
binding	O
sites	O
were	O
found	O
to	O
be	O
critical	O
for	O
response	O
to	O
the	O
pCD41	O
trans-activation	O
.	O

Activation	O
of	O
the	O
interleukin	O
6	O
gene	O
by	O
Mycobacterium	O
tuberculosis	O
or	O
lipopolysaccharide	O
is	O
mediated	O
by	O
nuclear	O
factors	O
NF-IL6	O
and	O
NF-kappa	O
B	O
[	O
published	O
erratum	O
appears	O
in	O
Proc	O
Natl	O
Acad	O
Sci	O
U	O
S	O
A	O
1995	O
Apr	O
11	O
;	O
92	O
(	O
8	O
)	O
:3632	O
]	O

The	O
host	O
response	O
to	O
Mycobacterium	O
tuberculosis	O
includes	O
granuloma	O
formation	O
at	O
sites	O
of	O
infection	O
and	O
systemic	O
symptoms	O
.	O

Cytokines	O
have	O
been	O
identified	O
by	O
immunohistochemistry	O
in	O
granulomas	O
in	O
animal	O
models	O
of	O
bacillus	O
Calmette-Guerin	O
(	O
BCG	O
)	O
infection	O
and	O
are	O
released	O
by	O
mononuclear	O
phagocytes	O
upon	O
stimulation	O
by	O
mycobacterial	O
proteins	O
.	O

In	O
this	O
regard	O
,	O
the	O
cytokine	O
interleukin	O
6	O
(	O
IL-6	O
)	O
may	O
play	O
a	O
role	O
in	O
the	O
clinical	O
manifestations	O
and	O
pathological	O
events	O
of	O
tuberculosis	O
infection	O
.	O

We	O
have	O
demonstrated	O
that	O
lipoarabinomannan	O
(	O
LAM	O
)	O
from	O
the	O
mycobacterial	O
cell	O
wall	O
,	O
which	O
was	O
virtually	O
devoid	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
stimulated	O
mononuclear	O
phagocytes	O
to	O
release	O
IL-6	O
in	O
a	O
dose-response	O
manner	O
.	O

LAM	O
and	O
LPS	O
were	O
potent	O
inducers	O
of	O
IL-6	O
gene	O
expression	O
in	O
peripheral	O
blood	O
monocytes	O
.	O

Both	O
LAM-	O
and	O
LPS-inducible	O
IL-6	O
promoter	O
activity	O
was	O
localized	O
to	O
a	O
DNA	O
fragment	O
,	O
positions	O
-158	O
to	O
-49	O
,	O
by	O
deletion	O
analysis	O
and	O
chloramphenicol	O
acetyltransferase	O
assay	O
.	O

Two	O
nuclear	O
factor	O
NF-IL6	O
(	O
positions	O
-153	O
to	O
-145	O
and	O
-83	O
to	O
-75	O
)	O
and	O
one	O
nuclear	O
factor	O
NF-kappa	O
B	O
(	O
positions	O
-72	O
to	O
-63	O
)	O
motifs	O
are	O
present	O
within	O
this	O
fragment	O
.	O

Site-directed	O
mutagenesis	O
of	O
one	O
or	O
more	O
of	O
these	O
motifs	O
within	O
the	O
IL-6	O
promoter	O
demonstrated	O
that	O
each	O
has	O
positive	O
regulatory	O
activity	O
and	O
that	O
they	O
could	O
act	O
in	O
a	O
function-	O
and	O
orientation-independent	O
manner	O
.	O

Deletion	O
of	O
all	O
three	O
elements	O
abolished	O
inducibility	O
of	O
IL-6	O
promoter	O
activity	O
by	O
both	O
LAM	O
and	O
LPS	O
.	O

We	O
conclude	O
that	O
the	O
NF-IL6	O
and	O
NF-kappa	O
B	O
sites	O
mediate	O
IL-6	O
induction	O
in	O
response	O
to	O
both	O
LPS	O
and	O
LAM	O
,	O
acting	O
as	O
bacterial	O
or	O
mycobacterial	O
response	O
elements	O
.	O

Calcineurin	O
activates	O
transcription	O
from	O
the	O
GM-CSF	O
promoter	O
in	O
synergy	O
with	O
either	O
protein	O
kinase	O
C	O
or	O
NF-kappa	O
B/AP-1	O
in	O
T	O
cells	O
.	O

Two	O
cis-acting	O
elements	O
GM-kappa	O
B/GC-box	O
and	O
CLE0	O
,	O
of	O
the	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
gene	O
are	O
required	O
for	O
maximal	O
induction	O
in	O
Jurkat	O
T	O
cells	O
by	O
costimulation	O
with	O
phorbol-12-myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
Ca2+	O
ionophore	O
(	O
A23187	O
)	O
.	O

The	O
GM-kappa	O
B	O
sequence	O
is	O
recognized	O
by	O
NF-kappa	O
B	O
,	O
which	O
is	O
mainly	O
induced	O
by	O
PMA	O
.	O

The	O
CLE0	O
sequence	O
interacts	O
with	O
factors	O
,	O
related	O
to	O
a	O
PMA-induced	O
AP-1	O
and	O
a	O
PMA/A23187-induced	O
NF-AT	O
.	O

We	O
examined	O
whether	O
signal	O
transducing	O
components	O
in	O
T	O
cells	O
can	O
activate	O
transcription	O
of	O
the	O
GM-CSF	O
gene	O
.	O

Cotransfection	O
of	O
NF-kappa	O
B	O
(	O
p50/p65	O
)	O
-	O
or	O
AP-1	O
(	O
c-Jun/c-Fos	O
)	O
-	O
expression	O
vectors	O
into	O
Jurkat	O
cells	O
with	O
a	O
luciferase	O
reporter	O
containing	O
the	O
GM-CSF	O
promoter	O
did	O
not	B-Negation
stimulate	I-Negation
transcription	I-Negation
from	I-Negation
the	I-Negation
GM-CSF	I-Negation
promoter	I-Negation
.	O

In	O
contrast	O
,	O
cotransfection	O
with	O
a	O
combination	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
significantly	O
augmented	O
transcription	O
from	O
the	O
GM-CSF	O
promoter	O
containing	O
the	O
GM-kappa	O
B/GC-box	O
and	O
the	O
CLE0	O
(	O
AP-1/NF-AT	O
)	O
.	O

Expression	O
of	O
a	O
constitutively	O
active	O
calcineurin	O
(	O
CN	O
)	O
,	O
a	O
Ca2+/calmodulin-dependent	O
protein	O
phosphatase	O
,	O
potentiated	O
by	O
two	O
fold	O
the	O
transcriptional	O
activation	O
by	O
NF-kappa	O
B/AP-1	O
.	O

Both	O
constitutively	O
active	O
forms	O
of	O
CN	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
synergistically	O
activated	O
transcription	O
from	O
the	O
GM-CSF	O
promoter	O
.	O

These	O
results	O
suggest	O
that	O
cooperation	O
among	O
NF-kappa	O
B-	O
,	O
AP-1-	O
and	O
NF-AT-binding	O
sequences	O
is	O
required	O
for	O
induction	O
of	O
the	O
GM-CSF	O
gene	O
through	O
PKC-	O
and	O
Ca2+-	O
signaling	O
pathways	O
downstream	O
of	O
T	O
cell	O
activation	O
.	O

Characterization	O
of	O
NF	O
(	O
P	O
)	O
,	O
the	O
nuclear	O
factor	O
that	O
interacts	O
with	O
the	O
regulatory	O
P	O
sequence	O
(	O
5'-CGAAAATTTCC-3	O
'	O
)	O
of	O
the	O
human	O
interleukin-4	O
gene	O
:	O
relationship	O
to	O
NF-kappa	O
B	O
and	O
NF-AT	O
.	O

The	O
P	O
sequence	O
of	O
the	O
human	O
interleukin-4	O
(	O
IL-4	O
)	O
gene	O
,	O
which	O
was	O
defined	O
as	O
a	O
responsive	O
element	O
for	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
calcium	O
ionophore	O
(	O
A23187	O
)	O
in	O
Jurkat	O
T	O
cells	O
,	O
shares	O
sequence	O
similarity	O
with	O
the	O
NF-kappa	O
B	O
and	O
the	O
NF-AT	O
binding	O
sites	O
.	O

We	O
examined	O
whether	O
NF	O
(	O
P	O
)	O
,	O
a	O
nuclear	O
factor	O
specific	O
for	O
the	O
P	O
sequence	O
,	O
is	O
related	O
to	O
NF-kappa	O
B	O
and	O
NF-AT	O
.	O

NF-kappa	O
B	O
(	O
P65	O
or	O
P65/P50	O
heterodimer	O
)	O
bound	O
to	O
the	O
P	O
sequence	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
and	O
activated	O
transcription	O
through	O
the	O
P	O
sequence	O
when	O
expression	O
plasmids	O
were	O
cotransfected	O
with	O
P	O
sequence-driven	O
reporter	O
plasmids	O
in	O
Jurkat	O
T	O
cells	O
.	O

In	O
EMSAs	O
,	O
NF	O
(	O
P	O
)	O
binding	O
was	O
inhibited	O
by	O
the	O
unlabeled	O
NF-AT	O
binding	O
site	O
but	O
not	B-Negation
by	I-Negation
the	I-Negation
unlabeled	I-Negation
AP1	I-Negation
binding	I-Negation
site	I-Negation
and	O
purified	O
NF-AT	O
contained	O
an	O
activity	O
that	O
bound	O
to	O
the	O
P	O
sequence	O
.	O

Both	O
mobility	O
shift	O
and	O
sequence	O
specificity	O
of	O
NF-AT	O
were	O
similar	O
to	O
those	O
of	O
NF	O
(	O
P	O
)	O
and	O
only	O
a	O
small	O
amount	O
of	O
P65	O
was	O
detected	O
in	O
NF	O
(	O
P	O
)	O
in	O
crude	O
nuclear	O
extracts	O
.	O

These	O
results	O
indicate	O
that	O
the	O
component	O
(	O
s	O
)	O
of	O
NF-AT	O
has	O
the	O
potential	O
to	O
reconstitute	O
NF	O
(	O
P	O
)	O
whereas	O
NF-kappa	O
B	O
alone	O
can	O
not	O
account	O
for	O
NF	O
(	O
P	O
)	O
in	O
crude	O
extracts	O
.	O

Unlike	O
NF-AT	O
,	O
NF	O
(	O
P	O
)	O
does	O
not	B-Negation
contain	I-Negation
AP1	I-Negation
as	I-Negation
its	I-Negation
DNA	I-Negation
binding	I-Negation
component	I-Negation
.	O

Hypoxia	O
causes	O
the	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
through	O
the	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
on	O
tyrosine	O
residues	O
.	O

The	O
response	O
of	O
mammalian	O
cells	O
to	O
stress	O
is	O
controlled	O
by	O
transcriptional	O
regulatory	O
proteins	O
such	O
as	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
to	O
induce	O
a	O
wide	O
variety	O
of	O
early	O
response	O
genes	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
exposure	O
of	O
cells	O
to	O
hypoxia	O
(	O
0.02	O
%	O
O2	O
)	O
results	O
in	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
increased	O
NF-kappa	O
B	O
DNA	O
binding	O
activity	O
,	O
and	O
transactivation	O
of	O
a	O
reporter	O
gene	O
construct	O
containing	O
two	O
NF-kappa	O
B	O
DNA	O
binding	O
sites	O
.	O

Pretreatment	O
of	O
cells	O
with	O
protein	O
tyrosine	O
kinase	O
inhibitors	O
and	O
the	O
dominant	O
negative	O
allele	O
of	O
c-Raf-1	O
(	O
Raf	O
301	O
)	O
inhibited	O
I	O
kappa	O
B	O
alpha	O
degradation	O
,	O
NF-kappa	O
B	O
binding	O
,	O
and	O
transactivation	O
of	O
kappa	O
B	O
reporter	O
constructs	O
by	O
hypoxia	O
.	O

To	O
demonstrate	O
a	O
direct	O
link	O
between	O
changes	O
in	O
the	O
phosphorylation	O
pattern	O
of	O
I	O
kappa	O
B	O
alpha	O
with	O
NF-kappa	O
B	O
activation	O
,	O
we	O
immunoprecipitated	O
I	O
kappa	O
B	O
alpha	O
after	O
varying	O
times	O
of	O
hypoxic	O
exposure	O
and	O
found	O
that	O
its	O
tyrosine	O
phosphorylation	O
status	O
increased	O
during	O
hypoxic	O
exposure	O
.	O

Inhibition	O
of	O
the	O
transfer	O
of	O
tyrosine	O
phosphoryl	O
groups	O
onto	O
I	O
kappa	O
B	O
alpha	O
prevented	O
I	O
kappa	O
B	O
alpha	O
degradation	O
and	O
NF-kappa	O
B	O
binding	O
.	O

In	O
comparison	O
to	O
other	O
activators	O
of	O
NF-kappa	O
B	O
such	O
as	O
phorbol	O
myristate	O
acetate	O
or	O
tumor	O
necrosis	O
factor	O
,	O
we	O
did	O
not	B-Negation
detect	I-Negation
changes	I-Negation
in	I-Negation
the	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
status	I-Negation
of	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
following	I-Negation
treatment	I-Negation
with	I-Negation
either	I-Negation
of	I-Negation
these	I-Negation
agents	I-Negation
.	O

These	O
results	O
suggest	O
that	O
tyrosine	O
phosphorylation	O
of	O
I	O
kappa	O
B	O
alpha	O
during	O
hypoxia	O
is	O
an	O
important	O
proximal	O
step	O
which	O
precedes	O
its	O
dissociation	O
and	O
degradation	O
from	O
NF-kappa	O
B	O
.	O

A	O
transcriptional	O
regulatory	O
element	O
is	O
associated	O
with	O
a	O
nuclease-hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Analysis	O
of	O
the	O
chromatin	O
organization	O
of	O
the	O
integrated	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
genome	O
has	O
previously	O
revealed	O
a	O
major	O
constitutive	O
DNase	O
I-hypersensitive	O
site	O
associated	O
with	O
the	O
pol	O
gene	O
(	O
E.	O
Verdin	O
,	O
J.	O
Virol.	O
65:6790-6799	O
,	O
1991	O
)	O
.	O

In	O
the	O
present	O
report	O
,	O
high-resolution	O
mapping	O
of	O
this	O
site	O
with	O
DNase	O
I	O
and	O
micrococcal	O
nuclease	O
identified	O
a	O
nucleosome-free	O
region	O
centered	O
around	O
nucleotides	O
(	O
nt	O
)	O
4490	O
to	O
4766	O
.	O

A	O
500-bp	O
fragment	O
encompassing	O
this	O
hypersensitive	O
site	O
(	O
nt	O
4481	O
to	O
4982	O
)	O
exhibited	O
transcription-enhancing	O
activity	O
(	O
two-	O
to	O
threefold	O
)	O
when	O
it	O
was	O
cloned	O
in	O
its	O
natural	O
position	O
with	O
respect	O
to	O
the	O
HIV-1	O
promoter	O
after	O
transient	O
transfection	O
in	O
U937	O
and	O
CEM	O
cells	O
.	O

Using	O
in	O
vitro	O
footprinting	O
and	O
gel	O
shift	O
assays	O
,	O
we	O
have	O
identified	O
four	O
distinct	O
binding	O
sites	O
for	O
nuclear	O
proteins	O
within	O
this	O
positive	O
regulatory	O
element	O
.	O

Site	O
B	O
(	O
nt	O
4519	O
to	O
4545	O
)	O
specifically	O
bound	O
four	O
distinct	O
nuclear	O
protein	O
complexes	O
:	O
a	O
ubiquitous	O
factor	O
,	O
a	O
T-cell-specific	O
factor	O
,	O
a	O
B-cell-specific	O
factor	O
,	O
and	O
the	O
monocyte/macrophage-	O
and	O
B-cell-specific	O
transcription	O
factor	O
PU.1/Spi-1	O
.	O

In	O
most	O
HIV-1	O
isolates	O
in	O
which	O
this	B-Negation
PU	I-Negation
box	I-Negation
was	I-Negation
not	I-Negation
conserved	I-Negation
,	O
it	O
was	O
replaced	O
by	O
a	O
binding	O
site	O
for	O
the	O
related	O
factor	O
Ets1	O
.	O

Factors	O
binding	O
to	O
site	O
C	O
(	O
nt	O
4681	O
to	O
4701	O
)	O
had	O
a	O
DNA-binding	O
specificity	O
similar	O
to	O
that	O
of	O
factors	O
binding	O
to	O
site	O
B	O
,	O
except	O
for	O
PU.1/Spi-1	O
.	O

A	O
GC	O
box	O
containing	O
a	O
binding	O
site	O
for	O
Sp1	O
was	O
identified	O
(	O
nt	O
4623	O
to	O
4631	O
)	O
.	O

Site	O
D	O
(	O
nt	O
4816	O
to	O
4851	O
)	O
specifically	O
bound	O
a	O
ubiquitously	O
expressed	O
factor	O
.	O

These	O
results	O
identify	O
a	O
transcriptional	O
regulatory	O
element	O
associated	O
with	O
a	O
nuclease-hypersensitive	O
site	O
in	O
the	O
pol	O
gene	O
of	O
HIV-1	O
and	O
suggest	O
that	O
its	O
activity	O
may	O
be	O
controlled	O
by	O
a	O
complex	O
interplay	O
of	O
cis-regulatory	O
elements	O
.	O

Expression	O
of	O
v-src	O
in	O
T	O
cells	O
correlates	O
with	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
.	O

NF-kappa	O
B	O
is	O
a	O
rapidly	O
inducible	O
transcriptional	O
activator	O
that	O
responds	O
to	O
a	O
variety	O
of	O
signals	O
and	O
influences	O
the	O
expression	O
of	O
many	O
genes	O
involved	O
in	O
the	O
immune	O
response	O
.	O

Protein	O
tyrosine	O
kinases	O
transmit	O
signals	O
from	O
cytokine	O
and	O
immune	O
receptors	O
.	O

Very	O
little	O
information	O
exists	O
linking	O
these	O
two	O
important	O
classes	O
of	O
signaling	O
molecules	O
.	O

We	O
now	O
demonstrate	O
that	O
v-src	O
expression	O
correlates	O
with	O
nuclear	O
expression	O
of	O
a	O
kappa	O
B	O
binding	O
complex	O
similar	O
to	O
that	O
induced	O
by	O
phorbol	O
ester	O
and	O
ionomycin	O
,	O
as	O
detected	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
a	O
variety	O
of	O
kappa	O
B	O
sites	O
.	O

This	O
complex	O
was	O
blocked	O
by	O
the	O
tyrosine	O
kinase	O
inhibitor	O
,	O
herbimycin	O
A	O
.	O

The	O
v-src-induced	O
complex	O
comprised	O
the	O
p50	O
and	O
p65	O
components	O
of	O
NF-kappa	O
B	O
,	O
as	O
determined	O
by	O
supershift	O
and	O
immunoblot	O
analysis	O
.	O

As	O
a	O
functional	O
correlate	O
of	O
this	O
finding	O
,	O
transient	O
co-transfection	O
of	O
HIV-1	O
LTR	O
reporter	O
constructs	O
in	O
a	O
different	O
T	O
cell	O
line	O
demonstrated	O
that	O
v-src	O
activated	O
this	O
promoter	O
in	O
a	O
kappa	O
B-dependent	O
manner	O
.	O

We	O
found	O
that	O
transactivation	O
of	O
the	O
HIV-1	O
LTR	O
by	O
v-src	O
was	O
more	O
sensitive	O
to	O
mutations	O
of	O
the	O
proximal	O
,	O
rather	B-Negation
than	I-Negation
the	I-Negation
distal	I-Negation
,	O
kappa	O
B	O
element	O
.	O

The	O
implications	O
for	O
T	O
cell	O
receptor	O
signaling	O
and	O
HIV-1	O
gene	O
expression	O
are	O
considered	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Nef	O
protein	O
down-regulates	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
in	O
human	O
T	O
cells	O
in	O
vitro	O
after	O
T-cell	O
receptor	O
stimulation	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
negative	O
factor	O
(	O
Nef	O
)	O
has	O
been	O
shown	O
to	O
down-regulate	O
the	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
in	O
vitro	O
.	O

To	O
define	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
Nef	O
protein	O
,	O
the	O
signal	O
transduction	O
pathways	O
which	O
may	O
be	O
affected	O
in	O
T	O
cells	O
by	O
constitutive	O
expression	O
of	O
the	O
nef	O
gene	O
were	O
examined	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
tumor	O
necrosis	O
factor	O
,	O
interleukin-1	O
,	O
or	O
lipopolysaccharide	O
resulted	O
in	O
the	O
recruitment	O
of	O
transcriptional	O
factors	O
to	O
a	O
similar	O
level	O
whether	O
or	O
not	O
the	O
cells	O
expressed	O
the	O
nef	O
gene	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
by	O
mitogens	O
or	O
antibodies	O
to	O
the	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-CD3	O
complex	O
resulted	O
in	O
the	O
down-regulation	O
of	O
transcriptional	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
in	O
cells	O
expressing	O
the	O
nef	O
gene	O
compared	O
with	O
cells	O
not	B-Negation
expressing	I-Negation
the	I-Negation
nef	I-Negation
gene	I-Negation
.	O

Because	O
the	O
Nef	O
protein	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
surface	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
CD3-TCR	I-Negation
complex	I-Negation
,	O
we	O
conclude	O
that	O
the	O
Nef	O
protein	O
down-regulates	O
the	O
transcriptional	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
in	O
T	O
cells	O
in	O
vitro	O
through	O
an	O
effect	O
on	O
the	O
TCR-dependent	O
signal	O
transduction	O
pathway	O
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
neuroblastoma	O
cell	O
lines	O
.	O

The	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
a	O
eukaryotic	O
transcription	O
factor	O
.	O

In	O
B	O
cells	O
and	O
macrophages	O
it	O
is	O
constitutively	O
present	O
in	O
cell	O
nuclei	O
,	O
whereas	O
in	O
many	O
other	O
cell	O
types	O
,	O
NF-kappa	O
B	O
translocates	O
from	O
cytosol	O
to	O
nucleus	O
as	O
a	O
result	O
of	O
transduction	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
,	O
phorbol	O
ester	O
,	O
and	O
other	O
polyclonal	O
signals	O
.	O

Using	O
neuroblastoma	O
cell	O
lines	O
as	O
models	O
,	O
we	O
have	O
shown	O
that	O
in	O
neural	O
cells	O
NF-kappa	O
B	O
was	O
present	O
in	O
the	O
cytosol	O
and	O
translocated	O
into	O
nuclei	O
as	O
a	O
result	O
of	O
TNF	O
alpha	O
treatment	O
.	O

The	O
TNF	O
alpha-activated	O
NF-kappa	O
B	O
was	O
transcriptionally	O
functional	O
.	O

NF-kappa	B-Negation
B	I-Negation
activation	I-Negation
by	I-Negation
TNF	I-Negation
alpha	I-Negation
was	I-Negation
not	I-Negation
correlated	I-Negation
with	I-Negation
cell	I-Negation
differentiation	I-Negation
or	I-Negation
proliferation	I-Negation
.	O

However	O
,	O
reagents	O
such	O
as	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
and	O
the	O
phorbol	O
ester	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
induce	O
phenotypical	O
differentiation	O
of	O
the	O
SH-SY5Y	O
neuroblastoma	O
cell	O
line	O
,	O
activated	O
NF-kappa	O
B	O
,	O
but	O
only	O
in	O
that	O
particular	O
cell	O
line	O
.	O

In	O
a	O
NGF-responsive	O
rat	O
pheochromocytoma	O
cell	O
line	O
,	O
PC12	O
,	O
PMA	O
activated	O
NF-kappa	O
B	O
,	O
whereas	O
NGF	O
did	O
not	B-Negation
.	O

In	O
other	O
neuroblastoma	O
cell	O
lines	O
,	O
such	O
as	O
SK-N-Be	O
(	O
2	O
)	O
,	O
the	O
lack	B-Negation
of	I-Negation
PMA	I-Negation
induction	I-Negation
of	I-Negation
differentiation	I-Negation
was	O
correlated	O
with	O
the	O
lack	B-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
.	O

We	O
found	O
,	O
moreover	O
,	O
that	O
in	O
SK-N-Be	O
(	O
2	O
)	O
cells	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
enzymatic	O
activity	O
was	O
much	O
lower	O
compared	O
with	O
that	O
in	O
a	O
control	O
cell	O
line	O
and	O
that	O
the	O
low	O
PKC	O
enzymatic	O
activity	O
was	O
due	O
to	O
low	O
PKC	O
protein	O
expression	O
.	O

NF-kappa	B-Negation
B	I-Negation
was	I-Negation
not	I-Negation
activated	I-Negation
by	I-Negation
retinoic	I-Negation
acid	I-Negation
,	O
which	O
induced	O
morphological	O
differentiation	O
of	O
all	O
the	O
neuroblastoma	O
cell	O
lines	O
used	O
in	O
the	O
present	O
study	O
.	O

Thus	O
,	O
NF-kappa	O
B	O
activation	O
was	O
not	B-Negation
required	I-Negation
for	I-Negation
neuroblastoma	I-Negation
cell	I-Negation
differentiation	I-Negation
.	O

Furthermore	O
,	O
the	O
results	O
obtained	O
with	O
TNF	O
alpha	O
proved	O
that	O
NF-kappa	O
B	O
activation	O
was	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
induction	I-Negation
of	I-Negation
neuroblastoma	I-Negation
differentiation	I-Negation
.	O

A	O
novel	O
heterodimerization	O
partner	O
for	O
thyroid	O
hormone	O
receptor	O
.	O

Peroxisome	O
proliferator-activated	O
receptor	O
.	O

Retinoid-like	O
receptors	O
play	O
a	O
central	O
role	O
in	O
hormonal	O
responses	O
by	O
forming	O
heterodimers	O
with	O
other	O
nuclear	O
hormone	O
receptors	O
.	O

In	O
this	O
study	O
we	O
have	O
identified	O
the	O
peroxisome	O
proliferator-activated	O
receptor	O
(	O
PPAR	O
)	O
as	O
a	O
new	O
thyroid	O
hormone	O
receptor	O
(	O
THR	O
)	O
auxiliary	O
nuclear	O
protein	O
,	O
heterodimerizing	O
with	O
THR	O
in	O
solution	O
.	O

Although	O
these	O
heterodimers	O
do	O
not	B-Negation
recognize	I-Negation
a	I-Negation
classical	I-Negation
thyroid	I-Negation
hormone	I-Negation
response	I-Negation
element	I-Negation
(	I-Negation
TRE	I-Negation
)	I-Negation
characterized	I-Negation
by	I-Negation
direct	I-Negation
repeat	I-Negation
separated	I-Negation
by	I-Negation
four	I-Negation
nucleotides	I-Negation
(	I-Negation
DR+4	I-Negation
)	I-Negation
,	O
PPAR	O
behaves	O
as	O
a	O
dominant	O
negative	O
regulator	O
of	O
thyroid	O
hormone	O
(	O
TH	O
)	O
action	O
.	O

However	O
,	O
a	O
TH-dependent	O
positive	O
effect	O
is	O
elicited	O
by	O
selective	O
interaction	O
of	O
the	O
THR	O
beta-PPAR	O
but	O
not	B-Negation
the	I-Negation
THR	I-Negation
alpha-PPAR	I-Negation
heterodimer	I-Negation
with	I-Negation
a	I-Negation
novel	I-Negation
TRE	I-Negation
(	I-Negation
DR+2	I-Negation
)	I-Negation
.	O

The	O
critical	O
region	O
of	O
THR	O
beta	O
was	O
mapped	O
to	O
3	O
amino	O
acids	O
in	O
the	O
distal	O
box	O
of	O
the	O
DNA	O
binding	O
domain	O
.	O

Hence	O
,	O
PPAR	O
can	O
positively	O
or	O
negatively	O
influence	O
TH	O
action	O
depending	O
on	O
TRE	O
structure	O
and	O
THR	O
isotype	O
.	O

Hypoxic	O
induction	O
of	O
interleukin-8	O
gene	O
expression	O
in	O
human	O
endothelial	O
cells	O
.	O

Because	O
leukocyte-mediated	O
tissue	O
damage	O
is	O
an	O
important	O
component	O
of	O
the	O
pathologic	O
picture	O
in	O
ischemia/reperfusion	O
,	O
we	O
have	O
sought	O
mechanisms	O
by	O
which	O
PMNs	O
are	O
directed	O
into	O
hypoxic	O
tissue	O
.	O

Incubation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
in	O
hypoxia	O
,	O
PO2	O
approximately	O
14-18	O
Torr	O
,	O
led	O
to	O
time-dependent	O
release	O
of	O
IL-8	O
antigen	O
into	O
the	O
conditioned	O
medium	O
;	O
this	O
was	O
accompanied	O
by	O
increased	O
chemotactic	O
activity	O
for	O
PMNs	O
,	O
blocked	O
by	O
antibody	O
to	O
IL-8	O
.	O

Production	O
of	O
IL-8	O
by	O
hypoxic	O
ECs	O
occurred	O
concomitantly	O
with	O
both	O
increased	O
levels	O
of	O
IL-8	O
mRNA	O
,	O
based	O
on	O
polymerase	O
chain	O
reaction	O
analysis	O
,	O
and	O
increased	O
IL-8	O
transcription	O
,	O
based	O
on	O
nuclear	O
run-on	O
assays	O
.	O

Northern	O
analysis	O
of	O
mRNA	O
from	O
hypoxic	O
ECs	O
also	O
demonstrated	O
increased	O
levels	O
of	O
mRNA	O
for	O
macrophage	O
chemotactic	O
protein-1	O
,	O
another	O
member	O
of	O
the	O
chemokine	O
superfamily	O
of	O
proinflammatory	O
cytokines	O
.	O

IL-8	O
gene	O
induction	O
was	O
associated	O
with	O
the	O
presence	O
of	O
increased	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
ECs	O
for	O
the	O
NF-kB	O
site	O
.	O

Studies	O
with	O
human	O
umbilical	O
vein	O
segments	O
exposed	O
to	O
hypoxia	O
also	O
demonstrated	O
increased	O
elaboration	O
of	O
IL-8	O
antigen	O
compared	O
with	O
normoxic	O
controls	O
.	O

In	O
mice	O
exposed	O
to	O
hypoxia	O
(	O
PO2	O
approximately	O
30-40	O
Torr	O
)	O
,	O
there	O
was	O
increased	O
pulmonary	O
leukostasis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloperoxidase	O
activity	O
in	O
tissue	O
homogenates	O
.	O

In	O
parallel	O
,	O
increased	O
levels	O
of	O
transcripts	O
for	O
IP-10	O
,	O
a	O
murine	O
homologue	O
in	O
the	O
chemokine	O
family	O
related	O
to	O
IL-8	O
,	O
were	O
observed	O
in	O
hypoxic	O
lung	O
tissue	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
hypoxia	O
constitutes	O
a	O
stimulus	O
for	O
leukocyte	O
chemotaxis	O
and	O
tissue	O
leukostasis	O
.	O

Function	O
of	O
NF-kappa	O
B/Rel	O
binding	O
sites	O
in	O
the	O
major	O
histocompatibility	O
complex	O
class	O
II	O
invariant	O
chain	O
promoter	O
is	O
dependent	O
on	O
cell-specific	O
binding	O
of	O
different	O
NF-kappa	O
B/Rel	O
subunits	O
.	O

The	O
promoter	O
of	O
the	O
human	O
major	O
histocompatibility	O
complex	O
class	O
II-associated	O
invariant-chain	O
gene	O
(	O
Ii	O
)	O
contains	O
two	O
NF-kappa	O
B/Rel	O
binding	O
sites	O
located	O
at	O
-109	O
to	O
-118	O
(	O
Ii	O
kappa	O
B-1	O
)	O
and	O
-163	O
to	O
-172	O
(	O
Ii	O
kappa	O
B-2	O
)	O
from	O
the	O
transcription	O
start	O
site	O
.	O

We	O
report	O
here	O
that	O
the	O
differential	O
function	O
of	O
each	O
of	O
these	O
NF-kappa	O
B/Rel	O
sites	O
in	O
several	O
distinct	O
cell	O
types	O
depends	O
on	O
cell-specific	O
binding	O
of	O
NF-kappa	O
B/Rel	O
transcription	O
factors	O
.	O

Ii	O
kappa	O
B-1	O
is	O
a	O
positive	O
regulatory	O
element	O
in	O
B-cell	O
lines	O
and	O
in	O
the	O
Ii-expressing	O
T-cell	O
line	O
,	O
H9	O
,	O
but	O
acts	O
as	O
a	O
negative	O
regulatory	O
element	O
in	O
myelomonocytic	O
and	O
glia	O
cell	O
lines	O
.	O

In	O
vivo	O
protein-DNA	O
contacts	O
are	O
detectable	O
at	O
Ii	O
kappa	O
B-1	O
in	O
cell	O
lines	O
in	O
which	O
this	O
site	O
is	O
functional	O
as	O
either	O
a	O
positive	O
or	O
negative	O
regulator	O
.	O

Electrophoretic	O
mobility	O
supershift	O
assays	O
determine	O
that	O
members	O
of	O
the	O
NF-kappa	O
B/Rel	O
family	O
of	O
transcription	O
factors	O
can	O
bind	O
to	O
this	O
site	O
in	O
vitro	O
and	O
that	O
DNA-binding	O
complexes	O
that	O
contain	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlate	O
with	O
positive	O
regulation	O
whereas	O
the	O
presence	O
of	O
p50	O
correlates	O
with	O
negative	O
regulation	O
.	O

Ii	O
kappa	O
B-2	O
is	O
a	O
site	O
of	O
positive	O
regulation	O
in	O
B-cell	O
lines	O
and	O
a	O
site	O
of	O
negative	O
regulation	O
in	O
H9	O
T	O
cells	O
,	O
myelomonocytic	O
,	O
and	O
glial	O
cell	O
lines	O
.	O

In	O
vivo	O
occupancy	O
of	O
this	O
site	O
is	O
observed	O
only	O
in	O
the	O
H9	O
T-cell	O
line	O
.	O

Again	O
,	O
in	O
vitro	O
supershift	O
studies	O
indicate	O
that	O
the	O
presence	O
of	O
p50	O
,	O
p52	O
,	O
p65	O
,	O
and	O
cRel	O
correlates	O
with	O
positive	O
function	O
whereas	O
the	O
presence	O
of	O
only	O
p50	O
and	O
p52	O
correlates	O
with	O
negative	O
function	O
.	O

This	O
differential	O
binding	O
of	O
specific	O
NF-kappa	O
B/Rel	O
subunits	O
is	O
likely	O
to	O
mediate	O
the	O
disparate	O
functions	O
of	O
these	O
two	O
NF-kappa	O
B/Rel	O
binding	O
sites	O
.	O

Positive	O
regulators	O
of	O
the	O
lineage-specific	O
transcription	O
factor	O
GATA-1	O
in	O
differentiating	O
erythroid	O
cells	O
.	O

The	O
zinc	O
finger	O
transcription	O
factor	O
GATA-1	O
is	O
a	O
major	O
regulator	O
of	O
gene	O
expression	O
in	O
erythroid	O
,	O
megakaryocyte	O
,	O
and	O
mast	O
cell	O
lineages	O
.	O

GATA-1	O
binds	O
to	O
WGATAR	O
consensus	O
motifs	O
in	O
the	O
regulatory	O
regions	O
of	O
virtually	O
all	O
erythroid	O
cell-specific	O
genes	O
.	O

Analyses	O
with	O
cultured	O
cells	O
and	O
cell-free	O
systems	O
have	O
provided	O
strong	O
evidence	O
that	O
GATA-1	O
is	O
involved	O
in	O
control	O
of	O
globin	O
gene	O
expression	O
during	O
erythroid	O
differentiation	O
.	O

Targeted	O
mutagenesis	O
of	O
the	O
GATA-1	O
gene	O
in	O
embryonic	O
stem	O
cells	O
has	O
demonstrated	O
its	O
requirement	O
in	O
normal	O
erythroid	O
development	O
.	O

Efficient	O
rescue	O
of	O
the	O
defect	O
requires	O
an	O
intact	O
GATA	O
element	O
in	O
the	O
distal	O
promoter	O
,	O
suggesting	O
autoregulatory	O
control	O
of	O
GATA-1	O
transcription	O
.	O

To	O
examine	O
whether	O
GATA-1	O
expression	O
involves	O
additional	O
regulatory	O
factors	O
or	O
is	O
maintained	O
entirely	O
by	O
an	O
autoregulatory	O
loop	O
,	O
we	O
have	O
used	O
a	O
transient	O
heterokaryon	O
system	O
to	O
test	O
the	O
ability	O
of	O
erythroid	O
factors	O
to	O
activate	O
the	O
GATA-1	O
gene	O
in	O
nonerythroid	O
nuclei	O
.	O

We	O
show	O
here	O
that	O
proerythroblasts	O
and	O
mature	O
erythroid	O
cells	O
contain	O
a	O
diffusible	O
activity	O
(	O
TAG	O
)	O
capable	O
of	O
transcriptional	O
activation	O
of	O
GATA-1	O
and	O
that	O
this	O
activity	O
decreases	O
during	O
the	O
terminal	O
differentiation	O
of	O
erythroid	O
cells	O
.	O

Nuclei	O
from	O
GATA-1-	O
mutant	O
embryonic	O
stem	O
cells	O
can	O
still	O
be	O
reprogrammed	O
to	O
express	O
their	O
globin	O
genes	O
in	O
erythroid	O
heterokaryons	O
,	O
indicating	O
that	O
de	O
novo	O
induction	O
of	O
GATA-1	O
is	O
not	O
required	O
for	O
globin	O
gene	O
activation	O
following	O
cell	O
fusion	O
.	O

Functional	O
block	O
for	O
1	O
alpha,25-dihydroxyvitamin	O
D3-mediated	O
gene	O
regulation	O
in	O
human	O
B	O
lymphocytes	O
.	O

Elements	O
necessary	O
for	O
the	O
steroid	O
hormone	O
1	O
alpha,25-dihydroxyvitamin	O
D3	O
(	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
)	O
to	O
induce	O
a	O
biological	O
response	O
include	O
the	O
presence	O
of	O
specific	O
intracellular	O
receptors	O
(	O
vitamin	O
D3	O
receptors	O
(	O
VDR	O
)	O
)	O
and	O
modulation	O
of	O
gene	O
expression	O
via	O
hormone-activated	O
receptor	O
binding	O
to	O
regulatory	O
regions	O
of	O
target	O
genes	O
.	O

These	O
parameters	O
were	O
examined	O
in	O
normal	O
and	O
Epstein-Barr	O
virus-immortalized	O
human	O
B	O
cells	O
and	O
compared	O
with	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3-responsive	O
cells	O
of	O
the	O
T	O
and	O
monocytic	O
lineages	O
.	O

Although	O
resting	O
tonsillar	O
B	O
cells	O
did	O
not	B-Negation
express	I-Negation
VDR	I-Negation
mRNA	I-Negation
,	O
activation	O
of	O
these	O
cells	O
with	O
interleukin-4	O
induced	O
VDR	O
in	O
the	O
absence	B-Negation
of	I-Negation
exogenously	I-Negation
supplemented	I-Negation
1	I-Negation
alpha,25-	I-Negation
(	I-Negation
OH	I-Negation
)	I-Negation
2D3	I-Negation
.	O

As	O
indicators	O
of	O
hormone-mediated	O
gene	O
regulation	O
we	O
analyzed	O
modulation	O
of	O
CD23	O
,	O
a	O
common	O
B	O
cell/monocyte	O
surface	O
antigen	O
,	O
and	O
24-hydroxylase	O
.	O

1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
inhibited	O
CD23	O
expression	O
in	O
U937	O
cells	O
,	O
yet	O
failed	B-Negation
to	I-Negation
modulate	I-Negation
CD23	I-Negation
expression	I-Negation
in	I-Negation
B	I-Negation
cells	I-Negation
.	O

Furthermore	O
,	O
1	O
alpha,25-	O
(	O
OH	O
)	O
2D3	O
induced	O
24-hydroxylase	O
mRNA	O
expression	O
and	O
metabolic	O
activity	O
in	O
both	O
U937	O
cells	O
and	O
lectin-activated	O
T	O
cells	O
,	O
yet	O
failed	B-Negation
to	I-Negation
induce	I-Negation
24-hydroxylase	I-Negation
mRNA	I-Negation
or	I-Negation
its	I-Negation
metabolic	I-Negation
activity	I-Negation
in	I-Negation
B	I-Negation
cells	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
although	O
human	O
B	O
lymphocytes	O
can	O
express	O
VDR	O
mRNA	O
and	O
protein	O
,	O
they	O
exhibit	O
a	O
functional	O
block	O
for	O
vitamin	O
D-dependent	O
gene	O
regulation	O
.	O

Effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
on	O
expression	O
of	O
proto-oncogene	O
c-fos	O
.	O

The	O
transcription	O
factor	O
AP-1	O
is	O
an	O
important	O
human	O
mediator	O
of	O
the	O
cellular	O
response	O
to	O
serum	O
,	O
growth	O
factors	O
,	O
and	O
phorbol	O
esters	O
such	O
as	O
12-O-tetradecanoyl-phorbol-13	O
acetate	O
(	O
TPA	O
)	O
.	O

The	O
AP-1	O
complex	O
consists	O
of	O
distinct	O
protein	O
heterodimers	O
encoded	O
by	O
the	O
proto-oncogene	O
c-fos	O
and	O
c-jun	O
mRNA	O
whose	O
gene	O
expression	O
can	O
be	O
induced	O
by	O
TPA	O
,	O
cyclic	O
AMP	O
and	O
growth	O
factors	O
.	O

Recent	O
findings	O
suggest	O
an	O
involvement	O
of	O
reactive	O
oxygen	O
species	O
in	O
the	O
pathway	O
of	O
TPA	O
and	O
protein	O
kinase	O
C	O
leading	O
to	O
expression	O
of	O
c-fos	O
and	O
c-jun	O
mRNA	O
.	O

To	O
investigate	O
the	O
role	O
of	O
reactive	O
oxygen	O
species	O
we	O
studied	O
the	O
effects	O
of	O
alpha-lipoic	O
acid	O
and	O
dihydrolipoic	O
acid	O
(	O
natural	O
thiol	O
antioxidants	O
)	O
on	O
the	O
expression	O
of	O
c-fos	O
mRNA	O
in	O
human	O
Jurkat	O
T	O
cells	O
.	O

When	O
cells	O
were	O
preincubated	O
with	O
dihydrolipoic	O
acid	O
(	O
0.2	O
mM	O
)	O
the	O
expression	O
of	O
c-fos	O
mRNA	O
was	O
suppressed	O
at	O
30	O
min	O
after	O
stimulation	O
of	O
TPA	O
(	O
0.5	O
microM	O
)	O
whereas	O
in	O
the	O
case	O
of	O
preincubation	O
of	O
alpha-lipoic	O
acid	O
(	O
0.2	O
microM	O
)	O
,	O
the	O
expression	O
was	O
enhanced	O
at	O
30	O
min	O
.	O

These	O
studies	O
support	O
the	O
idea	O
that	O
superoxide	O
anion	O
radical	O
plays	O
a	O
role	O
in	O
the	O
expression	O
of	O
c-fos	O
mRNA	O
.	O

Alternative	O
splicing	O
of	O
RNA	O
transcripts	O
encoded	O
by	O
the	O
murine	O
p105	O
NF-kappa	O
B	O
gene	O
generates	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
different	O
inhibitory	O
activities	O
.	O

The	O
gene	O
encoding	O
the	O
105-kDa	O
protein	O
(	O
p105	O
)	O
precursor	O
of	O
the	O
p50	O
subunit	O
of	O
transcription	O
factor	O
NF-kappa	O
B	O
also	O
encodes	O
a	O
p70	O
I	O
kappa	O
B	O
protein	O
,	O
I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
identical	O
to	O
the	O
C-terminal	O
607	O
amino	O
acids	O
of	O
p105	O
.	O

Here	O
we	O
show	O
that	O
alternative	O
RNA	O
splicing	O
generates	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
with	O
properties	O
different	O
from	O
those	O
of	O
p70	O
.	O

One	O
63-kDa	O
isoform	O
,	O
termed	O
I	O
kappa	O
B	O
gamma-1	O
,	O
which	O
lacks	B-Negation
59	I-Negation
amino	I-Negation
acids	I-Negation
C-terminal	I-Negation
to	I-Negation
ankyrin	I-Negation
repeat	I-Negation
7	I-Negation
,	O
has	O
a	O
novel	O
35-amino	O
acid	O
C	O
terminus	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
of	O
the	O
p105	O
gene	O
.	O

A	O
55-kDa	O
isoform	O
,	O
I	O
kappa	O
B	O
gamma-2	O
,	O
lacks	B-Negation
the	I-Negation
190	I-Negation
C-terminal	I-Negation
amino	I-Negation
acids	I-Negation
of	I-Negation
p70I	I-Negation
kappa	I-Negation
B	I-Negation
gamma	I-Negation
.	O

In	O
contrast	O
to	O
p70I	O
kappa	O
B	O
gamma	O
,	O
which	O
is	O
a	O
cytoplasmic	O
protein	O
,	O
I	O
kappa	O
B	O
gamma-1	O
is	O
found	O
in	O
both	O
the	O
cytoplasm	O
and	O
nucleus	O
,	O
whereas	O
I	O
kappa	O
B	O
gamma-2	O
is	O
predominantly	O
nuclear	O
.	O

The	O
I	O
kappa	O
B	O
gamma	O
isoforms	O
also	O
display	O
differences	O
in	O
specificity	O
and	O
affinity	O
for	O
Rel/NF-kappa	O
B	O
proteins	O
.	O

While	O
p70I	O
kappa	O
B	O
gamma	O
inhibits	O
p50-	O
,	O
p65-	O
,	O
and	O
c-Rel-mediated	O
transactivation	O
and/or	O
DNA	O
binding	O
,	O
both	O
I	O
kappa	O
B	O
gamma-1	O
and	O
I	O
kappa	O
B	O
gamma-2	O
are	O
specific	O
for	O
p50	O
and	O
have	O
different	O
affinities	O
for	O
this	O
subunit	O
.	O

The	O
absence	B-Negation
in	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
gamma-1	I-Negation
and	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
gamma-2	I-Negation
of	I-Negation
a	I-Negation
protein	I-Negation
kinase	I-Negation
A	I-Negation
site	I-Negation
whose	I-Negation
phosphorylation	I-Negation
modulates	I-Negation
p70I	I-Negation
kappa	I-Negation
B	I-Negation
gamma	I-Negation
inhibitory	I-Negation
activity	I-Negation
suggests	B-Speculation
that	I-Speculation
alternative	I-Speculation
RNA	I-Speculation
splicing	I-Speculation
may	I-Speculation
be	I-Speculation
used	I-Speculation
to	I-Speculation
generate	I-Speculation
I	I-Speculation
kappa	I-Speculation
B	I-Speculation
gamma	I-Speculation
isoforms	I-Speculation
that	I-Speculation
respond	I-Speculation
differently	I-Speculation
to	I-Speculation
intracellular	I-Speculation
signals	I-Speculation
.	O

Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
lymphoblastoid	O
cells	O
by	O
low-dose	O
ionizing	O
radiation	O
.	O

Nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
a	O
pleiotropic	O
transcription	O
factor	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
several	O
specific	O
genes	O
.	O

Recent	O
reports	O
demonstrated	O
that	O
ionizing	O
radiation	O
in	O
the	O
dose	O
range	O
of	O
2-50	O
Gy	O
results	O
in	O
expression	O
of	O
NF-kappa	O
B	O
in	O
human	O
KG-1	O
myeloid	O
leukemia	O
cells	O
and	O
human	O
B-lymphocyte	O
precursor	O
cells	O
;	O
the	O
precise	O
mechanism	O
involved	O
and	O
the	O
significance	O
are	O
not	O
yet	O
known	O
.	O

The	O
present	O
report	O
demonstrates	O
that	O
even	O
lower	O
doses	O
of	O
ionizing	O
radiation	O
,	O
0.25-2.0	O
Gy	O
,	O
are	O
capable	O
of	O
inducing	O
expression	O
of	O
NF-kappa	O
B	O
in	O
EBV-transformed	O
244B	O
human	O
lymphoblastoid	O
cells	O
.	O

These	O
results	O
are	O
in	O
a	O
dose	O
range	O
where	O
the	O
viability	O
of	O
the	O
cells	O
remains	O
very	O
high	O
.	O

After	O
exposure	O
to	O
137Cs	O
gamma	O
rays	O
at	O
a	O
dose	O
rate	O
of	O
1.17	O
Gy/min	O
,	O
a	O
maximum	O
in	O
expression	O
of	O
NF-kappa	O
B	O
was	O
seen	O
at	O
8	O
h	O
after	O
a	O
0.5-Gy	O
exposure	O
.	O

Time-course	O
studies	O
revealed	O
a	O
biphasic	O
time-dependent	O
expression	O
after	O
0.5-	O
,	O
1-	O
and	O
2-Gy	O
exposures	O
.	O

However	O
,	O
for	O
each	O
time	O
examined	O
,	O
the	O
expression	O
of	O
NF-kappa	O
B	O
was	O
maximum	O
after	O
the	O
0.5-Gy	O
exposure	O
.	O

The	O
expression	O
of	O
the	O
p50	O
and	O
p65	O
NF-kappa	O
B	O
subunits	O
was	O
also	O
shown	O
to	O
be	O
regulated	O
differentially	O
after	O
exposures	O
to	O
1.0	O
and	O
2.0	O
Gy	O
.	O

Some	O
antioxidants	O
inhibit	O
,	O
in	O
a	O
co-ordinate	O
fashion	O
,	O
the	O
production	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
IL-beta	O
,	O
and	O
IL-6	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

Some	O
antioxidants	O
,	O
including	O
butylated	O
hydroxyanisole	O
(	O
BHA	O
)	O
,	O
tetrahydropapaveroline	O
(	O
THP	O
)	O
,	O
nordihydroguiauretic	O
acid	O
,	O
and	O
10,11-dihydroxyaporphine	O
(	O
DHA	O
)	O
,	O
were	O
found	O
to	O
be	O
potent	O
inhibitors	O
of	O
the	O
production	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
,	O
IL-1	O
beta	O
,	O
and	O
IL-6	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
(	O
IC50s	O
in	O
the	O
low	O
micromolar	O
range	O
)	O
.	O

Inhibition	O
of	O
cytokine	O
production	O
was	O
gene	O
selective	O
and	O
not	B-Negation
due	I-Negation
to	I-Negation
general	I-Negation
effects	I-Negation
on	I-Negation
protein	I-Negation
synthesis	I-Negation
.	O

Inhibition	O
of	O
cytokine	O
production	O
by	O
PBMC	O
was	O
observed	O
also	O
when	O
other	O
inducers	O
were	O
used	O
(	O
staphylococci	O
,	O
silica	O
,	O
zymosan	O
)	O
.	O

Much	O
higher	O
concentrations	O
of	O
other	O
antioxidants	O
--	O
including	O
ascorbic	O
acid	O
,	O
trolox	O
,	O
alpha-tocopherol	O
,	O
butylated	O
hydroxytoluene	O
,	O
and	O
the	O
5-lipoxygenase	O
inhibitor	O
zileuton	O
--	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
production	I-Negation
of	I-Negation
these	I-Negation
cytokines	I-Negation
.	O

The	O
active	O
compounds	O
did	O
not	B-Negation
inhibit	I-Negation
IL-1-induced	I-Negation
production	I-Negation
of	I-Negation
IL-6	I-Negation
in	I-Negation
fibroblasts	I-Negation
,	O
showing	O
the	O
cell	O
selectivity	O
of	O
the	O
effect	O
.	O

Antioxidant-mediated	O
inhibition	O
of	O
cytokine	O
production	O
was	O
correlated	O
with	O
low	O
levels	O
of	O
the	O
corresponding	O
messenger	O
RNAs	O
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
THP	O
inhibited	O
transcription	O
of	O
the	O
IL-1	O
beta	O
gene	O
.	O

THP	O
decreased	O
the	O
concentration	O
of	O
the	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
detected	O
in	O
nuclear	O
extracts	O
of	O
PBMC	O
cultured	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
LPS	I-Negation
.	O

THP	O
and	O
DHA	O
markedly	O
decreased	O
the	O
levels	O
of	O
TNF-alpha	O
and	O
IL-1	O
beta	O
in	O
the	O
circulation	O
of	O
mice	O
following	O
LPS	O
injection	O
.	O

Thus	O
antioxidants	O
vary	O
widely	O
in	O
potency	O
as	O
inhibitors	O
of	O
the	O
activation	O
of	O
transcription	O
factors	O
and	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
pro-inflammatory	O
cytokines	O
.	O

Coordinate	O
inhibition	O
of	O
the	O
transcription	O
of	O
genes	O
for	O
inflammatory	O
cytokines	O
could	O
provide	O
a	O
strategy	O
for	O
therapy	O
of	O
diseases	O
with	O
inflammatory	O
pathogenesis	O
and	O
for	O
septic	O
shock	O
.	O

Central	O
nervous	O
system-derived	O
cells	O
express	O
a	O
kappa	O
B-binding	O
activity	O
that	O
enhances	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
in	O
vitro	O
and	O
facilitates	O
TAR-independent	O
transactivation	O
by	O
Tat	O
.	O

The	O
Tat	O
protein	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
is	O
a	O
potent	O
activator	O
of	O
long	O
terminal	O
repeat-directed	O
transcription	O
.	O

While	O
in	O
most	O
cell	O
types	O
,	O
activation	O
requires	O
interaction	O
of	O
Tat	O
with	O
the	O
unusual	O
transcription	O
element	O
TAR	O
,	O
astrocytic	O
glial	O
cells	O
support	O
TAR-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
by	O
Tat	O
.	O

This	O
alternative	O
pathway	O
of	O
Tat	O
activation	O
is	O
mediated	O
by	O
the	O
viral	O
enhancer	O
,	O
a	O
kappa	O
B	O
domain	O
capable	O
of	O
binding	O
the	O
prototypical	O
form	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
present	O
in	O
many	O
cell	O
types	O
,	O
including	O
T	O
lymphocytes	O
.	O

Tat	O
transactivation	O
mediated	O
by	O
the	O
kappa	O
B	O
domain	O
is	O
sufficient	O
to	O
allow	O
replication	O
of	O
TAR-deleted	O
mutant	O
HIV-1	O
in	O
astrocytes	O
.	O

The	O
present	O
study	O
demonstrates	O
the	O
existence	O
of	O
kappa	O
B-specific	O
binding	O
factors	O
present	O
in	O
human	O
glial	O
astrocytes	O
that	O
differ	O
from	O
prototypical	O
NF-kappa	O
B	O
.	O

The	O
novel	O
astrocyte-derived	O
kappa	O
B-binding	O
activity	O
is	O
retained	O
on	O
an	O
HIV-1	O
Tat	O
affinity	O
column	O
,	O
while	O
prototypical	O
NF-kappa	O
B	O
from	O
Jurkat	O
T	O
cells	O
is	O
not	B-Negation
.	O

In	O
vitro	O
transcription	O
studies	O
demonstrate	O
that	O
astrocyte-derived	O
kappa	O
B-binding	O
factors	O
activate	O
transcription	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
and	O
that	O
this	O
activation	O
is	O
dependent	O
on	O
the	O
kappa	O
B	O
domain	O
.	O

Moreover	O
,	O
TAR-independent	O
transactivation	O
of	O
HIV-1	O
transcription	O
is	O
reproduced	O
in	O
vitro	O
in	O
an	O
astrocyte	O
factor-dependent	O
manner	O
which	O
correlates	O
with	O
kappa	O
B-binding	O
activity	O
.	O

The	O
importance	O
of	O
the	O
central	O
nervous	O
system-enriched	O
kappa	O
B	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
HIV-1	O
expression	O
is	O
discussed	O
.	O

An	O
intricate	O
arrangement	O
of	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
regulates	O
activity	O
of	O
the	O
alpha	O
4	O
integrin	O
gene	O
promoter	O
.	O

alpha	O
4	O
integrins	O
mediate	O
cell-cell	O
and	O
cell-extracellular	O
matrix	O
interactions	O
that	O
are	O
critical	O
for	O
maturation	O
and	O
function	O
of	O
the	O
immune	O
system	O
as	O
well	O
as	O
differentiation	O
of	O
skeletal	O
muscle	O
.	O

Here	O
we	O
examine	O
molecular	O
mechanisms	O
controlling	O
the	O
pattern	O
of	O
alpha	O
4	O
expression	O
.	O

The	O
activity	O
of	O
constructs	O
containing	O
5	O
'	O
deletion	O
mutants	O
of	O
the	O
alpha	O
4	O
gene	O
promoter	O
was	O
compared	O
in	O
transfection	O
assays	O
into	O
cell	O
lines	O
that	O
express	O
alpha	O
4	O
and	O
cell	O
lines	O
that	O
do	O
not	B-Negation
.	O

The	O
sequence	O
between	O
position	O
-42	O
and	O
-76	O
base	O
pairs	O
(	O
bp	O
)	O
was	O
required	O
for	O
efficient	O
transcription	O
in	O
cells	O
that	O
express	O
alpha	O
4	O
,	O
but	O
it	O
showed	O
no	B-Negation
activity	I-Negation
in	I-Negation
HeLa	I-Negation
cells	I-Negation
,	I-Negation
which	I-Negation
do	I-Negation
not	I-Negation
express	I-Negation
alpha	I-Negation
4	I-Negation
.	O

Three	O
binding	O
sites	O
for	O
the	O
Ets	O
family	O
of	O
transcription	O
factors	O
are	O
found	O
in	O
this	O
region	O
:	O
two	O
adjacent	O
sites	O
at	O
positions	O
-50	O
and	O
-54	O
bp	O
and	O
a	O
more	O
5	O
'	O
site	O
at	O
position	O
-67	O
bp	O
.	O

Using	O
a	O
series	O
of	O
constructs	O
containing	O
deletions	O
and	O
mutations	O
in	O
this	O
region	O
,	O
we	O
found	O
that	O
the	O
3'-most	O
site	O
alone	O
was	O
sufficient	O
for	O
binding	O
GA-binding	O
protein	O
alpha	O
(	O
GABP	O
alpha	O
)	O
/GABP	O
beta	O
and	O
for	O
a	O
low	O
level	O
of	O
transcriptional	O
activation	O
.	O

When	O
all	O
three	O
sites	O
were	O
present	O
,	O
a	O
second	O
complex	O
``	O
a	O
``	O
was	O
detected	O
,	O
which	O
contains	O
an	O
unknown	O
member	O
of	O
the	O
Ets	O
family	O
.	O

Formation	O
of	O
complex	O
a	O
was	O
cell-type	O
specific	O
and	O
correlated	O
with	O
a	O
high	O
level	O
of	O
transcription	O
.	O

Deletion	O
of	O
the	O
5'-most	O
Ets	O
site	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
binding	I-Negation
to	I-Negation
GABP	I-Negation
alpha/GABP	I-Negation
beta	I-Negation
,	O
but	O
it	O
eliminated	O
a	O
.	O

Concomitant	O
with	O
this	O
loss	O
of	O
a	O
,	O
a	O
new	O
Ets-1-containing	O
complex	O
``	O
c	O
``	O
appeared	O
.	O

Complex	O
c	O
substituted	O
efficiently	O
for	O
complex	O
a	O
in	O
transcriptional	O
activation	O
.	O

We	O
conclude	O
that	O
although	O
neither	B-Negation
of	I-Negation
the	I-Negation
two	I-Negation
5'-most	I-Negation
Ets	I-Negation
sites	I-Negation
alone	I-Negation
binds	I-Negation
nuclear	I-Negation
protein	I-Negation
,	O
they	B-Speculation
appear	I-Speculation
to	I-Speculation
act	I-Speculation
as	I-Speculation
modulators	I-Speculation
which	I-Speculation
control	I-Speculation
the	I-Speculation
pattern	I-Speculation
of	I-Speculation
Ets	I-Speculation
proteins	I-Speculation
that	I-Speculation
bind	I-Speculation
the	I-Speculation
alpha	I-Speculation
4	I-Speculation
gene	I-Speculation
promoter	I-Speculation
.	O

This	O
arrangement	O
of	O
Ets	O
sites	O
,	O
coupled	O
with	O
the	O
tissue-	O
and	O
developmental-specific	O
expression	O
of	O
Ets	O
members	O
,	O
likely	O
play	O
a	O
key	O
role	O
in	O
defining	O
the	O
pattern	O
of	O
alpha	O
4	O
integrin	O
.	O

Lipopolysaccharide	O
induction	O
of	O
tissue	O
factor	O
gene	O
expression	O
in	O
monocytic	O
cells	O
is	O
mediated	O
by	O
binding	O
of	O
c-Rel/p65	O
heterodimers	O
to	O
a	O
kappa	O
B-like	O
site	O
.	O

Exposure	O
of	O
monocytic	O
cells	O
to	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
activates	O
the	O
NF-kappa	O
B/Rel	O
family	O
of	O
proteins	O
and	O
leads	O
to	O
the	O
rapid	O
induction	O
of	O
inflammatory	O
gene	O
products	O
,	O
including	O
tissue	O
factor	O
(	O
TF	O
)	O
.	O

TF	O
is	O
the	O
primary	O
cellular	O
initiator	O
of	O
the	O
coagulation	O
protease	O
cascades	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
a	O
nuclear	O
complex	O
from	O
human	O
monocytic	O
cells	O
that	O
bound	O
to	O
a	O
kappa	O
B-like	O
site	O
,	O
5'-CGGAGTTTCC-3	O
'	O
,	O
in	O
the	O
5'-flanking	O
region	O
of	O
the	O
human	O
TF	O
gene	O
.	O

This	O
nuclear	O
complex	O
was	O
activated	O
by	O
LPS	O
with	O
kinetics	O
that	O
preceded	O
induction	O
of	O
the	O
TF	O
gene	O
.	O

In	O
vitro	O
binding	O
studies	O
demonstrated	O
that	O
the	O
TF	O
site	O
bound	O
translated	O
c-Rel	O
and	O
p65	O
homodimers	O
but	O
not	B-Negation
p50/p65	I-Negation
heterodimers	I-Negation
or	I-Negation
p50	I-Negation
homodimers	I-Negation
.	O

Base-pair	O
substitutions	O
in	O
the	O
TF	O
site	O
indicated	O
that	O
the	O
presence	O
of	O
a	O
cytosine	O
at	O
position	O
1	O
precluded	O
binding	O
of	O
NF-kappa	O
B	O
.	O

In	O
fact	O
,	O
under	O
low-ionic-strength	O
conditions	O
,	O
the	O
TF	O
complex	O
did	O
not	B-Negation
migrate	I-Negation
with	I-Negation
translated	I-Negation
p50/p65	I-Negation
dimers	I-Negation
but	O
instead	O
comigrated	O
with	O
c-Rel/p65	O
dimers	O
.	O

Antibodies	O
against	O
the	O
NF-kappa	O
B	O
and	O
Rel	O
proteins	O
and	O
UV	O
cross-linking	O
studies	O
revealed	O
the	O
presence	O
of	O
c-Rel	O
and	O
p65	O
and	O
the	O
absence	B-Negation
of	I-Negation
p50	I-Negation
in	I-Negation
the	I-Negation
TF	I-Negation
complex	I-Negation
and	O
further	O
showed	O
that	O
c-Rel/p65	O
heterodimers	O
selectively	O
bound	O
to	O
the	O
TF	O
kappa	O
B-like	O
site	O
.	O

Functional	O
studies	O
indicated	O
that	O
the	O
TF	O
site	O
conferred	O
LPS	O
inducibility	O
on	O
a	O
heterologous	O
promoter	O
and	O
was	O
transactivated	O
by	O
c-Rel	O
or	O
p65	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
binding	O
of	O
c-Rel/p65	O
heterodimers	O
to	O
a	O
novel	O
kappa	O
B-like	O
site	O
mediated	O
LPS	O
induction	O
of	O
TF	O
gene	O
expression	O
in	O
monocytic	O
cells	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
Tat	O
upregulates	O
interleukin-2	O
secretion	O
in	O
activated	O
T	O
cells	O
.	O

Dysregulation	O
of	O
cytokines	O
secreted	O
by	O
T	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
Tat	O
on	O
interleukin-2	O
(	O
IL-2	O
)	O
expression	O
,	O
we	O
used	O
IL-2	O
promoter-chloramphenicol	O
acetyltransferase	O
constructs	O
and	O
IL-2-secreting	O
Jurkat	O
T	O
cells	O
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV-1	O
Tat	O
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
phytohemagglutinin	O
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL-2	O
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	O
T	O
cells	O
and	O
primary	O
T	O
cells	O
stimulated	O
by	O
extracellular	O
HIV-1	O
Tat	O
protein	O
.	O

Analysis	O
of	O
mRNA	O
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	O
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF-kappa	O
B	O
site	O
at	O
positions	O
-206	O
to	O
-195	O
of	O
the	O
IL-2	O
promoter	O
was	O
required	O
but	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
the	I-Negation
Tat	I-Negation
effect	I-Negation
.	O

The	O
Tat-mediated	O
increase	O
in	O
IL-2	O
promoter	O
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or-unlike	O
the	O
analogous	O
effect	O
of	O
human	O
T-cell	O
lymphotropic	O
virus	O
type	O
1	O
Tax-by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL-2	O
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	O
cells	O
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	O
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T-helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

Protein	O
kinase	O
C-zeta	O
mediates	O
NF-kappa	O
B	O
activation	O
in	O
human	O
immunodeficiency	O
virus-infected	O
monocytes	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
persistence	O
in	O
a	O
major	O
cell	O
reservoir	O
such	O
as	O
the	O
macrophage	O
remain	O
unknown	O
.	O

NF-kappa	O
B	O
is	O
a	O
transcription	O
factor	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
HIV	O
long	O
terminal	O
repeat	O
and	O
is	O
selectively	O
activated	O
following	O
HIV	O
infection	O
of	O
human	O
macrophages	O
.	O

Although	O
little	O
information	O
as	O
to	O
what	O
signal	O
transduction	O
pathways	O
mediate	O
NF-kappa	O
B	O
activation	O
in	O
monocytes-macrophages	O
is	O
available	O
,	O
our	O
previous	O
work	O
indicated	O
that	O
classical	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
isoenzymes	O
were	O
not	O
involved	O
in	O
the	O
HIV-mediated	O
NF-kappa	O
B	O
activation	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
focused	O
on	O
atypical	O
PKC	O
isoenzymes	O
.	O

PKC-zeta	O
belongs	O
to	O
this	O
family	O
and	O
is	O
known	O
to	O
be	O
an	O
important	O
step	O
in	O
NF-kappa	O
B	O
activation	O
in	O
other	O
cell	O
systems	O
.	O

Immunoblotting	O
experiments	O
with	O
U937	O
cells	O
demonstrate	O
that	O
PKC-zeta	O
is	O
present	O
in	O
these	O
cells	O
,	O
and	O
its	O
expression	O
can	O
be	O
downmodulated	O
by	O
antisense	O
oligonucleotides	O
(	O
AO	O
)	O
.	O

The	O
HIV-mediated	O
NF-kappa	O
B	O
activation	O
is	O
selectively	O
reduced	O
by	O
AO	O
to	O
PKC-zeta	O
.	O

In	O
addition	O
,	O
cotransfection	O
of	O
a	O
negative	O
dominant	O
molecule	O
of	O
PKC-zeta	O
(	O
PKC-zeta	O
mut	O
)	O
with	O
NF-kappa	O
B-dependent	O
reporter	O
genes	O
selectively	O
inhibits	O
the	O
HIV-	O
but	O
not	B-Negation
phorbol	I-Negation
myristate	I-Negation
acetate-	I-Negation
or	I-Negation
lipopolysaccharide-mediated	I-Negation
activation	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
.	O

That	O
PKC-zeta	O
is	O
specific	O
in	O
regulating	O
NF-kappa	O
B	O
is	O
concluded	O
from	O
the	O
inability	O
of	O
PKC-zeta	O
(	O
mut	O
)	O
to	O
interfere	O
with	O
the	O
basal	O
or	O
phorbol	O
myristate	O
acetate-inducible	O
CREB-	O
or	O
AP1-dependent	O
transcriptional	O
activity	O
.	O

Lastly	O
,	O
we	O
demonstrate	O
a	O
selective	O
inhibition	O
of	O
p24	O
production	O
by	O
HIV-infected	O
human	O
macrophages	O
when	O
treated	O
with	O
AO	O
to	O
PKC-zeta	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
atypical	O
PKC	O
isoenzymes	O
,	O
including	O
PKC-zeta	O
,	O
participate	O
in	O
the	O
signal	O
transduction	O
pathways	O
by	O
which	O
HIV	O
infection	O
results	O
in	O
the	O
activation	O
of	O
NF-kappa	O
B	O
in	O
human	O
monocytic	O
cells	O
and	O
macrophages	O
.	O

Initiation	O
binding	O
repressor	O
,	O
a	O
factor	O
that	O
binds	O
to	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
is	O
a	O
glycosylated	O
member	O
of	O
a	O
family	O
of	O
cell	O
growth	O
regulators	O
[	O
corrected	O
]	O
[	O
published	O
erratum	O
appears	O
in	O
Mol	O
Cell	O
Biol	O
1996	O
Feb	O
;	O
16	O
(	O
2	O
)	O
:735	O
]	O

Initiation	O
binding	O
repressor	O
[	O
corrected	O
]	O
(	O
IBR	O
)	O
is	O
a	O
chicken	O
erythrocyte	O
factor	O
(	O
apparent	O
molecular	O
mass	O
,	O
70	O
to	O
73	O
kDa	O
)	O
that	O
binds	O
to	O
the	O
sequences	O
spanning	O
the	O
transcription	O
initiation	O
site	O
of	O
the	O
histone	O
h5	O
gene	O
,	O
repressing	O
its	O
transcription	O
.	O

A	O
variety	O
of	O
other	O
cells	O
,	O
including	O
transformed	O
erythroid	O
precursors	O
,	O
do	O
not	B-Negation
have	I-Negation
IBR	I-Negation
but	O
a	O
factor	O
referred	O
to	O
as	O
IBF	O
(	O
68	O
to	O
70	O
kDa	O
)	O
that	O
recognizes	O
the	O
same	O
IBR	O
sites	O
.	O

We	O
have	O
cloned	O
the	O
IBR	O
cDNA	O
and	O
studied	O
the	O
relationship	O
of	O
IBR	O
and	O
IBF	O
.	O

IBR	O
is	O
a	O
503-amino-acid-long	O
acidic	O
protein	O
which	O
is	O
99.0	O
%	O
identical	O
to	O
the	O
recently	O
reported	O
human	O
NRF-1/alpha-Pal	O
factor	O
and	O
highly	O
related	O
to	O
the	O
invertebrate	O
transcription	O
factors	O
P3A2	O
and	O
erected	O
wing	O
gene	O
product	O
(	O
EWG	O
)	O
.	O

We	O
present	O
evidence	O
that	O
IBR	O
and	O
IBF	O
are	O
most	O
likely	O
identical	O
proteins	O
,	O
differing	O
in	O
their	O
degree	O
of	O
glycosylation	O
.	O

We	O
have	O
analyzed	O
several	O
molecular	O
aspects	O
of	O
IBR/F	O
and	O
shown	O
that	O
the	O
factor	O
associates	O
as	O
stable	O
homodimers	O
and	O
that	O
the	O
dimer	O
is	O
the	O
relevant	O
DNA-binding	O
species	O
.	O

The	O
evolutionarily	O
conserved	O
N-terminal	O
half	O
of	O
IBR/F	O
harbors	O
the	O
DNA-binding/dimerization	O
domain	O
(	O
outer	O
limits	O
,	O
127	O
to	O
283	O
)	O
,	O
one	O
or	O
several	O
casein	O
kinase	O
II	O
sites	O
(	O
37	O
to	O
67	O
)	O
,	O
and	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
(	O
89	O
to	O
106	O
)	O
which	O
appears	O
to	O
be	O
necessary	O
for	O
nuclear	O
targeting	O
.	O

Binding	O
site	O
selection	O
revealed	O
that	O
the	O
alternating	O
RCGCRYGCGY	O
consensus	O
constitutes	O
high-affinity	O
IBR/F	O
binding	O
sites	O
and	O
that	O
the	O
direct-repeat	O
palindrome	O
TGCGCATGCGCA	O
is	O
the	O
optimal	O
site	O
.	O

A	O
survey	O
of	O
genes	O
potentially	O
regulated	O
by	O
this	O
family	O
of	O
factors	O
primarily	O
revealed	O
genes	O
involved	O
in	O
growth-related	O
metabolism	O
.	O

Inhibition	O
of	O
NF-AT-dependent	O
transcription	O
by	O
NF-kappa	O
B	O
:	O
implications	O
for	O
differential	O
gene	O
expression	O
in	O
T	O
helper	O
cell	O
subsets	O
.	O

Activation	O
of	O
individual	O
CD4+	O
T	O
cells	O
results	O
in	O
differential	O
lymphokine	O
expression	O
:	O
interleukin	O
2	O
(	O
IL-2	O
)	O
is	O
preferentially	O
produced	O
by	O
T	O
helper	O
type	O
1	O
(	O
TH1	O
)	O
cells	O
,	O
which	O
are	O
involved	O
in	O
cell-mediated	O
immune	O
responses	O
,	O
whereas	O
IL-4	O
is	O
synthesized	O
by	O
TH2	O
cells	O
,	O
which	O
are	O
essential	O
for	O
humoral	O
immunity	O
.	O

The	O
Ca	O
(	O
2+	O
)	O
-dependent	O
factor	O
NF-ATp	O
plays	O
a	O
key	O
role	O
in	O
the	O
inducible	O
transcription	O
of	O
both	O
these	O
lymphokine	O
genes	O
.	O

However	O
,	O
while	O
IL2	O
expression	O
requires	O
the	O
contribution	O
of	O
Ca	O
(	O
2+	O
)	O
-	O
and	O
protein	O
kinase	O
C-dependent	O
signals	O
,	O
we	O
report	O
that	O
activation	O
of	O
human	O
IL4	O
transcription	O
through	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
pathway	O
is	O
diminished	O
by	O
protein	O
kinase	O
C	O
stimulation	O
in	O
Jurkat	O
T	O
cells	O
.	O

This	O
phenomenon	O
is	O
due	O
to	O
mutually	O
exclusive	O
binding	O
of	O
NF-ATp	O
and	O
NF-kappa	O
B	O
to	O
the	O
P	O
sequence	O
,	O
an	O
element	O
located	O
69	O
bp	O
upstream	O
of	O
the	O
IL4	O
transcription	O
initiation	O
site	O
.	O

Human	O
IL4	O
promoter-mediated	O
transcription	O
is	O
downregulated	O
in	O
Jurkat	O
cells	O
stimulated	O
with	O
the	O
NF-kappa	O
B-activating	O
cytokine	O
tumor	O
necrosis	O
factor	O
alpha	O
and	O
suppressed	O
in	O
RelA-overexpressing	O
cells	O
.	O

In	O
contrast	O
,	O
protein	O
kinase	O
C	O
stimulation	O
or	O
RelA	O
overexpression	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
activity	I-Negation
of	I-Negation
a	I-Negation
human	I-Negation
IL4	I-Negation
promoter	I-Negation
containing	I-Negation
a	I-Negation
mouse	I-Negation
P	I-Negation
sequence	I-Negation
,	I-Negation
which	I-Negation
is	I-Negation
a	I-Negation
higher-affinity	I-Negation
site	I-Negation
for	I-Negation
NF-ATp	I-Negation
and	I-Negation
a	I-Negation
lower-affinity	I-Negation
site	I-Negation
for	I-Negation
RelA	I-Negation
.	O

Thus	O
,	O
competition	O
between	O
two	O
general	O
transcriptional	O
activators	O
,	O
RelA	O
and	O
NF-ATp	O
,	O
mediates	O
the	O
inhibitory	O
effect	O
of	O
protein	O
kinase	O
C	O
stimulation	O
on	O
IL4	O
expression	O
and	O
may	O
contribute	O
to	O
differential	O
gene	O
expression	O
in	O
TH	O
cells	O
.	O

Functional	O
characterization	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
B	O
cell-specific	O
coactivator	O
BOB.1/OBF.1	O
.	O

B	O
cell-specific	O
transcriptional	O
promoter	O
activity	O
mediated	O
by	O
the	O
octamer	O
motif	O
requires	O
the	O
Oct1	O
or	O
Oct2	O
protein	O
and	O
additional	O
B	O
cell-restricted	O
cofactors	O
.	O

One	O
such	O
cofactor	O
,	O
BOB.1/OBF.1	O
,	O
was	O
recently	O
isolated	O
from	O
human	O
B	O
cells	O
.	O

Here	O
,	O
we	O
describe	O
the	O
isolation	O
and	O
detailed	O
characterization	O
of	O
the	O
murine	O
homolog	O
.	O

Full-length	O
cDNAs	O
and	O
genomic	O
clones	O
were	O
isolated	O
,	O
and	O
the	O
gene	O
structure	O
was	O
determined	O
.	O

Comparison	O
of	O
the	O
deduced	O
amino	O
acids	O
shows	O
88	O
%	O
sequence	O
identity	O
between	O
mouse	O
and	O
human	O
BOB.1/OBF.1	O
.	O

The	O
NH2-terminal	O
126	O
amino	O
acids	O
of	O
BOB.1/OBF.1	O
are	O
both	O
essential	O
and	O
sufficient	O
for	O
interaction	O
with	O
the	O
POU	O
domains	O
of	O
either	O
Oct1	O
or	O
Oct2	O
.	O

This	O
protein-protein	O
interaction	O
does	O
not	B-Negation
require	I-Negation
the	I-Negation
simultaneous	I-Negation
binding	I-Negation
of	I-Negation
Oct	I-Negation
proteins	I-Negation
to	I-Negation
DNA	I-Negation
,	O
and	O
high	O
resolution	O
footprinting	O
of	O
the	O
Oct-DNA	O
interaction	O
reveals	O
that	O
binding	O
of	O
BOB.1/OBF.1	O
to	O
Oct1	O
or	O
Oct2	O
does	O
not	B-Negation
alter	I-Negation
the	I-Negation
interaction	I-Negation
with	I-Negation
DNA	I-Negation
.	O

BOB.1/OBF.1	O
can	O
efficiently	O
activate	O
octamer-dependent	O
promoters	O
in	O
fibroblasts	O
;	O
however	O
,	O
it	O
fails	B-Negation
to	I-Negation
stimulate	I-Negation
octamer-dependent	I-Negation
enhancer	I-Negation
activity	I-Negation
.	O

Fusion	O
of	O
subdomains	O
of	O
BOB.1/OBF.1	O
with	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
reveals	O
that	O
both	O
NH2-	O
and	O
COOH-terminal	O
domains	O
of	O
BOB.1/OBF.1	O
contribute	O
to	O
full	O
transactivation	O
function	O
,	O
the	O
COOH-terminal	O
domain	O
is	O
more	O
efficient	O
in	O
this	O
transactivation	O
assay	O
.	O

Consistent	O
with	O
the	O
failure	B-Negation
of	I-Negation
full-length	I-Negation
BOB.1/OBF.1	I-Negation
to	I-Negation
stimulate	I-Negation
octamer-dependent	I-Negation
enhancer	I-Negation
elements	I-Negation
in	I-Negation
non	I-Negation
B	I-Negation
cells	I-Negation
,	O
the	O
GAL4	O
fusions	O
likewise	O
only	O
stimulate	O
from	O
a	O
promoter-proximal	O
position	O
.	O

Polymorphic	O
nucleotides	O
within	O
the	O
human	O
IL-4	O
promoter	O
that	O
mediate	O
overexpression	O
of	O
the	O
gene	O
.	O

Atopy	O
,	O
which	O
predisposes	O
individuals	O
to	O
develop	O
asthma	O
,	O
severe	O
systemic	O
anaphylaxis	O
,	O
and	O
atopic	O
dermatitis	O
,	O
is	O
usually	O
associated	O
with	O
dramatically	O
elevated	O
total	O
serum	O
IgE	O
levels	O
and	O
is	O
thought	O
to	O
be	O
controlled	O
by	O
a	O
major	O
susceptibility	O
gene	O
and	O
multiple	O
minor	O
susceptibility	O
genes	O
.	O

A	O
recent	O
sib-pair	O
analysis	O
revealed	O
a	O
tight	O
linkage	O
between	O
markers	O
on	O
5q31.1	O
and	O
a	O
major	O
susceptibility	O
gene	O
controlling	O
total	O
serum	O
IgE	O
levels	O
.	O

Due	O
to	O
its	O
location	O
within	O
this	O
cluster	O
and	O
its	O
biologic	O
role	O
in	O
Ig	O
class	O
switching	O
and	O
Th2	O
cell	O
differentiation	O
,	O
the	O
IL-4	O
gene	O
has	O
emerged	O
as	O
one	O
major	O
candidate	O
for	O
the	O
atopy	O
gene	O
.	O

In	O
one	O
model	O
,	O
polymorphisms	O
within	O
IL-4	O
regulatory	O
elements	O
might	O
result	O
in	O
overexpression	O
of	O
the	O
gene	O
,	O
amplifying	O
Th2	O
cell	O
differentiation	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

In	O
support	O
of	O
this	O
model	O
,	O
we	O
report	O
that	O
the	O
human	O
IL-4	O
promoter	O
exists	O
in	O
multiple	O
allelic	O
forms	O
that	O
exhibit	O
distinct	O
transcriptional	O
activities	O
in	O
IL-4-positive	O
T	O
cells	O
.	O

A	O
particular	O
allele	O
has	O
an	O
unusually	O
high	O
transcriptional	O
activity	O
.	O

A	O
nucleotide	O
substitution	O
within	O
a	O
recently	O
described	O
OAP40	O
element	O
located	O
just	O
upstream	O
of	O
an	O
NF-AT	O
site	O
(	O
P	O
sequence	O
)	O
appears	O
to	O
be	O
largely	O
responsible	O
for	O
the	O
increased	O
promotor	O
strength	O
of	O
this	O
particular	O
allelic	O
form	O
of	O
the	O
IL-4	O
promoter	O
.	O

In	O
EMSAs	O
,	O
this	O
substitution	O
results	O
in	O
a	O
markedly	O
enhanced	O
affinity	O
for	O
sequence-specific	O
complexes	O
exhibiting	O
an	O
AP-1	O
specificity	O
.	O

The	O
identification	O
of	O
allelic	O
nucleotides	O
,	O
which	O
results	O
in	O
overexpression	O
of	O
the	O
IL-4	O
gene	O
,	O
provides	O
specific	O
targets	O
for	O
a	O
comprehensive	O
screening	O
of	O
atopic	O
and	O
nonatopic	O
individuals	O
and	O
may	O
provide	O
a	O
clue	O
for	O
genetic	O
predisposition	O
for	O
atopy	O
.	O

IL-10	O
cooperates	O
with	O
TNF-alpha	O
to	O
activate	O
HIV-1	O
from	O
latently	O
and	O
acutely	O
infected	O
cells	O
of	O
monocyte/macrophage	O
lineage	O
.	O

IL-10	O
is	O
elevated	O
in	O
HIV-1-infected	O
individuals	O
and	O
has	O
been	O
implicated	O
in	O
disease	O
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
IL-10	O
on	O
the	O
activation	O
of	O
HIV-1	O
from	O
infected	O
monocytes	O
and	O
macrophages	O
.	O

Although	O
IL-10	O
alone	O
did	O
not	B-Negation
induce	I-Negation
HIV-1	I-Negation
replication	I-Negation
,	O
in	O
the	O
presence	O
of	O
TNF-alpha	O
,	O
IL-10	O
markedly	O
enhanced	O
virion	O
production	O
from	O
a	O
chronically	O
infected	O
promonocytic	O
cell	O
line	O
(	O
U1	O
)	O
and	O
in	O
acutely	O
infected	O
monocyte-derived	O
macrophages	O
.	O

Neutralizing	O
mAbs	O
to	O
IL-10	O
and	O
TNF-alpha	O
indicated	O
that	O
both	O
cytokines	O
were	O
essential	O
for	O
the	O
induction	O
and	O
were	O
required	O
to	O
generate	O
a	O
synergistic	O
increase	O
in	O
virus	O
expression	O
.	O

The	O
effects	O
of	O
the	O
two	O
cytokines	O
were	O
distinguishable	O
functionally	O
since	O
pretreatment	O
with	O
TNF-alpha	O
attenuated	O
the	O
cytokine	O
cooperativity	O
,	O
while	O
pretreatment	O
with	O
IL-10	O
potentiated	O
their	O
cooperativity	O
,	O
suggesting	O
that	O
IL-10	O
and	O
TNF-alpha	O
play	O
different	O
roles	O
in	O
the	O
activation	O
of	O
virus	O
.	O

Northern	O
blot	O
analysis	O
as	O
well	O
as	O
Ab	O
blocking	O
and	O
cytokine	O
secretion	O
studies	O
indicated	O
that	O
the	O
induction	O
of	O
either	O
endogenous	O
TNF-alpha	O
or	O
IL-10	O
was	O
not	O
involved	O
in	O
the	O
cooperativity	O
,	O
nor	O
was	O
an	O
up-regulation	O
of	O
TNF-alpha	O
receptors	O
.	O

In	O
combination	O
with	O
TNF-alpha	O
,	O
IL-10	O
stimulated	O
activating	O
protein-1	O
(	O
AP-1	O
)	O
and	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
binding	O
activities	O
and	O
cooperated	O
to	O
increase	O
HIV-1	O
steady-state	O
mRNA	O
levels	O
and	O
enhance	O
long	O
terminal	O
repeat-directed	O
transcription	O
through	O
activation	O
of	O
the	O
NF-kappa	O
B	O
binding	O
sites	O
,	O
suggesting	O
the	O
IL-10	O
effect	O
occurs	O
at	O
least	O
in	O
part	O
at	O
the	O
transcriptional	O
level	O
.	O

These	O
results	O
indicate	O
that	O
IL-10	O
,	O
in	O
addition	O
to	O
down-regulating	O
the	O
cellular	O
immune	O
response	O
to	O
HIV-1	O
,	O
may	O
also	O
play	O
a	O
role	O
in	O
TNF-alpha-mediated	O
activation	O
of	O
HIV-1	O
replication	O
in	O
the	O
monocyte/macrophage	O
lineage	O
.	O

The	O
promoter	O
and	O
5	O
'	O
flanking	O
sequences	O
controlling	O
human	O
B29	O
gene	O
expression	O
.	O

The	O
product	O
of	O
the	O
B-cell-specific	O
B29	O
gene	O
(	O
B29	O
,	O
Ig	O
beta	O
,	O
CD79b	O
)	O
is	O
essential	O
for	O
Ig-mediated	O
B-cell	O
activation	O
via	O
the	O
B-cell	O
antigen	O
receptor	O
complex	O
(	O
BCR	O
)	O
on	O
human	O
and	O
murine	O
B	O
lymphocytes	O
.	O

To	O
better	O
understand	O
the	O
regulation	O
of	O
this	O
pivotal	O
gene	O
,	O
we	O
have	O
analyzed	O
the	O
human	O
genomic	O
DNA	O
sequence	O
upstream	O
of	O
the	O
B29	O
ATG	O
start	O
codon	O
for	O
transcriptional	O
control	O
activity	O
.	O

The	O
human	O
B29	O
gene	O
lacks	B-Negation
either	I-Negation
a	I-Negation
TATA	I-Negation
or	I-Negation
a	I-Negation
CAAT	I-Negation
box	I-Negation
and	O
transcription	O
is	O
initiated	O
at	O
multiple	O
sites	O
.	O

The	O
minimal	O
promoter	O
of	O
the	O
human	O
B29	O
gene	O
is	O
contained	O
within	O
a	O
193-bp	O
region	O
5	O
'	O
of	O
these	O
multiple	O
start	O
sites	O
.	O

This	O
minimal	O
promoter	O
exhibits	O
B-cell-specific	O
activity	O
and	O
contains	O
SP1	O
,	O
ETS	O
,	O
OCT	O
,	O
and	O
IKAROS/LYF-1	O
transcription	O
factor	O
motifs	O
.	O

All	O
these	O
motifs	O
are	O
strikingly	O
conserved	O
in	O
sequence	O
and	O
placement	O
relative	O
to	O
the	O
previously	O
characterized	O
murine	O
B29	O
promoter	O
.	O

Additional	O
upstream	O
gene	O
segments	O
dramatically	O
affected	O
B29	O
minimal	O
promoter	O
activity	O
.	O

A	O
newly	O
identified	O
motif	O
called	O
the	O
B29	O
conserved	O
sequence	O
(	O
BCS	O
)	O
,	O
found	O
upstream	O
of	O
both	O
human	O
and	O
murine	O
B29	O
promoters	O
,	O
appears	O
to	O
stimulate	O
B29	O
transcription	O
through	O
a	O
novel	O
mechanism	O
.	O

A	O
single	O
BCS	O
had	O
little	O
effect	O
either	O
on	O
the	O
minimal	O
B29	O
promoter	O
or	O
on	O
a	O
heterologous	O
promoter	O
.	O

Instead	O
,	O
the	O
BCS	O
stimulated	O
transcription	O
by	O
counteracting	O
5	O
'	O
negative	O
regulatory	O
DNA	O
sequences	O
that	O
block	O
the	O
activity	O
of	O
the	O
B29	O
minimal	O
promoter	O
in	O
its	O
absence	O
.	O

These	O
findings	O
indicate	O
that	O
B29	O
gene	O
expression	O
is	O
controlled	O
by	O
the	O
complex	O
interplay	O
of	O
positive	O
and	O
negative	O
regulatory	O
elements	O
.	O

MEK1	O
and	O
the	O
extracellular	O
signal-regulated	O
kinases	O
are	O
required	O
for	O
the	O
stimulation	O
of	O
IL-2	O
gene	O
transcription	O
in	O
T	O
cells	O
.	O

TCR	O
engagement	O
stimulates	O
the	O
activation	O
of	O
the	O
protein	O
kinase	O
Raf-1	O
.	O

Active	O
Raf-1	O
phosphorylates	O
and	O
activates	O
the	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinase/extracellular	O
signal-regulated	O
kinase	O
kinase	O
1	O
(	O
MEK1	O
)	O
,	O
which	O
in	O
turn	O
phosphorylates	O
and	O
activates	O
the	O
MAP	O
kinases/extracellular	O
signal	O
regulated	O
kinases	O
,	O
ERK1	O
and	O
ERK2	O
.	O

Raf-1	O
activity	O
promotes	O
IL-2	O
production	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
MEK1	O
and	O
ERK	O
activities	O
also	O
stimulate	O
IL-2	O
gene	O
transcription	O
.	O

Expression	O
of	O
constitutively	O
active	O
Raf-1	O
or	O
MEK1	O
in	O
Jurkat	O
T	O
cells	O
enhanced	O
the	O
stimulation	O
of	O
IL-2	O
promoter-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
together	O
with	O
a	O
calcium	O
ionophore	O
the	O
expression	O
of	O
each	O
protein	O
was	O
sufficient	O
to	O
stimulate	O
NF-AT	O
activity	O
.	O

Expression	O
of	O
MEK1-interfering	O
mutants	O
inhibited	O
the	O
stimulation	O
of	O
IL-2	O
promoter-driven	O
transcription	O
and	O
blocked	O
the	O
ability	O
of	O
constitutively	O
active	O
Ras	O
and	O
Raf-1	O
to	O
costimulate	O
NF-AT	O
activity	O
with	O
a	O
calcium	O
ionophore	O
.	O

Expression	O
of	O
the	O
MAP	O
kinase-specific	O
phosphatase	O
,	O
MKP-1	O
,	O
which	O
blocks	O
ERK	O
activation	O
,	O
inhibited	O
IL-2	O
promoter	O
and	O
NF-AT-driven	O
transcription	O
stimulated	O
by	O
a	O
calcium	O
ionophore	O
and	O
PMA	O
,	O
and	O
in	O
addition	O
,	O
MKP-1	O
neutralized	O
the	O
transcriptional	O
enhancement	O
caused	O
by	O
active	O
Raf-1	O
and	O
MEK1	O
expression	O
.	O

We	O
conclude	O
that	O
the	O
MAP	O
kinase	O
signal	O
transduction	O
pathway	O
consisting	O
of	O
Raf-1	O
,	O
MEK1	O
,	O
and	O
ERK1	O
and	O
ERK2	O
functions	O
in	O
the	O
stimulation	O
IL-2	O
gene	O
transcription	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
NF-AT	O
signal	O
transduction	O
events	O
by	O
a	O
dominant-negative	O
form	O
of	O
calcineurin	O
.	O

An	O
inhibitory	O
,	O
``	O
dominant-negative	O
,	O
``	O
form	O
of	O
the	O
calcineurin	O
catalytic	O
(	O
A	O
)	O
subunit	O
was	O
prepared	O
,	O
which	O
lacks	B-Negation
the	I-Negation
calmodulin-binding	I-Negation
domain	I-Negation
,	I-Negation
autoinhibitory	I-Negation
domain	I-Negation
and	I-Negation
most	I-Negation
of	I-Negation
its	I-Negation
catalytic	I-Negation
core	I-Negation
but	O
possesses	O
the	O
regulatory	O
(	O
B	O
)	O
subunit	O
binding	O
domain	O
.	O

When	O
tested	O
for	O
its	O
ability	O
to	O
block	O
calcineurin-dependent	O
signaling	O
in	O
Jurkat	O
cells	O
,	O
expression	O
of	O
this	O
``	O
B-subunit	O
knock-out	O
``	O
(	O
BKO	O
)	O
construct	O
suppressed	O
reporter	O
gene	O
activity	O
driven	O
by	O
NF-AT	O
,	O
the	O
pivotal	O
promoter	O
element	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
gene	O
induction	O
.	O

Immunoprecipitation	O
of	O
epitope-labeled	O
BKO	O
demonstrated	O
for	O
the	O
formation	O
of	O
a	O
tight	O
complex	O
with	O
endogenous	O
B	O
subunit	O
in	O
Jurkat	O
cells	O
,	O
consistent	O
with	O
an	O
inhibitory	O
mechanism	O
that	O
involves	O
the	O
sequestration	O
of	O
the	O
B	O
subunit	O
.	O

Furthermore	O
,	O
the	O
sharply	O
reduced	O
NF-AT	O
activity	O
produced	O
by	O
co-transfecting	O
BKO	O
could	O
be	O
``	O
rescued	O
``	O
by	O
overexpression	O
of	O
transfected	O
B	O
subunit	O
,	O
suggesting	O
that	O
depletion	O
of	O
this	O
subunit	O
was	O
responsible	O
for	O
the	O
inhibition	O
.	O

These	O
data	O
suggest	O
the	O
potential	O
utility	O
of	O
agents	O
that	O
disrupt	O
calcineurin-mediated	O
signal	O
transduction	O
pathways	O
by	O
blocking	O
formation	O
of	O
the	O
catalytically	O
active	O
dimer	O
of	O
calcineurin	O
A	O
and	O
B	O
subunits	O
.	O

Cross-linking	O
of	O
Fc	O
gamma	O
receptors	O
activates	O
HIV-1	O
long	O
terminal	O
repeat-driven	O
transcription	O
in	O
human	O
monocytes	O
.	O

Elevation	O
of	O
the	O
levels	O
of	O
circulating	O
immune	O
complexes	O
frequently	O
accompanies	O
HIV-1	O
infection	O
and	O
is	O
a	O
prognostic	O
indicator	O
of	O
clinical	O
progression	O
from	O
asymptomatic	O
infection	O
to	O
AIDS	O
.	O

Here	O
we	O
report	O
that	O
cross-linking	O
of	O
Fc	O
gamma	O
RI	O
or	O
Fc	O
gamma	O
RII	O
by	O
adherent	O
human	O
IgG	O
or	O
by	O
specific	O
anti-Fc	O
gamma	O
R	O
mAb	O
activates	O
HIV-1	O
gene	O
expression	O
in	O
the	O
human	O
monocytic	O
cell	O
line	O
BF24	O
and	O
increased	O
HIV	O
RNA	O
expression	O
in	O
monocytes	O
from	O
HIV	O
infected	O
patients	O
as	O
assayed	O
by	O
reverse	O
transcription-PCR	O
.	O

In	O
THP-1	O
cells	O
,	O
Fc	O
gamma	O
R	O
cross-linking	O
induced	O
NF-kappa	O
B	O
,	O
which	O
is	O
known	O
to	O
bind	O
to	O
the	O
regulatory	O
region	O
of	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
and	O
to	O
activate	O
HIV-1	O
transcription	O
.	O

Anti-TNF-alpha	O
antibody	O
but	O
not	B-Negation
anti-IL-1	I-Negation
beta	I-Negation
antibody	I-Negation
strongly	O
inhibited	O
both	O
the	O
induction	O
of	O
HIV-1-LTR-driven	O
transcription	O
and	O
the	O
induction	O
of	O
NF-kappa	O
B	O
by	O
Fc	O
gamma	O
R	O
cross-linking	O
.	O

These	O
results	O
indicate	O
that	O
Fc	O
gamma	O
R	O
can	O
mediate	O
a	O
TNF-alpha-dependent	O
induction	O
of	O
HIV-1	O
gene	O
transcription	O
and	O
suggest	O
that	O
immune	O
complexes	O
may	O
contribute	O
to	O
the	O
pathophysiology	O
of	O
HIV-1	O
infection	O
by	O
augmenting	O
viral	O
replication	O
in	O
monocytes	O
.	O

The	O
effect	O
of	O
Toremifene	O
on	O
the	O
expression	O
of	O
some	O
genes	O
in	O
human	O
mononuclear	O
cells	O
.	O

Toremifene	O
exerts	O
multiple	O
and	O
varied	O
effects	O
on	O
the	O
gene	O
expression	O
of	O
human	O
peripheral	O
mononuclear	O
cells	O
.	O

After	O
short-term	O
,	O
in	O
vitro	O
exposure	O
to	O
therapeutical	O
levels	O
,	O
distinct	O
changes	O
in	O
P-glycoprotein	O
,	O
steroid	O
receptors	O
,	O
p53	O
and	O
Bcl-2	O
expression	O
take	O
place	O
.	O

In	O
view	O
of	O
the	O
increasing	O
use	O
of	O
antiestrogens	O
in	O
cancer	O
therapy	O
and	O
prevention	O
,	O
there	O
is	O
obvious	O
merit	O
in	O
long-term	O
in	O
vivo	O
studies	O
to	O
be	O
conducted	O
.	O

Identification	O
of	O
an	O
ionomycin/cyclosporin	O
A-responsive	O
element	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
enhancer	O
.	O

Activation	O
through	O
the	O
Ca2+/calcineurin	O
pathway	O
is	O
essential	O
to	O
the	O
transcription	O
of	O
many	O
cytokine	O
genes	O
.	O

The	O
conserved	O
cis-acting	O
sequence	O
,	O
GGAAAA	O
,	O
and	O
transcription	O
factors	O
binding	O
to	O
this	O
sequence	O
are	O
involved	O
in	O
the	O
response	O
to	O
increased	O
intracellular	O
Ca2+	O
concentrations	O
.	O

Here	O
we	O
report	O
the	O
identification	O
and	O
importance	O
of	O
the	O
same	O
sequence	O
in	O
a	O
non-cytokine	O
gene	O
,	O
the	O
human	O
T	O
cell	O
receptor	O
gamma	O
(	O
TCRG	O
)	O
enhancer	O
.	O

Results	O
from	O
site-directed	O
mutations	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
strongly	O
suggest	O
that	O
this	O
sequence	O
mediates	O
the	O
ionomycin-induced	O
activation	O
of	O
the	O
TCRG	O
enhancer	O
.	O

Our	O
studies	O
provide	O
an	O
explanation	O
for	O
a	O
previous	O
observation	O
that	O
TCRG	O
mRNA	O
levels	O
,	O
but	O
not	B-Negation
mRNA	I-Negation
levels	I-Negation
for	I-Negation
T	I-Negation
cell	I-Negation
receptor	I-Negation
alpha	I-Negation
and	I-Negation
-beta	I-Negation
,	O
are	O
increased	O
by	O
ionomycin	O
treatment	O
.	O

Inhibition	O
of	O
NF-kappa	O
B	O
activation	O
in	O
human	O
T-cell	O
lines	O
by	O
anetholdithiolthione	O
.	O

Nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
is	O
a	O
redox	O
sensitive	O
cytosolic	O
transcription	O
factor	O
.	O

Redox	O
regulation	O
of	O
NF-kappa	O
B	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
the	O
human	O
immuno-deficiency	O
virus	O
(	O
HIV	O
)	O
.	O

Therefore	O
,	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
acquired	O
immunodeficiency	O
syndrome	O
therapy	O
.	O

Anetholdithiolthione	O
(	O
ADT	O
,	O
5-	O
[	O
p-methoxyphenyl	O
]	O
-3H-1,2-dithiol-3-thione	O
)	O
is	O
an	O
antioxidant	O
which	O
has	O
been	O
used	O
to	O
protect	O
against	O
acetaminophen-	O
and	O
CCl4-induced	O
hepatotoxicity	O
,	O
lipid	O
peroxidation	O
,	O
radiation	O
injury	O
,	O
and	O
also	O
has	O
been	O
used	O
clinically	O
as	O
an	O
anti-choleretic	O
agent	O
.	O

The	O
present	O
study	O
examined	O
the	O
effect	O
of	O
ADT	O
pretreatment	O
on	O
NF-kappa	O
B	O
activation	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
such	O
as	O
H2O2	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
or	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
alpha	O
)	O
.	O

PMA	O
and	O
TNF	O
alpha	O
induced	O
activation	O
of	O
(	O
NF	O
)	O
-kappa	O
B	O
in	O
human	O
Jurkat	O
T-cells	O
was	O
partially	O
inhibited	O
by	O
ADT	O
(	O
0.1	O
mM	O
)	O
pretreatment	O
.	O

ADT	O
(	O
0.1	O
mM	O
)	O
also	O
inhibited	O
H2O2	O
induced	O
activation	O
of	O
the	O
transcription	O
factor	O
in	O
the	O
peroxide	O
sensitive	O
human	O
Wurzburg	O
T-cells	O
.	O

Furthermore	O
,	O
ADT	O
treated	O
Wurzburg	O
cells	O
had	O
significantly	O
higher	O
glutathione	O
levels	O
as	O
compared	O
with	O
untreated	O
cells	O
.	O

H2O2	O
induced	O
lipid	O
peroxidation	O
in	O
Wurzburg	O
cells	O
was	O
remarkably	O
inhibited	O
by	O
ADT	O
pretreatment	O
.	O

ADT	O
,	O
a	O
pro-glutathione	O
antioxidant	O
,	O
was	O
observed	O
to	O
be	O
capable	O
of	O
modulating	O
NF-kappa	O
B	O
activation	O
.	O

In	O
vivo	O
anergized	O
CD4+	O
T	O
cells	O
express	O
perturbed	O
AP-1	O
and	O
NF-kappa	O
B	O
transcription	O
factors	O
.	O

Anergy	O
is	O
a	O
major	O
mechanism	O
to	O
ensure	O
antigen-specific	O
tolerance	O
in	O
T	O
lymphocytes	O
in	O
the	O
adult	O
.	O

In	O
vivo	O
,	O
anergy	O
has	O
mainly	O
been	O
studied	O
at	O
the	O
cellular	O
level	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
T-cell-activating	O
superantigen	O
staphylococcal	O
enterotoxin	O
A	O
(	O
SEA	O
)	O
to	O
investigate	O
molecular	O
mechanisms	O
of	O
T-lymphocyte	O
anergy	O
in	O
vivo	O
.	O

Injection	O
of	O
SEA	O
to	O
adult	O
mice	O
activates	O
CD4+	O
T	O
cells	O
expressing	O
certain	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
variable	O
region	O
beta-chain	O
families	O
and	O
induces	O
strong	O
and	O
rapid	O
production	O
of	O
interleukin	O
2	O
(	O
IL-2	O
)	O
.	O

In	O
contrast	O
,	O
repeated	O
injections	O
of	O
SEA	O
cause	O
CD4+	O
T-cell	O
deletion	O
and	O
anergy	O
in	O
the	O
remaining	O
CD4+	O
T	O
cells	O
,	O
characterized	O
by	O
reduced	O
expression	O
of	O
IL-2	O
at	O
mRNA	O
and	O
protein	O
levels	O
.	O

We	O
analyzed	O
expression	O
of	O
AP-1	O
,	O
NF-kappa	O
B	O
,	O
NF-AT	O
,	O
and	O
octamer	O
binding	O
transcription	O
factors	O
,	O
which	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
IL-2	O
gene	O
promoter	O
activity	O
.	O

Large	O
amounts	O
of	O
AP-1	O
and	O
NF-kappa	O
B	O
and	O
significant	O
quantities	O
of	O
NF-AT	O
were	O
induced	O
in	O
SEA-activated	O
CD4+	O
spleen	O
T	O
cells	O
,	O
whereas	O
Oct-1	O
and	O
Oct-2	O
DNA	O
binding	O
activity	O
was	O
similar	O
in	O
both	O
resting	O
and	O
activated	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anergic	O
CD4+	O
T	O
cells	O
contained	O
severely	O
reduced	O
levels	O
of	O
AP-1	O
and	O
Fos/Jun-containing	O
NF-AT	O
complexes	O
but	O
expressed	O
significant	O
amounts	O
of	O
NF-kappa	O
B	O
and	O
Oct	O
binding	O
proteins	O
after	O
SEA	O
stimulation	O
.	O

Resolution	O
of	O
the	O
NF-kappa	O
B	O
complex	O
demonstrated	O
predominant	O
expression	O
of	O
p50-p65	O
heterodimers	O
in	O
activated	O
CD4+	O
T	O
cells	O
,	O
while	O
anergic	O
cells	O
mainly	O
expressed	O
the	O
transcriptionally	O
inactive	O
p50	O
homodimer	O
.	O

These	O
alterations	O
of	O
transcription	O
factors	O
are	O
likely	O
to	O
be	O
responsible	O
for	O
repression	O
of	O
IL-2	O
in	O
anergic	O
T	O
cells	O
.	O

Surfactant	O
suppresses	O
NF-kappa	O
B	O
activation	O
in	O
human	O
monocytic	O
cells	O
.	O

In	O
addition	O
to	O
biophysical	O
properties	O
,	O
pulmonary	O
surfactant	O
has	O
immunomodulatory	O
activity	O
.	O

We	O
previously	O
demonstrated	O
that	O
both	O
synthetic	O
(	O
Exosurf	O
)	O
and	O
modified	O
natural	O
surfactant	O
(	O
Survanta	O
)	O
downregulated	O
endotoxin-stimulated	O
inflammatory	O
c	O
ytokine	O
mRNA	O
levels	O
and	O
protein	O
products	O
(	O
tumor	O
necrosis	O
factor-alpha	O
[	O
TNF	O
]	O
,	O
interleukin-1-beta	O
[	O
IL-1	O
]	O
,	O
interleukin-6	O
[	O
IL-6	O
]	O
)	O
in	O
human	O
alveolar	O
macrophages	O
.	O

In	O
this	O
study	O
,	O
we	O
report	O
that	O
both	O
Exosurf	O
and	O
Survanta	O
suppress	O
TNF	O
mRNA	O
and	O
secretion	O
(	O
85	O
	O
4	O
%	O
mean	O
percent	O
inhibition	O
	O
SEM	O
by	O
Exosurf	O
;	O
71	O
	O
6	O
%	O
by	O
Survanta	O
)	O
by	O
endotoxin-stimulated	O
THP-1	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Because	O
surfactant	O
downregulated	O
inflammatory	O
cytokine	O
production	O
similarly	O
in	O
both	O
normal	O
human	O
alveolar	O
macrophages	O
and	O
the	O
THP-1	O
cell	O
line	O
,	O
we	O
used	O
this	O
cell	O
line	O
to	O
investigate	O
whether	O
surfactant	O
affected	O
transcriptional	O
mechanisms	O
.	O

Specifically	O
,	O
we	O
examined	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
because	O
it	O
is	O
crucial	O
in	O
transcriptional	O
regulation	O
of	O
many	O
inflammatory	O
cytokine	O
genes	O
including	O
TNF	O
,	O
IL-1	O
,	O
and	O
IL-6	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
both	O
surfactants	O
decreased	O
activation	O
of	O
NF-kappa	O
B	O
.	O

The	O
presence	O
of	O
both	O
p65	O
and	O
p50	O
NF-kappa	O
B	O
components	O
in	O
LPS-activated	O
THP-1	O
cells	O
was	O
confirmed	O
by	O
specific	O
antibody	O
induction	O
of	O
supershifts	O
in	O
mobility	O
assays	O
.	O

These	O
results	O
are	O
the	O
first	O
to	O
suggest	O
that	O
surfactant	O
's	O
suppressive	O
effects	O
on	O
inflammatory	O
cytokine	O
production	O
may	O
involve	O
transcriptional	O
regulation	O
through	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
.	O

A	O
mammalian	O
histone	O
deacetylase	O
related	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	O
[	O
see	O
comments	O
]	O

Trapoxin	O
is	O
a	O
microbially	O
derived	O
cyclotetrapeptide	O
that	O
inhibits	O
histone	O
deacetylation	O
in	O
vivo	O
and	O
causes	O
mammalian	O
cells	O
to	O
arrest	O
in	O
the	O
cell	O
cycle	O
.	O

A	O
trapoxin	O
affinity	O
matrix	O
was	O
used	O
to	O
isolate	O
two	O
nuclear	O
proteins	O
that	O
copurified	O
with	O
histone	O
deacetylase	O
activity	O
.	O

Both	O
proteins	O
were	O
identified	O
by	O
peptide	O
microsequencing	O
,	O
and	O
a	O
complementary	O
DNA	O
encoding	O
the	O
histone	O
deacetylase	O
catalytic	O
subunit	O
(	O
HD1	O
)	O
was	O
cloned	O
from	O
a	O
human	O
Jurkat	O
T	O
cell	O
library	O
.	O

As	O
the	O
predicted	O
protein	O
is	O
very	O
similar	O
to	O
the	O
yeast	O
transcriptional	O
regulator	O
Rpd3p	O
,	O
these	O
results	O
support	O
a	O
role	O
for	O
histone	O
deacetylase	O
as	O
a	O
key	O
regulator	O
of	O
eukaryotic	O
transcription	O
.	O

Coexpression	O
of	O
the	O
interleukin-13	O
and	O
interleukin-4	O
genes	O
correlates	O
with	O
their	O
physical	O
linkage	O
in	O
the	O
cytokine	O
gene	O
cluster	O
on	O
human	O
chromosome	O
5q23-31	O
.	O

Interleukin-13	O
(	O
IL-13	O
)	O
and	O
IL-4	O
are	O
cytokines	O
produced	O
by	O
T	O
cells	O
that	O
are	O
encoded	O
by	O
the	O
q23-31	O
region	O
of	O
human	O
chromosome	O
5	O
.	O

To	O
investigate	O
the	O
regulation	O
of	O
IL-13	O
gene	O
expression	O
by	O
T	O
cells	O
,	O
we	O
isolated	O
and	O
sequenced	O
the	O
human	O
IL-13	O
gene	O
,	O
analyzed	O
its	O
5'-flanking	O
region	O
for	O
potential	O
transcriptional	O
activation	O
elements	O
,	O
and	O
examined	O
its	O
expression	O
in	O
nontransformed	O
T-lineage	O
cell	O
populations	O
.	O

The	O
human	O
IL-13	O
gene	O
was	O
located	O
12.5-kb	O
upstream	O
of	O
the	O
IL-4	O
gene	O
and	O
2-kb	O
downstream	O
of	O
a	O
CpG	O
island	O
.	O

The	O
IL-13	O
gene	O
5	O
'	O
flank	O
region	O
included	O
a	O
segment	O
with	O
sequence	O
homology	O
to	O
P	O
elements	O
of	O
the	O
IL-4	O
promoter	O
involved	O
in	O
transcriptional	O
activation	O
in	O
T	O
cells	O
.	O

Mutation	O
of	O
the	O
IL-13	O
P	O
element	O
site	O
significantly	O
reduced	O
IL-13	O
promoter	O
activity	O
in	O
response	O
to	O
T-cell	O
activation	O
.	O

Oligonucleotides	O
containing	O
the	O
IL-13	O
or	O
IL-4	O
P	O
element	O
sites	O
specifically	O
bound	O
the	O
transcriptional	O
activator	O
protein	O
,	O
nuclear	O
factor-activated	O
T	O
cells	O
,	O
preformed	O
(	O
NF-ATp	O
)	O
,	O
when	O
incubated	O
with	O
nuclear	O
protein	O
extracts	O
from	O
activated	O
T	O
cells	O
.	O

Similar	O
to	O
IL-4	O
,	O
IL-13	O
mRNA	O
expression	O
was	O
highest	O
in	O
T-cell	O
populations	O
enriched	O
for	O
cells	O
that	O
had	O
previously	O
been	O
primed	O
in	O
vivo	O
or	O
in	O
vitro	O
,	O
indicating	O
that	O
priming	O
increases	O
the	O
expression	O
of	O
the	O
IL-13	O
and	O
IL-4	O
genes	O
in	O
a	O
coordinate	O
manner	O
.	O

Because	O
the	O
primed	O
T	O
cells	O
contain	O
higher	O
levels	O
of	O
nuclear	O
NF-ATp	O
,	O
capable	O
of	O
binding	O
to	O
P	O
elements	O
of	O
the	O
IL-4	O
and	O
IL-13	O
promoters	O
,	O
than	O
do	O
freshly-isolated	O
T	O
cells	O
,	O
the	O
NF-AT-binding	O
P	O
elements	O
are	O
attractive	O
candidates	O
to	O
mediate	O
the	O
coordinate	O
expression	O
of	O
these	O
two	O
cytokine	O
genes	O
.	O

Transactivation	O
of	O
the	O
interleukin-1alpha	O
promoter	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
and	O
type	O
II	O
Tax	O
proteins	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
-infected	O
T-cell	O
lines	O
constitutively	O
produce	O
high	O
levels	O
of	O
interleukin-1alpha	O
(	O
IL-1alpha	O
)	O
.	O

To	O
analyze	O
the	O
mechanisms	O
that	O
lead	O
to	O
the	O
expression	O
of	O
IL-1alpha	O
in	O
HTLV-I-infected	O
cell	O
lines	O
,	O
we	O
studied	O
regulatory	O
regions	O
of	O
the	O
human	O
IL-1alpha	O
promoter	O
involved	O
in	O
activation	O
of	O
the	O
IL-1alpha	O
gene	O
.	O

IL-1alpha	O
promoter	O
constructs	O
drive	O
transcription	O
of	O
the	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
gene	O
in	O
HTLV-I-positive	O
MT-2	O
cells	O
,	O
which	O
constitutively	O
produce	O
IL-1alpha	O
.	O

In	O
a	O
cotransfection	O
assay	O
,	O
the	O
Tax	O
protein	O
of	O
both	O
HTLV-I	O
and	O
HTLV-II	O
specifically	O
activated	O
transcription	O
from	O
the	O
IL-1alpha	O
promoter	O
in	O
an	O
uninfected	O
Jurkat	O
cell	O
line	O
.	O

A	B-Negation
mutant	I-Negation
Tax	I-Negation
protein	I-Negation
deficient	I-Negation
in	I-Negation
transactivation	I-Negation
of	I-Negation
genes	I-Negation
by	I-Negation
the	I-Negation
nuclear	I-Negation
factor	I-Negation
(	I-Negation
NF	I-Negation
)	I-Negation
-kappaB	I-Negation
pathway	I-Negation
was	I-Negation
unable	I-Negation
to	I-Negation
induce	I-Negation
transcriptional	I-Negation
activity	I-Negation
of	I-Negation
IL-1alpha	I-Negation
promoter-CAT	I-Negation
constructs	I-Negation
,	O
but	O
was	O
rescued	O
by	O
exogenous	O
provision	O
of	O
p65/p50	O
NF-kappaB	O
.	O

We	O
found	O
that	O
two	O
IL-1alpha	O
kappaB-like	O
sites	O
(	O
positions	O
-1,065	O
to	O
-1,056	O
and	O
+646	O
to	O
+655	O
)	O
specifically	O
formed	O
a	O
complex	O
with	O
NF-kappaB-containing	O
nuclear	O
extract	O
from	O
MT-2	O
cells	O
and	O
that	O
NF-kappaB	O
bound	O
with	O
higher	O
affinity	O
to	O
the	O
3	O
'	O
NF-kappaB	O
binding	O
site	O
than	O
to	O
the	O
5	O
'	O
NF-kappaB	O
site	O
.	O

Moreover	O
,	O
deletion	O
of	O
either	O
5	O
'	O
or	O
3	O
'	O
NF-kappaB	O
sites	O
reduced	O
IL-1alpha	O
promoter	O
activity	O
in	O
MT-2	O
cells	O
and	O
transactivation	O
of	O
the	O
IL-1alpha	O
promoter	O
by	O
exogenous	O
NF-kappaB	O
and	O
Tax	O
in	O
Jurkat	O
cells	O
.	O

These	O
data	O
suggest	O
a	O
general	O
role	O
for	O
Tax	O
induction	O
of	O
IL-1alpha	O
gene	O
transcription	O
by	O
the	O
NF-kappaB	O
pathway	O
.	O

Expression	O
of	O
IL-1alpha	O
by	O
HTLV-I	O
productively	O
infected	O
cells	O
may	O
be	O
important	O
in	O
the	O
hypercalcemia	O
,	O
osteolytic	O
bone	O
lesions	O
,	O
neutrophilia	O
,	O
elevation	O
of	O
C-reactive	O
protein	O
,	O
and	O
fever	O
frequently	O
seen	O
in	O
patients	O
with	O
HTLV-I-induced	O
adult	O
T-cell	O
leukemia/lymphoma	O
.	O

Soluble	O
tumor	O
necrosis	O
factor	O
receptors	O
inhibit	O
phorbol	O
myristate	O
acetate	O
and	O
cytokine-induced	O
HIV-1	O
expression	O
chronically	O
infected	O
U1	O
cells	O
.	O

Recombinant	O
human	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
binding	O
protein-1	O
(	O
r-h	O
TBP-1	O
)	O
and	O
recombinant	O
human	O
soluble	O
dimeric	O
TNF	O
receptor	O
(	O
rhu	O
TNFR	O
:	O
Fc	O
)	O
were	O
used	O
to	O
determine	O
the	O
relative	O
contributions	O
of	O
TNF	O
to	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
and	O
cytokine-induced	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Treatment	O
of	O
HIV-1-infected	O
promonocytic	O
U1	O
cells	O
with	O
r-h-TBP-1	O
or	O
rhu	O
TNFR	O
:	O
Fc	O
reduced	O
PMA-induced	O
HIV-1	O
p24	O
antigen	O
production	O
in	O
a	O
concentration-dependent	O
manner	O
,	O
with	O
a	O
maximal	O
inhibition	O
of	O
approximately	O
90	O
%	O
.	O

Maximal	O
inhibition	O
of	O
p24	O
antigen	O
production	O
in	O
T-lymphocytic	O
ACH-2	O
cells	O
was	O
47	O
%	O
with	O
r-hTBP-1	O
and	O
42	O
%	O
with	O
rhu	O
TNFR	O
:	O
Fc	O
.	O

r-hTBP-1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
also	O
decreased	O
p24	O
antigen	O
synthesized	O
by	O
U1	O
cells	O
in	O
response	O
to	O
other	O
stimuli	O
,	O
including	O
phytohemagglutinin	O
(	O
PHA	O
)	O
-induced	O
supernatant	O
,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
,	O
interleukin-6	O
,	O
and	O
TNF	O
.	O

Addition	O
of	O
r-hTBP-1	O
to	O
U1	O
cells	O
during	O
the	O
last	O
4	O
h	O
of	O
a	O
24	O
h	O
incubation	O
with	O
PMA	O
still	O
inhibited	O
p24	O
antigen	O
production	O
by	O
15	O
%	O
.	O

U1	O
cells	O
stimulated	O
with	O
10	O
(	O
-7	O
)	O
M	O
PMA	O
released	O
approximately	O
1	O
ng/ml	O
endogenous	O
TBP-1	O
with	O
an	O
initial	O
peak	O
observed	O
at	O
1	O
h	O
and	O
a	O
second	O
peak	O
at	O
24	O
h	O
after	O
PMA	O
stimulation	O
.	O

r-hTBP-1	O
also	O
partially	O
reversed	O
inhibition	O
of	O
U1	O
cellular	O
proliferation	O
caused	O
by	O
PMA	O
.	O

Both	O
r-hTBP-1	O
and	O
rhu	O
TNFR	O
:	O
Fc	O
blocked	O
PMA	O
induction	O
of	O
nuclear	O
factor	O
(	O
NK	O
)	O
-	O
kappa	O
B	O
DNA-binding	O
activity	O
in	O
U1	O
cells	O
in	O
association	O
with	O
decreases	O
in	O
HIV-1	O
replication	O
.	O

We	O
conclude	O
that	O
soluble	O
TNF	O
receptors	O
can	O
inhibit	O
stimuli-induced	O
HIV-1	O
expression	O
and	O
NK-	O
kappa	O
B	O
DNA-binding	O
activity	O
in	O
chronically	O
infected	O
U1	O
cells	O
.	O

AM580	O
,	O
a	O
stable	O
benzoic	O
derivative	O
of	O
retinoic	O
acid	O
,	O
has	O
powerful	O
and	O
selective	O
cyto-differentiating	O
effects	O
on	O
acute	O
promyelocytic	O
leukemia	O
cells	O
.	O

All-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
is	O
successfully	O
used	O
in	O
the	O
cyto-differentiating	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
.	O

Paradoxically	O
,	O
APL	O
cells	O
express	O
PML-RAR	O
,	O
an	O
aberrant	O
form	O
of	O
the	O
retinoic	O
acid	O
receptor	O
type	O
alpha	O
(	O
RAR	O
alpha	O
)	O
derived	O
from	O
the	O
leukemia-specific	O
t	O
(	O
15	O
;	O
17	O
)	O
chromosomal	O
translocation	O
.	O

We	O
show	O
here	O
that	O
AM580	O
,	O
a	O
stable	O
retinobenzoic	O
derivative	O
originally	O
synthesized	O
as	O
a	O
RAR	O
alpha	O
agonist	O
,	O
is	O
a	O
powerful	O
inducer	O
of	O
granulocytic	O
maturation	O
in	O
NB4	O
,	O
an	O
APL-derived	O
cell	O
line	O
,	O
and	O
in	O
freshly	O
isolated	O
APL	O
blasts	O
.	O

After	O
treatment	O
of	O
APL	O
cells	O
with	O
AM580	O
either	O
alone	O
or	O
in	O
combination	O
with	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
,	O
the	O
compound	O
induces	O
granulocytic	O
maturation	O
,	O
as	O
assessed	O
by	O
determination	O
of	O
the	O
levels	O
of	O
leukocyte	O
alkaline	O
phosphatase	O
,	O
CD11b	O
,	O
CD33	O
,	O
and	O
G-CSF	O
receptor	O
mRNA	O
,	O
at	O
concentrations	O
that	O
are	O
10-	O
to	O
100-fold	O
lower	O
than	O
those	O
of	O
ATRA	O
necessary	O
to	O
produce	O
similar	O
effects	O
.	O

By	O
contrast	O
,	O
AM580	O
is	O
not	B-Negation
effective	I-Negation
as	I-Negation
ATRA	I-Negation
in	I-Negation
modulating	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
these	I-Negation
differentiation	I-Negation
markers	I-Negation
in	I-Negation
the	I-Negation
HL-60	I-Negation
cell	I-Negation
line	I-Negation
and	I-Negation
in	I-Negation
freshly	I-Negation
isolated	I-Negation
granulocytes	I-Negation
obtained	I-Negation
from	I-Negation
the	I-Negation
peripheral	I-Negation
blood	I-Negation
of	I-Negation
chronic	I-Negation
myelogenous	I-Negation
leukemia	I-Negation
patients	I-Negation
during	I-Negation
the	I-Negation
stable	I-Negation
phase	I-Negation
of	I-Negation
the	I-Negation
disease	I-Negation
.	O

In	O
NB4	O
cells	O
,	O
two	O
other	O
synthetic	O
nonselective	O
RAR	O
ligands	O
are	O
capable	O
of	O
inducing	O
LAP	O
as	O
much	O
as	O
AM580	O
,	O
whereas	O
RAR	O
beta-	O
or	O
RAR	O
gamma-specific	O
ligands	O
are	O
totally	O
ineffective	O
.	O

These	O
results	O
show	O
that	O
AM580	O
is	O
more	O
powerful	O
than	O
ATRA	O
in	O
modulating	O
the	O
expression	O
of	O
differentiation	O
antigens	O
only	O
in	O
cells	O
in	O
which	O
PML-RAR	O
is	O
present	O
.	O

Binding	O
experiments	O
,	O
using	O
COS-7	O
cells	O
transiently	O
transfected	O
with	O
PML-RAR	O
and	O
the	O
normal	O
RAR	O
alpha	O
,	O
show	O
that	O
AM580	O
has	O
a	O
lower	O
affinity	O
than	O
ATRA	O
for	O
both	O
receptors	O
.	O

However	O
,	O
in	O
the	O
presence	O
of	O
PML-RAR	O
,	O
the	O
synthetic	O
retinoid	O
is	O
a	O
much	O
better	O
transactivator	O
of	O
retinoic	O
acid-responsive	O
element-containing	O
promoters	O
than	O
the	O
natural	O
retinoid	O
,	O
whereas	O
,	O
in	O
the	O
presence	O
of	O
RAR	O
alpha	O
,	O
AM580	O
and	O
ATRA	O
have	O
similar	O
activity	O
.	O

This	O
may	O
explain	O
the	O
strong	O
cyto-differentiating	O
potential	O
of	O
AM580	O
in	O
PML-RAR-containing	O
leukemic	O
cells	O
.	O

Transcriptional	O
basis	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
inducible	O
nitric	O
oxide	O
synthase	O
gene	O
to	O
lipopolysaccharide/interferon-gamma	O
.	O

The	O
work	O
reported	O
here	O
resolves	O
,	O
at	O
the	O
level	O
of	O
gene	O
regulation	O
,	O
the	O
controversy	O
as	O
to	O
whether	O
or	O
not	O
human	O
monocytes/macrophages	O
can	O
produce	O
nitric	O
oxide	O
(	O
NO	O
)	O
when	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
with	O
or	O
without	O
co-stimulation	O
by	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
.	O

Studies	O
included	O
structural	O
comparison	O
of	O
the	O
promoters	O
for	O
human	O
and	O
mouse	O
inducible	O
NO	O
synthase	O
(	O
iNOS	O
)	O
genes	O
,	O
transfection	O
and	O
assay	O
of	O
human	O
and	O
mouse	O
iNOS	O
promoter	O
regions	O
in	O
response	O
to	O
LPS	O
	O
IFN-gamma	O
,	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
of	O
kappa	O
B	O
response	O
elements	O
.	O

Two	O
explanations	O
for	O
hyporesponsiveness	O
of	O
the	O
human	O
iNOS	O
promoter	O
to	O
LPS	O
	O
IFN-gamma	O
were	O
found	O
:	O
(	O
1	O
)	O
multiple	O
inactivating	O
nucleotide	O
substitutions	O
in	O
the	O
human	O
counterpart	O
of	O
the	O
enhancer	O
element	O
that	O
has	O
been	O
shown	O
to	O
regulate	O
LPS/IFN-gamma	O
induced	O
expression	O
of	O
the	O
mouse	O
iNOS	O
gene	O
;	O
and	O
(	O
2	O
)	O
and	O
absence	B-Negation
of	I-Negation
one	I-Negation
or	I-Negation
more	I-Negation
nuclear	I-Negation
factors	I-Negation
in	I-Negation
human	I-Negation
macrophages	I-Negation
(	I-Negation
e.g.	I-Negation
,	I-Negation
an	I-Negation
LPS-inducible	I-Negation
nuclear	I-Negation
factor-kappa	I-Negation
B/Rel	I-Negation
complex	I-Negation
)	I-Negation
,	O
that	O
is	O
(	O
are	O
)	O
required	O
for	O
maximal	O
expression	O
of	O
the	O
gene	O
.	O

The	O
importance	O
of	O
resolution	O
of	O
this	O
controversy	O
is	O
that	O
future	O
research	O
in	O
this	O
area	O
should	O
be	O
directed	O
toward	O
the	O
understanding	O
of	O
alternative	O
mechanisms	O
that	O
can	O
result	O
in	O
the	O
successful	O
production	O
of	O
NO	O
.	O

GATA	O
transcription	O
factors	O
associate	O
with	O
a	O
novel	O
class	O
of	O
nuclear	O
bodies	O
in	O
erythroblasts	O
and	O
megakaryocytes	O
.	O

The	O
nuclear	O
distribution	O
of	O
GATA	O
transcription	O
factors	O
in	O
murine	O
haemopoietic	O
cells	O
was	O
examined	O
by	O
indirect	O
immunofluorescence	O
.	O

Specific	O
bright	O
foci	O
of	O
GATA-1	O
fluorescence	O
were	O
observed	O
in	O
erythroleukaemia	O
cells	O
and	O
primary	O
murine	O
erythroblasts	O
and	O
megakaryocytes	O
,	O
in	O
addition	O
to	O
diffuse	O
nucleoplasmic	O
localization	O
.	O

These	O
foci	O
,	O
which	O
were	O
preferentially	O
found	O
adjacent	O
to	O
nucleoli	O
or	O
at	O
the	O
nuclear	O
periphery	O
,	O
did	O
not	B-Negation
represent	I-Negation
sites	I-Negation
of	I-Negation
active	I-Negation
transcription	I-Negation
or	I-Negation
binding	I-Negation
of	I-Negation
GATA-1	I-Negation
to	I-Negation
consensus	I-Negation
sites	I-Negation
in	I-Negation
the	I-Negation
beta-globin	I-Negation
loci	I-Negation
.	O

Immunoelectron	O
microscopy	O
demonstrated	O
the	O
presence	O
of	O
intensely	O
labelled	O
structures	O
likely	O
to	O
represent	O
the	O
GATA-1	O
foci	O
seen	O
by	O
immunofluorescence	O
.	O

The	O
GATA-1	O
nuclear	O
bodies	O
differed	O
from	O
previously	O
described	O
nuclear	O
structures	O
and	O
there	O
was	O
no	B-Negation
co-localization	I-Negation
with	I-Negation
nuclear	I-Negation
antigens	I-Negation
involved	I-Negation
in	I-Negation
RNA	I-Negation
processing	I-Negation
or	I-Negation
other	I-Negation
ubiquitous	I-Negation
(	I-Negation
Spl	I-Negation
,	I-Negation
c-Jun	I-Negation
and	I-Negation
TBP	I-Negation
)	I-Negation
or	I-Negation
haemopoietic	I-Negation
(	I-Negation
NF-E2	I-Negation
)	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

Interestingly	O
,	O
GATA-2	O
and	O
GATA-3	O
proteins	O
also	O
localized	O
to	O
the	O
same	O
nuclear	O
bodies	O
in	O
cell	O
lines	O
co-expressing	O
GATA-1	O
and	O
-2	O
or	O
GATA-1	O
and	O
-3	O
gene	O
products	O
.	O

This	O
pattern	O
of	O
distribution	O
is	O
,	O
thus	O
far	O
,	O
unique	O
to	O
the	O
GATA	O
transcription	O
factors	O
and	O
suggests	O
a	O
protein-protein	O
interaction	O
with	O
other	O
components	O
of	O
the	O
nuclear	O
bodies	O
via	O
the	O
GATA	O
zinc	O
finger	O
domain	O
.	O

Modulation	O
of	O
endogenous	O
IL-1	O
beta	O
and	O
IL-1	O
receptor	O
antagonist	O
results	O
in	O
opposing	O
effects	O
on	O
HIV	O
expression	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

A	O
proportion	O
of	O
HIV-infected	O
individuals	O
experience	O
episodes	O
of	O
localized	O
or	O
systemic	O
bacterial	O
infections	O
caused	O
by	O
Gram-negative	O
bacteria	O
.	O

Many	O
of	O
the	O
clinical	O
side	O
effects	O
of	O
these	O
infections	O
are	O
associated	O
with	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
which	O
are	O
induced	O
primarily	O
by	O
LPS	O
,	O
a	O
constituent	O
of	O
the	O
bacterial	O
cell	O
wall	O
of	O
Gram-negative	O
bacteria	O
.	O

The	O
present	O
study	O
examines	O
the	O
mechanisms	O
involved	O
in	O
LPS-mediated	O
induction	O
of	O
HIV	O
expression	O
in	O
U1	O
cells	O
,	O
a	O
promonocytic	O
cell	O
line	O
chronically	O
infected	O
with	O
HIV	O
.	O

Stimulation	O
of	O
U1	O
cells	O
by	O
LPS	O
alone	O
induced	O
minimal	O
levels	O
of	O
HIV	O
expression	O
,	O
which	O
was	O
significantly	O
enhanced	O
by	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
.	O

Costimulation	O
of	O
U1	O
cells	O
with	O
LPS	O
plus	O
GM-CSF	O
resulted	O
in	O
the	O
accumulation	O
of	O
steady-state	O
levels	O
of	O
HIV	O
RNA	O
;	O
however	O
,	O
only	O
a	O
weak	O
induction	O
of	O
HIV	O
long	O
terminal	O
repeat-driven	O
transcription	O
,	O
which	B-Negation
was	I-Negation
not	I-Negation
associated	I-Negation
with	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
the	I-Negation
cellular	I-Negation
transcription	I-Negation
factor	I-Negation
nuclear	I-Negation
factor-kappa	I-Negation
B	I-Negation
,	O
was	O
noted	O
.	O

Costimulation	O
of	O
cells	O
with	O
LPS	O
plus	O
GM-CSF	O
induced	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL-8	O
,	O
IL-1	O
beta	O
and	O
IL-6	O
,	O
but	O
not	B-Negation
TNF-alpha	I-Negation
.	O

IL-1	O
receptor	O
antagonist	O
(	O
ra	O
)	O
inhibited	O
LPS	O
enhancement	O
of	O
HIV	O
expression	O
in	O
GM-CSF-stimulated	O
cells	O
,	O
suggesting	O
that	O
endogenous	O
IL-1	O
was	O
involved	O
in	O
LPS-mediated	O
viral	O
production	O
.	O

In	O
this	O
regard	O
,	O
anti-inflammatory	O
cytokines	O
inhibited	O
LPS	O
plus	O
GM-CSF-stimulated	O
HIV	O
expression	O
,	O
and	O
this	O
effect	O
closely	O
correlated	O
with	O
inhibition	O
of	O
IL-1	O
beta	O
release	O
and	O
,	O
in	O
particular	O
,	O
with	O
up-regulation	O
of	O
endogenous	O
IL-1ra	O
production	O
.	O

Thus	O
,	O
the	O
balance	O
between	O
an	O
endogenously	O
produced	O
viral	O
inducer	O
(	O
IL-1	O
beta	O
)	O
and	O
an	O
inhibitor	O
(	O
IL-1ra	O
)	O
may	O
represent	O
an	O
important	O
pathway	O
leading	O
to	O
modulation	O
of	O
HIV	O
expression	O
from	O
monocytic	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
interleukin-2	O
gene	O
in	O
normal	O
human	O
peripheral	O
blood	O
T	O
cells	O
.	O

Convergence	O
of	O
costimulatory	O
signals	O
and	O
differences	O
from	O
transformed	O
T	O
cells	O
.	O

To	O
study	O
transcriptional	O
regulation	O
in	O
normal	O
human	O
T	O
cells	O
,	O
we	O
have	O
optimized	O
conditions	O
for	O
transient	O
transfection	O
.	O

Interleukin-2	O
(	O
IL-2	O
)	O
promoter-reporter	O
gene	O
behavior	O
closely	O
parallels	O
the	O
endogenous	O
gene	O
in	O
response	O
to	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
signals	O
.	O

As	O
assessed	O
with	O
mutagenized	O
promoters	O
,	O
the	O
most	O
important	O
IL-2	O
cis-regulatory	O
elements	O
in	O
normal	O
T	O
cells	O
are	O
the	O
proximal	O
AP-1	O
site	O
and	O
the	O
NF-	O
kappaB	O
site	O
.	O

Both	O
primary	O
activation	O
,	O
with	O
phytohemagglutinin	O
or	O
antibodies	O
to	O
CD3	O
,	O
and	O
costimulation	O
,	O
provided	O
by	O
pairs	O
of	O
CD2	O
antibodies	O
or	O
B7-positive	O
(	O
B	O
cells	O
)	O
or	O
B7-negative	O
(	O
endothelial	O
)	O
accessory	O
cells	O
,	O
are	O
mediated	O
through	O
the	O
same	O
cis-elements	O
.	O

Interestingly	O
,	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
sites	O
are	O
much	O
less	O
important	O
in	O
normal	O
T	O
cells	O
than	O
in	O
Jurkat	O
T	O
cells	O
.	O

We	O
conclude	O
that	O
IL-2	O
transcriptional	O
regulation	O
differs	O
in	O
tumor	O
cell	O
lines	O
compared	O
with	O
normal	O
T	O
cells	O
and	O
that	O
different	O
costimulatory	O
signals	O
converge	O
on	O
the	O
same	O
cis-elements	O
in	O
the	O
IL-2	O
promoter	O
.	O

A	O
hydrophobic	O
domain	O
of	O
Ca2+-modulating	O
cyclophilin	O
ligand	O
modulates	O
calcium	O
influx	O
signaling	O
in	O
T	O
lymphocytes	O
.	O

Ca2+-modulating	O
cyclophilin	O
ligand	O
(	O
CAML	O
)	O
was	O
originally	O
described	O
as	O
a	O
cyclophilin	O
B-binding	O
protein	O
whose	O
overexpression	O
in	O
T	O
cells	O
causes	O
a	O
rise	O
in	O
intracellular	O
calcium	O
,	O
thus	O
activating	O
transcription	O
factors	O
responsible	O
for	O
the	O
early	O
immune	O
response	O
.	O

As	O
reported	O
here	O
,	O
structure-function	O
analysis	O
of	O
the	O
CAML	O
gene	O
in	O
Jurkat	O
T	O
cells	O
indicates	O
that	O
two	O
of	O
CAML	O
's	O
putative	O
membrane-spanning	O
domains	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
modulation	O
of	O
intracellular	O
calcium	O
.	O

We	O
propose	O
that	O
the	O
hydrophobic	O
C-terminal	O
tail	O
of	O
CAML	O
forms	O
its	O
effector	O
domain	O
,	O
thus	O
implicating	O
the	O
N-terminal	O
hydrophilic	O
domain	O
in	O
a	O
regulatory	O
role	O
.	O

These	O
findings	O
define	O
a	O
novel	O
protein	O
motif	O
that	O
functions	O
in	O
intracellular	O
calcium	O
signaling	O
.	O

Interactions	O
of	O
a	O
transcriptional	O
activator	O
in	O
the	O
env	O
gene	O
of	O
the	O
mouse	O
mammary	O
tumor	O
virus	O
with	O
activation-dependent	O
,	O
T	O
cell-specific	O
transacting	O
factors	O
.	O

The	O
mouse	O
mammary	O
tumor	O
virus	O
env	O
gene	O
contains	O
a	O
transcriptional	O
activator	O
(	O
META	O
)	O
that	O
can	O
control	O
transcription	O
of	O
the	O
adjacent	O
long	O
terminal	O
repeat	O
region	O
.	O

Transcriptional	O
control	O
by	O
META	O
parallels	O
that	O
of	O
several	O
lymphokine	O
genes	O
,	O
being	O
specific	O
to	O
T	O
cells	O
,	O
dependent	O
on	O
their	O
activation	O
,	O
and	O
inhibited	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporine	O
(	O
CsA	O
)	O
.	O

DNase	O
I	O
footprinting	O
indicated	O
that	O
nuclear	O
factors	O
from	O
activated	O
T	O
lymphocytes	O
bound	O
a	O
promoter-proximal	O
site	O
,	O
META	O
(	O
P	O
)	O
,	O
and	O
a	O
promoter-distal	O
site	O
,	O
META	O
(	O
D+	O
)	O
,	O
within	O
the	O
400-base	O
pair	O
META	O
region	O
.	O

Nuclear	O
factors	O
from	O
unstimulated	O
,	O
but	O
not	B-Negation
from	I-Negation
activated	I-Negation
cells	I-Negation
,	O
bound	O
a	O
site	O
,	O
META	O
(	O
D-	O
)	O
,	O
adjacent	O
to	O
META	O
(	O
D+	O
)	O
.	O

META	O
(	O
D+	O
)	O
directed	O
transcription	O
of	O
a	O
linked	O
luciferase	O
gene	O
,	O
and	O
gel	O
shift	O
analysis	O
revealed	O
binding	O
of	O
inducible	O
,	O
CsA-sensitive	O
T	O
cell	O
factors	O
,	O
in	O
parallel	O
with	O
transfection	O
results	O
.	O

Authentic	O
NFAT	O
and	O
NF-kappaB	O
targets	O
did	O
not	B-Negation
compete	I-Negation
for	I-Negation
the	I-Negation
META	I-Negation
(	I-Negation
D+	I-Negation
)	I-Negation
binding	I-Negation
factor	I-Negation
(	I-Negation
s	I-Negation
)	I-Negation
.	O

The	O
SV40	O
core	O
sequence	O
competed	O
for	O
META	O
(	O
D+	O
)	O
binding	O
factors	O
,	O
but	O
META	O
(	O
D+	O
)	O
failed	B-Negation
to	I-Negation
compete	I-Negation
for	I-Negation
the	I-Negation
complexes	I-Negation
obtained	I-Negation
with	I-Negation
the	I-Negation
SV40	I-Negation
probe	I-Negation
.	O

Our	O
results	O
,	O
taken	O
together	O
,	O
indicate	O
that	O
META	O
(	O
D+	O
)	O
is	O
a	O
novel	O
transcriptional	O
enhancer	O
element	O
that	O
is	O
similar	O
in	O
its	O
cell-type	O
specificity	O
,	O
activation	O
dependence	O
,	O
and	O
CsA	O
sensitivity	O
to	O
the	O
NFAT	O
element	O
.	O

It	O
may	O
be	O
relevant	O
to	O
the	O
role	O
of	O
MMTV	O
in	O
expression	O
of	O
Mls	O
antigens	O
or	O
the	O
induction	O
of	O
T	O
cell	O
lymphomas	O
.	O

Monocytic	O
cell	O
type-specific	O
transcriptional	O
induction	O
of	O
collagenase	O
.	O

Interstitial	O
collagenase	O
(	O
MMP-1	O
)	O
,	O
a	O
metalloproteinase	O
produced	O
by	O
resident	O
and	O
inflammatory	O
cells	O
during	O
connective	O
tissue	O
turnover	O
,	O
cleaves	O
type	O
I	O
collagen	O
fibrils	O
.	O

This	O
catalytic	O
event	O
is	O
rate	O
limiting	O
in	O
remodeling	O
of	O
tissues	O
rich	O
in	O
fibrillar	O
collagen	O
such	O
as	O
the	O
skin	O
and	O
lungs	O
.	O

The	O
regulation	O
of	O
collagenase	O
expression	O
is	O
cell-type	O
specific	O
;	O
bacterial	O
LPS	O
and	O
zymosan	O
,	O
a	O
yeast	O
cell	O
wall	O
derivative	O
,	O
are	O
potent	O
inducers	O
of	O
collagenase	O
expression	O
in	O
macrophages	O
,	O
but	O
do	O
not	B-Negation
alter	I-Negation
fibroblast	I-Negation
collagenase	I-Negation
expression	I-Negation
.	O

Since	O
promoter	B-Negation
elements	I-Negation
controlling	I-Negation
collagenase	I-Negation
transcription	I-Negation
in	I-Negation
monocytic	I-Negation
cells	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
previously	I-Negation
defined	I-Negation
,	O
we	O
sought	O
to	O
delineate	O
responsive	O
cis-acting	O
elements	O
of	O
the	O
collagenase	O
promoter	O
in	O
transiently	O
transfected	O
human	O
(	O
U937	O
)	O
and	O
murine	O
(	O
J774	O
)	O
monocytic	O
cell	O
lines	O
.	O

Deletion	O
constructs	O
containing	O
as	O
little	O
as	O
72	O
bp	O
of	O
5	O
'	O
-flanking	O
sequence	O
of	O
the	O
collagenase	O
promoter	O
were	O
sufficient	O
for	O
LPS-	O
or	O
zymosan-mediated	O
transcriptional	O
induction	O
,	O
whereas	O
phorbol	O
inducibility	O
exhibited	O
an	O
absolute	O
requirement	O
for	O
upstream	O
elements	O
including	O
the	O
polyoma	O
enhancer	O
A-binding	O
protein-3	O
site	O
(	O
-83	O
to	O
-91	O
)	O
and	O
TTCA	O
sequence	O
(	O
-102	O
to	O
-105	O
)	O
in	O
both	O
monocytic	O
cells	O
and	O
fibroblasts	O
.	O

Mutagenesis	O
of	O
the	O
activator	O
protein-1	O
[	O
AP-1	O
]	O
site	O
at	O
-72	O
abolished	O
basal	O
promoter	O
activity	O
and	O
LPS/zymosan	O
inducibility	O
,	O
while	O
mutagenesis	O
of	O
an	O
NF-kappaB-like	O
site	O
at	O
-20	O
to	O
-10	O
had	O
no	B-Negation
effect	I-Negation
.	O

Nuclear	O
extracts	O
from	O
LPS-	O
and	O
zymosan-treated	O
cells	O
showed	O
strong	O
AP-1	O
activity	O
by	O
gel-shift	O
analysis	O
,	O
and	O
supershift	O
analysis	O
showed	O
the	O
AP-1	O
complexes	O
contained	O
specific	O
members	O
of	O
both	O
the	O
jun	O
and	O
fos	O
gene	O
families	O
.	O

These	O
data	O
indicate	O
that	O
,	O
in	O
contrast	O
to	O
most	O
LPS	O
effects	O
,	O
AP-1	O
,	O
but	O
not	O
nuclear	O
factor-kappaB	O
,	O
mediates	O
LPS	O
induction	O
of	O
collagenase	O
transcription	O
in	O
macrophagelike	O
cells	O
.	O

Furthermore	O
,	O
as	O
compared	O
to	O
regulation	O
by	O
phorbol	O
ester	O
,	O
collagenase	O
induction	O
in	O
monocytic	O
cells	O
by	O
cell	O
wall	O
derivatives	O
of	O
bacteria	O
or	O
yeast	O
is	O
largely	O
independent	O
of	O
upstream	O
promoter	O
sequences	O
.	O

Inhibitory	O
effect	O
of	O
E3330	O
,	O
a	O
novel	O
quinone	O
derivative	O
able	O
to	O
suppress	O
tumor	O
necrosis	O
factor-alpha	O
generation	O
,	O
on	O
activation	O
of	O
nuclear	O
factor-kappa	O
B	O
.	O

(	O
2E	O
)	O
-3-	O
[	O
5-	O
(	O
2,3-Dimethoxy-6-methyl-1,4-benzoquinoyl	O
)	O
]	O
-2-nonyl-2-	O
propenoic	O
acid	O
(	O
E3330	O
)	O
,	O
is	O
a	O
novel	O
agent	O
with	O
hepatoprotective	O
activity	O
.	O

We	O
report	O
the	O
effect	O
of	O
E3330	O
on	O
transcriptional	O
activation	O
of	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
gene	O
and	O
on	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
activation	O
.	O

Nuclear	O
run-on	O
experiments	O
showed	O
that	O
E3330	O
decreases	O
transcriptional	O
activation	O
of	O
TNF-alpha	O
gene	O
induced	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
stimulation	O
in	O
human	O
peripheral	O
monocytes	O
.	O

To	O
investigate	O
the	O
inhibitory	O
mechanisms	O
,	O
we	O
constructed	O
a	O
secreted-type	O
placental	O
alkaline	O
phosphatase	O
(	O
PLAP	O
)	O
reporter	O
gene	O
whose	O
transcription	O
is	O
controlled	O
by	O
a	O
1.4-kb	O
human	O
TNF-alpha	O
promoter	O
.	O

A	O
stable	O
transformant	O
of	O
the	O
PLAP	O
reporter	O
gene	O
derived	O
from	O
human	O
monocytic	O
cell	O
line	O
showed	O
very	O
little	O
activity	O
on	O
the	O
promoter	O
before	O
stimulation	O
,	O
whereas	O
LPS	O
stimulation	O
led	O
to	O
a	O
dramatic	O
increase	O
in	O
PLAP	O
activity	O
.	O

E3330	O
inhibited	O
this	O
induced	O
promoter	O
activity	O
in	O
a	O
dose-dependent	O
manner	O
.	O

There	O
are	O
four	O
putative	O
NF-kappa	O
B	O
binding	O
sites	O
(	O
kappa	O
B-1	O
,	O
kappa	O
B-2	O
,	O
kappa	O
B-3	O
,	O
kappa	O
B-4	O
)	O
in	O
human	O
TNF-alpha	O
promoter	O
.	O

By	O
using	O
mutated	O
promoter-PLAP	O
plasmids	O
,	O
we	O
established	O
that	O
these	O
NF-kappa	O
B	O
sites	O
were	O
necessary	O
for	O
induction	O
of	O
TNF-alpha	O
transcription	O
on	O
stimulation	O
with	O
LPS	O
.	O

A	O
gel	O
retardation	O
experiment	O
with	O
synthetic	O
double-stranded	O
oligonucleotides	O
showed	O
that	O
activated	O
NF-kappa	O
B	O
consisting	O
of	O
p50/p65	O
heterodimer	O
bound	O
to	O
all	O
four	O
putative	O
NF-kappa	O
B	O
DNA	O
probes	O
,	O
suggesting	O
that	O
all	O
four	O
putative	O
NF-kappa	O
B	O
recognition	O
sites	O
play	O
an	O
important	O
role	O
in	O
inducible	O
TNF-alpha	O
expression	O
.	O

E3330	O
decreased	O
activated	O
NF-kappa	O
B	O
in	O
nuclei	O
,	O
suggesting	O
that	O
E3330	O
inhibits	O
NF-kappa	O
B	O
activation	O
and/or	O
translocation	O
of	O
the	O
nuclei	O
.	O

Western	O
blotting	O
analysis	O
with	O
anti-I	O
kappa	O
B-alpha	O
antibody	O
indicated	O
that	O
E3330	O
inhibited	O
degradation	O
of	O
I	O
kappa	O
B-alpha	O
,	O
which	O
is	O
an	O
inhibitory	O
protein	O
of	O
NF-kappa	O
B	O
,	O
in	O
LPS-stimulated	O
monocytes	O
.	O

E3330	O
may	O
suppress	O
the	O
production	O
of	O
active	O
oxygen	O
species	O
serving	O
as	O
common	O
messengers	O
to	O
activate	O
NF-kappa	O
B	O
.	O

The	O
role	O
of	O
p16	O
in	O
the	O
E2F-dependent	O
thymidine	O
kinase	O
regulation	O
.	O

The	O
role	O
of	O
alterations	O
of	O
the	O
MTS1	O
tumor	O
suppressor	O
gene	O
on	O
chromosome	O
9p21	O
,	O
which	O
encodes	O
p16	O
,	O
the	O
inhibitor	O
of	O
cyclin-dependent-kinase-4	O
and	O
6	O
,	O
in	O
tumorigenesis	O
is	O
not	O
yet	O
clear	O
.	O

Phosphorylation	O
of	O
the	O
retinoblastoma	O
protein	O
by	O
cyclin-dependent	O
kinases	O
4	O
and	O
6	O
prevents	O
its	O
interaction	O
with	O
the	O
transcription	O
factor	O
E2F	O
,	O
which	O
subsequently	O
promotes	O
the	O
expression	O
of	O
S	O
phase	O
regulated	O
genes	O
,	O
such	O
as	O
thymidine	O
kinase	O
.	O

Although	O
a	O
role	O
of	O
p16	O
in	O
this	O
regulation	O
has	O
been	O
presumed	O
,	O
there	O
is	O
no	O
proof	O
so	O
far	O
that	O
loss	O
of	O
this	O
tumor	O
suppressor	O
gene	O
really	O
affects	O
E2F-mediated	O
regulations	O
.	O

We	O
investigated	O
the	O
regulation	O
of	O
thymidine	O
kinase	O
in	O
phytohemagglutinin-stimulated	O
normal	O
human	O
lymphocytes	O
and	O
in	O
the	O
p16-negative	O
human	O
acute	O
lymphoblastic	O
leukemia	O
cell	O
lines	O
,	O
MOLT-4	O
and	O
CEM	O
.	O

Compared	O
to	O
normal	O
lymphocytes	O
,	O
MOLT-4	O
and	O
CEM	O
cells	O
exhibited	O
an	O
altered	O
cell	O
cycle	O
regulation	O
of	O
thymidine	O
kinase	O
,	O
a	O
much	O
higher	O
intracellular	O
activity	O
of	O
this	O
enzyme	O
,	O
and	O
higher	O
thymidine	O
kinase	O
mRNA	O
expression	O
.	O

Transient	O
expression	O
of	O
p16	O
in	O
normal	O
human	O
lymphocytes	O
caused	O
arrest	O
in	O
G1	O
,	O
but	O
was	O
without	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
cell	I-Negation
growth	I-Negation
of	I-Negation
MOLT-4	I-Negation
and	I-Negation
CEM	I-Negation
cells	I-Negation
,	O
although	O
all	O
of	O
them	O
express	O
functional	O
retinoblastoma	O
protein	O
.	O

Nevertheless	O
,	O
in	O
the	O
two	O
leukemia	O
cell	O
lines	O
transient	O
overexpression	O
of	O
p16	O
reestablished	O
the	O
normal	O
regulation	O
of	O
thymidine	O
kinase	O
,	O
paralleled	O
by	O
an	O
increase	O
of	O
the	O
underphosphorylated	O
form	O
of	O
retinoblastoma	O
protein	O
and	O
decrease	O
of	O
free	O
E2F	O
bound	O
to	O
its	O
motif	O
in	O
the	O
thymidine	O
kinase	O
promoter	O
.	O

We	O
demonstrate	O
that	O
loss	O
of	O
p16	O
causes	O
upregulation	O
of	O
this	O
DNA	O
precursor	O
pathway	O
enzyme	O
via	O
activation	O
of	O
E2F	O
by	O
a	O
mechanism	O
involving	O
retinoblastoma	O
protein	O
.	O

Rel-deficient	O
T	O
cells	O
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	O
3	O
and	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
.	O

The	O
c-rel	O
protooncogene	O
encodes	O
a	O
subunit	O
of	O
the	O
NF-kappa	O
B-like	O
family	O
of	O
transcription	O
factors	O
.	O

Mice	O
lacking	B-Negation
Rel	I-Negation
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	O
and	O
T	O
lymphocytes	O
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T-cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	O
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	O
surface	O
activation	O
markers	O
and	O
cytokine	O
production	O
in	O
mitogen-stimulated	O
Rel-/-	O
T	O
cells	O
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	O
2	O
receptor	O
alpha	O
(	O
IL-2R	O
alpha	O
)	O
chain	O
(	O
CD25	O
)	O
,	O
CD69	O
and	O
L-selectin	O
(	O
CD62	O
)	O
is	O
normal	O
in	O
mitogen-activated	O
Rel-/-	O
T	O
cells	O
,	O
but	O
cytokine	O
production	O
is	O
impaired	O
.	O

In	O
Rel-/-	O
splenic	O
T	O
cell	O
cultures	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	O
macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
,	O
and	O
gamma	O
interferon	O
(	O
IFN-gamma	O
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti-CD3	O
and	O
anti-CD28	O
stimulated	O
Rel-/-	O
T	O
cells	O
,	O
which	O
fail	B-Negation
to	I-Negation
proliferate	I-Negation
,	O
make	O
little	O
or	O
no	B-Negation
detectable	I-Negation
cytokines	I-Negation
.	O

Exogenous	O
IL-2	O
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3-	O
and	O
anti-CD28-treated	O
Rel-/-	O
T	O
cells	O
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF-alpha	O
,	O
and	O
IFN-gamma	O
,	O
but	O
not	B-Negation
IL-3	I-Negation
and	I-Negation
GM-CSF	I-Negation
expression	I-Negation
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen-activated	O
Rel-/-	O
T	O
cells	O
,	O
lipopolysaccharide-stimulated	O
Rel-/-	O
macrophages	O
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM-CSF	O
.	O

These	O
findings	O
establish	O
that	O
Rel	O
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	O
lymphocytes	O
for	O
production	O
of	O
IL-3	O
and	O
GM-CSF	O
.	O

Human	O
T	O
lymphotropic	O
virus-I	O
infection	O
of	O
human	O
T	O
lymphocytes	O
induces	O
expression	O
of	O
the	O
beta-galactoside-binding	O
lectin	O
,	O
galectin-3	O
.	O

Animal	O
lectins	O
play	O
important	O
roles	O
in	O
a	O
variety	O
of	O
biological	O
processes	O
via	O
their	O
recognition	O
of	O
glycoconjugates	O
.	O

Galectin-3	O
is	O
a	O
beta-galactoside-binding	O
lectin	O
previously	O
designated	O
as	O
epsilon	O
BP	O
(	O
IgE-binding	O
protein	O
)	O
,	O
CBP35	O
,	O
Mac-2	O
,	O
L-29	O
,	O
and	O
L-34	O
,	O
and	O
its	O
expression	O
has	O
been	O
associated	O
with	O
various	O
physiological	O
and	O
pathological	O
processes	O
,	O
including	O
cell	O
growth	O
,	O
tumor	O
transformation	O
,	O
and	O
metastasis	O
.	O

Galectin-3	O
is	O
widely	O
distributed	O
in	O
various	O
tissues	O
and	O
cell	O
types	O
and	O
is	O
expressed	O
in	O
many	O
leukocytes	O
,	O
with	B-Negation
the	I-Negation
notable	I-Negation
exception	I-Negation
of	I-Negation
B	I-Negation
and	I-Negation
T	I-Negation
lymphocytes	I-Negation
.	O

We	O
now	O
report	O
that	O
galectin-3	O
is	O
abundantly	O
expressed	O
in	O
a	O
number	O
of	O
human	O
T	O
lymphotropic	O
virus	O
(	O
HTLV	O
)	O
-I-infected	O
human	O
T	O
cell	O
lines	O
,	O
including	O
F6T	O
,	O
HUT	O
102	O
,	O
K3T	O
,	O
MT-2	O
,	O
and	O
SLB-I	O
,	O
but	O
is	O
not	B-Negation
expressed	I-Negation
in	I-Negation
non-HTLV-I-infected	I-Negation
T	I-Negation
cell	I-Negation
lines	I-Negation
such	I-Negation
as	I-Negation
Jurkat	I-Negation
,	I-Negation
CEM	I-Negation
,	I-Negation
and	I-Negation
MOLT-4	I-Negation
.	O

In	O
addition	O
,	O
the	O
galectin-3	O
level	O
was	O
markedly	O
increased	O
in	O
human	O
thymocytes	O
after	O
infection	O
with	O
HTLV-I	O
as	O
compared	O
with	O
uninfected	O
thymocytes	O
.	O

The	O
up-regulation	O
of	O
galectin-3	O
expression	O
appeared	O
to	O
correlate	O
well	O
with	O
HTLV-I	O
gene	O
expression	O
,	O
as	O
undetectable	O
or	O
very	O
low	O
levels	O
of	O
galectin-3	O
were	O
found	O
in	O
the	O
S1T	O
and	O
ATL-1K	O
cell	O
lines	O
,	O
which	O
are	O
nonproductively	O
infected	O
with	O
HTLV-I	O
.	O

In	O
co-transfection	O
experiments	O
,	O
the	O
galectin-3	O
promoter	O
was	O
significantly	O
up-regulated	O
by	O
expression	O
vectors	O
encoding	O
the	O
40-kd	O
Tax	O
protein	O
,	O
a	O
potent	O
transactivator	O
in	O
HTLV-I	O
.	O

Analysis	O
of	O
various	O
Tax	O
mutants	O
suggested	O
that	O
galectin-3	O
promoter	O
induction	O
is	O
dependent	O
on	O
activation	O
of	O
the	O
cyclic-AMP-responsive	O
element	O
binding	O
protein/activation	O
transcription	O
factor	O
family	O
of	O
transcription	O
factors	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
nuclear	O
factor-kappa	O
B/Rel	O
induction	O
.	O

Transfection	O
of	O
human	O
promonocytic	O
U-937	O
cells	O
with	O
an	O
HTLV-I	O
Tax	O
expression	O
vector	O
induced	O
galectin-3	O
expression	O
in	O
this	O
cell	O
line	O
.	O

Functionally	O
,	O
galectin-3	O
was	O
shown	O
to	O
activate	O
interleukin-2	O
production	O
in	O
Jurkat	O
T	O
cells	O
.	O

Together	O
,	O
these	O
findings	O
raise	O
the	O
possibility	O
that	O
HTLV-I	O
Tax	O
production	O
induces	O
the	O
transcription	O
and	O
subsequent	O
synthesis	O
and	O
secretion	O
of	O
galectin-3	O
,	O
which	O
in	O
turn	O
may	O
further	O
activate	O
these	O
T	O
cells	O
and	O
contribute	O
to	O
the	O
altered	O
properties	O
of	O
cell	O
growth	O
found	O
in	O
adult	O
T	O
cell	O
leukemia	O
induced	O
by	O
HTLV-I	O
.	O

Nuclear	O
appearance	O
of	O
a	O
factor	O
that	O
binds	O
the	O
CD28	O
response	O
element	O
within	O
the	O
interleukin-2	O
enhancer	O
correlates	O
with	O
interleukin-2	O
production	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
requires	O
the	O
combined	O
signaling	O
of	O
the	O
T	O
cell	O
receptor	O
and	O
costimulatory	O
molecules	O
such	O
as	O
CD28	O
.	O

The	O
ability	O
of	O
T	O
cells	O
to	O
produce	O
interleukin-2	O
(	O
IL-2	O
)	O
is	O
a	O
critical	O
control	O
point	O
in	O
T	O
lymphocyte	O
activation	O
.	O

The	O
IL-2	O
enhancer	O
contains	O
a	O
functional	O
motif	O
named	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
that	O
serves	O
a	O
role	O
as	O
a	O
target	O
for	O
mitogenic	O
T	O
cell	O
activation	O
signals	O
.	O

The	O
CD28RE	O
sequence	O
reveals	O
similarity	O
to	O
the	O
consensus	O
kappaB	O
binding	O
motif	O
.	O

Here	O
we	O
demonstrate	O
that	O
CD28RE	O
binds	O
an	O
inducible	O
protein	O
with	O
a	O
molecular	O
mass	O
of	O
approximately	O
35	O
kDa	O
called	O
nuclear	O
factor	O
of	O
mitogenic-activated	O
T	O
cells	O
(	O
NF-MATp35	O
)	O
that	O
is	O
clearly	O
different	O
from	O
the	O
known	O
NF-	O
kappaB/Rel	O
family	O
members	O
.	O

Induction	O
of	O
NF-MATp35	O
was	O
shown	O
to	O
depend	O
on	O
de	O
novo	O
protein	O
synthesis	O
and	O
was	O
restricted	O
to	O
T	O
cells	O
that	O
received	O
a	O
mitogenic	O
combination	O
of	O
T	O
cell	O
stimuli	O
,	O
not	O
necessarily	O
including	O
CD28	O
signaling	O
.	O

Nonmitogenic	O
T	O
cell	O
stimulation	O
did	O
not	B-Negation
result	I-Negation
in	I-Negation
appearance	I-Negation
of	I-Negation
NF-MATp35	I-Negation
.	O

These	O
results	O
indicate	O
that	O
mitogenic	O
combinations	O
of	O
T	O
cell	O
activation	O
signals	O
are	O
integrated	O
at	O
the	O
level	O
of	O
NF-MATp35	O
induction	O
.	O

Similar	O
to	O
its	O
effect	O
on	O
IL-2	O
production	O
,	O
cyclosporin	O
A	O
inhibited	O
the	O
induction	O
of	O
NF-MATp35	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
nuclear	O
appearance	O
of	O
NF-MATp35	O
shows	O
excellent	O
correlation	O
with	O
IL-2	O
production	O
,	O
which	O
is	O
a	O
unique	O
characteristic	O
among	O
nuclear	O
factors	O
implicated	O
in	O
the	O
control	O
of	O
IL-2	O
gene	O
expression	O
.	O

Preassociation	O
of	O
STAT1	O
with	O
STAT2	O
and	O
STAT3	O
in	O
separate	O
signalling	O
complexes	O
prior	O
to	O
cytokine	O
stimulation	O
.	O

A	O
variety	O
of	O
cytokines	O
and	O
growth	O
factors	O
act	O
through	O
an	O
induction	O
of	O
gene	O
expression	O
mediated	O
by	O
a	O
family	O
of	O
latent	O
transcription	O
factors	O
called	O
STAT	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
proteins	O
.	O

Ligand-induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
STATs	O
promotes	O
their	O
homodimer	O
and	O
heterodimer	O
formation	O
and	O
subsequent	O
nuclear	O
translocation	O
.	O

We	O
demonstrate	O
here	O
that	O
STAT	O
protein	O
heterocomplexes	O
exist	O
prior	O
to	O
cytokine	O
treatment	O
.	O

When	O
unstimulated	O
HeLa	O
cells	O
are	O
ruptured	O
in	O
hypotonic	O
buffer	O
without	B-Negation
salt	I-Negation
or	I-Negation
detergent	I-Negation
,	O
immunoadsorption	O
of	O
either	B-Speculation
STAT1	I-Speculation
or	I-Speculation
STAT2	I-Speculation
from	O
the	O
resulting	O
cytosol	O
yields	O
coimmunoadsorption	O
of	O
the	O
other	O
STAT	O
protein	O
.	O

Similarly	O
,	O
STAT1-STAT3	O
heterocomplexes	O
are	O
coimmunoadsorbed	O
from	O
hypotonic	O
cytosol	O
.	O

STAT1	O
and	O
STAT2	O
or	O
STAT1	O
and	O
STAT3	O
translated	O
in	O
reticulocyte	O
lysate	O
spontaneously	O
form	O
heterocomplexes	O
when	O
the	O
translation	O
lysates	O
are	O
mixed	O
at	O
0	O
degrees	O
C	O
.	O

Our	O
data	O
suggest	O
that	O
interferon-alpha	O
/beta-induced	O
tyrosine	O
phosphorylation	O
increases	O
the	O
stability	O
of	O
a	O
preexisting	O
,	O
latent	O
,	O
STAT1-STAT2	O
signaling	O
complex	O
.	O

Newly	O
translated	O
STAT1	O
binds	O
in	O
equilibrium	O
fashion	O
to	O
STAT2	O
and	O
STAT3	O
,	O
but	O
we	O
show	O
that	O
STAT2	O
and	O
STAT3	O
exist	O
in	O
separate	O
heterocomplexes	O
with	O
STAT1	O
,	O
consistent	O
with	O
a	O
model	O
in	O
which	O
STAT1	O
contains	O
a	O
common	O
binding	O
site	O
for	O
other	O
STAT	O
proteins	O
.	O

Permanent	O
occupancy	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
enhancer	O
by	O
NF-kappa	O
B	O
is	O
needed	O
for	O
persistent	O
viral	O
replication	O
in	O
monocytes	O
.	O

This	O
work	O
aimed	O
to	O
ascertain	O
the	O
role	O
of	O
kappaB-responsive	O
elements	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
enhancer	O
not	O
only	O
in	O
early	O
initiation	O
but	O
also	O
in	O
long-term	O
maintenance	O
of	O
proviral	O
transcription	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
three	O
main	O
approaches	O
.	O

The	O
first	O
was	O
to	O
abruptly	O
terminate	O
tumor	O
necrosis	O
factor-induced	O
NF-kappaB	O
binding	O
to	O
the	O
enhancer	O
sequences	O
in	O
U1	O
monocytic	O
cells	O
,	O
using	O
a	O
short	O
pulse	O
of	O
exogenous	O
tumor	O
necrosis	O
factor	O
.	O

This	O
resulted	O
in	O
concomitant	O
decrease	O
in	O
nuclear	O
NF-kappaB	O
DNA-binding	O
activity	O
and	O
endogenous	O
long	O
terminal	O
repeat	O
transcriptional	O
activity	O
.	O

The	O
second	O
was	O
to	O
suppress	O
the	O
permanent	O
NF-kappaB	O
translocation	O
induced	O
by	O
HIV-1	O
replication	O
itself	O
in	O
chronically	O
infected	O
U937	O
cells	O
,	O
using	O
a	O
specific	O
proteasome	O
inhibitor	O
(	O
Z-LLL-H	O
)	O
.	O

As	O
early	O
as	O
2	O
h	O
after	O
addition	O
of	O
the	O
inhibitor	O
to	O
the	O
culture	O
medium	O
,	O
there	O
was	O
an	O
inhibition	O
of	O
both	O
constitutive	O
activation	O
of	O
NF-kappaB	O
and	O
HIV-1	O
genome	O
expression	O
.	O

The	O
third	O
approach	O
was	O
to	O
monitor	O
the	O
replication	O
competence	O
in	O
U937	O
cells	O
of	O
an	O
infectious	O
HIV-1	O
provirus	O
carrying	O
point	O
mutations	O
in	O
the	O
kappaB-responsive	O
elements	O
of	O
both	O
long	O
terminal	O
repeats	O
.	O

Compared	O
with	O
its	O
wild-type	O
counterpart	O
,	O
this	O
mutated	O
provirus	O
showed	O
a	O
profoundly	O
decreased	O
,	O
Z-LLL-H-insensitive	O
transcriptional	O
and	O
replicative	O
activity	O
in	O
U937	O
monocytes	O
.	O

Together	O
,	O
our	O
results	O
indicate	O
that	O
occupancy	O
of	O
the	O
viral	O
enhancer	O
by	O
NF-kappaB	O
(	O
p50/p65	O
)	O
heterodimers	O
is	O
required	O
for	O
ongoing	O
transcription	O
of	O
integrated	O
HIV	O
provirus	O
in	O
monocytes	O
,	O
even	O
in	O
cells	O
chronically	O
infected	O
and	O
permanently	O
producing	O
functional	O
HIV	O
Tat	O
protein	O
.	O

Thus	O
,	O
the	O
ability	O
of	O
HIV-1	O
replication	O
to	O
activate	O
NF-kappaB	O
is	O
crucial	O
to	O
the	O
intense	O
self-perpetuated	O
viral	O
transcription	O
observed	O
in	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

Efficient	O
transcription	O
and	O
replication	O
of	O
simian	O
immunodeficiency	O
virus	O
in	O
the	O
absence	B-Negation
of	I-Negation
NF-kappaB	I-Negation
and	I-Negation
Sp1	I-Negation
binding	I-Negation
elements	I-Negation
.	O

Ten	O
mutants	O
of	O
the	O
simian	O
immunodeficiency	O
virus	O
(	O
SIV	O
)	O
SIVmac239	O
bearing	O
deletions	O
(	O
delta	O
)	O
or	O
substitutions	O
(	O
subst	O
)	O
in	O
the	O
NF-kappaB	O
and/or	O
Sp1	O
binding	O
elements	O
were	O
created	O
,	O
and	O
the	O
replicative	O
capacities	O
of	O
the	O
mutants	O
were	O
analyzed	O
.	O

All	O
mutants	O
,	O
including	O
one	O
extensively	O
mutagenized	O
strain	O
entirely	O
missing	B-Negation
the	I-Negation
NF-kappaB	I-Negation
and	I-Negation
four	I-Negation
Spl	I-Negation
binding	I-Negation
elements	I-Negation
,	O
replicated	O
with	O
wild-type	O
kinetics	O
and	O
to	O
a	O
wild-type	O
level	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
cultures	O
in	O
50	O
to	O
100	O
%	O
of	O
the	O
experiments	O
.	O

One	O
group	O
of	O
mutants	O
replicated	O
very	O
similarly	O
to	O
SIVmac239	O
in	O
kinetics	O
and	O
yield	O
in	O
CEMxl74	O
cells	O
(	O
2xNFKappaB	O
>	O
or	O
=	O
SlVmac239	O
approximately	O
deltaNFkappaB	O
approximately	O
deltaSpl234	O
approximately	O
substNFkappaB	O
approximately	O
substSpl2	O
approximately	O
substSp23	O
)	O
,	O
while	O
a	O
second	O
group	O
replicated	O
with	O
delayed	O
or	O
slightly	O
delayed	O
kinetics	O
in	O
CEMxl74	O
cells	O
(	O
SIVmac239	O
>	O
substSp34	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSp1	O
>	O
substSpl234	O
)	O
.	O

Reversions	B-Negation
or	I-Negation
additional	I-Negation
mutations	I-Negation
were	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
the	I-Negation
U3	I-Negation
and	I-Negation
R	I-Negation
regions	I-Negation
of	I-Negation
proviral	I-Negation
DNA	I-Negation
from	I-Negation
CEMxl74	I-Negation
cells	I-Negation
infected	I-Negation
with	I-Negation
the	I-Negation
SIVmac239	I-Negation
mutants	I-Negation
.	O

Similar	O
results	O
were	O
obtained	O
when	O
mutants	O
of	O
SIVmacMER	O
(	O
a	O
macrophage-competent	O
derivative	O
of	O
SIVmac239	O
)	O
were	O
tested	O
in	O
peripheral	O
blood	O
mononuclear	O
cell	O
and	O
CEMx174	O
cultures	O
.	O

However	O
,	O
the	O
growth	O
of	O
most	O
mutated	O
viruses	O
was	O
suppressed	O
in	O
primary	O
rhesus	O
monkey	O
alveolar	O
macrophages	O
(	O
SIVmacMER	O
approximately	O
2xNFkappaB	O
approximately	O
substNFkappaB	O
>	O
deltaNFkappaB	O
>	O
deltaNFkappaBdeltaSpl234	O
approximately	O
deltaNFkappaBdeltaSpl	O
>	O
deltaSpl234	O
approximately	O
substSpl2	O
>	O
substSp23	O
approximately	O
substSp34	O
approximately	O
substSpl234	O
>	O
or	O
=	O
SIVmac239	O
)	O
.	O

Thus	O
,	O
changes	O
in	O
the	O
Sp1	O
binding	O
sites	O
had	O
the	O
most	O
dramatic	O
effects	O
on	O
SIVmac	O
replication	O
in	O
primary	O
macrophage	O
cultures	O
.	O

Analysis	O
of	O
long	O
terminal	O
repeat-driven	O
secreted	O
alkaline	O
phosphatase	O
activity	O
in	O
transient	O
assays	O
showed	O
that	O
,	O
unlike	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
,	O
the	O
SIV	O
long	O
terminal	O
repeat	O
possesses	O
an	O
enhancer	O
region	O
just	O
upstream	O
of	O
the	O
NF-kappaB	O
element	O
which	O
maintains	O
significant	O
levels	O
of	O
basal	O
transcription	O
in	O
the	O
absence	B-Negation
of	I-Negation
NF-kappaB	I-Negation
and	I-Negation
Sp1	I-Negation
sites	I-Negation
.	O

This	O
region	O
is	O
responsive	O
to	O
transactivation	O
by	O
Tat	O
.	O

In	O
addition	O
,	O
the	O
SIV	O
TATA	O
box	O
was	O
shown	O
to	O
be	O
stronger	O
than	O
that	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
.	O

Therefore	O
,	O
the	O
surprisingly	O
high	O
replicative	O
capacity	O
of	O
NF-kappaB	O
and	O
Sp1	O
binding	O
site	O
mutants	O
of	O
SIVmac	O
is	O
due	O
to	O
unique	O
features	O
or	O
the	O
enhancer/promoter	O
region	O
.	O

Inactivation	O
of	O
IkappaBbeta	O
by	O
the	O
tax	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
:	O
a	O
potential	O
mechanism	O
for	O
constitutive	O
induction	O
of	O
NF-kappaB	O
.	O

In	O
resting	O
T	O
lymphocytes	O
,	O
the	O
transcription	O
factor	O
NF-kappaB	O
is	O
sequestered	O
in	O
the	O
cytoplasm	O
via	O
interactions	O
with	O
members	O
of	O
the	O
I	O
kappa	O
B	O
family	O
of	O
inhibitors	O
,	O
including	O
IkappaBalpha	O
and	O
IkappaBbeta	O
.	O

During	O
normal	O
T-cell	O
activation	O
,	O
IkappaBalpha	O
is	O
rapidly	O
phosphorylated	O
,	O
ubiquitinated	O
,	O
and	O
degraded	O
by	O
the	O
26S	O
proteasome	O
,	O
thus	O
permitting	O
the	O
release	O
of	O
functional	O
NF-kappaB	O
.	O

In	O
contrast	O
to	O
its	O
transient	O
pattern	O
of	O
nuclear	O
induction	O
during	O
an	O
immune	O
response	O
,	O
NF-kappaB	O
is	O
constitutively	O
activated	O
in	O
cells	O
expressing	O
the	O
Tax	O
transforming	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-1	O
)	O
.	O

Recent	O
studies	O
indicate	O
that	O
HTLV-1	O
Tax	O
targets	O
IkappaBalpha	O
to	O
the	O
ubiquitin-proteasome	O
pathway	O
.	O

However	O
,	O
it	O
remains	O
unclear	O
how	O
this	O
viral	O
protein	O
induces	O
a	O
persistent	O
rather	O
than	O
transient	O
NF-kappaB	O
response	O
.	O

In	O
this	O
report	O
,	O
we	O
provide	O
evidence	O
that	O
in	O
addition	O
to	O
acting	O
on	O
IkappaBalpha	O
,	O
Tax	O
stimulates	O
the	O
turnover	O
Of	O
IkappaBbeta	O
via	O
a	O
related	O
targeting	O
mechanism	O
.	O

Like	O
IkappaBalpha	O
,	O
Tax-mediated	O
breakdown	O
of	O
IkappaBbeta	O
in	O
transfected	O
T	O
lymphocytes	O
is	O
blocked	O
either	O
by	O
cell-permeable	O
proteasome	O
inhibitors	O
or	O
by	O
mutation	O
Of	O
IkappaBbeta	O
at	O
two	O
serine	O
residues	O
present	O
within	O
its	O
N-terminal	O
region	O
.	O

Despite	O
the	O
dual	O
specificity	O
of	O
HTLV-1	O
Tax	O
for	O
IkappaBalpha	O
and	O
IkappaBbeta	O
at	O
the	O
protein	O
level	O
,	O
Tax	O
selectively	O
stimulates	O
NF-kappaB-directed	O
transcription	O
of	O
the	O
IkappaBalpha	O
gene	O
.	O

Consequently	O
,	O
IkappaBbeta	O
protein	O
expression	O
is	O
chronically	O
downregulated	O
in	O
HTLV-1-infected	O
T	O
lymphocytes	O
.	O

These	O
findings	O
with	O
IkappaBbeta	O
provide	O
a	O
potential	O
mechanism	O
for	O
the	O
constitutive	O
activation	O
of	O
NF-kappaB	O
in	O
Tax-expressing	O
cells	O
.	O

Role	O
of	O
EGR1	O
in	O
regulation	O
of	O
stimulus-dependent	O
CD44	O
transcription	O
in	O
B	O
lymphocytes	O
.	O

The	O
immediate-early	O
gene	O
egr-1	O
encodes	O
a	O
transcription	O
factor	O
(	O
EGR1	O
)	O
that	O
links	O
B-cell	O
antigen	O
receptor	O
(	O
BCR	O
)	O
signals	O
to	O
downstream	O
activation	O
events	O
through	O
the	O
regulation	O
of	O
previously	O
unidentified	O
target	O
genes	O
.	O

Here	O
we	O
identify	O
the	O
gene	O
encoding	O
the	O
lymphocyte	O
homing	O
and	O
migration	O
protein	O
CD44	O
as	O
a	O
target	O
of	O
EGR1	O
regulation	O
in	O
B	O
cells	O
.	O

BCR-induced	O
increases	O
in	O
CD44	O
mRNA	O
expression	O
and	O
transcription	O
levels	O
are	O
shown	O
to	O
occur	O
in	O
EGR1-expressing	O
but	O
not	B-Negation
in	I-Negation
nonexpressing	I-Negation
subclones	I-Negation
of	I-Negation
the	I-Negation
B-cell	I-Negation
line	I-Negation
WEHI-231	I-Negation
.	O

Kinetics	O
of	O
egr-1	O
transcription	O
and	O
the	O
appearance	O
of	O
nuclear	O
EGR1	O
protein	O
precede	O
CD44	O
induction	O
and	O
occur	O
within	O
30	O
min	O
after	O
stimulation	O
in	O
the	O
EGR1-expressing	O
subclone	O
.	O

A	O
single	O
EGR1	O
binding	O
motif	O
is	O
demonstrated	O
at	O
bp	O
-301	O
of	O
the	O
human	O
CD44	O
promoter	O
.	O

Cotransfection	O
of	O
a	O
CD44	O
promoter-chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
with	O
an	O
egr-1	O
expression	O
vector	O
resulted	O
in	O
a	O
6.5-	O
to	O
8.5-fold	O
induction	O
of	O
transcriptional	O
activity	O
relative	O
to	O
an	O
empty	O
expression	O
vector	O
.	O

The	O
EGR1	O
binding	O
motif	O
was	O
shown	O
to	O
be	O
necessary	O
for	O
stimulus-induced	O
expression	O
of	O
a	O
CD44	O
promoter-chloramphenicol	O
acetyltransferase	O
reporter	O
construct	O
in	O
nontransformed	O
B	O
lymphocytes	O
and	O
was	O
required	O
for	O
transactivation	O
by	O
an	O
EGR1	O
expression	O
vector	O
in	O
a	O
B-cell	O
line	O
.	O

These	O
studies	O
identify	O
EGR1	O
as	O
an	O
intermediary	O
linking	O
BCR-derived	O
signals	O
to	O
the	O
induction	O
of	O
CD44	O
.	O

The	O
relevance	O
of	O
these	O
molecular	O
events	O
to	O
BCR	O
signal	O
transduction	O
and	O
antigen-stimulated	O
B-cell-mediated	O
immune	O
responses	O
is	O
discussed	O
.	O

Identification	O
of	O
an	O
inducible	O
regulator	O
of	O
c-myb	O
expression	O
during	O
T-cell	O
activation	O
.	O

Resting	O
T	O
cells	O
express	O
very	O
low	O
levels	O
of	O
c-Myb	O
protein	O
.	O

During	O
T-cell	O
activation	O
,	O
c-myb	O
expression	O
is	O
induced	O
and	O
much	O
of	O
the	O
increase	O
in	O
expression	O
occurs	O
at	O
the	O
transcriptional	O
level	O
.	O

We	O
identified	O
a	O
region	O
of	O
the	O
c-myb	O
5	O
'	O
flanking	O
sequence	O
that	O
increased	O
c-myb	O
expression	O
during	O
T-cell	O
activation	O
.	O

In	O
vivo	O
footprinting	O
by	O
ligation-mediated	O
PCR	O
was	O
performed	O
to	O
correlate	O
in	O
vivo	O
protein	O
binding	O
with	O
functional	O
activity	O
.	O

A	O
protein	O
footprint	O
was	O
visible	O
over	O
this	O
region	O
of	O
the	O
c-myb	O
5	O
'	O
flanking	O
sequence	O
in	O
activated	O
T	O
cells	O
but	O
not	B-Negation
in	I-Negation
unactivated	I-Negation
T	I-Negation
cells	I-Negation
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
with	O
nuclear	O
extract	O
from	O
activated	O
T	O
cells	O
and	O
an	O
oligonucleotide	O
of	O
this	O
binding	O
site	O
demonstrated	O
a	O
new	O
protein-DNA	O
complex	O
,	O
referred	O
to	O
as	O
CMAT	O
for	O
c-myb	O
in	O
activated	O
T	O
cells	O
;	O
this	O
complex	O
was	O
not	B-Negation
present	I-Negation
in	I-Negation
unactivated	I-Negation
T	I-Negation
cells	I-Negation
.	O

Because	O
the	O
binding	O
site	O
showed	O
some	O
sequence	O
similarity	O
with	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
binding	O
site	O
,	O
we	O
compared	O
the	O
kinetics	O
of	O
induction	O
of	O
the	O
two	O
binding	O
complexes	O
and	O
the	O
molecular	O
masses	O
of	O
the	O
two	O
proteins	O
.	O

Studies	O
of	O
the	O
kinetics	O
of	O
induction	O
showed	O
that	O
the	O
NFAT	O
EMSA	O
binding	O
complex	O
appeared	O
earlier	O
than	O
the	O
CMAT	O
complex	O
.	O

The	O
NFAT	O
protein	O
migrated	O
more	O
slowly	O
in	O
a	O
sodium	O
dodecyl	O
sulfate-polyacrylamide	O
gel	O
than	O
the	O
CMAT	O
protein	O
did	O
.	O

In	O
addition	O
,	O
an	O
antibody	O
against	O
NFAT	O
did	O
not	B-Negation
cross-react	I-Negation
with	I-Negation
the	I-Negation
CMAT	I-Negation
protein	I-Negation
.	O

The	O
appearance	O
of	O
the	O
CMAT	O
binding	O
complex	O
was	O
inhibited	O
by	O
both	O
cyclosporin	O
A	O
and	O
rapamycin	O
.	O

The	O
CMAT	O
protein	O
appears	O
to	O
be	O
a	O
novel	O
inducible	O
protein	O
involved	O
in	O
the	O
regulation	O
of	O
c-myb	O
expression	O
during	O
T-cell	O
activation	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
human	O
CD36	O
gene	O
promoter	O
:	O
identification	O
of	O
a	O
proximal	O
PEBP2/CBF	O
site	O
.	O

CD36	O
is	O
a	O
cell	O
surface	O
glycoprotein	O
composed	O
of	O
a	O
single	O
polypeptide	O
chain	O
,	O
which	O
interacts	O
with	O
thrombospondin	O
,	O
collagens	O
type	O
I	O
and	O
IV	O
,	O
oxidized	O
low	O
density	O
lipoprotein	O
,	O
fatty	O
acids	O
,	O
anionic	O
phospholipids	O
,	O
and	O
erythrocytes	O
parasitized	O
with	O
Plasmodium	O
falciparum	O
.	O

Its	O
expression	O
is	O
restricted	O
to	O
a	O
few	O
cell	O
types	O
,	O
including	O
monocyte/macrophages	O
.	O

In	O
these	O
cells	O
,	O
CD36	O
is	O
involved	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
,	O
and	O
foam	O
cell	O
formation	O
by	O
uptake	O
of	O
oxidized	O
low	O
density	O
lipoprotein	O
.	O

To	O
study	O
the	O
molecular	O
mechanisms	O
that	O
control	O
the	O
transcription	O
of	O
the	O
CD36	O
gene	O
in	O
monocytic	O
cells	O
we	O
have	O
isolated	O
and	O
analyzed	O
the	O
CD36	O
promoter	O
.	O

Transient	O
expression	O
experiments	O
of	O
5'-deletion	O
fragments	O
of	O
the	O
CD36	O
promoter	O
coupled	O
to	O
luciferase	O
demonstrated	O
that	O
as	O
few	O
as	O
158	O
base	O
pairs	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
were	O
sufficient	O
to	O
direct	O
the	O
monocyte-specific	O
transcription	O
of	O
the	O
reporter	O
gene	O
.	O

Within	O
the	O
above	O
region	O
,	O
the	O
fragment	O
spanning	O
nucleotides	O
-158	O
to	O
-90	O
was	O
required	O
for	O
optimal	O
transcription	O
in	O
monocytic	O
cells	O
.	O

Biochemical	O
analysis	O
of	O
the	O
region	O
-158/-90	O
revealed	O
a	O
binding	O
site	O
for	O
transcription	O
factors	O
of	O
the	O
polyomavirus	O
enhancer-binding	O
protein	O
2/core-binding	O
factor	O
(	O
PEBP2/CBF	O
)	O
family	O
at	O
position	O
-103	O
.	O

Disruption	O
of	O
the	O
PEBP2/CBF	O
site	O
markedly	O
diminished	O
the	O
role	O
of	O
the	O
PEBP2/CBF	O
factors	O
in	O
the	O
constitutive	O
transcription	O
of	O
the	O
CD36	O
gene	O
.	O

The	O
involvement	O
of	O
members	O
of	O
the	O
PEBP2/CBF	O
family	O
in	O
chromosome	O
translocations	O
associated	O
with	O
acute	O
myeloid	O
leukemia	O
,	O
and	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
myeloid-specific	O
genes	O
encoding	O
for	O
myeloperoxidase	O
,	O
elastase	O
,	O
and	O
the	O
colony-stimulating	O
factor	O
receptor	O
,	O
highlights	O
the	O
relevance	O
of	O
the	O
regulation	O
of	O
the	O
CD36	O
gene	O
promoter	O
in	O
monocytic	O
cells	O
by	O
members	O
of	O
the	O
PEBP2/CBF	O
family	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
stimulates	O
JAK2	O
signaling	O
pathway	O
and	O
rapidly	O
activates	O
p93fes	O
,	O
STAT1	O
p91	O
,	O
and	O
STAT3	O
p92	O
in	O
polymorphonuclear	O
leukocytes	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
,	O
supports	O
proliferation	O
,	O
differentiation	O
,	O
and	O
functional	O
activation	O
of	O
hemopoietic	O
cells	O
by	O
its	O
interaction	O
with	O
a	O
heterodimeric	O
receptor	O
.	O

Although	O
GM-CSF	O
receptor	O
is	O
devoid	O
of	O
tyrosine	O
kinase	O
enzymatic	O
activity	O
,	O
GM-CSF-induced	O
peripheral	O
blood	O
polymorphonuclear	O
leukocytes	O
(	O
PMN	O
)	O
functional	O
activation	O
is	O
mediated	O
by	O
the	O
phosphorylation	O
of	O
a	O
large	O
number	O
of	O
intracellular	O
signaling	O
molecules	O
.	O

We	O
have	O
previously	O
shown	O
that	O
JAK2	O
becomes	O
tyrosine-phosphorylated	O
in	O
response	O
to	O
GM-CSF	O
in	O
PMN	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
also	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
family	O
members	O
STAT1	O
p91	O
and	O
STAT3	O
p92	O
and	O
the	O
product	O
of	O
the	O
c-fps/fes	O
protooncogene	O
become	O
tyrosine-phosphorylated	O
upon	O
GM-CSF	O
stimulation	O
and	O
physically	O
associated	O
with	O
both	O
GM-CSF	O
receptor	O
beta	O
common	O
subunit	O
and	O
JAK2	O
.	O

Moreover	O
GM-CSF	O
was	O
able	O
to	O
induce	O
JAK2	O
and	O
p93fes	O
catalytic	O
activity	O
.	O

We	O
also	O
demonstrate	O
that	O
the	O
association	O
of	O
the	O
GM-CSF	O
receptor	O
beta	O
common	O
subunit	O
with	O
JAK2	O
is	O
ligand-dependent	O
.	O

Finally	O
we	O
demonstrate	O
that	O
GM-CSF	O
induces	O
a	O
DNA-binding	O
complex	O
that	O
contains	O
both	O
p91	O
and	O
p92	O
.	O

These	O
results	O
identify	O
a	O
new	O
signal	O
transduction	O
pathway	O
activated	O
by	O
GM-CSF	O
and	O
provide	O
a	O
mechanism	O
for	O
rapid	O
activation	O
of	O
gene	O
expression	O
in	O
GM-CSF-stimulated	O
PMN	O
.	O

CNI-1493	O
inhibits	O
monocyte/macrophage	O
tumor	O
necrosis	O
factor	O
by	O
suppression	O
of	O
translation	O
efficiency	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
mediates	O
a	O
wide	O
variety	O
of	O
disease	O
states	O
including	O
septic	O
shock	O
,	O
acute	O
and	O
chronic	O
inflammation	O
,	O
and	O
cachexia	O
.	O

Recently	O
,	O
a	O
multivalent	O
guanylhydrazone	O
(	O
CNI-1493	O
)	O
developed	O
as	O
an	O
inhibitor	O
of	O
macrophage	O
activation	O
was	O
shown	O
to	O
suppress	O
TNF	O
production	O
and	O
protect	O
against	O
tissue	O
inflammation	O
and	O
endotoxin	O
lethality	O
[	O
Bianchi	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Bloom	O
,	O
O.	O
,	O
Meistrell	O
,	O
M.	O
,	O
Zimmerman	O
,	O
G.A.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Donnelley	O
,	O
T.	O
,	O
Bucala	O
,	O
R.	O
,	O
Sherry	O
,	O
B.	O
,	O
Manogue	O
,	O
K.R.	O
,	O
Tortolani	O
,	O
A.J.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
K.J.	O
(	O
1995	O
)	O
Mol.Med.1	O
,	O
254-266	O
,	O
and	O
Bianchi	O
,	O
M.	O
,	O
Bloom	O
,	O
O.	O
,	O
Raabe	O
,	O
T.	O
,	O
Cohen	O
,	O
P.	O
S.	O
,	O
Chesney	O
,	O
J.	O
,	O
Sherry	O
,	O
B.	O
,	O
Schmidtmayerova	O
,	O
H.	O
,	O
Zhang	O
,	O
X.	O
,	O
Bukrinsky	O
,	O
M.	O
,	O
Ulrich	O
,	O
P.	O
,	O
Cerami	O
,	O
A.	O
&	O
Tracey	O
,	O
J.	O
(	O
1996	O
)	O
J.Exp.Med.	O
,	O
in	O
press	O
]	O
.	O

We	O
have	O
now	O
elucidated	O
the	O
mechanism	O
by	O
which	O
CNI-1493	O
inhibits	O
macrophage	O
TNF	O
synthesis	O
and	O
show	O
here	O
that	O
it	O
acts	O
through	O
suppression	O
of	O
TNF	O
translation	O
efficiency	O
.	O

CNI-1493	O
blocked	O
neither	B-Negation
the	I-Negation
lipopolysaccharide	I-Negation
(	I-Negation
LPS	I-Negation
)	I-Negation
-induced	I-Negation
increases	I-Negation
in	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
TNF	I-Negation
mRNA	I-Negation
nor	I-Negation
the	I-Negation
translocation	I-Negation
of	I-Negation
nuclear	I-Negation
factor	I-Negation
NF-kappa	I-Negation
B	I-Negation
to	I-Negation
the	I-Negation
nucleus	I-Negation
in	I-Negation
macrophages	I-Negation
activated	I-Negation
by	I-Negation
15	I-Negation
min	I-Negation
of	I-Negation
LPS	I-Negation
stimulation	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
CNI-1493	I-Speculation
does	I-Speculation
not	I-Speculation
interfere	I-Speculation
with	I-Speculation
early	I-Speculation
NF-kappa	I-Speculation
B-mediated	I-Speculation
transcriptional	I-Speculation
regulation	I-Speculation
of	I-Speculation
TNF	I-Speculation
.	O

However	O
,	O
synthesis	O
of	O
the	O
26-kDa	O
membrane	O
form	O
of	O
TNF	O
was	O
effectively	O
blocked	O
by	O
CNI-1493	O
.	O

Further	O
evidence	O
for	O
the	O
translational	O
suppression	O
of	O
TNF	O
is	O
given	O
by	O
experiments	O
using	O
chloram-phenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
constructs	O
containing	O
elements	O
of	O
the	O
TNF	O
gene	O
that	O
are	O
involved	O
in	O
TNF	O
translational	O
regulation	O
.	O

Both	O
the	O
5	O
'	O
and	O
3	O
'	O
untranslated	O
regions	O
of	O
the	O
TNF	O
gene	O
were	O
required	O
to	O
elicit	O
maximal	O
translational	O
suppression	O
by	O
CNI-1493	O
.	O

Identification	O
of	O
the	O
molecular	O
target	O
through	O
which	O
CNI-	O
1493	O
inhibits	O
TNF	O
translation	O
should	O
provide	O
insight	O
into	O
the	O
regulation	O
of	O
macrophage	O
activation	O
and	O
mechanisms	O
of	O
inflammation	O
.	O

STAT-related	O
transcription	O
factors	O
are	O
constitutively	O
activated	O
in	O
peripheral	O
blood	O
cells	O
from	O
acute	O
leukemia	O
patients	O
.	O

A	O
signal	O
transduction	O
pathway	O
activated	O
by	O
many	O
cytokines	O
has	O
recently	O
been	O
elaborated	O
.	O

The	O
JAK	O
kinases	O
and	O
the	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
factors	O
have	O
been	O
found	O
to	O
be	O
essential	O
components	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
presence	O
of	O
constitutively	O
activated	O
STAT	O
factors	O
in	O
peripheral	O
blood	O
cells	O
from	O
patients	O
with	O
acute	O
leukemia	O
.	O

We	O
used	O
oligonucleotide	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	O
gene	O
promoters	O
and	O
the	O
ISRE	O
probe	O
to	O
detect	O
STAT	O
proteins	O
in	O
nuclear	O
extracts	O
from	O
acute	O
leukemia	O
cells	O
in	O
bandshift	O
assays	O
.	O

Specific	O
DNA	O
protein	O
complex	O
formation	O
was	O
observed	O
with	O
the	O
probes	O
from	O
the	O
beta-casein	O
and	O
IRF-1	O
gene	O
promoters	O
,	O
but	O
not	B-Negation
with	I-Negation
the	I-Negation
ISRE	I-Negation
oligonucleotide	I-Negation
probe	I-Negation
,	O
when	O
cell	O
extracts	O
from	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
were	O
investigated	O
.	O

We	O
used	O
nonradioactive	O
oligonucleotides	O
as	O
competitors	O
to	O
show	O
the	O
specificity	O
of	O
the	O
complex	O
formation	O
.	O

Specific	O
antibodies	O
directed	O
against	O
the	O
individual	O
STAT	O
proteins	O
were	O
used	O
in	O
supershift	O
experiments	O
.	O

STAT5-	O
and	O
STAT1-related	O
factors	O
were	O
detected	O
in	O
ALL	O
and	O
STAT1-	O
,	O
STAT3-	O
,	O
and	O
STAT5-related	O
proteins	O
were	O
present	O
in	O
nuclear	O
cell	O
extracts	O
from	O
AML	O
.	O

Since	O
the	B-Negation
cells	I-Negation
were	I-Negation
not	I-Negation
treated	I-Negation
with	I-Negation
cytokines	I-Negation
before	I-Negation
the	I-Negation
nuclear	I-Negation
proteins	I-Negation
were	I-Negation
extracted	I-Negation
,	O
we	O
conclude	O
that	O
these	O
factors	O
are	O
constitutively	O
activated	O
in	O
vivo	O
.	O

It	O
is	O
likely	O
that	O
the	O
constitutive	O
activation	O
of	O
STAT	O
proteins	O
is	O
a	O
part	O
of	O
the	O
events	O
of	O
leukemogenesis	O
.	O

Reversible	O
differentiation	O
of	O
human	O
monoblastic	O
leukemia	O
U937	O
cells	O
by	O
ML-9	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
.	O

Human	O
monoblastic	O
leukemia	O
U937	O
cells	O
are	O
induced	O
to	O
differentiate	O
into	O
monocytes	O
and	O
macrophages	O
by	O
various	O
agents	O
.	O

We	O
have	O
shown	O
that	O
1-	O
(	O
5-chloronaphthalene-1-sulfonyl	O
)	O
-1H-hexahydro-1,4-diazepine	O
hydrochloride	O
(	O
ML-9	O
)	O
,	O
an	O
inhibitor	O
of	O
myosin	O
light	O
chain	O
kinase	O
,	O
induces	O
differentiation	O
of	O
monocytoid	O
leukemia	O
cell	O
lines	O
U937	O
and	O
THP-1	O
but	O
not	B-Negation
of	I-Negation
myeloblastic	I-Negation
leukemic	I-Negation
ML-1	I-Negation
cell	I-Negation
or	I-Negation
erythroleukemia	I-Negation
K562	I-Negation
cells	I-Negation
.	O

In	O
the	O
present	O
study	O
,	O
we	O
further	O
analyzed	O
the	O
effect	O
of	O
ML-9	O
in	O
comparison	O
with	O
that	O
of	O
1	O
alpha	O
,	O
25-dihydroxyvitamin	O
D3	O
(	O
VD3	O
)	O
a	O
typical	O
inducer	O
of	O
monocytic	O
differentiation	O
.	O

ML-9	O
induced	O
nitroblue	O
tetrazolium	O
(	O
NBT	O
)	O
-reducing	O
activity	O
of	O
U937	O
cell	O
more	O
rapidly	O
than	O
VD3	O
:	O
This	O
differentiation	O
marker	O
was	O
induced	O
significantly	O
after	O
incubation	O
with	O
ML-9	O
and	O
VD3	O
for	O
4	O
hours	O
and	O
1	O
day	O
,	O
respectively	O
.	O

ML-9	O
also	O
induced	O
alpha-naphthyl	O
acetate	O
esterase	O
(	O
ANAE	O
)	O
activity	O
,	O
another	O
monocytic	O
differentiation	O
marker	O
,	O
more	O
rapidly	O
than	O
VD3	O
.	O

The	O
maximum	O
levels	O
of	O
these	O
markers	O
induced	O
by	O
ML-9	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
VD3	O
,	O
but	O
after	O
removal	O
of	O
ML-9	O
from	O
the	O
medium	O
by	O
washing	O
the	O
cells	O
,	O
the	O
expressions	O
of	O
theses	O
markers	O
decreased	O
within	O
4	O
hours	O
and	O
reached	O
basal	O
levels	O
in	O
1	O
day	O
,	O
indicating	O
that	O
ML-9	O
's	O
induction	O
of	O
expression	O
of	O
differentiation-associated	O
phenotypes	O
was	O
reversible	O
.	O

The	O
growth	O
inhibition	O
of	O
U937	O
cells	O
by	O
ML-9	O
was	O
also	O
reversible	O
.	O

Similar	O
effects	O
were	O
observed	O
in	O
another	O
line	O
of	O
human	O
monoblastic	O
cells	O
,	O
THP-1	O
.	O

ML-9	O
had	O
little	O
or	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
morphology	I-Negation
of	I-Negation
U937	I-Negation
cells	I-Negation
but	O
increased	O
the	O
expression	O
of	O
monocyte-macrophage	O
lineage-associated	O
surface	O
antigen	O
,	O
CD14	O
,	O
to	O
some	O
extent	O
.	O

Irreversible	O
terminal	O
differentiation	O
induced	O
by	O
VD3	O
is	O
associated	O
with	O
down	O
regulation	O
of	O
the	O
expression	O
of	O
c-myc	O
and	O
upregulation	O
of	O
the	O
expression	O
of	O
c-fos	O
and	O
c-jun	O
,	O
but	O
ML-9	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
these	I-Negation
oncogenes	I-Negation
appreciably	I-Negation
.	O

ML-9-induced	O
differentiation	O
was	O
also	O
reversible	O
when	O
the	O
cells	O
were	O
cultured	O
with	O
cultured	O
with	O
ML-9	O
plus	O
an	O
anti-cancer	O
drug	O
such	O
as	O
1-beta-D-arabino-furanosylcytosine	O
or	O
daunomycin	O
.	O

it	O
became	O
irreversible	O
,	O
however	O
,	O
upon	O
simultaneous	O
treatment	O
with	O
dexamethasone	O
and	O
transforming	O
growth	O
factor-beta	O
1	O
(	O
TGF-beta	O
1	O
)	O
,	O
which	O
did	O
not	B-Negation
induce	I-Negation
differentiation	I-Negation
of	I-Negation
U937	I-Negation
cells	I-Negation
but	O
caused	O
growth	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
G0/G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

These	O
results	O
suggest	O
that	O
ML-9	O
should	O
be	O
useful	O
for	O
studying	O
the	O
mechanisms	O
of	O
monocytic	O
differentiation	O
.	O

Interferon-gamma	O
modulates	O
the	O
lipopolysaccharide-induced	O
expression	O
of	O
AP-1	O
and	O
NF-kappa	O
B	O
at	O
the	O
mRNA	O
and	O
protein	O
level	O
in	O
human	O
monocytes	O
.	O

Interferon-gamma	O
(	O
IFN-gamma	O
)	O
modulates	O
the	O
expression	O
of	O
several	O
cytokines	O
by	O
human	O
monocytes	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
view	O
of	O
these	O
findings	O
,	O
we	O
analyzed	O
the	O
effects	O
of	O
IFN-gamma	O
on	O
the	O
expression	O
of	O
different	O
transcription	O
factors	O
in	O
activated	O
human	O
monocytes	O
.	O

Priming	O
of	O
human	O
monocytes	O
with	O
IFN-gamma	O
resulted	O
in	O
the	O
down	O
regulation	O
of	O
c-fos	O
and	O
c-jun	O
mRNA	O
in	O
response	O
to	O
stimulation	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
compared	O
to	O
the	O
effects	O
of	O
LPS	O
alone	O
.	O

Not	O
only	O
was	O
this	O
effect	O
observed	O
at	O
the	O
mRNA	O
level	O
,	O
but	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
DNA	O
binding	O
capacity	O
was	O
affected	O
as	O
well	O
,	O
A	O
strong	O
reduction	O
was	O
observed	O
in	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
AP-1	O
in	O
the	O
presence	O
of	O
IFN-gamma	O
.	O

LPS-stimulated	O
monocytes	O
showed	O
an	O
increased	O
expression	O
of	O
p105	O
mRNA	O
,	O
the	O
precursor	O
of	O
the	O
p50	O
subunit	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
while	O
no	B-Negation
effect	I-Negation
was	I-Negation
noticed	I-Negation
on	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
p65	I-Negation
mRNA	I-Negation
.	O

In	O
contrast	O
,	O
IFN-gamma	O
priming	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
p105	I-Negation
transcripts	I-Negation
but	O
enhanced	O
the	O
expression	O
of	O
p65	O
mRNA	O
(	O
two-fold	O
)	O
.	O

Priming	O
with	O
IFN-gamma	O
followed	O
by	O
LPS	O
stimulation	O
resulted	O
in	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
p65	O
mRNA	O
.	O

This	O
was	O
due	O
to	O
an	O
increase	O
in	O
the	O
half-life	O
of	O
p65	O
mRNA	O
(	O
75	O
vs	O
150	O
minutes	O
)	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
unstimulated	O
monocytes	O
predominantly	O
expressed	O
p50	O
NF-kappa	O
B	O
.	O

Stimulation	O
with	O
LPS	O
or	O
IFN-gamma	O
resulted	O
in	O
the	O
expression	O
of	O
p50	O
and	O
p65	O
subunits	O
,	O
while	O
the	O
combination	O
of	O
IFN-gamma	O
plus	O
LPS	O
caused	O
a	O
further	O
increase	O
in	O
the	O
expression	O
of	O
NF-kappa	O
B	O
.	O

With	O
Western	O
blotting	O
,	O
it	O
was	O
shown	O
that	O
nuclear	O
extracts	O
from	O
monocytes	O
contained	O
p50	O
and	O
p65	O
protein	O
in	O
response	O
to	O
LPS	O
and	O
IFN-gamma	O
stimulation	O
.	O

However	O
,	O
the	O
combined	O
stimulation	O
did	O
not	B-Negation
result	I-Negation
in	I-Negation
enhanced	I-Negation
p50	I-Negation
and	I-Negation
p65	I-Negation
protein	I-Negation
expression	I-Negation
.	O

The	O
effects	O
of	O
IFN-gamma	O
on	O
the	O
transcription	O
factors	O
were	O
specific	O
,	O
since	O
no	B-Negation
change	I-Negation
was	I-Negation
observed	I-Negation
in	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
NF-IL-6	I-Negation
or	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
,	I-Negation
the	I-Negation
inhibitor	I-Negation
of	I-Negation
NF-kappa	I-Negation
B	I-Negation
.	O

We	O
conclude	O
that	O
the	O
effects	O
of	O
IFN-gamma	O
on	O
the	O
expression	O
of	O
the	O
transcription	O
factors	O
AP-1	O
and	O
NF-kappa	O
B	O
may	O
be	O
important	O
for	O
the	O
modulatory	O
effects	O
of	O
IFN-gamma	O
on	O
the	O
cytokine	O
expression	O
in	O
activated	O
human	O
monocytes	O
.	O

Expression	O
of	O
c-fos	O
and	O
c-jun	O
proteins	O
and	O
AP-1	O
binding	O
activity	O
during	O
cell	O
cycle	O
progression	O
of	O
HL60	O
cells	O
and	O
phytohemagglutinin-stimulated	O
lymphocytes	O
.	O

The	O
protein	O
products	O
of	O
the	O
c-fos	O
(	O
p62c-fos	O
)	O
and	O
c-jun	O
(	O
p39c-jun	O
)	O
genes	O
are	O
members	O
of	O
the	O
AP-1	O
transcription	O
factor	O
family	O
and	O
are	O
thought	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
during	O
the	O
cell	O
cycle	O
.	O

Most	O
studies	O
on	O
the	O
expression	O
of	O
these	O
proteins	O
in	O
relation	O
to	O
the	O
cell	O
cycle	O
have	O
been	O
performed	O
at	O
the	O
mRNA	O
level	O
,	O
and	O
therefore	O
do	O
not	B-Negation
give	I-Negation
direct	I-Negation
information	I-Negation
about	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
the	I-Negation
proteins	I-Negation
during	I-Negation
the	I-Negation
cell	I-Negation
cycle	I-Negation
.	O

We	O
have	O
used	O
Western	O
blotting	O
to	O
investigate	O
the	O
presence	O
of	O
these	O
proteins	O
during	O
the	O
cell	O
cycles	O
of	O
two	O
different	O
cellular	O
systems	O
:	O
a	O
continuously	O
growing	O
myeloid	O
leukemic	O
cell	O
line	O
,	O
HL60	O
,	O
and	O
normal	O
cells	O
stimulated	O
into	O
cycle	O
,	O
phyto-	O
hemagglutinin	O
(	O
PHA	O
)	O
-stimulated	O
normal	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

The	O
binding	O
activity	O
of	O
transcription	O
factor	O
AP-1	O
,	O
which	O
consists	O
of	O
dimers	O
of	O
Fos	O
and	O
Jun	O
family	O
proteins	O
,	O
was	O
also	O
studied	O
using	O
a	O
gel	O
shift	O
assay	O
.	O

We	O
found	O
nuclear	O
p62c-fos	O
,	O
p39c-jun	O
,	O
and	O
AP-1	O
binding	O
activity	O
throughout	O
the	O
cell	O
cycle	O
both	O
in	O
HL60	O
cells	O
and	O
in	O
PHA-stimulated	O
PBL	O
,	O
and	O
we	O
postulate	O
that	O
these	O
proteins	O
are	O
required	O
throughout	O
the	O
cell	O
cycle	O
and	O
not	B-Negation
transiently	I-Negation
in	I-Negation
the	I-Negation
G0	I-Negation
to	I-Negation
G1	I-Negation
transition	I-Negation
as	O
previous	O
mRNA	O
studies	O
have	O
indicated	O
.	O

We	O
demonstrated	O
an	O
uncoupling	O
of	O
AP-1	O
binding	O
activity	O
from	O
p62c-fos	O
,	O
and	O
p39c-jun	O
AP-1	O
activity	O
was	O
expressed	O
more	O
strongly	O
in	O
the	O
G1-	O
and	O
G2/M-phase	O
enriched	O
samples	O
than	O
in	O
the	O
S-phase	O
enriched	O
samples	O
of	O
HL60	O
cells	O
,	O
while	O
levels	O
of	O
nuclear	O
p62c-fos	O
and	O
p39c-jun	O
were	O
constant	O
.	O

Nuclei	O
of	O
unstimulated	O
PBL	O
from	O
different	O
donors	O
expressed	O
p62c-fos	O
and	O
p39c-jun	O
,	O
but	O
AP-1	B-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
the	I-Negation
majority	I-Negation
of	I-Negation
samples	I-Negation
.	O

Following	O
PHA	O
stimulation	O
of	O
PBL	O
,	O
the	O
increase	O
in	O
AP-1	O
activity	O
was	O
delayed	O
with	O
respect	O
to	O
the	O
augmentation	O
of	O
p39c-jun	O
expression	O
.	O

We	O
also	O
observed	O
that	O
cytoplasmic	O
p62c-fos	O
and	O
p39c-jun	O
were	O
present	O
in	O
HL60	O
cells	O
and	O
PHA-stimulated	O
PBL	O
.	O

However	O
,	O
no	B-Negation
cytoplasmic	I-Negation
p62c-fos	I-Negation
was	I-Negation
detected	I-Negation
in	I-Negation
unstimulated	I-Negation
PBL	I-Negation
,	O
although	O
in	O
some	O
cases	O
cytoplasmic	O
p39c-jun	O
was	O
detected	O
,	O
suggesting	B-Speculation
that	I-Speculation
subcellular	I-Speculation
compartmentalization	I-Speculation
of	I-Speculation
these	I-Speculation
proteinsmay	I-Speculation
occur	I-Speculation
under	I-Speculation
certain	I-Speculation
circumstances	I-Speculation
.	O

Involvement	O
of	O
intracellular	O
Ca2+	O
in	O
oxidant-induced	O
NF-kappa	O
B	O
activation	O
.	O

In	O
human	O
Jurkat	O
T	O
cells	O
and	O
its	O
subclone	O
Wurzburg	O
cells	O
oxidant	O
challenge	O
elevated	O
[	O
Ca2+	O
]	O
i	O
by	O
mobilizing	O
Ca2+	O
from	O
intracellular	O
stores	O
.	O

In	O
Jurkat	O
cells	O
this	O
effect	O
was	O
rapid	O
and	O
transient	O
,	O
but	O
in	O
Wurzburg	O
cells	O
the	O
response	O
was	O
slow	O
and	O
sustained	O
.	O

H2O2-induced	B-Negation
NF-kappaB	I-Negation
activation	I-Negation
in	I-Negation
Wurzburg	I-Negation
cells	I-Negation
was	I-Negation
not	I-Negation
influenced	I-Negation
by	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
extracellular	I-Negation
EGTA	I-Negation
but	O
was	O
totally	O
inhibited	O
in	O
cells	O
that	O
were	O
loaded	O
with	O
esterified	O
EGTA	O
.	O

In	O
Jurkat	O
cells	O
that	O
are	O
not	B-Negation
sensitive	I-Negation
to	I-Negation
H2O2-induced	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
,	O
H2O2	O
potentiated	O
NF-kappaB	O
activation	O
in	O
the	O
presence	O
of	O
sustained	O
high	O
[	O
Ca2+	O
]	O
i	O
following	O
thapsigargin	O
treatment	O
.	O

NF-kappaB	O
regulatory	O
effect	O
of	O
alpha-lipoate	O
and	O
N-acetylcysteine	O
appeared	O
to	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
their	O
ability	O
to	O
stabilize	O
elevation	O
of	O
[	O
Ca2+	O
]	O
i	O
following	O
oxidant	O
challenge	O
.	O

Results	O
of	O
this	O
study	O
indicate	O
that	O
a	O
sustained	O
elevated	O
[	O
Ca2+	O
]	O
i	O
is	O
a	O
significant	O
factor	O
in	O
oxidant-induced	O
NF-kappaB	O
activation	O
.	O

A	O
cell	O
type-specific	O
enhancer	O
in	O
the	O
human	O
B7.1	O
gene	O
regulated	O
by	O
NF-kappaB	O
.	O

The	O
costimulatory	O
molecule	O
B7.1	O
provides	O
a	O
second	O
signal	O
critical	O
for	O
T	O
cell	O
activation	O
.	O

The	O
distribution	O
of	O
this	O
integral	O
membrane	O
protein	O
is	O
restricted	O
to	O
certain	O
tissues	O
where	O
its	O
level	O
of	O
expression	O
is	O
modulated	O
by	O
multiple	O
exogenous	O
stimuli	O
.	O

To	O
identify	O
the	O
molecular	O
basis	O
for	O
specificity	O
and	O
inducibility	O
,	O
the	O
chromatin	O
configuration	O
of	O
the	O
human	O
B7.1	O
gene	O
was	O
examined	O
in	O
intact	O
nuclei	O
from	O
various	O
cell	O
types	O
.	O

The	O
identification	O
of	O
a	O
tissue-specific	O
deoxyribonuclease	O
I	O
hypersensitive	O
site	O
approximately	O
3kb	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
led	O
to	O
the	O
characterization	O
of	O
a	O
cell	O
type-specific	O
enhancer	O
region	O
.	O

This	O
183-bp	O
region	O
was	O
both	O
cell	O
type	O
specific	O
and	O
responsive	O
to	O
two	O
distinct	O
stimuli	O
,	O
lipopolysaccharide	O
and	O
dibutyryl	O
cAMP	O
,	O
known	O
to	O
regulate	O
B7.1	O
expression	O
.	O

Deletional	O
and	O
site-directed	O
mutagenesis	O
revealed	O
the	O
presence	O
of	O
multiple	O
functionally	O
critical	O
cis	O
elements	O
within	O
this	O
region	O
,	O
one	O
of	O
which	O
was	O
a	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
consensus	O
sequence	O
.	O

In	O
B7.1-positive	O
B	O
cells	O
,	O
this	O
element	O
bound	O
several	O
members	O
of	O
the	O
NF-kappaB	O
family	O
,	O
transcription	O
factors	O
already	O
implicated	O
in	O
signal	O
transduction	O
pathways	O
relevant	O
to	O
B7.1	O
expression	O
.	O

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
regulatory	O
elements	O
that	O
control	O
expression	O
of	O
a	O
gene	O
encoding	O
a	O
B7	O
costimulatory	O
molecule	O
.	O

Heat	O
shock	O
induces	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
promyelocyte	O
cell	O
line	O
OM10.1	O
.	O

A	O
long	O
period	O
of	O
clinical	O
latency	O
before	O
development	O
of	O
symptoms	O
is	O
characteristic	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
.	O

OM10.1	O
,	O
a	O
promyelocyte	O
cell	O
line	O
latently	O
infected	O
with	O
HIV-1	O
,	O
has	O
been	O
developed	O
as	O
a	O
model	O
for	O
studying	O
the	O
mechanism	O
of	O
viral	O
latency	O
and	O
the	O
activation	O
of	O
virus	O
expression	O
.	O

We	O
found	O
that	O
this	O
latently	O
infected	O
cell	O
line	O
with	O
heat	O
shock	O
at	O
42	O
degrees	O
C	O
for	O
2	O
h	O
resulted	O
in	O
a	O
high	O
level	O
of	O
HIV-1	O
production	O
without	B-Negation
addition	I-Negation
of	I-Negation
any	I-Negation
cytokines	I-Negation
.	O

The	O
mechanism	O
of	O
activation	O
was	O
analyzed	O
by	O
using	O
anti-TNF-alpha	O
antibody	O
and	O
various	O
inhibitors	O
.	O

Although	O
the	O
TNF-alpha	O
level	O
in	O
culture	O
supernatants	O
was	O
below	O
the	O
sensitivity	O
of	O
an	O
ELISA	O
assay	O
system	O
,	O
addition	O
of	O
anti-TNF-alpha	O
antibody	O
in	O
culture	O
medium	O
could	O
partially	O
suppress	O
the	O
heat	O
shock	O
induced	O
HIV-1	O
production	O
.	O

Staurosporine	O
(	O
PKC	O
inhibitor	O
)	O
,	O
pentoxifylline	O
(	O
NF-kappa	O
B	O
inhibitor	O
)	O
,	O
and	O
Ro5-3335	O
(	O
HIV-1	O
Tat	O
inhibitor	O
)	O
also	O
inhibited	O
significantly	O
the	O
heat	O
shock	O
induced	O
virus	O
activation	O
.	O

In	O
particular	O
,	O
staurosporine	O
achieved	O
approximately	O
90	O
%	O
inhibition	O
of	O
the	O
HIV-1	O
antigen	O
expression	O
in	O
heat	O
shock-treated	O
OM10.1	O
at	O
a	O
non-toxic	O
concentration	O
.	O

Although	O
the	O
mechanism	O
of	O
HIV-1	O
activation	O
with	O
heat	O
shock	O
has	O
not	O
been	O
fully	O
elucidated	O
yet	O
,	O
it	O
is	O
presumed	O
PKC	O
plays	O
an	O
important	O
role	O
in	O
HIV-1	O
activation	O
.	O

Thus	O
,	O
the	O
present	O
observations	O
will	O
provide	O
a	O
further	O
insight	O
into	O
the	O
pathogenesis	O
of	O
HIV-1	O
infections	O
.	O

Abundant	O
expression	O
of	O
erythroid	O
transcription	O
factor	O
P45	O
NF-E2	O
mRNA	O
in	O
human	O
peripheral	O
granurocytes	O
.	O

Transcription	O
factor	O
NF-E2	O
is	O
crucial	O
for	O
regulation	O
of	O
erythroid-specific	O
gene	O
expression	O
.	O

p45	O
subunit	O
of	O
NF-E2	O
contains	O
a	O
basic-leucine	O
zipper	O
domain	O
and	O
dimerizes	O
with	O
the	O
small	O
Maf	O
family	O
protein	O
to	O
form	O
functional	O
NF-E2	O
complex	O
.	O

While	O
p45	O
expression	O
was	O
shown	O
to	O
be	O
restricted	O
to	O
erythroid	O
cells	O
,	O
megakaryocytes	O
and	O
mast	O
cells	O
in	O
hematopoietic	O
lineage	O
,	O
we	O
found	O
in	O
this	O
study	O
that	O
p45	O
mRNA	O
is	O
abundantly	O
transcribed	O
in	O
the	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
granulocyte	O
fraction	O
of	O
human	O
peripheral	O
blood	O
cells	O
.	O

As	O
neutrophils	O
occupy	O
approximately	O
92	O
%	O
of	O
the	O
cells	O
in	O
this	O
fraction	O
,	O
the	O
cells	O
expressing	O
p45	O
is	O
most	O
likely	O
to	O
be	O
neutrophils	O
.	O

p45	O
mRNA	O
is	O
also	O
expressed	O
in	O
HL-60	O
promyelocytes	O
,	O
albeit	O
the	O
expression	O
level	O
is	O
much	O
lower	O
than	O
that	O
of	O
the	O
granulocyte	O
fraction	O
.	O

HL-60	O
cells	O
were	O
found	O
to	O
express	O
mafK	O
mRNA	O
,	O
indicating	O
the	O
presence	O
of	O
genuine	O
NF-E2	O
complex	O
in	O
the	O
cells	O
.	O

Although	O
p45	O
mRNA	O
is	O
transcribed	O
from	O
two	O
different	O
promoters	O
,	O
aNF-E2	O
promoter	O
and	O
fNF-E2	O
promoter	O
,	O
in	O
erythroid	O
and	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF-E2	O
promoter	O
.	O

The	O
expression	O
of	O
p45	O
megakaryocytic	O
lineage	O
cells	O
,	O
p45	O
mRNA	O
is	O
transcribed	O
only	O
from	O
aNF-E2	O
promoter	O
.	O

The	O
expression	O
of	O
p45	O
mRNA	O
in	O
the	O
neutrophils	O
declined	O
rapidly	O
after	O
transfer	O
of	O
the	O
cells	O
to	O
in	O
vitro	O
culture	O
and	O
G-CSF	O
could	O
not	B-Negation
sustain	I-Negation
the	I-Negation
expression	I-Negation
from	I-Negation
the	I-Negation
down-regulation	I-Negation
,	O
suggesting	B-Speculation
the	I-Speculation
E2	I-Speculation
may	I-Speculation
also	I-Speculation
participate	I-Speculation
in	I-Speculation
the	I-Speculation
regulation	I-Speculation
of	I-Speculation
neutrophil-specific	I-Speculation
gene	I-Speculation
expression	I-Speculation
.	O

Inhibition	O
of	O
p105	O
processing	O
by	O
NF-kappaB	O
proteins	O
in	O
transiently	O
transfected	O
cells	O
.	O

Regulation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
involves	O
proteasome-mediated	O
processing	O
of	O
the	O
NF-kappaB1	O
p105	O
precursor	O
protein	O
,	O
which	O
generates	O
the	O
p50	O
subunit	O
of	O
NF-kappaB	O
.	O

The	O
processing	O
of	O
p105	O
occurs	O
constitutively	O
in	O
vivo	O
but	O
can	O
be	O
markedly	O
enhanced	O
by	O
various	O
cellular	O
activation	O
agents	O
,	O
although	O
the	O
underlying	O
regulatory	O
mechanism	O
is	O
not	O
yet	O
clear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
signal-mediated	O
induction	O
of	O
p105	O
processing	O
in	O
human	O
T	O
cells	O
is	O
associated	O
with	O
de	O
novo	O
synthesis	O
of	O
this	O
precursor	O
protein	O
.	O

Transient	O
transfection	O
studies	O
performed	O
in	O
COS7	O
cells	O
revealed	O
that	O
the	O
newly	O
synthesized	O
p105	O
protein	O
appears	O
to	O
be	O
more	O
rapidly	O
processed	O
compared	O
to	O
its	O
accumulated	O
form	O
that	O
is	O
already	O
associated	O
with	O
the	O
processed	O
product	O
p50	O
.	O

Interestingly	O
,	O
the	O
processing	O
rate	O
of	O
p105	O
is	O
markedly	O
inhibited	O
in	O
cells	O
co-transfected	O
with	O
p50	O
or	O
other	O
NF-kappaB	O
subunits	O
,	O
including	O
RelA	O
and	O
c-Rel	O
,	O
that	O
physically	O
interact	O
with	O
p105	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
processing	O
of	O
p105	O
is	O
subject	O
to	O
negative	O
regulation	O
by	O
the	O
various	O
NF-kappaB	O
subunits	O
.	O

We	O
further	O
demonstrate	O
that	O
p105	O
undergoes	O
degradation	O
in	O
lipopolysaccharide-stimulated	O
human	O
monocytic	O
cells	O
.	O

However	O
,	O
the	O
inducible	O
degradation	O
of	O
p105	O
is	O
not	B-Negation
coupled	I-Negation
with	I-Negation
the	I-Negation
generation	I-Negation
of	I-Negation
p50	I-Negation
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
the	O
processing	O
and	O
inducible	O
degradation	O
of	O
p105	O
are	O
differentially	O
regulated	O
.	O

Identification	O
of	O
a	O
human	O
LIM-Hox	O
gene	O
,	O
hLH-2	O
,	O
aberrantly	O
expressed	O
in	O
chronic	O
myelogenous	O
leukaemia	O
and	O
located	O
on	O
9q33-34.1	O
.	O

We	O
describe	O
the	O
isolation	O
of	O
human	O
LH-2	O
,	O
a	O
putative	O
transcription	O
factor	O
containing	O
two	O
cysteine-rich	O
regions	O
(	O
LIM	O
domains	O
)	O
and	O
a	O
homeobox	O
(	O
Hox	O
)	O
DNA-binding	O
domain	O
.	O

High	O
levels	O
of	O
hLH-2	O
expression	O
were	O
observed	O
in	O
all	O
cases	O
of	O
chronic	O
myelogenous	O
leukaemia	O
(	O
CML	O
)	O
tested	O
,	O
regardless	O
of	O
disease	O
status	O
.	O

hLH-2	O
was	O
mapped	O
to	O
chromosome	O
9Q33-34.1	O
,	O
in	O
the	O
same	O
region	O
as	O
the	O
reciprocal	O
translocation	O
that	O
creates	O
the	O
BCR-ABL	O
chimera	O
of	O
the	O
Philadelphia	O
chromosome	O
(	O
Ph	O
'	O
)	O
,	O
the	O
hallmark	O
of	O
CML	O
;	O
hLH-2	O
was	O
retained	O
on	O
the	O
derivative	O
9	O
chromosome	O
and	O
is	O
therefore	O
centromeric	O
of	O
c-ABL	O
.	O

The	O
proximity	O
of	O
hLH-2	O
to	O
the	O
breakpoint	O
on	O
chromosome	O
9	O
raises	O
the	O
possibility	O
of	O
cis-activation	O
by	O
the	O
t	O
(	O
9	O
;	O
22	O
)	O
(	O
q34	O
;	O
q11	O
)	O
translocation	O
.	O

In	O
addition	O
to	O
finding	O
hLH-2	O
expression	O
in	O
all	O
cases	O
of	O
CML	O
,	O
expression	O
was	O
observed	O
in	O
lymphoid	O
malignancies	O
and	O
myeloid	O
cell	O
lines	O
,	O
but	O
not	B-Negation
in	I-Negation
primary	I-Negation
cases	I-Negation
of	I-Negation
acute	I-Negation
myelogenous	I-Negation
leukaemia	I-Negation
.	O

The	O
role	O
of	O
hLH-2	O
in	O
the	O
development	O
or	O
progression	O
of	O
leukaemia	O
is	O
not	O
known	O
.	O

However	O
,	O
hLH-2	O
may	O
prove	O
useful	O
as	O
a	O
marker	O
of	O
CML	O
for	O
monitoring	O
residual	O
disease	O
.	O

BCL-6	O
expression	O
during	O
B-cell	O
activation	O
.	O

Translocations	O
involving	O
the	O
BCL-6	O
gene	O
are	O
common	O
in	O
the	O
diffuse	O
large	O
cell	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
.	O

Invariably	O
,	O
the	O
BCL-6	O
coding	O
region	O
is	O
intact	O
,	O
but	O
its	O
5	O
'	O
untranslated	O
region	O
is	O
replaced	O
with	O
sequences	O
from	O
the	O
translocation	O
partner	O
.	O

The	O
present	O
study	O
shows	O
that	O
BCL-6	O
expression	O
is	O
regulated	O
in	O
lymphocytes	O
during	O
mitogenic	O
stimulation	O
.	O

Resting	O
B	O
and	O
T	O
lymphocytes	O
contain	O
high	O
levels	O
of	O
BCL-6	O
mRNA	O
.	O

Stimulation	O
of	O
mouse	O
B	O
cells	O
with	O
anti-IgM	O
or	O
IgD	O
antibodies	O
,	O
bacterial	O
lipopolysaccharide	O
,	O
phorbol	O
12-myristate	O
13-acetate	O
plus	O
ionomycin	O
,	O
or	O
CD40	O
ligand	O
led	O
to	O
a	O
five-fold	O
to	O
35-fold	O
decrease	O
in	O
BCL-6	O
mRNA	O
levels	O
.	O

Similar	O
downregulation	O
of	O
BCL-6	O
mRNA	O
was	O
seen	O
in	O
human	O
B	O
cells	O
stimulated	O
with	O
Staphylococcus	O
aureus	O
plus	O
interleukin-2	O
or	O
anti-IgM	O
antibodies	O
and	O
in	O
human	O
T	O
lymphocytes	O
stimulated	O
with	O
phytohemagglutinin	O
.	O

BCL-6	O
mRNA	O
levels	O
began	O
to	O
decrease	O
8	O
to	O
16	O
hours	O
after	O
stimulation	O
,	O
before	O
cells	O
entered	O
S	O
phase	O
.	O

Although	O
polyclonal	O
activation	O
of	O
B	O
cells	O
in	O
vitro	O
invariably	O
decreased	O
BCL-6	O
MRNA	O
expression	O
,	O
activated	O
B	O
cells	O
from	O
human	O
germinal	O
centers	O
expressed	O
BCL-6	O
mRNA	O
at	O
levels	O
comparable	O
to	O
the	O
levels	O
in	O
resting	O
B	O
cells	O
.	O

Despite	O
these	O
similar	O
mRNA	O
levels	O
,	O
BCL-6	O
protein	O
expression	O
was	O
threefold	O
to	O
34-fold	O
higher	O
in	O
germinal	O
center	O
B	O
cells	O
than	O
in	O
resting	O
B	O
cells	O
,	O
suggesting	O
that	O
BCL-6	O
protein	O
levels	O
are	O
controlled	O
by	O
translational	O
or	O
posttranslational	O
mechanisms	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
germinal	O
center	O
reaction	O
provides	O
unique	O
activation	O
signals	O
to	O
B	O
cells	O
that	O
allow	O
for	O
continued	O
,	O
high-level	O
BCL-6	O
expression	O
.	O

An	O
element	O
upstream	O
from	O
the	O
human	O
delta-globin-encoding	O
gene	O
specifically	O
enhances	O
beta-globin	O
reporter	O
gene	O
expression	O
in	O
murine	O
erythroleukemia	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
a	O
DNA-binding	O
factor	O
specific	O
to	O
adult	O
hematopoietic	O
cells	O
(	O
polypryrimidine-binding	O
factor	O
,	O
PYBF	O
)	O
binds	O
to	O
a	O
pyrimidine-rich	O
region	O
1	O
kb	O
upstream	O
from	O
the	O
human	O
delta-globin-encoding	O
gene	O
(	O
HBD	O
)	O
.	O

The	O
developmental	O
stage-specificity	O
of	O
PYBF	O
and	O
the	O
location	O
of	O
its	O
binding	O
site	O
between	O
the	O
fetal	O
and	O
adult	O
beta-globin	O
(	O
HBB	O
)	O
-like	O
genes	O
suggest	O
that	O
PBYF	O
and	O
its	O
binding	O
site	O
may	O
function	O
in	O
fetal-to-adult	O
globin	O
gene	O
switching	O
.	O

Here	O
,	O
we	O
describe	O
the	O
effect	O
of	O
383-bp	O
(	O
delta383	O
)	O
and	O
99-bp	O
(	O
delta99	O
)	O
sequences	O
containing	O
the	O
PYBF-binding	O
site	O
on	O
transcription	O
from	O
various	O
globin	O
and	O
non-globin	O
promoters	O
,	O
using	O
a	O
transient	O
assay	O
with	O
the	O
cat	O
reporter	O
gene	O
in	O
murine	O
erythroleukemia	O
(	O
MEL	O
)	O
cells	O
,	O
a	O
cell	O
line	O
with	O
abundant	O
PYBF	O
activity	O
.	O

We	O
show	O
that	O
both	O
delta383	O
and	O
delta99	O
specifically	O
enhance	O
expression	O
of	O
cat	O
for	O
plasmids	O
containing	O
a	O
human	O
adult	O
globin	O
(	O
HBB	O
)	O
promoter	O
,	O
whereas	O
expression	B-Negation
of	I-Negation
similar	I-Negation
constructs	I-Negation
using	I-Negation
human	I-Negation
fetal	I-Negation
(	I-Negation
A	I-Negation
gamma-	I-Negation
)	I-Negation
globin	I-Negation
(	I-Negation
HBG1	I-Negation
)	I-Negation
or	I-Negation
simian	I-Negation
virus	I-Negation
40	I-Negation
(	I-Negation
SV40	I-Negation
)	I-Negation
promoters	I-Negation
is	I-Negation
not	I-Negation
enhanced	I-Negation
.	O

The	O
results	O
suggest	O
that	O
PYBF	O
and	O
the	O
pyrimidine-rich	O
region	O
upstream	O
from	O
HBD	O
can	O
specifically	O
enhance	O
HBB	O
transcription	O
in	O
adult	O
erythroid	O
cells	O
.	O

A	O
novel	O
interferon	O
regulatory	O
factor	O
family	O
transcription	O
factor	O
,	O
ICSAT/Pip/LSIRF	O
,	O
that	O
negatively	O
regulates	O
the	O
activity	O
of	O
interferon-regulated	O
genes	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
cDNA	O
clone	O
encoding	O
interferon	O
(	O
IFN	O
)	O
consensus	O
sequence-binding	O
protein	O
in	O
adult	O
T-cell	O
leukemia	O
cell	O
line	O
or	O
activated	O
T	O
cells	O
(	O
ICSAT	O
)	O
;	O
this	O
protein	O
is	O
the	O
human	O
homolog	O
of	O
the	O
recently	O
cloned	O
Pip/LSIRF	O
.	O

ICSAT	O
is	O
structurally	O
most	O
closely	O
related	O
to	O
the	O
previously	O
cloned	O
ICSBP	O
,	O
a	O
member	O
of	O
the	O
IFN	O
regulatory	O
factor	O
(	O
IRF	O
)	O
family	O
of	O
proteins	O
that	O
binds	O
to	O
interferon	O
consensus	O
sequences	O
(	O
ICSs	O
)	O
found	O
in	O
many	O
promoters	O
of	O
the	O
IFN-regulated	O
genes	O
.	O

Among	O
T-cell	O
lines	O
investigated	O
,	O
ICSAT	O
was	O
abundantly	O
expressed	O
in	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-infected	O
T	O
cells	O
.	O

When	O
the	O
HTLV-1	O
tax	O
gene	O
was	O
expressed	O
or	O
phorbol	O
myristake	O
acetate-A23187	O
stimulation	O
was	O
used	O
,	O
ICSAT	O
expression	O
was	O
induced	O
in	O
Jurkat	O
cells	O
which	O
otherwise	O
do	O
not	B-Negation
express	I-Negation
ICSAT	I-Negation
.	O

When	O
the	O
binding	O
of	O
ICSAT	O
to	O
four	O
different	O
ICSs	O
was	O
tested	O
,	O
the	O
relative	O
differences	O
in	O
binding	O
affinities	O
for	O
those	O
ICSs	O
were	O
determined	O
.	O

To	O
study	O
the	O
functional	O
role	O
of	O
ICSAT	O
,	O
we	O
performed	O
cotransfection	O
experiments	O
with	O
the	O
human	O
embryonal	O
carcinoma	O
cell	O
line	O
N-Tera2	O
.	O

ICSAT	O
was	O
demonstrated	O
to	O
possess	O
repressive	O
function	O
over	O
the	O
gene	O
activation	O
induced	O
by	O
IFN	O
stimulation	O
or	O
by	O
IRF-1	O
cotransfection	O
.	O

Such	O
repressive	O
function	O
is	O
similar	O
to	O
that	O
seen	O
in	O
IRF-2	O
or	O
ICSBP	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
ICSAT	O
has	O
a	O
different	O
repressive	O
effect	O
from	O
that	O
of	O
IRF-2	O
or	O
ICSBP	O
in	O
some	O
IFN-responsive	O
reporter	O
constructs	O
.	O

These	O
results	O
suggest	O
that	O
a	O
novel	O
mechanism	O
of	O
gene	O
regulation	O
by	O
``	O
differential	O
repression	O
``	O
is	O
used	O
by	O
multiple	O
members	O
of	O
repressor	O
proteins	O
with	O
different	O
repressive	O
effects	O
on	O
the	O
IFN-responsive	O
genes	O
.	O

DNA	O
triplex	O
formation	O
selectively	O
inhibits	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
gene	O
expression	O
in	O
human	O
T	O
cells	O
.	O

Granulocyte-macrophage	O
colony-stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
a	O
hemopoietic	O
growth	O
factor	O
that	O
is	O
expressed	O
in	O
activated	O
T	O
cells	O
,	O
fibroblasts	O
,	O
macrophages	O
,	O
and	O
endothelial	O
cells	O
.	O

Although	O
GM-CSF	B-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
be	I-Speculation
essential	I-Speculation
for	I-Speculation
normal	I-Speculation
hemopoiesis	I-Speculation
,	O
overexpression	O
of	O
GM-CSF	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
some	O
diseases	O
such	O
as	O
myeloid	O
leukemia	O
and	O
chronic	O
inflammation	O
.	O

An	O
NF-kappaB/Rel	O
binding	O
site	O
within	O
the	O
GM-CSF	O
promoter	O
,	O
termed	O
the	O
kappaB	O
element	O
appears	O
to	O
be	O
important	O
for	O
controlling	O
expression	O
in	O
reporter	O
gene	O
assays	O
in	O
response	O
to	O
a	O
number	O
of	O
stimuli	O
in	O
T	O
cells	O
.	O

We	O
investigated	O
oligonucleotide-directed	O
triple	O
helix	O
formation	O
across	O
this	O
regulatory	O
sequence	O
as	O
a	O
potential	O
tool	O
to	O
inhibit	O
GM-CSF	O
gene	O
transcription	O
.	O

A	O
15-base	O
oligonucleotide	O
,	O
GM3	O
,	O
was	O
targeted	O
to	O
a	O
purine-rich	O
region	O
in	O
the	O
GM-CSF	O
proximal	O
promoter	O
,	O
which	O
overlaps	O
the	O
kappaB	O
element	O
.	O

Gel	O
mobility	O
shift	O
assays	O
and	O
DNase	O
I	O
footprinting	O
demonstrated	O
that	O
GM3	O
formed	O
a	O
sequence-specific	O
collinear	O
triplex	O
with	O
its	O
double-stranded	O
DNA	O
target	O
.	O

Triplex	O
formation	O
by	O
GM3	O
blocked	O
recombinant	O
and	O
nuclear	O
NF-kappaB	O
proteins	O
binding	O
to	O
the	O
GM-CSF	O
element	O
.	O

GM3	O
also	O
caused	O
selective	O
inhibition	O
of	O
the	O
human	O
T-cell	O
lymphotrophic	O
virus-1	O
Tax	O
transactivator-induced	O
luciferase	O
activity	O
from	O
a	O
reporter	O
construct	O
driven	O
by	O
the	O
GM-CSF	O
promoter	O
in	O
Jurkat	O
T	O
cells	O
.	O

Finally	O
,	O
GM3	O
greatly	O
reduced	O
the	O
concentration	O
of	O
endogenous	O
GM-CSF	O
mRNA	O
induced	O
by	O
different	O
stimuli	O
in	O
Jurkat	O
T	O
cells	O
but	O
did	O
not	B-Negation
affect	I-Negation
interleukin	I-Negation
3	I-Negation
mRNA	I-Negation
levels	I-Negation
in	I-Negation
the	I-Negation
same	I-Negation
cells	I-Negation
.	O

We	O
conclude	O
that	O
the	O
kappaB	O
element	O
in	O
the	O
GM-CSF	O
promoter	O
plays	O
a	O
central	O
role	O
in	O
the	O
transcriptional	O
activation	O
of	O
the	O
endogenous	O
GM-CSF	O
gene	O
.	O

Colinear	O
triplex	O
formation	O
acts	O
as	O
a	O
selective	O
transcriptional	O
repressor	O
of	O
the	O
GM-CSF	O
gene	O
and	O
may	O
have	O
potential	O
therapeutic	O
application	O
in	O
cases	O
of	O
undesirable	O
overexpression	O
of	O
this	O
protein	O
.	O

Receptors	O
for	O
interleukin	O
(	O
IL	O
)	O
-10	O
and	O
IL-6-type	O
cytokines	O
use	O
similar	O
signaling	O
mechanisms	O
for	O
inducing	O
transcription	O
through	O
IL-6	O
response	O
elements	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
the	O
receptor	O
for	O
interleukin	O
10	O
(	O
IL-10R	O
)	O
contains	O
two	O
box	O
3	O
sequence	O
motifs	O
that	O
have	O
been	O
identified	O
in	O
the	O
signal-transducing	O
receptor	O
subunits	O
for	O
IL-6-type	O
cytokines	O
and	O
noted	O
to	O
be	O
required	O
for	O
activating	O
STAT3	O
and	O
inducing	O
transcription	O
through	O
IL-6-responsive	O
elements	O
.	O

To	O
determine	O
whether	O
the	O
IL-10R	O
has	O
signaling	O
functions	O
similar	O
to	O
IL-6R	O
in	O
cells	O
normally	O
expressing	O
these	O
receptors	O
,	O
leukocytes	O
of	O
the	O
B-	O
,	O
T-	O
,	O
and	O
NK-cell	O
lineages	O
were	O
treated	O
with	O
either	O
cytokine	O
.	O

Both	O
cytokines	O
activated	O
factors	O
that	O
bound	O
to	O
the	O
sis-inducible	O
element	O
and	O
included	O
STAT1	O
and	O
STAT3	O
.	O

The	O
cell	O
response	O
to	O
IL-10	O
characteristically	O
differed	O
from	O
that	O
to	O
IL-2/IL-15	O
,	O
IL-4	O
,	O
and	O
interferon	O
gamma	O
.	O

The	O
signaling	O
capabilities	O
of	O
the	O
IL-10R	O
for	O
activating	O
specific	O
STAT	O
proteins	O
and	O
inducing	O
gene	O
transcription	O
were	O
defined	O
by	O
reconstitution	O
of	O
receptor	O
functions	O
in	O
transfected	O
tissue	O
culture	O
cells	O
.	O

COS-1	O
cells	O
,	O
co-expressing	O
the	O
human	O
IL-10R	O
and	O
individual	O
STAT	O
proteins	O
,	O
confirmed	O
a	O
preference	O
of	O
the	O
IL-10R	O
for	O
STAT3	O
and	O
STAT1	O
.	O

Unlike	O
many	O
hematopoietin	O
receptors	O
,	O
the	O
IL-10R	O
did	O
not	B-Negation
detectably	I-Negation
activate	I-Negation
STAT5	I-Negation
.	O

The	O
IL-10R	O
,	O
together	O
with	O
reporter	O
gene	O
constructs	O
containing	O
different	O
IL-6-responsive	O
gene	O
elements	O
,	O
reconstituted	O
in	O
hepatoma	O
cells	O
an	O
induction	O
of	O
transcription	O
by	O
IL-10	O
that	O
was	O
comparable	O
to	O
that	O
by	O
IL-6	O
.	O

This	B-Negation
regulation	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
appreciably	I-Negation
modified	I-Negation
by	I-Negation
enhanced	I-Negation
expression	I-Negation
of	I-Negation
STAT	I-Negation
proteins	I-Negation
.	O

The	O
similar	O
actions	O
of	O
IL-10R	O
and	O
IL-6R	O
on	O
the	O
induction	O
of	O
endogenous	O
IL-6-responsive	O
genes	O
were	O
demonstrated	O
in	O
hepatoma	O
cells	O
stably	O
expressing	O
the	O
IL-10R	O
.	O

These	O
receptor	O
functions	O
required	O
the	O
presence	O
of	O
the	O
box	O
3	O
motifs	O
,	O
as	O
shown	O
by	O
the	O
analysis	O
of	O
the	O
mouse	O
IL-10R	O
constructs	O
containing	O
progressively	O
truncated	O
cytoplasmic	O
domains	O
.	O

The	O
data	O
demonstrate	O
that	O
the	O
IL-10R	O
,	O
unlike	O
other	O
members	O
of	O
the	O
interferon	O
receptor	O
family	O
,	O
is	O
highly	O
effective	O
in	O
recruiting	O
the	O
signaling	O
pathways	O
of	O
IL-6-type	O
cytokine	O
receptors	O
.	O

Globin	O
gene	O
switching	O
.	O

In	O
vivo	O
protein-DNA	O
interactions	O
of	O
the	O
human	O
beta-globin	O
locus	O
in	O
erythroid	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
program	O
.	O

To	O
characterize	O
the	O
protein-DNA	O
interactions	O
important	O
for	O
the	O
developmental	O
control	O
of	O
the	O
human	O
beta-globin	O
locus	O
,	O
we	O
analyzed	O
by	O
in	O
vivo	O
dimethyl	O
sulfate	O
footprinting	O
erythroid	O
cells	O
expressing	O
either	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
developmental	O
program	O
.	O

In	O
the	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
of	O
the	O
beta-globin	O
locus	O
,	O
in	O
vivo	O
footprints	O
on	O
NF-E2	O
(	O
or	O
AP-1	O
)	O
and	O
GATA-1	O
motifs	O
remained	O
the	O
same	O
regardless	O
of	O
whether	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
genes	O
are	O
expressed	O
.	O

In	O
contrast	O
,	O
in	O
vivo	O
footprints	O
on	O
GT	O
(	O
CACCC	O
)	O
motifs	O
differed	O
between	O
the	O
cells	O
expressing	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
program	O
.	O

In	O
promoter	O
regions	O
,	O
the	O
actively	O
transcribed	O
genes	O
demonstrated	O
extensive	O
and	O
consistent	O
footprints	O
over	O
the	O
canonical	O
elements	O
,	O
such	O
as	O
CACCC	O
and	O
CCAAT	O
motifs	O
.	O

The	O
adult	O
globin	O
expressing	O
cells	O
displayed	O
more	O
extensive	O
footprints	O
than	O
the	O
fetal	O
globin	O
expressing	O
cells	O
in	O
the	O
3	O
'	O
regulatory	O
sequences	O
of	O
both	O
the	O
Agamma-	O
and	O
the	O
beta-globin	O
genes	O
,	O
suggesting	O
a	O
role	O
of	O
these	O
3	O
'	O
elements	O
in	O
beta-globin	O
gene	O
expression	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
bulk	O
of	O
protein-DNA	O
interactions	O
that	O
underlies	O
the	O
developmental	O
control	O
of	O
globin	O
genes	O
takes	O
place	O
in	O
the	O
gamma-	O
and	O
beta-globin	O
gene	O
promoters	O
,	O
and	O
that	O
GT	O
motifs	O
of	O
the	O
beta-globin	O
locus	O
LCR	O
may	O
play	O
a	O
role	O
in	O
the	O
developmental	O
regulation	O
of	O
human	O
beta-globin	O
gene	O
expression	O
,	O
perhaps	O
by	O
increasing	O
the	O
probability	O
of	O
interaction	O
of	O
the	O
LCR	O
holocomplex	O
with	O
the	O
fetal	O
or	O
the	O
adult	O
globin	O
gene	O
.	O

Octamer	O
binding	O
factors	O
and	O
their	O
coactivator	O
can	O
activate	O
the	O
murine	O
PU.1	O
(	O
spi-1	O
)	O
promoter	O
.	O

PU.1	O
(	O
spi-1	O
)	O
,	O
a	O
member	O
of	O
the	O
Ets	O
transcription	O
factor	O
family	O
,	O
is	O
predominantly	O
expressed	O
in	O
myeloid	O
and	O
B	O
cells	O
,	O
activates	O
many	O
B	O
cell	O
and	O
myeloid	O
genes	O
,	O
and	O
is	O
critical	O
for	O
development	O
of	O
both	O
of	O
these	O
lineages	O
.	O

Our	O
previous	O
studies	O
(	O
Chen	O
,	O
H.M.	O
,	O
Ray-Gallet	O
,	O
D.	O
,	O
Zhang	O
,	O
P.	O
,	O
Hetherington	O
,	O
C.J.	O
,	O
Gonzalez	O
,	O
D.A.	O
,	O
Zhang	O
,	O
D.-E.	O
,	O
Moreau-Gachelin	O
,	O
F.	O
,	O
and	O
Tenen	O
,	O
D.G.	O
(	O
1995	O
)	O
Oncogene	O
11	O
,	O
1549-1560	O
)	O
demonstrate	O
that	O
the	O
PU.1	O
promoter	O
directs	O
cell	O
type-specific	O
reporter	O
gene	O
expression	O
in	O
myeloid	O
cell	O
lines	O
,	O
and	O
that	O
PU.1	O
activates	O
its	O
own	O
promoter	O
in	O
an	O
autoregulatory	O
loop	O
.	O

Here	O
we	O
show	O
that	O
the	O
murine	O
PU.1	O
promoter	O
is	O
also	O
specifically	O
and	O
highly	O
functional	O
in	O
B	O
cell	O
lines	O
as	O
well	O
.	O

Oct-1	O
and	O
Oct-2	O
can	O
bind	O
specifically	O
to	O
a	O
site	O
at	O
base	O
pair	O
-55	O
in	O
vitro	O
,	O
and	O
this	O
site	O
is	O
specifically	O
protected	O
in	O
B	O
cells	O
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
two	O
other	O
sites	O
contribute	O
to	O
promoter	O
activity	O
in	O
B	O
cells	O
;	O
an	O
Sp1	O
binding	O
site	O
adjacent	O
to	O
the	O
octamer	O
site	O
,	O
and	O
the	O
PU.1	O
autoregulatory	O
site	O
.	O

Finally	O
,	O
we	O
show	O
that	O
the	O
B	O
cell	O
coactivator	O
OBF-1/Bob1/OCA-B	O
is	O
only	O
expressed	O
in	O
B	O
cells	O
and	O
not	B-Negation
in	I-Negation
myeloid	I-Negation
cells	I-Negation
,	O
and	O
that	O
OBF-1/Bob1/OCA-B	O
can	O
transactivate	O
the	O
PU.1	O
promoter	O
in	O
HeLa	O
and	O
myeloid	O
cells	O
.	O

This	O
B	O
cell	O
restricted	O
coactivator	O
may	O
be	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
expression	O
of	O
PU.1	O
mediated	O
by	O
the	O
octamer	O
site	O
.	O

Tissue-specific	O
activity	O
of	O
the	O
gammac	O
chain	O
gene	O
promoter	O
depends	O
upon	O
an	O
Ets	O
binding	O
site	O
and	O
is	O
regulated	O
by	O
GA-binding	O
protein	O
.	O

The	O
gammac	O
chain	O
is	O
a	O
subunit	O
of	O
multiple	O
cytokine	O
receptors	O
(	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
IL-4	O
,	O
IL-7	O
,	O
IL-9	O
,	O
and	O
IL-15	O
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
restricted	O
to	O
hematopoietic	O
lineages	O
.	O

A	O
defect	O
in	O
gammac	O
leads	O
to	O
the	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
characterized	O
by	O
a	O
block	O
in	O
T	O
cell	O
differentiation	O
.	O

In	O
order	O
to	O
better	O
characterize	O
the	O
human	O
gammac	O
promoter	O
and	O
define	O
the	O
minimal	O
tissue-specific	O
promoter	O
region	O
,	O
progressive	O
5'-deletion	O
constructs	O
of	O
a	O
segment	O
extending	O
1053	O
base	O
pairs	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
were	O
generated	O
and	O
tested	O
for	O
promoter	O
activity	O
in	O
various	O
hematopoietic	O
and	O
nonhematopoietic	O
cell	O
types	O
.	O

The	O
-1053/+34	O
construct	O
allowed	O
promoter	O
activity	O
only	O
in	O
cells	O
of	O
hematopoietic	O
origin	O
,	O
and	O
tissue	O
specificity	O
was	O
conserved	O
in	O
all	O
other	O
constructs	O
tested	O
.	O

The	O
region	O
downstream	O
of	O
-90	O
appeared	O
critical	O
for	O
basal	O
promoter	O
activity	O
.	O

It	O
contains	O
two	O
potential	O
Ets	O
binding	O
sites	O
conserved	O
in	O
the	O
murine	O
gammac	O
promoter	O
gene	O
,	O
one	O
of	O
which	O
was	O
found	O
essential	O
for	O
functional	O
promoter	O
activity	O
as	O
determined	O
by	O
mutational	O
analysis	O
.	O

The	O
functional	O
Ets	O
binding	O
site	O
was	O
found	O
to	O
bind	O
Ets	O
family	O
proteins	O
,	O
principally	O
GA-binding	O
protein	O
and	O
Elf-1	O
and	O
could	O
be	O
transactivated	O
by	O
GABPalpha	O
and	O
-beta	O
synergistically	O
.	O

These	O
results	O
indicate	O
that	O
,	O
as	O
already	O
reported	O
for	O
the	O
IL2Rbeta	O
promoter	O
,	O
GA-binding	O
protein	O
is	O
an	O
essential	O
component	O
of	O
gammac	O
basal	O
promoter	O
activity	O
.	O

Although	O
GABP	O
expression	O
is	O
not	B-Negation
restricted	I-Negation
to	I-Negation
the	I-Negation
hematopoietic	I-Negation
lineage	I-Negation
,	O
its	O
interaction	O
with	O
other	O
specific	O
factors	O
may	B-Speculation
contribute	I-Speculation
to	I-Speculation
the	I-Speculation
tissue-specific	I-Speculation
expression	I-Speculation
of	I-Speculation
the	I-Speculation
gammac	I-Speculation
gene	I-Speculation
.	O

Multiple	O
transcription	O
factors	O
are	O
required	O
for	O
activation	O
of	O
human	O
interleukin	O
9	O
gene	O
in	O
T	O
cells	O
.	O

The	O
genetic	O
elements	O
and	O
regulatory	O
mechanisms	O
responsible	O
for	O
human	O
interleukin	O
9	O
(	O
IL-9	O
)	O
gene	O
expression	O
in	O
a	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I-transformed	O
human	O
T	O
cell	O
line	O
,	O
C5MJ2	O
,	O
were	O
investigated	O
.	O

We	O
demonstrated	O
that	O
IL-9	O
gene	O
expression	O
is	O
controlled	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
transcriptional	O
activation	O
.	O

Transient	O
expression	O
of	O
the	O
luciferase	O
reporter	O
gene	O
linked	O
to	O
serially	O
deleted	O
sequences	O
of	O
the	O
5'-flanking	O
region	O
of	O
the	O
IL-9	O
gene	O
has	O
revealed	O
several	O
positive	O
and	O
negative	O
regulatory	O
elements	O
involved	O
in	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O

An	O
AP-1	O
site	O
at	O
-146	O
to	O
-140	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
expression	O
of	O
the	O
IL-9	O
gene	O
.	O

A	O
proximal	O
region	O
between	O
-46	O
and	O
-80	O
was	O
identified	O
as	O
the	O
minimum	O
sequence	O
for	O
the	O
basal	O
and	O
inducible	O
expression	O
of	O
the	O
IL-9	O
gene	O
in	O
C5MJ2	O
cells	O
.	O

Within	O
this	O
region	O
,	O
an	O
NF-kappaB	O
site	O
at	O
-59	O
to	O
-50	O
and	O
its	O
adjacent	O
20-base	O
pair	O
upstream	O
sequence	O
were	O
demonstrated	O
to	O
play	O
a	O
critical	O
role	O
for	O
the	O
IL-9	O
promoter	O
activity	O
.	O

DNA-protein	O
binding	O
studies	O
indicated	O
that	O
NF-kappaB	O
,	O
c-Jun	O
,	O
and	O
potentially	O
novel	O
proteins	O
(	O
around	O
35	O
kDa	O
)	O
can	O
bind	O
to	O
this	O
important	O
sequence	O
.	O

Mutations	O
at	O
different	O
sites	O
within	O
this	O
proximal	O
promoter	O
region	O
abolished	O
the	O
promoter	O
activity	O
as	O
well	O
as	O
the	O
DNA	O
binding	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
the	O
cooperation	O
of	O
different	O
transcription	O
factors	O
is	O
essential	O
for	O
IL-9	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

Mapping	O
of	O
the	O
transcriptional	O
repression	O
domain	O
of	O
the	O
lymphoid-specific	O
transcription	O
factor	O
oct-2A	O
.	O

The	O
lymphoid-specific	O
transcription	O
factor	O
Oct-2a	O
is	O
implicated	O
in	O
B	O
cell-specific	O
transcriptional	O
activity	O
via	O
the	O
octamer	O
motif	O
.	O

Structure/function	O
analysis	O
of	O
various	O
Oct-2a	O
effector	O
regions	O
in	O
the	O
context	O
of	O
the	O
GAL4	O
DNA-binding	O
domain	O
revealed	O
that	O
Oct-2a	O
contains	O
two	O
functionally	O
different	O
activation	O
domains	O
at	O
the	O
N	O
and	O
the	O
C	O
termini	O
.	O

The	O
transcriptional	O
activity	O
of	O
both	O
domains	O
is	O
strongly	O
potentiated	O
by	O
interactions	O
with	O
distinct	O
B	O
cell-specific	O
coactivators	O
.	O

Recently	O
,	O
we	O
have	O
identified	O
a	O
repression	O
domain	O
located	O
within	O
the	O
N	O
terminus	O
of	O
Oct-2a	O
(	O
amino	O
acids	O
2-99	O
)	O
.	O

When	O
this	O
domain	O
was	O
transferred	O
to	O
a	O
potent	O
activator	O
,	O
transcription	O
was	O
strongly	O
inhibited	O
.	O

In	O
this	O
study	O
we	O
present	O
a	O
deletion	O
analysis	O
of	O
the	O
N-terminal	O
region	O
of	O
Oct-2a	O
to	O
determine	O
the	O
minimal	O
repression	O
domain	O
.	O

We	O
identified	O
a	O
stretch	O
of	O
23	O
amino	O
acids	O
,	O
rich	O
in	O
serine	O
and	O
threonine	O
residues	O
,	O
which	O
was	O
responsible	O
for	O
most	O
of	O
the	O
repression	O
activity	O
.	O

We	O
show	O
that	O
repression	O
is	O
strongly	O
dependent	O
on	O
the	O
type	O
of	O
enhancer	O
present	O
in	O
the	O
reporter	O
plasmid	O
as	O
well	O
as	O
on	O
the	O
cell	O
line	O
tested	O
.	O

The	O
possibility	O
that	O
Oct-2a	O
can	O
act	O
as	O
an	O
activator	O
and/or	O
a	O
repressor	O
may	O
have	O
important	O
consequences	O
for	O
the	O
function	O
of	O
Oct-2a	O
in	O
B	O
cell	O
differentiation	O
and	O
other	O
developmental	O
processes	O
.	O

The	O
role	O
of	O
BSAP	O
(	O
Pax-5	O
)	O
in	O
B-cell	O
development	O
.	O

The	O
hierarchy	O
of	O
transcriptional	O
control	O
in	O
B-cell	O
development	O
has	O
recently	O
been	O
analyzed	O
by	O
targeted	O
gene	O
inactivation	O
in	O
the	O
mouse	O
.	O

In	O
this	O
manner	O
,	O
the	O
paired	O
box	O
containing	O
gene	O
Pax-5	O
,	O
encoding	O
the	O
B	O
cell	O
specific	O
transcription	O
factor	O
BSAP	O
,	O
has	O
been	O
shown	O
to	O
play	O
a	O
key	O
role	O
in	O
early	O
B	O
lymphopoiesis	O
.	O

Other	O
experimental	O
strategies	O
have	O
implicated	O
BSAP	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
isotype	O
switching	O
and	O
transcription	O
of	O
the	O
immunoglobulin	O
heavy-chain	O
gene	O
at	O
late	O
stages	O
of	O
B-cell	O
differentiation	O
.	O

Induction	O
of	O
CIITA	O
and	O
modification	O
of	O
in	O
vivo	O
HLA-DR	O
promoter	O
occupancy	O
in	O
normal	O
thymic	O
epithelial	O
cells	O
treated	O
with	O
IFN-gamma	O
:	O
similarities	O
and	O
distinctions	O
with	O
respect	O
to	O
HLA-DR-constitutive	O
B	O
cells	O
.	O

In	O
this	O
study	O
,	O
the	O
IFN-gamma	O
induction	O
of	O
MHC	O
class	O
II	O
gene	O
expression	O
in	O
primary	O
cultures	O
of	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
was	O
analyzed	O
.	O

This	O
cellular	O
system	O
offers	O
the	O
advantage	O
that	O
MHC	O
class	O
II	O
induction	O
is	O
studied	O
in	O
a	O
``	O
physiologic	O
``	O
cell	O
lineage	O
that	O
,	O
as	O
a	O
result	O
of	O
this	O
expression	O
within	O
the	O
thymus	O
,	O
is	O
thought	O
to	O
participate	O
to	O
the	O
selection	O
and	O
maturation	O
of	O
the	O
T	O
cells	O
.	O

It	O
was	O
found	O
that	O
the	O
MHC	O
class	O
II	O
gene	O
expression	O
was	O
associated	O
with	O
the	O
de	O
novo	O
transcription	O
of	O
the	O
gene	O
encoding	O
the	O
CIITA	O
trans-activator	O
,	O
a	O
crucial	O
MHC	O
class	O
II	O
gene	O
regulatory	O
factor	O
.	O

Furthermore	O
,	O
the	O
anatomy	O
of	O
interaction	O
between	O
the	O
MHC	O
class	O
II	O
DRA	O
promoter	O
and	O
corresponding	O
binding	O
factors	O
was	O
analyzed	O
by	O
in	O
vivo	O
DNAse	O
I	O
footprint	O
.	O

It	O
was	O
found	O
that	O
treatment	O
with	O
IFN-gamma	O
induces	O
changes	O
in	O
the	O
occupancy	O
of	O
the	O
DRA	O
gene	O
regulatory	O
sequences	O
by	O
nuclear	O
factors	O
.	O

The	O
resulting	O
occupancy	O
displays	O
strong	O
similarities	O
with	O
the	O
one	O
observed	O
in	O
the	O
MHC	O
class	O
II-constitutive	O
B	O
cells	O
,	O
represented	O
by	O
both	O
the	O
Burkitt	O
lymphoma	O
line	O
Raji	O
and	O
normal	O
tonsil-	O
derived	O
B	O
cells	O
.	O

However	O
,	O
some	O
peculiar	O
differences	O
were	O
observed	O
between	O
the	O
TEC	O
,	O
either	O
IFN-gamma-induced	O
or	O
not	B-Negation
,	O
and	O
the	O
constitutive	O
B	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
both	O
common	O
mechanisms	O
,	O
such	O
as	O
the	O
one	O
mediated	O
by	O
the	O
CIITA	O
trans-activator	O
,	O
and	O
distinct	O
tissue-specific	O
constraints	O
contribute	O
to	O
the	O
transcriptional	O
control	O
of	O
constitutive	O
and	O
IFN-gamma-induced	O
MHC	O
class	O
II	O
gene	O
expression	O
.	O

An	O
alternatively	O
spliced	O
isoform	O
of	O
the	O
Spi-B	O
transcription	O
factor	O
.	O

Spi-B	O
is	O
an	O
Ets	O
transcription	O
factor	O
related	O
to	O
the	O
oncoprotein	O
Spi-1/PU.1	O
and	O
highly	O
expressed	O
in	O
B	O
lymphoid	O
cells	O
.	O

The	O
Ets	O
proteins	O
share	O
a	O
conserved	O
Ets	O
domain	O
that	O
mediates	O
specific	O
DNA	O
binding	O
.	O

Spi-B	O
binds	O
DNA	O
sequences	O
containing	O
a	O
core	O
5'-GGAA-3	O
'	O
and	O
activates	O
transcription	O
through	O
this	O
motif	O
.	O

Up	O
to	O
date	O
,	O
the	O
biological	O
function	O
of	O
Spi-B	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
describe	O
the	O
characterization	O
of	O
an	O
alternatively	O
spliced	O
variant	O
of	O
Spi-B	O
,	O
named	O
deltaSpi-B	O
,	O
which	O
has	O
lost	O
the	O
Ets	O
domain	O
.	O

In	O
B	O
lymphoid	O
cells	O
,	O
deltaspi-B	O
and	O
spi-B	O
mRNAs	O
were	O
present	O
simultaneously	O
in	O
a	O
ratio	O
of	O
around	O
10	O
%	O
.	O

DeltaSpi-B	O
product	O
was	O
not	B-Negation
able	I-Negation
to	I-Negation
bind	I-Negation
DNA	I-Negation
and	O
was	O
recovered	O
in	O
cytoplasmic	O
cellular	O
extracts	O
.	O

We	O
raise	O
the	O
hypothesis	O
that	O
delta	O
Spi-B	O
might	O
affect	O
Spi-B	O
function	O
by	O
recruiting	O
factors	O
involved	O
in	O
Spi-B	O
activity	O
.	O

Interleukin	O
10	O
induced	O
c-fos	O
expression	O
in	O
human	O
B	O
cells	O
by	O
activation	O
of	O
divergent	O
protein	O
kinases	O
.	O

IL-10	O
is	O
a	O
potent	O
mediator	O
of	O
human	O
B	O
cell	O
growth	O
and	O
plasma	O
cell	O
formation	O
.	O

However	O
,	O
signal	O
transduction	O
of	O
IL-10	O
in	O
B	O
cells	O
is	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
the	O
effect	O
of	O
IL-10	O
on	O
the	O
expression	O
of	O
the	O
protooncogene	O
c-fos	O
was	O
investigated	O
,	O
because	O
Fos	O
plays	O
a	O
potential	O
role	O
in	O
the	O
regulation	O
of	O
B	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

B	O
cells	O
were	O
purified	O
from	O
buffy	O
coat	O
preparations	O
of	O
healthy	O
blood	O
donors	O
by	O
positive	O
selection	O
using	O
an	O
anti	O
CD20	O
monoclonal	O
antibody	O
and	O
a	O
MiniMACS	O
separation	O
unit	O
.	O

B	O
cells	O
were	O
prestimulated	O
with	O
SAC	O
for	O
48	O
hrs	O
.	O

Then	O
,	O
cells	O
were	O
incubated	O
with	O
medium	O
or	O
IL-10	O
(	O
100	O
ng/ml	O
)	O
for	O
10	O
to	O
120	O
min	O
.	O

RNA	O
was	O
extracted	O
by	O
phenol/chloroform	O
and	O
c-fos	O
expression	O
was	O
analyzed	O
by	O
PCR	O
assisted	O
mRNA	O
assay	O
.	O

A	O
significant	O
2-4	O
fold	O
increase	O
of	O
c-fos	O
expression	O
was	O
observed	O
within	O
30	O
min	O
of	O
stimulation	O
with	O
IL-10	O
(	O
p	O
<	O
0.01	O
)	O
.	O

After	O
2	O
hrs	O
c-fos	O
expression	O
declined	O
to	O
basal	O
levels	O
.	O

The	O
effect	O
of	O
IL-10	O
was	O
dose-dependent	O
with	O
a	O
maximum	O
stimulation	O
using	O
100	O
ng/ml	O
of	O
IL-10	O
.	O

The	B-Negation
IL-10	I-Negation
effect	I-Negation
on	I-Negation
c-fos	I-Negation
expression	I-Negation
was	I-Negation
not	I-Negation
blocked	I-Negation
by	I-Negation
polymyxin	I-Negation
B	I-Negation
.	O

Using	O
the	O
tyrosine	O
kinase	O
inhibitor	O
genistein	O
(	O
10	O
microM	O
)	O
a	O
complete	O
inhibition	O
of	O
IL-10	O
induced	O
c-fos	O
expression	O
was	O
observed	O
.	O

In	O
addition	O
,	O
H-7	O
(	O
10	O
microM	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
serine/threonine	O
kinases	O
,	O
significantly	O
blocked	O
IL-10	O
mediated	O
c-fos	O
expression	O
(	O
p	O
<	O
0.05	O
)	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
show	O
that	O
IL-10	O
induces	O
c-fos	O
expression	O
in	O
human	O
B-cells	O
by	O
activation	O
of	O
tyrosine	O
and	O
serine/threonine	O
kinases	O
.	O

Since	O
this	O
is	O
the	O
first	O
report	O
on	O
IL-10	O
induced	O
signal	O
transduction	O
,	O
these	O
data	O
may	O
help	O
to	O
identify	O
the	O
intracellular	O
mechanisms	O
by	O
which	O
IL-10	O
stimulates	O
human	O
B-cells	O
.	O

IL-10	O
inhibits	O
nuclear	O
factor-kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
CD3-stimulated	O
human	O
peripheral	O
T	O
lymphocytes	O
.	O

IL-10	O
markedly	O
reduces	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B/Rel	O
nuclear	O
activity	O
induced	O
in	O
PBMC	O
by	O
stimulation	O
with	O
the	O
anti-CD3	O
mAb	O
OKT3	O
.	O

The	O
inhibition	O
is	O
exerted	O
specifically	O
on	O
the	O
NF-kappa	O
B/Rel	O
activation	O
induced	O
by	O
mAb	O
OKT3	O
,	O
and	O
not	B-Negation
that	I-Negation
produced	I-Negation
by	I-Negation
PMA	I-Negation
.	O

As	O
judged	O
by	O
supershifting	O
the	O
DNA-protein	O
complexes	O
with	O
Abs	O
recognizing	O
specific	O
components	O
of	O
the	O
NF-kappa	O
B/Rel	O
protein	O
family	O
,	O
the	O
p50/p65	O
(	O
Rel	O
A	O
)	O
heterodimeric	O
form	O
of	O
NF-kappa	O
B	O
is	O
primarily	O
affected	O
.	O

The	O
maximal	O
effect	O
is	O
observed	O
at	O
the	O
IL-10	O
concentration	O
of	O
20	O
U/ml	O
.	O

IL-10	O
inhibitory	O
activity	O
is	O
exerted	O
on	O
T	O
lymphocytes	O
and	O
is	O
mediated	O
by	O
monocytes	O
.	O

Indeed	O
,	O
monocytes	O
pretreated	O
with	O
IL-10	O
are	O
able	O
so	O
inhibit	O
NF-kappa	O
B	O
nuclear	O
activity	O
in	O
purified	O
T	O
lymphocytes	O
stimulated	O
with	O
OKT3	O
.	O

Soluble	B-Negation
factors	I-Negation
do	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
be	I-Speculation
involved	I-Speculation
in	I-Speculation
the	I-Speculation
mechanism	I-Speculation
of	I-Speculation
inhibition	I-Speculation
.	O

On	O
the	O
other	O
hand	O
,	O
the	B-Negation
up-regulation	I-Negation
of	I-Negation
CD80	I-Negation
Ag	I-Negation
,	I-Negation
found	I-Negation
on	I-Negation
monocytes	I-Negation
obtained	I-Negation
from	I-Negation
PBMC	I-Negation
incubated	I-Negation
with	I-Negation
OKT3	I-Negation
,	I-Negation
is	I-Negation
not	I-Negation
detected	I-Negation
after	I-Negation
addition	I-Negation
of	I-Negation
IL-10	I-Negation
,	O
and	O
the	O
anti-CD28	O
mAb	O
CLB-CD28/1	O
restores	O
the	O
NF-kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
IL-10-inhibited	O
lymphocytes	O
.	O

Therefore	O
,	O
the	O
NF-kappa	O
B/Rel	O
inhibition	O
might	O
be	O
ascribed	O
to	O
a	O
lack	O
of	O
cooperation	O
between	O
accessory	O
cells	O
and	O
T	O
lymphocytes	O
,	O
resulting	O
from	O
down-regulation	O
of	O
a	O
costimulatory	O
molecule	O
,	O
such	O
as	O
CD80	O
,	O
produced	O
by	O
IL-10	O
on	O
activated	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
IL-10	O
can	O
inhibit	O
the	O
induction	O
of	O
NF-kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
CD3-stimulated	O
T	O
lymphocytes	O
.	O

Since	O
inappropriate	O
activation	O
of	O
kappa	O
B-driven	O
genes	O
has	O
a	O
physiopathologic	O
role	O
in	O
a	O
number	O
of	O
diseases	O
,	O
such	O
as	O
HIV	O
infection	O
,	O
our	O
findings	O
support	O
the	O
possibility	O
of	O
using	O
this	O
cytokine	O
to	O
suppress	O
an	O
undesirable	O
activation	O
of	O
these	O
transcription	O
factors	O
.	O

Activation	O
protein	O
1-dependent	O
transcriptional	O
activation	O
of	O
interleukin	O
2	O
gene	O
by	O
Ca2+/calmodulin	O
kinase	O
type	O
IV/Gr	O
.	O

The	O
Ca2+/calmodulin-dependent	O
protein	O
kinase	O
(	O
CaMK	O
)	O
type	O
IV/Gr	O
is	O
selectively	O
expressed	O
in	O
T	O
lymphocytes	O
and	O
is	O
activated	O
after	O
signaling	O
via	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
indicating	O
that	O
it	O
mediates	O
some	O
of	O
the	O
Ca	O
(	O
2+	O
)	O
-dependent	O
transcriptional	O
events	O
that	O
follow	O
TCR	O
engagement	O
.	O

Here	O
we	O
show	O
that	O
CaMKIV/Gr	O
induces	O
the	O
transcription	O
factor	O
activation	O
protein	O
1	O
(	O
AP-1	O
)	O
alone	O
or	O
in	O
synergy	O
with	O
T	O
cell	O
mitogens	O
and	O
with	O
the	O
p21ras	O
oncoprotein	O
.	O

CaMKIV/	O
Gr	O
signaling	O
is	O
associated	O
with	O
transcriptional	O
activation	O
of	O
c-fos	O
but	O
is	O
independent	O
of	O
p21ras	O
or	O
calcineurin	O
.	O

AP-1	O
is	O
an	O
integral	O
component	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
transcriptional	O
complex	O
,	O
which	O
is	O
required	O
for	O
interleukin	O
2	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

We	O
demonstrate	O
that	O
CaMKIV/Gr	O
reconstitutes	O
the	O
capacity	O
of	O
the	O
cytosolic	O
component	O
of	O
NFAT	O
to	O
direct	O
transcription	O
from	O
NFAT	O
sites	O
in	O
non-T	O
cells	O
.	O

These	O
results	O
reveal	O
a	O
central	O
role	O
for	O
CaMKIV/Gr	O
as	O
a	O
Ca	O
(	O
2+	O
)	O
-regulated	O
activator	O
of	O
gene	O
transcription	O
in	O
T	O
lymphocytes	O
.	O

Cytokine-modulating	O
activity	O
of	O
tepoxalin	O
,	O
a	O
new	O
potential	O
antirheumatic	O
.	O

Tepoxalin	O
is	O
a	O
new	O
dual	O
cyclooxygenase/5-lipoxygenase	O
anti-inflammatory	O
compound	O
currently	O
under	O
clinical	O
investigation	O
.	O

It	O
has	O
been	O
shown	O
to	O
possess	O
anti-inflammatory	O
activity	O
in	O
a	O
variety	O
of	O
animal	O
models	O
and	O
more	O
recently	O
to	O
inhibit	O
IL-2	O
induced	O
signal	O
transduction	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
cytokine	O
modulating	O
activity	O
of	O
tepoxalin	O
and	O
the	O
role	O
of	O
iron	O
in	O
these	O
effects	O
.	O

In	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
stimulated	O
with	O
OKT3/PMA	O
,	O
tepoxalin	O
inhibited	O
lymphocyte	O
proliferation	O
with	O
an	O
IC50	O
of	O
6	O
microM	O
.	O

Additionally	O
,	O
it	O
inhibited	O
the	O
production	O
of	O
LTB4	O
(	O
IC50	O
=	O
0.5	O
microM	O
)	O
and	O
the	O
cytokines	O
IL-2	O
,	O
IL-6	O
and	O
TNF	O
alpha	O
(	O
IC50	O
=	O
10-12	O
microM	O
)	O
.	O

Cytotoxicity	B-Negation
was	I-Negation
not	I-Negation
demonstrated	I-Negation
at	I-Negation
these	I-Negation
concentrations	I-Negation
.	O

Add-back	O
experiments	O
with	O
either	O
cytokines	O
(	O
IL-2	O
or	O
IL-6	O
)	O
,	O
LTB4	O
or	O
conditioned	O
media	O
failed	B-Negation
to	I-Negation
restore	I-Negation
the	I-Negation
proliferative	I-Negation
response	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
tepoxalin	I-Negation
.	O

However	O
,	O
the	O
concurrent	O
addition	O
of	O
iron	O
(	O
in	O
the	O
form	O
of	O
ferrous	O
or	O
ferric	O
chloride	O
and	O
other	O
iron	O
salts	O
)	O
reversed	O
the	O
inhibition	O
of	O
proliferation	O
caused	O
by	O
tepoxalin	O
.	O

Tepoxalin	O
also	O
inhibits	O
the	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
transcription	O
factor	O
which	O
acts	O
on	O
several	O
cytokine	O
genes	O
.	O

Tepoxalin	O
's	O
effect	O
on	O
NF	O
kappa	O
B	O
is	O
also	O
reversed	O
by	O
the	O
addition	O
of	O
iron	O
salts	O
.	O

These	O
data	O
suggest	O
that	O
the	O
action	O
of	O
tepoxalin	O
to	O
inhibit	O
proliferation	O
in	O
PBMC	O
may	O
be	O
at	O
least	O
in	O
part	O
due	O
to	O
its	O
ability	O
to	O
reduce	O
the	O
amount	O
of	O
available	O
iron	O
resulting	O
in	O
decreased	O
activation	O
of	O
NF	O
kappa	O
B	O
and	O
subsequent	O
inhibition	O
of	O
cytokine	O
production	O
.	O

Gene	O
transcription	O
through	O
activation	O
of	O
G-protein-coupled	O
chemoattractant	O
receptors	O
.	O

Receptors	O
for	O
leukocyte	O
chemoattractants	O
,	O
including	O
chemokines	O
,	O
are	O
traditionally	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
activation	O
of	O
special	O
leukocyte	O
functions	O
such	O
as	O
chemotaxis	O
,	O
degranulation	O
,	O
and	O
the	O
release	O
of	O
superoxide	O
anions	O
.	O

Recently	O
,	O
these	O
G-protein-coupled	O
serpentine	O
receptors	O
have	O
been	O
found	O
to	O
transduce	O
signals	O
leading	O
to	O
gene	O
transcription	O
and	O
translation	O
in	O
leukocytes	O
.	O

Transcription	O
factors	O
,	O
such	O
as	O
NF	O
kappa	O
B	O
and	O
AP-1	O
,	O
are	O
activated	O
upon	O
stimulation	O
of	O
the	O
cells	O
with	O
several	O
chemoattractants	O
at	O
physiologically	O
relevant	O
concentrations	O
.	O

Activation	O
of	O
transcription	O
factors	O
through	O
these	O
receptors	O
involves	O
G-protein	O
coupling	O
and	O
the	O
activation	O
of	O
protein	O
kinases	O
.	O

The	O
underlying	O
signaling	O
pathways	O
appear	O
to	O
be	O
different	O
from	O
those	O
utilized	O
by	O
TNF-alpha	O
,	O
a	O
better	O
characterized	O
cytokine	O
that	O
induces	O
the	O
transcription	O
of	O
immediate-early	O
genes	O
.	O

Chemoattractants	O
stimulate	O
the	O
expression	O
of	O
several	O
inflammatory	O
cytokines	O
and	O
chemokines	O
,	O
which	O
in	O
turn	O
may	O
activate	O
their	O
respective	O
receptors	O
and	O
initiate	O
an	O
autocrine	O
regulatory	O
mechanism	O
for	O
persistent	O
cytokine	O
and	O
chemokine	O
gene	O
expression	O
.	O

Regulation	O
of	O
gene	O
expression	O
at	O
early	O
stages	O
of	O
B-cell	O
and	O
T-cell	O
differentiation	O
.	O

The	O
expression	O
of	O
distinct	O
sets	O
of	O
genes	O
at	O
different	O
stages	O
of	O
B-lymphocyte	O
and	O
T-lymphocyte	O
differentiation	O
is	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
.	O

A	O
number	O
of	O
recent	O
studies	O
have	O
described	O
interactions	O
between	O
transcription	O
factors	O
in	O
lymphocytes	O
that	O
provide	O
new	O
insights	O
into	O
mechanisms	O
regulating	O
gene	O
expression	O
.	O

These	O
mechanisms	O
include	O
the	O
assembly	O
of	O
higher	O
order	O
nucleoprotein	O
complexes	O
and	O
other	O
protein-protein	O
interactions	O
that	O
enhance	O
the	O
functional	O
specificity	O
of	O
transcriptional	O
regulators	O
in	O
lymphocytes	O
.	O

Involvement	O
of	O
tyrosine	O
phosphorylation	O
in	O
endothelial	O
adhesion	O
molecule	O
induction	O
.	O

Induction	O
of	O
endothelial	O
adhesion	O
molecules	O
by	O
the	O
cytokine	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF	O
)	O
can	O
occur	O
independently	O
of	O
protein	O
kinase	O
C	O
and	O
activation	O
of	O
a	O
protein	O
tyrosine	O
kinase	O
(	O
PTK	O
)	O
has	O
recently	O
been	O
implicated	O
in	O
the	O
upregulation	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM-1	O
)	O
by	O
interleukin-4	O
(	O
IL-4	O
)	O
on	O
endothelial	O
cells	O
.	O

We	O
demonstrate	O
that	O
the	O
PTK	O
inhibitors	O
herbimycin	O
A	O
or	O
genistein	O
suppress	O
induction	O
of	O
endothelial	O
VCAM-1	O
and	O
E-selectin	O
,	O
as	O
well	O
as	O
subsequent	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
stimulated	O
by	O
TNF	O
.	O

Inhibition	O
studies	O
indicate	O
that	O
specific	O
tyrosine	O
phosphorylation	O
following	O
PTK	O
activation	O
is	O
involved	O
in	O
the	O
mobilization	O
of	O
the	O
transcription	O
factor	O
,	O
nuclear	O
factor	O
kappa	O
B	O
,	O
and	O
VCAM-1	O
mRNA	O
expression	O
.	O

This	O
may	O
have	O
implications	O
for	O
pathophysiological	O
conditions	O
that	O
involve	O
the	O
upregulation	O
of	O
these	O
molecules	O
(	O
e.g.	O
inflammation	O
and	O
atherosclerosis	O
)	O
.	O

Transcription	O
specific	O
differences	O
visualized	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
pattern	O
on	O
interphase	O
nuclei	O
of	O
different	O
cell	O
types	O
.	O

Application	O
of	O
a	O
``	O
formamide	O
free	O
``	O
and	O
thus	O
``	O
material	O
preserving	O
``	O
in	O
situ	O
hybridization	O
technique	O
using	O
the	O
cDNA	O
of	O
the	O
myf3	O
gene	O
revealed	O
the	O
following	O
results	O
:	O
Human	O
rhabdomyosarcoma	O
cells	O
,	O
characterized	O
by	O
a	O
high	O
expression	O
of	O
myf3	O
show	O
intensive	O
hybridization	O
signals	O
in	O
their	O
interphase	O
.	O

RNase	O
treatment	O
prior	O
to	O
hybridization	O
considerably	O
reduces	O
the	O
size	O
of	O
this	O
signals	O
.	O

In	O
comparison	O
,	O
isolated	O
nuclei	O
of	O
human	O
lymphocytes	O
in	O
which	O
no	B-Negation
need	I-Negation
for	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
this	I-Negation
gene	I-Negation
exists	I-Negation
,	O
show	O
barely	O
hybridization	O
signals	O
.	O

Correspondingly	O
,	O
RNase	O
treatment	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
hybridization	I-Negation
pattern	I-Negation
at	I-Negation
all	I-Negation
.	O

In	O
conclusion	O
an	O
increased	O
transcription	O
efficiency	O
of	O
a	O
cell	O
type	O
specific	O
gene	O
is	O
accompanied	O
by	O
a	O
higher	O
hybridization	O
accessibility	O
in	O
the	O
corresponding	O
cell	O
nuclei	O
.	O

Alpha	O
4	O
beta	O
1	O
(	O
CD49d/CD29	O
)	O
integrin	O
costimulation	O
of	O
human	O
T	O
cells	O
enhances	O
transcription	O
factor	O
and	O
cytokine	O
induction	O
in	O
the	O
absence	B-Negation
of	I-Negation
altered	I-Negation
sensitivity	I-Negation
to	I-Negation
anti-CD3	I-Negation
stimulation	I-Negation
.	O

The	O
integrin	O
alpha	O
4	O
beta	O
1	O
can	O
provide	O
a	O
costimulus	O
to	O
induce	O
IL-2	O
secretion	O
and	O
IL-2R	O
expression	O
leading	O
to	O
enhanced	O
proliferation	O
of	O
purified	O
,	O
peripheral	O
blood	O
T	O
cells	O
.	O

Similar	O
to	O
expression	O
of	O
IL-2	O
,	O
we	O
demonstrated	O
that	O
recombinant	O
vascular-cell	O
adhesion	O
molecule-1	O
,	O
when	O
co-immobilized	O
with	O
anti-CD3	O
mAb	O
,	O
significantly	O
enhanced	O
the	O
induction	O
of	O
transcription	O
factors	O
NF-AT	O
,	O
AP-1	O
,	O
and	O
NF-kappa	O
B	O
as	O
determined	O
by	O
electromobility	O
shift	O
assays	O
.	O

alpha	O
4	O
beta	O
1	O
ligation	O
alone	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
transcription	I-Negation
factor	I-Negation
binding	I-Negation
.	O

The	O
requirements	O
for	O
induction	O
of	O
transcription	O
factors	O
reflected	O
the	O
requirements	O
for	O
the	O
secretion	O
of	O
multiple	O
cytokines	O
,	O
including	O
IL-2	O
,	O
TNF-alpha	O
,	O
IFN-gamma	O
,	O
and	O
granulocyte	O
macrophage-CSF	O
.	O

In	O
contrast	O
to	O
freshly	O
isolated	O
T	O
cells	O
,	O
in	O
vitro-cultured	O
T	O
cells	O
did	O
not	B-Negation
require	I-Negation
costimulation	I-Negation
for	I-Negation
cytokine	I-Negation
secretion	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
anti-CD3	I-Negation
alone	I-Negation
.	O

Comparison	O
of	O
the	O
dose	O
response	O
to	O
anti-CD3	O
stimulation	O
demonstrated	O
that	O
half-maximal	O
induction	O
of	O
IL-2	O
was	O
achieved	O
using	O
the	O
same	O
dose	O
of	O
anti-CD3	O
for	O
both	O
freshly	O
isolated	O
and	O
cultured	O
T	O
cells	O
.	O

Furthermore	O
,	O
the	O
dose	O
of	O
OKT3	O
required	O
to	O
achieve	O
half-maximal	O
activation	O
was	O
the	O
same	O
using	O
PMA	O
or	O
different	O
concentrations	O
of	O
alpha	O
4	O
beta	O
1	O
ligands	O
.	O

Therefore	O
,	O
costimulation	O
by	O
alpha	O
4	O
beta	O
1	O
ligands	O
was	O
not	B-Negation
due	I-Negation
to	I-Negation
stabilization	I-Negation
of	I-Negation
the	I-Negation
interaction	I-Negation
of	I-Negation
the	I-Negation
cells	I-Negation
with	I-Negation
its	I-Negation
substrate	I-Negation
.	O

We	O
conclude	O
,	O
rather	O
,	O
that	O
alpha	O
4	O
beta	O
1	O
in	O
freshly	O
isolated	O
T	O
cells	O
delivers	O
a	O
distinct	O
signal	O
that	O
synergizes	O
early	O
with	O
signals	O
initiated	O
by	O
TCR/CD3	O
ligation	O
to	O
induce	O
DNA	O
binding	O
of	O
multiple	O
transcription	O
factors	O
required	O
for	O
cytokine	O
gene	O
induction	O
.	O

Apoptosis	O
mediated	O
by	O
HIV	O
protease	O
is	O
preceded	O
by	O
cleavage	O
of	O
Bcl-2	O
.	O

Expression	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV	O
)	O
protease	O
in	O
cultured	O
cells	O
leads	O
to	O
apoptosis	O
,	O
preceded	O
by	O
cleavage	O
of	O
bcl-2	O
,	O
a	O
key	O
negative	O
regulator	O
of	O
cell	O
death	O
.	O

In	O
contrast	O
,	O
a	O
high	O
level	O
of	O
bcl-2	O
protects	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
from	O
the	O
viral	O
protease	O
and	O
prevents	O
cell	O
death	O
following	O
HIV	O
infection	O
of	O
human	O
lymphocytes	O
,	O
while	O
reducing	O
the	O
yields	O
of	O
viral	O
structural	O
proteins	O
,	O
infectivity	O
,	O
and	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

We	O
present	O
a	O
model	O
for	O
HIV	O
replication	O
in	O
which	O
the	O
viral	O
protease	O
depletes	O
the	O
infected	O
cells	O
of	O
bcl-2	O
,	O
leading	O
to	O
oxidative	O
stress-dependent	O
activation	O
of	O
NF	O
kappa	O
B	O
,	O
a	O
cellular	O
factor	O
required	O
for	O
HIV	O
transcription	O
,	O
and	O
ultimately	O
to	O
cell	O
death	O
.	O

Purified	O
bcl-2	O
is	O
cleaved	O
by	O
HIV	O
protease	O
between	O
phenylalanine	O
112	O
and	O
alanine	O
113	O
.	O

The	O
results	O
suggest	O
a	O
new	O
option	O
for	O
HIV	O
gene	O
therapy	O
;	O
bcl-2	O
muteins	O
that	O
have	O
noncleavable	O
alterations	O
surrounding	O
the	O
HIV	O
protease	O
cleavage	O
site	O
.	O

Evidence	O
for	O
lowered	O
induction	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
activated	O
human	O
T	O
lymphocytes	O
during	O
aging	O
.	O

Transcription	O
factor	O
NF	O
kappa	O
B	O
(	O
nuclear	O
factor	O
kappa	O
B	O
)	O
is	O
induced	O
in	O
T	O
lymphocytes	O
from	O
young	O
individuals	O
following	O
activation	O
with	O
a	O
variety	O
of	O
stimuli	O
including	O
anti-CD3	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

In	O
contrast	O
,	O
activated	O
T	O
lymphocytes	O
from	O
older	O
individuals	O
show	O
a	O
significant	O
reduction	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
response	O
to	O
the	O
same	O
stimuli	O
.	O

The	B-Negation
age-related	I-Negation
decline	I-Negation
in	I-Negation
induction	I-Negation
of	I-Negation
NF	I-Negation
kappa	I-Negation
B	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
attributed	I-Negation
to	I-Negation
alteration	I-Negation
in	I-Negation
the	I-Negation
composition	I-Negation
of	I-Negation
subunits	I-Negation
,	O
p50	O
and	O
p65	O
were	O
found	O
to	O
be	O
the	O
predominant	O
subunits	O
of	O
induced	O
NF	O
kappa	O
B	O
in	O
T	O
cells	O
from	O
young	O
as	O
well	O
as	O
elderly	O
donors	O
.	O

Furthermore	O
,	O
similar	O
levels	O
of	O
NF	O
kappa	O
B	O
were	O
found	O
in	O
the	O
cytosols	O
of	O
unactivated	O
T	O
cells	O
from	O
both	O
young	O
and	O
elderly	O
donors	O
suggesting	O
that	O
precursor	O
levels	O
of	O
NF	O
kappa	O
B	O
remain	O
unaltered	O
during	O
aging	O
.	O

These	O
results	O
suggest	O
that	O
an	O
age-associated	O
decline	O
in	O
the	O
induction	O
of	O
NF	O
kappa	O
B	O
in	O
activated	O
T	O
cells	O
from	O
elderly	O
individuals	O
may	O
be	O
attributable	O
to	O
altered	O
regulation	O
of	O
the	O
inhibitor	O
,	O
I	O
kappa	O
B	O
,	O
and	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
dysregulation	O
accompanying	O
aging	O
.	O

Interaction	O
of	O
HTLV-I	O
Tax	O
with	O
the	O
human	O
proteasome	O
:	O
implications	O
for	O
NF-kappa	O
B	O
induction	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
has	O
been	O
etiologically	O
associated	O
with	O
the	O
development	O
of	O
the	O
adult	O
T-cell	O
leukemia	O
(	O
ATL	O
)	O
as	O
well	O
as	O
degenerative	O
neurologic	O
syndrome	O
termed	O
tropical	O
spastic	O
paraparesis	O
(	O
TSP	O
)	O
.	O

HTLV-I	O
encodes	O
a	O
potent	O
transactivator	O
protein	O
termed	O
Tax	O
that	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
process	O
of	O
T-cell	O
immortalization	O
.	O

Even	O
though	O
the	O
mechanisms	O
by	O
which	O
Tax	O
induces	O
transformation	O
are	O
still	O
unknown	O
,	O
it	O
seems	O
likely	O
that	O
the	O
ability	O
of	O
Tax	O
to	O
alter	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
plays	O
an	O
important	O
part	O
in	O
this	O
process	O
.	O

Tax	O
does	O
not	B-Negation
bind	I-Negation
directly	I-Negation
to	I-Negation
DNA	I-Negation
but	O
rather	O
deregulates	O
the	O
activity	O
of	O
cellular	O
transcription	O
factors	O
.	O

One	O
family	O
of	O
host	O
transcription	O
factors	O
whose	O
activity	O
is	O
altered	O
by	O
Tax	O
includes	O
NF-kappa	O
B/Rel	O
.	O

These	O
transcription	O
factors	O
are	O
post-transcriptionally	O
regulated	O
by	O
their	O
assembly	O
with	O
a	O
second	O
family	O
of	O
inhibitory	O
proteins	O
termed	O
I	O
kappa	O
B	O
that	O
serve	O
to	O
sequester	O
the	O
NF-kappa	O
B/Rel	O
complexes	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
cellular	O
activation	O
,	O
I	O
kappa	O
B	O
alpha	O
is	O
phosphorylated	O
,	O
polyubiquitinated	O
,	O
and	O
degraded	O
in	O
the	O
proteasome	O
.	O

This	O
proteolytic	O
event	O
liberates	O
NF-kappa	O
B	O
,	O
permitting	O
its	O
rapid	O
translocation	O
into	O
the	O
nucleus	O
where	O
it	O
binds	O
to	O
its	O
cognate	O
enhancer	O
elements	O
.	O

Similarly	O
,	O
the	O
p105	O
precursor	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
is	O
also	O
post-translationally	O
processed	O
in	O
the	O
proteasome	O
.	O

The	O
mechanisms	O
by	O
which	O
Tax	O
activates	O
NF-kappa	O
B	O
remain	O
unclear	O
,	O
and	O
findings	O
presented	O
in	O
the	O
literature	O
are	O
often	O
controversial	O
.	O

We	O
identified	O
a	O
physical	O
interaction	O
between	O
Tax	O
and	O
the	O
HsN3	O
subunit	O
of	O
the	O
human	O
proteasome	O
.	O

This	O
raises	O
the	O
intriguing	O
possibility	O
that	O
physical	O
association	O
of	O
the	O
HsN3	O
proteasome	O
subunit	O
with	O
HTLV-I	O
Tax	O
coupled	O
with	O
the	O
independent	O
interaction	O
of	O
Tax	O
with	O
either	O
p100	O
or	O
p65-I	O
kappa	O
B	O
alpha	O
targets	O
these	O
cytoplasmic	O
NF-kappa	O
B/Rel	O
complexes	O
to	O
the	O
proteasome	O
for	O
processing	O
.	O

Regulation	O
of	O
sialoadhesin	O
expression	O
on	O
rat	O
macrophages	O
.	O

Induction	O
by	O
glucocorticoids	O
and	O
enhancement	O
by	O
IFN-beta	O
,	O
IFN-gamma	O
,	O
IL-4	O
,	O
and	O
lipopolysaccharide	O
.	O

Sialoadhesin	O
is	O
a	O
macrophage-restricted	O
member	O
of	O
the	O
Ig	O
superfamily	O
that	O
mediates	O
adhesion	O
with	O
lymphoid	O
and	O
myeloid	O
cells	O
.	O

It	O
is	O
expressed	O
on	O
a	O
subpopulation	O
of	O
macrophages	O
in	O
lymphoid	O
tissues	O
and	O
in	O
chronic	O
inflammation	O
(	O
e.g.	O
,	O
during	O
autoimmune	O
diseases	O
)	O
.	O

We	O
have	O
studied	O
the	O
regulation	O
of	O
sialoadhesin	O
expression	O
in	O
vitro	O
and	O
show	O
that	O
glucocorticoids	O
(	O
GC	O
)	O
induce	O
sialoadhesin	O
expression	O
on	O
freshly	O
isolated	O
rat	O
macrophages	O
and	O
the	O
rat	O
macrophage	O
cell	O
line	O
R2	O
.	O

The	O
cytokines	O
IFN-beta	O
,	O
IFN-gamma	O
,	O
IL-4	O
,	O
and	O
LPS	O
,	O
although	O
unable	B-Negation
to	I-Negation
induce	I-Negation
sialoadhesin	I-Negation
expression	I-Negation
by	I-Negation
themselves	I-Negation
,	O
were	O
able	O
to	O
enhance	O
GC-mediated	O
induction	O
of	O
sialoadhesin	O
.	O

Sialoadhesin	O
expression	O
was	O
functional	O
as	O
shown	O
by	O
cell	O
adhesion	O
assays	O
with	O
human	O
RBCs	O
.	O

Northern	O
blotting	O
experiments	O
indicated	O
that	O
regulation	O
predominantly	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Comparison	O
of	O
the	O
different	O
combinations	O
of	O
GC	O
and	O
cytokines/LPS	O
revealed	O
differences	O
in	O
the	O
level	O
of	O
GC-dependent	O
enhancement	O
of	O
sialoadhesin	O
expression	O
,	O
with	O
IFN-beta	O
and	O
IL-4	O
being	O
more	O
potent	O
than	O
IFN-gamma	O
and	O
LPS	O
.	O

Moreover	O
,	O
the	O
effects	O
of	O
IFN-gamma	O
and	O
LPS	O
could	O
be	O
reproduced	O
by	O
priming	O
,	O
whereas	O
IFN-beta	O
and	O
IL-4	O
were	O
required	O
simultaneously	O
with	O
GC	O
.	O

The	O
regulation	O
of	O
sialoadhesin	O
expression	O
was	O
mediated	O
by	O
the	O
GC	O
receptor	O
,	O
and	O
not	B-Negation
by	I-Negation
mineralocorticoid	I-Negation
receptor	I-Negation
,	O
as	O
shown	O
by	O
inhibition	O
experiments	O
with	O
specific	O
antagonists	O
.	O

Finally	O
,	O
it	O
is	O
demonstrated	O
that	O
macrophages	O
in	O
the	O
adrenal	O
gland	O
,	O
the	O
major	O
site	O
of	O
endogenous	O
GC	O
production	O
,	O
express	O
sialoadhesin	O
.	O

This	O
study	O
demonstrates	O
that	O
GC	O
act	O
as	O
a	O
primary	O
inducer	O
of	O
sialoadhesin	O
expression	O
on	O
rat	O
macrophages	O
,	O
and	O
that	O
the	O
response	O
can	O
be	O
enhanced	O
by	O
IFN-beta	O
,	O
T	O
cell-derived	O
cytokines	O
,	O
or	O
LPS	O
.	O

Selenium-mediated	O
inhibition	O
of	O
transcription	O
factor	O
NF-kappa	O
B	O
and	O
HIV-1	O
LTR	O
promoter	O
activity	O
.	O

The	O
eukaryotic	O
transcription	O
factor	O
NF-kappa	O
B	O
is	O
involved	O
in	O
the	O
inducible	O
expression	O
of	O
various	O
inflammatory	O
genes	O
as	O
well	O
as	O
in	O
HIV-1	O
replication	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
is	O
induced	O
by	O
prooxidants	O
and	O
several	O
stimuli	O
eliciting	O
oxidative	O
stress	O
,	O
such	O
as	O
cytokines	O
,	O
lipopolysaccharide	O
,	O
UV	O
irradiation	O
and	O
other	O
mediators	O
.	O

Various	O
antioxidants	O
inhibit	O
NF-kappa	O
B	O
activation	O
in	O
response	O
to	O
these	O
stimuli	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
effects	O
of	O
selenium	O
,	O
an	O
integral	O
component	O
of	O
glutathione	O
peroxidase	O
(	O
GPX	O
)	O
,	O
on	O
NF-kappa	O
B	O
activation	O
.	O

In	O
selenium-deprived	O
Jurkat	O
and	O
ESb-L	O
T	O
lymphocytes	O
,	O
supplementation	O
of	O
selenium	O
led	O
to	O
a	O
substantial	O
increase	O
of	O
GPX	O
activity	O
.	O

Analysis	O
of	O
DNA	O
binding	O
revealed	O
that	O
NF-kappa	O
B	O
activation	O
in	O
response	O
to	O
TNF	O
was	O
significantly	O
inhibited	O
under	O
these	O
conditions	O
.	O

Likewise	O
,	O
reporter	O
gene	O
assays	O
using	O
luciferase	O
constructs	O
driven	O
by	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
showed	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	O
B	O
controlled	O
gene	O
expression	O
by	O
selenium	O
.	O

The	O
effects	O
of	O
selenium	O
were	O
specific	O
for	O
NF-kappa	O
B	O
,	O
since	O
the	B-Negation
activity	I-Negation
of	I-Negation
the	I-Negation
transcription	I-Negation
factor	I-Negation
AP-1	I-Negation
was	I-Negation
not	I-Negation
suppressed	I-Negation
.	O

These	O
data	O
suggest	O
that	O
selenium	O
supplementation	O
may	O
be	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
NF-kappa	O
B	O
target	O
genes	O
and	O
HIV-1	O
.	O

Transcriptional	O
and	O
posttranscriptional	O
regulation	O
of	O
erythroid	O
gene	O
expression	O
in	O
anthracycline-induced	O
differentiation	O
of	O
human	O
erythroleukemic	O
cells	O
.	O

Aclacinomycin	O
(	O
ACLA	O
)	O
and	O
doxorubicin	O
(	O
DOX	O
)	O
were	O
used	O
at	O
subtoxic	O
concentrations	O
to	O
induce	O
erythroid	O
differentiation	O
in	O
the	O
human	O
leukemic	O
cell	O
line	O
K562	O
.	O

Cell	O
hemoglobinization	O
was	O
accompanied	O
by	O
the	O
increased	O
expression	O
of	O
genes	O
encoding	O
gamma-globin	O
and	O
porphobilinogen	O
deaminase	O
(	O
PBGD	O
)	O
,	O
an	O
enzyme	O
of	O
heme	O
synthesis	O
.	O

By	O
using	O
run-on	O
assays	O
,	O
ACLA	O
was	O
shown	O
to	O
induce	O
an	O
enhancement	O
of	O
the	O
transcription	O
of	O
erythroid	O
genes	O
,	O
including	O
gamma-globin	O
,	O
PBGD	O
,	O
erythropoietin	O
receptor	O
,	O
and	O
GATA-1	O
transcription	O
factor	O
.	O

In	O
contrast	O
,	O
in	O
DOX-treated	O
cells	O
,	O
the	O
transcription	O
rate	O
of	O
these	O
genes	O
was	O
unchanged	O
in	O
comparison	O
with	O
control	O
cells	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
mRNA	O
synthesis	O
with	O
actinomycin	O
D	O
indicated	B-Speculation
that	I-Speculation
DOX	I-Speculation
induced	I-Speculation
an	I-Speculation
increased	I-Speculation
stability	I-Speculation
of	I-Speculation
PBGD	I-Speculation
and	I-Speculation
GATA-1	I-Speculation
mRNAs	I-Speculation
,	O
whereas	O
ACLA	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
half-lives	I-Negation
of	I-Negation
these	I-Negation
mRNAs	I-Negation
.	O

Because	O
the	O
increase	O
in	O
erythroid	O
mRNA	O
steady-state	O
level	O
in	O
anthracycline-treated	O
cells	O
was	O
inhibited	O
by	O
cycloheximide	O
,	O
this	O
suggests	O
that	O
transcriptional	O
activation	O
in	O
ACLA-treated	O
cells	O
and	O
mRNA	O
stabilization	O
in	O
DOX-treated	O
cells	O
were	O
dependent	O
on	O
de	O
novo	O
protein	O
synthesis	O
.	O

Finally	O
,	O
GATA-1	O
protein	O
level	O
was	O
shown	O
to	O
be	O
increased	O
in	O
ACLA-treated	O
but	O
not	B-Negation
in	I-Negation
DOX-treated	I-Negation
cells	I-Negation
.	O

These	O
two	O
anthracyclines	O
,	O
although	O
closely	O
related	O
in	O
their	O
structures	O
,	O
appeared	O
to	O
act	O
as	O
differentiation	O
inducers	O
by	O
distinct	O
mechanisms	O
.	O

Indeed	O
,	O
erythroid	O
gene	O
expression	O
was	O
demonstrated	O
to	O
be	O
regulated	O
transcriptionally	O
by	O
ACLA	O
and	O
mainly	O
posttranscriptionally	O
by	O
DOX	O
.	O

Induction	O
of	O
activator	O
protein	O
(	O
AP	O
)	O
-1	O
and	O
nuclear	O
factor-kappaB	O
by	O
CD28	O
stimulation	O
involves	O
both	O
phosphatidylinositol	O
3-kinase	O
and	O
acidic	O
sphingomyelinase	O
signals	O
.	O

A	O
major	O
obstacle	O
in	O
understanding	O
the	O
signaling	O
events	O
that	O
follow	O
CD28	O
receptor	O
ligation	O
arises	O
from	O
the	O
fact	O
that	O
CD28	O
acts	O
as	O
a	O
costimulus	O
to	O
TCR	O
engagement	O
,	O
making	O
it	O
difficult	O
to	O
assess	O
the	O
relative	O
contribution	O
of	O
CD28	O
signals	O
as	O
distinct	O
from	O
those	O
of	O
the	O
TCR	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
have	O
exploited	O
the	O
observation	O
that	O
activated	O
human	O
T	O
cell	O
blasts	O
can	O
be	O
stimulated	O
via	O
the	O
CD28	O
surface	O
molecule	O
in	O
the	O
absence	B-Negation
of	I-Negation
antigenic	I-Negation
challenge	I-Negation
;	O
thus	O
,	O
we	O
have	O
been	O
able	O
to	O
observe	O
the	O
response	O
of	O
normal	O
T	O
cells	O
to	O
CD28	O
activation	O
in	O
isolation	O
.	O

Using	O
this	O
system	O
,	O
we	O
observed	O
that	O
CD28	O
stimulation	O
by	O
B7-transfected	O
CHO	O
cells	O
induced	O
a	O
proliferative	O
response	O
in	O
T	O
cells	O
that	O
was	O
not	B-Negation
accompanied	I-Negation
by	I-Negation
measurable	I-Negation
IL-2	I-Negation
production	I-Negation
.	O

However	O
,	O
subsequent	O
analysis	O
of	O
transcription	O
factor	O
generation	O
revealed	O
that	O
B7	O
stimulation	O
induced	O
both	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
and	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
complexes	O
,	O
but	O
not	B-Negation
NF-AT	I-Negation
.	O

In	O
contrast	O
,	O
engagement	O
of	O
the	O
TCR	O
by	O
class	O
II	O
MHC/superantigen	O
,	O
either	O
with	O
or	O
without	B-Negation
CD28	I-Negation
ligation	I-Negation
,	O
resulted	O
in	O
the	O
induction	O
of	O
NF-AT	O
,	O
AP-1	O
,	O
and	O
NF-kappaB	O
as	O
well	O
as	O
IL-2	O
production	O
.	O

Using	O
selective	O
inhibitors	O
,	O
we	O
investigated	O
the	O
signaling	O
pathways	O
involved	O
in	O
the	O
CD28-mediated	O
induction	O
of	O
AP-1	O
and	O
NF-kappaB	O
.	O

This	O
revealed	O
that	O
NF-kappaB	O
generation	O
was	O
sensitive	O
to	O
chloroquine	O
,	O
an	O
inhibitor	O
of	O
acidic	O
sphingomyelinase	O
,	O
but	O
not	B-Negation
to	I-Negation
the	I-Negation
phosphatidylinositol	I-Negation
3-kinase	I-Negation
inhibitor	I-Negation
,	I-Negation
wortmannin	I-Negation
.	O

In	O
contrast	O
,	O
AP-1	O
generation	O
was	O
inhibited	O
by	O
wortmannin	O
and	O
was	O
also	O
variably	O
sensitive	O
to	O
chloroquine	O
.	O

These	O
data	O
suggest	O
that	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
CD28-derived	O
signals	O
can	O
stimulate	O
proliferation	O
at	O
least	O
in	O
part	O
via	O
NF-kappaB	O
and	O
AP-1	O
generation	O
,	O
and	O
that	O
this	O
response	O
uses	O
both	O
acidic	O
sphingomyelinase	O
and	O
phosphatidylinositol	O
3-kinase-linked	O
pathways	O
.	O

Second	B-Negation
messenger	I-Negation
up-regulation	I-Negation
of	I-Negation
androgen	I-Negation
receptor	I-Negation
gene	I-Negation
transcription	I-Negation
is	I-Negation
absent	I-Negation
in	I-Negation
androgen	I-Negation
insensitive	I-Negation
human	I-Negation
prostatic	I-Negation
carcinoma	I-Negation
cell	I-Negation
lines	I-Negation
,	I-Negation
PC-3	I-Negation
and	I-Negation
DU-145	I-Negation
.	O

A	O
theoretical	O
pathway	O
of	O
transcriptional	O
regulation	O
of	O
the	O
androgen	O
receptor	O
(	O
AR	O
)	O
gene	O
is	O
via	O
a	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
present	O
in	O
its	O
promoter	O
region	O
(	O
-508	O
to	O
-501	O
)	O
.	O

After	O
20	O
h	O
of	O
stimulation	O
with	O
8-bromo-cAMP	O
,	O
AR	O
mRNA	O
was	O
upregulated	O
in	O
LNCaP	O
but	O
not	B-Negation
in	I-Negation
either	I-Negation
PC-3	I-Negation
or	I-Negation
DU-145	I-Negation
cell	I-Negation
lines	I-Negation
.	O

We	O
have	O
demonstrated	O
that	O
the	O
level	O
of	O
CRE	O
binding	O
protein	O
(	O
CREB	O
)	O
was	O
the	O
same	O
in	O
all	O
cell	O
lines	O
and	O
that	O
the	O
putative	O
AR-CRE	O
forms	O
specific	O
and	O
compatible	O
protein	O
interactions	O
with	O
CREB	O
.	O

The	O
ability	O
to	O
regulate	O
AR	O
gene	O
transcription	O
via	O
the	O
second	O
messenger	O
pathway	O
is	O
lost	O
in	O
the	O
PC-3	O
and	O
DU-145	O
cell	O
lines	O
.	O

This	O
may	O
be	O
an	O
important	O
primary	O
mechanism	O
of	O
androgen	O
insensitivity	O
in	O
prostate	O
cancer	O
.	O

A	O
novel	O
immunosuppressive	O
factor	O
in	O
bovine	O
colostrum	O
blocks	O
activation	O
of	O
the	O
interleukin	O
2	O
gene	O
enhancer	O
at	O
the	O
NFAT	O
site	O
.	O

A	O
factor	O
in	O
bovine	O
colostrum	O
(	O
colostrum	O
inhibitory	O
factor	O
,	O
CIF	O
)	O
inhibits	O
interleukin	O
2	O
(	O
IL2	O
)	O
production	O
in	O
activated	O
T	O
helper	O
cells	O
by	O
blocking	O
the	O
accumulation	O
of	O
IL2	O
mRNA	O
.	O

To	O
determine	O
whether	O
CIF	O
blocks	O
at	O
the	O
level	O
of	O
IL2	O
transcription	O
,	O
we	O
introduced	O
reporter	O
plasmids	O
into	O
the	O
human	O
T	O
leukemia	O
cell	O
line	O
Jurkat	O
by	O
transient	O
transfection	O
.	O

These	O
contained	O
the	O
luciferase	O
gene	O
under	O
the	O
control	O
of	O
either	O
the	O
human	O
IL2	O
upstream	O
enhancer	O
region	O
(	O
segments	O
-326	O
to	O
+45	O
)	O
or	O
three	O
repeats	O
of	O
the	O
NFAT	O
element	O
contained	O
within	O
it	O
(	O
segments	O
-255	O
to	O
-285	O
)	O
.	O

Expression	O
of	O
luciferase	O
in	O
these	O
cells	O
was	O
induced	O
by	O
phorbol	O
myristate	O
acetate	O
plus	O
a	O
calcium	O
ionophore	O
.	O

CIF	O
inhibited	O
induction	O
of	O
either	O
construct	O
as	O
did	O
cyclosporine	O
,	O
which	O
is	O
known	O
to	O
block	O
activation	O
of	O
the	O
NFAT	O
element	O
.	O

CIF	O
failed	B-Negation
to	I-Negation
inhibit	I-Negation
several	I-Negation
other	I-Negation
enhancer	I-Negation
elements	I-Negation
.	O

The	O
NFAT-controlled	O
luciferase	O
gene	O
system	O
distinguishes	O
CIF	O
from	O
other	O
T	O
cell	O
inhibitory	O
activities	O
present	O
in	O
colostrum	O
,	O
in	O
particular	O
,	O
TGF	O
beta	O
1	O
and	O
TGF	O
beta	O
2	O
and	O
the	O
glucocorticoids	O
.	O

Stably	O
transfected	O
Jurkat	O
cells	O
behaved	O
similarly	O
to	O
the	O
transiently	O
transfected	O
ones	O
with	O
respect	O
to	O
inhibition	O
by	O
CIF	O
and	O
cyclosporine	O
.	O

The	O
NFAT-luc	O
assay	O
is	O
a	O
useful	O
technique	O
for	O
the	O
rapid	O
,	O
sensitive	O
measurement	O
of	O
CIF	O
or	O
other	O
immunosuppressants	O
with	O
a	O
similar	O
mode	O
of	O
action	O
.	O

The	O
state	O
of	O
maturation	O
of	O
monocytes	O
into	O
macrophages	O
determines	O
the	O
effects	O
of	O
IL-4	O
and	O
IL-13	O
on	O
HIV	O
replication	O
.	O

The	O
molecular	O
mechanisms	O
of	O
the	O
effects	O
of	O
IL-4	O
and	O
IL-13	O
on	O
HIV	O
infection	O
in	O
human	O
monocytes	O
as	O
they	O
matured	O
into	O
monocyte-derived	O
macrophages	O
over	O
7	O
days	O
were	O
investigated	O
using	O
HIV-1	O
(	O
BaL	O
)	O
,	O
and	O
low	O
passage	O
clinical	O
strains	O
.	O

IL-4	O
and	O
IL-13	O
up-regulated	O
the	O
expression	O
of	O
both	O
genomic	O
and	O
spliced	O
HIV	O
mRNA	O
in	O
monocytes	O
cultured	O
on	O
Teflon	O
,	O
as	O
determined	O
by	O
Northern	O
analysis	O
and	O
p24	O
Ag	O
assay	O
.	O

Using	O
a	O
nuclear	O
run-on	O
assay	O
,	O
IL-4	O
stimulation	O
was	O
shown	O
to	O
enhance	O
transcription	O
by	O
two-	O
to	O
threefold	O
.	O

IL-4	O
stimulated	O
nuclear	O
factor-kappaB	O
nuclear	O
translocation	O
and	O
binding	O
before	O
enhancement	O
of	O
HIV	O
RNA	O
expression	O
.	O

Conversely	O
,	O
IL-4	O
and	O
IL-13	O
markedly	O
and	O
significantly	O
inhibited	O
HIV	O
replication	O
at	O
the	O
transcriptional	O
level	O
in	O
monocyte-derived	O
macrophages	O
,	O
and	O
this	O
occurred	O
whether	O
these	O
cytokines	O
were	O
added	O
before	O
or	O
after	O
HIV	O
infection	O
.	O

The	O
reversal	O
from	O
stimulation	O
to	O
inhibition	O
occurred	O
after	O
3	O
to	O
5	O
days	O
of	O
adherence	O
to	O
plastic	O
.	O

IL-4	O
had	O
no	B-Negation
significant	I-Negation
effect	I-Negation
on	I-Negation
HIV	I-Negation
reverse	I-Negation
transcription	I-Negation
.	O

The	O
effect	O
of	O
both	O
cytokines	O
on	O
the	O
monocyte	O
maturation/differentiation	O
(	O
CD11b	O
,	O
CD13	O
,	O
and	O
CD26	O
)	O
and	O
other	O
macrophage	O
markers	O
(	O
CD14	O
and	O
CD68	O
)	O
was	O
examined	O
.	O

IL-4	O
enhanced	O
CD11b	O
,	O
but	O
inhibited	O
CD26	O
expression	O
and	O
delayed	O
CD13	O
loss	O
.	O

IL-13	O
had	O
similar	O
effects	O
on	O
CD11b	O
and	O
CD13	O
,	O
but	O
no	B-Negation
effect	I-Negation
on	I-Negation
CD26	I-Negation
.	O

Hence	O
,	O
these	O
cytokines	O
do	O
not	O
simply	O
enhance	O
monocyte	O
differentiation	O
,	O
but	O
have	O
complex	O
and	O
slightly	O
divergent	O
effects	O
that	O
impact	O
on	O
HIV	O
replication	O
probably	O
through	O
cell	O
signaling	O
pathways	O
and	O
nuclear	O
factor-kappaB	O
translocation	O
.	O

Engagement	O
of	O
the	O
Lewis	O
X	O
antigen	O
(	O
CD15	O
)	O
results	O
in	O
monocyte	O
activation	O
.	O

We	O
previously	O
reported	O
that	O
monocyte	O
adhesion	O
to	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
-treated	O
endothelial	O
cells	O
increased	O
expression	O
of	O
tissue	O
factor	O
and	O
CD36	O
on	O
monocytes	O
.	O

Using	O
immunological	O
cross-linking	O
to	O
mimic	O
receptor	O
engagement	O
by	O
natural	O
ligands	O
,	O
we	O
now	O
show	O
that	O
CD15	O
(	O
Lewis	O
X	O
)	O
,	O
a	O
monocyte	O
counter-receptor	O
for	O
endothelial	O
selectins	O
may	O
participate	O
in	O
this	O
response	O
.	O

We	O
used	O
cytokine	O
production	O
as	O
a	O
readout	O
for	O
monocyte	O
activation	O
and	O
found	O
that	O
CD15	O
cross-linking	O
induced	O
TNF-alpha	O
release	O
from	O
peripheral	O
blood	O
monocytes	O
and	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
MM6	O
.	O

Quantitative	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
showed	O
an	O
increase	O
in	O
steady-state	O
TNF-alpha	O
mRNA	O
after	O
3	O
to	O
4	O
hours	O
of	O
cross-linking	O
.	O

CD15	O
cross-linking	O
also	O
concomitantly	O
increased	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
)	O
mRNA	O
,	O
while	O
no	B-Negation
apparent	I-Negation
change	I-Negation
was	I-Negation
observed	I-Negation
in	I-Negation
the	I-Negation
levels	I-Negation
of	I-Negation
beta-actin	I-Negation
mRNA	I-Negation
,	O
indicating	O
specificity	O
.	O

To	O
examine	O
transcriptional	O
regulation	O
of	O
cytokine	O
genes	O
by	O
CD15	O
engagement	O
,	O
a	O
CAT	O
plasmid	O
reporter	O
construct	O
containing	O
IL-1	O
beta	O
promoter/enhancer	O
sequences	O
was	O
introduced	O
into	O
MM6	O
.	O

Subsequent	O
cross-linking	O
of	O
CD15	O
increased	O
CAT	O
activity	O
.	O

CD15	O
engagement	O
by	O
monoclonal	O
antibody	O
also	O
attenuated	O
IL-1	O
beta	O
transcript	O
degradation	O
,	O
demonstrating	O
that	O
signaling	O
via	O
CD15	O
also	O
had	O
posttranscriptional	O
effects	O
.	O

Nuclear	O
extracts	O
of	O
anti-CD15	O
cross-linked	O
cells	O
demonstrated	O
enhanced	O
levels	O
of	O
the	O
transcriptional	O
factor	O
activator	O
protein-1	O
,	O
minimally	O
changed	O
nuclear	O
factor-kappa	O
B	O
,	O
and	O
did	O
not	B-Negation
affect	I-Negation
SV40	I-Negation
promoter	I-Negation
specific	I-Negation
protein-1	I-Negation
.	O

We	O
conclude	O
that	O
engagement	O
of	O
CD15	O
on	O
monocytes	O
results	O
in	O
monocyte	O
activation	O
.	O

In	O
addition	O
to	O
its	O
well-recognized	O
adhesive	O
role	O
,	O
CD15	O
may	O
function	O
as	O
an	O
important	O
signaling	O
molecule	O
capable	O
of	O
initiating	O
proinflammatory	O
events	O
in	O
monocytes	O
that	O
come	O
into	O
contact	O
with	O
activated	O
endothelium	O
.	O

V3	O
loop	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
suppresses	O
interleukin	O
2-induced	O
T	O
cell	O
growth	O
[	O
published	O
erratum	O
appears	O
in	O
AIDS	O
Res	O
Hum	O
Retroviruses	O
1997	O
May	O
1	O
;	O
13	O
(	O
7	O
)	O
:633	O
]	O

We	O
tested	O
the	O
effect	O
of	O
three	O
linear	O
or	O
two	O
loop	O
peptides	O
derived	O
from	O
the	O
V3	O
region	O
of	O
the	O
HTLV-III	O
BH10	O
clone	O
or	O
the	O
SF2	O
strain	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
on	O
IL-2-driven	O
T	O
cell	O
proliferation	O
.	O

V3-BH10	O
,	O
which	O
consists	O
of	O
42	O
amino	O
acids	O
and	O
has	O
a	O
loop	O
structure	O
,	O
suppressed	O
IL-2-driven	O
proliferation	O
of	O
all	O
IL-2-dependent	O
cells	O
[	O
Kit225	O
,	O
ED-40515	O
(	O
+	O
)	O
,	O
KT-3	O
,	O
7-day	O
PHA-blasts	O
,	O
and	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
]	O
tested	O
,	O
whereas	O
it	O
did	O
not	B-Negation
suppress	I-Negation
the	I-Negation
cell	I-Negation
growth	I-Negation
of	I-Negation
IL-2-independent	I-Negation
cell	I-Negation
lines	I-Negation
(	I-Negation
Hut102	I-Negation
,	I-Negation
Molt-4	I-Negation
,	I-Negation
and	I-Negation
Jurkat	I-Negation
)	I-Negation
.	O

This	O
suppressive	O
effect	O
was	O
also	O
seen	O
in	O
IL-2-driven	O
cell	O
growth	O
of	O
CD8-positive	O
lymphocytes	O
purified	O
from	O
7-day	O
PHA-blasts	O
,	O
indicating	O
that	O
CD4	O
molecules	O
were	O
not	O
required	O
for	O
the	O
suppression	O
.	O

The	O
treatment	O
with	O
anti-V3	O
loop	O
monoclonal	O
antibody	O
(	O
902	O
antibody	O
)	O
completely	O
abolished	O
the	O
suppressive	O
effect	O
of	O
V3-BH10	O
.	O

In	O
addition	O
,	O
V3-BH10	O
generated	O
the	O
arrest	O
of	O
Kit225	O
cells	O
and	O
also	O
purified	O
CD8-positive	O
lymphocytes	O
in	O
G1	O
phase	O
in	O
the	O
presence	O
of	O
IL-2	O
.	O

Neither	B-Negation
chromatin	I-Negation
condensation	I-Negation
nor	I-Negation
DNA	I-Negation
fragmentation	I-Negation
was	I-Negation
detected	I-Negation
in	I-Negation
Kit225	I-Negation
cells	I-Negation
cultured	I-Negation
with	I-Negation
V3-BH10	I-Negation
and	I-Negation
IL-2	I-Negation
.	O

V3-BH10	O
neither	B-Negation
blocked	I-Negation
radiolabeled	I-Negation
IL-2	I-Negation
binding	I-Negation
to	I-Negation
IL-2	I-Negation
receptors	I-Negation
nor	I-Negation
affected	I-Negation
tyrosyl	I-Negation
phosphorylation	I-Negation
of	I-Negation
several	I-Negation
cellular	I-Negation
proteins	I-Negation
(	I-Negation
p120	I-Negation
,	I-Negation
p98	I-Negation
,	I-Negation
p96	I-Negation
,	I-Negation
p54	I-Negation
,	I-Negation
and	I-Negation
p38	I-Negation
)	I-Negation
,	I-Negation
which	I-Negation
is	I-Negation
immediately	I-Negation
induced	I-Negation
by	I-Negation
IL-2	I-Negation
stimulation	I-Negation
.	O

However	O
,	O
V3-BH10	O
enhanced	O
IL-2-induced	O
mRNA	O
expression	O
of	O
c-fos	O
but	O
not	B-Negation
c-myc	I-Negation
or	I-Negation
junB	I-Negation
.	O

Thus	O
,	O
the	O
binding	O
of	O
V3	O
loop	O
of	O
gp120	O
to	O
the	O
cell	O
surface	O
molecule	O
(	O
s	O
)	O
appears	O
to	O
affect	O
intracellular	O
IL-2	O
signaling	O
,	O
which	O
leads	O
to	O
the	O
suppression	O
of	O
IL-2-induced	O
T	O
cell	O
growth	O
.	O

Nuclear	O
factor-kappaB	O
activation	O
in	O
human	O
monocytes	O
stimulated	O
with	O
lipopolysaccharide	O
is	O
inhibited	O
by	O
fibroblast	O
conditioned	O
medium	O
and	O
exogenous	O
PGE2	O
.	O

The	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
is	O
thought	O
to	O
be	O
crucially	O
involved	O
in	O
the	O
gene	O
activation	O
of	O
several	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
fibroblast	O
conditioned	O
medium	O
(	O
FCM	O
)	O
is	O
able	O
to	O
inhibit	O
both	O
TNF	O
mRNA	O
accumulation	O
and	O
protein	O
release	O
in	O
peripheral	O
blood-derived	O
human	O
monocytes	O
(	O
PBM	O
)	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

In	O
this	O
study	O
we	O
have	O
investigated	O
the	O
effect	O
of	O
FCM	O
on	O
the	O
LPS-induced	O
DNA-binding	O
activity	O
of	O
NF-kappaB	O
,	O
by	O
means	O
of	O
electrophoretic	O
shift	O
assay	O
(	O
EMSA	O
)	O
.	O

We	O
provide	O
evidence	O
that	O
FCM	O
strongly	O
inhibits	O
the	O
LPS-induced	O
NF-kappaB	O
activation	O
in	O
PBM	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
exogenous	O
PGE2	O
mimics	O
the	O
NF-kappaB	O
inhibitory	O
effect	O
of	O
FCM	O
.	O

On	O
the	O
other	O
hand	O
,	O
FCM	O
produced	O
in	O
the	O
presence	O
of	O
indomethacin	O
does	O
not	B-Negation
inhibit	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
by	I-Negation
LPS	I-Negation
.	O

Our	O
results	O
lend	O
further	O
support	O
to	O
the	O
hypothesis	O
that	O
inflammatory	O
and	O
immune	O
responses	O
of	O
monocytes/macrophages	O
may	O
be	O
modulated	O
at	O
the	O
molecular	O
level	O
by	O
signals	O
originating	O
from	O
tissue	O
structural	O
cells	O
such	O
as	O
fibroblasts	O
.	O

Glycation-dependent	O
,	O
reactive	O
oxygen	O
species-mediated	O
suppression	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
in	O
HIT	O
cells	O
.	O

Prolonged	O
poor	O
glycemic	O
control	O
in	O
non-insulin-dependent	O
diabetes	O
mellitus	O
patients	O
often	O
leads	O
to	O
a	O
decline	O
in	O
insulin	O
secretion	O
from	O
pancreatic	O
beta	O
cells	O
,	O
accompanied	O
by	O
a	O
decrease	O
in	O
the	O
insulin	O
content	O
of	O
the	O
cells	O
.	O

As	O
a	O
step	O
toward	O
elucidating	O
the	O
pathophysiological	O
background	O
of	O
the	O
so-called	O
glucose	O
toxicity	O
to	O
pancreatic	O
beta	O
cells	O
,	O
we	O
induced	O
glycation	O
in	O
HIT-T15	O
cells	O
using	O
a	O
sugar	O
with	O
strong	O
deoxidizing	O
activity	O
,	O
D-ribose	O
,	O
and	O
examined	O
the	O
effects	O
on	O
insulin	O
gene	O
transcription	O
.	O

The	O
results	O
of	O
reporter	O
gene	O
analyses	O
revealed	O
that	O
the	O
insulin	O
gene	O
promoter	O
is	O
more	O
sensitive	O
to	O
glycation	O
than	O
the	O
control	O
beta-actin	O
gene	O
promoter	O
;	O
approximately	O
50	O
and	O
80	O
%	O
of	O
the	O
insulin	O
gene	O
promoter	O
activity	O
was	O
lost	O
when	O
the	O
cells	O
were	O
kept	O
for	O
3	O
d	O
in	O
the	O
presence	O
of	O
40	O
and	O
60	O
mM	O
D-ribose	O
,	O
respectively	O
.	O

In	O
agreement	O
with	O
this	O
,	O
decrease	O
in	O
the	O
insulin	O
mRNA	O
and	O
insulin	O
content	O
was	O
observed	O
in	O
the	O
glycation-induced	O
cells	O
.	O

Also	O
,	O
gel	O
mobility	O
shift	O
analyses	O
using	O
specific	O
antiserum	O
revealed	O
decrease	O
in	O
the	O
DNA-binding	O
activity	O
of	O
an	O
insulin	O
gene	O
transcription	O
factor	O
,	O
PDX-1/IPF1/STF-1	O
.	O

These	O
effects	O
of	O
D-ribose	O
seemed	O
almost	O
irreversible	O
but	O
could	O
be	O
prevented	O
by	O
addition	O
of	O
1	O
mM	O
aminoguanidine	O
or	O
10	O
mM	O
N-acetylcysteine	O
,	O
thus	O
suggesting	O
that	O
glycation	O
and	O
reactive	O
oxygen	O
species	O
,	O
generated	O
through	O
the	O
glycation	O
reaction	O
,	O
serve	O
as	O
mediators	O
of	O
the	O
phenomena	O
.	O

These	O
observations	O
suggest	O
that	O
protein	O
glycation	O
in	O
pancreatic	O
beta	O
cells	O
,	O
which	O
occurs	O
in	O
vivo	O
under	O
chronic	O
hyperglycemia	O
,	O
suppresses	O
insulin	O
gene	O
transcription	O
and	O
thus	O
can	O
explain	O
part	O
of	O
the	O
beta	O
cell	O
glucose	O
toxicity	O
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
PRE-I	O
enhancer	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
in	O
different	O
T	O
cell	O
subsets	O
.	O

The	O
immunomodulatory	O
cytokine	O
IL-4	O
affects	O
cells	O
of	O
most	O
hemopoietic	O
lineages	O
.	O

IL-4	O
is	O
secreted	O
by	O
activated	O
Th2	O
but	O
not	B-Negation
Th1	I-Negation
cells	I-Negation
and	O
plays	O
a	O
major	O
role	O
in	O
the	O
immune	O
response	O
by	O
modulating	O
the	O
differentiation	O
of	O
naive	O
Th	O
cells	O
toward	O
the	O
Th2	O
phenotype	O
.	O

We	O
have	O
previously	O
identified	O
an	O
enhancer	O
element	O
,	O
PRE-I	O
,	O
that	O
is	O
essential	O
for	O
the	O
function	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

To	O
investigate	O
the	O
mechanisms	O
responsible	O
for	O
tissue-specific	O
expression	O
of	O
the	O
IL-4	O
gene	O
,	O
we	O
analyzed	O
nuclear	O
factors	O
binding	O
to	O
the	O
PRE-I	O
site	O
and	O
compared	O
the	O
binding	O
activities	O
of	O
these	O
factors	O
to	O
the	O
IL-4	O
promoter	O
of	O
Th1	O
and	O
Th2	O
cells	O
.	O

We	O
show	O
that	O
PRE-I	O
interacts	O
with	O
PMA-	O
and	O
PMA/ionomycin-inducible	O
,	O
cyclosporin	O
A-sensitive	O
nuclear	O
factors	O
.	O

Using	O
anti-C/EBPbeta	O
(	O
NF-IL6	O
)	O
,	O
anti-C/EBPdelta	O
(	O
NF-IL6beta	O
)	O
,	O
anti-NF-ATc	O
,	O
anti-NF-ATp	O
,	O
anti-Fos	O
,	O
and	O
anti-Jun	O
Abs	O
we	O
demonstrate	O
that	O
the	O
previously	O
identified	O
PRE-I	O
binding	O
factor	O
POS-1	O
is	O
composed	O
of	O
different	O
transcription	O
factors	O
in	O
different	O
Th	O
cell	O
subsets	O
.	O

In	O
the	O
IL-4-producing	O
Th0-like	O
human	O
Jurkat	O
and	O
mouse	O
EL-4	O
cells	O
,	O
POS-1	O
(	O
designated	O
POS-1a	O
)	O
contains	O
NF-IL6beta	O
and	O
Jun	O
.	O

In	O
the	O
mouse	O
Th2	O
D10	O
cells	O
and	O
in	O
the	O
human	O
Th2	O
clones	O
,	O
POS-1	O
(	O
designated	O
POS-1b	O
)	O
contains	O
NF-IL6beta	O
,	O
Jun	O
,	O
and	O
NF-ATc/p	O
.	O

In	O
contrast	O
,	O
POS-1	B-Negation
was	I-Negation
not	I-Negation
found	I-Negation
in	I-Negation
nuclear	I-Negation
extracts	I-Negation
of	I-Negation
human	I-Negation
Th1	I-Negation
clones	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
PRE-I	O
may	O
play	O
a	O
role	O
in	O
the	O
differential	O
regulation	O
of	O
IL-4	O
gene	O
expression	O
levels	O
.	O

Inhibitory	O
effect	O
of	O
growth	O
hormone	O
on	O
TNF-alpha	O
secretion	O
and	O
nuclear	O
factor-kappaB	O
translocation	O
in	O
lipopolysaccharide-stimulated	O
human	O
monocytes	O
.	O

Several	O
studies	O
have	O
pointed	O
to	O
a	O
link	O
between	O
immune	O
and	O
endocrine	O
systems	O
,	O
including	O
a	O
regulatory	O
function	O
of	O
GH	O
on	O
monocyte	O
activation	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
human	O
THP-1	O
promonocytic	O
cells	O
,	O
engineered	O
by	O
gene	O
transfer	O
to	O
constitutively	O
produce	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
secreted	O
depressed	O
amounts	O
of	O
TNF-alpha	O
in	O
response	O
to	O
challenge	O
by	O
LPS	O
.	O

The	O
effect	O
of	O
GH	O
appears	O
to	O
occur	O
in	O
an	O
autocrine	O
fashion	O
,	O
since	O
the	O
inhibitory	O
effect	O
on	O
TNF-alpha	O
secretion	O
by	O
constitutive	O
GH	O
production	O
could	O
be	O
abolished	O
in	O
the	O
presence	O
of	O
anti-hGH	O
mAb	O
.	O

The	O
GH-induced	O
inhibitory	O
effect	O
was	O
also	O
observed	O
using	O
normal	O
human	O
monocytes	O
and	O
monocyte-derived	O
macrophages	O
.	O

Inhibition	O
of	O
TNF-alpha	O
production	O
by	O
THP-1-hGH-transfected	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
LPS	O
is	O
dependent	O
on	O
a	O
selective	O
pathway	O
,	O
since	O
no	B-Negation
inhibition	I-Negation
of	I-Negation
TNF-alpha	I-Negation
production	I-Negation
was	I-Negation
observed	I-Negation
when	I-Negation
cells	I-Negation
were	I-Negation
cultured	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
PMA	I-Negation
.	O

Inhibition	O
of	O
TNF-alpha	O
secretion	O
by	O
LPS-stimulated	O
THP-1-hGH	O
cells	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
nuclear	O
translocation	O
of	O
nuclear	O
factor-kappaB	O
.	O

The	O
capacity	O
of	O
GH	O
to	O
inhibit	O
LPS-induced	O
TNF-alpha	O
production	O
by	O
monocytes	O
without	B-Negation
altering	I-Negation
other	I-Negation
pathways	I-Negation
leading	I-Negation
to	I-Negation
TNF-alpha	I-Negation
production	I-Negation
may	B-Speculation
be	I-Speculation
of	I-Speculation
potential	I-Speculation
relevance	I-Speculation
in	I-Speculation
septic	I-Speculation
shock	I-Speculation
,	O
since	O
GH	O
is	O
available	O
for	O
clinical	O
use	O
.	O

Impaired	O
induction	O
of	O
c-fos/c-jun	O
genes	O
and	O
of	O
transcriptional	O
regulatory	O
proteins	O
binding	O
distinct	O
c-fos/c-jun	O
promoter	O
elements	O
in	O
activated	O
human	O
T	O
cells	O
during	O
aging	O
.	O

The	O
activation	O
of	O
transcriptional	O
factor	O
c-Fos/c-Jun	O
AP-1	O
is	O
essential	O
for	O
normal	O
T	O
cell	O
responsiveness	O
and	O
is	O
often	O
impaired	O
in	O
T	O
cells	O
during	O
aging	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
aberrancies	O
in	O
the	O
regulation	O
of	O
c-fos/c-jun	O
at	O
the	O
mRNA	O
or	O
protein	O
level	O
might	O
underlie	O
the	O
age-associated	O
impairments	O
of	O
AP-1	O
in	O
human	O
T	O
cells	O
.	O

Whereas	O
T	O
cells	O
from	O
young	O
subjects	O
stimulated	O
with	O
cross-linked	O
anti-CD3epsilon	O
mAb	O
OKT3	O
plus	O
PMA	O
or	O
with	O
the	O
lectin	O
PHA	O
plus	O
PMA	O
demonstrated	O
considerable	O
increases	O
in	O
c-Fos	O
protein	O
expression	O
,	O
the	O
expression	O
of	O
c-Fos	O
but	O
not	B-Negation
c-Jun	I-Negation
was	O
markedly	O
reduced	O
in	O
stimulated	O
T	O
cells	O
from	O
certain	O
elderly	O
subjects	O
.	O

In	O
addition	O
,	O
RNase	O
protection	O
assays	O
revealed	O
that	O
anti-CD3/PMA-stimulated	O
T	O
cells	O
from	O
a	O
substantial	O
proportion	O
of	O
elderly	O
subjects	O
exhibited	O
decreased	O
levels	O
of	O
c-fos	O
and/or	O
c-jun	O
mRNA	O
compared	O
to	O
T	O
cells	O
from	O
young	O
subjects	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
the	O
levels	O
of	O
nuclear	O
regulatory	O
proteins	O
recognizing	O
the	O
AP-1	O
consensus	O
TRE	O
motif	O
,	O
the	O
proximal	O
c-jun	O
TRE-like	O
promoter	O
element	O
,	O
and	O
the	O
c-fos	O
serum	O
response	O
element	O
(	O
SRE	O
)	O
were	O
determined	O
in	O
resting	O
and	O
stimulated	O
T	O
cells	O
.	O

Although	O
the	O
stimulation	O
of	O
T	O
cells	O
from	O
young	O
subjects	O
resulted	O
in	O
coordinated	O
increases	O
of	O
nuclear	O
protein	O
complexes	O
binding	O
the	O
AP-1	O
TRE	O
,	O
c-jun	O
TRE	O
,	O
and	O
c-fos	O
SRE	O
DNA	O
sequence	O
motifs	O
,	O
age-related	O
reductions	O
in	O
the	O
activation	O
of	O
AP-1	O
were	O
accompanied	O
by	O
decreased	O
levels	O
of	O
c-jun	O
TRE	O
and	O
c-fos	O
SRE	O
binding	O
complexes	O
.	O

Furthermore	O
,	O
the	O
nuclear	O
protein	O
complexes	O
binding	O
the	O
SRE	O
motif	O
induced	O
in	O
activated	O
T	O
cells	O
of	O
young	O
and	O
elderly	O
subjects	O
contained	O
serum	O
response	O
factor	O
and	O
Elk-1	O
pointing	O
toward	O
age-related	O
defects	O
in	O
the	O
activation	O
of	O
transcriptional	O
regulatory	O
proteins	O
distinct	O
from	O
c-jun/AP-1	O
.	O

These	O
results	O
suggest	O
that	O
underlying	O
aberrancies	O
in	O
the	O
induction	O
of	O
c-fos/c-jun	O
as	O
well	O
as	O
their	O
nuclear	O
regulatory	O
proteins	O
may	O
contribute	O
to	O
the	O
age-related	O
impairments	O
of	O
AP-1	O
activation	O
in	O
human	O
T	O
cells	O
.	O

Interaction	O
of	O
transcription	O
factors	O
RFX1	O
and	O
MIBP1	O
with	O
the	O
gamma	O
motif	O
of	O
the	O
negative	O
regulatory	O
element	O
of	O
the	O
hepatitis	O
B	O
virus	O
core	O
promoter	O
.	O

The	O
negative	O
regulatory	O
element	O
(	O
NRE	O
)	O
of	O
the	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
core	O
promoter	O
contains	O
three	O
subregions	O
which	O
act	O
synergistically	O
to	O
suppress	O
core	O
promoter	O
activity	O
.	O

One	O
of	O
these	O
subregions	O
,	O
NRE	O
gamma	O
,	O
is	O
active	O
in	O
both	O
HeLa	O
cervical	O
carcinoma	O
cells	O
and	O
Huh7	O
hepatoma	O
cells	O
and	O
was	O
found	O
to	O
be	O
bound	O
by	O
a	O
protein	O
factor	O
present	O
in	O
both	O
cell	O
types	O
.	O

Here	O
we	O
show	O
that	O
the	O
transcription	O
factor	O
RFX1	O
can	O
bind	O
to	O
NRE	O
gamma	O
and	O
transactivate	O
the	O
core	O
promoter	O
through	O
this	O
site	O
.	O

Mutations	O
which	O
abrogated	O
the	O
gene-suppressive	O
activity	O
of	O
NRE	O
gamma	O
prevented	O
RFX1	O
from	O
binding	O
to	O
NRE	O
gamma	O
.	O

In	O
addition	O
,	O
RFX1	O
can	O
bind	O
simultaneously	O
,	O
most	O
likely	O
as	O
a	O
heterodimer	O
,	O
with	O
the	O
transcription	O
factor	O
MIBP1	O
to	O
NRE	O
gamma	O
.	O

In	O
the	O
absence	B-Negation
of	I-Negation
a	I-Negation
cloned	I-Negation
MIBP1	I-Negation
gene	I-Negation
for	I-Negation
further	I-Negation
studies	I-Negation
,	O
we	O
hypothesize	B-Speculation
that	I-Speculation
RFX1	I-Speculation
acts	I-Speculation
with	I-Speculation
MIBP1	I-Speculation
to	I-Speculation
negatively	I-Speculation
regulate	I-Speculation
the	I-Speculation
core	I-Speculation
promoter	I-Speculation
activity	I-Speculation
through	I-Speculation
the	I-Speculation
NRE	I-Speculation
gamma	I-Speculation
site	I-Speculation
.	O

The	O
ability	O
of	O
RFX1	O
to	O
transactivate	O
the	O
core	O
promoter	O
raises	O
the	O
possibility	O
that	O
RFX1	O
may	O
play	O
a	O
dual	O
role	O
in	O
regulating	O
HBV	O
gene	O
expression	O
.	O

Differentiation-dependent	O
expression	O
of	O
a	O
human	O
carboxylesterase	O
in	O
monocytic	O
cells	O
and	O
transcription	O
factor	O
binding	O
to	O
the	O
promoter	O
.	O

Carboxylesterases	O
play	O
an	O
important	O
role	O
in	O
defense	O
and	O
clearance	O
mechanisms	O
of	O
the	O
monocyte/macrophage	O
system	O
.	O

During	O
the	O
differentiation	O
process	O
of	O
cells	O
from	O
the	O
monocytic	O
cell	O
line	O
THP-1	O
we	O
observed	O
a	O
transient	O
transcriptional	O
upregulation	O
of	O
a	O
human	O
carboxylesterase	O
analyzed	O
by	O
means	O
of	O
Northern	O
blots	O
.	O

In	O
PMA-treated	O
THP-1	O
cells	O
we	O
could	O
detect	O
three	O
major	O
transcription	O
initiation	O
sites	O
as	O
revealed	O
by	O
Nuclease	O
Protection	O
Assay	O
carried	O
out	O
with	O
two	O
overlapping	O
antisense	O
RNA	O
probes	O
.	O

We	O
have	O
recently	O
cloned	O
the	O
carboxylesterase	O
upstream	O
sequence	O
and	O
showed	O
its	O
basal	O
promoter	O
activity	O
in	O
CHO	O
cells	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
analysis	O
we	O
demonstrated	O
that	O
the	O
promoter	O
region	O
spanning	O
base	O
pairs	O
-1	O
to	O
-275	O
,	O
which	O
contains	O
several	O
putative	B-Speculation
binding	I-Speculation
sites	I-Speculation
for	I-Speculation
transcription	I-Speculation
factors	I-Speculation
,	O
is	O
bound	O
by	O
nuclear	O
factors	O
Sp1	O
and	O
IRBP	O
but	O
not	B-Negation
by	I-Negation
C/EBPs	I-Negation
.	O

Taken	O
together	O
these	O
data	O
indicate	O
that	O
carboxylesterase	O
gene	O
transcription	O
in	O
THP-1	O
cells	O
starts	O
at	O
multiple	O
initiation	O
sites	O
and	O
that	O
Sp1	O
and	O
IRBP	O
may	O
be	O
critical	O
factors	O
for	O
modulating	O
the	O
differentiation-dependent	O
transcription	O
of	O
this	O
human	O
carboxylesterase	O
gene	O
.	O

Characterization	O
of	O
the	O
human	O
platelet/endothelial	O
cell	O
adhesion	O
molecule-1	O
promoter	O
:	O
identification	O
of	O
a	O
GATA-2	O
binding	O
element	O
required	O
for	O
optimal	O
transcriptional	O
activity	O
.	O

Platelet/endothelial	O
cell	O
adhesion	O
molecule-1	O
(	O
PECAM-1	O
)	O
is	O
a	O
130-kD	O
member	O
of	O
the	O
Ig	O
gene	O
superfamily	O
that	O
is	O
expressed	O
on	O
platelets	O
,	O
endothelial	O
cells	O
,	O
and	O
certain	O
leukocyte	O
subsets	O
.	O

To	O
examine	O
the	O
factors	O
controlling	O
vascular-specific	O
expression	O
of	O
PECAM-1	O
,	O
we	O
cloned	O
the	O
5'-flanking	O
region	O
of	O
the	O
PECAM-1	O
gene	O
and	O
analyzed	O
its	O
transcriptional	O
activity	O
.	O

5'-Rapid	O
amplification	O
of	O
cDNA	O
ends	O
(	O
5'-RACE	O
)	O
analysis	O
showed	O
that	O
transcription	O
initiation	O
occurred	O
at	O
several	O
closely	O
spaced	O
nearby	O
sites	O
originating	O
approximately	O
204	O
bp	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
.	O

Analysis	O
of	O
the	O
sequence	O
immediately	O
upstream	O
from	O
the	O
transcription	O
initiation	O
site	O
(	O
TIS	O
)	O
showed	O
no	B-Negation
canonical	I-Negation
TATA	I-Negation
or	I-Negation
CAAT	I-Negation
elements	I-Negation
,	O
however	O
an	O
initiator	O
element	O
commonly	O
found	O
in	O
TATA-less	O
promoters	O
encompassed	O
the	O
TIS	O
.	O

5'-serially	O
truncated	O
PECAM-1	O
promoter	O
segments	O
cloned	O
in	O
front	O
of	O
a	O
luciferase	O
reporter	O
drove	O
transcription	O
in	O
both	O
a	O
lineage-	O
and	O
orientation-specific	O
manner	O
.	O

Putative	O
cis-acting	O
control	O
elements	O
present	O
within	O
a	O
300-bp	O
core	O
promoter	O
included	O
two	O
ets	O
sites	O
,	O
an	O
Sp1	O
site	O
,	O
tandem	O
E-box	O
domains	O
,	O
two	O
GATA-associated	O
sites	O
(	O
CACCC	O
)	O
,	O
an	O
AP-2	O
binding	O
site	O
,	O
and	O
a	O
GATA	O
element	O
at	O
-24	O
.	O

Mutational	O
analysis	O
showed	O
that	O
optimal	O
transcriptional	O
activity	O
required	O
the	O
GATA	O
sequence	O
at	O
position	O
-24	O
,	O
and	O
gel-shift	O
assays	O
further	O
showed	O
that	O
the	O
GATA-2	O
transcription	O
factor	O
,	O
but	O
not	B-Negation
GATA-1	I-Negation
,	O
bound	O
to	O
this	O
region	O
of	O
the	O
PECAM-1	O
promoter	O
.	O

Understanding	O
the	O
cis-	O
and	O
transacting	O
factors	O
that	O
regulate	O
the	O
tissue-specific	O
expression	O
of	O
PECAM-1	O
should	O
increase	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
vascular-specific	O
gene	O
expression	O
is	O
achieved	O
.	O

Cloning	O
of	O
the	O
novel	O
human	O
myeloid-cell-specific	O
C/EBP-epsilon	O
transcription	O
factor	O
.	O

Chicken	O
NF-M	O
transcription	O
factor	O
,	O
in	O
cooperation	O
with	O
either	O
c-Myb	O
or	O
v-Myb	O
,	O
is	O
active	O
in	O
the	O
combinatorial	O
activation	O
of	O
myeloid-cell-specific	O
genes	O
in	O
heterologous	O
cell	O
types	O
,	O
such	O
as	O
embryonic	O
fibroblasts	O
.	O

In	O
humans	O
,	O
similar	O
effects	O
were	O
observed	O
with	O
homologous	O
members	O
of	O
the	O
CCAAT/enhancer-binding	O
protein	O
(	O
C/EBP	O
)	O
family	O
of	O
transcriptional	O
regulators	O
,	O
especially	O
the	O
human	O
homolog	O
of	O
chicken	O
NF-M	O
,	O
C/EBP-beta	O
(	O
NF-IL6	O
)	O
.	O

However	O
,	O
the	O
NF-IL6	O
gene	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
nonmyeloid	O
cell	O
types	O
and	O
is	O
strongly	O
inducible	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
making	O
it	O
an	O
unlikely	O
candidate	O
to	O
have	O
an	O
exclusive	O
role	O
as	O
a	O
combinatorial	O
differentiation	O
switch	O
during	O
myelopoiesis	O
in	O
human	O
cells	O
.	O

By	O
using	O
a	O
reverse	O
transcription-PCR-based	O
approach	O
and	O
a	O
set	O
of	O
primers	O
specific	O
for	O
the	O
DNA-binding	O
domains	O
of	O
highly	O
homologous	O
members	O
of	O
the	O
C/EBP	O
family	O
of	O
transcriptional	O
regulators	O
,	O
we	O
have	O
cloned	O
a	O
novel	O
human	O
gene	O
encoding	O
a	O
member	O
of	O
the	O
C/EBP	O
gene	O
family	O
,	O
identified	O
as	O
the	O
human	O
homolog	O
of	O
CRP1	O
,	O
C/EBP-epsilon	O
.	O

A	O
1.2-kb	O
cDNA	O
encoding	O
full-length	O
human	O
C/EBP-epsilon	O
was	O
cloned	O
from	O
a	O
promyelocyte-late	O
myeloblast-derived	O
lambda	O
gt11	O
library	O
.	O

Molecular	O
analysis	O
of	O
the	O
cDNA	O
and	O
genomic	O
clones	O
indicated	O
the	O
presence	O
of	O
two	O
exons	O
encoding	O
a	O
protein	O
with	O
an	O
apparent	O
molecular	O
mass	O
of	O
32	O
kDa	O
and	O
a	O
pI	O
of	O
9.5	O
.	O

Primer	O
extension	O
analysis	O
of	O
C/EBP-epsilon	O
mRNA	O
detected	O
a	O
single	O
major	O
transcription	O
start	O
site	O
approximately	O
200	O
bp	O
upstream	O
of	O
the	O
start	O
codon	O
.	O

The	O
putative	O
promoter	O
area	O
is	O
similar	O
to	O
those	O
of	O
several	O
other	O
myeloid-cell-specific	O
genes	O
in	O
that	O
it	O
contains	O
no	B-Negation
TATAAA	I-Negation
box	I-Negation
but	O
has	O
a	O
number	O
of	O
purine-rich	O
stretches	O
with	O
multiple	O
sites	O
for	O
the	O
factors	O
of	O
the	O
Ets	O
family	O
of	O
transcriptional	O
regulators	O
.	O

Northern	O
blot	O
analyses	O
indicated	O
a	O
highly	O
restricted	O
mRNA	O
expression	O
pattern	O
,	O
with	O
the	O
strongest	O
expression	O
occurring	O
in	O
promyelocyte	O
and	O
late-myeloblast-like	O
cell	O
lines	O
.	O

Western	O
blot	O
and	O
immunoprecipitation	O
studies	O
using	O
rabbit	O
anti-C/EBP-epsilon	O
antibodies	O
raised	O
against	O
the	O
N-terminal	O
portion	O
of	O
C/EBP-epsilon	O
(	O
amino	O
acids	O
1	O
to	O
115	O
)	O
showed	O
that	O
C/EBP-epsilon	O
is	O
a	O
32-kDa	O
nuclear	O
phosphoprotein	O
.	O

The	O
human	O
C/EBP-epsilon	O
protein	O
exhibited	O
strong	O
and	O
specific	O
binding	O
to	O
double-stranded	O
DNA	O
containing	O
consensus	O
C/EBP	O
sites	O
.	O

Cotransfection	O
of	O
the	O
C/EBP-epsilon	O
sense	O
and	O
antisense	O
expression	O
constructs	O
together	O
with	O
chloramphenicol	O
acetyltransferase	O
reporter	O
vectors	O
containing	O
myeloid-cell-specific	O
c-mim	O
and	O
human	O
myeloperoxidase	O
promoters	O
suggested	O
a	O
role	O
for	O
C/EBP-epsilon	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
a	O
subset	O
of	O
myeloid-cell-specific	O
genes	O
.	O

Transient	O
tranfection	O
of	O
a	O
promyelocyte	O
cell	O
line	O
(	O
NB4	O
)	O
with	O
a	O
C/EBP-epsilon	O
expression	O
plasmid	O
increased	O
cell	O
growth	O
by	O
sevenfold	O
,	O
while	O
antisense	O
C/EBP-epsilon	O
caused	O
a	O
fivefold	O
decrease	O
in	O
clonal	O
growth	O
of	O
these	O
cells	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
ferritin	O
heavy-chain	O
gene	O
:	O
the	O
activity	O
of	O
the	O
CCAAT	O
binding	O
factor	O
NF-Y	O
is	O
modulated	O
in	O
heme-treated	O
Friend	O
leukemia	O
cells	O
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

The	O
ferritin	O
H-chain	O
gene	O
promoter	O
regulation	O
was	O
analyzed	O
in	O
heme-treated	O
Friend	O
leukemia	O
cells	O
(	O
FLCs	O
)	O
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

In	O
the	O
majority	O
of	O
cell	O
lines	O
studied	O
,	O
the	O
regulation	O
of	O
ferritin	O
expression	O
was	O
exerted	O
mostly	O
at	O
the	O
translational	O
level	O
.	O

However	O
,	O
in	O
differentiating	O
erythroid	O
cells	O
,	O
which	O
must	O
incorporate	O
high	O
levels	O
of	O
iron	O
to	O
sustain	O
hemoglobin	O
synthesis	O
,	O
and	O
in	O
macrophages	O
,	O
which	O
are	O
involved	O
in	O
iron	O
storage	O
,	O
transcriptional	O
regulation	O
seemed	O
to	O
be	O
a	O
relevant	O
mechanism	O
.	O

We	O
show	O
here	O
that	O
the	O
minimum	O
region	O
of	O
the	O
ferritin	O
H-gene	O
promoter	O
that	O
is	O
able	O
to	O
confer	O
transcriptional	O
regulation	O
by	O
heme	O
in	O
FLCs	O
to	O
a	O
reporter	O
gene	O
is	O
77	O
nucleotides	O
upstream	O
of	O
the	O
TATA	O
box	O
.	O

This	O
cis	O
element	O
binds	O
a	O
protein	O
complex	O
referred	O
to	O
as	O
HRF	O
(	O
heme-responsive	O
factor	O
)	O
,	O
which	O
is	O
greatly	O
enhanced	O
both	O
in	O
heme-treated	O
FLCs	O
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

The	O
CCAAT	O
element	O
present	O
in	O
reverse	O
orientation	O
in	O
this	O
promoter	O
region	O
of	O
the	O
ferritin	O
H-chain	O
gene	O
is	O
necessary	O
for	O
binding	O
and	O
for	O
gene	O
activity	O
,	O
since	O
a	O
single	O
point	O
mutation	O
is	O
able	O
to	O
abolish	O
the	O
binding	O
of	O
HRF	O
and	O
the	O
transcriptional	O
activity	O
in	O
transfected	O
cells	O
.	O

By	O
competition	O
experiments	O
and	O
supershift	O
assays	O
,	O
we	O
identified	O
the	O
induced	O
HRF	O
as	O
containing	O
at	O
least	O
the	O
ubiquitous	O
transcription	O
factor	O
NF-Y	O
.	O

NF-Y	O
is	O
formed	O
by	O
three	O
subunits	O
,	O
A	O
,	O
B	O
,	O
and	O
C	O
,	O
all	O
of	O
which	O
are	O
necessary	O
for	O
DNA	O
binding	O
.	O

Cotransfection	O
with	O
a	O
transdominant	O
negative	O
mutant	O
of	O
the	O
NF-YA	O
subunit	O
abolishes	O
the	O
transcriptional	O
activation	O
by	O
heme	O
,	O
indicating	O
that	O
NF-Y	O
plays	O
an	O
essential	O
role	O
in	O
this	O
activation	O
.	O

We	O
have	O
also	O
observed	O
a	O
differential	O
expression	O
of	O
the	O
NF-YA	O
subunit	O
in	O
heme-treated	O
and	O
control	O
FLCs	O
and	O
during	O
monocyte-to-macrophage	O
differentiation	O
.	O

Characterization	O
of	O
a	O
mutant	O
cell	O
line	O
that	O
does	O
not	B-Negation
activate	I-Negation
NF-kappaB	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
multiple	I-Negation
stimuli	I-Negation
.	O

Numerous	O
genes	O
required	O
during	O
the	O
immune	O
or	O
inflammation	O
response	O
as	O
well	O
as	O
the	O
adhesion	O
process	O
are	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
.	O

Associated	O
with	O
its	O
inhibitor	O
,	O
I	O
kappaB	O
,	O
NF-kappaB	O
resides	O
as	O
an	O
inactive	O
form	O
in	O
the	O
cytoplasm	O
.	O

Upon	O
stimulation	O
by	O
various	O
agents	O
,	O
I	O
kappaB	O
is	O
proteolyzed	O
and	O
NF-kappaB	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
activates	O
its	O
target	O
genes	O
.	O

The	O
transduction	O
pathways	O
that	O
lead	O
to	O
I	O
kappaB	O
inactivation	O
remain	O
poorly	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
cellular	O
mutant	O
,	O
the	O
70/Z3-derived	O
1.3E2	O
murine	O
pre-B	O
cell	O
line	O
,	O
that	O
does	O
not	B-Negation
activate	I-Negation
NF-kappaB	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
several	I-Negation
stimuli	I-Negation
.	O

We	O
demonstrate	O
that	O
upon	O
stimulation	O
by	O
lipopolysaccharide	O
,	O
Taxol	O
,	O
phorbol	O
myristate	O
acetate	O
,	O
interleukin-1	O
,	O
or	O
double-stranded	O
RNA	O
,	O
I	B-Negation
kappaB	I-Negation
alpha	I-Negation
is	I-Negation
not	I-Negation
degraded	I-Negation
,	O
as	O
a	O
result	O
of	O
an	O
absence	B-Negation
of	I-Negation
induced	I-Negation
phosphorylation	I-Negation
on	I-Negation
serines	I-Negation
32	I-Negation
and	I-Negation
36	I-Negation
.	O

Neither	B-Negation
a	I-Negation
mutation	I-Negation
in	I-Negation
I	I-Negation
kappaB	I-Negation
alpha	I-Negation
nor	I-Negation
a	I-Negation
mutation	I-Negation
in	I-Negation
p50	I-Negation
or	I-Negation
relA	I-Negation
,	I-Negation
the	I-Negation
two	I-Negation
major	I-Negation
subunits	I-Negation
of	I-Negation
NF-kappaB	I-Negation
in	I-Negation
this	I-Negation
cell	I-Negation
line	I-Negation
,	I-Negation
accounts	I-Negation
for	I-Negation
this	I-Negation
phosphorylation	I-Negation
defect	I-Negation
.	O

As	O
well	O
as	O
culminating	O
in	O
the	O
inducible	O
phosphorylation	O
of	O
I	O
kappaB	O
alpha	O
on	O
serines	O
32	O
and	O
36	O
,	O
all	O
the	O
stimuli	O
that	O
are	O
inactive	O
on	O
1.3E2	O
cells	O
exhibit	O
a	O
sensitivity	O
to	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
.	O

In	O
contrast	O
,	O
stimuli	O
such	O
as	O
hyperosmotic	O
shock	O
or	O
phosphatase	O
inhibitors	O
,	O
which	O
use	O
PDTC-insensitive	O
pathways	O
,	O
induce	O
I	O
kappaB	O
alpha	O
degradation	O
in	O
1.3E2	O
.	O

Analysis	O
of	O
the	O
redox	O
status	O
of	O
1.3E2	O
does	O
not	B-Negation
reveal	I-Negation
any	I-Negation
difference	I-Negation
from	I-Negation
wild-type	I-Negation
70Z/3	I-Negation
.	O

We	O
also	O
report	O
that	O
the	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-derived	O
Tax	O
trans-activator	O
induces	O
NF-kappaB	O
activity	O
in	O
1.3E2	O
,	O
suggesting	O
that	O
this	O
viral	O
protein	O
does	O
not	O
operate	O
via	O
the	O
defective	O
pathway	O
.	O

Finally	O
,	O
we	O
show	O
that	O
two	B-Negation
other	I-Negation
I	I-Negation
kappaB	I-Negation
molecules	I-Negation
,	I-Negation
I	I-Negation
kappaB	I-Negation
beta	I-Negation
and	I-Negation
the	I-Negation
recently	I-Negation
identified	I-Negation
I	I-Negation
kappaB	I-Negation
epsilon	I-Negation
,	I-Negation
are	I-Negation
not	I-Negation
degraded	I-Negation
in	I-Negation
the	I-Negation
1.3E2	I-Negation
cell	I-Negation
line	I-Negation
following	I-Negation
stimulation	I-Negation
.	O

Our	O
results	O
demonstrate	O
that	O
1.3E2	O
is	O
a	O
cellular	O
transduction	O
mutant	O
exhibiting	O
a	O
defect	O
in	O
a	O
step	O
that	O
is	O
required	O
by	O
several	O
different	O
stimuli	O
to	O
activate	O
NF-kappaB	O
.	O

In	O
addition	O
,	O
this	O
analysis	O
suggests	O
a	O
common	O
step	O
in	O
the	O
signaling	O
pathways	O
that	O
trigger	O
I	O
kappaB	O
alpha	O
,	O
I	O
kappaB	O
beta	O
,	O
and	O
I	O
kappaB	O
epsilon	O
degradation	O
.	O

Transcription	O
mediated	O
by	O
NFAT	O
is	O
highly	O
inducible	O
in	O
effector	O
CD4+	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
but	O
not	B-Negation
in	I-Negation
Th1	I-Negation
cells	I-Negation
.	O

Transcriptional	O
factors	O
of	O
the	O
NFAT	O
family	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
several	O
cytokine	O
genes	O
during	O
the	O
immune	O
response	O
,	O
such	O
as	O
the	O
genes	O
for	O
interleukin	O
2	O
(	O
IL-2	O
)	O
and	O
IL-4	O
,	O
among	O
others	O
.	O

Upon	O
antigen	O
stimulation	O
,	O
precursor	O
CD4+	O
T	O
helper	O
(	O
pTh	O
)	O
cells	O
proliferate	O
and	O
differentiate	O
into	O
two	O
populations	O
of	O
effector	O
cells	O
(	O
eTh1	O
and	O
eTh2	O
)	O
,	O
each	O
one	O
expressing	O
a	O
specific	O
pattern	O
of	O
cytokines	O
that	O
distinguishes	O
them	O
from	O
their	O
precursors	O
.	O

eTh2	O
cells	O
are	O
the	O
major	O
source	O
of	O
IL-4	O
,	O
while	O
gamma	O
interferon	O
is	O
produced	O
by	O
eTh1	O
cells	O
.	O

Here	O
we	O
have	O
used	O
reporter	O
transgenic	O
mice	O
to	O
show	O
that	O
DNA	O
binding	O
and	O
transcriptional	O
activities	O
of	O
NFAT	O
are	O
transiently	O
induced	O
during	O
the	O
differentiation	O
of	O
pTh	O
cells	O
into	O
either	O
eTh1	O
or	O
eTh2	O
cells	O
to	O
mediate	O
the	O
expression	O
of	O
IL-2	O
as	O
a	O
common	O
growth	O
factor	O
in	O
both	O
pathways	O
.	O

However	O
,	O
although	O
NFAT	O
DNA	O
binding	O
is	O
similarly	O
induced	O
in	O
both	O
eTh1	O
and	O
eTh2	O
cells	O
upon	O
antigen	O
stimulation	O
,	O
only	O
the	O
NFAT	O
complexes	O
present	O
in	O
eTh2	O
cells	O
are	O
able	O
to	O
mediate	O
high-level	O
transcription	O
,	O
and	O
relatively	O
little	O
NFAT	O
transcriptional	O
activity	O
was	O
induced	O
in	O
eTh1	O
cells	O
.	O

In	O
contrast	O
to	O
activated	O
pTh	O
cells	O
,	O
neither	B-Negation
eTh1	I-Negation
nor	I-Negation
eTh2	I-Negation
cells	I-Negation
produced	I-Negation
significant	I-Negation
IL-2	I-Negation
upon	I-Negation
stimulation	I-Negation
,	O
but	O
the	O
high	O
levels	O
of	O
NFAT	O
transcriptional	O
activities	O
directly	O
correlate	O
with	O
the	O
IL-4	O
production	O
induced	O
in	O
response	O
to	O
antigen	O
stimulation	O
in	O
eTh2	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
activated	O
NFAT	O
is	O
involved	O
in	O
the	O
effector	O
function	O
of	O
eTh2	O
cells	O
and	O
that	O
the	O
failure	O
of	O
eTh1	O
cells	O
to	O
produce	O
IL-4	O
in	O
response	O
to	O
an	O
antigen	O
is	O
due	O
,	O
at	O
least	O
partially	O
,	O
to	O
a	O
failure	O
to	O
induce	O
high-level	O
transcription	O
of	O
the	O
IL-4	O
gene	O
by	O
NFAT	O
.	O

Regulation	O
of	O
NFAT	O
could	O
be	O
therefore	O
a	O
critical	O
element	O
in	O
the	O
polarization	O
to	O
eTh1	O
or	O
eTh2	O
.	O

Constitutive	O
expression	O
of	O
p50	O
homodimer	O
in	O
freshly	O
isolated	O
human	O
monocytes	O
decreases	O
with	O
in	O
vitro	O
and	O
in	O
vivo	O
differentiation	O
:	O
a	O
possible	O
mechanism	O
influencing	O
human	O
immunodeficiency	O
virus	O
replication	O
in	O
monocytes	O
and	O
mature	O
macrophages	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replicates	O
more	O
efficiently	O
in	O
vitro	O
in	O
differentiated	O
macrophages	O
than	O
in	O
freshly	O
isolated	O
monocytes	O
.	O

We	O
investigated	O
whether	O
this	O
may	O
be	O
partly	O
explained	O
by	O
changes	O
in	O
expression	O
of	O
NF-kappaB	O
with	O
monocyte	O
differentiation	O
.	O

We	O
demonstrated	O
that	O
constitutive	O
expression	O
of	O
NF-kappaB	O
in	O
primary	O
human	O
monocytes	O
changed	O
significantly	O
with	O
differentiation	O
in	O
vitro	O
to	O
monocyte-derived	O
macrophages	O
(	O
MDMs	O
)	O
and	O
differentiation	O
in	O
vivo	O
to	O
alveolar	O
macrophages	O
(	O
AMs	O
)	O
.	O

Freshly	O
isolated	O
monocytes	O
constitutively	O
expressed	O
high	O
levels	O
of	O
transcriptionally	O
inactive	O
p50	O
homodimer	O
which	O
decreased	O
with	O
time	O
in	O
culture	O
in	O
favor	O
of	O
the	O
transcriptionally	O
active	O
p50/p65	O
and	O
p50/RelB	O
heterodimers	O
.	O

As	O
in	O
MDMs	O
,	O
AMs	O
constitutively	O
expressed	O
p50/p65	O
and	O
p50/RelB	O
although	O
at	O
lower	O
levels	O
.	O

HIV	O
infection	O
of	O
fresh	O
monocytes	O
failed	B-Negation
to	I-Negation
induce	I-Negation
p50/p65	I-Negation
as	I-Negation
seen	I-Negation
in	I-Negation
MDMs	I-Negation
.	O

The	O
replacement	O
of	O
p50	O
homodimers	O
with	O
transcriptionally	O
active	O
heterodimers	O
following	O
time	O
in	O
culture	O
may	O
partially	O
explain	O
the	O
progressive	O
increase	O
in	O
susceptibility	O
of	O
monocytes	O
to	O
HIV	O
infection	O
during	O
in	O
vitro	O
culture	O
.	O

The	O
change	O
in	O
NF-kappaB	O
components	O
with	O
monocyte	O
differentiation	O
in	O
vivo	O
may	O
also	O
explain	O
the	O
different	O
transcriptional	O
activities	O
of	O
these	O
cell	O
populations	O
in	O
HIV-infected	O
individuals	O
.	O

Identification	O
of	O
nucleotide	O
sequences	O
that	O
regulate	O
transcription	O
of	O
the	O
MCF13	O
murine	O
leukemia	O
virus	O
long	O
terminal	O
repeat	O
in	O
activated	O
T	O
cells	O
.	O

The	O
region	O
downstream	O
of	O
the	O
enhancer	O
(	O
DEN	O
)	O
of	O
the	O
long	O
terminal	O
repeat	O
of	O
the	O
mink	O
cell	O
focus-forming	O
murine	O
leukemia	O
virus	O
is	O
important	O
for	O
viral	O
pathogenicity	O
.	O

Another	O
important	O
activity	O
of	O
DEN	O
is	O
its	O
control	O
of	O
transcription	O
in	O
activated	O
T	O
cells	O
,	O
and	O
we	O
have	O
determined	O
that	O
an	O
NF-kappaB	O
site	O
is	O
critical	O
for	O
this	O
activity	O
.	O

Activation	O
of	O
the	O
NF-kappaB	O
transcription	O
factor	O
in	O
a	O
T-lymphocytic	O
cell	O
line	O
by	O
hypochlorous	O
acid	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
such	O
as	O
hydrogen	O
peroxide	O
serve	O
as	O
second	O
messengers	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
,	O
and	O
hence	O
in	O
the	O
activation	O
and	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
in	O
human	O
cells	O
.	O

During	O
inflammatory	O
reactions	O
,	O
many	O
oxidative	O
species	O
are	O
produced	O
,	O
one	O
of	O
which	O
is	O
hypochlorous	O
acid	O
(	O
HOCl	O
)	O
,	O
which	O
is	O
responsible	O
for	O
the	O
microbicidal	O
effects	O
of	O
activated	O
human	O
polymorphonuclear	O
leukocytes	O
.	O

Treatment	O
of	O
a	O
T-lymphocytic	O
cell	O
line	O
with	O
micromolar	O
concentrations	O
of	O
HOCl	O
promoted	O
the	O
appearance	O
of	O
transcription	O
factor	O
NF-kappaB	O
(	O
the	O
heterodimer	O
p50/p65	O
)	O
in	O
the	O
nucleus	O
of	O
the	O
cells	O
,	O
even	O
in	O
the	O
absence	B-Negation
of	I-Negation
de	I-Negation
novo	I-Negation
protein	I-Negation
synthesis	I-Negation
.	O

Western	O
blot	O
analysis	O
of	O
the	O
NF-kappaB	O
inhibitory	O
subunits	O
(	O
IkappaB	O
)	O
demonstrated	O
that	O
both	O
IkappaB-alpha	O
proteolysis	O
and	O
p105	O
processing	O
were	O
induced	O
by	O
the	O
treatment	O
.	O

NF-kappaB	O
activation	O
was	O
very	O
effective	O
when	O
cells	O
were	O
subjected	O
to	O
hyperthermia	O
before	O
being	O
treated	O
with	O
HOCl	O
.	O

Various	O
antioxidants	O
,	O
such	O
as	O
pyrrolidine	O
dithiocarbamate	O
,	O
p-bromophenacyl-bromide	O
and	O
nordihydroguaiaretic	O
acid	O
could	O
strongly	O
reduce	O
NF-kappaB	O
translocation	O
,	O
demonstrating	O
the	O
importance	O
of	O
oxidative	O
species	O
in	O
the	O
transduction	O
mechanism	O
.	O

Moreover	O
,	O
ACH-2	O
cells	O
treated	O
with	O
HOCl	O
or	O
H2O2	O
released	O
tumour	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
in	O
the	O
supernatants	O
.	O

The	O
importance	O
of	O
TNF-alpha	O
release	O
in	O
NF-kappaB	O
induction	O
by	O
HOCl	O
or	O
H2O2	O
was	O
demonstrated	O
by	O
the	O
fact	O
that	O
:	O
(	O
1	O
)	O
the	O
nuclear	O
appearance	O
of	O
NF-kappaB	O
was	O
promoted	O
in	O
untreated	O
cells	O
;	O
and	O
(	O
2	O
)	O
synergism	O
between	O
TNF-alpha	O
and	O
HOCl	O
was	O
detected	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
HOCl	O
should	O
be	O
considered	O
as	O
an	O
oxidative	O
species	O
capable	O
of	O
inducing	O
NF-kappaB	O
in	O
a	O
T-lymphocytic	O
cell	O
line	O
through	O
a	O
transduction	O
mechanism	O
involving	O
ROS	O
,	O
and	O
having	O
a	O
long-distance	O
effect	O
through	O
subsequent	O
TNF-alpha	O
release	O
.	O

Thymocytes	O
control	O
the	O
CD4	O
gene	O
differently	O
from	O
mature	O
T	O
lymphocytes	O
.	O

We	O
analyzed	O
the	O
activity	O
of	O
the	O
enhancer	O
,	O
the	O
promoter	O
and	O
the	O
silencer	O
of	O
the	O
human	O
CD4	O
gene	O
during	O
T	O
cell	O
development	O
using	O
transgenic	O
mice	O
.	O

Immunofluorescence	O
studies	O
on	O
thymic	O
populations	O
of	O
mice	O
carrying	O
transgenes	O
in	O
various	O
combinations	O
of	O
these	O
regulatory	O
DNA	O
elements	O
revealed	O
that	O
thymocytes	O
control	O
the	O
CD4	O
gene	O
in	O
a	O
different	O
manner	O
than	O
mature	O
peripheral	O
T	O
lymphocytes	O
.	O

The	O
5'-positive	O
regulatory	O
unit	O
,	O
consisting	O
of	O
the	O
promoter	O
and	O
the	O
5	O
'	O
enhancer	O
,	O
is	O
already	O
active	O
at	O
the	O
CD4-CD8-double-negative	O
(	O
DN	O
)	O
stage	O
of	O
development	O
.	O

However	O
,	O
its	O
activity	O
becomes	O
lower	O
in	O
the	O
double-positive	O
and	O
a	O
fraction	O
of	O
the	O
CD4+	O
CD8int/-	O
cell	O
population	O
,	O
indicating	O
that	O
an	O
additional	O
enhancer	O
,	O
located	O
in	O
either	O
the	O
first	O
or	O
the	O
third	O
intron	O
of	O
the	O
CD4	O
gene	O
,	O
is	O
required	O
for	O
CD4	O
gene	O
expression	O
in	O
this	O
population	O
.	O

The	O
other	O
studied	O
regulatory	O
element	O
is	O
the	O
minimal	O
CD4	O
silencer	O
which	O
inhibits	O
CD4	O
gene	O
expression	O
in	O
peripheral	O
CD8	O
T	O
lymphocytes	O
.	O

This	O
silencer	O
is	O
inactive	O
in	O
the	O
most	O
immature	O
DN	O
thymocytes	O
,	O
which	O
probably	O
use	O
a	O
distinct	O
silencer	O
mechanism	O
to	O
down-regulate	O
CD4	O
gene	O
expression	O
.	O

Unexpectedly	O
,	O
the	O
CD4	O
silencer	O
is	O
also	O
active	O
in	O
CD4+	O
CD8int/-	O
cells	O
of	O
the	O
thymus	O
,	O
implying	O
that	O
an	O
anti-silencer	O
may	O
be	O
required	O
to	O
resume	O
CD4	O
expression	O
in	O
this	O
cell	O
population	O
.	O

Altogether	O
,	O
the	O
CD4	O
gene	O
is	O
regulated	O
by	O
several	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
which	O
come	O
into	O
play	O
in	O
a	O
developmentally	O
coordinated	O
manner	O
.	O

Immune	O
hyperactivation	O
of	O
HIV-1-infected	O
T	O
cells	O
mediated	O
by	O
Tat	O
and	O
the	O
CD28	O
pathway	O
.	O

Human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
characterized	O
by	O
a	O
chronic	O
state	O
of	O
immune	O
hyperactivation	O
in	O
patients	O
.	O

Infection	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
with	O
HIV-1	O
in	O
vitro	O
resulted	O
in	O
increased	O
interleukin-2	O
(	O
IL-2	O
)	O
secretion	O
in	O
response	O
to	O
T	O
cell	O
activation	O
via	O
the	O
CD3	O
and	O
CD28	O
receptors	O
.	O

Expression	O
of	O
the	O
HIV-1	O
transactivator	O
Tat	O
recapitulated	O
this	O
phenotype	O
and	O
was	O
associated	O
with	O
increased	O
IL-2	O
secretion	O
in	O
response	O
to	O
costimulation	O
with	O
CD3	O
plus	O
CD28	O
.	O

IL-2	O
superinduction	O
by	O
Tat	O
occurred	O
at	O
the	O
transcriptional	O
level	O
,	O
was	O
mediated	O
by	O
the	O
CD28-responsive	O
element	O
in	O
the	O
IL-2	O
promoter	O
,	O
and	O
was	O
exclusively	O
dependent	O
on	O
the	O
29	O
amino	O
acids	O
encoded	O
by	O
the	O
second	O
exon	O
of	O
Tat	O
.	O

c-Rel	O
is	O
a	O
target	O
of	O
pentoxifylline-mediated	O
inhibition	O
of	O
T	O
lymphocyte	O
activation	O
.	O

The	O
possible	O
clinical	O
use	O
of	O
the	O
methyl	O
xanthine	O
derivative	O
,	O
pentoxifylline	O
(	O
PF	O
)	O
,	O
for	O
the	O
treatment	O
of	O
T	O
cell-dependent	O
diseases	O
is	O
being	O
noted	O
with	O
increasing	O
interest	O
.	O

In	O
this	O
paper	O
,	O
we	O
studied	O
the	O
molecular	O
consequences	O
of	O
PF	O
treatment	O
during	O
lymphocyte	O
activation	O
.	O

We	O
found	O
that	O
in	O
T	O
cells	O
,	O
anti-CD3-induced	O
c-Rel	O
expression	O
was	O
blocked	O
by	O
PF	O
,	O
whereas	O
the	O
induction	O
of	O
other	O
NF-kappaB	O
family	O
members	O
was	O
not	O
significantly	O
affected	O
.	O

However	O
,	O
induction	B-Negation
of	I-Negation
NF-AT	I-Negation
,	I-Negation
which	I-Negation
has	I-Negation
the	I-Negation
same	I-Negation
signaling	I-Negation
requirements	I-Negation
as	I-Negation
c-Rel	I-Negation
induction	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
inhibited	I-Negation
by	I-Negation
PF	I-Negation
.	O

Among	O
genes	O
that	O
respond	O
to	O
these	O
transcription	O
factors	O
,	O
IL-2	O
mRNA	O
induction	O
was	O
suppressed	O
by	O
PF	O
,	O
whereas	O
IL-2R	B-Negation
(	I-Negation
alpha	I-Negation
)	I-Negation
chain	I-Negation
mRNA	I-Negation
induction	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
.	O

These	O
observations	O
implicated	O
c-Rel	O
as	O
an	O
IL-2	O
promoter	O
factor	O
,	O
for	O
which	O
experimental	O
support	O
was	O
obtained	O
from	O
transient	O
transfection	O
experiments	O
.	O

In	O
contrast	O
with	O
the	O
observation	O
in	O
T	O
cells	O
,	O
c-Rel	B-Negation
induction	I-Negation
was	I-Negation
not	I-Negation
blocked	I-Negation
by	I-Negation
PF	I-Negation
in	I-Negation
B	I-Negation
cells	I-Negation
.	O

The	O
greater	O
selectivity	O
of	O
PF	O
,	O
compared	O
with	O
FK506	O
,	O
at	O
both	O
the	O
molecular	O
and	O
cellular	O
levels	O
may	O
prove	O
advantageous	O
in	O
manipulating	O
T	O
cell	O
responses	O
in	O
vivo	O
.	O

A	O
T	O
cell-specific	O
enhancer	O
in	O
the	O
interleukin-3	O
locus	O
is	O
activated	O
cooperatively	O
by	O
Oct	O
and	O
NFAT	O
elements	O
within	O
a	O
DNase	O
I-hypersensitive	O
site	O
.	O

Interleukin-3	O
(	O
IL-3	O
)	O
is	O
a	O
cytokine	O
that	O
is	O
expressed	O
primarily	O
in	O
activated	O
T	O
cells	O
.	O

Here	O
we	O
identified	O
an	O
inducible	O
T	O
cell-specific	O
enhancer	O
14	O
kb	O
upstream	O
of	O
the	O
IL-3	O
gene	O
that	O
responded	O
to	O
activation	O
of	O
T	O
cell	O
receptor	O
signaling	O
pathways	O
.	O

The	O
IL-3	O
enhancer	O
spanned	O
an	O
inducible	O
cyclosporin	O
A-sensitive	O
DNase	O
I-hypersensitive	O
site	O
found	O
only	O
in	O
T	O
cells	O
.	O

Four	O
NFAT-like	O
elements	O
exist	O
within	O
the	O
enhancer	O
.	O

The	O
two	O
most	O
active	O
NFAT-like	O
elements	O
were	O
located	O
at	O
the	O
center	O
of	O
the	O
DNase	O
I-hypersensitive	O
site	O
.	O

One	O
of	O
these	O
NFAT-like	O
elements	O
encompassed	O
overlapping	O
Oct-	O
and	O
NFATp/c-binding	O
sites	O
,	O
which	O
functioned	O
in	O
a	O
highly	O
synergistic	O
manner	O
.	O

We	O
suggest	O
that	O
the	O
T	O
cell-specific	O
expression	O
of	O
the	O
IL-3	O
gene	O
is	O
partly	O
controlled	O
through	O
the	O
enhancer	O
by	O
cooperation	O
between	O
Oct	O
and	O
NFAT	O
family	O
proteins	O
.	O

A	O
negative	O
regulatory	O
region	O
containing	O
a	O
glucocorticosteroid	O
response	O
element	O
(	O
nGRE	O
)	O
in	O
the	O
human	O
interleukin-1beta	O
gene	O
.	O

Interleukin-1	O
beta	O
(	O
IL-1beta	O
)	O
is	O
one	O
of	O
the	O
most	O
important	O
inflammatory	O
mediators	O
in	O
human	O
inflammatory	O
and	O
immunological	O
diseases	O
.	O

The	O
regulation	O
of	O
human	O
IL-1beta	O
gene	O
expression	O
has	O
been	O
studied	O
for	O
several	O
years	O
,	O
and	O
a	O
few	O
regulatory	O
elements	O
have	O
been	O
discovered	O
in	O
the	O
promoter	O
region	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
negative	O
regulation	O
of	O
IL-1beta	O
expression	O
at	O
the	O
transcriptional	O
level	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
anti-inflammatory	O
and	O
immunosuppressive	O
effects	O
.	O

We	O
have	O
identified	O
a	O
negative	O
regulatory	O
element	O
located	O
in	O
the	O
region	O
between	O
-685	O
and	O
-395	O
.	O

Within	O
this	O
region	O
,	O
a	O
19-bp	O
nuclear	O
factor	O
binding	O
site	O
(	O
-570	O
to	O
-552	O
)	O
was	O
characterized	O
by	O
DNase	O
I	O
footprinting	O
and	O
electromobility	O
shift	O
assay	O
.	O

A	O
consensus	O
sequence	O
for	O
a	O
negative	O
glucocorticoid	O
response	O
element	O
(	O
nGRE	O
)	O
and	O
a	O
transcription	O
activator	O
protein-2	O
binding	O
site	O
were	O
noted	O
within	O
this	O
footprint	O
.	O

Functional	O
studies	O
showed	O
a	O
2.5-fold	O
increase	O
in	O
promoter	O
activity	O
when	O
this	O
19-bp	O
binding	O
site	O
was	O
deleted	O
in	O
the	O
reporter	O
constructs	O
IL-1beta/CAT	O
and	O
IL-1beta/SV40	O
promoter/CAT	O
.	O

Dexamethasone	O
(	O
10	O
(	O
-8	O
)	O
M	O
)	O
repressed	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
production	O
by	O
75	O
%	O
in	O
the	O
wild-type	O
fragment	O
but	O
not	B-Negation
in	I-Negation
a	I-Negation
deletion	I-Negation
mutant	I-Negation
lacking	I-Negation
the	I-Negation
19-bp	I-Negation
site	I-Negation
.	O

A	O
protein	O
of	O
about	O
150	O
kD	O
that	O
bound	O
to	O
this	O
negative	O
regulatory	O
sequence	O
was	O
identified	O
by	O
UV	O
cross-linking	O
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
negative	O
regulatory	O
region	O
responsive	O
to	O
glucocorticoids	O
in	O
a	O
cytokine	O
gene	O
.	O

TRAMP	O
,	O
a	O
novel	O
apoptosis-mediating	O
receptor	O
with	O
sequence	O
homology	O
to	O
tumor	O
necrosis	O
factor	O
receptor	O
1	O
and	O
Fas	O
(	O
Apo-1/CD95	O
)	O
.	O

A	O
novel	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptor	O
family	O
,	O
designated	O
TRAMP	O
,	O
has	O
been	O
identified	O
.	O

The	O
structural	O
organization	O
of	O
the	O
393	O
amino	O
acid	O
long	O
human	O
TRAMP	O
is	O
most	O
homologous	O
to	O
TNF	O
receptor	O
1	O
.	O

TRAMP	O
is	O
abundantly	O
expressed	O
on	O
thymocytes	O
and	O
lymphocytes	O
.	O

Its	O
extracellular	O
domain	O
is	O
composed	O
of	O
four	O
cysteine-rich	O
domains	O
,	O
and	O
the	O
cytoplasmic	O
region	O
contains	O
a	O
death	O
domain	O
known	O
to	O
signal	O
apoptosis	O
.	O

Overexpression	O
of	O
TRAMP	O
leads	O
to	O
two	O
major	O
responses	O
,	O
NF-kappaB	O
activation	O
and	O
apoptosis	O
.	O

TRAMP-induced	O
cell	O
death	O
is	O
inhibited	O
by	O
an	O
inhibitor	O
of	O
ICE-like	O
proteases	O
,	O
but	O
not	B-Negation
by	I-Negation
Bcl-2	I-Negation
.	O

In	O
addition	O
,	O
TRAMP	B-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
interact	I-Speculation
with	I-Speculation
any	I-Speculation
of	I-Speculation
the	I-Speculation
known	I-Speculation
apoptosis-inducing	I-Speculation
ligands	I-Speculation
of	I-Speculation
the	I-Speculation
TNF	I-Speculation
family	I-Speculation
.	O

Involvement	O
of	O
Egr-1/RelA	O
synergy	O
in	O
distinguishing	O
T	O
cell	O
activation	O
from	O
tumor	O
necrosis	O
factor-alpha-induced	O
NF-kappa	O
B1	O
transcription	O
.	O

NF-kappa	O
B	O
is	O
an	O
important	O
transcription	O
factor	O
required	O
for	O
T	O
cell	O
proliferation	O
and	O
other	O
immunological	O
functions	O
.	O

The	O
NF-kappa	O
B1	O
gene	O
encodes	O
a	O
105-kD	O
protein	O
that	O
is	O
the	O
precursor	O
of	O
the	O
p50	O
component	O
of	O
NF-kappa	O
B	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
demonstrated	O
that	O
NF-kappa	O
B	O
regulates	O
the	O
NF-kappa	O
B1	O
gene	O
.	O

In	O
this	O
manuscript	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
T	O
cell	O
lines	O
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
and	O
phytohemagglutin	O
(	O
PHA	O
)	O
display	O
significantly	O
higher	O
levels	O
of	O
NF-kappa	O
B1	O
encoding	O
transcripts	O
than	O
cells	O
stimulated	O
with	O
tumor	O
necrosis	O
factor-alpha	O
,	O
despite	O
the	O
fact	O
that	O
both	O
stimuli	O
activate	O
NF-kappa	O
B	O
.	O

Characterization	O
of	O
the	O
NF-kappa	O
B1	O
promoter	O
identified	O
an	O
Egr-1	O
site	O
which	O
was	O
found	O
to	O
be	O
essential	O
for	O
both	O
the	O
PMA/PHA-mediated	O
induction	O
as	O
well	O
as	O
the	O
synergistic	O
activation	O
observed	O
after	O
the	O
expression	O
of	O
the	O
RelA	O
subunit	O
of	O
NF-kappa	O
B	O
and	O
Egr-1	O
.	O

Furthermore	O
,	O
Egr-1	O
induction	O
was	O
required	O
for	O
endogenous	O
NF-kappa	O
B1	O
gene	O
expression	O
,	O
since	O
PMA/PHA-stimulated	O
T	O
cell	O
lines	O
expressing	O
antisense	O
Egr-1	O
RNA	O
were	O
inhibited	O
in	O
their	O
ability	O
to	O
upregulate	O
NF-kappa	O
B1	O
transcription	O
.	O

Our	O
studies	O
indicate	O
that	O
transcriptional	O
synergy	O
mediated	O
by	O
activation	O
of	O
both	O
Egr-1	O
and	O
NF-kappa	O
B	O
may	O
have	O
important	O
ramifications	O
in	O
T	O
cell	O
development	O
by	O
upregulating	O
NF-kappa	O
B1	O
gene	O
expression	O
.	O

Differentiation	O
of	O
U-937	O
promonocytic	O
cells	O
by	O
etoposide	O
and	O
ICRF-193	O
,	O
two	O
antitumour	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
with	O
different	O
mechanisms	O
of	O
action	O
.	O

We	O
have	O
compared	O
the	O
action	O
on	O
U-937	O
human	O
promonocytic	O
leukemia	O
cells	O
of	O
two	O
DNA	O
topoisomerase	O
II	O
inhibitors	O
,	O
namely	O
the	O
epipodophyllotoxin	O
etoposide	O
and	O
the	O
bisdioxopiperazine	O
ICRF-193	O
.	O

One	O
hour	O
pulse-treatment	O
with	O
3	O
microM	O
etoposide	O
caused	O
topoisomerase	O
associated	O
,	O
primary	O
DNA	O
breakage	O
,	O
which	O
was	O
rapidly	O
followed	O
by	O
apoptosis	O
.	O

By	O
contrast	O
,	O
these	B-Negation
effects	I-Negation
were	I-Negation
not	I-Negation
observed	I-Negation
upon	I-Negation
pulse-treatment	I-Negation
with	I-Negation
6	I-Negation
microM	I-Negation
ICRF-193	I-Negation
.	O

However	O
,	O
continuous	O
treatments	O
with	O
subcytotoxic	O
concentrations	O
of	O
etoposide	O
(	O
0.15	O
microM	O
)	O
and	O
ICRF-193	O
(	O
0.3	O
microM	O
)	O
produced	O
several	O
similar	O
effects	O
,	O
namely	O
decreased	O
cell	O
proliferation	O
,	O
accumulation	O
of	O
cells	O
at	O
G2	O
,	O
increase	O
in	O
cell	O
mass	O
,	O
and	O
induction	O
of	O
differentiation	O
.	O

Under	O
these	O
conditions	O
,	O
etoposide	O
produced	O
a	O
biphasic	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
consisted	O
in	O
an	O
early	O
transient	O
activation	O
(	O
from	O
hours	O
1	O
to	O
6	O
)	O
of	O
the	O
membrane-bound	O
enzyme	O
followed	O
by	O
a	O
later	O
activation	O
(	O
hour	O
48	O
)	O
of	O
the	O
total	O
,	O
membrane-bound	O
and	O
cytosolic	O
enzyme	O
.	O

By	O
contrast	O
,	O
ICRF-193	O
only	O
provoked	O
a	O
late	O
activation	O
(	O
from	O
hours	O
72	O
to	O
96	O
)	O
of	O
the	O
total	O
enzyme	O
.	O

When	O
used	O
at	O
differentiation-inducing	O
concentrations	O
,	O
both	O
topoisomerase	O
inhibitors	O
caused	O
a	O
great	O
stimulation	O
of	O
AP-1	O
binding	O
activity	O
,	O
with	O
maximum	O
value	O
at	O
hour	O
12	O
in	O
etoposide-treated	O
cells	O
and	O
at	O
hour	O
48	O
in	O
ICRF-193-treated	O
cells	O
.	O

By	O
contrast	O
,	O
the	O
binding	O
activity	O
of	O
the	O
NF-kappa	O
(	O
B	O
)	O
and	O
EGR-1	O
transcription	O
factors	O
was	O
little	O
affected	O
.	O

It	O
is	O
concluded	O
that	O
topoisomerase	O
II	O
inhibitors	O
may	O
induce	O
the	O
differentiation	O
of	O
promonocytic	O
cells	O
,	O
independently	O
of	O
their	O
capacity	O
to	O
cause	O
DNA	O
strand	O
breaks	O
.	O

However	O
,	O
there	O
are	O
other	O
effects	O
,	O
such	O
as	O
the	O
early	O
activation	O
of	O
protein	O
kinase	O
C	O
,	O
which	O
are	O
probably	O
derived	O
from	O
the	O
production	O
of	O
primary	O
DNA	O
breakage	O
by	O
some	O
anti-topoisomerase	O
drugs	O
.	O

Nuclear	O
Rel-A	O
and	O
c-Rel	O
protein	O
complexes	O
are	O
differentially	O
distributed	O
within	O
human	O
thymocytes	O
.	O

Nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
/Rel	O
proteins	O
are	O
inducible	O
transcriptional	O
regulators	O
of	O
numerous	O
cellular	O
genes	O
.	O

They	O
are	O
particularly	O
abundant	O
in	O
lymphoid	O
tissues	O
and	O
are	O
thought	O
to	O
be	O
critical	O
for	O
the	O
transcription	O
of	O
genes	O
involved	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

We	O
have	O
reported	O
previously	O
that	O
a	O
nuclear	O
NF-kappa	O
B	O
activity	O
was	O
present	O
in	O
freshly	O
extracted	O
human	O
thymocytes	O
in	O
the	O
absence	B-Negation
of	I-Negation
in	I-Negation
vitro	I-Negation
treatment	I-Negation
of	I-Negation
these	I-Negation
cells	I-Negation
.	O

In	O
the	O
present	O
report	O
,	O
we	O
identified	O
NF-kappa	O
B	O
proteins	O
extracted	O
from	O
human	O
thymocyte	O
nuclei	O
as	O
being	O
p50/p65	O
and	O
p50/c-Rel	O
complexes	O
.	O

Immunochemical	O
and	O
immunofluorescent	O
staining	O
of	O
thymus	O
sections	O
using	O
specific	O
Abs	O
allowed	O
visualization	O
of	O
nuclear	O
NF-kappa	O
B	O
proteins	O
in	O
both	O
thymocytes	O
and	O
nonthymocyte	O
cells	O
.	O

This	O
detection	O
suggested	O
a	O
preferential	O
activation	O
of	O
p50/c-Rel	O
in	O
medullary	O
thymocytes	O
,	O
whereas	O
p50/p65	O
was	O
present	O
in	O
both	O
cortical	O
and	O
medullary	O
regions	O
of	O
human	O
thymus	O
lobules	O
.	O

However	O
,	O
the	O
intensity	O
of	O
p65	O
labeling	O
was	O
much	O
higher	O
in	O
several	O
thymocytes	O
from	O
the	O
medulla	O
.	O

p65	O
,	O
p50	O
,	O
and	O
c-Rel	O
activities	O
were	O
found	O
in	O
both	O
CD4-	O
and	O
CD8-positive	O
thymocytes	O
.	O

These	O
observations	O
suggest	O
that	O
p65	O
and	O
c-Rel	O
complexes	O
play	O
distinct	O
roles	O
in	O
gene	O
expression	O
and	O
that	O
both	O
forms	O
of	O
NF-kappa	O
B	O
play	O
critical	O
roles	O
during	O
late	O
stages	O
of	O
the	O
intrathymic	O
maturation	O
of	O
T	O
cells	O
.	O

Alteration	O
of	O
a	O
single	O
serine	O
in	O
the	O
basic	O
domain	O
of	O
the	O
Epstein-Barr	O
virus	O
ZEBRA	O
protein	O
separates	O
its	O
functions	O
of	O
transcriptional	O
activation	O
and	O
disruption	O
of	O
latency	O
.	O

The	O
ZEBRA	O
protein	O
from	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
activates	O
a	O
switch	O
from	O
the	O
latent	O
to	O
the	O
lytic	O
expression	O
program	O
of	O
the	O
virus	O
.	O

ZEBRA	O
,	O
a	O
member	O
of	O
the	O
bZIP	O
family	O
of	O
DNA-binding	O
proteins	O
,	O
is	O
a	O
transcriptional	O
activator	O
capable	O
of	O
inducing	O
expression	O
from	O
viral	O
lytic	O
cycle	O
promoters	O
.	O

It	O
had	O
previously	O
been	O
thought	O
that	O
ZEBRA	O
's	O
capacity	O
to	O
disrupt	O
EBV	O
latency	O
resided	O
primarily	O
in	O
its	O
ability	O
to	O
activate	O
transcription	O
of	O
genes	O
that	O
encode	O
products	O
required	O
for	O
lytic	O
replication	O
.	O

We	O
generated	O
a	O
point	O
mutant	O
of	O
ZEBRA	O
,	O
Z	O
(	O
S186A	O
)	O
,	O
that	B-Negation
was	I-Negation
not	I-Negation
impaired	I-Negation
in	I-Negation
its	I-Negation
ability	I-Negation
to	I-Negation
activate	I-Negation
transcription	I-Negation
;	O
however	O
,	O
this	O
mutation	O
abolished	O
its	O
ability	O
to	O
initiate	O
the	O
viral	O
lytic	O
cascade	O
.	O

The	O
mutant	O
,	O
containing	O
a	O
serine-to-alanine	O
substitution	O
in	O
the	O
DNA-binding	O
domain	O
of	O
the	O
protein	O
,	O
bound	O
to	O
several	O
known	O
ZEBRA-binding	O
sites	O
and	O
activated	O
transcription	O
from	O
reporters	O
bearing	O
known	O
ZEBRA-responsive	O
promoters	O
but	O
did	O
not	B-Negation
disrupt	I-Negation
latency	I-Negation
in	I-Negation
EBV-infected	I-Negation
cell	I-Negation
lines	I-Negation
.	O

Therefore	O
,	O
initiation	O
of	O
the	O
EBV	O
lytic	O
cycle	O
by	O
the	O
ZEBRA	O
protein	O
requires	O
a	O
function	O
in	O
addition	O
to	O
transcriptional	O
activation	O
;	O
a	O
change	O
of	O
serine	O
186	O
to	O
alanine	O
in	O
the	O
DNA-binding	O
domain	O
of	O
ZEBRA	O
abolished	O
this	O
additional	O
function	O
and	O
uncovered	O
a	O
new	O
role	O
for	O
the	O
ZEBRA	O
protein	O
in	O
disruption	O
of	O
EBV	O
latency	O
.	O

The	O
additional	O
function	O
that	O
is	O
required	O
for	O
initiation	O
of	O
the	O
lytic	O
viral	O
life	O
cycle	O
is	O
likely	O
to	O
require	O
phosphorylation	O
of	O
serine	O
186	O
of	O
the	O
ZEBRA	O
protein	O
,	O
which	O
may	O
influence	O
either	O
DNA	O
recognition	O
or	O
transcriptional	O
activation	O
of	O
lytic	O
viral	O
promoters	O
in	O
a	O
chromatinized	O
viral	O
episome	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
in	O
lipopolysaccharide-stimulated	O
U937	O
cells	O
.	O

During	O
the	O
course	O
of	O
serious	O
bacterial	O
infections	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
interacts	O
with	O
monocyte/macrophage	O
receptors	O
,	O
resulting	O
in	O
the	O
generation	O
of	O
inflammatory	O
cytokines	O
.	O

Transcription	O
factor	O
NF-kappaB	O
is	O
crucial	O
in	O
activating	O
the	O
transcription	O
of	O
genes	O
encoding	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
NF-kappaB	O
by	O
LPS	O
in	O
a	O
promonocytic	O
cell	O
line	O
(	O
U937	O
)	O
followed	O
a	O
rather	O
slow	O
kinetics	O
,	O
depending	O
on	O
the	O
rate	O
of	O
IkappaB-alpha	O
inhibitor	O
hydrolysis	O
.	O

No	B-Negation
degradation	I-Negation
of	I-Negation
p105	I-Negation
and	I-Negation
p100	I-Negation
inhibitors	I-Negation
was	I-Negation
observed	I-Negation
under	I-Negation
these	I-Negation
conditions	I-Negation
.	O

The	O
transduction	O
pathway	O
leading	O
to	O
NF-kappaB	O
activation	O
in	O
U937	O
cells	O
involved	O
the	O
intracellular	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
as	O
demonstrated	O
by	O
the	O
concomitant	O
inhibitory	O
effects	O
of	O
antioxidants	O
on	O
NF-kappaB	O
activation	O
and	O
the	O
emission	O
of	O
a	O
fluorescent	O
probe	O
reacting	O
intracellularly	O
with	O
hydrogen	O
peroxide	O
.	O

This	O
ROS	O
pathway	O
was	O
also	O
characterized	O
by	O
the	O
use	O
of	O
other	O
inhibitors	O
.	O

This	O
finding	O
indicates	O
that	O
phospholipase	O
A2	O
and	O
5-lipoxygenase	O
are	O
also	O
involved	O
.	O

However	O
,	O
the	B-Negation
NF-kappaB	I-Negation
activation	I-Negation
pathway	I-Negation
involving	I-Negation
the	I-Negation
acidic	I-Negation
sphingomyelinase	I-Negation
of	I-Negation
the	I-Negation
endolysosomial	I-Negation
membrane	I-Negation
did	I-Negation
not	I-Negation
seem	B-Speculation
to	I-Speculation
participate	I-Speculation
in	I-Speculation
the	I-Speculation
LPS-induced	I-Speculation
NF-kappaB	I-Speculation
activation	I-Speculation
in	I-Speculation
U937	I-Speculation
cells	I-Speculation
.	O

Possible	O
role	O
of	O
nuclear	O
factor-kappa	O
B	O
activity	O
in	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
.	O

Nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
plays	O
a	O
broad	O
role	O
in	O
gene	O
regulation	O
,	O
but	O
it	O
is	O
not	O
evident	O
whether	O
NF-kappa	O
B	O
acts	O
as	O
a	O
messenger	O
system	O
for	O
germline	O
C	O
epsilon	O
transcription	O
.	O

We	O
report	O
here	O
that	O
the	O
signaling	O
cascade	O
triggered	O
by	O
interleukin-4	O
(	O
IL-4	O
)	O
or	O
anti-CD40	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
participates	O
in	O
NF-kappa	O
B	O
activation	O
responsible	O
for	O
germline	O
C	O
epsilon	O
transcription	O
in	O
a	O
human	O
Burkitt	O
lymphoma	O
B	O
cell	O
line	O
,	O
DND39	O
.	O

Both	O
IL-4	O
and	O
anti-CD40	O
mAb	O
induced	O
activation	O
of	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3-kinase	O
)	O
,	O
translocation	O
of	O
a	O
zeta	O
isoform	O
of	O
protein	O
kinase	O
C	O
,	O
and	O
nuclear	O
expression	O
of	O
NF-kappa	O
B	O
.	O

All	O
such	O
events	O
were	O
abrogated	O
by	O
treatment	O
with	O
LY294002	O
,	O
a	O
specific	O
inhibitor	O
of	O
PI3-kinase	O
.	O

In	O
addition	O
,	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
antioxidant	O
,	O
decreased	O
NF-kappa	O
B	O
activation	O
caused	O
by	O
IL-4	O
,	O
anti-CD40	O
mAb	O
,	O
or	O
their	O
combination	O
.	O

NAC	O
was	O
also	O
effective	O
in	O
diminishing	O
germline	O
C	O
epsilon	O
transcription	O
,	O
and	O
its	O
potency	O
was	O
higher	O
in	O
cultures	O
costimulated	O
with	O
IL-4	O
and	O
anti-CD40	O
mAb	O
than	O
in	O
those	O
stimulated	O
with	O
IL-4	O
alone	O
.	O

These	O
results	O
indicate	O
that	O
IL-4	O
and	O
ligation	O
of	O
CD40	O
induce	O
NF-kappa	O
B	O
expression	O
via	O
at	O
least	O
a	O
mechanism	O
dependent	O
on	O
the	O
PI3-kinase	O
pathway	O
and	O
suggest	O
that	O
NF-kappa	O
B	O
sensitive	O
to	O
NAC	O
may	O
play	O
a	O
role	O
in	O
regulating	O
germline	O
C	O
epsilon	O
transcription	O
.	O

T-lymphocytes	O
from	O
individuals	O
with	O
filarial	O
inflammatory	O
disease	O
have	O
increased	O
transendothelial	O
migration	O
in	O
vitro	O
.	O

The	O
in	O
vitro	O
transendothelial	O
migration	O
of	O
circulating	O
filarial	O
antigen-specific	O
T-cells	O
was	O
examined	O
in	O
Wuchereria	O
banerofti	O
infection	O
.	O

Circulating	O
T-cells	O
from	O
individuals	O
with	O
filaria-induced	O
lymphatic	O
pathology	O
(	O
LP	O
)	O
had	O
significantly	O
greater	O
migration	O
through	O
unstimulated	O
HUVEC	O
monolayers	O
than	O
did	O
T-cells	O
from	O
asymptomatic	O
infected	O
(	O
MF	O
)	O
individuals	O
(	O
P	O
=	O
0.04	O
)	O
.	O

In	O
contrast	O
to	O
the	O
MF	O
individuals	O
where	O
no	B-Negation
effect	I-Negation
was	I-Negation
seen	I-Negation
,	O
transendothelial	O
migration	O
of	O
48-hr	O
filarial	O
antigen	O
stimulated	O
T-cells	O
from	O
LP	O
individuals	O
was	O
significantly	O
(	O
P	O
=	O
0.01	O
)	O
greater	O
than	O
migration	O
of	O
48-hr	O
media-stimulated	O
T-cells	O
.	O

In	O
six	O
of	O
seven	O
patients	O
examined	O
,	O
inhibition	O
of	O
the	O
VLA-4/VCAM-1	O
pathway	O
resulted	O
in	O
greater	O
than	O
50	O
%	O
inhibition	O
of	O
transendothelial	O
migration	O
of	O
T-cells	O
.	O

Suppression	O
by	O
azelastine	O
hydrochloride	O
of	O
NF-kappa	O
B	O
activation	O
involved	O
in	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
.	O

The	O
influence	O
of	O
the	O
anti-allergy	O
agent	O
azelastine	O
hydrochloride	O
(	O
Azeptin	O
)	O
on	O
NF-kappa	O
B	O
activation	O
associated	O
with	O
the	O
generation	O
of	O
cytokines	O
and	O
nitric	O
oxide	O
(	O
NO	O
)	O
was	O
investigated	O
in	O
various	O
kinds	O
of	O
human	O
and	O
mouse	O
cells	O
.	O

Azeptin	O
dose-dependently	O
suppressed	O
both	O
DNA	O
and	O
protein	O
synthesis	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HF	O
)	O
and	O
also	O
suppressed	O
blastogenesis	O
of	O
human	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
.	O

Generation	O
of	O
tumor	O
necrosis	O
factor-alpha	O
,	O
interleukin	O
1-beta	O
,	O
granulocyte-macrophage	O
colony-stimulating	O
factor	O
and	O
interleukin-6	O
from	O
10	O
(	O
-5	O
)	O
M	O
Azeptin-treated	O
PBL	O
and	O
human	O
monocytes	O
(	O
HM	O
)	O
was	O
decreased	O
to	O
approximately	O
1/3	O
to	O
2/3	O
of	O
the	O
control	O
levels	O
.	O

In	O
parallel	O
with	O
the	O
decreased	O
cytokine	O
generation	O
,	O
each	O
cytokine	O
mRNA	O
was	O
less	O
expressed	O
in	O
the	O
presence	O
of	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

In	O
addition	O
,	O
both	O
inducible	O
nitric	O
oxide	O
synthase-mRNA	O
level	O
and	O
NO	O
generation	O
in	O
mouse	O
peritoneal	O
macrophages	O
were	O
suppressed	O
by	O
10	O
(	O
-5	O
)	O
M	O
Azeptin	O
.	O

Being	O
compatible	O
with	O
those	O
results	O
,	O
Azeptin	O
(	O
10	O
(	O
-5	O
)	O
M	O
)	O
suppressed	O
activation	O
of	O
NF-kappa	O
B	O
in	O
PBL	O
,	O
HM	O
and	O
HF	O
.	O

These	O
results	O
appear	O
to	O
indicate	O
that	O
suppression	O
of	O
cytokine	O
and	O
NO	O
generation	O
by	O
Azeptin	O
results	O
at	O
least	O
partially	O
from	O
the	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
.	O

The	O
T	O
cell	O
activation	O
factor	O
NF-ATc	O
positively	O
regulates	O
HIV-1	O
replication	O
and	O
gene	O
expression	O
in	O
T	O
cells	O
.	O

Clinical	O
deterioration	O
in	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
infection	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
viral	O
replication	O
and	O
burden	O
in	O
the	O
peripheral	O
blood	O
and	O
lymphoid	O
organs	O
.	O

T	O
cell	O
activation	O
and	O
ensuing	O
cellular	O
gene	O
activation	O
can	O
be	O
critical	O
for	O
HIV-1	O
replication	O
.	O

The	O
hypothesis	O
that	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
may	O
influence	O
HIV-1	O
replication	O
is	O
therefore	O
compelling	O
given	O
the	O
tight	O
correlation	O
of	O
HIV-1	O
transcriptional	O
induction	O
to	O
T	O
cell	O
activation	O
.	O

We	O
report	O
that	O
certain	O
NF-AT	O
(	O
Rel	O
)	O
family	O
members	O
productively	O
bind	O
the	O
kappaB	O
regulatory	O
elements	O
,	O
synergize	O
with	O
NF-kappaB	O
and	O
Tat	O
in	O
transcriptional	O
activation	O
of	O
HIV-1	O
,	O
and	O
enhance	O
HIV-1	O
replication	O
in	O
T	O
cells	O
.	O

These	O
results	O
link	O
regulatory	O
factors	O
critical	O
to	O
T	O
cell	O
commitment	O
directly	O
to	O
HIV-1	O
replication	O
.	O

Differentiation	O
of	O
T-helper	O
lymphocytes	O
:	O
selective	O
regulation	O
by	O
members	O
of	O
the	O
STAT	O
family	O
of	O
transcription	O
factors	O
.	O

Interleukin-4	O
(	O
IL-4	O
)	O
and	O
interleukin-12	O
(	O
IL-12	O
)	O
control	O
the	O
differentiation	O
of	O
T-helper	O
cells	O
.	O

Here	O
we	O
summarize	O
studies	O
which	O
investigate	O
the	O
mechanism	O
by	O
which	O
these	O
cytokines	O
selectively	O
reprogramme	O
gene	O
expression	O
in	O
T-lymphocytes	O
.	O

Cytokine	O
stimulation	O
leads	O
to	O
the	O
phosphorylation	O
of	O
specific	O
tyrosine	O
residues	O
within	O
the	O
intracellular	O
domain	O
of	O
the	O
corresponding	O
cytokine	O
receptor	O
.	O

These	O
phosphotyrosines	O
serve	O
as	O
docking	O
sites	O
for	O
latent	O
,	O
cytoplasmic	O
transcription	O
factors	O
known	O
as	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
Stat	O
)	O
proteins	O
.	O

Receptor/Stat	O
interaction	O
is	O
mediated	O
by	O
the	O
src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
of	O
the	O
corresponding	O
Stat	O
protein	O
.	O

Although	O
Stat	O
binding	O
to	O
the	O
intracellular	O
domain	O
of	O
the	O
cytokine	O
receptor	O
strongly	O
depends	O
on	O
the	O
phosphotyrosine	O
residue	O
,	O
the	O
recruitment	O
of	O
a	O
specific	O
Stat	O
protein	O
is	O
dictated	O
by	O
amino	O
acid	O
residues	O
C-terminal	O
to	O
the	O
phosphotyrosine	O
.	O

Specific	O
docking	O
sites	O
within	O
individual	O
cytokine	O
receptors	O
have	O
been	O
identified	O
for	O
almost	O
all	O
Stat	O
proteins	O
.	O

The	O
direct	O
coupling	O
between	O
cytokine	O
receptor	O
and	O
transcription	O
factor	O
helps	O
to	O
explain	O
how	O
different	O
cytokines	O
elicit	O
distinct	O
patterns	O
of	O
gene	O
expression	O
.	O

Regulation	O
of	O
the	O
tissue	O
factor	O
gene	O
in	O
human	O
monocytic	O
cells	O
.	O

Role	O
of	O
AP-1	O
,	O
NF-kappa	O
B/Rel	O
,	O
and	O
Sp1	O
proteins	O
in	O
uninduced	O
and	O
lipopolysaccharide-induced	O
expression	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
expression	O
by	O
peripheral	O
blood	O
monocytes	O
during	O
sepsis	O
initiates	O
intravascular	O
thrombosis	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
rapidly	O
induces	O
TF	O
gene	O
transcription	O
in	O
monocytes	O
.	O

The	O
human	O
TF	O
promoter	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-1	O
,	O
c-Rel/p65	O
,	O
Egr-1	O
,	O
and	O
Sp1	O
.	O

NF-kappa	O
B/Rel	O
proteins	O
have	O
been	O
shown	O
to	O
physically	O
interact	O
with	O
both	O
AP-1	O
and	O
Sp1	O
proteins	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
uninduced	O
and	O
LPS-induced	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
THP-1	O
cells	O
.	O

Deletional	O
analysis	O
indicated	O
that	O
five	O
Sp1	O
sites	O
mediated	O
basal	O
expression	O
in	O
uninduced	O
cells	O
.	O

The	O
two	O
AP-1	O
sites	O
bound	O
c-Fos/c-Jun	O
heterodimers	O
in	O
both	O
unstimulated	O
and	O
LPS-stimulated	O
cells	O
.	O

Maximal	O
LPS	O
induction	O
of	O
the	O
TF	O
promoter	O
required	O
the	O
two	O
AP-1	O
sites	O
and	O
the	O
kappa	O
B	O
site	O
within	O
the	O
LPS	O
response	O
element	O
.	O

Disruption	O
of	O
the	O
conserved	O
spacing	O
between	O
the	O
proximal	O
AP-1	O
site	O
and	O
the	O
kappa	O
B	O
site	O
abolished	O
LPS	O
induction	O
.	O

Replacement	O
of	O
the	O
two	O
AP-1	O
sites	O
with	O
intrinsically	O
bent	O
DNA	O
partially	O
restored	O
LPS	O
induction	O
,	O
suggesting	O
an	O
additional	O
structural	O
role	O
for	O
the	O
AP-1	O
sites	O
.	O

Synergistic	O
transactivation	O
of	O
the	O
LPS	O
response	O
element	O
in	O
Drosophila	O
Schneider	O
cells	O
by	O
coexpression	O
of	O
c-Fos	O
,	O
c-Jun	O
,	O
c-Rel	O
,	O
and	O
p65	O
or	O
c-Jun	O
and	O
p65	O
required	O
the	O
transactivation	O
domains	O
of	O
c-Jun	O
and	O
p65	O
.	O

These	O
data	O
indicated	O
that	O
c-Fos/c-Jun	O
,	O
c-Rel/p65	O
,	O
and	O
Sp1	O
regulate	O
TF	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
.	O

Physical	O
interactions	O
between	O
Ets	O
and	O
NF-kappaB/NFAT	O
proteins	O
play	O
an	O
important	O
role	O
in	O
their	O
cooperative	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
enhancer	O
in	O
T	O
cells	O
.	O

The	O
transcriptional	O
regulatory	O
elements	O
of	O
many	O
inducible	O
T-cell	O
genes	O
contain	O
adjacent	O
or	O
overlapping	O
binding	O
sites	O
for	O
the	O
Ets	O
and	O
NF-kappaB/NFAT	O
families	O
of	O
transcription	O
factors	O
.	O

Similar	O
arrays	O
of	O
functionally	O
important	O
NF-kappaB/NFAT	O
and	O
Ets	O
binding	O
sites	O
are	O
present	O
in	O
the	O
transcriptional	O
enhancers	O
of	O
human	O
immunodeficiency	O
viruses	O
types	O
1	O
and	O
2	O
(	O
HIV-1	O
and	O
HIV-2	O
)	O
,	O
suggesting	O
that	O
this	O
pattern	O
of	O
nuclear	O
protein	O
binding	O
sites	O
reflects	O
an	O
evolutionarily	O
conserved	O
mechanism	O
for	O
regulating	O
inducible	O
T-cell	O
gene	O
expression	O
that	O
has	O
been	O
co-opted	O
during	O
HIV	O
evolution	O
.	O

Despite	O
these	O
findings	O
,	O
the	O
molecular	O
mechanisms	O
by	O
which	O
Ets	O
and	O
NF-kappaB/NFAT	O
proteins	O
cooperatively	O
regulate	O
inducible	O
T-cell	O
gene	O
expression	O
remained	O
unknown	O
.	O

In	O
the	O
studies	O
described	O
in	O
this	O
report	O
,	O
we	O
demonstrated	O
a	O
physical	O
interaction	O
between	O
multiple	O
Ets	O
and	O
NF-kappaB/NFAT	O
proteins	O
both	O
in	O
vitro	O
and	O
in	O
activated	O
normal	O
human	O
T	O
cells	O
.	O

This	O
interaction	O
is	O
mediated	O
by	O
the	O
Ets	O
domain	O
of	O
Ets	O
proteins	O
and	O
the	O
C-terminal	O
region	O
of	O
the	O
Rel	O
homology	O
domains	O
of	O
NF-kappaB/NFAT	O
proteins	O
.	O

In	O
addition	O
,	O
the	O
Ets-NF-kappaB/NFAT	O
interaction	O
requires	O
the	O
presence	O
of	O
DNA	O
binding	O
sites	O
for	O
both	O
proteins	O
,	O
as	O
it	O
is	O
abolished	O
by	O
the	O
DNA	O
intercalating	O
agents	O
propidium	O
iodide	O
and	O
ethidium	O
bromide	O
and	O
enhanced	O
by	O
the	O
presence	O
of	O
synthetic	O
oligonucleotides	O
containing	O
binding	O
sites	O
for	O
Ets	O
and	O
NF-kappaB	O
proteins	O
.	O

A	O
dominant-negative	O
mutant	O
of	O
NF-kappaB	O
p50	O
that	O
binds	O
DNA	O
but	O
fails	B-Negation
to	I-Negation
interact	I-Negation
with	I-Negation
Ets	I-Negation
proteins	I-Negation
inhibits	O
the	O
synergistic	O
activation	O
of	O
the	O
HIV-1	O
and	O
HIV-2	O
enhancers	O
by	O
NF-kappaB	O
(	O
p50	O
+	O
p65	O
)	O
and	O
Ets-1	O
,	O
suggesting	B-Speculation
that	I-Speculation
physical	I-Speculation
interaction	I-Speculation
between	I-Speculation
Ets	I-Speculation
and	I-Speculation
NF-kappaB	I-Speculation
proteins	I-Speculation
is	I-Speculation
required	I-Speculation
for	I-Speculation
the	I-Speculation
transcriptional	I-Speculation
activity	I-Speculation
of	I-Speculation
the	I-Speculation
HIV-1	I-Speculation
and	I-Speculation
HIV-2	I-Speculation
enhancers	I-Speculation
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
evolutionarily	O
conserved	O
physical	O
interactions	O
between	O
Ets	O
and	O
NF-kappaB/NFAT	O
proteins	O
are	O
important	O
in	O
regulating	O
the	O
inducible	O
expression	O
of	O
T-cell	O
genes	O
and	O
viruses	O
.	O

These	O
interactions	O
represent	O
a	O
potential	O
target	O
for	O
the	O
development	O
of	O
novel	O
immunosuppressive	O
and	O
antiviral	O
therapies	O
.	O

Oxidant-regulation	O
of	O
gene	O
expression	O
in	O
the	O
chronically	O
inflamed	O
intestine	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
the	O
chronic	O
gut	O
inflammation	O
observed	O
in	O
the	O
idiopathic	O
inflammatory	O
bowel	O
diseases	O
(	O
e.g.	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
)	O
is	O
associated	O
with	O
enhanced	O
production	O
of	O
leukocyte-derived	O
oxidants	O
.	O

Oxidants	O
such	O
as	O
hydrogen	O
peroxide	O
are	O
known	O
to	O
activate	O
certain	O
transcription	O
factors	O
such	O
as	O
nuclear	O
transcription	O
factor	O
kappa	O
beta	O
.	O

Nuclear	O
transcription	O
factor	O
kB	O
(	O
NF-kappa	O
B	O
)	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
and	O
pleiotropic	O
regulator	O
of	O
numerous	O
genes	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

This	O
transcription	O
factor	O
is	O
activated	O
via	O
the	O
selective	O
phosphorylation	O
,	O
ubiquination	O
and	O
degradation	O
of	O
its	O
inhibitor	O
protein	O
I-kB	O
thereby	O
allowing	O
translocation	O
of	O
NF-kappa	O
B	O
into	O
the	O
nucleus	O
where	O
it	O
upregulates	O
the	O
transcription	O
of	O
a	O
variety	O
of	O
adhesion	O
molecules	O
(	O
e.g.	O
ICAM-1	O
,	O
VCAM-1	O
)	O
,	O
cytokines	O
(	O
TNF	O
,	O
IL-1	O
,	O
IL-6	O
)	O
and	O
enzymes	O
(	O
iNOS	O
)	O
.	O

The	O
proteolytic	O
degradation	O
of	O
the	O
post-translationally	O
modified	O
I-kappa	O
B	O
is	O
known	O
to	O
be	O
mediated	O
by	O
the	O
26S	O
proteasome	O
complex	O
.	O

Based	O
upon	O
work	O
from	O
our	O
laboratory	O
,	O
we	O
propose	O
that	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
produces	O
significant	O
anti	O
inflammatory	O
activity	O
which	O
may	O
be	O
mediated	O
by	O
the	O
inhibition	O
of	O
transcription	O
of	O
certain	O
pro-inflammatory	O
mediators	O
and	O
adhesion	O
molecules	O
.	O

Expression	O
of	O
LAZ3/BCL6	O
in	O
follicular	O
center	O
(	O
FC	O
)	O
B	O
cells	O
of	O
reactive	O
lymph	O
nodes	O
and	O
FC-derived	O
non-Hodgkin	O
lymphomas	O
.	O

Chromosomal	O
translocation	O
resulting	O
in	O
abnormal	O
expression	O
of	O
the	O
LAZ3/BCL6	O
gene	O
in	O
B	O
cells	O
has	O
been	O
implicated	O
in	O
the	O
tumorigenesis	O
of	O
non-Hodgkin	O
lymphoma	O
(	O
NHL	O
)	O
.	O

Therefore	O
we	O
studied	O
the	O
expression	O
pattern	O
of	O
LAZ3/BCL6	O
by	O
in	O
situ	O
hybridization	O
with	O
synthetic	O
oligonucleotide	O
probes	O
in	O
frozen	O
tissue	O
sections	O
from	O
five	O
reactive	O
lymph	O
nodes	O
and	O
38	O
B	O
cell	O
and	O
non-B	O
NHL	O
.	O

In	O
addition	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
LAZ3/BCL6	O
by	O
Northern	O
blot	O
analysis	O
on	O
multiple	O
human	O
tissues	O
.	O

The	O
LAZ3/BCL6	O
transcript	O
was	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
muscle	O
,	O
peripheral	O
blood	O
leukocytes	O
,	O
and	O
weakly	O
in	O
normal	O
lymph	O
nodes	O
.	O

In	O
the	O
tumor	O
samples	O
,	O
expression	O
of	O
LAZ3/BCL6	O
was	O
observed	O
in	O
68	O
%	O
of	O
all	O
B	O
cell	O
NHL	O
and	O
none	B-Negation
of	I-Negation
the	I-Negation
non-B	I-Negation
lymphomas	I-Negation
.	O

All	O
cases	O
of	O
follicular	O
,	O
mixed	O
small	O
and	O
large	O
cell	O
lymphomas	O
showed	O
LAZ3/BCL6	O
expression	O
confined	O
to	O
the	O
neoplastic	O
follicles	O
.	O

A	O
follicular	O
expression	O
pattern	O
was	O
also	O
found	O
in	O
all	O
non-malignant	O
reactive	O
lymph	O
nodes	O
.	O

Hence	O
,	O
the	O
expression	O
of	O
LAZ3/BCL6	O
does	O
not	B-Negation
correlate	I-Negation
to	I-Negation
malignancy	I-Negation
,	O
but	O
reflects	O
the	O
origin	O
of	O
B	O
cells	O
from	O
the	O
germinal	O
centers	O
.	O

Induction	O
of	O
relA	O
(	O
p65	O
)	O
and	O
I	O
kappa	O
B	O
alpha	O
subunit	O
expression	O
during	O
differentiation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
to	O
macrophages	O
.	O

We	O
evaluated	O
the	O
expression	O
and	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
subunits	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
and	O
in	O
monocyte-derived	O
macrophages	O
(	O
MDMs	O
)	O
.	O

Constitutive	O
DNA	O
binding	O
activity	O
consisting	O
of	O
p50	O
homodimers	O
was	O
detected	O
in	O
nuclear	O
extracts	O
from	O
both	O
cell	O
types	O
.	O

An	O
additional	O
complex	O
composed	O
of	O
p50/RelA	O
(	O
p65	O
)	O
heterodimers	O
appeared	O
only	O
in	O
nuclear	O
extracts	O
from	O
7-day	O
MDMs	O
.	O

Immunoblot	O
analysis	O
showed	O
that	O
the	O
p50	O
subunit	O
was	O
constitutively	O
expressed	O
in	O
monocytes	O
and	O
MDMs	O
.	O

In	O
contrast	O
,	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
was	O
barely	O
detectable	O
in	O
monocytes	O
,	O
but	O
its	O
level	O
increased	O
markedly	O
in	O
MDMs	O
.	O

Analysis	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
revealed	O
that	O
the	O
stability	O
of	O
RelA	O
(	O
p65	O
)	O
mRNA	O
was	O
significantly	O
higher	O
in	O
MDMs	O
,	O
compared	O
with	O
monocytes	O
.	O

In	O
MDMs	O
,	O
an	O
upregulation	O
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
as	O
well	O
as	O
the	O
appearance	O
of	O
a	O
novel	O
M	O
(	O
r	O
)	O
40,000	O
form	O
of	O
I	O
kappa	O
B	O
alpha	O
were	O
also	O
observed	O
.	O

These	O
results	O
suggest	O
that	O
macrophage	O
differentiation	O
results	O
in	O
the	O
expression	O
of	O
active	O
p50/RelA	O
(	O
p65	O
)	O
heterodimers	O
with	O
the	O
capacity	O
to	O
activate	O
target	O
gene	O
expression	O
.	O

The	O
parallel	O
induction	O
of	O
I	O
kappa	O
B	O
alpha	O
synthesis	O
may	O
allow	O
for	O
the	O
continuous	O
presence	O
of	O
a	O
cytoplasmic	O
reservoir	O
of	O
p50/RelA	O
(	O
p65	O
)	O
complexes	O
that	O
are	O
readily	O
available	O
for	O
inducer-mediated	O
stimulation	O
.	O

Two	O
distinct	O
pathways	O
of	O
interleukin-5	O
synthesis	O
in	O
allergen-specific	O
human	O
T-cell	O
clones	O
are	O
suppressed	O
by	O
glucocorticoids	O
.	O

Glucocorticoids	O
(	O
GC	O
)	O
have	O
long	O
been	O
used	O
as	O
the	O
most	O
effective	O
agents	O
for	O
the	O
treatment	O
of	O
allergic	O
diseases	O
accompanied	O
by	O
eosinophilia	O
such	O
as	O
chronic	O
asthma	O
and	O
atopic	O
dermatitis	O
.	O

The	O
development	O
of	O
chronic	O
eosinophilic	O
inflammation	O
is	O
dependent	O
on	O
interleukin-5	O
(	O
IL-5	O
)	O
,	O
a	O
selective	O
eosinophil-activating	O
factor	O
,	O
produced	O
by	O
helper	O
T	O
cells	O
.	O

To	O
delineate	O
the	O
regulatory	O
mechanisms	O
of	O
human	O
IL-5	O
synthesis	O
,	O
we	O
established	O
allergen-specific	O
CD4+	O
T-cell	O
clones	O
from	O
asthmatic	O
patients	O
.	O

GC	O
efficiently	O
suppressed	O
IL-5	O
synthesis	O
of	O
T-cell	O
clones	O
activated	O
via	O
either	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
or	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
.	O

Induction	O
of	O
IL-5	O
mRNA	O
upon	O
TCR	O
and	O
IL-2R	O
stimulation	O
was	O
totally	O
inhibited	O
by	O
dexamethasone	O
.	O

Human	O
IL-5	O
promoter/enhancer-luciferase	O
gene	O
construct	O
transfected	O
to	O
T-cell	O
clones	O
was	O
transcribed	O
on	O
either	O
TCR	O
or	O
IL-2R	O
stimulation	O
and	O
was	O
clearly	O
downregulated	O
by	O
dexamethasone	O
,	O
indicating	O
that	O
the	O
approximately	O
500-bp	O
human	O
IL-5	O
gene	O
segment	O
located	O
5	O
'	O
upstream	O
of	O
the	O
coding	O
region	O
contains	O
activation-inducible	O
enhancer	O
elements	O
responsible	O
for	O
the	O
regulation	O
by	O
GC	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
suggested	O
that	O
AP-1	O
and	O
NF-kappaB	O
are	O
among	O
the	O
possible	O
targets	O
of	O
GC	O
actions	O
on	O
TCR-stimulated	O
T	O
cells	O
.	O

NF-AT	O
and	O
NF-kappaB	O
were	O
not	O
significantly	O
induced	O
by	O
IL-2	O
stimulation	O
.	O

Our	O
results	O
showing	O
that	O
GC	O
suppressed	O
IL-5	O
production	O
by	O
human	O
CD4+	O
T	O
cells	O
activated	O
by	O
two	O
distinct	O
stimuli	O
,	O
TCR	O
and	O
IL-2R	O
stimulation	O
,	O
underscore	O
the	O
efficacy	O
of	O
GC	O
in	O
the	O
treatment	O
of	O
allergic	O
diseases	O
via	O
suppression	O
of	O
T-cell	O
IL-5	O
synthesis	O
.	O

Involvement	O
of	O
an	O
SAF-like	O
transcription	O
factor	O
in	O
the	O
activation	O
of	O
serum	O
amyloid	O
A	O
gene	O
in	O
monocyte/macrophage	O
cells	O
by	O
lipopolysaccharide	O
.	O

Serum	O
amyloid	O
A	O
(	O
SAA	O
)	O
has	O
been	O
linked	O
to	O
atherosclerosis	O
because	O
of	O
its	O
ability	O
to	O
remodel	O
high-density	O
lipoprotein	O
by	O
the	O
depletion	O
of	O
apolipoprotein	O
A1	O
,	O
its	O
ability	O
to	O
bind	O
cholesterol	O
,	O
and	O
its	O
presence	O
in	O
the	O
atherosclerotic	O
plaques	O
of	O
coronary	O
and	O
carotid	O
arteries	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
induction	O
mechanism	O
of	O
SAA	O
gene	O
in	O
THP-1	O
monocyte/macrophage	O
cells	O
which	O
play	O
a	O
critical	O
role	O
in	O
the	O
development	O
of	O
atherosclerotic	O
fatty	O
streak	O
and	O
plaque	O
formation	O
.	O

We	O
and	O
others	O
have	O
shown	O
that	O
SAA	O
gene	O
is	O
induced	O
in	O
monocyte/macrophage	O
cells	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

By	O
promoter	O
function	O
analysis	O
,	O
we	O
show	O
that	O
the	O
SAA	O
promoter	O
sequence	O
between	O
-280	O
and	O
-226	O
can	O
confer	O
LPS	O
responsiveness	O
.	O

Gel	O
electrophoretic	O
mobility	O
shift	O
assay	O
detected	O
an	O
induced	O
DNA-binding	O
activity	O
in	O
these	O
cells	O
in	O
response	O
to	O
LPS	O
.	O

Characterization	O
of	O
the	O
DNA-binding	O
protein	O
by	O
UV	O
cross-linking	O
,	O
Southwestern	O
blot	O
,	O
and	O
antibody	O
ablation/supershift	O
assays	O
revealed	O
that	O
it	O
is	O
similar	O
to	O
a	O
recently	O
reported	O
nuclear	O
factor	O
designated	O
SAF	O
.	O

These	O
results	O
demonstrated	O
that	O
LPS-mediated	O
SAA	O
gene	O
induction	O
in	O
monocyte/macrophage	O
cells	O
is	O
primarily	O
due	O
to	O
the	O
induction	O
of	O
SAF	O
activity	O
.	O

Oncogenic	O
forms	O
of	O
NOTCH1	O
lacking	B-Negation
either	I-Negation
the	I-Negation
primary	I-Negation
binding	I-Negation
site	I-Negation
for	I-Negation
RBP-Jkappa	I-Negation
or	I-Negation
nuclear	I-Negation
localization	I-Negation
sequences	I-Negation
retain	O
the	O
ability	O
to	O
associate	O
with	O
RBP-Jkappa	O
and	O
activate	O
transcription	O
.	O

Truncated	O
forms	O
of	O
the	O
NOTCH1	O
transmembrane	O
receptor	O
engineered	O
to	O
resemble	O
mutant	O
forms	O
of	O
NOTCH1	O
found	O
in	O
certain	O
cases	O
of	O
human	O
T	O
cell	O
leukemia/lymphoma	O
(	O
T-ALL	O
)	O
efficiently	O
induce	O
T-ALL	O
when	O
expressed	O
in	O
the	O
bone	O
marrow	O
of	O
mice	O
.	O

Unlike	O
full-sized	O
NOTCH1	O
,	O
two	O
such	O
truncated	O
forms	O
of	O
the	O
protein	O
either	O
lacking	B-Negation
a	I-Negation
major	I-Negation
portion	I-Negation
of	I-Negation
the	I-Negation
extracellular	I-Negation
domain	I-Negation
(	I-Negation
DeltaE	I-Negation
)	I-Negation
or	O
consisting	O
only	O
of	O
the	O
intracellular	O
domain	O
(	O
ICN	O
)	O
were	O
found	O
to	O
activate	O
transcription	O
in	O
cultured	O
cells	O
,	O
presumably	B-Speculation
through	I-Speculation
RBP-Jkappa	I-Speculation
response	I-Speculation
elements	I-Speculation
within	I-Speculation
DNA	I-Speculation
.	O

Both	O
truncated	O
forms	O
also	O
bound	O
to	O
the	O
transcription	O
factor	O
RBP-Jkappa	O
in	O
extracts	O
prepared	O
from	O
human	O
and	O
murine	O
T-ALL	O
cell	O
lines	O
.	O

Transcriptional	O
activation	O
required	O
the	O
presence	O
of	O
a	O
weak	O
RBP-Jkappa-binding	O
site	O
within	O
the	O
NOTCH1	O
ankyrin	O
repeat	O
region	O
of	O
the	O
intracellular	O
domain	O
.	O

Unexpectedly	O
,	O
a	B-Negation
second	I-Negation
,	I-Negation
stronger	I-Negation
RBP-Jkappa-binding	I-Negation
site	I-Negation
,	I-Negation
which	I-Negation
lies	I-Negation
within	I-Negation
the	I-Negation
intracellular	I-Negation
domain	I-Negation
close	I-Negation
to	I-Negation
the	I-Negation
transmembrane	I-Negation
region	I-Negation
and	I-Negation
significantly	I-Negation
augments	I-Negation
association	I-Negation
with	I-Negation
RBP-Jkappa	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
needed	I-Negation
for	I-Negation
oncogenesis	I-Negation
or	I-Negation
for	I-Negation
transcriptional	I-Negation
activation	I-Negation
.	O

While	O
ICN	O
appeared	O
primarily	O
in	O
the	O
nucleus	O
,	O
DeltaE	O
localized	O
to	O
cytoplasmic	O
and	O
nuclear	O
membranes	O
,	O
suggesting	O
that	O
intranuclear	O
localization	O
is	O
not	O
essential	O
for	O
oncogenesis	O
or	O
transcriptional	O
activation	O
.	O

In	O
support	O
of	O
this	O
interpretation	O
,	O
mutation	O
of	O
putative	O
nuclear	O
localization	O
sequences	O
decreased	O
nuclear	O
localization	O
and	O
increased	O
transcriptional	O
activation	O
by	O
membrane-bound	O
DeltaE	O
.	O

Transcriptional	O
activation	O
by	O
this	O
mutant	O
form	O
of	O
membrane-bound	O
DeltaE	O
was	O
approximately	O
equivalent	O
to	O
that	O
produced	O
by	O
intranuclear	O
ICN	O
.	O

These	O
data	O
are	O
most	O
consistent	O
with	O
NOTCH1	O
oncogenesis	O
and	O
transcriptional	O
activation	O
being	O
independent	O
of	O
association	O
with	O
RBP-Jkappa	O
at	O
promoter	O
sites	O
.	O

Transcriptional	O
induction	O
of	O
collagenase-1	O
in	O
differentiated	O
monocyte-like	O
(	O
U937	O
)	O
cells	O
is	O
regulated	O
by	O
AP-1	O
and	O
an	O
upstream	O
C/EBP-beta	O
site	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
AP-1	O
site	O
and	O
a	O
distal	O
promoter	O
element	O
regulate	O
transcriptional	O
induction	O
of	O
collagenase-1	O
during	O
monocytic	O
differentiation	O
.	O

Chloramphenicol	O
acetyltransferase	O
expression	O
constructs	O
containing	O
regions	O
of	O
the	O
human	O
collagenase-1	O
promoter	O
were	O
stably	O
or	O
transiently	O
transfected	O
into	O
U937	O
cells	O
,	O
and	O
reporter	O
activity	O
was	O
assessed	O
at	O
various	O
times	O
after	O
the	O
onset	O
of	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-mediated	O
differentiation	O
.	O

Rapid	O
and	O
strong	O
induction	O
of	O
promoter	O
activity	O
was	O
lost	O
in	O
constructs	O
with	O
a	O
mutant	O
AP-1	O
element	O
;	O
however	O
,	O
at	O
16-96	O
h	O
post-PMA	O
,	O
the	O
mutant	O
collagenase-1	O
promoter	O
displayed	O
AP-1	O
independent	O
PMA-mediated	O
transactivation	O
.	O

The	O
AP-1	O
mutant	O
constructs	O
also	O
showed	O
delayed	O
transcriptional	O
activation	O
in	O
PMA-treated	O
fibroblasts	O
.	O

Western	O
and	O
supershift	O
analyses	O
indicated	O
that	O
functional	O
Jun	O
and	O
Fos	O
proteins	O
were	O
present	O
in	O
nuclear	O
extracts	O
of	O
PMA-differentiated	O
U937	O
cells	O
.	O

Promoter	O
deletion	O
constructs	O
demonstrated	O
the	O
potential	O
role	O
of	O
distal	O
promoter	O
sequences	O
in	O
regulating	O
collagenase-1	O
transcription	O
.	O

In	O
particular	O
,	O
Western	O
,	O
supershift	O
,	O
and	O
promoter	O
deletion	O
analyses	O
suggested	O
a	O
role	O
for	O
CCAAT/enhancer-binding	O
protein-beta	O
(	O
C/EBP-beta	O
)	O
binding	O
site	O
between	O
-2010	O
and	O
-1954	O
in	O
regulating	O
transcription	O
of	O
collagenase-1	O
in	O
monocytic	O
cells	O
.	O

Our	O
findings	O
suggest	O
that	O
distinct	O
regulatory	O
elements	O
,	O
acting	O
somewhat	O
independently	O
of	O
each	O
other	O
,	O
control	O
expression	O
of	O
collagenase-1	O
.	O

In	O
addition	O
,	O
our	O
data	O
suggests	O
that	O
the	O
rapid	O
PMA-mediated	O
induction	O
of	O
collagenase-1	O
transcription	O
is	O
controlled	O
by	O
a	O
mechanism	O
distinct	O
from	O
that	O
regulating	O
the	O
sustained	O
expression	O
of	O
this	O
proteinase	O
in	O
activated	O
macrophages	O
.	O

A	O
novel	O
genetic	O
system	O
to	O
isolate	O
a	O
dominant	O
negative	O
effector	O
on	O
DNA-binding	O
activity	O
of	O
Oct-2	O
.	O

Recent	O
studies	O
have	O
revealed	O
that	O
interactions	O
between	O
transcription	O
factors	O
play	O
an	O
important	O
role	O
in	O
regulation	O
of	O
gene	O
expression	O
in	O
eukaryotic	O
cells	O
.	O

To	O
isolate	O
cDNA	O
clones	O
that	O
dominantly	O
inhibit	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	O
,	O
chosen	O
as	O
a	O
representative	O
factor	O
,	O
we	O
have	O
developed	O
a	O
novel	O
screening	O
system	O
.	O

This	O
employs	O
an	O
Escherichia	O
coli	O
tester	O
strain	O
carrying	O
a	O
modified	O
lac	O
operon	O
as	O
a	O
reporter	O
gene	O
,	O
with	O
the	O
lac	O
operator	O
sequence	O
replaced	O
by	O
an	O
octamer	O
sequence	O
.	O

Oct-2	O
expressed	O
in	O
this	O
tester	O
strain	O
represses	O
the	O
expression	O
of	O
the	O
reporter	O
gene	O
and	O
changes	O
the	O
phenotype	O
of	O
the	O
cell	O
from	O
Lac+to	O
Lac-	O
.	O

Introduction	O
of	O
a	O
cDNA	O
expression	O
library	O
prepared	O
from	O
a	O
human	O
T-cell	O
line	O
into	O
the	O
Oct-2-harboring	O
tester	O
strain	O
allowed	O
selection	O
of	O
three	O
Lac+clones	O
out	O
of	O
1	O
x	O
10	O
(	O
5	O
)	O
transformants	O
.	O

One	O
of	O
them	O
,	O
hT86	O
,	O
encoding	O
a	O
putative	O
zinc	O
finger	O
protein	O
was	O
found	O
to	O
derepress	O
beta-galactosidase	O
activity	O
in	O
the	O
Oct-2-harboring	O
tester	O
strain	O
at	O
the	O
transcriptional	O
level	O
.	O

In	O
gel	O
mobility	O
shift	O
assays	O
,	O
hT86	O
attenuated	O
the	O
intensity	O
of	O
the	O
retarded	O
band	O
composed	O
of	O
the	O
octamer	O
probe	O
and	O
Oct-2	O
,	O
suggesting	O
a	O
dominant	O
negative	O
effect	O
on	O
the	O
DNA-binding	O
activity	O
of	O
Oct-2	O
.	O

The	O
strategy	O
described	O
here	O
provides	O
a	O
new	O
approach	O
for	O
studying	O
protein-protein	O
interactions	O
that	O
govern	O
the	O
complex	O
regulation	O
of	O
gene	O
expression	O
.	O

A	O
negative	O
role	O
for	O
phosphoinositide	O
3-kinase	O
in	O
T-cell	O
antigen	O
receptor	O
function	O
.	O

BACKGROUND	O
:	O
A	O
delicate	O
balance	O
between	O
positive	O
and	O
negative	O
regulatory	O
mechanisms	O
during	O
T-cell	O
activation	O
determines	O
the	O
specificity	O
and	O
magnitude	O
of	O
an	O
immune	O
response	O
.	O

Phosphoinositide	O
3-kinase	O
(	O
PI	O
3-kinase	O
)	O
is	O
activated	O
by	O
a	O
diverse	O
set	O
of	O
receptors	O
that	O
determine	O
T-cell	O
function	O
,	O
including	O
the	O
T-cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
,	O
the	O
costimulatory	O
receptor	O
CD28	O
,	O
and	O
negative	O
regulators	O
of	O
T-cell	O
activation	O
such	O
as	O
CTLA-4	O
.	O

PI	O
3-kinase	O
is	O
also	O
regulated	O
by	O
the	O
haematopoietic	O
cytokines	O
that	O
determine	O
T-cell	O
differentiation	O
and	O
lymphocyte	O
proliferation	O
.	O

PI	O
3-kinase	O
can	O
thus	O
dynamically	O
influence	O
the	O
outcome	O
of	O
the	O
immune	O
reactions	O
at	O
various	O
stages	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
importance	O
of	O
PI	O
3-kinase	O
in	O
TCR-directed	O
T-cell	O
activation	O
using	O
activated	O
or	O
inhibitory	O
versions	O
of	O
PI	O
3-kinase	O
.	O

RESULTS	O
:	O
Certain	B-Negation
aspects	I-Negation
of	I-Negation
TCR	I-Negation
responses	I-Negation
such	I-Negation
as	I-Negation
the	I-Negation
induction	I-Negation
of	I-Negation
transcriptional	I-Negation
activity	I-Negation
of	I-Negation
AP1	I-Negation
and	I-Negation
serum	I-Negation
response	I-Negation
factor	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
expression	I-Negation
of	I-Negation
the	I-Negation
mutant	I-Negation
forms	I-Negation
of	I-Negation
PI	I-Negation
3-kinase	I-Negation
.	O

We	O
found	O
,	O
however	O
,	O
that	O
PI	O
3-kinase	O
profoundly	O
influenced	O
the	O
transactivation	O
capacity	O
of	O
'nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
'	O
(	O
NF-AT	O
)	O
elicited	O
by	O
the	O
TCR	O
:	O
expression	O
of	O
an	O
activated	O
form	O
of	O
PI	O
3-kinase	O
inhibited	O
TCR-mediated	O
NF-AT	O
responses	O
,	O
whereas	O
expression	O
of	O
a	O
dominant	O
negative	O
mutant	O
of	O
PI	O
3-kinase	O
potently	O
enhanced	O
TCR-controlled	O
NF-AT	O
induction	O
.	O

These	B-Negation
effects	I-Negation
of	I-Negation
PI	I-Negation
3-kinase	I-Negation
were	I-Negation
not	I-Negation
mediated	I-Negation
by	I-Negation
previously	I-Negation
identified	I-Negation
PI	I-Negation
3-kinase	I-Negation
effectors	I-Negation
,	I-Negation
such	I-Negation
as	I-Negation
protein	I-Negation
kinase	I-Negation
B	I-Negation
,	I-Negation
a	I-Negation
positive	I-Negation
regulator	I-Negation
of	I-Negation
PI	I-Negation
3-kinase	I-Negation
,	I-Negation
or	I-Negation
the	I-Negation
GTPase	I-Negation
Rac	I-Negation
,	O
and	O
are	B-Speculation
therefore	I-Speculation
likely	I-Speculation
to	I-Speculation
involve	I-Speculation
a	I-Speculation
novel	I-Speculation
,	I-Speculation
as	I-Speculation
yet	I-Speculation
unknown	I-Speculation
,	I-Speculation
effector	I-Speculation
molecule	I-Speculation
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
establish	O
that	O
PI	O
3-kinase	O
can	O
both	O
positively	O
and	O
negatively	O
regulate	O
T-cell	O
function	O
,	O
and	O
uncover	O
a	O
previously	O
unrecognized	O
function	O
for	O
PI	O
3-kinase	O
in	O
T	O
cells	O
as	O
a	O
selective	O
negative	O
regulator	O
of	O
TCR-signalling	O
events	O
and	O
therefore	O
as	O
a	O
determinant	O
of	O
T-cell	O
homeostasis	O
.	O

NF-kappa	O
B-independent	O
suppression	O
of	O
HIV	O
expression	O
by	O
ascorbic	O
acid	O
.	O

Ascorbic	O
acid	O
(	O
ascorbate	O
or	O
vitamin	O
C	O
)	O
has	O
been	O
shown	O
to	O
suppress	O
the	O
induction	O
of	O
HIV	O
in	O
latently	O
infected	O
T	O
lymphocytic	O
cells	O
following	O
stimulation	O
with	O
a	O
tumor	O
promoter	O
(	O
PMA	O
)	O
and	O
inflammatory	O
cytokine	O
(	O
TNF-alpha	O
)	O
.	O

To	O
assess	O
whether	B-Speculation
this	I-Speculation
inhibition	I-Speculation
was	I-Speculation
mediated	I-Speculation
via	I-Speculation
modulation	I-Speculation
of	I-Speculation
the	I-Speculation
cellular	I-Speculation
transcription	I-Speculation
factor	I-Speculation
,	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
,	O
we	O
carried	O
out	O
gel	O
shift	O
analysis	O
on	O
nuclear	O
extracts	O
prepared	O
under	O
different	O
conditions	O
of	O
cell	O
stimulation	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
ascorbate	I-Negation
,	I-Negation
N-acetylcysteine	I-Negation
(	I-Negation
NAC	I-Negation
)	I-Negation
,	I-Negation
or	I-Negation
zidovudine	I-Negation
(	I-Negation
AZT	I-Negation
)	I-Negation
.	O

Pretreatment	O
of	O
ACH-2	O
T	O
cells	O
by	O
NAC	O
followed	O
by	O
stimulation	O
with	O
PMA	O
,	O
TNF-alpha	O
,	O
or	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
resulted	O
in	O
strong	O
suppression	O
of	O
NF-kappa	O
B	O
activation	O
.	O

In	O
contrast	O
,	O
neither	B-Negation
ascorbate	I-Negation
nor	I-Negation
AZT	I-Negation
affected	I-Negation
NF-kappa	I-Negation
B	I-Negation
activity	I-Negation
under	I-Negation
all	I-Negation
three	I-Negation
induction	I-Negation
conditions	I-Negation
in	I-Negation
the	I-Negation
ACH-2	I-Negation
cell	I-Negation
line	I-Negation
.	O

Ascorbate	O
and	O
AZT	O
also	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
following	I-Negation
TNF-alpha-	I-Negation
or	I-Negation
PMA-induced	I-Negation
stimulation	I-Negation
of	I-Negation
U1	I-Negation
promonocytic	I-Negation
cells	I-Negation
.	O

These	O
results	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
of	O
HIV	O
inhibition	O
by	O
ascorbate	O
is	O
not	O
mediated	O
via	O
NF-kappa	O
B	O
inhibition	O
,	O
unlike	O
that	O
seen	O
with	O
other	O
antioxidants	O
.	O

Lineage-	O
and	O
stage-specific	O
expression	O
of	O
runt	O
box	O
polypeptides	O
in	O
primitive	O
and	O
definitive	O
hematopoiesis	O
.	O

Translocations	O
involving	O
the	O
human	O
CBFA2	O
locus	O
have	O
been	O
associated	O
with	O
leukemia	O
.	O

This	O
gene	O
,	O
originally	O
named	O
AML1	O
,	O
is	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
gene	O
runt	O
that	O
controls	O
early	O
events	O
in	O
fly	O
embryogenesis	O
.	O

To	O
clarify	O
the	O
role	O
of	O
mammalian	O
runt	O
products	O
in	O
normal	O
and	O
leukemic	O
hematopoiesis	O
,	O
we	O
have	O
studied	O
their	O
pattern	O
of	O
expression	O
in	O
mouse	O
hematopoietic	O
tissues	O
in	O
the	O
adult	O
and	O
during	O
ontogeny	O
using	O
an	O
anti-runt	O
box	O
antiserum	O
.	O

In	O
the	O
adult	O
bone	O
marrow	O
,	O
we	O
found	O
expression	O
of	O
runt	O
polypeptides	O
in	O
differentiating	O
myeloid	O
cells	O
and	O
in	O
B	O
lymphocytes	O
.	O

Within	O
the	O
erythroid	O
lineage	O
,	O
runt	O
expression	O
is	O
biphasic	O
,	O
clearly	O
present	O
in	O
the	O
erythroblasts	O
of	O
early	O
blood	O
islands	O
and	O
of	O
the	O
fetal	O
liver	O
,	O
but	O
absent	B-Negation
in	I-Negation
the	I-Negation
adult	I-Negation
.	O

Biochemical	O
analysis	O
by	O
Western	O
blotting	O
of	O
fetal	O
and	O
adult	O
hematopoietic	O
populations	O
shows	O
several	O
runt	O
isoforms	O
.	O

At	O
least	O
one	O
of	O
them	O
appears	O
to	O
be	O
myeloid	O
specific	O
.	O

Cell-to-cell	O
contact	O
activates	O
the	O
long	O
terminal	O
repeat	O
of	O
human	O
immunodeficiency	O
virus	O
1	O
through	O
its	O
kappaB	O
motif	O
.	O

Cell-to-cell	O
contact	O
between	O
peripheral	O
blood	O
lymphocytes	O
and	O
transfected	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
HT29	O
activates	O
transcription	O
of	O
the	O
long	O
terminal	O
repeats	O
(	O
LTR	O
)	O
of	O
human	O
immunodeficiency	O
virus	O
.	O

HIV-1	O
LTR	O
transcription	O
is	O
controlled	O
by	O
a	O
complex	O
array	O
of	O
virus-encoded	O
and	O
cellular	O
proteins	O
.	O

Using	O
various	O
constructs	O
expressing	O
a	O
lacZ	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
intact	O
or	O
three	O
deleted	O
forms	O
of	O
HIV-1	O
LTR	O
,	O
we	O
obtained	O
evidence	O
that	O
the	O
kappaB	O
regulatory	O
elements	O
located	O
in	O
the	O
U3	O
region	O
are	O
involved	O
in	O
cell-to-cell	O
activation	O
of	O
HIV-1	O
LTR	O
.	O

Cell-to-cell	O
contact	O
activates	O
in	O
vitro	O
binding	O
of	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
p50/p65	O
heterodimer	O
to	O
an	O
HIV-1	O
kappaB	O
oligonucleotide	O
.	O

Cell-to-cell	O
contact	O
activation	O
of	O
NF-kappaB	O
was	O
only	O
partially	O
inhibited	O
by	O
100	O
microM	O
pyrrolidine	O
dithiocarbamate	O
and	O
was	B-Negation
not	I-Negation
correlated	I-Negation
with	I-Negation
a	I-Negation
significant	I-Negation
decrease	I-Negation
of	I-Negation
cellular	I-Negation
inhibitor	I-Negation
kappaB	I-Negation
alpha	I-Negation
.	O

NF-kappaB	O
nuclear	O
activation	O
was	O
not	B-Negation
detectable	I-Negation
before	I-Negation
1	I-Negation
h	I-Negation
after	I-Negation
cell	I-Negation
contact	I-Negation
and	O
was	O
dependent	O
on	O
protein	O
synthesis	O
.	O

HIV	O
does	O
not	B-Negation
replicate	I-Negation
in	I-Negation
naive	I-Negation
CD4	I-Negation
T	I-Negation
cells	I-Negation
stimulated	I-Negation
with	I-Negation
CD3/CD28	I-Negation
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
the	O
T	O
cell	O
tropic	O
strain	O
of	O
HIV	O
,	O
LAI	O
,	O
does	O
not	B-Negation
replicate	I-Negation
in	I-Negation
naive	I-Negation
CD4	I-Negation
T	I-Negation
cells	I-Negation
stimulated	I-Negation
by	I-Negation
cross-linking	I-Negation
CD3	I-Negation
and	I-Negation
CD28	I-Negation
.	O

In	O
contrast	O
,	O
LAI	O
replicates	O
well	O
in	O
memory	O
CD4	O
T	O
cells	O
stimulated	O
in	O
the	O
same	O
way	O
.	O

Unlike	O
this	O
physiologically	O
relevant	O
stimulation	O
,	O
PHA	O
stimulates	O
productive	O
LAI	O
replication	O
in	O
both	O
naive	O
and	O
memory	O
T	O
cells	O
.	O

These	O
studies	O
were	O
conducted	O
with	O
highly	O
purified	O
(	O
FACS-isolated	O
)	O
subsets	O
of	O
CD4	O
T	O
cells	O
identified	O
by	O
expression	O
of	O
both	O
CD45RA	O
and	O
CD62L	O
.	O

Remixing	O
of	O
purified	O
T	O
cells	O
showed	O
that	O
naive	O
T	O
cells	O
do	O
not	B-Negation
suppress	I-Negation
LAI	I-Negation
replication	I-Negation
in	I-Negation
memory	I-Negation
T	I-Negation
cells	I-Negation
and	O
that	O
memory	O
T	O
cells	O
do	O
not	B-Negation
restore	I-Negation
LAI	I-Negation
expression	I-Negation
in	I-Negation
naive	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
suppression	O
of	O
productive	O
LAI	O
replication	O
in	O
naive	O
T	O
cells	O
is	O
not	B-Negation
due	I-Negation
to	I-Negation
differential	I-Negation
expression	I-Negation
of	I-Negation
viral	I-Negation
coreceptors	I-Negation
,	I-Negation
nor	I-Negation
is	I-Negation
it	I-Negation
due	I-Negation
to	I-Negation
inhibition	I-Negation
of	I-Negation
activation	I-Negation
of	I-Negation
the	I-Negation
important	I-Negation
HIV	I-Negation
transcription	I-Negation
factors	I-Negation
,	I-Negation
nuclear	I-Negation
factor-kappaB	I-Negation
and	I-Negation
activator	I-Negation
protein-1	I-Negation
.	O

The	O
inherent	O
resistance	O
of	O
naive	O
T	O
cells	O
to	O
productive	O
HIV	O
infection	O
,	O
coupled	O
with	O
their	O
proliferative	O
advantage	O
as	O
demonstrated	O
here	O
,	O
provides	O
a	O
sound	O
basis	O
for	O
proposed	O
clinical	O
therapies	O
using	O
ex	O
vivo	O
expansion	O
and	O
reinfusion	O
of	O
CD4	O
T	O
cells	O
from	O
HIV-infected	O
adults	O
.	O

Nuclear	O
factor-kappa	O
B	O
potently	O
up-regulates	O
the	O
promoter	O
activity	O
of	O
RANTES	O
,	O
a	O
chemokine	O
that	O
blocks	O
HIV	O
infection	O
.	O

The	O
complex	O
network	O
of	O
cytokines	O
that	O
are	O
involved	O
in	O
inflammatory	O
and	O
immunoregulatory	O
responses	O
plays	O
a	O
critical	O
role	O
in	O
the	O
pathogenesis	O
of	O
HIV	O
infection	O
.	O

RANTES	O
(	O
regulated	O
upon	O
activation	O
,	O
normal	O
T	O
cell	O
expressed	O
and	O
secreted	O
)	O
is	O
a	O
cytokine	O
that	O
belongs	O
to	O
the	O
beta-chemokine	O
family	O
;	O
it	O
is	O
chemoattractant	O
for	O
CD4+/CD45RO	O
T	O
cells	O
,	O
it	O
is	O
produced	O
by	O
various	O
cell	O
types	O
including	O
CD8+	O
and	O
CD4+	O
T	O
cells	O
as	O
well	O
as	O
monocytes/macrophages	O
,	O
and	O
has	O
recently	O
been	O
shown	O
to	O
suppress	O
replication	O
of	O
macrophage-tropic	O
strains	O
of	O
HIV	O
in	O
CD4+	O
T	O
cells	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanisms	O
of	O
RANTES	O
expression	O
,	O
the	O
RANTES	O
promoter	O
region	O
was	O
analyzed	O
by	O
transient	O
expression	O
and	O
gel-mobility	O
shift	O
assays	O
.	O

We	O
demonstrate	O
that	O
:	O
1	O
)	O
RANTES	O
promoter	O
activity	O
is	O
up-regulated	O
by	O
PMA	O
plus	O
ionomycin	O
,	O
coexpression	O
of	O
the	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
,	O
the	O
proinflammatory	O
cytokines	O
TNF-alpha	O
and	O
IL-1	O
beta	O
,	O
and	O
the	O
CD28	O
costimulatory	O
pathway	O
;	O
2	O
)	O
the	O
RANTES	O
promoter	O
region	O
contains	O
four	O
NF-kappa	O
B	O
binding	O
sites	O
at	O
positions	O
-30	O
,	O
-44	O
,	O
-213	O
,	O
and	O
-579	O
relative	O
to	O
the	O
transcription	O
start	O
site	O
;	O
3	O
)	O
one	O
site	O
(	O
-213	O
)	O
is	O
an	O
NF-AT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
binding	O
site	O
that	O
also	O
has	O
weak	O
affinity	O
to	O
NF-kappa	O
B	O
,	O
and	O
the	O
most	O
distal	O
site	O
(	O
-579	O
)	O
also	O
serves	O
as	O
a	O
CD28-responsive	O
element	O
;	O
and	O
4	O
)	O
mutation	O
on	O
any	O
of	O
those	O
NF-kappa	O
B	O
sites	O
or	O
coexpression	O
of	O
I	O
kappa	O
B	O
alpha	O
(	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappa	O
B	O
)	O
markedly	O
reduced	O
the	O
promoter	O
activity	O
.	O

Thus	O
,	O
NF-kappa	O
B	O
,	O
a	O
potent	O
transcriptional	O
activator	O
of	O
HIV	O
expression	O
,	O
is	O
also	O
involved	O
in	O
the	O
expression	O
of	O
RANTES	O
,	O
a	O
chemokine	O
that	O
blocks	O
infection	O
by	O
macrophage-tropic	O
strains	O
of	O
HIV	O
.	O

Control	O
of	O
NFATx1	O
nuclear	O
translocation	O
by	O
a	O
calcineurin-regulated	O
inhibitory	O
domain	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
regulates	O
cytokine	O
gene	O
expression	O
in	O
T	O
cells	O
through	O
cis-acting	O
elements	O
located	O
in	O
the	O
promoters	O
of	O
several	O
cytokine	O
genes	O
.	O

NFATx1	O
,	O
which	O
is	O
preferentially	O
expressed	O
in	O
the	O
thymus	O
and	O
peripheral	O
blood	O
leukocytes	O
,	O
is	O
one	O
of	O
four	O
members	O
of	O
the	O
NFAT	O
family	O
of	O
transcription	O
factors	O
.	O

We	O
have	O
performed	O
domain	O
analysis	O
of	O
NFATx1	O
by	O
examining	O
the	O
effects	O
of	O
deletion	O
mutations	O
.	O

We	O
found	O
that	O
NFATx1	O
DNA	O
binding	O
activity	O
and	O
interaction	O
with	O
AP-1	O
polypeptides	O
were	O
dependent	O
on	O
its	O
central	O
Rel	O
similarity	O
region	O
and	O
that	O
transcriptional	O
activation	O
was	O
reduced	O
by	O
deletions	O
of	O
either	O
its	O
N-terminal	O
domain	O
or	O
its	O
C-terminal	O
domain	O
,	O
suggesting	O
the	O
presence	O
of	O
intrinsic	O
transcriptional	O
activation	O
motifs	O
in	O
both	O
regions	O
.	O

We	O
also	O
identified	O
a	O
potent	O
inhibitory	O
sequence	O
within	O
its	O
N-terminal	O
domain	O
.	O

We	O
show	O
that	O
the	O
inactivation	O
of	O
the	O
inhibition	O
was	O
dependent	O
on	O
the	O
activity	O
of	O
calcineurin	O
,	O
a	O
calcium-calmodulin-dependent	O
phosphatase	O
.	O

We	O
also	O
show	O
that	O
calcineurin	O
associated	O
with	O
the	O
N-terminal	O
domain	O
of	O
NFATx1	O
at	O
multiple	O
docking	O
sites	O
and	O
caused	O
a	O
reduction	O
of	O
size	O
,	O
indicative	O
of	O
dephosphorylation	O
,	O
in	O
NFATx1	O
.	O

We	O
have	O
mapped	O
the	O
inhibitory	O
activity	O
to	O
less	O
than	O
60	O
residues	O
,	O
containing	O
motifs	O
that	O
are	O
conserved	O
in	O
all	O
NFAT	O
proteins	O
.	O

Finally	O
,	O
we	O
demonstrate	O
that	O
deletion	O
in	O
NFATx1	O
of	O
the	O
mapped	O
60	O
residues	O
leads	O
to	O
its	O
nuclear	O
translocation	O
independent	O
of	O
calcium	O
signaling	O
.	O

Our	O
results	O
support	O
the	O
model	O
proposing	O
that	O
the	O
N-terminal	O
domain	O
confers	O
calcium-signaling	O
dependence	O
on	O
NFATx1	O
transactivation	O
activity	O
by	O
regulating	O
its	O
intracellular	O
localization	O
through	O
a	O
protein	O
module	O
that	O
associates	O
with	O
calcineurin	O
and	O
is	O
a	O
target	O
of	O
its	O
phosphatase	O
activity	O
.	O

Neuronal	O
(	O
type	O
I	O
)	O
nitric	O
oxide	O
synthase	O
regulates	O
nuclear	O
factor	O
kappaB	O
activity	O
and	O
immunologic	O
(	O
type	O
II	O
)	O
nitric	O
oxide	O
synthase	O
expression	O
.	O

Nitric	O
oxide	O
subserves	O
diverse	O
physiologic	O
roles	O
in	O
the	O
nervous	O
system	O
.	O

NO	O
is	O
produced	O
from	O
at	O
least	O
three	O
different	O
NO	O
synthase	O
(	O
NOS	O
)	O
isoforms	O
:	O
neuronal	O
NOS	O
(	O
nNOS	O
)	O
,	O
endothelial	O
NOS	O
,	O
and	O
immunologic	O
NOS	O
(	O
iNOS	O
)	O
.	O

We	O
show	O
that	O
nNOS	O
is	O
the	O
predominant	O
isoform	O
constitutively	O
expressed	O
in	O
glia	O
.	O

NO	O
derived	O
from	O
nNOS	O
in	O
glia	O
inhibits	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappaB	O
(	O
NF	O
kappaB	O
)	O
as	O
NOS	O
inhibitors	O
enhance	O
basal	O
NF	O
kappaB	O
activation	O
.	O

Pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
is	O
an	O
inhibitor	O
of	O
NF	O
kappaB	O
in	O
most	O
cells	O
;	O
however	O
,	O
we	O
show	O
that	O
PDTC	O
is	O
also	O
a	O
potent	O
scavenger	O
of	O
NO	O
through	O
formation	O
of	O
mononitrosyl	O
iron	O
complexes	O
with	O
PDTC	O
.	O

In	O
Jurkat	O
cells	O
,	O
a	O
human	O
T-cell	O
lymphoma	O
cell	O
line	O
,	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
induces	O
NF	O
kappaB	O
activation	O
that	O
is	O
inhibited	O
by	O
PDTC	O
.	O

Contrary	O
to	O
the	O
results	O
in	O
Jurkat	O
cells	O
,	O
PDTC	O
did	O
not	B-Negation
inhibit	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha-induced	I-Negation
NF	I-Negation
kappaB	I-Negation
activation	I-Negation
in	I-Negation
astrocytes	I-Negation
;	O
instead	O
PDTC	O
itself	O
induces	O
NF	O
kappaB	O
activation	O
in	O
astrocytes	O
,	O
and	O
this	B-Speculation
may	I-Speculation
be	I-Speculation
related	I-Speculation
to	I-Speculation
scavenging	I-Speculation
of	I-Speculation
endogenously	I-Speculation
produced	I-Speculation
NO	I-Speculation
by	I-Speculation
the	I-Speculation
PDTC	I-Speculation
iron	I-Speculation
complex	I-Speculation
.	O

In	O
astrocytes	O
PDTC	O
also	O
dramatically	O
induces	O
the	O
NF	O
kappaB-dependent	O
enzyme	O
,	O
iNOS	O
,	O
supporting	O
the	O
physiologic	O
relevance	O
of	O
endogenous	O
NO	O
regulation	O
of	O
NF	O
kappaB	O
.	O

NF	O
kappaB	O
activation	O
in	O
glia	O
from	O
mice	O
lacking	B-Negation
nNOS	I-Negation
responds	O
more	O
rapidly	O
to	O
PDTC	O
compared	O
with	O
astrocytes	O
from	O
wild-type	O
mice	O
.	O

Our	O
data	O
suggest	O
that	O
nNOS	O
in	O
astrocytes	O
regulates	O
NF	O
kappaB	O
activity	O
and	O
iNOS	O
expression	O
,	O
and	O
indicate	O
a	O
novel	O
regulatory	O
role	O
for	O
nNOS	O
in	O
tonically	O
suppressing	O
central	O
nervous	O
system	O
,	O
NF	O
kappaB-regulated	O
genes	O
.	O

Activation	O
of	O
the	O
NF-kappaB	O
pathway	O
by	O
inflammatory	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Activated	O
neutrophils	O
have	O
the	O
ability	O
to	O
upregulate	O
the	O
expression	O
of	O
many	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	O
and	O
chemokines	O
,	O
and	O
to	O
subsequently	O
release	O
the	O
corresponding	O
proteins	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
concerning	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
it	O
is	O
noteworthy	O
that	O
many	O
of	O
these	O
genes	O
depend	O
on	O
the	O
activation	O
of	O
transcription	O
factors	O
,	O
such	O
as	O
NF-kappaB	O
,	O
for	O
inducible	O
expression	O
.	O

We	O
therefore	O
investigated	O
whether	O
NF-kappaB/Rel	O
proteins	O
are	O
expressed	O
in	O
human	O
neutrophils	O
,	O
as	O
well	O
as	O
their	O
fate	O
on	O
cell	O
activation	O
.	O

We	O
now	O
report	O
that	O
dimers	O
consisting	O
of	O
p50	O
NFkappaB1	O
,	O
p65	O
RelA	O
,	O
and/or	O
c-Rel	O
are	O
present	O
in	O
neutrophils	O
and	O
that	O
the	O
greater	O
part	O
of	O
these	O
protein	O
complexes	O
is	O
physically	O
associated	O
with	O
cytoplasmic	O
IkappaB-alpha	O
in	O
resting	O
cells	O
.	O

Following	O
neutrophil	O
stimulation	O
with	O
proinflammatory	O
agonists	O
(	O
such	O
as	O
lipopolysaccharide	O
[	O
LPS	O
]	O
,	O
tumor	O
necrosis	O
factor-alpha	O
[	O
TNF-alpha	O
]	O
,	O
and	O
fMet-Leu-Phe	O
)	O
that	O
induce	O
the	O
production	O
of	O
cytokines	O
and	O
chemokines	O
in	O
these	O
cells	O
,	O
NF-kappaB/Rel	O
proteins	O
translocated	O
to	O
nuclear	O
fractions	O
,	O
resulting	O
in	O
a	O
transient	O
induction	O
of	O
NF-kappaB	O
DNA	O
binding	O
activity	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

The	O
onset	O
of	O
both	O
processes	O
was	O
found	O
to	O
be	O
closely	O
paralleled	O
by	O
,	O
and	O
dependent	O
on	O
,	O
IkappaB-alpha	O
degradation	O
.	O

Proinflammatory	O
neutrophil	O
stimuli	O
also	O
promoted	O
the	O
accumulation	O
of	O
IkappaB-alpha	O
mRNA	O
transcripts	O
,	O
resulting	O
in	O
the	O
reexpression	O
of	O
the	O
IkappaB-alpha	O
protein	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
constitutes	O
the	O
first	O
indication	O
that	O
NF-kappaB	O
activation	O
may	O
underlie	O
the	O
action	O
of	O
proinflammatory	O
stimuli	O
towards	O
human	O
neutrophil	O
gene	O
expression	O
and	O
,	O
as	O
such	O
,	O
adds	O
a	O
new	O
facet	O
to	O
our	O
understanding	O
of	O
neutrophil	O
biology	O
.	O

Regulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
:	O
role	O
of	O
B-cell-specific	O
activator	O
protein	O
.	O

Germline	O
transcripts	O
initiate	O
from	O
promoters	O
upstream	O
of	O
the	O
immunoglobulin	O
switch	O
region	O
,	O
and	O
are	O
necessary	O
to	O
target	O
the	O
appropriate	O
switch	O
region	O
for	O
recombination	O
and	O
switching	O
.	O

Different	O
cytokines	O
activate	O
transcription	O
at	O
the	O
appropriate	O
germline	O
promoter	O
.	O

Because	O
binding	O
sites	O
for	O
B-cell-specific	O
activator	O
protein	O
(	O
BSAP	O
)	O
are	O
located	O
upstream	O
of	O
several	O
switch	O
regions	O
in	O
the	O
immunoglobulin	O
heavy	O
chain	O
gene	O
cluster	O
,	O
BSAP	O
might	O
play	O
a	O
role	O
in	O
the	O
regulation	O
of	O
germline	O
transcription	O
and	O
isotype	O
switching	O
.	O

We	O
investigated	O
whether	O
BSAP	O
plays	O
a	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
epsilon	O
germline	O
promoter	O
in	O
human	O
B	O
cells	O
.	O

Our	O
results	O
showed	O
that	O
BSAP	O
plays	O
a	O
role	O
in	O
both	O
IL-4-dependent	O
induction	O
and	O
CD40-mediated	O
upregulation	O
of	O
human	O
epsilon	O
germline	O
transcription	O
.	O

BSAP	O
is	O
unique	O
among	O
the	O
transcription	O
factors	O
that	O
regulate	O
epsilon	O
germline	O
expression	O
,	O
because	O
it	O
is	O
B	O
cell	O
specific	O
,	O
and	O
is	O
at	O
the	O
merging	O
point	O
of	O
two	O
signalling	O
pathways	O
that	O
are	O
critical	O
for	O
IgE	O
switching	O
.	O

Retinoic	O
acid-induced	O
modulation	O
of	O
IL-2	O
mRNA	O
production	O
and	O
IL-2	O
receptor	O
expression	O
on	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Retinoic	O
acid	O
(	O
RA	O
)	O
has	O
important	O
immune-modulating	O
effects	O
on	O
both	O
T	O
and	O
B	O
cell	O
function	O
.	O

Our	O
laboratory	O
has	O
shown	O
that	O
RA	O
can	O
enhance	O
in	O
vitro	O
polyclonal	O
B	O
cell	O
immunoglobulin	O
(	O
Ig	O
)	O
response	O
.	O

Investigating	O
cytokines	O
known	O
to	O
affect	O
B	O
cell	O
differentiation	O
,	O
we	O
have	O
recently	O
shown	O
that	O
IL-6	O
production	O
is	O
augmented	O
by	O
RA	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
examined	O
the	O
immune	O
modulating	O
effects	O
of	O
RA	O
on	O
IL-2	O
mRNA	O
,	O
another	O
important	O
cytokine	O
for	O
B	O
cell	O
immunoglobulin	O
production	O
,	O
the	O
expression	O
of	O
IL-2	O
receptors	O
on	O
T	O
cells	O
,	O
and	O
the	O
RA	O
nuclear	O
receptors	O
.	O

METHODS	O
:	O
Purified	O
T	O
cells	O
were	O
obtained	O
from	O
adenoidal	O
tissues	O
,	O
and	O
incubated	O
with	O
RA	O
(	O
10	O
(	O
-7	O
)	O
M	O
)	O
or	O
DMSO	O
solvent/media	O
control	O
for	O
0	O
,	O
6-8	O
,	O
and	O
24	O
h	O
.	O

Total	O
mRNA	O
was	O
extracted	O
from	O
T	O
cells	O
,	O
and	O
using	O
RT-PCR	O
,	O
changes	O
in	O
the	O
production	O
of	O
IL-2	O
and	O
RA	O
receptors	O
(	O
RAR	O
)	O
-alpha	O
,	O
beta	O
,	O
gamma	O
mRNA	O
were	O
determined	O
.	O

The	O
effects	O
of	O
RA	O
on	O
IL-2-alpha	O
receptor	O
expression	O
was	O
determined	O
by	O
flow	O
cytometry	O
on	O
T	O
cells	O
.	O

CONCLUSION	O
:	O
These	O
studies	O
suggest	O
that	O
RA	O
can	O
augment	O
IL-2	O
mRNA	O
production	O
by	O
T	O
cells	O
with	O
a	O
possible	O
paracrine	O
effect	O
on	O
IL-2R-alpha	O
expression	O
.	O

These	O
changes	O
appear	O
to	O
be	O
mediated	O
by	O
RAR-alpha	O
.	O

Thus	O
,	O
IL-2	O
may	O
be	O
another	O
important	O
cytokine	O
modulated	O
by	O
RA	O
in	O
the	O
immune	O
response	O
.	O

Itk	O
,	O
a	O
T	O
cell-specific	O
tyrosine	O
kinase	O
,	O
is	O
required	O
for	O
CD2-mediated	O
interleukin-2	O
promoter	O
activation	O
in	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
.	O

We	O
investigated	O
the	O
functional	O
role	O
of	O
Itk	O
,	O
a	O
member	O
of	O
the	O
cytoplasmic	O
tyrosine	O
kinase	O
Tec	O
family	O
,	O
in	O
T	O
cell	O
activation	O
.	O

Stimulation	O
of	O
either	O
CD2	O
or	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
/CD3	O
on	O
Tcells	O
by	O
monoclonal	O
antibody-mediated	O
cross-linking	O
induced	O
tyrosine	O
phosphorylation	O
of	O
Itk	O
,	O
which	O
was	O
maximal	O
as	O
early	O
as	O
1	O
min	O
after	O
stimulation	O
.	O

The	O
tyrosine	O
kinase	O
activity	O
in	O
the	O
anti-Itk	O
immunoprecipitate	O
was	O
significantly	O
activated	O
upon	O
these	O
stimulations	O
.	O

Interleukin-2	O
(	O
IL-2	O
)	O
promoter	O
activity	O
stimulated	O
by	O
cross-linking	O
of	O
CD2	O
,	O
TCR/CD3	O
,	O
and	O
CD28	O
with	O
antibodies	O
was	O
significantly	O
reduced	O
by	O
transient	O
expression	O
of	O
an	O
Itk	O
mutant	O
lacking	B-Negation
the	I-Negation
kinase	I-Negation
activity	I-Negation
.	O

The	O
reduction	O
paralleled	O
a	O
decrease	O
in	O
tyrosine	O
phosphorylation	O
of	O
endogenous	O
wild-type	O
Itk	O
.	O

Stimulation	O
of	O
CD2	O
or	O
TCR/CD3	O
induced	O
activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
the	O
binding	O
site	O
of	O
which	O
is	O
included	O
in	O
the	O
IL-2	O
gene	O
promoter	O
.	O

The	O
activation	O
of	O
NFAT	O
was	O
also	O
impaired	O
by	O
expression	O
of	O
the	O
Itk	O
mutant	O
.	O

These	O
results	O
demonstrate	O
that	O
Itk	O
plays	O
a	O
role	O
in	O
IL-2	O
production	O
,	O
indicating	O
a	O
critical	O
involvement	O
of	O
Itk	O
in	O
the	O
initial	O
stage	O
of	O
T	O
cell	O
activation	O
by	O
mediating	O
signals	O
from	O
the	O
TCR/CD3	O
complex	O
,	O
CD2	O
,	O
and	O
CD28	O
.	O

Jak3	O
is	O
associated	O
with	O
CD40	O
and	O
is	O
critical	O
for	O
CD40	O
induction	O
of	O
gene	O
expression	O
in	O
B	O
cells	O
.	O

CD40	O
is	O
a	O
receptor	O
that	O
is	O
critical	O
for	O
the	O
survival	O
,	O
growth	O
,	O
differentiation	O
,	O
and	O
isotype	O
switching	O
of	O
B	O
lymphocytes	O
.	O

Although	O
CD40	O
lacks	B-Negation
intrinsic	I-Negation
tyrosine	I-Negation
kinase	I-Negation
activity	I-Negation
,	O
its	O
ligation	O
induces	O
protein	O
tyrosine	O
phosphorylation	O
,	O
which	O
is	O
necessary	O
for	O
several	O
CD40-mediated	O
events	O
.	O

We	O
show	O
that	O
engagement	O
of	O
CD40	O
induces	O
tyrosine	O
phosphorylation	O
and	O
activation	O
of	O
Jak3	O
as	O
well	O
as	O
of	O
STAT3	O
.	O

Jak3	O
is	O
constitutively	O
associated	O
with	O
CD40	O
,	O
and	O
this	O
interaction	O
requires	O
a	O
proline-rich	O
sequence	O
in	O
the	O
membrane-proximal	O
region	O
of	O
CD40	O
.	O

Deletion	O
of	O
this	O
sequence	O
abolishes	O
the	O
capacity	O
of	O
CD40	O
to	O
induce	O
expression	O
of	O
CD23	O
,	O
ICAM-1	O
,	O
and	O
lymphotoxin-alpha	O
genes	O
in	O
B	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
signaling	O
through	O
Jak3	O
is	O
activated	O
by	O
CD40	O
and	O
plays	O
an	O
important	O
role	O
in	O
CD40-mediated	O
functions	O
.	O

The	O
tumour	O
associated	O
cell	O
surface	O
antigen	O
A6H	O
is	O
costimulatory	O
for	O
human	O
CD4+	O
but	O
not	B-Negation
CD8+	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
A6H	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
recognizes	O
a	O
120,000-140,000	O
MW	O
antigen	O
that	O
is	O
expressed	O
at	O
similar	O
densities	O
on	O
85-90	O
%	O
of	O
human	O
CD4+	O
and	O
CD8+	O
T	O
cells	O
and	O
on	O
renal	O
cell	O
carcinomas	O
.	O

The	O
binding	O
of	O
the	O
A6H	O
mAb	O
induced	O
a	O
costimulatory	O
signal	O
in	O
anti-CD3	O
activated	O
T	O
cells	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
that	O
A6H	O
costimulated	O
cell	O
proliferation	O
and	O
cytokine	O
production	O
in	O
purified	O
CD4+	O
T	O
cells	O
.	O

Unexpectedly	O
,	O
the	O
CD8+	O
T-cell	O
subpopulation	O
failed	B-Negation
to	I-Negation
respond	I-Negation
.	O

CD4+	O
T	O
cells	O
costimulated	O
with	O
the	O
A6H	O
mAb	O
upregulated	O
CD80	O
,	O
CD86	O
,	O
CD71	O
,	O
interleukin-2	O
(	O
IL-2	O
)	O
R	O
alpha	O
,	O
IL-2R	O
beta	O
and	O
IL-2R	O
gamma	O
,	O
while	O
no	B-Negation
corresponding	I-Negation
up-regulation	I-Negation
of	I-Negation
these	I-Negation
cell	I-Negation
surface	I-Negation
molecules	I-Negation
was	I-Negation
seen	I-Negation
in	I-Negation
CD8+	I-Negation
T	I-Negation
cells	I-Negation
.	O

In	O
order	O
to	O
investigate	O
the	O
nature	O
of	O
the	O
A6H	O
mAb	O
costimulus	O
at	O
the	O
transcriptional	O
level	O
we	O
have	O
examined	O
induction	O
of	O
the	O
transcription	O
factors	O
OCT-1	O
,	O
AP-1	O
and	O
NF-kappa	O
B	O
which	O
are	O
known	O
to	O
be	O
transcriptional	O
regulators	O
of	O
several	O
cytokine	O
and	O
cytokine	O
receptor	O
genes	O
,	O
including	O
the	O
IL-2	O
and	O
IL-2R	O
genes	O
.	O

Co-ligation	O
of	O
the	O
A6H	O
antigen	O
and	O
the	O
CD3	O
complex	O
induced	O
expression	O
of	O
the	O
transcription	O
factor	O
AP-1	O
in	O
CD4+	O
T	O
cells	O
,	O
whereas	O
no	B-Negation
increase	I-Negation
in	I-Negation
NF-kappa	I-Negation
B	I-Negation
and	I-Negation
octamer-binding	I-Negation
(	I-Negation
Oct	I-Negation
)	I-Negation
proteins	I-Negation
was	I-Negation
seen	I-Negation
compared	I-Negation
to	I-Negation
T	I-Negation
cells	I-Negation
stimulated	I-Negation
with	I-Negation
anti-CD3	I-Negation
alone	I-Negation
.	O

Furthermore	O
,	O
no	B-Negation
induction	I-Negation
of	I-Negation
AP-1	I-Negation
was	I-Negation
seen	I-Negation
in	I-Negation
A6H	I-Negation
costimulated	I-Negation
CD8+	I-Negation
T	I-Negation
cells	I-Negation
.	O

These	O
results	O
suggests	O
that	O
both	O
proximal	O
steps	O
in	O
CD8+	O
T-cell	O
activation	O
as	O
well	O
as	O
the	O
later	O
phases	O
are	O
unresponsive	O
to	O
A6H	O
ligation	O
.	O

Molecular	O
differences	O
of	O
the	O
A6H	O
molecule	O
or	O
distinct	O
regulation	O
of	O
the	O
A6H	O
transduced	O
AP-1	O
activation	O
pathway	O
may	O
exist	O
in	O
CD4+	O
and	O
CD8+	O
T	O
cell	O
subpopulations	O
.	O

Structure	O
and	O
function	O
analysis	O
of	O
the	O
human	O
myeloid	O
cell	O
nuclear	O
differentiation	O
antigen	O
promoter	O
:	O
evidence	O
for	O
the	O
role	O
of	O
Sp1	O
and	O
not	B-Negation
of	I-Negation
c-Myb	I-Negation
or	I-Negation
PU.1	I-Negation
in	O
myelomonocytic	O
lineage-specific	O
expression	O
.	O

The	O
human	O
myeloid	O
nuclear	O
differentiation	O
antigen	O
(	O
MNDA	O
)	O
is	O
expressed	O
specifically	O
in	O
maturing	O
cells	O
of	O
the	O
myelomonocytic	O
lineage	O
and	O
in	O
monocytes	O
and	O
granulocytes	O
.	O

Epitope	O
enhancement	O
was	O
used	O
to	O
confirm	O
the	O
strict	O
lineage-	O
and	O
stage-specific	O
expression	O
of	O
MNDA	O
in	O
bone	O
marrow	O
as	O
well	O
as	O
in	O
other	O
paraffin-embedded	O
fixed	O
tissues	O
.	O

A	O
1-kb	O
region	O
of	O
the	O
gene	O
that	O
includes	O
5	O
'	O
flanking	O
sequence	O
was	O
reported	O
earlier	O
to	O
contain	O
functional	O
promoter	O
activity	O
and	O
was	O
specifically	O
demethylated	O
in	O
expressing	O
cells	O
in	O
contrast	O
to	O
null	O
cells	O
.	O

Further	O
analysis	O
has	O
revealed	O
that	O
this	O
1-kb	O
fragment	O
promotes	O
higher	O
reporter	O
gene	O
activity	O
in	O
MNDA-expressing	O
cells	O
than	O
non-expressing	O
cells	O
,	O
indicating	O
cell-specific	O
differences	O
in	O
transactivation	O
.	O

This	O
sequence	O
contains	O
consensus	O
elements	O
consistent	O
with	O
myeloid-specific	O
gene	O
expression	O
,	O
including	O
a	O
PU.1	O
consensus	O
site	O
near	O
the	O
major	O
transcription	O
start	O
site	O
and	O
a	O
cluster	O
of	O
c-Myb	O
sites	O
located	O
several	O
hundred	O
bases	O
upstream	O
of	O
this	O
region	O
.	O

However	O
,	O
analysis	O
of	O
deletion	O
mutants	O
localized	O
nearly	O
all	O
of	O
the	O
promoter	O
activity	O
to	O
a	O
short	O
region	O
(	O
-73	O
to	O
-16	O
)	O
that	O
did	O
not	B-Negation
include	I-Negation
the	I-Negation
cluster	I-Negation
of	I-Negation
c-Myb	I-Negation
sites	I-Negation
.	O

A	O
4-bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
(	O
GC	O
box	O
)	O
(	O
-20	O
)	O
reduced	O
overall	O
promoter	O
activity	O
of	O
the	O
1-kb	O
fragment	O
.	O

Mutation	O
of	O
the	O
PU.1	O
site	O
did	O
not	O
significantly	O
affect	O
promoter	O
activity	O
.	O

Only	O
a	O
small	O
region	O
(	O
-35	O
to	O
+22	O
)	O
including	O
the	O
Sp1	O
element	O
and	O
transcription	O
start	O
site	O
,	O
but	O
not	B-Negation
the	I-Negation
PU.1	I-Negation
site	I-Negation
was	O
footprinted	O
.	O

The	O
4-bp	O
mutation	O
of	O
the	O
core	O
Sp1	O
consensus	O
element	O
abolished	O
footprinting	O
at	O
the	O
site	O
and	O
an	O
antibody	O
super-shift	O
reaction	O
showed	O
that	O
Sp1	O
is	O
one	O
of	O
the	O
factors	O
binding	O
the	O
consensus	O
site	O
.	O

The	O
Sp1	O
site	O
also	O
co-localizes	O
with	O
a	O
DNase	O
I	O
hypersensitive	O
site	O
.	O

The	O
results	O
indicate	O
that	O
DNA	O
methylation	O
,	O
chromatin	O
structure	O
,	O
and	O
transactivation	O
at	O
an	O
Sp1	O
site	O
contribute	O
to	O
the	O
highly	O
restricted	O
expression	O
of	O
this	O
myelomonocytic	O
lineage	O
specific	O
gene	O
.	O

Inhibitor	O
(	O
IK	O
)	O
of	O
IFN-gamma	O
induced	O
HLA	O
class	O
II	O
antigens	O
expression	O
also	O
inhibits	O
HLA	O
class	O
II	O
constitutive	O
expression	O
in	O
the	O
human	O
Raji	O
B	O
cell	O
line	O
.	O

The	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
antigens	O
is	O
constitutive	O
in	O
professional	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
but	O
can	O
also	O
be	O
induced	O
by	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
on	O
the	O
majority	O
of	O
the	O
non	O
professional	O
APCs	O
(	O
e.g.	O
fibroblasts	O
)	O
.	O

We	O
have	O
recently	O
characterised	O
a	O
new	O
factor	O
called	O
IK	O
which	O
is	O
an	O
efficient	O
inhibitor	O
of	O
IFN-gamma	O
induction	O
of	O
MHC	O
class	O
II	O
antigens	O
expression	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
novel	O
role	O
for	O
IK	O
in	O
MHC	O
class	O
II	O
expression	O
since	O
over-expression	O
of	O
this	O
protein	O
by	O
stable	O
transfection	O
into	O
human	O
B	O
cells	O
led	O
to	O
a	O
total	O
disappearance	O
of	O
constitutive	O
MHC	O
class	O
II	O
mRNA	O
expression	O
.	O

The	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
is	O
necessary	O
for	O
both	O
constitutive	O
and	O
IFN-gamma	O
induced	O
MHC	O
class	O
II	O
expressions	O
.	O

Examination	O
of	O
CIITA	O
mRNA	O
in	O
IK	O
stably	O
transfected	O
clones	O
revealed	O
a	O
marked	O
reduction	O
of	O
CIITA	O
mRNA	O
transcription	O
.	O

Taken	O
together	O
these	O
results	O
demonstrate	O
that	O
the	O
IK	O
protein	O
plays	O
a	O
key	O
role	O
in	O
the	O
constitutive	O
expression	O
of	O
MHC	O
class	O
II	O
antigens	O
and	O
that	O
inhibition	O
induced	O
by	O
IK	O
is	O
upstream	O
of	O
CIITA	O
in	O
this	O
regulatory	O
pathway	O
.	O

An	O
enhancer-blocking	O
element	O
between	O
alpha	O
and	O
delta	O
gene	O
segments	O
within	O
the	O
human	O
T	O
cell	O
receptor	O
alpha/delta	O
locus	O
.	O

T	O
cell	O
receptor	O
(	O
TCR	O
)	O
alpha	O
and	O
delta	O
gene	O
segments	O
are	O
organized	O
within	O
a	O
single	O
genetic	O
locus	O
but	O
are	O
differentially	O
regulated	O
during	O
T	O
cell	O
development	O
.	O

An	O
enhancer-blocking	O
element	O
(	O
BEAD-1	O
,	O
for	O
blocking	O
element	O
alpha/delta	O
1	O
)	O
was	O
localized	O
to	O
a	O
2.0-kb	O
region	O
3	O
'	O
of	O
TCR	O
delta	O
gene	O
segments	O
and	O
5	O
'	O
of	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
within	O
this	O
locus	O
.	O

BEAD-1	O
blocked	O
the	O
ability	O
of	O
the	O
TCR	O
delta	O
enhancer	O
(	O
Edelta	O
)	O
to	O
activate	O
a	O
promoter	O
when	O
located	O
between	O
the	O
two	O
in	O
a	O
chromatin-integrated	O
construct	O
.	O

We	O
propose	O
that	O
BEAD-1	O
functions	O
as	O
a	O
boundary	O
that	O
separates	O
the	O
TCR	O
alpha/delta	O
locus	O
into	O
distinct	O
regulatory	O
domains	O
controlled	O
by	O
Edelta	O
and	O
the	O
TCR	O
alpha	O
enhancer	O
,	O
and	O
that	O
it	O
prevents	O
Edelta	O
from	O
opening	O
the	O
chromatin	O
of	O
the	O
TCR	O
alpha	O
joining	O
gene	O
segments	O
for	O
VDJ	O
recombination	O
at	O
an	O
early	O
stage	O
of	O
T	O
cell	O
development	O
.	O

Quantification	O
of	O
vitamin	O
D	O
receptor	O
mRNA	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
in	O
PBMC	O
:	O
lack	B-Negation
of	I-Negation
correspondence	I-Negation
with	I-Negation
common	I-Negation
allelic	I-Negation
variants	I-Negation
.	O

It	O
has	O
been	O
recently	O
claimed	O
that	O
polymorphism	O
for	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
influences	O
several	O
aspects	O
of	O
calcium	O
and	O
bone	O
metabolism	O
.	O

To	O
evaluate	O
the	O
physiologic	O
plausibility	O
of	O
these	O
claims	O
,	O
we	O
compared	O
the	O
abundance	O
of	O
the	O
VDR	O
mRNA	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
between	O
different	O
VDR	O
genotypes	O
using	O
a	O
quantitative	O
reverse	O
transcribed	O
polymerase	O
chain	O
reaction-based	O
method	O
.	O

The	O
method	O
is	O
based	O
on	O
the	O
coamplification	O
of	O
VDR	O
cDNA	O
and	O
an	O
internal	O
standard	O
consisting	O
of	O
known	O
concentrations	O
of	O
a	O
human	O
VDR	O
CDNA	O
mutated	O
at	O
a	O
BglII	O
restriction	O
site	O
;	O
the	O
interassay	O
coefficient	O
of	O
variation	O
is	O
11	O
%	O
.	O

To	O
validate	O
the	O
method	O
,	O
we	O
made	O
use	O
of	O
earlier	O
receptor	O
binding	O
studies	O
indicating	O
that	O
normal	O
human	O
monocytes	O
and	O
activated	O
,	O
but	O
not	O
resting	O
,	O
lymphocytes	O
expressed	O
the	O
VDR	O
.	O

The	O
concentration	O
of	O
the	O
VDR	O
mRNA	O
was	O
10	O
(	O
-8	O
)	O
to	O
10	O
(	O
-7	O
)	O
g/g	O
of	O
total	O
RNA	O
in	O
cell-sorted	O
monocytes	O
and	O
in	O
in	O
vitro	O
activated	O
lymphocytes	O
,	O
but	O
only	O
10	O
(	O
-12	O
)	O
g/g	O
of	O
total	O
mRNA	O
in	O
resting	O
lymphocytes	O
,	O
establishing	O
that	O
the	O
VDR	O
mRNA	O
determined	O
by	O
our	O
method	O
in	O
PBMCs	O
is	O
due	O
to	O
constitutive	O
expression	O
in	O
monocytes	O
.	O

Following	O
an	O
initial	O
genotype	O
screening	O
of	O
85	O
normal	O
volunteers	O
by	O
polymerase	O
chain	O
reaction	O
or	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
,	O
14	O
individuals	O
with	O
the	O
Bb	O
genotype	O
,	O
12	O
with	O
the	O
bb	O
genotype	O
,	O
and	O
12	O
with	O
the	O
BB	O
genotype	O
were	O
selected	O
.	O

The	O
concentration	O
of	O
the	O
VDR	O
mRNA	O
,	O
corrected	O
for	O
the	O
number	O
of	O
monocytes	O
,	O
was	O
similar	O
among	O
the	O
three	O
genotype	O
groups	O
,	O
as	O
were	O
the	O
other	O
variables	O
examined	O
:	O
serum	O
calcitriol	O
,	O
serum	O
osteocalcin	O
,	O
and	O
vertebral	O
and	O
hip	O
bone	O
density	O
.	O

We	O
conclude	O
that	O
VDR	O
polymorphism	O
does	O
not	B-Negation
affect	I-Negation
the	I-Negation
abundance	I-Negation
of	I-Negation
the	I-Negation
VDR	I-Negation
mRNA	I-Negation
.	O

Regulation	O
of	O
CD95	O
(	O
Fas	O
)	O
ligand	O
expression	O
by	O
TCR-mediated	O
signaling	O
events	O
.	O

Stimulation	O
of	O
mature	O
peripheral	O
T	O
cells	O
by	O
TCR	O
engagement	O
results	O
in	O
activation	O
of	O
signals	O
that	O
drive	O
induction	O
of	O
cytokine	O
gene	O
expression	O
and	O
clonal	O
expansion	O
.	O

However	O
,	O
under	O
some	O
conditions	O
,	O
engagement	O
of	O
the	O
TCR	O
leads	O
instead	O
to	O
apoptosis	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
TCR-stimulated	O
apoptosis	O
requires	O
expression	O
of	O
CD95	O
ligand	O
on	O
activated	O
T	O
cells	O
followed	O
by	O
an	O
interaction	O
between	O
CD95	O
ligand	O
and	O
the	O
CD95	O
receptor	O
also	O
expressed	O
on	O
this	O
population	O
.	O

The	O
experiments	O
reported	O
in	O
this	O
study	O
were	O
designed	O
to	O
address	O
the	O
signaling	O
events	O
triggered	O
by	O
TCR	O
engagement	O
that	O
are	O
important	O
for	O
regulating	O
CD95	O
ligand	O
gene	O
expression	O
.	O

To	O
approach	O
this	O
,	O
we	O
generated	O
a	O
luciferase	O
reporter	O
construct	O
containing	O
elements	O
of	O
the	O
CD95	O
ligand	O
promoter	O
.	O

Using	O
a	O
previously	O
described	O
mutant	O
of	O
the	O
Jurkat	O
T	O
cell	O
line	O
,	O
we	O
show	O
that	O
proximal	O
signaling	O
events	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
CD45	O
tyrosine	O
phosphatase	O
are	O
required	O
for	O
TCR-stimulated	O
CD95	O
ligand	O
expression	O
.	O

Transient	O
transfection	O
studies	O
demonstrate	O
further	O
that	O
TCR-stimulated	O
activation	O
of	O
the	O
Ras	O
signaling	O
pathway	O
is	O
required	O
for	O
optimal	O
activation	O
of	O
CD95	O
ligand	O
.	O

Next	O
,	O
in	O
an	O
effort	O
to	O
determine	O
critical	O
transcription	O
factors	O
that	O
regulate	O
CD95	O
ligand	O
expression	O
,	O
we	O
demonstrate	O
a	O
cyclosporin	O
A-sensitive	O
nuclear	O
factor-AT	O
response	O
element	O
in	O
the	O
promoter	O
region	O
of	O
this	O
gene	O
that	O
is	O
critical	O
for	O
optimal	O
CD95	O
ligand	O
reporter	O
activity	O
in	O
stimulated	O
T	O
cells	O
.	O

Together	O
,	O
these	O
studies	O
begin	O
a	O
dissection	O
of	O
the	O
biochemical	O
events	O
that	O
lead	O
to	O
expression	O
of	O
CD95	O
ligand	O
,	O
a	O
required	O
step	O
for	O
TCR-induced	O
apoptosis	O
.	O

CD40	O
is	O
a	O
functional	O
activation	O
antigen	O
and	O
B7-independent	O
T	O
cell	O
costimulatory	O
molecule	O
on	O
normal	O
human	O
lung	O
fibroblasts	O
.	O

CD40	O
is	O
an	O
important	O
signaling	O
and	O
activation	O
Ag	O
found	O
on	O
certain	O
bone	O
marrow-derived	O
cells	O
.	O

Recently	O
,	O
CD40	O
also	O
has	O
been	O
shown	O
to	O
be	O
expressed	O
by	O
mesenchymal	O
cells	O
,	O
including	O
human	O
fibroblasts	O
.	O

Little	O
is	O
known	O
about	O
the	O
role	O
of	O
CD40	O
in	O
fibroblasts	O
.	O

The	O
current	O
study	O
investigates	O
the	O
hypothesis	O
that	O
CD40	O
expressed	O
on	O
lung	O
fibroblasts	O
is	O
an	O
activation	O
structure	O
and	O
mechanism	O
for	O
interaction	O
with	O
hemopoietic	O
cells	O
.	O

Communication	O
between	O
resident	O
tissue	O
fibroblasts	O
and	O
T	O
cells	O
is	O
necessary	O
for	O
normal	O
wound	O
healing	O
,	O
and	O
can	O
be	O
pathologic	O
,	O
resulting	O
in	O
tissue	O
fibrosis	O
.	O

Signaling	O
through	O
CD40	O
with	O
soluble	O
CD40	O
ligand	O
stimulated	O
fibroblast	O
activation	O
,	O
as	O
evidenced	O
by	O
mobilization	O
of	O
nuclear	O
factor-kappaB	O
and	O
by	O
induction	O
of	O
the	O
proinflammatory	O
and	O
chemoattractant	O
cytokines	O
IL-6	O
and	O
IL-8	O
.	O

IFN-gamma-primed	O
lung	O
fibroblasts	O
costimulate	O
T	O
lymphocyte	O
proliferation	O
utilizing	O
CD40	O
,	O
but	O
not	B-Negation
the	I-Negation
well-studied	I-Negation
costimulatory	I-Negation
molecules	I-Negation
B7-1	I-Negation
and	I-Negation
B7-2	I-Negation
.	O

Data	O
reported	O
herein	O
support	O
the	O
hypothesis	O
that	O
cognate	O
interactions	O
between	O
tissue	O
fibroblasts	O
and	O
infiltrating	O
T	O
lymphocytes	O
,	O
via	O
the	O
CD40/CD40L	O
pathway	O
,	O
augment	O
inflammation	O
and	O
may	O
promote	O
fibrogenesis	O
by	O
activating	O
both	O
cell	O
types	O
.	O

Triggering	O
of	O
HLA-DR	O
antigens	O
differentially	O
modulates	O
tumor	O
necrosis	O
factor	O
alpha	O
release	O
by	O
B	O
cells	O
at	O
distinct	O
stage	O
of	O
maturation	O
.	O

Triggering	O
of	O
HLA	O
class	O
II	O
antigens	O
by	O
the	O
anti-HLA-DR	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
L243	O
significantly	O
(	O
P	O
<	O
0.05	O
)	O
and	O
differentially	O
enhanced	O
the	O
release	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
by	O
the	O
non-Hodgkin	O
's	O
lymphoma	O
cells	O
Ri-I	O
,	O
Ci-I	O
,	O
and	O
Sc-I	O
,	O
which	O
are	O
at	O
a	O
distinct	O
stage	O
of	O
B-cell	O
differentiation	O
,	O
and	O
by	O
the	O
more	O
mature	O
Burkitt	O
lymphoma	O
cell	O
Raji	O
;	O
in	O
contrast	O
,	O
it	O
did	O
not	B-Negation
induce	I-Negation
TNF-alpha	I-Negation
release	I-Negation
by	I-Negation
the	I-Negation
pre-B	I-Negation
leukemia	I-Negation
cells	I-Negation
Nalm-6	I-Negation
and	I-Negation
BV173	I-Negation
.	O

TNF-alpha	O
release	O
peaked	O
at	O
24	O
h	O
and	O
decreased	O
thereafter	O
,	O
and	O
it	O
was	O
dose	O
dependent	O
and	O
preceded	O
by	O
an	O
increase	O
of	O
TNF-alpha	O
mRNA	O
detectable	O
after	O
3	O
h	O
of	O
stimulation	O
with	O
mAb	O
L243	O
.	O

Secreted	O
TNF-alpha	O
mediated	O
the	O
enhancement	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
and	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
activity	O
;	O
in	O
fact	O
,	O
the	O
triggering	O
of	O
HLA-DR	O
antigens	O
in	O
the	O
presence	O
of	O
antihuman	O
TNF-alpha-neutralizing	O
antibodies	O
did	O
not	B-Negation
upregulate	I-Negation
NF-kappa	I-Negation
B	I-Negation
and	I-Negation
AP-1	I-Negation
.	O

In	O
contrast	O
,	O
released	O
TNF-alpha	O
was	O
not	B-Negation
responsible	I-Negation
for	I-Negation
the	I-Negation
homotypic	I-Negation
aggregation	I-Negation
of	I-Negation
Ri-I	I-Negation
,	I-Negation
Ci-I	I-Negation
,	I-Negation
Sc-I	I-Negation
,	I-Negation
and	I-Negation
Raji	I-Negation
cells	I-Negation
induced	I-Negation
by	I-Negation
mAb	I-Negation
L243	I-Negation
,	O
and	O
it	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
proliferation	I-Negation
of	I-Negation
B	I-Negation
cells	I-Negation
investigated	I-Negation
.	O

Altogether	O
,	O
our	O
data	O
demonstrate	O
that	O
:	O
(	O
a	O
)	O
the	O
ability	O
of	O
B	O
cells	O
to	O
release	O
TNF-alpha	O
after	O
triggering	O
of	O
HLA-DR	O
antigens	O
depends	O
on	O
their	O
stage	O
of	O
differentiation	O
;	O
(	O
b	O
)	O
levels	B-Speculation
of	I-Speculation
released	I-Speculation
TNF-alpha	I-Speculation
seem	I-Speculation
to	I-Speculation
correlate	I-Speculation
with	I-Speculation
the	I-Speculation
stage	I-Speculation
of	I-Speculation
B-cell	I-Speculation
maturation	I-Speculation
but	O
do	O
not	B-Negation
correlate	I-Negation
with	I-Negation
the	I-Negation
amounts	I-Negation
of	I-Negation
cell	I-Negation
surface	I-Negation
HLA-DR	I-Negation
antigens	I-Negation
;	O
(	O
c	O
)	O
secreted	O
TNF-alpha	O
regulates	O
the	O
levels	O
of	O
expression	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
by	O
an	O
autocrine	O
loop	O
;	O
and	O
(	O
d	O
)	O
intracellular	O
signals	O
mediating	O
TNF-alpha	O
release	O
by	O
B	O
cells	O
are	O
distinct	O
from	O
those	O
regulating	O
homotypic	O
aggregation	O
and	O
proliferation	O
.	O

Cytomegalovirus	O
immediate	O
early	O
genes	O
upregulate	O
interleukin-6	O
gene	O
expression	O
.	O

BACKGROUND	O
:	O
The	O
immediate	O
early	O
genes	O
(	O
IE	O
)	O
of	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
can	O
be	O
expressed	O
in	O
monocytic	O
cells	O
and	O
are	O
known	O
to	O
regulate	O
viral	O
and	O
cellular	O
genes	O
.	O

Interleukin-6	O
(	O
IL-6	O
)	O
plays	O
a	O
central	O
role	O
in	O
numerous	O
inflammatory	O
and	O
immune	O
processes	O
.	O

Interleukin-6	O
levels	O
are	O
increased	O
in	O
lung	O
transplant	O
patients	O
clinically	O
diagnosed	O
with	O
CMV	O
pneumonitis	O
.	O

The	O
regulation	O
of	O
IL-6	O
is	O
dependent	O
on	O
various	O
stimuli	O
that	O
include	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
viruses	O
,	O
and	O
other	O
cytokines	O
.	O

These	O
studies	O
examined	O
the	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
modulate	O
IL-6	O
production	O
.	O

METHODS	O
:	O
THP-1	O
cells	O
,	O
a	O
monocytic	O
cell	O
line	O
,	O
were	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
.	O

Interleukin-6	O
protein	O
and	O
IL-6	O
mRNA	O
were	O
measured	O
in	O
control	O
and	O
CMV	O
immediate	O
early	O
transfected	O
cells	O
.	O

Cotransfection	O
of	O
CMV	O
IE	O
genes	O
and	O
IL-6	O
chloramphenicol	O
acetyl	O
transferase	O
(	O
CAT	O
)	O
or	O
IL-6	O
luciferase	O
constructs	O
were	O
used	O
to	O
study	O
IL-6	O
promoter	O
activity	O
.	O

RESULTS	O
:	O
Interleukin-6	O
protein	O
and	O
mRNA	O
production	O
were	O
significantly	O
increased	O
in	O
cells	O
transfected	O
with	O
the	O
CMV	O
IE	O
genes	O
and	O
stimulated	O
with	O
LPS	O
compared	O
to	O
LPS-stimulated	O
control	O
cells	O
.	O

Cytomegalovirus	O
IE	O
gene	O
products	O
significantly	O
enhanced	O
LPS	O
stimulation	O
of	O
IL-6	O
promoter	O
activity	O
in	O
both	O
IL-6	O
CAT	O
and	O
IL-6	O
luciferase	O
assays	O
.	O

A	O
deletion	O
construct	O
that	O
contains	O
a	O
NF-kappa	O
B	O
site	O
but	O
is	O
missing	B-Negation
the	I-Negation
multiple	I-Negation
response	I-Negation
region	I-Negation
demonstrated	O
a	O
continued	O
increase	O
in	O
IL-6	O
luciferase	O
activity	O
in	O
LPS-stimulated	O
CMV	O
transfected	O
cells	O
.	O

CONCLUSION	O
:	O
Cytomegalovirus	O
immediate	O
early	O
gene	O
products	O
significantly	O
enhanced	O
expression	O
of	O
IL-6	O
in	O
LPS-stimulated	O
cells	O
.	O

The	O
increase	O
in	O
IL-6	O
luciferase	O
activity	O
occurs	O
in	O
the	O
absence	B-Negation
of	I-Negation
the	I-Negation
multiple	I-Negation
response	I-Negation
region	I-Negation
,	O
the	O
area	O
of	O
the	O
IL-6	O
promoter	O
responsive	O
to	O
IL-1	O
,	O
TNF	O
alpha	O
,	O
cyclic	O
amp	O
,	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
.	O

The	O
ability	O
of	O
CMV	O
IE	O
gene	O
products	O
to	O
enhance	O
IL-6	O
production	O
may	O
play	O
an	O
important	O
role	O
in	O
immune	O
inflammatory	O
states	O
associated	O
with	O
CMV	O
infection	O
.	O

Cellular	O
redox	O
status	O
influences	O
both	O
cytotoxic	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	O
killer	O
cells	O
.	O

The	O
role	O
of	O
cellular	O
redox	O
status	O
in	O
both	O
cytotoxic	O
activity	O
and	O
NF-kappa	O
B	O
activation	O
in	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
was	O
investigated	O
.	O

The	O
results	O
indicate	O
that	O
stimulation	O
of	O
NK	O
cells	O
,	O
either	O
freshly	O
isolated	O
from	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
or	O
long-term	O
cultured	O
NK	O
clones	O
,	O
with	O
specific	O
cell	O
targets	O
results	O
in	O
an	O
increased	O
binding	O
activity	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
transcription	O
factors	O
measured	O
by	O
gel	O
retardation	O
.	O

Pretreatment	O
of	O
NK	O
cells	O
with	O
the	O
antioxidant	O
pyrrolidine	O
dithiocarbarmate	O
(	O
PDTC	O
)	O
leads	O
to	O
the	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
but	O
the	O
AP-1	O
binding	O
to	O
DNA	O
was	O
superinduced	O
.	O

The	O
inhibition	O
of	O
NF-kappa	O
B	O
by	O
PDTC	O
paralleled	O
with	O
an	O
inhibition	O
of	O
spontaneous	O
cytotoxicity	O
mediated	O
by	O
NK	O
cells	O
.	O

Moreover	O
,	O
the	O
inhibitors	O
of	O
serine	O
proteases	O
,	O
N-alpha-tosyl-L-lysine	O
chloromethyl	O
ketone	O
and	O
N-alpha-tosyl-L-phenylalanine	O
chloromethyl	O
ketone	O
,	O
also	O
blocked	O
the	O
cytolytic	O
activity	O
of	O
NK	O
cells	O
against	O
the	O
sensitive	O
target	O
K562	O
.	O

In	O
contrast	O
,	O
NK	B-Negation
activity	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
pretreatment	I-Negation
of	I-Negation
the	I-Negation
effector	I-Negation
cells	I-Negation
with	I-Negation
the	I-Negation
proteasome	I-Negation
inhibitor	I-Negation
N-acetyl-leu-leu-norleucinal	I-Negation
which	I-Negation
selectively	I-Negation
inhibits	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
.	O

Altogether	O
,	O
these	O
results	O
support	O
the	O
hypothesis	O
that	O
the	O
activation	O
of	O
NK	O
cells	O
involved	O
transcriptional	O
and	O
post-transcriptional	O
events	O
,	O
and	O
that	O
reactive	O
intermediates	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
molecular	O
processes	O
related	O
with	O
the	O
generation	O
of	O
a	O
cytotoxic	O
response	O
by	O
NK	O
cells	O
.	O

Homodimerization	O
of	O
the	O
human	O
interleukin	O
4	O
receptor	O
alpha	O
chain	O
induces	O
Cepsilon	O
germline	O
transcripts	O
in	O
B	O
cells	O
in	O
the	O
absence	B-Negation
of	I-Negation
the	I-Negation
interleukin	I-Negation
2	I-Negation
receptor	I-Negation
gamma	I-Negation
chain	I-Negation
.	O

The	O
cytokines	O
interleukin	O
(	O
IL	O
)	O
-4	O
and	O
IL-13	O
play	O
a	O
critical	O
role	O
in	O
inducing	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
human	O
B	O
cells	O
.	O

The	O
IL-4	O
receptor	O
(	O
IL-4R	O
)	O
in	O
B	O
cells	O
is	O
composed	O
of	O
two	O
chains	O
,	O
the	O
IL-4-binding	O
IL-4Ralpha	O
chain	O
,	O
which	O
is	O
shared	O
with	O
the	O
IL-13R	O
,	O
and	O
the	O
IL-2Rgamma	O
(	O
gammac	O
)	O
chain	O
,	O
which	O
is	O
shared	O
with	O
IL-7R	O
,	O
IL-9R	O
,	O
and	O
IL-15R	O
.	O

IL-4	O
induces	O
Cepsilon	O
germline	O
transcripts	O
and	O
IgE	O
isotype	O
switching	O
in	O
B	O
cells	O
from	O
patients	O
with	O
gammac	O
chain	O
deficiency	O
.	O

Induction	O
of	O
Cepsilon	O
germline	O
transcripts	O
by	O
IL-4	O
in	O
B	O
cells	O
that	O
lack	B-Negation
the	I-Negation
gammac	I-Negation
chain	I-Negation
may	B-Speculation
involve	I-Speculation
signaling	I-Speculation
via	I-Speculation
the	I-Speculation
IL-13R	I-Speculation
.	O

Alternatively	O
,	O
the	O
IL-4Ralpha	O
chain	O
may	O
transduce	O
intracellular	O
signals	O
that	O
lead	O
to	O
Cepsilon	O
gene	O
transcription	O
independently	O
of	O
its	O
association	O
with	O
other	O
chains	O
.	O

We	O
show	O
that	O
ligand-induced	O
homodimerization	O
of	O
chimeric	O
surface	O
receptors	O
consisting	O
of	O
the	O
extracellular	O
and	O
transmembrane	O
domains	O
of	O
the	O
erythropoietin	O
receptor	O
and	O
of	O
the	O
intracellular	O
domain	O
of	O
IL-4Ralpha	O
induces	O
Janus	O
kinase	O
1	O
(	O
Jak1	O
)	O
activation	O
,	O
STAT6	O
activation	O
,	O
and	O
Cepsilon	O
germline	O
transcripts	O
in	O
human	O
B	O
cell	O
line	O
BJAB	O
.	O

Disruption	O
of	O
the	O
Jak1-binding	O
proline-rich	O
Box1	O
region	O
of	O
IL-4Ralpha	O
abolished	O
signaling	O
by	O
this	O
chimeric	O
receptor	O
.	O

Furthermore	O
,	O
B	O
cells	O
transfected	O
with	O
a	O
chimeric	O
CD8alpha/IL-4Ralpha	O
receptor	O
,	O
which	O
is	O
expressed	O
on	O
the	O
cell	O
surface	O
as	O
a	O
homodimer	O
,	O
constitutively	O
expressed	O
Cepsilon	O
germline	O
transcripts	O
.	O

These	O
results	O
suggest	O
that	O
homodimerization	O
of	O
the	O
IL-4Ralpha	O
chain	O
is	O
sufficient	O
to	O
transduce	O
Jak1-dependent	O
intracellular	O
signals	O
that	O
lead	O
to	O
IgE	O
isotype	O
switching	O
.	O

Characterization	O
of	O
peripheral	O
blood	O
T-lymphocytes	O
transduced	O
with	O
HTLV-I	O
Tax	O
mutants	O
with	O
different	O
trans-activating	O
phenotypes	O
.	O

Tax1	O
,	O
a	O
transcriptional	O
trans-activator	O
of	O
the	O
Human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
,	O
induces	O
the	O
expression	O
of	O
many	O
cellular	O
genes	O
through	O
interaction	O
with	O
at	O
least	O
three	O
distinct	O
cellular	O
transcription	O
factors	O
;	O
CREB/ATF	O
,	O
NF-kappaB	O
,	O
and	O
SRF	O
.	O

This	O
Tax1-induced	O
activation	O
of	O
cellular	O
genes	O
is	O
considered	O
to	O
be	O
a	O
critical	O
event	O
in	O
T-cell	O
transformation	O
by	O
HTLV-I	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
each	O
Tax1-inducible	O
transcriptional	O
pathway	O
in	O
T-cell	O
transformation	O
,	O
we	O
introduced	O
Tax1	O
mutants	O
with	O
different	O
trans-activating	O
phenotypes	O
into	O
peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
by	O
retroviral	O
vectors	O
.	O

Analysis	O
of	O
these	O
PBLs	O
revealed	O
that	O
activation	O
of	O
the	O
NF-kappaB	O
pathway	O
is	O
sufficient	O
to	O
promote	O
the	O
growth	O
response	O
to	O
IL-2	O
.	O

However	O
,	O
for	O
the	O
clonal	O
expansion	O
of	O
CD4+	O
T-cells	O
,	O
which	O
is	O
a	O
characteristic	O
result	O
of	O
HTLV-I	O
infection	O
,	O
activation	O
of	O
the	O
CREB/ATF	O
and	O
SRF	O
pathways	O
is	O
also	O
required	O
.	O

Involvement	O
of	O
the	O
N-terminal	O
region	O
of	O
the	O
human	O
mineralocorticoid	O
receptor	O
hormone-binding	O
domain	O
in	O
agonist	O
and	O
antagonist	O
binding	O
as	O
revealed	O
by	O
a	O
new	O
monoclonal	O
antibody	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
mechanism	O
of	O
binding	O
to	O
the	O
human	O
mineralocorticoid	O
receptor	O
(	O
hMR	O
)	O
,	O
we	O
developed	O
a	O
new	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
raised	O
against	O
the	O
hormone-binding	O
domain	O
(	O
HBD	O
)	O
.	O

For	O
this	O
purpose	O
,	O
mice	O
were	O
immunized	O
with	O
a	O
fusion	O
protein	O
including	O
the	O
sequence	O
Thr729-Lys984	O
of	O
hMR	O
.	O

After	O
ELISA	O
screening	O
,	O
mAb	O
18C7	O
was	O
selected	O
for	O
its	O
specificity	O
towards	O
the	O
HBD	O
.	O

This	O
antibody	O
recognized	O
both	O
the	O
denatured	O
and	O
native	O
MR	O
forms	O
,	O
as	O
well	O
as	O
the	O
hetero-oligomeric	O
MR	O
form	O
and	O
the	O
transformed	O
MR	O
state	O
.	O

By	O
using	O
several	O
HBD	O
subfragments	O
,	O
the	O
mAb	O
18C7	O
epitope	O
was	O
located	O
in	O
the	O
N-terminal	O
region	O
of	O
the	O
HBD	O
from	O
Thr729	O
to	O
Leu765	O
.	O

We	O
then	O
studied	O
the	O
effect	O
of	O
the	O
antibody	O
on	O
aldosterone	O
and	O
progesterone	O
binding	O
to	O
the	O
hMR	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
liganded	O
MR	O
,	O
it	O
was	O
able	O
to	O
partly	O
displace	O
(	O
20	O
%	O
)	O
the	O
hormone	O
from	O
its	O
binding	O
site	O
.	O

When	O
18C7	O
was	O
incubated	O
with	O
MR	O
before	O
aldosterone	O
or	O
progesterone	O
,	O
the	O
antibody	O
inhibited	O
75-80	O
%	O
of	O
the	O
binding	O
.	O

The	O
effect	O
of	O
18C7	O
on	O
the	O
binding	O
was	O
similar	O
with	O
both	O
hormones	O
.	O

A	O
sucrose	O
gradient	O
analysis	O
indicated	O
the	O
simultaneous	O
presence	O
of	O
two	O
kinds	O
of	O
receptor	O
complexes	O
:	O
the	O
steroid-MR	O
complex	O
and	O
the	O
antibody-MR	O
complex	O
.	O

After	O
its	O
associated	O
proteins	O
,	O
especially	O
the	O
heat-shock	O
protein	O
hsp90	O
,	O
had	O
been	O
cross-linked	O
with	O
the	O
hMR	O
by	O
dimethylpimelimidate	O
,	O
18C7	O
was	O
still	O
able	O
to	O
react	O
with	O
the	O
receptor	O
.	O

Our	O
results	O
indicated	O
that	O
the	O
epitope	O
recognized	O
by	O
18C7	O
was	O
directly	O
implicated	O
in	O
hormone	O
binding	O
.	O

The	O
lack	B-Negation
of	I-Negation
steroid	I-Negation
binding	I-Negation
of	I-Negation
HBD	I-Negation
mutants	I-Negation
with	I-Negation
the	I-Negation
Thr729-Leu765	I-Negation
sequence	I-Negation
deleted	I-Negation
[	O
Jalaguier	O
,	O
Mesnier	O
,	O
Leger	O
and	O
Auzou	O
(	O
1996	O
)	O
J.Steroid	O
Biochem.Mol.Biol.57	O
,	O
43-50	O
]	O
supports	O
this	O
hypothesis	O
.	O

Because	O
of	O
the	O
similar	O
behaviours	O
of	O
aldosterone	O
and	O
progesterone	O
,	O
we	O
conclude	O
that	O
the	O
N-terminal	O
Thr729-Leu765	O
region	O
of	O
the	O
HBD	O
is	O
similarly	O
involved	O
in	O
the	O
binding	O
of	O
both	O
hormones	O
.	O

Abnormal	O
T	O
lymphocyte	O
development	O
induced	O
by	O
targeted	O
overexpression	O
of	O
IkappaB	O
alpha	O
.	O

A	B-Speculation
role	I-Speculation
in	I-Speculation
thymic	I-Speculation
maturation	I-Speculation
for	I-Speculation
factors	I-Speculation
of	I-Speculation
the	I-Speculation
NF-kappaB	I-Speculation
family	I-Speculation
has	I-Speculation
long	I-Speculation
been	I-Speculation
suspected	I-Speculation
,	O
but	O
not	B-Negation
yet	I-Negation
proven	I-Negation
.	O

Transgenic	O
mice	O
with	O
a	O
lymphocyte-specific	O
defect	O
in	O
NF-kappaB	O
activation	O
were	O
produced	O
by	O
targeted	O
expression	O
of	O
human	O
IkappaB	O
alpha	O
.	O

The	O
thymic	O
cellularity	O
of	O
these	O
mice	O
was	O
significantly	O
decreased	O
.	O

The	O
proportion	O
of	O
mature	O
,	O
TCRhigh	O
thymocytes	O
of	O
the	O
alphabeta	O
lineage	O
was	O
reduced	O
,	O
and	O
the	O
remaining	O
TCRhigh	O
population	O
contained	O
an	O
unusually	O
high	O
proportion	O
of	O
double-positive	O
cells	O
.	O

This	O
defect	O
in	O
maturation	O
resulted	O
in	O
a	O
transgene	O
dose-dependent	O
reduction	O
in	O
peripheral	O
T	O
lymphocytes	O
,	O
with	O
the	O
CD8	O
lineage	O
being	O
more	O
severely	O
affected	O
.	O

These	O
data	O
provide	O
direct	O
evidence	O
for	O
the	O
involvement	O
of	O
NF-kappaB/Rel	O
family	O
proteins	O
in	O
late	O
stages	O
of	O
T	O
lymphocyte	O
development	O
,	O
coincident	O
with	O
positive	O
and	O
negative	O
selection	O
.	O

Sequential	O
development	O
of	O
structural	O
and	O
functional	O
alterations	O
in	O
T	O
cells	O
from	O
tumor-bearing	O
mice	O
.	O

The	O
TCR	O
alpha	O
beta	O
or	O
-gamma	O
delta	O
chains	O
bind	O
the	O
peptide	O
ligand	O
,	O
whereas	O
the	O
associated	O
CD3	O
delta	O
epsilon	O
gamma	O
and	O
TCR	O
zeta	O
subunits	O
couple	O
the	O
TCR	O
to	O
intracellular	O
signal	O
transduction	O
components	O
.	O

Recently	O
,	O
several	O
groups	O
have	O
described	O
marked	O
alterations	O
in	O
signal	O
transduction	O
elements	O
in	O
T	O
cells	O
from	O
cancer	O
patients	O
or	O
in	O
mice	O
bearing	O
tumor	O
for	O
a	O
few	O
weeks	O
(	O
>	O
26	O
days	O
)	O
.	O

The	O
sequence	O
in	O
which	O
these	O
alterations	O
develop	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
kinetics	O
of	O
the	O
development	O
of	O
alterations	O
in	O
signal	O
transduction	O
molecules	O
(	O
TCR	O
zeta	O
chain	O
,	O
NF	O
kappaB	O
family	O
proteins	O
,	O
and	O
tyrosine	O
kinase	O
p56	O
(	O
lck	O
)	O
)	O
in	O
mice	O
bearing	O
MC38	O
colon	O
adenocarcinoma	O
.	O

The	O
results	O
demonstrate	O
that	O
alterations	O
in	O
NF	O
kappaB	O
family	O
proteins	O
,	O
specifically	O
the	O
failure	B-Negation
of	I-Negation
p65	I-Negation
translocation	I-Negation
to	I-Negation
the	I-Negation
nucleus	I-Negation
,	O
occur	O
earlier	O
and	O
more	O
frequently	O
than	O
the	O
decrease	O
in	O
zeta-chain	O
.	O

These	O
defects	O
are	O
paralleled	O
by	O
an	O
impaired	O
ability	O
to	O
produce	O
Th1	O
cytokines	O
(	O
IL-2	O
and	O
IFN-gamma	O
)	O
.	O

These	O
initial	O
changes	O
are	O
followed	O
by	O
the	O
eventual	O
loss	O
of	O
TCR	O
zeta	O
chain	O
and	O
p56	O
(	O
lck	O
)	O
and	O
a	O
marked	O
decrease	O
in	O
cytotoxic	O
function	O
.	O

An	O
increased	O
rate	O
of	O
lysosomal	O
degradation	O
is	O
one	O
of	O
the	O
mechanisms	O
responsible	O
for	O
the	O
loss	O
of	O
zeta-chain	O
.	O

An	O
isotype-specific	O
activator	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
II	O
genes	O
that	O
is	O
independent	O
of	O
class	O
II	O
transactivator	O
.	O

Patients	O
with	O
one	O
type	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
combined	O
immunodeficiency	O
have	O
mutations	O
in	O
a	O
gene	O
termed	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
,	O
which	O
coordinately	O
controls	O
the	O
transcription	O
of	O
the	O
three	O
major	O
human	O
class	O
II	O
genes	O
,	O
HLA-DR	O
,	O
-DQ	O
,	O
and	O
-DP	O
.	O

However	O
,	O
the	O
experimentally	O
derived	O
B-lymphoblastoid	O
cell	O
line	O
,	O
clone	O
13	O
,	O
expresses	O
high	O
levels	O
of	O
HLADQ	O
in	O
the	O
absence	B-Negation
of	I-Negation
HLA-DR	I-Negation
and	I-Negation
HLA-DP	I-Negation
,	O
despite	O
its	O
mapping	O
by	O
complementation	O
analysis	O
to	O
this	O
group	O
.	O

It	O
was	O
possible	O
that	O
one	O
of	O
the	O
clone	O
13	O
CIITA	O
alleles	O
bore	O
a	O
mutation	O
that	O
allowed	O
HLA-DQ	O
,	O
but	O
not	O
HLA-DR	O
or	O
-DP	O
transcription	O
.	O

Alternatively	O
,	O
another	O
factor	O
,	O
distinct	O
from	O
CIITA	O
,	O
might	O
control	O
HLA-DQ	O
expression	O
.	O

We	O
report	O
here	O
that	O
ectopic	O
expression	O
of	O
CIITA	O
cDNAs	O
derived	O
by	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
from	O
clone	O
13	O
do	O
not	B-Negation
restore	I-Negation
expression	I-Negation
of	I-Negation
HLA-DQ	I-Negation
in	I-Negation
another	I-Negation
CIITA-deficient	I-Negation
cell	I-Negation
line	I-Negation
,	I-Negation
RJ2.2.5	I-Negation
.	O

In	O
addition	O
,	O
no	B-Negation
CIITA	I-Negation
protein	I-Negation
is	I-Negation
detectable	I-Negation
in	I-Negation
clone	I-Negation
13	I-Negation
nuclear	I-Negation
extracts	I-Negation
.	O

In	O
contrast	O
,	O
somatic	O
cell	O
fusion	O
between	O
clone	O
13	O
and	O
RJ2.2.5	O
restored	O
expression	O
of	O
the	O
HLA-DQ	O
haplotype	O
encoded	O
by	O
the	O
RJ2.2.5	O
DQB	O
gene	O
.	O

Taken	O
together	O
,	O
these	O
data	O
demonstrate	O
the	O
existence	O
of	O
an	O
HLA-DQ	O
isotype-specific	O
trans-acting	O
factor	O
,	O
which	O
functions	O
independently	O
of	O
CIITA	O
.	O

Induction	O
of	O
cytokine	O
expression	O
in	O
leukocytes	O
by	O
binding	O
of	O
thrombin-stimulated	O
platelets	O
.	O

BACKGROUND	O
:	O
Activated	O
platelets	O
tether	O
and	O
activate	O
myeloid	O
leukocytes	O
.	O

To	O
investigate	O
the	O
potential	O
relevance	O
of	O
this	O
mechanism	O
in	O
acute	O
myocardial	O
infarction	O
(	O
AMI	O
)	O
,	O
we	O
examined	O
cytokine	O
induction	O
by	O
leukocyte-platelet	O
adhesion	O
and	O
the	O
occurrence	O
of	O
leukocyte-platelet	O
conjugates	O
in	O
patients	O
with	O
AMI	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
obtained	O
peripheral	O
venous	O
blood	O
samples	O
in	O
20	O
patients	O
with	O
AMI	O
before	O
and	O
daily	O
for	O
5	O
days	O
after	O
direct	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
(	O
PTCA	O
)	O
and	O
in	O
20	O
patients	O
undergoing	O
elective	O
PTCA	O
.	O

Throughout	O
the	O
study	O
period	O
,	O
CD41	O
immunofluorescence	O
of	O
leukocytes	O
(	O
flow	O
cytometry	O
)	O
revealed	O
increased	O
leukocyte-platelet	O
adhesion	O
in	O
patients	O
with	O
AMI	O
compared	O
with	O
control	O
patients	O
(	O
mean	O
	O
SE	O
of	O
fluorescence	O
[	O
channels	O
]	O
before	O
PTCA	O
:	O
77	O
	O
16	O
versus	O
35	O
	O
9	O
;	O
P	O
=	O
.003	O
)	O
.	O

In	O
vitro	O
,	O
thrombin-stimulated	O
fixed	O
platelets	O
bound	O
to	O
neutrophils	O
and	O
monocytes	O
.	O

Within	O
2	O
hours	O
,	O
this	O
resulted	O
in	O
increased	O
mRNA	O
for	O
interleukin	O
(	O
IL	O
)	O
,1	O
beta	O
,	O
IL-8	O
,	O
and	O
monocyte	O
chemoattractant	O
protein	O
(	O
MCP	O
)	O
-1	O
in	O
unfractionated	O
leukocytes	O
.	O

After	O
4	O
hours	O
,	O
IL-1	O
beta	O
and	O
IL-8	O
concentration	O
of	O
the	O
cell-free	O
supernatant	O
had	O
increased	O
by	O
268	O
	O
36	O
%	O
and	O
210	O
	O
7	O
%	O
,	O
respectively	O
,	O
and	O
cellular	O
MCP-1	O
content	O
had	O
increased	O
by	O
170	O
	O
8	O
%	O
.	O

Addition	O
of	O
activated	O
platelets	O
to	O
adherent	O
monocytes	O
had	O
a	O
similar	O
effect	O
and	O
was	O
associated	O
with	O
nuclear	O
factor-kappa	O
B	O
activation	O
.	O

Inhibition	O
of	O
binding	O
by	O
anti-P	O
selectin	O
antibodies	O
reduced	O
the	O
effect	O
of	O
activated	O
platelets	O
on	O
cytokine	O
production	O
.	O

CONCLUSIONS	O
:	O
In	O
patients	O
with	O
AMI	O
,	O
leukocyte-platelet	O
adhesion	O
is	O
increased	O
.	O

Binding	O
of	O
activated	O
platelets	O
induces	O
IL-1	O
beta	O
,	O
IL-8	O
,	O
and	O
MCP-1	O
in	O
leukocytes	O
.	O

Our	O
findings	O
suggest	O
that	O
leukocyte-platelet	O
adhesion	O
contributes	O
to	O
the	O
regulation	O
of	O
inflammatory	O
responses	O
in	O
AMI	O
.	O

The	O
class	O
II	O
trans-activator	O
CIITA	O
interacts	O
with	O
the	O
TBP-associated	O
factor	O
TAFII32	O
.	O

The	O
class	O
II	O
trans-	O
activator	O
(	O
CIITA	O
)	O
is	O
the	O
main	O
transcriptional	O
co-activator	O
for	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
proteins	O
.	O

Its	O
N-terminal	O
125	O
amino	O
acids	O
function	O
as	O
an	O
independent	O
transcriptional	O
activation	O
domain	O
.	O

Analyses	O
of	O
the	O
primary	O
amino	O
acid	O
sequence	O
of	O
the	O
activation	O
domain	O
predict	O
the	O
presence	O
of	O
three	O
alpha-helices	O
,	O
each	O
with	O
a	O
high	O
proportion	O
of	O
acidic	O
residues	O
.	O

Using	O
site-directed	O
mutagenesis	O
,	O
we	O
found	O
that	O
two	O
of	O
these	O
predicted	O
alpha-helices	O
are	O
required	O
for	O
full	O
transcriptional	O
activation	O
by	O
CIITA	O
.	O

Moreover	O
,	O
a	O
CIITA	O
protein	O
in	O
which	O
both	O
functional	O
alpha-helices	O
have	O
been	O
deleted	O
displays	O
a	O
dominant	O
negative	O
phenotype	O
.	O

This	O
activation	O
domain	O
of	O
CIITA	O
interacts	O
with	O
the	O
32	O
kDa	O
subunit	O
of	O
the	O
general	O
transcription	O
complex	O
TFIID	O
,	O
TAFII32	O
.	O

Decreased	O
transcriptional	O
activation	O
by	O
N-terminal	O
deletions	O
of	O
CIITA	O
is	O
correlated	O
directly	O
with	O
their	O
reduced	O
binding	O
to	O
TAFII32	O
.	O

We	O
conclude	O
that	O
interactions	O
between	O
TAFII32	O
and	O
CIITA	O
are	O
responsible	O
for	O
activation	O
of	O
class	O
II	O
genes	O
.	O

Tap	O
:	O
a	O
novel	O
cellular	O
protein	O
that	O
interacts	O
with	O
tip	O
of	O
herpesvirus	O
saimiri	O
and	O
induces	O
lymphocyte	O
aggregation	O
.	O

Tip	O
of	O
herpesvirus	O
saimiri	O
associates	O
with	O
Lck	O
and	O
down-regulates	O
Lck-mediated	O
activation	O
.	O

We	O
identified	O
a	O
novel	O
cellular	O
Tip-associated	O
protein	O
(	O
Tap	O
)	O
by	O
a	O
yeast	O
two-hybrid	O
screen	O
.	O

Tap	O
associated	O
with	O
Tip	O
following	O
transient	O
expression	O
in	O
COS-1	O
cells	O
and	O
stable	O
expression	O
in	O
human	O
Jurkat-T	O
cells	O
.	O

Expression	O
of	O
Tip	O
and	O
Tap	O
in	O
Jurkat-T	O
cells	O
induced	O
dramatic	O
cell	O
aggregation	O
.	O

Aggregation	O
was	O
likely	O
caused	O
by	O
the	O
up-regulated	O
surface	O
expression	O
of	O
adhesion	O
molecules	O
including	O
integrin	O
alpha	O
,	O
L-selectin	O
,	O
ICAM-3	O
,	O
and	O
H-CAM	O
.	O

Furthermore	O
,	O
NF-kappaB	O
transcriptional	O
factor	O
of	O
aggregated	O
cells	O
had	O
approximately	O
40-fold	O
higher	O
activity	O
than	O
that	O
of	O
parental	O
cells	O
.	O

Thus	O
,	O
Tap	O
is	O
likely	O
to	O
be	O
an	O
important	O
cellular	O
mediator	O
of	O
Tip	O
function	O
in	O
T	O
cell	O
transformation	O
by	O
herpesvirus	O
saimiri	O
.	O

Transactivation	O
by	O
CIITA	O
,	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome-associated	O
factor	O
,	O
requires	O
participation	O
of	O
multiple	O
regions	O
of	O
the	O
TATA	O
box	O
binding	O
protein	O
.	O

CIITA	O
is	O
a	O
positive	O
regulator	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
gene	O
transcription	O
that	O
has	O
been	O
found	O
to	O
be	O
defective	O
in	O
one	O
of	O
the	O
five	O
complementation	O
groups	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex-negative	O
cell	O
lines	O
.	O

Its	O
N-terminal	O
region	O
is	O
capable	O
of	O
activating	O
transcription	O
from	O
a	O
reporter	O
gene	O
when	O
fused	O
to	O
a	O
DNA	O
binding	O
domain	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
transactivation	O
mediated	O
by	O
the	O
CIITA	O
activation	O
domain	O
by	O
studying	O
its	O
role	O
in	O
the	O
process	O
of	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Specifically	O
the	O
altered	O
specificity	O
TBP	O
(	O
TATA	O
box	O
binding	O
protein	O
)	O
assay	O
has	O
been	O
used	O
to	O
analyze	O
the	O
response	O
of	O
the	O
CIITA	O
activation	O
domain	O
to	O
mutations	O
in	O
TBP	O
known	O
to	O
disrupt	O
its	O
interaction	O
with	O
its	O
associated	O
general	O
factors	O
.	O

Transactivation	O
by	O
CIITA	O
was	O
extremely	O
sensitive	O
to	O
a	O
mutation	O
in	O
TBP	O
that	O
in	O
yeast	O
is	O
known	O
to	O
abolish	O
VP16-mediated	O
transcription	O
but	O
leaves	O
basal	O
transcription	O
unaffected	O
.	O

A	O
TBP	O
mutant	O
defective	O
in	O
interaction	O
with	O
TBP-associated	O
factor	O
TAFII250	O
also	O
failed	B-Negation
to	I-Negation
mediate	I-Negation
transactivation	I-Negation
through	I-Negation
the	I-Negation
CIITA	I-Negation
activation	I-Negation
domain	I-Negation
.	O

Certain	O
interactions	O
between	O
TBP	O
and	O
general	O
factors	O
that	O
are	O
specifically	O
required	O
for	O
acidic	O
activation	O
domains	O
were	O
also	O
required	O
for	O
CIITA-mediated	O
transactivation	O
to	O
reach	O
its	O
full	O
potential	O
.	O

Finally	O
,	O
like	O
VP16	O
,	O
CIITA	O
was	O
able	O
to	O
stimulate	O
elongation	O
of	O
transcription	O
.	O

Overall	O
the	O
mechanism	O
of	O
transactivation	O
by	O
the	O
human	O
B-cell-specific	O
CIITA	O
is	O
very	O
similar	O
to	O
that	O
mediated	O
by	O
the	O
herpes	O
virus	O
transactivator	O
VP16	O
in	O
the	O
ways	O
that	O
have	O
been	O
tested	O
.	O

Specific	O
complex	O
formation	O
between	O
the	O
type	O
II	O
bare	O
lymphocyte	O
syndrome-associated	O
transactivators	O
CIITA	O
and	O
RFX5	O
.	O

Two	O
of	O
the	O
genes	O
defective	O
in	O
the	O
five	O
complementation	O
groups	O
identified	O
in	O
the	O
class	O
II-negative	O
bare	O
lymphocyte	O
syndrome	O
or	O
corresponding	O
laboratory	O
mutants	O
have	O
been	O
cloned	O
.	O

One	O
gene	O
encodes	O
a	O
protein	O
,	O
RFX5	O
,	O
that	O
is	O
a	O
member	O
of	O
the	O
RFX	O
family	O
of	O
DNA	O
binding	O
proteins	O
.	O

The	O
other	O
,	O
CIITA	O
,	O
encodes	O
a	O
large	O
protein	O
with	O
a	O
defined	O
acidic	O
transcriptional	O
activation	O
domain	O
;	O
this	O
protein	O
does	O
not	B-Negation
interact	I-Negation
with	I-Negation
DNA	I-Negation
.	O

Expression	O
plasmids	O
encoding	O
regions	O
of	O
RFX5	O
fused	O
to	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
activated	O
transcription	O
from	O
a	O
reporter	O
construct	O
containing	O
GAL4	O
sites	O
in	O
a	O
cotransfection	O
assay	O
in	O
the	O
Raji	O
human	O
B	O
cell	O
line	O
.	O

However	O
,	O
these	O
plasmids	O
produced	O
transcriptional	O
activity	O
in	O
HeLa	O
cells	O
only	O
in	O
conjunction	O
with	O
interferon	O
gamma	O
stimulation	O
,	O
a	O
condition	O
in	O
which	O
expression	O
of	O
both	O
CIITA	O
and	O
class	O
II	O
major	O
histocompatibility	O
complex	O
surface	O
proteins	O
are	O
induced	O
.	O

Furthermore	O
,	O
these	O
plasmids	O
were	O
not	B-Negation
active	I-Negation
in	I-Negation
RJ2.2.5	I-Negation
,	I-Negation
an	I-Negation
in	I-Negation
vitro	I-Negation
mutagenized	I-Negation
derivative	I-Negation
of	I-Negation
Raji	I-Negation
in	I-Negation
which	I-Negation
both	I-Negation
copies	I-Negation
of	I-Negation
CIITA	I-Negation
are	I-Negation
defective	I-Negation
.	O

Transcriptional	O
activation	O
by	O
the	O
RFX5	O
fusion	O
protein	O
could	O
be	O
restored	O
in	O
RJ2.2.5	O
by	O
cotransfection	O
with	O
a	O
CIITA	O
expression	O
plasmid	O
.	O

Finally	O
,	O
a	O
direct	O
interaction	O
between	O
RFX5	O
and	O
CIITA	O
was	O
detected	O
with	O
the	O
yeast	O
two-hybrid	O
and	O
far-Western	O
blot	O
assays	O
.	O

Thus	O
,	O
RFX5	O
can	O
activate	O
transcription	O
only	O
in	O
cooperation	O
with	O
CIITA	O
.	O

RFX5	O
and	O
CIITA	O
associate	O
to	O
form	O
a	O
complex	O
capable	O
of	O
activating	O
transcription	O
from	O
class	O
II	O
major	O
histocompatibility	O
complex	O
promoters	O
.	O

In	O
this	O
complex	O
,	O
promoter	O
specificity	O
is	O
determined	O
by	O
the	O
DNA	O
binding	O
domain	O
of	O
RFX5	O
and	O
the	O
general	O
transcription	O
apparatus	O
is	O
recruited	O
by	O
the	O
acidic	O
activation	O
domain	O
of	O
CIITA	O
.	O

Reactive	O
oxygen	O
species	O
and	O
antioxidants	O
in	O
inflammatory	O
diseases	O
.	O

This	O
paper	O
aims	O
to	O
review	O
the	O
role	O
of	O
free	O
radical-induced	O
tissue	O
damage	O
and	O
antioxidant	O
defence	O
mechanisms	O
in	O
inflammatory	O
diseases	O
that	O
involve	O
pathogenic	O
processes	O
similar	O
to	O
the	O
periodontal	O
diseases	O
.	O

There	O
is	O
a	O
clearly	O
defined	O
and	O
substantial	O
role	O
for	O
free	O
radicals	O
or	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
periodontitis	O
,	O
but	O
little	O
research	O
has	O
been	O
performed	O
in	O
this	O
area	O
.	O

This	O
paper	O
reviews	O
the	O
considerable	O
data	O
available	O
relating	O
ROS	O
activity	O
and	O
antioxidant	O
defence	O
to	O
inflammatory	O
diseases	O
and	O
attempts	O
to	O
draw	O
parallels	O
with	O
periodontitis	O
,	O
in	O
an	O
effort	O
to	O
stimulate	O
more	O
periodontal	O
research	O
in	O
this	O
important	O
area	O
.	O

The	O
recent	O
discovery	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
reviewed	O
and	O
several	O
potential	O
pathways	O
for	O
cytokine-induced	O
periodontal	O
tissue	O
damage	O
,	O
mediated	O
by	O
NF-kappa	O
B1	O
are	O
discussed	O
.	O

Emphasis	O
is	O
placed	O
on	O
cytokines	O
that	O
have	O
been	O
studied	O
in	O
periodontitis	O
,	O
principally	O
TNF-alpha	O
,	O
IL-1	O
,	O
IL-6	O
,	O
IL-8	O
and	O
beta-interferon	O
.	O

The	O
link	O
between	O
cellular	O
production	O
of	O
such	O
important	O
mediators	O
of	O
inflammation	O
and	O
the	O
antioxidant	O
(	O
AO	O
)	O
thiols	O
,	O
cysteine	O
and	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
,	O
is	O
discussed	O
and	O
it	O
is	O
hypothesised	O
that	O
NF-kappa	O
B	O
antagonists	O
may	O
offer	O
important	O
therapeutic	O
benefits	O
.	O

Transcriptional	O
activity	O
and	O
constitutive	O
nuclear	O
localization	O
of	O
the	O
ETS	O
protein	O
Elf-1	O
.	O

Elf-1	O
is	O
a	O
lymphoid-specific	O
transcription	O
factor	O
that	O
belongs	O
to	O
the	O
ETS	O
protein	O
family	O
.	O

It	O
can	O
bind	O
to	O
DNA	O
target	O
sequences	O
within	O
a	O
variety	O
of	O
cytokine	O
genes	O
.	O

We	O
demonstrate	O
that	O
Elf-1	O
is	O
constitutively	O
localized	O
in	O
the	O
nucleus	O
which	O
is	O
dependent	O
on	O
the	O
presence	O
of	O
amino	O
acids	O
86-265	O
.	O

Analysis	O
of	O
Gal4-Elf-1	O
fusion	O
proteins	O
revealed	O
that	O
the	O
N-terminal	O
86	O
amino	O
acids	O
of	O
Elf-1	O
contain	O
a	O
transcriptional	O
activation	O
domain	O
,	O
the	O
activity	O
of	O
which	O
is	O
attenuated	O
by	O
an	O
internal	O
repression	O
domain	O
.	O

Furthermore	O
,	O
Elf-1	O
interacts	O
specifically	O
with	O
the	O
E74	O
target	O
sequence	O
and	O
can	O
stimulate	O
transcription	O
driven	O
by	O
the	O
E74	O
site	O
independent	O
of	O
mitogenic	O
signaling	O
.	O

Thus	O
,	O
Elf-1	O
is	O
able	O
to	O
stimulate	O
gene	O
transcription	O
which	O
may	O
be	O
required	O
for	O
the	O
development	O
and	O
activity	O
of	O
lymphocytes	O
.	O

Overexpression	O
of	O
HSF2-beta	O
inhibits	O
hemin-induced	O
heat	O
shock	O
gene	O
expression	O
and	O
erythroid	O
differentiation	O
in	O
K562	O
cells	O
.	O

Acquisition	O
of	O
heat	O
shock	O
factor	O
2	O
(	O
HSF2	O
)	O
DNA	O
binding	O
activity	O
is	O
accompanied	O
by	O
induced	O
transcription	O
of	O
heat	O
shock	O
genes	O
in	O
hemin-treated	O
K562	O
cells	O
undergoing	O
erythroid	O
differentiation	O
.	O

Previous	O
studies	O
revealed	O
that	O
HSF2	O
consists	O
of	O
two	O
alternatively	O
spliced	O
isoforms	O
,	O
HSF2-alpha	O
and	O
HSF2-beta	O
,	O
whose	O
relative	O
abundance	O
is	O
developmentally	O
regulated	O
and	O
varies	O
between	O
different	O
tissues	O
.	O

To	O
investigate	O
whether	O
the	O
molar	O
ratio	O
of	O
HSF2-alpha	O
and	O
HSF2-beta	O
isoforms	O
is	O
crucial	O
for	O
the	O
activation	O
of	O
HSF2	O
and	O
whether	O
the	O
HSF2	O
isoforms	O
play	O
functionally	O
distinct	O
roles	O
during	O
the	O
hemin-mediated	O
erythroid	O
differentiation	O
,	O
we	O
generated	O
cell	O
clones	O
expressing	O
different	O
levels	O
of	O
HSF2-alpha	O
and	O
HSF2-beta	O
.	O

We	O
show	O
that	O
in	O
parental	O
K562	O
cells	O
,	O
the	O
HSF2-alpha	O
isoform	O
is	O
predominantly	O
expressed	O
and	O
HSF2	O
can	O
be	O
activated	O
upon	O
hemin	O
treatment	O
.	O

In	O
contrast	O
,	O
when	O
HSF2-beta	O
is	O
expressed	O
at	O
levels	O
exceeding	O
those	O
of	O
endogenous	O
HSF2-alpha	O
,	O
the	O
hemin-induced	O
DNA	O
binding	O
activity	O
and	O
transcription	O
of	O
heat	O
shock	O
genes	O
are	O
repressed	O
,	O
whereas	O
overexpression	O
of	O
HSF2-alpha	O
results	O
in	O
an	O
enhanced	O
hemin	O
response	O
.	O

Furthermore	O
,	O
the	O
hemin-induced	O
accumulation	O
of	O
globin	O
,	O
known	O
as	O
a	O
marker	O
of	O
erythroid	O
differentiation	O
,	O
is	O
decreased	O
in	O
cells	O
overexpressing	O
HSF2-beta	O
.	O

We	O
suggest	O
that	O
HSF2-beta	O
acts	O
as	O
a	O
negative	O
regulator	O
of	O
HSF2	O
activity	O
during	O
hemin-mediated	O
erythroid	O
differentiation	O
of	O
K562	O
cells	O
.	O

Glucocorticoid-mediated	O
repression	O
of	O
cytokine	O
gene	O
transcription	O
in	O
human	O
arteritis-SCID	O
chimeras	O
.	O

Giant	O
cell	O
arteritis	O
(	O
GCA	O
)	O
is	O
a	O
vasculitic	O
syndrome	O
that	O
preferentially	O
affects	O
medium	O
and	O
large-sized	O
arteries	O
.	O

Glucocorticoid	O
therapy	O
resolves	O
clinical	O
symptoms	O
within	O
hours	O
to	O
days	O
,	O
but	O
therapy	O
has	O
to	O
be	O
continued	O
over	O
several	O
years	O
to	O
prevent	O
disease	O
relapses	O
.	O

It	O
is	O
not	O
known	O
whether	O
and	O
how	O
glucocorticoids	O
affect	O
the	O
function	O
of	O
the	O
inflammatory	O
infiltrate	O
or	O
why	O
the	O
disease	O
persists	O
subclinically	O
despite	O
chronic	O
treatment	O
.	O

GCA	O
is	O
self-sustained	O
in	O
temporal	O
arteries	O
engrafted	O
into	O
SCID	O
mice	O
,	O
providing	O
a	O
model	O
in	O
which	O
the	O
mechanisms	O
of	O
action	O
and	O
limitations	O
of	O
glucocorticoid	O
therapy	O
can	O
be	O
examined	O
in	O
vivo	O
.	O

Administration	O
of	O
dexamethasone	O
to	O
temporal	O
artery-SCID	O
chimeras	O
for	O
1	O
wk	O
induced	O
a	O
partial	O
suppression	O
of	O
T	O
cell	O
and	O
macrophage	O
function	O
as	O
indicated	O
by	O
the	O
reduced	O
tissue	O
concentrations	O
of	O
IL-2	O
,	O
IL-1beta	O
,	O
and	O
IL-6	O
mRNA	O
,	O
and	O
by	O
the	O
diminished	O
expression	O
of	O
inducible	O
NO	O
synthase	O
.	O

In	O
contrast	O
,	O
synthesis	O
of	O
IFN-gamma	O
mRNA	O
was	O
only	O
slightly	O
decreased	O
,	O
and	O
expression	O
of	O
TGF-beta1	O
was	O
unaffected	O
.	O

These	O
findings	O
correlated	O
with	O
activation	O
of	O
the	O
IkappaBalpha	O
gene	O
and	O
blockade	O
of	O
the	O
nuclear	O
translocation	O
of	O
NFkappaB	O
in	O
the	O
xenotransplanted	O
tissue	O
.	O

Dose-response	O
experiments	O
suggested	O
that	O
steroid	O
doses	O
currently	O
used	O
in	O
clinical	O
medicine	O
are	O
suboptimal	O
in	O
repressing	O
NFkappaB-mediated	O
cytokine	O
production	O
in	O
the	O
inflammatory	O
lesions	O
.	O

Chronic	O
steroid	O
therapy	O
was	O
able	O
to	O
deplete	O
the	O
T	O
cell	O
products	O
IL-2	O
and	O
IFN-gamma	O
,	O
whereas	O
the	O
activation	O
of	O
tissue-infiltrating	O
macrophages	O
was	O
only	O
partially	O
affected	O
.	O

IL-1beta	O
transcription	O
was	O
abrogated	O
;	O
in	O
contrast	O
,	O
TGF-beta1	O
mRNA	O
synthesis	O
was	O
steroid	O
resistant	O
.	O

The	O
persistence	O
of	O
TGF-beta1-transcribing	O
macrophages	O
,	O
despite	O
paralysis	O
of	O
T	O
cell	O
function	O
,	O
may	O
provide	O
an	O
explanation	O
for	O
the	O
chronicity	O
of	O
the	O
disease	O
,	O
and	O
may	O
identify	O
a	O
novel	O
therapeutic	O
target	O
in	O
this	O
inflammatory	O
vasculopathy	O
.	O

Histamine	O
modulates	O
the	O
expression	O
of	O
c-fos	O
through	O
cyclic	O
AMP	O
production	O
via	O
the	O
H2	O
receptor	O
in	O
the	O
human	O
promonocytic	O
cell	O
line	O
U937	O
.	O

We	O
examined	O
the	O
effects	O
of	O
histamine	O
and	O
its	O
agonists	O
on	O
the	O
expression	O
of	O
the	O
c-fos	O
and	O
c-myc	O
proto-oncogenes	O
at	O
the	O
transcriptional	O
and	O
translational	O
levels	O
in	O
the	O
human	O
promonocytic	O
U937	O
cell	O
line	O
.	O

Histamine	O
transiently	O
increased	O
cAMP	O
and	O
c-fos	O
expression	O
through	O
H2	O
receptors	O
.	O

Dibutyryl	O
cAMP	O
also	O
increased	O
c-fos	O
mRNA	O
and	O
protein	O
,	O
and	O
levels	O
remained	O
elevated	O
even	O
after	O
12	O
hr	O
of	O
treatment	O
.	O

Dose-dependence	O
studies	O
using	O
histamine	O
and	O
dimaprit	O
showed	O
that	O
the	O
EC50	O
values	O
for	O
cAMP	O
production	O
and	O
c-fos	O
increase	O
were	O
similar	O
,	O
suggesting	O
that	O
cAMP	O
might	O
be	O
involved	O
in	O
c-fos	O
induction	O
via	O
H2	O
receptors	O
.	O

Furthermore	O
,	O
studies	O
carried	O
out	O
using	O
H7	O
,	O
a	O
protein	O
kinase	O
A/protein	O
kinase	O
C	O
inhibitor	O
,	O
blocked	O
c-fos	O
induction	O
,	O
whereas	O
no	B-Negation
effect	I-Negation
was	I-Negation
observed	I-Negation
with	I-Negation
bisindolylmaleimide	I-Negation
,	I-Negation
a	I-Negation
specific	I-Negation
protein	I-Negation
kinase	I-Negation
C	I-Negation
inhibitor	I-Negation
.	O

No	B-Negation
modification	I-Negation
of	I-Negation
c-myc	I-Negation
expression	I-Negation
could	I-Negation
be	I-Negation
detected	I-Negation
on	I-Negation
treatment	I-Negation
with	I-Negation
histamine	I-Negation
or	I-Negation
its	I-Negation
analogues	I-Negation
.	O

Nevertheless	O
,	O
dibutyryl	O
cAMP	O
induced	O
a	O
down-regulation	O
of	O
the	O
levels	O
of	O
this	O
proto-oncogene	O
.	O

In	O
addition	O
,	O
dibutyryl	O
cAMP	O
inhibited	O
cell	O
growth	O
in	O
a	O
dose-dependent	O
manner	O
,	O
whereas	O
histamine	O
failed	B-Negation
to	I-Negation
affect	I-Negation
proliferation	I-Negation
and	I-Negation
differentiation	I-Negation
of	I-Negation
U937	I-Negation
cells	I-Negation
.	O

Cells	O
pretreated	O
with	O
dimaprit	O
showed	O
a	O
decrease	O
in	O
the	O
cAMP	O
response	O
to	O
subsequent	O
addition	O
of	O
H2	O
agonists	O
,	O
whereas	O
the	O
cAMP	O
response	O
to	O
prostaglandin	O
E2	O
remained	O
unaltered	O
.	O

This	O
homologous	O
mechanism	O
of	O
H2	O
receptor	O
desensitization	O
was	O
time	O
dependent	O
.	O

These	O
results	O
indicate	O
that	O
histamine	O
activates	O
several	O
mechanisms	O
involved	O
in	O
the	O
induction	O
of	O
differentiation	O
,	O
such	O
as	O
cAMP	O
and	O
c-fos	O
production	O
,	O
but	O
fails	O
to	O
promote	O
differentiation	O
of	O
U937	O
cells	O
,	O
apparently	O
due	O
to	O
the	O
rapid	O
desensitization	O
of	O
H2	O
receptors	O
.	O

Human	O
cytomegalovirus	O
induces	O
interleukin-8	O
production	O
by	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
,	O
through	O
acting	O
concurrently	O
on	O
AP-1-	O
and	O
NF-kappaB-binding	O
sites	O
of	O
the	O
interleukin-8	O
gene	O
.	O

Cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
induced	O
interleukin-8	O
(	O
IL-8	O
)	O
gene	O
transcription	O
in	O
a	O
human	O
monocytic	O
cell	O
line	O
,	O
THP-1	O
cells	O
,	O
leading	O
to	O
IL-8	O
secretion	O
.	O

The	O
functional	O
analysis	O
of	O
the	O
IL-8	O
gene	O
revealed	O
that	O
both	O
AP-1-	O
and	O
NF-kappaB	O
factor-binding	O
elements	O
were	O
involved	O
in	O
conferring	O
the	O
responsiveness	O
to	O
CMV	O
.	O

Moreover	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
CMV	O
induced	O
the	O
formation	O
of	O
NF-kappaB	O
and	O
AP-1	O
complexes	O
.	O

These	O
results	O
suggest	O
that	O
CMV	O
activates	O
these	O
transcriptional	O
factors	O
,	O
resulting	O
in	O
IL-8	O
gene	O
expression	O
.	O

Concomitant	O
downregulation	O
of	O
IgH	O
3	O
'	O
enhancer	O
activity	O
and	O
c-myc	O
expression	O
in	O
a	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
:	O
implications	O
for	O
dysregulation	O
of	O
translocated	O
c-myc	O
.	O

Regulation	O
of	O
immunoglobulin	O
heavy	O
chain	O
(	O
IgH	O
)	O
gene	O
expression	O
is	O
controlled	O
by	O
a	O
B	O
cell-specific	O
promoter	O
,	O
intronic	O
enhancer	O
and	O
additional	O
B	O
cell-specific	O
enhancer	O
elements	O
identified	O
recently	O
in	O
the	O
3	O
'	O
end	O
of	O
the	O
IgH	O
locus	O
.	O

One	O
of	O
the	O
latter	O
elements	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
,	O
is	O
of	O
particular	O
interest	O
:	O
(	O
1	O
)	O
it	O
is	O
B	O
cell-specific	O
and	O
active	O
only	O
in	O
late	O
B	O
cell	O
development	O
;	O
(	O
2	O
)	O
in	O
rodent	O
plasmacytomas	O
and	O
in	O
some	O
human	O
Burkitt	O
's	O
lymphomas	O
it	O
is	O
part	O
of	O
a	O
locus	O
control	O
region	O
(	O
LCR	O
)	O
that	O
is	O
involved	O
in	O
deregulation	O
of	O
the	O
c-myc	O
oncogene	O
as	O
a	O
result	O
of	O
translocation	O
into	O
the	O
IgH	O
locus	O
;	O
and	O
(	O
3	O
)	O
it	O
has	O
been	O
implicated	O
in	O
the	O
mechanisms	O
that	O
control	O
Ig	O
gene	O
class	O
switch	O
recombination	O
.	O

We	O
have	O
used	O
a	O
somatic	O
cell	O
hybridization	O
approach	O
to	O
genetically	O
analyse	O
regulation	O
of	O
the	O
activity	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
.	O

When	O
mouse	O
MPC11	O
plasmacytoma	O
cells	O
,	O
in	O
which	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
active	O
,	O
are	O
fused	O
with	O
fibroblasts	O
,	O
Ig	O
expression	O
is	O
extinguished	O
at	O
the	O
level	O
of	O
transcription	O
.	O

Here	O
we	O
show	O
that	O
in	O
a	O
MPC11	O
plasmacytoma	O
x	O
fibroblast	O
environment	O
,	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
transcriptionally	O
inactive	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
binding	B-Negation
of	I-Negation
several	I-Negation
B	I-Negation
cell-specific	I-Negation
transcription	I-Negation
factors	I-Negation
,	I-Negation
essential	I-Negation
for	I-Negation
IgH	I-Negation
3	I-Negation
'	I-Negation
enhancer	I-Negation
activity	I-Negation
,	I-Negation
is	I-Negation
lacking	I-Negation
,	O
which	O
may	B-Speculation
explain	I-Speculation
3	I-Speculation
'	I-Speculation
enhancer	I-Speculation
inactivity	I-Speculation
,	O
although	O
the	B-Speculation
binding	I-Speculation
of	I-Speculation
repressors	I-Speculation
can	I-Speculation
not	I-Speculation
be	I-Speculation
excluded	I-Speculation
.	O

Moreover	O
,	O
the	O
high	O
expression	O
level	O
of	O
c-myc	O
,	O
characteristic	O
of	O
the	O
parental	O
MPC11	O
cells	O
carrying	O
the	O
t	O
(	O
12	O
;	O
15	O
)	O
translocation	O
,	O
is	O
down-regulated	O
in	O
the	O
hybrids	O
to	O
that	O
in	O
unfused	O
fibroblasts	O
.	O

Therefore	O
,	O
inactivation	O
of	O
the	O
IgH	O
3	O
'	O
enhancer	O
is	O
a	O
multifactorial	O
process	O
affecting	O
several	O
transcription	O
factors	O
that	O
control	O
the	O
cell-specific	O
and	O
developmental	O
activity	O
of	O
the	O
enhancer	O
.	O

ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
synergistically	O
transactivate	O
the	O
human	O
GM-CSF	O
promoter	O
.	O

Activation	O
of	O
helper	O
T	O
cells	O
results	O
in	O
coordinate	O
expression	O
of	O
a	O
number	O
of	O
cytokines	O
involved	O
in	O
differentiation	O
,	O
proliferation	O
and	O
activation	O
of	O
the	O
haematopoietic	O
system	O
.	O

Granulocyte-macrophage	O
colony	O
stimulating	O
factor	O
(	O
GM-CSF	O
)	O
is	O
one	O
such	O
cytokine	O
,	O
whose	O
increased	O
expression	O
results	O
mostly	O
from	O
increases	O
in	O
transcription	O
.	O

Cis-acting	O
elements	O
with	O
NFkappaB	O
,	O
AP1	O
and	O
ETS-like	O
binding	O
motifs	O
have	O
been	O
identified	O
in	O
the	O
promoter	O
region	O
of	O
the	O
GM-CSF	O
gene	O
,	O
and	O
are	O
important	O
or	O
essential	O
for	O
transcriptional	O
activity	O
following	O
T	O
cell	O
activation	O
.	O

ETS1	O
is	O
a	O
transcription	O
factor	O
of	O
the	O
ETS	O
family	O
that	O
is	O
expressed	O
in	O
T	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
that	O
ETS1	O
can	O
transactivate	O
GM-CSF	O
in	O
Jurkat	O
T	O
cells	O
,	O
but	O
only	O
after	O
the	O
cells	O
have	O
been	O
stimulated	O
by	O
treatment	O
with	O
PMA	O
and	O
ionomycin	O
,	O
agents	O
that	O
mimic	O
T	O
cell	O
activation	O
.	O

Thus	O
we	O
proposed	O
that	O
ETS1	O
,	O
which	O
is	O
expressed	O
constitutively	O
in	O
Jurkat	O
cells	O
,	O
may	O
act	O
in	O
concert	O
with	O
PMA/ionomycin	O
inducible	O
factors	O
.	O

Here	O
we	O
show	O
that	O
ETS1	O
can	O
transactivate	O
a	O
GM-CSF	O
reporter	O
construct	O
in	O
unstimulated	O
Jurkat	O
cells	O
,	O
providing	O
that	O
either	O
NFkappaB	O
or	O
AP1	O
transcription	O
factors	O
are	O
supplied	O
by	O
co-transfection	O
.	O

We	O
confirm	O
that	O
binding	O
of	O
endogenous	O
NFkappaB	O
and	O
AP1	O
is	O
induced	O
following	O
PMA/ionomycin	O
treatment	O
of	O
T	O
cells	O
.	O

Transactivation	O
by	O
ETS1	O
,	O
NFkappaB	O
and	O
AP1	O
is	O
synergistic	O
,	O
and	O
mutation	O
of	O
the	O
individual	O
binding	O
sites	O
reveals	O
that	O
the	O
transcriptional	O
activities	O
of	O
these	O
factors	O
are	O
interdependent	O
.	O

Our	O
results	O
suggest	O
that	O
constitutive	O
ETS1	O
,	O
and	O
inducible	O
NFkappaB	O
and	O
AP1	O
,	O
cooperate	O
as	O
part	O
of	O
a	O
higher	O
order	O
transcriptional	O
complex	O
in	O
activated	O
T	O
cells	O
.	O

The	O
IL-4	O
receptor	O
alpha-chain	O
cytoplasmic	O
domain	O
is	O
sufficient	O
for	O
activation	O
of	O
JAK-1	O
and	O
STAT6	O
and	O
the	O
induction	O
of	O
IL-4-specific	O
gene	O
expression	O
.	O

The	O
common	O
gamma-chain	O
(	O
gamma	O
(	O
c	O
)	O
)	O
is	O
a	O
functional	O
component	O
of	O
the	O
IL-4R	O
,	O
yet	O
cells	O
lacking	B-Negation
gamma	I-Negation
(	I-Negation
c	I-Negation
)	I-Negation
are	O
able	O
to	O
respond	O
to	O
IL-4	O
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
a	O
surrogate	O
gamma'-chain	O
,	O
which	O
can	O
interact	O
with	O
the	O
IL-4R	O
alpha	O
chain	O
to	O
mediate	O
signaling	O
,	O
is	O
expressed	O
on	O
cells	O
lacking	O
gamma	O
(	O
c	O
)	O
.	O

An	O
alternative	O
possibility	O
is	O
that	O
in	O
the	O
absence	O
of	O
gamma	O
(	O
c	O
)	O
,	O
the	O
IL-4R	O
alpha	O
chain	O
is	O
able	O
to	O
transduce	O
signals	O
by	O
homodimerization	O
.	O

To	O
test	O
this	O
latter	O
possibility	O
,	O
a	O
chimeric	O
receptor	O
containing	O
the	O
extracellular	O
domain	O
of	O
c-kit	O
(	O
the	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
receptor	O
)	O
and	O
the	O
cytoplasmic	O
and	O
transmembrane	O
domains	O
of	O
the	O
IL-4R	O
alpha	O
chain	O
was	O
generated	O
.	O

Treatment	O
of	O
cells	O
expressing	O
the	O
chimeric	O
receptor	O
kit/IL-4R	O
alpha	O
with	O
SCF	O
induces	O
activation	O
of	O
the	O
IL-4R	O
alpha-associated	O
kinase	O
JAK-1	O
and	O
the	O
transcription	O
factor	O
STAT6	O
.	O

However	O
,	O
tyrosine	B-Negation
phosphorylation	I-Negation
of	I-Negation
JAK-3	I-Negation
,	I-Negation
which	I-Negation
associates	I-Negation
with	I-Negation
gamma	I-Negation
(	I-Negation
c	I-Negation
)	I-Negation
,	I-Negation
is	I-Negation
not	I-Negation
induced	I-Negation
by	I-Negation
SCF	I-Negation
in	I-Negation
these	I-Negation
cells	I-Negation
.	O

SCF-mediated	O
ligation	O
of	O
kit/IL-4R	O
alpha	O
is	O
sufficient	O
to	O
elicit	O
IL-4-specific	O
gene	O
expression	O
,	O
including	O
up-regulation	O
of	O
CD23	O
and	O
synthesis	O
of	O
germ-line	O
epsilon	O
transcripts	O
.	O

In	O
the	O
T	O
cell	O
line	O
CTLL2	O
,	O
ligation	O
of	O
kit/IL-4R	O
alpha	O
induces	O
cellular	O
proliferation	O
.	O

Finally	O
,	O
in	O
JAK-1-deficient	O
HeLa	O
cells	O
,	O
STAT6	O
activation	O
by	O
IL-4	O
is	O
completely	O
abolished	O
.	O

Together	O
,	O
these	O
data	O
demonstrate	O
that	O
the	O
IL-4R	O
alpha	O
cytoplasmic	O
domain	O
is	O
sufficient	O
to	O
activate	O
JAK-1	O
and	O
STAT6	O
and	O
to	O
induce	O
expression	O
of	O
IL-4	O
target	O
genes	O
,	O
thus	O
identifying	O
a	O
mechanism	O
by	O
which	O
IL-4	O
signaling	O
can	O
proceed	O
in	O
the	O
absence	B-Negation
of	I-Negation
JAK-3	I-Negation
and	I-Negation
gamma	I-Negation
(	I-Negation
c	I-Negation
)	I-Negation
.	O

Relief	O
of	O
cyclin	O
A	O
gene	O
transcriptional	O
inhibition	O
during	O
activation	O
of	O
human	O
primary	O
T	O
lymphocytes	O
via	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
.	O

Cyclin	O
A	O
transcription	O
is	O
cell	O
cycle	O
regulated	O
and	O
induced	O
by	O
cell	O
proliferative	O
signals	O
.	O

To	O
understand	O
the	O
mechanisms	O
underlined	O
in	O
this	O
regulation	O
in	O
normal	O
human	O
cells	O
,	O
we	O
have	O
analysed	O
in	O
vivo	O
protein-DNA	O
interactions	O
at	O
the	O
Cyclin	O
A	O
locus	O
in	O
primary	O
T	O
lymphocytes	O
.	O

Stimulation	O
of	O
purified	O
T	O
lymphocytes	O
by	O
a	O
combination	O
of	O
monoclonal	O
antibodies	O
directed	O
at	O
CD2	O
and	O
CD28	O
adhesion	O
molecules	O
gives	O
rise	O
to	O
a	O
long	O
lasting	O
proliferation	O
in	O
the	O
absence	B-Negation
of	I-Negation
accessory	I-Negation
cells	I-Negation
.	O

Cyclin	O
A	O
was	O
observed	O
after	O
4	O
days	O
of	O
costimulation	O
with	O
anti	O
CD2	O
+	O
CD28	O
whereas	O
stimulation	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
was	O
not	B-Negation
effective	I-Negation
.	O

In	O
vivo	O
genomic	O
DMS	O
footprinting	O
revealed	O
upstream	O
of	O
the	O
major	O
transcription	O
initiation	O
sites	O
,	O
the	O
presence	O
of	O
at	O
least	O
three	O
protein	O
binding	O
sites	O
,	O
two	O
of	O
which	O
were	O
constitutively	O
occupied	O
.	O

They	O
bind	O
in	O
vitro	O
respectively	O
ATF-1	O
and	O
NF-Y	O
proteins	O
.	O

The	O
third	O
site	O
was	O
occupied	O
in	O
quiescent	O
cells	O
or	O
in	O
cells	O
stimulated	O
by	O
anti	O
CD2	O
or	O
anti	O
CD28	O
alone	O
.	O

The	O
mitogenic	O
combination	O
of	O
anti	O
CD2	O
+	O
anti	O
CD28	O
released	O
the	O
footprint	O
as	O
cells	O
were	O
committed	O
to	O
proliferation	O
.	O

Consistent	O
with	O
theses	O
results	O
,	O
nuclear	O
extracts	O
prepared	O
from	O
quiescent	O
cells	O
formed	O
a	O
specific	O
complex	O
with	O
this	O
element	O
,	O
whereas	O
extracts	O
prepared	O
from	O
cells	O
treated	O
with	O
anti	O
CD2	O
+	O
anti	O
CD28	O
failed	B-Negation
to	I-Negation
do	I-Negation
so	I-Negation
after	I-Negation
cells	I-Negation
entered	I-Negation
a	I-Negation
proliferative	I-Negation
state	I-Negation
.	O

Interleukin-10	O
inhibits	O
interferon-gamma-induced	O
intercellular	O
adhesion	O
molecule-1	O
gene	O
transcription	O
in	O
human	O
monocytes	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
is	O
a	O
potent	O
monocyte	O
regulatory	O
cytokine	O
that	O
inhibits	O
gene	O
expression	O
of	O
proinflammatory	O
mediators	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
mechanism	O
by	O
which	O
IL-10	O
downregulates	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
on	O
the	O
cell	O
surface	O
of	O
normal	O
human	O
monocytes	O
activated	O
with	O
interferon-gamma	O
(	O
IFN-gamma	O
)	O
.	O

IL-10	O
inhibition	O
of	O
IFN-gamma-induced	O
ICAM-1	O
expression	O
was	O
apparent	O
as	O
early	O
as	O
3	O
hours	O
and	O
was	O
blocked	O
by	O
an	O
anti-IL-10	O
antibody	O
but	O
not	B-Negation
by	I-Negation
an	I-Negation
isotype-matched	I-Negation
control	I-Negation
antibody	I-Negation
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
IL-10	O
reduced	O
the	O
accumulation	O
of	O
ICAM-1	O
mRNA	O
in	O
IFN-gamma-stimulated	O
monocytes	O
.	O

IL-10	O
inhibition	O
of	O
ICAM-1	O
steady-state	O
mRNA	O
was	O
detected	O
at	O
3	O
hours	O
and	O
remained	O
at	O
24	O
hours	O
.	O

Nuclear	O
run-on	O
transcription	O
assays	O
showed	O
that	O
IL-10	O
inhibited	O
the	O
rate	O
of	O
IFN-gamma-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
,	O
and	O
mRNA	O
stability	O
studies	O
showed	O
that	O
IL-10	O
did	O
not	B-Negation
alter	I-Negation
the	I-Negation
half-life	I-Negation
of	I-Negation
IFN-gamma-induced	I-Negation
ICAM-1	I-Negation
message	I-Negation
.	O

Thus	O
,	O
IL-10	O
inhibits	O
IFN-gamma-induced	O
ICAM-1	O
expression	O
in	O
monocytes	O
primarily	O
at	O
the	O
level	O
of	O
gene	O
transcription	O
.	O

Activation	O
of	O
IFN-gamma-responsive	O
genes	O
requires	O
tyrosine	O
phosphorylation	O
of	O
the	O
transcriptional	O
factor	O
STAT-1alpha	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription-1alpha	O
)	O
.	O

However	O
,	O
IL-10	O
did	O
not	B-Negation
affect	I-Negation
IFN-gamma-induced	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
of	I-Negation
STAT-1alpha	I-Negation
or	I-Negation
alter	I-Negation
STAT-1alpha	I-Negation
binding	I-Negation
to	I-Negation
the	I-Negation
IFN-gamma	I-Negation
response	I-Negation
element	I-Negation
(	I-Negation
IRE	I-Negation
)	I-Negation
in	I-Negation
the	I-Negation
ICAM-1	I-Negation
promoter	I-Negation
.	O

Instead	O
,	O
IL-10	O
prevented	O
IFN-gamma-induced	O
binding	O
activity	O
at	O
the	O
NF-kappaB	O
site	O
of	O
the	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
-responsive	O
NF-kappaB/C-EBP	O
composite	O
element	O
in	O
the	O
ICAM-1	O
promoter	O
.	O

These	O
data	O
indicate	O
that	O
IL-10	O
inhibits	O
IFN-gamma-induced	O
transcription	O
of	O
the	O
ICAM-1	O
gene	O
by	O
a	O
regulatory	O
mechanism	O
that	O
may	O
involve	O
NF-kappaB	O
.	O

Biphasic	O
control	O
of	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
the	O
triggering	O
of	O
HLA-DR	O
antigens	O
expressed	O
on	O
B	O
cells	O
.	O

The	O
regulation	O
of	O
NF-kappa	O
B	O
activation	O
following	O
the	O
triggering	O
of	O
HLA-DR	O
antigens	O
by	O
mAb	O
L243	O
has	O
been	O
studied	O
at	O
various	O
times	O
in	O
Raji	O
cells	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
a	O
strong	O
increase	O
of	O
NF-kappa	O
B	O
DNA	O
binding	O
after	O
triggering	O
of	O
HLA-DR	O
antigens	O
.	O

Using	O
TNF-alpha-activity	O
neutralizing	O
antibodies	O
,	O
the	O
authors	O
demonstrated	O
that	O
the	O
upregulation	O
of	O
NF-kappa	O
B	O
was	O
found	O
to	O
depend	O
,	O
at	O
later	O
time	O
point	O
,	O
on	O
an	O
autocrine	O
effect	O
of	O
TNF-alpha	O
secreted	O
following	O
triggering	O
of	O
HLA-DR	O
antigens	O
.	O

In	O
contrast	O
,	O
it	O
was	O
found	O
to	O
be	O
TNF-alpha	O
independent	O
in	O
the	O
early	O
time	O
point	O
.	O

Moreover	O
,	O
the	O
upregulation	O
of	O
NF-kappa	O
B	O
binding	O
activity	O
is	O
regulated	O
by	O
the	O
triggering	O
of	O
selected	O
epitopes	O
of	O
HLA-DR	O
antigens	O
.	O

In	O
fact	O
,	O
mAb	O
L243	O
but	O
not	B-Negation
the	I-Negation
staphylococcal	I-Negation
superantigens	I-Negation
,	O
staphylococcal	O
exotoxin	O
toxic	O
shock	O
syndrome	O
toxin-I	O
or	O
staphylococcal	O
enterotoxin	O
B	O
,	O
regulate	O
the	O
NF-kappa	O
B	O
binding	O
activity	O
.	O

Comparison	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
and	O
Stat6	O
in	O
lymphoid	O
cells	O
and	O
mammary	O
epithelial	O
cells	O
.	O

Stat	O
(	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
)	O
and	O
Jak	O
(	O
Janus	O
kinases	O
)	O
proteins	O
are	O
central	O
components	O
in	O
the	O
signal	O
transduction	O
events	O
in	O
hematopoietic	O
and	O
epithelial	O
cells	O
.	O

They	O
are	O
rapidly	O
activated	O
by	O
various	O
cytokines	O
,	O
hormones	O
,	O
and	O
growth	O
factors	O
.	O

Upon	O
ligand	O
binding	O
and	O
cytokine	O
receptor	O
dimerization	O
,	O
Stat	O
proteins	O
are	O
phosphorylated	O
on	O
tyrosine	O
residues	O
by	O
Jak	O
kinases	O
.	O

Activated	O
Stat	O
proteins	O
form	O
homo-	O
or	O
heterodimers	O
,	O
translocate	O
to	O
the	O
nucleus	O
,	O
and	O
induce	O
transcription	O
from	O
responsive	O
genes	O
.	O

Stat5	O
and	O
Stat6	O
are	O
transcription	O
factors	O
active	O
in	O
mammary	O
epithelial	O
cells	O
and	O
immune	O
cells	O
.	O

Prolactin	O
activates	O
Stat5	O
,	O
and	O
interleukin-4	O
(	O
IL-4	O
)	O
activates	O
Stat6	O
.	O

Both	O
cytokines	O
are	O
able	O
to	O
stimulate	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
and	O
survival	O
.	O

We	O
investigated	O
the	O
transactivation	O
potential	O
of	O
Stat6	O
and	O
found	O
that	O
it	O
is	O
not	B-Negation
restricted	I-Negation
to	I-Negation
lymphocytes	I-Negation
.	O

IL-4-dependent	O
activation	O
of	O
Stat6	O
was	O
also	O
observed	O
in	O
HC11	O
mammary	O
epithelial	O
cells	O
.	O

In	O
these	O
cells	O
,	O
Stat6	O
activation	O
led	O
to	O
the	O
induction	O
of	O
the	O
beta-casein	O
gene	O
promoter	O
.	O

The	O
induction	O
of	O
this	O
promoter	O
was	O
confirmed	O
in	O
COS7	O
cells	O
.	O

The	O
glucocorticoid	O
receptor	O
was	O
able	O
to	O
further	O
enhance	O
IL-4-induced	O
gene	O
transcription	O
through	O
the	O
action	O
of	O
Stat6	O
.	O

Deletion	O
analysis	O
of	O
the	O
carboxyl-terminal	O
region	O
of	O
Stat6	O
and	O
recombination	O
of	O
this	O
region	O
with	O
a	O
heterologous	O
DNA	O
binding	O
domain	O
allowed	O
the	O
delimitation	O
and	O
characterization	O
of	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
.	O

The	O
potencies	O
of	O
the	O
transactivation	O
domains	O
of	O
Stat5	O
,	O
Stat6	O
,	O
and	O
viral	O
protein	O
VP16	O
were	O
compared	O
.	O

Stat6	O
had	O
a	O
transactivation	O
domain	O
which	O
was	O
about	O
10-fold	O
stronger	O
than	O
that	O
of	O
Stat5	O
.	O

In	O
pre-B	O
cells	O
(	O
Ba/F3	O
)	O
,	O
the	O
transactivation	O
domain	O
of	O
Stat6	O
was	O
IL-4	O
regulated	O
,	O
independently	O
from	O
its	O
DNA	O
binding	O
function	O
.	O

The	O
immediate-early	O
gene	O
product	O
Egr-1	O
regulates	O
the	O
human	O
interleukin-2	O
receptor	O
beta-chain	O
promoter	O
through	O
noncanonical	O
Egr	O
and	O
Sp1	O
binding	O
sites	O
.	O

The	O
interleukin-2	O
IL-2	O
receptor	O
beta-chain	O
(	O
IL-2Rbeta	O
)	O
is	O
an	O
essential	O
component	O
of	O
the	O
receptors	O
for	O
IL-2	O
and	O
IL-15	O
.	O

Although	O
IL-2Rbeta	O
is	O
constitutively	O
expressed	O
by	O
lymphocytes	O
,	O
its	O
expression	O
can	O
be	O
further	O
induced	O
by	O
a	O
number	O
of	O
stimuli	O
,	O
including	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
.	O

We	O
have	O
now	O
characterized	O
factors	O
that	O
bind	O
to	O
an	O
enhancer	O
region	O
located	O
between	O
nucleotides	O
-170	O
and	O
-139	O
of	O
the	O
human	O
IL-2Rbeta	O
promoter	O
.	O

Both	O
Sp1	O
and	O
Sp3	O
bound	O
to	O
the	O
5	O
'	O
portion	O
of	O
this	O
region	O
,	O
whereas	O
a	O
PMA-inducible	O
factor	O
(	O
PIF	O
)	O
mainly	O
bound	O
to	O
its	O
3	O
'	O
portion	O
and	O
bound	O
to	O
the	O
Sp	O
binding	O
motifs	O
as	O
well	O
.	O

In	O
Jurkat	O
T	O
cells	O
,	O
induction	O
of	O
PIF	O
DNA	O
binding	O
activity	O
was	O
rapidly	O
induced	O
,	O
required	O
de	O
novo	O
protein	O
synthesis	O
,	O
and	O
was	O
sustained	O
at	O
a	O
high	O
level	O
for	O
at	O
least	O
23	O
h	O
.	O

Interestingly	O
,	O
PIF	O
was	O
constitutively	O
activated	O
in	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1-transformed	O
MT-2	O
cells	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
PIF	O
is	O
Egr-1	O
based	O
on	O
its	O
recognition	O
by	O
anti-Egr-1	O
antisera	O
in	O
gel	O
mobility	O
shift	O
assays	O
,	O
even	O
though	O
the	O
IL-2Rbeta	O
DNA	O
binding	O
motif	O
differed	O
substantially	O
from	O
the	O
canonical	O
Egr-1	O
binding	O
site	O
.	O

In	O
addition	O
,	O
Egr-1	O
bound	O
to	O
the	O
Sp	O
binding	O
site	O
.	O

In	O
Jurkat	O
cells	O
,	O
both	O
sites	O
were	O
required	O
for	O
maximal	O
IL-2Rbeta	O
promoter	O
activity	O
,	O
and	O
in	O
HeLaS3	O
cells	O
,	O
transfection	O
of	O
Egr-1	O
could	O
drive	O
activity	O
of	O
a	O
reporter	O
construct	O
containing	O
both	O
sites	O
.	O

Moreover	O
,	O
Sp1	O
and	O
Egr-1	O
could	O
form	O
a	O
complex	O
with	O
kinetics	O
that	O
correlated	O
with	O
the	O
production	O
of	O
Egr-1	O
in	O
Jurkat	O
cells	O
upon	O
PMA	O
stimulation	O
.	O

Thus	O
,	O
Sp1	O
and	O
Egr-1	O
physically	O
and	O
functionally	O
cooperate	O
to	O
mediate	O
maximal	O
IL-2Rbeta	O
promoter	O
activity	O
.	O

Anti-Ehrlichia	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
induces	O
potent	O
proinflammatory	O
cytokine	O
mRNA	O
expression	O
in	O
human	O
monocytes	O
through	O
sustained	O
reduction	O
of	O
IkappaB-alpha	O
and	O
activation	O
of	O
NF-kappaB	O
.	O

Ehrlichia	O
chaffeensis	O
is	O
an	O
obligatory	O
intracellular	O
bacterium	O
that	O
infects	O
monocytes	O
and	O
macrophages	O
and	O
is	O
the	O
etiologic	O
agent	O
of	O
human	O
ehrlichiosis	O
in	O
the	O
United	O
States	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
the	O
exposure	O
of	O
human	O
monocytes	O
to	O
E.	O
chaffeensis	O
induces	O
the	O
expression	O
of	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
,	O
IL-8	O
,	O
and	O
IL-10	O
genes	O
in	O
vitro	O
but	O
not	B-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor	I-Negation
alpha	I-Negation
(	I-Negation
TNF-alpha	I-Negation
)	I-Negation
and	I-Negation
IL-6	I-Negation
mRNAs	I-Negation
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
anti-E.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
on	O
the	O
expression	O
of	O
major	O
proinflammatory	O
cytokines	O
in	O
human	O
monocytes	O
was	O
examined	O
.	O

Human	O
monocytic	O
cell	O
line	O
THP-1	O
was	O
treated	O
with	O
E.	O
chaffeensis	O
which	O
had	O
been	O
preincubated	O
with	O
human	O
anti-E.	O
chaffeensis	O
serum	O
for	O
2	O
h	O
,	O
and	O
the	O
levels	O
of	O
cytokine	O
mRNAs	O
were	O
evaluated	O
by	O
competitive	O
reverse	O
transcription-PCR	O
.	O

Anti-E.	O
chaffeensis	O
antibody	O
complexed	O
with	O
E.	O
chaffeensis	O
significantly	O
enhanced	O
mRNA	O
expression	O
of	O
IL-1beta	O
in	O
THP-1	O
cells	O
.	O

The	O
expression	O
of	O
TNF-alpha	O
and	O
IL-6	O
mRNAs	O
was	O
also	O
induced	O
.	O

The	O
levels	O
of	O
secreted	O
IL-1beta	O
,	O
TNF-alpha	O
,	O
and	O
IL-6	O
during	O
24	O
h	O
of	O
stimulation	O
were	O
comparable	O
to	O
those	O
induced	O
by	O
Escherichia	O
coli	O
lipopolysaccharide	O
at	O
1	O
microg/ml	O
.	O

Fab	O
fragment	O
of	O
anti-E.	O
chaffeensis	O
immunoglobulin	O
G	O
complexed	O
with	O
E.	O
chaffeensis	O
did	O
not	B-Negation
induce	I-Negation
any	I-Negation
of	I-Negation
these	I-Negation
three	I-Negation
cytokines	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
ehrlichial	I-Speculation
binding	I-Speculation
is	I-Speculation
required	I-Speculation
for	I-Speculation
IL-1beta	I-Speculation
mRNA	I-Speculation
expression	I-Speculation
and	I-Speculation
that	I-Speculation
binding	I-Speculation
of	I-Speculation
the	I-Speculation
immune	I-Speculation
complex	I-Speculation
to	I-Speculation
the	I-Speculation
Fc	I-Speculation
gamma	I-Speculation
receptor	I-Speculation
is	I-Speculation
required	I-Speculation
for	I-Speculation
TNF-alpha	I-Speculation
and	I-Speculation
IL-6	I-Speculation
mRNA	I-Speculation
expression	I-Speculation
and	I-Speculation
enhanced	I-Speculation
IL-1beta	I-Speculation
mRNA	I-Speculation
expression	I-Speculation
.	O

Furthermore	O
,	O
prolonged	O
degradation	O
of	O
IkappaB-alpha	O
and	O
activation	O
of	O
NF-kappaB	O
were	O
demonstrated	O
in	O
THP-1	O
cells	O
exposed	O
to	O
anti-E.	O
chaffeensis	O
serum	O
and	O
E.	O
chaffeensis	O
.	O

This	O
result	O
implies	O
that	O
development	O
of	O
anti-E.	O
chaffeensis	O
antibody	O
in	O
patients	O
can	O
result	O
in	O
the	O
production	O
of	O
major	O
proinflammatory	O
cytokines	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
ehrlichiosis	O
and	O
immune	O
responses	O
to	O
it	O
.	O

S-allyl	O
cysteine	O
inhibits	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
in	O
human	O
T	O
cells	O
.	O

Reactive	O
oxygen	O
species	O
are	O
involved	O
in	O
signal	O
transduction	O
pathways	O
leading	O
to	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
which	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
gene	O
transcription	O
.	O

We	O
recently	O
reported	O
that	O
a	O
garlic	O
compound	O
,	O
S-allyl	O
cysteine	O
(	O
SAC	O
)	O
,	O
protects	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cells	O
from	O
oxidant	O
injury	O
induced	O
by	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
.	O

In	O
this	O
study	O
we	O
determined	O
the	O
effects	O
of	O
SAC	O
on	O
NF-kappa	O
B	O
activation	O
in	O
human	O
T	O
lymphocytes	O
(	O
Jurkat	O
cells	O
)	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-	O
alpha	O
)	O
and	O
H2O2	O
.	O

Activated	O
NF-kappa	O
B	O
in	O
nuclear	O
extracts	O
was	O
measured	O
by	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
using	O
32P-labeled	O
probe	O
.	O

SAC	O
consistently	O
exhibited	O
a	O
dose-dependent	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
induced	O
by	O
both	O
TNF-alpha	O
and	O
H2O2	O
.	O

Supershift	O
with	O
specific	O
antibodies	O
to	O
NF-kappa	O
B	O
subunits	O
confirmed	O
that	O
the	O
inducible	O
retarded	O
bands	O
observed	O
in	O
the	O
EMSA	O
and	O
p65-p50	O
heterodimer	O
of	O
the	O
NF-kappa	O
B/Rel	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
SAC	O
may	O
act	O
via	O
antioxidant	O
mechanisms	O
to	O
block	O
NF-kappa	O
B	O
activation	O
in	O
Jurkat	O
cells	O
.	O

Effect	O
of	O
adenovirus	O
2	O
on	O
cellular	O
gene	O
activation	O
in	O
blood-derived	O
monocytes	O
and	O
macrophages	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
adenovirus	O
2	O
(	O
Ad2	O
)	O
infection	O
on	O
human	O
monocytes	O
and	O
monocyte-derived	O
macrophages	O
with	O
regard	O
to	O
expression	O
of	O
TNF-alpha	O
and	O
IL-1	O
beta	O
.	O

In	O
monocytes	O
,	O
the	O
virus	O
was	O
bound	O
to	O
the	O
surface	O
without	B-Negation
being	I-Negation
internalized	I-Negation
.	O

On	O
the	O
other	O
hand	O
,	O
Ad2	O
was	O
internalized	O
by	O
macrophages	O
.	O

No	B-Negation
virus	I-Negation
replication	I-Negation
and	I-Negation
no	I-Negation
transcription	I-Negation
of	I-Negation
the	I-Negation
Ad2	I-Negation
early	I-Negation
genes	I-Negation
was	I-Negation
observed	I-Negation
in	I-Negation
either	I-Negation
of	I-Negation
the	I-Negation
cells	I-Negation
.	O

Ad2	O
infection	O
induced	O
transient	O
increase	O
in	O
the	O
mRNA	O
levels	O
for	O
TNF-alpha	O
and	O
IL-1	O
beta	O
in	O
both	O
monocytes	O
and	O
in	O
macrophages	O
,	O
although	O
the	O
kinetics	O
of	O
the	O
transcription	O
was	O
slightly	O
different	O
.	O

The	O
production	O
of	O
both	O
cytokines	O
,	O
measured	O
by	O
ELISA	O
tests	O
,	O
was	O
enhanced	O
in	O
monocytes	O
.	O

In	O
macrophages	O
,	O
a	O
slight	O
enhancement	O
of	O
TNF-alpha	O
production	O
was	O
seen	O
,	O
whereas	O
IL-1	B-Negation
beta	I-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
.	O

The	O
data	O
indicate	O
that	O
cellular	O
genes	O
might	O
be	O
activated	O
by	O
Ad2	O
virus	O
infection	O
in	O
nonpermissive	O
cells	O
where	O
no	O
viral	O
gene	O
products	O
could	O
be	O
detected	O
.	O

Activation	O
of	O
nuclear	O
factor-kappa	O
B	O
by	O
beta-amyloid	O
peptides	O
and	O
interferon-gamma	O
in	O
murine	O
microglia	O
.	O

An	O
increasing	O
body	O
of	O
evidence	O
suggests	O
that	O
amyloid-beta	O
(	O
A	O
beta	O
)	O
peptides	O
and	O
microglia	O
are	O
crucially	O
involved	O
in	O
the	O
pathogenesis	O
of	O
Alzheimer	O
's	O
disease	O
.	O

In	O
an	O
effort	O
to	O
further	O
elucidate	O
the	O
biological	O
effects	O
of	O
A	O
beta	O
towards	O
microglia	O
,	O
we	O
investigated	O
the	O
ability	O
of	O
A	O
beta	O
peptides	O
to	O
activate	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
in	O
the	O
N9	O
murine	O
microglial	O
cell	O
line	O
.	O

Co-stimulation	O
of	O
microglia	O
with	O
suboptimal	O
concentrations	O
of	O
A	O
beta	O
(	O
25-35	O
)	O
and	O
100	O
U/ml	O
IFN	O
gamma	O
resulted	O
in	O
the	O
detection	O
of	O
a	O
specific	O
NF-kappa	O
B	O
DNA-binding	O
activity	O
in	O
nuclear	O
extracts	O
,	O
as	O
determined	O
in	O
gel	O
mobility	O
shift	O
assays	O
.	O

This	O
response	O
required	O
at	O
least	O
120	O
min	O
to	O
be	O
evident	O
and	O
supershift	O
experiments	O
revealed	O
that	O
the	O
NF-kappa	O
B	O
complex	O
contains	O
both	O
RelA	O
and	O
p50	O
.	O

Accordingly	O
,	O
immunoblot	O
experiments	O
showed	O
that	O
amongst	O
NF-kappa	O
B/Rel	O
proteins	O
,	O
RelA	O
and	O
p50	O
are	O
mobilized	O
to	O
the	O
nucleus	O
following	O
microglial	O
cell	O
stimulation	O
with	O
A	O
beta	O
(	O
25-35	O
)	O
plus	O
IFN	O
gamma	O
.	O

Higher	O
concentrations	O
of	O
A	O
beta	O
(	O
25-35	O
)	O
were	O
effective	O
by	O
themselves	O
in	O
inducing	O
NF-kappa	O
B	O
activation	O
,	O
both	O
in	O
the	O
N9	O
microglial	O
cell	O
line	O
and	O
in	O
rat	O
primary	O
microglia	O
,	O
as	O
well	O
as	O
in	O
human	O
monocytes	O
.	O

For	O
purposes	O
of	O
comparison	O
,	O
microglia	O
were	O
also	O
stimulated	O
with	O
bacterial	O
LPS	O
,	O
a	O
known	O
NF-kappa	O
B	O
inducer	O
.	O

As	O
expected	O
,	O
LPS	O
strongly	O
induced	O
the	O
formation	O
of	O
two	O
NF-kappa	O
B	O
DNA-binding	O
activities	O
,	O
one	O
of	O
which	O
was	O
identified	O
as	O
RelA/p50	O
.	O

The	O
LPS	O
response	O
was	O
also	O
more	O
rapid	O
,	O
as	O
it	O
was	O
already	O
evident	O
by	O
40	O
min	O
and	O
remained	O
sustained	O
for	O
up	O
to	O
3	O
h	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
NF-kappa	O
B	O
activation	O
might	O
constitute	O
one	O
of	O
the	O
mechanisms	O
underlying	O
the	O
inducible	O
expression	O
of	O
kappa	O
B-dependent	O
genes	O
in	O
microglia	O
stimulated	O
by	O
A	O
beta	O
peptides	O
and	O
IFN	O
gamma	O
,	O
or	O
by	O
LPS	O
.	O

AP-1	O
derived	O
from	O
mature	O
monocytes	O
and	O
astrocytes	O
preferentially	O
interacts	O
with	O
the	O
HTLV-I	O
promoter	O
central	O
21	O
bp	O
repeat	O
.	O

Characterization	O
of	O
the	O
cellular	O
transcription	O
factors	O
interacting	O
with	O
the	O
human	O
T	O
cell	O
lymphotropic	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
is	O
essential	O
to	O
dissecting	O
the	O
mechanisms	O
involved	O
in	O
viral	O
transcription	O
that	O
may	O
be	O
pertinent	O
to	O
the	O
oncogenic	O
and	O
neuropathogenic	O
processes	O
associated	O
with	O
HTLV-I	O
infection	O
in	O
both	O
the	O
immune	O
and	O
nervous	O
systems	O
.	O

Electrophoretic	O
mobility	O
shift	O
(	O
EMS	O
)	O
analyses	O
utilizing	O
oligonucleotides	O
homologous	O
to	O
each	O
of	O
the	O
21	O
bp	O
repeat	O
elements	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
cell	O
lines	O
of	O
lymphocytic	O
,	O
monocytic	O
,	O
neuronal	O
,	O
and	O
glial	O
cell	O
origin	O
have	O
demonstrated	O
differential	O
binding	O
of	O
cellular	O
factors	O
to	O
the	O
three	O
21	O
bp	O
repeats	O
(	O
1-4	O
)	O
.	O

ATF/CREB	O
and	O
Sp	O
family	O
members	O
interacted	O
with	O
the	O
21	O
bp	O
repeats	O
to	O
form	O
DNA-protein	O
complexes	O
common	O
to	O
all	O
cell	O
types	O
examined	O
.	O

However	O
,	O
a	O
unique	O
DNA-protein	O
complex	O
was	O
detected	O
when	O
the	O
promoter	O
central	O
21	O
bp	O
repeat	O
was	O
reacted	O
with	O
nuclear	O
extracts	O
derived	O
from	O
either	O
the	O
U-373	O
MG	O
glioblastoma	O
cell	O
line	O
or	O
the	O
THP-1	O
mature	O
monocytic	O
cell	O
line	O
.	O

Based	O
on	O
nucleotide	O
sequence	O
requirements	O
and	O
immunoreactivity	O
,	O
we	O
demonstrate	O
that	O
this	O
DNA-protein	O
complex	O
is	O
comprised	O
of	O
the	O
AP-1	O
components	O
,	O
Fos	O
and	O
Jun	O
.	O

Of	O
the	O
GATA-binding	O
proteins	O
,	O
only	O
GATA-4	O
selectively	O
regulates	O
the	O
human	O
IL-5	O
gene	O
promoter	O
in	O
IL-5	O
producing	O
cells	O
which	O
express	O
multiple	O
GATA-binding	O
proteins	O
.	O

Interleukin-5	O
(	O
IL-5	O
)	O
is	O
produced	O
by	O
T	O
lymphocytes	O
and	O
known	O
to	O
support	O
B	O
cell	O
growth	O
and	O
eosinophilic	O
differentiation	O
of	O
the	O
progenitor	O
cells	O
.	O

Using	O
ATL-16T	O
cells	O
which	O
express	O
IL-5	O
mRNA	O
,	O
we	O
have	O
identified	O
a	O
region	O
,	O
within	O
the	O
human	O
IL-5	O
gene	O
promoter	O
,	O
that	O
regulates	O
IL-5	O
gene	O
transcription	O
.	O

This	O
cis-acting	O
sequence	O
contains	O
the	O
core	O
binding	O
motif	O
,	O
(	O
A/T	O
)	O
GATA	O
(	O
A/G	O
)	O
,	O
for	O
GATA-binding	O
family	O
proteins	O
and	O
thus	O
suggests	O
the	O
involvement	O
of	O
these	O
family	O
members	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
cloning	O
of	O
human	O
GATA-4	O
(	O
hGATA-4	O
)	O
and	O
show	O
that	O
hGATA-4	O
selectively	O
interacts	O
with	O
the	O
-70	O
GATA	O
site	O
within	O
the	O
IL-5	O
proximal	O
promoter	O
region	O
.	O

By	O
promoter	O
deletion	O
and	O
mutation	O
analyses	O
,	O
we	O
established	O
this	O
region	O
as	O
a	O
positive	O
regulatory	O
element	O
.	O

Cotransfection	O
experiments	O
revealed	O
that	O
both	O
hGATA-4	O
and	O
PMA/A23187	O
stimulation	O
are	O
necessary	O
for	O
the	O
IL-5	O
promoter	O
activation	O
.	O

The	O
requirement	O
of	O
another	O
regulatory	O
element	O
called	O
CLE0	O
,	O
which	O
lies	O
downstream	O
of	O
the	O
-70	O
GATA	O
site	O
,	O
was	O
also	O
demonstrated	O
.	O

ATL-16T	O
cells	O
express	O
mRNA	O
of	O
three	O
GATA-binding	O
proteins	O
,	O
hGATA-2	O
,	O
hGATA-3	O
and	O
hGATA-4	O
,	O
and	O
each	O
of	O
them	O
has	O
a	O
potential	O
to	O
bind	O
to	O
the	O
consensus	O
(	O
A/T	O
)	O
GATA	O
(	O
G/	O
A	O
)	O
motif	O
.	O

However	O
,	O
using	O
ATL-16T	O
nuclear	O
extract	O
,	O
we	O
demonstrated	O
that	O
GATA-4	O
is	O
the	O
only	O
GATA-binding	O
protein	O
that	O
forms	O
specific	O
DNA-protein	O
complex	O
with	O
the	O
-70	O
GATA	O
site	O
.	O

The	O
electrophoretic	O
mobility	O
shift	O
assay	O
with	O
extracts	O
of	O
COS	O
cells	O
expressing	O
GATA-binding	O
proteins	O
showed	O
that	O
GATA-4	O
has	O
the	O
highest	O
binding	O
affinity	O
to	O
the	O
-70	O
GATA	O
site	O
among	O
the	O
three	O
GATA-binding	O
proteins	O
.	O

When	O
the	O
transactivation	O
ability	O
was	O
compared	O
among	O
the	O
three	O
,	O
GATA-4	O
showed	O
the	O
highest	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
selective	O
role	O
of	O
GATA-4	O
in	O
the	O
transcriptional	O
regulation	O
of	O
the	O
IL-5	O
gene	O
in	O
a	O
circumstance	O
where	O
multiple	O
members	O
of	O
the	O
GATA-binding	O
proteins	O
are	O
expressed	O
.	O

Inducible	O
expression	O
and	O
phosphorylation	O
of	O
coactivator	O
BOB.1/OBF.1	O
in	O
T	O
cells	O
[	O
see	O
comments	O
]	O

BOB.1/OBF.1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
constitutively	O
expressed	O
in	O
B	O
cells	O
and	O
interacts	O
with	O
the	O
Oct1	O
and	O
Oct2	O
transcription	O
factors	O
.	O

Upon	O
activation	O
of	O
Jurkat	O
T	O
cells	O
and	O
primary	O
murine	O
thymocytes	O
with	O
phorbol	O
esters	O
and	O
ionomycin	O
,	O
BOB.1/OBF.1	O
expression	O
and	O
transactivation	O
function	O
were	O
induced	O
.	O

BOB.1/OBF.1	O
was	O
phosphorylated	O
at	O
Ser184	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
this	O
modification	O
was	O
required	O
for	O
inducible	O
activation	O
.	O

Mutation	O
of	O
Ser184	O
also	O
diminished	O
transactivation	O
function	O
in	O
B	O
cells	O
,	O
suggesting	O
that	O
the	O
activating	O
phosphorylation	O
that	O
is	O
inducible	O
in	O
T	O
cells	O
is	O
constitutively	O
present	O
in	O
B	O
cells	O
.	O

Thus	O
,	O
BOB.1/OBF.1	O
is	O
a	O
transcriptional	O
coactivator	O
that	O
is	O
critically	O
regulated	O
by	O
posttranslational	O
modifications	O
to	O
mediate	O
cell	O
type-specific	O
gene	O
expression	O
.	O

Lipopolysaccharide	O
induction	O
of	O
the	O
tumor	O
necrosis	O
factor-alpha	O
promoter	O
in	O
human	O
monocytic	O
cells	O
.	O

Regulation	O
by	O
Egr-1	O
,	O
c-Jun	O
,	O
and	O
NF-kappaB	O
transcription	O
factors	O
.	O

Biosynthesis	O
of	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
is	O
predominantly	O
by	O
cells	O
of	O
the	O
monocytic	O
lineage	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
various	O
cis-acting	O
regulatory	O
elements	O
in	O
the	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induction	O
of	O
the	O
human	O
TNF-alpha	O
promoter	O
in	O
cells	O
of	O
monocytic	O
lineage	O
.	O

Functional	O
analysis	O
of	O
monocytic	O
THP-1	O
cells	O
transfected	O
with	O
plasmids	O
containing	O
various	O
lengths	O
of	O
TNF-alpha	O
promoter	O
localized	O
enhancer	O
elements	O
in	O
a	O
region	O
(	O
-182	O
to	O
-37	O
base	O
pairs	O
(	O
bp	O
)	O
)	O
that	O
were	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
TNF-alpha	O
gene	O
in	O
response	O
to	O
LPS	O
.	O

Two	O
regions	O
were	O
identified	O
:	O
region	O
I	O
(	O
-182	O
to	O
-162	O
bp	O
)	O
contained	O
an	O
overlapping	O
Sp1/Egr-1	O
site	O
,	O
and	O
region	O
II	O
(	O
-119	O
to	O
-88	O
)	O
contained	O
CRE	O
and	O
NF-kappaB	O
(	O
designated	O
kappaB3	O
)	O
sites	O
.	O

In	O
unstimulated	O
THP-1	O
,	O
CRE-binding	O
protein	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
c-Jun	O
complexes	O
were	O
found	O
to	O
bind	O
to	O
the	O
CRE	O
site	O
.	O

LPS	O
stimulation	O
increased	O
the	O
binding	O
of	O
c-Jun-containing	O
complexes	O
.	O

In	O
addition	O
,	O
LPS	O
stimulation	O
induced	O
the	O
binding	O
of	O
cognate	O
nuclear	O
factors	O
to	O
the	O
Egr-1	O
and	O
kappaB3	O
sites	O
,	O
which	O
were	O
identified	O
as	O
Egr-1	O
and	O
p50/p65	O
,	O
respectively	O
.	O

The	O
CRE	O
and	O
kappaB3	O
sites	O
in	O
region	O
II	O
together	O
conferred	O
strong	O
LPS	O
responsiveness	O
to	O
a	O
heterologous	O
promoter	O
,	O
whereas	O
individually	O
they	O
failed	B-Negation
to	I-Negation
provide	I-Negation
transcriptional	I-Negation
activation	I-Negation
.	O

Furthermore	O
,	O
increasing	O
the	O
spacing	O
between	O
the	O
CRE	O
and	O
the	O
kappaB3	O
sites	O
completely	O
abolished	O
LPS	O
induction	O
,	O
suggesting	O
a	O
cooperative	O
interaction	O
between	O
c-Jun	O
complexes	O
and	O
p50/p65	O
.	O

These	O
studies	O
indicate	O
that	O
maximal	O
LPS	O
induction	O
of	O
the	O
TNF-alpha	O
promoter	O
is	O
mediated	O
by	O
concerted	O
participation	O
of	O
at	O
least	O
two	O
separate	O
cis-acting	O
regulatory	O
elements	O
.	O

Role	O
of	O
the	O
X2	O
box	O
in	O
activated	O
transcription	O
from	O
the	O
DRA	O
promoter	O
in	O
B	O
cells	O
.	O

We	O
investigated	O
the	O
function	O
of	O
the	O
evolutionary	O
conserved	O
X2	O
box	O
in	O
the	O
promoter	O
of	O
the	O
HLA-DRA	O
gene	O
from	O
the	O
human	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
in	O
resting	O
and	O
activated	O
B	O
cells	O
.	O

NF-X2	O
,	O
which	O
contains	O
members	O
of	O
the	O
AP-1/ATF/CREB	O
families	O
of	O
transcription	O
factors	O
,	O
interacts	O
with	O
the	O
X2	O
box	O
(	O
5'-TGCGTCA-3	O
'	O
)	O
from	O
positions	O
-97	O
to	O
-91	O
in	O
the	O
DRA	O
promoter	O
.	O

In	O
resting	O
Raji	O
cells	O
,	O
little	O
to	O
no	B-Negation
binding	I-Negation
to	I-Negation
the	I-Negation
X2	I-Negation
box	I-Negation
was	I-Negation
observed	I-Negation
.	O

In	O
sharp	O
contrast	O
,	O
in	O
B	O
cells	O
treated	O
with	O
the	O
phorbol	O
ester	O
12-O-tetradecanoylphorbol-13-acetate	O
(	O
TPA	O
)	O
,	O
strong	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF-X2	O
containing	O
c-Fos	O
were	O
observed	O
.	O

As	O
determined	O
by	O
transient	O
expression	O
and	O
RNA	O
analyses	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
also	O
increased	O
rates	O
of	O
transcription	O
from	O
the	O
wild-type	O
DRA	O
promoter	O
but	O
not	B-Negation
from	I-Negation
a	I-Negation
DRA	I-Negation
promoter	I-Negation
bearing	I-Negation
clustered	I-Negation
point	I-Negation
mutations	I-Negation
in	I-Negation
the	I-Negation
X2	I-Negation
box	I-Negation
.	O

Since	O
the	O
co-expression	O
with	O
a	O
dominant	O
negative	O
c-Fos	O
abolished	O
the	O
responsiveness	O
to	O
TPA	O
,	O
we	O
conclude	O
that	O
activated	O
transcription	O
of	O
the	O
DRA	O
gene	O
depends	O
on	O
interactions	O
between	O
the	O
X2	O
box	O
and	O
NF-X2	O
,	O
which	O
contains	O
c-Fos	O
.	O

Rescue	O
by	O
cytokines	O
of	O
apoptotic	O
cell	O
death	O
induced	O
by	O
IL-2	O
deprivation	O
of	O
human	O
antigen-specific	O
T	O
cell	O
clones	O
.	O

The	O
control	O
of	O
cell	O
survival	O
and	O
cell	O
death	O
is	O
of	O
central	O
importance	O
in	O
tissues	O
with	O
high	O
cell	O
turnover	O
such	O
as	O
the	O
lymphoid	O
system	O
.	O

We	O
have	O
examined	O
the	O
effect	O
of	O
cytokines	O
on	O
IL-2	O
deprivation-induced	O
apoptosis	O
of	O
human	O
antigen-specific	O
T	O
helper	O
clones	O
with	O
different	O
cytokine	O
production	O
profiles	O
.	O

We	O
found	O
that	O
IL-2	O
,	O
interferon-alpha	O
(	O
IFN-alpha	O
)	O
,	O
and	O
IFN-beta	O
inhibited	O
IL-2	O
deprivation	O
apoptosis	O
in	O
Th0	O
,	O
Th1	O
,	O
and	O
Th2	O
clones	O
.	O

We	O
also	O
found	O
that	O
IL-2	O
protects	O
T	O
cell	O
clones	O
from	O
IL-2	O
deprivation	O
apoptosis	O
accompanying	O
active	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
P53	O
,	O
Rb	O
and	O
Bcl-xL	O
proteins	O
.	O

In	O
contrast	O
,	O
IFN-alpha/beta	O
rescued	O
T	O
cell	O
clones	O
from	O
apoptosis	O
without	B-Negation
active	I-Negation
proliferation	I-Negation
,	O
and	O
expression	O
of	O
apoptosis-associated	O
proteins	O
tested	O
so	O
far	O
was	O
unaffected	O
.	O

This	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
T	O
cells	O
treated	O
with	O
IL-2	O
contained	O
those	O
located	O
in	O
S	O
+	O
G2/M	O
phases	O
of	O
the	O
cell	O
cycle	O
,	O
whereas	O
the	O
vast	O
majority	O
of	O
T	O
cells	O
treated	O
with	O
IFN-alpha/beta	O
were	O
located	O
in	O
G0/G1	O
phase	O
.	O

IFN-alpha/beta	O
specifically	O
induced	O
tyrosine	O
phosphorylation	O
and	O
translocation	O
into	O
nucleus	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
2	O
protein	O
in	O
the	O
T	O
cell	O
clones	O
.	O

In	O
addition	O
,	O
over-expression	O
of	O
STAT2	O
by	O
transfection	O
of	O
the	O
cDNA	O
prevented	O
apoptosis	O
of	O
the	O
T	O
cell	O
clones	O
.	O

Our	O
present	O
study	O
shows	O
that	O
IFN-alpha	O
and	O
-beta	O
mediate	O
anti-apoptotic	O
effect	O
through	O
other	O
pathways	O
than	O
that	O
of	O
IL-2	O
in	O
growth	O
factor	O
deprivation	O
apoptosis	O
.	O

Association	O
between	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
and	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
in	O
adult	O
T-cell	O
leukemia	O
cells	O
.	O

It	O
is	O
known	O
that	O
the	O
expression	O
levels	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
in	O
adult	O
T	O
cell	O
leukemia	O
(	O
ATL	O
)	O
cells	O
are	O
high	O
,	O
whereas	O
those	O
in	O
T-lymphoid	O
cells	O
are	O
not	B-Negation
.	O

In	O
order	O
to	O
investigate	O
the	O
factors	O
that	O
influence	O
the	O
induction	O
of	O
ICAM-1	O
molecules	O
,	O
Northern	O
blot	O
analysis	O
to	O
measure	O
the	O
expression	O
level	O
of	O
ICAM-1	O
mRNAs	O
and	O
Southern	O
blot	O
hybridization	O
to	O
analyze	O
the	O
integration	O
of	O
human	O
T-cell-leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
provirus	O
were	O
done	O
.	O

The	O
levels	O
of	O
ICAM-1	O
mRNA	O
expression	O
of	O
ATL	O
cells	O
were	O
generally	O
higher	O
than	O
those	O
of	O
T-lymphoid	O
cells	O
.	O

However	O
,	O
ILT-mat	O
cells	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
although	O
they	O
were	O
ATL	O
cells	O
,	O
showed	O
rather	O
low	O
surface	O
ICAM-1	O
expression	O
and	O
ICAM-1	O
mRNA	O
expression	O
.	O

Southern	O
blot	O
hybridization	O
showed	O
that	O
only	O
two	O
and	O
four	O
bands	O
were	O
found	O
in	O
ILT-mat	O
and	O
ATL16T	O
(	O
-	O
)	O
cells	O
,	O
respectively	O
,	O
whereas	O
>	O
10	O
bands	O
were	O
detected	O
in	O
other	O
ATL	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
monoclonal	O
integration	O
of	O
HTLV-1	O
provirus	O
to	O
the	O
genome	O
of	O
T	O
cell	O
,	O
especially	O
the	O
number	O
of	O
integration	O
sites	O
,	O
is	O
one	O
of	O
the	O
factors	O
for	O
induction	O
of	O
ICAM-1	O
molecules	O
.	O

Transcription	O
factor	O
binding	O
sites	O
downstream	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
transcription	O
start	O
site	O
are	O
important	O
for	O
virus	O
infectivity	O
.	O

When	O
transcriptionally	O
active	O
,	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
promoter	O
contains	O
a	O
nucleosome-free	O
region	O
encompassing	O
both	O
the	O
promoter/enhancer	O
region	O
and	O
a	O
large	O
region	O
(	O
255	O
nucleotides	O
[	O
nt	O
]	O
)	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
.	O

We	O
have	O
previously	O
identified	O
new	O
binding	O
sites	O
for	O
transcription	O
factors	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
nt	O
465	O
to	O
720	O
)	O
:	O
three	O
AP-1	O
sites	O
(	O
I	O
,	O
II	O
,	O
and	O
III	O
)	O
,	O
an	O
AP3-like	O
motif	O
(	O
AP3-L	O
)	O
,	O
a	O
downstream	O
binding	O
factor	O
(	O
DBF	O
)	O
site	O
,	O
and	O
juxtaposed	O
Sp1	O
sites	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
DBF	O
site	O
is	O
an	O
interferon-responsive	O
factor	O
(	O
IRF	O
)	O
binding	O
site	O
and	O
that	O
the	O
AP3-L	O
motif	O
binds	O
the	O
T-cell-specific	O
factor	O
NF-AT	O
.	O

Mutations	O
that	O
abolish	O
the	O
binding	O
of	O
each	O
factor	O
to	O
its	O
cognate	O
site	O
are	O
introduced	O
in	O
an	O
infectious	O
HIV-1	O
molecular	O
clone	O
to	O
study	O
their	O
effect	O
on	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

Individual	O
mutation	O
of	O
the	O
DBF	O
or	O
AP3-L	O
site	O
as	O
well	O
as	O
the	O
double	O
mutation	O
AP-1	O
(	O
III	O
)	O
/AP3-L	O
did	O
not	B-Negation
affect	I-Negation
HIV-1	I-Negation
replication	I-Negation
compared	I-Negation
to	I-Negation
that	I-Negation
of	I-Negation
the	I-Negation
wild-type	I-Negation
virus	I-Negation
.	O

In	O
contrast	O
,	O
proviruses	O
carrying	O
mutations	O
in	O
the	O
Sp1	O
sites	O
were	O
totally	O
defective	O
in	O
terms	O
of	O
replication	O
.	O

Virus	O
production	O
occurred	O
with	O
slightly	O
delayed	O
kinetics	O
for	O
viruses	O
containing	O
combined	O
mutations	O
in	O
the	O
AP-1	O
(	O
III	O
)	O
,	O
AP3-L	O
,	O
and	O
DBF	O
sites	O
and	O
in	O
the	O
AP3-L	O
and	O
DBF-sites	O
,	O
whereas	O
viruses	O
mutated	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
and	O
AP3-L	O
sites	O
and	O
in	O
the	O
AP-1	O
(	O
I	O
,	O
II	O
,	O
III	O
)	O
,	O
AP3-L	O
,	O
and	O
DBF	O
sites	O
exhibited	O
a	O
severely	O
defective	O
replicative	O
phenotype	O
.	O

No	B-Negation
RNA-packaging	I-Negation
defect	I-Negation
could	I-Negation
be	I-Negation
measured	I-Negation
for	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
mutant	I-Negation
viruses	I-Negation
as	I-Negation
determined	I-Negation
by	I-Negation
quantification	I-Negation
of	I-Negation
their	I-Negation
HIV	I-Negation
genomic	I-Negation
RNA	I-Negation
.	O

Measurement	O
of	O
the	O
transcriptional	O
activity	O
of	O
the	O
HIV-1	O
promoter	O
after	O
transient	O
transfection	O
of	O
the	O
HIV-1	O
provirus	O
DNA	O
or	O
of	O
long	O
terminal	O
repeat-luciferase	O
constructs	O
showed	O
a	O
positive	O
correlation	O
between	O
the	O
transcriptional	O
and	O
the	O
replication	O
defects	O
for	O
most	O
mutants	O
.	O

The	O
role	O
of	O
nuclear	O
factor-kappa	O
B	O
in	O
cytokine	O
gene	O
regulation	O
.	O

Transcription	O
factors	O
are	O
DNA-binding	O
proteins	O
that	O
regulate	O
gene	O
expression	O
.	O

Nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
is	O
a	O
critical	O
transcription	O
factor	O
for	O
maximal	O
expression	O
of	O
many	O
cytokines	O
that	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
diseases	O
,	O
such	O
as	O
adult	O
respiratory	O
distress	O
syndrome	O
(	O
ARDS	O
)	O
and	O
sepsis	O
syndrome	O
.	O

Activation	O
and	O
regulation	O
of	O
NF-kappa	O
B	O
are	O
tightly	O
controlled	O
by	O
a	O
group	O
of	O
inhibitory	O
proteins	O
(	O
I	O
kappa	O
B	O
)	O
that	O
sequester	O
NF-kappa	O
B	O
in	O
the	O
cytoplasm	O
of	O
immune/inflammatory	O
effector	O
cells	O
.	O

NF-kappa	O
B	O
activation	O
involves	O
signaled	O
phosphorylation	O
,	O
ubiquitination	O
,	O
and	O
proteolysis	O
of	O
I	O
kappa	O
B	O
.	O

Liberated	O
NF-kappa	O
B	O
migrates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
binds	O
to	O
specific	O
promoter	O
sites	O
and	O
activates	O
gene	O
transcription	O
.	O

The	O
activation	O
of	O
NF-kappa	O
B	O
initiates	O
both	O
extracellular	O
and	O
intracellular	O
regulatory	O
events	O
that	O
result	O
in	O
autoregulation	O
of	O
the	O
inflammatory	O
cascade	O
through	O
modulation	O
of	O
NF-kappa	O
B	O
activation	O
.	O

Recently	O
,	O
activation	O
of	O
NF-kappa	O
B	O
has	O
been	O
linked	O
to	O
ARDS	O
and	O
has	O
been	O
shown	O
to	O
be	O
a	O
critical	O
proximal	O
step	O
in	O
the	O
initiation	O
of	O
neutrophilic	O
inflammation	O
in	O
animal	O
models	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
can	O
be	O
inhibited	O
in	O
vivo	O
by	O
treatment	O
with	O
antioxidants	O
,	O
corticosteroids	O
,	O
and	O
the	O
induction	O
of	O
endotoxin	O
tolerance	O
.	O

Identification	O
of	O
more	O
specific	O
and	O
efficacious	O
inhibitors	O
of	O
NF-kappa	O
B	O
activation	O
might	O
prove	O
beneficial	O
for	O
the	O
treatment	O
of	O
cytokine-mediated	O
inflammatory	O
diseases	O
.	O

Role	O
of	O
ascorbate	O
in	O
the	O
activation	O
of	O
NF-kappaB	O
by	O
tumour	O
necrosis	O
factor-alpha	O
in	O
T-cells	O
.	O

The	O
first	O
product	O
of	O
ascorbate	O
oxidation	O
,	O
the	O
ascorbate	O
free	O
radical	O
(	O
AFR	O
)	O
,	O
acts	O
in	O
biological	O
systems	O
mainly	O
as	O
an	O
oxidant	O
,	O
and	O
through	O
its	O
role	O
in	O
the	O
plasma	O
membrane	O
redox	O
system	O
exerts	O
different	O
effects	O
on	O
the	O
cell	O
.	O

We	O
have	O
investigated	O
the	O
role	O
of	O
ascorbate	O
,	O
AFR	O
and	O
dehydroascorbate	O
(	O
DHA	O
)	O
in	O
the	O
activation	O
of	O
the	O
NF-kappaB	O
transcription	O
factor	O
in	O
Jurkat	O
T-cells	O
stimulated	O
by	O
tumour	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

Here	O
we	O
show	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
that	O
ascorbate	O
increases	O
the	O
binding	O
of	O
NF-kappaB	O
to	O
DNA	O
in	O
TNF-alpha-stimulated	O
Jurkat	O
cells	O
.	O

The	O
ability	O
of	O
ascorbate	O
to	O
enhance	O
cytoplasmic	O
inhibitory	O
IkBalpha	O
protein	O
degradation	O
correlates	O
completely	O
with	O
its	O
capacity	O
to	O
induce	O
NF-kappaB	O
binding	O
to	O
DNA	O
and	O
to	O
potentiate	O
NF-kappaB-mediated	O
transactivation	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
promoter	O
in	O
TNF-alpha-stimulated	O
Jurkat	O
cells	O
but	O
not	B-Negation
in	I-Negation
cells	I-Negation
stimulated	I-Negation
with	I-Negation
PMA	I-Negation
plus	I-Negation
ionomycin	I-Negation
.	O

AFR	O
behaves	O
like	O
ascorbate	O
,	O
while	O
DHA	O
and	O
ascorbate	O
phosphate	O
do	O
not	B-Negation
affect	I-Negation
TNF-alpha-mediated	I-Negation
NF-kappaB	I-Negation
activation	I-Negation
.	O

These	O
results	O
provide	O
new	O
evidence	O
for	O
a	O
possible	O
relationship	O
between	O
the	O
activation	O
of	O
the	O
electron-transport	O
system	O
at	O
the	O
plasma	O
membrane	O
by	O
ascorbate	O
or	O
its	O
free	O
radical	O
and	O
redox-dependent	O
gene	O
transcription	O
in	O
T-cells	O
.	O

Pancreatic	O
islet	O
expression	O
studies	O
and	O
polymorphic	O
DNA	O
markers	O
in	O
the	O
genes	O
encoding	O
hepatocyte	O
nuclear	O
factor-3alpha	O
,	O
-3beta	O
,	O
-3gamma	O
,	O
-4gamma	O
,	O
and	O
-6	O
.	O

The	O
genes	O
encoding	O
the	O
functionally	O
related	O
hepatocyte	O
nuclear	O
factors	O
HNF-1alpha	O
and	O
HNF-4alpha	O
play	O
a	O
critical	O
role	O
in	O
normal	O
pancreatic	O
beta-cell	O
function	O
.	O

Mutations	O
in	O
these	O
liver-enriched	O
transcription	O
factors	O
result	O
in	O
two	O
forms	O
of	O
early-onset	O
type	O
2	O
diabetes	O
(	O
maturity-onset	O
diabetes	O
of	O
the	O
young	O
[	O
MODY	O
]	O
)	O
,	O
MODY3	O
and	O
MODY1	O
,	O
which	O
are	O
characterized	O
by	O
impaired	O
glucose-stimulated	O
insulin	O
secretion	O
,	O
early	O
disease	O
onset	O
,	O
and	O
autosomal	O
dominant	O
inheritance	O
.	O

The	O
transcriptional	O
hierarchy	O
of	O
HNFs	O
suggests	O
that	O
other	O
proteins	O
of	O
the	O
regulatory	O
cascade	O
might	O
be	O
responsible	O
for	O
other	O
forms	O
of	O
MODY	O
and/or	O
late-onset	O
type	O
2	O
diabetes	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
HNF-3alpha	O
,	O
-3beta	O
,	O
-3gamma	O
,	O
-4gamma	O
,	O
and	O
-6	O
are	O
expressed	O
in	O
pancreatic	O
beta-cells	O
.	O

We	O
report	O
the	O
identification	O
and	O
characterization	O
of	O
simple	O
tandem	O
repeat	O
DNA	O
polymorphisms	O
in	O
the	O
genes	O
encoding	O
HNF-3alpha	O
,	O
-3beta	O
,	O
-3gamma	O
,	O
-4gamma	O
,	O
and	O
-6	O
and	O
the	O
mapping	O
of	O
HNF-6	O
to	O
chromosome	O
bands	O
15q21.1-21.2	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
.	O

These	O
markers	O
will	O
be	O
useful	O
to	O
study	O
the	O
role	O
of	O
genetic	O
variation	O
in	O
these	O
genes	O
in	O
the	O
pathogenesis	O
of	O
type	O
2	O
diabetes	O
.	O

RP1	O
,	O
a	O
new	O
member	O
of	O
the	O
adenomatous	O
polyposis	O
coli-binding	O
EB1-like	O
gene	O
family	O
,	O
is	O
differentially	O
expressed	O
in	O
activated	O
T	O
cells	O
.	O

Cross-linking	O
of	O
the	O
CD3	O
and	O
CD28	O
molecules	O
on	O
T	O
lymphocytes	O
represents	O
one	O
of	O
the	O
most	O
effective	O
signals	O
for	O
T	O
lymphocyte	O
activation	O
and	O
triggering	O
of	O
their	O
cytotoxic	O
effector	O
function	O
.	O

To	O
identify	O
genes	O
that	O
are	O
expressed	O
in	O
T	O
cells	O
after	O
stimulation	O
,	O
mRNA	O
from	O
T	O
lymphocytes	O
that	O
had	O
been	O
activated	O
by	O
the	O
simultaneous	O
stimulation	O
of	O
the	O
CD3	O
and	O
CD28	O
trigger	O
molecules	O
was	O
transcribed	O
for	O
a	O
differential	O
mRNA	O
display	O
analysis	O
into	O
cDNA	O
and	O
was	O
compared	O
with	O
cDNA	O
from	O
CD28-	O
or	O
CD3-activated	O
or	O
resting	O
lymphocytes	O
.	O

Differential	O
expression	O
was	O
confirmed	O
subsequently	O
by	O
Northern	O
blot	O
analysis	O
.	O

One	O
of	O
the	O
cDNA	O
fragments	O
expressed	O
specifically	O
in	O
CD3-	O
and	O
CD28-activated	O
T	O
cells	O
was	O
designated	O
RP1	O
.	O

The	O
predictive	O
protein-coding	O
region	O
of	O
RP1	O
had	O
a	O
significant	O
homology	O
to	O
members	O
of	O
the	O
recently	O
found	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
protein-binding	O
EB1	O
gene	O
family	O
,	O
which	O
codes	O
for	O
yet	O
unknown	O
protein	O
(	O
s	O
)	O
.	O

Bacterially	O
expressed	O
RP1	O
protein	O
revealed	O
specific	O
binding	O
to	O
wild-type	O
but	O
not	B-Negation
to	I-Negation
mutated	I-Negation
APC	I-Negation
protein	I-Negation
.	O

The	O
rapid	O
up-regulation	O
of	O
RP1	O
mRNA	O
in	O
properly	O
activated	O
T	O
cells	O
suggests	O
that	O
this	O
gene	O
might	O
belong	O
to	O
the	O
immediate/early	O
gene	O
family	O
,	O
which	O
controls	O
the	O
signal	O
transduction	O
cascade	O
downstream	O
of	O
the	O
TCR	O
.	O

As	O
the	O
expression	O
level	O
of	O
the	O
RP1	O
gene	O
in	O
activated	O
T	O
cells	O
and	O
a	O
spectrum	O
of	O
tumor-derived	O
cell	O
lines	O
correlates	O
with	O
the	O
proliferative	O
status	O
of	O
the	O
cells	O
,	O
members	O
of	O
the	O
EB1-like	O
gene	O
family	O
may	O
not	O
only	O
be	O
involved	O
in	O
the	O
tumorigenesis	O
of	O
colorectal	O
cancers	O
but	O
may	O
also	O
play	O
a	O
role	O
in	O
the	O
proliferative	O
control	O
of	O
normal	O
cells	O
.	O

Involvement	O
of	O
Rel	O
,	O
Fos	O
,	O
and	O
Jun	O
proteins	O
in	O
binding	O
activity	O
to	O
the	O
IL-2	O
promoter	O
CD28	O
response	O
element/AP-1	O
sequence	O
in	O
human	O
T	O
cells	O
.	O

CD28	O
is	O
an	O
important	O
costimulatory	O
molecule	O
in	O
the	O
activation	O
of	O
human	O
T	O
cells	O
.	O

Costimulation	O
of	O
T	O
cells	O
through	O
both	O
the	O
Ag	O
receptor	O
and	O
CD28	O
leads	O
to	O
high	O
level	O
IL-2	O
production	O
,	O
which	O
is	O
vital	O
to	O
the	O
development	O
of	O
an	O
immune	O
response	O
in	O
vivo	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
CD28	O
stimulation	O
contributes	O
to	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
up-regulating	O
the	O
activity	O
of	O
several	O
transcription	O
factors	O
,	O
including	O
AP-1	O
and	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
/Rel	O
family	O
members	O
as	O
well	O
as	O
an	O
uncharacterized	O
transcription	O
factor	O
called	O
CD28	O
response	O
complex	O
.	O

While	O
several	O
lines	O
of	O
investigation	O
have	O
suggested	B-Speculation
that	I-Speculation
NF-kappaB/Rel	I-Speculation
family	I-Speculation
members	I-Speculation
make	I-Speculation
up	I-Speculation
the	I-Speculation
CD28	I-Speculation
response	I-Speculation
complex	I-Speculation
transcription	I-Speculation
factor	I-Speculation
,	O
other	O
work	O
has	O
not	B-Negation
supported	I-Negation
this	I-Negation
conclusion	I-Negation
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
CD28	O
response	O
element	O
(	O
CD28RE	O
)	O
does	O
not	O
function	O
independently	O
but	O
works	O
instead	O
in	O
conjunction	O
with	O
the	O
adjacent	O
promoter	O
proximal	O
AP-1-binding	O
site	O
and	O
this	O
hypothesis	O
is	O
confirmed	O
here	O
.	O

Also	O
in	O
the	O
current	O
study	O
,	O
binding	O
activity	O
to	O
the	O
CD28RE/AP-1	O
sequence	O
of	O
the	O
IL-2	O
promoter	O
is	O
evaluated	O
.	O

Although	O
four	O
specific	O
complexes	O
can	O
be	O
detected	O
binding	O
to	O
this	O
sequence	O
,	O
only	O
one	O
of	O
these	O
complexes	O
is	O
specific	O
for	O
both	O
the	O
CD28RE	O
and	O
the	O
adjacent	O
AP-1	O
site	O
.	O

Of	O
the	O
NF-kappaB/Rel	O
family	O
members	O
tested	O
,	O
this	O
CD28RE/AP-1-specific	O
complex	O
contains	O
predominantly	O
c-Rel	O
,	O
despite	O
the	O
fact	O
that	O
both	O
p50	O
and	O
RelA	O
can	O
efficiently	O
bind	O
to	O
the	O
CD28RE	O
.	O

c-Fos	O
and	O
c-Jun	O
are	O
also	O
found	O
in	O
this	O
CD28RE/AP-1-specific	O
complex	O
.	O

These	O
data	O
indicate	O
that	O
functional	O
complexes	O
encompassing	O
both	O
the	O
CD28RE	O
and	O
the	O
AP-1-binding	O
sites	O
influence	O
IL-2	O
promoter	O
activity	O
in	O
CD28-costimulated	O
T	O
cells	O
.	O

c-Myb	O
and	O
Ets	O
proteins	O
synergize	O
to	O
overcome	O
transcriptional	O
repression	O
by	O
ZEB	O
.	O

The	O
Zfh	O
family	O
of	O
zinc	O
finger/homeodomain	O
proteins	O
was	O
first	O
identified	O
in	O
Drosophila	O
where	O
it	O
is	O
required	O
for	O
differentiation	O
of	O
tissues	O
such	O
as	O
the	O
central	O
nervous	O
system	O
and	O
muscle	O
.	O

ZEB	O
,	O
a	O
vertebrate	O
homolog	O
of	O
Zfh-1	O
,	O
binds	O
a	O
subset	O
of	O
E	O
boxes	O
and	O
blocks	O
myogenesis	O
through	O
transcriptional	O
repression	O
of	O
muscle	O
genes	O
.	O

We	O
present	O
evidence	O
here	O
that	O
ZEB	O
also	O
has	O
an	O
important	O
role	O
in	O
controlling	O
hematopoietic	O
gene	O
transcription	O
.	O

Two	O
families	O
of	O
transcription	O
factors	O
that	O
are	O
required	O
for	O
normal	O
hematopoiesis	O
are	O
c-Myb	O
and	O
Ets	O
.	O

These	O
factors	O
act	O
synergistically	O
to	O
activate	O
transcription	O
,	O
and	O
this	O
synergy	O
is	O
required	O
for	O
transcription	O
of	O
at	O
least	O
several	O
important	O
hematopoietic	O
genes	O
.	O

ZEB	O
blocks	O
the	O
activity	O
of	O
c-Myb	O
and	O
Ets	O
individually	O
,	O
but	O
together	O
the	O
factors	O
synergize	O
to	O
resist	O
this	O
repression	O
.	O

Such	O
repression	O
imposes	O
a	O
requirement	O
for	O
both	O
c-Myb	O
and	O
Ets	O
for	O
transcriptional	O
activity	O
,	O
providing	O
one	O
explanation	O
for	O
why	O
synergy	O
between	O
these	O
factors	O
is	O
important	O
.	O

The	O
balance	O
between	O
repression	O
by	O
ZEB	O
and	O
transcriptional	O
activation	O
by	O
c-Myb/Ets	O
provides	O
a	O
flexible	O
regulatory	O
mechanism	O
for	O
controlling	O
gene	O
expression	O
in	O
hematopoietic	O
cells	O
.	O

We	O
demonstrate	O
that	O
one	O
target	O
of	O
this	O
positive/negative	O
regulation	O
in	O
vivo	O
is	O
the	O
alpha4	O
integrin	O
,	O
which	O
play	O
a	O
key	O
role	O
in	O
normal	O
hematopoiesis	O
and	O
function	O
of	O
mature	O
leukocytes	O
.	O

GABP	O
factors	O
bind	O
to	O
a	O
distal	O
interleukin	O
2	O
(	O
IL-2	O
)	O
enhancer	O
and	O
contribute	O
to	O
c-Raf-mediated	O
increase	O
in	O
IL-2	O
induction	O
.	O

Triggering	O
of	O
the	O
T-cell	O
receptor-CD3	O
complex	O
activates	O
two	O
major	O
signal	O
cascades	O
in	O
T	O
lymphocytes	O
,	O
(	O
i	O
)	O
Ca2+-dependent	O
signal	O
cascades	O
and	O
(	O
ii	O
)	O
protein	O
kinase	O
cascades	O
.	O

Both	O
signal	O
cascades	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
interleukin	O
2	O
(	O
IL-2	O
)	O
gene	O
during	O
T-cell	O
activation	O
.	O

Prominent	O
protein	O
kinase	O
cascades	O
are	O
those	O
that	O
activate	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinases	O
.	O

We	O
show	O
here	O
that	O
c-Raf	O
,	O
which	O
is	O
at	O
the	O
helm	O
of	O
the	O
classic	O
MAP-Erk	O
cascade	O
,	O
contributes	O
to	O
IL-2	O
induction	O
through	O
a	O
distal	O
enhancer	O
element	O
spanning	O
the	O
nucleotides	O
from	O
positions	O
-502	O
to	O
-413	O
in	O
front	O
of	O
the	O
transcriptional	O
start	O
site	O
of	O
the	O
IL-2	O
gene	O
.	O

Induction	O
of	O
this	O
distal	O
IL-2	O
enhancer	O
differs	O
from	O
induction	O
of	O
the	O
proximal	O
IL-2	O
promoter-enhancer	O
,	O
since	O
it	O
is	O
induced	O
by	O
phorbol	O
esters	O
alone	O
and	O
independent	O
from	O
Ca2+	O
signals	O
.	O

In	O
DNA-protein	O
binding	O
studies	O
,	O
we	O
detected	O
the	O
binding	O
of	O
transcription	O
factors	O
GABP	O
alpha	O
and	O
-beta	O
to	O
a	O
dyad	O
symmetry	O
element	O
(	O
DSE	O
)	O
of	O
the	O
distal	O
enhancer	O
,	O
which	O
is	O
formed	O
by	O
palindromic	O
binding	O
sites	O
of	O
Ets-like	O
factors	O
.	O

Introduction	O
of	O
point	O
mutations	O
suppressing	O
GABP	O
binding	O
to	O
the	O
DSE	O
interfered	O
with	O
the	O
induction	O
of	O
the	O
distal	O
enhancer	O
and	O
the	O
entire	O
IL-2	O
promoter-enhancer	O
,	O
while	O
overexpression	O
of	O
both	O
GABP	O
factors	O
enhanced	O
the	O
IL-2	O
promoter-enhancer	O
induction	O
.	O

Overexpression	O
of	O
BXB	O
,	O
a	O
constitutive	O
active	O
version	O
of	O
c-Raf	O
,	O
and	O
of	O
further	O
members	O
of	O
the	O
Ras-Raf-Erk	O
signal	O
cascade	O
exerted	O
an	O
increase	O
of	O
GABP-mediated	O
promoter-enhancer	O
induction	O
.	O

In	O
conjunction	O
with	O
previously	O
published	O
data	O
on	O
c-Raf-induced	O
phosphorylation	O
of	O
GABP	O
factors	O
(	O
E.Flory	O
,	O
A.	O
Hoffmeyer	O
,	O
U.Smola	O
,	O
U.R.Rapp	O
,	O
and	O
J.T.Bruder	O
,	O
J.Virol.70:2260-	O
2268	O
,	O
1996	O
)	O
,	O
these	O
results	O
indicate	O
a	O
contribution	O
of	O
GABP	O
factors	O
to	O
the	O
Raf-mediated	O
enhancement	O
of	O
IL-2	O
induction	O
during	O
T-cell	O
activation	O
.	O

The	O
product	O
of	O
the	O
murine	O
homolog	O
of	O
the	O
Drosophila	O
extra	O
sex	O
combs	O
gene	O
displays	O
transcriptional	O
repressor	O
activity	O
.	O

The	O
heterogeneous	O
nuclear	O
ribonucleoprotein	O
K	O
protein	O
represents	O
a	O
novel	O
class	O
of	O
proteins	O
that	O
may	O
act	O
as	O
docking	O
platforms	O
that	O
orchestrate	O
cross-talk	O
among	O
molecules	O
involved	O
in	O
signal	O
transduction	O
and	O
gene	O
expression	O
.	O

Using	O
a	O
fragment	O
of	O
K	O
protein	O
as	O
bait	O
in	O
the	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
isolated	O
a	O
cDNA	O
that	O
encodes	O
a	O
protein	O
whose	O
primary	O
structure	O
has	O
extensive	O
similarity	O
to	O
the	O
Drosophila	O
melanogaster	O
extra	O
sex	O
combs	O
(	O
esc	O
)	O
gene	O
product	O
,	O
Esc	O
,	O
a	O
putative	O
silencer	O
of	O
homeotic	O
genes	O
.	O

The	O
cDNA	O
that	O
we	O
isolated	O
is	O
identical	O
to	O
the	O
cDNA	O
of	O
the	O
recently	O
positionally	O
cloned	O
mouse	O
embryonic	O
ectoderm	O
development	O
gene	O
,	O
eed	O
.	O

Like	O
Esc	O
,	O
Eed	O
contains	O
six	O
WD-40	O
repeats	O
in	O
the	O
C-terminal	O
half	O
of	O
the	O
protein	O
and	O
is	O
thought	O
to	O
repress	O
homeotic	O
gene	O
expression	O
during	O
mouse	O
embryogenesis	O
.	O

Eed	O
binds	O
to	O
K	O
protein	O
through	O
a	O
domain	O
in	O
its	O
N	O
terminus	O
,	O
but	O
interestingly	O
,	O
this	B-Negation
domain	I-Negation
is	I-Negation
not	I-Negation
found	I-Negation
in	I-Negation
the	I-Negation
Drosophila	I-Negation
Esc	I-Negation
.	O

Gal4-Eed	O
fusion	O
protein	O
represses	O
transcription	O
of	O
a	O
reporter	O
gene	O
driven	O
by	O
a	O
promoter	O
that	O
contains	O
Gal4-binding	O
DNA	O
elements	O
.	O

Eed	O
also	O
represses	O
transcription	O
when	O
recruited	O
to	O
a	O
target	O
promoter	O
by	O
Gal4-K	O
protein	O
.	O

Point	O
mutations	O
within	O
the	O
eed	O
gene	O
that	O
are	O
responsible	O
for	O
severe	O
embryonic	O
development	O
abnormalities	O
abolished	O
the	O
transcriptional	O
repressor	O
activity	O
of	O
Eed	O
.	O

Results	O
of	O
this	O
study	O
suggest	O
that	O
Eed-restricted	O
homeotic	O
gene	O
expression	O
during	O
embryogenesis	O
reflects	O
the	O
action	O
of	O
Eed	O
as	O
a	O
transcriptional	O
repressor	O
.	O

The	O
Eed-mediated	O
transcriptional	O
effects	O
are	O
likely	O
to	O
reflect	O
the	O
interaction	O
of	O
Eed	O
with	O
multiple	O
molecular	O
partners	O
,	O
including	O
K	O
protein	O
.	O

Opposite	O
effects	O
of	O
the	O
acute	O
promyelocytic	O
leukemia	O
PML-retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
and	O
PLZF-RAR	O
alpha	O
fusion	O
proteins	O
on	O
retinoic	O
acid	O
signalling	O
.	O

Fusion	O
proteins	O
involving	O
the	O
retinoic	O
acid	O
receptor	O
alpha	O
(	O
RAR	O
alpha	O
)	O
and	O
the	O
PML	O
or	O
PLZF	O
nuclear	O
protein	O
are	O
the	O
genetic	O
markers	O
of	O
acute	O
promyelocytic	O
leukemias	O
(	O
APLs	O
)	O
.	O

APLs	O
with	O
the	O
PML-RAR	O
alpha	O
or	O
the	O
PLZF-RAR	O
alpha	O
fusion	O
protein	O
are	O
phenotypically	O
indistinguishable	O
except	O
that	O
they	O
differ	O
in	O
their	O
sensitivity	O
to	O
retinoic	O
acid	O
(	O
RA	O
)	O
-induced	O
differentiation	O
:	O
PML-RAR	O
alpha	O
blasts	O
are	O
sensitive	O
to	O
RA	O
and	O
patients	O
enter	O
disease	O
remission	O
after	O
RA	O
treatment	O
,	O
while	O
patients	O
with	O
PLZF-RAR	O
alpha	O
do	O
not	B-Negation
.	O

We	O
here	O
report	O
that	O
(	O
i	O
)	O
like	O
PML-RAR	O
alpha	O
expression	O
,	O
PLZF-RAR	O
alpha	O
expression	O
blocks	O
terminal	O
differentiation	O
of	O
hematopoietic	O
precursor	O
cell	O
lines	O
(	O
U937	O
and	O
HL-60	O
)	O
in	O
response	O
to	O
different	O
stimuli	O
(	O
vitamin	O
D3	O
,	O
transforming	O
growth	O
factor	O
beta1	O
,	O
and	O
dimethyl	O
sulfoxide	O
)	O
;	O
(	O
ii	O
)	O
PML-RAR	O
alpha	O
,	O
but	O
not	B-Negation
PLZF-RAR	I-Negation
alpha	I-Negation
,	O
increases	O
RA	O
sensitivity	O
of	O
hematopoietic	O
precursor	O
cells	O
and	O
restores	O
RA	O
sensitivity	O
of	O
RA-resistant	O
hematopoietic	O
cells	O
;	O
(	O
iii	O
)	O
PML-RAR	O
alpha	O
and	O
PLZF-RAR	O
alpha	O
have	O
similar	O
RA	O
binding	O
affinities	O
;	O
and	O
(	O
iv	O
)	O
PML-RAR	O
alpha	O
enhances	O
the	O
RA	O
response	O
of	O
RA	O
target	O
genes	O
(	O
those	O
for	O
RAR	O
beta	O
,	O
RAR	O
gamma	O
,	O
and	O
transglutaminase	O
type	O
II	O
[	O
TGase	O
]	O
)	O
in	O
vivo	O
,	O
while	O
PLZF-RAR	O
alpha	O
expression	O
has	O
either	O
no	B-Negation
effect	I-Negation
(	I-Negation
RAR	I-Negation
beta	I-Negation
)	I-Negation
or	O
an	O
inhibitory	O
activity	O
(	O
RAR	O
gamma	O
and	O
type	O
II	O
TGase	O
)	O
.	O

These	O
data	O
demonstrate	O
that	O
PML-RAR	O
alpha	O
and	O
PLZF-RAR	O
alpha	O
have	O
similar	O
(	O
inhibitory	O
)	O
effects	O
on	O
RA-independent	O
differentiation	O
and	O
opposite	O
(	O
stimulatory	O
or	O
inhibitory	O
)	O
effects	O
on	O
RA-dependent	O
differentiation	O
and	O
that	O
they	O
behave	O
in	O
vivo	O
as	O
RA-dependent	O
enhancers	O
or	O
inhibitors	O
of	O
RA-responsive	O
genes	O
,	O
respectively	O
.	O

Their	O
different	O
activities	O
on	O
the	O
RA	O
signalling	O
pathway	O
might	O
underlie	O
the	O
different	O
responses	O
of	O
PML-RAR	O
alpha	O
and	O
PLZF-RAR	O
alpha	O
APLs	O
to	O
RA	O
treatment	O
.	O

The	O
PLZF-RAR	O
alpha	O
fusion	O
protein	O
contains	O
an	O
approximately	O
120-amino-acid	O
N-terminal	O
motif	O
(	O
called	O
the	O
POZ	O
domain	O
)	O
,	O
which	O
is	O
also	O
found	O
in	O
a	O
variety	O
of	O
zinc	O
finger	O
proteins	O
and	O
a	O
group	O
of	O
poxvirus	O
proteins	O
and	O
which	O
mediates	O
protein-protein	O
interactions	O
.	O

Deletion	O
of	O
the	O
PLZF	O
POZ	O
domain	O
partially	O
abrogated	O
the	O
inhibitory	O
effect	O
of	O
PLZF-RAR	O
alpha	O
on	O
RA-induced	O
differentiation	O
and	O
on	O
RA-mediated	O
type	O
II	O
TGase	O
up-regulation	O
,	O
suggesting	O
that	O
POZ-mediated	O
protein	O
interactions	O
might	O
be	O
responsible	O
for	O
the	O
inhibitory	O
transcriptional	O
activities	O
of	O
PLZF-RAR	O
alpha	O
.	O

Induction	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
expression	O
in	O
monocytic	O
cells	O
by	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
.	O

Because	O
candidiasis	O
and	O
cryptococcosis	O
are	O
common	O
in	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
persons	O
,	O
the	O
effect	O
of	O
Cryptococcus	O
neoformans	O
and	O
Candida	O
albicans	O
on	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
was	O
examined	O
.	O

Stimulation	O
of	O
the	O
latently	O
HIV-infected	O
myelomonocytic	O
cell	O
line	O
OM-10.1	O
with	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
in	O
the	O
presence	O
of	O
pooled	O
human	O
serum	O
caused	O
a	O
ratio-dependent	O
increase	O
in	O
HIV	O
production	O
.	O

Induction	O
of	O
HIV	O
by	O
C.	O
neoformans	O
was	O
enhanced	O
by	O
anti-capsular	O
antibody	O
,	O
while	O
induction	O
by	O
both	O
organisms	O
was	O
inhibited	O
by	O
anti-TNF-alpha	O
antibody	O
.	O

In	O
THP-1	O
cells	O
transfected	O
with	O
HIV	O
plasmid	O
constructs	O
,	O
both	O
organisms	O
induced	O
transcription	O
from	O
the	O
HIV	O
long	O
terminal	O
repeat	O
that	O
was	O
dependent	O
on	O
intact	O
NF-kappaB	O
binding	O
sequences	O
.	O

Thus	O
,	O
C.	O
neoformans	O
and	O
C.	O
albicans	O
enhance	O
HIV	O
expression	O
in	O
monocytic	O
cells	O
through	O
a	O
TNF-alpha-	O
and	O
NF-kappaB-dependent	O
mechanism	O
.	O

In	O
HIV-infected	O
patients	O
,	O
such	O
enhancement	O
may	O
further	O
impair	O
host	O
immunity	O
and	O
could	O
accelerate	O
the	O
course	O
of	O
HIV	O
disease	O
.	O

A	O
human	O
homologue	O
of	O
the	O
Drosophila	O
Toll	O
protein	O
signals	O
activation	O
of	O
adaptive	O
immunity	O
[	O
see	O
comments	O
]	O

Induction	O
of	O
the	O
adaptive	O
immune	O
response	O
depends	O
on	O
the	O
expression	O
of	O
co-stimulatory	O
molecules	O
and	O
cytokines	O
by	O
antigen-presenting	O
cells	O
.	O

The	O
mechanisms	O
that	O
control	O
the	O
initial	O
induction	O
of	O
these	O
signals	O
upon	O
infection	O
are	O
poorly	O
understood	O
.	O

It	O
has	O
been	O
proposed	O
that	O
their	O
expression	O
is	O
controlled	O
by	O
the	O
non-clonal	O
,	O
or	O
innate	O
,	O
component	O
of	O
immunity	O
that	O
preceded	O
in	O
evolution	O
the	O
development	O
of	O
an	O
adaptive	O
immune	O
system	O
in	O
vertebrates	O
.	O

We	O
report	O
here	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
human	O
homologue	O
of	O
the	O
Drosophila	O
toll	O
protein	O
(	O
Toll	O
)	O
which	O
has	O
been	O
shown	O
to	O
induce	O
the	O
innate	O
immune	O
response	O
in	O
adult	O
Drosophila	O
.	O

Like	O
Drosophila	O
Toll	O
,	O
human	O
Toll	O
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
with	O
an	O
extracellular	O
domain	O
consisting	O
of	O
a	O
leucine-rich	O
repeat	O
(	O
LRR	O
)	O
domain	O
,	O
and	O
a	O
cytoplasmic	O
domain	O
homologous	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
human	O
interleukin	O
(	O
IL	O
)	O
-1	O
receptor	O
.	O

Both	O
Drosophila	O
Toll	O
and	O
the	O
IL-1	O
receptor	O
are	O
known	O
to	O
signal	O
through	O
the	O
NF-kappaB	O
pathway	O
.	O

We	O
show	O
that	O
a	O
constitutively	O
active	O
mutant	O
of	O
human	O
Toll	O
transfected	O
into	O
human	O
cell	O
lines	O
can	O
induce	O
the	O
activation	O
of	O
NF-kappaB	O
and	O
the	O
expression	O
of	O
NF-kappaB-controlled	O
genes	O
for	O
the	O
inflammatory	O
cytokines	O
IL-1	O
,	O
IL-6	O
and	O
IL-8	O
,	O
as	O
well	O
as	O
the	O
expression	O
of	O
the	O
co-stimulatory	O
molecule	O
B7.1	O
,	O
which	O
is	O
required	O
for	O
the	O
activation	O
of	O
naive	O
T	O
cells	O
.	O

Bcl-2	O
protein	O
inhibits	O
bufalin-induced	O
apoptosis	O
through	O
inhibition	O
of	O
mitogen-activated	O
protein	O
kinase	O
activation	O
in	O
human	O
leukemia	O
U937	O
cells	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
bufalin	O
,	O
which	O
is	O
an	O
active	O
principle	O
of	O
Chinese	O
medicine	O
,	O
chan'su	O
,	O
caused	O
apoptosis	O
in	O
human	O
leukemia	O
U937	O
cells	O
by	O
anomalous	O
activation	O
of	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
via	O
the	O
signaling	O
pathway	O
of	O
Ras	O
,	O
Raf-1	O
,	O
and	O
MAPK	O
kinase-1	O
.	O

Here	O
,	O
we	O
report	O
the	O
effect	O
of	O
overexpression	O
of	O
bcl-2	O
in	O
U937	O
cells	O
on	O
the	O
signaling	O
pathway	O
of	O
apoptosis	O
that	O
is	O
induced	O
by	O
bufalin	O
.	O

The	O
results	O
indicated	O
that	O
the	O
apoptosis	O
induced	O
by	O
bufalin	O
in	O
U937	O
cells	O
was	O
significantly	O
inhibited	O
by	O
overexpression	O
of	O
the	O
Bcl-2	O
protein	O
.	O

No	B-Negation
significant	I-Negation
difference	I-Negation
was	I-Negation
detected	I-Negation
in	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
MAPK	I-Negation
kinase-1	I-Negation
that	I-Negation
is	I-Negation
induced	I-Negation
by	I-Negation
bufalin	I-Negation
in	I-Negation
wild-type	I-Negation
or	I-Negation
Bcl-2-overexpressed	I-Negation
U937	I-Negation
cells	I-Negation
;	O
however	O
,	O
the	O
activation	O
of	O
MAPK	O
by	O
bufalin	O
was	O
significantly	O
attenuated	O
in	O
the	O
cells	O
overexpressing	O
Bcl-2	O
.	O

Bufalin	O
treatment	O
activated	O
activator	O
protein-1	O
transcriptional	O
activity	O
;	O
however	O
,	O
this	O
activation	O
was	O
decreased	O
to	O
40	O
%	O
in	O
bcl-2-overexpressed	O
U937	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
Bcl-2	O
acts	O
downstream	O
of	O
MAPK	O
kinase-1	O
but	O
upstream	O
of	O
MAPK	O
and	O
suggest	O
that	O
,	O
in	O
the	O
signaling	O
pathway	O
of	O
the	O
apoptotic	O
process	O
induced	O
by	O
bufalin	O
,	O
the	O
transcriptional	O
activity	O
of	O
activator	O
protein-1	O
may	O
be	O
down-regulated	O
through	O
the	O
inhibition	O
of	O
MAPK	O
activity	O
by	O
Bcl-2	O
.	O

A	O
shortened	O
life	O
span	O
of	O
EKLF-/-	O
adult	O
erythrocytes	O
,	O
due	O
to	O
a	O
deficiency	O
of	O
beta-globin	O
chains	O
,	O
is	O
ameliorated	O
by	O
human	O
gamma-globin	O
chains	O
.	O

Using	O
homologous	O
recombination	O
,	O
both	O
EKLF	O
alleles	O
in	O
murine	O
embryonic	O
stem	O
(	O
ES	O
)	O
cells	O
were	O
inactivated	O
.	O

These	O
EKLF-/-	O
ES	O
cells	O
were	O
capable	O
of	O
undergoing	O
in	O
vitro	O
differentiation	O
to	O
form	O
definitive	O
erythroid	O
colonies	O
that	O
were	O
similar	O
in	O
size	O
and	O
number	O
to	O
those	O
formed	O
by	O
wild-type	O
ES	O
cells	O
.	O

However	O
,	O
the	O
EKLF-/-	O
colonies	O
were	O
poorly	O
hemoglobinized	O
and	O
enucleated	O
erythrocytes	O
in	O
these	O
colonies	O
contained	O
numerous	O
Heinz	O
bodies	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
analyses	O
revealed	O
that	O
adult	O
and	O
embryonic	O
globin	O
genes	O
were	O
appropriately	O
regulated	O
,	O
with	B-Negation
the	I-Negation
exception	I-Negation
of	I-Negation
beta	I-Negation
h1-globin	I-Negation
,	I-Negation
which	I-Negation
continued	I-Negation
to	I-Negation
be	I-Negation
expressed	I-Negation
at	I-Negation
a	I-Negation
very	I-Negation
low	I-Negation
level	I-Negation
.	O

The	O
ratio	O
of	O
adult	O
beta-globin/alpha-globin	O
mRNA	O
in	O
the	O
mutant	O
ES	O
cells	O
was	O
1/15	O
of	O
that	O
in	O
wild-type	O
ES	O
cells	O
.	O

When	O
the	O
EKLF-/-	O
cells	O
were	O
injected	O
into	O
blastocysts	O
,	O
they	O
did	O
not	B-Negation
contribute	I-Negation
at	I-Negation
a	I-Negation
detectable	I-Negation
level	I-Negation
to	I-Negation
the	I-Negation
mature	I-Negation
erythrocyte	I-Negation
compartment	I-Negation
of	I-Negation
the	I-Negation
chimeric	I-Negation
animals	I-Negation
,	I-Negation
based	I-Negation
on	I-Negation
analysis	I-Negation
of	I-Negation
glucose	I-Negation
phosphate	I-Negation
isomerase-1	I-Negation
(	I-Negation
GPI-1	I-Negation
)	I-Negation
isozymes	I-Negation
and	I-Negation
hemoglobins	I-Negation
that	I-Negation
distinguish	I-Negation
ES	I-Negation
cell-derived	I-Negation
erythrocytes	I-Negation
from	I-Negation
host	I-Negation
blastocyst-derived	I-Negation
erythrocytes	I-Negation
.	O

In	O
contrast	O
,	O
semiquantitative	O
RT-PCR	O
analysis	O
of	O
RNA	O
from	O
reticulocytes	O
of	O
the	O
same	O
chimeric	O
animals	O
suggested	O
that	O
the	O
ES	O
cell-derived	O
reticulocytes	O
were	O
present	O
at	O
a	O
level	O
of	O
6	O
%	O
to	O
8	O
%	O
.	O

This	O
indicated	O
that	O
the	O
EKLF-/-	O
erythrocytes	O
in	O
adult	O
animals	O
must	O
be	O
short-lived	O
,	O
apparently	O
due	O
to	O
the	O
imbalance	O
of	O
beta-	O
versus	O
alpha-globin	O
chains	O
,	O
leading	O
to	O
the	O
precipitation	O
of	O
excess	O
alpha-globin	O
chains	O
to	O
form	O
Heinz	O
bodies	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
the	O
short	O
life	O
span	O
was	O
ameliorated	O
by	O
introduction	O
into	O
the	O
EKLF-/-	O
ES	O
cells	O
of	O
a	O
human	O
LCR/gamma-globin	O
gene	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
ES	O
cell-derived	O
reticulocytes	O
as	O
well	O
as	O
mature	O
erythrocytes	O
in	O
the	O
blood	O
of	O
the	O
chimeric	O
animals	O
.	O

Induction	O
of	O
nuclear	O
factor	O
kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphocytes	O
by	O
anti-HLA	O
class	O
I	O
monoclonal	O
antibodies	O
.	O

Monoclonal	O
antibodies	O
against	O
either	O
monomorphic	O
or	O
polymorphic	O
determinants	O
of	O
class	O
I	O
antigen	O
induced	O
in	O
PBMC	O
and	O
highly	O
purified	O
T	O
lymphocytes	O
the	O
nuclear	O
activity	O
of	O
NF-kappa	O
B/Rel	O
complexes	O
.	O

These	O
included	O
both	O
p50/p50	O
and	O
p50/p65	O
dimers	O
,	O
recognized	O
by	O
specific	O
antibodies	O
in	O
EMSA	O
.	O

The	O
induced	O
complexes	O
were	O
detectable	O
in	O
extracts	O
of	O
cells	O
incubated	O
with	O
anti-class	O
I	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
for	O
1.5	O
h	O
;	O
the	O
induction	O
was	O
maximal	O
at	O
5	O
h	O
,	O
persistent	O
at	O
16	O
h	O
and	O
no	B-Negation
longer	I-Negation
observed	I-Negation
at	I-Negation
40	I-Negation
h	I-Negation
.	O

The	O
mAb	O
failed	B-Negation
to	I-Negation
induce	I-Negation
NF-kappa	I-Negation
B/Rel	I-Negation
nuclear	I-Negation
activity	I-Negation
in	I-Negation
cells	I-Negation
incubated	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
3,4-dichloroisocoumarin	I-Negation
,	I-Negation
an	I-Negation
inhibitor	I-Negation
of	I-Negation
I	I-Negation
kappa	I-Negation
B-alpha	I-Negation
degradation	I-Negation
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
class	O
I	O
triggering	O
can	O
induce	O
the	O
activity	O
of	O
NF-kappa	O
B/Rel	O
nuclear	O
activity	O
in	O
peripheral	O
blood	O
T	O
lymphocytes	O
,	O
thereby	O
modulating	O
the	O
expression	O
of	O
genes	O
regulated	O
by	O
these	O
transcription	O
factors	O
.	O

Cyclosporin	O
A	O
interferes	O
with	O
the	O
inducible	O
degradation	O
of	O
NF-kappa	O
B	O
inhibitors	O
,	O
but	O
not	B-Negation
with	I-Negation
the	I-Negation
processing	I-Negation
of	I-Negation
p105/NF-kappa	I-Negation
B1	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

The	O
transcription	O
factor	O
NF-kappa	O
B	O
controls	O
the	O
induction	O
of	O
numerous	O
cytokine	O
promoters	O
during	O
the	O
activation	O
of	O
T	O
lymphocytes	O
.	O

Inhibition	O
of	O
T	O
cell	O
activation	O
by	O
the	O
immunosuppressants	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
and	O
FK506	O
exerts	O
a	O
suppressive	O
effect	O
on	O
the	O
induction	O
of	O
these	O
NF-kappa	O
B-controlled	O
cytokine	O
promoters	O
.	O

We	O
show	O
for	O
human	O
Jurkat	O
T	O
leukemia	O
cells	O
,	O
as	O
well	O
as	O
human	O
and	O
mouse	O
primary	O
T	O
lymphocytes	O
,	O
that	O
this	O
inhibitory	O
effect	O
is	O
accompanied	O
by	O
an	O
impaired	O
nuclear	O
translocation	O
of	O
the	O
Rel	O
proteins	O
c-Rel	O
,	O
RelA/p65	O
and	O
NF-kappa	O
B1/p50	O
,	O
whereas	O
the	O
nuclear	O
appearance	O
of	O
RelB	O
remains	O
unaffected	O
.	O

CsA	O
does	O
not	B-Negation
interfere	I-Negation
with	I-Negation
the	I-Negation
synthesis	I-Negation
of	I-Negation
Rel	I-Negation
proteins	I-Negation
,	O
but	O
prevents	O
the	O
inducible	O
degradation	O
of	O
cytosolic	O
NF-kappa	O
B	O
inhibitors	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
upon	O
T	O
cell	O
activation	O
.	O

CsA	O
neither	B-Negation
inhibits	I-Negation
the	I-Negation
processing	I-Negation
of	I-Negation
the	I-Negation
NF-kappa	I-Negation
B1	I-Negation
precursor	I-Negation
p105	I-Negation
to	I-Negation
p50	I-Negation
,	I-Negation
nor	I-Negation
does	I-Negation
it	I-Negation
``	I-Negation
stabilize	I-Negation
``	I-Negation
the	I-Negation
C-terminal	I-Negation
portion	I-Negation
of	I-Negation
p105	I-Negation
,	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
gamma	I-Negation
,	I-Negation
which	I-Negation
is	I-Negation
degraded	I-Negation
during	I-Negation
p105	I-Negation
processing	I-Negation
to	I-Negation
mature	I-Negation
p50	I-Negation
.	O

These	O
results	O
indicate	O
that	O
CsA	O
interferes	O
with	O
a	O
specific	O
event	O
in	O
the	O
signal-induced	O
degradation	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
,	O
but	O
does	O
not	O
affect	O
the	O
processing	O
of	O
NF-kappa	O
B1/p105	O
to	O
p50	O
.	O

EBF	O
and	O
E47	O
collaborate	O
to	O
induce	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
.	O

Early	O
B	O
cell	O
factor	O
(	O
EBF	O
)	O
and	O
E47	O
participate	O
in	O
the	O
transcriptional	O
control	O
of	O
early	O
B	O
lymphocyte	O
differentiation	O
.	O

With	O
the	O
aim	O
of	O
identifying	O
genetic	O
targets	O
for	O
these	O
transcription	O
factors	O
,	O
we	O
stably	O
transfected	O
cDNAs	O
encoding	O
EBF	O
or	O
a	O
covalent	O
homodimer	O
of	O
E47	O
,	O
individually	O
or	O
together	O
,	O
into	O
immature	O
hematopoietic	O
Ba/F3	O
cells	O
,	O
which	O
lack	B-Negation
both	I-Negation
factors	I-Negation
.	O

In	O
combination	O
,	O
EBF	O
and	O
E47	O
induce	O
efficient	O
expression	O
of	O
the	O
endogenous	O
immunoglobulin	O
surrogate	O
light	O
chain	O
genes	O
,	O
lambda5	O
and	O
VpreB	O
,	O
whereas	O
other	O
pre-B	O
cell-specific	O
genes	O
remain	O
silent	O
.	O

Multiple	O
functionally	O
important	O
EBF	O
and	O
E47	O
binding	O
sites	O
were	O
identified	O
in	O
the	O
lambda5	O
promoter/enhancer	O
region	O
,	O
indicating	O
that	O
lambda5	O
is	O
a	O
direct	O
genetic	O
target	O
for	O
these	O
transcription	O
factors	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
EBF	O
and	O
E47	O
synergize	O
to	O
activate	O
expression	O
of	O
a	O
subset	O
of	O
genes	O
that	O
define	O
an	O
early	O
stage	O
of	O
the	O
B	O
cell	O
lineage	O
.	O

Nuclear	O
levels	O
of	O
NF-kappaB	O
correlate	O
with	O
syncytium-forming	O
capacity	O
of	O
8e51	O
cells	O
,	O
expressing	O
a	O
defective	O
HIV	O
virus	O
.	O

The	O
double	O
NF-kappaB	O
site	O
identified	O
in	O
the	O
LTR	O
of	O
the	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
has	O
been	O
demonstrated	O
to	O
be	O
necessary	O
for	O
efficient	O
viral	O
transcription	O
.	O

In	O
this	O
report	O
we	O
present	O
the	O
characterisation	O
of	O
NF-kappaB	O
subunits	O
engaged	O
in	O
complexes	O
binding	O
to	O
the	O
HIV-1	O
NF-kappaB	O
site	O
in	O
human	O
8e51	O
T-cells	O
,	O
that	O
harbour	O
a	O
defective	O
HIV-1	O
.	O

At	O
least	O
four	O
different	O
specific	O
NF-kappaB	O
complexes	O
are	O
present	O
in	O
the	O
nucleus	O
of	O
these	O
cells	O
.	O

With	O
the	O
use	O
of	O
specific	O
antibodies	O
we	O
have	O
determined	O
the	O
composition	O
of	O
each	O
complex	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

The	O
results	O
show	O
the	O
presence	O
of	O
several	O
NF-kappaB	O
family	O
members	O
,	O
with	O
the	O
transactivating	O
RelA	O
being	O
engaged	O
in	O
multiple	O
complexes	O
.	O

The	O
importance	O
of	O
NF-kappaB	O
complexes	O
in	O
viral	O
functions	O
has	O
been	O
established	O
comparing	O
the	O
level	O
of	O
NF-kappaB	O
DNA-binding	O
complexes	O
with	O
syncytia-forming	O
activity	O
of	O
8e51	O
cells	O
.	O

In	O
fact	O
,	O
8e51	O
cells	O
that	O
had	O
almost	O
lost	O
their	O
syncytia-forming	O
capacity	O
were	O
found	O
to	O
contain	O
at	O
least	O
10	O
times	O
less	O
active	O
NF-kappaB	O
DNA-binding	O
complex	O
than	O
the	O
actively	O
fusing	O
cells	O
.	O

The	O
correlation	O
is	O
specific	O
as	O
the	O
level	O
of	O
at	O
least	O
three	O
other	O
transcription	O
factors	O
did	O
not	B-Negation
change	I-Negation
.	O

Differential	O
interaction	O
of	O
nuclear	O
factors	O
with	O
the	O
leukocyte-specific	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
.	O

The	O
leukocyte-specific	O
,	O
cytoskeleton-binding	O
pp52	O
(	O
LSP-1	O
,	O
WP-34	O
)	O
protein	O
is	O
widely	O
expressed	O
in	O
multiple	O
leukocyte	O
lineages	O
,	O
including	O
B	O
and	O
T	O
lymphocytes	O
,	O
granulocytes	O
,	O
and	O
macrophages	O
.	O

We	O
previously	O
detected	O
a	O
tissue-specific	O
promoter	O
preceding	O
the	O
exon	O
encoding	O
the	O
N	O
terminus	O
of	O
the	O
pp52	O
leukocyte	O
protein	O
.	O

Here	O
we	O
describe	O
the	O
functional	O
characterization	O
of	O
this	O
promoter	O
and	O
identification	O
of	O
the	O
factors	O
in	O
B	O
and	O
T	O
cells	O
that	O
regulate	O
its	O
activity	O
.	O

The	O
pp52	O
promoter	O
contains	O
an	O
initiator	O
specifying	O
the	O
unique	O
5	O
'	O
terminus	O
of	O
pp52	O
mRNA	O
,	O
tandem	O
pairs	O
of	O
Ets	O
and	O
SP1	O
motifs	O
,	O
and	O
a	O
lone	O
C/EBP	O
motif	O
.	O

All	O
these	O
motifs	O
are	O
essential	O
and	O
collectively	O
control	O
transcriptional	O
activity	O
.	O

DNA	O
binding	O
studies	O
and	O
Ab	O
supershift	O
assays	O
revealed	O
that	O
different	O
combinations	O
of	O
factors	O
interact	O
with	O
these	O
motifs	O
in	O
B	O
cells	O
vs	O
T	O
cells	O
.	O

The	O
Ets	O
motifs	O
are	O
preferentially	O
bound	O
by	O
PU-1	O
in	O
B	O
cell	O
extracts	O
from	O
all	O
stages	O
of	O
development	O
,	O
whereas	O
a	O
different	O
Ets	O
family	O
member	O
reacts	O
with	O
these	O
motifs	O
in	O
T	O
cell	O
extracts	O
.	O

The	O
C/EBP	O
motif	O
is	O
bound	O
by	O
Ig/EBP-1	O
in	O
pre-B	O
cell	O
and	O
T	O
cell	O
extracts	O
,	O
but	O
is	O
replaced	O
by	O
nuclear	O
factor-IL-6beta	O
or	O
a	O
nuclear	O
factor-IL-6beta-Ig/EBP-1	O
heterodimer	O
in	O
plasmacytoma	O
cell	O
extracts	O
.	O

Despite	O
its	O
reported	O
role	O
as	O
a	O
negative	O
regulator	O
of	O
transcription	O
,	O
Ig/EBP-1	O
appears	O
to	O
exert	O
a	O
stimulatory	O
effect	O
on	O
this	O
promoter	O
.	O

These	O
findings	O
reveal	O
the	O
features	O
controlling	O
the	O
pp52	O
promoter	O
in	O
B	O
and	O
T	O
cells	O
and	O
provide	O
the	O
foundation	O
for	O
determining	O
the	O
regulation	O
of	O
this	O
promoter	O
in	O
other	O
leukocyte	O
lineages	O
.	O

Transcription	O
factor	O
GATA-3	O
is	O
differentially	O
expressed	O
in	O
murine	O
Th1	O
and	O
Th2	O
cells	O
and	O
controls	O
Th2-specific	O
expression	O
of	O
the	O
interleukin-5	O
gene	O
.	O

Interleukin-5	O
(	O
IL-5	O
)	O
,	O
which	O
is	O
produced	O
by	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
but	O
not	B-Negation
by	I-Negation
Th1	I-Negation
cells	I-Negation
,	O
plays	O
a	O
key	O
role	O
in	O
the	O
development	O
of	O
eosinophilia	O
in	O
asthma	O
.	O

Despite	O
increasing	O
evidence	O
that	O
the	O
outcome	O
of	O
many	O
diseases	O
is	O
determined	O
by	O
the	O
ratio	O
of	O
the	O
two	O
subsets	O
of	O
CD4	O
(	O
+	O
)	O
T	O
helper	O
cells	O
,	O
Th1	O
and	O
Th2	O
,	O
the	O
molecular	O
basis	O
for	O
Th1-	O
and	O
Th2-	O
specific	O
gene	O
expression	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
previously	O
established	O
a	O
critical	O
role	O
for	O
the	O
transcription	O
factor	O
GATA-3	O
in	O
IL-5	O
promoter	O
activation	O
in	O
EL-4	O
cells	O
,	O
which	O
express	O
both	O
Th1-	O
and	O
Th2-type	O
cytokines	O
.	O

Our	O
studies	O
reported	O
here	O
demonstrate	O
that	O
GATA-3	O
is	O
critical	O
for	O
expression	O
of	O
the	O
IL-5	O
gene	O
in	O
bona	O
fide	O
Th2	O
cells	O
.	O

Whereas	O
mutations	O
in	O
the	O
GATA-3	O
site	O
abolished	O
antigen-	O
or	O
cAMP-	O
stimulated	O
IL-5	O
promoter	O
activation	O
in	O
Th2	O
cells	O
,	O
ectopic	O
expression	O
of	O
GATA-3	O
in	O
Th1	O
cells	O
or	O
in	O
a	O
non-lymphoid	O
,	O
non-IL-5-producing	O
cell	O
line	O
activated	O
the	O
IL-5	O
promoter	O
.	O

During	O
the	O
differentiation	O
of	O
naive	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
isolated	O
from	O
T	O
cell	O
receptor	O
transgenic	O
mice	O
,	O
GATA-3	O
gene	O
expression	O
was	O
up-regulated	O
in	O
developing	O
Th2	O
cells	O
,	O
but	O
was	O
down-regulated	O
in	O
Th1	O
cells	O
,	O
and	O
antigen-	O
or	O
cAMP-activated	O
Th2	O
cells	O
(	O
but	O
not	B-Negation
Th1	I-Negation
cells	I-Negation
)	O
expressed	O
the	O
GATA-3	O
protein	O
.	O

Thus	O
,	O
GATA-3	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
balance	O
between	O
Th1	O
and	O
Th2	O
subsets	O
in	O
immune	O
responses	O
.	O

Inhibition	O
of	O
GATA-3	O
activity	O
has	O
therapeutic	O
potential	O
in	O
the	O
treatment	O
of	O
asthma	O
and	O
other	O
hypereosinophilic	O
diseases	O
.	O

Inhibition	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
replication	O
in	O
vitro	O
by	O
a	O
novel	O
combination	O
of	O
anti-Tat	O
single-chain	O
intrabodies	O
and	O
NF-kappa	O
B	O
antagonists	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
Tat	O
,	O
an	O
early	O
regulatory	O
protein	O
that	O
is	O
critical	O
for	O
viral	O
gene	O
expression	O
and	O
replication	O
,	O
transactivates	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
via	O
its	O
binding	O
to	O
the	O
transactivation	O
response	O
element	O
(	O
TAR	O
)	O
and	O
,	O
along	O
with	O
other	O
cellular	O
factors	O
,	O
increases	O
viral	O
transcription	O
initiation	O
and	O
elongation	O
.	O

Tat	O
also	O
superactivates	O
the	O
HIV-1	O
promoter	O
through	O
a	O
TAR-independent	O
mechanism	O
,	O
including	O
tumor	O
necrosis	O
factor	O
alpha-induced	O
and	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
-dependent	O
activation	O
of	O
NF-kappa	O
B	O
,	O
and	O
inhibitors	O
of	O
Tat	O
and	O
NF-kappa	O
B	O
cooperatively	O
down-regulate	O
this	O
Tat-mediated	O
LTR	O
superactivation	O
.	O

In	O
this	O
study	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
using	O
two	O
PKC	O
(	O
NF-kappa	O
B	O
)	O
inhibitors	O
,	O
pentoxifylline	O
(	O
PTX	O
)	O
and	O
Go-6976	O
,	O
and	O
a	O
stably	O
expressed	O
anti-Tat	O
single-chain	O
intracellular	O
antibody	O
(	O
sFv	O
intrabody	O
)	O
was	O
employed	O
to	O
obtain	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

Treatment	O
of	O
cells	O
with	O
PTX	O
and	O
Go-6976	O
resulted	O
in	O
cooperative	O
inhibition	O
of	O
both	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
and	O
HIV-1	O
replication	O
.	O

In	O
addition	O
,	O
the	O
combined	O
use	O
of	O
anti-Tat	O
sFv	O
intrabodies	O
and	O
the	O
two	O
NF-kappa	O
B	O
inhibitors	O
retained	O
the	O
virus	O
in	O
the	O
latent	O
state	O
for	O
as	O
long	O
as	O
45	O
days	O
.	O

The	O
combined	O
treatment	O
resulted	O
in	O
more	O
durable	O
inhibition	O
of	O
HIV-1	O
replication	O
than	O
was	O
seen	O
with	O
the	O
NF-kappa	O
B	O
inhibitors	O
alone	O
or	O
the	O
anti-Tat	O
sFv	O
intrabodies	O
alone	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
in	O
future	O
clinical	O
gene	O
therapy	O
trials	O
,	O
a	O
combined	O
pharmacologic	O
and	O
genetic	O
strategy	O
like	O
the	O
one	O
reported	O
here	O
may	O
improve	O
the	O
survival	O
of	O
transduced	O
cells	O
and	O
prolong	O
clinical	O
benefit	O
.	O

Transcription	O
factors	O
in	O
immune-mediated	O
disease	O
.	O

A	O
large	O
amount	O
of	O
detailed	O
information	O
about	O
the	O
intracellular	O
proteins	O
regulating	O
NF-kappa	O
B	O
activation	O
and	O
the	O
cellular	O
response	O
to	O
NF-kappa	O
B	O
activation	O
has	O
emerged	O
recently	O
.	O

Several	O
small	O
molecules	O
,	O
an	O
antisense	O
oligonucleotide	O
,	O
and	O
gene	O
therapeutic	O
agents	O
that	O
inhibit	O
NF-kappa	O
b	O
activation	O
have	O
been	O
described	O
.	O

Despite	O
this	O
,	O
there	O
are	O
still	O
significant	O
gaps	O
in	O
our	O
understanding	O
of	O
this	O
process	O
and	O
its	O
consequences	O
.	O

In	O
contrast	O
,	O
the	O
characterization	O
of	O
transcription	O
factors	O
selectively	O
regulating	O
cytokine	O
production	O
by	O
CD4+	O
T	O
cell	O
subsets	O
is	O
at	O
a	O
very	O
early	O
stage	O
.	O

Three	O
interacting	O
proteins	O
have	O
recently	O
been	O
shown	O
to	O
contribute	O
to	O
subset-restricted	O
expression	O
of	O
the	O
IL-4	O
gene	O
.	O

There	O
are	O
other	O
elements	O
regulating	O
IL-4	O
gene	O
expression	O
,	O
however	O
,	O
and	O
the	O
relative	O
importance	O
of	O
these	O
recently	O
identified	O
proteins	O
has	O
yet	O
to	O
be	O
determined	O
.	O

CholecystokininB	O
receptor	O
from	O
human	O
Jurkat	O
lymphoblastic	O
T	O
cells	O
is	O
involved	O
in	O
activator	O
protein-1-responsive	O
gene	O
activation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
cholecystokinin	O
(	O
CCK	O
(	O
B	O
)	O
)	O
receptor	O
in	O
human	O
lymphoblastic	O
Jurkat	O
T	O
cells	O
.	O

We	O
investigated	O
the	O
trophic	O
effect	O
resulting	O
from	O
activation	O
of	O
such	O
a	O
receptor	O
by	O
using	O
the	O
reporter	O
gene	O
strategy	O
.	O

For	O
this	O
purpose	O
,	O
we	O
transiently	O
transfected	O
Jurkat	O
T	O
cells	O
with	O
the	O
reporter	O
plasmid	O
p	O
[	O
(	O
TRE	O
)	O
3-tk-Luc	O
]	O
and	O
found	O
that	O
CCK-8	O
was	O
able	O
to	O
dose-dependently	O
induce	O
luciferase	O
expression	O
related	O
to	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
activation	O
with	O
a	O
maximal	O
response	O
identical	O
to	O
that	O
obtained	O
with	O
compounds	O
known	O
to	O
activate	O
AP-1	O
complex	O
(	O
quantitatively	O
,	O
the	O
same	O
level	O
of	O
induction	O
was	O
obtained	O
with	O
1	O
nM	O
12-O-tetradecanoylphorbol-13-acetate	O
,	O
100	O
microM	O
diacylglycerol	O
,	O
or	O
4	O
nM	O
epidermal	O
growth	O
factor	O
)	O
.	O

The	O
involvement	O
of	O
the	O
CCK	O
(	O
B	O
)	O
receptor	O
in	O
such	O
a	O
stimulation	O
was	O
demonstrated	O
by	O
the	O
inhibiting	O
effect	O
of	O
the	O
selective	O
CCK	O
(	O
B	O
)	O
receptor	O
antagonist	O
PD-135,158	O
.	O

This	O
effect	O
was	O
confirmed	O
in	O
COS-7	O
cells	O
transfected	O
with	O
the	O
cDNA	O
of	O
CCK	O
(	O
B	O
)	O
receptor	O
cloned	O
from	O
Jurkat	O
T	O
cells	O
.	O

To	O
better	O
understand	O
the	O
AP-1-dependent	O
luciferase	O
expression	O
in	O
Jurkat	O
T	O
cells	O
,	O
we	O
tested	O
two	O
specific	O
inhibitors	O
of	O
serine/threonine	O
phosphatases-1	O
and	O
-2A	O
:	O
okadaic	O
acid	O
and	O
calyculin	O
A	O
.	O

These	O
compounds	O
strongly	O
increased	O
the	O
phorbol-12-myristate-13-acetate	O
response	O
,	O
whereas	O
we	O
have	O
not	B-Negation
observed	I-Negation
a	I-Negation
contribution	I-Negation
of	I-Negation
phosphatase	I-Negation
inhibitors	I-Negation
on	I-Negation
a	I-Negation
CCK-8-induced	I-Negation
luciferase	I-Negation
activity	I-Negation
.	O

To	O
confirm	O
that	O
CCK	O
(	O
B	O
)	O
receptors	O
are	O
involved	O
in	O
AP-1	O
response	O
,	O
we	O
investigated	O
the	O
CCK-8	O
effect	O
on	O
interleukin-2	O
expression	O
,	O
a	O
natural	O
endogenous	O
gene	O
regulated	O
by	O
several	O
factors	O
,	O
including	O
AP-1	O
.	O

In	O
Jurkat	O
T	O
cells	O
activated	O
by	O
phorbol-12-myristate-13-acetate	O
and	O
phytohemagglutinin	O
,	O
CCK-8	O
induced	O
IL-2	O
expression	O
.	O

This	O
induction	O
was	O
abolished	O
by	O
PD-135,158	O
.	O

Our	O
results	O
indicate	O
that	O
CCK-8	O
exerts	O
a	O
trophic	O
effect	O
in	O
Jurkat	O
T	O
cells	O
through	O
stimulation	O
of	O
CCK	O
(	O
B	O
)	O
receptors	O
by	O
modulation	O
of	O
expression	O
of	O
AP-1-regulated	O
genes	O
.	O

Epstein-Barr	O
virus	O
binding	O
to	O
CD21	O
activates	O
the	O
initial	O
viral	O
promoter	O
via	O
NF-kappaB	O
induction	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
,	O
an	O
oncogenic	O
human	O
herpesvirus	O
,	O
binds	O
to	O
and	O
infects	O
normal	O
human	O
B	O
lymphocytes	O
via	O
CD21	O
,	O
the	O
CR2	O
complement	O
receptor	O
.	O

Studies	O
of	O
the	O
mechanisms	O
that	O
enable	O
EBV	O
to	O
infect	O
nonactivated	O
,	O
noncycling	O
B	O
cells	O
provide	O
compelling	O
evidence	O
for	O
a	O
sequence	O
of	O
events	O
in	O
which	O
EBV	O
binding	O
to	O
CD21	O
on	O
purified	O
resting	O
human	O
B	O
cells	O
rapidly	O
activates	O
the	O
NF-kappaB	O
transcription	O
factor	O
,	O
which	O
,	O
in	O
turn	O
,	O
binds	O
to	O
and	O
mediates	O
transcriptional	O
activation	O
of	O
Wp	O
,	O
the	O
initial	O
viral	O
latent	O
gene	O
promoter	O
.	O

Thus	O
,	O
EBV	O
binding	O
to	O
its	O
cellular	O
receptor	O
on	O
resting	O
B	O
cells	O
triggers	O
an	O
NF-kappaB-dependent	O
intracellular	O
signaling	O
pathway	O
which	O
is	O
required	O
for	O
infection	O
.	O

Activation	O
of	O
transcription	O
factor	O
NF-kappa	O
B	O
by	O
phagocytic	O
stimuli	O
in	O
human	O
neutrophils	O
.	O

Phagocytosis	O
represents	O
an	O
important	O
physiological	O
trigger	O
for	O
the	O
inducible	O
expression	O
of	O
several	O
genes	O
in	O
human	O
neutrophils	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
DNA-binding	O
activity	O
primarily	O
consisting	O
of	O
the	O
classical	O
NF-kappa	O
B	O
heterodimer	O
,	O
p50/RelA	O
,	O
is	O
induced	O
in	O
phagocytosing	O
neutrophils	O
.	O

Under	O
these	O
conditions	O
,	O
NF-kappa	O
B	O
activation	O
was	O
found	O
to	O
be	O
a	O
rapid	O
and	O
transient	O
response	O
,	O
reaching	O
a	O
maximum	O
by	O
10-15	O
min	O
,	O
and	O
returning	O
to	O
near-basal	O
levels	O
by	O
30	O
min	O
.	O

In	O
neutrophils	O
undergoing	O
the	O
phagocytosis	O
of	O
opsonized	O
yeasts	O
,	O
the	O
onset	O
of	O
NF-kappa	O
B	O
activation	O
was	O
paralleled	O
by	O
a	O
decline	O
in	O
immunoreactive	O
I	O
kappa	O
B-alpha	O
protein	O
levels	O
,	O
and	O
the	O
cellular	O
I	O
kappa	O
B-alpha	O
pool	O
was	O
replenished	O
by	O
30	O
min	O
,	O
in	O
agreement	O
with	O
our	O
gel	O
shift	O
data	O
.	O

We	O
conclude	O
that	O
NF-kappa	O
B	O
activation	O
could	O
constitute	O
one	O
of	O
the	O
mechanisms	O
whereby	O
the	O
expression	O
of	O
kappa	O
B-responsive	O
genes	O
is	O
enhanced	O
in	O
phagocytosing	O
neutrophils	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
demonstration	O
that	O
phagocytic	O
stimuli	O
can	O
induce	O
NF-kappa	O
B	O
activation	O
in	O
human	O
neutrophils	O
.	O

Surfactant	O
protein	O
A	O
activates	O
NF-kappa	O
B	O
in	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
.	O

The	O
expression	O
of	O
many	O
genes	O
for	O
which	O
products	O
are	O
involved	O
in	O
inflammation	O
is	O
controlled	O
by	O
the	O
transcriptional	O
regulator	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappa	O
B	O
.	O

Because	O
surfactant	O
protein	O
(	O
SP	O
)	O
A	O
is	O
involved	O
in	O
local	O
host	O
defense	O
in	O
the	O
lung	O
and	O
alters	O
immune	O
cell	O
function	O
by	O
modulating	O
the	O
expression	O
of	O
proinflammatory	O
cytokines	O
as	O
well	O
as	O
surface	O
proteins	O
involved	O
in	O
inflammation	O
,	O
we	O
hypothesized	O
that	O
SP-A	O
exerts	O
its	O
action	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
activation	O
of	O
NF-kappa	O
B	O
.	O

We	O
used	O
gel	O
shift	O
assays	O
to	O
determine	O
whether	O
SP-A	O
activated	O
NF-kappa	O
B	O
in	O
the	O
THP-1	O
cell	O
line	O
,	O
a	O
human	O
monocytic	O
cell	O
line	O
.	O

Activation	O
of	O
NF-kappa	O
B	O
in	O
THP-1	O
cells	O
by	O
SP-A	O
doses	O
as	O
low	O
as	O
1	O
microgram/ml	O
occurred	O
within	O
30	O
min	O
of	O
SP-A	O
treatment	O
,	O
peaked	O
at	O
60	O
min	O
,	O
and	O
then	O
declined	O
.	O

This	O
activation	O
is	O
inhibited	O
by	O
known	O
inhibitors	O
of	O
NF-kappa	O
B	O
or	O
by	O
simultaneous	O
treatment	O
of	O
the	O
cells	O
with	O
surfactant	O
lipids	O
.	O

Moreover	O
,	O
the	O
NF-kappa	O
B	O
inhibitors	O
blocked	O
SP-A-dependent	O
increases	O
in	O
tumor	O
necrosis	O
factor-alpha	O
mRNA	O
levels	O
.	O

These	O
observations	O
suggest	O
a	O
mechanism	O
by	O
which	O
SP-A	O
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
some	O
lung	O
conditions	O
and	O
point	O
to	O
potential	O
therapeutic	O
measures	O
that	O
could	O
be	O
used	O
to	O
prevent	O
SP-A	O
induced	O
inflammation	O
in	O
the	O
lung	O
.	O

alpha-Tocopheryl	O
succinate	O
inhibits	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
by	O
suppressing	O
NF-kappa	O
B	O
mobilization	O
.	O

The	O
adherence	O
of	O
monocytes	O
to	O
activated	O
endothelium	O
is	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

Because	O
antioxidants	O
have	O
been	O
considered	O
to	O
be	O
of	O
antiatherosclerotic	O
potential	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
alpha-tocopherol	O
(	O
TCP	O
)	O
and	O
its	O
acetate	O
and	O
succinate	O
esters	O
on	O
monocyte	O
adhesion	O
to	O
cytokine-stimulated	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
.	O

Endothelial	O
cells	O
were	O
treated	O
with	O
TCP	O
,	O
alpha-tocopherol	O
acetate	O
(	O
TCP	O
acetate	O
)	O
,	O
or	O
alpha-tocopheryl	O
succinate	O
(	O
TCP	O
succinate	O
)	O
before	O
stimulation	O
with	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
or	O
interleukin-1	O
beta	O
(	O
IL-1	O
beta	O
;	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
.	O

Cytokine-stimulated	O
cell	O
surface	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
,	O
CD106	O
)	O
and	O
E-selectin	O
(	O
ELAM-1	O
,	O
CD62E	O
)	O
,	O
but	O
not	B-Negation
of	I-Negation
intercellular	I-Negation
adhesion	I-Negation
molecule-1	I-Negation
(	I-Negation
ICAM-1	I-Negation
,	I-Negation
CD54	I-Negation
)	I-Negation
,	O
was	O
time-	O
and	O
dose-dependently	O
inhibited	O
by	O
TCP	O
succinate	O
but	O
not	B-Negation
by	I-Negation
TCP	I-Negation
or	I-Negation
TCP	I-Negation
acetate	I-Negation
.	O

TCP	O
succinate	O
(	O
200	O
microM	O
,	O
24	O
h	O
)	O
reduced	O
TNF-induced	O
VCAM-1	O
and	O
E-selectin	O
expression	O
from	O
a	O
specific	O
mean	O
fluorescence	O
intensity	O
of	O
151	O
	O
28	O
to	O
12	O
	O
4	O
channels	O
and	O
from	O
225	O
	O
38	O
to	O
79	O
	O
21	O
channels	O
,	O
respectively	O
.	O

Succinate	O
alone	O
had	O
no	B-Negation
effect	I-Negation
.	O

Decreased	O
adhesion	O
molecule	O
expression	O
was	O
associated	O
with	O
a	O
reduction	O
of	O
monocytic	O
cell	O
adhesion	O
.	O

TCP	O
succinate	O
(	O
20	O
microM	O
,	O
72	O
h	O
)	O
,	O
but	O
not	B-Negation
TCP	I-Negation
(	I-Negation
200	I-Negation
microM	I-Negation
,	I-Negation
72	I-Negation
h	I-Negation
)	I-Negation
,	O
reduced	O
U-937	O
cell	O
adhesion	O
to	O
TNF-alpha-stimulated	O
(	O
10	O
U/ml	O
,	O
6	O
h	O
)	O
HUVEC	O
by	O
30	O
%	O
(	O
P	O
<	O
0.025	O
)	O
and	O
to	O
IL-1	O
beta-stimulated	O
HUVEC	O
by	O
56	O
%	O
(	O
P	O
<	O
0.010	O
)	O
.	O

Electrophoretic	O
mobility-shift	O
assays	O
of	O
HUVEC	O
nuclear	O
proteins	O
revealed	O
a	O
decrease	O
in	O
TNF-alpha-stimulated	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
after	O
pretreatment	O
of	O
HUVEC	O
with	O
TCP	O
succinate	O
but	O
not	B-Negation
with	I-Negation
TCP	I-Negation
,	I-Negation
TCP	I-Negation
acetate	I-Negation
,	I-Negation
or	I-Negation
succinate	I-Negation
alone	I-Negation
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
vitamin	O
E	O
derivative	O
TCP	O
succinate	O
prevents	O
monocytic	O
cell	O
adhesion	O
to	O
cytokine-stimulated	O
endothelial	O
cells	O
by	O
inhibiting	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
further	O
emphasizing	O
the	O
antiatherosclerotic	O
potential	O
of	O
lipid	O
soluble	O
antioxidants	O
.	O

Distinct	O
mechanisms	O
for	O
N-acetylcysteine	O
inhibition	O
of	O
cytokine-induced	O
E-selectin	O
and	O
VCAM-1	O
expression	O
.	O

We	O
have	O
examined	O
the	O
effects	O
of	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
well-characterized	O
,	O
thiol-containing	O
antioxidant	O
,	O
on	O
agonist-induced	O
monocytic	O
cell	O
adhesion	O
to	O
endothelial	O
cells	O
(	O
EC	O
)	O
.	O

NAC	O
inhibited	O
interleukin-1	O
(	O
IL-1	O
beta	O
)	O
-induced	O
,	O
but	O
not	B-Negation
basal	I-Negation
,	O
adhesion	O
with	O
50	O
%	O
inhibition	O
at	O
approximately	O
20	O
mM	O
.	O

Monocytic	O
cell	O
adhesion	O
to	O
EC	O
in	O
response	O
to	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
,	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
alpha-thrombin	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
was	O
similarly	O
inhibited	O
by	O
NAC	O
.	O

Unlike	O
published	O
studies	O
with	O
pyrrolidinedithiocarbamate	O
,	O
which	O
specifically	O
inhibited	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM-1	O
)	O
,	O
NAC	O
inhibited	O
IL-1	O
beta-induced	O
mRNA	O
and	O
cell	O
surface	O
expression	O
of	O
both	O
E-selectin	O
and	O
VCAM-1	O
.	O

NAC	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
half-life	I-Negation
of	I-Negation
E-selectin	I-Negation
or	I-Negation
VCAM-1	I-Negation
mRNA	I-Negation
.	O

Although	O
NAC	O
reduced	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
in	O
EC	O
as	O
measured	O
by	O
gel-shift	O
assays	O
using	O
an	O
oligonucleotide	O
probe	O
corresponding	O
to	O
the	O
consensus	O
NF-kappa	O
B	O
binding	O
sites	O
of	O
the	O
VCAM-1	O
gene	O
(	O
VCAM-NF-kappa	O
B	O
)	O
,	O
the	O
antioxidant	O
had	O
no	B-Negation
appreciable	I-Negation
effect	I-Negation
when	I-Negation
an	I-Negation
oligomer	I-Negation
corresponding	I-Negation
to	I-Negation
the	I-Negation
consensus	I-Negation
NF-kappa	I-Negation
B	I-Negation
binding	I-Negation
site	I-Negation
of	I-Negation
the	I-Negation
E-selectin	I-Negation
gene	I-Negation
(	I-Negation
E-selectin-NF-kappa	I-Negation
B	I-Negation
)	I-Negation
was	I-Negation
used	I-Negation
.	O

Because	O
NF-kappa	O
B	O
has	O
been	O
reported	O
to	O
be	O
redox	O
sensitive	O
,	O
we	O
studied	O
the	O
effects	O
of	O
NAC	O
on	O
the	O
EC	O
redox	O
environment	O
.	O

NAC	O
caused	O
an	O
expected	O
dramatic	O
increase	O
in	O
the	O
reduced	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
EC	O
.	O

In	O
vitro	O
studies	O
demonstrated	O
that	O
whereas	O
the	O
binding	O
affinity	O
of	O
NF-kappa	O
B	O
to	O
the	O
VCAM-NF-kappa	O
B	O
oligomer	O
peaked	O
at	O
a	O
GSH-to-oxidized	O
glutathione	O
(	O
GSSG	O
)	O
ratio	O
of	O
approximately	O
200	O
and	O
decreased	O
at	O
higher	O
ratios	O
,	O
the	O
binding	O
to	O
the	O
E-selectin-NF-kappa	O
B	O
oligomer	O
appeared	O
relatively	O
unaffected	O
even	O
at	O
ratios	O
>	O
400	O
,	O
i.e.	O
,	O
those	O
achieved	O
in	O
EC	O
treated	O
with	O
40	O
mM	O
NAC	O
.	O

These	O
results	O
suggest	O
that	O
NF-kappa	O
B	O
binding	O
to	O
its	O
consensus	O
sequences	O
in	O
the	O
VCAM-1	O
and	O
E-selectin	O
gene	O
exhibits	O
marked	O
differences	O
in	O
redox	O
sensitivity	O
,	O
allowing	O
for	O
differential	O
gene	O
expression	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
.	O

Our	O
data	O
also	O
demonstrate	O
that	O
NAC	O
increases	O
the	O
GSH-to-GSSG	O
ratio	O
within	O
the	O
EC	O
suggesting	O
one	O
possible	O
mechanism	O
through	O
which	O
this	O
antioxidant	O
inhibits	O
agonist-induced	O
monocyte	O
adhesion	O
to	O
EC	O
.	O

Human	O
monocyte	O
binding	O
to	O
fibronectin	O
enhances	O
IFN-gamma-induced	O
early	O
signaling	O
events	O
.	O

Leukocyte	O
integrins	O
are	O
fundamentally	O
important	O
in	O
modulating	O
adhesion	O
to	O
extracellular	O
matrix	O
components	O
and	O
to	O
other	O
cells	O
.	O

This	O
integrin-mediated	O
adhesion	O
controls	O
leukocyte	O
arrest	O
and	O
extravasation	O
during	O
the	O
onset	O
of	O
inflammatory	O
responses	O
.	O

Moreover	O
,	O
integrin-ligand	O
interactions	O
trigger	O
signaling	O
pathways	O
that	O
may	O
influence	O
leukocyte	O
phenotype	O
and	O
function	O
at	O
sites	O
of	O
inflammation	O
.	O

In	O
the	O
current	O
studies	O
,	O
we	O
evaluated	O
the	O
combinatorial	O
effects	O
of	O
monocyte	O
adhesion	O
and	O
IFN-gamma	O
on	O
intracellular	O
signaling	O
pathways	O
.	O

IFN-gamma	O
triggers	O
a	O
well-defined	O
signal	O
transduction	O
pathway	O
,	O
which	O
although	O
not	O
directly	O
stimulated	O
by	O
monocyte	O
adherence	O
to	O
fibronectin	O
or	O
arginine-glycine-aspartate	O
(	O
RGD	O
)	O
-coated	O
substrata	O
,	O
was	O
enhanced	O
significantly	O
in	O
these	O
matrix-adherent	O
cells	O
.	O

Compared	O
with	O
monocytes	O
in	O
suspension	O
or	O
adherent	O
on	O
plastic	O
surfaces	O
,	O
monocytes	O
adherent	O
to	O
fibronectin	O
or	O
RGD	O
exhibited	O
a	O
greater	O
than	O
threefold	O
increase	O
in	O
steady	O
state	O
levels	O
of	O
IFN-gamma-induced	O
mRNA	O
for	O
the	O
high	O
affinity	O
Fc	O
gammaRI	O
receptor	O
.	O

By	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
this	O
increase	O
in	O
mRNA	O
was	O
associated	O
with	O
a	O
5-	O
to	O
10-fold	O
increase	O
in	O
the	O
STAT1-containing	O
DNA-binding	O
complex	O
that	O
binds	O
to	O
Fc	O
gammaRI	O
promoter	O
elements	O
.	O

Furthermore	O
,	O
the	O
tyrosine	O
phosphorylation	O
of	O
STAT1	O
and	O
the	O
tyrosine	O
kinases	O
JAK1	O
and	O
JAK2	O
was	O
enhanced	O
significantly	O
in	O
RGD-adherent	O
monocytes	O
compared	O
with	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
mechanism	O
by	O
which	O
integrin-mediated	O
cell	O
adhesion	O
can	O
modulate	O
the	O
magnitude	O
of	O
cytokine-induced	O
signal	O
transduction	O
pathways	O
,	O
thereby	O
amplifying	O
cellular	O
events	O
leading	O
to	O
monocyte	O
activation	O
and	O
inflammation	O
.	O

The	O
carboxyl-terminal	O
cytoplasmic	O
domain	O
of	O
CD36	O
is	O
required	O
for	O
oxidized	O
low-density	O
lipoprotein	O
modulation	O
of	O
NF-kappaB	O
activity	O
by	O
tumor	O
necrosis	O
factor-alpha	O
.	O

The	O
binding	O
of	O
oxidized	O
low-density	O
lipoprotein	O
(	O
Ox	O
LDL	O
)	O
by	O
monocyte-macrophages	O
causes	O
pleiotropic	O
effects	O
,	O
including	O
changes	O
in	O
gene	O
expression	O
,	O
and	O
is	O
thought	O
to	O
represent	O
an	O
early	O
event	O
in	O
atherogenesis	O
.	O

The	O
integral	O
membrane	O
glycoprotein	O
CD36	O
appears	O
to	O
play	O
a	O
physiological	O
role	O
in	O
binding	O
and	O
uptake	O
of	O
Ox	O
LDL	O
by	O
monocyte-macrophages	O
,	O
although	O
the	O
molecular	O
events	O
associated	O
with	O
CD36-Ox	O
LDL	O
interaction	O
are	O
unknown	O
.	O

To	O
approach	O
this	O
issue	O
,	O
we	O
used	O
CD36	O
transfected	O
Chinese	O
hampster	O
ovary	O
(	O
CHO	O
)	O
cells	O
,	O
exposed	O
them	O
to	O
Ox	O
LDL	O
,	O
and	O
determined	O
changes	O
in	O
the	O
activity	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O

We	O
report	O
here	O
that	O
Ox	O
LDL	O
enhanced	O
DNA	O
binding	O
activity	O
of	O
nuclear	O
extracts	O
to	O
an	O
NF-kappaB	O
sequence	O
following	O
activation	O
of	O
CD36-producing	O
CHO	O
cells	O
with	O
the	O
proinflammatory	O
cytokine	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

This	O
enhanced	O
DNA	O
binding	O
activity	O
was	O
inhibited	O
by	O
coincubation	O
of	O
CD36	O
transfected	O
cells	O
with	O
the	O
human	O
CD36-specific	O
antibody	O
OKM5	O
.	O

We	O
also	O
determined	O
that	O
activation	O
of	O
NF-kappaB	O
DNA	O
binding	O
activity	O
required	O
an	O
intact	O
carboxyl-terminal	O
cytoplasmic	O
segment	O
on	O
CD36	O
.	O

Our	O
results	O
support	O
the	O
idea	O
that	O
human	O
CD36	O
mediates	O
signal	O
transduction	O
events	O
in	O
response	O
to	O
Ox	O
LDL	O
.	O

Transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

The	O
coordinated	O
production	O
of	O
all	O
blood	O
cells	O
from	O
a	O
common	O
stem	O
cell	O
is	O
a	O
highly	O
regulated	O
process	O
involving	O
successive	O
stages	O
of	O
commitment	O
and	O
differentiation	O
.	O

From	O
analyses	O
of	O
mice	O
deficient	O
in	O
transcription	O
factor	O
genes	O
and	O
from	O
the	O
characterizations	O
of	O
chromosome	O
breakpoints	O
in	O
human	O
leukemias	O
,	O
it	O
has	O
become	O
evident	O
that	O
transcription	O
factors	O
are	O
important	O
regulators	O
of	O
hematopoiesis	O
.	O

During	O
myelopoiesis	O
,	O
which	O
includes	O
the	O
development	O
of	O
granulocytic	O
and	O
monocytic	O
lineages	O
,	O
transcription	O
factors	O
from	O
several	O
families	O
are	O
active	O
,	O
including	O
AML1/CBF	O
beta	O
,	O
C/EBP	O
,	O
Ets	O
,	O
c-Myb	O
,	O
HOX	O
,	O
and	O
MZF-1	O
.	O

Few	O
of	O
these	O
factors	O
are	O
expressed	O
exclusively	O
in	O
myeloid	O
cells	O
;	O
instead	O
it	O
appears	O
that	O
they	O
cooperatively	O
regulate	O
transcription	O
of	O
myeloid-specific	O
genes	O
.	O

Here	O
we	O
discuss	O
recent	O
advances	O
in	O
transcriptional	O
regulation	O
during	O
myelopoiesis	O
.	O

Genomic	O
organization	O
,	O
sequence	O
,	O
and	O
transcriptional	O
regulation	O
of	O
the	O
human	O
eotaxin	O
gene	O
.	O

Eotaxin	O
is	O
an	O
eosinophil	O
specific	O
beta-chemokine	O
assumed	O
to	O
be	O
involved	O
in	O
eosinophilic	O
inflammatory	O
diseases	O
such	O
as	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
asthma	O
and	O
parasitic	O
infections	O
.	O

Its	O
expression	O
is	O
stimulus-	O
and	O
cell-specific	O
.	O

We	O
here	O
describe	O
the	O
genomic	O
organisation	O
(	O
3	O
exons	O
of	O
132	O
,	O
112	O
and	O
542	O
bp	O
and	O
2	O
introns	O
of	O
1211	O
and	O
378	O
bp	O
)	O
and	O
sequence	O
including	O
3	O
kb	O
of	O
DNA	O
from	O
the	O
immediate	O
5	O
'	O
upstream	O
region	O
of	O
the	O
human	O
eotaxin	O
gene	O
.	O

Among	O
the	O
regulatory	O
promoter	O
elements	O
potentially	O
regulating	O
eotaxin	O
gene	O
expression	O
and/or	O
mediating	O
the	O
effects	O
of	O
anti-inflammatory	O
drugs	O
we	O
identified	O
consensus	O
sequences	O
known	O
to	O
interact	O
with	O
nuclear	O
factors	O
like	O
NF-IL6	O
,	O
AP-1	O
,	O
a	O
NF-kappa-B	O
like	O
consensus	O
sequence	O
and	O
gamma-interferon-	O
as	O
well	O
as	O
glucocorticoid	O
response	O
elements	O
.	O

Rel/NF-kappa	O
B	O
transcription	O
factors	O
and	O
the	O
control	O
of	O
apoptosis	O
.	O

The	O
process	O
of	O
apoptosis	O
is	O
used	O
to	O
eliminate	O
unwanted	O
cells	O
from	O
a	O
wide	O
variety	O
of	O
organisms	O
.	O

Various	O
extracellular	O
signals	O
,	O
often	O
converging	O
in	O
common	O
intracellular	O
pathways	O
,	O
can	O
induce	O
apoptosis	O
in	O
a	O
cell-type-specific	O
fashion	O
.	O

Recent	O
work	O
from	O
several	O
laboratories	O
has	O
demonstrated	O
that	O
Rel/NF-kappa	O
B	O
transcription	O
factors	O
regulate	O
apoptosis	O
in	O
many	O
cell	O
types	O
.	O

In	O
most	O
cells	O
,	O
Rel/NF-kappa	O
B	O
transcription	O
factors	O
appear	O
to	O
mediate	O
survival	O
signals	O
that	O
protect	O
cells	O
from	O
apoptosis	O
;	O
however	O
,	O
under	O
some	O
circumstances	O
,	O
activation	O
of	O
these	O
factors	O
may	O
also	O
promote	O
apoptosis	O
.	O

The	O
role	O
of	O
Rel/NF-kappa	O
B	O
proteins	O
in	O
viral	O
oncogenesis	O
and	O
the	O
regulation	O
of	O
viral	O
transcription	O
.	O

Rel/NF-kappa	O
B	O
is	O
a	O
ubiquitous	O
transcription	O
factor	O
that	O
consists	O
of	O
multiple	O
polypeptide	O
subunits	O
,	O
and	O
is	O
subject	O
to	O
complex	O
regulatory	O
mechanisms	O
that	O
involve	O
protein-protein	O
interactions	O
,	O
phosphorylation	O
,	O
ubiquitination	O
,	O
proteolytic	O
degradation	O
,	O
and	O
nucleocytoplasmic	O
translocation	O
.	O

The	O
sophisticated	O
control	O
of	O
Rel/NF-kappa	O
B	O
activity	O
is	O
not	B-Negation
surprising	I-Negation
since	O
this	O
transcription	O
factor	O
is	O
involved	O
in	O
a	O
wide	O
array	O
of	O
cellular	O
responses	O
to	O
extracellular	O
cues	O
,	O
associated	O
with	O
growth	O
,	O
development	O
,	O
apoptosis	O
,	O
and	O
pathogen	O
invasion	O
.	O

Thus	O
,	O
it	O
is	O
not	B-Negation
unexpected	I-Negation
that	I-Negation
this	I-Negation
versatile	I-Negation
cellular	I-Negation
homeostatic	I-Negation
switch	I-Negation
would	I-Negation
be	I-Negation
affected	I-Negation
by	I-Negation
a	I-Negation
variety	I-Negation
of	I-Negation
viral	I-Negation
pathogens	I-Negation
,	I-Negation
which	I-Negation
have	I-Negation
evolved	I-Negation
mechanisms	I-Negation
to	I-Negation
utilize	I-Negation
various	I-Negation
aspects	I-Negation
of	I-Negation
Rel/NF-kappa	I-Negation
B	I-Negation
activity	I-Negation
to	I-Negation
facilitate	I-Negation
their	I-Negation
replication	I-Negation
,	I-Negation
cell	I-Negation
survival	I-Negation
and	I-Negation
possibly	I-Negation
evasion	I-Negation
of	I-Negation
immune	I-Negation
responses	I-Negation
.	O

This	O
review	O
will	O
cover	O
the	O
molecular	O
mechanisms	O
that	O
are	O
utilized	O
by	O
mammalian	O
oncogenic	O
viruses	O
to	O
affect	O
the	O
activity	O
of	O
Rel/NF-kappa	O
B	O
transcription	O
factors	O
and	O
the	O
role	O
of	O
Rel/NF-kappa	O
B	O
in	O
the	O
regulation	O
of	O
viral	O
gene	O
expression	O
and	O
replication	O
.	O

Abnormal	O
apoptosis	O
and	O
cell	O
cycle	O
progression	O
in	O
humans	O
exposed	O
to	O
methyl	O
tertiary-butyl	O
ether	O
and	O
benzene	O
contaminating	O
water	O
.	O

1.	O
In	O
this	O
study	O
we	O
hypothesized	O
that	O
in	O
individuals	O
with	O
certain	O
genetic	O
makeup	O
,	O
MTBE	O
,	O
benzene	O
or	O
their	O
metabolites	O
act	O
as	O
adducts	O
and	O
may	O
induce	O
programmed	O
cell	O
death	O
.	O

2.	O
Our	O
study	O
involved	O
a	O
group	O
of	O
60	O
male	O
and	O
female	O
subjects	O
who	O
were	O
exposed	O
to	O
MTBE	O
and	O
benzene-contaminated	O
water	O
concentrations	O
up	O
to	O
76	O
PPB	O
for	O
MTBE	O
and	O
14	O
PPB	O
for	O
benzene	O
,	O
for	O
a	O
period	O
of	O
5	O
to	O
8	O
years	O
.	O

For	O
comparison	O
,	O
we	O
recruited	O
a	O
control	O
group	O
consisting	O
of	O
32	O
healthy	O
males	O
and	O
females	O
with	O
similar	O
age	O
distribution	O
and	O
without	B-Negation
a	I-Negation
history	I-Negation
of	I-Negation
exposure	I-Negation
to	I-Negation
MTBE	I-Negation
or	I-Negation
benzene	I-Negation
.	O

3.	O
Peripheral	O
blood	O
lymphocytes	O
(	O
PBL	O
)	O
of	O
both	O
groups	O
were	O
tested	O
for	O
the	O
percentage	O
of	O
apoptotic	O
cells	O
and	O
cell	O
cycle	O
progression	O
using	O
flow	O
cytometry	O
.	O

4.	O
When	O
apoptotic	O
lymphocytes	O
from	O
exposed	O
individuals	O
were	O
compared	O
to	O
apoptotic	O
lymphocytes	O
from	O
the	O
control	O
group	O
,	O
statistically-significant	O
differences	O
between	O
each	O
mean	O
group	O
were	O
detected	O
(	O
26.4	O
	O
1.8	O
and	O
12.1	O
	O
1.3	O
,	O
respectively	O
)	O
,	O
indicating	O
an	O
increased	O
rate	O
of	O
apoptosis	O
in	O
80.5	O
%	O
of	O
exposed	O
individuals	O
(	O
P	O
<	O
0.0001	O
,	O
Mann-Whitney	O
U-Test	O
)	O
.	O

MTBE	O
and	O
benzene-induced	O
apoptosis	O
is	O
attributed	O
to	O
a	O
discrete	O
block	O
within	O
the	O
cell	O
cycle	O
progression	O
.	O

Because	O
cell	O
cycle	O
analysis	O
showed	O
that	O
in	O
PBL	O
from	O
chemically-exposed	O
individuals	O
,	O
between	O
20-50	O
%	O
of	O
cells	O
were	O
accumulated	O
at	O
the	O
S-G2/M	O
boundaries	O
.	O

5.	O
One	O
of	O
the	O
signaling	O
molecules	O
which	O
mediates	O
programmed	O
cell	O
death	O
is	O
nuclear	O
factor	O
Kappa-B	O
(	O
NF-kappa	O
B	O
)	O
.	O

NF-kappa	O
B	O
was	O
examined	O
as	O
one	O
of	O
the	O
many	O
molecular	O
mechanisms	O
for	O
mediating	O
cell	O
death	O
by	O
MTBE	O
and	O
benzene	O
.	O

Indeed	O
,	O
addition	O
of	O
inhibitors	O
of	O
NF-kappa	O
B	O
activation	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
to	O
the	O
lymphocytes	O
of	O
the	O
chemically-exposed	O
group	O
was	O
capable	O
of	O
inhibiting	O
programmed	O
cell	O
death	O
by	O
40	O
%	O
.	O

This	O
reversal	O
of	O
apoptosis	O
almost	O
to	O
the	O
control	O
level	O
by	O
inhibitor	O
of	O
NF-kappa	O
B	O
activation	O
may	O
indicate	O
involvement	O
of	O
this	O
signaling	O
molecule	O
in	O
MTBE	O
and	O
benzene	O
induction	O
of	O
programmed	O
cell	O
death	O
.	O

Activation	O
of	O
a	O
novel	O
gene	O
in	O
3q21	O
and	O
identification	O
of	O
intergenic	O
fusion	O
transcripts	O
with	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
in	O
leukemia	O
.	O

We	O
have	O
identified	O
a	O
novel	O
gene	O
,	O
GR6	O
,	O
located	O
within	O
the	O
leukemia	O
breakpoint	O
region	O
of	O
3q21	O
,	O
that	O
is	O
normally	O
expressed	O
in	O
early	O
fetal	O
development	O
but	O
not	B-Negation
in	I-Negation
adult	I-Negation
peripheral	I-Negation
blood	I-Negation
.	O

GR6	O
is	O
activated	O
in	O
the	O
UCSD-AML1	O
cell	O
line	O
and	O
in	O
a	O
leukemic	O
sample	O
,	O
both	O
of	O
which	O
carry	O
a	O
t	O
(	O
3	O
;	O
3	O
)	O
(	O
q21	O
;	O
q26	O
)	O
.	O

In	O
UCSD-AML1	O
,	O
we	O
have	O
also	O
identified	O
fusion	O
transcripts	O
between	O
the	O
ecotropic	O
viral	O
insertion	O
site	O
I	O
(	O
EVI1	O
)	O
gene	O
in	O
3q26	O
and	O
GR6	O
and	O
between	O
EVI1	O
and	O
Ribophorin	O
I	O
that	O
maps	O
30	O
kb	O
telomeric	O
to	O
GR6	O
in	O
3q21	O
.	O

All	O
fusions	O
splice	O
the	O
5	O
'	O
ends	O
of	O
the	O
3q21	O
genes	O
into	O
exon	O
2	O
of	O
the	O
EVI1	O
gene	O
,	O
an	O
event	O
that	O
is	O
similar	O
to	O
the	O
normal	O
intergenic	O
splicing	O
of	O
MDS1-EVI1	O
and	O
to	O
those	O
previously	O
documented	O
in	O
leukemias	O
with	O
t	O
(	O
3	O
;	O
21	O
)	O
and	O
t	O
(	O
3	O
;	O
12	O
)	O
,	O
in	O
which	O
acute	O
myelogenous	O
leukemia	O
1-EVI1	O
fusions	O
and	O
ETV6-EVI1	O
fusions	O
,	O
respectively	O
,	O
occur	O
.	O

The	O
Ribophorin	O
I-EVI1	O
fusion	O
in	O
particular	O
may	O
be	O
a	O
common	O
occurrence	O
in	O
t	O
(	O
3	O
;	O
3	O
)	O
.	O

Alcohol-induced	O
regulation	O
of	O
nuclear	O
regulatory	O
factor-kappa	O
beta	O
in	O
human	O
monocytes	O
.	O

Acute	O
ethanol	O
exposure	O
has	O
the	O
capacity	O
to	O
modulate	O
immune	O
functions	O
,	O
particularly	O
,	O
to	O
down	O
regulate	O
monocyte	O
production	O
of	O
inflammatory	O
cytokines	O
.	O

However	O
,	O
the	O
intracellular	O
mechanisms	O
for	O
these	O
effects	O
of	O
ethanol	O
are	O
yet	O
to	O
be	O
understood	O
.	O

Considering	O
that	O
nuclear	O
regulatory	O
factor-kappa	O
beta	O
(	O
NF-kappa	O
B	O
)	O
/Rel	O
is	O
a	O
common	O
regulatory	O
element	O
of	O
the	O
promoter	O
region	O
of	O
the	O
inflammatory	O
cytokine	O
genes	O
,	O
herein	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
acute	O
ethanol	O
affects	O
NF-kappa	O
B	O
activation	O
in	O
human	O
monocytes	O
.	O

Adherence-isolated	O
monocytes	O
showed	O
constitutive	O
DNA	O
binding	O
activity	O
of	O
NF-kappa	O
B	O
.	O

A	O
clinically	O
relevant	O
dose	O
(	O
25	O
mM	O
)	O
of	O
acute	O
ethanol	O
treatment	O
in	O
vitro	O
increased	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
monocytes	O
with	O
a	O
preferential	O
induction	O
of	O
the	O
inhibitory	O
,	O
p50/p50	O
,	O
NF-kappa	O
B/Rel	O
homodimer	O
,	O
and	O
resulted	O
in	O
no	B-Negation
induction	I-Negation
of	I-Negation
the	I-Negation
p65/p50	I-Negation
heterodimer	I-Negation
.	O

In	O
contrast	O
,	O
lipopolysaccharide	O
stimulation	O
primarily	O
induced	O
the	O
p65/p50	O
heterodimer	O
that	O
has	O
been	O
shown	O
to	O
result	O
in	O
gene	O
activation	O
.	O

Thus	O
,	O
such	O
unique	O
activation	O
of	O
the	O
inhibitory	O
p50/p50	O
homodimer	O
by	O
acute	O
ethanol	O
treatment	O
may	O
result	O
in	O
inhibition	O
rather	O
than	O
activation	O
of	O
NF-kappa	O
B-regulated	O
inflammatory	O
cytokine	O
genes	O
.	O

Consequently	O
,	O
these	O
results	O
suggest	O
that	O
physiologically	O
relevant	O
concentrations	O
of	O
ethanol	O
may	O
affect	O
production	O
of	O
inflammatory	O
cytokines	O
,	O
such	O
as	O
tumor	O
necrosis	O
factor-alpha	O
,	O
interleukin-1	O
beta	O
,	O
and	O
interleukin-6	O
by	O
disrupting	O
NF-kappa	O
B	O
signaling	O
in	O
monocytes	O
.	O

Four	O
P-like	O
elements	O
are	O
required	O
for	O
optimal	O
transcription	O
of	O
the	O
mouse	O
IL-4	O
gene	O
:	O
involvement	O
of	O
a	O
distinct	O
set	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein-1	O
family	O
proteins	O
.	O

We	O
previously	O
identified	O
the	O
P	O
sequence	O
as	O
a	O
critical	O
regulatory	O
element	O
of	O
the	O
human	O
IL-4	O
promoter	O
.	O

In	O
the	O
mouse	O
IL-4	O
promoter	O
,	O
there	O
are	O
five	O
elements	O
homologous	O
to	O
the	O
human	O
P	O
sequence	O
designated	O
conserved	O
lymphokine	O
element	O
0	O
(	O
CLE0	O
)	O
,	O
P	O
,	O
P2	O
,	O
P3	O
and	O
P4	O
.	O

To	O
characterize	O
the	O
role	O
of	O
these	O
P-like	O
elements	O
and	O
their	O
binding	O
factors	O
in	O
the	O
native	O
promoter	O
,	O
we	O
did	O
transient	O
transfection	O
and	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSA	O
)	O
.	O

Transfection	O
of	O
EL-4	O
cells	O
with	O
the	O
IL-4	O
promoter-reporter	O
constructs	O
carrying	O
mutated	O
P-like	O
elements	O
showed	O
that	O
four	O
P-like	O
elements	O
,	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
but	O
not	B-Negation
P3	I-Negation
,	O
were	O
required	O
for	O
optimal	O
activation	O
of	O
the	O
IL-4	O
promoter	O
.	O

EMSA	O
showed	O
that	O
both	O
constitutive	O
and	O
inducible	O
complexes	O
bound	O
to	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
,	O
whereas	O
only	O
a	O
constitutive	O
complex	O
bound	O
to	O
P3	O
.	O

In	O
competition	O
and	O
antibody	O
supershift	O
assays	O
in	O
EMSA	O
,	O
complexes	O
formed	O
with	O
P	O
or	O
P2	O
proved	O
to	O
contain	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
family	O
proteins	O
as	O
major	O
components	O
.	O

Activator	O
protein	O
(	O
AP	O
)	O
-1	O
family	O
proteins	O
interacted	O
with	O
CLE0	O
,	O
P	O
,	O
P2	O
and	O
P4	O
.	O

NFAT/AP-1	O
complex	O
formed	O
only	O
with	O
P	O
and	O
P2	O
.	O

Cross-competition	O
assays	O
among	O
the	O
P-like	O
elements	O
revealed	O
element-specific	O
and	O
common	O
complexes	O
.	O

Six	O
tandem	O
repeats	O
of	O
the	O
P	O
element	O
linked	O
to	O
the	O
SV40	O
promoter	O
responded	O
to	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
while	O
that	O
of	O
other	O
elements	O
did	O
not	B-Negation
.	O

It	O
would	O
thus	O
appear	O
that	O
components	O
of	O
each	O
P-like	O
element-binding	O
complexes	O
are	O
not	O
identical	O
and	O
may	O
coordinately	O
contribute	O
to	O
transcriptional	O
activity	O
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
inhibit	O
apoptosis	O
is	O
dependent	O
on	O
stimulus	O
and	O
cell	O
type	O
.	O

The	O
development	O
of	O
resistance	O
to	O
host	O
defense	O
mechanisms	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
and	O
Fas-mediated	O
apoptosis	O
of	O
transformed	O
or	O
virus-infected	O
cells	O
may	O
be	O
a	O
critical	O
component	O
in	O
the	O
development	O
of	O
disease	O
.	O

To	O
find	O
genes	O
that	O
protect	O
cells	O
from	O
apoptosis	O
,	O
we	O
used	O
an	O
expression	O
cloning	O
strategy	O
and	O
identified	O
BHRF1	O
,	O
an	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
early-lytic-cycle	O
protein	O
with	O
distant	O
homology	O
to	O
Bcl-2	O
,	O
as	O
an	O
anti-apoptosis	O
protein	O
.	O

Expression	O
of	O
BHRF1	O
in	O
MCF-Fas	O
cells	O
conferred	O
nearly	O
complete	O
resistance	O
against	O
both	O
anti-Fas	O
antibody	O
and	O
TNF-mediated	O
apoptosis	O
.	O

In	O
addition	O
,	O
BHRF1	O
protected	O
these	O
cells	O
from	O
monocyte-mediated	O
killing	O
but	O
failed	B-Negation
to	I-Negation
protect	I-Negation
them	I-Negation
from	I-Negation
killing	I-Negation
mediated	I-Negation
by	I-Negation
lymphokine-activated	I-Negation
killer	I-Negation
cells	I-Negation
.	O

The	O
ability	O
of	O
BHRF1	O
to	O
protect	O
MCF-Fas	O
cells	O
from	O
apoptosis	O
induced	O
by	O
various	O
stimuli	O
was	O
identical	O
to	O
that	O
of	O
Bcl-2	O
and	O
Bcl-xL	O
.	O

Moreover	O
,	O
the	O
mechanism	O
of	O
action	O
of	O
BHRF1	O
resembled	O
that	O
of	O
Bcl-2	O
and	O
Bcl-xL	O
as	O
it	O
inhibited	O
TNF-	O
and	O
anti-Fas-induced	O
activation	O
of	O
two	O
enzymes	O
participating	O
in	O
the	O
apoptosis	O
pathway	O
,	O
cytosolic	O
phospholipase	O
A2	O
and	O
caspase-3/CPP32	O
,	O
but	O
did	O
not	B-Negation
interfere	I-Negation
with	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
NF-kappaB-like	I-Negation
transcription	I-Negation
factors	I-Negation
.	O

A	O
putative	O
function	O
of	O
BHRF1	O
in	O
EBV-infected	O
epithelial	O
cells	O
may	O
be	O
to	O
protect	O
virus-infected	O
cells	O
from	O
TNF-	O
and/or	O
anti-Fas-	O
induced	O
cell	O
death	O
in	O
order	O
to	O
maximize	O
virus	O
production	O
.	O

Surprisingly	O
,	O
expression	O
of	O
neither	B-Negation
BHRF1	I-Negation
nor	I-Negation
Bcl-2	I-Negation
in	I-Negation
a	I-Negation
B-cell	I-Negation
line	I-Negation
,	I-Negation
BJAB	I-Negation
,	I-Negation
protected	I-Negation
the	I-Negation
cells	I-Negation
from	I-Negation
anti-Fas-mediated	I-Negation
apoptosis	I-Negation
even	O
though	O
they	O
increased	O
the	O
survival	O
of	O
serum-starved	O
cells	O
.	O

Thus	O
,	O
the	O
protective	O
role	O
of	O
BHRF1	O
against	O
apoptosis	O
resembles	O
that	O
of	O
Bcl-2	O
in	O
being	O
cell	O
type	O
specific	O
and	O
dependent	O
on	O
the	O
apoptotic	O
stimulus	O
.	O

NF-AT	O
activation	O
induced	O
by	O
a	O
CAML-interacting	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
.	O

Activation	O
of	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcription	O
factor	O
(	O
NF-AT	O
)	O
is	O
a	O
key	O
event	O
underlying	O
lymphocyte	O
action	O
.	O

The	O
CAML	O
(	O
calcium-modulator	O
and	O
cyclophilin	O
ligand	O
)	O
protein	O
is	O
a	O
coinducer	O
of	O
NF-AT	O
activation	O
when	O
overexpressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

A	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
was	O
isolated	O
by	O
virtue	O
of	O
its	O
affinity	O
for	O
CAML	O
.	O

Cross-linking	O
of	O
this	O
lymphocyte-specific	O
protein	O
,	O
designated	O
TACI	O
(	O
transmembrane	O
activator	O
and	O
CAML-interactor	O
)	O
,	O
on	O
the	O
surface	O
of	O
transfected	O
Jurkat	O
cells	O
with	O
TACI-specific	O
antibodies	O
led	O
to	O
activation	O
of	O
the	O
transcription	O
factors	O
NF-AT	O
,	O
AP-1	O
,	O
and	O
NFkappaB	O
.	O

TACI-induced	O
activation	O
of	O
NF-AT	O
was	O
specifically	O
blocked	O
by	O
a	O
dominant-negative	O
CAML	O
mutant	O
,	O
thus	O
implicating	O
CAML	O
as	O
a	O
signaling	O
intermediate	O
.	O

The	O
DNA	O
binding	O
domain	O
of	O
the	O
A-MYB	O
transcription	O
factor	O
is	O
responsible	O
for	O
its	O
B	O
cell-specific	O
activity	O
and	O
binds	O
to	O
a	O
B	O
cell	O
110-kDa	O
nuclear	O
protein	O
.	O

Expression	O
studies	O
as	O
well	O
as	O
the	O
use	O
of	O
transgenic	O
animals	O
have	O
demonstrated	O
that	O
the	O
A-MYB	O
transcription	O
factor	O
plays	O
central	O
and	O
specific	O
role	O
in	O
the	O
regulation	O
of	O
mature	O
B	O
cell	O
proliferation	O
and/or	O
differentiation	O
.	O

Furthermore	O
,	O
it	O
is	O
highly	O
expressed	O
in	O
Burkitt	O
's	O
lymphoma	O
cells	O
and	O
may	O
participate	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
.	O

We	O
have	O
therefore	O
investigated	O
the	O
transcriptional	O
activity	O
of	O
A-MYB	O
and	O
its	O
regulation	O
in	O
several	O
human	O
lymphoid	O
cell	O
lines	O
using	O
co-transfection	O
assays	O
and	O
show	O
that	O
A-MYB	O
is	O
transcriptionally	O
active	O
in	O
all	O
the	O
B	O
cell	O
lines	O
studied	O
,	O
but	O
not	B-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
.	O

In	O
particular	O
the	O
best	O
responder	O
cell	O
line	O
was	O
the	O
Burkitt	O
's	O
cell	O
line	O
Namalwa	O
.	O

The	O
activity	O
of	O
A-MYB	O
in	O
B	O
and	O
not	B-Negation
T	I-Negation
cells	I-Negation
was	O
observed	O
when	O
either	O
an	O
artificial	O
construct	O
or	O
the	O
c-MYC	O
promoter	O
was	O
used	O
as	O
a	O
reporter	O
.	O

Furthermore	O
,	O
the	O
functional	O
domains	O
responsible	O
for	O
DNA	O
binding	O
,	O
transactivation	O
,	O
and	O
negative	O
regulation	O
,	O
previously	O
characterized	O
in	O
a	O
fibroblast	O
context	O
,	O
were	O
found	O
to	O
have	O
similar	O
activity	O
in	O
B	O
cells	O
.	O

The	O
region	O
of	O
A-MYB	O
responsible	O
for	O
the	O
B	O
cell	O
specific	O
activity	O
was	O
defined	O
to	O
be	O
the	O
N-terminal	O
218	O
amino	O
acids	O
containing	O
the	O
DNA	O
binding	O
domain	O
.	O

Finally	O
,	O
a	O
110-kDa	O
protein	O
has	O
been	O
identified	O
in	O
the	O
nuclei	O
of	O
all	O
the	O
B	O
,	O
but	O
not	B-Negation
T	I-Negation
,	O
cell	O
lines	O
that	O
specifically	O
binds	O
to	O
this	O
A-MYB	O
N-terminal	O
domain	O
.	O

We	O
hypothesize	O
that	O
this	O
110-kDa	O
protein	O
may	O
be	O
a	O
functionally	O
important	O
B	O
cell-specific	O
co-activator	O
of	O
A-MYB	O
.	O

Evidence	O
that	O
calcineurin	O
is	O
rate-limiting	O
for	O
primary	O
human	O
lymphocyte	O
activation	O
.	O

Cyclosporine	O
(	O
CsA	O
)	O
is	O
both	O
a	O
clinical	O
immunosuppressive	O
drug	O
and	O
a	O
probe	O
to	O
dissect	O
intracellular	O
signaling	O
pathways	O
.	O

In	O
vitro	O
,	O
CsA	O
inhibits	O
lymphocyte	O
gene	O
activation	O
by	O
inhibiting	O
the	O
phosphatase	O
activity	O
of	O
calcineurin	O
(	O
CN	O
)	O
.	O

In	O
clinical	O
use	O
,	O
CsA	O
treatment	O
inhibits	O
50-75	O
%	O
of	O
CN	O
activity	O
in	O
circulating	O
leukocytes	O
.	O

We	O
modeled	O
this	O
degree	O
of	O
CN	O
inhibition	O
in	O
primary	O
human	O
leukocytes	O
in	O
vitro	O
in	O
order	O
to	O
study	O
the	O
effect	O
of	O
partial	O
CN	O
inhibition	O
on	O
the	O
downstream	O
signaling	O
events	O
that	O
lead	O
to	O
gene	O
activation	O
.	O

In	O
CsA-treated	O
leukocytes	O
stimulated	O
by	O
calcium	O
ionophore	O
,	O
the	O
degree	O
of	O
reduction	O
in	O
CN	O
activity	O
was	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
inhibition	O
of	O
each	O
event	O
tested	O
:	O
dephosphorylation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
proteins	O
,	O
nuclear	O
DNA	O
binding	O
,	O
activation	O
of	O
a	O
transfected	O
reporter	O
gene	O
construct	O
,	O
IFN-gamma	O
and	O
IL-2	O
mRNA	O
accumulation	O
,	O
and	O
IFN-gamma	O
production	O
.	O

Furthermore	O
,	O
the	O
degree	O
of	O
CN	O
inhibition	O
was	O
reflected	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
proliferation	O
and	O
IFN-gamma	O
production	O
in	O
the	O
allogeneic	O
mixed	O
lymphocyte	O
cultures	O
.	O

These	O
data	O
support	O
the	O
conclusion	O
that	O
CN	O
activity	O
is	O
rate-limiting	O
for	O
the	O
activation	O
of	O
primary	O
human	O
T	O
lymphocytes	O
.	O

Thus	O
,	O
the	O
reduction	O
of	O
CN	O
activity	O
observed	O
in	O
CsA-treated	O
patients	O
is	O
accompanied	O
by	O
a	O
similar	O
degree	O
of	O
reduction	O
in	O
lymphocyte	O
gene	O
activation	O
,	O
and	O
accounts	O
for	O
the	O
immunosuppression	O
observed	O
.	O

Cooperation	O
of	O
binding	O
sites	O
for	O
STAT6	O
and	O
NF	O
kappa	O
B/rel	O
in	O
the	O
IL-4-induced	O
up-regulation	O
of	O
the	O
human	O
IgE	O
germline	O
promoter	O
.	O

Ig	O
heavy	O
chain	O
class	O
switching	O
is	O
directed	O
by	O
cytokines	O
inducing	O
transcription	O
from	O
unrearranged	O
CH	O
genes	O
.	O

Subsequently	O
,	O
such	O
primed	O
cells	O
can	O
undergo	O
switch	O
recombination	O
to	O
express	O
the	O
selected	O
new	O
isotype	O
.	O

In	O
the	O
case	O
of	O
IgE	O
class	O
switching	O
,	O
IL-4	O
activates	O
the	O
IgE	O
germline	O
promoter	O
by	O
inducing	O
the	O
interaction	O
of	O
the	O
transcription	O
factor	O
STAT6	O
(	O
IL-4STAT	O
)	O
with	O
a	O
responsive	O
DNA	O
element	O
in	O
the	O
proximal	O
region	O
of	O
the	O
promoter	O
.	O

This	O
study	O
describes	O
the	O
characterization	O
of	O
two	O
additional	O
cis-acting	O
elements	O
that	O
interact	O
with	O
members	O
of	O
the	O
NF	O
kappa	O
B/rel	O
transcription	O
factor	O
family	O
in	O
an	O
IL-4-independent	O
fashion	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
show	O
that	O
the	O
nucleoprotein	O
complex	O
formed	O
on	O
the	O
upstream	O
site	O
(	O
NF	O
kappa	O
B1	O
)	O
contains	O
the	O
classical	O
p50/p65	O
heterodimer	O
.	O

The	O
complex	O
on	O
the	O
proximal	O
site	O
(	O
NF	O
kappa	O
B2	O
)	O
appears	O
to	O
be	O
composed	O
of	O
p50	O
and	O
relB	O
.	O

IgE	O
germline	O
promoter	O
reporter	O
gene	O
constructs	O
carrying	O
point	O
mutations	O
in	O
the	O
NF	O
kappa	O
B2	O
site	O
were	O
largely	O
unresponsive	O
to	O
IL-4	O
stimulation	O
in	O
transient	O
transfection	O
experiments	O
,	O
while	O
plasmids	O
with	O
similar	O
mutations	O
in	O
the	O
NF	O
kappa	O
B1	O
site	O
responded	O
to	O
cytokine	O
stimulation	O
better	O
than	O
the	O
wild-type	O
promoter	O
.	O

The	O
NF	O
kappa	O
B2	O
effect	O
was	O
dependent	O
on	O
the	O
presence	O
of	O
the	O
STAT6	O
binding	O
site	O
,	O
demonstrating	O
that	O
the	O
NF	O
kappa	O
B2	O
motif	O
is	O
necessary	O
but	O
not	B-Negation
sufficient	I-Negation
for	I-Negation
mediating	I-Negation
cytokine	I-Negation
up-regulation	I-Negation
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
a	O
NF	O
kappa	O
B/rel	O
binding	O
site	O
and	O
the	O
STAT6	O
response	O
element	O
conferred	O
IL-4	O
inducibility	O
to	O
a	O
heterologous	O
minimal	O
promoter	O
,	O
while	O
the	O
individual	O
sites	O
had	O
no	B-Negation
effect	I-Negation
.	O

The	O
available	O
data	O
suggest	O
that	O
the	O
NF	O
kappa	O
B2	O
nucleoprotein	O
complex	O
may	O
cooperate	O
with	O
DNA-bound	O
STAT6	O
to	O
achieve	O
IL-4-dependent	O
activation	O
of	O
the	O
human	O
IgE	O
germline	O
gene	O
.	O

Dual	O
effects	O
of	O
LPS	O
antibodies	O
on	O
cellular	O
uptake	O
of	O
LPS	O
and	O
LPS-induced	O
proinflammatory	O
functions	O
.	O

Human	O
phagocytes	O
recognize	O
bacterial	O
LPS	O
(	O
endotoxin	O
)	O
through	O
membrane	O
CD14	O
(	O
mCD14	O
)	O
,	O
a	O
proinflammatory	O
LPS	O
receptor	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
anti-LPS	O
Abs	O
neutralize	O
endotoxin	O
by	O
blocking	O
cellular	O
uptake	O
through	O
mCD14	O
.	O

Ab-associated	O
changes	O
in	O
the	O
uptake	O
and	O
cellular	O
distribution	O
of	O
FITC-LPS	O
were	O
assessed	O
by	O
flow	O
cytometry	O
and	O
laser	O
scanning	O
confocal	O
microscopy	O
in	O
human	O
CD14-transfected	O
Chinese	O
hamster	O
ovary	O
fibroblasts	O
(	O
CHO-CD14	O
cells	O
)	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

LPS	O
core-	O
and	O
O-side	O
chain-specific	O
mAbs	O
inhibited	O
mCD14-mediated	O
LPS	O
uptake	O
by	O
both	O
cell	O
types	O
in	O
the	O
presence	O
of	O
serum	O
.	O

O-side	O
chain-specific	O
mAb	O
concurrently	O
enhanced	O
complement-dependent	O
LPS	O
uptake	O
by	O
monocytes	O
through	O
complement	O
receptor-1	O
(	O
CR1	O
)	O
and	O
uptake	O
by	O
CHO-CD14	O
cells	O
involving	O
another	O
heat-labile	O
serum	O
factor	O
(	O
s	O
)	O
and	O
cell-associated	O
recognition	O
molecule	O
(	O
s	O
)	O
.	O

Core-specific	O
mAb	O
inhibited	O
mCD14-mediated	O
uptake	O
of	O
homologous	O
and	O
heterologous	O
LPS	O
,	O
while	O
producing	O
less	O
concurrent	O
enhancement	O
of	O
non-mCD14-mediated	O
LPS	O
uptake	O
.	O

The	O
modulation	O
by	O
anti-LPS	O
mAbs	O
of	O
mCD14-mediated	O
LPS	O
uptake	O
was	O
associated	O
with	O
inhibition	O
of	O
LPS-induced	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
translocation	O
and	O
TNF-alpha	O
secretion	O
in	O
CHO-CD14	O
cells	O
and	O
monocytes	O
,	O
respectively	O
,	O
while	O
mAb	O
enhancement	O
of	O
non-mCD14-mediated	O
LPS	O
uptake	O
stimulated	O
these	O
activities	O
.	O

LPS-specific	O
Abs	O
thus	O
mediate	O
anti-inflammatory	O
and	O
proinflammatory	O
functions	O
,	O
respectively	O
,	O
by	O
preventing	O
target	O
cell	O
uptake	O
of	O
LPS	O
through	O
mCD14	O
and	O
augmenting	O
uptake	O
through	O
CR1	O
or	O
other	O
cell	O
receptors	O
.	O

Human	O
neutrophils	O
express	O
GH-N	O
gene	O
transcripts	O
and	O
the	O
pituitary	O
transcription	O
factor	O
Pit-1b	O
.	O

Since	O
GH	O
stimulates	O
the	O
development	O
and	O
function	O
of	O
granulocytes	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
GH	O
in	O
granulocyte	O
subsets	O
.	O

By	O
immunocytochemistry	O
,	O
25	O
	O
7	O
%	O
of	O
the	O
human	O
neutrophils	O
were	O
shown	O
to	O
express	O
immunoreactive	O
GH	O
,	O
whereas	O
eosinophils	O
were	O
negative	O
.	O

Reversed	O
transcription	O
(	O
RT	O
)	O
-PCR	O
analysis	O
demonstrated	O
GH	O
mRNA	O
in	O
neutrophils	O
.	O

Restriction	O
analysis	O
revealed	O
that	O
neutrophils	O
express	O
the	O
GH-N	O
gene	O
but	O
not	B-Negation
the	I-Negation
GH-V	I-Negation
gene	I-Negation
.	O

Furthermore	O
,	O
we	O
demonstrated	O
by	O
western	O
blot	O
analysis	O
that	O
neutrophils	O
express	O
an	O
alternatively	O
spliced	O
variant	O
of	O
the	O
pituitary	O
transcription	O
factor	O
Pit-1	O
,	O
designated	O
Pit-1b	O
.	O

Interleukin-7	O
upregulates	O
the	O
interleukin-2-gene	O
expression	O
in	O
activated	O
human	O
T	O
lymphocytes	O
at	O
the	O
transcriptional	O
level	O
by	O
enhancing	O
the	O
DNA	O
binding	O
activities	O
of	O
both	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
activator	O
protein-1	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
studied	O
the	O
role	O
of	O
the	O
stromal-derived	O
cytokine	O
interleukin-7	O
(	O
IL-7	O
)	O
in	O
the	O
IL-2-gene	O
regulation	O
in	O
activated	O
T	O
lymphocytes	O
.	O

Production	O
of	O
IL-2	O
requires	O
the	O
formation	O
of	O
transcription	O
factors	O
involved	O
in	O
the	O
IL-2-gene	O
regulation	O
.	O

T-cell	O
receptor	O
(	O
TCR	O
)	O
/CD3	O
engagement	O
results	O
in	O
the	O
activation	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
,	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
,	O
whereas	O
the	O
CD28	O
responsive	O
complex	O
(	O
CD28RC	O
)	O
is	O
activated	O
in	O
response	O
to	O
the	O
CD28	O
signal	O
.	O

Costimulation	O
of	O
phytohemagglutinin/anti-CD28	O
activated	O
T	O
lymphocytes	O
with	O
IL-7	O
induces	O
a	O
fivefold	O
enhanced	O
IL-2-mRNA	O
accumulation	O
and	O
a	O
2.5-fold	O
enhanced	O
protein	O
secretion	O
.	O

The	O
IL-2-gene	O
transcription	O
rate	O
is	O
increased	O
3.4-fold	O
,	O
indicating	O
that	O
the	O
effect	O
of	O
IL-7	O
is	O
in	O
part	O
mediated	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
molecular	O
mechanisms	O
underlying	O
the	O
IL-7	O
effect	O
involve	O
the	O
upregulation	O
of	O
the	O
DNA	O
binding	O
activity	O
of	O
NFAT	O
(	O
60	O
%	O
)	O
and	O
AP-1	O
(	O
120	O
%	O
)	O
,	O
without	B-Negation
affecting	I-Negation
the	I-Negation
activities	I-Negation
of	I-Negation
NFkappaB	I-Negation
and	I-Negation
CD28RC	I-Negation
,	O
which	O
was	O
confirmed	O
by	O
transfection	O
assays	O
.	O

We	O
also	O
show	O
that	O
the	O
IL-7-induced	O
enhancement	O
of	O
the	O
AP-1-DNA	O
binding	O
activity	O
is	O
not	B-Negation
cyclosporin	I-Negation
A-sensitive	I-Negation
.	O

Since	O
AP-1	O
is	O
part	O
of	O
the	O
NFAT	O
complex	O
,	O
we	O
conclude	O
that	O
the	O
IL-7-signaling	O
pathway	O
is	O
involved	O
in	O
the	O
activation	O
of	O
the	O
fos	O
and	O
jun	O
proteins	O
of	O
which	O
AP-1	O
consists	O
.	O

Analysis	O
of	O
myeloid-associated	O
genes	O
in	O
human	O
hematopoietic	O
progenitor	O
cells	O
.	O

The	O
distribution	O
of	O
myeloid	O
lineage-associated	O
cytokine	O
receptors	O
and	O
lysosomal	O
proteins	O
was	O
analyzed	O
in	O
human	O
CD34+	O
cord	O
blood	O
cell	O
(	O
CB	O
)	O
subsets	O
at	O
different	O
stages	O
of	O
myeloid	O
commitment	O
by	O
reverse-transcriptase	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

The	O
highly	O
specific	O
granulomonocyte-associated	O
lysosomal	O
proteins	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
lysozyme	O
(	O
LZ	O
)	O
,	O
as	O
well	O
as	O
the	O
transcription	O
factor	O
PU.1	O
,	O
were	O
already	O
detectable	O
in	O
the	O
most	O
immature	O
CD34+Thy-1+	O
subset	O
.	O

Messenger	O
RNA	O
(	O
mRNA	O
)	O
levels	O
for	O
the	O
granulocyte-colony	O
stimulating	O
factor	O
(	O
G-CSF	O
)	O
receptor	O
,	O
granulocyte-macrophage	O
(	O
GM	O
)	O
-CSF	O
receptor	O
alpha	O
subunit	O
and	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
receptors	O
I	O
(	O
p55	O
)	O
and	O
II	O
(	O
p75	O
)	O
were	O
also	O
detected	O
in	O
this	O
subset	O
in	O
addition	O
to	O
c-kit	O
and	O
flt-3	O
,	O
receptors	O
known	O
to	O
be	O
expressed	O
on	O
progenitor	O
cells	O
.	O

By	O
contrast	O
,	O
the	B-Negation
monocyte-macrophage	I-Negation
colony	I-Negation
stimulating	I-Negation
factor	I-Negation
(	I-Negation
M-CSF	I-Negation
)	I-Negation
receptor	I-Negation
was	I-Negation
largely	I-Negation
absent	I-Negation
at	I-Negation
this	I-Negation
stage	I-Negation
and	I-Negation
in	I-Negation
the	I-Negation
CD34+Thy-1-CD45RA-	I-Negation
subsets	I-Negation
.	O

The	O
M-CSF	O
receptor	O
was	O
first	O
detectable	O
in	O
the	O
myeloid-committed	O
CD34+Thy-l-CD45RA+	O
subset	O
.	O

All	O
other	O
molecules	O
studied	O
were	O
found	O
to	O
be	O
expressed	O
at	O
this	O
stage	O
of	O
differentiation	O
.	O

Different	O
cocktails	O
of	O
the	O
identified	O
ligands	O
were	O
added	O
to	O
sorted	O
CD34+Thy-1+	O
single	O
cells	O
.	O

Low	O
proliferative	O
capacity	O
was	O
observed	O
after	O
1	O
week	O
in	O
culture	O
in	O
the	O
presence	O
of	O
stem	O
cell	O
factor	O
(	O
SCF	O
)	O
+	O
Flt-3	O
ligand	O
(	O
FL	O
)	O
+	O
G-CSF	O
.	O

Addition	O
of	O
GM-CSF	O
to	O
this	O
basic	O
cocktail	O
consistently	O
increased	O
the	O
clonogenic	O
capacity	O
of	O
single	O
CD34+Thy-1+	O
cells	O
,	O
and	O
this	O
effect	O
was	O
further	O
enhanced	O
(	O
up	O
to	O
72.3	O
	O
4.3	O
%	O
on	O
day	O
7	O
)	O
by	O
the	O
inclusion	O
of	O
TNF-alpha	O
.	O

In	O
conclusion	O
,	O
the	O
presence	O
of	O
myeloid-associated	O
growth	O
factor	O
receptor	O
transcripts	O
in	O
CD34+	O
CB	O
subsets	O
does	O
not	B-Negation
discriminate	I-Negation
the	I-Negation
various	I-Negation
stages	I-Negation
of	I-Negation
differentiation	I-Negation
,	I-Negation
with	I-Negation
the	I-Negation
exception	I-Negation
of	I-Negation
the	I-Negation
M-CSF	I-Negation
receptor	I-Negation
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
TNF-alpha	O
is	O
a	O
potent	O
costimulatory	O
factor	O
of	O
the	O
very	O
immature	O
CD34+Thy-1+	O
CB	O
subset	O
.	O

Monochloramine	O
inhibits	O
phorbol	O
ester-inducible	O
neutrophil	O
respiratory	O
burst	O
activation	O
and	O
T	O
cell	O
interleukin-2	O
receptor	O
expression	O
by	O
inhibiting	O
inducible	O
protein	O
kinase	O
C	O
activity	O
.	O

Monochloramine	O
derivatives	O
are	O
long	O
lived	O
physiological	O
oxidants	O
produced	O
by	O
neutrophils	O
during	O
the	O
respiratory	O
burst	O
.	O

The	O
effects	O
of	O
chemically	O
prepared	O
monochloramine	O
(	O
NH2Cl	O
)	O
on	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
PKC-mediated	O
cellular	O
responses	O
were	O
studied	O
in	O
elicited	O
rat	O
peritoneal	O
neutrophils	O
and	O
human	O
Jurkat	O
T	O
cells	O
.	O

Neutrophils	O
pretreated	O
with	O
NH2Cl	O
(	O
30-50	O
microM	O
)	O
showed	O
a	O
marked	O
decrease	O
in	O
the	O
respiratory	O
burst	O
activity	O
induced	O
by	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
,	O
which	O
is	O
a	O
potent	O
PKC	O
activator	O
.	O

These	O
cells	O
,	O
however	O
,	O
were	O
viable	O
and	O
showed	O
a	O
complete	O
respiratory	O
burst	O
upon	O
arachidonic	O
acid	O
stimulation	O
,	O
which	O
induces	O
the	O
respiratory	O
burst	O
by	O
a	O
PKC-independent	O
mechanism	O
.	O

The	O
NH2Cl-treated	O
neutrophils	O
showed	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
PMA-induced	O
phosphorylation	O
of	O
a	O
47-kDa	O
protein	O
,	O
which	O
corresponds	O
to	O
the	O
cytosolic	O
factor	O
of	O
NADPH	O
oxidase	O
,	O
p47	O
(	O
phox	O
)	O
.	O

Jurkat	O
T	O
cells	O
pretreated	O
with	O
NH2Cl	O
(	O
20-70	O
microM	O
)	O
showed	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
the	O
interleukin-2	O
receptor	O
alpha	O
chain	O
following	O
PMA	O
stimulation	O
.	O

This	O
was	O
also	O
accompanied	O
by	O
a	O
decrease	O
in	O
both	O
PKC	O
activity	O
and	O
nuclear	O
transcription	O
factor-kappaB	O
activation	O
,	O
also	O
without	B-Negation
loss	I-Negation
of	I-Negation
cell	I-Negation
viability	I-Negation
.	O

These	O
results	O
show	O
that	O
NH2Cl	O
inhibits	O
PKC-mediated	O
cellular	O
responses	O
through	O
inhibition	O
of	O
the	O
inducible	O
PKC	O
activity	O
.	O

HIV-1	O
Vpr	O
suppresses	O
immune	O
activation	O
and	O
apoptosis	O
through	O
regulation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
[	O
see	O
comments	O
]	O

The	O
HIV-1	O
accessory	O
gene	O
product	O
Vpr	O
can	O
influence	O
viral	O
pathogenesis	O
by	O
affecting	O
viral	O
replication	O
as	O
well	O
as	O
host	O
cell	O
transcription	O
and	O
proliferation	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
Vpr	O
on	O
host	O
cell	O
activation	O
and	O
confirm	O
that	O
it	O
influences	O
cellular	O
proliferation	O
.	O

However	O
,	O
we	O
have	O
also	O
found	O
that	O
Vpr	O
modulates	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-triggered	O
apoptosis	O
in	O
a	O
manner	O
similar	O
to	O
that	O
of	O
glucocorticoids	O
.	O

In	O
the	O
absence	B-Negation
of	I-Negation
TCR-mediated	I-Negation
activation	I-Negation
,	O
Vpr	O
induces	O
apoptosis	O
whereas	O
in	O
its	O
presence	O
,	O
Vpr	O
interrupts	O
the	O
expected	O
induction	O
of	O
apoptosis	O
.	O

This	O
regulation	O
of	O
apoptosis	O
is	O
linked	O
to	O
Vpr	O
suppression	O
of	O
NF-kappa	O
B	O
activity	O
via	O
the	O
induction	O
of	O
I	O
kappa	O
B	O
,	O
an	O
inhibitor	O
of	O
NF-kappa	O
B	O
.	O

Further	O
,	O
Vpr	O
suppresses	O
expression	O
of	O
IL-2	O
,	O
IL-10	O
,	O
IL-12	O
,	O
TNF	O
alpha	O
and	O
IL-4	O
,	O
all	O
of	O
which	O
are	O
NF-kappa	O
B-dependent	O
.	O

The	O
effects	O
of	O
Vpr	O
could	O
be	O
reversed	O
by	O
RU486	O
.	O

Our	O
finding	O
that	O
Vpr	O
can	O
regulate	O
NF-kappa	O
B	O
supports	O
the	O
hypothesis	O
that	O
some	O
aspects	O
of	O
viral	O
pathogenesis	O
are	O
the	O
consequence	O
of	O
cell	O
dysregulation	O
by	O
Vpr	O
.	O

The	O
tax	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
mediates	O
the	O
transactivation	O
of	O
the	O
c-sis/platelet-derived	O
growth	O
factor-B	O
promoter	O
through	O
interactions	O
with	O
the	O
zinc	O
finger	O
transcription	O
factors	O
Sp1	O
and	O
NGFI-A/Egr-1	O
.	O

Transcriptional	O
up-regulation	O
of	O
the	O
c-sis/platelet-derived	O
growth	O
factor-B	O
(	O
PDGF-B	O
)	O
proto-oncogene	O
by	O
the	O
Tax	O
protein	O
of	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
has	O
been	O
implicated	O
as	O
one	O
possible	O
mechanism	O
of	O
cellular	O
transformation	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
.	O

In	O
previous	O
work	O
,	O
we	O
identified	O
an	O
essential	O
site	O
in	O
the	O
c-sis/PDGF-B	O
promoter	O
,	O
Tax-responsive	O
element	O
1	O
(	O
TRE1	O
)	O
,	O
necessary	O
for	O
transactivation	O
by	O
Tax	O
.	O

We	O
also	O
identified	O
Sp1	O
,	O
Sp3	O
,	O
and	O
NGFI-A/Egr-1	O
as	O
the	O
primary	O
nuclear	O
transcription	O
factors	O
binding	O
to	O
TRE1	O
which	O
mediate	O
Tax	O
responsiveness	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
(	O
s	O
)	O
whereby	O
Tax	O
transactivates	O
the	O
c-sis/PDGF-B	O
proto-oncogene	O
.	O

In	O
vitro	O
transcription	O
assays	O
showed	O
that	O
Tax	O
was	O
able	O
to	O
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
a	O
template	O
containing	O
the	O
-257	O
to	O
+74	O
region	O
of	O
the	O
c-sis/PDGF-B	O
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
analysis	O
showed	O
that	O
Tax	O
increased	O
the	O
DNA	O
binding	O
activity	O
of	O
both	O
Sp1	O
and	O
NGFI-A/Egr-1	O
using	O
a	O
TRE1	O
probe	O
.	O

Analysis	O
of	O
Tax	O
mutants	O
showed	O
that	O
two	B-Negation
mutants	I-Negation
,	I-Negation
IEXC29S	I-Negation
and	I-Negation
IEXL320G	I-Negation
,	I-Negation
were	I-Negation
unable	I-Negation
to	I-Negation
significantly	I-Negation
transactivate	I-Negation
the	I-Negation
c-sis/PDGF-B	I-Negation
promoter	I-Negation
.	O

Finally	O
,	O
co-immunoprecipitation	O
analysis	O
revealed	O
that	O
Tax	O
is	O
able	O
to	O
stably	O
bind	O
to	O
both	O
Sp1	O
and	O
NGFI-A/Egr-1	O
.	O

Interestingly	O
,	O
co-immunoprecipitation	O
analysis	O
also	O
revealed	O
that	O
Tax	B-Negation
mutant	I-Negation
IEXC29S	I-Negation
is	I-Negation
unable	I-Negation
to	I-Negation
interact	I-Negation
with	I-Negation
NGFI-A/Egr-1	I-Negation
,	O
whereas	O
Tax	O
mutant	O
IEXL320G	O
is	O
able	O
to	O
interact	O
with	O
NGFI-A/Egr-1	O
.	O

Induction	O
of	O
endothelial	O
cell	O
surface	O
adhesion	O
molecules	O
by	O
tumor	O
necrosis	O
factor	O
is	O
blocked	O
by	O
protein	O
tyrosine	O
phosphatase	O
inhibitors	O
:	O
role	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

Recent	O
studies	O
from	O
our	O
laboratory	O
have	O
indicated	O
that	O
protein	O
tyrosine	O
phosphatase	O
(	O
PTPase	O
)	O
inhibitors	O
can	O
down-modulate	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-mediated	O
activation	O
of	O
the	O
nuclear	O
transcription	O
factor	O
NF-kappa	O
B	O
in	O
ML-1a	O
,	O
a	O
monocytic	O
cell	O
line	O
(	O
Singh	O
and	O
Aggarwal	O
,	O
J.	O
Biol.	O
Chem.	O
1995	O
:	O
270	O
:	O
10631	O
)	O
.	O

Since	O
TNF	O
is	O
one	O
of	O
the	O
major	O
inducers	O
of	O
various	O
adhesion	O
molecules	O
in	O
human	O
endothelial	O
cells	O
and	O
their	O
expression	O
is	O
known	O
to	O
require	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
we	O
examined	O
the	O
effect	O
of	O
PTPase	O
inhibitors	O
on	O
the	O
TNF-mediated	O
induction	O
of	O
intracellular	O
adhesion	O
molecule	O
(	O
ICAM	O
)	O
-1	O
,	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-1	O
and	O
endothelial	O
leukocyte	O
adhesion	O
molecule	O
(	O
ELAM	O
)	O
-1	O
.	O

Like	O
ML-1a	O
,	O
human	O
dermal	O
microvessel	O
endothelial	O
cells	O
(	O
MVEC	O
)	O
treated	O
with	O
TNF	O
rapidly	O
activated	O
(	O
within	O
30	O
min	O
)	O
NF-kappa	O
B	O
;	O
this	O
effect	O
was	O
completely	O
abolished	O
by	O
co-treatment	O
with	O
phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
a	O
specific	O
inhibitor	O
of	O
PTPase	O
.	O

The	O
induction	O
of	O
ICAM-1	O
,	O
VCAM-1	O
,	O
and	O
ELAM-1	O
by	O
TNF	O
in	O
MVEC	O
occurred	O
within	O
6	O
h	O
and	O
was	O
also	O
completely	O
down-regulated	O
by	O
PAO	O
in	O
a	O
dose-dependent	O
manner	O
.	O

PAO	O
was	O
found	O
to	O
be	O
effective	O
even	O
when	O
added	O
3	O
h	O
after	O
TNF	O
,	O
suggesting	O
a	O
rapid	O
mode	O
of	O
action	O
of	O
this	O
inhibitor	O
.	O

Besides	O
PAO	O
,	O
other	O
inhibitors	O
of	O
PTPase	O
,	O
including	O
pervanadate	O
and	O
diamide	O
,	O
also	O
blocked	O
TNF-dependent	O
NF-kappa	O
B	O
activation	O
and	O
induction	O
of	O
all	O
the	O
three	O
adhesion	O
proteins	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
the	O
attachment	O
of	O
monocytes	O
to	O
MVEC	O
was	O
also	O
blocked	O
by	O
the	O
PTPase	O
inhibitors	O
.	O

Thus	O
,	O
overall	O
,	O
our	O
results	O
demonstrate	O
that	O
a	O
PTPase	O
is	O
involved	O
either	O
directly	O
or	O
indirectly	O
in	O
the	O
pathway	O
leading	O
to	O
the	O
induction	O
of	O
endothelial	O
cell	O
adhesion	O
molecules	O
by	O
TNF	O
.	O

Because	O
of	O
their	O
role	O
in	O
cell	O
adhesion	O
,	O
PTPase	O
may	O
provide	O
a	O
novel	O
target	O
of	O
drug	O
development	O
for	O
treatment	O
of	O
inflammation	O
,	O
atherogenesis	O
,	O
and	O
tumor	O
metastasis	O
.	O

The	O
spatial	O
distribution	O
of	O
human	O
immunoglobulin	O
genes	O
within	O
the	O
nucleus	O
:	O
evidence	O
for	O
gene	O
topography	O
independent	O
of	O
cell	O
type	O
and	O
transcriptional	O
activity	O
.	O

The	O
three-dimensional	O
positioning	O
of	O
immunoglobulin	O
(	O
Ig	O
)	O
genes	O
within	O
the	O
nucleus	O
of	O
human	O
cells	O
was	O
investigated	O
using	O
in	O
situ	O
hybridization	O
and	O
confocal	O
microscopy	O
.	O

The	O
visualization	O
of	O
heavy	O
and	O
light	O
chain	O
genes	O
in	O
B-lymphoid	O
cells	O
showed	O
that	O
the	O
three	O
Ig	O
genes	O
are	O
differentially	O
and	O
nonrandomly	O
distributed	O
in	O
different	O
nuclear	O
subvolumes	O
:	O
the	O
kappa	O
genes	O
were	O
found	O
to	O
be	O
preferentially	O
confined	O
to	O
an	O
outer	O
nuclear	O
volume	O
,	O
whereas	O
the	O
gamma	O
and	O
lambda	O
genes	O
consistently	O
occupied	O
more	O
central	O
positions	O
within	O
the	O
nucleus	O
,	O
the	O
lambda	O
genes	O
being	O
more	O
interior	O
when	O
compared	O
with	O
the	O
gamma	O
genes	O
.	O

The	O
data	O
further	O
show	O
that	O
these	O
overall	O
topographical	O
distributions	O
are	O
independent	O
of	O
gene	O
transcriptional	O
activity	O
and	O
are	O
conserved	O
in	O
different	O
cell	O
types	O
.	O

Although	O
subtle	O
gene	O
movements	O
within	O
those	O
defined	O
topographical	O
regions	O
can	O
not	O
be	O
excluded	O
by	O
this	O
study	O
,	O
the	O
results	O
indicate	O
that	O
tissue	O
specificity	O
of	O
gene	O
expression	O
is	O
not	O
accompanied	O
by	O
drastic	O
changes	O
in	O
gene	O
nuclear	O
topography	O
,	O
rather	O
suggesting	O
that	O
gene	O
organization	O
within	O
the	O
nucleus	O
may	O
be	O
primarily	O
dependent	O
on	O
structural	O
constraints	O
imposed	O
on	O
the	O
respective	O
chromosomes	O
.	O

Transcriptional	O
activation	O
of	O
the	O
vascular	O
cell	O
adhesion	O
molecule-1	O
gene	O
in	O
T	O
lymphocytes	O
expressing	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
protein	O
.	O

Recruitment	O
and	O
extravasation	O
of	O
T	O
cells	O
through	O
the	O
blood-brain	O
barrier	O
are	O
favored	O
by	O
adhesion	O
molecule-mediated	O
interactions	O
of	O
circulating	O
T	O
cells	O
with	O
endothelial	O
cells	O
.	O

Since	O
a	O
common	O
pathological	O
finding	O
in	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
-associated	O
diseases	O
is	O
the	O
infiltration	O
of	O
HTLV-1-infected	O
T	O
lymphocytes	O
into	O
various	O
organs	O
,	O
we	O
have	O
looked	O
for	O
the	O
profile	O
of	O
adhesion	O
molecules	O
expressed	O
by	O
HTLV-1-transformed	O
T	O
cells	O
.	O

Flow	O
cytometry	O
analysis	O
indicated	O
that	O
these	O
cells	O
were	O
expressing	O
high	O
levels	O
of	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
(	O
VCAM-1	O
[	O
CD106	O
]	O
)	O
,	O
a	O
110-kDa	O
member	O
of	O
the	O
immunoglobulin	O
gene	O
superfamily	O
,	O
first	O
identified	O
on	O
endothelial	O
cells	O
stimulated	O
with	O
inflammatory	O
cytokines	O
.	O

This	O
adhesion	O
molecule	O
was	O
also	O
expressed	O
by	O
T	O
cells	O
obtained	O
from	O
one	O
patient	O
with	O
HTLV-1-associated	O
myelopathy/tropical	O
spastic	O
paraparesis	O
but	O
not	B-Negation
by	I-Negation
activated	I-Negation
T	I-Negation
cells	I-Negation
isolated	I-Negation
from	I-Negation
one	I-Negation
normal	I-Negation
blood	I-Negation
donor	I-Negation
.	O

The	O
role	O
of	O
the	O
viral	O
trans-activator	O
Tax	O
protein	O
in	O
the	O
induction	O
of	O
VCAM-1	O
was	O
first	O
indicated	O
by	O
the	O
detection	O
of	O
this	O
adhesion	O
molecule	O
on	O
Jurkat	O
T-cell	O
clones	O
stably	O
expressing	O
the	O
tax	O
gene	O
.	O

The	O
effect	O
of	O
Tax	O
on	O
VCAM-1	O
gene	O
transcription	O
was	O
next	O
confirmed	O
in	O
JPX-9	O
cells	O
,	O
a	O
subclone	O
of	O
Jurkat	O
cells	O
,	O
carrying	O
the	O
tax	O
sequences	O
under	O
the	O
control	O
of	O
an	O
inducible	O
promoter	O
.	O

Furthermore	O
,	O
deletion	O
and	O
mutation	O
analyses	O
of	O
the	O
VCAM-1	O
promoter	O
performed	O
with	O
chloramphenicol	O
acetyltransferase	O
constructs	O
revealed	O
that	O
Tax	O
was	O
trans	O
activating	O
the	O
VCAM-1	O
promoter	O
via	O
two	O
NF-kappaB	O
sites	O
present	O
at	O
bp	O
-72	O
and	O
-57	O
in	O
the	O
VCAM-1	O
gene	O
promoter	O
,	O
with	O
both	O
of	O
them	O
being	O
required	O
for	O
the	O
Tax-induced	O
expression	O
of	O
this	O
adhesion	O
molecule	O
.	O

Finally	O
,	O
gel	O
mobility	O
shift	O
assays	O
demonstrated	O
the	O
nuclear	O
translocation	O
of	O
proteins	O
specifically	O
bound	O
to	O
these	O
two	O
NF-kappaB	O
motifs	O
,	O
confirming	O
that	O
VCAM-1	O
was	O
induced	O
on	O
Tax-expressing	O
cells	O
in	O
a	O
kappaB-dependent	O
manner	O
.	O

Collectively	O
,	O
these	O
results	O
therefore	O
suggest	O
that	O
the	O
exclusive	O
Tax-induced	O
expression	O
of	O
VCAM-1	O
on	O
T	O
cells	O
may	O
represent	O
a	O
pivotal	O
event	O
in	O
the	O
progression	O
of	O
HTLV-1-associated	O
diseases	O
.	O

Blockade	O
of	O
T-cell	O
activation	O
by	O
dithiocarbamates	O
involves	O
novel	O
mechanisms	O
of	O
inhibition	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

Dithiocarbamates	O
(	O
DTCs	O
)	O
have	O
recently	O
been	O
reported	O
as	O
powerful	O
inhibitors	O
of	O
NF-kappaB	O
activation	O
in	O
a	O
number	O
of	O
cell	O
types	O
.	O

Given	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
the	O
regulation	O
of	O
gene	O
expression	O
in	O
the	O
inflammatory	O
response	O
,	O
NF-kappaB	O
inhibitors	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
drugs	O
for	O
inflammatory	O
diseases	O
.	O

We	O
show	O
here	O
that	O
DTCs	O
inhibited	O
both	O
interleukin	O
2	O
(	O
IL-2	O
)	O
synthesis	O
and	O
membrane	O
expression	O
of	O
antigens	O
which	O
are	O
induced	O
during	O
T-cell	O
activation	O
.	O

This	O
inhibition	O
,	O
which	O
occurred	O
with	O
a	O
parallel	O
activation	O
of	O
c-Jun	O
transactivating	O
functions	O
and	O
expression	O
,	O
was	O
reflected	O
by	O
transfection	O
experiments	O
at	O
the	O
IL-2	O
promoter	O
level	O
,	O
and	O
involved	O
not	O
only	O
the	O
inhibition	O
of	O
NF-kappaB-driven	O
reporter	O
activation	O
but	O
also	O
that	O
of	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
.	O

Accordingly	O
,	O
electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
indicated	O
that	O
pyrrolidine	O
DTC	O
(	O
PDTC	O
)	O
prevented	O
NF-kappaB	O
,	O
and	O
NFAT	O
DNA-binding	O
activity	O
in	O
T	O
cells	O
stimulated	O
with	O
either	O
phorbol	O
myristate	O
acetate	O
plus	O
ionophore	O
or	O
antibodies	O
against	O
the	O
CD3-T-cell	O
receptor	O
complex	O
and	O
simultaneously	O
activated	O
the	O
binding	O
of	O
AP-1	O
.	O

Furthermore	O
,	O
PDTC	O
differentially	O
targeted	O
both	O
NFATp	O
and	O
NFATc	O
family	O
members	O
,	O
inhibiting	O
the	O
transactivation	O
functions	O
of	O
NFATp	O
and	O
mRNA	O
induction	O
of	O
NFATc	O
.	O

Strikingly	O
,	O
Western	O
blotting	O
and	O
immunocytochemical	O
experiments	O
indicated	O
that	O
PDTC	O
promoted	O
a	O
transient	O
and	O
rapid	O
shuttling	O
of	O
NFATp	O
and	O
NFATc	O
,	O
leading	O
to	O
their	O
accelerated	O
export	O
from	O
the	O
nucleus	O
of	O
activated	O
T	O
cells	O
.	O

We	O
propose	O
that	O
the	O
activation	O
of	O
an	O
NFAT	O
kinase	O
by	O
PDTC	O
could	O
be	O
responsible	O
for	O
the	O
rapid	O
shuttling	O
of	O
the	O
NFAT	O
,	O
therefore	O
transiently	O
converting	O
the	O
sustained	O
transactivation	O
of	O
this	O
transcription	O
factor	O
that	O
occurs	O
during	O
lymphocyte	O
activation	O
,	O
and	O
show	O
that	O
c-Jun	O
NH2-terminal	O
kinase	O
(	O
JNK	O
)	O
can	O
act	O
by	O
directly	O
phosphorylating	O
NFATp	O
.	O

In	O
addition	O
,	O
the	O
combined	O
inhibitory	O
effects	O
on	O
NFAT	O
and	O
NF-KB	O
support	O
a	O
potential	O
use	O
of	O
DTCs	O
as	O
immunosuppressants	O
.	O

Suppression	O
of	O
nuclear	O
factor	O
kappa	O
B	O
and	O
CD18-mediated	O
leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
by	O
dexamethasone	O
.	O

PURPOSE	O
:	O
To	O
demonstrate	O
that	O
leukocyte	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
is	O
mediated	O
by	O
the	O
CD18	O
antigen	O
,	O
and	O
to	O
determine	O
whether	O
dexamethasone	O
directly	O
suppresses	O
adhesion	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NFkappaB	O
)	O
.	O

METHODS	O
:	O
Cultured	O
bovine	O
corneal	O
endothelium	O
was	O
stimulated	O
for	O
6	O
hours	O
by	O
40	O
micron/ml	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
.	O

Dexamethasone	O
was	O
added	O
1	O
hour	O
before	O
TNFalpha	O
stimulation	O
in	O
the	O
dexamethasone	O
group	O
.	O

After	O
stimulation	O
,	O
neutrophils	O
separated	O
from	O
a	O
healthy	O
human	O
volunteer	O
were	O
added	O
with	O
or	O
without	B-Negation
anti-CD18	I-Negation
antibody	I-Negation
.	O

The	O
culture	O
plate	O
was	O
settled	O
for	O
15	O
minutes	O
at	O
37	O
degrees	O
C	O
,	O
and	O
then	O
neutrophils	O
were	O
activated	O
by	O
N-formyl-methionyl-leucyl-phenylalanine	O
for	O
5	O
minutes	O
.	O

Nonadherent	O
neutrophils	O
were	O
removed	O
by	O
sealing	O
and	O
inverting	O
the	O
culture	O
well	O
.	O

The	O
intracellular	O
localization	O
of	O
NFkappaB	O
after	O
TNFalpha	O
simulation	O
was	O
determined	O
by	O
confocal	O
immunocytochemistry	O
using	O
an	O
anti-p65	O
antibody	O
.	O

RESULTS	O
:	O
Neutrophil	O
adhesion	O
to	O
cultured	O
corneal	O
endothelial	O
cells	O
increased	O
significantly	O
on	O
exposure	O
to	O
TNFalpha	O
(	O
451.4+/-45.4	O
cells/mm2	O
,	O
n	O
=	O
16	O
)	O
compared	O
to	O
control	O
(	O
156.7+/-27.3	O
cells/mm2	O
,	O
n	O
=	O
16	O
,	O
P	O
<	O
0.01	O
)	O
.	O

This	O
increased	O
adhesion	O
was	O
suppressed	O
by	O
the	O
addition	O
of	O
anti-CD18	O
antibody	O
(	O
157.6+/-25.1	O
cells/mm2	O
,	O
n	O
=	O
8	O
,	O
P	O
<	O
0.01	O
)	O
and	O
by	O
pretreatment	O
with	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
(	O
207.9+/-31.5	O
cells/mm2	O
,	O
n	O
=	O
10	O
,	O
P	O
<	O
0.01	O
)	O
.	O

Immunocytochemistry	O
60	O
minutes	O
after	O
stimulation	O
revealed	O
that	O
NFkappaB	O
was	O
located	O
in	O
the	O
cytoplasm	O
in	O
unstimulated	O
cells	O
;	O
however	O
,	O
the	O
addition	O
of	O
TNFalpha	O
caused	O
NFkappaB	O
to	O
translocate	O
into	O
the	O
nucleus	O
.	O

Pretreatment	O
with	O
dexamethasone	O
tapered	O
NFkappaB	O
translocation	O
into	O
the	O
nucleus	O
.	O

CONCLUSIONS	O
:	O
Leukocyte	O
adhesion	O
to	O
the	O
corneal	O
endothelium	O
was	O
shown	O
to	O
be	O
mediated	O
by	O
CD18	O
expressed	O
on	O
activated	O
leukocytes	O
.	O

Pretreatment	O
of	O
the	O
endothelium	O
with	O
dexamethasone	O
inhibited	O
leukocyte	O
adhesion	O
;	O
this	O
may	O
be	O
due	O
in	O
part	O
to	O
the	O
suppression	O
of	O
NFkappaB	O
entry	O
into	O
the	O
nucleus	O
.	O

Helenalin	O
,	O
an	O
anti-inflammatory	O
sesquiterpene	O
lactone	O
from	O
Arnica	O
,	O
selectively	O
inhibits	O
transcription	O
factor	O
NF-kappaB	O
[	O
see	O
comments	O
]	O

Alcoholic	O
extracts	O
prepared	O
form	O
Arnicae	O
flos	O
,	O
the	O
collective	O
name	O
for	O
flowerheads	O
from	O
Arnica	O
montana	O
and	O
A.	O
chamissonis	O
ssp.	O
foliosa	O
,	O
are	O
used	O
therapeutically	O
as	O
anti-inflammatory	O
remedies	O
.	O

The	O
active	O
ingredients	O
mediating	O
the	O
pharmacological	O
effect	O
are	O
mainly	O
sesquiterpene	O
lactones	O
,	O
such	O
as	O
helenalin	O
,	O
11alpha,13-dihydrohelenalin	O
,	O
chamissonolid	O
and	O
their	O
ester	O
derivatives	O
.	O

While	O
these	O
compounds	O
affect	O
various	O
cellular	O
processes	O
,	O
current	O
data	O
do	O
not	O
fully	O
explain	O
how	O
sesquiterpene	O
lactones	O
exert	O
their	O
anti-inflammatory	O
effect	O
.	O

We	O
show	O
here	O
that	O
helenalin	O
,	O
and	O
,	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
11alpha,13-dihydrohelenalin	O
and	O
chamissonolid	O
,	O
inhibit	O
activation	O
of	O
transcription	O
factor	O
NF-kappaB	O
.	O

This	O
difference	O
in	O
efficacy	O
,	O
which	O
correlates	O
with	O
the	O
compounds	O
'	O
anti-inflammatory	O
potency	O
in	O
vivo	O
,	O
may	O
be	O
explained	O
by	O
differences	O
in	O
structure	O
and	O
conformation	O
.	O

NF-kappaB	O
,	O
which	O
resides	O
in	O
an	O
inactive	O
,	O
cytoplasmic	O
complex	O
in	O
unstimulated	O
cells	O
,	O
is	O
activated	O
by	O
phosphorylation	O
and	O
degradation	O
of	O
its	O
inhibitory	O
subunit	O
,	O
IkappaB	O
.	O

Helenalin	O
inhibits	O
NF-kappaB	O
activation	O
in	O
response	O
to	O
four	O
different	O
stimuli	O
in	O
T-cells	O
,	O
B-cells	O
and	O
epithelial	O
cells	O
and	O
abrogates	O
kappaB-driven	O
gene	O
expression	O
.	O

This	O
inhibition	O
is	O
selective	O
,	O
as	O
the	B-Negation
activity	I-Negation
of	I-Negation
four	I-Negation
other	I-Negation
transcription	I-Negation
factors	I-Negation
,	I-Negation
Oct-1	I-Negation
,	I-Negation
TBP	I-Negation
,	I-Negation
Sp1	I-Negation
and	I-Negation
STAT	I-Negation
5	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
.	O

We	O
show	O
that	O
inhibition	O
is	O
not	B-Negation
due	I-Negation
to	I-Negation
a	I-Negation
direct	I-Negation
modification	I-Negation
of	I-Negation
the	I-Negation
active	I-Negation
NF-kappaB	I-Negation
heterodimer	I-Negation
.	O

Rather	O
,	O
helenalin	O
modifies	O
the	O
NF-kappaB/IkappaB	O
complex	O
,	O
preventing	O
the	O
release	O
of	O
IkappaB	O
.	O

These	O
data	O
suggest	O
a	O
molecular	O
mechanism	O
for	O
the	O
anti-inflammatory	O
effect	O
of	O
sesquiterpene	O
lactones	O
,	O
which	O
differs	O
from	O
that	O
of	O
other	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
indomethacin	O
and	O
acetyl	O
salicylic	O
acid	O
.	O

Involvement	O
of	O
different	O
transduction	O
pathways	O
in	O
NF-kappa	O
B	O
activation	O
by	O
several	O
inducers	O
.	O

Double-stimulation	O
was	O
used	O
to	O
demonstrate	O
that	O
,	O
in	O
a	O
T	O
lymphocytic	O
cell	O
line	O
(	O
CEM	O
)	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
rapidly	O
induced	O
NF-kappa	O
B	O
through	O
a	O
signaling	O
pathway	O
which	O
did	O
not	B-Negation
involve	I-Negation
reactive	I-Negation
oxygen	I-Negation
species	I-Negation
(	I-Negation
ROS	I-Negation
)	I-Negation
and	O
was	O
different	O
from	O
the	O
activation	O
triggered	O
by	O
either	O
H2O2	O
or	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

Since	O
these	O
latter	O
compounds	O
were	O
known	O
to	O
activate	O
NF-kappa	O
B	O
translocation	O
in	O
a	O
redox-sensitive	O
way	O
,	O
we	O
have	O
demonstrated	O
that	O
NF-kappa	O
B	O
activation	O
by	O
PMA	O
was	O
resistant	O
to	O
antioxidant	O
N-acetyl-L-cysteine	O
(	O
NAC	O
)	O
and	O
sensitive	O
to	O
kinase	O
inhibitors	O
staurosporine	O
and	O
H7	O
while	O
activation	O
by	O
H2O2	O
or	O
TNF-alpha	O
were	O
not	B-Negation
.	O

Dysregulation	O
of	O
monocytic	O
nuclear	O
factor-kappa	O
B	O
by	O
oxidized	O
low-density	O
lipoprotein	O
.	O

Nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
/Rel	O
transcription	O
factors	O
may	O
be	O
involved	O
in	O
atherosclerosis	O
,	O
as	O
is	O
suggested	O
by	O
the	O
presence	O
of	O
activated	O
NF-kappa	O
B	O
in	O
human	O
atherosclerotic	O
lesions	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
oxidized	O
LDL	O
(	O
oxLDL	O
)	O
on	O
the	O
NF-kappa	O
B	O
system	O
in	O
human	O
THP-1	O
monocytic	O
cells	O
as	O
well	O
as	O
adherent	O
monocytes	O
.	O

Our	O
results	O
demonstrate	O
that	O
short-term	O
incubation	O
of	O
these	O
cells	O
with	O
oxLDL	O
activated	O
p50/p65	O
containing	O
NF-kappa	O
B	O
dimers	O
and	O
induced	O
the	O
expression	O
of	O
the	O
target	O
gene	O
IL-8	O
.	O

This	O
activation	O
of	O
NF-kappa	O
B	O
was	O
inhibited	O
by	O
the	O
antioxidant	O
and	O
H2O2	O
scavenger	O
pyrrolidine	O
dithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
PSI	O
.	O

The	O
oxLDL-induced	O
NF-kappa	O
B	O
activation	O
was	O
accompanied	O
by	O
an	O
initial	O
depletion	O
of	O
I	O
kappa	O
B-alpha	O
followed	O
by	O
a	O
slight	O
transient	O
increase	O
in	O
the	O
level	O
of	O
this	O
inhibitor	O
protein	O
.	O

In	O
contrast	O
,	O
long-term	O
treatment	O
with	O
oxLDL	O
prevented	O
the	O
lipopolysaccharide-induced	O
depletion	O
of	O
I	O
kappa	O
B-alpha	O
,	O
accompanied	O
by	O
an	O
inhibition	O
of	O
both	O
NF-kappa	O
B	O
activation	O
and	O
the	O
expression	O
of	O
tumor	O
necrosis	O
factor-alpha	O
and	O
interleukin-1	O
beta	O
genes	O
.	O

These	O
observations	O
provide	O
additional	O
evidence	O
that	O
oxLDL	O
is	O
a	O
potent	O
modulator	O
of	O
gene	O
expression	O
and	O
suggest	O
that	O
(	O
dys	O
)	O
regulation	O
of	O
NF-kappa	O
B/Rel	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
atherogenesis	O
.	O

Suppression	O
of	O
MHC	O
class	O
II	O
expression	O
by	O
human	O
class	O
II	O
trans-activator	O
constructs	O
lacking	B-Negation
the	I-Negation
N-terminal	I-Negation
domain	I-Negation
.	O

The	O
class	O
II	O
trans-activator	O
(	O
CIITA	O
)	O
is	O
a	O
bi-	O
or	O
multi-functional	O
domain	O
protein	O
which	O
plays	O
a	O
critical	O
role	O
in	O
the	O
expression	O
of	O
MHC	O
class	O
II	O
genes	O
.	O

We	O
report	O
that	O
removal	O
of	O
the	O
N-terminal	O
151	O
amino	O
acids	O
,	O
encompassing	O
all	O
of	O
the	O
acidic	O
domain	O
but	O
leaving	O
intact	O
the	O
proline/serine/threonine-rich	O
domain	O
,	O
results	O
in	O
a	O
mutant	O
protein	O
with	O
potent	O
suppressive	O
properties	O
for	O
MHC	O
class	O
II	O
expression	O
.	O

HeLa	O
cells	O
stably	O
or	O
transiently	O
transfected	O
with	O
mutant	O
CIITA	O
constructs	O
showed	O
up	O
to	O
99	O
%	O
suppression	O
of	O
MHC	O
class	O
II	O
antigen	O
induction	O
by	O
IFN-gamma	O
and	O
marked	O
suppression	O
of	O
HLA-DRA	O
mRNA	O
expression	O
.	O

Transient	O
transfection	O
of	O
a	O
B	O
lymphoma	O
line	O
resulted	O
in	O
up	O
to	O
89	O
%	O
reduction	O
of	O
constitutive	O
MHC	O
class	O
II	O
expression	O
within	O
5	O
days	O
and	O
suppression	O
of	O
HLA-DRA	O
mRNA	O
synthesis	O
.	O

CD30-dependent	O
degradation	O
of	O
TRAF2	O
:	O
implications	O
for	O
negative	O
regulation	O
of	O
TRAF	O
signaling	O
and	O
the	O
control	O
of	O
cell	O
survival	O
.	O

CD30	O
is	O
a	O
cell-surface	O
receptor	O
that	O
can	O
augment	O
lymphocyte	O
activation	O
and	O
survival	O
through	O
its	O
ability	O
to	O
induce	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O

CD30	O
,	O
however	O
,	O
has	O
also	O
been	O
implicated	O
in	O
the	O
induction	O
of	O
apoptotic	O
cell	O
death	O
of	O
lymphocytes	O
.	O

Here	O
we	O
show	O
that	O
one	O
of	O
the	O
effects	O
of	O
CD30	O
signal	O
transduction	O
is	O
to	O
render	O
cells	O
sensitive	O
to	O
apoptosis	O
induced	O
by	O
the	O
type	O
1	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR1	O
)	O
.	O

This	O
sensitization	O
is	O
dependent	O
on	O
the	O
TRAF-binding	O
sites	O
within	O
the	O
CD30	O
cytoplasmic	O
domain	O
.	O

One	O
of	O
the	O
proteins	O
that	O
binds	O
to	O
these	O
sites	O
is	O
TRAF2	O
,	O
a	O
signal	O
transduction	O
molecule	O
that	O
is	O
also	O
utilized	O
by	O
TNFR1	O
to	O
mediate	O
the	O
activation	O
of	O
several	O
downstream	O
kinases	O
and	O
transcription	O
factors	O
.	O

During	O
CD30	O
signal	O
transduction	O
,	O
we	O
found	O
that	O
binding	O
of	O
TRAF2	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
CD30	O
results	O
in	O
the	O
rapid	O
depletion	O
of	O
TRAF2	O
and	O
the	O
associated	O
protein	O
TRAF1	O
by	O
proteolysis	O
.	O

These	O
data	O
suggest	O
a	O
model	O
in	O
which	O
CD30	O
limits	O
its	O
own	O
ability	O
to	O
transduce	O
cell	O
survival	O
signals	O
through	O
signal-coupled	O
depletion	O
of	O
TRAF2	O
.	O

Depletion	O
of	O
intracellular	O
TRAF2	O
and	O
its	O
coassociated	O
proteins	O
also	O
increased	O
the	O
sensitivity	O
of	O
the	O
cell	O
to	O
undergoing	O
apoptosis	O
during	O
activation	O
of	O
death-inducing	O
receptors	O
such	O
as	O
TNFR1	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
expression	O
of	O
a	O
dominant-negative	O
form	O
of	O
TRAF2	O
was	O
found	O
to	O
potentiate	O
TNFR1-mediated	O
death	O
.	O

These	O
studies	O
provide	O
a	O
potential	O
mechanism	O
through	O
which	O
CD30	O
,	O
as	O
well	O
as	O
other	O
TRAF-binding	O
members	O
of	O
the	O
TNFR	O
superfamily	O
,	O
can	O
negatively	O
regulate	O
cell	O
survival	O
.	O

TNFalpha	O
cooperates	O
with	O
the	O
protein	O
kinase	O
A	O
pathway	O
to	O
synergistically	O
increase	O
HIV-1	O
LTR	O
transcription	O
via	O
downstream	O
TRE-like	O
cAMP	O
response	O
elements	O
.	O

Activating	O
protein-1	O
(	O
AP-1	O
)	O
binding	O
TPA	O
responsive	O
elements	O
(	O
TRE	O
)	O
are	O
located	O
downstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
the	O
U5	O
region	O
of	O
the	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

These	O
downstream	O
sequence	O
elements	O
,	O
termed	O
DSE	O
,	O
can	O
bind	O
both	O
AP-1	O
and	O
CREB/ATF	O
transcription	O
factors	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
the	O
DSE	O
are	O
also	O
cAMP-responsive	O
elements	O
(	O
CRE	O
)	O
,	O
since	O
they	O
mediated	O
activation	O
signals	O
elicited	O
by	O
cholera	O
toxin	O
(	O
Ctx	O
)	O
,	O
a	O
potent	O
activator	O
of	O
the	O
cAMP-dependent	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
signal	O
transduction	O
pathway	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
the	O
HIV-1	O
DSE	O
can	O
mediate	O
the	O
transcriptional	O
synergy	O
elicited	O
by	O
the	O
combination	O
of	O
Ctx	O
and	O
TNFalpha	O
.	O

Ctx	O
combined	O
with	O
TNFalpha	O
or	O
IL-1beta	O
to	O
produce	O
a	O
synergistic	O
increase	O
in	O
p24	O
antigen	O
production	O
in	O
U1	O
promonocytic	O
cells	O
.	O

Transfection	O
studies	O
of	O
LTR	O
reporter	O
constructs	O
indicated	O
that	O
mutation	O
of	O
the	O
DSE	O
sites	O
abrogated	O
the	O
LTR-mediated	O
synergy	O
induced	O
by	O
Ctx	O
and	O
TNFalpha	O
,	O
whereas	O
the	O
synergy	O
induced	O
by	O
Ctx	O
and	O
IL-1beta	O
was	O
unaffected	O
,	O
suggesting	O
TNFalpha	O
and	O
IL-1beta	O
cooperate	O
differently	O
with	O
the	O
cAMP/PKA	O
activation	O
pathway	O
to	O
induce	O
HIV-1	O
expression	O
in	O
U1	O
cells	O
.	O

Because	O
the	O
DSE	O
are	O
also	O
TRE	O
sites	O
,	O
we	O
assessed	O
the	O
effect	O
of	O
the	O
agonist	O
combinations	O
on	O
AP-1-dependent	O
transcription	O
.	O

TNFalpha	O
as	O
well	O
as	O
IL-1beta	O
cooperated	O
with	O
Ctx	O
to	O
produce	O
a	O
synergistic	O
activation	O
of	O
AP-1-mediated	O
transcription	O
.	O

These	O
data	O
indicate	O
that	O
the	O
TRE-like	O
cAMP-responsive	O
DSE	O
sites	O
within	O
the	O
5'-untranslated	O
leader	O
can	O
mediate	O
the	O
transcriptional	O
cooperativity	O
between	O
TNFalpha	O
and	O
the	O
cAMP/PKA	O
pathway	O
.	O

Since	O
the	O
DSE	O
and	O
TRE	O
sites	O
can	B-Negation
not	I-Negation
bind	I-Negation
CREB/ATF	I-Negation
homodimers	I-Negation
,	O
we	O
propose	B-Speculation
a	I-Speculation
mechanism	I-Speculation
in	I-Speculation
which	I-Speculation
the	I-Speculation
HIV-1	I-Speculation
DSE	I-Speculation
bind	I-Speculation
heterodimers	I-Speculation
composed	I-Speculation
of	I-Speculation
both	I-Speculation
AP-1	I-Speculation
and	I-Speculation
CREB/ATF	I-Speculation
proteins	I-Speculation
.	O

Copyright	O
1997	O
Academic	O
Press	O
.	O

The	O
Epstein-Barr	O
virus	O
oncogene	O
product	O
latent	O
membrane	O
protein	O
1	O
engages	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
to	O
mediate	O
B	O
lymphocyte	O
growth	O
transformation	O
and	O
activate	O
NF-kappaB	O
.	O

The	O
Epstein-Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
essential	O
for	O
the	O
transformation	O
of	O
B	O
lymphocytes	O
into	O
lymphoblastoid	O
cell	O
lines	O
.	O

Previous	O
data	O
are	O
consistent	O
with	O
a	O
model	O
that	O
LMP1	O
is	O
a	O
constitutively	O
activated	O
receptor	O
that	O
transduces	O
signals	O
for	O
transformation	O
through	O
its	O
carboxyl-terminal	O
cytoplasmic	O
tail	O
.	O

One	O
transformation	O
effector	O
site	O
(	O
TES1	O
)	O
,	O
located	O
within	O
the	O
membrane	O
proximal	O
45	O
residues	O
of	O
the	O
cytoplasmic	O
tail	O
,	O
constitutively	O
engages	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factors	O
.	O

Signals	O
from	O
TES1	O
are	O
sufficient	O
to	O
drive	O
initial	O
proliferation	O
of	O
infected	O
resting	O
B	O
lymphocytes	O
,	O
but	O
most	O
lymphoblastoid	O
cells	O
infected	O
with	O
a	O
virus	O
that	O
does	O
not	B-Negation
express	I-Negation
the	I-Negation
155	I-Negation
residues	I-Negation
beyond	I-Negation
TES1	I-Negation
fail	B-Negation
to	I-Negation
grow	I-Negation
as	I-Negation
long-term	I-Negation
cell	I-Negation
lines	I-Negation
.	O

We	O
now	O
find	O
that	O
mutating	O
two	O
tyrosines	O
to	O
an	O
isoleucine	O
at	O
the	O
carboxyl	O
end	O
of	O
the	O
cytoplasmic	O
tail	O
cripples	O
the	O
ability	O
of	O
EBV	O
to	O
cause	O
lymphoblastoid	O
cell	O
outgrowth	O
,	O
thereby	O
marking	O
a	O
second	O
transformation	O
effector	O
site	O
,	O
TES2	O
.	O

A	O
yeast	O
two-hybrid	O
screen	O
identified	O
TES2	O
interacting	O
proteins	O
,	O
including	O
the	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
.	O

TRADD	O
was	O
the	O
only	O
protein	O
that	O
interacted	O
with	O
wild-type	O
TES2	O
and	O
not	B-Negation
with	I-Negation
isoleucine-mutated	I-Negation
TES2	I-Negation
.	O

TRADD	O
associated	O
with	O
wild-type	O
LMP1	O
but	O
not	B-Negation
with	I-Negation
isoleucine-mutated	I-Negation
LMP1	I-Negation
in	I-Negation
mammalian	I-Negation
cells	I-Negation
,	O
and	O
TRADD	O
constitutively	O
associated	O
with	O
LMP1	O
in	O
EBV-transformed	O
cells	O
.	O

In	O
transfection	O
assays	O
,	O
TRADD	O
and	O
TES2	O
synergistically	O
mediated	O
high-level	O
NF-kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
LMP1	O
appropriates	O
TRADD	O
to	O
enable	O
efficient	O
long-term	O
lymphoblastoid	O
cell	O
outgrowth	O
.	O

High-level	O
NF-kappaB	O
activation	O
also	O
appears	O
to	O
be	O
a	O
critical	O
component	O
of	O
long-term	O
outgrowth	O
.	O

Switching	O
gears	O
during	O
T-cell	O
maturation	O
:	O
RANTES	O
and	O
late	O
transcription	O
.	O

Although	O
much	O
is	O
understood	O
about	O
the	O
induction	O
of	O
genes	O
expressed	O
early	O
(	O
within	O
24	O
h	O
)	O
after	O
T-cell	O
activation	O
,	O
little	O
is	O
known	O
about	O
the	O
regulation	O
of	O
expression	O
of	O
genes	O
expressed	O
'late	O
'	O
(	O
three	O
or	O
more	O
days	O
)	O
post-stimulation	O
.	O

A	O
better	O
understanding	O
of	O
transcriptional	O
regulation	O
at	O
this	O
important	O
stage	O
of	O
T-cell	O
maturation	O
may	O
yield	O
new	O
insights	O
into	O
T-cell	O
development	O
and	O
new	O
immunotherapeutic	O
targets	O
.	O

Transcription	O
factor	O
NF-kappaB	O
regulates	O
inducible	O
Oct-2	O
gene	O
expression	O
in	O
precursor	O
B	O
lymphocytes	O
.	O

The	O
POU	O
transcription	O
factors	O
Oct-1	O
and	O
Oct-2	O
regulate	O
the	O
activity	O
of	O
octamer-dependent	O
promoters	O
,	O
including	O
those	O
that	O
direct	O
transcription	O
from	O
rearranged	O
immunoglobulin	O
genes	O
.	O

Unlike	O
Oct-1	O
,	O
which	O
is	O
constitutively	O
expressed	O
in	O
many	O
cell	O
types	O
,	O
Oct-2	O
expression	O
is	O
restricted	O
primarily	O
to	O
B	O
lymphocytes	O
and	O
can	O
be	O
induced	O
in	O
precursor	O
B	O
cells	O
by	O
stimulation	O
with	O
bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

However	O
,	O
the	O
precise	O
factors	O
that	O
mediate	O
this	O
induction	O
mechanism	O
remain	O
unknown	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
monitored	O
Oct-2	O
expression	O
in	O
cells	O
arrested	O
for	O
the	O
activation	O
of	O
NF-kappaB	O
,	O
an	O
LPS-responsive	O
member	O
of	O
the	O
Rel	O
transcription	O
factor	O
family	O
.	O

Despite	O
stimulation	O
with	O
LPS	O
,	O
disruption	O
of	O
the	O
NF-kappaB	O
signaling	O
pathway	O
in	O
precursor	O
B	O
cells	O
led	O
to	O
the	O
loss	O
of	O
inducible	O
Oct-2	O
DNA	O
binding	O
activity	O
in	O
vitro	O
and	O
the	O
suppression	O
of	O
Oct-2-directed	O
transcription	O
in	O
vivo	O
.	O

This	O
biochemical	O
defect	O
correlated	O
with	O
a	O
specific	O
block	O
to	O
Oct-2	O
gene	O
expression	O
at	O
the	O
level	O
of	O
transcription	O
,	O
whereas	O
the	O
expression	O
of	O
Oct-1	O
was	O
unaffected	O
.	O

The	O
finding	O
that	O
Oct-2	O
is	O
under	O
NF-kappaB	O
control	O
highlights	O
an	O
important	O
cross-talk	O
mechanism	O
involving	O
two	O
distinct	O
transcription	O
factor	O
families	O
that	O
regulate	O
B	O
lymphocyte	O
function	O
.	O

Paternal	O
expression	O
of	O
WT1	O
in	O
human	O
fibroblasts	O
and	O
lymphocytes	O
.	O

The	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
(	O
WT1	O
)	O
was	O
previously	O
identified	O
as	O
being	O
imprinted	O
,	O
with	O
frequent	O
maternal	O
expression	O
in	O
human	O
placentae	O
and	O
fetal	O
brains	O
.	O

We	O
examined	O
the	O
allele-specific	O
expression	O
of	O
WT1	O
in	O
cultured	O
human	O
fibroblasts	O
from	O
15	O
individuals	O
.	O

Seven	O
of	O
15	O
fibroblast	O
lines	O
were	O
heterozygous	O
for	O
polymorphic	O
alleles	O
,	O
and	O
the	O
expression	O
patterns	O
were	O
variable	O
,	O
i.e.	O
,	O
equal	O
,	O
unequal	O
or	O
monoallelic	O
paternal	O
expression	O
in	O
three	O
,	O
two	O
and	O
two	O
cases	O
,	O
respectively	O
.	O

Exclusive	O
paternal	O
expression	O
of	O
WT1	O
was	O
also	O
shown	O
in	O
non-cultured	O
peripheral	O
lymphocytes	O
from	O
the	O
latter	O
two	O
individuals	O
.	O

The	O
allele-specific	O
expression	O
profiles	O
of	O
other	O
imprinted	O
genes	O
,	O
IGF2	O
and	O
H19	O
,	O
on	O
human	O
chromosome	O
11	O
were	O
constant	O
and	O
consistent	O
with	O
those	O
in	O
other	O
tissues	O
.	O

Our	O
unexpected	O
observations	O
of	O
paternal	O
or	O
biallelic	O
expression	O
of	O
WT1	O
in	O
fibroblasts	O
and	O
lymphocytes	O
,	O
together	O
with	O
the	O
previous	O
findings	O
of	O
maternal	O
or	O
biallelic	O
expression	O
in	O
placentae	O
and	O
brains	O
,	O
suggest	O
that	O
the	O
allele-specific	O
regulatory	O
system	O
of	O
WT1	O
is	O
unique	O
and	O
may	O
be	O
controlled	O
by	O
a	O
putative	O
tissue-	O
and	O
individual-specific	O
modifier	O
.	O

Characterization	O
of	O
CD40	O
signaling	O
determinants	O
regulating	O
nuclear	O
factor-kappa	O
B	O
activation	O
in	O
B	O
lymphocytes	O
.	O

CD40	O
signaling	O
to	O
B	O
cells	O
is	O
important	O
for	O
generating	O
an	O
effective	O
humoral	O
immune	O
response	O
.	O

CD40	O
ligation	O
leads	O
to	O
B	O
cell	O
activation	O
events	O
such	O
as	O
proliferation	O
,	O
Ig	O
secretion	O
,	O
isotype	O
switching	O
,	O
and	O
up-regulation	O
of	O
cell	O
surface	O
molecules	O
,	O
as	O
well	O
as	O
the	O
generation	O
of	O
memory	O
B	O
cells	O
.	O

Many	O
of	O
these	O
events	O
are	O
dependent	O
upon	O
the	O
ability	O
of	O
CD40	O
to	O
activate	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
.	O

To	O
define	O
the	O
CD40	O
signaling	O
components	O
upstream	O
of	O
NF-kappa	O
B	O
activation	O
and	O
the	O
functional	O
consequences	O
downstream	O
of	O
NF-kappa	O
B	O
activation	O
,	O
we	O
examined	O
mouse	O
B	O
cell	O
transfectants	O
expressing	O
wild-type	O
or	O
mutant	O
human	O
CD40	O
.	O

Analysis	O
of	O
CD40	O
cytoplasmic	O
domain	O
truncation	O
and	O
point	O
mutants	O
defined	O
a	O
10-amino	O
acid	O
CD40	O
cytoplasmic	O
signaling	O
determinant	O
required	O
for	O
NF-kappa	O
B	O
activation	O
.	O

A	B-Negation
threonine	I-Negation
residue	I-Negation
at	I-Negation
position	I-Negation
234	I-Negation
,	I-Negation
previously	I-Negation
shown	I-Negation
to	I-Negation
be	I-Negation
important	I-Negation
for	I-Negation
CD40	I-Negation
association	I-Negation
with	I-Negation
TNF	I-Negation
receptor-associated	I-Negation
factor	I-Negation
2	I-Negation
(	I-Negation
TRAF2	I-Negation
)	I-Negation
,	I-Negation
TRAF3	I-Negation
,	I-Negation
and	I-Negation
TRAF5	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
.	O

This	O
suggests	O
that	O
in	O
B	O
cells	O
,	O
CD40-induced	O
NF-kappa	O
B	O
activation	O
can	O
occur	O
independently	O
of	O
TRAF2	O
and	O
TRAF5	O
association	O
.	O

NF-kappa	O
B	O
activation	O
was	O
independent	O
of	O
the	O
transmembrane	O
domain	O
of	O
CD40	O
,	O
suggesting	O
that	O
it	O
is	O
independent	O
of	O
p23	O
,	O
a	O
molecule	O
that	O
associates	O
with	O
CD40	O
in	O
a	O
region	O
other	O
than	O
the	O
cytoplasmic	O
domain	O
.	O

Proteasome-dependent	O
inhibitory	O
kappa	O
B	O
alpha	O
(	O
I	O
kappa	O
B	O
alpha	O
)	O
and	O
I	O
kappa	O
B	O
beta	O
degradation	O
occurred	O
downstream	O
of	O
CD40	O
ligation	O
and	O
preceded	O
CD40-mediated	O
NF-kappa	O
B	O
nuclear	O
translocation	O
.	O

CD40-	B-Negation
or	I-Negation
pervanadate-mediated	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
.	O

NF-kappa	O
B	O
activation	O
correlated	O
with	O
the	O
ability	O
of	O
CD40	O
to	O
induce	O
Ab	O
secretion	O
and	O
the	O
up-regulation	O
of	O
ICAM-1	O
and	O
LFA-1	O
.	O

However	O
,	O
NF-kappa	O
B	O
activation	O
was	O
insufficient	O
for	O
CD40-mediated	O
up-regulation	O
of	O
B7-1	O
,	O
Fas	O
,	O
and	O
CD23	O
.	O

Extinction	O
of	O
immunoglobulin	O
gene	O
expression	O
in	O
B	O
cells	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
is	O
preceded	O
by	O
rapid	O
nuclear	O
depletion	O
of	O
essential	O
transcription	O
factors	O
and	O
is	O
accompanied	O
by	O
widespread	O
inactivation	O
of	O
genes	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

When	O
immunoglobulin	O
(	O
Ig	O
)	O
expressing	O
B	O
cells	O
are	O
fused	O
with	O
non-B	O
cells	O
,	O
Ig	O
expression	O
is	O
rapidly	O
suppressed	O
at	O
the	O
level	O
of	O
transcription	O
,	O
a	O
phenomenon	O
termed	O
extinction	O
.	O

Here	O
we	O
demonstrate	O
that	O
fusion	O
of	O
HeLa	O
cells	O
with	O
either	O
diploid	O
or	O
tetraploid	O
B	O
cells	O
(	O
Daudi	O
)	O
results	O
in	O
widespread	O
extinction	O
of	O
several	O
other	O
B	O
cell-encoded	O
genes	O
that	O
are	O
expressed	O
in	O
a	O
B	O
cell-specific	O
manner	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
B	O
cell-expressed	O
genes	O
that	O
are	O
not	B-Negation
dependent	I-Negation
on	I-Negation
cell-specific	I-Negation
controls	I-Negation
is	O
unaffected	O
.	O

We	O
show	O
that	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
Ig	O
gene	O
extinction	O
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
lack	B-Negation
of	I-Negation
transcription	I-Negation
factors	I-Negation
that	I-Negation
are	I-Negation
essential	I-Negation
for	I-Negation
Ig	I-Negation
gene	I-Negation
transcription	I-Negation
.	O

These	O
transcription	O
factors	O
are	O
either	O
not	O
produced	O
due	O
to	O
block	O
of	O
transcription	O
of	O
their	O
respective	O
genes	O
(	O
Oct-2	O
,	O
OBF-1	O
,	O
PU.1	O
)	O
,	O
or	O
are	O
rendered	O
inactive	O
posttranslationally	O
(	O
NF-kappa	O
B	O
,	O
E47	O
)	O
.	O

By	O
isolating	O
Daudi	O
x	O
HeLa	O
heterokaryons	O
a	O
few	O
hours	O
after	O
fusion	O
,	O
we	O
have	O
studied	O
the	O
initial	O
fate	O
of	O
two	O
B	O
cell-specific	O
transcription	O
factors	O
involved	O
in	O
Ig	O
gene	O
transcription	O
,	O
Oct-2	O
and	O
NF-kappa	O
B	O
.	O

This	O
report	O
provides	O
the	O
first	O
demonstration	O
that	O
upon	O
fusion	O
with	O
HeLa	O
cells	O
,	O
the	O
nuclear	O
contents	O
of	O
B	O
cell-expressed	O
transcription	O
factors	O
are	O
depleted	O
within	O
a	O
few	O
hours	O
with	O
kinetics	O
that	O
are	O
as	O
fast	O
or	O
faster	O
than	O
that	O
of	O
Ig	O
gene	O
extinction	O
.	O

Thus	O
,	O
the	O
extinguishing	O
mechanism	O
is	O
effective	O
very	O
early	O
after	O
fusion	O
.	O

We	O
suggest	O
that	O
extinction	O
of	O
Ig	O
genes	O
is	O
part	O
of	O
a	O
global	O
mechanism	O
that	O
suppresses	O
the	O
differentiation	O
program	O
foreign	O
to	O
the	O
HeLa	O
phenotype	O
.	O

Regulation	O
of	O
Id3	O
cell	O
cycle	O
function	O
by	O
Cdk-2-dependent	O
phosphorylation	O
.	O

The	O
functions	O
of	O
basic	O
helix-loop-helix	O
(	O
bHLH	O
)	O
transcription	O
factors	O
in	O
activating	O
differentiation-linked	O
gene	O
expression	O
and	O
in	O
inducing	O
G1	O
cell	O
cycle	O
arrest	O
are	O
negatively	O
regulated	O
by	O
members	O
of	O
the	O
Id	O
family	O
of	O
HLH	O
proteins	O
.	O

These	O
bHLH	O
antagonists	O
are	O
induced	O
during	O
a	O
mitogenic	O
signalling	O
response	O
,	O
and	O
they	O
function	O
by	O
sequestering	O
their	O
bHLH	O
targets	O
in	O
inactive	O
heterodimers	O
that	O
are	B-Negation
unable	I-Negation
to	I-Negation
bind	I-Negation
to	I-Negation
specific	I-Negation
gene	I-Negation
regulatory	I-Negation
(	I-Negation
E	I-Negation
box	I-Negation
)	I-Negation
sequences	I-Negation
.	O

Recently	O
,	O
cyclin	O
E-Cdk2-	O
and	O
cyclin	O
A-Cdk2-dependent	O
phosphorylation	O
of	O
a	O
single	O
conserved	O
serine	O
residue	O
(	O
Ser5	O
)	O
in	O
Id2	O
has	O
been	O
shown	O
to	O
occur	O
during	O
late	O
G1-to-S	O
phase	O
transition	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
this	O
neutralizes	O
the	O
function	O
of	O
Id2	O
in	O
abrogating	O
E-box-dependent	O
bHLH	O
homo-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
(	O
E.Hara	O
,	O
M.Hall	O
,	O
and	O
G.Peters	O
,	O
EMBO	O
J.16:332-342	O
,	O
1997	O
)	O
.	O

We	O
now	O
show	O
that	O
an	O
analogous	O
cell-cycle-regulated	O
phosphorylation	O
of	O
Id3	O
alters	O
the	O
specificity	O
of	O
Id3	O
for	O
abrogating	O
both	O
E-box-dependent	O
bHLH	O
homo-	O
or	O
heterodimer	O
complex	O
formation	O
in	O
vitro	O
and	O
E-box-dependent	O
reporter	O
gene	O
function	O
in	O
vivo	O
.	O

Furthermore	O
,	O
compared	O
with	O
wild-type	O
Id3	O
,	O
an	B-Negation
Id3	I-Negation
Asp5	I-Negation
mutant	I-Negation
(	I-Negation
mimicking	I-Negation
phosphorylation	I-Negation
)	I-Negation
is	I-Negation
unable	I-Negation
to	I-Negation
promote	I-Negation
cell	I-Negation
cycle	I-Negation
S	I-Negation
phase	I-Negation
entry	I-Negation
in	I-Negation
transfected	I-Negation
fibroblasts	I-Negation
,	O
whereas	O
an	O
Id3	O
Ala5	O
mutant	O
(	O
ablating	O
phosphorylation	O
)	O
displays	O
an	O
activity	O
significantly	O
greater	O
than	O
that	O
of	O
wild-type	O
Id3	O
protein	O
.	O

Cdk2-dependent	O
phosphorylation	O
therefore	O
provides	O
a	O
switch	O
during	O
late	O
G1-to-S	O
phase	O
that	O
both	O
nullifies	O
an	O
early	O
G1	O
cell	O
cycle	O
regulatory	O
function	O
of	O
Id3	O
and	O
modulates	O
its	O
target	O
bHLH	O
specificity	O
.	O

These	O
data	O
also	O
demonstrate	O
that	O
the	O
ability	O
of	O
Id3	O
to	O
promote	O
cell	O
cycle	O
S	O
phase	O
entry	O
is	O
not	B-Negation
simply	I-Negation
a	I-Negation
function	I-Negation
of	I-Negation
its	I-Negation
ability	I-Negation
to	I-Negation
modulate	I-Negation
bHLH	I-Negation
heterodimer-dependent	I-Negation
gene	I-Negation
expression	I-Negation
and	O
establish	O
a	O
biologically	O
important	O
mechanism	O
through	O
which	O
Cdk2	O
and	O
Id-bHLH	O
functions	O
are	O
integrated	O
in	O
the	O
coordination	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Nuclear	O
accumulation	O
of	O
NFAT4	O
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

The	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
group	O
of	O
transcription	O
factors	O
is	O
retained	O
in	O
the	O
cytoplasm	O
of	O
quiescent	O
cells	O
.	O

NFAT	O
activation	O
is	O
mediated	O
in	O
part	O
by	O
induced	O
nuclear	O
import	O
.	O

This	O
process	O
requires	O
calcium-dependent	O
dephosphorylation	O
of	O
NFAT	O
caused	O
by	O
the	O
phosphatase	O
calcineurin	O
.	O

The	O
c-Jun	O
amino-terminal	O
kinase	O
(	O
JNK	O
)	O
phosphorylates	O
NFAT4	O
on	O
two	O
sites	O
.	O

Mutational	O
removal	O
of	O
the	O
JNK	O
phosphorylation	O
sites	O
caused	O
constitutive	O
nuclear	O
localization	O
of	O
NFAT4	O
.	O

In	O
contrast	O
,	O
JNK	O
activation	O
in	O
calcineurin-stimulated	O
cells	O
caused	O
nuclear	O
exclusion	O
of	O
NFAT4	O
.	O

These	O
findings	O
show	O
that	O
the	O
nuclear	O
accumulation	O
of	O
NFAT4	O
promoted	O
by	O
calcineurin	O
is	O
opposed	O
by	O
the	O
JNK	O
signal	O
transduction	O
pathway	O
.	O

Hypoxia	O
enhances	O
induction	O
of	O
endothelial	O
ICAM-1	O
:	O
role	O
for	O
metabolic	O
acidosis	O
and	O
proteasomes	O
.	O

Intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM-1	O
)	O
is	O
an	O
important	O
molecule	O
in	O
promotion	O
of	O
polymorphonuclear	O
neutrophil	O
transendothelial	O
migration	O
during	O
inflammation	O
.	O

Coincident	O
with	O
many	O
inflammatory	O
diseases	O
is	O
tissue	O
hypoxia	O
.	O

Thus	O
we	O
hypothesized	O
that	O
combinations	O
of	O
hypoxia	O
and	O
inflammatory	O
stimuli	O
may	O
differentially	O
regulate	O
expression	O
of	O
endothelial	O
ICAM-1	O
.	O

Human	O
endothelial	O
cells	O
were	O
exposed	O
to	O
hypoxia	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
added	I-Negation
lipopolysaccharide	I-Negation
(	I-Negation
LPS	I-Negation
)	I-Negation
and	O
examined	O
for	O
expression	O
of	O
functional	O
ICAM-1	O
.	O

Although	O
hypoxia	O
alone	O
did	O
not	B-Negation
induce	I-Negation
ICAM-1	I-Negation
,	O
the	O
combination	O
of	O
LPS	O
and	O
hypoxia	O
enhanced	O
(	O
3	O
	O
0.4-fold	O
over	O
normoxia	O
)	O
ICAM-1	O
expression	O
.	O

Combinations	O
of	O
hypoxia	O
and	O
LPS	O
significantly	O
increased	O
lymphocyte	O
binding	O
,	O
and	O
such	O
increases	O
were	O
inhibited	O
by	O
addition	O
of	O
anti-ICAM-1	O
antibodies	O
or	O
antisense	O
oligonucleotides	O
.	O

Hypoxic	O
endothelia	O
showed	O
a	O
>	O
10-fold	O
increase	O
in	O
sensitivity	O
to	O
inhibitors	O
of	O
proteasome	O
activation	O
,	O
and	O
combinations	O
of	O
hypoxia	O
and	O
LPS	O
enhanced	O
proteasome-dependent	O
cytoplasmic-to-nuclear	O
localization	O
of	O
the	O
nuclear	O
transcription	O
factor-kappa	O
B	O
p65	O
(	O
Rel	O
A	O
)	O
subunit	O
.	O

Such	O
proteasome	O
activation	O
correlated	O
with	O
hypoxia-evoked	O
decreases	O
in	O
both	O
extracellular	O
and	O
intracellular	O
pH	O
.	O

We	O
conclude	O
from	O
these	O
studies	O
that	O
endothelial	O
hypoxia	O
provides	O
a	O
novel	O
,	O
proteasome-dependent	O
stimulus	O
for	O
ICAM-1	O
induction	O
.	O

Modulation	O
of	O
mRNA	O
expression	O
of	O
a	O
novel	O
human	O
myeloid-selective	O
CCAAT/enhancer	O
binding	O
protein	O
gene	O
(	O
C/EBP	O
epsilon	O
)	O
.	O

Human	O
C/EBP	O
epsilon	O
is	O
a	O
newly	O
cloned	O
gene	O
coding	O
for	O
a	O
CCAAT/enhancer	O
binding	O
protein	O
that	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
myeloid	O
differentiation	O
.	O

Our	O
studies	O
showed	O
that	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
were	O
markedly	O
increased	O
in	O
NB4	O
cells	O
(	O
promyelocytic	O
leukemia	O
line	O
)	O
,	O
because	O
they	O
were	O
induced	O
by	O
9-cis	O
retinoic	O
acid	O
(	O
9-cis	O
RA	O
)	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

Accumulation	O
of	O
C/EBP	O
epsilon	O
mRNA	O
occurred	O
as	O
early	O
as	O
1	O
hour	O
after	O
exposure	O
of	O
NB4	O
cells	O
to	O
9-cis	O
RA	O
(	O
5	O
x	O
10	O
(	O
-7	O
)	O
mol/L	O
)	O
;	O
and	O
at	O
48	O
hours	O
,	O
levels	O
were	O
increased	O
by	O
5.1-fold	O
.	O

Dose-response	O
studies	O
showed	O
that	O
10	O
(	O
-7	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
9-cis	O
RA	O
(	O
12	O
hours	O
)	O
resulted	O
in	O
peak	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
;	O
but	O
even	O
10	O
(	O
-10	O
)	O
mol/L	O
9-cis	O
RA	O
increased	O
levels	O
of	O
these	O
transcripts	O
.	O

NB4	O
cells	O
pulse-exposed	O
(	O
30	O
minutes	O
)	O
to	O
all-trans	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
washed	O
,	O
and	O
cultured	O
(	O
3	O
days	O
)	O
with	O
either	O
dimethylsulfoxide	O
(	O
DMSO	O
)	O
or	O
hexamethylene	O
bisacetamide	O
(	O
HMBA	O
)	O
had	O
a	O
prominent	O
increase	O
in	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
and	O
an	O
increase	O
in	O
granulocytic	O
differentiation	O
,	O
but	O
exposure	O
to	O
either	O
DMSO	O
or	O
HMBA	O
alone	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
base	I-Negation
levels	I-Negation
of	I-Negation
C/EBP	I-Negation
epsilon	I-Negation
and	O
did	O
not	B-Negation
induce	I-Negation
differentiation	I-Negation
.	O

Macrophage-differentiation	O
of	O
NB4	O
reduced	O
levels	O
of	O
C/EBP	O
epsilon	O
mRNA	O
.	O

Nuclear	O
run-off	O
assays	O
and	O
half-life	O
studies	O
showed	O
that	O
accumulation	O
of	O
C/EBP	O
epsilon	O
mRNA	O
by	O
9-cis	O
RA	O
was	O
due	O
to	O
enhanced	O
transcription	O
.	O

Furthermore	O
,	O
this	O
C/EBP	O
epsilon	O
mRNA	O
accumulation	O
did	O
not	B-Negation
require	I-Negation
synthesis	I-Negation
of	I-Negation
new	I-Negation
protein	I-Negation
factors	I-Negation
because	O
9-cis	O
RA	O
induced	O
C/EBP	O
epsilon	O
mRNA	O
accumulation	O
in	O
the	O
absence	B-Negation
of	I-Negation
new	I-Negation
protein	I-Negation
synthesis	I-Negation
.	O

ATRA	O
also	O
induced	O
expression	O
of	O
C/EBP	O
epsilon	O
protein	O
in	O
NB4	O
cells	O
,	O
as	O
shown	O
by	O
Western	O
blotting	O
.	O

In	O
contrast	O
to	O
the	O
increase	O
of	O
C/EBP	O
epsilon	O
in	O
9-cis	O
RA-mediated	O
granulocytic	O
differentiation	O
,	O
the	O
DMSO-induced	O
differentiation	O
of	O
HL-60	O
cells	O
down	O
the	O
granulocytic	O
pathway	O
was	O
associated	O
with	O
an	O
initial	O
reduction	O
of	O
C/EBP	O
epsilon	O
mRNA	O
levels	O
.	O

In	O
summary	O
,	O
we	O
have	O
discovered	O
that	O
expression	O
of	O
C/EBP	O
epsilon	O
mRNA	O
is	O
markedly	O
enhanced	O
as	O
the	O
NB4	O
promyelocytes	O
are	O
induced	O
by	O
retinoids	O
to	O
differentiate	O
towards	O
granulocytes	O
.	O

This	O
induction	O
of	O
C/EBP	O
epsilon	O
mRNA	O
expression	O
is	O
transcriptionally	O
mediated	O
and	O
occurs	O
in	O
the	O
absence	B-Negation
of	I-Negation
synthesis	I-Negation
of	I-Negation
additional	I-Negation
protein	I-Negation
factors	I-Negation
.	O

We	O
suspect	O
that	O
the	O
C/EBP	O
epsilon	O
promoter/enhancer	O
contains	O
a	O
retinoic	O
acid-response	O
element	O
that	O
is	O
directly	O
stimulated	O
by	O
retinoids	O
.	O

Regulation	O
of	O
nuclear	O
factor-kappa	O
B	O
and	O
its	O
inhibitor	O
I	O
kappa	O
B-alpha/MAD-3	O
in	O
monocytes	O
by	O
Mycobacterium	O
tuberculosis	O
and	O
during	O
human	O
tuberculosis	O
.	O

Blood	O
monocytes	O
from	O
patients	O
with	O
active	O
tuberculosis	O
are	O
activated	O
in	O
vivo	O
,	O
as	O
evidenced	O
by	O
an	O
increase	O
in	O
the	O
stimulated	O
release	O
of	O
proinflammatory	O
cytokines	O
,	O
such	O
as	O
TNF-alpha	O
,	O
and	O
the	O
spontaneous	O
expression	O
of	O
IL-2R	O
.	O

Further	O
,	O
monocytes	O
from	O
patients	O
demonstrate	O
an	O
augmented	O
susceptibility	O
to	O
a	O
productive	O
infection	O
with	O
HIV-1	O
in	O
vitro	O
.	O

Mycobacterium	O
tuberculosis	O
and	O
its	O
components	O
are	O
strong	O
signals	O
to	O
activate	O
monocytes	O
to	O
production	O
of	O
cytokines	O
.	O

In	O
this	O
study	O
we	O
examined	O
the	O
basis	O
of	O
activation	O
of	O
monocytes	O
during	O
active	O
tuberculosis	O
and	O
by	O
M.	O
tuberculosis	O
.	O

We	O
found	O
a	O
constitutive	O
degradation	O
of	O
I	O
kappa	O
B-alpha	O
,	O
the	O
major	O
cytoplasmic	O
inhibitor	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
,	O
in	O
freshly	O
isolated	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
with	O
tuberculosis	O
.	O

In	O
contrast	O
,	O
I	O
kappa	O
B-alpha	O
levels	O
in	O
PBMC	O
and	O
monocytes	O
from	O
healthy	O
subjects	O
or	O
from	O
patients	O
with	O
nontuberculous	O
pulmonary	O
conditions	O
were	O
intact	O
.	O

Further	O
,	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
NF-kappa	O
B	O
was	O
activated	O
in	O
monocytes	O
from	O
tuberculous	O
patients	O
.	O

The	O
expression	O
of	O
I	O
kappa	O
B-alpha	O
gene	O
,	O
which	O
is	O
responsive	O
to	O
activation	O
by	O
NF-kappa	O
B	O
,	O
was	O
up-regulated	O
in	O
PBMC	O
and	O
monocytes	O
from	O
patients	O
,	O
but	O
not	B-Negation
in	I-Negation
mononuclear	I-Negation
cells	I-Negation
from	I-Negation
healthy	I-Negation
subjects	I-Negation
or	I-Negation
those	I-Negation
with	I-Negation
nontuberculous	I-Negation
lung	I-Negation
diseases	I-Negation
.	O

By	O
contrast	O
,	O
the	B-Negation
expression	I-Negation
of	I-Negation
other	I-Negation
adherence-associated	I-Negation
early	I-Negation
genes	I-Negation
,	I-Negation
such	I-Negation
as	I-Negation
IL-8	I-Negation
and	I-Negation
IL-1	I-Negation
beta	I-Negation
,	I-Negation
was	I-Negation
not	I-Negation
up-regulated	I-Negation
in	I-Negation
PBMC	I-Negation
of	I-Negation
tuberculous	I-Negation
patients	I-Negation
.	O

Further	O
,	O
M.	O
tuberculosis	O
and	O
its	O
tuberculin	O
,	O
purified	O
protein	O
derivative	O
,	O
induced	O
the	O
degradation	O
of	O
I	O
kappa	O
B-alpha	O
and	O
the	O
expression	O
of	O
I	O
kappa	O
B-alpha	O
mRNA	O
,	O
and	O
purified	O
protein	O
derivative	O
induced	O
the	O
activation	O
of	O
NF-kappa	O
B	O
in	O
monocytes	O
.	O

Expression	O
of	O
c-fos	O
correlates	O
with	O
IFN-alpha	O
responsiveness	O
in	O
Philadelphia	O
chromosome	O
positive	O
chronic	O
myelogenous	O
leukemia	O
.	O

This	O
study	O
evaluates	O
(	O
i	O
)	O
constitutive	O
levels	O
of	O
oncogene	O
and	O
p53	O
transcripts	O
in	O
chronic	O
phase	O
CML	O
patients	O
and	O
(	O
ii	O
)	O
their	O
modulations	O
subsequent	O
to	O
in	O
vivo	O
therapy	O
with	O
rIFN-alpha	O
2c	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
(	O
pbmc	O
)	O
and	O
bone	O
marrow	O
cells	O
of	O
26	O
patients	O
were	O
examined	O
for	O
c-fos	O
,	O
c-myc	O
,	O
p53	O
and	O
the	O
hybrid	O
bcr/abl	O
mRNA	O
levels	O
.	O

Results	O
indicated	O
that	O
(	O
i	O
)	O
constitutive	O
c-fos	O
transcript	O
levels	O
are	O
significantly	O
higher	O
in	O
patients	O
subsequently	O
responding	O
to	O
IFN-alpha	O
therapy	O
(	O
p	O
<	O
0.01	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
proportion	O
of	O
lymphocytes	O
(	O
r	O
=	O
0.6895	O
,	O
p	O
<	O
0.01	O
)	O
and	O
negatively	O
with	O
the	O
proportion	O
of	O
immature	O
cells	O
(	O
r	O
=	O
-0.568	O
,	O
p	O
<	O
0.01	O
)	O
contained	O
in	O
the	O
pbmc	O
preparations	O
tested	O
,	O
(	O
ii	O
)	O
constitutive	O
mRNA	O
levels	O
of	O
the	O
hybrid	O
bcr/abl	O
,	O
c-myc	O
and	O
p53	O
are	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
but	O
failed	O
to	O
relate	O
to	O
disease	O
parameters	O
,	O
and	O
(	O
iii	O
)	O
acute	O
and	O
chronic	O
in	O
vivo	O
exposure	O
to	O
IFN-alpha	O
is	O
accompanied	O
by	O
upregulation	O
of	O
c-fos	O
and	O
downregulation	O
of	O
c-myc	O
mRNA	O
levels	O
in	O
responder	O
patients	O
.	O

Molecular	O
cloning	O
and	O
functional	O
characterization	O
of	O
murine	O
cDNA	O
encoding	O
transcription	O
factor	O
NFATc	O
.	O

Transcription	O
factors	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
family	O
play	O
important	O
roles	O
in	O
immune	O
and	O
inflammatory	O
responses	O
by	O
regulating	O
the	O
expression	O
of	O
genes	O
encoding	O
cytokines	O
and	O
immunoregulatory	O
proteins	O
.	O

Here	O
we	O
describe	O
cloning	O
and	O
characterization	O
of	O
full-length	O
cDNA	O
encoding	O
murine	O
(	O
m	O
)	O
NFATc	O
which	O
predicts	O
that	O
the	O
protein	O
has	O
all	O
the	O
conserved	O
structural	O
motifs	O
of	O
NFAT	O
family	O
members	O
,	O
including	O
the	O
rel	O
homology	O
domain	O
,	O
the	O
NFAT	O
homology	O
domain	O
and	O
the	O
nuclear	O
translocation	O
signals	O
.	O

mNFATc	O
complexed	O
with	O
AP-1	O
bound	O
specifically	O
to	O
the	O
murine	O
IL-2	O
NFAT	O
recognition	O
sequence	O
and	O
activated	O
transcription	O
from	O
the	O
co-transfected	O
IL-2	O
promoter	O
in	O
COS-7	O
cells	O
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
the	O
cDNA	O
probe	O
hybridized	O
with	O
a	O
4.5	O
kb	O
transcript	O
which	O
is	O
highly	O
inducible	O
in	O
murine	O
T	O
cells	O
.	O

By	O
Northern	O
and	O
in	O
situ	O
hybridization	O
,	O
mNFATc	O
transcript	O
was	O
detected	O
from	O
the	O
early	O
stage	O
of	O
development	O
.	O

In	O
the	O
mouse	O
embryo	O
,	O
mNFATc	O
transcript	O
was	O
strongly	O
expressed	O
in	O
thymus	O
,	O
lung	O
and	O
submandibular	O
gland	O
and	O
weakly	O
in	O
skeletal	O
muscle	O
and	O
heart	O
suggesting	O
that	O
mNFATc	O
may	O
have	O
a	O
role	O
both	O
in	O
embryogenesis	O
and	O
in	O
mature	O
T	O
cells	O
.	O

Phosphatidylinositol	O
3-kinase	O
couples	O
the	O
interleukin-2	O
receptor	O
to	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
.	O

Cell	O
cycle	O
progression	O
initiated	O
by	O
interleukin-2	O
(	O
IL-2	O
)	O
in	O
T	O
cells	O
is	O
critical	O
for	O
lymphoproliferation	O
and	O
an	O
immune	O
response	O
.	O

Phosphatidyl	O
inositol	O
3-kinase	O
(	O
PI3K	O
)	O
is	O
activated	O
by	O
IL-2	O
.	O

However	O
,	O
nuclear	O
targets	O
for	O
PI3K	O
are	O
not	O
known	O
.	O

Here	O
we	O
identify	O
the	O
cell	O
cycle	O
regulator	O
E2F	O
as	O
an	O
IL-2	O
target	O
in	O
T	O
lymphocytes	O
and	O
PI3K	O
as	O
the	O
critical	O
signaling	O
pathway	O
.	O

We	O
eliminate	O
both	O
Stat5	O
and	O
Raf/MEK	O
pathways	O
from	O
E2F	O
regulation	O
.	O

Protein	O
kinase	O
B	O
(	O
PKB	O
)	O
is	O
activated	O
by	O
IL-2	O
via	O
PI3K	O
.	O

The	O
expression	O
of	O
an	O
active	O
PKB	O
is	O
sufficient	O
to	O
induce	O
E2F	O
activity	O
.	O

Inhibition	O
of	O
PI3K	O
inhibits	O
phosphorylation	O
of	O
Rb	O
,	O
induction	O
of	O
cyclin	O
D3	O
,	O
and	O
degradation	O
of	O
p27kip1	O
.	O

These	O
results	O
establish	O
a	O
crucial	O
PI3K/PKB-mediated	O
link	O
between	O
the	O
IL-2	O
teceptor	O
and	O
the	O
cell	O
cycle	O
machinery	O
.	O

Thiol	O
modulation	O
inhibits	O
the	O
interleukin	O
(	O
IL	O
)	O
-1-mediated	O
activation	O
of	O
an	O
IL-1	O
receptor-associated	O
protein	O
kinase	O
and	O
NF-kappa	O
B	O
.	O

The	O
interleukin-1	O
receptor	O
type	O
I	O
(	O
IL-1RI	O
)	O
is	O
associated	O
with	O
other	O
proteins	O
thus	O
forming	O
a	O
complex	O
system	O
by	O
which	O
IL-1	O
exerts	O
its	O
various	O
signals	O
.	O

The	O
initiating	O
event	O
is	O
still	O
uncertain	O
,	O
but	O
activation	O
of	O
a	O
recently	O
described	O
receptor-associated	O
protein	O
kinase	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
(	O
Martin	O
et	O
al.	O
,	O
Eur.J.Immunol.1994.24	O
:	O
1566	O
)	O
.	O

IL-1	O
signaling	O
is	O
commonly	O
accompanied	O
by	O
oxidative	O
processes	O
and	O
is	O
thought	O
to	O
be	O
subject	O
to	O
redox	O
regulation	O
.	O

We	O
therefore	O
investigated	O
whether	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	O
protein	O
kinase	O
could	O
be	O
a	O
target	O
for	O
redox	O
regulation	O
and	O
whether	O
an	O
altered	O
activity	O
of	O
the	O
kinase	O
could	O
influence	O
IL-1-mediated	O
NF-kappa	O
B	O
activation	O
.	O

A	O
murine	O
T	O
cell	O
line	O
,	O
EL4	O
,	O
was	O
stimulated	O
with	O
IL-1	O
with	O
and	O
without	B-Negation
pretreatment	I-Negation
with	I-Negation
different	I-Negation
compounds	I-Negation
known	I-Negation
to	I-Negation
influence	I-Negation
the	I-Negation
cellular	I-Negation
redox	I-Negation
status	I-Negation
.	O

Thiol	O
modifying	O
agents	O
like	O
diamide	O
,	O
menadione	O
,	O
pyrrolidine	O
dithiocarbamate	O
(	O
PDTC	O
)	O
,	O
diethyl	O
dithiocarbamate	O
or	O
phenylarsine	O
oxide	O
inhibited	O
the	O
IL-1-induced	O
activation	O
of	O
the	O
IL-1RI-associated	O
protein	O
kinase	O
.	O

N-Acetylcysteine	O
,	O
alpha	O
,	O
alpha'-dipyridyl	O
,	O
aminotriazole	O
or	O
nitrofurantoin	O
did	O
not	B-Negation
show	I-Negation
any	I-Negation
effect	I-Negation
.	O

The	O
inhibition	O
by	O
PDTC	O
was	O
reversible	O
unless	O
glutathione	O
synthesis	O
was	O
blocked	O
by	O
buthionine	O
sulfoximine	O
.	O

The	O
described	O
conditions	O
which	O
inhibited	O
or	O
prevented	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	O
kinase	O
similarly	O
impaired	O
the	O
activation	O
of	O
NF-kappa	O
B	O
in	O
EL4	O
cells	O
.	O

From	O
these	O
observations	O
we	O
conclude	O
that	O
free	O
thiols	O
in	O
the	O
IL-1RI	O
complex	O
are	O
essential	O
for	O
the	O
activation	O
of	O
the	O
IL-1RI-associated	O
protein	O
kinase	O
and	O
that	O
this	O
process	O
is	O
mandatory	O
for	O
IL-1	O
signaling	O
leading	O
to	O
NF-kappa	O
B	O
activation	O
.	O

ATF1	O
and	O
CREB	O
trans-activate	O
a	O
cell	O
cycle	O
regulated	O
histone	O
H4	O
gene	O
at	O
a	O
distal	O
nuclear	O
matrix	O
associated	O
promoter	O
element	O
.	O

Proteins	O
of	O
the	O
ATF/CREB	O
class	O
of	O
transcription	O
factors	O
stimulate	O
gene	O
expression	O
of	O
several	O
cell	O
growth-related	O
genes	O
through	O
protein	O
kinase	O
A-related	O
cAMP	O
response	O
elements	O
.	O

The	O
promoter	O
activity	O
of	O
cell	O
cycle	O
regulated	O
histone	O
H4	O
genes	O
is	O
regulated	O
by	O
at	O
least	O
four	O
principal	O
cis-acting	O
elements	O
which	O
mediate	O
G1/S	O
phase	O
control	O
and/or	O
enhancement	O
of	O
transcription	O
during	O
the	O
cell	O
cycle	O
.	O

Using	O
protein-DNA	O
interaction	O
assays	O
we	O
show	O
that	O
the	O
H4	O
promoter	O
contains	O
two	O
ATF/CREB	O
recognition	O
motifs	O
which	O
interact	O
with	O
CREB	O
,	O
ATF1	O
,	O
and	O
ATF2	O
but	O
not	B-Negation
with	I-Negation
ATF4/CREB2	I-Negation
.	O

One	O
ATF/CRE	O
motif	O
is	O
located	O
in	O
the	O
distal	O
promoter	O
at	O
the	O
nuclear	O
matrix-associated	O
Site	O
IV	O
,	O
and	O
the	O
second	O
motif	O
is	O
present	O
in	O
the	O
proximal	O
promoter	O
at	O
Site	O
I	O
.	O

Both	O
ATF/CRE	O
motifs	O
overlap	O
binding	O
sequences	O
for	O
the	O
multifunctional	O
YY1	O
transcription	O
factor	O
,	O
which	O
has	O
previously	O
been	O
shown	O
to	O
be	O
nuclear	O
matrix	O
associated	O
.	O

Subnuclear	O
fractionation	O
reveals	O
that	O
there	O
are	O
two	O
ATF1	O
isoforms	O
which	O
appear	O
to	O
differ	O
with	O
respect	O
to	O
DNA	O
binding	O
activity	O
and	O
partition	O
selectively	O
between	O
nuclear	O
matrix	O
and	O
nonmatrix	O
compartments	O
,	O
consistent	O
with	O
the	O
role	O
of	O
the	O
nuclear	O
matrix	O
in	O
regulating	O
gene	O
expression	O
.	O

Site-directed	O
mutational	O
studies	O
demonstrate	O
that	O
Site	O
I	O
and	O
Site	O
IV	O
together	O
support	O
ATF1-	O
and	O
CREB-induced	O
trans-activation	O
of	O
the	O
H4	O
promoter	O
.	O

Thus	O
,	O
our	O
data	O
establish	O
that	O
ATF/CREB	O
factors	O
functionally	O
modulate	O
histone	O
H4	O
gene	O
transcription	O
at	O
distal	O
and	O
proximal	O
promoter	O
elements	O
.	O

IL-2	O
and	O
IL-7	O
induce	O
heterodimerization	O
of	O
STAT5	O
isoforms	O
in	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Despite	O
differences	O
in	O
T	O
cell	O
responses	O
induced	O
by	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-7	O
,	O
both	O
cytokines	O
modulate	O
T	O
cell	O
functions	O
by	O
activation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
proteins	O
.	O

We	O
examined	O
the	O
contribution	O
of	O
the	O
two	O
isoforms	O
of	O
STAT5	O
,	O
STAT5A	O
and	O
STAT5B	O
,	O
to	O
IL-2-	O
and	O
IL-7-induced	O
activation	O
of	O
human	O
peripheral	O
blood	O
T	O
lymphoblasts	O
.	O

Both	O
cytokines	O
induced	O
assembly	O
of	O
STAT5A	O
and	O
STAT5B	O
containing	O
complexes	O
capable	O
of	O
binding	O
to	O
the	O
interferon-gamma	O
activation	O
sequence	O
(	O
GAS	O
)	O
,	O
and	O
these	O
complexes	O
rapidly	O
translocated	O
(	O
within	O
1	O
min	O
)	O
into	O
the	O
nucleus	O
of	O
IL-2-	O
or	O
IL-7-treated	O
cells	O
.	O

The	O
kinetics	O
of	O
this	O
translocation	O
were	O
delayed	O
in	O
IL-7-treated	O
as	O
compared	O
to	O
IL-2-treated	O
cells	O
.	O

IL-2	O
and	O
IL-7	O
were	O
equivalent	O
in	O
their	O
ability	O
to	O
induce	O
tyrosine	O
phosphorylation	O
of	O
STAT5A	O
and	O
STAT5B	O
and	O
to	O
facilitate	O
binding	O
of	O
these	O
STATs	O
to	O
an	O
immobilized	O
GAS	O
element	O
.	O

Both	O
IL-2	O
and	O
IL-7	O
induced	O
substantial	O
amounts	O
of	O
STAT5A/STAT5B	O
heterodimerization	O
.	O

Moreover	O
,	O
we	O
observed	O
constitutive	O
association	O
of	O
STAT3	O
with	O
each	O
STAT5	O
isomer	O
.	O

These	O
data	O
suggest	O
that	O
IL-2	O
and	O
IL-7	O
induce	O
assembly	O
of	O
STAT	O
heterodimers	O
in	O
a	O
similar	O
manner	O
and	O
that	O
subsequent	O
cellular	O
responses	O
may	O
be	O
driven	O
by	O
induction	O
of	O
similar	O
sets	O
of	O
genes	O
.	O

Molecular	O
mechanisms	O
of	O
anoxia/reoxygenation-induced	O
neutrophil	O
adherence	O
to	O
cultured	O
endothelial	O
cells	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
(	O
1	O
)	O
determine	O
the	O
time	O
course	O
of	O
neutrophil	O
adhesion	O
to	O
monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
that	O
were	O
exposed	O
to	O
60	O
minutes	O
of	O
anoxia	O
followed	O
by	O
30	O
to	O
600	O
minutes	O
of	O
reoxygenation	O
and	O
(	O
2	O
)	O
define	O
the	O
mechanisms	O
responsible	O
for	O
both	O
the	O
early	O
(	O
minutes	O
)	O
and	O
late	O
(	O
hours	O
)	O
hyperadhesivity	O
of	O
postanoxic	O
HUVECs	O
to	O
human	O
neutrophils	O
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
leads	O
to	O
a	O
biphasic	O
increase	O
in	O
neutrophil	O
adhesion	O
to	O
HUVECs	O
,	O
with	O
peak	O
responses	O
occurring	O
at	O
30	O
minutes	O
(	O
phase	O
1	O
)	O
and	O
240	O
minutes	O
(	O
phase	O
2	O
)	O
after	O
reoxygenation	O
.	O

Oxypurinol	O
and	O
catalase	O
inhibited	O
phase-1	O
adhesion	O
,	O
suggesting	O
a	O
role	O
for	O
xanthine	O
oxidase	O
and	O
H2O2	O
.	O

In	O
comparison	O
,	O
platelet	O
activating	O
factor	O
(	O
PAF	O
)	O
contributed	O
to	O
both	O
phases	O
of	O
neutrophil	O
adhesion	O
.	O

Anti-intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
and	O
anti-P-selectin	O
antibodies	O
(	O
monoclonal	O
antibodies	O
[	O
mAbs	O
]	O
)	O
attenuated	O
phase-1	O
neutrophil	O
adhesion	O
,	O
consistent	O
with	O
roles	O
for	O
constitutively	O
expressed	O
ICAM-1	O
and	O
enhanced	O
surface	O
expression	O
of	O
preformed	O
P-selectin	O
.	O

Phase-2	O
neutrophil	O
adhesion	O
was	O
attenuated	O
by	O
an	O
anti-E-selectin	O
mAb	O
,	O
indicating	O
a	O
dominant	O
role	O
of	O
this	O
adhesion	O
molecule	O
in	O
the	O
late	O
phase	O
response	O
.	O

Pretreatment	O
with	O
actinomycin	O
D	O
and	O
cycloheximide	O
or	O
with	O
competing	O
ds-oligonucleotides	O
containing	O
the	O
nuclear	O
factor-kappa	O
B	O
or	O
activator	O
protein-1	O
cognate	O
DNA	O
sequences	O
significantly	O
attenuated	O
phase-2	O
response	O
,	O
suggesting	O
a	O
role	O
for	O
de	O
novo	O
macromolecule	O
synthesis	O
.	O

Surface	O
expression	O
of	O
ICAM-1	O
,	O
P-selectin	O
,	O
and	O
E-selectin	O
on	O
HUVECs	O
correlated	O
with	O
the	O
phase-1	O
and	O
-2	O
neutrophil	O
adhesion	O
responses	O
.	O

Collectively	O
,	O
these	O
findings	O
indicate	O
that	O
A/R	O
elicits	O
a	O
two-phase	O
neutrophil-endothelial	O
cell	O
adhesion	O
response	O
that	O
involves	O
transcription-independent	O
and	O
transcription-dependent	O
surface	O
expression	O
of	O
different	O
endothelial	O
cell	O
adhesion	O
molecules	O
.	O

c-Rel	O
and	O
p65	O
subunits	O
bind	O
to	O
an	O
upstream	O
NF-kappaB	O
site	O
in	O
human	O
granulocyte	O
macrophage-colony	O
stimulating	O
factor	O
promoter	O
involved	O
in	O
phorbol	O
ester	O
response	O
in	O
5637	O
cells	O
.	O

To	O
further	O
clarify	O
the	O
complex	O
transcriptional	O
regulation	O
of	O
the	O
human	O
GM-CSF	O
gene	O
,	O
which	O
was	O
extensively	O
investigated	O
in	O
activated	O
T	O
cells	O
,	O
we	O
have	O
studied	O
the	O
role	O
of	O
an	O
upstream	O
NF-kappaB	O
like	O
site	O
in	O
the	O
5637	O
non-lymphoid	O
cell	O
line	O
,	O
which	O
derives	O
from	O
a	O
bladder	O
carcinoma	O
and	O
constitutively	O
produces	O
GM-CSF	O
.	O

This	O
sequence	O
,	O
named	O
the	O
A	O
element	O
,	O
has	O
an	O
active	O
role	O
on	O
GM-CSF	O
transcription	O
and	O
is	O
responsive	O
to	O
the	O
tumor	O
promoter	O
PMA	O
in	O
transient	O
transfection	O
experiments	O
.	O

We	O
describe	O
here	O
a	O
heterodimeric	O
binding	O
complex	O
of	O
NF-kappaB	O
subunits	O
(	O
c-Rel	O
and	O
p65	O
)	O
which	O
is	O
identical	O
to	O
the	O
one	O
obtained	O
using	O
the	O
HIV-LTR-kappaB	O
site	O
as	O
recognition	O
sequence	O
and	O
different	O
from	O
the	O
one	O
(	O
c-Rel	O
and	O
p50	O
)	O
observed	O
with	O
nuclear	O
extracts	O
from	O
Mo	O
T-lymphoid	O
HTLV-II	O
infected	O
cells	O
.	O

Cyclosporin	O
A	O
inhibits	O
monocyte	O
tissue	O
factor	O
activation	O
in	O
cardiac	O
transplant	O
recipients	O
.	O

BACKGROUND	O
:	O
Fibrin	O
deposition	O
and	O
thrombosis	O
have	O
been	O
implicated	O
in	O
both	O
allograft	O
rejection	O
and	O
vasculopathy	O
after	O
cardiac	O
transplantation	O
.	O

Because	O
monocytes	O
play	O
a	O
pivotal	O
role	O
in	O
the	O
pathophysiology	O
of	O
intravascular	O
coagulation	O
activation	O
through	O
their	O
ability	O
to	O
synthesize	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
we	O
asked	O
(	O
1	O
)	O
whether	O
monocyte	O
TF	O
activation	O
occurs	O
in	O
cardiac	O
transplant	O
recipients	O
and	O
(	O
2	O
)	O
whether	O
monocyte	O
TF	O
expression	O
is	O
affected	O
by	O
treatment	O
with	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
measured	O
levels	O
of	O
TF	O
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
highly	O
purified	O
monocytes/macrophages	O
from	O
10	O
consecutive	O
cardiac	O
transplant	O
recipients	O
and	O
10	O
healthy	O
control	O
subjects	O
.	O

TF	O
activity	O
generated	O
by	O
both	O
unstimulated	O
and	O
endotoxin-stimulated	O
cells	O
was	O
significantly	O
higher	O
in	O
transplant	O
recipients	O
than	O
in	O
control	O
subjects	O
(	O
P	O
<	O
.05	O
)	O
.	O

Increased	O
monocyte	O
TF	O
expression	O
in	O
transplant	O
recipients	O
was	O
shown	O
to	O
be	O
adversely	O
affected	O
by	O
treatment	O
with	O
CsA	O
:	O
TF	O
induction	O
was	O
markedly	O
reduced	O
by	O
CsA	O
serum	O
concentrations	O
reaching	O
peak	O
CsA	O
drug	O
levels	O
.	O

Inhibition	O
of	O
TF	O
induction	O
in	O
the	O
presence	O
of	O
high	O
CsA	O
blood	O
concentrations	O
was	O
also	O
observed	O
when	O
stimulation	O
of	O
cells	O
was	O
performed	O
with	O
interferon-gamma	O
or	O
interleukin-1beta	O
.	O

As	O
shown	O
by	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
respectively	O
,	O
treatment	O
with	O
CsA	O
leads	O
to	O
decreased	O
TF	O
mRNA	O
expression	O
and	O
reduced	O
activation	O
of	O
the	O
NF-kappaB	O
transcription	O
factor	O
,	O
which	O
is	O
known	O
to	O
contribute	O
to	O
the	O
induction	O
of	O
the	O
TF	O
promotor	O
in	O
human	O
monocytes	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
demonstrates	O
that	O
TF	O
activation	O
,	O
occurring	O
in	O
mononuclear	O
cells	O
of	O
cardiac	O
transplant	O
recipients	O
,	O
is	O
inhibited	O
by	O
treatment	O
with	O
CsA	O
.	O

Inhibition	O
of	O
monocyte	O
TF	O
induction	O
by	O
CsA	O
may	O
contribute	O
to	O
its	O
successful	O
use	O
in	O
cardiac	O
transplant	O
medicine	O
and	O
might	O
be	O
useful	O
in	O
managing	O
further	O
settings	O
of	O
vascular	O
pathology	O
also	O
known	O
to	O
involve	O
TF	O
expression	O
and	O
NF-kappaB	O
activation	O
.	O

Agonistic	O
activity	O
of	O
a	O
CD40-specific	O
single-chain	O
Fv	O
constructed	O
from	O
the	O
variable	O
regions	O
of	O
mAb	O
G28-5	O
.	O

A	O
single-chain	O
Fv	O
(	O
sFv	O
)	O
was	O
expressed	O
from	O
the	O
variable	O
regions	O
of	O
the	O
CD40-specific	O
mAb	O
G28-5	O
.	O

The	O
molecule	O
bound	O
CD40	O
with	O
a	O
high	O
affinity	O
(	O
2.2	O
nM	O
)	O
and	O
was	O
a	O
monomer	O
in	O
solution	O
.	O

Surprisingly	O
,	O
G28-5	O
sFv	O
was	O
a	O
potent	O
CD40	O
agonist	O
that	O
rapidly	O
crosslinked	O
CD40	O
on	O
the	O
cell	O
surface	O
but	O
did	O
not	B-Negation
crosslink	I-Negation
CD40-Ig	I-Negation
in	I-Negation
solution	I-Negation
.	O

G28-5	O
sFv	O
was	O
a	O
more	O
potent	O
agonist	O
than	O
G28-5	O
IgG	O
and	O
was	O
able	O
to	O
stimulate	O
CD40	O
responses	O
by	O
B	O
cells	O
and	O
monocytes	O
.	O

G28-5	O
IgG	O
partially	O
blocked	O
,	O
whereas	O
G28-5	O
sFv	O
augmented	O
CD40	O
responses	O
during	O
stimulation	O
with	O
natural	O
ligand	O
(	O
gp39-CD8	O
fusion	O
protein	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
functional	O
activity	O
of	O
ligands	O
built	O
from	O
the	O
binding	O
site	O
of	O
G28-5	O
is	O
highly	O
dependent	O
upon	O
the	O
size	O
and	O
physical	O
properties	O
of	O
the	O
molecule	O
both	O
in	O
solution	O
and	O
on	O
the	O
cell	O
surfaces	O
.	O

Competent	O
transcription	O
initiation	O
by	O
RNA	O
polymerase	O
II	O
in	O
cell-free	O
extracts	O
from	O
xeroderma	O
pigmentosum	O
groups	O
B	O
and	O
D	O
in	O
an	O
optimized	O
RNA	O
transcription	O
assay	O
.	O

The	O
human	O
autosomal	O
recessive	O
disease	O
,	O
xeroderma	O
pigmentosum	O
(	O
XP	O
)	O
,	O
can	O
result	O
from	O
mutations	O
in	O
any	O
one	O
of	O
seven	O
genes	O
,	O
designated	O
XPA	O
through	O
XPG	O
.	O

Of	O
these	O
,	O
the	O
XPB	O
and	O
XPD	O
genes	O
encode	O
proteins	O
that	O
are	O
subunits	O
of	O
a	O
general	O
transcription	O
factor	O
,	O
TFIIH	O
,	O
involved	O
in	O
both	O
nucleotide	O
excision	O
repair	O
(	O
NER	O
)	O
and	O
initiation	O
of	O
mRNA	O
transcription	O
by	O
RNA	O
polymerase	O
II	O
.	O

In	O
humans	O
,	O
mutation	O
of	O
the	O
XPB	O
or	O
XPD	O
gene	O
impairs	O
NER	O
,	O
resulting	O
in	O
hyper-sensitivity	O
to	O
sunlight	O
and	O
greatly	O
increased	O
skin	O
tumor	O
formation	O
.	O

However	O
,	O
no	B-Negation
transcription	I-Negation
deficiency	I-Negation
has	I-Negation
been	I-Negation
demonstrated	I-Negation
in	I-Negation
either	I-Negation
XP-B	I-Negation
or	I-Negation
XP-D	I-Negation
.	O

We	O
have	O
employed	O
an	O
optimized	O
cell-free	O
RNA	O
transcription	O
assay	O
to	O
analyze	O
transcription	O
activity	O
of	O
XP-B	O
and	O
XP-D	O
.	O

Although	O
the	O
growth	O
rate	O
was	O
normal	O
,	O
the	O
XP-B	O
and	O
XP-D	O
cells	O
contained	O
reduced	O
amounts	O
of	O
TFIIH	O
.	O

Extracts	O
prepared	O
from	O
XP-B	O
and	O
XP-D	O
lymphoblastoid	O
cells	O
exhibited	O
similar	O
transcription	O
activity	O
from	O
the	O
adenovirus	O
major	O
late	O
promoter	O
when	O
compared	O
to	O
that	O
in	O
extracts	O
from	O
normal	O
cells	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
the	O
XP-B	O
and	O
XP-D	O
lymphoblastoid	O
cells	O
do	O
not	B-Negation
have	I-Negation
impaired	I-Negation
RNA	I-Negation
transcription	I-Negation
activity	I-Negation
.	O

We	O
consider	O
the	O
possible	O
consequences	O
of	O
the	O
reduced	O
cellular	O
content	O
of	O
TFIIH	O
for	O
the	O
clinical	O
symptoms	O
in	O
XP-B	O
or	O
XP-D	O
patients	O
,	O
and	O
discuss	O
a	O
'conditional	O
phenotype	O
'	O
that	O
may	O
involve	O
an	O
impairment	O
of	O
cellular	O
function	O
only	O
under	O
certain	O
growth	O
conditions	O
.	O

Cyclosporin	O
A	O
inhibits	O
early	O
mRNA	O
expression	O
of	O
G0/G1	O
switch	O
gene	O
2	O
(	O
G0S2	O
)	O
in	O
cultured	O
human	O
blood	O
mononuclear	O
cells	O
.	O

Cyclosporin	O
A	O
(	O
CsA	O
)	O
may	O
achieve	O
its	O
immunosuppressive	O
effects	O
by	O
inhibiting	O
the	O
calcium-	O
and	O
calmodulin-dependent	O
phosphatase	O
calcineurin	O
which	O
is	O
required	O
for	O
activation	O
of	O
target	O
genes	O
by	O
members	O
of	O
the	O
NFAT	O
(	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
)	O
transcription	O
factor	O
family	O
.	O

Among	O
these	O
target	O
genes	O
is	O
the	O
gene	O
encoding	O
interleukin-2	O
(	O
IL2	O
)	O
,	O
a	O
cytokine	O
facilitating	O
progression	O
through	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

However	O
,	O
IL2	O
does	O
not	B-Negation
reverse	I-Negation
CsA	I-Negation
inhibition	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
at	I-Speculation
least	I-Speculation
one	I-Speculation
other	I-Speculation
NFAT-sensitive	I-Speculation
gene	I-Speculation
may	I-Speculation
be	I-Speculation
involved	I-Speculation
.	O

The	O
human	O
G0/G1	O
switch	O
gene	O
,	O
G0S2	O
,	O
has	O
potential	O
NFAT-binding	O
sites	O
in	O
the	O
5	O
'	O
flank	O
and	O
encodes	O
a	O
small	O
basic	O
potential	O
phosphoprotein	O
of	O
unknown	O
function	O
.	O

Using	O
a	O
sensitive	O
,	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
,	O
G0S2	O
mRNA	O
levels	O
were	O
assayed	O
in	O
cultured	O
blood	O
mononuclear	O
cells	O
.	O

Freshly	O
isolated	O
cells	O
contain	O
high	O
levels	O
of	O
G0S2	O
mRNA	O
which	O
rapidly	O
decline	O
.	O

This	O
``	O
spontaneous	O
stimulation	O
``	O
is	O
also	O
noted	O
with	O
some	O
other	O
G0S	O
genes	O
and	O
has	O
been	O
attributed	O
to	O
some	O
aspect	O
of	O
the	O
isolation	O
procedure	O
.	O

In	O
cells	O
that	O
have	O
been	O
preincubated	O
to	O
lower	O
mRNA	O
levels	O
,	O
there	O
is	O
a	O
transient	O
increase	O
in	O
G0S2	O
mRNA	O
,	O
peaking	O
between	O
1-2	O
h	O
,	O
in	O
response	O
to	O
Concanavalin-A	O
(	O
ConA	O
)	O
,	O
or	O
to	O
the	O
combination	O
of	O
phorbol	O
ester	O
(	O
TPA	O
)	O
,	O
and	O
the	O
calcium	O
ionophore	O
,	O
ionomycin	O
.	O

Both	O
these	O
responses	O
are	O
inhibited	O
by	O
CsA	O
.	O

Our	O
results	O
suggest	O
that	O
G0S2	O
expression	O
is	O
required	O
to	O
commit	O
cells	O
to	O
enter	O
the	O
G1	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
that	O
,	O
while	O
not	O
excluding	O
other	O
possible	O
targets	O
,	O
early	O
inhibition	O
of	O
G0S2	O
expression	O
by	O
CsA	O
may	O
be	O
important	O
in	O
achieving	O
immunosuppression	O
.	O

G0S2	O
may	O
be	O
of	O
value	O
as	O
a	O
reporter	O
gene	O
for	O
analyzing	O
the	O
mechanism	O
of	O
action	O
of	O
CsA	O
and	O
its	O
influence	O
on	O
the	O
positive	O
and	O
negative	O
selection	O
of	O
lymphocytes	O
in	O
response	O
to	O
self	O
and	O
not-self	O
antigens	O
.	O

Estrogen	O
receptor	O
diminishes	O
DNA-binding	O
activities	O
of	O
chicken	O
GATA-1	O
and	O
CACCC-binding	O
proteins	O
.	O

The	O
estrogen	O
receptor	O
(	O
ER	O
)	O
repressed	O
erythroid	O
differentiation	O
and	O
erythroid-specific	O
gene	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
ER	O
alpha	O
(	O
referred	O
to	O
throughout	O
as	O
ER	O
)	O
on	O
DNA-binding	O
activities	O
of	O
transcription	O
factors	O
involved	O
in	O
regulating	O
the	O
expression	O
of	O
erythroid-specific	O
genes	O
,	O
and	O
,	O
in	O
particular	O
,	O
the	O
histone	O
H5	O
gene	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
found	O
that	O
in	O
the	O
presence	O
of	O
rabbit	O
reticulocyte	O
lysate	O
,	O
human	O
ER	O
reduced	O
the	O
binding	O
activities	O
of	O
chicken	O
immature	O
erythrocyte	O
nuclear	O
extracted	O
proteins	O
to	O
GATA	O
and	O
CACCC	O
sites	O
in	O
the	O
H5	O
promoter	O
and	O
enhancer	O
.	O

In	O
contrast	O
,	O
the	B-Negation
binding	I-Negation
activities	I-Negation
of	I-Negation
NF1	I-Negation
and	I-Negation
Sp1	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
ER	I-Negation
.	O

Binding	O
of	O
ER	O
to	O
an	O
estrogen	O
response	O
element	O
was	O
enhanced	O
by	O
addition	O
of	O
rabbit	O
reticulocyte	O
lysate	O
.	O

This	O
lysate	O
was	O
also	O
necessary	O
for	O
ER	O
to	O
diminish	O
the	O
DNA-binding	O
activity	O
of	O
GATA-1	O
.	O

These	O
results	O
suggest	O
that	O
additional	O
factor	O
(	O
s	O
)	O
are	O
necessary	O
for	O
full	O
ER	O
function	O
.	O

Both	O
GATA-1	O
and	O
CACCC-binding	O
proteins	O
are	O
critical	O
for	O
the	O
developmentally	O
regulated	O
expression	O
of	O
erythroid-specific	O
genes	O
.	O

We	O
hypothesize	O
that	O
interference	O
in	O
DNA-binding	O
activities	O
of	O
GATA-1	O
and	O
CACCC-binding	O
proteins	O
is	O
the	O
mechanism	O
by	O
which	O
the	O
ER	O
inhibits	O
regulation	O
of	O
these	O
genes	O
.	O

Constitutive	O
expression	O
c-fos	O
,	O
c-jun	O
,	O
and	O
NF	O
kappa	O
B	O
mRNA	O
is	O
in	O
nucleated	O
fetal	O
blood	O
cells	O
and	O
up-regulation	O
of	O
c-fos	O
and	O
c-jun	O
with	O
anti-CD3	O
stimulation	O
.	O

Fetal	O
and	O
neonatal	O
lymphocytes	O
are	O
relatively	O
resistant	O
to	O
activation	O
and	O
cytokine	O
production	O
when	O
stimulated	O
either	O
via	O
their	O
T-cell	O
antigen	O
receptors	O
or	O
lectins	O
.	O

The	O
molecular	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
this	O
phenomenon	O
have	O
not	O
been	O
clearly	O
elucidated	O
.	O

We	O
have	O
hypothesized	O
that	O
such	O
defects	O
in	O
fetal/neonatal	O
T-cell	O
activation	O
may	O
be	O
due	O
to	O
lack	O
of	O
expression	O
of	O
the	O
transcriptional	O
regulatory	O
elements	O
required	O
for	O
T-cell	O
activation	O
.	O

We	O
used	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
to	O
examine	O
both	O
fetal	O
and	O
term	O
neonatal	O
cord	O
bloods	O
for	O
mRNA	O
expression	O
of	O
three	O
transcription	O
factors	O
implicated	O
in	O
T-cell	O
activation	O
:	O
c-jun	O
,	O
c-fos	O
,	O
and	O
NF	O
kappa	O
B	O
(	O
p50	O
subunit	O
)	O
.	O

We	O
demonstrate	O
that	O
mRNAs	O
for	O
all	O
three	O
of	O
these	O
regulatory	O
factors	O
are	O
expressed	O
in	O
fetal	O
blood	O
cells	O
by	O
the	O
27th	O
week	O
of	O
gestation	O
and	O
in	O
term	O
cord	O
bloods	O
.	O

Activation	O
of	O
term	O
infant	O
cord	O
blood	O
mononuclear	O
cells	O
with	O
anti-CD3	O
monoclonal	O
antibodies	O
resulted	O
in	O
up-regulation	O
of	O
both	O
c-jun	O
and	O
c-fos	O
mRNAs	O
within	O
15	O
min	O
of	O
stimulation	O
.	O

However	O
,	O
secretion	O
of	O
IL-2	O
by	O
anti-CD3-stimulated	O
cord	O
blood	O
mononuclear	O
cells	O
was	O
still	O
blunted	O
compared	O
with	O
control	O
cells	O
from	O
adults	O
.	O

We	O
conclude	O
that	O
fetal	O
nucleated	O
blood	O
cells	O
constitutively	O
express	O
important	O
genes	O
for	O
cytokine	O
regulation	O
and	O
are	O
able	O
to	O
increase	O
intracellular	O
accumulation	O
of	O
the	O
mRNAs	O
for	O
these	O
factors	O
in	O
response	O
to	O
anti-CD3	O
stimulation	O
.	O

Thus	O
,	O
qualitative	B-Negation
differences	I-Negation
in	I-Negation
the	I-Negation
capacity	I-Negation
to	I-Negation
regulate	I-Negation
these	I-Negation
factors	I-Negation
could	I-Negation
not	I-Negation
be	I-Negation
shown	I-Negation
in	I-Negation
fetal	I-Negation
blood	I-Negation
cells	I-Negation
.	O

Quantitative	O
experiments	O
comparing	O
binding	O
of	O
these	O
transcription	O
factors	O
to	O
the	O
IL-2	O
promoter	O
are	O
currently	O
under	O
investigation	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus-1	O
in	O
primary	O
human	O
T	O
cells	O
is	O
dependent	O
on	O
the	O
autocrine	O
secretion	O
of	O
tumor	O
necrosis	O
factor	O
through	O
the	O
control	O
of	O
nuclear	O
factor-kappa	O
B	O
activation	O
.	O

Tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-alpha	O
controls	O
T-cell	O
activation	O
and	O
is	O
a	O
major	O
inducer	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
replication	O
in	O
chronically	O
infected	O
cells	O
.	O

Therefore	O
,	O
we	O
have	O
investigated	O
its	O
role	O
in	O
primary	O
cultures	O
of	O
HIV-infected	O
human	O
T	O
lymphocytes	O
by	O
using	O
neutralizing	O
anti-TNF-alpha	O
antibodies	O
or	O
TNF-alpha	O
.	O

Primary	O
resting	O
T	O
lymphocytes	O
produced	O
TNF-alpha	O
and	O
supported	O
HIV	O
replication	O
after	O
T-cell	O
receptor	O
activation	O
.	O

Addition	O
of	O
neutralizing	O
anti-TNF-alpha	O
antibodies	O
drastically	O
reduced	O
p24	O
antigen	O
release	O
and	O
prevented	O
CD4+	O
cell	O
depletion	O
associated	O
with	O
infection	O
.	O

Anti-TNF-alpha	O
also	O
prevented	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappa	O
B	O
)	O
activation	O
,	O
and	O
a	O
good	O
correlation	O
between	O
this	O
inhibition	O
and	O
inhibition	O
of	O
HIV	O
replication	O
was	O
observed	O
.	O

Moreover	O
,	O
supplementing	O
the	O
cultures	O
with	O
high	O
doses	O
of	O
IL-2	O
reverted	O
anti-TNF-alpha	O
inhibition	O
of	O
cell	O
proliferation	O
but	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
inhibition	I-Negation
of	I-Negation
HIV	I-Negation
p24	I-Negation
antigen	I-Negation
release	I-Negation
or	I-Negation
NF-kappa	I-Negation
B	I-Negation
activation	I-Negation
in	I-Negation
the	I-Negation
same	I-Negation
cultures	I-Negation
.	O

Moreover	O
,	O
anti-TNF-alpha	O
inhibited	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
transcription	O
of	O
a	O
reporter	O
gene	O
in	O
primary	O
T	O
cells	O
in	O
response	O
to	O
activation	O
,	O
either	O
in	O
the	O
presence	O
or	O
the	O
absence	B-Negation
of	I-Negation
HIV-1	I-Negation
Tat	I-Negation
.	O

Our	O
results	O
support	O
an	O
important	O
role	O
for	O
autocrine	O
TNF-alpha	O
secretion	O
in	O
controlling	O
HIV	O
replication	O
in	O
primary	O
T	O
cells	O
because	O
of	O
its	O
ability	O
to	O
maintain	O
NF-kappa	O
B	O
elevated	O
in	O
the	O
nucleus	O
of	O
T	O
cells	O
.	O

A	O
thiol	O
antioxidant	O
regulates	O
IgE	O
isotype	O
switching	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor-kappaB	O
.	O

The	O
binding	O
site	O
for	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
is	O
present	O
at	O
the	O
promoter	O
region	O
of	O
the	O
germline	O
Cepsilon	O
gene	O
,	O
but	O
there	O
is	O
little	O
information	O
on	O
whether	O
this	O
factor	O
is	O
involved	O
in	O
regulating	O
IgE	O
synthesis	O
by	O
human	O
B	O
cells	O
.	O

Accordingly	O
,	O
we	O
studied	O
the	O
role	O
of	O
NF-kappaB	O
in	O
germline	O
Cepsilon	O
transcription	O
by	O
using	O
two	O
human	O
Burkitt	O
's	O
lymphoma	O
B	O
cell	O
lines	O
,	O
DND39	O
and	O
DG75	O
.	O

In	O
both	O
cell	O
lines	O
,	O
n-acetyl-L-cysteine	O
(	O
NAC	O
)	O
,	O
a	O
potent	O
thiol	O
antioxidant	O
,	O
inhibited	O
the	O
triggering	O
of	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	O
by	O
IL-4	O
and	O
by	O
anti-CD40	O
monoclonal	O
antibody	O
.	O

Although	O
IL-4	O
activated	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
6	O
in	O
addition	O
to	O
NF-kappaB	O
,	O
NAC	O
treatment	O
or	O
the	O
transfection	O
of	O
decoy	O
oligodeoxynucleotides	O
for	O
NF-kappaB	O
or	O
STAT6	O
only	O
partly	O
blocked	O
IL-4-induced	O
germline	O
Cepsilon	O
transcription	O
.	O

However	O
,	O
these	O
two	O
decoy	O
oligodeoxynucleotides	O
together	O
almost	O
completely	O
abrogated	O
IL-4-induced	O
germline	O
Cepsilon	O
transcription	O
.	O

Of	O
note	O
,	O
CD40-mediated	O
enhancement	O
of	O
IL-4-driven	O
germline	O
Cepsilon	O
transcription	O
was	O
markedly	O
decreased	O
by	O
NAC	O
or	O
by	O
a	O
decoy	O
oligodeoxynucleotide	O
for	O
NF-kappaB	O
.	O

The	O
effect	O
of	O
NAC	O
was	O
also	O
examined	O
on	O
deletional	O
switch	O
recombination	O
underlying	O
the	O
isotype	O
switch	O
to	O
IgE	O
.	O

NAC	O
inhibited	O
the	O
generation	O
of	O
Smu/Sepsilon	O
switch	O
fragments	O
in	O
normal	O
human	O
B	O
cells	O
costimulated	O
with	O
IL-4	O
and	O
anti-CD40	O
monoclonal	O
antibody	O
.	O

It	O
also	O
abolished	O
IL-4-induced	O
upregulation	O
of	O
CD40	O
but	O
promoted	O
upregulation	O
of	O
CD23	O
.	O

These	O
results	O
suggest	O
that	O
coordination	O
of	O
NF-kappaB	O
and	O
STAT6	O
may	O
be	O
required	O
for	O
induction	O
of	O
germline	O
Cepsilon	O
transcription	O
by	O
IL-4	O
,	O
and	O
that	O
CD40-mediated	O
NF-kappaB	O
activation	O
may	O
be	O
important	O
in	O
regulating	O
both	O
enhancement	O
of	O
germline	O
Cepsilon	O
transcription	O
and	O
class	O
switching	O
to	O
IgE	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
of	O
IL-5	O
synthesis	O
in	O
atopic	O
diseases	O
:	O
a	O
study	O
with	O
allergen-specific	O
human	O
helper	O
T	O
cells	O
.	O

BACKGROUND	O
:	O
Cytokines	O
produced	O
by	O
helper	O
T	O
cells	O
are	O
intimately	O
involved	O
in	O
chronic	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

OBJECTIVE	O
:	O
We	O
investigated	O
the	O
production	O
of	O
IL-5	O
,	O
a	O
potent	O
growth	O
factor	O
and	O
chemotactic	O
factor	O
for	O
eosinophils	O
,	O
by	O
CD4+	O
T	O
lymphocytes	O
in	O
patients	O
with	O
asthma	O
.	O

METHODS	O
:	O
Allergen-specific	O
T	O
cell	O
clones	O
and	O
T	O
cell	O
hybridomas	O
were	O
established	O
from	O
the	O
peripheral	O
blood	O
lymphocytes	O
of	O
patients	O
with	O
asthma	O
,	O
and	O
the	O
responses	O
to	O
various	O
stimuli	O
were	O
determined	O
.	O

RESULTS	O
:	O
After	O
nonspecific	O
stimulation	O
,	O
IL-5	O
production	O
by	O
CD4+	O
T	O
cells	O
from	O
both	O
atopic	O
and	O
nonatopic	O
subjects	O
with	O
asthma	O
was	O
significantly	O
enhanced	O
compared	O
with	O
that	O
by	O
cells	O
from	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
mononuclear	O
cells	O
from	O
atopic	O
asthma	O
patients	O
both	O
proliferated	O
and	O
produced	O
IL-5	O
after	O
incubation	O
with	O
mite	O
allergen	O
,	O
suggesting	O
that	O
mite-specific	O
helper	O
T	O
cells	O
were	O
involved	O
in	O
the	O
eosinophilic	O
inflammation	O
of	O
atopic	O
asthma	O
.	O

A	O
human	O
IL-5	O
promoter/enhancer	O
luciferase	O
gene	O
construct	O
transfected	O
into	O
IL-5-producing	O
T	O
cell	O
clones	O
was	O
clearly	O
transcribed	O
after	O
stimulation	O
,	O
indicating	O
that	O
the	O
515	O
base	O
pair	O
IL-5	O
gene	O
segment	O
upstream	O
of	O
the	O
coding	O
region	O
was	O
sufficient	O
to	O
respond	O
to	O
activating	O
signals	O
in	O
human	O
helper	O
T	O
cells	O
.	O

The	B-Negation
same	I-Negation
gene	I-Negation
segment	I-Negation
was	I-Negation
not	I-Negation
transcribed	I-Negation
in	I-Negation
IL-5-nonproducing	I-Negation
T	I-Negation
cell	I-Negation
clones	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
human	I-Speculation
T	I-Speculation
cell	I-Speculation
IL-5	I-Speculation
synthesis	I-Speculation
is	I-Speculation
regulated	I-Speculation
at	I-Speculation
the	I-Speculation
transcriptional	I-Speculation
level	I-Speculation
.	O

Experiments	O
with	O
T	O
cell	O
hybridomas	O
confirmed	O
these	O
findings	O
and	O
suggested	O
that	O
a	O
unique	O
transcription	O
factor	O
may	O
be	O
essential	O
for	O
human	O
IL-5	O
gene	O
transcription	O
.	O

CONCLUSION	O
:	O
Enhanced	O
IL-5	O
production	O
by	O
helper	O
T	O
cells	O
seems	O
to	O
cause	O
the	O
eosinophilic	O
inflammation	O
of	O
both	O
atopic	O
and	O
nonatopic	O
asthma	O
.	O

Elucidation	O
of	O
IL-5-specific	O
regulatory	O
mechanisms	O
may	O
facilitate	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
allergic	O
diseases	O
associated	O
with	O
eosinophilic	O
inflammation	O
.	O

Regulation	O
of	O
NF-kappa	O
B	O
activity	O
by	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
stability	O
.	O

Transcription	O
factor	O
NF-kappa	O
B	O
must	O
be	O
released	O
from	O
cytoplasmic	O
inhibitory	O
molecules	O
(	O
I	O
kappa	O
Bs	O
)	O
in	O
order	O
to	O
move	O
to	O
the	O
nucleus	O
and	O
to	O
activate	O
its	O
target	O
genes	O
.	O

Little	O
is	O
known	O
about	O
the	O
mechanisms	O
regulating	O
the	O
maintenance	O
of	O
constitutive	O
nuclear	O
NF-kappa	O
B	O
in	O
some	O
cell-types	O
and	O
of	O
sustained	O
nuclear	O
NF-kappa	O
B	O
activity	O
after	O
stimulation	O
.	O

Increased	O
turnover	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
constitutive	O
NF-kappa	O
B	O
activity	O
in	O
mature	O
B	O
cells	O
.	O

We	O
therefore	O
compared	O
the	O
turnover	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
in	O
mature	O
B	O
cells	O
and	O
HeLa	O
cells	O
.	O

Both	O
proteins	O
display	O
a	O
high	O
turnover	O
in	O
B	O
cells	O
although	O
I	O
kappa	O
B	O
beta	O
is	O
considerably	O
more	O
stable	O
than	O
I	O
kappa	O
B	O
alpha	O
.	O

The	O
half-life	O
of	O
both	O
inhibitors	O
is	O
increased	O
in	O
HeLa	O
cells	O
.	O

In	O
contrast	O
,	O
all	O
other	O
NF-kappa	O
B/I	O
kappa	O
B	O
molecules	O
tested	O
are	O
relatively	O
stable	O
in	O
both	O
cell-types	O
.	O

The	O
elevated	O
turnover	O
of	O
endogenous	O
I	O
kappa	O
B	O
alpha	O
in	O
Namalwa	O
cells	O
is	O
inhibited	O
by	O
a	O
proteasome	O
inhibitor	O
and	O
thus	O
seems	O
to	O
be	O
driven	O
by	O
the	O
same	O
degradation	O
machinery	O
as	O
the	O
slower	O
turnover	O
in	O
non-B	O
cells	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
processes	O
involved	O
in	O
persistent	O
activation	O
of	O
NF-kappa	O
B	O
.	O

TNF-alpha	O
signaling	O
leads	O
to	O
a	O
rapid	O
depletion	O
of	O
cellular	O
I	O
kappa	O
B	O
beta	O
pools	O
.	O

I	O
kappa	O
B	O
alpha	O
is	O
efficiently	O
resynthesized	O
whereas	O
I	O
kappa	O
B	O
beta	O
levels	O
stay	O
low	O
for	O
a	O
prolonged	O
time	O
.	O

NF-kappa	O
B	O
binding	O
activity	O
can	O
be	O
detected	O
for	O
several	O
hours	O
after	O
stimulation	O
.	O

We	O
found	O
that	O
removal	O
of	O
the	O
TNF-alpha	O
containing	O
medium	O
causes	O
a	O
rapid	O
decrease	O
in	O
nuclear	O
NF-kappa	O
B	O
.	O

A	O
phosphoform	O
of	O
newly	O
synthesized	O
I	O
kappa	O
B	O
alpha	O
is	O
visible	O
when	O
degradation	O
by	O
the	O
proteasome	O
is	O
inhibited	O
and	O
new	O
I	O
kappa	O
B	O
alpha	O
displays	O
the	O
same	O
properties	O
regarding	O
phosphorylation	O
and	O
degradation	O
in	O
response	O
to	O
a	O
second	O
inducer	O
.	O

There	O
is	O
no	B-Negation
significant	I-Negation
difference	I-Negation
in	I-Negation
the	I-Negation
turnover	I-Negation
of	I-Negation
pre-	I-Negation
and	I-Negation
post-inductive	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
alpha	I-Negation
.	O

These	O
observations	O
suggest	O
that	O
resynthesis	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
removal	O
of	O
the	O
stimulus	O
are	O
obligatory	O
steps	O
for	O
the	O
inactivation	O
of	O
nuclear	O
NF	O
kappa	O
B	O
.	O

Control	O
of	O
NF-kappa	O
B	O
activity	O
by	O
the	O
I	O
kappa	O
B	O
beta	O
inhibitor	O
.	O

The	O
transcription	O
factor	O
NF-kappa	O
B	O
is	O
maintained	O
in	O
an	O
inactive	O
cytoplasmic	O
state	O
by	O
I	O
kappa	O
B	O
inhibitors	O
.	O

In	O
mammalian	O
cells	O
,	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
proteins	O
have	O
been	O
purified	O
and	O
shown	O
to	O
be	O
the	O
inhibitors	O
of	O
NF-kappa	O
B	O
through	O
their	O
association	O
with	O
the	O
p65	O
or	O
c-Rel	O
subunits	O
.	O

In	O
addition	O
,	O
we	O
have	O
isolated	O
a	O
third	O
NF-kappa	O
B	O
inhibitor	O
,	O
I	O
kappa	O
B	O
epsilon	O
(	O
1	O
)	O
.	O

Upon	O
treatment	O
with	O
a	O
large	O
variety	O
of	O
inducers	O
,	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
are	O
proteolytically	O
degraded	O
,	O
resulting	O
in	O
NF-kappa	O
B	O
translocation	O
into	O
the	O
nucleus	O
.	O

Here	O
we	O
show	O
that	O
in	O
E29.1	O
T	O
cell	O
hybridoma	O
I	O
kappa	O
B	O
alpha	O
and	O
I	O
kappa	O
B	O
beta	O
are	O
equally	O
associated	O
with	O
p65	O
and	O
that	O
I	O
kappa	O
B	O
beta	O
is	O
degraded	O
in	O
response	O
to	O
TNF	O
alpha	O
in	O
contrast	O
to	O
what	O
has	O
been	O
originally	O
published	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
,	O
unlike	O
I	O
kappa	O
B	O
alpha	O
,	O
I	O
kappa	O
B	O
beta	O
is	O
constitutively	O
phosphorylated	O
and	O
resynthesized	O
as	O
a	O
hypophosphorylated	O
form	O
.	O

The	O
absence	B-Negation
of	I-Negation
slow	I-Negation
migrating	I-Negation
forms	I-Negation
of	I-Negation
I	I-Negation
kappa	I-Negation
B	I-Negation
beta	I-Negation
following	I-Negation
stimulation	I-Negation
suggests	B-Speculation
that	I-Speculation
the	I-Speculation
phosphorylation	I-Speculation
does	I-Speculation
not	I-Speculation
necessarily	I-Speculation
constitute	I-Speculation
the	I-Speculation
signal-induced	I-Speculation
event	I-Speculation
which	I-Speculation
targets	I-Speculation
the	I-Speculation
molecule	I-Speculation
for	I-Speculation
proteolysis	I-Speculation
.	O

NF-kappa	O
B/Rel	O
family	O
members	O
regulating	O
the	O
ICAM-1	O
promoter	O
in	O
monocytic	O
THP-1	O
cells	O
.	O

A	O
kappa	O
B-site	O
was	O
identified	O
in	O
the	O
promoter	O
of	O
the	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
gene	O
,	O
which	O
is	O
involved	O
in	O
regulation	O
of	O
ICAM-1	O
expression	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
and	O
glucocorticoids	O
.	O

We	O
now	O
report	O
on	O
the	O
transcription	O
factors	O
which	O
bind	O
and	O
transactivate	O
this	O
enhancer	O
sequence	O
.	O

In	O
vitro	O
,	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
appeared	O
to	O
bind	O
RelA	O
and	O
c-Rel	O
homodimers	O
as	O
well	O
as	O
heterodimers	O
with	O
NF-kappa	O
B1	O
,	O
but	O
weakly	O
NF-kappa	O
B1	O
homodimers	O
.	O

In	O
addition	O
,	O
both	O
RelA	O
and	O
c-Rel	O
,	O
but	O
not	B-Negation
NF-kappa	I-Negation
B1	I-Negation
,	O
were	O
shown	O
to	O
transactivate	O
an	O
ICAM-1	O
kappa	O
B-reporter	O
construct	O
.	O

In	O
monocytic	O
THP-1	O
cells	O
TNF-alpha	O
induced	O
two	O
nuclear	O
complexes	O
which	O
in	O
vitro	O
bound	O
to	O
the	O
ICAM-1	O
kappa	O
B	O
site	O
.	O

Using	O
antibodies	O
in	O
an	O
electrophoretic	O
mobility	O
supershift	O
assay	O
,	O
one	O
of	O
these	O
complexes	O
was	O
shown	O
to	O
contain	O
NF-kappa	O
B1	O
and	O
RelA	O
,	O
and	O
to	O
bind	O
with	O
higher	O
affinity	O
to	O
the	O
consensus	O
kappa	O
B	O
site	O
in	O
the	O
HIV	O
long	O
terminal	O
repeat	O
.	O

The	O
second	O
complex	O
contained	O
RelA	O
,	O
and	O
exhibited	O
higher	O
affinity	O
towards	O
the	O
ICAM-1	O
kappa	O
B	O
than	O
to	O
the	O
HIV	O
kappa	O
B	O
site	O
.	O

The	O
glucocorticoid	O
receptor	O
was	O
shown	O
to	O
repress	O
activity	O
of	O
both	O
the	O
RelA	O
homodimer	O
and	O
the	O
NF-kappa	O
B1/RelA	O
heterodimer	O
.	O

We	O
argue	O
that	O
in	O
vivo	O
RelA	O
homodimers	O
are	O
likely	O
to	O
play	O
a	O
dominant	O
role	O
in	O
TNF-alpha-induced	O
ICAM-1	O
transcription	O
in	O
monocytic	O
cells	O
.	O

LPS	O
tolerance	O
in	O
monocytes/macrophages	O
:	O
three	O
3	O
'	O
cytosins	O
are	O
required	O
in	O
the	O
DNA	O
binding	O
motif	O
for	O
detection	O
of	O
upregulated	O
NF-kappa	O
B	O
p50	O
homodimers	O
.	O

When	O
monocytes	O
are	O
stimulated	O
with	O
LPS	O
(	O
lipopolysaccharide	O
)	O
repeatedly	O
then	O
the	O
initially	O
high	O
expression	O
of	O
the	O
TNF	O
(	O
tumor	O
necrosis	O
factor	O
)	O
gene	O
is	O
only	O
very	O
low	O
,	O
i.e.	O
the	O
cells	O
are	O
tolerant	O
to	O
LPS	O
.	O

Tolerant	O
cells	O
still	O
express	O
the	O
CD14	O
receptor	O
and	O
they	O
can	O
still	O
be	O
activated	O
to	O
mobilize	O
NF-kappa	O
B	O
into	O
nucleus	O
.	O

Analysis	O
of	O
the	O
binding	O
proteins	O
employing	O
the	O
-605	O
motif	O
of	O
the	O
human	O
TNF	O
promoter	O
(	O
GGGGCTGTCCC	O
)	O
revealed	O
that	O
in	O
tolerant	O
cells	O
of	O
the	O
human	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
there	O
is	O
a	O
predominance	O
of	O
p50p50	O
of	O
NF-kappa	O
B	O
.	O

We	O
now	O
show	O
that	O
a	O
mutant	O
motif	O
that	O
exchanges	O
the	O
terminal	O
3	O
'	O
C	O
for	O
a	O
G	O
fails	B-Negation
to	I-Negation
bind	I-Negation
the	I-Negation
p50	I-Negation
homodimer	I-Negation
that	I-Negation
is	I-Negation
upregulated	I-Negation
in	I-Negation
LPS	I-Negation
toler	I-Negation
ant	I-Negation
human	I-Negation
Mono	I-Negation
Mac	I-Negation
6	I-Negation
cells	I-Negation
.	O

The	O
same	O
is	O
true	O
for	O
nuclear	O
extracts	O
taken	O
from	O
the	O
murine	O
P388D1	O
macrophage	O
cell	O
line	O
when	O
tested	O
with	O
the	O
-516	O
motif	O
of	O
the	O
murine	O
TNF	O
promoter	O
(	O
GGGGGCTTTCCC	O
)	O
.	O

Here	O
the	O
wild	O
type	O
motif	O
gives	O
efficient	O
binding	O
of	O
p50p50	O
that	O
again	O
is	O
upregulated	O
in	O
tolerant	O
cells	O
whereas	O
a	O
mutant	O
with	O
a	O
3	O
'	O
G	O
shows	O
hardly	O
any	O
binding	O
of	O
p50p50	O
.	O

Conversely	O
,	O
the	O
murine	O
kappa	O
light	O
chain	O
enhancer	O
motif	O
(	O
GGGGACTTTCCG	O
)	O
does	O
not	B-Negation
efficiently	I-Negation
bind	I-Negation
the	I-Negation
nuclear	I-Negation
p50p50	I-Negation
from	I-Negation
tolerant	I-Negation
murine	I-Negation
P388	I-Negation
macrophages	I-Negation
.	O

Binding	O
is	O
,	O
however	O
,	O
readily	O
detected	O
when	O
the	O
3	O
'	O
G	O
is	O
replaced	O
by	O
a	O
C	O
.	O

These	O
data	O
show	O
that	O
the	O
detection	O
of	O
upregulated	O
p50	O
homodimers	O
in	O
LPS	O
tolerant	O
cells	O
is	O
dependent	O
on	O
subtle	O
differences	O
in	O
the	O
sequence	O
of	O
the	O
DNA	O
binding	O
motif	O
.	O

Temporal	O
control	O
of	O
IgH	O
gene	O
expression	O
in	O
developing	O
B	O
cells	O
by	O
the	O
3	O
'	O
locus	O
control	O
region	O
.	O

The	O
suggested	O
roles	O
of	O
the	O
downstream	O
3	O
'	O
regions	O
acting	O
as	O
a	O
Locus	O
Control	O
Region	O
(	O
LCR	O
)	O
,	O
have	O
allowed	O
comparisons	O
to	O
be	O
made	O
between	O
the	O
regulation	O
of	O
the	O
IgH	O
locus	O
with	O
other	O
model	O
systems	O
whose	O
gene	O
expression	O
is	O
governed	O
by	O
LCR	O
activity	O
.	O

Here	O
we	O
summarize	O
the	O
importance	O
of	O
the	O
IgH	O
3'LCR	O
and	O
its	O
putative	O
functional	O
role	O
in	O
IgH	O
gene	O
expression	O
and	O
compare	O
it	O
with	O
the	O
5'LCR	O
regulatory	O
region	O
of	O
the	O
human	O
beta-globin	O
locus	O
.	O

Expression	O
of	O
transcription	O
factor	O
genes	O
after	O
influenza	O
A	O
virus	O
infection	O
.	O

Infection	O
of	O
human	O
monocytes	O
with	O
influenza	O
A	O
virus	O
induces	O
a	O
broad	O
range	O
of	O
proinflammatory	O
cytokines	O
and	O
mononuclear	O
cell	O
attracting	O
chemokines	O
before	O
the	O
infected	O
cells	O
undergo	O
apoptosis	O
.	O

The	O
underlying	O
mechanisms	O
by	O
which	O
the	O
corresponding	O
genes	O
are	O
transcriptionally	O
initiated	O
after	O
virus	O
infection	O
are	O
still	O
poorly	O
understood	O
.	O

Activation	B-Speculation
of	I-Speculation
NF-kappa	I-Speculation
B	I-Speculation
seems	I-Speculation
to	I-Speculation
play	I-Speculation
an	I-Speculation
important	I-Speculation
role	I-Speculation
in	I-Speculation
the	I-Speculation
regulation	I-Speculation
of	I-Speculation
many	I-Speculation
proinflammatory	I-Speculation
cytokine	I-Speculation
genes	I-Speculation
,	O
but	O
can	B-Speculation
not	I-Speculation
be	I-Speculation
the	I-Speculation
only	I-Speculation
mechanism	I-Speculation
,	O
since	O
several	O
cytokine	O
genes	O
lack	B-Negation
respective	I-Negation
binding	I-Negation
sites	I-Negation
in	I-Negation
their	I-Negation
promoter	I-Negation
regions	I-Negation
.	O

Therefore	O
,	O
we	O
additionally	O
investigated	O
other	O
transcription	O
factors	O
of	O
possible	O
importance	O
such	O
as	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
and	O
OTF-2	O
.	O

To	O
explore	O
long-term	O
regulatory	O
mechanisms	O
,	O
we	O
investigated	O
the	O
induction	O
of	O
transcription	O
factors	O
on	O
the	O
gene	O
expression	O
level	O
which	O
may	O
be	O
important	O
to	O
substitute	O
for	O
metabolized	O
transcription	O
factor	O
proteins	O
after	O
their	O
activation	O
.	O

We	O
identified	O
a	O
cell-type-specific	O
differential	O
response	O
:	O
CREB	O
,	O
CTF	O
,	O
OTF-1	O
,	O
OFT-2	O
,	O
and	O
NF-kappa	O
B	O
genes	O
were	O
strongly	O
induced	O
1	O
to	O
4	O
hours	O
after	O
influenza	O
A	O
virus	O
infection	O
in	O
the	O
monocytic	O
cell	O
line	O
Mono	O
Mac	O
6	O
,	O
while	O
in	O
freshly	O
prepared	O
human	O
monocytes	O
no	B-Negation
significant	I-Negation
changes	I-Negation
were	I-Negation
detected	I-Negation
.	O

In	O
infected	O
monocytes	O
,	O
which	O
die	O
by	O
apoptosis	O
,	O
the	O
expression	O
of	O
CREB	O
,	O
CTF	O
,	O
and	O
OTF-2	O
was	O
rather	O
suppressed	O
8	O
hours	O
after	O
infection	O
.	O

In	O
conclusion	O
,	O
the	O
long-term	O
regulation	O
of	O
transcription	O
factor	O
gene	O
expression	O
in	O
non-proliferating	O
cells	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
after	O
influenza	O
infection	O
since	O
in	O
apoptosisprone	O
cells	O
an	O
immediate	O
availability	O
of	O
transcription	O
factor	O
proteins	O
is	O
required	O
.	O

[	O
Molecular-biologic	O
aspects	O
of	O
interaction	O
between	O
nervous	O
and	O
immune	O
systems	O
]	O

The	O
problem	O
of	O
the	O
neuro-immuno	O
interactions	O
on	O
the	O
level	O
of	O
the	O
protein	O
trans-factors	O
,	O
stimulating	O
interleukin-2	O
(	O
IL-2	O
)	O
gene	O
expression	O
was	O
discussed	O
.	O

The	O
physico-chemical	O
and	O
functional	O
parameters	O
of	O
the	O
low	O
molecular	O
nuclear	O
proteins	O
(	O
SP	O
and	O
BP-	O
14	O
,	O
18	O
,	O
19	O
kDs	O
)	O
isolated	O
from	O
splenic	O
and	O
brain	O
cells	O
of	O
immunized	O
rats	O
were	O
studied	O
.	O

The	O
binding	O
of	O
these	O
proteins	O
to	O
the	O
regulatory	O
region	O
of	O
IL-2	O
gene	O
in	O
vitro	O
and	O
stimulation	O
of	O
the	O
IL-2mRNA	O
synthesis	O
in	O
splenic	O
T-lymphocytes	O
culture	O
in	O
normal	O
conditions	O
were	O
shown	O
.	O

The	O
protective	O
effect	O
of	O
SP	O
and	O
BP	O
on	O
the	O
IL-2mRNA	O
synthesis	O
in	O
stressful	O
conditions	O
and	O
by	O
the	O
T-cells	O
treatment	O
with	O
the	O
CsA	O
was	O
demonstrated	O
.	O

Induction	O
of	O
interleukin-12	O
p40	O
transcript	O
by	O
CD40	O
ligation	O
via	O
activation	O
of	O
nuclear	O
factor-kappaB	O
.	O

Interleukin-12	O
is	O
produced	O
in	O
response	O
to	O
infection	O
with	O
bacteria	O
or	O
parasites	O
or	O
to	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
in	O
monocytes/macrophages	O
and	O
dendritic	O
cells	O
,	O
and	O
also	O
generated	O
by	O
the	O
interaction	O
between	O
activated	O
T	O
cells	O
and	O
antigen-presenting	O
cells	O
via	O
CD40-CD40	O
ligand	O
(	O
CD40L	O
)	O
.	O

So	O
far	O
,	O
transcriptional	O
analyses	O
of	O
p40	O
have	O
been	O
carried	O
out	O
only	O
using	O
bacterial	O
constituents	O
such	O
as	O
LPS	O
as	O
stimuli	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
characterized	O
the	O
transcriptional	O
induction	O
of	O
p40	O
by	O
CD40	O
ligation	O
in	O
a	O
human	O
B	O
lymphoblastoid	O
cell	O
line	O
,	O
Daudi	O
,	O
and	O
a	O
human	O
acute	O
monocytic	O
leukemia	O
cell	O
line	O
,	O
THP-1	O
.	O

These	O
cells	O
,	O
stimulated	O
by	O
an	O
agonistic	O
monoclonal	O
antibody	O
against	O
CD40	O
or	O
by	O
transfection	O
with	O
a	O
CD40L	O
expression	O
vector	O
,	O
secreted	O
p40	O
and	O
showed	O
enhanced	O
p40	O
mRNA	O
expression	O
.	O

Sequence	O
analysis	O
of	O
the	O
p40	O
promoter	O
region	O
identified	O
two	O
potential	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
binding	O
sites	O
conserved	O
between	O
mouse	O
and	O
human	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
revealed	O
that	O
the	O
potential	O
NF-kappaB	O
binding	O
sequence	O
which	O
is	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
genes	O
formed	O
an	O
NF-kappaB	O
complex	O
with	O
nuclear	O
extract	O
from	O
Daudi	O
cells	O
stimulated	O
by	O
CD40	O
ligation	O
.	O

Moreover	O
,	O
transfection	O
of	O
Daudi	O
cells	O
with	O
the	O
polymerized	O
NF-kappaB	O
binding	O
sequence	O
ligated	O
to	O
a	O
thymidine	O
kinase/chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
plasmid	O
greatly	O
induced	O
CAT	O
activity	O
,	O
but	O
transfection	O
with	O
the	O
polymerized	O
mutated	O
NF-kappaB	O
binding	O
sequence	O
did	O
not	B-Negation
.	O

These	O
results	O
suggest	O
that	O
the	O
NF-kappaB	O
binding	O
site	O
located	O
around	O
120	O
bp	O
upstream	O
of	O
the	O
transcription	O
initiation	O
site	O
in	O
murine	O
and	O
human	O
p40	O
promoter	O
regions	O
could	O
be	O
important	O
for	O
the	O
p40	O
induction	O
by	O
CD40	O
ligation	O
via	O
activation	O
of	O
NF-kappaB	O
.	O

Oxidants	O
,	O
transcription	O
factors	O
,	O
and	O
intestinal	O
inflammation	O
.	O

It	O
is	O
now	O
well	O
appreciated	O
that	O
chronic	O
gut	O
inflammation	O
is	O
characterized	O
by	O
enhanced	O
production	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
.	O

Some	O
of	O
these	O
oxidants	O
are	O
known	O
to	O
modulate	O
the	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
that	O
are	O
involved	O
in	O
the	O
immune	O
and	O
inflammatory	O
responses	O
.	O

For	O
example	O
,	O
certain	O
oxidants	O
are	O
known	O
to	O
activate	O
the	O
nuclear	O
transcription	O
factor	O
kappa	O
B	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
variety	O
of	O
different	O
adhesion	O
molecules	O
,	O
cytokines	O
,	O
and	O
enzymes	O
.	O

Oxidants	O
are	O
also	O
known	O
to	O
activate	O
another	O
transcription	O
factor	O
,	O
activator	O
protein-1	O
.	O

This	O
transcription	O
factor	O
is	O
composed	O
of	O
products	O
from	O
the	O
fos	O
and	O
jun	O
proto-oncogene	O
family	O
and	O
is	O
believed	O
to	O
be	O
important	O
in	O
regulating	O
cell	O
growth	O
and	O
proliferation	O
.	O

Finally	O
,	O
oxidants	O
are	O
believed	O
to	O
promote	O
intestinal	O
epithelial	O
cell	O
apoptosis	O
,	O
and	O
the	O
B-cell	O
lymphoma/leukemia-2	O
gene	O
product	O
is	O
believed	O
to	O
inhibit	O
this	O
phenomenon	O
in	O
an	O
antioxidant-dependent	O
manner	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
nontoxic	O
concentrations	O
of	O
reactive	O
metabolites	O
of	O
oxygen	O
and	O
nitrogen	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
inflammatory	O
response	O
and	O
in	O
modulating	O
apoptosis	O
.	O

Cytokine	O
rescue	O
from	O
glucocorticoid	O
induced	O
apoptosis	O
in	O
T	O
cells	O
is	O
mediated	O
through	O
inhibition	O
of	O
IkappaBalpha	O
.	O

We	O
previously	O
reported	O
that	O
dexamethasone	O
(	O
DEX	O
)	O
,	O
a	O
synthetic	O
glucocorticoid	O
,	O
causes	O
apoptosis	O
in	O
mature	O
Th	O
cell	O
lines	O
,	O
and	O
that	O
this	O
induction	O
of	O
cell	O
death	O
is	O
prevented	O
by	O
specific	O
cytokines	O
,	O
namely	O
,	O
by	O
IL-2	O
in	O
Th1	O
cells	O
and	O
by	O
IL-4	O
in	O
Th2	O
cells	O
.	O

We	O
now	O
show	O
that	O
this	O
differential	O
rescue	O
by	O
specific	O
cytokines	O
in	O
Th	O
cells	O
correlates	O
with	O
the	O
level	O
of	O
IkappaBalpha	O
that	O
is	O
regulated	O
by	O
DEX	O
and	O
cytokines	O
.	O

In	O
both	O
cell	O
types	O
the	O
cellular	O
levels	O
of	O
IkappaBalpha	O
mRNA	O
and	O
protein	O
were	O
evaluated	O
by	O
DEX	O
treatment	O
.	O

Interestingly	O
,	O
the	O
DEX-mediated	O
IkappaBalpha	O
induction	O
was	O
completely	O
inhibited	O
by	O
IL-2	O
,	O
but	O
not	B-Negation
IL-4	I-Negation
,	O
in	O
Th1	O
cells	O
,	O
while	O
the	O
reverse	O
profile	O
was	O
seen	O
in	O
Th2	O
cells	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
cytokine	O
that	O
inhibits	O
the	O
induction	O
of	O
IkappaBalpha	O
by	O
DEX	O
,	O
also	O
rescues	O
these	O
cells	O
from	O
DEX-induced	O
apoptosis	O
,	O
although	O
the	O
rescue	O
cytokine	O
is	O
different	O
in	O
Th1	O
and	O
Th2	O
cells	O
.	O

Our	O
results	O
imply	O
that	O
T	O
cells	O
need	O
to	O
maintain	O
a	O
certain	O
level	O
of	O
NF-kappaB	O
transcriptional	O
activity	O
in	O
order	O
to	O
survive	O
;	O
up-	O
or	O
down-regulation	O
of	O
nuclear	O
NF	O
kappaB	O
through	O
modulation	O
of	O
IkappaBalpha	O
expression	O
by	O
cytokines	O
or	O
DEX	O
may	O
lead	O
to	O
cell	O
survival	O
or	O
cell	O
death	O
,	O
respectively	O
.	O

Xenogeneic	O
human	O
serum	O
promotes	O
leukocyte	O
adhesion	O
to	O
porcine	O
endothelium	O
under	O
flow	O
conditions	O
,	O
possibly	O
through	O
the	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappa	O
B	O
.	O

Endothelial	O
cell	O
activation	O
and	O
leukocyte	O
infiltration	O
are	O
a	O
consistent	O
feature	O
of	O
discordant	O
xenograft	O
rejection	O
.	O

Here	O
we	O
evaluated	O
whether	O
xenogeneic	O
serum	O
,	O
as	O
a	O
source	O
of	O
xenoreactive	O
natural	O
antibodies	O
and	O
complement	O
,	O
induced	O
endothelial	O
cell	O
activation	O
with	O
consequent	O
leukocyte	O
adhesion	O
under	O
flow	O
conditions	O
.	O

Porcine	O
aortic	O
endothelial	O
cells	O
(	O
PAEC	O
)	O
were	O
incubated	O
for	O
1	O
hr	O
30	O
min	O
or	O
5	O
hr	O
with	O
10	O
%	O
homologous	O
porcine	O
serum	O
(	O
control	O
)	O
or	O
10	O
%	O
xenogeneic	O
human	O
serum	O
and	O
then	O
perfused	O
with	O
total	O
human	O
leukocytes	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dynes/cm2	O
)	O
.	O

Adherent	O
cells	O
were	O
counted	O
by	O
digital	O
image	O
analysis	O
.	O

Xenogeneic	O
human	O
serum	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
as	O
compared	O
with	O
porcine	O
serum	O
.	O

A	O
similar	O
adhesive	O
response	O
was	O
elicited	O
by	O
TNF	O
alpha	O
(	O
100	O
U/ml	O
)	O
,	O
one	O
of	O
the	O
most	O
potent	O
inducers	O
of	O
endothelial	O
cell	O
adhesive	O
properties	O
,	O
here	O
used	O
as	O
positive	O
control	O
.	O

In	O
order	O
to	O
elucidate	O
possible	O
mechanisms	O
underlying	O
endothelial	O
cell	O
activation	O
by	O
xenogeneic	O
serum	O
,	O
we	O
focussed	O
on	O
transcription	O
factor	O
NF-kappa	O
B	O
,	O
a	O
central	O
regulator	O
for	O
the	O
induction	O
of	O
different	O
genes	O
,	O
including	O
adhesive	O
molecules	O
and	O
chemoattractants	O
.	O

By	O
confocal	O
fluorescence	O
microscopy	O
,	O
we	O
observed	O
a	O
positive	O
staining	O
for	O
NF-kappa	O
B	O
(	O
p65	O
subunit	O
)	O
in	O
the	O
nuclei	O
of	O
PAEC	O
exposed	O
for	O
1	O
hr	O
30	O
min	O
to	O
human	O
serum	O
,	O
which	O
indicated	O
NF-kappa	O
B	O
activation	O
in	O
this	O
setting	O
.	O

At	O
variance	O
,	O
in	O
PAEC	O
incubated	O
with	O
the	O
homologous	O
serum	O
,	O
NF-kappa	O
B	O
was	O
strictly	O
localized	O
in	O
the	O
cell	O
cytoplasm	O
.	O

Treatment	O
of	O
PAEC	O
exposed	O
to	O
xenogeneic	O
serum	O
with	O
the	O
NF-kappa	O
B	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
PDTC	O
,	O
25	O
microM	O
)	O
and	O
tosyl-phechloromethylketone	O
(	O
TPCK	O
,	O
25	O
microM	O
)	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
reduced	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
PAEC	O
treated	O
with	O
human	O
serum	O
alone	O
.	O

Findings	O
that	O
xenogeneic	O
serum	O
promotes	O
leukocyte-endothelium	O
interaction	O
possibly	O
through	O
NF-kappa	O
B	O
activation	O
might	O
be	O
relevant	O
for	O
designing	O
future	O
therapeutic	O
strategies	O
aimed	O
at	O
prolonging	O
xenograft	O
survival	O
.	O

Role	O
of	O
cyclic	O
AMP	O
response	O
element-binding	O
protein	O
in	O
cyclic	O
AMP	O
inhibition	O
of	O
NF-kappaB-mediated	O
transcription	O
.	O

The	O
NF-kappaB	O
family	O
of	O
transcription	O
factors	O
regulates	O
the	O
inducible	O
expression	O
of	O
a	O
variety	O
of	O
genes	O
.	O

Recently	O
,	O
we	O
showed	O
that	O
elevation	O
of	O
intracellular	O
cyclic	O
AMP	O
inhibits	O
NF-kappaB-mediated	O
transcription	O
in	O
human	O
monocytes	O
and	O
endothelial	O
cells	O
without	B-Negation
preventing	I-Negation
nuclear	I-Negation
translocation	I-Negation
of	I-Negation
NF-kappaB	I-Negation
complexes	I-Negation
.	O

The	O
present	O
study	O
examined	O
the	O
molecular	O
mechanism	O
of	O
this	O
inhibition	O
.	O

We	O
hypothesized	O
that	O
activation	O
of	O
the	O
protein	O
kinase	O
A	O
signaling	O
pathway	O
may	O
inhibit	O
NF-kappaB-mediated	O
transcription	O
by	O
phosphorylating	O
proteins	O
,	O
such	O
as	O
cAMP	O
response	O
element-binding	O
protein	O
(	O
CREB	O
)	O
,	O
which	O
compete	O
for	O
limiting	O
amounts	O
of	O
the	O
coactivator	O
CBP	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
amino-terminal	O
region	O
(	O
amino	O
acids	O
1-450	O
)	O
of	O
CBP	O
specifically	O
interacts	O
with	O
the	O
carboxyl-terminal	O
region	O
(	O
amino	O
acids	O
286-551	O
)	O
of	O
NF-kappaB	O
p65	O
(	O
RelA	O
)	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Functional	O
studies	O
using	O
human	O
endothelial	O
cells	O
demonstrated	O
that	O
overexpression	O
of	O
CBP	O
rescued	O
cAMP	O
inhibition	O
of	O
NF-kappaB-mediated	O
transcription	O
and	O
transcription	O
mediated	O
by	O
a	O
chimeric	O
protein	O
,	O
GAL4-p65	O
(	O
286-551	O
)	O
,	O
which	O
contained	O
the	O
GAL4	O
DNA	O
binding	O
domain	O
fused	O
to	O
the	O
carboxyl-terminal	O
region	O
of	O
p65	O
(	O
amino	O
acids	O
286-551	O
)	O
.	O

In	O
contrast	O
,	O
overexpression	O
of	O
CREB	O
inhibited	O
GAL4-p65	O
(	O
286-551	O
)	O
-mediated	O
transcription	O
.	O

These	O
results	O
suggest	O
that	O
activation	O
of	O
the	O
protein	O
kinase	O
A	O
pathway	O
inhibits	O
NF-kappaB	O
transcription	O
by	O
phosphorylating	O
CREB	O
,	O
which	O
competes	O
with	O
p65	O
for	O
limiting	O
amounts	O
of	O
CBP	O
.	O

Differential	O
induction	O
of	O
DNA-binding	O
activities	O
following	O
CD19	O
cross-linking	O
in	O
human	O
B	O
lineage	O
cells	O
.	O

The	O
B	O
cell-specific	O
cell	O
surface	O
molecule	O
CD19	O
is	O
expressed	O
at	O
all	O
stages	O
of	O
B	O
cell	O
development	O
,	O
including	O
normal	O
plasma	O
cells	O
,	O
and	O
mediates	O
signal	O
transduction	O
via	O
interaction	O
with	O
cytoplasmic	O
effector	O
proteins	O
.	O

Cross-linking	O
CD19	O
on	O
early	O
human	O
B	O
lineage	O
cells	O
induces	O
the	O
formation	O
of	O
a	O
CD19/Vav/phosphatidylinositol-3	O
kinase	O
complex	O
,	O
tyrosine	O
phosphorylation	O
of	O
CD19	O
and	O
Vav	O
,	O
and	O
activation	O
of	O
the	O
Ras	O
pathway	O
.	O

To	O
further	O
explore	O
the	O
ramifications	O
of	O
CD19	O
signaling	O
,	O
the	O
current	O
study	O
examined	O
whether	O
phosphorylation	O
of	O
Elk-1	O
,	O
activation	O
of	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
,	O
or	O
activation	O
of	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
transcription	O
factors	O
occurred	O
following	O
CD19	O
cross-linking	O
.	O

The	O
cells	O
used	O
were	O
the	O
BLIN-1	O
pre-B	O
cell	O
line	O
expressing	O
low	O
levels	O
of	O
cell	O
surface	O
mu	O
heavy	O
chain	O
associated	O
with	O
surrogate	O
light	O
chain	O
and	O
the	O
1E8	O
immature	O
B	O
cell	O
line	O
expressing	O
cell	O
surface	O
mu/kappa	O
.	O

Lysates	O
from	O
CD19	O
cross-linked	O
1E8	O
cells	O
induced	O
robust	O
phosphorylation	O
of	O
an	O
Elk-1	O
fusion	O
protein	O
in	O
vitro	O
,	O
whereas	O
no	B-Negation
phosphorylation	I-Negation
of	I-Negation
Elk-1	I-Negation
fusion	I-Negation
protein	I-Negation
occurred	I-Negation
using	I-Negation
lysates	I-Negation
from	I-Negation
CD19	I-Negation
cross-linked	I-Negation
BLIN-1	I-Negation
cells	I-Negation
.	O

An	O
electrophoretic	O
mobility	O
shift	O
assay	O
employing	O
AP-1	O
and	O
NF-kappaB	O
consensus	O
oligonucleotides	O
was	O
used	O
to	O
demonstrate	O
that	O
AP-1	O
-binding	O
activity	O
increased	O
,	O
while	O
constitutive	B-Negation
NF-kappaB-binding	I-Negation
activity	I-Negation
was	I-Negation
not	I-Negation
enhanced	I-Negation
,	O
following	O
2	O
h	O
of	O
CD19	O
cross-linking	O
in	O
1E8	O
cells	O
.	O

Supershift	O
experiments	O
revealed	O
that	O
JunD	O
and	O
c-Fos	O
proteins	O
mediated	O
anti-CD19	O
induced	O
AP-1-binding	O
activity	O
in	O
1E8	O
cells	O
.	O

In	O
contrast	O
,	O
CD19	O
cross-linking	O
in	O
BLIN-1	O
cells	O
resulted	O
in	O
the	O
induction	O
of	O
NF-kappaB	O
,	O
but	O
had	O
no	B-Negation
apparent	I-Negation
effect	I-Negation
on	I-Negation
AP-1-binding	I-Negation
activity	I-Negation
.	O

These	O
data	O
suggest	O
that	O
CD19-mediated	O
signal	O
transduction	O
activates	O
different	O
transcription	O
factors	O
at	O
juxtaposed	O
stages	O
of	O
B	O
cell	O
development	O
that	O
may	O
culminate	O
in	O
the	O
activation	O
or	O
suppression	O
of	O
distinct	O
sets	O
of	O
genes	O
.	O

Human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
quasispecies	O
differ	O
in	O
basal	O
transcription	O
and	O
nuclear	O
factor	O
recruitment	O
in	O
human	O
glial	O
cells	O
and	O
lymphocytes	O
.	O

The	O
generation	O
of	O
genomic	O
diversity	O
during	O
the	O
course	O
of	O
infection	O
has	O
the	O
potential	O
to	O
affect	O
all	O
aspects	O
of	O
HIV-1	O
replication	O
,	O
including	O
expression	O
of	O
the	O
proviral	O
genome	O
.	O

To	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
impact	O
of	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
sequence	O
diversity	O
on	O
LTR-directed	O
gene	O
expression	O
in	O
cells	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
and	O
immune	O
system	O
,	O
we	O
amplified	O
and	O
cloned	O
LTRs	O
from	O
proviral	O
DNA	O
in	O
HIV-1-infected	O
peripheral	O
blood	O
.	O

Sequence	O
analysis	O
of	O
nineteen	O
LTRs	O
cloned	O
from	O
2	O
adult	O
and	O
3	O
pediatric	O
patients	O
revealed	O
an	O
average	O
of	O
33	O
nucleotide	O
changes	O
(	O
with	O
respect	O
to	O
the	O
sequence	O
of	O
the	O
LAI	O
LTR	O
)	O
within	O
the	O
455-bp	O
U3	O
region	O
.	O

Transient	O
expression	O
analyses	O
in	O
cells	O
of	O
neuroglial	O
and	O
lymphocytic	O
origin	O
demonstrated	O
that	O
some	O
of	O
these	O
LTRs	O
had	O
activities	O
which	O
varied	O
significantly	O
from	O
the	O
LAI	O
LTR	O
in	O
U-373	O
MG	O
cells	O
(	O
an	O
astrocytoma	O
cell	O
line	O
)	O
as	O
well	O
as	O
in	O
Jurkat	O
cells	O
(	O
a	O
CD4-positive	O
lymphocyte	O
cell	O
line	O
)	O
.	O

While	O
LTRs	O
which	O
demonstrated	O
the	O
highest	O
activities	O
in	O
U-373	O
MG	O
cells	O
also	O
yielded	O
high	O
activities	O
in	O
Jurkat	O
cells	O
,	O
the	O
LTRs	O
were	O
generally	O
more	O
active	O
in	O
Jurkat	O
cells	O
when	O
compared	O
to	O
the	O
LAI	O
LTR	O
.	O

Differences	O
in	O
LTR	O
sequence	O
also	O
resulted	O
in	O
differences	O
in	O
transcription	O
factor	O
recruitment	O
to	O
cis-acting	O
sites	O
within	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
,	O
as	O
demonstrated	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

In	O
particular	O
,	O
naturally	O
occurring	O
sequence	O
variation	O
impacted	O
transcription	O
factor	O
binding	O
to	O
an	O
activating	O
transcription	O
factor/cAMP	O
response	O
element	O
binding	O
(	O
ATF/CREB	O
)	O
binding	O
site	O
(	O
located	O
between	O
the	O
LEF-1	O
and	O
distal	O
NF-kappaB	O
transcription	O
factor	O
binding	O
sites	O
)	O
that	O
we	O
identified	O
in	O
previous	O
studies	O
of	O
the	O
HIV-1	O
LTR	O
.	O

These	O
findings	O
suggest	O
that	O
LTR	O
sequence	O
changes	O
can	O
significantly	O
affect	O
basal	O
LTR	O
function	O
and	O
transcription	O
factor	O
recruitment	O
,	O
which	O
may	O
,	O
in	O
turn	O
,	O
alter	O
the	O
course	O
of	O
viral	O
replication	O
in	O
cells	O
of	O
CNS	O
and	O
immune	O
system	O
origin	O
.	O

Inhibition	O
of	O
nuclear	O
factor	O
kappaB	O
activation	O
attenuates	O
apoptosis	O
resistance	O
in	O
lymphoid	O
cells	O
.	O

Death-inducing	O
ligands	O
(	O
DILs	O
)	O
such	O
as	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNFalpha	O
)	O
or	O
the	O
cytotoxic	O
drug	O
doxorubicin	O
have	O
been	O
shown	O
to	O
activate	O
a	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
-dependent	O
program	O
that	O
may	O
rescue	O
cells	O
from	O
apoptosis	O
induction	O
.	O

We	O
demonstrate	O
here	O
that	O
TRAIL	O
(	O
TNF-related	O
apoptosis-inducing	O
ligand	O
)	O
,	O
a	O
recently	O
identified	O
DIL	O
,	O
also	O
activates	O
NFkappaB	O
in	O
lymphoid	O
cell	O
lines	O
in	O
a	O
kinetic	O
similar	O
to	O
TNFalpha	O
.	O

NFkappaB	O
activity	O
is	O
independent	O
from	O
FADD	O
,	O
caspases	O
,	O
and	O
apoptosis	O
induction	O
.	O

To	O
study	O
the	O
influence	O
of	O
NFkappaB	O
activity	O
on	O
apoptosis	O
mediated	O
by	O
TRAIL	O
,	O
CD95	O
,	O
TNFalpha	O
,	O
or	O
doxorubicin	O
,	O
NFkappaB	O
activation	O
was	O
inhibited	O
using	O
the	O
proteasome	O
inhibitor	O
N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal	O
or	O
transient	O
overexpression	O
of	O
mutant	O
IkappaBalpha	O
.	O

Sensitivity	O
for	O
induction	O
of	O
apoptosis	O
was	O
markedly	O
increased	O
by	O
these	O
treatments	O
in	O
apoptosis	O
sensitive	O
cell	O
lines	O
.	O

Moreover	O
,	O
both	O
in	O
cell	O
lines	O
and	O
in	O
primary	O
leukemia	O
cells	O
that	O
are	O
resistant	O
towards	O
induction	O
of	O
apoptosis	O
by	O
DILs	O
and	O
doxorubicin	O
,	O
antagonization	O
of	O
NFkappaB	O
activity	O
partially	O
restored	O
apoptosis	O
sensitivity	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
NFkappaB	O
activation	O
may	O
provide	O
a	O
molecular	O
approach	O
to	O
increase	O
apoptosis	O
sensitivity	O
in	O
anticancer	O
treatment	O
.	O

IL-2-induced	O
growth	O
of	O
CD8+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
cells	O
mediated	O
by	O
NF-kappaB	O
induction	O
and	O
IL-2	O
receptor	O
alpha	O
expression	O
.	O

The	O
binding	O
of	O
interleukin-2	O
(	O
IL-2	O
)	O
to	O
its	O
receptor	O
on	O
normal	O
T	O
cells	O
induces	O
nuclear	O
expression	O
of	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
,	O
activation	O
of	O
the	O
IL-2	O
receptor	O
(	O
IL-2R	O
)	O
alpha	O
chain	O
gene	O
,	O
and	O
cell	O
proliferation	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
role	O
of	O
IL-2R	O
signaling	O
in	O
the	O
growth	O
of	O
CD8+	O
T	O
cell	O
prolymphocytic	O
leukemia	O
(	O
T-PLL	O
)	O
cells	O
has	O
been	O
investigated	O
.	O

Flow	O
cytometry	O
revealed	O
that	O
primary	O
leukemia	O
cells	O
from	O
a	O
patient	O
with	O
CD8+	O
T-PLL	O
expressed	O
IL-2Ralpha	O
and	O
beta	O
chains	O
,	O
and	O
the	O
cells	O
showed	O
a	O
proliferative	O
response	O
and	O
an	O
increase	O
in	O
IL-2Ralpha	O
expression	O
on	O
culture	O
with	O
exogeneous	O
IL-2	O
.	O

Northern	O
blot	O
analysis	O
failed	B-Negation
to	I-Negation
detect	I-Negation
IL-2	I-Negation
mRNA	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
IL-2	I-Speculation
may	I-Speculation
act	I-Speculation
in	I-Speculation
a	I-Speculation
paracrine	I-Speculation
manner	I-Speculation
in	I-Speculation
vivo	I-Speculation
.	O

Electrophoretic	O
mobility-shift	O
assays	O
revealed	O
that	O
recombinant	O
IL-2	O
increased	O
NF-kappaB	O
binding	O
activity	O
in	O
nuclear	O
extracts	O
of	O
the	O
leukemia	O
cells	O
,	O
and	O
Northern	O
blot	O
analysis	O
showed	O
that	O
IL-2	O
increased	O
the	O
abundance	O
of	O
mRNAs	O
encoding	O
the	O
NF-kappaB	O
components	O
c-Rel	O
and	O
KBF1	O
in	O
these	O
cells	O
.	O

IL-2	O
binding	O
analysis	O
demonstrated	O
that	O
IL-2	O
markedly	O
increased	O
the	O
number	O
of	O
low	O
affinity	O
IL-2Rs	O
on	O
the	O
leukemia	O
cells	O
,	O
without	B-Negation
an	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
number	I-Negation
of	I-Negation
high-affinity	I-Negation
IL-2Rs	I-Negation
.	O

These	O
results	O
show	O
that	O
IL-2	O
is	O
capable	O
of	O
inducing	O
the	O
nuclear	O
expression	O
of	O
NF-kappaB	O
in	O
primary	O
CD8+	O
T-PLL	O
cells	O
,	O
and	O
that	O
this	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
at	O
a	O
pretranslational	O
level	O
.	O

The	O
human	O
toll	O
signaling	O
pathway	O
:	O
divergence	O
of	O
nuclear	O
factor	O
kappaB	O
and	O
JNK/SAPK	O
activation	O
upstream	O
of	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factor	O
6	O
(	O
TRAF6	O
)	O
.	O

The	O
human	O
homologue	O
of	O
Drosophila	O
Toll	O
(	O
hToll	O
)	O
is	O
a	O
recently	O
cloned	O
receptor	O
of	O
the	O
interleukin	O
1	O
receptor	O
(	O
IL-1R	O
)	O
superfamily	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
activation	O
of	O
adaptive	O
immunity	O
.	O

Signaling	O
by	O
hToll	O
is	O
shown	O
to	O
occur	O
through	O
sequential	O
recruitment	O
of	O
the	O
adapter	O
molecule	O
MyD88	O
and	O
the	O
IL-1R-associated	O
kinase	O
.	O

Tumor	O
necrosis	O
factor	O
receptor-activated	O
factor	O
6	O
(	O
TRAF6	O
)	O
and	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
-inducing	O
kinase	O
(	O
NIK	O
)	O
are	O
both	O
involved	O
in	O
subsequent	O
steps	O
of	O
NF-kappaB	O
activation	O
.	O

Conversely	O
,	O
a	O
dominant	O
negative	O
version	O
of	O
TRAF6	O
failed	B-Negation
to	I-Negation
block	I-Negation
hToll-induced	I-Negation
activation	I-Negation
of	I-Negation
stress-activated	I-Negation
protein	I-Negation
kinase/c-Jun	I-Negation
NH2-terminal	I-Negation
kinases	I-Negation
,	O
thus	O
suggesting	B-Speculation
an	I-Speculation
early	I-Speculation
divergence	I-Speculation
of	I-Speculation
the	I-Speculation
two	I-Speculation
pathways	I-Speculation
.	O

Coactivation	O
by	O
OCA-B	O
:	O
definition	O
of	O
critical	O
regions	O
and	O
synergism	O
with	O
general	O
cofactors	O
.	O

Molecular	O
dissection	O
of	O
the	O
B-cell-specific	O
transcription	O
coactivator	O
OCA-B	O
has	O
revealed	O
distinct	O
regions	O
important	O
,	O
respectively	O
,	O
for	O
recruitment	O
to	O
immunoglobulin	O
promoters	O
through	O
interaction	O
with	O
octamer-bound	O
Oct-1	O
and	O
for	O
subsequent	O
coactivator	O
function	O
.	O

Further	O
analysis	O
of	O
general	O
coactivator	O
requirements	O
showed	O
that	O
selective	O
removal	O
of	O
PC4	O
from	O
the	O
essential	O
USA	O
fraction	O
severely	O
impairs	O
Oct-1	O
and	O
OCA-B	O
function	O
in	O
a	O
cell-free	O
system	O
reconstituted	O
with	O
partially	O
purified	O
factors	O
.	O

Full	O
activity	O
can	O
be	O
restored	O
by	O
the	O
combined	O
action	O
of	O
recombinant	O
PC4	O
and	O
the	O
PC4-depleted	O
USA	O
fraction	O
,	O
thus	O
suggesting	O
a	O
joint	O
requirement	O
for	O
PC4	O
and	O
another	O
,	O
USA-derived	O
component	O
(	O
s	O
)	O
for	O
optimal	O
function	O
of	O
Oct-1/OCA-B	O
in	O
the	O
reconstituted	O
system	O
.	O

Indeed	O
,	O
USA-derived	O
PC2	O
was	O
found	O
to	O
act	O
synergistically	O
with	O
PC4	O
in	O
reproducing	O
the	O
function	O
of	O
intact	O
USA	O
in	O
the	O
assay	O
system	O
.	O

Consistent	O
with	O
the	O
requirement	O
for	O
PC4	O
in	O
the	O
reconstituted	O
system	O
,	O
OCA-B	O
was	O
found	O
to	O
interact	O
directly	O
with	O
PC4	O
.	O

Surprisingly	O
,	O
however	O
,	O
removal	O
of	O
PC4	O
from	O
the	O
unfractionated	O
nuclear	O
extract	O
has	O
no	B-Negation
detrimental	I-Negation
effect	I-Negation
on	I-Negation
OCA-B/Oct-1-dependent	I-Negation
transcription	I-Negation
.	O

These	O
results	O
lead	O
to	O
a	O
general	O
model	O
for	O
the	O
synergistic	O
function	O
of	O
activation	O
domains	O
in	O
Oct-1	O
and	O
OCA-B	O
(	O
mediated	O
by	O
the	O
combined	O
action	O
of	O
the	O
multiple	O
USA	O
components	O
)	O
and	O
,	O
further	O
,	O
suggest	O
a	O
functional	O
redundancy	O
in	O
general	O
coactivators	O
.	O

Limited	O
proteolysis	O
for	O
assaying	O
ligand	O
binding	O
affinities	O
of	O
nuclear	O
receptors	O
.	O

The	O
binding	O
of	O
natural	O
or	O
synthetic	O
ligands	O
to	O
nuclear	O
receptors	O
is	O
the	O
triggering	O
event	O
leading	O
to	O
gene	O
transcription	O
activation	O
or	O
repression	O
.	O

Ligand	O
binding	O
to	O
the	O
ligand	O
binding	O
domain	O
of	O
these	O
receptors	O
induces	O
conformational	O
changes	O
that	O
are	O
evidenced	O
by	O
an	O
increased	O
resistance	O
of	O
this	O
domain	O
to	O
proteases	O
.	O

In	O
vitro	O
labeled	O
receptors	O
were	O
incubated	O
with	O
various	O
synthetic	O
or	O
natural	O
agonists	O
or	O
antagonists	O
and	O
submitted	O
to	O
trypsin	O
digestion	O
.	O

Proteolysis	O
products	O
were	O
separated	O
by	O
SDS-PAGE	O
and	O
quantified	O
.	O

The	O
amount	O
of	O
trypsin-resistant	O
fragments	O
was	O
proportional	O
to	O
receptor	O
occupancy	O
by	O
the	O
ligand	O
,	O
and	O
allowed	O
the	O
determination	O
of	O
dissociation	O
constants	O
(	O
kDa	O
)	O
.	O

Using	O
the	O
wild-type	O
or	O
mutated	O
human	O
retinoic	O
acid	O
receptor	O
alpha	O
as	O
a	O
model	O
,	O
kDa	O
values	O
determined	O
by	O
classical	O
competition	O
binding	O
assays	O
using	O
tritiated	O
ligands	O
are	O
in	O
agreement	O
with	O
those	O
measured	O
by	O
the	O
proteolytic	O
assay	O
.	O

This	O
method	O
was	O
successfully	O
extended	O
to	O
human	O
retinoic	O
X	O
receptor	O
alpha	O
,	O
glucocorticoid	O
receptor	O
,	O
and	O
progesterone	O
receptor	O
,	O
thus	O
providing	O
a	O
basis	O
for	O
a	O
new	O
,	O
faster	O
assay	O
to	O
determine	O
simultaneously	O
the	O
affinity	O
and	O
conformation	O
of	O
receptors	O
when	O
bound	O
to	O
a	O
given	O
ligand	O
.	O

Mycobacterium	O
tuberculosis	O
mannose-capped	O
lipoarabinomannan	O
can	O
induce	O
NF-kappaB-dependent	O
activation	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
in	O
T	O
cells	O
.	O

Tuberculosis	O
has	O
emerged	O
as	O
an	O
epidemic	O
,	O
extended	O
by	O
the	O
large	O
number	O
of	O
individuals	O
infected	O
with	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
.	O

The	O
major	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
the	O
mycobacterial	O
cell	O
wall	O
component	O
mannose-capped	O
lipoarabinomannan	O
(	O
ManLAM	O
)	O
of	O
Mycobacterium	O
tuberculosis	O
(	O
M.	O
tuberculosis	O
)	O
could	O
activate	O
transcription	O
of	O
HIV-1	O
in	O
T	O
cells	O
with	O
the	O
use	O
of	O
an	O
in	O
vitro	O
cell	O
culture	O
system	O
.	O

These	O
experiments	O
are	O
of	O
prime	O
importance	O
considering	O
that	O
CD4-expressing	O
T	O
lymphocytes	O
represent	O
the	O
major	O
virus	O
reservoir	O
in	O
the	O
peripheral	O
blood	O
of	O
infected	O
individuals	O
.	O

Using	O
the	O
1G5	O
cell	O
line	O
harbouring	O
the	O
luciferase	O
reporter	O
gene	O
under	O
the	O
control	O
of	O
the	O
HIV-1	O
LTR	O
,	O
it	O
was	O
first	O
found	O
that	O
culture	O
protein	O
filtrates	O
(	O
CFP	O
)	O
from	O
M.	O
tuberculosis	O
or	O
purified	O
ManLAM	O
could	O
activate	O
HIV-1	O
LTR-dependent	O
gene	O
expression	O
unlike	O
similarly	O
prepared	O
CFP	O
extracts	O
devoid	O
of	O
ManLAM	O
.	O

The	O
implication	O
of	O
protein	O
tyrosine	O
kinase	O
(	O
s	O
)	O
,	O
protein	O
kinase	O
A	O
and/or	O
protein	O
kinase	O
C	O
was	O
highlighted	O
by	O
the	O
abrogation	O
of	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
using	O
herbimycin	O
A	O
and	O
H7	O
.	O

It	O
was	O
also	O
determined	O
,	O
using	O
electrophoresis	O
mobility	O
shift	O
assays	O
,	O
that	O
M.	O
tuberculosis	O
ManLAM	O
led	O
to	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
.	O

M.	O
tuberculosis	O
ManLAM	O
resulted	O
in	O
clear	O
induction	O
of	O
the	O
luciferase	O
gene	O
placed	O
under	O
the	O
control	O
of	O
the	O
wild-type	O
,	O
but	O
not	B-Negation
the	I-Negation
kappaB-mutated	I-Negation
,	O
HIV-1	O
LTR	O
region	O
.	O

Finally	O
,	O
the	O
ManLAM-mediated	O
activation	O
of	O
HIV-1	O
LTR	O
transcription	O
was	O
found	O
to	O
be	O
independent	O
of	O
the	O
autocrine	O
or	O
paracrine	O
action	O
of	O
endogenous	O
TNF-alpha	O
.	O

The	O
results	O
suggest	O
that	O
M.	O
tuberculosis	O
can	O
upregulate	O
HIV-1	O
expression	O
in	O
T	O
cells	O
and	O
could	O
thus	O
have	O
the	O
potential	O
to	O
influence	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
.	O

Oxidative	O
stress	O
suppresses	O
transcription	O
factor	O
activities	O
in	O
stimulated	O
lymphocytes	O
.	O

Effects	O
of	O
oxidative	O
stress	O
on	O
stimulation-dependent	O
signal	O
transduction	O
,	O
leading	O
to	O
IL-2	O
expression	O
,	O
were	O
studied	O
.	O

Purified	O
quiescent	O
human	O
blood	O
T	O
lymphocytes	O
were	O
subjected	O
to	O
:	O
(	O
i	O
)	O
acute	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
(	O
ii	O
)	O
chronic	O
exposure	O
to	O
hydrogen	O
peroxide	O
;	O
and	O
(	O
iii	O
)	O
acute	O
exposure	O
to	O
ionizing	O
radiation	O
.	O

The	O
cells	O
were	O
then	O
stimulated	O
for	O
6	O
h	O
.	O

DNA-binding	O
activities	O
(	O
determined	O
by	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
)	O
of	O
three	O
transcription	O
factors	O
:	O
NFkappaB	O
,	O
AP-1	O
and	O
NFAT	O
,	O
were	O
abolished	O
in	O
the	O
lymphocytes	O
by	O
all	O
three	O
modes	O
of	O
oxidative	O
stress	O
.	O

The	O
lymphocytes	O
exhibited	O
lipid	O
peroxidation	O
only	O
upon	O
exposure	O
to	O
the	O
lowest	O
level	O
of	O
hydrogen	O
peroxide	O
used	O
(	O
20	O
microM	O
)	O
.	O

All	O
three	O
modes	O
of	O
oxidative	O
stress	O
induced	O
catalase	O
activity	O
in	O
the	O
lymphocytes	O
.	O

The	O
only	O
exception	O
was	O
hydrogen	O
peroxide	O
at	O
20	O
microM	O
,	O
which	O
did	O
not	B-Negation
induce	I-Negation
catalase	I-Negation
activity	I-Negation
.	O

We	O
conclude	O
that	O
:	O
(	O
i	O
)	O
suppression	O
of	O
specific	O
transcription	O
factor	O
functions	O
can	O
potentially	B-Speculation
serve	I-Speculation
as	I-Speculation
a	I-Speculation
marker	I-Speculation
of	I-Speculation
exposure	I-Speculation
to	I-Speculation
oxidative	I-Speculation
stress	I-Speculation
and	I-Speculation
its	I-Speculation
effects	I-Speculation
on	I-Speculation
human	I-Speculation
lymphocytes	I-Speculation
;	O
(	O
ii	O
)	O
lipid	O
peroxidation	O
is	O
only	O
detectable	O
in	O
human	O
lymphocytes	O
upon	O
exposure	O
to	O
weak	O
oxidative	O
stress	O
which	O
does	O
not	B-Negation
induce	I-Negation
catalase	I-Negation
activity	I-Negation
;	O
(	O
iii	O
)	O
therefore	O
,	O
transcription	O
factor	O
DNA-binding	O
activities	O
are	O
more	O
sensitive	O
to	O
oxidative	O
stress	O
than	O
lipid	O
peroxidation	O
.	O

DNA	O
damaging	O
agents	O
induce	O
expression	O
of	O
Fas	O
ligand	O
and	O
subsequent	O
apoptosis	O
in	O
T	O
lymphocytes	O
via	O
the	O
activation	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
.	O

Apoptosis	O
induced	O
by	O
DNA	O
damage	O
and	O
other	O
stresses	O
can	O
proceed	O
via	O
expression	O
of	O
Fas	O
ligand	O
(	O
FasL	O
)	O
and	O
ligation	O
of	O
its	O
receptor	O
,	O
Fas	O
(	O
CD95	O
)	O
.	O

We	O
report	O
that	O
activation	O
of	O
the	O
two	O
transcription	O
factors	O
NF-kappa	O
B	O
and	O
AP-1	O
is	O
crucially	O
involved	O
in	O
FasL	O
expression	O
induced	O
by	O
etoposide	O
,	O
teniposide	O
,	O
and	O
UV	O
irradiation	O
.	O

A	O
nondegradable	O
mutant	O
of	O
I	O
kappa	O
B	O
blocked	O
both	O
FasL	O
expression	O
and	O
apoptosis	O
induced	O
by	O
DNA	O
damage	O
but	O
not	B-Negation
Fas	I-Negation
ligation	I-Negation
.	O

These	O
stimuli	O
also	O
induced	O
the	O
stress-activated	O
kinase	O
pathway	O
(	O
SAPK/JNK	O
)	O
,	O
which	O
was	O
required	O
for	O
the	O
maximal	O
induction	O
of	O
apoptosis	O
.	O

A	O
1.2	O
kb	O
FasL	O
promoter	O
responded	O
to	O
DNA	O
damage	O
,	O
as	O
well	O
as	O
coexpression	O
with	O
p65	O
Rel	O
or	O
Fos/Jun	O
.	O

Mutations	O
in	O
the	O
relevant	O
NF-kappa	O
B	O
and	O
AP-1	O
binding	O
sites	O
eliminated	O
these	O
responses	O
.	O

Thus	O
,	O
activation	O
of	O
NF-kappa	O
B	O
and	O
AP-1	O
contributes	O
to	O
stress-induced	O
apoptosis	O
via	O
the	O
expression	O
of	O
FasL	O
.	O

Thrombopoietin	O
supports	O
in	O
vitro	O
erythroid	O
differentiation	O
via	O
its	O
specific	O
receptor	O
c-Mpl	O
in	O
a	O
human	O
leukemia	O
cell	O
line	O
.	O

Thrombopoietin	O
(	O
TPO	O
)	O
acts	O
on	O
megakaryopoiesis	O
and	O
erythropoiesis	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
isolated	O
a	O
novel	O
subline	O
,	O
UT-7/GMT	O
,	O
from	O
the	O
human	O
leukemia	O
cell	O
line	O
UT-7/GM	O
(	O
N.	O
Komatsu	O
,	O
et	O
al.	O
,	O
Blood	O
,	O
89	O
:	O
4021-4033	O
,	O
1997	O
)	O
.	O

A	O
small	O
population	O
of	O
UT-7/GM	O
cells	O
positively	O
stained	O
for	O
hemoglobin	O
(	O
Hb	O
)	O
after	O
a	O
7-day	O
exposure	O
to	O
TPO	O
.	O

More	O
than	O
50	O
%	O
of	O
TPO-treated	O
UT-7/GMT	O
cells	O
positively	O
stained	O
for	O
Hb	O
.	O

Using	O
UT-7/GMT	O
cells	O
,	O
we	O
examined	O
how	O
TPO	O
promotes	O
hemoglobinization	O
.	O

TPO	O
induced	O
tyrosine	O
phosphorylation	O
of	O
the	O
TPO	O
receptor	O
but	O
not	B-Negation
the	I-Negation
erythropoietin	I-Negation
(	I-Negation
EPO	I-Negation
)	I-Negation
receptor	I-Negation
.	O

There	O
was	O
no	B-Negation
competition	I-Negation
between	I-Negation
TPO	I-Negation
and	I-Negation
EPO	I-Negation
for	I-Negation
binding	I-Negation
to	I-Negation
EPO	I-Negation
receptor	I-Negation
.	O

These	O
findings	O
suggest	O
that	O
TPO	O
has	O
a	O
direct	O
effect	O
on	O
hemoglobinization	O
via	O
a	O
specific	O
receptor	O
on	O
UT-7/GMT	O
cells	O
.	O

Isoelectric	O
focusing	O
demonstrated	O
that	O
TPO	O
induced	O
fetal	O
and	O
adult	O
Hb	O
synthesis	O
,	O
whereas	O
EPO	O
induced	O
embryonic	O
,	O
fetal	O
,	O
and	O
adult	O
Hb	O
synthesis	O
.	O

Thus	O
,	O
our	O
data	O
suggest	O
that	O
TPO	O
has	O
a	O
distinct	O
action	O
on	O
erythropoiesis	O
.	O

Redox	O
signals	O
and	O
NF-kappaB	O
activation	O
in	O
T	O
cells	O
.	O

Accumulating	O
data	O
from	O
a	O
number	O
of	O
laboratories	O
have	O
recently	O
indicated	O
that	O
the	O
response	O
of	O
transcription	O
factor	O
NF-kappaB	O
to	O
alterations	O
in	O
the	O
redox	O
homeostasis	O
of	O
cells	O
may	O
play	O
an	O
important	O
role	O
in	O
modulating	O
immune	O
function	O
.	O

The	O
activation	O
of	O
NF-kappaB	O
has	O
been	O
recognized	O
to	O
regulate	O
a	O
number	O
of	O
genes	O
necessary	O
for	O
normal	O
T	O
cell	O
responses	O
including	O
IL-2	O
,	O
IL-6	O
,	O
IL-8	O
,	O
and	O
several	O
T	O
cell	O
surface	O
receptors	O
.	O

Diminished	O
NF-kappaB	O
activity	O
has	O
been	O
shown	O
to	O
occur	O
in	O
T	O
cells	O
with	O
aging	O
,	O
suggesting	O
that	O
impaired	O
activation	O
of	O
NF-kappaB	O
might	O
occur	O
during	O
cellular	O
senescence	O
.	O

In	O
addition	O
,	O
aberrancies	O
in	O
NF-kappaB	O
activity	O
have	O
been	O
implicated	O
in	O
the	O
immunopathogenesis	O
of	O
diseases	O
involving	O
immune	O
or	O
inflammatory	O
processes	O
such	O
as	O
atherosclerosis	O
and	O
HIV-1	O
infection	O
.	O

The	O
role	O
of	O
H2O2	O
and	O
other	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
as	O
an	O
integratory	O
secondary	O
messenger	O
for	O
divergent	O
T	O
cell	O
signals	O
has	O
been	O
complicated	O
by	O
the	O
fact	O
that	O
various	O
T	O
cell	O
lines	O
and	O
peripheral	O
blood	O
T	O
cells	O
differ	O
markedly	O
in	O
the	O
levels	O
of	O
NF-kappaB	O
activation	O
induced	O
by	O
oxidant	O
stress	O
.	O

Additionally	O
,	O
proposed	O
pathways	O
of	O
NF-kappaB	O
activation	O
have	O
been	O
based	O
on	O
indirect	O
evidence	O
provided	O
by	O
experiments	O
which	O
used	O
antioxidants	O
to	O
inhibit	O
active	O
NF-kappaB	O
formation	O
.	O

Further	O
,	O
complete	O
activation	O
of	O
T	O
cells	O
requires	O
at	O
least	O
two	O
signals	O
,	O
one	O
that	O
stimulates	O
an	O
increase	O
in	O
intracellular	O
calcium	O
and	O
one	O
that	O
stimulates	O
enzymatic	O
processes	O
including	O
kinases	O
.	O

Similarly	O
,	O
substantial	O
evidence	O
indicates	O
that	O
full	O
activation	O
of	O
NF-kappaB	O
requires	O
dual	O
signals	O
.	O

The	O
ability	O
of	O
H2O2	O
or	O
other	O
ROS	O
to	O
induce	O
T	O
cell	O
signals	O
and	O
functional	O
responses	O
by	O
these	O
two	O
mechanisms	O
is	O
reviewed	O
and	O
the	O
specific	O
response	O
of	O
NF-kappaB	O
to	O
redox	O
changes	O
in	O
T	O
cells	O
is	O
examined	O
.	O

Data	O
are	O
also	O
presented	O
to	O
suggest	O
that	O
the	O
redox	O
regulation	O
in	O
NF-kappaB	O
activation	O
may	O
be	O
relevant	O
to	O
immune-related	O
diseases	O
and	O
to	O
aging	O
.	O

Fibrinogen	O
activates	O
NF-kappa	O
B	O
transcription	O
factors	O
in	O
mononuclear	O
phagocytes	O
.	O

Adhesion	O
to	O
extracellular	O
matrices	O
is	O
known	O
to	O
modulate	O
leukocyte	O
activation	O
,	O
although	O
the	O
mechanisms	O
are	O
not	O
fully	O
understood	O
.	O

Mononuclear	O
phagocytes	O
are	O
exposed	O
to	O
fibrinous	O
provisional	O
matrix	O
throughout	O
migration	O
into	O
inflammatory	O
foci	O
,	O
so	O
this	O
study	O
was	O
undertaken	O
to	O
determine	O
whether	O
fibrinogen	O
triggers	O
activation	O
of	O
NF-kappa	O
B	O
transcription	O
factors	O
.	O

U937	O
cells	O
differentiated	O
with	O
PMA	O
in	O
nonadherent	O
culture	O
were	O
shown	O
to	O
express	O
two	O
fibrinogen-binding	O
integrins	O
,	O
predominately	O
CD11b/CD18	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
CD11c/CD18	O
.	O

Cells	O
stimulated	O
with	O
fibrinogen	O
(	O
10-100	O
microg/ml	O
)	O
/Mn2+	O
(	O
50	O
microM	O
)	O
for	O
2	O
h	O
were	O
examined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
.	O

NF-kappa	O
B	O
activation	O
,	O
minimal	O
in	O
unstimulated	O
cells	O
,	O
was	O
substantially	O
up-regulated	O
by	O
fibrinogen	O
.	O

Fibrinogen	O
also	O
caused	O
activation	O
of	O
AP-1	O
,	O
but	O
not	B-Negation
SP1	I-Negation
or	I-Negation
cAMP	I-Negation
response	I-Negation
element-binding	I-Negation
protein	I-Negation
(	I-Negation
CREB	I-Negation
)	I-Negation
factors	I-Negation
.	O

Blocking	O
mAbs	O
against	O
CD18	O
and	O
CD11b	O
abrogated	O
fibrinogen-induced	O
NF-kappa	O
B	O
activation	O
.	O

To	O
determine	O
the	O
effects	O
on	O
transcriptional	O
regulation	O
,	O
U937	O
cells	O
were	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
HIV-1	O
enhancer	O
(	O
bearing	O
two	O
NF-kappa	O
B	O
sites	O
)	O
coupled	O
to	O
a	O
chloramphenicol	O
acetyltransferase	O
(	O
CAT	O
)	O
reporter	O
.	O

Cells	O
were	O
subsequently	O
stimulated	O
with	O
1	O
)	O
PMA	O
for	O
24	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
2.6-fold	O
,	O
2	O
)	O
fibrinogen/Mn2+	O
for	O
2	O
h	O
,	O
inducing	O
CAT	O
activity	O
by	O
3.2-fold	O
,	O
or	O
3	O
)	O
costimulation	O
with	O
fibrinogen	O
and	O
PMA	O
,	O
inducing	O
5.7-fold	O
the	O
CAT	O
activity	O
induced	O
by	O
PMA	O
alone	O
.	O

We	O
conclude	O
that	O
contact	O
with	O
fibrinogen-derived	O
proteins	O
may	O
contribute	O
to	O
mononuclear	O
phagocyte	O
activation	O
by	O
signaling	O
through	O
CD11b/CD18	O
,	O
resulting	O
in	O
selective	O
activation	O
of	O
transcriptional	O
regulatory	O
factors	O
,	O
including	O
NF-kappa	O
B	O
.	O

Ex	O
vivo	O
activation	O
of	O
tumor-draining	O
lymph	O
node	O
T	O
cells	O
reverses	O
defects	O
in	O
signal	O
transduction	O
molecules	O
.	O

The	O
adoptive	O
transfer	O
of	O
tumor-draining	O
lymph	O
node	O
(	O
LN	O
)	O
T	O
cells	O
activated	O
ex	O
vivo	O
with	O
anti-CD3	O
and	O
interleukin	O
2	O
(	O
IL-2	O
)	O
mediates	O
the	O
regression	O
of	O
the	O
poorly	O
immunogenic	O
murine	O
melanoma	O
D5	O
.	O

The	O
efficacy	O
of	O
the	O
activated	O
LN	O
cells	O
is	O
augmented	O
when	O
the	O
sensitizing	O
tumor	O
is	O
a	O
genetically	O
modified	O
variant	O
(	O
designated	O
D5G6	O
)	O
that	O
secretes	O
granulocyte/macrophage-colony-stimulating	O
factor	O
.	O

In	O
contrast	O
to	O
anti-CD3/IL-2-activated	O
LN	O
cells	O
,	O
adoptive	O
transfer	O
of	O
freshly	O
isolated	O
tumor-draining	O
LN	O
T	O
cells	O
has	O
no	B-Negation
therapeutic	I-Negation
activity	I-Negation
.	O

To	O
determine	O
whether	O
the	O
acquisition	O
of	O
antitumor	O
function	O
during	O
ex	O
vivo	O
activation	O
is	O
associated	O
with	O
modifications	O
in	O
signal	O
transduction	O
capacity	O
,	O
the	O
protein	O
tyrosine	O
kinases	O
p56lck	O
and	O
p59fyn	O
and	O
proteins	O
of	O
the	O
NF-kappaB	O
family	O
were	O
analyzed	O
in	O
tumor-draining	O
LN	O
T	O
cells	O
.	O

The	O
levels	O
of	O
p56lck	O
and	O
p59fyn	O
were	O
lower	O
in	O
tumor-draining	O
than	O
in	O
normal	O
LN	O
T	O
cells	O
and	O
production	O
of	O
tyrosine-phosphorylated	O
substrates	O
was	O
markedly	O
depressed	O
following	O
anti-CD3	O
stimulation	O
.	O

After	O
5-day	O
anti-CD3/IL-2	O
activation	O
,	O
levels	O
of	O
p56lck	O
and	O
p59fyn	O
and	O
protein	O
tyrosine	O
kinase	O
activity	O
increased	O
.	O

Interestingly	O
,	O
the	O
levels	O
of	O
p56lck	O
,	O
p59fyn	O
,	O
and	O
tyrosine	O
kinase	O
activity	O
were	O
higher	O
in	O
activated	O
T	O
cells	O
derived	O
from	O
LN	O
that	O
drained	O
D5G6	O
than	O
they	O
were	O
in	O
those	O
from	O
D5	O
tumors	O
.	O

In	O
contrast	O
,	O
the	O
cytoplasmic	O
levels	O
of	O
c-Rel	O
and	O
Rel	O
A	O
were	O
normal	O
in	O
freshly	O
isolated	O
tumor-draining	O
LN	O
,	O
as	O
was	O
nuclear	O
kappaB	O
DNA-binding	O
activity	O
induced	O
by	O
anti-CD3	O
mAb	O
or	O
phorbol	O
myristate	O
acetate	O
.	O

Stimulation	O
of	O
activated	O
LN	O
cells	O
with	O
D5	O
tumor	O
cells	O
induced	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	O
.	O

These	O
findings	O
indicate	O
that	O
the	O
recovery	O
of	O
proteins	O
mediating	O
signal	O
transduction	O
through	O
the	O
T	O
cell	O
receptor/CD3	O
complex	O
in	O
LN	O
T	O
cells	O
activated	O
ex	O
vivo	O
was	O
associated	O
with	O
the	O
acquisition	O
of	O
antitumor	O
function	O
.	O

Targeted	O
disruption	O
of	O
the	O
MyD88	O
gene	O
results	O
in	O
loss	O
of	O
IL-1-	O
and	O
IL-18-mediated	O
function	O
.	O

MyD88	O
,	O
originally	O
isolated	O
as	O
a	O
myeloid	O
differentiation	O
primary	O
response	O
gene	O
,	O
is	O
shown	O
to	O
act	O
as	O
an	O
adaptor	O
in	O
interleukin-1	O
(	O
IL-1	O
)	O
signaling	O
by	O
interacting	O
with	O
both	O
the	O
IL-1	O
receptor	O
complex	O
and	O
IL-1	O
receptor-associated	O
kinase	O
(	O
IRAK	O
)	O
.	O

Mice	O
generated	O
by	O
gene	O
targeting	O
to	O
lack	B-Negation
MyD88	I-Negation
have	O
defects	O
in	O
T	O
cell	O
proliferation	O
as	O
well	O
as	O
induction	O
of	O
acute	O
phase	O
proteins	O
and	O
cytokines	O
in	O
response	O
to	O
IL-1	O
.	O

Increases	O
in	O
interferon-gamma	O
production	O
and	O
natural	O
killer	O
cell	O
activity	O
in	O
response	O
to	O
IL-18	O
are	O
abrogated	O
.	O

In	O
vivo	O
Th1	O
response	O
is	O
also	O
impaired	O
.	O

Furthermore	O
,	O
IL-18-induced	O
activation	O
of	O
NF-kappaB	O
and	O
c-Jun	O
N-terminal	O
kinase	O
(	O
JNK	O
)	O
is	O
blocked	O
in	O
MyD88-/-	O
Th1-developing	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
MyD88	O
is	O
a	O
critical	O
component	O
in	O
the	O
signaling	O
cascade	O
that	O
is	O
mediated	O
by	O
IL-1	O
receptor	O
as	O
well	O
as	O
IL-18	O
receptor	O
.	O

Epstein-Barr	O
virus-transforming	O
protein	O
latent	O
infection	O
membrane	O
protein	O
1	O
activates	O
transcription	O
factor	O
NF-kappaB	O
through	O
a	O
pathway	O
that	O
includes	O
the	O
NF-kappaB-inducing	O
kinase	O
and	O
the	O
IkappaB	O
kinases	O
IKKalpha	O
and	O
IKKbeta	O
.	O

The	O
Epstein-Barr	O
virus	O
oncoprotein	O
latent	O
infection	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
is	O
a	O
constitutively	O
aggregated	O
pseudo-tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
that	O
activates	O
transcription	O
factor	O
NF-kappaB	O
through	O
two	O
sites	O
in	O
its	O
C-terminal	O
cytoplasmic	O
domain	O
.	O

One	O
site	O
is	O
similar	O
to	O
activated	O
TNFRII	O
in	O
associating	O
with	O
TNFR-associated	O
factors	O
TRAF1	O
and	O
TRAF2	O
,	O
and	O
the	O
second	O
site	O
is	O
similar	O
to	O
TNFRI	O
in	O
associating	O
with	O
the	O
TNFRI	O
death	O
domain	O
interacting	O
protein	O
TRADD	O
.	O

TNFRI	O
has	O
been	O
recently	O
shown	O
to	O
activate	O
NF-kappaB	O
through	O
association	O
with	O
TRADD	O
,	O
RIP	O
,	O
and	O
TRAF2	O
;	O
activation	O
of	O
the	O
NF-kappaB-inducing	O
kinase	O
(	O
NIK	O
)	O
;	O
activation	O
of	O
the	O
IkappaB	O
alpha	O
kinases	O
(	O
IKKalpha	O
and	O
IKKbeta	O
)	O
;	O
and	O
phosphorylation	O
of	O
IkappaB	O
alpha	O
.	O

IkappaB	O
alpha	O
phosphorylation	O
on	O
Ser-32	O
and	O
Ser-36	O
is	O
followed	O
by	O
its	O
degradation	O
and	O
NF-kappaB	O
activation	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
NF-kappaB	O
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
is	O
mediated	O
by	O
a	O
pathway	O
that	O
includes	O
NIK	O
,	O
IKKalpha	O
,	O
and	O
IKKbeta	O
.	O

Dominant	O
negative	O
mutants	O
of	O
NIK	O
,	O
IKKalpha	O
,	O
or	O
IKKbeta	O
substantially	O
inhibited	O
NF-kappaB	O
activation	O
by	O
LMP1	O
or	O
by	O
each	O
of	O
its	O
effector	O
sites	O
.	O

Dimethyldithiocarbamate	O
inhibits	O
in	O
vitro	O
activation	O
of	O
primary	O
human	O
CD4+	O
T	O
lymphocytes	O
.	O

Dithiocarbamates	O
(	O
DTC	O
)	O
,	O
a	O
diverse	O
group	O
of	O
industrial	O
and	O
therapeutic	O
chemicals	O
,	O
have	O
been	O
reported	O
to	O
inhibit	O
,	O
enhance	O
or	O
have	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
immune	I-Negation
system	I-Negation
.	O

These	O
apparent	O
inconsistencies	O
reflect	O
the	O
complexity	O
of	O
the	O
DTCs	O
biological	O
activities	O
and	O
are	O
probably	O
due	O
in	O
part	O
to	O
differences	O
in	O
dose	O
,	O
route	O
of	O
exposure	O
,	O
animal	O
species	O
used	O
and/or	O
specific	O
compound	O
tested	O
.	O

The	O
studies	O
described	O
herein	O
were	O
undertaken	O
to	O
investigate	O
the	O
immunotoxicity	O
of	O
one	O
member	O
of	O
this	O
family	O
,	O
dimethyldithiocarbamate	O
(	O
DMDTC	O
)	O
.	O

We	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
TNF-alpha-induced	O
activation	O
of	O
NF-kappaB	O
in	O
primary	O
human	O
CD4+	O
T	O
cells	O
.	O

This	B-Negation
inhibition	I-Negation
is	I-Negation
not	I-Negation
accompanied	I-Negation
by	I-Negation
a	I-Negation
loss	I-Negation
in	I-Negation
viability	I-Negation
,	O
and	O
DMDTC-treated	O
T	O
cells	O
retain	O
other	O
active	O
signaling	O
pathways	O
throughout	O
the	O
exposure	O
duration	O
.	O

The	O
inhibition	O
of	O
NF-kappaB	O
is	O
apparently	O
permanent	O
as	O
DMDTC-treated	O
T	O
cells	O
did	O
not	B-Negation
regain	I-Negation
normal	I-Negation
TNF-alpha	I-Negation
activation	I-Negation
,	I-Negation
even	I-Negation
after	I-Negation
72	I-Negation
h	I-Negation
in	I-Negation
culture	I-Negation
.	O

DMDTC	B-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
alter	I-Speculation
NF-kappaB	I-Speculation
directly	I-Speculation
as	O
pre-incubation	O
of	O
nuclear	O
extracts	O
with	O
DMDTC	B-Negation
does	I-Negation
not	I-Negation
diminish	O
binding	O
activity	O
of	O
this	O
protein	O
.	O

We	O
further	O
demonstrate	O
that	O
0.1-0.5	O
microM	O
DMDTC	O
inhibits	O
intracellular	O
IL-2	O
production	O
and	O
decreases	O
surface	O
expression	O
of	O
CD25	O
(	O
the	O
alpha	O
subunit	O
of	O
the	O
IL-2	O
receptor	O
)	O
in	O
T	O
cells	O
stimulated	O
with	O
phorbol	O
ester	O
.	O

These	O
data	O
demonstrate	O
that	O
DMDTC	O
is	O
a	O
potent	O
immunosuppressive	O
compound	O
in	O
vitro	O
.	O

The	O
small	O
GTP-binding	O
protein	O
Rho	O
potentiates	O
AP-1	O
transcription	O
in	O
T	O
cells	O
.	O

The	O
Rho	O
family	O
of	O
small	O
GTP-binding	O
proteins	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cytoskeletal	O
structure	O
,	O
gene	O
transcription	O
,	O
specific	O
cell	O
fate	O
development	O
,	O
and	O
transformation	O
.	O

We	O
demonstrate	O
in	O
this	O
report	O
that	O
overexpression	O
of	O
an	O
activated	O
form	O
of	O
Rho	O
enhances	O
AP-1	O
activity	O
in	O
Jurkat	O
T	O
cells	O
in	O
the	O
presence	O
of	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
,	O
but	O
activated	O
Rho	O
(	O
V14Rho	O
)	O
has	O
little	O
or	O
no	B-Negation
effect	I-Negation
on	I-Negation
NFAT	I-Negation
,	I-Negation
Oct-1	I-Negation
,	I-Negation
and	I-Negation
NF-kappaB	I-Negation
enhancer	I-Negation
element	I-Negation
activities	I-Negation
under	I-Negation
similar	I-Negation
conditions	I-Negation
.	O

Overexpression	O
of	O
a	O
V14Rho	O
construct	O
incapable	O
of	O
membrane	O
localization	O
(	O
CAAX	O
deleted	O
)	O
abolishes	O
PMA-induced	O
AP-1	O
transcriptional	O
activation	O
.	O

The	O
effect	O
of	O
Rho	O
on	O
AP-1	O
is	O
independent	O
of	O
the	O
mitogen-activated	O
protein	O
kinase	O
pathway	O
,	O
as	O
a	O
dominant-negative	O
MEK	O
and	O
a	O
MEK	O
inhibitor	O
(	O
PD98059	O
)	O
did	O
not	B-Negation
affect	I-Negation
Rho-induced	I-Negation
AP-1	I-Negation
activity	I-Negation
.	O

V14Rho	O
binds	O
strongly	O
to	O
protein	O
kinase	O
Calpha	O
(	O
PKCalpha	O
)	O
in	O
vivo	O
;	O
however	O
,	O
deletion	O
of	O
the	O
CAAX	O
site	O
on	O
V14Rho	O
severely	O
diminished	O
this	O
association	O
.	O

Evidence	O
for	O
a	O
role	O
for	O
PKCalpha	O
as	O
an	O
effector	O
of	O
Rho	O
was	O
obtained	O
by	O
the	O
observation	O
that	O
coexpression	O
of	O
the	O
N-terminal	O
domain	O
of	O
PKCalpha	O
blocked	O
the	O
effects	O
of	O
activated	O
Rho	O
plus	O
PMA	O
on	O
AP-1	O
transcriptional	O
activity	O
.	O

These	O
data	O
suggest	O
that	O
Rho	O
potentiates	O
AP-1	O
transcription	O
during	O
T-cell	O
activation	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
Tax	O
induction	O
of	O
NF-kappaB	O
involves	O
activation	O
of	O
the	O
IkappaB	O
kinase	O
alpha	O
(	O
IKKalpha	O
)	O
and	O
IKKbeta	O
cellular	O
kinases	O
.	O

Tax	O
corresponds	O
to	O
a	O
40-kDa	O
transforming	O
protein	O
from	O
the	O
pathogenic	O
retrovirus	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
that	O
activates	O
nuclear	O
expression	O
of	O
the	O
NF-kappaB/Rel	O
family	O
of	O
transcription	O
factors	O
by	O
an	O
unknown	O
mechanism	O
.	O

Tax	O
expression	O
promotes	O
N-terminal	O
phosphorylation	O
and	O
degradation	O
of	O
IkappaB	O
alpha	O
,	O
a	O
principal	O
cytoplasmic	O
inhibitor	O
of	O
NF-kappaB	O
.	O

Our	O
studies	O
now	O
demonstrate	O
that	O
HTLV-1	O
Tax	O
activates	O
the	O
recently	O
identified	O
cellular	O
kinases	O
IkappaB	O
kinase	O
alpha	O
(	O
IKKalpha	O
)	O
and	O
IKKbeta	O
,	O
which	O
normally	O
phosphorylate	O
IkappaB	O
alpha	O
on	O
both	O
of	O
its	O
N-terminal	O
regulatory	O
serines	O
in	O
response	O
to	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
and	O
interleukin-1	O
(	O
IL-1	O
)	O
stimulation	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
of	O
Tax	O
termed	O
M22	O
,	O
which	O
does	O
not	B-Negation
induce	I-Negation
NF-kappaB	I-Negation
,	O
fails	B-Negation
to	I-Negation
activate	I-Negation
either	I-Negation
IKKalpha	I-Negation
or	I-Negation
IKKbeta	I-Negation
.	O

Furthermore	O
,	O
endogenous	O
IKK	O
enzymatic	O
activity	O
was	O
significantly	O
elevated	O
in	O
HTLV-1-infected	O
and	O
Tax-expressing	O
T-cell	O
lines	O
.	O

Transfection	O
of	O
kinase-deficient	O
mutants	O
of	O
IKKalpha	O
and	O
IKKbeta	O
into	O
either	O
human	O
Jurkat	O
T	O
or	O
293	O
cells	O
also	O
inhibits	O
NF-kappaB-dependent	O
reporter	O
gene	O
expression	O
induced	O
by	O
Tax	O
.	O

Similarly	O
,	O
a	O
kinase-deficient	O
mutant	O
of	O
NIK	O
(	O
NF-kappaB-inducing	O
kinase	O
)	O
,	O
which	O
represents	O
an	O
upstream	O
kinase	O
in	O
the	O
TNF-alpha	O
and	O
IL-1	O
signaling	O
pathways	O
leading	O
to	O
IKKalpha	O
and	O
IKKbeta	O
activation	O
,	O
blocks	O
Tax	O
induction	O
of	O
NF-kappaB	O
.	O

However	O
,	O
plasma	O
membrane-proximal	O
elements	O
in	O
these	O
proinflammatory	O
cytokine	O
pathways	O
are	O
apparently	O
not	B-Negation
involved	I-Negation
since	O
dominant	O
negative	O
mutants	O
of	O
the	O
TRAF2	O
and	O
TRAF6	O
adaptors	O
,	O
which	O
effectively	O
block	O
signaling	O
through	O
the	O
cytoplasmic	O
tails	O
of	O
the	O
TNF-alpha	O
and	O
IL-1	O
receptors	O
,	O
respectively	O
,	O
do	O
not	B-Negation
inhibit	I-Negation
Tax	I-Negation
induction	I-Negation
of	I-Negation
NF-kappaB	I-Negation
.	O

Together	O
,	O
these	O
studies	O
demonstrate	O
that	O
HTLV-1	O
Tax	O
exploits	O
a	O
distal	O
part	O
of	O
the	O
proinflammatory	O
cytokine	O
signaling	O
cascade	O
leading	O
to	O
induction	O
of	O
NF-kappaB	O
.	O

The	O
pathological	O
alteration	O
of	O
this	O
cytokine	O
pathway	O
leading	O
to	O
NF-kappaB	O
activation	O
by	O
Tax	O
may	O
play	O
a	O
central	O
role	O
in	O
HTLV-1-mediated	O
transformation	O
of	O
human	O
T	O
cells	O
,	O
clinically	O
manifested	O
as	O
the	O
adult	O
T-cell	O
leukemia	O
.	O

A	O
CD28-associated	O
signaling	O
pathway	O
leading	O
to	O
cytokine	O
gene	O
transcription	O
and	O
T	O
cell	O
proliferation	O
without	B-Negation
TCR	I-Negation
engagement	I-Negation
.	O

Stimulation	O
of	O
resting	O
human	O
T	O
cells	O
with	O
the	O
CD28-specific	O
mAb	O
BW	O
828	O
induces	O
proliferation	O
and	O
cytokine	O
synthesis	O
without	B-Negation
further	I-Negation
requirement	I-Negation
for	I-Negation
TCR	I-Negation
coengagement	I-Negation
.	O

This	O
observation	O
prompted	O
us	O
to	O
postulate	O
that	O
signal	O
2	O
(	O
costimulatory	O
signal	O
)	O
alone	O
without	B-Negation
signal	I-Negation
1	I-Negation
(	I-Negation
TCR	I-Negation
signal	I-Negation
)	I-Negation
can	O
activate	O
T	O
cells	O
.	O

To	O
test	O
whether	O
this	O
putative	O
function	O
of	O
CD28	O
is	O
mediated	O
via	O
a	O
particular	O
signaling	O
pathway	O
,	O
we	O
compared	O
early	O
signaling	O
events	O
initiated	O
in	O
resting	O
T	O
cells	O
by	O
the	O
stimulatory	O
mAb	O
BW	O
828	O
with	O
signals	O
triggered	O
by	O
the	O
nonstimulating	O
CD28	O
mAb	O
9.3	O
.	O

Stimulation	O
of	O
T	O
cells	O
with	O
BW	O
828	O
induced	O
an	O
increase	O
in	O
intracellular	O
Ca2+	O
,	O
but	O
did	O
not	B-Negation
lead	I-Negation
to	I-Negation
detectable	I-Negation
activation	I-Negation
of	I-Negation
the	I-Negation
protein	I-Negation
kinases	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
and	I-Negation
c-Raf-1	I-Negation
.	O

This	O
pathway	O
resulted	O
in	O
the	O
induction	O
of	O
the	O
transcription	O
factors	O
NF-kappa	O
B	O
,	O
NF-AT	O
,	O
and	O
proteins	O
binding	O
to	O
the	O
CD28	O
response	O
element	O
of	O
the	O
IL-2	O
promoter	O
.	O

On	O
the	O
other	O
hand	O
,	O
stimulation	O
of	O
T	O
cells	O
with	O
mAb	O
9.3	O
increased	O
the	O
level	O
of	O
intracellular	O
Ca2+	O
and	O
triggered	O
the	O
activation	O
of	O
p56	O
(	O
lck	O
)	O
and	O
c-Raf-1	O
,	O
but	O
was	B-Negation
unable	I-Negation
to	I-Negation
induce	I-Negation
the	I-Negation
binding	I-Negation
of	I-Negation
transcription	I-Negation
factors	I-Negation
to	I-Negation
the	I-Negation
IL-2	I-Negation
promoter	I-Negation
.	O

In	O
contrast	O
to	O
the	O
differential	O
signaling	O
of	O
BW	O
828	O
and	O
9.3	O
in	O
resting	O
T	O
cells	O
,	O
the	O
two	O
mAbs	O
exhibited	O
a	O
similar	O
pattern	O
of	O
early	O
signaling	O
events	O
in	O
activated	O
T	O
cells	O
and	O
Jurkat	O
cells	O
(	O
p56	O
(	O
lck	O
)	O
activation	O
,	O
association	O
of	O
phosphatidylinositol	O
3-kinase	O
with	O
CD28	O
)	O
,	O
indicating	O
that	O
the	O
signaling	O
capacity	O
of	O
CD28	O
changes	O
with	O
activation	O
.	O

These	O
data	O
support	O
the	O
view	O
that	O
stimulation	O
through	O
CD28	O
can	O
induce	O
some	O
effector	O
functions	O
in	O
T	O
cells	O
and	O
suggest	O
that	O
this	O
capacity	O
is	O
associated	O
with	O
a	O
particular	O
pattern	O
of	O
early	O
signaling	O
events	O
.	O

Cyclosporin	O
A-resistant	O
transactivation	O
of	O
the	O
IL-2	O
promoter	O
requires	O
activity	O
of	O
okadaic	O
acid-sensitive	O
serine/threonine	O
phosphatases	O
.	O

Expression	O
of	O
the	O
IL-2	O
gene	O
requires	O
activation	O
of	O
T	O
cells	O
through	O
stimulation	O
of	O
the	O
TCR	O
and	O
costimulation	O
through	O
accessory	O
receptors	O
.	O

We	O
have	O
found	O
recently	O
that	O
okadaic	O
acid-sensitive	O
Ser/Thr	O
phosphatases	O
are	O
involved	O
in	O
a	O
cyclosporin	O
A-insensitive	O
pathway	O
that	O
selectively	O
transmits	O
costimulatory	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
analyzed	O
whether	O
activities	O
of	O
these	O
phosphatases	O
are	O
necessary	O
for	O
the	O
expression	O
of	O
the	O
IL-2	O
gene	O
.	O

In	O
both	O
activated	O
peripheral	O
blood	O
T	O
lymphocytes	O
and	O
activated	O
tumorigenic	O
T	O
cell	O
lines	O
,	O
IL-2	O
gene	O
expression	O
was	O
blocked	O
at	O
the	O
transcriptional	O
level	O
by	O
okadaic	O
acid	O
.	O

The	O
transcription	O
factors	O
active	O
at	O
the	O
IL-2	O
promoter	O
were	O
differentially	O
influenced	O
:	O
upon	O
down-modulation	O
of	O
okadaic	O
acid-sensitive	O
phosphatases	O
,	O
transactivation	O
by	O
octamer	O
,	O
NF-kappa	O
B	O
,	O
and	O
NF	O
of	O
activated	O
T	O
cells	O
proteins	O
was	O
abrogated	O
,	O
while	O
transactivation	O
by	O
AP-1	O
proteins	O
was	O
even	O
enhanced	O
.	O

Inducible	O
nitric	O
oxide	O
:	O
an	O
autoregulatory	O
feedback	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Inducible	O
nitric	O
oxide	O
(	O
iNO	O
)	O
is	O
produced	O
at	O
sites	O
of	O
vascular	O
inflammation	O
by	O
resident	O
and	O
nonresident	O
vascular	O
wall	O
cells	O
,	O
but	O
its	O
role	O
in	O
the	O
inflammatory	O
process	O
is	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
a	O
novel	O
function	O
of	O
iNO	O
is	O
to	O
terminate	O
inflammatory	O
processes	O
.	O

We	O
find	O
that	O
iNO	O
produced	O
by	O
murine	O
macrophage-like	O
cells	O
,	O
RAW264.7	O
,	O
can	O
inhibit	O
cytokine-induced	O
endothelial	O
cell	O
activation	O
in	O
a	O
separated	O
and	O
mixed	O
endothelial-RAW264.7	O
coculture	O
system	O
.	O

Both	O
iNO	O
production	O
and	O
endothelial	O
VCAM-1	O
expression	O
were	O
induced	O
simultaneously	O
with	O
bacterial	O
LPS	O
and	O
murine-specific	O
IFN-gamma	O
.	O

Inhibition	O
of	O
iNO	O
synthase	O
(	O
iNOS	O
)	O
activity	O
with	O
N	O
omega-monomethyl-L-arginine	O
in	O
endothelial-RAW264.7	O
cocultures	O
,	O
stimulated	O
with	O
murine-specific	O
IFN-gamma	O
and	O
LPS	O
,	O
decreased	O
iNO	O
production	O
by	O
86	O
%	O
,	O
augmented	O
VCAM-1	O
and	O
iNOS	O
expression	O
in	O
endothelial	O
and	O
RAW264.7	O
cells	O
,	O
respectively	O
,	O
and	O
increased	O
monocyte	O
adhesion	O
to	O
the	O
endothelial	O
cell	O
surface	O
.	O

Transient	O
transfection	O
studies	O
using	O
various	O
VCAM-1	O
promoter	O
constructs	O
demonstrated	O
that	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
VCAM-1	O
gene	O
transcription	O
were	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibitory	O
effects	O
of	O
iNO	O
on	O
kappa	O
B	O
cis-acting	O
elements	O
.	O

Immunofluorescence	O
studies	O
using	O
an	O
Ab	O
to	O
the	O
RelA	O
(	O
p65	O
)	O
subunit	O
of	O
nuclear	O
factor-kappa	O
B	O
revealed	O
that	O
iNO	O
inhibited	O
the	O
activation	O
of	O
nuclear	O
factor-kappa	O
B	O
.	O

These	O
studies	O
indicate	O
that	O
iNO	O
attenuates	O
iNOS	O
expression	O
in	O
macrophages	O
and	O
inhibits	O
monocyte	O
adhesion	O
to	O
endothelial	O
cells	O
,	O
and	O
suggest	O
that	O
endogenously	O
derived	O
iNO	O
may	O
be	O
an	O
important	O
autoregulatory	O
inhibitor	O
of	O
vascular	O
inflammation	O
.	O

Characterization	O
of	O
cytokine	O
differential	O
induction	O
of	O
STAT	O
complexes	O
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
.	O

Cytokines	O
,	O
IL-2	O
,	O
IL-4	O
,	O
IL-6	O
,	O
IL-7	O
,	O
IL-12	O
,	O
and	O
IL-15	O
are	O
key	O
regulators	O
of	O
human	O
peripheral	O
blood	O
T	O
and	O
NK	O
cell	O
activation	O
and	O
differentiation	O
but	O
the	O
precise	O
mechanisms	O
that	O
give	O
rise	O
to	O
their	O
differential	O
activities	O
within	O
these	O
cells	O
are	O
not	O
clear	O
.	O

Recent	O
studies	O
reveal	O
that	O
a	O
family	O
of	O
transcription	O
factors	O
,	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STATs	O
)	O
directly	O
mediate	O
many	O
cytokine	O
signals	O
.	O

We	O
analyzed	O
the	O
activation	O
of	O
STATs	O
in	O
primary	O
human	O
T	O
and	O
NK	O
cells	O
by	O
a	O
variety	O
of	O
specific	O
cytokines	O
.	O

We	O
demonstrate	O
that	O
IL-12	O
induces	O
STAT4	O
only	O
in	O
freshly	O
isolated	O
primary	O
NK	O
cells	O
,	O
but	O
not	B-Negation
in	I-Negation
primary	I-Negation
T	I-Negation
cells	I-Negation
,	O
consistent	O
with	O
the	O
lack	B-Negation
of	I-Negation
the	I-Negation
IL-12	I-Negation
receptor	I-Negation
in	I-Negation
resting	I-Negation
T	I-Negation
cells	I-Negation
.	O

In	O
contrast	O
,	O
IL-4	O
induces	O
different	O
C	O
epsilon	O
GAS	O
DNA-protein	O
binding	O
complexes	O
in	O
both	O
T	O
and	O
NK	O
cells	O
.	O

Moreover	O
,	O
IL-4	O
costimulation	O
with	O
IL-2	O
or	O
IL-12	O
does	O
not	B-Negation
alter	I-Negation
their	I-Negation
own	I-Negation
preferential	I-Negation
GAS-like	I-Negation
DNA	I-Negation
binding	I-Negation
patterns	I-Negation
when	I-Negation
C	I-Negation
epsilon-	I-Negation
,	I-Negation
Fc	I-Negation
gamma	I-Negation
RI-	I-Negation
,	I-Negation
and	I-Negation
SIE	I-Negation
GAS	I-Negation
motif	I-Negation
containing	I-Negation
oligonucleotide	I-Negation
probes	I-Negation
are	I-Negation
compared	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
induction	I-Speculation
of	I-Speculation
GAS-like	I-Speculation
DNA-protein	I-Speculation
binding	I-Speculation
complexes	I-Speculation
by	I-Speculation
IL-2	I-Speculation
,	I-Speculation
IL-4	I-Speculation
,	I-Speculation
and	I-Speculation
IL-12	I-Speculation
is	I-Speculation
highly	I-Speculation
selective	I-Speculation
and	I-Speculation
represents	I-Speculation
one	I-Speculation
important	I-Speculation
factor	I-Speculation
in	I-Speculation
determining	I-Speculation
specific	I-Speculation
gene	I-Speculation
activation	I-Speculation
.	O

In	O
addition	O
,	O
IL-6	O
and	O
IL-2	O
synergistically	O
induce	O
homo-	O
and	O
heterodimerized	O
STAT1	O
alpha	O
and	O
STAT3	O
in	O
both	O
NK	O
and	O
T	O
cells	O
,	O
consistent	O
with	O
their	O
reported	O
synergism	O
in	O
modulating	O
perforin	O
gene	O
expression	O
.	O

We	O
further	O
demonstrated	O
that	O
IL-2	O
,	O
-7	O
,	O
and	O
-15	O
induce	O
multiple	O
STAT	O
proteins	O
,	O
including	O
STAT5a	O
,	O
STAT5b	O
,	O
STAT1	O
alpha	O
,	O
STAT3	O
,	O
and	O
another	O
unidentified	O
Fc	O
gamma	O
RI	O
GAS	O
DNA-binding	O
protein	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
activated	O
STAT5a	O
and	O
STAT5b	O
proteins	O
form	O
distinct	O
Fc	O
gamma	O
RI	O
GAS	O
binding	O
patterns	O
in	O
T	O
and	O
NK	O
cells	O
,	O
suggesting	O
that	O
they	O
might	O
have	O
different	O
roles	O
in	O
gene	O
regulation	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
the	O
differential	O
responses	O
in	O
gene	O
expression	O
and	O
cell	O
activation	O
seen	O
in	O
primary	O
NK	O
and	O
T	O
cells	O
on	O
direct	O
stimulation	O
with	O
different	O
cytokines	O
may	O
be	O
a	O
direct	O
result	O
of	O
distinct	O
activation	O
of	O
STAT	O
transcription	O
factors	O
.	O

Inhibition	O
of	O
HIV-1	O
replication	O
by	O
combination	O
of	O
a	O
novel	O
inhibitor	O
of	O
TNF-alpha	O
with	O
AZT	O
.	O

The	O
small	O
molecule	O
S9a	O
was	O
derived	O
from	O
an	O
established	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
inhibitor	O
(	O
Canventol	O
)	O
by	O
replacement	O
of	O
the	O
isopropylidine	O
group	O
with	O
a	O
phenyl	O
ring	O
.	O

S9a	O
at	O
10	O
to	O
100	O
nM	O
inhibited	O
HIV	O
production	O
as	O
potently	O
as	O
3'-azido-3'-deoxythymidine	O
(	O
AZT	O
)	O
,	O
an	O
inhibitor	O
of	O
viral	O
reverse	O
transcriptase	O
.	O

Furthermore	O
,	O
S9a	O
and	O
AZT	O
in	O
combination	O
,	O
at	O
noncytoxic	O
concentrations	O
strongly	O
inhibited	O
HIV-1	O
replication	O
that	O
was	O
more	O
than	O
additive	O
and	O
substantially	O
prolonged	O
the	O
appearance	O
of	O
virus	O
both	O
in	O
acutely	O
infected	O
CD4+	O
lymphocytes	O
(	O
SupT	O
)	O
in	O
culture	O
and	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
infected	O
with	O
a	O
primary	O
HIV-1	O
isolate	O
.	O

S9a	O
inhibited	O
TNF-alpha	O
promoter-driven	O
reporter	O
gene	O
activity	O
.	O

It	O
was	O
proposed	O
that	O
the	O
mechanism	O
of	O
antiviral	O
action	O
of	O
S9a	O
was	O
on	O
the	O
host	O
cell	O
,	O
by	O
blocking	O
TNF-alpha	O
transcription	O
via	O
a	O
Tat-induced	O
tar-independent	O
loop	O
,	O
which	O
decreases	O
downstream	O
NF-kappaB	O
activation	O
of	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

S9a	O
was	O
superior	O
to	O
the	O
first	O
generation	O
compound	O
Canventol	O
,	O
which	O
was	O
superior	O
to	O
the	O
natural	O
compound	O
sarcophytol	O
A	O
,	O
demonstrating	O
that	O
further	O
structure-based	O
enhancement	O
of	O
potency	O
of	O
these	O
compounds	O
is	O
feasible	O
.	O

This	O
study	O
suggests	O
a	O
therapeutic	O
approach	O
against	O
AIDS	O
by	O
application	O
of	O
two	O
drugs	O
,	O
one	O
against	O
a	O
cellular	O
and	O
the	O
other	O
a	O
viral	O
target	O
,	O
which	O
may	O
provide	O
an	O
approach	O
to	O
the	O
problem	O
of	O
frequent	O
emergence	O
of	O
resistant	O
variants	O
to	O
combinations	O
of	O
drugs	O
that	O
target	O
only	O
HIV	O
genes	O
.	O

Retinoic	O
acid	O
inhibits	O
CD40	O
+	O
interleukin-4-mediated	O
IgE	O
production	O
in	O
vitro	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
retinoic	O
acid	O
(	O
RA	O
)	O
in	O
anti-CD40	O
+	O
interleukin-4	O
(	O
IL-4	O
)	O
-mediated	O
B-cell	O
activation	O
,	O
the	O
effect	O
of	O
10	O
(	O
-12	O
)	O
to	O
10	O
(	O
-6	O
)	O
mol/L	O
RA	O
was	O
studied	O
in	O
anti-CD40	O
(	O
1	O
microgram/mL	O
)	O
+	O
IL-4	O
(	O
5	O
ng/mL	O
)	O
-mediated	O
proliferation	O
and	O
Ig	O
synthesis	O
by	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
B	O
cells	O
in	O
healthy	O
donors	O
.	O

Anti-CD40	O
+	O
IL-4-mediated	O
proliferation	O
of	O
PBMC	O
and	O
B	O
cells	O
was	O
inhibited	O
by	O
RA	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
maximal	O
inhibition	O
of	O
62	O
%	O
	O
5	O
%	O
in	O
PBMC	O
and	O
55	O
%	O
	O
4.4	O
%	O
in	O
B	O
cells	O
by	O
all-trans	O
RA	O
,	O
and	O
58	O
%	O
	O
6.7	O
%	O
and	O
51	O
%	O
	O
4.7	O
%	O
,	O
respectively	O
by	O
13-cis	O
RA	O
.	O

IgE	O
synthesis	O
was	O
even	O
more	O
markedly	O
inhibited	O
by	O
RA	O
starting	O
at	O
concentrations	O
of	O
>	O
10	O
(	O
-14	O
)	O
mol/L	O
for	O
B	O
cells	O
and	O
>	O
10	O
(	O
-10	O
)	O
mol/L	O
for	O
PBMC	O
.	O

Maximal	O
inhibition	O
of	O
IgE	O
production	O
for	O
B	O
cells	O
was	O
at	O
10	O
(	O
-8	O
)	O
mol/L	O
for	O
all-trans	O
RA	O
(	O
94	O
%	O
	O
1.8	O
%	O
)	O
and	O
96	O
%	O
	O
3.2	O
%	O
for	O
13-cis	O
RA	O
.	O

Low	O
concentrations	O
of	O
RA	O
inhibiting	O
IgE	O
synthesis	O
(	O
10	O
(	O
-10	O
)	O
mol/L	O
)	O
affected	O
neither	B-Negation
B-cell	I-Negation
proliferation	I-Negation
nor	I-Negation
the	I-Negation
production	I-Negation
of	I-Negation
IgA	I-Negation
,	I-Negation
IgG	I-Negation
,	I-Negation
and	I-Negation
IgM	I-Negation
.	O

Elucidation	O
of	O
the	O
mechanism	O
involved	O
in	O
this	O
inhibition	O
of	O
IgE	O
production	O
shows	O
that	O
epsilon	O
germline	O
transcription	O
is	O
decreased	O
by	O
RA	O
,	O
whereas	O
production	B-Negation
of	I-Negation
interferon-gamma	I-Negation
(	I-Negation
IFN-gamma	I-Negation
)	I-Negation
was	I-Negation
not	I-Negation
enhanced	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
RA	I-Negation
.	O

To	O
differentiate	O
whether	O
the	O
RA	O
effect	O
was	O
mediated	O
by	O
RA	O
receptors	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
,	O
the	O
expression	O
of	O
the	O
retinoic	O
acid	O
receptors	O
(	O
RAR	O
)	O
was	O
examined	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
.	O

The	O
data	O
show	O
that	O
unstimulated	O
human	O
peripheral	O
B	O
cells	O
express	O
mRNA	O
of	O
the	O
RA	O
receptor	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
.	O

Using	O
retinoids	O
with	O
different	O
receptor	O
binding	O
specificity	O
(	O
CD336	O
,	O
CD437	O
,	O
CD2019	O
,	O
CD367	O
)	O
,	O
dose-dependent	O
inhibition	O
of	O
IgE	O
synthesis	O
was	O
shown	O
by	O
all	O
four	O
derivates	O
,	O
but	O
was	O
most	O
marked	O
by	O
an	O
RA	O
binding	O
the	O
alpha	O
receptor	O
with	O
high	O
specificity	O
.	O

Taken	O
together	O
,	O
this	O
study	O
shows	O
that	O
RA	O
inhibits	O
IgE	O
production	O
of	O
anti-CD40	O
+	O
IL-4-stimulated	O
B	O
cells	O
in	O
vitro	O
.	O

Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O

Nuclear	O
factor-kappaB	O
induction	O
in	O
CD45RO+	O
and	O
CD45RA+	O
T	O
cell	O
subsets	O
during	O
aging	O
.	O

An	O
increase	O
in	O
the	O
ratio	O
of	O
memory	O
to	O
naive	O
T	O
cells	O
has	O
been	O
postulated	O
to	O
underlie	O
immune	O
hyporesponsiveness	O
accompanying	O
aging	O
.	O

Our	O
analyses	O
of	O
the	O
induction	O
of	O
nuclear	O
factor-kappaB	O
(	O
NFkappaB	O
)	O
in	O
activated	O
memory	O
(	O
CD45RO+	O
)	O
and	O
naive	O
(	O
CD45RA+	O
)	O
T	O
cell	O
subsets	O
from	O
young	O
and	O
elderly	O
donors	O
has	O
demonstrated	O
that	O
,	O
regardless	O
of	O
donor	O
age	O
,	O
memory	O
T	O
cells	O
are	O
not	O
significantly	O
altered	O
in	O
their	O
responsiveness	O
to	O
TNF-alpha-mediated	O
induction	O
of	O
NFkappaB	O
.	O

Although	O
treatment	O
with	O
TNF-alpha	O
induced	O
nuclear	O
localization	O
of	O
NFkappaB	O
in	O
both	O
memory	O
and	O
naive	O
T	O
cell	O
subsets	O
,	O
irrespective	O
of	O
the	O
age	O
of	O
the	O
donor	O
,	O
the	O
levels	O
of	O
induced	O
NFkappaB	O
were	O
significantly	O
lower	O
in	O
both	O
subsets	O
of	O
T	O
cells	O
obtained	O
from	O
the	O
elderly	O
,	O
when	O
compared	O
to	O
those	O
in	O
young	O
.	O

Examination	O
of	O
IkappaB	O
alpha	O
regulation	O
revealed	O
that	O
TNF-alpha-mediated	O
degradation	O
of	O
IkappaB	O
alpha	O
in	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
from	O
the	O
elderly	O
was	O
severely	O
impaired	O
,	O
thus	O
contributing	O
to	O
the	O
lowered	O
induction	O
of	O
the	O
observed	O
NFkappaB	O
.	O

In	O
addition	O
,	O
this	O
age-related	O
decrease	O
in	O
induction	O
of	O
nuclear	O
NFkappaB	O
correlated	O
with	O
decrease	O
in	O
intracellular	O
IL-2	O
receptor	O
expression	O
and	O
anti-CD3-induced	O
proliferation	O
of	O
both	O
memory	O
and	O
naive	O
T	O
cells	O
subsets	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
the	O
age-related	O
hyporesponsiveness	O
can	O
not	O
be	O
attributed	O
to	O
a	O
skewing	O
of	O
the	O
T	O
cell	O
population	O
towards	O
a	O
memory	O
phenotype	O
in	O
the	O
elderly	O
.	O

Activation	O
of	O
E2F-mediated	O
transcription	O
by	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
Tax	O
protein	O
in	O
a	O
p16	O
(	O
INK4A	O
)	O
-negative	O
T-cell	O
line	O
.	O

The	O
human	O
T-cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
is	O
a	O
causative	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O

Although	O
the	O
exact	O
mechanism	O
by	O
which	O
HTLV-I	O
contributes	O
to	O
leukemogenesis	O
is	O
still	O
unclear	O
,	O
the	O
Tax	O
protein	O
is	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
this	O
process	O
.	O

This	O
40-kDa	O
polypeptide	O
is	O
able	O
to	O
interact	O
with	O
the	O
tumor	O
suppressor	O
p16	O
(	O
INK4A	O
)	O
.	O

Consequently	O
,	O
Tax	O
can	O
activate	O
the	O
signaling	O
pathway	O
that	O
lead	O
to	O
the	O
release	O
of	O
E2F	O
that	O
in	O
turn	O
induces	O
expression	O
of	O
factors	O
required	O
for	O
cell	O
cycle	O
progression	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
that	O
Tax	O
can	O
also	O
activate	O
E2F-mediated	O
transcription	O
independently	O
of	O
p16	O
(	O
INK4A	O
)	O
.	O

Indeed	O
,	O
when	O
Tax	O
is	O
coexpressed	O
with	O
the	O
E2F-1	O
transcription	O
factor	O
in	O
CEM	O
T-cells	O
,	O
which	O
lack	B-Negation
expression	I-Negation
of	I-Negation
p16	I-Negation
(	I-Negation
INK4A	I-Negation
)	I-Negation
,	O
it	O
strongly	O
potentiates	O
the	O
E2F-dependent	O
activation	O
of	O
a	O
reporter	O
construct	O
driven	O
by	O
a	O
promoter	O
containing	O
E2F	O
binding	O
sites	O
.	O

This	O
stimulation	O
is	O
abrogated	O
by	O
mutations	O
affecting	O
the	O
E2F-binding	O
sites	O
.	O

In	O
addition	O
,	O
Tax	O
also	O
stimulates	O
the	O
transcription	O
of	O
the	O
E2F-1	O
gene	O
itself	O
.	O

Using	O
Tax	O
mutants	O
that	O
fail	B-Negation
to	I-Negation
activate	I-Negation
either	I-Negation
ATF-	I-Negation
or	I-Negation
NF-kappaB-dependent	I-Negation
promoters	I-Negation
and	I-Negation
different	I-Negation
5	I-Negation
'	I-Negation
truncation	I-Negation
mutants	I-Negation
of	I-Negation
the	I-Negation
E2F-1	I-Negation
promoter	I-Negation
,	O
we	O
show	O
that	O
the	O
Tax-dependent	O
transcriptional	O
control	O
of	O
the	O
E2F1	O
gene	O
involves	O
,	O
at	O
least	O
in	O
part	O
,	O
the	O
ATF	O
binding	O
site	O
located	O
in	O
the	O
E2F-1	O
promoter	O
.	O

Glucocorticoid-induced	O
apoptosis	O
and	O
regulation	O
of	O
NF-kappaB	O
activity	O
in	O
human	O
leukemic	O
T	O
cells	O
.	O

Glucocorticoid-induced	O
apoptosis	O
was	O
investigated	O
in	O
glucocorticoid-sensitive	O
6TG1.1	O
and	O
resistant	O
ICR27TK.3	O
human	O
leukemic	O
T	O
cells	O
.	O

Following	O
glucocorticoid	O
treatment	O
of	O
6TG1.1	O
cells	O
,	O
chromatin	O
fragmentation	O
was	O
observed	O
after	O
a	O
delay	O
of	O
24	O
h	O
.	O

Fragmentation	B-Negation
was	I-Negation
not	I-Negation
observed	I-Negation
in	I-Negation
ICR27TK.3	I-Negation
cells	I-Negation
containing	I-Negation
mutant	I-Negation
glucocorticoid	I-Negation
receptors	I-Negation
(	I-Negation
L753F	I-Negation
)	I-Negation
that	I-Negation
are	I-Negation
activation-deficient	I-Negation
but	I-Negation
retain	I-Negation
the	I-Negation
ability	I-Negation
to	I-Negation
repress	I-Negation
AP-1	I-Negation
activity	I-Negation
.	O

Nor	B-Negation
was	I-Negation
fragmentation	I-Negation
observed	I-Negation
after	I-Negation
treatment	I-Negation
with	I-Negation
RU38486	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
repression	I-Speculation
of	I-Speculation
AP-1	I-Speculation
activity	I-Speculation
is	I-Speculation
not	I-Speculation
involved	I-Speculation
.	O

As	O
described	O
in	O
other	O
systems	O
,	O
fragmentation	O
required	O
ongoing	O
protein	O
synthesis	O
.	O

However	O
,	O
inhibition	O
of	O
protein	O
synthesis	O
with	O
cycloheximide	O
anytime	O
during	O
the	O
first	O
18	O
h	O
of	O
steroid	O
treatment	O
was	O
as	O
effective	O
in	O
blocking	O
chromatin	O
fragmentation	O
as	O
inhibition	O
for	O
the	O
entire	O
period	O
,	O
suggesting	O
that	O
synthesis	O
of	O
a	O
component	O
with	O
a	O
rapid	O
turnover	O
rate	O
is	O
required	O
.	O

Dexamethasone	O
treatment	O
completely	O
blocked	O
12-O-tetradecanoylphorbol	O
13-acetate	O
induction	O
of	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
activity	O
and	O
elicited	O
an	O
increase	O
in	O
the	O
amount	O
of	O
immunoreactive	O
IkappaB	O
alpha	O
in	O
sensitive	O
6TG1.1	O
cells	O
but	O
not	B-Negation
in	I-Negation
resistant	I-Negation
ICR27TK.3	I-Negation
cells	I-Negation
.	O

In	O
addition	O
,	O
mild	O
detergent	O
treatment	O
of	O
cell	O
extracts	O
indicated	O
that	O
a	O
substantial	O
amount	O
of	O
cytoplasmic	O
NF-kappaB	O
is	O
complexed	O
with	O
IkappaB	O
alpha	O
or	O
some	O
other	O
inhibitory	O
factor	O
.	O

These	O
results	O
suggest	O
that	O
induction	O
of	O
a	O
labile	O
inhibitory	O
factor	O
such	O
as	O
IkappaB	O
alpha	O
may	O
contribute	O
to	O
glucocorticoid-induced	O
apoptosis	O
.	O

Peripheral	O
T	O
lymphocytes	O
from	O
women	O
with	O
breast	O
cancer	O
exhibit	O
abnormal	O
protein	O
expression	O
of	O
several	O
signaling	O
molecules	O
.	O

We	O
examined	O
signaling	O
molecules	O
of	O
peripheral	O
blood	O
T	O
lymphocytes	O
obtained	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

In	O
6	O
of	O
14	O
patients	O
,	O
T	O
lymphocytes	O
displayed	O
an	O
impaired	O
ability	O
to	O
translocate	O
NFeB	O
p65	O
(	O
Rel-A	O
)	O
following	O
activation	O
by	O
anti-CD3	O
and	O
IL-2	O
.	O

This	O
observation	O
was	O
made	O
despite	O
normal	O
cytoplasmic	O
levels	O
of	O
the	O
Rel-A	O
protein	O
.	O

We	O
also	O
detected	O
abnormally	O
low	O
levels	O
of	O
the	O
signaling	O
molecules	O
T-cell	O
receptor	O
(	O
TCR	O
)	O
-zeta	O
,	O
ZAP-70	O
and	O
p56lck	O
in	O
4	O
of	O
14	O
breast	O
cancer	O
patients	O
,	O
i.e.	O
,	O
defects	O
in	O
T-cell	O
signaling	O
molecules	O
.	O

T	O
lymphocytes	O
from	O
6	O
of	O
the	O
14	O
patients	O
also	O
exhibited	O
an	O
increased	O
expression	O
of	O
the	O
dual	O
specificity	O
phosphatase	O
,	O
map	O
kinase	O
phosphatase-1	O
(	O
MKP-1	O
)	O
.	O

MKP-1	O
inactivates	O
MAP	O
kinase	O
and	O
therefore	O
may	O
interfere	O
with	O
the	O
activation	O
of	O
c-jun	O
and	O
c-fos	O
.	O

Abnormalities	O
of	O
I	O
or	O
more	O
signaling	O
molecules	O
were	O
found	O
in	O
9	O
of	O
14	O
patients	O
;	O
however	O
,	O
only	O
3	O
patients	O
had	O
T	O
cells	O
that	O
exhibited	O
all	O
5	O
defects	O
.	O

Our	O
data	O
have	O
implications	O
for	O
the	O
detection	O
of	O
potentially	O
dysfunctional	O
T	O
cells	O
in	O
patients	O
with	O
cancer	O
.	O

For	O
example	O
,	O
the	O
analysis	O
of	O
only	O
1	O
signaling	O
molecule	O
may	O
allow	O
patients	O
with	O
significant	O
defects	O
in	O
T-cell	O
signaling	O
to	O
go	O
unnoticed	O
.	O

Finally	O
,	O
despite	O
impaired	O
Rel-A	O
translocation	O
,	O
T	O
cells	O
were	O
capable	O
of	O
transcribing	O
IL-2	O
.	O

Impairments	O
in	O
the	O
translocation	O
of	O
Rel-B	O
and	O
c-Rel	O
further	O
suggest	O
that	O
the	O
NFKB	O
family	O
members	O
Rel-A	O
,	O
Rel-B	O
and	O
c-Rel	O
are	O
not	O
required	O
for	O
the	O
transcription	O
of	O
IL-2	O
in	O
the	O
peripheral	O
T	O
lymphocytes	O
of	O
patients	O
with	O
breast	O
cancer	O
.	O

Transcription	O
of	O
a	O
minimal	O
promoter	O
from	O
the	O
NF-IL6	O
gene	O
is	O
regulated	O
by	O
CREB/ATF	O
and	O
SP1	O
proteins	O
in	O
U937	O
promonocytic	O
cells	O
.	O

NF-IL6	O
is	O
an	O
important	O
transcriptional	O
regulator	O
of	O
genes	O
induced	O
in	O
activated	O
monocytes/macrophages	O
,	O
and	O
NF-IL6	O
is	O
the	O
only	O
CCAAT/enhancer-binding	O
protein	O
(	O
C/EBP	O
)	O
family	O
member	O
whose	O
steady-state	O
mRNA	O
levels	O
increase	O
upon	O
activation	O
of	O
monocytes	O
(	O
1	O
)	O
.	O

We	O
show	O
that	O
increased	O
transcription	O
of	O
the	O
NF-IL6	O
gene	O
is	O
responsible	O
,	O
at	O
least	O
in	O
part	O
,	O
for	O
induction	O
of	O
NF-IL6	O
mRNA	O
following	O
activation	O
of	O
U937	O
promonocytic	O
cells	O
.	O

We	O
have	O
identified	O
a	O
104-bp	O
minimal	O
promoter	O
region	O
of	O
the	O
NF-IL6	O
gene	O
that	O
is	O
sufficient	O
for	O
basal	O
and	O
activation-dependent	O
induction	O
of	O
transcription	O
in	O
U937	O
cells	O
.	O

This	O
region	O
contains	O
binding	O
sites	O
for	O
the	O
cAMP	O
response	O
element-binding	O
protein/activation	O
transcription	O
factor	O
(	O
CREB/ATF	O
)	O
and	O
Sp1	O
families	O
of	O
transcription	O
factors	O
.	O

Each	O
site	O
is	O
functionally	O
important	O
and	O
contributes	O
independently	O
to	O
transcription	O
of	O
the	O
NF-IL6	O
gene	O
in	O
U937	O
cells	O
.	O

CD30	O
is	O
a	O
CD40-inducible	O
molecule	O
that	O
negatively	O
regulates	O
CD40-mediated	O
immunoglobulin	O
class	O
switching	O
in	O
non-antigen-selected	O
human	O
B	O
cells	O
.	O

We	O
used	O
our	O
monoclonal	O
model	O
of	O
germinal	O
center	O
maturation	O
,	O
CL-01	O
B	O
cells	O
,	O
to	O
investigate	O
the	O
role	O
of	O
CD30	O
in	O
human	O
B	O
cell	O
differentiation	O
.	O

CL-01	O
cells	O
are	O
IgM+	O
IgD+	O
CD30+	O
and	O
switch	O
to	O
IgG	O
,	O
IgA	O
,	O
and	O
IgE	O
when	O
exposed	O
to	O
CD40L	O
and	O
IL-4	O
.	O

Switching	O
is	O
hampered	O
by	O
CD30	O
coengagement	O
,	O
possibly	O
through	O
interference	O
with	O
the	O
CD40-mediated	O
NF-kappaB-dependent	O
transcriptional	O
activation	O
of	O
downstream	O
C	O
(	O
H	O
)	O
genes	O
.	O

The	O
physiological	O
relevance	O
of	O
this	O
phenomenon	O
is	O
emphasized	O
by	O
similar	O
CD30-mediated	O
effects	O
in	O
naive	O
B	O
cells	O
.	O

Expression	O
of	O
CD30	O
by	O
these	O
cells	O
is	O
induced	O
by	O
CD40L	O
but	O
is	O
inhibited	O
by	O
B	O
cell	O
receptor	O
coengagement	O
and/or	O
exposure	O
to	O
IL-6	O
and	O
IL-12	O
.	O

Our	O
data	O
suggest	O
that	O
CD30	O
critically	O
regulates	O
the	O
CD40-mediated	O
differentiation	O
of	O
non-antigen-selected	O
human	O
B	O
cells	O
.	O

Induction	O
of	O
Mn	O
SOD	O
in	O
human	O
monocytes	O
without	B-Negation
inflammatory	I-Negation
cytokine	I-Negation
production	I-Negation
by	I-Negation
a	I-Negation
mutant	I-Negation
endotoxin	I-Negation
.	O

Endotoxin	O
selectively	O
induces	O
monocyte	O
Mn	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
without	B-Negation
affecting	I-Negation
levels	I-Negation
of	I-Negation
Cu	I-Negation
,	I-Negation
Zn	I-Negation
SOD	I-Negation
,	I-Negation
catalase	I-Negation
,	I-Negation
or	I-Negation
glutathione	I-Negation
peroxidase	I-Negation
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
structure-activity	O
relationship	O
and	O
the	O
mechanism	O
by	O
which	O
endotoxin	O
induces	O
Mn	O
SOD	O
.	O

In	O
this	O
study	O
we	O
demonstrated	O
that	O
a	O
mutant	O
Escherichia	O
coli	O
endotoxin	O
lacking	B-Negation
myristoyl	I-Negation
fatty	I-Negation
acid	I-Negation
at	I-Negation
the	I-Negation
3	I-Negation
'	I-Negation
R-3-hydroxymyristate	I-Negation
position	I-Negation
of	I-Negation
the	I-Negation
lipid	I-Negation
A	I-Negation
moiety	I-Negation
retained	O
its	O
full	O
capacity	O
to	O
coagulate	O
Limulus	O
amoebocyte	O
lysate	O
compared	O
with	O
the	O
wild-type	O
E.	O
coli	O
endotoxin	O
and	O
markedly	O
stimulated	O
the	O
activation	O
of	O
human	O
monocyte	O
nuclear	O
factor-kappaB	O
and	O
the	O
induction	O
of	O
Mn	O
SOD	O
mRNA	O
and	O
enzyme	O
activity	O
.	O

However	O
,	O
in	O
contrast	O
to	O
the	O
wild-type	O
endotoxin	O
,	O
it	O
failed	B-Negation
to	I-Negation
induce	I-Negation
significant	I-Negation
production	I-Negation
of	I-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
and	I-Negation
macrophage	I-Negation
inflammatory	I-Negation
protein-1alpha	I-Negation
by	I-Negation
monocytes	I-Negation
and	O
did	O
not	B-Negation
induce	I-Negation
the	I-Negation
phosphorylation	I-Negation
and	I-Negation
nuclear	I-Negation
translocation	I-Negation
of	I-Negation
mitogen-activated	I-Negation
protein	I-Negation
kinase	I-Negation
.	O

These	O
results	O
suggest	O
that	O
1	O
)	O
lipid	O
A	O
myristoyl	O
fatty	O
acid	O
,	O
although	O
it	O
is	O
important	O
for	O
the	O
induction	O
of	O
inflammatory	O
cytokine	O
production	O
by	O
human	O
monocytes	O
,	O
is	O
not	O
necessary	O
for	O
the	O
induction	O
of	O
Mn	O
SOD	O
,	O
2	O
)	O
endotoxin-mediated	O
induction	O
of	O
Mn	O
SOD	O
and	O
inflammatory	O
cytokines	O
are	O
regulated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
different	O
signal	O
transduction	O
pathways	O
,	O
and	O
3	O
)	O
failure	O
of	O
the	O
mutant	O
endotoxin	O
to	O
induce	O
tumor	O
necrosis	O
factor-alpha	O
production	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
its	O
inability	O
to	O
activate	O
mitogen-activated	O
protein	O
kinase	O
.	O

An	O
allosteric	O
drug	O
,	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
,	O
suppresses	O
HIV-1	O
replication	O
through	O
prevention	O
of	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	O
Tat	O
and	O
NF-kappa	O
B	O
.	O

The	O
efficacy	O
of	O
o	O
,	O
o'-bismyristoyl	O
thiamine	O
disulfide	O
(	O
BMT	O
)	O
was	O
examined	O
in	O
detail	O
against	O
HIV-1	O
laboratory	O
isolates	O
(	O
HTLV-IIIB	O
,	O
JRFL	O
,	O
and	O
MN	O
)	O
,	O
primary	O
isolates	O
(	O
KMT	O
and	O
KMO	O
)	O
,	O
and	O
simian	O
immunodeficiency	O
virus	O
(	O
SIVmac251	O
)	O
in	O
vitro	O
.	O

BMT	O
inhibited	O
the	O
replication	O
of	O
HIV-1	O
in	O
both	O
laboratory	O
and	O
primary	O
isolates	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
BMT	O
exhibited	O
antiviral	O
activity	O
against	O
SIVmac251	O
.	O

Minimizing	O
energy	O
studies	O
of	O
BMT	O
structure	O
reveal	O
that	O
a	O
trans-disulfide	O
of	O
thiamine	O
(	O
holo	O
drug	O
)	O
disulfide	O
(	O
TDS	O
,	O
protodrug	O
)	O
is	O
allosterically	O
transited	O
to	O
the	O
reactive	O
twisted	O
disulfide	O
of	O
BMT	O
(	O
allo	O
drug	O
)	O
by	O
o	O
,	O
o'-bismyristoyl	O
esterification	O
of	O
TDS	O
.	O

BMT	O
inhibits	O
nuclear	O
translocation	O
of	O
both	O
HIV-1	O
transactivator	O
(	O
TAT	O
)	O
and	O
the	O
cellular	O
transcriptional	O
nuclear	O
factor-KB	O
(	O
NF-kappa	O
B	O
)	O
,	O
resulting	O
in	O
the	O
suppression	O
of	O
HIV-1	O
replication	O
.	O

Retinoid	O
X	O
receptor	O
and	O
c-cerbA/thyroid	O
hormone	O
receptor	O
regulate	O
erythroid	O
cell	O
growth	O
and	O
differentiation	O
.	O

Nuclear	O
receptors	O
are	O
important	O
regulators	O
of	O
erythroid	O
cell	O
development	O
.	O

Here	O
we	O
investigated	O
the	O
impact	O
of	O
retinoid	O
X	O
receptor	O
(	O
RXR	O
)	O
,	O
retinoic	O
acid	O
receptor	O
(	O
RAR	O
)	O
,	O
and	O
of	O
the	O
c-erbA/thyroid	O
hormone	O
(	O
T3	O
)	O
receptor	O
(	O
c-erbA/TR	O
)	O
on	O
growth	O
and	O
differentiation	O
of	O
erythroid	O
cells	O
using	O
an	O
in	O
vitro	O
culture	O
system	O
of	O
stem	O
cell	O
factor-dependent	O
erythroid	O
progenitors	O
.	O

RXR	O
,	O
RAR	O
,	O
and	O
c-erbA/TR-specific	O
ligands	O
were	O
found	O
to	O
induce	O
erythroid-specific	O
gene	O
expression	O
and	O
to	O
accelerate	O
erythroid	O
differentiation	O
in	O
culture	O
,	O
with	O
T3	O
being	O
most	O
effective	O
.	O

Furthermore	O
,	O
while	O
ligand-activated	O
c-erbA/TR	O
accelerated	O
differentiation	O
,	O
unliganded	O
c-erbA/TR	O
effectively	O
blocked	O
differentiation	O
and	O
supported	O
sustained	O
progenitor	O
growth	O
in	O
culture	O
.	O

Thus	O
,	O
c-erbA/TR	O
appears	O
to	O
act	O
as	O
a	O
binary	O
switch	O
affecting	O
erythroid	O
cell	O
fate	O
:	O
unliganded	O
c-erbA/TR	O
supports	O
growth	O
while	O
ligand-activated	O
c-erbA/TR	O
induces	O
differentiation	O
.	O

Additionally	O
,	O
to	O
determine	O
the	O
impact	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
,	O
dominant	O
interfering	O
mutant	O
RXRs	O
,	O
lacking	B-Negation
the	I-Negation
transcriptional	I-Negation
activator	I-Negation
functions	I-Negation
AF-1	I-Negation
and	I-Negation
AF-2	I-Negation
,	I-Negation
or	I-Negation
AF-2	I-Negation
only	I-Negation
,	I-Negation
or	I-Negation
the	I-Negation
entire	I-Negation
DNA-binding	I-Negation
domain	I-Negation
,	O
were	O
introduced	O
into	O
erythroid	O
progenitor	O
cells	O
via	O
recombinant	O
retrovirus	O
vectors	O
and	O
analyzed	O
for	O
RXR-specific	O
effects	O
.	O

It	O
was	O
found	O
that	O
expression	O
of	O
wild-type	O
RXR	O
and	O
of	O
the	O
RXR	O
mutants	O
devoid	O
of	O
AF-1	O
and/or	O
AF-2	O
supported	O
a	O
transient	O
outgrowth	O
of	O
erythroid	O
cells	O
.	O

In	O
marked	O
contrast	O
,	O
expression	O
of	O
the	O
dominant	O
interfering	O
deltaDNA-binding	O
domain	O
RXR	O
,	O
containing	O
a	O
deletion	O
of	O
the	O
entire	O
DNA-binding	O
domain	O
,	O
was	O
incompatible	O
with	O
erythroid	O
cell	O
growth	O
in	O
vitro	O
,	O
suggesting	O
a	O
pivotal	O
role	O
of	O
RXR	O
for	O
erythroid	O
cell	O
development	O
.	O

Phosphatidylinositides	O
bind	O
to	O
plasma	O
membrane	O
CD14	O
and	O
can	O
prevent	O
monocyte	O
activation	O
by	O
bacterial	O
lipopolysaccharide	O
.	O

Although	O
bacterial	O
lipopolysaccharides	O
(	O
LPS	O
)	O
and	O
several	O
other	O
microbial	O
agonists	O
can	O
bind	O
to	O
mCD14	O
(	O
membrane	O
CD14	O
)	O
,	O
a	O
cell-surface	O
receptor	O
found	O
principally	O
on	O
monocytes	O
and	O
neutrophils	O
,	O
host-derived	O
mCD14	O
ligands	O
are	O
poorly	O
defined	O
.	O

We	O
report	O
here	O
that	O
phosphatidylinositol	O
(	O
PtdIns	O
)	O
,	O
phosphatidylinositol-4-phosphate	O
,	O
and	O
other	O
phosphatidylinositides	O
can	O
bind	O
to	O
mCD14	O
.	O

Phosphatidylserine	O
(	O
PS	O
)	O
,	O
another	O
anionic	O
glycerophospholipid	O
,	O
binds	O
to	O
mCD14	O
with	O
lower	O
apparent	O
affinity	O
than	O
does	O
PtdIns	O
.	O

LPS-binding	O
protein	O
,	O
a	O
lipid	O
transfer	O
protein	O
found	O
in	O
serum	O
,	O
facilitates	O
both	O
PS-	O
and	O
PtdIns-mCD14	O
binding	O
.	O

PtdIns	O
binding	O
to	O
mCD14	O
can	O
be	O
blocked	O
by	O
anti-CD14	O
monoclonal	O
antibodies	O
that	O
inhibit	O
LPS-mCD14	O
binding	O
,	O
and	O
PtdIns	O
can	O
inhibit	O
both	O
LPS-mCD14	O
binding	O
and	O
LPS-induced	O
responses	O
in	O
monocytes	O
.	O

Serum-equilibrated	O
PtdIns	O
also	O
binds	O
to	O
mCD14-expressing	O
cells	O
,	O
raising	O
the	O
possibility	O
that	O
endogenous	O
PtdIns	O
may	O
modulate	O
cellular	O
responses	O
to	O
LPS	O
and	O
other	O
mCD14	O
ligands	O
in	O
vivo	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
human	O
immunodeficiency	O
virus-induced	O
apoptosis	O
in	O
lymphoblastoid	O
T-cell-line-expressing	O
wild-type	O
and	O
mutated	O
CD4	O
receptors	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
presence	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
is	O
critical	O
for	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-induced	O
apoptosis	O
(	O
J.Corbeil	O
,	O
M.Tremblay	O
,	O
and	O
D.D.Richman	O
,	O
J.Exp.Med.183:39-48	O
,	O
1996	O
)	O
.	O

We	O
have	O
pursued	O
our	O
investigation	O
of	O
the	O
role	O
of	O
the	O
CD4	O
transduction	O
pathway	O
in	O
HIV-induced	O
apoptosis	O
.	O

To	O
do	O
this	O
,	O
wild-type	O
and	O
mutant	O
forms	O
of	O
the	O
CD4	O
cytoplasmic	O
tail	O
were	O
stably	O
expressed	O
in	O
the	O
lymphoblastoid	O
T-cell	O
line	O
A2.01	O
.	O

Apoptosis	O
was	O
prevented	O
when	O
CD4	O
truncated	O
at	O
residue	O
402	O
was	O
expressed	O
;	O
however	O
,	O
cells	O
expressing	O
mutated	O
receptors	O
that	O
do	O
not	B-Negation
associate	I-Negation
with	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
(	I-Negation
mutated	I-Negation
at	I-Negation
the	I-Negation
dicysteine	I-Negation
motif	I-Negation
and	I-Negation
truncated	I-Negation
at	I-Negation
residue	I-Negation
418	I-Negation
)	I-Negation
but	O
which	O
conserved	O
proximal	O
domains	O
of	O
the	O
cytoplasmic	O
tail	O
underwent	O
apoptosis	O
like	O
wild-	O
type	O
CD4	O
.	O

The	O
differences	O
between	O
wild-type	O
and	O
mutated	O
receptors	O
in	O
the	O
induction	O
of	O
apoptosis	O
were	O
not	B-Negation
related	I-Negation
to	I-Negation
levels	I-Negation
of	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
or	I-Negation
NF-	I-Negation
kappaB	I-Negation
activation	I-Negation
.	O

Initial	O
signaling	O
through	O
the	O
CD4	O
receptor	O
played	O
a	O
major	O
role	O
in	O
the	O
sensitization	O
of	O
HIV-infected	O
T	O
cells	O
to	O
undergo	O
apoptosis	O
.	O

Incubation	O
of	O
HIV-infected	O
cells	O
with	O
monoclonal	O
antibody	O
(	O
MAb	O
)	O
13B8-2	O
,	O
which	O
binds	O
to	O
CD4	O
in	O
a	O
region	O
critical	O
for	O
dimerization	O
of	O
the	O
receptor	O
,	O
prevented	O
apoptosis	O
without	B-Negation
inhibiting	I-Negation
HIV	I-Negation
replication	I-Negation
.	O

Moreover	O
,	O
the	O
apoptotic	O
process	O
was	O
not	B-Negation
related	I-Negation
to	I-Negation
Fas-Fas	I-Negation
ligand	I-Negation
interaction	I-Negation
;	O
however	O
,	O
an	O
antagonistic	O
anti-Fas	O
MAb	O
(	O
ZB-4	O
)	O
enhanced	O
apoptosis	O
in	O
HIV-infected	O
cells	O
without	B-Negation
inducing	I-Negation
apoptosis	I-Negation
in	I-Negation
uninfected	I-Negation
cells	I-Negation
.	O

These	O
observations	O
demonstrate	O
that	O
CD4	O
signaling	O
mediates	O
HIV-induced	O
apoptosis	O
by	O
a	O
mechanism	O
independent	O
of	O
Fas-Fas	O
ligand	O
interaction	O
,	O
does	O
not	B-Negation
require	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
signaling	I-Negation
,	O
and	O
may	B-Speculation
involve	I-Speculation
a	I-Speculation
critical	I-Speculation
region	I-Speculation
for	I-Speculation
CD4	I-Speculation
dimerization	I-Speculation
.	O

Low	O
CD3+CD28-induced	O
interleukin-2	O
production	O
correlates	O
with	O
decreased	O
reactive	O
oxygen	O
intermediate	O
formation	O
in	O
neonatal	O
T	O
cells	O
.	O

The	O
capacity	O
of	O
neonatal	O
T	O
cells	O
to	O
secrete	O
interleukin-2	O
(	O
IL-2	O
)	O
has	O
been	O
reported	O
to	O
be	O
variable	O
.	O

We	O
analysed	O
IL-2	O
production	O
in	O
purified	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
polyclonal	O
activator	O
phorbol	O
ester	O
+	O
calcium	O
ionophore	O
(	O
PDBu	O
+	O
iono	O
)	O
or	O
receptor-mediated	O
anti-CD3/anti-CD3+	O
anti-CD28	O
stimulation	O
.	O

PDBu	O
+	O
iono	O
induced	O
equally	O
high	O
IL-2	O
levels	O
in	O
both	O
groups	O
and	O
,	O
when	O
stimulated	O
with	O
plate-bound	O
anti-CD3	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
,	O
the	O
IL-2	O
secretion	O
by	O
neonatal	O
cells	O
was	O
undetectable	O
and	O
adult	O
cells	O
produced	O
low	O
amounts	O
of	O
IL-2	O
(	O
mean	O
331	O
	O
86	O
pg/ml	O
)	O
.	O

The	O
addition	O
of	O
anti-CD28	O
mAb	O
to	O
anti-CD3-stimulated	O
cells	O
markedly	O
increased	O
IL-2	O
production	O
in	O
both	O
cell	O
types	O
,	O
but	O
levels	O
of	O
IL-2	O
in	O
neonatal	O
T	O
cells	O
remained	O
clearly	O
lower	O
than	O
those	O
of	O
adult	O
T	O
cells	O
(	O
respective	O
mean	O
values	O
:	O
385	O
	O
109	O
pg/ml	O
and	O
4494	O
	O
1199	O
pg/ml	O
)	O
.	O

As	O
NF-kappa	O
B	O
is	O
a	O
critical	O
transcription	O
factor	O
in	O
the	O
control	O
of	O
IL-2	O
expression	O
,	O
we	O
next	O
analysed	O
its	O
nuclear	O
translocation	O
in	O
neonatal	O
and	O
adult	O
T	O
cells	O
using	O
the	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
,	O
because	O
induction	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROI	O
)	O
is	O
required	O
for	O
the	O
activation	O
of	O
NF-kappa	O
B	O
,	O
we	O
also	O
analysed	O
levels	O
of	O
intracellular	O
ROI	O
in	O
these	O
cells	O
using	O
the	O
ROI-reactive	O
fluorochrome	O
DCFH-DA	O
and	O
flow	O
cytometry	O
.	O

In	O
neonatal	O
T	O
cells	O
NF-kappa	O
B	O
activation	O
and	O
ROI	O
formation	O
after	O
anti-CD3	O
stimulation	O
were	O
low	O
compared	O
with	O
adult	O
T	O
cells	O
and	O
,	O
although	O
addition	O
of	O
anti-CD28	O
mAb	O
increased	O
induction	O
of	O
NF-kappa	O
B	O
and	O
ROI	O
formation	O
,	O
levels	B-Negation
similar	I-Negation
to	I-Negation
those	I-Negation
of	I-Negation
adults	I-Negation
were	I-Negation
not	I-Negation
achieved	I-Negation
.	O

After	O
PDBu	O
+	O
iono	O
stimulation	O
,	O
the	O
cells	O
showed	O
similar	O
ROI	O
formation	O
and	O
IL-2	O
secretion	O
.	O

Our	O
results	O
suggest	O
that	O
reduced	O
IL-2	O
production	O
by	O
neonatal	O
T	O
cells	O
is	O
specific	O
for	O
anti-CD3	O
and	O
anti-CD3+	O
anti-CD28-mediated	O
stimulation	O
and	O
that	O
these	O
activators	O
can	O
not	O
effectively	O
activate	O
the	O
ROI-NF-kappa	O
B	O
signalling	O
pathway	O
in	O
neonatal	O
T	O
cells	O
.	O

Activated	O
platelets	O
induce	O
monocyte	O
chemotactic	O
protein-1	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
on	O
endothelial	O
cells	O
[	O
see	O
comments	O
]	O

BACKGROUND	O
:	O
Platelet/endothelium	O
interaction	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
inflammation	O
and	O
atherosclerosis	O
.	O

The	O
role	O
of	O
platelets	O
for	O
monocyte	O
chemotactic	O
protein-1	O
(	O
MCP-1	O
)	O
secretion	O
and	O
surface	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
(	O
ICAM-1	O
)	O
on	O
endothelial	O
cells	O
has	O
been	O
assessed	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Monolayers	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
were	O
incubated	O
with	O
nonstimulated	O
or	O
ADP-activated	O
platelets	O
for	O
6	O
hours	O
,	O
and	O
secretion	O
of	O
MCP-1	O
and	O
surface	O
expression	O
of	O
ICAM-1	O
were	O
determined	O
by	O
ELISA	O
and	O
flow	O
cytometry	O
,	O
respectively	O
.	O

In	O
the	O
presence	O
of	O
ADP-activated	O
platelets	O
,	O
both	O
MCP-1	O
secretion	O
and	O
ICAM-1	O
surface	O
expression	O
were	O
significantly	O
increased	O
compared	O
with	O
nonstimulated	O
platelets	O
(	O
P	O
<	O
0.02	O
)	O
.	O

Activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
determined	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
and	O
kappaB-dependent	O
transcriptional	O
activity	O
was	O
enhanced	O
in	O
the	O
presence	O
of	O
activated	O
platelets	O
.	O

In	O
addition	O
,	O
ADP-activated	O
platelets	O
induced	O
MCP-1	O
and	O
ICAM-1	O
promoter-dependent	O
transcription	O
.	O

Liposomal	O
transfection	O
of	O
a	O
double-stranded	O
kappaB	O
phosphorothioate	O
oligonucleotide	O
,	O
but	O
not	B-Negation
of	I-Negation
the	I-Negation
mutated	I-Negation
form	I-Negation
,	O
inhibited	O
MCP-1	O
secretion	O
and	O
surface	O
expression	O
of	O
ICAM-1	O
on	O
activated	O
endothelium	O
(	O
P	O
<	O
0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
indicates	O
that	O
activated	O
platelets	O
modulate	O
chemotactic	O
(	O
MCP-1	O
)	O
and	O
adhesive	O
(	O
ICAM-1	O
)	O
properties	O
of	O
endothelial	O
cells	O
via	O
an	O
NF-kappaB-dependent	O
mechanism	O
.	O

Platelet-induced	O
activation	O
of	O
the	O
NF-kappaB	O
system	O
might	O
contribute	O
to	O
early	O
inflammatory	O
events	O
in	O
atherogenesis	O
.	O

Altered	O
DNA-binding	O
specificity	O
mutants	O
of	O
EKLF	O
and	O
Sp1	O
show	O
that	O
EKLF	O
is	O
an	O
activator	O
of	O
the	O
beta-globin	O
locus	O
control	O
region	O
in	O
vivo	O
.	O

The	O
locus	O
control	O
region	O
of	O
the	O
beta-globin	O
cluster	O
contains	O
five	O
DNase	O
I	O
hypersensitive	O
sites	O
(	O
5'HS1-5	O
)	O
required	O
for	O
locus	O
activation	O
.	O

5'HS3	O
contains	O
six	O
G-rich	O
motifs	O
that	O
are	O
essential	O
for	O
its	O
activity	O
.	O

Members	O
of	O
a	O
protein	O
family	O
,	O
characterized	O
by	O
three	O
zinc	O
fingers	O
highly	O
homologous	O
to	O
those	O
found	O
in	O
transcription	O
factor	O
Sp1	O
,	O
interact	O
with	O
these	O
motifs	O
.	O

Because	O
point	O
mutagenesis	O
can	B-Negation
not	I-Negation
distinguish	I-Negation
between	I-Negation
family	I-Negation
members	I-Negation
,	O
it	O
is	O
not	B-Speculation
known	I-Speculation
which	I-Speculation
protein	I-Speculation
activates	I-Speculation
5'HS3	I-Speculation
.	O

We	O
show	O
that	O
the	O
function	O
of	O
such	O
closely	O
related	O
proteins	O
can	O
be	O
distinguished	O
in	O
vivo	O
by	O
matching	O
point	O
mutations	O
in	O
5'HS3	O
with	O
amino	O
acid	O
changes	O
in	O
the	O
zinc	O
fingers	O
of	O
Sp1	O
and	O
EKLF	O
.	O

Testing	O
their	O
activity	O
in	O
transgenic	O
mice	O
shows	O
that	O
EKLF	O
is	O
a	O
direct	O
activator	O
of	O
5'HS3	O
.	O

NF-kappaB	O
only	O
partially	O
mediates	O
Epstein-Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
activation	O
of	O
B	O
cells	O
.	O

The	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
is	O
required	O
for	O
EBV-induced	O
immortalization	O
of	O
human	O
B	O
cells	O
and	O
causes	O
tumorigenic	O
transformation	O
of	O
cell	O
lines	O
.	O

LMP1	O
expression	O
induces	O
phenotypic	O
changes	O
resembling	O
B	O
cell	O
activation	O
,	O
such	O
as	O
cell	O
size	O
increase	O
and	O
up-regulation	O
of	O
cell	O
surface	O
activation	O
markers	O
.	O

LMP1	O
contains	O
two	O
domains	O
that	O
activate	O
the	O
transcription	O
factor	O
NF-kappaB	O
,	O
one	O
through	O
interactions	O
with	O
TRAF	O
proteins	O
and	O
the	O
other	O
with	O
the	O
TRADD	O
protein	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
importance	O
of	O
NF-kappaB	O
induction	O
in	O
the	O
up-regulation	O
of	O
the	O
B	O
cell	O
activation	O
markers	O
ICAM-1	O
and	O
CD71	O
by	O
LMP1	O
.	O

This	O
study	O
shows	O
that	O
expression	O
of	O
LMP1	O
activates	O
transcription	O
from	O
p50/p65-	O
and	O
c-Rel-	O
responsive	O
promoters	O
,	O
and	O
that	O
this	O
activity	O
can	O
be	O
completely	O
inhibited	O
by	O
expression	O
of	O
a	O
dominant	O
inhibitory	O
IkappaB	O
mutant	O
.	O

ICAM-1	O
and	O
CD71	O
are	O
nevertheless	O
up-regulated	O
by	O
LMP1	O
in	O
primary	O
B	O
cells	O
and	O
cell	O
lines	O
expressing	O
the	O
dominant	O
IkappaB	O
.	O

Furthermore	O
,	O
LMP1-induced	O
cell	O
size	O
increase	O
of	O
primary	O
B	O
cells	O
was	O
unaffected	O
by	O
IkappaB	O
expression	O
.	O

It	O
was	O
concluded	O
that	O
even	O
when	O
LMP1	B-Negation
is	I-Negation
unable	I-Negation
to	I-Negation
activate	I-Negation
NF-kappaB	I-Negation
,	O
it	O
is	O
still	O
capable	O
of	O
inducing	O
certain	O
characteristics	O
of	O
activated	O
B	O
cells	O
,	O
strongly	O
suggesting	B-Speculation
that	I-Speculation
LMP1	I-Speculation
can	I-Speculation
also	I-Speculation
activate	I-Speculation
cells	I-Speculation
independently	I-Speculation
of	I-Speculation
NF-kappaB	I-Speculation
.	O

Activation	O
of	O
distinct	O
transcription	O
factors	O
in	O
neutrophils	O
by	O
bacterial	O
LPS	O
,	O
interferon-gamma	O
,	O
and	O
GM-CSF	O
and	O
the	O
necessity	O
to	O
overcome	O
the	O
action	O
of	O
endogenous	O
proteases	O
.	O

Human	O
neutrophils	O
can	O
be	O
induced	O
to	O
actively	O
transcribe	O
a	O
number	O
of	O
early-response	O
genes	O
,	O
in	O
particular	O
those	O
encoding	O
cytokines	O
,	O
chemokines	O
,	O
and	O
the	O
high-affinity	O
surface	O
receptor	O
for	O
IgG	O
,	O
FcgammaRI	O
.	O

Although	O
little	O
is	O
known	O
to	O
date	O
about	O
the	O
regulation	O
of	O
gene	O
transcription	O
in	O
neutrophils	O
,	O
several	O
indications	O
point	O
to	O
a	O
role	O
for	O
distinct	O
transcription	O
factors	O
,	O
such	O
as	O
members	O
of	O
the	O
NF-kappaB	O
and	O
STAT	O
families	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
these	O
transcription	O
factors	O
become	O
activated	O
under	O
stimulatory	O
conditions	O
which	O
are	O
known	O
to	O
induce	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
conventional	O
procedures	O
employed	O
to	O
prepare	O
cellular	O
extracts	O
cause	O
the	O
release	O
of	O
proteolytic	O
activities	O
that	O
are	O
normally	O
stored	O
in	O
intracellular	O
granules	O
,	O
resulting	O
in	O
the	O
degradation	O
of	O
various	O
NF-kappaB/Rel	O
and	O
STAT	O
proteins	O
.	O

To	O
circumvent	O
this	O
problem	O
,	O
we	O
developed	O
an	O
alternative	O
procedure	O
which	O
allowed	O
us	O
to	O
show	O
that	O
in	O
neutrophils	O
,	O
LPS	O
and	O
TNFalpha	O
induce	O
a	O
NF-kappaB	O
DNA-binding	O
activity	O
which	O
essentially	O
consists	O
of	O
p50/RelA	O
dimers	O
,	O
and	O
that	O
IFNgamma	O
promotes	O
the	O
binding	O
of	O
STAT1	O
homodimers	O
to	O
the	O
IFNgamma	O
response	O
region	O
of	O
the	O
FcgammaRI	O
promoter	O
.	O

Moreover	O
,	O
we	O
report	O
that	O
neutrophil	O
stimulation	O
with	O
GM-CSF	O
results	O
in	O
the	O
formation	O
of	O
a	O
STAT5-containing	O
DNA-binding	O
activity	O
.	O

Collectively	O
,	O
the	O
current	O
findings	O
open	O
new	O
perspectives	O
about	O
mechanisms	O
that	O
are	O
likely	O
to	O
regulate	O
gene	O
transcription	O
in	O
neutrophils	O
.	O

In	O
addition	O
,	O
the	O
procedure	O
described	O
herein	O
could	O
prove	O
useful	O
in	O
other	O
cell	O
types	O
that	O
express	O
high	O
levels	O
of	O
endogenous	O
proteases	O
.	O

The	O
PEBP2betaMYH11	O
fusion	O
created	O
by	O
Inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
in	O
myeloid	O
leukemia	O
impairs	O
neutrophil	O
maturation	O
and	O
contributes	O
to	O
granulocytic	O
dysplasia	O
.	O

Chromosomal	O
translocations	O
involving	O
the	O
genes	O
encoding	O
the	O
alpha	O
and	O
beta	O
subunits	O
of	O
the	O
Pebp2/Cbf	O
transcription	O
factor	O
have	O
been	O
associated	O
with	O
human	O
acute	O
myeloid	O
leukemia	O
and	O
the	O
preleukemic	O
condition	O
,	O
myelodysplasia	O
.	O

Inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
fuses	O
the	O
gene	O
encoding	O
the	O
beta	O
subunit	O
of	O
Pebp2	O
to	O
the	O
MYH11	O
gene	O
encoding	O
a	O
smooth	O
muscle	O
myosin	O
heavy	O
chain	O
(	O
Smmhc	O
)	O
.	O

To	O
examine	O
the	O
effect	O
of	O
the	O
inv	O
(	O
16	O
)	O
(	O
p13	O
;	O
q22	O
)	O
on	O
myelopoiesis	O
,	O
we	O
used	O
the	O
hMRP8	O
promoter	O
element	O
to	O
generate	O
transgenic	O
mice	O
expressing	O
the	O
Pebp2beta	O
Smmhc	O
chimeric	O
fusion	O
protein	O
in	O
myeloid	O
cells	O
.	O

Neutrophil	O
maturation	O
was	O
impaired	O
in	O
PEBP2betaMYH11	O
transgenic	O
mice	O
.	O

Although	O
the	O
transgenic	O
mice	O
had	O
normal	O
numbers	O
of	O
circulating	O
neutrophils	O
,	O
their	O
bone	O
marrow	O
contained	O
increased	O
numbers	O
of	O
immature	O
neutrophilic	O
cells	O
,	O
which	O
exhibited	O
abnormal	O
characteristics	O
.	O

In	O
addition	O
,	O
PEBP2betaMYH11	O
inhibited	O
neutrophilic	O
differentiation	O
in	O
colonies	O
derived	O
from	O
hematopoietic	O
progenitors	O
.	O

Coexpression	O
of	O
both	O
PEBP2betaMYH11	O
and	O
activated	O
NRAS	O
induced	O
a	O
more	O
severe	O
phenotype	O
characterized	O
by	O
abnormal	O
nuclear	O
morphology	O
indicative	O
of	O
granulocytic	O
dysplasia	O
.	O

These	O
results	O
show	O
that	O
PEBP2betaMYH11	O
can	O
impair	O
neutrophil	O
development	O
and	O
provide	O
evidence	O
that	O
alterations	O
of	O
Pebp2	O
can	O
contribute	O
to	O
the	O
genesis	O
of	O
myelodysplasia	O
.	O

Transcription	O
factor	O
activation	O
in	O
lymphokine	O
activated	O
killer	O
cells	O
and	O
lymphocytes	O
from	O
patients	O
receiving	O
IL-2	O
immunotherapy	O
.	O

Administration	O
of	O
the	O
cytokine	O
interleukin-2	O
(	O
IL-2	O
)	O
can	O
result	O
in	O
therapeutic	O
benefits	O
for	O
individuals	O
with	O
renal	O
cell	O
carcinoma	O
and	O
melanoma	O
.	O

Here	O
we	O
report	O
an	O
analysis	O
of	O
the	O
transcription	O
factor	O
families	O
AP-1	O
,	O
Sp1	O
,	O
NF-kappaB	O
,	O
and	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
(	O
STAT	O
)	O
in	O
cancer	O
patients	O
'	O
lymphocytes	O
before	O
and	O
after	O
IL-2	O
immunotherapy	O
,	O
as	O
assessed	O
by	O
a	O
gel-shift	O
assay	O
.	O

An	O
in	O
vitro	O
surrogate	O
of	O
IL-2	O
immunotherapy	O
is	O
the	O
incubation	O
of	O
fresh	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
from	O
healthy	O
individuals	O
in	O
IL-2	O
for	O
several	O
days	O
,	O
resulting	O
in	O
the	O
production	O
of	O
lymphokine-activated	O
killer	O
(	O
LAK	O
)	O
activity	O
in	O
these	O
cultures	O
.	O

One	O
purpose	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
profile	O
of	O
transcription	O
factor	O
activation	O
in	O
these	O
different	O
populations	O
,	O
and	O
assess	O
whether	O
the	O
patterns	O
observed	O
correlated	O
with	O
functional	O
differences	O
in	O
these	O
cells	O
.	O

Prior	O
to	O
in	O
vivo	O
IL-2	O
administration	O
,	O
the	O
typical	O
binding	O
pattern	O
of	O
transcription	O
factors	O
in	O
PBMC	O
from	O
patients	O
resembled	O
that	O
seen	O
in	O
fresh	O
PBMC	O
from	O
healthy	O
individuals	O
.	O

Over	O
a	O
3-week	O
course	O
of	O
IL-2	O
therapy	O
,	O
in	O
most	O
patients	O
the	O
binding	O
patterns	O
of	O
AP-1	O
,	O
Sp1	O
,	O
and	O
NF-kappaB	O
proteins	O
changed	O
to	O
resemble	O
those	O
seen	O
in	O
PBMC	O
activated	O
by	O
IL-2	O
in	O
vitro	O
.	O

However	O
,	O
the	O
cells	O
obtained	O
from	O
IL-2-treated	O
patients	O
did	O
not	B-Negation
have	I-Negation
low-level	I-Negation
constitutive	I-Negation
expression	I-Negation
of	I-Negation
STAT	I-Negation
binding	I-Negation
factors	I-Negation
as	O
did	O
LAK	O
cells	O
.	O

When	O
these	O
patient	O
cells	O
were	O
further	O
stimulated	O
by	O
IL-2	O
in	O
vitro	O
,	O
additional	O
differences	O
in	O
STAT	O
induction	O
patterns	O
were	O
noted	O
.	O

These	O
data	O
provide	O
further	O
information	O
on	O
the	O
molecular	O
events	O
occurring	O
in	O
immune	O
cells	O
generated	O
through	O
in	O
vivo	O
and	O
in	O
vitro	O
administration	O
of	O
IL-2	O
,	O
and	O
further	O
document	O
that	O
there	O
is	O
not	B-Negation
a	I-Negation
precise	I-Negation
congruence	I-Negation
between	I-Negation
PBMC	I-Negation
activated	I-Negation
in	I-Negation
vivo	I-Negation
and	I-Negation
in	I-Negation
vitro	I-Negation
by	I-Negation
IL-2	I-Negation
.	O

A	O
critical	O
role	O
of	O
the	O
p75	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
p75TNF-R	O
)	O
in	O
organ	O
inflammation	O
independent	O
of	O
TNF	O
,	O
lymphotoxin	O
alpha	O
,	O
or	O
the	O
p55TNF-R	O
.	O

Despite	O
overwhelming	O
evidence	O
that	O
enhanced	O
production	O
of	O
the	O
p75	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
p75TNF-R	O
)	O
accompanies	O
development	O
of	O
specific	O
human	O
inflammatory	O
pathologies	O
such	O
as	O
multi-organ	O
failure	O
during	O
sepsis	O
,	O
inflammatory	O
liver	O
disease	O
,	O
pancreatitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
or	O
AIDS	O
,	O
the	O
function	O
of	O
this	O
receptor	O
remains	O
poorly	O
defined	O
in	O
vivo	O
.	O

We	O
show	O
here	O
that	O
at	O
levels	O
relevant	O
to	O
human	O
disease	O
,	O
production	O
of	O
the	O
human	O
p75TNF-R	O
in	O
transgenic	O
mice	O
results	O
in	O
a	O
severe	O
inflammatory	O
syndrome	O
involving	O
mainly	O
the	O
pancreas	O
,	O
liver	O
,	O
kidney	O
,	O
and	O
lung	O
,	O
and	O
characterized	O
by	O
constitutively	O
increased	O
NF-kappaB	O
activity	O
in	O
the	O
peripheral	O
blood	O
mononuclear	O
cell	O
compartment	O
.	O

This	O
process	O
is	O
shown	O
to	O
evolve	O
independently	O
of	O
the	O
presence	O
of	O
TNF	O
,	O
lymphotoxin	O
alpha	O
,	O
or	O
the	O
p55TNF-R	O
,	O
although	O
coexpression	O
of	O
a	O
human	O
TNF	O
transgene	O
accelerated	O
pathology	O
.	O

These	O
results	O
establish	O
an	O
independent	O
role	O
for	O
enhanced	O
p75TNF-R	O
production	O
in	O
the	O
pathogenesis	O
of	O
inflammatory	O
disease	O
and	O
implicate	O
the	O
direct	O
involvement	O
of	O
this	O
receptor	O
in	O
a	O
wide	O
range	O
of	O
human	O
inflammatory	O
pathologies	O
.	O

Potent	O
inhibition	O
of	O
HIV	O
type	O
1	O
replication	O
by	O
an	O
antiinflammatory	O
alkaloid	O
,	O
cepharanthine	O
,	O
in	O
chronically	O
infected	O
monocytic	O
cells	O
.	O

Cepharanthine	O
is	O
a	O
biscoclaurine	O
alkaloid	O
isolated	O
from	O
Stephania	O
cepharantha	O
Hayata	O
and	O
has	O
been	O
shown	O
to	O
have	O
antiinflammatory	O
,	O
antiallergic	O
,	O
and	O
immunomodulatory	O
activities	O
in	O
vivo	O
.	O

As	O
several	O
inflammatory	O
cytokines	O
and	O
oxidative	O
stresses	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
HIV-1	O
infection	O
,	O
we	O
investigated	O
the	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
-	O
and	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
HIV-1	O
replication	O
in	O
chronically	O
infected	O
cell	O
lines	O
.	O

Two	O
chronically	O
HIV-1-infected	O
cell	O
lines	O
,	O
U1	O
(	O
monocytic	O
)	O
and	O
ACH-2	O
(	O
T	O
lymphocytic	O
)	O
,	O
were	O
stimulated	O
with	O
TNF-alpha	O
or	O
PMA	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
concentrations	O
of	O
the	O
compound	O
.	O

HIV-1	O
replication	O
was	O
determined	O
by	O
p24	O
antigen	O
level	O
.	O

The	O
inhibitory	O
effects	O
of	O
cepharanthine	O
on	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
-driven	O
gene	O
expression	O
and	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
activation	O
were	O
also	O
examined	O
.	O

Cepharanthine	O
dose	O
dependently	O
inhibited	O
HIV-1	O
replication	O
in	O
TNF-alpha-	O
and	O
PMA-stimulated	O
U1	O
cells	O
but	O
not	B-Negation
in	I-Negation
ACH-2	I-Negation
cells	I-Negation
.	O

Its	O
50	O
%	O
effective	O
and	O
cytotoxic	O
concentrations	O
were	O
0.016	O
and	O
2.2	O
microg/ml	O
in	O
PMA-stimulated	O
U1	O
cells	O
,	O
respectively	O
.	O

Cepharanthine	O
was	O
found	O
to	O
suppress	O
HIV-1	O
LTR-driven	O
gene	O
expression	O
through	O
the	O
inhibition	O
of	O
NF-kappaB	O
activation	O
.	O

These	O
results	O
indicate	O
that	O
cepharanthine	O
is	O
a	O
highly	O
potent	O
inhibitor	O
of	O
HIV-1	O
replication	O
in	O
a	O
chronically	O
infected	O
monocytic	O
cell	O
line	O
.	O

Since	O
biscoclaurine	O
alkaloids	O
,	O
containing	O
cepharanthine	O
as	O
a	O
major	O
component	O
,	O
are	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
various	O
inflammatory	O
diseases	O
in	O
Japan	O
,	O
cepharanthine	O
should	O
be	O
further	O
pursued	O
for	O
its	O
chemotherapeutic	O
potential	O
in	O
HIV-1-infected	O
patients	O
.	O

Prostaglandin	O
E2	O
Up-regulates	O
HIV-1	O
long	O
terminal	O
repeat-driven	O
gene	O
activity	O
in	O
T	O
cells	O
via	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

Replication	O
of	O
human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
is	O
highly	O
dependent	O
on	O
the	O
state	O
of	O
activation	O
of	O
the	O
infected	O
cells	O
and	O
is	O
modulated	O
by	O
interactions	O
between	O
viral	O
and	O
host	O
cellular	O
factors	O
.	O

Prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
a	O
pleiotropic	O
immunomodulatory	O
molecule	O
,	O
is	O
observed	O
at	O
elevated	O
levels	O
during	O
HIV-1	O
infection	O
as	O
well	O
as	O
during	O
the	O
course	O
of	O
other	O
pathogenic	O
infections	O
.	O

In	O
1G5	O
,	O
a	O
Jurkat-derived	O
T	O
cell	O
line	O
stably	O
transfected	O
with	O
a	O
luciferase	O
gene	O
driven	O
by	O
HIV-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
,	O
we	O
found	O
that	O
PGE2	O
markedly	O
enhanced	O
HIV-1	O
LTR-mediated	O
reporter	O
gene	O
activity	O
.	O

Experiments	O
have	O
been	O
conducted	O
to	O
identify	O
second	O
messengers	O
involved	O
in	O
this	O
PGE2-dependent	O
up-regulating	O
effect	O
on	O
the	O
regulatory	O
element	O
of	O
HIV-1	O
.	O

In	O
this	O
study	O
,	O
we	O
present	O
evidence	O
indicating	O
that	O
signal	O
transduction	O
pathways	O
induced	O
by	O
PGE2	O
necessitate	O
the	O
participation	O
of	O
cyclic	O
AMP	O
,	O
protein	O
kinase	O
A	O
,	O
and	O
Ca2+	O
.	O

Experiments	O
conducted	O
with	O
different	O
HIV-1	O
LTR-based	O
vectors	O
suggested	O
that	O
PGE2-mediated	O
activation	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
transduced	O
via	O
both	O
NF-kappaB-dependent	O
and	O
-independent	O
signaling	O
pathways	O
.	O

The	O
involvement	O
of	O
NF-kappaB	O
in	O
the	O
PGE2-dependent	O
activating	O
effect	O
on	O
HIV-1	O
transcription	O
was	O
further	O
confirmed	O
using	O
a	O
kappaB-regulated	O
luciferase	O
encoding	O
vector	O
and	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Results	O
from	O
Northern	O
blot	O
and	O
flow	O
cytometric	O
analyses	O
,	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
selective	O
antagonist	O
indicated	O
that	O
PGE2	O
modulation	O
of	O
HIV-1	O
LTR-driven	O
reporter	O
gene	O
activity	O
in	O
studied	O
T	O
lymphoid	O
cells	O
is	O
transduced	O
via	O
the	O
EP4	O
receptor	O
subtype	O
.	O

These	O
results	O
suggest	O
that	O
secretion	O
of	O
PGE2	O
by	O
macrophages	O
in	O
response	O
to	O
infection	O
or	O
inflammatory	O
activators	O
could	O
induce	O
signaling	O
events	O
resulting	O
in	O
activation	O
of	O
proviral	O
DNA	O
present	O
into	O
T	O
cells	O
latently	O
infected	O
with	O
HIV-1	O
.	O

Fcgamma	O
receptor-mediated	O
mitogen-activated	O
protein	O
kinase	O
activation	O
in	O
monocytes	O
is	O
independent	O
of	O
Ras	O
.	O

Receptors	O
for	O
the	O
Fc	O
portion	O
of	O
immunoglobulin	O
molecules	O
(	O
FcR	O
)	O
present	O
on	O
leukocyte	O
cell	O
membranes	O
mediate	O
a	O
large	O
number	O
of	O
cellular	O
responses	O
that	O
are	O
very	O
important	O
in	O
host	O
defense	O
,	O
including	O
phagocytosis	O
,	O
cell	O
cytotoxicity	O
,	O
production	O
and	O
secretion	O
of	O
inflammatory	O
mediators	O
,	O
and	O
modulation	O
of	O
the	O
immune	O
response	O
.	O

Cross-linking	O
of	O
FcR	O
with	O
immune	O
complexes	O
leads	O
,	O
first	O
to	O
activation	O
of	O
protein-tyrosine	O
kinases	O
.	O

The	O
molecular	O
events	O
that	O
follow	O
and	O
that	O
transduce	O
signals	O
from	O
these	O
receptors	O
to	O
the	O
nucleus	O
are	O
still	O
poorly	O
defined	O
.	O

We	O
have	O
investigated	O
the	O
signal	O
transduction	O
pathway	O
from	O
Fc	O
receptors	O
that	O
leads	O
to	O
gene	O
activation	O
and	O
production	O
of	O
cytokines	O
in	O
monocytes	O
.	O

Cross-linking	O
of	O
FcR	O
,	O
on	O
the	O
THP-1	O
monocytic	O
cell	O
line	O
,	O
by	O
immune	O
complexes	O
resulted	O
in	O
both	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kappaB	O
and	O
interleukin	O
1	O
production	O
.	O

These	O
responses	O
were	O
completely	O
blocked	O
by	O
tyrosine	O
kinase	O
inhibitors	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
dominant	O
negative	O
mutants	O
of	O
Ras	O
and	O
Raf-1	O
,	O
in	O
these	O
cells	O
,	O
did	O
not	B-Negation
have	I-Negation
any	I-Negation
effect	I-Negation
on	I-Negation
FcR-mediated	I-Negation
nuclear	I-Negation
factor	I-Negation
activation	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
mitogen-activated	I-Speculation
protein	I-Speculation
kinase	I-Speculation
(	I-Speculation
MAPK	I-Speculation
)	I-Speculation
signaling	I-Speculation
pathway	I-Speculation
was	I-Speculation
not	I-Speculation
used	I-Speculation
by	I-Speculation
these	I-Speculation
receptors	I-Speculation
.	O

However	O
,	O
MAPK	O
activation	O
was	O
easily	O
detected	O
by	O
in	O
vitro	O
kinase	O
assays	O
,	O
after	O
FcR	O
cross-linking	O
with	O
immune	O
complexes	O
.	O

Using	O
the	O
specific	O
MAPK/extracellular	O
signal-regulated	O
kinase	O
kinase	O
(	O
MAPK	O
kinase	O
)	O
inhibitor	O
PD98059	O
,	O
we	O
found	O
that	O
MAPK	O
activation	O
is	O
necessary	O
for	O
FcR-dependent	O
activation	O
of	O
the	O
nuclear	O
factor	O
NF-kappaB	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
signaling	O
pathway	O
from	O
Fc	O
receptors	O
leading	O
to	O
expression	O
of	O
different	O
genes	O
important	O
to	O
leukocyte	O
biology	O
,	O
initiates	O
with	O
tyrosine	O
kinases	O
and	O
requires	O
MAPK	O
activation	O
;	O
but	O
in	O
contrast	O
to	O
other	O
tyrosine	O
kinase	O
receptors	O
,	O
FcR-mediated	O
MAPK	O
activation	O
does	O
not	O
involve	O
Ras	O
and	O
Raf	O
.	O

Differential	O
RNA	O
display	O
identifies	O
novel	O
genes	O
associated	O
with	O
decreased	O
vitamin	O
D	O
receptor	O
expression	O
.	O

To	O
characterize	O
further	O
the	O
function	O
of	O
the	O
intracellular	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
we	O
have	O
developed	O
stable	O
transfectant	O
variants	O
of	O
a	O
vitamin	O
D-responsive	O
cell	O
line	O
(	O
U937	O
)	O
which	O
express	O
either	O
decreased	O
or	O
increased	O
numbers	O
of	O
VDR	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
changes	O
in	O
gene	O
expression	O
associated	O
with	O
this	O
variable	O
VDR	O
expression	O
.	O

Initial	O
experiments	O
indicated	O
that	O
a	O
50	O
%	O
decrease	O
in	O
VDR	O
levels	O
was	O
associated	O
with	O
a	O
2-fold	O
increase	O
in	O
cell	O
proliferation	O
and	O
a	O
similar	O
rise	O
in	O
c-myc	O
mRNA	O
expression	O
.	O

Further	O
studies	O
were	O
carried	O
out	O
using	O
differential	O
RNA	O
display	O
(	O
DD	O
)	O
.	O

Sequence	O
analysis	O
of	O
DD	O
products	O
revealed	O
two	O
cDNAs	O
with	O
identity	O
to	O
known	O
gene	O
products	O
:	O
the	O
catalytic	O
sub-unit	O
of	O
DNA-protein	O
kinase	O
(	O
DNA-PK	O
(	O
CS	O
)	O
)	O
,	O
and	O
the	O
peroxisomal	O
enzyme	O
17beta-hydroxysteroid	O
dehydrogenase	O
type	O
IV	O
(	O
17beta-HSD	O
IV	O
)	O
.	O

Northern	O
analysis	O
confirmed	O
that	O
expression	O
of	O
both	O
mRNAs	O
was	O
reduced	O
in	O
cells	O
with	O
decreased	O
numbers	O
of	O
VDR	O
.	O

Down-regulation	O
of	O
17beta-HSD	O
IV	O
mRNA	O
expression	O
was	O
associated	O
with	O
enhanced	O
estradiol	O
inactivation	O
by	O
U937	O
cells	O
,	O
suggesting	O
a	O
link	O
between	O
estrogenic	O
pathways	O
and	O
cell	O
proliferation	O
.	O

Further	O
Northern	O
analyses	O
indicated	O
that	O
there	O
was	O
no	O
significant	O
change	O
in	O
17beta-HSD	O
IV	O
or	O
DNA-PK	O
(	O
CS	O
)	O
mRNA	O
levels	O
following	O
treatment	O
with	O
1,25	O
(	O
OH	O
)	O
2D3	O
,	O
although	O
expression	O
of	O
both	O
genes	O
varied	O
with	O
changes	O
in	O
cell	O
proliferation	O
.	O

These	O
data	O
suggest	O
that	O
,	O
in	O
addition	O
to	O
its	O
established	O
role	O
as	O
a	O
hormone-dependent	O
trans-activator	O
,	O
VDR	O
may	O
influence	O
gene	O
expression	O
by	O
ligand-independent	O
mechanisms	O
.	O

Downstream	O
activation	O
of	O
a	O
TATA-less	O
promoter	O
by	O
Oct-2	O
,	O
Bob1	O
,	O
and	O
NF-kappaB	O
directs	O
expression	O
of	O
the	O
homing	O
receptor	O
BLR1	O
to	O
mature	O
B	O
cells	O
.	O

The	O
chemokine	O
receptor	O
,	O
BLR1	O
,	O
is	O
a	O
major	O
regulator	O
of	O
the	O
microenvironmental	O
homing	O
of	O
B	O
cells	O
in	O
lymphoid	O
organs	O
.	O

In	O
vitro	O
studies	O
identify	O
three	O
essential	O
elements	O
of	O
the	O
TATA-less	O
blr1	O
core	O
promoter	O
that	O
confer	O
cell	O
type-	O
and	O
differentiation-specific	O
expression	O
in	O
the	O
B	O
cells	O
of	O
both	O
humans	O
and	O
mice	O
,	O
a	O
functional	O
promoter	O
region	O
(	O
-36	O
with	O
respect	O
to	O
the	O
transcription	O
start	O
site	O
)	O
,	O
a	O
NF-kappaB	O
motif	O
(	O
+44	O
)	O
,	O
and	O
a	O
noncanonical	O
octamer	O
motif	O
(	O
+157	O
)	O
.	O

The	O
importance	O
of	O
these	O
sites	O
was	O
confirmed	O
by	O
in	O
vivo	O
studies	O
in	O
gene-targeted	O
mice	O
deficient	O
of	O
either	O
Oct-2	O
,	O
Bob1	O
,	O
or	O
both	O
NF-kappaB	O
subunits	O
p50	O
and	O
p52	O
.	O

In	O
all	O
of	O
these	O
animals	O
,	O
the	O
expression	O
of	O
BLR1	O
was	O
reduced	O
or	O
absent	B-Negation
.	O

In	O
mice	O
deficient	O
only	O
of	O
p52/NF-kappaB	O
,	O
BLR1	O
expression	O
was	O
unaffected	O
.	O

Thus	O
our	O
data	O
demonstrate	O
that	O
BLR1	O
is	O
a	O
target	O
gene	O
for	O
Oct-2	O
,	O
Bob1	O
,	O
and	O
members	O
of	O
the	O
NF-kappaB/Rel	O
family	O
and	O
provides	O
a	O
link	O
to	O
the	O
impaired	O
B	O
cell	O
functions	O
in	O
mice	O
deficient	O
for	O
these	O
factors	O
.	O

Inhibition	O
of	O
RNA	O
polymerase	O
II	O
transcription	O
in	O
human	O
cells	O
by	O
synthetic	O
DNA-binding	O
ligands	O
[	O
see	O
comments	O
]	O

Sequence-specific	O
DNA-binding	O
small	O
molecules	O
that	O
can	O
permeate	O
human	O
cells	O
potentially	O
could	O
regulate	O
transcription	O
of	O
specific	O
genes	O
.	O

Multiple	O
cellular	O
DNA-binding	O
transcription	O
factors	O
are	O
required	O
by	O
HIV	O
type	O
1	O
for	O
RNA	O
synthesis	O
.	O

Two	O
pyrrole-imidazole	O
polyamides	O
were	O
designed	O
to	O
bind	O
DNA	O
sequences	O
immediately	O
adjacent	O
to	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
Ets-1	O
,	O
lymphoid-enhancer	O
binding	O
factor	O
1	O
,	O
and	O
TATA-box	O
binding	O
protein	O
.	O

These	O
synthetic	O
ligands	O
specifically	O
inhibit	O
DNA-binding	O
of	O
each	O
transcription	O
factor	O
and	O
HIV	O
type	O
1	O
transcription	O
in	O
cell-free	O
assays	O
.	O

When	O
used	O
in	O
combination	O
,	O
the	O
polyamides	O
inhibit	O
virus	O
replication	O
by	O
>	O
99	O
%	O
in	O
isolated	O
human	O
peripheral	O
blood	O
lymphocytes	O
,	O
with	O
no	B-Negation
detectable	I-Negation
cell	I-Negation
toxicity	I-Negation
.	O

The	O
ability	O
of	O
small	O
molecules	O
to	O
target	O
predetermined	O
DNA	O
sequences	O
located	O
within	O
RNA	O
polymerase	O
II	O
promoters	O
suggests	O
a	O
general	O
approach	O
for	O
regulation	O
of	O
gene	O
expression	O
,	O
as	O
well	O
as	O
a	O
mechanism	O
for	O
the	O
inhibition	O
of	O
viral	O
replication	O
.	O

Relationship	O
between	O
IkappaBalpha	O
constitutive	O
expression	O
,	O
TNFalpha	O
synthesis	O
,	O
and	O
apoptosis	O
in	O
EBV-infected	O
lymphoblastoid	O
cells	O
.	O

In	O
order	O
to	O
understand	O
the	O
role	O
of	O
NF-kappaB	O
in	O
EBV	O
transformation	O
we	O
have	O
established	O
stably	O
transfected	O
IkappaBalpha	O
into	O
lymphoblastoid	O
cells	O
.	O

Two	O
clones	O
were	O
obtained	O
in	O
which	O
the	O
loss	O
of	O
NF-kappaB	O
binding	O
activity	O
correlated	O
with	O
the	O
constitutive	O
expression	O
of	O
the	O
transgenic	O
IkappaBalpha	O
.	O

Protein	O
latency	O
expression	O
was	O
determined	O
by	O
immunocytochemistry	O
.	O

Expression	O
of	O
surface	O
markers	O
,	O
intracytoplasmic	O
content	O
of	O
cytokines	O
cell	O
cycle	O
analysis	O
after	O
BrdU	O
incorporation	O
and	O
DNA	O
staining	O
with	O
propidium	O
iodide	O
were	O
studied	O
by	O
flow	O
cytometry	O
.	O

Percentage	O
of	O
apoptotic	O
cells	O
was	O
determined	O
by	O
in-situ	O
labelling	O
of	O
DNA	O
strand	O
breaks	O
.	O

No	B-Negation
significative	I-Negation
changes	I-Negation
in	I-Negation
EBV	I-Negation
latency	I-Negation
nor	B-Negation
in	I-Negation
cell	I-Negation
surface	I-Negation
marker	I-Negation
expression	I-Negation
was	I-Negation
found	I-Negation
.	O

In	O
contrast	O
,	O
intracytoplasmic	O
TNFalpha	O
levels	O
were	O
strongly	O
reduced	O
in	O
transfected	O
clones	O
.	O

Furthermore	O
,	O
30	O
%	O
of	O
IkappaBalpha	O
transfected	O
cells	O
were	O
apoptotic	O
after	O
8	O
h	O
of	O
TNFalpha	O
treatment	O
.	O

This	O
correlated	O
with	O
a	O
strong	O
reduction	O
of	O
BrdU	O
incorporation	O
after	O
24	O
h	O
of	O
TNFalpha	O
treatment	O
.	O

No	B-Negation
effect	I-Negation
was	I-Negation
seen	I-Negation
with	I-Negation
non	I-Negation
transfected	I-Negation
cells	I-Negation
or	I-Negation
with	I-Negation
cells	I-Negation
transfected	I-Negation
with	I-Negation
a	I-Negation
control	I-Negation
plasmid	I-Negation
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNFalpha	O
gene	O
could	O
be	O
one	O
of	O
the	O
targets	O
of	O
NF-kappaB	O
in	O
EBV	O
infected	O
cells	O
and	O
that	O
NF-kappaB	O
protects	O
EBV-infected	O
cells	O
from	O
apoptosis	O
induced	O
by	O
TNFalpha	O
,	O
which	O
may	O
favour	O
the	O
proliferative	O
effect	O
of	O
this	O
cytokine	O
.	O

Uncoupling	O
activation-dependent	O
HS1	O
phosphorylation	O
from	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
transcriptional	O
activation	O
in	O
Jurkat	O
T	O
cells	O
:	O
differential	O
signaling	O
through	O
CD3	O
and	O
the	O
costimulatory	O
receptors	O
CD2	O
and	O
CD28	O
.	O

CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
are	O
functionally	O
distinct	O
receptors	O
on	O
T	O
lymphocytes	O
.	O

Engagement	O
of	O
any	O
of	O
these	O
receptors	O
induces	O
the	O
rapid	O
tyrosine	O
phosphorylation	O
of	O
a	O
shared	O
group	O
of	O
intracellular	O
signaling	O
proteins	O
,	O
including	O
Vav	O
,	O
Cbl	O
,	O
p85	O
phosphoinositide	O
3-kinase	O
,	O
and	O
the	O
Src	O
family	O
kinases	O
Lck	O
and	O
Fyn	O
.	O

Ligation	O
of	O
CD3	O
also	O
induces	O
the	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
,	O
a	O
75-kDa	O
hematopoietic	O
cell-specific	O
intracellular	O
signaling	O
protein	O
of	O
unknown	O
function	O
.	O

We	O
have	O
examined	O
changes	O
in	O
HS1	O
phosphorylation	O
after	O
differential	O
stimulation	O
of	O
CD3	O
,	O
CD2	O
,	O
and	O
CD28	O
to	O
elucidate	O
its	O
role	O
in	O
T	O
cells	O
and	O
to	O
further	O
delineate	O
the	O
signaling	O
pathways	O
recruited	O
by	O
these	O
receptors	O
.	O

Unlike	O
ligation	O
of	O
CD3	O
,	O
stimulation	O
with	O
anti-CD28	O
mAb	O
or	O
CHO	O
cells	O
expressing	O
the	O
CD28	O
ligands	O
CD80	O
or	O
CD86	O
did	O
not	B-Negation
lead	I-Negation
to	I-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
of	I-Negation
HS1	I-Negation
in	I-Negation
Jurkat	I-Negation
T	I-Negation
cells	I-Negation
.	O

Additionally	O
,	O
no	B-Negation
tyrosine	I-Negation
phosphorylation	I-Negation
of	I-Negation
HS1	I-Negation
was	I-Negation
induced	I-Negation
by	I-Negation
mitogenic	I-Negation
pairs	I-Negation
of	I-Negation
anti-CD2	I-Negation
mAbs	I-Negation
capable	I-Negation
of	I-Negation
activating	I-Negation
the	I-Negation
transcription	I-Negation
factor	I-Negation
NFAT	I-Negation
(	I-Negation
nuclear	I-Negation
factor	I-Negation
of	I-Negation
activated	I-Negation
T	I-Negation
cells	I-Negation
)	I-Negation
.	O

Costimulation	O
through	O
CD28	O
and/or	O
CD2	O
did	O
not	B-Negation
modulate	I-Negation
the	I-Negation
CD3-dependent	I-Negation
phosphorylation	I-Negation
of	I-Negation
HS1	I-Negation
.	O

In	O
vivo	O
studies	O
indicated	O
that	O
CD3-induced	O
HSI	O
phosphorylation	O
was	O
dependent	O
upon	O
both	O
the	O
Src	O
family	O
tyrosine	O
kinase	O
Lck	O
and	O
the	O
tyrosine	O
phosphatase	O
CD45	O
,	O
did	O
not	O
require	O
MEK1	O
kinase	O
activity	O
,	O
and	O
was	O
regulated	O
by	O
protein	O
kinase	O
C	O
activation	O
.	O

Thus	O
,	O
although	O
CD3	O
,	O
CD28	O
,	O
and	O
CD2	O
activate	O
many	O
of	O
the	O
same	O
signaling	O
molecules	O
,	O
they	O
differed	O
in	O
their	O
capacity	O
to	O
induce	O
the	O
tyrosine	O
phosphorylation	O
of	O
HSI	O
.	O

Furthermore	O
,	O
activation-dependent	O
tyrosine	O
phosphorylation	O
of	O
HS1	O
was	O
not	B-Negation
required	I-Negation
for	I-Negation
NFAT	I-Negation
transcriptional	I-Negation
activation	I-Negation
.	O

IL-7	O
reconstitutes	O
multiple	O
aspects	O
of	O
v-Abl-mediated	O
signaling	O
.	O

The	O
mechanism	O
by	O
which	O
early	O
lymphoid	O
cells	O
are	O
selectively	O
transformed	O
by	O
v-Abl	O
is	O
currently	O
unknown	O
.	O

Previous	O
studies	O
have	O
shown	O
constitutive	O
activation	O
of	O
IL-4	O
and	O
IL-7	O
signaling	O
pathways	O
,	O
as	O
measured	O
by	O
activation	O
of	O
Janus	O
protein	O
kinase	O
(	O
JAK	O
)	O
1	O
,	O
JAK3	O
,	O
STAT5	O
,	O
and	O
STAT6	O
,	O
in	O
pre-B	O
cells	O
transformed	O
by	O
v-Abl	O
.	O

To	O
determine	O
whether	O
activation	O
of	O
these	O
cytokine	O
signaling	O
pathways	O
by	O
v-Abl	O
is	O
important	O
in	O
the	O
cellular	O
events	O
induced	O
by	O
the	O
Abelson	O
murine	O
leukemia	O
virus	O
,	O
the	O
effects	O
of	O
IL-4	O
and	O
IL-7	O
on	O
pre-B	O
cells	O
transformed	O
with	O
a	O
temperature-sensitive	O
v-Abl	O
mutant	O
were	O
examined	O
.	O

Whereas	O
IL-4	O
had	O
little	O
or	O
no	B-Negation
effect	I-Negation
,	O
IL-7	O
delayed	O
both	O
the	O
apoptosis	O
and	O
cell	O
cycle	O
arrest	O
that	O
occur	O
upon	O
v-Abl	O
kinase	O
inactivation	O
.	O

IL-7	O
also	O
delayed	O
the	O
decreases	O
in	O
the	O
levels	O
of	O
c-Myc	O
,	O
Bcl-2	O
,	O
and	O
Bcl-xL	O
that	O
occur	O
upon	O
loss	O
of	O
v-Abl	O
kinase	O
activity	O
.	O

IL-7	O
did	O
not	B-Negation
maintain	I-Negation
v-Abl-mediated	I-Negation
differentiation	I-Negation
arrest	I-Negation
of	I-Negation
the	I-Negation
pre-B	I-Negation
cells	I-Negation
,	O
as	O
activation	O
of	O
NF-kappaB	O
and	O
RAG	O
gene	O
transcription	O
was	O
unaffected	O
by	O
IL-7	O
.	O

These	O
results	O
identify	O
a	O
potential	B-Speculation
role	I-Speculation
for	I-Speculation
IL-7	I-Speculation
signaling	I-Speculation
pathways	I-Speculation
in	I-Speculation
transformation	I-Speculation
by	I-Speculation
v-Abl	I-Speculation
while	O
demonstrating	O
that	O
a	O
combination	O
of	O
IL-4	O
and	O
IL-7	O
signaling	O
can	B-Negation
not	I-Negation
substitute	I-Negation
for	I-Negation
an	I-Negation
active	I-Negation
v-Abl	I-Negation
kinase	I-Negation
in	I-Negation
transformed	I-Negation
pre-B	I-Negation
cells	I-Negation
.	O

p21ras	O
initiates	O
Rac-1	O
but	O
not	B-Negation
phosphatidyl	I-Negation
inositol	I-Negation
3	I-Negation
kinase/PKB	I-Negation
,	O
mediated	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

p21ras	O
is	O
activated	O
by	O
the	O
T	O
cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
then	O
co-ordinates	O
important	O
signaling	O
pathways	O
for	O
T	O
lymphocyte	O
activation	O
.	O

Effector	O
pathways	O
for	O
this	O
guanine	O
nucleotide	O
binding	O
protein	O
in	O
T	O
cells	O
are	O
mediated	O
by	O
the	O
serine/threonine	O
kinase	O
Raf-1	O
and	O
the	O
Ras-related	O
GTPase	O
Rac-1	O
.	O

In	O
fibroblasts	O
,	O
an	O
important	O
effector	O
for	O
the	O
Ras	O
oncogene	O
is	O
Phosphatidylinositol	O
3-kinase	O
(	O
PtdIns	O
3-kinase	O
)	O
.	O

Activation	O
of	O
this	O
lipid	O
kinase	O
is	O
able	O
to	O
induce	O
critical	O
Rac-1	O
signaling	O
pathways	O
and	O
can	O
couple	O
p21ras	O
to	O
cell	O
survival	O
mechanisms	O
via	O
the	O
serine/threonine	O
kinase	O
Akt/PKB	O
.	O

The	B-Negation
role	I-Negation
of	I-Negation
PtdIns	I-Negation
3-kinase	I-Negation
in	I-Negation
Ras	I-Negation
signaling	I-Negation
in	I-Negation
T	I-Negation
cells	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
explored	I-Negation
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
ability	O
of	O
PtdIns	O
3-kinase	O
to	O
initiate	O
the	O
Rac-1	O
signaling	O
pathways	O
important	O
for	O
T	O
cell	O
activation	O
.	O

We	O
also	O
examined	O
the	O
possibility	O
that	O
Akt/PKB	O
is	O
regulated	O
by	O
Ras	O
signaling	O
pathways	O
in	O
T	O
lymphocytes	O
.	O

The	O
results	O
show	O
that	O
Ras	O
can	O
initiate	O
a	O
Rac-1	O
mediated	O
pathway	O
that	O
regulates	O
the	O
transcriptional	O
function	O
of	O
AP-1	O
complexes	O
.	O

PtdIns	O
3-kinase	O
signals	O
can	B-Negation
not	I-Negation
mimic	I-Negation
p21ras	I-Negation
and	I-Negation
induce	I-Negation
the	I-Negation
Rac	I-Negation
mediated	I-Negation
responses	I-Negation
of	I-Negation
AP-1	I-Negation
transcriptional	I-Negation
activation	I-Negation
.	O

Moreover	O
,	O
neither	B-Negation
TCR	I-Negation
or	I-Negation
Ras	I-Negation
activation	I-Negation
of	I-Negation
AP-1	I-Negation
is	I-Negation
dependent	I-Negation
on	I-Negation
PtdIns	I-Negation
3-kinase	I-Negation
.	O

PKB	O
is	O
activated	O
in	O
response	O
to	O
triggering	O
of	O
the	O
T	O
cell	O
antigen	O
receptor	O
;	O
PtdIns	O
3-kinase	O
activity	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
this	O
TCR	O
response	O
.	O

In	O
contrast	O
,	O
p21ras	B-Negation
signals	I-Negation
are	I-Negation
unable	I-Negation
to	I-Negation
induce	I-Negation
Akt/PKB	I-Negation
activity	I-Negation
in	I-Negation
T	I-Negation
cell	I-Negation
nor	B-Negation
is	I-Negation
Ras	I-Negation
function	I-Negation
required	I-Negation
for	I-Negation
Akt/PKB	I-Negation
activation	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
the	I-Negation
TCR	I-Negation
.	O

The	O
present	O
data	O
thus	O
highlight	O
that	O
PtdIns	O
3-kinase	O
and	O
Akt/PKB	O
are	O
not	B-Negation
universal	I-Negation
Ras	I-Negation
effector	I-Negation
molecules	I-Negation
.	O

Ras	O
can	O
initiate	O
Rac-1	O
regulated	O
signaling	O
pathways	O
in	O
the	O
context	O
of	O
T	O
cell	O
antigen	O
receptor	O
function	O
independently	O
of	O
PtdIns	O
3-kinase	O
activity	O
.	O

Signal	O
transduction	O
abnormalities	O
in	O
T	O
lymphocytes	O
from	O
patients	O
with	O
advanced	O
renal	O
carcinoma	O
:	O
clinical	O
relevance	O
and	O
effects	O
of	O
cytokine	O
therapy	O
.	O

Studies	O
have	O
demonstrated	O
abnormalities	O
of	O
the	O
CD3/T-cell	O
antigen	O
receptor	O
(	O
TCR	O
)	O
and	O
pathways	O
of	O
signal	O
transduction	O
in	O
T	O
lymphocytes	O
from	O
animals	O
and	O
patients	O
with	O
advanced	O
malignancy	O
.	O

Diminished	O
expression	O
of	O
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
that	O
are	O
associated	O
with	O
the	O
TCR	O
and	O
reduced	O
nuclear	O
localization	O
of	O
RelA	O
containing	O
nuclear	O
factor	O
kappaB	O
(	O
NFkappaB	O
)	O
complexes	O
have	O
been	O
noted	O
.	O

These	O
defects	O
have	O
been	O
described	O
in	O
T	O
cells	O
from	O
patients	O
with	O
malignant	O
melanoma	O
,	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
,	O
ovarian	O
cancer	O
,	O
and	O
colorectal	O
cancer	O
.	O

Preliminary	O
observations	O
also	O
indicate	O
possible	O
correlation	O
with	O
clinical	O
variables	O
such	O
as	O
stage	O
in	O
selected	O
instances	O
.	O

To	O
further	O
characterize	O
altered	O
expression	O
of	O
TCRzeta	O
,	O
p56	O
(	O
lck	O
)	O
,	O
and	O
impaired	O
activation	O
of	O
NFkappaB	O
,	O
T	O
lymphocytes	O
were	O
obtained	O
from	O
65	O
patients	O
with	O
RCC	O
,	O
the	O
majority	O
of	O
whom	O
were	O
receiving	O
combination	O
cytokine	O
therapy	O
[	O
interleukin	O
(	O
IL	O
)	O
-2	O
,	O
IFN	O
alpha-containing	O
regimens	O
]	O
and	O
37	O
control	O
individuals	O
.	O

In	O
29	O
of	O
these	O
patients	O
,	O
levels	O
of	O
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
were	O
determined	O
by	O
Western	O
blots	O
of	O
T-cell	O
lysates	O
and	O
semiquantitated	O
using	O
densitometry	O
.	O

Relative	O
levels	O
were	O
then	O
correlated	O
with	O
a	O
series	O
of	O
clinical	O
variables	O
including	O
response	O
to	O
therapy	O
,	O
performance	O
status	O
,	O
survival	O
,	O
disease	O
sites	O
,	O
age	O
,	O
and	O
others	O
.	O

In	O
another	O
group	O
of	O
28	O
patients	O
(	O
three	O
individuals	O
from	O
the	O
first	O
group	O
)	O
,	O
the	O
frequency	O
of	O
abnormal	O
NFkappaB	O
activation	O
was	O
studied	O
using	O
electrophoretic	O
mobility	O
shift	O
assays	O
after	O
activation	O
of	O
T	O
cells	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
or	O
anti-CD3	O
monoclonal	O
antibody	O
.	O

Changes	O
in	O
these	O
signaling	O
molecules	O
during	O
cytokine	O
treatment	O
were	O
also	O
investigated	O
.	O

TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
were	O
detected	O
in	O
the	O
peripheral	O
blood	O
T	O
cells	O
in	O
27	O
of	O
29	O
patients	O
,	O
and	O
overall	O
,	O
reduced	O
levels	O
were	O
noted	O
visually	O
in	O
12	O
of	O
29	O
(	O
41	O
%	O
)	O
and	O
13	O
of	O
29	O
(	O
45	O
%	O
)	O
individuals	O
,	O
respectively	O
.	O

When	O
levels	O
were	O
semiquantitated	O
using	O
densitometry	O
,	O
significant	O
decreases	O
of	O
TCRzeta	O
(	O
P	O
=	O
0.029	O
)	O
and	O
p56	O
(	O
lck	O
)	O
(	O
P	O
=	O
0.029	O
)	O
but	O
not	B-Negation
CD3epsilon	I-Negation
(	I-Negation
P	I-Negation
=	I-Negation
0.131	I-Negation
)	I-Negation
,	O
compared	O
with	O
control	O
levels	O
,	O
were	O
found	O
.	O

In	O
patients	O
treated	O
with	O
IL-2/IFN	O
alpha-based	O
therapy	O
,	O
relative	O
levels	O
of	O
TCRzeta	O
increased	O
significantly	O
(	O
P	O
=	O
0.002	O
)	O
on	O
day	O
15	O
of	O
cycle	O
one	O
compared	O
with	O
the	O
baseline	O
.	O

Correlations	B-Negation
of	I-Negation
TCRzeta	I-Negation
or	I-Negation
p56	I-Negation
(	I-Negation
lck	I-Negation
)	I-Negation
levels	I-Negation
with	I-Negation
response	I-Negation
or	I-Negation
disease	I-Negation
variables	I-Negation
,	I-Negation
except	I-Negation
for	I-Negation
lower	I-Negation
TCRzeta	I-Negation
levels	I-Negation
(	I-Negation
P	I-Negation
<	I-Negation
0.001	I-Negation
)	I-Negation
in	I-Negation
the	I-Negation
presence	I-Negation
of	I-Negation
bone	I-Negation
metastases	I-Negation
,	I-Negation
were	I-Negation
not	I-Negation
found	I-Negation
.	O

Abnormal	O
NFkappaB	O
activation	O
after	O
stimulation	O
with	O
phorbol	O
myristate	O
acetate/ionomycin	O
and/or	O
anti-CD3	O
monoclonal	O
antibody	O
was	O
found	O
in	O
59	O
%	O
of	O
patients	O
(	O
17	O
of	O
28	O
)	O
and	O
was	B-Negation
not	I-Negation
accounted	I-Negation
for	I-Negation
by	I-Negation
the	I-Negation
advanced	I-Negation
age	I-Negation
of	I-Negation
the	I-Negation
study	I-Negation
cohort	I-Negation
.	O

Activation	O
of	O
NFkappaB	O
in	O
peripheral	O
blood	O
T	O
cells	O
was	O
inducible	O
during	O
cytokine	O
therapy	O
in	O
four	O
of	O
six	O
individuals	O
who	O
displayed	O
impaired	O
NFkappaB	O
activity	O
prior	O
to	O
therapy	O
.	O

Moreover	O
,	O
impaired	B-Negation
activation	I-Negation
of	I-Negation
NFkappaB	I-Negation
does	I-Negation
not	I-Negation
appear	B-Speculation
linked	I-Speculation
to	I-Speculation
a	I-Speculation
reduction	I-Speculation
of	I-Speculation
TCRzeta	I-Speculation
expression	I-Speculation
,	O
because	O
in	O
five	O
patients	O
,	O
normal	O
TCRzeta	O
levels	O
were	O
present	O
although	O
kappaB	B-Negation
binding	I-Negation
was	I-Negation
not	I-Negation
inducible	I-Negation
.	O

In	O
the	O
majority	O
of	O
patients	O
with	O
advanced	O
RCC	O
,	O
peripheral	O
blood	O
T	O
cells	O
express	O
TCRzeta	O
and	O
p56	O
(	O
lck	O
)	O
,	O
and	O
in	O
a	O
subset	O
,	O
reduced	O
levels	O
of	O
these	O
TCRzeta	O
associated	O
molecules	O
are	O
seen	O
that	O
may	O
increase	O
during	O
cytokine-based	O
therapy	O
.	O

Abnormal	O
activation	O
of	O
NFkappaB	O
is	O
also	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
and	O
may	O
also	O
revert	O
to	O
normal	O
during	O
IL-2/IFN	O
alpha-based	O
treatment	O
.	O

This	O
alteration	O
in	O
NFkappaB	O
activation	O
occurred	O
in	O
the	O
presence	O
of	O
normal	O
expression	O
of	O
TCRzeta-associated	O
signaling	O
elements	O
.	O

The	O
clinical	O
significance	O
of	O
these	O
findings	O
remains	O
unclear	O
.	O

Transcriptional	O
regulation	O
of	O
lysosomal	O
acid	O
lipase	O
in	O
differentiating	O
monocytes	O
is	O
mediated	O
by	O
transcription	O
factors	O
Sp1	O
and	O
AP-2	O
.	O

Human	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
is	O
a	O
hydrolase	O
required	O
for	O
the	O
cleavage	O
of	O
cholesteryl	O
esters	O
and	O
triglycerides	O
derived	O
from	O
plasma	O
lipoproteins	O
.	O

It	O
is	O
shown	O
here	O
that	O
during	O
monocyte	O
to	O
macrophage	O
differentiation	O
,	O
the	O
expression	O
of	O
LAL-mRNA	O
is	O
induced	O
.	O

This	O
induction	O
is	O
dependent	O
on	O
protein	O
kinase	O
C	O
activity	O
and	O
protein	O
synthesis	O
.	O

The	O
cell	O
type-specific	O
increase	O
in	O
LAL	O
expression	O
is	O
further	O
investigated	O
in	O
the	O
THP-1	O
cell	O
line	O
with	O
respect	O
to	O
transcriptional	O
regulation	O
.	O

The	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
differentiates	O
into	O
macrophage-like	O
cells	O
when	O
treated	O
with	O
phorbol	O
esters	O
.	O

In	O
order	O
to	O
determine	O
the	O
cis-acting	O
elements	O
necessary	O
for	O
both	O
basal	O
and	O
phorbol	O
12-myristate-13	O
acetate	O
(	O
PMA	O
)	O
-enhanced	O
promoter	O
activity	O
,	O
we	O
performed	O
deletion	O
analysis	O
and	O
reporter	O
gene	O
assays	O
.	O

A	O
PMA	O
responsive	O
element	O
has	O
been	O
identified	O
between	O
-182	O
bp	O
and	O
-107	O
bp	O
upstream	O
of	O
the	O
major	O
transcription	O
start	O
site	O
.	O

Gel	O
mobility	O
shift	O
assays	O
demonstrated	O
that	O
binding	O
of	O
Sp1	O
and	O
AP-2	O
to	O
the	O
LAL	O
promoter	O
is	O
increased	O
by	O
PMA	O
in	O
THP-1	O
cells	O
.	O

Co-transfections	O
with	O
expression	O
plasmids	O
for	O
Sp1	O
and	O
AP-2	O
further	O
emphasized	O
the	O
important	O
role	O
of	O
these	O
transcription	O
factors	O
in	O
both	O
basal	O
and	O
PMA-enhanced	O
LAL	O
expression	O
.	O

Our	O
data	O
suggest	O
that	O
differentiation	O
dependent	O
increase	O
of	O
lysosomal	O
acid	O
lipase	O
(	O
LAL	O
)	O
expression	O
in	O
THP-1	O
cells	O
is	O
mediated	O
by	O
a	O
concerted	O
action	O
of	O
Sp1	O
and	O
AP-2	O
.	O

A	O
nongenomic	O
mechanism	O
for	O
progesterone-mediated	O
immunosuppression	O
:	O
inhibition	O
of	O
K+	O
channels	O
,	O
Ca2+	O
signaling	O
,	O
and	O
gene	O
expression	O
in	O
T	O
lymphocytes	O
.	O

The	O
mechanism	O
by	O
which	O
progesterone	O
causes	O
localized	O
suppression	O
of	O
the	O
immune	O
response	O
during	O
pregnancy	O
has	O
remained	O
elusive	O
.	O

Using	O
human	O
T	O
lymphocytes	O
and	O
T	O
cell	O
lines	O
,	O
we	O
show	O
that	O
progesterone	O
,	O
at	O
concentrations	O
found	O
in	O
the	O
placenta	O
,	O
rapidly	O
and	O
reversibly	O
blocks	O
voltage-gated	O
and	O
calcium-activated	O
K+	O
channels	O
(	O
KV	O
and	O
KCa	O
,	O
respectively	O
)	O
,	O
resulting	O
in	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

As	O
a	O
result	O
,	O
Ca2+	O
signaling	O
and	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NF-AT	O
)	O
-driven	O
gene	O
expression	O
are	O
inhibited	O
.	O

Progesterone	O
acts	O
distally	O
to	O
the	O
initial	O
steps	O
of	O
T	O
cell	O
receptor	O
(	O
TCR	O
)	O
-mediated	O
signal	O
transduction	O
,	O
since	O
it	O
blocks	O
sustained	O
Ca2+	O
signals	O
after	O
thapsigargin	O
stimulation	O
,	O
as	O
well	O
as	O
oscillatory	O
Ca2+	O
signals	O
,	O
but	O
not	B-Negation
the	I-Negation
Ca2+	I-Negation
transient	I-Negation
after	I-Negation
TCR	I-Negation
stimulation	I-Negation
.	O

K+	O
channel	O
blockade	O
by	O
progesterone	O
is	O
specific	O
;	O
other	O
steroid	O
hormones	O
had	O
little	O
or	O
no	B-Negation
effect	I-Negation
,	O
although	O
the	O
progesterone	O
antagonist	O
RU	O
486	O
also	O
blocked	O
KV	O
and	O
KCa	O
channels	O
.	O

Progesterone	O
effectively	O
blocked	O
a	O
broad	O
spectrum	O
of	O
K+	O
channels	O
,	O
reducing	O
both	O
Kv1.3	O
and	O
charybdotoxin-resistant	O
components	O
of	O
KV	O
current	O
and	O
KCa	O
current	O
in	O
T	O
cells	O
,	O
as	O
well	O
as	O
blocking	O
several	O
cloned	O
KV	O
channels	O
expressed	O
in	O
cell	O
lines	O
.	O

Progesterone	O
had	O
little	O
or	O
no	B-Negation
effect	I-Negation
on	I-Negation
a	I-Negation
cloned	I-Negation
voltage-gated	I-Negation
Na+	I-Negation
channel	I-Negation
,	I-Negation
an	I-Negation
inward	I-Negation
rectifier	I-Negation
K+	I-Negation
channel	I-Negation
,	I-Negation
or	I-Negation
on	I-Negation
lymphocyte	I-Negation
Ca2+	I-Negation
and	I-Negation
Cl-	I-Negation
channels	I-Negation
.	O

We	O
propose	O
that	O
direct	O
inhibition	O
of	O
K+	O
channels	O
in	O
T	O
cells	O
by	O
progesterone	O
contributes	O
to	O
progesterone-induced	O
immunosuppression	O
.	O

Role	O
of	O
IKK1	O
and	O
IKK2	O
in	O
lipopolysaccharide	O
signaling	O
in	O
human	O
monocytic	O
cells	O
.	O

Mononuclear	O
phagocytes	O
play	O
a	O
major	O
role	O
in	O
immune	O
and	O
inflammatory	O
responses	O
.	O

Bacterial	O
lipopolysaccharide	O
(	O
LPS	O
)	O
induces	O
monocytes	O
to	O
express	O
a	O
variety	O
of	O
genes	O
by	O
activating	O
the	O
NF-kappaB/Rel	O
transcription	O
factor	O
family	O
.	O

Recently	O
,	O
we	O
have	O
reported	O
that	O
the	O
tumor	O
necrosis	O
factor	O
and	O
interleukin	O
1	O
signaling	O
pathways	O
activate	O
two	O
kinases	O
,	O
IKK1	O
and	O
IKK2	O
.	O

Phosphorylation	O
of	O
the	O
IkappaB	O
cytoplasmic	O
inhibitors	O
,	O
IkappaBalpha	O
,	O
IkappaBbeta	O
,	O
and	O
IkappaBepsilon	O
,	O
by	O
these	O
kinases	O
triggers	O
proteolytic	O
degradation	O
and	O
the	O
release	O
of	O
NF-kappaB/Rel	O
proteins	O
into	O
the	O
nucleus	O
.	O

At	O
present	O
,	O
the	B-Negation
role	I-Negation
of	I-Negation
the	I-Negation
IKKs	I-Negation
in	I-Negation
LPS	I-Negation
signaling	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
investigated	I-Negation
.	O

Here	O
,	O
we	O
report	O
that	O
LPS	O
induces	O
IKK	O
activity	O
in	O
human	O
monocytes	O
and	O
THP-1	O
monocytic	O
cells	O
.	O

The	O
kinetics	O
of	O
activation	O
of	O
kinase	O
activity	O
in	O
monocytic	O
cells	O
are	O
relatively	O
slow	O
with	O
maximal	O
activity	O
observed	O
at	O
60	O
min	O
,	O
which	O
coincides	O
with	O
the	O
degradation	O
of	O
IkappaBs	O
and	O
the	O
nuclear	O
translocation	O
of	O
NF-kappaB	O
.	O

In	O
transfection	O
experiments	O
,	O
overexpression	O
of	O
wild	O
type	O
IKK1	O
,	O
a	O
dominant	O
negative	O
mutant	O
IKK1	O
(	O
K44M	O
)	O
,	O
or	O
wild	O
type	O
IKK2	O
did	O
not	B-Negation
affect	I-Negation
LPS-induced	I-Negation
kappaB-dependent	I-Negation
transcription	I-Negation
in	I-Negation
monocytic	I-Negation
cells	I-Negation
.	O

In	O
contrast	O
,	O
a	O
dominant	O
negative	O
mutant	O
of	O
IKK2	O
inhibited	O
LPS	O
induction	O
of	O
kappaB-dependent	O
transcription	O
in	O
a	O
dose-dependent	O
manner	O
.	O

These	O
results	O
indicate	O
that	O
LPS	O
induction	O
of	O
kappaB-dependent	O
gene	O
expression	O
in	O
human	O
monocytic	O
cells	O
requires	O
activation	O
of	O
IKK2	O
.	O

Effects	O
of	O
overexpression	O
of	O
IL-1	O
receptor-associated	O
kinase	O
on	O
NFkappaB	O
activation	O
,	O
IL-2	O
production	O
and	O
stress-activated	O
protein	O
kinases	O
in	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
.	O

The	O
association	O
and	O
activation	O
of	O
the	O
IL-1	O
receptor-associated	O
protein	O
kinase	O
(	O
IRAK	O
)	O
to	O
the	O
IL-1	O
receptor	O
complex	O
is	O
one	O
of	O
the	O
earliest	O
events	O
detectable	O
in	O
IL-1	O
signal	O
transduction	O
.	O

We	O
generated	O
permanent	O
clones	O
of	O
the	O
murine	O
T	O
cell	O
line	O
EL4	O
6.1	O
overexpressing	O
human	O
(	O
h	O
)	O
IRAK	O
to	O
evaluate	O
the	O
role	O
of	O
this	O
kinase	O
in	O
IL-1	O
signaling	O
.	O

Overexpression	O
of	O
hIRAK	O
enhanced	O
IL-1-stimulated	O
activation	O
of	O
the	O
transcription	O
factor	O
NFkappaB	O
,	O
whereas	O
a	O
truncated	O
form	O
(	O
N-IRAK	O
)	O
specifically	O
inhibited	O
IL-1-dependent	O
NFkappaB	O
activity	O
.	O

In	O
clones	O
stably	O
overexpressing	O
hIRAK	O
a	O
weak	O
constitutive	O
activation	O
of	O
NFkappaB	O
correlated	O
with	O
a	O
low	O
basal	O
IL-2	O
production	O
which	O
was	O
enhanced	O
in	O
an	O
IL-1-dependent	O
manner	O
.	O

Compared	O
to	O
the	O
parental	O
cell	O
line	O
the	O
dose-response	O
curve	O
of	O
IL-1-induced	O
IL-2	O
production	O
was	O
shifted	O
in	O
both	O
potency	O
and	O
efficacy	O
.	O

These	O
results	O
demonstrate	O
that	O
IRAK	O
directly	O
triggers	O
NFkappaB-mediated	O
gene	O
expression	O
in	O
EL4	O
cells	O
.	O

Qualitatively	O
different	O
effects	O
were	O
observed	O
for	O
the	O
IL-1-induced	O
activation	O
of	O
stress-activated	O
protein	O
(	O
SAP	O
)	O
kinases	O
:	O
permanent	O
overexpression	O
of	O
IRAK	O
did	O
not	B-Negation
affect	I-Negation
the	I-Negation
dose	I-Negation
dependence	I-Negation
but	O
prolonged	O
the	O
kinetics	O
of	O
IL-1-induced	O
activation	O
of	O
SAP	O
kinases	O
,	O
suggesting	B-Speculation
that	I-Speculation
this	I-Speculation
signaling	I-Speculation
branch	I-Speculation
may	I-Speculation
be	I-Speculation
regulated	I-Speculation
by	I-Speculation
distinct	I-Speculation
mechanisms	I-Speculation
.	O

Decreased	O
IL-12	O
production	O
and	O
Th1	O
cell	O
development	O
by	O
acetyl	O
salicylic	O
acid-mediated	O
inhibition	O
of	O
NF-kappaB	O
.	O

IL-12	O
is	O
a	O
75-kDa	O
heterodimeric	O
cytokine	O
composed	O
of	O
two	O
covalently	O
linked	O
p35	O
and	O
p40	O
chains	O
.	O

This	O
pro-inflammatory	O
cytokine	O
plays	O
a	O
prominent	O
role	O
in	O
the	O
development	O
of	O
Th1	O
cell-mediated	O
immune	O
responses	O
.	O

Th1	O
cell-mediated	O
immune	O
responses	O
have	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
chronic	O
inflammatory	O
autoimmune	O
diseases	O
.	O

Thus	O
,	O
IL-12	O
appears	O
to	O
be	O
a	O
critical	O
factor	O
in	O
the	O
generation	O
and	O
maintenance	O
of	O
chronic	O
inflammatory	O
conditions	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
a	O
commonly	O
prescribed	O
anti-inflammatory	O
drug	O
,	O
acetyl	O
salicylic	O
acid	O
(	O
ASA	O
)	O
,	O
on	O
IL-12	O
production	O
and	O
Th1	O
cell	O
development	O
.	O

ASA	O
was	O
found	O
to	O
inhibit	O
secretion	O
of	O
the	O
IL-12	O
heterodimer	O
as	O
well	O
as	O
p40	O
monomer	O
by	O
human	O
monocytic	O
cells	O
.	O

This	O
was	O
associated	O
with	O
the	O
down-regulation	O
of	O
IL-12p40	O
mRNA	O
expression	O
.	O

Analysis	O
of	O
the	O
regulation	O
of	O
the	O
p40	O
gene	O
promoter	O
revealed	O
that	O
ASA	O
inhibited	O
NF-kappaB	O
activation	O
and	O
binding	O
to	O
the	O
p40-kappaB	O
site	O
in	O
the	O
p40	O
promoter	O
,	O
leading	O
to	O
transcriptional	O
repression	O
of	O
the	O
p40	O
gene	O
.	O

Addition	O
of	O
ASA	O
to	O
an	O
in	O
vitro	O
T	O
helper	O
cell	O
differentiation	O
system	O
,	O
at	O
concentrations	O
compatible	O
with	O
plasma	O
levels	O
reached	O
during	O
anti-inflammatory	O
therapy	O
,	O
resulted	O
in	O
reduced	O
development	O
of	O
Th1	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
inhibition	O
of	O
NF-kappaB	O
activation	O
by	O
ASA	O
leads	O
to	O
down-regulation	O
of	O
IL-12	O
production	O
and	O
inhibition	O
of	O
Th1	O
cell	O
development	O
.	O

YM268	O
increases	O
the	O
glucose	O
uptake	O
,	O
cell	O
differentiation	O
,	O
and	O
mRNA	O
expression	O
of	O
glucose	O
transporter	O
in	O
3T3-L1	O
adipocytes	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
bis	O
[	O
4-	O
[	O
2,4-dioxo-5-thiazolidinyl	O
)	O
methyl	O
]	O
phenyl	O
]	O
methane	O
(	O
YM-268	O
)	O
,	O
a	O
thiazolidinedione	O
derivative	O
,	O
on	O
glucose	O
uptake	O
,	O
adipocyte	O
differentiation	O
through	O
peroxisome	O
proliferator-activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
,	O
and	O
phosphatidylinositol	O
3-kinase	O
(	O
PI	O
3-kinase	O
)	O
activity	O
in	O
cultured	O
cells	O
.	O

YM268	O
and	O
pioglitazone	O
dose-dependently	O
increased	O
the	O
2-deoxyglucose	O
uptake	O
in	O
3T3-L1	O
cells	O
.	O

YM268	O
facilitated	O
the	O
insulin-stimulated	O
triglyceride	O
accumulation	O
in	O
3T3-L1	O
adipocytes	O
and	O
increased	O
the	O
mRNA	O
expression	O
of	O
fatty	O
acid-binding	O
protein	O
.	O

YM268	O
,	O
with	O
and	O
without	B-Negation
insulin	I-Negation
,	O
increased	O
the	O
mRNA	O
expression	O
of	O
glucose	O
transporter	O
isoforms	O
such	O
as	O
GLUT1	O
and	O
GLUT4	O
,	O
indicating	O
enhancement	O
of	O
adipocyte	O
differentiation	O
.	O

Additionally	O
,	O
YM268	O
and	O
pioglitazone	O
showed	O
activity	O
of	O
the	O
PPARgamma	O
ligand	O
,	O
a	O
member	O
of	O
the	O
nuclear	O
receptor	O
superfamily	O
responsible	O
for	O
adipogenesis	O
.	O

To	O
examine	O
the	O
possible	O
involvement	O
of	O
the	O
increased	O
activity	O
of	O
PI	O
3-kinase	O
in	O
YM268-stimulated	O
glucose	O
uptake	O
,	O
the	O
enzyme	O
activity	O
was	O
estimated	O
by	O
measuring	O
the	O
phosphatidylinositol-3,4,5-trisphosphate	O
(	O
PI-3,4,5-P3	O
)	O
concentration	O
in	O
human	O
monocytic	O
cells	O
.	O

Insulin	O
dose-dependently	O
increased	O
the	O
PI-3,4,5-P3	O
production	O
but	O
YM268	O
had	O
no	B-Negation
significant	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
insulin-dependent	I-Negation
and	I-Negation
-independent	I-Negation
PI	I-Negation
3-kinase	I-Negation
activation	I-Negation
.	O

These	O
results	O
indicate	O
that	O
the	O
mechanism	O
by	O
which	O
YM268	O
increased	O
glucose	O
uptake	O
,	O
may	O
be	O
accounted	O
for	O
in	O
part	O
by	O
the	O
enhancement	O
of	O
GLUT1	O
and	O
GLUT4	O
expression	O
through	O
PPARgamma	O
activation	O
.	O

Interaction	O
of	O
sickle	O
erythrocytes	O
with	O
endothelial	O
cells	O
in	O
the	O
presence	O
of	O
endothelial	O
cell	O
conditioned	O
medium	O
induces	O
oxidant	O
stress	O
leading	O
to	O
transendothelial	O
migration	O
of	O
monocytes	O
.	O

The	O
abnormal	O
adherence	O
of	O
sickle	O
red	O
blood	O
cells	O
(	O
SS	O
RBC	O
)	O
to	O
endothelial	O
cells	O
has	O
been	O
thought	O
to	O
contribute	O
to	O
vascular	O
occlusion	O
,	O
a	O
major	O
cause	O
of	O
morbidity	O
in	O
sickle	O
cell	O
disease	O
(	O
SCD	O
)	O
.	O

We	O
determined	O
whether	O
the	O
interaction	O
of	O
SS	O
RBC	O
with	O
cultured	O
endothelial	O
cells	O
induced	O
cellular	O
oxidant	O
stress	O
that	O
would	O
culminate	O
in	O
expression	O
of	O
cell	O
adhesion	O
molecules	O
(	O
CAMs	O
)	O
involved	O
in	O
the	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
and	O
the	O
adherence	O
of	O
SS	O
reticulocytes	O
.	O

We	O
showed	O
that	O
the	O
interaction	O
of	O
SS	O
RBC	O
at	O
2	O
%	O
concentration	O
in	O
the	O
presence	O
of	O
multimers	O
of	O
von	O
Willebrand	O
factor	O
(	O
vWf	O
)	O
,	O
derived	O
from	O
endothelial	O
cell-derived	O
conditioned	O
medium	O
(	O
E-CM	O
)	O
with	O
cultured	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
,	O
resulted	O
in	O
a	O
fivefold	O
increased	O
formation	O
of	O
thiobarbituric	O
acid-reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
activation	O
of	O
the	O
transcription	O
factor	O
NF-kB	O
,	O
both	O
indicators	O
of	O
cellular	O
oxidant	O
stress	O
.	O

Normal	O
RBC	O
show	O
none	B-Negation
of	I-Negation
these	I-Negation
phenomena	I-Negation
.	O

The	O
oxidant	O
stress-induced	O
signaling	O
resulted	O
in	O
an	O
increased	O
surface	O
expression	O
of	O
a	O
subset	O
of	O
CAMs	O
,	O
ICAM-1	O
,	O
E-selectin	O
,	O
and	O
VCAM-1	O
in	O
HUVEC	O
.	O

The	O
addition	O
of	O
oxygen	O
radical	O
scavenger	O
enzymes	O
(	O
catalase	O
,	O
superoxide	O
dismutase	O
)	O
and	O
antioxidant	O
(	O
probucol	O
)	O
inhibited	O
these	O
events	O
.	O

Additionally	O
,	O
preincubation	O
of	O
HUVEC	O
with	O
a	O
synthetic	O
peptide	O
Arg-Gly-Asp	O
(	O
RGD	O
)	O
that	O
prevents	O
vWf-mediated	O
adhesion	O
of	O
SS	O
RBC	O
reduced	O
the	O
surface	O
expression	O
of	O
VCAM-1	O
and	O
NF-kB	O
activation	O
.	O

Furthermore	O
,	O
SS	O
RBC-induced	O
oxidant	O
stress	O
resulted	O
in	O
a	O
twofold	O
increase	O
in	O
the	O
transendothelial	O
migration	O
of	O
both	O
monocyte-like	O
HL-60	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
,	O
and	O
approximately	O
a	O
sixfold	O
increase	O
in	O
platelet-endothelial	O
cell	O
adhesion	O
molecule-1	O
(	O
PECAM-1	O
)	O
phosphorylation	O
,	O
each	O
of	O
which	O
was	O
blocked	O
by	O
protein	O
kinase	O
C	O
inhibitor	O
and	O
antioxidants	O
.	O

These	O
results	O
suggest	O
that	O
the	O
adherence/contact	O
of	O
SS	O
RBC	O
to	O
endothelial	O
cells	O
in	O
large	O
vessel	O
can	O
generate	O
enhanced	O
oxidant	O
stress	O
leading	O
to	O
increased	O
adhesion	O
and	O
diapedesis	O
of	O
monocytes	O
,	O
as	O
well	O
as	O
heightened	O
adherence	O
of	O
SS	O
reticulocytes	O
,	O
indicating	O
that	O
injury/activation	O
of	O
endothelium	O
can	O
contribute	O
to	O
vaso-occlusion	O
in	O
SCD	O
.	O

Tobacco	O
smoke	O
induces	O
coordinate	O
activation	O
of	O
HSF	O
and	O
inhibition	O
of	O
NFkappaB	O
in	O
human	O
monocytes	O
:	O
effects	O
on	O
TNFalpha	O
release	O
.	O

Tobacco	O
smoke	O
(	O
TS	O
)	O
exposure	O
is	O
a	O
major	O
risk	O
factor	O
for	O
human	O
disease	O
,	O
and	O
macrophages	O
of	O
healthy	O
smokers	O
have	O
a	O
depressed	O
capacity	O
to	O
release	O
cytokines	O
,	O
including	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
alpha	O
.	O

TS	O
induces	O
the	O
synthesis	O
of	O
heat	O
shock	O
(	O
HS	O
)	O
/stress	O
proteins	O
(	O
HSP	O
)	O
,	O
and	O
,	O
in	O
particular	O
,	O
of	O
Hsp70	O
.	O

We	O
determined	O
whether	O
Hsp70	O
induction	O
by	O
TS	O
was	O
mediated	O
by	O
the	O
activation	O
of	O
the	O
HS	O
transcription	O
factor	O
,	O
HSF	O
.	O

HSF	O
activation	O
has	O
been	O
shown	O
to	O
inhibit	O
NFkappaB	O
.	O

Thus	O
,	O
we	O
also	O
determined	O
the	O
effects	O
of	O
TS	O
on	O
NFkappaB	O
.	O

U937	O
cells	O
and	O
human	O
peripheral	O
blood	O
monocytes	O
were	O
exposed	O
to	O
TS	O
,	O
binding	O
activities	O
of	O
the	O
respective	O
transcription	O
factors	O
were	O
analyzed	O
,	O
and	O
Hsp70	O
expression	O
and	O
TNFalpha	O
release	O
were	O
determined	O
in	O
parallel	O
.	O

TS	O
activated	O
HSF	O
,	O
which	O
was	O
associated	O
with	O
Hsp70	O
overexpression	O
and	O
inhibition	O
of	O
NFkappaB	O
binding	O
activity	O
and	O
TNFalpha	O
release	O
.	O

The	O
altered	O
cytokine	O
profile	O
observed	O
in	O
smokers	O
may	O
relate	O
to	O
an	O
HSF/Hsp70-mediated	O
inhibition	O
of	O
NFkappaB	O
activity	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
beta-casein	O
gene	O
by	O
cytokines	O
:	O
cross-talk	O
between	O
STAT5	O
and	O
other	O
signaling	O
molecules	O
.	O

The	O
beta-casein	O
promoter	O
has	O
been	O
widely	O
used	O
to	O
monitor	O
the	O
activation	O
of	O
STAT	O
(	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
)	O
5	O
since	O
STAT5	O
was	O
originally	O
found	O
as	O
a	O
mediator	O
of	O
PRL-inducible	O
beta-casein	O
expression	O
.	O

However	O
,	O
not	O
only	O
is	O
expression	O
of	O
the	O
beta-casein	O
gene	O
regulated	O
by	O
STAT5	O
but	O
it	O
is	O
also	O
affected	O
by	O
other	O
molecules	O
such	O
as	O
glucocorticoid	O
and	O
Ras	O
.	O

In	O
this	O
report	O
,	O
we	O
describe	O
the	O
transcriptional	O
regulation	O
of	O
the	O
beta-casein	O
gene	O
by	O
cytokines	O
in	O
T	O
cells	O
.	O

We	O
have	O
found	O
that	O
the	O
beta-casein	O
gene	O
is	O
expressed	O
in	O
a	O
cytotoxic	O
T	O
cell	O
line	O
,	O
CTLL-2	O
,	O
in	O
response	O
to	O
interleukin-2	O
(	O
IL-2	O
)	O
,	O
which	O
activates	O
STAT5	O
.	O

While	O
IL-4	O
does	O
not	B-Negation
activate	I-Negation
STAT5	I-Negation
,	O
it	O
induces	O
expression	O
of	O
STAT5-regulated	O
genes	O
in	O
CTLL-2	O
,	O
i.e.	O
beta-casein	O
,	O
a	O
cytokine-inducible	O
SH2-containing	O
protein	O
(	O
CIS	O
)	O
,	O
and	O
oncostatin	O
M	O
(	O
OSM	O
)	O
,	O
suggesting	B-Speculation
that	I-Speculation
STAT6	I-Speculation
activated	I-Speculation
by	I-Speculation
IL-4	I-Speculation
substitutes	I-Speculation
for	I-Speculation
the	I-Speculation
function	I-Speculation
of	I-Speculation
STAT5	I-Speculation
in	I-Speculation
T	I-Speculation
cells	I-Speculation
.	O

IL-2-induced	O
beta-casein	O
expression	O
was	O
enhanced	O
by	O
dexamethasone	O
,	O
and	O
this	O
synergistic	O
effect	O
of	O
Dexamethasone	O
requires	O
the	O
sequence	O
between	O
-155	O
and	O
-193	O
in	O
the	O
beta-casein	O
promoter	O
.	O

Coincidentally	O
,	O
a	O
deletion	O
of	O
this	O
region	O
enhanced	O
the	O
IL-2-induced	O
expression	O
of	O
beta-casein	O
.	O

Expression	O
of	O
an	O
active	O
form	O
of	O
Ras	O
,	O
Ras	O
(	O
G12V	O
)	O
,	O
suppressed	O
the	O
IL-2-induced	O
beta-casein	O
and	O
OSM	O
gene	O
expression	O
,	O
and	O
the	O
negative	O
effect	O
of	O
Ras	O
is	O
mediated	O
by	O
the	O
region	O
between	O
-105	O
and	O
-193	O
in	O
the	O
beta-casein	O
promoter	O
.	O

In	O
apparent	O
contradiction	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
form	O
of	O
Ras	O
,	O
RasN17	O
,	O
also	O
inhibited	O
IL-2-induced	O
activation	O
of	O
the	O
promoter	O
containing	O
the	O
minimal	O
beta-casein	O
STAT5	O
element	O
as	O
well	O
as	O
the	O
promoters	O
of	O
CIS	O
and	O
OSM	O
.	O

In	O
addition	O
,	O
Ras	O
(	O
G12V	O
)	O
complemented	O
signaling	O
by	O
an	O
erythropoietin	O
receptor	O
mutant	O
defective	O
in	O
Ras	O
activation	O
and	O
augmented	O
the	O
activation	O
of	O
the	O
beta-casein	O
promoter	O
by	O
the	O
mutant	O
erythropoietin	O
receptor	O
signaling	O
,	O
suggesting	O
a	O
possible	O
role	O
of	O
Ras	O
in	O
Stat5-mediated	O
gene	O
expression	O
.	O

These	O
results	O
collectively	O
reveal	O
a	O
complex	O
interaction	O
of	O
STAT5	O
with	O
other	O
signaling	O
pathways	O
and	O
illustrate	O
that	O
regulation	O
of	O
gene	O
expression	O
requires	O
integration	O
of	O
opposing	O
signals	O
.	O

Transcription	O
factor	O
NF-kappaB	O
regulation	O
of	O
renal	O
fibrosis	O
during	O
ureteral	O
obstruction	O
.	O

Irrespective	O
of	O
the	O
etiology	O
,	O
many	O
kidney	O
diseases	O
result	O
in	O
inflammation	O
and	O
fibrosis	O
of	O
the	O
tubulointerstitium	O
,	O
with	O
the	O
subsequent	O
loss	O
of	O
renal	O
function	O
.	O

To	O
initiate	O
any	O
disease	O
process	O
or	O
for	O
any	O
disease	O
process	O
to	O
progress	O
,	O
there	O
must	O
be	O
changes	O
in	O
the	O
transcription	O
of	O
genes	O
within	O
the	O
affected	O
tissue	O
.	O

The	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	O
)	O
family	O
of	O
transcription	O
factors	O
regulates	O
genes	O
involved	O
in	O
inflammation	O
,	O
cell	O
proliferation	O
,	O
and	O
cell	O
differentiation	O
.	O

This	O
review	O
discusses	O
the	O
NF-kappaB	O
transcription	O
factor	O
family	O
in	O
general	O
and	O
the	O
association	O
of	O
NF-kappaB	O
activation	O
with	O
cellular/molecular	O
events	O
of	O
renal	O
inflammation	O
and	O
fibrosis	O
.	O

TAL1	O
and	O
LIM-only	O
proteins	O
synergistically	O
induce	O
retinaldehyde	O
dehydrogenase	O
2	O
expression	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
by	O
acting	O
as	O
cofactors	O
for	O
GATA3	O
.	O

Previously	O
,	O
we	O
have	O
shown	O
that	O
TAL1	O
and	O
the	O
LIM-only	O
protein	O
gene	O
(	O
LMO	O
)	O
are	O
regularly	O
coactivated	O
in	O
T-cell	O
acute	O
lymphoblastic	O
leukemia	O
(	O
T-ALL	O
)	O
.	O

This	O
observation	O
is	O
likely	O
to	O
relate	O
to	O
the	O
findings	O
that	O
TAL1	O
and	O
LMO	O
are	O
highly	O
synergistic	O
in	O
T-cell	O
tumorigenesis	O
in	O
double-transgenic	O
mice	O
.	O

To	O
understand	O
the	O
molecular	O
mechanisms	O
of	O
functional	O
synergy	O
between	O
TAL1	O
and	O
LMO	O
in	O
tumorigenesis	O
and	O
transcriptional	O
regulation	O
,	O
we	O
tried	O
to	O
identify	O
downstream	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
by	O
a	O
subtractive	O
PCR	O
method	O
.	O

One	O
of	O
the	O
isolated	O
genes	O
,	O
that	O
for	O
retinaldehyde	O
dehydrogenase	O
2	O
(	O
RALDH2	O
)	O
,	O
was	O
regularly	O
expressed	O
in	O
most	O
of	O
the	O
T-ALL	O
cell	O
lines	O
that	O
coexpressed	O
TAL1	O
and	O
LMO	O
.	O

Exogenously	O
transfected	O
TAL1	O
and	O
LMO	O
,	O
but	O
not	B-Negation
either	I-Negation
alone	I-Negation
,	O
induced	O
RALDH2	O
expression	O
in	O
a	O
T-ALL	O
cell	O
line	O
,	O
HPB-ALL	O
,	O
not	B-Negation
expressing	I-Negation
endogeneous	I-Negation
TAL1	I-Negation
or	I-Negation
LMO	I-Negation
.	O

The	O
RALDH2	O
transcripts	O
in	O
T-ALL	O
were	O
,	O
however	O
,	O
mostly	O
initiated	O
within	O
the	O
second	O
intron	O
.	O

Promoter	O
analysis	O
revealed	O
that	O
a	O
GATA	O
site	O
in	O
a	O
cryptic	O
promoter	O
in	O
the	O
second	O
intron	O
was	O
essential	O
and	O
sufficient	O
for	O
the	O
TAL1-	O
and	O
LMO-dependent	O
transcriptional	O
activation	O
,	O
and	O
GATA3	O
binds	O
to	O
this	O
site	O
.	O

In	O
addition	O
,	O
forced	O
expression	O
of	O
GATA3	O
potentiated	O
the	O
induction	O
of	O
RALDH2	O
by	O
TAL1	O
and	O
LMO	O
,	O
and	O
these	O
three	O
factors	O
formed	O
a	O
complex	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
TAL1	O
mutant	O
not	B-Negation
binding	I-Negation
to	I-Negation
DNA	I-Negation
also	O
activated	O
the	O
transcription	O
of	O
RALDH2	O
in	O
the	O
presence	O
of	O
LMO	O
and	O
GATA3	O
.	O

Collectively	O
,	O
we	O
have	O
identified	O
the	O
RALDH2	O
gene	O
as	O
a	O
first	O
example	O
of	O
direct	O
transcriptional	O
target	O
genes	O
regulated	O
by	O
TAL1	O
and	O
LMO	O
in	O
T-ALL	O
.	O

In	O
this	O
case	O
,	O
TAL1	O
and	O
LMO	O
act	O
as	O
cofactors	O
for	O
GATA3	O
to	O
activate	O
the	O
transcription	O
of	O
RALDH2	O
.	O

Granulocyte	O
colony-stimulating	O
factor	O
activates	O
a	O
72-kDa	O
isoform	O
of	O
STAT3	O
in	O
human	O
neutrophils	O
.	O

Granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
signaling	O
involves	O
activation	O
of	O
STATs	O
,	O
proteins	O
that	O
serve	O
the	O
dual	O
function	O
of	O
signal	O
transduction	O
and	O
activation	O
of	O
transcription	O
.	O

We	O
previously	O
demonstrated	O
that	O
G-CSF	O
activated	O
a	O
distinct	O
Stat3-like	O
protein	O
in	O
immature	O
and	O
mature	O
normal	O
myeloid	O
cells	O
,	O
StatG	O
.	O

StatG	O
in	O
normal	O
immature	O
human	O
myeloid	O
cells	O
,	O
i.e.	O
adult	O
CD34+	O
bone	O
marrow	O
cells	O
,	O
was	O
composed	O
of	O
Stat3beta	O
.	O

This	O
investigation	O
was	O
undertaken	O
to	O
determine	O
the	O
composition	O
of	O
StatG	O
in	O
mature	O
normal	O
human	O
myeloid	O
cells	O
,	O
i.e.	O
polymorphonuclear	O
neutrophilic	O
granulocytes	O
(	O
PMN	O
)	O
.	O

These	O
studies	O
revealed	O
that	O
the	O
major	O
protein	O
in	O
extracts	O
of	O
PMN	O
activated	O
by	O
G-CSF	O
to	O
bind	O
the	O
high-affinity	O
serum-inducible	O
element	O
(	O
hSIE	O
)	O
is	O
a	O
72-kDa	O
protein	O
that	O
cross-reacts	O
with	O
Stat3	O
monoclonal	O
antibody	O
,	O
which	O
we	O
have	O
designated	O
Stat3gamma	O
.	O

Stat3gamma	O
is	O
derived	O
from	O
Stat3alpha	O
by	O
limited	O
proteolysis	O
and	O
lacks	B-Negation
the	I-Negation
carboxyl-terminal	I-Negation
portion	I-Negation
of	I-Negation
Stat3alpha	I-Negation
.	O

Because	O
this	O
region	O
of	O
Stat3alpha	O
is	O
involved	O
in	O
transcriptional	O
activation	O
,	O
our	O
findings	O
suggest	O
the	O
possibility	O
that	O
Stat3gamma	O
may	O
be	O
transcriptionally	O
inactive	O
and	O
may	O
compete	O
with	O
Stat3alpha	O
for	O
Stat3	O
binding	O
sites	O
in	O
these	O
terminally	O
differentiated	O
myeloid	O
cells	O
.	O

Differential	O
effects	O
of	O
protein	O
kinase	O
C	O
inhibitors	O
on	O
fibronectin-induced	O
interleukin-beta	O
gene	O
transcription	O
,	O
protein	O
synthesis	O
and	O
secretion	O
in	O
human	O
monocytic	O
cells	O
.	O

Human	O
monocytic	O
cells	O
express	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
when	O
stimulated	O
with	O
the	O
extracellular	O
matrix	O
glycoprotein	O
,	O
fibronectin	O
(	O
FN	O
)	O
.	O

Protein	O
kinase	O
C	O
(	O
PKC	O
)	O
activation	O
is	O
considered	O
important	O
for	O
this	O
process	O
;	O
however	O
,	O
the	O
metabolic	O
steps	O
at	O
which	O
PKC	O
acts	O
upon	O
to	O
mediate	O
the	O
FN-induced	O
IL-1beta	O
response	O
remain	O
unclear	O
.	O

We	O
performed	O
an	O
analysis	O
of	O
the	O
mechanisms	O
by	O
which	O
two	O
PKC	O
inhibitors	O
,	O
Calphostin	O
C	O
and	O
Staurosporine	O
,	O
prevent	O
the	O
FN-induced	O
IL-1beta	O
response	O
.	O

Both	O
inhibitors	O
blocked	O
the	O
secretion	O
of	O
IL-1beta	O
protein	O
into	O
the	O
media	O
of	O
peripheral	O
blood	O
mononuclear	O
cells	O
exposed	O
to	O
FN	O
.	O

Immunoprecipitation	O
analysis	O
revealed	O
that	O
under	O
these	O
circumstances	O
,	O
Calphostin	O
C	O
inhibited	O
the	O
production	O
of	O
IL-1beta	O
protein	O
,	O
whereas	O
Staurosporine	O
allowed	O
protein	O
production	O
,	O
but	O
inhibited	O
its	O
secretion	O
.	O

To	O
determine	O
the	O
mechanisms	O
responsible	O
for	O
these	O
differences	O
,	O
we	O
turned	O
to	O
human	O
U937	O
promonocytic	O
cells	O
.	O

U937	O
cells	O
transfected	O
with	O
the	O
human	O
full-length	O
IL-1beta	O
promoter	O
connected	O
to	O
a	O
luciferase	O
reporter	O
gene	O
were	O
submitted	O
to	O
transcription	O
assays	O
,	O
Northern	O
blotting	O
,	O
and	O
DNA	O
electrophoresis	O
mobility	O
gel	O
shift	O
assays	O
.	O

These	O
studies	O
revealed	O
that	O
Calphostin	O
C	O
inhibited	O
the	O
nuclear	O
translocation	O
of	O
the	O
transcription	O
factor	O
activator	O
protein-1	O
(	O
AP-1	O
)	O
which	O
is	O
considered	O
necessary	O
for	O
FN	O
induction	O
of	O
IL-1beta	O
gene	O
transcription	O
,	O
and	O
prevented	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
alone	O
induced	O
AP-1	O
translocation	O
and	O
stimulation	O
of	O
the	O
gene	O
.	O

Overall	O
,	O
our	O
data	O
indicate	O
that	O
Calphostin	O
C	O
prevents	O
the	O
transcription	O
of	O
the	O
IL-1beta	O
gene	O
thereby	O
inhibiting	O
protein	O
synthesis	O
.	O

Based	O
on	O
the	O
high	O
specificity	O
of	O
this	O
compound	O
for	O
PKC	O
,	O
we	O
conclude	O
that	O
PKC	O
is	O
necessary	O
for	O
FN-induced	O
IL-1beta	O
protein	O
production	O
.	O

In	O
contrast	O
,	O
Staurosporine	O
prevented	O
secretion	O
of	O
IL-1beta	O
by	O
unknown	O
mechanisms	O
.	O

Membrane-associated	O
lymphotoxin	O
on	O
natural	O
killer	O
cells	O
activates	O
endothelial	O
cells	O
via	O
an	O
NF-kappaB-dependent	O
pathway	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
complement	O
in	O
small	O
animal	O
models	O
of	O
xenotransplantation	O
has	O
demonstrated	O
graft	O
infiltration	O
with	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
and	O
monocytes	O
associated	O
with	O
endothelial	O
cell	O
(	O
EC	O
)	O
activation	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
human	O
NK	O
cells	O
activate	O
porcine	O
EC	O
in	O
vitro	O
,	O
which	O
results	O
in	O
adhesion	O
molecule	O
expression	O
and	O
cytokine	O
secretion	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
the	O
NK	O
cell	O
line	O
NK92	O
to	O
define	O
the	O
molecular	O
and	O
cellular	O
basis	O
of	O
NK	O
cell-mediated	O
EC	O
activation	O
.	O

METHODS	O
:	O
EC	O
were	O
transfected	O
with	O
either	O
reporter	O
constructs	O
containing	O
the	O
luciferase	O
gene	O
driven	O
either	O
by	O
E-selectin	O
or	O
interleukin	O
(	O
IL	O
)	O
-8	O
promoters	O
or	O
a	O
synthetic	O
NF-kappaB-dependent	O
promoter	O
.	O

In	O
addition	O
,	O
a	O
dominant-negative	O
mutant	O
tumor	O
necrosis	O
factor	O
receptor	O
I	O
(	O
TNFRI	O
)	O
expression	O
vector	O
was	O
co-transfected	O
in	O
inhibition	O
studies	O
.	O

Forty-eight	O
hours	O
after	O
transfection	O
,	O
EC	O
were	O
stimulated	O
with	O
NK	O
cells	O
or	O
NK	O
cell	O
membrane	O
extracts	O
for	O
7	O
hr	O
and	O
activation	O
was	O
measured	O
by	O
a	O
luciferase	O
assay	O
.	O

RESULTS	O
:	O
Co-culture	O
of	O
NK	O
cells	O
with	O
transfected	O
EC	O
enhanced	O
E-selectin	O
,	O
IL-8	O
,	O
and	O
NF-kappaB-dependent	O
promoter	O
activity	O
.	O

NK	O
cell	O
membrane	O
extracts	O
retained	O
the	O
capacity	O
to	O
activate	O
EC	O
and	O
induced	O
nuclear	O
translocation	O
of	O
NF-kappaB	O
(	O
p50	O
and	O
p65	O
)	O
.	O

Western	O
blotting	O
of	O
NK	O
cell	O
and	O
membrane	O
extracts	O
detected	O
the	O
presence	O
of	O
Lymphotoxin-alpha	O
(	O
LTalpha	O
)	O
but	O
not	B-Negation
tumor	I-Negation
necrosis	I-Negation
factor-alpha	I-Negation
.	O

Furthermore	O
,	O
LTalpha	O
was	O
secreted	O
in	O
NK	O
:	O
EC	O
co-cultures	O
.	O

Co-transfection	O
with	O
dominant-negative	O
mutant	O
TNFRI	O
inhibited	O
EC	O
activation	O
by	O
NK	O
cell	O
membrane	O
extracts	O
and	O
by	O
NK	O
cells	O
by	O
80	O
%	O
and	O
47	O
%	O
,	O
respectively	O
.	O

The	O
same	O
pattern	O
of	O
inhibition	O
was	O
observed	O
using	O
anti-human	O
LT	O
sera	O
.	O

CONCLUSIONS	O
:	O
Human	O
NK	O
cell	O
membrane-bound	O
LT	O
signals	O
across	O
species	O
via	O
TNFRI	O
,	O
leading	O
to	O
NF-kappaB	O
nuclear	O
translocation	O
and	O
transcription	O
of	O
E-selectin	O
and	O
IL-8	O
,	O
which	O
results	O
in	O
EC	O
activation	O
.	O

The	O
discrepancy	O
in	O
the	O
degree	O
of	O
inhibition	O
by	O
membrane	O
extracts	O
and	O
NK	O
cells	O
with	O
mutant	O
TNFRI	O
suggests	O
that	O
additional	O
pathways	O
are	O
utilized	O
by	O
NK	O
cells	O
to	O
activate	O
EC	O
.	O

Cloning	O
of	O
ARE-containing	O
genes	O
by	O
AU-motif-directed	O
display	O
.	O

A	O
procedure	O
suitable	O
for	O
cloning	O
labile	O
mRNAs	O
that	O
contain	O
AU	O
motifs	O
is	O
presented	O
(	O
AU-DD	O
)	O
.	O

These	O
motifs	O
are	O
regulatory	O
sequences	O
within	O
the	O
so-called	O
AU-rich	O
elements	O
(	O
AREs	O
)	O
often	O
found	O
in	O
3	O
'	O
untranslated	O
regions	O
of	O
genes	O
such	O
as	O
cytokines	O
,	O
proto-oncogenes	O
,	O
and	O
transcription	O
factors	O
.	O

AU-DD	O
is	O
an	O
AU-motif-directed	O
differential	O
display	O
that	O
permits	O
the	O
identification	O
of	O
ARE-containing	O
genes	O
differentially	O
expressed	O
after	O
cell	O
activation	O
.	O

It	O
has	O
been	O
applied	O
to	O
peripheral	O
blood	O
monocytes	O
and	O
a	O
T	O
cell	O
clone	O
to	O
isolate	O
59	O
cDNA	O
fragments	O
associated	O
to	O
activation	O
.	O

Fourteen	O
percent	O
of	O
isolated	O
fragments	O
belong	O
to	O
already	O
known	O
genes	O
that	O
certainly	O
are	O
cytokines	O
and	O
transduction/transcription	O
factors	O
.	O

The	O
remaining	O
86	O
%	O
correspond	O
to	O
unknown	O
genes	O
of	O
which	O
92	O
%	O
have	O
been	O
confirmed	O
to	O
be	O
differentially	O
expressed	O
.	O

These	O
data	O
demonstrate	O
the	O
efficiency	O
of	O
the	O
system	O
and	O
support	O
the	O
notion	O
that	O
numerous	O
genes	O
falling	O
into	O
those	O
categories	O
remain	O
unidentified	O
and	O
that	O
they	O
can	O
be	O
cloned	O
by	O
this	O
method	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Signaling	O
pathways	O
mediated	O
by	O
the	O
TNF-	O
and	O
cytokine-receptor	O
families	O
target	O
a	O
common	O
cis-element	O
of	O
the	O
IFN	O
regulatory	O
factor	O
1	O
promoter	O
.	O

CD40	O
activation	O
of	O
B	O
cells	O
is	O
strongly	O
influenced	O
by	O
the	O
presence	O
of	O
cytokines	O
.	O

However	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
interplay	O
between	O
these	O
distinct	O
stimuli	O
is	O
not	O
clearly	O
delineated	O
.	O

IFN	O
regulatory	O
factor	O
1	O
(	O
IRF-1	O
)	O
is	O
a	O
transcription	O
factor	O
activated	O
by	O
either	O
CD40	O
or	O
cytokines	O
.	O

We	O
have	O
found	O
that	O
these	O
different	O
sets	O
of	O
signals	O
target	O
a	O
common	O
cis-acting	O
element	O
in	O
the	O
promoter	O
of	O
this	O
gene	O
,	O
the	O
IRF-1	O
gamma-activated	O
site	O
(	O
GAS	O
)	O
.	O

Targeting	B-Negation
of	I-Negation
the	I-Negation
IRF-1	I-Negation
GAS	I-Negation
is	I-Negation
not	I-Negation
confined	I-Negation
to	I-Negation
activation	I-Negation
via	I-Negation
CD40	I-Negation
but	O
extends	O
to	O
other	O
stimuli	O
that	O
mimic	O
the	O
CD40	O
signaling	O
cascade	O
,	O
like	O
TNF-alpha	O
and	O
EBV	O
.	O

In	O
contrast	O
to	O
induction	O
of	O
STATs	O
by	O
cytokines	O
,	O
the	O
IRF-1	O
GAS-binding	O
complex	O
activated	O
by	O
CD40	O
,	O
TNF-alpha	O
,	O
or	O
EBV	O
contains	O
Rel	O
proteins	O
,	O
specifically	O
p50	O
and	O
p65	O
.	O

In	O
this	O
system	O
,	O
simultaneous	O
exposure	O
to	O
CD40L	O
together	O
with	O
either	O
IL-4	O
or	O
IFN-gamma	O
does	O
not	B-Negation
lead	I-Negation
to	I-Negation
the	I-Negation
activation	I-Negation
of	I-Negation
novel	I-Negation
Rel/STAT	I-Negation
complexes	I-Negation
.	O

Given	O
the	O
importance	O
of	O
IRF-1	O
in	O
a	O
variety	O
of	O
biologic	O
functions	O
from	O
proliferation	O
to	O
apoptosis	O
,	O
our	O
findings	O
support	O
the	O
notion	O
that	O
modulation	O
of	O
IRF-1	O
levels	O
may	O
be	O
a	O
critical	O
control	O
point	O
in	O
B	O
cell	O
activation	O
.	O

Regulation	O
of	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
nuclear	O
import	O
in	O
T	O
lymphocytes	O
by	O
noninvasive	O
delivery	O
of	O
peptide	O
carrying	O
the	O
nuclear	O
localization	O
sequence	O
of	O
NF-kappa	O
B	O
p50	O
.	O

Activation	O
of	O
T	O
lymphocytes	O
by	O
Ags	O
or	O
cytokines	O
results	O
in	O
translocation	O
of	O
the	O
transcription	O
factors	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
NFAT	O
,	O
and	O
STAT	O
from	O
the	O
cytoplasm	O
into	O
the	O
nucleus	O
.	O

The	O
first	O
step	O
in	O
the	O
nuclear	O
import	O
process	O
is	O
recognition	O
of	O
a	O
nuclear	O
localization	O
sequence	O
(	O
NLS	O
)	O
within	O
the	O
karyophilic	O
protein	O
by	O
a	O
cytoplasmic	O
receptor	O
such	O
as	O
the	O
importin	O
(	O
karyopherin	O
)	O
-alpha	O
subunit	O
.	O

The	O
NLSs	O
of	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
and	O
NFAT	O
differ	O
and	O
the	B-Negation
NLS	I-Negation
of	I-Negation
STAT1	I-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
identified	I-Negation
.	O

Herein	O
we	O
demonstrate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
in	O
Jurkat	O
T	O
lymphocytes	O
is	O
significantly	O
inhibited	O
by	O
a	O
cell-permeable	O
peptide	O
carrying	O
the	O
NLS	O
of	O
the	O
NF-kappa	O
B	O
p50	O
subunit	O
.	O

NLS	O
peptide-mediated	O
disruption	O
of	O
the	O
nuclear	O
import	O
of	O
these	O
transcription	O
factors	O
results	O
in	O
inhibition	O
of	O
I	O
kappa	O
B	O
alpha	O
and	O
IL-2	O
gene	O
expression	O
,	O
processes	O
dependent	O
on	O
NF-kappa	O
B	O
or	O
the	O
combination	O
of	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
and	O
NFAT	O
.	O

Further	O
,	O
we	O
show	O
that	O
inhibitory	O
NLS	O
peptide	O
interacts	O
in	O
vitro	O
with	O
a	O
cytoplasmic	O
NLS	O
receptor	O
complex	O
comprised	O
of	O
the	O
Rch1/importin	O
(	O
karyopherin	O
)	O
-beta	O
heterodimer	O
expressed	O
in	O
Jurkat	O
T	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
the	O
inducible	O
nuclear	O
import	O
of	O
NF-kappa	O
B	O
,	O
AP-1	O
,	O
NFAT	O
,	O
and	O
STAT1	O
in	O
Jurkat	O
T	O
cells	O
can	O
be	O
regulated	O
by	O
NLS	O
peptide	O
delivered	O
noninvasively	O
to	O
the	O
cytoplasm	O
of	O
Jurkat	O
T	O
cells	O
to	O
target	O
members	O
of	O
the	O
importin	O
(	O
karyopherin	O
)	O
-alpha	O
beta	O
NLS	O
receptor	O
complex	O
.	O

Epithelial	O
cell-initiated	O
inflammation	O
plays	O
a	O
crucial	O
role	O
in	O
early	O
tissue	O
damage	O
in	O
amebic	O
infection	O
of	O
human	O
intestine	O
.	O

BACKGROUND	O
&	O
AIMS	O
:	O
Entamoeba	O
histolytica	O
infection	O
of	O
the	O
intestine	O
can	O
induce	O
severe	O
gut	O
inflammation	O
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
assess	O
the	O
role	O
of	O
the	O
host	O
inflammatory	O
response	O
in	O
the	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
and	O
the	O
role	O
of	O
the	O
intestinal	O
epithelial	O
cell	O
in	O
initiating	O
that	O
response	O
.	O

METHODS	O
:	O
E.	O
histolytica	O
infection	O
was	O
established	O
in	O
human	O
intestinal	O
xenografts	O
in	O
severe	O
combined	O
immunodeficient	O
(	O
SCID-HU-INT	O
)	O
mice	O
.	O

Human	O
intestinal	O
epithelial	O
cell	O
inflammatory	O
responses	O
to	O
amebic	O
infection	O
were	O
inhibited	O
by	O
the	O
intraluminal	O
administration	O
of	O
an	O
antisense	O
oligonucleotide	O
to	O
the	O
human	O
p65	O
subunit	O
of	O
nuclear	O
factor	O
kappaB	O
,	O
and	O
the	O
role	O
of	O
neutrophils	O
in	O
tissue	O
damage	O
observed	O
with	O
amebiasis	O
was	O
studied	O
by	O
depleting	O
neutrophils	O
from	O
SCID-HU-INT	O
mice	O
.	O

RESULTS	O
:	O
Administration	O
of	O
the	O
antisense	O
oligonucleotide	O
blocked	O
the	O
production	O
of	O
human	O
interleukin	O
1beta	O
and	O
interleukin	O
8	O
by	O
intestinal	O
epithelial	O
cells	O
and	O
inhibited	O
neutrophil	O
influx	O
into	O
the	O
E.	O
histolytica-infected	O
intestinal	O
xenografts	O
.	O

Inhibition	O
of	O
the	O
gut	O
inflammatory	O
response	O
by	O
the	O
antisense	O
oligonucleotide	O
or	O
the	O
depletion	O
of	O
neutrophils	O
from	O
SCID-HU-	O
INT	O
mice	O
blocked	O
the	O
increase	O
in	O
intestinal	O
permeability	O
observed	O
with	O
amebic	O
infection	O
.	O

CONCLUSIONS	O
:	O
Intestinal	O
epithelial	O
cells	O
initiate	O
an	O
inflammatory	O
response	O
with	O
resulting	O
neutrophil-mediated	O
tissue	O
damage	O
in	O
response	O
to	O
E.	O
histolytica	O
infection	O
;	O
this	O
inflammatory	O
cascade	O
can	O
be	O
blocked	O
by	O
inhibiting	O
the	O
transcription	O
of	O
genes	O
regulated	O
by	O
nuclear	O
factor	O
kappaB	O
.	O

In	O
vitro	O
suppression	O
of	O
programmed	O
cell	O
death	O
of	O
B	O
cells	O
by	O
tissue	O
inhibitor	O
of	O
metalloproteinases-1	O
.	O

Cellular	O
pathways	O
for	O
induction	O
of	O
programmed	O
cell	O
death	O
(	O
PCD	O
)	O
have	O
been	O
identified	O
,	O
but	O
little	O
is	O
known	O
about	O
specific	O
extracellular	O
matrix	O
processes	O
that	O
may	O
affect	O
apoptosis	O
along	O
those	O
pathways	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
were	O
assayed	O
for	O
their	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMP	O
)	O
-1	O
.	O

Results	O
indicate	O
that	O
TIMP-1-positive	O
BL	O
lines	O
show	O
resistance	O
to	O
cold-shock-induced	O
apoptosis	O
.	O

Furthermore	O
,	O
recombinant	O
TIMP-1	O
,	O
but	O
not	B-Negation
TIMP-2	I-Negation
or	I-Negation
a	I-Negation
synthetic	I-Negation
metalloproteinase	I-Negation
inhibitor	I-Negation
(	I-Negation
BB-94	I-Negation
)	I-Negation
,	O
confers	O
resistance	O
to	O
apoptosis	O
induced	O
by	O
both	O
CD95-dependent	O
and	O
-independent	O
(	O
cold	O
shock	O
,	O
serum	O
deprivation	O
,	O
and	O
gamma-radiation	O
)	O
pathways	O
in	O
TIMP-1-negative	O
BL	O
lines	O
.	O

TIMP-1	O
suppression	O
of	O
PCD	O
is	O
not	B-Negation
due	I-Negation
to	I-Negation
metalloproteinase	I-Negation
inhibition	I-Negation
,	O
as	O
reduction	O
and	O
alkylation	O
of	O
the	O
TIMP-1	O
did	O
not	B-Negation
abolish	I-Negation
this	I-Negation
activity	I-Negation
.	O

Retroviral	O
induction	O
of	O
TIMP-1	O
not	O
only	O
resulted	O
in	O
cell	O
survival	O
but	O
also	O
in	O
continued	O
DNA	O
synthesis	O
for	O
up	O
to	O
5	O
d	O
in	O
the	O
absence	O
of	O
serum	O
,	O
while	O
controls	O
underwent	O
apoptosis	O
.	O

This	O
resistance	O
to	O
apoptosis	O
is	O
reversed	O
by	O
anti-TIMP-1	O
antibodies	O
,	O
demonstrating	O
that	O
secreted	O
TIMP-1	O
is	O
active	O
in	O
blocking	O
apoptosis	O
.	O

Furthermore	O
,	O
TIMP-1	O
upregulation	O
induced	O
expression	O
of	O
Bcl-XL	O
but	O
not	B-Negation
Bcl-2	I-Negation
as	O
well	O
as	O
decreased	O
NF-kappaB	O
activity	O
as	O
compared	O
with	O
controls	O
.	O

These	O
results	O
demonstrate	O
that	O
TIMP-1	O
suppresses	O
apoptosis	O
in	O
B	O
cells	O
and	O
suggests	O
a	O
novel	O
activity	O
for	O
TIMP-1	O
in	O
tissue	O
homeostasis	O
.	O

Interleukin-12	O
expression	O
in	O
B	O
cells	O
by	O
transformation	O
with	O
Epstein-Barr	O
virus	O
.	O

Although	O
interleukin	O
(	O
IL	O
)	O
-12	O
was	O
originally	O
purified	O
from	O
an	O
Epstein-Barr	O
(	O
EBV	O
)	O
-transformed	O
B	O
cell	O
line	O
and	O
the	B-Speculation
high	I-Speculation
correlation	I-Speculation
of	I-Speculation
EBV	I-Speculation
infection	I-Speculation
and	I-Speculation
IL-12	I-Speculation
expression	I-Speculation
has	I-Speculation
been	I-Speculation
suggested	I-Speculation
,	O
no	B-Negation
study	I-Negation
has	I-Negation
reported	I-Negation
whether	I-Negation
EBV	I-Negation
infection	I-Negation
is	I-Negation
directly	I-Negation
linked	I-Negation
to	I-Negation
IL-12	I-Negation
expression	I-Negation
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
have	O
investigated	O
IL-12	O
expression	O
in	O
B	O
cells	O
during	O
in	O
vitro	O
transformation	O
with	O
EBV	O
.	O

Human	O
peripheral	O
B	O
cells	O
became	O
capable	O
of	O
constitutively	O
producing	O
p40	O
by	O
in	O
vitro	O
transformation	O
with	O
EBV	O
,	O
coincident	O
with	O
the	O
expression	O
of	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
of	O
EBV	O
.	O

These	O
B	O
cells	O
expressed	O
p40	O
and	O
p35	O
mRNA	O
,	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
stimulation	O
strongly	O
enhanced	O
p40	O
and	O
p70	O
production	O
.	O

Furthermore	O
,	O
transfection	O
with	O
LMP1	O
expression	O
vector	O
into	O
a	O
human	O
B	O
lymphoma	O
cell	O
line	O
,	O
Daudi	O
,	O
led	O
to	O
p40	O
production	O
with	O
nuclear	O
factor	O
(	O
NF	O
)	O
-kappaB	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
transformation	O
of	O
primary	O
B	O
cells	O
with	O
EBV	O
induces	O
IL-12	O
expression	O
potentially	O
through	O
LMP1	O
expression	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Anaphylatoxins	O
C5a	O
and	O
C3a	O
induce	O
nuclear	O
factor	O
kappaB	O
activation	O
in	O
human	O
peripheral	O
blood	O
monocytes	O
.	O

The	O
anaphylatoxins	O
C5a	O
and	O
C3a	O
are	O
involved	O
in	O
the	O
regulation	O
of	O
cytokine	O
production	O
.	O

In	O
this	O
study	O
the	O
capability	O
of	O
C5a	O
and	O
C3a	O
to	O
induce	O
transcription	O
factor	O
activation	O
was	O
examined	O
.	O

C5a	O
and	O
C3a	O
stimulation	O
of	O
human	O
peripheral	O
blood	O
monocytes	O
resulted	O
in	O
nuclear	O
expression	O
of	O
a	O
DNA	O
binding	O
activity	O
with	O
specificity	O
to	O
the	O
kappaB	O
sequence	O
.	O

The	O
p50	O
and	O
p65	O
proteins	O
,	O
constituents	O
of	O
the	O
prototypic	O
nuclear	O
factor	O
kappaB	O
,	O
were	O
identified	O
as	O
components	O
of	O
the	O
DNA-protein	O
complexes	O
by	O
anti-peptide	O
antibodies	O
in	O
gel	O
supershift	O
assays	O
.	O

C5a	O
induced	O
kappaB	O
binding	O
activity	O
was	O
detected	O
15	O
min	O
after	O
agonist	O
stimulation	O
,	O
peaked	O
at	O
30-40	O
min	O
,	O
and	O
remained	O
detectable	O
at	O
2	O
h	O
.	O

Binding	O
to	O
kappaB	O
sequence	O
was	O
accompanied	O
by	O
an	O
initial	O
decrease	O
and	O
subsequent	O
increase	O
in	O
the	O
cytoplasmic	O
IkappaBalpha	O
levels	O
,	O
as	O
detected	O
by	O
Western	O
blotting	O
using	O
an	O
anti-IkappaBalpha	O
antibody	O
.	O

Pertussis	O
toxin	O
treatment	O
markedly	O
decreased	O
kappaB	O
binding	O
activities	O
induced	O
by	O
both	O
C5a	O
and	O
C3a	O
,	O
whereas	O
cholera	O
toxin	O
displayed	O
no	B-Negation
inhibitory	I-Negation
effect	I-Negation
.	O

Neither	B-Negation
of	I-Negation
the	I-Negation
two	I-Negation
toxins	I-Negation
affected	I-Negation
kappaB	I-Negation
binding	I-Negation
activity	I-Negation
induced	I-Negation
by	I-Negation
TNFalpha	I-Negation
in	I-Negation
the	I-Negation
same	I-Negation
cells	I-Negation
.	O

These	O
results	O
imply	O
a	O
potential	O
role	O
of	O
the	O
anaphylatoxins	O
C5a	O
and	O
C3a	O
in	O
regulating	O
leukocytes	O
gene	O
expression	O
through	O
G	O
protein-coupled	O
transcription	O
factor	O
activation	O
.	O

Tpl-2	O
induces	O
IL-2	O
expression	O
in	O
T-cell	O
lines	O
by	O
triggering	O
multiple	O
signaling	O
pathways	O
that	O
activate	O
NFAT	O
and	O
NF-kappaB	O
.	O

The	O
Tpl-2	O
kinase	O
activates	O
the	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
and	O
induces	O
IL-2	O
expression	O
in	O
T-cell	O
lines	O
.	O

Here	O
we	O
show	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	O
is	O
inhibited	O
by	O
mutant	O
signaling	O
molecules	O
that	O
inhibit	O
the	O
mitogen-activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
or	O
the	O
calcineurin/NFAT	O
pathways	O
and	O
is	O
promoted	O
by	O
combinations	O
of	O
signaling	O
molecules	O
that	O
activate	O
these	O
pathways	O
.	O

We	O
,	O
therefore	O
,	O
conclude	O
that	O
signals	O
generated	O
by	O
the	O
convergence	O
of	O
the	O
MAPK	O
and	O
the	O
calcineurin/NFAT	O
pathway	O
are	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
by	O
Tpl-2	O
.	O

The	O
activation	O
of	O
both	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT-driven	O
minimal	O
promoter	O
were	O
shown	O
to	O
depend	O
on	O
signals	O
transduced	O
by	O
Raf1	O
.	O

However	O
,	O
it	O
was	O
only	O
the	O
IL-2	O
promoter	O
whose	O
activation	O
by	O
Tpl-2	O
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
MEK1S218/222A	O
and	O
the	O
MEK1/MEK2	O
inhibitor	O
PD098059	O
.	O

Since	O
the	O
activation	O
of	O
NFAT	O
is	O
MAPK-dependent	O
these	O
findings	O
suggested	O
that	O
the	O
activation	O
of	O
MAPK	O
by	O
Tpl-2	O
is	O
either	O
independent	O
or	O
only	O
partially	O
dependent	O
on	O
MEK1	O
and	O
MEK2	O
.	O

In	O
addition	O
,	O
they	O
suggested	O
that	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
is	O
under	O
the	O
control	O
of	O
not	O
only	O
NFAT	O
but	O
also	O
a	O
second	O
factor	O
whose	O
activation	O
is	O
MEK-dependent	O
.	O

Experiments	O
in	O
COS-1	O
and	O
EL-4	O
cells	O
confirmed	O
both	O
hypotheses	O
and	O
revealed	O
that	O
the	O
second	O
factor	O
activated	O
by	O
Tpl-2	O
is	O
NF-kappaB	O
.	O

While	O
the	O
activation	O
of	O
the	O
IL-2	O
promoter	O
and	O
an	O
NFAT-driven	O
minimal	O
promoter	O
by	O
Tpl-2	O
was	O
fully	O
blocked	O
by	O
the	O
dominant	O
negative	O
mutant	O
NFAT	O
delta418	O
,	O
it	O
was	O
only	O
partially	O
blocked	O
by	O
the	O
calcineurin	O
inhibitor	O
cyclosporin	O
A	O
suggesting	O
that	O
the	O
Tpl-2-mediated	O
NFAT	O
activation	O
is	O
under	O
the	O
control	O
of	O
a	O
combination	O
of	O
calcineurin-dependent	O
and	O
independent	O
pathways	O
.	O

Both	O
pathways	O
were	O
fully	O
blocked	O
by	O
Bcl-2	O
or	O
Bcl-X	O
(	O
L	O
)	O
.	O

Activation	O
of	O
human	O
macrophages	O
by	O
mechanical	O
ventilation	O
in	O
vitro	O
.	O

Positive-pressure	O
mechanical	O
ventilation	O
supports	O
gas	O
exchange	O
in	O
patients	O
with	O
respiratory	O
failure	O
but	O
is	O
also	O
responsible	O
for	O
significant	O
lung	O
injury	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
developed	O
an	O
in	O
vitro	O
model	O
in	O
which	O
isolated	O
lung	O
cells	O
can	O
be	O
submitted	O
to	O
a	O
prolonged	O
cyclic	O
pressure-stretching	O
strain	O
resembling	O
that	O
of	O
conventional	O
mechanical	O
ventilation	O
.	O

In	O
this	O
model	O
,	O
cells	O
cultured	O
on	O
a	O
Silastic	O
membrane	O
were	O
elongated	O
up	O
to	O
7	O
%	O
of	O
their	O
initial	O
diameter	O
,	O
corresponding	O
to	O
a	O
12	O
%	O
increase	O
in	O
cell	O
surface	O
.	O

The	O
lung	O
macrophage	O
was	O
identified	O
as	O
the	O
main	O
cellular	O
source	O
for	O
critical	O
inflammatory	O
mediators	O
such	O
as	O
tumor	O
necrosis	O
factor-alpha	O
,	O
the	O
chemokines	O
interleukin	O
(	O
IL	O
)	O
-8	O
and	O
-6	O
,	O
and	O
matrix	O
metalloproteinase-9	O
in	O
this	O
model	O
system	O
of	O
mechanical	O
ventilation	O
.	O

These	O
mediators	O
were	O
measured	O
in	O
supernatants	O
from	O
ventilated	O
alveolar	O
macrophages	O
,	O
monocyte-derived	O
macrophages	O
,	O
and	O
promonocytic	O
THP-1	O
cells	O
.	O

Nuclear	O
factor-kappaB	O
was	O
found	O
to	O
be	O
activated	O
in	O
ventilated	O
macrophages	O
.	O

Synergistic	O
proinflammatory	O
effects	O
of	O
mechanical	O
stress	O
and	O
molecules	O
such	O
as	O
bacterial	O
endotoxin	O
were	O
observed	O
,	O
suggesting	O
that	O
mechanical	O
ventilation	O
might	O
be	O
particularly	O
deleterious	O
in	O
preinjured	O
or	O
infected	O
lungs	O
.	O

Dexamethasone	O
prevented	O
IL-8	O
and	O
tumor	O
necrosis	O
factor-alpha	O
secretion	O
in	O
ventilated	O
macrophages	O
.	O

Mechanical	O
ventilation	O
induced	O
low	O
levels	O
of	O
IL-8	O
secretion	O
by	O
alveolar	O
type	O
II-like	O
cells	O
.	O

Other	O
lung	O
cell	O
types	O
such	O
as	O
endothelial	O
cells	O
,	O
bronchial	O
cells	O
,	O
and	O
fibroblasts	O
failed	B-Negation
to	I-Negation
produce	I-Negation
IL-8	I-Negation
in	I-Negation
response	I-Negation
to	I-Negation
a	I-Negation
prolonged	I-Negation
cyclic	I-Negation
pressure-stretching	I-Negation
load	I-Negation
.	O

This	O
model	O
is	O
of	O
particular	O
value	O
for	O
exploring	O
physical	O
stress-induced	O
signaling	O
pathways	O
,	O
as	O
well	O
as	O
for	O
testing	O
the	O
effects	O
of	O
novel	O
ventilatory	O
strategies	O
or	O
adjunctive	O
substances	O
aimed	O
at	O
modulating	O
cell	O
activation	O
induced	O
by	O
mechanical	O
ventilation	O
.	O

Stat6	O
inhibits	O
human	O
interleukin-4	O
promoter	O
activity	O
in	O
T	O
cells	O
.	O

The	O
differentiation	O
of	O
naive	O
T-helper	O
(	O
Th	O
)	O
cells	O
into	O
cytokine-secreting	O
effector	O
Th	O
cells	O
requires	O
exposure	O
to	O
multiple	O
signals	O
,	O
including	O
exogenous	O
cytokines	O
.	O

Interleukin-4	O
(	O
IL-4	O
)	O
plays	O
a	O
major	O
role	O
in	O
this	O
process	O
by	O
promoting	O
the	O
differentiation	O
of	O
IL-4-secreting	O
Th2	O
cells	O
.	O

In	O
Th2	O
cells	O
,	O
IL-4	O
gene	O
expression	O
is	O
tightly	O
controlled	O
at	O
the	O
level	O
of	O
transcription	O
by	O
the	O
coordinated	O
binding	O
of	O
multiple	O
transcription	O
factors	O
to	O
regulatory	O
elements	O
in	O
the	O
proximal	O
promoter	O
region	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cell	O
(	O
NFAT	O
)	O
family	O
members	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
IL-4	O
transcription	O
and	O
interact	O
with	O
up	O
to	O
five	O
sequences	O
(	O
termed	O
P0	O
through	O
P4	O
)	O
in	O
the	O
IL-4	O
promoter	O
.	O

The	O
molecular	O
mechanisms	O
by	O
which	O
IL-4	O
induces	O
expression	O
of	O
the	O
IL-4	O
gene	O
are	O
not	O
known	O
,	O
although	O
the	O
IL-4-activated	O
transcription	O
factor	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
6	O
(	O
Stat6	O
)	O
is	O
required	O
for	O
this	O
effect	O
.	O

We	O
report	O
here	O
that	O
Stat6	O
interacts	O
with	O
three	O
binding	O
sites	O
in	O
the	O
human	O
IL-4	O
promoter	O
by	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

These	O
sites	O
overlap	O
the	O
P1	O
,	O
P2	O
,	O
and	O
P4	O
NFAT	O
elements	O
.	O

To	O
investigate	O
the	O
role	O
of	O
Stat6	O
in	O
regulating	O
IL-4	O
transcription	O
,	O
we	O
used	O
Stat6-deficient	O
Jurkat	O
T	O
cells	O
with	O
different	O
intact	O
IL-4	O
promoter	O
constructs	O
in	O
cotransfection	O
assays	O
.	O

We	O
show	O
that	O
,	O
whereas	O
a	O
multimerized	O
response	O
element	O
from	O
the	O
germline	O
IgE	O
promoter	O
was	O
highly	O
induced	O
by	O
IL-4	O
in	O
Stat6-expressing	O
Jurkat	O
cells	O
,	O
the	O
intact	O
human	O
IL-4	O
promoter	O
was	O
repressed	O
under	O
similar	O
conditions	O
.	O

We	O
conclude	O
that	O
the	O
function	O
of	O
Stat6	O
is	O
highly	O
dependent	O
on	O
promoter	O
context	O
and	O
that	O
this	O
factor	O
promotes	O
IL-4	O
gene	O
expression	O
in	O
an	O
indirect	O
manner	O
.	O

Interleukin-10	O
and	O
transforming	O
growth	O
factor-beta	O
promoter	O
polymorphisms	O
in	O
allergies	O
and	O
asthma	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
and	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF-beta	O
)	O
are	O
inhibitory	O
for	O
B	O
and	O
T	O
cells	O
,	O
IgE	O
production	O
,	O
and	O
mast	O
cell	O
proliferation	O
,	O
and	O
they	O
induce	O
apoptosis	O
in	O
eosinophils	O
.	O

These	O
cytokines	O
are	O
therefore	O
candidate	O
genes	O
which	O
could	O
contribute	O
to	O
the	O
development	O
of	O
asthma	O
or	O
allergies	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
polymorphic	O
nucleotides	O
within	O
the	O
IL-10	O
and	O
TGF-beta	O
gene	O
promoters	O
would	O
link	O
to	O
the	O
expression	O
of	O
allergies	O
and	O
asthma	O
.	O

DNA	O
taken	O
from	O
families	O
with	O
an	O
asthmatic	O
proband	O
was	O
examined	O
for	O
base	O
exchanges	O
by	O
single-stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
.	O

We	O
demonstrated	O
the	O
presence	O
of	O
a	O
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
IL-10	O
gene	O
and	O
four	O
in	O
the	O
TGF-beta	O
gene	O
promoters	O
(	O
3	O
in	O
TGF-beta1	O
and	O
1	O
in	O
TGF-beta2	O
)	O
.	O

The	O
IL-10	O
gene	O
polymorphism	O
was	O
a	O
C-to-A	O
exchange	O
571	O
base	O
pairs	O
upstream	O
from	O
the	O
translation	O
start	O
site	O
and	O
was	O
present	O
between	O
consensus	O
binding	O
sequences	O
for	O
Sp1	O
and	O
elevated	O
total	O
serum	O
.	O

This	O
polymorphism	O
was	O
associated	O
with	O
elevated	O
total	O
serum	O
IgE	O
in	O
subjects	O
heterozygotic	O
or	O
homozygotic	O
for	O
this	O
base	O
exchange	O
(	O
p	O
<	O
0.009	O
)	O
.	O

The	O
base	O
exchange	O
at	O
-509	O
(	O
from	O
the	O
transcription	O
initiation	O
site	O
)	O
in	O
the	O
TGF-beta	O
promoter	O
also	O
linked	O
to	O
elevated	O
total	O
IgE	O
(	O
p	O
<	O
0.01	O
)	O
.	O

This	O
polymorphism	O
represented	O
a	O
C-to-T	O
base	O
exchange	O
which	O
induced	O
a	O
YY1	O
consensus	O
sequence	O
and	O
is	O
present	O
in	O
a	O
region	O
of	O
the	O
promoter	O
associated	O
with	O
negative	O
transcription	O
regulation	O
.	O

The	O
involvement	O
of	O
multiple	O
tumor	O
necrosis	O
factor	O
receptor	O
(	O
TNFR	O
)	O
-associated	O
factors	O
in	O
the	O
signaling	O
mechanisms	O
of	O
receptor	O
activator	O
of	O
NF-kappaB	O
,	O
a	O
member	O
of	O
the	O
TNFR	O
superfamily	O
.	O

Receptor	O
activator	O
of	O
NF-kappaB	O
(	O
RANK	O
)	O
is	O
a	O
recently	O
identified	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
and	O
is	O
expressed	O
on	O
activated	O
T	O
cells	O
and	O
dendritic	O
cells	O
.	O

Its	O
cognate	O
ligand	O
(	O
RANKL	O
)	O
plays	O
significant	O
roles	O
in	O
the	O
activation	O
of	O
dendritic	O
cell	O
function	O
and	O
osteoclast	O
differentiation	O
.	O

We	O
demonstrate	O
here	O
the	O
interaction	O
of	O
RANK	O
with	O
tumor	O
necrosis	O
factor	O
receptor-associated	O
factors	O
(	O
TRAFs	O
)	O
1	O
,	O
2	O
,	O
3	O
,	O
5	O
,	O
and	O
6	O
both	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Mapping	O
of	O
the	O
structural	O
requirements	O
for	O
TRAF/RANK	O
interaction	O
revealed	O
multiple	O
TRAF	O
binding	O
sites	O
clustered	O
in	O
two	O
distinct	O
domains	O
in	O
the	O
RANK	O
cytoplasmic	O
tail	O
.	O

These	O
TRAF	O
binding	O
domains	O
were	O
shown	O
to	O
be	O
functionally	O
important	O
for	O
the	O
RANK-dependent	O
induction	O
of	O
NF-kappaB	O
and	O
c-Jun	O
NH2-terminal	O
kinase	O
activities	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
these	O
TRAF	O
binding	O
sites	O
exhibited	O
selective	O
binding	O
for	O
different	O
TRAF	O
proteins	O
.	O

In	O
particular	O
,	O
TRAF6	O
interacted	O
with	O
membrane-proximal	O
determinants	O
distinct	O
from	O
those	O
binding	O
TRAFs	O
1	O
,	O
2	O
,	O
3	O
,	O
and	O
5	O
.	O

When	O
this	O
membrane-proximal	O
TRAF6	O
interaction	O
domain	O
was	O
deleted	O
,	O
RANK-mediated	O
NF-kappaB	O
signaling	O
was	O
completely	O
inhibited	O
while	O
c-Jun	O
NH2-terminal	O
kinase	O
activation	O
was	O
partially	O
inhibited	O
.	O

An	O
NH2-terminal	O
truncation	O
mutant	O
of	O
TRAF6	O
inhibited	O
RANKL-mediated	O
NF-kappaB	O
activation	O
,	O
but	O
failed	B-Negation
to	I-Negation
affect	I-Negation
constitutive	I-Negation
signaling	I-Negation
induced	I-Negation
by	I-Negation
receptor	I-Negation
overexpression	I-Negation
,	O
revealing	O
a	O
selective	O
role	O
for	O
TRAF6	O
in	O
ligand-induced	O
activation	O
events	O
.	O

The	O
control	O
of	O
lytic	O
replication	O
of	O
Epstein-Barr	O
virus	O
in	O
B	O
lymphocytes	O
(	O
Review	O
)	O
.	O

Uncontrolled	O
replication	O
of	O
a	O
virus	O
,	O
which	O
is	O
harmful	O
to	O
the	O
host	O
is	O
also	O
disadvantageous	O
to	O
the	O
virus	O
.	O

Most	O
viruses	O
can	B-Negation
not	I-Negation
compete	I-Negation
with	I-Negation
the	I-Negation
various	I-Negation
immune	I-Negation
mechanisms	I-Negation
and	O
become	O
eliminated	O
in	O
the	O
course	O
of	O
infection	O
.	O

Therefore	O
,	O
only	O
the	O
time	O
between	O
infection	O
and	O
eradication	O
remains	O
for	O
these	O
viruses	O
to	O
proliferate	O
.	O

A	O
few	O
viruses	O
,	O
like	O
the	O
Herpesviruses	O
or	O
the	O
papillomaviruses	O
,	O
however	O
,	O
have	O
developed	O
a	O
sophisticated	O
strategy	O
for	O
persisting	O
lifelong	O
,	O
usually	O
asymptomatically	O
in	O
the	O
host	O
,	O
hiding	O
from	O
the	O
immune	O
system	O
and	O
producing	O
infectious	O
progeny	O
at	O
the	O
same	O
time	O
.	O

This	O
strategy	O
depends	O
on	O
a	O
separation	O
of	O
latency	O
and	O
the	O
lytic	O
replication	O
,	O
either	O
by	O
time	O
due	O
to	O
differentiation-dependent	O
mechanisms	O
or	O
by	O
spatial	O
separation	O
as	O
the	O
result	O
of	O
different	O
host	O
cell	O
types	O
.	O

Both	O
are	O
true	O
for	O
the	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
.	O

B	O
cells	O
and	O
epithelial	O
cells	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
life	O
cycle	O
of	O
the	O
virus	O
.	O

The	O
former	O
can	O
become	O
latently	O
infected	O
and	O
are	O
thought	O
to	O
be	O
the	O
virus	O
reservoir	O
in	O
vivo	O
,	O
whereas	O
the	O
latter	O
were	O
shown	O
to	O
be	O
permissive	O
for	O
lytic	O
replication	O
.	O

However	O
,	O
replication	O
of	O
EBV	O
in	O
vivo	O
is	O
controlled	O
primarily	O
by	O
host	O
immune	O
mechanisms	O
selecting	O
for	O
cells	O
that	O
are	O
not	B-Negation
permissive	I-Negation
for	I-Negation
viral	I-Negation
replication	I-Negation
as	O
the	O
result	O
of	O
a	O
particular	O
set	O
of	O
transcription	O
factors	O
.	O

These	O
factors	O
control	O
the	O
activity	O
of	O
the	O
regulatory	O
immediate-early	O
genes	O
and	O
,	O
in	O
addition	O
,	O
lytic	O
and	O
latent	O
cycle	O
regulatory	O
genes	O
negatively	O
interfere	O
with	O
each	O
other	O
and	O
thus	O
link	O
cellular	O
and	O
viral	O
gene	O
regulatory	O
mechanisms	O
.	O

Disturbance	O
of	O
both	O
the	O
immune	O
surveillance	O
as	O
well	O
as	O
viral	O
gene	O
regulation	O
may	O
result	O
in	O
EBV-associated	O
disease	O
.	O

Human	O
immunodeficiency	O
virus	O
type-1	O
transcription	O
:	O
role	O
of	O
the	O
5'-untranslated	O
leader	O
region	O
(	O
review	O
)	O
.	O

Human	O
immunodeficiency	O
virus	O
type-1	O
(	O
HIV-1	O
)	O
transcription	O
is	O
dependent	O
on	O
the	O
interaction	O
of	O
host-cell	O
transcription	O
factors	O
with	O
cis-regulatory	O
DNA	O
elements	O
within	O
the	O
viral	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
.	O

Much	O
attention	O
has	O
focused	O
on	O
the	O
series	O
of	O
sequence	O
elements	O
upstream	O
of	O
the	O
transcriptional	O
initiation	O
site	O
in	O
the	O
U3	O
region	O
of	O
the	O
LTR	O
including	O
the	O
Sp1	O
and	O
NF-kappaB	O
binding	O
sites	O
.	O

Recent	O
studies	O
,	O
however	O
,	O
demonstrate	O
that	O
the	O
transcribed	O
5'-untranslated	O
leader	O
region	O
(	O
5'-UTR	O
)	O
also	O
contains	O
important	O
transcriptional	O
elements	O
.	O

These	O
regulatory	O
elements	O
situated	O
downstream	O
of	O
transcription	O
interact	O
with	O
constitutive	O
and	O
inducible	O
transcription	O
factors	O
,	O
mediate	O
transmission	O
of	O
cellular	O
activation	O
signals	O
,	O
and	O
are	O
important	O
for	O
efficient	O
HIV-1	O
transcription	O
and	O
replication	O
.	O

The	O
5'-UTR	O
contains	O
binding	O
sites	O
for	O
the	O
transcription	O
factors	O
AP-1	O
,	O
NF-kappaB	O
,	O
NF-AT	O
,	O
IRF	O
,	O
and	O
Sp1	O
.	O

Mutations	O
in	O
these	O
binding	O
sites	O
can	O
interfere	O
with	O
the	O
viral	O
response	O
to	O
cell	O
activation	O
signals	O
,	O
decrease	O
LTR	O
transcription	O
,	O
and	O
inhibit	O
viral	O
replication	O
.	O

The	O
5'-UTR	O
also	O
interacts	O
with	O
a	O
specific	O
nucleosome	O
that	O
is	O
rapidly	O
displaced	O
during	O
transcriptional	O
activation	O
of	O
the	O
latent	O
provirus	O
.	O

We	O
propose	O
that	O
the	O
inducible	O
transcription	O
factor	O
binding	O
sites	O
in	O
the	O
5'-UTR	O
comprise	O
a	O
downstream	O
enhancer	O
domain	O
that	O
can	O
function	O
independent	O
of	O
,	O
or	O
in	O
concert	O
with	O
,	O
the	O
LTR	O
promoter	O
to	O
rapidly	O
increase	O
latent	O
proviral	O
transcription	O
in	O
response	O
to	O
cell	O
activation	O
signals	O
.	O

In	O
this	O
review	O
,	O
we	O
describe	O
the	O
host-cell	O
transcription	O
factors	O
that	O
interact	O
with	O
the	O
5'-UTR	O
and	O
discuss	O
their	O
role	O
in	O
the	O
transcriptional	O
regulation	O
of	O
HIV-1	O
gene	O
expression	O
.	O

Molecular	O
cloning	O
of	O
FKHRL1P2	O
,	O
a	O
member	O
of	O
the	O
developmentally	O
regulated	O
fork	O
head	O
domain	O
transcription	O
factor	O
family	O
.	O

Here	O
we	O
report	O
the	O
expression	O
of	O
a	O
fork	O
head	O
domain	O
protein	O
in	O
human	O
T	O
helper	O
cells	O
.	O

We	O
cloned	O
and	O
characterized	O
a	O
fork	O
head	O
cDNA	O
from	O
human	O
T	O
helper	O
cell	O
mRNA	O
using	O
differential	O
display	O
RT-PCR	O
.	O

The	O
cDNA	O
contains	O
a	O
546-nucleotide	O
(	O
nt	O
)	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
that	O
codes	O
for	O
the	O
carboxyl-terminal	O
180	O
amino	O
acids	O
(	O
aa	O
)	O
of	O
the	O
recently	O
identified	O
fkhrl1	O
gene	O
.	O

This	O
ORF	O
does	O
not	B-Negation
contain	I-Negation
the	I-Negation
characteristic	I-Negation
DNA-binding	I-Negation
domain	I-Negation
found	I-Negation
in	I-Negation
members	I-Negation
of	I-Negation
the	I-Negation
forkhead	I-Negation
protein	I-Negation
family	I-Negation
.	O

In-vitro	O
transcription/translation	O
of	O
this	O
cDNA	O
expressed	O
a	O
protein	O
of	O
approximately	O
20	O
kDa	O
.	O

We	O
have	O
generated	O
antibodies	O
that	O
specifically	O
immunoprecipitated	O
the	O
in-vitro-translated	O
20-kDa	O
protein	O
.	O

This	O
antibody	O
also	O
recognizes	O
in	O
human	O
T	O
lymphocytes	O
a	O
70-kDa	O
protein	O
corresponding	O
in	O
size	O
to	O
that	O
predicted	O
for	O
the	O
fkhrl1	O
gene	O
product	O
.	O

The	O
mRNA	O
levels	O
for	O
fkhrl1	O
is	O
elevated	O
in	O
T	O
helper-induced	O
lymphocytes	O
in	O
comparison	O
to	O
PHA-stimulated	O
T	O
lymphocytes	O
.	O

Further	O
characterization	O
of	O
FKHRL1	O
and	O
its	O
related	O
family	O
members	O
should	O
shed	O
light	O
on	O
the	O
transcriptional	O
mechanisms	O
of	O
this	O
fork	O
head	O
gene	O
subfamily	O
and	O
their	O
role	O
in	O
T	O
helper	O
cell	O
differentiation	O
and	O
regulation	O
of	O
cell	O
growth	O
.	O

Activation	O
of	O
the	O
human	O
delta-globin	O
gene	O
promoter	O
in	O
primary	O
adult	O
erythroid	O
cells	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
or	O
insertion	O
of	O
an	O
erythroid	O
Kruppel-like	O
factor	O
(	O
EKLF	O
)	O
binding	O
site	O
in	O
the	O
delta	O
promoter	O
activates	O
its	O
expression	O
in	O
several	O
erythroid	O
cell	O
lines	O
.	O

We	O
extended	O
these	O
studies	O
using	O
a	O
novel	O
primary	O
human	O
adult	O
erythroid	O
cell	O
(	O
hAEC	O
)	O
system	O
to	O
investigate	O
these	O
effects	O
at	O
the	O
late	O
erythroblast	O
stage	O
.	O

Restoration	O
of	O
the	O
CCAAT	O
box	O
at	O
-70	O
bp	O
,	O
or	O
insertion	O
of	O
an	O
EKLF	O
binding	O
site	O
at	O
-85	O
bp	O
or	O
-95	O
bp	O
in	O
the	O
promoter	O
significantly	O
increased	O
delta	O
globin	O
gene	O
expression	O
in	O
hAEC	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
altered	O
CCAAT	O
box	O
(	O
CCAAC	O
)	O
and	O
the	O
lack	B-Negation
of	I-Negation
an	I-Negation
EKLF	I-Negation
binding	I-Negation
site	I-Negation
in	I-Negation
delta-globin	I-Negation
contribute	O
to	O
its	O
low	O
level	O
of	O
expression	O
in	O
the	O
hAEC	O
model	O
as	O
well	O
.	O

Interactions	O
between	O
the	O
class	O
II	O
transactivator	O
and	O
CREB	O
binding	O
protein	O
increase	O
transcription	O
of	O
major	O
histocompatibility	O
complex	O
class	O
II	O
genes	O
.	O

Class	O
II	O
major	O
histocompatibility	O
(	O
class	O
II	O
)	O
genes	O
are	O
regulated	O
in	O
a	O
B-cell-specific	O
and	O
gamma	O
interferon-inducible	O
fashion	O
.	O

The	O
master	O
switch	O
for	O
the	O
expression	O
of	O
these	O
genes	O
is	O
the	O
class	O
II	O
transactivator	O
(	O
CIITA	O
)	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
one	O
of	O
the	O
functions	O
of	O
CIITA	O
is	O
to	O
recruit	O
the	O
CREB	O
binding	O
protein	O
(	O
CBP	O
)	O
to	O
class	O
II	O
promoters	O
.	O

Not	O
only	O
functional	O
but	O
also	O
specific	O
binding	O
interactions	O
between	O
CIITA	O
and	O
CBP	O
were	O
demonstrated	O
.	O

Moreover	O
,	O
a	O
dominant	O
negative	O
form	O
of	O
CBP	O
decreased	O
the	O
activity	O
of	O
class	O
II	O
promoters	O
and	O
levels	O
of	O
class	O
II	O
determinants	O
on	O
the	O
surface	O
of	O
cells	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
class	O
II	O
gene	O
expression	O
by	O
the	O
glucocorticoid	O
hormone	O
could	O
be	O
attributed	O
to	O
the	O
squelching	O
of	O
CBP	O
by	O
the	O
glucocorticoid	O
receptor	O
.	O

We	O
conclude	O
that	O
CBP	O
,	O
a	O
histone	O
acetyltransferase	O
,	O
plays	O
an	O
important	O
role	O
in	O
the	O
transcription	O
of	O
class	O
II	O
genes	O
.	O

Nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
and	O
AP-1	O
are	O
insufficient	O
for	O
IL-2	O
promoter	O
activation	O
:	O
requirement	O
for	O
CD28	O
up-regulation	O
of	O
RE/AP	O
.	O

IL-2	O
gene	O
transcription	O
in	O
T	O
cells	O
requires	O
both	O
TCR	O
and	O
costimulatory	O
signals	O
.	O

IL-2	O
promoter	O
activation	O
in	O
Jurkat	O
T	O
cells	O
stimulated	O
with	O
superantigen	O
presented	O
by	O
Raji	O
B	O
cells	O
requires	O
CD28	O
activation	O
.	O

The	O
addition	O
of	O
rCTLA4Ig	O
,	O
which	O
blocks	O
CD28	O
binding	O
to	O
its	O
ligand	O
,	O
to	O
the	O
cultures	O
decreased	O
IL-2	O
promoter	O
activation	O
by	O
>	O
80	O
%	O
.	O

Interestingly	O
,	O
CTLA4Ig	O
did	O
not	O
significantly	O
inhibit	O
the	O
activation	O
of	O
either	O
NF	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
or	O
AP-1	O
reporters	O
.	O

Therefore	O
,	O
activation	O
of	O
NFAT	O
and	O
AP-1	O
is	O
insufficient	O
for	O
IL-2	O
promoter	O
activation	O
.	O

In	O
contrast	O
,	O
an	O
RE/AP	O
reporter	O
was	O
blocked	O
by	O
CTLA4Ig	O
by	O
>	O
90	O
%	O
.	O

Thus	O
,	O
the	O
requirement	O
for	O
CD28	O
in	O
IL-2	O
promoter	O
activation	O
appears	O
to	O
be	O
due	O
to	O
RE/AP	O
and	O
not	O
the	O
NFAT	O
or	O
AP-1	O
sites	O
.	O

In	O
addition	O
,	O
these	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
RE/AP	O
is	O
not	O
mediated	O
by	O
NFAT	O
,	O
because	O
activation	O
of	O
a	O
NFAT	O
reporter	O
is	O
not	O
affected	O
by	O
the	O
addition	O
of	O
CTLA4Ig	O
.	O

Phenylarsine	O
oxide	O
inhibits	O
ex	O
vivo	O
HIV-1	O
expression	O
.	O

Phenylarsine	O
oxide	O
(	O
PAO	O
)	O
,	O
which	O
is	O
described	O
as	O
an	O
inhibitor	O
of	O
tyrosine	O
phosphatase	O
activity	O
,	O
inhibits	O
H2O2	O
release	O
from	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
as	O
measured	O
by	O
electrochemistry	O
.	O

Since	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
is	O
known	O
to	O
be	O
favored	O
under	O
oxidative	O
stress	O
conditions	O
,	O
ex	O
vivo	O
experiments	O
using	O
uninfected	O
PBMCs	O
,	O
primary	O
monocytes	O
or	O
a	O
latently	O
infected	O
promonocytic	O
U1	O
cell	O
line	O
show	O
that	O
HIV-1	O
replication	O
and	O
reactivation	O
,	O
monitored	O
by	O
p24	O
antigen	O
measurement	O
,	O
are	O
inhibited	O
by	O
PAO	O
in	O
a	O
time-	O
and	O
concentration-dependent	O
manner	O
.	O

These	O
observations	O
can	O
be	O
linked	O
with	O
the	O
inhibition	O
of	O
NF-kappa	O
B	O
activation	O
when	O
uninfected	O
monocytes	O
are	O
induced	O
by	O
either	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF-alpha	O
)	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
or	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Interleukin-10	O
stabilizes	O
inhibitory	O
kappaB-alpha	O
in	O
human	O
monocytes	O
.	O

Interleukin-10	O
(	O
IL-10	O
)	O
protects	O
animals	O
from	O
lethal	O
endotoxemia	O
.	O

This	O
beneficial	O
effect	O
is	O
mediated	O
,	O
in	O
part	O
,	O
by	O
inhibition	O
of	O
inflammatory	O
cytokine	O
production	O
,	O
including	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
.	O

Evidence	O
suggests	O
that	O
IL-10	O
may	O
inhibit	O
activation	O
of	O
the	O
transcription	O
factor	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
through	O
an	O
unknown	O
mechanism	O
.	O

NF-kappaB	O
activation	O
in	O
response	O
to	O
inflammatory	O
signals	O
is	O
dependent	O
upon	O
degradation	O
of	O
its	O
associated	O
inhibitory	O
peptide	O
,	O
inhibitory	O
kappaB-alpha	O
(	O
IkappaB-alpha	O
)	O
.	O

We	O
hypothesized	O
that	O
IL-10	O
prevents	O
human	O
monocyte	O
NF-kappaB	O
activation	O
and	O
resultant	O
TNF-alpha	O
production	O
by	O
stabilization	O
of	O
IkappaB-alpha	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
effect	O
of	O
IL-10	O
on	O
lipopolysaccharide	O
(	O
LPS	O
)	O
-induced	O
human	O
monocyte	O
TNF-alpha	O
production	O
,	O
NF-kappaB	O
activation	O
,	O
and	O
IkappaB-alpha	O
degradation	O
.	O

Monocytes	O
were	O
isolated	O
from	O
human	O
donors	O
.	O

Cells	O
were	O
stimulated	O
with	O
endotoxin	O
(	O
LPS	O
,	O
100	O
ng/mL	O
)	O
with	O
and	O
without	B-Negation
human	I-Negation
IL-10	I-Negation
(	I-Negation
10	I-Negation
ng/mL	I-Negation
)	I-Negation
.	O

Following	O
stimulation	O
,	O
TNF-alpha	O
was	O
measured	O
in	O
cell	O
supernatants	O
by	O
ELISA	O
,	O
NF-kappaB	O
activity	O
by	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
and	O
IkappaB-alpha	O
levels	O
by	O
Western	O
blot	O
.	O

We	O
observed	O
that	O
after	O
LPS	O
stimulation	O
of	O
human	O
monocytes	O
,	O
TNF-alpha	O
increased	O
to	O
798+/-67	O
pg/mL	O
(	O
p	O
<	O
.001	O
versus	O
control	O
)	O
.	O

IL-10	O
attenuated	O
LPS-stimulated	O
TNF-alpha	O
production	O
(	O
297+/-54	O
;	O
p	O
<	O
.001	O
versus	O
LPS	O
alone	O
)	O
.	O

After	O
LPS	O
stimulation	O
in	O
human	O
monocytes	O
,	O
IkappaB-alpha	O
protein	O
levels	O
decreased	O
,	O
and	O
NF-kappaB	O
DNA	O
binding	O
increased	O
.	O

IL-10	O
pretreatment	O
prevented	O
LPS-induced	O
decreases	O
in	O
IkappaB-alpha	O
protein	O
levels	O
and	O
attenuated	O
NF-kappaB	O
DNA	O
binding	O
.	O

IL-10	O
appears	O
to	O
prevent	O
activation	O
of	O
NF-kappaB	O
by	O
preserving	O
IkappaB-alpha	O
protein	O
levels	O
,	O
leading	O
to	O
a	O
reduction	O
in	O
TNF-alpha	O
release	O
.	O

Regulation	O
of	O
fas-ligand	O
expression	O
during	O
activation-induced	O
cell	O
death	O
in	O
T	O
lymphocytes	O
via	O
nuclear	O
factor	O
kappaB	O
.	O

T	O
cell	O
receptor	O
engagement	O
activates	O
transcription	O
factors	O
important	O
for	O
cytokine	O
gene	O
regulation	O
.	O

Additionally	O
,	O
this	O
signaling	O
pathway	O
also	O
leads	O
to	O
activation-induced	O
apoptosis	O
in	O
T	O
lymphocytes	O
that	O
is	O
dependent	O
on	O
FasL	O
transcription	O
and	O
expression	O
.	O

Here	O
we	O
demonstrate	O
that	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
,	O
which	O
is	O
involved	O
in	O
the	O
transcriptional	O
regulation	O
of	O
many	O
cytokine	O
genes	O
expressed	O
in	O
activated	O
lymphocytes	O
,	O
also	O
plays	O
a	O
role	O
in	O
T	O
cell	O
activation-induced	O
FasL	O
expression	O
.	O

Inhibition	O
of	O
NF-kappaB	O
activity	O
in	O
a	O
T	O
cell	O
hybridoma	O
leads	O
to	O
decreased	O
FasL	O
expression	O
and	O
apoptosis	O
upon	O
T	O
cell	O
receptor	O
stimulation	O
.	O

We	O
identified	O
the	O
NF-kappaB	O
site	O
in	O
the	O
FasL	O
promoter	O
that	O
contributes	O
to	O
such	O
regulation	O
.	O

Co-expression	O
of	O
p65	O
(	O
Rel	O
A	O
)	O
with	O
the	O
FasL	O
promoter	O
enhanced	O
its	O
activity	O
,	O
and	O
co-expression	O
of	O
IkappaB	O
dramatically	O
inhibited	O
the	O
inducible	O
promoter	O
activity	O
.	O

In	O
contrast	O
,	O
the	B-Negation
transcription	I-Negation
factor	I-Negation
AP-1	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
activation-induced	I-Negation
FasL	I-Negation
promoter	I-Negation
activity	I-Negation
.	O

These	O
results	O
define	O
a	O
role	O
for	O
NF-kappaB	O
in	O
mediating	O
FasL	O
expression	O
during	O
T	O
cell	O
activation	O
.	O

X-rays-induced	O
secretion	O
of	O
cellular	O
factor	O
(	O
s	O
)	O
that	O
enhance	O
(	O
s	O
)	O
HIV-1	O
promoter	O
transcription	O
in	O
various	O
non-irradiated	O
transfected	O
cell	O
lines	O
.	O

Various	O
cellular	O
stress	O
agents	O
like	O
ionizing	O
radiation	O
exposure	O
could	O
activate	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-	O
1	O
)	O
replication	O
or	O
reporter	O
gene	O
expression	O
.	O

In	O
addition	O
,	O
extracellular	O
factor	O
(	O
s	O
)	O
released	O
by	O
X-ray-treated	O
human	O
colonic	O
carcinoma	O
cell	O
line	O
(	O
HT29	O
)	O
might	O
activate	O
the	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
in	O
non-irradiated	O
HT29	O
cells	O
.	O

In	O
the	O
present	O
report	O
we	O
show	O
that	O
in	O
various	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
,	O
X-ray	O
irradiation	O
up-regulates	O
HIV-1	O
LTR	O
transcription	O
through	O
the	O
kappaB	O
regulatory	O
elements	O
.	O

A	O
factor	O
(	O
s	O
)	O
,	O
which	O
is	O
processed	O
by	O
and	O
acts	O
upon	O
a	O
variety	O
of	O
cell	O
types	O
,	O
was	O
detected	O
by	O
addition	O
to	O
non-irradiated	O
cells	O
of	O
either	O
X-ray-treated	O
cells	O
or	O
a	O
conditioned	O
medium	O
taken	O
from	O
irradiated	O
cultures	O
.	O

The	O
magnitude	O
of	O
responsiveness	O
is	O
cell	O
type	O
dependent	O
.	O

In	O
addition	O
,	O
X-ray	O
activation	O
of	O
HIV-1	O
LTR	O
in	O
transiently	O
or	O
stably	O
transfected	O
cell	O
lines	O
is	O
inhibited	O
by	O
a	O
potent	O
antioxidant	O
drug	O
,	O
pyrrolidine	O
dithiocarbamate	O
and	O
by	O
another	O
drug	O
,	O
known	O
for	O
its	O
role	O
in	O
the	O
trapping	O
of	O
growth	O
factors	O
,	O
suramin	O
.	O

The	O
importance	O
of	O
these	O
observations	O
in	O
the	O
pathophysiology	O
of	O
patients	O
with	O
AIDS-related	O
cancers	O
treated	O
by	O
radiotherapy	O
remains	O
to	O
be	O
established	O
.	O

Reactivation	O
of	O
Kaposi	O
's	O
sarcoma-associated	O
herpesvirus	O
infection	O
from	O
latency	O
by	O
expression	O
of	O
the	O
ORF	O
50	O
transactivator	O
,	O
a	O
homolog	O
of	O
the	O
EBV	O
R	O
protein	O
.	O

Kaposi	O
's	O
sarcoma	O
(	O
KS	O
)	O
-associated	O
herpesvirus	O
(	O
KSHV	O
)	O
,	O
or	O
human	O
herpesvirus	O
8	O
,	O
is	O
a	O
lymphotropic	O
virus	O
strongly	O
linked	O
to	O
several	O
AIDS-related	O
neoplasms	O
.	O

The	O
primary	O
reservoir	O
of	O
infection	O
consists	O
of	O
latently	O
infected	O
B	O
lymphocytes	O
and	O
possibly	O
other	O
mononuclear	O
cells	O
.	O

Viral	O
reactivation	O
from	O
latency	O
and	O
spread	O
from	O
this	O
lymphoid	O
reservoir	O
is	O
presumably	O
required	O
for	O
development	O
of	O
nonlymphoid	O
tumors	O
like	O
KS	O
.	O

Here	O
we	O
show	O
that	O
deregulated	O
expression	O
of	O
a	O
single	O
viral	O
gene	O
,	O
ORF	O
50	O
,	O
which	O
encodes	O
a	O
transactivator	O
able	O
to	O
selectively	O
upregulate	O
delayed-early	O
viral	O
genes	O
,	O
suffices	O
to	O
disrupt	O
latency	O
and	O
induce	O
the	O
lytic	O
gene	O
cascade	O
in	O
latently	O
infected	O
B	O
cells	O
.	O

The	O
identification	O
of	O
this	O
gene	O
opens	O
the	O
way	O
to	O
studies	O
of	O
the	O
physiologic	O
mechanisms	O
controlling	O
reactvation	O
of	O
KSHV	O
from	O
latency	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Regulation	O
of	O
interleukin-1beta	O
transcription	O
by	O
Epstein-Barr	O
virus	O
involves	O
a	O
number	O
of	O
latent	O
proteins	O
via	O
their	O
interaction	O
with	O
RBP	O
.	O

Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
infects	O
B	O
cells	O
,	O
resulting	O
in	O
the	O
outgrowth	O
of	O
immortalised	O
lymphoblastoid	O
cell	O
lines	O
(	O
LCLs	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
through	O
the	O
use	O
of	O
intracellular	O
staining	O
that	O
interleukin-1beta	O
(	O
IL-1beta	O
)	O
is	O
expressed	O
in	O
LCLs	O
and	O
investigate	O
the	O
influence	O
of	O
the	O
individual	O
latent	O
proteins	O
on	O
the	O
expression	O
of	O
IL-1beta	O
.	O

Using	O
RT-PCR	O
,	O
IL-1beta	O
was	O
shown	O
to	O
be	O
up-regulated	O
in	O
EBV-transformed	O
LCLs	O
as	O
well	O
as	O
in	O
group	O
III	O
Burkitt	O
's	O
lymphoma	O
(	O
BL	O
)	O
cell	O
lines	O
,	O
compared	O
with	O
group	O
I	O
BL	O
cell	O
lines	O
.	O

The	O
up-regulation	O
of	O
IL-1beta	O
message	O
could	O
be	O
mediated	O
by	O
the	O
latent	O
membrane	O
protein-1	O
,	O
EBV	O
nuclear	O
proteins	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
6	O
genes	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
(	O
EMSAs	O
)	O
demonstrated	O
that	O
the	O
-300	O
region	O
of	O
the	O
IL-1beta	O
promoter	O
,	O
which	O
contains	O
a	O
nuclear	O
factor-kappaB	O
(	O
NF-kappaB	O
)	O
binding	O
site	O
,	O
contained	O
a	O
functional	O
RBP	O
binding	O
site	O
.	O

Binding	O
of	O
RBP	O
to	O
this	O
site	O
could	O
be	O
inhibited	O
by	O
addition	O
of	O
EBV	O
nuclear	O
proteins	O
3	O
and	O
6	O
,	O
suggesting	O
that	O
these	O
proteins	O
displace	O
RBP	O
from	O
its	O
recognition	O
sequence	O
,	O
removing	O
transcriptional	O
repression	O
and	O
allowing	O
gene	O
transcription	O
to	O
occur	O
.	O

In	O
group	O
I	O
BL	O
cells	O
,	O
containing	O
low	O
levels	O
of	O
NF-kappaB	O
,	O
only	O
RBP	O
binding	O
was	O
observed	O
in	O
EMSAs	O
,	O
whereas	O
NF-kappaB	O
binding	O
could	O
be	O
demonstrated	O
in	O
EBV-transformed	O
B	O
cell	O
lines	O
containing	O
high	O
levels	O
of	O
activated	O
NF-kappaB	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
latent	O
membrane	O
protein-1	O
led	O
to	O
activation	O
of	O
NF-kappaB	O
that	O
was	O
capable	O
of	O
binding	O
the	O
IL-1beta	O
promoter	O
.	O

The	O
study	O
demonstrates	O
that	O
EBV	O
can	O
up-regulate	O
IL-1beta	O
expression	O
,	O
possibly	O
by	O
using	O
RBP	O
,	O
NF-kappaB	O
,	O
or	O
both	O
.	O

Copyright	O
1998	O
Academic	O
Press	O
.	O

Characterization	O
of	O
the	O
human	O
elk-1	O
promoter	O
.	O

Potential	O
role	O
of	O
a	O
downstream	O
intronic	O
sequence	O
for	O
elk-1	O
gene	O
expression	O
in	O
monocytes	O
.	O

To	O
characterize	O
the	O
human	O
elk-1	O
promoter	O
,	O
we	O
mapped	O
the	O
transcriptional	O
start	O
site	O
and	O
isolated	O
elk-1-specific	O
genomic	O
phage	O
clones	O
that	O
contained	O
extensive	O
upstream	O
and	O
downstream	O
sequences	O
.	O

A	O
TATA-like	O
motif	O
was	O
identified	O
immediately	O
upstream	O
of	O
the	O
transcriptional	O
start	O
site	O
.	O

Functional	O
analyses	O
of	O
DNA	O
fragments	O
containing	O
the	O
TATA	O
element	O
and	O
the	O
identification	O
of	O
a	O
DNase	O
I-hypersensitive	O
chromatin	O
site	O
(	O
HS	O
1	O
)	O
in	O
close	O
proximity	O
to	O
the	O
TATA	O
box	O
suggest	O
that	O
the	O
identified	O
TATA	O
motif	O
is	O
important	O
for	O
elk-1	O
transcription	O
in	O
vivo	O
.	O

Sequences	O
upstream	O
and	O
downstream	O
from	O
the	O
TATA	O
box	O
were	O
found	O
to	O
contribute	O
to	O
elk-1	O
promoter	O
activity	O
.	O

A	O
second	O
hypersensitive	O
site	O
(	O
HS	O
2	O
)	O
was	O
identified	O
within	O
the	O
first	O
intron	O
in	O
pre-monocytic	O
cells	O
,	O
which	O
express	O
Elk-1	O
only	O
when	O
differentiating	O
to	O
monocytes	O
.	O

In	O
a	O
variety	O
of	O
other	O
cell	O
types	O
,	O
which	O
display	O
a	O
constitutive	O
Elk-1	O
expression	O
,	O
HS	O
2	O
did	O
not	B-Negation
exist	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
inducibility	I-Speculation
of	I-Speculation
elk-1	I-Speculation
expression	I-Speculation
is	I-Speculation
associated	I-Speculation
with	I-Speculation
the	I-Speculation
presence	I-Speculation
of	I-Speculation
HS	I-Speculation
2	I-Speculation
.	O

Egr-1	O
and	O
the	O
serum	O
response	O
factor	O
were	O
found	O
to	O
interact	O
specifically	O
with	O
the	O
intronic	O
sequence	O
at	O
+265	O
and	O
+448	O
,	O
respectively	O
.	O

Because	O
Egr-1	O
mRNA	O
and	O
protein	O
levels	O
were	O
observed	O
to	O
increase	O
significantly	O
before	O
induction	O
of	O
elk-1	O
expression	O
,	O
we	O
propose	O
that	O
Egr-1	O
is	O
important	O
for	O
the	O
regulation	O
of	O
elk-1	O
transcription	O
in	O
differentiating	O
monocytes	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
tax	O
protein	O
abrogates	O
interleukin-2	O
dependence	O
in	O
a	O
mouse	O
T-cell	O
line	O
.	O

Human	O
T-cell	O
leukemia	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia	O
.	O

Tax	O
,	O
the	O
viral	O
protein	O
,	O
is	O
thought	O
to	O
be	O
crucial	O
in	O
the	O
development	O
of	O
the	O
disease	O
,	O
since	O
it	O
transforms	O
healthy	O
T	O
cells	O
in	O
vitro	O
and	O
induces	O
tumors	O
in	O
transgenic	O
animals	O
.	O

We	O
examined	O
the	O
effect	O
of	O
Tax	O
activity	O
on	O
the	O
growth	O
of	O
the	O
interleukin-2	O
(	O
IL-2	O
)	O
-dependent	O
T-cell	O
line	O
CTLL-2	O
.	O

Stable	O
expression	O
of	O
Tax	O
in	O
CTLL-2	O
transformed	O
cell	O
growth	O
from	O
being	O
IL-2	O
dependent	O
to	O
IL-2	O
independent	O
.	O

Tax	O
stimulated	O
transcription	O
through	O
NF-kappaB	O
and	O
the	O
cyclic	O
AMP-responsive	O
element-like	O
sequence	O
in	O
the	O
HTLV-1	O
promoter	O
.	O

The	O
finding	O
of	O
Tax	O
mutants	O
segregating	O
these	O
two	O
pathways	O
suggested	O
that	O
the	O
NF-kappaB	O
pathway	O
was	O
essential	O
for	O
IL-2-independent	O
growth	O
of	O
CTLL-2	O
cells	O
while	O
the	O
CRE	O
pathway	O
was	O
unnecessary	O
.	O

However	O
,	O
both	O
pathways	O
were	O
necessary	O
for	O
another	O
transformation-related	O
activity	O
(	O
colony	O
formation	O
in	O
soft	O
agar	O
)	O
of	O
CTLL-2/Tax	O
.	O

Our	O
results	O
show	O
that	O
Tax	O
has	O
at	O
least	O
two	O
distinct	O
activities	O
on	O
T	O
cells	O
,	O
and	O
suggest	O
that	O
Tax	O
plays	O
a	O
crucial	O
role	O
in	O
IL-2-independent	O
T-cell	O
transformation	O
induced	O
by	O
HTLV-1	O
,	O
in	O
addition	O
to	O
its	O
well-known	O
IL-2-dependent	O
cell	O
transformation	O
.	O

Mildly	O
oxidized	O
low-density	O
lipoproteins	O
decrease	O
early	O
production	O
of	O
interleukin	O
2	O
and	O
nuclear	O
factor	O
kappaB	O
binding	O
to	O
DNA	O
in	O
activated	O
T-lymphocytes	O
.	O

Activated	O
T-lymphocytes	O
are	O
found	O
early	O
in	O
atherosclerosis	O
lesions	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
role	O
.	O

Oxidized	O
low-density	O
lipoproteins	O
(	O
oxLDLs	O
)	O
are	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lesions	O
,	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	O
inhibit	O
not	O
only	O
interleukin	O
(	O
IL	O
)	O
-2-receptor	O
expression	O
on	O
the	O
surface	O
of	O
in	O
vitro-activated	O
T-lymphocytes	O
but	O
also	O
their	O
proliferation	O
.	O

We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	O
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	O
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O

Mildly	O
oxLDLs	O
(	O
50	O
and	O
100	O
microgram/ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	O
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	O
by	O
phytohaemagglutinin	O
and	O
PMA+ionomycin	O
.	O

The	O
inhibition	O
of	O
IL-2	O
production	O
was	O
observed	O
in	O
the	O
CD3	O
(	O
+	O
)	O
T-lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA+ionomycin	O
.	O

The	O
study	O
of	O
NF-kappaB	O
showed	O
that	O
oxLDLs	O
led	O
to	O
a	O
decrease	O
of	O
activation-induced	O
p65/p50	O
NF-kappaB	O
heterodimer	O
binding	O
to	O
DNA	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
constitutive	O
nuclear	O
form	O
of	O
p50	O
dimer	O
was	O
unchanged	O
.	O

This	O
was	O
correlated	O
with	O
an	O
unchanged	O
level	O
of	O
the	O
active	O
form	O
of	O
the	O
cytosolic	O
inhibitor	O
protein	O
IkappaB-alpha	O
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	O
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	O
activation	O
mechanisms	O
.	O

Binding	O
of	O
HMG-I	O
(	O
Y	O
)	O
elicits	O
structural	O
changes	O
in	O
a	O
silencer	O
of	O
the	O
human	O
beta-globin	O
gene	O
.	O

Proteins	O
involved	O
in	O
repression	O
of	O
the	O
human	O
beta-globin	O
gene	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
sickle	O
cell	O
anemia	O
,	O
in	O
conjunction	O
with	O
therapy	O
to	O
reactivate	O
fetal	O
globin	O
genes	O
.	O

If	O
there	O
is	O
a	O
reciprocal	O
elevation	O
of	O
gamma-globin	O
expression	O
upon	O
repression	O
,	O
this	O
approach	O
could	O
be	O
useful	O
in	O
additional	O
hemoglobinopathies	O
.	O

We	O
previously	O
showed	O
that	O
repression	O
of	O
the	O
beta-globin	O
gene	O
appears	O
to	O
be	O
mediated	O
through	O
two	O
DNA	O
sequences	O
,	O
silencers	O
I	O
and	O
II	O
,	O
and	O
identified	O
a	O
protein	O
termed	O
BP1	O
which	O
binds	O
to	O
both	O
silencer	O
sequences	O
.	O

In	O
this	O
study	O
,	O
we	O
cloned	O
two	O
cDNAs	O
encoding	O
proteins	O
which	O
bind	O
to	O
an	O
oligonucleotide	O
in	O
silencer	O
I	O
containing	O
a	O
BP1	O
binding	O
site	O
.	O

These	O
cDNAs	O
correspond	O
to	O
HMG-I	O
and	O
HMG-Y	O
,	O
isoforms	O
regarded	O
as	O
architectural	O
proteins	O
.	O

We	O
demonstrate	O
that	O
binding	O
of	O
HMG-I	O
(	O
Y	O
)	O
to	O
this	O
oligonucleotide	O
causes	O
bending/flexure	O
of	O
the	O
DNA	O
.	O

HMG-I	O
(	O
Y	O
)	O
also	O
binds	O
to	O
a	O
second	O
oligonucleotide	O
containing	O
a	O
BP1	O
binding	O
site	O
located	O
in	O
a	O
negative	O
control	O
region	O
upstream	O
of	O
the	O
delta-globin	O
gene	O
,	O
suggesting	O
a	O
role	O
for	O
HMG-I	O
(	O
Y	O
)	O
in	O
repression	O
of	O
adult	O
globin	O
genes	O
.	O

Expression	O
studies	O
revealed	O
that	O
HMG-I	O
(	O
Y	O
)	O
is	O
ubiquitously	O
expressed	O
in	O
human	O
tissues	O
that	O
do	O
not	B-Negation
express	I-Negation
beta-globin	I-Negation
,	O
being	O
present	O
in	O
48	O
of	O
50	O
tissues	O
and	O
six	O
hematopoietic	O
cell	O
lines	O
examined	O
.	O

Furthermore	O
,	O
HMG-I	O
(	O
Y	O
)	O
expression	O
is	O
down-regulated	O
during	O
differentiation	O
of	O
primary	O
erythroid	O
cells	O
.	O

We	O
present	O
a	O
model	O
in	O
which	O
HMG-I	O
(	O
Y	O
)	O
alters	O
DNA	O
conformation	O
to	O
allow	O
binding	O
of	O
repressor	O
proteins	O
,	O
and	O
in	O
which	O
the	O
relative	O
amount	O
of	O
HMG-I	O
(	O
Y	O
)	O
helps	O
to	O
determine	O
the	O
repressive	O
state	O
of	O
the	O
beta-globin	O
gene	O
.	O

Regulation	O
of	O
IL-6	O
synthesis	O
in	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
by	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
.	O

The	O
anaphylatoxin	O
C3a	O
has	O
been	O
reported	O
to	O
have	O
immunomodulatory	O
effects	O
on	O
a	O
number	O
of	O
different	O
cell	O
types	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
on	O
gene	O
expression	O
and	O
protein	O
secretion	O
of	O
IL-6	O
in	O
human	O
PBMCs	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
LPS	O
or	O
IL-1beta	O
.	O

C3a	O
or	O
C3a	O
(	O
desArg	O
)	O
alone	O
exhibited	O
no	B-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
expression	I-Negation
or	I-Negation
secretion	I-Negation
of	I-Negation
IL-6	I-Negation
.	O

However	O
,	O
when	O
PBMC	O
were	O
stimulated	O
with	O
LPS	O
or	O
IL-1beta	O
,	O
both	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
were	O
found	O
to	O
enhance	O
IL-6	O
release	O
by	O
PBMC	O
in	O
a	O
dose-dependent	O
manner	O
.	O

Since	O
C3a	O
has	O
been	O
shown	O
to	O
induce	O
PGE2	O
production	O
by	O
monocytes	O
,	O
and	O
PGE2	O
has	O
been	O
shown	O
to	O
influence	O
cytokine	O
production	O
,	O
we	O
investigated	O
the	O
potential	O
role	O
of	O
PGE2	O
in	O
C3a-mediated	O
enhancement	O
of	O
LPS-	O
and	O
IL-1beta-induced	O
IL-6	O
production	O
.	O

Indomethacin	O
blocked	O
PGE2	O
release	O
,	O
but	O
had	O
no	B-Negation
influence	I-Negation
on	I-Negation
the	I-Negation
observed	I-Negation
effects	I-Negation
of	I-Negation
C3a	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
effects	I-Speculation
of	I-Speculation
C3a	I-Speculation
on	I-Speculation
IL-6	I-Speculation
production	I-Speculation
are	I-Speculation
independent	I-Speculation
of	I-Speculation
PGE2	I-Speculation
formation	I-Speculation
by	I-Speculation
monocytes	I-Speculation
.	O

Northern	O
blot	O
analysis	O
showed	O
that	O
C3a	O
as	O
well	O
as	O
C3a	O
(	O
desArg	O
)	O
enhanced	O
LPS-induced	O
mRNA	O
levels	O
for	O
IL-6	O
.	O

Pretreatment	O
of	O
PBMCs	O
with	O
pertussis	O
toxin	O
blocked	O
the	O
functions	O
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
,	O
indicating	O
that	O
the	O
actions	O
of	O
these	O
two	O
molecules	O
are	O
mediated	O
by	O
a	O
G	O
protein-coupled	O
pathway	O
.	O

Furthermore	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
C3a	O
and	O
C3a	O
(	O
desArg	O
)	O
on	O
induction	O
of	O
NF-kappaB	O
and	O
activating	O
protein-1	O
binding	O
.	O

Both	O
molecules	O
enhanced	O
LPS-induced	O
NF-kappaB	O
and	O
activating	O
protein-1	O
binding	O
activity	O
.	O

These	O
results	O
demonstrate	O
the	O
capacity	O
of	O
intact	O
C3a	O
and	O
its	O
circulating	O
des-Arg	O
form	O
to	O
exert	O
immunmodulatory	O
effects	O
in	O
vitro	O
.	O

Differential	O
monocyte	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
venous	O
and	O
arterial	O
endothelial	O
cells	O
.	O

We	O
compared	O
U-937	O
cell	O
adhesion	O
and	O
adhesion	O
molecule	O
expression	O
in	O
human	O
umbilical	O
venous	O
(	O
HUVECs	O
)	O
and	O
arterial	O
(	O
HUAECs	O
)	O
endothelial	O
cells	O
exposed	O
to	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
,	O
interleukin-1	O
,	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

TNF	O
and	O
LPS	O
stimulated	O
vascular	O
cell	O
adhesion	O
molecule	O
(	O
VCAM	O
)	O
-1	O
surface	O
expression	O
and	O
adhesion	O
of	O
U-937	O
monocyte-like	O
cells	O
to	O
HUVECs	O
but	O
not	B-Negation
to	I-Negation
HUAECs	I-Negation
.	O

Antibody	O
studies	O
demonstrated	O
that	O
in	O
HUVECs	O
at	O
least	O
75	O
%	O
of	O
the	O
adhesion	O
response	O
is	O
VCAM-1	O
mediated	O
.	O

Interleukin-1	O
stimulated	O
U-937	O
cell	O
adhesion	O
to	O
and	O
VCAM-1	O
surface	O
expression	O
in	O
both	O
HUVECs	O
and	O
HUAECs	O
.	O

Pyrrolidinedithiocarbamate	O
and	O
the	O
proteasome	O
inhibitor	O
MG-132	O
blocked	O
TNF-	O
and	O
LPS-stimulated	O
U-937	O
cell	O
adhesion	O
to	O
HUVECs	O
.	O

These	O
agents	O
also	O
significantly	O
decreased	O
TNF-	O
and	O
LPS-stimulated	O
increases	O
in	O
HUVEC	O
surface	O
VCAM-1	O
.	O

TNF	O
increased	O
VCAM-1	O
protein	O
and	O
mRNA	O
in	O
HUVECs	O
that	O
was	O
blocked	O
by	O
pyrrolidinedithiocarbamate	O
.	O

However	O
,	O
neither	B-Negation
TNF	I-Negation
or	I-Negation
LPS	I-Negation
stimulated	I-Negation
VCAM-1	I-Negation
expression	I-Negation
in	I-Negation
HUAECs	I-Negation
.	O

TNF	O
stimulated	O
expression	O
of	O
both	O
intercellular	O
adhesion	O
molecule-1	O
and	O
E-selectin	O
in	O
HUVECs	O
,	O
but	O
in	O
HUAECs	O
,	O
only	O
intercellular	O
adhesion	O
molecule-1	O
was	O
increased	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
demonstrated	O
no	B-Negation
difference	I-Negation
in	I-Negation
the	I-Negation
pattern	I-Negation
of	I-Negation
TNF-stimulated	I-Negation
nuclear	I-Negation
factor-kappaB	I-Negation
activation	I-Negation
between	I-Negation
HUVECs	I-Negation
and	I-Negation
HUAECs	I-Negation
.	O

These	O
studies	O
demonstrate	O
a	O
novel	O
and	O
striking	O
insensitivity	O
of	O
arterial	O
endothelium	O
to	O
the	O
effects	O
of	O
TNF	O
and	O
LPS	O
and	O
indicate	O
a	O
dissociation	O
between	O
the	O
ability	O
of	O
HUAECs	O
to	O
upregulate	O
nuclear	O
factor-kappaB	O
and	O
VCAM-1	O
.	O

Tissue	O
factor	O
expression	O
of	O
human	O
monocytes	O
is	O
suppressed	O
by	O
lysophosphatidylcholine	O
.	O

The	O
expression	O
of	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
the	O
principal	O
initiator	O
of	O
coagulation	O
,	O
is	O
increased	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Both	O
conditions	O
are	O
promoted	O
by	O
lysophosphatidylcholine	O
(	O
lysoPC	O
)	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
lysoPC	O
(	O
1	O
to	O
10	O
micromol/L	O
)	O
dose-dependently	O
reduced	O
TF	O
activity	O
in	O
human	O
monocytes	O
,	O
as	O
elicited	O
by	O
lipopolysaccharide	O
(	O
LPS	O
)	O
.	O

Lysophosphatidylethanolamine	O
(	O
lysoPE	O
)	O
and	O
other	O
lysophospholipids	O
did	O
not	B-Negation
affect	I-Negation
LPS-induced	I-Negation
TF	I-Negation
activity	I-Negation
of	I-Negation
human	I-Negation
monocytes	I-Negation
.	O

TF	O
antigen	O
expression	O
as	O
elicited	O
by	O
LPS	O
was	O
also	O
lowered	O
by	O
lysoPC	O
.	O

Phospholipid	O
analyses	O
indicated	O
a	O
selective	O
increase	O
in	O
the	O
lysoPC	O
content	O
of	O
the	O
monocytes	O
after	O
preincubation	O
with	O
the	O
lysophospholipid	O
.	O

LysoPC	O
inhibited	O
the	O
TF	O
activity	O
of	O
Mono	O
Mac-6	O
cells	O
to	O
a	O
similar	O
extent	O
as	O
in	O
the	O
monocytes	O
.	O

LPS	B-Negation
binding	I-Negation
to	I-Negation
plasma	I-Negation
membrane	I-Negation
receptors	I-Negation
and	I-Negation
internalization	I-Negation
of	I-Negation
LPS	I-Negation
into	I-Negation
monocytes	I-Negation
were	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
lysoPC	I-Negation
.	O

In	O
contrast	O
,	O
LPS-mediated	O
nuclear	O
binding	O
of	O
nuclear	O
factor-kappaB/Rel	O
to	O
a	O
TF-specific	O
kappaB	O
site	O
was	O
inhibited	O
by	O
lysoPC	O
.	O

Induction	O
of	O
TF	O
mRNA	O
expression	O
by	O
LPS	O
tended	O
to	O
be	O
partially	O
reduced	O
by	O
the	O
lysophospholipid	O
.	O

Preincubation	O
with	O
lysoPC	O
increased	O
monocytic	O
cAMP	O
levels	O
.	O

Inhibition	O
of	O
adenylyl	O
cyclase	O
by	O
pretreatment	O
with	O
2'-deoxy-3'-adenosine	O
monophosphate	O
partially	O
reversed	O
the	O
inhibition	O
of	O
TF	O
activity	O
promoted	O
by	O
lysoPC	O
.	O

In	O
conclusion	O
,	O
lysoPC	O
markedly	O
decreases	O
LPS-mediated	O
TF	O
expression	O
of	O
human	O
monocytes	O
,	O
the	O
effect	O
probably	O
being	O
mediated	O
by	O
both	O
transcriptional	O
and	O
posttranscriptional	O
mechanisms	O
.	O

LysoPC	O
may	O
thus	O
attenuate	O
activation	O
of	O
coagulation	O
during	O
inflammation	O
and	O
atherosclerosis	O
.	O

Intranuclear	O
targeted	O
delivery	O
of	O
functional	O
NF-kappaB	O
by	O
70	O
kDa	O
heat	O
shock	O
protein	O
.	O

The	O
70	O
kDa	O
heat	O
shock	O
protein	O
(	O
Hsp70	O
)	O
is	O
a	O
highly	O
conserved	O
,	O
ubiquitous	O
protein	O
involved	O
in	O
chaperoning	O
proteins	O
to	O
various	O
cellular	O
organelles	O
.	O

Here	O
we	O
show	O
that	O
when	O
added	O
exogenously	O
to	O
cells	O
,	O
Hsp70	O
is	O
readily	O
imported	O
into	O
both	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
a	O
cell-type-specific	O
fashion	O
.	O

We	O
exploited	O
this	O
ability	O
of	O
Hsp70	O
to	O
deliver	O
NF-kappaB	O
,	O
a	O
key	O
transcriptional	O
regulator	O
of	O
inflammatory	O
responses	O
.	O

We	O
demonstrate	O
that	O
a	O
fusion	O
protein	O
composed	O
of	O
a	O
C-terminal	O
Hsp70	O
peptide	O
and	O
the	O
p50	O
subunit	O
of	O
NF-kappaB	O
was	O
directed	O
into	O
the	O
nucleus	O
of	O
cells	O
,	O
could	O
bind	O
DNA	O
specifically	O
,	O
and	O
activated	O
Igkappa	O
expression	O
and	O
TNFalpha	O
production	O
.	O

We	O
therefore	O
propose	O
that	O
Hsp70	O
can	O
be	O
used	O
as	O
a	O
vehicle	O
for	O
intracytoplasmic	O
and	O
intranuclear	O
delivery	O
of	O
proteins	O
or	O
DNA	O
to	O
modulate	O
gene	O
expression	O
and	O
thereby	O
control	O
immune	O
responses	O
.	O

CD2	O
signalling	O
induces	O
phosphorylation	O
of	O
CREB	O
in	O
primary	O
lymphocytes	O
.	O

Promoter	O
sequences	O
responsive	O
to	O
cyclic	O
AMP	O
(	O
cAMP	O
)	O
are	O
found	O
in	O
a	O
number	O
of	O
cellular	O
genes	O
,	O
and	O
bind	O
transcription	O
factors	O
of	O
the	O
cAMP	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
/activating	O
transcription	O
factor-1	O
(	O
ATF-1	O
)	O
family	O
.	O

We	O
have	O
used	O
a	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
model	O
of	O
cAMP	O
response	O
element	O
(	O
CRE	O
)	O
transcription	O
to	O
investigate	O
the	O
influence	O
of	O
lymphocyte	O
activation	O
on	O
transcription	O
from	O
homologous	O
regions	O
in	O
the	O
viral	O
promoter	O
.	O

We	O
previously	O
demonstrated	O
increased	O
HTLV-1	O
transcription	O
following	O
CD2	O
but	O
not	B-Negation
CD3	I-Negation
receptor	I-Negation
cross-linking	I-Negation
.	O

We	O
hypothesized	O
that	O
this	O
increased	O
viral	O
transcription	O
was	O
mediated	O
,	O
in	O
part	O
,	O
through	O
the	O
phosphorylation	O
of	O
CREB	O
.	O

Therefore	O
,	O
we	O
investigated	O
CD2	O
and	O
CD3	O
receptor-mediated	O
signalling	O
in	O
primary	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

CD2	O
,	O
but	O
not	B-Negation
CD3	I-Negation
,	O
cross-linking	O
increased	O
cAMP	O
detected	O
by	O
competitive	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
approximately	O
fourfold	O
.	O

CD2	O
cross-linking	O
concurrently	O
increased	O
phosphorylation	O
of	O
CREB	O
detected	O
by	O
immunoblot	O
assay	O
eightfold	O
.	O

Consistent	O
with	O
post-translational	O
regulation	O
,	O
no	B-Negation
change	I-Negation
in	I-Negation
total	I-Negation
level	I-Negation
of	I-Negation
CREB	I-Negation
protein	I-Negation
was	I-Negation
observed	I-Negation
.	O

Phosphorylation	O
of	O
CREB	O
occurred	O
through	O
a	O
herbimycin	O
A	O
and	O
Rp-cAMP-sensitive	O
pathway	O
,	O
suggesting	O
phosphorylation	O
required	O
antecedent	O
activation	O
of	O
both	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
and	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
CD2	O
and	O
CD3	O
cross-linking	O
increased	O
binding	O
of	O
nuclear	O
proteins	O
to	O
a	O
radiolabelled	O
CRE	O
oligonucleotide	O
probe	O
in	O
electrophoretic	O
mobility	O
shift	O
assays	O
suggesting	O
that	O
lymphocyte	O
activation	O
enhances	O
binding	O
independently	O
of	O
phosphorylation	O
of	O
CREB	O
at	O
serine	O
133	O
.	O

These	O
data	O
indicate	O
specific	O
modulation	O
of	O
the	O
CREB/ATF-1	O
family	O
of	O
transcription	O
factors	O
by	O
the	O
CD2	O
signalling	O
pathway	O
and	O
suggest	O
CD2	O
receptor	O
modulation	O
of	O
CRE-mediated	O
transcription	O
following	O
ligand	O
engagement	O
(	O
e.g.	O
cell-to-cell	O
contact	O
)	O
.	O

Anoxia/reoxygenation-induced	O
tolerance	O
with	O
respect	O
to	O
polymorphonuclear	O
leukocyte	O
adhesion	O
to	O
cultured	O
endothelial	O
cells	O
.	O

A	O
nuclear	O
factor-kappaB-mediated	O
phenomenon	O
.	O

Exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
to	O
anoxia/reoxygenation	O
(	O
A/R	O
)	O
results	O
in	O
an	O
increase	O
in	O
polymorphonuclear	O
leukocyte	O
(	O
PMN	O
)	O
adhesion	O
to	O
HUVECs	O
.	O

This	O
A/R-induced	O
hyperadhesion	O
is	O
completely	O
prevented	O
by	O
a	O
previous	O
(	O
24	O
hours	O
earlier	O
)	O
exposure	O
of	O
HUVECs	O
to	O
A/R	O
.	O

This	O
phenomenon	O
has	O
been	O
termed	O
``	O
A/R	O
tolerance	O
.	O
``	O

Exposing	O
HUVECs	O
to	O
A/R	O
induces	O
an	O
increase	O
in	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	O
)	O
in	O
HUVEC	O
nuclei	O
within	O
4	O
hours	O
.	O

Interfering	O
with	O
either	O
NF-kappaB	O
activation	O
(	O
proteasome	O
inhibitor	O
)	O
or	O
translocation	O
(	O
double-stranded	O
oligonucleotides	O
containing	O
NF-kappaB	O
binding	O
sequence	O
)	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
ie	O
,	O
the	O
increase	O
in	O
A/R-induced	O
PMN	O
adhesion	O
to	O
HUVECs	O
is	O
the	O
same	O
after	O
the	O
first	O
and	O
second	O
A/R	O
challenges	O
)	O
.	O

NO	O
production	O
by	O
HUVECs	O
is	O
increased	O
after	O
the	O
second	O
A/R	O
challenge	O
,	O
but	O
not	B-Negation
after	I-Negation
the	I-Negation
first	I-Negation
A/R	I-Negation
challenge	I-Negation
.	O

Inhibition	O
of	O
NO	O
synthase	O
(	O
NOS	O
)	O
during	O
the	O
second	O
A/R	O
challenge	O
prevents	O
the	O
development	O
of	O
A/R	O
tolerance	O
with	O
respect	O
to	O
PMN	O
adhesion	O
.	O

However	O
,	O
while	O
HUVECs	O
contained	O
endothelial	O
NOS	O
protein	O
,	O
no	B-Negation
inducible	I-Negation
NOS	I-Negation
was	I-Negation
detected	I-Negation
in	I-Negation
either	I-Negation
tolerant	I-Negation
or	I-Negation
nontolerant	I-Negation
cells	I-Negation
.	O

Further	O
studies	O
indicated	O
that	O
inhibition	O
of	O
GTP-cyclohydrolase	O
I	O
(	O
an	O
enzyme	O
involved	O
in	O
de	O
novo	O
synthesis	O
of	O
an	O
important	O
cofactor	O
for	O
NOS	O
activity	O
,	O
tetrahydrobiopterin	O
)	O
prevented	O
the	O
generation	O
of	O
NO	O
in	O
A/R-tolerant	O
cells	O
.	O

Extracellular	O
generation	O
of	O
NO	O
(	O
NO	O
donor	O
)	O
did	O
not	B-Negation
effect	I-Negation
the	I-Negation
hyperadhesion	I-Negation
response	I-Negation
induced	I-Negation
by	I-Negation
the	I-Negation
initial	I-Negation
A/R	I-Negation
challenge	I-Negation
.	O

A/R	O
also	O
induced	O
an	O
oxidant	O
stress	O
in	O
naive	O
HUVECs	O
,	O
but	O
not	B-Negation
in	I-Negation
A/R-tolerant	I-Negation
HUVECs	I-Negation
.	O

Inhibition	O
of	O
NOS	O
during	O
the	O
second	O
A/R	O
insult	O
results	O
in	O
the	O
generation	O
of	O
an	O
oxidant	O
stress	O
similar	O
to	O
that	O
observed	O
after	O
the	O
first	O
A/R	O
challenge	O
.	O

Taken	O
together	O
,	O
the	O
findings	O
of	O
the	O
present	O
study	O
are	O
consistent	O
with	O
a	O
role	O
for	O
NF-kappaB	O
in	O
the	O
development	O
of	O
A/R	O
tolerance	O
(	O
with	O
respect	O
to	O
PMN	O
adhesion	O
)	O
,	O
perhaps	O
by	O
transcriptional	O
regulation	O
of	O
GTP-cyclohydrolase	O
.	O

The	O
increased	O
NO	O
production	O
during	O
the	O
second	O
A/R	O
insult	O
reduces	O
PMN	O
adhesion	O
most	O
likely	O
by	O
reducing	O
the	O
intracellular	O
oxidant	O
stress	O
induced	O
by	O
A/R	O
.	O

Role	O
of	O
Egr-2	O
in	O
up-regulation	O
of	O
Fas	O
ligand	O
in	O
normal	O
T	O
cells	O
and	O
aberrant	O
double-negative	O
lpr	O
and	O
gld	O
T	O
cells	O
.	O

We	O
previously	O
identified	O
a	O
Fas	O
ligand	O
regulatory	O
element	O
(	O
FLRE	O
)	O
in	O
the	O
Fas	O
ligand	O
(	O
fasL	O
)	O
promoter	O
that	O
binds	O
Egr	O
family	O
proteins	O
and	O
demonstrated	O
that	O
Egr-3	O
(	O
PILOT	O
)	O
but	O
not	B-Negation
Egr-1	I-Negation
(	I-Negation
NGFI-A	I-Negation
,	I-Negation
Krox-24	I-Negation
,	I-Negation
Tis-8	I-Negation
,	I-Negation
and	I-Negation
Zif-268	I-Negation
)	I-Negation
induces	O
transcription	O
of	O
fasL	O
.	O

The	O
aberrant	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
from	O
lpr/lpr	O
and	O
gld/gld	O
mice	O
,	O
which	O
have	O
mutations	O
in	O
the	O
genes	O
encoding	O
Fas	O
and	O
FasL	O
,	O
respectively	O
,	O
have	O
an	O
activated	O
phenotype	O
and	O
constitutively	O
express	O
high	O
levels	O
of	O
fasL	O
mRNA	O
,	O
prompting	O
us	O
to	O
ask	O
what	O
role	O
if	O
any	O
the	O
FLRE	O
and	O
Egr	O
family	O
proteins	O
have	O
in	O
this	O
aberrant	O
expression	O
of	O
fasL	O
.	O

Unstimulated	O
MRL-lpr/lpr	O
and	O
C3H-gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
constitutively	O
contained	O
high	O
levels	O
of	O
two	O
proteins	O
that	O
bound	O
to	O
the	O
FLRE	O
.	O

Supershift	O
analysis	O
revealed	O
these	O
proteins	O
to	O
be	O
Egr-1	O
and	O
Egr-2	O
(	O
Krox-20	O
)	O
;	O
Egr-3	B-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
.	O

Activation	O
of	O
normal	O
lymph	O
node	O
cells	O
resulted	O
in	O
increased	O
expression	O
of	O
Egr-1	O
,	O
-2	O
,	O
and	O
-3	O
.	O

As	O
with	O
egr-3	O
,	O
expression	O
of	O
egr-2	O
was	O
blocked	O
by	O
cyclosporin	O
A	O
.	O

Although	O
overexpressed	O
Egr-1	O
was	O
ineffective	O
,	O
overexpressed	O
Egr-2	O
was	O
as	O
potent	O
as	O
Egr-3	O
in	O
inducing	O
fasL	O
promoter-dependent	O
reporter	O
constructs	O
in	O
T	O
cell	O
hybridomas	O
and	O
HeLa	O
cells	O
,	O
and	O
both	O
up-regulated	O
endogenous	O
fasL	O
mRNA	O
in	O
HeLa	O
cells	O
.	O

FasL-dependent	O
reporter	O
constructs	O
in	O
MRL-lpr/lpr	O
and	O
C3H-gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
were	O
constitutively	O
active	O
,	O
and	O
this	O
activity	O
was	O
largely	O
prevented	O
by	O
mutation	O
of	O
the	O
critical	O
Egr	O
family	O
binding	O
element	O
.	O

Thus	O
,	O
Egr-2	O
,	O
in	O
addition	O
to	O
Egr-3	O
,	O
regulates	O
FasL	O
expression	O
in	O
activated	O
normal	O
T	O
cells	O
,	O
and	O
Egr-2	O
is	O
likely	O
to	O
play	O
a	O
direct	O
role	O
in	O
aberrant	O
fasL	O
up-regulation	O
in	O
lpr/lpr	O
and	O
gld/gld	O
CD4	O
(	O
-	O
)	O
CD8	O
(	O
-	O
)	O
T	O
cells	O
.	O

Involvement	O
of	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
in	O
interleukin-8	O
production	O
by	O
human	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
stimulated	O
with	O
lipopolysaccharide	O
or	O
Mycoplasma	O
fermentans	O
membrane	O
lipoproteins	O
.	O

Interleukin-8	O
(	O
IL-8	O
)	O
is	O
a	O
chemokine	O
that	O
belongs	O
to	O
the	O
alpha-chemokine	O
or	O
CXC	O
subfamily	O
and	O
is	O
produced	O
by	O
a	O
wide	O
variety	O
of	O
human	O
cells	O
,	O
including	O
monocytes	O
and	O
polymorphonuclear	O
cells	O
(	O
PMN	O
)	O
.	O

IL-8	O
is	O
secreted	O
in	O
response	O
to	O
inflammatory	O
stimuli	O
,	O
notably	O
bacterial	O
products	O
such	O
as	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
but	O
little	O
is	O
known	O
about	O
the	O
mechanisms	O
by	O
which	O
these	O
agents	O
mediate	O
IL-8	O
induction	O
.	O

In	O
this	O
report	O
,	O
we	O
show	O
that	O
Mycoplasma	O
fermentans	O
lipid-associated	O
membrane	O
proteins	O
(	O
LAMPf	O
)	O
induce	O
the	O
production	O
of	O
high	O
levels	O
of	O
IL-8	O
by	O
THP-1	O
(	O
human	O
monocyte	O
)	O
cells	O
and	O
PMN	O
at	O
the	O
same	O
extent	O
as	O
LPS	O
.	O

It	O
was	O
previously	O
demonstrated	O
that	O
stimulation	O
of	O
monocytic	O
cells	O
with	O
either	O
LPS	O
or	O
LAMPf	O
led	O
to	O
a	O
series	O
of	O
common	O
downstream	O
signaling	O
events	O
,	O
including	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
and	O
of	O
mitogen-activated	O
protein	O
kinase	O
cascades	O
.	O

By	O
using	O
PD-98059	O
and	O
SB203580	O
,	O
two	O
potent	O
and	O
selective	O
inhibitors	O
of	O
MEK1	O
(	O
a	O
kinase	O
upstream	O
of	O
ERK1/2	O
)	O
and	O
p38	O
,	O
respectively	O
,	O
we	O
have	O
demonstrated	O
that	O
both	O
ERK1/2	O
and	O
p38	O
cascades	O
play	O
a	O
key	O
role	O
in	O
the	O
production	O
of	O
IL-8	O
by	O
monocytes	O
and	O
PMN	O
stimulated	O
with	O
bacterial	O
fractions	O
.	O

T	O
cell	O
priming	O
enhances	O
IL-4	O
gene	O
expression	O
by	O
increasing	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
.	O

The	O
repetitive	O
activation	O
of	O
T	O
cells	O
(	O
priming	O
)	O
enhances	O
the	O
expression	O
of	O
many	O
cytokines	O
,	O
such	O
as	O
IL-4	O
,	O
but	O
not	B-Negation
others	I-Negation
,	I-Negation
such	I-Negation
as	I-Negation
IL-2	I-Negation
.	O

Molecular	O
mechanisms	O
underlying	O
selective	O
expression	O
of	O
cytokines	O
by	O
T	O
cells	O
remain	O
poorly	O
understood	O
.	O

Here	O
we	O
show	O
that	O
priming	O
of	O
CD4	O
T	O
cells	O
selectively	O
enhances	O
IL-4	O
expression	O
relative	O
to	O
IL-2	O
expression	O
by	O
a	O
transcriptional	O
mechanism	O
involving	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
(	O
NFAT	O
)	O
proteins	O
.	O

As	O
detected	O
by	O
in	O
vivo	O
footprinting	O
,	O
priming	O
markedly	O
increases	O
the	O
activation-dependent	O
engagement	O
of	O
the	O
P0	O
and	O
P1	O
NFAT-binding	O
elements	O
of	O
the	O
IL-4	O
promoter	O
.	O

Moreover	O
,	O
each	O
proximal	O
P	O
element	O
is	O
essential	O
for	O
optimal	O
IL-4	O
promoter	O
activity	O
.	O

Activated	O
primed	O
CD4	O
T	O
cells	O
contain	O
more	O
NFAT1	O
and	O
support	O
greater	O
NFAT-directed	O
transcription	O
than	O
unprimed	O
CD4	O
T	O
cells	O
,	O
while	O
activator	O
protein	O
1	O
binding	O
and	O
activator	O
protein	O
1-mediated	O
transcription	O
by	O
both	O
cell	O
types	O
is	O
similar	O
.	O

Increased	O
expression	O
of	O
wild-type	O
NFAT1	O
substantially	O
increases	O
IL-4	O
promoter	O
activity	O
in	O
unprimed	O
CD4	O
T	O
cells	O
,	O
suggesting	O
NFAT1	O
may	O
be	O
limiting	O
for	O
IL-4	O
gene	O
expression	O
in	O
this	O
cell	O
type	O
.	O

Furthermore	O
,	O
a	O
truncated	O
form	O
of	O
NFAT1	O
acts	O
as	O
a	O
dominant-negative	O
,	O
reducing	O
IL-4	O
promoter	O
activity	O
in	O
primed	O
CD4	O
T	O
cells	O
and	O
confirming	O
the	O
importance	O
of	O
endogenous	O
NFAT	O
to	O
increased	O
IL-4	O
gene	O
expression	O
by	O
effector	O
T	O
cells	O
.	O

NFAT1	O
appears	O
to	O
be	O
the	O
major	O
NFAT	O
family	O
member	O
responsible	O
for	O
the	O
initial	O
increased	O
expression	O
of	O
IL-4	O
by	O
primed	O
CD4	O
T	O
cells	O
.	O

Inhibition	O
of	O
NF-kappa	O
B	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
:	O
role	O
of	O
26S	O
proteasome	O
.	O

It	O
is	O
becoming	O
increasingly	O
apparent	O
that	O
NF-kappa	O
B	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
inflammatory	O
response	O
.	O

Data	O
obtained	O
from	O
studies	O
in	O
our	O
laboratories	O
demonstrate	O
that	O
the	O
proteasome	O
plays	O
an	O
important	O
role	O
in	O
the	O
inflammatory	O
cascade	O
by	O
regulating	O
the	O
activation	O
of	O
NF-kappa	O
B	O
.	O

Indeed	O
,	O
the	O
availability	O
of	O
selective	O
and	O
orally	O
active	O
proteasome	O
inhibitors	O
should	O
prove	O
useful	O
in	O
delineating	O
the	O
roles	O
of	O
the	O
proteasome	O
and	O
NF-kappa	O
B	O
in	O
other	O
pathophysiological	O
conditions	O
such	O
as	O
cancer	O
and	O
heart	O
disease	O
.	O

Comparison	O
of	O
HTLV-I	O
basal	O
transcription	O
and	O
expression	O
of	O
CREB/ATF-1/CREM	O
family	O
members	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
Jurkat	O
T	O
cells	O
.	O

HTLV-I	O
is	O
the	O
etiologic	O
agent	O
of	O
adult	O
T-cell	O
leukemia/lymphoma	O
and	O
is	O
associated	O
with	O
tropical	O
spastic	O
paraparesis/HTLV-I-associated	O
myelopathy	O
.	O

Following	O
integration	O
into	O
the	O
host	O
cell	O
genome	O
,	O
HTLV-I	O
replication	O
is	O
regulated	O
by	O
both	O
host	O
and	O
viral	O
mechanisms	O
that	O
control	O
transcription	O
.	O

Low	O
levels	O
of	O
viral	O
transcription	O
(	O
basal	O
transcription	O
)	O
occur	O
before	O
expression	O
of	O
the	O
virally	O
encoded	O
Tax	O
protein	O
(	O
Tax-mediated	O
transcription	O
)	O
.	O

Members	O
of	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
response	O
element	O
binding	O
(	O
CREB	O
)	O
/activating	O
transcription	O
factor	O
1	O
(	O
ATF-1	O
)	O
family	O
of	O
transcription	O
factors	O
bind	O
three	O
21-bp	O
repeats	O
(	O
Tax-responsive	O
element-1	O
,	O
or	O
TRE-1	O
)	O
within	O
the	O
viral	O
promoter	O
and	O
are	O
important	O
for	O
basal	O
and	O
Tax-mediated	O
transcription	O
.	O

Using	O
mitogen	O
stimulated	O
and	O
quiescent	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
Jurkat	O
cells	O
,	O
we	O
compared	O
differences	O
in	O
basal	O
transcription	O
and	O
amounts	O
and	O
binding	O
of	O
transcription	O
factors	O
with	O
TRE-1	O
.	O

We	O
demonstrate	O
that	O
amounts	O
of	O
transcriptionally	O
active	O
phosphorylated	O
CREB	O
protein	O
(	O
P-CREB	O
)	O
differ	O
between	O
activated	O
PBMC	O
and	O
Jurkat	O
cells	O
.	O

Following	O
stimulation	O
,	O
P-CREB	O
levels	O
remain	O
elevated	O
in	O
PBMC	O
for	O
up	O
to	O
24	O
hours	O
whereas	O
CREB	O
is	O
dephosphorylated	O
in	O
Jurkat	O
cells	O
within	O
4	O
hours	O
following	O
stimulation	O
.	O

The	O
differences	O
in	O
P-CREB	O
levels	O
between	O
PBMC	O
and	O
Jurkat	O
cells	O
were	O
directly	O
correlated	O
with	O
basal	O
transcription	O
of	O
HTLV-I	O
in	O
the	O
two	O
cell	O
types	O
.	O

Using	O
electrophoretic	O
mobility	O
shift	O
assays	O
,	O
we	O
determined	O
that	O
the	O
pattern	O
of	O
band	O
migration	O
differed	O
between	O
the	O
two	O
cell	O
types	O
.	O

These	O
data	O
demonstrate	O
that	O
PBMC	O
differentially	O
regulate	O
basal	O
HTLV-I	O
transcription	O
compared	O
with	O
Jurkat	O
T	O
cells	O
,	O
and	O
this	O
differential	O
regulation	O
is	O
due	O
,	O
in	O
part	O
to	O
differential	O
phosphorylation	O
and	O
binding	O
of	O
CREB/ATF-1	O
to	O
TRE-1	O
in	O
the	O
HTLV-I	O
promoter	O
.	O

We	O
demonstrate	O
the	O
utility	O
of	O
using	O
primary	O
lymphocyte	O
models	O
to	O
study	O
HTLV-I	O
transcription	O
in	O
the	O
context	O
of	O
cell	O
signaling	O
and	O
suggest	O
that	O
activated	O
PBMC	O
maintain	O
elevated	O
levels	O
of	O
P-CREB	O
,	O
which	O
promote	O
basal	O
HTLV-I	O
transcription	O
and	O
enhance	O
viral	O
persistence	O
in	O
vivo	O
.	O

NF-kappaB	O
activation	O
is	O
a	O
critical	O
regulator	O
of	O
human	O
granulocyte	O
apoptosis	O
in	O
vitro	O
.	O

During	O
beneficial	O
inflammation	O
,	O
potentially	O
tissue-damaging	O
granulocytes	O
undergo	O
apoptosis	O
before	O
being	O
cleared	O
by	O
phagocytes	O
in	O
a	O
non-phlogistic	O
manner	O
.	O

Here	O
we	O
show	O
that	O
the	O
rate	O
of	O
constitutive	O
apoptosis	O
in	O
human	O
neutrophils	O
and	O
eosinophils	O
is	O
greatly	O
accelerated	O
in	O
both	O
a	O
rapid	O
and	O
concentration-dependent	O
manner	O
by	O
the	O
fungal	O
metabolite	O
gliotoxin	O
,	O
but	O
not	B-Negation
by	I-Negation
its	I-Negation
inactive	I-Negation
analog	I-Negation
methylthiogliotoxin	I-Negation
.	O

This	O
induction	O
of	O
apoptosis	O
was	O
abolished	O
by	O
the	O
caspase	O
inhibitor	O
zVAD-fmk	O
,	O
correlated	O
with	O
the	O
inhibition	O
of	O
nuclear	O
factor-kappa	O
B	O
(	O
NF-kappaB	O
)	O
,	O
and	O
was	O
mimicked	O
by	O
a	O
cell	O
permeable	O
inhibitory	O
peptide	O
of	O
NF-kappaB	O
,	O
SN-50	O
;	O
other	O
NF-kappaB	O
inhibitors	O
,	O
curcumin	O
and	O
pyrrolidine	O
dithiocarbamate	O
;	O
and	O
the	O
proteasome	O
inhibitor	O
,	O
MG-132	O
.	O

Gliotoxin	O
also	O
augmented	O
dramatically	O
the	O
early	O
(	O
2-6	O
h	O
)	O
pro-apoptotic	O
effects	O
of	O
tumor	O
necrosis	O
factor-alpha	O
(	O
TNF-alpha	O
)	O
in	O
neutrophils	O
and	O
unmasked	O
the	O
ability	O
of	O
TNF-alpha	O
to	O
induce	O
eosinophil	O
apoptosis	O
.	O

In	O
neutrophils	O
,	O
TNF-alpha	O
caused	O
a	O
gliotoxin-inhibitable	O
activation	O
of	O
an	O
inducible	O
form	O
of	O
NF-kappaB	O
,	O
a	O
response	O
that	O
may	O
underlie	O
the	O
ability	O
of	O
TNF-alpha	O
to	O
delay	O
apoptosis	O
at	O
later	O
times	O
(	O
12-24	O
h	O
)	O
and	O
limit	O
its	O
early	O
killing	O
effect	O
.	O

Furthermore	O
,	O
cycloheximide	O
displayed	O
a	O
similar	O
capacity	O
to	O
enhance	O
TNF-alpha	O
induced	O
neutrophil	O
apoptosis	O
even	O
at	O
time	O
points	O
when	O
cycloheximide	O
alone	O
had	O
no	B-Negation
pro-apoptotic	I-Negation
effect	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
NF-kappaB	I-Speculation
may	I-Speculation
regulate	I-Speculation
the	I-Speculation
production	I-Speculation
of	I-Speculation
protein	I-Speculation
(	I-Speculation
s	I-Speculation
)	I-Speculation
which	I-Speculation
protect	I-Speculation
neutrophils	I-Speculation
from	I-Speculation
the	I-Speculation
cytotoxic	I-Speculation
effects	I-Speculation
of	I-Speculation
TNF-alpha	I-Speculation
.	O

These	O
data	O
shed	O
light	O
on	O
the	O
biochemical	O
and	O
molecular	O
mechanisms	O
regulating	O
human	O
granulocyte	O
apoptosis	O
and	O
,	O
in	O
particular	O
,	O
indicate	O
that	O
the	O
transcription	O
factor	O
NF-kappaB	O
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
the	O
physiological	O
cell	O
death	O
pathway	O
in	O
granulocytes	O
.	O

Lactobacilli	O
and	O
vaginal	O
host	O
defense	O
:	O
activation	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
long	O
terminal	O
repeat	O
,	O
cytokine	O
production	O
,	O
and	O
NF-kappaB	O
.	O

Lactobacilli	O
,	O
a	O
component	O
of	O
the	O
normal	O
vaginal	O
flora	O
,	O
can	O
activate	O
the	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-1	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
in	O
the	O
Jurkat	O
T	O
lymphocyte	O
and	O
THP-1	O
macrophage	O
cell	O
lines	O
.	O

Activation	O
of	O
the	O
LTR	O
in	O
Jurkat	O
cells	O
was	O
strongly	O
enhanced	O
by	O
vanadate	O
and	O
inhibited	O
by	O
catalase	O
,	O
implicating	O
H2O2	O
.	O

In	O
contrast	O
,	O
activation	O
in	O
THP-1	O
cells	O
occurred	O
in	O
the	O
absence	B-Negation
of	I-Negation
vanadate	I-Negation
and	O
was	O
unaffected	O
by	O
catalase	O
.	O

The	O
active	O
material	O
partitioned	O
into	O
the	O
phenol	O
layer	O
on	O
hot	O
aqueous	O
phenol	O
extraction	O
.	O

Lactobacilli	O
also	O
increased	O
tumor	O
necrosis	O
factor-alphaand	O
interleukin-1betaproduction	O
and	O
activated	O
NF-kappaB	O
in	O
THP-1	O
cells	O
and	O
increased	O
tumor	O
necrosis	O
factor-alphaproduction	O
by	O
human	O
monocytes	O
.	O

Human	O
vaginal	O
fluid	O
specimens	O
had	O
comparable	O
properties	O
,	O
which	O
correlated	O
with	O
their	O
bacterial	O
content	O
.	O

These	O
findings	O
suggest	O
the	O
presence	O
in	O
vaginal	O
fluid	O
of	O
agent	O
(	O
s	O
)	O
derived	O
from	O
indigenous	O
bacteria	O
that	O
can	O
activate	O
the	O
HIV-1	O
LTR	O
,	O
cytokine	O
production	O
,	O
and	O
NF-kappaB	O
in	O
cells	O
of	O
macrophage	O
lineage	O
,	O
with	O
possible	O
influence	O
on	O
vaginal	O
physiology	O
and	O
host	O
defense	O
.	O

High-level	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
in	O
thymocytes	O
requires	O
NF-kappaB	O
activation	O
through	O
interaction	O
with	O
thymic	O
epithelial	O
cells	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
interaction	O
of	O
infected	O
thymocytes	O
with	O
autologous	O
thymic	O
epithelial	O
cells	O
(	O
TEC	O
)	O
is	O
a	O
prerequisite	O
for	O
a	O
high	O
level	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
replication	O
in	O
thymocytes	O
(	O
M.Rothe	O
,	O
L.Chene	O
,	O
M.Nugeyre	O
,	O
F.Barre-Sinoussi	O
,	O
and	O
N.Israel	O
,	O
J.Virol.72:5852-5861	O
,	O
1998	O
)	O
.	O

We	O
report	O
here	O
that	O
this	O
activation	O
of	O
HIV	O
replication	O
takes	O
place	O
at	O
the	O
transcriptional	O
level	O
through	O
activation	O
of	O
the	O
Rel/NF-kappaB	O
transcription	O
factors	O
.	O

We	O
first	O
demonstrate	O
that	O
an	O
HIV-1	O
provirus	O
(	O
SF-2	O
strain	O
)	O
very	O
effectively	O
replicates	O
in	O
thymocytes	O
cocultured	O
with	O
TEC	O
whereas	O
this	O
provirus	O
,	O
with	O
kappaB	O
sites	O
deleted	O
,	O
fails	B-Negation
to	I-Negation
replicate	I-Negation
.	O

We	O
provide	O
evidence	O
that	O
several	O
NF-kappaB	O
complexes	O
are	O
constitutively	O
found	O
in	O
the	O
nuclei	O
of	O
thymocytes	O
either	O
freshly	O
isolated	O
from	O
the	O
thymus	O
or	O
maintained	O
in	O
coculture	O
with	O
autologous	O
or	O
heterologous	O
TEC	O
.	O

The	O
prevalent	O
complex	O
is	O
the	O
heterodimer	O
p50-p65	O
.	O

NF-kappaB	O
activity	O
is	O
tightly	O
correlated	O
with	O
the	O
transcriptional	O
activity	O
of	O
a	O
long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
of	O
HIV-1	O
transfected	O
in	O
thymocytes	O
.	O

The	O
cotransfection	O
of	O
this	O
LTR	O
with	O
a	O
mutated	O
IkappaBalpha	O
molecule	O
formally	O
demonstrates	O
that	O
LTR	O
transactivation	O
is	O
regulated	O
by	O
members	O
of	O
the	O
Rel/NF-kappaB	O
family	O
in	O
thymocytes	O
.	O

We	O
also	O
showed	O
that	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
and	O
to	O
a	O
lesser	O
extent	O
interleukin-1	O
(	O
IL-1	O
)	O
,	O
secreted	O
within	O
the	O
coculture	O
,	O
induce	O
NF-kappaB	O
activity	O
and	O
a	O
correlative	O
LTR	O
transactivation	O
.	O

However	O
IL-7	O
,	O
a	O
crucial	O
factor	O
for	O
thymopoiesis	O
that	O
is	O
secreted	O
mainly	O
by	O
TEC	O
,	O
is	O
a	O
necessary	O
cofactor	O
for	O
NF-kappaB	O
activation	O
elicited	O
by	O
TNF	O
or	O
IL-1	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
NF-kappaB	O
activation	O
,	O
required	O
for	O
a	O
high	O
level	O
of	O
HIV	O
replication	O
in	O
thymocytes	O
,	O
is	O
regulated	O
in	O
a	O
specific	O
manner	O
in	O
the	O
thymic	O
microenvironment	O
which	O
provides	O
the	O
necessary	O
cytokines	O
:	O
TNF	O
,	O
IL-1	O
,	O
and	O
IL-7	O
.	O

Cross-linking	O
of	O
CD44	O
on	O
rheumatoid	O
synovial	O
cells	O
up-regulates	O
VCAM-1	O
.	O

CD44	O
is	O
a	O
ubiquitous	O
molecule	O
also	O
known	O
as	O
hyaluronic	O
acid	O
or	O
homing	O
receptor	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
and	O
its	O
role	O
in	O
inflammation	O
,	O
for	O
example	O
,	O
rheumatoid	O
synovitis	O
,	O
are	O
currently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
propose	O
a	O
novel	O
function	O
for	O
CD44	O
.	O

Using	O
synovial	O
cells	O
from	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
patients	O
,	O
we	O
demonstrated	O
that	O
CD44	O
cross-linking	O
and	O
binding	O
to	O
hyaluronan	O
augmented	O
VCAM-1	O
expression	O
and	O
subsequently	O
VCAM-1-mediated	O
cell	O
adhesion	O
.	O

Briefly	O
,	O
we	O
found	O
that	O
1	O
)	O
rheumatoid	O
synovial	O
cells	O
highly	O
expressed	O
CD44	O
;	O
2	O
)	O
cross-linking	O
of	O
CD44	O
markedly	O
but	O
transiently	O
augmented	O
VCAM-1	O
expression	O
and	O
its	O
mRNA	O
transcription	O
much	O
more	O
than	O
did	O
IL-1beta	O
and	O
TNF-alpha	O
;	O
3	O
)	O
hyaluronan	O
,	O
especially	O
when	O
fragmented	O
,	O
also	O
up-regulated	O
VCAM-1	O
;	O
4	O
)	O
CD44	O
activated	O
the	O
transcription	O
factor	O
AP-1	O
;	O
and	O
5	O
)	O
the	O
integrin-dependent	O
adhesive	O
function	O
of	O
RA	O
synovial	O
cells	O
to	O
T	O
cells	O
was	O
also	O
amplified	O
by	O
CD44	O
cross-linking	O
.	O

These	O
results	O
indicate	O
that	O
the	O
adhesion	O
of	O
RA	O
synovial	O
cells	O
to	O
matrices	O
such	O
as	O
hyaluronic	O
acid	O
through	O
CD44	O
could	O
up-regulate	O
VCAM-1	O
expression	O
and	O
VCAM-1-mediated	O
adhesion	O
to	O
T	O
cells	O
,	O
which	O
might	O
in	O
turn	O
cause	O
activation	O
of	O
T	O
cells	O
and	O
synovial	O
cells	O
in	O
RA	O
synovitis	O
.	O

We	O
therefore	O
propose	O
that	O
such	O
cross-talking	O
among	O
distinct	O
adhesion	O
molecules	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
inflammation	O
,	O
including	O
RA	O
synovitis	O
.	O

Oleic	O
acid	O
inhibits	O
endothelial	O
activation	O
:	O
A	O
direct	O
vascular	O
antiatherogenic	O
mechanism	O
of	O
a	O
nutritional	O
component	O
in	O
the	O
mediterranean	O
diet	O
.	O

Because	O
oleic	O
acid	O
is	O
implicated	O
in	O
the	O
antiatherogenic	O
effects	O
attributed	O
to	O
the	O
Mediterranean	O
diet	O
,	O
we	O
investigated	O
whether	O
this	O
fatty	O
acid	O
can	O
modulate	O
endothelial	O
activation	O
,	O
ie	O
,	O
the	O
concerted	O
expression	O
of	O
gene	O
products	O
involved	O
in	O
leukocyte	O
recruitment	O
and	O
early	O
atherogenesis	O
.	O

We	O
incubated	O
sodium	O
oleate	O
with	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
0	O
to	O
72	O
hours	O
,	O
followed	O
by	O
coincubation	O
of	O
oleate	O
with	O
human	O
recombinant	O
tumor	O
necrosis	O
factor	O
,	O
interleukin	O
(	O
IL	O
)	O
-1alpha	O
,	O
IL-1beta	O
,	O
IL-4	O
,	O
Escherichia	O
coli	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
or	O
phorbol	O
12-myristate	O
13-acetate	O
for	O
a	O
further	O
6	O
to	O
24	O
hours	O
.	O

The	O
endothelial	O
expression	O
of	O
vascular	O
cell	O
adhesion	O
molecule-1	O
(	O
VCAM-1	O
)	O
,	O
E-selectin	O
,	O
and	O
intercellular	O
adhesion	O
molecule-1	O
was	O
monitored	O
by	O
cell	O
surface	O
enzyme	O
immunoassays	O
or	O
flow	O
cytometry	O
,	O
and	O
steady-state	O
levels	O
of	O
VCAM-1	O
mRNA	O
were	O
assessed	O
by	O
Northern	O
blot	O
analysis	O
.	O

At	O
10	O
to	O
100	O
micromol/L	O
for	O
>	O
24	O
hours	O
,	O
oleate	O
inhibited	O
the	O
expression	O
of	O
all	O
adhesion	O
molecules	O
tested	O
.	O

After	O
a	O
72-hour	O
incubation	O
with	O
oleate	O
and	O
a	O
further	O
16-hour	O
incubation	O
with	O
oleate	O
plus	O
1	O
microg/mL	O
LPS	O
,	O
VCAM-1	O
expression	O
was	O
reduced	O
by	O
>	O
40	O
%	O
compared	O
with	O
control	O
.	O

Adhesion	O
of	O
monocytoid	O
U937	O
cells	O
to	O
LPS-treated	O
endothelial	O
cells	O
was	O
reduced	O
concomitantly	O
.	O

Oleate	O
also	O
produced	O
a	O
quantitatively	O
similar	O
reduction	O
of	O
VCAM-1	O
mRNA	O
levels	O
on	O
Northern	O
blot	O
analysis	O
and	O
inhibited	O
nuclear	O
factor-kappaB	O
activation	O
on	O
electrophoretic	O
mobility	O
shift	O
assays	O
.	O

Incubation	O
of	O
endothelial	O
cells	O
with	O
oleate	O
for	O
72	O
hours	O
decreased	O
the	O
relative	O
proportions	O
of	O
saturated	O
(	O
palmitic	O
and	O
stearic	O
)	O
acids	O
in	O
total	O
cell	O
lipids	O
and	O
increased	O
the	O
proportions	O
of	O
oleate	O
in	O
total	O
cell	O
lipids	O
without	B-Negation
significantly	I-Negation
changing	I-Negation
the	I-Negation
relative	I-Negation
proportions	I-Negation
of	I-Negation
polyunsaturated	I-Negation
fatty	I-Negation
acids	I-Negation
.	O

Although	O
less	O
potent	O
than	O
polyunsaturated	O
fatty	O
acids	O
in	O
inhibiting	O
endothelial	O
activation	O
,	O
oleic	O
acid	O
may	O
contribute	O
to	O
the	O
prevention	O
of	O
atherogenesis	O
through	O
selective	O
displacement	O
of	O
saturated	O
fatty	O
acids	O
in	O
cell	O
membrane	O
phospholipids	O
and	O
a	O
consequent	O
modulation	O
of	O
gene	O
expression	O
for	O
molecules	O
involved	O
in	O
monocyte	O
recruitment	O
.	O

Functional	O
association	O
of	O
Nmi	O
with	O
Stat5	O
and	O
Stat1	O
in	O
IL-2-	O
and	O
IFNgamma-mediated	O
signaling	O
.	O

Using	O
the	O
coiled-coil	O
region	O
of	O
Stat5b	O
as	O
the	O
bait	O
in	O
a	O
yeast	O
two-hybrid	O
screen	O
,	O
we	O
identified	O
the	O
association	O
of	O
Nmi	O
,	O
a	O
protein	O
of	O
unknown	O
function	O
previously	O
reported	O
as	O
an	O
N-Myc	O
interactor	O
.	O

We	O
further	O
show	O
that	O
Nmi	O
interacts	O
with	O
all	O
STATs	O
except	O
Stat2	O
.	O

We	O
evaluated	O
two	O
cytokine	O
systems	O
,	O
IL-2	O
and	O
IFNgamma	O
,	O
and	O
demonstrate	O
that	O
Nmi	O
augments	O
STAT-mediated	O
transcription	O
in	O
response	O
to	O
these	O
cytokines	O
.	O

Interestingly	O
,	O
Nmi	O
lacks	B-Negation
an	I-Negation
intrinsic	I-Negation
transcriptional	I-Negation
activation	I-Negation
domain	I-Negation
;	O
instead	O
,	O
Nmi	O
enhances	O
the	O
association	O
of	O
CBP/p300	O
coactivator	O
proteins	O
with	O
Stat1	O
and	O
Stat5	O
,	O
and	O
together	O
with	O
CBP/p300	O
can	O
augment	O
IL-2-	O
and	O
IFNgamma-dependent	O
transcription	O
.	O

Therefore	O
,	O
our	O
data	O
not	O
only	O
reveal	O
that	O
Nmi	O
can	O
potentiate	O
STAT-dependent	O
transcription	O
,	O
but	O
also	O
suggest	O
that	O
it	O
can	O
augment	O
coactivator	O
protein	O
recruitment	O
to	O
at	O
least	O
some	O
members	O
of	O
a	O
group	O
of	O
sequence-specific	O
transcription	O
factors	O
.	O

Mining	O
prokaryotic	O
genomes	O
for	O
unknown	O
amino	O
acids	O
:	O
a	O
stop-codon-based	O
approach	O

Abstract	O

Background	O

Selenocysteine	O
and	O
pyrrolysine	O
are	O
the	O
21st	O
and	O
22nd	O
amino	O
acids	O
,	O
which	O
are	O
genetically	O
encoded	O
by	O
stop	O
codons	O
.	O

Since	O
a	O
number	O
of	O
microbial	O
genomes	O
have	O
been	O
completely	O
sequenced	O
to	O
date	O
,	O
it	O
is	O
tempting	O
to	O
ask	O
whether	O
the	O
23rd	O
amino	O
acid	O
is	O
left	O
undiscovered	O
in	O
these	O
genomes	O
.	O

Recently	O
,	O
a	O
computational	O
study	O
addressed	O
this	O
question	O
and	O
reported	O
that	O
no	B-Negation
tRNA	I-Negation
gene	I-Negation
for	I-Negation
unknown	I-Negation
amino	I-Negation
acid	I-Negation
was	I-Negation
found	I-Negation
in	I-Negation
genome	I-Negation
sequences	I-Negation
available	I-Negation
.	O

However	O
,	O
performance	O
of	O
the	O
tRNA	O
prediction	O
program	O
on	O
an	O
unknown	O
tRNA	O
family	O
,	O
which	O
may	O
have	O
atypical	O
sequence	O
and	O
structure	O
,	O
is	O
unclear	O
,	O
thereby	O
rendering	O
their	O
result	O
inconclusive	O
.	O

A	O
protein-level	O
study	O
will	O
provide	O
independent	O
insight	O
into	O
the	O
novel	O
amino	O
acid	O
.	O

Results	O

Assuming	O
that	O
the	O
23rd	O
amino	O
acid	O
is	O
also	O
encoded	O
by	O
a	O
stop	O
codon	O
,	O
we	O
systematically	O
predicted	O
proteins	O
that	O
contain	O
stop-codon-encoded	O
amino	O
acids	O
from	O
191	O
prokaryotic	O
genomes	O
.	O

Since	O
our	O
prediction	O
method	O
relies	O
only	O
on	O
the	O
conservation	O
patterns	O
of	O
primary	O
sequences	O
,	O
it	O
also	O
provides	O
an	O
opportunity	O
to	O
search	O
novel	O
selenoproteins	O
and	O
other	O
readthrough	O
proteins	O
.	O

It	O
successfully	O
recovered	O
many	O
of	O
currently	O
known	O
selenoproteins	O
and	O
pyrrolysine	O
proteins	O
.	O

However	O
,	O
no	B-Negation
promising	I-Negation
candidate	I-Negation
for	I-Negation
the	I-Negation
23rd	I-Negation
amino	I-Negation
acid	I-Negation
was	I-Negation
detected	I-Negation
,	O
and	O
only	O
one	O
novel	O
selenoprotein	O
was	O
predicted	O
.	O

Conclusion	O

Our	O
result	O
suggests	O
that	O
the	O
unknown	O
amino	O
acid	O
encoded	O
by	O
stop	O
codons	O
does	O
not	O
exist	O
,	O
or	O
its	O
phylogenetic	O
distribution	O
is	O
rather	O
limited	O
,	O
which	O
is	O
in	O
agreement	O
with	O
the	O
previous	O
study	O
on	O
tRNA	O
.	O

The	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
future	O
studies	O
to	O
explore	O
novel	O
readthrough	O
events	O
from	O
complete	O
genomes	O
,	O
which	O
are	O
rapidly	O
growing	O
.	O

Background	O

Stop	O
codon	O
readthrough	O
is	O
a	O
phenomenon	O
in	O
which	O
the	O
translation	O
process	O
does	O
not	B-Negation
terminate	I-Negation
at	I-Negation
a	I-Negation
stop	I-Negation
codon	I-Negation
,	O
and	O
an	O
amino	O
acid	O
is	O
inserted	O
there	O
instead	O
12	O
.	O

In	O
some	O
cases	O
,	O
the	O
inserted	O
amino	O
acid	O
is	O
not	B-Negation
one	I-Negation
of	I-Negation
the	I-Negation
20	I-Negation
amino	I-Negation
acids	I-Negation
but	O
a	O
noncanonical	O
one	O
.	O

Two	O
such	O
amino	O
acids	O
have	O
been	O
discovered	O
to	O
date	O
:	O
selenocysteine	O
34	O
and	O
pyrrolysine	O
56	O
.	O

Because	O
each	O
of	O
them	O
have	O
specialized	O
tRNA	O
genes	O
for	O
decoding	O
and	O
can	O
be	O
considered	O
extensions	O
of	O
the	O
standard	O
genetic	O
code	O
,	O
they	O
are	O
called	O
the	O
21st	O
and	O
22nd	O
amino	O
acids	O
,	O
respectively	O
.	O

Selenocysteine	O
,	O
the	O
21st	O
amino	O
acid	O
,	O
is	O
encoded	O
by	O
stop	O
codon	O
UGA	O
,	O
and	O
organisms	O
that	O
use	O
selenocysteine	O
have	O
been	O
found	O
from	O
all	O
three	O
domains	O
of	O
life	O
.	O

Its	O
insertion	O
into	O
UGA	O
is	O
directed	O
by	O
SECIS	O
(	O
selenocysteine	O
insertion	O
sequence	O
)	O
elements	O
,	O
a	O
stem-loop	O
structure	O
on	O
the	O
selenoprotein	O
mRNA	O
.	O

Along	O
with	O
the	O
progress	O
of	O
genome	O
sequencing	O
projects	O
,	O
computational	O
prediction	O
methods	O
of	O
selenocysteine-containing	O
proteins	O
(	O
selenoproteins	O
)	O
have	O
been	O
developed	O
by	O
several	O
research	O
groups	O
78910	O
,	O
and	O
the	O
repertoire	O
of	O
selenoproteins	O
has	O
been	O
greatly	O
expanded	O
1112	O
.	O

Pyrrolysine	O
,	O
the	O
22nd	O
amino	O
acid	O
encoded	O
by	O
stop	O
codon	O
UAG	O
,	O
was	O
recently	O
discovered	O
from	O
a	O
methanogenic	O
archaea	O
56	O
.	O

Currently	O
,	O
only	O
methanogenic	O
archaea	O
of	O
the	O
order	O
Methanosarcinales	O
and	O
one	O
bacterium	O
are	O
considered	O
to	O
utilize	O
pyrrolysine	O
13	O
.	O

The	O
limited	O
phylogenetic	O
distribution	O
of	O
pyrrolysine	O
suggests	O
that	O
its	O
incorporation	O
into	O
the	O
genetic	O
code	O
of	O
methanogen	O
is	O
relatively	O
recent	O
,	O
and	O
the	O
insertion	O
mechanism	O
of	O
a	O
novel	O
amino	O
acid	O
can	O
evolve	O
in	O
a	O
shorter	O
period	O
of	O
time	O
than	O
anticipated	O
.	O

This	O
raises	O
an	O
interesting	O
question	O
:	O
:	O
``	O
``	O
Is	O
there	O
a	O
23rd	O
amino	O
acid	O
``	O
?	O
``	O
.	O

If	O
such	O
an	O
amino	O
acid	O
is	O
discovered	O
,	O
it	O
will	O
deepen	O
our	O
understanding	O
of	O
the	O
evolution	O
and	O
diversity	O
of	O
the	O
genetic	O
code	O
.	O

Because	O
genome	O
sequences	O
of	O
various	O
prokaryotes	O
are	O
available	O
today	O
,	O
there	O
will	O
be	O
a	O
chance	O
to	O
discover	O
the	O
novel	O
amino	O
acid	O
via	O
analysis	O
of	O
these	O
genomes	O
.	O

Since	O
both	O
the	O
21st	O
and	O
22nd	O
amino	O
acids	O
are	O
encoded	O
by	O
stop	O
codons	O
,	O
the	O
prime	O
suspect	O
is	O
other	O
stop	O
codons	O
(	O
e.g.	O
stop	O
codon	O
UAA	O
)	O
,	O
although	O
the	O
possibility	O
of	O
sense	O
codons	O
certainly	O
remains	O
.	O

Using	O
this	O
clue	O
,	O
computational	O
screening	O
methods	O
of	O
the	O
23rd	O
amino	O
acid	O
can	O
be	O
designed	O
.	O

Recently	O
,	O
Lobanov	O
et	O
al.	O
addressed	O
this	O
problem	O
by	O
searching	O
tRNAs	O
with	O
anticodons	O
corresponding	O
to	O
stop	O
codons	O
14	O
.	O

They	O
analyzed	O
146	O
prokaryotic	O
genomes	O
,	O
but	O
no	B-Negation
likely	I-Negation
tRNA	I-Negation
of	I-Negation
the	I-Negation
novel	I-Negation
amino	I-Negation
acid	I-Negation
was	I-Negation
detected	I-Negation
.	O

They	O
concluded	O
that	O
the	O
23rd	O
amino	O
acid	O
would	O
have	O
a	O
limited	O
phylogenetic	O
distribution	O
,	O
if	O
it	O
exists	O
.	O

However	O
,	O
programs	O
for	O
tRNA	O
identification	O
are	O
based	O
on	O
the	O
features	O
of	O
known	O
tRNAs	O
and	O
do	O
not	O
necessarily	O
perform	O
well	O
on	O
unknown	O
ones	O
.	O

Actually	O
,	O
tRNASec	O
and	O
tRNAPyl	O
have	O
unusual	O
secondary	O
structures	O
515	O
and	O
often	O
escape	O
detection	O
by	O
programs	O
without	B-Negation
special	I-Negation
consideration	I-Negation
.	O

Lobanov	O
et	O
al.	O
thus	O
developed	O
a	O
sensitive	O
search	O
method	O
to	O
deal	O
with	O
this	O
problem	O
,	O
but	O
they	O
also	O
admitted	O
that	O
it	O
would	O
fail	O
to	O
identify	O
highly	O
unusual	O
tRNAs	O
.	O

There	O
is	O
another	O
approach	O
to	O
searching	O
for	O
the	O
23rd	O
amino	O
acid	O
.	O

By	O
enumerating	O
ORFs	O
that	O
have	O
an	O
inframe	O
stop	O
codon	O
from	O
genomes	O
and	O
examining	O
their	O
evolutionary	O
conservation	O
,	O
candidate	O
proteins	O
can	O
be	O
predicted	O
.	O

Because	O
such	O
an	O
ORF-based	O
study	O
is	O
independent	O
from	O
the	O
tRNA	O
analysis	O
,	O
it	O
can	O
either	O
identify	O
candidate	O
organisms	O
missed	O
by	O
the	O
previous	O
study	O
or	O
strengthen	O
its	O
negative	O
conclusion	O
.	O

Here	O
we	O
report	O
a	O
comprehensive	O
analysis	O
of	O
prokaryotic	O
ORFs	O
that	O
contain	O
an	O
inframe	O
stop	O
codon	O
.	O

Through	O
enumeration	O
of	O
theoretical	O
ORFs	O
and	O
inspection	O
of	O
their	O
evolutionary	O
conservation	O
,	O
candidates	O
of	O
readthrough	O
proteins	O
were	O
predicted	O
.	O

They	O
contained	O
many	O
of	O
the	O
known	O
proteins	O
with	O
stop-codon-encoded	O
amino	O
acids	O
,	O
but	O
almost	O
no	O
novel	O
candidates	O
were	O
identified	O
.	O

Therefore	O
,	O
the	O
unknown	O
amino	O
acid	O
,	O
if	O
it	O
is	O
encoded	O
by	O
a	O
stop	O
codon	O
,	O
is	O
unlikely	O
to	O
exist	O
in	O
the	O
current	O
databases	O
of	O
microbial	O
genomes	O
.	O

The	O
consequences	O
for	O
selenoproteins	O
and	O
other	O
readthrough	O
genes	O
are	O
also	O
discussed	O
.	O

Results	O

Basic	O
ideas	O

In	O
this	O
study	O
,	O
we	O
focus	O
on	O
theoretical	O
ORFs	O
with	O
one	O
inframe	O
stop	O
codon	O
,	O
termed	O
``	O
interrupted	O
ORFs	O
``	O
(	O
iORFs	O
)	O
(	O
Figure	O
1a	O
)	O
.	O

If	O
we	O
enumerate	O
all	O
iORFs	O
from	O
microbial	O
genomes	O
,	O
most	O
of	O
the	O
readthrough	O
genes	O
will	O
be	O
included	O
in	O
them	O
.	O

However	O
,	O
the	O
vast	O
majority	O
of	O
the	O
enumerated	O
iORFs	O
will	O
be	O
biologically	O
meaningless	O
.	O

To	O
filter	O
out	O
such	O
meaningless	O
iORFs	O
,	O
we	O
required	O
the	O
iORFs	O
to	O
have	O
at	O
least	O
one	O
homolog	O
in	O
other	O
genomes	O
,	O
because	O
evolutionary	O
conservation	O
of	O
primary	O
sequence	O
is	O
a	O
strong	O
indicator	O
of	O
functional	O
importance	O
.	O

However	O
,	O
this	O
condition	O
is	O
not	B-Negation
sufficient	I-Negation
,	O
since	O
two	O
major	O
problems	O
remain	O
:	O
:	O
pseudogenes	O
and	O
two	O
adjacent	O
genes	O
.	O

The	O
first	O
problem	O
is	O
that	O
even	O
if	O
an	O
iORF	O
has	O
homologs	O
in	O
other	O
species	O
,	O
it	O
could	O
be	O
a	O
pseudogene	O
or	O
a	O
product	O
of	O
sequencing	O
error	O
.	O

The	O
second	O
problem	O
is	O
that	O
adjacent	O
genes	O
on	O
the	O
same	O
reading	O
frame	O
may	O
satisfy	O
the	O
condition	O
of	O
conserved	O
iORFs	O
.	O

In	O
particular	O
,	O
gene	O
pairs	O
within	O
an	O
operon	O
are	O
problematic	O
because	O
their	O
gene	O
arrangement	O
is	O
often	O
conserved	O
.	O

If	O
the	O
intergenic	O
distance	O
between	O
two	O
genes	O
in	O
an	O
operon	O
happens	O
to	O
be	O
a	O
multiple	O
of	O
three	O
,	O
they	O
look	O
like	O
a	O
conserved	O
readthrough	O
gene	O
.	O

Basic	O
ideas	O
of	O
the	O
prediction	O
method	O

Basic	O
ideas	O
of	O
the	O
prediction	O
method	O
.	O

(	O
a	O
)	O
Schematic	O
illustration	O
of	O
an	O
interrupted	O
ORF	O
(	O
iORF	O
)	O
.	O

(	O
b	O
)	O
Readthrough	O
genes	O
can	O
be	O
distinguished	O
from	O
two	O
adjacent	O
genes	O
based	O
on	O
the	O
results	O
of	O
BLAST	O
searches	O
.	O

Boxes	O
denote	O
iORFs	O
,	O
and	O
	O
indicates	O
the	O
inframe	O
stop	O
codon	O
.	O

Shaded	O
regions	O
represent	O
actual	O
protein-coding	O
regions	O
.	O

If	O
an	O
iORF	O
codes	O
a	O
readthrough	O
protein	O
,	O
BLAST	O
hits	O
from	O
other	O
organisms	O
will	O
cover	O
the	O
inframe	O
stop	O
codon	O
.	O

In	O
contrast	O
,	O
if	O
the	O
iORF	O
consists	O
of	O
two	O
adjacent	O
genes	O
,	O
many	O
hits	O
that	O
do	O
not	B-Negation
cover	I-Negation
the	I-Negation
inframe	I-Negation
stop	I-Negation
codon	I-Negation
will	O
be	O
found	O
.	O

To	O
discriminate	O
them	O
from	O
true	O
readthrough	O
genes	O
,	O
evolutionary	O
information	O
was	O
exploited	O
.	O

In	O
order	O
to	O
eliminate	O
pseudogenes	O
and	O
sequencing	O
errors	O
,	O
conservation	O
of	O
iORFs	O
and	O
their	O
inframe	O
stop	O
codons	O
was	O
examined	O
.	O

Since	O
pseudogenes	O
are	O
less	O
conserved	O
,	O
and	O
sequencing	O
errors	O
are	O
relatively	O
rare	O
events	O
,	O
they	O
will	O
not	B-Negation
have	I-Negation
homologous	I-Negation
iORFs	I-Negation
in	I-Negation
other	I-Negation
species	I-Negation
.	O

Even	O
if	O
they	O
do	O
,	O
the	O
position	O
or	O
type	O
(	O
UAA	O
,	O
UAG	O
or	O
UGA	O
)	O
of	O
their	O
inframe	O
stop	O
codons	O
will	O
not	B-Negation
coincide	I-Negation
.	O

In	O
this	O
way	O
,	O
they	O
can	O
be	O
eliminated	O
as	O
candidates	O
.	O

A	O
drawback	O
of	O
this	O
criterion	O
is	O
that	O
it	O
limits	O
the	O
target	O
of	O
our	O
study	O
to	O
readthrough	O
genes	O
conserved	O
across	O
two	O
or	O
more	O
species	O
.	O

In	O
other	O
words	O
,	O
species-specific	O
readthrough	O
genes	O
are	O
not	B-Negation
in	I-Negation
the	I-Negation
scope	I-Negation
of	I-Negation
this	I-Negation
study	I-Negation
.	O

To	O
address	O
the	O
second	O
problem	O
,	O
adjacent	O
gene	O
pairs	O
were	O
filtered	O
out	O
by	O
examining	O
boundaries	O
of	O
sequence	O
alignments	O
between	O
iORFs	O
and	O
its	O
homologs	O
(	O
Figure	O
1b	O
)	O
.	O

The	O
stop-codon-encoded	O
amino	O
acids	O
of	O
prokaryotes	O
are	O
usually	O
located	O
inside	O
domains	O
,	O
the	O
units	O
of	O
evolutionary	O
sequence	O
conservation	O
.	O

Therefore	O
,	O
the	O
aligned	O
regions	O
of	O
readthrough	O
proteins	O
contain	O
their	O
inframe	O
stop	O
codon	O
.	O

Based	O
on	O
this	O
observation	O
,	O
each	O
iORF	O
was	O
required	O
to	O
have	O
:	O
:	O
(	O
i	O
)	O
at	O
least	O
one	O
homolog	O
from	O
other	O
organisms	O
that	O
covers	O
the	O
inframe	O
stop	O
codon	O
and	O
(	O
ii	O
)	O
no	B-Negation
homolog	I-Negation
that	I-Negation
does	I-Negation
not	I-Negation
cover	I-Negation
the	I-Negation
stop	I-Negation
codon	I-Negation
.	O

Note	O
that	O
,	O
however	O
,	O
if	O
the	O
whole	O
length	O
of	O
an	O
iORF	O
was	O
used	O
as	O
a	O
query	O
sequence	O
,	O
this	O
procedure	O
will	O
erroneously	O
discard	O
multidomain	O
readthrough	O
proteins	O
.	O

To	O
avoid	O
this	O
problem	O
,	O
a	O
partial	O
sequence	O
around	O
the	O
inframe	O
stop	O
codon	O
was	O
used	O
as	O
a	O
query	O
.	O

Prediction	O
procedure	O

The	O
prediction	O
schema	O
is	O
shown	O
in	O
Figure	O
2	O
.	O

A	O
total	O
of	O
191	O
prokaryotes	O
were	O
analyzed	O
in	O
this	O
study	O
,	O
of	O
which	O
166	O
are	O
bacteria	O
and	O
25	O
are	O
archaea	O
.	O

They	O
were	O
selected	O
from	O
328	O
prokaryotes	O
with	O
completely	O
sequenced	O
genomes	O
by	O
excluding	O
closely	O
related	O
species	O
.	O

From	O
the	O
genome	O
sequences	O
of	O
the	O
191	O
organisms	O
,	O
all	O
possible	O
iORFs	O
were	O
enumerated	O
.	O

Two	O
conditions	O
were	O
imposed	O
on	O
the	O
geometry	O
of	O
the	O
iORFs	O
(	O
Figure	O
1a	O
)	O
.	O

First	O
,	O
only	O
iORFs	O
longer	O
than	O
80	O
codons	O
were	O
extracted	O
.	O

Secondly	O
,	O
margins	O
between	O
the	O
inframe	O
stop	O
codon	O
and	O
both	O
termini	O
of	O
the	O
iORF	O
must	O
be	O
longer	O
than	O
10	O
codons	O
.	O

The	O
total	O
number	O
of	O
iORFs	O
extracted	O
under	O
these	O
conditions	O
was	O
2,969,958	O
.	O

Next	O
,	O
iORFs	O
that	O
overlap	O
RNA	O
genes	O
or	O
protein-coding	O
genes	O
in	O
different	O
reading	O
frames	O
were	O
discarded	O
.	O

This	O
test	O
significantly	O
reduced	O
the	O
number	O
of	O
iORFs	O
to	O
390,926	O
.	O

A	O
flowchart	O
of	O
the	O
prediction	O
procedure	O

A	O
flowchart	O
of	O
the	O
prediction	O
procedure	O
.	O

Several	O
steps	O
are	O
omitted	O
for	O
simplicity	O
.	O

Detailed	O
explanation	O
is	O
given	O
in	O
the	O
text	O
.	O

As	O
noted	O
above	O
,	O
the	O
target	O
of	O
this	O
study	O
is	O
evolutionarily	O
conserved	O
iORFs	O
.	O

Thus	O
,	O
it	O
was	O
examined	O
whether	O
the	O
iORFs	O
have	O
homologous	O
regions	O
in	O
other	O
genomes	O
.	O

The	O
390,926	O
iORFs	O
were	O
translated	O
into	O
amino	O
acid	O
sequences	O
and	O
subjected	O
to	O
TBLASTN	O
16	O
against	O
the	O
191	O
genome	O
sequences	O
.	O

Instead	B-Negation
of	I-Negation
the	I-Negation
whole	I-Negation
length	I-Negation
of	I-Negation
the	I-Negation
amino	I-Negation
acid	I-Negation
sequence	I-Negation
,	O
a	O
window	O
of	O
101	O
residues	O
centered	O
at	O
the	O
inframe	O
stop	O
codon	O
was	O
used	O
as	O
a	O
BLAST	O
query	O
.	O

After	O
the	O
BLAST	O
searches	O
,	O
iORFs	O
that	O
have	O
at	O
least	O
one	O
interspecific	O
hit	O
that	O
contains	O
the	O
inframe	O
stop	O
codon	O
were	O
collected	O
.	O

Whether	O
the	O
codon	O
aligned	O
to	O
the	O
inframe	O
stop	O
codon	O
is	O
a	O
nonsense	O
codon	O
or	O
not	O
was	O
neglected	O
at	O
this	O
stage	O
.	O

There	O
were	O
94,690	O
iORFs	O
that	O
have	O
interspecific	O
hits	O
.	O

The	O
result	O
of	O
the	O
above	O
homology	O
searches	O
was	O
also	O
used	O
for	O
the	O
boundary	O
analysis	O
(	O
Figure	O
1b	O
)	O
.	O

An	O
iORF	O
was	O
discarded	O
if	O
there	O
were	O
any	O
BLAST	O
hits	O
that	O
do	O
not	B-Negation
cover	I-Negation
the	I-Negation
inframe	I-Negation
stop	I-Negation
codon	I-Negation
.	O

A	O
total	O
of	O
26,003	O
iORF	O
satisfied	O
the	O
above	O
criteria	O
.	O

To	O
examine	O
intrafamily	O
conservation	O
of	O
the	O
inframe	O
stop	O
codons	O
,	O
these	O
iORFs	O
were	O
clustered	O
into	O
protein	O
families	O
based	O
on	O
sequence	O
similarity	O
.	O

After	O
removal	O
of	O
singletons	O
,	O
679	O
clusters	O
with	O
two	O
or	O
more	O
members	O
were	O
obtained	O
.	O

A	O
cluster	O
was	O
discarded	O
unless	O
all	O
members	O
of	O
the	O
cluster	O
had	O
the	O
same	O
type	O
of	O
inframe	O
stop	O
codons	O
(	O
UAA	O
,	O
UAG	O
or	O
UGA	O
)	O
.	O

The	O
locations	O
of	O
the	O
inframe	O
stop	O
codons	O
were	O
also	O
required	O
to	O
be	O
identical	O
in	O
the	O
multiple	O
sequence	O
alignment	O
of	O
the	O
cluster	O
members	O
.	O

These	O
conditions	O
reduced	O
the	O
number	O
of	O
clusters	O
to	O
273	O
.	O

Manual	O
inspection	O
of	O
these	O
273	O
clusters	O
revealed	O
that	O
they	O
still	O
contain	O
many	O
false	O
positives	O
that	O
are	O
unrelated	O
to	O
stop-codon-encoded	O
amino	O
acids	O
.	O

Hence	O
,	O
three-step	O
filtering	O
procedures	O
were	O
applied	O
to	O
remove	O
the	O
false	O
positives	O
.	O

Briefly	O
,	O
the	O
first	O
filter	O
assesses	O
protein-likeliness	O
based	O
on	O
the	O
signal	O
of	O
purifying	O
selection	O
,	O
while	O
the	O
second	O
and	O
third	O
filters	O
try	O
to	O
remove	O
adjacent	O
gene	O
pairs	O
using	O
the	O
pattern	O
of	O
BLAST	O
alignments	O
(	O
for	O
details	O
,	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

As	O
a	O
result	O
of	O
the	O
filtering	O
,	O
the	O
number	O
of	O
candidate	O
clusters	O
was	O
reduced	O
to	O
32	O
.	O

Through	O
manual	O
inspection	O
of	O
the	O
BLAST	O
alignments	O
,	O
11	O
clusters	O
were	O
discarded	O
because	O
they	O
are	O
highly	O
unlikely	O
to	O
code	O
readthrough	O
proteins	O
.	O

Known	O
proteins	O
in	O
the	O
predicted	O
clusters	O

The	O
clusters	O
predicted	O
by	O
our	O
method	O
are	O
summarized	O
in	O
Table	O
1	O
.	O

Of	O
the	O
21	O
clusters	O
,	O
15	O
were	O
known	O
selenoproteins	O
,	O
and	O
four	O
were	O
known	O
pyrrolysine	O
proteins	O
.	O

To	O
assess	O
the	O
sensitivity	O
of	O
our	O
method	O
,	O
the	O
result	O
was	O
compared	O
with	O
a	O
list	O
of	O
prokaryotic	O
selenoproteins	O
reported	O
by	O
Kryukov	O
and	O
Gladyshev	O
12	O
.	O

Since	O
our	O
target	O
is	O
readthrough	O
genes	O
conserved	O
across	O
two	O
or	O
more	O
species	O
,	O
such	O
selenoprotein	O
families	O
were	O
selected	O
from	O
their	O
list	O
.	O

There	O
were	O
15	O
families	O
satisfying	O
this	O
criterion	O
,	O
but	O
one	O
family	O
,	O
proline	O
reductase	O
,	O
was	O
excluded	O
because	O
it	O
was	O
found	O
in	O
only	O
one	O
organism	O
in	O
our	O
dataset	O
.	O

Of	O
the	O
14	O
families	O
,	O
11	O
were	O
found	O
in	O
our	O
prediction	O
result	O
.	O

The	O
three	O
families	O
we	O
failed	B-Negation
to	I-Negation
find	I-Negation
were	O
SelW-like	O
protein	O
,	O
peroxiredoxin	O
and	O
thiol	O
:	O
protein	O
disulphide	O
oxidoreductase	O
.	O

SelW-like	O
protein	O
was	O
below	O
the	O
threshold	O
of	O
detection	O
,	O
because	O
its	O
stop	O
codon	O
is	O
near	O
the	O
N-terminus	O
and	O
the	O
amino	O
acid	O
sequences	O
of	O
its	O
members	O
are	O
too	O
divergent	O
.	O

The	O
reason	O
why	O
the	B-Negation
two	I-Negation
other	I-Negation
families	I-Negation
were	I-Negation
not	I-Negation
detected	I-Negation
is	O
more	O
complex	O
.	O

Since	O
these	O
two	O
families	O
are	O
homologous	O
,	O
they	O
were	O
grouped	O
into	O
an	O
identical	O
cluster	O
at	O
the	O
clustering	O
stage	O
of	O
our	O
method	O
.	O

However	O
,	O
the	O
positions	O
of	O
selenocysteine	O
were	O
different	O
between	O
the	O
two	O
families	O
(	O
Figure	O
3	O
)	O
.	O

The	O
cluster	O
was	O
thus	O
discarded	O
because	O
of	O
an	O
apparent	O
lack	O
of	O
stop	O
codon	O
conservation	O
.	O

To	O
deal	O
with	O
a	O
situation	O
like	O
this	O
,	O
a	O
reexamination	O
of	O
the	O
clustering	O
threshold	O
and	O
subdivision	O
of	O
clusters	O
will	O
be	O
required	O
.	O

Predicted	O
clusters	O
of	O
readthrough	O
proteins	O

A	O
plus	O
sign	O
in	O
a	O
locus	O
indicates	O
that	O
the	O
genomic	O
coordinates	O
of	O
the	O
iORF	O
can	O
be	O
described	O
by	O
a	O
concatenation	O
of	O
two	O
genes	O
or	O
regions	O
.	O

For	O
example	O
,	O
``	O
GSU2293	O
+	O
downstream	O
``	O
means	O
that	O
the	O
iORF	O
consists	O
of	O
the	O
gene	O
GSU2293	O
and	O
its	O
downstream	O
sequence	O
.	O

HesB	B-Negation
family	I-Negation
was	I-Negation
not	I-Negation
clustered	I-Negation
into	I-Negation
one	I-Negation
family	I-Negation
,	O
because	O
their	O
sequences	O
were	O
too	O
short	O
and	O
diverged	O
.	O

Selenoprotein	B-Negation
families	I-Negation
we	I-Negation
failed	I-Negation
to	I-Negation
detect	I-Negation
because	O
of	O
nonconserved	O
location	O
of	O
stop	O
codons	O

Selenoprotein	B-Negation
families	I-Negation
we	I-Negation
failed	I-Negation
to	I-Negation
detect	I-Negation
because	O
of	O
nonconserved	O
location	O
of	O
stop	O
codons	O
.	O

Selenocysteine	O
residues	O
of	O
Peroxiredoxin-like	O
protein	O
families	O
constitute	O
homologous	O
redox	O
motifs	O
(	O
TXXU	O
and	O
UXXC	O
)	O
,	O
but	O
their	O
positions	O
are	O
different	O
between	O
two	O
families	O
.	O

Columns	O
are	O
colored	O
according	O
to	O
sequence	O
conservation	O
.	O

Selenocysteine	O
residues	O
are	O
shown	O
in	O
red	O
,	O
and	O
the	O
other	O
residues	O
in	O
the	O
redox	O
motifs	O
are	O
shown	O
in	O
yellow	O
.	O

Prx	O
;	O
Peroxiredoxin	O
,	O
TPO	O
;	O
thiol	O
:	O
protein	O
disulphide	O
oxidereductase	O
,	O
Adeh	O
;	O
Anaeromyxobacter	O
dehalogenans	O
,	O
Gmet	O
;	O
Geobacter	O
metallireducens	O
,	O
Gsul	O
;	O
G.	O
sulfurreducens	O
,	O
Dpsy	O
;	O
Desulfotalea	O
psychrophila	O
.	O

The	O
alignments	O
were	O
computed	O
using	O
ClustalW	O
,	O
and	O
the	O
figures	O
were	O
generated	O
using	O
Jalview	O
.	O

Of	O
the	O
four	O
pyrrolysine	O
proteins	O
detected	O
,	O
three	O
methylamine	O
methyltransferases	O
have	O
been	O
experimentally	O
confirmed	O
to	O
contain	O
pyrrolysine	O
617	O
.	O

The	O
rest	O
is	O
a	O
cluster	O
of	O
TetR-like	O
transcriptional	O
regulators	O
from	O
Methanosarcina	O
acetivorans	O
and	O
M.	O
barkeri	O
.	O

Since	O
the	O
genome	O
annotation	O
of	O
M.	O
acetivorans	O
describes	O
this	O
protein	O
as	O
a	O
gene	O
containing	O
an	O
inframe	O
amber	O
codon	O
,	O
we	O
classified	O
it	O
as	O
a	O
``	O
known	O
``	O
candidate	O
,	O
although	O
it	O
is	O
still	O
unclear	O
whether	O
it	O
really	O
contains	O
pyrrolysine	O
.	O

The	O
genome	O
annotation	O
of	O
M.	O
acetivorans	O
also	O
includes	O
several	O
amber-containing	O
genes	O
that	B-Negation
were	I-Negation
absent	I-Negation
from	I-Negation
our	I-Negation
prediction	I-Negation
result	I-Negation
.	O

They	O
are	O
a	O
methlycobamide	O
:	O
CoM	O
methylase	O
and	O
four	O
transposases	O
18	O
.	O

The	O
reason	O
why	O
they	B-Negation
were	I-Negation
not	I-Negation
detected	I-Negation
is	O
that	O
only	O
one	O
species	O
in	O
our	O
dataset	O
had	O
an	O
amber-containing	O
form	O
of	O
these	O
proteins	O
.	O

This	O
is	O
unavoidable	O
because	O
of	O
the	O
inability	O
of	O
our	O
method	O
to	O
detect	O
species-specific	O
readthrough	O
events	O
.	O

It	O
is	O
the	O
price	O
for	O
reliably	O
excluding	O
pseudogenes	O
and	O
sequencing	O
errors	O
.	O

Unknown	O
candidates	O
in	O
the	O
predicted	O
clusters	O

The	O
successful	O
detection	O
of	O
many	O
known	O
proteins	O
is	O
encouraging	O
,	O
because	O
our	O
method	O
relies	O
only	O
on	O
general	O
properties	O
of	O
proteins	O
that	O
contain	O
stop-codon-encoded	O
amino	O
acids	O
,	O
but	O
not	B-Negation
on	I-Negation
specific	I-Negation
features	I-Negation
of	I-Negation
selenocysteine	I-Negation
or	I-Negation
pyrrolysine	I-Negation
.	O

Therefore	O
,	O
unknown	O
clusters	O
in	O
our	O
candidates	O
have	O
possibilities	O
for	O
the	O
23rd	O
amino	O
acid	O
or	O
novel	O
readthrough	O
proteins	O
.	O

There	O
were	O
two	O
such	O
clusters	O
(	O
Table	O
1	O
)	O
.	O

The	O
first	O
cluster	O
is	O
comprised	O
of	O
c-type	O
cytochromes	O
from	O
-proteobacteria	O
Geobacter	O
sulfurreducens	O
and	O
G.	O
metallireducens	O
.	O

The	O
N-terminal	O
part	O
of	O
the	O
sequence	O
contains	O
five	O
CXXCH	O
heme-biding	O
motifs	O
,	O
while	O
the	O
C-terminal	O
part	O
has	O
no	B-Negation
similarity	I-Negation
with	I-Negation
any	I-Negation
characterized	I-Negation
proteins	I-Negation
.	O

Homology	O
search	O
against	O
unfinished	O
microbial	O
genomes	O
identified	O
seven	O
homologous	O
proteins	O
from	O
four	O
other	O
-proteobacteria	O
species	O
.	O

Multiple	O
sequence	O
alignment	O
of	O
these	O
sequences	O
is	O
shown	O
in	O
Figure	O
4a	O
.	O

Multiple	O
sequence	O
alignments	O
of	O
novel	O
candidate	O
proteins	O

Multiple	O
sequence	O
alignments	O
of	O
novel	O
candidate	O
proteins	O
.	O

(	O
a	O
)	O
A	O
selenoprotein	O
candidate	O
from	O
Geobacter	O
sulfurreducens	O
and	O
its	O
homologs	O
.	O

The	O
possible	O
selenocysteine	O
residues	O
are	O
shown	O
in	O
red	O
,	O
and	O
putative	O
heme-binding	O
motifs	O
are	O
underlined	O
.	O

Note	O
that	O
sequence	O
conservation	O
near	O
the	O
selenocysteine	O
is	O
comparable	O
to	O
that	O
of	O
the	O
N-terminal	O
cytochrome	O
domain	O
.	O

A	O
protein	O
Dpro_2	O
contains	O
yet	O
another	O
inframe	O
stop	O
codon	O
(	O
TAG	O
)	O
at	O
the	O
column	O
189	O
.	O

It	O
will	O
be	O
either	O
a	O
sequencing	O
error	O
or	O
a	O
pseudogene	O
.	O

Gsul	O
;	O
G.	O
sulfurreducens	O
,	O
Gmet	O
;	O
G.	O
metallireducens	O
,	O
Gura	O
;	O
G.	O
uraniumreducens	O
,	O
Gfrc	O
;	O
Geobacter	O
sp.	O
FRC-32	O
,	O
Dace	O
;	O
Desulfuromonas	O
acetoxidans	O
,	O
Dpro	O
;	O
Delta	O
proteobacterium	O
MLMS-1	O
.	O

(	O
b	O
)	O
Hypothetical	O
proteins	O
from	O
Geobacter	O
species	O
.	O

The	O
inframe	O
stop	O
codons	O
(	O
TAG	O
)	O
are	O
shown	O
in	O
red	O
.	O

This	O
cluster	O
is	O
probably	O
an	O
artifact	O
of	O
close	O
phylogenetic	O
relationship	O
.	O

We	O
expect	O
that	O
this	O
cluster	O
may	O
represent	O
a	O
novel	O
selenoprotein	O
family	O
.	O

This	O
is	O
because	O
the	O
inframe	O
stop	O
codons	O
of	O
these	O
proteins	O
are	O
exclusively	O
TGA	O
,	O
and	O
all	O
of	O
the	O
above	O
organisms	O
possess	O
selenocysteine	O
insertion	O
machinery	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

High	O
conservation	O
of	O
residues	O
near	O
the	O
inframe	O
stop	O
codon	O
also	O
suggests	O
the	O
importance	O
of	O
this	O
region	O
.	O

If	O
they	O
are	O
true	O
selenoproteins	O
,	O
this	O
protein	O
family	O
becomes	O
a	O
rare	O
instance	O
of	O
selenoprotein	O
that	O
lacks	B-Negation
non-selenocysteine	I-Negation
homologs	I-Negation
.	O

However	O
,	O
computational	O
analysis	O
of	O
sequences	O
immediately	O
downstream	O
of	O
the	O
inframe	O
stop	O
codons	O
failed	B-Negation
to	I-Negation
identify	I-Negation
SECIS	I-Negation
elements	I-Negation
,	O
which	O
is	O
a	O
hallmark	O
of	O
selenocysteine-containing	O
genes	O
.	O

Therefore	O
,	O
yet	O
another	O
possibility	O
is	O
that	O
they	O
are	O
a	O
highly	O
conserved	O
operon	O
.	O

An	O
experimental	O
verification	O
is	O
necessary	O
to	O
distinguish	O
these	O
two	O
possibilities	O
.	O

The	O
second	O
cluster	O
consists	O
of	O
two	O
hypothetical	O
proteins	O
,	O
again	O
from	O
G.	O
sulfurreducens	O
and	O
G.	O
metallireducens	O
(	O
Figure	O
4b	O
)	O
.	O

In	O
contrast	O
to	O
the	O
first	O
cluster	O
,	O
no	B-Negation
homolog	I-Negation
was	I-Negation
identified	I-Negation
from	I-Negation
other	I-Negation
species	I-Negation
.	O

This	O
cluster	O
is	O
probably	O
a	O
false	O
positive	O
and	O
not	O
readthrough	O
proteins	O
.	O

This	O
is	O
because	O
the	O
residues	O
near	O
the	O
inframe	O
stop	O
codons	O
are	O
poorly	O
conserved	O
.	O

Moreover	O
,	O
the	O
C-terminal	O
extensions	O
are	O
quite	O
short	O
(	O
about	O
20	O
aa	O
)	O
.	O

The	O
sequence	O
conservation	O
in	O
this	O
region	O
can	O
be	O
easily	O
explained	O
by	O
the	O
close	O
phylogenetic	O
relationship	O
between	O
the	O
two	O
species	O
.	O

In	O
summary	O
,	O
although	O
a	O
possible	O
selenoprotein	O
was	O
newly	O
identified	O
,	O
there	O
was	O
no	B-Negation
promising	I-Negation
candidate	I-Negation
for	I-Negation
an	I-Negation
unknown	I-Negation
amino	I-Negation
acid	I-Negation
encoded	I-Negation
by	I-Negation
a	I-Negation
stop	I-Negation
codon	I-Negation
.	O

Stop	O
codon	O
usage	O
in	O
the	O
pre-filtering	O
clusters	O

The	O
above	O
negative	O
result	O
could	O
be	O
explained	O
if	O
the	O
filtering	O
process	O
,	O
which	O
is	O
the	O
final	O
step	O
of	O
the	O
prediction	O
method	O
(	O
Figure	O
2	O
)	O
,	O
was	O
too	O
strict	O
.	O

Although	O
the	O
raw	O
output	O
of	O
the	O
search	O
for	O
evolutionarily	O
conserved	O
iORFs	O
was	O
273	O
clusters	O
,	O
most	O
of	O
them	O
were	O
discarded	O
at	O
the	O
subsequent	O
filtering	O
stage	O
.	O

Because	O
we	O
have	O
no	B-Negation
a	I-Negation
priori	I-Negation
knowledge	I-Negation
about	I-Negation
the	I-Negation
23rd	I-Negation
amino	I-Negation
acid	I-Negation
,	O
cutoff	O
thresholds	O
for	O
the	O
filtering	O
procedures	O
were	O
determined	O
based	O
on	O
the	O
known	O
readthrough	O
proteins	O
.	O

This	O
is	O
practically	O
indispensable	O
for	O
objective	O
classification	O
of	O
candidates	O
,	O
but	O
there	O
is	O
no	O
guarantee	O
that	O
unknown	O
proteins	O
with	O
the	O
23rd	O
amino	O
acid	O
will	O
score	O
higher	O
than	O
the	O
thresholds	O
.	O

To	O
explore	O
whether	O
a	O
number	O
of	O
good	O
candidates	O
lie	O
below	O
the	O
thresholds	O
,	O
the	O
273	O
clusters	O
were	O
analyzed	O
in	O
a	O
way	O
independent	O
from	O
filtering	O
.	O

If	O
an	O
organism	O
has	O
many	O
readthrough	O
proteins	O
,	O
proteins	O
from	O
the	O
organism	O
will	O
frequently	O
appear	O
in	O
the	O
273	O
clusters	O
.	O

Moreover	O
,	O
relative	O
usage	O
of	O
the	O
inframe	O
stop	O
codons	O
will	O
deviate	O
from	O
that	O
of	O
usual	O
termination	O
signals	O
in	O
the	O
proteome	O
.	O

Figure	O
5	O
shows	O
the	O
discrepancies	O
between	O
relative	O
usage	O
of	O
the	O
inframe	O
and	O
C-terminal	O
stop	O
codons	O
of	O
127	O
organisms	O
in	O
the	O
pre-filtering	O
clusters	O
.	O

Only	O
seven	O
organisms	O
had	O
statistically	O
significant	O
discrepancies	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
all	O
of	O
them	O
are	O
known	O
to	O
utilize	O
selenocysteine	O
or	O
pyrrolysine	O
.	O

Discrepancies	O
of	O
stop	O
codon	O
usages	O
between	O
the	O
inframe	O
and	O
C-terminal	O
stop	O
codons	O

Discrepancies	O
of	O
stop	O
codon	O
usages	O
between	O
the	O
inframe	O
and	O
C-terminal	O
stop	O
codons	O
.	O

The	O
inframe	O
stop	O
codon	O
usage	O
is	O
taken	O
from	O
the	O
pre-filtering	O
clusters	O
,	O
and	O
the	O
C-terminal	O
usage	O
is	O
computed	O
based	O
on	O
the	O
annotated	O
proteins	O
of	O
the	O
organism	O
.	O

Red	O
circle	O
:	O
an	O
organism	O
with	O
pyrrolysine	O
,	O
blue	O
;	O
selenocysteine	O
,	O
yellow	O
;	O
both	O
pyrrolysine	O
and	O
selenocysteine	O
,	O
white	O
;	O
neither	B-Negation
pyrrolysine	I-Negation
nor	I-Negation
selenocysteine	I-Negation
.	O

The	O
organisms	O
are	O
ordered	O
by	O
their	O
discrepancy	O
scores	O
.	O

The	O
discrepancy	O
score	O
is	O
the	O
negative	O
logarithm	O
of	O
a	O
p-value	O
of	O
Fisher	O
's	O
exact	O
test	O
.	O

The	O
dotted	O
line	O
indicates	O
significance	O
level	O
0.05	O
after	O
a	O
correction	O
for	O
multiple	O
testing	O
.	O

When	O
top	O
ten	O
organisms	O
were	O
examined	O
,	O
only	O
Gluconobacter	O
oxydans	O
was	O
an	O
organism	O
not	B-Negation
known	I-Negation
to	I-Negation
have	I-Negation
stop-codon-encoded	I-Negation
amino	I-Negation
acids	I-Negation
.	O

An	O
inspection	O
of	O
the	O
G.	O
oxydans	O
iORFs	O
in	O
the	O
273	O
clusters	O
revealed	O
that	O
their	O
inframe	O
stop	O
codons	O
are	O
dominated	O
by	O
TAA	O
,	O
but	O
all	O
of	O
them	O
belong	O
to	O
a	O
single	O
protein	O
cluster	O
associated	O
with	O
transposable	O
elements	O
.	O

Because	O
it	O
seems	B-Speculation
unlikely	I-Speculation
that	I-Speculation
an	I-Speculation
insertion	I-Speculation
system	I-Speculation
of	I-Speculation
novel	I-Speculation
amino	I-Speculation
acid	I-Speculation
evolves	I-Speculation
solely	I-Speculation
for	I-Speculation
transposable	I-Speculation
elements	I-Speculation
,	O
this	B-Negation
organism	I-Negation
can	I-Negation
not	I-Negation
be	O
considered	B-Speculation
as	I-Speculation
a	I-Speculation
good	I-Speculation
candidate	I-Speculation
of	I-Speculation
the	I-Speculation
23rd	I-Speculation
amino	I-Speculation
acid	I-Speculation
.	O

Sensitivity	O
of	O
this	O
test	O
is	O
not	O
high	O
because	O
many	O
organisms	O
that	O
utilize	O
selenocysteine	O
were	O
below	O
the	O
defined	O
threshold	O
.	O

However	O
,	O
the	O
result	O
agrees	O
with	O
the	O
filtering-dependent	O
analysis	O
that	O
no	B-Negation
candidate	I-Negation
of	I-Negation
the	I-Negation
novel	I-Negation
stop-codon-encoded	I-Negation
amino	I-Negation
acid	I-Negation
is	I-Negation
detectable	I-Negation
in	I-Negation
the	I-Negation
current	I-Negation
dataset	I-Negation
.	O

Discussion	O

As	O
the	O
number	O
of	O
completely	O
sequenced	O
genomes	O
increases	O
,	O
several	O
research	O
groups	O
started	O
to	O
predict	O
proteins	O
that	O
contain	O
stop-codon-encoded	O
amino	O
acids	O
through	O
computational	O
analyses	O
.	O

Most	O
of	O
them	O
are	O
aimed	O
at	O
identification	O
of	O
selenoproteins	O
,	O
reflecting	O
concerns	O
from	O
the	O
scientific	O
community	O
and	O
accumulated	O
knowledge	O
on	O
selenocysteine	O
.	O

In	O
order	O
to	O
improve	O
prediction	O
specificity	O
,	O
they	O
have	O
fully	O
exploited	O
the	O
known	O
features	O
of	O
selenocysteine	O
,	O
such	O
as	O
the	O
SECIS	O
elements	O
or	O
cysteine	O
homologs	O
,	O
which	O
have	O
cysteine	O
in	O
place	O
of	O
selenocysteine	O
.	O

However	O
,	O
since	O
the	O
target	O
of	O
this	O
study	O
is	O
the	O
23rd	O
amino	O
acid	O
,	O
and	O
there	O
is	O
no	B-Negation
a	I-Negation
priori	I-Negation
knowledge	I-Negation
,	O
only	O
general	O
properties	O
of	O
stop-codon-encoded	O
amino	O
acids	O
can	O
be	O
used	O
for	O
prediction	O
.	O

Such	O
general-purpose	O
algorithms	O
have	O
also	O
been	O
developed	O
to	O
date	O
.	O

The	O
method	O
of	O
Chaudhuri	O
and	O
Yeates	O
10	O
extracts	O
iORFs	O
from	O
microbial	O
genomes	O
and	O
analyzes	O
sequence	O
conservation	O
around	O
the	O
inframe	O
stop	O
codon	O
.	O

Their	O
method	O
is	O
thus	O
similar	O
to	O
ours	O
and	O
applicable	O
to	O
both	O
selenocysteine	O
and	O
pyrrolysine	O
.	O

Perrodou	O
et	O
al.	O
19	O
constructed	O
a	O
database	O
of	O
predicted	O
recoding	O
events	O
in	O
microbes	O
.	O

Their	O
method	O
is	O
applicable	O
not	O
only	O
to	O
stop	O
codon	O
readthrough	O
but	O
also	O
to	O
frameshift	O
.	O

However	O
,	O
both	O
of	O
them	O
did	O
not	B-Negation
apply	I-Negation
their	I-Negation
methods	I-Negation
to	I-Negation
search	I-Negation
for	I-Negation
novel	I-Negation
amino	I-Negation
acids	I-Negation
.	O

Therefore	O
,	O
the	B-Negation
question	I-Negation
of	I-Negation
the	I-Negation
23rd	I-Negation
amino	I-Negation
acid	I-Negation
has	I-Negation
not	I-Negation
been	I-Negation
investigated	I-Negation
from	I-Negation
the	I-Negation
viewpoint	I-Negation
of	I-Negation
coding	I-Negation
sequences	I-Negation
.	O

Additionally	O
,	O
the	O
previous	O
methods	O
can	B-Negation
not	I-Negation
effectively	I-Negation
discriminate	I-Negation
pseudogenes	I-Negation
from	I-Negation
readthrough	I-Negation
genes	I-Negation
.	O

For	O
instance	O
,	O
Chaudhuri	O
and	O
Yeates	O
reported	O
a	O
homolog	O
of	O
cobalamin	O
biosynthesis	O
protein	O
CobN	O
as	O
a	O
novel	O
candidate	O
of	O
pyrrolysine	O
protein	O
.	O

However	O
,	O
the	O
gene	O
is	O
probably	O
a	O
pseudogene	O
because	O
it	O
contains	O
an	O
inframe	O
TAA	O
codon	O
in	O
addition	O
to	O
the	O
TAG	O
codon	O
,	O
and	O
only	O
one	O
species	O
seems	O
to	O
have	O
the	O
amber-containing	O
form	O
of	O
the	O
gene	O
.	O

The	O
previous	O
methods	O
also	O
assume	O
that	O
proteins	O
with	O
stop-codon-encoded	O
amino	O
acids	O
will	O
have	O
non-readthrough	O
homologs	O
(	O
i.e.	O
,	O
homologous	O
proteins	O
that	O
do	O
not	O
have	O
inframe	O
stop	O
codons	O
)	O
.	O

However	O
,	O
that	O
is	O
not	O
necessarily	O
true	O
.	O

For	O
example	O
,	O
pyrrolysine-containing	O
monomethylamine	O
methyltransferases	O
adopt	O
TIM	O
barrel	O
fold	O
6	O
,	O
but	O
their	O
primary	O
sequences	O
do	O
not	B-Negation
exhibit	I-Negation
detectable	I-Negation
similarity	I-Negation
to	I-Negation
other	I-Negation
TIM	I-Negation
barrel	I-Negation
proteins	I-Negation
because	O
of	O
evolutionary	O
divergence	O
.	O

Dimethylamine	O
methyltransferases	O
also	O
lack	B-Negation
non-readthrough	I-Negation
homologs	I-Negation
.	O

Yet	O
another	O
example	O
is	O
glycine	O
reductase	O
selenoprotein	O
A	O
.	O

Only	O
the	O
selenocysteine-containing	O
form	O
of	O
the	O
enzyme	O
is	O
currently	O
known	O
20	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
not	B-Negation
to	I-Negation
assume	I-Negation
non-readthrough	I-Negation
homologs	I-Negation
for	I-Negation
exploring	I-Negation
novel	I-Negation
candidates	I-Negation
.	O

If	O
any	O
non-readthrough	O
homologs	O
are	O
registered	O
in	O
public	O
sequence	O
databases	O
,	O
a	O
careful	O
annotation	O
process	O
of	O
a	O
newly	O
sequenced	O
genome	O
will	O
be	O
able	O
to	O
detect	O
readthrough	O
genes	O
,	O
even	O
though	O
they	O
may	O
be	O
annotated	O
as	O
pseudogenes	O
.	O

However	O
,	O
if	O
all	O
members	O
of	O
a	O
gene	O
family	O
have	O
stop	O
codon	O
readthrough	O
,	O
correct	O
annotation	O
of	O
their	O
gene	O
structure	O
will	O
be	O
extremely	O
difficult	O
,	O
and	O
all	O
of	O
them	O
will	O
be	O
split	O
into	O
two	O
distinct	O
genes	O
.	O

The	O
method	O
reported	O
here	O
is	O
unique	O
in	O
that	O
it	O
does	O
not	B-Negation
assume	I-Negation
non-readthrough	I-Negation
homologs	I-Negation
.	O

Using	O
this	O
method	O
,	O
a	O
systematic	O
screening	O
of	O
the	O
23rd	O
amino	O
acid	O
and	O
other	O
readthrough	O
genes	O
was	O
carried	O
out	O
.	O

Many	O
of	O
the	O
currently	O
known	O
selenoproteins	O
and	O
pyrrolysine	O
proteins	O
were	O
recovered	O
,	O
indicating	O
the	O
effectiveness	O
of	O
this	O
approach	O
.	O

In	O
particular	O
,	O
successful	O
detection	O
of	O
pyrrolysine-containing	O
methyltransferases	O
and	O
selenoprotein	O
A	O
should	O
be	O
noted	O
.	O

However	O
,	O
almost	O
no	O
novel	O
candidates	O
for	O
readthrough	O
genes	O
were	O
predicted	O
.	O

What	O
can	O
be	O
concluded	O
from	O
this	O
result	O
?	O

The	O
most	O
likely	O
explanation	O
is	O
that	O
the	O
23rd	O
amino	O
acid	O
does	O
not	O
exist	O
,	O
or	O
its	O
distribution	O
on	O
the	O
tree	O
of	O
life	O
is	O
rather	O
limited	O
.	O

Although	O
a	O
broad	O
spectrum	O
of	O
taxonomic	O
groups	O
has	O
been	O
subjected	O
to	O
genome	O
sequencing	O
,	O
the	O
genomes	O
of	O
most	O
microbial	O
species	O
on	O
the	O
earth	O
have	O
yet	O
to	O
be	O
determined	O
.	O

The	O
unknown	O
amino	O
acid	O
may	O
be	O
used	O
by	O
these	O
species	O
.	O

Alternatively	O
,	O
only	O
one	O
organism	O
in	O
our	O
dataset	O
may	O
have	O
the	O
23rd	O
amino	O
acid	O
.	O

This	O
is	O
because	O
our	O
method	O
is	O
limited	O
to	O
readthrough	O
genes	O
conserved	O
across	O
two	O
or	O
more	O
species	O
.	O

If	O
the	O
novel	O
amino	O
acid	O
appears	O
in	O
younger	O
,	O
non-conserved	O
sequences	O
,	O
our	O
technique	O
will	O
miss	O
them	O
.	O

In	O
either	O
case	O
,	O
the	O
distribution	O
of	O
the	O
23rd	O
amino	O
acid	O
will	O
be	O
significantly	O
narrower	O
than	O
that	O
of	O
selenocysteine	O
,	O
which	O
has	O
scattered	O
but	O
wide	O
distribution	O
21	O
.	O

This	O
conclusion	O
coincides	O
with	O
and	O
strengthens	O
that	O
of	O
the	O
previous	O
research	O
on	O
tRNA	O
14	O
.	O

Yet	O
another	O
possibility	O
is	O
that	O
the	O
23rd	O
amino	O
acid	O
exists	O
but	O
is	O
not	O
encoded	O
by	O
stop	O
codons	O
.	O

It	O
is	O
well	O
known	O
that	O
the	O
genetic	O
code	O
varies	O
in	O
several	O
organisms	O
22	O
.	O

Thus	O
,	O
certain	O
organisms	O
may	O
use	O
one	O
of	O
the	O
sense	O
codons	O
for	O
the	O
novel	O
amino	O
acid	O
.	O

Because	O
codons	O
for	O
most	O
amino	O
acids	O
are	O
degenerate	O
,	O
redefinition	O
of	O
one	O
of	O
them	O
is	O
feasible	O
.	O

However	O
,	O
that	O
possibility	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
study	O
and	O
is	O
left	O
as	O
an	O
open	O
problem	O
.	O

Bioinformatics	O
analysis	O
of	O
unusual	O
tRNA	O
genes	O
and	O
codon	O
usage	O
may	O
provide	O
insights	O
into	O
this	O
problem	O
.	O

In	O
addition	O
to	O
the	O
23rd	O
amino	O
acid	O
,	O
our	O
method	O
can	O
simultaneously	O
explore	O
selenoproteins	O
and	O
other	O
readthrough	O
proteins	O
.	O

A	O
common	O
assumption	O
in	O
microbial	O
selenoprotein	O
predictions	O
is	O
that	O
selenoproteins	O
will	O
have	O
cysteine	O
homologs	O
.	O

Zhang	O
et	O
al.	O
20	O
examined	O
the	O
validity	O
of	O
this	O
assumption	O
using	O
a	O
SECIS-based	O
method	O
and	O
concluded	O
that	O
selenoproteins	O
without	B-Negation
cysteine	I-Negation
homologs	I-Negation
will	O
be	O
extremely	O
rare	O
.	O

Our	O
method	O
can	O
reassess	O
this	O
assumption	O
in	O
a	O
SECIS-independent	O
way	O
.	O

Such	O
selenoproteins	O
identified	O
through	O
our	O
screening	O
of	O
nearly	O
200	O
microbial	O
genomes	O
were	O
selenoprotein	O
A	O
and	O
only	O
one	O
uncertain	O
candidate	O
.	O

Therefore	O
,	O
selenoproteins	O
that	O
lack	B-Negation
cysteine	I-Negation
homologs	I-Negation
will	O
be	O
scarce	O
,	O
as	O
previously	O
reported	O
.	O

Other	O
readthrough	O
proteins	O
with	O
canonical	O
amino	O
acids	O
(	O
i.e.	O
,	O
proteins	O
that	O
have	O
canonical	O
amino	O
acids	O
at	O
their	O
inframe	O
stop	O
codons	O
)	O
are	O
quite	O
rare	O
in	O
prokaryotes	O
1	O
.	O

The	O
result	O
reported	O
here	O
is	O
in	O
agreement	O
,	O
but	O
it	O
is	O
not	B-Negation
conclusive	I-Negation
.	O

This	O
is	O
because	O
our	O
method	O
assumes	O
that	O
stop-codon-encoded	O
amino	O
acid	O
is	O
located	O
inside	O
a	O
domain	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
it	O
holds	O
true	O
in	O
prokaryotic	O
readthrough	O
with	O
canonical	O
amino	O
acids	O
.	O

At	O
least	O
,	O
only	O
one	O
experimentally-confirmed	O
example	O
from	O
a	O
pathogenic	O
strain	O
of	O
Escherichia	O
coli	O
23	O
,	O
whose	B-Negation
genome	I-Negation
is	I-Negation
not	I-Negation
yet	I-Negation
determined	I-Negation
,	O
does	O
not	B-Negation
obey	I-Negation
this	I-Negation
rule	I-Negation
.	O

What	O
can	O
be	O
concluded	O
from	O
our	O
result	O
is	O
that	O
this	O
type	O
of	O
readthrough	O
will	O
be	O
located	O
outside	O
of	O
domains	O
,	O
such	O
as	O
a	O
linker	O
between	O
two	O
domains	O
.	O

Such	O
a	O
stop	O
codon	O
may	O
behave	O
as	O
a	O
switch	O
that	O
regulates	O
production	O
of	O
short	O
and	O
long	O
isoforms	O
from	O
a	O
single	O
mRNA	O
,	O
as	O
in	O
readthrough	O
genes	O
from	O
viruses	O
24	O
.	O

Conclusion	O

To	O
explore	O
the	O
possibility	O
of	O
a	O
23rd	O
amino	O
acid	O
,	O
ORFs	O
in	O
prokaryotic	O
genomes	O
were	O
investigated	O
in	O
a	O
comprehensive	O
way	O
.	O

Although	O
many	O
of	O
the	O
currently	O
known	O
selenoproteins	O
and	O
pyrrolysine	O
proteins	O
were	O
successfully	O
detected	O
,	O
no	B-Negation
candidate	I-Negation
for	I-Negation
the	I-Negation
23rd	I-Negation
amino	I-Negation
acid	I-Negation
was	I-Negation
discovered	I-Negation
.	O

Therefore	O
,	O
if	O
such	O
an	O
amino	O
acid	O
exists	O
,	O
it	O
will	O
have	O
limited	O
distribution	O
in	O
the	O
tree	O
of	O
life	O
.	O

Alternatively	O
,	O
it	O
may	O
be	O
encoded	O
by	O
one	O
of	O
the	O
sense	O
codons	O
.	O

From	O
the	O
viewpoint	O
of	O
selenoprotein	O
prediction	O
,	O
the	O
sensitivity	O
of	O
our	O
method	O
was	O
lower	O
than	O
an	O
existing	O
method	O
.	O

However	O
,	O
our	O
method	O
has	O
several	O
unique	O
features	O
.	O

It	O
is	O
applicable	O
to	O
general	O
readthrough	O
genes	O
and	O
rigorously	O
excludes	O
pseudogenes	O
and	O
sequencing	O
errors	O
.	O

Moreover	O
,	O
it	O
does	O
not	B-Negation
assume	I-Negation
the	I-Negation
occurrence	I-Negation
of	I-Negation
non-readthrough	I-Negation
homologs	I-Negation
in	I-Negation
the	I-Negation
public	I-Negation
databases	I-Negation
.	O

It	O
will	O
help	O
in	O
identification	O
of	O
novel	O
readthrough	O
genes	O
from	O
the	O
rapidly	O
expanding	O
collection	O
of	O
complete	O
microbial	O
genomes	O
.	O

Methods	O

Enumeration	O
of	O
iORFs	O
from	O
prokaryotic	O
genomes	O

A	O
total	O
of	O
328	O
complete	O
genome	O
sequences	O
of	O
prokaryotes	O
were	O
downloaded	O
from	O
the	O
KEGG	O
FTP	O
site	O
25	O
in	O
April	O
2006	O
.	O

From	O
them	O
,	O
191	O
representative	O
organisms	O
were	O
selected	O
by	O
excluding	O
close	O
relatives	O
.	O

The	O
threshold	O
was	O
set	O
to	O
average	O
sequence	O
identity	O
90	O
%	O
of	O
two	O
house-keeping	O
genes	O
,	O
DNA	O
polymerase	O
III	O
	O
subunit	O
and	O
alanyl-tRNA	O
synthetase	O
.	O

From	O
these	O
191	O
genomes	O
,	O
iORFs	O
longer	O
than	O
80	O
codons	O
were	O
enumerated	O
using	O
inhouse	O
software	O
,	O
which	O
is	O
available	O
from	O
the	O
author	O
's	O
web	O
site	O
26	O
.	O

Both	O
upstream	O
and	O
downstream	O
regions	O
of	O
its	O
inframe	O
stop	O
codon	O
were	O
required	O
to	O
be	O
longer	O
than	O
10	O
codons	O
.	O

Two	O
stop	O
codons	O
of	O
an	O
iORF	O
(	O
i.e.	O
the	O
inframe	O
and	O
C-terminal	O
stops	O
)	O
can	O
be	O
any	O
combination	O
of	O
canonical	O
stop	O
codons	O
(	O
TAA	O
,	O
TAG	O
,	O
TGA	O
)	O
.	O

However	O
,	O
for	O
Mycoplasma	O
,	O
only	O
TAA	O
and	O
TAG	O
were	O
used	O
.	O

Three	O
codons	O
ATG	O
,	O
TTG	O
and	O
GTG	O
were	O
allowed	O
to	O
be	O
start	O
signals	O
.	O

The	O
iORFs	O
of	O
each	O
organism	O
were	O
compared	O
with	O
protein-coding	O
genes	O
of	O
the	O
organism	O
using	O
BLASTX	O
.	O

If	O
an	O
iORF	O
matched	O
any	O
protein-coding	O
genes	O
(	O
E-value	O
<	O
10-3	O
)	O
and	O
their	O
reading	O
frames	O
did	O
not	B-Negation
coincide	I-Negation
,	O
the	O
iORF	O
was	O
discarded	O
.	O

Similarly	O
,	O
iORFs	O
were	O
compared	O
with	O
RNA	O
genes	O
using	O
BLASTN	O
,	O
and	O
those	O
matched	O
with	O
the	O
RNAs	O
were	O
removed	O
.	O

Remaining	O
iORFs	O
were	O
translated	O
into	O
amino	O
acid	O
sequences	O
.	O

We	O
translated	O
all	O
three	O
types	O
of	O
nonsense	O
codons	O
into	O
the	O
one-letter	O
code	O
U	O
,	O
so	O
as	O
to	O
simplify	O
visual	O
inspection	O
of	O
sequence	O
alignments	O
.	O

Although	O
the	O
code	O
U	O
is	O
usually	O
for	O
selenocysteine	O
,	O
it	O
will	O
be	O
harmless	O
because	O
U	O
is	O
automatically	O
converted	O
into	O
	O
inside	O
the	O
BLAST	O
programs	O
.	O

Construction	O
of	O
clusters	O
of	O
conserved	O
iORFs	O

To	O
examine	O
evolutionary	O
conservation	O
of	O
the	O
iORFs	O
,	O
a	O
window	O
of	O
101	O
residues	O
around	O
the	O
inframe	O
stop	O
codon	O
was	O
extracted	O
and	O
subjected	O
to	O
TBLASTN	O
searches	O
against	O
the	O
above	O
191	O
genome	O
sequences	O
.	O

If	O
there	O
were	O
any	O
hits	O
(	O
E-value	O
<	O
0.01	O
)	O
in	O
other	O
organisms	O
,	O
and	O
if	O
the	O
hit	O
includes	O
10	O
upstream	O
and	O
10	O
downstream	O
residues	O
of	O
the	O
inframe	O
stop	O
codon	O
,	O
then	O
the	O
iORF	O
was	O
retained	O
.	O

However	O
,	O
if	O
there	O
were	O
any	O
hits	O
(	O
E-value	O
<	O
10-5	O
)	O
that	O
did	O
not	B-Negation
cover	I-Negation
the	I-Negation
inframe	I-Negation
stop	I-Negation
codon	I-Negation
,	O
the	O
iORF	O
was	O
discarded	O
.	O

Eligible	O
iORFs	O
were	O
then	O
clustered	O
using	O
BLASTCLUST	O
with	O
score	O
density	O
0.5	O
and	O
minimum	O
length	O
coverage	O
0.6	O
.	O

After	O
removing	O
singleton	O
clusters	O
,	O
multiple	O
sequence	O
alignments	O
of	O
the	O
remaining	O
clusters	O
were	O
computed	O
using	O
MAFFT	O
27	O
with	O
the	O
L-INS-i	O
option	O
.	O

Subsequently	O
,	O
conservation	O
of	O
the	O
inframe	O
stop	O
codons	O
in	O
each	O
cluster	O
was	O
examined	O
.	O

If	O
the	O
location	O
or	O
type	O
of	O
stop	O
codons	O
was	O
not	B-Negation
identical	I-Negation
,	O
the	O
cluster	O
was	O
discarded	O
.	O

Three-step	O
filtering	O
of	O
the	O
candidate	O
clusters	O

The	O
first	O
filter	O
examines	O
protein-likeliness	O
of	O
the	O
iORFs	O
.	O

This	O
filter	O
is	O
mainly	O
designed	O
to	O
remove	O
conserved	O
non-coding	O
sequences	O
(	O
CNS	O
)	O
immediately	O
downstream	O
of	O
non-readthrough	O
genes	O
.	O

If	O
we	O
measure	O
purifying	O
selection	O
for	O
amino	O
acid	O
sequences	O
by	O
the	O
ratio	O
of	O
nonsynonymous	O
to	O
synonymous	O
substitution	O
rates	O
(	O
dN/dS	O
)	O
,	O
a	O
protein	O
with	O
a	O
stop-codon-encoded	O
amino	O
acid	O
will	O
indicate	O
the	O
sign	O
of	O
selection	O
,	O
while	O
CNS	O
will	O
not	B-Negation
.	O

The	O
dN/dS	O
was	O
calculated	O
for	O
each	O
of	O
the	O
two	O
parts	O
flanking	O
the	O
inframe	O
stop	O
codon	O
in	O
an	O
iORF	O
using	O
codeml	O
program	O
in	O
the	O
PAML	O
package	O
28	O
.	O

Statistical	O
significance	O
was	O
estimated	O
by	O
likelihood	O
ratio	O
test	O
29	O
.	O

The	O
observed	O
alignment	O
was	O
fitted	O
to	O
two	O
distinct	O
substitution	O
models	O
,	O
one	O
of	O
which	O
estimates	O
dN/dS	O
from	O
the	O
data	O
,	O
and	O
the	O
other	O
fixes	O
it	O
to	O
1.0	O
.	O

Let	O
lfree	O
and	O
lfix	O
denote	O
log	O
likelihood	O
of	O
these	O
models	O
.	O

Then	O
,	O
2l	O
=	O
2	O
(	O
lfree	O
	O
lfix	O
)	O
approximately	O
follows	O
the	O
2	O
distribution	O
with	O
one	O
degree	O
of	O
freedom	O
.	O

If	O
dN/dS	O
was	O
less	O
than	O
1.0	O
,	O
and	O
the	O
statistics	O
2l	O
was	O
larger	O
than	O
a	O
threshold	O
,	O
we	O
regard	O
it	O
as	O
a	O
sign	O
of	O
purifying	O
selection	O
.	O

In	O
this	O
study	O
,	O
the	O
threshold	O
was	O
set	O
to	O
5.0	O
(	O
corresponds	O
to	O
P	O
<	O
0.025	O
)	O
so	O
that	O
the	O
known	O
readthrough	O
proteins	O
score	O
higher	O
than	O
the	O
threshold	O
.	O

For	O
each	O
of	O
the	O
above	O
clusters	O
,	O
an	O
all-against-all	O
comparison	O
of	O
cluster	O
members	O
was	O
performed	O
.	O

If	O
any	O
pair	O
exhibits	O
such	O
signals	O
in	O
both	O
the	O
N-	O
and	O
C-terminal	O
parts	O
,	O
the	O
cluster	O
was	O
retained	O
.	O

Even	O
if	O
both	O
the	O
upstream	O
and	O
downstream	O
regions	O
of	O
the	O
inframe	O
stop	O
codon	O
code	O
proteins	O
,	O
they	O
may	O
be	O
two	O
adjacent	O
genes	O
instead	O
of	O
a	O
readthrough	O
protein	O
.	O

The	O
second	O
and	O
third	O
filtering	O
processes	O
remove	O
such	O
genes	O
based	O
on	O
BLAST	O
alignment	O
patterns	O
.	O

Although	O
the	O
boundary	O
analysis	O
applied	O
previously	O
has	O
the	O
same	O
goal	O
(	O
Figure	O
1b	O
)	O
,	O
some	O
gene	O
pairs	O
escaped	O
elimination	O
.	O

To	O
enhance	O
sensitivity	O
of	O
the	O
filters	O
,	O
the	O
whole	O
length	O
of	O
an	O
iORF	O
was	O
used	O
as	O
a	O
BLAST	O
query	O
instead	B-Negation
of	I-Negation
the	I-Negation
partial	I-Negation
sequence	I-Negation
,	O
and	O
the	O
size	O
of	O
the	O
BLAST	O
database	O
was	O
increased	O
from	O
the	O
191	O
nonredundant	O
genomes	O
to	O
the	O
328	O
complete	O
genomes	O
in	O
GenomeNet	O
and	O
246	O
draft	O
genome	O
sequences	O
downloaded	O
from	O
GenBank	O
in	O
May	O
2006	O
.	O

The	O
second	O
filter	O
inspects	O
synteny	O
of	O
iORFs	O
.	O

If	O
the	O
N-	O
and	O
C-terminal	O
parts	O
of	O
an	O
iORF	O
have	O
distinct	O
but	O
closely	O
arranged	O
BLAST	O
hits	O
in	O
other	O
genomes	O
,	O
it	O
strongly	O
suggests	O
the	O
iORF	O
is	O
actually	O
two	O
adjacent	O
genes	O
.	O

Translated	O
sequences	O
of	O
iORFs	O
in	O
the	O
pre-filtering	O
clusters	O
were	O
subjected	O
to	O
TBLASTN	O
searches	O
against	O
the	O
genome	O
database	O
.	O

If	O
both	O
the	O
best	O
hits	O
of	O
the	O
N-	O
and	O
C-terminal	O
parts	O
are	O
statistically	O
significant	O
(	O
E-value	O
<	O
10-5	O
)	O
,	O
and	O
distance	O
between	O
them	O
is	O
less	O
than	O
1	O
kbp	O
,	O
we	O
call	O
these	O
hits	O
'syntenic	O
hits	O
'	O
.	O

If	O
any	O
syntenic	O
hits	O
with	O
non-coinciding	O
reading	O
frames	O
were	O
found	O
,	O
the	O
cluster	O
was	O
removed	O
.	O

The	O
third	O
filter	O
uses	O
co-occurrence	O
of	O
residues	O
around	O
the	O
inframe	O
stop	O
codon	O
as	O
another	O
source	O
of	O
information	O
for	O
screening	O
stop	O
codon	O
readthrough	O
.	O

Suppose	O
a	O
window	O
of	O
21	O
residues	O
centered	O
at	O
the	O
inframe	O
stop	O
codon	O
.	O

In	O
prokaryotes	O
,	O
most	O
stop-codon-encoded	O
amino	O
acids	O
are	O
located	O
inside	O
a	O
domain	O
,	O
the	O
unit	O
of	O
evolutionary	O
sequence	O
conservation	O
.	O

Therefore	O
,	O
in	O
an	O
ideal	O
situation	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
the	I-Negation
21	I-Negation
residues	I-Negation
in	I-Negation
alignments	I-Negation
will	O
be	O
synchronized	O
.	O

In	O
contrast	O
,	O
if	O
the	O
iORF	O
is	O
actually	O
two	O
adjacent	O
genes	O
,	O
then	O
upstream	O
and	O
downstream	O
residues	O
of	O
the	O
stop	O
codon	O
will	O
appear	O
separately	O
in	O
many	O
alignments	O
.	O

We	O
defined	O
a	O
co-occurrence	O
matrix	O
as	O
a	O
21	O
	O
21	O
matrix	O
whose	O
(	O
i	O
,	O
j	O
)	O
-th	O
element	O
represents	O
how	O
often	O
residue	O
i	O
and	O
j	O
appeared	O
simultaneously	O
in	O
N	O
alignments	O
.	O

The	O
matrix	O
elements	O
were	O
subsequently	O
normalized	O
to	O
the	O
number	O
of	O
alignments	O
N	O
.	O

By	O
definition	O
,	O
the	O
more	O
often	O
the	O
upstream	O
and	O
downstream	O
residues	O
of	O
the	O
inframe	O
stop	O
codon	O
co-occur	O
in	O
the	O
alignments	O
,	O
the	O
higher	O
the	O
density	O
in	O
the	O
upper	O
right	O
quarter	O
of	O
the	O
matrix	O
.	O

If	O
average	O
density	O
in	O
the	O
quarter	O
was	O
lower	O
than	O
0.85	O
,	O
the	O
cluster	O
was	O
filtered	O
out	O
.	O

Stop	O
codon	O
usage	O

For	O
each	O
organism	O
,	O
its	O
iORFs	O
were	O
extracted	O
from	O
the	O
pre-filtering	O
clusters	O
,	O
and	O
codon	O
usage	O
at	O
the	O
inframe	O
stop	O
positions	O
was	O
counted	O
.	O

Codon	O
usage	O
at	O
the	O
C-terminal	O
stop	O
codons	O
in	O
its	O
proteome	O
was	O
also	O
computed	O
using	O
data	O
of	O
coding	O
sequences	O
downloaded	O
from	O
KEGG	O
GENES	O
25	O
.	O

These	O
data	O
were	O
combined	O
into	O
a	O
3	O
	O
2	O
matrix	O
,	O
and	O
Fisher	O
's	O
exact	O
test	O
was	O
applied	O
.	O

The	O
p-value	O
was	O
corrected	O
for	O
multiple	O
testing	O
using	O
the	O
Bonferroni	O
correction	O
because	O
there	O
were	O
127	O
organisms	O
in	O
the	O
pre-filtering	O
clusters	O
.	O

Probabilistic	O
prediction	O
and	O
ranking	O
of	O
human	O
protein-protein	O
interactions	O

Abstract	O

Background	O

Although	O
the	O
prediction	O
of	O
protein-protein	O
interactions	O
has	O
been	O
extensively	O
investigated	O
for	O
yeast	O
,	O
few	O
such	O
datasets	O
exist	O
for	O
the	O
far	O
larger	O
proteome	O
in	O
human	O
.	O

Furthermore	O
,	O
it	O
has	O
recently	O
been	O
estimated	O
that	O
the	O
overall	O
average	O
false	O
positive	O
rate	O
of	O
available	O
computational	O
and	O
high-throughput	O
experimental	O
interaction	O
datasets	O
is	O
as	O
high	O
as	O
90	O
%	O
.	O

Results	O

The	O
prediction	O
of	O
human	O
protein-protein	O
interactions	O
was	O
investigated	O
by	O
combining	O
orthogonal	O
protein	O
features	O
within	O
a	O
probabilistic	O
framework	O
.	O

The	O
features	O
include	O
co-expression	O
,	O
orthology	O
to	O
known	O
interacting	O
proteins	O
and	O
the	O
full-Bayesian	O
combination	O
of	O
subcellular	O
localization	O
,	O
co-occurrence	O
of	O
domains	O
and	O
post-translational	O
modifications	O
.	O

A	O
novel	O
scoring	O
function	O
for	O
local	O
network	O
topology	O
was	O
also	O
investigated	O
.	O

This	O
topology	O
feature	O
greatly	O
enhanced	O
the	O
predictions	O
and	O
together	O
with	O
the	O
full-Bayes	O
combined	O
features	O
,	O
made	O
the	O
largest	O
contribution	O
to	O
the	O
predictions	O
.	O

Using	O
a	O
conservative	O
threshold	O
,	O
our	O
most	O
accurate	O
predictor	O
identifies	O
37606	O
human	O
interactions	O
,	O
32892	O
(	O
80	O
%	O
)	O
of	O
which	O
are	O
not	B-Negation
present	I-Negation
in	I-Negation
other	I-Negation
publicly	I-Negation
available	I-Negation
large	I-Negation
human	I-Negation
interaction	I-Negation
datasets	I-Negation
,	O
thus	O
substantially	O
increasing	O
the	O
coverage	O
of	O
the	O
human	O
interaction	O
map	O
.	O

A	O
subset	O
of	O
the	O
32892	O
novel	O
predicted	O
interactions	O
have	O
been	O
independently	O
validated	O
.	O

Comparison	O
of	O
the	O
prediction	O
dataset	O
to	O
other	O
available	O
human	O
interaction	O
datasets	O
estimates	O
the	O
false	O
positive	O
rate	O
of	O
the	O
new	O
method	O
to	O
be	O
below	O
80	O
%	O
which	O
is	O
competitive	O
with	O
other	O
methods	O
.	O

Since	O
the	O
new	O
method	O
scores	O
and	O
ranks	O
all	O
human	O
protein	O
pairs	O
,	O
smaller	O
subsets	O
of	O
higher	O
quality	O
can	O
be	O
generated	O
thus	O
leading	O
to	O
even	O
lower	O
false	O
positive	O
prediction	O
rates	O
.	O

Conclusion	O

The	O
set	O
of	O
interactions	O
predicted	O
in	O
this	O
work	O
increases	O
the	O
coverage	O
of	O
the	O
human	O
interaction	O
map	O
and	O
will	O
help	O
determine	O
the	O
highest	O
confidence	O
human	O
interactions	O
.	O

Background	O

Protein-protein	O
interactions	O
perform	O
and	O
regulate	O
fundamental	O
cellular	O
processes	O
.	O

The	O
comprehensive	O
study	O
of	O
such	O
interactions	O
on	O
a	O
genome-wide	O
scale	O
will	O
lead	O
to	O
a	O
clearer	O
understanding	O
of	O
diverse	O
cellular	O
processes	O
and	O
of	O
the	O
molecular	O
mechanisms	O
of	O
disease	O
.	O

Although	O
the	O
determination	O
of	O
interactions	O
by	O
small-scale	O
laboratory	O
techniques	O
is	O
impractical	O
for	O
a	O
complete	O
proteome	O
on	O
the	O
grounds	O
of	O
cost	O
and	O
time	O
,	O
several	O
experimental	O
techniques	O
now	O
exist	O
to	O
determine	O
protein-protein	O
interactions	O
in	O
a	O
high-throughput	O
manner	O
1	O
.	O

High-throughput	O
datasets	O
have	O
been	O
generated	O
for	O
model	O
organisms	O
such	O
as	O
yeast	O
23456	O
,	O
worm	O
7	O
and	O
fly	O
89	O
as	O
well	O
as	O
Escherichia	O
coli	O
10	O
.	O

In	O
addition	O
,	O
the	O
first	O
broad-focus	O
experimental	O
datasets	O
for	O
the	O
human	O
interactome	O
have	O
recently	O
been	O
published	O
1112	O
.	O

Interactions	O
determined	O
by	O
high-throughput	O
methods	O
are	O
generally	O
considered	O
to	O
be	O
less	O
reliable	O
than	O
those	O
obtained	O
by	O
low-throughput	O
studies	O
1314	O
and	O
as	O
a	O
consequence	O
efforts	O
are	O
also	O
underway	O
to	O
extract	O
evidence	O
for	O
interactions	O
from	O
the	O
literature	O
151617	O
.	O

Analysis	O
of	O
the	O
high-throughput	O
datasets	O
has	O
shown	O
that	O
they	O
overlap	O
very	O
little	O
with	O
each	O
other	O
,	O
suggesting	O
that	O
their	O
coverage	O
is	O
low	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
estimated	O
recently	O
that	O
the	O
current	O
yeast	O
and	O
human	O
protein	O
interaction	O
maps	O
are	O
only	O
50	O
%	O
and	O
10	O
%	O
complete	O
,	O
respectively	O
18	O
.	O

The	O
low	O
coverage	O
and	O
variable	O
quality	O
of	O
the	O
experimental	O
interaction	O
datasets	O
have	O
prompted	O
many	O
groups	O
to	O
investigate	O
computational	O
methods	O
to	O
predict	O
interactions	O
or	O
to	O
determine	O
the	O
most	O
likely	O
interactions	O
seen	O
in	O
the	O
high-throughput	O
datasets	O
.	O

The	O
different	O
approaches	O
to	O
predict	O
interactions	O
can	O
be	O
grouped	O
into	O
five	O
main	O
categories	O
:	O

1	O
)	O
Predictors	O
based	O
on	O
sequence	O
and	O
structure	O
exploit	O
the	O
observation	O
that	O
some	O
pairs	O
of	O
sequence	O
motifs	O
,	O
domains	O
and	O
structural	O
families	O
tend	O
to	O
interact	O
preferentially	O
.	O

Some	O
methods	O
predict	O
interaction	O
from	O
sequence-motifs	O
found	O
to	O
be	O
over-represented	O
in	O
interacting	O
protein	O
pairs	O
19	O
,	O
or	O
by	O
considering	O
the	O
physico-chemical	O
properties	O
and	O
the	O
location	O
of	O
groups	O
of	O
amino	O
acids	O
in	O
the	O
sequence	O
2021	O
.	O

Others	O
investigate	O
the	O
co-occurrence	O
in	O
interacting	O
proteins	O
of	O
specific	O
protein	O
domains	O
or	O
their	O
structural	O
family	O
classification	O
2223	O
.	O

When	O
three-dimensional	O
structures	O
are	O
available	O
for	O
both	O
proteins	O
thought	O
to	O
interact	O
,	O
high	O
quality	O
predictions	O
and	O
additional	O
information	O
such	O
as	O
the	O
residues	O
involved	O
in	O
the	O
interaction	O
and	O
their	O
binding	O
affinity	O
may	O
be	O
estimated	O
(	O
reviewed	O
in	O
24	O
)	O
.	O

Similarly	O
,	O
when	O
two	O
proteins	O
show	O
clear	O
sequence	O
similarity	O
to	O
proteins	O
that	O
exist	O
in	O
a	O
complex	O
for	O
which	O
the	O
three-dimensional	O
structure	O
is	O
known	O
,	O
detailed	O
predictions	O
of	O
the	O
atomic-level	O
interactions	O
may	O
be	O
made	O
.	O

For	O
example	O
,	O
the	O
major	O
complexes	O
in	O
yeast	O
have	O
been	O
predicted	O
by	O
this	O
strategy	O
25	O
.	O

2	O
)	O
Predictors	O
based	O
on	O
comparative	O
genomics	O
have	O
been	O
exploited	O
primarily	O
in	O
prokaryotes	O
.	O

They	O
consider	O
the	O
physical	O
location	O
of	O
genes	O
,	O
as	O
well	O
as	O
their	O
pattern	O
of	O
occurrence	O
and	O
evolutionary	O
rate	O
,	O
to	O
predict	O
interactions	O
or	O
functional	O
relationships	O
between	O
protein	O
pairs	O
.	O

Some	O
predictors	O
make	O
use	O
of	O
the	O
observation	O
that	O
neighboring	O
genes	O
whose	O
relative	O
location	O
is	O
conserved	O
across	O
several	O
prokaryotic	O
organisms	O
are	O
likely	O
to	O
interact	O
26	O
.	O

Other	O
predictors	O
exploit	O
the	O
observation	O
that	O
gene	O
pairs	O
that	O
co-occur	O
in	O
related	O
species	O
or	O
that	O
co-evolve	O
also	O
tend	O
to	O
be	O
more	O
likely	O
to	O
interact	O
27282930	O
.	O

In	O
addition	O
,	O
domains	O
that	O
exist	O
as	O
separate	O
proteins	O
in	O
some	O
genomes	O
but	O
are	O
also	O
seen	O
fused	O
in	O
a	O
single	O
protein	O
in	O
other	O
genomes	O
have	O
been	O
used	O
to	O
suggest	O
the	O
isolated	O
domains	O
may	O
interact	O
3132	O
.	O

3	O
)	O
Predictors	O
based	O
on	O
orthology	O
work	O
on	O
the	O
assumption	O
that	O
the	O
orthologs	O
of	O
a	O
protein	O
pair	O
that	O
are	O
known	O
to	O
interact	O
in	O
one	O
organism	O
will	O
also	O
interact	O
.	O

Such	O
relationships	O
are	O
often	O
referred	O
to	O
as	O
interologs	O
33	O
.	O

For	O
example	O
,	O
at	O
BLAST	O
e-values	O
below	O
10-10	O
,	O
it	O
has	O
been	O
shown	O
that	O
1630	O
%	O
of	O
yeast	O
interactions	O
can	O
be	O
transferred	O
to	O
the	O
worm	O
34	O
while	O
further	O
studies	O
have	O
estimated	O
that	O
a	O
joint	O
e-value	O
below	O
10-70	O
is	O
required	O
to	O
transfer	O
interactions	O
reliably	O
between	O
organisms	O
35	O
.	O

Interologs	O
have	O
been	O
used	O
to	O
predict	O
protein-protein	O
interactions	O
in	O
human	O
36	O
.	O

4	O
)	O
Predictors	O
based	O
on	O
functional	O
features	O
exploit	O
non-sequence	O
information	O
to	O
infer	O
interactions	O
.	O

Some	O
predictors	O
exploit	O
the	O
observation	O
that	O
there	O
is	O
a	O
significant	O
correlation	O
in	O
the	O
expression	O
levels	O
of	O
transcripts	O
encoding	O
proteins	O
that	O
interact	O
37	O
.	O

Since	O
proteins	O
must	O
be	O
co-localized	O
in	O
order	O
to	O
interact	O
,	O
protein	O
subcellular	O
localization	O
has	O
often	O
been	O
used	O
to	O
assess	O
the	O
quality	O
of	O
interaction	O
datasets	O
3839	O
.	O

Similarly	O
,	O
interacting	O
proteins	O
are	O
also	O
often	O
involved	O
in	O
similar	O
cellular	O
processes	O
,	O
so	O
Gene	O
Ontology	O
``	O
process	O
``	O
and	O
``	O
function	O
``	O
annotations	O
have	O
been	O
exploited	O
to	O
predict	O
interactions	O
and	O
validate	O
high-throughput	O
datasets	O
163638	O
.	O

5	O
)	O
Predictors	O
have	O
exploited	O
similarities	O
in	O
the	O
network	O
topology	O
of	O
known	O
interaction	O
datasets	O
to	O
predict	O
novel	O
interactions	O
.	O

In	O
one	O
study	O
,	O
the	O
local	O
topology	O
of	O
small-world	O
networks	O
has	O
been	O
used	O
to	O
assess	O
the	O
quality	O
of	O
interaction	O
datasets	O
and	O
predict	O
novel	O
interactions	O
40	O
while	O
Gerstein	O
and	O
colleagues	O
have	O
investigated	O
the	O
prediction	O
of	O
interactions	O
by	O
the	O
identification	O
of	O
missing	O
edges	O
in	O
almost	O
fully	O
connected	O
complexes	O
41	O
.	O

In	O
addition	O
to	O
these	O
diverse	O
approaches	O
,	O
some	O
groups	O
have	O
combined	O
concepts	O
from	O
several	O
of	O
the	O
above	O
categories	O
in	O
integrative	O
frameworks	O
.	O

The	O
first	O
such	O
predictor	O
integrated	O
co-expression	O
data	O
,	O
co-essentiality	O
as	O
well	O
as	O
biological	O
function	O
in	O
a	O
nave	O
Bayes	O
network	O
to	O
provide	O
proteome-wide	O
de	O
novo	O
prediction	O
of	O
yeast	O
protein	O
interactions	O
37	O
.	O

Subsequently	O
,	O
the	O
combination	O
of	O
many	O
more	O
diverse	O
features	O
was	O
investigated	O
using	O
different	O
frameworks	O
to	O
predict	O
yeast	O
protein-protein	O
interactions	O
,	O
increasing	O
the	O
prediction	O
accuracy	O
and	O
allowing	O
an	O
assessment	O
of	O
the	O
limits	O
of	O
genomic	O
integration	O
424344	O
.	O

The	O
integration	O
of	O
diverse	O
genomic	O
features	O
has	O
also	O
been	O
useful	O
in	O
the	O
investigation	O
of	O
the	O
related	O
but	O
broader	O
problem	O
of	O
predicting	O
protein-protein	O
associations	O
as	O
well	O
as	O
complex	O
and	O
pathway	O
membership	O
(	O
see	O
for	O
example	O
45	O
)	O
.	O

Although	O
,	O
many	O
computational	O
methods	O
have	O
investigated	O
the	O
prediction	O
of	O
protein-protein	O
interactions	O
,	O
few	O
have	O
so	O
far	O
been	O
applied	O
to	O
the	O
human	O
proteome	O
.	O

The	O
first	O
large-scale	O
prediction	O
of	O
the	O
human	O
interactome	O
map	O
involved	O
transferring	O
interactions	O
from	O
model	O
organisms	O
36	O
.	O

This	O
resulted	O
in	O
over	O
70000	O
predicted	O
physical	O
interactions	O
involving	O
approximately	O
6200	O
human	O
proteins	O
.	O

A	O
second	O
method	O
integrated	O
expression	O
data	O
,	O
orthology	O
,	O
protein	O
domain	O
data	O
and	O
functional	O
annotations	O
into	O
a	O
probabilistic	O
framework	O
and	O
resulted	O
in	O
the	O
prediction	O
of	O
nearly	O
40000	O
human	O
protein	O
interactions	O
46	O
.	O

It	O
has	O
recently	O
been	O
estimated	O
that	O
the	O
false-positive	O
rates	O
of	O
these	O
computational	O
datasets	O
as	O
well	O
as	O
of	O
available	O
high-throughput	O
human	O
interaction	O
datasets	O
are	O
,	O
on	O
average	O
,	O
as	O
high	O
as	O
90	O
%	O
and	O
their	O
coverage	O
is	O
only	O
approximately	O
10	O
%	O
,	O
indicating	O
that	O
more	O
such	O
efforts	O
are	O
needed	O
to	O
increase	O
the	O
coverage	O
and	O
confidence	O
we	O
have	O
in	O
current	O
maps	O
of	O
the	O
human	O
interactome	O
18	O
.	O

In	O
this	O
paper	O
,	O
the	O
prediction	O
of	O
physical	O
interactions	O
between	O
human	O
proteins	O
has	O
been	O
investigated	O
by	O
integrating	O
in	O
a	O
Bayesian	O
framework	O
several	O
different	O
pieces	O
of	O
evidence	O
including	O
orthology	O
,	O
functional	O
features	O
and	O
local	O
network	O
topology	O
.	O

In	O
order	O
to	O
increase	O
the	O
accuracy	O
and	O
coverage	O
of	O
the	O
predictions	O
,	O
different	O
types	O
of	O
negative	O
data	O
(	O
non-interacting	O
protein	O
pairs	O
)	O
were	O
explored	O
to	O
train	O
the	O
predictor	O
.	O

The	O
most	O
accurate	O
of	O
the	O
predictors	O
was	O
then	O
used	O
to	O
assess	O
the	O
likelihood	O
of	O
pair-wise	O
interaction	O
for	O
over	O
20000	O
human	O
proteins	O
from	O
the	O
IPI	O
(	O
International	O
Protein	O
Index	O
)	O
database	O
.	O

These	O
predictions	O
provide	O
a	O
likelihood	O
of	O
interaction	O
for	O
over	O
260	O
million	O
human	O
protein	O
pairs	O
and	O
lead	O
to	O
the	O
prediction	O
of	O
over	O
37000	O
human	O
interactions	O
.	O

They	O
should	O
thus	O
augment	O
current	O
knowledge	O
of	O
the	O
human	O
interactome	O
as	O
well	O
as	O
the	O
understanding	O
of	O
the	O
relationship	O
between	O
distinct	O
cellular	O
processes	O
.	O

Results	O
and	O
discussion	O

Architecture	O
of	O
the	O
predictor	O
and	O
training	O
of	O
the	O
modules	O

The	O
prediction	O
of	O
human	O
protein-protein	O
interactions	O
was	O
investigated	O
in	O
a	O
Bayesian	O
framework	O
by	O
considering	O
combinations	O
of	O
individual	O
protein	O
features	O
known	O
to	O
be	O
indicative	O
of	O
interaction	O
.	O

The	O
seven	O
individual	O
features	O
considered	O
are	O
summarized	O
in	O
Table	O
1	O
and	O
detailed	O
in	O
the	O
Methods	O
section	O
.	O

As	O
indicated	O
in	O
Table	O
1	O
,	O
the	O
different	O
features	O
were	O
grouped	O
into	O
five	O
distinct	O
modules	O
:	O
Expression	O
(	O
E	O
)	O
,	O
Orthology	O
(	O
O	O
)	O
,	O
Combined	O
(	O
C	O
)	O
,	O
Disorder	O
(	O
D	O
)	O
and	O
Transitive	O
(	O
T	O
)	O
.	O

Figure	O
1	O
illustrates	O
the	O
training	O
scheme	O
and	O
architecture	O
of	O
the	O
method	O
.	O

The	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Disorder	O
modules	O
can	O
calculate	O
likelihood	O
ratios	O
(	O
LR	O
)	O
of	O
interaction	O
independently	O
and	O
are	O
referred	O
to	O
as	O
the	O
Group	O
A	O
modules	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
product	O
of	O
their	O
likelihood	O
ratios	O
is	O
referred	O
to	O
as	O
the	O
Preliminary	O
Score	O
.	O

The	O
Transitive	O
module	O
considers	O
the	O
local	O
topology	O
of	O
the	O
network	O
predicted	O
by	O
the	O
group	O
A	O
modules	O
and	O
thus	O
requires	O
the	O
completion	O
of	O
their	O
analysis	O
to	O
calculate	O
its	O
own	O
likelihood	O
ratios	O
of	O
interaction	O
(	O
Figure	O
1B	O
)	O
.	O

As	O
such	O
,	O
all	O
combinations	O
of	O
the	O
Group	O
A	O
modules	O
can	O
be	O
used	O
to	O
predict	O
interaction	O
in	O
the	O
presence	O
or	O
absence	B-Negation
of	I-Negation
the	I-Negation
Transitive	I-Negation
module	I-Negation
.	O

In	O
the	O
absence	B-Negation
of	I-Negation
the	I-Negation
Transitive	I-Negation
module	I-Negation
,	O
the	O
Preliminary	O
Score	O
is	O
used	O
as	O
the	O
final	O
likelihood	O
ratio	O
output	O
by	O
the	O
predictor	O
.	O

Features	O
considered	O
in	O
the	O
prediction	O
of	O
interactions	O
for	O
each	O
module	O

Architecture	O
of	O
the	O
predictor	O
and	O
likelihoods	O
of	O
the	O
modules	O

Architecture	O
of	O
the	O
predictor	O
and	O
likelihoods	O
of	O
the	O
modules	O
.	O

The	O
predictor	O
consists	O
of	O
two	O
different	O
parts	O
(	O
A	O
and	O
B	O
)	O
which	O
are	O
trained	O
consecutively	O
.	O

The	O
Group	O
A	O
modules	O
(	O
shown	O
in	O
panel	O
A	O
)	O
are	O
trained	O
in	O
parallel	O
.	O

The	O
likelihood	O
ratios	O
(	O
LR	O
)	O
for	O
most	O
of	O
their	O
states	O
are	O
shown	O
in	O
panel	O
A	O
(	O
their	O
complete	O
likelihood	O
ratios	O
are	O
available	O
in	O
Additional	O
File	O
4	O
)	O
.	O

The	O
product	O
of	O
the	O
likelihood	O
ratios	O
of	O
all	O
Group	O
A	O
modules	O
considered	O
in	O
a	O
given	O
prediction	O
is	O
referred	O
to	O
as	O
the	O
preliminary	O
score	O
(	O
PS	O
)	O
and	O
can	O
be	O
calculated	O
for	O
all	O
human	O
protein	O
pairs	O
.	O

If	O
the	B-Negation
Transitive	I-Negation
module	I-Negation
is	I-Negation
not	I-Negation
considered	I-Negation
,	O
the	O
final	O
likelihood	O
ratios	O
assigned	O
to	O
all	O
protein	O
pairs	O
is	O
the	O
preliminary	O
score	O
(	O
PS	O
)	O
.	O

If	O
the	O
Transitive	O
module	O
is	O
considered	O
,	O
the	O
local	O
topology	O
of	O
the	O
network	O
determined	O
by	O
the	O
assignment	O
of	O
preliminary	O
scores	O
to	O
all	O
protein	O
pairs	O
considered	O
in	O
the	O
training	O
set	O
is	O
used	O
to	O
calculate	O
the	O
likelihood	O
ratios	O
for	O
the	O
transitive	O
module	O
(	O
shown	O
in	O
panel	O
B	O
)	O
for	O
every	O
protein	O
pair	O
in	O
the	O
training	O
set	O
.	O

The	O
final	O
likelihood	O
ratio	O
is	O
then	O
the	O
product	O
of	O
the	O
preliminary	O
score	O
calculated	O
in	O
panel	O
A	O
and	O
the	O
likelihood	O
ratio	O
output	O
by	O
the	O
transitive	O
module	O
in	O
panel	O
B	O
.	O

For	O
the	O
Orthology	O
module	O
:	O
YL	O
,	O
YM	O
,	O
YH	O
:	O
yeast	O
low	O
,	O
medium	O
and	O
high	O
scoring	O
bins	O
;	O
FL	O
,	O
FM	O
,	O
FH	O
:	O
fly	O
low	O
,	O
medium	O
and	O
high	O
scoring	O
bins	O
;	O
WL	O
,	O
WM	O
,	O
WH	O
:	O
worm	O
low	O
,	O
medium	O
and	O
high	O
scoring	O
bins	O
;	O
HM	O
and	O
HL	O
:	O
medium	O
and	O
low	O
scoring	O
bins	O
for	O
human	O
protein	O
pairs	O
that	O
have	O
human	O
paralogs	O
;	O
>	O
1	O
organism	O
:	O
bin	O
for	O
human	O
protein	O
pairs	O
that	O
have	O
interologs	O
in	O
more	O
than	O
one	O
organism	O
.	O

For	O
the	O
Combined	O
module	O
,	O
	O
refers	O
to	O
the	O
lowest	O
scoring	O
bin	O
(	O
for	O
the	O
domain	O
(	O
Dom	O
)	O
,	O
post-translational	O
modification	O
(	O
PTM	O
)	O
and	O
subcellular	O
localization	O
(	O
Loc	O
)	O
features	O
)	O
,	O
	O
refers	O
to	O
the	O
second	O
lowest	O
scoring	O
bin	O
and	O
+	O
,	O
++	O
,	O
+++	O
refer	O
respectively	O
to	O
the	O
third	O
highest	O
,	O
second	O
highest	O
and	O
highest	O
scoring	O
bins	O
.	O

The	O
likelihood	O
ratios	O
of	O
interaction	O
are	O
evaluated	O
for	O
each	O
module	O
by	O
considering	O
the	O
relative	O
proportions	O
of	O
positive	O
and	O
negative	O
training	O
examples	O
that	O
have	O
a	O
specific	O
state	O
(	O
i.e.	O
that	O
fall	O
in	O
a	O
particular	O
bin	O
of	O
a	O
module	O
)	O
.	O

The	O
datasets	O
used	O
to	O
train	O
the	O
predictor	O
consisted	O
of	O
26896	O
known	O
human	O
protein	O
interactions	O
extracted	O
from	O
the	O
Human	O
Protein	O
Reference	O
Database	O
(	O
HPRD	O
)	O
15	O
and	O
approximately	O
100	O
times	O
more	O
randomly	O
chosen	O
protein	O
pairs	O
used	O
as	O
negative	O
examples	O
.	O

The	O
composition	O
of	O
the	O
datasets	O
and	O
likelihood	O
ratio	O
calculations	O
are	O
explained	O
in	O
greater	O
detail	O
in	O
the	O
Methods	O
section	O
.	O

Once	O
the	O
final	O
likelihood	O
ratio	O
of	O
interaction	O
(	O
LRfinal	O
)	O
is	O
calculated	O
for	O
a	O
given	O
protein	O
pair	O
as	O
shown	O
in	O
Figure	O
1B	O
,	O
it	O
is	O
possible	O
to	O
estimate	O
the	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
by	O
multiplying	O
the	O
final	O
likelihood	O
ratio	O
by	O
the	O
prior	O
odds	O
ratio	O
of	O
interaction	O
.	O

Protein	O
pairs	O
that	O
have	O
a	O
posterior	O
odds	O
of	O
interaction	O
above	O
1	O
are	O
more	O
likely	O
to	O
interact	O
than	O
not	O
to	O
interact	O
,	O
thus	O
providing	O
an	O
obvious	O
threshold	O
to	O
predict	O
interacting	O
proteins	O
.	O

Estimates	O
for	O
the	O
prior	O
odds	O
ratio	O
of	O
interaction	O
vary	O
.	O

Previous	O
interaction	O
studies	O
on	O
yeast	O
and	O
human	O
use	O
prior	O
odds	O
ratios	O
that	O
range	O
from	O
1/600	O
to	O
>	O
1/400	O
37434647	O
.	O

The	O
evaluation	O
of	O
this	O
ratio	O
is	O
difficult	O
because	O
not	O
all	O
true	O
interactions	O
are	O
known	O
.	O

As	O
detailed	O
in	O
Methods	O
,	O
the	O
prior	O
odds	O
ratio	O
for	O
human	O
protein	O
interaction	O
was	O
explored	O
by	O
considering	O
different	O
versions	O
and	O
subsets	O
of	O
human	O
interaction	O
datasets	O
.	O

This	O
suggested	O
that	O
there	O
is	O
insufficient	O
data	O
currently	O
available	O
to	O
determine	O
a	O
reliable	O
ratio	O
for	O
human	O
.	O

Accordingly	O
,	O
we	O
selected	O
a	O
prior	O
odds	O
ratio	O
of	O
interaction	O
of	O
1/400	O
which	O
is	O
similar	O
to	O
current	O
estimates	O
for	O
yeast	O
and	O
is	O
probably	O
still	O
quite	O
conservative	O
.	O

Thus	O
,	O
the	O
likelihood	O
ratio	O
threshold	O
to	O
predict	O
interactions	O
is	O
400	O
.	O

Likelihood	O
ratios	O
of	O
the	O
modules	O

Figure	O
1	O
summarizes	O
the	O
likelihood	O
ratios	O
computed	O
for	O
the	O
five	O
modules	O
.	O

The	O
different	O
modules	O
differ	O
in	O
the	O
range	O
of	O
likelihood	O
ratio	O
values	O
achieved	O
by	O
their	O
different	O
states	O
.	O

The	O
Orthology	O
and	O
Combined	O
modules	O
both	O
have	O
states	O
that	O
achieve	O
likelihood	O
ratios	O
above	O
400	O
(	O
as	O
high	O
as	O
1207	O
for	O
the	O
Orthology	O
module	O
and	O
613	O
for	O
the	O
Combined	O
module	O
)	O
,	O
indicating	O
that	O
both	O
these	O
modules	O
can	O
,	O
on	O
their	O
own	O
,	O
predict	O
some	O
interacting	O
protein	O
pairs	O
with	O
a	O
posterior	O
odds	O
ratio	O
above	O
1	O
.	O

The	O
Expression	O
module	O
follows	O
trends	O
seen	O
in	O
previous	O
studies	O
with	O
increasing	O
likelihood	O
ratios	O
of	O
interaction	O
reflecting	O
increasing	O
expression	O
correlation	O
3746	O
.	O

However	O
,	O
since	O
the	O
highest	O
likelihood	O
ratio	O
for	O
the	O
expression	O
datasets	O
that	O
we	O
consider	O
is	O
33	O
,	O
they	O
are	O
not	B-Negation
sufficient	I-Negation
on	I-Negation
their	I-Negation
own	I-Negation
to	I-Negation
predict	I-Negation
interacting	I-Negation
protein	I-Negation
pairs	I-Negation
with	I-Negation
a	I-Negation
posterior	I-Negation
odds	I-Negation
ratio	I-Negation
above	I-Negation
1	I-Negation
.	O

Similarly	O
,	O
but	O
in	O
a	O
much	O
more	O
pronounced	O
way	O
,	O
the	O
Disorder	O
module	O
is	O
only	O
slightly	O
predictive	O
of	O
interaction	O
,	O
with	O
a	O
maximum	O
likelihood	O
ratio	O
of	O
1.8	O
.	O

Most	O
states	O
of	O
the	O
Orthology	O
module	O
achieve	O
higher	O
likelihood	O
ratios	O
than	O
the	O
highest	O
obtained	O
by	O
the	O
Expression	O
and	O
Disorder	O
modules	O
.	O

This	O
is	O
not	B-Negation
surprising	I-Negation
as	O
the	O
transfer	O
of	O
interacting	O
orthologs	O
(	O
known	O
as	O
interologs	O
33	O
)	O
from	O
one	O
organism	O
to	O
another	O
is	O
a	O
popular	O
method	O
to	O
predict	O
interactions	O
(	O
see	O
for	O
example	O
3448	O
)	O
,	O
particularly	O
in	O
the	O
case	O
of	O
organisms	O
like	O
human	O
for	O
which	O
only	O
a	O
small	O
proportion	O
of	O
interactions	O
are	O
known	O
.	O

The	O
direct	O
transfer	O
of	O
interactions	O
to	O
human	O
from	O
either	O
yeast	O
,	O
fly	O
or	O
worm	O
does	O
not	O
alone	O
result	O
in	O
a	O
posterior	O
odds	O
ratio	O
above	O
1	O
(	O
as	O
the	O
likelihood	O
ratios	O
of	O
interaction	O
for	O
all	O
yeast	O
,	O
fly	O
and	O
worm	O
bins	O
in	O
the	O
Orthology	O
module	O
are	O
below	O
400	O
)	O
.	O

This	O
is	O
not	B-Negation
surprising	I-Negation
as	O
previous	O
studies	O
have	O
indicated	B-Speculation
that	I-Speculation
quite	I-Speculation
stringent	I-Speculation
joint	I-Speculation
E-values	I-Speculation
must	I-Speculation
be	I-Speculation
used	I-Speculation
to	I-Speculation
transfer	I-Speculation
interactions	I-Speculation
safely	I-Speculation
between	I-Speculation
organisms	I-Speculation
3435	O
.	O

In	O
contrast	O
,	O
the	O
consideration	O
of	O
human	O
interactions	O
paralogous	O
to	O
the	O
human	O
protein	O
pairs	O
under	O
investigation	O
results	O
in	O
likelihood	O
ratios	O
of	O
431	O
and	O
1034	O
(	O
depending	O
on	O
how	O
close	O
the	O
paralogs	O
are	O
as	O
described	O
in	O
Methods	O
)	O
which	O
is	O
much	O
higher	O
than	O
those	O
obtained	O
for	O
any	O
single	O
model	O
organism	O
.	O

This	O
agrees	O
with	O
a	O
recent	O
report	O
that	O
suggested	O
protein-protein	O
interactions	O
are	O
more	O
conserved	O
within	O
species	O
than	O
across	O
species	O
49	O
.	O

The	O
Combined	O
module	O
uses	O
domain	O
co-occurrence	O
,	O
post-translational	O
modification	O
(	O
PTM	O
)	O
co-occurrence	O
and	O
subcellular	O
localization	O
information	O
to	O
predict	O
interaction	O
.	O

These	O
features	O
were	O
originally	O
investigated	O
separately	O
,	O
as	O
shown	O
in	O
Figure	O
3	O
,	O
but	O
their	O
combination	O
into	O
one	O
module	O
that	O
considers	O
all	O
dependencies	O
between	O
them	O
achieves	O
higher	O
accuracy	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
and	O
higher	O
likelihood	O
ratios	O
(	O
as	O
can	O
be	O
seen	O
by	O
comparing	O
to	O
Figure	O
1	O
)	O
while	O
still	O
being	O
computationally	O
feasible	O
.	O

Additionally	O
,	O
this	O
combination	O
circumvents	O
possible	O
problems	O
of	O
dependence	O
between	O
these	O
features	O
.	O

Likelihood	O
ratios	O
of	O
the	O
features	O
that	O
form	O
the	O
Combined	O
module	O
,	O
considered	O
separately	O

Likelihood	O
ratios	O
of	O
the	O
features	O
that	O
form	O
the	O
Combined	O
module	O
,	O
considered	O
separately	O
.	O

The	O
Combined	O
module	O
considers	O
simultaneously	O
three	O
distinct	O
features	O
:	O
the	O
co-occurrence	O
of	O
both	O
domains	O
and	O
PTMs	O
as	O
well	O
as	O
the	O
subcellular	O
co-localization	O
of	O
proteins	O
.	O

Here	O
the	O
likelihood	O
ratios	O
of	O
these	O
features	O
considered	O
separately	O
are	O
shown	O
.	O

In	O
panel	O
A	O
,	O
all	O
domain	O
pairs	O
considered	O
were	O
given	O
scores	O
and	O
likelihood	O
ratios	O
were	O
estimated	O
for	O
different	O
values	O
of	O
these	O
scores	O
.	O

Similarly	O
,	O
shown	O
in	O
panel	O
B	O
are	O
the	O
likelihood	O
ratios	O
for	O
different	O
values	O
of	O
PTM	O
co-occurrence	O
scores	O
.	O

Panel	O
C	O
shows	O
the	O
likelihood	O
ratios	O
for	O
protein	O
pairs	O
localized	O
to	O
different	O
sets	O
of	O
cellular	O
compartments	O
.	O

Previous	O
methods	O
have	O
investigated	O
the	O
use	O
of	O
co-occurring	O
domains	O
to	O
predict	O
interaction	O
(	O
see	O
for	O
example	O
2346	O
)	O
.	O

Many	O
pairs	O
of	O
domains	O
co-occur	O
in	O
proteins	O
known	O
to	O
interact	O
.	O

When	O
investigated	O
as	O
a	O
separate	O
feature	O
,	O
the	O
chi-square	O
score	O
of	O
co-occurrence	O
of	O
domain	O
pairs	O
correlates	O
well	O
with	O
the	O
likelihood	O
of	O
interaction	O
of	O
protein	O
pairs	O
that	O
contain	O
these	O
domains	O
,	O
with	O
the	O
highest	O
chi-square	O
score	O
bin	O
obtaining	O
a	O
likelihood	O
ratio	O
of	O
14	O
,	O
as	O
shown	O
in	O
Figure	O
3A	O
.	O

Similarly	O
,	O
the	O
co-occurrence	O
of	O
PTMs	O
is	O
also	O
predictive	O
of	O
interaction	O
,	O
with	O
its	O
highest	O
scoring	O
bin	O
obtaining	O
a	O
likelihood	O
ratio	O
of	O
6	O
as	O
shown	O
in	O
Figure	O
3B	O
.	O

Lists	O
of	O
high	O
scoring	O
domain	O
pairs	O
and	O
PTM	O
pairs	O
are	O
shown	O
in	O
Additional	O
Files	O
1	O
and	O
2	O
.	O

Subcellular	O
localization	O
has	O
been	O
extensively	O
used	O
both	O
to	O
assess	O
the	O
quality	O
of	O
interaction	O
datasets	O
115051	O
and	O
to	O
generate	O
examples	O
of	O
non-interacting	O
protein	O
pairs	O
to	O
use	O
as	O
negative	O
datasets	O
when	O
training	O
and	O
testing	O
predictors	O
3746	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
use	O
of	O
localization	O
was	O
investigated	O
as	O
a	O
feature	O
predictive	O
of	O
interaction	O
.	O

Four	O
possible	B-Speculation
localization	I-Speculation
states	I-Speculation
were	O
considered	O
for	O
protein	O
pairs	O
:	O
:	O
same	O
compartment	O
,	O
neighboring	O
compartments	O
,	O
different	O
non-neighboring	O
compartments	O
and	O
absence	B-Negation
of	I-Negation
localization	I-Negation
annotation	I-Negation
(	O
more	O
details	O
are	O
given	O
in	O
the	O
Methods	O
section	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
3C	O
,	O
the	O
likelihood	O
ratio	O
of	O
same	O
compartment	O
protein	O
pairs	O
was	O
found	O
to	O
be	O
twice	O
as	O
high	O
as	O
that	O
of	O
randomly	O
chosen	O
or	O
non-annotated	O
protein	O
pairs	O
whereas	O
different	O
non-neighboring	O
protein	O
pairs	O
are	O
more	O
than	O
three	O
times	O
less	O
likely	O
to	O
interact	O
than	O
random	O
protein	O
pairs	O
.	O

Individual	O
localization	O
features	O
achieve	O
low	O
interaction	O
likelihood	O
ratios	O
.	O

However	O
,	O
when	O
integrated	O
into	O
the	O
Combined	O
module	O
,	O
domain	O
,	O
PTM	O
and	O
localization	O
information	O
together	O
achieve	O
likelihood	O
ratios	O
that	O
are	O
high	O
enough	O
to	O
predict	O
interaction	O
on	O
their	O
own	O
(	O
i.e.	O
above	O
400	O
)	O
.	O

As	O
expected	O
,	O
the	O
highest	O
likelihood	O
ratio	O
bins	O
for	O
the	O
Combined	O
module	O
are	O
those	O
representing	O
the	O
highest	O
combinations	O
of	O
the	O
three	O
features	O
separately	O
.	O

The	O
transitive	O
module	O
enhances	O
the	O
preliminary	O
likelihood	O
score	O
(	O
PS	O
)	O
(	O
calculated	O
using	O
the	O
group	O
A	O
modules	O
)	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
resulting	O
network	O
which	O
is	O
assessed	O
using	O
the	O
neighborhood	O
topology	O
score	O
as	O
detailed	O
in	O
the	O
Methods	O
section	O
.	O

The	O
likelihood	O
ratios	O
for	O
different	O
values	O
of	O
the	O
neighborhood	O
topology	O
score	O
are	O
shown	O
in	O
Figure	O
1B	O
.	O

The	O
Transitive	O
module	O
is	O
highly	O
predictive	O
of	O
interaction	O
and	O
achieves	O
likelihood	O
ratios	O
as	O
high	O
as	O
229	O
.	O

This	B-Negation
module	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
used	I-Negation
alone	I-Negation
as	O
it	O
requires	O
as	O
input	O
the	O
output	O
of	O
at	O
least	O
one	O
group	O
A	O
module	O
.	O

However	O
,	O
it	O
can	O
predict	O
interacting	O
protein	O
pairs	O
with	O
a	O
posterior	O
odds	O
ratio	O
above	O
1.0	O
when	O
used	O
in	O
combination	O
with	O
any	O
single	O
module	O
in	O
group	O
A	O
(	O
as	O
the	O
product	O
of	O
the	O
highest	O
likelihood	O
ratios	O
of	O
the	O
transitive	O
module	O
and	O
any	O
group	O
A	O
module	O
is	O
greater	O
than	O
400	O
as	O
can	O
be	O
seen	O
from	O
Figure	O
1	O
)	O
.	O

Independence	O
of	O
the	O
modules	O

The	O
final	O
likelihood	O
ratio	O
output	O
by	O
the	O
predictor	O
is	O
only	O
representative	O
of	O
the	O
true	O
likelihood	O
of	O
interaction	O
of	O
a	O
protein	O
pair	O
if	O
the	O
modules	O
considered	O
are	O
independent	O
.	O

If	O
the	O
modules	O
were	O
not	B-Negation
independent	I-Negation
,	O
some	B-Speculation
likelihood	I-Speculation
ratios	I-Speculation
would	I-Speculation
likely	B-Speculation
be	I-Speculation
overestimated	I-Speculation
,	I-Speculation
particularly	I-Speculation
for	I-Speculation
protein	I-Speculation
pairs	I-Speculation
that	I-Speculation
achieve	I-Speculation
simultaneously	I-Speculation
high	I-Speculation
likelihoods	I-Speculation
for	I-Speculation
non-independent	I-Speculation
features	I-Speculation
.	O

Conversely	O
,	O
some	O
likelihood	O
ratios	O
would	O
be	O
underestimated	O
for	O
protein	O
pairs	O
achieving	O
simultaneously	O
low	O
likelihoods	O
for	O
non-independent	O
features	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
some	O
of	O
the	O
features	O
considered	O
here	O
are	O
indeed	O
independent	O
43	O
.	O

Independence	O
of	O
all	O
modules	O
used	O
in	O
our	O
predictor	O
was	O
verified	O
by	O
calculating	O
Pearson	O
correlation	O
coefficients	O
for	O
all	O
pairs	O
of	O
modules	O
.	O

As	O
shown	O
in	O
Table	O
2	O
,	O
all	O
modules	O
considered	O
are	O
independent	O
,	O
since	O
the	O
highest	O
Pearson	O
correlation	O
coefficients	O
computed	O
are	O
well	O
below	O
any	O
value	O
considered	O
significant	O
.	O

Pairwise	O
Pearson	O
correlation	O
for	O
all	O
modules	O

Accuracy	O
of	O
the	O
predictors	O

All	O
combinations	O
of	O
modules	O
were	O
examined	O
to	O
determine	O
which	O
of	O
the	O
resulting	O
predictors	O
achieved	O
the	O
highest	O
prediction	O
accuracy	O
.	O

In	O
order	O
to	O
analyze	O
the	O
predictions	O
,	O
five-fold	O
cross	O
validation	O
experiments	O
were	O
performed	O
and	O
the	O
area	O
under	O
partial	O
ROC	O
(	O
receiver	O
operator	O
characteristic	O
)	O
curves	O
(	O
partial	O
AUCs	O
)	O
measured	O
.	O

ROC50	O
and	O
ROC100	O
curves	O
were	O
selected	O
as	O
they	O
consider	O
a	O
large	O
enough	O
number	O
of	O
positives	O
to	O
include	O
all	O
protein	O
pairs	O
predicted	O
to	O
have	O
a	O
posterior	O
odds	O
ratio	O
above	O
1.0	O
by	O
all	O
the	O
predictors	O
investigated	O
.	O

Protein	O
pairs	O
predicted	O
to	O
have	O
a	O
posterior	O
odds	O
ratio	O
below	O
1.0	O
have	O
an	O
estimated	O
true	O
positive	O
rate	O
below	O
50	O
%	O
and	O
thus	O
are	O
more	O
likely	O
not	O
to	O
interact	O
than	O
to	O
interact	O
.	O

These	O
protein	O
pairs	O
are	O
therefore	O
not	B-Negation
of	I-Negation
interest	I-Negation
in	I-Negation
this	I-Negation
context	I-Negation
.	O

The	O
area	O
under	O
all	O
ROCn	O
curves	O
considered	O
is	O
relatively	O
low	O
because	O
of	O
the	O
high	O
proportion	O
of	O
negatives	O
with	O
respect	O
to	O
positives	O
in	O
the	O
training	O
and	O
test	O
sets	O
(	O
100:1	O
)	O
.	O

Table	O
3	O
summarizes	O
the	O
characteristics	O
of	O
19	O
different	O
predictors	O
and	O
shows	O
accuracy	O
measures	O
.	O

Individual	O
modules	O
do	O
not	B-Negation
achieve	I-Negation
high	I-Negation
scores	I-Negation
for	I-Negation
the	I-Negation
areas	I-Negation
under	I-Negation
the	I-Negation
ROC50	I-Negation
and	I-Negation
ROC100	I-Negation
.	O

In	O
fact	O
,	O
all	O
ROC50	O
AUC	O
values	O
achieved	O
by	O
individual	O
modules	O
are	O
below	O
0.025	O
and	O
the	O
Expression	O
and	O
Disorder	O
modules	O
do	O
not	B-Negation
predict	I-Negation
any	I-Negation
protein	I-Negation
pairs	I-Negation
(	I-Negation
positive	I-Negation
or	I-Negation
negative	I-Negation
)	I-Negation
above	I-Negation
a	I-Negation
posterior	I-Negation
odds	I-Negation
ratio	I-Negation
of	I-Negation
1	I-Negation
,	O
which	O
is	O
expected	O
as	O
the	O
highest	O
likelihood	O
ratios	O
they	O
achieve	O
are	O
lower	O
than	O
400	O
(	O
see	O
Figure	O
1A	O
)	O
.	O

As	O
more	O
Group	O
A	O
modules	O
are	O
considered	O
within	O
the	O
same	O
predictor	O
,	O
the	O
ROCn	O
AUC	O
scores	O
increase	O
significantly	O
,	O
as	O
would	O
be	O
expected	O
since	O
these	O
features	O
are	O
independent	O
(	O
as	O
shown	O
in	O
Table	O
2	O
)	O
and	O
thus	O
contribute	O
different	O
information	O
to	O
the	O
prediction	O
.	O

For	O
example	O
,	O
the	O
predictor	O
that	O
considers	O
both	O
the	O
Expression	O
and	O
Combined	O
modules	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.033	O
compared	O
to	O
0.003	O
and	O
0.022	O
respectively	O
for	O
the	O
individual	O
modules	O
.	O

However	O
,	O
the	O
Disorder	O
module	O
does	O
not	O
contribute	O
significantly	O
to	O
the	O
prediction	O
as	O
predictors	O
that	O
consider	O
it	O
do	O
not	B-Negation
,	I-Negation
in	I-Negation
general	I-Negation
,	I-Negation
do	I-Negation
better	I-Negation
than	I-Negation
their	I-Negation
counterparts	I-Negation
that	I-Negation
do	I-Negation
not	I-Negation
use	I-Negation
it	I-Negation
.	O

For	O
example	O
,	O
both	O
the	O
Expression-Orthology	O
predictor	O
and	O
the	O
Expression-Orthology-Disorder	O
predictor	O
achieve	O
a	O
ROC50	O
AUC	O
of	O
0.024	O
.	O

The	O
Disorder	O
module	O
offers	O
the	O
advantage	O
of	O
increasing	O
the	O
coverage	O
of	O
the	O
prediction	O
as	O
a	O
disorder	O
score	O
is	O
calculated	O
for	O
all	O
protein	O
pairs	O
.	O

However	O
,	O
this	O
appears	O
to	O
add	O
more	O
noise	O
to	O
the	O
prediction	O
without	O
increasing	O
the	O
accuracy	O
.	O

Prediction	O
accuracy	O
of	O
different	O
combinations	O
of	O
modules	O

As	O
the	O
scores	O
of	O
the	O
predictors	O
increase	O
,	O
so	O
do	O
the	O
number	O
of	O
interactions	O
predicted	O
above	O
different	O
posterior	O
odds	O
ratio	O
thresholds	O
(	O
see	O
lower	O
portion	O
of	O
Table	O
3	O
)	O
.	O

For	O
example	O
,	O
the	O
Expression-Orthology	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.024	O
and	O
predicts	O
5670	O
interactions	O
at	O
a	O
posterior	O
odds	O
ratio	O
greater	O
than	O
1	O
whereas	O
the	O
Expression-Orthology-Combined	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.044	O
and	O
predicts	O
over	O
15000	O
interactions	O
at	O
a	O
posterior	O
odds	O
ratio	O
above	O
1	O
.	O

The	O
best	O
combination	O
of	O
Group	O
A	O
modules	O
is	O
the	O
predictor	O
consisting	O
of	O
the	O
Expression	O
,	O
Orthology	O
and	O
Combined	O
modules	O
.	O

The	O
Transitive	O
module	O
,	O
which	O
can	O
only	O
be	O
used	O
in	O
combination	O
with	O
other	O
modules	O
,	O
increases	O
substantially	O
the	O
scores	O
and	O
number	O
of	O
interactions	O
predicted	O
.	O

The	O
right-hand	O
portion	O
of	O
Table	O
3	O
shows	O
the	O
accuracy	O
measures	O
for	O
the	O
highest	O
scoring	O
subset	O
of	O
predictors	O
that	O
consider	O
the	O
Transitive	O
module	O
.	O

The	O
Transitive	O
module	O
enhances	O
the	O
prediction	O
by	O
identifying	O
among	O
protein	O
pairs	O
with	O
a	O
relatively	O
high	O
preliminary	O
score	O
those	O
that	O
are	O
most	O
likely	O
to	O
interact	O
,	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
network	O
around	O
them	O
.	O

For	O
example	O
,	O
the	O
ROC50	O
AUC	O
rises	O
from	O
0.044	O
to	O
0.075	O
when	O
the	O
Transitive	O
module	O
is	O
added	O
to	O
the	O
Expression-Orthology-Combined	O
predictor	O
,	O
and	O
the	O
number	O
of	O
predictions	O
above	O
a	O
posterior	O
odds	O
ratio	O
of	O
1	O
doubles	O
from	O
15330	O
to	O
34780	O
.	O

Once	O
again	O
,	O
the	O
Disorder	O
module	O
does	O
not	B-Negation
contribute	I-Negation
positively	I-Negation
to	I-Negation
the	I-Negation
prediction	I-Negation
.	O

Its	O
inclusion	O
does	O
not	B-Negation
increase	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
measures	I-Negation
of	I-Negation
accuracy	I-Negation
considered	I-Negation
.	O

The	O
predictor	O
that	O
considers	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
is	O
the	O
one	O
that	O
achieves	O
the	O
highest	O
accuracy	O
overall	O
.	O

It	O
is	O
this	O
predictor	O
that	O
is	O
further	O
analyzed	O
in	O
the	O
next	O
sections	O
.	O

Comparison	O
to	O
predictions	O
generated	O
using	O
alternative	O
training	O
sets	O

In	O
this	O
work	O
training	O
sets	O
were	O
used	O
that	O
comprised	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
,	O
with	O
the	O
negatives	O
randomly	O
selected	O
and	O
filtered	O
to	O
remove	O
any	O
known	O
or	O
suspected	O
positives	O
(	O
see	O
Methods	O
)	O
.	O

Other	O
groups	O
have	O
used	O
negative	O
:	O
positive	O
ratios	O
ranging	O
from	O
1	O
to	O
more	O
than	O
600	O
(	O
see	O
for	O
example	O
374752	O
)	O
.	O

In	O
addition	O
,	O
several	O
groups	O
use	O
localization-derived	O
negatives	O
(	O
i.e.	O
protein	O
pairs	O
that	B-Negation
are	I-Negation
not	I-Negation
annotated	I-Negation
as	I-Negation
being	I-Negation
localized	I-Negation
to	I-Negation
the	I-Negation
same	I-Negation
cellular	I-Negation
compartment	I-Negation
)	O
rather	B-Negation
than	I-Negation
randomly	I-Negation
chosen	I-Negation
negatives	I-Negation
(	O
see	O
for	O
example	O
374346	O
)	O
.	O

These	O
issues	O
have	O
been	O
investigated	O
previously	O
53	O
.	O

Since	O
the	O
choice	O
of	O
negative	O
training	O
data	O
may	O
influence	O
the	O
method	O
,	O
the	O
choice	O
of	O
different	O
training	O
sets	O
in	O
the	O
context	O
of	O
the	O
probabilistic	O
predictor	O
presented	O
here	O
was	O
investigated	O
to	O
determine	O
which	O
type	O
of	O
training	O
set	O
offers	O
the	O
highest	O
accuracy	O
.	O

Table	O
4	O
compares	O
the	O
accuracy	O
of	O
predictors	O
trained	O
with	O
negative	O
:	O
positive	O
ratios	O
of	O
1:100	O
and	O
1:1	O
and	O
tested	O
by	O
five-fold	O
cross	O
validation	O
.	O

Ratios	B-Negation
greater	I-Negation
than	I-Negation
100	I-Negation
were	I-Negation
not	I-Negation
considered	I-Negation
because	O
they	O
are	O
computationally	O
infeasible	O
given	O
the	O
size	O
of	O
our	O
datasets	O
and	O
the	O
architecture	O
of	O
the	O
predictor	O
.	O

To	O
perform	O
such	O
a	O
comparison	O
,	O
the	O
EOCT	O
predictor	O
(	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
was	O
trained	O
on	O
datasets	O
consisting	O
of	O
either	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
or	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
and	O
then	O
tested	O
on	O
both	O
types	O
of	O
datasets	O
.	O

As	O
shown	O
in	O
Table	O
4	O
,	O
the	O
predictors	O
trained	O
on	O
datasets	O
containing	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
perform	O
significantly	O
better	O
than	O
those	O
trained	O
on	O
datasets	O
containing	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
.	O

For	O
example	O
,	O
the	O
1:1	O
pos	O
:	O
neg	O
trained	O
predictor	O
achieves	O
a	O
ROC50	O
AUC	O
of	O
0.0645	O
whereas	O
its	O
1:100	O
pos	O
:	O
neg	O
trained	O
counterpart	O
achieves	O
a	O
0.0747	O
ROC50	O
AUC	O
.	O

This	O
could	O
be	O
due	O
to	O
the	O
fact	O
that	O
the	O
number	O
of	O
non-interacting	O
protein	O
pairs	O
outweighs	O
greatly	O
the	O
number	O
of	O
interacting	O
protein	O
pairs	O
in	O
cells	O
.	O

When	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
are	O
used	O
in	O
training	O
,	O
the	B-Speculation
diversity	I-Speculation
that	I-Speculation
exists	I-Speculation
in	I-Speculation
the	I-Speculation
non-interacting	I-Speculation
protein	I-Speculation
pair	I-Speculation
space	I-Speculation
may	I-Speculation
not	B-Negation
be	I-Negation
captured	I-Negation
,	O
thus	O
resulting	O
in	O
misleading	O
likelihood	O
ratios	O
for	O
the	O
predictive	O
modules	O
.	O

It	O
should	O
be	O
noted	O
that	O
predictors	O
tested	O
on	O
datasets	O
consisting	O
of	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
achieve	O
much	O
higher	O
accuracy	O
measures	O
than	O
those	O
tested	O
on	O
datasets	O
containing	O
100	O
times	O
more	O
negatives	O
than	O
positives	O
.	O

This	O
is	O
because	O
the	O
number	O
of	O
positives	O
scoring	O
higher	O
than	O
the	O
highest	O
scoring	O
n	O
negatives	O
,	O
for	O
a	O
given	O
value	O
of	O
n	O
and	O
a	O
given	O
predictor	O
,	O
will	O
be	O
greater	O
if	O
there	O
are	O
equal	O
numbers	O
of	O
positives	O
and	O
negatives	O
in	O
the	O
test	O
set	O
than	O
if	O
there	O
are	O
more	O
negatives	O
than	O
positives	O
.	O

Influence	O
of	O
the	O
negative	O
:	O
positive	O
training	O
set	O
ratio	O
on	O
the	O
prediction	O
accuracy	O

The	O
ROCn	O
AUCs	O
are	O
an	O
average	O
of	O
five	O
separate	O
experiments	O
(	O
each	O
of	O
which	O
is	O
itself	O
a	O
five-fold	O
cross	O
validation	O
experiment	O
)	O
.	O

Their	O
standard	O
deviation	O
is	O
shown	O
in	O
parenthesis	O
.	O

The	O
effect	O
of	O
localization-derived	O
negatives	O
rather	B-Negation
than	I-Negation
randomly	I-Negation
chosen	I-Negation
negatives	I-Negation
was	O
also	O
investigated	O
to	O
see	O
if	B-Speculation
it	I-Speculation
would	I-Speculation
increase	I-Speculation
the	I-Speculation
prediction	I-Speculation
accuracy	I-Speculation
.	O

A	O
criticism	O
of	O
randomly	O
chosen	O
negatives	O
is	O
that	O
they	O
will	O
contain	O
some	O
true	O
interactors	O
.	O

However	O
,	O
the	O
set	O
of	O
interacting	O
pairs	O
in	O
the	O
full	O
protein	O
pair	O
space	O
is	O
small	O
and	O
thus	O
the	O
contamination	O
rate	O
of	O
randomly	O
chosen	O
negative	O
datasets	O
will	O
in	O
fact	O
be	O
very	O
low	O
.	O

Contamination	O
is	O
probably	O
below	O
1	O
%	O
,	O
which	O
is	O
likely	O
lower	O
than	O
the	O
contamination	O
rate	O
of	O
the	O
positive	O
dataset	O
as	O
discussed	O
in	O
47	O
.	O

Localization-derived	O
negatives	O
,	O
on	O
the	O
other	O
hand	O
,	O
should	O
be	O
free	O
of	O
contamination	O
,	O
if	O
the	O
localization	O
annotations	O
are	O
complete	O
and	O
accurate	O
,	O
both	O
conditions	O
that	O
are	O
difficult	O
to	O
obtain	O
as	O
discussed	O
in	O
54	O
.	O

However	O
,	O
one	O
can	O
argue	O
that	O
localization-derived	O
negatives	O
might	B-Speculation
not	I-Speculation
be	I-Speculation
able	I-Speculation
to	I-Speculation
capture	I-Speculation
the	I-Speculation
full	I-Speculation
diversity	I-Speculation
of	I-Speculation
the	I-Speculation
non-interacting	I-Speculation
protein	I-Speculation
space	I-Speculation
since	O
many	O
proteins	O
in	O
the	O
same	O
cellular	O
compartment	O
do	O
not	B-Negation
interact	I-Negation
.	O

In	O
addition	O
,	O
proteins	O
specific	O
to	O
a	O
cellular	O
compartment	O
may	O
have	O
different	O
characteristics	O
to	O
proteins	O
in	O
other	O
compartments	O
.	O

Such	O
predictors	O
may	B-Speculation
not	I-Speculation
generalize	I-Speculation
well	I-Speculation
when	O
predicting	O
on	O
cell-wide	O
protein	O
pairs	O
which	O
consist	O
not	O
only	O
of	O
non-colocalized	O
non-interacting	O
pairs	O
but	O
also	O
numerous	O
protein	O
pairs	O
that	O
do	O
not	B-Negation
interact	I-Negation
but	O
are	O
present	O
in	O
the	O
same	O
cellular	O
compartment	O
.	O

These	O
issues	O
have	O
been	O
discussed	O
previously	O
52	O
.	O

In	O
order	O
to	O
see	O
if	O
different	O
types	O
of	O
negatives	O
could	O
influence	O
the	O
accuracy	O
of	O
the	O
predictors	O
developed	O
here	O
we	O
generated	O
negative	O
training/test	O
sets	O
as	O
in	O
46	O
by	O
identifying	O
all	O
pairs	O
of	O
human	O
proteins	O
for	O
which	O
one	O
protein	O
is	O
annotated	O
as	O
being	O
nuclear	O
and	O
the	O
other	O
is	O
annotated	O
as	O
being	O
localized	O
to	O
the	O
plasma	O
membrane	O
in	O
the	O
HPRD	O
database	O
15	O
.	O

The	O
Combined	O
module	O
for	O
these	O
predictors	O
only	O
considers	O
domains	O
and	O
PTMs	O
but	O
not	B-Negation
subcellular	I-Negation
localization	I-Negation
as	O
this	O
would	B-Speculation
result	I-Speculation
in	I-Speculation
using	I-Speculation
this	I-Speculation
feature	I-Speculation
both	I-Speculation
in	I-Speculation
the	I-Speculation
selection	I-Speculation
of	I-Speculation
the	I-Speculation
training	I-Speculation
set	I-Speculation
and	I-Speculation
as	I-Speculation
a	I-Speculation
feature	I-Speculation
predictive	I-Speculation
of	I-Speculation
interaction	I-Speculation
.	O

The	O
localization-derived	O
negative	O
trained	O
predictor	O
tested	O
on	O
sets	O
containing	O
localization-derived	O
negatives	O
achieves	O
a	O
lower	O
accuracy	O
than	O
that	O
of	O
the	O
random	O
negative	O
trained	O
predictor	O
tested	O
on	O
a	O
test	O
set	O
containing	O
randomly-generated	O
negatives	O
(	O
0.0686	O
+/-	O
0.0010	O
vs	O
0.0747	O
+/-	O
0.0022	O
)	O
.	O

This	O
is	O
most	O
likely	O
due	O
to	O
the	O
fact	O
that	O
the	O
localization-derived	O
negative	O
trained	O
predictor	O
can	O
not	O
take	O
full	O
advantage	O
of	O
the	O
Transitive	O
module	O
,	O
since	O
the	O
network	O
resulting	O
from	O
the	O
predictions	O
of	O
the	O
Group	O
A	O
modules	O
likely	O
does	O
not	O
sample	O
the	O
whole	O
protein	O
pair	O
space	O
well	O
.	O

Our	O
predictor	O
trained	O
with	O
randomly	O
generated	O
negatives	O
and	O
a	O
negative	O
:	O
positive	O
ratio	O
of	O
100	O
performs	O
the	O
best	O
out	O
of	O
all	O
the	O
combinations	O
of	O
training	O
sets	O
investigated	O
.	O

It	O
is	O
this	O
predictor	O
that	O
is	O
further	O
analyzed	O
in	O
subsequent	O
sections	O
.	O

Contribution	O
of	O
the	O
modules	O

The	O
relative	O
contribution	O
of	O
the	O
modules	O
to	O
the	O
prediction	O
of	O
interaction	O
was	O
investigated	O
in	O
order	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
predictive	O
power	O
and	O
areas	O
of	O
highest	O
usefulness	O
of	O
the	O
different	O
modules	O
.	O

To	O
do	O
this	O
,	O
all	O
protein	O
pairs	O
were	O
considered	O
that	O
achieve	O
an	O
estimated	O
posterior	O
odds	O
ratio	O
>	O
1	O
when	O
the	O
EOCT	O
predictor	O
was	O
trained	O
on	O
the	O
full	O
datasets	O
without	B-Negation
cross-validation	I-Negation
.	O

This	O
set	O
consists	O
of	O
37606	O
distinct	O
predicted	O
interactions	O
and	O
is	O
referred	O
to	O
as	O
the	O
LR400	O
dataset	O
(	O
all	O
these	O
interactions	O
are	O
listed	O
and	O
ranked	O
in	O
Additional	O
File	O
3	O
)	O
.	O

These	O
protein	O
pairs	O
represent	O
the	O
most	O
probable	O
interactors	O
with	O
respect	O
to	O
the	O
features	O
considered	O
,	O
among	O
all	O
protein	O
pairs	O
examined	O
by	O
the	O
predictor	O
.	O

To	O
investigate	O
the	O
individual	O
contribution	O
of	O
each	O
module	O
,	O
we	O
looked	O
at	O
the	O
number	O
of	O
interactions	O
predicted	O
out	O
of	O
all	O
LR400	O
pairs	O
as	O
a	O
function	O
of	O
the	O
minimum	O
likelihood	O
ratio	O
of	O
each	O
module	O
.	O

As	O
shown	O
in	O
Figure	O
4A	O
,	O
all	O
modules	O
contribute	O
positively	O
(	O
i.e.	O
contribute	O
a	O
likelihood	O
ratio	O
greater	O
than	O
1.0	O
)	O
to	O
the	O
prediction	O
of	O
a	O
certain	O
proportion	O
of	O
the	O
interactions	O
in	O
the	O
LR400	O
dataset	O
.	O

The	O
Transitive	O
module	O
and	O
to	O
an	O
even	O
greater	O
extent	O
,	O
the	O
Combined	O
module	O
contribute	O
positively	O
to	O
the	O
prediction	O
of	O
a	O
very	O
high	O
proportion	O
of	O
the	O
LR400	O
protein	O
pairs	O
(	O
73	O
%	O
and	O
91	O
%	O
of	O
the	O
LR400	O
interactions	O
have	O
likelihood	O
ratios	O
greater	O
than	O
1	O
for	O
the	O
Transitive	O
and	O
Combined	O
modules	O
respectively	O
)	O
.	O

The	O
Transitive	O
module	O
provides	O
a	O
likelihood	O
ratio	O
of	O
91	O
for	O
the	O
prediction	O
of	O
over	O
70	O
%	O
of	O
the	O
LR400	O
interactions	O
.	O

The	O
Combined	O
module	O
provides	O
positive	O
evidence	O
for	O
the	O
highest	O
number	O
of	O
interactions	O
of	O
the	O
LR400	O
dataset	O
.	O

However	O
,	O
the	O
value	O
of	O
the	O
likelihood	O
ratio	O
it	O
contributes	O
is	O
below	O
20	O
for	O
over	O
50	O
%	O
of	O
protein	O
pairs	O
in	O
the	O
LR400	O
dataset	O
(	O
which	O
means	O
that	O
for	O
these	O
protein	O
pairs	O
,	O
the	O
Combined	O
module	O
must	O
be	O
used	O
in	O
combination	O
with	O
other	O
modules	O
to	O
achieve	O
a	O
total	O
likelihood	O
ratio	O
above	O
400	O
)	O
.	O

The	O
Combined	O
module	O
does	O
,	O
however	O
,	O
achieve	O
likelihood	O
ratios	O
high	O
enough	O
to	O
predict	O
over	O
two	O
thousand	O
interactions	O
of	O
the	O
LR400	O
dataset	O
on	O
its	O
own	O
,	O
less	O
than	O
15	O
%	O
of	O
which	O
are	O
present	O
in	O
the	O
training	O
set	O
.	O

The	O
Orthology	O
module	O
contributes	O
to	O
the	O
prediction	O
of	O
only	O
8474	O
protein	O
pairs	O
in	O
the	O
LR400	O
dataset	O
(	O
23	O
%	O
)	O
.	O

However	O
,	O
a	O
large	O
majority	O
(	O
>	O
75	O
%	O
)	O
of	O
these	O
8474	O
predicted	O
interactions	O
achieve	O
likelihood	O
ratios	O
above	O
200	O
from	O
this	O
module	O
.	O

In	O
fact	O
,	O
almost	O
40	O
%	O
of	O
these	O
LR400	O
interactions	O
achieve	O
a	O
likelihood	O
ratio	O
above	O
400	O
from	O
the	O
Orthology	O
module	O
.	O

This	O
indicates	O
that	O
most	O
interactions	O
predicted	O
by	O
the	O
Orthology	O
module	O
(	O
alone	O
or	O
in	O
combination	O
with	O
other	O
modules	O
)	O
are	O
based	O
on	O
the	O
highest	O
scoring	O
Orthology	O
bins	O
(	O
see	O
Figure	O
1A	O
)	O
which	O
are	O
the	O
most	O
conserved	O
yeast	O
interactions	O
(	O
whose	O
bin	O
achieves	O
a	O
likelihood	O
ratio	O
of	O
237	O
)	O
,	O
as	O
well	O
as	O
human	O
paralogous	O
interactions	O
and	O
interactions	O
found	O
in	O
more	O
than	O
one	O
model	O
organism	O
(	O
both	O
of	O
which	O
achieve	O
a	O
likelihood	O
well	O
above	O
400	O
)	O
.	O

Few	O
interactions	O
in	O
the	O
LR400	O
dataset	O
are	O
predicted	O
on	O
the	O
basis	O
of	O
having	O
interacting	O
orthologs	O
in	O
worm	O
or	O
fly	O
alone	O
.	O

The	O
Expression	O
module	O
provides	O
positive	O
evidence	O
for	O
a	O
little	O
less	O
than	O
half	O
the	O
predictions	O
in	O
the	O
LR400	O
dataset	O
.	O

However	O
,	O
as	O
previously	O
noted	O
,	O
the	O
highest	O
likelihood	O
provided	O
by	O
this	O
module	O
is	O
33	O
and	O
thus	O
the	O
Expression	O
module	O
can	B-Negation
not	I-Negation
predict	I-Negation
interaction	I-Negation
on	I-Negation
its	I-Negation
own	I-Negation
.	O

Contribution	O
of	O
the	O
modules	O

Contribution	O
of	O
the	O
modules	O
.	O

To	O
examine	O
the	O
contribution	O
of	O
the	O
different	O
modules	O
,	O
we	O
plotted	O
the	O
number	O
of	O
interactions	O
predicted	O
among	O
all	O
LR400	O
interactions	O
(	O
all	O
interactions	O
predicted	O
using	O
the	O
full	O
predictor	O
that	O
obtain	O
a	O
likelihood	O
ratio	O
of	O
interaction	O
greater	O
than	O
400	O
)	O
as	O
a	O
function	O
of	O
the	O
minimum	O
likelihood	O
ratio	O
of	O
individual	O
modules	O
(	O
in	O
panel	O
A	O
)	O
or	O
of	O
combinations	O
of	O
modules	O
(	O
in	O
panel	O
B	O
)	O
.	O

In	O
the	O
case	O
of	O
combinations	O
of	O
modules	O
(	O
panel	O
B	O
)	O
,	O
the	O
minimum	O
likelihood	O
ratio	O
is	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
of	O
the	O
modules	O
considered	O
.	O

Thus	O
for	O
example	O
,	O
the	O
product	O
of	O
the	O
expression	O
and	O
orthology	O
ratios	O
is	O
greater	O
than	O
1	O
for	O
almost	O
20000	O
LR400	O
interactions	O
and	O
greater	O
than	O
10	O
for	O
approximately	O
10000	O
LR400	O
interactions	O
(	O
dark	O
blue	O
diamonds	O
in	O
panel	O
B	O
)	O
.	O

E	O
:	O
Expression	O
module	O
,	O
O	O
:	O
Orthology	O
module	O
,	O
C	O
:	O
Combined	O
module	O
,	O
T	O
:	O
Transitive	O
module	O
.	O

Figure	O
4B	O
summarizes	O
the	O
contributions	O
of	O
different	O
combinations	O
of	O
modules	O
.	O

The	O
Combined	O
and	O
Transitive	O
modules	O
contribute	O
the	O
most	O
to	O
the	O
prediction	O
of	O
interactions	O
.	O

They	O
alone	O
can	O
predict	O
approximately	O
27000	O
of	O
the	O
37606	O
interactions	O
of	O
the	O
LR400	O
dataset	O
.	O

When	O
they	O
are	O
both	O
present	O
,	O
regardless	O
of	O
which	O
other	O
modules	O
are	O
also	O
present	O
,	O
they	O
predict	O
over	O
70	O
%	O
of	O
the	O
LR400	O
interactions	O
.	O

When	O
either	B-Negation
of	I-Negation
these	I-Negation
two	I-Negation
modules	I-Negation
is	I-Negation
absent	I-Negation
,	O
fewer	O
than	O
12500	O
interactions	O
are	O
predicted	O
.	O

In	O
contrast	O
,	O
the	O
two	O
remaining	O
modules	O
(	O
Expression	O
and	O
Orthology	O
)	O
can	O
predict	O
approximately	O
5000	O
interactions	O
together	O
.	O

This	O
is	O
interesting	O
as	O
many	O
of	O
the	O
publicly	O
available	O
predicted	O
interaction	O
datasets	O
mentioned	O
in	O
the	O
Background	O
section	O
use	O
mainly	O
orthology	O
transfer	O
from	O
model	O
organisms	O
to	O
identify	O
interactions	O
.	O

As	O
the	O
majority	O
of	O
the	O
LR400	O
interactions	O
are	O
derived	O
from	O
the	O
Combined	O
and	O
Transitive	O
modules	O
,	O
it	O
is	O
possible	O
that	O
the	O
method	O
is	O
identifying	O
a	O
large	O
subset	O
of	O
interactions	O
that	O
are	O
not	O
common	O
to	O
previous	O
human	O
protein	O
interaction	O
datasets	O
.	O

This	O
is	O
discussed	O
further	O
in	O
the	O
next	O
section	O
.	O

The	O
curve	O
representing	O
the	O
full	O
predictor	O
(	O
consisting	O
of	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
is	O
also	O
represented	O
in	O
Figure	O
4B	O
(	O
the	O
dark	O
green	O
squares	O
)	O
.	O

By	O
definition	O
,	O
it	O
predicts	O
all	O
proteins	O
in	O
the	O
LR400	O
dataset	O
at	O
likelihood	O
ratios	O
equal	O
to	O
or	O
above	O
400	O
(	O
this	O
is	O
how	O
the	O
LR400	O
dataset	O
was	O
generated	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
curve	O
illustrates	O
the	O
number	O
of	O
interactions	O
that	O
are	O
predicted	O
above	O
likelihood	O
ratios	O
of	O
400	O
and	O
more	O
.	O

As	O
shown	O
in	O
Figure	O
4B	O
,	O
the	O
full	O
predictor	O
predicts	O
approximately	O
20000	O
interactions	O
at	O
a	O
total	O
likelihood	O
ratio	O
of	O
1600	O
(	O
which	O
is	O
equivalent	O
to	O
an	O
estimated	O
posterior	O
odds	O
ratio	O
of	O
4	O
)	O
.	O

At	O
a	O
likelihood	O
ratio	O
of	O
4000	O
,	O
approximately	O
11000	O
interactions	O
are	O
predicted	O
and	O
at	O
a	O
likelihood	O
ratio	O
of	O
8000	O
,	O
approximately	O
6500	O
interactions	O
are	O
predicted	O
.	O

We	O
verified	O
that	O
the	O
increasing	O
estimated	O
posterior	O
odds	O
ratios	O
translated	O
into	O
better	O
predictive	O
value	O
.	O

Figure	O
5	O
shows	O
the	O
true	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
posterior	O
odds	O
ratios	O
as	O
measured	O
by	O
five-fold	O
cross	O
validation	O
.	O

As	O
the	O
posterior	O
odds	O
ratio	O
increases	O
,	O
the	O
false	O
positive	O
rate	O
decreases	O
and	O
the	O
relative	O
proportion	O
of	O
true	O
positives	O
increases	O
when	O
compared	O
to	O
the	O
proportion	O
of	O
false	O
positives	O
.	O

Accordingly	O
,	O
subsets	O
of	O
very	O
high	O
quality	O
predictions	O
may	O
be	O
generated	O
by	O
choosing	O
a	O
suitably	O
high	O
posterior	O
odds	O
ratio	O
threshold	O
.	O

True	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
estimated	O
posterior	O
odds	O
ratios	O

True	O
positive	O
rate	O
versus	O
false	O
positive	O
rate	O
for	O
different	O
estimated	O
posterior	O
odds	O
ratios	O
.	O

The	O
true	O
positive	O
rate	O
(	O
TPR	O
)	O
versus	O
false	O
positive	O
rate	O
(	O
FPR	O
)	O
is	O
plotted	O
for	O
different	O
values	O
of	O
the	O
posterior	O
odds	O
ratio	O
estimated	O
for	O
the	O
dataset	O
by	O
five-fold	O
cross-validation	O
.	O

As	O
the	O
posterior	O
odds	O
ratio	O
increases	O
,	O
the	O
false	O
positive	O
rate	O
decreases	O
and	O
the	O
ratio	O
of	O
the	O
true	O
positive	O
rate	O
divided	O
by	O
the	O
false	O
positive	O
ratio	O
increases	O
.	O

Thus	O
,	O
higher	O
quality	O
datasets	O
can	O
be	O
generated	O
by	O
requiring	O
higher	O
posterior	O
odds	O
ratios	O
.	O

The	O
TPR	O
is	O
calculated	O
as	O
the	O
number	O
of	O
true	O
positives	O
predicted	O
divided	O
by	O
the	O
total	O
number	O
of	O
positives	O
in	O
the	O
test	O
set	O
.	O

The	O
FPR	O
is	O
calculated	O
as	O
the	O
number	O
of	O
false	O
positives	O
predicted	O
divided	O
by	O
the	O
total	O
number	O
of	O
negatives	O
in	O
the	O
test	O
set	O
.	O

Comparison	O
to	O
other	O
interaction	O
datasets	O

The	O
false	O
positive	O
rate	O
(	O
FPR	O
)	O
of	O
our	O
predictor	O
was	O
estimated	O
by	O
the	O
method	O
of	O
D'Haeseleer	O
and	O
Church	O
1855	O
and	O
used	O
to	O
compare	O
it	O
to	O
other	O
prediction	O
datasets	O
.	O

The	O
Ramani	O
interaction	O
dataset	O
that	O
was	O
automatically	O
extracted	O
from	O
the	O
literature	O
16	O
as	O
well	O
as	O
all	O
new	O
interactions	O
present	O
in	O
the	O
October	O
2006	O
version	O
of	O
the	O
manually	O
curated	O
HPRD	O
database	O
15	O
(	O
but	O
none	B-Negation
of	I-Negation
the	I-Negation
interactions	I-Negation
also	I-Negation
present	I-Negation
in	I-Negation
earlier	I-Negation
versions	I-Negation
of	I-Negation
the	I-Negation
HPRD	I-Negation
which	I-Negation
were	I-Negation
used	I-Negation
to	I-Negation
train	I-Negation
our	I-Negation
predictor	I-Negation
)	I-Negation
were	I-Negation
taken	I-Negation
as	I-Negation
reference	I-Negation
datasets	I-Negation
.	O

The	O
D'Haeseleer	O
and	O
Church	O
method	O
compares	O
two	O
experimental	O
datasets	O
to	O
a	O
reference	O
set	O
and	O
assumes	O
that	O
all	O
intersections	O
between	O
the	O
three	O
datasets	O
contain	O
true	O
positives	O
.	O

It	O
is	O
thus	O
possible	O
to	O
estimate	O
the	O
number	O
of	O
true	O
positives	O
predicted	O
by	O
an	O
experimental	O
dataset	O
by	O
comparing	O
the	O
number	O
of	O
interactions	O
present	O
in	O
the	O
different	O
intersections	O
of	O
the	O
two	O
experimental	O
methods	O
and	O
the	O
reference	O
dataset	O
(	O
for	O
details	O
,	O
see	O
1855	O
)	O
.	O

Here	O
,	O
we	O
compare	O
three	O
human	O
interaction	O
prediction	O
datasets	O
:	O
the	O
Rhodes	O
probabilistic	O
dataset	O
46	O
,	O
the	O
Lehner	O
orthology-derived	O
dataset	O
36	O
and	O
the	O
most	O
accurate	O
of	O
our	O
predictors	O
(	O
the	O
LR400	O
subset	O
of	O
the	O
predictor	O
considering	O
the	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Transitive	O
modules	O
)	O
.	O

We	O
estimated	O
false	O
positive	O
rates	O
for	O
each	O
of	O
the	O
datasets	O
by	O
comparing	O
them	O
two	O
by	O
two	O
to	O
one	O
of	O
the	O
reference	O
datasets	O
,	O
thus	O
generating	O
4	O
to	O
6	O
different	O
estimates	O
of	O
false	O
positive	O
rates	O
for	O
each	O
computational	O
dataset	O
,	O
as	O
shown	O
in	O
Figure	O
6A	O
(	B-Negation
the	I-Negation
two	I-Negation
Lehner	I-Negation
datasets	I-Negation
were	I-Negation
not	I-Negation
compared	I-Negation
to	I-Negation
each	I-Negation
other	I-Negation
,	O
which	O
is	O
why	O
they	O
have	O
fewer	O
FPR	O
estimates	O
)	O
.	O

The	O
rates	O
estimated	O
for	O
the	O
Rhodes	O
and	O
Lehner	O
datasets	O
are	O
similar	O
to	O
previous	O
estimates	O
18	O
.	O

The	O
estimated	O
false	O
positive	O
rates	O
for	O
the	O
LR400	O
,	O
Rhodes	O
and	O
core	O
Lehner	O
are	O
quite	O
similar	O
(	O
an	O
average	O
of	O
76	O
%	O
FPR	O
for	O
both	O
the	O
LR400	O
and	O
core	O
Lehner	O
datasets	O
and	O
78	O
%	O
for	O
the	O
Rhodes	O
dataset	O
)	O
and	O
well	O
below	O
the	O
overall	O
average	O
false-positive	O
rate	O
of	O
90	O
%	O
estimated	O
for	O
most	O
available	O
human	O
high-throughput	O
experimental	O
and	O
prediction	O
interaction	O
datasets	O
18	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
Rhodes	O
,	O
Lehner	O
and	O
Ramani	O
datasets	O
annotate	O
interactions	O
as	O
a	O
relationship	O
between	O
human	O
genes	O
and	O
not	B-Negation
their	I-Negation
protein	I-Negation
products	I-Negation
directly	I-Negation
.	O

However	O
,	O
not	O
all	O
proteins	O
encoded	O
by	O
a	O
single	O
gene	O
will	O
necessarily	O
interact	O
with	O
all	O
protein	O
products	O
encoded	O
by	O
a	O
second	O
gene	O
,	O
even	O
if	O
one	O
such	O
protein	O
pair	O
does	O
.	O

This	O
is	O
why	O
we	O
describe	O
interactions	O
as	O
a	O
relationship	O
between	O
two	O
proteins	O
,	O
allowing	O
for	O
a	O
more	O
precise	O
description	O
of	O
the	O
interaction	O
.	O

To	O
compare	O
our	O
predictions	O
to	O
these	O
datasets	O
,	O
we	O
consider	O
that	O
two	O
genes	O
interact	O
if	O
at	O
least	O
one	O
of	O
their	O
respective	O
protein	O
products	O
interact	O
.	O

Comparison	O
to	O
other	O
interaction	O
datasets	O

Comparison	O
to	O
other	O
interaction	O
datasets	O
.	O

The	O
false	O
positive	O
rates	O
shown	O
in	O
panel	O
A	O
were	O
estimated	O
for	O
the	O
LR400	O
dataset	O
as	O
well	O
as	O
the	O
Rhodes	O
[	O
46	O
]	O
and	O
Lehner	O
[	O
36	O
]	O
predictions	O
using	O
the	O
method	O
described	O
in	O
[	O
18	O
,	O
55	O
]	O
by	O
comparing	O
them	O
two-by-two	O
to	O
a	O
reference	O
dataset	O
.	O

The	O
number	O
and	O
overlap	O
of	O
distinct	O
proteins	O
(	O
shown	O
in	O
B	O
)	O
and	O
distinct	O
interactions	O
(	O
shown	O
in	O
C	O
)	O
are	O
shown	O
for	O
the	O
LR400	O
dataset	O
,	O
the	O
Rhodes	O
prediction	O
dataset	O
and	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
.	O

In	O
Figure	O
6B	O
and	O
6C	O
,	O
we	O
compare	O
the	O
number	O
of	O
distinct	O
proteins	O
and	O
distinct	O
interactions	O
of	O
the	O
LR400	O
dataset	O
to	O
those	O
of	O
the	O
Rhodes	O
prediction	O
dataset	O
and	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
which	O
was	O
used	O
to	O
train	O
our	O
predictor	O
.	O

The	O
Rhodes	O
dataset	O
was	O
trained	O
using	O
an	O
earlier	O
version	O
of	O
the	O
HPRD	O
.	O

As	O
can	O
be	O
seen	O
in	O
Figure	O
6	O
,	O
the	O
intersections	O
between	O
the	O
three	O
datasets	O
considered	O
are	O
low	O
,	O
especially	O
when	O
comparing	O
the	O
interactions	O
.	O

Both	O
the	O
Rhodes	O
dataset	O
and	O
our	O
LR400	O
dataset	O
predict	O
interactions	O
involving	O
many	O
proteins	O
that	O
are	O
not	B-Negation
even	I-Negation
present	I-Negation
in	I-Negation
their	I-Negation
positive	I-Negation
training	I-Negation
set	I-Negation
(	I-Negation
the	I-Negation
HPRD	I-Negation
)	I-Negation
.	O

Many	O
of	O
the	O
predictions	O
in	O
these	O
two	O
datasets	O
concern	O
protein	O
pairs	O
and	O
proteins	O
that	O
are	O
not	B-Negation
present	I-Negation
in	I-Negation
other	I-Negation
datasets	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
they	I-Speculation
cover	I-Speculation
different	I-Speculation
regions	I-Speculation
of	I-Speculation
the	I-Speculation
human	I-Speculation
interaction	I-Speculation
space	I-Speculation
.	O

As	O
suggested	O
in	O
18	O
,	O
by	O
making	O
more	O
such	O
datasets	O
available	O
,	O
it	O
will	O
be	O
possible	O
to	O
increase	O
our	O
coverage	O
of	O
the	O
interaction	O
space	O
and	O
determine	O
the	O
most	O
likely	O
human	O
interactions	O
.	O

Another	O
human	O
interaction	O
dataset	O
has	O
recently	O
become	O
available	O
:	O
the	O
IntNetDB	O
56	O
.	O

It	O
was	O
generated	O
by	O
integrating	O
seven	O
different	O
features	O
(	O
four	O
of	O
which	O
involve	O
transferring	O
interactions	O
or	O
characteristics	O
of	O
protein	O
pairs	O
from	O
model	O
organisms	O
to	O
human	O
)	O
in	O
a	O
probabilistic	O
framework	O
.	O

Interactions	O
were	O
predicted	O
above	O
a	O
TP/FP	O
ratio	O
(	O
number	O
of	O
true	O
positives	O
divided	O
by	O
the	O
number	O
of	O
false	O
positives	O
in	O
the	O
test	O
set	O
)	O
of	O
1	O
.	O

Using	O
such	O
a	O
threshold	O
,	O
the	O
authors	O
claim	O
to	O
predict	O
180	O
010	O
human	O
interactions	O
.	O

We	O
do	O
not	B-Negation
compare	I-Negation
our	I-Negation
predictions	I-Negation
to	I-Negation
this	I-Negation
dataset	I-Negation
because	O
such	O
a	O
threshold	O
of	O
TP/FP	O
>	O
1	O
does	O
not	B-Negation
correspond	I-Negation
to	I-Negation
a	I-Negation
posterior	I-Negation
odds	I-Negation
threshold	I-Negation
>	I-Negation
1	I-Negation
.	O

Depending	O
on	O
the	O
positive-to-negative	O
ratio	O
used	O
in	O
the	O
datasets	O
,	O
TP/FP	O
>	O
1	O
might	O
correspond	O
to	O
an	O
average	O
posterior	O
odds	O
ratio	O
of	O
1	O
.	O

In	O
contrast	O
,	O
the	O
average	O
posterior	O
odds	O
ratio	O
of	O
our	O
LR400	O
dataset	O
is	O
above	O
700	O
.	O

In	O
comparison	O
,	O
by	O
using	O
a	O
threshold	O
of	O
TP/FP	O
>	O
1	O
in	O
our	O
test	O
set	O
,	O
we	O
predict	O
over	O
1	O
000	O
000	O
human	O
interactions	O
.	O

We	O
do	O
not	B-Negation
believe	I-Negation
that	I-Negation
the	I-Negation
quality	I-Negation
of	I-Negation
this	I-Negation
large	I-Negation
number	I-Negation
of	I-Negation
predictions	I-Negation
is	I-Negation
high	I-Negation
enough	I-Negation
to	I-Negation
warrant	I-Negation
their	I-Negation
publication	I-Negation
since	O
the	O
great	O
majority	O
of	O
these	O
protein	O
pairs	O
achieve	O
a	O
posterior	O
odds	O
ratio	O
below	O
1	O
.	O

Independent	O
validation	O

Although	O
the	O
overlap	O
between	O
the	O
LR400	O
dataset	O
and	O
the	O
HPRD-derived	O
positive	O
training	O
set	O
is	O
below	O
10	O
%	O
as	O
shown	O
in	O
Figure	O
6C	O
,	O
the	O
proportion	O
of	O
interactions	O
common	O
to	O
these	O
two	O
sets	O
is	O
not	B-Negation
equally	I-Negation
distributed	I-Negation
for	I-Negation
all	I-Negation
posterior	I-Negation
odds	I-Negation
ratios	I-Negation
of	I-Negation
interaction	I-Negation
values	I-Negation
.	O

As	O
shown	O
in	O
Figure	O
7	O
,	O
while	O
less	O
than	O
3	O
%	O
of	O
the	O
protein	O
pairs	O
predicted	O
to	O
interact	O
at	O
posterior	O
odds	O
ratios	O
between	O
1	O
and	O
2	O
overlap	O
with	O
the	O
HPRD	O
dataset	O
used	O
for	O
training	O
,	O
this	O
value	O
increases	O
to	O
over	O
50	O
%	O
for	O
the	O
highest	O
scoring	O
subsets	O
of	O
the	O
LR400	O
dataset	O
.	O

These	O
highest	O
scoring	O
predictions	O
receive	O
high	O
likelihood	O
ratios	O
of	O
interaction	O
from	O
all	O
four	O
predictive	O
modules	O
and	O
represent	O
the	O
strongest	O
examples	O
of	O
interaction	O
as	O
evaluated	O
by	O
our	O
predictor	O
.	O

Such	O
examples	O
include	O
interactions	O
that	O
allow	O
the	O
formation	O
of	O
well-known	O
protein	O
complexes	O
such	O
as	O
the	O
proteasome	O
,	O
the	O
MCM	O
protein	O
complex	O
involved	O
in	O
the	O
initiation	O
of	O
genome	O
replication	O
,	O
replication	O
factor	O
C	O
,	O
the	O
TBP/TAF	O
complex	O
(	O
TBP-associated	O
factors	O
)	O
and	O
the	O
EIF	O
complex	O
(	O
eukaryotic	O
translation	O
initiation	O
factors	O
)	O
.	O

The	O
highest	O
scoring	O
predictions	O
in	O
the	O
LR400	O
dataset	O
thus	O
mainly	O
represent	O
interactions	O
present	O
in	O
the	O
HPRD	O
dataset	O
as	O
well	O
as	O
interactions	O
between	O
proteins	O
that	O
have	O
strong	O
sequence	O
identity	O
to	O
these	O
known	O
interacting	O
pairs	O
.	O

However	O
,	O
as	O
the	O
posterior	O
odds	O
ratio	O
decreases	O
,	O
the	O
overlap	O
between	O
the	O
predictions	O
and	O
the	O
HPRD-derived	O
training	O
set	O
decreases	O
.	O

Some	O
subsets	O
of	O
quite	O
high	O
posterior	O
odds	O
have	O
much	O
smaller	O
overlaps	O
with	O
the	O
training	O
set	O
.	O

For	O
example	O
,	O
interactions	O
predicted	O
at	O
posterior	O
odds	O
ratios	O
between	O
128	O
and	O
2048	O
have	O
a	O
20	O
to	O
30	O
%	O
overlap	O
with	O
the	O
training	O
set	O
as	O
shown	O
in	O
Figure	O
7	O
.	O

Although	O
many	B-Negation
of	I-Negation
these	I-Negation
novel	I-Negation
predictions	I-Negation
have	I-Negation
not	I-Negation
been	I-Negation
previously	I-Negation
investigated	I-Negation
in	I-Negation
the	I-Negation
literature	I-Negation
,	O
there	O
exists	O
experimental	O
evidence	O
supporting	O
a	O
subset	O
of	O
these	O
predictions	O
which	O
is	O
not	B-Negation
present	I-Negation
in	I-Negation
the	I-Negation
June	I-Negation
2006	I-Negation
version	I-Negation
of	I-Negation
the	I-Negation
HPRD	I-Negation
used	I-Negation
to	I-Negation
train	I-Negation
our	I-Negation
predictor	I-Negation
,	O
thus	O
providing	O
independent	O
validation	O
of	O
our	O
method	O
.	O

Five	O
such	O
validated	O
predictions	O
are	O
reported	O
here	O
:	O

Overlap	O
of	O
different	O
subsets	O
of	O
the	O
LR400	O
dataset	O
with	O
the	O
HPRD-derived	O
training	O
set	O

Overlap	O
of	O
different	O
subsets	O
of	O
the	O
LR400	O
dataset	O
with	O
the	O
HPRD-derived	O
training	O
set	O
.	O

The	O
number	O
of	O
interactions	O
predicted	O
and	O
the	O
proportion	O
of	O
overlap	O
with	O
the	O
training	O
set	O
(	O
which	O
was	O
derived	O
from	O
the	O
HPRD	O
)	O
were	O
calculated	O
for	O
subsets	O
of	O
the	O
LR400	O
dataset	O
of	O
different	O
posterior	O
odds	O
ratios	O
.	O

-TCPTP	O
was	O
predicted	O
to	O
interact	O
with	O
STAT6	O
at	O
a	O
posterior	O
odds	O
ratio	O
of	O
4300	O
.	O

It	O
has	O
been	O
recently	O
reported	O
that	O
TCPTP	O
,	O
the	O
only	O
protein	O
tyrosine	O
phosphatase	O
known	O
to	O
localize	O
to	O
the	O
nucleus	O
,	O
dephosphorylates	O
STAT6	O
in	O
this	O
cellular	O
compartment	O
,	O
which	O
may	O
in	O
turn	O
lead	O
to	O
the	O
suppression	O
of	O
Interleukine-4	O
(	O
IL-4	O
)	O
induced	O
signaling	O
57	O
.	O

-N-WASP	O
and	O
ARP3	O
achieve	O
a	O
predicted	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
of	O
2700	O
.	O

A	O
recent	O
report	O
suggested	O
that	O
the	O
IQGAP1	O
protein	O
can	O
activate	O
N-WASP	O
thus	O
changing	O
its	O
conformation	O
and	O
allowing	O
it	O
to	O
bind	O
the	O
ARP2/3	O
complex	O
,	O
which	O
in	O
turn	O
directs	O
the	O
generation	O
of	O
branched	O
actin	O
filaments	O
required	O
for	O
the	O
extension	O
of	O
a	O
lamellipodium	O
58	O
.	O

-The	O
VAMP3-VTI1A	O
interaction	O
was	O
predicted	O
with	O
a	O
posterior	O
odds	O
ratio	O
of	O
1518	O
.	O

Both	O
these	O
proteins	O
are	O
believed	O
to	O
be	O
part	O
of	O
the	O
SNARE	O
(	O
soluble	O
N-ethylmaleimide-sensitive	O
factor	O
attachment	O
protein	O
receptor	O
)	O
family	O
of	O
proteins	O
which	O
are	O
involved	O
in	O
membrane	O
fusion	O
events	O
.	O

VTI1A	O
is	O
a	O
trans-Golgi-network-localized	O
putative	O
t-SNARE	O
59	O
and	O
VAMP3	O
is	O
an	O
early/recycling	O
endosomal	O
v-SNARE	O
60	O
.	O

These	O
two	O
proteins	O
were	O
recently	O
shown	O
to	O
interact	O
,	O
leading	O
to	O
their	O
functional	O
implication	O
in	O
the	O
post-Golgi	O
retrograde	O
transport	O
step	O
61	O
.	O

-CDK2	O
and	O
MCM4	O
were	O
predicted	O
to	O
interact	O
at	O
a	O
posterior	O
odds	O
ratio	O
of	O
62	O
.	O

CDK2	O
has	O
recently	O
been	O
shown	O
to	O
phosphorylate	O
MCM4	O
,	O
a	O
subunit	O
of	O
a	O
putative	O
replicative	O
helicase	O
essential	O
for	O
DNA	O
replication	O
,	O
on	O
two	O
distinct	O
residues	O
,	O
leading	O
to	O
a	O
change	O
in	O
its	O
affinity	O
to	O
chromatin	O
and	O
its	O
enrichment	O
in	O
the	O
nucleolus	O
62	O
.	O

-Sam68	O
and	O
Smad2	O
achieve	O
a	O
predicted	O
posterior	O
odds	O
ratio	O
of	O
32	O
.	O

This	O
interaction	O
has	O
been	O
experimentally	O
demonstrated	O
by	O
large-scale	O
yeast-two-hybrid	O
analysis	O
of	O
the	O
Smad	O
signaling	O
system	O
63	O
.	O

Our	O
probabilistic	O
predictor	O
therefore	O
not	O
only	O
reproduces	O
and	O
completes	O
well-known	O
protein	O
complexes	O
but	O
also	O
identifies	O
novel	O
interactions	O
,	O
a	O
subset	O
of	O
which	O
have	O
been	O
independently	O
validated	O
.	O

Conclusion	O

The	O
current	O
human	O
protein	O
interaction	O
map	O
is	O
estimated	O
to	O
be	O
only	O
10	O
%	O
complete	O
18	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
prediction	O
of	O
human	O
protein-protein	O
interactions	O
in	O
an	O
effort	O
to	O
increase	O
the	O
coverage	O
of	O
the	O
human	O
interactome	O
while	O
simultaneously	O
providing	O
high	O
quality	O
predictions	O
.	O

By	O
considering	O
several	O
different	O
types	O
of	O
orthogonal	O
and	O
quite	O
distinct	O
features	O
including	O
expression	O
,	O
orthology	O
,	O
combined	O
protein	O
characteristics	O
and	O
local	O
network	O
topology	O
,	O
we	O
predicted	O
over	O
37000	O
human	O
protein	O
interactions	O
and	O
explored	O
a	O
subspace	O
of	O
the	O
human	O
interactome	O
that	B-Negation
has	I-Negation
not	I-Negation
been	I-Negation
investigated	I-Negation
by	I-Negation
previous	I-Negation
large	I-Negation
interaction	I-Negation
datasets	I-Negation
.	O

Our	O
investigation	O
led	O
us	O
to	O
compare	O
the	O
influence	O
of	O
different	O
training	O
sets	O
on	O
the	O
prediction	O
accuracy	O
.	O

The	O
use	O
of	O
randomly	O
generated	O
negative	O
training	O
examples	O
and	O
large	O
negative-to-positive	O
ratios	O
in	O
the	O
training	O
set	O
generated	O
the	O
most	O
accurate	O
predictors	O
in	O
the	O
context	O
of	O
our	O
model	O
.	O

A	O
comparison	O
to	O
other	O
large	O
human	O
interaction	O
datasets	O
revealed	O
the	O
average	O
false	O
positive	O
rate	O
of	O
our	O
dataset	O
to	O
be	O
76	O
%	O
,	O
which	O
is	O
much	O
lower	O
than	O
the	O
overall	O
average	O
for	O
most	O
large	O
scale	O
,	O
currently	O
available	O
,	O
human	O
interaction	O
datasets	O
(	O
experimental	O
and	O
computational	O
)	O
estimated	O
to	O
be	O
90	O
%	O
18	O
.	O

A	O
subset	O
of	O
our	O
novel	O
predictions	O
have	O
been	O
independently	O
validated	O
by	O
identifying	O
recent	O
reports	O
that	O
experimentally	O
investigated	O
and	O
confirmed	O
that	O
these	O
protein	O
pairs	O
do	O
interact	O
.	O

We	O
provide	O
all	O
our	O
predictions	O
ranked	O
according	O
to	O
the	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
in	O
Additional	O
File	O
3	O
.	O

It	O
is	O
thus	O
possible	O
to	O
restrict	O
the	O
dataset	O
to	O
the	O
highest	O
scoring	O
protein	O
pairs	O
(	O
and	O
only	O
choose	O
for	O
example	O
,	O
protein	O
pairs	O
that	O
have	O
an	O
estimated	O
true	O
positive	O
rate	O
of	O
interaction	O
above	O
90	O
%	O
)	O
.	O

By	O
making	O
this	O
human	O
interaction	O
prediction	O
dataset	O
publicly	O
available	O
,	O
it	O
is	O
our	O
hope	O
that	O
it	O
will	O
help	O
to	O
identify	O
the	O
most	O
high-confidence	O
interactions	O
,	O
leading	O
to	O
a	O
more	O
complete	O
and	O
accurate	O
human	O
interaction	O
map	O
.	O

Methods	O

Datasets	O

In	O
order	O
to	O
investigate	O
the	O
likelihood	O
of	O
interaction	O
of	O
human	O
proteins	O
,	O
62322	O
human	O
protein	O
sequences	O
were	O
downloaded	O
from	O
the	O
International	O
Protein	O
Index	O
(	O
IPI	O
)	O
database	O
(	O
version	O
3.16	O
)	O
64	O
.	O

Some	O
of	O
these	O
proteins	O
are	O
alternative	O
transcripts	O
of	O
the	O
same	O
gene	O
but	O
can	O
have	O
distinct	O
interaction	O
partners	O
.	O

Known	O
interactions	O
were	O
downloaded	O
from	O
the	O
Human	O
Protein	O
Reference	O
Database	O
(	O
HPRD	O
;	O
June	O
2006	O
version	O
)	O
15	O
.	O

Duplicate	B-Negation
interactions	I-Negation
and	I-Negation
self-interactions	I-Negation
were	I-Negation
not	I-Negation
considered	I-Negation
.	O

Additionally	O
,	O
some	B-Negation
proteins	I-Negation
were	I-Negation
not	I-Negation
recovered	I-Negation
in	I-Negation
the	I-Negation
conversion	I-Negation
between	I-Negation
different	I-Negation
identifiers	I-Negation
.	O

This	O
resulted	O
in	O
26896	O
distinct	O
human	O
protein	O
interactions	O
involving	O
7531	O
distinct	O
human	O
proteins	O
present	O
in	O
the	O
initial	O
IPI	O
dataset	O
.	O

The	O
26896	O
interactions	O
from	O
the	O
June	O
2006	O
version	O
of	O
the	O
HPRD	O
were	O
used	O
as	O
the	O
positive	O
dataset	O
in	O
the	O
training/testing	O
of	O
the	O
predictor	O
.	O

Two	O
different	O
sets	O
of	O
non-interacting	O
protein	O
pairs	O
were	O
investigated	O
:	O
the	O
main	O
analysis	O
employed	O
a	O
randomly-generated	O
negative	O
dataset	O
but	O
this	O
was	O
also	O
compared	O
to	O
a	O
localization-derived	O
negative	O
dataset	O
.	O

Both	O
non-interacting	O
protein	O
datasets	O
were	O
cleaned	O
by	O
removing	O
all	O
protein	O
pairs	O
that	O
came	O
from	O
the	O
positive	O
dataset	O
as	O
well	O
as	O
protein	O
pairs	O
that	O
were	O
annotated	O
as	O
interacting	O
in	O
other	O
databases	O
(	O
DIP	O
65	O
:	O
679	O
interactions	O
,	O
BIND	O
66	O
:	O
2650	O
interactions	O
)	O
,	O
or	O
predicted	O
to	O
interact	O
in	O
other	O
studies	O
(	O
OPHID	O
67	O
:	O
21815	O
interactions	O
)	O
.	O

Of	O
the	O
62322	O
human	O
proteins	O
from	O
the	O
initial	O
IPI	O
dataset	O
,	O
22889	O
were	O
characterized	O
by	O
at	O
least	O
one	O
of	O
the	O
features	O
that	O
we	O
considered	O
to	O
predict	O
interaction	O
(	O
see	O
the	O
Features	O
section	O
)	O
.	O

These	O
22889	O
human	O
proteins	O
are	O
encoded	O
by	O
16904	O
distinct	O
genes	O
and	O
are	O
referred	O
to	O
as	O
the	O
Informative	O
Protein	O
Set	O
.	O

The	O
randomly-generated	O
negative	O
dataset	O
used	O
for	O
the	O
training	O
and	O
testing	O
of	O
the	O
predictor	O
was	O
created	O
by	O
selecting	O
protein	O
pairs	O
at	O
random	O
from	O
the	O
Informative	O
Protein	O
Set	O
.	O

In	O
contrast	O
,	O
the	O
localization-derived	O
negative	O
dataset	O
was	O
created	O
by	O
selecting	O
protein	O
pairs	O
from	O
the	O
Informative	O
Protein	O
Set	O
for	O
which	O
the	O
HPRD	O
15	O
annotates	O
one	O
as	O
being	O
primarily	O
in	O
the	O
plasma	O
membrane	O
and	O
the	O
other	O
as	O
primarily	O
in	O
the	O
nucleus	O
.	O

Training	O
and	O
testing	O
was	O
performed	O
with	O
5-fold	O
cross-validation	O
.	O

In	O
addition	O
,	O
positive	O
to	O
negative	O
ratios	O
of	O
1:1	O
and	O
1:100	O
were	O
considered	O
.	O

The	O
predictions	O
were	O
compared	O
to	O
the	O
literature-mined	O
Ramani	O
dataset	O
16	O
,	O
the	O
orthology-derived	O
Lehner	O
prediction	O
dataset	O
36	O
and	O
the	O
probabilistic	O
Rhodes	O
prediction	O
dataset	O
46	O
.	O

All	O
three	O
datasets	O
identify	O
the	O
interactions	O
by	O
stating	O
the	O
names	O
and/or	O
gene	O
locus	O
IDs	O
of	O
the	O
genes	O
that	O
encode	O
the	O
interacting	O
proteins	O
.	O

In	O
contrast	O
,	O
we	O
work	O
directly	O
on	O
the	O
protein	O
sequences	O
and	O
so	O
related	O
the	O
gene	O
annotations	O
to	O
our	O
protein	O
identifiers	O
by	O
extracting	O
Entrez	O
Gene	O
IDs	O
corresponding	O
to	O
the	O
IPI	O
protein	O
entries	O
from	O
the	O
IPI	O
cross-reference	O
files	O
(	O
for	O
the	O
IPI	O
release	O
3.24	O
)	O
64	O
.	O

Ensembl	O
gene	O
identifiers	O
(	O
Ensembl	O
42	O
)	O
were	O
also	O
matched	O
to	O
Entrez	O
Locus	O
IDs	O
(	O
NCBI36	O
)	O
using	O
BioMart	O
68	O
.	O

Some	B-Negation
gene-gene	I-Negation
entries	I-Negation
were	I-Negation
not	I-Negation
recovered	I-Negation
in	I-Negation
the	I-Negation
conversion	I-Negation
between	I-Negation
different	I-Negation
identifiers	I-Negation
,	I-Negation
or	I-Negation
due	I-Negation
to	I-Negation
the	I-Negation
deletion	I-Negation
or	I-Negation
replacement	I-Negation
of	I-Negation
some	I-Negation
Entrez	I-Negation
Locus	I-Negation
IDs	I-Negation
.	O

Despite	O
this	O
,	O
37714	O
gene-gene	O
interactions	O
were	O
recovered	O
from	O
the	O
Rhodes	O
dataset	O
and	O
6132	O
interactions	O
from	O
the	O
Ramani	O
dataset	O
as	O
well	O
as	O
64306	O
and	O
10454	O
interactions	O
from	O
the	O
Lehner	O
full	O
and	O
core	O
datasets	O
respectively	O
.	O

Learning	O
method	O

Semi-nave	O
Bayes	O
classifiers	O
were	O
used	O
to	O
measure	O
the	O
likelihood	O
of	O
interaction	O
of	O
two	O
proteins	O
given	O
the	O
presence	O
of	O
the	O
features	O
considered	O
.	O

This	O
learning	O
method	O
was	O
chosen	O
because	O
it	O
allows	O
the	O
integration	O
of	O
highly	O
heterogeneous	O
data	O
in	O
a	O
model	O
that	O
is	O
easy	O
to	O
interpret	O
and	O
that	O
can	O
readily	O
accommodate	O
missing	O
data	O
.	O

The	O
transparency	O
of	O
the	O
method	O
allows	O
the	O
straightforward	O
determination	O
of	O
which	O
features	O
are	O
most	O
predictive	O
of	O
interaction	O
at	O
the	O
level	O
of	O
the	O
whole	O
proteome	O
as	O
well	O
as	O
for	O
individual	O
protein	O
pairs	O
.	O

The	O
prediction	O
of	O
protein	O
interaction	O
is	O
a	O
binary	O
problem	O
which	O
can	O
be	O
expressed	O
in	O
Bayesian	O
formalism	O
.	O

We	O
are	O
interested	O
in	O
determining	O
the	O
posterior	O
odds	O
ratio	O
of	O
interaction	O
of	O
two	O
proteins	O
,	O
given	O
the	O
presence	O
of	O
the	O
features	O
we	O
are	O
considering	O
.	O

This	O
posterior	O
odds	O
ratio	O
can	O
be	O
re-written	O
using	O
Bayes	O
rule	O
:	O
Opost	O
=	O
P	O
(	O
I|f1	O
,	O
...	O
,	O
fn	O
)	O
P	O
(	O
~I|f1	O
,	O
...	O
,	O
fn	O
)	O
=P	O
(	O
f1	O
,	O
...	O
,	O
fn|I	O
)	O
P	O
(	O
I	O
)	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn	O
)	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn|~I	O
)	O
P	O
(	O
~I	O
)	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn	O
)	O
=P	O
(	O
f1	O
,	O
...	O
,	O
fn|I	O
)	O
P	O
(	O
I	O
)	O
P	O
(	O
f	O
,	O
...	O
,	O
fn|~IP	O
(	O
~I	O
)	O
=P	O
(	O
I	O
)	O
P	O
(	O
~IP	O
(	O
f1	O
,	O
...	O
,	O
fn|I	O
)	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn|~I	O
)	O
=OpriorLR	O
(	O
1	O
,	O
...	O
,	O
fn	O
)	O
where	O
I	O
is	O
a	O
binary	O
variable	O
representing	O
interaction	O
,	O
~I	O
represents	O
non-interaction	O
,	O
f1	O
through	O
fn	O
are	O
the	O
features	O
we	O
are	O
considering	O
,	O
Oprior	O
is	O
the	O
prior	O
odds	O
ratio	O
and	O
LR	O
is	O
the	O
likelihood	O
ratio	O
.	O

If	O
the	O
features	O
considered	O
are	O
independent	O
,	O
the	O
likelihood	O
ratio	O
LR	O
can	O
be	O
calculated	O
as	O
the	O
product	O
of	O
the	O
individual	O
likelihood	O
ratios	O
with	O
respect	O
to	O
the	O
features	O
considered	O
separately	O
.	O

If	O
the	O
features	O
are	O
not	B-Negation
independent	I-Negation
,	O
all	O
possible	O
combinations	O
of	O
all	O
states	O
of	O
these	O
features	O
must	O
be	O
considered	O
,	O
which	O
can	B-Speculation
be	I-Speculation
computationally	I-Speculation
quite	I-Speculation
intensive	I-Speculation
.	O

In	O
the	O
independent	O
case	O
,	O
the	O
likelihood	O
ratio	O
can	O
be	O
calculated	O
as	O
:	O
LR	O
(	O
f1	O
,	O
...	O
,	O
fn	O
)	O
=	O
[	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn|I	O
)	O
P	O
(	O
f1	O
,	O
...	O
,	O
fn|~I	O
)	O
]	O
=i=1n	O
[	O
P	O
(	O
fi|I	O
)	O
P	O
(	O
fi~I	O
)	O
]	O

The	O
likelihood	O
ratios	O
for	O
the	O
different	O
features	O
considered	O
can	O
be	O
estimated	O
by	O
evaluating	O
the	O
ratio	O
of	O
the	O
proportion	O
of	O
interacting	O
and	O
non-interacting	O
proteins	O
for	O
which	O
a	O
particular	O
state	O
of	O
the	O
feature	O
is	O
true	O
in	O
the	O
training	O
set	O
(	O
i.e.	O
by	O
determining	O
to	O
which	O
bin	O
of	O
the	O
feature	O
the	O
protein	O
pair	O
belongs	O
,	O
for	O
every	O
protein	O
pair	O
in	O
the	O
positive	O
and	O
negative	O
training	O
sets	O
)	O
.	O

More	O
precisely	O
,	O
the	O
training	O
step	O
consisted	O
of	O
calculating	O
the	O
respective	O
proportions	O
of	O
positive	O
and	O
negative	O
examples	O
that	O
fall	O
into	O
each	O
bin	O
of	O
the	O
feature	O
(	O
s	O
)	O
considered	O
(	O
i.e.	O
that	O
have	O
a	O
particular	O
state	O
)	O
.	O

The	O
likelihood	O
ratio	O
of	O
interaction	O
for	O
a	O
given	O
state	O
is	O
simply	O
the	O
ratio	O
of	O
the	O
proportion	O
of	O
all	O
positives	O
that	O
have	O
that	O
state	O
divided	O
by	O
the	O
proportion	O
of	O
all	O
negatives	O
that	O
have	O
that	O
same	O
state	O
.	O

When	O
a	O
particular	O
state	O
of	O
a	O
feature	O
occurs	O
only	O
in	O
positive	O
examples	O
(	O
known	O
interacting	O
proteins	O
)	O
,	O
the	O
likelihoods	O
are	O
set	O
to	O
the	O
highest	O
non-infinite	O
value	O
of	O
any	O
state	O
for	O
that	O
feature	O
(	O
to	O
avoid	O
infinite	O
values	O
)	O
.	O

Additionally	O
,	O
when	O
no	B-Negation
data	I-Negation
are	I-Negation
available	I-Negation
for	I-Negation
a	I-Negation
specific	I-Negation
feature	I-Negation
(	I-Negation
for	I-Negation
a	I-Negation
given	I-Negation
pair	I-Negation
of	I-Negation
proteins	I-Negation
)	I-Negation
,	O
the	O
likelihood	O
of	O
the	O
feature	O
is	O
set	O
to	O
1.0	O
.	O

For	O
a	O
detailed	O
calculation	O
of	O
the	O
likelihoods	O
see	O
Additional	O
File	O
4	O
.	O

Prior	O
odds	O
ratio	O
estimate	O

The	O
prior	O
odds	O
ratio	O
(	O
Oprior	O
)	O
is	O
difficult	O
to	O
estimate	O
because	O
we	O
do	O
not	B-Negation
know	I-Negation
all	I-Negation
the	I-Negation
true	I-Negation
interactions	I-Negation
,	I-Negation
even	I-Negation
for	I-Negation
a	I-Negation
small	I-Negation
subset	I-Negation
of	I-Negation
proteins	I-Negation
.	O

The	O
prior	O
odds	O
ratio	O
of	O
interaction	O
for	O
yeast	O
was	O
estimated	O
by	O
combining	O
all	O
protein-protein	O
interactions	O
(	O
but	O
only	O
those	O
related	O
to	O
direct	O
physical	O
interactions	O
,	O
and	O
no	B-Negation
entries	I-Negation
derived	I-Negation
by	I-Negation
synthetic	I-Negation
lethal-type	I-Negation
experiments	I-Negation
)	I-Negation
from	I-Negation
the	I-Negation
BIND	I-Negation
,	I-Negation
DIP	I-Negation
and	I-Negation
GRID	I-Negation
databases	I-Negation
656669	O
.	O

This	O
subset	O
of	O
interactions	O
contains	O
36466	O
distinct	O
interactions	O
involving	O
5202	O
distinct	O
proteins	O
,	O
thus	O
resulting	O
in	O
a	O
prior	O
odds	O
ratio	O
of	O
1/370	O
.	O

This	O
is	O
most	O
likely	O
a	O
conservative	O
estimate	O
since	O
a	O
certain	O
proportion	O
of	O
interactions	O
remain	O
unknown	O
and	O
so	O
when	O
more	O
data	O
become	O
available	O
,	O
the	O
prior	O
odds	O
ratio	O
will	O
increase	O
.	O

For	O
human	O
proteins	O
,	O
12191	O
distinct	O
interactions	O
were	O
recovered	O
,	O
involving	O
5164	O
human	O
proteins	O
from	O
the	O
September	O
2005	O
version	O
of	O
the	O
HPRD	O
15	O
and	O
26896	O
distinct	O
interactions	O
involving	O
7531	O
human	O
proteins	O
from	O
the	O
June	O
2006	O
version	O
,	O
leading	O
respectively	O
to	O
prior	O
odds	O
estimates	O
of	O
1/1093	O
and	O
1/1053	O
.	O

However	O
,	O
taking	O
the	O
subset	O
of	O
5164	O
proteins	O
from	O
the	O
September	O
2005	O
version	O
that	O
are	O
seen	O
in	O
the	O
June	O
2006	O
version	O
(	O
20842	O
distinct	O
interactions	O
)	O
,	O
gave	O
a	O
prior	O
odds	O
of	O
interaction	O
estimate	O
of	O
1/639	O
.	O

Thus	O
,	O
between	O
the	O
two	O
releases	O
of	O
the	O
HPRD	O
,	O
there	O
was	O
a	O
large	O
increase	O
in	O
the	O
number	O
of	O
interactions	O
for	O
this	O
subset	O
of	O
proteins	O
and	O
this	O
is	O
likely	O
to	O
continue	O
for	O
at	O
least	O
the	O
next	O
few	O
releases	O
.	O

Accordingly	O
,	O
it	O
is	O
reasonable	O
to	O
conclude	O
that	O
there	O
are	O
not	B-Negation
enough	I-Negation
known	I-Negation
human	I-Negation
interactions	I-Negation
to	I-Negation
calculate	I-Negation
a	I-Negation
realistic	I-Negation
and	I-Negation
stable	I-Negation
estimate	I-Negation
of	I-Negation
the	I-Negation
prior	I-Negation
odds	I-Negation
ratio	I-Negation
of	I-Negation
interactions	I-Negation
for	I-Negation
human	I-Negation
.	O

As	O
a	O
consequence	O
,	O
a	O
prior	O
odds	O
ratio	O
of	O
1/400	O
was	O
used	O
for	O
all	O
work	O
in	O
the	O
paper	O
,	O
which	O
is	O
similar	O
to	O
the	O
estimate	O
for	O
yeast	O
and	O
is	O
likely	O
still	O
an	O
underestimate	O
of	O
the	O
true	O
value	O
.	O

Features	O

Seven	O
distinct	O
features	O
combined	O
into	O
five	O
modules	O
were	O
investigated	O
as	O
summarized	O
in	O
Table	O
1	O
and	O
described	O
below	O
.	O

1	O
.	O

Expression	O
module	O

Expression	O
data	O
were	O
downloaded	O
from	O
the	O
Gene	O
Expression	O
Omnibus	O
70	O
.	O

The	O
GDS596	O
dataset	O
was	O
used	O
which	O
examines	O
gene	O
expression	O
profiles	O
from	O
79	O
physiologically	O
normal	O
tissues	O
obtained	O
from	O
various	O
sources	O
71	O
.	O

Expression	O
data	O
were	O
recovered	O
for	O
10642	O
distinct	O
transcripts	O
in	O
158	O
different	O
arrays	O
(	O
2	O
arrays	O
per	O
tissue	O
)	O
.	O

Pearson	O
correlations	O
were	O
calculated	O
for	O
all	O
56620761	O
transcript	O
pairs	O
and	O
correlation	O
values	O
were	O
grouped	O
into	O
20	O
bins	O
of	O
increasing	O
co-expression	O
.	O

2	O
.	O

Orthology	O
module	O

Orthology	O
maps	O
between	O
human	O
and	O
yeast	O
,	O
worm	O
and	O
fly	O
were	O
downloaded	O
from	O
the	O
InParanoid	O
database	O
72	O
.	O

Interaction	O
datasets	O
for	O
model	O
organisms	O
were	O
downloaded	O
from	O
the	O
BIND	O
66	O
,	O
DIP	O
65	O
and	O
GRID	O
69	O
databases	O
.	O

Orthology	O
interaction	O
data	O
were	O
classified	O
into	O
13	O
bins	O
.	O

High	O
,	O
medium	O
and	O
low	O
confidence	O
bins	O
were	O
defined	O
for	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
in	O
either	O
yeast	O
,	O
fly	O
or	O
worm	O
(	O
for	O
a	O
total	O
of	O
9	O
bins	O
)	O
.	O

The	O
high	O
confidence	O
bins	O
were	O
populated	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
that	O
both	O
achieve	O
an	O
InParanoid	O
score	O
of	O
1	O
(	O
i.e.	O
both	O
proteins	O
involved	O
in	O
an	O
interaction	O
in	O
another	O
organism	O
are	O
respectively	O
the	O
best	O
orthology	O
match	O
for	O
the	O
two	O
human	O
proteins	O
under	O
consideration	O
)	O
.	O

The	O
medium	O
confidence	O
bins	O
were	O
populated	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
but	O
only	O
one	O
of	O
the	O
interacting	O
orthologs	O
has	O
an	O
InParanoid	O
score	O
of	O
1	O
.	O

The	O
low	O
confidence	O
bins	O
were	O
filled	O
by	O
human	O
protein	O
pairs	O
that	O
have	O
interacting	O
orthologs	O
according	O
to	O
InParanoid	O
but	O
neither	B-Negation
achieves	I-Negation
a	I-Negation
score	I-Negation
of	I-Negation
1	I-Negation
(	O
i.e.	O
neither	O
is	O
the	O
best	O
match	O
for	O
the	O
two	O
human	O
proteins	O
under	O
consideration	O
)	O
.	O

The	O
orthology	O
module	O
has	O
four	O
additional	O
bins	O
:	O
two	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
interacting	O
paralogs	O
in	O
human	O
(	O
a	O
medium	O
and	O
a	O
low	O
confidence	O
bin	O
which	O
use	O
the	O
same	O
definition	O
as	O
above	O
for	O
the	O
model	O
organisms	O
)	O
,	O
one	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
interacting	O
homologs	O
in	O
more	O
than	O
one	O
organism	O
(	O
these	O
can	O
be	O
orthologs	O
in	O
yeast	O
,	O
worm	O
or	O
fly	O
,	O
or	O
paralogs	O
in	O
human	O
)	O
and	O
one	O
bin	O
for	O
human	O
pairs	O
that	O
have	O
only	O
non-interacting	O
orthologs	O
.	O

3	O
.	O

Combined	O
module	O

This	O
module	O
incorporates	O
three	O
distinct	O
features	O
in	O
a	O
non-nave	O
Bayesian	O
framework	O
:	O
subcellular	O
localization	O
,	O
domain	O
co-occurrence	O
and	O
post-translational	O
modification	O
co-occurrence	O
.	O

Subcellular	O
localization	O

PSLT	O
(	O
Protein	O
Subcellular	O
Localization	O
Tool	O
)	O
subcellular	O
localization	O
predictions	O
54	O
were	O
used	O
to	O
classify	O
protein	O
pairs	O
in	O
one	O
of	O
four	O
groups	O
:	O
:	O
pairs	O
of	O
proteins	O
predicted	O
to	O
be	O
in	O
the	O
same	O
compartment	O
,	O
pairs	O
of	O
proteins	O
predicted	O
to	O
be	O
in	O
neighboring	O
compartments	O
(	O
cytosol-nucleus	O
,	O
endoplasmic	O
reticulum-Golgi	O
,	O
Golgi-cytosol	O
,	O
cytosol-plasma	O
membrane	O
,	O
and	O
plasma	O
membrane-secreted	O
)	O
,	O
pairs	O
of	O
proteins	O
predicted	O
in	O
different	O
non-neighboring	O
compartments	O
and	O
pairs	O
of	O
proteins	O
for	O
which	O
there	O
were	O
no	B-Negation
localization	I-Negation
predictions	I-Negation
.	O

Neighboring	O
compartments	O
were	O
chosen	O
as	O
compartment	O
pairs	O
sharing	O
a	O
high	O
proportion	O
of	O
proteins	O
,	O
as	O
investigated	O
previously	O
54	O
.	O

Co-occurrence	O
of	O
domains	O

The	O
chi-square	O
test	O
was	O
used	O
as	O
a	O
measure	O
of	O
the	O
likelihood	O
of	O
co-occurrence	O
of	O
specific	O
InterPro	O
domains	O
and	O
motifs	O
73	O
in	O
protein	O
pairs	O
.	O

Chi-square	O
scores	O
were	O
calculated	O
for	O
all	O
pairs	O
of	O
domains/motifs	O
that	O
occurred	O
in	O
the	O
training	O
data	O
and	O
were	O
then	O
grouped	O
into	O
5	O
bins	O
of	O
increasing	O
value	O
.	O

Additionally	O
,	O
Pfam	O
74	O
domain	O
pairs	O
known	O
to	O
interact	O
from	O
three-dimensional	O
structures	O
75	O
were	O
included	O
in	O
the	O
highest	O
Chi-square	O
score	O
bin	O
.	O

When	O
protein	O
pairs	O
contained	O
more	O
than	O
one	O
domain	O
pair	O
,	O
the	O
domain	O
pair	O
assigned	O
to	O
the	O
highest	O
Chi-square	O
score	O
bin	O
was	O
used	O
to	O
assign	O
a	O
likelihood	O
of	O
interaction	O
.	O

Post-translational	O
modification	O
(	O
PTM	O
)	O
pair	O
co-occurrence	O

Likelihoods	O
were	O
assessed	O
using	O
a	O
PTM	O
pair	O
enrichment	O
score	O
calculated	O
as	O
the	O
probability	O
of	O
co-occurrence	O
of	O
two	O
specific	O
PTMs	O
in	O
all	O
pairs	O
of	O
interacting	O
protein	O
pairs	O
divided	O
by	O
the	O
probability	O
of	O
occurrence	O
of	O
both	O
of	O
these	O
PTMs	O
separately	O
:	O
PTM_score=P	O
(	O
PTM	O
[	O
i	O
]	O
,	O
PTM	O
[	O
j	O
]	O
|I	O
)	O
P	O
(	O
PTM	O
[	O
i	O
]	O
|I	O
)	O
P	O
(	O
PTM	O
[	O
j	O
]	O
|I	O
)	O
where	O
PTM	O
[	O
i	O
]	O
and	O
PTM	O
[	O
j	O
]	O
are	O
distinct	O
PTMs	O
and	O
I	O
is	O
the	O
set	O
of	O
all	O
interacting	O
proteins	O
that	O
were	O
used	O
to	O
train	O
the	O
predictor	O
.	O

The	O
annotations	O
of	O
PTMs	O
in	O
human	O
proteins	O
were	O
downloaded	O
from	O
UniProt	O
76	O
and	O
HPRD	O
15	O
.	O

PTM	O
instances	O
described	O
as	O
``	O
predicted	O
``	O
,	O
``	O
probable	O
``	O
or	O
``	O
possible	O
``	O
were	O
excluded	O
,	O
leaving	O
3439	O
distinct	O
proteins	O
with	O
PTM	O
annotations	O
in	O
the	O
training	O
set	O
.	O

The	O
PTM	O
pair	O
enrichment	O
scores	O
were	O
grouped	O
into	O
4	O
bins	O
of	O
increasing	O
value	O
.	O

The	O
localization	O
,	O
co-occurrence	O
of	O
domains	O
,	O
and	O
PTMs	O
were	O
considered	O
simultaneously	O
to	O
measure	O
their	O
predictive	O
power	O
in	O
assessing	O
the	O
likelihood	O
of	O
protein	O
interaction	O
.	O

To	O
do	O
this	O
,	O
all	O
possible	O
combinations	O
of	O
the	O
4	O
localization	O
bins	O
,	O
5	O
chi-square	O
domain-co-occurrence	O
bins	O
and	O
4	O
PTM_score	O
bins	O
were	O
investigated	O
and	O
are	O
referred	O
to	O
as	O
the	O
combined	O
module	O
.	O

4	O
.	O

Disorder	O
module	O

It	O
has	O
been	O
suggested	O
that	O
unstructured	O
regions	O
of	O
proteins	O
are	O
often	O
involved	O
in	O
binding	O
interactions	O
,	O
particularly	O
in	O
the	O
case	O
of	O
transient	O
interactions	O
77	O
.	O

Protein	O
intrinsic	O
disorder	O
was	O
predicted	O
for	O
all	O
proteins	O
considered	O
by	O
using	O
the	O
VSL2B	O
predictor	O
78	O
.	O

The	O
disorder	O
score	O
for	O
protein	O
pairs	O
was	O
then	O
calculated	O
as	O
the	O
sum	O
of	O
percent	O
disorder	O
for	O
each	O
protein	O
of	O
the	O
pair	O
.	O

Disorder	O
scores	O
were	O
grouped	O
into	O
6	O
bins	O
of	O
increasing	O
value	O
.	O

The	O
Expression	O
,	O
Orthology	O
,	O
Combined	O
and	O
Disorder	O
modules	O
are	O
referred	O
collectively	O
as	O
the	O
Group	O
A	O
modules	O
.	O

Likelihood	O
ratios	O
for	O
each	O
of	O
the	O
Group	O
A	O
modules	O
are	O
illustrated	O
in	O
Figure	O
1A	O
(	O
see	O
Additional	O
File	O
4	O
for	O
complete	O
likelihood	O
ratios	O
for	O
every	O
possible	O
state	O
of	O
these	O
modules	O
and	O
for	O
detailed	O
calculations	O
of	O
these	O
likelihood	O
ratios	O
)	O
.	O

5	O
.	O

Transitive	O
module	O

The	O
transitive	O
module	O
works	O
on	O
the	O
premise	O
that	O
a	O
pair	O
of	O
proteins	O
is	O
more	O
likely	O
to	O
interact	O
if	O
it	O
shares	O
interacting	O
partners	O
.	O

It	O
does	O
this	O
by	O
considering	O
the	O
local	O
topology	O
of	O
the	O
network	O
predicted	O
by	O
the	O
integration	O
of	O
the	O
Group	O
A	O
modules	O
as	O
depicted	O
in	O
Figure	O
2	O
.	O

Thus	O
,	O
the	O
transitive	O
module	O
takes	O
as	O
input	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
of	O
all	O
other	O
modules	O
considered	O
by	O
the	O
predictor	O
(	O
as	O
illustrated	O
in	O
Figure	O
1B	O
)	O
.	O

For	O
each	O
pair	O
of	O
proteins	O
in	O
the	O
training	O
set	O
,	O
the	O
product	O
of	O
the	O
likelihood	O
ratios	O
from	O
all	O
other	O
modules	O
(	O
referred	O
to	O
as	O
the	O
preliminary	O
score	O
(	O
PS	O
)	O
in	O
Figure	O
1	O
)	O
was	O
calculated	O
for	O
all	O
protein	O
pairs	O
neighboring	O
the	O
pair	O
(	O
i.e.	O
all	O
protein	O
pairs	O
which	O
involve	O
one	O
protein	O
from	O
the	O
initial	O
protein	O
pair	O
under	O
study	O
and	O
for	O
which	O
it	O
is	O
possible	O
to	O
calculate	O
such	O
a	O
score	O
)	O
.	O

All	O
preliminary	O
scores	O
above	O
10	O
were	O
kept	O
.	O

This	O
parameter	O
was	O
determined	O
empirically	O
.	O

A	O
neighborhood	O
topology	O
score	O
T	O
was	O
then	O
calculated	O
as	O
follows	O
:	O

Transitive	O
module	O
hypothesis	O

Transitive	O
module	O
hypothesis	O
.	O

The	O
Transitive	O
module	O
investigates	O
whether	O
two	O
proteins	O
(	O
such	O
as	O
i	O
and	O
j	O
)	O
that	O
share	O
many	O
common	O
interactors	O
and	O
have	O
few	O
additional	O
interactors	O
that	O
are	O
not	O
common	O
to	O
both	O
proteins	O
are	O
more	O
likely	O
to	O
interact	O
than	O
two	O
proteins	O
(	O
such	O
as	O
i	O
'	O
and	O
j	O
'	O
)	O
that	O
share	O
few	O
common	O
interactors	O
.	O

T=eEcse1+|Ei\Ec|+|Ej\Ec|	O
where	O
Ec	O
is	O
the	O
set	O
of	O
edges	O
that	O
connect	O
proteins	O
i	O
and	O
j	O
to	O
their	O
common	O
interactors	O
,	O
Ei	O
is	O
the	O
set	O
of	O
edges	O
that	O
involve	O
protein	O
i	O
,	O
se	O
is	O
the	O
score	O
(	O
likelihood	O
ratio	O
)	O
of	O
edge	O
e	O
and	O
Ei\Ec	O
refers	O
to	O
the	O
set	O
difference	O
of	O
Ei	O
and	O
Ec	O
.	O

For	O
a	O
given	O
set	O
of	O
neighbors	O
,	O
T	O
increases	O
as	O
the	O
interactions	O
with	O
these	O
neighbors	O
become	O
more	O
likely	O
(	O
as	O
the	O
sum	O
of	O
se	O
increases	O
)	O
.	O

Additionally	O
,	O
the	O
topology	O
score	O
T	O
of	O
a	O
pair	O
of	O
proteins	O
increases	O
as	O
the	O
proportion	O
of	O
likely	O
interactors	O
that	O
these	O
two	O
proteins	O
share	O
increases	O
.	O

The	O
topology	O
scores	O
were	O
grouped	O
into	O
5	O
bins	O
of	O
increasing	O
value	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
neighborhood	O
topology	O
score	O
calculated	O
for	O
a	O
given	O
protein	O
pair	O
does	O
not	B-Negation
consider	I-Negation
the	I-Negation
preliminary	I-Negation
score	I-Negation
assigned	I-Negation
to	I-Negation
that	I-Negation
protein	I-Negation
pair	I-Negation
.	O

It	O
only	O
considers	O
the	O
preliminary	O
scores	O
of	O
its	O
neighbors	O
and	O
so	O
is	O
truly	O
based	O
on	O
the	O
local	O
network	O
topology	O
around	O
that	O
protein	O
pair	O
.	O

Accordingly	O
,	O
the	O
likelihood	O
ratio	O
the	O
transitive	O
module	O
outputs	O
for	O
a	O
given	O
protein	O
pair	O
is	O
independent	O
of	O
the	O
likelihood	O
ratio	O
calculated	O
by	O
the	O
Group	O
A	O
modules	O
for	O
this	O
same	O
protein	O
pair	O
.	O

Correlation	O
analysis	O

The	O
Pearson	O
correlation	O
between	O
pairs	O
of	O
modules	O
was	O
estimated	O
by	O
taking	O
150	O
samples	O
of	O
10000	O
protein	O
pairs	O
each	O
and	O
calculating	O
the	O
Pearson	O
correlation	O
of	O
the	O
likelihood	O
ratios	O
for	O
the	O
two	O
modules	O
considered	O
,	O
for	O
each	O
sample	O
.	O

The	O
reported	O
correlation	O
values	O
are	O
the	O
average	O
of	O
the	O
150	O
experiments	O
.	O

Samples	O
of	O
the	O
protein	O
pair	O
space	O
were	O
taken	O
instead	B-Negation
of	I-Negation
considering	I-Negation
the	I-Negation
whole	I-Negation
space	I-Negation
as	O
this	O
was	O
more	O
computationally	O
tractable	O
.	O

Accuracy	O
measurements	O

The	O
accuracy	O
of	O
the	O
predictors	O
was	O
measured	O
by	O
performing	O
five-fold	O
cross	O
validation	O
experiments	O
in	O
which	O
the	O
datasets	O
were	O
randomly	O
divided	O
into	O
five	O
non-overlapping	O
sets	O
,	O
four	O
of	O
which	O
were	O
used	O
to	O
train	O
the	O
predictor	O
while	O
the	O
fifth	O
was	O
used	O
to	O
test	O
the	O
prediction	O
accuracy	O
.	O

The	O
accuracy	O
reported	O
is	O
the	O
average	O
measured	O
for	O
all	O
combinations	O
of	O
training	O
and	O
testing	O
sets	O
using	O
these	O
five	O
sets	O
.	O

Testing	O
was	O
done	O
by	O
predicting	O
the	O
total	O
likelihood	O
scores	O
for	O
all	O
protein	O
pairs	O
in	O
the	O
test	O
set	O
using	O
the	O
models	O
computed	O
in	O
the	O
training	O
phase	O
and	O
then	O
counting	O
the	O
number	O
of	O
pairs	O
that	O
were	O
well	O
predicted	O
.	O

We	O
used	O
the	O
area	O
under	O
partial	O
ROC	O
curves	O
as	O
a	O
measure	O
of	O
accuracy	O
.	O

Receiver	O
operator	O
characteristic	O
(	O
ROC	O
)	O
curves	O
plot	O
the	O
true	O
positive	O
rate	O
versus	O
the	O
false	O
positive	O
rate	O
over	O
their	O
full	O
range	O
of	O
possible	O
values	O
.	O

In	O
some	O
circumstances	O
,	O
it	O
is	O
more	O
informative	O
to	O
use	O
partial	O
ROC	O
curves	O
(	O
ROCn	O
curves	O
)	O
which	O
illustrate	O
the	O
number	O
of	O
true	O
positives	O
identified	O
by	O
the	O
predictor	O
that	O
score	O
higher	O
than	O
the	O
n	O
highest	O
scoring	O
negatives	O
,	O
plotted	O
for	O
all	O
values	O
from	O
0	O
to	O
n	O
.	O

There	O
are	O
many	O
more	O
negatives	O
than	O
positives	O
in	O
our	O
datasets	O
and	O
this	O
is	O
also	O
thought	O
to	O
be	O
true	O
for	O
the	O
full	O
protein	O
interaction	O
networks	O
we	O
are	O
modeling	O
.	O

Since	O
the	O
aim	O
is	O
to	O
identify	O
the	O
largest	O
number	O
of	O
true	O
interacting	O
pairs	O
while	O
leaving	O
out	O
as	O
many	O
non-interacting	O
pairs	O
as	O
possible	O
,	O
it	O
is	O
most	O
informative	O
to	O
measure	O
the	O
performance	O
of	O
the	O
predictor	O
under	O
conditions	O
of	O
very	O
low	O
false-positive	O
rates	O
.	O

Accordingly	O
,	O
ROC50	O
and	O
ROC100	O
curves	O
were	O
analyzed	O
because	O
given	O
the	O
size	O
of	O
the	O
datasets	O
,	O
these	O
curves	O
consider	O
all	O
the	O
protein	O
pairs	O
predicted	O
to	O
have	O
a	O
posterior	O
odds	O
ratio	O
above	O
1.0	O
,	O
for	O
all	O
the	O
predictors	O
investigated	O
.	O

The	O
area	O
under	O
ROC	O
curves	O
is	O
often	O
used	O
as	O
a	O
summary	O
measure	O
of	O
accuracy	O
.	O

For	O
ROCn	O
curves	O
,	O
it	O
can	O
be	O
calculated	O
as	O
AUC	O
ROCn	O
=	O
1nT	O
(	O
i=1nTi	O
)	O
where	O
i	O
takes	O
on	O
values	O
from	O
1	O
to	O
n	O
,	O
T	O
is	O
the	O
total	O
number	O
of	O
positives	O
in	O
the	O
test	O
set	O
and	O
Ti	O
is	O
the	O
number	O
of	O
positives	O
that	O
score	O
higher	O
than	O
the	O
ith	O
highest	O
scoring	O
negative	O
.	O

A	O
novel	O
ensemble	O
learning	O
method	O
for	O
de	O
novo	O
computational	O
identification	O
of	O
DNA	O
binding	O
sites	O

Abstract	O

Background	O

Despite	O
the	O
diversity	O
of	O
motif	O
representations	O
and	O
search	O
algorithms	O
,	O
the	O
de	O
novo	O
computational	O
identification	O
of	O
transcription	O
factor	O
binding	O
sites	O
remains	O
constrained	O
by	O
the	O
limited	O
accuracy	O
of	O
existing	O
algorithms	O
and	O
the	O
need	O
for	O
user-specified	O
input	O
parameters	O
that	O
describe	O
the	O
motif	O
being	O
sought	O
.	O

Results	O

We	O
present	O
a	O
novel	O
ensemble	O
learning	O
method	O
,	O
SCOPE	O
,	O
that	O
is	O
based	O
on	O
the	O
assumption	O
that	O
transcription	O
factor	O
binding	O
sites	O
belong	O
to	O
one	O
of	O
three	O
broad	O
classes	O
of	O
motifs	O
:	O
:	O
non-degenerate	O
,	O
degenerate	O
and	O
gapped	O
motifs	O
.	O

SCOPE	O
employs	O
a	O
unified	O
scoring	O
metric	O
to	O
combine	O
the	O
results	O
from	O
three	O
motif	O
finding	O
algorithms	O
each	O
aimed	O
at	O
the	O
discovery	O
of	O
one	O
of	O
these	O
classes	O
of	O
motifs	O
.	O

We	O
found	O
that	O
SCOPE	O
's	O
performance	O
on	O
78	O
experimentally	O
characterized	O
regulons	O
from	O
four	O
species	O
was	O
a	O
substantial	O
and	O
statistically	O
significant	O
improvement	O
over	O
that	O
of	O
its	O
component	O
algorithms	O
.	O

SCOPE	O
outperformed	O
a	O
broad	O
range	O
of	O
existing	O
motif	O
discovery	O
algorithms	O
on	O
the	O
same	O
dataset	O
by	O
a	O
statistically	O
significant	O
margin	O
.	O

Conclusion	O

SCOPE	O
demonstrates	O
that	O
combining	O
multiple	O
,	O
focused	O
motif	O
discovery	O
algorithms	O
can	O
provide	O
a	O
significant	O
gain	O
in	O
performance	O
.	O

By	O
building	O
on	O
components	O
that	O
efficiently	O
search	O
for	O
motifs	O
without	B-Negation
user-defined	I-Negation
parameters	I-Negation
,	O
SCOPE	O
requires	O
as	O
input	O
only	O
a	O
set	O
of	O
upstream	O
sequences	O
and	O
a	O
species	O
designation	O
,	O
making	O
it	O
a	O
practical	O
choice	O
for	O
non-expert	O
users	O
.	O

A	O
user-friendly	O
web	O
interface	O
,	O
Java	O
source	O
code	O
and	O
executables	O
are	O
available	O
at	O
http	O
:	O
//genie.dartmouth.edu/scope	O
.	O

Backgound	O

The	O
computational	O
discovery	O
of	O
DNA	O
binding	O
sites	O
for	O
previously	O
uncharacterized	O
transcription	O
factors	O
in	O
groups	O
of	O
co-regulated	O
genes	O
is	O
a	O
well-studied	O
problem	O
with	O
a	O
great	O
deal	O
of	O
practical	O
relevance	O
to	O
the	O
biologist	O
,	O
since	O
such	O
binding	O
sites	O
provide	O
targets	O
for	O
mutational	O
analyses	O
(	O
for	O
reviews	O
see	O
123	O
)	O
.	O

The	O
position-specific	O
variability	O
of	O
transcription	O
factor	O
binding	O
sites	O
makes	O
their	O
de	O
novo	O
identification	O
challenging	O
.	O

Many	O
computational	O
motif	O
finding	O
methods	O
are	O
based	O
on	O
the	O
observation	O
that	O
transcription	O
factor	O
binding	O
sites	O
occur	O
more	O
often	O
than	O
expected	O
by	O
chance	O
in	O
the	O
upstream	O
regions	O
of	O
the	O
set	O
of	O
genes	O
regulated	O
by	O
the	O
same	O
transcription	O
factor	O
1	O
.	O

The	O
problem	O
thus	O
simplifies	O
to	O
the	O
identification	O
of	O
overrepresented	O
motifs	O
in	O
a	O
given	O
set	O
of	O
upstream	O
sequences	O
.	O

Motif	O
finding	O
programs	O
rely	O
on	O
a	O
search	O
algorithm	O
to	O
optimize	O
a	O
motif	O
model	O
(	O
an	O
abstract	O
representation	O
of	O
a	O
set	O
of	O
transcription	O
factor	O
binding	O
sites	O
)	O
.	O

Most	O
recent	O
programs	O
represent	O
motifs	O
as	O
position	O
weight	O
matrices	O
(	O
PWMs	O
)	O
,	O
which	O
record	O
the	O
frequency	O
of	O
each	O
base	O
at	O
every	O
position	O
in	O
the	O
motif	O
.	O

Other	O
motif	O
finding	O
programs	O
have	O
relied	O
on	O
the	O
use	O
of	O
consensus	O
motif	O
models	O
(	O
in	O
which	O
every	O
base	O
is	O
represented	O
by	O
a	O
letter	O
of	O
the	O
15-letter	O
IUPAC	O
code	O
,	O
which	O
accounts	O
for	O
degeneracies	O
as	O
well	O
as	O
single	O
bases	O
)	O
or	O
k-mismatch	O
motif	O
models	O
(	O
in	O
which	O
a	O
non-degenerate	O
word	O
with	O
at	O
most	O
k	O
allowed	O
mismatches	O
is	O
used	O
to	O
represent	O
the	O
word	O
)	O
.	O

Regardless	O
of	O
the	O
motif	O
model	O
used	O
,	O
a	O
search	O
for	O
all	O
overrepresented	O
motifs	O
of	O
any	O
length	O
and	O
degree	O
of	O
degeneracy	O
leads	O
to	O
a	O
dauntingly	O
large	O
search	O
space	O
.	O

Thus	O
,	O
motif	O
finding	O
algorithms	O
restrict	O
their	O
search	O
space	O
by	O
using	O
simplified	O
motif	O
representations	O
,	O
employing	O
heuristic	O
search	O
strategies	O
that	O
are	O
prone	O
to	O
local	O
optima	O
,	O
or	O
invoking	O
additional	O
parameters	O
to	O
limit	O
the	O
search	O
space	O
and	O
thereby	O
pass	O
some	O
of	O
the	O
optimization	O
process	O
off	O
to	O
the	O
user	O
3	O
.	O

Program	O
parameters	O
(	O
such	O
as	O
motif	O
length	O
,	O
number	O
of	O
occurrences	O
and	O
orientation	O
)	O
that	B-Negation
can	I-Negation
not	I-Negation
be	I-Negation
reasonably	I-Negation
specified	I-Negation
by	I-Negation
the	I-Negation
user	I-Negation
without	I-Negation
prior	I-Negation
knowledge	I-Negation
about	I-Negation
the	I-Negation
true	I-Negation
binding	I-Negation
sites	I-Negation
are	O
referred	O
to	O
as	O
nuisance	O
parameters	O
4	O
.	O

Selection	O
of	O
the	O
correct	O
settings	O
for	O
these	O
parameters	O
is	O
a	O
crucial	O
step	O
in	O
motif	O
finding	O
,	O
and	O
is	O
often	O
assumed	O
to	O
be	O
the	O
domain	O
of	O
experts	O
.	O

In	O
a	O
recent	O
evaluation	O
,	O
Hu	O
and	O
colleagues	O
4	O
compared	O
the	O
performance	O
of	O
five	O
motif	O
finders	O
on	O
a	O
single	O
prokaryotic	O
genome	O
,	O
systematically	O
exploring	O
the	O
effects	O
of	O
nuisance	O
parameters	O
,	O
including	O
expected	O
motif	O
length	O
and	O
number	O
of	O
occurrences	O
.	O

Every	O
motif	O
finder	O
they	O
tested	O
was	O
found	O
to	O
be	O
sensitive	O
to	O
values	O
used	O
for	O
these	O
parameters	O
.	O

Guidance	B-Negation
on	I-Negation
the	I-Negation
specific	I-Negation
parameter	I-Negation
settings	I-Negation
to	I-Negation
use	I-Negation
for	I-Negation
given	I-Negation
motif	I-Negation
finding	I-Negation
situations	I-Negation
is	I-Negation
not	I-Negation
provided	I-Negation
in	I-Negation
most	I-Negation
publications	I-Negation
presenting	I-Negation
motif	I-Negation
finders	I-Negation
.	O

Even	O
assuming	O
that	O
optimal	O
parameter	O
settings	O
exist	O
for	O
a	O
motif	O
finding	O
program	O
for	O
each	O
specific	O
situation	O
,	O
for	O
the	O
typical	O
biologist	O
looking	O
to	O
identify	O
motifs	O
in	O
a	O
set	O
of	O
uncharacterized	O
sequences	O
,	O
acquiring	O
such	O
expertise	O
is	O
an	O
onerous	O
task	O
.	O

Nuisance	O
parameters	O
complicate	O
the	O
interpretation	O
of	O
performance	O
comparisons	O
as	O
well	O
.	O

A	O
recent	O
large-scale	O
performance	O
comparison	O
between	O
thirteen	O
different	O
motif	O
finding	O
tools	O
used	O
expert	O
knowledge	O
in	O
setting	O
the	O
parameters	O
for	O
every	O
program	O
5	O
.	O

Several	O
of	O
the	O
programs	O
contributing	O
to	O
the	O
performance	O
comparison	O
were	O
run	O
with	O
different	O
parameter	O
settings	O
for	O
each	O
regulon	O
,	O
and	O
in	O
some	O
cases	O
,	O
motifs	O
were	O
hand	O
filtered	O
as	O
a	O
post-processing	O
step	O
.	O

Such	O
performance	O
comparisons	O
evaluate	O
not	O
just	O
algorithms	O
but	O
also	O
the	O
expertise	O
of	O
the	O
users	O
,	O
making	O
it	O
difficult	O
for	O
a	O
first-time	O
user	O
to	O
select	O
a	O
motif	O
finder	O
on	O
a	O
principled	O
basis	O
.	O

A	O
key	O
result	O
of	O
the	O
Tompa	O
,	O
et	O
al.	O
study	O
was	O
the	O
finding	O
that	O
all	O
of	O
the	O
motif	O
finders	O
had	O
roughly	O
the	O
same	O
average	O
performance	O
under	O
a	O
wide	O
range	O
of	O
conditions	O
and	O
test	O
statistics	O
5	O
.	O

This	O
finding	O
was	O
particularly	O
notable	O
because	O
the	O
motif	O
finders	O
studied	O
employed	O
a	O
wide	O
range	O
of	O
motif	O
representations	O
,	O
scoring	O
functions	O
and	O
search	O
strategies	O
and	O
all	O
were	O
operated	O
under	O
the	O
most	O
favorable	O
conditions	O
possible	O
.	O

Although	O
the	O
average	O
performance	O
of	O
the	O
programs	O
did	O
not	O
differ	O
significantly	O
,	O
the	O
authors	O
found	O
that	O
,	O
for	O
each	O
pair	O
of	O
programs	O
,	O
each	O
program	O
performed	O
better	O
than	O
the	O
other	O
on	O
some	O
subset	O
of	O
the	O
data	O
5	O
.	O

Previous	O
studies	O
over	O
smaller	O
numbers	O
of	O
motif	O
finders	O
have	O
found	O
that	O
no	B-Negation
program	I-Negation
clearly	I-Negation
stands	I-Negation
out	I-Negation
as	I-Negation
superior	I-Negation
to	I-Negation
the	I-Negation
others	I-Negation
and	O
each	O
program	O
outperforms	O
all	O
others	O
on	O
some	O
subset	O
of	O
the	O
regulons	O
678	O
.	O

This	O
diversity	O
of	O
performance	O
has	O
led	O
a	O
number	O
of	O
authors	O
to	O
speculate	O
that	O
ensemble	O
methods	O
,	O
comprising	O
multiple	O
motif	O
finders	O
,	O
may	O
lead	O
to	O
improvements	O
in	O
accuracy	O
158	O
.	O

Ensemble	O
methods	O
,	O
well	O
known	O
in	O
the	O
machine	O
learning	O
community	O
9	O
,	O
are	O
typically	O
composed	O
of	O
multiple	O
methods	O
comprising	O
different	O
search	O
strategies	O
(	O
or	O
the	O
same	O
search	O
strategies	O
with	O
different	O
initiation	O
settings	O
or	O
random	O
restarts	O
)	O
with	O
a	O
unified	O
objective	O
function	O
.	O

The	O
final	O
predictions	O
are	O
chosen	O
from	O
the	O
ensemble	O
of	O
methods	O
by	O
a	O
learning	O
rule	O
,	O
which	O
may	O
be	O
as	O
simple	O
as	O
finding	O
the	O
maximum	O
score	O
from	O
all	O
the	O
methods	O
,	O
or	O
as	O
complex	O
as	O
optimizing	O
a	O
weighted	O
scoring	O
scheme	O
from	O
among	O
the	O
methods	O
.	O

The	O
construction	O
of	O
this	O
learning	O
rule	O
is	O
key	O
to	O
the	O
performance	O
of	O
an	O
ensemble	O
learning	O
method	O
,	O
as	O
the	O
performance	O
of	O
an	O
ensemble	O
method	O
with	O
an	O
ineffective	O
learning	O
rule	O
will	O
be	O
the	O
average	O
of	O
the	O
performance	O
of	O
its	O
component	O
algorithms	O
.	O

In	O
this	O
context	O
,	O
we	O
note	O
that	O
Tompa	O
et	O
al.	O
5	O
found	O
that	O
,	O
although	O
every	O
motif	O
finding	O
program	O
tested	O
had	O
some	O
regulons	O
on	O
which	O
its	O
performance	O
was	O
clearly	O
superior	O
,	O
it	O
was	O
not	B-Negation
possible	I-Negation
a	I-Negation
priori	I-Negation
to	I-Negation
predict	I-Negation
which	I-Negation
motif	I-Negation
finder	I-Negation
represented	I-Negation
the	I-Negation
best	I-Negation
choice	I-Negation
under	I-Negation
any	I-Negation
given	I-Negation
set	I-Negation
of	I-Negation
conditions	I-Negation
5	O
.	O

This	O
observation	O
serves	O
to	O
illustrate	O
the	O
challenges	O
to	O
the	O
construction	O
of	O
an	O
effective	O
learning	O
rule	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
only	O
one	O
study	O
to	O
date	O
has	O
explored	O
ensemble	O
learning	O
in	O
motif	O
finding	O
.	O

Hu	O
,	O
Li	O
and	O
Kihara	O
4	O
described	O
a	O
simple	O
ensemble	O
method	O
wherein	O
the	O
component	O
programs	O
were	O
random	O
restarts	O
of	O
the	O
same	O
stochastic	O
algorithm	O
(	O
such	O
as	O
Gibbs	O
sampling	O
or	O
Expectation	O
Maximization	O
)	O
and	O
the	O
learning	O
rule	O
was	O
a	O
voting	O
scheme	O
in	O
which	O
the	O
results	O
of	O
each	O
random	O
restart	O
cast	O
a	O
``	O
vote	O
``	O
for	O
which	O
positions	O
in	O
the	O
DNA	O
sequence	O
should	O
be	O
part	O
of	O
the	O
final	O
reported	O
motif	O
(	O
hereafter	O
,	O
we	O
refer	O
to	O
this	O
as	O
the	O
HLK	O
method	O
)	O
.	O

Under	O
this	O
scheme	O
,	O
the	O
authors	O
found	O
that	O
ensemble	O
learning	O
resulted	O
in	O
an	O
increase	O
in	O
performance	O
ranging	O
from	O
6	O
to	O
45	O
%	O
.	O

The	O
HLK	O
voting	O
method	O
provides	O
a	O
framework	O
wherein	O
a	O
number	O
of	O
different	O
motifs	O
finders	O
can	O
be	O
combined	O
under	O
the	O
heuristic	O
that	O
if	O
several	O
motif	O
finders	O
make	O
the	O
same	O
(	O
or	O
overlapping	O
)	O
prediction	O
,	O
then	O
that	O
prediction	O
is	O
accurate	O
.	O

Here	O
we	O
present	O
a	O
novel	O
ensemble	O
motif	O
finder	O
based	O
on	O
a	O
different	O
conceptual	O
approach	O
.	O

Rather	B-Negation
than	I-Negation
randomly	I-Negation
restarting	I-Negation
the	I-Negation
same	I-Negation
search	I-Negation
algorithm	I-Negation
or	I-Negation
comparing	I-Negation
multiple	I-Negation
search	I-Negation
strategies	I-Negation
that	I-Negation
all	I-Negation
search	I-Negation
for	I-Negation
the	I-Negation
same	I-Negation
global	I-Negation
optimum	I-Negation
(	I-Negation
and	I-Negation
are	I-Negation
potentially	I-Negation
vulnerable	I-Negation
to	I-Negation
the	I-Negation
same	I-Negation
local	I-Negation
optima	I-Negation
)	I-Negation
,	O
our	O
algorithm	O
assumes	B-Speculation
that	I-Speculation
the	I-Speculation
``	I-Speculation
``	I-Speculation
biological	I-Speculation
significance	I-Speculation
surface	I-Speculation
``	I-Speculation
``	I-Speculation
primarily	I-Speculation
consists	I-Speculation
of	I-Speculation
three	I-Speculation
local	I-Speculation
optima	I-Speculation
,	I-Speculation
and	I-Speculation
that	I-Speculation
one	I-Speculation
of	I-Speculation
these	I-Speculation
peaks	I-Speculation
represents	I-Speculation
the	I-Speculation
global	I-Speculation
optimum	I-Speculation
.	O

Thus	O
,	O
our	O
ensemble	O
uses	O
three	O
specialized	O
algorithms	O
whose	O
search	O
spaces	O
restrict	O
them	O
to	O
each	O
of	O
these	O
three	O
local	O
optima	O
(	O
BEAM	O
for	O
non-degenerate	O
motifs	O
,	O
PRISM	O
for	O
degenerate	O
motifs	O
and	O
SPACER	O
for	O
bipartite	O
motifs	O
)	O
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
the	O
greedy	O
search	O
strategies	O
employed	O
by	O
each	O
of	O
these	O
methods	O
allow	O
them	O
to	O
reliably	O
search	O
their	O
respective	O
motif	O
domains	O
without	B-Negation
the	I-Negation
use	I-Negation
of	I-Negation
nuisance	I-Negation
parameters	I-Negation
,	O
as	O
the	O
algorithms	O
themselves	O
efficiently	O
optimize	O
the	O
parameters	O
that	O
are	O
typically	O
forced	O
on	O
the	O
users	O
101112	O
.	O

The	O
results	O
of	O
these	O
component	O
algorithms	O
are	O
then	O
combined	O
using	O
a	O
learning	O
rule	O
that	O
is	O
simply	O
the	O
maximum	O
score	O
returned	O
by	O
each	O
component	O
algorithm	O
.	O

To	O
make	O
comparisons	O
possible	O
,	O
the	O
motif	O
scores	O
returned	O
by	O
each	O
algorithm	O
are	O
penalized	O
according	O
to	O
the	O
complexity	O
of	O
the	O
motif	O
.	O

The	O
resulting	O
ensemble	O
algorithm	O
,	O
SCOPE	O
,	O
has	O
no	B-Negation
nuisance	I-Negation
parameters	I-Negation
and	O
performs	O
significantly	O
better	O
than	O
its	O
component	O
algorithms	O
.	O

In	O
addition	O
,	O
we	O
find	O
that	O
SCOPE	O
performs	O
favorably	O
compared	O
to	O
a	O
diverse	O
range	O
of	O
existing	O
methods	O
and	O
is	O
robust	O
to	O
the	O
presence	O
of	O
extraneous	O
sequences	O
in	O
its	O
input	O
.	O

Results	O

Algorithm	O

SCOPE	O
takes	O
as	O
input	O
a	O
set	O
of	O
sequences	O
U	O
that	O
are	O
upstream	O
of	O
a	O
set	O
of	O
genes	O
G	O
that	O
are	O
thought	O
to	O
be	O
coregulated	O
.	O

The	O
ultimate	O
goal	O
of	O
a	O
motif	O
finder	O
is	O
to	O
identify	O
the	O
specific	O
subsequences	O
	O
in	O
U	O
that	O
act	O
as	O
binding	O
sites	O
for	O
the	O
transcription	O
factor	O
(	O
s	O
)	O
that	O
regulate	O
G	O
.	O

In	O
practice	O
,	O
sets	O
of	O
binding	O
sites	O
are	O
represented	O
using	O
a	O
motif	O
.	O

We	O
have	O
found	O
that	O
simple	O
consensus	O
motifs	O
over	O
the	O
full	O
IUPAC	O
alphabet	O
(	O
a	O
15-letter	O
code	O
consisting	O
of	O
the	O
bases	O
A	O
,	O
T	O
,	O
C	O
,	O
G	O
and	O
all	O
possible	O
combinations	O
)	O
provide	O
enough	O
representational	O
power	O
to	O
adequately	O
describe	O
	O
,	O
while	O
still	O
allowing	O
for	O
an	O
efficient	O
search	O
34	O
.	O

While	O
alternative	O
representations	O
,	O
such	O
as	O
position	O
weight	O
matrices	O
(	O
PWMs	O
)	O
are	O
more	O
expressive	O
,	O
their	O
heuristic	O
searches	O
are	O
prone	B-Speculation
to	I-Speculation
local	I-Speculation
optima	I-Speculation
and	O
often	O
do	O
not	B-Negation
perform	I-Negation
well	I-Negation
in	I-Negation
practice	I-Negation
@	O
34111213	O
@	O
.	O

SCOPE	O
has	O
three	O
component	O
algorithms	O
,	O
BEAM	O
,	O
PRISM	O
and	O
SPACER	O
,	O
which	O
search	O
for	O
non-degenerate	O
,	O
short	O
degenerate	O
,	O
and	O
long	O
,	O
highly	O
degenerate	O
and	O
``	O
gapped	O
``	O
motifs	O
,	O
respectively	O
(	O
Figure	O
1	O
)	O
.	O

Each	O
motif	O
is	O
scored	O
considering	O
one	O
or	O
both	O
strands	O
and	O
the	O
motif	O
is	O
marked	O
to	O
indicate	O
which	O
calculation	O
scores	O
higher	O
.	O

The	O
results	O
of	O
the	O
three	O
algorithms	O
are	O
merged	O
and	O
sorted	O
.	O

Artifactual	O
motifs	O
,	O
whose	O
significance	O
can	O
be	O
accounted	O
for	O
by	O
higher	O
scoring	O
motifs	O
that	O
they	O
overlap	O
,	O
are	O
identified	O
and	O
removed	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S1	O
)	O
.	O

Flow	O
diagram	O
for	O
SCOPE	O

Flow	O
diagram	O
for	O
SCOPE	O
.	O

BEAM	O
and	O
SPACER	O
are	O
run	O
independently	O
;	O
PRISM	O
runs	O
on	O
the	O
top	O
100	O
motifs	O
output	O
by	O
BEAM	O
.	O

For	O
yeast	O
(	O
whose	O
upstream	O
regions	O
are	O
standardized	O
to	O
800	O
bp	O
)	O
,	O
BEAM	O
and	O
PRISM	O
use	O
the	O
overrepresentation-KS	O
objective	O
function	O
(	O
so/ks	O
)	O
,	O
while	O
SPACER	O
's	O
slower	O
running	O
time	O
requires	O
the	O
simpler	O
overrepresentation	O
objective	O
function	O
(	O
so	O
)	O
.	O

The	O
top	O
5	O
motifs	O
from	O
SPACER	O
are	O
rescored	O
using	O
the	O
combined	O
objective	O
function	O
.	O

For	O
bacteria	O
and	O
Drosophila	O
,	O
upstream	O
regions	O
are	O
defined	O
to	O
be	O
the	O
intergenic	O
region	O
upstream	O
of	O
each	O
gene	O
;	O
thus	O
,	O
the	B-Negation
KS	I-Negation
objective	I-Negation
function	I-Negation
is	I-Negation
not	I-Negation
used	I-Negation
.	O

The	O
results	O
of	O
each	O
program	O
are	O
sorted	O
by	O
Sig	O
and	O
lower	O
scoring	O
motifs	O
that	O
substantially	O
overlap	O
higher	O
scoring	O
motifs	O
are	O
removed	O
.	O

The	O
filtered	O
lists	O
of	O
motifs	O
from	O
the	O
three	O
programs	O
are	O
finally	O
merged	O
by	O
Sig	O
score	O
.	O

Repetitive	O
motifs	O
are	O
identified	O
and	O
removed	O
during	O
all	O
stages	O
.	O

Each	O
of	O
SCOPE	O
's	O
three	O
component	O
algorithms	O
seeks	O
to	O
maximize	O
the	O
same	O
objective	O
function	O
over	O
a	O
different	O
class	O
of	O
motifs	O
.	O

Let	O
M	O
be	O
a	O
random	O
variable	O
over	O
the	O
full	O
space	O
of	O
IUPAC	O
words	O
.	O

The	O
statistical	O
significance	O
p	O
(	O
M	O
=	O
m	O
)	O
of	O
a	O
particular	O
word	O
m	O
is	O
determined	O
by	O
the	O
distribution	O
of	O
M	O
over	O
the	O
entire	O
space	O
of	O
upstream	O
sequences	O
in	O
the	O
given	O
species	O
.	O

In	O
general	O
,	O
we	O
seek	O
to	O
maximize	O
-log	O
(	O
p	O
(	O
M	O
=	O
m	O
)	O
)	O
.	O

All	B-Negation
values	I-Negation
of	I-Negation
M	I-Negation
are	I-Negation
not	I-Negation
,	O
however	O
,	O
equally	O
likely	B-Speculation
a	I-Speculation
priori	I-Speculation
.	O

For	O
example	O
,	O
it	O
is	O
quite	O
likely	O
that	O
there	O
exists	O
an	O
extremely	O
long	O
sequence	O
that	O
is	O
entirely	O
unique	O
to	O
U	O
.	O

Such	O
a	O
unique	O
sequence	O
would	O
appear	O
to	O
be	O
highly	O
significant	O
,	O
until	O
we	O
consider	O
that	O
we	O
have	O
in	O
effect	O
searched	O
all	O
possible	O
sequences	O
until	O
we	O
found	O
one	O
that	O
is	O
unique	O
.	O

To	O
correct	O
for	O
this	O
multiple	O
hypothesis	O
testing	O
problem	O
,	O
van	O
Helden	O
et	O
al.	O
14	O
proposed	O
using	O
a	O
Bonferroni	O
correction	O
,	O
in	O
which	O
p	O
(	O
M	O
=	O
m	O
)	O
is	O
penalized	O
by	O
the	O
number	O
of	O
motifs	O
N	O
of	O
length	O
|m|	O
:	O

Sig	O
=	O
-log	O
(	O
p	O
(	O
M	O
=	O
m	O
)	O
N	O
)	O
.	O

Thus	O
,	O
if	O
m	O
=	O
``	O
ACGT	O
``	O
,	O
N	O
=	O
44	O
.	O

We	O
employed	O
this	O
same	O
definition	O
of	O
Sig	O
for	O
BEAM	O
,	O
our	O
algorithm	O
that	O
searches	O
for	O
non-degenerate	O
motifs	O
10	O
.	O

Defining	O
N	O
for	O
degenerate	O
or	O
bipartite	O
motifs	O
raises	O
a	O
significant	O
conceptual	O
challenge	O
.	O

Van	O
Helden	O
et	O
al.	O
14	O
chose	O
to	O
use	O
the	O
same	O
definition	O
,	O
but	O
limited	O
their	O
search	O
to	O
a	O
small	O
number	O
of	O
degenerate	O
bases	O
.	O

In	O
contrast	O
,	O
we	O
have	O
proposed	B-Speculation
that	I-Speculation
all	B-Speculation
characters	I-Speculation
should	I-Speculation
not	B-Negation
be	I-Negation
treated	I-Negation
equally	I-Negation
,	O
but	O
should	B-Speculation
be	I-Speculation
penalized	I-Speculation
in	I-Speculation
proportion	I-Speculation
to	I-Speculation
the	I-Speculation
information	I-Speculation
provided	I-Speculation
by	I-Speculation
them	I-Speculation
1112	O
.	O

By	O
this	O
logic	O
,	O
``	O
``	B-Negation
ACGT	I-Negation
``	I-Negation
``	I-Negation
will	I-Negation
not	I-Negation
be	I-Negation
penalized	I-Negation
differently	I-Negation
from	I-Negation
``	I-Negation
``	I-Negation
ACNNNNGT	I-Negation
``	I-Negation
``	O
,	O
as	O
both	O
have	O
the	O
same	O
number	O
of	O
bases	O
that	O
contribute	O
any	O
information	O
to	O
protein-DNA	O
binding	O
.	O

Building	O
on	O
this	O
intuition	O
,	O
one	O
can	O
argue	O
that	O
the	O
characters	O
``	O
``	O
A	O
``	O
``	O
and	O
``	O
``	O
not-A	O
``	O
``	O
(	O
IUPAC	O
character	O
``	O
``	O
B	O
``	O
)	O
``	O
are	O
roughly	O
equivalent	O
,	O
while	O
``	O
``	O
A	O
or	O
G	O
``	O
``	O
(	O
IUPAC	O
character	O
``	O
``	O
R	O
``	O
)	O
``	O
is	O
different	O
from	O
``	O
``	O
A	O
``	O
``	O
as	O
there	O
are	O
six	O
ways	O
to	O
define	O
a	O
combination	O
of	O
two	O
bases	O
,	O
while	O
only	O
four	O
ways	O
to	O
define	O
a	O
combination	O
of	O
one	O
base	O
or	O
three	O
bases	O
.	O

For	O
motif	O
m	O
=	O
m1m2	O
...	O
mn	O
,	O
we	O
can	O
therefore	O
define	O
N	O
=	O
	O
Choose	O
(	O
4	O
,	O
|mi|	O
)	O
,	O
where	O
|mi|	O
is	O
the	O
number	O
of	O
DNA	O
bases	O
covered	O
by	O
the	O
IUPAC	O
character	O
mi	O
.	O

In	O
the	O
case	O
were	O
both	O
orientations	O
of	O
the	O
motif	O
are	O
considered	O
,	O
this	O
number	O
is	O
adjusted	O
to	O
account	O
for	O
palindromes	O
.	O

The	O
resulting	O
Sig	O
score	O
thus	O
penalizes	O
motifs	O
based	O
on	O
their	O
length	O
and	O
degeneracy	O
,	O
enabling	O
fair	O
comparisons	O
to	O
be	O
made	O
between	O
different	O
motif	O
classes	O
.	O

Testing	O

Evaluation	O
of	O
objective	O
functions	O
used	O
by	O
SCOPE	O

Each	O
component	O
algorithm	O
in	O
SCOPE	O
efficiently	O
searches	O
its	O
restricted	O
search	O
space	O
,	O
keeping	O
SCOPE	O
's	O
runtime	O
low	O
(	O
average	O
runtime	O
on	O
our	O
datasets	O
were	O
about	O
one	O
minute	O
)	O
.	O

This	O
efficiency	O
allowed	O
us	O
to	O
explore	O
several	O
objective	O
functions	O
for	O
scoring	O
the	O
statistical	O
significance	O
p	O
(	O
M	O
=	O
m	O
)	O
of	O
motifs	O
.	O

These	O
objective	O
functions	O
were	O
as	O
follows	O
:	O
position	O
bias	O
(	O
based	O
on	O
the	O
Kolmogorov-Smirnov	O
,	O
or	O
KS	O
,	O
statistic	O
)	O
,	O
overrepresentation	O
(	O
a	O
Poisson-based	O
measure	O
based	O
on	O
how	O
often	O
a	O
motif	O
occurs	O
in	O
U	O
)	O
and	O
coverage	O
(	O
a	O
Poisson-based	O
measure	O
based	O
on	O
how	O
many	O
upstream	O
sequences	O
contain	O
the	O
motif	O
)	O
.	O

For	O
precise	O
definitions	O
,	O
see	O
Methods	O
.	O

To	O
establish	O
which	O
objective	O
function	O
(	O
or	O
combination	O
of	O
functions	O
)	O
was	O
most	O
suitable	O
,	O
we	O
tested	O
each	O
objective	O
function	O
independently	O
of	O
SCOPE	O
,	O
using	O
a	O
subset	O
of	O
the	O
S.	O
cerevisiae	O
dataset	O
.	O

The	O
measure	O
used	O
to	O
assess	O
the	O
biological	O
relevance	O
of	O
a	O
motif	O
was	O
accuracy	O
,	O
a	O
measure	O
of	O
the	O
nucleotide	O
level	O
overlap	O
between	O
a	O
motif	O
and	O
the	O
known	O
binding	O
sites	O
(	O
for	O
details	O
see	O
Methods	O
)	O
.	O

From	O
each	O
regulon	O
from	O
the	O
SCPD	O
database	O
15	O
we	O
selected	O
ten	O
six-mers	O
at	O
random	O
from	O
the	O
upstream	O
sequences	O
and	O
ten	O
six-mers	O
at	O
random	O
from	O
the	O
collection	O
of	O
known	O
binding	O
sites	O
for	O
that	O
regulon	O
.	O

For	O
each	O
of	O
these	O
sampled	O
six-mers	O
,	O
we	O
calculated	O
accuracy	O
with	O
respect	O
to	O
the	O
known	O
binding	O
sites	O
.	O

We	O
also	O
calculated	O
the	O
Sig	O
score	O
for	O
each	O
six-mer	O
,	O
using	O
four	O
objective	O
functions	O
(	O
KS	O
,	O
overrepresentation	O
,	O
coverage	O
and	O
combined	O
KS-overrepresentation	O
)	O
.	O

We	O
then	O
plotted	O
Sig	O
versus	O
accuracy	O
for	O
each	O
objective	O
function	O
,	O
to	O
determine	O
which	O
objective	O
functions	O
correlated	O
most	O
strongly	O
with	O
biological	O
relevance	O
(	O
Figure	O
2	O
)	O
.	O

Correlation	O
between	O
accuracy	O
and	O
Sig	O
scores	O

Correlation	O
between	O
accuracy	O
and	O
Sig	O
scores	O
.	O

Non-degenerate	O
6-mers	O
from	O
S.	O
cerevisiae	O
were	O
scored	O
according	O
to	O
Sig	O
scores	O
based	O
on	O
(	O
a	O
)	O
Overrepresentation	O
,	O
(	O
b	O
)	O
Overrepresentation-KS	O
,	O
(	O
c	O
)	O
Coverage	O
and	O
(	O
d	O
)	O
KS	O
metrics	O
of	O
statistical	O
significance	O
.	O

The	O
6-mers	O
were	O
randomly	O
sampled	O
from	O
both	O
the	O
upstream	O
regions	O
and	O
the	O
known	O
binding	O
sites	O
to	O
ensure	O
coverage	O
or	O
a	O
wide	O
range	O
of	O
accuracy	O
.	O

The	O
x-axis	O
plots	O
the	O
Bonferroni-corrected	O
and	O
log2	O
transformed	O
Sig	O
score	O
for	O
each	O
metric	O
.	O

The	O
red	O
lines	O
indicate	O
the	O
95th	O
Sig	O
percentile	O
.	O

These	O
plots	O
demonstrate	O
that	O
overrepresentation	O
is	O
a	O
closer	O
approximation	O
to	O
biological	O
relevance	O
than	O
coverage	O
or	O
KS	O
alone	O
.	O

Adding	O
KS	O
to	O
overrepresentation	O
modestly	O
improved	O
the	O
correlation	O
by	O
13	O
%	O
(	O
as	O
compared	O
to	O
overrepresentation	O
alone	O
)	O
to	O
R2	O
=	O
0.28	O
.	O

To	O
assess	O
the	O
degree	O
of	O
class	O
separation	O
achieved	O
by	O
the	O
two	O
objective	O
functions	O
,	O
we	O
ranked	O
the	O
sampled	O
six-mers	O
by	O
Sig	O
score	O
,	O
and	O
calculated	O
the	O
percentage	O
of	O
motifs	O
with	O
high	O
Sig	O
scores	O
(	O
in	O
the	O
95th	O
percentile	O
and	O
above	O
)	O
that	O
possessed	O
a	O
reasonable	O
degree	O
of	O
overlap	O
with	O
the	O
known	O
binding	O
sites	O
(	O
accuracy	O
	O
0.10	O
)	O
.	O

By	O
the	O
overrepresentation	O
measure	O
,	O
74.4	O
%	O
of	O
high	O
scoring	O
motifs	O
had	O
accuracy	O
=	O
0.10	O
,	O
while	O
79.1	O
%	O
of	O
high	O
scoring	O
motifs	O
by	O
KS-overrepresentation	O
had	O
accuracy	O
	O
0.10	O
.	O

This	O
analysis	O
suggests	O
that	O
more	O
complex	O
objective	O
functions	O
may	O
provide	O
a	O
better	O
estimate	O
of	O
biological	O
significance	O
than	O
the	O
overrepresentation	O
objective	O
functions	O
commonly	O
used	O
.	O

We	O
thus	O
chose	O
to	O
run	O
SCOPE	O
using	O
the	O
overrepresentation-KS	O
combined	O
objective	O
function	O
on	O
the	O
S.	O
cerevisiae	O
dataset	O
,	O
in	O
which	O
the	O
upstream	O
regions	O
are	O
of	O
fixed	O
length	O
.	O

We	O
used	O
the	O
overrepresentation	O
objective	O
function	O
for	O
the	O
other	O
species	O
,	O
as	O
our	O
upstream	O
definitions	O
for	O
those	O
species	O
were	O
of	O
variable	O
length	O
due	O
to	O
the	O
available	O
annotations	O
.	O

Because	O
identifying	O
the	O
genomic	O
positions	O
of	O
highly	O
degenerate	O
bipartite	O
motifs	O
is	O
prohibitively	O
slow	O
,	O
initial	O
rankings	O
of	O
motifs	O
for	O
SPACER	O
were	O
computed	O
using	O
the	O
overrepresentation	O
objective	O
function	O
,	O
and	O
the	O
overrepresentation-KS	O
objective	O
function	O
was	O
used	O
only	O
to	O
produce	O
the	O
final	O
ordering	O
and	O
scores	O
.	O

Although	O
the	O
KS	O
objective	O
function	O
is	O
computationally	O
expensive	O
(	O
linear	O
in	O
the	O
frequency	O
of	O
the	O
motif	O
in	O
the	O
genome	O
)	O
,	O
the	O
SCOPE	O
algorithms	O
all	O
aggressively	O
limit	O
the	O
search	O
space	O
,	O
thereby	O
making	O
the	O
use	O
of	O
this	O
objective	O
function	O
	O
and	O
exploration	O
of	O
other	O
complex	O
objective	O
functions	O
	O
possible	O
.	O

The	O
surprisingly	O
low	O
correlations	O
between	O
Sig	O
and	O
accuracy	O
may	O
indicate	O
that	O
the	O
objective	O
functions	O
employed	O
by	O
motif	O
finding	O
programs	O
are	O
only	O
a	O
first	O
approximation	O
to	O
biological	O
significance	O
.	O

Indeed	O
,	O
previous	O
studies	O
have	O
reported	O
little	O
or	O
no	B-Negation
correlation	I-Negation
between	O
the	O
significance	O
measures	O
of	O
various	O
motif	O
finders	O
and	O
measures	O
of	O
accuracy	O
416	O
.	O

Further	O
research	O
into	O
more	O
biologically	O
accurate	O
objective	O
functions	O
may	O
yield	O
better	O
performance	O
for	O
motif	O
discovery	O
algorithms	O
.	O

Evaluation	O
of	O
SCOPE	O
performance	O
and	O
ensemble	O
learning	O
scheme	O

We	O
first	O
assessed	O
the	O
performance	O
of	O
the	O
optimized	O
SCOPE	O
framework	O
on	O
synthetic	O
datasets	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S2	O
)	O
.	O

SCOPE	O
performed	O
well	O
on	O
the	O
synthetic	O
datasets	O
,	O
correctly	O
identifying	O
92	O
%	O
of	O
planted	O
motifs	O
that	O
are	O
over-represented	O
relative	O
to	O
background	O
(	O
those	O
motifs	O
with	O
a	O
Sig	O
score	O
of	O
greater	O
than	O
5	O
;	O
Figure	O
3	O
)	O
.	O

Performance	O
at	O
different	O
overrepresentation	O
Sig	O
values	O
on	O
synthetic	O
data	O

Performance	O
at	O
different	O
overrepresentation	O
Sig	O
values	O
on	O
synthetic	O
data	O
.	O

A	O
motif	O
was	O
``	O
found	O
``	O
if	O
the	O
top	O
scoring	O
motif	O
returned	O
by	O
SCOPE	O
overlapped	O
the	O
planted	O
motif	O
by	O
at	O
least	O
50	O
%	O
.	O

Different	O
Sig	O
values	O
were	O
achieved	O
by	O
varying	O
the	O
number	O
of	O
upstream	O
regions	O
,	O
the	O
number	O
of	O
motifs	O
per	O
upstream	O
region	O
,	O
and	O
the	O
number	O
of	O
extraneous	O
upstream	O
regions	O
without	B-Negation
planted	I-Negation
motifs	I-Negation
.	O

A	O
Sig	O
value	O
of	O
0	O
implies	O
that	O
one	O
motif	O
of	O
that	O
significance	O
is	O
expected	O
by	O
chance	O
.	O

While	O
synthetic	O
test	O
sets	O
are	O
useful	O
in	O
algorithmic	O
development	O
and	O
initial	O
testing	O
,	O
the	O
results	O
of	O
such	O
tests	O
must	O
be	O
taken	O
with	O
a	O
grain	O
of	O
salt	O
,	O
as	O
they	O
are	O
highly	O
dependent	O
on	O
the	O
model	O
used	O
to	O
generate	O
the	O
test	O
sets	O
6	O
.	O

We	O
therefore	O
tested	O
SCOPE	O
on	O
an	O
extensive	O
array	O
of	O
regulons	O
with	O
known	O
binding	O
sites	O
(	O
for	O
details	O
of	O
datasets	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
)	O
.	O

We	O
ran	O
SCOPE	O
on	O
each	O
regulon	O
and	O
,	O
following	O
the	O
scoring	O
methodology	O
used	O
by	O
Sinha	O
and	O
Tompa	O
6	O
,	O
we	O
computed	O
the	O
accuracy	O
for	O
each	O
of	O
the	O
top	O
three	O
motifs	O
reported	O
by	O
SCOPE	O
against	O
the	O
known	O
binding	O
sites	O
.	O

The	O
motifs	O
reported	O
by	O
SCOPE	O
overlap	O
to	O
a	O
large	O
extent	O
with	O
the	O
published	O
cis-regulatory	O
elements	O
(	O
as	O
discussed	O
in	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
,	O
a	O
difference	O
of	O
one	O
base	O
pair	O
length	O
between	O
the	O
reported	O
motif	O
and	O
the	O
published	O
cis-regulatory	O
element	O
results	O
in	O
an	O
expected	O
accuracy	O
of	O
about	O
0.25	O
)	O
.	O

SCOPE	O
was	O
run	O
on	O
78	O
regulons	O
from	O
S.	O
cerevisiae	O
,	O
B.	O
subtilis	O
,	O
E.	O
coli	O
and	O
D.	O
melanogaster	O
.	O

On	O
these	O
datasets	O
,	O
SCOPE	O
's	O
average	O
accuracy	O
was	O
0.28	O
,	O
0.29	O
,	O
0.16	O
,	O
and	O
0.08	O
respectively	O
.	O

SCOPE	O
's	O
reported	O
accuracy	O
was	O
significantly	O
higher	O
than	O
any	O
of	O
its	O
component	O
algorithms	O
(	O
Table	O
1	O
)	O
.	O

Indeed	O
,	O
we	O
found	O
that	O
SCOPE	O
increased	O
accuracy	O
by	O
3144	O
%	O
over	O
BEAM	O
,	O
PRISM	O
or	O
SPACER	O
alone	O
.	O

This	O
improvement	O
was	O
achieved	O
by	O
combining	O
BEAM	O
's	O
high	O
positive	O
predictive	O
value	O
(	O
PPV	O
)	O
with	O
PRISM	O
's	O
high	O
sensitivity	O
(	O
Figure	O
4	O
)	O
.	O

Sensitivity	O
is	O
defined	O
here	O
as	O
the	O
fraction	O
of	O
the	O
known	O
binding	O
sites	O
(	O
at	O
the	O
nucleotide	O
level	O
)	O
predicted	O
by	O
the	O
motif	O
finder	O
,	O
and	O
PPV	O
is	O
defined	O
as	O
the	O
fraction	O
of	O
nucleotides	O
predicted	O
by	O
the	O
motif	O
finder	O
that	O
correspond	O
to	O
the	O
known	O
binding	O
sites	O
(	O
see	O
Methods	O
for	O
details	O
)	O
.	O

Summary	O
results	O
for	O
performance	O
comparisons	O
between	O
SCOPE	O
and	O
its	O
component	O
algorithms	O
,	O
on	O
all	O
regulons	O
.	O

A	O
``	O
Win	O
``	O
is	O
a	O
regulon	O
for	O
which	O
a	O
program	O
had	O
the	O
highest	O
accuracy	O
and	O
that	O
accuracy	O
was	O
at	O
least	O
0.10	O
.	O

Programs	O
in	O
a	O
two-way	O
tie	O
are	O
credited	O
with	O
0.5	O
wins	O
each	O
,	O
so	O
by	O
construction	O
,	O
SCOPE	O
can	O
at	O
best	O
share	O
a	O
win	O
with	O
one	O
of	O
the	O
other	O
programs	O
.	O

A	O
perfect	O
winner-take-all	O
ensemble	O
method	O
would	O
have	O
the	O
same	O
number	O
of	O
wins	O
as	O
all	O
the	O
component	O
algorithms	O
combined	O
.	O

A	O
``	O
clear	O
win	O
(	O
loss	O
)	O
``	O
is	O
a	O
regulon	O
for	O
which	O
SCOPE	O
's	O
accuracy	O
was	O
at	O
least	O
0.10	O
higher	O
(	O
lower	O
)	O
than	O
the	O
other	O
program	O
.	O

The	O
p-value	O
reported	O
for	O
the	O
paired	O
t-test	O
was	O
Bonferroni-corrected	O
to	O
account	O
for	O
multiple	O
(	O
three	O
)	O
comparisons	O
.	O

Average	O
and	O
standard	O
error	O
of	O
sensitivity	O
and	O
PPV	O
for	O
the	O
component	O
algorithms	O
of	O
SCOPE	O
on	O
all	O
78	O
regulons	O

Average	O
and	O
standard	O
error	O
of	O
sensitivity	O
and	O
PPV	O
for	O
the	O
component	O
algorithms	O
of	O
SCOPE	O
on	O
all	O
78	O
regulons	O
.	O

Bars	O
represent	O
standard	O
error	O
.	O

An	O
ensemble	O
motif	O
finder	O
with	O
a	O
learning	O
rule	O
that	O
is	O
no	B-Negation
better	I-Negation
than	I-Negation
random	I-Negation
will	O
provide	O
an	O
accuracy	O
that	O
is	O
equal	O
to	O
the	O
average	O
of	O
its	O
three	O
component	O
algorithms	O
.	O

To	O
provide	O
a	O
basis	O
for	O
evaluating	O
the	O
performance	O
of	O
SCOPE	O
's	O
learning	O
rule	O
,	O
we	O
constructed	O
an	O
ensemble	O
learning	O
method	O
(	O
referred	O
to	O
here	O
as	O
BASELINE	O
)	O
from	O
the	O
results	O
of	O
BEAM	O
,	O
PRISM	O
and	O
SPACER	O
,	O
by	O
randomly	O
selecting	O
one	O
of	O
the	O
accuracies	O
from	O
these	O
three	O
programs	O
for	O
each	O
regulon	O
.	O

Over	O
120,000	O
trials	O
,	O
BASELINE	O
's	O
average	O
performance	O
on	O
this	O
dataset	O
was	O
0.176	O
with	O
a	O
standard	O
deviation	O
of	O
0.013	O
.	O

BASELINE	O
's	O
average	O
score	O
never	O
exceeded	O
that	O
of	O
SCOPE	O
(	O
p	O
<	O
8.25	O
	O
10-6	O
)	O
.	O

When	O
compared	O
to	O
its	O
component	O
algorithms	O
,	O
SCOPE	O
picked	O
the	O
highest	O
accuracy	O
motif	O
in	O
66	O
%	O
of	O
the	O
cases	O
(	O
as	O
opposed	O
to	O
33	O
%	O
for	O
a	O
random	O
selection	O
between	O
three	O
algorithms	O
)	O
.	O

These	O
results	O
suggest	O
that	O
SCOPE	O
's	O
learning	O
rule	O
is	O
highly	O
effective	O
,	O
though	O
it	O
may	O
certainly	O
be	O
improved	O
further	O
.	O

Of	O
course	O
,	O
SCOPE	O
's	O
learning	O
rule	O
is	O
extremely	O
simple	O
,	O
and	O
more	O
complex	O
learning	O
rules	O
may	O
allow	O
SCOPE	O
to	O
approach	O
its	O
theoretical	O
upper	O
bound	O
.	O

One	O
rule	O
that	O
may	O
prove	O
effective	O
is	O
to	O
weight	O
the	O
output	O
of	O
each	O
algorithm	O
according	O
to	O
(	O
for	O
example	O
)	O
the	O
frequency	O
of	O
occurrence	O
of	O
each	O
class	O
of	O
motif	O
(	O
non-degenerate	O
,	O
short	O
degenerate	O
or	O
long	O
degenerate	O
)	O
in	O
the	O
species	O
or	O
by	O
learning	O
the	O
appropriate	O
weights	O
on	O
a	O
representative	O
training	O
set	O
,	O
creating	O
,	O
in	O
effect	O
,	O
a	O
Nave	O
Bayesian	O
Network	O
.	O

The	O
training	O
of	O
a	O
more	O
complex	O
learning	O
rule	O
must	O
,	O
however	O
,	O
be	O
performed	O
in	O
a	O
cross-validation	O
framework	O
,	O
and	O
the	O
size	O
of	O
the	O
available	O
dataset	O
of	O
regulons	O
will	O
place	O
a	O
practical	O
limit	O
on	O
the	O
complexity	O
of	O
the	O
learning	O
rule	O
that	O
can	O
be	O
devised	O
.	O

Comparison	O
with	O
other	O
motif	O
finding	O
programs	O

To	O
provide	O
a	O
frame	O
of	O
reference	O
for	O
SCOPE	O
's	O
performance	O
,	O
we	O
ran	O
ten	O
other	O
popular	O
motif	O
finders	O
on	O
these	O
datasets	O
(	O
for	O
details	O
and	O
references	O
see	O
Table	O
2	O
)	O
.	O

We	O
ran	O
all	O
programs	O
directly	O
from	O
their	O
websites	O
,	O
leaving	O
all	O
parameters	O
at	O
their	O
defaults	O
.	O

The	O
only	O
parameter	O
that	O
we	O
specified	O
(	O
where	O
available	O
)	O
was	O
the	O
species	O
from	O
which	O
the	O
background	O
sequences	O
were	O
derived	O
.	O

Thus	O
,	O
the	O
results	O
of	O
this	O
performance	O
comparison	O
may	O
be	O
interpreted	O
as	O
a	O
comparison	O
against	O
other	O
motif	O
finders	O
when	O
those	O
motif	O
finders	O
are	O
run	O
using	O
their	O
default	O
values	O
.	O

Motif	O
discovery	O
algorithms	O
used	O
in	O
the	O
performance	O
comparison	O
.	O

Nuisance	O
parameters	O
are	O
parameters	O
that	O
can	O
not	O
be	O
precisely	O
defined	O
without	O
knowledge	O
of	O
the	O
true	O
binding	O
sites	O
(	O
such	O
as	O
motif	O
length	O
,	O
number	O
of	O
occurrences	O
and	O
orientation	O
)	O
.	O

For	O
MotifSampler	O
and	O
wConsensus	O
,	O
the	O
lower	O
part	O
of	O
the	O
range	O
indicates	O
required	O
parameters	O
,	O
while	O
the	O
upper	O
part	O
indicates	O
the	O
total	O
number	O
of	O
parameters	O
,	O
including	O
``	O
power	O
user	O
``	O
parameters	O
that	O
the	O
program	O
authors	O
stress	O
should	O
typically	O
be	O
left	O
as	O
default	O
.	O

Motif	O
model	O
abbreviations	O
:	O
cons	O
=	O
consensus	O
;	O
PWM	O
=	O
position	O
weight	O
matrix	O
;	O
mis	O
=	O
consensus	O
with	O
predefined	O
number	O
of	O
allowed	O
non-position-specific	O
mismatches	O
.	O

SCOPE	O
has	O
no	B-Negation
user-adjustable	I-Negation
parameters	I-Negation
,	O
although	O
its	O
component	O
algorithms	O
do	O
contain	O
a	O
number	O
of	O
internal	O
parameters	O
``	O
(	O
``	O
hyperparameters	O
``	O
)	O
``	O
that	O
govern	O
their	O
search	O
over	O
common	O
nuisance	O
parameters	O
.	O

On	O
synthetic	O
datasets	O
,	O
we	O
found	O
SCOPE	O
's	O
component	O
algorithms	O
to	O
be	O
quite	O
robust	O
to	O
the	O
settings	O
of	O
these	O
hyperparameters	O
.	O

We	O
have	O
therefore	O
fixed	O
those	O
parameters	O
to	O
reasonable	O
values	O
and	O
do	O
not	B-Negation
expose	I-Negation
them	I-Negation
to	I-Negation
the	I-Negation
user	I-Negation
101112	O
.	O

This	O
construction	O
means	O
that	O
SCOPE	O
can	O
only	O
run	O
in	O
a	O
default	O
configuration	O
.	O

We	O
compared	O
the	O
motif	O
finding	O
programs	O
using	O
the	O
criteria	O
set	O
forth	O
in	O
Sinha	O
and	O
Tompa	O
,	O
including	O
average	O
accuracy	O
and	O
the	O
number	O
of	O
total	O
wins	O
(	O
highest	O
accuracy	O
on	O
a	O
regulon	O
,	O
where	O
that	O
accuracy	O
is	O
at	O
least	O
0.1	O
)	O
6	O
.	O

On	O
this	O
dataset	O
,	O
SCOPE	O
had	O
the	O
highest	O
score	O
by	O
both	O
criteria	O
(	O
Figure	O
5a	O
)	O
.	O

The	O
cumulative	O
distribution	O
of	O
accuracy	O
shows	O
that	O
SCOPE	O
had	O
the	O
most	O
high-scoring	O
motifs	O
at	O
every	O
level	O
(	O
Figure	O
5b	O
)	O
.	O

When	O
we	O
looked	O
at	O
the	O
number	O
of	O
clear	O
head-to-head	O
wins	O
(	O
such	O
a	O
win	O
is	O
taken	O
to	O
occur	O
when	O
the	O
difference	O
in	O
accuracy	O
between	O
SCOPE	O
and	O
another	O
motif	O
finder	O
is	O
greater	O
than	O
0.1	O
6	O
)	O
,	O
we	O
found	O
that	O
SCOPE	O
scored	O
a	O
clear	O
majority	O
(	O
82	O
%	O
)	O
of	O
clear	O
head-to-head	O
wins	O
(	O
Figure	O
5c	O
)	O
.	O

The	O
average	O
accuracies	O
of	O
BEAM	O
,	O
PRISM	O
and	O
SPACER	O
on	O
this	O
dataset	O
were	O
similar	O
to	O
those	O
of	O
the	O
ten	O
other	O
programs	O
.	O

Performance	O
comparisons	O

Performance	O
comparisons	O
.	O

(	O
a	O
)	O
Mean	O
and	O
standard	O
error	O
of	O
accuracy	O
for	O
each	O
of	O
78	O
regulons	O
.	O

(	O
b	O
)	O
Cumulative	O
distribution	O
of	O
accuracy	O
for	O
each	O
program	O
.	O

(	O
c	O
)	O
Fraction	O
of	O
regulons	O
with	O
a	O
clear	O
outcome	O
(	O
margin	O
of	O
difference	O
in	O
accuracy	O
between	O
two	O
programs	O
was	O
greater	O
than	O
0.10	O
)	O
won	O
by	O
SCOPE	O
.	O

Program	O
abbreviations	O
and	O
details	O
in	O
Table	O
2	O
;	O
performance	O
details	O
in	O
tables	O
S1	O
and	O
S2	O
in	O
Additional	O
file	O
1	O
.	O

A	O
formal	O
statistical	O
analysis	O
found	O
that	O
SCOPE	O
's	O
performance	O
margin	O
over	O
the	O
other	O
motif	O
finders	O
run	O
on	O
this	O
dataset	O
was	O
statistically	O
significant	O
at	O
p	O
<	O
10-5	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
)	O
.	O

Corroborating	O
the	O
results	O
of	O
previously	O
published	O
performance	O
comparisons	O
@	O
14567	O
@	O
,	O
none	B-Negation
of	I-Negation
the	I-Negation
other	I-Negation
programs	I-Negation
showed	I-Negation
a	I-Negation
statistically	I-Negation
significant	I-Negation
difference	I-Negation
relative	I-Negation
to	I-Negation
the	I-Negation
other	I-Negation
nine	I-Negation
.	O

Similarly	O
,	O
none	B-Negation
of	I-Negation
SCOPE	I-Negation
's	I-Negation
component	I-Negation
algorithms	I-Negation
outperformed	I-Negation
the	I-Negation
other	I-Negation
ten	I-Negation
programs	I-Negation
on	I-Negation
this	I-Negation
dataset	I-Negation
by	I-Negation
a	I-Negation
statistically	I-Negation
significant	I-Negation
margin	I-Negation
.	O

SCOPE	O
's	O
high	O
accuracy	O
was	O
a	O
reflection	O
of	O
both	O
high	O
PPV	O
and	O
high	O
sensitivity	O
(	O
Figure	O
6a	O
;	O
see	O
Methods	O
for	O
a	O
precise	O
definition	O
)	O
.	O

By	O
these	O
measures	O
,	O
SCOPE	O
was	O
the	O
only	O
program	O
that	O
scored	O
highly	O
in	O
both	O
sensitivity	O
and	O
PPV	O
(	O
ranking	O
first	O
and	O
second	O
respectively	O
)	O
.	O

In	O
contrast	O
,	O
none	B-Negation
of	I-Negation
the	I-Negation
other	I-Negation
motif	I-Negation
finders	I-Negation
that	I-Negation
performed	I-Negation
well	I-Negation
by	I-Negation
one	I-Negation
criterion	I-Negation
performed	I-Negation
well	I-Negation
by	I-Negation
the	I-Negation
other	I-Negation
,	O
as	O
shown	O
by	O
the	O
average	O
ranks	O
for	O
each	O
motif	O
finder	O
over	O
both	O
sensitivity	O
and	O
PPV	O
(	O
Figure	O
6b	O
)	O
.	O

(	O
a	O
)	O
Average	O
and	O
standard	O
error	O
of	O
sensitivity	O
and	O
PPV	O
for	O
each	O
program	O
on	O
all	O
78	O
regulons	O

(	O
a	O
)	O
Average	O
and	O
standard	O
error	O
of	O
sensitivity	O
and	O
PPV	O
for	O
each	O
program	O
on	O
all	O
78	O
regulons	O
.	O

In	O
cases	O
where	O
the	O
program	O
failed	B-Negation
to	I-Negation
return	I-Negation
a	I-Negation
result	I-Negation
,	O
the	O
sensitivity	O
is	O
0	O
and	O
the	O
PPV	O
is	O
undefined	O
.	O

Cases	B-Negation
where	I-Negation
a	I-Negation
program	I-Negation
did	I-Negation
not	I-Negation
support	I-Negation
the	I-Negation
species	I-Negation
were	I-Negation
not	I-Negation
included	I-Negation
.	O

(	O
b	O
)	O
Ranks	O
on	O
this	O
plot	O
were	O
computed	O
by	O
taking	O
the	O
average	O
of	O
sensitivity	O
and	O
PPV	O
ranks	O
for	O
each	O
program	O
.	O

Performance	O
in	O
the	O
presence	O
of	O
extraneous	O
upstream	O
sequences	O

In	O
practice	O
,	O
microarray	O
co-expression	O
data	O
are	O
often	O
used	O
to	O
identify	O
genes	O
in	O
a	O
particular	O
regulon	O
.	O

This	O
approach	O
identifies	O
genes	O
that	O
are	O
either	O
directly	O
or	O
indirectly	O
regulated	O
by	O
the	O
transcription	O
factor	O
of	O
interest	O
.	O

Therefore	O
,	O
sets	O
of	O
genes	O
identified	O
from	O
co-expression	O
data	O
may	O
often	O
contain	O
multiple	O
extraneous	O
upstream	O
sequences	O
.	O

Adding	O
sequences	O
that	O
do	O
not	B-Negation
contain	I-Negation
binding	I-Negation
sites	I-Negation
decreases	O
the	O
signal-to-noise	O
ratio	O
,	O
making	O
motif	O
finding	O
more	O
difficult	O
4	O
.	O

We	O
thus	O
tested	O
SCOPE	O
's	O
performance	O
on	O
regulons	O
containing	O
additional	O
extraneous	O
upstream	O
sequences	O
.	O

For	O
all	O
33	O
regulons	O
in	O
the	O
SCPD	O
dataset	O
,	O
we	O
added	O
randomly	O
selected	O
upstream	O
S.	O
cerevisiae	O
sequences	O
such	O
that	O
the	O
total	O
number	O
of	O
extraneous	O
sequences	O
was	O
between	O
0.5	O
and	O
4	O
times	O
the	O
number	O
of	O
true	O
upstream	O
sequences	O
in	O
the	O
regulon	O
.	O

SCOPE	O
's	O
accuracy	O
on	O
this	O
dataset	O
was	O
remarkably	O
stable	O
in	O
the	O
presence	O
of	O
extraneous	O
sequences	O
.	O

Figure	O
7	O
shows	O
the	O
aggregate	O
results	O
of	O
this	O
test	O
,	O
with	O
the	O
SCPD	O
regulons	O
divided	O
into	O
three	O
groups	O
based	O
on	O
SCOPE	O
's	O
accuracy	O
on	O
the	O
true	O
regulon	O
.	O

For	O
each	O
set	O
of	O
regulons	O
,	O
SCOPE	O
's	O
performance	O
decayed	O
gradually	O
as	O
increasing	O
numbers	O
of	O
extraneous	O
genes	O
were	O
added	O
to	O
the	O
regulon	O
.	O

These	O
results	O
were	O
consistent	O
with	O
the	O
relationship	O
between	O
the	O
Sig	O
score	O
and	O
performance	O
on	O
synthetic	O
datasets	O
(	O
Figure	O
2	O
)	O
.	O

Robustness	O
of	O
SCOPE	O
performance	O
on	O
S.	O
cerevisiae	O
regulons	O
containing	O
extraneous	O
upstream	O
sequences	O

Robustness	O
of	O
SCOPE	O
performance	O
on	O
S.	O
cerevisiae	O
regulons	O
containing	O
extraneous	O
upstream	O
sequences	O
.	O

Increasing	O
quantities	O
of	O
randomly	O
selected	O
upstream	O
regions	O
were	O
added	O
to	O
each	O
regulon	O
.	O

The	O
bold	O
red	O
line	O
is	O
the	O
average	O
across	O
all	O
regulons	O
,	O
while	O
each	O
of	O
the	O
other	O
lines	O
represent	O
the	O
performance	O
of	O
SCOPE	O
on	O
one-third	O
of	O
the	O
total	O
S.	O
cerevisiae	O
regulons	O
.	O

The	O
y-axis	O
shows	O
the	O
average	O
accuracy	O
for	O
each	O
group	O
of	O
regulons	O
.	O

The	O
x-axis	O
shows	O
the	O
ratio	O
of	O
extraneous	O
upstream	O
sequences	O
to	O
bona	O
fide	O
ones	O
.	O

Discussion	O

The	O
field	O
of	O
motif	O
finding	O
is	O
saturated	O
with	O
a	O
large	O
number	O
of	O
algorithms	O
representing	O
myriad	O
search	O
strategies	O
,	O
objective	O
functions	O
and	O
motif	O
models	O
.	O

Yet	O
remarkably	O
,	O
performance	O
comparisons	O
consistently	O
reveal	O
disappointing	O
performance	O
for	O
motif	O
finders	O
and	O
fail	B-Negation
to	I-Negation
find	I-Negation
any	I-Negation
statistical	I-Negation
significance	I-Negation
between	I-Negation
them	I-Negation
.	O

A	O
brief	O
survey	O
of	O
the	O
per-regulon	O
results	O
of	O
these	O
performance	O
comparisons	O
yields	O
two	O
key	O
observations	O
:	O
(	O
1	O
)	O
there	O
are	O
many	O
regulons	O
for	O
which	O
a	O
large	O
number	O
of	O
programs	O
find	O
a	O
small	O
portion	O
of	O
the	O
binding	O
sites	O
(	O
though	O
not	O
necessarily	O
the	O
same	O
portion	O
)	O
;	O
and	O
(	O
2	O
)	O
every	O
program	O
has	O
a	O
respectable	O
number	O
of	O
``	O
wins	O
``	O
(	O
i.e.	O
every	O
program	O
is	O
the	O
best	O
existing	O
program	O
on	O
some	O
handful	O
of	O
regulons	O
145678	O
.	O

Such	O
observations	O
are	O
common	O
in	O
many	O
machine	O
learning	O
applications	O
,	O
and	O
are	O
the	O
direct	O
result	O
of	O
complex	O
search	O
spaces	O
that	O
force	O
restrictions	O
on	O
either	O
the	O
search	O
strategy	O
or	O
the	O
representation	O
of	O
the	O
solution	O
space	O
(	O
in	O
this	O
case	O
,	O
the	O
motif	O
model	O
used	O
to	O
represent	O
the	O
motifs	O
)	O
.	O

For	O
example	O
,	O
YMF	O
and	O
RSAT	O
are	O
guaranteed	O
to	O
find	O
the	O
optimal	O
solutions	O
in	O
their	O
motif	O
space	O
(	O
fixed-length	O
motifs	O
with	O
limited	O
degeneracies	O
)	O
,	O
but	O
that	O
space	O
is	O
limited	O
to	O
the	O
point	O
that	O
optimality	O
provides	O
no	O
clear	O
advantage	O
over	O
the	O
other	O
methods	O
.	O

Conversely	O
,	O
the	O
PWM-based	O
methods	O
have	O
an	O
apparently	O
more	O
powerful	O
motif	O
model	O
17	O
,	O
but	O
their	O
search	O
strategies	O
can	B-Negation
not	I-Negation
guarantee	I-Negation
optimality	I-Negation
and	O
often	O
terminate	O
at	O
local	O
optima	O
.	O

The	O
HLK	O
ensemble	O
method	O
4	O
successfully	O
exploits	O
the	O
first	O
key	O
observation	O
above	O
.	O

By	O
running	O
the	O
same	O
(	O
stochastic	O
)	O
algorithm	O
multiple	O
times	O
and	O
using	O
a	O
voting	O
method	O
,	O
those	O
subsequences	O
of	O
the	O
binding	O
sites	O
that	O
are	O
repeatedly	O
reported	O
become	O
clear	O
while	O
the	O
spurious	O
bases	O
are	O
eliminated	O
.	O

Hu	O
and	O
colleagues	O
report	O
that	O
this	O
method	O
increased	O
accuracy	O
and	O
proposed	O
that	O
their	O
approach	O
may	O
prove	O
effective	O
when	O
running	O
different	O
algorithms	O
as	O
well	O
4	O
.	O

The	O
limitation	O
arises	O
,	O
however	O
,	O
in	O
regulons	O
where	O
only	O
one	O
program	O
has	O
a	O
high	O
accuracy	O
and	O
the	O
others	O
fail	B-Negation
to	I-Negation
find	I-Negation
any	I-Negation
portion	I-Negation
of	I-Negation
the	I-Negation
binding	I-Negation
sites	I-Negation
.	O

In	O
such	O
cases	O
,	O
it	O
is	O
likely	O
that	O
a	O
voting-based	O
ensemble	O
will	O
follow	O
the	O
crowd	O
and	O
fail	O
to	O
find	O
the	O
true	O
binding	O
site	O
.	O

The	O
second	O
observation	O
,	O
that	O
all	O
motif	O
finders	O
win	O
some	O
number	O
of	O
regulons	O
and	O
often	O
perform	O
roughly	O
the	O
same	O
on	O
average	O
,	O
is	O
broadly	O
consistent	O
with	O
a	O
theorem	O
in	O
the	O
Machine	O
Learning	O
field	O
referred	O
to	O
as	O
the	O
No	O
Free	O
Lunch	O
Theorem	O
1819	O
.	O

Briefly	O
,	O
this	O
theorem	O
states	O
that	O
,	O
averaged	O
over	O
all	O
datasets	O
,	O
the	O
performance	O
of	O
all	O
search	O
algorithms	O
are	O
exactly	O
the	O
same	O
,	O
with	O
the	O
corollary	O
that	O
two	O
algorithms	O
will	O
have	O
the	O
exact	O
same	O
number	O
of	O
wins	O
in	O
relation	O
to	O
each	O
other	O
.	O

In	O
practice	O
,	O
this	O
theorem	O
argues	O
for	O
the	O
use	O
of	O
specialized	O
domain	O
knowledge	O
20	O
,	O
where	O
available	O
,	O
and	O
may	O
suggest	O
that	O
similar	O
average	O
performance	O
across	O
a	O
diversity	O
of	O
approaches	O
is	O
an	O
indication	O
of	O
the	O
diversity	O
of	O
the	O
datasets	O
themselves	O
.	O

Thus	O
,	O
motif	O
finders	O
designed	O
for	O
one	O
class	O
of	O
motifs	O
will	O
win	O
on	O
regulons	O
containing	O
those	O
motifs	O
,	O
but	O
will	O
perform	O
poorly	O
on	O
other	O
regulons	O
,	O
while	O
more	O
general	O
motif	O
finders	O
will	O
tend	O
to	O
have	O
more	O
consistently	O
mediocre	O
performance	O
.	O

In	O
this	O
light	O
,	O
SCOPE	B-Speculation
can	I-Speculation
be	I-Speculation
seen	I-Speculation
as	I-Speculation
leveraging	I-Speculation
the	I-Speculation
second	I-Speculation
key	I-Speculation
observation	I-Speculation
by	I-Speculation
embracing	I-Speculation
the	I-Speculation
No	I-Speculation
Free	I-Speculation
Lunch	I-Speculation
Theorem	I-Speculation
:	O
:	O
rather	B-Negation
than	I-Negation
boost	I-Negation
average	I-Negation
performance	I-Negation
by	I-Negation
taking	I-Negation
the	I-Negation
average	I-Negation
results	I-Negation
of	I-Negation
three	I-Negation
general	I-Negation
purpose	I-Negation
algorithms	I-Negation
,	O
SCOPE	O
uses	O
highly	O
specialized	O
algorithms	O
and	O
assumes	B-Speculation
each	I-Speculation
will	I-Speculation
perform	I-Speculation
strongly	I-Speculation
on	I-Speculation
some	I-Speculation
regulons	I-Speculation
and	I-Speculation
weakly	I-Speculation
on	I-Speculation
others	I-Speculation
(	I-Speculation
and	I-Speculation
that	I-Speculation
the	I-Speculation
unified	I-Speculation
scoring	I-Speculation
metric	I-Speculation
can	I-Speculation
tell	I-Speculation
the	I-Speculation
difference	I-Speculation
)	I-Speculation
.	O

The	O
working	O
hypothesis	O
is	O
,	O
in	O
effect	O
,	O
that	O
the	O
local	O
maxima	O
are	O
predictable	O
(	O
corresponding	O
to	O
one	O
of	O
three	O
motif	O
classes	O
)	O
and	O
exploitable	O
(	O
we	O
can	O
find	O
the	O
local	O
maxima	O
in	O
each	O
class	O
and	O
choose	O
whichever	O
is	O
higher	O
)	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
there	O
was	O
very	O
little	O
overlap	O
among	O
the	O
component	O
algorithms	O
of	O
SCOPE	O
(	O
each	O
wins	O
about	O
20	O
of	O
the	O
78	O
regulons	O
,	O
with	O
very	O
few	O
ties	O
)	O
and	O
,	O
by	O
taking	O
the	O
maximum	O
score	O
from	O
those	O
three	O
local	O
maxima	O
,	O
SCOPE	O
tended	O
to	O
choose	O
the	O
motif	O
with	O
the	O
highest	O
accuracy	O
in	O
a	O
clear	O
majority	O
of	O
the	O
cases	O
(	O
66	O
%	O
,	O
compared	O
to	O
33	O
%	O
for	O
a	O
random	O
learning	O
rule	O
)	O
.	O

Furthermore	O
,	O
SCOPE	O
not	O
only	O
significantly	O
outperformed	O
its	O
components	O
on	O
this	O
dataset	O
,	O
it	O
also	O
outperformed	O
a	O
number	O
of	O
general	O
purpose	O
algorithms	O
that	O
seek	O
to	O
find	O
the	O
global	O
maximum	O
in	O
a	O
single	O
pass	O
.	O

Of	O
course	O
,	O
based	O
on	O
the	O
No	O
Free	O
Lunch	O
Theorem	O
,	O
SCOPE	O
's	O
performance	O
averaged	O
over	O
all	O
theoretically	O
possible	O
datasets	O
will	O
still	O
converge	O
to	O
that	O
of	O
the	O
other	O
motif	O
finding	O
approaches	O
(	O
including	O
random	O
guessing	O
)	O
.	O

As	O
the	O
physical	O
properties	O
of	O
transcription	O
factors	O
will	O
inevitably	O
constrain	O
the	O
structure	O
of	O
their	O
binding	O
sites	O
,	O
biologically	O
relevant	O
datasets	O
comprise	O
a	O
subset	O
of	O
the	O
space	O
of	O
all	O
theoretically	O
possible	O
sequences	O
.	O

Our	O
test	O
set	O
of	O
78	O
regulons	O
was	O
selected	O
in	O
a	O
blinded	O
manner	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
)	O
,	O
thus	O
these	O
results	O
suggest	O
the	O
generalizability	O
of	O
SCOPE	O
's	O
use	O
of	O
domain	O
knowledge	O
on	O
biologically	O
relevant	O
datasets	O
from	O
these	O
species	O
.	O

These	B-Negation
observations	I-Negation
are	I-Negation
not	I-Negation
offered	I-Negation
as	I-Negation
definitive	I-Negation
proof	I-Negation
that	I-Negation
there	I-Negation
are	I-Negation
only	I-Negation
three	I-Negation
classes	I-Negation
of	I-Negation
motifs	I-Negation
;	O
rather	O
,	O
they	O
show	O
that	O
power	O
can	O
be	O
gained	O
by	O
identifying	O
distinct	O
motif	O
classes	O
and	O
combining	O
specialized	O
algorithms	O
with	O
a	O
unified	O
scoring	O
rule	O
.	O

It	O
is	O
possible	O
that	O
more	O
power	O
could	O
be	O
gained	O
by	O
identifying	O
other	O
distinct	O
motif	O
classes	O
and	O
adding	O
algorithms	O
that	O
explicitly	O
search	O
for	O
those	O
classes	O
.	O

For	O
example	O
,	O
Zinc	O
finger	O
transcription	O
factors	O
have	O
been	O
demonstrated	O
to	O
bind	O
three	O
triplets	O
of	O
nucleotides	O
which	O
overlap	O
at	O
their	O
third	O
base	O
positions	O
21	O
.	O

This	O
observation	O
could	O
be	O
leveraged	O
by	O
a	O
search	O
algorithm	O
that	O
explicitly	O
searches	O
for	O
motifs	O
matching	O
this	O
unique	O
structure	O
.	O

Thus	O
,	O
all	O
nondegenerate	O
triplets	O
in	O
a	O
set	O
of	O
upstream	O
regions	O
could	O
be	O
scored	O
and	O
the	O
highest-scoring	O
triplets	O
combined	O
into	O
a	O
single	O
five-mer	O
with	O
a	O
two-base	O
degeneracy	O
(	O
corresponding	O
to	O
the	O
IUPAC	O
characters	O
R	O
,	O
Y	O
,	O
W	O
,	O
S	O
,	O
K	O
or	O
M	O
)	O
at	O
the	O
middle	O
position	O
.	O

The	O
highest-scoring	O
five-mers	O
could	O
then	O
be	O
combined	O
with	O
the	O
highest	O
scoring	O
triplets	O
to	O
generate	O
a	O
seven-mer	O
with	O
two-base	O
degeneracies	O
at	O
positions	O
three	O
and	O
five	O
.	O

Provided	O
the	O
appropriate	O
Bonferroni	O
correction	O
is	O
applied	O
for	O
this	O
new	O
class	O
of	O
motifs	O
,	O
these	O
motifs	O
may	O
be	O
easily	O
compared	O
with	O
the	O
results	O
from	O
BEAM	O
,	O
PRISM	O
and	O
SPACER	O
,	O
thereby	O
extending	O
the	O
SCOPE	O
ensemble	O
to	O
include	O
a	O
fourth	O
class	O
of	O
motifs	O
.	O

We	O
note	O
,	O
however	O
,	O
that	O
as	O
more	O
methods	O
are	O
added	O
to	O
SCOPE	O
,	O
it	O
will	O
be	O
increasingly	O
difficult	O
to	O
devise	O
a	O
scoring	O
metric	O
that	O
can	O
accurately	O
choose	O
the	O
best	O
result	O
from	O
among	O
the	O
components	O
.	O

SCOPE	O
may	O
also	O
serve	O
as	O
a	O
complementary	O
approach	O
to	O
the	O
HLK	O
method	O
.	O

For	O
example	O
,	O
the	O
parameters	O
of	O
many	O
methods	O
can	O
be	O
set	O
to	O
search	O
for	O
specific	O
classes	O
of	O
motifs	O
(	O
such	O
as	O
bipartite	O
versus	O
non-bipartite	O
motifs	O
)	O
.	O

Thus	O
,	O
analogous	O
to	O
the	O
ensemble	O
method	O
described	O
in	O
this	O
paper	O
,	O
one	O
may	O
build	O
a	O
hierarchical	O
ensemble	O
that	O
first	O
searches	O
each	O
motif	O
class	O
by	O
the	O
HLK	O
method	O
using	O
a	O
number	O
of	O
algorithms	O
or	O
random	O
restarts	O
,	O
and	O
then	O
uses	O
the	O
SCOPE	O
method	O
to	O
choose	O
the	O
best	O
result	O
from	O
among	O
the	O
motif	O
classes	O
.	O

One	O
constraint	O
associated	O
with	O
such	O
an	O
approach	O
is	O
the	O
run-time	O
.	O

A	O
second	O
constraint	O
associated	O
with	O
a	O
hierarchical	O
ensemble	O
learning	O
method	O
is	O
the	O
multiplicative	O
increase	O
in	O
the	O
number	O
of	O
parameters	O
associated	O
with	O
it	O
,	O
though	O
this	O
problem	O
may	O
be	O
ameliorated	O
by	O
the	O
use	O
of	O
parameter-free	O
algorithms	O
that	O
employ	O
restricted	O
search	O
spaces	O
.	O

An	O
important	O
factor	O
to	O
consider	O
when	O
taking	O
the	O
best	O
of	O
multiple	O
runs	O
is	O
the	O
relative	O
size	O
of	O
the	O
search	O
space	O
.	O

Certainly	O
to	O
maintain	O
statistical	O
validity	O
,	O
some	O
correction	O
must	O
be	O
made	O
for	O
multiple	O
hypothesis	O
testing	O
.	O

Furthermore	O
,	O
the	O
effects	O
of	O
multiple	O
testing	O
may	O
bias	O
the	O
results	O
in	O
favor	O
of	O
one	O
of	O
the	O
component	O
algorithms	O
.	O

To	O
ensure	O
statistical	O
validity	O
and	O
avoid	O
such	O
a	O
bias	O
,	O
we	O
developed	O
a	O
simple	O
Bonferroni-like	O
correction	O
,	O
which	O
penalized	O
every	O
proposed	O
motif	O
proportional	O
to	O
its	O
length	O
and	O
degree	O
of	O
degeneracy	O
,	O
resulting	O
in	O
a	O
modest	O
improvement	O
of	O
8	O
%	O
in	O
SCOPE	O
's	O
accuracy	O
.	O

Although	O
our	O
test	O
set	O
of	O
78	O
regulons	O
gave	O
us	O
enough	O
power	O
to	O
find	O
significance	O
between	O
SCOPE	O
and	O
its	O
components	O
or	O
other	O
algorithms	O
,	O
it	O
did	O
not	B-Negation
provide	I-Negation
enough	I-Negation
power	I-Negation
to	I-Negation
disentangle	I-Negation
the	I-Negation
effects	I-Negation
of	I-Negation
small	I-Negation
improvements	I-Negation
(	I-Negation
such	I-Negation
as	I-Negation
the	I-Negation
Bonferroni	I-Negation
correction	I-Negation
,	I-Negation
the	I-Negation
objective	I-Negation
function	I-Negation
that	I-Negation
takes	I-Negation
position	I-Negation
bias	I-Negation
into	I-Negation
account	I-Negation
,	I-Negation
or	I-Negation
scoring	I-Negation
motifs	I-Negation
based	I-Negation
off	I-Negation
one	I-Negation
or	I-Negation
both	I-Negation
strands	I-Negation
)	I-Negation
,	I-Negation
especially	I-Negation
in	I-Negation
the	I-Negation
rigorous	I-Negation
cross-validation	I-Negation
framework	I-Negation
necessary	I-Negation
to	I-Negation
decipher	I-Negation
precisely	I-Negation
which	I-Negation
aspects	I-Negation
contribute	I-Negation
significantly	I-Negation
to	I-Negation
the	I-Negation
performance	I-Negation
.	O

Nevertheless	O
,	O
as	O
larger	O
datasets	O
become	O
available	O
,	O
SCOPE	O
's	O
efficient	O
search	O
strategy	O
makes	O
it	O
an	O
ideal	O
platform	O
for	O
exploring	O
the	O
effect	O
of	O
focused	O
improvements	O
to	O
the	O
motif	O
finding	O
approach	O
described	O
,	O
such	O
as	O
the	O
use	O
of	O
complex	O
objective	O
functions	O
that	O
may	O
better	O
approximate	O
biological	O
significance	O
.	O

The	O
comparisons	O
to	O
other	O
motif	O
finding	O
programs	O
in	O
this	O
study	O
are	O
provided	O
to	O
place	O
SCOPE	O
's	O
performance	O
in	O
the	O
broader	O
context	O
of	O
the	O
motif	O
finding	O
field	O
,	O
particularly	O
when	O
viewed	O
from	O
the	O
standpoint	O
of	O
the	O
practicing	O
``	O
bench	O
``	O
biologist	O
.	O

Any	O
performance	O
comparison	O
must	O
be	O
interpreted	O
with	O
caution	O
,	O
since	O
the	O
results	O
are	O
highly	O
dependent	O
on	O
the	O
dataset	O
used	O
,	O
the	O
conditions	O
of	O
the	O
testing	O
and	O
the	O
metrics	O
used	O
for	O
evaluation	O
.	O

With	O
this	O
in	O
mind	O
,	O
we	O
sought	O
to	O
evaluate	O
a	O
wide	O
representation	O
of	O
motif	O
finders	O
on	O
a	O
large	O
number	O
of	O
regulons	O
using	O
performance	O
metrics	O
consistent	O
with	O
previous	O
studies	O
67	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
dataset	O
represents	O
the	O
largest	O
set	O
of	O
biologically	O
relevant	O
regulons	O
used	O
for	O
performance	O
comparisons	O
to	O
date	O
.	O

Whereas	O
previous	O
performance	O
comparisons	O
attempt	O
to	O
optimize	O
the	O
parameters	O
of	O
the	O
programs	O
in	O
question	O
467	O
or	O
allow	O
expert	O
users	O
to	O
tune	O
their	O
own	O
programs	O
and	O
manually	O
filter	O
both	O
the	O
input	O
and	O
output	O
5	O
we	O
intentionally	O
made	O
our	O
comparisons	O
between	O
programs	O
without	B-Negation
manually	I-Negation
optimizing	I-Negation
any	I-Negation
parameters	I-Negation
for	I-Negation
any	I-Negation
species	I-Negation
so	I-Negation
as	I-Negation
to	I-Negation
emulate	I-Negation
typical	I-Negation
use	I-Negation
conditions	I-Negation
.	O

Our	O
comparison	O
thus	O
complements	O
the	O
recent	O
large	O
scale	O
study	O
of	O
Tompa	O
et	O
al.	O
,	O
who	O
gauge	O
performance	O
under	O
optimal	O
conditions	O
on	O
semi-synthetic	O
data	O
sets	O
5	O
,	O
as	O
well	O
as	O
the	O
study	O
of	O
Hu	O
et	O
al.	O
,	O
who	O
explore	O
the	O
effect	O
of	O
parameter	O
optimization	O
on	O
a	O
handful	O
of	O
popular	O
motif	O
finders	O
4	O
.	O

Although	O
the	O
present	O
philosophy	O
of	O
performance	O
comparison	O
implicitly	O
benefits	O
SCOPE	O
,	O
which	O
has	O
no	B-Negation
parameters	I-Negation
to	I-Negation
optimize	I-Negation
,	O
it	O
is	O
arguably	O
the	O
most	O
relevant	O
comparison	O
possible	O
for	O
the	O
typical	O
biologist	O
.	O

Although	O
previous	O
studies	O
have	O
shown	O
the	O
potential	O
importance	O
of	O
choosing	O
parameters	O
carefully	O
46	O
,	O
we	O
note	O
that	O
the	O
results	O
we	O
obtained	O
under	O
default	O
settings	O
were	O
quite	O
similar	O
to	O
those	O
reported	O
in	O
previous	O
studies	O
(	O
for	O
details	O
,	O
see	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
)	O
.	O

Arguably	O
,	O
systematic	O
parameter	O
optimization	O
for	O
each	O
of	O
these	O
programs	O
may	O
well	O
yield	O
higher	O
accuracy	O
scores	O
than	O
those	O
reported	O
here	O
.	O

However	O
,	O
in	O
order	O
to	O
avoid	O
the	O
pitfall	O
of	O
overfitting	O
to	O
the	O
dataset	O
,	O
such	O
parameter	O
optimization	O
must	O
be	O
performed	O
using	O
cross-validation	O
or	O
some	O
other	O
resampling	O
technique	O
92223	O
.	O

We	O
note	O
that	O
all	O
the	O
motif	O
finders	O
tested	O
,	O
including	O
SCOPE	O
,	O
performed	O
poorly	O
on	O
the	O
Drosophila	O
dataset	O
.	O

Although	O
SCOPE	O
had	O
the	O
highest	O
accuracy	O
on	O
this	O
dataset	O
,	O
that	O
accuracy	O
was	O
significantly	O
less	O
than	O
on	O
the	O
bacterial	O
and	O
yeast	O
data	O
.	O

Especially	O
poor	O
performance	O
on	O
Drosophila	O
was	O
also	O
reported	O
in	O
the	O
Tompa	O
et	O
al.	O
performance	O
comparison	O
,	O
indicating	O
that	O
this	O
difficulty	O
is	O
not	O
limited	O
to	O
the	O
current	O
dataset	O
5	O
.	O

One	O
possible	O
cause	O
of	O
poor	O
performance	O
in	O
this	O
study	O
is	O
that	O
the	O
``	O
``	O
regulons	O
``	O
``	O
are	O
derived	O
from	O
enhancer	O
regions	O
defined	O
in	O
an	O
earlier	O
computational	O
paper	O
24	O
.	O

Whereas	O
a	O
background	O
set	O
of	O
promoter	O
regions	O
is	O
easy	O
to	O
identify	O
,	O
it	O
is	O
not	O
clear	O
how	O
to	O
define	O
a	O
reasonable	O
genomic	O
sample	O
of	O
enhancers	O
.	O

Thus	O
,	O
the	O
background	O
sequences	O
used	O
by	O
SCOPE	O
and	O
the	O
other	O
programs	O
may	O
not	O
be	O
representative	O
of	O
the	O
``	O
``	O
true	O
``	O
``	O
background	O
model	O
of	O
enhancers	O
,	O
leading	O
to	O
inaccurate	O
statistics	O
.	O

The	O
persistently	O
poor	O
performance	O
of	O
motif	O
finders	O
on	O
Drosophila	O
regulons	O
thus	O
highlights	O
the	O
importance	O
of	O
using	O
well-defined	O
background	O
sequences	O
to	O
calibrate	O
the	O
statistics	O
of	O
the	O
objective	O
functions	O
being	O
optimized	O
.	O

Recently	O
,	O
algorithms	O
have	O
been	O
reported	O
that	O
predict	O
enhancer	O
regions	O
on	O
a	O
genome	O
wide	O
scale	O
[	O
2425262728	O
]	O
.	O

It	O
is	O
possible	O
that	O
using	O
such	O
algorithms	O
to	O
define	O
a	O
collection	O
of	O
background	O
enhancer	O
sequences	O
may	O
improve	O
the	O
performance	O
of	O
SCOPE	O
,	O
as	O
well	O
as	O
that	O
of	O
the	O
other	O
motif	O
finders	O
,	O
on	O
Drosophila	O
.	O

Conclusion	O

Ensemble	O
methods	O
hold	O
the	O
potential	O
for	O
providing	O
improvements	O
in	O
motif	O
finding	O
accuracy	O
without	B-Negation
resorting	I-Negation
to	I-Negation
the	I-Negation
use	I-Negation
of	I-Negation
additional	I-Negation
data	I-Negation
(	I-Negation
such	I-Negation
as	I-Negation
phylogenetic	I-Negation
information	I-Negation
or	I-Negation
characterization	I-Negation
of	I-Negation
the	I-Negation
domain	I-Negation
structure	I-Negation
of	I-Negation
the	I-Negation
transcription	I-Negation
factor	I-Negation
)	I-Negation
,	I-Negation
which	I-Negation
are	I-Negation
not	I-Negation
always	I-Negation
available	I-Negation
.	O

Typically	O
,	O
ensemble	O
learning	O
methods	O
are	O
plagued	O
with	O
certain	O
liabilities	O
,	O
such	O
as	O
increased	O
runtimes	O
,	O
logistical	O
complexity	O
and	O
a	O
multiplicity	O
of	O
nuisance	O
parameters	O
,	O
all	O
of	O
which	O
grow	O
with	O
the	O
number	O
of	O
programs	O
run	O
.	O

In	O
the	O
machine	O
learning	O
field	O
,	O
ensemble	O
methods	O
have	O
coexisted	O
for	O
many	O
years	O
with	O
non-ensemble	O
methods	O
,	O
with	O
no	O
clear	O
superiority	O
having	O
been	O
established	O
between	O
the	O
two	O
.	O

SCOPE	O
serves	O
as	O
a	O
proof-of-concept	O
,	O
demonstrating	O
an	O
efficient	O
and	O
effective	O
approach	O
to	O
ensemble-based	O
motif	O
finding	O
.	O

By	O
dividing	O
the	O
search	O
space	O
into	O
tractable	O
domains	O
,	O
SCOPE	O
mitigates	O
the	O
potential	O
liabilities	O
associated	O
with	O
ensemble	O
methods	O
,	O
resulting	O
in	O
a	O
program	O
that	O
is	O
capable	O
of	O
finding	O
cis-regulatory	O
elements	O
of	O
arbitrary	O
length	O
,	O
degree	O
of	O
degeneracy	O
,	O
motif	O
orientation	O
and	O
frequency	O
of	O
occurrence	O
.	O

Its	O
strong	O
performance	O
,	O
rapid	O
runtime	O
and	O
freedom	O
from	O
nuisance	O
parameters	O
make	O
it	O
a	O
simple	O
and	O
effective	O
tool	O
for	O
the	O
biologist	O
.	O

Methods	O

Accuracy	O
,	O
Sensitivity	O
and	O
Positive	O
Predictive	O
Value	O

Each	O
algorithm	O
's	O
accuracy	O
for	O
each	O
regulon	O
was	O
measured	O
via	O
the	O
Phi	O
score	O
(	O
also	O
referred	O
to	O
as	O
nucleotide	O
level	O
performance	O
coefficient	O
,	O
or	O
nPC	O
,	O
in	O
previous	O
performance	O
comparisons	O
45611	O
.	O

This	O
metric	O
,	O
first	O
proposed	O
by	O
Pevzner	O
and	O
Sze	O
29	O
,	O
measures	O
the	O
degree	O
of	O
overlap	O
between	O
the	O
actual	O
instances	O
of	O
two	O
motifs	O
(	O
or	O
sets	O
of	O
motifs	O
)	O
m1	O
and	O
m2	O
in	O
the	O
set	O
of	O
co-regulated	O
upstream	O
sequences	O
.	O

The	O
Phi	O
score	O
can	O
be	O
defined	O
as	O
follows	O
:	O
let	O
U	O
be	O
a	O
unique	O
numbering	O
of	O
all	O
the	O
bases	O
in	O
the	O
upstream	O
sequences	O
of	O
a	O
given	O
gene	O
set	O
,	O
and	O
IU	O
(	O
m	O
)	O
	O
U	O
be	O
the	O
set	O
of	O
bases	O
that	O
are	O
covered	O
by	O
actual	O
instances	O
of	O
m	O
in	O
U	O
.	O

Phi	O
is	O
then	O
defined	O
as	O
the	O
ratio	O
of	O
the	O
number	O
of	O
bases	O
occupied	O
by	O
the	O
actual	O
instances	O
of	O
both	O
the	O
motifs	O
,	O
to	O
the	O
total	O
number	O
of	O
bases	O
occupied	O
by	O
the	O
actual	O
instances	O
of	O
either	O
of	O
the	O
two	O
motifs	O
:	O

U	O
(	O
m1	O
,	O
m2	O
)	O
=	O
[	O
IU	O
(	O
m1	O
)	O
	O
IU	O
(	O
m2	O
)	O
]	O
/	O
[	O
IU	O
(	O
m1	O
)	O
	O
IU	O
(	O
m2	O
)	O
]	O
.	O

This	O
metric	O
therefore	O
takes	O
both	O
false	O
positives	O
and	O
false	O
negatives	O
into	O
account	O
at	O
the	O
level	O
of	O
the	O
individual	O
bases	O
that	O
are	O
actually	O
covered	O
by	O
the	O
motif	O
.	O

As	O
in	O
Hu	O
et	O
al.	O
4	O
,	O
we	O
define	O
accuracy	O
to	O
be	O
the	O
Phi	O
score	O
between	O
the	O
known	O
and	O
predicted	O
binding	O
sites	O
.	O

Changing	O
the	O
denominator	O
of	O
the	O
Phi	O
equation	O
to	O
be	O
IU	O
(	O
mi	O
)	O
yields	O
the	O
sensitivity	O
(	O
if	O
mi	O
represents	O
the	O
true	O
binding	O
sites	O
)	O
or	O
the	O
positive	O
predictive	O
value	O
(	O
PPV	O
,	O
if	O
mi	O
represents	O
the	O
reported	O
binding	O
sites	O
)	O
.	O

See	O
Additional	O
file	O
1	O
,	O
section	O
S3	O
,	O
for	O
a	O
discussion	O
on	O
the	O
use	O
of	O
Phi	O
score	O
for	O
measuring	O
accuracy	O
.	O

Objective	O
functions	O
for	O
Statistical	O
Significance	O

In	O
line	O
with	O
other	O
motif	O
finders	O
,	O
we	O
have	O
used	O
statistical	O
significance	O
as	O
a	O
surrogate	O
for	O
biological	O
significance	O
.	O

Since	O
the	B-Negation
latter	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
defined	I-Negation
without	I-Negation
data	I-Negation
that	I-Negation
obviates	I-Negation
the	I-Negation
need	I-Negation
for	I-Negation
computational	I-Negation
motif	I-Negation
finding	I-Negation
,	O
objective	O
functions	O
that	O
approximate	O
biological	O
significance	O
are	O
critical	O
.	O

In	O
this	O
section	O
,	O
we	O
detail	O
the	O
objective	O
functions	O
we	O
used	O
and	O
their	O
effect	O
on	O
SCOPE	O
's	O
performance	O
.	O

For	O
any	O
motif	O
m	O
,	O
each	O
objective	O
function	O
provides	O
a	O
definition	O
for	O
p	O
(	O
m	O
)	O
,	O
the	O
probability	O
of	O
observing	O
a	O
motif	O
with	O
the	O
same	O
sufficient	O
statistics	O
as	O
m	O
assuming	O
a	O
particular	O
null	O
model	O
.	O

This	O
p-value	O
is	O
used	O
in	O
the	O
computation	O
of	O
the	O
Sig	O
score	O
(	O
see	O
Results	O
)	O
.	O

Overrepresentation	O

The	O
most	O
common	O
statistical	O
test	O
in	O
motif	O
finding	O
is	O
based	O
on	O
overrepresentation	O
,	O
which	O
can	O
be	O
roughly	O
defined	O
as	O
the	O
probability	O
that	O
a	O
motif	O
m	O
that	O
is	O
observed	O
C	O
(	O
m	O
)	O
times	O
in	O
the	O
regulon	O
would	O
occur	O
at	O
least	O
C	O
(	O
m	O
)	O
times	O
in	O
a	O
random	O
collection	O
of	O
the	O
same	O
number	O
of	O
genes	O
.	O

In	O
the	O
context	O
of	O
consensus	O
motifs	O
,	O
overrepresentation	O
is	O
expressed	O
in	O
terms	O
of	O
a	O
multinomial	O
model	O
,	O
in	O
which	O
each	O
position	O
i	O
in	O
each	O
gene	O
j	O
is	O
a	O
random	O
variable	O
Xij	O
that	O
can	O
take	O
on	O
any	O
motif	O
allowed	O
by	O
the	O
particular	O
motif	O
model	O
.	O

The	O
probability	O
of	O
seeing	O
m	O
at	O
least	O
C	O
(	O
m	O
)	O
times	O
in	O
the	O
regulon	O
can	O
be	O
approximated	O
by	O
the	O
Poisson	O
distribution	O
:	O
p	O
(	O
m	O
)	O
=	O
kC	O
(	O
m	O
)	O
[	O
(	O
ke-	O
)	O
/k	O
!	O
]	O
where	O
	O
is	O
the	O
expectation	O
of	O
C	O
(	O
m	O
)	O
with	O
respect	O
to	O
the	O
null	O
motif	O
distribution	O
and	O
the	O
number	O
of	O
positions	O
in	O
the	O
regulon	O
.	O

A	O
detailed	O
justification	O
of	O
this	O
approach	O
was	O
given	O
by	O
Carlson	O
et	O
al.	O
11	O
.	O

The	O
expectation	O
	O
is	O
most	O
accurately	O
modeled	O
using	O
Maximum	O
Likelihood	O
Estimators	O
(	O
MLEs	O
)	O
computed	O
as	O
the	O
actual	O
proportion	O
of	O
any	O
given	O
motif	O
in	O
the	O
complete	O
set	O
of	O
all	O
upstream	O
sequences	O
in	O
the	O
genome	O
10	O
.	O

These	O
MLEs	O
are	O
implemented	O
as	O
lookups	O
of	O
exact	O
substrings	O
,	O
which	O
can	O
be	O
performed	O
efficiently	O
using	O
a	O
suffix	O
array	O
data	O
structure	O
101112	O
.	O

Coverage	O

A	O
simple	O
modification	O
to	O
the	O
overrepresentation	O
objective	O
function	O
is	O
coverage	O
,	O
which	O
is	O
identical	O
to	O
overrepresentation	O
with	O
the	O
modification	O
that	O
C	O
(	O
m	O
)	O
is	O
the	O
number	O
of	O
upstream	O
regions	O
in	O
the	O
regulon	O
that	O
have	O
one	O
or	O
more	O
instances	O
of	O
m	O
and	O
	O
,	O
the	O
expectation	O
of	O
C	O
(	O
m	O
)	O
,	O
is	O
determined	O
from	O
the	O
proportion	O
of	O
upstream	O
regions	O
in	O
the	O
genome	O
that	O
contain	O
the	O
motif	O
.	O

While	O
this	O
objective	O
function	O
prevents	O
a	O
single	O
upstream	O
region	O
from	O
dominating	O
a	O
motif	O
's	O
score	O
,	O
it	O
fails	B-Negation
to	I-Negation
account	I-Negation
for	I-Negation
multiple	I-Negation
instances	I-Negation
of	I-Negation
a	I-Negation
binding	I-Negation
site	I-Negation
in	I-Negation
a	I-Negation
single	I-Negation
gene	I-Negation
that	I-Negation
may	I-Negation
arise	I-Negation
due	I-Negation
to	I-Negation
cooperative	I-Negation
binding	I-Negation
.	O

Positional	O
bias	O

Transcription	O
factors	O
often	O
require	O
their	O
binding	O
sites	O
to	O
be	O
located	O
in	O
a	O
restricted	O
range	O
relative	O
to	O
the	O
start	O
of	O
transcription	O
.	O

One	O
well	O
known	O
example	O
is	O
TBP	O
(	O
TATA-binding	O
protein	O
)	O
,	O
which	O
localizes	O
the	O
RNA	O
polymerase	O
complex	O
by	O
binding	O
the	O
TATA-box	O
motif	O
roughly	O
25	O
bases	O
upstream	O
of	O
the	O
transcription	O
start	O
site	O
30	O
.	O

While	O
other	O
examples	O
of	O
binding	O
sites	O
with	O
positional	O
restrictions	O
are	O
well	O
known	O
,	O
few	O
motif	O
finders	O
incorporate	O
position	O
in	O
their	O
scoring	O
function	O
.	O

In	O
the	O
case	O
where	O
all	O
upstream	O
regions	O
are	O
the	O
same	O
length	O
,	O
the	O
Kolmogorov-Smirnov	O
(	O
KS	O
)	O
statistic	O
provides	O
a	O
natural	O
test	O
for	O
positional	O
bias	O
.	O

The	O
Kolmogorov-Smirnov	O
(	O
KS	O
)	O
statistic	O
is	O
a	O
non-parametric	O
statistic	O
that	O
measures	O
the	O
probability	O
that	O
two	O
samples	O
are	O
drawn	O
from	O
the	O
same	O
distribution	O
.	O

Let	O
X	O
be	O
the	O
sample	O
that	O
we	O
wish	O
to	O
compare	O
to	O
some	O
reference	O
sample	O
Y	O
.	O

The	O
KS	O
statistic	O
is	O
defined	O
to	O
be	O
the	O
maximum	O
absolute	O
difference	O
between	O
the	O
unbiased	O
cumulative	O
distribution	O
functions	O
of	O
X	O
and	O
Y	O
.	O

The	O
KS	O
statistic	O
has	O
a	O
well-defined	O
distribution	O
from	O
which	O
a	O
p-value	O
can	O
be	O
easily	O
computed	O
.	O

Kuiper	O
's	O
variation	O
was	O
used	O
to	O
increase	O
sensitivity	O
in	O
the	O
tails	O
of	O
the	O
distribution	O
31	O
.	O

In	O
the	O
context	O
of	O
motifs	O
,	O
we	O
defined	O
the	O
test	O
sample	O
X	O
for	O
a	O
motif	O
m	O
to	O
be	O
the	O
set	O
of	O
starting	O
positions	O
(	O
with	O
respect	O
to	O
transcription	O
start	O
sites	O
)	O
of	O
m	O
in	O
the	O
regulon	O
.	O

The	O
reference	O
sample	O
Y	O
is	O
defined	O
as	O
the	O
set	O
of	O
starting	O
positions	O
of	O
m	O
in	O
all	O
upstream	O
regions	O
in	O
the	O
genome	O
.	O

Thus	O
,	O
pKS	O
(	O
m	O
)	O
is	O
a	O
measure	O
of	O
how	O
m	O
is	O
localized	O
differently	O
in	O
the	O
regulon	O
than	O
in	O
the	O
genome	O
as	O
a	O
whole	O
.	O

It	O
is	O
also	O
possible	O
to	O
define	O
Y	O
as	O
the	O
uniform	O
distribution	O
;	O
however	O
,	O
we	O
found	O
that	O
many	O
motifs	O
had	O
non-uniform	O
distributions	O
throughout	O
all	O
upstream	O
regions	O
of	O
the	O
genome	O
,	O
possibly	O
as	O
an	O
artifact	O
of	O
the	O
non-uniform	O
AT/CG	O
distributions	O
in	O
upstream	O
regions	O
32	O
.	O

Combining	O
overrepresentation	O
and	O
positional	O
bias	O

Since	O
overrepresentation	O
and	O
KS	O
are	O
independent	O
,	O
the	O
probabilities	O
can	O
simply	O
be	O
multiplied	O
together	O
to	O
yield	O
the	O
probability	O
of	O
randomly	O
sampling	O
a	O
motif	O
with	O
a	O
given	O
degree	O
of	O
overrepresentation	O
and	O
positional	O
bias	O
.	O

Motif	O
orientation	O

Many	O
transcription	O
factors	O
will	O
bind	O
motifs	O
on	O
either	O
DNA	O
strand	O
.	O

Others	O
,	O
such	O
as	O
the	O
general	O
transcription	O
factor	O
TBP	O
(	O
TATA-Binding	O
Protein	O
)	O
,	O
require	O
a	O
specific	O
orientation	O
and	O
will	O
only	O
function	O
if	O
bound	O
to	O
motifs	O
on	O
a	O
specific	O
DNA	O
strand	O
30	O
.	O

In	O
scoring	O
a	O
motif	O
m	O
,	O
a	O
choice	O
must	O
therefore	O
be	O
made	O
as	O
to	O
whether	O
or	O
not	O
the	O
reverse	O
complement	O
mR	O
of	O
m	O
will	O
be	O
considered	O
to	O
be	O
the	O
same	O
motif	O
as	O
m	O
.	O

Most	O
programs	O
assume	O
motif	O
orientation	O
does	O
not	B-Negation
matter	I-Negation
and	O
so	O
define	O
m	O
=	O
mR	O
.	O

Such	O
an	O
assumption	O
may	O
be	O
overly	O
generous	O
	O
as	O
the	O
TBP	O
example	O
above	O
makes	O
clear	O
,	O
the	O
transcriptional	O
machinery	O
of	O
a	O
cell	O
is	O
clearly	O
able	O
to	O
differentiate	O
between	O
the	O
two	O
strands	O
.	O

We	O
thus	O
chose	O
to	O
attach	O
a	O
flag	O
to	O
each	O
motif	O
,	O
indicating	O
whether	O
or	O
not	O
the	O
motif	O
should	O
be	O
orientation-neutral	O
.	O

BEAM	O
and	O
SPACER	O
thus	O
enumerate	O
and	O
evaluate	O
all	O
motifs	O
with	O
both	O
values	O
of	O
this	O
flag	O
.	O

SCOPE	O
reports	O
that	O
orientation	O
does	O
matter	O
(	O
i.e.	O
m	O
	O
mR	O
)	O
for	O
17	O
%	O
of	O
the	O
regulons	O
in	O
our	O
biological	O
test	O
set	O
.	O

Reuse	O
of	O
structural	O
domaindomain	O
interactions	O
in	O
protein	O
networks	O

Abstract	O

Background	O

Protein	O
interactions	O
are	O
thought	O
to	O
be	O
largely	O
mediated	O
by	O
interactions	O
between	O
structural	O
domains	O
.	O

Databases	O
such	O
as	O
iPfam	O
relate	O
interactions	O
in	O
protein	O
structures	O
to	O
known	O
domain	O
families	O
.	O

Here	O
,	O
we	O
investigate	O
how	O
the	O
domain	O
interactions	O
from	O
the	O
iPfam	O
database	O
are	O
distributed	O
in	O
protein	O
interactions	O
taken	O
from	O
the	O
HPRD	O
,	O
MPact	O
,	O
BioGRID	O
,	O
DIP	O
and	O
IntAct	O
databases	O
.	O

Results	O

We	O
find	O
that	O
known	O
structural	O
domain	O
interactions	O
can	O
only	O
explain	O
a	O
subset	O
of	O
419	O
%	O
of	O
the	O
available	O
protein	O
interactions	O
,	O
nevertheless	O
this	O
fraction	O
is	O
still	O
significantly	O
bigger	O
than	O
expected	O
by	O
chance	O
.	O

There	O
is	O
a	O
correlation	O
between	O
the	O
frequency	O
of	O
a	O
domain	O
interaction	O
and	O
the	O
connectivity	O
of	O
the	O
proteins	O
it	O
occurs	O
in	O
.	O

Furthermore	O
,	O
a	O
large	O
proportion	O
of	O
protein	O
interactions	O
can	O
be	O
attributed	O
to	O
a	O
small	O
number	O
of	O
domain	O
interactions	O
.	O

We	O
conclude	O
that	O
many	O
,	O
but	O
not	O
all	O
,	O
domain	O
interactions	O
constitute	O
reusable	O
modules	O
of	O
molecular	O
recognition	O
.	O

A	O
substantial	O
proportion	O
of	O
domain	O
interactions	O
are	O
conserved	O
between	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
.	O

These	O
domains	O
are	O
related	O
to	O
essential	O
cellular	O
functions	O
,	O
suggesting	O
that	O
many	O
domain	O
interactions	O
were	O
already	O
present	O
in	O
the	O
last	O
universal	O
common	O
ancestor	O
.	O

Conclusion	O

Our	O
results	O
support	O
the	O
concept	O
of	O
domain	O
interactions	O
as	O
reusable	O
,	O
conserved	O
building	O
blocks	O
of	O
protein	O
interactions	O
,	O
but	O
also	O
highlight	O
the	O
limitations	O
currently	O
imposed	O
by	O
the	O
small	O
number	O
of	O
available	O
protein	O
structures	O
.	O

Background	O

One	O
way	O
to	O
understand	O
a	O
protein	O
's	O
function	O
is	O
to	O
look	O
at	O
its	O
composition	O
of	O
conserved	O
domains	O
.	O

Such	O
families	O
of	O
related	O
sequence	O
regions	O
,	O
collected	O
in	O
the	O
Pfam	O
database	O
1	O
,	O
usually	O
constitute	O
structurally	O
and	O
functionally	O
conserved	O
modules	O
.	O

It	O
is	O
assumed	O
that	O
binding	O
interfaces	O
,	O
too	O
,	O
are	O
conserved	O
evolutionary	O
modules	O
that	O
are	O
reused	O
between	O
proteins	O
of	O
different	O
functions	O
and	O
retained	O
during	O
evolution	O
23	O
.	O

Therefore	O
,	O
domaindomain	O
interactions	O
are	O
often	O
regarded	O
as	O
the	O
currency	O
of	O
proteinprotein	O
interactions	O
.	O

Based	O
on	O
this	O
assumption	O
,	O
Ng	O
et	O
al.	O
described	O
an	O
approach	O
to	O
predict	O
domaindomain	O
interactions	O
using	O
literature	O
curation	O
,	O
evolutionary	O
history	O
and	O
the	O
distribution	O
of	O
domains	O
in	O
protein	O
interactions	O
4	O
.	O

Wuchty	O
et	O
al.	O
compared	O
the	O
relationship	O
between	O
this	O
set	O
of	O
predicted	O
interacting	O
domain	O
pairs	O
to	O
the	O
domain	O
coocurrence	O
network	O
5	O
.	O

More	O
recently	O
,	O
other	O
groups	O
have	O
come	O
up	O
with	O
sophisticated	O
statistical	O
methods	O
to	O
estimate	O
putatively	O
interacting	O
domain	O
pairs	O
,	O
based	O
on	O
the	O
assumption	O
of	O
domain	O
reusability	O
678910	O
.	O

However	O
,	O
none	B-Negation
of	I-Negation
these	I-Negation
approaches	I-Negation
offers	I-Negation
structural	I-Negation
evidence	I-Negation
that	I-Negation
the	I-Negation
predicted	I-Negation
domain	I-Negation
pairs	I-Negation
are	I-Negation
able	I-Negation
to	I-Negation
form	I-Negation
an	I-Negation
interaction	I-Negation
.	O

For	O
complexes	O
with	O
known	O
structure	O
,	O
it	O
has	O
been	O
shown	O
that	O
domains	O
can	O
mediate	O
interactions	O
1112	O
.	O

Such	O
interactions	O
between	O
pairs	O
of	O
domains	O
are	O
stored	O
in	O
the	O
iPfam	O
database	O
13	O
.	O

The	O
structural	O
evidence	O
lends	O
strong	O
support	O
to	O
the	O
inferred	O
domain	O
pair	O
,	O
resulting	O
in	O
a	O
high	O
confidence	O
set	O
of	O
domain	O
pairs	O
.	O

Unfortunately	O
,	O
the	O
selection	O
of	O
complexes	O
in	O
the	O
PDB	O
database	O
of	O
protein	O
structures	O
14	O
is	O
rather	O
small	O
and	O
biased	O
15	O
.	O

There	O
is	O
often	O
only	O
a	O
single	O
structure	O
that	O
shows	O
a	O
certain	O
protein	O
pair	O
to	O
interact	O
,	O
while	O
other	O
complexes	O
like	O
haemoglobin	O
have	O
been	O
crystalized	O
dozens	O
of	O
times	O
.	O

This	O
makes	O
it	O
difficult	O
to	O
assess	O
whether	O
some	O
domain	O
pairs	O
act	O
as	O
reusable	O
modules	O
in	O
protein	O
interactions	O
from	O
PDB	O
data	O
alone	O
.	O

High-throughput	O
experiments	O
161718	O
and	O
extensive	O
literature	O
curation	O
efforts	O
19	O
have	O
yielded	O
large	O
databases	O
of	O
protein	O
interactions	O
2021222324	O
.	O

Despite	O
the	O
continuing	O
growth	O
of	O
protein	O
interaction	O
databases	O
,	O
even	O
the	O
best	O
studied	O
protein	O
interaction	O
network	O
of	O
S.	O
cerevisiae	O
is	O
thought	O
to	O
be	O
incomplete	O
and	O
inaccurate	O
252627	O
.	O

Given	O
that	O
this	O
network	O
already	O
comprises	O
around	O
60000	O
interactions	O
,	O
questions	O
arise	O
as	O
to	O
how	O
such	O
networks	O
have	O
evolved	O
and	O
how	O
they	O
are	O
organised	O
.	O

Furthermore	O
,	O
methods	O
for	O
assessing	O
the	O
quality	O
of	O
high-throughput	O
experimental	O
results	O
are	O
in	O
high	O
demand	O
due	O
to	O
the	O
error	O
prone	O
nature	O
of	O
the	O
methods	O
used	O
.	O

In	O
this	O
study	O
,	O
we	O
investigate	O
how	O
pairs	O
of	O
protein	O
families	O
taken	O
from	O
iPfam	O
are	O
distributed	O
in	O
experimental	O
protein	O
interactions	O
from	O
five	O
major	O
model	O
species	O
.	O

This	O
allows	O
us	O
to	O
address	O
a	O
number	O
of	O
questions	O
:	O
:	O
what	O
proportion	O
of	O
each	O
organism	O
's	O
protein	O
interaction	O
network	O
,	O
its	O
interactome	O
,	O
can	O
be	O
attributed	O
to	O
a	O
known	O
domaindomain	O
interaction	O
?	O

How	O
conserved	O
are	O
domaindomain	O
pairs	O
between	O
species	O
,	O
and	O
how	O
many	O
interacting	O
domain	O
pairs	O
are	O
still	O
unknown	O
?	O

Results	O

iPfam	O
domain	O
pairs	O
are	O
overrepresented	O
in	O
experimental	O
protein	O
interactions	O

We	O
analysed	O
the	O
distribution	O
of	O
Pfam	O
families	O
known	O
to	O
interact	O
from	O
a	O
PDB	O
structure	O
(	O
iPfam	O
domain	O
pairs	O
)	O
in	O
experimentally	O
derived	O
protein	O
interactions	O
(	O
experimental	O
interactions	O
)	O
.	O

The	O
experimental	O
interactions	O
were	O
filtered	O
to	O
only	O
include	O
interactions	O
with	O
exactly	O
two	O
partners	O
(	O
see	O
Methods	O
)	O
.	O

The	O
fraction	O
of	O
experimental	O
interactions	O
that	O
contain	O
at	O
least	O
one	O
iPfam	O
domain	O
pair	O
is	O
referred	O
to	O
as	O
the	O
iPfam	O
coverage	O
.	O

Accordingly	O
,	O
the	O
fraction	O
of	O
experimental	O
interactions	O
that	O
contains	O
any	O
pair	O
of	O
Pfam	O
domains	O
(	O
excluding	O
the	O
iPfam	O
domain	O
pairs	O
)	O
is	O
called	O
the	O
Pfam	O
coverage	O
.	O

Figure	O
1	O
shows	O
the	O
Pfam	O
and	O
iPfam	O
coverage	O
for	O
the	O
analysed	O
species	O
as	O
a	O
column	O
chart	O
.	O

The	O
number	O
of	O
resolved	O
protein	O
interactions	O
varies	O
greatly	O
between	O
species	O
,	O
as	O
does	O
the	O
size	O
of	O
the	O
underlying	O
proteome	O
(	O
see	O
Table	O
1	O
)	O
.	O

The	O
Pfam	O
coverage	O
,	O
coloured	O
red	O
in	O
Figure	O
1	O
,	O
lies	O
between	O
49.46	O
%	O
and	O
66.73	O
%	O
.	O

Given	O
that	O
74	O
%	O
of	O
all	O
UniProt	O
proteins	O
contain	O
at	O
least	O
one	O
Pfam	O
match	O
,	O
this	O
is	O
not	B-Negation
by	I-Negation
itself	I-Negation
surprising	I-Negation
.	O

The	O
iPfam	O
coverage	O
,	O
shown	O
in	O
blue	O
,	O
is	O
much	O
smaller	O
,	O
ranging	O
from	O
2.92	O
%	O
in	O
D.	O
melanogaster	O
to	O
19.02	O
%	O
in	O
H.	O
sapiens	O
.	O

In	O
S.	O
cerevisiae	O
the	O
species	O
with	O
the	O
most	O
comprehensively	O
studied	O
interactome	O
,	O
the	O
iPfam	O
coverage	O
is	O
4.47	O
%	O
.	O

Comparison	O
of	O
coverage	O
of	O
iPfam	O
domain	O
pairs	O
on	O
protein	O
interactions	O

Comparison	O
of	O
coverage	O
of	O
iPfam	O
domain	O
pairs	O
on	O
protein	O
interactions	O
.	O

For	O
each	O
species	O
,	O
the	O
height	O
of	O
the	O
column	O
reflects	O
the	O
number	O
of	O
known	O
proteinprotein	O
interactions	O
in	O
the	O
data	O
set	O
.	O

The	O
columns	O
are	O
split	O
according	O
to	O
the	O
proportion	O
of	O
interactions	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O
(	O
blue	O
)	O
,	O
that	O
contain	O
any	O
other	O
Pfam	O
domains	O
on	O
both	O
proteins	O
(	O
red	O
)	O
,	O
and	O
those	O
that	O
contain	O
no	B-Negation
Pfam	I-Negation
domain	I-Negation
pair	I-Negation
(	O
yellow	O
)	O
.	O

iPfam	O
domain	O
pair	O
coverage	O
on	O
protein	O
interactions	O

For	O
each	O
species	O
,	O
we	O
list	O
the	O
size	O
of	O
the	O
proteome	O
as	O
defined	O
in	O
Integr8	O
and	O
the	O
fraction	O
of	O
this	O
proteome	O
that	O
is	O
represented	O
in	O
the	O
protein	O
interaction	O
sets	O
,	O
followed	O
by	O
the	O
total	O
number	O
of	O
binary	O
protein	O
interactions	O
and	O
the	O
fraction	O
of	O
those	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O
.	O

The	O
last	O
two	O
columns	O
show	O
the	O
results	O
of	O
the	O
network	O
shuffling	O
experiments	O
.	O

The	O
relatively	O
low	O
iPfam	O
coverage	O
is	O
by	O
itself	O
a	O
disappointing	O
finding	O
.	O

However	O
,	O
the	O
fact	O
that	O
only	O
a	O
small	O
fraction	O
of	O
protein	O
interactions	O
contain	O
known	O
domain	O
pairs	O
could	O
be	O
a	O
result	O
of	O
the	O
scarcity	O
of	O
available	O
structures	O
of	O
protein	O
complexes	O
.	O

Therefore	O
,	O
we	O
asked	O
whether	O
the	O
observed	O
iPfam	O
coverage	O
is	O
larger	O
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O

To	O
test	O
this	O
,	O
we	O
created	O
1000	O
random	O
networks	O
per	O
species	O
using	O
the	O
algorithm	O
described	O
in	O
Methods	O
.	O

We	O
then	O
calculated	O
the	O
iPfam	O
coverage	O
on	O
the	O
protein	O
interactions	O
in	O
each	O
randomised	O
network	O
.	O

Mean	O
and	O
standard	O
deviations	O
of	O
the	O
randomisation	O
experiments	O
are	O
shown	O
in	O
Table	O
1	O
.	O

No	B-Negation
P	I-Negation
value	I-Negation
(	I-Negation
see	I-Negation
Methods	I-Negation
)	I-Negation
was	I-Negation
greater	I-Negation
than	I-Negation
1.84	I-Negation
	O
10-06	O
.	O

This	O
proves	O
that	O
the	O
observed	O
iPfam	O
coverage	O
is	O
significantly	O
higher	O
than	O
expected	O
and	O
iPfam	O
domain	O
pairs	O
are	O
enriched	O
in	O
real	O
experimental	O
protein	O
interactions	O
.	O

Few	O
iPfam	O
domain	O
pairs	O
are	O
responsible	O
for	O
a	O
majority	O
of	O
the	O
coverage	O

To	O
understand	O
why	O
iPfam	O
domain	O
pairs	O
occur	O
more	O
often	O
in	O
experimental	O
interactions	O
than	O
expected	O
by	O
chance	O
,	O
we	O
analysed	O
the	O
two	O
largest	O
data	O
sets	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
in	O
more	O
detail	O
.	O

In	O
the	O
following	O
paragraph	O
,	O
we	O
will	O
call	O
the	O
experimental	O
interactions	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O
the	O
covered	O
experimental	O
interactions	O
.	O

In	O
Figure	O
2	O
,	O
we	O
compare	O
the	O
distribution	O
of	O
iPfam	O
domain	O
pairs	O
on	O
the	O
number	O
of	O
experimental	O
interactions	O
for	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
.	O

This	O
plot	O
reflects	O
how	O
many	O
iPfam	O
domain	O
pairs	O
cover	O
how	O
many	O
experimental	O
interactions	O
.	O

Domain	O
pairs	O
that	O
cluster	O
to	O
the	O
left	O
of	O
the	O
plot	O
can	O
be	O
called	O
specific	O
domain	O
pairs	O
,	O
as	O
they	O
only	O
occur	O
in	O
very	O
few	O
covered	O
experimental	O
interactions	O
.	O

Conversely	O
,	O
domain	O
pairs	O
that	O
cluster	O
to	O
the	O
right	O
of	O
the	O
plot	O
occur	O
in	O
a	O
large	O
number	O
of	O
different	O
covered	O
experimental	O
interactions	O
and	O
can	O
be	O
called	O
promiscuous	O
domain	O
pairs	O
.	O

Frequencies	O
of	O
iPfam	O
domain	O
pairs	O
in	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
protein	O
interactions	O

Frequencies	O
of	O
iPfam	O
domain	O
pairs	O
in	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
protein	O
interactions	O
.	O

Each	O
point	O
in	O
this	O
graph	O
represents	O
a	O
set	O
of	O
protein	O
interactions	O
.	O

The	O
abscissa	O
reflects	O
the	O
number	O
of	O
interactions	O
in	O
each	O
set	O
that	O
contain	O
the	O
same	O
iPfam	O
domain	O
pair	O
.	O

The	O
ordinate	O
shows	O
the	O
number	O
of	O
distinct	O
such	O
sets	O
,	O
each	O
defined	O
by	O
a	O
different	O
iPfam	O
domain	O
pair	O
.	O

In	O
both	O
H.	O
sapiens	O
(	O
blue	O
)	O
and	O
S.	O
cerevisiae	O
(	O
green	O
)	O
a	O
small	O
number	O
of	O
iPfam	O
domain	O
pairs	O
covers	O
a	O
large	O
fraction	O
of	O
the	O
interactome	O
,	O
whereas	O
in	O
E.	O
coli	O
,	O
no	B-Negation
iPfam	I-Negation
domain	I-Negation
occurs	I-Negation
in	I-Negation
more	I-Negation
than	I-Negation
4	I-Negation
experimental	I-Negation
interactions	I-Negation
at	I-Negation
a	I-Negation
time	I-Negation
.	O

Dotted	O
lines	O
denote	O
fitted	O
monomial	O
functions	O
,	O
showing	O
that	O
the	O
distributions	O
follow	O
a	O
power	O
law	O
.	O

All	O
three	O
distributions	O
in	O
Figure	O
2	O
resemble	O
a	O
power	O
law	O
distribution	O
,	O
according	O
to	O
the	O
good	O
fit	O
of	O
log-linear	O
functions	O
(	O
log	O
(	O
f	O
(	O
x	O
)	O
)	O
=	O
k	O
log	O
x	O
+	O
log	O
a	O
)	O
shown	O
as	O
dotted	O
lines	O
.	O

The	O
slopes	O
k	O
of	O
the	O
H.	O
sapiens	O
and	O
S.	O
cerevisiae	O
distributions	O
are	O
very	O
similar	O
(	O
-1.53	O
and	O
-1.60	O
,	O
respectively	O
)	O
,	O
while	O
E.	O
coli	O
has	O
a	O
markedly	O
smaller	O
slope	O
(	O
-2.78	O
)	O
.	O

This	O
suggests	O
that	O
the	O
ratio	O
of	O
specific	O
to	O
promiscuous	O
iPfam	O
domain	O
pairs	O
is	O
very	O
similar	O
in	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
,	O
whereas	O
E.	O
coli	O
features	O
fewer	O
multiply	O
reoccurring	O
iPfam	O
domain	O
pairs	O
.	O

The	O
power	O
law	O
distribution	O
of	O
iPfam	O
frequencies	O
implies	O
that	O
the	O
majority	O
of	O
covered	O
protein	O
interactions	O
can	O
be	O
attributed	O
to	O
a	O
minority	O
of	O
iPfam	O
domain	O
pairs	O
.	O

51.7	O
%	O
of	O
the	O
iPfam	O
domain	O
pairs	O
in	O
S.	O
cerevisiae	O
and	O
45.3	O
%	O
in	O
H.	O
sapiens	O
are	O
seen	O
in	O
just	O
one	O
experimental	O
interaction	O
.	O

Conversely	O
,	O
92.4	O
%	O
of	O
H.	O
sapiens	O
and	O
85.4	O
%	O
of	O
S.	O
cerevisiae	O
covered	O
experimental	O
interactions	O
contain	O
an	O
iPfam	O
domain	O
pair	O
that	O
occurs	O
more	O
than	O
once	O
.	O

Even	O
more	O
,	O
half	O
of	O
the	O
covered	O
experimental	O
interactions	O
in	O
H.	O
sapiens	O
contain	O
an	O
iPfam	O
domain	O
pair	O
that	O
occurs	O
in	O
more	O
than	O
16	O
different	O
experimental	O
interactions	O
(	O
5	O
for	O
S.	O
cerevisiae	O
)	O
.	O

Degree	O
distribution	O
and	O
iPfam	O
domain	O
pair	O
frequency	O
are	O
correlated	O

We	O
reasoned	O
that	O
if	O
there	O
are	O
iPfam	O
domain	O
pairs	O
that	O
act	O
as	O
reusable	O
modules	O
in	O
protein	O
interactions	O
,	O
then	O
highly	O
connected	O
proteins	O
should	O
also	O
be	O
more	O
likely	O
to	O
contain	O
promiscuous	O
iPfam	O
domain	O
pairs	O
and	O
vice-versa	O
.	O

For	O
each	O
node	O
(	O
i.e.	O
protein	O
)	O
in	O
the	O
filtered	O
H.	O
sapiens	O
and	O
S.	O
cerevisiae	O
protein	O
interaction	O
network	O
,	O
we	O
calculated	O
its	O
degree	O
,	O
defined	O
as	O
the	O
number	O
of	O
adjacent	O
edges	O
(	O
i.e.	O
interactions	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
we	O
counted	O
the	O
number	O
of	O
iPfam	O
domain	O
pairs	O
on	O
the	O
adjacent	O
edges	O
.	O

In	O
Figure	O
3	O
,	O
we	O
plot	O
the	O
mean	O
number	O
of	O
iPfam	O
domain	O
pairs	O
relative	O
to	O
the	O
degree	O
of	O
the	O
node	O
.	O

Average	O
frequency	O
of	O
iPfam	O
domain	O
pairs	O
relative	O
to	O
degree	O
of	O
node	O

Average	O
frequency	O
of	O
iPfam	O
domain	O
pairs	O
relative	O
to	O
degree	O
of	O
node	O
.	O

Each	O
point	O
represents	O
a	O
protein	O
in	O
the	O
interaction	O
networks	O
of	O
H.	O
sapiens	O
(	O
blue	O
)	O
and	O
S.	O
cerevisiae	O
(	O
green	O
)	O
.	O

For	O
each	O
protein	O
,	O
we	O
calculate	O
the	O
degree	O
,	O
defined	O
as	O
the	O
number	O
of	O
interactions	O
the	O
protein	O
is	O
involved	O
in	O
.	O

On	O
the	O
y-axis	O
,	O
we	O
show	O
the	O
average	O
number	O
of	O
iPfam	O
domain	O
pairs	O
in	O
edges	O
adjacent	O
to	O
proteins	O
of	O
degree	O
x	O
.	O

We	O
calculated	O
a	O
Spearman	O
correlation	O
of	O
0.68	O
and	O
0.71	O
,	O
for	O
H.	O
sapiens	O
and	O
S.	O
cerevisiae	O
.	O

The	O
correlation	O
is	O
outlined	O
by	O
dotted	O
lines	O
.	O

We	O
find	O
that	O
for	O
proteins	O
from	O
a	O
degree	O
of	O
1	O
to	O
50	O
,	O
there	O
is	O
strong	O
correlation	O
in	O
both	O
H.	O
sapiens	O
and	O
S.	O
cerevisiae	O
(	O
Spearman	O
correlation	O
coefficients	O
of	O
0.68	O
and	O
0.71	O
,	O
respectively	O
)	O
between	O
degree	O
and	O
number	O
of	O
iPfam	O
domain	O
pairs	O
on	O
adjacent	O
edges	O
.	O

For	O
the	O
1.2	O
%	O
of	O
proteins	O
in	O
H.	O
sapiens	O
and	O
6.4	O
%	O
in	O
S.	O
cerevisiae	O
which	O
have	O
a	O
degree	O
higher	O
than	O
50	O
,	O
the	O
correlation	O
gradually	O
diminishes	O
.	O

Promiscuous	O
domain	O
pairs	O

Additional	O
file	O
1	O
contains	O
a	O
list	O
of	O
all	O
iPfam	O
domain	O
pairs	O
and	O
their	O
frequencies	O
in	O
the	O
experimental	O
protein	O
interactions	O
,	O
while	O
Additional	O
file	O
4	O
lists	O
the	O
frequencies	O
of	O
the	O
single	O
domains	O
.	O

Interactions	O
between	O
protein	O
kinase	O
domains	O
(	O
Pkinase	O
,	O
Pfam	O
acc.	O
PF00069	O
and	O
Pkinase_Tyr	O
,	O
Pfam	O
acc.	O
PF07714	O
)	O
are	O
the	O
most	O
frequent	O
iPfam	O
domain	O
pairs	O
,	O
as	O
well	O
as	O
interactions	O
involving	O
recognition	O
domains	O
such	O
as	O
SH2	O
or	O
SH3	O
.	O

In	O
S.	O
cerevisiae	O
,	O
the	O
Proteasome	O
family	O
(	O
Pfam	O
acc.	O
PF00227	O
,	O
a	O
family	O
of	O
peptidases	O
)	O
and	O
WD40	O
(	O
Pfam	O
acc.	O
PF00400	O
,	O
a	O
repeat	O
involved	O
in	O
multimer	O
assembly	O
)	O
are	O
also	O
amongst	O
the	O
five	O
most	O
frequent	O
iPfam	O
domain	O
pairs	O
.	O

As	O
expected	O
,	O
more	O
frequent	O
domains	O
are	O
also	O
more	O
likely	O
to	O
be	O
found	O
as	O
pairs	O
in	O
interacting	O
proteins	O
.	O

It	O
should	O
be	O
noted	O
however	O
that	O
in	O
the	O
PDB	O
structures	O
,	O
some	O
of	O
the	O
observed	O
domain	O
pairs	O
(	O
Pkinase_Tyr	O
	O
SH3_1	O
,	O
Pkinase_C	O
	O
Pkinase	O
and	O
others	O
)	O
are	O
only	O
seen	O
to	O
interact	O
within	O
one	O
protein	O
(	O
intrachain	O
interactions	O
)	O
as	O
opposed	O
to	O
interactions	O
between	O
two	O
distinct	O
proteins	O
(	O
interchain	O
interaction	O
)	O
.	O

The	O
table	O
in	O
Additional	O
file	O
5	O
lists	O
the	O
number	O
of	O
PDB	O
structures	O
for	O
each	O
iPfam	O
domain	O
pair	O
,	O
distinguishing	O
between	O
intrachain	O
and	O
interchain	O
interactions	O
.	O

Looking	O
for	O
example	O
at	O
the	O
covered	O
experimental	O
interactions	O
in	O
H.	O
sapiens	O
(	O
Additional	O
file	O
1	O
)	O
,	O
only	O
8	O
out	O
of	O
the	O
100	O
most	O
frequent	O
iPfam	O
domain	O
pairs	O
are	O
seen	O
in	O
intrachain	O
interactions	O
exclusively	O
,	O
while	O
61	O
are	O
exclusive	O
to	O
interchain	O
interactions	O
and	O
31	O
are	O
seen	O
in	O
both	O
.	O

A	O
possible	O
explanation	O
for	O
the	O
occurrence	O
of	O
purely	O
intrachain	O
iPfam	O
domain	O
pairs	O
in	O
the	O
covered	O
experimental	O
interactions	O
is	O
that	O
they	O
frequently	O
cooccur	O
together	O
on	O
the	O
same	O
protein	O
with	O
other	O
iPfam	O
domain	O
pairs	O
.	O

A	O
list	O
of	O
all	O
combinations	O
of	O
iPfam	O
domains	O
(	O
the	O
domain	O
architecture	O
)	O
on	O
interacting	O
proteins	O
is	O
given	O
in	O
Additional	O
file	O
2	O
.	O

It	O
reveals	O
that	O
certain	O
iPfam	O
domains	O
such	O
as	O
SH2	O
,	O
SH3_1	O
or	O
Pkinase_tyr	O
frequently	O
occur	O
in	O
the	O
same	O
architecture	O
.	O

Without	B-Negation
further	I-Negation
experiments	I-Negation
,	O
we	O
can	B-Speculation
not	I-Speculation
assign	I-Speculation
the	I-Speculation
correct	I-Speculation
interacting	I-Speculation
domains	I-Speculation
with	I-Speculation
certainty	I-Speculation
.	O

This	O
highlights	O
a	O
basic	O
assumption	O
of	O
this	O
study	O
that	O
could	O
be	O
a	O
source	O
of	O
error	O
.	O

We	O
assume	O
that	O
interacting	O
proteins	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O
interact	O
through	O
these	O
domains	O
.	O

This	O
,	O
of	O
course	O
,	O
is	O
not	O
necessarily	O
the	O
case	O
.	O

Although	O
it	O
has	O
been	O
shown	O
that	O
sequence	O
similarity	O
is	O
linked	O
to	O
the	O
mode	O
of	O
interaction	O
28	O
,	O
not	O
every	O
protein	O
interaction	O
that	O
contains	O
an	O
iPfam	O
domain	O
pair	O
is	O
necessarily	O
mediated	O
by	O
exactly	O
this	O
domain	O
pair	O
.	O

To	O
gain	O
a	O
rough	O
estimate	O
of	O
the	O
false	O
positive	O
rate	O
due	O
to	O
this	O
assumption	O
,	O
we	O
counted	O
how	O
many	O
protein	O
pairs	O
in	O
the	O
PDB	O
contain	O
an	O
iPfam	O
domain	O
pair	O
that	O
does	O
not	B-Negation
mediate	I-Negation
an	I-Negation
interaction	I-Negation
in	I-Negation
one	I-Negation
complex	I-Negation
structure	I-Negation
but	O
does	O
so	O
in	O
another	O
.	O

3671	O
out	O
of	O
a	O
total	O
of	O
5380	O
interacting	O
protein	O
pairs	O
from	O
the	O
PDB	O
contain	O
an	O
iPfam	O
domain	O
pair	O
that	O
does	O
not	B-Negation
interact	I-Negation
in	I-Negation
one	I-Negation
complex	I-Negation
structure	I-Negation
but	O
does	O
so	O
in	O
another	O
.	O

This	O
means	O
that	O
for	O
more	O
than	O
32	O
%	O
of	O
the	O
protein	O
interactions	O
in	O
the	O
PDB	O
,	O
the	O
iPfam	O
domain	O
pair	O
assignment	O
is	O
correct	O
.	O

For	O
the	O
remaining	O
68	O
%	O
,	O
the	O
iPfam	O
domain	O
pair	O
assignments	O
are	O
wrong	O
in	O
one	O
case	O
but	O
correct	O
in	O
another	O
.	O

The	O
real	O
false	O
positive	O
rate	O
is	O
likely	O
to	O
be	O
smaller	O
,	O
because	O
some	O
iPfam	O
domain	O
pairs	O
might	O
still	O
independently	O
mediate	O
an	O
interaction	O
with	O
a	O
different	O
,	O
possibly	O
unknown	O
,	O
partner	O
protein	O
.	O

iPfam	O
domain	O
pairs	O
are	O
enriched	O
in	O
S.	O
cerevisiae	O
complexes	O

We	O
tested	O
whether	O
iPfam	O
domain	O
pairs	O
are	O
enriched	O
in	O
known	O
protein	O
complexes	O
from	O
S.	O
cerevisiae	O
.	O

This	O
is	O
interesting	O
firstly	O
because	O
domaindomain	O
interactions	O
are	O
thought	O
to	O
be	O
more	O
common	O
in	O
obligate	O
interactions	O
.	O

Secondly	O
,	O
the	O
described	O
modularity	O
of	O
known	O
S.	O
cerevisiae	O
complexes	O
lends	O
support	O
to	O
the	O
assumption	O
that	O
the	O
underlying	O
iPfam	O
domain	O
pairs	O
are	O
modular	O
.	O

In	O
fact	O
,	O
we	O
find	O
a	O
two-fold	O
enrichment	O
for	O
iPfam	O
domain	O
pairs	O
in	O
the	O
complexes	O
described	O
by	O
Gavin	O
et	O
al.	O
29	O
.	O

From	O
the	O
294	O
binary	O
protein	O
interactions	O
in	O
this	O
data	O
set	O
,	O
24	O
contained	O
an	O
iPfam	O
domain	O
pair	O
,	O
which	O
corresponds	O
to	O
a	O
coverage	O
of	O
8.16	O
%	O
(	O
P	O
value	O
2.7	O
	O
10-47	O
)	O
.	O

We	O
also	O
analysed	O
the	O
full	O
dataset	O
of	O
protein	O
complexes	O
.	O

From	O
491	O
complexes	O
described	O
by	O
Gavin	O
et	O
al.	O
,	O
157	O
contained	O
at	O
least	O
one	O
pair	O
of	O
proteins	O
with	O
an	O
iPfam	O
domain	O
pair	O
(	O
31.9	O
%	O
)	O
.	O

In	O
total	O
we	O
found	O
617	O
pairs	O
of	O
proteins	O
that	O
contained	O
an	O
iPfam	O
domain	O
pair	O
.	O

Interestingly	O
,	O
we	O
find	O
that	O
the	O
distribution	O
of	O
iPfam	O
domain	O
pairs	O
on	O
complexes	O
is	O
uneven	O
.	O

When	O
we	O
drew	O
617	O
protein	O
pairs	O
randomly	O
from	O
all	O
possible	O
protein	O
pairs	O
in	O
the	O
complexes	O
,	O
we	O
covered	O
192	O
complexes	O
on	O
average	O
,	O
with	O
a	O
standard	O
deviation	O
of	O
7.22	O
.	O

The	O
probability	O
of	O
covering	O
only	O
157	O
complexes	O
is	O
just	O
6.24	O
	O
10-07	O
.	O

Thus	O
,	O
some	O
complexes	O
contain	O
a	O
greater	O
number	O
of	O
iPfam	O
domain	O
pairs	O
,	O
while	O
other	O
complexes	O
do	O
not	B-Negation
contain	I-Negation
any	I-Negation
at	I-Negation
all	I-Negation
.	O

This	O
suggests	O
that	O
some	O
sets	O
of	O
domain	O
pairs	O
are	O
specific	O
to	O
certain	O
complexes	O
or	O
pathways	O
.	O

Typical	O
examples	O
are	O
the	O
RNA	O
polymerase	O
II	O
complex	O
(	O
IntAct	O
id	O
:	O
EBI-815049	O
)	O
or	O
the	O
U1	O
snRNP	O
complex	O
which	O
contain	O
numerous	O
iPfam	O
domain	O
pairs	O
that	O
are	O
specific	O
to	O
these	O
complexes	O
.	O

iPfam	O
domain	O
pairs	O
are	O
conserved	O
between	O
species	O

Within	O
the	O
3	O
to	O
19	O
%	O
of	O
experimental	O
interactions	O
covered	O
by	O
iPfam	O
,	O
we	O
analysed	O
the	O
conservation	O
of	O
iPfam	O
domain	O
pairs	O
between	O
species	O
.	O

We	O
call	O
an	O
iPfam	O
domain	O
pair	O
conserved	O
when	O
the	O
same	O
pair	O
is	O
observed	O
in	O
experimental	O
interactions	O
of	O
two	O
different	O
species	O
.	O

The	O
matrix	O
in	O
Table	O
2	O
shows	O
the	O
pair-wise	O
conservation	O
of	O
iPfam	O
domain	O
pairs	O
.	O

For	O
each	O
species	O
,	O
a	O
maximum	O
of	O
40	O
%	O
to	O
90	O
%	O
of	O
iPfam	O
domain	O
pairs	O
can	O
also	O
be	O
found	O
in	O
another	O
species	O
,	O
although	O
not	O
all	O
overlaps	O
are	O
as	O
large	O
.	O

Matrix	O
of	O
mutual	O
shared	O
iPfam	O
domain	O
pairs	O

The	O
Table	O
shows	O
the	O
number	O
of	O
co-occurences	O
of	O
iPfam	O
domain	O
pairs	O
between	O
two	O
species	O
.	O

The	O
right-most	O
column	O
lists	O
the	O
total	O
number	O
of	O
unique	O
iPfam	O
pairs	O
found	O
in	O
each	O
species	O
'	O
experimental	O
interactions	O
.	O

Figure	O
4	O
shows	O
a	O
Venn	O
diagram	O
of	O
the	O
mutual	O
overlaps	O
between	O
the	O
two	O
eukaryotes	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
and	O
the	O
prokaryote	O
E.	O
coli	O
.	O

While	O
the	O
eukaryotes	O
share	O
524	O
domain	O
pairs	O
,	O
only	O
158	O
iPfam	O
domain	O
pairs	O
are	O
shared	O
between	O
S.	O
cerevisiae	O
and	O
E.	O
coli	O
,	O
and	O
only	O
135	O
between	O
E.	O
coli	O
and	O
H.	O
sapiens	O
.	O

Remarkably	O
,	O
53	O
%	O
of	O
the	O
observed	O
iPfam	O
domain	O
pairs	O
in	O
E.	O
coli	O
are	O
also	O
observed	O
in	O
one	O
of	O
the	O
two	O
eukaryotes	O
,	O
and	O
107	O
iPfam	O
domain	O
pairs	O
are	O
even	O
conserved	O
amongst	O
all	O
three	O
species	O
.	O

The	O
iPfam	O
domains	O
in	O
these	O
pairs	O
are	O
related	O
to	O
housekeeping	O
activities	O
such	O
as	O
translation	O
,	O
replication	O
or	O
ATP	O
synthesis	O
.	O

Additional	O
file	O
3	O
contains	O
a	O
list	O
of	O
the	O
conserved	O
iPfam	O
domain	O
pairs	O
.	O

Venn	O
diagramm	O
showing	O
the	O
fractions	O
of	O
iPfam	O
domain	O
pairs	O
found	O
in	O
the	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
binary	O
protein	O
interaction	O
sets	O

Venn	O
diagramm	O
showing	O
the	O
fractions	O
of	O
iPfam	O
domain	O
pairs	O
found	O
in	O
the	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
binary	O
protein	O
interaction	O
sets	O
.	O

The	O
three	O
circles	O
represent	O
the	O
iPfam	O
domain	O
pairs	O
observed	O
in	O
the	O
respective	O
species	O
.	O

The	O
overlaps	O
denote	O
co-observed	O
iPfam	O
domain	O
pairs	O
.	O

The	O
grey	O
set	O
in	O
the	O
background	O
represents	O
iPfam	O
domain	O
pairs	O
not	B-Negation
found	I-Negation
in	I-Negation
the	I-Negation
three	I-Negation
species	I-Negation
.	O

We	O
also	O
compared	O
the	O
iPfam	O
domain	O
pair	O
frequencies	O
between	O
H.	O
sapiens	O
and	O
S.	O
cerevisiae	O
directly	O
.	O

We	O
derive	O
a	O
Spearman	O
correlation	O
coefficient	O
of	O
0.50	O
for	O
the	O
frequencies	O
of	O
all	O
524	O
iPfam	O
domain	O
pairs	O
that	O
are	O
conserved	O
between	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
.	O

To	O
test	O
whether	O
the	O
correlation	O
is	O
an	O
artefact	O
of	O
the	O
distribution	O
of	O
the	O
values	O
,	O
we	O
recalculated	O
the	O
correlation	O
1000	O
times	O
,	O
each	O
time	O
shuffling	O
one	O
distribution	O
randomly	O
.	O

From	O
these	O
random	O
results	O
,	O
we	O
derive	O
a	O
P	O
value	O
of	O
3.6	O
	O
10-30	O
that	O
the	O
observed	O
correlation	O
is	O
random	O
.	O

This	O
suggests	O
that	O
iPfam	O
domain	O
pairs	O
with	O
a	O
large	O
number	O
of	O
occurrences	O
in	O
one	O
species	O
tend	O
also	O
to	O
be	O
more	O
frequent	O
in	O
the	O
other	O
.	O

Predicting	O
the	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O
in	O
nature	O

Our	O
analysis	O
allow	O
us	O
to	O
estimate	O
how	O
many	O
iPfam	O
domain	O
pairs	O
would	O
eventually	O
cover	O
all	O
protein	O
interactions	O
.	O

This	O
corresponds	O
to	O
the	O
predictions	O
made	O
by	O
Aloy	O
and	O
Russel	O
2	O
.	O

Similar	O
to	O
their	O
approach	O
,	O
we	O
make	O
a	O
linear	O
estimation	O
with	O
the	O
following	O
factors	O
:	O

S	O
The	O
number	O
of	O
iPfam	O
domain	O
pairs	O
observed	O
in	O
species	O
S	O

S	O
The	O
number	O
of	O
observed	O
interactions	O
in	O
species	O
S	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O

S	O
The	O
total	O
number	O
of	O
observed	O
interactions	O
in	O
species	O
S	O

S	O
The	O
number	O
of	O
proteins	O
from	O
species	O
S	O
that	O
are	O
seen	O
in	O
an	O
interaction	O
screen	O

S	O
The	O
proteome	O
size	O
for	O
species	O
S	O

S	O
The	O
number	O
of	O
Pfam	O
domains	O
observed	O
in	O
all	O
protein	O
of	O
species	O
S	O

	O
The	O
total	O
number	O
of	O
known	O
Pfam	O
domains	O

We	O
denote	O
the	O
estimated	O
number	O
of	O
iPfam	O
domain	O
pairs	O
in	O
species	O
S	O
with	O
x^S	O
.	O

The	O
formula	O
we	O
apply	O
is	O
x^S=SSSSS	O

This	O
means	O
we	O
scale	O
the	O
observed	O
number	O
of	O
iPfam	O
domain	O
pairs	O
to	O
cover	O
all	O
observed	O
interactions	O
.	O

We	O
then	O
use	O
the	O
relative	O
proteome	O
coverage	O
to	O
estimate	O
the	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O
in	O
all	O
proteins	O
.	O

Finally	O
,	O
we	O
follow	O
the	O
argument	O
of	O
Aloy	O
and	O
Russel	O
that	O
the	O
number	O
of	O
Pfam	O
families	O
seen	O
in	O
species	O
S	O
indicates	O
the	O
fraction	O
of	O
the	O
protein	O
universe	O
represented	O
in	O
the	O
species	O
.	O

We	O
therefore	O
predict	O
the	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O
x^	O
as	O
x^=x^SS	O
.	O

Both	O
parameters	O
and	O
results	O
of	O
the	O
calculation	O
are	O
shown	O
in	O
Table	O
3	O
.	O

The	O
estimates	O
for	O
the	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O
ranges	O
from	O
33813	O
to	O
120511	O
,	O
with	O
an	O
average	O
of	O
76918	O
.	O

Prediction	O
of	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O

S	O
The	O
total	O
number	O
of	O
observed	O
interactions	O
in	O
species	O
S	O

S	O
The	O
number	O
of	O
observed	O
interactions	O
in	O
species	O
S	O
that	O
contain	O
an	O
iPfam	O
domain	O
pair	O

S	O
The	O
proteome	O
size	O
for	O
species	O
S	O

S	O
The	O
number	O
of	O
proteins	O
from	O
species	O
S	O
that	O
are	O
seen	O
in	O
an	O
interaction	O
screen	O

S	O
The	O
number	O
of	O
iPfam	O
domain	O
pairs	O
observed	O
in	O
species	O
S	O

The	O
predicted	O
total	O
number	O
of	O
iPfam	O
domain	O
pairs	O
in	O
species	O
S	O

	O
The	O
total	O
number	O
of	O
known	O
Pfam	O
domains	O

S	O
The	O
number	O
of	O
Pfam	O
domains	O
observed	O
in	O
all	O
protein	O
of	O
species	O
S	O

The	O
estimated	O
total	O
number	O
of	O
iPfam	O
domains	O
in	O
all	O
species	O

Prediction	O
results	O
are	O
shown	O
in	O
bold	O
font	O
.	O

Discussion	O

iPfam	O
coverage	O
is	O
low	O

The	O
coverage	O
of	O
iPfam	O
on	O
experimentally	O
derived	O
protein	O
interactions	O
is	O
low	O
.	O

For	O
S.	O
cerevisiae	O
,	O
the	O
species	O
with	O
the	O
best	O
mapped	O
interactome	O
,	O
only	O
4.47	O
%	O
of	O
the	O
protein	O
interactions	O
contain	O
an	O
iPfam	O
domain	O
pair	O
.	O

Even	O
in	O
H.	O
sapiens	O
,	O
where	O
we	O
suspect	B-Speculation
a	I-Speculation
positive	I-Speculation
bias	I-Speculation
due	I-Speculation
to	I-Speculation
the	I-Speculation
overrepresentation	I-Speculation
of	I-Speculation
disease-related	I-Speculation
proteins	I-Speculation
in	I-Speculation
both	I-Speculation
the	I-Speculation
PDB	I-Speculation
and	I-Speculation
protein	I-Speculation
interaction	I-Speculation
databases	I-Speculation
,	O
81	O
%	O
of	O
protein	O
interactions	O
do	O
not	B-Negation
contain	I-Negation
an	I-Negation
iPfam	I-Negation
domain	I-Negation
pair	I-Negation
.	O

This	O
reveals	O
the	O
limits	O
of	O
our	O
understanding	O
of	O
the	O
molecular	O
structure	O
of	O
protein	O
interactions	O
.	O

Figure	O
1	O
also	O
shows	O
that	O
a	O
majority	O
of	O
protein	O
interactions	O
contains	O
at	O
least	O
one	O
pair	O
of	O
Pfam	O
domains	O
.	O

While	O
there	O
is	O
no	B-Negation
structural	I-Negation
information	I-Negation
about	I-Negation
putative	I-Negation
interactions	I-Negation
between	I-Negation
these	I-Negation
pairs	I-Negation
,	O
this	O
fraction	O
can	O
already	O
be	O
analysed	O
using	O
statistical	O
methods	O
to	O
identify	O
putative	O
domain	O
interactions	O
7910	O
.	O

This	O
in	O
turn	O
creates	O
new	O
targets	O
for	O
future	O
structural	O
genomics	O
projects	O
30	O
.	O

Prioritising	O
these	O
targets	O
according	O
to	O
the	O
number	O
of	O
covered	O
experimental	O
interactions	O
could	O
increase	O
the	O
coverage	O
of	O
databases	O
like	O
iPfam	O
quickly	O
.	O

We	O
find	O
,	O
however	O
,	O
that	O
iPfam	O
domain	O
pairs	O
occur	O
significantly	O
more	O
often	O
in	O
experimental	O
interactions	O
than	O
would	O
be	O
expected	O
by	O
chance	O
.	O

This	O
requires	O
that	O
at	O
least	O
a	O
subset	O
of	O
the	O
iPfam	O
domain	O
pairs	O
are	O
reused	O
in	O
several	O
experimental	O
interactions	O
.	O

iPfam	O
domain	O
pairs	O
can	O
act	O
as	O
modules	O

Despite	O
the	O
low	O
overall	O
coverage	O
,	O
iPfam	O
domain	O
pairs	O
are	O
found	O
in	O
more	O
protein	O
interactions	O
than	O
would	O
be	O
expected	O
by	O
chance	O
(	O
see	O
Table	O
1	O
)	O
.	O

This	O
statistical	O
overrepresentation	O
suggests	O
that	O
certain	O
iPfam	O
domain	O
pairs	O
constitute	O
modules	O
of	O
molecular	O
recognition	O
which	O
are	O
reused	O
in	O
different	O
protein	O
interactions	O
2	O
.	O

In	O
fact	O
,	O
we	O
find	O
a	O
characteristic	O
power	O
law	O
distribution	O
when	O
we	O
plot	O
the	O
histogram	O
of	O
experimental	O
interactions	O
per	O
iPfam	O
domain	O
pair	O
,	O
see	O
Figure	O
2	O
.	O

This	O
underlines	O
that	O
a	O
few	O
promiscuous	O
iPfam	O
domain	O
pairs	O
are	O
responsible	O
for	O
the	O
majority	O
of	O
the	O
iPfam	O
coverage	O
.	O

These	O
iPfam	O
domain	O
pairs	O
are	O
most	O
likely	O
to	O
be	O
reusable	O
modules	O
.	O

In	O
fact	O
,	O
we	O
find	O
the	O
most	O
frequent	O
iPfam	O
domain	O
pairs	O
to	O
be	O
recognition	O
domains	O
in	O
signal	O
transduction	O
.	O

Conversely	O
,	O
a	O
large	O
number	O
of	O
iPfam	O
domain	O
pairs	O
are	O
specific	O
to	O
a	O
small	O
number	O
of	O
protein	O
interactions	O
.	O

This	O
implies	O
that	O
recognition	O
specificity	O
amongst	O
proteins	O
is	O
often	O
achieved	O
by	O
maintaining	O
an	O
exclusive	O
interacting	O
domain	O
pair	O
.	O

This	O
could	O
pose	O
a	O
problem	O
for	O
purely	O
statistical	O
approaches	O
to	O
infer	O
domain	O
interactions	O
:	O
:	O
if	O
for	O
many	O
interfaces	O
the	O
real	O
interacting	O
domain	O
pair	O
will	O
only	O
occur	O
once	O
in	O
an	O
interactome	O
,	O
it	O
will	O
be	O
hard	O
to	O
elucidate	O
this	O
on	O
a	O
statistical	O
basis	O
.	O

The	O
concept	O
of	O
modularity	O
of	O
interacting	O
domain	O
pairs	O
is	O
furthermore	O
supported	O
by	O
the	O
positive	O
correlation	O
between	O
the	O
number	O
of	O
protein	O
interactions	O
an	O
iPfam	O
domain	O
pair	O
is	O
seen	O
in	O
and	O
the	O
connectivity	O
of	O
the	O
interacting	O
proteins	O
.	O

We	O
hypothesise	O
that	O
if	O
during	O
the	O
course	O
of	O
evolution	O
a	O
protein	O
is	O
duplicated	O
,	O
it	O
is	O
likely	O
to	O
retain	O
connections	O
with	O
other	O
proteins	O
which	O
contain	O
the	O
same	O
domain	O
interaction	O
modules	O
.	O

It	O
is	O
clear	O
,	O
however	O
,	O
that	O
even	O
though	O
recognition	O
domains	O
are	O
reused	O
in	O
various	O
proteins	O
,	O
their	O
specificity	O
is	O
bound	O
to	O
be	O
controlled	O
.	O

Many	O
domaindomain	O
interfaces	O
remain	O
to	O
be	O
resolved	O

We	O
tried	O
to	O
estimate	O
how	O
many	O
iPfam	O
domain	O
pairs	O
exists	O
in	O
all	O
interactomes	O
.	O

Our	O
predictions	O
lie	O
almost	O
an	O
order	O
of	O
magnitude	O
higher	O
than	O
the	O
10000	O
domain	O
interaction	O
types	O
proposed	O
by	O
Aloy	O
and	O
Russel	O
2	O
.	O

While	O
all	O
such	O
estimates	O
should	O
be	O
taken	O
with	O
caution	O
,	O
our	O
results	O
show	O
that	O
at	O
best	O
10	O
%	O
of	O
all	O
structural	O
domain	O
pairs	O
are	O
represented	O
in	O
iPfam	O
.	O

The	O
statistical	O
approaches	O
described	O
in	O
the	O
introduction	O
can	O
only	O
cover	O
a	O
small	O
fraction	O
of	O
this	O
domaininteraction	O
space	O
.	O

Riley	O
et	O
al.	O
for	O
example	O
report	O
only	O
3005	O
interacting	O
domain	O
pairs	O
which	O
could	O
be	O
inferred	O
from	O
protein	O
interactions	O
7	O
.	O

Even	O
under	O
the	O
assumption	O
that	O
many	O
interactions	O
involve	O
short	O
linear	O
motifs	O
,	O
it	O
seems	O
likely	O
that	O
a	O
large	O
number	O
of	O
domain	O
interactions	O
remain	O
to	O
be	O
resolved	O
.	O

iPfam	O
domain	O
pairs	O
are	O
conserved	O
during	O
evolution	O

iPfam	O
domain	O
pairs	O
are	O
not	O
only	O
recurrent	O
within	O
the	O
protein	O
interaction	O
network	O
of	O
one	O
species	O
.	O

They	O
also	O
appear	O
to	O
be	O
conserved	O
between	O
species	O
.	O

In	O
a	O
small	O
set	O
of	O
protein	O
structures	O
from	O
S.	O
cerevisiae	O
,	O
it	O
has	O
been	O
shown	O
that	O
interacting	O
domain	O
pairs	O
are	O
more	O
conserved	O
than	O
non-interacting	O
domain	O
pairs	O
10	O
.	O

Here	O
,	O
we	O
call	O
an	O
iPfam	O
domain	O
pair	O
conserved	O
if	O
there	O
are	O
protein	O
interactions	O
in	O
two	O
species	O
which	O
contain	O
the	O
same	O
iPfam	O
domain	O
pair	O
.	O

In	O
a	O
recent	O
study	O
31	O
,	O
Gandhi	O
et	O
al.	O
have	O
assessed	O
the	O
conservation	O
of	O
protein	O
interactions	O
as	O
the	O
co-occurrence	O
of	O
orthologous	O
interacting	O
proteins	O
.	O

They	O
found	O
only	O
16	O
orthologous	O
interacting	O
protein	O
pairs	O
that	O
were	O
conserved	O
in	O
S.	O
cerevisiae	O
,	O
C.	O
elegans	O
,	O
D.	O
melanogaster	O
and	O
H.	O
sapiens	O
.	O

Conversely	O
,	O
we	O
find	O
that	O
71	O
iPfam	O
domain	O
pairs	O
are	O
conserved	O
in	O
the	O
experimental	O
interactions	O
of	O
these	O
species	O
.	O

Even	O
between	O
a	O
prokaryote	O
like	O
E.	O
coli	O
and	O
the	O
two	O
eukaryotes	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
there	O
is	O
a	O
considerable	O
proportion	O
of	O
conserved	O
iPfam	O
domain	O
pairs	O
,	O
to	O
the	O
extent	O
that	O
53	O
%	O
of	O
the	O
iPfam	O
domain	O
pairs	O
from	O
E.	O
coli	O
are	O
also	O
observed	O
in	O
a	O
eukaryote	O
(	O
Table	O
2	O
)	O
.	O

107	O
domain	O
pairs	O
are	O
shared	O
between	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
.	O

These	O
domains	O
are	O
predominantly	O
related	O
to	O
transcription	O
,	O
translation	O
and	O
other	O
basic	O
essential	O
cellular	O
activities	O
,	O
which	O
is	O
in	O
congruence	O
with	O
the	O
findings	O
of	O
Gandhi	O
et	O
al	O
.	O

Although	O
the	O
low	O
overall	O
iPfam	O
coverage	O
hampers	O
the	O
interpretation	O
of	O
our	O
results	O
,	O
it	O
looks	O
as	O
if	O
there	O
has	O
been	O
a	O
diversification	O
of	O
domain	O
interactions	O
from	O
E.	O
coli	O
to	O
H.	O
sapiens	O
.	O

While	O
more	O
than	O
half	O
of	O
the	O
iPfam	O
domain	O
pairs	O
in	O
E.	O
coli	O
have	O
been	O
retained	O
throughout	O
evolution	O
,	O
numerous	O
new	O
ones	O
seem	O
to	O
have	O
emerged	O
in	O
eukaryotic	O
development	O
.	O

The	O
significant	O
positive	O
correlation	O
in	O
the	O
frequency	O
of	O
iPfam	O
domain	O
pairs	O
conserved	O
between	O
S.	O
cerevisiae	O
and	O
H.	O
sapiens	O
also	O
suggests	O
that	O
the	O
binding	O
interfaces	O
are	O
more	O
often	O
kept	O
or	O
even	O
reused	O
rather	O
than	O
lost	O
in	O
the	O
course	O
of	O
evolution	O
.	O

Conversely	O
,	O
this	O
also	O
raises	O
the	O
question	O
of	O
whether	O
one	O
could	O
establish	O
a	O
comprehensive	O
set	O
of	O
domain	O
interactions	O
that	O
were	O
present	O
in	O
the	O
last	O
universal	O
common	O
ancestor	O
.	O

Conclusion	O

In	O
this	O
study	O
,	O
we	O
addressed	O
the	O
utility	O
of	O
current	O
knowledge	O
about	O
structural	O
domain	O
interactions	O
in	O
order	O
to	O
interpret	O
experimental	O
protein	O
interactions	O
.	O

Disappointingly	O
,	O
only	O
a	O
small	O
fraction	O
of	O
all	O
experimental	O
interactions	O
can	O
be	O
attributed	O
to	O
a	O
known	O
domain	O
interaction	O
.	O

Within	O
this	O
subset	O
of	O
interactions	O
,	O
we	O
nevertheless	O
made	O
several	O
reassuring	O
observations	O
:	O
structural	O
domain	O
pairs	O
are	O
enriched	O
in	O
experimental	O
protein	O
interactions	O
.	O

Some	O
of	O
the	O
domain	O
pairs	O
seem	O
to	O
mediate	O
a	O
large	O
number	O
of	O
protein	O
interactions	O
,	O
thus	O
acting	O
as	O
reusable	O
connectors	O
.	O

This	O
property	O
is	O
also	O
conserved	O
between	O
species	O
.	O

Taken	O
as	O
a	O
whole	O
,	O
this	O
further	O
underlines	O
that	O
solving	O
structures	O
of	O
protein	O
complexes	O
should	O
be	O
an	O
important	O
focus	O
for	O
future	O
structural	O
genomics	O
projects	O
.	O

Targeting	O
the	O
most	O
frequent	O
domain	O
pairs	O
would	O
increase	O
the	O
coverage	O
of	O
databases	O
such	O
as	O
iPfam	O
,	O
shedding	O
more	O
light	O
onto	O
the	O
molecular	O
mechanisms	O
underpinning	O
cellular	O
networks	O
.	O

Methods	O

Protein	O
interaction	O
data	O

The	O
complete	O
interaction	O
sets	O
from	O
BioGRID	O
20	O
,	O
DIP	O
21	O
,	O
HPRD	O
22	O
,	O
IntAct	O
23	O
and	O
MPact	O
24	O
were	O
downloaded	O
.	O

A	O
wide	O
range	O
of	O
databases	O
were	O
used	O
to	O
cover	O
as	O
many	O
distinct	O
experimental	O
data	O
sets	O
as	O
possible	O
.	O

BioGRID	O
for	O
example	O
contains	O
a	O
large	O
manually	O
curated	O
set	O
of	O
protein	O
interactions	O
for	O
S.	O
cerevisiae	O
19	O
.	O

Similarily	O
,	O
HPRD	O
hosts	O
a	O
set	O
of	O
manually	O
curated	O
protein	O
interactions	O
for	O
H.	O
sapiens	O
.	O

IntAct	O
on	O
the	O
other	O
hand	O
contains	O
results	O
from	O
high-throughput	O
screens	O
and	O
integrates	O
data	O
from	O
other	O
protein	O
interaction	O
databases	O
as	O
part	O
of	O
the	O
IMEx	O
collaboration	O
.	O

The	O
MPact	O
database	O
combines	O
the	O
manually	O
curated	O
S.	O
cerevisiae	O
protein	O
complexes	O
data	O
set	O
formerly	O
known	O
as	O
the	O
MIPS	O
complexes	O
with	O
other	O
high-throughput	O
interaction	O
experiments	O
data	O
.	O

Taken	O
together	O
,	O
these	O
databases	O
represent	O
most	O
of	O
the	O
protein	O
interactions	O
currently	O
stored	O
in	O
machine-accessible	O
form	O
.	O

Despite	O
great	O
efforts	O
to	O
unify	O
access	O
to	O
protein	O
interaction	O
data	O
32	O
,	O
acquiring	O
large	O
data	O
sets	O
from	O
diverse	O
sources	O
is	O
still	O
far	O
from	O
trivial	O
and	O
error	O
prone	O
.	O

The	O
PSI-MI	O
XML	O
data	O
exchange	O
format	O
provided	O
by	O
the	O
aforementioned	O
databases	O
was	O
used	O
to	O
generate	O
a	O
local	O
relational	O
database	O
of	O
protein	O
interactions	O
.	O

All	O
entries	O
were	O
mapped	O
to	O
UniProt	O
33	O
by	O
either	O
relying	O
on	O
existing	O
annotations	O
from	O
the	O
source	O
databases	O
or	O
by	O
pair-wise	O
sequence	O
alignment	O
to	O
all	O
UniProt	O
proteins	O
from	O
the	O
same	O
species	O
as	O
the	O
query	O
protein	O
.	O

The	O
direct	O
sequence	O
comparison	O
was	O
performed	O
using	O
pmatch	O
,	O
a	O
very	O
fast	O
pairwise	O
alignment	O
algorithm	O
developed	O
by	O
Richard	O
Durbin	O
(	O
unpublished	O
,	O
source	O
code	O
available	O
34	O
)	O
.	O

Species	O

To	O
allow	O
cross-species	O
comparisons	O
,	O
the	O
data	O
were	O
split	O
into	O
five	O
distinct	O
species	O
sets	O
:	O
E.	O
coli	O
,	O
S.	O
cerevisiae	O
,	O
C.	O
elegans	O
,	O
D.	O
melanogaster	O
and	O
H.	O
sapiens	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
proportion	O
of	O
proteins	O
for	O
which	O
an	O
interaction	O
is	O
known	O
varies	O
greatly	O
between	O
the	O
species	O
,	O
see	O
Table	O
1	O
.	O

This	O
might	O
affect	O
the	O
results	O
if	O
there	O
is	O
a	O
systematic	O
bias	O
on	O
the	O
composition	O
of	O
a	O
protein	O
interaction	O
set	O
.	O

To	O
prevent	O
bias	O
from	O
multiple	O
alternative	O
versions	O
of	O
the	O
same	O
protein	O
,	O
all	O
interacting	O
proteins	O
were	O
mapped	O
to	O
reference	O
proteomes	O
as	O
defined	O
by	O
Integr8	O
35	O
,	O
again	O
using	O
pmatch	O
.	O

An	O
average	O
of	O
	O
16	O
%	O
of	O
interaction	O
entries	O
were	O
lost	O
in	O
the	O
mapping	O
process	O
,	O
either	O
if	O
no	B-Negation
sequence	I-Negation
was	I-Negation
provided	I-Negation
with	I-Negation
the	I-Negation
original	I-Negation
entry	I-Negation
or	O
if	O
no	B-Negation
significant	I-Negation
matching	I-Negation
sequence	I-Negation
could	I-Negation
be	I-Negation
found	I-Negation
in	I-Negation
Integr8	I-Negation
.	O

The	O
total	O
number	O
of	O
missing	O
proteins	O
will	O
be	O
lower	O
,	O
as	O
several	O
entries	O
from	O
different	O
databases	O
refer	O
to	O
the	O
same	O
sequence	O
.	O

iPfam	O

The	O
iPfam	O
database	O
is	O
derived	O
from	O
protein	O
structures	O
deposited	O
in	O
the	O
PDB	O
.	O

Regions	O
in	O
every	O
protein	O
structure	O
that	O
match	O
a	O
Pfam	O
domain	O
are	O
scanned	O
for	O
interactions	O
with	O
residues	O
in	O
another	O
Pfam	O
domain	O
.	O

All	O
such	O
interacting	O
domain	O
pairs	O
are	O
stored	O
in	O
a	O
database	O
together	O
with	O
detailed	O
information	O
on	O
the	O
residues	O
involved	O
13	O
.	O

Every	O
pair	O
of	O
Pfam	O
families	O
that	O
are	O
found	O
to	O
interact	O
in	O
a	O
PDB	O
structure	O
are	O
called	O
an	O
iPfam	O
domain	O
pair	O
throughout	O
the	O
text	O
.	O

Single	O
Pfam	O
families	O
that	O
are	O
part	O
of	O
an	O
iPfam	O
domain	O
pair	O
are	O
then	O
called	O
iPfam	O
domains	O
.	O

For	O
example	O
,	O
in	O
PDB	O
entry	O
1k9a	O
the	O
two	O
iPfam	O
domains	O
SH2	O
(	O
Pfam	O
accession	O
PF00017	O
)	O
and	O
Pkinase_Tyr	O
(	O
PF07714	O
)	O
interact	O
,	O
therefore	O
they	O
form	O
an	O
iPfam	O
domain	O
pair	O
.	O

In	O
this	O
study	O
,	O
iPfam	O
version	O
21	O
was	O
employed	O
,	O
containing	O
2837	O
iPfam	O
domains	O
,	O
forming	O
4030	O
iPfam	O
domain	O
pairs	O
.	O

Figure	O
5	O
shows	O
the	O
species	O
distribution	O
of	O
iPfam	O
domain	O
pairs	O
.	O

H.	O
sapiens	O
,	O
E.	O
coli	O
and	O
S.	O
cerevisiae	O
are	O
clearly	O
over-represented	O
compared	O
to	O
the	O
other	O
1113	O
species	O
with	O
less	O
than	O
179	O
complex	O
structures	O
.	O

Some	O
iPfam	O
domain	O
pairs	O
are	O
seen	O
to	O
form	O
interactions	O
between	O
distinct	O
peptide	O
chains	O
in	O
the	O
structure	O
(	O
interchain	O
)	O
,	O
while	O
others	O
form	O
an	O
interaction	O
between	O
two	O
distinct	O
domains	O
within	O
the	O
same	O
chain	O
(	O
intrachain	O
)	O
.	O

In	O
iPfam	O
version	O
21	O
,	O
there	O
are	O
3407	O
interchain	O
and	O
1171	O
intrachain	O
domain	O
pairs	O
,	O
which	O
means	O
that	O
548	O
domain	O
pairs	O
mediate	O
both	O
inter-	O
and	O
intrachain	O
interactions	O
.	O

In	O
this	O
analysis	O
,	O
both	O
types	O
of	O
domain	O
interactions	O
were	O
used	O
equivalently	O
,	O
assuming	O
that	O
intrachain	O
interactions	O
can	O
become	O
interchain	O
interactions	O
and	O
vice-versa	O
as	O
a	O
result	O
of	O
a	O
gene-fission/fusion	O
events	O
.	O

Species	O
distribution	O
of	O
iPfam	O
domain	O
pairs	O

Species	O
distribution	O
of	O
iPfam	O
domain	O
pairs	O
.	O

This	O
pie	O
chart	O
shows	O
how	O
many	O
iPfam	O
domain	O
pairs	O
were	O
found	O
in	O
PDB	O
structures	O
from	O
each	O
species	O
.	O

The	O
total	O
number	O
is	O
larger	O
than	O
the	O
4030	O
unique	O
iPfam	O
pairs	O
in	O
the	O
database	O
because	O
an	O
iPfam	O
pair	O
can	O
be	O
found	O
in	O
structures	O
from	O
several	O
species	O
.	O

Filtering	O

There	O
are	O
many	O
types	O
of	O
experiments	O
used	O
to	O
derive	O
protein	O
interactions	O
,	O
with	O
different	O
properties	O
and	O
error	O
rates	O
.	O

For	O
this	O
analysis	O
,	O
solely	O
the	O
properties	O
of	O
physically	O
interacting	O
proteins	O
is	O
of	O
interest	O
.	O

Therefore	O
,	O
only	O
interactions	O
between	O
exactly	O
two	O
proteins	O
per	O
experiment	O
were	O
considered	O
.	O

That	O
means	O
all	O
protein	O
complex	O
data	O
that	O
were	O
derived	O
by	O
co-purification	O
methods	O
were	O
removed	O
,	O
unless	O
a	O
particular	O
experiment	O
had	O
identified	O
exactly	O
two	O
binding	O
partners	O
.	O

All	O
genetic	O
interactions	O
were	O
also	O
removed	O
.	O

Random	O
networks	O

Randomised	O
protein	O
interaction	O
networks	O
with	O
identical	O
degree	O
distributions	O
were	O
generated	O
from	O
the	O
original	O
filtered	O
experimental	O
interaction	O
data	O
for	O
each	O
species	O
.	O

In	O
each	O
randomisation	O
step	O
,	O
a	O
mapping	O
is	O
created	O
that	O
assigns	O
every	O
node	O
a	O
randomly	O
chosen	O
replacement	O
node	O
.	O

In	O
this	O
way	O
the	O
edges	O
of	O
the	O
network	O
remain	O
in	O
place	O
,	O
while	O
the	O
nodes	O
are	O
shuffled	O
randomly	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
degree	O
distribution	O
per	O
node	O
is	O
not	B-Negation
maintained	I-Negation
.	O

Instead	O
,	O
this	O
behaviour	O
simulates	O
a	O
network	O
with	O
a	O
high	O
false	O
positive	O
rate	O
.	O

P	O
values	O

P	O
values	O
for	O
observations	O
x	O
were	O
calculated	O
as	O
P	O
(	O
X	O
	O
x	O
)	O
=	O
f	O
(	O
x	O
;	O
	O
,	O
	O
)	O
,	O
where	O
f	O
(	O
x	O
;	O
	O
,	O
	O
)	O
is	O
the	O
probability	O
density	O
function	O
of	O
the	O
normal	O
distribution	O
with	O
mean	O
	O
and	O
standard	O
deviation	O
	O
.	O

	O
and	O
	O
are	O
estimated	O
through	O
the	O
randomisation	O
experiments	O
.	O

The	O
density	O
function	O
thus	O
provides	O
the	O
probability	O
that	O
a	O
value	O
less	O
than	O
or	O
equal	O
to	O
x	O
is	O
observed	O
by	O
chance	O
,	O
given	O
the	O
distribution	O
estimated	O
by	O
a	O
random	O
resampling	O
method	O
.	O

Where	O
appropriate	O
,	O
the	O
inverse	O
probability	O
P	O
(	O
X	O
>	O
x	O
)	O
=	O
1	O
-	O
f	O
(	O
x	O
;	O
	O
,	O
	O
)	O
was	O
applied	O
.	O

Two	O
Distinct	O
E3	O
Ubiquitin	O
Ligases	O
Have	O
Complementary	O
Functions	O
in	O
the	O
Regulation	O
of	O
Delta	O
and	O
Serrate	O
Signaling	O
in	O
Drosophila	O

Abstract	O

Signaling	O
by	O
the	O
Notch	O
ligands	O
Delta	O
(	O
Dl	O
)	O
and	O
Serrate	O
(	O
Ser	O
)	O
regulates	O
a	O
wide	O
variety	O
of	O
essential	O
cell-fate	O
decisions	O
during	O
animal	O
development	O
.	O

Two	O
distinct	O
E3	O
ubiquitin	O
ligases	O
,	O
Neuralized	O
(	O
Neur	O
)	O
and	O
Mind	O
bomb	O
(	O
Mib	O
)	O
,	O
have	O
been	O
shown	O
to	O
regulate	O
Dl	O
signaling	O
in	O
Drosophila	O
melanogaster	O
and	O
Danio	O
rerio	O
,	O
respectively	O
.	O

While	O
the	O
neur	O
and	O
mib	O
genes	O
are	O
evolutionarily	O
conserved	O
,	O
their	B-Negation
respective	I-Negation
roles	I-Negation
in	I-Negation
the	I-Negation
context	I-Negation
of	I-Negation
a	I-Negation
single	I-Negation
organism	I-Negation
have	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
examined	I-Negation
.	O

We	O
show	O
here	O
that	O
the	O
Drosophila	O
mind	O
bomb	O
(	O
D-mib	O
)	O
gene	O
regulates	O
a	O
subset	O
of	O
Notch	O
signaling	O
events	O
,	O
including	O
wing	O
margin	O
specification	O
,	O
leg	O
segmentation	O
,	O
and	O
vein	O
determination	O
,	O
that	O
are	O
distinct	O
from	O
those	O
events	O
requiring	O
neur	O
activity	O
.	O

D-mib	O
also	O
modulates	O
lateral	O
inhibition	O
,	O
a	O
neur-	O
and	O
Dl-dependent	O
signaling	O
event	O
,	O
suggesting	O
that	O
D-mib	O
regulates	O
Dl	O
signaling	O
.	O

During	O
wing	O
development	O
,	O
expression	O
of	O
D-mib	O
in	O
dorsal	O
cells	O
appears	O
to	O
be	O
necessary	O
and	O
sufficient	O
for	O
wing	O
margin	O
specification	O
,	O
indicating	O
that	O
D-mib	O
also	O
regulates	O
Ser	O
signaling	O
.	O

Moreover	O
,	O
the	O
activity	O
of	O
the	O
D-mib	O
gene	O
is	O
required	O
for	O
the	O
endocytosis	O
of	O
Ser	O
in	O
wing	O
imaginal	O
disc	O
cells	O
.	O

Finally	O
,	O
ectopic	O
expression	O
of	O
neur	O
in	O
D-mib	O
mutant	O
larvae	O
rescues	O
the	O
wing	O
D-mib	O
phenotype	O
,	O
indicating	O
that	O
Neur	O
can	O
compensate	O
for	O
the	O
lack	O
of	O
D-mib	O
activity	O
.	O

We	O
conclude	O
that	O
D-mib	O
and	O
Neur	O
are	O
two	O
structurally	O
distinct	O
proteins	O
that	O
have	O
similar	O
molecular	O
activities	O
but	O
distinct	O
developmental	O
functions	O
in	O
Drosophila	O
.	O

Introduction	O

Cell-to-cell	O
signaling	O
mediated	O
by	O
receptors	O
of	O
the	O
Notch	O
(	O
N	O
)	O
family	O
has	O
been	O
implicated	O
in	O
various	O
developmental	O
decisions	O
in	O
organisms	O
ranging	O
from	O
nematodes	O
to	O
mammals	O
[	O
1	O
]	O
.	O

N	O
is	O
well-known	O
for	O
its	O
role	O
in	O
lateral	O
inhibition	O
,	O
a	O
key	O
patterning	O
process	O
that	O
organizes	O
the	O
regular	O
spacing	O
of	O
distinct	O
cell	O
types	O
within	O
groups	O
of	O
equipotent	O
cells	O
.	O

Additionally	O
,	O
N	O
mediates	O
inductive	O
signaling	O
between	O
cells	O
with	O
distinct	O
identities	O
.	O

In	O
both	O
signaling	O
events	O
,	O
N	O
signals	O
via	O
a	O
conserved	O
mechanism	O
that	O
involves	O
the	O
cleavage	O
and	O
release	O
from	O
the	O
membrane	O
of	O
the	O
N	O
intracellular	O
domain	O
that	O
acts	O
as	O
a	O
transcriptional	O
co-activator	O
for	O
DNA-binding	O
proteins	O
of	O
the	O
CBF1/Suppressor	O
of	O
Hairless/Lag-2	O
(	O
CSL	O
)	O
family	O
[	O
2	O
]	O
.	O

Two	O
transmembrane	O
ligands	O
of	O
N	O
are	O
known	O
in	O
Drosophila	O
,	O
Delta	O
(	O
Dl	O
)	O
and	O
Serrate	O
(	O
Ser	O
)	O
[	O
3	O
]	O
.	O

Dl	O
and	O
Ser	O
have	O
distinct	O
functions	O
.	O

For	O
instance	O
,	O
Dl	O
(	O
but	O
not	B-Negation
Ser	I-Negation
)	I-Negation
is	O
essential	O
for	O
lateral	O
inhibition	O
during	O
early	O
neurogenesis	O
in	O
the	O
embryo	O
[	O
4	O
]	O
.	O

Conversely	O
,	O
Ser	O
(	O
but	O
not	B-Negation
Dl	I-Negation
)	I-Negation
is	O
specifically	O
required	O
for	O
segmental	O
patterning	O
[	O
5	O
]	O
.	O

Some	O
developmental	O
decisions	O
,	O
however	O
,	O
require	O
the	O
activity	O
of	O
both	O
genes	O
:	O
Dl	O
and	O
Ser	O
are	O
both	O
required	O
for	O
the	O
specification	O
of	O
wing	O
margin	O
cells	O
during	O
imaginal	O
development	O
[	O
6,7,8,9,10	O
]	O
.	O

These	O
different	O
requirements	O
for	O
Dl	O
and	O
Ser	O
appear	O
to	O
primarily	O
result	O
from	O
their	O
non-overlapping	O
expression	O
patterns	O
rather	O
than	O
from	O
distinct	O
signaling	O
properties	O
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
Dl	O
and	O
Ser	O
have	O
been	O
proposed	O
to	O
act	O
redundantly	O
in	O
the	O
sensory	O
bristle	O
lineage	O
where	O
they	O
are	O
co-expressed	O
(	O
[	O
11	O
]	O
;	O
note	O
,	O
however	O
,	O
that	O
results	O
from	O
another	O
study	O
have	O
indicated	O
a	O
non-redundant	O
function	O
for	O
Dl	O
in	O
the	O
bristle	O
lineage	O
[	O
12	O
]	O
)	O
.	O

Furthermore	O
,	O
Dl	O
and	O
Ser	O
appear	O
to	O
be	O
partially	O
interchangeable	O
because	O
the	O
forced	O
expression	O
of	O
Ser	O
can	O
partially	O
rescue	O
the	O
Dl	O
neurogenic	O
phenotype	O
[	O
13	O
]	O
.	O

Additionally	O
,	O
the	O
ectopic	O
expression	O
of	O
Dl	O
can	O
partially	O
rescue	O
the	O
Ser	O
wing	O
phenotype	O
[	O
14	O
]	O
.	O

The	O
notion	O
that	O
Dl	O
and	O
Ser	O
have	O
similar	O
signaling	O
properties	O
has	O
,	O
however	O
,	O
recently	O
been	O
challenged	O
by	O
the	O
observation	O
that	O
human	O
homologs	O
of	O
Dl	O
and	O
Ser	O
have	O
distinct	O
instructive	O
signaling	O
activity	O
[	O
15	O
]	O
.	O

Endocytosis	O
has	O
recently	O
emerged	O
as	O
a	O
key	O
mechanism	O
regulating	O
the	O
signaling	O
activity	O
of	O
Dl	O
.	O

First	O
,	O
clonal	O
analysis	O
in	O
Drosophila	O
has	O
suggested	O
that	O
dynamin-dependent	O
endocytosis	O
is	O
required	O
not	O
only	O
in	O
signal-receiving	O
cells	O
but	O
also	O
in	O
signal-sending	O
cells	O
to	O
promote	O
N	O
activation	O
[	O
16	O
]	O
.	O

Second	O
,	O
mutant	O
Dl	O
proteins	O
that	O
are	O
endocytosis	O
defective	O
exhibit	O
reduced	O
signaling	O
activity	O
[	O
17	O
]	O
.	O

Third	O
,	O
two	O
distinct	O
E3	O
ubiquitin	O
ligases	O
,	O
Neuralized	O
(	O
Neur	O
)	O
and	O
Mind	O
bomb	O
(	O
Mib	O
)	O
,	O
have	O
recently	O
been	O
shown	O
to	O
regulate	O
Dl	O
endocytosis	O
and	O
N	O
activation	O
in	O
Drosophila	O
and	O
Danio	O
rerio	O
,	O
respectively	O
[	O
18,19,20,21,22,23,24,25	O
]	O
.	O

Ubiquitin	O
is	O
a	O
76-amino-acid	O
polypeptide	O
that	O
is	O
covalently	O
linked	O
to	O
substrates	O
in	O
a	O
multi-step	O
process	O
that	O
involves	O
a	O
ubiquitin-activating	O
enzyme	O
(	O
E1	O
)	O
,	O
a	O
ubiquitin-conjugating	O
enzyme	O
(	O
E2	O
)	O
,	O
and	O
a	O
ubiquitinprotein	O
ligase	O
(	O
E3	O
)	O
.	O

E3s	O
recognize	O
specific	O
substrates	O
and	O
catalyze	O
the	O
transfer	O
of	O
ubiquitin	O
to	O
the	O
protein	O
substrate	O
.	O

Ubiquitin	O
was	O
first	O
identified	O
as	O
a	O
tag	O
for	O
proteins	O
destined	O
for	O
degradation	O
.	O

More	O
recently	O
,	O
ubiquitin	O
has	O
also	O
been	O
shown	O
to	O
serve	O
as	O
a	O
signal	O
for	O
endocytosis	O
[	O
26,27	O
]	O
.	O

Mib	O
in	O
D.	O
rerio	O
and	O
Neur	O
in	O
Drosophila	O
and	O
Xenopus	O
have	O
been	O
shown	O
to	O
associate	O
with	O
Dl	O
,	O
regulate	O
Dl	O
ubiquitination	O
,	O
and	O
promote	O
its	O
endocytosis	O
[	O
18,19,20,22,25,28	O
]	O
.	O

Moreover	O
,	O
genetic	O
and	O
transplantation	O
studies	O
have	O
indicated	O
that	O
both	O
Neur	O
and	O
Mib	O
act	O
in	O
a	O
non-autonomous	O
manner	O
[	O
18,21,22,23,25,29	O
]	O
,	O
indicating	O
that	O
endocytosis	O
of	O
Dl	O
is	O
associated	O
with	O
increased	O
Dl	O
signaling	O
activity	O
.	O

Finally	O
,	O
epsin	O
,	O
a	O
regulator	O
of	O
endocytosis	O
that	O
contains	O
a	O
ubiquitin-interacting	O
motif	O
and	O
that	O
is	O
known	O
in	O
Drosophila	O
as	O
Liquid	O
facet	O
,	O
is	O
essential	O
for	O
Dl	O
signaling	O
[	O
30,31	O
]	O
.	O

In	O
one	O
study	O
,	O
Liquid	O
facet	O
was	O
proposed	O
to	O
target	O
Dl	O
to	O
an	O
endocytic	O
recycling	O
compartment	O
,	O
suggesting	O
that	O
recycling	O
of	O
Dl	O
may	O
be	O
required	O
for	O
signaling	O
.	O

Accordingly	O
,	O
signaling	B-Speculation
would	I-Speculation
not	B-Negation
be	I-Negation
linked	I-Negation
directly	I-Negation
to	I-Negation
endocytosis	I-Negation
,	O
but	O
endocytosis	O
would	B-Speculation
be	I-Speculation
prerequisite	I-Speculation
for	I-Speculation
signaling	I-Speculation
[	O
30	O
]	O
.	O

How	O
endocytosis	O
of	O
Dl	O
leads	O
to	O
the	O
activation	O
of	O
N	O
remains	O
to	O
be	O
elucidated	O
.	O

Also	O
,	O
whether	O
the	O
signaling	O
activity	O
of	O
Ser	O
is	O
similarly	O
regulated	O
by	O
endocytosis	O
is	O
not	O
known	O
.	O

Neur	O
and	O
Mib	O
proteins	O
completely	O
differ	O
in	O
primary	O
structure	O
.	O

Drosophila	O
Neur	O
is	O
a	O
754-amino-acid	O
protein	O
that	O
contains	O
two	O
conserved	O
Neur	O
homology	O
repeats	O
of	O
unknown	O
function	O
and	O
one	O
C-terminal	O
catalytic	O
really	O
interesting	O
new	O
gene	O
(	O
RING	O
)	O
domain	O
.	O

D.	O
rerio	O
Mib	O
(	O
also	O
known	O
as	O
DIP-1	O
in	O
the	O
mouse	O
[	O
32	O
]	O
)	O
is	O
a	O
1,030-amino-acid	O
protein	O
with	O
one	O
ZZ	O
zinc	O
finger	O
domain	O
surrounded	O
by	O
two	O
Mib/HERC2	O
domains	O
,	O
two	O
Mib	O
repeats	O
,	O
eight	O
ankyrin	O
repeats	O
,	O
two	O
atypical	O
RING	O
domains	O
,	O
and	O
one	O
C-terminal	O
catalytic	O
RING	O
domain	O
.	O

Both	O
genes	O
have	O
been	O
conserved	O
from	O
flies	O
to	O
mammals	O
[	O
18,19,33,34	O
]	O
.	O

While	O
genetic	O
analysis	O
has	O
revealed	O
that	O
neur	O
in	O
Drosophila	O
and	O
mib	O
in	O
D.	O
rerio	O
are	O
strictly	O
required	O
for	O
N	O
signaling	O
,	O
knockout	O
studies	O
of	O
mouse	O
Neur1	O
has	O
indicated	O
that	O
NEUR1	O
is	O
not	O
strictly	O
required	O
for	O
N	O
signaling	O
[	O
33,34	O
]	O
.	O

One	O
possible	O
explanation	O
is	O
functional	O
redundancy	O
with	O
the	O
mouse	O
Neur2	O
gene	O
.	O

Conversely	O
,	O
the	O
function	O
of	O
Drosophila	O
mib	O
(	O
D-mib	O
)	O
,	O
the	O
homolog	O
of	O
D.	O
rerio	O
mib	O
gene	O
,	O
is	O
not	O
known	O
.	O

To	O
establish	O
the	O
respective	O
roles	O
of	O
these	O
two	O
distinct	O
E3	O
ligases	O
in	O
the	O
context	O
of	O
a	O
single	O
model	O
organism	O
,	O
we	O
have	O
studied	O
the	O
function	O
of	O
the	O
Drosophila	O
D-mib	O
gene	O
.	O

We	O
report	O
here	O
that	O
D-mib	O
,	O
like	O
D.	O
rerio	O
Mib	O
,	O
appears	O
to	O
regulate	O
Dl	O
signaling	O
during	O
leg	O
segmentation	O
,	O
wing	O
vein	O
formation	O
,	O
and	O
lateral	O
inhibition	O
in	O
the	O
adult	O
notum	O
.	O

We	O
further	O
show	O
that	O
D-mib	O
is	O
specifically	O
required	O
for	O
Ser	O
endocytosis	O
and	O
signaling	O
during	O
wing	O
development	O
,	O
indicating	O
for	O
the	O
first	O
time	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
endocytosis	O
regulates	O
Ser	O
signaling	O
.	O

Interestingly	O
,	O
the	O
D-mib	O
activity	O
was	O
found	O
necessary	O
for	O
a	O
subset	O
of	O
N	O
signaling	O
events	O
that	O
are	O
distinct	O
from	O
those	O
requiring	O
the	O
activity	O
of	O
the	O
neur	O
gene	O
.	O

Nevertheless	O
,	O
the	O
ectopic	O
expression	O
of	O
Neur	O
compensates	O
for	O
the	O
loss	O
of	O
D-mib	O
activity	O
in	O
the	O
wing	O
,	O
indicating	O
that	O
Neur	O
and	O
D-mib	O
have	O
overlapping	O
functions	O
.	O

We	O
conclude	O
that	O
D-mib	O
and	O
Neur	O
are	O
two	O
structurally	O
distinct	O
proteins	O
with	O
similar	O
molecular	O
activities	O
but	O
distinct	O
and	O
complementary	O
functions	O
in	O
Drosophila	O
.	O

Results	O

Isolation	O
of	O
D-mib	O
Mutations	O

The	O
closest	O
Drosophila	O
homolog	O
of	O
the	O
vertebrate	O
mib	O
gene	O
is	O
the	O
predicted	O
gene	O
CG5841	O
,	O
D-mib	O
[	O
18	O
]	O
.	O

The	O
D-mib	O
mutations	O
identified	O
are	O
shown	O
in	O
Figure	O
1	O
.	O

A	O
P-element	O
inserted	O
into	O
the	O
5	O
?	O
untranslated	O
region	O
of	O
the	O
D-mib	O
gene	O
was	O
recently	O
isolated	O
(	O
http	O
:	O
//flypush.imgen.bcm.tmc.edu/pscreen/	O
)	O
(	O
Figure	O
1A	O
)	O
.	O

Insertion	O
of	O
this	O
P-element	O
confers	O
late	O
pupal	O
lethality	O
.	O

Lethality	O
was	O
reverted	O
by	O
precise	O
excision	O
of	O
the	O
P-element	O
,	O
suggesting	O
that	O
insertion	O
of	O
this	O
P-element	O
is	O
a	O
D-mib	O
mutation	O
,	O
referred	O
to	O
as	O
D-mib1	O
.	O

A	O
13.6-kb	O
deletion	O
that	O
removes	O
the	O
entire	O
D-mib	O
coding	O
region	O
was	O
selected	O
by	O
imprecise	O
excision	O
of	O
this	O
P-element	O
.	O

This	O
deletion	O
represents	O
a	O
null	O
allele	O
of	O
D-mib	O
and	O
was	O
named	O
D-mib2	O
.	O

This	O
deletion	O
also	O
deletes	O
the	O
3	O
?	O
flanking	O
RpS31	O
gene	O
(	O
Figure	O
1A	O
)	O
.	O

The	O
D-mib1	O
and	O
D-mib2mutant	O
alleles	O
did	O
not	B-Negation
complement	I-Negation
the	I-Negation
l	I-Negation
(	I-Negation
3	I-Negation
)	I-Negation
72CdaJ12	I-Negation
and	I-Negation
l	I-Negation
(	I-Negation
3	I-Negation
)	I-Negation
72CdaI5	I-Negation
lethal	I-Negation
mutations	I-Negation
that	I-Negation
have	I-Negation
been	I-Negation
mapped	I-Negation
to	I-Negation
the	I-Negation
same	I-Negation
cytological	I-Negation
interval	I-Negation
as	I-Negation
the	I-Negation
D-mib	I-Negation
gene	I-Negation
[	I-Negation
35	I-Negation
]	I-Negation
.	O

This	O
indicates	O
that	O
these	O
two	O
lethal	O
mutations	O
are	O
D-mib	O
mutant	O
alleles	O
,	O
and	O
they	O
were	O
therefore	O
renamed	O
D-mib3	O
and	O
D-mib4	O
,	O
respectively	O
.	O

The	O
D-mib1	O
and	O
D-mib3	O
mutations	O
behave	O
as	O
genetic	O
null	O
alleles	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

In	O
contrast	O
,	O
D-mib4	O
is	O
a	O
partial	O
loss-of-function	O
allele	O
because	O
flies	O
trans-heterozygous	O
for	O
D-mib4	O
and	O
any	O
other	O
D-mib	O
null	O
alleles	O
are	O
viable	O
.	O

These	O
four	O
mutations	O
identify	O
the	O
CG5841	O
gene	O
as	O
D-mib	O
by	O
the	O
following	O
evidence	O
.	O

First	O
,	O
lethality	O
of	O
homozygous	O
D-mib1	O
pupae	O
is	O
associated	O
with	O
the	O
insertion	O
of	O
a	O
P-element	O
into	O
the	O
5	O
?	O
UTR	O
of	O
the	O
D-mib	O
gene	O
.	O

Second	O
,	O
genomic	O
sequencing	O
of	O
the	O
D-mib3	O
allele	O
revealed	O
the	O
presence	O
of	O
a	O
stop	O
codon	O
at	O
position	O
258	O
(	O
Figure	O
1B	O
)	O
.	O

This	O
allele	O
is	O
therefore	O
predicted	O
to	O
produce	O
a	O
truncated	O
protein	O
devoid	O
of	O
the	O
catalytic	O
RING	O
domain	O
,	O
consistent	O
with	O
D-mib3	O
being	O
a	O
null	O
allele	O
.	O

Genomic	O
sequencing	O
of	O
the	O
D-mib4	O
allele	O
showed	O
that	O
this	O
mutation	O
is	O
associated	O
with	O
a	O
valine-to-methionine	O
substitution	O
at	O
a	O
conserved	O
position	O
in	O
the	O
second	O
Mib	O
repeat	O
(	O
Figure	O
1B	O
)	O
.	O

Third	O
,	O
Western	O
blot	O
analysis	O
showed	O
that	O
the	O
D-mib	O
protein	O
was	O
not	B-Negation
detectable	I-Negation
in	I-Negation
imaginal	I-Negation
disc	I-Negation
and	I-Negation
brain	I-Negation
complex	I-Negation
extracts	I-Negation
prepared	I-Negation
from	I-Negation
homozygous	I-Negation
D-mib1	I-Negation
and	I-Negation
D-mib1/D-mib2	I-Negation
larvae	I-Negation
(	O
Figure	O
1C	O
and	O
C	O
?	O
)	O
.	O

Fourth	O
,	O
the	O
leaky	O
,	O
GAL4-independent	O
expression	O
of	O
a	O
UAS-D-mib	O
transgene	O
fully	O
rescued	O
the	O
lethality	O
of	O
D-mib1/D-mib2	O
flies	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
;	O
see	O
also	O
Figure	O
1H	O
)	O
.	O

Thus	O
,	O
our	O
analysis	O
identified	O
both	O
complete	O
and	O
partial	O
D-mib	O
loss-of-function	O
alleles	O
.	O

Molecular	O
and	O
Genetic	O
Characterization	O
of	O
D-mib	O
Mutations	O

(	O
A	O
)	O
Molecular	O
map	O
of	O
the	O
D-mib	O
locus	O
showing	O
the	O
position	O
of	O
the	O
P-element	O
inserted	O
into	O
the	O
5	O
?	O
untranslated	O
region	O
(	O
allele	O
D-mib1	O
)	O
and	O
the	O
13.6	O
kb	O
deletion	O
that	O
removes	O
the	O
D-mib	O
and	O
the	O
RpS31	O
genes	O
(	O
allele	O
D-mib2	O
)	O
.	O

Transcribed	O
regions	O
are	O
indicated	O
with	O
arrows	O
,	O
and	O
exons	O
are	O
indicated	O
with	O
boxes	O
.	O

Open	O
reading	O
frames	O
are	O
shown	O
in	O
black	O
.	O

(	O
B	O
)	O
Domain	O
composition	O
of	O
D-mib	O
and	O
D.	O
rerio	O
Mib	O
.	O

Both	O
proteins	O
show	O
identical	O
domain	O
organization	O
.	O

D-mib	O
has	O
an	O
N-terminal	O
ZZ	O
zinc	O
finger	O
flanked	O
on	O
either	O
side	O
by	O
a	O
Mib/HERC2	O
(	O
M-H	O
)	O
domain	O
,	O
followed	O
by	O
two	O
Mib	O
repeats	O
,	O
six	O
ankyrin	O
repeats	O
,	O
two	O
atypical	O
RING	O
domains	O
,	O
and	O
a	O
C-terminal	O
protypical	O
RING	O
that	O
has	O
been	O
associated	O
with	O
catalytic	O
E3	O
ubiquitin	O
ligase	O
activity	O
.	O

The	O
D-mib3	O
mutant	O
allele	O
is	O
predicted	O
to	O
produce	O
a	O
truncated	O
protein	O
devoid	O
of	O
E3	O
ubiquitin	O
ligase	O
activity	O
whereas	O
the	O
D-mib4	O
protein	O
carries	O
a	O
mutation	O
at	O
a	O
conserved	O
position	O
in	O
the	O
second	O
Mib	O
repeat	O
.	O

(	O
C	O
and	O
C	O
?	O
)	O
Western	O
blot	O
analysis	O
of	O
D-mib	O
(	O
C	O
)	O
.	O

The	O
endogenous	O
D-mib	O
protein	O
(	O
predicted	O
size	O
:	O
130	O
kDa	O
)	O
was	O
detected	O
in	O
S2	O
cells	O
(	O
lane	O
2	O
)	O
and	O
in	O
imaginal	O
discs	O
from	O
wild-type	O
larvae	O
(	O
lane	O
3	O
)	O
but	O
was	O
not	B-Negation
detectable	I-Negation
in	I-Negation
homozygous	I-Negation
D-mib1	I-Negation
(	I-Negation
lane	I-Negation
4	I-Negation
)	I-Negation
and	I-Negation
D-mib1/D-mib3	I-Negation
(	I-Negation
lane	I-Negation
5	I-Negation
)	I-Negation
third	I-Negation
instar	I-Negation
larvae	I-Negation
.	O

The	O
D-mib	O
protein	O
produced	O
in	O
transfected	O
S2	O
cells	O
from	O
the	O
cDNA	O
used	O
in	O
this	O
study	O
(	O
lane	O
1	O
)	O
runs	O
exactly	O
as	O
endogenous	O
D-mib	O
(	O
lane	O
2	O
)	O
.	O

Panel	O
C	O
?	O
shows	O
a	O
Red	O
Ponceau	O
staining	O
of	O
the	O
gel	O
with	O
the	O
same	O
protein	O
samples	O
as	O
in	O
panel	O
C	O
.	O

(	O
DH	O
)	O
Wings	O
from	O
wild-type	O
(	O
D	O
)	O
,	O
D-mib1	O
(	O
E	O
)	O
,	O
SerRX82/Serrev6.1	O
(	O
F	O
)	O
,	O
D-mib2/D-mib4	O
(	O
G	O
)	O
,	O
and	O
UAS-D-mib2/+	O
;	O
D-mib1/D-mib2	O
flies	O
(	O
H	O
)	O
.	O

D-mib	O
(	O
E	O
)	O
and	O
Ser	O
(	O
F	O
)	O
mutant	O
flies	O
showed	O
similar	O
wing	O
loss	O
phenotypes	O
.	O

The	O
D-mib	O
mutant	O
phenotype	O
could	O
be	O
almost	O
fully	O
rescued	O
by	O
a	O
leaky	O
UAS-D-mib	O
transgene	O
(	O
H	O
)	O
.	O

(	O
D	O
?	O
)	O
and	O
(	O
G	O
?	O
)	O
show	O
high	O
magnification	O
views	O
of	O
(	O
D	O
)	O
and	O
(	O
G	O
)	O
,	O
respectively	O
,	O
to	O
show	O
that	O
D-mib2/D-mib4	O
mutant	O
flies	O
(	O
G	O
?	O
)	O
exhibited	O
ectopic	O
sensilla	O
(	O
arrowheads	O
)	O
along	O
vein	O
L3	O
.	O

(	O
IN	O
)	O
Nota	O
(	O
IK	O
)	O
and	O
legs	O
(	O
LN	O
)	O
from	O
wild-type	O
(	O
I	O
and	O
L	O
)	O
,	O
D-mib1	O
(	O
J	O
and	O
M	O
)	O
,	O
and	O
SerRX82/Serrev6.1	O
(	O
K	O
and	O
N	O
)	O
flies	O
.	O

D-mib	O
mutant	O
flies	O
showed	O
a	O
weak	O
neurogenic	O
phenotype	O
(	O
J	O
)	O
that	B-Negation
was	I-Negation
not	I-Negation
observed	I-Negation
in	I-Negation
Ser	I-Negation
mutant	I-Negation
flies	I-Negation
(	I-Negation
K	I-Negation
)	I-Negation
.	O

Ectopic	O
sensory	O
organs	O
in	O
D-mib	O
mutant	O
flies	O
developed	O
from	O
ectopic	B-Negation
sensory	I-Negation
organ	I-Negation
precursor	I-Negation
cells	I-Negation
(	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

D-mib	O
(	O
M	O
)	O
and	O
Ser	O
(	O
N	O
)	O
mutant	O
legs	O
also	O
showed	O
distinct	O
growth	O
and/or	O
elongation	O
defects	O
.	O

Arrows	O
in	O
(	O
J	O
)	O
show	O
ectopic	O
macrochaetes	O
.	O

Arrows	O
in	O
(	O
LN	O
)	O
indicate	O
the	O
joints	O
.	O

Ti	O
,	O
tibia	O
;	O
t1	O
to	O
t5	O
,	O
tarsal	O
segments	O
1	O
to	O
5	O
.	O

D-mib	O
Regulates	O
Dl	O
Signaling	O

Complete	O
loss	O
of	O
zygotic	O
D-mib	O
activity	O
in	O
homozygous	O
D-mib1	O
and	O
trans-heterozygous	O
D-mib2/D-mib3	O
,	O
D-mib1/D-mib3	O
and	O
D-mib1/D-mib2	O
individuals	O
led	O
to	O
late	O
pupal	O
lethality	O
.	O

Mutant	O
pupae	O
died	O
as	O
pharate	O
adults	O
showing	O
ectopic	O
macrochaetes	O
,	O
increased	O
microchaete	O
density	O
on	O
the	O
dorsal	O
thorax	O
(	O
Figure	O
1I	O
and	O
1J	O
)	O
,	O
short	O
legs	O
lacking	B-Negation
tarsal	I-Negation
segmentation	I-Negation
(	O
Figure	O
1L	O
and	O
1M	O
)	O
,	O
and	O
nearly	O
complete	O
loss	O
of	O
eye	O
and	O
wing	O
tissues	O
(	O
Figure	O
1D	O
and	O
1E	O
)	O
.	O

Tissue	O
losses	O
were	O
associated	O
with	O
a	O
dramatic	O
reduction	O
in	O
size	O
of	O
the	O
eye	O
field	O
and	O
of	O
the	O
wing	O
pouch	O
in	O
mutant	O
discs	O
of	O
third	O
instar	O
larvae	O
(	O
Figure	O
2A2E	O
)	O
.	O

Hypomorphic	O
D-mib2/D-mib4	O
mutant	O
flies	O
only	O
showed	O
ectopic	O
sensory	O
organs	O
,	O
rough	O
eyes	O
,	O
small	O
wings	O
,	O
and	O
thickened	O
veins	O
(	O
Figure	O
1D	O
,	O
1D	O
?	O
,	O
1G	O
,	O
and	O
1G	O
?	O
;	O
data	B-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

All	O
these	O
phenotypes	O
may	O
result	O
from	O
reduced	O
N	O
signaling	O
.	O

More	O
specifically	O
,	O
the	O
bristle	O
and	O
leg	O
phenotypes	O
are	O
likely	O
to	O
result	O
from	O
reduced	O
signaling	O
by	O
Dl	O
(	O
and	O
not	O
by	O
Ser	O
)	O
.	O

Indeed	O
,	O
a	O
reduction	O
in	O
Dl-mediated	O
lateral	O
inhibition	O
can	O
result	O
in	O
ectopic	O
sensory	O
organs	O
and	O
increased	O
bristle	O
density	O
on	O
the	O
body	O
surface	O
.	O

In	O
contrast	O
,	O
a	O
complete	O
loss	O
of	O
Ser	O
signaling	O
had	O
no	B-Negation
effect	I-Negation
on	I-Negation
bristle	I-Negation
density	I-Negation
(	O
Figure	O
1K	O
)	O
.	O

Likewise	O
,	O
loss	O
of	O
Dl	O
signaling	O
has	O
been	O
shown	O
to	O
result	O
in	O
short	O
unsegmented	O
legs	O
,	O
similar	O
to	O
the	O
ones	O
seen	O
in	O
the	O
absence	O
of	O
D-mib	O
activity	O
(	O
Figure	O
1M	O
)	O
,	O
whereas	O
a	O
complete	O
loss	O
of	O
Ser	O
activity	O
led	O
to	O
the	O
formation	O
of	O
elongated	O
unsegmented	O
legs	O
(	O
Figure	O
1N	O
)	O
[	O
36,37,38	O
]	O
.	O

Finally	O
,	O
the	O
vein	O
phenotype	O
seen	O
in	O
D-mib	O
hypomorphic	O
flies	O
is	O
similar	O
to	O
the	O
one	O
seen	O
in	O
Dlts	O
mutant	O
flies	O
[	O
39	O
]	O
.	O

Together	O
,	O
these	O
observations	O
suggest	O
that	O
D-mib	O
regulates	O
Dl	O
signaling	O
in	O
several	O
developmental	O
contexts	O
.	O

Consistent	O
with	O
this	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
D-mib	O
binds	O
Dl	O
and	O
promotes	O
Dl	O
signaling	O
and	O
that	O
overexpression	O
of	O
D-mib	O
down-regulates	O
the	O
accumulation	O
of	O
Dl	O
at	O
the	O
cell	O
surface	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
D-mib	O
and	O
neur	O
Genes	O
Have	O
Distinct	O
Functions	O
during	O
Wing	O
Development	O

(	O
AE	O
)	O
Wing	O
imaginal	O
discs	O
(	O
BE	O
)	O
from	O
wild-type	O
(	O
B	O
and	O
D	O
)	O
,	O
D-mib1	O
(	O
C	O
)	O
,	O
and	O
D-mib1/D-mib2	O
(	O
E	O
)	O
third	O
instar	O
larvae	O
stained	O
for	O
Cut	O
(	O
B	O
and	O
C	O
)	O
and	O
wg-lacZ	O
(	O
D	O
and	O
E	O
)	O
.	O

D-mib	O
mutant	O
discs	O
showed	O
a	O
dramatically	O
reduced	O
size	O
of	O
the	O
wing	O
pouch	O
(	O
see	O
diagram	O
in	O
[	O
A	O
]	O
showing	O
the	O
different	O
regions	O
of	O
the	O
wing	O
imaginal	O
disc	O
;	O
V	O
,	O
ventral	O
;	O
D	O
,	O
dorsal	O
)	O
,	O
as	O
well	O
as	O
a	O
complete	O
loss	O
of	O
Cut	O
and	O
wg-lacZ	O
(	O
red	O
arrows	O
in	O
[	O
BE	O
]	O
)	O
expression	O
at	O
the	O
wing	O
margin	O
.	O

Expression	O
of	O
wg-lacZ	O
in	O
the	O
hinge	O
region	O
(	O
arrowheads	O
in	O
[	O
D	O
]	O
and	O
[	O
E	O
]	O
)	O
and	O
the	O
accumulation	O
of	O
Cut	O
in	O
sensory	O
cells	O
(	O
small	O
arrows	O
in	O
[	O
B	O
]	O
and	O
[	O
C	O
]	O
)	O
and	O
muscle	O
precursor	O
cells	O
(	O
large	O
arrowheads	O
in	O
[	O
B	O
]	O
and	O
[	O
C	O
]	O
)	O
appeared	O
to	O
be	O
largely	O
unaffected	O
)	O
.	O

(	B-Negation
F	I-Negation
and	I-Negation
F	I-Negation
?	I-Negation
)	I-Negation
Expression	I-Negation
of	I-Negation
Cut	I-Negation
(	I-Negation
red	I-Negation
)	I-Negation
at	I-Negation
the	I-Negation
wing	I-Negation
margin	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
the	I-Negation
complete	I-Negation
loss	I-Negation
of	I-Negation
neur	I-Negation
activity	I-Negation
in	I-Negation
neur1F65	I-Negation
mutant	I-Negation
clones	I-Negation
(	O
indicated	O
by	O
the	O
loss	O
of	O
the	O
nuclear	O
green	O
fluorescent	O
protein	O
[	O
GFP	O
]	O
marker	O
,	O
in	O
green	O
)	O
.	O

Bar	O
is	O
50	O
?	O
m	O
in	O
(	O
BE	O
)	O
and	O
20	O
?	O
m	O
in	O
(	O
F	O
and	O
F	O
?	O
)	O
.	O

D-mib	O
and	O
neur	O
Have	O
Distinct	O
Functions	O

We	O
then	O
studied	O
in	O
more	O
detail	O
the	O
function	O
of	O
D-mib	O
during	O
wing	O
development	O
.	O

Growth	O
of	O
the	O
wing	O
pouch	O
depends	O
on	O
the	O
activity	O
of	O
an	O
organizing	O
center	O
located	O
at	O
the	O
dorsal-ventral	O
(	O
D-V	O
)	O
boundary	O
[	O
40,41	O
]	O
.	O

This	O
boundary	O
is	O
established	O
in	O
first	O
instar	O
larvae	O
and	O
is	O
defined	O
by	O
the	O
apterous	O
expression	O
boundary	O
.	O

Apterous	O
activates	O
the	O
expression	O
of	O
the	O
Ser	O
and	O
fringe	O
genes	O
in	O
dorsal	O
cells	O
.	O

High	O
levels	O
of	O
Ser	O
in	O
dorsal	O
cells	O
activate	O
N	O
in	O
trans	O
in	O
ventral	O
cells	O
and	O
suppress	O
N	O
activation	O
in	O
cis	O
in	O
dorsal	O
cells	O
,	O
whereas	O
Fringe	O
modifies	O
N	O
in	O
dorsal	O
cells	O
such	O
that	O
dorsal	O
cells	O
located	O
at	O
the	O
D-V	O
boundary	O
respond	O
to	O
Dl	O
.	O

Thus	O
,	O
composite	O
signaling	O
by	O
Ser	O
and	O
Dl	O
leads	O
to	O
symmetric	O
N	O
activation	O
in	O
margin	O
cells	O
located	O
along	O
the	O
D-V	O
boundary	O
[	O
8,9,42,43	O
]	O
.	O

N	O
then	O
regulates	O
the	O
expression	O
of	O
the	O
vestigial	O
and	O
wingless	O
(	O
wg	O
)	O
genes	O
that	O
cooperate	O
to	O
promote	O
growth	O
of	O
the	O
wing	O
pouch	O
.	O

N	O
also	O
regulates	O
expression	O
of	O
the	O
cut	O
gene	O
in	O
margin	O
cells	O
[	O
44	O
]	O
.	O

Thus	O
,	O
loss	O
of	O
N	O
signaling	O
results	O
in	O
a	O
reduction	O
in	O
size	O
of	O
the	O
wing	O
pouch	O
accompanied	O
by	O
the	O
loss	O
of	O
cut	O
and	O
wg	O
expression	O
along	O
the	O
D-V	O
boundary	O
.	O

A	O
complete	O
loss	O
of	O
Cut	O
and	O
Wg	O
accumulation	O
and	O
wg-lacZ	O
expression	O
was	O
observed	O
in	O
the	O
central	O
region	O
of	O
third	O
instar	O
D-mib	O
mutant	O
wing	O
discs	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

Thus	O
,	O
the	O
D-mib	O
wing	O
phenotype	O
may	O
result	O
from	O
defective	O
N	O
inductive	O
signaling	O
at	O
the	O
D-V	O
boundary	O
.	O

We	O
conclude	O
that	O
the	O
activity	O
of	O
the	O
D-mib	O
gene	O
is	O
required	O
for	O
the	O
specification	O
of	O
the	O
wing	O
margin	O
and	O
,	O
hence	O
,	O
growth	O
of	O
the	O
wing	O
pouch	O
.	O

Interestingly	O
,	O
wing	B-Negation
margin	I-Negation
formation	I-Negation
and	I-Negation
expression	I-Negation
of	I-Negation
Cut	I-Negation
are	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
the	I-Negation
complete	I-Negation
loss	I-Negation
of	I-Negation
neur	I-Negation
activity	I-Negation
(	O
Figure	O
2F	O
and	O
2F	O
?	O
)	O
[	O
45	O
]	O
.	O

Similarly	O
,	O
loss	O
of	O
neur	O
activity	O
had	O
no	B-Negation
detectable	I-Negation
effect	I-Negation
on	I-Negation
leg	I-Negation
segmentation	I-Negation
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
and	O
vein	O
determination	O
[	O
45	O
]	O
,	O
two	O
processes	O
shown	O
here	O
to	O
depend	O
on	O
D-mib	O
gene	O
activity	O
.	O

We	O
therefore	O
conclude	O
that	O
D-mib	O
and	O
neur	O
have	O
distinct	O
and	O
complementary	O
functions	O
in	O
Drosophila	O
.	O

D-mib	O
Co-Localizes	O
with	O
Dl	O
and	O
Ser	O
at	O
the	O
Apical	O
Cortex	O

We	O
next	O
studied	O
the	O
subcellular	O
localization	O
of	O
D-mib	O
(	O
Figure	O
3	O
)	O
.	O

Anti-D-mib	O
antibodies	O
were	O
generated	O
that	O
specifically	O
detected	O
D-mib	O
on	O
Western	O
blots	O
(	O
see	O
Figure	O
1C	O
)	O
and	O
on	O
fixed	O
tissues	O
(	O
Figure	O
3FF	O
?	O
)	O
.	O

Using	O
these	O
antibodies	O
,	O
we	O
found	O
that	O
D-mib	O
was	O
detected	O
in	O
all	O
imaginal	O
disc	O
cells	O
(	O
Figure	O
3A	O
and	O
3B	O
)	O
.	O

We	O
then	O
examined	O
D-mib	O
subcellular	O
distribution	O
in	O
epithelial	O
cells	O
located	O
along	O
the	O
edge	O
of	O
the	O
wing	O
discs	O
because	O
cross-sectional	O
imaging	O
affords	O
better	O
resolution	O
along	O
the	O
apical-basal	O
axis	O
.	O

D-mib	O
co-localized	O
with	O
Ser	O
,	O
Dl	O
,	O
and	O
N	O
at	O
the	O
apical	O
cortex	O
(	O
Figure	O
3B3D	O
?	O
?	O
?	O
)	O
.	O

Dl	O
and	O
Ser	O
were	O
also	O
detected	O
in	O
large	O
intracellular	O
vesicles	O
that	O
probably	O
correspond	O
to	O
multivesicular	O
bodies	O
in	O
that	O
they	O
also	O
stained	O
for	O
hepatocyte	O
growth	O
factor-regulated	O
tyrosine	O
kinase	O
substrate	O
[	O
46	O
]	O
(	O
Figure	O
3B3C	O
``	O
'	O
?	O
?	O
?	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
intracellular	O
dots	O
seen	O
with	O
the	O
anti-D-mib	O
antibodies	O
were	O
distinct	O
from	O
the	O
Dl-	O
and	O
Ser-positive	O
dots	O
and	O
appeared	O
to	O
result	O
from	O
background	O
staining	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
reduced	O
cytoplasmic	O
staining	O
seen	O
in	O
D-mib	O
mutant	O
cells	O
(	O
Figure	O
3F3F	O
?	O
?	O
)	O
``	O
suggests	O
that	O
D-mib	O
is	O
also	O
present	O
in	O
the	O
cytoplasm	O
.	O

A	O
similar	O
localization	O
at	O
the	O
apical	O
cortex	O
and	O
in	O
the	O
cytoplasm	O
was	O
seen	O
for	O
a	O
functional	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
:	O
:	O
D-mib	O
fusion	O
protein	O
(	O
see	O
Figure	O
6	O
below	O
)	O
.	O

These	O
localization	O
data	O
suggest	O
that	O
D-mib	O
may	O
act	O
at	O
the	O
apical	O
cortex	O
to	O
regulate	O
the	O
activity	O
of	O
Dl	O
and/or	O
Ser	O
.	O

D-mib	O
Co-Localizes	O
with	O
Dl	O
and	O
Ser	O
at	O
the	O
Apical	O
Cell	O
Cortex	O

(	O
A	O
and	O
A	O
?	O
)	O
D-mib	O
(	O
green	O
)	O
is	O
detected	O
in	O
all	O
cells	O
of	O
the	O
wing	O
imaginal	O
disc	O
.	O

In	O
(	O
A	O
)	O
,	O
Ser	O
is	O
in	O
red	O
and	O
Discs-large	O
(	O
Dlg	O
)	O
is	O
in	O
blue	O
.	O

(	O
BD	O
?	O
?	O
?	O
)	O
D-mib	O
(	O
green	O
in	O
B	O
,	O
B	O
?	O
,	O
C	O
,	O
C	O
?	O
,	O
D	O
,	O
and	O
D	O
?	O
)	O
co-localized	O
with	O
Ser	O
(	O
red	O
in	O
[	O
B	O
and	O
B	O
?	O
?	O
]	O
)	O
,	O
Dl	O
(	O
red	O
in	O
[	O
C	O
and	O
C	O
?	O
?	O
]	O
)	O
,	O
N	O
(	O
red	O
in	O
[	O
D	O
and	O
D	O
?	O
?	O
]	O
)	O
,	O
and	O
E-Cadherin	O
(	O
E-Cad	O
;	O
blue	O
in	O
[	O
D	O
and	O
D	O
?	O
?	O
?	O
]	O
)	O
and	O
was	O
found	O
apical	O
to	O
Discs-large	O
(	O
Dlg	O
;	O
blue	O
in	O
[	O
B	O
,	O
B	O
?	O
?	O
?	O
,	O
C	O
,	O
and	O
C	O
?	O
?	O
?	O
]	O
)	O
in	O
notum	O
cells	O
located	O
at	O
the	O
edges	O
of	O
the	O
wing	O
discs	O
.	O

(	O
EE	O
?	O
?	O
)	O
D-mib	O
(	O
green	O
in	O
[	O
E	O
and	O
E	O
?	O
]	O
)	O
co-localized	O
with	O
Dl	O
(	O
red	O
in	O
[	O
E	O
and	O
E	O
?	O
?	O
]	O
)	O
at	O
the	O
apical	O
cortex	O
of	O
wing	O
pouch	O
cells	O
.	O

(	B-Negation
FF	I-Negation
?	I-Negation
?	I-Negation
)	I-Negation
D-mib	I-Negation
staining	I-Negation
at	I-Negation
the	I-Negation
apical	I-Negation
cortex	I-Negation
(	I-Negation
blue	I-Negation
in	I-Negation
[	I-Negation
F	I-Negation
and	I-Negation
F	I-Negation
?	I-Negation
]	I-Negation
)	I-Negation
was	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
D-mib2	I-Negation
mutant	I-Negation
clone	I-Negation
(	I-Negation
marked	I-Negation
by	I-Negation
loss	I-Negation
of	I-Negation
nuclear	I-Negation
GFP	I-Negation
staining	I-Negation
;	O
green	O
in	O
[	O
F	O
]	O
)	O
.	O

Loss	O
of	O
D-mib	O
activity	O
has	O
no	B-Negation
detectable	I-Negation
effect	I-Negation
on	I-Negation
the	I-Negation
apical	I-Negation
accumulation	I-Negation
of	I-Negation
Dl	I-Negation
(	O
red	O
in	O
[	O
F	O
and	O
F	O
?	O
?	O
]	O
)	O
.	O

Bar	O
is	O
50	O
?	O
m	O
for	O
(	O
A	O
and	O
A	O
?	O
)	O
and	O
10	O
?	O
m	O
for	O
(	O
BF	O
?	O
?	O
)	O
.	O

D-mib	O
Is	O
Required	O
in	O
Dorsal	O
Cells	O
for	O
Margin	O
Expression	O
of	O
Cut	O

Large	O
dorsal	O
clones	O
of	O
D-mib2	O
mutant	O
cells	O
(	O
marked	O
by	O
the	O
loss	O
of	O
nuclear	O
GFP	O
,	O
in	O
green	O
)	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
Cut	O
(	O
red	O
)	O
expression	O
(	O
A	O
and	O
B	O
)	O
.	O

This	O
indicates	O
that	O
D-mib	O
is	O
required	O
for	O
Ser	O
signaling	O
by	O
dorsal	O
cells	O
.	O

In	O
contrast	O
,	O
ventral	O
clones	O
did	O
not	B-Negation
prevent	I-Negation
the	I-Negation
expression	I-Negation
of	I-Negation
Cut	I-Negation
(	I-Negation
C	I-Negation
and	I-Negation
D	I-Negation
)	I-Negation
,	O
implying	B-Speculation
that	I-Speculation
D-mib	I-Speculation
is	I-Speculation
not	I-Speculation
strictly	I-Speculation
required	I-Speculation
for	I-Speculation
Dl	I-Speculation
signaling	I-Speculation
.	O

Note	O
that	O
mutant	O
ventral	O
cells	O
abutting	O
wild-type	O
dorsal	O
cells	O
expressed	O
Cut	O
(	O
arrow	O
in	O
[	O
D	O
]	O
)	O
,	O
indicating	O
that	O
D-mib	O
is	O
not	O
required	O
for	O
N	O
signal	O
transduction	O
.	O

Low-magnification	O
views	O
of	O
the	O
wing	O
portion	O
of	O
the	O
discs	O
are	O
shown	O
in	O
(	O
A	O
)	O
and	O
(	O
C	O
)	O
.	O

(	O
B	O
)	O
and	O
(	O
D	O
)	O
show	O
high-magnification	O
views	O
of	O
the	O
areas	O
boxed	O
in	O
(	O
A	O
)	O
and	O
(	O
C	O
)	O
,	O
respectively	O
.	O

D-mib	O
Regulates	O
the	O
Cell-Surface	O
Level	O
of	O
Ser	O

We	O
next	O
examined	O
the	O
potential	O
role	O
of	O
D-mib	O
in	O
regulating	O
Dl	O
and	O
Ser	O
distribution	O
in	O
wing	O
imaginal	O
discs	O
.	O

We	O
focused	O
our	O
analysis	O
on	O
the	O
notum	O
region	O
since	O
D-mib	O
mutant	O
discs	O
have	O
no	B-Negation
wing	I-Negation
pouch	I-Negation
(	O
Figure	O
4	O
)	O
.	O

Dl	O
and	O
Ser	O
co-localized	O
both	O
at	O
the	O
apical	O
cortex	O
and	O
in	O
large	O
intracellular	O
vesicles	O
in	O
wild-type	O
cells	O
(	O
Figure	O
4A4C	O
?	O
)	O
.	O

The	O
complete	O
loss	O
of	O
D-mib	O
activity	O
in	O
D-mib1	O
mutant	O
discs	O
did	O
not	B-Negation
detectably	I-Negation
change	I-Negation
the	I-Negation
subcellular	I-Negation
localization	I-Negation
of	I-Negation
Dl	I-Negation
(	O
Figure	O
4C	O
,	O
4C	O
?	O
,	O
4F	O
,	O
and	O
4F	O
?	O
)	O
.	O

In	O
contrast	O
,	O
the	O
accumulation	O
of	O
Ser	O
at	O
the	O
apical	O
cortex	O
was	O
strongly	O
increased	O
(	O
Figure	O
4E	O
)	O
and	O
Ser	O
accumulation	O
in	O
Dl-positive	O
vesicles	O
was	O
dramatically	O
reduced	O
(	O
Figure	O
4E	O
?	O
)	O
in	O
D-mib1	O
mutant	O
discs	O
.	O

Similar	O
results	O
were	O
also	O
obtained	O
in	O
D-mib2	O
mutant	O
clones	O
,	O
which	O
showed	O
strongly	O
elevated	O
levels	O
of	O
cortical	O
Ser	O
(	O
Figure	O
4H	O
)	O
whereas	O
the	B-Negation
amount	I-Negation
of	I-Negation
Dl	I-Negation
at	I-Negation
the	I-Negation
apical	I-Negation
cortex	I-Negation
was	I-Negation
not	I-Negation
detectably	I-Negation
modified	I-Negation
(	O
see	O
Figures	O
3F3F	O
?	O
?	O
and	O
4J	O
)	O
.	O

Of	O
note	O
,	O
loss	O
of	O
D-mib2	O
activity	O
in	O
clones	O
did	O
not	B-Negation
block	I-Negation
the	I-Negation
accumulation	I-Negation
of	I-Negation
Ser	I-Negation
into	I-Negation
intracellular	I-Negation
dots	I-Negation
(	O
Figure	O
4H	O
?	O
)	O
.	O

Thus	O
,	O
trafficking	O
of	O
Ser	O
towards	O
this	O
intracellular	O
compartment	O
is	O
,	O
at	O
least	O
in	O
part	O
,	O
D-mib-independent	O
.	O

We	O
therefore	O
conclude	O
that	O
the	O
D-mib	O
gene	O
is	O
required	O
to	O
regulate	O
the	O
level	O
of	O
Ser	O
at	O
the	O
apical	O
cortex	O
of	O
wing	O
disc	O
cells	O
.	O

D-mib	O
Is	O
Required	O
to	O
Down-Regulate	O
Ser	O
at	O
the	O
Apical	O
Cortex	O

(	O
AF	O
?	O
)	O
Distribution	O
of	O
Dl	O
(	O
green	O
)	O
and	O
Ser	O
(	O
red	O
)	O
in	O
the	O
notum	O
region	O
of	O
wild-type	O
(	O
AC	O
?	O
)	O
and	O
D-mib1	O
mutant	O
(	O
DF	O
?	O
)	O
wing	O
imaginal	O
discs	O
.	O

The	O
boxed	O
areas	O
in	O
(	O
A	O
)	O
and	O
(	O
D	O
)	O
are	O
shown	O
at	O
higher	O
magnification	O
in	O
(	O
BF	O
?	O
)	O
.	O

The	O
specific	O
loss	O
of	O
Ser	O
accumulation	O
into	O
intracellular	O
vesicles	O
(	O
compare	O
[	O
E	O
?	O
]	O
with	O
[	O
B	O
?	O
]	O
)	O
correlated	O
with	O
the	O
elevated	O
levels	O
of	O
Ser	O
seen	O
at	O
the	O
apical	O
cortex	O
of	O
D-mib	O
mutant	O
cells	O
(	O
compare	O
[	O
E	O
]	O
with	O
[	O
B	O
]	O
)	O
.	O

(	O
GJ	O
?	O
)	O
Ser	O
(	O
red	O
in	O
[	O
H	O
and	O
H	O
?	O
]	O
)	O
accumulated	O
at	O
the	O
apical	O
cortex	O
(	O
H	O
)	O
as	O
well	O
as	O
in	O
intracellular	O
dots	O
(	O
H	O
?	O
)	O
in	O
D-mib2	O
mutant	O
cells	O
(	O
marked	O
by	O
the	O
loss	O
of	O
nuclear	O
GFP	O
;	O
green	O
in	O
[	O
G	O
]	O
)	O
.	O

Cut	O
is	O
shown	O
in	O
blue	O
(	O
G	O
)	O
.	O

The	B-Negation
distribution	I-Negation
of	I-Negation
Dl	I-Negation
(	I-Negation
red	I-Negation
in	I-Negation
[	I-Negation
J	I-Negation
and	I-Negation
J	I-Negation
?	I-Negation
]	I-Negation
)	I-Negation
was	I-Negation
not	I-Negation
affected	I-Negation
by	I-Negation
the	I-Negation
loss	I-Negation
of	I-Negation
D-mib	I-Negation
activity	I-Negation
.	O

Low-magnification	O
views	O
of	O
the	O
wing	O
portion	O
of	O
the	O
discs	O
are	O
shown	O
in	O
(	O
G	O
)	O
and	O
(	O
I	O
)	O
.	O

(	O
H	O
and	O
H	O
?	O
)	O
and	O
(	O
J	O
and	O
J	O
?	O
)	O
show	O
high	O
magnification	O
views	O
of	O
the	O
areas	O
boxed	O
in	O
(	O
G	O
)	O
and	O
(	O
I	O
)	O
,	O
respectively	O
.	O

Clone	O
boundaries	O
are	O
outlined	O
in	O
(	O
H	O
and	O
H	O
?	O
)	O
and	O
(	O
J	O
and	O
J	O
?	O
)	O
.	O

Bar	O
is	O
40	O
?	O
m	O
for	O
(	O
A	O
,	O
D	O
,	O
G	O
)	O
,	O
5	O
?	O
m	O
for	O
(	O
BC	O
?	O
and	O
EF	O
?	O
)	O
,	O
and	O
10	O
?	O
m	O
for	O
(	O
HJ	O
?	O
)	O
.	O

D-mib	O
Is	O
Required	O
for	O
Ser	O
Endocytosis	O

Ubiquitin-mediated	O
endocytosis	O
is	O
thought	O
to	O
depend	O
on	O
monoubiquitination	O
.	O

Thus	O
,	O
by	O
analogy	O
with	O
the	O
function	O
of	O
Mib	O
in	O
D.	O
rerio	O
[	O
18,28	O
]	O
,	O
we	O
suggest	O
that	O
D-mib	O
may	O
directly	O
monoubiquitinate	O
Ser	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
we	O
show	O
in	O
a	O
companion	O
paper	O
that	O
D-mib	O
binds	O
Ser	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

Moreover	O
,	O
a	O
mutation	O
in	O
the	O
C-terminal	O
catalytic	O
RING	O
domain	O
of	O
D-mib	O
abolished	O
its	O
ability	O
to	O
internalize	O
Ser	O
in	O
transfected	O
S2	O
cells	O
(	O
R.	O
L.	O
B.	O
and	O
F.	O
S.	O
,	O
unpublished	O
data	O
)	O
implying	O
that	O
the	O
E3	O
ubiquitin	O
ligase	O
activity	O
of	O
D-mib	O
is	O
required	O
for	O
Ser	O
internalization	O
.	O

Biochemical	O
analysis	O
of	O
the	O
ubiquitination	O
events	O
regulated	O
by	O
D-mib	O
will	O
be	O
needed	O
to	O
further	O
define	O
the	O
mechanism	O
by	O
which	O
D-mib	O
regulates	O
the	O
endocytosis	O
of	O
Ser	O
in	O
vivo	O
.	O

To	O
test	O
whether	O
this	O
specific	O
increase	O
in	O
the	O
level	O
of	O
Ser	O
at	O
the	O
apical	O
cortex	O
resulted	O
from	O
reduced	O
Ser	O
endocytosis	O
in	O
D-mib	O
mutant	O
cells	O
,	O
we	O
followed	O
the	O
endocytosis	O
of	O
Ser	O
in	O
living	O
imaginal	O
discs	O
using	O
an	O
antibody	O
uptake	O
assay	O
.	O

Briefly	O
,	O
dissected	O
wing	O
discs	O
were	O
cultured	O
for	O
15	O
min	O
in	O
the	O
presence	O
of	O
antibodies	O
that	O
recognize	O
the	O
extracellular	O
part	O
of	O
Ser	O
or	O
Dl	O
,	O
then	O
washed	O
,	O
cultured	O
for	O
another	O
45	O
min	O
in	O
medium	O
without	B-Negation
antibodies	I-Negation
,	O
and	O
then	O
fixed	O
.	O

The	O
uptake	O
of	O
anti-Ser	O
and	O
anti-Dl	O
antibodies	O
was	O
then	O
assessed	O
using	O
secondary	O
antibodies	O
.	O

The	O
results	O
are	O
shown	O
in	O
Figure	O
5	O
.	O

Using	O
this	O
assay	O
,	O
we	O
found	O
that	O
anti-Ser-and	O
anti-Dl	O
antibodies	O
were	O
internalized	O
in	O
wild-type	O
epithelial	O
cells	O
(	O
Figure	O
5A5C	O
?	O
?	O
)	O
.	O

The	O
complete	O
loss	O
of	O
D-mib	O
activity	O
in	O
D-mib1	O
wing	O
discs	O
did	O
not	O
significantly	O
change	O
the	O
internalization	O
of	O
anti-Dl	O
antibodies	O
(	O
Figure	O
5D	O
``	O
?	O
?	O
,	O
5E	O
``	O
?	O
?	O
,	O
and	O
5F	O
?	O
?	O
)	O
``	O
,	O
indicating	O
that	O
D-mib	O
is	O
not	O
required	O
for	O
Dl	O
endocytosis	O
in	O
this	O
tissue	O
.	O

However	O
,	O
the	O
loss	O
of	O
D-mib	O
activity	O
strongly	O
inhibited	O
the	O
endocytosis	O
of	O
anti-Ser	O
antibodies	O
(	O
Figure	O
5E	O
?	O
)	O
.	O

Moreover	O
,	O
high	O
levels	O
of	O
anti-Ser	O
antibodies	O
were	O
seen	O
at	O
the	O
apical	O
surface	O
(	O
Figure	O
5D	O
?	O
and	O
5F	O
?	O
)	O
,	O
confirming	O
that	O
D-mib	O
mutant	O
cells	O
accumulate	O
high	O
levels	O
of	O
Ser	O
at	O
their	O
surface	O
.	O

We	O
therefore	O
conclude	O
that	O
D-mib	O
is	O
specifically	O
required	O
for	O
the	O
endocytosis	O
of	O
Ser	O
in	O
wing	O
discs	O
.	O

D-mib	O
Is	O
Required	O
for	O
Ser	O
Endocytosis	O

Localization	O
of	O
the	O
anti-Ser	O
(	O
red	O
)	O
and	O
anti-Dl	O
(	O
green	O
)	O
antibodies	O
that	O
have	O
been	O
internalized	O
by	O
wild-type	O
(	O
AC	O
?	O
?	O
)	O
and	O
D-mib1	O
mutant	O
(	O
DF	O
?	O
?	O
)	O
cells	O
in	O
the	O
notum	O
region	O
of	O
wing	O
discs	O
.	O

(	O
AA	O
?	O
?	O
)	O
and	O
(	O
DD	O
?	O
?	O
)	O
show	O
apical	O
sections	O
and	O
(	O
BB	O
?	O
?	O
)	O
and	O
(	O
EE	O
?	O
?	O
)	O
show	O
basal	O
sections	O
.	O

(	O
CC	O
?	O
?	O
)	O
and	O
(	O
FF	O
?	O
?	O
)	O
show	O
confocal	O
z-sections	O
.	O

The	O
z-section	O
axes	O
are	O
shown	O
with	O
a	O
double-headed	O
arrow	O
in	O
(	O
A	O
)	O
and	O
(	O
D	O
)	O
.	O

Internalized	O
anti-Ser	O
and	O
anti-Dl	O
antibodies	O
co-localized	O
in	O
wild-type	O
cells	O
.	O

In	O
contrast	O
,	O
high	O
levels	O
of	O
anti-Ser	O
antibodies	O
were	O
detected	O
at	O
the	O
cell	O
surface	O
of	O
D-mib	O
mutant	O
epithelial	O
cells	O
whereas	O
anti-Dl	O
antibodies	O
were	O
efficiently	O
internalized	O
.	O

Bar	O
is	O
10	O
?	O
m	O
for	O
all	O
panels	O
.	O

D-mib	O
Regulates	O
Ser	O
Signaling	O

The	O
regulation	O
of	O
Ser	O
endocytosis	O
by	O
D-mib	O
suggests	O
that	O
D-mib	O
may	O
regulate	O
Ser	O
signaling	O
.	O

Ser	O
expression	O
is	O
restricted	O
to	O
dorsal	O
cells	O
in	O
second	O
instar	O
wing	O
imaginal	O
discs	O
[	O
7,10,44,47,48	O
]	O
.	O

Ser	O
in	O
dorsal	O
cells	O
signals	O
across	O
the	O
D-V	O
boundary	O
to	O
activate	O
N	O
in	O
ventral	O
cells	O
[	O
8,9	O
]	O
.	O

If	O
D-mib	O
is	O
required	O
for	O
Ser	O
signaling	O
during	O
wing	O
development	O
,	O
then	O
loss	O
of	O
D-mib	O
activity	O
in	O
dorsal	O
cells	O
should	O
affect	O
the	O
specification	O
of	O
the	O
wing	O
margin	O
in	O
a	O
non-autonomous	O
manner	O
.	O

Loss	O
of	O
D-mib	O
activity	O
in	O
large	O
dorsal	O
clones	O
of	O
D-mib2	O
mutant	O
cells	O
resulted	O
in	O
a	O
loss	O
of	O
Cut	O
expression	O
at	O
the	O
D-V	O
interface	O
(	O
Figure	O
6A	O
and	O
6B	O
)	O
.	O

The	O
lack	B-Negation
of	I-Negation
Cut	I-Negation
expression	I-Negation
in	I-Negation
wild-type	I-Negation
ventral	I-Negation
cells	I-Negation
abutting	I-Negation
the	I-Negation
D-V	I-Negation
boundary	I-Negation
indicates	B-Speculation
that	I-Speculation
D-mib	I-Speculation
is	I-Speculation
required	I-Speculation
for	I-Speculation
Ser	I-Speculation
signaling	I-Speculation
by	I-Speculation
dorsal	I-Speculation
cells	I-Speculation
and	I-Speculation
acts	I-Speculation
in	I-Speculation
a	I-Speculation
non-autonomous	I-Speculation
manner	I-Speculation
to	I-Speculation
activate	I-Speculation
N	I-Speculation
in	I-Speculation
ventral	I-Speculation
cells	I-Speculation
.	O

Conversely	O
,	O
loss	O
of	O
D-mib	O
activity	O
in	O
large	O
ventral	O
clones	O
(	O
Figure	O
6C	O
and	O
6D	O
)	O
did	O
not	B-Negation
disrupt	I-Negation
margin	I-Negation
specification	I-Negation
,	O
indicating	B-Speculation
that	I-Speculation
D-mib	I-Speculation
is	I-Speculation
not	I-Speculation
strictly	I-Speculation
required	I-Speculation
for	I-Speculation
Dl	I-Speculation
signaling	I-Speculation
by	I-Speculation
ventral	I-Speculation
cells	I-Speculation
.	O

However	O
,	O
a	O
narrowing	O
of	O
the	O
Cut-positive	O
margin	O
was	O
observed	O
(	O
Figure	O
6D	O
)	O
,	O
suggesting	O
that	O
D-mib	O
contributes	O
to	O
regulating	O
the	O
level	O
of	O
Dl	O
signaling	O
.	O

Of	O
note	O
,	O
ventral	O
D-mib	O
mutant	O
cells	O
expressed	O
Cut	O
,	O
implying	O
that	O
D-mib	O
is	O
not	O
required	O
for	O
N	O
signal	O
transduction	O
.	O

We	O
next	O
tested	O
whether	O
expression	O
of	O
D-mib	O
in	O
dorsal	O
cells	O
is	O
sufficient	O
to	O
rescue	O
the	O
D-mib	O
wing	O
phenotype	O
.	O

D-mib	O
was	O
expressed	O
in	O
dorsal	O
cells	O
of	O
D-mib2/D-mib3	O
mutant	O
discs	O
using	O
Ser-GAL4	O
.	O

Similarly	O
to	O
the	O
expression	O
of	O
the	O
Ser	O
gene	O
,	O
Ser-GAL4	O
expression	O
is	O
restricted	O
to	O
dorsal	O
cells	O
in	O
second/early	O
third	O
instar	O
larvae	O
and	O
is	O
weakly	O
expressed	O
in	O
ventral	O
cells	O
in	O
mid/late	O
third	O
instar	O
larvae	O
,	O
i.e.	O
,	O
after	O
margin	O
cell	O
specification	O
[	O
49,50	O
]	O
.	O

Expression	O
of	O
D-mib	O
in	O
dorsal	O
cells	O
was	O
sufficient	O
to	O
rescue	O
growth	O
of	O
the	O
wing	O
pouch	O
and	O
of	O
the	O
expression	O
of	O
Cut	O
in	O
margin	O
cells	O
in	O
D-mib	O
mutant	O
discs	O
(	O
Figure	O
7A	O
)	O
.	O

This	O
result	O
confirmed	O
that	O
D-mib	O
regulates	O
Ser	O
signaling	O
by	O
dorsal	O
cells	O
.	O

A	O
similar	O
rescue	O
was	O
observed	O
with	O
a	O
YFP	O
:	O
:	O
D-mib	O
protein	O
(	O
Figure	O
7B7B	O
?	O
)	O
	O
,	O
indicating	O
that	O
YFP	O
:	O
:	O
D-mib	O
is	O
functional	O
.	O

YFP	O
:	O
:	O
D-mib	O
localized	O
at	O
the	O
apical	O
cortex	O
and	O
in	O
the	O
cytoplasm	O
(	O
Figure	O
7C7	O
D	O
?	O
?	O
?	O
)	O
,	O
as	O
seen	O
for	O
endogenous	O
D-mib	O
(	O
see	O
Figure	O
3	O
)	O
.	O

YFP	O
:	O
:	O
D-mib	O
co-localized	O
with	O
Dl	O
and	O
Ser	O
at	O
the	O
apical	O
cortex	O
of	O
cells	O
expressing	O
low	O
levels	O
of	O
YFP	O
:	O
:	O
D-mib	O
.	O

However	O
,	O
cells	O
expressing	O
high	O
levels	O
of	O
YFP	O
:	O
:	O
D-mib	O
showed	O
a	O
strong	O
reduction	O
in	O
the	O
level	O
of	O
both	O
Dl	O
and	O
Ser	O
at	O
the	O
cortex	O
(	O
Figure	O
7C7C	O
?	O
?	O
?	O
)	O
'	O
``	O
,	O
further	O
indicating	O
that	O
D-mib	O
down-regulates	O
the	O
levels	O
of	O
both	O
Ser	O
and	O
Dl	O
at	O
the	O
apical	O
cortex	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

Expression	O
of	O
D-mib	O
in	O
Dorsal	O
Cells	O
Is	O
Sufficient	O
to	O
Rescue	O
the	O
D-mib	O
Mutant	O
Phenotype	O

(	O
A	O
)	O
Expression	O
of	O
D-mib	O
(	O
green	O
)	O
in	O
dorsal	O
cells	O
,	O
using	O
Ser-GAL4	O
,	O
rescued	O
the	O
growth	O
of	O
the	O
wing	O
pouch	O
and	O
margin	O
Cut	O
(	O
red	O
)	O
expression	O
in	O
D-mib2/D-mib3	O
mutant	O
discs	O
.	O

(	O
BD	O
?	O
?	O
?	O
)	O
Ser-GAL4-driven	O
expression	O
of	O
YFP	O
:	O
:	O
D-mib	O
(	O
green	O
)	O
rescued	O
the	O
D-mib2/D-mib3	O
phenotype	O
and	O
strongly	O
reduced	O
the	O
level	O
of	O
Dl	O
(	O
blue	O
in	O
[	O
B	O
,	O
B	O
?	O
,	O
C	O
,	O
C	O
?	O
?	O
,	O
D	O
,	O
and	O
D	O
?	O
?	O
]	O
)	O
and	O
Ser	O
(	O
red	O
in	O
[	O
B	O
,	O
B	O
?	O
?	O
,	O
C	O
,	O
C	O
?	O
?	O
?	O
,	O
D	O
,	O
and	O
D	O
?	O
?	O
?	O
]	O
)	O
in	O
dorsal	O
cells	O
.	O

(	O
CD	O
?	O
?	O
?	O
)	O
are	O
high-magnification	O
views	O
(	O
apical	O
[	O
CC	O
?	O
?	O
?	O
]	O
and	O
basal	O
[	O
DD	O
?	O
?	O
?	O
]	O
)	O
of	O
the	O
disc	O
shown	O
in	O
(	O
BB	O
?	O
?	O
)	O
.	O

YFP	O
:	O
:	O
D-mib	O
co-localized	O
with	O
Dl	O
and	O
Ser	O
at	O
the	O
apical	O
cortex	O
in	O
cells	O
expressing	O
only	O
low	O
levels	O
of	O
YFP	O
:	O
:	O
D-mib	O
.	O

Bar	O
is	O
50	O
?	O
m	O
for	O
(	O
AB	O
?	O
?	O
)	O
and	O
10	O
?	O
m	O
for	O
(	O
CD	O
?	O
?	O
?	O
)	O
.	O

D-mib	O
Acts	O
Downstream	O
of	O
Ser	O
and	O
Upstream	O
of	O
Activated	O
N	O

The	O
functional	O
assay	O
was	O
then	O
used	O
to	O
genetically	O
position	O
the	O
requirement	O
for	O
the	O
D-mib	O
gene	O
activity	O
relative	O
to	O
Ser	O
and	O
N	O
(	O
Figure	O
8	O
)	O
.	O

Expression	O
of	O
an	O
activated	O
version	O
of	O
N	O
,	O
Ncdc10	O
[	O
51	O
]	O
,	O
led	O
to	O
the	O
activation	O
of	O
Cut	O
and	O
promoted	O
growth	O
in	O
dorsal	O
cells	O
of	O
D-mib2/D-mib3	O
mutant	O
discs	O
(	O
Figure	O
8C	O
)	O
.	O

This	O
indicates	O
that	O
D-mib	O
acts	O
at	O
a	O
step	O
upstream	O
of	O
N	O
activation	O
.	O

By	O
contrast	O
,	O
elevated	O
levels	O
of	O
Ser	O
expression	O
failed	B-Negation
to	I-Negation
restore	I-Negation
Cut	I-Negation
expression	I-Negation
and	I-Negation
growth	I-Negation
of	I-Negation
the	I-Negation
wing	I-Negation
pouch	I-Negation
in	I-Negation
D-mib2/D-mib3	I-Negation
mutant	I-Negation
larvae	I-Negation
(	O
Figure	O
8B	O
)	O
.	O

This	O
confirms	O
that	O
Ser	O
signaling	O
requires	O
the	O
activity	O
of	O
the	O
D-mib	O
gene	O
,	O
i.e.	O
,	O
that	O
D-mib	O
acts	O
downstream	O
of	O
Ser	O
.	O

Expression	O
of	O
Neur	O
in	O
Dorsal	O
Cells	O
Is	O
Sufficient	O
to	O
Rescue	O
the	O
D-mib	O
Mutant	O
Phenotype	O

D-mib2/D-mib3	O
mutant	O
discs	O
expressing	O
GFP	O
(	O
A	O
)	O
(	O
GFP	O
staining	O
not	B-Negation
shown	I-Negation
)	I-Negation
,	O
Ser	O
(	O
B	O
)	O
,	O
Ncdc10	O
(	O
C	O
)	O
,	O
or	O
Neur	O
(	O
D	O
)	O
under	O
the	O
control	O
of	O
Ser-GAL4	O
were	O
stained	O
for	O
Cut	O
(	O
red	O
)	O
.	O

Expression	O
of	O
Ser	O
in	O
dorsal	O
cells	O
did	O
not	B-Negation
rescue	I-Negation
the	I-Negation
D-mib2/D-mib3	I-Negation
wing	I-Negation
pouch	I-Negation
mutant	I-Negation
phenotype	I-Negation
(	O
compare	O
[	O
B	O
]	O
with	O
[	O
A	O
]	O
)	O
,	O
consistent	O
with	O
D-mib	O
being	O
required	O
for	O
Ser	O
signaling	O
.	O

By	O
contrast	O
,	O
expression	O
of	O
Ncdc10	O
,	O
an	O
activated	O
version	O
of	O
N	O
,	O
led	O
to	O
the	O
deregulated	O
growth	O
of	O
the	O
dorsal	O
compartment	O
and	O
the	O
expression	O
of	O
Cut	O
in	O
most	O
dorsal	O
cells	O
(	O
C	O
)	O
,	O
indicating	O
that	O
activated	O
N	O
acts	O
downstream	O
of	O
D-mib	O
.	O

Expression	O
of	O
Neur	O
in	O
dorsal	O
cells	O
was	O
sufficient	O
to	O
compensate	O
for	O
the	O
loss	O
of	O
D-mib	O
activity	O
(	O
D	O
)	O
.	O

Bar	O
is	O
40	O
?	O
m	O
for	O
all	O
panels	O
.	O

neur	O
and	O
D-mib	O
Functions	O
Partially	O
Overlap	O

The	O
different	O
requirements	O
for	O
neur	O
and	O
D-mib	O
gene	O
activity	O
may	O
suggest	O
that	O
Neur	O
and	O
D-mib	O
have	O
distinct	O
molecular	O
activities	O
.	O

Alternatively	O
,	O
this	O
difference	O
may	O
reflect	O
a	O
difference	O
in	O
gene	O
expression	O
.	O

Consistent	O
with	O
the	O
latter	O
hypothesis	O
,	O
the	B-Negation
neur	I-Negation
gene	I-Negation
is	I-Negation
not	I-Negation
expressed	I-Negation
in	I-Negation
wing	I-Negation
pouch	I-Negation
and	I-Negation
wing	I-Negation
margin	I-Negation
cells	I-Negation
,	I-Negation
where	I-Negation
it	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
,	O
and	O
appears	B-Speculation
to	I-Speculation
be	I-Speculation
expressed	I-Speculation
only	I-Speculation
in	I-Speculation
sensory	I-Speculation
cells	I-Speculation
[	I-Speculation
52	I-Speculation
]	I-Speculation
,	I-Speculation
where	I-Speculation
it	I-Speculation
is	I-Speculation
required	I-Speculation
.	O

By	O
contrast	O
,	O
D-mib	O
appears	O
to	O
be	O
uniformly	O
expressed	O
in	O
imaginal	O
discs	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
examined	O
whether	O
the	O
forced	O
ubiquitous	O
expression	O
of	O
the	O
neur	O
gene	O
can	O
suppress	O
the	O
D-mib	O
loss-of-function	O
phenotype	O
.	O

Expression	O
of	O
Neur	O
,	O
using	O
actin-GAL4	O
,	O
restored	O
growth	O
of	O
the	O
wing	O
pouch	O
and	O
formation	O
of	O
the	O
wing	O
margin	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

Moreover	O
,	O
expression	O
of	O
Neur	O
in	O
dorsal	O
cells	O
,	O
using	O
Ser-GAL4	O
,	O
was	O
sufficient	O
to	O
rescue	O
growth	O
of	O
the	O
wing	O
pouch	O
as	O
well	O
as	O
the	O
expression	O
of	O
Cut	O
in	O
margin	O
cells	O
in	O
D-mib	O
mutant	O
discs	O
(	O
Figure	O
8D	O
)	O
.	O

We	O
conclude	O
that	O
ectopic	O
expression	O
of	O
Neur	O
compensates	O
for	O
the	O
loss	O
of	O
D-mib	O
activity	O
.	O

In	O
a	O
converse	O
experiment	O
,	O
we	O
found	O
that	O
the	O
neur-driven	O
expression	O
of	O
D-mib	O
,	O
using	O
neurPGAL4	O
,	O
did	O
not	B-Negation
rescue	I-Negation
the	I-Negation
cuticular	I-Negation
neurogenic	I-Negation
phenotype	I-Negation
of	I-Negation
neurPGAL4/neur1F65	I-Negation
embryos	I-Negation
.	O

Three	O
UAS-D-mib	O
transgenic	O
lines	O
were	O
tested	O
,	O
and	O
none	B-Negation
showed	I-Negation
detectable	I-Negation
rescue	I-Negation
whereas	O
the	O
two	O
UAS-neur	O
lines	O
used	O
as	O
positive	O
controls	O
either	B-Speculation
fully	I-Speculation
or	I-Speculation
partially	I-Speculation
rescued	O
the	O
cuticular	O
neurogenic	O
phenotype	O
of	O
neurPGAL4/neur1F65	O
embryos	O
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
;	O
UAS-D-mib+/+	O
,	O
neurPGAL4+/+	O
embryos	O
developed	O
normally	O
)	O
.	O

This	O
indicates	O
that	O
a	O
key	O
function	O
of	O
Neur	O
in	O
the	O
embryo	O
can	O
not	O
be	O
provided	O
by	O
D-mib	O
.	O

We	O
therefore	O
suggest	O
that	O
Neur	O
and	O
D-mib	O
functions	O
overlap	O
but	O
are	O
not	O
strictly	O
identical	O
.	O

Discussion	O

Many	O
recent	O
studies	O
have	O
revealed	O
that	O
endocytosis	O
plays	O
multiple	O
roles	O
in	O
the	O
regulation	O
of	O
N	O
signaling	O
(	O
reviewed	O
in	O
[	O
2	O
]	O
;	O
see	O
also	O
[	O
53,54	O
]	O
)	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
conserved	O
E3	O
ubiquitin	O
ligases	O
Neur	O
and	O
D-mib	O
have	O
similar	O
molecular	O
activities	O
in	O
the	O
regulation	O
of	O
Dl	O
and	O
Ser	O
endocytosis	O
but	O
distinct	O
developmental	O
functions	O
in	O
Drosophila	O
.	O

Our	O
analysis	O
first	O
establishes	O
that	O
D-mib	O
regulates	O
Ser	O
signaling	O
during	O
wing	O
development	O
.	O

First	O
,	O
clonal	O
analysis	O
revealed	O
that	O
the	O
activity	O
of	O
the	O
D-mib	O
gene	O
is	O
specifically	O
required	O
in	O
dorsal	O
cells	O
for	O
the	O
expression	O
of	O
Cut	O
at	O
the	O
wing	O
margin	O
.	O

Second	O
,	O
expression	O
of	O
D-mib	O
in	O
the	O
dorsal	O
Ser-signaling	O
cells	O
was	O
sufficient	O
to	O
rescue	O
the	O
D-mib	O
mutant	O
wing	O
phenotype	O
.	O

Third	O
,	O
results	O
from	O
an	O
in	O
vivo	O
antibody	O
uptake	O
assay	O
indicated	O
that	O
the	O
endocytosis	O
of	O
Ser	O
(	O
but	O
not	O
of	O
Dl	O
)	O
was	O
strongly	O
inhibited	O
in	O
D-mib	O
mutant	O
cells	O
.	O

This	O
inhibition	O
correlated	O
with	O
the	O
strong	O
accumulation	O
of	O
Ser	O
(	O
but	O
not	B-Negation
Dl	I-Negation
)	I-Negation
at	O
the	O
apical	O
cortex	O
of	O
D-mib	O
mutant	O
cells	O
.	O

Thus	O
,	O
an	O
essential	O
function	O
of	O
D-mib	O
in	O
the	O
wing	O
is	O
to	O
regulate	O
the	O
endocytosis	O
of	O
Ser	O
in	O
dorsal	O
cells	O
to	O
non-autonomously	O
promote	O
the	O
activation	O
of	O
N	O
along	O
the	O
D-V	O
boundary	O
.	O

By	O
analogy	O
,	O
the	O
defective	O
growth	O
of	O
the	O
eye	O
tissue	O
may	O
similarly	O
result	O
from	O
the	O
lack	O
of	O
Ser	O
signaling	O
and	O
of	O
N	O
activation	O
along	O
the	O
D-V	O
boundary	O
[	O
55	O
]	O
.	O

Because	O
D-mib	O
co-localizes	O
with	O
Ser	O
at	O
the	O
apical	O
cortex	O
of	O
wing	O
disc	O
cells	O
,	O
acts	O
in	O
a	O
RING-finger-dependent	O
manner	O
to	O
regulate	O
Ser	O
endocytosis	O
in	O
S2	O
cells	O
(	O
R.	O
L.	O
B.	O
and	O
F.	O
S.	O
,	O
unpublished	O
results	O
)	O
,	O
and	O
physically	O
associates	O
with	O
Ser	O
in	O
co-immunoprecipitation	O
experiments	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
,	O
D-mib	O
may	O
ubiquitinate	O
Ser	O
and	O
directly	O
regulate	O
its	O
endocytosis	O
.	O

Our	O
analysis	O
further	O
suggests	O
that	O
endocytosis	O
of	O
Ser	O
is	O
required	O
for	O
Ser	O
signaling	O
.	O

This	O
conclusion	O
is	O
consistent	O
with	O
observations	O
made	O
earlier	O
showing	O
that	O
secreted	O
versions	O
of	O
Ser	O
can	B-Negation
not	I-Negation
activate	I-Negation
N	I-Negation
but	O
instead	O
antagonize	O
Ser	O
signaling	O
[	O
56,57	O
]	O
.	O

Thus	O
,	O
endocytosis	O
of	O
both	O
N	O
ligands	O
appears	O
to	O
be	O
strictly	O
required	O
for	O
N	O
activation	O
in	O
Drosophila	O
.	O

Different	O
models	O
have	O
been	O
proposed	O
to	O
explain	O
how	O
endocytosis	O
of	O
the	O
ligand	O
,	O
which	O
removes	O
the	O
ligand	O
from	O
the	O
cell	O
surface	O
,	O
results	O
in	O
N	O
receptor	O
activation	O
(	O
discussed	O
in	O
[	O
17,20,21,30	O
]	O
)	O
.	O

Interestingly	O
,	O
the	B-Negation
strong	I-Negation
requirement	I-Negation
for	I-Negation
Dl	I-Negation
and	I-Negation
Ser	I-Negation
endocytosis	I-Negation
seen	I-Negation
in	I-Negation
Drosophila	I-Negation
is	I-Negation
not	I-Negation
conserved	I-Negation
in	I-Negation
Caenorhabditis	I-Negation
elegans	I-Negation
,	I-Negation
in	I-Negation
which	I-Negation
secreted	I-Negation
ligands	I-Negation
have	I-Negation
been	I-Negation
shown	I-Negation
to	I-Negation
be	I-Negation
functional	I-Negation
[	O
58,59	O
]	O
.	O

Noticeably	O
,	O
there	O
is	O
no	B-Negation
C.	I-Negation
elegans	I-Negation
Mib	I-Negation
homolog	I-Negation
,	O
and	O
the	B-Speculation
function	I-Speculation
of	I-Speculation
C.	I-Speculation
elegans	I-Speculation
neur	I-Speculation
(	I-Speculation
F10D7.5	I-Speculation
)	I-Speculation
is	I-Speculation
not	I-Speculation
known	I-Speculation
.	O

We	O
speculate	O
that	O
endocytosis	O
of	O
the	O
ligands	O
may	O
have	O
evolved	O
as	O
a	O
means	O
to	O
ensure	O
tight	O
spatial	O
regulation	O
of	O
the	O
activation	O
of	O
N	O
.	O

Our	O
analysis	O
also	O
establishes	O
that	O
the	O
activity	O
of	O
the	O
D-mib	O
gene	O
is	O
required	O
for	O
a	O
subset	O
of	O
N	O
signaling	O
events	O
that	O
are	O
distinct	O
from	O
those	O
that	O
require	O
the	O
activity	O
of	O
the	O
neur	O
gene	O
.	O

We	O
have	O
shown	O
that	O
the	O
D-mib	O
gene	O
regulates	O
wing	O
margin	O
formation	O
,	O
leg	O
segmentation	O
,	O
and	O
vein	O
formation	O
,	O
whereas	O
none	B-Negation
of	I-Negation
these	I-Negation
three	I-Negation
processes	I-Negation
depend	I-Negation
on	I-Negation
neur	I-Negation
gene	I-Negation
activity	I-Negation
(	O
[	O
45,60	O
]	O
;	O
this	O
study	O
)	O
.	O

Conversely	O
,	O
the	O
activity	O
of	O
the	O
neur	O
gene	O
is	O
essential	O
for	O
binary	O
cell-fate	O
decisions	O
in	O
the	O
bristle	O
lineage	O
[	O
22	O
]	O
that	O
do	O
not	B-Negation
require	I-Negation
the	I-Negation
activity	I-Negation
of	I-Negation
the	I-Negation
D-mib	I-Negation
gene	I-Negation
(	B-Negation
no	I-Negation
bristle	I-Negation
defects	I-Negation
were	I-Negation
seen	I-Negation
in	I-Negation
D-mib	I-Negation
mutant	I-Negation
flies	I-Negation
)	I-Negation
.	O

The	O
activity	O
of	O
the	O
neur	O
gene	O
is	O
also	O
required	O
for	O
lateral	O
inhibition	O
during	O
neurogenesis	O
in	O
embryos	O
and	O
pupae	O
[	O
4,45,61	O
]	O
.	O

This	O
process	O
is	O
largely	O
independent	O
of	O
D-mib	O
gene	O
activity	O
since	O
the	O
complete	O
loss	O
of	O
D-mib	O
function	O
only	O
resulted	O
in	O
a	O
mild	O
neurogenic	O
phenotype	O
in	O
the	O
notum	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
neur	O
and	O
D-mib	O
genes	O
have	O
largely	O
distinct	O
and	O
complementary	O
functions	O
in	O
Drosophila	O
.	O

Whether	O
a	O
similar	O
functional	O
relationship	O
between	O
Neur	O
and	O
D-mib	O
exists	O
in	O
vertebrates	O
awaits	O
the	O
study	O
of	O
the	O
D.	O
rerio	O
neur	O
genes	O
and/or	O
of	O
the	O
murine	O
Mib	O
and	O
Neur	O
genes	O
.	O

The	B-Negation
functional	I-Negation
differences	I-Negation
observed	I-Negation
between	I-Negation
D-mib	I-Negation
and	I-Negation
neur	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
simply	I-Negation
explained	I-Negation
by	I-Negation
obvious	I-Negation
differences	I-Negation
in	I-Negation
molecular	I-Negation
activity	I-Negation
and/or	I-Negation
substrate	I-Negation
specificity	I-Negation
.	O

First	O
,	O
both	O
Neur	O
and	O
D-mib	O
physically	O
interact	O
with	O
Dl	O
(	O
[	O
20	O
]	O
;	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
and	O
promote	O
the	O
down-regulation	O
of	O
Dl	O
from	O
the	O
apical	O
membrane	O
when	O
overexpressed	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

Furthermore	O
,	O
Dl	O
signaling	O
appears	O
to	O
require	O
the	O
activity	O
of	O
either	O
Neur	O
or	O
D-mib	O
,	O
depending	O
on	O
the	O
developmental	O
contexts	O
.	O

We	O
have	O
shown	O
here	O
that	O
specific	O
aspects	O
of	O
the	O
D-mib	O
phenotype	O
in	O
legs	O
and	O
in	O
the	O
notum	O
can	B-Negation
not	I-Negation
simply	I-Negation
result	I-Negation
from	I-Negation
loss	I-Negation
of	I-Negation
Ser	I-Negation
signaling	I-Negation
and	O
are	O
consistent	B-Speculation
with	I-Speculation
reduced	I-Speculation
Dl	I-Speculation
signaling	I-Speculation
,	O
suggesting	B-Speculation
that	I-Speculation
D-mib	I-Speculation
regulates	I-Speculation
Dl	I-Speculation
signaling	I-Speculation
.	O

Consistent	O
with	O
this	O
interpretation	O
,	O
overexpression	O
studies	O
indicate	O
that	O
D-mib	O
up-regulates	O
the	O
signaling	O
activity	O
of	O
Dl	O
,	O
whereas	O
a	O
dominant-negative	O
form	O
of	O
D-mib	O
inhibits	O
it	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

We	O
note	O
,	O
however	O
,	O
that	O
no	B-Negation
clear	I-Negation
defects	I-Negation
in	I-Negation
Dl	I-Negation
subcellular	I-Negation
localization	I-Negation
and/or	I-Negation
trafficking	I-Negation
were	I-Negation
observed	I-Negation
in	I-Negation
D-mib	I-Negation
mutant	I-Negation
cells	I-Negation
.	O

It	O
is	O
conceivable	O
that	O
the	O
contribution	O
of	O
D-mib	O
to	O
the	O
endocytosis	O
of	O
Dl	O
is	O
masked	O
by	O
the	O
activity	O
of	O
D-mib-independent	O
processes	O
that	O
may	O
,	O
or	O
may	O
not	O
,	O
be	O
linked	O
to	O
Dl	O
signaling	O
.	O

We	O
have	O
also	O
shown	O
that	O
,	O
reciprocally	O
,	O
Neur	O
and	O
D-mib	O
may	O
similarly	O
regulate	O
Ser	O
.	O

Neur	O
and	O
D-mib	O
were	O
shown	O
to	O
similarly	O
promote	O
down-regulation	O
of	O
Ser	O
from	O
the	O
cell	O
surface	O
when	O
overexpressed	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
.	O

Moreover	O
,	O
D-mib	O
binds	O
Ser	O
(	O
E.	O
C.	O
Lai	O
,	O
F.	O
Roegiers	O
,	O
X.	O
Qin	O
,	O
R.	O
Le	O
Borgne	O
,	O
F.	O
Schweisguth	O
,	O
et	O
al.	O
,	O
unpublished	O
data	O
)	O
and	O
regulates	O
Ser	O
signaling	O
(	O
this	O
study	O
)	O
.	O

Whether	O
endogenous	O
Neur	O
binds	O
and	O
activates	O
Ser	O
remains	O
to	O
be	O
tested	O
.	O

However	O
,	O
the	O
ability	O
of	O
Neur	O
to	O
rescue	O
the	O
D-mib	O
mutant	O
wing	O
phenotype	O
when	O
expressed	O
in	O
dorsal	O
cells	O
strongly	O
indicates	O
that	O
Neur	O
can	O
promote	O
Ser	O
signaling	O
.	O

Together	O
,	O
these	O
data	O
indicate	O
that	O
Neur	O
and	O
D-mib	O
have	O
similar	O
molecular	O
activities	O
.	O

D-mib	O
and	O
Neur	O
may	O
have	O
identical	O
molecular	O
activities	O
but	O
distinct	O
expression	O
patterns	O
,	O
hence	O
distinct	O
functions	O
at	O
the	O
level	O
of	O
the	O
organism	O
.	O

Consistent	O
with	O
this	O
possibility	O
,	O
D-mib	O
is	O
uniformly	O
distributed	O
in	O
imaginal	O
discs	O
,	O
whereas	O
Neur	O
is	O
specifically	O
detected	O
in	O
sensory	O
cells	O
[	O
52	O
]	O
.	O

Importantly	O
,	O
the	O
rescue	O
of	O
the	O
D-mib	O
mutant	O
phenotype	O
by	O
ectopic	O
expression	O
of	O
Neur	O
strongly	O
supports	O
this	O
interpretation	O
.	O

This	O
result	O
further	O
suggests	O
that	O
Neur	O
can	O
regulate	O
Ser	O
signaling	O
.	O

Consistent	O
with	O
this	O
idea	O
,	O
overexpression	O
of	O
Neur	O
in	O
imaginal	O
discs	O
resulted	O
in	O
a	O
strong	O
reduction	O
of	O
Ser	O
accumulation	O
at	O
the	O
apical	O
cortex	O
(	O
data	O
not	B-Negation
shown	I-Negation
)	I-Negation
.	O

Thus	O
,	O
despite	O
their	O
obvious	O
structural	O
differences	O
,	O
Neur	O
and	O
D-mib	O
appear	O
to	O
act	O
similarly	O
to	O
promote	O
the	O
endocytosis	O
of	O
Dl	O
and	O
Ser	O
.	O

Nevertheless	O
,	O
our	O
observation	O
that	O
D-mib	O
could	B-Negation
not	I-Negation
compensate	I-Negation
for	I-Negation
the	I-Negation
loss	I-Negation
of	I-Negation
neur	I-Negation
activity	I-Negation
in	I-Negation
the	I-Negation
embryo	I-Negation
indicates	B-Speculation
that	I-Speculation
D-mib	I-Speculation
and	I-Speculation
Neur	I-Speculation
have	I-Speculation
overlapping	I-Speculation
rather	I-Speculation
than	I-Speculation
identical	I-Speculation
molecular	I-Speculation
activities	I-Speculation
.	O

In	O
conclusion	O
,	O
Neur	O
and	O
D-mib	O
appear	O
to	O
have	O
similar	O
molecular	O
activities	O
in	O
the	O
regulation	O
of	O
Dl	O
and	O
Ser	O
endocytosis	O
but	O
distinct	O
developmental	O
functions	O
in	O
Drosophila	O
.	O

The	O
conservation	O
from	O
Drosophila	O
to	O
mammals	O
of	O
these	O
two	O
structurally	O
distinct	O
but	O
functionally	O
similar	O
E3	O
ubiquitin	O
ligases	O
is	O
likely	O
to	O
reflect	O
a	O
combination	O
of	O
evolutionary	O
advantages	O
associated	O
with	O
:	O
(	O
i	O
)	O
specialized	O
expression	O
pattern	O
,	O
as	O
evidenced	O
by	O
the	O
cell-specific	O
expression	O
of	O
the	O
neur	O
gene	O
in	O
sensory	O
organ	O
precursor	O
cells	O
[	O
52	O
]	O
;	O
(	O
ii	O
)	O
specialized	O
function	O
,	O
as	O
suggested	O
by	O
the	O
role	O
of	O
murine	O
MIB	O
in	O
TNF	O
?	O
?	O
signaling	O
[	O
32	O
]	O
;	O
(	O
iii	O
)	O
regulation	O
of	O
protein	O
stability	O
,	O
localization	O
,	O
and/or	O
activity	O
.	O

For	O
instance	O
,	O
Neur	O
,	O
but	O
not	B-Negation
D-mib	I-Negation
,	O
localizes	O
asymmetrically	O
during	O
asymmetric	O
sensory	O
organ	O
precursor	O
cell	O
divisions	O
[	O
22	O
]	O
.	O

Materials	O
and	O
Methods	O

Flies	O
.	O

The	O
D-mib1	O
mutation	O
corresponds	O
to	O
the	O
EY97600	O
P-element	O
insertion	O
generated	O
by	O
the	O
Gene	O
Disruption	O
Project	O
(	O
http	O
:	O
//flypush.imgen.bcm.tmc.edu/pscreen/	O
)	O
.	O

The	O
D-mib2	O
allele	O
was	O
selected	O
as	O
w-	O
D-mib	O
mutant	O
derivative	O
by	O
imprecise	O
excision	O
of	O
the	O
EY97600	O
P-element	O
.	O

The	O
precise	O
breakpoints	O
of	O
the	O
D-mib2	O
deletion	O
were	O
determined	O
by	O
sequencing	O
a	O
PCR	O
fragment	O
amplified	O
from	O
genomic	O
DNA	O
prepared	O
from	O
D-mib2	O
homozygous	O
larvae	O
.	O

The	O
l	O
(	O
3	O
)	O
72CdaJ12	O
and	O
l	O
(	O
3	O
)	O
72CdaI5	O
alleles	O
originally	O
isolated	O
by	O
[	O
35	O
]	O
failed	B-Negation
to	I-Negation
complement	I-Negation
the	I-Negation
D-mib1	I-Negation
and	I-Negation
D-mib2	I-Negation
mutations	I-Negation
and	O
were	O
renamed	O
D-mib3	O
and	O
D-mib4	O
.	O

The	O
D-mib1	O
,	O
D-mib2	O
,	O
and	O
D-mib3	O
alleles	O
appear	O
to	O
be	O
genetically	O
null	O
alleles	O
since	O
the	O
phenotypes	O
of	O
D-mib1/D-mib1	O
and	O
D-mib1/D-mib3	O
mutant	O
pupae	O
are	O
indistinguishable	O
from	O
the	O
ones	O
seen	O
in	O
D-mib1/D-mib2	O
and	O
D-mib2/D-mib3	O
pupae	O
.	O

Sequence	O
analysis	O
of	O
the	O
D-mib3	O
and	O
D-mib4	O
alleles	O
was	O
carried	O
on	O
PCR	O
products	O
prepared	O
from	O
genomic	O
DNA	O
prepared	O
from	O
D-mib3/D-mib2	O
and	O
D-mib4/D-mib2	O
mutant	O
pupae	O
.	O

Genomic	O
DNA	O
from	O
l	O
(	O
3	O
)	O
72Cda/D-mib2	O
mutant	O
pupae	O
was	O
used	O
as	O
control	O
for	O
polymorphism	O
.	O

D-mib2	O
mutant	O
clones	O
were	O
generated	O
in	O
y	O
w	O
hs-flp	O
;	O
FRT2A	O
D-mib2/FRT2A	O
M	O
(	O
3	O
)	O
i55	O
ubi-nlsGFP	O
larvae	O
.	O

neur1F65	O
mutant	O
clones	O
were	O
generated	O
as	O
previously	O
described	O
[	O
22	O
]	O
.	O

UAS-D-mib	O
and	O
UAS-YFP	O
:	O
:	O
D-mib	O
lines	O
were	O
generated	O
via	O
standard	O
P-element	O
transformation	O
.	O

These	O
constructs	O
were	O
derived	O
from	O
the	O
SD05267	O
cDNA	O
obtained	O
from	O
ResGen	O
(	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Cloning	O
details	O
for	O
these	O
constructs	O
are	O
available	O
upon	O
request	O
.	O

UAS-Dl	O
(	O
gift	O
from	O
M.	O
Muskavith	O
)	O
,	O
UAS-Ser	O
(	O
gift	O
from	O
R.	O
Fleming	O
)	O
,	O
UAS-Neur	O
(	O
gift	O
from	O
C.	O
Delidakis	O
)	O
,	O
UAS-Ncdc10	O
(	O
gift	O
of	O
T.	O
Klein	O
)	O
,	O
Ser-GAL4	O
lines	O
,	O
and	O
Ser	O
mutant	O
alleles	O
are	O
described	O
in	O
FlyBase	O
(	O
http	O
:	O
//flybase.bio.indiana.edu/	O
)	O
.	O

Antibodies	O
.	O

Dissected	O
imaginal	O
discs	O
were	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
(	O
15	O
min	O
)	O
and	O
incubated	O
with	O
antibodies	O
at	O
room	O
temperature	O
in	O
PBS	O
1X	O
with	O
0.1	O
%	O
TritonX-100	O
.	O

Rabbit	O
polyclonal	O
anti-D-mib	O
antibodies	O
were	O
raised	O
against	O
the	O
CYNERKTDDSELPGN	O
peptide	O
(	O
CovalAb	O
,	O
Lyon	O
,	O
France	O
)	O
.	O

Immunopurified	O
anti-D-mib	O
antibodies	O
(	O
rabbit	O
541	O
)	O
were	O
used	O
(	O
immunofluorescence	O
,	O
1:100	O
;	O
Western	O
blot	O
,	O
1:1,000	O
)	O
.	O

Other	O
primary	O
antibodies	O
were	O
mouse	O
anti-Cut	O
(	O
2B10	O
;	O
Developmental	O
Studies	O
Hybridoma	O
Bank	O
[	O
DSHB	O
,	O
Iowa	O
City	O
,	O
Iowa	O
,	O
United	O
States	O
]	O
;	O
1:500	O
)	O
;	O
rat	O
anti-DE-Cadherin	O
(	O
gift	O
from	O
T.	O
Uemura	O
;	O
1:50	O
)	O
;	O
guinea	O
pig	O
anti-Discs-large	O
(	O
gift	O
from	O
P.	O
Bryant	O
;	O
1:3,000	O
)	O
;	O
anti-	O
?	O
-galactosidase	O
(	O
Cappel	O
[	O
MP	O
Biomedicals	O
,	O
Irvine	O
,	O
California	O
,	O
United	O
States	O
]	O
;	O
1:1,000	O
)	O
;	O
mouse	O
anti-DeltaECD	O
(	O
C594.9B	O
;	O
DSHB	O
;	O
1:1,000	O
)	O
;	O
mouse	O
anti-NotchECD	O
(	O
C548.2H	O
;	O
DSHB	O
;	O
1:1,000	O
)	O
;	O
rat	O
anti-Ser	O
(	O
gift	O
from	O
K.	O
Irvine	O
;	O
1:2,000	O
)	O
;	O
rat	O
anti-Ser	O
(	O
gift	O
from	O
S.	O
Cohen	O
;	O
1:200	O
)	O
;	O
rabbit	O
anti-Ser	O
(	O
gift	O
from	O
E.	O
Knust	O
;	O
1:10	O
)	O
;	O
and	O
guinea	O
pig	O
anti-Senseless	O
(	O
gift	O
from	O
H.	O
Bellen	O
;	O
1:3,000	O
)	O
.	O

Cy2-	O
,	O
Cy3-	O
,	O
and	O
Cy5-coupled	O
secondary	O
antibodies	O
were	O
from	O
Jackson	O
Laboratory	O
(	O
Bar	O
Harbor	O
,	O
Maine	O
,	O
United	O
States	O
)	O
.	O

Alexa488-coupled	O
secondary	O
antibodies	O
and	O
phalloidin	O
were	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
Oregon	O
,	O
United	O
States	O
)	O
.	O

Images	O
were	O
acquired	O
on	O
a	O
Leica	O
(	O
Wetzlar	O
,	O
Germany	O
)	O
SP2	O
microscope	O
and	O
assembled	O
using	O
Adobe	O
Photoshop	O
(	O
Adobe	O
Systems	O
,	O
San	O
Jose	O
,	O
California	O
,	O
United	O
States	O
)	O
.	O

Endocytosis	O
assay	O
.	O

Third	O
instar	O
larvae	O
wing	O
discs	O
were	O
dissected	O
in	O
Schneider	O
's	O
Drosophila	O
medium	O
(	O
Gibco	O
BRL	O
,	O
San	O
Diego	O
,	O
California	O
,	O
United	O
States	O
)	O
containing	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
Gibco	O
BRL	O
)	O
.	O

Wing	O
discs	O
were	O
cut	O
between	O
the	O
wing	O
pouch	O
and	O
the	O
thorax	O
to	O
facilitate	O
antibody	O
diffusion	O
.	O

Wing	O
discs	O
were	O
cultured	O
for	O
15	O
min	O
with	O
mouse	O
anti-Dl	O
(	O
C5949B	O
at	O
1:100	O
)	O
and	O
rat	O
anti-Ser	O
antibody	O
(	O
1:500	O
;	O
from	O
K.	O
Irvine	O
)	O
.	O

Following	O
three	O
medium	O
changes	O
and	O
a	O
45-min	O
chase	O
period	O
,	O
wing	O
discs	O
were	O
fixed	O
and	O
incubated	O
with	O
secondary	O
antibodies	O
.	O

RAG1	O
Core	O
and	O
V	O
(	O
D	O
)	O
J	O
Recombination	O
Signal	O
Sequences	O
Were	O
Derived	O
from	O
Transib	O
Transposons	O

Abstract	O

The	O
V	O
(	O
D	O
)	O
J	O
recombination	O
reaction	O
in	O
jawed	O
vertebrates	O
is	O
catalyzed	O
by	O
the	O
RAG1	O
and	O
RAG2	O
proteins	O
,	O
which	O
are	O
believed	O
to	O
have	O
emerged	O
approximately	O
500	O
million	O
years	O
ago	O
from	O
transposon-encoded	O
proteins	O
.	O

Yet	O
no	B-Negation
transposase	I-Negation
sequence	I-Negation
similar	I-Negation
to	I-Negation
RAG1	I-Negation
or	I-Negation
RAG2	I-Negation
has	I-Negation
been	I-Negation
found	I-Negation
.	O

Here	O
we	O
show	O
that	O
the	O
approximately	O
600-amino	O
acid	O
	O
core	O
	O
region	O
of	O
RAG1	O
required	O
for	O
its	O
catalytic	O
activity	O
is	O
significantly	O
similar	O
to	O
the	O
transposase	O
encoded	O
by	O
DNA	O
transposons	O
that	O
belong	O
to	O
the	O
Transib	O
superfamily	O
.	O

This	O
superfamily	O
was	O
discovered	O
recently	O
based	O
on	O
computational	O
analysis	O
of	O
the	O
fruit	O
fly	O
and	O
African	O
malaria	O
mosquito	O
genomes	O
.	O

Transib	O
transposons	O
also	O
are	O
present	O
in	O
the	O
genomes	O
of	O
sea	O
urchin	O
,	O
yellow	O
fever	O
mosquito	O
,	O
silkworm	O
,	O
dog	O
hookworm	O
,	O
hydra	O
,	O
and	O
soybean	O
rust	O
.	O

We	O
demonstrate	O
that	O
recombination	O
signal	O
sequences	O
(	O
RSSs	O
)	O
were	O
derived	O
from	O
terminal	O
inverted	O
repeats	O
of	O
an	O
ancient	O
Transib	O
transposon	O
.	O

Furthermore	O
,	O
the	O
critical	O
DDE	O
catalytic	O
triad	O
of	O
RAG1	O
is	O
shared	O
with	O
the	O
Transib	O
transposase	O
as	O
part	O
of	O
conserved	O
motifs	O
.	O

We	O
also	O
studied	O
several	O
divergent	O
proteins	O
encoded	O
by	O
the	O
sea	O
urchin	O
and	O
lancelet	O
genomes	O
that	O
are	O
25	O
%	O
-30	O
%	O
identical	O
to	O
the	O
RAG1	O
N-terminal	O
domain	O
and	O
the	O
RAG1	O
core	O
.	O

Our	O
results	O
provide	O
the	O
first	O
direct	O
evidence	O
linking	O
RAG1	O
and	O
RSSs	O
to	O
a	O
specific	O
superfamily	O
of	O
DNA	O
transposons	O
and	O
indicate	O
that	O
the	O
V	O
(	O
D	O
)	O
J	O
machinery	O
evolved	O
from	O
transposons	O
.	O

We	O
propose	O
that	O
only	O
the	O
RAG1	O
core	O
was	O
derived	O
from	O
the	O
Transib	O
transposase	O
,	O
whereas	O
the	O
N-terminal	O
domain	O
was	O
assembled	O
from	O
separate	O
proteins	O
of	O
unknown	O
function	O
that	O
may	O
still	O
be	O
active	O
in	O
sea	O
urchin	O
,	O
lancelet	O
,	O
hydra	O
,	O
and	O
starlet	O
sea	O
anemone	O
.	O

We	O
also	O
suggest	O
that	O
the	O
RAG2	O
protein	O
was	O
not	O
encoded	O
by	O
ancient	O
Transib	O
transposons	O
but	O
emerged	O
in	O
jawed	O
vertebrates	O
as	O
a	O
counterpart	O
of	O
RAG1	O
necessary	O
for	O
the	O
V	O
(	O
D	O
)	O
J	O
recombination	O
reaction	O
.	O

Introduction	O

The	O
immune	O
system	O
of	O
jawed	O
vertebrates	O
detects	O
and	O
destroys	O
foreign	O
invaders	O
,	O
including	O
bacteria	O
and	O
viruses	O
,	O
by	O
a	O
specific	O
response	O
to	O
an	O
unlimited	O
number	O
of	O
antigens	O
expressed	O
by	O
them	O
.	O

The	O
antigens	O
can	O
be	O
identified	O
after	O
they	O
are	O
specifically	O
bound	O
by	O
surface	O
receptors	O
of	O
vertebrate	O
B	O
and	O
T	O
immune	O
cells	O
(	O
BCRs	O
and	O
TCRs	O
,	O
respectively	O
)	O
.	O

Because	O
the	B-Negation
vast	I-Negation
repertoire	I-Negation
of	I-Negation
BCRs	I-Negation
and	I-Negation
TCRs	I-Negation
can	I-Negation
not	I-Negation
be	I-Negation
encoded	I-Negation
genetically	I-Negation
,	O
ancestors	O
of	O
jawed	O
vertebrates	O
adopted	O
an	O
elegant	O
combinatorial	O
solution	O
[	O
1	O
]	O
.	O

The	O
variable	O
portions	O
of	O
the	O
BCR	O
and	O
TCR	O
genes	O
are	O
composed	O
of	O
separate	O
V	O
(	O
variable	O
)	O
,	O
D	O
(	O
diversity	O
)	O
,	O
and	O
J	O
(	O
joining	O
)	O
segments	O
,	O
which	O
are	O
represented	O
by	O
fewer	O
than	O
a	O
few	O
hundred	O
copies	O
each	O
.	O

In	O
a	O
B	O
and	O
T	O
cell	O
site-specific	O
recombination	O
reaction	O
,	O
commonly	O
known	O
as	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
one	O
V	O
,	O
one	O
D	O
,	O
and	O
one	O
J	O
segment	O
are	O
joined	O
together	O
into	O
a	O
single	O
exon	O
encoding	O
the	O
variable	O
antigen-binding	O
region	O
of	O
the	O
receptor	O
.	O

In	O
addition	O
to	O
this	O
combinatorial	O
diversity	O
,	O
further	O
diversity	O
is	O
generated	O
by	O
small	O
insertions	O
and	O
deletions	O
at	O
junctions	O
between	O
the	O
joined	O
segments	O
.	O

In	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
DNA	O
cleavage	O
is	O
catalyzed	O
by	O
two	O
proteins	O
encoded	O
by	O
the	O
recombination-activating	O
genes	O
,	O
approximately	O
1040-amino	O
acid	O
(	O
aa	O
)	O
RAG1	O
and	O
approximately	O
530-aa	O
RAG2	O
[	O
2,3	O
]	O
.	O

The	O
site	O
specificity	O
of	O
the	O
recombination	O
is	O
defined	O
by	O
the	O
binding	O
of	O
RAG1/2	O
to	O
RSSs	O
flanking	O
the	O
V	O
,	O
D	O
,	O
and	O
J	O
segments	O
[	O
4	O
]	O
.	O

All	O
RSSs	O
can	O
be	O
divided	O
into	O
two	O
groups	O
,	O
referred	O
to	O
as	O
RSS12	O
and	O
RSS23	O
,	O
and	O
consist	O
of	O
conserved	O
heptamer	O
and	O
nonamer	O
sequences	O
separated	O
by	O
a	O
variable	O
spacer	O
either	O
12	O
	O
1	O
(	O
RSS12	O
)	O
or	O
23	O
	O
1	O
(	O
RSS23	O
)	O
bp	O
long	O
[	O
47	O
]	O
.	O

During	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
RAG1/2	O
complex	O
binds	O
one	O
RSS12	O
and	O
one	O
RSS23	O
,	O
bringing	O
them	O
into	O
juxtaposition	O
,	O
and	O
cuts	O
the	O
chromosome	O
between	O
the	O
RSS	O
heptamers	O
and	O
the	O
corresponding	O
V	O
and	O
D	O
,	O
D	O
and	O
J	O
,	O
or	O
V	O
and	O
J	O
coding	O
segments	O
[	O
3,8	O
]	O
.	O

A	O
rule	O
requiring	O
that	O
efficient	O
V	O
(	O
D	O
)	O
J	O
recombination	O
occur	O
between	O
RSS12	O
and	O
RSS23	O
is	O
known	O
as	O
the	O
	O
12/23	O
	O
rule	O
[	O
1	O
]	O
.	O

Even	O
prior	O
to	O
the	O
discovery	O
of	O
RAG1	O
and	O
RAG2	O
,	O
it	O
had	O
been	O
suggested	O
that	O
the	O
first	O
two	O
RSSs	O
were	O
originally	O
terminal	O
inverted	O
repeats	O
(	O
TIRs	O
)	O
of	O
an	O
ancient	O
transposon	O
whose	O
accidental	O
insertion	O
into	O
a	O
gene	O
ancestral	O
to	O
BCR	O
and	O
TCR	O
,	O
followed	O
by	O
gene	O
duplications	O
,	O
triggered	O
the	O
emergence	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
machinery	O
[	O
4	O
]	O
.	O

Later	O
,	O
this	O
model	O
was	O
expanded	O
by	O
the	O
suggestion	O
that	O
both	O
RAG1	O
and	O
RAG2	O
might	O
have	O
evolved	O
from	O
a	O
transposase	O
(	O
TPase	O
)	O
that	O
catalyzed	O
transpositions	O
of	O
ancient	O
transposons	O
flanked	O
by	O
TIRs	O
that	O
were	O
precursors	O
of	O
RSSs	O
[	O
9	O
]	O
.	O

This	O
model	O
has	O
received	O
additional	O
support	O
through	O
observations	O
of	O
similar	O
biochemical	O
reactions	O
in	O
transposition	O
and	O
V	O
(	O
D	O
)	O
J	O
recombination	O
[	O
10,11	O
]	O
.	O

Finally	O
,	O
it	O
was	O
demonstrated	O
that	O
RAG1/2	O
catalyzed	O
transpositions	O
of	O
a	O
DNA	O
segment	O
flanked	O
by	O
RSS12	O
and	O
RSS23	O
in	O
vitro	O
[	O
12,13	O
]	O
and	O
in	O
vivo	O
in	O
yeast	O
[	O
14	O
]	O
.	O

In	O
vertebrates	O
,	O
in	O
vivo	O
RAG-mediated	O
transpositions	O
are	O
strongly	O
suppressed	O
,	O
probably	O
to	O
minimize	O
potential	O
harm	O
to	O
genome	O
function	O
.	O

So	O
far	O
,	O
only	O
one	O
putative	O
instance	O
of	O
such	O
a	O
transposition	O
has	O
been	O
reported	O
[	O
15	O
]	O
.	O

However	O
,	O
given	O
the	O
lack	B-Negation
of	I-Negation
significant	I-Negation
structural	I-Negation
similarities	I-Negation
between	I-Negation
RAGs	I-Negation
and	I-Negation
known	I-Negation
TPases	I-Negation
,	O
the	B-Speculation
	I-Speculation
RAG	I-Speculation
transposon	I-Speculation
	I-Speculation
model	I-Speculation
[	I-Speculation
9,12,13,16	I-Speculation
]	I-Speculation
remained	I-Speculation
unproven	I-Speculation
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
RAG1	O
core	O
and	O
RSSs	O
were	O
derived	O
from	O
a	O
TPase	O
and	O
TIRs	O
encoded	O
by	O
ancient	O
DNA	O
transposons	O
from	O
the	O
Transib	O
superfamily	O
[	O
17	O
]	O
.	O

The	O
Transib	O
superfamily	O
is	O
one	O
of	O
ten	O
superfamilies	O
of	O
DNA	O
transposons	O
detected	O
so	O
far	O
in	O
eukaryotes	O
[	O
17	O
]	O
.	O

Like	O
other	O
DNA	O
transposons	O
,	O
Transib	O
transposons	O
exist	O
as	O
autonomous	O
and	O
nonautonomous	O
elements	O
.	O

The	O
autonomous	O
Transib	O
transposons	O
are	O
34	O
kb	O
long	O
and	O
code	O
for	O
an	O
approximately	O
700-aa	O
TPase	O
that	O
is	O
not	O
similar	O
to	O
TPases	O
from	O
any	O
other	O
transposon	O
superfamilies	O
.	O

Computational	O
analysis	O
of	O
Transib	O
elements	O
,	O
including	O
their	O
numerous	O
insertions	O
into	O
copies	O
of	O
other	O
transposons	O
,	O
demonstrated	O
that	O
Transib	O
transposons	O
are	O
flanked	O
by	O
5-bp	O
target	O
site	O
duplications	O
(	O
TSDs	O
)	O
,	O
which	O
also	O
distinguishes	O
this	O
superfamily	O
from	O
all	O
the	O
others	O
[	O
17	O
]	O
.	O

Transib	O
transpositions	O
are	O
expected	O
to	O
be	O
catalyzed	O
by	O
the	O
binding	O
of	O
the	O
TPase	O
to	O
TIRs	O
of	O
autonomous	O
and	O
nonautonomous	O
transposons	O
[	O
17	O
]	O
.	O

As	O
discussed	O
in	O
this	O
paper	O
,	O
in	O
addition	O
to	O
the	O
fruit	O
fly	O
(	O
Drosophila	O
melanogaster	O
)	O
and	O
African	O
malaria	O
mosquito	O
(	O
Anopheles	O
gambiae	O
)	O
genomes	O
,	O
in	O
which	O
Transib	O
transposons	O
were	O
originally	O
discovered	O
,	O
these	O
genes	O
are	O
also	O
present	O
in	O
diverse	O
animals	O
(	O
Table	O
S1	O
)	O
,	O
including	O
other	O
species	O
of	O
fruit	O
fly	O
(	O
e.g.	O
,	O
Drosophila	O
pseudoobscura	O
,	O
Drosophila	O
willistoni	O
)	O
,	O
yellow	O
fever	O
mosquito	O
(	O
Anopheles	O
aegypti	O
)	O
,	O
silkworm	O
(	O
Bombyx	O
mori	O
)	O
,	O
red	O
flour	O
beetle	O
(	O
Tribolium	O
castaneum	O
)	O
,	O
dog	O
hookworm	O
(	O
Ancylostoma	O
caninum	O
)	O
,	O
freshwater	O
flatworm	O
(	O
Schmidtea	O
mediterranea	O
)	O
,	O
hydra	O
(	O
Hydra	O
magnipapillata	O
)	O
,	O
sea	O
urchin	O
(	O
Strongylocentrotus	O
purpuratus	O
)	O
,	O
and	O
soybean	O
rust	O
(	O
Phakopsora	O
pachyrhizi	O
)	O
.	O

Genomes	O
of	O
plants	O
and	O
vertebrates	O
seem	O
to	O
be	O
free	O
of	O
any	O
recognizable	O
Transib	O
transposons	O
(	O
Figure	O
1	O
)	O
.	O

Schematic	O
Presentation	O
of	O
Transib	O
transposons	O
,	O
RAG1	O
,	O
RAG2	O
,	O
and	O
RAG1-Like	O
Proteins	O
in	O
Eukaryotes	O

The	O
basic	O
timescale	O
of	O
the	O
evolutionary	O
tree	O
is	O
based	O
on	O
published	O
literature	O
[	O
4951	O
]	O
.	O

Red	O
circles	O
mark	O
species	O
in	O
which	O
Transib	O
TPases	O
were	O
found	O
.	O

Gray	O
squares	O
indicate	O
RAG2	O
;	O
orange	O
and	O
blue	O
ellipses	O
show	O
the	O
RAG1	O
core	O
and	O
RAG1	O
N-terminal	O
domain	O
,	O
respectively	O
.	O

Overall	O
taxonomy	O
,	O
including	O
common	O
and	O
Latin	O
names	O
,	O
is	O
reported	O
on	O
the	O
right	O
side	O
of	O
the	O
figure	O
.	O

A	O
question	O
mark	O
at	O
the	O
lamprey	O
lineage	O
indicates	O
insufficient	O
sequence	O
data	O
.	O

A	O
lack	B-Negation
of	I-Negation
any	I-Negation
labels	I-Negation
means	O
that	O
the	O
Transib	O
TPase	O
and	O
RAG1/2	O
are	O
not	B-Negation
present	I-Negation
in	I-Negation
the	I-Negation
sequenced	I-Negation
portions	I-Negation
of	I-Negation
the	I-Negation
corresponding	I-Negation
genomes	I-Negation
.	O

Among	O
branches	O
lacking	B-Negation
Transib	I-Negation
TPases	I-Negation
,	O
only	O
lamprey	B-Negation
and	I-Negation
crocodile	I-Negation
genomes	I-Negation
are	I-Negation
not	I-Negation
extensively	I-Negation
sequenced	I-Negation
to	I-Negation
date	I-Negation
.	O

In	O
sea	O
anemone	O
,	O
the	O
RAG1	O
corelike	O
protein	O
is	O
capped	O
by	O
the	O
ring	O
finger	O
motif	O
,	O
which	O
also	O
forms	O
the	O
C-terminus	O
in	O
the	O
RAG1	O
N-terminal	O
domain	O
.	O

In	O
fungi	O
,	O
the	O
Transib	O
TPase	O
was	O
detected	O
in	O
soybean	O
rust	O
only	O
.	O

Results	O

Detection	O
of	O
Similarity	O
between	O
Transib	O
TPases	O
and	O
RAG1	O

Using	O
protein	O
sequences	O
of	O
seven	O
known	O
Transib	O
TPases	O
(	O
Transib1	O
through	O
Transib4	O
and	O
Transib1_AG	O
through	O
Transib3_AG	O
from	O
D.	O
melanogaster	O
and	O
A.	O
gambiae	O
,	O
respectively	O
)	O
[	O
17	O
]	O
as	O
queries	O
in	O
a	O
standard	O
BLASTP	O
search	O
against	O
all	O
GenBank	O
proteins	O
,	O
we	O
found	O
that	O
the	O
approximately	O
60-aa	O
C-terminal	O
portion	O
of	O
the	O
Transib2_AG	O
TPase	O
was	O
35	O
%	O
-38	O
%	O
identical	O
to	O
the	O
C-terminal	O
portion	O
of	O
the	O
RAG1	O
core	O
(	O
Figure	O
S1	O
)	O
.	O

However	O
,	O
this	O
similarity	O
was	O
only	O
marginally	O
significant	O
(	O
E	O
=	O
0.07	O
where	O
the	O
E-value	O
is	O
an	O
expected	O
number	O
of	O
sequences	O
matching	O
by	O
chance	O
;	O
Table	O
1	O
)	O
.	O

In	O
another	O
search	O
against	O
GenBank	O
,	O
using	O
PSI-BLAST	O
[	O
18	O
]	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
with	O
the	O
Transib2_AG	O
TPase	O
as	O
a	O
query	O
,	O
we	O
found	O
that	O
two	O
unclassified	O
proteins	O
(	O
GenBank	O
gi	O
30923617	O
and	O
30923765	O
;	O
annotated	O
as	O
hypothetical	O
proteins	O
)	O
and	O
RAG1s	O
constituted	O
the	O
only	O
group	O
of	O
any	O
GenBank	O
proteins	O
similar	O
to	O
the	O
Transib2_AG	O
TPase	O
(	O
Table	O
1	O
)	O
.	O

The	O
statistical	O
significance	O
of	O
similarity	O
between	O
the	O
TPase	O
and	O
RAG1s	O
was	O
measured	O
by	O
Ei	O
=	O
0.025	O
,	O
where	O
Ei	O
is	O
the	O
E-value	O
threshold	O
for	O
the	O
first	O
inclusion	O
of	O
RAG1	O
sequences	O
into	O
the	O
PSI-BLAST	O
iterations	O
[	O
18	O
]	O
(	O
Materials	O
and	O
Methods	O
)	O
.	O

The	O
observed	O
improvement	O
in	O
significance	O
of	O
the	O
Transib/RAG1	O
similarity	O
(	O
from	O
E	O
=	O
0.07	O
in	O
BLASTP	O
to	O
Ei	O
=	O
0.025	O
in	O
PSI-BLAST	O
;	O
Table	O
1	O
)	O
was	O
due	O
to	O
the	O
fact	O
that	O
both	O
151-aa	O
and	O
123-aa	O
hypothetical	O
GenBank	O
proteins	O
were	O
apparent	O
remnants	O
of	O
Transib	O
TPases	O
(	O
approximately	O
40	O
%	O
identity	O
to	O
the	O
Transib2_AG	O
TPase	O
,	O
E	O
<	O
10-10	O
in	O
BLASTP	O
)	O
.	O

The	O
RAG1	O
proteins	O
appeared	O
to	O
be	O
more	O
similar	O
to	O
the	O
position-specific	O
scoring	O
matrix	O
(	O
PSSM	O
)	O
created	O
by	O
PSI-BLAST	O
based	O
on	O
multiple	O
alignment	O
of	O
the	O
Transib2_AG	O
TPase	O
and	O
two	O
Transib	O
TPase-like	O
proteins	O
,	O
than	O
to	O
the	O
solo	O
Transib2_AG	O
TPase	O
in	O
the	O
BLASTP	O
search	O
.	O

Given	O
the	O
latter	O
observation	O
,	O
we	O
decided	O
to	O
improve	O
the	O
quality	O
of	O
the	O
PSSM	O
constructed	O
by	O
PSI-BLAST	O
for	O
different	O
Transib	O
TPase	O
sequences	O
.	O

To	O
achieve	O
that	O
,	O
we	O
combined	O
protein	O
sequences	O
of	O
the	O
seven	O
known	O
Transib	O
TPases	O
with	O
the	O
set	O
of	O
all	O
GenBank	O
proteins	O
.	O

As	O
a	O
result	O
,	O
Ei-values	O
for	O
matches	O
of	O
RAG1s	O
to	O
a	O
new	O
PSSM	O
based	O
on	O
alignment	O
of	O
nine	O
Transib	O
TPases	O
(	O
the	O
two	O
GenBank	O
TPase-like	O
proteins	O
plus	O
seven	O
added	O
TPases	O
)	O
noticeably	O
dropped	O
in	O
comparison	O
with	O
the	O
Ei-values	O
obtained	O
for	O
the	O
PSSM	O
constructed	O
in	O
the	O
previous	O
step	O
based	O
on	O
alignment	O
of	O
the	O
three	O
TPases	O
(	O
Table	O
1	O
)	O
.	O

To	O
support	O
the	O
observation	O
that	O
Ei-values	O
of	O
matches	O
between	O
RAG1s	O
and	O
the	O
Transib	O
TPase	O
PSSM	O
decrease	O
as	O
the	O
number	O
of	O
TPase	O
sequences	O
used	O
for	O
construction	O
of	O
the	O
PSSM	O
increases	O
,	O
we	O
identified	O
six	O
new	O
Transib	O
TPases	O
(	O
Transib5	O
,	O
Transib3_DP	O
,	O
Transib4_DP	O
,	O
Transib1_AA	O
,	O
Transib2_AA	O
,	O
Transib3_AA	O
;	O
Figure	O
S2	O
)	O
.	O

During	O
the	O
next	O
step	O
of	O
the	O
PSI-BLAST	O
analysis	O
,	O
the	O
original	O
GenBank	O
set	O
was	O
combined	O
with	O
13	O
Transib	O
TPases	O
.	O

Again	O
,	O
Ei-values	O
of	O
matches	O
between	O
RAG1s	O
and	O
the	O
new	O
PSSM	O
derived	O
from	O
multiple	O
alignment	O
of	O
15	O
Transib	O
TPases	O
(	O
the	O
two	O
GenBank	O
proteins	O
plus	O
all	O
our	O
TPases	O
)	O
were	O
much	O
smaller	O
(	O
approximately	O
10-610-3	O
;	O
Table	O
1	O
)	O
than	O
those	O
obtained	O
based	O
on	O
the	O
PSSM	O
constructed	O
from	O
the	O
nine	O
TPases	O
at	O
the	O
preceding	O
step	O
(	O
approximately	O
10-310-2	O
)	O
.	O

In	O
the	O
final	O
step	O
,	O
we	O
identified	O
one	O
more	O
set	O
of	O
five	O
new	O
Transib	O
TPases	O
(	O
Transib1_DP	O
,	O
Transib2_DP	O
,	O
Transib4_AA	O
,	O
Transib5_AA	O
,	O
and	O
Transib1_SP	O
)	O
.	O

When	O
all	O
18	O
TPases	O
were	O
combined	O
with	O
the	O
original	O
GenBank	O
set	O
,	O
the	O
Ei	O
values	O
of	O
matches	O
between	O
RAG1s	O
and	O
the	O
Transib	O
PSSM	O
dropped	O
significantly	O
further	O
(	O
10-910-4	O
;	O
Table	O
1	O
)	O
.	O

During	O
the	O
final	O
revision	O
of	O
this	O
manuscript	O
,	O
we	O
identified	O
an	O
intermediate	O
RAG1-like	O
sequence	O
in	O
Hydra	O
magnipapillata	O
,	O
called	O
RAG1L_HM	O
,	O
which	O
is	O
significantly	O
similar	O
to	O
both	O
RAG1	O
and	O
Transib	O
TPase	O
,	O
as	O
shown	O
later	O
.	O

This	O
direct	O
result	O
represents	O
an	O
independent	O
validation	O
of	O
our	O
analysis	O
.	O

The	O
PSI-BLAST	O
PSSM	O
of	O
Transib	O
TPases	O
approximates	O
conservation/variability	O
of	O
the	O
Transib	O
TPase	O
consensus	O
sequence	O
.	O

The	O
more	O
diverse	O
the	O
TPases	O
used	O
in	O
determining	O
the	O
PSSM	O
,	O
the	O
more	O
accurate	O
is	O
the	O
approximation	O
;	O
some	O
of	O
the	O
insect	O
Transib	O
TPases	O
are	O
less	O
than	O
30	O
%	O
identical	O
to	O
each	O
other	O
,	O
as	O
shown	O
in	O
Figure	O
2	O
.	O

The	O
RAG1	O
Ei	O
values	O
decreased	O
as	O
the	O
number	O
of	O
Transib	O
TPases	O
used	O
for	O
the	O
PSSM	O
construction	O
increased	O
due	O
to	O
the	O
fact	O
that	O
RAG1	O
evolved	O
from	O
a	O
Transib	O
TPase	O
.	O

In	O
all	O
cases	O
,	O
the	O
E	O
values	O
obtained	O
after	O
several	O
rounds	O
of	O
iterations	O
were	O
less	O
than	O
10-20	O
at	O
the	O
point	O
of	O
convergence	O
.	O

Nearly	O
the	O
entire	O
sequences	O
of	O
several	O
Transib	O
TPases	O
,	O
excluding	O
their	O
100140-aa	O
N-terminal	O
domains	O
,	O
converged	O
with	O
an	O
approximately	O
600-aa	O
portion	O
of	O
RAG1	O
defined	O
by	O
positions	O
approximately	O
3601010	O
(	O
Figure	O
S3	O
)	O
.	O

This	O
portion	O
of	O
RAG1	O
corresponds	O
to	O
the	O
	O
RAG1	O
core	O
,	O
	O
hereafter	O
numbered	O
relative	O
to	O
human	O
RAG1	O
(	O
residues	O
3871011	O
)	O
,	O
which	O
along	O
with	O
RAG2	O
is	O
known	O
to	O
be	O
sufficient	O
to	O
perform	O
V	O
(	O
D	O
)	O
J	O
cleavage	O
even	O
after	O
deletions	O
of	O
the	O
383-aa	O
N-terminal	O
and	O
32-aa	O
C-terminal	O
portions	O
of	O
RAG1	O
[	O
19,20	O
]	O
.	O

During	O
studies	O
reported	O
here	O
,	O
we	O
identified	O
11	O
additional	O
new	O
families	O
of	O
Transib	O
transposons	O
and	O
TPases	O
(	O
see	O
Figure	O
S2	O
)	O
that	O
are	O
well	O
preserved	O
in	O
the	O
genomes	O
of	O
fruit	O
flies	O
(	O
Transib5	O
in	O
D.	O
melanogaster	O
;	O
and	O
Transib1_DP	O
,	O
Transib2_DP	O
,	O
Transib3_DP	O
,	O
and	O
Transib4_DP	O
in	O
D.	O
pseudoobscura	O
)	O
,	O
mosquitoes	O
(	O
Transib1_AA	O
,	O
Transib2_AA	O
,	O
Transib3_AA	O
,	O
Transib4_AA	O
,	O
and	O
Transib5_AA	O
from	O
A.	O
aegypti	O
)	O
and	O
sea	O
urchin	O
(	O
Transib1_SP	O
)	O
.	O

Transib1_SP	O
is	O
the	O
first	O
Transib	O
transposon	O
identified	O
outside	O
of	O
insect	O
genomes	O
.	O

A	O
well-preserved	O
4132-bp	O
Transib1_SP	O
element	O
(	O
contig	O
7839	O
,	O
positions	O
3764506	O
)	O
is	O
flanked	O
by	O
a	O
5-bp	O
CGGCG	O
TSD	O
,	O
and	O
it	O
encodes	O
a	O
676-aa	O
TPase	O
(	O
two	O
exons	O
)	O
that	O
is	O
most	O
similar	O
to	O
the	O
Transib2	O
TPase	O
(	O
34	O
%	O
identity	O
)	O
.	O

Based	O
on	O
the	O
currently	O
available	O
sequence	O
data	O
,	O
we	O
also	O
reconstructed	O
portions	O
of	O
TPases	O
that	O
were	O
missed	O
in	O
previous	O
studies	O
[	O
17	O
]	O
(	O
Materials	O
and	O
Methods	O
;	O
see	O
Figure	O
S2	O
)	O
.	O

Using	O
the	O
Transib1_SP	O
TPase	O
as	O
a	O
query	O
in	O
TBLASTN	O
searches	O
against	O
all	O
GenBank	O
sections	O
(	O
NR	O
,	O
HTGs	O
,	O
WGS	O
,	O
dbGSS	O
,	O
dbEST	O
,	O
dbSTS	O
,	O
and	O
Trace	O
Archives	O
)	O
we	O
also	O
found	O
diverse	O
Transib	O
TPases	O
in	O
silkworm	O
,	O
red	O
flour	O
beetle	O
,	O
dog	O
hookworm	O
,	O
freshwater	O
flatworm	O
,	O
soybean	O
rust	O
,	O
and	O
hydra	O
(	O
Table	O
S1	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
recently	O
sequenced	O
genomes	O
of	O
honeybee	O
,	O
roundworms	O
,	O
fish	O
,	O
frog	O
,	O
mammals	O
,	O
sea	O
squirts	O
,	O
plants	O
,	O
and	O
fungi	O
(	O
except	O
soybean	O
rust	O
)	O
do	O
not	B-Negation
contain	I-Negation
any	I-Negation
detectable	I-Negation
Transib	I-Negation
transposons	I-Negation
(	O
see	O
Figure	O
1	O
)	O
.	O

The	O
observed	O
patchy	O
distribution	O
could	O
be	O
caused	O
by	O
horizontal	O
transfers	O
and	O
extinctions	O
of	O
Transib	O
transposons	O
in	O
eukaryotic	O
species	O
.	O

Significance	O
of	O
Similarities	O
between	O
the	O
Transib	O
TPases	O
and	O
RAG1	O
Core	O

The	O
first	O
column	O
lists	O
all	O
18	O
Transib	O
TPases	O
used	O
as	O
queries	O
in	O
our	O
analysis	O
,	O
and	O
the	O
shaded	O
areas	O
indicate	O
those	O
added	O
to	O
the	O
original	O
set	O
of	O
all	O
GenBank	O
proteins	O
in	O
subsequent	O
PSI-BLAST	O
searches	O
.	O

The	O
original	O
GenBank	O
set	O
included	O
two	O
incomplete	O
Transib	O
TPase-like	O
proteins	O
.	O

Column	O
2	O
lists	O
E-values	O
of	O
best	O
matches	O
between	O
RAG1s	O
and	O
Transib	O
TPases	O
detected	O
in	O
BLASTP	O
searches	O
against	O
the	O
original	O
GenBank	O
set	O
.	O

Column	O
3	O
reports	O
Ei-values	O
of	O
best	O
matches	O
between	O
RAG1s	O
and	O
a	O
PSSM	O
derived	O
from	O
the	O
chosen	O
query	O
sequence	O
and	O
the	O
two	O
GenBank	O
TPase-like	O
proteins	O
in	O
PSI-BLAST	O
searches	O
against	O
the	O
original	O
set	O
of	O
all	O
GenBank	O
proteins	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Columns	O
46	O
report	O
the	O
Ei-values	O
for	O
best	O
matches	O
between	O
RAG1s	O
and	O
a	O
Transib-derived	O
PSSM	O
after	O
adding	O
7	O
,	O
13	O
,	O
and	O
18	O
Transib	O
TPases	O
to	O
the	O
GenBank	O
set	O
,	O
respectively	O
.	O

The	O
numbers	O
of	O
the	O
PSI-BLAST	O
iterations	O
after	O
which	O
the	O
entire	O
RAG1	O
core	O
significantly	O
aligned	O
with	O
the	O
TPases	O
are	O
indicated	O
in	O
parentheses	O
.	O

Ei-values	O
greater	O
than	O
1	O
are	O
indicated	O
by	O
dashes	O
.	O

Each	O
empty	O
cell	O
indicates	O
that	O
the	B-Negation
corresponding	I-Negation
TPase	I-Negation
query	I-Negation
was	I-Negation
not	I-Negation
used	I-Negation
at	I-Negation
the	I-Negation
particular	I-Negation
stage	I-Negation
of	I-Negation
PSI-BLAST	I-Negation
analysis	I-Negation
.	O

Diversity	O
of	O
the	O
Transib	O
TPases	O
and	O
RAG1	O
CoreLike	O
Proteins	O
in	O
Animals	O

The	O
phylogenetic	O
tree	O
was	O
obtained	O
by	O
using	O
the	O
neighbor-joining	O
algorithm	O
implemented	O
in	O
MEGA	O
[	O
44	O
]	O
.	O

Evolutionary	O
distance	O
for	O
each	O
pair	O
of	O
protein	O
sequences	O
was	O
measured	O
as	O
the	O
proportion	O
of	O
aa	O
sites	O
at	O
which	O
the	O
two	O
sequences	O
were	O
different	O
.	O

Its	O
scale	O
is	O
shown	O
by	O
the	O
horizontal	O
bar	O
.	O

Bootstrap	O
values	O
higher	O
than	O
60	O
%	O
are	O
reported	O
at	O
the	O
corresponding	O
nodes	O
.	O

Species	O
abbreviations	O
are	O
as	O
follows	O
:	O
AA	O
,	O
yellow	O
fever	O
mosquito	O
;	O
AG	O
,	O
African	O
malaria	O
mosquito	O
;	O
BF	O
,	O
lancelet	O
;	O
CL	O
,	O
bull	O
shark	O
;	O
DP	O
,	O
D.	O
pseudoobscura	O
fruit	O
fly	O
;	O
FR	O
,	O
fugu	O
fish	O
;	O
HM	O
,	O
hydra	O
;	O
HS	O
,	O
human	O
;	O
NV	O
,	O
starlet	O
sea	O
anemone	O
;	O
SP	O
,	O
sea	O
urchin	O
;	O
XL	O
,	O
frog	O
.	O

(	O
Transib1	O
through	O
Transib5	O
are	O
from	O
D.	O
melanogaster	O
fruit	O
fly	O
.	O
)	O

Common	O
Structural	O
Hallmarks	O
of	O
the	O
Transib	O
TPase	O
and	O
RAG1	O
Core	O

All	O
three	O
core	O
residues	O
from	O
the	O
catalytic	O
DDE	O
triad	O
in	O
the	O
RAG1	O
proteins	O
(	O
residues	O
603	O
,	O
711	O
,	O
and	O
965	O
)	O
that	O
are	O
necessary	O
for	O
V	O
(	O
D	O
)	O
J	O
recombination	O
[	O
21,22	O
]	O
are	O
conserved	O
in	O
the	O
Transib	O
TPases	O
(	O
Figures	O
3	O
and	O
Figure	O
S3	O
)	O
.	O

This	O
includes	O
the	O
distances	O
between	O
the	O
second	O
D	O
and	O
E	O
residues	O
,	O
which	O
are	O
much	O
longer	O
in	O
Transib	O
transposons	O
(	O
206214	O
aa	O
)	O
and	O
RAG1	O
(	O
253	O
aa	O
)	O
than	O
in	O
DDE	O
TPases	O
from	O
other	O
studied	O
superfamilies	O
(	O
e.g.	O
,	O
approximately	O
35-aa	O
in	O
Mariner/Tc1	O
[	O
23	O
]	O
,	O
2-aa	O
in	O
P	O
[	O
23	O
]	O
,	O
approximately	O
35-aa	O
in	O
Harbinger	O
[	O
24	O
]	O
,	O
with	O
hAT	O
as	O
an	O
exception	O
(	O
325-aa	O
,	O
[	O
25	O
]	O
)	O
.	O

Moreover	O
,	O
each	O
catalytic	O
residue	O
is	O
a	O
part	O
of	O
a	O
motif	O
that	O
is	O
conserved	O
in	O
the	O
Transib	O
TPases	O
and	O
RAG1	O
(	O
motifs	O
4	O
,	O
6	O
,	O
and	O
10	O
in	O
Figures	O
3	O
and	O
Figure	O
S3	O
)	O
.	O

The	O
RAG1	O
core	O
is	O
composed	O
of	O
the	O
N-terminal	O
region	O
and	O
the	O
central	O
and	O
C-terminal	O
domains	O
(	O
[	O
26,27	O
]	O
.	O

The	O
N-terminal	O
region	O
includes	O
the	O
RSS	O
nonamer-binding	O
regions	O
(	O
residues	O
387480	O
)	O
,	O
referred	O
to	O
as	O
NBR	O
[	O
28,29	O
]	O
.	O

The	O
two	O
terminal	O
motifs	O
of	O
RAG1	O
NBR	O
are	O
conserved	O
in	O
the	O
Transib	O
TPases	O
(	O
Figure	O
S3	O
)	O
,	O
which	O
indicates	O
that	O
they	O
may	O
be	O
important	O
for	O
their	O
binding	O
to	O
the	O
Transib	O
TIRs	O
during	O
transposition	O
(	O
the	O
RSS-like	O
structure	O
of	O
TIRs	O
is	O
described	O
below	O
;	O
Figure	O
4	O
)	O
.	O

The	O
central	O
domain	O
of	O
the	O
RAG1	O
core	O
(	O
residues	O
531763	O
)	O
includes	O
two	O
aspartic	O
acid	O
residues	O
from	O
the	O
DDE	O
triad	O
and	O
is	O
also	O
thought	O
to	O
be	O
involved	O
in	O
binding	O
to	O
the	O
RSS	O
heptamer	O
and	O
RAG2	O
[	O
30,31	O
]	O
.	O

The	O
C-terminal	O
domain	O
of	O
RAG1	O
(	O
residues	O
7641011	O
)	O
is	O
the	O
portion	O
of	O
RAG1	O
that	O
is	O
most	O
conserved	O
between	O
RAG1	O
and	O
Transib	O
TPases	O
.	O

In	O
addition	O
to	O
the	O
catalytic	O
activity	O
attributed	O
to	O
the	O
last	O
residue	O
of	O
the	O
DDE	O
triad	O
,	O
this	O
domain	O
has	O
a	O
strong	O
nonspecific	O
DNA-binding	O
affinity	O
because	O
it	O
binds	O
to	O
coding	O
DNA	O
upstream	O
of	O
the	O
RSS	O
heptamer	O
,	O
and	O
is	O
thought	O
to	O
be	O
involved	O
in	O
RAG1	O
dimerization	O
[	O
26,27	O
]	O
.	O

This	O
domain	O
is	O
predicted	O
to	O
function	O
analogously	O
in	O
Transib	O
transposons	O
.	O

Several	O
other	O
motifs	O
conserved	O
in	O
Transib	O
TPases	O
and	O
RAG1	O
include	O
aa	O
residues	O
that	O
have	O
been	O
shown	O
experimentally	O
to	O
be	O
important	O
for	O
specific	O
functions	O
in	O
V	O
(	O
D	O
)	O
J	O
recombination	O
(	O
Figure	O
S3	O
)	O
.	O

Based	O
on	O
this	O
information	O
,	O
the	O
function	O
of	O
these	O
motifs	O
in	O
Transib	O
TPases	O
is	O
expected	O
to	O
be	O
similar	O
to	O
that	O
in	O
RAG1	O
.	O

Among	O
the	O
most	O
conserved	O
motifs	O
,	O
motif	O
5	O
(	O
see	O
Figures	O
3	O
and	O
Figure	O
S3	O
)	O
is	O
of	O
particular	O
interest	O
because	O
its	O
function	O
is	O
not	O
known	O
yet	O
but	O
is	O
expected	O
to	O
play	O
a	O
role	O
both	O
V	O
(	O
D	O
)	O
J	O
recombination	O
and	O
Transib	O
transposition	O
.	O

In	O
conjunction	O
with	O
detailed	O
studies	O
of	O
the	O
Transib	O
superfamily	O
,	O
we	O
also	O
analyzed	O
the	O
remaining	O
nine	O
known	O
superfamilies	O
of	O
DNA	O
transposons	O
defined	O
by	O
diverse	O
TPases	O
(	O
see	O
Table	O
1	O
in	O
[	O
24	O
]	O
)	O
.	O

Some	O
of	O
these	O
TPases	O
,	O
including	O
Mariner	O
,	O
Harbinger	O
,	O
P	O
,	O
and	O
hAT	O
,	O
also	O
contain	O
the	O
catalytic	O
DDE	O
triad	O
[	O
23	O
]	O
.	O

However	O
,	O
based	O
on	O
PSI-BLAST	O
searches	O
,	O
no	B-Negation
significant	I-Negation
similarities	I-Negation
between	I-Negation
these	I-Negation
nine	I-Negation
TPases	I-Negation
and	I-Negation
RAG1	I-Negation
protein	I-Negation
were	I-Negation
found	I-Negation
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

Therefore	O
,	O
given	O
that	O
the	O
only	O
significant	O
similarity	O
of	O
the	O
RAG1	O
core	O
was	O
to	O
the	O
Transib	O
TPase	O
,	O
the	O
RAG1	O
core	O
was	O
re-confirmed	O
as	O
belonging	O
to	O
the	O
Transib	O
superfamily	O
.	O

In	O
addition	O
to	O
the	O
statistically	O
significant	O
similarity	O
between	O
the	O
approximately	O
600-aa	O
RAG1	O
core	O
and	O
Transib	O
TPases	O
,	O
there	O
are	O
two	O
other	O
lines	O
of	O
evidence	O
suggesting	O
evolution	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
machinery	O
from	O
Transib	O
DNA	O
transposons	O
.	O

They	O
include	O
the	O
characteristic	O
TSDs	O
and	O
structure	O
of	O
the	O
TIRs	O
discussed	O
in	O
the	O
next	O
two	O
sections	O
.	O

Multiple	O
Alignment	O
of	O
Ten	O
Conserved	O
Motifs	O
in	O
the	O
RAG1	O
Core	O
Proteins	O
and	O
Transib	O
TPases	O

The	O
motifs	O
are	O
underlined	O
and	O
numbered	O
from	O
1	O
to	O
10	O
.	O

Starting	O
positions	O
of	O
the	O
motifs	O
immediately	O
follow	O
the	O
corresponding	O
protein	O
names	O
.	O

Distances	O
between	O
the	O
motifs	O
are	O
indicated	O
in	O
numbers	O
of	O
aa	O
residues	O
.	O

Black	O
circles	O
denote	O
conserved	O
residues	O
that	O
form	O
the	O
RAG1/Transib	O
catalytic	O
DDE	O
triad	O
.	O

The	O
RAG1	O
proteins	O
are	O
as	O
follows	O
:	O
RAG1_XL	O
(	O
GenBank	O
GI	O
no.	O
2501723	O
,	O
Xenopus	O
laevis	O
,	O
frog	O
)	O
,	O
RAG1_HS	O
(	O
4557841	O
,	O
Homo	O
sapiens	O
,	O
human	O
)	O
,	O
RAG1_GG	O
(	O
131826	O
,	O
Gallus	O
gallus	O
,	O
chicken	O
)	O
,	O
RAG1_CL	O
(	O
1470117	O
,	O
Carcharhinus	O
leucas	O
,	O
bull	O
shark	O
)	O
,	O
RAG1_FR	O
(	O
4426834	O
,	O
Fugu	O
rubripes	O
,	O
fugu	O
fish	O
)	O
.	O

Coloring	O
scheme	O
[	O
43	O
]	O
reflects	O
physiochemical	O
properties	O
of	O
amino	O
acids	O
:	O
black	O
shading	O
marks	O
hydrophobic	O
residues	O
,	O
blue	O
indicates	O
charged	O
(	O
white	O
font	O
)	O
,	O
positively	O
charged	O
(	O
red	O
font	O
)	O
,	O
and	O
negatively	O
charged	O
(	O
green	O
font	O
)	O
;	O
red	O
indicates	O
proline	O
(	O
blue	O
font	O
)	O
and	O
glycine	O
(	O
green	O
font	O
)	O
;	O
gray	O
indicates	O
aliphatic	O
(	O
red	O
font	O
)	O
and	O
aromatic	O
(	O
blue	O
font	O
)	O
;	O
green	O
indicates	O
polar	O
(	O
black	O
font	O
)	O
and	O
amphoteric	O
(	O
red	O
font	O
)	O
;	O
and	O
yellow	O
indicates	O
tiny	O
(	O
blue	O
font	O
)	O
and	O
small	O
(	O
green	O
font	O
)	O
.	O

The	O
species	O
abbreviations	O
for	O
the	O
Transib	O
transposons	O
are	O
as	O
follows	O
:	O
AA	O
,	O
yellow	O
fever	O
mosquito	O
;	O
AG	O
,	O
African	O
malaria	O
mosquito	O
;	O
DP	O
,	O
D.	O
pseudoobscura	O
fruit	O
fly	O
.	O

(	O
Transib1	O
through	O
Transib5	O
are	O
from	O
the	O
fruitfly	O
D.	O
melanogaster	O
.	O
)	O

Structural	O
Similarities	O
between	O
the	O
Transib	O
TIRs	O
and	O
V	O
(	O
D	O
)	O
J	O
RSS	O
Signals	O

The	O
species	O
abbreviations	O
are	O
:	O
AA	O
,	O
yellow	O
fever	O
mosquito	O
;	O
AG	O
,	O
African	O
malaria	O
mosquito	O
;	O
DM	O
,	O
D.	O
melanogaster	O
fruit	O
fly	O
DP	O
,	O
D.	O
pseudoobscura	O
fruit	O
fly	O
;	O
SP	O
,	O
sea	O
urchin	O
.	O

(	O
Transib1	O
through	O
Transib5	O
are	O
from	O
the	O
fruit	O
fly	O
D.	O
melanogaster	O
.	O
)	O

(	O
A	O
)	O
Frequencies	O
of	O
the	O
most	O
frequent	O
nucleotides	O
at	O
each	O
position	O
of	O
the	O
consensus	O
sequence	O
of	O
the	O
5	O
?	O
TIRs	O
of	O
transposons	O
that	O
belong	O
to	O
20	O
families	O
of	O
Transib	O
transposons	O
identified	O
in	O
fruit	O
flies	O
and	O
mosquitoes	O
.	O

The	O
RSS23	O
consensus	O
sequence	O
is	O
shown	O
immediately	O
under	O
the	O
TIRs	O
consensus	O
sequence	O
.	O

The	O
most	O
conserved	O
nucleotides	O
in	O
the	O
RSS23	O
heptamer	O
and	O
nonamer	O
,	O
which	O
are	O
necessary	O
for	O
efficient	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
are	O
highlighted	O
.	O

The	O
23	O
	O
1	O
bp	O
variable	O
spacer	O
is	O
marked	O
by	O
Ns	O
.	O

(	O
B	O
)	O
Non-gapped	O
alignment	O
of	O
consensus	O
sequences	O
of	O
5	O
?	O
TIRs	O
from	O
21	O
families	O
of	O
Transib	O
transposons	O
.	O

(	O
C	O
)	O
The	O
12/23	O
rule	O
follows	O
from	O
the	O
basic	O
structure	O
of	O
TIRs	O
of	O
the	O
consensus	O
sequences	O
of	O
transposons	O
that	O
belong	O
to	O
the	O
Transib5	O
,	O
Transib2_AG	O
,	O
TransibN1_AG	O
,	O
TransibN2_AG	O
,	O
and	O
TransibN3_AG	O
families	O
.	O

The	O
5	O
?	O
TIRs	O
of	O
these	O
transposons	O
are	O
aligned	O
with	O
the	O
corresponding	O
3	O
?	O
TIRs	O
.	O

Structures	O
of	O
the	O
5	O
?	O
and	O
3	O
?	O
TIRs	O
resemble	O
RSS12	O
and	O
RSS23	O
,	O
respectively	O
.	O

Similar	O
Length	O
of	O
TSDs	O
and	O
Target	O
Site	O
Composition	O
in	O
Transib	O
and	O
RAG1/2-Mediated	O
Transpositions	O

It	O
has	O
been	O
known	O
that	O
RAG1-mediated	O
transposition	O
in	O
vitro	O
,	O
both	O
intermolecular	O
and	O
intramolecular	O
,	O
is	O
most	O
frequently	O
accompanied	O
by	O
5-bp	O
TSDs	O
[	O
12,13	O
]	O
.	O

In	O
one	O
study	O
[	O
12	O
]	O
,	O
35	O
of	O
38	O
(	O
92	O
%	O
)	O
TSDs	O
generated	O
during	O
RAG-mediated	O
intermolecular	O
transposition	O
were	O
5	O
bp	O
long	O
,	O
and	O
the	O
remaining	O
8	O
%	O
were	O
either	O
4	O
or	O
3	O
bp	O
long	O
.	O

Also	O
,	O
69	O
%	O
of	O
36	O
TSDs	O
recovered	O
during	O
RAG-mediated	O
intramolecular	O
transpositions	O
were	O
5	O
bp	O
in	O
length	O
;	O
of	O
the	O
remaining	O
ones	O
,	O
28	O
%	O
were	O
4	O
bp	O
and	O
3	O
%	O
were	O
3	O
bp	O
long	O
.	O

In	O
another	O
study	O
[	O
13	O
]	O
,	O
six	O
of	O
six	O
TSDs	O
detected	O
in	O
the	O
intermolecular	O
transposition	O
were	O
5	O
bp	O
long	O
.	O

Intramolecular	O
transposition	O
mediated	O
by	O
murine	O
RAG1/2	O
proteins	O
was	O
also	O
studied	O
recently	O
in	O
vivo	O
in	O
yeast	O
[	O
14	O
]	O
.	O

Again	O
,	O
60	O
%	O
of	O
TSDs	O
recovered	O
in	O
26	O
events	O
were	O
5	O
bp	O
long	O
[	O
14	O
]	O
.	O

Given	O
the	O
predominance	O
of	O
5-bp	O
TSDs	O
,	O
it	O
is	O
striking	O
that	O
Transib	O
transposons	O
belong	O
to	O
the	O
only	O
superfamily	O
of	O
eukaryotic	O
DNA	O
transposons	O
with	O
5-bp	O
TSDs	O
generated	O
upon	O
insertions	O
into	O
the	O
genome	O
[	O
17,24	O
]	O
.	O

To	O
illustrate	O
the	O
characteristic	O
5-bp	O
TSDs	O
,	O
we	O
show	O
copies	O
of	O
Transib	O
transposons	O
with	O
intact	O
5	O
?	O
and	O
3	O
?	O
TIRs	O
from	O
diverse	O
families	O
of	O
Transib	O
transposons	O
present	O
in	O
the	O
D.	O
melanogaster	O
,	O
D.	O
pseudoobscura	O
,	O
A.	O
gambiae	O
,	O
and	O
S.	O
purpuratus	O
genomes	O
(	O
Figure	O
S4	O
)	O
.	O

Moreover	O
,	O
some	O
families	O
show	O
high	O
target	O
site	O
specificity	O
,	O
e.g.	O
,	O
Transib-N1_AG	O
and	O
Transib-N2_AG	O
integrate	O
preferentially	O
at	O
cCASTGg	O
and	O
cCAWTGc	O
,	O
respectively	O
(	O
TSDs	O
are	O
capitalized	O
)	O
.	O

RAG1/2-mediated	O
transpositions	O
also	O
show	O
significant	O
target	O
specificity	O
,	O
presumably	O
reflecting	O
the	O
original	O
specificity	O
of	O
the	O
Transib	O
TPase	O
[	O
12	O
]	O
.	O

Indigenous	O
properties	O
of	O
the	O
Transib	O
TPase	O
,	O
that	O
were	O
not	O
related	O
directly	O
to	O
RAG1	O
functions	O
,	O
including	O
those	O
responsible	O
for	O
the	O
precise	O
5-bp	O
length	O
of	O
TSDs	O
,	O
might	O
have	O
been	O
altered	O
during	O
evolution	O
of	O
RAG1	O
,	O
leading	O
to	O
occasional	O
4-bp	O
and	O
3-bp	O
TSDs	O
that	O
are	O
atypical	O
for	O
Transib	O
transposons	O
.	O

Both	O
RAG1/2-mediated	O
and	O
Transib	O
transpositions	O
show	O
strong	O
preference	O
for	O
GC-rich	O
target	O
sites	O
[	O
1214,32	O
]	O
,	O
even	O
though	O
genomes	O
hosting	O
Transib	O
transposons	O
are	O
AT-rich	O
(	O
Figure	O
S4	O
;	O
Table	O
2	O
)	O
.	O

Structure	O
of	O
Transib	O
TIRs	O

The	O
structure	O
and	O
conservation	O
patterns	O
of	O
the	O
38-bp	O
termini	O
of	O
Transib	O
transposons	O
from	O
21	O
different	O
families	O
closely	O
resemble	O
those	O
of	O
RSSs	O
,	O
suggesting	O
that	O
the	O
latter	O
were	O
derived	O
from	O
termini	O
of	O
ancient	O
Transib	O
transposons	O
(	O
Figures	O
4	O
and	O
S4	O
)	O
.	O

The	O
38-bp	O
consensus	O
TIR	O
of	O
Transib	O
transposons	O
consists	O
of	O
a	O
conserved	O
5	O
?	O
-	O
CACAATG	O
heptamer	O
separated	O
by	O
a	O
variable	O
23-bp	O
spacer	O
from	O
an	O
AAAAAAATC-3	O
?	O
nonamer	O
.	O

This	O
corresponds	O
closely	O
to	O
the	O
structure	O
of	O
RSSs	O
,	O
which	O
are	O
composed	O
of	O
the	O
conserved	O
heptamers	O
5	O
?	O
-	O
CACAGTG	O
separated	O
by	O
a	O
variable	O
22-bp	O
spacers	O
from	O
ACAAAAACC-like	O
nonamers	O
[	O
1,57	O
]	O
.	O

Only	O
bases	O
at	O
positions	O
1	O
through	O
3	O
in	O
the	O
heptamer	O
and	O
at	O
positions	O
5	O
and	O
6	O
in	O
the	O
nonamer	O
are	O
universally	O
conserved	O
in	O
RSSs	O
and	O
absolutely	O
essential	O
for	O
efficient	O
V	O
(	O
D	O
)	O
J	O
recombination	O
[	O
57	O
]	O
.	O

The	O
corresponding	O
positions	O
are	O
perfectly	O
conserved	O
in	O
all	O
Transib	O
transposons	O
(	O
Figure	O
4A	O
and	O
4B	O
;	O
excluding	O
the	O
85	O
%	O
conserved	O
position	O
34	O
in	O
the	O
Transib	O
consensus	O
that	O
corresponds	O
to	O
position	O
5	O
in	O
the	O
RSS	O
nonamer	O
)	O
.	O

The	O
probability	O
of	O
the	O
observed	O
match	O
between	O
the	O
RSS	O
and	O
Transib	O
termini	O
to	O
occur	O
by	O
chance	O
is	O
less	O
than	O
10-3	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
.	O

Although	O
most	O
Transib	O
families	O
are	O
represented	O
by	O
transposons	O
flanked	O
by	O
TIRs	O
similar	O
to	O
RSS23	O
(	O
Figure	O
4A	O
)	O
,	O
several	O
families	O
include	O
transposons	O
with	O
5	O
?	O
and	O
3	O
?	O
termini	O
similar	O
to	O
RSS12	O
and	O
RSS23	O
,	O
respectively	O
(	O
Figure	O
4C	O
)	O
.	O

Therefore	O
,	O
even	O
the	O
12/23	O
rule	O
[	O
1	O
]	O
can	O
be	O
derived	O
directly	O
from	O
the	O
sequence	O
structure	O
of	O
known	O
Transib	O
transposons	O
.	O

RAG1	O
CoreLike	O
Sequences	O
in	O
the	O
Sea	O
Urchin	O
,	O
Lancelet	O
,	O
Starlet	O
Sea	O
Anemone	O
,	O
and	O
Hydra	O
Genomes	O

Using	O
RAG1	O
proteins	O
as	O
query	O
sequences	O
in	O
a	O
WU	O
BLAST	O
search	O
against	O
sea	O
urchin	O
contigs	O
sequenced	O
at	O
Baylor	O
College	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
we	O
identified	O
eight	O
proteins	O
approximately	O
30	O
%	O
identical	O
to	O
portions	O
of	O
the	O
RAG1	O
core	O
and	O
approximately	O
50	O
%	O
identical	O
to	O
each	O
other	O
(	O
see	O
Figures	O
2	O
,	O
5	O
,	O
and	O
S5	O
)	O
.	O

Only	O
one	O
protein	O
is	O
present	O
in	O
two	O
copies	O
,	O
which	O
are	O
94	O
%	O
identical	O
to	O
each	O
other	O
at	O
the	O
DNA	O
level	O
(	O
contigs	O
81987	O
and	O
6797	O
)	O
.	O

Both	O
copies	O
appear	O
to	O
be	O
encoded	O
by	O
pseudogenes	O
damaged	O
by	O
a	O
stop	O
codon	O
at	O
the	O
same	O
position	O
of	O
each	O
protein	O
.	O

Interestingly	O
,	O
the	O
6,690-bp	O
contig	O
6797	O
harbours	O
two	O
additional	O
defective	O
pseudogenes	O
coding	O
for	O
different	O
RAG1	O
corelike	O
proteins	O
(	O
Figure	O
5	O
)	O
.	O

We	O
also	O
identified	O
a	O
597-aa	O
protein	O
sequence	O
encoded	O
by	O
a	O
single	O
open	O
reading	O
frame	O
(	O
contig	O
29068	O
,	O
positions	O
11572944	O
)	O
,	O
which	O
is	O
28	O
%	O
identical	O
to	O
nearly	O
the	O
entire	O
RAG1	O
core	O
(	O
positions	O
4611002	O
in	O
the	O
human	O
RAG1	O
,	O
Figure	O
S5	O
)	O
.	O

Extensive	O
analysis	O
of	O
the	O
flanks	O
failed	B-Negation
to	I-Negation
show	I-Negation
any	I-Negation
hallmarks	I-Negation
of	I-Negation
putative	I-Negation
transposons	I-Negation
that	I-Negation
might	I-Negation
be	I-Negation
associated	I-Negation
with	I-Negation
this	I-Negation
RAG1-like	I-Negation
protein	I-Negation
,	O
and	O
we	O
did	O
not	B-Negation
find	I-Negation
any	I-Negation
evidence	I-Negation
indicating	I-Negation
that	I-Negation
other	I-Negation
RAG1	I-Negation
corelike	I-Negation
proteins	I-Negation
are	I-Negation
encoded	I-Negation
by	I-Negation
transposable	I-Negation
elements	I-Negation
(	O
Figure	O
5	O
)	O
.	O

Using	O
FGENESH	O
[	O
33	O
]	O
,	O
we	O
detected	O
that	O
the	O
RAG1	O
corelike	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
in	O
the	O
contig	O
29068	O
forms	O
a	O
terminal	O
exon	O
(	O
positions	O
11542947	O
)	O
of	O
an	O
incomplete	O
hypothetical	O
gene	O
composed	O
of	O
two	O
exons	O
(	O
internal	O
and	O
terminal	O
;	O
see	O
Figure	O
S6	O
)	O
.	O

The	O
3	O
?	O
terminal	O
portion	O
of	O
the	O
internal	O
exon	O
encodes	O
a	O
protein	O
sequence	O
that	O
appears	O
to	O
be	O
marginally	O
similar	O
to	O
an	O
approximately	O
50-aa	O
fragment	O
of	O
the	O
RAG1	O
core	O
(	O
positions	O
394454	O
in	O
human	O
RAG1	O
;	O
Figure	O
S5	O
)	O
.	O

The	O
RAG1	O
corelike	O
protein	O
in	O
whole	O
genome	O
shotgun	O
(	O
WGS	O
)	O
contig	O
12509	O
(	O
Figure	O
5	O
)	O
also	O
seems	O
to	O
be	O
encoded	O
by	O
the	O
last	O
exon	O
starting	O
at	O
position	O
1650	O
of	O
a	O
hypothetical	O
RAG1-like	O
gene	O
.	O

Although	O
the	O
two	O
proteins	O
are	O
only	O
38	O
%	O
identical	O
to	O
each	O
other	O
,	O
they	O
share	O
common	O
features	O
:	O
(	O
1	O
)	O
their	B-Negation
N-terminal	I-Negation
portions	I-Negation
are	I-Negation
missing	I-Negation
and	O
the	O
RAG1-like	O
sequences	O
start	O
at	O
positions	O
17	O
or	O
18	O
;	O
(	O
2	O
)	O
in	O
both	O
proteins	O
the	O
first	O
aa	O
residue	O
overlaps	O
with	O
the	O
acceptor	O
splice	O
site	O
;	O
and	O
(	O
3	O
)	O
their	O
similarity	O
to	O
RAG1	O
starts	O
at	O
positions	O
corresponding	O
to	O
position	O
470	O
of	O
the	O
human	O
RAG1	O
.	O

Remarkably	O
,	O
the	O
acceptor	O
splice	O
site	O
positions	O
in	O
the	O
sea	O
urchin	O
RAG1	O
corelike	O
proteins	O
closely	O
correspond	O
to	O
those	O
in	O
RAG1	O
from	O
teleosts	O
(	O
i.e.	O
,	O
most	O
of	O
the	O
living	O
ray-finned	O
or	O
bony	O
fish	O
)	O
,	O
in	O
which	O
RAG1	O
is	O
split	O
by	O
an	O
intron	O
at	O
position	O
homologous	O
to	O
Gly460	O
in	O
human	O
RAG1	O
[	O
34	O
]	O
.	O

Using	O
the	O
same	O
RAG1	O
query	O
sequences	O
in	O
a	O
TBLASTN	O
search	O
against	O
WGS	O
trace	O
sequences	O
from	O
the	O
lancelet	O
(	O
Branchiostoma	O
floridae	O
)	O
genome	O
recently	O
sequenced	O
at	O
the	O
Joint	O
Genome	O
Institute	O
(	O
see	O
Materials	O
and	O
Methods	O
)	O
,	O
we	O
found	O
that	O
the	O
lancelet	O
genome	O
encodes	O
protein	O
sequences	O
approximately	O
35	O
%	O
identical	O
to	O
the	O
RAG1	O
core	O
(	O
Figure	O
S5	O
;	O
RAG1L_BF	O
;	O
BLASTP	O
E-value	O
is	O
equal	O
to	O
10-34	O
)	O
.	O

Again	O
,	O
as	O
in	O
the	O
case	O
of	O
the	O
sea	O
urchin	O
sequences	O
,	O
the	O
lancelet	O
RAG1	O
corelike	O
elements	O
show	O
no	B-Negation
hallmarks	I-Negation
of	I-Negation
transposons	I-Negation
(	B-Negation
data	I-Negation
not	I-Negation
shown	I-Negation
)	I-Negation
.	O

However	O
,	O
unlike	O
highly	O
conserved	O
RAG1	O
proteins	O
,	O
the	O
RAG1	O
corelike	O
proteins	O
are	O
remarkably	O
diverse	O
(	O
see	O
Figure	O
2	O
)	O
.	O

During	O
the	O
second	O
review	O
of	O
the	O
manuscript	O
of	O
this	O
article	O
,	O
we	O
were	O
kindly	O
informed	O
by	O
Dr	O
.	O

Herv	O
Philippe	O
of	O
a	O
RAG1	O
corelike	O
sequence	O
present	O
the	O
starlet	O
sea	O
anemone	O
(	O
Nematostella	O
vectensis	O
)	O
.	O

After	O
that	O
,	O
we	O
screened	O
all	O
available	O
Trace	O
Archives	O
(	O
Materials	O
and	O
Methods	O
)	O
and	O
detected	O
additional	O
RAG1-like	O
proteins	O
.	O

In	O
starlet	O
sea	O
anemone	O
,	O
several	O
approximately	O
1000-bp	O
WGS	O
trace	O
sequences	O
were	O
found	O
(	O
e.g.	O
,	O
GenBank	O
Trace	O
Archive	O
IDs	O
668021618	O
,	O
558173651	O
,	O
568641192	O
,	O
and	O
599572062	O
)	O
,	O
which	O
encode	O
protein	O
,	O
called	O
RAG1L_NV	O
,	O
that	O
is	O
approximately	O
30	O
%	O
identical	O
to	O
the	O
human	O
RAG1	O
core	O
(	O
positions	O
284802	O
,	O
TBLASTN	O
,	O
10-26	O
<	O
E	O
<	O
10-7	O
)	O
.	O

We	O
also	O
found	O
several	O
approximately	O
1000-bp	O
WGS	O
trace	O
sequences	O
of	O
Hydra	O
magnipapillata	O
(	O
Trace	O
Archive	O
IDs	O
688654311	O
,	O
647073738	O
,	O
666995387	O
,	O
687186526	O
,	O
688683890	O
,	O
and	O
688948453	O
)	O
,	O
coding	O
for	O
protein	O
sequences	O
26	O
%	O
-30	O
%	O
identical	O
to	O
the	O
RAG1	O
core	O
(	O
positions	O
753-995	O
,	O
E-value	O
is	O
approximately	O
equal	O
to	O
10-7	O
in	O
a	O
BLASTX	O
search	O
against	O
GenBank	O
)	O
.	O

Using	O
these	O
trace	O
sequences	O
,	O
we	O
partially	O
assembled	O
a	O
hydra	O
gene	O
,	O
called	O
RAG1L_NM	O
,	O
which	O
encodes	O
the	O
RAG1	O
corelike	O
protein	O
.	O

Remarkably	O
,	O
the	O
hydra	O
RAG1L_NM	O
protein	O
turned	O
out	O
to	O
be	O
significantly	O
similar	O
to	O
the	O
Transib	O
TPase	O
(	O
26	O
%	O
identity	O
;	O
E-value	O
is	O
approximately	O
equal	O
to	O
10-14	O
in	O
a	O
BLASTX	O
search	O
against	O
GenBank	O
proteins	O
combined	O
with	O
the	O
Transib	O
TPase	O
sequences	O
)	O
.	O

Therefore	O
,	O
the	O
hydra	O
RAG1	O
corelike	O
protein	O
provides	O
the	O
first	O
direct	O
link	O
between	O
the	O
RAG1	O
core	O
and	O
Transib	O
TPase	O
.	O

Schematic	O
Structure	O
of	O
the	O
Sea	O
Urchin	O
RAG1-Like	O
Sequences	O

Contig	O
accession	O
numbers	O
are	O
shown	O
in	O
the	O
left	O
column	O
.	O

Inverted	O
complement	O
contigs	O
are	O
marked	O
by	O
	O
c	O
	O
followed	O
by	O
the	O
contig	O
number	O
.	O

In	O
each	O
contig	O
,	O
RAG1-like	O
proteins	O
(	O
white	O
rectangle	O
)	O
are	O
schematically	O
aligned	O
with	O
the	O
human	O
RAG1	O
core	O
(	O
top	O
rectangle	O
)	O
.	O

Nucleotide	O
positions	O
of	O
the	O
RAG1-like	O
sequences	O
are	O
shown	O
beneath	O
the	O
white	O
rectangles	O
.	O

Three	O
pairs	O
of	O
recently	O
duplicated	O
sequences	O
(	O
nucleotide	O
identity	O
is	O
higher	O
than	O
95	O
%	O
)	O
are	O
underlined	O
by	O
red	O
,	O
green	O
,	O
and	O
black	O
lines	O
,	O
respectively	O
.	O

Transposable	O
and	O
repetitive	O
elements	O
detected	O
in	O
the	O
flanking	O
regions	O
are	O
marked	O
by	O
painted	O
rectangles	O
.	O

Names	O
of	O
these	O
elements	O
are	O
shown	O
above	O
the	O
rectangles	O
.	O

Asterisks	O
denote	O
stop	O
codons	O
in	O
the	O
corresponding	O
RAG1-like	O
sequences	O
.	O

BLASTP	O
E-values	O
characterizing	O
similarities	O
between	O
the	O
sea	O
urchin	O
and	O
RAG1	O
proteins	O
are	O
shown	O
above	O
the	O
white	O
rectangles	O
.	O

Multiple	O
alignment	O
of	O
these	O
protein	O
sequences	O
is	O
reported	O
in	O
Figure	O
S5	O
.	O

N-TerminalLike	O
Domain	O
of	O
RAG1	O
in	O
the	O
Sea	O
Urchin	O
,	O
Lancelet	O
,	O
Starlet	O
Sea	O
Anemone	O
,	O
and	O
Hydra	O
Genomes	O

A	O
separate	O
analysis	O
of	O
the	O
assembled	O
sea	O
urchin	O
sequences	O
yielded	O
seven	O
sequences	O
encoding	O
three	O
diverse	O
proteins	O
that	O
were	O
significantly	O
similar	O
to	O
the	O
380-aa	O
N-terminal	O
domain	O
of	O
RAG1	O
(	O
BLASTX	O
,	O
E	O
<	O
10-4	O
)	O
,	O
excluding	O
the	O
100-aa	O
N-terminus	O
(	O
Figure	O
6	O
)	O
.	O

The	O
first	O
305-aa	O
protein	O
is	O
encoded	O
by	O
contig	O
1226	O
,	O
and	O
its	O
recently	O
duplicated	O
copies	O
are	O
on	O
contigs	O
1219	O
and	O
1222	O
(	O
approximately	O
95	O
%	O
identical	O
to	O
each	O
other	O
at	O
the	O
protein	O
level	O
)	O
.	O

The	O
second	O
,	O
195-aa	O
protein	O
(	O
contig	O
83099	O
)	O
is	O
the	O
shortest	O
.	O

It	O
is	O
only	O
approximately	O
26	O
%	O
identical	O
to	O
the	O
first	O
protein	O
and	O
more	O
than	O
90	O
%	O
identical	O
at	O
the	O
DNA	O
level	O
to	O
its	O
duplicate	O
on	O
contig	O
86231	O
.	O

We	O
also	O
found	O
a	O
third	O
protein	O
on	O
contig	O
768	O
that	O
contains	O
unique	O
motifs	O
in	O
its	O
N-terminal	O
regions	O
that	O
best	O
match	O
the	O
homologous	O
regions	O
of	O
RAG1	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
unassembled	O
WGS	O
trace	O
sequences	O
encode	O
two	O
other	O
proteins	O
,	O
P4_SP	O
and	O
P5_SP	O
,	O
similar	O
to	O
the	O
N-terminal	O
RAG1	O
domain	O
(	O
Figure	O
6	O
)	O
.	O

By	O
analyzing	O
the	O
lancelet	O
WGS	O
traces	O
,	O
we	O
also	O
found	O
that	O
the	O
lancelet	O
genome	O
encodes	O
five	O
different	O
proteins	O
similar	O
to	O
the	O
N-terminal	O
domain	O
of	O
RAG1	O
(	O
BLASTP	O
E	O
values	O
in	O
searches	O
against	O
all	O
GenBank	O
proteins	O
were	O
in	O
a	O
range	O
of	O
10-1410-7	O
)	O
.	O

DNA	O
sequences	O
coding	O
for	O
these	O
proteins	O
,	O
P1_BF	O
through	O
P5_BF	O
,	O
were	O
manually	O
assembled	O
from	O
overlapping	O
WGS	O
sequences	O
(	O
data	O
available	O
upon	O
request	O
)	O
.	O

The	O
proteins	O
detected	O
in	O
the	O
sea	O
urchin	O
and	O
lancelet	O
genome	O
share	O
a	O
ring	O
finger	O
motif	O
as	O
well	O
as	O
two	O
novel	O
motifs	O
matching	O
the	O
N-terminal	O
RAG1	O
domain	O
(	O
Figure	O
6	O
)	O
and	O
remotely	O
resembling	O
C-x2-C	O
zinc	O
finger	O
motifs	O
.	O

The	O
new	O
conserved	O
motifs	O
are	O
H-x3-L-x3-C-R-x-C-G	O
and	O
D-x3-I-h-P-x2-F-C-x2-C	O
,	O
and	O
their	O
function	O
remains	O
to	O
be	O
determined	O
.	O

It	O
is	O
thought	O
that	O
the	O
ring	O
finger	O
motif	O
of	O
RAG1	O
functions	O
as	O
a	O
zinc-binding	O
domain	O
,	O
is	O
involved	O
in	O
dimerization	O
[	O
30,35	O
]	O
,	O
and	O
acts	O
as	O
an	O
E3	O
ligase	O
in	O
the	O
ubiquitylation	O
[	O
36	O
]	O
.	O

It	O
also	O
likely	O
that	O
the	O
N-terminal	O
RAG1	O
and	O
RAG1-like	O
proteins	O
share	O
an	O
additional	O
conserved	O
motif	O
W-x-p-h-x	O
(	O
36	O
)	O
-C-x2-C	O
that	O
resides	O
between	O
conserved	O
motif	O
2	O
and	O
the	O
ring	O
finger	O
(	O
Figure	O
6	O
)	O
.	O

None	O
of	O
the	O
sea	O
urchin	O
and	O
lancelet	O
proteins	O
align	O
to	O
the	O
approximately	O
100-aa	O
N-terminus	O
of	O
RAG1	O
,	O
which	O
may	O
indicate	O
that	O
this	O
portion	O
is	O
missing	O
from	O
the	O
genome	O
or	O
highly	O
diverged	O
and	O
difficult	O
to	O
detect	O
.	O

It	O
is	O
also	O
worth	O
noting	O
that	O
this	O
portion	O
corresponds	O
to	O
a	O
separate	O
exon	O
in	O
some	O
teleosts	O
(	O
see	O
Discussion	O
)	O
.	O

The	O
ring	O
finger	O
motif	O
itself	O
is	O
also	O
present	O
in	O
several	O
sea	O
urchin	O
proteins	O
unrelated	O
to	O
RAG1	O
but	O
significantly	O
similar	O
to	O
diverse	O
proteins	O
associated	O
with	O
immune	O
and	O
developmental	O
systems	O
as	O
well	O
as	O
regulation	O
of	O
transcription	O
.	O

To	O
test	O
whether	O
the	O
reported	O
sea	O
urchin	O
sequences	O
represent	O
a	O
true	O
RAG1-like	O
match	O
,	O
we	O
cut	O
off	O
the	O
ring	O
finger	O
motif	O
and	O
repeated	O
the	O
BLASTP	O
search	O
against	O
all	O
GenBank	O
proteins	O
.	O

Even	O
without	B-Negation
the	I-Negation
finger	I-Negation
,	O
the	O
remaining	O
portions	O
of	O
the	O
sea	O
urchin	O
sequences	O
were	O
significantly	O
similar	O
to	O
the	O
corresponding	O
portions	O
of	O
RAG1	O
.	O

BLASTP	O
E-values	O
were	O
910-9	O
,	O
710-5	O
,	O
and	O
10-3	O
for	O
the	O
P5_SP	O
,	O
P4_SP	O
,	O
and	O
768_SP	O
sequences	O
,	O
respectively	O
;	O
because	O
both	O
the	O
low-complexity	O
filter	O
and	O
composition-based	O
statistics	O
were	O
applied	O
,	O
the	O
corresponding	O
E-values	O
were	O
estimated	O
very	O
conservatively	O
.	O

BLASTP	O
searches	O
of	O
the	O
sea	O
urchin	O
sequences	O
against	O
all	O
GenBank	O
proteins	O
,	O
excluding	B-Negation
RAG1	I-Negation
,	O
detected	O
only	O
the	O
ring	O
finger	O
domain	O
of	O
the	O
sea	O
urchin	O
sequences	O
.	O

E-values	O
of	O
these	O
matches	O
were	O
much	O
higher	O
than	O
the	O
E-values	O
of	O
similarities	O
to	O
the	O
RAG1	O
proteins	O
(	O
SP_768	O
:	O
0.04	O
versus	O
710-7	O
;	O
SP_86231	O
:	O
310-4	O
versus	O
710-7	O
;	O
SP_1226	O
:	O
10-4	O
versus	O
210-7	O
;	O
P4_SP	O
:	O
10	O
versus	O
210-7	O
;	O
P5_SP	O
does	O
not	B-Negation
have	I-Negation
ring	I-Negation
finger	I-Negation
and	O
matches	O
RAG1	O
only	O
,	O
E-value	O
==	O
910-7	O
)	O
.	O

Based	O
on	O
the	O
same	O
approach	O
,	O
our	O
study	O
found	O
that	O
the	O
starlet	O
sea	O
anemone	O
and	O
hydra	O
genomes	O
also	O
encode	O
several	O
families	O
of	O
the	O
N-terminal	O
RAG1	O
domain	O
that	B-Speculation
appear	I-Speculation
to	I-Speculation
be	I-Speculation
separate	I-Speculation
from	I-Speculation
the	I-Speculation
RAG1	I-Speculation
corelike	I-Speculation
proteins	I-Speculation
(	O
data	O
not	B-Negation
shown	I-Negation
)	I-Negation
.	O

The	O
only	O
exception	O
was	O
the	O
already	O
mentioned	O
sea	O
anemone	O
RAG1	O
corelike	O
sequence	O
.	O

The	O
approximately	O
90-aa	O
N-terminus	O
of	O
the	O
latter	O
sequence	O
is	O
the	O
ring	O
finger	O
(	O
E	O
<	O
10-7	O
,	O
multiple	O
BLASTP	O
matches	O
against	O
known	O
ring	O
fingers	O
in	O
GenBank	O
)	O
.	O

Multiple	O
Alignment	O
of	O
the	O
RAG1	O
N-Terminal	O
Domain	O
and	O
Sea	O
Urchin	O
Protein	O
Sequences	O

RAG1_HS	O
,	O
RAG1_PD	O
,	O
RAG1_SS	O
,	O
RAG1_RM	O
,	O
and	O
RAG1_LM	O
mark	O
the	O
human	O
(	O
GenBank	O
accession	O
number	O
NP_000439	O
)	O
,	O
lungfish	O
(	O
AAS75810	O
)	O
,	O
pig	O
(	O
BAC54968	O
)	O
,	O
stripe-sided	O
rhabdornis	O
or	O
Rhabdornis	O
mysticalis	O
bird	O
(	O
AAQ76078	O
)	O
,	O
and	O
latimeria	O
(	O
AAS75807	O
)	O
proteins	O
,	O
respectively	O
.	O

The	O
sea	O
urchin	O
and	O
lancelet	O
proteins	O
are	O
marked	O
by	O
	O
_SP	O
	O
and	O
	O
_BF	O
	O
following	O
the	O
identification	O
numbers	O
of	O
the	O
corresponding	O
contigs	O
.	O

Protein	O
sequences	O
assembled	O
from	O
the	O
sea	O
urchin	O
and	O
lancelet	O
WGS	O
Trace	O
Archives	O
are	O
denoted	O
as	O
P4-P5_SP	O
and	O
P1-P5_BF	O
,	O
respectively	O
.	O

Three	O
conserved	O
motifs	O
are	O
underlined	O
and	O
numbered	O
.	O

The	O
third	O
conserved	O
motif	O
is	O
known	O
as	O
the	O
ring	O
finger	O
.	O

Distances	O
from	O
the	O
protein	O
N-termini	O
are	O
indicated	O
by	O
numbers	O
.	O

Discussion	O

The	O
significant	O
similarity	O
between	O
the	O
Transib	O
TPases	O
and	O
RAG1	O
core	O
,	O
the	O
common	O
structure	O
of	O
the	O
Transib	O
TIRs	O
and	O
RSSs	O
,	O
as	O
well	O
as	O
the	O
similar	O
size	O
of	O
TSDs	O
characterizing	O
transpositions	O
of	O
Transib	O
transposons	O
and	O
transpositions	O
catalyzed	O
by	O
RAG1	O
and	O
RAG2	O
,	O
directly	O
support	O
the	O
25-year-old	O
hypothesis	O
of	O
a	O
transposon-related	O
origin	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
machinery	O
.	O

Previously	O
,	O
the	O
	O
RAG	O
transposon	O
	O
hypothesis	O
was	O
open	O
to	O
challenge	O
by	O
alternative	O
models	O
of	O
convergent	O
evolution	O
.	O

Because	O
there	O
were	O
no	B-Negation
known	I-Negation
TPases	I-Negation
similar	I-Negation
to	I-Negation
RAG1	I-Negation
,	O
it	O
could	B-Speculation
be	I-Speculation
argued	I-Speculation
that	I-Speculation
RAG1	I-Speculation
independently	I-Speculation
developed	I-Speculation
some	I-Speculation
TPase-like	I-Speculation
properties	I-Speculation
,	I-Speculation
rather	I-Speculation
than	I-Speculation
deriving	I-Speculation
them	I-Speculation
from	I-Speculation
a	I-Speculation
TE-encoded	I-Speculation
TPase	I-Speculation
[	O
24	O
]	O
.	O

These	O
arguments	O
can	O
now	O
be	O
put	O
to	O
rest	O
.	O

As	O
shown	O
in	O
this	O
paper	O
,	O
the	O
RAG1	O
core	O
was	O
derived	O
from	O
a	O
Transib	O
TPase	O
,	O
but	O
given	O
the	O
low	O
identity	O
between	O
the	O
Transib	O
TPase	O
and	O
the	O
RAG1	O
core	O
(	O
14	O
%	O
17	O
%	O
)	O
it	O
is	O
not	O
clear	O
whether	O
the	O
ancestral	O
transposon	O
was	O
a	O
member	O
of	O
the	O
group	O
of	O
canonical	O
Transib	O
transposons	O
preserved	O
in	O
modern	O
genomes	O
of	O
insects	O
,	O
hydra	O
,	O
and	O
sea	O
urchin	O
(	O
see	O
Figure	O
1	O
)	O
,	O
or	O
a	O
member	O
of	O
an	O
unknown	O
group	O
of	O
Transib	O
transposons	O
that	O
encoded	O
a	O
TPase	O
that	O
was	O
more	O
similar	O
to	O
RAG1	O
core	O
than	O
to	O
the	O
canonical	O
TPase	O
from	O
the	O
currently	O
known	O
Transib	O
transposons	O
.	O

Furthermore	O
,	O
after	O
its	O
recruitment	O
,	O
the	O
RAG1	O
core	O
most	O
likely	O
went	O
through	O
a	O
period	O
of	O
intensive	O
transformations	O
due	O
to	O
diversifying/positive	O
selection	O
,	O
which	O
further	O
decreased	O
its	O
similarity	O
to	O
Transib	O
TPase	O
.	O

Afterwards	O
,	O
the	O
RAG1	O
genes	O
continued	O
to	O
evolve	O
at	O
a	O
slow	O
and	O
steady	O
pace	O
under	O
stabilizing	O
selection	O
,	O
as	O
indicated	O
by	O
the	O
observed	O
conservation	O
of	O
the	O
RAG1	O
core	O
(	O
79	O
%	O
identity	O
between	O
sharks	O
and	O
mammals	O
)	O
.	O

Some	O
of	O
the	O
intermediate	O
stages	O
of	O
RAG1	O
evolution	O
can	O
be	O
inferred	O
from	O
analysis	O
of	O
the	O
sea	O
urchin	O
in	O
which	O
RAG1-like	O
proteins	O
were	O
recently	O
observed	O
[	O
37	O
]	O
,	O
and	O
from	O
analysis	O
of	O
the	O
lancelet	O
,	O
starlet	O
sea	O
anemone	O
,	O
and	O
hydra	O
genomes	O
.	O

Based	O
on	O
the	O
presence	O
of	O
stop	O
codons	O
disrupting	O
some	O
of	O
the	O
RAG1-like	O
sequences	O
,	O
it	O
has	O
been	O
suggested	O
[	O
37	O
]	O
that	O
the	O
sea	O
urchin	O
sequences	O
represent	O
remnants	O
of	O
transposable	O
elements	O
.	O

Typically	O
,	O
TPase-coding	O
autonomous	O
DNA	O
transposons	O
are	O
present	O
in	O
only	O
a	O
few	O
complete	O
copies	O
per	O
genome	O
.	O

At	O
the	O
same	O
time	O
,	O
sequences	O
homologous	O
to	O
their	O
terminal	O
portions	O
,	O
including	O
specific	O
TIRs	O
,	O
are	O
usually	O
abundant	O
due	O
to	O
the	O
proliferation	O
of	O
nonautonomous	O
DNA	O
transposons	O
fueled	O
by	O
the	O
TPase	O
expressed	O
by	O
the	O
corresponding	O
low-copy	O
autonomous	O
elements	O
.	O

Therefore	O
,	O
even	O
if	O
only	O
30	O
%	O
of	O
the	O
sea	O
urchin	O
genome	O
has	O
been	O
sequenced	O
to	O
date	O
,	O
it	O
is	O
expected	O
that	O
the	O
regions	O
flanking	O
the	O
TPase	O
portions	O
of	O
potential	O
autonomous	O
elements	O
should	O
be	O
similar	O
to	O
numerous	O
nonautonomous	O
elements	O
.	O

So	O
far	O
,	O
we	O
have	O
found	O
no	B-Negation
evidence	I-Negation
of	I-Negation
such	I-Negation
similarities	I-Negation
.	O

Detailed	O
analysis	O
of	O
regions	O
flanking	O
the	O
sea	O
urchin	O
RAG1-like	O
DNA	O
coding	O
sequences	O
revealed	O
a	O
variety	O
of	O
different	O
transposable	O
elements	O
inserted	O
in	O
the	O
proximity	O
of	O
the	O
coding	O
sequences	O
(	O
see	O
Figure	O
5	O
)	O
.	O

Nevertheless	O
,	O
based	O
on	O
the	O
orientations	O
and	O
relative	O
positions	O
of	O
these	O
transposons	O
,	O
none	B-Negation
of	I-Negation
them	I-Negation
appears	B-Speculation
to	I-Speculation
be	I-Speculation
associated	I-Speculation
with	I-Speculation
the	I-Speculation
RAG1-like	I-Speculation
sequences	I-Speculation
(	O
see	O
Figure	O
5	O
)	O
.	O

We	O
also	O
could	O
not	B-Negation
identify	I-Negation
the	I-Negation
5-bp	I-Negation
TSDs	I-Negation
and	I-Negation
TIRs	I-Negation
characteristic	I-Negation
of	I-Negation
the	I-Negation
Transib	I-Negation
superfamily	I-Negation
.	O

Still	O
,	O
given	O
that	O
only	O
one	O
third	O
of	O
the	O
sea	O
urchin	O
genome	O
is	O
currently	O
assembled	O
as	O
a	O
set	O
of	O
contigs	O
longer	O
than	O
several	O
thousand	O
nucleotides	O
(	O
the	O
remaining	O
portion	O
is	O
represented	O
by	O
short	O
WGS	O
sequences	O
)	O
,	O
we	O
can	O
not	O
rule	O
out	O
the	O
possibility	O
that	O
the	O
sea	O
urchin	O
RAG1-like	O
proteins	O
are	O
remnants	O
of	O
an	O
unknown	O
branch	O
of	O
Transib	O
transposons	O
.	O

Given	O
that	O
the	O
genomes	O
of	O
lancelet	O
,	O
hydra	O
,	O
and	O
starlet	O
sea	O
anemone	O
are	O
currently	O
available	O
only	O
as	O
unassembled	O
WGS	O
traces	O
,	O
the	O
question	O
whether	O
the	O
corresponding	O
RAG1-like	O
sequences	O
are	O
remnants	O
of	O
transposons	O
or	O
genes/pseudogenes	O
must	O
be	O
left	O
open	O
.	O

The	O
alternative	O
possibility	O
is	O
that	O
the	O
sea	O
urchin	O
RAG1	O
corelike	O
sequences	O
represent	O
diverse	O
genes	O
and	O
pseudogenes	O
that	O
belong	O
to	O
a	O
rapidly	O
evolving	O
multigene	O
family	O
.	O

This	O
opens	O
the	O
tantalizing	O
possibility	O
that	O
the	O
RAG1	O
core	O
was	O
recruited	O
from	O
a	O
Transib	O
TPase	O
in	O
a	O
common	O
ancestor	O
of	O
Bilaterians	O
and	O
Cnidarians	O
,	O
and	O
subsequently	O
lost	O
in	O
nematodes	O
,	O
insects	O
,	O
and	O
sea	O
squirts	O
(	O
see	O
Figure	O
1	O
)	O
.	O

Furthermore	O
,	O
given	O
that	O
the	O
sea	O
urchin	O
,	O
lancelet	O
,	O
hydra	O
,	O
and	O
starlet	O
sea	O
anemone	O
genomes	O
harbor	O
several	O
highly	O
divergent	O
N-terminallike	O
domains	O
,	O
separate	O
from	O
the	O
RAG1	O
corelike	O
sequences	O
and	O
known	O
transposable	O
elements	O
,	O
it	O
is	O
very	O
likely	O
that	O
the	O
N-terminallike	O
domains	O
of	O
RAG1	O
also	O
form	O
a	O
multigene	O
family	O
that	O
can	O
be	O
traced	O
back	O
to	O
a	O
common	O
ancestor	O
of	O
Deuterostomes	O
(	O
see	O
Figure	O
1	O
)	O
.	O

If	O
so	O
,	O
then	O
both	O
N-terminal	O
and	O
core	O
domains	O
of	O
RAG1	O
might	O
have	O
been	O
derived	O
from	O
different	O
genes	O
present	O
in	O
a	O
common	O
ancestor	O
of	O
Deuterostomes	O
.	O

Alternatively	O
,	O
the	O
N-terminal	O
domain	O
of	O
RAG1	O
might	O
have	O
been	O
derived	O
from	O
a	O
separate	O
,	O
unknown	O
transposon	O
.	O

The	O
N-terminal	O
domain	O
of	O
RAG1	O
has	O
long	O
been	O
viewed	O
as	O
distinct	O
from	O
the	O
core	O
domain	O
due	O
to	O
its	O
lack	B-Negation
of	I-Negation
direct	I-Negation
involvement	I-Negation
in	I-Negation
the	I-Negation
V	I-Negation
(	I-Negation
D	I-Negation
)	I-Negation
J	I-Negation
recombination	I-Negation
reaction	I-Negation
.	O

In	O
the	O
sea	O
urchin	O
,	O
lancelet	O
,	O
hydra	O
,	O
and	O
starlet	O
sea	O
anemone	O
genomes	O
,	O
the	B-Negation
RAG1	I-Negation
corelike	I-Negation
sequences	I-Negation
and	I-Negation
the	I-Negation
N-terminal	I-Negation
domainlike	I-Negation
sequences	I-Negation
do	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
be	I-Speculation
linked	I-Speculation
to	I-Speculation
each	I-Speculation
other	I-Speculation
or	I-Speculation
to	I-Speculation
any	I-Speculation
other	I-Speculation
proteins	I-Speculation
.	O

The	O
only	O
notable	O
exception	O
is	O
the	O
anemone	O
RAG1	O
corelike	O
protein	O
sequence	O
,	O
which	O
is	O
capped	O
by	O
the	O
90-aa	O
ring	O
finger	O
motif	O
.	O

Taken	O
together	O
with	O
the	O
fact	O
that	O
only	O
the	O
RAG1	O
core	O
is	O
significantly	O
similar	O
to	O
Transib	O
TPase	O
,	O
the	O
data	O
suggest	O
that	O
the	O
vertebrate	O
RAG1	O
represents	O
a	O
fusion	O
of	O
once	O
separate	O
proteins	O
.	O

This	O
is	O
consistent	O
with	O
the	O
observation	O
that	O
in	O
teleosts	O
,	O
(	O
bony	O
fish	O
)	O
the	O
RAG1	O
gene	O
is	O
divided	O
into	O
exons	O
by	O
either	O
one	O
or	O
two	O
introns	O
.	O

As	O
a	O
result	O
,	O
the	O
RAG1	O
core	O
is	O
split	O
into	O
separate	O
exons	O
at	O
the	O
aa	O
position	O
that	O
corresponds	O
to	O
position	O
460	O
in	O
the	O
human	O
RAG1gene	O
[	O
29,34,38	O
]	O
.	O

The	O
core-like	O
sequences	O
encoded	O
by	O
the	O
sea	O
urchin	O
WGS	O
sequence	O
contigs	O
29068	O
and	O
12509	O
correspond	O
to	O
either	O
the	O
second	O
or	O
third	O
RAG1	O
exon	O
in	O
teleosts	O
(	O
depending	O
on	O
the	O
number	O
of	O
introns	O
)	O
,	O
which	O
is	O
remarkably	O
consistent	O
with	O
the	O
fusion	O
model	O
.	O

The	O
same	O
model	O
predicts	O
that	O
the	O
N-terminal	O
domain	O
of	O
RAG1	O
could	O
also	O
be	O
assembled	O
from	O
two	O
separate	O
domains	O
based	O
on	O
the	O
presence	O
of	O
the	O
second	O
intron	O
in	O
some	O
teleosts	O
,	O
splitting	O
the	O
N-terminal	O
domain	O
into	O
the	O
102-aa	O
N-terminal	O
subdomain	O
and	O
the	O
rest	O
[	O
34	O
]	O
.	O

As	O
indicated	O
above	O
,	O
this	O
subdomain	O
,	O
corresponding	O
to	O
the	O
first	O
exon	O
in	O
the	O
genes	O
split	O
by	O
two	O
introns	O
,	O
appears	O
to	O
be	O
missing	O
in	O
the	O
sea	O
urchin	O
,	O
lancelet	O
,	O
hydra	O
,	O
and	O
starlet	O
sea	O
anemone	O
N-terminallike	O
proteins	O
.	O

It	O
may	O
be	O
encoded	O
by	O
a	O
separate	O
exon	O
that	O
is	O
difficult	O
to	O
detect	O
given	O
its	O
short	O
length	O
and	O
the	O
high	O
level	O
of	O
sequence	O
divergence	O
between	O
these	O
species	O
and	O
vertebrates	O
,	O
or	O
it	O
might	O
have	O
been	O
added	O
in	O
vertebrates	O
.	O

Similarly	O
,	O
the	O
RAG1	O
corelike	O
protein	O
in	O
the	O
sea	O
urchin	O
genome	O
is	O
shorter	O
in	O
its	O
N-terminal	O
part	O
than	O
the	O
core	O
domain	O
in	O
vertebrates	O
and	O
the	O
corresponding	O
Transib	O
TPase	O
.	O

Again	O
,	O
it	O
is	O
unclear	O
if	O
this	O
part	O
is	O
not	O
present	O
in	O
sea	O
urchins	O
or	O
simply	O
undetectable	O
due	O
to	O
its	O
small	O
size	O
and	O
the	O
high	O
sequence	O
divergence	O
.	O

It	O
is	O
currently	O
believed	O
that	O
both	O
RAG1	O
and	O
RAG2	O
proteins	O
were	O
originally	O
encoded	O
by	O
the	O
same	O
transposon	O
recruited	O
in	O
a	O
common	O
ancestor	O
of	O
jawed	O
vertebrates	O
[	O
3,12,13,16	O
]	O
.	O

However	O
,	O
none	B-Negation
of	I-Negation
the	I-Negation
Transib	I-Negation
transposons	I-Negation
identified	I-Negation
so	I-Negation
far	I-Negation
encode	I-Negation
any	I-Negation
proteins	I-Negation
other	I-Negation
than	I-Negation
the	I-Negation
Transib/RAG	I-Negation
TPase	I-Negation
.	O

Also	O
,	O
we	O
could	O
not	B-Negation
find	I-Negation
any	I-Negation
RAG2-like	I-Negation
sequences	I-Negation
in	I-Negation
the	I-Negation
recently	I-Negation
sequenced	I-Negation
sea	I-Negation
urchin	I-Negation
,	I-Negation
lancelet	I-Negation
,	I-Negation
hydra	I-Negation
,	I-Negation
and	I-Negation
sea	I-Negation
anemone	I-Negation
genomes	I-Negation
,	I-Negation
which	I-Negation
encode	I-Negation
RAG1-like	I-Negation
sequences	I-Negation
.	O

Autonomous	O
DNA	O
transposons	O
from	O
the	O
MuDR	O
,	O
Harbinger	O
,	O
and	O
En/Spm	O
superfamilies	O
are	O
each	O
known	O
to	O
encode	O
a	O
second	O
regulatory	O
protein	O
[	O
23,24	O
]	O
,	O
whereas	O
some	O
transposons	O
from	O
these	O
superfamilies	O
encode	O
the	O
TPase	O
only	O
.	O

Therefore	O
,	O
it	O
is	O
in	O
principle	O
possible	O
that	O
an	O
ancient	O
vertebrate	O
Transib	O
that	O
was	O
a	O
direct	O
ancestor	O
of	O
the	O
RAG1	O
core	O
also	O
encoded	O
a	O
second	O
protein	O
,	O
the	O
direct	O
ancestor	O
of	O
RAG2	O
.	O

Nevertheless	O
,	O
the	O
apparent	O
lack	O
of	O
RAG2-like	O
proteins	O
in	O
the	O
sequenced	O
portion	O
of	O
the	O
sea	O
urchin	O
,	O
lancelet	O
,	O
hydra	O
,	O
and	O
sea	O
anemone	O
genomes	O
,	O
as	O
well	O
as	O
in	O
Transib	O
transposons	O
suggests	O
that	O
RAG2	O
was	O
introduced	O
in	O
a	O
separate	O
event	O
in	O
jawless	O
vertebrates	O
.	O

However	O
,	O
given	O
the	O
low	O
30	O
%	O
identity	O
between	O
the	O
RAG1	O
and	O
sea	O
urchin/lancelet/sea	O
squirt	O
RAG1-like	O
proteins	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
the	O
ancestral	O
RAG2	O
protein	O
went	O
through	O
a	O
period	O
of	O
strong	O
diversification	O
driven	O
by	O
positive	O
selection	O
,	O
and	O
it	O
can	O
no	O
longer	O
be	O
identified	O
by	O
sequence	O
comparisons	O
but	O
may	O
still	O
be	O
present	O
in	O
invertebrates	O
.	O

In	O
any	O
case	O
,	O
the	O
origin	O
of	O
the	O
V	O
(	O
D	O
)	O
J	O
recombination	O
system	O
in	O
jawless	O
vertebrates	O
appears	O
to	O
be	O
a	O
culmination	O
of	O
earlier	O
evolutionary	O
processes	O
rather	O
than	O
an	O
isolated	O
event	O
associated	O
with	O
insertion	O
of	O
a	O
single	O
transposon	O
.	O

If	O
so	O
,	O
detailed	O
studies	O
of	O
individual	O
components	O
,	O
including	O
active	O
Transib	O
transposons	O
and	O
invertebrate	O
proteins	O
homologous	O
to	O
RAG1	O
elements	O
can	O
bring	O
new	O
breakthroughs	O
in	O
our	O
understanding	O
of	O
evolutionary	O
and	O
mechanistic	O
aspects	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
.	O

The	O
observed	O
sequence	O
similarity	O
between	O
the	O
RAG1	O
and	O
Transib	O
TPase	O
protein	O
can	O
help	O
to	O
identify	O
aa	O
residues	O
in	O
the	O
TPase	O
that	O
are	O
crucial	O
for	O
transposition	O
of	O
Transib	O
transposons	O
.	O

For	O
instance	O
,	O
on	O
the	O
basis	O
of	O
the	O
TPase	O
comparison	O
to	O
RAG1	O
(	O
see	O
Figures	O
S1	O
and	O
S3	O
)	O
,	O
we	O
were	O
able	O
to	O
identify	O
correct	O
positions	O
of	O
the	O
last	O
two	O
aa	O
residues	O
in	O
the	O
DDE	O
catalytic	O
triad	O
(	O
see	O
Figure	O
2	O
in	O
[	O
17	O
]	O
)	O
,	O
missed	O
in	O
our	O
previous	O
study	O
due	O
to	O
insufficient	O
data	O
.	O

Interestingly	O
,	O
only	O
two	O
cysteines	O
of	O
the	O
zinc	O
finger	O
B	O
(	O
ZFB	O
)	O
C2H2	O
motif	O
in	O
RAG1	O
(	O
residues	O
695761	O
)	O
involved	O
in	O
its	O
binding	O
to	O
RAG2	O
[	O
30,31	O
]	O
are	O
perfectly	O
conserved	O
in	O
the	O
Transib	O
TPases	O
(	O
motif	O
7	O
;	O
see	O
Figures	O
3	O
and	O
Figure	O
S3	O
)	O
.	O

The	O
remaining	O
portion	O
of	O
the	O
ZFB	O
motif	O
was	O
probably	O
lost	O
in	O
TPases	O
of	O
insect	O
Transib	O
transposons	O
,	O
which	O
do	O
not	O
encode	O
RAG2-like	O
proteins	O
.	O

Notably	O
,	O
two	O
ZFB	O
cysteines	O
are	O
part	O
of	O
the	O
conserved	O
SxxCxxC	O
motif	O
,	O
and	O
mutations	O
of	O
the	O
serine	O
from	O
the	O
same	O
motif	O
cause	O
severe	O
defects	O
in	O
RAG1	O
transpositions	O
in	O
vitro	O
[	O
32	O
]	O
.	O

Therefore	O
,	O
the	O
presence	O
of	O
serine	O
in	O
this	O
motif	O
is	O
expected	O
to	O
be	O
crucial	O
to	O
Transib	O
transpositions	O
.	O

After	O
submission	O
of	O
our	O
manuscript	O
,	O
additional	O
biochemical	O
evidence	O
favoring	O
evolution	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
from	O
transposable	O
elements	O
was	O
reported	O
[	O
25	O
]	O
.	O

Analogously	O
to	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
transposition	O
of	O
the	O
fly	O
Hermes	O
transposon	O
,	O
which	O
belongs	O
to	O
the	O
hAT	O
superfamily	O
,	O
is	O
also	O
characterized	O
by	O
a	O
double-strand	O
break	O
via	O
hairpin	O
formation	O
on	O
flanking	O
DNA	O
and	O
3	O
?	O
OH	O
joining	O
to	O
the	O
target	O
DNA	O
[	O
25	O
]	O
.	O

However	O
,	O
although	O
the	O
observed	O
biochemical	O
relationship	O
between	O
the	O
hAT	O
TPase	O
and	O
V	O
(	O
D	O
)	O
J	O
recombination	O
is	O
a	O
step	O
forward	O
in	O
our	O
understanding	O
of	O
transposition	O
reaction	O
,	O
several	O
arguments	O
strongly	O
suggest	O
that	O
V	O
(	O
D	O
)	O
J	O
machinery	O
evolved	O
from	O
a	O
Transib	O
rather	O
than	O
from	O
hAT	O
transposon	O
.	O

First	O
,	O
as	O
we	O
mentioned	O
previously	O
,	O
there	O
is	O
no	O
significant	O
sequence	O
identity	O
between	O
hAT	O
TPases	O
and	O
RAG1	O
,	O
even	O
if	O
one	O
employs	O
a	O
PSI-BLAST	O
search	O
with	O
most	O
relaxed	O
parameters	O
(	O
i.e.	O
,	O
E	O
<	O
10	O
,	O
no	B-Negation
filters	I-Negation
,	O
no	B-Negation
composition-based	I-Negation
statistics	I-Negation
)	O
.	O

Second	O
,	O
although	O
RAG1/2-mediated	O
transpositions	O
are	O
characterized	O
by	O
5-bp	O
(	O
sometimes	O
4-bp	O
)	O
TSDs	O
,	O
all	O
known	O
hAT	O
transposons	O
are	O
characterized	O
by	O
8-bp	O
TSDs	O
.	O

Third	O
,	O
unlike	O
in	O
the	O
case	O
of	O
Transib	O
transposons	O
,	O
TIRs	O
of	O
hAT	O
transposons	O
are	O
different	O
from	O
RSS	O
both	O
in	O
terms	O
of	O
DNA	O
sequence	O
similarities	O
and	O
their	O
conservation	O
patterns	O
(	O
Figure	O
S7	O
)	O
.	O

Fourth	O
,	O
hAT-	O
and	O
RAG1/2-mediated	O
transpositions	O
differ	O
dramatically	O
in	O
terms	O
of	O
the	O
GC	O
content	O
of	O
their	O
target	O
sites	O
:	O
Unlike	O
Transib	O
transposons	O
and	O
RAG1	O
transpositions	O
occurring	O
in	O
GC-rich	O
DNA	O
,	O
hAT	O
transposons	O
tend	O
to	O
be	O
integrated	O
into	O
AT-rich	O
regions	O
(	O
Table	O
S2	O
)	O
.	O

All	O
four	O
arguments	O
strongly	O
favor	O
evolution	O
of	O
V	O
(	O
D	O
)	O
J	O
machinery	O
from	O
a	O
Transib	O
transposon	O
.	O

Most	O
likely	O
,	O
the	O
Transib	O
transpositions	O
are	O
also	O
characterized	O
by	O
hairpin	O
intermediates	O
formed	O
by	O
the	O
ends	O
of	O
the	O
donor	O
DNA	O
double-strand	O
breaks	O
,	O
as	O
observed	O
during	O
V	O
(	O
D	O
)	O
J	O
recombination	O
and	O
hAT	O
transposition	O
.	O

Materials	O
and	O
Methods	O

DNA	O
and	O
protein	O
sequences	O
.	O

Assembled	O
D.	O
pseudoobscura	O
sequences	O
were	O
downloaded	O
from	O
the	O
Human	O
Genome	O
Sequencing	O
Center	O
at	O
Baylor	O
College	O
of	O
Medicine	O
through	O
the	O
Web	O
site	O
at	O
http	O
:	O
//hgsc.bcm.tmc.edu/projects/drosophila/	O
on	O
2	O
March	O
2004	O
.	O

Preliminary	O
A.	O
aegypti	O
sequence	O
data	O
were	O
obtained	O
from	O
The	O
Institute	O
for	O
Genomic	O
Research	O
through	O
the	O
Web	O
site	O
at	O
http	O
:	O
//www.tigr.org	O
on	O
4	O
March	O
2004	O
.	O

Assembled	O
D.	O
melanogaster	O
sequences	O
were	O
downloaded	O
from	O
the	O
Berkeley	O
Drosophila	O
Genome	O
Project	O
at	O
http	O
:	O
//www.fruitfly.org/sequence/download.html	O
on	O
17	O
February	O
2004	O
.	O

Partially	O
assembled	O
S.	O
purpuratus	O
contig	O
sequences	O
were	O
downloaded	O
on	O
12	O
August	O
2004	O
from	O
the	O
Baylor	O
College	O
of	O
Medicine	O
through	O
the	O
Web	O
site	O
at	O
ftp	O
:	O
//ftp.hgsc.bcm.tmc.edu/pub/data/Spurpuratus/blast/Spur20030922-genome	O
.	O

In	O
addition	O
to	O
the	O
assembled	O
contigs	O
,	O
Baylor	O
College	O
of	O
Medicine	O
,	O
Human	O
Genome	O
Sequencing	O
Center	O
(	O
http	O
:	O
//www.hgsc.bcm.tmc.edu	O
)	O
produced	O
an	O
approximately	O
8-Gb	O
set	O
of	O
short	O
unassembled	O
WGS	O
sequences	O
,	O
called	O
	O
traces	O
	O
,	O
which	O
cover	O
nearly	O
the	O
entire	O
sea	O
urchin	O
genome	O
.	O

We	O
downloaded	O
these	O
sequences	O
from	O
the	O
GenBank	O
Trace	O
Archive	O
at	O
the	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
;	O
ftp	O
:	O
//ftp.ncbi.nih.gov/pub/TraceDB/strongylocentrotus_purpuratus/	O
)	O
on	O
17	O
November	O
2004	O
.	O

Also	O
,	O
we	O
downloaded	O
an	O
approximately	O
5-Gb	O
set	O
of	O
unassembled	O
traces	O
that	O
cover	O
almost	O
completely	O
the	O
600-Mb	O
genome	O
of	O
Florida	O
lancelet	O
(	O
ftp	O
:	O
//ftp.ncbi.nih.gov/pub/TraceDB/branchiostoma_floridae/	O
;	O
3	O
December	O
2004	O
)	O
.	O

These	O
sequences	O
were	O
produced	O
and	O
deposited	O
in	O
the	O
GenBank	O
Trace	O
Archive	O
by	O
Department	O
of	O
Energy	O
Joint	O
Genomic	O
Institute	O
(	O
http	O
:	O
//www.jgi.doe.gov/	O
)	O
.	O

All	O
other	O
DNA	O
and	O
protein	O
sequences	O
were	O
accessed	O
from	O
GenBank	O
(	O
NCBI	O
)	O
through	O
the	O
server	O
at	O
http	O
:	O
//www.ncbi.nih.gov/Genbank/	O
and	O
from	O
Ensembl	O
(	O
EMBL-EBI	O
and	O
Sanger	O
Institute	O
)	O
via	O
the	O
server	O
at	O
http	O
:	O
//www.ensembl.org	O
.	O

Sequences	O
of	O
the	O
Transib1	O
through	O
Transib4	O
and	O
Transib1_AG	O
through	O
Transib3_AG	O
transposons	O
[	O
17	O
]	O
were	O
obtained	O
from	O
the	O
D.	O
melanogaster	O
(	O
drorep.ref	O
)	O
and	O
A.	O
gambiae	O
(	O
angrep.ref	O
)	O
sections	O
of	O
Repbase	O
Update	O
[	O
39	O
]	O
at	O
Genetic	O
Information	O
Research	O
Institute	O
(	O
http	O
:	O
//www.girinst.org	O
)	O
.	O

Sequence	O
analysis	O
.	O

Computer-assisted	O
identification	O
and	O
reconstruction	O
of	O
the	O
Transib	O
transposons	O
was	O
done	O
as	O
described	O
previously	O
[	O
17,4042	O
]	O
.	O

DNA	O
sequence	O
analysis	O
including	O
local	O
sequence	O
alignments	O
,	O
multiple	O
alignments	O
,	O
and	O
reconstruction	O
of	O
the	O
Transib	O
consensus	O
sequences	O
was	O
done	O
using	O
software	O
developed	O
at	O
Genetic	O
Information	O
Research	O
Institute	O
(	O
available	O
upon	O
request	O
)	O
and	O
WU-BLASTN	O
2.0	O
(	O
http	O
:	O
//blast.wustl.edu	O
)	O
.	O

To	O
avoid	O
background	O
noise	O
introduced	O
by	O
mutations	O
,	O
Transib	O
relics	O
,	O
whose	O
TPase-coding	O
regions	O
contained	O
numerous	O
stop	O
codons	O
and	O
indels	O
,	O
were	O
ignored	O
unless	O
several	O
copies	O
were	O
available	O
.	O

(	O
We	O
included	O
in	O
the	O
analysis	O
incomplete	O
relics	O
of	O
the	O
Transib25_AA	O
TPases	O
represented	O
by	O
single	O
DNA	O
copies	O
.	O
)	O

Prediction	O
of	O
putative	O
exons	O
and	O
introns	O
encoded	O
by	O
the	O
Transib	O
consensus	O
sequences	O
was	O
done	O
with	O
FGENESH	O
[	O
33	O
]	O
(	O
at	O
http	O
:	O
//www.softberry.com	O
)	O
.	O

Multiple	O
alignments	O
of	O
distantly	O
related	O
RAG1	O
and	O
Transib	O
TPase	O
protein	O
sequences	O
were	O
created	O
by	O
T-Coffee	O
[	O
40	O
]	O
.	O

Shading	O
and	O
minor	O
manual	O
refinements	O
of	O
the	O
aligned	O
sequences	O
were	O
done	O
using	O
Genedoc	O
[	O
43	O
]	O
.	O

Phylogenetic	O
trees	O
were	O
produced	O
by	O
using	O
MEGA3	O
[	O
44	O
]	O
.	O

Some	O
of	O
the	O
sea	O
urchin	O
sequences	O
encoding	O
the	O
RAG1	O
N-terminal	O
domain	O
were	O
assembled	O
from	O
traces	O
based	O
on	O
the	O
Baylor	O
BAC-Fisher	O
server	O
at	O
http	O
:	O
//www.hgsc.bcm.tmc.edu/BAC-Fisher/	O
(	O
the	O
results	O
of	O
assembly	O
were	O
verified	O
manually	O
)	O
.	O

All	O
GenBank	O
proteins	O
were	O
downloaded	O
from	O
ftp	O
:	O
//ftp.ncbi.nih.gov/blast/DB/fasta/nr	O
(	O
February	O
2004	O
)	O
and	O
were	O
combined	O
into	O
a	O
single	O
set	O
with	O
the	O
identified	O
Transib	O
TPases	O
.	O

No	B-Negation
Transib	I-Negation
TPases	I-Negation
had	I-Negation
been	I-Negation
deposited	I-Negation
or	I-Negation
annotated	I-Negation
previously	I-Negation
in	I-Negation
GenBank	I-Negation
,	O
except	O
for	O
two	O
short	O
hypothetical	O
proteins	O
predicted	O
automatically	O
during	O
annotation	O
of	O
the	O
D.	O
melanogaster	O
genome	O
:	O
151-aa	O
gi:30923617	O
and	O
123-aa	O
gi:30923765	O
.	O

These	O
proteins	O
are	O
apparent	O
fragments	O
of	O
Transib	O
TPases	O
encoded	O
by	O
relics	O
of	O
Transib	O
transposons	O
,	O
including	O
Transib5_DM	O
.	O

A	O
standalone	O
2001	O
version	O
of	O
PSI	O
(	O
Position-Specific	O
Iterating	O
)	O
-BLAST	O
[	O
18,45	O
]	O
was	O
used	O
for	O
detection	O
of	O
proteins	O
that	O
were	O
significantly	O
similar	O
to	O
TPases	O
encoded	O
by	O
Transib	O
and	O
other	O
superfamilies	O
of	O
DNA	O
transposons	O
.	O

The	O
PSI-BLAST	O
program	O
[	O
18,45	O
]	O
is	O
much	O
more	O
sensitive	O
than	O
a	O
regular	O
BLAST	O
search	O
due	O
to	O
the	O
use	O
of	O
PSSM	O
)	O
PSI-BLAST	O
first	O
performs	O
a	O
standard	O
BLASTP	O
search	O
of	O
a	O
protein	O
query	O
against	O
a	O
protein	O
database	O
and	O
constructs	O
a	O
multiple	O
alignment	O
of	O
matches	O
exceeding	O
a	O
certain	O
E-value	O
threshold	O
(	O
called	O
Ei	O
value	O
for	O
the	O
inclusion	O
of	O
sequences	O
into	O
PSI-BLAST	O
iterations	O
)	O
.	O

From	O
this	O
alignment	O
,	O
a	O
PSSM	O
is	O
constructed	O
.	O

The	O
PSSM	O
is	O
a	O
weight	O
matrix	O
indicating	O
the	O
relative	O
occurrence	O
of	O
each	O
of	O
the	O
20	O
aa	O
at	O
each	O
position	O
in	O
the	O
alignment	O
.	O

This	O
new	O
PSSM	O
is	O
used	O
as	O
the	O
score	O
matrix	O
for	O
a	O
new	O
BLAST	O
search	O
in	O
a	O
second	O
iteration	O
.	O

The	O
process	O
is	O
repeated	O
for	O
a	O
specific	O
number	O
of	O
iterations	O
or	O
until	O
convergence	O
,	O
when	O
no	B-Negation
additional	I-Negation
proteins	I-Negation
are	I-Negation
added	I-Negation
on	I-Negation
successive	I-Negation
iterations	I-Negation
.	O

The	O
use	O
of	O
a	O
PSSM	O
in	O
place	O
of	O
a	O
fixed	O
generic	O
substitution	O
matrix	O
such	O
as	O
BLOSUM62	O
results	O
in	O
a	O
much	O
more	O
sensitive	O
BLAST	O
search	O
[	O
18,45	O
]	O
.	O

Important	O
practical	O
aspects	O
of	O
using	O
PSI-BLAST	O
were	O
recently	O
described	O
[	O
46	O
]	O
.	O

To	O
ensure	O
that	O
a	B-Negation
conservation	I-Negation
profile	I-Negation
for	I-Negation
the	I-Negation
Transib	I-Negation
TPases	I-Negation
and	I-Negation
RAG1	I-Negation
proteins	I-Negation
was	I-Negation
not	I-Negation
produced	I-Negation
by	I-Negation
a	I-Negation
systematic	I-Negation
error	I-Negation
,	O
we	O
employed	O
a	O
procedure	O
of	O
	O
step-wise	O
	O
PSI-BLAST	O
iterations	O
.	O

In	O
this	O
procedure	O
we	O
studied	O
dependence	O
of	O
Ei	O
values	O
on	O
the	O
number	O
of	O
the	O
Transib	O
TPases	O
combined	O
with	O
the	O
GenBank	O
proteins	O
.	O

The	O
following	O
protocol	O
describes	O
the	O
procedure	O
:	O
(	O
1	O
)	O
Use	O
a	O
GenBank	O
set	O
combined	O
with	O
N	O
number	O
of	O
Transib	O
TPases	O
(	O
in	O
our	O
studies	O
,	O
N	O
was	O
equal	O
to	O
7	O
,	O
13	O
,	O
and	O
18	O
)	O
,	O
(	O
2	O
)	O
run	O
PSI-BLAST	O
against	O
GenBank	O
combined	O
with	O
TPases	O
using	O
each	O
TPase	O
as	O
a	O
query	O
or	O
seed	O
,	O
(	O
3	O
)	O
select	O
only	O
Transib	O
TPase	O
sequences	O
with	O
E-values	O
less	O
than	O
10-5	O
to	O
define	O
the	O
PSSM	O
,	O
(	O
4	O
)	O
take	O
the	O
best	O
E-value	O
(	O
Ei	O
)	O
obtained	O
by	O
PSI-BLAST	O
for	O
RAG1s	O
when	O
PSSM	O
is	O
constructed	O
without	B-Negation
RAG1	I-Negation
,	O
then	O
(	O
5	O
)	O
repeat	O
these	O
operations	O
for	O
different	O
numbers	O
(	O
N	O
)	O
of	O
TPases	O
.	O

Significant	O
convergence	O
of	O
RAG1	O
and	O
Transib	O
TPases	O
was	O
observed	O
to	O
be	O
independent	O
of	O
the	O
particular	O
type	O
of	O
substitution	O
matrix	O
(	O
the	O
same	O
result	O
was	O
observed	O
for	O
both	O
BLOSUM62	O
and	O
PAM70	O
matrixes	O
)	O
.	O

To	O
avoid	O
detection	O
of	O
false	O
similarities	O
caused	O
by	O
simple	O
repeats	O
and	O
coiled	O
coils	O
,	O
the	O
PSI-BLAST	O
search	O
was	O
performed	O
using	O
stringent	O
conditions	O
with	O
the	O
SEG	O
[	O
47	O
]	O
and	O
COILS	O
[	O
48	O
]	O
filters	O
masking	O
all	O
low-complexity	O
regions	O
and	O
coiled	O
coils	O
,	O
respectively	O
;	O
composition-based	O
statistics	O
[	O
45	O
]	O
were	O
also	O
employed	O
.	O

The	O
probability	O
P1	O
that	O
the	O
5	O
?	O
terminus	O
of	O
a	O
transposon	O
from	O
a	O
particular	O
Transib	O
family	O
would	O
match	O
by	O
chance	O
an	O
RSS	O
at	O
its	O
most	O
conserved	O
positions	O
(	O
positions	O
1-3	O
in	O
the	O
RSS	O
heptamer	O
,	O
and	O
positions	O
5	O
and	O
6	O
in	O
the	O
RSS	O
nonamer	O
)	O
was	O
estimated	O
based	O
on	O
the	O
following	O
formula	O
:	O
P1	O
=	O
fC	O
	O
fA	O
	O
fC	O
	O
fA	O
	O
fA	O
,	O
where	O
fC	O
(	O
0.2	O
)	O
and	O
fA	O
(	O
0.3	O
)	O
are	O
frequencies	O
of	O
C	O
and	O
A	O
in	O
a	O
set	O
of	O
38-bp	O
5	O
?	O
termini	O
of	O
Transib	O
transposons	O
from	O
21	O
families	O
(	O
see	O
Figure	O
4	O
)	O
.	O

The	O
value	O
of	O
P1	O
is	O
0.001	O
,	O
indicating	O
a	O
significant	O
similarity	O
between	O
Transib	O
TIRs	O
and	O
RSS	O
.	O

Indeed	O
,	O
given	O
that	O
these	O
five	O
positions	O
conserved	O
in	O
RSS	O
are	O
conserved	O
in	O
all	O
TIRs	O
from	O
21	O
families	O
of	O
Transib	O
transposons	O
,	O
and	O
the	O
average	O
identity	O
between	O
these	O
38-bp	O
TIRs	O
is	O
only	O
49	O
%	O
,	O
the	O
chance	O
of	O
randomly	O
matching	O
these	O
positions	O
in	O
TIRs	O
from	O
all	O
21	O
families	O
is	O
extremely	O
small	O
.	O

TBLASTN	O
searches	O
against	O
the	O
Trace	O
Archive	O
were	O
performed	O
by	O
using	O
the	O
BLAST	O
client	O
(	O
blastcl3	O
or	O
netblast	O
at	O
ftp	O
:	O
//ftp.ncbi.nlm.nih.gov/blast/executables/LATEST/	O
,	O
which	O
accesses	O
the	O
NCBI	O
BLAST	O
search	O
engine	O
.	O

Names	O
of	O
all	O
available	O
Trace	O
Databases	O
were	O
taken	O
from	O
a	O
list	O
of	O
databases	O
at	O
http	O
:	O
//www.ncbi.nlm.nih.gov/blast/mmtrace.shtml	O
.	O

Preferential	O
Insertion	O
of	O
Transib	O
transposons	O
into	O
GC-Rich	O
Sites	O

Each	O
of	O
the	O
35-bp	O
insertion	O
sites	O
corresponds	O
to	O
two	O
20-bp	O
DNA	O
fragments	O
flanking	O
a	O
genomic	O
Transib	O
element	O
at	O
its	O
5	O
?	O
and	O
3	O
?	O
termini	O
.	O

One	O
of	O
the	O
5-bp	O
TSDs	O
flanking	O
the	O
3	O
?	O
terminus	O
of	O
a	O
Transib	O
was	O
excluded	O
in	O
each	O
case	O
.	O

Analogously	O
,	O
the	O
15-bp	O
insertion	O
sites	O
were	O
composed	O
of	O
two	O
10-bp	O
flanking	O
fragm	O
.	O

Supporting	O
Information	O

Similarity	O
between	O
C-Terminal	O
Portions	O
of	O
the	O
Transib2_AG	O
TPase	O
and	O
RAG1	O

Two	O
examples	O
extracted	O
from	O
the	O
NCBI	O
BLASTP	O
output	O
illustrate	O
similarity	O
between	O
the	O
approximately	O
60-aa	O
C-terminal	O
portions	O
of	O
the	O
Transib2_AG	O
TPase	O
(	O
which	O
we	O
used	O
as	O
a	O
query	O
in	O
a	O
BLASTP	O
search	O
against	O
all	O
GenBank	O
proteins	O
)	O
and	O
the	O
RAG1	O
core	O
.	O

Multiple	O
Alignment	O
of	O
Transib	O
TPases	O

The	O
catalytic	O
DDE	O
triad	O
is	O
marked	O
by	O
black	O
rectangles	O
.	O

Amino	O
acids	O
are	O
shaded	O
on	O
the	O
basis	O
of	O
their	O
physiochemical	O
properties	O
according	O
to	O
the	O
color	O
scheme	O
implemented	O
in	O
Genedoc	O
[	O
43	O
]	O
:	O
Black	O
shading	O
marks	O
hydrophobic	O
residues	O
,	O
blue	O
indicates	O
charged	O
(	O
white	O
font	O
)	O
,	O
positively	O
charged	O
(	O
red	O
font	O
)	O
,	O
and	O
negatively	O
charged	O
(	O
green	O
font	O
)	O
;	O
red	O
indicates	O
proline	O
(	O
blue	O
font	O
)	O
and	O
glycine	O
(	O
green	O
font	O
)	O
;	O
gray	O
indicates	O
aliphatic	O
(	O
red	O
font	O
)	O
and	O
aromatic	O
(	O
blue	O
font	O
)	O
;	O
green	O
indicates	O
polar	O
(	O
black	O
font	O
)	O
and	O
amphoteric	O
(	O
red	O
font	O
)	O
;	O
yellow	O
indicates	O
tiny	O
(	O
blue	O
font	O
)	O
and	O
small	O
(	O
green	O
font	O
)	O
.	O

The	O
species	O
abbreviations	O
are	O
as	O
follows	O
:	O
SP	O
,	O
sea	O
urchin	O
;	O
DP	O
,	O
D.	O
pseudoobscura	O
fruit	O
fly	O
;	O
AG	O
,	O
African	O
malaria	O
mosquito	O
;	O
AA	O
,	O
yellow	O
fever	O
mosquito	O
.	O

Transib1	O
through	O
Transib5	O
are	O
from	O
the	O
D.	O
melanogaster	O
fruit	O
fly	O
genome	O
.	O

Multiple	O
Alignment	O
of	O
the	O
RAG1	O
Core	O
and	O
Transib	O
TPase	O
Proteins	O

The	O
shading	O
scheme	O
is	O
the	O
same	O
as	O
in	O
Figure	O
S2	O
.	O

The	O
catalytic	O
DDE	O
triad	O
is	O
marked	O
by	O
black	O
rectangles	O
.	O

RAG1	O
aa	O
whose	O
replacements	O
resulted	O
in	O
previously	O
detected	O
defects	O
of	O
V	O
(	O
D	O
)	O
J	O
recombination	O
[	O
31	O
]	O
are	O
marked	O
by	O
color	O
rectangles	O
indicated	O
below	O
the	O
alignment	O
blocks	O
;	O
red	O
indicates	O
DNA	O
binding	O
defect	O
;	O
green	O
indicates	O
nicking	O
defect	O
;	O
cyan	O
indicates	O
hairpin	O
defect	O
;	O
blue	O
indicates	O
joining	O
mutants	O
;	O
yellow	O
indicates	O
catalytic	O
mutants	O
;	O
gray	O
indicates	O
joining/transposition	O
.	O

Presence	O
and	O
absence	B-Negation
of	I-Negation
corresponding	I-Negation
residues	I-Negation
in	I-Negation
the	I-Negation
Transib	I-Negation
TPases	I-Negation
are	O
indicated	O
by	O
+	O
and	O
-	O
,	O
respectively	O
.	O

Conserved	O
motifs	O
are	O
marked	O
by	O
lines	O
numbered	O
from	O
1	O
to	O
10	O
.	O

The	O
species	O
abbreviations	O
are	O
as	O
follows	O
:	O
DP	O
,	O
D.	O
pseudoobscura	O
fruit	O
fly	O
;	O
AG	O
,	O
African	O
malaria	O
mosquito	O
;	O
AA	O
,	O
yellow	O
fever	O
mosquito	O
;	O
GG	O
,	O
chicken	O
;	O
HS	O
,	O
human	O
;	O
XL	O
,	O
frog	O
;	O
CL	O
,	O
bull	O
shark	O
;	O
FR	O
,	O
fugu	O
fish	O
.	O

TSDs	O
in	O
Transposons	O
from	O
Different	O
Transib	O
Families	O

For	O
each	O
family	O
,	O
DNA	O
copies	O
of	O
transposons	O
are	O
aligned	O
to	O
the	O
corresponding	O
consensus	O
sequence	O
.	O

The	O
consensus	O
sequence	O
is	O
shown	O
in	O
the	O
top	O
line	O
.	O

Dots	O
indicate	O
nucleotide	O
identity	O
with	O
the	O
consensus	O
sequence	O
;	O
hyphens	O
represent	O
alignment	O
gaps	O
.	O

Internal	B-Negation
portions	I-Negation
of	I-Negation
transposons	I-Negation
are	I-Negation
not	I-Negation
shown	I-Negation
and	O
are	O
marked	O
by	O
xxx	O
.	O

TSDs	O
are	O
highlighted	O
.	O

Coordinates	O
of	O
the	O
reported	O
elements	O
are	O
shown	O
in	O
the	O
first	O
two	O
columns	O
(	O
sequence	O
name	O
,	O
beginning	O
to	O
end	O
)	O
.	O

(	O
A	O
)	O
TransibN1_AG	O
family	O
from	O
mosquito	O
.	O

(	O
B	O
)	O
TransibN2_AG	O
family	O
from	O
mosquito	O
.	O

(	O
C	O
)	O
TransibN3_AG	O
family	O
from	O
mosquito	O
.	O

(	O
D	O
)	O
TransibN1_DP	O
family	O
from	O
fruit	O
fly	O
.	O

(	O
E	O
)	O
Hopper	O
family	O
from	O
fruit	O
fly	O
.	O

(	O
F	O
)	O
TransibN1_DM	O
family	O
from	O
fruit	O
fly	O
.	O

(	O
G	O
)	O
TransibN1_SP	O
family	O
from	O
sea	O
urchin	O
.	O

Multiple	O
Alignment	O
of	O
the	O
RAG1	O
Core	O
and	O
RAG1	O
CoreLike	O
Proteins	O
Encoded	O
by	O
the	O
Sea	O
Urchin	O
and	O
Lancelet	O
Genomes	O

The	O
shading	O
scheme	O
is	O
the	O
same	O
as	O
in	O
Figure	O
S2	O
and	O
S3	O
.	O

The	O
species	O
abbreviations	O
are	O
as	O
follows	O
:	O
SP	O
,	O
sea	O
urchin	O
;	O
BF	O
,	O
lancelet	O
;	O
HS	O
,	O
human	O
;	O
CL	O
,	O
bull	O
shark	O
;	O
GG	O
,	O
chicken	O
;	O
XL	O
,	O
frog	O
;	O
FR	O
,	O
fugu	O
fish	O
.	O

The	O
lancelet	O
RAG1L_BF	O
protein	O
is	O
encoded	O
by	O
several	O
overlapping	O
WGS	O
trace	O
sequences	O
(	O
for	O
example	O
,	O
GenBank	O
Trace	O
Archive	O
identification	O
numbers	O
543943730	O
,	O
538583629	O
)	O
.	O

RAG1-Like	O
Protein	O
SP_29068	O
in	O
the	O
Sea	O
Urchin	O
Contig	O
29068	O

(	O
A	O
)	O
Exon/intron	O
structure	O
of	O
the	O
SP_29068	O
gene	O
is	O
reported	O
based	O
on	O
the	O
FGENESH	O
prediction	O
.	O

(	O
B	O
)	O
Alignment	O
of	O
the	O
predicted	O
protein	O
and	O
human	O
RAG1	O
(	O
29	O
%	O
identity	O
,	O
E	O
=	O
10-43	O
.	O

The	O
intron	O
in	O
SP_29068	O
is	O
inserted	O
between	O
residues	O
shaded	O
in	O
green	O
and	O
red	O
.	O

Gly460	O
that	O
harbors	O
the	O
intron	O
in	O
the	O
teleost	O
RAG1	O
is	O
shaded	O
in	O
black	O
.	O

Structure	O
of	O
hAT	O
5	O
?	O
Termini	O

Non-gapped	O
alignment	O
of	O
consensus	O
sequences	O
of	O
5	O
?	O
termini	O
of	O
transposons	O
from	O
22	O
different	O
families	O
is	O
shown	O
beneath	O
the	O
RSS23	O
consensus	O
sequence	O
,	O
composed	O
of	O
the	O
RSS	O
heptamer	O
and	O
nonamer	O
.	O

The	O
most	O
conserved	O
nucleotides	O
in	O
the	O
heptamer	O
and	O
nonamer	O
,	O
which	O
are	O
necessary	O
for	O
efficient	O
V	O
(	O
D	O
)	O
J	O
recombination	O
,	O
are	O
highlighted	O
.	O

Among	O
the	O
necessary	O
RSS	O
nucleotides	O
,	O
only	O
one	O
,	O
marked	O
by	O
a	O
+	O
corresponds	O
to	O
a	O
nucleotide	O
that	O
is	O
100	O
%	O
conserved	O
in	O
hAT	O
transposons	O
.	O

The	O
critical	O
third	O
nucleotide	O
of	O
the	O
hAT	O
5	O
?	O
termini	O
is	O
always	O
G	O
,	O
as	O
opposed	O
to	O
C	O
in	O
the	O
RSS	O
heptamer	O
.	O

It	O
is	O
also	O
clear	O
from	O
the	O
alignment	O
that	O
the	O
hAT	O
termini	O
do	O
not	B-Negation
have	I-Negation
any	I-Negation
second	I-Negation
conserved	I-Negation
block	I-Negation
,	O
which	B-Speculation
is	I-Speculation
expected	I-Speculation
to	I-Speculation
be	I-Speculation
preserved	I-Speculation
if	I-Speculation
RSSs	I-Speculation
have	I-Speculation
evolved	I-Speculation
from	I-Speculation
hAT	I-Speculation
termini	I-Speculation
.	O

Hobo	O
(	O
GenBank	O
number	O
X04705	O
)	O
,	O
Homer	O
(	O
AF110403	O
)	O
,	O
Hermes	O
(	O
L34807	O
)	O
,	O
Ac9	O
(	O
K01904	O
)	O
,	O
Tam3_AM	O
(	O
X55078	O
)	O
,	O
TAG1	O
(	O
L12220	O
)	O
,	O
Pegasus	O
(	O
U47019	O
)	O
are	O
active	O
hAT	O
transposons	O
from	O
fruit	O
fly	O
,	O
Queensland	O
fruit	O
fly	O
,	O
house	O
fly	O
,	O
maize	O
,	O
snapdragon	O
,	O
thale-cress	O
,	O
and	O
African	O
malaria	O
mosquito	O
,	O
respectively	O
.	O

HOPPER_BD	O
is	O
from	O
oriental	O
fruit	O
fly	O
(	O
GenBank	O
AF486809	O
)	O
.	O

The	O
consensus	O
sequences	O
of	O
hAT-1N_DP	O
and	O
hAT-1N_DP	O
(	O
nonautonomous	O
transposons	O
from	O
fruit	O
fly	O
,	O
D.	O
pseudoobscura	O
)	O
;	O
HAT1N_DR	O
,	O
hAT-2n1_DR	O
,	O
and	O
hAT-N19_DR	O
(	O
nonautonomous	O
transposons	O
from	O
zebrafish	O
)	O
;	O
CHARLIE1A	O
and	O
CHESHIRE	O
(	O
human	O
)	O
;	O
hAT-N1_SP	O
(	O
sea	O
urchin	O
)	O
;	O
ATHAT1	O
,	O
ATHAT7	O
,	O
and	O
ATHAT10	O
(	O
thale-cress	O
)	O
;	O
PegasusA	O
,	O
HATN4_AG	O
,	O
and	O
hAT-2N_AG	O
(	O
African	O
malaria	O
mosquito	O
)	O
were	O
reported	O
in	O
Repbase	O
Update	O
.	O

Transib	O
TPase	O
in	O
Eukaryotes	O

Columns	O
1	O
and	O
2	O
list	O
common	O
and	O
Latin	O
names	O
of	O
species	O
whose	O
genomes	O
contain	O
Transib	O
TPase	O
sequences	O
.	O

Column	O
3	O
shows	O
GenBank	O
sections	O
collecting	O
corresponding	O
sequences	O
:	O
``	O
NR	O
``	O
,	O
``	O
WGS	O
``	O
,	O
``	O
EST	O
``	O
,	O
and	O
``	O
HTGS	O
``	O
are	O
names	O
of	O
GenBank	O
sections	O
;	O
``	O
tr	O
``	O
stands	O
for	O
	O
Trace	O
Archives.	O
	O
Column	O
4	O
shows	O
a	O
range	O
of	O
E-values	O
of	O
matches	O
between	O
the	O
sea	O
urchin	O
Transib	O
TPase	O
(	O
Transib1_SP	O
)	O
and	O
TPases	O
encoded	O
by	O
the	O
listed	O
species	O
that	O
were	O
detected	O
in	O
TBLASTN	O
searches	O
against	O
corresponding	O
sections	O
of	O
GenBank	O
.	O

Matches	O
to	O
the	O
Transib	O
TPase	O
observed	O
for	O
Oryza	O
sativa	O
indica	O
(	O
seven	O
sequences	O
from	O
Trace	O
Archives	O
,	O
10-48	O
<	O
E	O
<	O
10-13	O
)	O
were	O
discarded	O
as	O
a	O
likely	O
sequencing	O
contamination	O
,	O
based	O
on	O
the	O
fact	O
that	O
these	O
sequences	O
were	O
over	O
80	O
%	O
identical	O
to	O
Hydra	O
magnipapillata	O
traces	O
(	O
the	O
hydra	O
Trace	O
Archive	O
dataset	O
contains	O
over	O
100	O
sequences	O
matching	O
the	O
TPase	O
,	O
and	O
hydra	O
Transib	O
TPase	O
sequences	O
are	O
also	O
present	O
in	O
the	O
dbEST	O
section	O
of	O
GenBank	O
)	O
.	O

Analogously	O
,	O
matches	O
to	O
the	O
Transib	O
TPase	O
detected	O
in	O
the	O
AC011430	O
HTGs	O
and	O
AADC01054609	O
WGS	O
GenBank	O
sequences	O
,	O
which	O
were	O
annotated	O
as	O
portions	O
of	O
the	O
human	O
genome	O
,	O
were	O
discarded	O
as	O
products	O
of	O
contamination	O
(	O
these	O
sequences	O
contain	O
100	O
%	O
identical	O
copies	O
of	O
the	O
non-long	O
terminal	O
repeat	O
(	O
LTR	O
)	O
retrotransposon	O
G2_DM	O
[	O
17	O
]	O
from	O
D.	O
melanogaster	O
)	O
.	O

GC	O
Content	O
of	O
Target	O
Sites	O
for	O
hAT	O
Transposons	O

The	O
table	O
shows	O
that	O
hAT	O
transposons	O
are	O
inserted	O
preferentially	O
into	O
GC-rich	O
sites	O
.	O

Each	O
of	O
the	O
35-bp	O
insertion	O
sites	O
corresponds	O
to	O
two	O
14-bp	O
and	O
13-bp	O
DNA	O
fragments	O
flanking	O
a	O
genomic	O
hAT	O
element	O
at	O
its	O
5	O
?	O
and	O
3	O
?	O
termini	O
;	O
one	O
of	O
the	O
8-bp	O
TSDs	O
(	O
flanking	O
the	O
3	O
?	O
terminus	O
of	O
a	O
transposon	O
)	O
was	O
excluded	O
in	O
each	O
case	O
.	O

Analogously	O
,	O
the	O
15-bp	O
insertion	O
sites	O
were	O
composed	O
of	O
two	O
4-bp	O
and	O
3-bp	O
flanking	O
fragments	O
.	O

(	O
1	O
)	O
GenBank	O
accession	O
number	O
U47019	O
;	O
(	O
2	O
)	O
Repbase	O
Update	O
,	O
the	O
angrep.ref	O
section	O
;	O
(	O
3	O
)	O
GenBank	O
X04705	O
;	O
(	O
4	O
)	O
Repbase	O
Update	O
,	O
the	O
drorep.ref	O
section	O
;	O
(	O
5	O
)	O
Repbase	O
Update	O
,	O
spurep.ref	O
;	O
(	O
6	O
)	O
Repbase	O
Updates	O
,	O
the	O
zebrep.ref	O
section	O
.	O

Copies	O
of	O
Pegasus	O
,	O
HATN4_AG	O
,	O
and	O
HAT2N_AG	O
were	O
identified	O
in	O
the	O
mosquito	O
A.	O
gambiae	O
genome	O
;	O
Hobo	O
and	O
hAT-1N_DP	O
in	O
the	O
D.	O
melanogaster	O
and	O
D.	O
pseudoobscura	O
fruit	O
fly	O
genomes	O
,	O
respectively	O
;	O
HAT-1N_SP	O
in	O
the	O
sea	O
urchin	O
genome	O
;	O
and	O
HAT1N_DR	O
,	O
HAT-2N1_DR	O
,	O
and	O
HAT-N19_DR	O
in	O
the	O
zebrafish	O
genome	O
.	O

A	O
Role	O
for	O
Adenosine	O
Deaminase	O
in	O
Drosophila	O
Larval	O
Development	O

Abstract	O

Adenosine	O
deaminase	O
(	O
ADA	O
)	O
is	O
an	O
enzyme	O
present	O
in	O
all	O
organisms	O
that	O
catalyzes	O
the	O
irreversible	O
deamination	O
of	O
adenosine	O
and	O
deoxyadenosine	O
to	O
inosine	O
and	O
deoxyinosine	O
.	O

Both	O
adenosine	O
and	O
deoxyadenosine	O
are	O
biologically	O
active	O
purines	O
that	O
can	O
have	O
a	O
deep	O
impact	O
on	O
cellular	O
physiology	O
;	O
notably	O
,	O
ADA	O
deficiency	O
in	O
humans	O
causes	O
severe	O
combined	O
immunodeficiency	O
.	O

We	O
have	O
established	O
a	O
Drosophila	O
model	O
to	O
study	O
the	O
effects	O
of	O
altered	O
adenosine	O
levels	O
in	O
vivo	O
by	O
genetic	O
elimination	O
of	O
adenosine	O
deaminase-related	O
growth	O
factor-A	O
(	O
ADGF-A	O
)	O
,	O
which	O
has	O
ADA	O
activity	O
and	O
is	O
expressed	O
in	O
the	O
gut	O
and	O
hematopoietic	O
organ	O
.	O

Here	O
we	O
show	O
that	O
the	O
hemocytes	O
(	O
blood	O
cells	O
)	O
are	O
the	O
main	O
regulator	O
of	O
adenosine	O
in	O
the	O
Drosophila	O
larva	O
,	O
as	O
was	O
speculated	O
previously	O
for	O
mammals	O
.	O

The	O
elevated	O
level	O
of	O
adenosine	O
in	O
the	O
hemolymph	O
due	O
to	O
lack	B-Negation
of	I-Negation
ADGF-A	I-Negation
leads	O
to	O
apparently	B-Speculation
inconsistent	I-Speculation
phenotypic	I-Speculation
effects	I-Speculation
:	O
precocious	O
metamorphic	O
changes	O
including	O
differentiation	O
of	O
macrophage-like	O
cells	O
and	O
fat	O
body	O
disintegration	O
on	O
one	O
hand	O
,	O
and	O
delay	O
of	O
development	O
with	O
block	O
of	O
pupariation	O
on	O
the	O
other	O
.	O

The	O
block	O
of	O
pupariation	O
appears	O
to	O
involve	O
signaling	O
through	O
the	O
adenosine	O
receptor	O
(	O
AdoR	O
)	O
,	O
but	O
fat	O
body	O
disintegration	O
,	O
which	O
is	O
promoted	O
by	O
action	O
of	O
the	O
hemocytes	O
,	O
seems	O
to	O
be	O
independent	O
of	O
the	O
AdoR	O
.	O

The	O
existence	O
of	O
such	O
an	O
independent	O
mechanism	O
has	O
also	O
been	O
suggested	O
in	O
mammals	O
.	O

Introduction	O

Adenosine	O
deaminase	O
(	O
ADA	O
)	O
is	O
an	O
enzyme	O
present	O
in	O
all	O
organisms	O
that	O
catalyzes	O
the	O
irreversible	O
deamination	O
of	O
adenosine	O
and	O
deoxyadenosine	O
to	O
inosine	O
and	O
deoxyinosine	O
.	O

It	O
is	O
a	O
critically	O
important	O
enzyme	O
for	O
human	O
survival	O
because	O
its	O
congenital	O
absence	O
causes	O
severe	O
combined	O
immunodeficiency	O
disease	O
(	O
SCID	O
)	O
.	O

ADA	O
deficiency	O
accounts	O
for	O
about	O
20	O
%	O
of	O
all	O
types	O
of	O
SCID	O
[	O
1	O
]	O
.	O

It	O
is	O
one	O
of	O
the	O
most	O
severe	O
human	O
immunodeficiencies	O
and	O
is	O
associated	O
with	O
depletion	O
of	O
all	O
three	O
major	O
categories	O
of	O
lymphocytes	O
:	O
T	O
cells	O
,	O
B	O
cells	O
,	O
and	O
natural	O
killer	O
cells	O
,	O
resulting	O
in	O
impaired	O
cellular	O
immunity	O
and	O
decreased	O
production	O
of	O
immunoglobulins	O
[	O
2	O
]	O
.	O

Without	B-Negation
intervention	I-Negation
,	O
the	O
affected	O
individuals	O
die	O
from	O
opportunistic	O
infections	O
within	O
the	O
first	O
few	O
months	O
of	O
life	O
.	O

ADA	O
occurs	O
as	O
a	O
soluble	O
monomer	O
in	O
all	O
human	O
cells	O
,	O
but	O
also	O
exists	O
as	O
	O
ecto-ADA	O
,	O
	O
bound	O
to	O
the	O
membrane	O
glycoprotein	O
CD26/dipeptidyl	O
peptidase	O
IV	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
this	O
form	O
of	O
ADA	O
regulates	O
extracellular	O
adenosine	O
levels	O
[	O
3	O
]	O
.	O

ADA	O
deficiency	O
is	O
accompanied	O
by	O
greatly	O
elevated	O
levels	O
of	O
the	O
ADA	O
substrates	O
adenosine	O
and	O
deoxyadenosine	O
,	O
both	O
of	O
which	O
are	O
biologically	O
active	O
purines	O
that	O
can	O
have	O
a	O
deep	O
impact	O
on	O
cellular	O
physiology	O
.	O

Adenosine	O
is	O
not	O
just	O
a	O
metabolite	O
;	O
it	O
is	O
also	O
a	O
signaling	O
molecule	O
that	O
regulates	O
numerous	O
cellular	O
functions	O
by	O
binding	O
to	O
G	O
protein-coupled	O
adenosine	O
receptors	O
(	O
A1	O
,	O
A2a	O
,	O
A2b	O
,	O
and	O
A3	O
in	O
mammals	O
)	O
that	O
can	O
regulate	O
intracellular	O
cyclic	O
adenosine	O
monophosphate	O
[	O
4	O
]	O
.	O

Deoxyadenosine	O
is	O
a	O
cytotoxic	O
metabolite	O
released	O
by	O
various	O
cell	O
populations	O
that	O
undergo	O
programmed	O
cell	O
death	O
;	O
it	O
can	O
kill	O
cells	O
through	O
a	O
mechanism	O
that	O
includes	O
disturbances	O
in	O
deoxynucleotide	O
metabolism	O
[	O
5	O
]	O
.	O

Extracellular	O
adenosine	O
is	O
now	O
considered	O
an	O
important	O
stress	O
hormone	O
that	O
is	O
released	O
in	O
excessive	O
amounts	O
in	O
the	O
vicinity	O
of	O
immune	O
cells	O
during	O
both	O
systemic	O
and	O
cellular	O
stress	O
[	O
6	O
]	O
.	O

The	O
predominant	O
source	O
of	O
extracellular	O
adenosine	O
during	O
systemic	O
activation	O
of	O
the	O
stress	O
system	O
is	O
the	O
sympathetic	O
nervous	O
system	O
[	O
7	O
]	O
.	O

Specific	O
inflammatory	O
stimuli	O
such	O
as	O
bacterial	O
products	O
are	O
also	O
capable	O
of	O
triggering	O
adenosine	O
release	O
from	O
immune	O
cells	O
[	O
8	O
]	O
.	O

These	O
data	O
are	O
in	O
line	O
with	O
evidence	O
demonstrating	O
a	O
dramatic	O
increase	O
in	O
extracellular	O
adenosine	O
levels	O
under	O
conditions	O
associated	O
with	O
multiple	O
organ	O
failure	O
,	O
which	O
is	O
the	O
cause	O
of	O
50	O
%	O
80	O
%	O
of	O
all	O
deaths	O
in	O
surgical	O
intensive	O
care	O
units	O
[	O
6	O
]	O
.	O

ADA	O
is	O
not	B-Negation
the	I-Negation
only	I-Negation
adenosine	I-Negation
deaminase	I-Negation
in	I-Negation
mammalian	I-Negation
cells	I-Negation
.	O

Recently	O
,	O
the	O
cat	O
eye	O
syndrome	O
critical	O
region	O
protein	O
1	O
(	O
CECR1	O
)	O
gene	O
was	O
identified	O
and	O
shown	O
to	O
encode	O
a	O
protein	O
representing	O
a	O
subfamily	O
of	O
proteins	O
related	O
to	O
but	O
distinct	O
from	O
classical	O
ADAs	O
[	O
9	O
]	O
.	O

The	O
duplication	O
of	O
a	O
small	O
region	O
of	O
chromosome	O
22	O
containing	O
this	O
gene	O
is	O
associated	O
with	O
	O
cat	O
eye	O
syndrome	O
,	O
	O
a	O
disorder	O
characterized	O
by	O
hypoplastic	O
kidneys	O
,	O
congenital	O
heart	O
malformation	O
,	O
and	O
anomalous	O
pulmonary	O
venous	O
connections	O
.	O

The	O
founding	O
member	O
of	O
this	O
subfamily	O
is	O
encoded	O
by	O
insect-derived	O
growth	O
factor	O
(	O
IDGF	O
)	O
[	O
10	O
]	O
,	O
and	O
homologs	O
have	O
been	O
described	O
in	O
various	O
organisms	O
[	O
1114	O
]	O
.	O

We	O
have	O
previously	O
found	O
six	O
Drosophila	O
genes	O
with	O
sequence	O
similarity	O
to	O
the	O
CECR1	O
subfamily	O
[	O
15	O
]	O
.	O

Their	O
products	O
are	O
mitogenic	O
on	O
Drosophila	O
cells	O
,	O
and	O
at	O
least	O
two	O
of	O
them	O
(	O
ADGF-A	O
and	O
ADGF-D	O
)	O
exhibit	O
strong	O
ADA	O
activity	O
,	O
which	O
is	O
necessary	O
for	O
their	O
mitogenic	O
function	O
.	O

We	O
therefore	O
named	O
them	O
adenosine	O
deaminase-related	O
growth	O
factors	O
(	O
ADGFs	O
)	O
.	O

We	O
also	O
demonstrated	O
that	O
adenosine	O
functions	O
as	O
a	O
negative	O
signal	O
for	O
cell	O
proliferation	O
and	O
concluded	O
that	O
ADGFs	O
stimulate	O
cell	O
growth	O
in	O
vitro	O
by	O
depletion	O
of	O
extracellular	O
adenosine	O
[	O
16	O
]	O
.	O

Drosophila	O
also	O
contains	O
a	O
gene	O
,	O
termed	O
Ada	O
,	O
with	O
sequence	O
similarity	O
to	O
human	O
ADA	O
,	O
but	O
as	O
we	O
have	O
previously	O
shown	O
the	O
product	O
of	O
this	O
gene	O
is	O
most	O
likely	O
not	O
an	O
active	O
ADA	O
[	O
16	O
]	O
.	O

In	O
this	O
report	O
we	O
show	O
that	O
a	O
null	O
mutation	O
in	O
Drosophila	O
ADGF-A	O
gene	O
leads	O
to	O
dramatically	O
increased	O
levels	O
of	O
adenosine	O
and	O
deoxyadenosine	O
in	O
the	O
larval	O
hemolymph	O
.	O

This	O
increase	O
leads	O
to	O
larval	O
death	O
associated	O
with	O
the	O
disintegration	O
of	O
fat	O
body	O
and	O
the	O
development	O
of	O
melanotic	O
tumors	O
.	O

We	O
present	O
a	O
detailed	O
analysis	O
of	O
the	O
hematopoietic	O
defects	O
associated	O
with	O
the	O
adgf-a	O
mutation	O
,	O
show	O
a	O
genetic	O
interaction	O
of	O
this	O
mutation	O
with	O
signaling	O
through	O
the	O
Drosophila	O
adenosine	O
receptor	O
(	O
AdoR	O
,	O
encoded	O
by	O
the	O
gene	O
CG9753	O
)	O
and	O
with	O
regulation	O
of	O
premetamorphic	O
changes	O
by	O
ecdysone	O
,	O
as	O
well	O
as	O
a	O
genetic	O
interaction	O
of	O
ADGF-A	O
with	O
a	O
major	O
innate	O
immunity	O
regulatorthe	O
Toll	O
signaling	O
pathway	O
.	O

Results	O

Mutation	O
in	O
the	O
ADGF-A	O
Gene	O
Causes	O
Larval	O
Death	O
and	O
Melanotic	O
Tumors	O

We	O
produced	O
mutations	O
in	O
five	O
of	O
the	O
six	O
ADGF	O
genes	O
by	O
homologous	O
recombination	O
mutagenesis	O
[	O
17	O
]	O
and	O
showed	O
that	O
loss	O
of	O
the	O
most	O
abundantly	O
expressed	O
gene	O
,	O
ADGF-A	O
,	O
leads	O
to	O
death	O
in	O
the	O
larval	O
or	O
pupal	O
stage	O
.	O

Under	O
optimal	O
conditions	O
(	O
2030	O
isolated	O
homozygous	O
larvae	O
per	O
vial	O
)	O
,	O
about	O
60	O
%	O
of	O
larvae	O
homozygous	O
for	O
the	O
adgf-a	O
mutation	O
reach	O
the	O
third	O
instar	O
.	O

Development	O
during	O
the	O
third	O
larval	O
instar	O
is	O
significantly	O
delayed	O
,	O
and	O
wandering	O
homozygous	O
larvae	O
usually	O
appear	O
2	O
d	O
after	O
their	O
heterozygous	O
siblings	O
,	O
which	O
start	O
wandering	O
at	O
about	O
5	O
d	O
of	O
development	O
.	O

Some	O
homozygous	O
third-instar	O
larvae	O
can	O
be	O
found	O
alive	O
in	O
the	O
vial	O
even	O
after	O
10	O
d	O
of	O
development	O
.	O

Mutant	O
third-instar	O
larvae	O
show	O
fat	O
body	O
disintegration	O
(	O
Figure	O
1A	O
and	O
1B	O
)	O
and	O
multiple	O
melanotic	O
tumors	O
(	O
Figure	O
1C	O
)	O
,	O
predominantly	O
in	O
the	O
caudal	O
part	O
of	O
the	O
body	O
and	O
accompanied	O
by	O
disintegration	O
of	O
the	O
fat	O
body	O
.	O

Melanization	B-Negation
of	I-Negation
the	I-Negation
lymph	I-Negation
glands	I-Negation
was	I-Negation
never	I-Negation
observed	I-Negation
in	I-Negation
these	I-Negation
larvae	I-Negation
,	O
and	O
the	O
imaginal	O
discs	O
and	O
brain	O
appear	O
normal	O
.	O

Less	O
than	O
30	O
%	O
of	O
homozygotes	O
eventually	O
pupate	O
.	O

Homozygous	O
pupae	O
usually	O
die	O
soon	O
after	O
pupariation	O
;	O
in	O
some	O
cases	O
they	O
develop	O
normal	O
head	O
and	O
thorax	O
imaginal	O
structures	O
;	O
however	O
,	O
abdominal	O
parts	O
usually	O
do	O
not	B-Negation
develop	I-Negation
.	O

There	O
is	O
also	O
an	O
abnormal	O
curvature	O
(	O
to	O
the	O
right	O
)	O
of	O
the	O
pupal	O
abdomen	O
(	O
Figure	O
1D	O
)	O
.	O

Less	O
than	O
2	O
%	O
of	O
mutant	O
pupae	O
develop	O
normally	O
and	O
eventually	O
emerge	O
as	O
adults	O
without	B-Negation
any	I-Negation
obvious	I-Negation
abnormalities	I-Negation
besides	I-Negation
the	I-Negation
abdominal	I-Negation
curvature	I-Negation
;	O
some	O
of	O
them	O
are	O
sterile	O
.	O

To	O
confirm	O
that	O
the	O
mutant	O
phenotype	O
is	O
caused	O
solely	O
by	O
a	O
mutation	O
in	O
the	O
ADGF-A	O
gene	O
,	O
we	O
created	O
transgenic	O
flies	O
carrying	O
the	O
ADGF-A	O
gene	O
under	O
a	O
heat-shock	O
promoter	O
(	O
HS-ADGF-A	O
)	O
.	O

The	O
adgf-a	O
homozygous	O
flies	O
carrying	O
the	O
HS-ADGF-A	O
construct	O
showed	O
survival	O
rates	O
significantly	O
higher	O
than	O
adgf-a	O
even	O
without	B-Negation
heat	I-Negation
shock	I-Negation
,	O
probably	B-Speculation
due	I-Speculation
to	I-Speculation
leaky	I-Speculation
expression	I-Speculation
of	I-Speculation
the	I-Speculation
HS-ADGF-A	I-Speculation
construct	I-Speculation
(	O
Figure	O
2A	O
)	O
.	O

However	O
,	O
while	O
non-heat	O
shocked	O
animals	O
still	O
produced	O
many	O
melanotic	O
tumors	O
,	O
only	O
22	O
%	O
of	O
animals	O
that	O
were	O
heat	O
shocked	O
as	O
late	O
embryos/early	O
first	O
instar	O
developed	O
these	O
tumors	O
(	O
Figure	O
2B	O
)	O
.	O

This	O
result	O
confirms	O
that	O
the	O
mutant	O
phenotype	O
is	O
caused	O
by	O
the	O
mutation	O
in	O
the	O
ADGF-A	O
gene	O
.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
even	O
more	O
efficient	O
rescue	O
achieved	O
by	O
expression	O
of	O
transgenically	O
provided	O
ADGF-A	O
in	O
the	O
lymph	O
glands	O
using	O
the	O
Gal4/UAS	O
system	O
(	O
see	O
below	O
)	O
.	O

adgf-a	O
Mutant	O
Phenotype	O

(	O
A	O
and	O
B	O
)	O
Fat	O
body	O
disintegration	O
visualized	O
by	O
GFP	O
expression	O
driven	O
by	O
Cg-Gal4	O
driver	O
in	O
the	O
fat	O
body	O
.	O

While	O
adgf-a/+	O
heterozygous	O
third	O
instar	O
larvae	O
have	O
normal	O
flat	O
layers	O
of	O
fat	O
body	O
(	O
A	O
)	O
,	O
adgf-a	O
mutant	O
showed	O
extensive	O
fat	O
body	O
disintegration	O
into	O
small	O
pieces	O
of	O
tissue	O
(	O
B	O
)	O
.	O

(	O
C	O
)	O
Multiple	O
melanotic	O
tumors	O
present	O
in	O
adgf-a	O
mutant	O
third-instar	O
larva	O
.	O

(	O
D	O
)	O
An	O
adgf-a	O
mutant	O
pupa	O
with	O
typical	O
abdominal	O
curvature	O
.	O

Rescue	O
of	O
the	O
adgf-a	O
Mutant	O
Phenotype	O
by	O
Expression	O
of	O
ADGF-A	O
in	O
Different	O
Tissues	O

(	O
A	O
)	O
Percentage	O
of	O
pupae	O
(	O
blue	O
bars	O
)	O
and	O
adult	O
flies	O
(	O
purple	O
bars	O
)	O
demonstrating	O
the	O
larval	O
and	O
pupal	O
survival	O
,	O
respectively	O
,	O
of	O
the	O
adgf-a	O
mutant	O
flies	O
rescued	O
by	O
expression	O
of	O
transgenic	O
ADGF-A	O
in	O
different	O
tissues	O
.	O

Along	O
the	O
x-axis	O
(	O
which	O
is	O
shared	O
with	O
[	O
B	O
]	O
)	O
,	O
the	O
rescue	O
experiments	O
are	O
shown	O
(	O
marked	O
by	O
the	O
Gal4	O
driver	O
used	O
for	O
expression	O
of	O
ADGF-A	O
except	O
for	O
first	O
three	O
sets	O
of	O
barsthe	O
first	O
set	O
presents	O
only	O
an	O
adgf-a	O
mutant	O
,	O
the	O
second	O
an	O
adgf-a	O
mutant	O
carrying	O
HS-ADGF-A	O
construct	O
without	B-Negation
heat	I-Negation
shock	I-Negation
,	O
and	O
the	O
third	O
with	O
heat	O
shock	O
)	O
and	O
the	O
y-axis	O
represents	O
percentage	O
of	O
pupae	O
and	O
adult	O
flies	O
out	O
of	O
the	O
total	O
number	O
of	O
transferred	O
first-instar	O
larvae	O
of	O
particular	O
genotype	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
four	O
times	O
(	O
with	O
2030	O
animals	O
in	O
each	O
vial	O
)	O
and	O
the	O
standard	O
error	O
is	O
shown	O
.	O

(	O
B	O
)	O
Percentage	O
of	O
late	O
third-instar	O
larvae	O
with	O
melanotic	O
tumors	O
.	O

The	O
x-axis	O
is	O
shared	O
with	O
(	O
A	O
)	O
(	O
described	O
above	O
)	O
.	O

The	O
y-axis	O
shows	O
the	O
percentage	O
of	O
larvae	O
with	O
tumors	O
out	O
of	O
all	O
larvae	O
of	O
each	O
genotype	O
examined	O
for	O
(	O
A	O
)	O
.	O

The	O
adgf-a	O
Mutant	O
Phenotype	O
Is	O
Associated	O
with	O
Elevated	O
Levels	O
of	O
Adenosine	O
and/or	O
Deoxyadenosine	O

Using	O
liquid	O
chromatography	O
and	O
mass	O
spectrometry	O
of	O
deproteinated	O
hemolymph	O
samples	O
,	O
we	O
measured	O
adenosine	O
concentrations	O
in	O
hemolymph	O
of	O
mutant	O
and	O
wild-type	O
third-instar	O
larvae	O
.	O

The	O
adenosine	O
concentration	O
in	O
the	O
adgf-a	O
mutant	O
was	O
1.14	O
	O
0.26	O
?	O
M	O
compared	O
to	O
less	O
than	O
0.08	O
?	O
M	O
in	O
the	O
wild	O
type	O
,	O
and	O
the	O
deoxyadenosine	O
concentration	O
in	O
mutants	O
was	O
1.66	O
	O
0.99	O
?	O
M	O
compared	O
to	O
an	O
undetectable	O
level	O
in	O
the	O
wild	O
type	O
.	O

The	O
Catalytic	O
Activity	O
of	O
ADGF-A	O
Is	O
Required	O
for	O
Its	O
Function	O

To	O
test	O
whether	O
the	O
function	O
of	O
ADGF-A	O
in	O
vivo	O
is	O
also	O
dependent	O
on	O
its	O
catalytic	O
activity	O
,	O
we	O
produced	O
two	O
versions	O
of	O
the	O
UAS-ADGF-A	O
construct	O
[	O
18	O
]	O
:	O
one	O
carrying	O
wild-type	O
cDNA	O
of	O
ADGF-A	O
and	O
one	O
carrying	O
an	O
ADGF-A	O
cDNA	O
with	O
a	O
mutation	O
causing	O
a	O
substitution	O
of	O
two	O
amino	O
acids	O
(	O
H386G	O
and	O
A387E	O
)	O
in	O
the	O
catalytic	O
domain	O
[	O
16	O
]	O
.	O

Two	O
different	O
lines	O
carrying	O
the	O
wild-type	O
UAS-ADGF-A	O
expression	O
construct	O
together	O
with	O
an	O
Actin-Gal4	O
driver	O
(	O
providing	O
ubiquitous	O
expression	O
)	O
both	O
completely	O
rescued	O
the	O
mutant	O
phenotype	O
,	O
whereas	O
larvae	O
with	O
UAS-ADGF-A	O
but	O
without	B-Negation
the	I-Negation
driver	I-Negation
showed	O
the	O
typical	O
mutant	O
phenotype	O
.	O

However	O
,	O
neither	B-Negation
of	I-Negation
the	I-Negation
two	I-Negation
lines	I-Negation
carrying	I-Negation
the	I-Negation
mutated	I-Negation
version	I-Negation
of	I-Negation
the	I-Negation
UAS-ADGF-A	I-Negation
(	I-Negation
producing	I-Negation
full-length	I-Negation
protein	I-Negation
detected	I-Negation
by	I-Negation
anti-myc	I-Negation
antibody	I-Negation
;	I-Negation
see	I-Negation
Materials	I-Negation
and	I-Negation
Methods	I-Negation
)	I-Negation
showed	I-Negation
any	I-Negation
rescue	I-Negation
of	I-Negation
the	I-Negation
mutant	I-Negation
phenotype	I-Negation
.	O

This	O
result	O
therefore	O
demonstrates	O
that	O
the	O
catalytic	O
activity	O
of	O
ADGF-A	O
is	O
required	O
for	O
its	O
function	O
in	O
vivo	O
.	O

Hemocyte	O
Development	O
Is	O
Affected	O
in	O
the	O
adgf-a	O
Mutant	O

We	O
investigated	O
the	O
number	O
and	O
morphology	O
of	O
hemocytes	O
(	O
blood	O
cells	O
)	O
in	O
the	O
hemolymph	O
of	O
the	O
adgf-a	O
late	O
third-instar	O
larvae	O
(	O
Figures	O
3	O
and	O
4	O
)	O
.	O

These	O
larvae	O
contain	O
an	O
average	O
of	O
seven-fold	O
more	O
hemocytes	O
in	O
circulation	O
than	O
wild-type	O
larvae	O
(	O
Figure	O
3	O
)	O
.	O

In	O
contrast	O
to	O
normal	O
larval	O
plasmatocytes	O
,	O
which	O
remain	O
rounded	O
after	O
settling	O
down	O
on	O
the	O
substrate	O
(	O
Figure	O
4A	O
)	O
,	O
most	O
of	O
the	O
cells	O
in	O
the	O
adgf-a	O
mutant	O
(	O
more	O
than	O
75	O
%	O
)	O
are	O
strongly	O
adhesive	O
and	O
,	O
after	O
they	O
are	O
deposited	O
in	O
a	O
drop	O
of	O
hemolymph	O
on	O
a	O
microscope	O
slide	O
,	O
develop	O
filamentous	O
and	O
membranous	O
extensions	O
(	O
Figure	O
4B4D	O
)	O
.	O

An	O
average	O
of	O
7	O
%	O
of	O
hemocytes	O
in	O
the	O
adgf-a	O
mutant	O
are	O
lamellocytes	O
(	O
Figures	O
3	O
and	O
4E	O
)	O
,	O
large	O
flat	O
cells	O
that	O
are	O
not	B-Negation
present	I-Negation
in	I-Negation
circulation	I-Negation
of	I-Negation
wild-type	I-Negation
larvae	I-Negation
under	I-Negation
normal	I-Negation
conditions	I-Negation
[	O
19	O
]	O
.	O

Crystal	O
cells	O
were	O
also	O
detected	O
in	O
excess	O
,	O
with	O
mutant	O
larvae	O
carrying	O
several	O
hundred	O
while	O
there	O
are	O
fewer	O
than	O
a	O
hundred	O
of	O
these	O
cells	O
in	O
the	O
wild	O
type	O
(	O
Figure	O
5	O
)	O
.	O

The	O
lymph	O
glands	O
normally	O
do	O
not	B-Negation
release	I-Negation
hemocytes	I-Negation
into	I-Negation
the	I-Negation
hemolymph	I-Negation
before	I-Negation
metamorphosis	I-Negation
[	O
20	O
]	O
;	O
instead	O
,	O
they	O
are	O
released	O
during	O
metamorphosis	O
when	O
the	O
lymph	O
glands	O
disperse	O
[	O
19	O
]	O
.	O

However	O
,	O
the	O
lymph	O
glands	O
of	O
adgf-a	O
mutant	O
larvae	O
are	O
already	O
dispersed	O
in	O
the	O
late	O
third	O
instar	O
.	O

This	O
process	O
is	O
similar	O
to	O
normal	O
metamorphic	O
changes	O
,	O
in	O
which	O
the	O
hemocytes	O
are	O
first	O
released	O
from	O
the	O
front	O
lobes	O
,	O
and	O
the	O
posterior	O
lobes	O
disperse	O
later	O
.	O

To	O
analyze	O
hemocytes	O
in	O
living	O
larvae	O
,	O
we	O
used	O
the	O
Hemolectin	O
marker	O
(	O
Hml	O
)	O
[	O
21	O
]	O
.	O

We	O
compared	O
the	O
number	O
and	O
distribution	O
of	O
hemocytes	O
stained	O
by	O
GFP	O
in	O
flies	O
carrying	O
hml-Gal4	O
UAS-GFP	O
in	O
wild-type	O
and	O
mutant	O
backgrounds	O
.	O

While	O
there	O
are	O
relatively	O
few	O
hemocytes	O
,	O
mostly	O
free-floating	O
in	O
the	O
hemolymph	O
,	O
in	O
early	O
third-instar	O
wild-type	O
larvae	O
(	O
see	O
Figure	O
4I	O
)	O
,	O
a	O
much	O
higher	O
number	O
of	O
hemocytes	O
,	O
which	O
are	O
mostly	O
attached	O
to	O
the	O
tissues	O
under	O
the	O
integument	O
(	O
described	O
as	O
sessile	O
hemocytes	O
in	O
[	O
19	O
]	O
)	O
,	O
was	O
observed	O
in	O
mutant	O
larvae	O
(	O
see	O
Figure	O
4J	O
)	O
.	O

A	O
similar	O
behavior	O
was	O
detected	O
later	O
in	O
wild-type	O
larvae	O
,	O
toward	O
the	O
end	O
of	O
the	O
third	O
instar	O
(	O
see	O
Figure	O
4H	O
)	O
.	O

At	O
this	O
stage	O
,	O
the	O
Hml	O
marker	O
disappeared	O
from	O
the	O
most	O
of	O
the	O
hemocytes	O
in	O
mutants	O
(	O
see	O
Figure	O
4F	O
and	O
4G	O
)	O
.	O

Number	O
of	O
Circulating	O
Hemocytes	O
in	O
Late	O
Third-Instar	O
Larvae	O

Genotypes	O
are	O
shown	O
along	O
the	O
x-axis	O
,	O
and	O
the	O
number	O
of	O
hemocytes/larva	O
along	O
the	O
y-axis	O
.	O

Each	O
bar	O
shows	O
the	O
number	O
of	O
all	O
circulating	O
hemocytes	O
,	O
and	O
the	O
gray	O
part	O
of	O
the	O
bars	O
represent	O
the	O
lamellocyte	O
population	O
.	O

Each	O
count	O
was	O
repeated	O
five	O
to	O
ten	O
times	O
and	O
the	O
standard	O
error	O
is	O
shown	O
.	O

Hemocyte	O
Abnormalities	O
in	O
adgf-a	O
Mutant	O
Larvae	O

(	O
AE	O
)	O
Differential	O
interference	O
contrast	O
microscopy	O
of	O
living	O
circulating	O
hemocytes	O
(	O
magnification	O
200	O
;	O
scale	O
bar	O
,	O
10	O
?	O
m	O
)	O
.	O

Round	O
,	O
nonadhesive	O
plasmatocytes	O
from	O
wild-type	O
larva	O
(	O
A	O
)	O
.	O

Hemocytes	O
from	O
the	O
adgf-a	O
mutant	O
developing	O
filamentous	O
extensions	O
(	O
B	O
and	O
C	O
)	O
or	O
membranous	O
extension	O
surrounding	O
the	O
cell	O
(	O
D	O
)	O
.	O

Large	O
flat	O
lamellocyte	O
from	O
the	O
adgf-a	O
mutant	O
(	O
E	O
)	O
.	O

(	O
F	O
and	O
G	O
)	O
Differential	O
interference	O
contrast	O
and	O
fluorescent	O
microscopy	O
(	O
merged	O
image	O
)	O
of	O
living	O
circulating	O
hemocytes	O
stained	O
by	O
the	O
Hml-GFP	O
marker	O
(	O
magnification	O
100	O
;	O
scale	O
bar	O
,	O
10	O
?	O
m	O
)	O
.	O

While	O
most	O
of	O
the	O
cells	O
from	O
wild-type	O
larvae	O
are	O
GFP-positive	O
(	O
F	O
)	O
,	O
just	O
few	O
of	O
the	O
cells	O
from	O
late	O
third	O
instar	O
adgf-a	O
larvae	O
are	O
stained	O
by	O
GFP	O
at	O
this	O
stage	O
(	O
G	O
)	O
.	O

(	O
HJ	O
)	O
Fluorescence	O
microscopy	O
of	O
living	O
larvae	O
with	O
Hml-GFP	O
stained	O
hemocytes	O
(	O
magnification	O
40	O
;	O
scale	O
bar	O
,	O
100	O
?	O
m	O
)	O
.	O

Posterior	O
part	O
of	O
late	O
third-instar	O
wild-type	O
larva	O
(	O
H	O
)	O
.	O

Middle	O
sections	O
of	O
early	O
third-instar	O
larvae	O
of	O
wild	O
type	O
(	O
I	O
)	O
and	O
adgf-a	O
mutant	O
(	O
J	O
)	O
.	O

Crystal	O
Cells	O
in	O
Late	O
Third	O
Instar	O
Larvae	O

Crystal	O
cells	O
were	O
visualized	O
by	O
heating	O
larvae	O
of	O
different	O
genotypes	O
at	O
60	O
C	O
for	O
10	O
min	O
[	O
46	O
]	O
.	O

(	O
A	O
)	O
Wild-type	O
larva	O
,	O
(	O
B	O
)	O
adgf-a	O
single	O
mutant	O
,	O
(	O
C	O
)	O
adoR	O
adgf-a	O
double	O
mutant	O
(	O
scale	O
bar	O
,	O
0.5	O
mm	O
)	O
.	O

The	O
adgf-a	O
Mutant	O
Phenotype	O
Is	O
Rescued	O
by	O
Expression	O
of	O
ADGF-A	O
in	O
the	O
Lymph	O
Glands	O

To	O
distinguish	O
which	O
tissues	O
require	O
ADGF-A	O
expression	O
for	O
proper	O
development	O
,	O
we	O
tested	O
for	O
rescue	O
of	O
adgf-a	O
lethality	O
by	O
expressing	O
ADGF-A	O
in	O
specific	O
subsets	O
of	O
larval	O
tissues	O
.	O

A	O
transgenic	O
line	O
carrying	O
the	O
UAS-ADGF-A	O
construct	O
on	O
Chromosome	O
II	O
was	O
crossed	O
to	O
lines	O
expressing	O
the	O
Gal4	O
driver	O
[	O
18	O
]	O
in	O
different	O
tissues	O
(	O
Table	O
1	O
)	O
.	O

Since	O
ADGF-A	O
is	O
normally	O
expressed	O
in	O
the	O
larval	O
lymph	O
glands	O
[	O
16	O
]	O
,	O
and	O
the	O
mutant	O
phenotype	O
is	O
characterized	O
by	O
abnormal	O
hemocyte	O
development	O
,	O
special	O
consideration	O
was	O
given	O
to	O
lines	O
expressing	O
the	O
Gal4	O
driver	O
in	O
the	O
lymph	O
glands	O
and/or	O
circulating	O
hemocytes	O
.	O

No	B-Negation
line	I-Negation
expressing	I-Negation
the	I-Negation
Gal4	I-Negation
driver	I-Negation
exclusively	I-Negation
in	I-Negation
the	I-Negation
lymph	I-Negation
glands	I-Negation
has	I-Negation
been	I-Negation
reported	I-Negation
,	O
so	O
we	O
used	O
a	O
combination	O
of	O
lines	O
sharing	O
in	O
common	O
the	O
feature	O
of	O
Gal4	O
driver	O
expression	O
in	O
the	O
lymph	O
glands	O
.	O

The	O
results	O
(	O
see	O
Figure	O
2	O
and	O
Table	O
1	O
)	O
clearly	O
demonstrate	O
that	O
expression	O
of	O
ADGF-A	O
in	O
the	O
lymph	O
glands	O
(	O
driven	O
by	O
Cg-Gal4	O
,	O
e33C-Gal4	O
,	O
or	O
c564-Gal4	O
)	O
,	O
but	O
not	B-Negation
in	I-Negation
any	I-Negation
other	I-Negation
tissue	I-Negation
examined	I-Negation
,	O
is	O
necessary	O
and	O
sufficient	O
to	O
fully	O
rescue	O
the	O
adgf-a	O
lethality	O
.	O

In	O
e33C-Gal4/UAS-ADGF-A	O
,	O
strong	O
expression	O
of	O
ADGF-A	O
in	O
all	O
lobes	O
of	O
developing	O
lymph	O
glands	O
(	O
but	O
not	O
in	O
circulating	O
hemocytes	O
)	O
reduces	O
the	O
number	O
of	O
hemocytes	O
in	O
the	O
hemolymph	O
to	O
almost	O
normal	O
levels	O
(	O
see	O
Figure	O
3	O
)	O
.	O

The	O
number	O
of	O
hemocytes	O
is	O
also	O
reduced	O
,	O
but	O
to	O
a	O
lesser	O
extent	O
in	O
larvae	O
rescued	O
by	O
Cg-Gal4/UAS-ADGF-A	O
.	O

However	O
,	O
when	O
assayed	O
by	O
survival	O
rate	O
and	O
melanotic	O
tumor	O
formation	O
,	O
the	O
rescue	O
by	O
Cg-Gal4	O
is	O
full	O
and	O
similar	O
to	O
that	O
of	O
e33C-Gal4	O
(	O
see	O
Figure	O
2	O
)	O
.	O

The	O
difference	O
in	O
effectiveness	O
may	O
be	O
explained	O
by	O
the	O
different	O
expression	O
patterns	O
of	O
the	O
drivers	O
.	O

Cg-Gal4	O
is	O
expressed	O
only	O
in	O
certain	O
compartments	O
of	O
lymph	O
gland	O
lobes	O
containing	O
relatively	O
mature	O
hemocytes	O
,	O
and	O
strongly	O
in	O
most	O
circulating	O
hemocytes	O
[	O
22	O
,	O
23	O
]	O
.	O

The	O
C564-Gal4	O
driver	O
is	O
not	B-Negation
expressed	I-Negation
as	I-Negation
strongly	I-Negation
as	I-Negation
e33C-Gal4	I-Negation
,	O
but	O
is	O
still	O
uniformly	O
expressed	O
in	O
the	O
lymph	O
glands	O
;	O
it	O
also	O
fully	O
rescued	O
the	O
mutant	O
phenotype	O
.	O

We	O
have	O
tried	O
two	O
different	O
insertions	O
of	O
the	O
Dot-Gal4	O
construct	O
.	O

The	O
Dot-Gal411C	O
on	O
Chromosome	O
II	O
,	O
which	O
shows	O
weak	O
expression	O
[	O
24	O
]	O
,	O
did	O
not	B-Negation
rescue	I-Negation
the	I-Negation
phenotype	I-Negation
,	O
but	O
a	O
Dot-Gal443A	O
insertion	O
on	O
Chromosome	O
X	O
,	O
which	O
shows	O
stronger	O
expression	O
,	O
rescued	O
approximately	O
half	O
of	O
the	O
mutant	O
animals	O
(	O
Figure	O
2	O
)	O
.	O

Nearly	O
all	O
rescued	O
individuals	O
were	O
males	O
,	O
suggesting	B-Speculation
that	I-Speculation
expression	I-Speculation
of	I-Speculation
the	I-Speculation
Gal4	I-Speculation
driver	I-Speculation
was	I-Speculation
influenced	I-Speculation
by	I-Speculation
X-chromosome	I-Speculation
dosage	I-Speculation
compensation	I-Speculation
,	I-Speculation
and	I-Speculation
expression	I-Speculation
in	I-Speculation
females	I-Speculation
heterozygous	I-Speculation
for	O
Dot-Gal4	B-Negation
was	I-Negation
not	I-Negation
strong	I-Negation
enough	I-Negation
for	I-Negation
rescue	I-Negation
.	O

Expression	B-Negation
of	I-Negation
ADGF-A	I-Negation
in	I-Negation
salivary	I-Negation
glands	I-Negation
and	I-Negation
fat	I-Negation
body	I-Negation
(	I-Negation
as	I-Negation
well	I-Negation
as	I-Negation
in	I-Negation
other	I-Negation
tissues	I-Negation
)	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
full	I-Negation
rescue	I-Negation
,	O
as	O
demonstrated	O
by	O
use	O
of	O
the	O
Cg-Gal4	O
,	O
Dot-Gal4	O
,	O
but	O
especially	O
by	O
e33C-Gal4	O
driver	O
,	O
and	O
is	O
also	O
not	B-Negation
sufficient	I-Negation
to	I-Negation
rescue	I-Negation
the	I-Negation
phenotype	I-Negation
at	I-Negation
all	I-Negation
,	O
as	O
demonstrated	O
by	O
T110-Gal4	O
and	O
Lsp2-Gal4	O
(	O
Table	O
1	O
)	O
.	O

Since	O
ADGF-A	O
is	O
strongly	O
expressed	O
in	O
embryonic	O
mesoderm	O
[	O
16	O
]	O
,	O
we	O
have	O
tried	O
to	O
rescue	O
the	O
phenotype	O
by	O
the	O
expression	O
of	O
ADGF-A	O
in	O
embryonic	O
and	O
larval	O
muscle	O
cells	O
using	O
the	O
Dmef2-Gal4	O
driver	O
[	O
25	O
]	O
.	O

No	B-Negation
rescue	I-Negation
of	I-Negation
the	I-Negation
phenotype	I-Negation
,	I-Negation
including	I-Negation
body	I-Negation
shape	I-Negation
of	I-Negation
escaping	I-Negation
pupae	I-Negation
,	I-Negation
was	I-Negation
observed	I-Negation
.	O

The	O
only	O
line	O
showing	O
significant	O
(	O
but	O
not	B-Negation
complete	I-Negation
)	I-Negation
rescue	O
of	O
adgf-a	O
survival	O
without	B-Negation
expression	I-Negation
in	I-Negation
the	I-Negation
lymph	I-Negation
glands	I-Negation
was	O
GawB5015	O
(	O
see	O
Figure	O
2	O
)	O
,	O
which	O
expresses	O
the	O
Gal4	O
driver	O
very	O
strongly	O
and	O
specifically	O
in	O
the	O
ring	O
gland	O
and	O
salivary	O
glands	O
(	O
as	O
well	O
as	O
very	O
weak	O
and	O
spotty	O
expression	O
in	O
imaginal	O
discs	O
[	O
unpublished	O
data	O
]	O
)	O
.	O

However	O
,	O
expression	O
of	O
ADGF-A	O
driven	O
by	O
GawB5015	O
does	O
not	B-Negation
prevent	I-Negation
the	I-Negation
formation	I-Negation
of	I-Negation
melanotic	I-Negation
tumors	I-Negation
(	O
see	O
Figure	O
2B	O
)	O
.	O

Ablation	O
of	O
Hemocytes	O
in	O
Mutant	O
Larvae	O
Reduces	O
Fat	O
Body	O
Disintegration	O
and	O
Melanotic	O
Tumor	O
Formation	O

The	O
l	O
(	O
3	O
)	O
hematopoiesis	O
missing	O
(	O
l	O
[	O
3	O
]	O
hem	O
)	O
mutation	O
reduces	O
cell	O
division	O
in	O
larval	O
proliferating	O
tissues	O
and	O
thus	O
dramatically	O
reduces	O
the	O
number	O
of	O
hemocytes	O
in	O
larvae	O
.	O

It	O
also	O
suppresses	O
the	O
hemocyte	O
overproliferation	O
and	O
associated	O
defects	O
observed	O
in	O
the	O
hopscotchTumorous-lethal	O
mutant	O
[	O
26	O
]	O
.	O

We	O
therefore	O
used	O
the	O
l	O
(	O
3	O
)	O
hem1	O
mutation	O
to	O
test	O
whether	O
the	O
reduction	O
of	O
hemocyte	O
number	O
in	O
the	O
adgf-a	O
mutant	O
affects	O
the	O
phenotype	O
.	O

We	O
recombined	O
this	O
mutation	O
onto	O
the	O
chromosome	O
containing	O
the	O
adgf-a	O
mutation	O
and	O
found	O
that	O
in	O
homozygous	O
l	O
(	O
3	O
)	O
hem1	O
,	O
adgf-a	O
double	O
mutants	O
the	O
number	O
of	O
hemocytes	O
is	O
significantly	O
reduced	O
compared	O
to	O
the	O
adgf-a	O
single	O
mutants	O
(	O
see	O
Figure	O
3	O
)	O
.	O

Furthermore	O
,	O
while	O
90	O
%	O
of	O
adgf-a	O
mutant	O
larvae	O
showed	O
disintegration	O
of	O
fat	O
body	O
,	O
only	O
40	O
%	O
of	O
l	O
(	O
3	O
)	O
hem1	O
,	O
adgf-a	O
double	O
mutants	O
(	O
total	O
number	O
of	O
counted	O
animals	O
was	O
82	O
)	O
show	O
the	O
disintegration	O
(	O
Figure	O
6A	O
)	O
.	O

Similarly	O
,	O
melanotic	O
tumor	O
formation	O
is	O
significantly	O
suppressed	O
by	O
l	O
(	O
3	O
)	O
hem1	O
,	O
with	O
only	O
55	O
%	O
of	O
double	O
mutants	O
showing	O
melanotic	O
tumors	O
compared	O
to	O
more	O
than	O
83	O
%	O
in	O
adgf-a	O
(	O
Figure	O
6A	O
)	O
.	O

However	O
,	O
the	B-Negation
delay	I-Negation
in	I-Negation
development	I-Negation
and	I-Negation
block	I-Negation
of	I-Negation
pupariation	I-Negation
(	I-Negation
Figure	I-Negation
6B	I-Negation
)	I-Negation
,	I-Negation
as	I-Negation
well	I-Negation
as	I-Negation
the	I-Negation
pupal	I-Negation
body	I-Negation
shape	I-Negation
,	I-Negation
were	I-Negation
not	I-Negation
influenced	I-Negation
by	I-Negation
this	I-Negation
mutation	I-Negation
.	O

This	O
shows	O
that	O
the	O
effect	O
on	O
hemocyte	O
development	O
is	O
related	O
to	O
only	O
one	O
other	O
aspect	O
of	O
the	O
adgf-a	O
phenotypenamely	O
,	O
fat	O
body	O
disintegrationand	O
the	O
developmental	O
arrest	O
of	O
adgf-a	O
mutants	O
is	O
probably	O
independent	O
of	O
this	O
process	O
.	O

Suppression	O
of	O
the	O
adgf-a	O
Mutant	O
Phenotype	O
by	O
Mutations	O
in	O
Other	O
Genes	O

(	O
A	O
)	O
Percentage	O
of	O
late	O
third-instar	O
larvae	O
with	O
melanotic	O
tumors	O
(	O
black	O
bars	O
)	O
and	O
fat	O
body	O
disintegration	O
(	O
green	O
bars	O
)	O
.	O

The	O
x-axis	O
(	O
which	O
is	O
shared	O
with	O
[	O
B	O
]	O
)	O
,	O
shows	O
the	O
genotype	O
.	O

The	O
y-axis	O
shows	O
the	O
percentage	O
of	O
larvae	O
with	O
tumors	O
and	O
fat	O
body	O
disintegration	O
.	O

(	O
B	O
)	O
Survival	O
rate	O
of	O
double	O
mutants	O
compared	O
to	O
single	O
adgf-a	O
mutant	O
.	O

The	O
y-axis	O
shows	O
the	O
percentage	O
of	O
the	O
pupae	O
(	O
blue	O
bars	O
)	O
and	O
adult	O
flies	O
(	O
purple	O
bars	O
)	O
demonstrating	O
the	O
larval	O
and	O
pupal	O
survival	O
,	O
respectively	O
.	O

Each	O
experiment	O
was	O
repeated	O
at	O
least	O
four	O
times	O
(	O
with	O
2030	O
animals	O
in	O
each	O
vial	O
)	O
and	O
the	O
standard	O
error	O
is	O
shown	O
.	O

Block	O
in	O
Activation	O
of	O
Macrophages	O
Suppresses	O
Disintegration	O
of	O
Fat	O
Body	O

Previous	O
results	O
suggest	O
that	O
fat	O
body	O
disintegration	O
might	O
be	O
caused	O
by	O
the	O
action	O
of	O
hemocytes	O
.	O

Embryonic	O
macrophages	O
express	O
the	O
scavenger	O
receptor	O
encoded	O
by	O
croquemort	O
(	O
crq	O
)	O
,	O
which	O
allows	O
them	O
to	O
bind	O
and	O
remove	O
apoptotic	O
corpses	O
[	O
27	O
]	O
.	O

We	O
therefore	O
tested	O
whether	O
a	O
mutation	O
in	O
the	O
crq	O
gene	O
would	O
block	O
the	O
suggested	O
interaction	O
between	O
hemocytes	O
and	O
fat	O
body	O
in	O
adgf-a	O
mutant	O
larvae	O
.	O

We	O
used	O
the	O
mutation	O
crqKG01679	O
,	O
caused	O
by	O
a	O
P-element	O
insertion	O
in	O
the	O
first	O
untranslated	O
exon	O
of	O
crq	O
,	O
which	O
leads	O
to	O
pupal	O
lethality	O
.	O

The	B-Negation
number	I-Negation
of	I-Negation
crystal	I-Negation
cells	I-Negation
was	I-Negation
not	I-Negation
increased	I-Negation
and	O
lamellocytes	B-Negation
were	I-Negation
not	I-Negation
detected	I-Negation
in	I-Negation
crq	I-Negation
,	I-Negation
adgf-a	I-Negation
double	I-Negation
mutants	I-Negation
(	O
see	O
Figure	O
3	O
)	O
.	O

The	O
double	O
mutants	O
showed	O
a	O
lower	O
number	O
of	O
circulating	O
hemocytes	O
than	O
the	O
single	O
mutant	O
,	O
but	O
there	O
was	O
still	O
a	O
significant	O
increase	O
in	O
this	O
number	O
compared	O
to	O
wild	O
type	O
(	O
see	O
Figure	O
3	O
)	O
,	O
and	O
the	O
cells	O
showed	O
increased	O
clumping	O
.	O

None	B-Negation
of	I-Negation
the	I-Negation
double-mutant	I-Negation
larvae	I-Negation
showed	I-Negation
either	I-Negation
disintegration	I-Negation
of	I-Negation
fat	I-Negation
body	I-Negation
or	I-Negation
melanotic	I-Negation
tumor	I-Negation
formation	I-Negation
(	O
Figure	O
6A	O
)	O
.	O

Even	O
the	O
adgf-a	O
mutant	O
larvae	O
heterozygous	O
for	O
the	O
crq	O
mutation	O
(	O
crq/CyO	O
GFP	O
;	O
adgf-a/adgf-a	O
)	O
showed	O
significant	O
suppression	O
of	O
the	O
fat	O
body	O
disintegration	O
,	O
with	O
most	O
of	O
the	O
tissue	O
staying	O
compact	O
in	O
bigger	O
pieces	O
and	O
never	B-Negation
disintegrating	I-Negation
to	I-Negation
single	I-Negation
adipose	I-Negation
cells	I-Negation
;	O
melanotic	O
tumors	O
were	O
rarely	O
observed	O
.	O

This	O
shows	O
that	O
the	O
block	O
of	O
the	O
putative	O
interaction	O
between	O
fat	O
body	O
and	O
macrophage-like	O
cells	O
(	O
which	O
are	O
still	O
present	O
in	O
double	O
mutants	O
)	O
suppresses	O
the	O
fat	O
body	O
disintegration	O
,	O
further	O
strengthening	O
the	O
hypothesis	O
that	O
the	O
disintegration	O
is	O
caused	O
by	O
hemocytes	O
.	O

In	O
addition	O
,	O
the	O
absence	O
of	O
lamellocytes	O
and	O
the	O
normal	O
number	O
of	O
crystal	O
cells	O
in	O
the	O
double	O
mutant	O
strongly	O
suggest	O
that	O
the	O
differentiation	O
of	O
these	O
cells	O
and	O
thus	O
melanotic	O
tumor	O
formation	O
is	O
a	O
secondary	O
reaction	O
to	O
fat	O
body	O
disintegration	O
,	O
rather	O
than	O
a	O
primary	O
effect	O
of	O
the	O
adgf-a	O
mutation	O
.	O

Mutation	O
in	O
a	O
Putative	O
Adenosine	O
Receptor	O
Suppresses	O
the	O
Block	O
of	O
Pupariation	O
in	O
adgf-a	O

We	O
have	O
identified	O
a	O
putative	O
homolog	O
of	O
the	O
mammalian	O
adenosine	O
receptor	O
family	O
in	O
the	O
Drosophila	O
genome	O
,	O
AdoR	O
,	O
and	O
produced	O
a	O
null	O
mutation	O
in	O
this	O
gene	O
using	O
homologous	O
recombination	O
(	O
adoR	O
;	O
ED	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
adoR	O
mutants	O
are	O
fully	O
viable	O
.	O

We	O
used	O
this	O
mutant	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
increased	O
level	O
of	O
adenosine	O
in	O
the	O
adgf-a	O
mutant	O
contributes	O
to	O
the	O
mutant	O
phenotype	O
by	O
its	O
effect	O
on	O
signaling	O
through	O
the	O
adenosine	O
receptor	O
.	O

The	O
results	O
show	O
that	O
introducing	O
the	O
adoR	O
mutation	O
into	O
the	O
adgf-a	O
background	O
significantly	O
increases	O
pupariation	O
,	O
as	O
well	O
as	O
adult	O
emerging	O
rate	O
,	O
compared	O
to	O
the	O
adgf-a	O
single	O
mutant	O
(	O
Figure	O
6B	O
)	O
.	O

When	O
the	O
earlier	O
lethality	O
was	O
avoided	O
by	O
picking	O
up	O
larvae	O
after	O
molt	O
to	O
the	O
third	O
instar	O
,	O
the	O
pupariation	O
rate	O
of	O
adoR	O
,	O
adgf-a	O
double	O
mutant	O
was	O
comparable	O
to	O
wild	O
type	O
as	O
well	O
as	O
to	O
the	O
single	O
adgf-a	O
mutant	O
treated	O
with	O
ecdysone	O
(	O
Figure	O
7A	O
)	O
.	O

Development	O
during	O
the	O
third	O
instar	O
is	O
much	O
less	O
delayed	O
in	O
the	O
double	O
mutant	O
,	O
with	O
most	O
of	O
the	O
larvae	O
pupariating	O
within	O
1	O
d	O
after	O
their	O
heterozygous	O
siblings	O
(	O
Figure	O
7A	O
)	O
.	O

The	O
adoR	O
mutation	O
also	O
significantly	O
reduced	O
melanotic	O
tumor	O
formation	O
in	O
the	O
adgf-a	O
mutant	O
(	O
see	O
Figure	O
6A	O
)	O
,	O
but	O
disintegration	O
of	O
the	O
fat	O
body	O
appeared	O
at	O
the	O
same	O
rate	O
as	O
in	O
the	O
single	O
mutant	O
(	O
see	O
Figure	O
6A	O
)	O
.	O

While	O
the	O
number	O
of	O
macrophage-like	O
cells	O
in	O
circulation	O
is	O
not	O
significantly	O
changed	O
in	O
the	O
double	O
mutant	O
,	O
the	O
number	O
of	O
lamellocytes	O
is	O
decreased	O
(	O
see	O
Figure	O
3	O
)	O
,	O
but	O
the	O
number	O
of	O
crystal	O
cells	O
is	O
normal	O
(	O
see	O
Figure	O
5A	O
and	O
5C	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
adenosine	O
signaling	O
through	O
the	O
adenosine	O
receptor	O
is	O
involved	O
in	O
the	O
developmental	O
arrest	O
of	O
adgf-a	O
mutant	O
,	O
but	O
that	O
it	O
does	O
not	B-Negation
play	I-Negation
a	I-Negation
role	I-Negation
in	I-Negation
fat	I-Negation
body	I-Negation
disintegration	I-Negation
and	I-Negation
macrophage	I-Negation
differentiation	I-Negation
.	O

Ecdysone	O
Regulation	O
of	O
Development	O
in	O
adgf-a	O

(	O
A	O
)	O
Larvae	O
of	O
different	O
genotypes	O
were	O
collected	O
after	O
L2/L3	O
molt	O
,	O
and	O
the	O
number	O
of	O
puparia	O
was	O
counted	O
at	O
different	O
time	O
points	O
(	O
x-axis	O
:	O
hours	O
after	O
egg	O
laying	O
)	O
.	O

The	O
y-axis	O
shows	O
the	O
percentage	O
of	O
puparia	O
out	O
of	O
all	O
collected	O
third-instar	O
larvae	O
(	O
three	O
vials	O
each	O
with	O
30	O
animals	O
;	O
the	O
standard	O
error	O
is	O
shown	O
)	O
.	O

(	O
B	O
and	O
C	O
)	O
Ring	O
gland	O
morphology	O
in	O
arrested	O
adgf-a	O
larvae	O
.	O

Approximately	O
8-d	O
old	O
mutant	O
larva	O
(	O
i.e.	O
,	O
3	O
d	O
after	O
normal	O
pupariation	O
)	O
with	O
very	O
extensive	O
fat	O
body	O
disintegration	O
(	O
note	O
the	O
transparency	O
of	O
larva	O
in	O
the	O
middle	O
part	O
with	O
small	O
white	O
pieces	O
of	O
fat	O
body	O
)	O
(	O
B	O
)	O
.	O

The	O
ring	O
gland	O
dissected	O
from	O
this	O
larva	O
(	O
C	O
)	O
shows	O
morphology	O
of	O
the	O
normal	O
ring	O
gland	O
before	O
the	O
degenerative	O
changes	O
of	O
prothoracic	O
gland	O
starts	O
(	O
compare	O
to	O
schematic	O
diagram	O
to	O
the	O
left	O
of	O
[	O
C	O
]	O
,	O
from	O
[	O
28	O
]	O
)	O
.	O

(	O
DF	O
)	O
Expression	O
of	O
GFP-marked	O
glue	O
protein	O
(	O
Sgs	O
?	O
3-GFP	O
)	O
in	O
salivary	O
gland	O
of	O
the	O
adgf-a	O
mutant	O
larvae	O
and	O
pupae	O
.	O

All	O
late	O
third-instar	O
larvae	O
express	O
the	O
glue	O
protein	O
as	O
shown	O
on	O
dissected	O
salivary	O
gland	O
(	O
D	O
)	O
.	O

Some	O
mutants	O
show	O
typical	O
expulsion	O
from	O
the	O
glands	O
with	O
GFP	O
totally	O
external	O
to	O
the	O
puparial	O
case	O
(	O
E	O
)	O
,	O
while	O
others	O
do	O
not	B-Negation
expel	I-Negation
glue	I-Negation
proteins	I-Negation
even	I-Negation
after	I-Negation
puparium	I-Negation
formation	I-Negation
(	I-Negation
F	I-Negation
)	I-Negation
.	O

Hormonal	O
Regulation	O
in	O
the	O
adgf-a	O
Mutant	O

The	O
delayed	O
development	O
and	O
low	O
pupariation	O
rate	O
in	O
the	O
adgf-a	O
mutant	O
larvae	O
(	O
see	O
Figures	O
2A	O
and	O
7A	O
)	O
could	O
be	O
caused	O
by	O
an	O
effect	O
on	O
hormonal	O
regulation	O
of	O
development	O
.	O

The	O
main	O
source	O
of	O
developmental	O
hormones	O
in	O
the	O
Drosophila	O
larva	O
is	O
the	O
ring	O
gland	O
,	O
composed	O
of	O
the	O
prothoracic	O
gland	O
,	O
corpus	O
allatum	O
,	O
and	O
corpus	O
cardiacum	O
[	O
28	O
]	O
.	O

The	O
prothoracic	O
gland	O
releases	O
the	O
steroid	O
molting	O
hormone	O
ecdysone	O
,	O
which	O
is	O
converted	O
to	O
an	O
active	O
form	O
,	O
20-hydroxyecdysone	O
(	O
20E	O
)	O
,	O
by	O
the	O
fat	O
body	O
as	O
well	O
as	O
some	O
of	O
the	O
target	O
organs	O
[	O
29	O
]	O
.	O

The	O
block	O
of	O
pupariation	O
in	O
the	O
adgf-a	O
mutant	O
suggested	O
that	O
the	O
level	O
of	O
ecdysone	O
in	O
these	O
larvae	O
might	O
not	O
be	O
sufficient	O
to	O
initiate	O
pupariation	O
.	O

To	O
test	O
this	O
possibility	O
,	O
we	O
tried	O
to	O
rescue	O
the	O
phenotype	O
by	O
feeding	O
mutant	O
larvae	O
20E	O
,	O
which	O
can	O
initiate	O
pupariation	O
in	O
the	O
ecd1	O
mutant	O
,	O
which	O
has	O
an	O
extremely	O
low	O
level	O
of	O
ecdysone	O
[	O
30,31	O
]	O
.	O

The	O
results	O
(	O
Figure	O
7A	O
)	O
clearly	O
demonstrate	O
that	O
the	O
adgf-a	O
mutant	O
larvae	O
are	O
responsive	O
to	O
ecdysone	O
and	O
that	O
this	O
treatment	O
restores	O
the	O
pupariation	O
frequency	O
to	O
almost	O
wild-type	O
level	O
.	O

The	O
delay	O
in	O
development	O
is	O
also	O
significantly	O
reduced	O
(	O
Figure	O
7A	O
)	O
.	O

Since	O
the	O
adgf-a	O
mutant	O
shows	O
certain	O
precocious	O
metamorphic	O
changes	O
(	O
macrophage	O
differentiation	O
and	O
fat	O
body	O
disintegration	O
)	O
,	O
we	O
speculated	O
that	O
a	O
reduced	O
ecdysteroid	O
level	O
could	O
be	O
caused	O
by	O
precocious	O
degeneration	O
of	O
the	O
prothoracic	O
part	O
of	O
the	O
ring	O
gland	O
.	O

However	O
,	O
the	B-Negation
overall	I-Negation
structure	I-Negation
of	I-Negation
the	I-Negation
ring	I-Negation
gland	I-Negation
is	I-Negation
not	I-Negation
visibly	I-Negation
affected	I-Negation
even	I-Negation
in	I-Negation
the	I-Negation
oldest	I-Negation
larvae	I-Negation
(	I-Negation
10	I-Negation
d	I-Negation
,	I-Negation
i.e.	I-Negation
,	I-Negation
5	I-Negation
d	I-Negation
after	I-Negation
the	I-Negation
heterozygous	I-Negation
siblings	I-Negation
pupariated	I-Negation
)	I-Negation
with	I-Negation
a	I-Negation
fully	I-Negation
disintegrated	I-Negation
fat	I-Negation
body	I-Negation
(	O
Figure	O
7B	O
and	O
7C	O
)	O
.	O

We	O
also	O
used	O
a	O
transgenic	O
line	O
carrying	O
the	O
Sgs	O
?	O
3-GFP	O
construct	O
,	O
which	O
was	O
previously	O
used	O
to	O
monitor	O
the	O
effects	O
of	O
ecdysteroid	O
levels	O
on	O
glue	O
protein	O
expression	O
in	O
salivary	O
glands	O
[	O
32	O
]	O
.	O

All	O
analyzed	O
adgf-a	O
mutant	O
larvae	O
carrying	O
the	O
Sgs	O
?	O
3-GFP	O
construct	O
showed	O
normal	O
expression	O
of	O
Sgs-GFP	O
in	O
salivary	O
glands	O
(	O
Figure	O
7D	O
)	O
.	O

Mutants	O
that	O
pupariated	O
usually	O
showed	O
typical	O
GFP	O
expectoration	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
high	O
premetamorphic	O
peak	O
of	O
ecdysteroids	O
(	O
Figure	O
7E	O
)	O
.	O

In	O
some	O
cases	O
,	O
GFP	O
was	O
secreted	O
into	O
the	O
lumen	O
of	O
salivary	O
glands	O
,	O
but	O
was	B-Negation
not	I-Negation
expectorated	I-Negation
(	O
Figure	O
7F	O
)	O
,	O
which	O
is	O
similar	O
to	O
the	O
defect	O
seen	O
in	O
animals	O
expressing	O
the	O
dominant-negative	O
form	O
of	O
ecdysone	O
receptor	O
driven	O
by	O
the	O
Sgs3-Gal4	O
driver	O
[	O
33	O
]	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
target	O
tissues	O
of	O
adgf-a	O
mutants	O
are	O
normally	O
responsive	O
to	O
ecdysteroids	O
and	O
that	O
they	O
are	O
probably	O
capable	O
of	O
releasing	O
ecdysteroids	O
,	O
although	O
the	O
level	O
of	O
ecdysteroids	O
might	O
vary.	O
?	O
>	O

ADGF-A	O
Genetically	O
Interacts	O
with	O
Toll	O
Signaling	O
Pathway	O

The	O
antimicrobial	O
response	O
of	O
Drosophila	O
includes	O
at	O
least	O
two	O
distinct	O
signaling	O
pathways	O
[	O
34	O
]	O
the	O
Toll	O
signaling	O
pathway	O
,	O
which	O
leads	O
to	O
the	O
activation	O
of	O
two	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NF-	O
?	O
B	O
)	O
factors	O
,	O
Dorsal-related	O
immunity	O
factor	O
(	O
DIF	O
)	O
and	O
dorsal	O
(	O
DL	O
)	O
;	O
and	O
the	O
immune	O
deficiency	O
protein	O
pathway	O
activating	O
the	O
third	O
NF-	O
?	O
B	O
factor	O
,	O
Relish	O
(	O
REL	O
)	O
.	O

A	O
zygotic	O
null	O
mutation	O
in	O
cactus	O
(	O
cact	O
;	O
a	O
Drosophila	O
inhibitor	O
of	O
NF-	O
?	O
B	O
)	O
leads	O
to	O
hyperproliferation	O
of	O
hemocytes	O
,	O
melanotic	O
tumor	O
formation	O
,	O
disintegration	O
of	O
fat	O
body	O
,	O
and	O
slower	O
larval	O
development	O
,	O
with	O
60	O
%	O
larval	O
lethality	O
,	O
as	O
well	O
as	O
a	O
thin	O
body-shape	O
phenotype	O
[	O
35	O
]	O
.	O

All	O
of	O
these	O
phenotypes	O
are	O
strikingly	O
similar	O
to	O
the	O
abnormalities	O
seen	O
in	O
adgf-a	O
mutants	O
,	O
which	O
was	O
our	O
first	O
clue	O
as	O
to	O
a	O
possible	O
interaction	O
of	O
ADGF-A	O
with	O
the	O
Toll	O
signaling	O
pathway	O
.	O

We	O
hypothesized	O
that	O
the	O
activity	O
of	O
ADGF-A	O
is	O
suppressed	O
by	O
Toll	O
signaling	O
,	O
resulting	O
in	O
similar	O
phenotypes	O
of	O
the	O
adgf-a	O
mutation	O
and	O
constitutive	O
activation	O
of	O
Toll	O
pathway	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
crossed	O
transgenic	O
flies	O
carrying	O
ADGF-A	O
gene	O
under	O
the	O
control	O
of	O
a	O
heat-shock	O
promoter	O
on	O
Chromosome	O
II	O
(	O
HS-ADGF-A	O
)	O
with	O
cactE8	O
(	O
a	O
lethal	O
allele	O
of	O
cact	O
on	O
Chromosome	O
II	O
,	O
which	O
,	O
in	O
combination	O
with	O
cactD13	O
,	O
results	O
in	O
a	O
zygotic	O
null	O
combination	O
,	O
or	O
,	O
with	O
cactIIIG	O
,	O
results	O
in	O
zygotic	O
hypomorphic	O
combination	O
)	O
.	O

Overexpression	O
of	O
ADGF-A	O
in	O
animals	O
with	O
a	O
hypomorphic	O
cact	O
combination	O
(	O
cactE8/cactIIIG	O
)	O
increased	O
the	O
adult	O
survival	O
rate	O
almost	O
4-fold	O
(	O
Figure	O
8A	O
)	O
.	O

The	O
rescue	O
could	O
be	O
increased	O
by	O
multiple	O
heat	O
shocks	O
before	O
pupariation	O
to	O
7-fold	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
suppression	O
of	O
melanotic	O
tumor	O
formation	O
is	O
also	O
significant	O
(	O
from	O
more	O
than	O
80	O
%	O
down	O
to	O
26	O
%	O
,	O
Figure	O
8B	O
)	O
.	O

The	O
most	O
severe	O
cact	O
null	O
mutation	O
(	O
cactE8/cactD13	O
)	O
,	O
leading	O
to	O
developmental	O
arrest	O
in	O
larvae	O
(	O
less	O
than	O
8	O
%	O
pupate	O
)	O
,	O
is	O
partially	O
rescued	O
in	O
animals	O
with	O
overexpression	O
of	O
ADGF-A	O
when	O
the	O
pupariation	O
rate	O
is	O
increased	O
3-fold	O
(	O
Figure	O
8A	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
ADGF-A	O
overexpression	O
can	O
partially	O
rescue	O
the	O
effects	O
of	O
constitutively	O
active	O
Toll	O
signaling	O
in	O
larvae	O
,	O
mainly	O
the	O
developmental	O
arrest	O
,	O
but	O
also	O
the	O
melanotic	O
tumor	O
formation	O
,	O
in	O
the	O
case	O
of	O
hypomorphic	O
cact	O
mutants	O
.	O

Genetic	O
Interactions	O
of	O
Toll	O
Signaling	O
and	O
ADGF-A	O

Survival	O
rate	O
and	O
melanotic	O
tumor	O
formation	O
were	O
compared	O
in	O
mutants	O
in	O
the	O
Toll	O
signaling	O
pathway	O
and	O
in	O
similar	O
mutants	O
with	O
overexpression	O
of	O
ADGF-A	O
using	O
the	O
HS-ADGF-A	O
construct	O
.	O

(	O
A	O
)	O
The	O
bar	O
graph	O
shows	O
the	O
percentage	O
of	O
the	O
pupae	O
(	O
blue	O
bars	O
)	O
and	O
adult	O
flies	O
(	O
purple	O
bars	O
)	O
demonstrating	O
the	O
larval	O
and	O
pupal	O
survival	O
of	O
each	O
genotype	O
.	O

The	O
x-axis	O
shows	O
the	O
genotypes	O
and	O
is	O
shared	O
with	O
(	O
B	O
)	O
.	O

Flies	O
heterozygous	O
for	O
the	O
cact	O
mutation	O
were	O
used	O
as	O
a	O
control	O
.	O

(	O
B	O
)	O
Percentage	O
of	O
late	O
third	O
instar	O
larvae	O
presenting	O
melanotic	O
tumor	O
formation	O
.	O

Discussion	O

ADA	O
Deficiency	O
in	O
Drosophila	O
Causes	O
Abnormal	O
Hemocyte	O
Development	O
,	O
Melanotic	O
Tumor	O
Formation	O
,	O
Fat	O
Body	O
Degeneration	O
,	O
and	O
Delayed	O
Development	O

We	O
have	O
established	O
an	O
ADA	O
deficiency	O
model	O
in	O
Drosophila	O
in	O
order	O
to	O
study	O
the	O
effects	O
of	O
altered	O
adenosine	O
levels	O
in	O
vivo	O
.	O

We	O
produced	O
a	O
loss-of-function	O
mutation	O
in	O
the	O
ADGF-A	O
gene	O
,	O
which	O
produces	O
a	O
product	O
(	O
ADGF-A	O
)	O
with	O
ADA	O
activity	O
.	O

When	O
homozygous	O
,	O
the	O
mutation	O
causes	O
abnormal	O
hemocyte	O
development	O
,	O
leading	O
to	O
melanotic	O
tumor	O
formation	O
[	O
36	O
]	O
,	O
as	O
well	O
as	O
fat-body	O
disintegration	O
associated	O
with	O
death	O
during	O
the	O
larval	O
stage	O
or	O
delayed	O
transition	O
to	O
the	O
pupal	O
stage	O
of	O
development	O
.	O

In	O
agreement	O
with	O
our	O
previous	O
study	O
using	O
cells	O
cultured	O
in	O
vitro	O
[	O
16	O
]	O
,	O
here	O
we	O
have	O
shown	O
that	O
ADA	O
enzymatic	O
activity	O
is	O
essential	O
for	O
ADGF-A	O
function	O
in	O
vivo	O
,	O
when	O
this	O
function	O
is	O
assayed	O
by	O
testing	O
for	O
rescue	O
of	O
the	O
mutant	O
phenotype	O
.	O

Just	O
as	O
increased	O
levels	O
of	O
both	O
ADA	O
substrates	O
,	O
adenosine	O
and	O
deoxyadenosine	O
,	O
are	O
found	O
in	O
blood	O
of	O
SCID	O
patients	O
[	O
5	O
]	O
,	O
adgf-a	O
mutant	O
larvae	O
also	O
have	O
elevated	O
levels	O
of	O
adenosine	O
and	O
deoxyadenosine	O
,	O
indicating	O
that	O
the	O
mutant	O
phenotype	O
is	O
caused	O
by	O
disturbance	O
in	O
the	O
turnover	O
of	O
these	O
nucleosides	O
.	O

Expression	O
of	O
ADGF-A	O
only	O
in	O
the	O
lymph	O
glands	O
is	O
sufficient	O
to	O
fully	O
rescue	O
the	O
mutant	O
phenotype	O
,	O
indicating	O
that	O
the	O
hemocytes	O
within	O
the	O
lymph	O
glands	O
play	O
a	O
major	O
role	O
in	O
regulation	O
of	O
adenosine	O
levels	O
in	O
the	O
hemolymph	O
.	O

A	O
similar	O
regulatory	O
role	O
has	O
also	O
been	O
attributed	O
to	O
blood	O
cells	O
in	O
humans	O
[	O
5	O
]	O
.	O

This	O
suggests	O
a	O
function	O
for	O
ADGF-A	O
within	O
the	O
lymph	O
gland	O
.	O

However	O
,	O
ADGF-A	O
behaves	O
as	O
a	O
soluble	O
growth	O
factor	O
and	O
could	O
be	O
released	O
from	O
the	O
lymph	O
gland	O
to	O
activate	O
targets	O
elsewhere	O
in	O
the	O
larval	O
body	O
.	O

Our	O
results	O
show	O
that	O
ADGF-A	O
functions	O
by	O
limiting	O
the	O
level	O
of	O
extracellular	O
adenosine	O
,	O
and	O
in	O
this	O
way	O
the	O
protein	O
could	O
have	O
a	O
systemic	O
function	O
even	O
if	O
it	O
were	O
restricted	O
to	O
its	O
tissue	O
of	O
origin	O
.	O

Although	O
our	O
tests	O
did	O
not	B-Speculation
exclude	I-Speculation
a	I-Speculation
role	I-Speculation
for	I-Speculation
ADGF-A	I-Speculation
in	I-Speculation
circulating	I-Speculation
hemocytes	I-Speculation
(	I-Speculation
which	I-Speculation
constitute	I-Speculation
a	I-Speculation
separate	I-Speculation
lineage	I-Speculation
from	I-Speculation
the	I-Speculation
lymph	I-Speculation
gland	I-Speculation
hemocytes	I-Speculation
[	O
20	O
]	O
)	O
,	O
we	O
showed	O
that	O
expression	B-Negation
of	I-Negation
ADGF-A	I-Negation
in	I-Negation
circulating	I-Negation
hemocytes	I-Negation
is	I-Negation
not	I-Negation
required	I-Negation
for	I-Negation
rescue	I-Negation
of	I-Negation
the	I-Negation
adgf-a	I-Negation
mutant	I-Negation
phenotype	I-Negation
,	O
since	O
e33C-Gal4/UAS-ADGF-A	O
?	O
which	O
expresses	O
ADGF-A	O
in	O
the	O
lymph	O
gland	O
but	O
not	O
in	O
circulating	O
hemocytes	O
?	O
fully	O
rescued	O
the	O
phenotype	O
.	O

ADGF-A	O
Is	O
Involved	O
in	O
Hemocyte	O
Differentiation	O
in	O
the	O
Lymph	O
Glands	O

Late	O
third-instar	O
larvae	O
homozygous	O
for	O
the	O
adgf-a	O
mutation	O
contain	O
,	O
on	O
average	O
,	O
seven	O
times	O
more	O
hemocytes	O
in	O
circulation	O
than	O
wild-type	O
larvae	O
,	O
and	O
most	O
of	O
these	O
cells	O
show	O
strong	O
adhesive	O
properties	O
compared	O
to	O
normal	O
larval	O
plasmatocytes	O
,	O
which	O
remain	O
rounded	O
after	O
settling	O
down	O
on	O
the	O
substrate	O
.	O

Although	O
these	O
cells	O
share	O
other	O
characteristics	O
with	O
plasmatocytes	O
,	O
they	B-Negation
are	I-Negation
normally	I-Negation
not	I-Negation
seen	I-Negation
in	I-Negation
circulation	I-Negation
until	O
they	O
are	O
released	O
from	O
the	O
lymph	O
glands	O
at	O
the	O
onset	O
of	O
metamorphosis	O
under	O
the	O
regulation	O
of	O
ecdysone	O
to	O
serve	O
as	O
phagocytes	O
for	O
histolysing	O
tissues	O
during	O
metamorphosisthus	O
,	O
they	O
are	O
referred	O
to	O
as	O
pupal	O
macrophages	O
[	O
19	O
]	O
.	O

In	O
agreement	O
with	O
the	O
presence	O
of	O
these	O
cells	O
in	O
circulation	O
,	O
at	O
least	O
the	O
first	O
lobes	O
of	O
the	O
lymph	O
glands	O
are	O
usually	O
completely	O
dispersed	O
in	O
late	O
third-instar	O
mutant	O
larvae	O
.	O

This	O
indication	O
of	O
precocious	O
metamorphic	O
changes	O
[	O
36	O
]	O
in	O
the	O
mutant	O
is	O
further	O
supported	O
by	O
the	O
finding	O
that	O
hemocytes	O
aggregate	O
in	O
a	O
segmental	O
pattern	O
in	O
early	O
rather	B-Negation
than	I-Negation
late	I-Negation
third	O
instar	O
(	O
see	O
Figure	O
4H4J	O
)	O
,	O
and	O
that	O
the	O
hemocytes	O
lose	O
expression	O
of	O
Hemolectin	O
in	O
late	O
third-instar	O
larvae	O
rather	B-Negation
than	I-Negation
at	I-Negation
the	I-Negation
onset	I-Negation
of	I-Negation
metamorphosis	I-Negation
(	O
see	O
Figure	O
4G	O
)	O
[	O
21	O
]	O
.	O

Recent	O
studies	O
show	O
that	O
the	O
Toll	O
signaling	O
pathway	O
,	O
which	O
is	O
already	O
known	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
innate	O
immunity	O
of	O
both	O
Drosophila	O
and	O
mammals	O
[	O
34	O
]	O
,	O
may	O
also	O
be	O
involved	O
in	O
the	O
control	O
of	O
hemocyte	O
differentiation	O
in	O
the	O
Drosophila	O
larva	O
.	O

Constitutive	O
activation	O
of	O
Toll	O
signaling	O
leads	O
to	O
developmental	O
arrest	O
and	O
hematopoietic	O
defects	O
associated	O
with	O
melanotic	O
tumor	O
formation	O
[	O
35	O
]	O
,	O
similar	O
to	O
the	O
phenotype	O
of	O
the	O
adgf-a	O
mutant	O
.	O

Our	O
work	O
also	O
shows	O
that	O
forced	O
expression	O
of	O
the	O
ADGF-A	O
gene	O
can	O
rescue	O
the	O
effects	O
of	O
overactive	O
Toll	O
signaling	O
,	O
suggesting	O
that	O
ADGF-A	O
might	O
function	O
downstream	O
of	O
Toll	O
signaling	O
to	O
control	O
its	O
effects	O
.	O

This	O
conclusion	O
is	O
consistent	O
with	O
the	O
existence	O
of	O
a	O
putative	O
binding	O
site	O
for	O
Dorsal	O
(	O
one	O
of	O
two	O
known	O
effectors	O
of	O
Toll	O
signaling	O
)	O
in	O
the	O
ADGF-A	O
promoter	O
(	O
Figure	O
9	O
)	O
.	O

It	O
will	O
be	O
important	O
to	O
explore	O
this	O
connection	O
further	O
,	O
since	O
recent	O
studies	O
suggest	O
an	O
interaction	O
between	O
adenosine	O
signaling	O
and	O
the	O
NF-	O
?	O
B	O
signaling	O
pathway	O
,	O
which	O
is	O
the	O
mammalian	O
counterpart	O
of	O
the	O
Toll	O
pathway	O
[	O
37	O
]	O
.	O

Schematic	O
Map	O
of	O
the	O
ADGF-A	O
Gene	O
with	O
Promoter	O
Analysis	O

The	O
ADGF-A	O
gene	O
contains	O
four	O
exons	O
and	O
two	O
transcriptional	O
starts	O
[	O
17,47	O
]	O
.	O

We	O
analyzed	O
sequences	O
preceding	O
both	O
transcriptional	O
starts	O
for	O
the	O
presence	O
of	O
known	O
transcriptional	O
factor	O
binding	O
sites	O
using	O
the	O
software	O
program	O
Gene2Promoter	O
(	O
Genomatix	O
Software	O
GmbH	O
)	O
.	O

Selected	O
sites	O
are	O
represented	O
by	O
color	O
bars	O
in	O
approximate	O
positions	O
of	O
promoter	O
regions	O
.	O

The	O
legend	O
under	O
the	O
sequence	O
show	O
the	O
names	O
of	O
transcription	O
factors	O
binding	O
to	O
matching	O
colored	O
binding	O
sites	O
.	O

Precocious	O
Fat-Body	O
Disintegration	O
Caused	O
by	O
Mutant	O
Hemocytes	O

One	O
of	O
the	O
most	O
remarkable	O
features	O
of	O
the	O
adgf-a	O
mutant	O
phenotype	O
is	O
the	O
disintegration	O
of	O
the	O
fat	O
body	O
in	O
third-instar	O
larvae	O
,	O
another	O
indication	O
of	O
precocious	O
metamorphic	O
changes	O
since	O
the	O
disintegration	O
normally	O
occurs	O
much	O
later	O
,	O
during	O
pupal	O
life	O
.	O

Furthermore	O
,	O
our	O
study	O
of	O
this	O
mutant	O
provides	O
strong	O
evidence	O
that	O
the	O
fat	O
body	O
disintegration	O
is	O
promoted	O
by	O
the	O
action	O
of	O
hemocytes	O
.	O

Fat	O
body	O
disintegration	O
was	O
significantly	O
suppressed	O
when	O
the	O
hemocyte	O
number	O
was	O
reduced	O
using	O
the	O
l	O
(	O
3	O
)	O
hem1	O
mutation	O
[	O
26	O
]	O
,	O
and	O
fully	O
blocked	O
by	O
the	O
croquemort	O
(	O
crq	O
)	O
mutation	O
[	O
27	O
]	O
which	O
affects	O
a	O
CD36-related	O
receptor	O
(	O
Croquemort	O
)	O
expressed	O
on	O
macrophages	O
and	O
required	O
in	O
phagocytosis	O
of	O
apoptotic	O
cells	O
.	O

Human	O
CD36	O
is	O
a	O
scavenger	O
receptor	O
which	O
,	O
in	O
combination	O
with	O
the	O
macrophage	O
vitronectin	O
receptor	O
and	O
thrombospondin	O
,	O
binds	O
apoptotic	O
cells	O
.	O

A	B-Negation
similar	I-Negation
role	I-Negation
of	I-Negation
Croquemort	I-Negation
for	I-Negation
removing	I-Negation
histolysing	I-Negation
tissues	I-Negation
during	I-Negation
Drosophila	I-Negation
metamorphosis	I-Negation
has	I-Negation
not	I-Negation
yet	I-Negation
been	I-Negation
tested	I-Negation
,	O
but	O
seems	B-Speculation
likely	I-Speculation
since	O
the	O
crq	O
mutant	O
used	O
in	O
this	O
study	O
(	O
crqKG01679	O
)	O
is	O
lethal	O
in	O
pupae	O
.	O

The	O
idea	O
that	O
hemocytes	O
are	O
involved	O
in	O
fat	O
body	O
dissociation	O
in	O
Drosophila	O
is	O
further	O
supported	O
by	O
work	O
on	O
the	O
flesh	O
fly	O
Sarcophaga	O
.	O

Natori	O
's	O
group	O
showed	O
that	O
proteinase	O
cathepsin	O
B	O
was	O
released	O
from	O
pupal	O
hemocytes	O
when	O
they	O
interacted	O
with	O
the	O
fat	O
body	O
,	O
and	O
that	O
this	O
enzyme	O
digested	O
the	O
basement	O
membrane	O
of	O
the	O
fat	O
body	O
,	O
causing	O
the	O
tissue	O
to	O
dissociate	O
[	O
38,39	O
]	O
.	O

They	O
also	O
showed	O
that	O
the	O
interaction	O
of	O
hemocytes	O
with	O
the	O
fat	O
body	O
is	O
mediated	O
by	O
a	O
120-kDa	O
membrane	O
protein	O
localized	O
specifically	O
on	O
pupal	O
hemocytes	O
[	O
40	O
]	O
.	O

This	B-Speculation
protein	I-Speculation
was	I-Speculation
suggested	I-Speculation
to	I-Speculation
be	I-Speculation
a	I-Speculation
scavenger	I-Speculation
receptor	I-Speculation
,	O
but	O
it	B-Negation
does	I-Negation
not	I-Negation
seem	B-Speculation
to	I-Speculation
be	I-Speculation
homologous	I-Speculation
to	I-Speculation
Drosophila	I-Speculation
Croquemort	I-Speculation
(	O
unpublished	O
data	O
)	O
.	O

Work	O
by	O
Franc	O
et	O
al.	O
[	O
27	O
]	O
is	O
consistent	O
with	O
the	O
idea	O
that	O
more	O
than	O
one	O
scavenger	O
receptor	O
is	O
involved	O
in	O
this	O
process	O
.	O

Possible	O
Signaling	O
Role	O
for	O
Adenosine	O

The	O
precocious	O
metamorphic	O
changes	O
that	O
appear	O
to	O
occur	O
in	O
response	O
to	O
elevated	O
adenosine	O
in	O
the	O
adgf-a	O
mutant	O
larvae	O
lead	O
to	O
the	O
suggestion	O
that	O
adenosine	O
may	O
act	O
as	O
a	O
regulatory	O
signal	O
for	O
these	O
processes	O
during	O
normal	O
development	O
.	O

One	O
possibility	O
is	O
that	O
adenosine	O
acts	O
as	O
a	O
downstream	O
effector	O
of	O
ecdysone-regulated	O
prepupal	O
changes	O
,	O
and	O
that	O
the	O
increase	O
in	O
adenosine	O
concentration	O
is	O
mediated	O
by	O
ecdysone-induced	O
down-regulation	O
of	O
ADGF-A	O
expression	O
.	O

This	O
is	O
supported	O
by	O
the	O
presence	O
of	O
multiple	O
sites	O
for	O
ecdysone-inducible	O
transcription	O
regulators	O
in	O
the	O
ADGF-A	O
promoter	O
(	O
Figure	O
9	O
)	O
.	O

Adenosine	O
could	B-Speculation
serve	I-Speculation
as	I-Speculation
a	I-Speculation
signal	I-Speculation
for	I-Speculation
macrophage	I-Speculation
differentiation	I-Speculation
,	O
and	O
the	O
lack	B-Negation
of	I-Negation
adenosine	I-Negation
deaminase	I-Negation
activity	I-Negation
due	O
to	O
the	O
adgf-a	O
mutation	O
could	B-Speculation
cause	I-Speculation
precocious	I-Speculation
differentiation	I-Speculation
of	I-Speculation
these	I-Speculation
cells	I-Speculation
in	I-Speculation
mutant	I-Speculation
larvae	I-Speculation
.	O

We	O
are	O
now	O
carrying	O
out	O
direct	O
tests	O
of	O
the	O
idea	O
that	O
the	O
differentiation	O
of	O
hemocytes	O
in	O
mutant	O
larvae	O
is	O
caused	O
by	O
elevated	O
adenosine	O
.	O

If	O
confirmed	O
,	O
this	O
effect	O
would	O
have	O
general	O
significance	O
,	O
since	O
in	O
ADA-deficient	O
mice	O
,	O
inflammatory	O
changes	O
in	O
the	O
lungs	O
include	O
an	O
accumulation	O
of	O
activated	O
alveolar	O
macrophages	O
[	O
41	O
]	O
,	O
and	O
this	O
could	O
also	O
be	O
mediated	O
by	O
elevated	O
adenosine	O
.	O

Elevated	O
Adenosine	O
Delays	O
Development	O
and	O
Inhibits	O
Pupariation	O

The	O
elevated	O
adenosine	O
in	O
the	O
adgf-a	O
mutant	O
larvae	O
leads	O
to	O
precocious	O
changes	O
(	O
hemocyte	O
differentiation	O
and	O
fat	O
body	O
disintegration	O
)	O
resembling	O
those	O
normally	O
occurring	O
at	O
the	O
time	O
of	O
metamorphosis	O
,	O
but	O
it	O
also	O
is	O
associated	O
with	O
an	O
apparently	O
opposite	O
effect	O
,	O
in	O
that	O
it	O
causes	O
a	O
significant	O
delay	O
in	O
progress	O
through	O
the	O
third	O
larval	O
instar	O
and	O
a	O
decrease	O
in	O
the	O
frequency	O
of	O
successful	O
pupariation	O
(	O
formation	O
of	O
the	O
puparium	O
from	O
the	O
larval	O
cuticle	O
)	O
,	O
which	O
is	O
one	O
of	O
the	O
earliest	O
steps	O
in	O
metamorphosis	O
.	O

We	O
conclude	O
that	O
the	O
mutation	O
has	O
additional	O
effects	O
on	O
the	O
hormonal	O
regulation	O
of	O
development	O
.	O

One	O
possible	O
explanation	O
for	O
the	O
developmental	O
delay	O
and	O
failure	O
to	O
pupariate	O
is	O
that	O
the	O
adgf-a	O
mutation	O
affects	O
the	O
production	O
or	O
release	O
of	O
ecdysteroid	O
hormones	O
from	O
the	O
major	O
endocrine	O
organ	O
of	O
the	O
Drosophila	O
larvathe	O
ring	O
gland	O
.	O

This	O
is	O
supported	O
by	O
the	O
fact	O
that	O
pupariation	O
rate	O
and	O
survival	O
of	O
the	O
adgf-a	O
mutant	O
can	O
be	O
significantly	O
improved	O
by	O
expression	O
of	O
transgenic	O
ADGF-A	O
in	O
the	O
ring	O
gland	O
and	O
salivary	O
glands	O
.	O

We	O
suggest	O
that	O
this	O
somehow	O
interferes	O
with	O
the	O
regulation	O
of	O
hormone	O
release	O
.	O

Other	O
mutants	O
with	O
hormonal	O
dysregulation	O
show	O
delayed	O
larval	O
development	O
and	O
failure	B-Negation
to	I-Negation
pupariate	I-Negation
[	O
42,43	O
]	O
.	O

Presumably	O
the	O
elevated	O
adenosine	O
in	O
the	O
adgf-a	O
mutant	O
blocks	O
the	O
production	O
or	O
release	O
of	O
ecdysone	O
from	O
the	O
ring	O
gland	O
by	O
an	O
unknown	O
mechanism	O
.	O

This	O
idea	O
is	O
supported	O
by	O
our	O
finding	O
that	O
both	O
pupariation	O
rate	O
and	O
survival	O
of	O
the	O
adgf-a	O
mutant	O
can	O
also	O
be	O
improved	O
by	O
feeding	O
the	O
mutant	O
larvae	O
with	O
20E	O
in	O
the	O
diet	O
(	O
see	O
Figure	O
7A	O
)	O
.	O

Thus	O
it	O
is	O
clear	O
that	O
the	O
adgf-a	O
mutant	O
is	O
arrested	O
in	O
development	O
due	O
to	O
an	O
effect	O
of	O
the	O
mutation	O
on	O
hormone	O
production	O
from	O
the	O
ring	O
gland	O
.	O

The	O
arrest	O
of	O
development	O
in	O
the	O
adgf-a	O
mutants	O
was	O
significantly	O
suppressed	O
by	O
loss	O
of	O
the	O
adenosine	O
receptor	O
caused	O
by	O
the	O
adoR	O
mutation	O
:	O
larvae	O
simply	O
homozygous	O
for	O
adgf-a	O
pupated	O
after	O
two	O
or	O
more	O
days	O
,	O
whereas	O
larvae	O
also	O
homozygous	O
for	O
adoR	O
pupated	O
within	O
1	O
d	O
after	O
their	O
heterozygous	O
siblings	O
(	O
see	O
Figure	O
7A	O
)	O
.	O

Therefore	O
,	O
adenosine	O
signaling	O
through	O
the	O
AdoR	O
must	O
play	O
a	O
role	O
in	O
the	O
developmental	O
arrest	O
of	O
the	O
adgf-a	O
mutant	O
,	O
and	O
this	O
is	O
most	O
likely	O
mediated	O
by	O
signaling	O
to	O
the	O
ring	O
gland	O
,	O
where	O
AdoR	O
is	O
expressed	O
(	O
ED	O
,	O
unpublished	O
data	O
)	O
.	O

The	O
mutation	O
in	O
AdoR	O
does	O
not	B-Negation
block	I-Negation
macrophage	I-Negation
differentiation	I-Negation
and	I-Negation
fat-body	I-Negation
disintegration	I-Negation
,	O
so	O
this	O
effect	O
must	B-Speculation
involve	I-Speculation
another	I-Speculation
,	I-Speculation
as	I-Speculation
yet	I-Speculation
uncharacterized	I-Speculation
mechanism	I-Speculation
independent	I-Speculation
of	I-Speculation
AdoR	I-Speculation
signaling	I-Speculation
.	O

Work	O
using	O
adenosine-receptor	O
deficient	O
mammalian	O
cells	O
also	O
suggested	O
the	O
existence	O
of	O
a	O
novel	O
,	O
undefined	O
adenosine	O
signaling	O
mechanism	O
[	O
44	O
]	O
.	O

However	O
,	O
we	O
can	O
not	O
exclude	O
the	O
role	O
of	O
elevated	O
deoxyadenosine	O
in	O
these	O
effects	O
.	O

Drosophila	O
,	O
now	O
with	O
the	O
advantage	O
of	O
the	O
well-characterized	O
adgf-a	O
mutant	O
,	O
could	O
serve	O
as	O
an	O
ideal	O
model	O
system	O
in	O
which	O
to	O
investigate	O
this	O
mechanism	O
.	O

Concluding	O
Remarks	O

In	O
our	O
previous	O
work	O
using	O
cells	O
cultured	O
in	O
vitro	O
,	O
we	O
showed	O
that	O
,	O
as	O
in	O
mammals	O
,	O
adenosine	O
can	O
block	O
proliferation	O
and/or	O
survival	O
of	O
some	O
Drosophila	O
cell	O
types	O
[	O
16	O
]	O
.	O

In	O
the	O
present	O
work	O
,	O
we	O
have	O
established	O
a	O
Drosophila	O
model	O
to	O
study	O
altered	O
levels	O
of	O
adenosine	O
and	O
deoxyadenosine	O
in	O
vivo	O
,	O
and	O
we	O
have	O
shown	O
that	O
loss	O
of	O
ADGF-A	O
function	O
causes	O
an	O
increase	O
of	O
these	O
nucleosides	O
in	O
larval	O
hemolymph	O
.	O

Although	O
the	O
adgf-a	O
mutation	O
leads	O
to	O
larval	O
or	O
pupal	O
death	O
,	O
we	O
have	O
shown	O
that	O
this	O
is	O
not	B-Negation
due	I-Negation
to	I-Negation
the	I-Negation
adenosine	I-Negation
or	I-Negation
deoxyadenosine	I-Negation
simply	I-Negation
blocking	I-Negation
cellular	I-Negation
proliferation	I-Negation
or	I-Negation
survival	I-Negation
,	O
as	O
the	O
experiments	O
in	O
vitro	O
would	B-Speculation
suggest	I-Speculation
.	O

Rather	O
,	O
this	O
mutation	O
leads	O
to	O
an	O
increase	O
in	O
number	O
of	O
hemocytes	O
at	O
the	O
end	O
of	O
larval	O
development	O
due	O
to	O
the	O
differentiation	O
and	O
release	O
of	O
hemocytes	O
from	O
the	O
lymph	O
glands	O
.	O

Hemocytes	O
also	O
differentiate	O
and	O
are	O
released	O
from	O
the	O
lymph	O
glands	O
during	O
systemic	O
infection	O
[	O
19	O
]	O
.	O

Together	O
with	O
our	O
result	O
suggesting	O
an	O
interaction	O
between	O
Toll	O
signaling	O
and	O
ADGF-A	O
,	O
this	O
leads	O
to	O
the	O
hypothesis	O
that	O
adenosine	O
controls	O
hemocyte	O
differentiation	O
in	O
response	O
to	O
infection	O
,	O
and	O
that	O
it	O
signals	O
through	O
the	O
adenosine	O
receptor	O
to	O
postpone	O
the	O
next	O
developmental	O
step	O
,	O
metamorphosis	O
.	O

This	O
would	O
be	O
consistent	O
with	O
the	O
role	O
of	O
adenosine	O
as	O
a	O
	O
stress	O
hormone	O
	O
in	O
mammals	O
[	O
6	O
]	O
.	O

A	O
similar	O
process	O
of	O
hemocyte	O
differentiation	O
and	O
release	O
from	O
the	O
lymph	O
glands	O
normally	O
takes	O
place	O
at	O
the	O
onset	O
of	O
metamorphosis	O
,	O
when	O
pupal	O
macrophages	O
remove	O
histolyzing	O
tissues	O
.	O

The	O
ADGF-A	O
promoter	O
contains	O
consensus	O
binding	O
sites	O
for	O
effectors	O
of	O
both	O
Toll	O
and	O
ecdysone	O
signaling	O
.	O

This	O
raises	O
the	O
possibility	O
that	O
adenosine	O
plays	O
a	O
role	O
in	O
the	O
control	O
of	O
metamorphosis	O
as	O
well	O
as	O
in	O
the	O
response	O
to	O
stress	O
.	O

Materials	O
and	O
Methods	O

Fly	O
strains	O
and	O
genetics	O

For	O
standard	O
procedures	O
,	O
flies	O
were	O
raised	O
at	O
25	O
C	O
on	O
a	O
standard	O
cornmeal-agar-yeast-molasses	O
diet	O
supplemented	O
with	O
0.3	O
%	O
Nipagin	O
to	O
retard	O
mold	O
growth	O
.	O

Oregon	O
flies	O
were	O
used	O
as	O
the	O
wild-type	O
Drosophila	O
strain	O
,	O
but	O
in	O
most	O
cases	O
the	O
y	O
w	O
strain	O
was	O
used	O
as	O
a	O
control	O
since	O
most	O
mutations	O
were	O
carried	O
in	O
the	O
y	O
w	O
background	O
.	O

A	O
mutation	O
in	O
the	O
ADGF-A	O
gene	O
on	O
Chromosome	O
III	O
was	O
obtained	O
as	O
described	O
earlier	O
[	O
17	O
]	O
.	O

In	O
this	O
study	O
,	O
the	O
mutation	O
described	O
as	O
adgf-akarel	O
was	O
used	O
in	O
all	O
experiments	O
and	O
is	O
referred	O
to	O
here	O
as	O
adgf-a	O
.	O

A	O
mutation	O
in	O
the	O
adenosine	O
receptor	O
gene	O
on	O
Chromosome	O
III	O
was	O
produced	O
by	O
the	O
ends-out	O
targeting	O
method	O
(	O
ED	O
,	O
unpublished	O
data	O
)	O
and	O
is	O
referred	O
to	O
here	O
as	O
adoR	O
.	O

Transgenic	O
flies	O
carrying	O
HS-ADGF-A	O
,	O
UAS-ADGF-Amyc	O
,	O
and	O
UAS-mutADGF-Amyc	O
construct	O
(	O
see	O
description	O
below	O
)	O
were	O
produced	O
by	O
a	O
modified	O
P-element	O
transformation	O
method	O
[	O
45	O
]	O
.	O

HS-ADGF-A	O
,	O
UAS-ADGF-Amyc	O
[	O
2A	O
]	O
,	O
UAS-ADGF-Amyc	O
[	O
7A	O
]	O
,	O
UAS-mutADGF-Amyc	O
[	O
1A	O
]	O
,	O
andUAS-mutADGF-Amyc	O
[	O
3B	O
]	O
,	O
all	O
insertions	O
on	O
Chromosome	O
II	O
,	O
were	O
isolated	O
and	O
used	O
in	O
this	O
work	O
.	O

The	O
following	O
markers	O
and	O
mutations	O
were	O
obtained	O
from	O
the	O
Bloomington	O
stock	O
center	O
,	O
accessible	O
at	O
http	O
:	O
//fly.bio.indiana.edu/	O
(	O
stock	O
numbers	O
provided	O
in	O
parentheses	O
)	O
:	O
Hml-GFP	O
marker	O
(	O
Hml-Gal4/UAS-GFP	O
)	O
expressing	O
GFP	O
in	O
embryonic	O
and	O
larval	O
hemocytes	O
on	O
Chromosome	O
II	O
(	O
BL-6397	O
)	O
,	O
the	O
l	O
(	O
3	O
)	O
hem1	O
mutation	O
on	O
Chromosome	O
III	O
(	O
BL-6184	O
)	O
,	O
and	O
the	O
crqKG01679	O
mutation	O
in	O
the	O
crq	O
gene	O
on	O
Chromosome	O
II	O
(	O
BL-14900	O
)	O
.	O

Mutants	O
in	O
Toll	O
signaling	O
pathway	O
were	O
obtained	O
from	O
Dr.	O
S.	O
Govind	O
:	O
cactE8	O
,	O
cactIIIG	O
,	O
and	O
cactD13	O
mutations	O
in	O
the	O
cact	O
gene	O
on	O
Chromosome	O
II	O
.	O

The	O
Gal4/UAS	O
[	O
18	O
]	O
system	O
was	O
used	O
for	O
protein	O
misexpression	O
.	O

The	O
following	O
were	O
obtained	O
from	O
the	O
Bloomington	O
stock	O
center	O
(	O
stock	O
numbers	O
in	O
parenthesis	O
)	O
:	O
Cg-Gal4	O
on	O
Chromosome	O
II	O
(	O
BL-7011	O
)	O
,	O
Pw+mW.hs=GawB5015	O
on	O
II	O
(	O
BL-2721	O
)	O
,	O
Pw+mW.hs=GawBc564	O
on	O
II	O
(	O
BL-6982	O
)	O
,	O
Pw+mW.hs=GawBT110	O
on	O
II	O
(	O
BL-6998	O
)	O
,	O
Hml-Gal4	O
on	O
II	O
(	O
BL-6396	O
)	O
,	O
Dot-Gal443A	O
on	O
X	O
(	O
BL-6903	O
)	O
,	O
Dot-Gal411C	O
on	O
II	O
(	O
BL-6902	O
)	O
,	O
and	O
Lsp2-Gal4	O
(	O
BL-6357	O
)	O
on	O
III	O
.	O

The	O
Pen2.4-GAL4e33C	O
lethal	O
insertion	O
on	O
Chromosome	O
III	O
was	O
obtained	O
from	O
Dr.	O
N.	O
Perrimon	O
's	O
lab	O
,	O
and	O
the	O
Dmef2-Gal4	O
driver	O
on	O
II	O
from	O
Dr.	O
A.	O
Michelson	O
.	O

Expression	O
information	O
of	O
these	O
Gal4	O
drivers	O
is	O
provided	O
in	O
Table	O
1	O
.	O

A	O
stock	O
carrying	O
the	O
ubiquitous	O
actin-Gal4	O
driver	O
(	O
P-actin-Gal4	O
UAS-GFP/CyO	O
;	O
lethal	O
insertion	O
on	O
Chromosome	O
II	O
)	O
was	O
obtained	O
from	O
Dr.	O
R.	O
Sousa	O
.	O

To	O
recognize	O
homozygous	O
larvae	O
,	O
balancer	O
chromosomes	O
with	O
the	O
GFP	O
marker	O
were	O
used	O
:	O
CyO	O
Pw+mW.hs=Ubi-GFP.S65TPAD1	O
(	O
BL-4559	O
)	O
and	O
TM3	O
Pw+mC=ActGFPJMR2	O
Ser	O
(	O
BL-4888	O
)	O
.	O

Transgenic	O
flies	O
SgsGFP-1	O
(	O
insertion	O
on	O
Chromosome	O
X	O
)	O
and	O
SgsGFP-2	O
(	O
insertion	O
on	O
Chromosome	O
II	O
)	O
containing	O
the	O
chimeric	O
gene	O
construct	O
Sgs	O
?	O
3-GFP	O
were	O
obtained	O
from	O
Dr.	O
A.	O
J.	O
Andres	O
.	O

For	O
expression	O
of	O
ADGF-A	O
using	O
the	O
HS-ADGF-A	O
construct	O
,	O
flies	O
were	O
heat	O
shocked	O
as	O
late	O
embryos/early	O
first	O
instars	O
at	O
37	O
C	O
for	O
30	O
min	O
.	O

In	O
all	O
rescue	O
experiments	O
,	O
30	O
freshly	O
hatched	O
homozygous	O
first-instar	O
larvae	O
were	O
selected	O
using	O
a	O
GFP	O
dissecting	O
microscope	O
and	O
transferred	O
into	O
fresh	O
vials	O
(	O
at	O
least	O
four	O
vials	O
for	O
each	O
variant	O
)	O
.	O

They	O
were	O
left	O
to	O
develop	O
at	O
25	O
C	O
and	O
examined	O
as	O
wandering	O
third-instar	O
larvae	O
,	O
pupae	O
,	O
and	O
adults	O
.	O

Ecdysone	O
treatment	O

Mutant	O
larvae	O
were	O
raised	O
on	O
plates	O
with	O
yeast	O
paste	O
at	O
25	O
C	O
and	O
transferred	O
to	O
vials	O
with	O
glucose-yeast	O
medium	O
(	O
control	O
)	O
or	O
with	O
glucose-yeast	O
medium	O
containing	O
20-hydroxyecdysone	O
(	O
H-5142	O
;	O
Sigma-Aldrich	O
,	O
St	O
.	O

Louis	O
,	O
Missouri	O
,	O
United	O
States	O
)	O
at	O
a	O
concentration	O
of	O
0.5	O
mg/ml	O
shortly	O
after	O
the	O
L2/L3	O
molt	O
.	O

Numbers	O
of	O
puparia	O
were	O
counted	O
at	O
12-h	O
intervals	O
after	O
the	O
120-h	O
time	O
point	O
(	O
when	O
the	O
first	O
control	O
larvae	O
start	O
to	O
pupariate	O
)	O
.	O

The	O
ecd1	O
flies	O
(	O
Bloomington	O
stock	O
BL-218	O
)	O
served	O
as	O
a	O
control	O
for	O
the	O
functional	O
20E	O
diet	O
[	O
31	O
]	O
:	O
flies	O
were	O
raised	O
at	O
22	O
C	O
(	O
permissive	O
temperature	O
for	O
the	O
temperature-sensitive	O
ecd1	O
mutation	O
)	O
and	O
transferred	O
to	O
vials	O
with	O
control	O
or	O
20E-containing	O
diet	O
and	O
raised	O
at	O
29	O
C	O
(	O
restrictive	O
temperature	O
)	O
.	O

Fat	O
body	O
observation	O

Living	O
late	O
third-instar	O
larvae	O
were	O
washed	O
and	O
examined	O
in	O
PBS	O
using	O
a	O
standard	O
dissecting	O
microscope	O
with	O
transmitted	O
light	O
.	O

For	O
finer	O
analysis	O
,	O
the	O
fat	O
body	O
was	O
dissected	O
from	O
larvae	O
in	O
PBS	O
and	O
observed	O
using	O
a	O
dissecting	O
microscope	O
.	O

GFP-stained	O
fat	O
body	O
was	O
observed	O
in	O
living	O
,	O
etherized	O
larvae	O
in	O
PBS	O
solution	O
on	O
a	O
standard	O
microscopic	O
slide	O
with	O
a	O
coverslip	O
under	O
a	O
fluorescence	O
microscope	O
.	O

Hemocyte	O
counts	O
and	O
observations	O

Circulating	O
hemocytes	O
were	O
obtained	O
by	O
opening	O
two	O
late	O
third-instar	O
larvae	O
in	O
30	O
?	O
l	O
of	O
PBS	O
.	O

This	O
allowed	O
us	O
to	O
collect	O
all	O
hemolymph	O
from	O
the	O
larvae	O
in	O
a	O
defined	O
volume	O
.	O

The	O
solution	O
with	O
circulating	O
hemocytes	O
was	O
mixed	O
by	O
gently	O
pipetting	O
,	O
and	O
part	O
was	O
transferred	O
into	O
the	O
chamber	O
of	O
an	O
improved	O
Neubauer	O
hemocytometer	O
.	O

Cell	O
number	O
was	O
recounted	O
to	O
one	O
animal	O
equivalent	O
.	O

Hemocyte	O
morphology	O
was	O
observed	O
by	O
differential	O
interference	O
contrast	O
microscopy	O
of	O
living	O
cells	O
in	O
Shields	O
and	O
Sang	O
Insect	O
Medium	O
(	O
Sigma-Aldrich	O
)	O
obtained	O
by	O
the	O
same	O
procedure	O
as	O
for	O
counting	O
.	O

To	O
observe	O
hemocyte	O
morphology	O
,	O
samples	O
were	O
analyzed	O
at	O
least	O
10	O
min	O
after	O
the	O
deposition	O
of	O
solution	O
with	O
hemocytes	O
,	O
in	O
order	O
to	O
allow	O
the	O
cells	O
to	O
adhere	O
to	O
the	O
surface	O
of	O
the	O
slide	O
.	O

Crystal	O
cells	O
were	O
visualized	O
by	O
heating	O
larvae	O
at	O
60	O
C	O
for	O
10	O
min	O
in	O
a	O
water	O
bath	O
[	O
46	O
]	O
.	O

GFP-stained	O
hemocytes	O
were	O
observed	O
in	O
living	O
,	O
etherized	O
larvae	O
in	O
PBS	O
solution	O
on	O
a	O
standard	O
microscopic	O
slide	O
with	O
a	O
coverslip	O
under	O
the	O
fluorescence	O
microscope	O
or	O
by	O
deposition	O
of	O
hemocytes	O
in	O
PBS	O
as	O
for	O
counting	O
and	O
observing	O
under	O
the	O
fluorescence	O
microscope	O
.	O

Transgenic	O
constructs	O

Wild-type	O
cDNA	O
for	O
ADGF-A	O
was	O
amplified	O
by	O
PCR	O
using	O
proofreading	O
DNA	O
polymerase	O
(	O
ProofStart	O
;	O
Invitrogen	O
,	O
Carlsbad	O
,	O
California	O
,	O
United	O
States	O
)	O
from	O
a	O
pOT2	O
vector	O
containing	O
the	O
ADGF-A	O
EST-clone	O
(	O
GH08276	O
)	O
using	O
the	O
following	O
primers	O
:	O
5	O
?	O
-	O
CGTCTAGAATGTCGCCAGTCATCCGCC-3	O
?	O
(	O
5	O
?	O
end	O
primer	O
with	O
XbaI	O
tail	O
)	O
and	O
5	O
?	O
-	O
GCTGATCATCAATCGATCCGTTGACTGGGGGA-3	O
?	O
(	O
3	O
?	O
end	O
primer	O
with	O
BclI	O
tail	O
)	O
.	O

The	O
PCR	O
product	O
was	O
cloned	O
into	O
the	O
pGEM-T	O
Easy	O
vector	O
(	O
Promega	O
,	O
Madison	O
,	O
Wisconsin	O
,	O
United	O
States	O
)	O
,	O
and	O
the	O
resulting	O
plasmid	O
(	O
ADGF-A-pGEM	O
)	O
was	O
cut	O
by	O
NotI/SpeI	O
restriction	O
enzymes	O
.	O

The	O
ADGF-A	O
fragment	O
was	O
then	O
cloned	O
into	O
the	O
pCaSpeR-hs	O
)	O
vector	O
cut	O
by	O
NotI/XbaI	O
to	O
obtain	O
the	O
HS-ADGF-A	O
construct	O
.	O

The	O
myc	O
tag	O
was	O
added	O
to	O
the	O
C	O
terminus	O
of	O
the	O
ADGF-A	O
protein	O
for	O
detection	O
by	O
anti-c-Myc	O
antibody	O
(	O
Sigma-Aldrich	O
)	O
.	O

To	O
produce	O
a	O
UAS-ADGF-Amyc	O
construct	O
,	O
the	O
ADGF-A	O
fragment	O
was	O
amplified	O
(	O
by	O
ProofStart	O
from	O
pOT2	O
vector	O
)	O
using	O
the	O
following	O
primers	O
:	O
5	O
?	O
-	O
AATCTCGAGCTCATCATGTCGCCAGTCATC-3	O
?	O
(	O
5	O
?	O
end	O
with	O
XhoI	O
tail	O
)	O
and	O
5	O
?	O
-	O
TATCTAGATCGATCCGTTGACTGGGGG-3	O
?	O
(	O
3	O
?	O
end	O
with	O
XbaI	O
tail	O
)	O
.	O

The	O
fragment	O
was	O
cut	O
by	O
XhoI/XbaI	O
and	O
cloned	O
into	O
the	O
pUAST	O
vector	O
modified	O
by	O
MZ	O
.	O

The	O
sequence	O
encoding	O
the	O
myc-tag	O
5	O
?	O
-	O
GAGCAAAAGCTCATTTCTGAAGAGGACTTG-3	O
?	O
plus	O
a	O
stop	O
codon	O
was	O
inserted	O
into	O
XbaI	O
site	O
of	O
pUAST	O
(	O
using	O
the	O
XbaI	O
site	O
on	O
the	O
5	O
?	O
end	O
and	O
the	O
NheI	O
site	O
on	O
the	O
3	O
?	O
end	O
)	O
cut	O
by	O
XhoI/XbaI	O
.	O

A	O
mutated	O
versionUAS-mutADGF-Amycwas	O
prepared	O
in	O
the	O
same	O
way	O
as	O
UAS-ADGF-Amyc	O
,	O
but	O
pBLUESCRIPT	O
containing	O
mutated	O
ADGF-A	O
cDNA	O
was	O
used	O
as	O
a	O
template	O
.	O

The	O
mutated	O
version	O
of	O
ADGF-A	O
(	O
carrying	O
a	O
mutation	O
causing	O
the	O
substitution	O
of	O
two	O
amino	O
acidsHis386	O
and	O
Ala387	O
for	O
Glu	O
and	O
Leu	O
,	O
respectively	O
)	O
in	O
the	O
catalytic	O
domain	O
,	O
shown	O
to	O
abolish	O
adenosine	O
deaminase	O
activity	O
[	O
16	O
]	O
,	O
was	O
prepared	O
by	O
recombinant	O
PCR	O
using	O
the	O
following	O
recombinant	O
primers	O
:	O
5	O
?	O
-	O
TCTACTTCGAGCTCGGAGAAACAAACTGGTTCGGT-3	O
?	O
and	O
5	O
?	O
-	O
CTCCGAGCTCGAAGTAGAAATCAATGTCATCG-3	O
?	O
and	O
the	O
same	O
5	O
?	O
and	O
3	O
?	O
end	O
primers	O
as	O
above	O
.	O

Adenosine	O
and	O
deoxyadenosine	O
concentrations	O
measurement	O

The	O
detection	O
method	O
used	O
liquid	O
chromatography	O
and	O
mass	O
spectrometry	O
(	O
LC/MS	O
method	O
)	O
of	O
deproteinated	O
hemolymph	O
samples	O
.	O

Larval	O
hemolymph	O
was	O
collected	O
from	O
several	O
larvae	O
and	O
centrifuged	O
to	O
pellet	O
the	O
hemocytes	O
.	O

1	O
?	O
l	O
of	O
hemolymph	O
was	O
diluted	O
in	O
99	O
?	O
l	O
of	O
buffer	O
.	O

The	O
sample	O
was	O
introduced	O
in	O
CH3CN-0.05	O
%	O
TFA	O
(	O
50:50	O
)	O
either	O
via	O
a	O
syringe	O
pump	O
at	O
3	O
?	O
l/min	O
or	O
via	O
an	O
RP-C18	O
150	O
mm	O
	O
1	O
mm	O
Symmetry	O
C8	O
column	O
at	O
50	O
?	O
l/min	O
employing	O
an	O
LCQ	O
electrospray	O
ion	O
source	O
operated	O
at	O
4.2	O
kV	O
.	O

The	O
peaks	O
were	O
then	O
identified	O
using	O
the	O
electrospray	O
MSN	O
mass	O
spectra	O
obtained	O
by	O
the	O
collision-induced	O
decomposition	O
of	O
the	O
MH+	O
ion	O
and	O
its	O
product	O
ions	O
in	O
a	O
series	O
of	O
MSN	O
experiments	O
that	O
were	O
performed	O
with	O
the	O
ion	O
trap	O
mass	O
spectrometer	O
.	O

The	O
sugar	O
moiety	O
was	O
cleaved	O
off	O
the	O
adenosine	O
molecule	O
and	O
produced	O
ion	O
with	O
a	O
molecular	O
weight	O
of	O
136	O
(	O
adenine	O
)	O
,	O
which	O
was	O
then	O
detected	O
by	O
MS	O
.	O

A	O
comparison	O
of	O
programmed	O
cell	O
death	O
between	O
species	O

Abstract	O

Key	O
components	O
of	O
the	O
programmed	O
cell	O
death	O
pathway	O
are	O
conserved	O
between	O
Caenorhabditis	O
elegans	O
,	O
Drosophila	O
melanogaster	O
and	O
humans	O
.	O

The	O
search	O
for	O
additional	O
homologs	O
has	O
been	O
facilitated	O
by	O
the	O
availability	O
of	O
the	O
entire	O
genomic	O
sequence	O
for	O
each	O
of	O
these	O
organisms	O
.	O

Programmed	O
cell	O
death	O
is	O
a	O
conserved	O
,	O
gene-directed	O
mechanism	O
for	O
the	O
elimination	O
of	O
unnecessary	O
or	O
dangerous	O
cells	O
from	O
an	O
organism	O
.	O

The	O
core	O
cell	O
death	O
pathway	O
was	O
first	O
defined	O
through	O
genetic	O
analysis	O
in	O
the	O
nematode	O
Caenorhabditis	O
elegans	O
and	O
has	O
since	O
been	O
found	O
to	O
be	O
conserved	O
in	O
species	O
as	O
diverse	O
as	O
Drosophila	O
melanogaster	O
and	O
Homo	O
sapiens	O
.	O

The	O
rapid	O
progress	O
of	O
the	O
various	O
genome	O
sequencing	O
projects	O
has	O
greatly	O
accelerated	O
the	O
discovery	O
of	O
homologs	O
for	O
key	O
components	O
of	O
the	O
cell	O
death	O
pathway	O
as	O
well	O
as	O
for	O
its	O
regulators	O
.	O

The	O
C.	O
elegans	O
genome	O
sequence	O
was	O
completed	O
two	O
years	O
ago	O
[	O
1	O
]	O
,	O
and	O
both	O
the	O
Drosophila	O
[	O
2	O
]	O
and	O
human	O
genomes	O
are	O
essentially	O
completely	O
sequenced	O
at	O
this	O
point	O
.	O

Although	O
many	O
components	O
of	O
the	O
programmed	O
cell	O
death	O
pathway	O
are	O
conserved	O
between	O
species	O
,	O
there	O
are	O
some	O
important	O
differences	O
as	O
well	O
.	O

The	O
core	O
cell	O
death	O
pathway	O

Programmed	O
cell	O
death	O
has	O
long	O
been	O
known	O
to	O
be	O
a	O
part	O
of	O
normal	O
development	O
,	O
but	O
it	O
was	O
not	O
until	O
the	O
discovery	O
of	O
the	O
first	O
genes	O
essential	O
for	O
the	O
phenomenon	O
that	O
our	O
understanding	O
of	O
the	O
events	O
leading	O
up	O
to	O
the	O
deliberate	O
elimination	O
of	O
a	O
cell	O
began	O
to	O
take	O
shape	O
.	O

Before	O
this	O
time	O
,	O
programmed	O
cell	O
death	O
was	O
defined	O
by	O
a	O
set	O
of	O
specific	O
morphological	O
characteristics	O
,	O
including	O
chromatin	O
condensation	O
,	O
nuclear	O
shrinkage	O
and	O
blebbing	O
of	O
the	O
plasma	O
membrane	O
that	O
could	O
be	O
observed	O
in	O
dying	O
cells	O
;	O
the	O
term	O
apoptosis	O
was	O
coined	O
to	O
distinguish	O
this	O
type	O
of	O
cell	O
death	O
from	O
necrotic	O
deaths	O
resulting	O
from	O
injury	O
[	O
3,4	O
]	O
.	O

Four	O
genes	O
make	O
up	O
the	O
core	O
programmed	O
cell	O
death	O
pathway	O
in	O
C.	O
elegans	O
,	O
three	O
of	O
which	O
,	O
egl-1	O
(	O
egg	O
laying	O
abnormal	O
)	O
,	O
ced-3	O
(	O
cell	O
death	O
abnormal	O
)	O
,	O
and	O
ced-4	O
,	O
are	O
pro-apoptotic	O
and	O
one	O
,	O
ced-9	O
,	O
is	O
anti-apoptotic	O
(	O
reviewed	O
in	O
[	O
5	O
]	O
)	O
.	O

There	O
was	O
considerable	O
excitement	O
in	O
the	O
field	O
when	O
potential	O
mammalian	O
and	O
Drosophila	O
homologs	O
for	O
ced-3	O
,	O
ced-4	O
,	O
ced-9	O
,	O
and	O
egl-1	O
were	O
discovered	O
.	O

The	O
CED-3	O
protein	O
is	O
one	O
of	O
a	O
continuously	O
growing	O
family	O
of	O
specific	O
cysteine	O
proteases	O
,	O
termed	O
caspases	O
,	O
that	O
are	O
thought	O
to	O
be	O
the	O
executioners	O
of	O
programmed	O
cell	O
death	O
.	O

At	O
least	O
fourteen	O
mammalian	O
caspases	O
have	O
been	O
identified	O
,	O
and	O
they	O
are	O
grouped	O
into	O
two	O
classes	O
on	O
the	O
basis	O
of	O
their	O
proteolytic	O
specificities	O
(	O
reviewed	O
in	O
[	O
6	O
]	O
)	O
.	O

Class	O
1	O
caspases	O
are	O
mainly	O
involved	O
in	O
cytokine	O
maturation	O
,	O
while	O
Class	O
2	O
caspases	O
act	O
mainly	O
in	O
apoptosis	O
.	O

Class	O
2	O
has	O
been	O
further	O
subdivided	O
into	O
two	O
groups	O
:	O
upstream	O
or	O
initiator	O
caspases	O
(	O
group	O
1	O
)	O
,	O
and	O
downstream	O
or	O
effector	O
caspases	O
(	O
group	O
2	O
)	O
.	O

Initiator	O
caspases	O
are	O
thought	O
to	O
be	O
at	O
the	O
beginning	O
of	O
a	O
proteolytic	O
cascade	O
that	O
amplifies	O
the	O
cell	O
death	O
signal	O
and	O
results	O
in	O
the	O
activation	O
of	O
the	O
effector	O
caspases	O
.	O

Initiator	O
caspases	O
usually	O
have	O
long	O
pro-domains	O
,	O
while	O
effector	O
caspases	O
have	O
short	O
pro-domains	O
.	O

Drosophila	O
has	O
at	O
least	O
eight	O
caspases	O
,	O
five	O
of	O
which	O
have	O
been	O
at	O
least	O
partially	O
characterized	O
(	O
Dcp-1	O
,	O
Dcp-2/Dredd	O
,	O
drICE	O
,	O
Dronc	O
,	O
and	O
Decay	O
)	O
and	O
three	O
uncharacterized	O
ones	O
found	O
encoded	O
in	O
the	O
genome	O
sequence	O
[	O
7	O
]	O
.	O

C.	O
elegans	O
appears	O
to	O
have	O
only	O
a	O
single	O
caspase	O
-	O
CED-3	O
-	O
that	O
is	O
essential	O
for	O
all	O
developmental	O
cell	O
death	O
,	O
despite	O
having	O
three	O
other	O
caspases	O
in	O
its	O
genome	O
[	O
8,9	O
]	O
.	O

Three	O
Drosophila	O
caspases	O
-	O
Dcp-2/Dredd	O
,	O
Dronc	O
,	O
and	O
one	O
known	O
only	O
as	O
a	O
sequence	O
in	O
the	O
genome	O
database	O
-	O
have	O
long	O
pro-domains	O
and	O
are	O
thus	O
likely	O
initiator	O
caspases	O
;	O
another	O
four	O
-	O
Dcp-1	O
,	O
drICE	O
,	O
Decay	O
,	O
and	O
another	O
one	O
found	O
in	O
the	O
genome	O
database	O
-	O
have	O
short	O
pro-domains	O
and	O
are	O
probably	O
effector	O
caspases	O
.	O

In	O
addition	O
,	O
Dcp-1	O
has	O
a	O
substrate	O
specificity	O
that	O
is	O
very	O
similar	O
to	O
that	O
of	O
two	O
effector	O
caspases	O
,	O
mammalian	O
caspase	O
3	O
and	O
C.	O
elegans	O
CED-3	O
[	O
10	O
]	O
.	O

Interestingly	O
,	O
Dronc	O
appears	O
to	O
have	O
a	O
substrate	O
specificity	O
that	O
is	O
so	O
far	O
unique	O
among	O
caspases	O
:	O
while	O
all	O
other	O
known	O
caspases	O
have	O
only	O
been	O
shown	O
to	O
cleave	O
after	O
aspartate	O
residues	O
,	O
Dronc	O
can	O
also	O
cleave	O
after	O
glutamate	O
residues	O
[	O
11	O
]	O
.	O

This	O
unusual	O
substrate	O
specificity	O
may	O
explain	O
why	O
Dronc	O
is	O
resistant	O
to	O
inhibition	O
by	O
the	O
pan-caspase	O
inhibitor	O
p35	O
.	O

On	O
the	O
basis	O
of	O
current	O
data	O
,	O
it	O
seems	O
that	O
CED-4	O
functions	O
to	O
help	O
activate	O
the	O
caspase	O
CED-3	O
,	O
and	O
CED-9	O
blocks	O
this	O
activation	O
through	O
physical	O
interaction	O
with	O
CED-4	O
.	O

Endogenous	O
CED-4	O
is	O
normally	O
localized	O
to	O
the	O
mitochondria	O
by	O
CED-9	O
,	O
unless	O
EGL-1	O
is	O
expressed	O
[	O
12,13	O
]	O
.	O

If	O
EGL-1	O
is	O
expressed	O
,	O
the	O
interaction	O
between	O
CED-4	O
and	O
CED-9	O
ceases	O
,	O
and	O
CED-4	O
translocates	O
to	O
the	O
nuclear	O
membrane	O
where	O
it	O
activates	O
CED-3	O
,	O
resulting	O
in	O
programmed	O
cell	O
death	O
.	O

Only	O
one	O
mammalian	O
CED-4	O
homolog	O
,	O
Apaf-1	O
,	O
has	O
been	O
extensively	O
characterized	O
to	O
date	O
,	O
but	O
it	O
too	O
aids	O
in	O
caspase	O
activation	O
.	O

Like	O
CED-4	O
,	O
Apaf-1	O
requires	O
dATP	O
for	O
caspase	O
activation	O
,	O
but	O
Apaf-1	O
requires	O
cytochrome	O
c	O
in	O
addition	O
[	O
14	O
]	O
.	O

Knock-out	O
studies	O
have	O
shown	O
that	O
mice	O
deficient	O
for	O
Apaf-1	O
have	O
reduced	O
cell	O
death	O
in	O
certain	O
tissues	O
,	O
further	O
supporting	O
a	O
role	O
for	O
Apaf-1	O
in	O
programmed	O
cell	O
death	O
.	O

Drosophila	O
has	O
recently	O
been	O
shown	O
also	O
to	O
have	O
a	O
CED-4/Apaf-1	O
homolog	O
,	O
named	O
Dark/HAC-1/Dapaf-1	O
(	O
reviewed	O
in	O
[	O
15	O
]	O
)	O
.	O

The	O
Drosophila	O
homolog	O
is	O
more	O
similar	O
to	O
Apaf-1	O
than	O
to	O
CED-4	O
:	O
it	O
has	O
the	O
WD	O
repeats	O
found	O
in	O
Apaf-1	O
,	O
which	O
potentially	O
function	O
in	O
binding	O
regulatory	O
proteins	O
such	O
as	O
cytochrome	O
c	O
.	O

Like	O
Apaf-1	O
and	O
CED-4	O
,	O
loss	O
of	O
function	O
mutations	O
in	O
dark/hac-1/dapaf-1	O
result	O
in	O
a	O
reduction	O
in	O
developmental	O
programmed	O
cell	O
death	O
.	O

Intriguingly	O
,	O
the	O
transcription	O
of	O
the	O
Drosophila	O
CED-4/Apaf-1	O
homolog	O
is	O
upregulated	O
in	O
response	O
to	O
both	O
X-ray	O
and	O
ultraviolet	O
irradiation	O
,	O
suggesting	O
that	O
death-inducing	O
stimuli	O
can	O
feed	O
into	O
the	O
cell	O
death	O
pathway	O
at	O
this	O
step	O
[	O
16	O
]	O
.	O

CED-9	O
and	O
EGL-1	O
belong	O
to	O
a	O
large	O
family	O
of	O
proteins	O
related	O
to	O
the	O
mammalian	O
anti-apoptotic	O
protein	O
Bcl-2	O
.	O

This	O
family	O
-	O
with	O
at	O
least	O
19	O
members	O
,	O
divided	O
into	O
pro-	O
and	O
anti-apoptotic	O
subgroups	O
-	O
has	O
been	O
largely	O
defined	O
by	O
protein-protein	O
interactions	O
among	O
its	O
members	O
(	O
reviewed	O
in	O
[	O
17	O
]	O
)	O
.	O

CED-9	O
has	O
mammalian	O
counterparts	O
in	O
the	O
anti-apoptotic	O
subgroup	O
of	O
Bcl-2	O
family	O
members	O
,	O
while	O
EGL-1	O
has	O
mammalian	O
counterparts	O
in	O
the	O
pro-apoptotic	O
subgroup	O
.	O

Besides	O
binding	O
to	O
Apaf-1	O
,	O
just	O
as	O
CED-9	O
binds	O
and	O
thereby	O
regulates	O
CED-4	O
activity	O
,	O
mammalian	O
Bcl-2	O
family	O
members	O
have	O
been	O
proposed	O
to	O
regulate	O
mitochondrial	O
homeostasis	O
and	O
the	O
release	O
of	O
pro-apoptotic	O
factors	O
such	O
as	O
cytochrome	O
c	O
(	O
reviewed	O
in	O
[	O
17	O
]	O
)	O
.	O

The	O
rate	O
of	O
mitochondrial	O
release	O
of	O
cytochrome	O
c	O
in	O
mammalian	O
cells	O
undergoing	O
apoptosis	O
was	O
recently	O
measured	O
and	O
found	O
to	O
be	O
rapid	O
[	O
18	O
]	O
.	O

Indeed	O
,	O
most	O
mitochondria	O
released	O
all	O
their	O
cytochrome	O
c	O
within	O
a	O
one	O
minute	O
period	O
in	O
a	O
temperature-independent	O
manner	O
,	O
suggesting	O
that	O
an	O
enzymatic	O
transport	O
mechanism	O
is	O
probably	O
not	O
involved	O
.	O

There	O
is	O
no	O
clear	O
evidence	O
for	O
cytochrome	O
c	O
release	O
during	O
apoptosis	O
in	O
C.	O
elegans	O
or	O
Drosophila	O
,	O
however	O
.	O

Nevertheless	O
,	O
a	O
specific	O
epitope	O
is	O
uncovered	O
on	O
cytochrome	O
c	O
in	O
Drosophila	O
mitochondria	O
during	O
apoptosis	O
and	O
this	O
may	O
be	O
sufficient	O
to	O
help	O
activate	O
Dark/HAC-1/Dapaf-1	O
;	O
and	O
death-inducing	O
stimuli	O
result	O
in	O
an	O
increase	O
in	O
cytochrome	O
c	O
in	O
Drosophila	O
cultured-cell	O
lysates	O
[	O
19,20	O
]	O
.	O

There	O
is	O
no	B-Negation
apparent	I-Negation
need	I-Negation
for	I-Negation
cytochrome	I-Negation
c	I-Negation
release	I-Negation
in	I-Negation
C.	I-Negation
elegans	I-Negation
,	O
since	O
CED-4	O
does	O
not	B-Negation
require	I-Negation
it	I-Negation
to	I-Negation
activate	I-Negation
CED-3	I-Negation
.	O

Recently	O
,	O
a	O
pro-apoptotic	O
Drosophila	O
Bcl-2	O
family	O
member	O
was	O
identified	O
with	O
the	O
help	O
of	O
the	O
database	O
of	O
genomic	O
sequence	O
;	O
this	O
gene	O
is	O
most	O
closely	O
related	O
to	O
mammalian	O
Bok	O
and	O
potentially	O
regulates	O
apoptosis	O
in	O
the	O
fly	O
[	O
21,22,23,24	O
]	O
.	O

The	O
Drosophila	O
Bok	O
homolog	O
interacts	O
with	O
several	O
anti-apoptotic	O
,	O
but	O
not	B-Negation
with	I-Negation
several	I-Negation
pro-apoptotic	I-Negation
,	I-Negation
Bcl-2	I-Negation
family	I-Negation
members	I-Negation
and	O
,	O
therefore	O
,	O
possibly	B-Speculation
functions	I-Speculation
by	I-Speculation
antagonizing	I-Speculation
pro-survival	I-Speculation
proteins	I-Speculation
.	O

Ectopic	O
expression	O
of	O
Bok	O
protein	O
promotes	O
apoptosis	O
in	O
transgenic	O
flies	O
as	O
well	O
as	O
in	O
cultured	O
cells	O
.	O

While	O
one	O
group	O
reports	O
that	O
the	O
caspase	O
inhibitor	O
p35	O
can	O
block	O
apoptosis	O
induced	O
by	O
Drosophila	O
Bok	O
[	O
22	O
]	O
,	O
another	O
group	O
did	O
not	B-Negation
see	I-Negation
p35	I-Negation
inhibition	I-Negation
[	O
23	O
]	O
.	O

This	O
difference	O
may	O
be	O
due	O
to	O
the	O
slightly	O
different	O
constructs	O
used	O
in	O
the	O
experiments	O
and	O
the	O
different	O
assay	O
systems	O
.	O

A	O
third	O
group	O
shows	O
that	O
peptide	O
caspase	O
inhibitors	O
can	O
block	O
Drosophila	O
Bok-mediated	O
apoptosis	O
in	O
cell	O
culture	O
,	O
lending	O
support	O
to	O
a	O
model	O
in	O
which	O
expression	O
of	O
Bok	O
protein	O
leads	O
to	O
caspase	O
activation	O
[	O
24	O
]	O
.	O

Interestingly	O
,	O
ectopic	O
expression	O
of	O
Drosophila	O
Bok	O
sensitizes	O
the	O
developing	O
eye	O
to	O
cell	O
death	O
induced	O
by	O
ultraviolet	O
irradiation	O
[	O
21	O
]	O
.	O

Genetically	O
,	O
this	O
Drosophila	O
Bcl-2	O
family	O
member	O
appears	O
to	O
function	O
upstream	O
of	O
,	O
or	O
in	O
parallel	O
to	O
,	O
the	O
Drosophila	O
ced-4/apaf-1	O
homolog	O
and	O
downstream	O
of	O
,	O
or	O
in	O
parallel	O
to	O
,	O
the	O
Drosophila	O
regulators	O
of	O
apoptosis	O
,	O
reaper	O
,	O
hid	O
,	O
and	O
grim	O
[	O
22	O
]	O
.	O

The	O
core	O
components	O
of	O
the	O
cell	O
death	O
pathway	O
are	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
core	O
pathway	O
of	O
programmed	O
cell	O
death	O
.	O

Multiple	O
pathways	O
lead	O
to	O
the	O
activation	O
of	O
the	O
executioners	O
of	O
death	O
,	O
the	O
caspases	O
(	O
reviewed	O
in	O
[	O
53	O
]	O
)	O
.	O

IAPs	O
(	O
inhibitors	O
of	O
apoptosis	O
)	O
have	O
been	O
shown	O
to	O
block	O
the	O
conversion	O
of	O
pro-caspases	O
into	O
active	O
enzymes	O
,	O
and	O
Reaper	O
,	O
Hid	O
,	O
Grim	O
,	O
and	O
Diablo/Smac	O
prevent	O
IAPs	O
from	O
carrying	O
out	O
this	O
protective	O
function	O
.	O

Caspases	O
can	O
also	O
be	O
activated	O
with	O
the	O
aid	O
of	O
Apaf-1	O
,	O
which	O
in	O
turn	O
appears	O
to	O
be	O
regulated	O
by	O
cytochrome	O
c	O
and	O
dATP	O
.	O

The	O
Bcl-2	O
family	O
appears	O
to	O
function	O
in	O
regulating	O
the	O
release	O
of	O
pro-apoptotic	O
components	O
from	O
mitochondria	O
as	O
well	O
as	O
by	O
possibly	O
inhibiting	O
Apaf-1	O
directly	O
.	O

This	O
pathway	O
integrates	O
knowledge	O
gained	O
in	O
multiple	O
species	O
,	O
showing	O
that	O
apoptosis	O
appears	O
to	O
be	O
regulated	O
in	O
a	O
similar	O
manner	O
regardless	O
of	O
the	O
organism	O
.	O

One	O
notable	O
exception	O
is	O
that	O
the	B-Negation
C.elegans	I-Negation
homologs	I-Negation
of	I-Negation
IAPs	I-Negation
do	I-Negation
not	I-Negation
appear	B-Speculation
to	I-Speculation
function	I-Speculation
in	I-Speculation
programmed	I-Speculation
cell	I-Speculation
death	I-Speculation
.	O

Regulation	O
of	O
programmed	O
cell	O
death	O

Studies	O
of	O
Drosophila	O
have	O
yielded	O
great	O
insights	O
into	O
how	O
programmed	O
cell	O
death	O
is	O
regulated	O
(	O
reviewed	O
in	O
[	O
25	O
]	O
)	O
.	O

In	O
addition	O
to	O
the	O
core	O
pathway	O
,	O
several	O
essential	O
regulators	O
have	O
been	O
characterized	O
in	O
Drosophila	O
.	O

A	O
region	O
in	O
the	O
genome	O
which	O
contains	O
the	O
genes	O
reaper	O
,	O
head	O
involution	O
defective	O
(	O
hid	O
)	O
,	O
and	O
grim	O
has	O
been	O
shown	O
to	O
be	O
essential	O
for	O
virtually	O
all	O
developmental	O
cell	O
death	O
in	O
the	O
Drosophila	O
embryo	O
.	O

The	O
three	O
proteins	O
encoded	O
by	O
these	O
genes	O
have	O
no	O
significant	O
homology	O
to	O
any	O
other	O
known	O
proteins	O
except	O
for	O
a	O
small	O
stretch	O
of	O
similarity	O
at	O
the	O
amino	O
terminus	O
that	O
is	O
shared	O
by	O
all	O
three	O
but	O
no	B-Negation
other	I-Negation
known	I-Negation
proteins	I-Negation
.	O

Each	O
of	O
these	O
three	O
genes	O
can	O
induce	O
programmed	O
cell	O
death	O
when	O
overexpressed	O
in	O
the	O
developing	O
Drosophila	O
eye	O
or	O
in	O
various	O
tissue-culture	O
assays	O
.	O

In	O
addition	O
,	O
Reaper	O
,	O
Hid	O
and	O
Grim	O
are	O
able	O
to	O
induce	O
apoptosis	O
in	O
heterologous	O
systems	O
,	O
suggesting	O
that	O
vertebrate	O
homologs	O
of	O
these	O
proteins	O
exist	O
(	O
reviewed	O
in	O
[	O
26	O
]	O
)	O
.	O

Further	O
evidence	O
for	O
the	O
existence	O
of	O
vertebrate	O
homologs	O
of	O
Reaper	O
,	O
Hid	O
,	O
and	O
Grim	O
come	O
from	O
observations	O
that	O
these	O
three	O
proteins	O
are	O
able	O
to	O
bind	O
a	O
class	O
of	O
inhibitors	O
of	O
apoptosis	O
,	O
or	O
IAPs	O
.	O

IAPs	O
were	O
first	O
discovered	O
in	O
baculovirus	O
,	O
but	O
have	O
since	O
been	O
shown	O
to	O
play	O
a	O
vital	O
role	O
in	O
blocking	O
apoptosis	O
in	O
Drosophila	O
as	O
well	O
as	O
in	O
mammals	O
(	O
reviewed	O
in	O
[	O
27	O
]	O
)	O
.	O

Also	O
,	O
Hid	O
has	O
been	O
shown	O
to	O
be	O
negatively	O
regulated	O
by	O
survival	O
signals	O
mediated	O
by	O
receptor	O
tyrosine	O
kinases	O
through	O
the	O
Ras	O
and	O
mitogen-activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
pathway	O
,	O
which	O
is	O
also	O
well	O
conserved	O
in	O
mammals	O
[	O
28,29	O
]	O
.	O

More	O
recently	O
,	O
reports	O
of	O
a	O
potential	O
functional	O
mammalian	O
analog	O
of	O
Reaper	O
,	O
Hid	O
,	O
and	O
Grim	O
have	O
been	O
published	O
[	O
30,31	O
]	O
.	O

Although	O
Diablo/Smac	O
shares	O
no	B-Negation
sequence	I-Negation
homology	I-Negation
with	I-Negation
Reaper	I-Negation
,	I-Negation
Hid	I-Negation
,	I-Negation
or	I-Negation
Grim	I-Negation
,	O
it	O
too	O
can	O
bind	O
IAPs	O
,	O
preventing	O
them	O
from	O
inhibiting	O
caspase	O
activation	O
,	O
and	O
thereby	O
inducing	O
apoptosis	O
.	O

Furthermore	O
,	O
Diablo/Smac	O
interacts	O
through	O
its	O
amino	O
terminus	O
with	O
the	O
BIR	O
(	O
baculovirus	O
IAP	O
repeat	O
)	O
domains	O
of	O
IAPs	O
,	O
similar	O
to	O
Reaper	O
,	O
Hid	O
,	O
and	O
Grim	O
[	O
32,33	O
]	O
.	O

An	O
important	O
difference	O
between	O
the	O
function	O
of	O
Diablo/Smac	O
and	O
Reaper	O
,	O
Hid	O
,	O
and	O
Grim	O
is	O
that	O
Diablo/Smac	O
is	O
not	B-Negation
pro-apoptotic	I-Negation
by	I-Negation
itself	I-Negation
when	I-Negation
overexpressed	I-Negation
,	O
but	O
instead	O
requires	O
a	O
death-inducing	O
stimulus	O
to	O
promote	O
apoptosis	O
,	O
unlike	O
the	O
three	O
Drosophila	O
proteins	O
.	O

Table	O
1	O
provides	O
a	O
summary	O
of	O
the	O
conserved	O
regulators	O
of	O
cell	O
death	O
across	O
species	O
.	O

In	O
contrast	O
to	O
cell	O
death	O
effectors	O
such	O
as	O
caspases	O
,	O
the	O
cell	O
death	O
regulators	O
Reaper	O
and	O
Grim	O
are	O
specifically	O
expressed	O
several	O
hours	O
before	O
apoptosis	O
in	O
cells	O
destined	O
to	O
die	O
(	O
reviewed	O
in	O
[	O
26	O
]	O
)	O
.	O

The	O
expression	O
of	O
reaper	O
has	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
distinct	O
stimuli	O
,	O
including	O
X-irradiation	O
,	O
steroid	O
hormone	O
signaling	O
and	O
a	O
block	O
in	O
cell	O
differentiation	O
(	O
[	O
34,35,36	O
]	O
and	O
A.-F.	O
Lambin	O
and	O
H.S.	O
,	O
unpublished	O
observations	O
)	O
.	O

Recently	O
,	O
a	O
Drosophila	O
p53	O
ortholog	O
was	O
identified	O
by	O
searching	O
the	O
genome	O
database	O
(	O
reviewed	O
in	O
[	O
37	O
]	O
)	O
,	O
and	O
it	O
was	O
shown	O
to	O
bind	O
a	O
specific	O
region	O
of	O
the	O
reaper	O
promoter	O
,	O
thereby	O
potentially	O
regulating	O
reaper	O
transcription	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O

Furthermore	O
,	O
the	O
reaper	O
promoter	O
was	O
also	O
shown	O
to	O
contain	O
a	O
response	O
element	O
for	O
the	O
complex	O
made	O
up	O
of	O
the	O
steroid	O
hormone	O
ecdysone	O
and	O
its	O
receptor	O
[	O
36	O
]	O
.	O

The	O
observation	O
that	O
transcription	O
of	O
both	O
reaper	O
and	O
dark/hac-1/dapaf-1	O
can	O
be	O
induced	O
by	O
ionizing	O
radiation	O
suggests	O
that	O
these	O
death-inducing	O
signals	O
can	O
feed	O
into	O
the	O
cell	O
death	O
pathway	O
at	O
multiple	O
points	O
.	O

Unlike	O
reaper	O
and	O
grim	O
,	O
hid	O
appears	O
to	O
be	O
regulated	O
not	O
only	O
transcriptionally	O
but	O
also	O
post-translationally	O
by	O
the	O
Ras-MAP	O
kinase	O
pathway	O
[	O
28,29	O
]	O
.	O

This	O
additional	O
level	O
of	O
control	O
for	O
hid	O
could	O
explain	O
the	O
observation	O
that	O
hid	O
is	O
expressed	O
in	O
cells	O
that	O
are	O
doomed	O
to	O
die	O
as	O
well	O
as	O
in	O
cells	O
that	O
continue	O
to	O
survive	O
[	O
38	O
]	O
.	O

A	O
second	O
class	O
of	O
key	O
apoptotic	O
regulators	O
in	O
Drosophila	O
is	O
the	O
IAP	O
family	O
.	O

IAPs	O
contain	O
at	O
least	O
one	O
,	O
and	O
up	O
to	O
three	O
,	O
BIR	O
domains	O
,	O
which	O
are	O
important	O
for	O
protein-protein	O
interactions	O
,	O
and	O
often	O
a	O
carboxy-terminal	O
RING	O
domain	O
(	O
reviewed	O
in	O
[	O
27	O
]	O
)	O
.	O

While	O
several	O
IAPs	O
have	O
been	O
implicated	O
in	O
inhibiting	O
apoptosis	O
,	O
proteins	O
with	O
single	O
BIR	O
domains	O
can	O
also	O
have	O
functions	O
in	O
cell	O
cycle	O
regulation	O
and	O
cytokinesis	O
[	O
39,40	O
]	O
.	O

In	O
fact	O
,	O
Saccharomyces	O
cerevisiae	O
contains	O
neither	B-Negation
caspases	I-Negation
nor	I-Negation
an	I-Negation
apoptotic	I-Negation
program	I-Negation
,	O
but	O
it	O
does	O
have	O
an	O
IAP-like	O
protein	O
with	O
a	O
single	O
BIR	O
domain	O
that	O
functions	O
in	O
regulating	O
cell	O
division	O
[	O
41	O
]	O
,	O
suggesting	B-Speculation
that	I-Speculation
the	I-Speculation
IAPs	I-Speculation
are	I-Speculation
diverse	I-Speculation
family	I-Speculation
with	I-Speculation
only	I-Speculation
some	I-Speculation
members	I-Speculation
being	I-Speculation
anti-apoptotic	I-Speculation
:	O
hence	O
this	O
protein	O
family	O
is	O
more	O
accurately	O
referred	O
to	O
as	O
BIR-containing	O
proteins	O
(	O
BIRPs	O
)	O
.	O

Three	O
Drosophila	O
BIRPs	O
have	O
been	O
shown	O
to	O
be	O
inhibitors	O
of	O
apoptosis	O
,	O
Diap1	O
,	O
Diap2	O
,	O
and	O
Deterin	O
[	O
42,43,44,45	O
]	O
.	O

Of	O
these	O
,	O
Diap1	O
has	O
been	O
most	O
extensively	O
characterized	O
;	O
it	O
can	O
block	O
cell	O
death	O
caused	O
by	O
the	O
ectopic	O
expression	O
of	O
reaper	O
,	O
hid	O
,	O
and	O
grim	O
(	O
reviewed	O
in	O
[	O
26	O
]	O
)	O
.	O

In	O
addition	O
,	O
Diap1	O
is	O
able	O
to	O
block	O
the	O
cell	O
death	O
induced	O
by	O
the	O
Drosophila	O
caspases	O
Dcp-1	O
or	O
drICE	O
in	O
Saccharomyces	O
,	O
as	O
well	O
as	O
apoptosis	O
induced	O
by	O
the	O
expression	O
of	O
drICE	O
in	O
insect	O
cell	O
culture	O
[	O
46,47,48	O
]	O
.	O

Loss-of-function	O
mutants	O
in	O
diap1	O
have	O
a	O
very	O
striking	O
early	O
embryonic	O
phenotype	O
:	O
virtually	O
all	O
cells	O
display	O
an	O
apoptotic	O
morphology	O
,	O
as	O
well	O
as	O
displaying	O
DNA	O
fragmentation	O
seen	O
by	O
TUNEL	O
labeling	O
,	O
four	O
to	O
five	O
hours	O
into	O
development	O
[	O
47,49,50	O
]	O
.	O

This	O
phenotype	O
is	O
especially	O
noteworthy	O
since	O
it	O
manifests	O
itself	O
several	O
hours	O
before	O
the	O
first	O
developmental	O
cell	O
deaths	O
are	O
normally	O
observed	O
in	O
the	O
Drosophila	O
embryo	O
,	O
and	O
it	O
clearly	O
shows	O
that	O
diap1	O
is	O
vital	O
for	O
normal	O
development	O
.	O

In	O
general	O
,	O
IAPs	O
are	O
thought	O
to	O
function	O
at	O
the	O
caspase	O
activation	O
step	O
in	O
the	O
cell	O
death	O
pathway	O
,	O
binding	O
to	O
the	O
inactive	O
,	O
pro-domain-containing	O
caspase	O
zymogen	O
and	O
preventing	O
it	O
from	O
being	O
processed	O
into	O
the	O
active	O
enzyme	O
(	O
reviewed	O
in	O
[	O
27	O
]	O
)	O
.	O

Reaper	O
,	O
Hid	O
,	O
Grim	O
,	O
and	O
Diablo/Smac	O
can	O
physically	O
interact	O
with	O
IAPs	O
,	O
thereby	O
inhibiting	O
the	O
anti-apoptotic	O
activity	O
of	O
IAPs	O
and	O
allowing	O
caspase	O
activation	O
.	O

Further	O
insight	O
into	O
a	O
possible	O
mechanism	O
for	O
IAP	O
function	O
was	O
recently	O
gained	O
when	O
IAPs	O
were	O
observed	O
to	O
have	O
ubiquitin	O
ligase	O
activity	O
[	O
51,52	O
]	O
.	O

It	O
was	O
shown	O
that	O
certain	O
cellular	O
IAPs	O
can	O
be	O
degraded	O
in	O
a	O
proteasome-dependent	O
manner	O
prior	O
to	O
thymocyte	O
apoptosis	O
.	O

These	O
IAPs	O
are	O
also	O
capable	O
of	O
auto-ubiquitination	O
,	O
an	O
activity	O
shown	O
to	O
require	O
the	O
RING	O
domain	O
[	O
52	O
]	O
.	O

In	O
addition	O
,	O
IAPs	O
can	O
mono-ubiquitinate	O
several	O
caspases	O
in	O
vitro	O
,	O
possibly	O
marking	O
them	O
for	O
degradation	O
,	O
and	O
again	O
,	O
this	O
activity	O
requires	O
the	O
RING	O
domain	O
[	O
51	O
]	O
.	O

The	O
exact	O
role	O
of	O
the	O
ubiquitination	O
pathway	O
in	O
regulating	O
apoptosis	O
is	O
still	O
unclear	O
.	O

Even	O
the	O
role	O
of	O
the	O
RING	O
domain	O
in	O
IAPs	O
is	O
open	O
to	O
debate	O
:	O
mutations	O
in	O
the	O
RING	O
domain	O
of	O
endogenous	O
diap1	O
can	O
be	O
either	O
pro-	O
or	O
anti-apoptotic	O
,	O
depending	O
on	O
the	O
death-inducing	O
stimulus	O
(	O
[	O
49	O
]	O
and	O
J.	O
Agapite	O
,	O
L.	O
Goyal	O
,	O
K.	O
McCall	O
and	O
H.S.	O
,	O
unpublished	O
observations	O
)	O
.	O

Conservation	O
of	O
key	O
regulators	O
of	O
programmed	O
cell	O
death	O
between	O
species	O

Strengths	O
and	O
limitations	O
of	O
genomic	O
analysis	O

The	O
completed	O
genomes	O
of	O
C.	O
elegans	O
and	O
Drosophila	O
have	O
already	O
yielded	O
a	O
wealth	O
of	O
information	O
.	O

New	O
cell	O
death	O
gene	O
homologs	O
are	O
being	O
described	O
at	O
a	O
very	O
rapid	O
pace	O
,	O
often	O
by	O
several	O
laboratories	O
at	O
once	O
.	O

Using	O
information	O
from	O
the	O
genome	O
project	O
,	O
C.	O
elegans	O
was	O
shown	O
to	O
contain	O
several	O
potential	O
caspases	O
in	O
addition	O
to	O
CED-3	O
,	O
but	O
none	B-Negation
of	I-Negation
these	I-Negation
has	I-Negation
been	I-Negation
shown	I-Negation
to	I-Negation
function	I-Negation
in	I-Negation
programmed	I-Negation
cell	I-Negation
death	I-Negation
[	O
9	O
]	O
.	O

In	O
addition	O
,	O
while	O
C.	O
elegans	O
has	O
two	O
BIR-domain-containing	O
proteins	O
,	O
neither	B-Negation
appears	B-Speculation
to	I-Speculation
regulate	I-Speculation
cell	I-Speculation
death	I-Speculation
:	O
BIR-1	O
has	O
been	O
demonstrated	O
to	O
be	O
essential	O
for	O
cytokinesis	O
instead	O
[	O
39	O
]	O
.	O

Hence	O
,	O
C.	O
elegans	O
seems	O
to	O
have	O
a	O
mechanism	O
for	O
regulating	O
caspase	O
activation	O
that	O
differs	O
from	O
that	O
of	O
mammals	O
and	O
Drosophila	O
,	O
in	O
that	O
it	O
relies	O
solely	O
on	O
the	O
two	O
Bcl-2	O
family	O
members	O
[	O
53	O
]	O
.	O

For	O
Drosophila	O
,	O
the	O
genome	O
project	O
played	O
a	O
key	O
role	O
in	O
the	O
identification	O
of	O
the	O
Bcl-2	O
family	O
member	O
(	O
s	O
)	O
and	O
the	O
CED-4/Apaf-1	O
homolog	O
,	O
showing	O
that	O
the	O
core	O
cell	O
death	O
pathway	O
is	O
conserved	O
in	O
Drosophila	O
as	O
well	O
.	O

Various	O
other	O
homologs	O
for	O
cell	O
death	O
genes	O
,	O
including	O
three	O
additional	O
caspase-like	O
sequences	O
and	O
a	O
second	O
Bcl-2	O
family	O
member	O
have	O
been	O
identified	O
in	O
the	O
Drosophila	O
genome	O
sequence	O
[	O
7	O
]	O
and	O
will	O
undoubtedly	O
be	O
published	O
in	O
the	O
near	O
future	O
.	O

And	O
analysis	O
of	O
the	O
human	O
genomic	O
sequence	O
is	O
sure	O
to	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
the	O
number	O
of	O
mammalian	O
homologs	O
for	O
the	O
various	O
components	O
of	O
the	O
cell	O
death	O
pathway	O
.	O

While	O
it	O
is	O
clear	O
that	O
the	O
search	O
for	O
homologs	O
of	O
known	O
cell	O
death	O
genes	O
has	O
been	O
greatly	O
facilitated	O
by	O
the	O
availability	O
of	O
the	O
entire	O
genome	O
sequence	O
for	O
C.	O
elegans	O
,	O
Drosophila	O
,	O
and	O
humans	O
,	O
there	O
are	O
limitations	O
to	O
this	O
strategy	O
.	O

For	O
instance	O
,	O
the	O
small	O
size	O
of	O
the	O
Reaper	O
protein	O
-	O
only	O
of	O
65	O
amino	O
acids	O
-	O
makes	O
it	O
extremely	O
difficult	O
to	O
identify	O
homologs	O
on	O
the	O
basis	O
of	O
genomic	O
sequence	O
information	O
in	O
other	O
species	O
:	O
current	O
gene-finding	O
programs	O
typically	O
require	O
an	O
open	O
reading	O
frame	O
of	O
at	O
least	O
70	O
amino	O
acids	O
.	O

Furthermore	O
,	O
there	O
is	O
considerable	O
divergence	O
even	O
among	O
cell	O
death	O
proteins	O
with	O
clearly	O
homologous	O
functions	O
,	O
such	O
as	O
CED-4/Apaf-1	O
and	O
even	O
CED-9/Bcl-2	O
,	O
and	O
sequence	O
homology	O
between	O
these	O
genes	O
was	O
recognized	O
only	O
after	O
the	O
genes	O
and	O
their	O
products	O
had	O
been	O
functionally	O
characterized	O
.	O

Nevertheless	O
,	O
in	O
combination	O
with	O
traditional	O
approaches	O
including	O
genetics	O
and	O
biochemistry	O
,	O
knowledge	O
of	O
the	O
genome	O
sequence	O
for	O
model	O
organisms	O
will	O
undoubtedly	O
continue	O
to	O
drive	O
our	O
rapidly	O
increasing	O
insights	O
into	O
the	O
molecular	O
basis	O
of	O
programmed	O
cell	O
death	O
.	O

Multiple	O
RNA-protein	O
interactions	O
in	O
Drosophila	O
dosage	O
compensation	O

Abstract	O

From	O
worms	O
to	O
humans	O
,	O
recognizing	O
and	O
modifying	O
a	O
specific	O
chromosome	O
is	O
essential	O
for	O
dosage	O
compensation	O
,	O
the	O
mechanism	O
by	O
which	O
equal	O
X-linked	O
gene	O
expression	O
in	O
males	O
and	O
females	O
is	O
achieved	O
.	O

Recent	O
molecular	O
genetic	O
and	O
biochemical	O
studies	O
have	O
provided	O
new	O
insights	O
into	O
how	O
regulatory	O
factors	O
in	O
Drosophila	O
are	O
recruited	O
and	O
assembled	O
on	O
the	O
X	O
chromosome	O
,	O
leading	O
to	O
the	O
essential	O
hypertranscription	O
of	O
its	O
genes	O
.	O

Distinct	O
mechanisms	O
of	O
dosage	O
compensation	O

Dosage	O
compensation	O
,	O
which	O
ensures	O
that	O
the	O
expression	O
of	O
X-linked	O
genes	O
is	O
equal	O
in	O
males	O
and	O
females	O
,	O
is	O
an	O
essential	O
process	O
in	O
organisms	O
that	O
have	O
sex	O
chromosomes	O
.	O

Because	O
sex	O
chromosomes	O
appeared	O
relatively	O
late	O
in	O
evolution	O
,	O
dosage	O
compensation	O
evolved	O
independently	O
in	O
different	O
organisms	O
and	O
is	O
accomplished	O
by	O
distinct	O
mechanisms	O
.	O

For	O
example	O
,	O
in	O
Caenorhabditis	O
elegans	O
,	O
dosage	O
compensation	O
occurs	O
in	O
the	O
homogametic	O
hermaphrodite	O
(	O
XX	O
)	O
by	O
the	O
down-regulation	O
of	O
virtually	O
all	O
genes	O
on	O
the	O
two	O
X	O
chromosomes	O
by	O
about	O
50	O
%	O
.	O

In	O
mammals	O
,	O
dosage	O
compensation	O
also	O
occurs	O
in	O
the	O
homogametic	O
sex	O
(	O
the	O
female	O
)	O
by	O
X	O
inactivation	O
,	O
whereby	O
an	O
entire	O
X	O
chromosome	O
forms	O
a	O
distinct	O
,	O
heterochromatic	O
,	O
transcriptionally	O
inactive	O
nuclear	O
structure	O
known	O
as	O
the	O
Barr	O
body	O
.	O

Consequently	O
,	O
each	O
gene	O
on	O
the	O
single	O
active	O
X	O
chromosome	O
in	O
female	O
cells	O
and	O
the	O
corresponding	O
gene	O
on	O
the	O
single	O
X	O
chromosome	O
in	O
male	O
cells	O
are	O
expressed	O
at	O
equal	O
levels	O
.	O

In	O
Drosophila	O
,	O
dosage	O
compensation	O
is	O
achieved	O
in	O
the	O
heterogametic	O
male	O
by	O
a	O
twofold	O
chromosome-wide	O
up-regulation	O
(	O
hypertranscription	O
)	O
of	O
essentially	O
all	O
genes	O
on	O
the	O
single	O
X	O
chromosome	O
.	O

In	O
C.	O
elegans	O
and	O
Drosophila	O
,	O
several	O
proteins	O
with	O
different	O
molecular	O
functions	O
involved	O
in	O
dosage	O
compensation	O
have	O
been	O
identified	O
.	O

Much	O
attention	O
has	O
been	O
dedicated	O
to	O
the	O
elusive	O
question	O
of	O
how	O
the	O
compensated	O
or	O
inactivated	O
chromosomes	O
are	O
recognized	O
by	O
these	O
proteins	O
,	O
and	O
three	O
recent	O
papers	O
investigating	O
some	O
of	O
these	O
aspects	O
in	O
Drosophila	O
have	O
provided	O
new	O
insights	O
into	O
this	O
mystery	O
[	O
1,2,3	O
]	O
.	O

At	O
least	O
one	O
common	O
theme	O
has	O
emerged	O
in	O
Drosophila	O
and	O
mammals	O
of	O
how	O
the	O
dosage-compensated	O
chromosomes	O
are	O
marked	O
and	O
eventually	O
recognized	O
by	O
regulatory	O
proteins	O
:	O
the	O
use	O
of	O
non-coding	O
RNAs	O
transcribed	O
from	O
genes	O
located	O
on	O
the	O
X	O
chromosome	O
itself	O
[	O
4,5,6,7	O
]	O
.	O

These	O
RNAs	O
,	O
Xist	O
(	O
X-inactive	O
specific	O
transcript	O
)	O
in	O
mammals	O
,	O
and	O
roX1	O
and	O
roX2	O
(	O
RNA	O
on	O
the	O
X	O
)	O
in	O
Drosophila	O
,	O
are	O
structurally	O
unrelated	O
,	O
yet	O
they	O
share	O
the	O
intriguing	O
property	O
of	O
remaining	O
tightly	O
associated	O
with	O
the	O
X	O
chromosome	O
.	O

In	O
mammals	O
,	O
Xist	O
RNA	O
is	O
transcribed	O
only	O
from	O
the	O
inactive	O
X	O
,	O
with	O
which	O
it	O
associates	O
at	O
its	O
site	O
of	O
synthesis	O
and	O
then	O
spreads	O
over	O
the	O
entire	O
chromosome	O
through	O
an	O
unknown	O
mechanism	O
[	O
8	O
]	O
.	O

It	O
is	O
assumed	O
that	O
Xist	O
RNA	O
provides	O
a	O
mark	O
for	O
specific	O
histones	O
(	O
for	O
example	O
,	O
histone	O
macroH2A1.2	O
)	O
,	O
as	O
well	O
as	O
proteins	O
deacetylating	O
histones	O
and	O
methylating	O
many	O
of	O
the	O
X-linked	O
genes	O
at	O
GpC	O
dinucleotides	O
[	O
9,10,11	O
]	O
;	O
all	O
these	O
events	O
are	O
important	O
for	O
maintaining	O
the	O
silenced	O
state	O
of	O
the	O
inactivated	O
X	O
.	O

The	O
Drosophila	O
dosage	O
compensation	O
complex	O

In	O
Drosophila	O
,	O
the	O
dosage	O
compensation	O
complex	O
(	O
DCC	O
)	O
is	O
composed	O
of	O
five	O
proteins	O
encoded	O
by	O
the	O
male-specific	O
lethal	O
genes	O
,	O
male-specific	O
lethal-1	O
,	O
-2	O
,	O
-3	O
(	O
msl1	O
,	O
msl2	O
and	O
msl3	O
)	O
,	O
maleless	O
(	O
mle	O
)	O
and	O
males	O
absent	O
on	O
the	O
first	O
(	O
mof	O
)	O
,	O
and	O
at	O
least	O
two	O
non-coding	O
RNAs	O
,	O
roX1	O
and	O
roX2	O
(	O
for	O
a	O
review	O
see	O
[	O
12	O
]	O
)	O
.	O

The	O
MSL	O
proteins	O
colocalize	O
to	O
hundreds	O
of	O
sites	O
along	O
the	O
single	O
male	O
X	O
chromosome	O
;	O
they	O
all	O
are	O
essential	O
for	O
the	O
hypertranscription	O
of	O
the	O
X-chromosomal	O
genes	O
in	O
males	O
,	O
as	O
male	O
but	O
not	B-Negation
female	I-Negation
animals	O
die	O
during	O
development	O
when	O
they	O
are	O
mutant	O
for	O
any	O
one	O
of	O
the	O
five	O
msl	O
genes	O
.	O

Hypertranscription	O
is	O
a	O
consequence	O
of	O
at	O
least	O
one	O
chromatin	O
modification	O
:	O
the	O
acetylation	O
of	O
histone	O
H4	O
at	O
Lys16	O
,	O
which	O
is	O
thought	O
to	O
``	O
loosen	O
``	O
chromatin	O
structure	O
,	O
thereby	O
allowing	O
the	O
general	O
transcription	O
machinery	O
easier	O
access	O
to	O
the	O
regulatory	O
regions	O
of	O
most	O
X-linked	O
genes	O
[	O
13	O
]	O
.	O

The	O
role	O
of	O
the	O
roX	O
genes	O
and	O
roX	O
RNAs	O
in	O
this	O
process	O
is	O
still	O
unclear	O
.	O

Localization	O
studies	O
of	O
MSL	O
proteins	O
in	O
male	O
nuclei	O
carrying	O
autosomal	O
roX1	O
or	O
roX2	O
transgenes	O
showed	O
that	O
the	O
roX	O
genes	O
or	O
RNAs	O
recruit	O
the	O
entire	O
set	O
of	O
MSL	O
proteins	O
to	O
their	O
transgenic	O
location	O
and	O
can	O
lead	O
locally	O
to	O
acetylation	O
of	O
histone	O
H4	O
[	O
1,14	O
]	O
.	O

Moreover	O
,	O
the	O
DCCs	O
can	O
spread	O
,	O
by	O
several	O
hundred	O
kilobases	O
,	O
into	O
neighboring	O
autosomal	O
DNA	O
.	O

These	O
experiments	O
indicated	O
that	O
the	O
roX	O
genes	O
might	O
function	O
as	O
nuclear	O
entry	O
sites	O
for	O
the	O
assembly	O
of	O
the	O
MSL	O
proteins	O
on	O
the	O
X	O
chromosome	O
.	O

Little	O
was	O
known	O
,	O
however	O
,	O
about	O
the	O
specific	O
role	O
of	O
the	O
roX	O
RNAs	O
during	O
the	O
formation	O
of	O
the	O
DCC	O
.	O

The	O
three	O
recent	O
papers	O
[	O
1,2,3	O
]	O
have	O
now	O
started	O
to	O
address	O
the	O
role	O
of	O
the	O
roX	O
genes	O
in	O
this	O
process	O
and	O
investigated	O
which	O
MSL	O
proteins	O
interact	O
with	O
the	O
roX	O
RNAs	O
.	O

Meller	O
et	O
al.	O
[	O
1	O
]	O
took	O
advantage	O
of	O
the	O
fact	O
that	O
dosage	O
compensation	O
can	O
be	O
initiated	O
and	O
analyzed	O
in	O
females	O
ectopically	O
expressing	O
the	O
male-specific	O
MSL2	O
protein	O
.	O

These	O
females	O
hypertranscribe	O
their	O
two	O
X	O
chromosomes	O
and	O
therefore	O
die	O
during	O
development	O
,	O
but	O
they	O
can	O
be	O
rescued	O
if	O
any	O
other	O
msl	O
mutation	O
is	O
present	O
.	O

It	O
has	O
been	O
shown	O
previously	O
,	O
using	O
a	O
similar	O
strategy	O
,	O
that	O
the	O
DCC	O
is	O
assembled	O
in	O
an	O
ordered	O
sequence	O
(	O
Figure	O
1	O
)	O
.	O

For	O
example	O
,	O
MSL1	O
and	O
MSL2	O
are	O
the	O
first	O
proteins	O
to	O
bind	O
to	O
the	O
X	O
chromosome	O
;	O
in	O
the	O
absence	O
of	O
all	O
other	O
MSL	O
proteins	O
they	O
associate	O
with	O
about	O
35	O
sites	O
,	O
the	O
so-called	O
chromatin	O
entry	O
sites	O
.	O

MSL1	O
and	O
MSL2	O
are	O
interdependent	O
,	O
however	O
:	O
they	O
require	O
each	O
other	O
for	O
binding	O
[	O
15	O
]	O
.	O

MLE	O
appears	O
to	O
be	O
the	O
next	O
protein	O
to	O
join	O
the	O
growing	O
DCC	O
as	O
it	O
is	O
found	O
at	O
reduced	O
levels	O
at	O
some	O
of	O
these	O
35	O
sites	O
when	O
the	O
remaining	O
two	O
proteins	O
,	O
MSL3	O
and	O
MOF	O
,	O
are	O
absent	O
[	O
16	O
]	O
.	O

These	O
latter	O
two	O
proteins	O
require	O
all	O
the	O
other	O
MSL	O
proteins	O
to	O
be	O
present	O
to	O
enable	O
them	O
to	O
associate	O
with	O
the	O
X	O
chromosome	O
.	O

Importantly	O
,	O
all	O
MSLs	O
are	O
required	O
to	O
generate	O
the	O
normal	O
DCC	O
distribution	O
to	O
the	O
hundreds	O
of	O
sites	O
throughout	O
the	O
entire	O
X	O
chromosome	O
.	O

Meller	O
et	O
al.	O
[	O
1	O
]	O
have	O
now	O
analyzed	O
and	O
compared	O
roX	O
RNA	O
and	O
MSL	O
protein	O
distribution	O
in	O
females	O
ectopically	O
expressing	O
MSL2	O
but	O
lacking	B-Negation
other	I-Negation
MSL	I-Negation
proteins	I-Negation
.	O

They	O
found	O
that	O
roX1	O
and	O
roX2	O
RNAs	O
are	O
associated	O
with	O
the	O
X	O
chromosome	O
at	O
different	O
stages	O
and	O
sites	O
during	O
the	O
assembly	O
of	O
the	O
DCC	O
.	O

When	O
the	O
MLE	O
protein	O
,	O
which	O
encodes	O
an	O
RNA	O
helicase	O
,	O
was	O
absent	O
,	O
both	O
roX	O
RNAs	O
were	O
found	O
only	O
at	O
their	O
site	O
of	O
transcription	O
but	O
not	B-Negation
in	I-Negation
any	I-Negation
other	I-Negation
of	I-Negation
the	I-Negation
35	I-Negation
entry	I-Negation
sites	I-Negation
where	I-Negation
MSL1	I-Negation
and	I-Negation
MSL2	I-Negation
were	I-Negation
present	I-Negation
,	O
suggesting	B-Speculation
that	I-Speculation
neither	I-Speculation
of	I-Speculation
the	I-Speculation
roX	I-Speculation
RNAs	I-Speculation
can	I-Speculation
be	I-Speculation
integrated	I-Speculation
in	I-Speculation
a	I-Speculation
minimal	I-Speculation
MSL1-MSL2	I-Speculation
complex	I-Speculation
.	O

When	O
MSL3	B-Negation
was	I-Negation
absent	I-Negation
in	I-Negation
these	I-Negation
females	I-Negation
,	O
however	O
,	O
roX2	O
but	O
not	B-Negation
roX1	I-Negation
RNA	I-Negation
was	O
found	O
at	O
the	O
entry	O
35	O
sites	O
.	O

These	O
findings	O
indicate	O
that	O
roX2	O
might	O
be	O
incorporated	O
into	O
this	O
partial	O
DCC	O
complex	O
in	O
an	O
MLE-dependent	O
manner	O
and	O
that	O
roX1	O
RNA	O
is	O
incorporated	O
at	O
a	O
later	O
stage	O
,	O
together	O
with	O
MSL3	O
and	O
perhaps	O
MOF	O
.	O

Further	O
evidence	O
that	O
at	O
least	O
roX2	O
RNA	O
is	O
an	O
integral	O
part	O
of	O
the	O
DCC	O
comes	O
from	O
independent	O
immunoprecipitation	O
experiments	O
from	O
all	O
three	O
groups	O
[	O
1,2,3	O
]	O
using	O
extracts	O
from	O
Drosophila	O
S2	O
cells	O
that	O
express	O
all	O
the	O
MSLs	O
and	O
roX2	O
RNA	O
.	O

Surprisingly	O
,	O
Akthar	O
et	O
al.	O
[	O
2	O
]	O
found	O
that	O
DCC	O
lacking	B-Negation
MLE	I-Negation
but	O
containing	O
the	O
remaining	O
MSLs	O
still	O
precipitated	O
roX2	O
RNA	O
.	O

The	O
ordered	O
assembly	O
data	O
from	O
Meller	O
et	O
al.	O
[	O
1	O
]	O
as	O
well	O
as	O
the	O
fact	O
that	O
MLE	O
is	O
the	O
only	O
protein	O
in	O
the	O
DCC	O
featuring	O
a	O
known	O
RNA-binding	O
domain	O
pointed	O
towards	O
the	O
RNA	O
helicase	O
MLE	O
as	O
the	O
primary	O
candidate	O
for	O
a	O
partner	O
for	O
the	O
roX2	O
RNA	O
.	O

Akthar	O
et	O
al.	O
[	O
2	O
]	O
turned	O
their	O
focus	O
towards	O
the	O
MOF	O
protein	O
as	O
a	O
potential	O
candidate	O
for	O
interaction	O
with	O
roX2	O
RNA	O
.	O

MOF	O
is	O
the	O
crucial	O
component	O
that	O
links	O
the	O
DCC	O
to	O
the	O
X-chromosome-specific	O
acetylated	O
form	O
of	O
histone	O
H4	O
.	O

MOF	O
encodes	O
an	O
827	O
amino-acid	O
protein	O
containing	O
an	O
amino	O
terminus	O
of	O
unknown	O
function	O
,	O
a	O
chromodomain	O
,	O
a	O
zinc	O
finger	O
and	O
a	O
carboxy-terminal	O
histone	O
acetyltransferase	O
(	O
HAT	O
)	O
domain	O
.	O

The	O
HAT	O
domain	O
of	O
MOF	O
is	O
responsible	O
for	O
histone	O
H4	O
acetylation	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
as	O
shown	O
by	O
Smith	O
et	O
al.	O
[	O
3	O
]	O
.	O

Interestingly	O
,	O
immunoprecipitation	O
assays	O
using	O
extracts	O
from	O
SL-2	O
cells	O
transfected	O
with	O
wild-type	O
or	O
mutant	O
mof	O
genes	O
indicated	O
that	O
the	O
chromodomain	O
is	O
essential	O
for	O
the	O
specific	O
interaction	O
between	O
MOF	O
and	O
roX2	O
,	O
but	O
that	O
the	O
amino-terminal	O
region	O
and	O
HAT	O
domain	O
were	O
not	O
essential	O
for	O
this	O
interaction	O
.	O

Akthar	O
et	O
al.	O
[	O
2	O
]	O
then	O
tested	O
the	O
putative	O
RNA-binding	O
property	O
of	O
MOF	O
directly	O
using	O
electromobility	O
shift	O
assays	O
.	O

MOF	O
appeared	O
to	O
bind	O
to	O
RNA	O
rather	O
non-specifically	O
,	O
but	O
preferred	O
RNA	O
to	O
DNA	O
.	O

In	O
agreement	O
with	O
the	O
immunoprecipitation	O
results	O
,	O
they	O
found	O
that	O
an	O
intact	O
chromodomain	O
is	O
essential	O
for	O
RNA	O
binding	O
,	O
whereas	O
the	O
amino	O
terminus	O
or	O
the	O
HAT	O
domain	O
of	O
MOF	O
was	O
not	O
essential	O
.	O

Furthermore	O
,	O
they	O
also	O
showed	O
that	O
MSL3	O
,	O
which	O
features	O
two	O
chromodomains	O
on	O
its	O
own	O
,	O
also	O
shows	O
roX	O
RNA	O
binding	O
properties	O
.	O

Although	O
the	O
specificity	O
of	O
these	O
interactions	O
remains	O
to	O
be	O
investigated	O
,	O
the	O
findings	O
of	O
Akthar	O
and	O
coworkers	O
[	O
2	O
]	O
provide	O
a	O
new	O
possible	O
role	O
for	O
chromodomains	O
involved	O
in	O
RNA	O
binding	O
.	O

Chromodomains	O
are	O
modules	O
of	O
about	O
50	O
amino	O
acids	O
found	O
in	O
a	O
number	O
of	O
proteins	O
from	O
yeast	O
to	O
mammals	O
;	O
the	O
function	O
of	O
these	O
proteins	O
vary	O
,	O
but	O
they	O
are	O
most	O
often	O
associated	O
with	O
gene	O
silencing	O
and	O
chromatin	O
remodeling	O
events	O
;	O
significantly	O
,	O
many	O
chromodomain-containing	O
proteins	O
are	O
associated	O
on	O
chromosomes	O
with	O
heterochromatin	O
or	O
heterochromatin-like	O
regions	O
(	O
reviewed	O
in	O
[	O
17	O
]	O
)	O
.	O

The	O
specific	O
role	O
of	O
the	O
chromodomain	O
is	O
unknown	O
,	O
but	O
chromodomain	O
swapping	O
experiments	O
in	O
Drosophila	O
suggest	O
that	O
they	O
might	O
be	O
protein	O
interaction	O
modules	O
[	O
18	O
]	O
.	O

Thus	O
,	O
the	O
data	O
by	O
Akthar	O
et	O
al.	O
[	O
2	O
]	O
suggests	O
a	O
new	O
and	O
rather	O
unexpected	O
role	O
for	O
these	O
modules	O
in	O
RNA	O
binding	O
.	O

It	O
is	O
intriguing	O
to	O
speculate	O
that	O
the	O
chromodomain	O
of	O
other	O
remodeling	O
proteins	O
also	O
exert	O
their	O
activity	O
through	O
RNA	O
interactions	O
and	O
that	O
RNAs	O
might	O
be	O
more	O
common	O
than	O
generally	O
appreciated	O
in	O
transcriptional	O
regulation	O
.	O

Ordered	O
assembly	O
of	O
MSL	O
proteins	O
and	O
roX	O
RNA	O
increases	O
stability	O
of	O
the	O
DCC	O
.	O

The	O
first	O
step	O
of	O
assembly	O
involves	O
the	O
recognition	O
of	O
about	O
35	O
chromosomal	O
entry	O
sites	O
by	O
a	O
preDCC	O
consisting	O
of	O
MSL1	O
and	O
MSL2	O
.	O

This	O
recognition	O
does	O
not	B-Negation
require	I-Negation
any	I-Negation
of	I-Negation
the	I-Negation
known	I-Negation
roX	I-Negation
RNAs	I-Negation
.	O

In	O
the	O
next	O
step	O
,	O
roX2	O
and	O
MLE	O
enter	O
the	O
complex	O
to	O
form	O
a	O
more	O
stable	O
primary	O
DCC	O
(	O
PrimDCC	O
)	O
at	O
these	O
35	O
sites	O
.	O

Spreading	O
throughout	O
the	O
entire	O
X	O
chromosome	O
requires	O
the	O
formation	O
of	O
the	O
complete	O
complex	O
by	O
addition	O
of	O
MOF	O
and	O
MSL3	O
.	O

The	O
sequential	O
addition	O
of	O
new	O
components	O
,	O
particularly	O
the	O
roX2	O
RNA	O
,	O
might	O
induce	O
changes	O
in	O
the	O
structure	O
of	O
already	O
incorporated	O
components	O
(	O
illustrated	O
by	O
ovals	O
becoming	O
circles	O
)	O
,	O
increasing	O
the	O
stability	O
of	O
the	O
DCC	O
.	O

MLE	O
might	O
be	O
removed	O
in	O
vitro	O
(	O
for	O
example	O
,	O
by	O
elevated	O
ionic	O
strength	O
)	O
without	O
destroying	O
the	O
entire	O
complex	O
,	O
because	O
of	O
the	O
stabilizing	O
presence	O
of	O
MOF-MSL3	O
.	O

The	O
role	O
of	O
roX1	O
RNA	O
is	O
not	O
clear	O
,	O
but	O
it	O
is	O
integrated	O
late	O
in	O
this	O
process	O
,	O
together	O
with	O
or	O
after	O
MOF	O
and	O
MSL3	O
;	O
roX1	O
might	O
provide	O
additional	O
stability	O
to	O
the	O
mature	O
DCC	O
(	O
MatDCC	O
)	O
.	O

So	O
,	O
roX1	O
and	O
roX2	O
might	O
be	O
partially	O
redundant	O
.	O

Multiple	O
RNA-protein	O
interactions	O
within	O
the	O
DCC	O

How	O
can	O
we	O
reconcile	O
the	O
findings	O
of	O
Akthar	O
et	O
al.	O
[	O
2	O
]	O
and	O
Meller	O
et	O
al.	O
[	O
1	O
]	O
?	O

First	O
,	O
it	O
might	B-Speculation
be	I-Speculation
relevant	I-Speculation
that	I-Speculation
the	I-Speculation
co-immunoprecipitations	I-Speculation
and	I-Speculation
the	I-Speculation
in	I-Speculation
vitro	I-Speculation
binding	I-Speculation
experiments	I-Speculation
were	I-Speculation
performed	I-Speculation
with	I-Speculation
SL-2	I-Speculation
cell	I-Speculation
extracts	I-Speculation
,	O
cells	O
in	O
which	O
dosage	B-Speculation
compensation	I-Speculation
appears	I-Speculation
not	B-Negation
to	I-Negation
be	I-Negation
necessary	I-Negation
;	O
SL-2	O
cells	O
,	O
like	O
other	O
Drosophila	O
cell	O
lines	O
,	O
can	O
become	O
aneuploid	O
without	B-Negation
reduced	I-Negation
viability	I-Negation
.	O

The	O
soluble	O
DCCs	O
from	O
these	O
extracts	O
are	O
therefore	O
not	B-Negation
necessarily	I-Negation
functional	I-Negation
and	O
might	B-Speculation
differ	I-Speculation
from	I-Speculation
those	I-Speculation
in	I-Speculation
males	I-Speculation
.	O

Second	O
,	O
the	O
interaction	O
between	O
roX	O
RNA	O
and	O
MOF	O
protein	O
appears	O
to	O
lack	O
specificity	O
.	O

The	O
lack	O
of	O
specificity	O
might	O
be	O
attributed	O
to	O
a	O
number	O
of	O
reasons	O
,	O
such	O
as	O
the	O
absence	O
of	O
other	O
MSL	O
components	O
,	O
the	O
presence	O
of	O
other	O
RNAs	O
interacting	O
with	O
MOF	O
,	O
or	O
worse	O
,	O
it	O
might	O
reflect	O
a	O
property	O
of	O
MOF	O
without	O
functional	O
significance	O
:	O
that	O
is	O
,	O
MOF	O
might	O
not	O
contact	O
RNA	O
at	O
all	O
in	O
vivo	O
.	O

Keeping	O
this	O
cautious	O
note	O
in	O
mind	O
,	O
a	O
more	O
attractive	O
alternative	O
could	O
be	O
envisioned	O
.	O

The	O
main	O
proposition	O
of	O
this	O
model	O
is	O
that	O
roX2	O
can	O
interact	O
with	O
both	O
MLE	O
and	O
MOF	O
,	O
and	O
perhaps	O
even	O
other	O
MSL	O
proteins	O
,	O
as	O
both	O
roX	O
RNAs	O
are	O
certainly	O
large	O
enough	O
to	O
accommodate	O
binding	O
sites	O
for	O
several	O
proteins	O
[	O
6	O
]	O
.	O

If	O
such	O
a	O
scenario	O
is	O
correct	O
,	O
each	O
of	O
the	O
interactions	O
between	O
different	O
components	O
of	O
the	O
DCC	O
might	O
be	O
quite	O
weak	O
,	O
and	O
perhaps	O
not	O
even	O
highly	O
specific	O
,	O
but	O
in	O
the	O
context	O
of	O
additional	O
interactions	O
becomes	O
more	O
stable	O
.	O

The	O
addition	O
of	O
each	O
new	O
component	O
might	O
therefore	O
strengthen	O
existing	O
interactions	O
by	O
optimizing	O
contacts	O
between	O
binding	O
surfaces	O
through	O
adjustments	O
in	O
the	O
higher-order	O
structure	O
of	O
the	O
components	O
(	O
Figure	O
1	O
)	O
.	O

Evidence	O
from	O
co-immunoprecipitation	O
experiments	O
indicates	O
that	O
MSL1	O
and	O
MSL2	O
interact	O
directly	O
with	O
each	O
other	O
,	O
a	O
notion	O
supported	O
by	O
the	O
MSL1-MSL2	O
association	O
at	O
the	O
35	O
chromosomal	O
entry	O
sites	O
in	O
the	O
absence	O
of	O
any	O
other	O
MSLs	O
(	O
the	O
preDCC	O
;	O
Figure	O
1	O
)	O
.	O

The	O
addition	O
of	O
both	O
MLE	O
and	O
roX2	O
RNA	O
might	O
allow	O
the	O
formation	O
of	O
a	O
primary	O
complex	O
(	O
the	O
primDCC	O
)	O
,	O
which	O
might	O
be	O
stabilized	O
by	O
the	O
direct	O
interaction	O
of	O
a	O
structural	O
motif	O
of	O
roX2	O
RNA	O
with	O
the	O
MLE	O
protein	O
,	O
as	O
well	O
as	O
interactions	O
of	O
this	O
complex	O
with	O
MSL1	O
and	O
MSL2	O
.	O

The	O
primDCC	O
might	O
then	O
be	O
reinforced	O
by	O
the	O
addition	O
of	O
the	O
remaining	O
two	O
proteins	O
,	O
MSL3	O
and	O
MOF	O
,	O
one	O
or	O
both	O
of	O
which	O
might	O
recognize	O
other	O
motifs	O
within	O
the	O
roX2	O
RNA	O
,	O
to	O
form	O
the	O
mature	O
complex	O
(	O
matDCC	O
)	O
.	O

Finally	O
,	O
matDCC	O
might	O
be	O
further	O
stabilized	O
by	O
the	O
addition	O
of	O
roX1	O
RNA	O
,	O
which	O
could	O
interact	O
with	O
several	O
of	O
the	O
MSLs	O
and	O
perhaps	O
roX2	O
RNA	O
as	O
well	O
.	O

Significantly	O
,	O
assembly	O
and	O
disassembly	O
of	O
the	O
complex	O
might	O
not	O
necessarily	O
follow	O
the	O
same	O
order	O
.	O

For	O
example	O
,	O
once	O
the	O
complex	O
is	O
formed	O
,	O
removal	B-Speculation
(	I-Speculation
for	I-Speculation
example	I-Speculation
,	I-Speculation
by	I-Speculation
high	I-Speculation
ionic	I-Speculation
strength	I-Speculation
)	I-Speculation
of	I-Speculation
a	I-Speculation
single	I-Speculation
component	I-Speculation
brought	I-Speculation
in	I-Speculation
relatively	I-Speculation
early	I-Speculation
(	I-Speculation
such	I-Speculation
as	I-Speculation
MLE	I-Speculation
)	I-Speculation
might	I-Speculation
be	O
possible	B-Speculation
without	B-Negation
affecting	I-Negation
the	I-Negation
rest	I-Negation
of	I-Negation
the	I-Negation
complex	I-Negation
.	O

One	O
major	O
task	O
at	O
hand	O
now	O
will	O
be	O
to	O
resolve	O
the	O
specificities	O
of	O
the	O
proposed	O
interactions	O
between	O
the	O
various	O
MSL	O
proteins	O
and	O
the	O
roX	O
RNAs	O
.	O

This	O
could	O
be	O
done	O
by	O
carrying	O
out	O
detailed	O
in	O
vitro	O
studies	O
,	O
which	O
might	O
not	O
be	O
easy	O
to	O
perform	O
;	O
many	O
MSL	O
proteins	O
are	O
difficult	O
to	O
express	O
stably	O
in	O
bacteria	O
or	O
eukaryotic	O
expression	O
systems	O
.	O

An	O
alternative	O
might	O
be	O
to	O
establish	O
a	O
heterologous	O
in	O
vivo	O
system	O
such	O
as	O
yeast	O
,	O
where	O
protein-protein	O
and	O
RNA-protein	O
interactions	O
can	O
be	O
readily	O
detected	O
using	O
sensitive	O
reporter	O
assays	O
.	O

A	O
second	O
important	O
question	O
is	O
whether	O
the	O
roX	O
genes	O
have	O
the	O
same	O
,	O
overlapping	O
or	O
complementing	O
functions	O
.	O

Although	O
roX1	O
mutant	O
males	O
are	O
fully	O
viable	O
[	O
7	O
]	O
,	O
it	O
was	O
suggested	O
that	O
roX1	O
mutant	O
males	O
lacking	O
a	O
large	O
number	O
of	O
additional	O
genes	O
,	O
including	O
roX2	O
,	O
have	O
a	O
lethal	O
dosage-compensation	O
phenotype	O
because	O
the	O
DCC	O
fails	O
to	O
assemble	O
on	O
the	O
X	O
chromosome	O
[	O
19	O
]	O
.	O

Unfortunately	O
,	O
no	B-Negation
roX2	I-Negation
mutations	I-Negation
have	I-Negation
been	I-Negation
recovered	I-Negation
yet	O
;	O
they	O
would	B-Speculation
be	I-Speculation
important	I-Speculation
tools	I-Speculation
for	I-Speculation
validating	I-Speculation
the	I-Speculation
significance	I-Speculation
of	I-Speculation
the	I-Speculation
roX	I-Speculation
RNAs	I-Speculation
in	I-Speculation
vivo	I-Speculation
.	O

Furthermore	O
,	O
roX1	O
and	O
roX2	O
are	O
only	O
the	O
first	O
two	O
of	O
about	O
35	O
chromatin	O
entry	O
sites	O
,	O
although	O
perhaps	O
they	O
are	O
the	O
most	O
important	O
ones	O
.	O

The	O
nature	O
of	O
the	O
remaining	O
33	O
sites	O
is	O
entirely	O
unclear	O
and	O
there	O
is	O
,	O
as	O
yet	O
,	O
no	O
evidence	O
that	O
they	O
contain	O
other	O
roX-like	O
RNAs	O
.	O

This	O
brings	O
us	O
to	O
the	O
largest	O
of	O
all	O
mysteries	O
,	O
namely	O
how	O
the	O
DCC	O
is	O
spread	O
along	O
the	O
X	O
chromosome	O
.	O

One	O
possibility	O
is	O
that	O
the	O
remaining	O
33	O
or	O
so	O
sites	O
are	O
``	O
stations	O
'	O
that	O
serve	O
as	O
spreading	O
facilitators	O
in	O
the	O
form	O
of	O
DNA	O
elements	O
.	O

Thus	O
,	O
primDCCs	O
and/or	O
mature	O
(	O
mat	O
)	O
DCCs	O
,	O
originating	O
from	O
the	O
roX	O
entry	O
sites	O
,	O
might	O
hop	O
from	O
one	O
``	O
station	O
``	O
to	O
the	O
next	O
and	O
eventually	O
reach	O
all	O
the	O
entry	O
sites	O
distributed	O
along	O
the	O
entire	O
X	O
chromosome	O
[	O
1	O
]	O
.	O

From	O
these	O
sites	O
,	O
they	O
then	O
reach	O
into	O
the	O
neighboring	O
chromatin	O
regions	O
by	O
yet	O
another	O
mechanism	O
.	O

One	O
final	O
thought	O
:	O
the	O
dosage	O
compensation	O
machinery	O
in	O
C.	O
elegans	O
acts	O
on	O
the	O
two	O
X	O
chromosomes	O
in	O
the	O
hermaphrodite	O
by	O
twofold	O
down-regulation	O
of	O
gene	O
expression	O
.	O

Six	O
proteins	O
are	O
essential	O
for	O
this	O
process	O
and	O
they	O
associate	O
with	O
the	O
X	O
chromosomes	O
;	O
four	O
of	O
them	O
are	O
related	O
to	O
factors	O
involved	O
in	O
chromosome	O
condensation	O
during	O
mitosis	O
in	O
other	O
systems	O
.	O

Not	O
unlike	O
in	O
Drosophila	O
,	O
the	O
DCC	O
complex	O
of	O
C.	O
elegans	O
is	O
also	O
assembled	O
in	O
an	O
ordered	O
sequence	O
,	O
but	O
no	B-Negation
RNAs	I-Negation
have	I-Negation
been	I-Negation
identified	I-Negation
that	I-Negation
might	I-Negation
be	I-Negation
involved	I-Negation
in	I-Negation
this	I-Negation
assembly	I-Negation
process	I-Negation
[	O
20	O
]	O
;	O
either	B-Speculation
there	I-Speculation
will	I-Speculation
be	I-Speculation
yet	I-Speculation
another	I-Speculation
surprising	I-Speculation
turn	I-Speculation
in	I-Speculation
this	I-Speculation
multifaceted	I-Speculation
process	I-Speculation
or	I-Speculation
the	I-Speculation
CroX	I-Speculation
(	I-Speculation
C.	I-Speculation
elegans	I-Speculation
roX	I-Speculation
)	I-Speculation
RNAs	I-Speculation
wait	I-Speculation
to	I-Speculation
be	I-Speculation
discovered	I-Speculation
.	O

